Rsid Chr Position Ref P_value Gwas_trait Gene_symbol Variant_type Pubmedid rs568632519 chr1 565596 G A 7.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs10751454 chr1 807512 A G 2.20E-13 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 5.40E-21 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 7.70E-09 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs3748592 chr1 880238 A G 1.09E-04 Smoking initiation NOC2L intron 24665060 rs7526076 chr1 998395 A G 2.84E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3934834 chr1 1005806 C T 6.00E-07 Body mass index / / 19851299 rs6689308 chr1 1029805 A G 5.62E-04 Eating disorders C1orf159 intron 23568457 rs6687776 chr1 1030565 C T 9.40E-05 Post-operative nausea and vomiting C1orf159 intron 21694509 rs7545952 chr1 1031060 A G 1.68E-04 Eating disorders (purging via substances) C1orf159 intron 23568457 rs12145826 chr1 1066029 G A 6.14E-05 Celiac disease / / 23936387 rs11260603 chr1 1079198 T C 4.00E-07 IgG glycosylation / / 23382691 rs4442317 chr1 1106784 T C 5.26E-04 Smoking initiation / / 24665060 rs11260542 chr1 1110019 A G 8.24E-04 Alcohol dependence TTLL10 intron 20201924 rs3819001 chr1 1138913 T C 5.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TNFRSF18 UTR-3 23648065 rs11260562 chr1 1165310 G A 6.12E-04 Multiple complex diseases SDF4 intron 17554300 rs715643 chr1 1172907 C T 2.61E-04 Celiac disease / / 23936387 rs6697886 chr1 1173611 G A 9.70E-05 Alcohol dependence / / 21703634 rs11804831 chr1 1194804 T C 2.46E-05 Waist Circumference UBE2J2 intron pha003023 rs12103 chr1 1247494 T C 8.00E-13 Inflammatory bowel disease CPSF3L cds-synon 23128233 rs151152085 chr1 1322654 C T 0.000061 Breast cancer(er negative) CCNL2 missense 23555315 rs1695824 chr1 1365570 A C 4.23E-04 Multiple complex diseases / / 17554300 rs819976 chr1 1421531 C A 1.30E-05 Odorant perception ATAD3B cds-synon 23910658 rs9439462 chr1 1462766 C T 7.57E-05 Cognitive impairment induced by topiramate ATAD3A intron 22091778 rs3766178 chr1 1478180 T C 3.26E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 1.89E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 6.44E-05 Glucose levels SSU72 intron pha003061 rs2296716 chr1 1497824 C T 8.76E-07 Glucose levels SSU72 intron pha003058 rs2296716 chr1 1497824 C T 2.54E-05 Glucose levels SSU72 intron pha003061 rs4648782 chr1 1542186 G A 5.44E-04 Smoking initiation / / 24665060 rs28464684 chr1 1566160 T C 1.64E-04 Intracranial aneurysm / / 22286173 rs7531583 chr1 1706160 A G 9.21E-04 Acute lung injury /DK intron 22295056 rs9786963 chr1 1759026 T C 3.01E-04 Alzheimer's disease GNB1 intron 17998437 rs10907192 chr1 1793111 A G 7.59E-05 Cognitive performance GNB1 intron 19734545 rs7511905 chr1 1793786 A C 1.64E-04 Alzheimer's disease GNB1 intron 17998437 rs3855951 chr1 1804302 C T 1.55E-04 Alzheimer's disease GNB1 intron 17998437 rs7525092 chr1 1810090 C T 9.86E-05 Lung function (forced expiratory volume in 1 second) GNB1 intron pha003103 rs6688000 chr1 1823922 A G 3.16E-04 Alzheimer's disease / / 17998437 rs3820011 chr1 1888193 C A 4.91E-04 Smoking initiation KIAA1751 missense 24665060 rs2803291 chr1 1892325 T C 7.55E-04 Acute lung injury KIAA1751 intron 22295056 rs3795277 chr1 1981118 A C 1.11E-05 Celiac disease PRKCZ nearGene-5 23936387 rs884080 chr1 2026749 A G 4.53E-04 Urate levels PRKCZ intron 23263486 rs3128296 chr1 2068906 G T 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRKCZ intron 23648065 rs425277 chr1 2069172 C T 2.00E-08 Height PRKCZ intron 20881960 rs3753242 chr1 2069681 C T 8.80E-05 Response to lithium treatment in bipolar disorder PRKCZ intron 19448189 rs3753242 chr1 2069681 C T 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) PRKCZ intron 21107309 rs424079 chr1 2071340 C A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262669 chr1 2082489 G A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262683 chr1 2155869 C T 1.33E-05 Cognitive test performance / / 20125193 rs2460000 chr1 2156362 A G 1.36E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 1.51E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 3.14E-05 HIV-1 progression to AIDS and death / / 21811574 rs10797416 chr1 2182342 T C 0.0000837 Coronary artery disease SKI intron 23202125 rs6673129 chr1 2202774 C T 1.37E-05 Cognitive test performance SKI intron 20125193 rs12045693 chr1 2205581 C A 3.00E-06 IgG glycosylation SKI intron 23382691 rs2843163 chr1 2227422 C T 7.45E-04 Response to cytidine analogues (gemcitabine) SKI intron 24483146 rs12562937 chr1 2229478 C T 3.50E-06 Urinary metabolites SKI intron 21572414 rs2173049 chr1 2240006 T C 8.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SKI UTR-3 20877124 rs2643902 chr1 2245439 T C 3.77E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2645077 chr1 2249236 G A 1.68E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12080256 chr1 2251357 C A 1.98E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2055204 chr1 2280661 G A 4.19E-04 Smoking initiation MORN1 intron 24665060 rs7527871 chr1 2281726 A C 8.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MORN1 intron 23648065 rs2843130 chr1 2283313 C G 4.06E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 1.22E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 9.85E-05 Blood Pressure MORN1 intron pha003039 rs2840531 chr1 2286408 C T 3.69E-04 Body mass index MORN1 intron 21701565 rs2494428 chr1 2339074 C T 9.97E-04 HIV-1 viral setpoint PEX10 intron 17641165 rs7556447 chr1 2346099 C G 7.90E-06 Parkinson's disease (age of onset) / / 19772629 rs4648843 chr1 2366316 C T 1.20E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10910078 chr1 2390588 T C 3.13E-07 Non-obstructive azoospermia / / 22197933 rs10910078 chr1 2390588 T C 0.00000663 Autism spectrum disorders / / 22412387 rs2477686 chr1 2392648 G C 6.00E-12 Non-obstructive azoospermia / / 22197933 rs11588930 chr1 2408834 G A 0.000055 Coronary artery calcification PLCH2 intron 23727086 rs2477703 chr1 2425992 C T 9.99E-04 Amyotrophic lateral sclerosis (sporadic) PLCH2 intron 24529757 rs2236395 chr1 2446880 A G 6.30E-05 Rheumatoid arthritis PANK4 intron 22446963 rs12073504 chr1 2452979 C G 5.00E-06 Obesity-related traits PANK4 intron 23251661 rs10797431 chr1 2501222 G T 0.0000144 Primary biliary cirrhosis / / 22961000 rs10797432 chr1 2501338 C T 3.00E-12 Ulcerative colitis / / 23128233 rs734999 chr1 2513216 C T 3.00E-09 Ulcerative colitis / / 21297633 rs10910097 chr1 2521430 C T 1.29E-04 Multiple complex diseases FAM213B UTR-3 17554300 rs10752747 chr1 2524915 G T 6.31E-10 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3748816 chr1 2526746 A G 3.00E-09 Celiac disease MMEL1 missense 20190752 rs3748816 chr1 2526746 A G 3.00E-09 Asthma MMEL1 missense 21150878 rs3748816 chr1 2526746 A G 3.28E-09 Celiac disease and Rheumatoid arthritis MMEL1 missense 21383967 rs3748816 chr1 2526746 A G 1.60E-12 Multiple sclerosis MMEL1 missense 21833088 rs3748816 chr1 2526746 A G 3.28E-09 Multiple sclerosis MMEL1 missense 22190364 rs3748816 chr1 2526746 A G 0.000000021 Primary sclerosing cholangitis MMEL1 missense 22521342 rs3748816 chr1 2526746 A G 7.41E-12 Primary sclerosing cholangitis MMEL1 missense 23603763 rs2843401 chr1 2528133 T C 6.60E-09 Rheumatoid arthritis MMEL1 intron 23143596 rs2843401 chr1 2528133 T C 7.24E-10 Rheumatoid arthritis (CCP positive) MMEL1 intron 23143596 rs2843403 chr1 2529097 T C 0.000000794 Graves' disease MMEL1 intron 22922229 rs2843403 chr1 2529097 T C 0.00000563 Graves' disease and Hashimoto's thyroiditis MMEL1 intron 22922229 rs10910099 chr1 2533552 A C 5.40E-07 Multiple complex diseases MMEL1 intron 17554300 rs12138909 chr1 2538738 C T 5.61E-08 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs12138909 chr1 2538738 C T 9.18E-05 Cognitive impairment induced by topiramate MMEL1 intron 22091778 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 22057235 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 23143596 rs10910108 chr1 2539532 A G 0.000331 Primary biliary cirrhosis (anti-mitochondrial antibody positive) MMEL1 intron 22936693 rs6684865 chr1 2546229 G A 5.37E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648654 chr1 2553083 G A 0.00067 Primary biliary cirrhosis MMEL1 intron 22936693 rs3890745 chr1 2553624 T C 5.73E-06 Multiple complex diseases MMEL1 intron 17554300 rs3890745 chr1 2553624 T C 1.00E-07 Rheumatoid arthritis MMEL1 intron 18794853 rs3890745 chr1 2553624 T C 4.00E-06 Rheumatoid arthritis MMEL1 intron 20453842 rs3890745 chr1 2553624 T C 1.00E-07 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3890745 chr1 2553624 T C 5.60E-06 Rheumatoid arthritis MMEL1 intron 22446963 rs3890745 chr1 2553624 T C 1.00E-06 Rheumatoid arthritis MMEL1 intron 24449572 rs4474198 chr1 2553758 C T 4.75E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648356 chr1 2709164 C A 4.28E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs4648356 chr1 2709164 C A 1.00E-14 Multiple sclerosis / / 21833088 rs2377041 chr1 2713327 C T 8.89E-05 Serum metabolites / / 19043545 rs4648482 chr1 2749921 T C 7.74E-05 Aortic root size / / 21223598 rs11580768 chr1 2799480 C T 3.85E-06 Ankle-brachial index / / 22199011 rs2842909 chr1 2859724 C T 7.79E-04 Taste perception / / 22132133 rs7548727 chr1 2865778 T C 4.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2485944 chr1 2883858 C T 7.27E-05 Major depressive disorder / / 22472876 rs12044030 chr1 2889577 C T 3.62E-05 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 1.91E-06 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 5.97E-05 Cholesterol / / pha003078 rs1572657 chr1 2902128 C T 3.33E-05 Fibrinogen / / pha003068 rs7534897 chr1 2928421 C T 0.0000755 Salmonella-induced pyroptosis / / 22837397 rs2142569 chr1 2944527 G A 4.00E-06 Substance dependence phenotypes / / 24832863 rs12409277 chr1 2957600 T C 1.00E-06 Body mass (lean) / / 24863034 rs2297829 chr1 2984087 C A 6.38E-04 White matter integrity / / 22425255 rs6695131 chr1 3000924 T C 0.00069 Salmonella-induced pyroptosis PRDM16 intron 22837397 rs2981884 chr1 3002072 A G 9.40E-06 Panic disorder PRDM16 intron 19165232 rs7538096 chr1 3057661 T C 1.92E-05 Hemoglobin PRDM16 intron pha003098 rs7538096 chr1 3057661 T C 1.71E-05 Erythrocyte counts PRDM16 intron pha003099 rs2651899 chr1 3083712 T C 4.00E-09 Migraine PRDM16 intron 21666692 rs2651899 chr1 3083712 T C 4.20E-04 Migraine PRDM16 intron 22683712 rs2651899 chr1 3083712 T C 1.56E-05 Migraine without aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 2.54E-04 Migraine with aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 3.06E-04 Migraine - clinic-based PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.00E-14 Migraine PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.34E-14 Migraine PRDM16 intron 23793025 rs17390062 chr1 3089849 T C 5.26E-05 Coronary heart disease PRDM16 intron 21606135 rs12737500 chr1 3094708 C T 7.67E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs12737500 chr1 3094708 C T 1.90E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs17390167 chr1 3094831 C G 1.70E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12750165 chr1 3095491 A G 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12733843 chr1 3097073 G A 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12072073 chr1 3130016 T C 6.49E-04 Alzheimer's disease PRDM16 intron 22005930 rs10909901 chr1 3131235 C T 4.80E-04 Alzheimer's disease PRDM16 intron 22005930 rs2817145 chr1 3133422 T A 7.54E-04 Alzheimer's disease PRDM16 intron 22005930 rs10492940 chr1 3197747 C A 4.12E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs16823802 chr1 3199217 C T 3.43E-05 Tunica Media PRDM16 intron pha003036 rs12565013 chr1 3203137 A C 3.43E-05 Tunica Media PRDM16 intron pha003036 rs4648377 chr1 3211458 A C 9.21E-04 Tourette syndrome PRDM16 intron 22889924 rs2455136 chr1 3218329 A T 9.75E-05 Self-reported allergy PRDM16 intron 23817569 rs2500283 chr1 3218923 G C 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs2500282 chr1 3219497 A G 1.18E-04 Self-reported allergy PRDM16 intron 23817569 rs4233025 chr1 3223280 C T 9.54E-05 Self-reported allergy PRDM16 intron 23817569 rs4648473 chr1 3223764 A G 9.91E-05 Self-reported allergy PRDM16 intron 23817569 rs4145901 chr1 3223955 A G 9.18E-05 Self-reported allergy PRDM16 intron 23817569 rs2500278 chr1 3225940 C T 8.60E-04 Amyotrophic Lateral Sclerosis PRDM16 intron 17362836 rs2483261 chr1 3227416 C G 1.48E-04 Self-reported allergy PRDM16 intron 23817569 rs2483262 chr1 3229134 G T 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs12409315 chr1 3229258 A G 5.57E-05 Multiple complex diseases PRDM16 intron 17554300 rs16824089 chr1 3230544 T C 3.61E-06 Tunica Media PRDM16 intron pha003036 rs4648477 chr1 3251975 G A 1.29E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648477 chr1 3251975 G A 1.29E-08 Facial morphology PRDM16 intron 23028347 rs4648478 chr1 3252007 C T 1.12E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648478 chr1 3252007 C T 1.12E-08 Facial morphology PRDM16 intron 23028347 rs7516150 chr1 3253889 C T 2.52E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7516150 chr1 3253889 C T 2.52E-08 Facial morphology PRDM16 intron 23028347 rs7552331 chr1 3253941 G A 3.97E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7552331 chr1 3253941 G A 3.97E-08 Facial morphology PRDM16 intron 23028347 rs1572037 chr1 3254369 T C 2.45E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1572037 chr1 3254369 T C 2.45E-08 Facial morphology PRDM16 intron 23028347 rs1999527 chr1 3256108 C A 1.72E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1999527 chr1 3256108 C A 1.72E-08 Facial morphology PRDM16 intron 23028347 rs4648379 chr1 3261516 C T 1.13E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648379 chr1 3261516 C T 1.13E-08 Facial morphology PRDM16 intron 23028347 rs12748963 chr1 3275149 C T 1.74E-04 Epilepsy PRDM16 intron 22116939 rs17399569 chr1 3278959 C T 4.00E-05 Response to statin therapy PRDM16 intron 20339536 rs11807862 chr1 3279268 T A 2.20E-06 Response to statin therapy PRDM16 intron 20339536 rs6658356 chr1 3280253 G A 2.00E-06 Response to statin therapy PRDM16 intron 20339536 rs6424073 chr1 3285628 G A 3.21E-04 Cognitive decline PRDM16 intron 23732972 rs12135987 chr1 3289524 G A 5.22E-05 Cognitive performance PRDM16 intron 19734545 rs868688 chr1 3300807 C T 8.70E-04 Response to cytadine analogues (cytosine arabinoside) PRDM16 intron 24483146 rs10492939 chr1 3302871 G A 9.12E-06 Bilirubin levels,in serum PRDM16 intron 19389676 rs2493278 chr1 3307746 T C 7.17E-04 Parkinson's disease PRDM16 intron 17052657 rs11578011 chr1 3318532 T C 5.41E-05 Elbow pain PRDM16 intron pha003008 rs2493285 chr1 3333595 G A 4.01E-04 Sudden cardiac arrest PRDM16 intron 21658281 rs3806164 chr1 3380057 G A 2.66E-04 Smoking quantity ARHGEF16 missense 24665060 rs2185639 chr1 3389727 C T 9.17E-05 Relative hand skill in reading disability ARHGEF16 missense 24068947 rs2821041 chr1 3404227 C T 9.71E-05 Relative hand skill in reading disability / / 24068947 rs4648505 chr1 3405296 T C 4.13E-05 Relative hand skill in reading disability MEGF6 UTR-3 24068947 rs10909969 chr1 3480149 C T 8.03E-05 Bipolar disorder MEGF6 intron 17486107 rs2821017 chr1 3520871 G A 5.18E-05 Caffeine consumption MEGF6 intron 21490707 rs4276857 chr1 3544346 T C 1.22E-04 Bipolar disorder TPRG1L intron 18317468 rs2208993 chr1 3575833 C G,T 4.05E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs2224718 chr1 3576060 T C 6.86E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs3765696 chr1 3587505 T C 2.50E-04 Body mass index TP73 intron 17255346 rs12027041 chr1 3591448 G C 1.08E-05 Multiple complex diseases TP73 intron 17554300 rs12027041 chr1 3591448 G C 3.50E-09 Progranulin levels TP73 intron 21087763 rs12027041 chr1 3591448 G C 3.50E-09 Myocardial infarction TP73 intron 21211798 rs3765736 chr1 3616601 C T 2.10E-05 Heart Rate TP73 intron pha003054 rs6424090 chr1 3628677 A G 4.33E-04 Sarcoidosis TP73 intron 19165924 rs9662633 chr1 3649562 G A 6.00E-06 Visceral adipose tissue adjusted for BMI TP73 cds-synon 22589738 rs12562437 chr1 3651031 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio TP73 UTR-3 22589738 rs10910018 chr1 3651409 G A 2.00E-06 Visceral fat TP73 UTR-3 22589738 rs3737589 chr1 3662845 A G 4.33E-04 Lung function (forced expiratory volume in 1 second) TP73-AS1 intron 24023788 rs12120656 chr1 3665867 G T 1.06E-04 Type 2 diabetes / / 17463246 rs12120656 chr1 3665867 G T 9.39E-04 Lymphocyte counts / / 22286170 rs76597070 chr1 3669356 G A 3.00E-06 Obesity-related traits CCDC27 missense 23251661 rs1181889 chr1 3671027 T C 3.29E-04 Type 2 diabetes CCDC27 intron 17463246 rs2275837 chr1 3686318 G A 9.72E-04 Multiple complex diseases CCDC27 intron 17554300 rs1175550 chr1 3691528 A G 8.62E-15 Red blood cell traits LOC388588 intron 23222517 rs1175550 chr1 3691528 A G 5.00E-10 Blood trace element (Cu levels) LOC388588 intron 23720494 rs1175549 chr1 3691727 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC388588 intron 22628534 rs1175549 chr1 3691727 A C 0.0000265 Otitis media (children 3 years old or younger) LOC388588 intron 23133572 rs1175549 chr1 3691727 A C 1.35E-14 Red blood cell traits LOC388588 intron 23222517 rs2799182 chr1 3696000 T C 1.06E-07 Red blood cell traits / / 23222517 rs8379 chr1 3696890 A C 1.76E-08 Red blood cell traits LRRC47 UTR-3 23222517 rs9424283 chr1 3705226 C G 3.14E-04 Lymphocyte counts LRRC47 intron 22286170 rs7513053 chr1 3709487 A G 4.26E-13 Red blood cell traits LRRC47 intron 23222517 rs6667255 chr1 3711689 T C 1.74E-13 Red blood cell traits LRRC47 intron 23222517 rs7535775 chr1 3719057 G A 3.90E-07 Red blood cell traits / / 23222517 rs2154068 chr1 3720965 A G 9.34E-08 Red blood cell traits / / 23222517 rs12135894 chr1 3728061 C T 1.93E-09 Red blood cell traits / / 23222517 rs2027548 chr1 3739512 G A 7.99E-04 Amyotrophic Lateral Sclerosis CEP104 intron 17362836 rs6688969 chr1 3743391 C T 4.48E-09 Red blood cell traits CEP104 intron 23222517 rs7511793 chr1 3744249 A G 2.21E-12 Red blood cell traits CEP104 intron 23222517 rs7545274 chr1 3744261 C A 8.86E-04 Alcohol dependence CEP104 intron 21314694 rs7545274 chr1 3744261 C A 3.25E-13 Red blood cell traits CEP104 intron 23222517 rs2275833 chr1 3745721 C T 3.34E-11 Red blood cell traits CEP104 intron 23222517 rs2298224 chr1 3756155 T C 4.91E-04 Multiple complex diseases CEP104 intron 17554300 rs17412654 chr1 3758493 T C 6.42E-09 Red blood cell traits CEP104 intron 23222517 rs7538067 chr1 3761772 C T 3.69E-08 Red blood cell traits CEP104 intron 23222517 rs10492942 chr1 3764216 C T 8.34E-12 Red blood cell traits CEP104 intron 23222517 rs16824230 chr1 3766240 A G 6.22E-13 Red blood cell traits CEP104 intron 23222517 rs10909804 chr1 3770929 C T 8.20E-13 Red blood cell traits CEP104 intron 23222517 rs10797348 chr1 3781096 C A 4.39E-10 Red blood cell traits DFFB intron 23222517 rs4074709 chr1 3796948 G T 1.00E-04 Information processing speed DFFB intron 21130836 rs4073324 chr1 3797995 C T 2.17E-04 Cholesterol DFFB intron 17255346 rs4131373 chr1 3807388 G A 9.14E-06 HIV-1 viral setpoint C1orf174 cds-synon 17641165 rs4131373 chr1 3807388 G A 1.29E-05 AIDS progression C1orf174 cds-synon 19115949 rs6701422 chr1 3808171 T C 6.03E-05 Epilepsy (remission after treatment) C1orf174 intron 23962720 rs12082157 chr1 3811810 T C 1.01E-05 HIV-1 viral setpoint C1orf174 intron 17641165 rs6687869 chr1 3821216 G A 1.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs6687869 chr1 3821216 G A 4.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs35583447 chr1 3829614 A G 5.48E-05 Epilepsy (remission after treatment) LOC100133612 intron 23962720 rs35241263 chr1 3831232 A G 8.64E-05 Epilepsy (remission after treatment) / / 23962720 rs10737395 chr1 4007558 C A 3.62E-04 Blood pressure LOC728716 intron 17255346 rs10737395 chr1 4007558 C A 2.69E-05 Common variable immunodeficiency LOC728716 intron 21497890 rs4654479 chr1 4009694 G A 3.36E-04 Blood pressure LOC728716 intron 17255346 rs12031275 chr1 4026068 G A,T 9.20E-06 Serum metabolites / / 19043545 rs4654521 chr1 4028282 C T 1.49E-05 Serum metabolites / / 19043545 rs3935162 chr1 4031327 G A 9.20E-05 Serum metabolites / / 19043545 rs12722968 chr1 4065348 C T 1.48E-04 Birth weight / / 17255346 rs79004239 chr1 4080348 C T 0.00006336 Sarcoidosis / / 22952805 rs7514530 chr1 4120311 C T 9.16E-05 Coronary heart disease / / pha003030 rs7524800 chr1 4121584 A G 5.17E-05 Coronary heart disease / / pha003030 rs6669278 chr1 4123099 C T 0.00004214 Sarcoidosis / / 22952805 rs6673959 chr1 4123117 A G 7.97E-06 Hearing function / / 21493956 rs4391636 chr1 4130684 T C 7.17E-04 Multiple complex diseases / / 17554300 rs12021796 chr1 4133241 T G 6.22E-04 Multiple complex diseases / / 17554300 rs10915417 chr1 4137042 C G 2.54E-04 Multiple complex diseases / / 17554300 rs10915421 chr1 4145615 T C 2.94E-05 Coronary heart disease / / pha003030 rs10915424 chr1 4146369 G A 3.59E-05 Coronary heart disease / / pha003030 rs4600014 chr1 4157198 A G 6.61E-05 Alzheimer's disease / / 17998437 rs10915428 chr1 4158955 G T 3.67E-05 Kawasaki disease / / 22446961 rs4400585 chr1 4182785 G T 7.00E-04 Alzheimer's disease / / 17998437 rs4400585 chr1 4182785 G T 1.58E-04 Alzheimer's disease / / pha002879 rs10915437 chr1 4183006 A G 1.56E-04 Migraine with aura / / 23793025 rs10915437 chr1 4183006 A G 3.00E-08 Migraine - clinic-based / / 23793025 rs10915437 chr1 4183006 A G 6.13E-04 Migraine / / 23793025 rs12409803 chr1 4193426 G A 0.00000354 HDL cholesterol particle diameter / / 23263444 rs6663939 chr1 4197256 C T 0.00000387 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 0.00000389 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 2.86E-05 Waist Circumference / / pha003024 rs16840838 chr1 4201349 G A 1.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4654492 chr1 4201815 C T 2.79E-04 Multiple complex diseases / / 17554300 rs12143662 chr1 4202993 C T 0.00000395 HDL cholesterol particle diameter / / 23263444 rs4654497 chr1 4224558 T C 1.09E-04 Type 2 diabetes / / 17463246 rs4654497 chr1 4224558 T C 9.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3890729 chr1 4230712 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs16840958 chr1 4285991 T C 5.45E-04 Multiple complex diseases / / 17554300 rs12132422 chr1 4295304 A G 4.32E-04 Alcohol dependence / / 20201924 rs1908490 chr1 4312205 C T 7.20E-06 Coronary heart disease / / pha003035 rs966321 chr1 4315204 G T 8.00E-06 Factor VII / / 17903294 rs966321 chr1 4315204 G T 2.20E-08 Tanning / / 19340012 rs966321 chr1 4315204 G T 8.84E-04 Common variable immunodeficiency / / 21497890 rs966321 chr1 4315204 G T 1.05E-05 Coronary heart disease / / pha003035 rs964715 chr1 4316784 T C 4.10E-05 Bladder cancer / / 24163127 rs2411738 chr1 4326368 G A 6.22E-06 Coronary heart disease / / pha003035 rs6677984 chr1 4330287 A G 2.84E-05 Coronary heart disease / / pha003035 rs16838549 chr1 4343581 G A 7.23E-05 Multiple complex diseases / / 17554300 rs351615 chr1 4370385 G A 2.68E-05 Alzheimer's disease / / 17998437 rs351596 chr1 4377911 C T 9.71E-04 Multiple complex diseases / / 17554300 rs351596 chr1 4377911 C T 6.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs7418164 chr1 4380518 G A 2.78E-04 Multiple complex diseases / / 17554300 rs2171985 chr1 4381253 G T 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs496925 chr1 4396552 C T 2.12E-04 Multiple complex diseases / / 17554300 rs528291 chr1 4414045 A G 3.53E-04 Taste perception / / 22132133 rs349390 chr1 4423896 T C 8.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16838812 chr1 4424115 A G 4.02E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 2.17E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 7.10E-07 Glioma (high-grade) / / 19578366 rs75411 chr1 4425414 C T 3.63E-06 Obesity-related traits / / 23251661 rs589870 chr1 4440749 C T 6.09E-06 Obesity-related traits / / 23251661 rs12037374 chr1 4443108 C T 1.50E-05 Urinary metabolites / / 21572414 rs239339 chr1 4444539 G T 3.00E-06 Obesity-related traits / / 23251661 rs6679220 chr1 4459689 T C 1.00E-04 Diabetic nephropathy / / pha002866 rs12116790 chr1 4464933 A G 7.14E-04 Type 2 diabetes / / 17463246 rs349403 chr1 4474002 A G 9.50E-05 Body mass index LOC284661 intron 20818722 rs4654432 chr1 4481215 C T 7.84E-04 Multiple complex diseases LOC284661 intron 17554300 rs4654432 chr1 4481215 C T 7.20E-05 Diabetic nephropathy LOC284661 intron pha002866 rs4654433 chr1 4481632 G A 9.90E-05 Diabetic nephropathy LOC284661 intron pha002866 rs1762814 chr1 4496256 C T 1.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10737409 chr1 4522466 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4654438 chr1 4559901 T C 2.00E-06 Smooth-surface caries / / 24556642 rs9660574 chr1 4560405 G A 3.22E-06 Smooth-surface caries / / 24556642 rs4654548 chr1 4562476 G A 4.09E-06 Smooth-surface caries / / 24556642 rs10753381 chr1 4565906 C T 1.76E-06 Smooth-surface caries / / 24556642 rs1762826 chr1 4572778 C T 7.89E-05 Waist Circumference / / pha003023 rs608203 chr1 4581585 T C 5.94E-04 Stroke / / pha002886 rs608492 chr1 4598001 G C 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs592726 chr1 4599243 C T 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs542688 chr1 4600621 C G 2.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs694935 chr1 4603324 T A 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs241215 chr1 4604104 T A 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs17348839 chr1 4605403 C A 3.22E-08 Multiple complex diseases / / 17554300 rs241220 chr1 4608204 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs241221 chr1 4609050 T C 5.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs241278 chr1 4629408 T C 9.31E-04 Type 2 diabetes / / 17463246 rs7526879 chr1 4630483 C T 6.15E-04 Type 2 diabetes / / 17463246 rs1541318 chr1 4634978 A G 1.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1541318 chr1 4634978 A G 4.33E-04 Smoking initiation / / 24665060 rs1157688 chr1 4636767 T C 4.79E-05 Obesity (extreme) / / 21935397 rs515279 chr1 4643688 T A,C,G 9.32E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs504274 chr1 4648573 C T 2.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs504274 chr1 4648573 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs589176 chr1 4660552 A G 5.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs11590266 chr1 4668423 A G 2.50E-05 Urinary metabolites / / 21572414 rs3896439 chr1 4668670 G A 2.00E-08 Dental caries / / 23064961 rs6668002 chr1 4682104 T C 9.98E-05 Asthma / / pha003127 rs12403290 chr1 4682532 C A 2.50E-05 Urinary metabolites / / 21572414 rs875807 chr1 4685672 A G 4.20E-05 Triglycerides / / pha003080 rs7553610 chr1 4687874 G A 5.72E-04 Smoking initiation / / 24665060 rs2101195 chr1 4697300 C T 4.27E-04 Type 2 diabetes / / 17463246 rs7533451 chr1 4705931 G A 5.59E-04 Alzheimer's disease / / 17998437 rs3947662 chr1 4718551 G T 1.10E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs12409187 chr1 4733793 G A 6.54E-05 Aging (time to event) AJAP1 intron 21782286 rs11588881 chr1 4737383 C T 3.47E-04 Type 2 diabetes AJAP1 intron 17463246 rs11588881 chr1 4737383 C T 1.30E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs11588881 chr1 4737383 C T 3.84E-05 Homeostasis model assessment of beta-cell function (interaction) AJAP1 intron 24204828 rs2071995 chr1 4738678 C T 3.79E-05 QT interval AJAP1 intron 22726844 rs1076944 chr1 4748305 G T 2.04E-04 Epilepsy AJAP1 intron 22116939 rs7525374 chr1 4754057 A G 4.43E-04 Myopia (pathological) AJAP1 intron 21095009 rs7518469 chr1 4756276 G T 2.44E-04 Alzheimer's disease (late onset) AJAP1 intron 21379329 rs3766964 chr1 4792184 T C 1.10E-05 Urinary metabolites AJAP1 intron 21572414 rs16839536 chr1 4793580 C G 6.27E-04 Multiple complex diseases AJAP1 intron 17554300 rs414176 chr1 4805106 A C 1.60E-06 Urinary metabolites AJAP1 intron 21572414 rs422988 chr1 4819117 A C 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs397559 chr1 4820799 C T 9.92E-04 Multiple complex diseases AJAP1 intron 17554300 rs397559 chr1 4820799 C T 5.24E-04 Alzheimer's disease AJAP1 intron 17998437 rs397559 chr1 4820799 C T 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs424723 chr1 4824742 C T 7.60E-05 Intelligence AJAP1 intron 21826061 rs2743979 chr1 4825152 G A 6.44E-05 Intelligence AJAP1 intron 21826061 rs7518471 chr1 4828606 C T 7.27E-05 Hepatocellular carcinoma AJAP1 intron 22807686 rs423285 chr1 4831076 C T 0.0000586 Follicular lymphoma AJAP1 intron 23025665 rs11805709 chr1 4847594 C T 1.21E-06 Serum metabolites / / 19043545 rs12028290 chr1 4889912 C A 3.99E-06 Multiple complex diseases / / 17554300 rs12094945 chr1 4933154 T G 1.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2031246 chr1 4959786 A G 1.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2031246 chr1 4959786 A G 3.45E-05 Waist-Hip Ratio / / pha003013 rs2031246 chr1 4959786 A G 7.70E-05 Waist-Hip Ratio / / pha003028 rs41524347 chr1 4972186 T G 9.00E-04 Multiple complex diseases / / 17554300 rs10915670 chr1 4975417 G A 1.60E-05 Diabetes Mellitus / / pha003060 rs10915671 chr1 4983217 G A 6.25E-05 Type 1 diabetes / / 18978792 rs12045266 chr1 4996275 G T 3.30E-06 Urinary metabolites / / 21572414 rs12048035 chr1 4996307 C G 2.20E-06 Urinary metabolites / / 21572414 rs17349719 chr1 5001809 A G 4.47E-04 Multiple complex diseases / / 17554300 rs12754637 chr1 5023321 G A 5.33E-05 Colorectal cancer / / 19723657 rs7525837 chr1 5030660 G A 9.29E-26 Narcolepsy / / 19629137 rs7518523 chr1 5031561 A G 5.44E-05 Serum metabolites / / 19043545 rs12757902 chr1 5036234 G A 3.86E-05 Cardiovascular disease / / pha003064 rs10915307 chr1 5063293 G A 3.13E-04 Type 2 diabetes / / 17463246 rs10915310 chr1 5068210 A G 1.06E-04 Type 2 diabetes / / 17463246 rs10799151 chr1 5068245 A G 2.44E-04 Type 2 diabetes / / 17463246 rs12047764 chr1 5077552 T C 8.99E-04 Type 2 diabetes / / 17463246 rs9439507 chr1 5090997 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs10915329 chr1 5114102 C T 9.18E-05 Glucose levels / / pha003058 rs6603832 chr1 5127543 A G 4.72E-05 Personality dimensions / / 18957941 rs10915336 chr1 5137666 G A 3.70E-05 Parkinson's disease (familial) / / 18985386 rs12047111 chr1 5142784 A G 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2334263 chr1 5142818 T C 4.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6680801 chr1 5145066 G A 6.20E-04 Aortic root size / / 21223598 rs3101225 chr1 5156245 A C 7.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7513590 chr1 5170712 A G 5.00E-06 Anthropometric traits / / 19260139 rs12743573 chr1 5204164 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10753353 chr1 5211134 T C 0.000505473 Hypertension (early onset hypertension) / / 22479346 rs12026977 chr1 5231170 T C 5.97E-04 Smoking initiation / / 24665060 rs12041491 chr1 5253436 G A 4.03E-04 Multiple complex diseases / / 17554300 rs16840183 chr1 5280502 T G 1.15E-05 Alcohol consumption / / 23953852 rs677735 chr1 5295176 A G 5.84E-05 Alcohol consumption / / 23953852 rs2353169 chr1 5296844 T C 9.98E-05 stroke (ischemic) / / 17434096 rs12135834 chr1 5309667 C T 7.50E-04 Coronary heart disease / / 21606135 rs4465222 chr1 5310258 T C 4.93E-06 Alcohol consumption / / 23953852 rs6686714 chr1 5310609 G T 8.90E-04 Coronary heart disease / / 21606135 rs12732868 chr1 5334637 T G 4.55E-07 Schizophrenia / / 21926974 rs17423547 chr1 5341464 T C 4.98E-05 Orofacial clefts / / 22419666 rs604664 chr1 5343032 T C 1.73E-04 Cholesterol / / 17255346 rs557477 chr1 5346474 T G 1.90E-06 Urinary metabolites / / 21572414 rs7530063 chr1 5352492 T C 3.10E-05 Cognitive function / / 24684796 rs912988 chr1 5354844 C T 6.00E-06 Major depressive disorder / / 23377640 rs9439521 chr1 5368589 G A 3.37E-04 Multiple complex diseases / / 17554300 rs9439522 chr1 5368747 T G 2.09E-04 Multiple complex diseases / / 17554300 rs9439523 chr1 5368769 A G 3.14E-04 Multiple complex diseases / / 17554300 rs9439525 chr1 5369177 G A 4.52E-04 Multiple complex diseases / / 17554300 rs12040942 chr1 5371159 C A 3.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10915413 chr1 5371579 C T 2.13E-04 Multiple complex diseases / / 17554300 rs4478820 chr1 5371934 A G 2.40E-04 Multiple complex diseases / / 17554300 rs874995 chr1 5386597 A T 9.96E-04 Type 2 diabetes / / 17463246 rs16840538 chr1 5390209 A G 7.97E-04 Multiple complex diseases / / 17554300 rs1326005 chr1 5403585 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7364349 chr1 5421533 G A 5.89E-04 Smoking initiation / / 24665060 rs11801594 chr1 5426110 T C 7.56E-05 Platelet counts / / pha003100 rs6603835 chr1 5475663 C A 1.00E-04 Prostate cancer / / 21743057 rs6688540 chr1 5478901 C T 5.33E-04 Multiple complex diseases / / 17554300 rs6688540 chr1 5478901 C T 8.00E-05 Prostate cancer / / 21743057 rs6603839 chr1 5480101 C T 5.02E-04 Multiple complex diseases / / 17554300 rs10907211 chr1 5492043 C A 5.52E-04 Rheumatoid arthritis / / 21452313 rs9787315 chr1 5544659 G C 5.31E-04 Multiple complex diseases / / 17554300 rs9787315 chr1 5544659 G C 0.000192 Salmonella-induced pyroptosis / / 22837397 rs9729637 chr1 5545452 G T 0.0000295 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 0.0000824 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 4.20E-04 Myasthenia gravis / / 23055271 rs12128558 chr1 5569491 C A 2.61E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17028213 chr1 5615931 C T 4.75E-04 Multiple complex diseases / / 17554300 rs7523214 chr1 5625929 C G 2.30E-07 Urinary metabolites / / 21572414 rs7528859 chr1 5661009 T A 2.34E-05 Migraine - clinic-based / / 23793025 rs7528859 chr1 5661009 T A 5.00E-06 Migraine with aura / / 23793025 rs11260661 chr1 5671493 G C 9.34E-04 Type 2 diabetes / / 17463246 rs17426290 chr1 5683697 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1775401 chr1 5686132 C T 4.82E-04 Multiple complex diseases / / 17554300 rs770683 chr1 5689702 A G 7.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs17028416 chr1 5689921 G C 4.94E-04 Multiple complex diseases / / 17554300 rs17426695 chr1 5696425 G A 3.87E-05 Cognitive test performance / / 20125193 rs6670965 chr1 5696677 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10492947 chr1 5699475 C A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11260666 chr1 5699634 G A 2.67E-04 Multiple complex diseases / / 17554300 rs4845812 chr1 5707816 C T 5.00E-06 Metabolite levels (MHPG) / / 23319000 rs1775408 chr1 5717138 A G 7.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12038771 chr1 5723643 G A 1.60E-05 Multiple complex diseases / / 17554300 rs707580 chr1 5724940 T C 3.18E-04 Multiple complex diseases / / 17554300 rs2649071 chr1 5753350 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs796396 chr1 5764879 A G 1.40E-05 Urinary metabolites / / 21572414 rs2649086 chr1 5782769 T C 8.96E-05 Diabetes (gestational) / / 22233651 rs2842258 chr1 5790498 A G 8.72E-04 Type 2 diabetes / / 17463246 rs17028719 chr1 5795008 A G 8.90E-07 Alcohol dependence / / 22096494 rs17028719 chr1 5795008 A G 3.20E-06 Alcohol and nictotine co-dependence / / 22488850 rs17429690 chr1 5814135 G A 4.58E-04 Multiple complex diseases / / 17554300 rs9661578 chr1 5881752 C T 4.53E-05 Cocaine dependence / / 23958962 rs9661578 chr1 5881752 C T 6.10E-05 Cocaine dependence / / 23958962 rs548726 chr1 5913621 T C 5.00E-07 Response to taxane treatment (placlitaxel) / / 23006423 rs4908559 chr1 5944138 A G 1.77E-04 Smoking cessation NPHP4 intron 18519826 rs4908559 chr1 5944138 A G 6.32E-04 Smoking cessation NPHP4 intron 18519826 rs2282281 chr1 5948677 G A 3.19E-07 Smoking cessation NPHP4 intron 18519826 rs3747987 chr1 5966119 T C 5.74E-05 Smoking cessation NPHP4 intron 18519826 rs551207 chr1 6007446 C T 9.65E-05 Height NPHP4 intron pha003011 rs4908458 chr1 6033973 C T 0.000085 Panic disorder NPHP4 intron 23149450 rs4908458 chr1 6033973 C T 8.50E-05 Serum tamsulosin hydrochloride concentration NPHP4 intron 23151678 rs4908639 chr1 6038583 G C 1.32E-06 Smoking cessation NPHP4 intron 18519826 rs806104 chr1 6042934 G A 2.40E-04 Bipolar disorder NPHP4 intron 19259986 rs4908728 chr1 6102419 C T 9.28E-05 Femoral neck bone geometry KC/B2 intron 22087292 rs6685332 chr1 6109173 G A 3.40E-04 Response to cytadine analogues (cytosine arabinoside) KC/B2 intron 24483146 rs3789541 chr1 6141325 G A 1.54E-05 Bone mineral density KC/B2 intron 19181680 rs3789541 chr1 6141325 G A 1.69E-04 Alzheimer's disease (late onset) KC/B2 intron 21379329 rs7531562 chr1 6177202 G T 5.66E-04 Multiple complex diseases CHD5 intron 17554300 rs731975 chr1 6222501 C A 4.80E-05 Cognitive function CHD5 intron 24684796 rs709209 chr1 6278414 A G 1.07E-07 QT interval RNF207 missense 19305409 rs846111 chr1 6279370 G C 1.00E-16 QT interval RNF207 missense 19305408 rs846111 chr1 6279370 G C 4.00E-16 QT interval RNF207 missense 19305409 rs4908541 chr1 6291810 A G 8.58E-05 Cognitive test performance ICMT intron 20125193 rs114389068 chr1 6314183 C T 0.0000607 Menopause (age at onset) GPR153 cds-synon 23424626 rs10489535 chr1 6343825 G A 6.69E-04 Multiple complex diseases ACOT7 intron 17554300 rs17029376 chr1 6409979 A G 4.80E-04 Multiple complex diseases ACOT7 intron 17554300 rs4582826 chr1 6461530 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs373598296 chr1 6511582 AG A 6.32E-04 Smoking quantity ESPN intron 24665060 rs9434774 chr1 6511582 A G 6.32E-04 Smoking quantity ESPN intron 24665060 rs3007421 chr1 6530189 G A 7.70E-05 Alzheimer's disease PLEKHG5 intron 19136949 rs3007421 chr1 6530189 G A 7.79E-05 Waist Circumference PLEKHG5 intron pha003025 rs3935435 chr1 6572175 G A 1.10E-04 Myasthenia gravis PLEKHG5 intron 23055271 rs7540913 chr1 6581877 G A 7.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs13513 chr1 6585804 C T 5.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs7548042 chr1 6586070 C T 4.27E-04 Multiple complex diseases NOL9 intron 17554300 rs11122083 chr1 6593532 G A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10746502 chr1 6607199 T C 2.61E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10864625 chr1 6614230 G A 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs10864625 chr1 6614230 G A 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs925745 chr1 6615690 A G 0.00008794 Sarcoidosis TAS1R1 intron 22952805 rs11587438 chr1 6631431 C T 4.00E-06 White blood cell types TAS1R1 intron 21738478 rs11122100 chr1 6638064 T C 3.94E-05 Cognitive performance TAS1R1 intron 19734545 rs4908932 chr1 6639847 G T 1.37E-04 Tourette syndrome / / 22889924 rs731024 chr1 6644723 G A 4.58E-04 Alcohol dependence ZBTB48 intron 24277619 rs731024 chr1 6644723 G A 7.96E-04 Response to alcohol consumption (flushing response) ZBTB48 intron 24277619 rs1556036 chr1 6651728 C T 1.06E-04 Multiple complex diseases KLHL21 UTR-3 17554300 rs1556036 chr1 6651728 C T 4.54E-05 Heart Rate KLHL21 UTR-3 pha003051 rs4587589 chr1 6657355 C T 1.07E-04 Multiple complex diseases KLHL21 intron 17554300 rs11583755 chr1 6672729 A C 2.30E-05 Crohn's disease (time to surgery) / / 23665963 rs10779795 chr1 6677064 A G 8.53E-04 Alcohol dependence PHF13 intron 24277619 rs2072948 chr1 6679848 C T 6.73E-05 Blood Pressure PHF13 intron pha003049 rs2235564 chr1 6713114 C T 5.97E-05 Multiple complex diseases D/JC11 intron 17554300 rs2235564 chr1 6713114 C T 1.81E-05 Blood Pressure D/JC11 intron pha003049 rs6577584 chr1 6715390 T G 1.86E-05 Blood Pressure D/JC11 intron pha003049 rs2281190 chr1 6720990 C A 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs6659873 chr1 6723806 T G 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs277686 chr1 6747897 C G 9.43E-05 Multiple complex diseases D/JC11 intron 17554300 rs278020 chr1 6764643 C T 9.62E-04 Alcohol dependence / / 24277619 rs278021 chr1 6764663 T C 2.90E-05 Kidney function and endocine traits / / 17903292 rs277672 chr1 6771607 G T 5.32E-04 Multiple complex diseases / / 17554300 rs202577 chr1 6784053 A G 5.59E-04 Multiple complex diseases / / 17554300 rs449250 chr1 6797684 G A 5.90E-05 Coronary restenosis / / 21878436 rs422111 chr1 6823923 A G 2.50E-05 Urinary metabolites / / 21572414 rs448886 chr1 6829582 C A 2.50E-05 Malaria / / 19465909 rs12088027 chr1 6884248 T C 4.20E-04 Heart Failure CAMTA1 intron pha002884 rs10864244 chr1 6908448 G A 5.40E-05 Coffee consumption CAMTA1 intron 21357676 rs17029988 chr1 6938689 C T 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CAMTA1 intron 20031582 rs12751613 chr1 6978622 A C 6.74E-04 Heart Failure CAMTA1 intron pha002884 rs11586158 chr1 7002266 A G 7.97E-04 Smoking quantity CAMTA1 intron 24665060 rs7538627 chr1 7006698 T A 4.45E-04 Smoking quantity CAMTA1 intron 24665060 rs7554752 chr1 7014444 G A 3.15E-04 Smoking quantity CAMTA1 intron 24665060 rs884736 chr1 7015105 T C 0.0001 Gains in maximal O2 uptake response CAMTA1 intron 21183627 rs884736 chr1 7015105 T C 7.45E-05 Coronary restenosis CAMTA1 intron 21878436 rs1013248 chr1 7019816 T G 4.96E-04 Alzheimer's disease CAMTA1 intron 17998437 rs17030082 chr1 7029262 G A 4.28E-04 Alzheimer's disease CAMTA1 intron 17998437 rs6679134 chr1 7035830 A G 2.02E-04 Alzheimer's disease CAMTA1 intron 17998437 rs1317016 chr1 7048043 C G 5.01E-05 Blood pressure CAMTA1 intron 24001895 rs12043302 chr1 7055024 C T 6.95E-05 Waist Circumference CAMTA1 intron pha003023 rs17030152 chr1 7083719 T C 3.46E-04 Barrett's esophagus CAMTA1 intron 24121790 rs6686587 chr1 7099660 G A 1.68E-04 Heart Failure CAMTA1 intron pha002884 rs4908591 chr1 7110510 G A 2.71E-04 Alzheimer's disease (late onset) CAMTA1 intron 21379329 rs11120822 chr1 7113112 G C 1.00E-06 Stearic acid (18:0) plasma levels CAMTA1 intron 23362303 rs7553100 chr1 7117542 A G 5.80E-06 Urinary metabolites CAMTA1 intron 21572414 rs10779671 chr1 7119489 A G 4.60E-06 Urinary metabolites CAMTA1 intron 21572414 rs9434833 chr1 7144893 C T 2.30E-06 Urinary metabolites CAMTA1 intron 21572414 rs4908443 chr1 7179721 T C 1.08E-04 Parkinson's disease CAMTA1 intron 17052657 rs4908443 chr1 7179721 T C 6.68E-06 Coronary heart disease CAMTA1 intron pha003030 rs7527889 chr1 7213619 C T 4.33E-05 Multiple complex diseases CAMTA1 intron 17554300 rs6680365 chr1 7236810 A G 0.0000538 Migraine CAMTA1 intron 22678113 rs6680365 chr1 7236810 A G 5.38E-05 Migraine CAMTA1 intron 22683712 rs1304711 chr1 7270320 A C 9.95E-04 Type 2 diabetes CAMTA1 intron 17463246 rs17030589 chr1 7278776 C G 5.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs4908449 chr1 7292700 T C 2.00E-05 Episodic memory CAMTA1 intron 17470457 rs6577427 chr1 7314231 T C 6.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs7547519 chr1 7316136 A G 7.00E-09 Episodic memory CAMTA1 intron 17470457 rs7549382 chr1 7320903 C G 1.00E-04 Episodic memory CAMTA1 intron 17470457 rs2071924 chr1 7352974 G A 4.84E-04 Lung function (forced vital capacity) CAMTA1 intron 24023788 rs10489142 chr1 7363310 A G 7.16E-04 Alcohol dependence CAMTA1 intron 21314694 rs6668927 chr1 7377498 C T 8.98E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12563394 chr1 7380747 A G 4.56E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12739426 chr1 7386456 C A 4.91E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301460 chr1 7389944 A C 3.25E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301461 chr1 7389977 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits CAMTA1 intron 17848626 rs705680 chr1 7402502 T C 6.68E-04 Multiple complex diseases CAMTA1 intron 17554300 rs845244 chr1 7406114 A G 7.96E-04 Multiple complex diseases CAMTA1 intron 17554300 rs705677 chr1 7409910 A C 2.00E-04 Episodic memory CAMTA1 intron 17470457 rs845237 chr1 7412051 A G 7.94E-04 Smoking cessation CAMTA1 intron 24665060 rs1894655 chr1 7417290 T C 8.38E-04 Alzheimer's disease CAMTA1 intron 22005930 rs4908626 chr1 7422216 G T 5.54E-04 Alzheimer's disease CAMTA1 intron 22005930 rs6677597 chr1 7422919 G T 5.45E-04 Alzheimer's disease CAMTA1 intron 22005930 rs1418489 chr1 7425064 A G 2.52E-06 Asthma (childhood onset) CAMTA1 intron 23829686 rs845222 chr1 7429092 T G 7.74E-04 Type 2 diabetes CAMTA1 intron 17463246 rs3752543 chr1 7430394 T C 5.39E-04 Alzheimer's disease CAMTA1 intron 22005930 rs11579620 chr1 7432615 G A 4.71E-04 Alzheimer's disease CAMTA1 intron 22005930 rs845218 chr1 7433862 T C 4.04E-04 Smoking cessation CAMTA1 intron 24665060 rs6677949 chr1 7445435 C A 2.30E-04 Smoking cessation CAMTA1 intron 24665060 rs845233 chr1 7446240 T C 2.26E-04 Smoking cessation CAMTA1 intron 24665060 rs7524314 chr1 7449971 G A 6.85E-05 Body Mass Index CAMTA1 intron pha003020 rs2097518 chr1 7460433 G A 3.67E-04 Alzheimer's disease CAMTA1 intron 17998437 rs11120917 chr1 7478076 C T 1.45E-05 Anxiety in major depressive disorder CAMTA1 intron 24047446 rs11120917 chr1 7478076 C T 9.19E-04 Heart Failure CAMTA1 intron pha002884 rs11120921 chr1 7485306 C T 4.90E-04 Response to taxane treatment (placlitaxel) CAMTA1 intron 23006423 rs17030828 chr1 7491320 C T 3.81E-04 Type 2 diabetes CAMTA1 intron 17463246 rs947678 chr1 7492616 A C 6.00E-04 Episodic memory CAMTA1 intron 17470457 rs1193221 chr1 7492991 T G 4.72E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs1307984 chr1 7497547 C T 9.31E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs2185789 chr1 7500182 G A 7.26E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs17030881 chr1 7502288 A C,G 5.13E-05 Type 2 diabetes CAMTA1 intron 17463246 rs17030881 chr1 7502288 A C,G 2.06E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12119558 chr1 7504737 G A 5.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMTA1 intron 20877124 rs1616122 chr1 7521585 C T 5.00E-06 Periodontal microbiota CAMTA1 intron 22699663 rs1149332 chr1 7528846 C T 5.00E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 5.79E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 9.00E-07 Puberty onset (breast development) CAMTA1 intron 24770850 rs2796483 chr1 7541345 C T 9.70E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs17030993 chr1 7549488 T C 7.91E-05 Coronary heart disease CAMTA1 intron pha003056 rs1750849 chr1 7552326 G C 4.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs12033734 chr1 7566789 C G 9.48E-04 Insulin resistance CAMTA1 intron 21901158 rs12063665 chr1 7568588 T G 1.70E-05 Non-word repetition CAMTA1 intron 23738518 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 17293876 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 19184112 rs7536730 chr1 7635253 G T 4.99E-04 Multiple complex diseases CAMTA1 intron 17554300 rs941017 chr1 7655998 T C 4.87E-05 Cognitive impairment induced by topiramate CAMTA1 intron 22091778 rs6691275 chr1 7670013 T C 3.10E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs2056674 chr1 7670217 T A 5.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs4908663 chr1 7712132 G A 1.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAMTA1 intron 24023788 rs17376559 chr1 7718093 G A 9.40E-05 Serum metabolites CAMTA1 intron 19043545 rs3011925 chr1 7721360 G A 3.00E-06 PR interval in Tripanosoma cruzi seropositivity CAMTA1 intron 24324551 rs1891215 chr1 7727854 T C 7.64E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs1891216 chr1 7728391 T G 9.66E-06 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6661392 chr1 7735950 C T 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6673977 chr1 7736097 A G 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs2995032 chr1 7753132 T C 4.39E-06 Multiple complex diseases CAMTA1 intron 17554300 rs2995034 chr1 7770901 C T 4.43E-06 Multiple complex diseases CAMTA1 intron 17554300 rs12563101 chr1 7777673 G A 1.15E-11 Metabolite levels CAMTA1 intron 22286219 rs2032563 chr1 7801288 G A 4.02E-04 Longevity CAMTA1 intron 22279548 rs9919223 chr1 7812398 A G 9.18E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12093175 chr1 7818318 G T 2.53E-04 Multiple complex diseases CAMTA1 intron 17554300 rs41402249 chr1 7822723 G C 3.37E-04 Multiple complex diseases CAMTA1 intron 17554300 rs11587479 chr1 7823085 A C 5.40E-05 Stroke CAMTA1 intron pha002886 rs707458 chr1 7832212 C T 6.82E-05 Crohn's disease VAMP3 intron 18587394 rs697673 chr1 7837842 T C 2.64E-05 Stroke VAMP3 intron pha002886 rs228641 chr1 7862899 T C 6.93E-04 Smoking initiation PER3 intron 24665060 rs35426314 chr1 7869968 G A 4.28E-16 HDL cholesterol PER3 missense 23063622 rs4908482 chr1 7877488 A G 8.48E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs2797685 chr1 7879063 C T 7.00E-09 Crohn's disease PER3 intron 21102463 rs228688 chr1 7879130 T G 7.40E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs228691 chr1 7880469 A G 9.71E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs10462020 chr1 7880683 T G 8.39E-06 Type 2 diabetes PER3 missense 21647700 rs228694 chr1 7883834 A G 9.73E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs707472 chr1 7906008 G T 3.63E-06 Crohn's disease / / 18587394 rs12566535 chr1 7924094 G A 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs504560 chr1 7926542 A G 9.16E-05 Asthma / / pha003127 rs228725 chr1 7929819 T C 0.000130044 Primary sclerosing cholangitis / / 23603763 rs228703 chr1 7944264 A G 4.96E-04 Aortic root size / / 21223598 rs227163 chr1 7961206 C T 3.00E-09 Rheumatoid arthritis / / 24390342 rs227163 chr1 7961206 C T 3.90E-04 Rheumatoid arthritis / / 24390342 rs664673 chr1 7970075 C T 7.70E-05 Endometriosis / / 21151130 rs679563 chr1 7971078 G A 6.40E-04 Endometriosis / / 23104006 rs161811 chr1 7999602 C T 5.65E-04 Multiple complex diseases TNFRSF9 intron 17554300 rs9657955 chr1 8001358 G A 0.000000484 Triglycerides TNFRSF9 intron 23063622 rs226473 chr1 8008968 T C 9.52E-05 Atrial fibrillation / / 21846873 rs35675666 chr1 8021973 G T 5.00E-09 Ulcerative colitis PARK7 intron 21297633 rs35675666 chr1 8021973 G T 1.00E-15 Inflammatory bowel disease PARK7 intron 23128233 rs161802 chr1 8042826 G T 2.00E-07 Stroke (ischemic) PARK7 intron 24262325 rs12727642 chr1 8046672 C A 9.00E-08 Celiac disease / / 20190752 rs12727642 chr1 8046672 C A 5.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs225132 chr1 8095500 T G 6.00E-08 Stroke (ischemic) / / 24262325 rs12748993 chr1 8129507 A G 9.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7539255 chr1 8133352 T C 6.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10864330 chr1 8168564 C T 8.00E-05 Lung adenocarcinoma / / 22797724 rs7527904 chr1 8189854 T C 0.0000861 Primary sclerosing cholangitis / / 23603763 rs7542367 chr1 8199263 T C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs9434617 chr1 8200328 T C 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs1455701 chr1 8213010 T C 6.99E-05 HDL cholesterol / / pha003075 rs11121129 chr1 8268095 G A 2.16E-04 Scoliosis / / 21216876 rs11121129 chr1 8268095 G A 0.000000017 Psoriasis / / 23143594 rs411654 chr1 8274807 A G 5.64E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs385137 chr1 8274963 T C 4.35E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs421490 chr1 8275284 A G 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7513908 chr1 8302619 G A 1.90E-05 Major depressive disorder / / 21042317 rs438895 chr1 8338355 G A 7.00E-06 Economic and political preferences / / 22566634 rs11121152 chr1 8357221 C T 8.04E-04 Multiple complex diseases / / 17554300 rs12727604 chr1 8365102 G A 4.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9628987 chr1 8386730 A C 5.00E-06 Breast cancer SLC45A1 intron 23468962 rs2305016 chr1 8395441 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) SLC45A1 intron 20708005 rs202161082 chr1 8397995 G A 0.00015 Breast cancer SLC45A1 missense 23555315 rs2252865 chr1 8422676 T C 3.00E-06 Schizophrenia RERE intron 21926974 rs2252865 chr1 8422676 T C 1.78E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 2.38E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 3.54E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.26E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 8.16E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 9.41E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) RERE intron 23453885 rs2252865 chr1 8422676 T C 0.000219 Bipolar disorder RERE intron 23637625 rs2252865 chr1 8422676 T C 0.000476 Schizophrenia RERE intron 23637625 rs10779702 chr1 8423510 A G 4.75E-04 Prostate cancer mortality RERE intron 20978177 rs894875 chr1 8432136 C T 3.85E-04 Self-reported allergy RERE intron 23817569 rs6678140 chr1 8436802 C T 2.81E-04 Self-reported allergy RERE intron 23817569 rs2708633 chr1 8439625 C A 2.68E-04 Self-reported allergy RERE intron 23817569 rs3765971 chr1 8445360 C T 2.61E-04 Self-reported allergy RERE intron 23817569 rs2120461 chr1 8447722 C T 3.00E-06 Bone mineral density RERE intron 22504420 rs2120461 chr1 8447722 C T 2.15E-04 Self-reported allergy RERE intron 23817569 rs2661863 chr1 8452725 T C 2.55E-04 Self-reported allergy RERE intron 23817569 rs301791 chr1 8468372 A T 8.20E-05 Prostate cancer mortality RERE intron 20978177 rs301791 chr1 8468372 A T 2.59E-04 Self-reported allergy RERE intron 23817569 rs301790 chr1 8469284 G C 1.93E-04 Self-reported allergy RERE intron 23817569 rs301789 chr1 8469337 A G 2.59E-04 Self-reported allergy RERE intron 23817569 rs1763839 chr1 8473336 G A 3.35E-04 Self-reported allergy RERE intron 23817569 rs302714 chr1 8486131 A C 1.74E-04 Self-reported allergy RERE intron 23817569 rs301797 chr1 8487323 C A 2.66E-04 Self-reported allergy RERE intron 23817569 rs301798 chr1 8488565 A G 8.07E-07 Glaucoma-related traits RERE intron 22058429 rs301798 chr1 8488565 A G 2.53E-04 Self-reported allergy RERE intron 23817569 rs301799 chr1 8489302 C T 3.00E-06 Thyroid peroxidase antibody positivity RERE intron 24586183 rs302719 chr1 8490320 T G 5.03E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 4.03E-05 Schizophrenia RERE intron 19571811 rs172531 chr1 8495590 A G 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 2.32E-04 Self-reported allergy RERE intron 23817569 rs301801 chr1 8495945 T C 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs301801 chr1 8495945 T C 2.33E-04 Self-reported allergy RERE intron 23817569 rs2784739 chr1 8497558 T G 6.76E-04 Self-reported allergy RERE intron 23817569 rs301803 chr1 8498680 A T 2.08E-04 Self-reported allergy RERE intron 23817569 rs2784740 chr1 8501057 T A 6.11E-04 Self-reported allergy RERE intron 23817569 rs301819 chr1 8501786 A G 5.84E-05 Vitiligo RERE intron 20410501 rs301819 chr1 8501786 A G 8.85E-09 Vitiligo RERE intron 21326295 rs301818 chr1 8503242 G A 2.78E-04 Self-reported allergy RERE intron 23817569 rs11121182 chr1 8522553 C A 1.70E-05 Urinary metabolites RERE intron 21572414 rs4908760 chr1 8526142 G A 7.00E-15 Vitiligo RERE intron 20410501 rs4908760 chr1 8526142 G A 3.54E-14 Vitiligo RERE intron 22561518 rs11806357 chr1 8526642 T C 1.85E-05 Multiple complex diseases RERE intron 17554300 rs11121194 chr1 8569906 C T 5.77E-04 Vitiligo RERE intron 20410501 rs17386406 chr1 8643497 G A 9.71E-04 Type 2 diabetes RERE intron 17463246 rs6679128 chr1 8702530 C T 9.07E-05 Multiple complex diseases RERE intron 17554300 rs7547833 chr1 8742451 C T 8.18E-05 Alzheimer's disease RERE intron 22005930 rs11121220 chr1 8755282 A G 1.61E-05 Multiple complex diseases RERE intron 17554300 rs12025126 chr1 8759554 T C 6.00E-08 Vertical cup-disc ratio RERE intron 20548946 rs12025126 chr1 8759554 T C 2.66E-04 Glaucoma-related traits RERE intron 22058429 rs12025126 chr1 8759554 T C 3.18E-04 Glaucoma-related traits RERE intron 22058429 rs4908773 chr1 8769728 T C 4.95E-04 Type 2 diabetes RERE intron 17463246 rs4908778 chr1 8804888 C G 5.85E-04 Smoking initiation RERE intron 24665060 rs12024032 chr1 8808185 C T 4.82E-04 Type 2 diabetes RERE intron 17463246 rs4908511 chr1 8812390 G C 5.28E-04 Type 2 diabetes RERE intron 17463246 rs12410886 chr1 8878809 A C 7.90E-05 Birth weight / / 17255346 rs11582339 chr1 8898807 G T 1.43E-04 Birth weight / / 17255346 rs10864368 chr1 8918313 T C 2.50E-05 Urinary metabolites / / 21572414 rs4418632 chr1 8994112 T C 1.23E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12091891 chr1 9000220 A G 8.56E-04 Alcohol dependence / / 20201924 rs1475734 chr1 9000628 G T 0.000695441 Hypertension (early onset hypertension) / / 22479346 rs11809994 chr1 9005269 A C 0.000013 Mean arterial pressure / / 22510845 rs1409147 chr1 9005320 A G 0.0000063 Panic disorder / / 23149450 rs1409147 chr1 9005320 A G 6.30E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs2274327 chr1 9009406 C T 7.10E-04 Multiple complex diseases CA6 missense 17554300 rs2274327 chr1 9009406 C T 3.74E-04 Smoking initiation CA6 missense 24665060 rs2274328 chr1 9009444 A C 1.96E-04 Body mass index CA6 missense 17255346 rs7513804 chr1 9045124 C T 1.10E-04 Multiple complex diseases / / 17554300 rs9803645 chr1 9049872 C T 4.90E-05 Cognitive test performance / / 20125193 rs12031065 chr1 9079154 C T 2.73E-05 Non-small cell lung cancer SLC2A7 intron 21866343 rs12145292 chr1 9118596 C A 7.96E-05 Orofacial clefts SLC2A5 intron 22419666 rs6694527 chr1 9119028 G A 1.32E-11 HDL cholesterol SLC2A5 intron 23063622 rs3820034 chr1 9129867 G A 1.24E-05 Follicle stimulating hormone SLC2A5 UTR-5 24049095 rs12080794 chr1 9151325 C T 9.00E-06 Response to antidepressant treatment (citalopram) / / 23726668 rs1001567 chr1 9194614 G T 3.08E-05 Atopy / / 21625490 rs11802925 chr1 9228624 T C 9.09E-05 Schizophrenia / / 19571809 rs4908527 chr1 9234143 C T 1.80E-05 Urinary metabolites / / 21572414 rs10489436 chr1 9285721 A G 8.83E-04 Longevity / / 22279548 rs6662509 chr1 9317604 C T 3.00E-10 Height H6PD intron 23563607 rs9435168 chr1 9331952 A G 7.64E-06 Fibrinogen / / pha003068 rs7517538 chr1 9332703 T C 1.06E-07 Lymphocyte counts / / 22286170 rs1294028 chr1 9364634 A G 2.00E-04 Schizophrenia SPSB1 intron 19197363 rs630075 chr1 9370911 A G 7.00E-05 Triglycerides SPSB1 intron 19074352 rs9660159 chr1 9382469 G A 5.27E-04 Amyotrophic lateral sclerosis (sporadic) SPSB1 intron 24529757 rs4908842 chr1 9387311 T C 5.90E-05 Triglycerides SPSB1 intron 19074352 rs926247 chr1 9394008 T C 2.97E-04 Type 2 diabetes SPSB1 intron 17463246 rs478103 chr1 9402403 T C 2.02E-05 Sudden cardiac arrest SPSB1 intron 21658281 rs11121380 chr1 9408959 A C 5.00E-08 Response to tocilizumab in rheumatoid arthritis SPSB1 intron 22491018 rs11121382 chr1 9411469 G C 4.09E-06 Parkinson's disease (motor and cognition) SPSB1 intron 22658654 rs11121382 chr1 9411469 G C 4.00E-06 Immune response to anthrax vaccine SPSB1 intron 22658931 rs9435244 chr1 9417946 G A 1.90E-05 Urinary metabolites SPSB1 intron 21572414 rs9435245 chr1 9419290 T C 2.80E-06 Urinary metabolites SPSB1 intron 21572414 rs9308447 chr1 9432390 C T 5.00E-07 Dental caries / / 23064961 rs17393334 chr1 9432911 G A 1.45E-05 Major depressive disorder / / 19107115 rs17393468 chr1 9438540 T C 1.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9787285 chr1 9499246 G A 7.24E-05 Myopia (pathological) / / 23049088 rs9787285 chr1 9499246 G A 4.57E-05 Hodgkin's lymphoma / / 24149102 rs10735516 chr1 9507004 T G 0.000098 Salmonella-induced pyroptosis / / 22837397 rs12034064 chr1 9508955 T C 5.23E-04 Hodgkin's lymphoma / / 24149102 rs10864424 chr1 9510088 G T 5.14E-05 Glucose levels / / pha003057 rs10746490 chr1 9525697 G A 2.57E-04 Common variable immunodeficiency / / 21497890 rs6679380 chr1 9533238 C T 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs12023288 chr1 9602962 C A 2.77E-04 Alzheimer's disease SLC25A33 intron 24755620 rs11121441 chr1 9610125 C T 9.12E-05 Multiple complex diseases SLC25A33 intron 17554300 rs6660810 chr1 9615158 G A 7.02E-04 Alzheimer's disease SLC25A33 intron 24755620 rs4423053 chr1 9621407 A G 3.75E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430273 chr1 9624113 C A 3.84E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430274 chr1 9624285 A G 4.22E-04 Alzheimer's disease SLC25A33 intron 24755620 rs12124860 chr1 9627103 G A 7.74E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430152 chr1 9632396 T G 3.29E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430153 chr1 9637227 A G 3.18E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430332 chr1 9645372 C T 3.18E-04 Alzheimer's disease / / 24755620 rs9430174 chr1 9647137 G A 3.28E-04 Alzheimer's disease / / 24755620 rs6669846 chr1 9650571 C T 1.91E-04 Multiple complex diseases TMEM201 intron 17554300 rs6540961 chr1 9650729 A G 4.60E-04 Alzheimer's disease TMEM201 intron 24755620 rs3923984 chr1 9653835 A G 7.57E-04 Alzheimer's disease TMEM201 intron 24755620 rs7544083 chr1 9654197 T C 5.89E-04 Alzheimer's disease TMEM201 intron 24755620 rs4073710 chr1 9655795 G A 1.71E-04 Glycosylated haemoglobin levels TMEM201 intron 17255346 rs11121464 chr1 9695888 T C 4.60E-05 Intracerebral hemorrhage / / 24656865 rs12568084 chr1 9734287 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs12568084 chr1 9734287 G A 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs9430635 chr1 9738786 C G 3.63E-04 Multiple complex diseases PIK3CD intron 17554300 rs4240910 chr1 9750457 T C 9.15E-04 Multiple complex diseases PIK3CD intron 17554300 rs11121482 chr1 9777529 A G 0.00000146 Cholesterol,total PIK3CD intron 23063622 rs12032209 chr1 9897001 A C 1.10E-05 Urinary metabolites / / 21572414 rs1933734 chr1 9902128 T C 9.36E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1220421 chr1 10008221 G A 2.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NM/T1 intron 20031582 rs7516611 chr1 10013014 A C,G,T 8.80E-06 Urinary metabolites NM/T1 intron 21572414 rs2890358 chr1 10027540 G A 3.00E-06 Lymphocyte counts NM/T1 intron 22286170 rs12082318 chr1 10036009 G A 9.07E-05 Cognitive impairment induced by topiramate NM/T1 intron 22091778 rs12136213 chr1 10046460 A G 4.05E-04 Alzheimer's disease (late onset) / / 21379329 rs12140058 chr1 10049177 T G 0.000858 Antisocial behavior / / 23077488 rs2295294 chr1 10190884 A T 0.0000086 Lumbar spine bone mineral density UBE4B intron 22692763 rs2295294 chr1 10190884 A T 0.000377 Lumbar spine bone mineral density (males) UBE4B intron 22692763 rs12092513 chr1 10231463 C T 1.18E-05 Coronary heart disease UBE4B intron pha003032 rs11121524 chr1 10232534 C G 5.45E-04 Alcohol dependence UBE4B intron 21314694 rs2180184 chr1 10235946 T C 5.36E-04 Self-reported allergy UBE4B intron 23817569 rs6541080 chr1 10236039 G A 2.50E-05 Urinary metabolites UBE4B intron 21572414 rs7418410 chr1 10236402 C T 4.34E-04 Alzheimer's disease (late onset) UBE4B intron 21379329 rs7418410 chr1 10236402 C T 1.10E-05 Urinary metabolites UBE4B intron 21572414 rs2180185 chr1 10246129 G C 1.40E-05 Urinary metabolites / / 21572414 rs4348727 chr1 10265606 G A 1.51E-04 Self-reported allergy / / 23817569 rs17396340 chr1 10286176 G A 3.00E-08 Mean platelet volume KIF1B intron 22139419 rs10492969 chr1 10286358 T C 8.90E-04 Type 2 diabetes and 6 quantitative traits KIF1B intron 17848626 rs12751375 chr1 10291874 C G 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs374529040 chr1 10291874 C CAG 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs12136376 chr1 10296452 C T 1.22E-04 Self-reported allergy KIF1B intron 23817569 rs12755094 chr1 10305711 T C 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs6700866 chr1 10306038 A G 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs946501 chr1 10309580 G C 4.52E-04 Self-reported allergy KIF1B intron 23817569 rs4846207 chr1 10313811 T C 4.50E-04 Self-reported allergy KIF1B intron 23817569 rs4846208 chr1 10313839 T C 1.39E-04 Self-reported allergy KIF1B intron 23817569 rs12402052 chr1 10318652 C G 1.24E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846210 chr1 10322153 A G 1.27E-04 Self-reported allergy KIF1B intron 23817569 rs12757288 chr1 10323921 T C 4.14E-04 Self-reported allergy KIF1B intron 23817569 rs12064209 chr1 10326184 C G 1.02E-04 Multiple complex diseases KIF1B intron 17554300 rs1339458 chr1 10328338 C T 1.31E-04 Self-reported allergy KIF1B intron 23817569 rs12131785 chr1 10341516 C T 1.50E-05 Bulimia nervosa KIF1B intron 23568457 rs912962 chr1 10348712 A C 9.60E-05 Triglycerides KIF1B intron 19074352 rs10492972 chr1 10353112 T C 3.00E-10 Multiple sclerosis KIF1B intron 18997785 rs7520935 chr1 10354271 G T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs3753037 chr1 10355834 C T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs2275424 chr1 10356562 C A 1.44E-04 Self-reported allergy KIF1B intron 23817569 rs1536263 chr1 10378914 T C 1.23E-04 Self-reported allergy KIF1B intron 23817569 rs17401924 chr1 10384439 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs17401966 chr1 10385471 A G 2.00E-18 Hepatocellular carcinoma KIF1B intron 20676096 rs17401966 chr1 10385471 A G 1.70E-18 Hepatitis B KIF1B intron 21750111 rs17401966 chr1 10385471 A G 1.70E-18 Hepatocellular carcinoma (hepatitis B virus related) KIF1B intron 23242368 rs17401966 chr1 10385471 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs12734551 chr1 10391536 T G 1.10E-04 Self-reported allergy KIF1B intron 23817569 rs1556916 chr1 10403482 G A 3.80E-04 Self-reported allergy KIF1B intron 23817569 rs11576866 chr1 10414432 A G 1.01E-04 Self-reported allergy KIF1B intron 23817569 rs7546364 chr1 10418815 G A 3.67E-04 Self-reported allergy KIF1B intron 23817569 rs3748578 chr1 10420918 G A 1.12E-04 Self-reported allergy KIF1B intron 23817569 rs12403443 chr1 10423988 A G 5.81E-06 Self-reported allergy KIF1B intron 23817569 rs17411502 chr1 10431158 T C 9.65E-05 Self-reported allergy KIF1B intron 23817569 rs11121551 chr1 10435170 T C 3.89E-04 Self-reported allergy KIF1B intron 23817569 rs11121552 chr1 10435324 C A 1.15E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846216 chr1 10447792 T A 5.16E-04 Lymphocyte counts LOC100287506 intron 22286170 rs6679596 chr1 10454502 A T 6.43E-04 Type 2 diabetes LOC100287506 intron 17463246 rs3737155 chr1 10459779 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits PGD intron 17848626 rs3737155 chr1 10459779 G A 2.39E-04 Self-reported allergy PGD intron 23817569 rs1889309 chr1 10479678 G A 1.23E-04 Self-reported allergy PGD intron 23817569 rs544289 chr1 10499236 A G 2.19E-04 Alzheimer's disease APITD1 intron 24755620 rs2847337 chr1 10502710 A G 4.80E-05 Alzheimer's disease APITD1 UTR-3 24755620 rs1307489 chr1 10507236 A G 4.80E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307490 chr1 10508679 T C 5.17E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307494 chr1 10509703 C T 5.27E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs666103 chr1 10511589 T C 1.01E-04 Alzheimer's disease CORT cds-synon 24755620 rs1307497 chr1 10512056 T C 8.91E-06 Alzheimer's disease CORT UTR-3 21627779 rs1307497 chr1 10512056 T C 9.03E-04 Self-reported allergy CORT UTR-3 23817569 rs1307497 chr1 10512056 T C 1.78E-04 Alzheimer's disease CORT UTR-3 24755620 rs6540931 chr1 10512509 T C 9.11E-04 Self-reported allergy / / 23817569 rs2483686 chr1 10515414 T C 1.03E-04 Alzheimer's disease / / 24755620 rs944973 chr1 10516393 C G 3.35E-06 Alzheimer's disease / / 21627779 rs685746 chr1 10537437 C G 2.33E-06 Self-reported allergy PEX14 intron 23817569 rs607941 chr1 10539543 C T 1.01E-05 Self-reported allergy PEX14 intron 23817569 rs668805 chr1 10544547 G A 7.24E-07 Self-reported allergy PEX14 intron 23817569 rs669701 chr1 10544725 A G 1.53E-06 Self-reported allergy PEX14 intron 23817569 rs596537 chr1 10554709 G T 2.49E-06 Self-reported allergy PEX14 intron 23817569 rs620405 chr1 10554794 T C 2.41E-06 Self-reported allergy PEX14 intron 23817569 rs622623 chr1 10555257 C T 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs636291 chr1 10556097 G A 3.21E-06 Self-reported allergy PEX14 intron 23817569 rs648324 chr1 10556447 G T 1.55E-06 Self-reported allergy PEX14 intron 23817569 rs648399 chr1 10556485 T C 1.66E-06 Self-reported allergy PEX14 intron 23817569 rs662064 chr1 10557251 T C 1.59E-06 Self-reported allergy PEX14 intron 23817569 rs660725 chr1 10557544 A G 1.84E-06 Self-reported allergy PEX14 intron 23817569 rs647281 chr1 10558210 G A 9.25E-05 Alzheimer's disease PEX14 intron 24755620 rs589400 chr1 10561282 A G 1.06E-06 Self-reported allergy PEX14 intron 23817569 rs2506901 chr1 10563492 A G 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs10864459 chr1 10563609 A G 2.01E-06 Self-reported allergy PEX14 intron 23817569 rs10864460 chr1 10563671 G C 4.48E-06 Self-reported allergy PEX14 intron 23817569 rs2506902 chr1 10563681 C T 2.10E-04 Primary sclerosing cholangitis PEX14 intron 19944697 rs2506902 chr1 10563681 C T 1.62E-06 Self-reported allergy PEX14 intron 23817569 rs2781230 chr1 10563717 G A 2.94E-06 Self-reported allergy PEX14 intron 23817569 rs2847344 chr1 10564675 G A 7.47E-07 Self-reported allergy PEX14 intron 23817569 rs616488 chr1 10566215 A G 2.00E-10 Breast cancer PEX14 intron 23535729 rs616488 chr1 10566215 A G 1.00E-08 Breast cancer PEX14 intron 23535733 rs616488 chr1 10566215 A G 3.79E-06 Self-reported allergy PEX14 intron 23817569 rs616402 chr1 10566272 C T 5.50E-07 Self-reported allergy PEX14 intron 23817569 rs12129512 chr1 10572967 G T 1.40E-04 Self-reported allergy PEX14 intron 23817569 rs1411402 chr1 10579545 G T 4.64E-07 Self-reported allergy PEX14 intron 23817569 rs2483677 chr1 10580891 C T 3.99E-07 Self-reported allergy PEX14 intron 23817569 rs2056417 chr1 10581658 G A 4.00E-07 Self-reported allergy PEX14 intron 23817569 rs2480782 chr1 10593296 G T 6.77E-04 Alzheimer's disease PEX14 intron 24755620 rs2026792 chr1 10594790 A G 7.02E-06 Self-reported allergy PEX14 intron 23817569 rs12375 chr1 10596341 C T 8.28E-06 Self-reported allergy PEX14 cds-synon 23817569 rs2480777 chr1 10597551 C T 9.76E-06 Self-reported allergy PEX14 intron 23817569 rs2506892 chr1 10598216 G A 1.27E-05 Self-reported allergy PEX14 intron 23817569 rs2480775 chr1 10606996 G T 3.09E-05 Neuroblastoma PEX14 intron pha002895 rs12120962 chr1 10609505 G A 5.26E-05 Hearing function PEX14 intron 17255346 rs10864463 chr1 10613560 A G 9.93E-05 Neuroblastoma PEX14 intron pha002895 rs12127400 chr1 10613660 C T 4.55E-05 Hearing function PEX14 intron 17255346 rs17035305 chr1 10616505 C A 1.53E-05 Self-reported allergy PEX14 intron 23817569 rs12028449 chr1 10617034 G A 1.62E-05 Self-reported allergy PEX14 intron 23817569 rs11121587 chr1 10618109 A G 1.38E-05 Self-reported allergy PEX14 intron 23817569 rs11121594 chr1 10626922 G C 4.04E-04 Alzheimer's disease PEX14 intron 17998437 rs6687502 chr1 10633273 G A 4.10E-04 Alzheimer's disease PEX14 intron 17998437 rs12741973 chr1 10638604 C T 7.00E-06 optic disc size (rim) PEX14 intron 20395239 rs284272 chr1 10653628 G T 5.48E-04 Smoking cessation PEX14 intron 24665060 rs10864468 chr1 10655709 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284267 chr1 10656351 C A 1.20E-04 Multiple complex diseases PEX14 intron 17554300 rs11121598 chr1 10658202 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs11121599 chr1 10666735 A G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs12722934 chr1 10668379 A T 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs6666075 chr1 10669098 C G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs3790630 chr1 10673094 C T 6.83E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284238 chr1 10678488 A T 1.61E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284237 chr1 10678610 G A 2.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284235 chr1 10678843 C T 7.11E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs190775 chr1 10683683 G T 2.39E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs185864 chr1 10687726 G C 9.06E-07 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284303 chr1 10690883 C T 9.06E-07 Alcohol dependence (age at onset) PEX14 nearGene-3 24962325 rs284301 chr1 10694125 G A 1.12E-06 Alcohol dependence (age at onset) / / 24962325 rs61776290 chr1 10694907 C T 2.00E-07 Alcohol dependence (age at onset) / / 24962325 rs284243 chr1 10705880 A G 2.90E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs778228 chr1 10708142 A G 1.64E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284300 chr1 10709309 C G 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284298 chr1 10710255 G A 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284296 chr1 10712089 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284295 chr1 10712097 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs2242287 chr1 10714911 T C 6.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs476164 chr1 10719566 T C 7.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284322 chr1 10725498 G A 5.54E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284320 chr1 10727020 T C 4.30E-04 Obesity,menopause CASZ1 intron 21424828 rs284320 chr1 10727020 T C 2.02E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs11121604 chr1 10730002 A G 3.11E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs61776326 chr1 10742120 G A 7.20E-07 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284261 chr1 10743749 G A 2.80E-04 Multiple complex diseases CASZ1 intron 17554300 rs516243 chr1 10750432 A G 9.00E-06 Migraine - clinic-based CASZ1 intron 23793025 rs11805515 chr1 10767785 T C 7.44E-05 Cognitive test performance CASZ1 intron 20125193 rs710133 chr1 10771488 C T 1.86E-04 Type 2 diabetes CASZ1 intron 17463246 rs284233 chr1 10777260 G A 9.38E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs284254 chr1 10786314 A G 6.14E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs880315 chr1 10796866 T C 3.00E-10 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 7.00E-07 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 1.52E-04 Blood pressure (age interaction) CASZ1 intron 24954895 rs880315 chr1 10796866 T C 5.45E-05 Blood pressure (age interaction) CASZ1 intron 24954895 rs12046278 chr1 10799577 T C 5.00E-06 Systolic blood pressure CASZ1 intron 19430479 rs12046278 chr1 10799577 T C 5.00E-06 Coronary heart disease CASZ1 intron 21347282 rs4845843 chr1 10801585 G A 3.63E-05 Multiple complex diseases CASZ1 intron 17554300 rs205483 chr1 10814938 C T 0.0000725 Nonsyndromic striae distensae (stretch marks) CASZ1 intron 23633020 rs205484 chr1 10815421 T C 4.49E-05 Blood pressure CASZ1 intron 17255346 rs205472 chr1 10832322 G A 7.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs205474 chr1 10832861 C T 3.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1613696 chr1 10838798 C T 2.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1776219 chr1 10874152 T G 3.62E-04 Multiple complex diseases / / 17554300 rs527676 chr1 10891777 G A 3.71E-04 Lymphocyte counts / / 22286170 rs4845960 chr1 10947580 G A 9.25E-05 ldl cholesterol / / pha003076 rs10864479 chr1 10968730 T G 9.01E-04 Type 2 diabetes / / 17463246 rs1280985 chr1 10984406 T A 1.90E-05 Coffee consumption / / 21357676 rs1281014 chr1 11009543 G A 4.47E-04 Multiple complex diseases C1orf127 intron 17554300 rs138476809 chr1 11009844 G A 0.00044 Breast cancer C1orf127 missense 23555315 rs2003046 chr1 11032827 C A 9.60E-07 Ewing sarcoma C1orf127 intron 22327514 rs2003046 chr1 11032827 C A 1.99E-10 Male-pattern baldness C1orf127 intron 22693459 rs12565727 chr1 11033082 A G 9.00E-11 Male-pattern baldness C1orf127 intron 22693459 rs9659356 chr1 11034817 A G 1.29E-09 Male-pattern baldness C1orf127 intron 22693459 rs11576658 chr1 11037736 C T 9.20E-08 Ewing sarcoma C1orf127 intron 22327514 rs11576658 chr1 11037736 C T 1.06E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121667 chr1 11038476 C T 1.17E-09 Male-pattern baldness C1orf127 intron 22693459 rs7542158 chr1 11040193 G A 1.20E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121671 chr1 11043780 C A,T 4.48E-04 Alcohol dependence / / 24277619 rs9430158 chr1 11043861 G C 2.43E-08 Male-pattern baldness / / 22693459 rs7547568 chr1 11044829 T A 2.20E-08 Male-pattern baldness / / 22693459 rs9430161 chr1 11046855 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs9430161 chr1 11046855 G T 1.00E-20 Ewing sarcoma / / 22327514 rs12085877 chr1 11087687 C T 0.00000166 Triglycerides MASP2 missense 23063622 rs12072993 chr1 11094362 A G 0.000000013 Cholesterol,total MASP2 intron 23063622 rs12142107 chr1 11097867 C T 0.00031 Prostate cancer (non-advanced prostate cancer) MASP2 cds-synon 23555315 rs12139042 chr1 11167146 G A 1.00E-11 Corneal curvature MTOR UTR-3 24963161 rs17036350 chr1 11171226 C T 4.00E-13 Corneal curvature MTOR intron 21665993 rs2300095 chr1 11265717 A G 3.69E-06 Obesity MTOR intron 22484627 rs74225573 chr1 11280994 T C 6.00E-18 Corneal curvature MTOR intron 24963161 rs12124983 chr1 11286178 T C 8.11E-04 Type 2 diabetes MTOR intron 17463246 rs17036631 chr1 11347492 C T 5.41E-06 Job-related exhaustion UBIAD1 UTR-3 23620144 rs11121720 chr1 11364920 T C 2.00E-04 Job-related exhaustion / / 23620144 rs4845992 chr1 11383839 A T 9.32E-05 Type 2 diabetes / / 17463246 rs4845992 chr1 11383839 A T 4.90E-04 Multiple complex diseases / / 17554300 rs2982384 chr1 11401745 G A 6.00E-04 Multiple complex diseases / / 17554300 rs2744854 chr1 11419868 C T 1.64E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6661145 chr1 11485666 T C 9.60E-05 White matter hyperintensity burden / / 21681796 rs3123602 chr1 11489175 G A 7.90E-05 White matter hyperintensity burden / / 21681796 rs877309 chr1 11489678 A G 7.80E-05 White matter hyperintensity burden / / 21681796 rs3099624 chr1 11496994 C T 2.08E-07 Alopecia areata / / 22027810 rs3099627 chr1 11499388 A G 3.80E-28 Narcolepsy / / 19629137 rs11577773 chr1 11516521 C T 1.08E-04 Smoking initiation / / 24665060 rs12026602 chr1 11518397 C T 5.25E-04 Smoking initiation / / 24665060 rs12046038 chr1 11525533 A G 1.68E-04 Heart Failure / / pha002885 rs6674692 chr1 11533011 C T 7.40E-04 Multiple complex diseases / / 17554300 rs10159458 chr1 11534053 A C 5.59E-04 Multiple complex diseases / / 17554300 rs6674713 chr1 11550632 G C 6.32E-05 Multiple complex diseases PTCHD2 intron 17554300 rs2745276 chr1 11641283 G A 2.40E-05 Triglycerides / / 19074352 rs2817644 chr1 11647669 C T 7.80E-06 Triglycerides / / 19074352 rs1810483 chr1 11671329 C A 9.15E-04 Aortic root size / / 21223598 rs7550768 chr1 11680283 C T 1.96E-07 Schizophrenia / / 21926974 rs17037122 chr1 11689663 A G 5.20E-04 Schizophrenia / / 19197363 rs2336030 chr1 11736600 C T 1.00E-06 Visceral adipose tissue adjusted for BMI MAD2L2 intron 22589738 rs4846033 chr1 11788564 A G 4.00E-06 Schizophrenia / / 18347602 rs4075033 chr1 11811234 A G 4.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11121822 chr1 11814216 G A 4.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1133398 chr1 11814631 A G 6.43E-04 Schizophrenia / / 19197363 rs12132479 chr1 11836450 A G 2.90E-07 Natriuretic peptide levels C1orf167 intron 21273288 rs7538516 chr1 11836682 C T 8.70E-10 Natriuretic peptide levels C1orf167 missense 21273288 rs140362679 chr1 11836811 G A 6.87E-05 Acne (severe) C1orf167 intron 24927181 rs6541001 chr1 11837367 C T 8.60E-07 Natriuretic peptide levels C1orf167 UTR-3 21273288 rs10864540 chr1 11838099 A G 1.72E-05 Alcohol and nictotine co-dependence C1orf167 UTR-3 20158304 rs12134663 chr1 11838646 A C 2.70E-07 Natriuretic peptide levels LOC100506310 intron 21273288 rs12134663 chr1 11838646 A C 3.00E-21 Homocysteine levels LOC100506310 intron 23824729 rs6697244 chr1 11838848 G T 7.40E-10 Natriuretic peptide levels LOC100506310 missense 21273288 rs4845882 chr1 11843167 A G 7.20E-10 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846047 chr1 11843632 C G 6.10E-04 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846048 chr1 11846252 G A 6.10E-04 Natriuretic peptide levels MTHFR UTR-3 21273288 rs3737967 chr1 11847449 G A 2.00E-04 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537516 chr1 11847861 G A 1.10E-06 Natriuretic peptide levels MTHFR UTR-3 21273288 rs1537514 chr1 11848068 G C 1.90E-07 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537514 chr1 11848068 G C 1.36E-04 Blood pressure LOC100506310 missense 22100073 rs4846049 chr1 11850365 T G 9.70E-12 Natriuretic peptide levels MTHFR UTR-3 21273288 rs4846049 chr1 11850365 T G 1.48E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.60E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.90E-82 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.90E-19 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.96E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 3.71E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 5.20E-07 Blood pressure MTHFR UTR-3 22100073 rs2274976 chr1 11850927 C T 2.30E-06 Natriuretic peptide levels MTHFR missense 21273288 rs3818762 chr1 11851003 G C 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs3818762 chr1 11851003 G C 1.30E-25 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 1.60E-05 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 3.20E-99 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 8.80E-15 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs576853093 chr1 11851003 G GCACACACACACAC 1.30E-25 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 1.60E-05 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.20E-99 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 8.80E-15 Blood pressure MTHFR intron 22100073 rs13306556 chr1 11852110 C T 1.70E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306556 chr1 11852110 C T 2.90E-04 Atrial fibrillation MTHFR intron 21846873 rs13306556 chr1 11852110 C T 1.27E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs1476413 chr1 11852300 C T 2.90E-12 Natriuretic peptide levels MTHFR intron 21273288 rs1476413 chr1 11852300 C T 1.20E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 1.70E-45 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 2.28E-05 Coronary heart disease MTHFR intron pha003030 rs17375901 chr1 11852516 C T 6.00E-07 Atrial fibrillation MTHFR intron 19597492 rs4846051 chr1 11854457 G A 1 Drug response to Methotrexate MTHFR cds-synon 16439441 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801131 chr1 11854476 T G 8.30E-12 Natriuretic peptide levels MTHFR missense 21273288 rs1801131 chr1 11854476 T G 3.10E-36 Blood pressure MTHFR missense 22100073 rs1801131 chr1 11854476 T G 8.40E-06 Blood pressure MTHFR missense 22100073 rs12121543 chr1 11854671 C A 1.80E-15 Natriuretic peptide levels MTHFR intron 21273288 rs12121543 chr1 11854671 C A 3.20E-05 Blood pressure MTHFR intron 22100073 rs1994798 chr1 11854755 G A 2.40E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1994798 chr1 11854755 G A 5.60E-04 Blood pressure MTHFR intron 22100073 rs2066462 chr1 11854896 G A 1.50E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs6541003 chr1 11855867 G A 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11418485 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11710708 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12453860 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12915598 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 17488658 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 18381794 rs1801133 chr1 11856378 G A 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19208607 rs1801133 chr1 11856378 G A 4.36E-13 Folate pathway vitamin levels MTHFR missense 19303062 rs1801133 chr1 11856378 G A 9.30E-05 Homocysteine levels,in plasma MTHFR missense 19525478 rs1801133 chr1 11856378 G A 8.00E-35 Homocysteine levels MTHFR missense 20031578 rs1801133 chr1 11856378 G A 2.36E-07 Schizophrenia MTHFR missense 22037552 rs1801133 chr1 11856378 G A 1.75E-11 homocysteine levels MTHFR missense 23696881 rs1801133 chr1 11856378 G A 4.00E-104 Homocysteine levels MTHFR missense 23824729 rs1801133 chr1 11856378 G A 5.42E-04 Schizophrenia MTHFR missense 24043878 rs17421511 chr1 11857788 G A 2.90E-07 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 9.38E-05 Response to mTOR inhibitor (rapamycin) MTHFR intron 24009623 rs17037388 chr1 11858036 A G 3.00E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 4.00E-04 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 6.20E-05 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 8.80E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 1.00E-04 Blood pressure MTHFR intron 22100073 rs17421560 chr1 11858324 G A 1.60E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306553 chr1 11860117 A G 2.40E-04 Atrial fibrillation MTHFR intron 21846873 rs11121832 chr1 11860120 T C 3.00E-05 Natriuretic peptide levels MTHFR intron 21273288 rs2066471 chr1 11860458 C T 2.80E-07 Natriuretic peptide levels MTHFR intron 21273288 rs7533315 chr1 11860683 T C 1.90E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 3.10E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.00E-04 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.70E-05 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 9.60E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 8.00E-04 Atrial fibrillation MTHFR intron 21846873 rs17037390 chr1 11860843 G A 3.71E-06 Blood pressure MTHFR intron 22100073 rs17037396 chr1 11862047 C T 1.00E-07 Natriuretic peptide levels MTHFR intron 21273288 rs17037396 chr1 11862047 C T 2.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17037396 chr1 11862047 C T 1.81E-04 Blood pressure MTHFR intron 22100073 rs17037397 chr1 11862163 C A 1.80E-06 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.48E-05 Esophageal cancer (squamous cell) MTHFR intron 22960999 rs17367504 chr1 11862778 A G 2.00E-13 Systolic blood pressure MTHFR intron 19430483 rs17367504 chr1 11862778 A G 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs17367504 chr1 11862778 A G 1.10E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 1.80E-05 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.00E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.60E-06 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 2.10E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17367504 chr1 11862778 A G 2.00E-13 Coronary heart disease MTHFR intron 21347282 rs17367504 chr1 11862778 A G 2.00E-13 Blood pressure MTHFR intron 21378095 rs17367504 chr1 11862778 A G 3.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17367504 chr1 11862778 A G 2.00E-16 Blood pressure MTHFR intron 21909110 rs17367504 chr1 11862778 A G 8.72E-22 Systolic blood pressure MTHFR intron 21909115 rs17367504 chr1 11862778 A G 1.20E-06 Blood pressure MTHFR intron 22100073 rs2066470 chr1 11863057 G A 4.20E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs2066470 chr1 11863057 G A 1.40E-04 Atrial fibrillation MTHFR cds-synon 21846873 rs2066470 chr1 11863057 G A 7.74E-05 Blood pressure MTHFR cds-synon 22100073 rs7553194 chr1 11864149 G A 5.80E-08 Natriuretic peptide levels MTHFR intron 21273288 rs3753582 chr1 11865542 A C 1.30E-08 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 1.70E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 3.00E-05 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 6.00E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 7.90E-06 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 1.70E-05 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 3.00E-04 Atrial fibrillation MTHFR intron 21846873 rs13306561 chr1 11865804 A G 3.24E-06 Blood pressure MTHFR intron 22100073 rs13306560 chr1 11866183 C T 1.20E-08 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 2.90E-11 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 3.40E-05 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 5.40E-06 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 6.10E-06 Blood pressure CLCN6 UTR-5 21060006 rs3737965 chr1 11866451 G A 1.30E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs3737964 chr1 11867044 T A,C,G 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs4846054 chr1 11869230 C T 6.70E-11 Natriuretic peptide levels CLCN6 intron 21273288 rs4846056 chr1 11869578 T C 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 1.70E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 4.30E-04 Atrial fibrillation CLCN6 intron 21846873 rs17037425 chr1 11870383 G A 1.22E-05 Blood pressure CLCN6 intron 22100073 rs6687229 chr1 11872656 C T 8.70E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs12123964 chr1 11872714 A C 2.00E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs12404124 chr1 11873869 G T 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLCN6 intron 20877124 rs12404124 chr1 11873869 G T 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs198391 chr1 11876417 C T 1.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2076001 chr1 11879267 A G 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs2076002 chr1 11879360 G A 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198393 chr1 11879685 C T 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2050265 chr1 11879699 A G 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs198399 chr1 11883629 T A 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs12567136 chr1 11883731 C T 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs2076003 chr1 11884147 T C 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs2076004 chr1 11886813 G A 8.90E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs7537765 chr1 11887303 A G 6.50E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs535107 chr1 11889468 A G 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs503040 chr1 11890695 C T 1.70E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2236797 chr1 11892650 C T 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs17037452 chr1 11895675 A G 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075538 chr1 11896602 T C 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198406 chr1 11897592 A G 3.00E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075539 chr1 11897758 G A 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs198408 chr1 11898130 T A 5.50E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2272803 chr1 11898789 G T 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs1023252 chr1 11899033 G T 4.00E-16 Natriuretic peptide levels CLCN6 intron 21273288 rs198413 chr1 11900802 T C 1.68E-04 Multiple complex diseases CLCN6 UTR-3 17554300 rs17350396 chr1 11900838 A G 1.80E-07 Natriuretic peptide levels CLCN6 UTR-3 21273288 rs14078 chr1 11903010 G A 4.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLCN6 UTR-3 21844884 rs198358 chr1 11904076 T C 3.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198358 chr1 11904076 T C 1.15E-05 Atrial fibrillation / / 21846873 rs7552330 chr1 11904092 G A 8.20E-08 Natriuretic peptide levels / / 21273288 rs5068 chr1 11905974 A G 2.10E-04 Atrial fibrillation NPPA UTR-3 21846873 rs5068 chr1 11905974 A G 3.18E-05 Blood pressure NPPA UTR-3 22100073 rs5065 chr1 11906068 A G 1 Drug response to Amlodipine NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Chlorthalidone NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Doxazosin NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Lisinopril NPPA-AS1 intron 18212314 rs5063 chr1 11907648 C T 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPPA missense 20877124 rs5063 chr1 11907648 C T 5.00E-08 Natriuretic peptide levels NPPA missense 21273288 rs198372 chr1 11909514 G A 3.00E-04 Blood pressure NPPA nearGene-5 21060006 rs632793 chr1 11910677 A G 2.14E-15 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs632793 chr1 11910677 A G 3.60E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 4.00E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 1.10E-04 Blood pressure / / 22100073 rs6668352 chr1 11914829 G A 1.70E-18 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 1.95E-13 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198388 chr1 11917340 C T 3.90E-10 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 7.10E-04 Blood pressure / / 22100073 rs198389 chr1 11919271 A G 1.70E-12 Natriuretic peptide levels / / 21273288 rs12406089 chr1 11921181 C G 3.50E-16 Natriuretic peptide levels / / 21273288 rs12406383 chr1 11921993 C A 3.70E-18 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 5.30E-16 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 2.00E-05 Blood pressure / / 22100073 rs6676300 chr1 11925300 A G 5.75E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6676300 chr1 11925300 A G 9.30E-14 Natriuretic peptide levels / / 21273288 rs116228357 chr1 11925732 C T 6.00E-04 Polycystic ovary syndrome / / 22178785 rs1318408 chr1 11925781 A G 8.60E-05 Natriuretic peptide levels / / 21273288 rs12562952 chr1 11927056 T C 3.39E-11 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12562952 chr1 11927056 T C 3.60E-04 Natriuretic peptide levels / / 21273288 rs1009592 chr1 11928714 C G 4.00E-11 Natriuretic peptide levels / / 21273288 rs11801879 chr1 11928819 T C 1.80E-05 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 4.00E-04 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 6.00E-06 Blood pressure / / 21060006 rs1009591 chr1 11928830 T C 2.60E-08 Natriuretic peptide levels / / 21273288 rs1009591 chr1 11928830 T C 9.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11803049 chr1 11928895 G A 1.07E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11803049 chr1 11928895 G A 5.90E-06 Natriuretic peptide levels / / 21273288 rs11804222 chr1 11936514 G A 3.23E-05 Alcohol withdrawal symptoms / / 22072270 rs12724129 chr1 11957639 C T 6.83E-06 Asthma / / 20698975 rs12085006 chr1 11958723 A G 6.00E-10 Folate pathway vitamin levels / / 19744961 rs11800086 chr1 11971749 G A 2.53E-04 Glycosylated haemoglobin levels / / 17255346 rs7554547 chr1 11973888 A G 3.47E-04 Tourette syndrome / / 22889924 rs6682554 chr1 11986621 T C 7.16E-05 Neuroblastoma / / pha002895 rs2273289 chr1 12018290 T C 0.000000129 Major depressive disorder age at onset<15 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.000000448 Major depressive disorder age at onset<20 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000134 Major depressive disorder age at onset<35 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000392 Major depressive disorder age at onset<25 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000436 Major depressive disorder age at onset<30 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 3.19E-05 Anxiety and major depressive disorder PLOD1 intron 24047446 rs1540923 chr1 12032030 A G 4.09E-04 Myocardial Infarction PLOD1 intron pha002873 rs1474868 chr1 12044164 C T 8.97E-04 Myocardial Infarction MFN2 intron pha002873 rs2336384 chr1 12046063 G T 1.00E-08 Platelet counts MFN2 intron 22139419 rs2878677 chr1 12053264 T C 1.61E-05 Schizophrenia MFN2 intron 19571811 rs2295283 chr1 12082926 A G 0.0002 Migraine MIIP missense 22678113 rs17037598 chr1 12153413 G T 1.13E-04 Response to cytidine analogues (gemcitabine) TNFRSF8 intron 24483146 rs11569837 chr1 12157740 C T 7.64E-04 Smoking quantity TNFRSF8 intron 24665060 rs11121868 chr1 12170974 C T 9.52E-04 Type 2 diabetes TNFRSF8 intron 17463246 rs2230624 chr1 12175658 G A,T 0.00026 Breast cancer TNFRSF8 missense 23555315 rs646249 chr1 12180124 G A 2.60E-05 Urinary metabolites TNFRSF8 intron 21572414 rs2230625 chr1 12186058 A G 3.47E-04 Taste perception TNFRSF8 missense 22132133 rs535068 chr1 12189561 G A 5.32E-06 Carotenoid and tocopherol levels TNFRSF8 intron 19185284 rs1148472 chr1 12194451 T C 0.0000922 post-traumatic stress disorder TNFRSF8 intron 22869035 rs1148472 chr1 12194451 T C 9.22E-05 Schizophrenia TNFRSF8 intron 22883433 rs686190 chr1 12223839 T C 8.58E-04 Multiple complex diseases / / 17554300 rs1061622 chr1 12252955 T G 1 Drug response to Infliximab TNFRSF1B missense 18565259 rs1061622 chr1 12252955 T G 0.0003 Stroke TNFRSF1B missense 23422753 rs5746059 chr1 12262792 A G 4.42E-04 Response to TNF antagonist treatment TNFRSF1B intron 21061259 rs235219 chr1 12264355 A G 1.26E-05 Type 1 diabetes TNFRSF1B intron 21980299 rs5746068 chr1 12267555 C G 0.00000154 HDL cholesterol TNFRSF1B UTR-3 23063622 rs1061628 chr1 12267999 C T 1.30E-05 Urinary metabolites TNFRSF1B UTR-3 21572414 rs235216 chr1 12269624 C T 1.25E-11 HDL cholesterol TNFRSF1B nearGene-3 23063622 rs235216 chr1 12269624 C T 4.12E-10 Cholesterol,total TNFRSF1B nearGene-3 23063622 rs374450 chr1 12305286 G A 9.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VPS13D intron 20877124 rs374450 chr1 12305286 G A 8.75E-05 Myopia (pathological) VPS13D intron 21095009 rs235243 chr1 12319994 G T 9.55E-05 Major depressive disorder VPS13D intron 21621269 rs148728975 chr1 12419883 G A 7.00E-07 Asthma VPS13D intron 24406073 rs11121906 chr1 12488475 C A 7.95E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs6683371 chr1 12492582 A G 8.69E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs12406819 chr1 12577209 G A 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12406819 chr1 12577209 G A 6.34E-05 Myopia (pathological) / / 21095009 rs760943 chr1 12598434 T C 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6659122 chr1 12615069 G T 8.43E-05 Smoking initiation / / 24665060 rs3128451 chr1 12641488 G T 2.80E-04 Amyotrophic Lateral Sclerosis DHRS3 intron 17827064 rs12045736 chr1 12654035 C T 9.86E-05 Glycosylated haemoglobin levels DHRS3 intron 17255346 rs13376289 chr1 12661179 G T 2.04E-04 Celiac disease DHRS3 intron 23936387 rs6689733 chr1 12680180 G A 3.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3000896 chr1 12682574 T C 6.42E-05 Monocyte chemoattractant protein-1 / / pha003071 rs3010931 chr1 12684324 C T 3.90E-04 Alcohol dependence / / 20201924 rs12070206 chr1 12689692 G A 4.52E-05 Cognitive test performance / / 20125193 rs4845911 chr1 12693125 G A 1.33E-05 Non-obstructive azoospermia / / 22541561 rs2489258 chr1 12700815 T C 7.45E-04 Obesity (extreme) / / 21935397 rs7512542 chr1 12702393 C T 6.38E-06 Multiple complex diseases / / 17554300 rs7512542 chr1 12702393 C T 1.36E-28 Narcolepsy / / 19629137 rs17458785 chr1 12709554 G A 1.29E-05 Waist-Hip Ratio AADACL4 intron pha003013 rs17458785 chr1 12709554 G A 2.09E-05 Waist-Hip Ratio AADACL4 intron pha003028 rs11121955 chr1 12723184 G A 9.09E-05 Blood Pressure AADACL4 intron pha003047 rs2489260 chr1 12741240 G A 8.00E-06 Obesity-related traits / / 23251661 rs3010948 chr1 12754569 C T 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17038464 chr1 12786444 G A 8.56E-05 Response to mTOR inhibitor (rapamycin) AADACL3 UTR-3 24009623 rs3010903 chr1 12796044 G T 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17038489 chr1 12805936 T C 4.26E-04 Multiple complex diseases / / 17554300 rs1812242 chr1 12835868 T C 8.68E-05 Glycosylated haemoglobin levels PRAMEF12 missense 17255346 rs111797423 chr1 12836235 C T 2.20E-11 Metabolite levels PRAMEF12 cds-synon 22286219 rs1856638 chr1 12910136 A G 6.59E-06 Multiple complex diseases / / 17554300 rs41468748 chr1 12911096 G T 4.22E-06 Multiple complex diseases / / 17554300 rs11580598 chr1 13783354 C T 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2940310 chr1 13805706 C T 0.000690619 Hypertension (early onset hypertension) LRRC38 intron 22479346 rs3845607 chr1 13806039 T C 2.25E-04 Alzheimer's disease (late onset) LRRC38 intron 21379329 rs2990683 chr1 13841055 T C 9.87E-04 Alzheimer's disease / / 17998437 rs3856278 chr1 13859570 A G 5.06E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 5.87E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 8.61E-04 Response to TNF antagonist treatment / / 21061259 rs10927872 chr1 13885203 C T 5.07E-04 Obesity (extreme) / / 21935397 rs12735797 chr1 13905218 G A 1.36E-04 White matter integrity / / 22425255 rs2885135 chr1 13906527 G C 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2361030 chr1 13906554 C T 7.98E-04 Coronary Artery Disease / / 17634449 rs2361030 chr1 13906554 C T 9.37E-05 White matter integrity / / 22425255 rs2361030 chr1 13906554 C T 7.72E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10927903 chr1 13912887 G A 3.11E-05 Response to cytadine analogues (cytosine arabinoside) PDPN intron 24483146 rs10927905 chr1 13916997 T C 2.53E-04 Celiac disease PDPN intron 23936387 rs16852000 chr1 13920167 T G 5.12E-04 Multiple complex diseases PDPN intron 17554300 rs11587701 chr1 13946497 A G 8.61E-04 Bipolar disorder,schizoaffective / / 19567891 rs11587701 chr1 13946497 A G 1.50E-05 Urinary metabolites / / 21572414 rs11587701 chr1 13946497 A G 0.0000267 Coronary artery calcification / / 23394302 rs10927910 chr1 13948765 G A 9.37E-04 Multiple complex diseases / / 17554300 rs17390405 chr1 13949087 G A 6.99E-04 Depression (quantitative trait) / / 20800221 rs12143609 chr1 13957405 C T 5.83E-04 Type 2 diabetes / / 17463246 rs16852640 chr1 13971360 G A 9.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2495057 chr1 14035513 T C 8.15E-04 Suicide attempts in bipolar disorder PRDM2 intron 21423239 rs2495053 chr1 14040030 T C 3.80E-04 Type 2 diabetes PRDM2 intron 17463246 rs2495053 chr1 14040030 T C 2.60E-05 Anger PRDM2 intron 24489884 rs6429794 chr1 14045394 T G 1.41E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203631 chr1 14067208 A G 3.20E-04 Multiple complex diseases PRDM2 intron 17554300 rs2359756 chr1 14096420 A G 4.17E-04 Response to alcohol consumption (flushing response) PRDM2 intron 24277619 rs1203651 chr1 14109114 A G 9.46E-04 Multiple complex diseases PRDM2 cds-synon 17554300 rs1980471 chr1 14118119 C G 9.94E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203639 chr1 14120432 C T 8.44E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203638 chr1 14121892 G T 1.29E-04 Parkinson's disease PRDM2 intron 17052657 rs2744692 chr1 14125227 T C 5.11E-05 Vaspin levels PRDM2 intron 22907691 rs2697992 chr1 14125496 G C 4.97E-05 Vaspin levels PRDM2 intron 22907691 rs2245218 chr1 14139826 C T 4.61E-05 Parkinson's disease PRDM2 intron 16252231 rs1203690 chr1 14162023 T G 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2744671 chr1 14195122 T C 6.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs16853069 chr1 14196212 T C 4.89E-04 Insulin resistance / / 21901158 rs17350970 chr1 14216150 C T 6.50E-06 Urinary metabolites / / 21572414 rs2697979 chr1 14221528 G A 4.61E-05 Atopic dermatitis / / 23042114 rs6429800 chr1 14228077 G A 1.40E-06 Urinary metabolites / / 21572414 rs7536590 chr1 14232891 C T 7.17E-04 Insulin resistance / / 21901158 rs7543809 chr1 14232929 T C 4.40E-04 Insulin resistance / / 21901158 rs12745720 chr1 14240110 C T 1.10E-05 HIV-1 viral setpoint / / 17641165 rs12122426 chr1 14240350 A C 9.28E-05 Elbow pain / / pha003008 rs10489150 chr1 14253566 A G 4.00E-05 Body Mass Index / / pha003019 rs6661262 chr1 14254750 G A 1.30E-04 Schizophrenia / / 19197363 rs7538374 chr1 14255978 T G 1.72E-04 Multiple complex diseases / / 17554300 rs16853208 chr1 14257199 T C 3.11E-04 Multiple complex diseases / / 17554300 rs2206585 chr1 14261909 G T 7.12E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 2.87E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 6.73E-05 Body Mass Index / / pha003022 rs4661455 chr1 14277864 T C 4.54E-04 Type 2 diabetes / / 17463246 rs2359896 chr1 14280562 G A 8.82E-06 Body Mass Index / / pha003019 rs2359896 chr1 14280562 G A 2.44E-05 Body Mass Index / / pha003022 rs12024045 chr1 14297220 A G 9.77E-04 Multiple complex diseases / / 17554300 rs10489148 chr1 14313480 G T 2.00E-05 Multiple complex diseases / / 17554300 rs6691183 chr1 14320651 C A 1.44E-04 Multiple complex diseases / / 17554300 rs12129723 chr1 14331940 G A 8.66E-04 Alzheimer's disease / / 22005930 rs6429822 chr1 14342347 G A 2.89E-05 Rheumatoid arthritis / / 17804836 rs4661465 chr1 14345544 G A 9.62E-05 Hypertension / / 19609347 rs3929673 chr1 14353071 T G 3.94E-04 Alzheimer's disease / / 22005930 rs4662075 chr1 14353195 C G 9.77E-04 Alzheimer's disease / / 22005930 rs4662076 chr1 14357851 T G 5.90E-06 Alzheimer's disease (late onset) / / 21460841 rs7527934 chr1 14358424 G T 5.87E-06 Alzheimer's disease (late onset) / / 21460841 rs10754905 chr1 14361699 C T 6.89E-06 Alzheimer's disease (late onset) / / 21460841 rs7551069 chr1 14361749 A G 6.65E-06 Alzheimer's disease (late onset) / / 21460841 rs2359909 chr1 14364585 G T 7.53E-06 Alzheimer's disease (late onset) / / 21460841 rs2359910 chr1 14364963 A G 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10733140 chr1 14365171 C A 7.70E-06 Alzheimer's disease (late onset) / / 21460841 rs7514368 chr1 14368784 T C 8.25E-06 Alzheimer's disease (late onset) / / 21460841 rs6662320 chr1 14370368 A G 7.80E-05 Major depressive disorder / / 21042317 rs6671878 chr1 14372093 T A 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10737917 chr1 14372776 T A 9.71E-06 Alzheimer's disease (late onset) / / 21460841 rs10737918 chr1 14385135 A G 8.10E-05 Major depressive disorder / / 21042317 rs16853528 chr1 14388300 T C 2.23E-04 Multiple complex diseases / / 17554300 rs10733143 chr1 14390137 A G 7.60E-05 Major depressive disorder / / 21042317 rs7515917 chr1 14439042 T C 6.83E-04 Type 2 diabetes / / 17463246 rs10429936 chr1 14450545 T C 9.58E-04 Type 2 diabetes / / 17463246 rs16853613 chr1 14455748 A G 4.38E-04 Multiple complex diseases / / 17554300 rs929125 chr1 14477944 G A 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs568434 chr1 14523180 C A 3.85E-04 Aortic root size / / 21223598 rs4478803 chr1 14559081 C T 3.97E-04 Insulin resistance / / 21901158 rs4478803 chr1 14559081 C T 7.70E-04 Intelligence (childhood) / / 23358156 rs10928056 chr1 14585648 G A 8.20E-04 Alcohol dependence / / 20201924 rs12406699 chr1 14598055 C T 2.58E-04 IgE levels / / 17255346 rs1416623 chr1 14649876 T C 0.000566716 Hypertension (early onset hypertension) / / 22479346 rs12121975 chr1 14673385 G T 7.25E-04 Substance dependence / / 21818250 rs12134023 chr1 14677729 C A 3.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4113453 chr1 14680899 G A 9.33E-05 Major depressive disorder / / 21621269 rs820671 chr1 14692271 A G 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803270 chr1 14700804 A G 4.89E-06 Alzheimer's disease (late onset) / / 21460841 rs10927416 chr1 14708719 A C 2.59E-04 Multiple complex diseases / / 17554300 rs12085004 chr1 14773232 G A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4450012 chr1 14775550 C T 9.80E-06 Urinary metabolites / / 21572414 rs16850285 chr1 14787410 C T 5.87E-04 Obesity (extreme) / / 21935397 rs2480054 chr1 14792535 A G 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs16850320 chr1 14795469 G C 3.36E-04 Type 2 diabetes / / 17463246 rs16850332 chr1 14796547 T A 4.44E-05 Type 2 diabetes / / 17463246 rs16850384 chr1 14822916 T C 5.88E-05 Multiple complex diseases / / 17554300 rs11807837 chr1 14841189 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12733185 chr1 14842486 G A 5.37E-05 Fibrinogen / / pha003068 rs2105239 chr1 14857643 A G 3.00E-04 Chronic fatigue syndrome / / 21912186 rs4661292 chr1 14915147 G A 7.72E-04 Multiple complex diseases / / 17554300 rs10803289 chr1 14934220 G A 8.92E-04 Multiple complex diseases KAZN intron 17554300 rs11579756 chr1 14947920 T C 0.000117 Schizophrenia KAZN intron 23637625 rs4661295 chr1 14999190 C T 2.41E-04 Multiple complex diseases KAZN intron 17554300 rs6429673 chr1 15025974 A G 1.51E-05 Response to tocilizumab in rheumatoid arthritis KAZN intron 22491018 rs4661300 chr1 15038771 T G 5.58E-04 Multiple complex diseases KAZN intron 17554300 rs4661515 chr1 15038791 A T 7.03E-04 Multiple complex diseases KAZN intron 17554300 rs12136961 chr1 15039673 G A 8.30E-04 Multiple complex diseases KAZN intron 17554300 rs6698433 chr1 15065915 G C 8.86E-04 Alzheimer's disease KAZN intron 22005930 rs6690550 chr1 15066365 T C 8.93E-04 Alzheimer's disease KAZN intron 22005930 rs10803311 chr1 15066944 T C 9.91E-04 Alzheimer's disease KAZN intron 22005930 rs4661302 chr1 15092813 G A 1.30E-05 Urinary metabolites KAZN intron 21572414 rs4661303 chr1 15101472 C T 5.33E-04 Multiple complex diseases KAZN intron 17554300 rs804125 chr1 15111927 G T 7.91E-05 Coronary heart disease KAZN intron pha003055 rs1721831 chr1 15115510 T C 3.11E-05 Birth weight KAZN intron 17255346 rs1630519 chr1 15116208 G T 6.49E-05 Coronary heart disease KAZN intron pha003055 rs1721829 chr1 15117060 A G 2.26E-05 Coronary heart disease KAZN intron pha003055 rs10489353 chr1 15140362 G A 9.54E-06 Serum metabolites KAZN intron 19043545 rs17368807 chr1 15153369 G A 1.80E-05 Urinary metabolites KAZN intron 21572414 rs3845593 chr1 15162350 A G 8.77E-05 Non-alcoholic fatty liver disease histology (other) KAZN intron 20708005 rs7416912 chr1 15194562 G T 3.78E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs2803396 chr1 15197909 T C 4.80E-06 Glioma (high-grade) KAZN intron 19578366 rs12029721 chr1 15216489 A G 7.91E-06 Retinopathy in non-diabetics KAZN intron 23393555 rs12410007 chr1 15264270 A G 0.00000003 Brain microstructure and intellectual performance KAZN intron 22723713 rs10927602 chr1 15295333 A G 5.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KAZN intron 20877124 rs7544674 chr1 15297249 T A 1.61E-04 Multiple complex diseases KAZN intron 17554300 rs4661553 chr1 15304859 C T 2.23E-04 Multiple complex diseases KAZN intron 17554300 rs7529561 chr1 15328151 A C 3.53E-04 Alcohol consumption (maxi-drinks) KAZN intron 24277619 rs7539545 chr1 15331603 A T 8.30E-06 Urinary metabolites KAZN intron 21572414 rs6681053 chr1 15334782 T C 6.26E-05 Fibrinogen KAZN intron pha003068 rs11578349 chr1 15338903 G T 9.20E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs6429702 chr1 15339902 T G 7.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KAZN intron 20031582 rs6429703 chr1 15339960 T C 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) KAZN intron 23648065 rs10927631 chr1 15346330 T C 4.70E-06 Urinary metabolites KAZN intron 21572414 rs6657768 chr1 15346891 T A 3.00E-07 Urinary metabolites KAZN intron 21572414 rs6667220 chr1 15347640 G A 8.00E-06 Chronic obstructive pulmonary disease-related biomarkers KAZN intron 23144326 rs4520412 chr1 15359967 C T 4.01E-04 Multiple complex diseases KAZN intron 17554300 rs6674129 chr1 15363223 A C 1.83E-05 Blood Pressure KAZN intron pha003046 rs12138732 chr1 15377554 G A 8.70E-06 Urinary metabolites KAZN intron 21572414 rs1513548 chr1 15379185 T C 8.66E-05 Aortic root size KAZN intron 21223598 rs476859 chr1 15428508 C T 8.25E-05 Aortic root size KAZN intron 21223598 rs496567 chr1 15435257 A G 3.84E-04 Type 2 diabetes KAZN intron 17463246 rs6659639 chr1 15440156 G A 5.17E-05 Crohn's disease KAZN intron 17684544 rs761301 chr1 15471992 T G 9.70E-05 Psoriasis C1orf126 intron 19169255 rs10927689 chr1 15484465 A G 1.33E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851354 chr1 15495620 T C 4.84E-05 Tuberculosis TMEM51 intron 24057671 rs7539166 chr1 15495905 T G 4.57E-98 Multiple complex diseases TMEM51 intron 17554300 rs16851358 chr1 15500332 C T 1.43E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851358 chr1 15500332 C T 2.50E-05 Urinary metabolites TMEM51 intron 21572414 rs10754886 chr1 15502481 C T 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs10754887 chr1 15502539 A G 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs4661326 chr1 15527323 C T 4.65E-05 Bipolar disorder and schizophrenia TMEM51 intron 20889312 rs3820064 chr1 15542073 G A 4.05E-04 Multiple complex diseases TMEM51 intron 17554300 rs10927733 chr1 15543268 C G 3.90E-04 Smoking initiation TMEM51 intron 24665060 rs549 chr1 15546825 A G 1.60E-04 Osteoarthritis TMEM51 UTR-3 19508968 rs12124285 chr1 15548397 G A 9.72E-04 Multiple complex diseases / / 17554300 rs10737909 chr1 15548636 G T 2.00E-07 Migraine / / 23793025 rs10737909 chr1 15548636 G T 8.91E-05 Migraine without aura / / 23793025 rs11585832 chr1 15569822 G A 3.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1752020 chr1 15572133 A G 1.00E-05 Urinary metabolites / / 21572414 rs12144738 chr1 15591641 T C 7.25E-04 Tourette syndrome FHAD1 intron 22889924 rs12725686 chr1 15608418 C T 2.00E-11 Brain microstructure and intellectual performance FHAD1 intron 22723713 rs10803378 chr1 15626718 G A 6.91E-05 Socioeconomic Factors FHAD1 intron pha003066 rs10127456 chr1 15653872 G A 3.18E-05 Serum metabolites FHAD1 intron 19043545 rs7532826 chr1 15677932 A G 5.23E-05 Gallstones FHAD1 intron 17632509 rs16851617 chr1 15699117 G A 3.78E-04 Insulin resistance FHAD1 intron 21901158 rs2249097 chr1 15699327 G C 5.25E-06 Multiple complex diseases FHAD1 intron 17554300 rs2496330 chr1 15718470 T G 6.66E-05 Multiple complex diseases FHAD1 intron 17554300 rs1883426 chr1 15726116 A T 6.20E-05 Primary sclerosing cholangitis / / 19944697 rs742361 chr1 15726566 G A 6.11E-05 Cardiovascular disease / / pha003065 rs742362 chr1 15726791 A G 2.34E-04 Multiple complex diseases / / 17554300 rs2473344 chr1 15728289 T C 4.10E-05 Primary sclerosing cholangitis / / 19944697 rs2092324 chr1 15733394 G A 9.19E-05 Serum metabolites / / 19043545 rs2092324 chr1 15733394 G A 7.56E-05 Insulin resistance / / 21901158 rs2496321 chr1 15743884 A C 2.75E-04 Alcohol dependence EFHD2 intron 20201924 rs2496320 chr1 15744271 T C 5.26E-04 Alcohol dependence EFHD2 intron 20201924 rs11579489 chr1 15790639 G A 3.00E-06 Stroke (ischemic) CELA2A intron 22384361 rs2901964 chr1 15792426 C G 5.00E-06 Erectile dysfunction and prostate cancer treatment CELA2A intron 20932654 rs6675825 chr1 15811346 C T 7.95E-05 Serum metabolites CELA2B intron 19043545 rs4233533 chr1 15829187 G A 0.0000734 Cholesterol,total CASP9 intron 23063622 rs4646043 chr1 15832110 T G 1.10E-04 Coronary heart disease CASP9 intron 21966275 rs2308939 chr1 15833450 G A,C,T 3.36E-11 Cholesterol,total CASP9 missense 23063622 rs2308939 chr1 15833450 G A,C,T 4.29E-09 HDL cholesterol CASP9 missense 23063622 rs2308941 chr1 15844718 G A 2.14E-04 Acute lung injury CASP9 missense 22295056 rs12124078 chr1 15869899 A G 9.49E-22 Chronic kidney disease D/JC16 intron 22479191 rs78309148 chr1 15871023 G A 0.00067 Prostate cancer D/JC16 missense 23555315 rs59905655 chr1 16071010 C T 2.00E-06 Obesity-related traits TMEM82 missense 23251661 rs12725198 chr1 16080171 G A 3.00E-06 Cardiac Troponin-T levels / / 23247143 rs938295 chr1 16087260 C T 6.30E-04 Endometriosis FBLIM1 intron 23104006 rs10737910 chr1 16109669 C T 2.99E-04 Type 2 diabetes FBLIM1 intron 17463246 rs4661661 chr1 16161836 T C 3.20E-04 Smoking cessation / / 24665060 rs4661663 chr1 16161958 G T 1.23E-04 Smoking cessation / / 24665060 rs10737911 chr1 16167855 T C 1.90E-05 Type 2 diabetes FLJ37453 intron 17463246 rs6668183 chr1 16173814 G C 2.06E-04 Heart rate FLJ37453 intron 23583979 rs7552077 chr1 16196759 A G 3.30E-05 Type 2 diabetes SPEN intron 17463246 rs4661670 chr1 16212219 G T 4.63E-04 Smoking cessation SPEN intron 24665060 rs10927873 chr1 16251900 C T 4.90E-04 Heart Failure SPEN intron pha002885 rs848210 chr1 16259813 A G 4.41E-05 Type 2 diabetes SPEN missense 17463246 rs926619 chr1 16279386 C G 3.40E-04 Smoking cessation ZBTB17 intron 24665060 rs4661346 chr1 16282776 G C 8.81E-05 Serum metabolites ZBTB17 intron 19043545 rs10927875 chr1 16299312 C T 1.00E-09 Dilated cardiomyopathy ZBTB17 intron 21459883 rs4661681 chr1 16321523 T C 2.34E-04 Smoking cessation / / 24665060 rs1739843 chr1 16343254 T C 5.28E-13 Dilated cardiomyopathy HSPB7 intron 20975947 rs1056207 chr1 16344827 G A 6.97E-05 Smoking cessation HSPB7 UTR-5 24665060 rs1889785 chr1 16348729 G A 4.45E-06 Heart rate CLCNKA intron 23583979 rs1972359 chr1 16356187 C T 4.12E-04 Smoking cessation CLCNKA intron 24665060 rs1805152 chr1 16356501 G A 5.96E-05 Cholesterol CLCNKA missense pha003078 rs883867 chr1 16358085 C A 1.11E-04 Smoking cessation CLCNKA intron 24665060 rs9442193 chr1 16367339 G A 1.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs9442235 chr1 16393357 T G 6.00E-06 Cognitive performance FAM131C intron 19734545 rs17416878 chr1 16446980 A G 3.70E-07 Kawasaki disease / / 22446962 rs17416878 chr1 16446980 A G 0.000486 Salmonella-induced pyroptosis / / 22837397 rs1497406 chr1 16505320 A G 3.00E-19 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs1497406 chr1 16505320 A G 4.00E-08 Gamma gluatamyl transferase levels / / 22010049 rs6677710 chr1 16507618 T C 1.30E-04 Multiple complex diseases / / 17554300 rs4537547 chr1 16510798 A G 1.12E-04 Multiple complex diseases / / 17554300 rs12740413 chr1 16515879 C T 0.000013 Aging / / 22445811 rs6697459 chr1 16518866 T G 1.23E-04 Multiple complex diseases / / 17554300 rs221032 chr1 16525549 C T 5.73E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs221035 chr1 16526529 G A 3.20E-12 Lymphocyte counts ARHGEF19 intron 22286170 rs221049 chr1 16530850 T G 4.75E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs10489599 chr1 16585818 A G 6.00E-04 Chronic fatigue syndrome FBXO42 intron 21912186 rs6603859 chr1 16706075 G T 1 Drug response to Daunorubicin C1orf144 intron 18451141 rs12138174 chr1 16715466 T C 9.36E-04 Acute lung injury C1orf144 intron 22295056 rs11543230 chr1 16785564 C T 4.96E-04 Multiple complex diseases NECAP2 UTR-3 17554300 rs156851 chr1 16814994 C T 2.80E-04 Height CROCCP3 intron 17255346 rs156869 chr1 16830508 G A 3.19E-04 Height / / 17255346 rs4316363 chr1 16924151 T C 5.73E-04 Multiple complex diseases / / 17554300 rs3851919 chr1 16924335 A G 9.69E-05 Multiple complex diseases / / 17554300 rs1977269 chr1 17004850 C A,G,T 4.06E-05 Platelet counts / / pha003100 rs12563353 chr1 17037560 A G 3.00E-05 Psoriasis ESPNP intron 20953190 rs3915536 chr1 17045646 C T 1.05E-04 Type 2 diabetes ESPNP intron 17463246 rs6586513 chr1 17216331 C A 4.00E-06 Allergic rhinitis / / 22036096 rs9435730 chr1 17305903 G A 3.97E-04 Response to taxane treatment (placlitaxel) MFAP2 intron 23006423 rs2284746 chr1 17306675 C G 4.00E-29 Height MFAP2 intron 20881960 rs2284746 chr1 17306675 C G 1.10E-19 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 1.90E-08 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 4.10E-13 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 8.00E-16 Pulmonary function MFAP2 intron 21946350 rs2284746 chr1 17306675 C G 6.40E-04 Coronary heart disease MFAP2 intron 21966275 rs2284746 chr1 17306675 C G 2.00E-11 Pulmonary function (interaction) MFAP2 intron 23284291 rs2284746 chr1 17306675 C G 5.00E-15 Height MFAP2 intron 23563607 rs3754511 chr1 17310019 G A 1.72E-04 Response to taxane treatment (placlitaxel) MFAP2 nearGene-5 23006423 rs9435736 chr1 17323449 T C 7.78E-04 Response to taxane treatment (placlitaxel) ATP13A2 intron 23006423 rs6684770 chr1 17325955 G A 2.54E-04 Multiple complex diseases ATP13A2 intron 17554300 rs3738814 chr1 17331676 A G 2.00E-07 Height ATP13A2 intron 20189936 rs2647168 chr1 17340878 C T 1.96E-04 Lymphocyte counts / / 22286170 rs34916635 chr1 17371298 C T 1.20E-04 Atrial fibrillation SDHB missense 21846873 rs2746533 chr1 17394046 A G 8.23E-05 Menopause (age at onset) PADI2 UTR-3 22267201 rs2235927 chr1 17394775 G A 1.21E-06 Asthma PADI2 UTR-3 23181788 rs3818042 chr1 17398849 G A 5.31E-04 Pulmonary function PADI2 intron 20010834 rs730387 chr1 17410557 G A 9.52E-06 Rheumatoid arthritis PADI2 intron 19503088 rs2977272 chr1 17536952 C T 7.66E-04 Obesity (extreme) PADI1 intron 21935397 rs2977235 chr1 17557178 C T 1.90E-05 Urinary metabolites PADI1 intron 21572414 rs4268393 chr1 17559196 T C 4.60E-06 Urinary metabolites PADI1 intron 21572414 rs3003412 chr1 17564847 C T 3.85E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) PADI1 intron 24192120 rs2977310 chr1 17564990 T C 5.28E-05 Age-related macular degeneration PADI1 intron pha002890 rs2977225 chr1 17573439 T C 2.13E-04 Vaspin levels / / 22907691 rs2977225 chr1 17573439 T C 0.000213 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3003419 chr1 17573988 G A 3.59E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12562867 chr1 17576638 A C 1.00E-04 Prostate cancer PADI3 intron 21743057 rs4363467 chr1 17586653 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits PADI3 intron 17848626 rs3003426 chr1 17588162 G A 1.39E-05 Serum metabolites PADI3 intron 19043545 rs3003429 chr1 17591679 T C 4.00E-07 Pulmonary function (interaction) PADI3 intron 23284291 rs2977293 chr1 17599444 C T 8.79E-05 Cognitive test performance PADI3 intron 20125193 rs2977293 chr1 17599444 C T 5.77E-05 Heart Rate PADI3 intron pha003053 rs2977293 chr1 17599444 C T 1.14E-06 Heart Rate PADI3 intron pha003054 rs11585118 chr1 17605774 C A 2.24E-08 Common traits (Other) PADI3 intron 20585627 rs12568771 chr1 17613809 A G 1.94E-04 Age-related macular degeneration / / 22125219 rs7548900 chr1 17622654 C A 3.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1886302 chr1 17635396 A G 1.63E-04 Age-related macular degeneration PADI4 intron 22125219 rs10788664 chr1 17647475 C T 0.00076 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs10888024 chr1 17649796 A G 0.000224 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748041 chr1 17655407 C T 0.000268 Schizophrenia PADI4 intron 22440650 rs11203366 chr1 17657534 G A 1.57E-07 Rheumatoid arthritis PADI4 missense 21452313 rs11203366 chr1 17657534 G A 0.000436 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs11203367 chr1 17657616 T C 0.000285 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs1635597 chr1 17659556 A G 9.19E-04 Multiple complex diseases PADI4 intron 17554300 rs874881 chr1 17660499 G C 8.18E-04 Response to taxane treatment (placlitaxel) PADI4 missense 23006423 rs1635594 chr1 17661805 A G 7.30E-05 Rheumatoid arthritis PADI4 intron 24782177 rs1748035 chr1 17661996 T C 7.05E-04 Multiple complex diseases PADI4 intron 17554300 rs1748035 chr1 17661996 T C 0.000313 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748033 chr1 17662662 T C 0.000313 fMRI brain tests in schizophrenia PADI4 cds-synon 22440650 rs1635586 chr1 17664770 A G 5.23E-05 Rheumatoid arthritis PADI4 intron 21452313 rs11203368 chr1 17666508 C T 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 intron 20877124 rs11203368 chr1 17666508 C T 2.61E-08 Rheumatoid arthritis PADI4 intron 21452313 rs2301888 chr1 17672730 G A 1.00E-18 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 6.00E-09 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 8.00E-13 Rheumatoid arthritis PADI4 intron 24390342 rs2240339 chr1 17674108 C T 1.46E-10 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240339 chr1 17674108 C T 2.57E-10 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.90E-09 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.91E-09 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240335 chr1 17674537 C A 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 cds-synon 20877124 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21452313 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21505073 rs2240335 chr1 17674537 C A 2.30E-05 Rheumatoid arthritis PADI4 cds-synon 21673997 rs7538876 chr1 17722363 G A 4.00E-12 Basal cell carcinoma PADI6 intron 18849993 rs7538876 chr1 17722363 G A 4.00E-12 Nasopharyngeal carcinoma PADI6 intron 20512145 rs7538876 chr1 17722363 G A 7.00E-14 Basal cell carcinoma PADI6 intron 24403052 rs6586542 chr1 17763566 G C 8.56E-05 Lymphocyte counts RCC2 intron 22286170 rs2883272 chr1 17773159 G A 1.41E-05 Intelligence / / 21826061 rs2883272 chr1 17773159 G A 9.42E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6659366 chr1 17800419 A G 2.69E-05 Body mass index / / 17255346 rs2254135 chr1 17834742 C T 3.00E-06 Response to hepatitis C treatment / / 22095909 rs2248129 chr1 17855824 C T 8.09E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2244300 chr1 17857601 G A 4.73E-05 Aging (time to event) / / 21782286 rs2477735 chr1 17869179 T C 2.70E-04 Alcohol dependence ARHGEF10L intron 20201924 rs10788679 chr1 17916962 A G 5.11E-06 Esophageal cancer (squamous cell) ARHGEF10L intron 22960999 rs6693036 chr1 17919817 T C 3.00E-06 Obesity-related traits ARHGEF10L intron 23251661 rs17469160 chr1 17998920 G C 6.95E-04 Type 2 diabetes ARHGEF10L intron 17463246 rs7522419 chr1 18033499 A G 3.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs7522419 chr1 18033499 A G 6.46E-06 Height / / pha003010 rs7522419 chr1 18033499 A G 9.95E-07 Height / / pha003011 rs2185324 chr1 18040004 C T 2.18E-06 Height / / pha003011 rs1553400 chr1 18042035 A G 4.64E-06 Height / / pha003010 rs1553400 chr1 18042035 A G 6.10E-07 Height / / pha003011 rs260514 chr1 18052645 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7512028 chr1 18059244 T C 5.76E-04 Multiple complex diseases / / 17554300 rs7534822 chr1 18086999 T G 2.15E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs7547331 chr1 18090929 T C 5.86E-05 Multiple complex diseases ACTL8 intron 17554300 rs10888060 chr1 18099283 G A 3.07E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs11577496 chr1 18105498 G A 2.60E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs16830757 chr1 18124527 C T 0.0000596 Primary sclerosing cholangitis ACTL8 intron 23603763 rs500035 chr1 18132269 G A 4.29E-04 Multiple complex diseases ACTL8 intron 17554300 rs1890788 chr1 18156864 A G 5.50E-06 Urinary metabolites / / 21572414 rs7545559 chr1 18158156 C T 5.50E-06 Urinary metabolites / / 21572414 rs12097284 chr1 18159342 C T 2.46E-05 Intelligence / / 21826061 rs12097284 chr1 18159342 C T 0.0002 Migraine / / 22678113 rs495347 chr1 18163922 C T 6.06E-05 Sarcoidosis / / 19165924 rs807455 chr1 18171347 C T 6.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs697760 chr1 18179816 G T 6.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs647619 chr1 18183424 G A 3.00E-04 Personality dimensions / / 23903073 rs587276 chr1 18193604 C T 2.10E-06 Urinary metabolites / / 21572414 rs11203223 chr1 18196800 T G 6.90E-07 Urinary metabolites / / 21572414 rs11203224 chr1 18201633 G A 2.30E-06 Urinary metabolites / / 21572414 rs7538231 chr1 18202181 G A 1.30E-06 Urinary metabolites / / 21572414 rs578987 chr1 18203380 C G 3.13E-04 Type 2 diabetes / / 17463246 rs1339934 chr1 18236459 A G 6.78E-06 Obesity-related traits / / 23251661 rs1339934 chr1 18236459 A G 9.18E-04 Alcohol dependence / / 24277619 rs12087706 chr1 18241309 C T 9.12E-04 Alzheimer's disease / / 17998437 rs6686929 chr1 18244707 C T 3.00E-06 Obesity-related traits / / 23251661 rs673567 chr1 18278257 G A 2.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs673567 chr1 18278257 G A 4.89E-05 Osteoarthritis (knee and hip) / / 21177295 rs673567 chr1 18278257 G A 8.00E-04 Osteoarthritis (knee and hip) / / 21177295 rs1192573 chr1 18286068 G A 0.00008906 Sarcoidosis / / 22952805 rs794229 chr1 18289233 G T 1.98E-04 Type 2 diabetes / / 17463246 rs4920402 chr1 18289481 G A 8.20E-04 Multiple complex diseases / / 17554300 rs4920402 chr1 18289481 G A 2.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16861326 chr1 18294487 G A 2.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs2095842 chr1 18297407 A G 2.56E-04 Multiple complex diseases / / 17554300 rs2095842 chr1 18297407 A G 8.25E-05 Alzheimer's disease / / 17998437 rs2095842 chr1 18297407 A G 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs871644 chr1 18297688 G A 2.40E-04 Multiple complex diseases / / 17554300 rs871644 chr1 18297688 G A 8.56E-05 Alzheimer's disease / / 17998437 rs871644 chr1 18297688 G A 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1192633 chr1 18304543 G A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11588830 chr1 18314621 C T 1.87E-04 Multiple complex diseases / / 17554300 rs11588830 chr1 18314621 C T 5.83E-04 Alzheimer's disease / / 17998437 rs16861410 chr1 18335597 C G 0.0001988 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861410 chr1 18335597 C G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1192621 chr1 18337250 T A 8.20E-05 Thyroid peroxidase antibody levels / / 24586183 rs1192622 chr1 18337268 A G 6.93E-04 Type 2 diabetes / / 17463246 rs1192625 chr1 18339791 T C 7.52E-06 Carotenoid and tocopherol levels / / 19185284 rs1108624 chr1 18342807 G A 0.0002527 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1108624 chr1 18342807 G A 2.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs794237 chr1 18342964 A G 3.99E-04 Alzheimer's disease / / 24755620 rs16861446 chr1 18348784 C T 0.0002954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861446 chr1 18348784 C T 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861481 chr1 18360161 G A 0.0001653 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861481 chr1 18360161 G A 1.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861517 chr1 18374542 G A 0.0004773 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861517 chr1 18374542 G A 4.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9659407 chr1 18387310 G A 8.58E-04 Heart Failure / / pha002884 rs9286088 chr1 18391974 A C 1.30E-05 stroke (ischemic) / / 17434096 rs4920421 chr1 18392608 C T 5.50E-05 Endometriosis / / 21151130 rs4920422 chr1 18392752 C A 2.52E-04 Alcohol dependence / / 21314694 rs4920425 chr1 18408139 C T 8.06E-06 Heart Failure / / pha002884 rs9804128 chr1 18425011 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs12739708 chr1 18426428 C T 3.27E-04 Myopia (pathological) / / 21095009 rs12724674 chr1 18431501 G A 5.96E-13 Multiple complex diseases / / 17554300 rs1342569 chr1 18438351 T C 4.17E-04 Myopia (pathological) IGSF21 intron 21095009 rs10443386 chr1 18444514 C A 4.10E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs16861578 chr1 18447490 C A 2.99E-04 Response to taxane treatment (placlitaxel) IGSF21 intron 23006423 rs12735521 chr1 18450321 C T 4.70E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs987293 chr1 18451900 A G 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IGSF21 intron 24023788 rs9726285 chr1 18484945 G C 2.50E-05 Urinary metabolites IGSF21 intron 21572414 rs17435018 chr1 18487906 C T 2.01E-05 Response to citalopram treatment IGSF21 intron 19846067 rs4920300 chr1 18490061 C T 1.34E-04 Vaspin levels IGSF21 intron 22907691 rs4920300 chr1 18490061 C T 0.0001343 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit IGSF21 intron 22907730 rs9728569 chr1 18510033 T G 9.75E-05 Cholesterol IGSF21 intron pha003083 rs1033190 chr1 18528848 G T 6.15E-04 Alcohol dependence IGSF21 intron 20201924 rs4920311 chr1 18563991 G C 6.60E-04 Atrial fibrillation IGSF21 intron 21846873 rs371505 chr1 18586420 C A 8.88E-04 Alzheimer's disease IGSF21 intron 17998437 rs516656 chr1 18589743 C G 5.37E-04 Alzheimer's disease IGSF21 intron 17998437 rs1555219 chr1 18630150 T C 8.84E-04 Coronary Artery Disease IGSF21 intron 17634449 rs11260978 chr1 18632801 A G 3.91E-04 Atopy IGSF21 intron 21625490 rs761585 chr1 18633940 G A 7.70E-04 Coronary Artery Disease IGSF21 intron 17634449 rs4920475 chr1 18643335 C T 9.09E-04 Multiple complex diseases IGSF21 intron 17554300 rs4920478 chr1 18655339 G A 5.00E-06 Urinary metabolites IGSF21 intron 21572414 rs33947700 chr1 18665124 C T 9.55E-04 Multiple complex diseases IGSF21 intron 17554300 rs542634 chr1 18672774 G A 4.08E-05 Height IGSF21 intron pha003011 rs16861827 chr1 18678170 C T 2.00E-04 Pancreatic cancer IGSF21 intron 23180869 rs16861827 chr1 18678170 C T 5.91E-05 Tuberculosis IGSF21 intron 24057671 rs12125819 chr1 18696135 G A 3.94E-04 Suicide attempts in bipolar disorder IGSF21 intron 21423239 rs12566510 chr1 18705694 A G 9.18E-04 Multiple complex diseases / / 17554300 rs10492995 chr1 18707373 A C 2.71E-04 Fibrinogen / / 17255346 rs10492995 chr1 18707373 A C 4.67E-04 HIV-1 viral setpoint / / 17641165 rs7538442 chr1 18716278 A G 7.04E-05 Orofacial clefts / / 20023658 rs1336131 chr1 18722737 G T 5.74E-05 Diabetes (gestational) / / 22233651 rs1336122 chr1 18761124 A G 8.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs1336128 chr1 18765308 A G 5.35E-04 Multiple complex diseases / / 17554300 rs1568339 chr1 18766761 C A 2.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs7535812 chr1 18786779 C G 1.12E-04 Coronary heart disease / / 21606135 rs1414642 chr1 18787446 C T 2.88E-06 Phospholipid levels (plasma) / / 21829377 rs3007728 chr1 18794241 C T 1.67E-06 Phospholipid levels (plasma) / / 21829377 rs3007729 chr1 18795255 T C 8.46E-06 Lung adenocarcinoma / / 19836008 rs3007729 chr1 18795255 T C 5.00E-06 Diabetic retinopathy / / 21441570 rs16862008 chr1 18801486 G A 3.33E-06 Phospholipid levels (plasma) / / 21829377 rs7528206 chr1 18807117 T C 5.06E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2992745 chr1 18809896 A T 8.60E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs3007719 chr1 18811668 T C 8.70E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs72646406 chr1 18815045 A G 0.0000556 Sarcoidosis / / 22952805 rs909950 chr1 18824363 G A 3.12E-04 Type 2 diabetes / / 17463246 rs17351871 chr1 18838322 G C 8.75E-04 Obesity (extreme) / / 21935397 rs12401403 chr1 18863502 A G 2.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs114799364 chr1 18900554 C T 2.72E-06 Prostate cancer / / 24185611 rs4920334 chr1 18913558 T C 7.68E-04 Multiple complex diseases / / 17554300 rs4920516 chr1 18913618 G C 7.63E-04 Multiple complex diseases / / 17554300 rs6684839 chr1 18920685 G A 8.60E-06 Urinary metabolites / / 21572414 rs4920520 chr1 18929842 G A 8.22E-05 Cleft lip / / 20436469 rs4920520 chr1 18929842 G A 6.45E-06 Orofacial clefts / / 22863734 rs4920522 chr1 18940380 C T 4.61E-06 Cleft lip / / 20436469 rs4920522 chr1 18940380 C T 9.41E-07 Orofacial clefts / / 22863734 rs7541797 chr1 18951985 G C 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 6.55E-07 Cleft lip / / 20436469 rs17352100 chr1 18952112 C T 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 3.25E-07 Orofacial clefts / / 22863734 rs766325 chr1 18956458 G A 2.21E-06 Cleft lip PAX7 nearGene-5 20436469 rs766325 chr1 18956458 G A 7.39E-07 Orofacial clefts PAX7 nearGene-5 22863734 rs10907325 chr1 18964021 A T 2.54E-04 Body mass index PAX7 intron 21701565 rs10907325 chr1 18964021 A T 5.31E-04 Body mass index PAX7 intron 21701565 rs7364475 chr1 18965061 C T 2.77E-04 Orofacial clefts PAX7 intron 22863734 rs10907326 chr1 18965360 T G 2.90E-04 Body mass index PAX7 intron 21701565 rs10907326 chr1 18965360 T G 6.00E-04 Body mass index PAX7 intron 21701565 rs11583072 chr1 18966007 G T 1.42E-06 Orofacial clefts PAX7 intron 22863734 rs56675509 chr1 18971634 G C 1.03E-05 Orofacial clefts PAX7 intron 22863734 rs9439713 chr1 18972776 G A 2.87E-06 Orofacial clefts PAX7 intron 22863734 rs9439714 chr1 18976489 T C 7.02E-08 Orofacial clefts PAX7 intron 22863734 rs4920524 chr1 18978372 T G 4.94E-08 Orofacial clefts PAX7 intron 22863734 rs6695765 chr1 18979320 T C 2.43E-06 Cleft lip PAX7 intron 20436469 rs6695765 chr1 18979320 T C 1.12E-06 Orofacial clefts PAX7 intron 22863734 rs742071 chr1 18979874 G T 1.57E-07 Cleft lip PAX7 intron 20436469 rs742071 chr1 18979874 G T 7.00E-09 Orofacial clefts PAX7 intron 22863734 rs6659735 chr1 18983697 G A,C,T 8.13E-06 Cleft lip PAX7 intron 20436469 rs6659735 chr1 18983697 G A,C,T 1.36E-06 Orofacial clefts PAX7 intron 22863734 rs56075776 chr1 18986508 G A 2.16E-06 Orofacial clefts PAX7 intron 22863734 rs1339063 chr1 18989575 A T 5.84E-06 Orofacial clefts PAX7 intron 22863734 rs2236835 chr1 18990251 G A 8.00E-06 Body mass index PAX7 intron 23669352 rs4920338 chr1 18990793 C T 2.36E-05 Cleft lip PAX7 intron 20436469 rs4920338 chr1 18990793 C T 8.39E-07 Orofacial clefts PAX7 intron 22863734 rs4920339 chr1 18991005 C T 1.29E-06 Orofacial clefts PAX7 intron 22863734 rs12141588 chr1 18995326 C T 2.84E-04 Suicide attempts in bipolar disorder PAX7 intron 21423239 rs16862125 chr1 18999794 C A 5.00E-04 Smoking initiation PAX7 intron 24665060 rs2236832 chr1 18999831 A G 9.70E-05 Waist Circumference PAX7 intron pha003025 rs545793 chr1 19016522 G C 3.05E-04 Smoking initiation PAX7 intron 24665060 rs2236826 chr1 19019980 T C 5.34E-04 Smoking initiation PAX7 intron 24665060 rs2236824 chr1 19032272 G C 2.00E-06 Response to amphetamines PAX7 intron 22952603 rs624761 chr1 19044877 C T 7.65E-05 Amyotrophic Lateral Sclerosis PAX7 intron 17827064 rs2743189 chr1 19056382 C T 6.91E-04 Alcohol dependence PAX7 intron 21314694 rs2236805 chr1 19057730 G A 2.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PAX7 intron 24023788 rs1160680 chr1 19080506 A G 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7414734 chr1 19094738 G A 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4920344 chr1 19104381 A G 6.19E-04 Multiple complex diseases / / 17554300 rs6669544 chr1 19109036 C G 4.40E-06 Urinary metabolites / / 21572414 rs4920537 chr1 19109183 C T 4.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs12566799 chr1 19123033 G A 2.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7411058 chr1 19134260 A G 2.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7411577 chr1 19134834 A C 8.12E-05 Alzheimer's disease (age of onset) / / 22005931 rs7417542 chr1 19135214 G A 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12063142 chr1 19139517 C T 5.00E-07 Parkinson's disease / / 20070850 rs72651812 chr1 19141142 C G 1.88E-05 Acne (severe) / / 24927181 rs6662718 chr1 19169613 G A 2.37E-05 Alzheimer's disease (age of onset) TAS1R2 intron 22005931 rs28441017 chr1 19206334 G A 9.00E-06 Anorexia nervosa ALDH4A1 intron 23568457 rs4911977 chr1 19239515 T C 3.55E-05 Multiple complex diseases IFFO2 intron 17554300 rs6698642 chr1 19255671 C T 2.32E-07 Facial morphology IFFO2 intron 22341974 rs4912013 chr1 19284564 T C 1.45E-04 Alcohol dependence / / 21314694 rs16862426 chr1 19321495 C T 9.00E-08 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs6690097 chr1 19323050 G C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7523455 chr1 19332076 A G 2.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs28829049 chr1 19349281 C T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7527580 chr1 19378508 G A 7.67E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 8.72E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 7.13E-04 Stroke / / pha002887 rs12123383 chr1 19386585 A C 4.00E-06 Response to amphetamines / / 22952603 rs3748761 chr1 19400691 C G 8.54E-04 Alzheimer's disease UBR4 nearGene-3 17998437 rs10158468 chr1 19402390 T C 9.95E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs2146866 chr1 19405237 A G 8.46E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs12740975 chr1 19437923 G A 6.43E-04 Schizophrenia UBR4 intron 19197363 rs2274001 chr1 19464773 C T 5.94E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs1009806 chr1 19500551 T C 8.07E-04 Schizophrenia UBR4 intron 19197363 rs710880 chr1 19564049 G A 4.84E-04 Multiple complex diseases KIAA0090 intron 17554300 rs710865 chr1 19568972 A G 1.00E-07 Brain structure KIAA0090 intron 20171287 rs10917275 chr1 19576035 T C 6.83E-06 Serum metabolites KIAA0090 intron 19043545 rs2073102 chr1 19583330 G C 9.98E-04 Alzheimer's disease MRTO4 intron 24755620 rs1042380 chr1 19584004 G A 1.54E-05 Serum metabolites MRTO4 cds-synon 19043545 rs7527253 chr1 19593199 T C 7.79E-04 Alzheimer's disease / / 24755620 rs10917331 chr1 19604101 G A 6.88E-04 Alzheimer's disease / / 24755620 rs1738025 chr1 19609254 T C 1.42E-04 Height AKR7A3 missense 17255346 rs1738023 chr1 19611241 T C 1.26E-04 Height AKR7A3 missense 17255346 rs859217 chr1 19640698 G A 9.37E-04 Multiple complex diseases PQLC2 intron 17554300 rs2064378 chr1 19644855 G A 3.70E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs4912069 chr1 19645673 G A 3.98E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs2268809 chr1 19667552 C T 3.83E-04 Multiple complex diseases CAPZB intron 17554300 rs72651465 chr1 19671766 T A 4.06E-04 Acne (severe) CAPZB intron 24927181 rs191942 chr1 19691754 G A 8.33E-04 Multiple complex diseases CAPZB intron 17554300 rs214321 chr1 19693128 C A 5.71E-05 Multiple complex diseases CAPZB intron 17554300 rs10917434 chr1 19707302 G A 8.72E-04 Type 2 diabetes CAPZB intron 17463246 rs7667 chr1 19718824 G A 8.00E-06 Crohn's disease and psoriasis CAPZB intron 22482804 rs12403041 chr1 19730927 A G 8.03E-04 Multiple complex diseases CAPZB intron 17554300 rs4244002 chr1 19738190 C T 5.80E-04 Multiple complex diseases CAPZB intron 17554300 rs1472565 chr1 19755030 T C 6.30E-05 Hypothyroidism CAPZB intron 22493691 rs2088828 chr1 19757646 C A 2.59E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs12137160 chr1 19763379 C T 8.47E-04 Multiple complex diseases CAPZB intron 17554300 rs12137162 chr1 19763396 C A 8.25E-04 Multiple complex diseases CAPZB intron 17554300 rs10799810 chr1 19764032 G A 2.43E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs4911995 chr1 19765004 G C 1.70E-04 Multiple complex diseases CAPZB intron 17554300 rs4911996 chr1 19765205 G C 8.24E-04 Multiple complex diseases CAPZB intron 17554300 rs12045440 chr1 19765518 T G 5.48E-04 Type 2 diabetes CAPZB intron 17463246 rs12045440 chr1 19765518 T G 2.00E-11 Thyroid volume CAPZB intron 21565293 rs12045440 chr1 19765518 T G 3.00E-14 Thyroid volume CAPZB intron 21565293 rs4911997 chr1 19765669 G A 3.22E-04 Multiple complex diseases CAPZB intron 17554300 rs10492997 chr1 19769371 C T 3.49E-04 Multiple complex diseases CAPZB intron 17554300 rs1002365 chr1 19797248 T C 9.90E-05 Hypothyroidism CAPZB intron 22493691 rs3813986 chr1 19801268 C T 2.76E-04 Multiple complex diseases CAPZB intron 17554300 rs10799817 chr1 19805997 C G 8.22E-04 Type 2 diabetes CAPZB intron 17463246 rs924519 chr1 19806259 C T 7.67E-04 Type 2 diabetes CAPZB intron 17463246 rs6664461 chr1 19809171 C T 9.57E-06 Insulin Resistance CAPZB intron pha003062 rs6664461 chr1 19809171 C T 1.27E-05 Insulin-related traits CAPZB intron pha003063 rs1995311 chr1 19820119 T G 1.87E-04 Tuberculosis / / 22306650 rs873095 chr1 19823329 G A 4.70E-08 Thyroid function / / 20826269 rs2314146 chr1 19824008 A G 5.80E-06 Thyroid stimulating hormone / / 24852370 rs6683419 chr1 19827780 G A 3.00E-07 Thyroid stimulating hormone / / 24852370 rs16822442 chr1 19827970 A G 3.30E-08 Thyroid function / / 20826269 rs11807599 chr1 19831939 C T 6.00E-08 Thyroid function / / 20826269 rs11806434 chr1 19832437 G A 5.70E-08 Thyroid function / / 20826269 rs12136721 chr1 19832987 C G 5.70E-08 Thyroid function / / 20826269 rs4394682 chr1 19837537 A G 4.00E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.50E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.00E-18 Thyroid volume / / 21565293 rs568931048 chr1 19839115 A AC 3.50E-08 Thyroid function / / 20826269 rs568931048 chr1 19839115 A AC 3.00E-18 Thyroid volume / / 21565293 rs10799824 chr1 19841174 G A 3.50E-08 Thyroid function / / 20826269 rs10799824 chr1 19841174 G A 1.00E-08 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 3.00E-14 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 4.00E-21 Thyroid hormone levels / / 23408906 rs10917468 chr1 19843354 T C 1.00E-14 Thyroid volume / / 21565293 rs10917468 chr1 19843354 T C 0.00025 Prostate cancer / / 23555315 rs10917469 chr1 19843576 A G 9.95E-04 Multiple complex diseases / / 17554300 rs10917469 chr1 19843576 A G 3.20E-08 Thyroid function / / 20826269 rs6426809 chr1 19858271 C T 4.51E-04 Alzheimer's disease / / 17998437 rs10917477 chr1 19861106 A G 2.00E-08 Thyroid function / / 22494929 rs10917477 chr1 19861106 A G 6.80E-05 Blood Pressure / / pha003048 rs4912122 chr1 19876438 A G 8.79E-04 Multiple complex diseases / / 17554300 rs10917493 chr1 19882170 T G 2.42E-05 Insulin Resistance / / pha003062 rs717536 chr1 19905646 G C 4.42E-04 Multiple complex diseases / / 17554300 rs1770480 chr1 19916784 C T 4.41E-08 Thyroid function / / 22494929 rs2745217 chr1 19921747 C T 1.46E-08 Thyroid function / / 22494929 rs2792043 chr1 19924662 A C 2.77E-08 Thyroid function MINOS1 intron 22494929 rs860847 chr1 19927553 C A 7.04E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1770483 chr1 19930252 T A 7.03E-04 Multiple complex diseases MINOS1 intron 17554300 rs1770483 chr1 19930252 T A 9.34E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1320978 chr1 19947973 A G 2.25E-08 Thyroid function MINOS1 intron 22494929 rs10917504 chr1 19965927 C A 1.00E-04 Prostate cancer C1orf151-NBL1 intron 21743057 rs6693503 chr1 19987294 A G 0.0000161 Uterine leiomyomata / / 23040493 rs16822732 chr1 20015300 G A 5.30E-05 Asthma TMCO4 intron 11022011 rs2050121 chr1 20016849 G A 6.76E-05 Blood pressure (response to calcium channel blocker) TMCO4 intron 24192120 rs3748748 chr1 20018195 G A 6.63E-05 Asthma TMCO4 intron 11022011 rs3748748 chr1 20018195 G A 4.78E-04 Orofacial clefts TMCO4 intron 22863734 rs3934191 chr1 20026572 A G 3.51E-04 Response to cytidine analogues (gemcitabine) TMCO4 intron 24483146 rs3929668 chr1 20052373 C T 6.97E-04 Lymphocyte counts TMCO4 intron 22286170 rs10917526 chr1 20056933 G A 2.30E-05 Urinary metabolites TMCO4 intron 21572414 rs3850533 chr1 20061456 T C 2.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) TMCO4 intron 23648065 rs12140071 chr1 20110436 T C 9.81E-05 Parent of origin effect on language impairment (paternal) TMCO4 intron 24571439 rs10799837 chr1 20135612 G A 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317209 chr1 20140036 G A 2.00E-10 Ulcerative colitis / / 20228799 rs1317209 chr1 20140036 G A 2.00E-10 Asthma / / 21907864 rs3767216 chr1 20140340 A G 2.77E-05 Sudden cardiac arrest / / 21658281 rs3806308 chr1 20142866 C T 7.00E-09 Ulcerative colitis / / 19122664 rs10799839 chr1 20148249 C T 4.43E-05 Blood Pressure / / pha003045 rs10799839 chr1 20148249 C T 4.51E-05 Blood Pressure / / pha003047 rs10917552 chr1 20158334 T C 0.0005392 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10917552 chr1 20158334 T C 5.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2314762 chr1 20158604 T G 6.46E-05 Blood pressure / / 24001895 rs4271183 chr1 20163290 T G 2.48E-05 Pulmonary function / / 19300500 rs12137940 chr1 20165383 C A 2.72E-05 Pulmonary function / / 19300500 rs6426833 chr1 20171860 G A 5.00E-13 Ulcerative colitis / / 19122664 rs6426833 chr1 20171860 G A 2.00E-11 Ulcerative colitis / / 19915572 rs6426833 chr1 20171860 G A 2.00E-21 Ulcerative colitis / / 20228799 rs6426833 chr1 20171860 G A 4.00E-35 Ulcerative colitis / / 21297633 rs6426833 chr1 20171860 G A 2.00E-68 Ulcerative colitis / / 23128233 rs6426833 chr1 20171860 G A 7.22E-08 Ulcerative colitis / / 23511034 rs10917558 chr1 20173972 C T 2.99E-05 Pulmonary function / / 19300500 rs6690967 chr1 20183342 C T 4.42E-04 Blood pressure / / 17255346 rs12117495 chr1 20183445 A G 6.54E-05 Pulmonary function / / 19300500 rs16823043 chr1 20184603 G A 2.88E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7531128 chr1 20187321 G A 2.00E-05 Urinary metabolites / / 21572414 rs6686814 chr1 20187511 C T 7.44E-05 Longevity / / 20304771 rs16823061 chr1 20190672 G A 7.05E-05 Longevity / / 20304771 rs7517912 chr1 20192876 A T 6.64E-05 Longevity / / 20304771 rs12064952 chr1 20197978 G C 5.00E-05 Longevity / / 20304771 rs4654903 chr1 20200990 A G 7.00E-09 Ulcerative colitis / / 23511034 rs12124726 chr1 20209469 A C 2.55E-08 Sickle cell anemia (severity) OTUD3 intron 20029952 rs4654910 chr1 20213087 C A 4.70E-05 Longevity OTUD3 intron 20304771 rs1339717 chr1 20222500 G A 8.52E-04 Alzheimer's disease OTUD3 intron 22005930 rs4654925 chr1 20227723 G C,T 9.00E-22 Ulcerative colitis OTUD3 intron 20228798 rs4654925 chr1 20227723 G C,T 9.00E-22 Multiple sclerosis OTUD3 intron 22190364 rs10916668 chr1 20233086 G A 7.82E-05 Pulmonary function OTUD3 missense 19300500 rs10492999 chr1 20237760 A G 7.83E-05 Pulmonary function OTUD3 UTR-3 19300500 rs1046548 chr1 20238343 A G 9.66E-04 Suicide attempts in bipolar disorder OTUD3 UTR-3 21423239 rs17401847 chr1 20238466 A G 1.35E-05 Longevity OTUD3 UTR-3 20304771 rs12028511 chr1 20247674 C A 1.97E-04 Alzheimer's disease (late onset) PLA2G2E intron 21379329 rs2233687 chr1 20250799 C T 3.89E-05 Waist-Hip Ratio / / pha003029 rs1093733 chr1 20258473 T C 6.72E-04 Alzheimer's disease / / 22005930 rs818968 chr1 20279405 C T 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4655010 chr1 20287919 C A 1.14E-05 Post-operative nausea and vomiting / / 21694509 rs12568139 chr1 20311676 A G 3.33E-04 Smoking quantity / / 24665060 rs3767225 chr1 20399643 T C 6.64E-04 Type 2 diabetes PLA2G5 intron 17463246 rs10916704 chr1 20400991 G T 1.47E-10 Cholesterol,total PLA2G5 intron 23063622 rs10916704 chr1 20400991 G T 4.52E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573213 chr1 20402010 A C 0.000000331 Cholesterol,total PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 0.000000425 Triglycerides PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 1.60E-10 Cholesterol,total PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.39E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.45E-08 Cholesterol,total PLA2G5 intron 23063622 rs10916705 chr1 20413887 C G 8.65E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 9.05E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 2.18E-04 Smoking quantity PLA2G5 intron 24665060 rs11573291 chr1 20417765 G A 2.55E-04 Multiple complex diseases PLA2G5 UTR-3 17554300 rs6699362 chr1 20423099 T G 7.55E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4655155 chr1 20427541 C T 1.08E-04 Alzheimer's disease (late onset) / / 21379329 rs492738 chr1 20429861 C A 4.17E-04 Alzheimer's disease (late onset) / / 21379329 rs1567102 chr1 20444473 C T 0.00079897 Hypertension (early onset hypertension) PLA2G2D intron 22479346 rs623784 chr1 20452434 A C,G,T 8.67E-06 Obesity-related traits / / 23251661 rs12722987 chr1 20455220 C A 7.00E-06 Obesity-related traits / / 23251661 rs12745152 chr1 20469854 G A 3.58E-05 Cardiovascular disease PLA2G2F intron pha003064 rs12025316 chr1 20494741 C G 4.32E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301472 chr1 20498914 C T 4.41E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 1.06E-05 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 8.65E-04 Response to cytadine analogues (cytosine arabinoside) PLA2G2C intron 24483146 rs10916718 chr1 20501442 T C 1.57E-05 Platelet counts PLA2G2C intron 21507922 rs2301478 chr1 20501974 G A 1.87E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10799612 chr1 20502761 C G 3.30E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs3179690 chr1 20518226 G A 3.11E-08 Secreted IFN-gamma response to smallpox vaccine UBXN10 UTR-3 22661280 rs7517797 chr1 20532401 T C 7.11E-04 Multiple complex diseases / / 17554300 rs10799615 chr1 20541370 A G 0.0002 Migraine / / 22678113 rs7533370 chr1 20542980 A G 9.51E-04 Multiple complex diseases / / 17554300 rs6692412 chr1 20561095 C T 8.85E-04 Multiple complex diseases / / 17554300 rs4655165 chr1 20562389 G A 2.74E-05 Cleft lip / / 20436469 rs2157508 chr1 20572621 T C 4.65E-05 Serum metabolites / / 19043545 rs2157508 chr1 20572621 T C 1.11E-04 Smoking cessation / / 24665060 rs6426624 chr1 20572638 A G 8.55E-05 Serum metabolites / / 19043545 rs2157510 chr1 20572894 A G 4.65E-05 Serum metabolites / / 19043545 rs743983 chr1 20583322 T G 4.10E-05 Serum metabolites / / 19043545 rs17354986 chr1 20585773 C T 6.84E-04 Acute lung injury / / 22295056 rs966366 chr1 20592340 T C 8.54E-07 Type 2 diabetes / / 17463246 rs966366 chr1 20592340 T C 1.62E-04 Acute lung injury / / 22295056 rs2017456 chr1 20598351 C T 8.14E-04 Type 2 diabetes / / 17463246 rs4655183 chr1 20604014 A C 1.24E-04 Type 2 diabetes / / 17463246 rs12116793 chr1 20625777 C A 1.76E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs12134413 chr1 20630594 A C 1.42E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs16823838 chr1 20631012 C G 8.65E-04 Multiple complex diseases VWA5B1 intron 17554300 rs12140623 chr1 20632815 G A 3.06E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs11809335 chr1 20635722 A G 6.67E-05 Height VWA5B1 intron pha003011 rs12124623 chr1 20667464 G T 5.67E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs10916782 chr1 20726556 G A 7.79E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs912813 chr1 20728889 T A 1.50E-05 Urinary metabolites LOC339505 intron 21572414 rs879484 chr1 20729212 T C 4.85E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs10753498 chr1 20733376 T C 1.10E-05 Urinary metabolites LOC339505 intron 21572414 rs7514144 chr1 20735869 C T 9.09E-05 Common variable immunodeficiency LOC339505 intron 21497890 rs10799633 chr1 20740016 C A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC339505 intron 20877124 rs1886737 chr1 20745074 C A 2.00E-04 Type 2 diabetes LOC339505 intron 17463246 rs974332 chr1 20745485 T C 3.47E-04 Multiple complex diseases LOC339505 intron 17554300 rs10916799 chr1 20767524 C T 4.90E-06 Blood Pressure / / pha003040 rs750070 chr1 20769184 A C 4.81E-05 Blood Pressure / / pha003040 rs10799636 chr1 20770887 T C 6.06E-05 Body Mass Index / / pha003006 rs97922 chr1 20804065 T G 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs609210 chr1 20849079 C T 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698887 chr1 20857064 G A 7.91E-04 Multiple complex diseases / / 17554300 rs660423 chr1 20865703 T C 6.17E-04 Aortic root size / / 21223598 rs561411 chr1 20866328 C T 8.50E-04 Aortic root size / / 21223598 rs667357 chr1 20872694 C T 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12072199 chr1 20877812 T C 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs675397 chr1 20883422 T C 3.47E-05 Bladder cancer / / 19648920 rs677214 chr1 20883816 C T 4.19E-04 Iron levels / / pha002876 rs639400 chr1 20900123 C T 2.10E-05 Urinary metabolites / / 21572414 rs532545 chr1 20915172 C T 1 Drug response to Cytarabine / / 19458626 rs532545 chr1 20915172 C T 1 Drug response to Daunorubicin / / 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 15224082 rs2072671 chr1 20915701 A C 1 Drug response to Carboplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cisplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Fluorouracil CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cytarabine CDA missense 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Daunorubicin CDA missense 19458626 rs517483 chr1 20930035 C T 2.69E-05 Leukocyte Counts CDA intron pha003091 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 15224082 rs60369023 chr1 20931474 G A 1 Drug response to Carboplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Cisplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Fluorouracil CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 17194903 rs527912 chr1 20934283 G A 9.40E-05 Type 2 diabetes CDA intron 17463248 rs527912 chr1 20934283 G A 7.42E-05 Adipocyte fatty acid-binding protein concentration,in serum CDA intron 21863005 rs573337 chr1 20936233 C G 1.00E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 2.70E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 1.17E-04 Acute lung injury CDA intron 22295056 rs1048977 chr1 20945055 C T 1 Drug response to Gemcitabine CDA cds-synon 15224082 rs3820321 chr1 20962827 G A 4.00E-05 Type 2 diabetes PINK1 intron 17463248 rs2298298 chr1 20964328 A G 9.00E-05 Personality dimensions PINK1 intron 18957941 rs3102071 chr1 20968011 A G 8.90E-05 Personality dimensions PINK1 intron 18957941 rs2298299 chr1 20974802 A G 2.00E-04 Acute lung injury PINK1 intron 22295056 rs1573132 chr1 20978024 C A 3.20E-04 Schizophrenia(treatment response to risperidone) DDOST nearGene-3 19850283 rs622525 chr1 20979818 A T 8.90E-05 Personality dimensions DDOST intron 18957941 rs607254 chr1 20980880 G A 3.40E-05 Type 2 diabetes DDOST intron 17463248 rs589709 chr1 20983987 G A 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs640742 chr1 20984554 A C 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs623817 chr1 20986078 G A 3.10E-05 Type 2 diabetes DDOST intron 17463248 rs674114 chr1 20989672 G A 6.80E-05 Type 2 diabetes DDOST nearGene-5 17463248 rs630484 chr1 20992606 G T 4.80E-05 Type 2 diabetes KIF17 intron 17463248 rs12118760 chr1 20999804 T C 2.20E-05 Type 2 diabetes KIF17 intron 17463248 rs12025912 chr1 21002699 T C 2.35E-04 Acute lung injury KIF17 intron 22295056 rs12025916 chr1 21002726 T C 2.17E-04 Acute lung injury KIF17 intron 22295056 rs2296223 chr1 21011182 G A 0.0005775 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF17 intron 23233654 rs2296223 chr1 21011182 G A 5.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF17 intron 23233662 rs17407280 chr1 21020405 C T 3.60E-04 Type 2 diabetes KIF17 intron 17463246 rs149579175 chr1 21051116 G A 0.00022 Breast cancer SH2D5 missense 23555315 rs10916852 chr1 21052693 G T 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs35472344 chr1 21052693 GC G 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs951805 chr1 21060356 G A 2.90E-05 Urinary metabolites / / 21572414 rs1021077 chr1 21106016 T C 1.20E-05 Urinary metabolites HP1BP3 intron 21572414 rs10916891 chr1 21199974 T G 1.51E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916891 chr1 21199974 T G 2.02E-04 Lymphocyte counts EIF4G3 intron 22286170 rs4654885 chr1 21220491 T C 4.21E-09 Multiple complex diseases EIF4G3 intron 17554300 rs10157616 chr1 21244582 T C 1.88E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916901 chr1 21245001 A G 0.000041 Mean arterial pressure EIF4G3 intron 22510845 rs3767248 chr1 21276854 A G 4.14E-04 Coronary heart disease EIF4G3 intron 21971053 rs12021529 chr1 21306161 T C 7.25E-05 Multiple complex diseases EIF4G3 intron 17554300 rs10916930 chr1 21395357 T C 2.70E-04 Multiple complex diseases EIF4G3 intron 17554300 rs2282714 chr1 21587849 G A 1.53E-04 Myopia (pathological) ECE1 intron 21095009 rs3026862 chr1 21604387 C G 3.18E-10 LDL cholesterol ECE1 intron 23063622 rs213010 chr1 21639167 A G 3.89E-04 Alzheimer's disease (late onset) ECE1 intron 21379329 rs213032 chr1 21654735 T C 6.00E-06 Obesity-related traits ECE1 intron 23251661 rs3026815 chr1 21664475 C T 3.08E-06 Personality dimensions ECE1 intron 18957941 rs3026815 chr1 21664475 C T 1.77E-05 Depression (quantitative trait) ECE1 intron 20800221 rs213006 chr1 21678600 T G 2.00E-05 Depression (quantitative trait) / / 20800221 rs12736884 chr1 21725505 G C 3.90E-04 Alcohol dependence / / 20201924 rs12750103 chr1 21736327 A G 9.00E-11 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs12750103 chr1 21736327 A G 9.00E-11 Airflow obstruction / / 22837378 rs1566524 chr1 21737466 C A,G,T 4.01E-04 Insulin resistance / / 21901158 rs10916983 chr1 21742737 T C 3.19E-04 Bipolar disorder,schizoaffective / / 19567891 rs10916983 chr1 21742737 T C 9.15E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1976403 chr1 21766453 A C 2.00E-50 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs4654748 chr1 21786068 C T 8.00E-18 Folate pathway vitamin levels NBPF3 intron 19303062 rs4654748 chr1 21786068 C T 4.00E-11 Folate pathway vitamin levels NBPF3 intron 19744961 rs4654748 chr1 21786068 C T 6.73E-09 Vitamin B6 NBPF3 intron 23696881 rs10799701 chr1 21820990 A G 3.00E-20 Metabolic traits / / 21886157 rs1780324 chr1 21821757 A G 7.00E-15 Liver enzyme levels / / 18940312 rs1780324 chr1 21821757 A G 7.14E-05 Blood cell counts and other traits / / 20139978 rs1697421 chr1 21823292 C T 1.00E-27 Phosphorus levels / / 20558539 rs1697421 chr1 21823292 C T 0.00082 Prostate cancer / / 23555315 rs1697421 chr1 21823292 C T 2.00E-20 Blood metabolite ratios / / 24816252 rs1697421 chr1 21823292 C T 3.00E-14 Blood metabolite ratios / / 24816252 rs6667242 chr1 21826566 A G 1.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs16825455 chr1 21837755 A G 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ALPL intron 23648065 rs7535497 chr1 21840709 T G 6.43E-04 Type 2 diabetes ALPL intron 17463246 rs7523855 chr1 21840886 C T 6.04E-04 Type 2 diabetes ALPL intron 17463246 rs1890431 chr1 21852078 C T 6.48E-05 Tunica Media ALPL intron pha003036 rs1697414 chr1 21874996 T A 6.98E-04 Multiple complex diseases ALPL intron 17554300 rs885814 chr1 21875916 C T 6.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis ALPL intron 22569225 rs885813 chr1 21877074 C T 3.49E-05 Lactate dehydrogenase levels ALPL intron 20981236 rs3767155 chr1 21885195 C T 3.09E-04 Alzheimer's disease ALPL intron 24755620 rs1767429 chr1 21889340 A G 1.93E-04 Alzheimer's disease ALPL intron 24755620 rs1256335 chr1 21890386 G A 1.00E-15 Folate pathway vitamin levels ALPL intron 19744961 rs3738097 chr1 21894816 T C 9.86E-04 Type 2 diabetes ALPL intron 17463246 rs3767142 chr1 21901558 G A 3.27E-04 Alzheimer's disease ALPL intron 24755620 rs2242420 chr1 21904529 C T 5.00E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs2242420 chr1 21904529 C T 5.08E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs7515386 chr1 21921736 G A 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4654973 chr1 21927820 C G 7.22E-04 Obesity (extreme) RAP1GAP intron 21935397 rs829370 chr1 21933193 C T 3.99E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs861212 chr1 21935433 G T 8.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GAP intron 20877124 rs829417 chr1 21943136 C T 1 Drug response to Etoposide RAP1GAP intron 17537913 rs829418 chr1 21943504 A G 7.54E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs829406 chr1 21949462 A G 1.36E-04 Fibrinogen RAP1GAP intron 17255346 rs829406 chr1 21949462 A G 9.04E-04 Coronary heart disease RAP1GAP intron 21606135 rs829411 chr1 21953138 A G 6.91E-04 Acute lung injury RAP1GAP intron 22295056 rs1531829 chr1 21953304 G A 7.69E-04 Multiple complex diseases RAP1GAP intron 17554300 rs829412 chr1 21953436 A G 2.71E-04 Type 2 diabetes RAP1GAP intron 17463246 rs829412 chr1 21953436 A G 7.03E-04 Multiple complex diseases RAP1GAP intron 17554300 rs4654974 chr1 21954294 T C 7.64E-05 Cognitive test performance RAP1GAP intron 20125193 rs4654974 chr1 21954294 T C 2.59E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426770 chr1 21955744 G C 2.61E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426674 chr1 21957239 G C 2.69E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs11591167 chr1 21958536 C T 2.14E-05 Mammographic density RAP1GAP intron 22532574 rs9426771 chr1 21958739 G A,C,T 3.87E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426772 chr1 21959590 T C 8.84E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs6679565 chr1 21962551 G A 2.13E-04 Coronary heart disease RAP1GAP intron 21606135 rs12142081 chr1 21966833 G T 4.92E-05 Cognitive test performance RAP1GAP intron 20125193 rs6426721 chr1 21972480 G A 2.23E-04 Multiple complex diseases RAP1GAP intron 17554300 rs12128325 chr1 22002867 G A 3.50E-06 Urinary metabolites / / 21572414 rs333188 chr1 22040294 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) USP48 intron 20708005 rs7554400 chr1 22052387 T C 1.58E-05 Cognitive performance USP48 intron 19734545 rs6664218 chr1 22055917 A G 1.29E-05 Cognitive performance USP48 intron 19734545 rs333204 chr1 22080775 A G 3.00E-05 Cognitive performance USP48 intron 19734545 rs541552 chr1 22081011 T C 3.00E-05 Cognitive performance USP48 intron 19734545 rs6667223 chr1 22088841 G A 3.74E-05 Lymphocyte counts USP48 intron 22286170 rs884726 chr1 22110418 T C 1.21E-05 Cognitive performance / / 19734545 rs10917047 chr1 22124166 C T 4.34E-05 Cognitive performance / / 19734545 rs12737091 chr1 22174518 G T 3.78E-05 Aortic root size HSPG2 cds-synon 21223598 rs142149919 chr1 22188296 G A 0.00000049 Breast cancer HSPG2 missense 23555315 rs1869780 chr1 22222455 G T 1.42E-04 Multiple complex diseases HSPG2 missense 17554300 rs3820285 chr1 22336277 C G 7.30E-04 Iris characteristics CELA3A missense 21835309 rs3117048 chr1 22345093 A G 7.25E-04 Kawasaki disease / / 21326860 rs3117048 chr1 22345093 A G 8.28E-05 Major depressive disorder / / 22472876 rs2501299 chr1 22345647 C T 5.47E-05 Major depressive disorder / / 22472876 rs760923 chr1 22357217 G T 2.30E-04 Endometriosis / / 23104006 rs2473277 chr1 22361845 G A 5.88E-04 Schizophrenia / / 19197363 rs2473277 chr1 22361845 G A 3.75E-06 Schizophrenia / / 19571811 rs2473277 chr1 22361845 G A 1.00E-04 Endometriosis / / 21151130 rs2501279 chr1 22368342 C T 1.90E-05 Endometriosis / / 21151130 rs2501276 chr1 22373624 C T 2.00E-07 Immune response to smallpox vaccine (IL-6) / / 22610502 rs2056975 chr1 22408527 A G 5.53E-04 Multiple complex diseases CDC42 intron 17554300 rs2268179 chr1 22414785 G T 0.00000134 Uterine leiomyomata CDC42 intron 23040493 rs2268177 chr1 22415410 A T 1.50E-08 Bone mineral density (paediatric,total body less head) CDC42 intron 24945404 rs2268177 chr1 22415410 A T 9.70E-11 Bone mineral density (paediatric,skull) CDC42 intron 24945404 rs10917151 chr1 22422721 G A 7.00E-09 Endometriosis / / 23472165 rs7412010 chr1 22436446 G C 2.30E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7412010 chr1 22436446 G C 2.50E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7412010 chr1 22436446 G C 2.60E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs4654783 chr1 22439520 T C 2.00E-04 Endometriosis / / 23104006 rs3765350 chr1 22447316 A G 3.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 3.60E-11 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 4.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 6.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 7.00E-10 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-09 Endometriosis WNT4 intron 23472165 rs2235529 chr1 22450487 C T 1.00E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 1.20E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-07 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.10E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 9.70E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs12042083 chr1 22472732 G A 1.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs12042083 chr1 22472732 G A 3.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 3.60E-05 Endometriosis / / 21151130 rs7515106 chr1 22473410 T C 2.10E-06 Endometriosis / / 23104006 rs7515106 chr1 22473410 T C 1.50E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 7.80E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs7542242 chr1 22477493 C T 2.90E-06 Endometriosis / / 21151130 rs7517829 chr1 22480159 A G 2.30E-05 Coffee consumption / / 21357676 rs16826658 chr1 22485871 T G 2.00E-06 Endometriosis / / 20601957 rs16826658 chr1 22485871 T G 3.50E-05 Endometriosis / / 21151130 rs16826658 chr1 22485871 T G 4.61E-05 Calcium levels / / pha003085 rs7521902 chr1 22490724 C A 5.00E-06 Ovarian cancer / / 20852632 rs7521902 chr1 22490724 C A 4.20E-05 Endometriosis / / 21151130 rs7521902 chr1 22490724 C A 1.00E-10 Bone mineral density / / 22504420 rs7521902 chr1 22490724 C A 3.00E-11 Endometriosis / / 23104006 rs7521902 chr1 22490724 C A 1.58E-05 Bone mineral density (paediatric,total body less head) / / 24945404 rs7521902 chr1 22490724 C A 3.30E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.32E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.81E-07 Bone mineral density (paediatric,upper limb) / / 24945404 rs2807357 chr1 22491984 A G 5.42E-04 Multiple complex diseases / / 17554300 rs3920498 chr1 22492887 G C 1.00E-10 Bone mineral density (paediatric,skull) / / 24945404 rs3920498 chr1 22492887 G C 2.00E-12 Bone mineral density (paediatric,skull) / / 24945404 rs2807356 chr1 22493672 T C 3.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs909813 chr1 22496703 G A 8.82E-04 Multiple complex diseases / / 17554300 rs17360053 chr1 22499530 T C 9.00E-06 Obesity-related traits / / 23251661 rs12568557 chr1 22500228 T C 5.35E-04 Smoking cessation / / 24665060 rs16826705 chr1 22501716 C T 3.83E-04 Multiple complex diseases / / 17554300 rs742356 chr1 22501846 A G 3.10E-06 Endometriosis / / 23104006 rs2744704 chr1 22503550 A T 7.16E-05 Aging (time to event) / / 21782286 rs2744718 chr1 22523727 T C 2.88E-04 Osteoarthritis (knee and hip) / / 21177295 rs2744718 chr1 22523727 T C 3.66E-05 Osteoarthritis (knee and hip) / / 21177295 rs2473249 chr1 22537071 C T 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473250 chr1 22537649 A G 7.77E-04 Alcohol dependence / / 24277619 rs2473256 chr1 22539529 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1883418 chr1 22540161 G A 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs760917 chr1 22545088 T A 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1569583 chr1 22547352 T C 4.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2505709 chr1 22547479 C T 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473268 chr1 22549172 G A 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2491213 chr1 22549397 G A 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs732266 chr1 22550624 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505711 chr1 22551925 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs3856181 chr1 22552969 C G 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2744747 chr1 22571462 T C 7.60E-04 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 9.00E-07 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 7.00E-06 IgG glycosylation / / 23382691 rs2744757 chr1 22577937 C G 5.20E-04 Testosterone levels / / 22675492 rs2807339 chr1 22578063 T C 7.82E-04 Bipolar disorder,schizoaffective / / 19567891 rs2807339 chr1 22578063 T C 3.10E-04 Testosterone levels / / 22675492 rs2143101 chr1 22578436 G A 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2744759 chr1 22579798 T G 6.47E-05 Cleft lip / / 20436469 rs12737805 chr1 22612690 A G 7.37E-04 HIV-1 viral setpoint / / 17641165 rs6690148 chr1 22648411 C T 2.12E-04 Type 2 diabetes / / 17463246 rs1934477 chr1 22664774 T C 9.62E-04 Acute lung injury / / 22295056 rs1934478 chr1 22665210 G A 9.99E-04 Acute lung injury / / 22295056 rs10493012 chr1 22672846 A G 2.65E-04 Multiple complex diseases / / 17554300 rs12742784 chr1 22682366 C T 1.10E-09 Bone mineral density (spine) / / 19801982 rs12756978 chr1 22684755 G C 1.50E-08 Bone mineral density (spine) / / 19801982 rs10753536 chr1 22685251 G A 8.90E-05 Endometriosis / / 21151130 rs11810369 chr1 22687651 G A 1.50E-08 Bone mineral density (spine) / / 19801982 rs12750721 chr1 22689273 G A 1.20E-08 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 4.50E-10 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 9.00E-06 Endometriosis / / 21151130 rs7537281 chr1 22692078 A T 4.90E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 5.00E-16 Bone mineral density (hip) / / 18445777 rs7524102 chr1 22698447 A G 9.00E-09 Bone mineral density (spine) / / 18445777 rs7524102 chr1 22698447 A G 1.00E-16 Bone mineral density (hip) / / 19079262 rs7524102 chr1 22698447 A G 3.00E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 3.00E-07 Ulcerative colitis / / 19915572 rs7524102 chr1 22698447 A G 3.80E-06 Endometriosis / / 21151130 rs7524102 chr1 22698447 A G 2.00E-13 Ulcerative colitis / / 21297633 rs7524102 chr1 22698447 A G 1.00E-06 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 9.00E-07 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 3.00E-09 Dupuytren's disease / / 21732829 rs7524102 chr1 22698447 A G 0.00038 Prostate cancer / / 23555315 rs34920465 chr1 22700351 A G 3.00E-08 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 3.00E-13 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 6.01E-10 Bone mineral density / / 24249740 rs12568930 chr1 22702231 T C 4.60E-10 Bone mineral density (spine) / / 19801982 rs12568930 chr1 22702231 T C 1.40E-07 Ulcerative colitis / / 19915572 rs12568930 chr1 22702231 T C 2.80E-06 Endometriosis / / 21151130 rs12568930 chr1 22702231 T C 1.00E-17 Inflammatory bowel disease / / 23128233 rs12561997 chr1 22702280 G A 6.30E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 2.00E-08 Bone mineral density (spine) / / 19079262 rs6696981 chr1 22702858 G T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 3.70E-06 Endometriosis / / 21151130 rs6696981 chr1 22702858 G T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6696981 chr1 22702858 G T 0.00063 Prostate cancer / / 23555315 rs10493013 chr1 22703035 T C 4.80E-10 Bone mineral density (spine) / / 19801982 rs11803476 chr1 22703325 C T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6684375 chr1 22706434 C T 4.80E-10 Bone mineral density (spine) / / 19801982 rs6684479 chr1 22706534 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs6426748 chr1 22707565 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs10917221 chr1 22709136 T C 4.83E-04 Aortic root size / / 21223598 rs7550872 chr1 22711378 T C 2.00E-09 Bone mineral density (spine) / / 19801982 rs7550872 chr1 22711378 T C 2.70E-06 Endometriosis / / 21151130 rs6426749 chr1 22711473 G C 9.00E-08 Bone mineral density (hip) / / 19801982 rs6426749 chr1 22711473 G C 3.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6426749 chr1 22711473 G C 7.00E-57 Bone mineral density / / 22504420 rs6426749 chr1 22711473 G C 0.00018 Prostate cancer / / 23555315 rs6426749 chr1 22711473 G C 1.06E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 7.58E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 9.79E-09 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 2.27E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs2185341 chr1 22725825 C T 2.10E-05 Caffeine consumption / / 21490707 rs2185341 chr1 22725825 C T 9.63E-04 Tourette syndrome / / 22889924 rs7543680 chr1 22731269 G A 1.00E-10 Bone mineral density (spine) / / 19079262 rs10917225 chr1 22733144 T C 4.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs4655059 chr1 22735906 A C 1.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs111724808 chr1 22737946 T G 4.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs113487266 chr1 22737951 T C 4.03E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111245681 chr1 22737964 T C 8.71E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76652604 chr1 22738033 G T 4.33E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4515757 chr1 22744686 T C 7.29E-05 Body Mass Index / / pha003020 rs10917234 chr1 22782602 A G 4.78E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4233289 chr1 22790455 A C 6.40E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655067 chr1 22814289 T C 3.98E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655068 chr1 22814354 C T 4.13E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209753 chr1 22821968 T C 9.94E-04 Lymphocyte counts ZBTB40 intron 22286170 rs209722 chr1 22843428 G A 4.72E-04 Type 2 diabetes ZBTB40 intron 17463246 rs7551801 chr1 22846452 C G 4.51E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209709 chr1 22877813 G A 1.56E-04 Heart Failure / / pha002885 rs606002 chr1 22915753 T C 7.40E-05 Lipoproteins EPHA8 missense pha003079 rs209693 chr1 22922026 T G 4.32E-04 Type 2 diabetes EPHA8 intron 17463246 rs209705 chr1 22934644 A G 4.42E-04 Type 2 diabetes / / 17463246 rs158761 chr1 22954372 C A 8.58E-04 Alcohol dependence / / 24277619 rs12033074 chr1 22966609 C G 1.05E-04 Type 2 diabetes C1QA nearGene-3 17463246 rs6690827 chr1 22967496 G A 1.05E-04 Type 2 diabetes / / 17463246 rs2935537 chr1 22970514 G A 0.000000125 Triglycerides C1QC UTR-5 23063622 rs294189 chr1 22983464 G T 0.00008678 Sarcoidosis C1QB intron 22952805 rs631090 chr1 22986403 T C 8.80E-05 Systemic sclerosis C1QB intron 21750679 rs631090 chr1 22986403 T C 5.91E-04 Response to cytidine analogues (gemcitabine) C1QB intron 24483146 rs201673207 chr1 22991643 C CAG 1 Drug response to Etoposide / / 17537913 rs647955 chr1 22991643 C G 1 Drug response to Etoposide / / 17537913 rs1010011 chr1 23056136 C A 2.08E-04 Taste perception EPHB2 intron 22132133 rs12732926 chr1 23057190 G A 3.83E-05 Cognitive test performance EPHB2 intron 20125193 rs10753541 chr1 23061992 T C 8.71E-05 Serum metabolites EPHB2 intron 19043545 rs7516175 chr1 23096818 A C 5.27E-04 Schizophrenia EPHB2 intron 19197363 rs6692683 chr1 23102856 G A 3.95E-04 Suicide attempts in bipolar disorder EPHB2 intron 21423239 rs893961 chr1 23118173 T C 3.85E-04 Multiple complex diseases EPHB2 intron 17554300 rs4506436 chr1 23127876 T C 3.71E-04 Gallstones EPHB2 intron 17632509 rs12723359 chr1 23137761 G A 5.67E-05 Testicular dysgenesis syndrome EPHB2 intron 22140272 rs7536195 chr1 23142496 C T 3.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs893966 chr1 23144006 C T 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs4654821 chr1 23160272 T A,C,G 4.40E-05 Crohn's disease EPHB2 intron 20570966 rs4654824 chr1 23183130 C T 5.49E-04 Schizophrenia EPHB2 intron 19197363 rs10799771 chr1 23206684 A G 8.35E-05 Insulin Resistance EPHB2 intron pha003062 rs10799771 chr1 23206684 A G 6.63E-05 Insulin-related traits EPHB2 intron pha003063 rs309543 chr1 23225322 A G 4.35E-04 Suicide attempts in bipolar disorder EPHB2 intron 21041247 rs1832047 chr1 23266939 G A 7.20E-04 Alcohol dependence / / 20201924 rs587168 chr1 23371608 A C 1.42E-04 Oral cancers (chewing tobacco related) KDM1A intron 22503698 rs5027299 chr1 23375693 A G 1.19E-18 Multiple complex diseases KDM1A intron 17554300 rs5027299 chr1 23375693 A G 2.88E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers KDM1A intron 21775533 rs11587694 chr1 23477511 T C 3.31E-04 Myocardial Infarction LUZP1 intron pha002873 rs2806561 chr1 23504795 A G 6.89E-05 Panic disorder / / 19165232 rs674386 chr1 23521835 G A 0.0000442 LDL cholesterol / / 23063622 rs1738475 chr1 23536891 C G 3.00E-12 Height / / 20881960 rs10917360 chr1 23539010 G A 7.19E-06 Myocardial Infarction / / pha002873 rs1047694 chr1 23628436 C T 8.89E-06 Height / / 22021425 rs2849021 chr1 23631714 T G 6.15E-06 Height / / 22021425 rs665977 chr1 23696152 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZNF436 UTR-5 22628534 rs649458 chr1 23712528 T A 1.64E-04 QT interval TCEA3 intron 22726844 rs2275355 chr1 23724183 C T 3.51E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TCEA3 intron 21483023 rs6682786 chr1 23743296 A G 7.30E-05 Schizophrenia(treatment response to risperidone) TCEA3 intron 19850283 rs1077514 chr1 23766233 C T 7.39E-04 Multiple complex diseases ASAP3 intron 17554300 rs1077514 chr1 23766233 C T 6.00E-09 Cholesterol,total ASAP3 intron 24097068 rs7522616 chr1 23794914 A G 6.30E-05 Alcohol dependence ASAP3 intron 21703634 rs12142232 chr1 23816120 T G 2.19E-05 Blood Pressure / / pha003044 rs2282720 chr1 23839769 A G 1.68E-04 Schizophrenia(treatment response to risperidone) E2F2 intron 19850283 rs3218148 chr1 23851787 G A 1.97E-04 Bulimia nervosa E2F2 intron 23568457 rs11574 chr1 23885498 T C 1.24E-04 Height ID3 missense 17255346 rs4514282 chr1 23912167 C T 2.66E-04 Alzheimer's disease / / 17998437 rs6677615 chr1 23942802 G A 2.60E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 7.20E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1317329 chr1 23966837 C T 5.69E-04 Intracranial aneurysm MDS2 intron 20613766 rs12084240 chr1 23980452 C G 3.66E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11577033 chr1 24038231 T C 4.10E-04 Alcohol dependence / / 20201924 rs11577033 chr1 24038231 T C 5.70E-04 Alcohol dependence / / 20201924 rs10917420 chr1 24062987 C T 0.00000183 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs10917420 chr1 24062987 C T 3.25E-05 Tuberculosis / / 24057671 rs11591202 chr1 24102080 A C 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506963 intron 20877124 rs7521571 chr1 24281021 G A 1.09E-04 Vaspin levels / / 22907691 rs7521571 chr1 24281021 G A 0.0001089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17338135 chr1 24286897 C T 9.49E-06 Obesity-related traits PNRC2 intron 23251661 rs114176962 chr1 24290676 G A 1.10E-04 Obesity-related traits / / 17903300 rs6667686 chr1 24300849 T C 2.00E-06 Obesity-related traits SRSF10 intron 23251661 rs7553231 chr1 24347103 T C 2.30E-04 Alcohol dependence / / 20201924 rs7553231 chr1 24347103 T C 5.00E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 4.20E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 7.90E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 2.50E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 5.90E-04 Alcohol dependence / / 20201924 rs4649163 chr1 24379601 T C 4.70E-05 Vaspin levels / / 22907691 rs4649163 chr1 24379601 T C 0.000047 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4649163 chr1 24379601 T C 0.0002016 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4649171 chr1 24395575 A G 1.25E-04 Vaspin levels MYOM3 intron 22907691 rs4649171 chr1 24395575 A G 0.0001247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit MYOM3 intron 22907730 rs4276861 chr1 24412447 T C 1.41E-04 Vaspin levels MYOM3 intron 22907691 rs4276861 chr1 24412447 T C 0.000141 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks MYOM3 intron 22907730 rs11249132 chr1 24413907 C A 2.35E-04 Alzheimer's disease MYOM3 intron 22005930 rs4276859 chr1 24416133 C T 4.20E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 4.90E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 2.80E-04 Alzheimer's disease MYOM3 cds-synon 22005930 rs12568789 chr1 24422626 C T 1.78E-04 Suicide attempts in bipolar disorder MYOM3 intron 21423239 rs3934861 chr1 24431956 G A 4.00E-06 Bipolar disorder (mood-incongruent) MYOM3 intron 23092984 rs3934861 chr1 24431956 G A 7.41E-05 Body Mass Index MYOM3 intron pha003009 rs12062136 chr1 24433006 C A 6.69E-04 Parkinson's disease MYOM3 intron 17052657 rs12062136 chr1 24433006 C A 2.55E-05 AIDS progression MYOM3 intron 19115949 rs12062136 chr1 24433006 C A 4.48E-06 Height MYOM3 intron pha003011 rs7534564 chr1 24437063 A G 9.83E-05 Non-alcoholic fatty liver disease histology (other) MYOM3 intron 20708005 rs7534564 chr1 24437063 A G 1.36E-06 Body Mass Index MYOM3 intron pha003009 rs7534564 chr1 24437063 A G 2.58E-07 Height MYOM3 intron pha003010 rs7534564 chr1 24437063 A G 7.83E-10 Height MYOM3 intron pha003011 rs11249175 chr1 24440043 C T 9.96E-04 Acute lung injury / / 22295056 rs6686007 chr1 24442907 T C 8.12E-04 Acute lung injury / / 22295056 rs11249201 chr1 24452399 T C 1.21E-04 Multiple complex diseases IL22RA1 intron 17554300 rs7513249 chr1 24472083 C T 1.25E-04 Hearing function / / 17255346 rs4648940 chr1 24475177 C T 3.50E-05 Alcohol dependence / / 24277619 rs4330872 chr1 24476370 C T 4.55E-05 Height / / pha003011 rs10903032 chr1 24480864 G A 1.90E-04 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs10903034 chr1 24480905 C T 3.02E-06 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs12028945 chr1 24482004 G A 1.60E-04 Endometriosis IL28RA UTR-3 21151130 rs11249006 chr1 24482474 G A 4.20E-05 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs4649195 chr1 24485941 T C 3.20E-04 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs1416834 chr1 24486660 G A 3.60E-06 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs6698365 chr1 24497823 G T 1.18E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs6698365 chr1 24497823 G T 6.50E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893318 chr1 24505944 G T 2.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 1.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 9.84E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs7552167 chr1 24518643 A G 8.50E-12 Psoriasis / / 23143594 rs7552167 chr1 24518643 A G 6.00E-05 Erythrocyte counts / / pha003099 rs4649203 chr1 24519920 G A 7.00E-08 Psoriasis / / 20953190 rs12046369 chr1 24526135 G T 5.60E-05 Blood Pressure / / pha003048 rs16860738 chr1 24532144 T C 9.67E-04 Alcohol dependence LOC284632 intron 21314694 rs11249039 chr1 24552835 A G 8.30E-05 Creatinine levels / / 20222955 rs10903062 chr1 24556756 G A 2.60E-05 Creatinine levels / / 20222955 rs7517309 chr1 24572806 A G 2.80E-05 Creatinine levels / / 20222955 rs12407356 chr1 24578011 G A 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs6670533 chr1 24584490 G A 6.00E-06 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs7535789 chr1 24607419 T C 1.88E-04 Multiple complex diseases / / 17554300 rs10794657 chr1 24626174 A G 2.00E-07 Adiponectin levels / / 22479202 rs2248219 chr1 24645356 A G 7.72E-05 Orofacial clefts GRHL3 nearGene-5 22419666 rs16829445 chr1 24659047 G C 5.76E-04 Multiple complex diseases GRHL3 intron 17554300 rs9424363 chr1 24773803 T A 7.68E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NIPAL3 intron 24192120 rs11249117 chr1 24780356 C A 1.00E-04 Information processing speed NIPAL3 intron 21130836 rs195717 chr1 24826104 G A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCAN3AS intron 20877124 rs196402 chr1 24838493 A G 1.50E-05 Reading and spelling RCAN3 intron 23738518 rs11801912 chr1 24861373 T C 1.47E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11801547 chr1 24861399 A G 1.40E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11799673 chr1 24861471 G A 2.57E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs6669881 chr1 24862749 A G 1.30E-04 Suicide attempts in bipolar disorder RCAN3 UTR-3 21423239 rs10489444 chr1 24863530 C T 9.06E-05 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs7540973 chr1 24864576 G T 1.32E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs6697800 chr1 24867540 G A 1.30E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs2809964 chr1 24875490 C T 3.88E-05 Lung adenocarcinoma LOC100506985 intron 19836008 rs6424099 chr1 24881126 C T 6.00E-05 Asthma LOC100506985 intron 20698975 rs2809963 chr1 24889450 A T 3.12E-04 Suicide attempts in bipolar disorder C1orf130 intron 21423239 rs2809963 chr1 24889450 A T 0.0000137 HDL cholesterol particle diameter C1orf130 intron 23263444 rs9729036 chr1 24917543 A G 4.43E-04 Multiple complex diseases C1orf130 intron 17554300 rs12072370 chr1 24967165 G A 1.30E-04 Insulin resistance / / 21901158 rs4601530 chr1 25044111 C T 2.00E-12 Height / / 20881960 rs3131499 chr1 25076296 A T 9.20E-04 Multiple complex diseases CLIC4 intron 17554300 rs10732912 chr1 25128123 A C 3.39E-04 Multiple complex diseases CLIC4 intron 17554300 rs3131513 chr1 25193155 G A 2.00E-06 Alcohol dependence / / 23942779 rs3131513 chr1 25193155 G A 3.20E-04 Nicotine use / / 23942779 rs3131513 chr1 25193155 G A 3.50E-04 Illicit drug use / / 23942779 rs4648881 chr1 25197155 G A 0.000000466 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs4648881 chr1 25197155 G A 0.000084 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs4648881 chr1 25197155 G A 0.000213 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs11249196 chr1 25216152 T A 7.52E-04 Multiple complex diseases / / 17554300 rs2236851 chr1 25243554 C T 4.30E-05 Taste perception RUNX3 intron 22132133 rs7551188 chr1 25273200 T C 9.00E-06 Crohn's disease RUNX3 intron 23266558 rs876109 chr1 25273288 T C 9.49E-04 Alzheimer's disease RUNX3 intron 22005930 rs72657048 chr1 25289734 C G 3.80E-06 Celiac disease RUNX3 intron 22057235 rs7536201 chr1 25293084 T C 2.30E-12 Psoriasis / / 23143594 rs10903118 chr1 25294878 T C 7.00E-04 Ankylosing spondylitis / / 21743469 rs10751776 chr1 25296743 A C 7.00E-06 IgG glycosylation / / 23382691 rs11249215 chr1 25297184 G A 9.23E-04 Type 2 diabetes / / 17463246 rs11249215 chr1 25297184 G A 9.00E-11 Ankylosing spondylitis / / 21743469 rs11581762 chr1 25298408 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10903122 chr1 25303576 A G 2.00E-10 Celiac disease / / 20190752 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21150878 rs10903122 chr1 25303576 A G 1.73E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21907864 rs10903122 chr1 25303576 A G 1.73E-10 Multiple sclerosis / / 22190364 rs12567208 chr1 25308531 T G 1.31E-04 Prion diseases / / 22210626 rs9438880 chr1 25322574 A G 1.14E-04 Prion diseases / / 22210626 rs11249232 chr1 25331585 A G 3.09E-04 Aortic root size / / 21223598 rs755394 chr1 25333899 T C 7.75E-04 Aortic root size / / 21223598 rs10903126 chr1 25344155 A G 9.76E-05 Cognitive test performance / / 20125193 rs387240 chr1 25359929 T C 1.00E-05 Urinary metabolites / / 21572414 rs4649057 chr1 25375177 T C 1.70E-05 Urinary metabolites / / 21572414 rs11248971 chr1 25375583 G A 1.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs369427 chr1 25378444 A G 5.60E-06 Urinary metabolites / / 21572414 rs10489162 chr1 25379395 C G 2.00E-05 Urinary metabolites / / 21572414 rs10903024 chr1 25397349 T C 2.25E-04 Body mass index / / 17255346 rs16830335 chr1 25400812 T C 0.0005013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16830335 chr1 25400812 T C 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs427614 chr1 25401437 G A 3.25E-09 HDL cholesterol particle diameter / / 23263444 rs380337 chr1 25401850 A G 3.08E-09 HDL cholesterol particle diameter / / 23263444 rs10903027 chr1 25402624 C T 5.00E-06 IgG glycosylation / / 23382691 rs12076534 chr1 25405012 G A 0.0004577 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12076534 chr1 25405012 G A 4.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7514299 chr1 25405809 T A 0.0004568 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7514299 chr1 25405809 T A 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10493026 chr1 25407854 G T 7.31E-05 Waist-Hip Ratio / / pha003028 rs12091321 chr1 25407933 C G 0.0004562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12091321 chr1 25407933 C G 4.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12081177 chr1 25408685 G T 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12081177 chr1 25408685 G T 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7533661 chr1 25413466 G A 0.0004311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7533661 chr1 25413466 G A 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11588172 chr1 25421990 T C 9.02E-06 Chronic obstructive pulmonary disease / / 19300482 rs803313 chr1 25434242 T C 8.23E-05 Major depressive disorder / / 21621269 rs7530932 chr1 25467161 G A 8.20E-04 Alcohol dependence / / 20201924 rs2064251 chr1 25469913 G A 9.72E-06 Anorexia nervosa / / 21079607 rs6600257 chr1 25472465 G A 0.0000344 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12736858 chr1 25521090 C T 1.20E-05 Hypothyroidism / / 22493691 rs11248998 chr1 25529362 C T 5.60E-05 Hypothyroidism / / 22493691 rs77353590 chr1 25535051 C T 0.0000542 Menopause (age at onset) / / 23424626 rs1043879 chr1 25570081 T C 2.00E-09 Erythrocyte sedimentation rate C1orf63 missense 21700265 rs1043879 chr1 25570081 T C 1.34E-04 Myocardial Infarction C1orf63 missense pha002883 rs1830962 chr1 25623967 A G 4.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RHD intron 21844884 rs3091242 chr1 25674785 C T 2.00E-13 Erythrocyte sedimentation rate TMEM50A intron 21700265 rs1293259 chr1 25695835 G A 2.90E-71 Rhesus system E antigen RHCE intron 22611595 rs926438 chr1 25753638 C T 5.57E-04 Multiple complex diseases / / 17554300 rs926438 chr1 25753638 C T 8.77E-05 Smoking behavior / / 20418889 rs873308 chr1 25758655 G A 4.64E-09 Triglycerides TMEM57 intron 19060911 rs873308 chr1 25758655 G A 0.00000113 LDL cholesterol TMEM57 intron 23063622 rs11802413 chr1 25760920 C T 3.03E-04 Multiple complex diseases TMEM57 intron 17554300 rs11802413 chr1 25760920 C T 4.11E-05 Smoking behavior TMEM57 intron 20418889 rs7541095 chr1 25761291 T C 4.73E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 3.95E-04 Multiple complex diseases TMEM57 intron 17554300 rs10903129 chr1 25768937 A G 5.00E-10 Cholesterol,total TMEM57 intron 19060911 rs10903129 chr1 25768937 A G 2.30E-04 Lipid levels TMEM57 intron 19936222 rs10903129 chr1 25768937 A G 3.87E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 5.00E-13 Erythrocyte sedimentation rate TMEM57 intron 21700265 rs12027135 chr1 25775733 A T 3.98E-05 Smoking behavior TMEM57 intron 20418889 rs12027135 chr1 25775733 A T 1.00E-10 LDL cholesterol TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 4.00E-11 Cholesterol,total TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 2.00E-14 LDL cholesterol TMEM57 intron 24097068 rs12027135 chr1 25775733 A T 5.00E-12 Cholesterol,total TMEM57 intron 24097068 rs61776821 chr1 25885528 G A 0.0000781 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776822 chr1 25885592 G A 0.0000664 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776823 chr1 25887525 G A 0.0000744 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs12096438 chr1 25889422 C T 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6687605 chr1 25889632 T C 0.0000396 Nonsyndromic striae distensae (stretch marks) LDLRAP1 missense 23633020 rs6701596 chr1 25889917 T C 0.0000365 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6661159 chr1 25890050 A G 0.0000392 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs28969504 chr1 25890189 A G 0.0000387 Nonsyndromic striae distensae (stretch marks) LDLRAP1 cds-synon 23633020 rs4075184 chr1 25890835 G A 0.0000348 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856239 chr1 25891174 G A 0.000038 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs56214942 chr1 25891959 G A 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11799800 chr1 25891971 C T 0.0000386 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4400597 chr1 25892298 G T 0.0000381 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856240 chr1 25892525 T C 0.0000424 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4523506 chr1 25893221 G T 0.0000382 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4603124 chr1 25893243 G A 0.0000652 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11563 chr1 25894853 G T 0.00005 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs7491 chr1 25895238 C T 0.0000527 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs3924236 chr1 25895406 C T 0.0000714 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs3924235 chr1 25895526 G A 0.0000637 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs4659357 chr1 25900240 G A 5.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs2065970 chr1 26051523 A G 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1C1 intron 20877124 rs2065970 chr1 26051523 A G 6.02E-08 Common variable immunodeficiency MAN1C1 intron 21497890 rs2744768 chr1 26057309 T G 9.90E-05 Hypothyroidism MAN1C1 intron 22493691 rs2786876 chr1 26073443 T C 7.97E-04 Smoking quantity MAN1C1 intron 24665060 rs12130495 chr1 26085398 G T 1.10E-04 Pulmonary emphysema MAN1C1 intron 24383474 rs17163225 chr1 26087669 T G 1.50E-04 Multiple complex diseases MAN1C1 intron 17554300 rs17163225 chr1 26087669 T G 0.0000029 Mean arterial pressure MAN1C1 intron 22510845 rs3820514 chr1 26110065 A G 7.14E-04 Smoking quantity MAN1C1 intron 24665060 rs11247740 chr1 26137025 T A 1.34E-04 Multiple complex diseases SEPN1 intron 17554300 rs6872 chr1 26144674 G A 2.98E-06 Phospholipid levels (plasma) SEPN1 UTR-3 21829377 rs7552868 chr1 26155201 G T 4.48E-05 HDL cholesterol FAM54B intron pha003075 rs213627 chr1 26172111 A G 3.38E-05 HDL cholesterol C1orf135 intron pha003075 rs11247815 chr1 26176728 C T 4.95E-04 Multiple complex diseases C1orf135 intron 17554300 rs1257163 chr1 26250059 C T 0.000162905 Hypertension (early onset hypertension) / / 22479346 rs2275101 chr1 26310213 T C 3.19E-04 Intracranial aneurysm PAFAH2 intron 20613766 rs12743484 chr1 26335929 G A 1.50E-04 Intracranial aneurysm / / 20613766 rs17163470 chr1 26351382 T C 2.10E-04 Multiple complex diseases EXTL1 intron 17554300 rs12072473 chr1 26353367 G A 7.87E-05 Cognitive impairment induced by topiramate EXTL1 intron 22091778 rs1938404 chr1 26358202 G A 7.17E-04 Bipolar disorder EXTL1 intron 19259986 rs1317709 chr1 26384690 T G 5.18E-04 Alzheimer's disease TRIM63 intron 17998437 rs1317709 chr1 26384690 T G 8.27E-04 Bipolar disorder TRIM63 intron 19259986 rs2275949 chr1 26385150 G C 2.39E-04 Alzheimer's disease TRIM63 intron 17998437 rs2997447 chr1 26387423 G A 2.91E-06 Waist-hip ratio TRIM63 intron 20935629 rs2783681 chr1 26441207 A C 5.76E-04 Multiple complex diseases PDIK1L intron 17554300 rs868551 chr1 26475521 A G 6.90E-05 Malaria / / 19465909 rs11247864 chr1 26517667 T C 0.00000311 Lumbar spine bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11247864 chr1 26517667 T C 0.000805 Femoral neck bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11809207 chr1 26521140 G A 6.00E-08 Height CATSPER4 intron 19343178 rs17257155 chr1 26526439 A G 4.53E-04 Alzheimer's disease CATSPER4 missense 17998437 rs17257155 chr1 26526439 A G 7.68E-32 Narcolepsy CATSPER4 missense 19629137 rs4585968 chr1 26535146 G A 2.25E-04 Heart Failure / / pha002884 rs11579247 chr1 26549637 G A 6.93E-05 Cognitive performance / / 19734545 rs10493028 chr1 26552921 T C 3.73E-05 Cognitive performance / / 19734545 rs2050473 chr1 26554096 C G 5.01E-06 Statin-induced myopathy / / 21826682 rs2050475 chr1 26565665 G A 6.89E-04 Multiple complex diseases CEP85 intron 17554300 rs17163749 chr1 26568165 A G 3.80E-04 Primary sclerosing cholangitis CEP85 intron 19944697 rs10902723 chr1 26568542 T C 9.00E-06 Obesity-related traits CEP85 intron 23251661 rs3795686 chr1 26582091 G A 0.00076 Breast cancer CEP85 missense 23555315 rs12757113 chr1 26597144 G A 2.88E-04 Alzheimer's disease CEP85 intron 17998437 rs3795685 chr1 26601385 G A 9.99E-04 Alzheimer's disease CEP85 intron 17998437 rs6598955 chr1 26619649 C T 4.00E-06 Obesity-related traits UBXN11 intron 23251661 rs6598955 chr1 26619649 C T 7.00E-06 Obesity-related traits UBXN11 intron 23251661 rs12068388 chr1 26621596 G A 1 Drug response to Etoposide UBXN11 intron 17537913 rs7541416 chr1 26622911 G A 2.40E-05 Tuberculosis UBXN11 intron 24057671 rs4290051 chr1 26624327 G A 2.72E-04 Multiple complex diseases UBXN11 intron 17554300 rs12726972 chr1 26639634 G A 1.08E-04 Alzheimer's disease UBXN11 intron 17998437 rs11247915 chr1 26650550 C A 5.00E-06 Obesity-related traits AIM1L intron 23251661 rs7544018 chr1 26651132 C G 6.86E-04 Lymphocyte counts AIM1L intron 22286170 rs12563321 chr1 26666502 C T 0.0000287 Uterine leiomyomata AIM1L intron 23040493 rs10902742 chr1 26676257 G T 0.0000591 Uterine leiomyomata AIM1L intron 23040493 rs4233461 chr1 26681306 G A 6.24E-05 Elbow pain / / pha003008 rs9438620 chr1 26716136 C T 8.21E-04 Schizophrenia / / 19197363 rs11587947 chr1 26719264 C T 9.69E-06 Obesity-related traits / / 23251661 rs12722898 chr1 26721287 G A 1.13E-04 Vaspin levels / / 22907691 rs12722898 chr1 26721287 G A 0.0000728 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12722898 chr1 26721287 G A 0.0001126 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7532866 chr1 26741544 A G 3.00E-08 Height LIN28A intron 20881960 rs12728900 chr1 26746807 G A 0.0000228 Otitis media (children 3 years old or younger) LIN28A intron 23133572 rs6656196 chr1 26758773 G A 2.93E-08 Red blood cell traits DHDDS UTR-5 23222517 rs3811461 chr1 26759149 A G 1.06E-07 Red blood cell traits DHDDS intron 23222517 rs11247958 chr1 26767367 C T 6.01E-08 Red blood cell traits DHDDS intron 23222517 rs4659374 chr1 26779270 C T 4.95E-06 Leprosy DHDDS intron 22019778 rs3816539 chr1 26786627 G A 1.33E-07 Red blood cell traits DHDDS missense 23222517 rs6690458 chr1 26789787 T C 1.25E-07 Red blood cell traits DHDDS intron 23222517 rs6675469 chr1 26789813 G A 1.44E-07 Red blood cell traits DHDDS intron 23222517 rs2290588 chr1 26797508 C T 8.13E-08 Red blood cell traits DHDDS UTR-3 23222517 rs4659375 chr1 26804090 G A 7.92E-08 Red blood cell traits / / 23222517 rs7530096 chr1 26820218 G A 2.35E-07 Red blood cell traits / / 23222517 rs4970498 chr1 26844195 G A 1.69E-07 Red blood cell traits / / 23222517 rs12046497 chr1 26847640 C T 2.01E-07 Red blood cell traits / / 23222517 rs12094989 chr1 26848386 C T 2.96E-07 Red blood cell traits / / 23222517 rs4970466 chr1 26849312 G A 2.17E-07 Red blood cell traits / / 23222517 rs7539320 chr1 26850665 C T 1.97E-07 Red blood cell traits / / 23222517 rs6670311 chr1 26865485 C G 0.000000201 Triglycerides RPS6KA1 intron 23063622 rs282177 chr1 26899125 C T 6.39E-05 Multiple sclerosis RPS6KA1 intron 17660530 rs190737 chr1 26899444 C A 4.40E-04 Nonalcoholic fatty liver disease RPS6KA1 intron 21423719 rs2229714 chr1 26900708 G A 1.51E-06 Dilated cardiomyopathy RPS6KA1 UTR-3 20975947 rs6699237 chr1 26925843 C T 2.69E-05 Multiple complex diseases / / 17554300 rs17162257 chr1 26929002 T G 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6598860 chr1 27021684 G A 7.73E-04 Alzheimer's disease ARID1A nearGene-5 24755620 rs4589135 chr1 27041714 T C 9.58E-04 Alzheimer's disease ARID1A intron 24755620 rs12742115 chr1 27079931 T C 8.94E-05 Response to mTOR inhibitor (rapamycin) ARID1A intron 24009623 rs12748152 chr1 27138393 C T 1.00E-09 Triglycerides / / 24097068 rs12748152 chr1 27138393 C T 1.00E-15 HDL cholesterol / / 24097068 rs12748152 chr1 27138393 C T 3.00E-12 LDL cholesterol / / 24097068 rs17162339 chr1 27252823 C A 3.36E-04 Multiple complex diseases NUDC intron 17554300 rs12239134 chr1 27272864 C T 5.66E-05 Multiple complex diseases NUDC UTR-3 17554300 rs6669265 chr1 27361219 G A 5.97E-07 Hearing function / / 21493956 rs2256674 chr1 27375717 A G 4.30E-04 Blood pressure / / 17255346 rs5810 chr1 27426219 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 UTR-3 21423239 rs6598870 chr1 27428321 T C 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12118026 chr1 27432745 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12123077 chr1 27437217 A G 9.51E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs11806219 chr1 27448048 G A 5.57E-11 Triglycerides SLC9A1 intron 23063622 rs11807614 chr1 27464917 A G 1.15E-13 Triglycerides SLC9A1 intron 23063622 rs11247611 chr1 27467984 C T 8.73E-06 Post-operative nausea and vomiting SLC9A1 intron 21694509 rs12751422 chr1 27493679 T C 5.50E-04 Type 2 diabetes / / 17463246 rs12117956 chr1 27497582 A G 0.0000397 Uterine leiomyomata / / 23040493 rs6687674 chr1 27537101 G A 0.0000467 Uterine leiomyomata / / 23040493 rs12565684 chr1 27661037 T C 7.81E-05 Response to mTOR inhibitor (rapamycin) TMEM222 intron 24009623 rs187197622 chr1 27677375 G A 0.000038 Breast cancer(er negative) SYTL1 missense 23555315 rs1138294 chr1 27688633 G A 6.79E-04 Premature ovarian failure MAP3K6 missense 19508998 rs11548323 chr1 27731651 C T 2.00E-06 Estradiol plasma levels (breast cancer) WASF2 UTR-3 23518928 rs2474293 chr1 27755669 A C 7.08E-04 Multiple complex diseases WASF2 intron 17554300 rs6598886 chr1 27849300 T C 8.20E-05 Multiple complex diseases / / 17554300 rs6598886 chr1 27849300 T C 2.04E-05 Myocardial Infarction / / pha002873 rs7512595 chr1 27857171 A G 9.40E-05 Myocardial Infarction / / pha002873 rs17357586 chr1 27873001 G C 1.10E-04 Multiple complex diseases AHDC1 intron 17554300 rs17162040 chr1 27883227 T C 3.18E-04 Response to taxane treatment (placlitaxel) AHDC1 intron 23006423 rs4908343 chr1 27931698 G A 1.21E-07 Esophageal cancer (squamous cell) / / 20729853 rs6658795 chr1 27960011 C T 3.92E-04 Multiple complex diseases FGR intron 17554300 rs73494 chr1 27975384 A G 3.86E-06 Bipolar disorder / / 17486107 rs17162722 chr1 27997568 C T 5.95E-04 Multiple complex diseases IFI6 intron 17554300 rs10902662 chr1 27998394 C T 6.86E-04 Type 2 diabetes IFI6 intron 17463246 rs2788686 chr1 28012280 G C 1.37E-04 Type 2 diabetes / / 17463246 rs6598902 chr1 28105709 T C 6.57E-08 Gallstones STX12 intron 17632509 rs1467464 chr1 28211650 T C 3.99E-04 Smoking initiation C1orf38 intron 24665060 rs6564 chr1 28212975 C T 5.78E-04 Smoking initiation C1orf38 UTR-3 24665060 rs3766396 chr1 28221554 A G 2.09E-04 Lymphocyte counts RPA2 intron 22286170 rs2295367 chr1 28224312 C T 2.04E-07 Lymphocyte counts RPA2 intron 22286170 rs6679432 chr1 28227665 T C 6.36E-04 Smoking initiation RPA2 intron 24665060 rs2474470 chr1 28234999 C T 5.36E-04 Smoking initiation RPA2 intron 24665060 rs6700473 chr1 28236682 G A 2.20E-04 Smoking initiation RPA2 intron 24665060 rs4409675 chr1 28262409 A T 2.00E-06 Corneal astigmatism SMPDL3B intron 23322567 rs12565238 chr1 28299346 C T 3.39E-04 Type 2 diabetes EYA3 UTR-3 17463246 rs7529792 chr1 28306250 C T 8.12E-04 Schizophrenia EYA3 intron 19197363 rs2492958 chr1 28314423 A G 5.51E-07 Multiple complex diseases EYA3 intron 17554300 rs10493035 chr1 28315461 C T 1.98E-04 Type 2 diabetes EYA3 intron 17463246 rs17162928 chr1 28343518 G T 3.40E-04 Type 2 diabetes EYA3 intron 17463246 rs2311587 chr1 28416898 G A 3.40E-04 Type 2 diabetes / / 17463246 rs2486674 chr1 28420384 A G 4.65E-05 Post-operative nausea and vomiting / / 21694509 rs11247752 chr1 28426001 T G 2.10E-05 Urinary metabolites / / 21572414 rs1769711 chr1 28455037 A G 8.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10751727 chr1 28461661 T C 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6679420 chr1 28500834 G A 0.000000146 LDL cholesterol PTAFR intron 23063622 rs17162987 chr1 28521479 T C 2.59E-04 Multiple complex diseases PTAFR nearGene-5 17554300 rs12129745 chr1 28572317 G C 1.96E-05 Lymphocyte counts / / 22286170 rs4252976 chr1 28962633 G A 6.97E-04 Smoking initiation TAF12 intron 24665060 rs9426394 chr1 29007729 G T 2.09E-05 Smoking initiation GMEB1 intron 24665060 rs2236861 chr1 29139756 G A 0.0005 Coronary artery calcification OPRD1 intron 23727086 rs2236861 chr1 29139756 G A 7.31E-05 Height OPRD1 intron pha003011 rs678849 chr1 29145188 C T 9.36E-06 Amyotrophic Lateral Sclerosis OPRD1 intron 17827064 rs797397 chr1 29151183 G A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OPRD1 intron 22628534 rs419335 chr1 29151844 A G 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs538485 chr1 29164561 T G 8.30E-06 Urinary metabolites OPRD1 intron 21572414 rs4654323 chr1 29168957 G T 6.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs595725 chr1 29172715 C A 5.30E-04 Breast cancer and prostate cancer OPRD1 intron 17903305 rs16837730 chr1 29180014 C T 4.00E-04 Upper aerodigestive tract cancers OPRD1 intron 21437268 rs6690810 chr1 29186859 A G 3.18E-12 Multiple complex diseases OPRD1 intron 17554300 rs157217 chr1 29208997 A G 1.81E-04 Multiple complex diseases / / 17554300 rs203279 chr1 29242454 T A 2.41E-04 Multiple complex diseases EPB41 intron 17554300 rs157208 chr1 29245406 T C 3.14E-04 Birth weight EPB41 intron 17255346 rs150088 chr1 29262533 A G 8.32E-05 Serum metabolites EPB41 intron 19043545 rs204057 chr1 29272057 C A 1.82E-04 Birth weight EPB41 intron 17255346 rs1038493 chr1 29288078 A G 4.55E-05 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2985334 chr1 29345027 T G 3.50E-05 Sleep and circadian phenotypes EPB41 intron 17903308 rs2985334 chr1 29345027 T G 6.00E-06 Amyotrophic lateral sclerosis (sporadic) EPB41 intron 24529757 rs2788890 chr1 29352653 G C 6.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs4654388 chr1 29397790 A G 5.75E-04 Multiple complex diseases EPB41 intron 17554300 rs2503015 chr1 29407230 T A 7.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2254241 chr1 29418033 A G 2.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs12039988 chr1 29425833 G A 8.63E-04 Tourette syndrome EPB41 intron 22889924 rs12045777 chr1 29429004 C T 2.43E-04 Sleep time EPB41 intron 23728906 rs578800 chr1 29437106 G A 1.68E-04 Multiple complex diseases EPB41 intron 17554300 rs1994859 chr1 29497820 C T 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SRSF4 intron 20031582 rs3094740 chr1 29507647 G C 9.25E-04 Multiple complex diseases SRSF4 intron 17554300 rs1128400 chr1 29542637 A G 8.80E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MECR missense 20031582 rs2640467 chr1 29556158 T C 4.72E-05 Amyotrophic lateral sclerosis (sporadic) MECR intron 24529757 rs12057666 chr1 29571758 T G 2.13E-04 Multiple complex diseases PTPRU intron 17554300 rs1032425 chr1 29575605 C A 3.79E-04 Amyotrophic lateral sclerosis (sporadic) PTPRU intron 24529757 rs7550930 chr1 29594563 T C 8.03E-06 Asthma PTPRU intron 21790008 rs7518159 chr1 29621460 C T 1.72E-07 Multiple complex diseases PTPRU intron 17554300 rs9426315 chr1 29625375 G A 2.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRU intron 20031582 rs3737606 chr1 29630956 A G 5.24E-05 Bipolar disorder and schizophrenia PTPRU intron 20889312 rs12735793 chr1 29636976 G A 1.60E-06 Primary sclerosing cholangitis PTPRU intron 21151127 rs1997865 chr1 29643881 T A 2.50E-05 Urinary metabolites PTPRU intron 21572414 rs761429 chr1 29678592 G A 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs761430 chr1 29678774 C A 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4654339 chr1 29742743 T C 0.00004661 Sarcoidosis / / 22952805 rs6426360 chr1 29743391 T C 0.00002399 Sarcoidosis / / 22952805 rs6657309 chr1 29743408 A G 0.0000793 Sarcoidosis / / 22952805 rs1408857 chr1 29743630 C T 0.000007098 Sarcoidosis / / 22952805 rs10799133 chr1 29745602 A G 0.00002337 Sarcoidosis / / 22952805 rs4431811 chr1 29746380 A G 0.00006519 Sarcoidosis / / 22952805 rs6686991 chr1 29747162 G T 0.00006337 Sarcoidosis / / 22952805 rs10753338 chr1 29747573 A C 0.00003257 Sarcoidosis / / 22952805 rs9426341 chr1 29747979 G T 0.00001326 Sarcoidosis / / 22952805 rs6700562 chr1 29748777 C T 0.00006355 Sarcoidosis / / 22952805 rs2182112 chr1 29749659 T C 0.00001413 Sarcoidosis / / 22952805 rs2147782 chr1 29749776 T C 0.0000468 Sarcoidosis / / 22952805 rs1408863 chr1 29750255 A G 0.00008708 Sarcoidosis / / 22952805 rs1408862 chr1 29750448 T C 0.00008833 Sarcoidosis / / 22952805 rs9426445 chr1 29752947 A G 0.00005496 Sarcoidosis / / 22952805 rs10915268 chr1 29753610 G A 3.10E-06 Urinary metabolites / / 21572414 rs977497 chr1 29754433 A G 0.00004048 Sarcoidosis / / 22952805 rs10915272 chr1 29754708 G A 2.40E-06 Urinary metabolites / / 21572414 rs1359465 chr1 29756066 C T 0.00002194 Sarcoidosis / / 22952805 rs10915275 chr1 29761294 G T 0.00007444 Sarcoidosis / / 22952805 rs2182111 chr1 29764800 A T 0.00006852 Sarcoidosis / / 22952805 rs4654355 chr1 29794279 G A 4.95E-05 Serum metabolites / / 19043545 rs6426365 chr1 29806634 A G 3.53E-04 Schizophrenia / / 19197363 rs6664690 chr1 29827798 C T 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12069708 chr1 29854675 A C 3.88E-04 Alzheimer's disease / / 17998437 rs12071830 chr1 29854740 T G 6.67E-04 Alzheimer's disease / / 17998437 rs7547083 chr1 29859057 G A 4.27E-04 Alzheimer's disease / / 17998437 rs6426342 chr1 29859764 G C 6.06E-04 Alzheimer's disease / / 17998437 rs10914282 chr1 30062973 G A 8.99E-04 Multiple complex diseases / / 17554300 rs1932397 chr1 30063197 C T 7.10E-05 Type 2 diabetes / / 17463248 rs1932397 chr1 30063197 C T 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603927 chr1 30064009 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603926 chr1 30066155 A G 7.00E-05 Type 2 diabetes / / 17463248 rs6603926 chr1 30066155 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs9660251 chr1 30068857 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs9662524 chr1 30070403 G C 7.30E-05 Type 2 diabetes / / 17463248 rs9662524 chr1 30070403 G C 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs915409 chr1 30071270 T C 7.30E-05 Type 2 diabetes / / 17463248 rs915409 chr1 30071270 T C 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949306 chr1 30072549 A G 6.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1932392 chr1 30074983 T C 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9286938 chr1 30077101 T C 9.10E-05 Type 2 diabetes / / 17463248 rs9286938 chr1 30077101 T C 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs9659523 chr1 30077600 A C 1.00E-04 Type 2 diabetes / / 17463248 rs9659523 chr1 30077600 A C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949293 chr1 30078801 T C 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs436400 chr1 30079888 T A 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949178 chr1 30081323 G A 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949291 chr1 30081359 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs271306 chr1 30082664 G C 1.00E-04 Type 2 diabetes / / 17463248 rs271306 chr1 30082664 G C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10798895 chr1 30086662 G A 3.30E-05 Type 2 diabetes / / 17460697 rs10798895 chr1 30086662 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949283 chr1 30090260 A G 8.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs2044073 chr1 30093697 G T 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2044072 chr1 30093908 G A 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs16832700 chr1 30094324 C T 8.44E-04 Multiple complex diseases / / 17554300 rs4949611 chr1 30103858 G A 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs502545 chr1 30109482 G A 5.56E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9442466 chr1 30111858 C T 6.60E-04 Myopia (pathological) / / 21095009 rs271327 chr1 30115843 A G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs175249 chr1 30116035 C G 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs692787 chr1 30117517 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs271385 chr1 30119005 T C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs271383 chr1 30120287 A C 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs271372 chr1 30126979 A G 6.50E-04 Type 2 diabetes / / 17463246 rs271372 chr1 30126979 A G 7.40E-06 Urinary metabolites / / 21572414 rs187954 chr1 30134604 C A 8.65E-06 Alcohol and nictotine co-dependence / / 20158304 rs175250 chr1 30134671 T C 5.14E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 3.83E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 9.80E-06 Urinary metabolites / / 21572414 rs166604 chr1 30148652 T C 2.60E-04 Type 2 diabetes / / 17463246 rs520527 chr1 30149566 T C 2.73E-04 Type 2 diabetes / / 17463246 rs271351 chr1 30152120 G A,C,T 9.17E-04 Multiple complex diseases / / 17554300 rs4259710 chr1 30184426 A G 5.03E-04 Multiple complex diseases / / 17554300 rs1866967 chr1 30185662 A G 3.49E-05 Pulmonary function / / 19300500 rs1866967 chr1 30185662 A G 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs4949268 chr1 30186956 T C 8.03E-05 Pulmonary function / / 19300500 rs6673417 chr1 30188608 T C 7.94E-05 Pulmonary function / / 19300500 rs17262657 chr1 30191649 T C 3.39E-05 Pulmonary function / / 19300500 rs10914271 chr1 30213840 T C 8.05E-05 Height / / pha003010 rs10914271 chr1 30213840 T C 4.99E-05 Height / / pha003011 rs920600 chr1 30222525 A G 5.31E-05 Height / / pha003010 rs920600 chr1 30222525 A G 3.03E-05 Height / / pha003011 rs12045312 chr1 30234753 A G 5.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12145316 chr1 30245413 C T 6.30E-05 Height / / pha003011 rs6691847 chr1 30265652 T C 7.00E-06 Non-alcoholic fatty liver disease / / 23535911 rs10914475 chr1 30278550 C T 4.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2166884 chr1 30288207 G A 1.53E-04 Schizophrenia / / 19197363 rs12748731 chr1 30301308 T C 8.61E-06 IgE levels / / 17255346 rs12145293 chr1 30314005 A G 3.89E-04 Smoking initiation / / 24665060 rs12145156 chr1 30318156 G T 4.43E-04 Smoking initiation / / 24665060 rs921197 chr1 30319889 G A 8.03E-04 Schizophrenia / / 19197363 rs7512834 chr1 30322046 C T 3.69E-04 Schizophrenia / / 19197363 rs12134222 chr1 30348925 C A 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2197783 chr1 30359165 T C 3.65E-04 Type 2 diabetes / / 17463246 rs1001709 chr1 30359862 G A 5.50E-07 Urinary metabolites / / 21572414 rs12090063 chr1 30360122 C T 9.45E-04 Alzheimer's disease / / 22005930 rs10798921 chr1 30399109 A G 7.45E-04 Multiple complex diseases / / 17554300 rs4949232 chr1 30410502 A C 1.98E-06 Major depressive disorder / / 22472876 rs16833076 chr1 30414182 T G 1.70E-05 Urinary metabolites / / 21572414 rs16833076 chr1 30414182 T G 3.02E-05 Major depressive disorder / / 22472876 rs1498243 chr1 30415026 G A 3.89E-05 Major depressive disorder / / 22472876 rs1354366 chr1 30415774 G C 2.15E-04 Type 2 diabetes / / 17463246 rs10798928 chr1 30417560 C T 2.00E-04 Type 2 diabetes / / 17463246 rs11583644 chr1 30419370 G A 4.41E-04 Type 2 diabetes / / 17463246 rs4949522 chr1 30420739 A G 6.52E-04 Type 2 diabetes / / 17463246 rs4949237 chr1 30420873 T C 2.45E-04 Type 2 diabetes / / 17463246 rs4949238 chr1 30422596 A G 3.20E-05 Major depressive disorder / / 22472876 rs10914667 chr1 30423829 T A 2.22E-04 Type 2 diabetes / / 17463246 rs12407717 chr1 30426014 C T 4.00E-05 Major depressive disorder / / 21042317 rs12407717 chr1 30426014 C T 1.20E-06 Major depressive disorder / / 22472876 rs267700 chr1 30430366 T G 3.11E-06 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 8.50E-07 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 3.00E-06 Schizophrenia / / 21926974 rs4949526 chr1 30432219 T C 4.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs4949526 chr1 30432219 T C 0.000111 Schizophrenia / / 23637625 rs6694545 chr1 30437268 A G 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6694545 chr1 30437268 A G 3.91E-04 Smoking cessation / / 24665060 rs12401298 chr1 30439760 A G 3.95E-05 Major depressive disorder / / 22472876 rs10753284 chr1 30445050 T C 3.25E-04 Smoking cessation / / 24665060 rs904300 chr1 30459412 T C 7.64E-04 Smoking cessation / / 24665060 rs4949241 chr1 30459797 G A 9.93E-05 Major depressive disorder / / 22472876 rs409226 chr1 30472960 A G 5.46E-05 Heart Rate / / pha003053 rs452132 chr1 30478996 A G 3.35E-05 Heart Rate / / pha003053 rs404170 chr1 30485741 A G 6.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs397310 chr1 30486849 C A 5.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs387055 chr1 30486853 A G 7.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs373073 chr1 30491129 G A 5.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs267721 chr1 30496978 A G 6.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs267720 chr1 30497242 G T 6.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs12732511 chr1 30501138 C T 6.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12140391 chr1 30506347 C T 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs17341620 chr1 30508461 G A 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145453 chr1 30513725 T C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860031 chr1 30525714 A G 3.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs11580589 chr1 30529289 A G 9.29E-06 Bipolar disorder / / 19488044 rs11580589 chr1 30529289 A G 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs11580589 chr1 30529289 A G 2.48E-05 Bipolar Disorder / / pha002858 rs11580622 chr1 30529446 A C 7.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs391479 chr1 30530885 T C 2.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs433112 chr1 30531039 T C 1.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs391725 chr1 30532738 C A 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs419527 chr1 30532849 T G 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs16833203 chr1 30533883 C T 5.53E-04 Nicotine dependence / / 17158188 rs746758 chr1 30536711 T C 3.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs369715 chr1 30554684 G A 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12755901 chr1 30561353 G A 0.000094 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6670744 chr1 30561697 C G 0.0000991 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11584193 chr1 30565805 G C 0.0000872 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs61759065 chr1 30565900 A T 0.0000943 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs910696 chr1 30567596 G A 3.00E-06 Smoking behavior / / 19247474 rs2076977 chr1 30574158 T C 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376909 chr1 30574667 T G 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12088570 chr1 30575319 C T 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs12742458 chr1 30576573 T C 5.40E-05 Endometriosis / / 21151130 rs10915026 chr1 30578274 C T 0.0000786 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10915029 chr1 30578922 C T 5.26E-04 Multiple complex diseases / / 17554300 rs12122307 chr1 30606563 G A 0.0007337 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12122307 chr1 30606563 G A 7.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2180233 chr1 30627712 C T 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6425881 chr1 30659586 G A 2.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs7523165 chr1 30660403 A G 7.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12072928 chr1 30660839 T G 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10915040 chr1 30663554 A G 4.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs16833396 chr1 30687128 C A 4.13E-05 Body Mass Index / / pha003007 rs13375139 chr1 30691713 C T 6.94E-05 Alcohol consumption / / 23743675 rs59765152 chr1 30691817 C T 6.03E-05 Alcohol consumption / / 23743675 rs2142714 chr1 30692598 G A 6.69E-04 Smoking cessation / / 24665060 rs2142713 chr1 30692648 T C 6.54E-04 Smoking cessation / / 24665060 rs11806668 chr1 30694698 C T 3.76E-05 Body Mass Index / / pha003007 rs11806668 chr1 30694698 C T 8.44E-05 Body Mass Index / / pha003015 rs2179163 chr1 30709045 C T 6.72E-04 Smoking cessation / / 24665060 rs58267302 chr1 30731997 T C 5.75E-05 Alcohol consumption / / 23743675 rs459233 chr1 30750679 A G 3.86E-04 Aortic root size / / 21223598 rs376299 chr1 30754821 T G 5.29E-06 Intelligence / / 21826061 rs58245 chr1 30755532 G A 1.34E-06 Intelligence / / 21826061 rs463128 chr1 30759956 T C 2.65E-05 Intelligence / / 21826061 rs463128 chr1 30759956 T C 7.23E-04 Heart Failure / / pha002884 rs460911 chr1 30761304 G A 2.29E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 5.87E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 8.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs411238 chr1 30787227 G A 9.70E-05 Heart Failure / / pha002884 rs117311 chr1 30789341 C A 3.27E-04 Alzheimer's disease / / 17998437 rs437709 chr1 30792212 G A 4.19E-05 Triglycerides / / pha002904 rs6688031 chr1 30802598 C T 7.97E-04 Multiple complex diseases / / 17554300 rs10799104 chr1 30883503 C T 3.77E-04 Multiple complex diseases / / 17554300 rs11577262 chr1 30918166 T C 4.01E-04 Endometrial cancer / / 24096698 rs11577262 chr1 30918166 T C 7.90E-05 Endometrial cancer / / 24096698 rs454774 chr1 30923203 G T 2.10E-05 Malaria / / 19465909 rs262603 chr1 30941636 A C 2.74E-04 Multiple complex diseases / / 17554300 rs262584 chr1 30946775 C A 2.42E-04 Taste perception / / 22132133 rs12408702 chr1 30975928 C T 3.40E-06 Urinary metabolites / / 21572414 rs16833790 chr1 30980131 A G 4.20E-06 Urinary metabolites / / 21572414 rs3104429 chr1 30985076 T C 1.50E-05 Urinary metabolites / / 21572414 rs72650565 chr1 30993931 T C 9.07E-06 Stroke (ischemic) / / 21957438 rs6692098 chr1 30998096 A C 2.19E-04 Multiple complex diseases / / 17554300 rs4949613 chr1 31006103 A G 2.47E-04 Multiple complex diseases / / 17554300 rs51397 chr1 31013775 T C 8.97E-04 Body mass index / / 21701565 rs1484837 chr1 31017683 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs904257 chr1 31022237 A G 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs3104434 chr1 31023291 G T 4.97E-04 Smoking initiation / / 24665060 rs2377368 chr1 31024967 G A 7.94E-04 Type 2 diabetes / / 17463246 rs3104425 chr1 31034663 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs530973 chr1 31062295 C T 8.93E-05 Dengue shock syndrome / / 22001756 rs609015 chr1 31070154 A G 7.19E-04 Multiple complex diseases / / 17554300 rs6426041 chr1 31074793 T G 6.14E-06 Serum metabolites / / 19043545 rs633832 chr1 31081441 G A 5.13E-04 Multiple complex diseases / / 17554300 rs544789 chr1 31083478 A G 3.01E-04 Multiple complex diseases / / 17554300 rs1188446 chr1 31163456 A G 3.76E-04 Body mass index / / 21701565 rs1188445 chr1 31163876 G A 1.10E-05 Obesity-related traits / / 17658951 rs1188444 chr1 31164624 T C 8.27E-04 White matter integrity / / 22425255 rs716486 chr1 31167561 G A 1.90E-06 Urinary metabolites / / 21572414 rs1033867 chr1 31167998 T C 3.97E-05 Longevity / / 20304771 rs1149023 chr1 31176942 G T 9.93E-04 Multiple complex diseases / / 17554300 rs912218 chr1 31180714 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4949290 chr1 31203860 G A 2.36E-05 Colorectal cancer / / 21242260 rs3795437 chr1 31206806 T C 8.09E-05 Longevity LAPTM5 intron 20304771 rs12404920 chr1 31206957 T C 7.88E-05 Longevity LAPTM5 intron 20304771 rs10914189 chr1 31207781 C T 6.26E-04 Smoking initiation LAPTM5 intron 24665060 rs1188349 chr1 31223657 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) LAPTM5 intron 20189245 rs12063364 chr1 31272051 A G 2.37E-04 Osteoarthritis / / 19508968 rs2377570 chr1 31298769 A G 0.000063 Primary sclerosing cholangitis / / 22521342 rs4949316 chr1 31315593 G C 9.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs2488230 chr1 31320651 G A 3.63E-05 Prostate cancer / / 22923026 rs3935266 chr1 31330844 G A 9.68E-05 Prostate cancer / / 22923026 rs947643 chr1 31461438 G A 2.17E-04 Type 2 diabetes PUM1 intron 17463246 rs7536851 chr1 31471702 A C 2.29E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753241 chr1 31490614 A G 2.20E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753242 chr1 31494475 T G 2.16E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs6694709 chr1 31520472 A C 7.75E-04 Tourette syndrome PUM1 intron 22889924 rs7526662 chr1 31539051 A G 1.86E-05 Systemic lupus erythematosus / / pha002867 rs11577241 chr1 31647583 G C 2.95E-04 Depression (quantitative trait) / / 20800221 rs2066163 chr1 31650749 A G 2.92E-04 Depression (quantitative trait) / / 20800221 rs4949356 chr1 31653988 A G 2.91E-04 Depression (quantitative trait) NKAIN1 UTR-3 20800221 rs6425715 chr1 31658678 A G 2.89E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6693735 chr1 31659496 C G 5.26E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2377717 chr1 31673263 C T 7.79E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs4949197 chr1 31676938 A G 9.22E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798827 chr1 31682312 T G 8.72E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2889710 chr1 31682380 G A 5.03E-04 Response to cytidine analogues (gemcitabine) NKAIN1 intron 24483146 rs10753244 chr1 31683500 A G 6.74E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798828 chr1 31683890 C T 7.23E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs12033154 chr1 31686085 A G 6.69E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6699372 chr1 31704333 G A 9.47E-04 Coronary Artery Disease NKAIN1 intron 17634449 rs17440445 chr1 31722562 A G 7.84E-05 Multiple complex diseases / / 17554300 rs17440445 chr1 31722562 A G 6.19E-04 Taste perception / / 22132133 rs7515867 chr1 31724744 T C 5.83E-05 Multiple complex diseases / / 17554300 rs7515988 chr1 31731061 A G 2.59E-06 Multiple complex diseases / / 17554300 rs10753245 chr1 31731208 T C 1.16E-04 Multiple complex diseases / / 17554300 rs12725881 chr1 31736123 T C 9.55E-05 Multiple complex diseases SNRNP40 intron 17554300 rs41412349 chr1 31769752 T G 1.41E-04 Multiple complex diseases / / 17554300 rs6696341 chr1 31782052 A G 7.82E-04 Taste perception ZCCHC17 intron 22132133 rs6679365 chr1 31787866 G T 6.34E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7523438 chr1 31788313 A G 6.26E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7556340 chr1 31788453 T A 2.94E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10914355 chr1 31796985 G A 3.82E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10798845 chr1 31822636 G A 4.29E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949389 chr1 31824023 G A 2.74E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs3795432 chr1 31829873 C T 9.66E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949391 chr1 31833706 G T 2.88E-04 Multiple complex diseases ZCCHC17 intron 17554300 rs17495262 chr1 31837632 C T 2.63E-04 Multiple complex diseases ZCCHC17 UTR-3 17554300 rs7523777 chr1 31839136 A G 0.0000017 Cholesterol,total FABP3 intron 23063622 rs11578034 chr1 31842153 C T 3.36E-04 Iron levels FABP3 intron pha002876 rs951545 chr1 31844665 G A 4.86E-04 Multiple complex diseases FABP3 intron 17554300 rs951545 chr1 31844665 G A 1.70E-05 Urinary metabolites FABP3 intron 21572414 rs6425744 chr1 31850657 A G 2.50E-05 Urinary metabolites / / 21572414 rs1995585 chr1 31855474 A G 2.84E-04 Multiple complex diseases / / 17554300 rs10914372 chr1 31857998 A G 4.83E-04 Iron levels / / pha002876 rs12122236 chr1 31858901 T C 2.84E-04 Multiple complex diseases / / 17554300 rs905929 chr1 31862917 G C 4.50E-06 Urinary metabolites / / 21572414 rs7534378 chr1 31863558 G A 5.21E-04 Multiple complex diseases / / 17554300 rs7534465 chr1 31863663 G A 3.85E-04 Multiple complex diseases / / 17554300 rs6659255 chr1 31869669 C T 0.000072 Carotid intima media thickness / / 23152477 rs1039630 chr1 31881472 T C 8.72E-05 Alcohol dependence SERINC2 nearGene-5 21703634 rs2839939 chr1 31881637 T C 7.80E-05 Multiple complex diseases SERINC2 nearGene-5 17554300 rs4478858 chr1 31883925 T C 8.96E-05 Alcohol dependence SERINC2 intron 21703634 rs4478858 chr1 31883925 T C 3.00E-08 Alcohol dependence SERINC2 intron 23455491 rs1934290 chr1 31884180 T C 1.40E-04 Multiple complex diseases SERINC2 intron 17554300 rs12037108 chr1 31895394 T C 5.93E-04 Multiple complex diseases SERINC2 intron 17554300 rs4949402 chr1 31898234 T C 9.44E-05 Alcohol dependence SERINC2 cds-synon 21703634 rs2275435 chr1 31898536 C T 9.53E-05 Alcohol dependence SERINC2 intron 21703634 rs7548985 chr1 31915981 C T 3.08E-04 Multiple complex diseases / / 17554300 rs4261154 chr1 31921862 G A 7.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10798854 chr1 31934343 G A 3.63E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4949419 chr1 31977336 A G 1.40E-05 Multiple complex diseases / / 17554300 rs10914424 chr1 31980298 C T 5.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10914427 chr1 31982584 G A 8.91E-04 Response to cytidine analogues (gemcitabine) LOC284551 nearGene-5 24483146 rs6667261 chr1 31992493 T C 6.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6669615 chr1 31997793 C T 9.57E-04 Multiple complex diseases / / 17554300 rs12125499 chr1 32000490 G T 1.20E-05 Cognitive performance / / 19734545 rs12125499 chr1 32000490 G T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949437 chr1 32012283 T C 8.25E-04 Coronary Artery Disease / / 17634449 rs6425775 chr1 32034245 A C 0.00063 Salmonella-induced pyroptosis / / 22837397 rs10914446 chr1 32054094 A C 2.65E-04 Type 2 diabetes / / 17463246 rs4949448 chr1 32062066 G T 2.36E-04 Type 2 diabetes / / 17463246 rs6681414 chr1 32070234 G A 2.47E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2271933 chr1 32092525 A G 8.29E-04 Type 2 diabetes HCRTR1 missense 17463246 rs2271933 chr1 32092525 A G 9.80E-05 Speech perception in dyslexia HCRTR1 missense 19786962 rs10798882 chr1 32108547 C G 6.99E-04 Type 2 diabetes PEF1 intron 17463246 rs7524405 chr1 32108579 C A 6.62E-04 Type 2 diabetes PEF1 intron 17463246 rs4949455 chr1 32114793 G A 4.32E-04 Type 2 diabetes / / 17463246 rs909002 chr1 32139635 C T 9.30E-04 Type 2 diabetes COL16A1 intron 17463246 rs4949458 chr1 32142332 T G 4.67E-05 Pulmonary function COL16A1 intron 20010835 rs4949459 chr1 32142354 G T 2.22E-05 Pulmonary function COL16A1 intron 20010835 rs2297679 chr1 32157009 G T 3.00E-05 Educational attainment COL16A1 intron 21694764 rs12040661 chr1 32209650 G A 8.13E-04 Taste perception BAI2 intron 22132133 rs10914477 chr1 32240262 G A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8179509 chr1 32273434 A G 5.69E-04 Smoking initiation SPOCD1 intron 24665060 rs16834735 chr1 32276442 C T 6.26E-05 Orofacial clefts SPOCD1 intron 20023658 rs11589992 chr1 32300130 T C 3.65E-05 Serum metabolites / / 19043545 rs16834744 chr1 32312698 T G 5.80E-04 Multiple complex diseases / / 17554300 rs7521293 chr1 32315551 C A 2.20E-06 Urinary metabolites / / 21572414 rs671101 chr1 32336098 A G 1.70E-04 Myasthenia gravis / / 23055271 rs671101 chr1 32336098 A G 7.83E-05 Alcohol consumption / / 23953852 rs682654 chr1 32371523 C A 2.36E-06 Alcohol consumption / / 23953852 rs639233 chr1 32372881 C T 2.06E-06 Alcohol consumption PTP4A2 UTR-3 23953852 rs563978 chr1 32390324 C T 2.08E-05 Tunica Media PTP4A2 intron pha003037 rs591833 chr1 32397890 G A 1.98E-06 Alcohol consumption PTP4A2 intron 23953852 rs646370 chr1 32401166 A G 4.06E-05 Alcohol consumption PTP4A2 intron 23953852 rs680327 chr1 32438231 A G 0.000622 Height (Pygmy height) / / 22570615 rs680328 chr1 32438234 A G 0.000622 Height (Pygmy height) / / 22570615 rs16834895 chr1 32602531 A C 6.95E-04 Multiple complex diseases KP/6 intron 17554300 rs6425793 chr1 32668428 A G 9.63E-06 Anorexia nervosa CCDC28B intron 23568457 rs12032332 chr1 32672932 G A 1.60E-05 Schizophrenia IQCC missense 19571808 rs747020 chr1 32697934 G A 6.98E-04 Coronary Artery Disease MTMR9LP intron 17634449 rs747020 chr1 32697934 G A 7.54E-04 Schizophrenia MTMR9LP intron 19197363 rs747020 chr1 32697934 G A 8.20E-06 Schizophrenia MTMR9LP intron 19571808 rs747020 chr1 32697934 G A 1.40E-05 Urinary metabolites MTMR9LP intron 21572414 rs587707 chr1 32699227 T C 4.15E-04 Multiple complex diseases MTMR9LP intron 17554300 rs669538 chr1 32711360 C T 0.00042 Endometrial cancer / / 22426144 rs16834954 chr1 32784954 T C 1.27E-04 Multiple complex diseases HDAC1 intron 17554300 rs7532909 chr1 32826793 T C 8.22E-04 Multiple complex diseases / / 17554300 rs2270537 chr1 32829281 G A 4.00E-05 HIV-1 control TSSK3 cds-synon 20041166 rs11588497 chr1 33030461 A G 2.21E-05 Height ZBTB8A intron pha003010 rs11588497 chr1 33030461 A G 9.53E-06 Height ZBTB8A intron pha003011 rs359955 chr1 33134774 A C 2.27E-05 Coronary heart disease RBBP4 intron pha003056 rs696626 chr1 33195429 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs699006 chr1 33199367 C G 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4951771 chr1 33233223 C T 9.32E-04 Multiple complex diseases KIAA1522 intron 17554300 rs881393 chr1 33256645 G C 2.73E-04 Multiple complex diseases YARS intron 17554300 rs10914621 chr1 33277080 C T 1.59E-04 Multiple complex diseases YARS intron 17554300 rs12760548 chr1 33280648 T G 2.73E-04 Multiple complex diseases YARS intron 17554300 rs61739743 chr1 33292008 G A 0.00025 Prostate cancer S100PBP missense 23555315 rs16835198 chr1 33326681 G T 2.19E-04 Multiple complex diseases / / 17554300 rs11811702 chr1 33350183 G A 5.82E-06 Multiple sclerosis / / 19525953 rs1284373 chr1 33355923 C T 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCA intron 20877124 rs7527330 chr1 33380108 T G 7.64E-04 HIV-1 viral setpoint / / 17641165 rs194655 chr1 33421461 T C 4.17E-04 Multiple complex diseases RNF19B intron 17554300 rs10914658 chr1 33530750 G A 6.06E-15 Gender / / 22362730 rs638130 chr1 33585070 A G 1.97E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) ADC intron 24192120 rs654947 chr1 33599915 T C 1.90E-05 Urinary metabolites / / 21572414 rs689187 chr1 33611890 C A,G,T 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM62 UTR-3 20877124 rs3912145 chr1 33614162 T C 1.40E-04 Iris characteristics TRIM62 intron 21835309 rs676069 chr1 33622077 T C 7.10E-04 Alcohol dependence TRIM62 intron 21314694 rs587042 chr1 33638736 C T 8.81E-05 Hypertension (early onset hypertension) TRIM62 intron 22479346 rs587910 chr1 33643361 A G 2.40E-05 Urinary metabolites TRIM62 intron 21572414 rs636561 chr1 33645971 C T 9.80E-06 Urinary metabolites TRIM62 intron 21572414 rs9729837 chr1 33673559 T G 6.51E-05 Coronary Artery Disease / / 17634449 rs6425809 chr1 33702965 G C 4.38E-04 Multiple complex diseases / / 17554300 rs4653002 chr1 33770526 T C 0.000689932 Hypertension (early onset hypertension) / / 22479346 rs10914692 chr1 33832933 G A 0.000525414 Hypertension (early onset hypertension) PHC2 missense 22479346 rs12127097 chr1 33850890 T C 6.68E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6661037 chr1 33872593 T C 2.21E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1998623 chr1 33893290 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4653135 chr1 33893830 C T 5.92E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12032996 chr1 33920586 G A 7.10E-06 Urinary metabolites / / 21572414 rs12565140 chr1 33928758 T C 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs4653152 chr1 33931116 G A 3.88E-05 Prostate cancer / / pha002878 rs10798953 chr1 33937135 T C 2.04E-05 Alcohol dependence / / 19581569 rs16835496 chr1 33938845 A G 9.09E-04 Response to cytidine analogues (gemcitabine) ZSCAN20 intron 24483146 rs10798959 chr1 33983019 C T 8.00E-06 Metabolite levels (HVA/MHPG ratio) CSMD2 intron 23319000 rs12751162 chr1 34014134 C A 1.26E-05 Common variable immunodeficiency CSMD2 intron 21497890 rs915108 chr1 34023749 T C 5.88E-05 Lung cancer CSMD2 intron 18978787 rs6701268 chr1 34041191 T G 2.20E-04 Alcohol dependence CSMD2 intron 20201924 rs6701268 chr1 34041191 T G 1.43E-04 Schizophrenia CSMD2 intron 21747397 rs6425830 chr1 34044616 A G 6.40E-06 Urinary metabolites CSMD2 intron 21572414 rs416391 chr1 34048268 C T 3.40E-04 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 4.00E-05 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 3.99E-05 Alcoholism CSMD2 intron pha002892 rs1493988 chr1 34068364 G T 8.80E-04 Alzheimer's disease CSMD2 intron 22005930 rs564148 chr1 34173820 C T 9.00E-06 Response to amphetamines CSMD2 intron 22952603 rs612279 chr1 34173973 A G 8.91E-06 Response to amphetamines CSMD2 intron 22952603 rs570408 chr1 34174424 G A 8.03E-06 Response to amphetamines CSMD2 intron 22952603 rs16835742 chr1 34180842 G T 8.00E-08 Intelligence CSMD2 intron 22449649 rs7533254 chr1 34181830 G A 9.45E-04 Alcohol dependence CSMD2 intron 21314694 rs667892 chr1 34189552 C T 6.03E-06 Prion diseases CSMD2 intron 22210626 rs555733 chr1 34194736 T C 4.34E-05 Prion diseases CSMD2 intron 22210626 rs508796 chr1 34197058 T C 1.36E-05 Prion diseases CSMD2 intron 22210626 rs554862814 chr1 34203689 TACTC T 8.69E-06 Prion diseases CSMD2 intron 22210626 rs6661190 chr1 34203689 T C 8.69E-06 Prion diseases CSMD2 intron 22210626 rs512332 chr1 34206933 A G 2.02E-04 Response to cytadine analogues (cytosine arabinoside) CSMD2 intron 24483146 rs513049 chr1 34206979 G C 8.44E-04 Multiple complex diseases CSMD2 intron 17554300 rs475622 chr1 34207470 G A 1.12E-05 Prion diseases CSMD2 intron 22210626 rs1550545 chr1 34210087 G A 9.91E-06 Prion diseases CSMD2 intron 22210626 rs4578181 chr1 34210532 G A 9.47E-06 Prion diseases CSMD2 intron 22210626 rs9943159 chr1 34213077 A G 3.05E-06 Prion diseases CSMD2 intron 22210626 rs989661 chr1 34217931 C T 3.08E-04 Multiple complex diseases CSMD2 intron 17554300 rs474474 chr1 34238283 T C 0.00087 Prostate cancer CSMD2 missense 23555315 rs476463 chr1 34248064 G A 1.00E-06 Brain structure CSMD2 intron 20171287 rs717030 chr1 34249330 T C 5.37E-05 Lipoproteins CSMD2 intron pha003079 rs6425838 chr1 34254416 C T 6.04E-05 Cognitive test performance CSMD2 intron 20125193 rs545170 chr1 34256734 T C 3.32E-05 Body mass (lean) CSMD2 intron 19268274 rs10914782 chr1 34267945 T C 9.19E-05 Serum metabolites CSMD2 intron 19043545 rs12567192 chr1 34270994 T C 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10914783 chr1 34271055 G A 2.71E-06 Multiple complex diseases CSMD2 intron 17554300 rs10798993 chr1 34276880 A G 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10798994 chr1 34277174 T C 2.16E-04 Smoking quantity CSMD2 intron 24665060 rs11587451 chr1 34277979 A G 4.66E-04 Smoking quantity CSMD2 intron 24665060 rs3845473 chr1 34282691 G A 5.18E-05 Smoking quantity CSMD2 intron 24665060 rs3845476 chr1 34283894 A G 1.57E-04 Smoking quantity CSMD2 intron 24665060 rs3842834 chr1 34284118 G A 5.19E-04 Premature ovarian failure CSMD2 intron 19508998 rs3842834 chr1 34284118 G A 2.30E-04 Smoking quantity CSMD2 intron 24665060 rs12067054 chr1 34291676 C T 7.60E-05 Smoking quantity CSMD2 intron 24665060 rs3845477 chr1 34291836 A G 1.29E-04 Smoking quantity CSMD2 intron 24665060 rs10914789 chr1 34294874 T C 8.40E-04 Primary sclerosing cholangitis CSMD2 intron 19944697 rs6425850 chr1 34308585 T G 7.28E-04 Smoking initiation CSMD2 intron 24665060 rs746667 chr1 34312179 C G 7.78E-04 Alzheimer's disease CSMD2 intron 17998437 rs11542686 chr1 34329968 A G 1.40E-36 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 3.00E-20 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 4.00E-14 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 6.80E-08 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs1321627 chr1 34331390 C G 6.43E-04 Alzheimer's disease CSMD2 intron 17998437 rs1108927 chr1 34333267 T G 7.79E-05 Cognitive impairment induced by topiramate CSMD2 intron 22091778 rs12122958 chr1 34340819 C G 7.76E-04 Multiple complex diseases CSMD2 intron 17554300 rs6425855 chr1 34346361 G T 3.99E-04 Smoking cessation CSMD2 intron 24665060 rs4653358 chr1 34349815 C A 4.67E-04 Smoking cessation CSMD2 intron 24665060 rs2281597 chr1 34359858 G C 5.00E-07 Attention deficit hyperactivity disorder CSMD2 intron 18839057 rs911216 chr1 34375199 A C 7.30E-04 Alcohol dependence CSMD2 intron 20201924 rs7536114 chr1 34379375 T G 1.20E-04 Alcohol dependence CSMD2 intron 20201924 rs12029535 chr1 34383662 T C 7.71E-04 Multiple complex diseases CSMD2 intron 17554300 rs12031839 chr1 34386710 A G 3.10E-06 Urinary metabolites CSMD2 intron 21572414 rs7555410 chr1 34394682 C A 4.13E-05 Lung function (forced expiratory volume in 1 second) CSMD2 intron 17255346 rs7555410 chr1 34394682 C A 5.56E-04 Suicide attempts in bipolar disorder CSMD2 intron 21423239 rs504471 chr1 34418942 A G 2.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CSMD2 intron 23648065 rs7529498 chr1 34472274 T C 0.000802662 Hypertension (early onset hypertension) CSMD2 intron 22479346 rs504527 chr1 34473608 A C 3.20E-05 Lipid traits CSMD2 intron 17903299 rs2358756 chr1 34479922 T C 2.73E-05 Alcoholism CSMD2 intron pha002893 rs12563211 chr1 34486225 C T 6.55E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs16836204 chr1 34486486 C T 4.30E-04 Type 2 diabetes CSMD2 intron 17463246 rs2118109 chr1 34490918 C T 6.41E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs2164581 chr1 34491558 A G 6.82E-05 Alcoholism CSMD2 intron pha002893 rs10914850 chr1 34496094 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs10914851 chr1 34496126 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs12035502 chr1 34499772 C T 4.28E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs2625684 chr1 34505115 T C 7.65E-04 Alcohol consumption (maxi-drinks) CSMD2 intron 24277619 rs9426003 chr1 34602870 G A 4.93E-04 Amyotrophic lateral sclerosis (sporadic) CSMD2 intron 24529757 rs1335855 chr1 34648046 T C 5.80E-04 Type 2 diabetes C1orf94 intron 17463246 rs11584467 chr1 34665219 G A 8.00E-07 Urinary metabolites C1orf94 intron 21572414 rs12128858 chr1 34723928 T C 2.01E-05 Response to metformin / / 21186350 rs771404 chr1 34726167 G A,C,T 6.21E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12039643 chr1 34727726 G T 1.20E-05 Urinary metabolites / / 21572414 rs10914894 chr1 34734066 G A 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1414470 chr1 34736287 G A 3.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs880017 chr1 34741605 A G 2.07E-04 Kawasaki disease / / 21326860 rs771392 chr1 34748815 C G 1.64E-08 Corneal structure / / 22003120 rs771390 chr1 34750936 T C 6.00E-07 Epilepsy (generalized) / / 22949513 rs6704508 chr1 34756509 T G 2.17E-04 White matter integrity / / 22425255 rs11588801 chr1 34761911 T C 2.59E-04 White matter integrity / / 22425255 rs1404350 chr1 34764974 A C 4.66E-04 Heart Failure / / pha002884 rs7523842 chr1 34765880 T G 4.49E-04 Heart Failure / / pha002884 rs10732274 chr1 34790295 A G 5.84E-04 Heart Failure / / pha002884 rs1917247 chr1 34805625 C A 1.87E-04 Type 2 diabetes / / 17463246 rs6695784 chr1 34815393 A G 2.98E-04 Acute lung injury / / 22295056 rs2294193 chr1 34866656 C T 7.40E-04 White matter integrity / / 22425255 rs2092028 chr1 34872737 A G 2.35E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2092028 chr1 34872737 A G 7.00E-05 Lung function (forced vital capacity) / / 24023788 rs1883109 chr1 34892913 C A 8.92E-05 Potassium levels / / pha003086 rs17385253 chr1 34895009 T C 3.30E-05 Neuroticism / / 17667963 rs2142534 chr1 34900172 A G 9.16E-05 Myopia (pathological) / / 21095009 rs4653032 chr1 34902910 C A 1.82E-05 Asthma / / 23181788 rs10753308 chr1 34907148 A G 7.61E-04 Nicotine dependence / / 17158188 rs10489377 chr1 34915676 G A 0.0000836 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67211730 chr1 34917267 T A 0.0000837 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10914952 chr1 34919213 G A 1.64E-04 Attention deficit hyperactivity disorder / / pha002875 rs2075933 chr1 34921075 C T 8.35E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1016091 chr1 34924596 C T 7.41E-04 Taste perception / / 22132133 rs4653040 chr1 34930403 G A 0.0000792 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs798076 chr1 34936568 G A 3.00E-04 Smoking quantity / / 24665060 rs10914956 chr1 34938132 C A 0.0000659 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3845485 chr1 34985459 A G 1.63E-28 Narcolepsy / / 19629137 rs7556065 chr1 34988276 A T 7.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10914967 chr1 34989237 G A 6.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs4587532 chr1 34994991 C G 1.80E-05 Urinary metabolites / / 21572414 rs4653054 chr1 35009882 C T 2.10E-05 Urinary metabolites / / 21572414 rs6665029 chr1 35040991 T C 2.51E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1886340 chr1 35069285 G A 1.11E-05 Coronary heart disease / / pha003030 rs12048230 chr1 35070977 G A 1.88E-04 Alzheimer's disease (late onset) / / 21460841 rs4653061 chr1 35072298 G A 4.77E-05 Coronary heart disease / / pha003030 rs10914991 chr1 35074860 A T 8.76E-05 Schizophrenia(age at onset) / / 21688384 rs12117895 chr1 35079250 G A 4.01E-05 Schizophrenia(age at onset) / / 21688384 rs2147384 chr1 35082968 A C 3.62E-05 Schizophrenia(age at onset) / / 21688384 rs7544557 chr1 35084074 T C 3.06E-05 Coronary heart disease / / pha003030 rs10799074 chr1 35087725 G A 1.57E-04 Alzheimer's disease (late onset) / / 21460841 rs4653067 chr1 35088484 C A 2.97E-05 Schizophrenia(age at onset) / / 21688384 rs2359631 chr1 35090073 T C 6.37E-05 Pancreatic cancer / / pha002889 rs7547341 chr1 35090895 A C 2.74E-04 Alzheimer's disease (late onset) / / 21460841 rs6667879 chr1 35094437 G A 5.14E-04 Acute lung injury / / 22295056 rs7548924 chr1 35095368 C T 5.56E-04 Acute lung injury / / 22295056 rs868501 chr1 35097520 C T 5.56E-04 Acute lung injury / / 22295056 rs612353 chr1 35113184 A G 9.05E-05 Attention deficit hyperactivity disorder / / pha002875 rs12048853 chr1 35119247 C T 8.14E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs725790 chr1 35148448 A C 0.00000693 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs41495144 chr1 35149756 G C 9.00E-04 Multiple complex diseases / / 17554300 rs10915020 chr1 35157716 T A 0.00000054 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836898 chr1 35159859 C T 0.000000728 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836900 chr1 35159912 T C 9.63E-04 Multiple complex diseases / / 17554300 rs12030047 chr1 35160305 A C 3.47E-04 Multiple complex diseases / / 17554300 rs1932768 chr1 35165972 G A 0.00000136 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs2145390 chr1 35283939 T C 1.85E-05 Formal thought disorder in schizophrenia / / 22648509 rs7526035 chr1 35289039 G A 9.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs11264139 chr1 35303369 A G 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6703979 chr1 35315737 C T 3.00E-05 Lung cancer / / 18978790 rs7525948 chr1 35353904 G A 4.12E-04 Iron levels DLGAP3 intron pha002876 rs10493064 chr1 35369014 T A 1.00E-04 Information processing speed DLGAP3 intron 21130836 rs11263872 chr1 35446830 G A 1.50E-05 HIV-1 control / / 20041166 rs12407202 chr1 35462487 C T 1.50E-05 HIV-1 control ZMYM6 intron 20041166 rs2335466 chr1 35617631 A C 8.32E-04 Multiple complex diseases / / 17554300 rs1498111 chr1 35641608 A G 9.97E-04 Multiple complex diseases / / 17554300 rs11264112 chr1 35645343 A C 2.39E-04 Hearing function / / 17255346 rs11264112 chr1 35645343 A C 2.58E-04 Multiple complex diseases / / 17554300 rs3738694 chr1 35648316 C T 2.38E-04 Hearing function / / 17255346 rs10908385 chr1 35654725 G A 7.55E-05 Multiple complex diseases SFPQ intron 17554300 rs11264114 chr1 35656064 T A 5.07E-04 Multiple complex diseases SFPQ intron 17554300 rs11264115 chr1 35656664 G A 7.04E-04 Multiple complex diseases SFPQ intron 17554300 rs7543044 chr1 35674311 A G 1.23E-04 Type 2 diabetes / / 17463246 rs673604 chr1 35687815 T C 6.00E-06 Endometrial cancer / / 21499250 rs593461 chr1 35709777 G A 5.54E-06 Rheumatoid arthritis / / 17804836 rs659215 chr1 35843029 C T 7.45E-05 Multiple complex diseases ZMYM4 intron 17554300 rs10908393 chr1 35854157 G C 5.52E-04 Multiple complex diseases ZMYM4 intron 17554300 rs10157137 chr1 35901222 A G 1.27E-06 Multiple complex diseases KIAA0319L intron 17554300 rs2275247 chr1 35908451 T C 1.00E-10 Systemic lupus erythematosus and Systemic sclerosis KIAA0319L intron 23740937 rs1203137 chr1 35951038 A G 2.42E-04 Type 2 diabetes KIAA0319L intron 17463246 rs1635718 chr1 35974469 C G 5.87E-04 Type 2 diabetes KIAA0319L intron 17463246 rs2074676 chr1 36027711 G A 8.76E-04 Multiple complex diseases NCDN intron 17554300 rs11264179 chr1 36056721 T C 2.70E-05 Coffee consumption TFAP2E intron 21357676 rs953035 chr1 36079508 G A 2.00E-05 Rheumatoid arthritis PSMB2 intron 17804836 rs676614 chr1 36107510 C A 6.34E-04 Multiple complex diseases / / 17554300 rs11264186 chr1 36149745 A G 5.70E-04 Multiple complex diseases / / 17554300 rs636658 chr1 36151125 C G 4.26E-04 Multiple complex diseases / / 17554300 rs2095247 chr1 36153830 C T 9.26E-04 Multiple complex diseases / / 17554300 rs12048483 chr1 36159594 A C 6.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) / / 21239504 rs1333647 chr1 36161383 C A,G,T 5.15E-04 Lymphocyte counts / / 22286170 rs6688464 chr1 36172195 G A 4.40E-05 Bipolar disorder / / 19488044 rs6688464 chr1 36172195 G A 6.00E-05 Bipolar Disorder / / pha002858 rs6696354 chr1 36176509 T C 0.000006 Mean arterial pressure / / 22510845 rs577483 chr1 36205166 A G 9.16E-04 Multiple complex diseases CLSPN intron 17554300 rs577483 chr1 36205166 A G 2.37E-05 Bipolar disorder CLSPN intron 19488044 rs577483 chr1 36205166 A G 3.31E-05 Bipolar Disorder CLSPN intron pha002858 rs535638 chr1 36216835 C T 5.87E-04 Multiple complex diseases CLSPN intron 17554300 rs535638 chr1 36216835 C T 2.80E-05 Bipolar disorder CLSPN intron 19488044 rs535638 chr1 36216835 C T 3.92E-05 Bipolar Disorder CLSPN intron pha002858 rs16822339 chr1 36220558 C A 7.50E-04 Multiple complex diseases CLSPN intron 17554300 rs11263830 chr1 36345798 G A 9.82E-04 Multiple complex diseases / / 17554300 rs645383 chr1 36373823 C G 7.06E-04 Multiple complex diseases EIF2C1 intron 17554300 rs581459 chr1 36375110 C T 1.96E-04 Multiple complex diseases EIF2C1 intron 17554300 rs12031138 chr1 36407806 A G 8.51E-04 Multiple complex diseases EIF2C3 intron 17554300 rs12041193 chr1 36412760 C T 5.31E-04 Multiple complex diseases EIF2C3 intron 17554300 rs683622 chr1 36443569 A G 4.52E-04 Multiple complex diseases EIF2C3 intron 17554300 rs7542179 chr1 36461122 G A 3.23E-04 Multiple complex diseases EIF2C3 intron 17554300 rs491603 chr1 36532316 T C 8.45E-10 Central corneal thickness / / 21098505 rs3767703 chr1 36555758 C T 5.94E-09 Central corneal thickness ADPRHL2 intron 21098505 rs7550047 chr1 36567343 A G 2.26E-09 Central corneal thickness COL8A2 nearGene-5 21098505 rs7553155 chr1 36568236 A T 2.90E-05 Urinary metabolites / / 21572414 rs96067 chr1 36571920 G A 5.40E-13 Central corneal thickness / / 21098505 rs96067 chr1 36571920 G A 3.00E-11 Corneal structure / / 23291589 rs274137 chr1 36577945 T C 1.30E-05 Urinary metabolites / / 21572414 rs12074848 chr1 36585077 C T 9.98E-09 Central corneal thickness / / 21098505 rs4653160 chr1 36599547 C T 1.24E-06 Central corneal thickness / / 21098505 rs7522400 chr1 36613380 A G 6.68E-07 Central corneal thickness TRAPPC3 intron 21098505 rs522468 chr1 36653677 T G 3.80E-04 Alcohol dependence / / 20201924 rs200307550 chr1 36786521 A G 0.00014 Breast cancer (ER positive) SH3D21 missense 23555315 rs200307550 chr1 36786521 A G 0.00026 Breast cancer SH3D21 missense 23555315 rs12116935 chr1 36789546 A G 0.00000698 Alcohol dependence / / 23691058 rs3795498 chr1 36807481 C T 8.47E-04 Glycosylated haemoglobin levels STK40 missense 17255346 rs10796882 chr1 36818066 G A 2.26E-04 Glycosylated haemoglobin levels STK40 intron 17255346 rs11583322 chr1 36822312 T C 3.20E-04 Alcohol dependence STK40 intron 20201924 rs11583322 chr1 36822312 T C 0.000000011 Alcohol dependence STK40 intron 23691058 rs4451521 chr1 36831264 C G 1.56E-04 Alcohol dependence STK40 intron 21314694 rs11577980 chr1 36836476 C T 7.05E-04 Suicide attempts in bipolar disorder STK40 intron 21423239 rs1339767 chr1 36855957 G C 2.14E-04 Glycosylated haemoglobin levels / / 17255346 rs884925 chr1 36861993 A G 4.51E-04 Alzheimer's disease LSM10 intron 22005930 rs884925 chr1 36861993 A G 7.27E-04 Smoking initiation LSM10 intron 24665060 rs4653186 chr1 36862929 T G 2.55E-04 Alzheimer's disease LSM10 intron 22005930 rs16822823 chr1 36874242 A G 7.44E-04 Alcohol dependence / / 21314694 rs6702784 chr1 36904720 A C 4.00E-06 Diabetic retinopathy OSCP1 intron 21441570 rs953517 chr1 36910277 C T 5.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs11263898 chr1 36912531 G A 7.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs6425987 chr1 36924676 A G 6.00E-04 Alzheimer's disease MRPS15 intron 22005930 rs3917991 chr1 36934805 C G 6.30E-04 Atrial fibrillation CSF3R missense 21846873 rs3917989 chr1 36935128 G A 2.53E-04 Lymphocyte counts CSF3R intron 22286170 rs3917924 chr1 36945653 G A 2.33E-05 Hemoglobin CSF3R intron pha003096 rs3917924 chr1 36945653 G A 3.60E-05 Hematocrit CSF3R intron pha003097 rs11263901 chr1 36960626 G A 2.04E-06 Hearing function / / 21493956 rs4481816 chr1 36977811 G C 5.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11263915 chr1 37019556 G A 5.54E-05 Waist Circumference / / pha003023 rs7540413 chr1 37040374 T C 9.59E-04 Heart Failure / / pha002884 rs4653197 chr1 37041069 C T 9.10E-04 Multiple complex diseases / / 17554300 rs12567252 chr1 37041357 A C 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4653210 chr1 37074351 T G 2.60E-05 Systemic sclerosis / / 21750679 rs12090333 chr1 37077776 C T 6.64E-04 Alzheimer's disease / / 17998437 rs6685372 chr1 37126710 G A 4.43E-04 Multiple complex diseases / / 17554300 rs1076773 chr1 37136423 C T 4.37E-04 Type 2 diabetes / / 17463246 rs743012 chr1 37136670 G A 5.01E-04 Multiple complex diseases / / 17554300 rs7528341 chr1 37141174 C T 4.91E-04 Multiple complex diseases / / 17554300 rs34305923 chr1 37144140 C T 4.86E-04 Multiple complex diseases / / 17554300 rs589249 chr1 37162352 A G 3.00E-07 Schizophrenia / / 23894747 rs7515535 chr1 37182396 T A 8.19E-04 Multiple complex diseases / / 17554300 rs1395455 chr1 37185190 A G 3.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1002655 chr1 37192677 C G 3.20E-05 Schizophrenia / / 19571811 rs1002656 chr1 37192741 C T 8.65E-04 Multiple complex diseases / / 17554300 rs6425998 chr1 37197720 T C 6.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7549591 chr1 37198352 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs502808 chr1 37212617 G A 5.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1472823 chr1 37220721 G A 2.30E-05 Urinary metabolites / / 21572414 rs1472823 chr1 37220721 G A 6.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12083196 chr1 37233430 T C 2.70E-05 Urinary metabolites / / 21572414 rs12083196 chr1 37233430 T C 4.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs525798 chr1 37240886 G T 1.60E-05 Urinary metabolites / / 21572414 rs11801494 chr1 37250088 C T 0.0002 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs528137 chr1 37280785 C T 2.75E-05 Amyotrophic lateral sclerosis (sporadic) GRIK3 intron 24529757 rs484017 chr1 37303737 T C 4.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs547390 chr1 37317442 G A 8.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs1587526 chr1 37362476 T C 6.90E-04 Cognitive impairment induced by topiramate GRIK3 intron 22091778 rs41344852 chr1 37398177 G C 8.34E-05 Multiple complex diseases GRIK3 intron 17554300 rs613720 chr1 37525676 C A 4.00E-05 Serum metabolites / / 19043545 rs218422 chr1 37537709 T C 1.37E-04 Cholesterol / / 17255346 rs760964 chr1 37574864 G A 6.94E-04 Multiple complex diseases / / 17554300 rs215773 chr1 37596240 G T 6.01E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 3.30E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 1.72E-04 Arthritis (juvenile idiopathic) / / 22354554 rs215791 chr1 37606291 T C 2.80E-04 Multiple complex diseases / / 17554300 rs41387646 chr1 37612620 A G 1.00E-04 Multiple complex diseases / / 17554300 rs4653252 chr1 37622070 C A 2.22E-05 Serum metabolites / / 19043545 rs998176 chr1 37636117 G A 3.84E-05 Serum metabolites / / 19043545 rs4653254 chr1 37644737 T C 1.06E-05 Serum metabolites / / 19043545 rs1501540 chr1 37723078 A G 2.24E-04 Multiple complex diseases / / 17554300 rs905108 chr1 37724364 A T 5.63E-04 Multiple complex diseases / / 17554300 rs6426015 chr1 37770623 A G 6.96E-06 Common variable immunodeficiency / / 21497890 rs6426016 chr1 37773586 T C 9.57E-05 Femoral neck bone geometry / / 22087292 rs3898790 chr1 37774697 T G 6.70E-05 Femoral neck bone geometry / / 22087292 rs11264024 chr1 37777759 G A 8.84E-05 Femoral neck bone geometry / / 22087292 rs1411931 chr1 37782874 A G 5.80E-05 Lipid traits / / 17903299 rs761158 chr1 37787733 A G 7.70E-06 Urinary metabolites / / 21572414 rs6659871 chr1 37794345 G A 4.77E-04 Type 2 diabetes / / 17463246 rs2811615 chr1 37861304 G C 7.01E-04 Type 2 diabetes / / 17463246 rs875361 chr1 37865954 G A 1.96E-04 Myopia (pathological) / / 21095009 rs2811626 chr1 37880752 T C 1.60E-05 Myopia (pathological) / / 21095009 rs16824119 chr1 37888656 G A 9.31E-05 Myopia (pathological) / / 21095009 rs4428850 chr1 37889172 G T 7.85E-05 Myopia (pathological) / / 21095009 rs10796907 chr1 37900173 A G 2.81E-05 Lymphocyte counts / / pha003094 rs10796907 chr1 37900173 A G 6.75E-06 Neutrophil count / / pha003095 rs11264049 chr1 37902135 T C 1.49E-04 Multiple complex diseases / / 17554300 rs6700586 chr1 37957376 G A 4.80E-06 Alopecia areata / / 22027810 rs9253 chr1 37958813 C G 4.00E-06 Hemostatic factors and hematological phenotypes MEAF6 UTR-3 17903294 rs215864 chr1 37967774 C A 3.30E-05 Chronic obstructive pulmonary disease MEAF6 intron 19300482 rs116251390 chr1 38032607 C T 0.00026 Breast cancer (ER positive) GNL2 missense 23555315 rs10908355 chr1 38035286 G T 1.58E-04 Lymphocyte counts GNL2 intron 22286170 rs4074961 chr1 38092723 C T 4.00E-13 Axial length RSPO1 intron 24144296 rs4653314 chr1 38117562 T C 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs573381957 chr1 38117562 TC T 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs615530 chr1 38161694 A G 8.41E-04 Alcohol dependence CDCA8 intron 20201924 rs3790623 chr1 38169578 G A 3.42E-05 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs3790623 chr1 38169578 G A 6.54E-04 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs531454 chr1 38173597 A G 5.22E-04 Alcohol dependence CDCA8 intron 20201924 rs7822 chr1 38174987 T C 4.84E-04 Suicide attempts in bipolar disorder CDCA8 UTR-3 21423239 rs7541350 chr1 38191538 T C 7.58E-06 Prostate cancer EPHA10 intron pha002878 rs17464981 chr1 38192537 T C 8.93E-06 Prostate cancer EPHA10 intron pha002878 rs731174 chr1 38196841 T C 5.00E-06 Prostate cancer (gene x gene interaction) EPHA10 intron 22219177 rs482818 chr1 38233399 C G 9.59E-04 Multiple complex diseases / / 17554300 rs12117544 chr1 38247153 T A 8.00E-06 Cognitive performance / / 20125193 rs579689 chr1 38256166 G A 6.54E-04 Multiple complex diseases / / 17554300 rs12563037 chr1 38258644 G C 2.29E-04 Multiple complex diseases / / 17554300 rs2291297 chr1 38272660 G A 6.90E-05 Hypothyroidism YRDC intron 22493691 rs28411352 chr1 38278579 C T 3.00E-12 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 6.00E-09 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 7.80E-05 Rheumatoid arthritis MTF1 UTR-3 24390342 rs3748682 chr1 38279987 T C 9.00E-06 Hypothyroidism MTF1 UTR-3 22493691 rs12751325 chr1 38289383 T C 8.40E-05 Hypothyroidism MTF1 cds-synon 22493691 rs12742756 chr1 38347417 A G 1.50E-05 Hypothyroidism INPP5B intron 22493691 rs12728438 chr1 38349400 G A 6.00E-05 Hypothyroidism INPP5B intron 22493691 rs4634868 chr1 38465315 G A 4.70E-05 Inflammatory demyelinating disease FHL3 intron 19850125 rs11211383 chr1 38482356 T G 1.12E-05 Alcohol consumption UTP11L intron 23953852 rs535056 chr1 38522092 T C 1.85E-05 Cognitive test performance / / 20125193 rs1108183 chr1 38559394 C G 7.69E-04 Multiple complex diseases / / 17554300 rs11206585 chr1 38568328 T C 5.29E-05 Erythrocyte counts / / pha003099 rs7547921 chr1 38602073 C A 6.13E-05 Type 2 diabetes / / 17463246 rs7547921 chr1 38602073 C A 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs883220 chr1 38616871 C A 2.83E-05 Rheumatoid arthritis / / 17804836 rs883220 chr1 38616871 C A 9.63E-07 Rheumatoid arthritis / / 19503088 rs883220 chr1 38616871 C A 0.000000021 Rheumatoid arthritis / / 23143596 rs883220 chr1 38616871 C A 2.09E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs12131057 chr1 38624129 G A 4.00E-07 Rheumatoid arthritis / / 20453842 rs6693777 chr1 38630862 A G 3.72E-06 Panic disorder / / 19165232 rs12140275 chr1 38633879 A T 2.00E-09 Rheumatoid arthritis / / 24390342 rs12140275 chr1 38633879 A T 4.00E-09 Rheumatoid arthritis / / 24390342 rs7544568 chr1 38639208 G A 3.21E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs17534243 chr1 38650917 A G 8.45E-04 Multiple complex diseases / / 17554300 rs898978 chr1 38667704 T G 2.86E-04 Multiple complex diseases / / 17554300 rs7537377 chr1 38682207 A G 4.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6685558 chr1 38687060 T C 8.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1755302 chr1 38704189 A G 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12095190 chr1 38711632 G A 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11802770 chr1 38721663 T C 3.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs12075234 chr1 38738214 A G 1.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs12075234 chr1 38738214 A G 3.27E-05 Coronary heart disease / / pha003032 rs1543632 chr1 38747960 C T 6.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2798809 chr1 38792565 A G 3.33E-16 Triglycerides / / 23063622 rs11210569 chr1 38805929 T C 4.40E-05 Chronic obstructive pulmonary disease / / 19300482 rs6679637 chr1 38806630 G A 6.29E-05 Systemic sclerosis / / 21750679 rs6701668 chr1 38845585 C A 9.87E-04 Type 2 diabetes / / 17463246 rs17478958 chr1 38851959 A C 6.29E-04 Tourette syndrome / / 22889924 rs12132779 chr1 38876635 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11806392 chr1 38876866 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6678251 chr1 38880715 T C 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6600426 chr1 38884018 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs6600426 chr1 38884018 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4290027 chr1 38884529 G A 9.42E-06 Cognitive decline / / 23207651 rs1932362 chr1 38910848 G A 5.20E-04 Tourette syndrome / / 22889924 rs2252153 chr1 38919423 G A 3.00E-05 Prostate cancer / / 21743057 rs2252059 chr1 38919983 G A 3.00E-05 Prostate cancer / / 21743057 rs11590421 chr1 38994115 G A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4970603 chr1 39041667 T C 4.05E-05 Coronary heart disease / / pha003030 rs4970605 chr1 39047119 G A 1.92E-19 Multiple complex diseases / / 17554300 rs12026014 chr1 39060495 G A 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2985763 chr1 39065974 G A 1.64E-06 Schizophrenia / / 20185149 rs2985763 chr1 39065974 G A 2.83E-05 Bipolar disorder / / 20451256 rs1925382 chr1 39077100 G A 4.44E-04 HIV-1 viral setpoint / / 17641165 rs3011197 chr1 39079046 A G 1.83E-04 Glycosylated haemoglobin levels / / 17255346 rs3011199 chr1 39079150 A C 4.15E-04 Multiple complex diseases / / 17554300 rs12077396 chr1 39080101 G C 1.46E-05 Glycosylated haemoglobin levels / / 17255346 rs4970606 chr1 39081829 A G 5.32E-05 Glycosylated haemoglobin levels / / 17255346 rs11211081 chr1 39115477 A G 8.00E-05 Coronary heart disease / / pha003030 rs724321 chr1 39123603 G A 1.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17484092 chr1 39147240 T C 2.46E-04 Multiple complex diseases / / 17554300 rs17484306 chr1 39159100 T C 6.12E-04 Type 2 diabetes / / 17463246 rs17484306 chr1 39159100 T C 5.11E-04 Multiple complex diseases / / 17554300 rs10493084 chr1 39164153 G A 1.40E-04 Crohn's disease / / 17684544 rs4970620 chr1 39165402 G C 5.14E-04 Multiple complex diseases / / 17554300 rs10890338 chr1 39166659 G A 1.05E-04 Multiple complex diseases / / 17554300 rs12409323 chr1 39169671 G A 9.74E-05 Type 2 diabetes and other traits / / 19734900 rs17556883 chr1 39197064 T C 0.000065 Endometrial cancer / / 22426144 rs12065672 chr1 39199381 C A 3.78E-04 Multiple complex diseases / / 17554300 rs4246510 chr1 39217894 G C 2.19E-04 Multiple complex diseases / / 17554300 rs4970625 chr1 39221925 C A 4.06E-05 Duodenal ulcer / / 22387998 rs4970625 chr1 39221925 C A 4.96E-05 Monocyte counts / / pha003089 rs12043383 chr1 39229313 T C 3.91E-04 Alzheimer's disease / / 17998437 rs4970627 chr1 39238597 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1320454 chr1 39291144 C A 5.11E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16825583 chr1 39302499 A G 4.95E-04 Multiple complex diseases / / 17554300 rs7541734 chr1 39302880 C T 4.36E-05 Bipolar disorder / / 17486107 rs4494114 chr1 39339682 T C 6.07E-05 Type 2 diabetes GJA9-MYCBP intron 17463246 rs4491033 chr1 39352083 T G 8.83E-05 Type 2 diabetes RHBDL2 UTR-3 17463246 rs9438980 chr1 39355371 A G 2.50E-04 Type 2 diabetes RHBDL2 intron 17463246 rs6674910 chr1 39357157 A G 1.02E-04 Type 2 diabetes RHBDL2 intron 17463246 rs7539067 chr1 39359694 T C 1.08E-04 Type 2 diabetes RHBDL2 intron 17463246 rs4246511 chr1 39380385 T C 9.00E-17 Menopause (age at onset) RHBDL2 intron 22267201 rs6422258 chr1 39406644 T C 9.16E-04 Suicide attempts in bipolar disorder RHBDL2 intron 21423239 rs6600281 chr1 39412766 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4475740 chr1 39425489 A G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7550511 chr1 39427374 A C 8.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs12127660 chr1 39434565 C T 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7537437 chr1 39439538 G A 8.20E-07 Menopause (age at onset) / / 22267201 rs7537437 chr1 39439538 G A 2.38E-10 Lymphocyte counts / / 22286170 rs7538228 chr1 39477635 T G 4.81E-04 Schizophrenia / / 19197363 rs6663155 chr1 39498491 G A 4.81E-04 Schizophrenia NDUFS5 intron 19197363 rs10465799 chr1 39518006 G A 3.03E-04 Schizophrenia / / 19197363 rs260970 chr1 39551242 G A 0.000680168 Hypertension (early onset hypertension) MACF1 intron 22479346 rs11580989 chr1 39583686 T C 4.17E-05 Birth weight MACF1 intron 17255346 rs628523 chr1 39624761 A G 8.49E-04 Type 2 diabetes MACF1 intron 17463246 rs7538300 chr1 39652764 C A 8.33E-05 HDL particle features MACF1 intron pha002900 rs663978 chr1 39679685 A G 1.15E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 8.57E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 4.24E-04 Aortic root size MACF1 intron 21223598 rs3120282 chr1 39772180 T C 8.07E-04 Response to cytadine analogues (cytosine arabinoside) MACF1 intron 24483146 rs2296172 chr1 39835817 A G 7.80E-05 HDL particle features MACF1 missense pha002900 rs587404 chr1 39908506 G A 7.10E-05 Rheumatoid arthritis MACF1 missense 21673997 rs587404 chr1 39908506 G A 6.18E-05 HDL particle features MACF1 missense pha002900 rs2296173 chr1 39913351 A G 8.82E-05 HDL particle features MACF1 intron pha002900 rs1180379 chr1 39915035 G A 3.04E-04 Coronary Artery Disease MACF1 intron 17634449 rs687848 chr1 39919234 A G 5.10E-05 Rheumatoid arthritis MACF1 intron 21673997 rs4660762 chr1 39926824 G A 7.53E-05 Response to hepatitis C treatment MACF1 intron 19684573 rs3738676 chr1 39991588 G T 8.03E-04 Stroke BMP8A UTR-3 pha002886 rs17264866 chr1 40022777 C G 1.56E-07 Multiple complex diseases / / 17554300 rs4660293 chr1 40028180 A G 1.37E-04 Multiple complex diseases PABPC4 intron 17554300 rs4660293 chr1 40028180 A G 4.00E-10 HDL cholesterol PABPC4 intron 20686565 rs4660293 chr1 40028180 A G 3.00E-18 HDL cholesterol PABPC4 intron 24097068 rs4660293 chr1 40028180 A G 2.65E-05 HDL particle features PABPC4 intron pha002900 rs11577939 chr1 40036669 G C 4.54E-05 Longevity PABPC4 intron 20304771 rs2293476 chr1 40036847 G C 1.94E-04 Multiple complex diseases PABPC4 intron 17554300 rs11206377 chr1 40049104 A G 3.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs7539261 chr1 40050503 A T 1.28E-04 Multiple complex diseases / / 17554300 rs12037222 chr1 40064961 G A 6.00E-11 C-reactive protein / / 21300955 rs3916164 chr1 40069939 G A 3.00E-10 Red blood cell traits / / 23222517 rs6600293 chr1 40083819 C A 3.87E-05 Lymphocyte counts / / 22286170 rs1148945 chr1 40096053 T C 5.50E-04 Body mass index HEYL intron 21701565 rs784611 chr1 40125988 T A 9.30E-05 Response to lithium treatment in bipolar disorder NT5C1A intron 19448189 rs873917 chr1 40132795 T G 8.00E-06 Amyotrophic lateral sclerosis NT5C1A intron 19451621 rs784600 chr1 40139553 C T 3.22E-04 Multiple complex diseases / / 17554300 rs784600 chr1 40139553 C T 7.97E-05 Caffeine consumption / / 21490707 rs785108 chr1 40152676 T C 9.64E-04 Multiple complex diseases HPCAL4 intron 17554300 rs538302 chr1 40153748 T C 5.49E-04 Coronary Artery Disease HPCAL4 intron 17634449 rs538758 chr1 40155188 A G 1.70E-04 Multiple complex diseases HPCAL4 intron 17554300 rs546422 chr1 40158828 C T 5.20E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs7553968 chr1 40222660 G C 0.0000882 post-traumatic stress disorder PPIE intron 22869035 rs7553968 chr1 40222660 G C 8.82E-05 Schizophrenia PPIE intron 22883433 rs12123153 chr1 40248931 A G 2.03E-04 Smoking initiation BMP8B intron 24665060 rs7531010 chr1 40275071 G A 7.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1999574 chr1 40288051 G A 2.60E-04 Intelligence (childhood) / / 23358156 rs11206937 chr1 40290011 A G 7.30E-06 Osteoarthritis / / 22566624 rs17569868 chr1 40292911 A C 5.74E-04 Multiple complex diseases / / 17554300 rs230275 chr1 40301897 G C 1.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs12123609 chr1 40303627 C T 9.76E-04 Multiple complex diseases / / 17554300 rs230310 chr1 40307719 A G 6.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) TRIT1 intron 24325915 rs3134615 chr1 40362066 C A 5.56E-04 Response to taxane treatment (placlitaxel) MYCL1 UTR-3 23006423 rs3134613 chr1 40364803 C A 8.76E-04 Schizophrenia MYCL1 intron 19197363 rs3117088 chr1 40369232 T C 7.53E-04 Schizophrenia / / 19197363 rs3117096 chr1 40389966 A G 3.70E-04 Smoking initiation / / 24665060 rs3131706 chr1 40413098 T C 2.37E-04 Nicotine dependence / / 17158188 rs3131703 chr1 40419681 A G 4.34E-04 Smoking initiation / / 24665060 rs3103778 chr1 40433771 A G 3.29E-04 Schizophrenia(treatment response to risperidone) MFSD2A intron 19850283 rs3103778 chr1 40433771 A G 2.40E-05 Urinary metabolites MFSD2A intron 21572414 rs3103778 chr1 40433771 A G 9.00E-06 PR interval MFSD2A intron 23534349 rs12402428 chr1 40503725 T C 6.52E-04 Alcohol dependence / / 21314694 rs16826852 chr1 40531094 A G 6.47E-04 Alcohol dependence CAP1 intron 21314694 rs16826856 chr1 40534842 T A 8.52E-04 Type 2 diabetes CAP1 intron 17463246 rs6688203 chr1 40549930 C A 6.60E-04 Alcohol dependence PPT1 intron 21314694 rs7513553 chr1 40553333 G T 6.43E-04 Rheumatoid arthritis PPT1 intron 21452313 rs12118846 chr1 40553444 A G 6.98E-04 Smoking cessation PPT1 intron 24665060 rs3131651 chr1 40555321 C T 1.44E-05 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.33E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.50E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3122438 chr1 40555802 G A 3.48E-04 Rheumatoid arthritis PPT1 intron 21452313 rs4660390 chr1 40560399 C T 9.30E-04 HIV-1 viral setpoint PPT1 intron 17641165 rs10889147 chr1 40561471 C T 2.88E-04 Rheumatoid arthritis PPT1 intron 21452313 rs6700346 chr1 40588548 C T 4.30E-05 Glioma (high-grade) / / 19578366 rs6600318 chr1 40601636 T C 5.52E-04 Alcohol dependence / / 20201924 rs12074893 chr1 40628119 C T 4.43E-04 Alcohol dependence RLF intron 20201924 rs4600036 chr1 40636387 G T 1.10E-05 Glioma (high-grade) RLF intron 19578366 rs6600320 chr1 40647407 A G 4.20E-05 Glioma (high-grade) RLF intron 19578366 rs12144950 chr1 40680128 A G 4.80E-04 Iris characteristics RLF intron 21835309 rs16827120 chr1 40765561 G A 0.00000194 HDL cholesterol / / 23063622 rs41480445 chr1 40766618 C T 8.20E-04 Multiple complex diseases COL9A2 UTR-3 17554300 rs407752 chr1 40803855 G A 7.30E-04 Bipolar disorder / / 19259986 rs2235701 chr1 40883095 C T 7.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity SMAP2 intron 24324551 rs427371 chr1 40883266 A G 6.80E-04 Multiple complex diseases SMAP2 intron 17554300 rs427371 chr1 40883266 A G 1.87E-04 Orofacial clefts SMAP2 intron 22863734 rs10489434 chr1 40922062 T C 9.10E-04 Alzheimer's disease ZNF643 intron 24755620 rs10489435 chr1 40922377 C T 5.12E-04 Body mass index ZNF643 intron 21701565 rs736861 chr1 40931003 A G 3.78E-04 Multiple complex diseases / / 17554300 rs736861 chr1 40931003 A G 5.21E-04 Schizophrenia / / 19197363 rs10789144 chr1 40955156 A T 6.64E-05 Multiple sclerosis ZNF642 intron 17660530 rs4604685 chr1 40976258 T C 7.24E-05 Cognitive test performance DEM1 intron 20125193 rs2184878 chr1 40994050 T C 8.67E-05 Cognitive test performance / / 20125193 rs1999822 chr1 41026749 G A 3.00E-05 Response to antidepressants / / 19736353 rs6677621 chr1 41053260 C T 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs16827403 chr1 41057570 A C 8.32E-05 Cognitive test performance / / 20125193 rs16827403 chr1 41057570 A C 1.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16827403 chr1 41057570 A C 2.05E-05 Lipoproteins / / pha003079 rs590775 chr1 41065744 A G 7.85E-04 Type 2 diabetes / / 17463246 rs3767955 chr1 41104475 G A 3.60E-04 Response to taxane treatment (placlitaxel) RIMS3 intron 23006423 rs12562229 chr1 41105238 A G 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS3 intron 20877124 rs1534955 chr1 41107699 C G 8.97E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs11208590 chr1 41108149 T C 1.80E-05 Age-related macular degeneration RIMS3 intron 20861866 rs11208590 chr1 41108149 T C 5.49E-05 Age-related macular degeneration RIMS3 intron 21197116 rs11208590 chr1 41108149 T C 1.97E-05 Age-related macular degeneration RIMS3 intron pha000001 rs11208590 chr1 41108149 T C 6.28E-06 Age-related macular degeneration RIMS3 intron pha002856 rs2780944 chr1 41115608 C T 4.60E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs12728027 chr1 41115671 T C 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs200548994 chr1 41115671 TG T 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs10458576 chr1 41117899 G A 4.20E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs4332353 chr1 41130424 G A 4.42E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs965949 chr1 41154407 G A 9.17E-04 Major depressive disorder / / 22472876 rs2274956 chr1 41212950 G A 5.51E-04 Schizophrenia NFYC intron 19197363 rs2361651 chr1 41230214 G A 3.37E-04 Body mass index NFYC intron 17255346 rs823682 chr1 41231057 C T 6.34E-04 Schizophrenia NFYC intron 19197363 rs4660456 chr1 41239511 A G 4.00E-06 Platelet counts / / 21507922 rs823673 chr1 41240519 C T 3.94E-05 Pulmonary function in asthmatics / / 23541324 rs2769255 chr1 41245354 C T 5.17E-06 Aging (time to event) / / 21782286 rs2251413 chr1 41245859 C A 3.53E-04 Birth weight / / 17255346 rs11806175 chr1 41292969 C T 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3767943 chr1 41293419 G A 9.18E-05 Chronic obstructive pulmonary disease KCNQ4 intron 19300482 rs11801911 chr1 41293857 C A 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3754175 chr1 41294897 G A 8.49E-04 Multiple complex diseases KCNQ4 intron 17554300 rs913378 chr1 41298652 T C 8.60E-04 Amyotrophic lateral sclerosis (sporadic) KCNQ4 intron 24529757 rs12402583 chr1 41306571 T C 0.000059 Prostate cancer (advanced) / / 23555315 rs12564411 chr1 41319052 A G 1.35E-04 Type 2 diabetes / / 17463246 rs6600354 chr1 41348072 C A 3.68E-05 HDL cholesterol / / pha003074 rs11209104 chr1 41349252 A T 4.80E-04 Type 2 diabetes / / 17463246 rs1576100 chr1 41367298 T A 2.68E-04 IgE levels / / 17255346 rs12407657 chr1 41396308 A T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11580126 chr1 41421336 G A 3.87E-05 Serum albumin level / / pha003084 rs12067645 chr1 41425864 G A 2.54E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12408576 chr1 41464437 A G 9.51E-04 Response to taxane treatment (placlitaxel) CTPS intron 23006423 rs17357905 chr1 41484317 T C 4.85E-04 Alcohol dependence SLFNL1 intron 21314694 rs6678816 chr1 41485589 G T 4.95E-04 Response to taxane treatment (placlitaxel) SLFNL1 intron 23006423 rs1138293 chr1 41486245 C T 4.43E-04 Fibrinogen SLFNL1 missense 17255346 rs17357954 chr1 41487337 G T 5.45E-04 Response to taxane treatment (placlitaxel) SLFNL1 UTR-5 23006423 rs6686842 chr1 41530871 T C 2.00E-08 Height SCMH1 intron 18391952 rs2268677 chr1 41542504 A C 2.45E-04 Type 2 diabetes SCMH1 intron 17463246 rs2024860 chr1 41562243 C T 6.92E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs721651 chr1 41563329 A C 7.54E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs213753 chr1 41607331 A G 5.45E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs12127030 chr1 41638398 A C 8.06E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs6672508 chr1 41666571 C G 9.53E-04 Alcohol dependence SCMH1 intron 21314694 rs6672914 chr1 41666929 C T 6.34E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs11209718 chr1 41688938 C T 3.00E-09 Height SCMH1 intron 23563607 rs3845571 chr1 41716039 A C 5.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2154319 chr1 41745770 T C 2.00E-12 Height / / 20881960 rs12035913 chr1 41757057 C T 1.62E-04 Type 2 diabetes / / 17463246 rs2364535 chr1 41766236 G A 2.76E-05 Type 2 diabetes / / 17463246 rs4233488 chr1 41781013 T C 0.000000976 Triglycerides / / 23063622 rs2363810 chr1 41783873 G A 5.04E-04 Type 2 diabetes / / 17463246 rs2363810 chr1 41783873 G A 1.02E-05 Lipid levels / / 19016617 rs2363810 chr1 41783873 G A 2.35E-05 Lipid levels / / 19016617 rs12042464 chr1 41786854 G A 8.05E-04 Type 2 diabetes / / 17463246 rs12042464 chr1 41786854 G A 5.79E-04 Bipolar disorder,schizoaffective / / 19567891 rs12043581 chr1 41788265 G A 7.11E-04 Type 2 diabetes / / 17463246 rs12043581 chr1 41788265 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs17362424 chr1 41794403 G T 8.56E-04 Type 2 diabetes / / 17463246 rs4660187 chr1 41799160 G A 8.52E-04 Alzheimer's disease / / 24755620 rs12757611 chr1 41808972 G A 6.52E-04 Type 2 diabetes / / 17463246 rs12757611 chr1 41808972 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs12047439 chr1 41809640 T A 9.06E-04 Type 2 diabetes / / 17463246 rs12047439 chr1 41809640 T A 4.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs6660265 chr1 41818676 T C 6.75E-04 Bipolar disorder,schizoaffective / / 19567891 rs4660527 chr1 41821779 G A 2.09E-05 Recombination rate / / 21698098 rs7547654 chr1 41831361 G C 5.15E-05 Obesity (extreme) FOXO6 intron 21935397 rs1317558 chr1 41839083 C T 6.17E-04 Suicide attempts in bipolar disorder FOXO6 intron 21423239 rs4660531 chr1 41839822 G T 3.00E-06 Bipolar disorder FOXO6 intron 21926972 rs2810583 chr1 41880343 C T 9.68E-05 IgE levels / / 17255346 rs10493095 chr1 41881922 A G 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs114174493 chr1 41892201 G A 0.00035944 Sarcoidosis / / 22952805 rs12142181 chr1 41912985 C T 1.92E-06 Prion diseases / / 22210626 rs11590973 chr1 41926652 C T 9.45E-06 Bipolar disorder / / 18317468 rs2492074 chr1 41933422 C T 1.25E-04 Self-reported allergy / / 23817569 rs10789371 chr1 41938428 A G 6.20E-06 Dietary macronutrient intake / / 23372041 rs734359 chr1 41945902 C T 1.98E-14 Cholesterol,total EDN2 intron 23063622 rs734359 chr1 41945902 C T 2.44E-15 LDL cholesterol EDN2 intron 23063622 rs734359 chr1 41945902 C T 8.42E-12 Triglycerides EDN2 intron 23063622 rs11210344 chr1 41972880 G T 4.19E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs3738577 chr1 41973349 G A 2.92E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs11809423 chr1 41976529 C T 0.0003424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HIVEP3 missense 23233654 rs11809423 chr1 41976529 C T 3.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) HIVEP3 missense 23233662 rs633297 chr1 41985453 C A,T 1.36E-04 Alzheimer's disease HIVEP3 intron 17998437 rs646228 chr1 41986066 C A 7.82E-04 Alzheimer's disease HIVEP3 intron 17998437 rs679449 chr1 41988634 C A 9.16E-04 Alzheimer's disease HIVEP3 intron 17998437 rs687766 chr1 41998849 C G 3.21E-04 Alzheimer's disease HIVEP3 intron 17998437 rs12121881 chr1 42002738 C T 5.65E-04 Type 2 diabetes HIVEP3 intron 17463246 rs182676510 chr1 42003977 C T 0.00037173 Sarcoidosis HIVEP3 intron 22952805 rs114060246 chr1 42004054 C A 0.00038402 Sarcoidosis HIVEP3 intron 22952805 rs10493102 chr1 42008521 G T 7.95E-04 Type 2 diabetes HIVEP3 intron 17463246 rs10789394 chr1 42026023 G A 8.10E-05 Malaria HIVEP3 intron 19465909 rs4509569 chr1 42037875 T C 4.16E-04 Type 2 diabetes HIVEP3 intron 17463246 rs1815257 chr1 42041479 A C 3.83E-04 Intracranial aneurysm HIVEP3 intron 22286173 rs1570355 chr1 42042317 C T 2.35E-04 Alzheimer's disease HIVEP3 intron 17998437 rs6600380 chr1 42054814 A G 3.92E-04 Alzheimer's disease HIVEP3 intron 17998437 rs943374 chr1 42056194 A G 4.78E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6700352 chr1 42071438 T G 6.76E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs12045563 chr1 42073905 T C 5.86E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs17363834 chr1 42076607 C T 9.59E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs11210498 chr1 42077958 T G 7.58E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2148635 chr1 42082452 T C 1.10E-05 Urinary metabolites HIVEP3 intron 21572414 rs7519983 chr1 42083369 G A 6.75E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6600384 chr1 42085141 G A 6.50E-06 Urinary metabolites HIVEP3 intron 21572414 rs16828495 chr1 42085437 A G 9.00E-05 Multiple complex diseases HIVEP3 intron 17554300 rs6658500 chr1 42088344 C T 8.70E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210499 chr1 42089703 T C 5.80E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210501 chr1 42091634 T C 7.28E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs1109255 chr1 42091708 C T 5.45E-04 Disc degeneration (lumbar) HIVEP3 intron 24216480 rs752010 chr1 42093015 C T 2.00E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2077172 chr1 42093340 A G 2.31E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6664724 chr1 42093821 G A 4.27E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2038978 chr1 42094719 A G 2.65E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6681441 chr1 42098321 G A 1.90E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs4083593 chr1 42099583 A G 6.77E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210503 chr1 42101134 A G 2.26E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10890151 chr1 42101843 C A 6.92E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10789405 chr1 42101962 C T 2.13E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210509 chr1 42109311 T C 4.96E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 6.33E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 5.40E-05 Cognitive function HIVEP3 intron 24684796 rs2148636 chr1 42119844 T C 9.10E-06 Urinary metabolites HIVEP3 intron 21572414 rs12077598 chr1 42172773 T A 5.22E-05 Self-reported allergy HIVEP3 intron 23817569 rs2036962 chr1 42177347 C T 1.00E-04 Self-reported allergy HIVEP3 intron 23817569 rs2036961 chr1 42178084 G A 5.05E-05 Multiple complex diseases HIVEP3 intron 17554300 rs4526604 chr1 42182144 T C 1.04E-04 Self-reported allergy HIVEP3 intron 23817569 rs6600388 chr1 42189456 A G 1.22E-04 Self-reported allergy HIVEP3 intron 23817569 rs11210517 chr1 42198081 C T 8.34E-04 Multiple complex diseases HIVEP3 intron 17554300 rs710235 chr1 42202714 T C 1.78E-05 Asthma HIVEP3 intron 20920776 rs4284254 chr1 42213076 G A 1.98E-06 Asthma HIVEP3 intron 20920776 rs12126740 chr1 42223909 C T 7.38E-04 Alzheimer's disease HIVEP3 intron 17998437 rs2165303 chr1 42228019 A G 8.78E-05 Self-reported allergy HIVEP3 intron 23817569 rs732554 chr1 42230644 C G 1.08E-04 Self-reported allergy HIVEP3 intron 23817569 rs4660206 chr1 42234757 A G 2.09E-04 Self-reported allergy HIVEP3 intron 23817569 rs7517484 chr1 42250456 T C 3.16E-06 Asthma HIVEP3 intron 20920776 rs12137296 chr1 42251918 G A 7.25E-06 Type 2 diabetes HIVEP3 intron 21573907 rs349439 chr1 42259008 G T 6.08E-04 Lymphocyte counts HIVEP3 intron 22286170 rs17373758 chr1 42259133 C A 8.29E-04 Multiple complex diseases HIVEP3 intron 17554300 rs10493098 chr1 42261889 T C 6.91E-04 Schizophrenia HIVEP3 intron 19197363 rs10493097 chr1 42262138 C A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HIVEP3 intron 20877124 rs16828722 chr1 42270666 C T 5.63E-05 Major depressive disorder HIVEP3 intron 22472876 rs349423 chr1 42297124 C T 9.00E-06 Bronchopulmonary dysplasia HIVEP3 intron 23897914 rs972352 chr1 42297604 A C 6.73E-04 Insulin resistance HIVEP3 intron 21901158 rs655198 chr1 42326017 A G 8.87E-05 Asthma HIVEP3 intron 20159242 rs525382 chr1 42329120 T G 2.76E-04 Type 2 diabetes HIVEP3 intron 17463246 rs609572 chr1 42329303 C T 2.42E-04 Type 2 diabetes HIVEP3 intron 17463246 rs12734651 chr1 42330585 C A 3.75E-04 Schizophrenia HIVEP3 intron 19197363 rs12734651 chr1 42330585 C A 9.46E-05 Orofacial clefts HIVEP3 intron 22419666 rs11210537 chr1 42345723 G A 6.39E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs11210537 chr1 42345723 G A 6.99E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 5.17E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 6.00E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 4.55E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 5.73E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs1408946 chr1 42364249 G C 1.08E-05 Personality dimensions HIVEP3 intron 18957941 rs6600391 chr1 42371447 C T 2.73E-06 Asthma (childhood onset) HIVEP3 intron 23829686 rs661428 chr1 42451518 A C 4.52E-04 Smoking initiation HIVEP3 intron 24665060 rs642112 chr1 42453317 C A,G,T 7.88E-04 Multiple complex diseases HIVEP3 intron 17554300 rs7546128 chr1 42473659 C A 1.88E-04 Smoking initiation HIVEP3 intron 24665060 rs10736422 chr1 42480320 C T 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs6689536 chr1 42487523 T C 2.24E-04 Smoking initiation HIVEP3 intron 24665060 rs4660212 chr1 42496399 A G 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs12042133 chr1 42499365 C A 3.54E-04 Smoking initiation HIVEP3 intron 24665060 rs6696291 chr1 42500421 A G 5.62E-04 Smoking initiation HIVEP3 intron 24665060 rs12758407 chr1 42507013 T G 4.29E-05 Self-reported allergy / / 23817569 rs10437061 chr1 42515695 C T 1.94E-04 Multiple complex diseases / / 17554300 rs2042065 chr1 42516770 A C 6.30E-04 Smoking initiation / / 24665060 rs11210581 chr1 42556915 T C 5.33E-04 Smoking initiation / / 24665060 rs6672120 chr1 42577444 T C 5.13E-04 Multiple complex diseases / / 17554300 rs4660218 chr1 42597873 A G 7.78E-04 Smoking initiation / / 24665060 rs7542228 chr1 42598964 A G 7.76E-04 Smoking initiation / / 24665060 rs7539864 chr1 42601648 C G,T 7.76E-05 Self-reported allergy / / 23817569 rs12119339 chr1 42608400 G A 6.04E-04 Smoking initiation / / 24665060 rs11210601 chr1 42613302 T C 1.21E-04 Smoking initiation / / 24665060 rs4660610 chr1 42616910 G A 1.49E-04 Smoking initiation / / 24665060 rs3754283 chr1 42617032 A G 1.35E-04 Smoking initiation / / 24665060 rs11210604 chr1 42623672 T G 3.01E-07 Panic disorder / / 19165232 rs11210604 chr1 42623672 T G 3.64E-23 Narcolepsy / / 19629137 rs624614 chr1 42647914 A G 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs12402117 chr1 42738366 G A 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FOXJ3 intron 23648065 rs12402117 chr1 42738366 G A 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) FOXJ3 intron 23648065 rs2494366 chr1 42798204 C T 1.80E-04 Type 2 diabetes and 6 quantitative traits FOXJ3 intron 17848626 rs2494366 chr1 42798204 C T 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs913426 chr1 42806191 A G 2.73E-04 Taste perception / / 22132133 rs6679533 chr1 42835396 C T 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9803864 chr1 42879737 T G 8.36E-04 Response to taxane treatment (placlitaxel) RIMKLA intron 23006423 rs1055055 chr1 42880516 T C 5.97E-04 Type 2 diabetes RIMKLA cds-synon 17463246 rs16829473 chr1 42885523 C A,G,T 2.84E-04 Multiple complex diseases RIMKLA UTR-3 17554300 rs11210643 chr1 42893164 G A 8.28E-04 Multiple complex diseases / / 17554300 rs3748845 chr1 42901082 A C 5.11E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4660634 chr1 42901173 C T 4.92E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10890197 chr1 42902906 C T 7.07E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10493108 chr1 42908102 A C 6.15E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4622104 chr1 42978242 C T 3.64E-04 Multiple complex diseases / / 17554300 rs4607934 chr1 42983413 G A 2.10E-04 Multiple complex diseases / / 17554300 rs7411957 chr1 43008018 G A 5.33E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829623 chr1 43009319 T C 7.70E-04 Multiple complex diseases CCDC30 intron 17554300 rs12408987 chr1 43052471 T G 5.32E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829846 chr1 43133657 C T 3.60E-04 Smoking initiation PPIH intron 24665060 rs12046563 chr1 43137280 A G 9.42E-05 Oral cancers (chewing tobacco related) PPIH intron 22503698 rs3895305 chr1 43154492 G T 6.19E-04 Lymphocyte counts YBX1 intron 22286170 rs4660656 chr1 43197508 G A,C,T 7.55E-04 Parkinson's disease / / 17052657 rs323716 chr1 43277312 T C 9.80E-06 Glioma (high-grade) CCDC23 intron 19578366 rs17381767 chr1 43281728 C T 7.01E-04 Insulin resistance CCDC23 intron 21901158 rs7540604 chr1 43299835 T C 6.56E-05 Bipolar disorder ERMAP intron 19488044 rs7520697 chr1 43315966 G A 4.96E-05 Cognitive test performance ZNF691 intron 20125193 rs4660234 chr1 43319272 C T 2.66E-06 Gallstones / / 17632509 rs12070405 chr1 43357369 G T 5.93E-06 Asthma (childhood onset) / / 23829686 rs16830039 chr1 43366503 T G 1.52E-04 Cholesterol / / 17255346 rs3820548 chr1 43398396 A G 3.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC2A1 intron 24023788 rs5031048 chr1 43406154 C G 4.74E-04 Multiple complex diseases SLC2A1 intron 17554300 rs11808361 chr1 43419215 C T 0.00029 Coronary artery calcification SLC2A1 intron 23727086 rs841839 chr1 43430084 C A 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs2367159 chr1 43432589 T C 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs841572 chr1 43436051 G A 1.58E-05 Cardiovascular disease / / pha003065 rs11210774 chr1 43450729 C T 3.84E-05 Serum metabolites / / 19043545 rs1754154 chr1 43470766 G T 5.95E-05 Blood Pressure / / pha002903 rs634669 chr1 43505440 T C 4.17E-04 Insulin resistance / / 21901158 rs588662 chr1 43530154 A G 8.35E-04 Multiple complex diseases / / 17554300 rs1198394 chr1 43540338 G A 9.07E-04 Alcohol dependence / / 21314694 rs519789 chr1 43580261 G A 0.00039631 Sarcoidosis / / 22952805 rs16830359 chr1 43596384 G A 8.59E-31 Narcolepsy / / 19629137 rs16830359 chr1 43596384 G A 1.00E-07 Cardiac hypertrophy / / 21348951 rs585655 chr1 43597014 G A 1.36E-04 Insulin resistance / / 21901158 rs490876 chr1 43600931 T C 1.32E-04 Insulin resistance / / 21901158 rs601504 chr1 43603715 G C 5.77E-04 Type 2 diabetes / / 17463246 rs601504 chr1 43603715 G C 4.64E-04 Insulin resistance / / 21901158 rs545220 chr1 43605870 G A 7.84E-04 Insulin resistance / / 21901158 rs16830399 chr1 43610139 C G 8.61E-05 Multiple complex diseases / / 17554300 rs16830399 chr1 43610139 C G 9.36E-04 Insulin resistance / / 21901158 rs475093 chr1 43616337 G C 9.80E-05 Gallstones FAM183A intron 17632509 rs12033506 chr1 43618969 G T 7.43E-05 Insulin resistance FAM183A intron 21901158 rs76382232 chr1 43628307 T C 0.0004086 Sarcoidosis / / 22952805 rs621559 chr1 43645411 G A 2.00E-06 Telomere length WDR65 intron 21460395 rs663824 chr1 43649508 A G 0.0000819 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity WDR65 missense 22945461 rs513009 chr1 43663376 A G 9.69E-04 Insulin resistance WDR65 intron 21901158 rs150404479 chr1 43688550 T C 1.00E-06 Bipolar disorder (body mass index interaction) WDR65 missense 24322204 rs2484714 chr1 43699970 G A 2.56E-05 Alzheimer's disease WDR65 cds-synon 17998437 rs3862227 chr1 43720994 A G 5.53E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs11210819 chr1 43721710 G A 9.26E-04 Alzheimer's disease / / 17998437 rs2151673 chr1 43741224 G A 8.51E-04 Aortic root size / / 21223598 rs6697017 chr1 43751701 C T 2.18E-04 Celiac disease / / 23936387 rs34783763 chr1 43757762 T C 2.52E-05 Celiac disease / / 23936387 rs1098182 chr1 43785768 G C 4.51E-05 Response to taxane treatment (placlitaxel) TIE1 intron 23006423 rs11210834 chr1 43787437 A G 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TIE1 intron 20877124 rs17292650 chr1 43803807 G T 1.64E-05 Platelet counts MPL missense 21507922 rs12731981 chr1 43804340 G A 3.66E-04 Smoking initiation MPL missense 24665060 rs2069387 chr1 43828080 T G 1.64E-05 Platelet counts CDC20 intron 21507922 rs1999674 chr1 43881941 A G 8.41E-05 Serum metabolites SZT2 intron 19043545 rs2782651 chr1 43920686 C G 4.98E-05 Serum metabolites HYI nearGene-5 19043545 rs12069733 chr1 43941508 G A 1.37E-07 Parkinson's disease / / 17052657 rs6429604 chr1 43955148 A G 1.52E-04 Depression (quantitative trait) / / 20800221 rs6687571 chr1 43957515 G A 3.56E-05 Personality dimensions / / 18957941 rs6687571 chr1 43957515 G A 1.60E-04 Depression (quantitative trait) / / 20800221 rs7417538 chr1 43959942 G A 1.61E-04 Depression (quantitative trait) / / 20800221 rs2039529 chr1 43960479 A G 7.57E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 18957941 rs2039528 chr1 43960530 A G 7.25E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 21173776 rs6675341 chr1 43970956 C T 1.18E-04 Depression (quantitative trait) / / 20800221 rs10749849 chr1 43974489 G A 1.87E-04 Depression (quantitative trait) / / 20800221 rs1413937 chr1 43975238 G A 1.63E-04 Depression (quantitative trait) / / 20800221 rs10890251 chr1 43976266 A C 2.24E-05 Personality dimensions / / 18957941 rs10890251 chr1 43976266 A C 3.10E-04 Depression (quantitative trait) / / 20800221 rs11210858 chr1 43978837 T C 3.05E-04 Depression (quantitative trait) / / 20800221 rs11210859 chr1 43979782 G A 3.04E-04 Depression (quantitative trait) / / 20800221 rs1413938 chr1 43981265 C T 3.08E-04 Depression (quantitative trait) / / 20800221 rs2367617 chr1 43981961 A G 3.08E-04 Depression (quantitative trait) / / 20800221 rs11210862 chr1 43984142 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs1413939 chr1 43984627 G C 1.66E-04 Depression (quantitative trait) / / 20800221 rs11210863 chr1 43985678 C T 3.21E-04 Depression (quantitative trait) / / 20800221 rs11210864 chr1 43991832 G A 2.23E-05 Personality dimensions / / 18957941 rs11210864 chr1 43991832 G A 4.91E-04 Depression (quantitative trait) / / 20800221 rs11577317 chr1 43992893 A G 4.07E-04 Depression (quantitative trait) / / 20800221 rs11590627 chr1 43999120 T C 2.12E-04 Depression (quantitative trait) PTPRF intron 20800221 rs2819332 chr1 44005280 G A 5.00E-06 Amyotrophic lateral sclerosis (age of onset) PTPRF intron 22959728 rs2782640 chr1 44009033 C T 5.04E-04 Smoking initiation PTPRF intron 24665060 rs2782641 chr1 44013355 G A 1.56E-04 Smoking initiation PTPRF intron 24665060 rs2819333 chr1 44014573 A T 5.34E-04 Smoking initiation PTPRF intron 24665060 rs11582876 chr1 44062827 C T 6.75E-04 Alcohol dependence PTPRF intron 21314694 rs11210886 chr1 44071546 G A 8.15E-04 Multiple complex diseases PTPRF intron 17554300 rs11210886 chr1 44071546 G A 6.48E-04 Obesity (extreme) PTPRF intron 21935397 rs11210888 chr1 44076630 C T 5.55E-04 Obesity (extreme) PTPRF intron 21935397 rs11804031 chr1 44081912 A G 5.40E-04 Obesity (extreme) PTPRF intron 21935397 rs16831024 chr1 44084620 G T 5.36E-04 Obesity (extreme) PTPRF intron 21935397 rs11210893 chr1 44101767 T G 4.61E-04 Obesity (extreme) / / 21935397 rs11210894 chr1 44102587 C T 4.60E-04 Obesity (extreme) / / 21935397 rs11210896 chr1 44103275 G A 4.59E-04 Obesity (extreme) / / 21935397 rs660899 chr1 44117006 G T 4.00E-06 Hypertension risk in short sleep duration KDM4A intron 22322875 rs4336891 chr1 44126440 G A 5.47E-04 Obesity (extreme) KDM4A intron 21935397 rs669446 chr1 44129779 A G 7.08E-04 Parkinson's disease KDM4A intron 17052657 rs669446 chr1 44129779 A G 5.00E-06 Amyotrophic lateral sclerosis (age of onset) KDM4A intron 22959728 rs10789441 chr1 44130564 A G 5.98E-04 Obesity (extreme) KDM4A intron 21935397 rs304303 chr1 44178070 T G 1.29E-05 Alopecia areata ST3GAL3 intron 22027810 rs12410155 chr1 44188465 A C 2.00E-04 Information processing speed ST3GAL3 intron 21130836 rs4660260 chr1 44195353 T C 2.55E-06 Alopecia areata ST3GAL3 intron 22027810 rs12733500 chr1 44208306 T G 6.11E-05 Pulmonary function ST3GAL3 intron 20010835 rs2367725 chr1 44215828 C A,G,T 9.00E-06 Aging (time to event) ST3GAL3 intron 21782286 rs7520053 chr1 44226657 A G 8.93E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs12760274 chr1 44249344 A G 8.33E-05 Alcohol consumption ST3GAL3 intron 23953852 rs6701645 chr1 44254514 C T 6.84E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12741964 chr1 44254586 G A 1.12E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs16831192 chr1 44255687 G A 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12122504 chr1 44256819 C G 7.70E-07 Red blood cell traits ST3GAL3 intron 23222517 rs11210927 chr1 44266420 A G 7.27E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12133508 chr1 44277746 C T 6.06E-07 Red blood cell traits ST3GAL3 intron 23222517 rs37458 chr1 44290530 A G 0.00014 Breast cancer ST3GAL3 missense 23555315 rs3791073 chr1 44297673 T C 3.58E-04 Insulin resistance ST3GAL3 intron 21901158 rs3011217 chr1 44303266 A G 7.64E-05 Receptive language ability ST3GAL3 intron 24687471 rs3011225 chr1 44319373 G A 7.00E-08 Amyotrophic lateral sclerosis (age of onset) ST3GAL3 intron 22959728 rs2906466 chr1 44322220 A G 3.90E-05 Brain structure ST3GAL3 intron 22504417 rs2906457 chr1 44338575 A C 5.59E-05 Cognitive performance ST3GAL3 intron 19734545 rs2906457 chr1 44338575 A C 9.84E-06 Brain structure ST3GAL3 intron 22504417 rs2428853 chr1 44343173 C G 3.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2788371 chr1 44343962 A G 9.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2527776 chr1 44345292 G A 1.17E-05 Brain structure ST3GAL3 intron 22504417 rs803676 chr1 44352458 A G 7.60E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2428854 chr1 44356185 C A 7.90E-05 Response to statin therapy ST3GAL3 intron 20339536 rs803683 chr1 44358148 G T 8.00E-05 Response to statin therapy ST3GAL3 intron 20339536 rs16831389 chr1 44363143 C T 1.47E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs783304 chr1 44365457 A G 5.85E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs16831424 chr1 44387353 C T 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12569336 chr1 44391288 T A 2.31E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs12561948 chr1 44396196 A G 2.54E-04 Alzheimer's disease ST3GAL3 UTR-3 24755620 rs4448553 chr1 44411589 A G 3.90E-05 Brain structure / / 22504417 rs7556565 chr1 44416090 C T 3.46E-05 Brain structure IPO13 intron 22504417 rs6675620 chr1 44417630 C T 3.60E-05 Brain structure IPO13 intron 22504417 rs2301993 chr1 44426025 G A 4.10E-05 Brain structure IPO13 intron 22504417 rs7161 chr1 44438974 C T 2.75E-06 Systemic lupus erythematosus and Systemic sclerosis DPH2 UTR-3 23740937 rs1362153 chr1 44469031 T C 7.00E-06 Alcohol dependence (age at onset) SLC6A9 intron 24962325 rs2485993 chr1 44503040 A G 8.60E-05 Schizophrenia / / 24253340 rs751442 chr1 44509551 A C 5.44E-04 Nicotine dependence / / 17158188 rs751442 chr1 44509551 A C 8.78E-05 Schizophrenia / / 24253340 rs2158822 chr1 44519447 G C 4.50E-06 Urinary metabolites / / 21572414 rs11210949 chr1 44535401 T C 0.0000629 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs942755 chr1 44537401 G A 0.0000803 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662888 chr1 44602159 G A 2.68E-04 Type 2 diabetes / / 17463246 rs2799480 chr1 44684995 T C 9.11E-04 Alzheimer's disease DMAP1 intron 22005930 rs4660781 chr1 44700764 A G 8.86E-05 Stroke ERI3 intron pha002887 rs1778905 chr1 44724788 A G 7.40E-04 Alzheimer's disease ERI3 intron 22005930 rs2799475 chr1 44727612 T C 8.48E-04 Alzheimer's disease ERI3 intron 22005930 rs325168 chr1 44731068 T G 7.03E-04 Type 2 diabetes ERI3 intron 17463246 rs10890295 chr1 44745450 T A 3.72E-04 Type 2 diabetes ERI3 intron 17463246 rs459358 chr1 44745624 C T 5.82E-04 Alzheimer's disease ERI3 intron 22005930 rs325163 chr1 44751710 T C 5.87E-04 Alzheimer's disease ERI3 intron 22005930 rs325160 chr1 44759392 C G 1.70E-04 Type 2 diabetes ERI3 intron 17463246 rs325160 chr1 44759392 C G 1.30E-05 Lipid levels ERI3 intron 18193043 rs325154 chr1 44764677 C T 9.33E-04 Alzheimer's disease ERI3 intron 22005930 rs12058010 chr1 44765646 C T 1.50E-05 Urinary metabolites ERI3 intron 21572414 rs6429535 chr1 44766071 C T 2.22E-04 Type 2 diabetes ERI3 intron 17463246 rs11210982 chr1 44793760 G A 1.97E-04 Alzheimer's disease ERI3 intron 22005930 rs2524353 chr1 44807164 C T 8.52E-04 Type 2 diabetes ERI3 intron 17463246 rs172853 chr1 44809445 T G 6.35E-04 Alzheimer's disease ERI3 intron 22005930 rs226065 chr1 44819375 A G 5.69E-04 Alzheimer's disease ERI3 intron 22005930 rs226069 chr1 44822097 G A 4.05E-04 Alzheimer's disease / / 22005930 rs4660790 chr1 44828525 G T 8.60E-05 Stroke / / pha002887 rs3888585 chr1 44856052 C A 9.06E-05 Cognitive test performance / / 20125193 rs7555873 chr1 44912147 T C 4.95E-04 Multiple complex diseases RNF220 intron 17554300 rs12071805 chr1 44921331 C G 1.29E-04 Multiple complex diseases RNF220 intron 17554300 rs9804150 chr1 44951245 A G 8.67E-05 Lung function (forced expiratory volume in 1 second) RNF220 intron pha003102 rs781775 chr1 44972309 G A 3.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs781774 chr1 44972337 G A 5.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781771 chr1 44974082 T C 1.40E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781770 chr1 44974119 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs12138940 chr1 44974796 A G 2.50E-05 Anxiety in major depressive disorder RNF220 intron 24047446 rs781790 chr1 44976806 A G 5.91E-05 Cognitive impairment induced by topiramate RNF220 intron 22091778 rs781790 chr1 44976806 A G 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs272531 chr1 44988433 G A 3.66E-04 Schizophrenia RNF220 intron 19197363 rs272531 chr1 44988433 G A 6.68E-05 Insulin resistance RNF220 intron 21901158 rs272537 chr1 44992714 A T 5.40E-06 Urinary metabolites RNF220 intron 21572414 rs746733 chr1 44999614 G A 3.55E-05 F-cell distribution RNF220 intron 21326311 rs7525212 chr1 45029679 G A,T 3.92E-04 Schizophrenia RNF220 intron 19197363 rs270716 chr1 45054866 A G 1.20E-05 Urinary metabolites RNF220 intron 21572414 rs459160 chr1 45080932 T C 1.73E-04 Body mass index RNF220 intron 17255346 rs459160 chr1 45080932 T C 8.20E-04 Multiple complex diseases RNF220 intron 17554300 rs461043 chr1 45081101 T C 1.56E-11 Multiple complex diseases RNF220 intron 17554300 rs1051648 chr1 45116935 C T 6.82E-05 Cognitive test performance RNF220 UTR-3 20125193 rs17391430 chr1 45234389 G A 2.24E-04 Multiple complex diseases / / 17554300 rs12072767 chr1 45258232 C T 0.00042089 Sarcoidosis / / 22952805 rs6676749 chr1 45264545 T G 3.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11584440 chr1 45268356 C A 3.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 intron 21844884 rs11211036 chr1 45270024 G C 2.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 cds-synon 21844884 rs11211037 chr1 45275551 A C 1.75E-04 Longevity BTBD19 intron 22279548 rs11211040 chr1 45291908 G A 5.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTCH2 intron 21844884 rs3795720 chr1 45307506 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTCH2 intron 21245432 rs6429550 chr1 45311749 G A 1.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6429550 chr1 45311749 G A 9.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7517439 chr1 45312867 G A 2.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7517639 chr1 45313150 G A 3.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6692487 chr1 45317392 G A 4.79E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11579580 chr1 45318718 C G 5.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11211044 chr1 45318752 C T 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs12733586 chr1 45327230 G A 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs7528461 chr1 45331753 G A 5.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263975 chr1 45358527 T C 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs263977 chr1 45360287 T G 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs3767490 chr1 45360658 A C 4.40E-04 Multiple complex diseases EIF2B3 intron 17554300 rs608649 chr1 45363887 T C 2.69E-04 Multiple complex diseases EIF2B3 intron 17554300 rs1572379 chr1 45369086 A G 6.38E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs12093313 chr1 45371160 G A 9.53E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs11211053 chr1 45373666 G A 5.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263966 chr1 45376737 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs452989 chr1 45417184 T C 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs11211059 chr1 45430218 C T 7.16E-05 Multiple complex diseases EIF2B3 intron 17554300 rs489676 chr1 45452227 G C 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 UTR-5 21245432 rs264011 chr1 45460832 A G 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7528534 chr1 45470130 T C 1.98E-05 Type 2 diabetes HECTD3 intron 17463246 rs7528534 chr1 45470130 T C 9.52E-04 Multiple complex diseases HECTD3 intron 17554300 rs2050869 chr1 45503639 G A 9.85E-05 Serum metabolites ZSWIM5 intron 19043545 rs3850855 chr1 45523893 T C 5.45E-04 Cocaine dependence ZSWIM5 intron 23958962 rs3850855 chr1 45523893 T C 6.09E-06 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 2.39E-04 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 3.43E-06 Cocaine dependence ZSWIM5 intron 23958962 rs346733 chr1 45585207 C T 1.57E-04 HIV-1 viral setpoint ZSWIM5 intron 17641165 rs1226757 chr1 45592886 G A 1.57E-04 Smoking quantity ZSWIM5 intron 24665060 rs346718 chr1 45610429 G T 4.07E-04 Multiple complex diseases ZSWIM5 intron 17554300 rs1938300 chr1 45672783 T C 1.38E-05 Cocaine dependence / / 23958962 rs1938300 chr1 45672783 T C 1.71E-04 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 1.55E-04 HIV-1 viral setpoint / / 17641165 rs2997460 chr1 45694796 C T 4.18E-06 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 7.66E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 1.49E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 2.66E-04 Cocaine dependence / / 23958962 rs1938297 chr1 45740469 T C 2.55E-05 Smoking quantity / / 24665060 rs4233497 chr1 45763753 T C 3.00E-04 HIV-1 viral setpoint / / 17641165 rs3219487 chr1 45798555 T C 4.19E-04 Insulin resistance MUTYH intron 21901158 rs3219487 chr1 45798555 T C 2.78E-05 Lymphocyte counts MUTYH intron 22286170 rs9429157 chr1 45808863 G A 0.00079 Prostate cancer TOE1 missense 23555315 rs9429072 chr1 45810091 A G 6.26E-05 Femoral neck bone geometry TESK2 UTR-3 22087292 rs2153608 chr1 45813941 A G 5.72E-05 Femoral neck bone geometry TESK2 intron 22087292 rs9429076 chr1 45819489 T C 6.88E-04 Insulin resistance TESK2 intron 21901158 rs7543428 chr1 45839643 A G 3.70E-05 Femoral neck bone geometry TESK2 intron 22087292 rs11211101 chr1 45849311 G C 3.16E-07 Lymphocyte counts TESK2 intron 22286170 rs2487442 chr1 45857176 G C 2.26E-04 Insulin resistance TESK2 intron 21901158 rs2487442 chr1 45857176 G C 8.78E-05 Femoral neck bone geometry TESK2 intron 22087292 rs1771551 chr1 45883643 C G 9.06E-04 Insulin resistance TESK2 intron 21901158 rs1771551 chr1 45883643 C G 5.95E-05 Femoral neck bone geometry TESK2 intron 22087292 rs4660306 chr1 45978675 T C 2.00E-09 Homocysteine levels PRDX1 intron 23824729 rs16832557 chr1 45978923 T C 6.62E-06 Multiple complex diseases PRDX1 intron 17554300 rs10736426 chr1 45984353 G A 9.85E-04 Amyotrophic lateral sclerosis (sporadic) PRDX1 intron 24529757 rs487174 chr1 46009536 A G 1.70E-05 Urinary metabolites / / 21572414 rs3748645 chr1 46035470 G A 4.97E-05 Amyotrophic lateral sclerosis (sporadic) AKR1A1 intron 24529757 rs1053941 chr1 46084383 G T 5.00E-11 Blood metabolite levels /SP UTR-3 24816252 rs11211176 chr1 46223086 G A 6.48E-06 Multiple sclerosis / / 17660530 rs6680211 chr1 46315007 C G 7.11E-04 Nicotine dependence MAST2 intron 17158188 rs6429582 chr1 46321843 T C 3.76E-04 Multiple complex diseases MAST2 intron 17554300 rs6429582 chr1 46321843 T C 6.00E-05 Malaria MAST2 intron 19465909 rs12732188 chr1 46333358 G A 2.00E-04 Cognitive impairment induced by topiramate MAST2 intron 22091778 rs10890361 chr1 46346234 T A 6.46E-04 Multiple complex diseases MAST2 intron 17554300 rs10890361 chr1 46346234 T A 9.40E-06 Malaria MAST2 intron 19465909 rs10890363 chr1 46356148 A G 6.28E-04 Multiple complex diseases MAST2 intron 17554300 rs10890363 chr1 46356148 A G 9.10E-05 Malaria MAST2 intron 19465909 rs4545281 chr1 46360054 C T 5.82E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 6.63E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 5.20E-05 Malaria MAST2 intron 19465909 rs4660905 chr1 46461587 A G 3.83E-04 Hearing function MAST2 intron 17255346 rs4073846 chr1 46462881 A G 7.46E-04 Multiple complex diseases MAST2 intron 17554300 rs11579634 chr1 46466391 C T 6.98E-04 Multiple complex diseases MAST2 intron 17554300 rs2236560 chr1 46495434 G A 8.02E-04 Type 2 diabetes MAST2 intron 17463246 rs1622208 chr1 46498375 A G 9.69E-04 Hearing function MAST2 cds-synon 17255346 rs1052607 chr1 46499526 A G 9.34E-05 Calcium levels MAST2 missense pha003085 rs1768809 chr1 46502836 A C 1.15E-04 Multiple complex diseases / / 17554300 rs1768808 chr1 46503217 C T 1.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7538978 chr1 46505054 G A 2.86E-04 Hearing function / / 17255346 rs1707322 chr1 46505147 A G 3.78E-04 Hearing function / / 17255346 rs1707321 chr1 46505309 A G 2.08E-04 Multiple complex diseases / / 17554300 rs785467 chr1 46521559 A T 8.02E-04 Hearing function PIK3R3 missense 17255346 rs785465 chr1 46522577 A C 3.78E-04 Hearing function PIK3R3 intron 17255346 rs1613296 chr1 46546852 T G 3.73E-04 Hearing function PIK3R3 intron 17255346 rs785495 chr1 46587887 T C 5.14E-04 Multiple complex diseases PIK3R3 intron 17554300 rs1983261 chr1 46617981 G A 4.95E-04 Multiple complex diseases / / 17554300 rs17102048 chr1 46622385 G A 0.000749 Height (Pygmy height) / / 22570615 rs3855959 chr1 46633874 T C 3.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7538871 chr1 46671997 A G 6.20E-05 Multiple complex diseases POMGNT1 intron 17554300 rs9793263 chr1 46722389 A G 5.33E-04 Coronary heart disease RAD54L intron 21606135 rs2295465 chr1 46726057 A C 3.87E-05 Multiple complex diseases RAD54L intron 17554300 rs12410307 chr1 46730398 G A 1.94E-04 Coronary heart disease RAD54L intron 21606135 rs17102098 chr1 46741211 A G 0.0000116 Cholesterol,total RAD54L intron 23696881 rs12142240 chr1 46747301 T C 4.70E-05 Menopause (age at onset) LRRC41 intron 22267201 rs4660344 chr1 46805222 A G 2.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 2.25E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 6.80E-04 Osteoarthritis (knee and hip) / / 21177295 rs2145408 chr1 46861907 A G 7.42E-04 Type 2 diabetes FAAH intron 17463246 rs2145408 chr1 46861907 A G 7.96E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs6429600 chr1 46864511 G A 8.06E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs324423 chr1 46885104 A G 7.92E-04 Multiple complex diseases / / 17554300 rs116435220 chr1 46890686 C T 2.18E-08 Cholesterol,total / / 23696881 rs1571138 chr1 46895641 A G 2.53E-04 Multiple complex diseases / / 17554300 rs10890398 chr1 46925594 T C 3.93E-04 Smoking quantity / / 24665060 rs11211287 chr1 46939999 G C 8.10E-05 Immunoglobulin A / / 20694011 rs7542172 chr1 46990681 G A 2.00E-12 Blood metabolite levels / / 24816252 rs1267301 chr1 46992853 C G 3.45E-04 Multiple complex diseases / / 17554300 rs12564756 chr1 47018447 C T 6.60E-04 Smoking quantity LOC100507423 intron 24665060 rs1054743 chr1 47035643 T C 8.45E-04 Type 2 diabetes MKNK1 intron 17463246 rs744096 chr1 47107390 A G 5.04E-04 Multiple complex diseases ATPAF1 intron 17554300 rs744096 chr1 47107390 A G 9.25E-05 Serum metabolites ATPAF1 intron 19043545 rs1933932 chr1 47109328 C T 8.90E-04 Alcohol dependence ATPAF1 intron 21314694 rs2289447 chr1 47118168 C T 2.20E-08 Asthma (childhood onset) ATPAF1 intron 21696813 rs620431 chr1 47118189 G T 4.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs1150068 chr1 47118918 A G 2.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs11211334 chr1 47121419 T C 1.69E-04 Multiple complex diseases ATPAF1 intron 17554300 rs11211334 chr1 47121419 T C 1.76E-05 Serum metabolites ATPAF1 intron 19043545 rs611468 chr1 47124479 A G 5.11E-04 Multiple complex diseases ATPAF1 intron 17554300 rs611468 chr1 47124479 A G 6.63E-05 Serum metabolites ATPAF1 intron 19043545 rs7354865 chr1 47124999 C T 4.68E-04 Multiple complex diseases ATPAF1 intron 17554300 rs12094663 chr1 47134321 T G 3.42E-04 Multiple complex diseases / / 17554300 rs1025806 chr1 47139103 C T 5.24E-04 Multiple complex diseases ATPAF1-AS1 missense 17554300 rs1025806 chr1 47139103 C T 3.59E-05 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs1025806 chr1 47139103 C T 9.73E-04 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs625590 chr1 47139675 C T 4.55E-04 Multiple complex diseases / / 17554300 rs1048380 chr1 47142538 G A 1.00E-04 Asthma (childhood onset) KIAA0494 UTR-3 21696813 rs1048351 chr1 47143480 C T 3.08E-05 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs1048351 chr1 47143480 C T 8.72E-04 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs7412469 chr1 47146533 T C 5.46E-04 Multiple complex diseases KIAA0494 intron 17554300 rs7412469 chr1 47146533 T C 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs7412469 chr1 47146533 T C 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2275380 chr1 47147728 C T 1.25E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2275380 chr1 47147728 C T 4.99E-05 Serum metabolites KIAA0494 intron 19043545 rs1150064 chr1 47148044 T A 8.79E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs2119301 chr1 47153547 C A,G,T 6.54E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2304745 chr1 47154272 C T 3.60E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2304745 chr1 47154272 C T 9.76E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 9.68E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 3.62E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 9.78E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 3.97E-04 Multiple complex diseases KIAA0494 intron 17554300 rs3766217 chr1 47159109 G T 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs34932727 chr1 47161275 G A 4.38E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 3.44E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 9.26E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 3.26E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 8.75E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 3.10E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 8.29E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 2.26E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs1440486 chr1 47167238 C T 3.11E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 8.20E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 3.07E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 8.04E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 3.06E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 8.01E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10158678 chr1 47176606 C T 1.81E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2218189 chr1 47176818 T C 1.00E-04 Asthma (childhood onset) KIAA0494 intron 21696813 rs12071983 chr1 47178065 T C 1.52E-04 Multiple complex diseases KIAA0494 intron 17554300 rs6688195 chr1 47178195 C T 2.98E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs6688195 chr1 47178195 C T 7.82E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10789491 chr1 47179310 A G 1.00E-06 Response to hepatitis C treatment KIAA0494 intron 22095909 rs3766215 chr1 47181022 C T 2.94E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766215 chr1 47181022 C T 7.60E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 2.92E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 7.36E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766212 chr1 47184181 C T 3.04E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs3766212 chr1 47184181 C T 9.27E-05 Serum metabolites KIAA0494 UTR-5 19043545 rs3766211 chr1 47184196 A G 4.54E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs8851 chr1 47184569 G C 3.33E-05 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs8851 chr1 47184569 G C 7.96E-04 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs17102473 chr1 47185155 G A 2.65E-05 Alzheimer's disease (late onset) / / 23565137 rs17102473 chr1 47185155 G A 6.41E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 3.26E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 9.80E-06 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 2.89E-04 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 9.66E-06 Alzheimer's disease (late onset) / / 23565137 rs6670495 chr1 47187908 T A 7.93E-06 Asthma (childhood onset) / / 21696813 rs4660957 chr1 47188150 G T 1.48E-05 Multiple complex diseases / / 17554300 rs6662321 chr1 47220059 C T 9.00E-04 Asthma (childhood onset) / / 21696813 rs201934421 chr1 47226827 TC T 2.21E-05 HDL cholesterol / / pha003075 rs986034 chr1 47226827 T G 2.21E-05 HDL cholesterol / / pha003075 rs11583588 chr1 47234335 G A 6.44E-05 Schizophrenia / / pha002859 rs1572603 chr1 47272403 G A 3.19E-04 White matter integrity CYP4B1 intron 22425255 rs4646486 chr1 47278997 T C 5.76E-05 White matter integrity CYP4B1 intron 22425255 rs4646487 chr1 47279175 C T 1 Drug response to Docetaxel CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 1 Drug response to Thalidomide CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 6.68E-05 White matter integrity CYP4B1 missense 22425255 rs4646492 chr1 47281183 C T 2.91E-05 White matter integrity CYP4B1 intron 22425255 rs4646493 chr1 47281302 A G 3.22E-05 White matter integrity CYP4B1 intron 22425255 rs17102599 chr1 47283344 G T 0.000000147 Triglycerides CYP4B1 intron 23063622 rs17102599 chr1 47283344 G T 0.000000176 Cholesterol,total CYP4B1 intron 23063622 rs4646495 chr1 47283505 G A,T 5.03E-05 White matter integrity CYP4B1 intron 22425255 rs12059860 chr1 47284923 T C 8.00E-06 Testosterone levels CYP4B1 UTR-3 22675492 rs17102644 chr1 47318400 G A 1.51E-05 White matter integrity CYP4Z2P intron 22425255 rs6665009 chr1 47321982 T C 1.78E-05 White matter integrity CYP4Z2P intron 22425255 rs6678639 chr1 47331966 A G 8.00E-86 Blood metabolite ratios CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 1.00E-14 Blood metabolite levels CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 5.00E-11 Blood metabolite levels CYP4Z2P intron 24816252 rs6687264 chr1 47374039 T C 1.51E-05 White matter integrity / / 22425255 rs11587251 chr1 47392596 G A 1.70E-04 White matter integrity / / 22425255 rs9333029 chr1 47396162 A G 2.00E-61 Blood metabolite levels CYP4A11 intron 24816252 rs9333016 chr1 47399034 C T 2.62E-05 Diabetes Mellitus CYP4A11 intron pha003059 rs9332998 chr1 47404186 T C 5.00E-32 Metabolic traits CYP4A11 intron 21886157 rs10789496 chr1 47416441 T C 9.30E-05 HIV-1 control / / 20041166 rs10789496 chr1 47416441 T C 4.32E-05 Diabetes Mellitus / / pha003059 rs150968551 chr1 47428558 T G 4.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs9727862 chr1 47481616 G A 5.82E-04 Alcohol dependence / / 20201924 rs9727862 chr1 47481616 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12140581 chr1 47517960 G C 8.07E-04 Smoking quantity / / 24665060 rs4926805 chr1 47572046 C T 4.01E-05 Orofacial clefts CYP4Z1 intron 22419666 rs7531972 chr1 47661620 A C 5.53E-05 Prion diseases / / 22210626 rs741959 chr1 47676233 A G 4.36E-07 Red blood cell traits / / 23222517 rs2070930 chr1 47683464 G A 6.03E-04 Insulin resistance TAL1 UTR-3 21901158 rs977747 chr1 47684677 T G 6.32E-07 Red blood cell traits TAL1 UTR-3 23222517 rs2984618 chr1 47690438 G T 8.50E-07 Red blood cell traits TAL1 intron 23222517 rs11211480 chr1 47693220 A G 3.22E-08 Red blood cell traits TAL1 intron 23222517 rs7534271 chr1 47693981 C G 8.61E-09 Red blood cell traits TAL1 intron 23222517 rs11211481 chr1 47694167 A G 5.30E-09 Red blood cell traits TAL1 intron 23222517 rs2798349 chr1 47698703 G A 2.50E-04 Multiple complex diseases / / 17554300 rs6700838 chr1 47700027 C T 1.01E-08 Red blood cell traits / / 23222517 rs1015890 chr1 47702229 G A 8.55E-07 Red blood cell traits / / 23222517 rs911910 chr1 47706970 G A 2.15E-08 Red blood cell traits / / 23222517 rs11211483 chr1 47707435 G C 1.04E-04 Insulin resistance / / 21901158 rs10890472 chr1 47708112 G T 4.96E-08 Red blood cell traits / / 23222517 rs13376679 chr1 47726087 T C 0.00013 Prostate cancer STIL missense 23555315 rs9436412 chr1 47766604 A G 6.58E-04 Multiple complex diseases STIL intron 17554300 rs17103186 chr1 47854514 C T 3.00E-12 Corneal curvature / / 24963161 rs60078183 chr1 47857307 G A 8.20E-12 Corneal curvature / / 24963161 rs6673934 chr1 47870564 G C 1.75E-05 Intracerebral hemorrhage / / 24656865 rs4926854 chr1 47870661 C T 4.31E-05 Intracerebral hemorrhage / / 24656865 rs55718554 chr1 47871581 C G 2.35E-05 Intracerebral hemorrhage / / 24656865 rs17103227 chr1 47889417 T C 9.78E-04 Coronary heart disease / / 21971053 rs2820972 chr1 47891585 T C 1.00E-33 Metabolite levels / / 22286219 rs527430 chr1 47918821 G A 4.00E-07 Response to antidepressant treatment / / 22041458 rs6588397 chr1 47943032 C T 1.49E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11582540 chr1 48009997 C A 3.00E-06 Response to amphetamines / / 22952603 rs502392 chr1 48017067 T C 2.21E-05 stroke (ischemic) / / 17434096 rs17420782 chr1 48019222 A G 9.00E-06 Anxiety in major depressive disorder / / 24047446 rs685001 chr1 48025063 C A 9.00E-06 Obesity-related traits / / 23251661 rs2507007 chr1 48046320 G T 2.40E-04 Major depressive disorder / / 21042317 rs12402772 chr1 48062278 C T 1.81E-05 Type 2 diabetes / / 17463246 rs10890492 chr1 48063350 G A 1.41E-04 Renal cell carcinoma / / 22010048 rs12742768 chr1 48065019 A G 3.37E-04 Stroke / / pha002886 rs11211579 chr1 48095100 A G 4.24E-04 Insulin resistance / / 21901158 rs2506991 chr1 48098406 A G 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2506987 chr1 48100829 A G 3.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1876598 chr1 48102145 A C 2.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2457058 chr1 48102692 A G 3.39E-05 Follicular lymphoma / / 21533074 rs12133618 chr1 48215337 C T 8.00E-06 Urinary metabolites / / 21572414 rs1561572 chr1 48216886 G A 8.95E-04 Taste perception / / 22132133 rs11584807 chr1 48220454 C T 3.95E-05 Bilirubin levels,in serum / / 19389676 rs12085966 chr1 48229395 C T 2.92E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC388630 UTR-3 24023788 rs12038866 chr1 48234217 G C 8.36E-04 Suicide attempts in bipolar disorder LOC388630 intron 21041247 rs6588505 chr1 48254782 C T 1.51E-04 White matter integrity LOC388630 intron 22425255 rs6588505 chr1 48254782 C T 9.00E-06 Obesity-related traits LOC388630 intron 23251661 rs4927069 chr1 48262619 A C 8.29E-04 White matter integrity LOC388630 intron 22425255 rs10890501 chr1 48270907 T G 5.35E-04 White matter integrity LOC388630 intron 22425255 rs6698119 chr1 48274987 A G 7.00E-06 Bone mineral density (BMD),in women LOC388630 intron 20164292 rs875398 chr1 48275263 G A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs6667893 chr1 48287014 C T 1.58E-05 White matter integrity LOC388630 intron 22425255 rs11211611 chr1 48288016 C A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs10890506 chr1 48295033 A G 1.72E-05 White matter integrity LOC388630 intron 22425255 rs12031340 chr1 48299660 T C 7.73E-06 Testosterone levels LOC388630 intron 22675492 rs10890507 chr1 48309587 T C 2.81E-04 White matter integrity LOC388630 intron 22425255 rs11211621 chr1 48319515 C T 9.94E-05 White matter integrity LOC388630 intron 22425255 rs946836 chr1 48321221 C T 5.00E-06 White matter integrity LOC388630 intron 22425255 rs367993311 chr1 48331522 CA CCA,CTG 5.64E-04 Taste perception LOC388630 intron 22132133 rs7536189 chr1 48331522 C T 5.64E-04 Taste perception LOC388630 intron 22132133 rs10890510 chr1 48334490 A C 1.58E-04 White matter integrity LOC388630 intron 22425255 rs884133 chr1 48335405 T C 7.26E-04 Insulin resistance LOC388630 intron 21901158 rs7556536 chr1 48335976 T A 7.32E-05 Serum metabolites LOC388630 intron 19043545 rs10493130 chr1 48341005 G A 1.92E-04 White matter integrity LOC388630 intron 22425255 rs12048888 chr1 48343224 T C 1.54E-05 White matter integrity LOC388630 intron 22425255 rs1497095 chr1 48386888 C T 3.79E-04 White matter integrity LOC388630 intron 22425255 rs10493131 chr1 48387427 C T 4.68E-04 Intracranial aneurysm LOC388630 intron 20613766 rs11211632 chr1 48406460 A G 1.44E-05 White matter integrity LOC388630 intron 22425255 rs11584659 chr1 48444398 C T 7.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC388630 intron 20877124 rs17103980 chr1 48445208 C A 7.25E-04 Insulin resistance LOC388630 intron 21901158 rs6695419 chr1 48479075 G A 9.69E-06 Multiple complex diseases / / 17554300 rs303925 chr1 48503280 C T 5.00E-04 Type 2 diabetes / / 17463246 rs6588642 chr1 48507037 C G 4.27E-04 Type 2 diabetes / / 17463246 rs7549671 chr1 48512119 C T 4.59E-04 Type 2 diabetes / / 17463246 rs560004 chr1 48549673 T C 8.91E-04 Bone mass and geometry / / 17903296 rs555774 chr1 48556111 G A 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs17428691 chr1 48567117 G A 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs12741362 chr1 48606878 G A 4.47E-04 Smoking initiation SKINTL intron 24665060 rs17104225 chr1 48630940 C T 2.36E-05 Multiple complex diseases SKINTL intron 17554300 rs11205449 chr1 48647124 T G 5.92E-05 Serum metabolites SKINTL intron 19043545 rs11205449 chr1 48647124 T G 3.57E-05 Orofacial clefts SKINTL intron 22419666 rs1740109 chr1 48672113 C A,G 8.93E-04 Obesity (extreme) / / 21935397 rs533598 chr1 48673521 C A 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs537303 chr1 48673936 T C 6.45E-04 Obesity (extreme) / / 21935397 rs490631 chr1 48683405 A T 5.96E-04 Obesity (extreme) / / 21935397 rs960722 chr1 48683611 C T 1.28E-05 Orofacial clefts / / 22419666 rs212989 chr1 48695081 G A 9.84E-04 Obesity (extreme) SLC5A9 missense 21935397 rs540944 chr1 48705879 T C 5.78E-04 Obesity (extreme) SLC5A9 intron 21935397 rs850763 chr1 48708228 G T 8.96E-04 Obesity (extreme) SLC5A9 STOP-GAIN 21935397 rs986027 chr1 48713394 C T 9.10E-06 Stroke (ischemic) SLC5A9 UTR-3 22384361 rs498502 chr1 48725096 G C 6.36E-04 Multiple complex diseases / / 17554300 rs12085605 chr1 48784409 C G 6.31E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1418105 chr1 48785665 C T 6.35E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2067692 chr1 48796120 C A 6.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205475 chr1 48802740 C A 6.64E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs3767614 chr1 48804443 G C 5.86E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs968183 chr1 48818458 T C 6.66E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs17429004 chr1 48823047 A G 8.92E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs932087 chr1 48824156 A T 7.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205480 chr1 48839282 A T 5.70E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205481 chr1 48843171 C G 6.02E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2252984 chr1 48867985 C T 2.32E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803280 chr1 48880280 G A 1.89E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1416048 chr1 48882926 A G 2.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255264 chr1 48911430 C T 3.16E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255525 chr1 48925577 T G 2.01E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803282 chr1 48932772 C G 3.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2245681 chr1 48937351 G C 1.91E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2798127 chr1 48951377 T A 7.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs17470284 chr1 48959577 G A 3.78E-06 Gallstones / / 17632509 rs12032082 chr1 48965583 C T 6.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs12722731 chr1 48988124 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12078199 chr1 48992153 A C 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2798119 chr1 48996065 T C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2246557 chr1 49001780 C T 5.34E-04 Acute lung injury AGBL4 intron 22295056 rs2803270 chr1 49031238 C T 9.16E-07 Esophageal cancer (squamous cell) AGBL4 intron 22960999 rs11802042 chr1 49033734 A C 9.73E-04 Acute lung injury AGBL4 intron 22295056 rs2798095 chr1 49036512 G A 5.40E-06 Urinary metabolites AGBL4 intron 21572414 rs17373183 chr1 49037217 C T 3.04E-04 Type 2 diabetes AGBL4 intron 17463246 rs17104522 chr1 49040423 C T 1.21E-04 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs10493134 chr1 49042952 A G 4.92E-05 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs6665839 chr1 49043877 C T 1.80E-06 Urinary metabolites AGBL4 intron 21572414 rs319960 chr1 49059615 C T 1.91E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs11583036 chr1 49064097 T C 2.67E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 2.70E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 3.11E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.45E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.70E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 7.74E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs320027 chr1 49082023 C T 2.20E-05 Urinary metabolites AGBL4 intron 21572414 rs12566140 chr1 49087404 G A 7.85E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs11205517 chr1 49092039 T C 2.82E-04 Type 2 diabetes AGBL4 intron 17463246 rs7516699 chr1 49098326 A G 1.50E-05 Urinary metabolites AGBL4 intron 21572414 rs12562662 chr1 49104486 T C 7.33E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 8.74E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 9.10E-06 Urinary metabolites AGBL4 intron 21572414 rs12058997 chr1 49107826 T C 8.69E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs973886 chr1 49120520 T G 2.57E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs6674328 chr1 49122201 C T 2.70E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556311 chr1 49123567 G A 3.06E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556329 chr1 49123618 G C 3.07E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs444167 chr1 49138646 A G 9.44E-04 Myopia (pathological) AGBL4 intron 21095009 rs319959 chr1 49145514 G T 0.000268 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs319981 chr1 49151886 A G 0.000494 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs6695778 chr1 49164688 A C 3.12E-05 Multiple complex diseases AGBL4 intron 17554300 rs4926747 chr1 49165860 C T 4.60E-05 Lung adenocarcinoma AGBL4 intron 22797724 rs320062 chr1 49179307 T C 1.83E-04 Amyotrophic lateral sclerosis (sporadic) AGBL4 intron 24529757 rs17104710 chr1 49179498 G A 8.94E-05 Cognitive impairment induced by topiramate AGBL4 intron 22091778 rs1385152 chr1 49193394 G T 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AGBL4 intron 20877124 rs6661901 chr1 49196060 G A 5.30E-05 Asthma (bronchodilator response) BEND5 intron 22792082 rs4926749 chr1 49203349 C A 5.80E-05 Creatinine levels BEND5 intron 20222955 rs11588373 chr1 49215159 T A 1.79E-04 Insulin resistance BEND5 intron 21901158 rs12407980 chr1 49220637 G A 4.23E-04 Insulin resistance BEND5 intron 21901158 rs12086219 chr1 49221303 G A 6.95E-05 Multiple complex diseases BEND5 intron 17554300 rs1934377 chr1 49237975 C A 7.38E-04 Multiple complex diseases BEND5 intron 17554300 rs7514802 chr1 49268066 T C 7.43E-04 Multiple complex diseases AGBL4 intron 17554300 rs4457622 chr1 49346828 C T 3.96E-04 Body mass index AGBL4 intron 17255346 rs4457622 chr1 49346828 C T 1.02E-04 Type 2 diabetes AGBL4 intron 17463246 rs2032022 chr1 49388622 T G 9.34E-05 Alzheimer's disease AGBL4 intron 22832961 rs1343432 chr1 49396989 G C 1.82E-04 Major depressive disorder AGBL4 intron 22472876 rs17105335 chr1 49436107 T C 5.42E-05 Amyotrophic Lateral Sclerosis AGBL4 intron 18057069 rs3121514 chr1 49451272 T C 6.41E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs3118223 chr1 49463801 G A 8.20E-04 Crohn's disease AGBL4 intron 17684544 rs3127556 chr1 49468025 G A 9.12E-04 Multiple complex diseases AGBL4 intron 17554300 rs6669433 chr1 49482703 A C 7.67E-04 Multiple complex diseases AGBL4 intron 17554300 rs7536787 chr1 49525465 C T 9.39E-04 Multiple complex diseases AGBL4 intron 17554300 rs11205596 chr1 49541827 G T 7.84E-04 Type 2 diabetes AGBL4 intron 17463246 rs11205596 chr1 49541827 G T 9.20E-05 Personality dimensions AGBL4 intron 18957941 rs6588238 chr1 49552036 C T 3.95E-05 Multiple complex diseases AGBL4 intron 17554300 rs7527364 chr1 49566557 A G 5.64E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs590503 chr1 49581006 C T 8.42E-04 Alzheimer's disease AGBL4 intron 22005930 rs483330 chr1 49591977 G A 5.11E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs11591141 chr1 49664304 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs925043 chr1 49695123 G A,C,T 4.99E-12 Gout AGBL4 intron pha001406 rs1431638 chr1 49762418 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs17105629 chr1 49799321 T C 2.89E-04 Multiple complex diseases AGBL4 intron 17554300 rs6659225 chr1 49822433 T C 2.50E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs1415985 chr1 49930749 T C 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs1933271 chr1 49949006 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs1949995 chr1 49975795 G C 0.0004159 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs1949995 chr1 49975795 G C 4.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2178085 chr1 50023956 C T 2.70E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs17105712 chr1 50052684 T C 3.45E-04 Multiple complex diseases AGBL4 intron 17554300 rs10888663 chr1 50081573 A C 7.91E-04 Alzheimer's disease AGBL4 intron 24755620 rs2211459 chr1 50104642 G A 6.40E-04 Alzheimer's disease AGBL4 intron 24755620 rs2051086 chr1 50105201 T A,C 9.08E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs2051086 chr1 50105201 T A,C 0.0005304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs2051086 chr1 50105201 T A,C 5.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2051086 chr1 50105201 T A,C 5.30E-04 Response to antipsychotic treatment AGBL4 intron 23241943 rs1343161 chr1 50110850 G A 3.30E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs4408195 chr1 50128198 G A 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs12135410 chr1 50141741 T C 6.96E-04 Alzheimer's disease AGBL4 intron 24755620 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs4926829 chr1 50220117 C T 7.32E-04 Alzheimer's disease AGBL4 intron 24755620 rs12144042 chr1 50229397 G A 7.74E-04 Alzheimer's disease AGBL4 intron 24755620 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs6675647 chr1 50308556 C T 6.08E-04 Multiple complex diseases AGBL4 intron 17554300 rs4926833 chr1 50311454 G A 0.0008306 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs4926833 chr1 50311454 G A 8.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs12067197 chr1 50366482 A G 6.50E-04 Alzheimer's disease AGBL4 intron 24755620 rs7518987 chr1 50426542 A G 6.34E-04 Alzheimer's disease AGBL4 intron 24755620 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs12758298 chr1 50484613 C A 1.80E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs10888678 chr1 50509729 G A 9.07E-04 Alzheimer's disease / / 24755620 rs4525085 chr1 50534526 A G 6.40E-04 Alzheimer's disease ELAVL4 intron 24755620 rs4926548 chr1 50547166 T A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs6673246 chr1 50554373 G A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 20885792 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 21460841 rs11205682 chr1 50567676 T C 6.94E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11205683 chr1 50570665 G A 7.92E-04 Alzheimer's disease ELAVL4 intron 24755620 rs2480693 chr1 50588665 C T 7.58E-04 Multiple complex diseases ELAVL4 intron 17554300 rs9436447 chr1 50590732 G A 7.90E-04 Alcohol dependence ELAVL4 intron 20201924 rs9436447 chr1 50590732 G A 8.10E-04 Alcohol dependence ELAVL4 intron 20201924 rs2494884 chr1 50591405 G T 2.43E-04 Multiple complex diseases ELAVL4 intron 17554300 rs2494884 chr1 50591405 G T 7.70E-05 Creatinine levels ELAVL4 intron pha003069 rs12092053 chr1 50607029 T G 6.00E-06 Obesity-related traits ELAVL4 intron 23251661 rs12081193 chr1 50698759 C A 8.70E-05 Coffee consumption / / 21357676 rs4926853 chr1 50709222 A G 8.56E-04 Type 2 diabetes / / 17463246 rs4926853 chr1 50709222 A G 0.0003 Migraine / / 22678113 rs1393637 chr1 50753599 C T 5.13E-04 Bipolar disorder / / 19259986 rs1875635 chr1 50765982 G A 8.60E-05 Body Mass Index / / pha003009 rs12566635 chr1 50791465 T C 4.81E-04 Smoking cessation / / 24665060 rs6689749 chr1 50800516 G T 4.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6657279 chr1 50808295 A G 5.90E-05 Panic disorder / / 19165232 rs1110220 chr1 50815397 A G 7.30E-05 Lung adenocarcinoma / / 22797724 rs11205712 chr1 50817701 G A 5.24E-05 Multiple complex diseases / / 17554300 rs7517924 chr1 50844929 T G 8.34E-04 Multiple complex diseases / / 17554300 rs2055491 chr1 50852769 T C 4.77E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 1.88E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 8.88E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1278537 chr1 50882159 G T 7.10E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.40E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.60E-04 Alcohol dependence / / 20201924 rs7550594 chr1 50891093 C T 9.64E-07 Schizophrenia / / 21926974 rs7550594 chr1 50891093 C T 1.33E-04 Self-reported allergy / / 23817569 rs4381241 chr1 50907438 T C 1.50E-04 Alcohol dependence FAF1 intron 20201924 rs4381241 chr1 50907438 T C 1.70E-04 Alcohol dependence FAF1 intron 20201924 rs17106184 chr1 50909985 G A 4.00E-09 Type 2 diabetes FAF1 intron 24509480 rs956084 chr1 50911347 C T 1.50E-10 HDL cholesterol FAF1 intron 23063622 rs12134715 chr1 50912441 A C 2.38E-05 Personality dimensions FAF1 intron 22628180 rs12134715 chr1 50912441 A C 1.37E-05 Self-reported allergy FAF1 intron 23817569 rs12565493 chr1 50917596 T C 2.47E-05 Personality dimensions FAF1 intron 22628180 rs12565493 chr1 50917596 T C 1.57E-05 Self-reported allergy FAF1 intron 23817569 rs12142848 chr1 50918388 C T 2.41E-05 Personality dimensions FAF1 intron 22628180 rs12142848 chr1 50918388 C T 1.60E-05 Self-reported allergy FAF1 intron 23817569 rs12133928 chr1 50919942 T C 2.66E-05 Personality dimensions FAF1 intron 22628180 rs12133928 chr1 50919942 T C 1.48E-05 Self-reported allergy FAF1 intron 23817569 rs12063722 chr1 50931102 C T 5.85E-04 Multiple complex diseases FAF1 intron 17554300 rs12562938 chr1 50931160 C T 3.25E-05 Personality dimensions FAF1 intron 22628180 rs3827730 chr1 50937848 T C 1.40E-06 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.10E-05 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.00E-06 Depression and alcohol dependence FAF1 intron 22064162 rs3827730 chr1 50937848 T C 1.42E-06 Alcoholism FAF1 intron pha002892 rs3827730 chr1 50937848 T C 4.08E-05 Alcoholism FAF1 intron pha002893 rs3789576 chr1 50945526 G T 9.78E-04 Response to cytidine analogues (gemcitabine) FAF1 intron 24483146 rs12116432 chr1 50949724 A T 3.65E-05 Personality dimensions FAF1 intron 22628180 rs12116432 chr1 50949724 A T 2.14E-05 Self-reported allergy FAF1 intron 23817569 rs9645408 chr1 50983135 T C 3.28E-05 Self-reported allergy FAF1 intron 23817569 rs11205726 chr1 50986057 C T 4.30E-05 Self-reported allergy FAF1 intron 23817569 rs10888691 chr1 50991426 G C 4.37E-05 Self-reported allergy FAF1 intron 23817569 rs12135541 chr1 50997461 T C 4.82E-05 Self-reported allergy FAF1 intron 23817569 rs12137729 chr1 50999860 T C 4.44E-05 Self-reported allergy FAF1 intron 23817569 rs3789584 chr1 51029387 T C 2.22E-04 Multiple complex diseases FAF1 intron 17554300 rs12118892 chr1 51029609 G T 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12118892 chr1 51029609 G T 4.88E-05 Self-reported allergy FAF1 intron 23817569 rs12073534 chr1 51034926 T C 6.90E-05 Self-reported allergy FAF1 intron 23817569 rs12122697 chr1 51043243 G T 6.04E-05 Self-reported allergy FAF1 intron 23817569 rs3789585 chr1 51051105 G C 6.13E-05 Self-reported allergy FAF1 intron 23817569 rs11205738 chr1 51060054 G A 6.10E-05 Self-reported allergy FAF1 intron 23817569 rs12568008 chr1 51076822 G A 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12568008 chr1 51076822 G A 5.47E-05 Self-reported allergy FAF1 intron 23817569 rs17106336 chr1 51078564 T C 2.78E-04 Multiple complex diseases FAF1 intron 17554300 rs17106336 chr1 51078564 T C 1.20E-05 Urinary metabolites FAF1 intron 21572414 rs17106336 chr1 51078564 T C 5.65E-05 Self-reported allergy FAF1 intron 23817569 rs11205741 chr1 51079296 C A 6.93E-05 Self-reported allergy FAF1 intron 23817569 rs10888700 chr1 51086337 T C 1.22E-04 Multiple complex diseases FAF1 intron 17554300 rs11577903 chr1 51086847 T C 4.45E-05 Self-reported allergy FAF1 intron 23817569 rs11205743 chr1 51087465 C G 9.30E-06 Multiple complex diseases FAF1 intron 17554300 rs11205743 chr1 51087465 C G 4.72E-05 Self-reported allergy FAF1 intron 23817569 rs10788929 chr1 51090942 T C 8.81E-05 Self-reported allergy FAF1 intron 23817569 rs12120719 chr1 51092829 T C 1.95E-05 Self-reported allergy FAF1 intron 23817569 rs11577260 chr1 51094117 G A 6.61E-05 Self-reported allergy FAF1 intron 23817569 rs11205748 chr1 51100042 A G 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs12567589 chr1 51110167 C T 7.73E-05 Self-reported allergy FAF1 intron 23817569 rs11205750 chr1 51113531 A G 7.60E-05 Self-reported allergy FAF1 intron 23817569 rs11205752 chr1 51116645 T C 7.12E-05 Self-reported allergy FAF1 intron 23817569 rs10888703 chr1 51118706 C A 6.58E-05 Self-reported allergy FAF1 intron 23817569 rs12117653 chr1 51123315 C A 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs11205760 chr1 51174330 C T 1.67E-05 Multiple complex diseases FAF1 intron 17554300 rs11205760 chr1 51174330 C T 3.40E-05 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 6.90E-04 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 3.37E-05 Alcoholism FAF1 intron pha002892 rs6680846 chr1 51188674 G C 3.16E-04 Multiple complex diseases FAF1 intron 17554300 rs12239279 chr1 51304834 G A 1.48E-05 Height FAF1 intron 22021425 rs12092977 chr1 51410517 T C 6.40E-15 HDL cholesterol FAF1 intron 23063622 rs3813634 chr1 51475488 G A 7.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs3813634 chr1 51475488 G A 4.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12092511 chr1 51477088 G A 6.85E-04 Multiple complex diseases / / 17554300 rs12092511 chr1 51477088 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs7555006 chr1 51480258 A G 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17391905 chr1 51546140 T G 3.00E-10 Ventricular conduction / / 21076409 rs11807353 chr1 51615023 C A 1.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11205821 chr1 51631884 C T 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 8.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12728955 chr1 51709522 T C 8.27E-05 Schizophrenia (cytomegalovirus infection interaction) RNF11 intron 23358160 rs6701572 chr1 51719315 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF11 intron 20877124 rs3748615 chr1 51753722 G A 1.91E-04 Response to cytidine analogues (gemcitabine) TTC39A UTR-3 24483146 rs17392930 chr1 51753904 G A,C,T 0.0000104 LDL cholesterol particle diameter TTC39A missense 23263444 rs11205836 chr1 51804731 C T 3.40E-05 Diabetes Mellitus TTC39A intron pha003060 rs6659736 chr1 51814274 C T 1.30E-07 Lymphocyte counts / / 22286170 rs6673480 chr1 51859242 C T 2.00E-06 IgE grass sensitization EPS15 intron 22036096 rs7411629 chr1 52005824 T C 0.0000684 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10399893 chr1 52010157 G A 2.50E-05 Urinary metabolites / / 21572414 rs10399889 chr1 52010203 C T 1.60E-05 Urinary metabolites / / 21572414 rs12732738 chr1 52032789 A G 2.80E-05 Urinary metabolites / / 21572414 rs13375698 chr1 52059408 T A 2.26E-04 Multiple complex diseases / / 17554300 rs856614 chr1 52252006 A G 2.32E-05 Body Mass Index OSBPL9 intron pha003006 rs856614 chr1 52252006 A G 2.26E-05 Body Mass Index OSBPL9 intron pha003019 rs856614 chr1 52252006 A G 2.42E-05 Body Mass Index OSBPL9 intron pha003020 rs1004815 chr1 52258725 T A,C,G 3.00E-05 Alcohol dependence NRD1 intron 21703634 rs1417364 chr1 52263082 G A 9.18E-06 Alcohol dependence NRD1 intron 21703634 rs8375 chr1 52266242 G A,C,T 2.00E-05 Smoking behavior NRD1 cds-synon 20418888 rs7551758 chr1 52274078 T G 1.30E-05 Smoking behavior NRD1 intron 20418888 rs2747525 chr1 52284018 A C 4.80E-06 Smoking behavior NRD1 intron 20418888 rs11205896 chr1 52290984 T G 1.70E-05 Smoking behavior NRD1 cds-synon 20418888 rs2077725 chr1 52293570 G A 1.60E-05 Smoking behavior NRD1 intron 20418888 rs2077725 chr1 52293570 G A 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs11205897 chr1 52298151 C T 2.50E-05 Smoking behavior NRD1 intron 20418888 rs6702037 chr1 52310756 A G 6.30E-06 Smoking behavior NRD1 intron 20418888 rs4422953 chr1 52310882 C T 8.70E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 6.40E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs883058 chr1 52317231 T A 1.10E-05 Smoking behavior NRD1 intron 20418888 rs7526552 chr1 52320559 T C 1.90E-05 Smoking behavior NRD1 intron 20418888 rs6691091 chr1 52323772 G C 4.60E-05 Smoking behavior NRD1 intron 20418888 rs2842576 chr1 52324228 C T 6.07E-06 Alcohol dependence NRD1 intron 20202923 rs2842576 chr1 52324228 C T 7.90E-06 Alcohol dependence NRD1 intron 21703634 rs2842576 chr1 52324228 C T 2.50E-04 Alcohol dependence NRD1 intron 21956439 rs6588415 chr1 52334047 A G 1.10E-05 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 6.30E-06 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 5.42E-05 Prostate cancer NRD1 intron pha002878 rs1890946 chr1 52342427 T C 6.00E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.40E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs138608728 chr1 52344157 G A 0.000012 Breast cancer (ER positive) NRD1 missense 23555315 rs736756 chr1 52344414 A C 2.90E-05 Smoking behavior NRD1 UTR-5 20418888 rs11205902 chr1 52348769 G T 2.91E-04 Alzheimer's disease / / 17998437 rs11205902 chr1 52348769 G T 5.00E-05 Smoking behavior / / 20418888 rs6588416 chr1 52375424 T C 2.94E-04 Alzheimer's disease RAB3B UTR-3 17998437 rs6588416 chr1 52375424 T C 7.80E-05 Serum metabolites RAB3B UTR-3 19043545 rs1954260 chr1 52391032 C T 4.70E-06 Smoking behavior RAB3B intron 20418888 rs11205911 chr1 52396312 A G 6.30E-07 Smoking behavior RAB3B intron 20418888 rs12566236 chr1 52396943 G T 7.10E-07 Smoking behavior RAB3B intron 20418888 rs10888740 chr1 52400097 A G 2.60E-06 Smoking behavior RAB3B intron 20418888 rs6698110 chr1 52404141 T C 2.10E-07 Smoking behavior RAB3B intron 20418888 rs1935289 chr1 52406872 T C 4.60E-06 Smoking behavior RAB3B intron 20418888 rs2809943 chr1 52416140 C T 4.18E-04 Alzheimer's disease RAB3B intron 17998437 rs2809943 chr1 52416140 C T 5.15E-05 Serum metabolites RAB3B intron 19043545 rs2809944 chr1 52417538 T C 6.91E-05 Multiple sclerosis RAB3B intron 20598377 rs7541308 chr1 52418121 G T 1.70E-06 Smoking behavior RAB3B intron 20418888 rs6686975 chr1 52423134 G A 6.70E-06 Smoking behavior RAB3B intron 20418888 rs10888743 chr1 52423167 C T 4.20E-06 Smoking behavior RAB3B intron 20418888 rs12039206 chr1 52569002 A G 7.09E-04 Multiple complex diseases / / 17554300 rs1288706 chr1 52754871 G A 7.59E-05 Erythrocyte counts ZFYVE9 intron pha003099 rs2753399 chr1 52774357 T C 0.0000116 Menopause (age at onset) ZFYVE9 intron 23424626 rs2762819 chr1 52798033 G A 9.21E-04 Insulin resistance ZFYVE9 intron 21901158 rs9633423 chr1 52836139 G A 1.70E-05 Smoking behavior / / 20418888 rs9633423 chr1 52836139 G A 4.71E-11 Lymphocyte counts / / 22286170 rs3087476 chr1 52854961 G A 2.57E-04 Insulin resistance ORC1 missense 21901158 rs835036 chr1 52997240 T C 1.40E-05 Smoking behavior ZCCHC11 intron 20418888 rs12138419 chr1 53056187 G A 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17374258 chr1 53110002 C T 2.46E-05 Menopause (age at onset) FAM159A intron 22267201 rs706497 chr1 53114736 T C 4.70E-05 Myasthenia gravis FAM159A intron 23055271 rs856721 chr1 53162156 C A 0.00056 Salmonella-induced pyroptosis SELRC1 intron 22837397 rs374662 chr1 53164549 C A 0.00022 Salmonella-induced pyroptosis / / 22837397 rs440871 chr1 53173052 C T 0.000303 Salmonella-induced pyroptosis / / 22837397 rs425520 chr1 53179805 C G 0.000312 Salmonella-induced pyroptosis / / 22837397 rs6703127 chr1 53180565 C T 0.000235 Salmonella-induced pyroptosis / / 22837397 rs146750 chr1 53183447 C G 0.000403 Salmonella-induced pyroptosis / / 22837397 rs374849 chr1 53185631 G A 0.000378 Salmonella-induced pyroptosis / / 22837397 rs269293 chr1 53187767 A C 0.000454 Salmonella-induced pyroptosis / / 22837397 rs4926930 chr1 53217335 A G 0.000789 Salmonella-induced pyroptosis ZYG11B intron 22837397 rs505444 chr1 53251860 T C 4.68E-30 Narcolepsy ZYG11B intron 19629137 rs12731800 chr1 53286967 A G 2.10E-06 Urinary metabolites ZYG11B intron 21572414 rs551591 chr1 53301876 A G 0.0000573 Salmonella-induced pyroptosis / / 22837397 rs504816 chr1 53307957 T G 0.000035 Salmonella-induced pyroptosis / / 22837397 rs514406 chr1 53330458 A G 5.73E-04 Multiple complex diseases ZYG11A intron 17554300 rs514881 chr1 53336737 C T 0.000561 Salmonella-induced pyroptosis ZYG11A intron 22837397 rs481440 chr1 53344976 C T 8.08E-04 Alcohol dependence ZYG11A intron 21314694 rs139969883 chr1 53377291 C T 0.000069 Breast cancer ECHDC2 missense 23555315 rs11206061 chr1 53455899 T C 7.43E-04 Suicide attempts in bipolar disorder SCP2 intron 21423239 rs11581638 chr1 53459690 C T 6.00E-04 Multiple complex diseases SCP2 UTR-3 17554300 rs11588200 chr1 53512519 G T 5.07E-04 Multiple complex diseases SCP2 intron 17554300 rs6664845 chr1 53514497 C G 8.84E-04 Multiple complex diseases SCP2 intron 17554300 rs4926946 chr1 53515101 C A 5.51E-04 Multiple complex diseases SCP2 intron 17554300 rs17107767 chr1 53517997 T C 7.30E-04 Multiple complex diseases / / 17554300 rs12096165 chr1 53518049 T G 9.29E-04 Multiple complex diseases / / 17554300 rs11584649 chr1 53530487 C T 3.75E-04 Multiple complex diseases PODN intron 17554300 rs17107812 chr1 53532920 C A 5.08E-04 Insulin resistance PODN intron 21901158 rs6697308 chr1 53534687 C G 8.47E-04 Multiple complex diseases PODN intron 17554300 rs2275456 chr1 53536025 T C 0.0000031 Chronic obstructive pulmonary disease (moderate to severe) PODN intron 22986903 rs11583585 chr1 53554406 T C 2.98E-04 Type 2 diabetes SLC1A7 intron 17463246 rs4926953 chr1 53569492 T C 2.57E-04 Type 2 diabetes SLC1A7 intron 17463246 rs17108032 chr1 53580585 G A 0.000000667 Triglycerides SLC1A7 cds-synon 23063622 rs17108032 chr1 53580585 G A 5.41E-10 Cholesterol,total SLC1A7 cds-synon 23063622 rs3820201 chr1 53581670 A G 1.00E-06 Hippocampal atrophy SLC1A7 intron 22745009 rs3753600 chr1 53591287 G A 1.37E-11 Triglycerides SLC1A7 intron 23063622 rs3753600 chr1 53591287 G A 2.85E-11 HDL cholesterol SLC1A7 intron 23063622 rs34418279 chr1 53608425 C A 3.33E-04 Multiple complex diseases / / 17554300 rs7556421 chr1 53619482 C T 8.42E-05 Height / / pha003011 rs6695567 chr1 53629585 G A 3.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6695567 chr1 53629585 G A 4.00E-06 Systemic lupus erythematosus / / 21408207 rs1288331 chr1 53631049 T C 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7531337 chr1 53641911 C A 6.66E-04 Type 2 diabetes / / 17463246 rs12058755 chr1 53670451 G A 2.46E-08 Cholesterol,total CPT2 intron 23063622 rs11578832 chr1 53674542 G A 5.20E-04 Coronary heart disease CPT2 intron 21966275 rs13375749 chr1 53695882 T C 8.30E-04 Myocardial infarction MAGOH intron 21107343 rs13375749 chr1 53695882 T C 3.00E-28 Blood metabolite levels MAGOH intron 24816252 rs2297656 chr1 53701581 A G 5.28E-05 Bipolar disorder and schizophrenia MAGOH intron 20889312 rs17785382 chr1 53707953 A G 2.73E-05 Bipolar disorder and schizophrenia LOC100507564 intron 20889312 rs17785382 chr1 53707953 A G 5.59E-07 Bipolar disorder LOC100507564 intron 22182935 rs17785382 chr1 53707953 A G 1.74E-05 Schizophrenia LOC100507564 intron pha002857 rs5177 chr1 53711735 G C 8.10E-05 Bipolar disorder and schizophrenia LRP8 UTR-3 20889312 rs5177 chr1 53711735 G C 5.00E-05 Schizophrenia LRP8 UTR-3 pha002857 rs5176 chr1 53711809 T G 3.44E-37 LDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 5.12E-52 HDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 6.51E-78 Cholesterol,total LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 8.86E-21 Triglycerides LRP8 UTR-3 23063622 rs5174 chr1 53712727 C T 3.40E-05 Schizophrenia LRP8 missense 21791550 rs5174 chr1 53712727 C T 0.000000094 Psychosis LRP8 missense 23164818 rs10788950 chr1 53713336 A G 5.50E-04 Response to taxane treatment (placlitaxel) LRP8 intron 23006423 rs11206127 chr1 53713549 G A 4.25E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs11206127 chr1 53713549 G A 3.16E-05 Schizophrenia LRP8 intron pha002857 rs869987 chr1 53723190 G T 3.86E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs869987 chr1 53723190 G T 4.54E-05 Schizophrenia LRP8 intron pha002857 rs869988 chr1 53723349 T C 5.85E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs2297661 chr1 53723965 C G 0.00000038 Cholesterol,total LRP8 intron 23063622 rs1288489 chr1 53772544 C G 1.60E-04 Type 2 diabetes LRP8 intron 17463246 rs2788032 chr1 53777631 A C 6.00E-06 Body mass index (interaction) LRP8 intron 23192594 rs2788032 chr1 53777631 A C 1.18E-04 Amyotrophic lateral sclerosis (sporadic) LRP8 intron 24529757 rs872314 chr1 53787483 A G 5.92E-06 Multiple complex diseases LRP8 intron 17554300 rs3820198 chr1 53792651 A C 2.70E-05 Alcohol dependence LRP8 missense 22096494 rs12354192 chr1 53796783 C T 2.39E-04 Multiple complex diseases / / 17554300 rs1416095 chr1 53808693 A G 1.20E-05 Alcohol dependence / / 22096494 rs10888780 chr1 53813684 A G 3.72E-05 Cognitive test performance / / 20125193 rs12041966 chr1 53832697 T C 9.88E-05 Type 2 diabetes / / 17463246 rs17108398 chr1 53845985 G A 2.50E-05 Urinary metabolites / / 21572414 rs6660818 chr1 53857444 T A 7.30E-06 Urinary metabolites / / 21572414 rs114216682 chr1 53871085 G C 7.00E-08 Chronic obstructive pulmonary disease / / 21685187 rs1776421 chr1 53884457 C T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9436924 chr1 53913080 C T 7.30E-06 Nicotine use / / 23942779 rs41366756 chr1 53917443 C T 5.48E-04 Multiple complex diseases / / 17554300 rs41443646 chr1 53921571 T C 8.18E-04 Multiple complex diseases / / 17554300 rs1108989 chr1 53929463 T A 6.69E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs1288632 chr1 53929536 C G 5.71E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs11579575 chr1 53936718 G T 9.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1296438 chr1 53937177 A G 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1296438 chr1 53937177 A G 1.00E-04 Illicit drug use / / 23942779 rs1296438 chr1 53937177 A G 6.20E-04 Non-substance related behavioral disinhibition / / 23942779 rs1296438 chr1 53937177 A G 7.90E-06 Nicotine use / / 23942779 rs17108559 chr1 53947868 C T 1.48E-04 Multiple complex diseases / / 17554300 rs1298637 chr1 53958603 C T 1.60E-04 Illicit drug use / / 23942779 rs1298637 chr1 53958603 C T 3.80E-04 Non-substance related behavioral disinhibition / / 23942779 rs1298637 chr1 53958603 C T 5.00E-06 Nicotine use / / 23942779 rs943519 chr1 53965546 C T 5.17E-05 Cognitive test performance / / 20125193 rs10749691 chr1 53974987 G T 1.30E-05 Response to statin therapy GLIS1 intron 20339536 rs10749691 chr1 53974987 G T 2.85E-05 Smoking initiation GLIS1 intron 24665060 rs475322 chr1 53975436 C A 5.19E-04 Smoking initiation GLIS1 intron 24665060 rs2280511 chr1 53976188 C T 2.60E-05 Response to statin therapy GLIS1 intron 20339536 rs6588480 chr1 53978119 A G 8.00E-06 Response to statin therapy GLIS1 intron 20339536 rs11206169 chr1 54005060 C T 8.02E-04 Type 2 diabetes GLIS1 intron 17463246 rs3889128 chr1 54009233 G C 3.10E-05 Anger GLIS1 intron 24489884 rs2986655 chr1 54011192 A G 2.96E-05 stroke (ischemic) GLIS1 intron 17434096 rs41488848 chr1 54011503 G C 2.83E-04 Multiple complex diseases GLIS1 intron 17554300 rs12141264 chr1 54020542 C T 2.75E-05 Myopia (pathological) GLIS1 intron 23049088 rs2873096 chr1 54029856 C A 3.83E-04 Lung function (forced vital capacity) GLIS1 intron 24023788 rs2091407 chr1 54032698 G A 2.50E-05 Urinary metabolites GLIS1 intron 21572414 rs11206174 chr1 54038523 G C 2.40E-05 Urinary metabolites GLIS1 intron 21572414 rs10788958 chr1 54040670 C G 2.50E-06 Digit length ratio GLIS1 intron 20303062 rs4926603 chr1 54041558 G A 6.00E-06 Digit length ratio GLIS1 intron 20303062 rs2950250 chr1 54042714 T G 9.50E-07 Digit length ratio GLIS1 intron 20303062 rs3108391 chr1 54042889 C T 6.40E-06 Digit length ratio GLIS1 intron 20303062 rs4634849 chr1 54043110 C T 8.40E-06 Digit length ratio GLIS1 intron 20303062 rs11585273 chr1 54043386 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs11585344 chr1 54043786 G A 6.70E-06 Digit length ratio GLIS1 intron 20303062 rs12089978 chr1 54045180 T C 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs12084713 chr1 54045226 G A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs17386087 chr1 54045624 T C 4.90E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386087 chr1 54045624 T C 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs17386108 chr1 54045718 T A 4.93E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386108 chr1 54045718 T A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs12137291 chr1 54046217 G T 8.50E-06 Digit length ratio GLIS1 intron 20303062 rs941129 chr1 54046556 T C 7.89E-05 Cognitive test performance GLIS1 intron 20125193 rs3006884 chr1 54047225 G A 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs12140369 chr1 54047882 A T 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2950252 chr1 54048719 C G 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2948045 chr1 54051898 T C 1.20E-06 Digit length ratio GLIS1 intron 20303062 rs4926604 chr1 54051924 T C 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs6588482 chr1 54054618 T A 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs1879735 chr1 54055693 A G 1.40E-06 Digit length ratio GLIS1 intron 20303062 rs4927011 chr1 54058231 C T 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.90E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.14E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy GLIS1 intron 23834954 rs10888795 chr1 54061446 G A 8.70E-06 Digit length ratio GLIS1 intron 20303062 rs6588483 chr1 54061779 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3013754 chr1 54061978 A C 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs2948053 chr1 54062273 A G 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs10159298 chr1 54064240 C T 3.19E-05 Body Composition GLIS1 intron pha003012 rs10159298 chr1 54064240 C T 9.02E-05 Body Mass Index GLIS1 intron pha003021 rs17382220 chr1 54066599 A T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs4927012 chr1 54068016 C T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs6663966 chr1 54070013 C T 0.000052 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 GLIS1 intron 21873659 rs17382457 chr1 54071428 G A 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs12563871 chr1 54071610 A G 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs3013749 chr1 54072759 A T 5.00E-05 Height GLIS1 intron 19396169 rs2948048 chr1 54074729 G A 6.35E-05 Body Composition GLIS1 intron pha003012 rs7542387 chr1 54078923 A G 5.80E-06 Digit length ratio GLIS1 intron 20303062 rs11801290 chr1 54079964 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3006898 chr1 54083312 T C 9.79E-05 Body Composition GLIS1 intron pha003012 rs2141079 chr1 54120873 C T 5.37E-04 Parkinson's disease GLIS1 intron 17052657 rs17109076 chr1 54129705 A G 7.00E-04 Multiple complex diseases GLIS1 intron 17554300 rs2950243 chr1 54135651 A G 5.80E-04 Multiple complex diseases GLIS1 intron 17554300 rs797913 chr1 54198562 C T 9.28E-04 Alcohol dependence GLIS1 intron 21314694 rs12075528 chr1 54199484 C T 4.88E-04 Alcohol dependence GLIS1 intron 21314694 rs761490 chr1 54216654 C G 3.00E-05 Social communication problems / / 24047820 rs4354491 chr1 54314043 C T 3.27E-06 Body Mass Index / / pha003019 rs4354491 chr1 54314043 C T 4.20E-05 Body Mass Index / / pha003020 rs4354491 chr1 54314043 C T 5.98E-05 Body Mass Index / / pha003022 rs11206226 chr1 54320337 A G 5.00E-06 Nonalcoholic fatty liver disease YIPF1 intron 22719876 rs6588492 chr1 54328025 G A 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs6681549 chr1 54328814 G A 8.83E-04 Type 2 diabetes YIPF1 intron 17463246 rs6588493 chr1 54328988 C A 8.41E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541049 chr1 54343294 T C 7.11E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541170 chr1 54343462 T C 6.46E-04 Type 2 diabetes YIPF1 intron 17463246 rs6680026 chr1 54345792 C T 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs12131461 chr1 54366364 G A 1.27E-05 Body Mass Index DIO1 intron pha003019 rs12131461 chr1 54366364 G A 6.05E-05 Body Mass Index DIO1 intron pha003020 rs3766467 chr1 54373185 G A,C,T 7.76E-05 Obesity (extreme) DIO1 intron 21935397 rs2235544 chr1 54375570 C A 3.00E-18 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 5.00E-15 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 8.00E-32 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 6.00E-07 Multiple myeloma (hyperdiploidy) DIO1 intron 23502783 rs12073655 chr1 54393492 C A 6.11E-05 Obesity (extreme) HSPB11 intron 21935397 rs11206252 chr1 54397240 G A 6.14E-05 Obesity (extreme) HSPB11 intron 21935397 rs12092723 chr1 54422901 C G 2.77E-04 Multiple complex diseases LRRC42 intron 17554300 rs12092723 chr1 54422901 C G 7.00E-05 Obesity (extreme) LRRC42 intron 21935397 rs10888828 chr1 54441756 A G 2.20E-04 Obesity (extreme) / / 21935397 rs114147144 chr1 54443865 T C 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11206266 chr1 54443867 C T 2.21E-04 Obesity (extreme) / / 21935397 rs638749 chr1 54450490 A G 9.82E-04 Myopia (pathological) / / 21095009 rs7515322 chr1 54450901 A G 7.26E-05 Multiple complex diseases / / 17554300 rs7515322 chr1 54450901 A G 1.91E-04 Obesity (extreme) / / 21935397 rs7525809 chr1 54451080 G A 3.62E-04 Multiple complex diseases / / 17554300 rs7525809 chr1 54451080 G A 1.91E-04 Obesity (extreme) / / 21935397 rs145889899 chr1 54476084 C T 0.00000014 Breast cancer(er negative) LDLRAD1 splice-5 23555315 rs145889899 chr1 54476084 C T 0.00000025 Breast cancer LDLRAD1 splice-5 23555315 rs17109656 chr1 54476147 G A 9.03E-05 Multiple complex diseases LDLRAD1 intron 17554300 rs17109656 chr1 54476147 G A 1.68E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs11805505 chr1 54480410 T A 6.49E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs12047169 chr1 54487417 C T 6.61E-04 Myopia (pathological) / / 21095009 rs6694292 chr1 54566190 G A 4.75E-04 Coronary Artery Disease / / 17634449 rs6694397 chr1 54566310 G A 5.03E-04 Coronary Artery Disease / / 17634449 rs12063422 chr1 54585415 T C 1.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs581554 chr1 54614409 C T 7.91E-04 Coronary heart disease CDCP2 intron 21606135 rs11587789 chr1 54615599 A C 4.50E-04 Alzheimer's disease CDCP2 intron 22005930 rs7519887 chr1 54619404 C T 7.27E-05 Cognitive test performance CDCP2 UTR-5 20125193 rs10493175 chr1 54636977 T C 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 3.23E-04 Coronary heart disease / / 21606135 rs682705 chr1 54637417 G A 9.07E-06 Parkinson's disease / / 16252231 rs7520966 chr1 54645262 T C 2.96E-05 Parkinson's disease CYB5RL intron 16252231 rs1890566 chr1 54668278 A G 8.00E-07 Migraine MRPL37 intron 23793025 rs17392549 chr1 54677786 G A 8.16E-04 Telomere length MRPL37 intron 23900074 rs4061073 chr1 54696743 A G 0.0000131 Carotid intima media thickness SSBP3 intron 23152477 rs4061073 chr1 54696743 A G 3.29E-04 Stroke SSBP3 intron pha002887 rs688383 chr1 54718489 T C 3.34E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs655274 chr1 54721930 C T 2.61E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs3766432 chr1 54729952 G C 6.98E-13 Metabolite levels SSBP3 intron 22286219 rs3766431 chr1 54730036 G A 1.60E-05 Smoking behavior SSBP3 intron 20418888 rs679200 chr1 54732940 A G 1.65E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs603901 chr1 54741767 C T 4.21E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs11206315 chr1 54743408 G A 0.00000625 Child behavior checklist/1.5-5 pervasive developmental problems SSBP3 intron 23049896 rs9326028 chr1 54750625 T C 9.68E-04 Aortic root size SSBP3 intron 21223598 rs4927081 chr1 54756342 T C 5.81E-04 Alcohol dependence SSBP3 intron 20201924 rs6678619 chr1 54762350 G A 6.85E-04 HIV-1 viral setpoint SSBP3 intron 17641165 rs4927086 chr1 54766101 T C 3.89E-04 Taste perception SSBP3 intron 22132133 rs7523947 chr1 54766816 C T 2.21E-04 Parkinson's disease SSBP3 intron 17052657 rs17390642 chr1 54768377 A G 2.00E-04 Taste perception SSBP3 intron 22132133 rs11206329 chr1 54777562 A G 6.31E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs7524749 chr1 54779243 G A 6.34E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs12021758 chr1 54787049 T C 5.96E-04 Multiple complex diseases SSBP3 intron 17554300 rs12021758 chr1 54787049 T C 1.62E-04 Gallstones SSBP3 intron 17632509 rs17110393 chr1 54790576 G A 1.10E-05 Urinary metabolites SSBP3 intron 21572414 rs12404565 chr1 54796148 T C 4.32E-04 Multiple complex diseases SSBP3 intron 17554300 rs2317387 chr1 54830569 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) SSBP3 intron 20189245 rs11206344 chr1 54852994 C A 7.49E-05 Longevity SSBP3 intron 20304771 rs6690450 chr1 54854079 C A 9.09E-05 Longevity SSBP3 intron 20304771 rs213490 chr1 54854984 G A 8.02E-05 Longevity SSBP3 intron 20304771 rs213496 chr1 54869816 T C 2.68E-04 Body mass index SSBP3 intron 21701565 rs213496 chr1 54869816 T C 3.16E-04 Body mass index SSBP3 intron 21701565 rs4244644 chr1 54883163 C T 9.65E-05 Response to citalopram treatment / / 19846067 rs4927107 chr1 54888245 A C 3.85E-05 Response to citalopram treatment / / 19846067 rs7550485 chr1 54928493 G A 9.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs190963 chr1 54946847 G A 1.70E-06 Glioma (high-grade) / / 19578366 rs4927133 chr1 54953523 T C 4.98E-05 Cognitive test performance / / 20125193 rs299895 chr1 54962448 C T 7.60E-04 Multiple complex diseases / / 17554300 rs1888182 chr1 54967890 C T 8.64E-04 Taste perception / / 22132133 rs299881 chr1 54968494 T C 3.17E-04 Taste perception / / 22132133 rs4927134 chr1 54984107 A C 0.000000041 Dependent (behavior influenced) stressful life events / / 23237013 rs4927134 chr1 54984107 A C 0.000000058 Stressful life events / / 23237013 rs11809810 chr1 55023706 A G 5.07E-09 Triglycerides ACOT11 intron 23063622 rs449484 chr1 55030530 A G 1.51E-04 Body mass index ACOT11 intron 21701565 rs449484 chr1 55030530 A G 4.97E-05 Body mass index ACOT11 intron 21701565 rs537696 chr1 55031313 C A 3.26E-04 Blood pressure ACOT11 intron 17255346 rs300280 chr1 55033869 T C 4.74E-06 Waist Circumference ACOT11 intron pha003023 rs300271 chr1 55046039 G T 5.23E-05 Waist Circumference ACOT11 intron pha003023 rs17110757 chr1 55049806 G A 7.90E-07 Glioma (high-grade) ACOT11 intron 19578366 rs1702002 chr1 55060548 C T 1.32E-04 Body mass index ACOT11 intron 21701565 rs1702002 chr1 55060548 C T 3.74E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 1.91E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 4.11E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 1.20E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 2.45E-04 Body mass index ACOT11 intron 21701565 rs17398958 chr1 55071769 G T 4.47E-05 Coronary heart disease ACOT11 intron pha003031 rs2289015 chr1 55075062 C T 1.74E-05 Response to treatment for acute lymphoblastic leukemia FAM151A missense 19176441 rs2117262 chr1 55089880 A G 8.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOT11 intron 20877124 rs10736390 chr1 55103945 A G 1.88E-05 Pancreatic cancer / / 23180869 rs1368882 chr1 55107019 G A 2.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs1368882 chr1 55107019 G A 2.10E-04 Nicotine use / / 23942779 rs1368882 chr1 55107019 G A 2.90E-04 Alcohol dependence / / 23942779 rs10888859 chr1 55117520 G A 2.00E-04 Cognitive impairment induced by topiramate HEATR8 intron 22091778 rs558184 chr1 55123936 C T 3.50E-07 Urinary metabolites HEATR8 intron 21572414 rs1529783 chr1 55129564 T C 4.62E-04 Multiple complex diseases HEATR8 intron 17554300 rs1180937 chr1 55191644 T C 8.38E-05 Prostate cancer TTC4 intron pha002878 rs61768793 chr1 55193477 A G 7.40E-11 Metabolite levels TTC4 intron 22286219 rs2873551 chr1 55217907 T C 2.60E-05 Type 2 diabetes / / 19184112 rs2108035 chr1 55218155 C T 2.41E-04 Blood pressure / / 17255346 rs2108035 chr1 55218155 C T 7.47E-04 Schizophrenia / / 19197363 rs2240396 chr1 55223190 C T 2.98E-06 Blood pressure PARS2 UTR-3 17255346 rs1180955 chr1 55225846 T C 1.22E-05 Serum metabolites PARS2 intron 19043545 rs1180948 chr1 55228159 C G 1.11E-05 Serum metabolites PARS2 intron 19043545 rs10430114 chr1 55234711 G T 1.76E-06 Blood pressure / / 17255346 rs10888879 chr1 55243590 G T 1.35E-05 Multiple complex diseases / / 17554300 rs12740946 chr1 55244197 T C 7.52E-05 Stroke / / pha002887 rs619476 chr1 55263551 T C 5.39E-04 Response to cytidine analogues (gemcitabine) TTC22 intron 24483146 rs671108 chr1 55266797 G C 5.72E-04 Response to cytidine analogues (gemcitabine) TTC22 missense 24483146 rs689322 chr1 55267509 G A 6.94E-04 Schizophrenia TTC22 nearGene-5 21674006 rs616315 chr1 55278841 G A 3.26E-04 Response to cytidine analogues (gemcitabine) C1orf177 intron 24483146 rs7549251 chr1 55304970 G A 1.80E-06 Stroke (ischemic) C1orf177 intron 22384361 rs17111100 chr1 55307693 C A 2.73E-04 Response to cytadine analogues (cytosine arabinoside) C1orf177 UTR-3 24483146 rs11206451 chr1 55311452 C T 2.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs687912 chr1 55312440 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs683737 chr1 55314142 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1138030 chr1 55317685 G A 2.16E-04 Response to cytadine analogues (cytosine arabinoside) DHCR24 UTR-3 24483146 rs642737 chr1 55333453 A G 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DHCR24 intron 20877124 rs1469344 chr1 55386167 C T 1.30E-05 Urinary metabolites / / 21572414 rs677321 chr1 55387362 C T 5.67E-04 Type 2 diabetes / / 17463246 rs678358 chr1 55387637 G T 7.04E-04 Type 2 diabetes / / 17463246 rs41517445 chr1 55389569 A G 4.47E-04 Type 2 diabetes / / 17463246 rs7522847 chr1 55394678 A G 3.42E-04 Cocaine dependence / / 23958962 rs7522847 chr1 55394678 A G 4.22E-04 Cocaine dependence / / 23958962 rs604778 chr1 55397406 T C 9.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6588538 chr1 55398277 C T 1.10E-06 Urinary metabolites / / 21572414 rs11206473 chr1 55398932 G A 9.20E-07 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 1.30E-05 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 2.11E-06 LDL cholesterol / / 23726366 rs11206476 chr1 55405850 G T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11206480 chr1 55416827 G T 1.92E-04 Cholesterol / / 17255346 rs11206482 chr1 55419855 C T 2.97E-04 Cholesterol / / 17255346 rs10218716 chr1 55425286 A G,T 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7523658 chr1 55428397 C T 2.35E-04 Cholesterol / / 17255346 rs7551937 chr1 55430634 G A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 17293876 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 19184112 rs2317948 chr1 55434443 T G 9.78E-05 Lactate dehydrogenase levels / / 20981236 rs1015979 chr1 55449273 C T 6.43E-04 Alzheimer's disease TMEM61 intron 17998437 rs13374752 chr1 55453391 A G 6.11E-06 Asthma (childhood onset) TMEM61 intron 23829686 rs2495513 chr1 55457815 C T 3.98E-05 Longevity / / 21612516 rs34561376 chr1 55464986 G A 0.0008 Prostate cancer BSND missense 23555315 rs759914 chr1 55465594 G T 6.16E-05 Atopy BSND intron 21625490 rs6682884 chr1 55474325 A C 1.00E-05 Urinary metabolites BSND UTR-3 21572414 rs4339899 chr1 55474476 C G 1.10E-05 Urinary metabolites BSND nearGene-3 21572414 rs2495505 chr1 55484810 C T 4.23E-05 Cognitive test performance / / 20125193 rs2479418 chr1 55494877 A G 5.28E-05 LDL lipoproteins / / pha002902 rs11206510 chr1 55496039 T C 4.00E-11 LDL cholesterol / / 18193043 rs11206510 chr1 55496039 T C 7.50E-06 Lipid levels / / 18193044 rs11206510 chr1 55496039 T C 4.00E-08 LDL cholesterol / / 19060906 rs11206510 chr1 55496039 T C 1.00E-08 Myocardial infarction (early onset) / / 19198609 rs11206510 chr1 55496039 T C 1.00E-10 LDL cholesterol / / 20864672 rs11206510 chr1 55496039 T C 1.00E-08 Coronary heart disease / / 21347282 rs11206510 chr1 55496039 T C 9.00E-08 Coronary heart disease / / 21378990 rs11206510 chr1 55496039 T C 2.44E-11 Metabolite levels / / 22286219 rs11206510 chr1 55496039 T C 9.10E-08 Pericardial fat / / 22589742 rs11206510 chr1 55496039 T C 1.66E-14 Cholesterol,total / / 23063622 rs11206510 chr1 55496039 T C 1.89E-15 LDL cholesterol / / 23063622 rs11206510 chr1 55496039 T C 0.00000015 LDL cholesterol / / 23100282 rs11206510 chr1 55496039 T C 0.0000076 Apolipoprotein B levels / / 23100282 rs11206510 chr1 55496039 T C 1.50E-07 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs11206510 chr1 55496039 T C 0.0000703 Coronary artery disease with myocardial infarction / / 23202125 rs11206510 chr1 55496039 T C 0.000207 Triglycerides / / 23202125 rs11206510 chr1 55496039 T C 1.55E-21 Coronary artery disease (CAD) (males) / / 23202125 rs11206510 chr1 55496039 T C 2.04E-21 Coronary artery disease (CAD) age <=50 / / 23202125 rs11206510 chr1 55496039 T C 3.54E-20 Cholesterol,total / / 23202125 rs11206510 chr1 55496039 T C 4.07E-11 Coronary artery disease (CAD) (females) / / 23202125 rs11206510 chr1 55496039 T C 5.23E-20 LDL cholesterol / / 23202125 rs11206510 chr1 55496039 T C 7.12E-41 Coronary artery disease (CAD) age >50 / / 23202125 rs11206510 chr1 55496039 T C 2.03E-04 Coronary artery disease / / 24262325 rs2479415 chr1 55498745 C T 0.0000206 Circulating PCSK9 levels / / 22460556 rs2182833 chr1 55500429 A G 2.19E-09 Cholesterol,total / / 23063622 rs2182833 chr1 55500429 A G 2.76E-09 LDL cholesterol / / 23063622 rs10788994 chr1 55500976 C T 1.06E-09 Cholesterol,total / / 23063622 rs10788994 chr1 55500976 C T 5.40E-10 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.11E-09 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.68E-09 Cholesterol,total / / 23063622 rs17111503 chr1 55503448 A G 1.86E-11 Cholesterol,total PCSK9 nearGene-5 23063622 rs17111503 chr1 55503448 A G 6.29E-11 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-28 LDL cholesterol PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 4.00E-24 Cholesterol,total PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 0.000179 Circulating PCSK9 levels PCSK9 nearGene-5 22460556 rs2479409 chr1 55504650 G A 1.03E-09 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 3.64E-09 Cholesterol,total PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-39 Cholesterol,total PCSK9 nearGene-5 24097068 rs2479409 chr1 55504650 G A 3.00E-50 LDL cholesterol PCSK9 nearGene-5 24097068 rs11591147 chr1 55505647 G T 2.00E-44 LDL cholesterol PCSK9 missense 18193044 rs11591147 chr1 55505647 G T 1.60E-07 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.80E-10 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.08E-10 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 4.95E-12 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 1.10E-09 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.15E-10 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.29E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.20E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.30E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.00E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.57E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 4.59E-12 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 5.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.00E-22 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.75E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 8.20E-18 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PCSK9 missense 20031582 rs11591147 chr1 55505647 G T 2.00E-44 Coronary heart disease PCSK9 missense 21347282 rs11591147 chr1 55505647 G T 5.00E-09 Response to statin therapy (LDL-C) PCSK9 missense 22331829 rs11591147 chr1 55505647 G T 2.05E-14 LDL cholesterol PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 2.20E-15 Circulating PCSK9 levels PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 1.73E-28 LDL cholesterol PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.74E-14 LDL cholesterol (female) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 8.15E-18 LDL cholesterol (male) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.46E-52 Cholesterol,total PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 3.11E-59 LDL cholesterol PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 0.000836 LDL cholesterol PCSK9 missense 23236364 rs2479410 chr1 55505861 G A 1.38E-10 Cholesterol,total PCSK9 intron 23063622 rs2479410 chr1 55505861 G A 3.92E-11 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 1.58E-10 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 6.41E-09 Cholesterol,total PCSK9 intron 23063622 rs499718 chr1 55512549 T C 0.000165996 Primary sclerosing cholangitis PCSK9 intron 23603763 rs2495478 chr1 55512995 G A 1.00E-07 Wilms tumor PCSK9 intron 22544364 rs28362225 chr1 55513358 C A 5.81E-09 Triglycerides PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000198 Cholesterol,total PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000253 LDL cholesterol PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 3.63E-08 Cholesterol,total PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 5.85E-08 LDL cholesterol PCSK9 intron 23063622 rs11800231 chr1 55517940 G A,T 1.02E-10 LDL cholesterol PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 0.000000108 LDL cholesterol (female) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 0.0000308 LDL cholesterol (male) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 4.65E-11 LDL cholesterol PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 2.38E-14 Cholesterol,total PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 6.85E-08 LDL cholesterol PCSK9 intron 23236364 rs2483205 chr1 55518316 C T 0.00000119 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 0.000000166 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 3.51E-09 Cholesterol,total PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 1.09E-13 LDL cholesterol PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 2.83E-13 Cholesterol,total PCSK9 intron 23063622 rs7552841 chr1 55518752 C T 7.90E-05 Coronary heart disease PCSK9 intron 21966275 rs499883 chr1 55519174 G A 1.45E-11 LDL cholesterol PCSK9 intron 22629316 rs499883 chr1 55519174 G A 1.29E-18 LDL cholesterol PCSK9 intron 23063622 rs499883 chr1 55519174 G A 7.16E-17 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 1.44E-09 LDL cholesterol PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 3.03E-12 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 0.00000742 LDL cholesterol PCSK9 intron 23236364 rs634272 chr1 55520265 T C 3.57E-10 LDL cholesterol PCSK9 intron 23063622 rs634272 chr1 55520265 T C 4.16E-11 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000133 LDL cholesterol PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000247 LDL cholesterol (male) PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000369 Total cholesterol in males PCSK9 intron 23063622 rs557435 chr1 55520864 A G 5.92E-08 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 4.34E-05 LDL lipoproteins PCSK9 intron pha002902 rs471705 chr1 55521242 T G 3.23E-14 LDL cholesterol PCSK9 intron 23063622 rs471705 chr1 55521242 T G 7.84E-16 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 0.00000124 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 2.18E-08 LDL cholesterol PCSK9 intron 23063622 rs533375 chr1 55523361 A G 0.00000111 Cholesterol,total PCSK9 intron 23063622 rs533375 chr1 55523361 A G 1.16E-08 LDL cholesterol PCSK9 intron 23063622 rs562556 chr1 55524237 G A 0.00000029 LDL cholesterol PCSK9 missense 23063622 rs565436 chr1 55524601 G A 1.17E-09 LDL cholesterol PCSK9 intron 23063622 rs565436 chr1 55524601 G A 1.32E-09 Cholesterol,total PCSK9 intron 23063622 rs483462 chr1 55525400 G A 7.99E-04 Substance dependence PCSK9 intron 21818250 rs11206517 chr1 55526428 T G 1.34E-08 LDL cholesterol PCSK9 intron 23063622 rs631220 chr1 55527479 A G 0.000000207 LDL cholesterol PCSK9 intron 23063622 rs643257 chr1 55527918 C T 0.000000359 LDL cholesterol PCSK9 intron 23063622 rs505151 chr1 55529187 G A 9.88E-10 LDL cholesterol PCSK9 missense 22629316 rs505151 chr1 55529187 G A 1.91E-10 LDL cholesterol PCSK9 missense 23236364 rs505151 chr1 55529187 G A 3.09E-09 Cholesterol,total PCSK9 missense 23236364 rs17111568 chr1 55537198 G A 1.74E-04 Multiple complex diseases USP24 intron 17554300 rs17111584 chr1 55546696 T C 5.80E-04 Response to statin therapy (LDL-C) USP24 intron 22331829 rs683880 chr1 55546895 T C 5.67E-04 Substance dependence USP24 intron 21818250 rs17111652 chr1 55590465 C T 9.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) USP24 intron 22566498 rs17111657 chr1 55591283 C A 8.89E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs17111684 chr1 55625548 C T 2.00E-17 LDL cholesterol USP24 intron 23726366 rs17111689 chr1 55627525 C G 5.07E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs1115058 chr1 55653588 C T 8.79E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs4926670 chr1 55662680 C T 3.07E-05 LDL lipoproteins USP24 intron pha002902 rs6671533 chr1 55670896 G C 3.94E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6703366 chr1 55673420 T G 6.08E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6668777 chr1 55683807 A C 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs7529366 chr1 55685344 A G 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs17111725 chr1 55686616 A G 8.95E-05 Serum metabolites / / 19043545 rs17111725 chr1 55686616 A G 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7512894 chr1 55696547 G A 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10788998 chr1 55699023 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs11206538 chr1 55715412 C T 1.13E-05 Esophageal cancer (squamous cell) / / 22960999 rs12409228 chr1 55725176 C T 0.0000692 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1018101 chr1 55725288 A G 0.0000641 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10888908 chr1 55726519 T C 1.42E-14 Metabolite levels / / 22286219 rs6662286 chr1 55730327 T C 1.46E-11 Metabolite levels / / 22286219 rs2088487 chr1 55739925 T C 1.97E-11 Metabolite levels / / 22286219 rs4927214 chr1 55742322 T C 6.59E-04 Type 2 diabetes / / 17463246 rs12239436 chr1 55742837 G A 5.00E-06 Coronary heart disease / / 21347282 rs1874774 chr1 55743297 T G 2.90E-04 Type 2 diabetes / / 17463246 rs12071742 chr1 55747825 G A 6.03E-04 Alzheimer's disease / / 22005930 rs17111834 chr1 55748606 G A 6.07E-04 Alzheimer's disease / / 22005930 rs17111847 chr1 55749478 T C 6.10E-04 Alzheimer's disease / / 22005930 rs10493202 chr1 55764106 A C 2.96E-04 Type 2 diabetes / / 17846124 rs207154 chr1 55781281 T C 1.18E-04 Blood pressure / / 17255346 rs207154 chr1 55781281 T C 1.79E-11 Metabolite levels / / 22286219 rs6676932 chr1 55785672 T C 3.20E-04 Blood pressure / / 17255346 rs17111925 chr1 55789351 G A 2.46E-05 Diabetic nephropathy / / pha002852 rs17111925 chr1 55789351 G A 6.56E-05 Diabetic nephropathy / / pha002864 rs726815 chr1 55790861 C T 3.88E-04 Blood pressure / / 17255346 rs10489488 chr1 55792722 G A 2.90E-04 Blood pressure / / 17255346 rs964219 chr1 55793244 A G 6.78E-05 Blood pressure / / 17255346 rs207167 chr1 55798859 T C 3.63E-12 Metabolite levels / / 22286219 rs207160 chr1 55803411 C T 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs207155 chr1 55804902 T C 2.40E-05 Blood pressure / / 17255346 rs207155 chr1 55804902 T C 1.28E-10 Metabolite levels / / 22286219 rs207150 chr1 55806465 T C 1.38E-05 Blood pressure / / 17255346 rs207150 chr1 55806465 T C 1.10E-06 LDL lipoproteins / / pha002902 rs207145 chr1 55808143 C T 4.68E-05 Blood pressure / / 17255346 rs207138 chr1 55811215 C T 1.84E-04 Vaspin levels / / 22907691 rs207138 chr1 55811215 C T 0.0001842 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs207136 chr1 55814164 C T 2.06E-05 Blood pressure / / 17255346 rs207136 chr1 55814164 C T 3.39E-04 Type 2 diabetes / / 17463246 rs207135 chr1 55814244 C T 2.06E-05 Blood pressure / / 17255346 rs207135 chr1 55814244 C T 4.76E-04 Type 2 diabetes / / 17463246 rs207129 chr1 55814908 A G 1.48E-10 Metabolite levels / / 22286219 rs207127 chr1 55815584 G A 2.26E-05 Blood pressure / / 17255346 rs207127 chr1 55815584 G A 3.92E-06 LDL lipoproteins / / pha002902 rs880385 chr1 55820099 T G 7.69E-04 Multiple complex diseases / / 17554300 rs2179853 chr1 55820713 A C 1.06E-05 Blood pressure / / 17255346 rs2802881 chr1 55831918 T C 6.60E-06 Blood pressure / / 17255346 rs7520205 chr1 55834309 G A 1.80E-06 Urinary metabolites / / 21572414 rs2746685 chr1 55837603 A G 6.60E-06 Blood pressure / / 17255346 rs3946077 chr1 55838572 G A 2.50E-05 Urinary metabolites / / 21572414 rs2746683 chr1 55841735 A C 3.76E-05 Blood pressure / / 17255346 rs2802877 chr1 55843810 C T 3.76E-05 Blood pressure / / 17255346 rs2802857 chr1 55863658 A G 3.00E-04 Blood pressure / / 17255346 rs761483 chr1 55874284 C T 1.42E-04 Blood pressure / / 17255346 rs6673648 chr1 55894893 C A 7.39E-05 Blood pressure / / 17255346 rs17406602 chr1 55909030 A G 3.84E-04 Sarcoidosis / / 19165924 rs12068336 chr1 55929930 G A 6.51E-05 Multiple complex diseases / / 17554300 rs11206601 chr1 55931747 T C 1.08E-04 Multiple complex diseases / / 17554300 rs874664 chr1 55933344 A G 1.58E-04 Multiple complex diseases / / 17554300 rs12568687 chr1 55934389 C T 1.58E-04 Multiple complex diseases / / 17554300 rs7532502 chr1 55938887 G A 3.22E-04 Multiple complex diseases / / 17554300 rs2649629 chr1 55953290 G A 5.48E-05 Blood pressure / / 17255346 rs1998013 chr1 55958030 C T 5.00E-13 Metabolite levels (atherosclerosis) / / 22916037 rs1780542 chr1 55963519 A G 2.09E-04 Blood pressure / / 17255346 rs1740125 chr1 55965199 C T 3.30E-04 Blood pressure / / 17255346 rs1740123 chr1 55969501 C T 3.25E-04 Blood pressure / / 17255346 rs1740118 chr1 55981250 G A 1.45E-04 Blood pressure / / 17255346 rs1695960 chr1 55983525 G A 3.27E-04 Blood pressure / / 17255346 rs356086 chr1 55994302 A G 2.85E-07 Common variable immunodeficiency / / 21497890 rs2649627 chr1 55998405 C T 4.21E-04 Blood pressure / / 17255346 rs6658576 chr1 56035952 T C 0.00039 Prostate cancer / / 23555315 rs17416739 chr1 56055848 C T 4.17E-08 Multiple complex diseases / / 17554300 rs17416739 chr1 56055848 C T 3.78E-07 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs4926690 chr1 56056400 G A 6.88E-05 Lymphocyte counts / / pha003094 rs4926690 chr1 56056400 G A 8.54E-05 Neutrophil count / / pha003095 rs10888935 chr1 56060951 T A 7.00E-07 Inflammatory biomarkers / / 22228203 rs6704127 chr1 56070382 A C 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1587432 chr1 56074120 A G 2.42E-04 Acute lung injury / / 22295056 rs1392132 chr1 56079739 T G 1.84E-04 Schizophrenia / / 20832056 rs17418151 chr1 56102010 C G 6.84E-05 Multiple sclerosis / / 17660530 rs1165472 chr1 56108604 A G 4.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs10443215 chr1 56112774 C T 9.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs72669744 chr1 56116505 C T 1.00E-19 Lipid metabolism phenotypes / / 22286219 rs17112596 chr1 56120296 C T 5.02E-20 Metabolite levels / / 22286219 rs9436520 chr1 56137245 A G 8.73E-05 Hemoglobin concentration / / 20534544 rs2767503 chr1 56152725 T G 7.09E-05 Hemoglobin concentration / / 20534544 rs12565309 chr1 56157154 G A 1.82E-04 Alzheimer's disease (late onset) / / 21379329 rs9326037 chr1 56163458 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs1183736 chr1 56183163 A C 3.76E-04 Hemoglobin concentration / / 20534544 rs11206661 chr1 56191097 C G 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs76831627 chr1 56198190 G T 6.66E-05 Acne (severe) / / 24927181 rs1165500 chr1 56219293 A C 3.59E-05 Telomere length / / 23900074 rs12061007 chr1 56233601 A G 7.54E-04 Multiple complex diseases / / 17554300 rs12061007 chr1 56233601 A G 2.84E-05 Lymphocyte counts / / 22286170 rs12092608 chr1 56240702 T C 4.81E-05 Telomere length / / 23900074 rs3122555 chr1 56263555 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6588574 chr1 56287724 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6659096 chr1 56292073 C A 4.24E-04 Multiple complex diseases / / 17554300 rs4497258 chr1 56317834 G A 9.72E-05 Bipolar disorder / / 19259986 rs9326038 chr1 56326293 G A 5.56E-06 Serum metabolites / / 19043545 rs6656739 chr1 56351783 T G 4.91E-04 Multiple complex diseases / / 17554300 rs6684428 chr1 56359813 T A 5.00E-07 Airflow obstruction / / 22837378 rs6699599 chr1 56405040 T C 7.31E-04 Smoking quantity LOC100507652 intron 24665060 rs7534660 chr1 56421196 G C 7.00E-04 Multiple complex diseases / / 17554300 rs7512875 chr1 56421399 C T 7.54E-04 Multiple complex diseases / / 17554300 rs6694316 chr1 56425121 G T 1.06E-05 Tuberculosis / / 24057671 rs2192102 chr1 56429031 C A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12409063 chr1 56432184 G A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs11206704 chr1 56444449 C T 6.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206709 chr1 56448410 T C 5.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206729 chr1 56516424 T C 1.31E-04 Aortic root size / / 21223598 rs7512228 chr1 56574395 C T 5.67E-04 Aortic root size / / 21223598 rs778126 chr1 56605334 T G 6.54E-04 Aortic root size / / 21223598 rs1537226 chr1 56615004 G T 2.49E-04 Multiple complex diseases / / 17554300 rs2792788 chr1 56740723 T C 9.08E-04 Insulin resistance / / 21901158 rs1581995 chr1 56745004 C T 1.44E-05 Leprosy / / 22019778 rs10888965 chr1 56750081 T C 5.28E-04 Insulin resistance / / 21901158 rs12118755 chr1 56750366 C T 4.62E-05 Cognitive test performance / / 20125193 rs1341347 chr1 56763781 A G 5.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005884 chr1 56771709 C T 6.41E-04 Eye color / / 23118974 rs3005885 chr1 56776172 T A 6.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994553 chr1 56785889 T G 2.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005897 chr1 56786595 C T 3.78E-04 Barrett's esophagus / / 24121790 rs12138574 chr1 56790773 C T 9.64E-06 Biliary atresia / / 20460270 rs3005907 chr1 56790785 T A 1.76E-04 Type 2 diabetes / / 17463246 rs3005914 chr1 56797754 T C 7.17E-05 Erythrocyte counts / / pha003101 rs3121168 chr1 56798123 G T 9.62E-05 Erythrocyte counts / / pha003101 rs2994565 chr1 56798308 A G 7.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994565 chr1 56798308 A G 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6670695 chr1 56799648 T A,C 0.00043318 Sarcoidosis / / 22952805 rs11206793 chr1 56802112 A T 8.66E-04 Depression (quantitative trait) / / 20800221 rs12079898 chr1 56804358 G A 7.34E-05 Depression (quantitative trait) / / 20800221 rs17113792 chr1 56829396 A G 7.88E-04 Depression (quantitative trait) / / 20800221 rs17113795 chr1 56840459 T A 7.85E-04 Depression (quantitative trait) / / 20800221 rs17113799 chr1 56844652 T C 5.47E-04 Depression (quantitative trait) / / 20800221 rs7539724 chr1 56845274 A G 5.42E-04 Depression (quantitative trait) / / 20800221 rs7538333 chr1 56848954 C T 1.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206801 chr1 56850686 C A 6.00E-08 AB1-42 levels / / 20932310 rs11206802 chr1 56851200 G A 4.72E-04 Depression (quantitative trait) / / 20800221 rs4373790 chr1 56852348 C T 4.53E-04 Depression (quantitative trait) / / 20800221 rs7521622 chr1 56869084 T A 1.48E-04 Spine bone size / / 23207799 rs1931077 chr1 56870735 T C 5.64E-04 Spine bone size / / 23207799 rs3005922 chr1 56873524 G A 5.97E-04 Smoking quantity / / 24665060 rs11206803 chr1 56877509 C T 3.12E-04 Type 2 diabetes / / 17463246 rs884277 chr1 56881763 A G 1.43E-04 Type 2 diabetes / / 17463246 rs4363444 chr1 56898998 C T 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs875153 chr1 56900270 C T 4.30E-05 Celiac disease / / 17558408 rs7550882 chr1 56903392 C T 8.33E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 9.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 1.61E-10 Tumor biomarkers / / 23300138 rs2780293 chr1 56905072 A G 1.61E-10 Type 2 diabetes / / 23300278 rs6588628 chr1 56905211 A G 4.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6421495 chr1 56905445 T A 4.09E-04 Alcohol dependence / / 21314694 rs4319365 chr1 56907720 G A 5.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6694114 chr1 56909550 G A 9.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11206814 chr1 56918048 C T 0.0000267 Aging / / 22445811 rs7525717 chr1 56927638 G A 0.00000576 Aging / / 22445811 rs17114036 chr1 56962821 A G 4.00E-19 Coronary heart disease PPAP2B intron 21378990 rs17114036 chr1 56962821 A G 3.81E-19 Pericardial fat PPAP2B intron 22589742 rs17114036 chr1 56962821 A G 0.000266 Coronary artery disease (CAD) (females) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 0.000823 Coronary artery disease (CAD) age <=50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.43E-09 Coronary artery disease (CAD) age >50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 2.16E-08 Coronary artery disease with myocardial infarction PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 5.80E-12 Coronary artery disease PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 8.07E-08 Coronary artery disease (CAD) (males) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.00E-08 Coronary artery disease PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 2.00E-08 Coronary artery disease or large artery stroke PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 3.00E-08 Coronary artery disease or ischemic stroke PPAP2B intron 24262325 rs17114046 chr1 56966350 A G 2.00E-07 Coronary heart disease PPAP2B intron 21378988 rs17114046 chr1 56966350 A G 3.00E-07 Coronary heart disease PPAP2B intron 21846871 rs17114046 chr1 56966350 A G 4.04E-06 Coronary heart disease PPAP2B intron 22319020 rs4912314 chr1 56968477 C T 2.02E-05 Sickle cell anemia (severity) PPAP2B intron 20029952 rs4912314 chr1 56968477 C T 2.90E-05 Urinary metabolites PPAP2B intron 21572414 rs1361823 chr1 56990399 G A 7.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PPAP2B intron 21844884 rs2404715 chr1 57008778 C T 3.75E-15 Coronary heart disease PPAP2B intron 21378990 rs1041602 chr1 57013198 C T 4.06E-04 Schizophrenia PPAP2B intron 19197363 rs1261411 chr1 57017739 C T 2.10E-05 Urinary metabolites PPAP2B intron 21572414 rs1777275 chr1 57032468 A C 1.10E-05 Lymphocyte counts PPAP2B intron 22286170 rs12038246 chr1 57069614 A T 3.26E-04 Multiple complex diseases / / 17554300 rs12038246 chr1 57069614 A T 5.10E-04 Coronary heart disease / / 21966275 rs2404986 chr1 57084155 T C 7.86E-04 Multiple complex diseases / / 17554300 rs2404987 chr1 57088605 T C 8.61E-05 Blood Pressure / / pha003045 rs2404987 chr1 57088605 T C 6.21E-05 Blood Pressure / / pha003047 rs10888995 chr1 57094025 T A 6.98E-04 Multiple complex diseases / / 17554300 rs10888995 chr1 57094025 T A 2.60E-05 Urinary metabolites / / 21572414 rs10889000 chr1 57100380 G A 9.96E-06 Lymphocyte counts / / 22286170 rs2746349 chr1 57126650 C T 7.80E-06 Urinary metabolites PRKAA2 intron 21572414 rs2746347 chr1 57126919 C T 4.00E-07 Lymphocyte counts PRKAA2 intron 22286170 rs2179761 chr1 57157544 G A 2.20E-05 Urinary metabolites PRKAA2 intron 21572414 rs1342382 chr1 57177388 T A 0.00007 Asthma PRKAA2 UTR-3 18401594 rs1342382 chr1 57177388 T A 2.10E-05 Urinary metabolites PRKAA2 UTR-3 21572414 rs6656021 chr1 57202872 A T 4.48E-04 Multiple complex diseases C1orf168 intron 17554300 rs6658790 chr1 57203011 T C 3.20E-04 Multiple complex diseases C1orf168 intron 17554300 rs12137718 chr1 57203226 A G 1.70E-05 Urinary metabolites C1orf168 intron 21572414 rs1156845 chr1 57209695 T C 1.99E-04 Schizophrenia C1orf168 intron 21674006 rs11206912 chr1 57211204 C G 1.70E-04 Multiple complex diseases C1orf168 intron 17554300 rs7555378 chr1 57218159 G A 6.55E-04 Multiple complex diseases C1orf168 intron 17554300 rs857107 chr1 57222599 T C 2.74E-05 Lymphocyte counts C1orf168 intron 22286170 rs17372114 chr1 57243454 T C 1.20E-05 Urinary metabolites C1orf168 intron 21572414 rs17372114 chr1 57243454 T C 5.00E-07 Resistin levels C1orf168 intron 22843503 rs1738403 chr1 57246559 G A 3.79E-04 Multiple complex diseases C1orf168 intron 17554300 rs1774825 chr1 57249558 A C 1.99E-05 Response to cholinesterase inhibitors in Alzheimer's disease C1orf168 intron 23374588 rs10889017 chr1 57259632 C G 2.70E-05 Urinary metabolites C1orf168 intron 21572414 rs6662617 chr1 57269521 A G 9.00E-06 Obesity-related traits C1orf168 intron 23251661 rs10489622 chr1 57275653 T C 8.18E-04 Alzheimer's disease C1orf168 intron 17998437 rs10489622 chr1 57275653 T C 2.45E-04 Alzheimer's disease C1orf168 intron pha002879 rs12048846 chr1 57291520 A G 4.49E-04 Type 2 diabetes / / 17463246 rs10489623 chr1 57317559 A G 7.14E-05 Major depressive disorder (broad) / / 20038947 rs1329449 chr1 57319629 G A 8.14E-05 Major depressive disorder (broad) C8A nearGene-5 20038947 rs6697767 chr1 57326073 A G 3.88E-11 LDL cholesterol C8A intron 23063622 rs7339932 chr1 57333483 G T 0.000000109 LDL cholesterol C8A intron 23063622 rs2269119 chr1 57336775 G C 9.78E-05 Major depressive disorder (broad) C8A intron 20038947 rs1885002 chr1 57340381 A G 1.71E-05 Major depressive disorder (broad) C8A intron 20038947 rs6588657 chr1 57348436 C T 5.32E-05 Lymphocyte counts C8A intron 22286170 rs6694643 chr1 57349407 A T 6.23E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697228 chr1 57349464 T C 9.14E-05 Major depressive disorder (broad) C8A intron 20038947 rs6683663 chr1 57356476 A G 5.69E-05 Major depressive disorder (broad) C8A intron 20038947 rs11206932 chr1 57362007 T A 6.27E-05 Major depressive disorder (broad) C8A intron 20038947 rs3768215 chr1 57362787 C T 6.89E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697608 chr1 57363037 G A 1.02E-15 LDL cholesterol C8A intron 23063622 rs17114548 chr1 57367041 T A 2.26E-04 Insulin resistance C8A intron 21901158 rs17114555 chr1 57373778 G A 0.00000179 LDL cholesterol C8A missense 23063622 rs17373091 chr1 57391310 C T 1.50E-05 Urinary metabolites / / 21572414 rs17301090 chr1 57391429 G C 1.50E-05 Urinary metabolites / / 21572414 rs605648 chr1 57395251 T C 8.94E-04 Alcohol dependence C8B intron 24277619 rs2025006 chr1 57396276 C T 2.10E-05 Urinary metabolites C8B intron 21572414 rs9661996 chr1 57401110 C A 4.16E-04 Alzheimer's disease (late onset) C8B intron 21379329 rs1013579 chr1 57422484 C T 5.15E-05 Glycosylated haemoglobin levels C8B missense 17255346 rs856843 chr1 57427251 C A 9.96E-04 Alcohol dependence C8B intron 21314694 rs1774909 chr1 57447740 T C 9.61E-04 Coronary Artery Disease / / 17634449 rs1774908 chr1 57447820 T C 4.50E-04 Coronary Artery Disease / / 17634449 rs11206948 chr1 57450486 T C 2.06E-22 Narcolepsy / / 19629137 rs11206955 chr1 57467935 A G 5.79E-05 Alzheimer's disease DAB1 intron 17998437 rs11206955 chr1 57467935 A G 2.19E-04 Alzheimer's disease DAB1 intron pha002879 rs12035887 chr1 57468791 G T 8.06E-05 Alzheimer's disease DAB1 intron 17998437 rs697580 chr1 57477034 G C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs1854508 chr1 57478856 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 7.02E-04 Alzheimer's disease DAB1 intron 17998437 rs11810899 chr1 57481284 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 2.01E-04 Alzheimer's disease DAB1 intron pha002879 rs6668269 chr1 57481828 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs17114816 chr1 57481883 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3754268 chr1 57484663 A G 3.75E-04 Alzheimer's disease DAB1 intron 17998437 rs3754268 chr1 57484663 A G 1.70E-05 Urinary metabolites DAB1 intron 21572414 rs706360 chr1 57490074 C T 1.30E-05 Urinary metabolites DAB1 intron 21572414 rs706361 chr1 57490333 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3768206 chr1 57498094 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs4912233 chr1 57498643 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs12118564 chr1 57500176 G C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11206964 chr1 57524101 T C 9.79E-04 Multiple complex diseases DAB1 intron 17554300 rs476744 chr1 57535630 G A 1.36E-05 Epilepsy (remission after treatment) DAB1 intron 23962720 rs534080 chr1 57584721 G A 4.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs17541203 chr1 57625932 T C 2.00E-06 Pubertal anthropometrics DAB1 intron 23449627 rs4124453 chr1 57633048 C G 0.0008539 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs4124453 chr1 57633048 C G 8.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs7533282 chr1 57633496 T G 4.19E-05 Cognitive performance DAB1 intron 19734545 rs7533282 chr1 57633496 T G 0.0008524 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs7533282 chr1 57633496 T G 8.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17115233 chr1 57636071 G A 0.0008644 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115233 chr1 57636071 G A 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs17115240 chr1 57640066 T C 0.000584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115240 chr1 57640066 T C 5.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17541479 chr1 57640721 C T 2.06E-04 Hearing function DAB1 intron 17255346 rs11810300 chr1 57654660 C T 9.01E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs1394397 chr1 57656611 A G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs480836 chr1 57662361 G A 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs17115341 chr1 57665932 C T 7.39E-04 Alcohol dependence DAB1 intron 21314694 rs197597 chr1 57683417 C T 3.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs1504584 chr1 57690336 T C 4.00E-04 Multiple complex diseases DAB1 intron 17554300 rs1504584 chr1 57690336 T C 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs1604885 chr1 57690668 C A 1.36E-04 Multiple complex diseases DAB1 intron 17554300 rs1604885 chr1 57690668 C A 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs12130571 chr1 57698001 C A 8.78E-04 Alcohol dependence DAB1 intron 21314694 rs2764664 chr1 57741163 T C 1.56E-04 Taste perception DAB1 intron 22132133 rs12057381 chr1 57769516 G A 8.44E-06 Prostate cancer DAB1 intron 24185611 rs736109 chr1 57783651 C T 3.93E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12401342 chr1 57793948 C A 4.32E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs90940 chr1 57795436 T C 1.30E-06 Non-small cell lung cancer DAB1 intron 21866343 rs267650 chr1 57795780 T C 4.94E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6587767 chr1 57800285 C T 8.24E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12061812 chr1 57802603 C A 7.19E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 4.61E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 1.64E-05 Blood Pressure DAB1 intron pha003039 rs12087888 chr1 57802759 T C 1.14E-05 Blood Pressure DAB1 intron pha003045 rs12087888 chr1 57802759 T C 6.72E-05 Blood Pressure DAB1 intron pha003047 rs11207010 chr1 57802886 G C 3.54E-07 Non-small cell lung cancer DAB1 intron 21866343 rs11207011 chr1 57803349 G A 1.57E-05 Blood Pressure DAB1 intron pha003039 rs11207011 chr1 57803349 G A 1.11E-05 Blood Pressure DAB1 intron pha003045 rs11207011 chr1 57803349 G A 6.50E-05 Blood Pressure DAB1 intron pha003047 rs10159302 chr1 57805550 A C 9.00E-06 HIV-1 control DAB1 intron 20041166 rs1077424 chr1 57810304 G C 6.50E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6687842 chr1 57815932 C A 2.66E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207016 chr1 57816224 C A 5.88E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1424467 chr1 57816489 G A 9.47E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1862925 chr1 57822311 C T 1.01E-05 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 8.18E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 6.60E-05 Blood Pressure DAB1 intron pha003039 rs10889039 chr1 57828545 C T 1.65E-05 Non-small cell lung cancer DAB1 intron 21866343 rs2216808 chr1 57837089 G A 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047073 chr1 57841631 G C 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047071 chr1 57841662 C T 3.66E-05 Blood Pressure DAB1 intron pha003039 rs2405697 chr1 57843007 G A 1.76E-05 Non-small cell lung cancer DAB1 intron 21866343 rs3909556 chr1 57846985 C T 6.55E-07 Non-small cell lung cancer DAB1 intron 21866343 rs3738552 chr1 57852513 C A,G,T 1.11E-04 Multiple complex diseases DAB1 intron 17554300 rs3861834 chr1 57854103 G A 2.83E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115722 chr1 57855219 T C 4.04E-04 Multiple complex diseases DAB1 intron 17554300 rs507466 chr1 57855425 A G 5.14E-04 Multiple complex diseases DAB1 intron 17554300 rs532926 chr1 57855876 T C 7.66E-05 Serum metabolites DAB1 intron 19043545 rs566847 chr1 57857310 T G 9.02E-04 Multiple complex diseases DAB1 intron 17554300 rs566847 chr1 57857310 T G 6.66E-05 Serum metabolites DAB1 intron 19043545 rs567773 chr1 57857390 C A 2.23E-05 Non-small cell lung cancer DAB1 intron 21866343 rs540431 chr1 57859521 G A 1.25E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207026 chr1 57860215 A T 9.61E-05 Serum metabolites DAB1 intron 19043545 rs17425189 chr1 57862949 T C 5.99E-07 Non-small cell lung cancer DAB1 intron 21866343 rs2405994 chr1 57871016 G A 8.95E-06 Non-small cell lung cancer DAB1 intron 21866343 rs11585751 chr1 57872987 G A 9.67E-06 Non-small cell lung cancer DAB1 intron 21866343 rs269042 chr1 57874048 T A 2.27E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115765 chr1 57874866 C T 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs269060 chr1 57881463 T C 0.0000865 Salmonella-induced pyroptosis DAB1 intron 22837397 rs11207036 chr1 57904853 A G 4.12E-04 Rheumatoid arthritis DAB1 intron 21452313 rs12045017 chr1 57914548 C G 6.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DAB1 intron 20031582 rs17426429 chr1 57920416 G A 9.11E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17115807 chr1 57921505 T C 1.76E-04 Height DAB1 intron 17255346 rs10493223 chr1 57934034 C T 3.03E-04 Lung function (forced vital capacity) DAB1 intron 24023788 rs10493223 chr1 57934034 C T 5.92E-05 Eosinophil counts DAB1 intron pha003088 rs2691462 chr1 57954416 C T 3.42E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1341320 chr1 57966528 G A 7.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs1341320 chr1 57966528 G A 5.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) DAB1 intron 24535457 rs1524715 chr1 58003409 A T 6.15E-04 Coronary Artery Disease DAB1 intron 17634449 rs11207058 chr1 58003804 C A 6.73E-04 Coronary Artery Disease DAB1 intron 17634449 rs1524716 chr1 58005178 A C 2.82E-04 Coronary Artery Disease DAB1 intron 17634449 rs1880443 chr1 58015312 G A 9.88E-04 Coronary Artery Disease DAB1 intron 17634449 rs12083422 chr1 58049270 C T 1.97E-21 Multiple complex diseases DAB1 intron 17554300 rs1572945 chr1 58069523 C T 7.85E-06 Blood pressure DAB1 intron 17255346 rs1935046 chr1 58075285 C T 1.39E-05 Blood pressure DAB1 intron 17255346 rs10493231 chr1 58075542 C A 1.77E-04 Blood pressure DAB1 intron 17255346 rs1524721 chr1 58079584 G A 4.56E-05 Blood pressure DAB1 intron 17255346 rs1341316 chr1 58087789 A G 8.24E-05 Type 2 diabetes and other traits DAB1 intron 19734900 rs17116134 chr1 58093163 C T 3.40E-04 Multiple complex diseases DAB1 intron 17554300 rs1539053 chr1 58099707 A G 7.09E-06 Type 2 diabetes and other traits DAB1 intron 19734900 rs1539053 chr1 58099707 A G 7.10E-06 Alzheimer's disease (late onset) DAB1 intron 21460841 rs7522826 chr1 58126517 T C 8.33E-05 Response to mTOR inhibitor (rapamycin) DAB1 intron 24009623 rs3131729 chr1 58198767 C T 9.87E-06 Kawasaki disease DAB1 intron 21221998 rs10493232 chr1 58229635 C G 7.30E-04 Type 2 diabetes DAB1 intron 17463246 rs1886140 chr1 58231158 A G 0.0000065 Asthma (exacerbation) DAB1 intron 23706709 rs2406282 chr1 58232329 T G 7.58E-04 Type 2 diabetes DAB1 intron 17463246 rs1323827 chr1 58232720 A G 8.72E-04 Type 2 diabetes DAB1 intron 17463246 rs1408141 chr1 58245641 A C 6.24E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1924268 chr1 58249119 A C 3.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1581762 chr1 58251060 A G 5.86E-05 Intelligence DAB1 intron 21826061 rs1581763 chr1 58251248 T C 3.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323835 chr1 58253042 G A 3.58E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs12565523 chr1 58256148 T G 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs12568292 chr1 58256191 C A 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1408146 chr1 58256479 T C 6.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs35738462 chr1 58256544 T C 2.00E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1323836 chr1 58256909 T G 6.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323838 chr1 58257250 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs7554147 chr1 58257587 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1886143 chr1 58258134 G T 6.57E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs7544843 chr1 58263767 G A 3.53E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs2406284 chr1 58269042 T C 6.96E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs706412 chr1 58317833 A G 4.41E-04 Parkinson's disease DAB1 intron 17052657 rs706412 chr1 58317833 A G 1.26E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs985795 chr1 58319828 T G 2.00E-06 Bulimia nervosa DAB1 intron 23568457 rs852801 chr1 58321909 G A 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852802 chr1 58323943 T C 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852806 chr1 58324779 A G 6.48E-04 Parkinson's disease DAB1 intron 17052657 rs852806 chr1 58324779 A G 1.01E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs764742 chr1 58326194 G A 6.95E-05 Obesity (extreme) DAB1 intron 21935397 rs852807 chr1 58329157 A G 9.39E-04 Parkinson's disease DAB1 intron 17052657 rs852807 chr1 58329157 A G 2.77E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs2038379 chr1 58336058 C T 1.06E-04 Mammographic density DAB1 intron 22532574 rs722187 chr1 58339643 C T 5.35E-04 Parkinson's disease DAB1 intron 17052657 rs722187 chr1 58339643 C T 1.50E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202824 chr1 58349005 T C 1.50E-05 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202834 chr1 58360111 T C 4.82E-04 Multiple complex diseases DAB1 intron 17554300 rs1022636 chr1 58360565 C G 1.50E-04 Multiple complex diseases DAB1 intron 17554300 rs1202835 chr1 58362123 C T 3.04E-04 Multiple complex diseases DAB1 intron 17554300 rs1202837 chr1 58365396 G A 4.83E-04 Multiple complex diseases DAB1 intron 17554300 rs6679454 chr1 58367236 A G 3.00E-07 Immune reponse to smallpox (secreted IL-10) DAB1 intron 22610502 rs1202849 chr1 58370098 T C 4.48E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs12118826 chr1 58373450 G A 2.49E-06 Mammographic density DAB1 intron 22532574 rs1884487 chr1 58375966 T C 7.78E-04 Smoking quantity DAB1 intron 24665060 rs12125894 chr1 58376445 T C 3.26E-06 Mammographic density DAB1 intron 22532574 rs4412616 chr1 58422760 A C 7.39E-05 Serum metabolites DAB1 intron 19043545 rs1343635 chr1 58431135 T C 8.66E-04 Schizophrenia DAB1 intron 19197363 rs1343635 chr1 58431135 T C 6.49E-05 Cognitive performance DAB1 intron 19734545 rs1343635 chr1 58431135 T C 7.70E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1187981 chr1 58441667 T C 5.05E-05 Cognitive performance DAB1 intron 19734545 rs1187984 chr1 58443065 T A,G 1.73E-05 Multiple complex diseases DAB1 intron 17554300 rs4912290 chr1 58452314 G A 5.77E-05 Antineutrophil cytoplasmic antibody-associated vasculitis DAB1 intron 22808956 rs1187995 chr1 58454436 C G 4.13E-05 Multiple complex diseases DAB1 intron 17554300 rs17434789 chr1 58457604 T C 1.72E-04 Multiple complex diseases DAB1 intron 17554300 rs17131774 chr1 58514090 A G 6.98E-05 Major depressive disorder DAB1 intron 21621269 rs2764675 chr1 58522420 T G 2.66E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17116805 chr1 58531206 C T 1.32E-04 Multiple complex diseases DAB1 intron 17554300 rs17116836 chr1 58537102 G A 1.00E-04 Prostate cancer DAB1 intron 21743057 rs3121907 chr1 58540836 T C 9.13E-04 Type 2 diabetes DAB1 intron 17463246 rs873989 chr1 58556598 T C 1.30E-04 Neuroticism DAB1 intron 17667963 rs1776184 chr1 58563007 C T 7.15E-04 Multiple complex diseases DAB1 intron 17554300 rs1213770 chr1 58571279 T C 3.12E-05 QT interval DAB1 intron 22726844 rs1342876 chr1 58578612 T C 6.56E-04 Multiple complex diseases DAB1 intron 17554300 rs558475 chr1 58601866 C A 2.28E-04 Glycosylated haemoglobin levels DAB1 intron 17255346 rs6667829 chr1 58610928 T G 2.60E-05 Urinary metabolites DAB1 intron 21572414 rs637081 chr1 58631192 G A 0.00044547 Sarcoidosis DAB1 intron 22952805 rs3905539 chr1 58651750 C T 5.33E-04 Multiple complex diseases DAB1 intron 17554300 rs1953811 chr1 58654363 C T 7.41E-04 Multiple complex diseases DAB1 intron 17554300 rs507981 chr1 58656147 T G 8.49E-05 Body Fat Distribution DAB1 intron pha003016 rs507981 chr1 58656147 T G 2.43E-05 Body Fat Distribution DAB1 intron pha003017 rs507981 chr1 58656147 T G 1.46E-05 Body Fat Distribution DAB1 intron pha003018 rs17117101 chr1 58671217 G T 2.60E-04 Multiple complex diseases DAB1 intron 17554300 rs1832489 chr1 58673515 G C 2.32E-04 Multiple complex diseases DAB1 intron 17554300 rs10889086 chr1 58673708 T C 4.14E-05 Body Fat Distribution DAB1 intron pha003017 rs10889086 chr1 58673708 T C 2.53E-05 Body Fat Distribution DAB1 intron pha003018 rs946311 chr1 58676997 G A 2.30E-05 Body Fat Distribution DAB1 intron pha003017 rs946311 chr1 58676997 G A 2.08E-05 Body Fat Distribution DAB1 intron pha003018 rs2185166 chr1 58684088 T C 2.85E-05 Body Fat Distribution DAB1 intron pha003017 rs2185166 chr1 58684088 T C 2.38E-05 Body Fat Distribution DAB1 intron pha003018 rs17117148 chr1 58693743 G C 1.05E-06 Retinopathy in non-diabetics DAB1 intron 23393555 rs574802 chr1 58730127 T C 8.11E-04 HIV-1 viral setpoint / / 17641165 rs17117233 chr1 58743154 C T 1.70E-06 Thyroid function / / 20826269 rs6668411 chr1 58746316 T C 1.42E-04 Multiple complex diseases / / 17554300 rs11576201 chr1 58756648 G A 9.00E-07 Thyroid function / / 20826269 rs527409 chr1 58757915 T C 1.00E-06 Kawasaki disease / / 21221998 rs10493251 chr1 58764081 C T 5.80E-07 Thyroid function / / 20826269 rs1924565 chr1 58779442 T G 3.55E-04 Alzheimer's disease / / 24755620 rs10493240 chr1 58784150 G T 5.62E-04 Alzheimer's disease / / 24755620 rs1213640 chr1 58794017 A C 8.20E-04 Alzheimer's disease / / 24755620 rs3861824 chr1 58807217 G A 6.29E-05 HIV(mother-to-child transmission) / / 20487506 rs6587811 chr1 58826916 G A 7.35E-04 Multiple complex diseases / / 17554300 rs4912335 chr1 58834962 C T 9.38E-04 Multiple complex diseases / / 17554300 rs6699998 chr1 58845645 G A 9.50E-04 Multiple complex diseases / / 17554300 rs17496683 chr1 58848671 G A 2.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs849492 chr1 58857598 C A 9.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs338934 chr1 58857666 A G 7.20E-04 Tourette syndrome / / 22889924 rs338934 chr1 58857666 A G 3.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs849481 chr1 58866940 G A 2.29E-04 Multiple complex diseases / / 17554300 rs3850540 chr1 58872823 G C 6.27E-04 Multiple complex diseases / / 17554300 rs849469 chr1 58894050 T C 3.30E-06 Urinary metabolites / / 21572414 rs706430 chr1 58903338 A G 8.02E-06 Cardiovascular disease / / 18179892 rs12086988 chr1 58903733 C G 6.17E-07 Lymphocyte counts / / 22286170 rs706457 chr1 58920920 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1000476 chr1 58921516 T C 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407003 chr1 58939634 G A 8.46E-05 Height / / pha003011 rs338228 chr1 58943030 G C 1.36E-04 Multiple complex diseases / / 17554300 rs2271004 chr1 58996203 T C 5.74E-04 Lymphocyte counts OMA1 intron 22286170 rs12139475 chr1 59005187 G A 4.01E-04 Multiple complex diseases OMA1 intron 17554300 rs638065 chr1 59036625 C T 8.00E-06 Word reading / / 23738518 rs6683669 chr1 59041092 G A 2.90E-05 Rheumatoid arthritis (ACPA-negative) TACSTD2 nearGene-3 24532677 rs201254365 chr1 59042425 C A 0.000000163 Prostate-specific antigen TACSTD2 missense 23555315 rs17117889 chr1 59055724 A G 2.78E-04 Depression (quantitative trait) / / 20800221 rs11579447 chr1 59100106 T G 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs232907 chr1 59102834 C A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs232905 chr1 59104500 G A 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs232904 chr1 59105260 C T 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232902 chr1 59106153 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs232899 chr1 59107652 G A 2.23E-04 Depression (quantitative trait) / / 20800221 rs232895 chr1 59108799 C T 2.47E-04 Depression (quantitative trait) / / 20800221 rs232894 chr1 59109001 T C 2.56E-04 Depression (quantitative trait) / / 20800221 rs232892 chr1 59110018 C T 2.56E-04 Depression (quantitative trait) / / 20800221 rs7527235 chr1 59110167 A C 9.57E-04 Multiple complex diseases / / 17554300 rs232891 chr1 59110502 C T 4.41E-04 Depression (quantitative trait) / / 20800221 rs232885 chr1 59112057 C A 8.53E-04 Multiple complex diseases / / 17554300 rs232885 chr1 59112057 C A 5.70E-04 Lipid traits / / 17903299 rs232885 chr1 59112057 C A 2.58E-04 Depression (quantitative trait) / / 20800221 rs232882 chr1 59113033 G A 2.60E-04 Depression (quantitative trait) / / 20800221 rs17117956 chr1 59114347 T C,G 2.58E-04 Depression (quantitative trait) / / 20800221 rs232877 chr1 59115293 A T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs232876 chr1 59115781 C T 2.52E-04 Depression (quantitative trait) / / 20800221 rs232874 chr1 59118656 T G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232871 chr1 59119072 A G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232867 chr1 59119180 A T 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232863 chr1 59119701 C A 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs232862 chr1 59119881 T C 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs232860 chr1 59120563 A G 2.93E-04 Depression (quantitative trait) MYSM1 UTR-3 20800221 rs232857 chr1 59120650 C T 3.97E-04 Suicide attempts in bipolar disorder MYSM1 UTR-3 21423239 rs232777 chr1 59125683 C T 2.80E-04 Depression (quantitative trait) MYSM1 missense 20800221 rs232778 chr1 59126616 A G 1.97E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232779 chr1 59126676 A C 5.01E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232780 chr1 59127207 T C 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs6587835 chr1 59127936 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs10430103 chr1 59128193 A C 8.66E-04 Multiple complex diseases MYSM1 intron 17554300 rs232782 chr1 59128237 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232783 chr1 59129516 G T 5.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232784 chr1 59129644 A C 9.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232786 chr1 59130229 A C 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232787 chr1 59130407 C T 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232788 chr1 59130614 C T 5.14E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232790 chr1 59131311 G T 5.13E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232794 chr1 59133024 T G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232795 chr1 59133268 A G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs675871 chr1 59136875 C T 5.05E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs513436 chr1 59137273 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs542750 chr1 59138172 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs17118097 chr1 59141365 G A 1.44E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912369 chr1 59145958 C A 6.72E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs4912372 chr1 59146221 A G 5.98E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2746083 chr1 59161678 C A 5.19E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2811893 chr1 59162148 T C 3.00E-07 Diabetic retinopathy MYSM1 intron 21310492 rs2811893 chr1 59162148 T C 2.50E-05 Urinary metabolites MYSM1 intron 21572414 rs6677560 chr1 59162793 A G 1.50E-05 Urinary metabolites MYSM1 intron 21572414 rs11207296 chr1 59165042 A C 5.67E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912202 chr1 59174026 G A 2.96E-04 Depression (quantitative trait) / / 20800221 rs11582157 chr1 59177924 A G 6.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs17264915 chr1 59180394 C A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811856 chr1 59184738 T C 1.00E-04 Prostate cancer / / 21743057 rs11583201 chr1 59186777 G A 6.04E-04 Depression (quantitative trait) / / 20800221 rs12747063 chr1 59190140 C A 7.22E-04 Depression (quantitative trait) / / 20800221 rs12405774 chr1 59191545 G A 8.91E-04 Depression (quantitative trait) / / 20800221 rs7524931 chr1 59197556 G C 8.86E-04 Depression (quantitative trait) / / 20800221 rs1323281 chr1 59201820 A T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760480 chr1 59203121 T C 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760482 chr1 59204825 T C 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1969772 chr1 59205102 G A 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12137541 chr1 59209416 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6677589 chr1 59230033 G A 1.90E-04 Lipid traits / / 17903299 rs17356414 chr1 59319508 C T 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs4601609 chr1 59325626 T C 5.00E-06 Cognitive performance LOC100131060 intron 19734545 rs6676059 chr1 59329756 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs12133457 chr1 59330763 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs17118349 chr1 59351143 C T 8.07E-04 Alcohol dependence LOC100131060 intron 20201924 rs927743 chr1 59368947 G T 1.00E-04 Schizophrenia / / 19197363 rs6699576 chr1 59422826 G T 1.19E-04 Multiple complex diseases / / 17554300 rs3949912 chr1 59423103 G A 9.17E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7543260 chr1 59435688 T C 2.35E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7543260 chr1 59435688 T C 9.78E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7537319 chr1 59443050 G A 4.03E-04 Taste perception / / 22132133 rs2985883 chr1 59464838 G A 9.89E-05 Type 2 diabetes / / 17463246 rs2716139 chr1 59471986 A C 1.57E-04 Type 2 diabetes / / 17463246 rs12031587 chr1 59472053 C T 2.66E-04 Type 2 diabetes / / 17463246 rs2716140 chr1 59472397 A C 1.37E-04 Type 2 diabetes / / 17463246 rs2716121 chr1 59474554 C T 1.63E-04 Type 2 diabetes / / 17463246 rs17464532 chr1 59483091 G C 8.17E-04 Multiple complex diseases / / 17554300 rs2716133 chr1 59483255 T A 1.28E-04 Type 2 diabetes / / 17463246 rs12030196 chr1 59483320 A C 1.98E-04 Type 2 diabetes / / 17463246 rs17118549 chr1 59484327 C T 1.40E-05 Amyotrophic lateral sclerosis / / 17671248 rs2764924 chr1 59484502 G A 9.95E-05 Type 2 diabetes / / 17463246 rs11207369 chr1 59485091 G T 2.28E-04 Type 2 diabetes / / 17463246 rs2764922 chr1 59485277 G A 1.26E-04 Type 2 diabetes / / 17463246 rs3010334 chr1 59485823 C T 1.58E-04 Type 2 diabetes / / 17463246 rs12748496 chr1 59486551 G A 2.23E-04 Type 2 diabetes / / 17463246 rs9436591 chr1 59489803 A G 2.57E-05 Fibrinogen / / 17255346 rs6587843 chr1 59540811 C T 3.21E-05 Fibrinogen / / 17255346 rs4424536 chr1 59544435 G A 1.80E-05 Fibrinogen / / 17255346 rs2989868 chr1 59553662 G A 3.72E-05 Fibrinogen / / 17255346 rs3010322 chr1 59567199 G A 5.61E-05 Prion diseases / / 22210626 rs1114505 chr1 59572316 T C 6.75E-04 Depression (quantitative trait) / / 20800221 rs6704170 chr1 59582235 G A 8.69E-05 Height / / pha003011 rs3861829 chr1 59590817 G A 2.29E-05 Cognitive test performance / / 20125193 rs11207409 chr1 59606640 G A 7.30E-04 Type 2 diabetes HSD52 intron 17463246 rs17118876 chr1 59616910 C G 0.0000149 Polycystic ovary syndrome / / 22951595 rs17118876 chr1 59616910 C G 1.49E-05 Intracranial aneurysm / / 22961961 rs474103 chr1 59619571 T G 6.42E-05 Response to hepatitis C treatment / / 19684573 rs331645 chr1 59637387 G A 3.06E-05 Response to hepatitis C treatment / / 19684573 rs17119055 chr1 59658543 G A 1.78E-04 Bipolar disorder / / 18317468 rs17119087 chr1 59669115 T C 2.47E-04 Bipolar disorder / / 18317468 rs331633 chr1 59680579 A G 2.94E-04 Insulin resistance / / 21901158 rs12402265 chr1 59690602 G A 6.67E-04 Heart Failure / / pha002884 rs6700125 chr1 59702797 T C 1.80E-05 Amyotrophic lateral sclerosis / / 17671248 rs6690993 chr1 59703982 G A 2.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs12142820 chr1 59716043 A T 5.10E-04 Alcohol dependence / / 21314694 rs835367 chr1 59762468 A G 2.00E-06 Obesity-related traits FGGY nearGene-5 23251661 rs9787234 chr1 59796808 C T 7.79E-06 Obesity-related traits FGGY intron 23251661 rs17119280 chr1 59799161 G A 7.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) FGGY intron 19875103 rs835382 chr1 59799511 A T 9.66E-04 Multiple complex diseases FGGY intron 17554300 rs835441 chr1 59823244 C T 2.38E-04 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 8.54E-05 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 2.94E-04 Multiple complex diseases FGGY intron 17554300 rs7539697 chr1 59832762 G A 6.40E-06 Obesity-related traits FGGY intron 23251661 rs835435 chr1 59844471 G A 6.88E-06 Obesity-related traits FGGY cds-synon 23251661 rs7534016 chr1 59853319 A G 5.00E-06 Obesity-related traits FGGY intron 23251661 rs11583924 chr1 59858582 G A 0.00047 Salmonella-induced pyroptosis FGGY intron 22837397 rs835425 chr1 59860544 G A 2.02E-04 IgE levels FGGY intron 17255346 rs1390694 chr1 59865755 A G 1.30E-13 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 2.00E-14 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 3.20E-23 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 5.60E-18 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs17096906 chr1 59868942 A G 5.82E-04 Multiple complex diseases FGGY intron 17554300 rs17119472 chr1 59919752 A G 5.70E-04 Multiple complex diseases FGGY intron 17554300 rs648883 chr1 59979255 C A 6.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FGGY intron 20031582 rs2798652 chr1 60007275 T C 1.54E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs11583338 chr1 60033913 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs11583825 chr1 60034402 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs4497239 chr1 60045220 A G 7.10E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs2407603 chr1 60045290 G A 5.59E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs10493267 chr1 60058706 A G 3.53E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs12745808 chr1 60068731 A G 7.63E-06 Platelet counts FGGY intron 21507922 rs12727131 chr1 60084516 G A 3.00E-06 Neutrophil count FGGY intron 21507922 rs4522023 chr1 60111987 G A 6.09E-04 Smoking quantity FGGY intron 24665060 rs10889148 chr1 60119961 T C 3.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs10889148 chr1 60119961 T C 1.12E-05 Smoking quantity FGGY intron 24665060 rs6587867 chr1 60134050 A G 1.22E-05 Smoking quantity FGGY intron 24665060 rs4072736 chr1 60142112 G C 1.99E-05 Multiple complex diseases FGGY intron 17554300 rs4357555 chr1 60161256 G A 9.52E-05 Blood pressure (response to angiotensin II receptor blocker) FGGY intron 24192120 rs11207507 chr1 60166147 G C 7.36E-04 Multiple complex diseases FGGY intron 17554300 rs6661666 chr1 60168554 A C 4.37E-05 Hodgkin's lymphoma FGGY intron 24149102 rs1933213 chr1 60183673 G T 5.00E-04 Obesity (extreme) FGGY intron 21935397 rs9436182 chr1 60185680 C A 5.37E-04 Obesity (extreme) FGGY intron 21935397 rs1890211 chr1 60198238 A T 9.05E-05 Multiple complex diseases FGGY intron 17554300 rs1890212 chr1 60198430 G A 6.28E-04 Coronary heart disease FGGY intron 21971053 rs674949 chr1 60240601 G A 2.30E-05 Urinary metabolites / / 21572414 rs9436605 chr1 60243182 T G 0.00000409 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs9436605 chr1 60243182 T G 9.65E-04 Self-reported allergy / / 23817569 rs9436188 chr1 60257931 A G 5.61E-05 Parkinson's disease / / 17052657 rs9436188 chr1 60257931 A G 1.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12057866 chr1 60272522 A G 4.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11207520 chr1 60275095 T G 2.93E-04 Parkinson's disease / / 17052657 rs11207520 chr1 60275095 T G 6.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11207520 chr1 60275095 T G 1.52E-04 Common variable immunodeficiency / / 21497890 rs3767996 chr1 60281712 A G 5.08E-04 Response to cytidine analogues (gemcitabine) HOOK1 intron 24483146 rs3767999 chr1 60289241 T G 2.48E-04 Schizophrenia HOOK1 intron 19197363 rs1155002 chr1 60373775 T C 1.11E-04 Dental caries CYP2J2 intron 21940522 rs11572245 chr1 60381437 C G 9.73E-04 Type 2 diabetes CYP2J2 intron 17463246 rs890291 chr1 60437812 C T 1.50E-05 Urinary metabolites / / 21572414 rs7411728 chr1 60446789 G A 6.30E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs642307 chr1 60460733 C A 1.87E-04 IgE levels C1orf87 intron 17255346 rs12041866 chr1 60484531 C T 7.93E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs17120013 chr1 60494107 G A 9.12E-04 Type 2 diabetes C1orf87 intron 17463246 rs17120017 chr1 60495735 G A 3.86E-04 Multiple complex diseases C1orf87 intron 17554300 rs677129 chr1 60499928 A G 6.49E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs680390 chr1 60505578 A G 4.19E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs7543186 chr1 60531017 C A 1.45E-04 Alzheimer's disease (late onset) C1orf87 intron 21379329 rs17120082 chr1 60534428 C G 1.04E-04 Hearing function C1orf87 intron 17255346 rs17120143 chr1 60559382 A G 8.66E-04 Multiple complex diseases / / 17554300 rs583848 chr1 60568038 T A 1.90E-06 Urinary metabolites / / 21572414 rs686119 chr1 60579899 A T 4.62E-04 Weight loss (gastric bypass surgery) / / 23643386 rs6677345 chr1 60581154 T C 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs684867 chr1 60586930 C A 2.70E-05 Urinary metabolites / / 21572414 rs688026 chr1 60587677 C T 1.90E-05 Urinary metabolites / / 21572414 rs634161 chr1 60589775 T C 2.17E-04 Alzheimer's disease / / 17998437 rs616637 chr1 60593303 G A 2.40E-05 Urinary metabolites / / 21572414 rs87061 chr1 60594980 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs646860 chr1 60598301 G A 6.50E-04 Volumetric brain MRI / / 17903297 rs601344 chr1 60600945 A G 2.90E-05 Glioma (high-grade) / / 19578366 rs656464 chr1 60601856 T C 5.97E-04 Multiple complex diseases / / 17554300 rs619806 chr1 60602824 A C 7.06E-04 Alzheimer's disease / / 22005930 rs671094 chr1 60602865 G C 7.04E-04 Alzheimer's disease / / 22005930 rs582695 chr1 60607442 A G 6.77E-04 Alzheimer's disease / / 22005930 rs609462 chr1 60609043 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs609462 chr1 60609043 C T 8.68E-04 Alzheimer's disease / / 22005930 rs655146 chr1 60611029 G T 3.20E-05 Glioma (high-grade) / / 19578366 rs656416 chr1 60611269 A G 7.54E-04 Alzheimer's disease / / 22005930 rs618570 chr1 60615397 G C 4.98E-06 Periodontitis (PAL4Q3) / / 24024966 rs620794 chr1 60615839 G C 4.99E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207574 chr1 60626168 A G 8.74E-04 Multiple complex diseases / / 17554300 rs922356 chr1 60631000 G A 4.68E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120284 chr1 60634158 G T 4.54E-06 Periodontitis (PAL4Q3) / / 24024966 rs12072323 chr1 60639683 G T 4.65E-06 Periodontitis (PAL4Q3) / / 24024966 rs7534167 chr1 60661493 G T 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs12125049 chr1 60667702 C T 4.20E-07 Glioma (high-grade) / / 19578366 rs7530841 chr1 60667936 A C 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs1381890 chr1 60669529 T C 4.55E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120349 chr1 60671732 G T 3.83E-06 Periodontitis (PAL4Q3) / / 24024966 rs12122772 chr1 60672543 A C 7.54E-04 Multiple complex diseases / / 17554300 rs12081932 chr1 60681873 C T 4.32E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207580 chr1 60691150 G T 4.31E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120400 chr1 60691588 G A 4.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs4529739 chr1 60704783 T C 2.69E-06 Breast cancer (survival) / / 20332263 rs12741643 chr1 60752854 A G 0.000247 Salmonella-induced pyroptosis / / 22837397 rs298171 chr1 60785950 A T 4.60E-05 Response to statin therapy / / 20339536 rs298170 chr1 60787155 A G 4.30E-05 Response to statin therapy / / 20339536 rs454776 chr1 60794707 C T 4.00E-05 Response to statin therapy / / 20339536 rs2992354 chr1 60795185 T C 4.00E-05 Response to statin therapy / / 20339536 rs390331 chr1 60800662 T C 1.60E-05 Response to statin therapy / / 20339536 rs298166 chr1 60806703 T G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs427970 chr1 60815042 C T 2.20E-05 Response to statin therapy / / 20339536 rs12137879 chr1 60815316 C T 5.41E-05 LDL lipoproteins / / pha002902 rs11585396 chr1 60817360 C A 6.19E-06 Diabetes Mellitus / / pha003059 rs17120557 chr1 60817919 T A 9.73E-04 Multiple complex diseases / / 17554300 rs298128 chr1 60848538 A G 6.50E-05 Information processing speed / / 21130836 rs298137 chr1 60855214 C T 4.82E-05 Eosinophil counts / / pha003088 rs403304 chr1 60869362 G T 6.27E-04 Smoking initiation / / 24665060 rs298157 chr1 60872291 C T 9.55E-04 Stroke / / pha002887 rs298154 chr1 60874869 C G 2.23E-04 Multiple complex diseases / / 17554300 rs298152 chr1 60875777 G A 2.79E-04 Multiple complex diseases / / 17554300 rs298151 chr1 60875812 T C 2.98E-04 Multiple complex diseases / / 17554300 rs298149 chr1 60875939 C T 2.47E-04 Multiple complex diseases / / 17554300 rs626286 chr1 60876100 C G 6.59E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 1.52E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 8.76E-05 Leukocyte Counts / / pha003091 rs298160 chr1 60879175 G A 1.63E-05 Basophils / / pha003087 rs7551363 chr1 60888999 T G 6.94E-04 Obesity (extreme) / / 21935397 rs1501227 chr1 60907394 G A 7.10E-05 Response to statin therapy / / 20339536 rs12760685 chr1 60909142 C T 5.37E-04 Smoking initiation / / 24665060 rs4915695 chr1 60962168 A G 6.10E-05 Cognitive test performance / / 20125193 rs4915695 chr1 60962168 A G 1.70E-05 Cortisol secretion,in saliva / / 21316860 rs4636500 chr1 60975806 T C 1.08E-04 Multiple complex diseases / / 17554300 rs4915697 chr1 60983285 T C 1.47E-04 Multiple complex diseases / / 17554300 rs12138423 chr1 60986573 G A 7.53E-05 Major depressive disorder / / 22472876 rs4515823 chr1 60993142 T G 3.09E-04 Multiple complex diseases / / 17554300 rs10889182 chr1 60998195 T G 1.62E-07 Bipolar disorder / / 22182935 rs10889182 chr1 60998195 T G 6.94E-05 Major depressive disorder / / 22472876 rs10889184 chr1 61006050 G A 7.33E-05 Major depressive disorder / / 22472876 rs11207633 chr1 61007182 A G 1.54E-07 Bipolar disorder / / 22182935 rs11207633 chr1 61007182 A G 4.65E-05 Major depressive disorder / / 22472876 rs10889187 chr1 61010758 G A 1.30E-07 Bipolar disorder / / 22182935 rs10889187 chr1 61010758 G A 4.44E-05 Major depressive disorder / / 22472876 rs10889189 chr1 61025026 C G 5.51E-05 Multiple complex diseases / / 17554300 rs10889189 chr1 61025026 C G 7.56E-07 Bipolar disorder / / 22182935 rs4564178 chr1 61030369 C T 6.73E-05 Body mass (lean) / / 19268274 rs1461356 chr1 61037015 G A 4.42E-07 Multiple complex diseases / / 17554300 rs12565755 chr1 61041875 T C 5.00E-08 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12565755 chr1 61041875 T C 0.000153 Salmonella-induced pyroptosis / / 22837397 rs1381171 chr1 61042598 T C 1.79E-05 Major depressive disorder / / 22472876 rs1572358 chr1 61056625 T C 1.86E-05 Major depressive disorder / / 22472876 rs2989476 chr1 61059259 G C 1.71E-07 Multiple complex diseases / / 17554300 rs2989476 chr1 61059259 G C 2.00E-06 Bipolar disorder / / 21254220 rs2989476 chr1 61059259 G C 3.00E-06 Bipolar disorder / / 21738484 rs3896178 chr1 61061996 G A 1.30E-05 Multiple complex diseases / / 17554300 rs3896178 chr1 61061996 G A 4.62E-05 Serum metabolites / / 19043545 rs3896178 chr1 61061996 G A 2.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs484743 chr1 61062474 G A 3.70E-07 Multiple complex diseases / / 17554300 rs537110 chr1 61084790 T C 7.35E-04 Schizophrenia / / 19197363 rs2987775 chr1 61087726 A G 4.89E-05 Multiple complex diseases / / 17554300 rs2447043 chr1 61087920 A G 7.36E-05 Multiple complex diseases / / 17554300 rs472913 chr1 61095558 G C 2.00E-07 Bipolar disorder / / 19416921 rs555070 chr1 61099680 G A 1.09E-05 Multiple complex diseases / / 17554300 rs1399162 chr1 61169395 A G 8.79E-04 Type 2 diabetes / / 17463246 rs10493294 chr1 61170724 G A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1514178 chr1 61205469 T C 3.01E-04 Type 2 diabetes / / 17463246 rs1514178 chr1 61205469 T C 2.00E-07 Phospholipid levels (plasma) / / 21829377 rs6650097 chr1 61264342 A G 4.66E-04 Smoking cessation / / 24665060 rs17302852 chr1 61274799 T C 9.87E-04 Coronary heart disease / / 21606135 rs1877734 chr1 61282089 G A 0.000636172 Hypertension (early onset hypertension) / / 22479346 rs648787 chr1 61296240 G A 1.11E-05 Body Mass Index / / pha003006 rs643397 chr1 61300983 A G 7.73E-04 Acute lung injury / / 22295056 rs574095 chr1 61327635 G A 2.90E-05 Urinary metabolites / / 21572414 rs12138640 chr1 61338655 G A 7.94E-04 Multiple complex diseases / / 17554300 rs12028543 chr1 61368719 G A 8.80E-04 Obesity (extreme) / / 21935397 rs575726 chr1 61369313 G A 2.70E-05 Urinary metabolites / / 21572414 rs12035256 chr1 61463825 C T 3.38E-05 Coronary heart disease / / pha003031 rs12035256 chr1 61463825 C T 9.78E-05 Coronary heart disease / / pha003056 rs1779865 chr1 61483042 T G 1.86E-05 Myopia (severe) / / 23933737 rs2173345 chr1 61485568 A C 9.59E-05 Myopia (severe) / / 23933737 rs11207695 chr1 61554927 C T 1.86E-04 Type 2 diabetes NFIA intron 17463246 rs964091 chr1 61567939 G A 1.52E-04 Type 2 diabetes NFIA intron 17463246 rs10493302 chr1 61571392 T C 2.27E-05 Type 2 diabetes NFIA intron 17463246 rs6693597 chr1 61582546 T G 7.01E-05 Parkinson's disease NFIA intron 21248740 rs12403502 chr1 61606969 T A 8.97E-05 Type 2 diabetes NFIA intron 17463246 rs2008968 chr1 61607034 C T 1.01E-04 Response to taxane treatment (placlitaxel) NFIA intron 23006423 rs334728 chr1 61609007 C T 8.60E-04 Coronary Artery Disease NFIA intron 17634449 rs334699 chr1 61620496 A G 2.00E-07 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 5.00E-12 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 6.00E-07 Thyroid hormone levels NFIA intron 23408906 rs168022 chr1 61629453 G A 8.63E-04 Rheumatoid arthritis NFIA intron 21452313 rs334716 chr1 61639503 G A 7.09E-04 Coronary Artery Disease NFIA intron 17634449 rs12086591 chr1 61647156 T G 2.53E-04 Type 2 diabetes NFIA intron 17463246 rs7552300 chr1 61688282 C T 5.82E-06 Asthma (childhood onset) NFIA intron 23829686 rs17121853 chr1 61708978 C G 5.07E-04 Prostate cancer mortality NFIA intron 20978177 rs17377428 chr1 61729721 G A 9.70E-06 Urinary metabolites NFIA intron 21572414 rs17121875 chr1 61731652 A C 7.10E-07 Urinary metabolites NFIA intron 21572414 rs437021 chr1 61738270 C T 1.00E-06 Biomarkers NFIA intron 17903293 rs41492448 chr1 61769989 T C 4.40E-04 Multiple complex diseases NFIA intron 17554300 rs2363876 chr1 61776742 C T 3.61E-04 Smoking initiation NFIA intron 24665060 rs41423747 chr1 61781106 C T 3.80E-06 Urinary metabolites NFIA intron 21572414 rs6691768 chr1 61791863 G A 1.00E-07 Celiac disease NFIA intron 20190752 rs6691941 chr1 61792008 G A 3.43E-04 Smoking initiation NFIA intron 24665060 rs11801720 chr1 61798624 A G 0.000287 Salmonella-induced pyroptosis NFIA intron 22837397 rs9436636 chr1 61812773 G A 5.30E-05 Breast cancer NFIA intron 22452962 rs41350144 chr1 61815799 A T 3.00E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 8.99E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 1.61E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs2024789 chr1 61817001 G C 2.00E-06 Bipolar disorder NFIA intron 22925353 rs7528918 chr1 61818422 A G 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs17121983 chr1 61820072 C G 4.00E-07 Bipolar disorder NFIA intron 22925353 rs7556462 chr1 61821819 T C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs7553582 chr1 61824375 C T 4.00E-06 Bipolar disorder NFIA intron 22925353 rs41453448 chr1 61824389 G A 2.00E-07 Bipolar disorder NFIA intron 22925353 rs1125777 chr1 61831890 C T 2.00E-07 Bipolar disorder NFIA intron 22925353 rs12568010 chr1 61831938 A G 2.00E-07 Bipolar disorder NFIA intron 22925353 rs10489911 chr1 61838509 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIA intron 20877124 rs17356748 chr1 61843343 C G 5.69E-04 Multiple complex diseases NFIA intron 17554300 rs2474388 chr1 61859802 G T 1.89E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs10889219 chr1 61861554 T C 8.36E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2180201 chr1 61864119 G C 2.18E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs1474872 chr1 61864231 C A 2.29E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2474384 chr1 61868766 C T 5.15E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs7535730 chr1 61871356 A G 8.06E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs9436640 chr1 61873677 T G 5.00E-18 Ventricular conduction NFIA intron 21076409 rs9436640 chr1 61873677 T G 7.44E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs6587924 chr1 61895257 C A 8.05E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 9.49E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 6.00E-18 Electrocardiographic conduction measures NFIA intron 23463857 rs12404081 chr1 61941846 A G 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281350 chr1 61949463 T G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4915748 chr1 61954169 C T 2.70E-05 Methamphetamine dependence / / 23594818 rs10889228 chr1 61958583 C T 9.94E-04 Multiple complex diseases / / 17554300 rs3890764 chr1 61961953 G A 7.61E-04 Parkinson's disease / / 16252231 rs3890764 chr1 61961953 G A 1.08E-05 Body Mass Index / / pha003009 rs3890764 chr1 61961953 G A 9.39E-05 Weight / / pha003027 rs35231142 chr1 61964427 C T 4.47E-04 Multiple complex diseases / / 17554300 rs12036419 chr1 61971449 G A 5.92E-04 Multiple complex diseases / / 17554300 rs2499516 chr1 61977297 G T 5.42E-04 Multiple complex diseases / / 17554300 rs7512200 chr1 61978694 A G 5.82E-04 Multiple complex diseases / / 17554300 rs1933299 chr1 62000281 T G 6.05E-05 Taste perception / / 22132133 rs2365269 chr1 62060213 A G 6.47E-05 Lactate dehydrogenase levels / / 20981236 rs12036661 chr1 62077191 C T 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7545391 chr1 62078347 T C 3.23E-05 Body Mass Index / / pha003014 rs12137416 chr1 62087783 C T 2.71E-04 Alzheimer's disease / / 17998437 rs1933293 chr1 62089261 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12118986 chr1 62103814 C A 4.43E-05 Height / / pha003010 rs12118986 chr1 62103814 C A 7.23E-05 Height / / pha003011 rs2886326 chr1 62111054 A G 0.0005946 Hypertension (early onset hypertension) / / 22479346 rs6681890 chr1 62114181 G A 3.94E-06 Psoriasis / / 20953190 rs10889249 chr1 62119809 T C 1.63E-04 Stroke / / pha002886 rs11207801 chr1 62126262 G A 6.91E-05 Hypertension (early onset hypertension) / / 22479346 rs6694023 chr1 62130167 A G 7.90E-05 Major depressive disorder / / 21621269 rs9783018 chr1 62135356 T C 2.52E-22 Narcolepsy / / 19629137 rs12117475 chr1 62142097 G A 9.59E-04 Alzheimer's disease / / 17998437 rs17122715 chr1 62190897 A G 5.49E-04 Multiple complex diseases TM2D1 UTR-5 17554300 rs2365498 chr1 62312654 G A 6.90E-04 Myocardial Infarction I/DL intron pha002883 rs4598521 chr1 62341157 T C 7.05E-04 Coronary Artery Disease I/DL intron 17634449 rs6685516 chr1 62342230 T C 4.80E-04 Myasthenia gravis I/DL intron 23055271 rs9326052 chr1 62356590 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) I/DL intron 20189245 rs4915788 chr1 62357407 T G 1.62E-04 Type 2 diabetes I/DL intron 17463246 rs1056513 chr1 62380298 G A 1.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 6.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 8.00E-06 Obesity-related traits I/DL missense 23251661 rs11207864 chr1 62380658 C T 6.34E-04 Iron levels I/DL intron pha002876 rs2482863 chr1 62387598 T C 9.34E-05 Response to taxane treatment (placlitaxel) I/DL intron 23006423 rs11207865 chr1 62387652 A G 3.99E-04 Myocardial Infarction I/DL intron pha002883 rs10889271 chr1 62400487 C T 1.39E-04 Type 2 diabetes I/DL intron 17463246 rs10889272 chr1 62402549 C T 1.00E-04 Alcoholism (heaviness of drinking) I/DL intron 21529783 rs11207877 chr1 62426771 C T 3.45E-04 Type 2 diabetes I/DL intron 17463246 rs7512525 chr1 62427888 C T 2.60E-04 Type 2 diabetes I/DL intron 17463246 rs1123777 chr1 62488522 T C 2.10E-05 Urinary metabolites I/DL intron 21572414 rs2499818 chr1 62489450 A G 9.32E-05 Smoking initiation I/DL intron 24665060 rs11585888 chr1 62499673 G A 3.38E-04 Alzheimer's disease I/DL intron 22005930 rs6673889 chr1 62504123 T C 3.40E-04 Alzheimer's disease I/DL intron 22005930 rs6685442 chr1 62504194 A G 7.78E-04 Alzheimer's disease I/DL intron 22005930 rs6661849 chr1 62504715 G C 4.01E-04 Alzheimer's disease I/DL intron 22005930 rs17378995 chr1 62504841 T C 6.34E-04 Alzheimer's disease I/DL intron 22005930 rs7539653 chr1 62504958 A G 4.72E-04 Alzheimer's disease I/DL intron 22005930 rs7519802 chr1 62505280 G A 4.69E-04 Alzheimer's disease I/DL intron 22005930 rs10493313 chr1 62511018 T A 5.46E-04 Alzheimer's disease I/DL intron 22005930 rs11576777 chr1 62512735 T G 5.49E-04 Alzheimer's disease I/DL intron 22005930 rs11579010 chr1 62513239 A G 8.21E-04 Alzheimer's disease I/DL intron 22005930 rs2498982 chr1 62516683 G C 8.72E-04 Response to taxane treatment (placlitaxel) I/DL missense 23006423 rs12072096 chr1 62523223 A G 8.82E-04 Alzheimer's disease I/DL intron 17998437 rs6682776 chr1 62556579 A T 6.99E-04 Alzheimer's disease I/DL intron 22005930 rs10127438 chr1 62560928 C T 9.32E-04 Multiple complex diseases I/DL intron 17554300 rs6700644 chr1 62575981 T C 7.77E-04 Alzheimer's disease I/DL intron 17998437 rs12044746 chr1 62580201 G A 1.44E-04 Multiple complex diseases I/DL intron 17554300 rs2476194 chr1 62594593 C T 5.93E-04 Myopia (pathological) I/DL cds-synon 21095009 rs11207909 chr1 62607786 G A 1.00E-04 Multiple complex diseases I/DL intron 17554300 rs17123151 chr1 62623177 G A 0.0002 Migraine I/DL intron 22678113 rs10889294 chr1 62630362 A C 2.41E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 8.14E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 9.86E-04 Alzheimer's disease / / 22005930 rs2457832 chr1 62635116 C T 6.87E-04 Multiple complex diseases / / 17554300 rs6687095 chr1 62635246 G T 8.57E-04 Alzheimer's disease / / 22005930 rs2481703 chr1 62644118 A G 7.60E-05 Cognitive test performance / / 20125193 rs2481703 chr1 62644118 A G 3.68E-04 Acute lung injury / / 22295056 rs4019803 chr1 62687104 A G 3.20E-05 Cognitive test performance / / 20125193 rs2067994 chr1 62708339 A G 8.39E-05 Cognitive performance KANK4 intron 19734545 rs958802 chr1 62723566 C T 1.45E-04 Celiac disease KANK4 intron 23936387 rs17123303 chr1 62733826 T C 8.27E-04 Body mass index KANK4 intron 21701565 rs12038843 chr1 62736841 A G 4.90E-04 Alzheimer's disease (late onset) KANK4 intron 21379329 rs17123324 chr1 62741296 G A 4.07E-04 Suicide attempts in bipolar disorder KANK4 intron 21041247 rs765691 chr1 62759848 T A 8.25E-05 Serum metabolites KANK4 intron 19043545 rs2765265 chr1 62761379 C T 5.82E-04 Multiple complex diseases KANK4 intron 17554300 rs201504584 chr1 62761907 CAGAGT C 1.72E-05 Waist Circumference KANK4 intron pha003023 rs6704270 chr1 62761907 C A 1.72E-05 Waist Circumference KANK4 intron pha003023 rs2182241 chr1 62805139 G C 2.10E-04 Multiple complex diseases / / 17554300 rs6675459 chr1 62818217 T C 7.82E-04 Insulin resistance / / 21901158 rs997532 chr1 62842677 G A 5.57E-04 White matter integrity / / 22425255 rs3949904 chr1 62848090 G A 8.50E-05 Celiac disease / / 17558408 rs3949904 chr1 62848090 G A 1.20E-05 Urinary metabolites / / 21572414 rs3949904 chr1 62848090 G A 7.22E-05 Tunica Media / / pha003036 rs7523497 chr1 62853146 A G 6.76E-08 Non-obstructive azoospermia / / 22197933 rs7523622 chr1 62890510 C A 8.62E-04 Alcohol dependence / / 21314694 rs10493324 chr1 62898142 C T 0.00045776 Sarcoidosis / / 22952805 rs626787 chr1 62901243 C G 4.41E-05 Multiple complex diseases / / 17554300 rs626787 chr1 62901243 C G 6.01E-12 Metabolite levels / / 22286219 rs631106 chr1 62901807 C A 4.67E-12 Metabolite levels / / 22286219 rs9436221 chr1 62903359 T C 1.47E-11 Metabolite levels USP1 intron 22286219 rs9436222 chr1 62903363 C G 1.48E-11 Metabolite levels USP1 intron 22286219 rs9436223 chr1 62903547 C T 1.60E-11 Metabolite levels USP1 intron 22286219 rs12029068 chr1 62904295 C T 5.69E-12 Metabolite levels USP1 intron 22286219 rs9436661 chr1 62904575 T G 9.09E-11 Metabolite levels USP1 intron 22286219 rs10493322 chr1 62905893 C T 8.40E-12 Metabolite levels USP1 intron 22286219 rs638714 chr1 62906489 G T 8.44E-12 Metabolite levels USP1 intron 22286219 rs638305 chr1 62906537 G T 8.46E-12 Metabolite levels USP1 intron 22286219 rs637723 chr1 62906728 C T 6.25E-12 Metabolite levels USP1 intron 22286219 rs656297 chr1 62907595 A G 5.90E-12 Metabolite levels USP1 intron 22286219 rs642845 chr1 62908235 T C 8.35E-12 Metabolite levels USP1 intron 22286219 rs641540 chr1 62908538 A G 8.35E-12 Metabolite levels USP1 intron 22286219 rs598253 chr1 62911341 T C 8.45E-12 Metabolite levels USP1 intron 22286219 rs11207969 chr1 62911751 A G 5.65E-12 Metabolite levels USP1 intron 22286219 rs659656 chr1 62912120 C G 8.46E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 4.91E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 9.00E-06 Lipid traits USP1 intron 24386095 rs783291 chr1 62914978 G A 2.97E-11 Metabolite levels USP1 intron 22286219 rs11207970 chr1 62915473 C T 8.34E-12 Metabolite levels USP1 intron 22286219 rs583609 chr1 62916796 T C 5.80E-12 Metabolite levels USP1 UTR-3 22286219 rs583609 chr1 62916796 T C 3.23E-08 Cholesterol,total USP1 UTR-3 23063622 rs597470 chr1 62917796 T G 1.46E-11 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 8.35E-12 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 4.25E-08 Cholesterol,total / / 23063622 rs597076 chr1 62917865 T A 1.44E-11 Metabolite levels / / 22286219 rs630144 chr1 62918864 A G 8.36E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 7.74E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 5.00E-07 Lipid traits / / 24386095 rs636497 chr1 62920029 A G 8.36E-12 Metabolite levels / / 22286219 rs624660 chr1 62920388 C A 5.64E-12 Metabolite levels / / 22286219 rs634341 chr1 62921422 T C 8.46E-12 Metabolite levels DOCK7 intron 22286219 rs3913007 chr1 62921586 T C 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs4350231 chr1 62922660 G A 1.40E-12 Metabolite levels DOCK7 intron 22286219 rs12023489 chr1 62923858 G A 1.63E-12 Metabolite levels DOCK7 intron 22286219 rs12037659 chr1 62923863 C T 8.47E-12 Metabolite levels DOCK7 intron 22286219 rs1305520 chr1 62926057 A T 2.08E-12 Metabolite levels DOCK7 intron 22286219 rs1167996 chr1 62927797 T G 1.58E-11 Metabolite levels DOCK7 intron 22286219 rs998403 chr1 62928549 G A 3.96E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.30E-06 Lipid levels DOCK7 intron 18193043 rs1167998 chr1 62931632 C A 2.00E-12 Triglycerides DOCK7 intron 19060911 rs1167998 chr1 62931632 C A 4.10E-09 Lipid levels DOCK7 intron 19936222 rs1167998 chr1 62931632 C A 2.21E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.20E-27 Cholesterol,total DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.49E-27 Triglycerides DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.78E-16 Triglycerides in males DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 6.86E-09 LDL cholesterol DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 8.48E-10 Triglycerides in females DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.71E-06 Triglycerides DOCK7 intron pha003081 rs1167998 chr1 62931632 C A 8.52E-06 Lipid levels DOCK7 intron pha003082 rs1168002 chr1 62934308 A G 3.72E-12 Metabolite levels DOCK7 intron 22286219 rs1007205 chr1 62936912 T C 1.13E-10 Metabolite levels DOCK7 intron 22286219 rs10889330 chr1 62939466 G C 8.38E-12 Metabolite levels DOCK7 intron 22286219 rs1979722 chr1 62940097 G A 3.65E-12 Metabolite levels DOCK7 intron 22286219 rs10889331 chr1 62943007 G T 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168009 chr1 62943954 G A 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168010 chr1 62943979 G A 9.31E-11 Metabolite levels DOCK7 intron 22286219 rs1183260 chr1 62945418 A G 3.25E-11 Metabolite levels DOCK7 intron 22286219 rs6587976 chr1 62945631 C T 8.30E-12 Metabolite levels DOCK7 intron 22286219 rs1305521 chr1 62949034 A G 1.99E-11 Metabolite levels DOCK7 intron 22286219 rs11207974 chr1 62949960 T C 1.95E-11 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 6.05E-12 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 8.00E-15 Metabolite levels (atherosclerosis) DOCK7 intron 22916037 rs10493326 chr1 62953373 G A 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK7 intron 20877124 rs1690761 chr1 62955862 C T 1.28E-11 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.55E-12 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.85E-06 Triglycerides DOCK7 intron pha003081 rs10889333 chr1 62957030 G A 9.52E-06 Lipid levels DOCK7 intron pha003082 rs10889334 chr1 62957199 C G 5.73E-12 Metabolite levels DOCK7 intron 22286219 rs10789112 chr1 62957758 T C 5.80E-12 Metabolite levels DOCK7 intron 22286219 rs10889335 chr1 62960101 A G 3.45E-13 Metabolite levels DOCK7 cds-synon 22286219 rs1168041 chr1 62960250 T C 1.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168040 chr1 62960575 T C 1.96E-12 Metabolite levels DOCK7 intron 22286219 rs1168036 chr1 62962734 A G 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs1002687 chr1 62963737 G A 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168034 chr1 62963914 G C 6.42E-11 Metabolite levels DOCK7 intron 22286219 rs35529421 chr1 62965621 T A,G 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168032 chr1 62967747 A G 1.84E-12 Metabolite levels DOCK7 intron 22286219 rs1168031 chr1 62967987 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168030 chr1 62968491 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168029 chr1 62969402 G A 3.00E-13 Lipid metabolism phenotypes DOCK7 intron 22286219 rs1168028 chr1 62969431 G A 7.37E-12 Metabolite levels DOCK7 intron 22286219 rs1168027 chr1 62970184 T C 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168026 chr1 62970996 T C 8.47E-13 Metabolite levels DOCK7 intron 22286219 rs1184865 chr1 62973795 A G 6.12E-13 Metabolite levels DOCK7 intron 22286219 rs1168042 chr1 62974150 A T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207976 chr1 62976751 G A 7.36E-12 Metabolite levels DOCK7 intron 22286219 rs11207977 chr1 62977307 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs1781212 chr1 62977419 G A 1.30E-12 Metabolite levels DOCK7 intron 22286219 rs1168044 chr1 62977558 A C 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs10889336 chr1 62980410 T C 5.73E-13 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 2.24E-12 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 5.31E-06 Triglycerides DOCK7 intron pha003081 rs10889337 chr1 62980607 G A 8.43E-06 Lipid levels DOCK7 intron pha003082 rs12090886 chr1 62981440 G A 3.97E-11 Metabolite levels DOCK7 intron 22286219 rs12090886 chr1 62981440 G A 2.42E-08 Cholesterol,total DOCK7 intron 23063622 rs1168045 chr1 62982891 C A,T 7.62E-12 Metabolite levels DOCK7 intron 22286219 rs1168045 chr1 62982891 C A,T 2.64E-08 Cholesterol,total DOCK7 intron 23063622 rs11207979 chr1 62982994 G A 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 1.86E-08 Cholesterol,total DOCK7 intron 23063622 rs1168047 chr1 62983751 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168047 chr1 62983751 C T 2.15E-08 Cholesterol,total DOCK7 intron 23063622 rs10889338 chr1 62984897 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889338 chr1 62984897 C T 1.45E-08 Cholesterol,total DOCK7 intron 23063622 rs1168050 chr1 62986955 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168050 chr1 62986955 C T 2.66E-08 Cholesterol,total DOCK7 intron 23063622 rs1690766 chr1 62987289 T C 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1781195 chr1 62988972 T C 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1627591 chr1 62989807 C T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11577840 chr1 62991369 T C 2.68E-12 Metabolite levels DOCK7 intron 22286219 rs12062275 chr1 62991905 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207980 chr1 62992749 T C 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs12403207 chr1 62993620 T C 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs1168015 chr1 62996046 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168013 chr1 62996838 C G 5.27E-04 Type 2 diabetes DOCK7 intron 17463246 rs1168013 chr1 62996838 C G 6.00E-08 Triglycerides DOCK7 intron 20864672 rs1168013 chr1 62996838 C G 5.87E-12 Metabolite levels DOCK7 intron 22286219 rs4915840 chr1 62999595 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11327850 chr1 62999675 CT C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs7534572 chr1 62999675 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168018 chr1 63001120 A C 2.04E-11 Metabolite levels DOCK7 intron 22286219 rs1168017 chr1 63002551 A G 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs7548877 chr1 63005950 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207981 chr1 63006087 C A 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168023 chr1 63006595 A T 5.62E-12 Metabolite levels DOCK7 intron 22286219 rs1781221 chr1 63006842 A C 5.96E-12 Metabolite levels DOCK7 intron 22286219 rs11207982 chr1 63007182 C T 3.90E-12 Metabolite levels DOCK7 intron 22286219 rs1184547 chr1 63007228 G A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168022 chr1 63007721 A T 5.63E-12 Metabolite levels DOCK7 intron 22286219 rs1168021 chr1 63009900 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1168020 chr1 63009956 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1179765 chr1 63010110 G C 5.65E-12 Metabolite levels DOCK7 intron 22286219 rs12074528 chr1 63010871 T C 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889339 chr1 63012056 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889340 chr1 63012071 A C 4.07E-12 Metabolite levels DOCK7 intron 22286219 rs11207983 chr1 63012107 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs2029763 chr1 63013134 A G 5.38E-12 Metabolite levels DOCK7 intron 22286219 rs11207984 chr1 63013396 C T 5.98E-12 Metabolite levels DOCK7 intron 22286219 rs11207985 chr1 63013786 A G 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10789113 chr1 63015199 A T 3.92E-12 Metabolite levels DOCK7 intron 22286219 rs11207986 chr1 63018170 T C 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10159255 chr1 63020816 C A 5.27E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-18 LDL cholesterol DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 5.00E-41 Cholesterol,total DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 9.00E-43 Triglycerides DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-32 LDL cholesterol DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 3.00E-74 Triglycerides DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 4.00E-80 Cholesterol,total DOCK7 intron 24097068 rs2131926 chr1 63026011 C T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs10889343 chr1 63026429 T G 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs4329540 chr1 63027024 C T 3.29E-12 Metabolite levels DOCK7 intron 22286219 rs10889344 chr1 63033941 T C 6.14E-12 Metabolite levels DOCK7 intron 22286219 rs10789114 chr1 63034222 T C 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs7555577 chr1 63034363 A C 6.27E-12 Metabolite levels DOCK7 intron 22286219 rs12116574 chr1 63037837 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs6696502 chr1 63039533 C T 2.42E-12 Metabolite levels DOCK7 intron 22286219 rs12038768 chr1 63040728 G T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207990 chr1 63041086 T C 6.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207992 chr1 63041800 T G 4.15E-12 Metabolite levels DOCK7 intron 22286219 rs1472257 chr1 63042126 A G 5.17E-12 Metabolite levels DOCK7 intron 22286219 rs10789116 chr1 63042738 A G 4.00E-12 Metabolite levels DOCK7 intron 22286219 rs11207993 chr1 63044464 C T 5.70E-04 Lipid levels DOCK7 intron 19802338 rs11207993 chr1 63044464 C T 6.10E-05 Cognitive test performance DOCK7 intron 20125193 rs1748201 chr1 63045506 A C 2.56E-11 Metabolite levels DOCK7 intron 22286219 rs1748200 chr1 63046039 T C 6.24E-12 Metabolite levels DOCK7 intron 22286219 rs1629122 chr1 63046578 C A 6.26E-12 Metabolite levels DOCK7 intron 22286219 rs9436224 chr1 63048275 A C 4.26E-11 Metabolite levels DOCK7 intron 22286219 rs34465969 chr1 63048276 A C 8.93E-12 Metabolite levels DOCK7 intron 22286219 rs35194512 chr1 63048277 A C 4.14E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 5.02E-04 Type 2 diabetes DOCK7 intron 17463246 rs11207995 chr1 63049551 A C 3.86E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 6.00E-10 Lipid traits DOCK7 intron 24386095 rs1748195 chr1 63049593 C G 9.24E-04 Type 2 diabetes DOCK7 intron 17463246 rs1748195 chr1 63049593 C G 2.00E-10 Triglycerides DOCK7 intron 18193043 rs1748195 chr1 63049593 C G 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs1748195 chr1 63049593 C G 1.27E-13 Cholesterol,total DOCK7 intron 23063622 rs1748195 chr1 63049593 C G 3.08E-13 Triglycerides DOCK7 intron 23063622 rs12042319 chr1 63049819 G A 5.15E-04 Type 2 diabetes DOCK7 intron 17463246 rs12042319 chr1 63049819 G A 3.24E-07 Cardiovascular disease DOCK7 intron 18179892 rs12042319 chr1 63049819 G A 5.85E-12 Metabolite levels DOCK7 intron 22286219 rs3850634 chr1 63050598 T G 3.93E-12 Metabolite levels DOCK7 intron 22286219 rs12048208 chr1 63055280 G A 0.00000003 Triglycerides DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 2.05E-09 Cholesterol,total DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 9.52E-05 LDL lipoproteins DOCK7 intron pha002902 rs11207996 chr1 63055470 G A 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 0.000000623 Triglycerides DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.0000821 Triglycerides (males) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.000551 Triglycerides (females) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 1.10E-09 LDL cholesterol DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 1.79E-28 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 5.47E-23 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 6.75E-29 Cholesterol,total DOCK7 intron 23063622 rs2366636 chr1 63056670 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748199 chr1 63057136 T C 3.36E-12 Metabolite levels DOCK7 intron 22286219 rs6690733 chr1 63060311 A C 5.66E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 8.91E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 1.03E-10 LDL cholesterol DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 4.27E-24 Triglycerides DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 6.33E-29 Cholesterol,total DOCK7 intron 23063622 rs17123725 chr1 63063830 T C 0.00000118 Triglycerides ANGPTL3 intron 23063622 rs17123725 chr1 63063830 T C 4.04E-08 LDL cholesterol ANGPTL3 intron 23063622 rs10789117 chr1 63072265 A C 6.37E-12 Metabolite levels DOCK7 intron 22286219 rs10789117 chr1 63072265 A C 0.00000021 LDL cholesterol (female) DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.04E-09 LDL cholesterol DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.87E-23 Triglycerides DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 8.71E-29 Cholesterol,total DOCK7 intron 23063622 rs6675401 chr1 63073975 C T 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs6678483 chr1 63074442 C A 6.42E-12 Metabolite levels DOCK7 intron 22286219 rs10889347 chr1 63075826 G A 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889348 chr1 63078222 A T 8.08E-13 Metabolite levels DOCK7 intron 22286219 rs10889349 chr1 63081919 A G 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs61471917 chr1 63084030 G A 4.28E-12 Metabolite levels DOCK7 intron 22286219 rs10889350 chr1 63085266 C T 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs12239736 chr1 63085997 T A 3.74E-11 Metabolite levels DOCK7 intron 22286219 rs6587980 chr1 63090858 C T 6.91E-12 Metabolite levels DOCK7 intron 22286219 rs10157265 chr1 63093617 C T 4.34E-12 Metabolite levels DOCK7 intron 22286219 rs11485618 chr1 63094207 A G 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789118 chr1 63094692 A G 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs7520810 chr1 63095711 C T 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789119 chr1 63098235 G A 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs10889352 chr1 63099023 T C 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs2366638 chr1 63099577 G A 4.33E-12 Metabolite levels DOCK7 intron 22286219 rs1570694 chr1 63103217 A G 4.12E-12 Metabolite levels DOCK7 intron 22286219 rs12047226 chr1 63105538 T C 4.17E-12 Metabolite levels DOCK7 intron 22286219 rs7539035 chr1 63106767 C A 5.47E-04 Type 2 diabetes DOCK7 intron 17463246 rs7539035 chr1 63106767 C A 4.54E-06 Lymphocyte counts DOCK7 intron 22286170 rs7539035 chr1 63106767 C A 6.69E-12 Metabolite levels DOCK7 intron 22286219 rs995000 chr1 63107526 C T 5.40E-04 Type 2 diabetes DOCK7 intron 17463246 rs995000 chr1 63107526 C T 1.91E-11 Metabolite levels DOCK7 intron 22286219 rs11208000 chr1 63108374 A G 5.01E-12 Metabolite levels DOCK7 intron 22286219 rs993013 chr1 63111069 G T 1.27E-11 Metabolite levels DOCK7 intron 22286219 rs1168085 chr1 63112320 C G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1168086 chr1 63112389 A G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs746735 chr1 63113511 C A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168089 chr1 63113719 T C 2.34E-11 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 4.36E-04 Type 2 diabetes DOCK7 intron 17463246 rs10889353 chr1 63118196 A C 3.00E-07 Triglycerides DOCK7 intron 19060906 rs10889353 chr1 63118196 A C 4.00E-12 Cholesterol,total DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 8.00E-06 LDL cholesterol DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 1.40E-04 Lipid levels DOCK7 intron 19802338 rs10889353 chr1 63118196 A C 1.19E-13 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.30E-14 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.40E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.60E-11 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 2.77E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 3.00E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 7.30E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.96E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 2.00E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 8.00E-06 Coronary heart disease DOCK7 intron 21347282 rs10889353 chr1 63118196 A C 4.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 1.41E-08 Cholesterol,total DOCK7 intron 23063622 rs10889353 chr1 63118196 A C 9.39E-10 Lipid traits DOCK7 intron 24386095 rs10889353 chr1 63118196 A C 4.07E-05 LDL lipoproteins DOCK7 intron pha002902 rs10889353 chr1 63118196 A C 4.05E-06 Triglycerides DOCK7 intron pha003081 rs10889353 chr1 63118196 A C 8.46E-06 Lipid levels DOCK7 intron pha003082 rs1168097 chr1 63120371 C T 4.27E-12 Metabolite levels DOCK7 intron 22286219 rs1168097 chr1 63120371 C T 2.34E-08 Cholesterol,total DOCK7 intron 23063622 rs1168098 chr1 63121294 G A 4.25E-12 Metabolite levels DOCK7 intron 22286219 rs1168099 chr1 63122859 C A 2.11E-11 Metabolite levels DOCK7 intron 22286219 rs4495740 chr1 63124465 T G 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs1168102 chr1 63127705 C T 5.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168103 chr1 63128081 C T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs10889354 chr1 63129082 T C 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs11208001 chr1 63130431 C T 4.46E-12 Metabolite levels DOCK7 intron 22286219 rs2479464 chr1 63130991 G A 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs1168132 chr1 63133468 T A 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 3.50E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 4.77E-06 Triglycerides DOCK7 intron pha003081 rs4587594 chr1 63133930 G A 9.92E-06 Lipid levels DOCK7 intron pha003082 rs1168124 chr1 63139730 C T 4.61E-12 Metabolite levels DOCK7 intron 22286219 rs11208004 chr1 63145439 G A 3.43E-12 Metabolite levels DOCK7 intron 22286219 rs10889356 chr1 63155349 G A 1.00E-10 Metabolite levels / / 22286219 rs1168114 chr1 63156043 A G 2.26E-11 Metabolite levels / / 22286219 rs12136083 chr1 63163073 T C 1.33E-11 Metabolite levels / / 22286219 rs2182866 chr1 63163591 G A,C,T 4.94E-04 Multiple complex diseases / / 17554300 rs880694 chr1 63173284 C T 3.29E-06 Triglycerides / / pha003081 rs880694 chr1 63173284 C T 1.07E-05 Lipid levels / / pha003082 rs4409689 chr1 63177365 C T 3.29E-06 Triglycerides / / pha003081 rs4409689 chr1 63177365 C T 1.07E-05 Lipid levels / / pha003082 rs7518497 chr1 63177696 A C 1.42E-11 Metabolite levels / / 22286219 rs9787151 chr1 63179138 C T 3.29E-06 Triglycerides / / pha003081 rs9787151 chr1 63179138 C T 1.07E-05 Lipid levels / / pha003082 rs4915849 chr1 63180740 G A 4.95E-04 Multiple complex diseases / / 17554300 rs12130333 chr1 63191777 C T 6.34E-04 Type 2 diabetes / / 17463246 rs12130333 chr1 63191777 C T 2.00E-08 Triglycerides / / 18193044 rs12130333 chr1 63191777 C T 2.25E-11 Triglycerides / / 23063622 rs12130333 chr1 63191777 C T 4.78E-16 Cholesterol,total / / 23063622 rs6679002 chr1 63199936 G T 2.00E-15 Blood metabolite levels / / 24816252 rs17316337 chr1 63268989 A G 0.000668 fMRI brain tests in schizophrenia ATG4C intron 22440650 rs6683832 chr1 63276904 G A 5.60E-05 Blood Phenotypes ATG4C intron 17903294 rs11582138 chr1 63277459 A G 4.12E-04 Lung function (forced expiratory volume in 1 second) ATG4C intron 17255346 rs12042640 chr1 63366796 T C 1.71E-06 Aging (time to event) / / 21782286 rs56337244 chr1 63368615 C T 7.99E-11 Metabolite levels / / 22286219 rs200589189 chr1 63384292 T TG 1.43E-04 Alcohol dependence / / 21314694 rs7556152 chr1 63384292 T G 1.43E-04 Alcohol dependence / / 21314694 rs13376351 chr1 63389782 G A 8.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780882 chr1 63405427 C A 8.57E-05 Information processing speed / / 21130836 rs2780883 chr1 63410619 A G 2.00E-04 Information processing speed / / 21130836 rs4915858 chr1 63411308 A G 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-04 Breast cancer (survival) / / 22232737 rs2065585 chr1 63414401 G A 9.10E-06 Urinary metabolites / / 21572414 rs12121455 chr1 63433037 C T 8.79E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2150031 chr1 63441761 A G 6.43E-05 Elbow pain / / pha003008 rs6696619 chr1 63452789 T C 1.89E-04 Premature ovarian failure / / 19508998 rs17124192 chr1 63456797 A G 5.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17124200 chr1 63459814 G A 1.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3818637 chr1 63466655 A G 6.14E-06 Hemoglobin concentration / / 20534544 rs17124237 chr1 63470187 A C 4.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs7541201 chr1 63478358 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs12143251 chr1 63478914 C G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs12038327 chr1 63480004 T C 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2026786 chr1 63480641 T A,G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17124318 chr1 63480730 C G,T 4.00E-06 Weight / / 20966902 rs17124318 chr1 63480730 C G,T 6.00E-07 Body mass index / / 20966902 rs17124399 chr1 63489983 C T 1.18E-05 Hemoglobin concentration / / 20534544 rs944188 chr1 63492959 C A 2.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs944188 chr1 63492959 C A 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 6.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6664042 chr1 63501851 C T 4.58E-05 Waist Circumference / / pha003023 rs7519367 chr1 63502030 G A 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6694848 chr1 63503606 A G 7.95E-04 Multiple complex diseases / / 17554300 rs6694848 chr1 63503606 A G 7.19E-06 Waist Circumference / / pha003023 rs1874930 chr1 63507395 A C 3.10E-04 Hemoglobin concentration / / 20534544 rs881939 chr1 63517230 T C 4.60E-05 Response to TNF antagonist treatment / / 21061259 rs11208115 chr1 63521755 T C 3.10E-04 Hemoglobin concentration / / 20534544 rs17124480 chr1 63529093 A G 2.52E-05 Response to TNF antagonist treatment / / 21061259 rs12039756 chr1 63536774 T C 7.11E-04 Response to TNF antagonist treatment / / 21061259 rs11808494 chr1 63545178 A G 4.55E-04 Alzheimer's disease (late onset) / / 21379329 rs953654 chr1 63549282 C T 5.91E-06 Kawasaki disease / / 21221998 rs6673535 chr1 63562762 C T 6.58E-05 Multiple complex diseases / / 17554300 rs1498942 chr1 63566915 C T 2.43E-04 Gallstones / / 17632509 rs10493340 chr1 63591129 A G 2.00E-06 Blood pressure / / 17903302 rs6692500 chr1 63603161 C T 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887808 chr1 63614961 G A 4.62E-06 Stroke (ischemic) / / 22941190 rs6588016 chr1 63638791 G A 0.0000126 Tuberculosis with late age of onset LINC00466 intron 22551897 rs7554824 chr1 63641989 C A 6.44E-05 Obesity (extreme) LINC00466 intron 21935397 rs7515372 chr1 63643251 C A 6.39E-05 Obesity (extreme) LINC00466 intron 21935397 rs11208148 chr1 63645215 A C 3.60E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs4253945 chr1 63655914 C T 6.11E-04 Obesity (extreme) LINC00466 intron 21935397 rs12724092 chr1 63657649 C G 6.05E-04 Obesity (extreme) LINC00466 intron 21935397 rs1328589 chr1 63674914 T G 6.50E-05 Asthma LINC00466 intron 20159242 rs997791 chr1 63694517 G A 5.79E-05 Smoking initiation LINC00466 intron 24665060 rs12240186 chr1 63697711 A G 5.19E-05 Smoking initiation LINC00466 intron 24665060 rs1328586 chr1 63698424 T C 1.00E-04 Smoking initiation LINC00466 intron 24665060 rs1854335 chr1 63703330 C A 4.16E-04 Multiple complex diseases LINC00466 intron 17554300 rs10493343 chr1 63713524 C A 1.37E-05 Asthma LINC00466 intron 20159242 rs10493343 chr1 63713524 C A 5.12E-05 Smoking initiation LINC00466 intron 24665060 rs4915889 chr1 63719825 A G 2.61E-05 Smoking initiation LINC00466 intron 24665060 rs538071 chr1 63720224 T C 6.19E-04 Multiple complex diseases LINC00466 intron 17554300 rs952998 chr1 63743891 C G 1.41E-04 Multiple complex diseases LINC00466 intron 17554300 rs2031402 chr1 63744393 T C 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LINC00466 intron 20031582 rs12747934 chr1 63767597 G A 1.87E-05 Celiac disease LINC00466 intron 23936387 rs2367270 chr1 63775056 C A 3.82E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs6588025 chr1 63790503 T C 3.96E-05 Celiac disease FOXD3 UTR-3 23936387 rs10749738 chr1 63793155 A G 1.99E-04 Celiac disease / / 23936387 rs12021563 chr1 63812269 C T 3.40E-05 Personality dimensions / / 18957941 rs12021563 chr1 63812269 C T 4.69E-05 Lymphocyte counts / / 22286170 rs7522426 chr1 63821329 G A 3.18E-04 Alzheimer's disease (late onset) / / 21379329 rs12135006 chr1 63861211 C A 3.33E-04 Aortic root size ALG6 intron 21223598 rs4630153 chr1 63881552 C T 5.68E-04 Glycosylated haemoglobin levels ALG6 missense 17255346 rs3009577 chr1 63914117 A G 2.54E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs6588044 chr1 63958304 G A 2.25E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs17391823 chr1 63986865 T C 4.89E-04 Lymphocyte counts ITGB3BP intron 22286170 rs217478 chr1 63991267 T C 3.43E-04 Alzheimer's disease (late onset) EFCAB7 cds-synon 21379329 rs17125177 chr1 64075768 T C 1.38E-04 Amyotrophic lateral sclerosis (sporadic) PGM1 intron 24529757 rs855314 chr1 64095111 A G 5.94E-05 Celiac disease PGM1 missense 23936387 rs2269252 chr1 64098065 T C 2.64E-05 Multiple complex diseases PGM1 intron 17554300 rs34922283 chr1 64100478 A AT 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs6588052 chr1 64100478 A T 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs2269248 chr1 64102114 A G 6.91E-04 Obesity (extreme) PGM1 intron 21935397 rs2301054 chr1 64107028 A G 6.81E-08 Alcohol consumption PGM1 intron 21665994 rs2269247 chr1 64107284 C T 2.98E-07 Alcohol consumption PGM1 intron 21665994 rs2269246 chr1 64107491 T C 7.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 7.43E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 4.47E-06 Type 1 diabetes PGM1 intron 21980299 rs2269241 chr1 64108771 T C 1.23E-05 Multiple complex diseases PGM1 intron 17554300 rs2269241 chr1 64108771 T C 4.00E-07 Type 1 diabetes PGM1 intron 19430480 rs2269241 chr1 64108771 T C 3.57E-08 Alcohol consumption PGM1 intron 21665994 rs2269240 chr1 64109264 T C 8.21E-08 Alcohol consumption PGM1 intron 21665994 rs2269239 chr1 64109359 C G 7.43E-07 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 3.37E-09 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 1.37E-07 Alcohol consumption PGM1 intron 21665994 rs11576729 chr1 64114429 G T 9.15E-08 Alcohol consumption PGM1 intron 21665994 rs2269238 chr1 64117537 G T 1.98E-06 Multiple complex diseases PGM1 intron 17554300 rs2269238 chr1 64117537 G T 7.19E-08 Alcohol consumption PGM1 intron 21665994 rs2269235 chr1 64118915 A G 3.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269234 chr1 64118976 A G 4.47E-08 Alcohol consumption PGM1 intron 21665994 rs2269233 chr1 64119346 T C 3.15E-08 Alcohol consumption PGM1 intron 21665994 rs12027168 chr1 64120613 T C 6.25E-08 Alcohol consumption PGM1 intron 21665994 rs2749100 chr1 64124979 G T 4.44E-05 Multiple complex diseases PGM1 intron 17554300 rs2749100 chr1 64124979 G T 7.63E-07 Alcohol consumption PGM1 intron 21665994 rs11208264 chr1 64125072 T C 3.38E-05 Multiple complex diseases PGM1 intron 17554300 rs11208264 chr1 64125072 T C 9.37E-07 Alcohol consumption PGM1 intron 21665994 rs11208265 chr1 64125234 G T 7.24E-05 Multiple complex diseases PGM1 intron 17554300 rs8294 chr1 64125368 C T 2.32E-09 Alcohol consumption PGM1 UTR-3 21665994 rs4643 chr1 64125439 A C 2.17E-06 Multiple complex diseases PGM1 UTR-3 17554300 rs4643 chr1 64125439 A C 2.31E-09 Alcohol consumption PGM1 UTR-3 21665994 rs855350 chr1 64127004 C T 9.58E-07 Alcohol consumption / / 21665994 rs2749097 chr1 64127468 C G 2.00E-09 Alcohol consumption (transferrin glycosylation) / / 21665994 rs2013012 chr1 64128209 C T 1.99E-04 Multiple complex diseases / / 17554300 rs1506397 chr1 64145283 C G 6.01E-08 Alcohol consumption / / 21665994 rs1395246 chr1 64147162 G C 4.61E-32 Narcolepsy / / 19629137 rs1395246 chr1 64147162 G C 7.71E-06 Height / / 20400458 rs1354718 chr1 64147950 A G 7.97E-05 HIV-1 viral setpoint / / 21490045 rs7548548 chr1 64151369 G C 9.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7548548 chr1 64151369 G C 1.04E-07 Alcohol consumption / / 21665994 rs2819157 chr1 64166213 C T 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12087869 chr1 64166968 T C 4.83E-05 Lung adenocarcinoma / / 19836008 rs2658407 chr1 64172809 A C 2.67E-04 Hearing function / / 17255346 rs4915914 chr1 64177299 G A 1.65E-04 Hearing function / / 17255346 rs2819172 chr1 64192575 G A 7.50E-05 Height / / pha003011 rs4915919 chr1 64195043 A C 2.09E-06 Diabetes Mellitus / / pha003059 rs11208281 chr1 64199752 C T 1.63E-04 Multiple complex diseases / / 17554300 rs1754546 chr1 64216658 A G 4.97E-05 Cognitive performance / / 19734545 rs11208285 chr1 64221643 T A 6.23E-05 Bipolar disorder / / 19488044 rs11208285 chr1 64221643 T A 9.59E-05 Bipolar Disorder / / pha002863 rs2819130 chr1 64231541 G A 2.10E-04 Crohn's disease / / 17435756 rs2819130 chr1 64231541 G A 8.84E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7552384 chr1 64237404 G C 5.30E-07 Fetal hemoglobin levels / / 18245381 rs620019 chr1 64240929 T C 8.84E-04 Alcohol consumption (maxi-drinks) ROR1 intron 24277619 rs659406 chr1 64256018 C T 1.00E-04 Serum metabolites ROR1 intron 19043545 rs659406 chr1 64256018 C T 2.01E-05 Diabetes Mellitus ROR1 intron pha003059 rs602227 chr1 64256988 A G 4.52E-05 Diabetes Mellitus ROR1 intron pha003059 rs596985 chr1 64277035 A G 4.13E-05 Crohn's disease ROR1 intron 23850713 rs631029 chr1 64312152 G A 7.97E-04 Multiple complex diseases ROR1 intron 17554300 rs675893 chr1 64317180 G T 8.59E-04 Multiple complex diseases ROR1 intron 17554300 rs7513180 chr1 64339801 G A 7.85E-05 Cognitive test performance ROR1 intron 20125193 rs11208308 chr1 64340452 T C 4.38E-05 Body Mass Index ROR1 intron pha003014 rs687578 chr1 64346361 C G,T 8.35E-04 Alzheimer's disease ROR1 intron 17998437 rs662986 chr1 64348148 A G 4.43E-04 Alzheimer's disease ROR1 intron 17998437 rs662437 chr1 64348338 T C 5.19E-04 Alzheimer's disease ROR1 intron 17998437 rs855851 chr1 64351518 T C 1.06E-04 Multiple complex diseases ROR1 intron 17554300 rs3861946 chr1 64383389 C A 6.69E-04 Heart Failure ROR1 intron pha002884 rs285339 chr1 64442169 G A 8.80E-05 Lung adenocarcinoma ROR1 intron 22797724 rs285385 chr1 64469469 G A,T 8.33E-04 Multiple complex diseases ROR1 intron 17554300 rs834485 chr1 64484485 C T 5.01E-04 Myocardial Infarction ROR1 intron pha002883 rs834487 chr1 64486207 A G 4.57E-04 Multiple complex diseases ROR1 intron 17554300 rs834487 chr1 64486207 A G 3.31E-04 Alzheimer's disease ROR1 intron 17998437 rs1260836 chr1 64488856 G A 9.31E-04 Alzheimer's disease ROR1 intron 22005930 rs1260836 chr1 64488856 G A 7.01E-04 Myocardial Infarction ROR1 intron pha002883 rs1260817 chr1 64502933 T G 3.52E-04 Type 2 diabetes ROR1 intron 17463246 rs1260773 chr1 64534922 G A 2.00E-04 Myasthenia gravis ROR1 intron 23055271 rs10493354 chr1 64541533 G A 7.68E-04 Type 2 diabetes ROR1 intron 17463246 rs10493354 chr1 64541533 G A 7.00E-06 Urinary metabolites ROR1 intron 21572414 rs12409562 chr1 64550053 A G 1.42E-04 Alzheimer's disease (late onset) ROR1 intron 21379329 rs3933251 chr1 64560848 T G 4.73E-05 Bladder cancer ROR1 intron 19648920 rs2806541 chr1 64566396 G A 6.83E-05 Bladder cancer ROR1 intron 19648920 rs2762849 chr1 64596766 T C 2.32E-05 Bipolar disorder and schizophrenia ROR1 intron 20889312 rs10489902 chr1 64607328 T G 5.55E-04 Type 2 diabetes ROR1 intron 17846124 rs12025819 chr1 64612395 C A 1.16E-05 Hearing function ROR1 intron 17255346 rs6588083 chr1 64614011 T C 9.49E-05 Schizophrenia ROR1 intron 19197363 rs3884549 chr1 64628407 T A 0.0002287 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs3884549 chr1 64628407 T A 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915657 chr1 64630026 G C 8.48E-05 Femoral neck bone geometry ROR1 intron 22087292 rs4915657 chr1 64630026 G C 0.0002301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915657 chr1 64630026 G C 2.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915658 chr1 64630237 A G 0.0006204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915658 chr1 64630237 A G 6.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs6676128 chr1 64635283 T C 0.0002429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs6676128 chr1 64635283 T C 2.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs7534614 chr1 64640415 C G 0.000237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs7534614 chr1 64640415 C G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs11208376 chr1 64640898 T G 0.0001836 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs11208376 chr1 64640898 T G 1.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs10489900 chr1 64646624 A G 2.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11208377 chr1 64647608 C T 0.0001924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11208377 chr1 64647608 C T 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4333885 chr1 64649858 A G 0.0001938 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4333885 chr1 64649858 A G 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7546930 chr1 64649955 G A 0.0002012 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7546930 chr1 64649955 G A 2.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6681495 chr1 64652405 T C 0.0002016 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6681495 chr1 64652405 T C 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11208380 chr1 64656971 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs11208383 chr1 64659070 G A 9.14E-04 Multiple complex diseases / / 17554300 rs825175 chr1 64679749 C T 2.70E-05 Urinary metabolites UBE2U intron 21572414 rs41529245 chr1 64707668 G A 7.88E-04 Aortic root size UBE2U intron 21223598 rs4915956 chr1 64712355 T A 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4915962 chr1 64751610 G A 2.85E-05 Body Mass Index / / pha003014 rs11583668 chr1 64785839 A T 9.75E-04 Type 2 diabetes / / 17463246 rs4915972 chr1 64791688 T C 3.49E-05 Body Mass Index / / pha003014 rs1390473 chr1 64804379 A G 1.60E-04 Renal cell carcinoma / / 24220910 rs17126437 chr1 64811160 G T 3.42E-05 Body Mass Index / / pha003014 rs10493358 chr1 64812821 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1390484 chr1 64831392 T C 7.91E-05 Post-operative nausea and vomiting / / 21694509 rs1514966 chr1 64834710 A G 3.33E-04 Smoking initiation / / 24665060 rs10493359 chr1 64837281 T C 2.44E-04 Smoking initiation / / 24665060 rs6588092 chr1 64855419 A G 1.16E-04 Smoking initiation / / 24665060 rs11208446 chr1 64868352 G A 9.00E-06 Bilirubin levels / / 22085899 rs305535 chr1 64914437 A C 7.77E-06 Sodium levels / / pha003093 rs305544 chr1 64918776 C T 7.69E-06 Sodium levels / / pha003093 rs12128329 chr1 64925891 G A 1.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs764457 chr1 64981488 C T 5.19E-04 Premature ovarian failure CACHD1 intron 19508998 rs9326061 chr1 64986799 G C 1.60E-05 Urinary metabolites CACHD1 intron 21572414 rs893075 chr1 64998367 T C 1.85E-04 Multiple complex diseases CACHD1 intron 17554300 rs17126643 chr1 65010606 T G 6.43E-05 Alcohol consumption CACHD1 intron 23953852 rs6681578 chr1 65013586 T C 5.06E-08 Schizophrenia CACHD1 intron 21926974 rs1436751 chr1 65064340 A G 2.71E-04 Aortic root size CACHD1 intron 21223598 rs2375268 chr1 65069961 A G 1.28E-04 Aortic root size CACHD1 intron 21223598 rs12407953 chr1 65084275 G C 9.65E-05 Schizophrenia(age at onset) CACHD1 intron 21688384 rs12097652 chr1 65085942 A G 8.86E-04 Aortic root size CACHD1 intron 21223598 rs2118102 chr1 65099978 G A 1.15E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CACHD1 intron 21775533 rs751666 chr1 65100865 T C 8.07E-04 Smoking quantity CACHD1 intron 24665060 rs111303300 chr1 65109273 A C 0.00005063 Sarcoidosis CACHD1 intron 22952805 rs111631599 chr1 65109276 T C 0.0000501 Sarcoidosis CACHD1 intron 22952805 rs1561168 chr1 65115319 G A 3.05E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CACHD1 intron 17982456 rs1561168 chr1 65115319 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs1561167 chr1 65115513 T A 9.70E-06 Urinary metabolites CACHD1 intron 21572414 rs7552864 chr1 65119146 T C 7.10E-06 Urinary metabolites CACHD1 intron 21572414 rs7517300 chr1 65128071 T C 7.50E-06 Urinary metabolites CACHD1 intron 21572414 rs11208492 chr1 65128375 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs11208493 chr1 65128395 C T 5.40E-06 Urinary metabolites CACHD1 intron 21572414 rs7513574 chr1 65135341 G T 1.75E-06 Diabetes (gestational) CACHD1 intron 22233651 rs2478156 chr1 65144191 G C 2.10E-05 Iron levels CACHD1 intron 21208937 rs17126889 chr1 65156862 T C 2.75E-04 Response to cytadine analogues (cytosine arabinoside) CACHD1 intron 24483146 rs1926304 chr1 65161230 T G 8.51E-04 Iron levels / / pha002876 rs2148323 chr1 65161633 T C 8.53E-04 Iron levels / / pha002876 rs11208510 chr1 65167537 T A 4.85E-04 Nonalcoholic fatty liver disease / / 21423719 rs11208512 chr1 65170405 T C 1.44E-04 Alzheimer's disease / / 24755620 rs7530486 chr1 65182826 T C 9.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs7530486 chr1 65182826 T C 3.00E-04 Alzheimer's disease (late onset) / / 21379329 rs7530486 chr1 65182826 T C 6.92E-04 Alzheimer's disease / / 24755620 rs1926310 chr1 65188498 G C 3.70E-04 Type 2 diabetes / / 17463246 rs1926312 chr1 65193698 A T 2.91E-04 Alzheimer's disease / / 22005930 rs10493367 chr1 65206148 A G 3.50E-04 Alzheimer's disease / / 22005930 rs998125 chr1 65211521 A G 3.17E-04 Alzheimer's disease RAVER2 intron 22005930 rs12038159 chr1 65212345 G A 3.79E-04 Alzheimer's disease RAVER2 intron 22005930 rs12043554 chr1 65214034 T C 4.13E-04 Alzheimer's disease RAVER2 intron 22005930 rs12040026 chr1 65214219 G A 4.05E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493368 chr1 65220035 T A 4.84E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493369 chr1 65221656 G A 4.60E-04 Alzheimer's disease RAVER2 intron 22005930 rs17126970 chr1 65221766 T C 5.26E-04 Alzheimer's disease RAVER2 intron 22005930 rs12049564 chr1 65221984 A G 5.36E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208518 chr1 65223510 C T 4.50E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208519 chr1 65223552 T C 5.70E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208520 chr1 65227239 G A 9.16E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208521 chr1 65228129 G A 6.49E-04 Alzheimer's disease RAVER2 intron 22005930 rs6671355 chr1 65231009 T A 9.30E-04 Alzheimer's disease RAVER2 intron 22005930 rs12029333 chr1 65235586 A G 9.85E-04 Alzheimer's disease RAVER2 intron 22005930 rs3790529 chr1 65280620 G A 9.50E-05 HIV-1 control RAVER2 intron 20041166 rs12353950 chr1 65299088 A C 6.81E-05 Type 2 diabetes JAK1 UTR-3 17463246 rs17390055 chr1 65304953 T C 7.83E-05 Type 2 diabetes JAK1 intron 17463246 rs4916005 chr1 65309387 T C 2.98E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs10789166 chr1 65312813 A G 3.21E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs12093269 chr1 65331786 C T 3.00E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs3818753 chr1 65339232 A G 1.62E-08 LDL cholesterol JAK1 intron 23063622 rs10889504 chr1 65390503 G C 6.44E-04 Multiple complex diseases JAK1 intron 17554300 rs17127168 chr1 65408513 A G 8.35E-04 Suicide attempts in bipolar disorder JAK1 intron 21423239 rs11579758 chr1 65445542 G A 1.50E-05 Urinary metabolites / / 21572414 rs3014983 chr1 65460691 C T 2.30E-05 Urinary metabolites / / 21572414 rs519282 chr1 65487083 T G 5.95E-06 Glaucoma (primary open-angle) / / 22605921 rs11208575 chr1 65509848 G A 7.61E-04 Multiple complex diseases / / 17554300 rs478665 chr1 65515533 A G 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs2375675 chr1 65553193 A C 4.33E-05 Varicose Veins / / pha001411 rs1572664 chr1 65580328 C A 2.25E-05 Leukocyte Counts / / pha003091 rs11208589 chr1 65580573 T C 6.06E-05 Leukocyte Counts / / pha003091 rs6588114 chr1 65585503 C T 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588115 chr1 65585799 T A 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695432 chr1 65586115 C T 0.000091 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695445 chr1 65586154 C A 0.0000636 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696301 chr1 65586815 G A 0.0000893 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7515954 chr1 65587028 T C 0.0000704 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551568 chr1 65587239 G C 0.0000266 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551569 chr1 65587240 G A 0.0000401 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs36003337 chr1 65587853 T C 0.0000645 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35192521 chr1 65587857 A T 0.0000632 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044147 chr1 65588329 C A,T 0.0000633 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12037302 chr1 65588420 A G 0.0000673 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044210 chr1 65588500 C T 0.0000845 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7513657 chr1 65589947 G A 0.0000789 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588117 chr1 65590511 A G 0.0000828 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588118 chr1 65590762 A G 0.0000663 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588119 chr1 65590965 C T 0.0000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4375305 chr1 65591114 C T 0.000078 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548217 chr1 65591956 G A 0.00008 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548059 chr1 65591966 C T 0.0000798 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548222 chr1 65591969 G C 0.0000827 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17127361 chr1 65594282 A G 6.30E-04 Type 2 diabetes / / 17463246 rs1109374 chr1 65633497 T C 7.97E-05 Nicotine smoking AK4 intron 19268276 rs4916031 chr1 65681543 T C 9.80E-05 Multiple complex diseases AK4 intron 17554300 rs4916032 chr1 65681622 G T 8.81E-05 Multiple complex diseases AK4 intron 17554300 rs1889925 chr1 65687556 G A 8.23E-04 Alcohol consumption (maxi-drinks) AK4 intron 24277619 rs1336472 chr1 65695930 G A 4.00E-10 Venous thromboembolism (gene x gene interaction) AK4 UTR-3 23509962 rs1889928 chr1 65710802 A G 1.50E-06 Urinary metabolites / / 21572414 rs10889531 chr1 65714118 G T 9.10E-07 Urinary metabolites / / 21572414 rs1613638 chr1 65716872 T C 9.36E-04 Type 2 diabetes / / 17463246 rs1613638 chr1 65716872 T C 3.40E-06 Urinary metabolites / / 21572414 rs550075 chr1 65723174 C A 3.10E-06 Urinary metabolites / / 21572414 rs2477786 chr1 65732242 C T 2.10E-24 Progranulin levels D/JC6 intron 21087763 rs2477786 chr1 65732242 C T 2.10E-24 Myocardial infarction D/JC6 intron 21211798 rs2477786 chr1 65732242 C T 4.70E-06 Urinary metabolites D/JC6 intron 21572414 rs4916041 chr1 65782658 T A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2281855 chr1 65785372 G A 5.25E-05 Attention deficit hyperactivity disorder D/JC6 intron 22420046 rs6588131 chr1 65801562 C A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2375699 chr1 65808281 G A 1 Drug response to Etoposide D/JC6 intron 17537913 rs1413885 chr1 65815659 C T 3.00E-07 Anticoagulant levels D/JC6 intron 22216198 rs7541003 chr1 65832352 A T 5.96E-04 Multiple complex diseases D/JC6 intron 17554300 rs6588144 chr1 65858088 T C 6.85E-04 Smoking initiation D/JC6 intron 24665060 rs4332387 chr1 65859108 G C 4.37E-04 Smoking initiation D/JC6 intron 24665060 rs11208645 chr1 65861798 A G 2.76E-05 Cognitive impairment induced by topiramate D/JC6 intron 22091778 rs4655762 chr1 65869274 C T 1.90E-04 Alzheimer's disease D/JC6 intron 22005930 rs2148682 chr1 65869489 T C 3.03E-04 Alzheimer's disease D/JC6 intron 22005930 rs11208646 chr1 65873605 A T 2.47E-04 Alzheimer's disease D/JC6 intron 22005930 rs10493377 chr1 65879252 A G 7.81E-05 Atopy D/JC6 UTR-3 21625490 rs9436735 chr1 65885061 C G 1.65E-13 LDL cholesterol LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 3.01E-13 Cholesterol,total LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 5.33E-08 HDL cholesterol LEPR nearGene-5 23063622 rs9436297 chr1 65888854 T C 5.90E-05 Glioma (high-grade) LEPR intron 19578366 rs9436299 chr1 65892888 C A 0.00000721 C-reactive protein LEPR intron 23505291 rs17127608 chr1 65893941 C T 3.13E-14 LDL cholesterol LEPR intron 23063622 rs3790433 chr1 65894342 C T 3.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7534511 chr1 65895130 A G 7.23E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436300 chr1 65895264 A G 6.74E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436301 chr1 65895927 T C 1.44E-08 Soluble leptin receptor levels LEPR intron 20167575 rs9436302 chr1 65896561 G A 4.40E-10 Soluble leptin receptor levels LEPR intron 20167575 rs9436303 chr1 65896674 A G 1.19E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1887285 chr1 65897747 A G 2.90E-05 Schizophrenia LEPROT UTR-3 19571809 rs7602 chr1 65897951 G A 6.04E-10 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1045895 chr1 65897981 G A 5.10E-05 Coffee consumption LEPROT UTR-3 21357676 rs9436742 chr1 65898331 C T 2.49E-09 LDL cholesterol LEPROT UTR-3 23063622 rs1046011 chr1 65898996 C T 7.34E-09 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1046011 chr1 65898996 C T 0.00000889 C-reactive protein LEPROT UTR-3 23505291 rs11804091 chr1 65903879 A G 2.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs970468 chr1 65906490 C A 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs9436747 chr1 65911607 T C 2.60E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6657868 chr1 65913707 A G 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655811 chr1 65923157 C G 3.40E-07 Soluble leptin receptor levels LEPR intron 20167575 rs6669354 chr1 65925349 T G 2.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7555955 chr1 65937479 A G 0.00000894 C-reactive protein LEPR intron 23505291 rs12409877 chr1 65943872 A G 0.0000444 C-reactive protein LEPR intron 23505291 rs2025804 chr1 65946121 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2025804 chr1 65946121 G A 0.00000636 C-reactive protein LEPR intron 23505291 rs2025803 chr1 65946506 A G 2.61E-06 Lymphocyte counts LEPR intron 22286170 rs10158579 chr1 65950056 T C 2.81E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11808888 chr1 65952781 G A 2.86E-10 Soluble leptin receptor levels LEPR intron 20167575 rs17127673 chr1 65955725 A G 3.94E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10128072 chr1 65957096 A C 3.48E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327121 chr1 65957337 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs17127677 chr1 65958274 G T 3.90E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6702545 chr1 65960036 G T 0.0000615 C-reactive protein LEPR intron 23505291 rs11800909 chr1 65961780 A G 7.10E-07 Soluble leptin receptor levels LEPR intron 20167575 rs17127690 chr1 65962949 A G 4.33E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6694528 chr1 65963016 C T 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11800275 chr1 65963704 T A 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 0.0000046 C-reactive protein LEPR intron 23505291 rs10157275 chr1 65966503 C T 2.39E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327115 chr1 65966839 T G 6.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2104564 chr1 65969430 C T 9.87E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 6.02E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 0.0000796 C-reactive protein LEPR intron 23505291 rs12062820 chr1 65970495 T C 8.09E-04 Multiple complex diseases LEPR intron 17554300 rs12062820 chr1 65970495 T C 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10889557 chr1 65970704 A G,T 7.67E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208656 chr1 65970787 A G 7.72E-04 Multiple complex diseases LEPR intron 17554300 rs11208656 chr1 65970787 A G 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs12079231 chr1 65971155 C G 6.13E-10 Soluble leptin receptor levels LEPR intron 20167575 rs7516840 chr1 65972595 C G 5.93E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208657 chr1 65973353 G A 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12068561 chr1 65973953 T C 6.21E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6672331 chr1 65975847 G C 2.74E-04 Menarche (age at onset) LEPR intron 21102462 rs1327116 chr1 65976051 A C 6.30E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889558 chr1 65976966 A G 6.29E-13 Soluble leptin receptor levels LEPR intron 20167575 rs7533108 chr1 65977844 C G 6.38E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2767485 chr1 65978917 T C 5.97E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208659 chr1 65979280 T C 2.00E-09 Obesity (early onset extreme) LEPR intron 23563609 rs1171274 chr1 65980838 C T 6.07E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171275 chr1 65982633 C T 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1180445 chr1 65982919 T C 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1475397 chr1 65983158 C T 3.76E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1475398 chr1 65983257 C G 1.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1627238 chr1 65986079 G A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1782755 chr1 65986804 C A 3.10E-04 Multiple complex diseases LEPR intron 17554300 rs1782755 chr1 65986804 C A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171276 chr1 65987449 A G 2.75E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171278 chr1 65988146 C T 2.45E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171279 chr1 65988493 C T 4.09E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12135802 chr1 65992140 A G 4.87E-05 Diabetes Mellitus LEPR intron pha003060 rs1751492 chr1 65992625 C T 6.00E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1782754 chr1 65993348 G A 9.66E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6697315 chr1 65993556 C T 3.50E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2154381 chr1 65995701 G A 7.27E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171269 chr1 65996802 T C 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171270 chr1 65997841 G A 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749753 chr1 65998467 A G 6.21E-05 Cognitive test performance LEPR intron 20125193 rs1171271 chr1 65998790 C T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1177681 chr1 65999119 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171272 chr1 65999811 G T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1022981 chr1 66000034 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1186403 chr1 66000533 C T 7.45E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171261 chr1 66001402 T C 3.79E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171262 chr1 66001746 A T 1.57E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171263 chr1 66001933 T C 1.75E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171264 chr1 66003014 C G 2.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171265 chr1 66003252 A G 3.54E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171266 chr1 66003824 T C 2.42E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171267 chr1 66003854 T G 1.43E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1782763 chr1 66007900 C T 5.62E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 5.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 0.0000249 C-reactive protein LEPR intron 23505291 rs6673324 chr1 66031063 G A 6.85E-12 Soluble leptin receptor levels LEPR intron 20167575 rs7519977 chr1 66033496 G A 1.38E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10158279 chr1 66033696 T G 1.18E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137100 chr1 66036441 A G 1.87E-11 Soluble leptin receptor levels LEPR missense 20167575 rs10789184 chr1 66036962 G A 1.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12033452 chr1 66038435 C A 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6657632 chr1 66038666 A G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 0.0000734 C-reactive protein LEPR intron 23505291 rs35919106 chr1 66039425 C CG 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655517 chr1 66039425 C T 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655518 chr1 66039858 T G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4655680 chr1 66041469 G T 7.76E-13 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 1.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 0.0000095 C-reactive protein LEPR intron 23505291 rs3790425 chr1 66043112 A G 4.30E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3790425 chr1 66043112 A G 0.0000202 C-reactive protein LEPR intron 23505291 rs3790424 chr1 66044013 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343982 chr1 66045251 C T 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343981 chr1 66045328 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208675 chr1 66045424 T A,G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789185 chr1 66045864 G C 2.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10493379 chr1 66045927 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6691346 chr1 66046397 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938487 chr1 66047267 T C 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208676 chr1 66048123 A G 3.48E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6673591 chr1 66048389 A G 2.10E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208677 chr1 66048417 A G 3.52E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938489 chr1 66048622 A G 9.45E-05 Body Mass Index LEPR intron pha003009 rs12038998 chr1 66049128 C A 3.27E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12038998 chr1 66049128 C A 0.0000326 C-reactive protein LEPR intron 23505291 rs10889563 chr1 66049167 A G 1.93E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655528 chr1 66049489 A G 3.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208679 chr1 66049738 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789186 chr1 66050477 G A 2.07E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6676495 chr1 66052117 G A 1.99E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6676419 chr1 66052209 C T 9.15E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4370791 chr1 66052228 A G 1.68E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12028951 chr1 66053081 G A 1.65E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 1.58E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 0.0000369 C-reactive protein LEPR intron 23505291 rs12042884 chr1 66053192 C G 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3828039 chr1 66053556 A G 1.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749754 chr1 66054640 G A 5.65E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 2.81E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 1.56E-08 Amyloid A Levels LEPR intron 21124955 rs12564626 chr1 66056542 G A 5.00E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208682 chr1 66056596 G A 4.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889567 chr1 66057050 T C 7.49E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10449758 chr1 66057117 A G 4.88E-11 Soluble leptin receptor levels LEPR intron 20167575 rs2154380 chr1 66057441 T C 4.83E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10736402 chr1 66058000 C T 4.86E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137101 chr1 66058513 A G 4.45E-11 Soluble leptin receptor levels LEPR missense 20167575 rs4655537 chr1 66058801 A G 3.04E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655537 chr1 66058801 A G 6.64E-10 C-reactive protein LEPR intron 23505291 rs10889568 chr1 66059445 T C 2.98E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889568 chr1 66059445 T C 0.0000198 C-reactive protein LEPR intron 23505291 rs10732836 chr1 66059460 C T 4.29E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655539 chr1 66059663 A T 4.23E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6669117 chr1 66061072 T C 4.25E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 2.96E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 0.0000168 C-reactive protein LEPR intron 23505291 rs3762274 chr1 66064113 T C 1.28E-08 Soluble leptin receptor levels LEPR intron 20167575 rs3828033 chr1 66064710 C T 1.27E-08 Soluble leptin receptor levels LEPR intron 20167575 rs11801408 chr1 66075136 C T 0.0000753 C-reactive protein LEPR intron 23505291 rs6690625 chr1 66077590 T G 9.49E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6690625 chr1 66077590 T G 2.42E-08 C-reactive protein LEPR intron 23505291 rs6678033 chr1 66077624 G A 7.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6678033 chr1 66077624 G A 1.21E-09 Amyloid A Levels LEPR intron 21124955 rs6678033 chr1 66077624 G A 1.19E-08 C-reactive protein LEPR intron 23844046 rs12040007 chr1 66080160 G A 1.08E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 4.76E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 9.34E-08 C-reactive protein LEPR intron 23505291 rs4655556 chr1 66080563 G A 1.22E-09 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs35308591 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs35308591 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs4655557 chr1 66080787 T C 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655557 chr1 66080787 T C 1.58E-08 C-reactive protein LEPR intron 23844046 rs1938484 chr1 66081282 C A 1.26E-09 Soluble leptin receptor levels LEPR intron 20167575 rs34499590 chr1 66081791 C T 5.80E-15 LDL cholesterol LEPR missense 23063622 rs34499590 chr1 66081791 C T 7.22E-09 Triglycerides LEPR missense 23063622 rs10889569 chr1 66086194 A T 4.71E-10 Amyloid A Levels LEPR intron 21124955 rs10889569 chr1 66086194 A T 9.00E-09 C-reactive protein LEPR intron 23844046 rs7516341 chr1 66088143 T C 4.27E-10 Amyloid A Levels LEPR intron 21124955 rs7516341 chr1 66088143 T C 1.57E-08 C-reactive protein LEPR intron 23844046 rs6700896 chr1 66089782 C T 3.00E-14 C-reactive protein LEPR intron 19567438 rs6700896 chr1 66089782 C T 5.93E-10 Amyloid A Levels LEPR intron 21124955 rs6700896 chr1 66089782 C T 2.71E-08 C-reactive protein LEPR intron 23844046 rs6588153 chr1 66092017 T A 4.87E-10 Amyloid A Levels LEPR intron 21124955 rs6588153 chr1 66092017 T A 8.74E-09 C-reactive protein LEPR intron 23844046 rs1892535 chr1 66097181 G A 6.24E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12025906 chr1 66101384 T C 6.90E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1805096 chr1 66102257 G A 1.92E-10 Amyloid A Levels LEPR cds-synon 21124955 rs1805096 chr1 66102257 G A 2.00E-09 C-reactive protein LEPR cds-synon 22939635 rs1805096 chr1 66102257 G A 2.20E-14 C-reactive protein LEPR cds-synon 23505291 rs1805096 chr1 66102257 G A 2.25E-08 C-reactive protein LEPR cds-synon 23844046 rs7518632 chr1 66103350 C A,G,T 5.03E-09 Soluble leptin receptor levels LEPR nearGene-3 20167575 rs1892534 chr1 66105944 C T 7.00E-21 C-reactive protein / / 18439548 rs1892534 chr1 66105944 C T 1.33E-09 Amyloid A Levels / / 21124955 rs1892534 chr1 66105944 C T 1.23E-07 C-reactive protein / / 23844046 rs1892534 chr1 66105944 C T 4.77E-07 Inflammation / / pha002897 rs7531867 chr1 66107546 G A 4.44E-10 Amyloid A Levels / / 21124955 rs7531867 chr1 66107546 G A 1.19E-08 C-reactive protein / / 23844046 rs1938492 chr1 66117829 A C 2.33E-10 Amyloid A Levels / / 21124955 rs1938492 chr1 66117829 A C 5.00E-14 Fibrinogen / / 23969696 rs2186245 chr1 66118064 C T 4.74E-09 Soluble leptin receptor levels / / 20167575 rs12130476 chr1 66124850 G C 4.57E-09 Soluble leptin receptor levels / / 20167575 rs12145237 chr1 66124882 C T 6.03E-09 Soluble leptin receptor levels / / 20167575 rs10789192 chr1 66125770 G A 3.27E-10 Amyloid A Levels / / 21124955 rs10789192 chr1 66125770 G A 1.78E-08 C-reactive protein / / 23844046 rs4655772 chr1 66130398 A G 0.0000336 Height (Pygmy height) / / 22570615 rs11208700 chr1 66133443 A T 2.20E-06 Soluble leptin receptor levels / / 20167575 rs11208700 chr1 66133443 A T 9.84E-09 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 1.78E-08 C-reactive protein / / 23844046 rs12042807 chr1 66134052 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042807 chr1 66134052 T C 1.78E-08 C-reactive protein / / 23844046 rs12043772 chr1 66135034 T A 6.03E-09 Soluble leptin receptor levels / / 20167575 rs11807752 chr1 66138575 A G 5.08E-04 Alzheimer's disease / / 17998437 rs11208707 chr1 66139513 C T 7.24E-09 Soluble leptin receptor levels / / 20167575 rs10736403 chr1 66140396 A G 7.30E-09 Soluble leptin receptor levels / / 20167575 rs10749756 chr1 66140511 C T 7.58E-09 Soluble leptin receptor levels / / 20167575 rs12567606 chr1 66141884 A G 1.30E-09 Soluble leptin receptor levels / / 20167575 rs12117858 chr1 66142094 C T 7.61E-09 Soluble leptin receptor levels / / 20167575 rs4655778 chr1 66142336 G A 7.87E-09 Soluble leptin receptor levels / / 20167575 rs4655779 chr1 66142530 A G 7.69E-09 Soluble leptin receptor levels / / 20167575 rs4655780 chr1 66142777 C A 7.84E-09 Soluble leptin receptor levels / / 20167575 rs34796214 chr1 66142972 A AG 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655782 chr1 66142972 A G 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 2.40E-06 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 9.57E-09 Amyloid A Levels / / 21124955 rs10158937 chr1 66144876 A C 1.45E-08 Soluble leptin receptor levels / / 20167575 rs11208709 chr1 66146017 G A 7.85E-09 Soluble leptin receptor levels / / 20167575 rs11208710 chr1 66146039 A G 7.32E-09 Soluble leptin receptor levels / / 20167575 rs12026918 chr1 66146246 C G 7.62E-09 Soluble leptin receptor levels / / 20167575 rs11208711 chr1 66147846 G T 3.12E-10 Amyloid A Levels / / 21124955 rs11208711 chr1 66147846 G T 3.23E-08 C-reactive protein / / 23844046 rs2375803 chr1 66152889 T C 5.74E-04 Alzheimer's disease / / 17998437 rs4655582 chr1 66153363 C G 3.20E-10 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 2.60E-06 Soluble leptin receptor levels / / 20167575 rs12022410 chr1 66153933 A G 9.51E-09 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 0.0000336 Height (Pygmy height) / / 22570615 rs4655583 chr1 66155407 C A 3.40E-09 Soluble leptin receptor levels / / 20167575 rs4655584 chr1 66155515 T G 2.29E-10 Amyloid A Levels / / 21124955 rs4655584 chr1 66155515 T G 3.33E-08 C-reactive protein / / 23844046 rs4655585 chr1 66155627 T C 2.30E-10 Amyloid A Levels / / 21124955 rs4655585 chr1 66155627 T C 3.53E-08 C-reactive protein / / 23844046 rs2211651 chr1 66156021 G T 1.66E-10 Amyloid A Levels / / 21124955 rs2211651 chr1 66156021 G T 1.02E-06 Inflammation / / pha002897 rs2889195 chr1 66156730 C T 6.60E-04 Lipid traits / / 17903299 rs2889195 chr1 66156730 C T 3.00E-10 Amyloid A Levels / / 21124955 rs2889195 chr1 66156730 C T 5.95E-07 Inflammation / / pha002897 rs12042379 chr1 66158464 G T 8.21E-09 Soluble leptin receptor levels / / 20167575 rs11208720 chr1 66159055 A G 7.08E-09 Soluble leptin receptor levels / / 20167575 rs4655792 chr1 66159264 T G 4.70E-09 Soluble leptin receptor levels / / 20167575 rs4655793 chr1 66159278 C A 5.07E-09 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 3.60E-06 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 5.29E-09 Amyloid A Levels / / 21124955 rs4655794 chr1 66159301 T C 0.0000336 Height (Pygmy height) / / 22570615 rs4655795 chr1 66159368 G T 4.02E-09 Soluble leptin receptor levels / / 20167575 rs6664534 chr1 66160075 T A 3.80E-09 Soluble leptin receptor levels / / 20167575 rs6588156 chr1 66160433 A G 3.13E-09 Soluble leptin receptor levels / / 20167575 rs6588158 chr1 66160621 T C 1.99E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 2.23E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 4.00E-62 C-reactive protein / / 21300955 rs4420065 chr1 66161461 T C 6.67E-07 Inflammation / / pha002897 rs6667615 chr1 66162630 A G 3.07E-09 Soluble leptin receptor levels / / 20167575 rs67564250 chr1 66162630 AA AAA,AGC 3.07E-09 Soluble leptin receptor levels / / 20167575 rs6667616 chr1 66162631 A C 3.03E-09 Soluble leptin receptor levels / / 20167575 rs4394621 chr1 66165836 G A 3.84E-09 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 5.10E-06 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 2.82E-11 Amyloid A Levels / / 21124955 rs7524581 chr1 66166499 T C 0.000301 Height (Pygmy height) / / 22570615 rs4425959 chr1 66167819 G A 5.88E-09 Soluble leptin receptor levels / / 20167575 rs4425959 chr1 66167819 G A 2.02E-08 Amyloid A Levels / / 21124955 rs7541434 chr1 66168499 A C 6.50E-06 Soluble leptin receptor levels / / 20167575 rs7541434 chr1 66168499 A C 1.35E-11 Amyloid A Levels / / 21124955 rs10889576 chr1 66168566 T C 7.26E-09 Soluble leptin receptor levels / / 20167575 rs10889576 chr1 66168566 T C 1.31E-08 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 4.00E-07 Metabolic traits / / 19060910 rs12753193 chr1 66169679 G A 5.50E-06 Soluble leptin receptor levels / / 20167575 rs12753193 chr1 66169679 G A 1.22E-11 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 0.000537 Height (Pygmy height) / / 22570615 rs12753193 chr1 66169679 G A 3.76E-07 Inflammation / / pha002897 rs17416194 chr1 66171192 G A 2.50E-08 Amyloid A Levels / / 21124955 rs12121677 chr1 66171970 T C 5.57E-04 Alcohol dependence / / 20201924 rs17407727 chr1 66172006 C A 1.80E-08 Amyloid A Levels / / 21124955 rs10493383 chr1 66174932 C G 9.94E-08 Pure-tone audiometry / / pha001966 rs4278348 chr1 66175395 T C 3.54E-08 Amyloid A Levels / / 21124955 rs7532805 chr1 66183130 G A 4.64E-08 Amyloid A Levels / / 21124955 rs17127955 chr1 66193548 A G 2.73E-04 Multiple complex diseases / / 17554300 rs4338330 chr1 66195239 C T 7.30E-04 Type 2 diabetes / / 17463246 rs4288572 chr1 66201022 G A 1.33E-08 Amyloid A Levels / / 21124955 rs10789198 chr1 66202755 G A 1.20E-08 Amyloid A Levels / / 21124955 rs4655800 chr1 66211691 A G 1.54E-08 Amyloid A Levels / / 21124955 rs11208728 chr1 66213043 A G 1.48E-08 Amyloid A Levels / / 21124955 rs12131840 chr1 66231771 C T 1.30E-06 Soluble leptin receptor levels / / 20167575 rs12046844 chr1 66238379 G A 5.84E-04 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6659197 chr1 66239897 A C 8.25E-05 Coronary heart disease / / 21606135 rs4384209 chr1 66279125 A G 2.00E-06 Economic and political preferences (feminism/equality) PDE4B intron 22566634 rs10493389 chr1 66310865 T C 7.00E-06 Echocardiographic traits PDE4B intron 17903301 rs4353064 chr1 66357675 A C 3.91E-04 Stroke PDE4B intron pha002887 rs17128103 chr1 66368865 C T 4.34E-04 Alcohol dependence PDE4B intron 21314694 rs11809491 chr1 66420658 G T 8.03E-11 LDL cholesterol PDE4B intron 23063622 rs2503209 chr1 66484652 T C 2.85E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2503215 chr1 66490013 A T 2.32E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553522 chr1 66492484 T A 1.36E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455031 chr1 66492628 C T 3.26E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553844 chr1 66492784 T A 2.75E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7525758 chr1 66494755 A G 8.78E-05 Cognitive test performance PDE4B intron 20125193 rs2455033 chr1 66500466 T C 8.99E-04 Type 2 diabetes PDE4B intron 17463246 rs2455033 chr1 66500466 T C 4.48E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2489905 chr1 66501072 A T 4.39E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455013 chr1 66516557 A G 5.77E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs12040042 chr1 66517050 A G 3.46E-06 Systemic lupus erythematosus and Systemic sclerosis PDE4B intron 23740937 rs2503222 chr1 66518697 C T 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2455012 chr1 66520998 A G 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455012 chr1 66520998 A G 7.00E-07 Staphylococcus aureus infection PDE4B intron 24847357 rs4492586 chr1 66528569 T C 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs9436757 chr1 66528892 G A 6.72E-04 Multiple complex diseases PDE4B intron 17554300 rs9436757 chr1 66528892 G A 3.07E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs1500963 chr1 66529821 G A 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2503228 chr1 66547142 A G 2.71E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs17455267 chr1 66549751 G A 3.63E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs4655595 chr1 66558759 A G 2.70E-06 Type 2 diabetes PDE4B intron 17463249 rs4655595 chr1 66558759 A G 2.68E-06 Multiple complex diseases PDE4B intron 17554300 rs1566527 chr1 66569098 T A 8.82E-05 Serum metabolites PDE4B intron 19043545 rs596662 chr1 66603875 A C 3.30E-05 Diabetic retinopathy PDE4B intron 21441570 rs17128445 chr1 66610968 G A 5.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs673143 chr1 66620119 G A 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs582237 chr1 66621527 A G 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs2485381 chr1 66627732 G A 8.44E-04 Alcohol dependence PDE4B intron 24277619 rs11208807 chr1 66634921 C T 3.63E-05 Amyotrophic Lateral Sclerosis PDE4B intron 18057069 rs556303 chr1 66635795 T A 7.40E-05 Diabetic retinopathy PDE4B intron 21441570 rs6656638 chr1 66645924 G A 1.26E-04 Self-reported allergy PDE4B intron 23817569 rs490094 chr1 66647385 A G 2.08E-26 Narcolepsy PDE4B intron 19629137 rs486438 chr1 66674663 A C 0.00000182 Triglycerides PDE4B intron 23063622 rs486438 chr1 66674663 A C 3.45E-11 LDL cholesterol PDE4B intron 23063622 rs10493398 chr1 66674738 G A 6.07E-04 Schizophrenia PDE4B intron 21674006 rs567279 chr1 66688029 G T 0.00000031 Cholesterol,total PDE4B intron 23063622 rs567279 chr1 66688029 G T 1.28E-09 Triglycerides PDE4B intron 23063622 rs567279 chr1 66688029 G T 4.13E-21 LDL cholesterol PDE4B intron 23063622 rs17423910 chr1 66689109 A G 4.67E-05 Acute lymphoblastic leukemia (childhood) PDE4B intron 22076464 rs952635 chr1 66691885 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits PDE4B intron 17848626 rs1358751 chr1 66725267 A G 0.00019 Coronary artery calcification PDE4B intron 23727086 rs6700403 chr1 66735601 T C 1.49E-04 Nicotine smoking PDE4B intron 19268276 rs12728294 chr1 66740467 T C 5.42E-05 Nicotine smoking PDE4B intron 19268276 rs499320 chr1 66745060 G A 3.77E-05 Lung function (forced expiratory volume in 1 second) PDE4B intron 24023788 rs499320 chr1 66745060 G A 3.79E-04 Lung function (forced vital capacity) PDE4B intron 24023788 rs12060491 chr1 66745352 A G 9.92E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE4B intron 24023788 rs519044 chr1 66756717 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 9.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs2312065 chr1 66762737 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) PDE4B intron 20189245 rs12030788 chr1 66768129 A G 4.09E-04 Multiple complex diseases PDE4B intron 17554300 rs6683977 chr1 66769100 G C 5.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs17427907 chr1 66805270 T C 6.20E-04 Multiple complex diseases PDE4B intron 17554300 rs2788646 chr1 66806953 T C 3.30E-04 Volumetric brain MRI PDE4B intron 17903297 rs17128817 chr1 66812100 C T 3.75E-08 LDL cholesterol PDE4B intron 23063622 rs4655835 chr1 66814826 T C 5.40E-04 Taste perception PDE4B intron 22132133 rs2275644 chr1 66831099 G A 8.13E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs7538869 chr1 66831322 T G 8.14E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783036 chr1 66831370 G A 5.91E-04 Smoking initiation PDE4B cds-synon 24665060 rs2311985 chr1 66834815 A G 8.19E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783051 chr1 66849410 C A 2.00E-05 Urinary metabolites / / 21572414 rs783050 chr1 66849448 T G 2.00E-05 Urinary metabolites / / 21572414 rs783048 chr1 66849905 C T 2.00E-05 Urinary metabolites / / 21572414 rs6701234 chr1 66851897 T G 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs6703929 chr1 66852161 T C 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs6691740 chr1 66852802 C A 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs12239708 chr1 66854570 T A 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs12406429 chr1 66856026 G A 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1341246 chr1 66879613 C G 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10493405 chr1 66920877 G A 3.03E-04 Hearing function / / 17255346 rs1832420 chr1 66939920 A G 4.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs10749760 chr1 66946306 G C 2.88E-04 Multiple complex diseases / / 17554300 rs4393126 chr1 66952788 G A 5.21E-04 Multiple complex diseases / / 17554300 rs4567260 chr1 66953482 G A 1.54E-05 Blood pressure / / 17255346 rs11208877 chr1 66954924 C A 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11208878 chr1 66955878 C T 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1338209 chr1 66957094 T C 6.91E-04 Multiple complex diseases / / 17554300 rs1025994 chr1 66957148 G A 7.15E-04 Multiple complex diseases / / 17554300 rs1025991 chr1 66958183 T G 8.43E-04 Multiple complex diseases / / 17554300 rs1020381 chr1 66960715 A G 6.35E-05 Blood pressure / / 17255346 rs1415975 chr1 66962193 C T 1.72E-04 Blood pressure / / 17255346 rs6588201 chr1 66963631 G T 7.86E-04 Multiple complex diseases / / 17554300 rs7544886 chr1 66968939 T C 5.90E-04 Multiple complex diseases / / 17554300 rs7555470 chr1 66969013 A C 8.14E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 2.11E-04 Blood pressure / / 17255346 rs7533097 chr1 66969084 C T 6.06E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 0.000216 Colorectal cancer vs. adenoma controls / / 22532847 rs7533837 chr1 66986781 A G 6.18E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 7.19E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 9.21E-04 Alzheimer's disease / / 17998437 rs12040232 chr1 66992277 T C 8.61E-05 Multiple complex diseases / / 17554300 rs1338203 chr1 66992613 A G 7.86E-05 Multiple complex diseases / / 17554300 rs6689313 chr1 66994889 A C 5.31E-05 Multiple complex diseases / / 17554300 rs12750223 chr1 67019819 A G 3.60E-07 Urinary metabolites SGIP1 intron 21572414 rs10889627 chr1 67023343 T C,G 9.12E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs7537440 chr1 67031907 T G 9.16E-04 Type 2 diabetes SGIP1 intron 22158537 rs10889630 chr1 67034789 C T 3.74E-05 Tuberculosis SGIP1 intron 20694014 rs12125455 chr1 67034992 G A 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs12131909 chr1 67037898 C G 6.10E-07 Urinary metabolites SGIP1 intron 21572414 rs4655625 chr1 67039730 C T 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs1373909 chr1 67040875 A G 9.75E-04 Type 2 diabetes SGIP1 intron 22158537 rs6699200 chr1 67041309 T C 3.28E-05 Tuberculosis SGIP1 intron 20694014 rs1867631 chr1 67046126 C A 5.00E-06 Menopause (age at onset) SGIP1 intron 23307926 rs4147266 chr1 67048743 T G 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs2166307 chr1 67052736 T C 7.16E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs12049347 chr1 67061496 C T 2.50E-07 Urinary metabolites SGIP1 intron 21572414 rs12117202 chr1 67062569 C G,T 5.54E-05 Tuberculosis SGIP1 intron 20694014 rs6588207 chr1 67066555 A G 4.24E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10443224 chr1 67074053 T C 9.66E-04 Multiple complex diseases SGIP1 intron 17554300 rs10889635 chr1 67075575 G A 2.52E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs11208921 chr1 67076054 C G 6.81E-05 Tuberculosis SGIP1 intron 20694014 rs12141816 chr1 67082018 G A 5.73E-05 Tuberculosis SGIP1 intron 20694014 rs11208923 chr1 67082442 A G 1.60E-06 Urinary metabolites SGIP1 intron 21572414 rs10493412 chr1 67082759 G C 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs6656912 chr1 67083671 T C 4.24E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs17436311 chr1 67083792 A G 5.17E-05 Tuberculosis SGIP1 intron 20694014 rs6588210 chr1 67084419 G C 9.18E-04 Multiple complex diseases SGIP1 intron 17554300 rs12129319 chr1 67084783 C G 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs12131306 chr1 67086547 C T 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs4655641 chr1 67089764 C T 1.00E-06 Urinary metabolites SGIP1 intron 21572414 rs1536112 chr1 67107225 A G 1.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs2147776 chr1 67107403 T C 3.86E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6588213 chr1 67107894 C T 6.90E-04 Multiple complex diseases SGIP1 intron 17554300 rs17490057 chr1 67109277 G C 0.0006 Prostate cancer SGIP1 missense 23555315 rs6689755 chr1 67113050 G A 2.27E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs12726588 chr1 67113648 T C 1.40E-06 Urinary metabolites SGIP1 intron 21572414 rs1925341 chr1 67115084 A G 8.23E-04 Taste perception SGIP1 intron 22132133 rs1998716 chr1 67117106 T A 1.31E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6681460 chr1 67123057 A G 7.30E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs6681460 chr1 67123057 A G 7.00E-06 Presence of antiphospholipid antibodies SGIP1 intron 23509613 rs1570814 chr1 67124943 C T 2.80E-06 Urinary metabolites SGIP1 intron 21572414 rs6689451 chr1 67142852 G A 2.12E-04 Multiple complex diseases SGIP1 intron 17554300 rs11811699 chr1 67143760 A G 2.59E-04 Multiple complex diseases SGIP1 intron 17554300 rs10789215 chr1 67151185 T C 8.51E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2146904 chr1 67160336 A G 4.37E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10493414 chr1 67161716 T A 6.41E-04 Multiple complex diseases SGIP1 intron 17554300 rs4143025 chr1 67167548 C T 6.46E-04 Multiple complex diseases SGIP1 intron 17554300 rs3738167 chr1 67171266 G T 7.55E-05 Fibrinogen SGIP1 intron pha003068 rs17129365 chr1 67174554 A G 6.84E-04 Type 2 diabetes SGIP1 intron 17463246 rs10889649 chr1 67178005 G A 8.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs1498354 chr1 67180489 T A 8.58E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs11208951 chr1 67188107 C T 8.24E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs536410 chr1 67191084 T C 1.69E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2483704 chr1 67195353 G A 3.63E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2916 chr1 67216697 G A 1.87E-07 Electroencephalogram traits,in brain / / 20421487 rs6695554 chr1 67230205 T G 9.40E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs12727422 chr1 67235320 C A 8.60E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs7535868 chr1 67235541 C T 9.90E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs55899951 chr1 67260378 A C 0.00009391 Sarcoidosis / / 22952805 rs56107937 chr1 67260398 G A 0.00008219 Sarcoidosis / / 22952805 rs7543667 chr1 67260854 A T 0.0000963 Sarcoidosis / / 22952805 rs17129478 chr1 67288443 T G 1.20E-05 Urinary metabolites WDR78 intron 21572414 rs1925399 chr1 67349271 G C 9.44E-04 Type 2 diabetes WDR78 intron 17463246 rs1925408 chr1 67365034 C T 9.47E-04 Multiple complex diseases WDR78 intron 17554300 rs1925411 chr1 67370292 C T 4.20E-06 Crohn's disease WDR78 intron 17804789 rs1983860 chr1 67372061 G T 3.58E-06 Crohn's disease WDR78 intron 17804789 rs12083687 chr1 67406962 G A 9.07E-04 Multiple complex diseases MIER1 intron 17554300 rs2985824 chr1 67410171 A G 8.09E-04 Multiple complex diseases MIER1 intron 17554300 rs12090955 chr1 67412261 G T 6.35E-04 Multiple complex diseases MIER1 intron 17554300 rs4655662 chr1 67416432 T C 3.57E-04 Celiac disease MIER1 intron 23936387 rs3008871 chr1 67419089 G A 7.69E-04 Multiple complex diseases MIER1 intron 17554300 rs4655663 chr1 67430103 G A 8.17E-04 Multiple complex diseases MIER1 intron 17554300 rs2985797 chr1 67431499 T C 8.12E-04 Multiple complex diseases MIER1 intron 17554300 rs12137403 chr1 67437043 C A,T 4.97E-04 Multiple complex diseases MIER1 intron 17554300 rs4620509 chr1 67449941 A G 6.13E-06 Crohn's disease MIER1 intron 17804789 rs4486425 chr1 67460791 T C 5.47E-05 Crohn's disease / / 17804789 rs2815351 chr1 67477980 A G 4.47E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755242 chr1 67479598 T C 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755244 chr1 67484470 T C 7.98E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2065002 chr1 67487119 C A 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755245 chr1 67487964 C G 7.82E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755246 chr1 67488984 A G 6.12E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815361 chr1 67494591 G T 5.53E-05 Amyotrophic lateral sclerosis (sporadic) SLC35D1 intron 24529757 rs12091194 chr1 67495728 C T 3.30E-05 Odorant perception SLC35D1 intron 23910658 rs17129627 chr1 67503666 C G 9.17E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815371 chr1 67504313 A G 5.43E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 9.25E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 8.04E-05 Crohn's disease SLC35D1 intron 17804789 rs1024228 chr1 67512695 A G 1.23E-05 Crohn's disease SLC35D1 intron 17804789 rs1024229 chr1 67512903 G T 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs1024230 chr1 67512920 A C 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs2208577 chr1 67513574 A C 8.91E-05 Crohn's disease SLC35D1 intron 17804789 rs2208577 chr1 67513574 A C 3.00E-04 Celiac disease SLC35D1 intron 23936387 rs2755259 chr1 67517022 T C 1.87E-06 Crohn's disease SLC35D1 intron 17804789 rs2755262 chr1 67521736 T C 2.01E-06 Crohn's disease SLC35D1 nearGene-5 17804789 rs11208994 chr1 67525043 A G 1.51E-08 Crohn's disease / / 17804789 rs12097741 chr1 67528006 A C 8.51E-05 Rheumatoid arthritis / / 17804836 rs2755263 chr1 67529243 A G 5.13E-05 Crohn's disease / / 17804789 rs17129659 chr1 67579395 C T 8.32E-07 Crohn's disease C1orf141 intron 17804789 rs11209002 chr1 67590461 T C 2.00E-07 Crohn's disease C1orf141 intron 17804789 rs7515029 chr1 67596372 A G 1.82E-09 Multiple complex diseases / / 17554300 rs3762318 chr1 67597119 G A 4.19E-05 Psoriasis / / 20953187 rs3762318 chr1 67597119 G A 3.00E-11 Leprosy / / 22019778 rs3762318 chr1 67597119 G A 1.24E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs2024825 chr1 67597977 T C 1.86E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs4655679 chr1 67599657 C T 3.16E-12 Multiple complex diseases / / 17554300 rs4655679 chr1 67599657 C T 2.00E-07 Crohn's disease / / 17804789 rs12069782 chr1 67600101 C T 3.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12095536 chr1 67600142 T C 1.41E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12090164 chr1 67600163 G A 8.76E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs11209003 chr1 67601132 G T 1.00E-08 Crohn's disease / / 17804789 rs1321156 chr1 67604702 G C 9.99E-04 Coronary Artery Disease / / 17634449 rs10789224 chr1 67605134 T C 2.47E-12 Multiple complex diseases / / 17554300 rs9729046 chr1 67607082 C G 5.87E-05 Crohn's disease / / 17804789 rs7539795 chr1 67609446 A G 4.18E-07 Multiple complex diseases / / 17554300 rs4655683 chr1 67611613 G A 2.95E-04 Crohn's disease / / 17068223 rs4655683 chr1 67611613 G A 4.76E-05 Crohn's disease / / 17804789 rs4655684 chr1 67611772 C T 1.29E-11 Multiple complex diseases / / 17554300 rs6588245 chr1 67611799 C T 3.01E-07 Multiple complex diseases / / 17554300 rs10889657 chr1 67615487 T C 2.31E-05 Crohn's disease / / 17804789 rs11209008 chr1 67623298 G A 8.79E-09 Crohn's disease / / 17804789 rs10889661 chr1 67625309 T A 3.56E-05 Crohn's disease / / 17804789 rs11465759 chr1 67632404 T G 0.000000299 Triglycerides IL23R intron 23063622 rs11465759 chr1 67632404 T G 1.02E-11 LDL cholesterol IL23R intron 23063622 rs11465759 chr1 67632404 T G 5.52E-12 Cholesterol,total IL23R intron 23063622 rs10889664 chr1 67635475 C T 4.15E-05 Crohn's disease IL23R intron 17804789 rs76418789 chr1 67648596 G A 2.00E-10 Crohn's disease IL23R missense 23850713 rs6588248 chr1 67652984 T G 8.81E-06 Leprosy IL23R intron 22019778 rs2064689 chr1 67653010 G A 8.52E-05 Crohn's disease IL23R intron 17068223 rs2064689 chr1 67653010 G A 1.00E-07 Crohn's disease IL23R intron 17804789 rs17375018 chr1 67655147 G A 1.13E-08 Multiple complex diseases IL23R intron 17554300 rs17375018 chr1 67655147 G A 8.71E-05 Crohn's disease IL23R intron 17804789 rs6664119 chr1 67655895 C T 9.51E-08 Multiple complex diseases IL23R intron 17554300 rs12401432 chr1 67656931 C G 6.44E-05 Crohn's disease IL23R intron 17804789 rs10489630 chr1 67662622 A C 7.07E-05 Crohn's disease IL23R intron 17068223 rs10489630 chr1 67662622 A C 1.26E-05 Crohn's disease IL23R intron 17804789 rs714512 chr1 67664154 T G 1.60E-05 Crohn's disease IL23R intron 17804789 rs7556198 chr1 67665543 A G 1.48E-06 Crohn's disease IL23R intron 17804789 rs11209018 chr1 67667291 G A 3.17E-12 Multiple complex diseases IL23R intron 17554300 rs1004820 chr1 67670133 T G 4.58E-05 Crohn's disease IL23R intron 17804789 rs1004819 chr1 67670213 G A 1.78E-14 Crohn's disease IL23R intron 17068223 rs1004819 chr1 67670213 G A 6.25E-06 Crohn's disease IL23R intron 17804789 rs2902440 chr1 67670916 G A 8.81E-09 Crohn's disease IL23R intron 17804789 rs7539625 chr1 67672765 G A 2.15E-08 Crohn's disease IL23R intron 17804789 rs11805303 chr1 67675516 C T 6.00E-12 Crohn's disease IL23R intron 17554300 rs11805303 chr1 67675516 C T 1.82E-39 Crohn's disease IL23R intron 18587394 rs10889669 chr1 67675728 T G 6.53E-06 Crohn's disease IL23R intron 17804789 rs790632 chr1 67678922 C A 1.86E-05 Serum metabolites IL23R intron 19043545 rs2019262 chr1 67679990 G A 9.20E-05 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-13 Inflammatory bowel disease IL23R intron 17068223 rs7517847 chr1 67681669 T G 3.00E-12 Crohn's disease IL23R intron 17435756 rs7517847 chr1 67681669 T G 7.80E-06 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels IL23R intron 24823311 rs7518660 chr1 67685443 G A 6.18E-08 Crohn's disease IL23R intron 17804789 rs11465802 chr1 67685598 A C 5.04E-07 Crohn's disease IL23R intron 17804789 rs10789228 chr1 67687064 C T 1.00E-04 Crohn's disease IL23R intron 17804789 rs10489629 chr1 67688349 T C 1.62E-11 Crohn's disease IL23R intron 17068223 rs10489629 chr1 67688349 T C 5.04E-12 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 7.93E-10 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 9.37E-05 Smoking quantity IL23R intron 24665060 rs2201841 chr1 67694202 A G 1.10E-14 Crohn's disease IL23R intron 17068223 rs2201841 chr1 67694202 A G 5.36E-12 Multiple complex diseases IL23R intron 17554300 rs2201841 chr1 67694202 A G 3.16E-08 Crohn's disease IL23R intron 17804789 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 19169254 rs2201841 chr1 67694202 A G 1.00E-13 Ulcerative colitis IL23R intron 20228799 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 20953187 rs2201841 chr1 67694202 A G 1.30E-13 Multiple sclerosis IL23R intron 22190364 rs12031203 chr1 67696547 G A 1.33E-06 Crohn's disease IL23R intron 17804789 rs11804284 chr1 67699254 T C 2.64E-17 Crohn's disease IL23R intron 17804789 rs12030948 chr1 67701765 G T 3.33E-05 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.33E-16 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.50E-15 Crohn's disease IL23R intron 17447842 rs11465804 chr1 67702526 T G 9.00E-04 Psoriasis IL23R intron 17587057 rs11465804 chr1 67702526 T G 2.08E-05 Crohn's disease IL23R intron 17804789 rs11465804 chr1 67702526 T G 7.00E-63 Crohn's disease IL23R intron 18587394 rs11465804 chr1 67702526 T G 1.00E-06 Crohn's disease IL23R intron 20570966 rs11465804 chr1 67702526 T G 7.00E-63 Asthma IL23R intron 21150878 rs11465804 chr1 67702526 T G 6.20E-06 Ankylosing spondylitis IL23R intron 21743469 rs11465804 chr1 67702526 T G 6.66E-63 Multiple sclerosis IL23R intron 22190364 rs10489628 chr1 67704107 G A 1.96E-04 Crohn's disease IL23R intron 17068223 rs10489628 chr1 67704107 G A 7.63E-07 Multiple complex diseases IL23R intron 17554300 rs10489628 chr1 67704107 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) IL23R intron 17982456 rs11209026 chr1 67705958 G A 4.00E-11 Inflammatory bowel disease IL23R missense 17068223 rs11209026 chr1 67705958 G A 2.00E-18 Crohn's disease IL23R missense 17447842 rs11209026 chr1 67705958 G A 4.76E-04 Multiple complex diseases IL23R missense 17554300 rs11209026 chr1 67705958 G A 1.40E-04 Psoriasis IL23R missense 17587057 rs11209026 chr1 67705958 G A 2.17E-07 Crohn's disease IL23R missense 17684544 rs11209026 chr1 67705958 G A 1.32E-08 Crohn's disease IL23R missense 17804789 rs11209026 chr1 67705958 G A 2.15E-68 Crohn's disease IL23R missense 18587394 rs11209026 chr1 67705958 G A 7.00E-11 Inflammatory bowel disease IL23R missense 18758464 rs11209026 chr1 67705958 G A 1.00E-08 Ulcerative colitis IL23R missense 19122664 rs11209026 chr1 67705958 G A 3.00E-10 Ulcerative colitis IL23R missense 19915572 rs11209026 chr1 67705958 G A 9.00E-14 Ankylosing spondylitis IL23R missense 20062062 rs11209026 chr1 67705958 G A 7.00E-07 Psoriasis IL23R missense 20953190 rs11209026 chr1 67705958 G A 1.00E-64 Crohn's disease IL23R missense 21102463 rs11209026 chr1 67705958 G A 5.00E-28 Ulcerative colitis IL23R missense 21297633 rs11209026 chr1 67705958 G A 2.00E-17 Ankylosing spondylitis IL23R missense 21743469 rs11209026 chr1 67705958 G A 4.00E-21 Crohn's disease IL23R missense 22293688 rs11209026 chr1 67705958 G A 1.00E-18 Crohn's disease IL23R missense 22412388 rs11209026 chr1 67705958 G A 4.00E-14 Crohn's disease IL23R missense 22936669 rs11209026 chr1 67705958 G A 8.00E-161 Inflammatory bowel disease IL23R missense 23128233 rs6682033 chr1 67708670 A G 4.10E-04 Crohn's disease IL23R intron 17068223 rs6682033 chr1 67708670 A G 4.33E-05 Smoking quantity IL23R intron 24665060 rs1343151 chr1 67719129 G A 2.74E-12 Crohn's disease IL23R intron 17068223 rs1343151 chr1 67719129 G A 2.30E-09 Crohn's disease IL23R intron 17447842 rs1343151 chr1 67719129 G A 3.16E-08 Crohn's disease IL23R intron 17804789 rs1343151 chr1 67719129 G A 1.91E-05 Response to acetaminophen (hepatotoxicity) IL23R intron 21177773 rs1343151 chr1 67719129 G A 2.24E-04 Smoking quantity IL23R intron 24665060 rs1008193 chr1 67719911 C G 8.52E-05 Smoking quantity IL23R intron 24665060 rs6693831 chr1 67720867 T C 9.44E-05 HIV-1 viral setpoint IL23R intron 22174851 rs6693831 chr1 67720867 T C 0.0008156 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IL23R intron 23233654 rs6693831 chr1 67720867 T C 8.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) IL23R intron 23233662 rs10889675 chr1 67722216 C A 1.36E-05 Multiple complex diseases IL23R intron 17554300 rs10889676 chr1 67722567 C A 3.36E-07 Crohn's disease IL23R intron 17804789 rs4655694 chr1 67723552 G A 0.0005315 Sarcoidosis IL23R intron 22952805 rs10889677 chr1 67725120 C A 3.40E-14 Crohn's disease IL23R UTR-3 17068223 rs10889677 chr1 67725120 C A 2.40E-06 Crohn's disease IL23R UTR-3 17447842 rs10889677 chr1 67725120 C A 2.00E-07 Crohn's disease IL23R UTR-3 17804789 rs10889677 chr1 67725120 C A 1.00E-08 Ulcerative colitis IL23R UTR-3 19122664 rs9988642 chr1 67726104 T C 3.16E-08 Crohn's disease IL23R nearGene-3 17804789 rs9988642 chr1 67726104 T C 1.10E-26 Psoriasis IL23R nearGene-3 23143594 rs2000252 chr1 67727555 C T 2.63E-04 Smoking quantity / / 24665060 rs12567232 chr1 67728018 G A 2.00E-07 Crohn's disease / / 17804789 rs6669582 chr1 67730055 A G 1.38E-07 Crohn's disease / / 17804789 rs10789230 chr1 67730628 G T 2.37E-08 Crohn's disease / / 17804789 rs7547569 chr1 67731368 T C 2.99E-05 Crohn's disease / / 17804789 rs7539328 chr1 67732603 G A 8.44E-07 Crohn's disease / / 17068223 rs11583760 chr1 67735948 C T 3.95E-05 Crohn's disease / / 17804789 rs11209032 chr1 67740092 G A 5.50E-13 Crohn's disease / / 17068223 rs11209032 chr1 67740092 G A 8.00E-05 Ankylosing spondylitis / / 21743469 rs11209033 chr1 67744500 C G 1.47E-10 Multiple complex diseases / / 17554300 rs11209033 chr1 67744500 C G 1.44E-06 Crohn's disease / / 17804789 rs6660226 chr1 67744601 G A 5.98E-08 Multiple complex diseases / / 17554300 rs6660226 chr1 67744601 G A 1.08E-05 Behcet's disease / / 23291587 rs12141431 chr1 67747023 G C 5.00E-13 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 5.38E-11 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 8.36E-05 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 5.89E-11 Multiple complex diseases / / 17554300 rs7546245 chr1 67750474 T C 4.71E-06 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 2.80E-04 Ankylosing spondylitis / / 21743469 rs11209039 chr1 67751193 A G 1.34E-07 Multiple complex diseases / / 17554300 rs11209040 chr1 67752671 G A,C 8.43E-05 Crohn's disease / / 17804789 rs1495966 chr1 67753353 T C 6.09E-05 Behcet's disease / / pha002888 rs1495965 chr1 67753508 C T 3.55E-09 Crohn's disease / / 17068223 rs1495965 chr1 67753508 C T 2.00E-11 Behcet's disease / / 20622879 rs1495965 chr1 67753508 C T 6.99E-05 Behcet's disease / / pha002888 rs924080 chr1 67760140 T C 3.83E-06 Crohn's disease / / 17068223 rs924080 chr1 67760140 T C 7.00E-09 Behcet's disease / / 20622878 rs924080 chr1 67760140 T C 5.36E-06 Behcet's disease / / 23291587 rs924080 chr1 67760140 T C 5.35E-06 Behcet's disease / / pha002888 rs3762317 chr1 67772582 A G 8.40E-04 Alcohol dependence / / 20201924 rs56194793 chr1 67790598 T C 2.24E-37 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209050 chr1 67791736 A C 9.60E-19 Primary biliary cirrhosis IL12RB2 intron 21399635 rs10489626 chr1 67793171 C G 0.0000048 Triglycerides IL12RB2 intron 23063622 rs191377276 chr1 67793935 T A 0.000033 Prostate cancer (advanced) IL12RB2 missense 23555315 rs72678531 chr1 67798445 T C 1.00E-23 Primary biliary cirrhosis (anti-mitochondrial antibody positive) IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.66E-23 Primary biliary cirrhosis IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 4.13E-19 Primary biliary cirrhosis in females IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.47E-38 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209051 chr1 67798895 C T 1.93E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs10889681 chr1 67799170 T C 1.67E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs6659932 chr1 67802371 A C 4.97E-19 Primary biliary cirrhosis IL12RB2 intron 22936693 rs3790566 chr1 67814440 T C 8.24E-08 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790567 chr1 67822377 A G 1.77E-05 Multiple complex diseases IL12RB2 intron 17554300 rs3790567 chr1 67822377 A G 3.00E-11 Primary biliary cirrhosis IL12RB2 intron 19458352 rs3790567 chr1 67822377 A G 8.00E-12 Primary biliary cirrhosis IL12RB2 intron 20639880 rs3790567 chr1 67822377 A G 1.97E-04 Systemic sclerosis IL12RB2 intron 21779181 rs3790567 chr1 67822377 A G 2.45E-05 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790568 chr1 67836060 G A 5.27E-04 Diabetic retinopathy IL12RB2 intron 20871662 rs12759271 chr1 67906853 G T 6.84E-04 Stroke / / 22306652 rs12116575 chr1 67912259 C T 7.82E-04 Stroke / / 22306652 rs1954118 chr1 67914487 T A 1.48E-04 Multiple complex diseases / / 17554300 rs6657603 chr1 67935310 T G 2.22E-04 Gallstones / / 17632509 rs12037907 chr1 67972435 A C 8.14E-05 Colorectal cancer / / 19723657 rs11209101 chr1 67989691 C A 5.60E-06 Hemoglobin / / pha003098 rs6686812 chr1 67991360 A G 6.13E-05 Hemoglobin / / pha003098 rs7524558 chr1 67993782 C T 4.33E-04 Multiple complex diseases / / 17554300 rs1340592 chr1 68021103 G A 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6693292 chr1 68023168 A C 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4081356 chr1 68032769 G T 1.58E-04 Rheumatoid arthritis / / 21452313 rs11209119 chr1 68038390 G A 1.20E-04 Rheumatoid arthritis / / 21452313 rs12083789 chr1 68044856 A T 9.92E-04 Multiple complex diseases / / 17554300 rs9919329 chr1 68046274 C T 8.90E-04 Rheumatoid arthritis / / 21452313 rs787538 chr1 68050630 T C 6.00E-05 Asthma and hay fever / / 24388013 rs787539 chr1 68051023 C T 6.00E-04 Lymphocyte counts / / 22286170 rs787520 chr1 68055306 A G 3.77E-04 Multiple complex diseases / / 17554300 rs2105262 chr1 68058216 G A 9.45E-04 Type 2 diabetes / / 17463246 rs787498 chr1 68071100 C T 2.36E-04 Body mass index / / 21701565 rs787498 chr1 68071100 C T 3.61E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 3.45E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 4.16E-04 Body mass index / / 21701565 rs10789239 chr1 68101467 T C 6.79E-04 Type 2 diabetes / / 17463246 rs12129053 chr1 68105186 G A 3.29E-06 Schizophrenia / / 24253340 rs12129053 chr1 68105186 G A 1.53E-05 Hypertension / / pha003041 rs344924 chr1 68105453 A G 3.00E-07 non-small cell lung cancer / / 23478653 rs12076129 chr1 68106197 G T 9.97E-05 Waist Circumference / / pha003024 rs12076129 chr1 68106197 G T 5.89E-05 Waist Circumference / / pha003025 rs12076129 chr1 68106197 G T 7.87E-05 Weight / / pha003027 rs11209133 chr1 68106505 T C 1.88E-05 Waist Circumference / / pha003024 rs11209133 chr1 68106505 T C 1.27E-05 Waist Circumference / / pha003025 rs11209133 chr1 68106505 T C 3.72E-05 Weight / / pha003026 rs11209133 chr1 68106505 T C 5.20E-05 Weight / / pha003027 rs12134425 chr1 68117203 T G 6.60E-05 Insulin-related traits / / pha003063 rs344938 chr1 68126437 G A 7.71E-04 Obesity (extreme) / / 21935397 rs12748843 chr1 68128130 A C 4.20E-04 Multiple complex diseases / / 17554300 rs11209138 chr1 68128639 G A 4.68E-04 Multiple complex diseases / / 17554300 rs344931 chr1 68135838 T C 8.67E-04 Obesity (extreme) / / 21935397 rs3783468 chr1 68152363 G A 5.29E-04 Parkinson's disease GADD45A intron 17052657 rs598602 chr1 68161837 A G 9.39E-04 Obesity (extreme) / / 21935397 rs41335250 chr1 68162655 A G 2.57E-04 Multiple complex diseases / / 17554300 rs7419 chr1 68167491 C T 3.26E-04 Multiple complex diseases GNG12 UTR-3 17554300 rs12036629 chr1 68189166 G A 2.10E-04 Multiple complex diseases GNG12 intron 17554300 rs11209143 chr1 68189965 G A 2.46E-04 Multiple complex diseases GNG12 intron 17554300 rs604256 chr1 68191951 T C 2.05E-04 Type 2 diabetes GNG12 intron 17463246 rs2803461 chr1 68194025 A G 2.79E-04 Type 2 diabetes GNG12 intron 17463246 rs2803462 chr1 68194151 G A 2.09E-04 Type 2 diabetes GNG12 intron 17463246 rs632959 chr1 68197671 A G 2.07E-04 Type 2 diabetes GNG12 intron 17463246 rs3766272 chr1 68221471 A G 4.08E-04 Multiple complex diseases GNG12 intron 17554300 rs12121525 chr1 68223227 G A 7.10E-05 HIV-1 control GNG12 intron 20041166 rs12061806 chr1 68256929 C T 7.00E-04 Multiple complex diseases GNG12 intron 17554300 rs1276300 chr1 68258818 G A 5.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276301 chr1 68259402 T C 5.40E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276303 chr1 68260778 C T 6.30E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276304 chr1 68260901 G C 6.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276305 chr1 68262269 T C 6.00E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276309 chr1 68262903 A G 6.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276311 chr1 68264927 A G 6.60E-05 White matter hyperintensity burden GNG12 intron 21681796 rs11209156 chr1 68273407 C T 5.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs6671283 chr1 68282901 A G 1.31E-05 Response to tamoxifen in breast cancer GNG12 intron 22180457 rs12239301 chr1 68283171 A G 0.00038 Coronary artery calcification GNG12 intron 23727086 rs2492874 chr1 68283492 C A 6.80E-05 White matter hyperintensity burden GNG12 intron 21681796 rs12132247 chr1 68284145 C T 0.00005 Coronary artery calcification GNG12 intron 23727086 rs2154376 chr1 68327576 T C 8.50E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1938446 chr1 68335624 G A 8.70E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs10157622 chr1 68337493 G A 8.60E-04 Multiple complex diseases LOC100289178 intron 17554300 rs10157622 chr1 68337493 G A 8.30E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12143705 chr1 68342367 T G 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs7554886 chr1 68345009 G C 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095487 chr1 68346631 G A 2.60E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095488 chr1 68346632 G A 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs8179318 chr1 68352002 A G 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1344148 chr1 68354321 G A 2.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12132081 chr1 68354648 C T 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 4.45E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1892525 chr1 68355614 G C 7.20E-07 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 0.0000579 white matter hyperintensity burden LOC100289178 intron 23674528 rs11209171 chr1 68356836 A T 2.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11209171 chr1 68356836 A T 0.000142 white matter hyperintensity burden LOC100289178 intron 23674528 rs11590313 chr1 68357032 G A 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11590313 chr1 68357032 G A 0.0000737 white matter hyperintensity burden LOC100289178 intron 23674528 rs7520899 chr1 68358177 C T 1.70E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7520899 chr1 68358177 C T 0.0000634 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521135 chr1 68358247 G T 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521135 chr1 68358247 G T 0.0000625 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521244 chr1 68358336 G C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521244 chr1 68358336 G C 0.0000668 white matter hyperintensity burden LOC100289178 intron 23674528 rs12025677 chr1 68359887 T C 5.50E-04 Multiple complex diseases LOC100289178 intron 17554300 rs12025677 chr1 68359887 T C 1.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12025677 chr1 68359887 T C 0.0000609 white matter hyperintensity burden LOC100289178 intron 23674528 rs10789247 chr1 68360980 A C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10789247 chr1 68360980 A C 0.0000621 white matter hyperintensity burden LOC100289178 intron 23674528 rs10889722 chr1 68361428 G A 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10889722 chr1 68361428 G A 0.0000628 white matter hyperintensity burden LOC100289178 intron 23674528 rs12073947 chr1 68363490 A C 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12073947 chr1 68363490 A C 0.0000233 white matter hyperintensity burden LOC100289178 intron 23674528 rs1317272 chr1 68363580 A G 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs1317272 chr1 68363580 A G 0.000032 white matter hyperintensity burden LOC100289178 intron 23674528 rs12405649 chr1 68386944 G C 7.08E-04 Smoking initiation LOC100289178 intron 24665060 rs17130402 chr1 68424715 C A 1.59E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1926283 chr1 68448661 A G 2.29E-10 Common variable immunodeficiency LOC100289178 intron 21497890 rs1926278 chr1 68453859 C T 2.99E-05 Tuberculosis LOC100289178 intron 24057671 rs12141436 chr1 68463212 G A 7.23E-04 Alzheimer's disease LOC100289178 intron 22005930 rs1926289 chr1 68465932 T C 7.39E-04 Alzheimer's disease LOC100289178 intron 22005930 rs7553612 chr1 68479872 C T 4.33E-06 Liver disease in chronic hepatitis B virus infection LOC100289178 intron 24065354 rs12069862 chr1 68491995 G A 5.42E-04 Anorexia nervosa LOC100289178 intron 23568457 rs4433365 chr1 68500883 G C 3.79E-04 Multiple complex diseases LOC100289178 intron 17554300 rs269340 chr1 68561012 T C 2.28E-04 Major depressive disorder LOC100289178 intron 22472876 rs9436797 chr1 68567418 G A 4.81E-05 Vaspin levels WLS intron 22907691 rs9436797 chr1 68567418 G A 0.0000481 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks WLS intron 22907730 rs11805150 chr1 68568921 T C 8.01E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 6.72E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 4.50E-05 Height WLS intron pha003011 rs1337406 chr1 68573853 G A 3.20E-05 Cognitive performance WLS intron 19734545 rs269352 chr1 68579397 G A 3.92E-05 Height WLS intron pha003010 rs269352 chr1 68579397 G A 5.41E-05 Height WLS intron pha003011 rs14130 chr1 68584745 A G 7.98E-07 Height WLS intron pha003010 rs14130 chr1 68584745 A G 1.74E-05 Height WLS intron pha003011 rs12046920 chr1 68586620 T G 7.43E-06 Height WLS intron pha003010 rs12046920 chr1 68586620 T G 1.70E-05 Weight WLS intron pha003027 rs10158352 chr1 68587777 T C 9.59E-05 Insulin-related traits WLS intron pha003063 rs2566784 chr1 68602735 G T 3.30E-08 Bone mineral density (spine) WLS intron 19801982 rs1864570 chr1 68604773 G A 7.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) WLS intron 23648065 rs9970306 chr1 68613579 C T 1.40E-08 Bone mineral density (spine) WLS intron 19801982 rs3762371 chr1 68620762 G A 2.20E-08 Bone mineral density (spine) WLS intron 19801982 rs12733835 chr1 68622994 C A 2.70E-09 Bone mineral density (spine) WLS intron 19801982 rs2566759 chr1 68631792 G A 1.40E-11 Bone mineral density (spine) WLS intron 19801982 rs2566758 chr1 68632483 C T 4.10E-09 Bone mineral density (spine) WLS intron 19801982 rs1367448 chr1 68633924 G A 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) WLS intron 23648065 rs1367447 chr1 68634030 C T 1.70E-12 Bone mineral density (spine) WLS intron 19801982 rs1864569 chr1 68634257 G A 6.43E-04 Alzheimer's disease WLS intron 24755620 rs1430742 chr1 68635075 T C 3.00E-13 Bone mineral density (spine) WLS intron 19801982 rs2566755 chr1 68635390 T C 2.00E-12 Bone mineral density (hip) WLS intron 19801982 rs2195682 chr1 68635743 C T 1.20E-12 Bone mineral density (spine) WLS intron 19801982 rs2772304 chr1 68636580 C A 2.10E-08 Bone mineral density (spine) WLS intron 19801982 rs4233320 chr1 68638451 G T 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs17482952 chr1 68639385 A G 3.66E-04 Bone mineral density (paediatric,total body less head) WLS intron 24945404 rs17482952 chr1 68639385 A G 3.92E-04 Bone mineral density (paediatric,skull) WLS intron 24945404 rs6677666 chr1 68640101 C T 3.80E-13 Bone mineral density (spine) WLS intron 19801982 rs878548 chr1 68640286 A G 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs891528 chr1 68640353 A G 3.50E-09 Bone mineral density (spine) WLS intron 19801982 rs891527 chr1 68641160 A T 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs2566754 chr1 68641238 T G 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs944082 chr1 68643091 T C 1.10E-11 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.60E-13 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.00E-45 Bone mineral density WLS intron 22504420 rs12407028 chr1 68647716 T C 0.000313 Lumbar spine bone mineral density (premenopausal) WLS intron 23074152 rs2772300 chr1 68648026 G A 5.70E-13 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.00E-11 Bone mineral density WLS intron 24249740 rs2820500 chr1 68658961 T C 3.20E-10 Bone mineral density (spine) WLS intron 19801982 rs2820500 chr1 68658961 T C 4.66E-04 Obesity (extreme) WLS intron 21935397 rs1036066 chr1 68660205 A C 8.20E-10 Bone mineral density (spine) WLS intron 19801982 rs1036066 chr1 68660205 A C 4.53E-04 Obesity (extreme) WLS intron 21935397 rs12568456 chr1 68661486 T G 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 1.10E-09 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 4.21E-04 Obesity (extreme) WLS intron 21935397 rs2116046 chr1 68662252 G A 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 9.90E-10 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 4.36E-04 Obesity (extreme) WLS intron 21935397 rs919540 chr1 68663143 C T 9.30E-10 Bone mineral density (spine) WLS intron 19801982 rs919540 chr1 68663143 C T 4.48E-04 Obesity (extreme) WLS intron 21935397 rs17130567 chr1 68663847 A G 1.60E-12 Bone mineral density (spine) WLS intron 19801982 rs7554551 chr1 68665023 T C 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs2149823 chr1 68668292 C T 5.02E-04 Multiple complex diseases WLS intron 17554300 rs2772286 chr1 68685389 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WLS intron 20877124 rs12563946 chr1 68692744 G A 3.49E-04 Multiple complex diseases WLS intron 17554300 rs12097456 chr1 68703087 C T 9.88E-04 Alcohol dependence / / 24277619 rs2772294 chr1 68703843 G A 1.91E-05 Psoriasis / / 18364390 rs3001033 chr1 68708808 G A 4.72E-04 Multiple complex diseases / / 17554300 rs1360181 chr1 68714135 T C 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12730489 chr1 68735304 C T 5.47E-05 Intelligence / / 21826061 rs1360182 chr1 68738278 T C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs3923451 chr1 68757334 C T 4.40E-05 Osteoarthritis (knee and hip) / / 21177295 rs3923451 chr1 68757334 C T 4.91E-05 Osteoarthritis (knee and hip) / / 21177295 rs11209261 chr1 68785213 T A 3.00E-06 Airflow obstruction / / 22837378 rs4926354 chr1 68803646 T C 2.88E-04 Gallstones / / 17632509 rs4926381 chr1 68816800 C T 9.79E-05 ldl cholesterol / / pha003076 rs11209290 chr1 68871027 G A 9.41E-05 Cognitive test performance / / 20125193 rs11209290 chr1 68871027 G A 8.87E-10 Parkinson's disease / / 21812969 rs10518295 chr1 68884158 G A 6.30E-05 Endometriosis / / 21151130 rs10493443 chr1 68884722 T C 1.62E-04 Statin-induced myopathy / / 21826682 rs12030710 chr1 68899762 G A 6.50E-05 Endometriosis RPE65 intron 21151130 rs114379164 chr1 68905294 G A,C 0.00021 Prostate cancer RPE65 missense 23555315 rs17130691 chr1 68905981 T A 9.35E-05 Smoking cessation RPE65 intron 24665060 rs17130694 chr1 68909113 C T 6.82E-04 Smoking cessation RPE65 intron 24665060 rs2012235 chr1 68912755 T C 0.0000209 Uterine leiomyomata RPE65 intron 23040493 rs435066 chr1 68927513 T C 4.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 5.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 8.00E-06 IgG glycosylation / / 23382691 rs10889769 chr1 68931366 A G 2.96E-04 Multiple complex diseases / / 17554300 rs10789263 chr1 68949139 T C 5.06E-04 Multiple complex diseases DEPDC1 intron 17554300 rs1041046 chr1 69002658 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1924529 chr1 69022171 G A 4.81E-04 Multiple complex diseases / / 17554300 rs12132065 chr1 69047142 T G 7.18E-06 Personality dimensions / / 22628180 rs10518303 chr1 69050472 A G 3.02E-04 Multiple complex diseases / / 17554300 rs7547034 chr1 69063771 T C 8.47E-06 Personality dimensions / / 22628180 rs2507205 chr1 69068554 T C 2.38E-04 Smoking cessation / / 24665060 rs11209332 chr1 69088662 G A 6.27E-04 Multiple complex diseases / / 17554300 rs12136070 chr1 69089971 C T 8.84E-04 Multiple complex diseases / / 17554300 rs1492075 chr1 69156133 A G 1.24E-04 Alzheimer's disease (late onset) / / 21379329 rs854285 chr1 69158190 T G 8.04E-05 Post-operative nausea and vomiting / / 21694509 rs12405430 chr1 69168941 T G 8.00E-05 Endometriosis / / 21151130 rs9988609 chr1 69315228 A G 5.78E-05 Telomere length / / 24795349 rs17435919 chr1 69439156 G A 3.44E-04 Multiple complex diseases / / 17554300 rs4650310 chr1 69445925 A G 9.64E-04 Prostate cancer / / 23023329 rs6588344 chr1 69446281 T G 3.05E-05 Duodenal ulcer / / 22387998 rs2842040 chr1 69516639 G A 9.79E-04 Alcohol dependence / / 24277619 rs1507860 chr1 69520596 G A 4.80E-05 Malaria / / 19465909 rs1507860 chr1 69520596 G A 9.00E-06 Soluble leptin receptor levels / / 20167575 rs906474 chr1 69526551 G C 9.63E-04 Response to TNF antagonist treatment / / 21061259 rs1567214 chr1 69526682 G C 1.20E-06 Soluble leptin receptor levels / / 20167575 rs12131089 chr1 69529365 C A 6.10E-06 Soluble leptin receptor levels / / 20167575 rs2456910 chr1 69554417 A G 9.21E-04 Multiple complex diseases / / 17554300 rs1281556 chr1 69568991 G A 2.76E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1281556 chr1 69568991 G A 4.19E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17436927 chr1 69577933 C G 6.38E-04 Type 2 diabetes / / 17463246 rs4147141 chr1 69579252 G A 6.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs4147141 chr1 69579252 G A 8.00E-06 Inattentive symptoms / / 18821565 rs12086324 chr1 69681190 C T 1.04E-04 Alcohol dependence / / 24277619 rs4650135 chr1 69684997 T C 5.00E-06 Inattentive symptoms / / 18821565 rs4650135 chr1 69684997 T C 3.71E-04 Smoking quantity / / 24665060 rs2901175 chr1 69688646 C G 2.30E-05 Urinary metabolites / / 21572414 rs5010843 chr1 69694205 G A 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12404688 chr1 69815440 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11209440 chr1 69851078 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1926256 chr1 69879074 C T 4.12E-05 HDL cholesterol / / pha003074 rs4388647 chr1 69886702 T C 1.40E-05 Urinary metabolites / / 21572414 rs11209457 chr1 69894849 G A 0.000000485 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs12135013 chr1 69895080 T G 5.50E-05 HDL cholesterol / / pha003074 rs9326089 chr1 69909410 A C 1.01E-04 Hearing function / / 17255346 rs17495923 chr1 69915596 C A 2.30E-05 Urinary metabolites / / 21572414 rs10789294 chr1 69939539 G C 6.72E-05 Progressive supranuclear palsy / / 21685912 rs1952142 chr1 69948854 C G 7.92E-05 Progressive supranuclear palsy / / 21685912 rs1341795 chr1 69960136 T G 3.94E-05 Progressive supranuclear palsy / / 21685912 rs12048011 chr1 69969838 C T 8.38E-04 Type 2 diabetes / / 17463246 rs10889833 chr1 69975660 G A 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs4589058 chr1 69993512 A G 3.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1935244 chr1 70003853 C A 9.41E-04 Alzheimer's disease / / 22005930 rs1341784 chr1 70007663 T C 8.63E-05 Lymphocyte counts / / pha003094 rs10889836 chr1 70010325 C T 7.32E-04 Alzheimer's disease / / 22005930 rs947420 chr1 70014986 C T 2.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4650295 chr1 70029922 C T 9.44E-05 Lymphocyte counts / / pha003094 rs4650295 chr1 70029922 C T 7.95E-05 Neutrophil count / / pha003095 rs1245058 chr1 70048064 C T 4.10E-05 Lipid traits / / 17903299 rs1749517 chr1 70064870 G C 6.00E-05 Triglycerides / / 19074352 rs11809230 chr1 70084797 C T 1.20E-05 Urinary metabolites / / 21572414 rs12030270 chr1 70085637 G C 7.50E-04 Alzheimer's disease / / 22005930 rs11209505 chr1 70097194 A G 4.80E-05 Lymphocyte counts / / pha003094 rs2066296 chr1 70097708 T G 9.92E-05 Orofacial clefts / / 22419666 rs2066296 chr1 70097708 T G 4.80E-05 Lymphocyte counts / / pha003094 rs1245072 chr1 70115756 A T 1.80E-05 Blood Phenotypes / / 17903294 rs7515290 chr1 70116825 A G 5.15E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12044761 chr1 70121115 G A 3.44E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12023616 chr1 70121268 A G 2.93E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 1.10E-05 Urinary metabolites / / 21572414 rs800930 chr1 70126607 G A 2.77E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 4.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1417437 chr1 70154441 T C 4.00E-06 Orofacial clefts / / 22419666 rs1417437 chr1 70154441 T C 9.00E-06 Orofacial clefts / / 22419666 rs11209521 chr1 70157066 T C 5.81E-04 Multiple complex diseases / / 17554300 rs1417436 chr1 70160178 T C 1.16E-05 Orofacial clefts / / 22419666 rs10889850 chr1 70207079 T G 2.00E-06 Body mass index / / 24348519 rs17131023 chr1 70219191 T C 3.70E-27 Narcolepsy / / 19629137 rs17397812 chr1 70225832 G A 2.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs75115510 chr1 70243630 C T 2.79E-04 Acne (severe) LRRC7 intron 24927181 rs2175743 chr1 70295901 C T 3.58E-05 Parkinson's disease (motor and cognition) LRRC7 intron 22658654 rs2175743 chr1 70295901 C T 3.58E-05 Immune response to anthrax vaccine LRRC7 intron 22658931 rs12734666 chr1 70297051 A G 2.60E-05 Urinary metabolites LRRC7 intron 21572414 rs6686752 chr1 70302082 C T 1.61E-04 Multiple complex diseases LRRC7 intron 17554300 rs6691577 chr1 70302201 A G 9.23E-05 Multiple complex diseases LRRC7 intron 17554300 rs12086732 chr1 70313699 G A,T 7.59E-04 Multiple complex diseases LRRC7 intron 17554300 rs6703428 chr1 70316302 A G 1.22E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 1.09E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 2.40E-05 Urinary metabolites LRRC7 intron 21572414 rs2226284 chr1 70335682 T C 4.58E-04 Multiple complex diseases LRRC7 intron 17554300 rs2226284 chr1 70335682 T C 3.00E-08 Hypertension risk in short sleep duration LRRC7 intron 22322875 rs12037173 chr1 70355981 A G 4.00E-06 Attention deficit hyperactivity disorder LRRC7 intron 21784300 rs17131083 chr1 70359726 C T 0.000313 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs1023008 chr1 70404540 A T 6.00E-06 Obesity-related traits LRRC7 intron 23251661 rs17131089 chr1 70415779 T C 0.000657 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs12035355 chr1 70460238 C T 1.41E-04 Multiple complex diseases LRRC7 intron 17554300 rs721242 chr1 70492561 C T 3.95E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17097485 chr1 70492884 T G 9.09E-06 Bipolar disorder (mania) LRRC7 intron 23326512 rs10493463 chr1 70493703 C T 1.72E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17131142 chr1 70499912 G T 2.82E-04 Multiple complex diseases LRRC7 intron 17554300 rs10493467 chr1 70500691 G A 7.46E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs7547666 chr1 70594571 T G 2.00E-05 Urinary metabolites / / 21572414 rs654025 chr1 70602342 C T 2.60E-06 Urinary metabolites / / 21572414 rs2274913 chr1 70689215 T C 5.72E-05 Cognitive decline SRSF11 intron 22054870 rs3767207 chr1 70709759 G A 8.84E-05 Cognitive decline SRSF11 intron 22054870 rs3767206 chr1 70715093 G A 4.52E-04 Suicide,with and without major depression SRSF11 intron 22059935 rs664051 chr1 70869116 G A 2.94E-04 Alcohol dependence / / 24277619 rs672203 chr1 70887099 A G 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) CTH intron 24025145 rs17131304 chr1 70892915 A T 2.61E-11 HDL cholesterol CTH intron 23063622 rs145785987 chr1 70896038 T C 0.000031 Prostate cancer CTH missense 23555315 rs145785987 chr1 70896038 T C 0.000063 Prostate cancer (non-advanced prostate cancer) CTH missense 23555315 rs12561944 chr1 70910065 A G 4.60E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 8.90E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 4.65E-05 Alcoholism / / pha002892 rs12561944 chr1 70910065 A G 8.87E-05 Alcoholism / / pha002893 rs555671 chr1 70913726 G A 1.50E-05 Urinary metabolites / / 21572414 rs10458561 chr1 70921173 G A 4.00E-07 Antipsychotic-induced QTc interval prolongation / / 20921969 rs8179319 chr1 70934259 G A 6.32E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs17131317 chr1 70947746 A G 1.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs17131318 chr1 70947851 A T 1.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12094445 chr1 70953934 C T 1.29E-05 Suicide attempts in bipolar disorder / / 21423239 rs2651248 chr1 70957413 G T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 7.97E-05 Body Mass Index / / pha003006 rs1333680 chr1 70963368 T C 2.67E-05 Waist Circumference / / pha003024 rs2807907 chr1 70986488 A G 5.51E-05 Body Mass Index / / pha003020 rs2651244 chr1 70995562 G A 2.00E-08 Inflammatory bowel disease / / 23128233 rs2651244 chr1 70995562 G A 7.49E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs17131783 chr1 70997811 G A 6.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs2780747 chr1 71002192 A G 7.30E-04 Multiple complex diseases / / 17554300 rs2780748 chr1 71002220 A T 5.34E-04 Multiple complex diseases / / 17554300 rs582435 chr1 71010207 C T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9425029 chr1 71011845 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9424946 chr1 71011982 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6700601 chr1 71012395 C A 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4650061 chr1 71013233 A G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4515743 chr1 71014024 T G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4546874 chr1 71014538 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs3121981 chr1 71014641 T C 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4649923 chr1 71028151 G A 1.70E-05 Urinary metabolites / / 21572414 rs4649923 chr1 71028151 G A 4.98E-05 Post-operative nausea and vomiting / / 21694509 rs3121983 chr1 71028815 A G 2.10E-05 Urinary metabolites / / 21572414 rs11209658 chr1 71103816 T C 1.60E-04 Myopia (pathological) / / 21095009 rs10889884 chr1 71120020 C T 9.38E-05 Cognitive test performance / / 20125193 rs1334995 chr1 71127061 A G 2.29E-04 Osteoarthritis / / 19508968 rs1334995 chr1 71127061 A G 9.29E-04 Myopia (pathological) / / 21095009 rs6683555 chr1 71132536 C T 2.24E-04 Myopia (pathological) / / 21095009 rs2820529 chr1 71134588 T C 7.03E-04 Myopia (pathological) / / 21095009 rs2782763 chr1 71142202 T C 2.38E-04 Osteoarthritis / / 19508968 rs2820526 chr1 71153714 C A 2.86E-05 Heart Rate / / pha003053 rs1334997 chr1 71154117 T C 1.42E-05 Glucose levels / / pha003058 rs3001038 chr1 71163715 G A 2.59E-04 Myopia (pathological) / / 21095009 rs2820551 chr1 71163908 G A 5.41E-06 Glucose levels / / pha003058 rs2820551 chr1 71163908 G A 8.38E-05 Glucose levels / / pha003061 rs2421787 chr1 71195538 G A 6.84E-04 Myopia (pathological) / / 21095009 rs2421787 chr1 71195538 G A 3.19E-05 Glucose levels / / pha003058 rs11209689 chr1 71229637 G T 6.85E-05 Myopia (pathological) / / 21095009 rs7547597 chr1 71241232 C A 6.85E-05 Myopia (pathological) / / 21095009 rs10889889 chr1 71250352 A C 9.08E-05 Receptive language ability / / 24687471 rs10493479 chr1 71251704 T C 1.13E-04 Myopia (pathological) / / 21095009 rs2260454 chr1 71255441 G A 3.31E-04 Premature ovarian failure / / 19508998 rs1409982 chr1 71267891 C T 9.33E-05 Receptive language ability / / 24687471 rs1327455 chr1 71273323 T A 5.67E-05 Multiple complex diseases / / 17554300 rs2257772 chr1 71275174 G A 1.11E-04 Myopia (pathological) / / 21095009 rs4603079 chr1 71286947 C T 1.39E-05 Glucose levels / / pha003058 rs4603079 chr1 71286947 C T 9.87E-05 Glucose levels / / pha003061 rs1409988 chr1 71291825 G A 1.39E-05 Glucose levels / / pha003058 rs1409988 chr1 71291825 G A 9.87E-05 Glucose levels / / pha003061 rs2182707 chr1 71294542 G T 1.94E-04 Myopia (pathological) / / 21095009 rs17131450 chr1 71296002 G A 1.70E-06 Stevens-Johnson syndrome / / 20947153 rs959 chr1 71318261 T C 7.95E-05 Myopia (pathological) PTGER3 UTR-3 21095009 rs6664305 chr1 71321740 C T 2.94E-04 Myopia (pathological) PTGER3 intron 21095009 rs1409986 chr1 71331498 A G 0.00000101 Obstructive sleep apnea PTGER3 intron 23155414 rs1325949 chr1 71337193 T C 2.00E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7543182 chr1 71339973 C A 2.50E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7555874 chr1 71343960 C T 4.60E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs1409978 chr1 71353104 T C 4.39E-04 Myopia (pathological) PTGER3 intron 21095009 rs4998697 chr1 71358190 T C 4.96E-05 Basophils PTGER3 intron pha003087 rs1327464 chr1 71366238 G A 1.00E-04 Response to interferon beta in multiple sclerosis PTGER3 intron 18195134 rs875727 chr1 71373738 T C 7.15E-19 Glaucoma (primary open-angle) PTGER3 intron 22419738 rs578096 chr1 71394683 T C 5.04E-04 Psoriasis PTGER3 intron 20953187 rs12097924 chr1 71398902 G T 4.70E-05 Orofacial clefts PTGER3 intron 22419666 rs13374231 chr1 71403260 G C 3.75E-05 Orofacial clefts PTGER3 intron 22419666 rs651265 chr1 71415135 A G 6.18E-04 Psoriasis PTGER3 intron 20953187 rs5697 chr1 71436747 C A 4.23E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs909848 chr1 71443150 T C 7.00E-06 IgG glycosylation PTGER3 intron 23382691 rs11209733 chr1 71471750 C G 9.30E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs12130153 chr1 71471875 T C 9.32E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs2268062 chr1 71485299 T C 3.97E-04 Type 2 diabetes PTGER3 intron 17463246 rs2817864 chr1 71503105 T G 1.07E-05 Platelet counts PTGER3 intron 21507922 rs2817866 chr1 71503447 G A 6.43E-05 Post-operative nausea and vomiting PTGER3 intron 21694509 rs12402425 chr1 71520017 G A 7.88E-04 Response to taxane treatment (placlitaxel) ZRANB2-AS1 intron 23006423 rs2796200 chr1 71658888 A G 2.45E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs2796200 chr1 71658888 A G 4.23E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs12131265 chr1 71712223 C T 1.34E-05 Alcohol dependence / / 23089632 rs11209757 chr1 71728900 T G 1.29E-05 Alcohol dependence / / 23089632 rs12405821 chr1 71876406 G T 2.33E-04 Type 2 diabetes NEGR1 intron 17463246 rs11209780 chr1 71876652 G A 1.78E-04 Multiple complex diseases NEGR1 intron 17554300 rs2056206 chr1 71936910 T C 2.42E-05 Blood pressure NEGR1 intron 24001895 rs6662613 chr1 71964277 G T 2.50E-05 Urinary metabolites NEGR1 intron 21572414 rs6675439 chr1 71986552 T C 9.10E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 4.20E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 8.18E-04 Alzheimer's disease NEGR1 intron 24755620 rs7535916 chr1 72018365 T C 1.69E-06 Multiple complex diseases NEGR1 intron 17554300 rs10889921 chr1 72045626 T C 7.25E-05 Progressive supranuclear palsy NEGR1 intron 21685912 rs1334992 chr1 72051206 C A 1.00E-04 Cognitive impairment induced by topiramate NEGR1 intron 22091778 rs10493485 chr1 72071129 A T 2.00E-06 Hemostatic factors and hematological phenotypes NEGR1 intron 17903294 rs10493486 chr1 72079898 G A 2.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NEGR1 intron 20877124 rs12136092 chr1 72093635 G A 4.03E-04 Multiple complex diseases NEGR1 intron 17554300 rs10889923 chr1 72099161 G C 1.91E-05 Multiple complex diseases NEGR1 intron 17554300 rs1577396 chr1 72101417 T C 5.11E-06 Multiple complex diseases NEGR1 intron 17554300 rs1041676 chr1 72104447 C T 4.73E-05 Cognitive decline NEGR1 intron 22054870 rs17091720 chr1 72222002 T C 1.95E-04 Multiple complex diseases NEGR1 intron 17554300 rs12024388 chr1 72253577 T C 7.62E-05 Diabetic nephropathy NEGR1 intron pha002852 rs12141391 chr1 72274473 C A 7.00E-06 Systemic lupus erythematosus NEGR1 intron 18204098 rs1350648 chr1 72287866 G T 9.28E-04 Multiple complex diseases NEGR1 intron 17554300 rs546741 chr1 72289671 G A 8.25E-04 Multiple complex diseases NEGR1 intron 17554300 rs554161 chr1 72343350 T A 8.67E-04 Multiple complex diseases NEGR1 intron 17554300 rs2114213 chr1 72404727 C A 6.44E-04 Multiple complex diseases NEGR1 intron 17554300 rs11209875 chr1 72413527 T G 4.60E-04 Smoking initiation NEGR1 intron 24665060 rs6703903 chr1 72415949 C A 3.03E-04 Smoking initiation NEGR1 intron 24665060 rs6677919 chr1 72455832 G A 4.92E-04 Smoking initiation NEGR1 intron 24665060 rs6661979 chr1 72458685 C T 3.82E-04 Smoking initiation NEGR1 intron 24665060 rs111868476 chr1 72459050 G C 1.90E-11 Metabolite levels NEGR1 intron 22286219 rs1937186 chr1 72461042 A G 1.97E-04 Lung function (forced expiratory volume in 1 second) NEGR1 intron 17255346 rs147218787 chr1 72461269 T C 0.00054379 Sarcoidosis NEGR1 intron 22952805 rs12139692 chr1 72461382 C T 3.46E-05 Vascular dementia NEGR1 intron 22116812 rs12042679 chr1 72481896 T C 5.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines NEGR1 intron 21844884 rs1486087 chr1 72509490 T C 4.75E-04 Alzheimer's disease (late onset) NEGR1 intron 21379329 rs988421 chr1 72549836 C T 4.30E-05 Parkinson's disease NEGR1 intron 17052657 rs10493493 chr1 72569309 G T 3.14E-05 Lymphocyte counts NEGR1 intron pha003094 rs1486096 chr1 72584184 G A 1.92E-05 HDL cholesterol NEGR1 intron pha003075 rs1486096 chr1 72584184 G A 6.52E-05 Lymphocyte counts NEGR1 intron pha003094 rs1545932 chr1 72622312 T G 1.04E-04 Multiple complex diseases NEGR1 intron 17554300 rs1157072 chr1 72634912 A G 6.43E-04 Nicotine smoking NEGR1 intron 19268276 rs2298152 chr1 72654730 A G 9.31E-05 Erythrocyte counts NEGR1 intron pha003099 rs1675356 chr1 72683226 C T 6.31E-05 HDL cholesterol NEGR1 intron pha003075 rs1194269 chr1 72703860 G A 8.43E-05 HDL cholesterol NEGR1 intron pha003075 rs1776012 chr1 72717743 A G 8.90E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 4.60E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 9.32E-05 HDL cholesterol NEGR1 intron pha003075 rs1620977 chr1 72729142 A G 3.49E-04 Taste perception NEGR1 intron 22132133 rs1380995 chr1 72733841 A T 1.60E-04 Self-reported allergy NEGR1 intron 23817569 rs12137231 chr1 72735458 T C 1.80E-04 Self-reported allergy NEGR1 intron 23817569 rs9326098 chr1 72740734 C G 5.19E-04 Multiple complex diseases NEGR1 intron 17554300 rs3101336 chr1 72751185 T C 1.10E-07 Smoking behavior / / 20418888 rs3101336 chr1 72751185 T C 1.00E-13 Obesity / / 23563607 rs3101336 chr1 72751185 T C 2.00E-08 Obesity (early onset extreme) / / 23563609 rs2568958 chr1 72765116 G A 1.00E-11 Body mass index / / 19079260 rs2568958 chr1 72765116 G A 2.00E-08 Weight / / 19079260 rs2568958 chr1 72765116 G A 9.90E-08 Smoking behavior / / 20418888 rs2568958 chr1 72765116 G A 2.00E-14 Body mass index / / 23563607 rs2568958 chr1 72765116 G A 4.00E-16 Obesity / / 23563607 rs2815752 chr1 72812440 G A 6.00E-08 Body mass index / / 19079261 rs2815752 chr1 72812440 G A 6.00E-08 Smoking behavior / / 20418888 rs2815752 chr1 72812440 G A 2.00E-22 Body mass index / / 20935630 rs2815752 chr1 72812440 G A 5.90E-07 Menarche (age at onset) / / 21102462 rs2815752 chr1 72812440 G A 1.61E-22 Body mass index / / 23001569 rs990871 chr1 72823713 C T 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs7531118 chr1 72837239 T C 2.00E-17 Obesity / / 23563607 rs10789336 chr1 72838406 G A 1.00E-06 Body mass index / / 23669352 rs1993709 chr1 72838529 A G 5.00E-13 Obesity (early onset extreme) / / 23563609 rs17092613 chr1 72871597 A G 1.36E-04 Multiple complex diseases / / 17554300 rs12406365 chr1 72874258 G A 4.36E-05 Major depressive disorder (broad) / / 20038947 rs17092663 chr1 72879614 G A 5.73E-04 Alzheimer's disease / / 22005930 rs10789340 chr1 72940273 A G 5.43E-04 Type 2 diabetes / / 17463246 rs1775368 chr1 72992580 A T 6.70E-05 Type 2 diabetes / / 17846125 rs17092900 chr1 73003410 A G 8.39E-04 Multiple complex diseases / / 17554300 rs2245438 chr1 73042360 G A 7.48E-04 Multiple complex diseases / / 17554300 rs4649963 chr1 73109325 A C 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7524643 chr1 73135952 T A 1.17E-04 Body mass index / / 23669352 rs10127441 chr1 73150180 G T 4.98E-04 Multiple complex diseases / / 17554300 rs2841187 chr1 73236826 C T 4.70E-05 Iron levels / / 21208937 rs10889990 chr1 73245168 G A 5.10E-05 Malaria / / 19465909 rs10889991 chr1 73245256 G A 7.70E-05 Malaria / / 19465909 rs7546928 chr1 73311542 G A 3.94E-04 Multiple complex diseases / / 17554300 rs1405051 chr1 73348484 G A 1.40E-04 Longevity and age-related phenotypes / / 17903295 rs6689491 chr1 73352029 C A 2.00E-05 Longevity and age-related phenotypes / / 17903295 rs6657082 chr1 73353328 A T 5.50E-05 Longevity and age-related phenotypes / / 17903295 rs10789351 chr1 73373796 C A 7.77E-04 Alzheimer's disease / / 17998437 rs10493513 chr1 73379589 G A 1.50E-06 Longevity and age-related phenotypes / / 17903295 rs10493514 chr1 73380512 T C 2.80E-06 Longevity and age-related phenotypes / / 17903295 rs17093667 chr1 73394093 T A 8.75E-05 Alzheimer's disease / / 17998437 rs4274011 chr1 73482160 G A 6.89E-04 Alzheimer's disease / / 17998437 rs4650199 chr1 73652122 T C 0.000000598 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210177 chr1 73655821 A G 0.000000759 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12069039 chr1 73658085 G C 0.00000119 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7514832 chr1 73658507 A T 0.00000111 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10890018 chr1 73662169 A G 0.00000114 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7522520 chr1 73664563 C T 0.00000124 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650201 chr1 73665844 A G 0.00000103 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.000000251 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.00000154 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210187 chr1 73715233 T C 0.000000597 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650206 chr1 73720577 T C 0.00000062 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4571923 chr1 73736562 G A 0.00000113 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.000000897 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.00000184 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000459 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000833 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10789368 chr1 73814159 A G 0.00000282 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10493515 chr1 73815631 T G 2.30E-05 Longevity and age-related phenotypes / / 17903295 rs2340400 chr1 73821281 T C 6.87E-05 Blood Pressure / / pha003039 rs10789369 chr1 73824909 A G 4.00E-10 Schizophrenia / / 23974872 rs11210220 chr1 73849655 T G 6.55E-05 Major depressive disorder / / 22472876 rs11210222 chr1 73849687 T C 8.57E-05 Major depressive disorder / / 22472876 rs1923236 chr1 73853826 T C 5.38E-04 Insulin resistance / / 21901158 rs11210226 chr1 73854284 A G 2.74E-04 Insulin resistance / / 21901158 rs10493517 chr1 73858351 G A 4.20E-05 Longevity and age-related phenotypes / / 17903295 rs10493518 chr1 73860631 G A 3.60E-05 Longevity and age-related phenotypes / / 17903295 rs1885251 chr1 73866020 G T 0.000000233 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7543202 chr1 73872885 A G,T 6.36E-04 Insulin resistance / / 21901158 rs11210235 chr1 73878194 T C 0.000000257 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10465868 chr1 73880654 A G 0.000000243 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7521446 chr1 73890390 T C 0.000000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210242 chr1 73897809 C T 0.000000393 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210243 chr1 73898030 C G 1.24E-04 Multiple complex diseases / / 17554300 rs4113050 chr1 73910055 T C 0.000000611 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs4350155 chr1 73911420 C G 5.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11210251 chr1 73912799 C G 0.00000041 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs505725 chr1 73930405 C A 0.00000328 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs622421 chr1 73930493 A G 0.00000498 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210255 chr1 73931737 G A 0.0000022 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs17570390 chr1 73938246 T C 5.29E-05 Major depressive disorder / / 21621269 rs12754690 chr1 73939898 C T 0.00000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs482063 chr1 73942338 G A 1.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1578022 chr1 73944277 C G 0.0000593 Major depressive disorder / / 23149448 rs17511652 chr1 73962827 C G 5.41E-04 Type 2 diabetes / / 17463246 rs17511652 chr1 73962827 C G 7.70E-04 Multiple complex diseases / / 17554300 rs11210266 chr1 73964312 G T 0.00000404 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs2341260 chr1 74054060 C T 4.00E-06 Cardiac Troponin-T levels / / 23247143 rs1566585 chr1 74069017 A C 2.93E-05 Creatinine levels / / pha003069 rs11210304 chr1 74074098 A G 2.99E-05 Creatinine levels / / pha003069 rs2341263 chr1 74083035 C T 3.00E-06 Metabolite levels (X-11787) / / 23934736 rs11210308 chr1 74084868 C A 4.49E-04 Aortic root size / / 21223598 rs11210317 chr1 74087657 T G 2.79E-05 Creatinine levels / / pha003069 rs7553862 chr1 74109213 G A 9.10E-06 Urinary metabolites / / 21572414 rs4606267 chr1 74112883 G A 2.23E-06 Common variable immunodeficiency / / 21497890 rs1909068 chr1 74116666 G A 7.70E-04 Multiple complex diseases / / 17554300 rs4584347 chr1 74141838 C T 4.66E-04 Sudden cardiac arrest / / 21658281 rs4478768 chr1 74151090 T G 2.65E-05 Hypertension / / pha003042 rs4326578 chr1 74157945 A G 4.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2342207 chr1 74158592 T C 4.21E-05 Hypertension / / pha003042 rs9425128 chr1 74169283 C T 6.27E-04 Alcohol dependence / / 20201924 rs1497840 chr1 74174778 G A 7.91E-04 Heart Failure / / pha002884 rs2132999 chr1 74236657 G A 7.95E-04 Multiple complex diseases / / 17554300 rs7544208 chr1 74255352 A T 4.18E-04 Multiple complex diseases / / 17554300 rs1497842 chr1 74259955 G C 1.62E-04 Multiple complex diseases / / 17554300 rs1340430 chr1 74264128 A G 2.04E-05 Multiple complex diseases / / 17554300 rs1340429 chr1 74264228 A G 2.31E-04 Multiple complex diseases / / 17554300 rs1340428 chr1 74265781 A G 3.18E-04 Multiple complex diseases / / 17554300 rs7516730 chr1 74265891 A T 1.55E-04 Multiple complex diseases / / 17554300 rs72683874 chr1 74317594 T C 3.76E-11 Metabolite levels / / 22286219 rs6672527 chr1 74338530 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6672527 chr1 74338530 C T 6.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6672527 chr1 74338530 C T 6.02E-04 Myocardial Infarction / / pha002883 rs11210359 chr1 74339167 G A 8.00E-06 Bipolar disorder and schizophrenia / / 21057379 rs11210361 chr1 74339944 T C 3.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs967881 chr1 74343741 G A 3.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs17520168 chr1 74344519 T C 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17579506 chr1 74344710 T C 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs11210363 chr1 74349846 G A 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2789708 chr1 74357210 T A 1.37E-05 Suicide attempts in bipolar disorder / / 21041247 rs2792075 chr1 74357362 C T 1.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs10890086 chr1 74361786 C A 1.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1770494 chr1 74363716 A G 5.84E-04 Multiple complex diseases / / 17554300 rs12747535 chr1 74363988 A G 2.48E-04 Multiple complex diseases / / 17554300 rs17094575 chr1 74364041 G T 8.50E-06 Urinary metabolites / / 21572414 rs1340434 chr1 74365646 C T 2.85E-04 Multiple complex diseases / / 17554300 rs1340434 chr1 74365646 C T 4.97E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210366 chr1 74367555 C T 7.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs4650235 chr1 74370640 A G 9.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs7544252 chr1 74376862 G C 4.69E-06 Suicide attempts in bipolar disorder / / 21041247 rs12062996 chr1 74377795 T C 4.66E-06 Suicide attempts in bipolar disorder / / 21041247 rs7550937 chr1 74379312 G A 4.63E-06 Suicide attempts in bipolar disorder / / 21041247 rs1768649 chr1 74379949 A G 4.62E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210368 chr1 74380471 G A 4.60E-06 Suicide attempts in bipolar disorder / / 21041247 rs10493526 chr1 74385680 T C 5.38E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733260 chr1 74387277 T C 4.53E-06 Suicide attempts in bipolar disorder / / 21041247 rs1340424 chr1 74387876 C G 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs12076161 chr1 74388884 A C 5.11E-06 Suicide attempts in bipolar disorder / / 21041247 rs12077198 chr1 74388935 A G 5.09E-06 Suicide attempts in bipolar disorder / / 21041247 rs7533599 chr1 74393112 G A 4.21E-06 Suicide attempts in bipolar disorder / / 21041247 rs12081389 chr1 74395561 T A 4.19E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733262 chr1 74396896 T C 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs12082647 chr1 74398127 A C 4.29E-04 Multiple complex diseases / / 17554300 rs12082647 chr1 74398127 A C 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890092 chr1 74402318 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10890093 chr1 74402825 G T 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890094 chr1 74402888 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733265 chr1 74403128 G C 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1340447 chr1 74403780 C A 4.31E-04 Multiple complex diseases / / 17554300 rs1340447 chr1 74403780 C A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs2733267 chr1 74405054 G A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10493528 chr1 74412652 T A 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs2789706 chr1 74413924 T C 9.38E-05 Suicide attempts in bipolar disorder / / 21041247 rs1417259 chr1 74418437 T G 3.17E-06 Suicide attempts in bipolar disorder / / 21041247 rs7544238 chr1 74419407 C A 3.18E-06 Suicide attempts in bipolar disorder / / 21041247 rs1361463 chr1 74422211 T A 8.21E-05 Multiple complex diseases / / 17554300 rs1361463 chr1 74422211 T A 3.41E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210377 chr1 74423383 G T 3.43E-06 Suicide attempts in bipolar disorder / / 21041247 rs12116914 chr1 74423618 T G 3.44E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064944 chr1 74429944 A G 3.48E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064998 chr1 74430102 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210383 chr1 74435508 C A 2.51E-04 Multiple complex diseases / / 17554300 rs11210383 chr1 74435508 C A 3.58E-06 Suicide attempts in bipolar disorder / / 21041247 rs6424568 chr1 74440382 G A 6.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs12138557 chr1 74442523 C A 3.29E-04 Multiple complex diseases / / 17554300 rs12138557 chr1 74442523 C A 3.71E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890101 chr1 74445584 C T 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9662322 chr1 74452323 G T 4.84E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210389 chr1 74454701 A C 2.64E-05 Suicide attempts in bipolar disorder / / 21041247 rs11210390 chr1 74454776 C T 2.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs2343194 chr1 74457400 G A 4.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs4650237 chr1 74459849 T G 2.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs6663201 chr1 74460997 T C 7.90E-06 Suicide attempts in bipolar disorder / / 21041247 rs6660710 chr1 74461136 A G 7.88E-06 Suicide attempts in bipolar disorder / / 21041247 rs4556311 chr1 74461828 G A 3.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2343196 chr1 74462422 T C 7.91E-06 Suicide attempts in bipolar disorder / / 21041247 rs1384883 chr1 74501477 C T 9.28E-05 Orofacial clefts LRRIQ3 intron 22419666 rs7535929 chr1 74560002 T G 8.72E-05 Orofacial clefts LRRIQ3 intron 22419666 rs10493529 chr1 74623448 A T 2.18E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs10493529 chr1 74623448 A T 1.90E-05 Subclinical atherosclerosis LRRIQ3 intron 17903303 rs1483790 chr1 74627358 T C 2.74E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs17591292 chr1 74646058 C T 5.38E-04 Alcohol dependence LRRIQ3 intron 21314694 rs518769 chr1 74699912 G A 1.96E-04 Suicide attempts in bipolar disorder FPGT-TNNI3K intron 21423239 rs12118620 chr1 74727955 C G 5.00E-16 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs12118620 chr1 74727955 C G 8.00E-12 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs516569 chr1 74782279 A G 5.87E-04 Myopia (pathological) TNNI3K intron 21095009 rs1527683 chr1 74822937 T C 8.71E-04 Suicide attempts in bipolar disorder TNNI3K intron 21423239 rs699842 chr1 74874431 T C 7.52E-04 Acute lung injury TNNI3K intron 22295056 rs7517677 chr1 74880189 T G 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs17095295 chr1 74895901 G A 3.43E-04 Multiple complex diseases TNNI3K intron 17554300 rs17095295 chr1 74895901 G A 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs477159 chr1 74898117 G A 0.0000338 post-traumatic stress disorder TNNI3K intron 22869035 rs477159 chr1 74898117 G A 3.38E-05 Schizophrenia TNNI3K intron 22883433 rs792884 chr1 74899573 T G 0.0000157 post-traumatic stress disorder TNNI3K intron 22869035 rs792884 chr1 74899573 T G 1.57E-05 Schizophrenia TNNI3K intron 22883433 rs643371 chr1 74900897 A C 0.0000987 post-traumatic stress disorder TNNI3K intron 22869035 rs643371 chr1 74900897 A C 9.87E-05 Schizophrenia TNNI3K intron 22883433 rs1325604 chr1 74907316 G A 0.000085 post-traumatic stress disorder TNNI3K intron 22869035 rs1325604 chr1 74907316 G A 8.50E-05 Schizophrenia TNNI3K intron 22883433 rs6690871 chr1 74977277 A G 9.69E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 9.94E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 1.07E-08 Obesity TNNI3K intron 22484627 rs984167 chr1 74981547 A T 8.20E-05 HDL particle features TNNI3K intron 21283740 rs1514177 chr1 74991402 C G 5.00E-09 Obesity TNNI3K intron 23563607 rs1514175 chr1 74991644 A G 8.00E-14 Body mass index TNNI3K intron 20935630 rs1514175 chr1 74991644 A G 6.38E-05 Body mass index TNNI3K intron 22344219 rs1514175 chr1 74991644 A G 8.16E-14 Body mass index TNNI3K intron 23001569 rs1514175 chr1 74991644 A G 3.00E-11 Body mass index TNNI3K intron 23669352 rs1514174 chr1 74993063 C T 6.00E-06 Pubertal anthropometrics TNNI3K intron 23449627 rs1514174 chr1 74993063 C T 1.00E-08 Obesity TNNI3K intron 23563607 rs113313252 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs12142020 chr1 75000011 A T 4.32E-11 Body mass index TNNI3K intron 23669352 rs201167096 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs3894212 chr1 75001683 T G 1.80E-04 Type 2 diabetes and 6 quantitative traits TNNI3K intron 17848626 rs7541513 chr1 75014195 G A 2.30E-04 Iris characteristics / / 21835309 rs10789396 chr1 75014362 T C 7.82E-04 Obesity (extreme) / / 21935397 rs4287129 chr1 75016147 T G 5.46E-05 Type 2 diabetes / / 17463246 rs3931879 chr1 75030642 A T 4.70E-04 Type 2 diabetes / / 17463246 rs2305549 chr1 75055419 T C 5.48E-04 Heart Failure C1orf173 missense pha002885 rs41337449 chr1 75099977 T C 9.08E-05 Multiple complex diseases C1orf173 intron 17554300 rs17095690 chr1 75106741 G A 1.65E-05 Attention deficit hyperactivity disorder C1orf173 intron 20732627 rs696666 chr1 75146093 T C 4.15E-04 Type 2 diabetes / / 17463246 rs696667 chr1 75149512 A G 3.07E-04 Type 2 diabetes / / 17463246 rs696668 chr1 75149922 G T 3.07E-04 Type 2 diabetes / / 17463246 rs575533 chr1 75155657 T C 8.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12061533 chr1 75158118 A G 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1340985 chr1 75160724 A G 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6662846 chr1 75170143 A C 4.20E-05 Glioma (high-grade) / / 19578366 rs17552114 chr1 75172652 T C 9.54E-04 Coronary Artery Disease CRYZ cds-synon 17634449 rs11485264 chr1 75197533 A G 1.00E-04 Cognitive impairment induced by topiramate CRYZ intron 22091778 rs3931020 chr1 75235317 T C 6.00E-12 Resistin levels / / 22843503 rs17095902 chr1 75240211 A G 9.70E-04 Major depressive disorder / / 22472876 rs1409785 chr1 75248122 G A 6.50E-07 Glioma (high-grade) / / 19578366 rs7547190 chr1 75252764 C T 4.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs1575983 chr1 75262196 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11161851 chr1 75298782 T C 7.00E-06 Visceral fat / / 22589738 rs12747472 chr1 75311462 T C 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs12120668 chr1 75321017 G C 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12033503 chr1 75326398 C T 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743570 chr1 75333502 G C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs7552148 chr1 75340175 C T 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6664850 chr1 75352327 G A 2.04E-04 Height / / 17255346 rs6664850 chr1 75352327 G A 6.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1327098 chr1 75361993 G A 7.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs17562236 chr1 75374025 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12755578 chr1 75374854 C G 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs12121720 chr1 75386937 G A 5.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs12127639 chr1 75395198 C G 6.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs12129191 chr1 75395327 A G 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs12732265 chr1 75398270 T C 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10782637 chr1 75403587 C A 6.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs17096151 chr1 75425129 C T 8.45E-05 Aging (time to event) / / 21782286 rs11162286 chr1 75427397 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522882 chr1 75442994 T A 4.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2346344 chr1 75446663 T G 4.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3845358 chr1 75449592 A C 2.41E-04 Height / / 17255346 rs3845358 chr1 75449592 A C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs12743802 chr1 75458806 G A 3.85E-05 Paclitaxel-induced neuropathy / / 23776197 rs10493550 chr1 75460333 G A 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs3912426 chr1 75462461 A G 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6693646 chr1 75466410 G T 4.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs12750340 chr1 75469124 C T 5.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs696676 chr1 75479163 A G 9.69E-04 Type 2 diabetes / / 17463246 rs12089365 chr1 75486214 A G 4.77E-04 Multiple complex diseases / / 17554300 rs12089365 chr1 75486214 A G 6.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6703099 chr1 75534319 T C 8.69E-04 Type 2 diabetes / / 17463246 rs2077678 chr1 75534827 A G 4.40E-05 Kidney function and endocine traits / / 17903292 rs7541725 chr1 75549806 T C 7.21E-04 Multiple complex diseases / / 17554300 rs11162495 chr1 75555722 T G 8.83E-04 Type 2 diabetes / / 17463246 rs12138223 chr1 75615026 A G,T 6.82E-05 Serum metabolites LHX8 intron 19043545 rs7545324 chr1 75662563 A G 8.88E-05 Body Mass Index / / pha003015 rs1405311 chr1 75675047 T G 8.88E-05 Body Mass Index SLC44A5 intron pha003015 rs149696907 chr1 75693501 G A 0.000037 Breast cancer SLC44A5 missense 23555315 rs41385949 chr1 75702129 C T 7.43E-04 Multiple complex diseases SLC44A5 intron 17554300 rs616827 chr1 75703209 G T 1.61E-05 Body Mass Index SLC44A5 intron pha003015 rs596098 chr1 75722892 G A 8.73E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249675 chr1 75770625 C T 7.00E-06 Capecitabine sensitivity SLC44A5 intron 22864933 rs11163089 chr1 75778546 C T 7.71E-04 Type 2 diabetes SLC44A5 intron 17463246 rs1249667 chr1 75779988 G A 5.13E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1262045 chr1 75781308 T G 3.09E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249666 chr1 75781855 T C 2.57E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249664 chr1 75785042 T C 3.31E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097953 chr1 75801795 A G 8.35E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs10493574 chr1 75803142 C T 6.74E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096776 chr1 75808190 C T 6.93E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097955 chr1 75811152 T C 6.89E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096782 chr1 75812191 T C 5.11E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249811 chr1 75863089 G A 1.50E-06 Urinary metabolites SLC44A5 intron 21572414 rs4540592 chr1 75883281 T C 3.33E-06 Total ventricular volume SLC44A5 intron 21116278 rs12410333 chr1 75895626 T C 5.12E-06 Total ventricular volume SLC44A5 intron 21116278 rs10493575 chr1 75903516 G A 3.42E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040079 chr1 75906421 G T 3.29E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040082 chr1 75906874 A G 3.23E-06 Total ventricular volume SLC44A5 intron 21116278 rs2347218 chr1 75911113 A G 1.40E-06 Urinary metabolites SLC44A5 intron 21572414 rs2587031 chr1 75911769 G A 1.60E-06 Urinary metabolites SLC44A5 intron 21572414 rs1857353 chr1 75913826 C T 2.00E-06 MRI atrophy measures SLC44A5 intron 21116278 rs4598448 chr1 75963934 G A 8.85E-04 Alzheimer's disease SLC44A5 intron 17998437 rs12401888 chr1 75967778 C T 8.68E-04 Glycemic traits (pregnancy) SLC44A5 intron 23903356 rs13373826 chr1 75970795 A G 2.93E-09 Multiple complex diseases SLC44A5 intron 17554300 rs211786 chr1 75992019 A G 6.81E-04 Multiple complex diseases SLC44A5 intron 17554300 rs7553832 chr1 76091427 G A 2.47E-04 Hemoglobin concentration / / 20534544 rs211718 chr1 76106675 T C 4.63E-06 Serum metabolites / / 19043545 rs211718 chr1 76106675 T C 1.00E-63 Metabolite levels / / 20037589 rs211718 chr1 76106675 T C 2.00E-71 Metabolic traits / / 21886157 rs2347540 chr1 76119468 G A 2.50E-05 Esophageal cancer (squamous cell) / / 22960999 rs1535740 chr1 76134765 C A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7552404 chr1 76135946 A G 1.00E-77 Blood metabolite levels / / 24816252 rs7552404 chr1 76135946 A G 3.00E-43 Blood metabolite levels / / 24816252 rs12045299 chr1 76154750 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12045299 chr1 76154750 T C 8.40E-04 Myopia (pathological) / / 21095009 rs4949874 chr1 76161889 T C 2.00E-172 Blood metabolite ratios / / 24816252 rs1391520 chr1 76174752 A C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1391520 chr1 76174752 A C 8.40E-04 Myopia (pathological) / / 21095009 rs1251079 chr1 76189445 T C 4.90E-04 Type 2 diabetes ACADM nearGene-5 17463246 rs12744608 chr1 76206490 G T 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs1146579 chr1 76209792 T A,C,G 1.80E-05 Serum metabolites ACADM intron 19043545 rs11161510 chr1 76210289 C T 1.72E-06 Serum metabolites ACADM intron 19043545 rs11161511 chr1 76210477 C T 3.33E-06 Serum metabolites ACADM intron 19043545 rs1146581 chr1 76213024 T G 7.96E-05 Attention deficit hyperactivity disorder ACADM intron 22420046 rs9660848 chr1 76214508 G A 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs11161521 chr1 76216330 T C 1.00E-63 Blood metabolite levels ACADM intron 24816252 rs11161521 chr1 76216330 T C 6.00E-100 Blood metabolite levels ACADM intron 24816252 rs1694419 chr1 76219801 G A 2.49E-05 Serum metabolites ACADM intron 19043545 rs1146586 chr1 76227974 C T 2.91E-10 LDL cholesterol ACADM intron 23063622 rs1146634 chr1 76252011 G A 1.70E-05 Urinary metabolites RABGGTB intron 21572414 rs5745309 chr1 76261914 T G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 nearGene-5 24483146 rs1146644 chr1 76264788 T C 2.50E-05 Urinary metabolites MSH4 intron 21572414 rs5745331 chr1 76273313 A G 3.47E-04 Alcohol dependence MSH4 intron 20201924 rs5745354 chr1 76275178 G A 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs1144337 chr1 76278877 T A,C,G 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs12024645 chr1 76284395 A G 5.71E-04 Myopia (pathological) MSH4 intron 21095009 rs1251272 chr1 76289004 C T 0.0003488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1251272 chr1 76289004 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12076093 chr1 76301656 G A 0.0003491 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12076093 chr1 76301656 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs10873738 chr1 76302233 A G 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs10873738 chr1 76302233 A G 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs9970840 chr1 76303720 A G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 intron 24483146 rs12090712 chr1 76304215 C T 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12090712 chr1 76304215 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7514912 chr1 76307558 A G 0.0003499 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7514912 chr1 76307558 A G 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7548391 chr1 76307595 C T 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7548391 chr1 76307595 C T 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs1603734 chr1 76311632 T C 0.0003512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1603734 chr1 76311632 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs2047435 chr1 76313874 C A,T 0.0003518 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs2047435 chr1 76313874 C A,T 3.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12409592 chr1 76317549 G A 6.86E-04 Myopia (pathological) MSH4 intron 21095009 rs11161887 chr1 76386305 A G 4.50E-04 Myopia (pathological) ASB17 intron 21095009 rs10873804 chr1 76394150 C A 2.62E-04 Myopia (pathological) ASB17 intron 21095009 rs3795251 chr1 76397972 C T 2.62E-04 Myopia (pathological) ASB17 missense 21095009 rs1251594 chr1 76415210 A C 0.0003271 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251594 chr1 76415210 A C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6685657 chr1 76417440 G A 9.74E-04 Alzheimer's disease / / 17998437 rs1251588 chr1 76420745 C T 7.06E-04 Myocardial Infarction / / pha002883 rs12405994 chr1 76435420 A T 3.80E-07 Malaria / / 19465909 rs1251539 chr1 76436260 C A 0.0003236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251539 chr1 76436260 C A 3.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417402 chr1 76437196 G A 5.00E-07 Malaria / / 19465909 rs12566984 chr1 76438011 G T 4.20E-04 Myopia (pathological) / / 21095009 rs1251560 chr1 76451190 T C 0.0003173 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251560 chr1 76451190 T C 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417403 chr1 76454816 C T 0.0003162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1417403 chr1 76454816 C T 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1340686 chr1 76455075 G A 0.0003152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1340686 chr1 76455075 G A 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1361488 chr1 76455765 A C 0.0003164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1361488 chr1 76455765 A C 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770878 chr1 76456329 C T 0.0003182 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770878 chr1 76456329 C T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770879 chr1 76456512 C G 0.0003197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770879 chr1 76456512 C G 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12731410 chr1 76464725 C A 9.49E-04 Depression (quantitative trait) / / 20800221 rs12122440 chr1 76477207 A C 2.00E-06 Pubertal anthropometrics / / 23449627 rs12753569 chr1 76484014 G T 8.00E-06 Personality dimensions / / 20691247 rs3179693 chr1 76484827 G A 8.73E-05 Type 2 diabetes / / 17463246 rs6672844 chr1 76486884 A G 1.10E-04 Type 2 diabetes / / 17463246 rs17598972 chr1 76487108 T C 6.84E-04 Type 2 diabetes / / 17463246 rs10493577 chr1 76489223 A T 2.84E-04 Type 2 diabetes / / 17463246 rs11162069 chr1 76489779 A T 1.22E-04 Type 2 diabetes / / 17463246 rs17097922 chr1 76490425 C G 1.07E-04 Type 2 diabetes / / 17463246 rs17097929 chr1 76491041 G T 1.27E-04 Type 2 diabetes / / 17463246 rs1866254 chr1 76492334 T C 2.81E-05 Type 2 diabetes / / 17463246 rs946161 chr1 76510513 A G 3.04E-05 Multiple complex diseases / / 17554300 rs17097997 chr1 76510789 T A 3.25E-04 Type 2 diabetes / / 17463246 rs1251493 chr1 76518108 T A 1.35E-04 Type 2 diabetes / / 17463246 rs1340688 chr1 76520630 T G 1.45E-04 Type 2 diabetes / / 17463246 rs17098034 chr1 76532801 A C 7.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251465 chr1 76538396 G A 7.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251575 chr1 76557784 A G 6.05E-05 stroke (ischemic) ST6GAL/C3 intron 17434096 rs915404 chr1 76602662 A G 2.80E-09 Adiponectin levels ST6GAL/C3 intron 20887962 rs7548049 chr1 76608072 C T 0.00005091 Sarcoidosis ST6GAL/C3 intron 22952805 rs2706183 chr1 76617830 G A 7.80E-05 Adverse response to radiation therapy ST6GAL/C3 intron 23719583 rs2783658 chr1 76620313 C T 2.40E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs425110 chr1 76625747 A G 1.63E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs3011997 chr1 76627054 C T 2.60E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs1414403 chr1 76627868 G A 5.36E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs517036 chr1 76680525 T C 3.25E-06 F-cell distribution ST6GAL/C3 intron 21326311 rs547342 chr1 76687275 A G 5.47E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs547342 chr1 76687275 A G 1.09E-05 F-cell distribution ST6GAL/C3 intron 21326311 rs17098442 chr1 76700296 C G 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs17098450 chr1 76700697 G A 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs544858 chr1 76725259 A G 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ST6GAL/C3 intron 24023788 rs6696780 chr1 76731907 G A 8.47E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs12079387 chr1 76746838 C A,T 3.99E-05 Orofacial clefts ST6GAL/C3 intron 22419666 rs10873876 chr1 76772328 T C 4.00E-06 Acute lymphoblastic leukemia (childhood) ST6GAL/C3 intron 19684603 rs10873876 chr1 76772328 T C 4.00E-06 Nasopharyngeal carcinoma ST6GAL/C3 intron 20512145 rs3884182 chr1 76774201 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs2392030 chr1 76784636 T C 8.37E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs4421636 chr1 76785393 C T 8.46E-04 Myocardial Infarction ST6GAL/C3 intron pha002883 rs11585239 chr1 76785765 A G 0.0004475 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11585239 chr1 76785765 A G 4.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098734 chr1 76787267 A G 0.000402 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098734 chr1 76787267 A G 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098736 chr1 76787466 G T 0.0003996 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098736 chr1 76787466 G T 4.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4628548 chr1 76791163 G A 9.30E-04 Alzheimer's disease ST6GAL/C3 intron 24755620 rs10493590 chr1 76794327 C G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493590 chr1 76794327 C G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs10493591 chr1 76796785 A G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493591 chr1 76796785 A G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4408196 chr1 76798359 A C 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs4408196 chr1 76798359 A C 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17672606 chr1 76799446 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17672606 chr1 76799446 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs1325290 chr1 76801781 C G 1.30E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs752819 chr1 76803522 G A 5.63E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs752819 chr1 76803522 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs752819 chr1 76803522 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7539896 chr1 76806274 C G 0.0007443 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7539896 chr1 76806274 C G 7.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7516680 chr1 76806409 G A 0.0007424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7516680 chr1 76806409 G A 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098793 chr1 76809752 A G 0.0007408 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098793 chr1 76809752 A G 7.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs12562911 chr1 76822600 A G 7.62E-04 Alcohol dependence ST6GAL/C3 intron 21314694 rs7524886 chr1 76826279 C T 6.00E-05 Immunoglobulin A ST6GAL/C3 intron 20694011 rs12239582 chr1 76837237 A C 2.70E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 5.86E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs12144344 chr1 76839536 C T 2.20E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 6.00E-07 Serum vitamin D-binding protein levels ST6GAL/C3 intron 24740207 rs12144344 chr1 76839536 C T 3.52E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs1540964 chr1 76840728 A C 7.65E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1540964 chr1 76840728 A C 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs1359468 chr1 76851135 A G 7.18E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1359468 chr1 76851135 A G 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs6667721 chr1 76867853 G A 1.30E-05 Bone mineral density (BMD),in women ST6GAL/C3 intron 20164292 rs11577449 chr1 76869325 T A 0.000167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11577449 chr1 76869325 T A 1.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7515898 chr1 76871716 G A 0.000709798 Hypertension (early onset hypertension) ST6GAL/C3 intron 22479346 rs4949631 chr1 76898955 G A 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs4949718 chr1 76899464 T C 2.23E-05 Type 2 diabetes ST6GAL/C3 intron 17463246 rs4949718 chr1 76899464 T C 1.00E-06 Liver enzyme levels (aspartate transaminase) ST6GAL/C3 intron 24124411 rs4949718 chr1 76899464 T C 2.00E-07 Liver enzyme levels (alanine transaminase) ST6GAL/C3 intron 24124411 rs1436086 chr1 76973245 G T 1.10E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs315087 chr1 76989264 T C 1.67E-05 Tuberculosis ST6GAL/C3 intron 24057671 rs410076 chr1 77001631 G A 1.03E-07 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 7.34E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 5.24E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs6675095 chr1 77016065 G A 3.57E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs315049 chr1 77023273 G A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 3.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 4.32E-06 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 8.14E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 6.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs7513970 chr1 77041694 G A 5.95E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs2117905 chr1 77052596 A G 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315039 chr1 77054590 T C 6.75E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs56012468 chr1 77055776 C T 2.00E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs2574775 chr1 77069228 G A 2.71E-04 Smoking initiation ST6GAL/C3 intron 24665060 rs2647389 chr1 77072458 T C 3.60E-05 Multiple sclerosis ST6GAL/C3 intron 17660530 rs665178 chr1 77075591 C T 0.000175 Salmonella-induced pyroptosis ST6GAL/C3 intron 22837397 rs485141 chr1 77083864 C A 7.38E-05 Coronary restenosis ST6GAL/C3 intron 21878436 rs3748712 chr1 77098483 A T 9.38E-04 Multiple complex diseases / / 17554300 rs12134580 chr1 77121319 T C 7.52E-05 Depression (quantitative trait) / / 23290196 rs551585 chr1 77126373 C A 3.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs664576 chr1 77179690 T C 8.58E-05 Neuroblastoma / / pha002895 rs7534158 chr1 77188392 C T 6.40E-05 Blood pressure / / 19114657 rs619463 chr1 77196032 C A 9.43E-05 Cardiovascular disease / / pha003064 rs2221083 chr1 77221362 A G 4.28E-05 LDL lipoproteins / / pha002902 rs4506508 chr1 77256336 C A 1.15E-04 Multiple complex diseases / / 17554300 rs11162212 chr1 77256966 C A 6.42E-04 Body mass index / / 21701565 rs4586020 chr1 77265640 C A 4.85E-05 Odorant perception / / 23910658 rs17099699 chr1 77372136 C G 5.46E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12567699 chr1 77437423 G A 4.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C5 intron 20877124 rs4949764 chr1 77462662 T C 1.45E-05 Response to Vitamin E supplementation ST6GAL/C5 intron 22437554 rs199698 chr1 77506217 C T 6.71E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs199699 chr1 77507030 T C 2.49E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12084236 chr1 77507127 A G 1.68E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs41515647 chr1 77517009 C A 6.67E-06 Multiple complex diseases ST6GAL/C5 intron 17554300 rs191827 chr1 77548518 T C 1.70E-05 Urinary metabolites / / 21572414 rs1048575 chr1 77558057 G C 9.89E-04 Obesity (extreme) PIGK UTR-3 21935397 rs2069224 chr1 77560216 C T 4.62E-04 Obesity (extreme) PIGK intron 21935397 rs11162271 chr1 77563988 G A 5.10E-04 Obesity (extreme) PIGK intron 21935397 rs11806823 chr1 77565415 A G 5.18E-04 Obesity (extreme) PIGK intron 21935397 rs4949766 chr1 77569489 C T 5.32E-04 Obesity (extreme) PIGK intron 21935397 rs7538430 chr1 77590961 A G 5.29E-04 Obesity (extreme) PIGK intron 21935397 rs1146675 chr1 77630053 G A 5.22E-04 Obesity (extreme) PIGK intron 21935397 rs1779174 chr1 77694640 C T 8.98E-04 Type 2 diabetes / / 17463246 rs12091579 chr1 77697013 C T 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407610 chr1 77707310 A T 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1592340 chr1 77719729 G A 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518441 chr1 77726980 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10518441 chr1 77726980 A G 6.12E-05 Prostate cancer / / pha002878 rs2799549 chr1 77727898 T C 5.03E-05 Cognitive test performance / / 20125193 rs1167220 chr1 77729805 G A 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1988302 chr1 77731287 C A 4.80E-06 Urinary metabolites / / 21572414 rs940283 chr1 77737217 C T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518446 chr1 77740836 G C 2.00E-04 Coronary Artery Disease / / 17634449 rs1851736 chr1 77747248 G T 2.40E-06 Urinary metabolites / / 21572414 rs7517698 chr1 77749363 G A,C 5.75E-07 Multiple sclerosis AK5 intron 17660530 rs10747353 chr1 77751193 A C 3.49E-04 Epilepsy AK5 intron 22116939 rs10782645 chr1 77754853 G A 2.67E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs2689683 chr1 77755686 C T 4.60E-06 Urinary metabolites AK5 intron 21572414 rs2689676 chr1 77764869 G A 7.90E-06 Urinary metabolites AK5 intron 21572414 rs10493603 chr1 77768778 A G 8.78E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs10493603 chr1 77768778 A G 3.26E-04 Epilepsy AK5 intron 22116939 rs2815319 chr1 77775066 A G 1.40E-05 Urinary metabolites AK5 intron 21572414 rs12751884 chr1 77784762 A G 3.11E-04 Epilepsy AK5 intron 22116939 rs2602951 chr1 77791025 T G 1.10E-05 Urinary metabolites AK5 intron 21572414 rs2815326 chr1 77798945 C T 8.90E-06 Urinary metabolites AK5 intron 21572414 rs17378915 chr1 77804242 A G 2.10E-05 Urinary metabolites AK5 intron 21572414 rs1463324 chr1 77806954 G A 7.40E-06 Urinary metabolites AK5 intron 21572414 rs1010196 chr1 77815566 C T 4.34E-04 Epilepsy AK5 intron 22116939 rs12073962 chr1 77817304 G C 5.20E-04 Suicide attempts in bipolar disorder AK5 intron 21423239 rs6672375 chr1 77818143 A G 4.20E-05 Leukocyte Counts AK5 intron pha003091 rs1377733 chr1 77819743 A G 6.20E-04 Heart Failure AK5 intron pha002885 rs10493604 chr1 77826732 T G 6.85E-05 Odorant perception AK5 intron 23910658 rs10493604 chr1 77826732 T G 2.37E-04 Stroke AK5 intron pha002887 rs7546131 chr1 77844602 G A 6.47E-06 Sodium levels AK5 intron pha003093 rs6663047 chr1 77865140 G A 3.24E-06 Sodium levels AK5 intron pha003093 rs4949802 chr1 77876353 T C 4.20E-05 Response to alcohol consumption (flushing response) AK5 intron 24277619 rs10873937 chr1 77879827 C T 1.31E-04 Nicotine smoking AK5 intron 19268276 rs12131772 chr1 77883671 C G 2.55E-04 Nicotine smoking AK5 intron 19268276 rs6658302 chr1 77908985 A G 5.18E-04 Multiple complex diseases AK5 intron 17554300 rs1498405 chr1 77927948 A G 8.73E-04 Obesity (extreme) AK5 intron 21935397 rs11162351 chr1 77944732 C G 5.65E-04 Multiple complex diseases AK5 intron 17554300 rs6695572 chr1 77945635 G A 2.63E-09 Narcolepsy AK5 intron 19629137 rs6695572 chr1 77945635 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs6698295 chr1 77945965 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs4949803 chr1 77951083 C T 1.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels AK5 intron 20031582 rs2088518 chr1 77951330 A T 2.80E-04 Obesity (extreme) AK5 intron 21935397 rs9324162 chr1 77954804 A G 1.46E-04 Obesity (extreme) AK5 intron 21935397 rs17380544 chr1 77958712 G A 4.79E-04 Obesity (extreme) AK5 intron 21935397 rs2803155 chr1 77958837 A C 6.27E-04 Obesity (extreme) AK5 intron 21935397 rs11162355 chr1 77961074 G T 6.70E-04 Obesity (extreme) AK5 intron 21935397 rs7514041 chr1 77964269 G A 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 3.33E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 2.56E-05 Brain structure AK5 intron 22504417 rs3112830 chr1 77966494 A T 5.68E-05 Multiple complex diseases AK5 intron 17554300 rs2803152 chr1 77966756 T C 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs12049202 chr1 77967523 C T 2.95E-05 Brain structure AK5 intron 22504417 rs12040471 chr1 77968401 T A 3.42E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 3.45E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 2.66E-05 Brain structure AK5 intron 22504417 rs17380796 chr1 77976117 A G 7.04E-05 Obesity (extreme) AK5 intron 21935397 rs12729914 chr1 77980235 T C 4.00E-04 Obesity (extreme) AK5 intron 21935397 rs11811611 chr1 77982017 C T 3.99E-04 Obesity (extreme) AK5 intron 21935397 rs12042177 chr1 77986638 A G 3.63E-04 Obesity (extreme) AK5 intron 21935397 rs3509 chr1 78025551 C T 7.98E-04 Multiple complex diseases AK5 UTR-3 17554300 rs3509 chr1 78025551 C T 3.41E-04 Lymphocyte counts AK5 UTR-3 22286170 rs3509 chr1 78025551 C T 7.21E-04 Response to taxane treatment (placlitaxel) AK5 UTR-3 23006423 rs728741 chr1 78029365 A G 4.80E-05 Cognitive function / / 24684796 rs17381664 chr1 78048331 T C 3.00E-08 Obesity ZZZ3 intron 23563607 rs1389790 chr1 78089399 T C 5.90E-05 Cognitive function ZZZ3 intron 24684796 rs17100965 chr1 78206733 A G 6.71E-04 Multiple complex diseases USP33 intron 17554300 rs12085547 chr1 78295506 G A 9.69E-04 Suicide attempts in bipolar disorder FAM73A intron 21423239 rs9729667 chr1 78349214 C T 6.84E-05 Recombination rate NEXN-AS1 intron 21698098 rs1166706 chr1 78359029 T C 5.60E-05 Cognitive function NEXN intron 24684796 rs1166706 chr1 78359029 T C 8.70E-05 Cognitive function NEXN intron 24684796 rs11807240 chr1 78418776 G A 9.39E-04 Amyotrophic lateral sclerosis (sporadic) FUBP1 intron 24529757 rs17383213 chr1 78433531 T C 1.99E-04 Smoking initiation FUBP1 intron 24665060 rs11162405 chr1 78469660 A G 2.54E-05 Bipolar disorder / / 21926972 rs7524504 chr1 78494732 G T 3.75E-04 Multiple complex diseases / / 17554300 rs6424659 chr1 78501215 T C 7.55E-05 Cognitive impairment induced by topiramate / / 22091778 rs631045 chr1 78557514 G A 1.44E-06 Lymphocyte counts GIPC2 intron 22286170 rs718294 chr1 78564196 G A 3.35E-04 Alzheimer's disease GIPC2 intron 17998437 rs1022103 chr1 78589598 T C 2.43E-05 Personality dimensions GIPC2 intron 22628180 rs554298 chr1 78604614 G A 0.00000231 Sasang constitution (Soeum) / / 22394158 rs17101358 chr1 78605081 A G 3.74E-05 Multiple complex diseases / / 17554300 rs17391694 chr1 78623626 C T 6.82E-07 Lung adenocarcinoma / / 19836008 rs17391694 chr1 78623626 C T 2.00E-11 Height / / 20881960 rs17391694 chr1 78623626 C T 3.00E-09 Crohn's disease / / 23128233 rs1890850 chr1 78641967 G A 3.32E-05 Personality dimensions / / 22628180 rs17101475 chr1 78643674 C T 2.47E-04 Multiple complex diseases / / 17554300 rs4385660 chr1 78655779 G A 1.61E-05 Personality dimensions / / 22628180 rs11162429 chr1 78665643 A G 3.30E-05 Personality dimensions / / 22628180 rs12406019 chr1 78678130 A G 6.87E-04 Multiple complex diseases / / 17554300 rs2882801 chr1 78717850 G A 1.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MGC27382 intron 24023788 rs10489948 chr1 78747540 T C 6.42E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 8.92E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 1.70E-05 Asthma MGC27382 intron 22561531 rs2882802 chr1 78762998 A G 2.45E-04 Birth weight MGC27382 intron 17255346 rs2104621 chr1 78772009 G C 2.15E-06 Serum metabolites MGC27382 intron 19043545 rs7545762 chr1 78772285 T A 8.88E-04 Type 2 diabetes MGC27382 intron 17463246 rs12064888 chr1 78805511 A G 5.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) MGC27382 intron 24236485 rs648425 chr1 78887208 T C 8.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs674345 chr1 78894934 C T 6.87E-04 Alzheimer's disease / / 22005930 rs3753380 chr1 78956432 T C 1 Drug response to Latanoprost / / 17467803 rs3766354 chr1 78957550 G A 5.00E-04 Myocardial infarction PTGFR intron 21107343 rs1575397 chr1 78977962 G C 3.23E-04 Smoking initiation PTGFR intron 24665060 rs672561 chr1 78987302 T C 9.00E-06 IgG glycosylation PTGFR intron 23382691 rs3766345 chr1 78990275 C G 7.19E-05 Orofacial clefts PTGFR intron 22419666 rs473027 chr1 78992202 A G 8.44E-04 Multiple complex diseases PTGFR intron 17554300 rs473027 chr1 78992202 A G 7.12E-05 Serum metabolites PTGFR intron 19043545 rs1265663 chr1 78997913 C T 0.000000744 Triglycerides PTGFR intron 23063622 rs12060353 chr1 79001920 T G 7.28E-04 Coronary heart disease PTGFR intron 21606135 rs3766332 chr1 79001994 A T 2.90E-04 Multiple complex diseases PTGFR intron 17554300 rs3766332 chr1 79001994 A T 0.00028 Coronary artery calcification PTGFR intron 23727086 rs12074883 chr1 79002544 C T 2.94E-04 Coronary heart disease PTGFR UTR-3 21606135 rs12737480 chr1 79036992 C T 4.00E-05 Lung cancer / / 18978790 rs6424779 chr1 79041520 C T 8.00E-05 Lung cancer / / 18978790 rs3820093 chr1 79095526 G A 1.07E-05 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs1981071 chr1 79102726 C T 2.50E-04 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs273252 chr1 79106899 T C 8.93E-06 Serum metabolites IFI44L intron 19043545 rs4650590 chr1 79110518 A G 5.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) IFI44L UTR-3 23648065 rs1333971 chr1 79133774 C T 3.49E-04 Multiple complex diseases / / 17554300 rs4650376 chr1 79176868 C T 2.00E-06 IgG glycosylation / / 23382691 rs1033999 chr1 79211929 C T 9.86E-05 Waist-Hip Ratio / / pha003013 rs1033999 chr1 79211929 C T 3.58E-05 Waist-Hip Ratio / / pha003028 rs1751529 chr1 79214489 G A 9.12E-05 Waist-Hip Ratio / / pha003013 rs1751529 chr1 79214489 G A 3.30E-05 Waist-Hip Ratio / / pha003028 rs12133510 chr1 79221675 A G 2.31E-04 Coronary heart disease / / 21606135 rs10493613 chr1 79223199 T C 8.88E-05 Waist-Hip Ratio / / pha003028 rs1937023 chr1 79225626 C T 8.18E-05 Waist-Hip Ratio / / pha003028 rs1937020 chr1 79227956 C T 4.00E-06 Anorexia nervosa / / 23568457 rs4650608 chr1 79238015 T C 5.42E-04 Multiple complex diseases / / 17554300 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder / / 22182935 rs4650608 chr1 79238015 T C 8.49E-07 Major depressive disorder / / 22472876 rs4650608 chr1 79238015 T C 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4650608 chr1 79238015 T C 0.000206 Schizophrenia / / 23637625 rs4650608 chr1 79238015 T C 1.22E-05 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 1.77E-04 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder and schizophrenia / / 24280982 rs10873996 chr1 79246505 G A 8.11E-05 Waist-Hip Ratio / / pha003013 rs10873996 chr1 79246505 G A 9.80E-05 Waist-Hip Ratio / / pha003028 rs12730292 chr1 79254762 C G 5.00E-06 Bipolar disorder / / 21926972 rs10873998 chr1 79263805 T C 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs12034709 chr1 79272660 T C 9.31E-04 Myocardial Infarction / / pha002883 rs1937028 chr1 79277854 T C 7.00E-04 Parkinson's disease / / 17052657 rs12136365 chr1 79288819 T C 7.64E-05 Serum metabolites / / 19043545 rs12044353 chr1 79295415 G A 7.09E-05 Serum metabolites / / 19043545 rs2352513 chr1 79295552 A G,T 6.22E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 9.50E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 6.30E-04 Coronary heart disease / / 21606135 rs6680564 chr1 79300939 A C 7.80E-05 Serum metabolites / / 19043545 rs6680564 chr1 79300939 A C 5.40E-04 Coronary heart disease / / 21606135 rs12026347 chr1 79303750 C T 8.83E-04 Coronary heart disease / / 21606135 rs1248482 chr1 79319633 T A 4.25E-05 Serum metabolites / / 19043545 rs1248482 chr1 79319633 T A 6.67E-06 Recombination rate / / 21698098 rs1780731 chr1 79336024 C T 6.34E-05 Serum metabolites / / 19043545 rs2996691 chr1 79336607 T G 9.84E-05 Body Mass Index / / pha003020 rs2882958 chr1 79353290 A G 2.80E-05 Urinary metabolites / / 21572414 rs10518589 chr1 79353515 A T 2.40E-05 Self-reported allergy / / 23817569 rs17411879 chr1 79358211 A C 3.75E-05 Serum metabolites ELTD1 intron 19043545 rs17411879 chr1 79358211 A C 3.52E-04 Coronary heart disease ELTD1 intron 21606135 rs3811438 chr1 79403450 T C 1.68E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs12029928 chr1 79437368 C T 1.20E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs1352556 chr1 79460634 C G 1.10E-05 Urinary metabolites ELTD1 intron 21572414 rs1352556 chr1 79460634 C G 9.26E-04 Coronary heart disease ELTD1 intron 21606135 rs17406957 chr1 79500085 T C 4.81E-04 Type 2 diabetes / / 17463246 rs6687262 chr1 79509109 T C 2.00E-06 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 4.00E-07 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 5.00E-07 IgG glycosylation / / 23382691 rs17131734 chr1 79520923 T C 8.83E-04 Multiple complex diseases / / 17554300 rs1332829 chr1 79543571 C A 8.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17408443 chr1 79583385 T C 5.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs11162635 chr1 79587564 A G 8.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs228465 chr1 79613934 T C 3.93E-04 Multiple complex diseases / / 17554300 rs228563 chr1 79646219 C A 7.50E-04 Type 2 diabetes / / 17463246 rs228563 chr1 79646219 C A 2.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs41416051 chr1 79646680 A T 1.72E-04 Multiple complex diseases / / 17554300 rs7529406 chr1 79682535 A C 6.13E-05 Chronic obstructive pulmonary disease / / 19300482 rs12027718 chr1 79836598 C T 2.40E-05 Major depressive disorder (broad) / / 20038947 rs11811462 chr1 79839129 A G 2.36E-05 Major depressive disorder (broad) / / 20038947 rs3015033 chr1 79847236 G A 2.27E-05 Major depressive disorder (broad) / / 20038947 rs3015042 chr1 79851769 C T 2.20E-05 Major depressive disorder (broad) / / 20038947 rs3015046 chr1 79853343 G A 2.13E-05 Major depressive disorder (broad) / / 20038947 rs3015049 chr1 79853708 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3015063 chr1 79856108 A G 1.98E-05 Major depressive disorder (broad) / / 20038947 rs3015065 chr1 79856314 A G 1.96E-05 Major depressive disorder (broad) / / 20038947 rs3000157 chr1 79858023 T A 4.91E-05 Major depressive disorder (broad) / / 20038947 rs12030324 chr1 79861842 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3000162 chr1 79864610 C T 2.26E-05 Major depressive disorder (broad) / / 20038947 rs3000165 chr1 79870833 G A 2.81E-05 Major depressive disorder (broad) / / 20038947 rs3000166 chr1 79873161 C T 2.92E-05 Major depressive disorder (broad) / / 20038947 rs12046087 chr1 79886246 C A 3.34E-05 Major depressive disorder (broad) / / 20038947 rs12039488 chr1 79892025 G A 3.45E-05 Major depressive disorder (broad) / / 20038947 rs12041009 chr1 79896125 T C 3.49E-05 Major depressive disorder (broad) / / 20038947 rs3000140 chr1 80000648 G T 2.00E-06 Obesity-related traits / / 23251661 rs11162772 chr1 80116138 A G 6.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6698618 chr1 80129920 C T 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs7533906 chr1 80134123 C T 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6681417 chr1 80147123 G A 3.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs11162785 chr1 80148857 T G 9.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1479739 chr1 80150038 A T 3.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12076080 chr1 80150181 T C 1.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874059 chr1 80150246 G A 2.77E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524174 chr1 80159221 A C 2.47E-05 Attention deficit hyperactivity disorder / / 20732627 rs722589 chr1 80174338 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12569151 chr1 80176139 A G 3.30E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1317042 chr1 80177985 C T 3.03E-04 Hearing function / / 17255346 rs1524183 chr1 80179889 G A,C 8.63E-05 Schizophrenia / / 19571809 rs1524183 chr1 80179889 G A,C 1.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524183 chr1 80179889 G A,C 4.82E-05 Schizophrenia / / pha002857 rs6424669 chr1 80190866 G C 1.60E-05 Attention deficit hyperactivity disorder / / 20732627 rs6424669 chr1 80190866 G C 2.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs7539380 chr1 80192565 A T 6.02E-05 Personality dimensions / / 18957941 rs6672282 chr1 80199565 G A 5.93E-05 Schizophrenia / / 19571809 rs6672282 chr1 80199565 G A 5.49E-06 Attention deficit hyperactivity disorder / / 20732627 rs6672282 chr1 80199565 G A 3.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874067 chr1 80207766 A T 2.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs7543390 chr1 80218574 A C 1.06E-05 Attention deficit hyperactivity disorder / / 20732627 rs7543390 chr1 80218574 A C 7.31E-06 Bipolar disorder and schizophrenia / / 20889312 rs1464732 chr1 80220979 A C 4.90E-05 Schizophrenia / / 19571809 rs1464732 chr1 80220979 A C 5.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs7517325 chr1 80226910 G T 8.25E-05 Hearing function / / 17255346 rs3927739 chr1 80233281 C T 9.89E-05 Schizophrenia / / 19571809 rs3927739 chr1 80233281 C T 5.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12024204 chr1 80243001 A G 6.00E-06 Endometriosis / / 21151130 rs1568764 chr1 80258075 G A 5.63E-04 Smoking quantity / / 24665060 rs1916849 chr1 80267607 G A 6.01E-05 Glucose levels / / pha003058 rs1880268 chr1 80269886 A G 0.000705 Height (Pygmy height) / / 22570615 rs12046936 chr1 80271579 C T 9.02E-05 Personality dimensions / / 18957941 rs11162826 chr1 80276868 C T 5.94E-04 Smoking quantity / / 24665060 rs11577790 chr1 80277272 C A 4.63E-04 Premature ovarian failure / / 19508998 rs12744944 chr1 80278733 G A 2.67E-06 Post-operative nausea and vomiting / / 21694509 rs12744944 chr1 80278733 G A 9.60E-06 Endometriosis / / 23104006 rs7523939 chr1 80285992 C T 4.01E-05 Schizophrenia / / 20832056 rs12024531 chr1 80287742 C T 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11162830 chr1 80289838 G T 3.29E-04 Schizophrenia / / 20832056 rs6424675 chr1 80324850 A G 9.98E-05 Schizophrenia / / 19571809 rs6424675 chr1 80324850 A G 1.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs1830893 chr1 80361955 G T 2.65E-04 Multiple complex diseases / / 17554300 rs10493640 chr1 80365091 A T 1.95E-04 Multiple complex diseases / / 17554300 rs1325203 chr1 80369991 A G 7.44E-05 Multiple complex diseases / / 17554300 rs12123414 chr1 80384756 G A 8.67E-29 Narcolepsy / / 19629137 rs7518019 chr1 80388657 A G 0.00013 Cognitive impairment (no dementia) / / 23042215 rs12085600 chr1 80416562 A G 5.61E-04 Multiple complex diseases / / 17554300 rs7524563 chr1 80416987 G T 1.20E-04 Scoliosis / / 21216876 rs12031699 chr1 80435627 C T 2.98E-06 Scoliosis / / 21216876 rs17104170 chr1 80441636 A T 9.83E-04 Multiple complex diseases / / 17554300 rs2050470 chr1 80452405 T C 1.40E-06 Urinary metabolites / / 21572414 rs12085038 chr1 80460168 C T 6.33E-06 Obesity-related traits / / 23251661 rs1041705 chr1 80463537 T G 1.20E-05 Urinary metabolites / / 21572414 rs10493631 chr1 80477880 T C 5.00E-06 Obesity-related traits / / 23251661 rs1340682 chr1 80483406 A G 7.82E-05 Lactate dehydrogenase levels / / 20981236 rs4650447 chr1 80484171 A G 5.21E-04 Multiple complex diseases / / 17554300 rs10493658 chr1 80513706 A C 4.41E-04 Multiple complex diseases / / 17554300 rs10518631 chr1 80513790 A G 3.29E-06 Multiple complex diseases / / 17554300 rs12120142 chr1 80513847 T C 2.14E-04 Multiple complex diseases / / 17554300 rs7549131 chr1 80514496 A G 2.12E-04 Multiple complex diseases / / 17554300 rs6424682 chr1 80514544 G T 2.57E-04 Multiple complex diseases / / 17554300 rs6424683 chr1 80514574 T C 3.66E-04 Multiple complex diseases / / 17554300 rs6699236 chr1 80514706 T C 2.70E-06 Multiple complex diseases / / 17554300 rs6699329 chr1 80514773 T C 2.83E-04 Multiple complex diseases / / 17554300 rs12123981 chr1 80515241 G A 1.75E-04 Multiple complex diseases / / 17554300 rs10493660 chr1 80531263 A G 3.06E-04 Multiple complex diseases / / 17554300 rs981126 chr1 80531794 T A 2.09E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 2.48E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 8.93E-04 Premature ovarian failure / / 19508998 rs1414411 chr1 80538189 T C 5.20E-05 Malaria / / 19465909 rs6424687 chr1 80542078 G A 0.0000686 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10782716 chr1 80544581 A G 1.13E-04 Multiple complex diseases / / 17554300 rs12087239 chr1 80552566 T G 1.60E-05 Urinary metabolites / / 21572414 rs6658821 chr1 80562482 T A 6.50E-04 Multiple complex diseases / / 17554300 rs6658821 chr1 80562482 T A 1.60E-07 Urinary metabolites / / 21572414 rs11162922 chr1 80572058 A G 1.80E-06 Multiple complex diseases / / 17554300 rs12401477 chr1 80582021 A C 1.30E-07 Urinary metabolites / / 21572414 rs4384179 chr1 80586993 G A 1.09E-05 Premature ovarian failure / / 19508998 rs4384179 chr1 80586993 G A 1.09E-05 Other erythrocyte phenotypes / / 19862010 rs11162928 chr1 80588364 C T 3.70E-06 Urinary metabolites / / 21572414 rs12119851 chr1 80589958 A C 6.40E-06 Urinary metabolites / / 21572414 rs7512762 chr1 80596275 C A 1.09E-04 Multiple complex diseases / / 17554300 rs4471217 chr1 80596899 A G 4.20E-06 Urinary metabolites / / 21572414 rs6673937 chr1 80606877 C T 7.75E-04 Multiple complex diseases / / 17554300 rs6686600 chr1 80606901 A G 7.20E-06 Urinary metabolites / / 21572414 rs12144259 chr1 80608086 C T 4.60E-06 Urinary metabolites / / 21572414 rs7544729 chr1 80613215 A G 7.56E-04 Premature ovarian failure / / 19508998 rs12407162 chr1 80613801 T C 2.80E-06 Urinary metabolites / / 21572414 rs11162943 chr1 80619109 C T 6.22E-05 Multiple complex diseases / / 17554300 rs10874118 chr1 80638947 G A 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4503307 chr1 80641525 C T 1.30E-05 Lung adenocarcinoma / / 22797724 rs7521092 chr1 80644813 C A 1.48E-04 Multiple complex diseases / / 17554300 rs17104471 chr1 80653552 A G 2.70E-06 Lung adenocarcinoma / / 22797724 rs10493661 chr1 80659055 G A 2.80E-05 Lung adenocarcinoma / / 22797724 rs12044546 chr1 80670378 C T 2.00E-05 Urinary metabolites / / 21572414 rs3014989 chr1 80710753 A T 3.10E-06 Urinary metabolites / / 21572414 rs1418818 chr1 80711659 T C 2.80E-06 Urinary metabolites / / 21572414 rs1687816 chr1 80734553 T A 1.30E-05 Urinary metabolites / / 21572414 rs11162963 chr1 80734581 C T 4.00E-06 Aging (time to event) / / 21782286 rs1954338 chr1 80741675 A G 5.09E-04 Parkinson's disease / / 17052657 rs1776286 chr1 80741898 C A 2.80E-05 Urinary metabolites / / 21572414 rs41338944 chr1 80793418 T C 1.95E-05 Multiple complex diseases / / 17554300 rs35020936 chr1 80804503 A G 2.12E-05 Multiple complex diseases / / 17554300 rs2389026 chr1 80811353 C G 2.52E-05 Multiple complex diseases / / 17554300 rs1781780 chr1 80825325 T C 8.37E-04 Multiple complex diseases / / 17554300 rs2997195 chr1 80838880 C T 3.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs1896250 chr1 80857194 G A 7.89E-10 Multiple complex diseases / / 17554300 rs1549556 chr1 80858494 C T 6.11E-04 Multiple complex diseases / / 17554300 rs6424701 chr1 80867299 A T 9.99E-05 Multiple complex diseases / / 17554300 rs6677470 chr1 80869792 A G 5.81E-04 Smoking initiation / / 24665060 rs17390593 chr1 80876340 C A 2.59E-04 Multiple complex diseases / / 17554300 rs3909721 chr1 80877080 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1896251 chr1 80888808 C T 7.62E-05 Cognitive performance / / 19734545 rs12118390 chr1 80911114 G A 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs718003 chr1 80956319 T C 5.05E-04 Alzheimer's disease / / 24755620 rs12022941 chr1 80984672 A G 2.90E-04 Multiple complex diseases / / 17554300 rs12026235 chr1 80992047 T C 5.27E-04 Multiple complex diseases / / 17554300 rs11163043 chr1 81002200 A G 6.50E-05 Multiple complex diseases / / 17554300 rs12080797 chr1 81014137 T C 1.50E-05 Urinary metabolites / / 21572414 rs10493664 chr1 81024403 T C 2.50E-04 Sarcoidosis / / 19165924 rs11163056 chr1 81039056 G A 1.82E-04 Alzheimer's disease / / 17998437 rs10874143 chr1 81042755 A C 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10493672 chr1 81111793 G T 1.99E-04 Multiple complex diseases / / 17554300 rs7542755 chr1 81130780 G A 9.20E-05 Body Mass Index / / pha002896 rs17105337 chr1 81143088 T C 0.000843 Salmonella-induced pyroptosis / / 22837397 rs952756 chr1 81150622 A G 3.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs841671 chr1 81156849 C T 4.22E-04 Self-reported allergy / / 23817569 rs5020501 chr1 81208897 G A,T 7.23E-05 Cognitive test performance / / 20125193 rs2389062 chr1 81212060 A C 8.59E-04 Body mass index / / 21701565 rs41340345 chr1 81305845 G A 4.78E-04 Coronary Artery Disease / / 17634449 rs1953745 chr1 81355884 T C 7.83E-04 Smoking quantity / / 24665060 rs4650355 chr1 81376282 C T 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12739375 chr1 81377308 A G 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493682 chr1 81377571 G A 8.08E-04 Alzheimer's disease / / 17998437 rs10493682 chr1 81377571 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338129 chr1 81378256 C A 4.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338128 chr1 81378292 A G 6.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10493683 chr1 81378769 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493684 chr1 81378929 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2185044 chr1 81379082 T C 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2152988 chr1 81379238 C T 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2152988 chr1 81379238 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1415929 chr1 81380131 T C 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415929 chr1 81380131 T C 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338127 chr1 81384148 C T 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1339118 chr1 81391273 T C,G 2.27E-04 Smoking initiation / / 24665060 rs1415936 chr1 81398439 C A 2.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415935 chr1 81398711 A G 2.13E-04 Smoking initiation / / 24665060 rs10874182 chr1 81401098 C T 4.92E-04 Alcohol dependence / / 24277619 rs10874184 chr1 81401550 A G 1.27E-04 Smoking initiation / / 24665060 rs12751933 chr1 81404227 G A 1.34E-04 Smoking initiation / / 24665060 rs7515605 chr1 81430056 G A 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs6684037 chr1 81432941 G A 7.04E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs7537835 chr1 81433165 G A 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs7537835 chr1 81433165 G A 1.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6694777 chr1 81436522 G T 9.19E-05 Body Composition / / pha003012 rs1863618 chr1 81450244 G A 7.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1863618 chr1 81450244 G A 5.23E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs919139 chr1 81450754 C T 6.69E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10874192 chr1 81452990 G A 4.64E-04 Myopia (pathological) / / 21095009 rs11163177 chr1 81453334 T G 1.60E-05 Urinary metabolites / / 21572414 rs1426787 chr1 81453585 G T 3.07E-05 Body Composition / / pha003012 rs1426787 chr1 81453585 G T 4.34E-05 Body Mass Index / / pha003021 rs6424732 chr1 81455333 G C 4.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1030414 chr1 81468442 A G 4.94E-04 Stroke / / pha002886 rs17105836 chr1 81526130 A G 3.77E-04 Tourette syndrome / / 22889924 rs11583080 chr1 81530739 T C 3.86E-04 Aortic root size / / 21223598 rs672797 chr1 81560554 C A 4.20E-08 Type 1 diabetes / / 17632545 rs11163194 chr1 81578784 A G 8.34E-04 Alzheimer's disease / / 22005930 rs1195693 chr1 81579076 A G 1.50E-05 Urinary metabolites / / 21572414 rs1146408 chr1 81581873 C T 2.70E-05 Urinary metabolites / / 21572414 rs1195699 chr1 81583172 A G 2.10E-05 Urinary metabolites / / 21572414 rs12128534 chr1 81586357 G A 9.19E-04 Alzheimer's disease / / 22005930 rs1648692 chr1 81588340 G C 8.98E-04 Alzheimer's disease / / 22005930 rs1648690 chr1 81589935 G C 7.72E-04 Alzheimer's disease / / 22005930 rs1768400 chr1 81591135 A G 7.58E-04 Alzheimer's disease / / 22005930 rs1426788 chr1 81592062 T C 7.62E-04 Alzheimer's disease / / 22005930 rs1648689 chr1 81592929 C T 7.67E-04 Alzheimer's disease / / 22005930 rs1768395 chr1 81594126 T G 2.60E-05 Urinary metabolites / / 21572414 rs1752219 chr1 81597906 C T 7.33E-04 Alzheimer's disease / / 22005930 rs1768389 chr1 81598101 T C 2.60E-05 Urinary metabolites / / 21572414 rs1768388 chr1 81598364 A G 6.98E-04 Alzheimer's disease / / 22005930 rs1146414 chr1 81601170 G C 7.30E-04 Body mass index / / 21701565 rs1146414 chr1 81601170 G C 8.75E-04 Body mass index / / 21701565 rs1146416 chr1 81601541 C T 9.33E-04 Alzheimer's disease / / 22005930 rs17106034 chr1 81609864 C T 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.49E-05 Scoliosis / / 21216876 rs10493685 chr1 81622201 G A 1.60E-04 Type 2 diabetes / / 17846125 rs3898651 chr1 81622580 T G 4.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17106106 chr1 81624781 C T 3.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4120877 chr1 81656725 G T 3.66E-05 Cognitive performance / / 19734545 rs10874202 chr1 81688359 A G 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4650518 chr1 81699270 C T 4.10E-07 Urinary metabolites / / 21572414 rs9645301 chr1 81704582 A T 1.00E-04 Type 2 diabetes / / 17463246 rs4650519 chr1 81720233 C A 7.46E-04 Multiple complex diseases / / 17554300 rs1547674 chr1 81745893 C T 8.79E-05 Multiple complex diseases / / 17554300 rs10782752 chr1 81755537 G A 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782752 chr1 81755537 G A 7.00E-04 Smoking initiation / / 24665060 rs1327613 chr1 81764583 T A 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12027847 chr1 81766037 G A 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10158280 chr1 81768971 T C 9.39E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2182766 chr1 81796468 A G 9.14E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs111722172 chr1 81811786 G T 2.80E-11 Metabolite levels / / 22286219 rs11163267 chr1 81843506 T A,C 7.76E-04 Smoking initiation / / 24665060 rs10874238 chr1 81872593 G A 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6681688 chr1 81881212 C T 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs4336893 chr1 81887417 T C 9.46E-04 Multiple complex diseases / / 17554300 rs4362026 chr1 81890814 T G 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10782760 chr1 81896746 A G 6.93E-05 Serum metabolites / / 19043545 rs11163298 chr1 81924594 C T 2.15E-05 Type 2 diabetes / / 17463246 rs3924703 chr1 81944199 A G 0.000000068 Mean arterial pressure / / 22510845 rs12142040 chr1 81949079 A G 2.50E-05 Urinary metabolites / / 21572414 rs11163323 chr1 81986458 C T 0.000017 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 / / 21873659 rs11586072 chr1 81987161 C A 1.66E-04 Type 2 diabetes / / 17463246 rs17420488 chr1 81992020 G A 2.30E-05 Urinary metabolites / / 21572414 rs17454529 chr1 81995750 G A 3.74E-04 Multiple complex diseases / / 17554300 rs17454592 chr1 81996353 G A 5.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs17106650 chr1 81999759 G A 3.42E-05 Response to TNF antagonist treatment / / 21061259 rs12022306 chr1 82026353 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7532624 chr1 82029505 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1924558 chr1 82061064 T G 9.75E-05 Height / / 17255346 rs6671683 chr1 82068875 G C 1.54E-04 Multiple complex diseases / / 17554300 rs17456217 chr1 82073276 G C 4.44E-04 Multiple complex diseases / / 17554300 rs11809789 chr1 82074852 G A 6.00E-06 Bilirubin levels / / 22085899 rs17456431 chr1 82086743 G C 4.24E-04 Multiple complex diseases / / 17554300 rs17423111 chr1 82103535 G A 9.23E-04 Multiple complex diseases / / 17554300 rs12117862 chr1 82110055 T C 1.11E-04 Coronary heart disease / / 21606135 rs480304 chr1 82123485 C A 5.92E-04 Smoking quantity / / 24665060 rs561278 chr1 82132298 A C 3.13E-04 Smoking quantity / / 24665060 rs11578678 chr1 82168757 T C 7.18E-04 Body mass index / / 21701565 rs11163350 chr1 82170329 C T 2.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11163350 chr1 82170329 C T 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.87E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12129647 chr1 82182566 G A 4.83E-05 Intracerebral hemorrhage / / 24656865 rs9285611 chr1 82183055 C T 1.70E-05 Pulmonary function / / 17903307 rs9285611 chr1 82183055 C T 1.88E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9324183 chr1 82195760 G T 6.10E-06 Height / / 17255346 rs9324183 chr1 82195760 G T 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12139644 chr1 82197327 G A 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1391475 chr1 82210952 T C 1.27E-04 IgE levels / / 17255346 rs1391475 chr1 82210952 T C 1.70E-05 Crohn's disease / / 20570966 rs9782905 chr1 82219539 A G 3.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9324187 chr1 82225803 G T 1.77E-04 Response to TNF antagonist treatment / / 21061259 rs11163372 chr1 82247248 C T 3.00E-06 Temperament / / 22832960 rs1391478 chr1 82248794 A G 2.97E-04 Response to TNF antagonist treatment / / 21061259 rs1391478 chr1 82248794 A G 8.78E-04 Body mass index / / 21701565 rs371363 chr1 82349354 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits LPHN2 intron 17848626 rs371363 chr1 82349354 C T 2.58E-06 Paclitaxel sensitivity in NCI60 cancer cell lines LPHN2 intron 21314952 rs12401346 chr1 82352612 T C 5.54E-04 Response to TNF antagonist treatment LPHN2 intron 21061259 rs1341260 chr1 82364661 T C 6.61E-04 Nicotine dependence LPHN2 intron 17158188 rs284227 chr1 82379446 C T 7.55E-05 Celiac disease LPHN2 intron 23936387 rs626085 chr1 82384574 C T 3.95E-04 Alzheimer's disease LPHN2 intron 22005930 rs993906 chr1 82390698 T C 1.89E-04 Alzheimer's disease LPHN2 intron 22005930 rs6681544 chr1 82398544 C T 6.00E-06 Metabolite levels (X-11787) LPHN2 intron 23934736 rs1475394 chr1 82412099 C T 9.31E-05 Triglycerides LPHN2 intron pha003080 rs385367 chr1 82415199 A G 7.65E-05 Celiac disease LPHN2 intron 23936387 rs1327022 chr1 82436281 G A 8.58E-04 Major depressive disorder LPHN2 intron 22472876 rs9438724 chr1 82438148 A C 7.56E-05 Celiac disease LPHN2 intron 23936387 rs10518658 chr1 82461630 T C 9.93E-05 Triglycerides / / pha003080 rs4970642 chr1 82465731 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17472507 chr1 82479448 G A 4.27E-05 Triglycerides / / pha003080 rs4291539 chr1 82503816 C T 2.37E-05 Longevity / / 21612516 rs11163417 chr1 82517645 T C 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4486485 chr1 82526505 G C 2.60E-05 Urinary metabolites / / 21572414 rs11163422 chr1 82566070 A T 7.80E-04 Multiple complex diseases / / 17554300 rs10493708 chr1 82571186 A G 4.80E-04 Multiple complex diseases / / 17554300 rs17436254 chr1 82762033 A G 8.68E-06 Obesity-related traits / / 23251661 rs785584 chr1 82762700 T C 7.43E-06 Obesity-related traits / / 23251661 rs1770678 chr1 82765052 T C 7.00E-06 Obesity-related traits / / 23251661 rs11579674 chr1 82836557 A G 2.13E-04 Insulin resistance / / 21901158 rs11163467 chr1 82848122 C T 5.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1290281 chr1 82857453 G A 3.95E-04 Multiple complex diseases / / 17554300 rs10437023 chr1 82901026 G A 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 2.02E-05 Parkinson's disease / / pha002868 rs2225083 chr1 82960385 G A 9.58E-04 Eye color / / 23118974 rs7523716 chr1 82964864 G T 4.52E-04 Alzheimer's disease / / 17998437 rs7537124 chr1 82964897 A T 4.89E-04 Alzheimer's disease / / 17998437 rs10747397 chr1 82965159 T C 5.18E-04 Alzheimer's disease / / 17998437 rs12745149 chr1 82991633 T C 7.89E-04 Body mass index / / 21701565 rs318422 chr1 83019476 A G 1.61E-04 Multiple complex diseases / / 17554300 rs11579295 chr1 83036341 A G 8.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9729834 chr1 83039338 G A 4.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17108556 chr1 83052706 G A 1.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10874322 chr1 83054799 C T 2.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs1281400 chr1 83055625 C G 7.14E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2011057 chr1 83058155 C T 3.61E-05 Post-operative nausea and vomiting / / 21694509 rs2011057 chr1 83058155 C T 5.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163526 chr1 83096605 A G 5.75E-04 Smoking initiation / / 24665060 rs1361196 chr1 83097024 T C 7.36E-05 Bipolar disorder / / 19488044 rs1416079 chr1 83097138 A G 1.09E-05 Bipolar disorder / / 19488044 rs1416078 chr1 83097228 T C 7.20E-05 Bipolar disorder / / 19488044 rs6604921 chr1 83098959 T C 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs17493817 chr1 83101655 A G 3.90E-05 Parkinson's disease (age of onset) / / 19772629 rs373905 chr1 83112722 C T 2.06E-05 Alcohol dependence / / 21703634 rs428943 chr1 83115057 A G 3.48E-04 Alzheimer's disease (late onset) / / 21379329 rs453456 chr1 83117369 G A 2.04E-05 Alcohol dependence / / 21703634 rs2787985 chr1 83118044 T G 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs2787985 chr1 83118044 T G 1.20E-05 Alcohol dependence / / 21703634 rs10874325 chr1 83118256 G C 5.37E-05 Serum metabolites / / 19043545 rs1433761 chr1 83132400 A C 9.33E-05 Alcohol dependence / / 21703634 rs3845616 chr1 83135055 A G 7.02E-04 Smoking cessation / / 24665060 rs12239057 chr1 83136159 C T 2.94E-04 Lung function (forced vital capacity) / / 24023788 rs10493722 chr1 83171994 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs9324200 chr1 83172488 A G 4.10E-06 Erythrocyte counts / / pha003090 rs1469744 chr1 83173469 T C 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469744 chr1 83173469 T C 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469743 chr1 83178180 G T 5.92E-05 Alcohol dependence / / 21703634 rs12744723 chr1 83184129 C T 7.16E-05 Alcohol dependence / / 21703634 rs10493727 chr1 83188821 C T 4.51E-05 Alcohol dependence / / 21703634 rs1338361 chr1 83196421 T C 5.74E-05 Alcohol dependence / / 21703634 rs11588508 chr1 83202936 A G 5.61E-05 Alcohol dependence / / 21703634 rs11588936 chr1 83203139 T A 5.43E-05 Alcohol dependence / / 21703634 rs2060361 chr1 83204106 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs17109039 chr1 83221252 G T 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11807023 chr1 83225779 C T 3.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs320909 chr1 83227702 T G 7.97E-04 Type 2 diabetes / / 17463246 rs11163566 chr1 83230397 C A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6429835 chr1 83231866 C T 3.79E-05 Alcohol dependence / / 21703634 rs17505362 chr1 83233401 G A 1.24E-04 Multiple complex diseases / / 17554300 rs6429839 chr1 83266863 G A 0.0000829 Tuberculosis with late age of onset / / 22551897 rs17109259 chr1 83291401 C A 1.37E-04 Multiple complex diseases / / 17554300 rs11163585 chr1 83311835 C T 9.00E-07 Response to antipsychotic treatment / / 20195266 rs1146366 chr1 83358442 G A 4.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1440447 chr1 83412781 T C 9.77E-04 Type 2 diabetes / / 17463246 rs4146730 chr1 83444431 G A 2.10E-05 Urinary metabolites / / 21572414 rs2289445 chr1 83451691 C T 3.57E-05 Smoking initiation / / 24665060 rs7556305 chr1 83464725 A G 3.58E-04 Stroke / / pha002886 rs6702898 chr1 83465825 C T 2.66E-04 Stroke / / pha002886 rs6668833 chr1 83473598 T C 1.05E-05 Bipolar disorder,affective / / 20528957 rs1930278 chr1 83486078 A G 4.47E-04 Celiac disease / / 23936387 rs12742923 chr1 83489844 C T 8.00E-07 HIV-associated dementia / / 22628157 rs10487981 chr1 83530267 T C 3.32E-04 Parkinson's disease / / 16252231 rs323973 chr1 83535877 C A 5.91E-04 Type 2 diabetes / / 17463246 rs323973 chr1 83535877 C A 9.10E-04 Multiple complex diseases / / 17554300 rs17344386 chr1 83541990 T C 4.71E-05 Parkinson's disease / / 16252231 rs323932 chr1 83553972 A C 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 9.97E-04 Multiple complex diseases / / 17554300 rs6684000 chr1 83554149 A G 5.99E-04 Sarcoidosis / / 19165924 rs537877 chr1 83572881 G T 4.97E-05 Cognitive test performance / / 20125193 rs11163687 chr1 83665119 A G 3.60E-08 Glioma (high-grade) / / 19578366 rs11163695 chr1 83701382 A C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs12403322 chr1 83701728 A G 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2077053 chr1 83716959 C T 1.10E-05 Iron levels / / 21208937 rs11163719 chr1 83792651 G A 4.27E-04 Multiple complex diseases / / 17554300 rs4907021 chr1 83857369 G A 9.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs2260390 chr1 83871950 G A 3.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs17130039 chr1 83964564 T A,G 9.73E-05 Multiple complex diseases / / 17554300 rs3861696 chr1 83975531 G A 7.38E-05 Coronary heart disease / / pha003032 rs10493740 chr1 83989898 G T 3.55E-04 Heart Failure / / pha002884 rs4142781 chr1 84024341 C T 8.85E-04 Multiple complex diseases / / 17554300 rs12097883 chr1 84059930 C T 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs4363435 chr1 84067452 G A 5.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163783 chr1 84086070 T C 3.91E-04 Acute lung injury / / 22295056 rs10874398 chr1 84088645 G C 6.56E-04 Acute lung injury / / 22295056 rs6695005 chr1 84091702 G C 6.01E-04 Acute lung injury / / 22295056 rs11163786 chr1 84093452 A G 6.25E-04 Acute lung injury / / 22295056 rs10874400 chr1 84094265 G A 9.91E-04 Acute lung injury / / 22295056 rs12563303 chr1 84094411 G A 9.91E-04 Acute lung injury / / 22295056 rs12562642 chr1 84094604 T C 9.91E-04 Acute lung injury / / 22295056 rs12562651 chr1 84094868 A G 9.91E-04 Acute lung injury / / 22295056 rs11163788 chr1 84095392 C A 9.73E-04 Acute lung injury / / 22295056 rs11163794 chr1 84111016 T C 6.16E-04 Acute lung injury / / 22295056 rs11163795 chr1 84111208 C G 6.16E-04 Acute lung injury / / 22295056 rs8179422 chr1 84111398 C G 6.29E-04 Acute lung injury / / 22295056 rs8179462 chr1 84111468 T C 6.74E-04 Acute lung injury / / 22295056 rs4907033 chr1 84111799 T A 3.81E-04 Acute lung injury / / 22295056 rs4457599 chr1 84112891 G A 1.77E-05 Alzheimer's disease / / 21098978 rs4457599 chr1 84112891 G A 6.44E-04 Acute lung injury / / 22295056 rs4539154 chr1 84113159 G A 1.76E-05 Alzheimer's disease / / 21098978 rs2068611 chr1 84113646 C T 1.75E-05 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 2.74E-07 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 9.23E-04 Acute lung injury / / 22295056 rs12035245 chr1 84115574 T C 8.85E-04 Acute lung injury / / 22295056 rs12566397 chr1 84116576 G A 9.46E-04 Acute lung injury / / 22295056 rs10218575 chr1 84123370 G C 6.90E-04 Multiple complex diseases / / 17554300 rs17577039 chr1 84204198 A G 2.90E-05 HIV-1 control / / 20041166 rs6683294 chr1 84218373 G A 2.90E-05 HIV-1 control / / 20041166 rs17129137 chr1 84219787 C T 8.60E-05 Tunica Media / / pha003038 rs17129251 chr1 84228589 G A 3.49E-04 Alzheimer's disease / / 24755620 rs17129289 chr1 84232748 T C 7.00E-06 Obesity-related traits / / 23251661 rs11163843 chr1 84252434 C A 9.36E-04 Multiple complex diseases / / 17554300 rs7552393 chr1 84254551 A G 5.00E-07 Select biomarker traits / / 17903293 rs7539409 chr1 84254735 G A 1.00E-06 Alzheimer's Disease / / 20061627 rs6676587 chr1 84276429 T C 6.81E-04 Multiple complex diseases / / 17554300 rs2179763 chr1 84295861 A G 9.54E-04 Tourette syndrome / / 22889924 rs970457 chr1 84296540 C T 5.41E-04 Depression (quantitative trait) / / 20800221 rs3738575 chr1 84296983 A G 5.35E-04 Tourette syndrome / / 22889924 rs932448 chr1 84308491 C T 8.02E-04 Alzheimer's disease / / 24755620 rs6576951 chr1 84312493 T C 2.80E-05 Urinary metabolites / / 21572414 rs6692233 chr1 84327214 G A 1.02E-04 Multiple complex diseases / / 17554300 rs12118434 chr1 84328629 G A 5.58E-05 Multiple complex diseases / / 17554300 rs2024591 chr1 84329235 C T 1.95E-05 Multiple complex diseases / / 17554300 rs11163862 chr1 84355418 T A 2.39E-04 Multiple complex diseases TTLL7 intron 17554300 rs12142944 chr1 84380880 C T 9.72E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10465746 chr1 84387632 T G 8.00E-06 Obesity-related traits TTLL7 intron 23251661 rs481354 chr1 84409393 G C 2.60E-04 Multiple complex diseases TTLL7 intron 17554300 rs7551787 chr1 84419297 T C 2.47E-04 Multiple complex diseases TTLL7 intron 17554300 rs4907191 chr1 84444165 G A 6.37E-05 Multiple complex diseases TTLL7 intron 17554300 rs10493743 chr1 84444412 T C 8.53E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10493744 chr1 84444752 T C 7.32E-05 Multiple complex diseases TTLL7 intron 17554300 rs12042443 chr1 84444766 G A 4.67E-04 Multiple complex diseases TTLL7 intron 17554300 rs1886769 chr1 84471134 C A 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs11163887 chr1 84474718 G A 6.01E-04 Multiple complex diseases / / 17554300 rs955524 chr1 84490456 G A 2.42E-04 Multiple complex diseases / / 17554300 rs669110 chr1 84498812 G A 2.40E-04 Multiple complex diseases / / 17554300 rs626376 chr1 84516043 T C 5.23E-04 Multiple complex diseases / / 17554300 rs810915 chr1 84516349 A C 6.50E-04 Multiple complex diseases / / 17554300 rs1811643 chr1 84527291 G A 3.61E-04 Multiple complex diseases / / 17554300 rs2892811 chr1 84527394 T C 9.18E-04 Multiple complex diseases / / 17554300 rs663521 chr1 84530053 T G 4.03E-04 Multiple complex diseases / / 17554300 rs12031680 chr1 84535297 C A 6.81E-04 Multiple complex diseases / / 17554300 rs1565823 chr1 84576620 G A 1.00E-04 Cognitive impairment induced by topiramate PRKACB intron 22091778 rs1016379 chr1 84590129 A G 2.21E-04 Multiple complex diseases PRKACB intron 17554300 rs12723299 chr1 84590315 C T 3.33E-04 Multiple complex diseases PRKACB intron 17554300 rs2139931 chr1 84590527 A G 2.01E-04 Multiple complex diseases PRKACB intron 17554300 rs11163905 chr1 84594399 G A 6.49E-04 Multiple complex diseases PRKACB intron 17554300 rs903263 chr1 84622513 G T 1.00E-06 Breast cancer (male) PRKACB intron 23001122 rs1057738 chr1 84670816 A C 3.88E-05 Cognitive impairment induced by topiramate PRKACB UTR-3 22091778 rs12088543 chr1 84717983 T C 3.31E-05 Male fertility / / 22633400 rs606816 chr1 84720376 C A 1.01E-06 Monocyte counts / / pha003089 rs621750 chr1 84721408 G A 1.01E-06 Monocyte counts / / pha003089 rs11163933 chr1 84728627 C T 9.04E-05 Male fertility / / 22633400 rs11163934 chr1 84728697 C A 3.49E-05 Male fertility / / 22633400 rs12047850 chr1 84729134 A C 3.46E-05 Type 2 diabetes / / 17463246 rs316672 chr1 84743949 T G 1.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 6.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.52E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.74E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.42E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 3.57E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 6.14E-06 Cognitive impairment induced by topiramate / / 22091778 rs17373911 chr1 84745603 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6697296 chr1 84759975 C A 2.42E-04 Multiple complex diseases / / 17554300 rs1085093 chr1 84761348 T C 3.00E-06 Metabolic syndrome / / 20694148 rs316662 chr1 84787312 A C 4.46E-07 Obesity-related traits SAMD13 intron 23251661 rs315553 chr1 84792973 G T 4.00E-06 Obesity-related traits SAMD13 intron 23251661 rs315540 chr1 84816587 A C 6.96E-06 Obesity-related traits / / 23251661 rs315535 chr1 84820409 C T 6.62E-05 Major depressive disorder (broad) / / 20038947 rs315535 chr1 84820409 C T 7.38E-06 Obesity-related traits / / 23251661 rs17478556 chr1 84852123 G C 1.02E-05 Bipolar disorder UOX intron 19488044 rs17478556 chr1 84852123 G C 2.93E-05 Bipolar Disorder UOX intron pha002863 rs12752696 chr1 84856633 C T 8.23E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs621869 chr1 84856784 T C 5.85E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) UOX intron 24192120 rs10082174 chr1 84859152 C G 6.92E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs12144715 chr1 84865230 A T 7.00E-06 Response to hepatitis C treatment D/SE2B intron 22095909 rs634531 chr1 84866855 T C 2.33E-04 Obesity (extreme) D/SE2B intron 21935397 rs604708 chr1 84868961 T C 8.00E-06 IgG glycosylation D/SE2B intron 23382691 rs3116406 chr1 84874242 C G 7.83E-05 Obesity (extreme) D/SE2B intron 21935397 rs3768250 chr1 84880380 T C 9.21E-05 Obesity (extreme) D/SE2B cds-synon 21935397 rs1506702 chr1 84894055 T C 9.51E-05 Obesity (extreme) / / 21935397 rs1340596 chr1 84896033 C A 8.30E-05 Diabetic retinopathy / / 21441570 rs7514800 chr1 84896441 G A 1.04E-04 Obesity (extreme) / / 21935397 rs959363 chr1 84898321 A C 1.27E-04 Obesity (extreme) / / 21935397 rs10874441 chr1 84899304 G A 1.32E-04 Obesity (extreme) / / 21935397 rs1340598 chr1 84904099 T C 2.72E-04 Obesity (extreme) / / 21935397 rs10493746 chr1 84904279 G A 4.14E-04 Obesity (extreme) / / 21935397 rs4345821 chr1 84907970 T C 2.64E-04 Obesity (extreme) / / 21935397 rs12755232 chr1 84918056 A C 2.38E-04 Obesity (extreme) / / 21935397 rs12729133 chr1 84922553 C T 1.28E-04 Obesity (extreme) / / 21935397 rs7540794 chr1 84924179 A T 1.29E-04 Obesity (extreme) / / 21935397 rs2794217 chr1 84962577 T C 4.30E-05 Intracerebral hemorrhage RPF1 intron 24656865 rs2659173 chr1 84981405 T A 4.78E-05 Intracerebral hemorrhage SPATA1 intron 24656865 rs17113057 chr1 85101762 C G 1.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17113057 chr1 85101762 C G 8.03E-04 Smoking quantity / / 24665060 rs2911613 chr1 85111124 C A 2.59E-05 Progressive supranuclear palsy SSX2IP UTR-3 21685912 rs818526 chr1 85198264 T C 8.16E-05 Monocyte counts / / pha003089 rs12744552 chr1 85216685 T C 5.17E-05 Orofacial clefts / / 20023658 rs1750491 chr1 85226299 T C 2.00E-06 Dental caries / / 23064961 rs1770566 chr1 85227586 A G 1.40E-06 Glioma (high-grade) / / 19578366 rs9661368 chr1 85234868 A G 3.15E-05 Personality dimensions / / 18957941 rs1620453 chr1 85234978 C A 7.58E-04 Body mass index / / 21701565 rs1417296 chr1 85236777 G T 1.17E-05 Personality dimensions / / 18957941 rs11576745 chr1 85240246 C T 9.13E-04 Alcohol dependence / / 21314694 rs11576745 chr1 85240246 C T 7.70E-05 Coronary heart disease / / pha003055 rs10782529 chr1 85268243 C T 4.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy / / 23118302 rs10873658 chr1 85271091 C T 9.54E-04 Alzheimer's disease / / 22005930 rs4243771 chr1 85276032 A T 6.44E-04 Alzheimer's disease / / 22005930 rs9728717 chr1 85290409 T C 9.00E-06 Economic and political preferences (time) LPAR3 intron 22566634 rs11161467 chr1 85305197 A T 5.73E-04 Multiple complex diseases LPAR3 intron 17554300 rs1983853 chr1 85311192 C T 2.00E-06 Type 1 diabetes LPAR3 intron 18840781 rs12062882 chr1 85313108 C T 6.34E-04 Alzheimer's disease LPAR3 intron 24755620 rs4907103 chr1 85316840 G T 0.0000977 Schizophrenia LPAR3 intron 23637625 rs942683 chr1 85319741 C T 8.45E-04 Alzheimer's disease LPAR3 intron 22005930 rs942684 chr1 85319822 T C 8.50E-04 Alzheimer's disease LPAR3 intron 22005930 rs10873661 chr1 85328096 G A 6.11E-06 Coronary heart disease LPAR3 intron pha003055 rs1325273 chr1 85332120 T C 1.55E-05 Coronary heart disease LPAR3 intron pha003055 rs4243774 chr1 85356878 T C 2.00E-06 Smoking cessation LPAR3 intron 24665060 rs4579776 chr1 85357025 A G 8.64E-04 Type 2 diabetes LPAR3 intron 17463246 rs12057637 chr1 85392616 A C 1.94E-05 Personality dimensions MCOLN2 intron 18957941 rs12145073 chr1 85394258 T G 7.14E-06 Serum dimethylarginine levels (asymmetric) MCOLN2 intron 24159190 rs17117593 chr1 85398979 C T 7.77E-04 Type 2 diabetes MCOLN2 intron 17463246 rs1325277 chr1 85400114 C A 5.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) MCOLN2 intron 23648065 rs597630 chr1 85419947 T C 5.47E-05 Lymphocyte counts MCOLN2 intron 22286170 rs41383647 chr1 85426256 T C 2.60E-05 Urinary metabolites MCOLN2 intron 21572414 rs6576739 chr1 85468319 T G 3.22E-04 Lymphocyte counts / / 22286170 rs17119333 chr1 85485170 C G 5.30E-06 Urinary metabolites MCOLN3 intron 21572414 rs41461649 chr1 85509512 C T 2.60E-05 Urinary metabolites MCOLN3 intron 21572414 rs6576745 chr1 85529628 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 5.00E-09 Venous thromboembolism (gene x gene interaction) WDR63 intron 23509962 rs17099213 chr1 85537706 T C 1.70E-05 Urinary metabolites WDR63 intron 21572414 rs17120570 chr1 85539127 G A 2.88E-04 Smoking initiation WDR63 intron 24665060 rs709764 chr1 85560264 G A 3.79E-05 Cognitive impairment induced by topiramate WDR63 intron 22091778 rs2050842 chr1 85582549 G A 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs6576749 chr1 85583162 C G 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs10873688 chr1 85605433 C T 3.26E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10873688 chr1 85605433 C T 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7532792 chr1 85609928 G A 1.44E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs930912 chr1 85617482 T A 4.43E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161535 chr1 85621174 A T 4.34E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7511739 chr1 85622457 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17122364 chr1 85627099 A G 7.13E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs4907138 chr1 85628953 C T 8.17E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs145522533 chr1 85646380 A G 2.99E-06 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs11161543 chr1 85653831 G A 1.63E-04 Alzheimer's disease SYDE2 intron 22005930 rs12144280 chr1 85654216 T C 1.85E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) SYDE2 intron 24159190 rs12144280 chr1 85654216 T C 3.58E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs72722607 chr1 85654397 G A 1.00E-09 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs112356857 chr1 85657385 G A 6.77E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs709788 chr1 85676959 A G 1.10E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs709788 chr1 85676959 A G 3.70E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12028498 chr1 85677283 G C 6.88E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12732108 chr1 85678877 G A 6.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7540356 chr1 85679100 A G 1.02E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722624 chr1 85681964 G A 9.27E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722628 chr1 85682652 G A 3.93E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782542 chr1 85683583 G T 1.30E-04 Alzheimer's disease / / 22005930 rs12125292 chr1 85685189 T C 2.55E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs10782543 chr1 85689134 G A 1.04E-04 Alzheimer's disease / / 22005930 rs72722632 chr1 85689491 G A 4.12E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722638 chr1 85693127 G A 1.94E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17123650 chr1 85694671 C T 1.34E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11583836 chr1 85696534 T A 1.35E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161556 chr1 85701014 A T 1.28E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6671589 chr1 85702868 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722643 chr1 85703134 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722644 chr1 85703544 A C 2.31E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7515154 chr1 85704435 C T 1.99E-05 Anxiety and major depressive disorder / / 24047446 rs10747317 chr1 85705346 G A 3.28E-04 Alzheimer's disease / / 22005930 rs6663690 chr1 85705801 C T 1.20E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs60156243 chr1 85706839 C T 1.09E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782544 chr1 85707253 T C 1.98E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs4949892 chr1 85707822 C T 1.03E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11577656 chr1 85708279 C T 1.66E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12065422 chr1 85715978 C G 5.70E-04 Lymphocyte counts C1orf52 UTR-3 22286170 rs10158486 chr1 85720007 T C 2.59E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 4.32E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 6.18E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 2.42E-06 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 4.37E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 1.73E-07 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 4.28E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 8.89E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs4949926 chr1 85724328 C T 6.45E-07 Serum dimethylarginine levels (asymmetric) C1orf52 cds-synon 24159190 rs71652692 chr1 85725426 G T 1.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs71652692 chr1 85725426 G T 1.17E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs71652692 chr1 85725426 G T 3.02E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161574 chr1 85727044 T C 2.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 1.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 4.66E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs10493763 chr1 85727218 T C 9.55E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2647395 chr1 85728664 C G 8.92E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs2647394 chr1 85729987 A G 4.87E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 1.29E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 5.86E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 1.78E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126112 chr1 85730595 C T 6.29E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 8.54E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs113428154 chr1 85730627 T C 2.63E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126141 chr1 85730696 C T 2.04E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12126141 chr1 85730696 C T 4.53E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126141 chr1 85730696 C T 6.37E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2735590 chr1 85731310 T C 2.32E-06 Serum dimethylarginine levels (symmetric) BCL10 nearGene-3 24159190 rs1060846 chr1 85732065 A G 3.23E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs962409 chr1 85732941 A C 3.43E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs2252408 chr1 85733929 C T 2.20E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs12134420 chr1 85738308 C T 4.80E-08 Serum dimethylarginine levels (symmetric) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 1.24E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 5.91E-10 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs2735594 chr1 85741921 G C 1.62E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs78416998 chr1 85742155 G A 1.86E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 UTR-5 24159190 rs78416998 chr1 85742155 G A 1.93E-08 Serum dimethylarginine levels (asymmetric) BCL10 UTR-5 24159190 rs2735593 chr1 85742338 G C 1.61E-07 Serum dimethylarginine levels (asymmetric) LOC646626 missense 24159190 rs11555520 chr1 85743452 G A 6.79E-05 Body Mass Index LOC646626 UTR-3 pha003009 rs12136214 chr1 85745566 C T 3.51E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs116057745 chr1 85746632 A G 1.63E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6698331 chr1 85746929 T C 3.28E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs6693365 chr1 85749715 C G 2.22E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2133183 chr1 85750598 C T 1.01E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12729231 chr1 85754207 C T 2.62E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161584 chr1 85755127 A G 6.04E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6668948 chr1 85757406 T C 1.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 3.33E-09 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 6.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34743622 chr1 85760353 A G 1.43E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12754032 chr1 85760508 T C 2.50E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs35654640 chr1 85760543 T TG 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs57483398 chr1 85760543 T C 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs141922542 chr1 85761234 G A 2.38E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs141922542 chr1 85761234 G A 2.81E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161585 chr1 85761663 G C 9.53E-04 Alzheimer's disease / / 22005930 rs11161585 chr1 85761663 G C 1.49E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161586 chr1 85761786 T C 1.31E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11590047 chr1 85763154 C T 1.22E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161588 chr1 85763861 G A 1.19E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2030075 chr1 85763899 C T 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs34983308 chr1 85764134 G A 1.35E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34983308 chr1 85764134 G A 6.37E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11161589 chr1 85764886 A G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161590 chr1 85764998 A G 5.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10782547 chr1 85765293 C G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11583827 chr1 85765682 G C 1.23E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11587512 chr1 85765798 A G 6.43E-05 Serum metabolites / / 19043545 rs11587512 chr1 85765798 A G 1.24E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161591 chr1 85765990 C T 1.46E-11 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161592 chr1 85766230 C A 1.18E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7554249 chr1 85767794 C T 2.98E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7554249 chr1 85767794 C T 6.37E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.80E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs61771982 chr1 85768644 G A 5.29E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs12093484 chr1 85768860 A G 1.02E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs17125445 chr1 85769032 C T 1.01E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11585614 chr1 85770620 T C 9.69E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs2012099 chr1 85771452 C T 8.21E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2012099 chr1 85771452 C T 9.22E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs233100 chr1 85772009 G A 1.00E-06 Multiple sclerosis / / 21833088 rs233101 chr1 85772334 A G 2.01E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233101 chr1 85772334 A G 6.21E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233102 chr1 85772701 C A 2.08E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233102 chr1 85772701 C A 6.19E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs138851971 chr1 85774687 G A 1.70E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs138851971 chr1 85774687 G A 3.62E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs35240561 chr1 85775217 C G 1.00E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs35240561 chr1 85775217 C G 2.21E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35240561 chr1 85775217 C G 5.65E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12047189 chr1 85775448 A C 4.26E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12122154 chr1 85775865 C T 8.53E-04 Alzheimer's disease / / 22005930 rs4949897 chr1 85776121 G C 9.33E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34561661 chr1 85777250 C T 1.48E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34561661 chr1 85777250 C T 2.30E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs34561661 chr1 85777250 C T 8.80E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722663 chr1 85777534 T G 7.90E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs4949889 chr1 85778344 G A 5.18E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs1874807 chr1 85779393 G A 1.62E-04 Alzheimer's disease / / 22005930 rs1874807 chr1 85779393 G A 4.60E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs72722665 chr1 85780781 T C 1.46E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722665 chr1 85780781 T C 2.96E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12042780 chr1 85780903 A G 2.41E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233108 chr1 85781720 C T 2.54E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233108 chr1 85781720 C T 3.12E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10489510 chr1 85782571 C G 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10489510 chr1 85782571 C G 6.42E-04 Menopause (age at onset) / / 22267201 rs10489510 chr1 85782571 C G 1.17E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233109 chr1 85783101 T C 2.38E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233109 chr1 85783101 T C 4.30E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 1.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12138621 chr1 85783970 T C 4.52E-13 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 6.12E-14 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161597 chr1 85784936 G A 1.12E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 4.21E-13 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 6.25E-14 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 1.20E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 3.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 1.54E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 4.39E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 3.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 8.88E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.52E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.18E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.13E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.10E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs1498375 chr1 85787323 T A 3.09E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498375 chr1 85787323 T A 3.43E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 3.11E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 4.11E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 6.76E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 2.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 4.46E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.15E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 1.03E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 8.32E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300633 chr1 85788826 A G 2.31E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 6.59E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 7.09E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.63E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722671 chr1 85791003 T C 1.50E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.82E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 3.18E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 5.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.25E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.72E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.26E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.76E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.68E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.90E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.69E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 4.06E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 8.04E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 2.38E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs731194 chr1 85795951 G A 3.06E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.07E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 6.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 2.33E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 3.35E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 3.37E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 2.12E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-20 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-40 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 2.19E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474121 chr1 85798038 G A 2.46E-23 Narcolepsy DDAH1 intron 19629137 rs2389913 chr1 85798075 T C 3.96E-04 Multiple complex diseases DDAH1 intron 17554300 rs12121675 chr1 85798484 A G 3.40E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 7.82E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 9.04E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 7.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 8.58E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 9.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 2.03E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 3.83E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 2.02E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 3.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 2.01E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 3.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 2.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 3.91E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.41E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 5.47E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 8.94E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 2.62E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 6.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 1.77E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 4.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 1.76E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 4.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 2.76E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 3.02E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs74599242 chr1 85804747 T A 4.42E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12035116 chr1 85804837 C T 1.03E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 1.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 4.95E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 1.49E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 4.92E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 2.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 3.27E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 5.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 1.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 5.78E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.18E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.50E-04 Renal cell carcinoma DDAH1 intron 24220910 rs12717763 chr1 85808164 T A 1.25E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 2.61E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 4.61E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 1.36E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 6.33E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 1.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 2.67E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 4.73E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 1.26E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 2.51E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 4.56E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 1.34E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 6.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949898 chr1 85811652 A G 5.29E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.59E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 1.66E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 2.74E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2230820 chr1 85816134 T C 1.33E-13 Serum dimethylarginine levels (symmetric) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 2.12E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 3.75E-14 Serum dimethylarginine levels (asymmetric) DDAH1 cds-synon 24159190 rs41301261 chr1 85816224 G A 1.48E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 2.33E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 6.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.45E-05 Cognitive performance DDAH1 intron 19734545 rs2076699 chr1 85817295 G A 1.38E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 2.13E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.42E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs180841827 chr1 85817542 A G 1.60E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 1.68E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 6.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 1.27E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 6.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 1.39E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 2.19E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 3.89E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 1.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 2.27E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 4.13E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 1.23E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 6.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 2.12E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 4.33E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 1.17E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474123 chr1 85827452 G A 1.08E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.08E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 1.42E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 2.03E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 3.60E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.37E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.53E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 4.53E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 8.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 1.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 2.31E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 9.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 4.71E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 6.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12038426 chr1 85831790 A C 1.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.39E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.99E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 9.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs75481609 chr1 85834202 G C 3.02E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 4.94E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 6.26E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 4.60E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 7.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 8.19E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722691 chr1 85835439 T C 1.33E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 3.94E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 5.06E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 9.99E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 2.07E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 3.52E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 4.53E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498377 chr1 85836436 G A 1.54E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722692 chr1 85837169 G C 8.05E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 3.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 7.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949899 chr1 85838237 G A,T 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 1.04E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 2.86E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs140056707 chr1 85838505 T G 2.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 1.44E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 2.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 3.61E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 7.05E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1391556 chr1 85841056 C G 2.02E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 3.54E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 6.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 2.39E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 3.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 5.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722697 chr1 85843863 G C 2.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2064510 chr1 85844330 G C 1.60E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 1.88E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 4.43E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 6.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 2.26E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 4.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4512701 chr1 85844835 G A 1.51E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4631749 chr1 85844852 T C 1.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 3.42E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 6.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 2.35E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 3.31E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 7.51E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 1.00E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 2.22E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 1.43E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 3.04E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 5.51E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 2.31E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 3.23E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 5.58E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.49E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 8.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 9.50E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 1.28E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 3.58E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 5.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 3.20E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 1.25E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 4.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 1.00E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 4.37E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 7.49E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 3.84E-04 Alzheimer's disease DDAH1 intron 22005930 rs11161606 chr1 85853902 T C 1.59E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 8.93E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 1.48E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 7.70E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 3.75E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 7.28E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 1.09E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 4.97E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 6.68E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 1.92E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 3.03E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724610 chr1 85856396 G C 1.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1342323 chr1 85857574 A T 9.59E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs77529889 chr1 85857838 A G 3.29E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12033483 chr1 85858123 C T 9.67E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 5.03E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 2.82E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 7.72E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 2.09E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7515261 chr1 85859804 C T 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10747318 chr1 85859910 A G 1.27E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 3.78E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.28E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.52E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10873701 chr1 85860374 C T 1.31E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 2.72E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 5.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4428939 chr1 85861564 A G 1.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 2.60E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 5.16E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.09E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.97E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161609 chr1 85862736 G T 2.09E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 2.56E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 5.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12034249 chr1 85864391 C T 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 2.41E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.74E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.88E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.08E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.24E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 3.62E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 3.80E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.11E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.85E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 2.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 5.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 1.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 2.32E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 2.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 4.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 2.38E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 5.39E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357635 chr1 85868798 A G 9.48E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357636 chr1 85869042 A C 5.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 1.57E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 2.29E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 3.30E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.52E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.63E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 4.52E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 1.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 2.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.11E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 1.66E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 3.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 1.11E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 7.53E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 1.68E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 3.72E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 4.79E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 1.08E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 2.36E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 3.22E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 2.93E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.37E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 3.05E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.08E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.84E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 4.91E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 3.33E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 7.51E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7546931 chr1 85880976 T C 6.88E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782549 chr1 85881278 T G 6.39E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 1.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 2.28E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2016104 chr1 85882871 G A 7.83E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1975755 chr1 85882905 A G 2.09E-04 Alzheimer's disease DDAH1 intron 22005930 rs1975755 chr1 85882905 A G 6.90E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1006988 chr1 85883320 C G 2.05E-04 Alzheimer's disease DDAH1 intron 22005930 rs7525786 chr1 85884076 C T 8.87E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 1.84E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 5.10E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10873702 chr1 85884101 T C 7.81E-05 Alzheimer's disease DDAH1 intron 22005930 rs10873702 chr1 85884101 T C 6.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783046 chr1 85884365 G A 5.31E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2124139 chr1 85884370 T C 7.50E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384213 chr1 85884621 G A 7.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 2.71E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 3.49E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 4.15E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1965876 chr1 85885178 A G 7.45E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608537 chr1 85885731 C G 7.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.40E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.54E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.93E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 1.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 3.84E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.99E-04 Alzheimer's disease DDAH1 intron 22005930 rs6697083 chr1 85887775 A T 1.59E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6420965 chr1 85888480 C T 3.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523995 chr1 85888986 A C 1.74E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7521189 chr1 85889596 G A 5.43E-04 Alzheimer's disease DDAH1 intron 22005930 rs7521189 chr1 85889596 G A 7.71E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.41E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.94E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523994 chr1 85890726 G A 2.17E-04 Alzheimer's disease DDAH1 intron 22005930 rs1523994 chr1 85890726 G A 7.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 3.36E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 5.45E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 6.12E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6672870 chr1 85891457 G T 7.10E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 5.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 7.00E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2389948 chr1 85892383 C G 8.16E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 1.03E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 2.29E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7540393 chr1 85893728 C T 7.67E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.19E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.29E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 4.79E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12029221 chr1 85893977 G C 1.92E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146374 chr1 85894027 G A 1.45E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561614 chr1 85894864 G A 2.32E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561422 chr1 85894932 T A 4.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146377 chr1 85895609 C T 5.27E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 1.24E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 2.28E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.15E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 5.18E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146378 chr1 85895820 G A 1.72E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 1.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 6.21E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 1.24E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.67E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 1.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.66E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 2.20E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 9.72E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 2.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 7.87E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 8.02E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 8.58E-04 Alcohol dependence DDAH1 intron 21314694 rs11161614 chr1 85898160 T G 3.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 4.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 6.50E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35956189 chr1 85898461 G A,T 8.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs990916 chr1 85898508 A G 1.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.44E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.03E-05 Neuroblastoma DDAH1 intron pha002895 rs506082 chr1 85899215 A C 1.90E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506082 chr1 85899215 A C 8.32E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 1.14E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 2.60E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.55E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.88E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 6.24E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 1.16E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 7.78E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.67E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 4.06E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 2.69E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 6.92E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs570121 chr1 85901598 C T 7.99E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3851268 chr1 85901887 T A 7.97E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs483530 chr1 85901919 A T 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs71582955 chr1 85901919 AT A 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs539714 chr1 85904338 C T 2.15E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 6.99E-05 Cognitive performance DDAH1 intron 19734545 rs12130591 chr1 85904985 G A 3.68E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 3.90E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 5.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 3.68E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 6.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17388696 chr1 85905427 G A 1.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs604974 chr1 85905705 A G 1.20E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 2.18E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 3.65E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 4.12E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 2.18E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 3.88E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 1.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 3.21E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 1.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.77E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs499869 chr1 85907851 A T 1.36E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1261681 chr1 85908282 A G 9.07E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1240939 chr1 85908649 T G 1.01E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 1.35E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 2.04E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 8.71E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs661686 chr1 85909210 T C 5.13E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 3.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 9.03E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 3.14E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 9.70E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 8.57E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 9.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 2.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 4.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 6.53E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 1.83E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 5.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 8.23E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 2.43E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 8.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2124140 chr1 85912143 G T 1.36E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs600098 chr1 85912584 T C 2.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs530006 chr1 85913508 G T 6.85E-04 Alzheimer's disease DDAH1 intron 22005930 rs530006 chr1 85913508 G T 8.13E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 3.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.77E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724639 chr1 85913632 C G 8.72E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs631817 chr1 85913740 T C 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 1.16E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 5.79E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 1.24E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 3.84E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs659070 chr1 85915149 A G 2.66E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11587876 chr1 85915183 T C 4.15E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 2.73E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 3.36E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 4.23E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 7.11E-04 Myopia (pathological) DDAH1 intron 21095009 rs2935 chr1 85917563 G A 2.61E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 3.16E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17127710 chr1 85918009 C T 4.36E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146382 chr1 85918101 C T 3.46E-04 Alzheimer's disease DDAH1 intron 22005930 rs1146382 chr1 85918101 C T 2.09E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 1.30E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.97E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 1.21E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 5.84E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 1.79E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12717764 chr1 85920219 G C 5.78E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.80E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.92E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 1.62E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 3.10E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 2.21E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 4.83E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 6.31E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36104818 chr1 85923472 G A 2.38E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 1.69E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 2.92E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 5.09E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 7.49E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 1.42E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 2.67E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 1.92E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 5.77E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs597168 chr1 85925028 T C 3.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 1.18E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 4.89E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 5.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17389112 chr1 85925235 C T 4.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.55E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6658151 chr1 85926281 A T 4.71E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783057 chr1 85926726 G A 9.89E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 6.49E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12032315 chr1 85927407 C T 7.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 1.23E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 5.11E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 6.20E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1241320 chr1 85928237 A C 1.11E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949905 chr1 85928564 T C 3.46E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161619 chr1 85928811 C T 9.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs529582 chr1 85929008 T C 7.89E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs527762 chr1 85929214 C A 5.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044882 chr1 85931014 G T 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61223539 chr1 85931843 T C 1.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 3.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 6.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs149635670 chr1 85934276 C T 1.34E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs665091 chr1 85935422 T G 1.67E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs535723 chr1 85936622 T G 4.18E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 4.89E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 9.92E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 4.87E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 9.93E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12060713 chr1 85938487 G A 5.04E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 4.26E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 9.69E-05 Height DDAH1 intron pha003011 rs7540169 chr1 85938736 T C 6.31E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 1.00E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 2.25E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 9.32E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 1.06E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 2.88E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 3.48E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 2.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 3.77E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 1.95E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 2.57E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 3.37E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 1.53E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.56E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.07E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.57E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 2.23E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.25E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 6.34E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs975880 chr1 85939935 C A 6.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 1.24E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 3.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 4.62E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 1.27E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 2.03E-30 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 5.44E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 1.68E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 3.66E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 9.43E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724655 chr1 85940875 C G 1.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146395 chr1 85951597 T C 0.000713015 Hypertension (early onset hypertension) DDAH1 intron 22479346 rs2066357 chr1 85971357 G A 3.00E-04 Psoriasis DDAH1 intron 20953189 rs677691 chr1 85974030 A C 4.85E-04 Suicide attempts in bipolar disorder DDAH1 intron 21423239 rs577177 chr1 85995113 A G 3.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DDAH1 intron 20031582 rs17099678 chr1 86006208 C T 7.94E-04 Alzheimer's disease DDAH1 intron 17998437 rs17099679 chr1 86008398 A G 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs12734233 chr1 86008536 G A 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs17127884 chr1 86021696 G A 4.93E-04 Multiple complex diseases DDAH1 intron 17554300 rs7543409 chr1 86049823 C T 2.20E-06 Urinary metabolites / / 21572414 rs6576779 chr1 86061662 C T 3.20E-06 Urinary metabolites / / 21572414 rs11578464 chr1 86072408 T G 1.40E-05 Urinary metabolites / / 21572414 rs12566306 chr1 86074635 C A 1.47E-05 Cognitive impairment induced by topiramate / / 22091778 rs1999186 chr1 86085545 G A 6.51E-04 Alcohol dependence / / 24277619 rs143554335 chr1 86105750 C T 6.48E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2970548 chr1 86118447 A G 9.64E-04 Multiple complex diseases ZNHIT6 UTR-3 17554300 rs3753786 chr1 86175554 A G 2.00E-05 Urinary metabolites / / 21572414 rs6672312 chr1 86176188 C T 2.80E-05 Urinary metabolites / / 21572414 rs2389972 chr1 86190666 A G 0.000107 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs6682235 chr1 86208801 C T 2.26E-04 Multiple complex diseases COL24A1 intron 17554300 rs147783303 chr1 86210343 A G 7.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) COL24A1 intron 24159190 rs392038 chr1 86233871 G A 1.68E-04 Smoking initiation COL24A1 intron 24665060 rs313728 chr1 86245155 C T 1.10E-04 Smoking initiation COL24A1 intron 24665060 rs10158651 chr1 86274325 G T 2.39E-06 Lipid levels COL24A1 intron 19913121 rs11161691 chr1 86319439 A G 8.51E-04 Type 2 diabetes COL24A1 intron 17463246 rs2046159 chr1 86330589 A G 1.20E-05 Height COL24A1 intron 21194676 rs2046159 chr1 86330589 A G 7.10E-07 Height COL24A1 intron 21194676 rs7554796 chr1 86331245 C T 7.47E-04 Type 2 diabetes COL24A1 intron 17463246 rs7542433 chr1 86351624 C A 9.84E-04 Self-reported allergy COL24A1 intron 23817569 rs1858556 chr1 86371149 T C 0.00007 Asthma COL24A1 intron 18401594 rs10493777 chr1 86377028 C T 0.00007 Asthma COL24A1 intron 18401594 rs12723176 chr1 86413022 C T 9.56E-04 Type 2 diabetes COL24A1 intron 17463246 rs2134411 chr1 86463640 G A 2.37E-05 Multiple complex diseases COL24A1 intron 17554300 rs10873740 chr1 86464262 T C 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs11161717 chr1 86464981 A G 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs17128651 chr1 86465736 G A 1.10E-04 Alcohol dependence COL24A1 intron 20201924 rs17128651 chr1 86465736 G A 7.70E-04 Alcohol dependence COL24A1 intron 20201924 rs12143304 chr1 86505755 A G 4.78E-05 Major depressive disorder COL24A1 intron 20516156 rs583315 chr1 86526618 C T 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL24A1 intron 20877124 rs17415692 chr1 86533142 C T 5.81E-05 Platelet counts COL24A1 intron pha003100 rs10873744 chr1 86549569 G A 9.76E-04 Lymphocyte counts COL24A1 intron 22286170 rs10493786 chr1 86553669 A C 9.90E-04 Type 2 diabetes and 6 quantitative traits COL24A1 intron 17848626 rs1605417 chr1 86563632 C G 8.37E-05 Acute lymphoblastic leukemia (childhood) COL24A1 intron 19684603 rs12044349 chr1 86566278 T C 3.79E-04 Multiple complex diseases COL24A1 intron 17554300 rs7540048 chr1 86622285 C T 0.000000285 LDL cholesterol / / 23063622 rs1507294 chr1 86637089 T G 1.90E-04 Multiple complex diseases / / 17554300 rs6687339 chr1 86638265 A G 8.42E-04 Type 2 diabetes / / 17463246 rs6576808 chr1 86638748 G A 7.33E-05 Parkinson's disease / / 21738487 rs12083520 chr1 86693196 A C 4.14E-04 Alzheimer's disease / / 17998437 rs11587664 chr1 86714346 G A 2.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1323035 chr1 86784804 C A 5.47E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs272500 chr1 86827633 A T 5.18E-13 Lymphocyte counts ODF2L intron 22286170 rs421105 chr1 86838158 C T 5.20E-04 Smoking initiation ODF2L cds-synon 24665060 rs272514 chr1 86845563 T C 6.45E-04 Multiple complex diseases ODF2L intron 17554300 rs1407719 chr1 86851420 A G 8.76E-05 Lung function (forced expiratory volume in 1 second) ODF2L intron pha003102 rs5026277 chr1 86885620 C T 1.89E-04 Smoking initiation / / 24665060 rs1334149 chr1 86899021 A G 8.58E-05 Socioeconomic Factors CLCA2 intron pha003067 rs17409304 chr1 86900372 C G 5.09E-04 Multiple complex diseases CLCA2 missense 17554300 rs11161828 chr1 86902967 A G 9.51E-04 Coronary heart disease CLCA2 intron 21971053 rs2390059 chr1 86909493 C T 9.77E-04 Coronary heart disease CLCA2 cds-synon 21971053 rs2791519 chr1 86934176 T G 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2791516 chr1 86938706 C T 1.05E-06 Systemic lupus erythematosus and Systemic sclerosis CLCA1 intron 23740937 rs5744329 chr1 86940715 G A 1.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLCA1 intron 20031582 rs926064 chr1 86941348 G A 6.46E-04 Type 2 diabetes CLCA1 intron 17463246 rs1321695 chr1 86947747 C A 4.37E-04 Type 2 diabetes CLCA1 intron 17463246 rs2791508 chr1 86954398 T C 1.84E-05 Multiple complex diseases CLCA1 intron 17554300 rs1321689 chr1 86959796 C T 2.78E-04 Smoking initiation CLCA1 intron 24665060 rs1028575 chr1 86966851 T C 2.34E-04 Nicotine dependence / / 17158188 rs2791480 chr1 86968584 C G 4.38E-05 Nicotine dependence / / 17158188 rs17129266 chr1 86969110 G C 6.15E-04 Multiple complex diseases / / 17554300 rs7538979 chr1 86971778 A G 9.15E-04 Multiple complex diseases / / 17554300 rs1321687 chr1 86974034 C A 9.59E-04 Nicotine dependence / / 17158188 rs1321686 chr1 86974115 C T 9.72E-04 Nicotine dependence / / 17158188 rs12734135 chr1 86992633 C T 9.89E-04 Multiple complex diseases / / 17554300 rs12750427 chr1 86995816 A G 1.38E-04 Type 2 diabetes / / 17463246 rs1575177 chr1 87000484 T C 3.79E-05 Waist Circumference / / pha003023 rs11161841 chr1 87003472 T A 7.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782575 chr1 87020617 G T 0.0003651 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CLCA4 intron 23233654 rs10782575 chr1 87020617 G T 3.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs10782575 chr1 87020617 G T 7.44E-05 Amyotrophic lateral sclerosis (sporadic) CLCA4 intron 24529757 rs772605 chr1 87028669 A G 9.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs772601 chr1 87032324 A G 7.45E-04 Multiple complex diseases CLCA4 intron 17554300 rs772598 chr1 87039945 A G 7.57E-04 Type 2 diabetes CLCA4 intron 17463246 rs1953652 chr1 87051201 C T 4.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 5.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 9.00E-06 IgG glycosylation / / 23382691 rs539145 chr1 87122714 G T 3.83E-04 Multiple complex diseases / / 17554300 rs11161871 chr1 87140602 C A 8.92E-04 Type 2 diabetes / / 17463246 rs3766008 chr1 87184393 C T 6.48E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs3766008 chr1 87184393 C T 2.13E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263462 chr1 87188921 G A 6.44E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263462 chr1 87188921 G A 1.02E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263482 chr1 87201299 T C 6.36E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263482 chr1 87201299 T C 1.01E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263480 chr1 87203757 C G 4.90E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263480 chr1 87203757 C G 9.19E-05 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs376906 chr1 87212934 G A 4.94E-04 Depression (quantitative trait) SH3GLB1 UTR-3 20800221 rs376906 chr1 87212934 G A 1.99E-04 Suicide attempts in bipolar disorder SH3GLB1 UTR-3 21423239 rs263491 chr1 87223804 T G 4.95E-04 Depression (quantitative trait) / / 20800221 rs263491 chr1 87223804 T G 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs263489 chr1 87227431 A T 4.97E-04 Depression (quantitative trait) / / 20800221 rs263489 chr1 87227431 A T 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs263485 chr1 87234742 A G 5.05E-04 Depression (quantitative trait) / / 20800221 rs263485 chr1 87234742 A G 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs166412 chr1 87242062 T G 1.43E-04 Multiple complex diseases / / 17554300 rs691531 chr1 87245278 C T 9.90E-07 Multiple complex diseases / / 17554300 rs691481 chr1 87246014 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs691241 chr1 87246327 A G 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs692441 chr1 87255790 T C 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs525467 chr1 87256056 G A 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs797979 chr1 87258974 G T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12074463 chr1 87259306 T C 9.52E-04 Parkinson's disease / / 17052657 rs12074463 chr1 87259306 T C 0.0003261 Sarcoidosis / / 22952805 rs492895 chr1 87260215 A G 0.00058066 Sarcoidosis / / 22952805 rs797978 chr1 87263948 A G 0.00059295 Sarcoidosis / / 22952805 rs691396 chr1 87265806 T C 5.03E-05 C-Reactive Protein / / pha003070 rs691369 chr1 87266144 G A 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs691135 chr1 87266383 T A 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs691155 chr1 87269292 C T 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6698706 chr1 87276009 T A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335853 chr1 87288314 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs17129524 chr1 87288755 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782586 chr1 87292548 C G 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7539403 chr1 87297001 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12142266 chr1 87297849 T C 9.89E-04 Obesity (extreme) / / 21935397 rs12142266 chr1 87297849 T C 1.20E-04 Suicidal ideation / / 22030708 rs17418454 chr1 87482713 G A 6.05E-04 HIV-1 viral setpoint HS2ST1 intron 17641165 rs6576860 chr1 87485257 C T 4.80E-04 Insulin resistance HS2ST1 intron 21901158 rs17452535 chr1 87488653 A G 5.49E-05 Stroke HS2ST1 intron pha002886 rs17452535 chr1 87488653 A G 4.14E-05 Glucose levels HS2ST1 intron pha003061 rs12120670 chr1 87577135 T A 3.71E-04 Depression (quantitative trait) / / 20800221 rs7553864 chr1 87613358 T C 3.00E-06 Smoking behavior LOC339524 intron 19247474 rs10873823 chr1 87660268 A T 2.79E-05 Bipolar disorder / / 19488044 rs6576874 chr1 87675036 G A 8.57E-05 Erythrocyte counts / / pha003101 rs7542364 chr1 87687466 A G 5.03E-05 Erythrocyte counts / / pha003101 rs10873824 chr1 87688394 A G 1.42E-05 Mathematical ability / / 24801482 rs7546843 chr1 87699558 A G 5.79E-04 Multiple complex diseases / / 17554300 rs6576878 chr1 87705031 A G 6.00E-06 White blood cell types / / 21738478 rs1109790 chr1 87710779 G A 3.31E-05 Multiple complex diseases / / 17554300 rs882573 chr1 87711640 A T 9.19E-04 Multiple complex diseases / / 17554300 rs4655937 chr1 87712256 C T 7.87E-04 Type 2 diabetes / / 17463246 rs4655937 chr1 87712256 C T 5.28E-04 Multiple complex diseases / / 17554300 rs10493797 chr1 87720928 G C 1.79E-04 Multiple complex diseases / / 17554300 rs1411705 chr1 87728263 G C 1.49E-04 Multiple complex diseases / / 17554300 rs11583437 chr1 87729323 A G 1.75E-04 Multiple complex diseases / / 17554300 rs1888340 chr1 87731239 G A 2.52E-04 Multiple complex diseases / / 17554300 rs12035326 chr1 87739930 A G 0.000138 Salmonella-induced pyroptosis / / 22837397 rs6576888 chr1 87746317 T G 4.72E-05 Serum metabolites / / 19043545 rs6576888 chr1 87746317 T G 5.87E-06 Post-operative nausea and vomiting / / 21694509 rs6576888 chr1 87746317 T G 4.30E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10127691 chr1 87748856 T C 4.00E-05 Prostate cancer / / 21743057 rs6675584 chr1 87752776 C A 7.01E-06 Blood pressure (response to calcium channel blocker) / / 24192120 rs6688319 chr1 87752886 A C 6.02E-04 Type 2 diabetes / / 17463246 rs6688319 chr1 87752886 A C 3.52E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6576889 chr1 87762304 C T 1.40E-05 Urinary metabolites / / 21572414 rs11161973 chr1 87769531 T C 2.50E-05 Urinary metabolites / / 21572414 rs879988 chr1 87774197 G T 2.50E-05 Urinary metabolites / / 21572414 rs4655952 chr1 87776842 G A 2.50E-05 Urinary metabolites / / 21572414 rs17422436 chr1 87834794 G A 8.60E-04 Type 2 diabetes LOC100505768 intron 23209189 rs11161992 chr1 87835674 C T 5.55E-04 Taste perception LOC100505768 intron 22132133 rs12094766 chr1 87836555 T C 8.62E-04 Multiple complex diseases LOC100505768 intron 17554300 rs11161993 chr1 87838608 A G 1.61E-04 Taste perception / / 22132133 rs11582903 chr1 87846054 C A 3.94E-06 Aging (time to event) / / 21782286 rs11162001 chr1 87862587 C T 9.59E-04 Alzheimer's disease / / 24755620 rs4655956 chr1 87868540 A G 8.56E-04 Alzheimer's disease / / 24755620 rs12758097 chr1 87877226 G A 2.26E-04 Tourette syndrome / / 22889924 rs12758097 chr1 87877226 G A 8.61E-04 Alzheimer's disease / / 24755620 rs1006625 chr1 87877540 A G 8.55E-04 Alzheimer's disease / / 24755620 rs10873844 chr1 87882213 C T 9.67E-04 Alzheimer's disease / / 24755620 rs12565028 chr1 87921397 C T 1.00E-05 Urinary metabolites / / 21572414 rs17131727 chr1 87950279 T C 2.64E-04 Tourette syndrome / / 22889924 rs12410191 chr1 88036573 T G 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs902296 chr1 88039284 C A 5.13E-04 Multiple complex diseases / / 17554300 rs902296 chr1 88039284 C A 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9433138 chr1 88055578 G A 6.42E-04 Depression (quantitative trait) / / 20800221 rs60417255 chr1 88055640 G T 0.0000469 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696952 chr1 88071963 A G 2.51E-04 Schizophrenia / / 20832056 rs11162051 chr1 88078503 C T 4.79E-04 Smoking quantity / / 24665060 rs923545 chr1 88083782 G A 4.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4655977 chr1 88086152 T C 3.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4655978 chr1 88087990 C G 5.30E-06 Urinary metabolites / / 21572414 rs1490166 chr1 88119200 C T 1.40E-05 Urinary metabolites / / 21572414 rs1414648 chr1 88128663 T C 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12132154 chr1 88129038 C A 8.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs6678935 chr1 88131531 G T 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs983332 chr1 88132380 G T 5.00E-06 Response to TNF antagonist treatment / / 18615156 rs983332 chr1 88132380 G T 1.50E-04 Endometriosis / / 21151130 rs10922746 chr1 88149030 A C 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17130103 chr1 88150542 T C 1.89E-10 Multiple complex diseases / / 17554300 rs17130108 chr1 88154873 A C 8.71E-04 Multiple complex diseases / / 17554300 rs12568911 chr1 88166163 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs305467 chr1 88168623 T A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10801871 chr1 88176320 A G 3.70E-05 Primary sclerosing cholangitis / / 19944697 rs305445 chr1 88208135 G A 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs35214987 chr1 88226329 G C 2.40E-05 Urinary metabolites / / 21572414 rs35214987 chr1 88226329 G C 9.00E-07 Cognitive function / / 24684796 rs2436974 chr1 88240066 G A 5.63E-04 Iron levels / / pha002876 rs1369036 chr1 88261805 A G 3.42E-06 Multiple complex diseases / / 17554300 rs2491281 chr1 88287371 C T 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs6673871 chr1 88301277 A G 3.92E-04 Smoking initiation / / 24665060 rs2491302 chr1 88313724 T C 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs10218533 chr1 88335474 T C 0.000517 Salmonella-induced pyroptosis / / 22837397 rs41341750 chr1 88338185 A C 9.36E-05 Multiple complex diseases / / 17554300 rs3008440 chr1 88343418 A G 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs2503248 chr1 88358924 T C 1.45E-04 IgE levels / / 17255346 rs2503251 chr1 88363167 C A 3.50E-04 Multiple complex diseases / / 17554300 rs2503253 chr1 88363289 T C 3.78E-05 IgE levels / / 17255346 rs2503256 chr1 88364454 A G 1.24E-04 IgE levels / / 17255346 rs17130220 chr1 88399387 T C 2.98E-05 Multiple complex diseases / / 17554300 rs10489945 chr1 88413589 C T 8.39E-04 Schizophrenia / / 19197363 rs6691335 chr1 88416590 T C 6.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs1413536 chr1 88423397 C T 1.64E-04 Coronary heart disease / / 21606135 rs2991716 chr1 88423966 T C 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1413527 chr1 88430037 T C 6.12E-05 Serum metabolites / / 19043545 rs1334331 chr1 88441066 C A 1.18E-04 Coronary heart disease / / 21606135 rs3008465 chr1 88453303 A C 8.07E-04 HIV-1 viral setpoint / / 17641165 rs12133568 chr1 88495250 A G 3.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4265406 chr1 88497975 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs12133500 chr1 88499703 G C 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs12567534 chr1 88500903 A G 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs12143926 chr1 88504370 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12566596 chr1 88506791 G C 2.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs12117077 chr1 88512371 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923014 chr1 88513365 C T 2.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655998 chr1 88514186 A C 2.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656000 chr1 88514400 G A 2.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656001 chr1 88514430 A G 2.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656002 chr1 88514728 C T 1.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923015 chr1 88514979 T A 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656003 chr1 88515494 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs12568661 chr1 88519718 G A 5.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12118601 chr1 88521377 C T 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655864 chr1 88521416 T A 5.08E-04 Multiple complex diseases / / 17554300 rs4656008 chr1 88524540 G T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs10754315 chr1 88529368 T C 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656013 chr1 88604157 C T 6.57E-04 Obesity (extreme) / / 21935397 rs1336578 chr1 88610289 C T 6.58E-06 Serum metabolites / / 19043545 rs1336578 chr1 88610289 C T 6.44E-06 Stroke (ischemic) / / 22941190 rs17130276 chr1 88621694 A C 8.77E-04 Multiple complex diseases / / 17554300 rs12032672 chr1 88625636 A C 1.00E-06 Periodontal microbiota / / 22699663 rs1932754 chr1 88634245 G A 9.50E-05 Serum metabolites / / 19043545 rs1932754 chr1 88634245 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12041762 chr1 88641601 C T 3.30E-05 Diabetic retinopathy / / 21441570 rs12041762 chr1 88641601 C T 8.19E-05 Heart Rate / / pha003054 rs12567486 chr1 88645313 T C 7.70E-05 Diabetic retinopathy / / 21441570 rs4656020 chr1 88646891 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs10923035 chr1 88647092 C T 2.01E-04 Taste perception / / 22132133 rs10923038 chr1 88651771 C A 4.00E-07 Serum protein levels (sST2) / / 23999434 rs12755168 chr1 88657007 T G 5.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1932757 chr1 88665329 T C 7.08E-05 Coronary heart disease / / 21606135 rs6698308 chr1 88666005 A G 2.74E-04 Multiple complex diseases / / 17554300 rs12032086 chr1 88673612 T C 6.70E-04 Type 2 diabetes / / 17463246 rs10493803 chr1 88673676 G T 1.85E-04 Coronary heart disease / / 21606135 rs12403601 chr1 88674545 G T 2.14E-04 Coronary heart disease / / 21606135 rs10923044 chr1 88681580 T C 7.72E-05 Coronary heart disease / / 21606135 rs6684410 chr1 88682190 C T 9.66E-05 Multiple complex diseases / / 17554300 rs4300194 chr1 88699950 T C 1.16E-04 Coronary heart disease / / 21606135 rs12730130 chr1 88701591 T A 1.21E-04 Coronary heart disease / / 21606135 rs673212 chr1 88728999 C G 3.40E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs472473 chr1 88738404 G A 4.37E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1295491 chr1 88740865 T C 1.69E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1288671 chr1 88741916 G C 7.31E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs569619 chr1 88742010 T G 1.36E-04 Coronary heart disease / / 21606135 rs10923053 chr1 88743657 A G 1.33E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6679982 chr1 88757128 C T 3.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6692873 chr1 88760420 C T 3.10E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs608410 chr1 88770663 T C 7.44E-04 Coronary heart disease / / 21606135 rs591604 chr1 88779226 A C,G,T 1.90E-04 Coronary heart disease / / 21606135 rs589824 chr1 88779625 C T 6.17E-05 Coronary heart disease / / 21606135 rs555994 chr1 88780562 C T 1.11E-05 Coronary heart disease / / 21606135 rs473821 chr1 88781342 C T 3.09E-06 Coronary heart disease / / 21606135 rs687790 chr1 88786051 C T 5.57E-05 Orofacial clefts / / 22419666 rs127382 chr1 88788948 T C 4.21E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 1.43E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 6.04E-05 Orofacial clefts / / 22419666 rs480054 chr1 88791432 G A 1.97E-04 Coronary heart disease / / 21606135 rs2179965 chr1 88802012 A G 1.00E-06 Cognitive test performance / / 17903297 rs766353 chr1 88821516 A G 2.18E-04 Coronary heart disease / / 21606135 rs6682490 chr1 88825290 T A 6.25E-04 Coronary heart disease / / 21606135 rs9428070 chr1 88838394 G T 1.35E-04 Aortic root size / / 21223598 rs9287153 chr1 88840027 T A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs400666 chr1 88855885 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs507241 chr1 88855999 A G 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10801891 chr1 88906024 G A 7.33E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12723729 chr1 88919469 A G 6.96E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2044264 chr1 88965798 A G 0.000097 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs306336 chr1 88972879 A G 0.00000194 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs12409611 chr1 88973472 T C 0.0000102 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6671025 chr1 88979447 C A 0.0000122 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10493815 chr1 89016499 G A 4.77E-05 Neutrophil count / / pha003095 rs306298 chr1 89020534 G A 7.70E-05 Parkinson's disease (age of onset) / / 19772629 rs642773 chr1 89040252 C T 0.000057 Tuberculosis with late age of onset / / 22551897 rs642773 chr1 89040252 C T 4.65E-04 Myocardial Infarction / / pha002883 rs12024611 chr1 89072924 G A 3.94E-05 Celiac disease / / 23936387 rs17130538 chr1 89079544 C T 1.79E-06 Retinopathy in non-diabetics / / 23393555 rs1373259 chr1 89081648 A G 4.40E-06 Urinary metabolites / / 21572414 rs662452 chr1 89104124 T C 7.67E-04 Multiple complex diseases / / 17554300 rs7534720 chr1 89116300 T C 5.44E-05 Celiac disease / / 23936387 rs6699417 chr1 89123443 C T 5.00E-09 Height / / 20881960 rs6699417 chr1 89123443 C T 3.33E-05 Monocyte counts / / pha003089 rs10493817 chr1 89126887 T G 1.54E-04 Celiac disease / / 23936387 rs10493817 chr1 89126887 T G 7.68E-05 Monocyte counts / / pha003089 rs10754252 chr1 89133812 G A 3.33E-05 Monocyte counts / / pha003089 rs1490738 chr1 89137605 A C 0.000148 Coronary artery disease / / 23202125 rs6698181 chr1 89143305 C T 5.30E-05 Type 2 diabetes / / 17463246 rs12145922 chr1 89146234 C A 2.40E-05 Height / / 21194676 rs12145922 chr1 89146234 C A 2.70E-08 Height / / 21194676 rs12145922 chr1 89146234 C A 3.30E-04 Height / / 21194676 rs12145922 chr1 89146234 C A 4.00E-11 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs3806340 chr1 89148793 G T 5.63E-05 Monocyte counts / / pha003089 rs430600 chr1 89225976 T C 1.72E-04 Celiac disease PKN2 cds-synon 23936387 rs12744822 chr1 89247191 A T 0.00018 Coronary artery calcification PKN2 intron 23727086 rs786911 chr1 89265248 T C 1.92E-04 Celiac disease PKN2 intron 23936387 rs786911 chr1 89265248 T C 7.53E-05 Monocyte counts PKN2 intron pha003089 rs786921 chr1 89286673 G A 2.87E-04 Celiac disease PKN2 intron 23936387 rs10801687 chr1 89307261 G A 2.38E-04 Celiac disease / / 23936387 rs10801687 chr1 89307261 G A 7.53E-05 Monocyte counts / / pha003089 rs17130643 chr1 89341408 C T 4.00E-06 Obesity-related traits GTF2B intron 23251661 rs7524919 chr1 89372589 G A 0.000678964 Hypertension (early onset hypertension) / / 22479346 rs10922510 chr1 89373702 C T 7.84E-05 Bipolar disorder / / 20451256 rs11805182 chr1 89375410 C T 7.78E-05 Bipolar disorder / / 20451256 rs13375223 chr1 89376633 C T 2.63E-05 Bipolar disorder / / 20451256 rs7538497 chr1 89384717 T G 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs7524728 chr1 89384950 C T 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs17472003 chr1 89409488 A G 6.44E-05 Bipolar disorder CCBL2 intron 20451256 rs10922530 chr1 89427252 G A 8.70E-07 Pulmonary function CCBL2 intron 17903307 rs3753683 chr1 89427571 G C 1.87E-06 Pulmonary function CCBL2 intron 17903307 rs1409149 chr1 89429149 T C 9.12E-06 Pulmonary function CCBL2 intron 17903307 rs10518418 chr1 89437113 G T 7.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCBL2 intron 20031582 rs1409150 chr1 89473175 T C 4.28E-04 Prostate cancer mortality GBP3 UTR-3 20978177 rs4656078 chr1 89479074 C T 9.86E-04 Alzheimer's disease GBP3 missense 24755620 rs10801705 chr1 89500382 G A 2.07E-04 Parkinson's disease / / 17052657 rs2149186 chr1 89505043 G T 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6675866 chr1 89517810 T C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs12408132 chr1 89517918 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs12740160 chr1 89551004 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs12725861 chr1 89566096 G A 9.50E-04 Alzheimer's disease (late onset) / / 21460841 rs2209957 chr1 89583573 A G 8.52E-05 ldl cholesterol GBP2 intron pha003077 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 20885792 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922573 chr1 89588380 A G 8.30E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922574 chr1 89589383 T C 6.53E-04 Suicide attempts in bipolar disorder GBP2 intron 21041247 rs2893089 chr1 89630721 G T 6.54E-04 Suicide attempts in bipolar disorder GBP7 intron 21041247 rs615739 chr1 89643644 A G 3.35E-05 Cholesterol / / pha003083 rs6703905 chr1 89656749 C T 1.43E-04 Bipolar disorder GBP4 intron 18317468 rs7547610 chr1 89696603 G A 6.99E-04 Myocardial Infarction / / pha002873 rs2209307 chr1 89723344 G A 7.62E-05 Multiple complex diseases / / 17554300 rs148301962 chr1 89726438 G A 0.000029 Breast cancer (ER positive) GBP5 cds-synon 23555315 rs1117177 chr1 89787286 A G 4.88E-05 Hypertension / / pha003041 rs6669828 chr1 89804195 G A 1.50E-05 Urinary metabolites / / 21572414 rs7511795 chr1 89842459 T C 9.70E-05 Iron levels GBP6 intron 21208937 rs928652 chr1 89849201 C G 7.80E-05 Parkinson's disease (familial) GBP6 intron 18985386 rs1984129 chr1 89857106 G A 5.20E-05 Parkinson's disease (familial) / / 18985386 rs1984129 chr1 89857106 G A 6.86E-05 Alzheimer's disease (late onset) / / 21379329 rs928656 chr1 89859768 C T 9.73E-05 Alzheimer's disease (late onset) / / 21379329 rs12098051 chr1 89890973 G T 3.60E-05 Intracerebral hemorrhage / / 24656865 rs12753970 chr1 89893138 A G 1.90E-05 Personality dimensions / / 22628180 rs7545722 chr1 89894471 A G 6.40E-05 Parkinson's disease (familial) / / 18985386 rs72953868 chr1 89896790 G A 1.43E-05 Intracerebral hemorrhage / / 24656865 rs72953868 chr1 89896790 G A 3.57E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 2.43E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 4.46E-05 Intracerebral hemorrhage / / 24656865 rs4259628 chr1 89927234 G A 1.43E-04 Coronary Artery Disease / / 17634449 rs3929231 chr1 89927727 C T 1.49E-04 Coronary Artery Disease / / 17634449 rs6692501 chr1 89935101 A G 1.50E-05 Urinary metabolites / / 21572414 rs1585364 chr1 89972062 G T 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2125724 chr1 90000410 C G 1.46E-05 Personality dimensions LRRC8B intron 22628180 rs9428043 chr1 90005132 T C 4.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs9428043 chr1 90005132 T C 9.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922107 chr1 90022796 A G 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.73E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 4.13E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922106 chr1 90025519 C A 9.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs17099922 chr1 90027582 C T 0.000871 Salmonella-induced pyroptosis LRRC8B intron 22837397 rs10922664 chr1 90032940 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 9.28E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6428557 chr1 90066090 T G 3.53E-04 Multiple complex diseases / / 17554300 rs6428558 chr1 90066415 T C 2.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1215494 chr1 90066806 G A 1.60E-05 Bone mineral density (BMD),in women / / 20164292 rs1215547 chr1 90072888 C T 3.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6428561 chr1 90102619 G A 1.34E-04 Nicotine smoking LRRC8C intron 19268276 rs10754283 chr1 90112431 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) LRRC8C intron 24529757 rs2390794 chr1 90125566 G A 1.23E-04 Nicotine smoking LRRC8C intron 19268276 rs2390794 chr1 90125566 G A 1.13E-08 Metabolite levels LRRC8C intron 23281178 rs10801766 chr1 90125934 C T 7.86E-09 Metabolite levels LRRC8C intron 23281178 rs17494625 chr1 90126393 G A 7.88E-04 Body mass index LRRC8C intron 21701565 rs10737709 chr1 90126813 A T 2.27E-08 Metabolite levels LRRC8C intron 23281178 rs2146338 chr1 90221128 C T 2.87E-07 Lymphocyte counts / / 22286170 rs1215582 chr1 90239551 A G 4.46E-05 Bipolar disorder / / 19488044 rs1215582 chr1 90239551 A G 8.52E-05 Bipolar Disorder / / pha002863 rs7549625 chr1 90251996 G A 9.57E-04 Multiple complex diseases / / 17554300 rs10754295 chr1 90322384 C T 6.56E-05 Serum metabolites LRRC8D intron 19043545 rs2802031 chr1 90339669 A G 4.68E-04 Coronary Artery Disease LRRC8D intron 17634449 rs4658342 chr1 90356770 T G 6.71E-04 Taste perception LRRC8D intron 22132133 rs1938032 chr1 90357651 G A 7.05E-04 Type 2 diabetes LRRC8D intron 17463246 rs2703986 chr1 90447918 G T 5.45E-05 Personality dimensions / / 18957941 rs2490113 chr1 90456097 C G 2.24E-05 Personality dimensions / / 18957941 rs10922743 chr1 90492517 A G 7.97E-05 Blood Pressure ZNF326 intron pha003046 rs2816855 chr1 90501669 A G 8.90E-05 Serum metabolites / / 19043545 rs17130950 chr1 90511157 C T 7.46E-04 Type 2 diabetes / / 17463246 rs2813746 chr1 90539764 C A 1.72E-06 Temporal lobe volumes / / 20197096 rs2813747 chr1 90539813 T G 8.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2390866 chr1 90546731 A G 8.70E-05 Coronary heart disease / / pha003032 rs2390866 chr1 90546731 A G 8.56E-05 Fibrinogen / / pha003068 rs17130969 chr1 90556150 G T 3.77E-05 Height / / pha003011 rs2813760 chr1 90569361 A G 4.59E-05 Hypertension / / 19609347 rs2813760 chr1 90569361 A G 4.21E-05 Fibrinogen / / pha003068 rs1329644 chr1 90575147 T C 7.41E-05 Height / / pha003010 rs12409406 chr1 90582562 C T 2.58E-05 Fibrinogen / / pha003068 rs4456078 chr1 90594990 C T 1.38E-04 Body mass index / / 17255346 rs6428571 chr1 90600934 C T 1.19E-05 Colorectal cancer / / 21242260 rs6428572 chr1 90601121 T C 2.22E-05 Cognitive test performance / / 20125193 rs3922967 chr1 90626396 C T 3.15E-05 Gaucher disease severity / / 22388998 rs17130996 chr1 90660195 G C 5.08E-04 Type 2 diabetes / / 17463246 rs17130996 chr1 90660195 G C 5.80E-06 Urinary metabolites / / 21572414 rs17130997 chr1 90664986 A G 8.15E-05 Hearing function / / 17255346 rs10922809 chr1 90668256 G T 2.32E-04 Hearing function / / 17255346 rs7553296 chr1 90671625 C A 1.98E-04 Cholesterol / / 17255346 rs10754299 chr1 90674002 G A 2.28E-04 Cholesterol / / 17255346 rs4233435 chr1 90738800 C T 2.36E-04 Type 2 diabetes / / 17463246 rs3923534 chr1 90739291 C A 6.50E-04 Type 2 diabetes / / 17463246 rs12060187 chr1 90753594 G A 2.01E-04 Type 2 diabetes / / 17463246 rs4578202 chr1 90799813 C T 6.18E-05 Multiple complex diseases / / 17554300 rs10801805 chr1 90820257 G A 3.00E-06 Upper aerodigestive tract cancers / / 21437268 rs17131014 chr1 90830678 C G 7.10E-04 Multiple complex diseases / / 17554300 rs4658158 chr1 90849539 C T 8.92E-04 Bipolar disorder,schizoaffective / / 19567891 rs10218464 chr1 90866978 A T 9.47E-07 Response to antidepressants / / 20360315 rs6701608 chr1 90869227 A C 4.66E-07 Response to antidepressants / / 20360315 rs17131041 chr1 90873828 C T 9.89E-04 Multiple complex diseases / / 17554300 rs2136093 chr1 90875888 T C 4.00E-07 Response to antidepressants / / 20360315 rs1472887 chr1 90879608 T C 5.85E-07 Response to antidepressants / / 20360315 rs7522605 chr1 90894538 G C 7.72E-07 Response to antidepressants / / 20360315 rs1027854 chr1 90915627 A G 7.55E-07 Response to antidepressants / / 20360315 rs1337576 chr1 90916072 A G 2.35E-06 Response to antidepressants / / 20360315 rs506368 chr1 90920022 G A 7.49E-07 Response to antidepressants / / 20360315 rs2136094 chr1 90925982 C A 5.86E-07 Response to antidepressants / / 20360315 rs10801814 chr1 90931765 T C 9.17E-04 Coronary Artery Disease / / 17634449 rs2390582 chr1 90943907 A G 2.00E-05 Biomarkers / / 17903293 rs2390582 chr1 90943907 A G 1.00E-06 Coronary artery calcification / / 17903303 rs699526 chr1 90952184 G A 7.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10159226 chr1 91010959 G A 4.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10922885 chr1 91091083 G A 3.53E-04 Multiple complex diseases / / 17554300 rs4233429 chr1 91099903 T G 9.23E-06 Personality dimensions / / 23658558 rs10754306 chr1 91132104 C T 5.62E-06 Lipid traits / / 21777205 rs12046571 chr1 91137786 G T 6.41E-04 Alzheimer's disease / / 24755620 rs12116456 chr1 91141196 G A 8.28E-05 Alcoholism / / pha002893 rs12116456 chr1 91141196 G A 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs17131133 chr1 91155931 A G 5.10E-05 Alcohol dependence / / 20201924 rs17131133 chr1 91155931 A G 5.10E-05 Alcoholism / / pha002893 rs17131133 chr1 91155931 A G 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs10922903 chr1 91159586 T C 2.80E-05 Urinary metabolites / / 21572414 rs12133004 chr1 91175419 T C 2.70E-05 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 8.80E-04 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 2.75E-05 Alcoholism / / pha002893 rs4101233 chr1 91238773 C T 4.66E-05 Serum metabolites / / 19043545 rs6676886 chr1 91244343 C G 5.90E-05 Serum metabolites / / 19043545 rs3845561 chr1 91246342 G A 5.15E-05 Serum metabolites / / 19043545 rs10922924 chr1 91252863 G A 9.46E-05 Serum metabolites LOC100505821 intron 19043545 rs3843306 chr1 91288130 T A 5.00E-06 Pulmonary function decline LOC100505821 intron 22424883 rs17131213 chr1 91291013 A T 1.76E-05 Serum metabolites LOC100505821 intron 19043545 rs2390647 chr1 91358183 T C 9.65E-14 Gender / / 22362730 rs165284 chr1 91523553 A T 8.60E-05 Longevity and age-related phenotypes / / 17903295 rs469846 chr1 91529589 G A 3.43E-05 Systemic lupus erythematosus / / pha002867 rs164898 chr1 91569689 G A 6.00E-06 Metabolic syndrome / / 20694148 rs458190 chr1 91600305 G A 2.99E-04 Smoking cessation / / 24665060 rs609256 chr1 91602617 A T 4.26E-05 Smoking cessation / / 24665060 rs17482259 chr1 91619499 G T 7.45E-06 Serum metabolites / / 19043545 rs613217 chr1 91620228 G A 5.38E-04 Smoking cessation / / 24665060 rs599513 chr1 91622835 T C 3.74E-04 Smoking cessation / / 24665060 rs616710 chr1 91626325 T C 4.56E-04 Smoking cessation / / 24665060 rs17542509 chr1 91636192 C A 9.85E-04 Type 2 diabetes / / 17463246 rs665484 chr1 91663930 C A 2.30E-04 Primary sclerosing cholangitis / / 19944697 rs635894 chr1 91667917 A G 2.43E-04 Smoking cessation / / 24665060 rs635894 chr1 91667917 A G 5.41E-06 Height / / pha003010 rs635894 chr1 91667917 A G 6.90E-05 Height / / pha003011 rs12563349 chr1 91683648 G A 2.22E-04 Type 2 diabetes / / 17463246 rs11487636 chr1 91695097 A C 4.58E-04 Alzheimer's disease (late onset) / / 21379329 rs12403887 chr1 91699151 A C 1.49E-04 Type 2 diabetes / / 17463246 rs281966 chr1 91738762 T C 3.75E-04 Alzheimer's disease (late onset) HFM1 intron 21379329 rs12567930 chr1 91800946 A G 4.65E-04 Type 2 diabetes HFM1 intron 17463246 rs11166001 chr1 91872374 C T 5.71E-04 Multiple complex diseases / / 17554300 rs383730 chr1 91881997 C G 5.40E-07 Intracranial aneurysm / / 20364137 rs17485896 chr1 91887372 T C 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12744237 chr1 91901342 T A 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6683496 chr1 91917977 T G 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7540260 chr1 91919533 A G 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs505892 chr1 91937695 A G 6.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs497379 chr1 91938724 C T 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs522712 chr1 91943207 T G 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10493847 chr1 91944713 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6604023 chr1 91944897 G C 4.29E-06 Coronary artery calcification / / 22144573 rs546872 chr1 91970335 C T 5.15E-04 Multiple complex diseases CDC7 intron 17554300 rs483532 chr1 91980447 A G 2.07E-05 Body Mass Index CDC7 cds-synon pha003007 rs483532 chr1 91980447 A G 1.33E-05 Weight CDC7 cds-synon pha003027 rs1983170 chr1 91986482 G A 5.21E-05 Body Mass Index CDC7 intron pha003007 rs1983170 chr1 91986482 G A 2.15E-05 Weight CDC7 intron pha003027 rs6688261 chr1 91987034 C T 9.09E-04 Multiple complex diseases CDC7 intron 17554300 rs12127718 chr1 91997490 T A 9.40E-06 Digit length ratio / / 20303062 rs595801 chr1 91999640 A G 2.51E-04 Multiple complex diseases / / 17554300 rs17501381 chr1 92003919 T C 3.77E-05 Cognitive decline / / 23732972 rs17501512 chr1 92012481 G C 2.13E-04 Cognitive decline / / 23732972 rs963911 chr1 92014051 G T 2.01E-04 Glycosylated haemoglobin levels / / 17255346 rs963911 chr1 92014051 G T 1.22E-39 Narcolepsy / / 19629137 rs11164935 chr1 92015389 C A 1.48E-05 Glycosylated haemoglobin levels / / 17255346 rs1949009 chr1 92016653 T C 2.62E-05 Body Mass Index / / pha003007 rs1949009 chr1 92016653 T C 4.17E-06 Weight / / pha003027 rs17131491 chr1 92017649 A C 7.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12134245 chr1 92021464 C T 6.24E-05 Weight / / pha003027 rs6687904 chr1 92025262 A G 6.89E-05 Blood Pressure / / pha003043 rs4658231 chr1 92041502 A G 4.38E-04 Obesity (extreme) / / 21935397 rs4658232 chr1 92042039 G A 4.27E-04 Obesity (extreme) / / 21935397 rs17131499 chr1 92061160 C T 8.96E-04 Obesity (extreme) / / 21935397 rs12031250 chr1 92061445 T C 8.45E-04 Obesity (extreme) / / 21935397 rs12029135 chr1 92062074 C T 8.42E-04 Obesity (extreme) / / 21935397 rs4658238 chr1 92064082 C T 1.10E-05 Urinary metabolites / / 21572414 rs12028899 chr1 92064350 T C 8.41E-04 Obesity (extreme) / / 21935397 rs12024768 chr1 92065464 G T 7.62E-04 Obesity (extreme) / / 21935397 rs1192415 chr1 92077097 G A 3.00E-07 optic disc size (disc) / / 20395239 rs1192415 chr1 92077097 G A 3.00E-28 Optic disc parameters / / 20548946 rs1192415 chr1 92077097 G A 8.00E-17 Optic disc parameters / / 21307088 rs1192415 chr1 92077097 G A 9.31E-12 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 1.02E-11 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.22E-09 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.95E-12 Glaucoma-related traits / / 22058429 rs4658104 chr1 92087522 G A 9.53E-04 Alzheimer's disease / / 24755620 rs1887054 chr1 92099741 G A 6.93E-05 Asthma / / 23181788 rs2478168 chr1 92100560 A G 4.90E-04 Multiple complex diseases / / 17554300 rs12410523 chr1 92120137 G A 8.92E-05 Alcohol consumption / / 23743675 rs11165262 chr1 92153974 T C 2.39E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs12082710 chr1 92155337 T C 2.45E-04 Testicular dysgenesis syndrome TGFBR3 intron 22140272 rs12133463 chr1 92156208 C T 7.99E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs7549755 chr1 92157808 T C 9.95E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs3754021 chr1 92158751 T C 8.65E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs1926261 chr1 92162920 C T 8.25E-06 Celiac disease and Rheumatoid arthritis TGFBR3 intron 21383967 rs3767569 chr1 92173371 C T 3.25E-04 Type 2 diabetes TGFBR3 intron 17463246 rs2046736 chr1 92175008 C T 2.68E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 5.82E-05 Diabetes (gestational) TGFBR3 intron 22233651 rs17512269 chr1 92177062 C T 3.27E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 1.06E-04 Cognitive function TGFBR3 intron 24684796 rs11165354 chr1 92194322 C A 4.00E-06 Type 2 diabetes TGFBR3 intron 23209189 rs11165354 chr1 92194322 C A 3.34E-04 Heart Failure TGFBR3 intron pha002884 rs10783003 chr1 92195746 C T 2.60E-06 Type 2 diabetes TGFBR3 intron 23209189 rs7517044 chr1 92198162 A G 1.90E-06 Type 2 diabetes TGFBR3 intron 23209189 rs12403389 chr1 92208764 G C 9.63E-06 Bone mineral density TGFBR3 intron 19249006 rs2029356 chr1 92209311 T C 4.00E-04 Atrial fibrillation TGFBR3 intron 21846873 rs17131547 chr1 92211020 G A 9.98E-04 Multiple complex diseases TGFBR3 intron 17554300 rs17131547 chr1 92211020 G A 1.00E-06 Bone mineral density TGFBR3 intron 19249006 rs17131547 chr1 92211020 G A 3.60E-04 Atrial fibrillation TGFBR3 intron 21846873 rs284170 chr1 92214628 T C 5.72E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs284172 chr1 92214851 A T 5.16E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs11165441 chr1 92224347 G A 3.01E-05 Multiple sclerosis TGFBR3 intron 19525953 rs284198 chr1 92238167 G T 5.95E-04 White matter integrity TGFBR3 intron 22425255 rs12751910 chr1 92243307 G A 7.30E-06 Urinary metabolites TGFBR3 intron 21572414 rs17443164 chr1 92246048 C G 1.00E-05 Urinary metabolites TGFBR3 intron 21572414 rs6683840 chr1 92249817 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TGFBR3 intron 20877124 rs1329980 chr1 92254946 T C 0.00000109 HDL cholesterol TGFBR3 intron 23063622 rs1329980 chr1 92254946 T C 4.78E-08 LDL cholesterol TGFBR3 intron 23063622 rs2489188 chr1 92332489 C T 9.09E-04 Alcohol dependence TGFBR3 intron 21314694 rs6680614 chr1 92358371 G T 5.12E-04 Type 2 diabetes TGFBR3 intron 17463246 rs7550034 chr1 92364576 A G 8.81E-04 Alzheimer's disease TGFBR3 intron 17998437 rs34856868 chr1 92554283 G A 2.00E-06 Obesity-related traits BTBD8 missense 23251661 rs11166141 chr1 92561392 A G 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6684317 chr1 92563120 C G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs11166144 chr1 92563373 G A 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128646 chr1 92564147 A T 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128645 chr1 92564644 C T 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs981583 chr1 92571295 T A 0.000658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs981583 chr1 92571295 T A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs4658290 chr1 92572296 C G 0.0006583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs4658290 chr1 92572296 C G 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875204 chr1 92579675 G A 0.0005029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875204 chr1 92579675 G A 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7533077 chr1 92584519 A G 0.0005404 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7533077 chr1 92584519 A G 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542358 chr1 92587233 A G 0.0002718 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542358 chr1 92587233 A G 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542373 chr1 92587270 A G 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542373 chr1 92587270 A G 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2391114 chr1 92587687 G A 0.000419 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2391114 chr1 92587687 G A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604080 chr1 92588993 T A 0.0004021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs6604080 chr1 92588993 T A 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851273 chr1 92589511 G A 0.0003817 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851273 chr1 92589511 G A 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875209 chr1 92590826 A G 0.0003662 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875209 chr1 92590826 A G 3.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851272 chr1 92591916 G A 0.0003492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851272 chr1 92591916 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851271 chr1 92592222 T C 0.0003508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851271 chr1 92592222 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875214 chr1 92597344 G C 0.0003533 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875214 chr1 92597344 G C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157469 chr1 92598705 T C 0.0003681 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157469 chr1 92598705 T C 3.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157470 chr1 92598807 T A 0.0003574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157470 chr1 92598807 T A 3.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1982720 chr1 92600183 C G 0.0003529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1982720 chr1 92600183 C G 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs12119246 chr1 92602477 A G 0.0002028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs12119246 chr1 92602477 A G 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2839877 chr1 92604320 G T 0.0003596 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2839877 chr1 92604320 G T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2893200 chr1 92608029 G A 0.00038 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2893200 chr1 92608029 G A 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604082 chr1 92641607 C A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 intron 23233662 rs1483022 chr1 92646021 G A 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 cds-synon 23233662 rs565156 chr1 92647532 C A 6.95E-04 IgE levels KIAA1107 missense 17255346 rs12069690 chr1 92667250 T C 0.00060524 Sarcoidosis / / 22952805 rs191562237 chr1 92668558 T G 0.00061753 Sarcoidosis / / 22952805 rs77814661 chr1 92676992 G A 0.00062982 Sarcoidosis / / 22952805 rs146182052 chr1 92678371 A G 0.00064211 Sarcoidosis / / 22952805 rs3131824 chr1 92689936 G A 3.01E-05 Alcohol consumption C1orf146 intron 23953852 rs3122320 chr1 92705638 C T 4.76E-05 Alcohol consumption C1orf146 intron 23953852 rs61732740 chr1 92709824 G C 0.0006544 Sarcoidosis C1orf146 missense 22952805 rs149037808 chr1 92710088 A G 0.00066669 Sarcoidosis C1orf146 intron 22952805 rs1487539 chr1 92739699 C T 2.75E-05 Alcohol consumption GLMN intron 23953852 rs3103177 chr1 92756507 A G 2.54E-05 Alcohol consumption GLMN intron 23953852 rs116334257 chr1 92767507 C T 0.00067898 Sarcoidosis RPAP2 intron 22952805 rs146695390 chr1 92769759 T C 0.00069127 Sarcoidosis RPAP2 intron 22952805 rs147871470 chr1 92775941 G A 0.00070356 Sarcoidosis RPAP2 intron 22952805 rs145384375 chr1 92787153 T C 0.00071585 Sarcoidosis RPAP2 intron 22952805 rs6668685 chr1 92791812 G T 3.17E-05 Alcohol consumption RPAP2 intron 23953852 rs138848285 chr1 92797991 T C 0.00072814 Sarcoidosis RPAP2 intron 22952805 rs1906279 chr1 92816148 T C 2.41E-05 Alcohol consumption RPAP2 intron 23953852 rs2046616 chr1 92831569 G A 0.0005366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPAP2 intron 23233654 rs2046616 chr1 92831569 G A 5.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPAP2 intron 23233662 rs79703486 chr1 92846017 T C 0.00074043 Sarcoidosis RPAP2 intron 22952805 rs114670042 chr1 92863966 G A 0.00075272 Sarcoidosis / / 22952805 rs2025607 chr1 92890344 C T 2.89E-05 Alcohol consumption / / 23953852 rs11164607 chr1 92947138 A C 7.72E-05 Multiple sclerosis GFI1 intron 17660530 rs7540564 chr1 92957826 C A 3.09E-05 Schizophrenia / / 19571809 rs2031494 chr1 92965969 T C 4.08E-05 Alcohol consumption / / 23953852 rs4970698 chr1 92972933 T C 3.47E-05 Alcohol consumption / / 23953852 rs10782922 chr1 92974595 G A 3.03E-05 Alcohol consumption EVI5 UTR-3 23953852 rs4970700 chr1 92975493 A G 2.31E-04 Multiple sclerosis EVI5 UTR-3 17660530 rs4970700 chr1 92975493 A G 7.81E-05 Schizophrenia EVI5 UTR-3 19571809 rs1886682 chr1 92977275 A G 3.09E-05 Alcohol consumption EVI5 UTR-3 23953852 rs6603979 chr1 92979354 A G 4.00E-05 Alcohol consumption EVI5 cds-synon 23953852 rs1408916 chr1 92992627 G A 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs4970712 chr1 92993547 A C 4.90E-05 Alcohol consumption EVI5 intron 23953852 rs6603981 chr1 92993807 C T 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs7515577 chr1 93009438 C A 3.00E-08 Cholesterol,total EVI5 intron 20686565 rs7515577 chr1 93009438 C A 2.00E-08 Cholesterol,total EVI5 intron 24097068 rs4847377 chr1 93023150 A C 5.43E-05 Alcohol consumption EVI5 intron 23953852 rs1556562 chr1 93034023 G T 4.78E-05 Alcohol consumption EVI5 intron 23953852 rs12743520 chr1 93037112 C A 4.78E-05 Multiple sclerosis EVI5 intron 17660530 rs10782936 chr1 93041906 A G 8.11E-05 Schizophrenia EVI5 intron 19571809 rs11808092 chr1 93073228 C A 1.50E-05 Multiple sclerosis EVI5 missense 19525955 rs6682801 chr1 93074541 G A 6.61E-05 Schizophrenia EVI5 intron 19571809 rs1415296 chr1 93090476 G C 7.17E-05 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 1.68E-04 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 7.55E-06 Multiple sclerosis EVI5 intron 19525953 rs10735781 chr1 93121107 G C 6.97E-05 Schizophrenia EVI5 intron 19571809 rs10735781 chr1 93121107 G C 4.50E-09 Multiple sclerosis EVI5 intron 21833088 rs11800848 chr1 93127927 A C 2.88E-05 Multiple sclerosis EVI5 intron 17660530 rs77382266 chr1 93144726 G A 2.30E-09 Joint damage severity in rheumatoid arthritis EVI5 intron 23696630 rs11810217 chr1 93148377 C T 6.00E-15 Multiple sclerosis EVI5 intron 21833088 rs11810217 chr1 93148377 C T 3.20E-04 Multiple sclerosis EVI5 intron 24234648 rs4847267 chr1 93155347 C T 3.61E-04 Multiple sclerosis EVI5 intron 17660530 rs34202284 chr1 93160002 G A 4.49E-05 Multiple sclerosis EVI5 intron 17660530 rs6680578 chr1 93176878 T A 2.08E-04 Multiple sclerosis EVI5 intron 17660530 rs11164814 chr1 93261373 A G 1.99E-05 Multiple sclerosis / / 19525953 rs6604026 chr1 93303603 T C 8.00E-06 Multiple sclerosis RPL5 intron 17660530 rs6604026 chr1 93303603 T C 3.00E-06 Multiple sclerosis RPL5 intron 19525955 rs6604026 chr1 93303603 T C 3.61E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs6604026 chr1 93303603 T C 1.01E-05 Schizophrenia RPL5 intron pha002857 rs10782945 chr1 93304272 C T 9.52E-05 Schizophrenia RPL5 intron 19571809 rs10782945 chr1 93304272 C T 5.88E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs10782945 chr1 93304272 C T 7.36E-06 Schizophrenia RPL5 intron pha002857 rs10874744 chr1 93306317 G A 7.39E-05 Alcohol consumption RPL5 intron 23953852 rs7514280 chr1 93320869 C T 7.08E-05 Multiple sclerosis FAM69A intron 17660530 rs7514280 chr1 93320869 C T 1.36E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7514280 chr1 93320869 C T 9.85E-06 Schizophrenia FAM69A intron pha002857 rs10874746 chr1 93323971 T C 1.09E-05 Multiple sclerosis FAM69A intron 17660530 rs10874746 chr1 93323971 T C 3.51E-05 Schizophrenia FAM69A intron 19571809 rs10874746 chr1 93323971 T C 7.00E-11 Height FAM69A intron 20881960 rs10874746 chr1 93323971 T C 6.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs10874746 chr1 93323971 T C 3.17E-05 Schizophrenia FAM69A intron pha002857 rs111536942 chr1 93332055 C T 0.00076501 Sarcoidosis FAM69A intron 22952805 rs2811600 chr1 93334138 C T 1.71E-05 Multiple sclerosis FAM69A intron 17660530 rs2811600 chr1 93334138 C T 8.28E-05 Schizophrenia FAM69A intron 19571809 rs2811600 chr1 93334138 C T 1.18E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811600 chr1 93334138 C T 1.59E-06 Schizophrenia FAM69A intron pha002857 rs77039154 chr1 93338642 G C 0.0007773 Sarcoidosis FAM69A intron 22952805 rs2811593 chr1 93343891 T C 2.24E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811593 chr1 93343891 T C 2.91E-06 Schizophrenia FAM69A intron pha002857 rs35183060 chr1 93346928 A T 4.91E-05 Multiple sclerosis FAM69A intron 17660530 rs35183060 chr1 93346928 A T 1.52E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs35183060 chr1 93346928 A T 5.50E-06 Schizophrenia FAM69A intron pha002857 rs7536563 chr1 93349046 A G 2.27E-05 Multiple sclerosis FAM69A intron 17660530 rs7536563 chr1 93349046 A G 5.09E-05 Schizophrenia FAM69A intron 19571809 rs7536563 chr1 93349046 A G 1.16E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7536563 chr1 93349046 A G 2.24E-06 Schizophrenia FAM69A intron pha002857 rs10782946 chr1 93352669 G A 8.52E-05 Alcohol consumption FAM69A intron 23953852 rs2391177 chr1 93353943 G A 7.81E-05 Alcohol consumption FAM69A intron 23953852 rs2481713 chr1 93354889 G T 6.86E-05 Alcohol consumption FAM69A intron 23953852 rs2263247 chr1 93364067 T C 7.68E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.11E-05 Multiple sclerosis FAM69A intron 17660530 rs2255723 chr1 93368309 G T 1.39E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2255723 chr1 93368309 G T 7.20E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.94E-06 Schizophrenia FAM69A intron pha002857 rs12066638 chr1 93375391 C G 7.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12066638 chr1 93375391 C G 3.64E-06 Schizophrenia FAM69A intron pha002857 rs11164835 chr1 93379093 G A 5.36E-05 Multiple sclerosis FAM69A intron 17660530 rs11164835 chr1 93379093 G A 9.84E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs11164835 chr1 93379093 G A 1.46E-06 Schizophrenia FAM69A intron pha002857 rs9651257 chr1 93385136 T C 3.40E-05 Multiple sclerosis FAM69A intron 17660530 rs9651257 chr1 93385136 T C 2.02E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs9651257 chr1 93385136 T C 4.49E-06 Schizophrenia FAM69A intron pha002857 rs7515257 chr1 93393718 G A 7.86E-05 Alcohol consumption FAM69A intron 23953852 rs11164838 chr1 93395378 C T 6.01E-05 Multiple sclerosis FAM69A intron 17660530 rs11164838 chr1 93395378 C T 6.81E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs6698233 chr1 93397300 C T 7.62E-05 Alcohol consumption FAM69A intron 23953852 rs10493863 chr1 93399694 T C 7.95E-05 Alcohol consumption FAM69A intron 23953852 rs7542608 chr1 93401194 A G 7.18E-05 Alcohol consumption FAM69A intron 23953852 rs12745968 chr1 93401837 A G 8.01E-05 Multiple sclerosis FAM69A intron 17660530 rs12745968 chr1 93401837 A G 8.97E-05 Schizophrenia FAM69A intron 19571809 rs12745968 chr1 93401837 A G 8.00E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12745968 chr1 93401837 A G 1.04E-06 Schizophrenia FAM69A intron pha002857 rs17380908 chr1 93402551 C T 5.74E-05 Multiple sclerosis FAM69A intron 17660530 rs4847386 chr1 93420907 G A 1.18E-04 Parkinson's disease FAM69A intron 17052657 rs10874753 chr1 93429087 C A 1.85E-06 Bipolar disorder and schizophrenia / / 20889312 rs10874753 chr1 93429087 C A 4.57E-06 Schizophrenia / / pha002857 rs514235 chr1 93438456 T C 6.81E-06 Bipolar disorder and schizophrenia / / 20889312 rs6671268 chr1 93439821 T C 1.97E-04 Parkinson's disease / / 17052657 rs660870 chr1 93445417 C A 4.81E-05 Schizophrenia / / 19571809 rs660870 chr1 93445417 C A 2.60E-06 Bipolar disorder and schizophrenia / / 20889312 rs660870 chr1 93445417 C A 3.16E-05 Schizophrenia / / pha002857 rs521428 chr1 93445497 G A 2.12E-05 Multiple sclerosis / / 17660530 rs521428 chr1 93445497 G A 5.65E-05 Schizophrenia / / 19571809 rs521428 chr1 93445497 G A 2.52E-06 Bipolar disorder and schizophrenia / / 20889312 rs521428 chr1 93445497 G A 4.57E-05 Schizophrenia / / pha002857 rs532834 chr1 93468062 A T 1.82E-07 Multiple sclerosis / / 17660530 rs496465 chr1 93474165 A G 9.75E-05 Multiple sclerosis / / 17660530 rs12067005 chr1 93543119 A G 3.97E-05 Intelligence / / 21826061 rs1856027 chr1 93544131 T C 4.36E-04 Type 2 diabetes / / 22158537 rs12128131 chr1 93546299 T G 4.60E-04 Type 2 diabetes MTF2 intron 22158537 rs2295423 chr1 93581024 T C 7.67E-04 Type 2 diabetes MTF2 intron 22158537 rs2391228 chr1 93606940 G A 4.19E-05 Intelligence / / 21826061 rs1572343 chr1 93616202 T C 4.74E-04 Type 2 diabetes TMED5 UTR-3 22158537 rs1060622 chr1 93620393 G A 6.46E-04 Type 2 diabetes TMED5 missense 22158537 rs2783489 chr1 93626984 C T 2.85E-04 Type 2 diabetes TMED5 intron 22158537 rs4847235 chr1 93627727 T C 4.09E-04 Type 2 diabetes TMED5 intron 22158537 rs2152358 chr1 93634009 G A 8.16E-04 Type 2 diabetes TMED5 intron 22158537 rs10874762 chr1 93639101 T G 6.04E-04 Type 2 diabetes TMED5 intron 22158537 rs1335679 chr1 93645182 C T 6.26E-04 Type 2 diabetes TMED5 intron 22158537 rs7535628 chr1 93648728 T C 3.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs6682670 chr1 93649732 A G 6.09E-04 Type 2 diabetes CCDC18 intron 22158537 rs7517363 chr1 93652785 C T 5.04E-04 Type 2 diabetes CCDC18 intron 22158537 rs11164879 chr1 93655522 G A 6.66E-04 Type 2 diabetes CCDC18 intron 22158537 rs7513705 chr1 93666349 T C 3.14E-04 Type 2 diabetes CCDC18 intron 22158537 rs12030549 chr1 93669218 T C 6.01E-04 Type 2 diabetes CCDC18 intron 22158537 rs531358 chr1 93676011 C T 5.62E-04 Type 2 diabetes CCDC18 intron 22158537 rs2765545 chr1 93677269 G A 3.64E-04 Type 2 diabetes CCDC18 intron 22158537 rs661126 chr1 93678968 T G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs612037 chr1 93682878 G A 4.47E-04 Type 2 diabetes CCDC18 intron 22158537 rs797668 chr1 93694789 C G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs3754186 chr1 93711782 T A 7.77E-04 Type 2 diabetes CCDC18 intron 22158537 rs622608 chr1 93715219 G A 4.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs693737 chr1 93724924 G A 5.29E-04 Type 2 diabetes CCDC18 intron 22158537 rs2296558 chr1 93736555 C T 7.59E-04 Type 2 diabetes CCDC18 intron 22158537 rs6541401 chr1 93738948 G A 7.98E-04 Type 2 diabetes CCDC18 intron 22158537 rs9432681 chr1 93761896 A G 7.49E-04 Type 2 diabetes / / 22158537 rs6680107 chr1 93770880 G A 7.78E-04 Type 2 diabetes / / 22158537 rs9432453 chr1 93771629 G A 6.64E-04 Type 2 diabetes / / 22158537 rs1000607 chr1 93772001 T C 7.37E-04 Type 2 diabetes / / 22158537 rs4240966 chr1 93774812 C A 7.02E-04 Type 2 diabetes / / 22158537 rs4000699 chr1 93779805 C T 5.53E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2031226 chr1 93786764 G T 5.97E-04 Type 2 diabetes LOC100131564 intron 22158537 rs6703310 chr1 93788740 T G 6.01E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2391254 chr1 93795166 A T 2.38E-04 Type 2 diabetes LOC100131564 intron 22158537 rs942196 chr1 93802264 T A 5.04E-04 Type 2 diabetes LOC100131564 intron 22158537 rs3767964 chr1 93815490 T C 2.86E-04 Type 2 diabetes DR1 intron 22158537 rs4847240 chr1 93817946 A G 2.59E-04 Type 2 diabetes DR1 intron 22158537 rs12044883 chr1 93820575 G A 3.09E-04 Type 2 diabetes DR1 intron 22158537 rs11164938 chr1 93939870 A G 5.49E-04 Alcohol dependence FNBP1L intron 21314694 rs4847428 chr1 93942442 A G 7.55E-05 Serum metabolites FNBP1L intron 19043545 rs4847431 chr1 93984804 G C 3.92E-05 Nicotine dependence FNBP1L intron 17158188 rs237425 chr1 94012287 G A 9.56E-05 Pancreatic cancer FNBP1L intron pha002874 rs2295330 chr1 94037329 C T 6.09E-04 Coronary heart disease BCAR3 cds-synon 21971053 rs6667494 chr1 94038847 G A 0.00007483 Sarcoidosis BCAR3 intron 22952805 rs17110111 chr1 94042207 C T 5.81E-05 Insulin resistance BCAR3 intron 21901158 rs236316 chr1 94044597 C T 1.27E-07 Intelligence BCAR3 intron 21826061 rs3950119 chr1 94049237 T C 3.04E-05 Intelligence BCAR3 intron 21826061 rs236322 chr1 94056279 G T 7.48E-05 Intelligence BCAR3 intron 21826061 rs236330 chr1 94059554 C T 5.40E-04 Intelligence (childhood) BCAR3 intron 23358156 rs6677770 chr1 94066635 T C 5.96E-05 Intelligence BCAR3 intron 21826061 rs12739747 chr1 94077247 T A 1.81E-04 Insulin resistance BCAR3 intron 21901158 rs236313 chr1 94089708 A C 2.24E-05 Asthma BCAR3 intron 23181788 rs236301 chr1 94113981 C T 8.72E-05 Intelligence BCAR3 intron 21826061 rs236292 chr1 94120564 T C 5.28E-04 Type 2 diabetes BCAR3 intron 17463246 rs11580965 chr1 94129664 A T 4.47E-05 Insulin resistance BCAR3 intron 21901158 rs236285 chr1 94132788 G A 5.92E-05 Intelligence BCAR3 intron 21826061 rs2102629 chr1 94172121 A G 2.62E-04 Smoking cessation / / 24665060 rs12132625 chr1 94213931 G C 1.28E-04 Multiple complex diseases / / 17554300 rs4240956 chr1 94223769 A T 3.90E-06 Urinary metabolites / / 21572414 rs2818164 chr1 94237195 G T 4.20E-06 Urinary metabolites / / 21572414 rs2143990 chr1 94249517 T C 4.20E-06 Urinary metabolites / / 21572414 rs17100392 chr1 94281597 A G 7.74E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17100392 chr1 94281597 A G 7.74E-05 Immune response to anthrax vaccine / / 22658931 rs6664719 chr1 94334724 A C 9.50E-06 Urinary metabolites / / 21572414 rs11165029 chr1 94348081 C A 8.91E-04 Multiple complex diseases / / 17554300 rs11165029 chr1 94348081 C A 7.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11165047 chr1 94440105 G A 4.60E-05 Multiple complex diseases / / 17554300 rs11165048 chr1 94440182 G A 4.13E-05 Multiple complex diseases / / 17554300 rs12404808 chr1 94440302 C T 2.80E-05 Multiple complex diseases / / 17554300 rs12404811 chr1 94440332 C T 5.64E-05 Multiple complex diseases / / 17554300 rs12410905 chr1 94444197 T C 3.12E-05 Multiple complex diseases / / 17554300 rs1413899 chr1 94444481 G A 2.53E-05 Multiple complex diseases / / 17554300 rs35550403 chr1 94445595 G A 2.75E-05 Multiple complex diseases / / 17554300 rs41351346 chr1 94445793 T C 3.14E-05 Multiple complex diseases / / 17554300 rs41353346 chr1 94445839 T C 3.35E-05 Multiple complex diseases / / 17554300 rs17110714 chr1 94457555 A G 1.99E-04 Multiple complex diseases / / 17554300 rs17110736 chr1 94462769 G A 5.00E-06 Dialysis-related mortality ABCA4 intron 21546767 rs1800555 chr1 94463617 C T 2.57E-04 Insulin resistance ABCA4 missense 21901158 rs12070273 chr1 94466088 A G 4.66E-05 Height ABCA4 intron pha003011 rs4147864 chr1 94467238 G A 4.66E-05 Height ABCA4 intron pha003011 rs4147863 chr1 94471154 C T 8.89E-04 Response to alcohol consumption (flushing response) ABCA4 intron 24277619 rs11165063 chr1 94477649 C G 9.70E-06 Urinary metabolites ABCA4 intron 21572414 rs567370 chr1 94478573 C T 7.30E-06 Urinary metabolites ABCA4 intron 21572414 rs915200 chr1 94481904 C T 3.30E-04 Type 2 diabetes ABCA4 intron 17463246 rs11806129 chr1 94482377 A G 1.17E-11 LDL cholesterol ABCA4 intron 23063622 rs11806129 chr1 94482377 A G 7.08E-08 Cholesterol,total ABCA4 intron 23063622 rs61754056 chr1 94486905 C T 0.000000163 Prostate-specific antigen ABCA4 missense 23555315 rs472908 chr1 94487354 G A 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA4 intron 20877124 rs1320502 chr1 94501799 C T 1.51E-04 Multiple complex diseases ABCA4 intron 17554300 rs12087003 chr1 94503183 A G 1.83E-09 LDL cholesterol ABCA4 intron 23063622 rs12087003 chr1 94503183 A G 1.86E-08 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 0.00000191 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 6.65E-10 LDL cholesterol ABCA4 intron 23063622 rs3789399 chr1 94511717 G C 8.67E-05 Meningococcal disease ABCA4 intron 20694013 rs544830 chr1 94512893 C T 3.60E-05 Meningococcal disease ABCA4 intron 20694013 rs4147836 chr1 94516474 C T 2.40E-04 Obesity (extreme) ABCA4 intron 21935397 rs1191231 chr1 94516985 A C 6.89E-05 Meningococcal disease ABCA4 intron 20694013 rs497511 chr1 94523113 G A 1.76E-05 Meningococcal disease ABCA4 intron 20694013 rs550060 chr1 94524784 A G 1.84E-05 Meningococcal disease ABCA4 intron 20694013 rs521538 chr1 94525623 A G 1.25E-05 Orofacial clefts ABCA4 intron 22863734 rs4147833 chr1 94528363 C T 1.50E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847273 chr1 94529743 A G 1.82E-05 Obesity (extreme) ABCA4 intron 21935397 rs6661519 chr1 94530163 C A 1.87E-05 Obesity (extreme) ABCA4 intron 21935397 rs1007347 chr1 94530518 T C 2.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs1191232 chr1 94531192 A G 8.67E-06 Orofacial clefts ABCA4 intron 22863734 rs3789405 chr1 94531324 T C 2.10E-05 Obesity (extreme) ABCA4 intron 21935397 rs3789407 chr1 94531606 G C 8.77E-05 Obesity (extreme) ABCA4 intron 21935397 rs4140392 chr1 94532013 C T 9.45E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 3.93E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 2.00E-06 Palmitoleic acid (16:1n-7) plasma levels ABCA4 intron 23362303 rs2151849 chr1 94535174 A G 3.62E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789412 chr1 94536067 C T 3.95E-04 Obesity (extreme) ABCA4 intron 21935397 rs12759306 chr1 94537642 C A 2.68E-05 Tunica Media ABCA4 intron pha003034 rs1761375 chr1 94538011 G A 3.94E-04 Amyotrophic lateral sclerosis (sporadic) ABCA4 intron 24529757 rs4847274 chr1 94540069 G C 0.00084 Salmonella-induced pyroptosis ABCA4 intron 22837397 rs2275035 chr1 94545160 C T 3.74E-05 Cleft lip ABCA4 intron 20436469 rs2275035 chr1 94545160 C T 4.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs4147827 chr1 94548080 C G 2.58E-05 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 5.70E-12 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 3.00E-12 Orofacial clefts ABCA4 intron 22863734 rs560426 chr1 94553438 C T 5.00E-10 Orofacial clefts ABCA4 intron 22863734 rs563429 chr1 94553866 A G 6.33E-05 Orofacial clefts ABCA4 intron 22863734 rs4847196 chr1 94554453 G A 2.27E-05 Cleft lip ABCA4 intron 20436469 rs4847196 chr1 94554453 G A 7.55E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847196 chr1 94554453 G A 8.08E-05 Coronary heart disease ABCA4 intron pha003030 rs952499 chr1 94558425 T C 7.19E-07 Cleft lip ABCA4 intron 20436469 rs952499 chr1 94558425 T C 7.18E-08 Orofacial clefts ABCA4 intron 22863734 rs2068334 chr1 94559715 G A 6.13E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147823 chr1 94561272 A C 7.51E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147822 chr1 94561489 A G 2.68E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789422 chr1 94566311 C T 0.000027 Coronary artery calcification ABCA4 intron 23727086 rs2297636 chr1 94568822 T C 5.83E-06 Cleft lip ABCA4 intron 20436469 rs481931 chr1 94570016 G T 8.57E-08 Cleft lip ABCA4 intron 20436469 rs570926 chr1 94570218 T C 3.24E-07 Cleft lip ABCA4 intron 20436469 rs1211213 chr1 94571420 A G 5.50E-05 Cleft lip ABCA4 intron 20436469 rs4147816 chr1 94574780 C T 3.01E-04 Type 2 diabetes ABCA4 intron 17463246 rs4147816 chr1 94574780 C T 6.51E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.12E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.90E-10 Orofacial clefts ABCA4 intron 22863734 rs4147811 chr1 94575056 C T 4.02E-08 Cleft lip ABCA4 intron 20436469 rs3827712 chr1 94575171 T C 8.57E-08 Cleft lip ABCA4 intron 20436469 rs3789432 chr1 94575308 T C 1.39E-07 Cleft lip ABCA4 intron 20436469 rs2297634 chr1 94576968 T C 2.50E-05 Age-related macular degeneration ABCA4 intron 20861866 rs2297634 chr1 94576968 T C 2.27E-05 Age-related macular degeneration ABCA4 intron 21197116 rs2297634 chr1 94576968 T C 4.39E-05 Orofacial clefts ABCA4 intron 22863734 rs2297634 chr1 94576968 T C 3.18E-05 Age-related macular degeneration ABCA4 intron pha002856 rs10782976 chr1 94581125 G A 4.77E-05 Cleft lip ABCA4 intron 20436469 rs4147804 chr1 94582227 G A 7.25E-06 Cleft lip ABCA4 intron 20436469 rs4147803 chr1 94582293 G C 4.67E-06 Cleft lip ABCA4 intron 20436469 rs4147799 chr1 94584459 A G 7.70E-05 HDL particle features ABCA4 intron 21283740 rs3789451 chr1 94586328 C T 8.45E-06 Cleft lip ABCA4 intron 20436469 rs3789451 chr1 94586328 C T 3.56E-07 Orofacial clefts ABCA4 intron 22863734 rs3789452 chr1 94587501 T A 7.30E-07 Cleft lip ABCA4 nearGene-5 20436469 rs2151846 chr1 94587687 T G 1.61E-07 Cleft lip ABCA4 nearGene-5 20436469 rs11802196 chr1 94594043 A C 9.98E-06 Cleft lip / / 20436469 rs11802196 chr1 94594043 A C 1.55E-06 Orofacial clefts / / 22863734 rs6686599 chr1 94596831 G A 3.73E-06 Cleft lip / / 20436469 rs6686599 chr1 94596831 G A 1.96E-06 Orofacial clefts / / 22863734 rs1931565 chr1 94596867 A G 1.02E-05 Orofacial clefts / / 22863734 rs2774920 chr1 94611300 A G 1.00E-06 D-dimer levels / / 21502573 rs1411701 chr1 94635028 G A 5.88E-07 Orofacial clefts ARHGAP29 UTR-3 22863734 rs2274788 chr1 94674726 T C 6.26E-05 Cognitive test performance ARHGAP29 intron 20125193 rs2274788 chr1 94674726 T C 1.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARHGAP29 intron 23400010 rs6541340 chr1 94678512 T C 1.45E-05 Orofacial clefts ARHGAP29 intron 22863734 rs3789688 chr1 94691240 T C 2.46E-06 Orofacial clefts ARHGAP29 intron 22863734 rs12750249 chr1 94721660 T C 4.00E-06 IgG glycosylation LOC100505940 intron 23382691 rs11165110 chr1 94752469 G A 1.02E-04 Orofacial clefts LOC100505940 intron 22863734 rs11584317 chr1 94792449 C T 7.63E-04 Smoking initiation LOC100505940 intron 24665060 rs2172133 chr1 94803032 A G 1.61E-05 Orofacial clefts / / 22863734 rs12057415 chr1 94829769 T C 3.52E-05 Cleft lip / / 20436469 rs12057415 chr1 94829769 T C 2.05E-06 Orofacial clefts / / 22863734 rs2391467 chr1 94850443 A G 2.11E-05 Cleft lip / / 20436469 rs2391467 chr1 94850443 A G 1.10E-06 Orofacial clefts / / 22863734 rs598962 chr1 94916649 A C,G,T 2.28E-10 Cholesterol,total ABCD3 intron 23063622 rs598962 chr1 94916649 A C,G,T 2.56E-13 LDL cholesterol ABCD3 intron 23063622 rs529642 chr1 94979573 G C 4.97E-04 Multiple complex diseases ABCD3 intron 17554300 rs1144302 chr1 95000114 C T 0.000000962 LDL cholesterol F3 intron 23063622 rs1144302 chr1 95000114 C T 0.00000227 Cholesterol,total F3 intron 23063622 rs3917608 chr1 95004486 T G 3.49E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 3.47E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 0.00000169 Cholesterol,total F3 intron 23063622 rs698945 chr1 95011785 A G 5.60E-04 Multiple complex diseases / / 17554300 rs1146509 chr1 95029581 G T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2022309 chr1 95052476 G T 4.00E-08 End-stage coagulation / / 23381943 rs12029080 chr1 95053353 T G 6.00E-52 D-dimer levels / / 21502573 rs698941 chr1 95055219 C T 1.90E-06 Urinary metabolites / / 21572414 rs12079330 chr1 95058953 G A 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1778214 chr1 95061355 G A 8.04E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1747649 chr1 95062032 G A 8.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7542900 chr1 95070041 T C 6.00E-06 Type 2 diabetes / / 22238593 rs11807669 chr1 95070114 T C 2.30E-04 Lipopolysaccharide induced cytokine levels / / 23823136 rs4474258 chr1 95081445 C T 5.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) / / 24025145 rs12725598 chr1 95093341 G C 5.84E-04 Insulin resistance / / 21901158 rs2971940 chr1 95111759 A G 4.95E-04 Multiple complex diseases / / 17554300 rs947386 chr1 95117157 C T 5.68E-05 Alcohol and nictotine co-dependence / / 20158304 rs841361 chr1 95151813 C T 9.36E-07 Autism / / 22843504 rs841329 chr1 95169762 G A 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391423 chr1 95240361 C T 4.62E-05 Major depressive disorder (broad) / / 20038947 rs12743267 chr1 95249306 C T 3.40E-04 Alcohol dependence / / 20201924 rs11165257 chr1 95302135 G T 2.74E-04 Alcohol dependence SLC44A3 intron 20201924 rs3849303 chr1 95320536 G A 8.43E-04 Amyotrophic lateral sclerosis (sporadic) SLC44A3 intron 24529757 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 17293876 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 19184112 rs859098 chr1 95330372 G A 6.04E-04 Premature ovarian failure SLC44A3 missense 19508998 rs859098 chr1 95330372 G A 8.21E-05 Cognitive impairment induced by topiramate SLC44A3 missense 22091778 rs859098 chr1 95330372 G A 4.58E-05 Blood Pressure SLC44A3 missense pha002903 rs859096 chr1 95333068 G T 3.60E-05 Response to Vitamin E supplementation SLC44A3 intron 22437554 rs859096 chr1 95333068 G T 9.47E-04 Iron levels SLC44A3 intron pha002876 rs859096 chr1 95333068 G T 3.28E-05 Blood Pressure SLC44A3 intron pha002903 rs17520351 chr1 95334187 C T 4.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) SLC44A3 intron 23934736 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron 19880490 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron pha002876 rs10493878 chr1 95337418 T C 2.96E-05 Lipoproteins SLC44A3 intron pha003079 rs7531174 chr1 95338091 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits SLC44A3 intron 17848626 rs6700314 chr1 95346659 G A 3.91E-04 Multiple complex diseases SLC44A3 intron 17554300 rs12067920 chr1 95379758 A G 3.55E-04 Response to taxane treatment (placlitaxel) CNN3 intron 23006423 rs860873 chr1 95387208 G A 2.00E-14 Stearic acid (18:0) plasma levels CNN3 intron 23362303 rs11165281 chr1 95429780 G T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698046 chr1 95449282 A G 4.59E-04 Multiple complex diseases ALG14 intron 17554300 rs2391388 chr1 95485825 A C 3.00E-11 Palmitic acid (16:0) plasma levels ALG14 intron 23362303 rs6675668 chr1 95515637 T G 2.00E-18 Stearic acid (18:0) plasma levels ALG14 intron 23362303 rs6674604 chr1 95517539 C A 1.67E-05 Cleft lip ALG14 intron 20436469 rs12037609 chr1 95518483 C T 5.56E-04 Multiple complex diseases ALG14 intron 17554300 rs4630159 chr1 95543678 G T 8.03E-04 Multiple complex diseases / / 17554300 rs4950058 chr1 95548151 T C 8.65E-04 Multiple complex diseases / / 17554300 rs9437689 chr1 95549536 C T 5.00E-08 Phospholipid levels (plasma) / / 22359512 rs4950059 chr1 95551129 C T 2.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7512953 chr1 95554294 T G 2.30E-05 Malaria / / 19465909 rs7512953 chr1 95554294 T G 2.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12562498 chr1 95555165 C T 2.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12563154 chr1 95562187 C T 2.24E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs4950076 chr1 95577297 T C 7.04E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs11165315 chr1 95592609 A G 4.93E-04 Smoking initiation TMEM56 intron 24665060 rs7366121 chr1 95596496 G T 0.000253322 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874905 chr1 95598593 A C 1.82E-04 Smoking initiation TMEM56 intron 24665060 rs12039183 chr1 95611650 A G 0.00039702 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10157405 chr1 95614838 T C 8.89E-05 Fibrinogen TMEM56 intron pha003068 rs997370 chr1 95619368 T G 0.000217114 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165321 chr1 95619743 G A 0.000208004 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs2148796 chr1 95622341 C T 0.000125941 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874906 chr1 95630658 T C 0.000291725 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs965314 chr1 95633722 A G 8.35E-05 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165334 chr1 95638667 A G 9.78E-05 Non-alcoholic fatty liver disease histology (other) TMEM56 intron 20708005 rs11165334 chr1 95638667 A G 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10458508 chr1 95643224 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs6703408 chr1 95656546 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs1556742 chr1 95674341 C A 7.43E-05 Hypertension (early onset hypertension) TMEM56-RWDD3 intron 22479346 rs1414896 chr1 95692310 G A 2.00E-06 Non-alcoholic fatty liver disease histology (AST) TMEM56-RWDD3 intron 20708005 rs6671200 chr1 95697529 A C 2.00E-15 Stearic acid (18:0) plasma levels TMEM56-RWDD3 intron 23362303 rs6671200 chr1 95697529 A C 6.72E-05 Fibrinogen TMEM56-RWDD3 intron pha003068 rs2182021 chr1 95769863 C T 3.52E-05 Fibrinogen / / pha003068 rs12118116 chr1 95774330 T C 2.75E-06 Fibrinogen / / pha003068 rs2236390 chr1 95776788 C T 7.89E-05 Stroke / / pha002886 rs17113360 chr1 95782459 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113368 chr1 95786229 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113374 chr1 95789364 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391635 chr1 95794306 C T 5.36E-04 Type 2 diabetes / / 17463246 rs11165389 chr1 95815863 T G 3.47E-11 Schizophrenia / / 22037555 rs11590181 chr1 95818596 T G 3.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11165396 chr1 95823682 C T 2.50E-05 Urinary metabolites / / 21572414 rs11165403 chr1 95829158 T G 6.92E-04 Type 2 diabetes / / 17463246 rs11165406 chr1 95832611 G A 2.50E-05 Urinary metabolites / / 21572414 rs7531902 chr1 95835124 A G 2.82E-04 Alzheimer's disease (late onset) / / 21379329 rs11586346 chr1 95861202 A C 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113478 chr1 95861722 C G 1.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs4950054 chr1 95890977 C T 2.10E-05 Urinary metabolites / / 21572414 rs4949963 chr1 95906877 T A 2.10E-05 Urinary metabolites / / 21572414 rs12032935 chr1 95915727 G T 2.30E-05 Urinary metabolites / / 21572414 rs12040149 chr1 95915823 C A 2.40E-05 Urinary metabolites / / 21572414 rs979015 chr1 95920476 A G 1.08E-05 C-Reactive Protein / / pha003070 rs12409850 chr1 95947820 A G 4.54E-05 Body Mass Index / / pha003019 rs12409850 chr1 95947820 A G 1.26E-05 Body Mass Index / / pha003020 rs1577863 chr1 95967757 G A 2.94E-04 HIV-1 viral setpoint / / 17641165 rs11165433 chr1 95976798 A G 8.79E-05 Obesity (extreme) / / 21935397 rs1582123 chr1 95977445 A G 1.00E-04 Obesity (extreme) / / 21935397 rs945827 chr1 95981576 G A 9.56E-05 Obesity (extreme) / / 21935397 rs876394 chr1 95982340 T C 8.36E-05 Body Mass Index / / pha003020 rs945826 chr1 95984156 G A 9.24E-04 Type 2 diabetes / / 17463246 rs945826 chr1 95984156 G A 9.45E-05 Obesity (extreme) / / 21935397 rs881713 chr1 95985066 G A 6.34E-04 Multiple complex diseases / / 17554300 rs881713 chr1 95985066 G A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs881713 chr1 95985066 G A 8.44E-04 Stroke / / pha002886 rs11165434 chr1 95986339 G T 4.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs491043 chr1 95987974 A G 1.04E-04 Obesity (extreme) / / 21935397 rs12135050 chr1 95992463 G A 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522301 chr1 95993281 C T 1.06E-04 Obesity (extreme) / / 21935397 rs611087 chr1 95995427 A G 1.07E-04 Obesity (extreme) / / 21935397 rs12136757 chr1 95997068 T C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs12141480 chr1 95998883 G C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1509178 chr1 96001525 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs563232 chr1 96008701 C T 9.95E-05 Obesity (extreme) / / 21935397 rs678378 chr1 96008944 A G 4.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1355136 chr1 96019439 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs519693 chr1 96023412 C T 5.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396626 chr1 96025546 G A 3.36E-05 Partial epilepsies / / 20522523 rs1396626 chr1 96025546 G A 3.32E-05 Epilepsy / / 22116939 rs12145270 chr1 96025590 T A 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125877 chr1 96025725 C G 7.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125905 chr1 96025809 C G 8.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs592158 chr1 96102889 G C 9.11E-04 Type 2 diabetes / / 17463246 rs6693882 chr1 96145968 A G 2.00E-06 Pain / / 19207018 rs12142219 chr1 96148182 A G 8.79E-05 Orofacial clefts / / 22419666 rs7554994 chr1 96152973 T C 4.26E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1931260 chr1 96173170 T C 7.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1931255 chr1 96187319 G A 5.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2051029 chr1 96309286 G A 5.92E-05 Platelet counts / / pha003100 rs12564173 chr1 96311796 T G 6.14E-05 Platelet counts / / pha003100 rs4949973 chr1 96316274 T C 9.70E-04 Multiple complex diseases / / 17554300 rs11165503 chr1 96317398 A G 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342397 chr1 96343511 C T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10874963 chr1 96343561 C G 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1539359 chr1 96347574 C T 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12122872 chr1 96348379 C T 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1418454 chr1 96357521 G A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165509 chr1 96359485 A G 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165510 chr1 96365162 C T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165512 chr1 96366519 G A 3.51E-04 Gallstones / / 17632509 rs17420083 chr1 96422669 G A 9.78E-04 Type 2 diabetes / / 17463246 rs1889060 chr1 96425796 A T 3.40E-06 Urinary metabolites / / 21572414 rs619758 chr1 96481173 T C 2.90E-05 Urinary metabolites / / 21572414 rs10518593 chr1 96501069 C A 9.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs161110 chr1 96504076 G T 2.20E-05 Urinary metabolites / / 21572414 rs184412 chr1 96505335 G A 2.20E-05 Urinary metabolites / / 21572414 rs150892 chr1 96516252 C T 2.50E-05 Urinary metabolites / / 21572414 rs222887 chr1 96526728 G T 9.04E-05 Eosinophil counts / / pha003088 rs1144326 chr1 96541099 A G 2.20E-05 Urinary metabolites / / 21572414 rs223246 chr1 96551837 A C 1.40E-05 Urinary metabolites / / 21572414 rs223245 chr1 96552025 G A 1.40E-05 Urinary metabolites / / 21572414 rs12089599 chr1 96586426 C T 1.00E-05 Urinary metabolites / / 21572414 rs1222069 chr1 96595179 A C 1.60E-05 Cognitive function / / 24684796 rs2391735 chr1 96604969 A G 1.31E-04 Multiple complex diseases / / 17554300 rs321580 chr1 96647642 A G 2.43E-05 Smoking initiation / / 24665060 rs321564 chr1 96655156 C A,G,T 3.42E-05 Smoking initiation / / 24665060 rs321566 chr1 96656104 C T 4.13E-04 Type 2 diabetes / / 17463246 rs321567 chr1 96656207 C T 3.17E-04 Smoking initiation / / 24665060 rs17114704 chr1 96666138 T G 5.94E-05 Cognitive test performance / / 20125193 rs17374320 chr1 96673887 G T 3.49E-04 Alzheimer's disease / / 17998437 rs17365931 chr1 96679692 C T 8.05E-04 Alzheimer's disease / / 17998437 rs321588 chr1 96688818 G A 6.81E-05 Blood Pressure / / pha003040 rs901469 chr1 96723560 A G 5.71E-05 Cognitive test performance / / 20125193 rs324867 chr1 96755467 C T 8.78E-04 Multiple complex diseases / / 17554300 rs10874992 chr1 96775958 G A 8.80E-06 Urinary metabolites / / 21572414 rs11165585 chr1 96780748 A G 7.20E-06 Urinary metabolites / / 21572414 rs11165590 chr1 96791584 T G 8.50E-06 Urinary metabolites / / 21572414 rs17114928 chr1 96793488 C T 2.50E-05 Urinary metabolites / / 21572414 rs4000377 chr1 96802619 A T 2.10E-06 Urinary metabolites / / 21572414 rs324870 chr1 96803851 T C 1.00E-04 Tuberculosis / / 20694014 rs162018 chr1 96817319 C T 5.76E-04 Multiple complex diseases / / 17554300 rs12737060 chr1 96819473 T C 1.00E-05 Urinary metabolites / / 21572414 rs6593598 chr1 96908637 T C 6.06E-04 Insulin resistance / / 21901158 rs927512 chr1 96932939 A G 4.15E-04 Insulin resistance / / 21901158 rs1973993 chr1 96943994 T C 1.00E-06 Weight / / 19079260 rs1973993 chr1 96943994 T C 1.30E-05 Smoking behavior / / 20418888 rs1555543 chr1 96944797 A C 4.00E-10 Body mass index / / 20935630 rs1555543 chr1 96944797 A C 3.68E-10 Body mass index / / 23001569 rs1967769 chr1 96993449 T C 2.05E-04 Multiple complex diseases / / 17554300 rs3912027 chr1 96993603 G T 2.09E-04 Multiple complex diseases / / 17554300 rs12120893 chr1 97007132 C T 2.30E-05 Urinary metabolites / / 21572414 rs17426562 chr1 97036113 G A 9.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10783050 chr1 97037083 T C 4.00E-06 Body mass index / / 19079260 rs10783050 chr1 97037083 T C 2.80E-06 Smoking behavior / / 20418888 rs11165690 chr1 97113731 T C 1.78E-06 Schizophrenia / / 19571811 rs12071951 chr1 97113915 T G 5.00E-07 Schizophrenia / / 22688191 rs6673531 chr1 97115049 G A 1.41E-05 Bipolar disorder / / 21771265 rs1496116 chr1 97152559 T C 1.78E-09 Narcolepsy / / 19629137 rs7544736 chr1 97164343 A G 6.00E-07 Schizophrenia / / 19571811 rs10875032 chr1 97198331 G T 8.99E-06 Bipolar disorder PTBP2 intron 21771265 rs10489798 chr1 97245046 A G 6.20E-05 Electrocardiographic traits and heart rate variability PTBP2 intron 17903306 rs12725199 chr1 97293792 C A 2.00E-04 Systolic blood pressure / / 19430483 rs12740489 chr1 97296935 G A 6.73E-05 Blood Pressure / / pha002903 rs635578 chr1 97304571 C A 5.72E-04 Type 2 diabetes / / 17463246 rs559734 chr1 97304868 G C 8.48E-04 Lymphocyte counts / / 22286170 rs11584143 chr1 97316690 G A 1.22E-04 Epilepsy / / 22116939 rs1401836 chr1 97332684 C T 1.82E-05 Type 2 diabetes / / 17463246 rs11165731 chr1 97340388 A G 1.02E-04 Type 2 diabetes / / 17463246 rs12069698 chr1 97352212 C G 9.96E-05 Type 2 diabetes / / 17463246 rs6675133 chr1 97353641 T C 1.50E-05 Type 2 diabetes / / 17463246 rs2681194 chr1 97365977 C T 9.67E-05 Blood Pressure / / pha002903 rs2681194 chr1 97365977 C T 2.42E-05 Height / / pha003011 rs950390 chr1 97374535 A T 9.55E-05 Type 2 diabetes / / 17463246 rs950390 chr1 97374535 A T 5.07E-04 Multiple complex diseases / / 17554300 rs4433451 chr1 97378162 C T 3.23E-05 Type 2 diabetes / / 17463246 rs2030342 chr1 97388226 C T 9.42E-05 Height / / pha003010 rs2030342 chr1 97388226 C T 1.27E-05 Height / / pha003011 rs6659733 chr1 97404744 A G 5.23E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 6.02E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 5.34E-04 Multiple complex diseases / / 17554300 rs11165745 chr1 97428382 T G 8.09E-05 Epilepsy (remission after treatment) / / 23962720 rs10493888 chr1 97434827 G C 3.29E-04 Type 2 diabetes / / 17463246 rs10493888 chr1 97434827 G C 9.06E-05 Epilepsy (remission after treatment) / / 23962720 rs3002273 chr1 97439491 G T 7.51E-05 Height / / pha003011 rs10493889 chr1 97447183 T C 8.00E-04 Colorectal cancer / / 17618283 rs182358 chr1 97463150 C T 8.90E-06 Major depressive disorder / / 21042317 rs290822 chr1 97469304 C G 3.38E-08 Pure-tone audiometry / / pha001964 rs290825 chr1 97477667 A G 8.99E-04 Multiple complex diseases / / 17554300 rs11165765 chr1 97490921 C T 9.87E-04 Multiple complex diseases / / 17554300 rs6656001 chr1 97498401 T A 3.35E-04 Multiple complex diseases / / 17554300 rs6664634 chr1 97498499 G A 2.91E-04 Multiple complex diseases / / 17554300 rs11165783 chr1 97569544 T C 7.50E-05 Tooth agenesis (third molar) DPYD intron 24172245 rs1399291 chr1 97576922 C T 2.55E-05 Hypertension DPYD intron 21082022 rs9437663 chr1 97585937 A G 6.49E-04 Suicide attempts in bipolar disorder DPYD intron 21423239 rs10493890 chr1 97588830 C T 6.33E-04 Cognition,early reading ability DPYD intron 17684495 rs6593634 chr1 97635212 A C 4.39E-04 HIV-1 viral setpoint DPYD intron 17641165 rs10875053 chr1 97636966 C G 3.74E-04 Coronary Artery Disease DPYD intron 17634449 rs7529372 chr1 97647338 C T 3.45E-08 Metabolite levels DPYD intron 23281178 rs6656660 chr1 97649209 G T 3.45E-08 Metabolite levels DPYD intron 23281178 rs4128473 chr1 97672838 T C 5.16E-08 Metabolite levels DPYD intron 23281178 rs17116566 chr1 97686367 A G 2.57E-04 Multiple complex diseases DPYD intron 17554300 rs17116594 chr1 97701403 C T 6.96E-04 Response to taxane treatment (placlitaxel) DPYD intron 23006423 rs12758854 chr1 97711561 G A 0.0000572 Tuberculosis with late age of onset DPYD intron 22551897 rs493517 chr1 97721227 A G 5.13E-05 Partial epilepsies DPYD intron 20522523 rs495257 chr1 97721392 A G 6.06E-05 Partial epilepsies DPYD intron 20522523 rs644428 chr1 97737704 C T 7.31E-04 Multiple complex diseases DPYD intron 17554300 rs7512040 chr1 97781640 G A,C,T 7.35E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs10875069 chr1 97793775 T G 3.48E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs1607779 chr1 97794265 C A 3.51E-05 Cognitive impairment induced by topiramate DPYD intron 22091778 rs11165846 chr1 97819667 C G 9.00E-06 Platelet counts DPYD intron 21507922 rs12403997 chr1 97832736 G A 2.24E-04 Vaspin levels DPYD intron 22907691 rs12403997 chr1 97832736 G A 0.0002237 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs11165851 chr1 97845577 T A 4.63E-24 Narcolepsy DPYD intron 19629137 rs6665429 chr1 97853619 C T 3.25E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs4950031 chr1 97854245 T G 1.16E-04 Vaspin levels DPYD intron 22907691 rs4950031 chr1 97854245 T G 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7538155 chr1 97855144 T C 1.16E-04 Vaspin levels DPYD intron 22907691 rs7538155 chr1 97855144 T C 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7530072 chr1 97856731 C T 7.57E-04 Myopia (pathological) DPYD intron 21095009 rs7530072 chr1 97856731 C T 1.16E-04 Vaspin levels DPYD intron 22907691 rs7530072 chr1 97856731 C T 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs955850 chr1 97857761 T C 6.01E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs11165870 chr1 97895762 T C 4.34E-05 Serum metabolites DPYD intron 19043545 rs11165870 chr1 97895762 T C 7.16E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs2225882 chr1 97896277 T G 4.94E-04 Multiple complex diseases DPYD intron 17554300 rs7517433 chr1 97898232 T C 3.50E-05 Left ventricular hypertrophy DPYD intron pha003052 rs12129397 chr1 97900552 A T 7.07E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs11165873 chr1 97902790 A T 7.05E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4949953 chr1 97904780 T C 7.03E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7517899 chr1 97907753 C T 6.48E-04 Alzheimer's disease DPYD intron 22005930 rs1415681 chr1 97908878 T G 4.08E-05 Left ventricular hypertrophy DPYD intron pha003052 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 12668918 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 15093568 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17000684 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17121937 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17350823 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 18299612 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 19147868 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 9817272 rs3897854 chr1 97918306 C T 6.33E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs12354219 chr1 97920956 T C 6.32E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7531138 chr1 97923499 T A 1.52E-04 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7550959 chr1 97926839 G A 9.59E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4451581 chr1 97949431 A C 2.10E-05 Inflammatory demyelinating disease DPYD intron 19850125 rs2811182 chr1 97971440 G A 2.74E-05 Amyotrophic lateral sclerosis (sporadic) DPYD intron 24529757 rs11165887 chr1 97974659 G A 1.50E-05 Urinary metabolites DPYD intron 21572414 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 17848752 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 9918128 rs7519652 chr1 97984103 C A 2.70E-05 Urinary metabolites DPYD intron 21572414 rs2811173 chr1 97992257 C T 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) DPYD intron 23648065 rs2786785 chr1 97997645 A T 2.00E-04 Cognitive impairment induced by topiramate DPYD intron 22091778 rs4950041 chr1 98003908 A G 4.34E-04 Alzheimer's disease (late onset) DPYD intron 21379329 rs6663357 chr1 98044939 A C 7.94E-04 Response to cytadine analogues (cytosine arabinoside) DPYD intron 24483146 rs7533902 chr1 98079228 T C 1.20E-04 Obesity-related traits DPYD intron 17903300 rs17117003 chr1 98082388 A C 1.34E-04 Multiple complex diseases DPYD intron 17554300 rs2786508 chr1 98141828 C T 4.42E-06 Sleep duration DPYD intron 22105623 rs2297595 chr1 98165091 T C 1 Drug response to Capecitabine DPYD missense 19104657 rs2297595 chr1 98165091 T C 1 Drug response to Fluorouracil DPYD missense 19104657 rs10493895 chr1 98271226 A C 1.60E-05 Blood Phenotypes DPYD intron 17903294 rs4246514 chr1 98297731 C G 4.21E-04 Multiple complex diseases DPYD intron 17554300 rs4421623 chr1 98316285 T G 9.57E-04 Multiple complex diseases DPYD intron 17554300 rs4372296 chr1 98320492 C A 9.17E-04 Multiple complex diseases DPYD intron 17554300 rs4379706 chr1 98322379 C T 9.29E-04 Multiple complex diseases DPYD intron 17554300 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 17848752 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 9918128 rs9324380 chr1 98461132 G C 2.20E-05 Urinary metabolites MIR137HG intron 21572414 rs77177281 chr1 98471702 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity MIR137HG intron 24324551 rs1198572 chr1 98497176 A C 3.14E-05 Aging (time to event) MIR137HG intron 21782286 rs1625579 chr1 98502934 G T 2.00E-11 Schizophrenia MIR137HG intron 21926974 rs1625579 chr1 98502934 G T 2.00E-11 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MIR137HG intron 23453885 rs1625579 chr1 98502934 G T 0.00000376 Schizophrenia MIR137HG intron 23637625 rs12410326 chr1 98546248 T C 1.64E-05 Multiple complex diseases / / 17554300 rs1198588 chr1 98552832 A T 5.00E-07 Schizophrenia / / 22688191 rs1198588 chr1 98552832 A T 2.00E-12 Schizophrenia / / 23974872 rs1507061 chr1 98569656 G A 1.61E-05 Major depressive disorder / / 21621269 rs6679864 chr1 98579211 A G 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs355374 chr1 98588753 A G 0.000317882 Hypertension (early onset hypertension) / / 22479346 rs17117765 chr1 98601247 T C 5.26E-04 Multiple complex diseases / / 17554300 rs2632303 chr1 98617672 T C 5.85E-04 Multiple complex diseases / / 17554300 rs2660309 chr1 98622407 C T 4.35E-05 Hypertension (early onset hypertension) / / 22479346 rs12734505 chr1 98627901 A G 2.34E-05 Major depressive disorder / / 21621269 rs10493900 chr1 98645213 A G 7.10E-05 Cardiovascular disease / / 17903304 rs698997 chr1 98659529 C T 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11577139 chr1 98666125 C A 8.00E-07 Prostate cancer / / 21743057 rs11165973 chr1 98719851 G A 4.03E-07 Multiple complex diseases LOC729987 intron 17554300 rs6664206 chr1 98840567 A T 1.13E-04 Alzheimer's disease (late onset) / / 21460841 rs17118281 chr1 98848697 A G 5.96E-05 Alzheimer's disease (late onset) / / 21460841 rs1328306 chr1 98882770 T C 2.40E-05 Urinary metabolites / / 21572414 rs17118459 chr1 98925555 T C 5.55E-05 Multiple complex diseases / / 17554300 rs4950128 chr1 98927114 C A,G 4.78E-04 Type 2 diabetes / / 17463246 rs1434364 chr1 98927742 C T 3.78E-04 Type 2 diabetes / / 17463246 rs770918 chr1 98928937 A G 9.10E-04 Crohn's disease / / 17684544 rs648124 chr1 98937092 C T 1.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs591520 chr1 98964498 A G 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs591545 chr1 98964518 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs3867319 chr1 98964760 G A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs12064487 chr1 99021875 G A 0.00080188 Sarcoidosis / / 22952805 rs12129212 chr1 99096771 T C 1.00E-04 Prostate cancer / / 21743057 rs4402170 chr1 99129503 C G 6.98E-04 Multiple complex diseases SNX7 intron 17554300 rs6577322 chr1 99164434 G A 5.71E-04 Multiple complex diseases SNX7 cds-synon 17554300 rs9727115 chr1 99177253 G A 2.00E-07 Proinsulin levels SNX7 intron 21873549 rs12725220 chr1 99184798 G A 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) SNX7 intron 23648065 rs17118895 chr1 99209996 A G 9.15E-05 Multiple complex diseases SNX7 intron 17554300 rs6674890 chr1 99231152 A T 8.50E-04 Multiple complex diseases / / 17554300 rs4908035 chr1 99236025 T C 1.01E-04 Multiple complex diseases / / 17554300 rs1384168 chr1 99242320 C T 6.07E-05 Multiple complex diseases / / 17554300 rs7524208 chr1 99290670 C T 4.40E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11166132 chr1 99317472 A C 4.36E-04 Fibrinogen / / 17255346 rs11166132 chr1 99317472 A C 6.22E-04 Type 2 diabetes / / 17463246 rs1358432 chr1 99318760 G A 4.36E-04 Fibrinogen / / 17255346 rs1358431 chr1 99318835 A G 4.36E-04 Fibrinogen / / 17255346 rs10493905 chr1 99334877 A G 4.44E-04 Multiple complex diseases / / 17554300 rs11166135 chr1 99348836 A G 1.00E-06 Dental caries / / 23064961 rs984271 chr1 99358358 G T 4.63E-04 Alzheimer's disease LPPR5 UTR-3 22005930 rs1481501 chr1 99359944 A G 3.18E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875195 chr1 99365922 C T 1.84E-04 Alzheimer's disease LPPR5 intron 22005930 rs1871786 chr1 99366163 T C 5.01E-04 Alzheimer's disease LPPR5 intron 22005930 rs6679030 chr1 99366837 T C 6.49E-04 Alzheimer's disease LPPR5 intron 22005930 rs6675949 chr1 99366952 A G 1.09E-04 Taste perception LPPR5 intron 22132133 rs1383832 chr1 99367844 G A 4.86E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875196 chr1 99378914 G A 9.57E-05 Rheumatoid arthritis LPPR5 intron 17804836 rs1471581 chr1 99382491 A G 8.93E-04 Coronary Artery Disease LPPR5 intron 17634449 rs1571500 chr1 99386293 T C 2.00E-06 Dental caries LPPR5 intron 23259602 rs2497750 chr1 99407351 A G 3.07E-04 Height LPPR5 intron 17255346 rs382051 chr1 99426616 C T 6.19E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs6682665 chr1 99433123 T G 4.94E-04 Multiple complex diseases LPPR5 intron 17554300 rs1360152 chr1 99440212 A T 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs309061 chr1 99443077 T G 7.57E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs12084355 chr1 99449969 T C 6.38E-04 Multiple complex diseases LPPR5 intron 17554300 rs10443196 chr1 99453287 T C 9.00E-06 Obesity-related traits LPPR5 intron 23251661 rs10489924 chr1 99458974 T C 7.00E-04 Crohn's disease LPPR5 intron 17684544 rs10489925 chr1 99461323 T C 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs7413228 chr1 99484386 A C 6.83E-04 Heart Failure LOC100129620 intron pha002885 rs12030123 chr1 99486885 G A 1.38E-04 Heart Failure LOC100129620 intron pha002885 rs1350176 chr1 99495135 G T 5.78E-04 Heart Failure LOC100129620 intron pha002885 rs7530449 chr1 99515902 T G 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs10493907 chr1 99516241 C G 4.90E-04 Multiple complex diseases LOC100129620 intron 17554300 rs897603 chr1 99518345 A G 5.16E-06 Obesity-related traits LOC100129620 intron 23251661 rs10747502 chr1 99524047 A G 1.00E-09 Myopia (pathological) LOC100129620 intron 23049088 rs10747502 chr1 99524047 A G 5.00E-07 Obesity-related traits LOC100129620 intron 23251661 rs12409665 chr1 99530067 T G 3.18E-05 Parkinson's disease (motor and cognition) LOC100129620 intron 22658654 rs12409665 chr1 99530067 T G 3.18E-05 Immune response to anthrax vaccine LOC100129620 intron 22658931 rs17119481 chr1 99533944 A C 2.39E-04 Alzheimer's disease (late onset) LOC100129620 intron 21379329 rs17119481 chr1 99533944 A C 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs12411241 chr1 99551140 A G 2.44E-05 Blood Pressure LOC100129620 intron pha003050 rs17119565 chr1 99583493 C A 6.03E-04 Multiple complex diseases LOC100129620 intron 17554300 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) LOC100129620 intron 23648065 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) LOC100129620 intron 23648065 rs302748 chr1 99597328 A G 7.57E-04 Myopia (pathological) LOC100129620 intron 21095009 rs302748 chr1 99597328 A G 7.47E-05 Blood Pressure LOC100129620 intron pha003044 rs863686 chr1 99610153 A G 9.73E-06 Hearing function LOC100129620 intron 21493956 rs587509 chr1 99615714 C T 4.86E-06 Hearing function / / 21493956 rs621215 chr1 99619424 G A 3.73E-06 Hearing function / / 21493956 rs687101 chr1 99637572 G A 6.25E-07 Hearing function / / 21493956 rs604876 chr1 99641020 T C 1.91E-06 Hearing function / / 21493956 rs638723 chr1 99641669 A G 6.59E-07 Hearing function / / 21493956 rs668206 chr1 99643963 G T 9.64E-07 Hearing function / / 21493956 rs6577368 chr1 99644223 A G 4.72E-04 Insulin resistance / / 21901158 rs712937 chr1 99645446 A G 3.15E-07 Hearing function / / 21493956 rs712936 chr1 99647039 T C 2.84E-07 Hearing function / / 21493956 rs712934 chr1 99648976 T A 2.33E-07 Hearing function / / 21493956 rs712932 chr1 99651500 G C 2.32E-07 Hearing function / / 21493956 rs12080341 chr1 99653855 A G 3.30E-04 Insulin resistance / / 21901158 rs712931 chr1 99654168 G T 2.38E-07 Hearing function / / 21493956 rs819786 chr1 99654527 G A 2.39E-07 Hearing function / / 21493956 rs819785 chr1 99655620 G A 2.41E-07 Hearing function / / 21493956 rs3911410 chr1 99660145 G A 2.44E-06 Hearing function / / 21493956 rs664835 chr1 99663968 T A 4.74E-07 Hearing function / / 21493956 rs819778 chr1 99665186 A G 5.00E-07 Hearing function / / 21493956 rs645441 chr1 99670057 T G 5.65E-07 Hearing function / / 21493956 rs685267 chr1 99671349 A C 8.37E-07 Hearing function / / 21493956 rs819797 chr1 99687402 G A 5.74E-06 Ankle-brachial index / / 22199011 rs7530667 chr1 99691732 T C 8.43E-06 Ankle-brachial index / / 22199011 rs819746 chr1 99693744 C A 5.04E-06 Ankle-brachial index / / 22199011 rs819748 chr1 99695168 C A 4.19E-06 Ankle-brachial index / / 22199011 rs819750 chr1 99697063 G T 5.11E-04 Ankle-brachial index / / 22199011 rs819756 chr1 99701930 C T 9.71E-06 Ankle-brachial index / / 22199011 rs6577370 chr1 99711864 C A 8.71E-71 Multiple complex diseases / / 17554300 rs6577370 chr1 99711864 C A 4.29E-04 Smoking initiation / / 24665060 rs819910 chr1 99764226 C T 1.14E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs819914 chr1 99765872 G A 2.15E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs712878 chr1 99780284 T C 1.91E-05 Lung function (forced vital capacity) / / pha003104 rs12135248 chr1 99780891 A G 8.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743824 chr1 99782957 C A 5.00E-06 Non-alcoholic fatty liver disease histology (other) / / 23213074 rs12140879 chr1 99793111 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325957 chr1 99794023 T C 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1419059 chr1 99911058 T C 0.0007631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1419059 chr1 99911058 T C 7.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs713265 chr1 99937037 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17120530 chr1 99952060 A G 0.000141 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17120530 chr1 99952060 A G 1.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12032219 chr1 99953165 G A 0.00006866 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12032219 chr1 99953165 G A 6.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4623724 chr1 99954032 C G 0.0004875 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4623724 chr1 99954032 C G 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4908327 chr1 99993077 C T 5.89E-04 Multiple complex diseases / / 17554300 rs11166266 chr1 99999237 C T 1.87E-14 Gender / / 22362730 rs12135239 chr1 100041459 G A 3.24E-04 Lymphocyte counts / / 22286170 rs6702619 chr1 100046246 T G 0.000000577 Colorectal cancer / / 22532847 rs6702619 chr1 100046246 T G 3.29E-08 Colorectal cancer vs. adenoma controls / / 22532847 rs7543130 chr1 100049785 C A 1.00E-07 Aortic root size / / 19584346 rs1361378 chr1 100071637 T C 7.87E-04 Multiple complex diseases / / 17554300 rs11166284 chr1 100087539 A T 2.80E-05 Urinary metabolites / / 21572414 rs12077588 chr1 100089604 T G 5.61E-05 Multiple complex diseases / / 17554300 rs4908005 chr1 100161691 G T 1.00E-05 Urinary metabolites / / 21572414 rs6679943 chr1 100163271 T C 2.74E-04 Alzheimer's disease / / 24755620 rs12024467 chr1 100190830 G A 0.000242 Salmonella-induced pyroptosis FRRS1 intron 22837397 rs17121183 chr1 100248380 T C 9.68E-04 Alzheimer's disease / / 22005930 rs12023333 chr1 100267478 T C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6689305 chr1 100268991 G A 9.00E-06 White matter integrity (interaction) / / 23218918 rs1493617 chr1 100270735 C A 3.07E-05 Personality dimensions / / 22628180 rs11166344 chr1 100272171 G C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9887771 chr1 100276744 C G 1.04E-04 Alzheimer's disease / / 24755620 rs11166358 chr1 100305320 T C 7.37E-05 Hearing impairment / / 19047183 rs17121403 chr1 100335977 A G 7.00E-06 Pulmonary function decline AGL missense 22424883 rs903125 chr1 100352470 C A 3.64E-04 Alzheimer's disease AGL intron 24755620 rs3753494 chr1 100358103 C T 3.30E-04 Alzheimer's disease AGL missense 24755620 rs3818568 chr1 100377789 C T 9.50E-06 Urinary metabolites AGL intron 21572414 rs17121644 chr1 100385430 C T 4.78E-05 Age-related macular degeneration AGL intron pha002890 rs2149194 chr1 100401929 G T 1.00E-05 Urinary metabolites / / 21572414 rs1541044 chr1 100411287 T C 6.59E-04 Alzheimer's disease / / 24755620 rs6701658 chr1 100426978 A G 4.60E-05 Glioma (high-grade) / / 19578366 rs7530361 chr1 100462860 T C 5.40E-05 Glioma (high-grade) SLC35A3 intron 19578366 rs7518943 chr1 100463422 C A 1.27E-04 Alzheimer's disease SLC35A3 intron 17998437 rs7518943 chr1 100463422 C A 1.96E-04 Alzheimer's disease SLC35A3 intron pha002879 rs11166389 chr1 100466279 G A 6.10E-08 Glioma (high-grade) SLC35A3 intron 19578366 rs495871 chr1 100474456 C T 3.21E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs575323 chr1 100482396 G A 3.32E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs501700 chr1 100520311 G A 2.40E-05 Glioma (high-grade) HIAT1 intron 19578366 rs560659 chr1 100523536 G A 1.92E-04 Alzheimer's disease HIAT1 intron 17998437 rs560659 chr1 100523536 G A 1.01E-04 Alzheimer's disease HIAT1 intron pha002879 rs644835 chr1 100543962 A G 3.10E-05 Glioma (high-grade) HIAT1 intron 19578366 rs640030 chr1 100574992 C T 3.10E-05 Glioma (high-grade) SASS6 intron 19578366 rs663519 chr1 100592653 A G 5.59E-05 Vascular dementia SASS6 intron 22116812 rs687513 chr1 100598867 C T 5.10E-05 Glioma (high-grade) CCDC76 missense 19578366 rs6681721 chr1 100609639 C T 2.47E-05 Age-related macular degeneration CCDC76 cds-synon pha002890 rs12733952 chr1 100611571 C T 4.78E-05 Alzheimer's disease CCDC76 intron pha002879 rs506044 chr1 100611931 A G 2.60E-05 Glioma (high-grade) CCDC76 intron 19578366 rs6677080 chr1 100633469 T A 1.44E-04 Alzheimer's disease LRRC39 intron pha002879 rs11166407 chr1 100637708 G A 2.00E-05 Alzheimer's disease LRRC39 intron 17998437 rs11166407 chr1 100637708 G A 2.01E-05 Alzheimer's disease LRRC39 intron pha002879 rs11166412 chr1 100656265 C T 2.16E-04 Alzheimer's disease DBT UTR-3 pha002879 rs2810424 chr1 100663679 T C 6.30E-06 Glioma (high-grade) DBT intron 19578366 rs12021720 chr1 100672060 T C 1.50E-07 Glioma (high-grade) DBT missense 19578366 rs4143055 chr1 100690122 T C 1.42E-04 Alzheimer's disease DBT intron 17998437 rs4143055 chr1 100690122 T C 2.54E-05 Alzheimer's disease DBT intron pha002879 rs3806237 chr1 100715782 T C 2.00E-04 Cognitive impairment induced by topiramate DBT nearGene-5 22091778 rs17454070 chr1 100732855 T C 1.00E-04 Information processing speed RTCD1 intron 21130836 rs3119186 chr1 100781537 T C 7.42E-04 Multiple complex diseases / / 17554300 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma / / 23677573 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma (including hyperplasic) / / 23677573 rs478859 chr1 100796120 T C 0.0000274 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs7534479 chr1 100798137 G A 6.30E-04 Depression (quantitative trait) / / 20800221 rs4907906 chr1 100802399 T C 3.70E-06 Urinary metabolites / / 21572414 rs10783130 chr1 100806897 C G 3.41E-08 Metabolite levels / / 23281178 rs11166439 chr1 100808286 G C 3.20E-08 Metabolite levels / / 23281178 rs529224 chr1 100818178 G C 1.57E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A UTR-5 20031582 rs17420882 chr1 100818728 T G 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A intron 20031582 rs630646 chr1 100822776 G A 3.40E-06 Urinary metabolites CDC14A intron 21572414 rs17122341 chr1 100843757 C A 1.30E-05 Urinary metabolites CDC14A intron 21572414 rs7512321 chr1 100862989 C G 3.38E-04 Multiple complex diseases CDC14A intron 17554300 rs584350 chr1 100908324 A G 5.20E-06 Urinary metabolites CDC14A intron 21572414 rs10493923 chr1 100930254 C T 1.20E-05 Urinary metabolites CDC14A intron 21572414 rs17122625 chr1 100944262 G A 1.38E-04 Multiple complex diseases CDC14A intron 17554300 rs2809823 chr1 101003762 C A 1.80E-05 Post-operative nausea and vomiting GPR88 UTR-5 21694509 rs2030048 chr1 101006577 A G 3.99E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GPR88 UTR-3 20031582 rs1874779 chr1 101012512 G A 3.40E-06 Urinary metabolites / / 21572414 rs12038174 chr1 101013455 C T 1.60E-06 Urinary metabolites / / 21572414 rs11166474 chr1 101015181 C T 1.70E-06 Urinary metabolites / / 21572414 rs10875308 chr1 101024423 T C 8.76E-05 Kawasaki disease / / 22081228 rs1335751 chr1 101027524 T C 2.00E-06 Urinary metabolites / / 21572414 rs10875310 chr1 101027566 C T 9.90E-06 Urinary metabolites / / 21572414 rs1542837 chr1 101029768 T C 3.15E-05 Kawasaki disease / / 22081228 rs2809791 chr1 101039059 C T 5.30E-04 Multiple complex diseases / / 17554300 rs2647327 chr1 101041766 G A 1.80E-05 Urinary metabolites / / 21572414 rs10493929 chr1 101043928 A C 1.60E-05 Urinary metabolites / / 21572414 rs10875317 chr1 101045438 G T 1.80E-05 Urinary metabolites / / 21572414 rs7524322 chr1 101047730 C G 7.60E-06 Urinary metabolites / / 21572414 rs12728424 chr1 101055002 G A 7.27E-05 Kawasaki disease / / 22081228 rs11583008 chr1 101085094 A G 1.11E-06 Kawasaki disease / / 22081228 rs17412243 chr1 101094662 G A 6.91E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs2484535 chr1 101107748 C T 5.24E-06 Kawasaki disease LOC100128787 intron 22081228 rs955336 chr1 101108982 G A 4.00E-04 Type 2 diabetes LOC100128787 intron 17463246 rs17412577 chr1 101109431 C T 4.00E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs10493934 chr1 101124201 T A 2.75E-05 Tardive dyskinesia / / 20939080 rs1932351 chr1 101142049 C T 1.79E-06 Kawasaki disease / / 22081228 rs2050471 chr1 101175651 C T 9.08E-06 Kawasaki disease / / 22081228 rs3783599 chr1 101183887 C T 0.00000017 Triglycerides VCAM1 nearGene-5 23063622 rs3176860 chr1 101187219 A G 6.24E-04 Depression (quantitative trait) VCAM1 intron 20800221 rs3917056 chr1 101195902 G C 2.61E-09 Triglycerides VCAM1 intron 23063622 rs3181088 chr1 101198708 C T 3.61E-04 Suicide attempts in bipolar disorder VCAM1 intron 21423239 rs3176874 chr1 101199886 A G 2.18E-05 Alcohol dependence VCAM1 intron 21703634 rs3783621 chr1 101204495 C A 9.03E-04 Multiple complex diseases VCAM1 UTR-3 17554300 rs11586136 chr1 101236137 T C 8.35E-06 Primary biliary cirrhosis / / 21399635 rs17123397 chr1 101276999 A G 8.17E-05 Smoking cessation / / 24665060 rs7541397 chr1 101322866 A G 4.61E-05 Smoking cessation / / 24665060 rs11812031 chr1 101327772 A G 5.72E-04 Smoking cessation / / 24665060 rs12048904 chr1 101331536 T C 4.00E-08 Multiple sclerosis / / 21833088 rs7543296 chr1 101348100 C A 4.42E-04 Smoking cessation EXTL2 intron 24665060 rs2893468 chr1 101355549 A G 5.62E-04 Smoking cessation EXTL2 intron 24665060 rs3737580 chr1 101360215 C T 1.53E-04 Depression (quantitative trait) EXTL2 UTR-5 20800221 rs11579723 chr1 101396743 G T 3.03E-04 Smoking cessation SLC30A7 intron 24665060 rs11581062 chr1 101407519 A G 3.00E-10 Multiple sclerosis SLC30A7 intron 21833088 rs12023712 chr1 101462232 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs12119832 chr1 101463138 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs11166536 chr1 101476712 G C 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs17409729 chr1 101535778 T G 7.00E-05 Response to lithium treatment in bipolar disorder LOC100506051 intron 19448189 rs17450029 chr1 101540999 T C 3.00E-06 QT interval (interaction) LOC100506051 intron 23459443 rs950038 chr1 101549316 A G 4.80E-04 Type 2 diabetes and 6 quantitative traits LOC100506029 intron 17848626 rs17410015 chr1 101551926 T C 2.00E-06 Response to antipsychotic treatment LOC100506029 intron 20195266 rs12756986 chr1 101604753 T C 2.00E-04 Blood pressure / / 17255346 rs17417367 chr1 101620729 A G 6.70E-05 Alcohol dependence / / 22096494 rs17123757 chr1 101622960 T C 7.57E-05 Blood pressure / / 17255346 rs1999134 chr1 101681468 A C 4.50E-05 Heart Rate / / pha003053 rs12404070 chr1 101682050 T C 4.95E-04 Multiple complex diseases / / 17554300 rs12404070 chr1 101682050 T C 1.13E-05 Personality dimensions / / 22628180 rs33967958 chr1 101701481 T C 1.00E-04 Cognitive impairment induced by topiramate S1PR1 nearGene-5 22091778 rs17100954 chr1 101704029 G A 0.000026 Coronary artery calcification S1PR1 intron 23727086 rs12090529 chr1 101707126 T C 1.20E-05 HIV-1 control S1PR1 nearGene-3 20041166 rs12097137 chr1 101709445 G T 1.87E-13 HDL cholesterol / / 23063622 rs12097137 chr1 101709445 G T 2.64E-11 Cholesterol,total / / 23063622 rs2031959 chr1 101711783 T G 8.70E-04 Atrial fibrillation / / 21846873 rs765344 chr1 101716688 C T 8.46E-05 Cognitive test performance / / 20125193 rs7532171 chr1 101724951 C T 3.81E-05 Alcohol and nictotine co-dependence / / 20158304 rs7520706 chr1 101751884 T G 1.69E-04 Amyotrophic lateral sclerosis / / 20801718 rs13376006 chr1 101768580 G C 1.15E-04 Type 2 diabetes / / 17463246 rs17124135 chr1 101770101 A G 8.44E-04 Multiple complex diseases / / 17554300 rs9433784 chr1 101784340 G T 7.19E-04 Alcohol dependence / / 21314694 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs11802191 chr1 101834723 C A 7.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1491643 chr1 101849423 G A 2.86E-05 Cholesterol / / pha003083 rs6577245 chr1 101849830 G A 1.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12403551 chr1 101864215 G A 3.28E-06 Alopecia areata / / 22027810 rs10493947 chr1 101868793 G A 5.83E-04 Multiple complex diseases / / 17554300 rs10493947 chr1 101868793 G A 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1826316 chr1 101872865 C T 1.50E-06 Parkinson's disease / / 20711177 rs2338971 chr1 101880005 T C 4.00E-10 Parkinson's disease / / 24511991 rs2338971 chr1 101880005 T C 5.00E-10 Parkinson's disease / / 24511991 rs4908144 chr1 101889855 T C 0.0000153 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662461 chr1 101891186 C G 0.0000121 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11581429 chr1 101913527 C T 9.34E-04 Multiple complex diseases / / 17554300 rs12118351 chr1 101919802 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10493955 chr1 101922436 A T 6.79E-04 Multiple complex diseases / / 17554300 rs10493955 chr1 101922436 A T 1.30E-05 Urinary metabolites / / 21572414 rs1777877 chr1 101930897 G T 7.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777867 chr1 101937782 C T 1.52E-04 Multiple complex diseases / / 17554300 rs1777867 chr1 101937782 C T 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1948368 chr1 101938477 G A 6.00E-06 Bipolar disorder / / 18711365 rs1948368 chr1 101938477 G A 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs726646 chr1 101938663 T G 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1361812 chr1 101939689 T G 1.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs1419103 chr1 101940656 A T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 9.73E-06 Cognitive impairment induced by topiramate / / 22091778 rs1776911 chr1 101941385 A T 5.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1776907 chr1 101945977 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1776905 chr1 101947657 T A 5.70E-05 Multiple complex diseases / / 17554300 rs387176 chr1 101963766 G A 7.32E-05 Multiple complex diseases / / 17554300 rs396954 chr1 101964376 T A 2.76E-05 Multiple complex diseases / / 17554300 rs374982 chr1 101973050 G A 4.53E-04 Insulin resistance / / 21901158 rs263908 chr1 101973613 C A 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs263912 chr1 101975151 T G 2.20E-06 Parkinson's disease / / 20711177 rs263906 chr1 101978334 T C 2.42E-05 Bipolar disorder / / 21926972 rs263906 chr1 101978334 T C 0.000483 Bipolar disorder / / 23070075 rs263918 chr1 101984932 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs263918 chr1 101984932 C T 8.97E-04 Major depressive disorder / / 22472876 rs1688582 chr1 101992222 A G 2.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs12137486 chr1 101994207 C T 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1199575 chr1 101996097 G A 3.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs12748695 chr1 102000069 C A 6.96E-04 Type 2 diabetes / / 17463246 rs721021 chr1 102016643 T A 9.37E-04 Multiple complex diseases / / 17554300 rs721018 chr1 102016712 G A 5.98E-04 Multiple complex diseases / / 17554300 rs4626910 chr1 102017100 T C 9.03E-04 Multiple complex diseases / / 17554300 rs6665373 chr1 102017438 T G 8.78E-04 Multiple complex diseases / / 17554300 rs984132 chr1 102030001 C T 2.47E-04 Multiple complex diseases / / 17554300 rs11164278 chr1 102184478 T C 0.0000468 Polycystic ovary syndrome / / 22951595 rs11164278 chr1 102184478 T C 4.68E-05 Intracranial aneurysm / / 22961961 rs2225904 chr1 102193896 G A 8.68E-04 Alzheimer's disease / / 24755620 rs1445227 chr1 102199014 A G 3.50E-05 Squamous cell carcinoma / / 23341777 rs1445227 chr1 102199014 A G 8.95E-04 Alzheimer's disease / / 24755620 rs12565816 chr1 102200090 T G 8.95E-04 Alzheimer's disease / / 24755620 rs10493963 chr1 102222083 T C 3.30E-05 Relative hand skill in reading disability / / 24068947 rs12022918 chr1 102225750 C T 2.36E-05 Relative hand skill in reading disability / / 24068947 rs7536591 chr1 102226863 T C 5.24E-05 Relative hand skill in reading disability / / 24068947 rs959163 chr1 102228731 G A 2.88E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12026998 chr1 102229779 C A 7.27E-04 Multiple complex diseases / / 17554300 rs4908181 chr1 102233475 T C 3.39E-04 Coronary heart disease / / 21971053 rs10874514 chr1 102234964 C T 2.00E-09 Lipid levels / / 18193044 rs1470438 chr1 102239205 G A 5.78E-05 Relative hand skill in reading disability / / 24068947 rs1020368 chr1 102241441 C T 4.35E-05 Relative hand skill in reading disability / / 24068947 rs11164301 chr1 102243101 G A 4.49E-04 Lung function (forced vital capacity) / / 24023788 rs10782852 chr1 102249785 C T 2.48E-05 Relative hand skill in reading disability / / 24068947 rs559183695 chr1 102249785 C CTTCTTTCTAAAGAAAGAGTTTGATGGTTTATCAT 2.48E-05 Relative hand skill in reading disability / / 24068947 rs11164304 chr1 102256943 T C 2.39E-05 Relative hand skill in reading disability / / 24068947 rs10493976 chr1 102263909 C T 8.16E-04 Schizophrenia / / 19197363 rs1854169 chr1 102274276 C T 6.53E-06 Osteoarthritis OLFM3 intron 22763110 rs4907956 chr1 102312703 G T 5.83E-06 Alcohol dependence OLFM3 intron 20202923 rs4907956 chr1 102312703 G T 2.40E-05 Alcohol dependence OLFM3 intron 21703634 rs4907956 chr1 102312703 G T 0.0000507 Nicotine dependence (smoking) OLFM3 intron 22377092 rs1336798 chr1 102351870 T C 0.0000374 Nicotine dependence (smoking) D/JA1P5 intron 22377092 rs12731963 chr1 102382404 T C 0.000047 Nicotine dependence (smoking) OLFM3 intron 22377092 rs755181 chr1 102404247 T C 7.67E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs1415088 chr1 102413524 C A 4.92E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs4907957 chr1 102423144 T C 2.70E-07 Urinary metabolites OLFM3 intron 21572414 rs4907957 chr1 102423144 T C 0.00000068 Common carotid artery thickness (far walls) OLFM3 intron 23487405 rs4907957 chr1 102423144 T C 0.00000114 Common carotid artery thickness (average of near and far wall measures) OLFM3 intron 23487405 rs10782865 chr1 102453599 A T 8.84E-04 Type 2 diabetes OLFM3 intron 17463246 rs10493964 chr1 102484211 A G 2.91E-06 Varicose Veins / / pha001413 rs6675297 chr1 102548118 G C 3.54E-04 Multiple complex diseases / / 17554300 rs11578152 chr1 102577021 A G 2.30E-05 Urinary metabolites / / 21572414 rs11164386 chr1 102578097 T G 8.57E-05 Multiple complex diseases / / 17554300 rs10493978 chr1 102579307 C T 7.16E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 6.11E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 2.20E-05 Urinary metabolites / / 21572414 rs1938355 chr1 102677845 T C 1.18E-04 Bipolar disorder / / 19259986 rs10874555 chr1 102687572 G A 1.80E-05 Urinary metabolites / / 21572414 rs12731867 chr1 102699430 G A 4.26E-04 Type 2 diabetes / / 17463246 rs11164428 chr1 102706193 C G 2.50E-06 Stroke (ischemic) / / 21957438 rs10782879 chr1 102708517 A G 1.12E-04 Multiple complex diseases / / 17554300 rs11804344 chr1 102722923 C G 3.37E-04 Gallstones / / 17632509 rs17126268 chr1 102726399 T C 1.58E-05 Glomerular filtration rate / / 24351856 rs17126268 chr1 102726399 T C 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs12120258 chr1 102734951 G T 1.58E-05 Glomerular filtration rate / / 24351856 rs12120258 chr1 102734951 G T 9.64E-05 Chronic kidney disease / / 24351856 rs12140211 chr1 102739517 C T 1.48E-05 Glomerular filtration rate / / 24351856 rs12140211 chr1 102739517 C T 7.59E-04 Chronic kidney disease / / 24351856 rs2889234 chr1 102742475 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12407943 chr1 102760382 G T 9.31E-04 Heart Failure / / pha002884 rs1261698 chr1 102794417 C A 3.31E-05 Vitiligo / / 19890347 rs1272970 chr1 102829724 T G 6.43E-04 Multiple complex diseases / / 17554300 rs1572999 chr1 102830435 A G 8.28E-04 Multiple complex diseases / / 17554300 rs1573002 chr1 102830754 G A 8.74E-04 Multiple complex diseases / / 17554300 rs200979159 chr1 102830754 GTC G 8.74E-04 Multiple complex diseases / / 17554300 rs1418096 chr1 102830849 T C 5.70E-04 Multiple complex diseases / / 17554300 rs1361461 chr1 102925321 C T 9.16E-04 Multiple complex diseases / / 17554300 rs12752401 chr1 102967150 C T 1.90E-04 Cholesterol / / 17255346 rs12035823 chr1 102995218 T C 5.81E-04 Tourette syndrome / / 22889924 rs1517426 chr1 103040474 G T 5.75E-04 Type 2 diabetes / / 17463246 rs11164556 chr1 103080187 G A 6.17E-05 Blood Pressure / / pha003050 rs11164559 chr1 103088742 G T 7.74E-05 Bone mineral density / / 19181680 rs7533876 chr1 103110933 G A 5.17E-06 Response to metformin / / 21186350 rs7533876 chr1 103110933 G A 1.60E-06 Urinary metabolites / / 21572414 rs10874639 chr1 103133909 A G 3.00E-06 Protein quantitative trait loci / / 18464913 rs10493982 chr1 103171983 G A 2.42E-05 Bilirubin levels,in serum / / 19389676 rs720315 chr1 103175049 T A 2.89E-05 Bilirubin levels,in serum / / 19389676 rs1376359 chr1 103203107 T C 8.78E-05 Coronary restenosis / / 21878436 rs1376359 chr1 103203107 T C 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs478830 chr1 103230040 A C 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs514077 chr1 103231606 T C 5.09E-06 Bilirubin levels,in serum / / 19389676 rs606756 chr1 103238392 C T 3.90E-04 Multiple complex diseases / / 17554300 rs11164597 chr1 103238444 T C 3.72E-04 Schizophrenia / / 20832056 rs2598461 chr1 103298338 C A 2.11E-04 Lung function (forced vital capacity) / / 24023788 rs1241181 chr1 103347865 G A 1.18E-04 Multiple complex diseases COL11A1 intron 17554300 rs1241182 chr1 103348100 A C 2.00E-04 Alcohol dependence COL11A1 intron 20201924 rs1241182 chr1 103348100 A C 4.30E-04 Alcohol dependence COL11A1 intron 20201924 rs17446095 chr1 103372775 C A 3.09E-05 Bipolar disorder,affective COL11A1 intron 20528957 rs3753841 chr1 103379918 G A 9.00E-10 Glaucoma (primary open-angle) COL11A1 missense 22922875 rs4908274 chr1 103389914 A T 1.09E-04 Schizophrenia COL11A1 intron 20832056 rs12138977 chr1 103393457 C T 8.30E-05 Information processing speed COL11A1 intron 21130836 rs3102053 chr1 103422730 T C 3.00E-04 Pseudoexfoliation syndrome COL11A1 intron 20808326 rs1012281 chr1 103427407 T C 2.60E-05 Urinary metabolites COL11A1 intron 21572414 rs2615977 chr1 103452392 A C 3.88E-06 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs2615977 chr1 103452392 A C 9.91E-05 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs12756627 chr1 103457229 A G 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12724152 chr1 103458395 C A 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11809524 chr1 103459537 C T 9.00E-06 Bone mineral density COL11A1 intron 22504420 rs12723167 chr1 103463624 G A 7.26E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12733933 chr1 103465596 G A 7.29E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11164661 chr1 103541331 G A 2.76E-05 Schizophrenia COL11A1 intron 19571811 rs1415363 chr1 103552935 A G 6.73E-04 Smoking initiation COL11A1 intron 24665060 rs1572521 chr1 103562868 T G 1.42E-11 Triglycerides COL11A1 intron 23063622 rs4338381 chr1 103572927 A G 1.60E-10 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 3.40E-05 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 9.00E-07 Height COL11A1 intron 21194676 rs6577357 chr1 103589265 T A 1.13E-04 Aortic root size / / 21223598 rs1572516 chr1 103591909 A C 5.94E-04 Multiple complex diseases / / 17554300 rs1572516 chr1 103591909 A C 4.60E-06 Urinary metabolites / / 21572414 rs10874684 chr1 103596035 C T 9.86E-04 Multiple complex diseases / / 17554300 rs10874684 chr1 103596035 C T 3.60E-06 Urinary metabolites / / 21572414 rs17127531 chr1 103601156 G A 7.40E-04 Multiple complex diseases / / 17554300 rs17127531 chr1 103601156 G A 2.90E-06 Urinary metabolites / / 21572414 rs872317 chr1 103609693 T C 1.22E-05 Bilirubin levels,in serum / / 19389676 rs1337199 chr1 103611252 G A 1.73E-05 Bilirubin levels,in serum / / 19389676 rs12131191 chr1 103621727 G A 3.00E-06 Urinary metabolites / / 21572414 rs3861744 chr1 103622234 A G 2.77E-05 Bilirubin levels,in serum / / 19389676 rs1358459 chr1 103636607 C T 2.60E-05 Urinary metabolites / / 21572414 rs1528202 chr1 103662258 C T 2.70E-05 Urinary metabolites / / 21572414 rs6683683 chr1 103671460 G A 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1406139 chr1 103683335 G A 1.84E-05 Bilirubin levels,in serum / / 19389676 rs10493998 chr1 103728254 C T 2.40E-05 Urinary metabolites / / 21572414 rs4907992 chr1 103763252 A G 4.85E-04 Alcohol dependence / / 20201924 rs7524694 chr1 104019631 T C 7.00E-06 Obesity-related traits / / 23251661 rs1930212 chr1 104324819 A G 6.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10881490 chr1 104381824 C T 3.17E-04 Tourette syndrome / / 22889924 rs1930206 chr1 104393357 C G 3.78E-04 Blood pressure / / 17255346 rs1579026 chr1 104405855 G A 8.50E-04 HIV-1 viral setpoint / / 17641165 rs1930192 chr1 104408821 A C 9.57E-04 HIV-1 viral setpoint / / 17641165 rs1999480 chr1 104419830 T C 8.55E-04 HIV-1 viral setpoint / / 17641165 rs12143917 chr1 104433984 G A 4.68E-04 Iron levels / / pha002876 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / 19880490 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / pha002876 rs1182580 chr1 104446782 C T 2.37E-05 Multiple sclerosis / / 19525953 rs41419745 chr1 104452958 T A 4.41E-06 Multiple sclerosis / / 17660530 rs11185337 chr1 104476678 C A 3.49E-05 Multiple sclerosis / / 17660530 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / 19880490 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / pha002876 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / 19880490 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / pha002876 rs144192269 chr1 104488097 G A 0.00000196 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs41445945 chr1 104489522 G C 3.64E-04 Multiple complex diseases / / 17554300 rs1330388 chr1 104492281 T C 6.77E-04 Iron levels / / pha002876 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / 19880490 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / pha002876 rs12126657 chr1 104511450 G A,C 9.28E-04 Obesity (extreme) / / 21935397 rs517139 chr1 104522097 T C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs6586440 chr1 104534262 C T 7.09E-04 Multiple complex diseases / / 17554300 rs1330408 chr1 104546820 C T 7.32E-04 Iron levels / / pha002876 rs4141899 chr1 104547617 T C 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12026645 chr1 104562381 A G 9.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12031508 chr1 104572622 A T 8.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / 19880490 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / pha002876 rs3934285 chr1 104598941 G A 2.00E-06 Obesity-related traits / / 23251661 rs10494003 chr1 104621168 G C 1.60E-04 Multiple complex diseases / / 17554300 rs11185373 chr1 104621467 A T 2.57E-04 Multiple complex diseases / / 17554300 rs1999228 chr1 104629019 A G 1.85E-04 Multiple complex diseases / / 17554300 rs11800756 chr1 104637412 C T 2.83E-04 Multiple complex diseases / / 17554300 rs10494007 chr1 104638728 A G 2.43E-04 Type 2 diabetes / / 17846124 rs12144936 chr1 104682747 C G 9.59E-04 Obesity (extreme) / / 21935397 rs1932466 chr1 104706300 G A 0.000041 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1932465 chr1 104706506 G C 5.61E-06 Type 2 diabetes / / 17846124 rs1932465 chr1 104706506 G C 5.60E-06 Type 2 diabetes / / 21647700 rs10494009 chr1 104710766 G C 1.06E-04 Type 2 diabetes / / 17846124 rs200895163 chr1 104719055 C CT 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7523109 chr1 104719055 C T 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12407548 chr1 104731827 A G 2.10E-04 Multiple complex diseases / / 17554300 rs7527726 chr1 104736011 C A 5.16E-05 Post-operative nausea and vomiting / / 21694509 rs11185389 chr1 104747846 A G 7.56E-04 Alzheimer's disease / / 17998437 rs59602554 chr1 104748342 C A 0.0000321 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 3.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs3866247 chr1 104778806 C T 6.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs12067058 chr1 104779012 G A 1.82E-04 Multiple complex diseases / / 17554300 rs4633297 chr1 104798629 G A 6.17E-04 Multiple complex diseases / / 17554300 rs12407649 chr1 104798853 C A 5.10E-05 Cortisol secretion,in saliva / / 21316860 rs12086216 chr1 104800294 C T 9.30E-05 HIV-1 control / / 20041166 rs7555154 chr1 104818279 G C 5.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1497676 chr1 104820635 C T 6.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6586471 chr1 104846498 T C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11185422 chr1 104849763 G A 1.20E-05 Telomere length / / 23001564 rs10881542 chr1 104852738 T C 2.00E-06 Glaucoma (primary open-angle) / / 22922875 rs10785866 chr1 104887259 G A 7.53E-05 Cortisol secretion,in saliva / / 21316860 rs9662111 chr1 104894847 G A 4.85E-05 Telomere length / / 23001564 rs2646709 chr1 104954647 C T 6.37E-04 Alzheimer's disease / / 17998437 rs1448395 chr1 104966942 T C 9.44E-04 HIV-1 viral setpoint / / 17641165 rs11184169 chr1 104978179 C T 3.43E-04 Type 2 diabetes / / 17463246 rs11184173 chr1 104986052 C T 2.50E-04 IgE levels / / 17255346 rs11184173 chr1 104986052 C T 2.99E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs12744616 chr1 104987296 G T 8.12E-04 Type 2 diabetes / / 17463246 rs7411648 chr1 104997471 C T 6.97E-05 Heart Rate / / pha003053 rs12090634 chr1 104997692 G T 6.90E-05 Heart Rate / / pha003053 rs12035511 chr1 105051438 A C 4.66E-04 Acute lung injury / / 22295056 rs12752353 chr1 105054589 T G 4.66E-04 Acute lung injury / / 22295056 rs381728 chr1 105055075 T A 3.33E-04 Insulin resistance / / 21901158 rs12042136 chr1 105063644 A G 7.33E-04 Acute lung injury / / 22295056 rs316951 chr1 105076810 C T 2.48E-05 Celiac disease / / 23936387 rs11184197 chr1 105081773 G A 3.22E-05 Cortisol secretion,in saliva / / 21316860 rs12022925 chr1 105081913 T G 8.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6695172 chr1 105086051 T C 2.61E-05 Cortisol secretion,in saliva / / 21316860 rs12026360 chr1 105088785 G A 5.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2121956 chr1 105089396 A G 2.03E-05 Cortisol secretion,in saliva / / 21316860 rs2121956 chr1 105089396 A G 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs316942 chr1 105090738 A G 2.36E-04 Insulin resistance / / 21901158 rs316942 chr1 105090738 A G 2.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448378 chr1 105091696 T C 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11578246 chr1 105095501 T G 5.16E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2084447 chr1 105102314 A G 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 2.70E-05 Type 2 diabetes / / 17460697 rs7553985 chr1 105106498 T C 2.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 7.75E-04 Iron levels / / pha002876 rs12172730 chr1 105111535 G A 4.87E-05 Parkinson's disease / / 19915575 rs2166890 chr1 105112356 C T 2.40E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 3.00E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 1.21E-05 Cortisol secretion,in saliva / / 21316860 rs11184211 chr1 105115188 A G 3.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448394 chr1 105118613 G A 4.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11184213 chr1 105119392 C T 8.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs114152980 chr1 105119612 C T 0.000074 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12568560 chr1 105140299 G A 6.81E-05 Cortisol secretion,in saliva / / 21316860 rs4847178 chr1 105144179 T C 3.10E-05 Personality dimensions / / 18957941 rs10494020 chr1 105189711 A G 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7532749 chr1 105219763 T G 8.81E-04 Type 2 diabetes / / 17463246 rs7532749 chr1 105219763 T G 9.25E-04 Multiple complex diseases / / 17554300 rs7532749 chr1 105219763 T G 7.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12725071 chr1 105220965 C T 4.52E-06 Asthma / / 20698975 rs7543757 chr1 105227914 T C 5.37E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7543757 chr1 105227914 T C 4.60E-06 Adiposity / / 19461586 rs7543757 chr1 105227914 T C 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6702883 chr1 105243080 A G 3.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12117597 chr1 105282847 T C 1.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11578700 chr1 105292119 A C 5.07E-05 Paget's disease / / 20436471 rs11578700 chr1 105292119 A C 5.26E-05 Paget's disease / / 21623375 rs1481397 chr1 105303590 C T 2.60E-05 Urinary metabolites / / 21572414 rs1871782 chr1 105304918 C A 1.80E-05 Urinary metabolites / / 21572414 rs11184300 chr1 105312623 A G 9.64E-05 Waist Circumference / / pha003023 rs7523359 chr1 105324488 C T 1.70E-05 Urinary metabolites / / 21572414 rs12036613 chr1 105325538 G A 9.50E-06 Urinary metabolites / / 21572414 rs12043310 chr1 105332372 G A 1.20E-05 Urinary metabolites / / 21572414 rs12042214 chr1 105344196 T C 1.50E-05 Urinary metabolites / / 21572414 rs12038712 chr1 105395417 T C 7.20E-06 Urinary metabolites / / 21572414 rs11811929 chr1 105396240 C T 5.12E-04 Prostate cancer mortality / / 20978177 rs11811929 chr1 105396240 C T 2.30E-05 Urinary metabolites / / 21572414 rs12029384 chr1 105425455 C G 1.80E-06 Urinary metabolites / / 21572414 rs1376368 chr1 105449139 C T 4.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7526166 chr1 105453412 T G 2.64E-04 Multiple complex diseases / / 17554300 rs2084670 chr1 105469987 C T 3.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs6702908 chr1 105475361 C T 8.39E-04 Multiple complex diseases / / 17554300 rs1466154 chr1 105476957 A C 4.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1466153 chr1 105476963 C A 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs11184372 chr1 105489615 T C 1.82E-04 Multiple complex diseases / / 17554300 rs4548451 chr1 105502327 T A 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs994239 chr1 105505952 T G 5.31E-05 Multiple complex diseases / / 17554300 rs12136584 chr1 105507435 C A 3.29E-04 Multiple complex diseases / / 17554300 rs7550524 chr1 105507848 A G 1.99E-04 Multiple complex diseases / / 17554300 rs991024 chr1 105508155 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9729540 chr1 105509351 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6657473 chr1 105511033 C A,T 4.34E-05 Multiple complex diseases / / 17554300 rs4466665 chr1 105525087 T A 4.21E-04 Multiple complex diseases / / 17554300 rs12039264 chr1 105537204 A G 6.95E-04 Multiple complex diseases / / 17554300 rs11184409 chr1 105541666 A T 8.49E-06 Personality dimensions / / 22628180 rs1158909 chr1 105552128 T A 5.04E-04 Multiple complex diseases / / 17554300 rs11184413 chr1 105552936 A C 4.25E-04 Multiple complex diseases / / 17554300 rs2923300 chr1 105561345 A G 3.24E-04 Multiple complex diseases / / 17554300 rs2122691 chr1 105568426 G T 3.24E-04 Multiple complex diseases / / 17554300 rs2923297 chr1 105569484 T C 6.00E-04 Multiple complex diseases / / 17554300 rs2034525 chr1 105574256 T C 0.0000038 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs12410176 chr1 105593913 C T 2.32E-04 White matter integrity / / 22425255 rs1584633 chr1 105612342 C T 7.58E-04 Prostate cancer mortality / / 20978177 rs11184448 chr1 105688179 A G 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17015466 chr1 105688537 G A 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4601631 chr1 105720963 A C 8.93E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6667576 chr1 105725458 C T 7.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11184469 chr1 105735780 A G 4.31E-05 Substance dependence / / 21818250 rs6583163 chr1 105993658 T C 8.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12118827 chr1 106001235 G A 9.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12735409 chr1 106001606 G A 9.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7512514 chr1 106002632 C T 8.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12144596 chr1 106005296 T A 8.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2501603 chr1 106007141 A G 8.25E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12740181 chr1 106007454 C T 8.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1516156 chr1 106032070 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1516155 chr1 106034597 G A 7.11E-04 Obesity (extreme) / / 21935397 rs11184596 chr1 106057617 T C 1.83E-05 Duodenal ulcer / / 22387998 rs12120660 chr1 106086980 A G 6.40E-06 Urinary metabolites / / 21572414 rs12120660 chr1 106086980 A G 6.50E-04 Smoking initiation / / 24665060 rs777080 chr1 106099097 A C 2.25E-04 Coronary Artery Disease / / 17634449 rs10785759 chr1 106124761 C T 5.52E-04 Smoking initiation / / 24665060 rs11807640 chr1 106161451 C T 1.99E-05 Coronary heart disease / / pha003030 rs2842597 chr1 106172488 G A 1.92E-05 Coronary heart disease / / pha003030 rs12743318 chr1 106195966 C T 0.000446678 Hypertension (early onset hypertension) / / 22479346 rs1163495 chr1 106242233 G A 8.62E-04 Multiple complex diseases / / 17554300 rs1163499 chr1 106243931 G C 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs790966 chr1 106244640 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163521 chr1 106328719 T C 3.45E-22 Narcolepsy / / 19629137 rs11184708 chr1 106430287 A T 2.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs17016501 chr1 106438336 C T 3.77E-05 Coronary heart disease / / pha003056 rs17016501 chr1 106438336 C T 6.03E-06 Diabetes Mellitus / / pha003060 rs7515037 chr1 106446157 T G 2.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs940426 chr1 106449970 C T 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1380289 chr1 106453318 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11184717 chr1 106477681 A C 9.30E-06 Urinary metabolites / / 21572414 rs498428 chr1 106570045 G T 3.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11184734 chr1 106590173 C T 1.95E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 1.72E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 5.94E-13 Esophageal cancer / / 21642993 rs12408810 chr1 106640943 C T 9.00E-06 Obesity (early onset extreme) / / 23563609 rs1889463 chr1 106653622 T C 7.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1031339 chr1 106701386 T A 9.81E-04 Multiple complex diseases / / 17554300 rs11184786 chr1 106726037 C T 1.55E-06 Common variable immunodeficiency / / 21497890 rs10881372 chr1 106753277 C T 7.88E-05 Blood Pressure / / pha003043 rs12724740 chr1 106780771 A G 0.0007921 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12724740 chr1 106780771 A G 7.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12733837 chr1 106781522 T A 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4431871 chr1 106810236 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2150037 chr1 106832596 C G 9.27E-05 Tuberculosis / / 20694014 rs7517409 chr1 106833140 C A 1.50E-05 Urinary metabolites / / 21572414 rs2210094 chr1 106833610 C G 7.77E-05 Tuberculosis / / 20694014 rs1330225 chr1 106835943 T C 1.00E-08 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 1.22E-04 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 7.00E-09 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330226 chr1 106843175 C T 2.70E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 4.64E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 8.56E-05 Bone mineral traits,in men / / 21427758 rs12117640 chr1 106878317 G T 2.11E-04 Alzheimer's disease (late onset) / / 21379329 rs7538613 chr1 106882826 G A 3.19E-04 Alzheimer's disease (late onset) / / 21379329 rs11184870 chr1 106887181 C T 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs11184871 chr1 106887450 G A 2.73E-06 Left ventricular mass / / 21212386 rs11184871 chr1 106887450 G A 2.87E-04 Alzheimer's disease (late onset) / / 21379329 rs12565323 chr1 106906072 G A 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs2026790 chr1 106914392 A C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17433090 chr1 106933198 G A 0.0004882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17433090 chr1 106933198 G A 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6582965 chr1 106937705 C G 4.76E-05 Odorant perception / / 23910658 rs2988394 chr1 106963817 T A 5.51E-05 Multiple complex diseases / / 17554300 rs10881403 chr1 106990083 T A 4.24E-05 Glaucoma (primary open-angle) / / 22605921 rs1575738 chr1 107031734 C T 2.70E-05 Urinary metabolites / / 21572414 rs12045753 chr1 107056847 G A 1.62E-06 Glaucoma (primary open-angle) / / 22605921 rs12025734 chr1 107075244 G A 6.17E-05 Glaucoma (primary open-angle) / / 22605921 rs11184922 chr1 107106193 C T 7.29E-04 Taste perception / / 22132133 rs4440890 chr1 107110129 G A 5.79E-05 Personality dimensions / / 18957941 rs10494045 chr1 107112572 C A 6.61E-05 AIDS progression / / 19115949 rs4915129 chr1 107113504 C T 9.40E-05 Personality dimensions / / 18957941 rs4915129 chr1 107113504 C T 6.60E-05 AIDS progression / / 19115949 rs12121466 chr1 107149412 A C 2.52E-04 Longevity / / 22279548 rs10785799 chr1 107191485 A G 6.11E-05 Cervical cancer / / 24700089 rs10494048 chr1 107195059 G T 9.66E-05 Prostate cancer / / pha002878 rs10881442 chr1 107219644 C T 8.91E-05 Intelligence / / 21826061 rs10881442 chr1 107219644 C T 5.65E-05 Lipoproteins / / pha003079 rs6703591 chr1 107222150 G A 6.68E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4342878 chr1 107227063 T A 2.65E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4462181 chr1 107230730 A G 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4336881 chr1 107232816 A C 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10785805 chr1 107233800 G A 5.15E-05 Intelligence / / 21826061 rs10785805 chr1 107233800 G A 5.32E-05 Lipoproteins / / pha003079 rs4914986 chr1 107255899 T A 1.38E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4436418 chr1 107264055 T C 2.17E-04 Multiple complex diseases / / 17554300 rs9887893 chr1 107279889 G A 7.26E-05 Intelligence / / 21826061 rs2176758 chr1 107281362 C T 1.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6686425 chr1 107289810 C T 9.96E-04 Type 2 diabetes / / 17463246 rs1519883 chr1 107291768 C T 3.51E-05 Intelligence / / 21826061 rs12097821 chr1 107336301 G T 6.00E-10 Non-obstructive azoospermia / / 22197933 rs12119184 chr1 107338996 G A 6.02E-05 Intelligence / / 21826061 rs12024651 chr1 107404931 G A 6.36E-06 Glaucoma (primary open-angle) / / 22605921 rs3968588 chr1 107425864 G A 3.42E-04 Multiple complex diseases / / 17554300 rs1519881 chr1 107432265 A G 7.00E-06 Urinary metabolites / / 21572414 rs12726652 chr1 107432576 G A 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs12726652 chr1 107432576 G A 0.000248 Salmonella-induced pyroptosis / / 22837397 rs10494055 chr1 107449940 T C 8.17E-04 Multiple complex diseases / / 17554300 rs12125971 chr1 107463643 C T 7.00E-06 Intelligence / / 22449649 rs17495607 chr1 107501181 T C 4.08E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17496332 chr1 107546375 A G 1.00E-11 Sex hormone-binding globulin levels / / 22829776 rs17496332 chr1 107546375 A G 2.00E-07 Sex hormone-binding globulin levels / / 22829776 rs10494056 chr1 107547919 C A 4.29E-06 AIDS / / 19754311 rs6675948 chr1 107557477 C G 3.80E-04 Iris characteristics / / 21835309 rs10047147 chr1 107561147 C T 6.70E-05 Height / / pha003010 rs10881455 chr1 107561546 G A 6.70E-05 Height / / pha003010 rs4118325 chr1 107577832 G A 6.00E-07 AIDS / / 19754311 rs4118325 chr1 107577832 G A 5.82E-05 Height / / pha003010 rs11185057 chr1 107596964 T C 6.23E-05 Height / / pha003010 rs17018290 chr1 107609774 C G 5.85E-04 Multiple complex diseases / / 17554300 rs1762495 chr1 107634116 T C 3.40E-05 AIDS / / 19754311 rs1762495 chr1 107634116 T C 1.94E-04 Scoliosis / / 21216876 rs6583007 chr1 107676684 C T 2.49E-04 Fibrinogen / / 17255346 rs4481881 chr1 107686418 T C 3.08E-05 Orofacial clefts NTNG1 intron 20023658 rs4307594 chr1 107693167 T C 2.00E-05 Orofacial clefts NTNG1 intron 20023658 rs6681613 chr1 107717689 G A 5.39E-07 Lymphocyte counts NTNG1 intron 22286170 rs6694986 chr1 107829678 T C 4.00E-04 Pulmonary function NTNG1 intron 23932459 rs10494067 chr1 107830858 A C 6.00E-06 Anorexia nervosa NTNG1 intron 21079607 rs4604720 chr1 107837159 G A 3.15E-05 Asthma NTNG1 intron 23181788 rs17509160 chr1 107855013 C T 6.70E-05 Pulmonary function NTNG1 intron 23932459 rs7411507 chr1 107865978 G A 1.91E-05 Prostate cancer NTNG1 intron 18264096 rs6672549 chr1 107874959 G A 2.07E-04 Celiac disease NTNG1 intron 23936387 rs12747408 chr1 107920219 C T 1.95E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs12747408 chr1 107920219 C T 1.95E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs7544259 chr1 107929543 A G 1.51E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs7544259 chr1 107929543 A G 1.51E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs2587899 chr1 107946650 G T 9.87E-04 Multiple complex diseases NTNG1 intron 17554300 rs17018944 chr1 107955428 A G 4.20E-04 Multiple complex diseases NTNG1 intron 17554300 rs12731224 chr1 107961159 A G 3.49E-06 Body Mass Index NTNG1 intron pha003007 rs12731224 chr1 107961159 A G 5.07E-05 Body Mass Index NTNG1 intron pha003015 rs480392 chr1 107979396 A C 1.38E-08 Triglycerides NTNG1 cds-synon 23063622 rs480392 chr1 107979396 A C 1.77E-08 HDL cholesterol NTNG1 cds-synon 23063622 rs1373337 chr1 107980407 G A 2.04E-05 Body Mass Index NTNG1 intron pha003007 rs1444038 chr1 107981316 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs1444038 chr1 107981316 G A 1.82E-05 Body Mass Index NTNG1 intron pha003007 rs12735678 chr1 107984135 T C 1.76E-05 Body Mass Index NTNG1 intron pha003007 rs17019069 chr1 107985632 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs590987 chr1 107986409 G A 4.08E-04 Multiple complex diseases NTNG1 intron 17554300 rs17531774 chr1 107987328 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs17531997 chr1 107992327 C G 6.55E-04 Smoking quantity NTNG1 intron 24665060 rs17466589 chr1 107992571 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs521721 chr1 108001448 G A 1.99E-04 Multiple complex diseases NTNG1 intron 17554300 rs96501 chr1 108018847 C T 2.90E-05 Urinary metabolites NTNG1 intron 21572414 rs96501 chr1 108018847 C T 1.79E-04 Celiac disease NTNG1 intron 23936387 rs653383 chr1 108021506 C T 2.00E-04 Cognitive impairment induced by topiramate NTNG1 intron 22091778 rs650251 chr1 108026510 T G 1.16E-04 Multiple complex diseases / / 17554300 rs11808800 chr1 108040994 T C 9.41E-06 Mathematical ability / / 24801482 rs533165 chr1 108070545 C T 8.89E-04 Multiple complex diseases / / 17554300 rs521420 chr1 108074669 C G 2.60E-05 Urinary metabolites / / 21572414 rs17535067 chr1 108074954 G A 9.90E-06 Urinary metabolites / / 21572414 rs608827 chr1 108076343 C T 5.13E-04 Aortic root size / / 21223598 rs12565052 chr1 108079880 G C 6.70E-05 Response to statin therapy / / 20339536 rs12564555 chr1 108085686 T C 3.30E-05 Response to statin therapy / / 20339536 rs12566146 chr1 108091675 T C 5.80E-05 Response to statin therapy / / 20339536 rs2769668 chr1 108115145 T C 1.30E-05 Urinary metabolites VAV3 UTR-3 21572414 rs1410403 chr1 108123685 C T 3.33E-04 Schizophrenia VAV3 intron 20832056 rs1328199 chr1 108127895 C T 1.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 intron 24023788 rs11803410 chr1 108141478 G A 5.68E-04 Multiple complex diseases VAV3 intron 17554300 rs1410406 chr1 108156360 G A 0.000650658 Hypertension (early onset hypertension) VAV3 intron 22479346 rs11185151 chr1 108173844 C T 9.50E-06 Digit length ratio VAV3 intron 20303062 rs4915061 chr1 108176019 G A 2.17E-04 Multiple complex diseases VAV3 intron 17554300 rs12752530 chr1 108176582 A C 2.50E-04 Multiple complex diseases VAV3 intron 17554300 rs6693140 chr1 108181947 C T 2.83E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs4914952 chr1 108184270 C A 9.60E-06 Digit length ratio VAV3 intron 20303062 rs12410676 chr1 108185309 G A 1.52E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 missense 24023788 rs4557997 chr1 108192390 C T 9.16E-05 Heart rate VAV3 intron 23583979 rs12077977 chr1 108199479 C T 1.35E-04 Multiple complex diseases VAV3 intron 17554300 rs17479604 chr1 108203647 C A 6.98E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs2494047 chr1 108212860 T C 7.00E-04 Multiple complex diseases VAV3 intron 17554300 rs12140510 chr1 108213416 C T 8.74E-04 Suicide attempts in bipolar disorder VAV3 intron 21423239 rs2494052 chr1 108218925 G T 1.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6677871 chr1 108238325 T C 5.14E-04 Parkinson's disease VAV3 intron 16252231 rs17019729 chr1 108245664 T C 4.10E-05 Hypothyroidism VAV3 intron 22493691 rs6583042 chr1 108246246 A G 5.60E-06 Hypothyroidism VAV3 intron 22493691 rs2494069 chr1 108246853 C T 4.52E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.37E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.80E-05 Hypothyroidism VAV3 intron 22493691 rs17019810 chr1 108268801 C T 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019810 chr1 108268801 C T 2.00E-06 Hypothyroidism VAV3 intron 22493691 rs17019823 chr1 108269953 A C 6.46E-04 Multiple complex diseases VAV3 intron 17554300 rs17019823 chr1 108269953 A C 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019823 chr1 108269953 A C 8.00E-09 Hypothyroidism VAV3 intron 22493691 rs17019828 chr1 108270130 T C 3.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6674340 chr1 108273631 A G 5.00E-05 Hypothyroidism VAV3 intron 22493691 rs7519428 chr1 108281720 G A 3.60E-05 Cognitive function VAV3 intron 24684796 rs12031375 chr1 108286368 A G 3.20E-05 Cognitive function VAV3 intron 24684796 rs6583045 chr1 108286971 A G 2.57E-05 Major depression (suicidal thoughts and behavior) VAV3 intron 21750702 rs41486546 chr1 108298979 T A 1.60E-05 Urinary metabolites VAV3 intron 21572414 rs12142335 chr1 108302922 G A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs7417283 chr1 108303686 C T 4.51E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7417283 chr1 108303686 C T 5.59E-06 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7514025 chr1 108307642 C T 6.52E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6690837 chr1 108312656 T C 8.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6583048 chr1 108313258 C T 5.44E-04 Glycemic traits (pregnancy) VAV3 cds-synon 23903356 rs4462178 chr1 108315137 C T 8.45E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs4914959 chr1 108319079 G A 3.76E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914960 chr1 108321313 A G 5.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7521681 chr1 108322535 G A 7.00E-07 Asthma and hay fever VAV3 intron 24388013 rs4514263 chr1 108325510 G A 3.87E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185177 chr1 108325738 G A 3.04E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.95E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 7.31E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 9.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 5.89E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 7.01E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs17020055 chr1 108336533 A C 6.50E-09 Hypothyroidism VAV3 intron 22493691 rs10494076 chr1 108338327 A G 3.10E-05 Blood Phenotypes VAV3 intron 17903294 rs17020088 chr1 108351812 T C 5.40E-09 Hypothyroidism VAV3 intron 22493691 rs4612651 chr1 108356293 C T 1.21E-04 Celiac disease VAV3 intron 23936387 rs12126655 chr1 108356820 A G 2.00E-08 Thyroid stimulating hormone VAV3 intron 24722205 rs4915076 chr1 108359505 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs4915077 chr1 108366016 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs7537000 chr1 108376302 A G 3.00E-04 Cognitive impairment induced by topiramate VAV3 intron 22091778 rs7537000 chr1 108376302 A G 2.11E-04 Celiac disease VAV3 intron 23936387 rs9787296 chr1 108382827 A G 4.66E-04 Thyroid stimulating hormone VAV3 intron 24852370 rs10494080 chr1 108402075 C A 7.37E-04 Multiple complex diseases VAV3 intron 17554300 rs10494080 chr1 108402075 C A 9.72E-05 Celiac disease VAV3 intron 23936387 rs10494081 chr1 108402103 C T 9.76E-04 Type 2 diabetes VAV3 intron 17463246 rs1360564 chr1 108411794 T C 7.58E-05 Waist-Hip Ratio VAV3 intron pha003028 rs11185191 chr1 108418552 T A 6.95E-04 Multiple complex diseases VAV3 intron 17554300 rs11185215 chr1 108450627 A G 3.96E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs345314 chr1 108462844 C T 2.14E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs1571965 chr1 108519529 C T 0.00001 HDL cholesterol particle diameter / / 23263444 rs12121990 chr1 108523670 G T 0.00035 Prostate cancer / / 23555315 rs2336645 chr1 108524174 T G 7.67E-05 AIDS progression / / 19115949 rs1219765 chr1 108541909 A G 9.77E-05 Sodium levels / / pha003093 rs12071280 chr1 108555998 T C 5.37E-04 Multiple complex diseases / / 17554300 rs1781070 chr1 108569698 G A 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12569350 chr1 108588372 G A 7.82E-04 Substance dependence / / 21818250 rs1777454 chr1 108596968 T G 8.55E-04 Substance dependence / / 21818250 rs1777478 chr1 108612220 C T 9.23E-04 Multiple complex diseases / / 17554300 rs1781064 chr1 108615524 G A 4.25E-04 Taste perception / / 22132133 rs2996918 chr1 108621812 A G 1.52E-05 Cognitive performance / / 19734545 rs10881502 chr1 108641819 T C 8.12E-04 Coronary Artery Disease / / 17634449 rs11185272 chr1 108662219 C T 5.01E-05 Information processing speed / / 21130836 rs1777450 chr1 108663295 T C 4.41E-05 Cognitive performance / / 19734545 rs665659 chr1 108663841 C G 8.26E-05 Serum metabolites / / 19043545 rs17513833 chr1 108680234 C T 6.50E-04 Amyotrophic lateral sclerosis (sporadic) SLC25A24 intron 24529757 rs10494090 chr1 108693336 A G 5.30E-13 Glioma (high-grade) SLC25A24 intron 19578366 rs559761 chr1 108700637 C A 4.58E-04 Alzheimer's disease (late onset) SLC25A24 intron 21379329 rs662590 chr1 108719572 G A 7.93E-05 Multiple complex diseases SLC25A24 intron 17554300 rs490680 chr1 108724518 A G 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs490680 chr1 108724518 A G 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs491785 chr1 108724693 G A 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs491785 chr1 108724693 G A 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs828999 chr1 108744934 G A 5.70E-05 Glioma (high-grade) / / 19578366 rs7418288 chr1 108754099 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6694641 chr1 108755582 T C 1.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6583070 chr1 108756690 G A 1.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2152560 chr1 108762012 G A 5.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11185305 chr1 108763904 C T 5.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4970822 chr1 108859231 C A 1.60E-05 White matter hyperintensity burden / / 21681796 rs4970821 chr1 108859314 T C 3.06E-07 Esophageal cancer (squamous cell) / / 22960999 rs12117427 chr1 108863863 A G 1.80E-05 White matter hyperintensity burden / / 21681796 rs949905 chr1 108870158 T C 1.90E-05 White matter hyperintensity burden / / 21681796 rs2275563 chr1 108877608 G T 1.40E-05 White matter hyperintensity burden / / 21681796 rs12404827 chr1 108888654 A G 4.60E-05 Major depressive disorder / / 21042317 rs7512836 chr1 109052161 C T 6.08E-05 Multiple complex diseases / / 17554300 rs7515114 chr1 109052264 C A 8.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6666724 chr1 109084300 C T 6.07E-04 Alzheimer's disease / / 24755620 rs1353722 chr1 109098737 A C 6.51E-04 Alzheimer's disease / / 24755620 rs1353725 chr1 109098932 A G 6.51E-04 Alzheimer's disease / / 24755620 rs11102031 chr1 109101851 C T 7.97E-04 Alzheimer's disease / / 24755620 rs943806 chr1 109156284 C T 1.62E-06 Asthma (childhood onset) FAM102B intron 23829686 rs17026815 chr1 109271037 T C 0.0007494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FNDC7 intron 23233654 rs17026815 chr1 109271037 T C 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) FNDC7 intron 23233662 rs4970810 chr1 109273610 G A 6.14E-04 Response to cytidine analogues (gemcitabine) FNDC7 intron 24483146 rs1690726 chr1 109330016 G A 6.73E-04 Multiple complex diseases STXBP3 intron 17554300 rs1149160 chr1 109336794 G C 9.90E-04 Multiple complex diseases STXBP3 intron 17554300 rs17555669 chr1 109356394 T A 0.0006625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17555669 chr1 109356394 T A 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1277216 chr1 109359231 A C 4.70E-04 Pulmonary function AK/D1 intron 23932459 rs1277213 chr1 109359502 A G 3.27E-04 Response to cytidine analogues (gemcitabine) AK/D1 intron 24483146 rs6683747 chr1 109376539 C A 6.44E-04 Amyotrophic lateral sclerosis (sporadic) AK/D1 intron 24529757 rs1277014 chr1 109386466 A G 2.76E-04 Multiple complex diseases AK/D1 intron 17554300 rs1277203 chr1 109392837 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) AK/D1 intron 23648065 rs11583007 chr1 109392853 C T 8.00E-05 Prostate cancer AK/D1 intron 21743057 rs9440631 chr1 109394524 G A 1.45E-05 Tuberculosis AK/D1 missense 22306650 rs6667820 chr1 109400568 A G 5.44E-04 Multiple complex diseases SRG7 intron 17554300 rs12752417 chr1 109400639 G T 4.47E-04 Aortic root size SRG7 intron 21223598 rs11587109 chr1 109405971 C T 9.68E-04 Acute lung injury / / 22295056 rs7523050 chr1 109417679 C A 3.70E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 4.80E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 9.90E-07 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs839854 chr1 109471634 T G 1.59E-04 Response to taxane treatment (placlitaxel) GPSM2 intron 23006423 rs12030 chr1 109472813 T C 1.90E-05 Urinary metabolites CLCC1 UTR-3 21572414 rs10607 chr1 109473017 C T 3.67E-05 Smoking quantity CLCC1 UTR-3 24665060 rs193139 chr1 109483975 T C 3.20E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 3.90E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 9.50E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs338466 chr1 109486196 A G 4.62E-05 Response to taxane treatment (placlitaxel) CLCC1 cds-synon 23006423 rs839547 chr1 109494147 A G 1.42E-04 Response to taxane treatment (placlitaxel) CLCC1 intron 23006423 rs28634276 chr1 109611326 T G 7.45E-04 Response to taxane treatment (placlitaxel) TAF13 intron 23006423 rs531842 chr1 109689314 C T 1.08E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 8.94E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 2.36E-04 Lymphocyte counts KIAA1324 intron 22286170 rs648673 chr1 109727284 C G 4.26E-04 Multiple complex diseases KIAA1324 intron 17554300 rs4268379 chr1 109778237 C T 0.000000732 Coronary artery disease SARS intron 23202125 rs611060 chr1 109782190 C T 2.55E-04 Obesity (extreme) / / 21935397 rs4246519 chr1 109783555 A G 1.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs586254 chr1 109784781 A G 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs585362 chr1 109789795 C T 7.97E-09 Triglycerides / / 19060911 rs585362 chr1 109789795 C T 1.29E-20 Cholesterol,total / / 23063622 rs585362 chr1 109789795 C T 3.76E-25 LDL cholesterol / / 23063622 rs10858082 chr1 109798721 G A 7.00E-05 Response to statin therapy CELSR2 intron 20339536 rs10858082 chr1 109798721 G A 1.80E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs10858082 chr1 109798721 G A 1.28E-20 LDL cholesterol CELSR2 intron 23063622 rs10858082 chr1 109798721 G A 2.64E-23 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.06E-14 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.23E-14 LDL cholesterol CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 9.17E-07 Non-small cell lung cancer (survival) CELSR2 intron 23704207 rs6698843 chr1 109806834 C T 2.91E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6698843 chr1 109806834 C T 7.82E-15 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 1.15E-14 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 3.71E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6657811 chr1 109807283 A T 2.00E-08 LDL cholesterol CELSR2 intron 18262040 rs6657811 chr1 109807283 A T 6.60E-07 Response to statin therapy CELSR2 intron 20339536 rs6657811 chr1 109807283 A T 2.40E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs6657811 chr1 109807283 A T 3.02E-30 LDL cholesterol CELSR2 intron 23063622 rs6657811 chr1 109807283 A T 8.92E-31 Cholesterol,total CELSR2 intron 23063622 rs41279714 chr1 109813485 C T 7.08E-12 Metabolite levels CELSR2 intron 22286219 rs17035665 chr1 109813719 C T 0.000000283 Cholesterol,total CELSR2 intron 23063622 rs17035665 chr1 109813719 C T 4.19E-08 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.19E-04 Type 2 diabetes CELSR2 intron 17463246 rs4970834 chr1 109814880 C T 1.44E-05 Multiple complex diseases CELSR2 intron 17554300 rs4970834 chr1 109814880 C T 3.43E-04 Coronary Artery Disease CELSR2 intron 17634449 rs4970834 chr1 109814880 C T 1.70E-06 Cardiovascular disease CELSR2 intron 18179892 rs4970834 chr1 109814880 C T 3.00E-11 LDL cholesterol CELSR2 intron 18262040 rs4970834 chr1 109814880 C T 9.53E-09 Triglycerides CELSR2 intron 19060911 rs4970834 chr1 109814880 C T 2.00E-14 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 4.60E-17 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 2.00E-08 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 5.18E-09 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 4.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 intron 20032323 rs4970834 chr1 109814880 C T 4.10E-07 Response to statin therapy CELSR2 intron 20339536 rs4970834 chr1 109814880 C T 1.29E-10 Lipid levels CELSR2 intron 20370913 rs4970834 chr1 109814880 C T 6.85E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 20442857 rs4970834 chr1 109814880 C T 4.41E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs4970834 chr1 109814880 C T 0.000000175 HDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.78E-64 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 4.70E-59 Cholesterol,total CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 0.000157 LDL cholesterol CELSR2 intron 23236364 rs611917 chr1 109815252 A G 1.50E-10 LDL cholesterol CELSR2 intron 18262040 rs611917 chr1 109815252 A G 9.63E-13 Triglycerides CELSR2 intron 19060911 rs611917 chr1 109815252 A G 2.20E-09 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 2.90E-12 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 1.97E-06 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 6.69E-07 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 2.50E-05 Response to statin therapy CELSR2 intron 20339536 rs611917 chr1 109815252 A G 4.71E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs611917 chr1 109815252 A G 1.19E-39 Cholesterol,total CELSR2 intron 23063622 rs611917 chr1 109815252 A G 4.78E-40 LDL cholesterol CELSR2 intron 23063622 rs611917 chr1 109815252 A G 2.49E-07 LDL lipoproteins CELSR2 intron pha002902 rs7528419 chr1 109817192 A G 2.41E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 8.09E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs7528419 chr1 109817192 A G 6.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs7528419 chr1 109817192 A G 1.65E-08 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs7528419 chr1 109817192 A G 1.00E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs7528419 chr1 109817192 A G 1.12E-11 Metabolite levels CELSR2 UTR-3 22286219 rs7528419 chr1 109817192 A G 1.69E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 3.44E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 6.28E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 1.48E-68 LDL cholesterol CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 8.70E-67 Cholesterol,total CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 9.02E-09 HDL cholesterol CELSR2 UTR-3 23063622 rs11102967 chr1 109817245 C A,G,T 0.000000411 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.20E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs12740374 chr1 109817590 G T 2.00E-42 LDL cholesterol CELSR2 UTR-3 19060906 rs12740374 chr1 109817590 G T 1.82E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 4.70E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs12740374 chr1 109817590 G T 5.50E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs12740374 chr1 109817590 G T 9.00E-29 Coronary heart disease CELSR2 UTR-3 21347282 rs12740374 chr1 109817590 G T 6.61E-14 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs12740374 chr1 109817590 G T 8.70E-09 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs12740374 chr1 109817590 G T 1.46E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs12740374 chr1 109817590 G T 3.60E-13 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 8.00E-16 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 1.24E-11 Metabolite levels CELSR2 UTR-3 22286219 rs12740374 chr1 109817590 G T 2.89E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 5.06E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 7.47E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 1.35E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.00E-66 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.75E-69 LDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 2.00E-22 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 23118302 rs12740374 chr1 109817590 G T 1.63E-17 LDL cholesterol CELSR2 UTR-3 23236364 rs12740374 chr1 109817590 G T 4.43E-13 Cholesterol,total CELSR2 UTR-3 23236364 rs660240 chr1 109817838 T C 3.80E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs660240 chr1 109817838 T C 8.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs660240 chr1 109817838 T C 1.00E-26 LDL cholesterol CELSR2 UTR-3 20864672 rs660240 chr1 109817838 T C 2.00E-22 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs660240 chr1 109817838 T C 7.39E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs660240 chr1 109817838 T C 2.38E-12 Metabolite levels CELSR2 UTR-3 22286219 rs660240 chr1 109817838 T C 4.09E-11 LDL cholesterol CELSR2 UTR-3 23063622 rs660240 chr1 109817838 T C 6.59E-12 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 3.10E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs629301 chr1 109818306 G T 2.01E-08 Triglycerides CELSR2 UTR-3 19060911 rs629301 chr1 109818306 G T 1.76E-08 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 6.50E-09 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 5.40E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs629301 chr1 109818306 G T 1.00E-170 LDL cholesterol CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 6.00E-131 Cholesterol,total CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 1.17E-11 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs629301 chr1 109818306 G T 1.78E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs629301 chr1 109818306 G T 2.62E-12 Metabolite levels CELSR2 UTR-3 22286219 rs629301 chr1 109818306 G T 1.19E-07 Coronary heart disease CELSR2 UTR-3 22319020 rs629301 chr1 109818306 G T 1.44E-43 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 1.57E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 5.68E-38 Cholesterol,total CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 0.00016 Coronary artery calcification CELSR2 UTR-3 23727086 rs629301 chr1 109818306 G T 2.00E-170 Cholesterol,total CELSR2 UTR-3 24097068 rs629301 chr1 109818306 G T 5.00E-241 LDL cholesterol CELSR2 UTR-3 24097068 rs646776 chr1 109818530 C T 3.00E-29 LDL cholesterol / / 18193044 rs646776 chr1 109818530 C T 4.80E-20 LDL cholesterol / / 18262040 rs646776 chr1 109818530 C T 2.00E-12 LDL cholesterol / / 19060910 rs646776 chr1 109818530 C T 8.00E-23 LDL cholesterol / / 19060911 rs646776 chr1 109818530 C T 9.00E-22 Cholesterol,total / / 19060911 rs646776 chr1 109818530 C T 8.00E-12 Myocardial infarction (early onset) / / 19198609 rs646776 chr1 109818530 C T 3.50E-24 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 4.90E-19 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 1.03E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 2.40E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 1.20E-32 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.60E-13 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.77E-53 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.20E-20 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.40E-27 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 3.70E-39 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 4.97E-46 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 5.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.29E-19 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 7.10E-11 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 9.20E-12 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs646776 chr1 109818530 C T 4.00E-06 Response to statin therapy / / 20339536 rs646776 chr1 109818530 C T 2.00E-30 Progranulin levels / / 21087763 rs646776 chr1 109818530 C T 2.41E-06 Cardiovascular disease risk factors / / 21239051 rs646776 chr1 109818530 C T 8.00E-12 Coronary heart disease / / 21347282 rs646776 chr1 109818530 C T 6.00E-10 Coronary heart disease / / 21378988 rs646776 chr1 109818530 C T 9.37E-09 Cardiovascular disease risk factors / / 21943158 rs646776 chr1 109818530 C T 3.10E-17 Coronary heart disease / / 21966275 rs646776 chr1 109818530 C T 2.15E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs646776 chr1 109818530 C T 2.65E-12 Metabolite levels / / 22286219 rs646776 chr1 109818530 C T 1.20E-68 Cholesterol,total / / 23063622 rs646776 chr1 109818530 C T 6.19E-09 HDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 7.90E-74 LDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 0.00000024 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 0.000095 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 3.90E-41 Apolipoprotein B levels / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 LDL cholesterol / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs646776 chr1 109818530 C T 3.96E-08 Cholesterol,total / / 23236364 rs646776 chr1 109818530 C T 0.00021 Coronary artery calcification / / 23727086 rs646776 chr1 109818530 C T 2.19E-12 LDL lipoproteins / / pha002902 rs646776 chr1 109818530 C T 7.39E-05 Cholesterol / / pha003073 rs646776 chr1 109818530 C T 2.68E-05 Cholesterol / / pha003078 rs3902354 chr1 109819296 C A 1.00E-08 Cholesterol,total / / 24886709 rs55882046 chr1 109819981 C T 2.27E-10 Cholesterol,total / / 23063622 rs55882046 chr1 109819981 C T 6.94E-10 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.02E-08 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.96E-09 Cholesterol,total / / 23063622 rs583104 chr1 109821307 G T 1.15E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 2.18E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs583104 chr1 109821307 G T 5.37E-12 Metabolite levels / / 22286219 rs583104 chr1 109821307 G T 0.000000141 HDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 3.58E-67 LDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 6.01E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 4.80E-14 Lipid levels / / 18193043 rs602633 chr1 109821511 T G 5.70E-14 LDL cholesterol / / 18262040 rs602633 chr1 109821511 T G 2.21E-07 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 3.15E-08 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 9.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs602633 chr1 109821511 T G 8.40E-08 Response to statin therapy / / 20339536 rs602633 chr1 109821511 T G 5.00E-08 LDL cholesterol / / 21977987 rs602633 chr1 109821511 T G 1.38E-16 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs602633 chr1 109821511 T G 5.44E-12 Metabolite levels / / 22286219 rs602633 chr1 109821511 T G 0.000000128 HDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 5.86E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 6.92E-65 LDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 0.0000342 Coronary artery disease (CAD) (females) / / 23202125 rs602633 chr1 109821511 T G 1.32E-18 Coronary artery disease (CAD) (males) / / 23202125 rs602633 chr1 109821511 T G 2.23E-16 Coronary artery disease with myocardial infarction / / 23202125 rs602633 chr1 109821511 T G 2.77E-20 Coronary artery disease (CAD) age <=50 / / 23202125 rs602633 chr1 109821511 T G 4.97E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs602633 chr1 109821511 T G 1.00E-08 Coronary artery disease / / 24262325 rs1277930 chr1 109822143 G A 5.75E-12 Metabolite levels / / 22286219 rs1277930 chr1 109822143 G A 2.64E-12 LDL cholesterol / / 23063622 rs1277930 chr1 109822143 G A 9.43E-14 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 9.00E-08 Type 2 diabetes / / 17463246 rs599839 chr1 109822166 G A 2.19E-05 Multiple complex diseases / / 17554300 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 17634449 rs599839 chr1 109822166 G A 1.00E-07 LDL cholesterol / / 18179892 rs599839 chr1 109822166 G A 6.00E-33 LDL cholesterol / / 18193043 rs599839 chr1 109822166 G A 3.00E-21 Lipid levels / / 18193044 rs599839 chr1 109822166 G A 1.00E-33 LDL cholesterol / / 18262040 rs599839 chr1 109822166 G A 4.31E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 4.79E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 6.00E-08 Response to statin therapy / / 20339536 rs599839 chr1 109822166 G A 3.70E-16 Lipid levels / / 20370913 rs599839 chr1 109822166 G A 3.00E-15 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs599839 chr1 109822166 G A 2.82E-04 Cardiovascular disease risk factors / / 21239051 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 21347282 rs599839 chr1 109822166 G A 3.00E-10 Coronary heart disease / / 21378990 rs599839 chr1 109822166 G A 2.00E-19 Metabolite levels / / 21909109 rs599839 chr1 109822166 G A 1.12E-08 Cardiovascular disease risk factors / / 21943158 rs599839 chr1 109822166 G A 2.63E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs599839 chr1 109822166 G A 4.13E-12 Metabolite levels / / 22286219 rs599839 chr1 109822166 G A 2.89E-10 Pericardial fat / / 22589742 rs599839 chr1 109822166 G A 0.000000153 HDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 1.21E-57 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 1.43E-59 LDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 0.000000556 HDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 2.94E-168 LDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 4.12E-130 Cholesterol,total / / 23202125 rs599839 chr1 109822166 G A 1.00E-08 Coronary artery disease or ischemic stroke / / 24262325 rs599839 chr1 109822166 G A 8.00E-17 Coronary artery disease or large artery stroke / / 24262325 rs35358959 chr1 109824250 G A 6.63E-11 Metabolite levels PSRC1 cds-synon 22286219 rs657420 chr1 109826136 C T 3.94E-16 LDL cholesterol / / 23063622 rs657420 chr1 109826136 C T 8.38E-15 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 2.07E-12 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 4.11E-16 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.05E-19 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.81E-21 Cholesterol,total / / 23063622 rs41306199 chr1 109835163 C T 1.43E-20 Cholesterol,total MYBPHL UTR-3 23063622 rs41306199 chr1 109835163 C T 8.49E-18 LDL cholesterol MYBPHL UTR-3 23063622 rs12127701 chr1 109838264 A G 7.31E-11 Cholesterol,total MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 8.07E-12 LDL cholesterol MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 0.000271 Coronary artery disease MYBPHL intron 23202125 rs629001 chr1 109838918 C T 2.87E-12 Cholesterol,total MYBPHL missense 23063622 rs629001 chr1 109838918 C T 6.36E-13 LDL cholesterol MYBPHL missense 23063622 rs7515901 chr1 109839896 C T 0.0000073 Coronary artery disease MYBPHL intron 23202125 rs592107 chr1 109848726 A T 8.16E-05 Cognitive test performance MYBPHL intron 20125193 rs413582 chr1 109851126 C T 1.02E-09 Cholesterol,total / / 23063622 rs413582 chr1 109851126 C T 3.67E-11 LDL cholesterol / / 23063622 rs2228604 chr1 109884775 T G 4.67E-04 Multiple complex diseases SORT1 cds-synon 17554300 rs4970843 chr1 109887191 T C 0.00032 LDL cholesterol (female) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol (male) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.83E-09 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 1.52E-11 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 4.71E-13 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.97E-11 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.98E-09 Cholesterol,total SORT1 intron 23063622 rs1149175 chr1 109922377 G A 4.48E-04 Multiple complex diseases SORT1 intron 17554300 rs10858092 chr1 109943893 C T 2.69E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs7518013 chr1 109944078 T C 2.91E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs17586966 chr1 109955569 T C 1.61E-04 Type 2 diabetes PSMA5 intron 17463246 rs17586966 chr1 109955569 T C 4.17E-25 Narcolepsy PSMA5 intron 19629137 rs10776807 chr1 109956156 G A,C 2.42E-04 Multiple complex diseases PSMA5 intron 17554300 rs4970760 chr1 109985439 A G 2.97E-04 Multiple complex diseases / / 17554300 rs1933182 chr1 109999838 A C 1.00E-07 Chronic kidney disease / / 20383146 rs1933182 chr1 109999838 A C 3.18E-07 Chronic kidney disease / / 22479191 rs10857787 chr1 110010289 C T 9.44E-04 Multiple complex diseases SYPL2 intron 17554300 rs12049330 chr1 110031188 T G 6.00E-06 Major depressive disorder ATXN7L2 intron 20125088 rs1043274 chr1 110042444 C T 9.00E-06 Obesity-related traits CYB561D1 UTR-3 23251661 rs6677291 chr1 110056126 C T 9.35E-05 Alcohol withdrawal symptoms / / 22072270 rs528815 chr1 110061479 C T 1.50E-05 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 1.24E-04 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 9.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs475381 chr1 110062040 A T 1.16E-05 Multiple complex diseases / / 17554300 rs2692705 chr1 110063313 G C 1.41E-05 Multiple complex diseases / / 17554300 rs6537803 chr1 110063540 G A 7.54E-05 Alcohol withdrawal symptoms / / 22072270 rs528077 chr1 110065752 C A 1.43E-04 Multiple complex diseases / / 17554300 rs529773 chr1 110065906 A G 1.03E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 2.30E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 4.03E-04 Lymphocyte counts / / 22286170 rs558370 chr1 110071113 A G 2.76E-04 Multiple complex diseases / / 17554300 rs7536291 chr1 110075608 G A 4.29E-05 Multiple complex diseases / / 17554300 rs1434285 chr1 110080809 G T 2.26E-09 Lymphocyte counts / / 22286170 rs7550711 chr1 110082886 C T 5.00E-06 Stearic acid (18:0) plasma levels GPR61 intron 23362303 rs6537837 chr1 110119732 C T 1.00E-06 Major depressive disorder G/I3 intron 20125088 rs17024258 chr1 110147321 C T 9.00E-12 Obesity G/T2 intron 23563607 rs510619 chr1 110157364 C T 2.03E-04 Amyotrophic Lateral Sclerosis G/T2 nearGene-5 17362836 rs2071487 chr1 110233081 T C 2.00E-05 Urinary metabolites GSTM1 cds-synon 21572414 rs10857796 chr1 110235032 A G 6.68E-05 Femoral neck bone geometry GSTM1 intron 22087292 rs11101992 chr1 110266754 A C 0.00048 Coronary artery calcification / / 23727086 rs3814309 chr1 110277403 T C 4.01E-09 Lymphocyte counts GSTM3 UTR-3 22286170 rs146952826 chr1 110280921 C T 0.0000044 Breast cancer(er negative) GSTM3 missense 23555315 rs11591171 chr1 110298107 A C 3.14E-05 Cognitive test performance EPS8L3 intron 20125193 rs11581614 chr1 110329003 T C 2.00E-04 Systolic blood pressure / / 19430483 rs11581614 chr1 110329003 T C 0.00081417 Sarcoidosis / / 22952805 rs17024863 chr1 110331262 C T 8.45E-04 Multiple complex diseases / / 17554300 rs10494112 chr1 110352477 A G 1.67E-14 Paget's disease / / 20436471 rs10494112 chr1 110352477 A G 7.00E-35 Paget's disease / / 21623375 rs3887891 chr1 110358890 C T 2.10E-05 Lipid levels / / 18193043 rs499345 chr1 110361682 C A 3.02E-16 Paget's disease / / 20436471 rs484959 chr1 110366083 T C 5.00E-24 Paget's disease / / 20436471 rs525566 chr1 110375695 G A 7.41E-05 Parkinson's disease / / 17052657 rs6537883 chr1 110405271 T C 3.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs6695237 chr1 110415626 G A 4.00E-05 Coronary Artery Disease / / 17634449 rs453577 chr1 110426778 G A 6.17E-04 Multiple complex diseases / / 17554300 rs333960 chr1 110439480 C T 2.00E-07 Obesity-related traits / / 23251661 rs185460835 chr1 110447555 A T 0.00082646 Sarcoidosis / / 22952805 rs333949 chr1 110451043 C T 7.63E-06 Obesity-related traits / / 23251661 rs333951 chr1 110451690 T C 7.71E-05 Serum metabolites CSF1 nearGene-5 19043545 rs333970 chr1 110466338 C A 0.000740986 Hypertension (early onset hypertension) CSF1 cds-synon 22479346 rs333947 chr1 110470764 G A 9.55E-04 Multiple complex diseases CSF1 intron 17554300 rs7540934 chr1 110483773 G A 3.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs390923 chr1 110499669 A G 5.90E-04 Endometriosis / / 23104006 rs11577194 chr1 110500175 T C 6.54E-04 Type 2 diabetes / / 17463246 rs1466788 chr1 110618730 A G 3.00E-16 Blood metabolite levels / / 24816252 rs17025426 chr1 110645327 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs493039 chr1 110646246 A T 4.72E-04 Smoking cessation / / 24665060 rs11576956 chr1 110646858 A G 3.00E-04 Endometriosis / / 23104006 rs514341 chr1 110652880 C T 6.00E-06 Alcohol dependence (age at onset) / / 24962325 rs4641310 chr1 110654498 G A 2.01E-05 Type 2 diabetes / / 17463246 rs2168144 chr1 110657532 G A 1.42E-05 Type 2 diabetes / / 17463246 rs11102055 chr1 110662374 A G 1.29E-04 Type 2 diabetes / / 17463246 rs11102058 chr1 110666410 A G 1.70E-05 Type 2 diabetes / / 17463246 rs7518801 chr1 110677921 A C 3.58E-04 Alzheimer's disease (late onset) / / 21379329 rs924181 chr1 110680114 G A 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs4839165 chr1 110681542 T G 4.59E-04 Alzheimer's disease (late onset) / / 21379329 rs10494113 chr1 110684287 T C 4.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1123250 chr1 110686356 A G 9.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs975512 chr1 110690577 G A 6.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2002384 chr1 110698651 A G 3.59E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4838931 chr1 110701071 T C 2.26E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs1010891 chr1 110712154 G A 2.08E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs6689641 chr1 110720400 A G 7.10E-04 Pulmonary function SLC6A17 intron 23932459 rs12128502 chr1 110723699 G A 1.50E-05 Urinary metabolites SLC6A17 intron 21572414 rs11802526 chr1 110724507 G A 4.03E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4839223 chr1 110728459 A G 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs4839225 chr1 110729248 C T 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2011688 chr1 110729404 C T 0.00000442 VLDL cholesterol particle diameter SLC6A17 intron 23263444 rs495959 chr1 110732133 C T 1.26E-05 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs17025524 chr1 110733674 C T 2.20E-06 Urinary metabolites SLC6A17 intron 21572414 rs2784140 chr1 110738296 G A 6.12E-05 Cytomegalovirus antibody response SLC6A17 cds-synon 21993531 rs2784140 chr1 110738296 G A 4.26E-06 Acute lymphoblastic leukemia (B-cell precursor) SLC6A17 cds-synon 23996088 rs642655 chr1 110738990 A C 4.43E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2761442 chr1 110739864 A G 4.86E-05 Cytomegalovirus antibody response SLC6A17 intron 21993531 rs958798 chr1 110770223 G T 6.27E-04 Parkinson's disease KCNC4 intron 17052657 rs958798 chr1 110770223 G T 4.00E-07 Self-rated health KCNC4 intron 20707712 rs12138917 chr1 110791822 C T 8.71E-04 Multiple complex diseases / / 17554300 rs2209158 chr1 110795018 A C 1.10E-05 Urinary metabolites / / 21572414 rs4839282 chr1 110814129 T A 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs6682717 chr1 110815623 G C 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs3904626 chr1 110816491 T C 1.75E-04 Cholesterol / / 17255346 rs3904626 chr1 110816491 T C 7.46E-04 Multiple complex diseases / / 17554300 rs2885145 chr1 110817219 A G 1.75E-04 Cholesterol / / 17255346 rs2885145 chr1 110817219 A G 6.03E-04 Multiple complex diseases / / 17554300 rs2361047 chr1 110819387 A G 1.75E-04 Cholesterol / / 17255346 rs2361047 chr1 110819387 A G 6.08E-04 Multiple complex diseases / / 17554300 rs11102076 chr1 110819974 C T 1.75E-04 Cholesterol / / 17255346 rs11102076 chr1 110819974 C T 9.39E-04 Multiple complex diseases / / 17554300 rs3849178 chr1 110820295 A G 1.75E-04 Cholesterol / / 17255346 rs3849178 chr1 110820295 A G 5.60E-04 Multiple complex diseases / / 17554300 rs3820662 chr1 110821383 G A 8.20E-05 Cholesterol / / 17255346 rs3820662 chr1 110821383 G A 7.76E-04 Multiple complex diseases / / 17554300 rs4838977 chr1 110823116 G A 1.75E-04 Cholesterol / / 17255346 rs4838977 chr1 110823116 G A 5.49E-04 Multiple complex diseases / / 17554300 rs638531 chr1 110829417 G A 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs638531 chr1 110829417 G A 2.42E-05 Alzheimer's disease / / 22832961 rs626971 chr1 110831331 T C 4.25E-04 Insulin resistance LOC440600 intron 21901158 rs637686 chr1 110839445 A T 3.70E-05 Immunoglobulin A LOC440600 intron 20694011 rs4112315 chr1 110842415 C T 6.51E-04 Multiple complex diseases LOC440600 intron 17554300 rs532121 chr1 110844894 T C 2.12E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs650290 chr1 110846510 T A 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs473411 chr1 110846616 C T 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs17358933 chr1 110849205 G A 1.62E-04 Multiple complex diseases LOC440600 intron 17554300 rs17358933 chr1 110849205 G A 8.37E-04 Alcohol dependence LOC440600 intron 21314694 rs9645348 chr1 110854963 G A 5.50E-06 Urinary metabolites LOC440600 intron 21572414 rs1466806 chr1 110861927 C T 8.40E-06 Urinary metabolites LOC440600 intron 21572414 rs1160505 chr1 110863039 G C 2.64E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs4838992 chr1 110864149 A G 6.17E-04 Multiple sclerosis LOC440600 intron 17660530 rs12568839 chr1 110877085 C T 1.54E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs12022711 chr1 110880586 C T 6.92E-05 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs1572263 chr1 110885736 G A 7.81E-04 Suicide attempts in bipolar disorder RBM15 intron 21423239 rs4501839 chr1 110895987 T G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6669004 chr1 110906780 G A 5.22E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12028977 chr1 110907716 C T 5.96E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6673423 chr1 110916018 T C 6.50E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12126890 chr1 110922814 G A 3.08E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs814759 chr1 110930882 C G 5.17E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs7556440 chr1 110931112 A G 4.56E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6657333 chr1 110960311 T G 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6537657 chr1 110961722 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11102104 chr1 110966784 T G 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2132989 chr1 110967354 A T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6687382 chr1 110969946 C T 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12048154 chr1 110974489 A G 2.10E-05 Urinary metabolites / / 21572414 rs7534322 chr1 110989088 A C 3.38E-04 Alzheimer's disease / / 17998437 rs62623571 chr1 110996652 C T 0.00028 Breast cancer PROK1 missense 23555315 rs11102110 chr1 111003201 C T 9.47E-05 Alzheimer's disease / / 22832961 rs12407530 chr1 111003777 T C 2.40E-05 Urinary metabolites / / 21572414 rs12407530 chr1 111003777 T C 8.34E-05 Alzheimer's disease / / 22832961 rs4839431 chr1 111033809 T C 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs6537663 chr1 111034818 T C 2.21E-04 Fibrinogen / / 17255346 rs12031009 chr1 111040235 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7543509 chr1 111051999 A G 5.34E-05 Parkinson's disease / / 17052657 rs1281179 chr1 111056389 T C 3.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17025957 chr1 111062049 C T 3.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17025978 chr1 111069611 G A 6.60E-06 Type 2 diabetes / / 17463248 rs17025982 chr1 111070294 T C 7.80E-06 Type 2 diabetes / / 17463248 rs7522150 chr1 111077162 G T 4.75E-04 Myopia (pathological) / / 21095009 rs7553144 chr1 111084462 C T 6.53E-04 Myopia (pathological) / / 21095009 rs2790372 chr1 111087124 C A 7.50E-05 Type 2 diabetes / / 17463248 rs2790372 chr1 111087124 C A 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2799765 chr1 111088151 T C 8.50E-05 Type 2 diabetes / / 17463248 rs1626078 chr1 111089239 C T 8.90E-05 Type 2 diabetes / / 17463248 rs1625029 chr1 111089405 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1622675 chr1 111089642 A T 8.30E-05 Type 2 diabetes / / 17463248 rs1627572 chr1 111089670 G A 8.90E-05 Type 2 diabetes / / 17463248 rs1281173 chr1 111094802 C T 8.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 1.74E-04 Multiple complex diseases / / 17554300 rs903050 chr1 111098766 T C 8.01E-05 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 8.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs6537668 chr1 111100562 T C 4.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12407862 chr1 111102214 C T 3.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs6656346 chr1 111103688 G A 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs1105101 chr1 111104913 C G 5.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs6537671 chr1 111106530 T C 5.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs7526907 chr1 111111368 A G 7.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs923826 chr1 111114154 A G 0.000706 Salmonella-induced pyroptosis / / 22837397 rs17684735 chr1 111131424 T C 2.87E-05 Birth weight / / 17255346 rs4839069 chr1 111137811 A G 6.05E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KC/2 intron 24023788 rs41404544 chr1 111142811 T C 5.58E-05 Response to metformin KC/2 intron 21186350 rs12047887 chr1 111144007 G A 2.81E-05 Cognitive test performance KC/2 intron 20125193 rs4839542 chr1 111155595 C T 1.25E-05 Cognitive test performance KC/2 intron 20125193 rs2172514 chr1 111166960 G A 9.19E-04 Response to TNF antagonist treatment KC/2 intron 21061259 rs41451648 chr1 111176693 T C 3.69E-04 Type 2 diabetes / / 17463246 rs41451648 chr1 111176693 T C 1.24E-04 Multiple complex diseases / / 17554300 rs7513434 chr1 111186329 C T 2.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs2797533 chr1 111186784 C T 4.60E-04 Alcohol dependence / / 20201924 rs12084550 chr1 111198184 T C 2.20E-05 Urinary metabolites / / 21572414 rs2640487 chr1 111206885 C T 3.20E-04 Alcohol dependence / / 20201924 rs1319782 chr1 111211533 C T 8.60E-04 Alcohol dependence / / 20201924 rs2640480 chr1 111213248 C A 4.30E-04 Alcohol dependence / / 20201924 rs12061304 chr1 111237685 A G 1.00E-06 Panic disorder / / 19165232 rs12061304 chr1 111237685 A G 0.0000613 Panic disorder / / 23149450 rs12061304 chr1 111237685 A G 6.13E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11102149 chr1 111240982 G C 3.14E-06 Panic disorder / / 19165232 rs11102149 chr1 111240982 G C 0.0000615 Panic disorder / / 23149450 rs11102149 chr1 111240982 G C 6.15E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12085135 chr1 111243375 C G 4.69E-04 Fibrinogen / / 17255346 rs12085135 chr1 111243375 C G 5.04E-04 Multiple complex diseases / / 17554300 rs343602 chr1 111257724 A G 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343602 chr1 111257724 A G 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343604 chr1 111258770 T C 4.32E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs4839556 chr1 111262340 G A 3.60E-04 Myasthenia gravis / / 23055271 rs343614 chr1 111276629 G A 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs343778 chr1 111281285 A G 0.00002168 Sarcoidosis / / 22952805 rs41453452 chr1 111295050 G C 3.09E-04 Alcohol dependence / / 21314694 rs420033 chr1 111295674 G A 6.17E-05 Alcohol dependence / / 19581569 rs440156 chr1 111295948 G A 4.23E-04 Type 2 diabetes / / 17463246 rs508446 chr1 111309830 C T 4.38E-04 Type 2 diabetes / / 17463246 rs574508 chr1 111311541 C T 3.49E-04 Type 2 diabetes / / 17463246 rs528752 chr1 111312272 A G 3.58E-04 Type 2 diabetes / / 17463246 rs526874 chr1 111312489 T C 6.31E-04 Type 2 diabetes / / 17463246 rs488147 chr1 111319892 A G 9.17E-04 Type 2 diabetes / / 17463246 rs1999511 chr1 111322419 C A 6.60E-05 Myasthenia gravis / / 23055271 rs343810 chr1 111330896 C T 8.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs343819 chr1 111342490 C T 1.50E-04 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 8.00E-06 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 7.98E-06 Alcoholism / / pha002893 rs518785 chr1 111359802 G A 1.57E-11 Lymphocyte counts / / 22286170 rs6685538 chr1 111393622 G A 4.00E-04 Alcohol dependence / / 20201924 rs6677149 chr1 111393713 T A 8.64E-04 Type 2 diabetes / / 17846124 rs6677149 chr1 111393713 T A 4.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688638 chr1 111394866 T C 3.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688644 chr1 111395110 T C 4.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs12566518 chr1 111395388 G T 4.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs4631693 chr1 111396088 C T 3.10E-04 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.50E-05 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.53E-05 Alcoholism / / pha002892 rs718463 chr1 111396606 G A 2.30E-04 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.30E-05 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.28E-05 Alcoholism / / pha002892 rs12730405 chr1 111396915 A G 2.80E-04 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.40E-05 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.44E-05 Alcoholism / / pha002892 rs6672672 chr1 111397090 C T 3.10E-04 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.20E-05 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.22E-05 Alcoholism / / pha002892 rs6687919 chr1 111397176 T G 1.50E-04 Alcohol dependence / / 20201924 rs6687919 chr1 111397176 T G 4.40E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 1.50E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 4.40E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 1.70E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 4.80E-04 Alcohol dependence / / 20201924 rs11102170 chr1 111401239 T C 5.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs17637944 chr1 111401704 T C 2.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs6696248 chr1 111404291 T C 4.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs6701134 chr1 111406899 A G 2.90E-04 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.60E-05 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.65E-05 Alcoholism / / pha002892 rs7513168 chr1 111412912 T C 1.50E-05 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.90E-04 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.49E-05 Alcoholism / / pha002893 rs2885805 chr1 111417915 C A 5.00E-06 Cytomegalovirus antibody response CD53 intron 21993531 rs2885805 chr1 111417915 C A 0.000000215 Tuberculosis with late age of onset CD53 intron 22551897 rs1494320 chr1 111422188 T C 0.00000279 Tuberculosis with late age of onset CD53 intron 22551897 rs4839583 chr1 111433622 C T 1.33E-04 Multiple complex diseases CD53 intron 17554300 rs2070748 chr1 111434711 C T 2.35E-05 Multiple complex diseases CD53 intron 17554300 rs1712675 chr1 111463053 G C 3.16E-04 Multiple complex diseases / / 17554300 rs12567355 chr1 111463624 G A 9.00E-06 Obesity-related traits / / 23251661 rs1774766 chr1 111466602 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1774766 chr1 111466602 T C 1.38E-05 Body Mass Index / / pha003021 rs1418425 chr1 111468886 T C 0.00000964 Aging / / 22445811 rs1418425 chr1 111468886 T C 0.0000535 Tuberculosis with late age of onset / / 22551897 rs12724986 chr1 111595360 T A 7.08E-04 Alzheimer's disease / / 22005930 rs12087782 chr1 111602976 A T 8.11E-04 Alzheimer's disease / / 22005930 rs12752511 chr1 111641712 A G 8.93E-04 Alzheimer's disease / / 22005930 rs11102212 chr1 111642031 A G 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17026872 chr1 111646770 G A 8.98E-04 Alzheimer's disease / / 22005930 rs325894 chr1 111652548 T C 2.87E-05 Bipolar disorder / / 21771265 rs325921 chr1 111664343 A G 2.74E-05 Bipolar disorder DRAM2 intron 21771265 rs1335645 chr1 111684276 A G 7.00E-09 Liver enzyme levels (gamma-glutamyl transferase) CEPT1 intron 22001757 rs17026995 chr1 111706368 A G 5.85E-04 Multiple complex diseases CEPT1 intron 17554300 rs608881 chr1 111730901 C T 4.90E-04 Type 2 diabetes DENND2D cds-synon 17463246 rs2764546 chr1 111762482 G A 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2182114 chr1 111784227 C T 9.00E-04 Type 2 diabetes and 6 quantitative traits CHI3L2 intron 17848626 rs2182114 chr1 111784227 C T 8.20E-05 Lipid traits CHI3L2 intron 17903299 rs942697 chr1 111791503 G C 5.02E-15 Lymphocyte counts / / 22286170 rs6691256 chr1 111796627 C A 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17654531 chr1 111799685 A G 1.16E-05 Parkinson's disease / / pha002868 rs4838896 chr1 111821777 T C 5.87E-06 Nephrolithiasis / / 22396660 rs12027550 chr1 111821946 C G 8.84E-05 Longevity / / 20304771 rs4323713 chr1 111823220 G T 4.70E-04 Crohn's disease RP11-165H20.1 intron 17684544 rs4240529 chr1 111824744 A G 8.32E-06 Paget's disease / / 20436471 rs12401767 chr1 111829797 G A 3.36E-05 Nephrolithiasis / / 22396660 rs3806448 chr1 111832205 G A 1.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 4.96E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 2.35E-05 Nephrolithiasis / / 22396660 rs4240530 chr1 111853581 C T 8.40E-04 Alcohol dependence CHIA intron 20201924 rs4839122 chr1 111854207 T C 5.05E-04 Alcohol dependence CHIA intron 21314694 rs11590452 chr1 111863942 C T 7.06E-04 Multiple complex diseases / / 17554300 rs11102249 chr1 111864700 G A 7.17E-08 Metabolite levels / / 23281178 rs12029516 chr1 111884013 C T 8.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9645351 chr1 111894870 G A 2.49E-04 Response to cytadine analogues (cytosine arabinoside) C1orf88 UTR-3 24483146 rs2050605 chr1 111903304 T C 3.89E-05 Vitiligo / / 19890347 rs17027501 chr1 111905989 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1764807 chr1 111956206 C T 6.75E-04 Type 2 diabetes / / 17463246 rs1419093 chr1 111962152 T C 0.000294 Salmonella-induced pyroptosis OVGP1 intron 22837397 rs1264913 chr1 111974935 A G 2.08E-04 Type 2 diabetes / / 17463246 rs6692745 chr1 112019159 A G 1.66E-04 Lymphocyte counts C1orf162 intron 22286170 rs7737 chr1 112026152 C T 1.63E-04 Heart rate ADORA3 UTR-3 23583979 rs1361133 chr1 112027033 G T 4.39E-06 Corneal structure ADORA3 intron 22003120 rs3767602 chr1 112029763 G A 9.76E-05 Cognitive performance ADORA3 intron 19734545 rs41320847 chr1 112049950 A G 2.16E-04 Multiple complex diseases ADORA3 intron 17554300 rs6537704 chr1 112052105 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA3 intron 20877124 rs6537704 chr1 112052105 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA3 intron 20877124 rs1539582 chr1 112095646 A G 5.83E-04 Multiple complex diseases ADORA3 intron 17554300 rs9988442 chr1 112096662 C T 0.00000062 Triglycerides ADORA3 intron 23063622 rs13376212 chr1 112103480 C A 8.30E-04 Coronary heart disease ADORA3 intron 21966275 rs10776733 chr1 112107669 A G 7.00E-06 Obesity-related traits ADORA3 nearGene-5 23251661 rs17663802 chr1 112108667 A C 5.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs1415797 chr1 112125404 G C 2.65E-04 Type 2 diabetes / / 17463246 rs10494137 chr1 112127299 G A 9.89E-04 Type 2 diabetes / / 17463246 rs10857899 chr1 112127718 G A 3.06E-06 Parkinson's disease / / pha002868 rs2800880 chr1 112130624 T C 9.34E-05 Monocyte counts / / pha003089 rs1890548 chr1 112135958 T C 9.47E-05 Tunica Media / / pha003038 rs6677933 chr1 112139008 T C 5.10E-06 Urinary metabolites / / 21572414 rs2786991 chr1 112147569 T C 4.09E-05 Tunica Media LOC100129269 intron pha003038 rs2477425 chr1 112152602 T C 1.88E-05 Serum metabolites / / 19043545 rs508594 chr1 112165171 T G 1.94E-05 Tunica Media RAP1A intron pha003038 rs1324889 chr1 112183640 A G 2.11E-05 Tunica Media RAP1A intron pha003038 rs494453 chr1 112192122 T C 4.00E-08 Osteoporosis RAP1A intron 20548944 rs11576942 chr1 112203185 G T 4.85E-05 Serum metabolites RAP1A intron 19043545 rs575208 chr1 112206391 T C 1.56E-05 Tunica Media RAP1A intron pha003038 rs10489469 chr1 112234084 G T 8.04E-04 Schizophrenia RAP1A intron 19197363 rs17028287 chr1 112244798 A T 3.20E-06 Urinary metabolites RAP1A intron 21572414 rs197437 chr1 112274653 A G 6.28E-04 Obesity (extreme) FAM212B intron 21935397 rs11102329 chr1 112276608 T C 5.61E-04 Obesity (extreme) FAM212B intron 21935397 rs11102329 chr1 112276608 T C 4.83E-05 Coronary heart disease FAM212B intron pha003032 rs11102329 chr1 112276608 T C 2.27E-05 Monocyte chemoattractant protein-1 FAM212B intron pha003071 rs17568965 chr1 112279555 T A 1.80E-04 Lymphocyte counts FAM212B intron 22286170 rs3754026 chr1 112283838 T C 9.65E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs197394 chr1 112286309 T C 4.71E-04 Multiple complex diseases FAM212B intron 17554300 rs197394 chr1 112286309 T C 5.95E-04 Obesity (extreme) FAM212B intron 21935397 rs881249 chr1 112286948 G C 2.19E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs2076589 chr1 112292547 C T 3.85E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs197380 chr1 112292706 A T 9.62E-04 Obesity (extreme) FAM212B intron 21935397 rs197381 chr1 112292778 T G 9.65E-04 Obesity (extreme) FAM212B intron 21935397 rs191803 chr1 112300120 G C 9.78E-04 Obesity (extreme) DDX20 intron 21935397 rs197404 chr1 112302886 G A 9.94E-04 Obesity (extreme) DDX20 intron 21935397 rs499842 chr1 112304184 C G 4.78E-04 Suicide attempts in bipolar disorder DDX20 intron 21423239 rs197409 chr1 112307615 A G 8.95E-04 Obesity (extreme) DDX20 intron 21935397 rs197410 chr1 112307875 T C 9.19E-04 Obesity (extreme) DDX20 intron 21935397 rs197411 chr1 112308178 G A 9.26E-04 Obesity (extreme) DDX20 intron 21935397 rs197414 chr1 112309123 C A 9.45E-04 Obesity (extreme) DDX20 missense 21935397 rs197414 chr1 112309123 C A 2.22E-05 Coronary heart disease DDX20 missense pha003032 rs197414 chr1 112309123 C A 1.04E-05 Monocyte chemoattractant protein-1 DDX20 missense pha003071 rs85276 chr1 112309331 T C 9.45E-04 Obesity (extreme) DDX20 missense 21935397 rs85276 chr1 112309331 T C 2.22E-05 Coronary heart disease DDX20 missense pha003032 rs85276 chr1 112309331 T C 1.04E-05 Monocyte chemoattractant protein-1 DDX20 missense pha003071 rs7522845 chr1 112312305 A G 9.42E-04 Obesity (extreme) / / 21935397 rs544941 chr1 112312334 A T 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11803207 chr1 112314565 T C 9.40E-04 Obesity (extreme) / / 21935397 rs499817 chr1 112314822 A G 9.39E-04 Obesity (extreme) / / 21935397 rs12138774 chr1 112317692 C G 9.43E-04 Obesity (extreme) / / 21935397 rs535317 chr1 112320800 C T 5.71E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs17722309 chr1 112339880 T C 8.06E-05 Waist Circumference KCND3 intron pha003024 rs12096089 chr1 112349066 A C 2.79E-04 Type 2 diabetes KCND3 intron 17463246 rs12096089 chr1 112349066 A C 1.90E-04 Multiple complex diseases KCND3 intron 17554300 rs12059906 chr1 112349596 G A 2.24E-04 Multiple complex diseases KCND3 intron 17554300 rs17028612 chr1 112349657 G A 5.09E-04 Type 2 diabetes KCND3 intron 17463246 rs17028612 chr1 112349657 G A 2.49E-04 Multiple complex diseases KCND3 intron 17554300 rs17028627 chr1 112351440 G C 5.83E-04 Type 2 diabetes KCND3 intron 17463246 rs17028627 chr1 112351440 G C 1.54E-04 Multiple complex diseases KCND3 intron 17554300 rs626737 chr1 112385812 T C 9.24E-04 HIV-1 viral setpoint KCND3 intron 17641165 rs12044963 chr1 112392360 G T 9.00E-10 Immune reponse to smallpox (secreted IFN-alpha) KCND3 intron 22610502 rs2788612 chr1 112416363 T C 1.05E-12 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs2788612 chr1 112416363 T C 6.00E-16 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs7415980 chr1 112421677 C T 5.28E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs528779 chr1 112424077 C T 4.19E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs11102353 chr1 112426519 T G 8.27E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs612790 chr1 112426577 C G 3.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs2813862 chr1 112427918 C G 2.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1767283 chr1 112428953 T C 2.57E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1767283 chr1 112428953 T C 2.80E-10 P wave duration KCND3 intron 24850809 rs605604 chr1 112433863 C A 2.96E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs605604 chr1 112433863 C A 2.17E-10 P wave duration KCND3 intron 24850809 rs2798334 chr1 112437344 T C 9.21E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs2798334 chr1 112437344 T C 1.00E-06 Visceral adipose tissue adjusted for BMI KCND3 intron 22589738 rs2798334 chr1 112437344 T C 8.00E-11 P wave duration KCND3 intron 24850809 rs2813865 chr1 112437956 A G 7.92E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs894848 chr1 112438818 A G 4.47E-04 Multiple complex diseases KCND3 intron 17554300 rs2995807 chr1 112450636 T C 6.15E-05 Depression (quantitative trait) KCND3 intron 23290196 rs2120436 chr1 112451447 C T 4.38E-09 P wave duration KCND3 intron 24850809 rs2034124 chr1 112451681 A G 3.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs12090194 chr1 112454822 C T 3.08E-09 P wave duration KCND3 intron 24850809 rs4839182 chr1 112456538 A G 1.69E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs4839183 chr1 112456882 A G 7.19E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443926 chr1 112461902 A G 5.12E-09 P wave duration KCND3 intron 24850809 rs1545300 chr1 112464004 C T 5.06E-09 P wave duration KCND3 intron 24850809 rs17029069 chr1 112464376 C T 8.00E-06 Cardiac repolarization KCND3 intron 22683750 rs12408551 chr1 112467932 T C 1.60E-04 Body mass index KCND3 intron 17255346 rs11102355 chr1 112470093 T C 1.26E-04 Body mass index KCND3 intron 17255346 rs2010749 chr1 112470581 T C 8.08E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443927 chr1 112471029 C G 8.24E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443927 chr1 112471029 C G 5.35E-09 P wave duration KCND3 intron 24850809 rs12025303 chr1 112474929 C T 4.60E-06 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs12025303 chr1 112474929 C T 7.40E-05 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs12145374 chr1 112480536 A C 2.78E-10 P wave duration KCND3 intron 24850809 rs1373290 chr1 112501812 T C 5.07E-05 Information processing speed KCND3 intron 21130836 rs11102365 chr1 112507906 G C 7.84E-04 Response to cytadine analogues (cytosine arabinoside) KCND3 intron 24483146 rs3000747 chr1 112538477 T C 2.10E-04 Multiple complex diseases LOC643355 intron 17554300 rs3000752 chr1 112547125 T G 8.34E-04 White matter integrity / / 22425255 rs7548711 chr1 112550542 T C 2.32E-04 White matter integrity / / 22425255 rs12562249 chr1 112555423 G A 9.34E-04 White matter integrity / / 22425255 rs17739527 chr1 112570739 T C 8.63E-04 Type 2 diabetes / / 17463246 rs4839202 chr1 112586954 G A 8.31E-04 Bipolar disorder,schizoaffective / / 19567891 rs4839202 chr1 112586954 G A 8.94E-04 Alzheimer's disease / / 22005930 rs655856 chr1 112594445 G A 6.17E-04 Alzheimer's disease / / 22005930 rs1838300 chr1 112595728 T G 4.56E-04 Alzheimer's disease / / 22005930 rs269079 chr1 112597532 A G 6.00E-04 Alzheimer's disease / / 22005930 rs269131 chr1 112613028 A G 1.63E-04 Multiple complex diseases / / 17554300 rs6691573 chr1 112613106 T C 1.66E-04 Colorectal cancer / / 24836286 rs1440176 chr1 112643780 T A 1.31E-04 Coronary Artery Disease / / 17634449 rs2788424 chr1 112731802 C T 5.52E-04 Type 2 diabetes / / 17463246 rs1440169 chr1 112732217 C T 3.98E-04 Type 2 diabetes / / 17463246 rs6670755 chr1 112732305 A G 4.46E-04 Type 2 diabetes / / 17463246 rs1416203 chr1 112762293 A G 4.46E-04 Type 2 diabetes / / 17463246 rs17029953 chr1 112822460 A G 9.74E-04 Multiple complex diseases / / 17554300 rs7555668 chr1 112856570 C T 3.00E-06 Cognitive performance / / 20125193 rs1105182 chr1 112888147 T A 8.10E-04 Insulin resistance / / 21901158 rs1343275 chr1 112897590 G A 2.25E-05 Information processing speed / / 21130836 rs2492506 chr1 112940944 G A 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs2492510 chr1 112951159 A G 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs1175645 chr1 112981412 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits CTTNBP2NL intron 17848626 rs2256883 chr1 112991698 T C 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL cds-synon 20877124 rs1759692 chr1 112993998 A G 2.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs2488787 chr1 113005808 T A 8.73E-04 Parkinson's disease / / 16252231 rs11102479 chr1 113006804 G A 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12097320 chr1 113009795 T C 7.28E-04 Multiple complex diseases / / 17554300 rs6692731 chr1 113019182 C T 0.000000304 Triglycerides WNT2B intron 23063622 rs2780266 chr1 113025285 G C 7.33E-04 Multiple complex diseases WNT2B intron 17554300 rs3790606 chr1 113052186 G C 5.80E-05 Parkinson's disease (age of onset) WNT2B intron 19772629 rs7516521 chr1 113054936 T G 4.36E-11 HDL cholesterol WNT2B intron 23063622 rs17030475 chr1 113086626 T C 3.63E-04 Multiple complex diseases ST7L intron 17554300 rs17030613 chr1 113190807 A C 3.42E-04 Amyotrophic Lateral Sclerosis CAPZA1 intron 17362836 rs17030613 chr1 113190807 A C 1.00E-08 Blood pressure CAPZA1 intron 21572416 rs17030613 chr1 113190807 A C 8.00E-06 Blood pressure CAPZA1 intron 21572416 rs2932529 chr1 113193364 G A 5.70E-05 Electrocardiographic traits and heart rate variability CAPZA1 intron 17903306 rs3790598 chr1 113196896 G A 1.91E-04 Alcohol dependence CAPZA1 intron 20201924 rs2932538 chr1 113216543 A G 8.00E-06 Blood pressure / / 21909110 rs2932538 chr1 113216543 A G 1.00E-09 Systolic blood pressure / / 21909115 rs2932538 chr1 113216543 A G 3.00E-07 Hypertension / / 21909115 rs4839257 chr1 113219388 A T 9.70E-04 Multiple complex diseases MOV10 intron 17554300 rs2306936 chr1 113246630 G A 6.65E-04 Multiple complex diseases RHOC intron 17554300 rs12144044 chr1 113248791 C A 5.70E-04 Multiple complex diseases RHOC intron 17554300 rs11590090 chr1 113313563 C A 3.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs4378202 chr1 113331134 C T 5.43E-04 Multiple complex diseases / / 17554300 rs10857978 chr1 113338649 T C 3.49E-05 Hypertension / / 21082022 rs11804649 chr1 113348570 C T 5.60E-05 Lipoproteins / / pha003079 rs4838968 chr1 113360437 G C 1.38E-11 Corneal structure / / 22003120 rs7550843 chr1 113452233 T G 2.47E-05 Smoking initiation / / 24665060 rs7551223 chr1 113452613 T A 6.13E-04 Smoking initiation / / 24665060 rs11585690 chr1 113456368 A C 4.87E-04 Celiac disease SLC16A1 UTR-3 23936387 rs11804107 chr1 113472147 C A 0.000000167 HDL cholesterol SLC16A1 intron 23063622 rs6691781 chr1 113710616 C T 3.61E-04 Multiple complex diseases / / 17554300 rs7555991 chr1 113755018 C T 0.000470398 Hypertension (early onset hypertension) / / 22479346 rs773602 chr1 113781358 C T 3.93E-04 Parkinson's disease / / 17052657 rs773564 chr1 113824297 C T 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs773564 chr1 113824297 C T 0.00075 Endometrial cancer / / 22426144 rs773563 chr1 113824805 A C 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12047722 chr1 113868398 G A 8.71E-04 Multiple complex diseases / / 17554300 rs7546431 chr1 113869497 G A 5.20E-08 Metabolite levels / / 23281178 rs1342652 chr1 113874491 T A 5.41E-04 Multiple complex diseases / / 17554300 rs4839312 chr1 113876419 T C 9.92E-04 Multiple complex diseases / / 17554300 rs2153894 chr1 113878311 C T 7.69E-04 Multiple complex diseases / / 17554300 rs1578712 chr1 113880299 T G 5.50E-04 Self-reported allergy / / 23817569 rs12026077 chr1 113883467 A G 5.15E-04 Multiple complex diseases / / 17554300 rs10494157 chr1 113891038 G A 5.32E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12723859 chr1 113891396 A G 2.98E-05 Multiple complex diseases / / 17554300 rs4839315 chr1 113896837 A G 7.98E-04 Multiple complex diseases / / 17554300 rs10494161 chr1 113919454 C G 4.07E-04 Coronary heart disease / / 21606135 rs12049447 chr1 113922845 C T 1.17E-06 Multiple complex diseases / / 17554300 rs12049447 chr1 113922845 C T 4.11E-06 Type 1 diabetes / / 18978792 rs10458459 chr1 113967405 C T 9.26E-07 Multiple complex diseases MAGI3 intron 17554300 rs10458459 chr1 113967405 C T 3.28E-06 Type 1 diabetes MAGI3 intron 18978792 rs12030900 chr1 113974263 A G 1.20E-06 Multiple complex diseases MAGI3 intron 17554300 rs12030900 chr1 113974263 A G 4.62E-06 Type 1 diabetes MAGI3 intron 18978792 rs1573996 chr1 113985456 A G 1.86E-06 Multiple complex diseases MAGI3 intron 17554300 rs1573996 chr1 113985456 A G 2.44E-06 Type 1 diabetes MAGI3 intron 18978792 rs12045559 chr1 113996866 G T 1.50E-06 Multiple complex diseases MAGI3 intron 17554300 rs12739961 chr1 113996947 C T 3.98E-04 Multiple complex diseases MAGI3 intron 17554300 rs4839321 chr1 114047464 G A 9.07E-04 Coronary heart disease MAGI3 intron 21606135 rs12022849 chr1 114063523 A G 8.25E-07 Multiple complex diseases MAGI3 intron 17554300 rs12022849 chr1 114063523 A G 3.36E-06 Type 1 diabetes MAGI3 intron 18978792 rs6694861 chr1 114063592 A G 8.00E-04 Chronic fatigue syndrome MAGI3 intron 21912186 rs10858000 chr1 114075796 C T 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs2153977 chr1 114080071 C T 4.70E-06 Fasting plasma glucose MAGI3 intron 19060907 rs2153977 chr1 114080071 C T 5.56E-06 Rheumatoid arthritis MAGI3 intron 19503088 rs2153977 chr1 114080071 C T 2.72E-06 Glucose levels MAGI3 intron pha002899 rs10858002 chr1 114082932 A G 3.66E-08 Multiple complex diseases MAGI3 intron 17554300 rs10858002 chr1 114082932 A G 1.64E-04 Coronary Artery Disease MAGI3 intron 17634449 rs17031648 chr1 114084105 T A 6.37E-04 Coronary Artery Disease MAGI3 intron 17634449 rs4456089 chr1 114084544 C T 1.07E-11 Multiple complex diseases MAGI3 intron 17554300 rs17013326 chr1 114089316 G A 1.87E-10 Multiple complex diseases MAGI3 intron 17554300 rs12035317 chr1 114096097 T G 3.12E-07 Rheumatoid arthritis MAGI3 intron 19503088 rs12035317 chr1 114096097 T G 8.74E-05 Glucose levels MAGI3 intron pha002899 rs1343128 chr1 114108252 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1418958 chr1 114110836 A T 2.00E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1343125 chr1 114111036 A G 1.80E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1343125 chr1 114111036 A G 1.55E-10 Multiple complex diseases MAGI3 intron 17554300 rs1217201 chr1 114123773 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1113523 chr1 114129474 A G 4.64E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217236 chr1 114132712 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217228 chr1 114139359 T G 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217227 chr1 114139616 C T 5.94E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217226 chr1 114139922 C T 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217226 chr1 114139922 C T 9.93E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217225 chr1 114139991 G A 6.82E-04 Multiple complex diseases MAGI3 intron 17554300 rs1217225 chr1 114139991 G A 2.13E-05 Type 1 diabetes MAGI3 intron 18978792 rs79925084 chr1 114148011 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs78563144 chr1 114156217 G A 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs3761931 chr1 114157023 G A 2.40E-05 Urinary metabolites MAGI3 intron 21572414 rs1217200 chr1 114161116 C A 7.23E-13 Multiple complex diseases MAGI3 intron 17554300 rs77911012 chr1 114161807 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs1217192 chr1 114162194 G A 4.00E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1217193 chr1 114162619 C G 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs1230666 chr1 114173410 A G 3.62E-10 Multiple complex diseases MAGI3 intron 17554300 rs1230666 chr1 114173410 A G 1.95E-06 Arthritis (juvenile idiopathic) MAGI3 intron 22354554 rs1230666 chr1 114173410 A G 2.00E-08 Thyroid peroxidase antibody levels MAGI3 intron 24586183 rs3747998 chr1 114186138 G C 6.40E-06 Urinary metabolites MAGI3 intron 21572414 rs1777237 chr1 114187371 G A 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs1146182 chr1 114196883 C A 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs79247801 chr1 114203971 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs76231474 chr1 114206036 C T 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs1146187 chr1 114212571 A G 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs77600616 chr1 114213935 G C 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs17274634 chr1 114217527 T C 6.50E-06 Urinary metabolites MAGI3 intron 21572414 rs1230658 chr1 114218451 C G 1.05E-12 Multiple complex diseases MAGI3 intron 17554300 rs61742849 chr1 114226143 G A 6.00E-06 Bulimia nervosa MAGI3 missense 23568457 rs4839335 chr1 114233871 G A 1.37E-05 Rheumatoid arthritis / / 17804836 rs4839335 chr1 114233871 G A 5.66E-09 Rheumatoid arthritis / / 19503088 rs4839335 chr1 114233871 G A 3.20E-04 Myasthenia gravis / / 23055271 rs1111695 chr1 114243899 C A 2.91E-07 Rheumatoid arthritis PHTF1 intron 19503088 rs1230649 chr1 114244177 G T 6.95E-13 Multiple complex diseases PHTF1 intron 17554300 rs74901666 chr1 114248264 G A 3.04E-06 Obesity-related traits PHTF1 intron 23251661 rs6698586 chr1 114249382 C T 1.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs1230647 chr1 114253639 C T 1.52E-05 Rheumatoid arthritis PHTF1 intron 17804836 rs1230647 chr1 114253639 C T 6.42E-09 Rheumatoid arthritis PHTF1 intron 19503088 rs1230647 chr1 114253639 C T 3.80E-04 Myasthenia gravis PHTF1 intron 23055271 rs1981319 chr1 114267645 C A 1.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs2273758 chr1 114280717 A C 2.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs2273758 chr1 114280717 A C 1.28E-07 Multiple complex diseases PHTF1 intron 17554300 rs78089789 chr1 114282370 C G 3.04E-06 Obesity-related traits PHTF1 intron 23251661 rs6679677 chr1 114303808 C A 8.00E-24 Type 1 diabetes / / 17554260 rs6679677 chr1 114303808 C A 5.00E-26 Type 1 diabetes / / 17554300 rs6679677 chr1 114303808 C A 6.00E-25 Rheumatoid arthritis / / 17554300 rs6679677 chr1 114303808 C A 4.95E-09 Crohn's disease / / 18587394 rs6679677 chr1 114303808 C A 6.00E-42 Rheumatoid arthritis / / 18794853 rs6679677 chr1 114303808 C A 1.00E-40 Type 1 diabetes / / 18978792 rs6679677 chr1 114303808 C A 8.00E-24 Multiple sclerosis / / 22190364 rs6679677 chr1 114303808 C A 1.07E-06 Arthritis (juvenile idiopathic) / / 22354554 rs6679677 chr1 114303808 C A 3.00E-13 Hypothyroidism / / 22493691 rs6679677 chr1 114303808 C A 2.00E-15 Crohn's disease / / 23128233 rs6679677 chr1 114303808 C A 1.11E-18 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs6679677 chr1 114303808 C A 3.19E-25 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs6679677 chr1 114303808 C A 3.45E-11 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs3789598 chr1 114318727 C A 2.00E-05 Rheumatoid arthritis RSBN1 intron 17159887 rs2797409 chr1 114330202 T C 9.69E-06 Rheumatoid arthritis RSBN1 intron 17804836 rs2797409 chr1 114330202 T C 6.90E-11 Rheumatoid arthritis RSBN1 intron 19503088 rs2797409 chr1 114330202 T C 2.60E-04 Myasthenia gravis RSBN1 intron 23055271 rs2797409 chr1 114330202 T C 2.81E-04 Systemic lupus erythematosus and Systemic sclerosis RSBN1 intron 23740937 rs2040040 chr1 114331645 T A 6.90E-06 Urinary metabolites RSBN1 intron 21572414 rs1217396 chr1 114338236 C T 2.60E-13 Multiple complex diseases RSBN1 intron 17554300 rs1217380 chr1 114343336 G A 3.00E-05 Rheumatoid arthritis RSBN1 intron 17159887 rs78399433 chr1 114346137 T C 3.04E-06 Obesity-related traits RSBN1 intron 23251661 rs75453168 chr1 114348204 T C 3.04E-06 Obesity-related traits RSBN1 intron 23251661 rs6537798 chr1 114351706 C A 7.95E-07 Multiple complex diseases RSBN1 intron 17554300 rs3811021 chr1 114356663 A G 4.46E-04 Cognition,early reading ability PTPN22 UTR-3 17684495 rs1217413 chr1 114357750 G A 4.00E-08 Rheumatoid arthritis PTPN22 intron 17159887 rs1217395 chr1 114374435 C T 1.00E-05 Rheumatoid arthritis PTPN22 intron 17159887 rs2476601 chr1 114377568 A G 2.00E-80 Type 1 diabetes / / 17554260 rs2476601 chr1 114377568 A G 1.00E-07 Type 1 diabetes / / 17632545 rs2476601 chr1 114377568 A G 2.00E-11 Rheumatoid arthritis / / 17804836 rs2476601 chr1 114377568 A G 5.20E-06 Systemic lupus erythematosus / / 18204446 rs2476601 chr1 114377568 A G 1.00E-08 Crohn's disease / / 18587394 rs2476601 chr1 114377568 A G 9.00E-85 Type 1 diabetes / / 19430480 rs2476601 chr1 114377568 A G 2.00E-21 Rheumatoid arthritis / / 19503088 rs2476601 chr1 114377568 A G 1.00E-07 Vitiligo / / 20410501 rs2476601 chr1 114377568 A G 9.00E-74 Rheumatoid arthritis / / 20453842 rs2476601 chr1 114377568 A G 4.00E-09 Crohn's disease / / 21102463 rs2476601 chr1 114377568 A G 1.00E-08 Asthma / / 21150878 rs2476601 chr1 114377568 A G 1.00E-08 Rheumatoid arthritis / / 21156761 rs2476601 chr1 114377568 A G 9.82E-09 Vitiligo / / 21326295 rs2476601 chr1 114377568 A G 9.10E-74 Celiac disease and Rheumatoid arthritis / / 21383967 rs2476601 chr1 114377568 A G 2.00E-111 Type 1 diabetes autoantibodies / / 21829393 rs2476601 chr1 114377568 A G 5.93E-80 Type 1 diabetes / / 21980299 rs2476601 chr1 114377568 A G 3.40E-12 Multiple sclerosis / / 22190364 rs2476601 chr1 114377568 A G 6.20E-71 Rheumatoid arthritis / / 22446963 rs2476601 chr1 114377568 A G 3.90E-13 Hypothyroidism / / 22493691 rs2476601 chr1 114377568 A G 6.10E-13 Vitiligo / / 22561518 rs2476601 chr1 114377568 A G 3.74E-15 Hashimoto's thyroiditis / / 22922229 rs2476601 chr1 114377568 A G 4.03E-16 Graves' disease / / 22922229 rs2476601 chr1 114377568 A G 9.69E-23 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs2476601 chr1 114377568 A G 8.00E-10 Myasthenia gravis / / 23055271 rs2476601 chr1 114377568 A G 0.000175 Rheumatoid arthritis (CCP negative) / / 23143596 rs2476601 chr1 114377568 A G 7.50E-77 Rheumatoid arthritis / / 23143596 rs2476601 chr1 114377568 A G 9.23E-78 Rheumatoid arthritis (CCP positive) / / 23143596 rs2476601 chr1 114377568 A G 6.60E-170 Rheumatoid arthritis / / 24390342 rs2476601 chr1 114377568 A G 9.00E-170 Rheumatoid arthritis / / 24390342 rs2476601 chr1 114377568 A G 5.00E-33 Rheumatoid arthritis / / 24449572 rs138092829 chr1 114380886 T C 0.0000016 Breast cancer (ER positive) PTPN22 missense 23555315 rs1217407 chr1 114393748 A G 9.00E-06 Rheumatoid arthritis PTPN22 intron 17159887 rs1217407 chr1 114393748 A G 1.50E-05 Rheumatoid arthritis PTPN22 intron 17804836 rs1217407 chr1 114393748 A G 5.29E-09 Rheumatoid arthritis PTPN22 intron 19503088 rs1217407 chr1 114393748 A G 2.40E-04 Myasthenia gravis PTPN22 intron 23055271 rs1217410 chr1 114396816 C T 1.00E-05 Rheumatoid arthritis PTPN22 intron 17159887 rs3789609 chr1 114397799 C T 6.50E-06 Urinary metabolites PTPN22 intron 21572414 rs1217418 chr1 114401231 A G 1.63E-07 Rheumatoid arthritis PTPN22 intron 19503088 rs1217418 chr1 114401231 A G 4.47E-04 Lung function (forced expiratory volume in 1 second) PTPN22 intron 24023788 rs79241487 chr1 114401782 G A 3.04E-06 Obesity-related traits PTPN22 intron 23251661 rs2488457 chr1 114415368 G A,C 1.95E-13 Multiple complex diseases LOC100287722 intron 17554300 rs1235005 chr1 114417437 C G 5.11E-08 Multiple complex diseases LOC100287722 intron 17554300 rs6665194 chr1 114417843 G A 4.18E-07 Rheumatoid arthritis LOC100287722 intron 19503088 rs1217384 chr1 114419760 G C 6.00E-07 Urinary metabolites BCL2L15 UTR-3 21572414 rs12566340 chr1 114420328 C T 9.64E-05 Rheumatoid arthritis BCL2L15 UTR-3 17804836 rs12566340 chr1 114420328 C T 3.99E-09 Rheumatoid arthritis BCL2L15 UTR-3 19503088 rs7529353 chr1 114420462 G A 7.69E-05 Rheumatoid arthritis BCL2L15 UTR-3 17804836 rs7529353 chr1 114420462 G A 4.81E-10 Rheumatoid arthritis BCL2L15 UTR-3 19503088 rs7529353 chr1 114420462 G A 4.80E-04 Myasthenia gravis BCL2L15 UTR-3 23055271 rs2358994 chr1 114429461 G A 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BCL2L15 intron 20877124 rs10776775 chr1 114436482 G A 4.70E-10 Multiple complex diseases LOC100287722 intron 17554300 rs10776775 chr1 114436482 G A 2.73E-05 Arthritis (juvenile idiopathic) LOC100287722 intron 22354554 rs1217401 chr1 114438951 A G 2.33E-05 Multiple complex diseases AP4B1 missense 17554300 rs1217401 chr1 114438951 A G 2.67E-05 Type 1 diabetes AP4B1 missense 18978792 rs141417436 chr1 114442885 A G 0.000041 Breast cancer(er negative) AP4B1 missense 23555315 rs12079716 chr1 114444594 T G 2.00E-06 Obesity-related traits AP4B1 intron 23251661 rs6661817 chr1 114447034 G C 6.02E-10 Multiple complex diseases AP4B1 intron 17554300 rs11552449 chr1 114448389 C A,G,T 2.00E-08 Breast cancer DCLRE1B missense 23535729 rs3811019 chr1 114471583 C G 9.24E-12 Multiple complex diseases / / 17554300 rs12127377 chr1 114489973 A G 8.89E-05 Alzheimer's disease HIPK1 intron 21098978 rs1553450 chr1 114490780 A G 8.03E-05 Alzheimer's disease HIPK1 intron 21098978 rs11102707 chr1 114493583 G A 7.90E-05 Alzheimer's disease HIPK1 intron 21098978 rs12129050 chr1 114496607 A G 8.06E-05 Alzheimer's disease HIPK1 intron 21098978 rs11102709 chr1 114512083 G C 7.36E-05 Alzheimer's disease HIPK1 intron 21098978 rs10108 chr1 114516330 C T 7.23E-05 Alzheimer's disease HIPK1 UTR-3 21098978 rs6537801 chr1 114525552 C T 3.93E-04 Aortic root size / / 21223598 rs11810241 chr1 114529760 A G 1.60E-05 Bipolar disorder / / 19488044 rs11810241 chr1 114529760 A G 3.55E-05 Bipolar Disorder / / pha002863 rs12029840 chr1 114531480 C T 1.46E-06 Multiple complex diseases / / 17554300 rs12029840 chr1 114531480 C T 4.30E-06 Stroke (ischemic) / / 22384361 rs7520320 chr1 114535293 C T 7.42E-06 Multiple complex diseases / / 17554300 rs3006971 chr1 114536207 G A 6.57E-06 Rheumatoid arthritis / / 19503088 rs1503836 chr1 114541498 G T 9.76E-06 Rheumatoid arthritis / / 19503088 rs12402202 chr1 114541955 A C 5.90E-04 Type 2 diabetes / / 17463246 rs10494164 chr1 114546528 A G 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10494164 chr1 114546528 A G 7.25E-06 Rheumatoid arthritis / / 19503088 rs2938323 chr1 114546804 G A 3.88E-06 Rheumatoid arthritis / / 19503088 rs77730918 chr1 114548091 G A 2.47E-06 Obesity-related traits / / 23251661 rs2938330 chr1 114555118 T C 7.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4274061 chr1 114555337 C A 2.63E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2938345 chr1 114568164 A T 4.40E-07 Urinary metabolites / / 21572414 rs2938340 chr1 114577595 C G 8.50E-07 Urinary metabolites / / 21572414 rs3006995 chr1 114578864 A G 9.50E-08 Urinary metabolites / / 21572414 rs10776776 chr1 114583160 T G 9.10E-08 Urinary metabolites / / 21572414 rs12092195 chr1 114583472 T C 1.74E-06 Obesity-related traits / / 23251661 rs2938317 chr1 114586587 T C 6.40E-08 Urinary metabolites / / 21572414 rs78972990 chr1 114587196 A G 6.96E-06 Obesity-related traits / / 23251661 rs2938334 chr1 114591798 T C 2.60E-04 Iris characteristics / / 21835309 rs3007005 chr1 114592265 G T 1.90E-08 Urinary metabolites / / 21572414 rs3007007 chr1 114594412 C A 9.20E-09 Urinary metabolites / / 21572414 rs2938351 chr1 114594919 G A 2.30E-08 Urinary metabolites / / 21572414 rs3007012 chr1 114606156 T C 1.10E-07 Urinary metabolites / / 21572414 rs79079833 chr1 114607364 T C 2.00E-06 Obesity-related traits / / 23251661 rs1330700 chr1 114618054 C T 2.40E-05 Urinary metabolites / / 21572414 rs58491015 chr1 114622458 T C 4.56E-06 Obesity-related traits / / 23251661 rs2774291 chr1 114631167 A G 1.50E-05 Urinary metabolites / / 21572414 rs9659122 chr1 114639504 T C 3.99E-05 Multiple complex diseases SYT6 intron 17554300 rs9659122 chr1 114639504 T C 7.43E-04 Response to TNF antagonist treatment SYT6 intron 21061259 rs9659029 chr1 114643892 C A 9.96E-05 Multiple complex diseases SYT6 intron 17554300 rs9659029 chr1 114643892 C A 6.36E-04 Response to TNF antagonist treatment SYT6 intron 21061259 rs519553 chr1 114655222 A G 2.00E-04 Type 2 diabetes SYT6 intron 17463246 rs519553 chr1 114655222 A G 9.30E-06 Urinary metabolites SYT6 intron 21572414 rs2774307 chr1 114670969 A G 8.33E-04 Type 2 diabetes SYT6 intron 17463246 rs2774307 chr1 114670969 A G 8.00E-06 Breast cancer (prognosis) SYT6 intron 23319801 rs500739 chr1 114677029 G T 6.99E-04 Alzheimer's disease SYT6 intron 17998437 rs529989 chr1 114677948 C A 4.70E-05 Nicotine use SYT6 intron 23942779 rs529989 chr1 114677948 C A 6.00E-06 Illicit drug use SYT6 intron 23942779 rs529989 chr1 114677948 C A 5.22E-05 Inflammation SYT6 intron pha002897 rs11102738 chr1 114677997 T C 9.87E-06 Calcium levels SYT6 intron pha003085 rs12038780 chr1 114681240 C T 4.55E-05 Lung function (forced expiratory volume in 1 second) SYT6 intron pha003103 rs2774298 chr1 114687012 T C 5.74E-04 Suicide attempts in bipolar disorder SYT6 intron 21423239 rs2291369 chr1 114688434 G A 6.99E-04 Suicide attempts in bipolar disorder SYT6 intron 21423239 rs11576155 chr1 114713151 C T 9.25E-04 Multiple complex diseases / / 17554300 rs17535387 chr1 114713359 G T 6.86E-05 Potassium levels / / pha003086 rs2774292 chr1 114715584 G A 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs2629817 chr1 114716196 C T 3.77E-05 Anxiety and major depressive disorder / / 24047446 rs6695728 chr1 114720926 G A 1.27E-04 Multiple complex diseases / / 17554300 rs1158366 chr1 114735242 C A 4.19E-05 Amyotrophic lateral sclerosis / / 23624525 rs1158366 chr1 114735242 C A 2.89E-05 Odorant perception / / 23910658 rs6537816 chr1 114750905 A G 7.67E-04 Alzheimer's disease / / 17998437 rs209897 chr1 114752415 G A 8.41E-04 Alzheimer's disease / / 17998437 rs6670053 chr1 114780835 T C 9.83E-04 Multiple complex diseases / / 17554300 rs6671139 chr1 114782179 A G 8.48E-04 Type 2 diabetes / / 17463246 rs6666714 chr1 114794857 C T 2.82E-07 Facial morphology / / 22341974 rs12146102 chr1 114799870 A G 2.74E-07 Facial morphology / / 22341974 rs41470845 chr1 114856929 T A 6.86E-04 Multiple complex diseases / / 17554300 rs10858044 chr1 114869468 C T 4.51E-04 Type 2 diabetes / / 17463246 rs9429542 chr1 114928743 C T 2.55E-04 Multiple complex diseases / / 17554300 rs6537825 chr1 114948281 A G 3.00E-08 Autism TRIM33 missense 24189344 rs11582563 chr1 114959540 G A 1.98E-07 Autism TRIM33 intron 24189344 rs11582563 chr1 114959540 G A 1.28E-05 Heart Failure TRIM33 intron pha002885 rs11585926 chr1 114973690 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11589568 chr1 114996324 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11589568 chr1 114996324 T C 1.28E-05 Heart Failure TRIM33 intron pha002885 rs7511633 chr1 114999277 G A 1.65E-04 Alzheimer's disease (late onset) TRIM33 intron 21379329 rs7511633 chr1 114999277 G A 1.98E-07 Autism TRIM33 intron 24189344 rs6661053 chr1 115039119 T C 1.65E-04 Alzheimer's disease (late onset) TRIM33 intron 21379329 rs6661053 chr1 115039119 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11102800 chr1 115040932 C T 5.82E-08 Autism TRIM33 intron 24189344 rs3827735 chr1 115052708 C A 3.22E-05 Autism TRIM33 intron 24189344 rs3827735 chr1 115052708 C A 6.39E-08 Autism TRIM33 intron 24189344 rs11102807 chr1 115061584 A G 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs11102807 chr1 115061584 A G 4.06E-08 Autism / / 24189344 rs10858047 chr1 115073876 T C 2.23E-05 Autism / / 24189344 rs11587400 chr1 115079658 C T 8.36E-08 Autism / / 24189344 rs1877455 chr1 115099092 C T 6.72E-08 Autism / / 24189344 rs1877455 chr1 115099092 C T 8.70E-08 Autism / / 24189344 rs7539721 chr1 115171649 C T 2.39E-05 Autism DENND2C intron 24189344 rs10858049 chr1 115196166 A G 9.54E-05 Periodontitis (Chronic) DENND2C intron 25008200 rs6537841 chr1 115200808 A G 2.04E-05 Autism DENND2C intron 24189344 rs761755 chr1 115222434 G A 2.55E-05 Autism AMPD1 intron 24189344 rs12407408 chr1 115234275 G A 4.70E-04 Smoking initiation AMPD1 intron 24665060 rs926938 chr1 115239816 A G 4.00E-08 Autism AMPD1 nearGene-5 24189344 rs11558867 chr1 115259599 G GG,GT 2.77E-08 Autism CSDE1 UTR-3 24189344 rs8453 chr1 115259599 G T 2.77E-08 Autism CSDE1 UTR-3 24189344 rs1065634 chr1 115259768 T C 2.30E-05 Urinary metabolites CSDE1 UTR-3 21572414 rs10489525 chr1 115263685 G A 1.20E-05 Urinary metabolites CSDE1 intron 21572414 rs10489525 chr1 115263685 G A 5.51E-06 Autism CSDE1 intron 24189344 rs10489525 chr1 115263685 G A 9.33E-08 Autism CSDE1 intron 24189344 rs2798657 chr1 115355281 C T 2.96E-05 F-cell distribution / / 21326311 rs360603 chr1 115389709 A G 5.48E-04 Fibrinogen / / 17255346 rs360614 chr1 115399940 T G 3.40E-04 Fibrinogen SYCP1 intron 17255346 rs12741053 chr1 115407873 T C 7.68E-04 Suicide attempts in bipolar disorder SYCP1 intron 21041247 rs12741053 chr1 115407873 T C 9.07E-04 Heart Failure SYCP1 intron pha002885 rs360589 chr1 115470852 T C 1.15E-05 Body Composition SYCP1 intron pha003012 rs360589 chr1 115470852 T C 1.66E-05 Body Mass Index SYCP1 intron pha003021 rs360595 chr1 115473206 G A 9.11E-05 Alcohol consumption SYCP1 intron 23953852 rs360668 chr1 115481598 G A 5.63E-04 Fibrinogen SYCP1 intron 17255346 rs2008873 chr1 115497162 T A 6.43E-04 Suicide attempts in bipolar disorder SYCP1 intron 21041247 rs7526486 chr1 115528289 C T 9.63E-04 Alzheimer's disease SYCP1 intron 24755620 rs1321108 chr1 115572365 A G 2.09E-05 Alcohol consumption TSHB nearGene-5 23953852 rs1998008 chr1 115580540 A C 1.94E-05 Alcohol consumption / / 23953852 rs12046203 chr1 115580731 T C 4.09E-04 Multiple complex diseases / / 17554300 rs11102878 chr1 115590998 T C 6.89E-05 Alcohol consumption TSPAN2 UTR-3 23953852 rs6537850 chr1 115602119 T C 3.87E-04 Multiple complex diseases TSPAN2 intron 17554300 rs1321106 chr1 115609203 C T 2.36E-04 Alzheimer's disease (late onset) TSPAN2 intron 21379329 rs717275 chr1 115610091 T C 6.90E-05 Personality dimensions TSPAN2 intron 18957941 rs1286366 chr1 115617856 T C 1.55E-05 Body Composition TSPAN2 intron pha003012 rs1286366 chr1 115617856 T C 7.57E-06 Body Mass Index TSPAN2 intron pha003021 rs17479252 chr1 115621860 C T 9.95E-04 Alcohol dependence TSPAN2 intron 21314694 rs910623 chr1 115624404 A G 5.80E-04 Obesity-related traits TSPAN2 intron 17903300 rs2144549 chr1 115625348 C T 2.50E-04 Type 2 diabetes and 6 quantitative traits TSPAN2 intron 17848626 rs1966175 chr1 115633281 A G 2.11E-04 Multiple complex diseases / / 17554300 rs10218480 chr1 115666678 T C 7.64E-04 Type 2 diabetes / / 17463246 rs11581510 chr1 115672145 G A 5.70E-04 Alcohol dependence / / 20201924 rs11581510 chr1 115672145 G A 8.40E-04 Alcohol dependence / / 20201924 rs2078371 chr1 115677183 T C 1.10E-05 Migraine / / 21666692 rs2078371 chr1 115677183 T C 1.80E-04 Myasthenia gravis / / 23055271 rs12134493 chr1 115677946 C A 1.19E-05 Migraine - clinic-based / / 23793025 rs12134493 chr1 115677946 C A 5.00E-08 Migraine without aura / / 23793025 rs12134493 chr1 115677946 C A 5.00E-14 Migraine / / 23793025 rs12134493 chr1 115677946 C A 6.19E-04 Migraine with aura / / 23793025 rs6691441 chr1 115722813 C T 5.13E-04 Multiple complex diseases / / 17554300 rs9803637 chr1 115722917 G A 6.98E-04 Multiple complex diseases / / 17554300 rs742872 chr1 115726190 C T 2.60E-04 Multiple complex diseases / / 17554300 rs742871 chr1 115726316 T C 3.86E-04 Multiple complex diseases / / 17554300 rs195207 chr1 115727948 C A 8.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9429549 chr1 115733494 C T 2.57E-05 Multiple complex diseases / / 17554300 rs195204 chr1 115734091 T C 9.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs10489532 chr1 115735049 C T 9.73E-05 Multiple complex diseases / / 17554300 rs10489532 chr1 115735049 C T 2.20E-05 Urinary metabolites / / 21572414 rs973836 chr1 115735898 T A 5.95E-04 Multiple complex diseases / / 17554300 rs12035380 chr1 115739084 C T 0.000706 Asthma / / 22502797 rs11806316 chr1 115753482 G A 0.00000151 Coronary artery disease / / 23202125 rs1040605 chr1 115759830 A G 8.14E-04 Multiple complex diseases / / 17554300 rs971723 chr1 115774074 A C 9.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1294378 chr1 115777538 G A 5.00E-06 Personality dimensions / / 18957941 rs1777719 chr1 115782068 A G 0.000336 Asthma / / 22502797 rs7542599 chr1 115782754 T C 8.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs10489531 chr1 115783002 G A 9.70E-04 Volumetric brain MRI / / 17903297 rs2268793 chr1 115831783 C T 6.78E-04 Suicide attempts in bipolar disorder NGF intron 21423239 rs10489530 chr1 115839680 G A 8.65E-04 Alcohol dependence NGF intron 21314694 rs4573519 chr1 115843087 T C 2.91E-04 Multiple complex diseases NGF intron 17554300 rs4839435 chr1 115858104 G A 8.40E-04 Body mass index NGF intron 21701565 rs7523654 chr1 115861265 T C 7.14E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs12060354 chr1 115868382 A G 3.29E-04 Multiple complex diseases NGF intron 17554300 rs4839436 chr1 115869089 G C 1.49E-05 Bipolar disorder and schizophrenia NGF intron 20889312 rs10776799 chr1 115873047 G T 6.31E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs10776799 chr1 115873047 G T 4.84E-05 Bipolar disorder NGF intron 21926972 rs10776799 chr1 115873047 G T 2.52E-05 Major depressive disorder NGF intron 22472876 rs10776799 chr1 115873047 G T 0.00000968 Bipolar disorder NGF intron 23637625 rs4332358 chr1 115875645 C T 5.00E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs10858075 chr1 115877522 C T 3.37E-04 Epilepsy NGF intron 22116939 rs17033706 chr1 115877624 G A 8.60E-05 Bipolar disorder and schizophrenia NGF intron 20889312 rs17033706 chr1 115877624 G A 8.27E-05 Major depressive disorder NGF intron 22472876 rs10776801 chr1 115882541 A G 4.76E-06 Arthritis (juvenile idiopathic) NGF nearGene-5 22354554 rs12405977 chr1 115895377 A G 8.29E-05 Femoral neck bone geometry / / 22087292 rs12136101 chr1 115910335 T C 1.78E-04 Parkinson's disease / / 17052657 rs7552722 chr1 115921355 T C 7.00E-06 Non-alcoholic fatty liver disease / / 23535911 rs990267 chr1 115941974 T C 5.72E-04 Insulin resistance / / 21901158 rs484395 chr1 115945738 A T 7.94E-05 Insulin resistance / / 21901158 rs1327126 chr1 115973920 C T 8.46E-05 Type 2 diabetes / / 17463246 rs9429756 chr1 116017908 A G 9.66E-05 Post-operative nausea and vomiting / / 21694509 rs9429756 chr1 116017908 A G 8.85E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs17033862 chr1 116033426 C T 3.86E-04 Multiple complex diseases / / 17554300 rs538254 chr1 116072652 C T 4.77E-20 Metabolite levels / / 22286219 rs1409807 chr1 116074080 G A 6.95E-04 Type 2 diabetes / / 17463246 rs3860222 chr1 116136810 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3860222 chr1 116136810 C T 4.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs10494177 chr1 116155498 T C 7.46E-04 Type 2 diabetes / / 17846124 rs4240548 chr1 116170427 T C 5.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs4839464 chr1 116174524 T C 4.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs17034114 chr1 116200790 C T 1.00E-04 Cognitive impairment induced by topiramate VANGL1 intron 22091778 rs10923133 chr1 116201064 T C 6.80E-05 Personality dimensions VANGL1 intron 18957941 rs10801911 chr1 116203864 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VANGL1 intron 20877124 rs10801911 chr1 116203864 A G 4.01E-04 Smoking initiation VANGL1 intron 24665060 rs10923142 chr1 116204661 C T 9.33E-05 Soluble levels of adhesion molecules VANGL1 intron pha003072 rs10801913 chr1 116214279 A G 5.53E-05 Myocardial Infarction VANGL1 intron pha002873 rs12137412 chr1 116214846 C T 2.64E-04 Alzheimer's disease (late onset) VANGL1 intron 21379329 rs6699583 chr1 116223306 T G 4.66E-05 Myocardial Infarction VANGL1 intron pha002873 rs17034230 chr1 116239266 C T 5.79E-04 Depression (quantitative trait) VANGL1 UTR-3 20800221 rs3811006 chr1 116240212 C T 5.85E-04 Depression (quantitative trait) VANGL1 UTR-3 20800221 rs17034260 chr1 116245150 C T 7.01E-04 HIV-1 viral setpoint CASQ2 intron 17641165 rs4423004 chr1 116253342 C A 3.42E-04 Myocardial Infarction CASQ2 intron pha002873 rs3010396 chr1 116273788 A G 3.64E-04 Myocardial Infarction CASQ2 intron pha002873 rs10754356 chr1 116292469 A G 2.50E-05 Urinary metabolites CASQ2 intron 21572414 rs4564143 chr1 116293963 T C 2.50E-05 Urinary metabolites CASQ2 intron 21572414 rs4839478 chr1 116295007 G A 1.38E-04 Lung function (forced expiratory volume in 1 second) CASQ2 intron 17255346 rs4074536 chr1 116310967 T C 2.00E-08 Ventricular conduction CASQ2 missense 21076409 rs12039739 chr1 116333111 C T 3.91E-06 Multiple complex diseases / / 17554300 rs12040622 chr1 116333773 C A 3.06E-05 Cholesterol / / 17255346 rs12040622 chr1 116333773 C A 6.87E-04 Heart Failure / / pha002885 rs10494185 chr1 116337217 T G 1.88E-04 Lung function (forced vital capacity) / / 24023788 rs10494185 chr1 116337217 T G 1.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4272626 chr1 116348427 T C 7.69E-05 Multiple complex diseases / / 17554300 rs2811586 chr1 116368612 C T 1.38E-04 Bipolar disorder / / 18317468 rs10399824 chr1 116371836 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2797198 chr1 116373246 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811570 chr1 116385122 T C 3.01E-04 Alzheimer's disease (late onset) / / 21379329 rs10923616 chr1 116387058 G A 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs10923633 chr1 116391331 A C 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342723 chr1 116433092 C G 1.22E-04 Insulin resistance / / 21901158 rs1155342 chr1 116453761 A G 5.84E-04 Multiple complex diseases / / 17554300 rs7538141 chr1 116465009 G A 3.27E-04 Multiple complex diseases / / 17554300 rs10923806 chr1 116469435 G A 7.24E-06 Longevity / / 21612516 rs7520415 chr1 116478617 G A 5.55E-04 Multiple complex diseases / / 17554300 rs10923885 chr1 116499503 G C 5.84E-04 Multiple complex diseases / / 17554300 rs10923924 chr1 116521362 C A 1.80E-06 Multiple complex diseases SLC22A15 intron 17554300 rs12071340 chr1 116524839 C T 5.84E-04 Multiple complex diseases SLC22A15 intron 17554300 rs12726299 chr1 116525672 G A 1.50E-07 Autism SLC22A15 intron 22843504 rs1775698 chr1 116537950 G A 1.00E-04 Cognitive impairment induced by topiramate SLC22A15 intron 22091778 rs17035172 chr1 116579016 T G 7.88E-05 Bipolar disorder SLC22A15 intron 19488044 rs12093582 chr1 116704771 G A 5.19E-04 Myocardial Infarction / / pha002873 rs12079216 chr1 116733698 G A 7.58E-06 Multiple complex diseases / / 17554300 rs1884989 chr1 116740195 T C 7.22E-06 Multiple complex diseases / / 17554300 rs4839516 chr1 116740450 C A 4.00E-07 Word reading / / 23738518 rs10923995 chr1 116751013 G A 2.30E-05 Urinary metabolites / / 21572414 rs12125273 chr1 116776537 T C 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12121082 chr1 116778098 G A 9.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12131904 chr1 116784149 A C 9.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11583110 chr1 116793745 C A 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs2184484 chr1 116801420 A G 4.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs12746213 chr1 116810249 C T 2.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12091470 chr1 116812681 T G 9.94E-05 Multiple complex diseases / / 17554300 rs12089467 chr1 116819325 C T 2.87E-04 Hearing function / / 17255346 rs6665077 chr1 116880188 G A 6.55E-04 Multiple complex diseases / / 17554300 rs6660918 chr1 116889275 G T 3.77E-06 Multiple complex diseases / / 17554300 rs6660918 chr1 116889275 G T 9.11E-05 Insulin resistance / / 21901158 rs1407717 chr1 116913613 T C 1.39E-08 LDL cholesterol / / 23063622 rs12070283 chr1 116922853 G A 8.97E-04 Insulin resistance ATP1A1 intron 21901158 rs41464748 chr1 116932771 G A 1.63E-04 Type 2 diabetes ATP1A1 intron 17463246 rs12130872 chr1 116933372 G A,C,T 5.57E-04 Smoking cessation ATP1A1 intron 24665060 rs12092869 chr1 116959495 G C 5.00E-04 Insulin resistance ATP1A1OS intron 21901158 rs7544671 chr1 116965558 C T 2.90E-04 Multiple complex diseases / / 17554300 rs17035635 chr1 116965829 T C 1.54E-04 Multiple complex diseases / / 17554300 rs17035658 chr1 116988030 C T 6.87E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs12128828 chr1 116991956 A G 9.31E-04 Multiple complex diseases / / 17554300 rs12067801 chr1 116996509 G A 1.73E-04 Insulin resistance / / 21901158 rs12067801 chr1 116996509 G A 3.03E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs6669460 chr1 117019315 C G 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6671978 chr1 117019614 C T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12085912 chr1 117019988 G C 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12090008 chr1 117020344 C G 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs17035862 chr1 117032885 G C 3.90E-04 Self-reported allergy / / 23817569 rs12025416 chr1 117038287 T C 1.16E-09 Multiple sclerosis LOC100506459 intron 19525953 rs12025416 chr1 117038287 T C 1.00E-07 Multiple sclerosis LOC100506459 intron 21244703 rs10802189 chr1 117056730 C T 7.28E-05 Diabetes Mellitus / / pha003060 rs758518 chr1 117081810 A G 7.63E-05 Diabetes Mellitus CD58 intron pha003059 rs12044852 chr1 117087779 C A 1.90E-05 Multiple sclerosis CD58 intron 17660530 rs1335532 chr1 117100957 A G 1.00E-07 Multiple sclerosis CD58 intron 19525955 rs1335532 chr1 117100957 A G 3.00E-16 Multiple sclerosis CD58 intron 21833088 rs1335532 chr1 117100957 A G 1.51E-09 Multiple sclerosis CD58 intron 22190364 rs1335532 chr1 117100957 A G 1.20E-08 Multiple sclerosis CD58 intron 24234648 rs1335532 chr1 117100957 A G 7.83E-06 Diabetes Mellitus CD58 intron pha003059 rs2300747 chr1 117104215 A G 3.00E-10 Multiple sclerosis CD58 intron 19525953 rs2300747 chr1 117104215 A G 4.40E-10 Multiple sclerosis CD58 intron 21833088 rs2300747 chr1 117104215 A G 6.00E-09 Multiple sclerosis CD58 intron 22190364 rs17036023 chr1 117129711 A G 5.00E-06 Asthma (childhood onset) IGSF3 intron 23829686 rs517857 chr1 117207065 C T 4.34E-04 Response to cytadine analogues (cytosine arabinoside) IGSF3 intron 24483146 rs17400882 chr1 117227332 G C 6.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs699710 chr1 117228773 A G 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs699710 chr1 117228773 A G 6.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs568359 chr1 117231902 T C 1.69E-04 Schizophrenia / / 20832056 rs2050655 chr1 117235278 T C 4.93E-04 Multiple complex diseases / / 17554300 rs41359245 chr1 117250252 C T 1.36E-04 Multiple complex diseases / / 17554300 rs11586238 chr1 117263138 C G 3.74E-04 Type 2 diabetes / / 17463246 rs11586238 chr1 117263138 C G 4.85E-04 Multiple complex diseases / / 17554300 rs11586238 chr1 117263138 C G 1.30E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs11586238 chr1 117263138 C G 1.00E-09 Multiple sclerosis / / 22190364 rs11586238 chr1 117263138 C G 1.50E-05 Rheumatoid arthritis / / 22446963 rs11586238 chr1 117263138 C G 3.69E-10 Rheumatoid arthritis / / 23143596 rs624988 chr1 117263790 T C 1.20E-05 Rheumatoid arthritis / / 24390342 rs624988 chr1 117263790 T C 8.00E-10 Rheumatoid arthritis / / 24390342 rs519264 chr1 117271568 T C 6.32E-06 Serum metabolites / / 19043545 rs497573 chr1 117271612 A G 5.66E-06 Serum metabolites / / 19043545 rs11582506 chr1 117277321 A G 8.60E-04 Type 2 diabetes / / 17463246 rs11582506 chr1 117277321 A G 8.16E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs798000 chr1 117280696 C T 0.00000431 Rheumatoid arthritis (CCP positive) / / 23143596 rs798000 chr1 117280696 C T 0.0000062 Rheumatoid arthritis / / 23143596 rs798037 chr1 117308238 A C 0.000442935 Hypertension (early onset hypertension) CD2 intron 22479346 rs699738 chr1 117311147 C A 0.000501718 Hypertension (early onset hypertension) CD2 missense 22479346 rs798023 chr1 117339802 G A 3.55E-04 Multiple complex diseases / / 17554300 rs6428670 chr1 117367190 T C 2.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7555532 chr1 117398643 A T 7.31E-04 Type 2 diabetes / / 17463246 rs12037202 chr1 117426406 T C 1.21E-04 Body mass index / / 17255346 rs1122726 chr1 117431253 A G 1.17E-04 Multiple complex diseases / / 17554300 rs10923158 chr1 117442421 C T 6.06E-06 Waist-Hip Ratio / / pha003013 rs10923158 chr1 117442421 C T 1.38E-06 Waist-Hip Ratio / / pha003028 rs2182605 chr1 117463537 T C 9.12E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs2806864 chr1 117469781 C G 6.00E-07 Erectile dysfunction and prostate cancer treatment PTGFRN intron 20932654 rs12078461 chr1 117472049 G A 2.02E-179 Multiple complex diseases PTGFRN intron 17554300 rs2246315 chr1 117477572 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PTGFRN intron 22628534 rs2806880 chr1 117479245 C T 1.61E-04 Multiple complex diseases PTGFRN intron 17554300 rs6692981 chr1 117479752 T C 3.93E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs4641299 chr1 117483361 G A 4.27E-04 Schizophrenia(treatment response to risperidone) PTGFRN intron 19850283 rs4433378 chr1 117491123 A G 4.84E-06 Type 2 diabetes PTGFRN intron 17463246 rs12566708 chr1 117499648 A G 5.53E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs17036665 chr1 117514048 A G 2.94E-04 Body mass index PTGFRN intron 17255346 rs17036665 chr1 117514048 A G 2.48E-04 Type 2 diabetes PTGFRN intron 17463246 rs10801922 chr1 117529458 G A 0.00085104 Sarcoidosis PTGFRN missense 22952805 rs3829881 chr1 117531813 T C 1.05E-04 Acne (severe) PTGFRN UTR-3 24927181 rs3829881 chr1 117531813 T C 5.47E-05 Serum albumin level PTGFRN UTR-3 pha003084 rs10801925 chr1 117541054 C T 9.14E-04 Multiple complex diseases / / 17554300 rs2764851 chr1 117548322 C G 2.17E-04 Alzheimer's disease CD101 intron 17998437 rs2764850 chr1 117550623 A G 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CD101 intron 20877124 rs2764850 chr1 117550623 A G 1.83E-04 Acne (severe) CD101 intron 24927181 rs7551890 chr1 117552321 T G 3.23E-05 Multiple complex diseases CD101 intron 17554300 rs6686551 chr1 117573173 T C 1.57E-04 Lung function (forced vital capacity) CD101 intron 24023788 rs6686551 chr1 117573173 T C 4.69E-04 Lung function (forced expiratory volume in 1 second) CD101 intron 24023788 rs1289666 chr1 117638270 C T 4.70E-04 Weight loss (gastric bypass surgery) TTF2 intron 23643386 rs2477719 chr1 117651363 T G 7.53E-04 Lymphocyte counts / / 22286170 rs907661 chr1 117747094 T A 2.10E-05 Urinary metabolites VTCN1 intron 21572414 rs12046117 chr1 117751365 C T 1.00E-06 Arthritis (juvenile idiopathic) VTCN1 intron 19116933 rs41490749 chr1 117751736 G A 6.91E-05 Type 2 diabetes VTCN1 intron 17463246 rs3806373 chr1 117754059 T C 4.38E-04 Alcohol dependence / / 20201924 rs4659229 chr1 117755800 T C 3.98E-04 Type 2 diabetes / / 17463246 rs7537801 chr1 117757911 C G 3.35E-04 Type 2 diabetes / / 17463246 rs1892409 chr1 117759325 C T 5.59E-04 Alcohol dependence / / 20201924 rs12098035 chr1 117759451 C T 5.95E-04 Alcohol dependence / / 20201924 rs10801944 chr1 117761373 G C 1.38E-04 Type 2 diabetes / / 17463246 rs6692758 chr1 117773202 G A 1.72E-04 Type 2 diabetes / / 17463246 rs1146284 chr1 117809327 A G 6.47E-04 Amyotrophic lateral sclerosis / / 23624525 rs10801954 chr1 117809849 A G 6.05E-04 Smoking cessation / / 24665060 rs6683482 chr1 117813173 T A 1.15E-04 Multiple complex diseases / / 17554300 rs12125871 chr1 117816368 A G 7.39E-05 Lung adenocarcinoma / / 19836008 rs7521942 chr1 117817937 C T 1.15E-04 Alzheimer's disease / / 24755620 rs1289817 chr1 117829295 C A 1.39E-04 Alzheimer's disease / / 24755620 rs12142453 chr1 117833996 G T 2.70E-05 Urinary metabolites / / 21572414 rs12122172 chr1 117841156 C T 1.70E-05 Urinary metabolites / / 21572414 rs11577581 chr1 117850886 G A 3.51E-04 Alzheimer's disease / / 24755620 rs12410934 chr1 117854559 T C 1.90E-05 Urinary metabolites / / 21572414 rs12403240 chr1 117862312 A G 6.80E-04 Alzheimer's disease / / 24755620 rs12088312 chr1 117878314 C T 6.93E-04 Alzheimer's disease / / 24755620 rs7514323 chr1 118002719 A G 3.20E-06 Prostate cancer (early onset) MAN1A2 intron 24740154 rs1290539 chr1 118029601 T G 4.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MAN1A2 intron 24023788 rs10923323 chr1 118048968 G A 9.39E-04 Alzheimer's disease MAN1A2 intron 24755620 rs2622366 chr1 118078875 C T 1.40E-05 Prostate cancer / / 18264096 rs10923347 chr1 118118765 G A 6.79E-04 Multiple complex diseases / / 17554300 rs12730116 chr1 118133230 G C 5.04E-04 Type 2 diabetes / / 17463246 rs1808806 chr1 118174222 A G 5.91E-04 Multiple complex diseases / / 17554300 rs319506 chr1 118185332 T C 3.86E-04 Type 2 diabetes / / 17463246 rs319498 chr1 118194657 A G 6.10E-04 Type 2 diabetes / / 17463246 rs377875 chr1 118201128 T C 5.35E-04 Multiple complex diseases / / 17554300 rs377875 chr1 118201128 T C 6.11E-04 Smoking cessation / / 24665060 rs7549770 chr1 118209904 G A 1.90E-04 Multiple complex diseases / / 17554300 rs963264 chr1 118225110 A G 6.25E-04 Type 2 diabetes / / 17463246 rs965574 chr1 118225308 C G 6.70E-04 Type 2 diabetes / / 17463246 rs965574 chr1 118225308 C G 1.46E-04 Multiple complex diseases / / 17554300 rs731017 chr1 118225681 T C 5.22E-04 Type 2 diabetes / / 17463246 rs731017 chr1 118225681 T C 1.21E-04 Multiple complex diseases / / 17554300 rs10754358 chr1 118233846 C T 1.96E-05 Reading and spelling / / 23738518 rs319490 chr1 118281894 G A 6.06E-04 Type 2 diabetes / / 17463246 rs11586992 chr1 118288903 G A 2.16E-04 Alzheimer's disease / / 22005930 rs12740113 chr1 118292742 C T 1.37E-04 Alzheimer's disease / / 22005930 rs319464 chr1 118293093 A G 3.16E-05 Fibrinogen / / 17255346 rs12731636 chr1 118296638 G T 1.17E-04 Alzheimer's disease / / 22005930 rs12408188 chr1 118296695 A G 1.41E-04 Alzheimer's disease / / 22005930 rs319471 chr1 118297105 T C 2.96E-04 Fibrinogen / / 17255346 rs12725531 chr1 118298914 A T 3.85E-04 Alzheimer's disease / / 22005930 rs379058 chr1 118301575 T A 1.15E-04 Alzheimer's disease / / 22005930 rs1371 chr1 118406208 A C 5.08E-04 Suicide attempts in bipolar disorder GDAP2 UTR-3 21423239 rs77073478 chr1 118441771 G A 0.000015 Breast cancer(er negative) GDAP2 missense 23555315 rs749003 chr1 118531980 C T 4.81E-04 Premature ovarian failure SPAG17 intron 19508998 rs4144543 chr1 118536585 G A 6.99E-04 Alzheimer's disease SPAG17 intron 24755620 rs6428727 chr1 118575757 T C 6.14E-04 Alzheimer's disease SPAG17 intron 24755620 rs10733099 chr1 118577067 G T 4.37E-04 Alzheimer's disease SPAG17 intron 24755620 rs7551906 chr1 118689892 T C 4.12E-05 Multiple complex diseases SPAG17 intron 17554300 rs6700302 chr1 118699633 C G 2.61E-04 Alzheimer's disease SPAG17 intron 24755620 rs10923505 chr1 118730945 G A 9.83E-04 Alzheimer's disease / / 24755620 rs10923507 chr1 118731761 C T 3.72E-04 Alzheimer's disease / / 24755620 rs6685352 chr1 118732429 G A 3.73E-04 Alzheimer's disease / / 24755620 rs1777268 chr1 118739713 T G 1.18E-04 Multiple complex diseases / / 17554300 rs1782411 chr1 118740017 A G 1.18E-04 Multiple complex diseases / / 17554300 rs9661113 chr1 118799439 T C 2.94E-04 Coronary heart disease / / 21606135 rs7551954 chr1 118799927 C T 3.21E-04 Coronary heart disease / / 21606135 rs10802017 chr1 118810834 T C 2.41E-04 Coronary heart disease / / 21606135 rs7527203 chr1 118816729 C T 2.00E-06 Obesity-related traits / / 23251661 rs7515420 chr1 118823147 A G 3.25E-04 Coronary heart disease / / 21606135 rs1938283 chr1 118831937 C A 3.31E-04 Coronary heart disease / / 21606135 rs1938275 chr1 118841141 T C 7.59E-06 Lipoproteins / / pha003079 rs11576263 chr1 118842089 T C 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10923537 chr1 118846667 A G 5.58E-05 Lipoproteins / / pha003079 rs7513580 chr1 118849909 G A 2.65E-05 Multiple complex diseases / / 17554300 rs9428104 chr1 118855587 A G 6.00E-23 Height / / 20881960 rs7534091 chr1 118864616 A G 2.00E-16 Height / / 23563607 rs4375253 chr1 118864968 C T 8.11E-05 Alcohol dependence / / 21703634 rs17038182 chr1 118868405 G C 1.47E-04 Multiple complex diseases / / 17554300 rs17038182 chr1 118868405 G C 5.00E-07 Height / / 19396169 rs10802023 chr1 118878656 T C 2.18E-05 Alcohol dependence / / 21703634 rs12083887 chr1 118881689 A G 1.85E-04 Alzheimer's disease (late onset) / / 20885792 rs12735613 chr1 118883973 G A 4.00E-11 Height / / 18391952 rs12735613 chr1 118883973 G A 1.70E-05 Height / / 19396169 rs12735613 chr1 118883973 G A 1.94E-05 Height / / 19893584 rs2474937 chr1 118902978 A G 8.00E-10 Congenital heart malformation / / 23708190 rs10923556 chr1 118903196 C T 8.77E-05 Alcohol dependence / / 21703634 rs12135821 chr1 118943449 G A 9.13E-05 Alzheimer's disease (late onset) / / 20885792 rs1146338 chr1 118987451 T C 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1146337 chr1 118987765 A G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1213994 chr1 118989522 A G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2798449 chr1 118992961 G A 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1146335 chr1 119002799 C T 6.17E-04 Schizophrenia / / 19197363 rs1146333 chr1 119005483 C A 2.94E-04 Multiple complex diseases / / 17554300 rs1146324 chr1 119013403 T C 4.32E-04 Schizophrenia / / 19197363 rs1146320 chr1 119016240 A C 3.79E-04 Schizophrenia / / 19197363 rs1229119 chr1 119023640 C T 2.91E-05 Schizophrenia / / 19197363 rs1146313 chr1 119026090 C T 2.16E-05 Schizophrenia / / 19197363 rs12408596 chr1 119034534 T C 2.78E-04 Schizophrenia / / 19197363 rs12145150 chr1 119042243 A C 1.49E-05 Alzheimer's disease (late onset) / / 21379329 rs4659090 chr1 119068372 C T 8.62E-04 Type 2 diabetes / / 17463246 rs4659090 chr1 119068372 C T 4.79E-04 Alzheimer's disease / / 24755620 rs4659091 chr1 119068639 G T 4.79E-04 Alzheimer's disease / / 24755620 rs6660988 chr1 119068677 C T 7.98E-04 Multiple complex diseases / / 17554300 rs1830853 chr1 119069110 T C 7.33E-05 Alzheimer's disease / / 24755620 rs10923586 chr1 119069342 T C 5.11E-04 Alzheimer's disease / / 24755620 rs942584 chr1 119076921 C A 2.05E-04 Alzheimer's disease / / 24755620 rs6428751 chr1 119079566 A G 4.08E-04 Multiple complex diseases / / 17554300 rs6428751 chr1 119079566 A G 8.39E-04 Alzheimer's disease / / 24755620 rs12134541 chr1 119084491 A C 3.52E-04 Multiple complex diseases / / 17554300 rs4590660 chr1 119085082 G A 5.57E-04 Multiple complex diseases / / 17554300 rs11590971 chr1 119099887 T C 4.44E-04 Multiple complex diseases / / 17554300 rs11590559 chr1 119099981 A G 8.69E-04 Alzheimer's disease / / 24755620 rs12022971 chr1 119101922 T C 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17185776 chr1 119102839 T C 5.95E-06 Asthma / / 21790008 rs17257972 chr1 119106612 G A 1.00E-04 Schizophrenia / / 19197363 rs1936068 chr1 119108658 T C 5.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10754383 chr1 119117474 C A 4.97E-06 Relative hand skill in reading disability / / 24068947 rs10802044 chr1 119117589 G C 1.00E-04 Prostate cancer / / 21743057 rs10802044 chr1 119117589 G C 9.47E-05 Relative hand skill in reading disability / / 24068947 rs1343298 chr1 119123811 T C 7.45E-06 Relative hand skill in reading disability / / 24068947 rs1911166 chr1 119126331 T C 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1911166 chr1 119126331 T C 4.38E-06 Relative hand skill in reading disability / / 24068947 rs4329498 chr1 119133609 T C 1.76E-04 Schizophrenia / / 19197363 rs4659105 chr1 119138227 A G 8.01E-06 Relative hand skill in reading disability / / 24068947 rs12138163 chr1 119139697 G A 4.21E-06 Relative hand skill in reading disability / / 24068947 rs4658990 chr1 119140388 G A 4.20E-06 Relative hand skill in reading disability / / 24068947 rs4659109 chr1 119142879 C A 4.08E-06 Relative hand skill in reading disability / / 24068947 rs4463652 chr1 119143773 A G 4.17E-06 Relative hand skill in reading disability / / 24068947 rs10802047 chr1 119144432 A T 2.00E-06 Relative hand skill in reading disability / / 24068947 rs10802047 chr1 119144432 A T 2.37E-06 Relative hand skill in reading disability / / 24068947 rs12137431 chr1 119146884 T C 4.16E-06 Relative hand skill in reading disability / / 24068947 rs12120076 chr1 119148939 C G 4.22E-06 Relative hand skill in reading disability / / 24068947 rs10802049 chr1 119149428 C T 4.15E-06 Relative hand skill in reading disability / / 24068947 rs4659111 chr1 119150184 G T 4.24E-06 Relative hand skill in reading disability / / 24068947 rs10923630 chr1 119152617 A G 4.17E-06 Relative hand skill in reading disability / / 24068947 rs10157240 chr1 119153953 G T 5.02E-06 Relative hand skill in reading disability / / 24068947 rs1742854 chr1 119157211 G T 4.19E-06 Relative hand skill in reading disability / / 24068947 rs6685605 chr1 119159490 T G 2.82E-05 Relative hand skill in reading disability / / 24068947 rs10923636 chr1 119185080 C T 2.04E-04 Multiple complex diseases / / 17554300 rs10923636 chr1 119185080 C T 1.10E-05 Urinary metabolites / / 21572414 rs2360627 chr1 119188329 C T 2.50E-05 Urinary metabolites / / 21572414 rs12143914 chr1 119203300 C T 2.90E-05 Parkinson's disease (age of onset) / / 19772629 rs7521782 chr1 119253471 C T 3.28E-04 Alzheimer's disease (late onset) / / 21379329 rs4144542 chr1 119259807 G T 2.88E-04 Alzheimer's disease (late onset) / / 21379329 rs4144542 chr1 119259807 G T 8.90E-06 Urinary metabolites / / 21572414 rs6688928 chr1 119261698 A G 9.55E-05 Relative hand skill in reading disability / / 24068947 rs10923658 chr1 119272779 G A 4.34E-04 Schizophrenia / / 19197363 rs17022367 chr1 119282172 G A 5.06E-05 Relative hand skill in reading disability / / 24068947 rs369417542 chr1 119282172 G GA 5.06E-05 Relative hand skill in reading disability / / 24068947 rs12039075 chr1 119285701 A G 5.41E-05 Relative hand skill in reading disability / / 24068947 rs1570816 chr1 119291382 A G 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs17185832 chr1 119293640 A G 1.02E-04 Premature ovarian failure / / 19508998 rs12063988 chr1 119295915 C T 1.68E-04 Alzheimer's disease (late onset) / / 21379329 rs10923668 chr1 119296728 C T 1.00E-05 Urinary metabolites / / 21572414 rs9787117 chr1 119296803 C G 8.40E-06 Urinary metabolites / / 21572414 rs2764473 chr1 119300747 T C 2.00E-05 Urinary metabolites / / 21572414 rs10923673 chr1 119316263 T G 3.06E-04 Longevity / / 22279548 rs1853774 chr1 119318683 C T 4.89E-04 Schizophrenia / / 19197363 rs4659120 chr1 119319805 A G 1.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2485961 chr1 119344903 T C 7.81E-04 Schizophrenia / / 19197363 rs1766799 chr1 119367975 T C 8.15E-05 Relative hand skill in reading disability / / 24068947 rs1766803 chr1 119383818 T C 1.67E-04 Schizophrenia / / 19197363 rs868157 chr1 119392083 T G 1.59E-04 Multiple complex diseases / / 17554300 rs1766807 chr1 119406760 A G 6.56E-04 Schizophrenia / / 19197363 rs7552120 chr1 119419556 C T 4.81E-05 Multiple complex diseases / / 17554300 rs1014098 chr1 119458215 C T 4.28E-04 Multiple complex diseases TBX15 intron 17554300 rs10923702 chr1 119485466 C T 9.76E-04 Alzheimer's disease TBX15 intron 22005930 rs6701231 chr1 119495661 C G 4.13E-09 Waist-hip ratio TBX15 intron 20935629 rs1155949 chr1 119496579 C T 6.07E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 intron 24023788 rs78411379 chr1 119496772 A G 0.0000962 Menopause (age at onset) TBX15 intron 23424626 rs12143789 chr1 119497154 G C 3.70E-04 Multiple complex diseases TBX15 intron 17554300 rs984222 chr1 119503843 C G 9.00E-25 Waist-hip ratio TBX15 intron 20935629 rs10923714 chr1 119512913 G A 7.49E-04 Alcohol dependence TBX15 intron 21314694 rs10923714 chr1 119512913 G A 6.80E-05 Waist-hip ratio TBX15 intron 23966867 rs10923714 chr1 119512913 G A 4.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 intron 24023788 rs12742627 chr1 119525788 G A 2.14E-04 Height TBX15 intron 17255346 rs7545737 chr1 119533823 A G 4.64E-05 Brain structure TBX15 nearGene-5 22504417 rs7545737 chr1 119533823 A G 2.58E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 nearGene-5 24023788 rs1409158 chr1 119538890 C T 8.99E-04 Multiple complex diseases / / 17554300 rs1409158 chr1 119538890 C T 6.86E-09 Lymphocyte counts / / 22286170 rs7522839 chr1 119542855 G T 6.82E-06 Waist-hip ratio / / 20935629 rs2765542 chr1 119560326 T A 5.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17185996 chr1 119608732 T C 2.43E-06 Waist-hip ratio WARS2 intron 20935629 rs17023211 chr1 119624967 C T 1.41E-04 Multiple complex diseases WARS2 intron 17554300 rs10494221 chr1 119634224 C T 3.65E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) WARS2 intron 17982456 rs1341580 chr1 119657057 T G 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WARS2 intron 20877124 rs6677940 chr1 119659849 A G 1.77E-04 Cholesterol WARS2 intron 17255346 rs4387216 chr1 119680296 C T 5.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WARS2 intron 20877124 rs116411856 chr1 119701541 G A 0.0000816 Menopause (age at onset) / / 23424626 rs868675 chr1 119773596 T C 6.28E-04 Heart Failure / / pha002884 rs12730226 chr1 119789289 C T 4.92E-05 Post-operative nausea and vomiting / / 21694509 rs1341797 chr1 119795133 G A 7.00E-05 Alcohol dependence / / 20201924 rs1341797 chr1 119795133 G A 6.95E-05 Alcoholism / / pha002892 rs35171095 chr1 119797210 C G 5.25E-04 Type 2 diabetes / / 17463246 rs11580295 chr1 119836236 C T 7.07E-05 Lung adenocarcinoma / / 19836008 rs11580295 chr1 119836236 C T 4.36E-05 Partial epilepsies / / 20522523 rs12040905 chr1 119853231 C G 7.36E-05 Aging (time to event) / / 21782286 rs1891224 chr1 119854742 G A 1.90E-06 Alcohol dependence / / 22096494 rs699770 chr1 119860975 A G 1.04E-04 Alzheimer's disease / / 17998437 rs699771 chr1 119871977 C A,G,T 8.87E-06 Alcohol dependence / / 20202923 rs699771 chr1 119871977 C A,G,T 2.80E-05 Alcohol dependence / / 21956439 rs699771 chr1 119871977 C A,G,T 1.70E-06 Alcohol dependence / / 22096494 rs699771 chr1 119871977 C A,G,T 3.40E-06 Alcohol and nictotine co-dependence / / 22488850 rs838528 chr1 119899035 G T 9.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3753264 chr1 119909514 A G 5.25E-05 HIV-1 progression to AIDS and death HAO2 nearGene-5 21811574 rs2005390 chr1 119940381 T G 8.90E-04 Stroke / / pha002887 rs12141041 chr1 119952776 T C 2.00E-12 Blood metabolite levels / / 24816252 rs17023793 chr1 120019818 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs41415744 chr1 120021211 G T 8.82E-04 Multiple complex diseases / / 17554300 rs2011191 chr1 120023888 G A 9.50E-04 Multiple complex diseases / / 17554300 rs911244 chr1 120023971 C T 9.52E-04 Multiple complex diseases / / 17554300 rs911244 chr1 120023971 C T 7.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs4567318 chr1 120030539 G C 4.75E-04 Multiple complex diseases / / 17554300 rs10802112 chr1 120091434 T C 2.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4659200 chr1 120099980 C T 7.00E-04 Obesity-related traits / / 17903300 rs41427946 chr1 120109260 C T 4.22E-26 Narcolepsy / / 19629137 rs4659203 chr1 120110104 T C 1.11E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10923875 chr1 120150949 T C 1.29E-04 Type 2 diabetes / / 17463246 rs10923875 chr1 120150949 T C 2.43E-04 Multiple complex diseases / / 17554300 rs347905 chr1 120180034 A G 2.09E-04 Birth weight ZNF697 intron 17255346 rs347905 chr1 120180034 A G 8.11E-05 Chronic Hepatitis C infection ZNF697 intron 21725309 rs481357 chr1 120200843 T C 7.19E-05 Aging (time to event) / / 21782286 rs541503 chr1 120208297 T C 3.00E-12 Serum metabolites / / 20037589 rs1163251 chr1 120209755 T C 7.00E-27 Blood metabolite levels / / 24816252 rs12025390 chr1 120216287 C T 5.40E-05 Cognitive performance / / 19734545 rs478093 chr1 120255126 A G 2.00E-14 Metabolite levels (Glycine metabolism) PHGDH intron 23378610 rs477992 chr1 120257576 A G 5.99E-05 Serum metabolites PHGDH intron 19043545 rs477992 chr1 120257576 A G 3.00E-14 Metabolic traits PHGDH intron 21886157 rs942835 chr1 120263018 T C 4.50E-04 Coronary heart disease PHGDH intron 21606135 rs894079 chr1 120263657 A G 7.55E-05 Coronary heart disease PHGDH intron 21606135 rs920513 chr1 120272606 C A 6.94E-04 Multiple complex diseases PHGDH intron 17554300 rs17024167 chr1 120282232 T C 1.46E-05 Tunica Media PHGDH intron pha003034 rs17258425 chr1 120286863 A G 5.51E-05 Multiple complex diseases PHGDH nearGene-3 17554300 rs608358 chr1 120289407 C A 8.83E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs532208 chr1 120292279 G T 5.65E-05 Serum metabolites HMGCS2 intron 19043545 rs4659233 chr1 120303332 G A 5.99E-04 Smoking initiation HMGCS2 intron 24665060 rs12562383 chr1 120305525 A T 1.82E-05 Serum metabolites HMGCS2 intron 19043545 rs3790692 chr1 120309868 A G 3.15E-05 Serum metabolites HMGCS2 intron 19043545 rs935059 chr1 120333201 A T 4.86E-05 Serum metabolites / / 19043545 rs947268 chr1 120376477 C G 7.90E-04 Type 2 diabetes / / 17846126 rs140014891 chr1 120384066 C T 0.00048 Breast cancer NBPF7 missense 23555315 rs10923915 chr1 120404592 G A 9.96E-05 Multiple complex diseases / / 17554300 rs2843027 chr1 120425577 A C 4.73E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7547168 chr1 120435163 A G 7.36E-05 Magnesium levels / / pha003092 rs2793823 chr1 120437718 G A 1.05E-04 Type 2 diabetes ADAM30 cds-synon 17463246 rs2641352 chr1 120446063 T C 0.000031 Type 2 diabetes (females) / / 22885922 rs3897478 chr1 120451190 T C 2.00E-11 Crohn's disease / / 23128233 rs835575 chr1 120456563 G A,C,T 9.25E-06 Type 2 diabetes NOTCH2 UTR-3 17463246 rs10127888 chr1 120498250 C G 1.00E-05 Type 2 diabetes NOTCH2 intron 17463246 rs17186372 chr1 120500951 C G 0.0002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 NOTCH2 intron 21873659 rs2934381 chr1 120506108 G A 8.43E-06 Type 2 diabetes NOTCH2 intron 17463246 rs2453044 chr1 120508524 A G 1.37E-05 Type 2 diabetes NOTCH2 intron 17463246 rs10923931 chr1 120517959 G T 8.70E-08 Type 2 diabetes NOTCH2 intron 17463246 rs10923931 chr1 120517959 G T 4.26E-05 Multiple complex diseases NOTCH2 intron 17554300 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 18372903 rs10923931 chr1 120517959 G T 4.00E-08 Coronary heart disease NOTCH2 intron 21347282 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 21647700 rs10923931 chr1 120517959 G T 0.000013 Type 2 diabetes NOTCH2 intron 22885922 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 23300278 rs2793831 chr1 120523902 T C 3.68E-06 Type 2 diabetes NOTCH2 intron 17463246 rs6683357 chr1 121164607 G A 2.56E-05 Alzheimer's disease (late onset) / / 21379329 rs6600671 chr1 121200490 T G 6.00E-07 Hip geometry / / 17903296 rs6600671 chr1 121200490 T G 6.64E-04 Alzheimer's disease / / 24755620 rs2319969 chr1 121207335 C T 8.21E-04 Alzheimer's disease / / 24755620 rs2319971 chr1 121226982 G T 4.09E-04 Alzheimer's disease / / 24755620 rs4147001 chr1 121236110 T C 4.67E-05 Cognitive test performance / / 20125193 rs41500448 chr1 121238279 A G 4.38E-04 Multiple complex diseases / / 17554300 rs11249433 chr1 121280613 A G 2.30E-05 Type 2 diabetes EMBP1 intron 17293876 rs11249433 chr1 121280613 A G 2.30E-05 Type 2 diabetes EMBP1 intron 19184112 rs11249433 chr1 121280613 A G 7.00E-10 Breast cancer EMBP1 intron 19330030 rs11249433 chr1 121280613 A G 7.00E-10 Nasopharyngeal carcinoma EMBP1 intron 20512145 rs11249433 chr1 121280613 A G 2.00E-26 Breast cancer EMBP1 intron 23535729 rs11249431 chr1 121286203 A C,G,T 4.70E-05 Type 2 diabetes EMBP1 intron 17293876 rs11249431 chr1 121286203 A C,G,T 4.70E-05 Type 2 diabetes EMBP1 intron 19184112 rs11249431 chr1 121286203 A C,G,T 4.64E-04 Alzheimer's disease (late onset) EMBP1 intron 21379329 rs11249395 chr1 121311799 G A 3.02E-04 Alzheimer's disease (late onset) / / 21379329 rs141066291 chr1 144922638 T A 0.000079 Breast cancer(er negative) PDE4DIP missense 23555315 rs61805374 chr1 144931387 T G 0.00031 Prostate cancer PDE4DIP missense 23555315 rs1778596 chr1 144991278 T A 8.66E-15 Gender PDE4DIP intron 22362730 rs587667473 chr1 144992181 A C 2.00E-06 Capecitabine sensitivity PDE4DIP intron 22864933 rs12136740 chr1 145104261 T G 3.84E-04 Coronary heart disease SEC22B intron 21971053 rs10797649 chr1 145394955 C A 4.28E-05 Taste perception / / 22132133 rs12091564 chr1 145395604 T C 2.00E-07 Coronary heart disease / / 21626137 rs10218795 chr1 145416056 C T 2.00E-07 Coronary heart disease HFE2 intron 21626137 rs6661602 chr1 145428296 C T 2.76E-04 Alcohol dependence / / 21314694 rs2031370 chr1 145471860 T C 2.63E-04 Amyotrophic lateral sclerosis (sporadic) ANKRD34A intron 24529757 rs16827018 chr1 145545225 T G 1.27E-04 Celiac disease / / 23936387 rs720899 chr1 145550922 A C,G,T 3.58E-05 Cognitive test performance ANKRD35 intron 20125193 rs10494240 chr1 145551515 A G 9.70E-04 Multiple complex diseases ANKRD35 intron 17554300 rs12125340 chr1 145554450 T C 3.36E-04 Multiple complex diseases ANKRD35 intron 17554300 rs143087712 chr1 145562149 C A 0.000093 Breast cancer(er negative) ANKRD35 missense 23555315 rs6424380 chr1 145571398 T C 1.25E-04 Alcohol dependence / / 21314694 rs17352344 chr1 145586048 T C 5.60E-06 Contrast sensitivity PIAS3 UTR-3 24152035 rs2004659 chr1 145588184 T A,C,G 3.35E-08 Urate levels NUDT17 intron 23263486 rs2004659 chr1 145588184 T A,C,G 3.90E-05 Epilepsy (remission after treatment) NUDT17 intron 23962720 rs9286836 chr1 145588536 C T 3.39E-05 Epilepsy (remission after treatment) NUDT17 intron 23962720 rs9729027 chr1 145592073 A T 2.58E-05 Epilepsy (remission after treatment) / / 23962720 rs1887806 chr1 145594799 C T 2.69E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs913513 chr1 145595423 G A 2.70E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs2018027 chr1 145595820 A G 2.70E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs9728345 chr1 145597417 C A 3.15E-08 Urate levels POLR3C intron 23263486 rs9728345 chr1 145597417 C A 2.72E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs11587821 chr1 145599038 G T 2.01E-08 Urate levels POLR3C intron 23263486 rs11587821 chr1 145599038 G T 2.74E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs10752826 chr1 145602791 C G 1.89E-08 Urate levels POLR3C intron 23263486 rs10752826 chr1 145602791 C G 2.78E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs4970859 chr1 145605318 C T 3.57E-08 Urate levels POLR3C intron 23263486 rs4970859 chr1 145605318 C T 2.80E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs12402787 chr1 145609971 T C 1.69E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs61816194 chr1 145614468 C T 2.65E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12732381 chr1 145630536 T A 2.52E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs17354594 chr1 145632500 A G 3.63E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12402867 chr1 145636226 G A 1.96E-08 Urate levels RNF115 intron 23263486 rs12402867 chr1 145636226 G A 2.62E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12724816 chr1 145639324 G T 1.87E-08 Urate levels RNF115 intron 23263486 rs12724816 chr1 145639324 G T 2.67E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs11583404 chr1 145640157 T C 2.63E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12405132 chr1 145644984 C T 3.01E-08 Urate levels RNF115 intron 23263486 rs12405132 chr1 145644984 C T 2.45E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12744221 chr1 145645606 C T 6.00E-06 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12729321 chr1 145645820 G T 2.44E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2040085 chr1 145651861 G A 2.26E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2040086 chr1 145651876 C A 2.56E-08 Urate levels RNF115 intron 23263486 rs2040086 chr1 145651876 C A 2.26E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2799107 chr1 145660663 G A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12725120 chr1 145661313 C T 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2318299 chr1 145662666 T C 1.56E-08 Urate levels RNF115 intron 23263486 rs2318299 chr1 145662666 T C 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs718942 chr1 145662853 T A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs34958017 chr1 145666719 G A 1.27E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12728500 chr1 145667088 C A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs1680663 chr1 145671455 C G 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs35687015 chr1 145674149 T A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs112745056 chr1 145674825 T A 3.49E-06 Osteoarthritis RNF115 intron 21871595 rs11591191 chr1 145675931 T C 2.09E-08 Urate levels RNF115 intron 23263486 rs11591191 chr1 145675931 T C 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12750384 chr1 145681484 T C 1.36E-08 Urate levels RNF115 intron 23263486 rs12750384 chr1 145681484 T C 2.03E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs34695381 chr1 145683334 G C 2.09E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2624756 chr1 145687529 G A 9.08E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs17354678 chr1 145689271 A G 1.70E-09 Urate levels / / 23263486 rs17354678 chr1 145689271 A G 9.37E-05 Epilepsy (remission after treatment) / / 23962720 rs12123298 chr1 145690472 C A,G,T 1.55E-09 Urate levels / / 23263486 rs17352469 chr1 145693383 A G 4.51E-09 Urate levels / / 23263486 rs17352469 chr1 145693383 A G 2.90E-05 Epilepsy (remission after treatment) / / 23962720 rs2231375 chr1 145696694 G A 3.06E-09 Urate levels CD160 intron 23263486 rs2231375 chr1 145696694 G A 2.86E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1778523 chr1 145698023 C G 2.86E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471634 chr1 145702115 C T 2.84E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1023945 chr1 145703115 T C 2.51E-08 Urate levels CD160 intron 23263486 rs1970612 chr1 145703590 G T 2.81E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1552172 chr1 145704759 T A 3.91E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs12755149 chr1 145704918 T A 2.80E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471628 chr1 145707057 A T 9.51E-09 Urate levels CD160 intron 23263486 rs1471629 chr1 145707240 C A 2.72E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471630 chr1 145707297 A G 2.38E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs2449411 chr1 145708698 T C 3.17E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs4970874 chr1 145709394 T C 1.81E-10 Urate levels CD160 intron 23263486 rs4970874 chr1 145709394 T C 2.34E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs35880546 chr1 145713071 T C 2.18E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs744877 chr1 145714376 G T 6.82E-09 Urate levels CD160 intron 23263486 rs9728526 chr1 145716763 G A 3.68E-08 Urate levels / / 23263486 rs3753436 chr1 145718113 A G 2.36E-08 Urate levels / / 23263486 rs10910845 chr1 145723120 A C 1.57E-08 Uric acid levels / / 19503597 rs10910845 chr1 145723120 A C 3.90E-08 Urate levels / / 20884846 rs10910845 chr1 145723120 A C 4.87E-25 Urate levels / / 23263486 rs1967017 chr1 145723645 T C 5.00E-09 Uric acid levels / / 19503597 rs1967017 chr1 145723645 T C 4.00E-08 Urate levels / / 20884846 rs1967017 chr1 145723645 T C 3.16E-26 Urate levels / / 23263486 rs1471633 chr1 145723739 A C 3.77E-09 Uric acid levels / / 19503597 rs1471633 chr1 145723739 A C 3.60E-08 Urate levels / / 20884846 rs1471633 chr1 145723739 A C 1.00E-29 Urate levels / / 23263486 rs12129861 chr1 145725689 G A 3.00E-09 Uric acid levels / / 19503597 rs12129861 chr1 145725689 G A 5.38E-20 Urate levels / / 23263486 rs900347 chr1 145726727 A G 2.14E-18 Urate levels / / 23263486 rs1797052 chr1 145727683 C T 8.00E-09 Contrast sensitivity PDZK1 UTR-5 24152035 rs1298954 chr1 145730160 A G 7.16E-19 Urate levels PDZK1 intron 23263486 rs9659930 chr1 145730701 G C 7.32E-14 Urate levels PDZK1 intron 23263486 rs882210 chr1 145732946 G C 1.72E-08 Urate levels PDZK1 intron 23263486 rs9728619 chr1 145736438 T C 3.99E-08 Uric acid levels PDZK1 intron 19503597 rs9728619 chr1 145736438 T C 3.11E-21 Urate levels PDZK1 intron 23263486 rs2355388 chr1 146499296 C T 3.40E-05 Serum metabolites LOC728989 intron 19043545 rs1853782 chr1 146508774 C T 0.0000451 Salmonella-induced pyroptosis LOC728989 intron 22837397 rs12122100 chr1 146508934 C T 1.00E-06 HIV-1 control LOC728989 intron 20041166 rs6665411 chr1 146547095 G A 5.10E-06 HIV-1 control / / 20041166 rs11239930 chr1 146560564 G A 2.00E-06 AIDS progression / / 21502085 rs6593732 chr1 146566324 T C 7.63E-04 Type 2 diabetes / / 17463246 rs17359526 chr1 146580479 T C 9.82E-04 Type 2 diabetes / / 17463246 rs6693631 chr1 146580724 T C 9.82E-04 Type 2 diabetes / / 17463246 rs75365816 chr1 146593915 G A 0.00086333 Sarcoidosis / / 22952805 rs79365757 chr1 146593944 G C 0.00087562 Sarcoidosis / / 22952805 rs111666024 chr1 146594841 G T 0.00088791 Sarcoidosis / / 22952805 rs12065005 chr1 146600482 A G 4.71E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11239934 chr1 146604423 G C 3.57E-05 Multiple complex diseases / / 17554300 rs1348316 chr1 146643555 A G 1.23E-05 Waist-Hip Ratio PRKAB2 intron pha003029 rs2077749 chr1 146652637 A G 3.75E-05 Multiple complex diseases LOC100505794 intron 17554300 rs7532458 chr1 146676901 A G 5.39E-06 Multiple complex diseases FMO5 intron 17554300 rs10900325 chr1 146692174 T C 2.95E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 2.37E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 8.76E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 9.34E-05 Orofacial clefts FMO5 intron 22419666 rs7537483 chr1 146709877 C G 5.99E-04 Multiple complex diseases / / 17554300 rs7537483 chr1 146709877 C G 2.93E-04 Body mass index / / 21701565 rs3820130 chr1 146724003 A G 2.92E-04 Body mass index CHD1L intron 21701565 rs3737845 chr1 146724408 G A 3.04E-04 Body mass index CHD1L intron 21701565 rs17160062 chr1 146731367 T C 6.38E-04 Body mass index CHD1L intron 21701565 rs4950392 chr1 146736548 G A,C,T 8.51E-05 Body Mass Index CHD1L intron pha003019 rs10793656 chr1 146751272 T A,C,G 4.96E-04 Lung function (forced expiratory volume in 1 second) CHD1L intron 24023788 rs7516430 chr1 146767062 A G 7.66E-06 Orofacial clefts CHD1L intron 22419666 rs6538 chr1 146767353 G A 4.83E-04 Lung function (forced expiratory volume in 1 second) CHD1L UTR-3 24023788 rs945742 chr1 146785157 A G 9.80E-05 Body Mass Index / / pha003019 rs11239984 chr1 146791729 G A 3.96E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2353983 chr1 146813137 C T 9.66E-05 Serum metabolites / / 19043545 rs2353983 chr1 146813137 C T 9.53E-05 Orofacial clefts / / 22419666 rs4626937 chr1 146826675 T C 4.40E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2353987 chr1 146827556 G T 4.26E-05 Body Mass Index / / pha003019 rs11240009 chr1 146842342 A G 8.24E-05 Post-operative nausea and vomiting / / 21694509 rs4950322 chr1 146854836 G A 2.00E-07 Protein quantitative trait loci / / 18464913 rs4950322 chr1 146854836 G A 7.00E-07 Protein quantitative trait loci / / 18464913 rs12408395 chr1 146906368 G A 4.20E-05 Post-operative nausea and vomiting LOC100289211 intron 21694509 rs6678706 chr1 146917617 G A 9.34E-04 Type 2 diabetes LOC100289211 intron 17463246 rs11240053 chr1 146923557 G A 1.30E-05 HIV-1 control LOC100289211 intron 20041166 rs11240065 chr1 146940196 T C 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs148158062 chr1 146940196 T TGTTCCTTC 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs56352300 chr1 146940196 T TGTTCCTTC 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs2803533 chr1 146954674 G A 1.51E-06 Esophageal cancer (squamous cell) LOC100289211 intron 22960999 rs12406844 chr1 146969411 C T 2.98E-04 Epilepsy LOC100289211 intron 22116939 rs2000072 chr1 146970568 G A,C,T 3.69E-05 Personality dimensions LOC100289211 intron 18957941 rs2000072 chr1 146970568 G A,C,T 9.44E-05 Bipolar disorder LOC100289211 intron 19488044 rs2000072 chr1 146970568 G A,C,T 5.54E-05 Bipolar Disorder LOC100289211 intron pha002863 rs10900374 chr1 146970946 G A 6.32E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs1845807 chr1 146973797 G A 6.22E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs586000 chr1 146976138 T C 6.67E-04 Coronary Artery Disease LOC100289211 intron 17634449 rs631288 chr1 146979516 C T 4.06E-05 Type 2 diabetes LOC100289211 intron 17463246 rs631288 chr1 146979516 C T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity LOC100289211 intron 24324551 rs17160321 chr1 146984463 G A 9.65E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs17160322 chr1 146984515 A G 9.65E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs17160327 chr1 146985525 G T 9.58E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs1013587 chr1 146986473 A G 9.63E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs12046574 chr1 146989520 C T 9.60E-06 Stroke (ischemic) / / 21957438 rs4950328 chr1 147004811 T C 5.14E-04 Parkinson's disease / / 16252231 rs3806218 chr1 147011783 T C 3.74E-04 Parkinson's disease / / 16252231 rs12072533 chr1 147017524 A C 4.69E-04 Nicotine dependence BCL9 intron 17158188 rs594206 chr1 147020456 A C,G,T 6.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) BCL9 intron 24025145 rs716703 chr1 147021148 C T 5.39E-04 Nicotine dependence BCL9 intron 17158188 rs10494251 chr1 147023894 C T 9.83E-05 Crohn's disease BCL9 intron 17684544 rs4950461 chr1 147033573 G A 4.57E-05 Alzheimer's disease (late onset) BCL9 intron 21379329 rs7526407 chr1 147070609 T C 2.20E-04 Multiple complex diseases BCL9 intron 17554300 rs583583 chr1 147083114 C T 6.00E-07 Schizophrenia (negative symptoms) BCL9 intron 23382809 rs12129752 chr1 147099287 G T 5.77E-04 Smoking initiation / / 24665060 rs10157759 chr1 147107123 C T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs6663082 chr1 147107966 G A 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10494248 chr1 147108260 G A 7.90E-04 Crohn's disease / / 17684544 rs11579007 chr1 147136284 G A 4.40E-05 Lymphocyte counts ACP6 intron 22286170 rs13374159 chr1 147142457 C T 6.26E-04 Alcohol dependence ACP6 UTR-5 20201924 rs1001193 chr1 147166377 A G 4.12E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6593803 chr1 147205770 T C 6.34E-05 Cognitive test performance / / 20125193 rs6593807 chr1 147213954 G A 6.86E-04 Insulin resistance / / 21901158 rs2353 chr1 147222372 A G 1.02E-05 Cognitive test performance / / 20125193 rs1891498 chr1 147226791 A G 9.00E-06 Cognitive performance / / 20125193 rs2232190 chr1 147231373 A G 2.20E-04 Atrial fibrillation GJA5 UTR-5 21846873 rs10793704 chr1 147239987 T A 5.07E-04 Insulin resistance GJA5 intron 21901158 rs10793705 chr1 147240307 C A,G,T 6.16E-04 Multiple complex diseases GJA5 intron 17554300 rs6670327 chr1 147241723 A C 5.65E-05 Insulin resistance GJA5 intron 21901158 rs10900396 chr1 147242596 G A 8.13E-04 Insulin resistance GJA5 intron 21901158 rs1342705 chr1 147254256 C T 2.70E-04 Crohn's disease / / 17684544 rs10494257 chr1 147254569 T C 5.00E-04 Crohn's disease / / 17684544 rs12061877 chr1 147264252 T C 3.39E-04 Type 2 diabetes / / 17463246 rs11240124 chr1 147268211 A C 1.37E-04 Multiple complex diseases / / 17554300 rs11240129 chr1 147282508 C T 0.000751746 Hypertension (early onset hypertension) / / 22479346 rs12069680 chr1 147284943 G A 2.38E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs12069680 chr1 147284943 G A 3.10E-04 Fasting insulin (interaction) / / 24204828 rs12076930 chr1 147285007 T C 0.000751746 Hypertension (early onset hypertension) / / 22479346 rs10458586 chr1 147288094 G C 8.54E-04 Multiple complex diseases / / 17554300 rs1086603 chr1 147288276 G A 1.12E-25 Narcolepsy / / 19629137 rs1353428 chr1 147326222 C A 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1353428 chr1 147326222 C A 1.00E-04 Tetralogy of Fallot / / 23297363 rs1353428 chr1 147326222 C A 1.44E-05 Basophils / / pha003087 rs10900403 chr1 147340734 T G 4.64E-05 Basophils / / pha003087 rs1495962 chr1 147342037 C A 3.15E-04 Heart rate / / 23583979 rs903786 chr1 147364001 G A,C,T 6.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs903786 chr1 147364001 G A,C,T 1.10E-04 Major depressive disorder / / 21042317 rs903785 chr1 147364076 A C 1.30E-04 Major depressive disorder / / 21042317 rs903784 chr1 147364099 C A,G,T 1.40E-04 Major depressive disorder / / 21042317 rs2352834 chr1 147365020 G A,C,T 4.70E-04 Major depressive disorder / / 21042317 rs7512708 chr1 147369425 C G 6.02E-04 Multiple complex diseases / / 17554300 rs17160783 chr1 147379941 A G 2.46E-05 Hirschsprung's disease GJA8 intron 19196962 rs2132397 chr1 147381558 G A,C,T 1.28E-05 Age-related macular degeneration GJA8 nearGene-3 pha000002 rs1763457 chr1 147795678 T C 2.87E-04 Tourette syndrome / / 22889924 rs12561867 chr1 147801691 G A 1.29E-04 IgE levels / / 17255346 rs2932433 chr1 147806677 C T 8.97E-04 Multiple complex diseases / / 17554300 rs11579261 chr1 149039120 C T 2.38E-11 Neuroblastoma / / 19536264 rs17162082 chr1 149040066 C T 7.16E-04 Multiple complex diseases / / 17554300 rs17162082 chr1 149040066 C T 2.38E-11 Neuroblastoma / / 19536264 rs17161949 chr1 149045105 T C 2.38E-11 Neuroblastoma / / 19536264 rs6673776 chr1 149060682 T C 2.38E-11 Neuroblastoma / / 19536264 rs17162074 chr1 149064521 G A 2.38E-11 Neuroblastoma / / 19536264 rs11587304 chr1 149147738 C A 3.62E-11 Neuroblastoma / / 19536264 rs3853524 chr1 149160437 C T 7.83E-11 Neuroblastoma / / 19536264 rs3738319 chr1 149815323 G A 6.23E-04 Taste perception / / 22132133 rs16835135 chr1 149880483 A G 1.36E-06 White blood cell count SV2A intron 21738479 rs11205277 chr1 149892872 A G 1.00E-10 Height / / 18391951 rs11205277 chr1 149892872 A G 5.00E-32 Height / / 20881960 rs7544531 chr1 149897217 C A,T 6.49E-06 White blood cell count SF3B4 intron 21738479 rs11205303 chr1 149906413 T C 4.00E-23 Height MTMR11 missense 23563607 rs1061955 chr1 149914357 G A 4.00E-06 Obesity-related traits OTUD7B UTR-3 23251661 rs16833178 chr1 149996352 G A 7.19E-04 Multiple complex diseases / / 17554300 rs12063329 chr1 150002436 T C 6.92E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11205321 chr1 150026207 T C 1.72E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12058524 chr1 150066384 C T 2.03E-06 Uric acid levels VPS45 intron 21294900 rs7517537 chr1 150114083 C T 1.80E-06 Uric acid levels VPS45 intron 21294900 rs7521783 chr1 150143193 T C 7.97E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7521783 chr1 150143193 T C 0.000558 Bipolar disorder / / 23637625 rs11205347 chr1 150210120 C T 1.36E-06 White blood cell count / / 21738479 rs12138787 chr1 150246070 T C 3.06E-04 Schizophrenia C1orf54 intron 19197363 rs942453 chr1 150257262 A G 1.84E-04 Schizophrenia C1orf51 intron 19197363 rs12139286 chr1 150262455 G A 6.53E-06 Schizophrenia / / 19571811 rs12403795 chr1 150278389 C T 5.00E-06 Illicit drug use MRPS21 intron 23942779 rs11806171 chr1 150310827 A C 2.87E-04 Heart rate PRPF3 intron 23583979 rs11587682 chr1 150324284 C T 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) PRPF3 intron 23453885 rs834234 chr1 150352494 C G 4.87E-04 Type 2 diabetes RPRD2 intron 17463246 rs834234 chr1 150352494 C G 2.61E-04 Multiple complex diseases RPRD2 intron 17554300 rs834238 chr1 150366469 C A 3.56E-04 Type 2 diabetes RPRD2 intron 17463246 rs834238 chr1 150366469 C A 1.71E-04 Multiple complex diseases RPRD2 intron 17554300 rs698915 chr1 150388318 A G 5.07E-06 Post-operative nausea and vomiting RPRD2 intron 21694509 rs12738490 chr1 150402419 T C 8.87E-04 Multiple complex diseases RPRD2 intron 17554300 rs12738490 chr1 150402419 T C 1.99E-07 Major depressive disorder RPRD2 intron 22472876 rs12726415 chr1 150402613 C G 3.84E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs11581051 chr1 150426409 C G 1.05E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs10888582 chr1 150428819 G A 3.88E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs12029359 chr1 150432802 G A 3.23E-05 Neuroblastoma RPRD2 intron pha002895 rs4451552 chr1 150455854 G C 2.77E-04 Type 2 diabetes / / 17463246 rs4451552 chr1 150455854 G C 9.80E-05 Multiple complex diseases / / 17554300 rs4446975 chr1 150456169 C T 3.93E-04 Type 2 diabetes / / 17463246 rs7542068 chr1 150463772 C G 4.03E-04 Lung function (forced expiratory volume in 1 second) TARS2 intron 17255346 rs7542068 chr1 150463772 C G 9.14E-06 Panic disorder TARS2 intron 19165232 rs9661040 chr1 150483236 A C 7.95E-04 Type 2 diabetes ECM1 intron 17463246 rs9661040 chr1 150483236 A C 2.43E-04 Multiple complex diseases ECM1 intron 17554300 rs12132918 chr1 150498138 C T 1.38E-04 Schizophrenia / / 19197363 rs12119250 chr1 150528885 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) ADAMTSL4 intron 20708005 rs6655975 chr1 150542128 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11204666 chr1 150543128 C T 3.60E-04 Coronary heart disease / / 21966275 rs11204666 chr1 150543128 C T 0.0000212 Coronary artery disease / / 23202125 rs1913117 chr1 150552534 G A 0.000000135 Triglycerides MCL1 nearGene-5 23063622 rs1355637 chr1 150582438 C A,G,T 5.10E-06 Parkinson's disease (age of onset) / / 19772629 rs2055975 chr1 150618632 A C 3.46E-04 Tourette syndrome / / 22889924 rs4970926 chr1 150673684 T C 2.00E-04 Cognitive impairment induced by topiramate HORMAD1 intron 22091778 rs2230061 chr1 150727539 G A 4.00E-08 Fat body mass CTSS missense 24064335 rs12568757 chr1 150729793 G A 7.44E-06 Lymphocyte counts CTSS intron 22286170 rs7518440 chr1 150790762 A G 0.000000172 Cholesterol,total ARNT intron 23063622 rs7518440 chr1 150790762 A G 4.06E-08 HDL cholesterol ARNT intron 23063622 rs10305685 chr1 150811005 T C 3.47E-08 HDL cholesterol ARNT intron 23063622 rs10305650 chr1 150848977 G A 2.01E-08 HDL cholesterol ARNT intron 23063622 rs7412746 chr1 150860471 C T 9.00E-11 Melanoma / / 21983785 rs7412746 chr1 150860471 C T 1.90E-04 Melanoma / / 24980573 rs2272214 chr1 150931462 G A 2.80E-05 Urinary metabolites SETDB1 intron 21572414 rs4451553 chr1 150937329 C T 1.18E-05 Sphingolipid levels / / 19798445 rs267738 chr1 150940625 T G 2.36E-04 Tourette syndrome CERS2 missense 22889924 rs267738 chr1 150940625 T G 1.00E-07 Rhegmatogenous retinal detachment CERS2 missense 23585552 rs4970988 chr1 150950062 G A 1.00E-07 Urate levels / / 23263486 rs267734 chr1 150951477 T C 1.00E-12 Chronic kidney disease / / 20383146 rs267734 chr1 150951477 T C 1.03E-04 Lymphocyte counts / / 22286170 rs267734 chr1 150951477 T C 3.66E-09 Chronic kidney disease / / 22479191 rs267734 chr1 150951477 T C 2.00E-05 Glomerular filtration rate / / 23535967 rs267733 chr1 150958836 A C,G,T 6.71E-04 Tourette syndrome ANXA9 missense 22889924 rs267733 chr1 150958836 A C,G,T 5.00E-09 LDL cholesterol ANXA9 missense 24097068 rs11204754 chr1 150961254 T C 6.44E-05 Melanoma ANXA9 intron 21926416 rs1722784 chr1 150961869 A G 2.00E-06 Melanoma ANXA9 intron 21926416 rs771204 chr1 150974162 G A 2.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM63A intron 24023788 rs771205 chr1 150975108 T C 6.75E-04 Alzheimer's disease FAM63A missense 24755620 rs3738479 chr1 150997842 T A 9.00E-04 Chronic kidney disease PRUNE intron 21931561 rs4970989 chr1 151003600 T A 5.00E-04 Acute lung injury PRUNE intron 22295056 rs4970991 chr1 151004003 T C 6.46E-04 Acute lung injury PRUNE intron 22295056 rs7550434 chr1 151008928 G A 6.51E-04 Acute lung injury BNIPL nearGene-5 22295056 rs955955 chr1 151011543 G A 4.95E-05 Cognitive impairment induced by topiramate BNIPL intron 22091778 rs2091219 chr1 151012060 A G 8.51E-04 Acute lung injury BNIPL intron 22295056 rs6694158 chr1 151014134 C G 7.02E-04 Type 2 diabetes BNIPL intron 17463246 rs12068365 chr1 151015868 G A 4.95E-05 Cognitive impairment induced by topiramate BNIPL missense 22091778 rs6587552 chr1 151018861 A G 5.34E-04 Type 2 diabetes BNIPL intron 17463246 rs6587553 chr1 151019180 A G 3.86E-04 Type 2 diabetes BNIPL UTR-3 17463246 rs2902810 chr1 151026815 C T 4.90E-04 Endometriosis CDC42SE1 intron 23104006 rs2140709 chr1 151036816 A G 1.95E-04 Type 2 diabetes MLLT11 intron 17463246 rs11204774 chr1 151062957 G A 1.72E-04 Multiple complex diseases GABPB2 missense 17554300 rs11204774 chr1 151062957 G A 6.13E-05 Cognitive impairment induced by topiramate GABPB2 missense 22091778 rs11807526 chr1 151115997 A C 9.81E-04 Obesity (extreme) SEMA6C intron 21935397 rs6689566 chr1 151143166 C T 2.39E-04 Suicide attempts in bipolar disorder TMOD4 intron 21423239 rs11204785 chr1 151150857 T C 3.35E-05 Magnesium levels VPS72 intron pha003092 rs10749660 chr1 151174772 A G 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs4520422 chr1 151179943 C T 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs7532935 chr1 151210789 C T 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs4971030 chr1 151280995 T C 8.81E-05 Magnesium levels PI4KB intron pha003092 rs1056847 chr1 151288172 G A 8.81E-05 Magnesium levels PI4KB cds-synon pha003092 rs5022636 chr1 151295061 A G 5.56E-05 Magnesium levels PI4KB intron pha003092 rs2025900 chr1 151331304 A T 1.39E-04 Multiple complex diseases / / 17554300 rs2800953 chr1 151338570 G A 9.47E-05 Multiple complex diseases SELENBP1 intron 17554300 rs2769265 chr1 151344150 C A 4.83E-05 Brain structure SELENBP1 intron 22504417 rs2769264 chr1 151344741 T G 2.71E-05 Brain structure SELENBP1 intron 22504417 rs2769264 chr1 151344741 T G 3.00E-20 Blood trace element (Cu levels) SELENBP1 intron 23720494 rs4971036 chr1 151351060 G A 2.68E-04 IgE levels / / 17255346 rs2769270 chr1 151355858 G A 1.20E-05 Urinary metabolites / / 21572414 rs2296840 chr1 151372047 C T 1 Drug response to Desipramine PSMB4 UTR-5 18504423 rs2296840 chr1 151372047 C T 1 Drug response to Fluoxetine PSMB4 UTR-5 18504423 rs7172 chr1 151372138 G A 3.90E-22 Progranulin levels PSMB4 cds-synon 21087763 rs7172 chr1 151372138 G A 3.90E-22 Myocardial infarction PSMB4 cds-synon 21211798 rs16833263 chr1 151433133 T C 5.26E-04 Smoking cessation / / 24665060 rs10888419 chr1 151484219 A C 0.000587 Salmonella-induced pyroptosis CGN intron 22837397 rs7552458 chr1 151488782 T G 7.33E-04 Cervical cancer CGN intron 21716314 rs11204838 chr1 151493814 C T 4.00E-04 Cervical cancer CGN intron 21716314 rs2337359 chr1 151495796 T C 7.98E-04 Cervical cancer CGN intron 21716314 rs1573130 chr1 151497140 T C 7.77E-04 Cervical cancer CGN intron 21716314 rs1573129 chr1 151497376 G A 8.79E-04 Multiple complex diseases CGN intron 17554300 rs6678068 chr1 151501737 T C 6.22E-05 Asthma CGN intron pha003128 rs1891593 chr1 151535916 C T 2.57E-04 Alzheimer's disease TUFT1 intron 17998437 rs12751350 chr1 151550673 G A 1.85E-04 Gallstones TUFT1 intron 17632509 rs12122920 chr1 151588735 G A 5.90E-04 Endometriosis SNX27 intron 23104006 rs6690942 chr1 151629958 A G 9.95E-04 Response to cytidine analogues (gemcitabine) SNX27 intron 24483146 rs1211981 chr1 151632646 T C 4.70E-04 Endometriosis SNX27 intron 23104006 rs1048694 chr1 151669997 C A 7.63E-04 Aortic root size SNX27 UTR-3 21223598 rs1308145 chr1 151673350 T C 9.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) CELF3 UTR-3 23648065 rs1308152 chr1 151679441 T C 1.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CELF3 intron 23648065 rs1308152 chr1 151679441 T C 3.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) CELF3 intron 23648065 rs2280474 chr1 151681567 G A 5.10E-04 Coronary heart disease CELF3 intron 21966275 rs3762302 chr1 151684262 T C 3.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CELF3 intron 23648065 rs939592 chr1 151686983 T A 1.10E-05 Serum metabolites CELF3 intron 19043545 rs868360 chr1 151691148 C T 6.96E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs6696250 chr1 151695271 T C 1.50E-04 Endometriosis RIIAD1 intron 23104006 rs2298294 chr1 151701345 A G 5.39E-04 Response to cytidine analogues (gemcitabine) RIIAD1 UTR-3 24483146 rs11204885 chr1 151747970 A G 8.71E-12 Non-obstructive azoospermia TDRKH cds-synon 22197933 rs11204885 chr1 151747970 A G 1.45E-04 Lung function (forced vital capacity) TDRKH cds-synon 24023788 rs4845579 chr1 151770138 T C 8.50E-04 Multiple complex diseases / / 17554300 rs9017 chr1 151778683 C T 7.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) RORC UTR-3 23648065 rs11588634 chr1 151780686 T A 2.64E-04 Suicide attempts in bipolar disorder RORC intron 21041247 rs11588258 chr1 151780728 A T 2.66E-04 Suicide attempts in bipolar disorder RORC intron 21041247 rs1521177 chr1 151782130 G T 3.91E-05 Soluble levels of adhesion molecules RORC intron pha003072 rs7540530 chr1 151790858 G A 1.89E-04 Type 2 diabetes RORC intron 22158537 rs4845604 chr1 151801680 G A 4.00E-16 Inflammatory bowel disease RORC intron 23128233 rs3811418 chr1 151805049 A G 4.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RORC nearGene-5 20877124 rs11204897 chr1 151809066 A G 1.09E-07 Hair morphology / / 19896111 rs7536659 chr1 151816718 T C 2.58E-05 Serum metabolites / / 19043545 rs6587625 chr1 151820324 T C 7.12E-05 Orofacial clefts THEM5 missense 22419666 rs2279503 chr1 151824089 T C 9.40E-07 Urinary metabolites THEM5 intron 21572414 rs4845624 chr1 151827813 G A 1.35E-06 White blood cell count / / 21738479 rs2879130 chr1 151830098 C T 5.81E-05 Orofacial clefts / / 22419666 rs12566232 chr1 151839838 A C 6.00E-19 Blood metabolite levels / / 24816252 rs6685187 chr1 151858888 A G 3.00E-26 Blood metabolite levels THEM4 intron 24816252 rs10788817 chr1 151882856 C G 3.00E-13 Metabolite levels / / 24625756 rs10788819 chr1 151895093 C T 2.00E-08 Hair morphology / / 19896111 rs10788819 chr1 151895093 C T 1.32E-07 Common traits (Other) / / 20585627 rs3007711 chr1 151897377 G T 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs3007685 chr1 151898037 T G 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs6686874 chr1 151915740 G A 5.51E-05 Gallstones / / 17632509 rs6693388 chr1 151930645 T C 4.00E-38 Blood metabolite ratios / / 24816252 rs7541099 chr1 151938763 C T 9.84E-04 Type 2 diabetes / / 17463246 rs2999531 chr1 151971497 C T 1.16E-07 Lymphocyte counts / / 22286170 rs3007671 chr1 151999347 G T 3.46E-17 Hair morphology / / 19896111 rs3007671 chr1 151999347 G T 6.03E-28 Common traits (Other) / / 20585627 rs3007671 chr1 151999347 G T 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs3007671 chr1 151999347 G T 2.45E-04 Tourette syndrome / / 22889924 rs2999547 chr1 152002663 A C 3.43E-17 Hair morphology / / 19896111 rs2999547 chr1 152002663 A C 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12123975 chr1 152004804 A G 1.14E-18 Hair morphology / / 19896111 rs12130862 chr1 152027015 A T 3.12E-28 Hair morphology / / 19896111 rs3007684 chr1 152034430 G T 1.29E-10 Common traits (Other) / / 20585627 rs3124314 chr1 152037515 T C 4.00E-06 Hair morphology / / 19896111 rs16833835 chr1 152059580 G C 8.58E-05 Multiple complex diseases TCHHL1 missense 17554300 rs17646946 chr1 152062767 G A 1.50E-31 Hair morphology / / 19896111 rs17646946 chr1 152062767 G A 2.00E-42 Common traits (Other) / / 20585627 rs11204925 chr1 152073120 A G 1.01E-06 White blood cell count / / 21738479 rs9050 chr1 152079314 C A 3.91E-10 Atopic dermatitis TCHH UTR-3 23886662 rs9050 chr1 152079314 C A 4.00E-06 Atopic dermatitis TCHH UTR-3 23886662 rs9050 chr1 152079314 C A 4.30E-07 Atopic dermatitis TCHH UTR-3 23886662 rs11803731 chr1 152083325 A T 3.00E-31 Hair morphology TCHH missense 19896111 rs4845418 chr1 152136230 G C 4.43E-29 Hair morphology / / 19896111 rs1496036 chr1 152140016 G A 6.67E-06 Hair morphology / / 19896111 rs969359 chr1 152144260 C T 5.88E-04 Multiple complex diseases / / 17554300 rs7527318 chr1 152224948 C T 6.04E-04 Insulin resistance / / 21901158 rs7541297 chr1 152225041 A T 4.78E-04 Insulin resistance / / 21901158 rs11204971 chr1 152259078 A G 5.02E-09 Atopic dermatitis / / 21666691 rs3126085 chr1 152300817 G A 6.00E-12 Atopic dermatitis / / 21666691 rs1858483 chr1 152310086 T C 2.63E-10 Hair morphology FLG-AS1 intron 19896111 rs3120665 chr1 152316590 A G 4.00E-06 Personality dimensions FLG-AS1 intron 20691247 rs3120667 chr1 152318161 A G 2.00E-06 Eating disorders FLG-AS1 intron 23568457 rs1923504 chr1 152360184 T C 1.92E-06 White blood cell count / / 21738479 rs10888485 chr1 152363581 A G 5.16E-06 White blood cell count / / 21738479 rs2146117 chr1 152416909 A T 1.60E-05 Urinary metabolites / / 21572414 rs6587673 chr1 152430152 G A 2.82E-08 Common traits (Other) / / 20585627 rs6700998 chr1 152434009 T G 3.31E-08 Common traits (Other) / / 20585627 rs6661961 chr1 152442289 T C 9.00E-11 Atopic dermatitis / / 23886662 rs908922 chr1 152454591 G A 4.00E-06 Hair morphology / / 19896111 rs1199156 chr1 152459747 T C 7.18E-05 Hematocrit / / pha003097 rs6669608 chr1 152475233 A G 8.22E-06 Hair morphology / / 19896111 rs499913 chr1 152476743 T A 0.00000072 Asthma / / 23040885 rs4845779 chr1 152479176 T C 9.33E-11 Common traits (Other) / / 20585627 rs1885531 chr1 152480233 T G 0.0000037 Asthma / / 23040885 rs6658925 chr1 152482801 A G 3.59E-04 Coronary heart disease / / 21606135 rs2105117 chr1 152484129 G A 9.77E-08 Common traits (Other) LCE5A missense 20585627 rs3753451 chr1 152485227 T G 7.41E-08 Common traits (Other) / / 20585627 rs73004856 chr1 152487917 G A 3.00E-06 Obesity-related traits CRCT1 missense 23251661 rs1053590 chr1 152488428 T C 8.13E-08 Common traits (Other) CRCT1 UTR-3 20585627 rs548252 chr1 152489742 C T 8.11E-04 Multiple complex diseases / / 17554300 rs548252 chr1 152489742 C T 7.96E-04 Coronary heart disease / / 21606135 rs4845783 chr1 152492559 G A 6.00E-06 Asthma / / 21804549 rs499697 chr1 152493154 G A 1.00E-10 Common traits (Other) / / 20585627 rs1538084 chr1 152496012 A C 5.01E-07 Asthma / / 21804549 rs12116609 chr1 152497685 C T 4.17E-08 Common traits (Other) / / 20585627 rs4845443 chr1 152507156 G A 9.82E-04 Coronary heart disease / / 21606135 rs1001149 chr1 152508562 C T 2.22E-06 Monocyte chemoattractant protein-1 / / pha003071 rs549044 chr1 152514332 C T 3.11E-05 F-cell distribution / / 21326311 rs6587688 chr1 152529622 T C 1.47E-07 Asthma / / 21804549 rs4240887 chr1 152530510 A G 3.16E-08 Common traits (Other) / / 20585627 rs4240889 chr1 152534954 C A 6.87E-04 Endometrial cancer / / 24096698 rs4845790 chr1 152536760 C T 2.87E-05 Glucose levels / / pha003058 rs4845791 chr1 152536784 G A 3.76E-05 Glucose levels / / pha003058 rs10888501 chr1 152537954 G A 1.00E-06 Response to antipsychotic treatment / / 19721433 rs17659359 chr1 152538358 G C 2.48E-05 Schizophrenia LCE3E UTR-3 20185149 rs7516108 chr1 152542229 T C 2.30E-05 Psoriasis / / 19169255 rs7516108 chr1 152542229 T C 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7516108 chr1 152542229 T C 3.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4085613 chr1 152550018 T G 7.00E-30 Psoriasis / / 19169255 rs4085613 chr1 152550018 T G 7.00E-30 Multiple sclerosis / / 22190364 rs4085613 chr1 152550018 T G 1.54E-05 Personality dimensions / / 22628180 rs4112788 chr1 152551276 A G 6.30E-09 Psoriasis / / 19169255 rs4112788 chr1 152551276 A G 3.00E-10 Psoriasis / / 20953190 rs4112788 chr1 152551276 A G 1.57E-05 Personality dimensions / / 22628180 rs477392 chr1 152555176 C G 1.36E-05 Personality dimensions / / 22628180 rs12067374 chr1 152568230 C G 2.72E-06 Personality dimensions / / 22628180 rs6677595 chr1 152590187 C T 1.34E-05 Personality dimensions / / 22628180 rs6677595 chr1 152590187 C T 2.10E-33 Psoriasis / / 23143594 rs6701307 chr1 152590444 G A 1.34E-05 Personality dimensions / / 22628180 rs6693105 chr1 152590663 T C 1.39E-05 Personality dimensions / / 22628180 rs4845446 chr1 152590750 T C 1.39E-05 Personality dimensions / / 22628180 rs4845449 chr1 152591024 T A 1.32E-05 Personality dimensions / / 22628180 rs1886734 chr1 152591142 A C 1.70E-08 Psoriasis / / 19169255 rs1886734 chr1 152591142 A C 1.37E-05 Personality dimensions / / 22628180 rs4845450 chr1 152591200 T C 1.70E-05 Personality dimensions / / 22628180 rs4845454 chr1 152592184 C T 9.80E-09 Psoriasis / / 19169255 rs4845454 chr1 152592184 C T 1.36E-05 Personality dimensions / / 22628180 rs1581803 chr1 152592281 G T 1.35E-05 Personality dimensions / / 22628180 rs6700158 chr1 152592828 T G 1.34E-05 Personality dimensions / / 22628180 rs10888503 chr1 152593549 C T 1.39E-05 Personality dimensions / / 22628180 rs6702463 chr1 152598711 T A 1.43E-05 Personality dimensions / / 22628180 rs4845459 chr1 152603842 C A 1.48E-05 Personality dimensions / / 22628180 rs16834273 chr1 152609951 C G 3.87E-05 Multiple complex diseases / / 17554300 rs16834276 chr1 152610224 T G 1.76E-04 Multiple complex diseases / / 17554300 rs11205051 chr1 152610256 A C 1.29E-04 Multiple complex diseases / / 17554300 rs1325508 chr1 152612910 T C 4.30E-05 Multiple complex diseases / / 17554300 rs1325508 chr1 152612910 T C 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989834 chr1 152618544 A T 1.27E-04 Multiple complex diseases / / 17554300 rs1325507 chr1 152619264 G A 8.48E-05 Multiple complex diseases / / 17554300 rs1325507 chr1 152619264 G A 5.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11205060 chr1 152624426 C T 5.40E-05 Multiple complex diseases / / 17554300 rs908929 chr1 152624922 A G 5.05E-05 Multiple complex diseases / / 17554300 rs908929 chr1 152624922 A G 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10888505 chr1 152625148 A G 1.59E-04 Multiple complex diseases / / 17554300 rs10888505 chr1 152625148 A G 8.56E-04 Alcohol dependence / / 20201924 rs11205061 chr1 152626061 A G 9.71E-05 Multiple complex diseases / / 17554300 rs10888507 chr1 152626270 C G 1.29E-04 Multiple complex diseases / / 17554300 rs12096806 chr1 152643160 G A 3.22E-04 Alcohol dependence / / 20201924 rs12060809 chr1 152648950 T C 4.80E-04 Alcohol dependence LCE2C UTR-3 20201924 rs3904415 chr1 152672756 C T 2.85E-05 Multiple complex diseases / / 17554300 rs11205084 chr1 152684306 A G 3.77E-05 Multiple complex diseases / / 17554300 rs2224986 chr1 152684866 C T 2.74E-05 Multiple complex diseases / / 17554300 rs1332498 chr1 152690448 T C 3.30E-05 Bone mineral density / / 21927923 rs16834421 chr1 152712747 G A 7.96E-06 Multiple complex diseases / / 17554300 rs16834421 chr1 152712747 G A 6.36E-04 Insulin resistance / / 21901158 rs11205096 chr1 152715824 C A 1.56E-04 Multiple complex diseases / / 17554300 rs12023710 chr1 152719318 T C 8.44E-06 Multiple complex diseases / / 17554300 rs12023710 chr1 152719318 T C 2.02E-04 Insulin resistance / / 21901158 rs11578927 chr1 152728472 A C 2.75E-04 HIV-1 viral setpoint / / 17641165 rs2297487 chr1 152734390 C T 1.87E-04 Multiple complex diseases KPRP UTR-3 17554300 rs1591077 chr1 152734796 G A 2.36E-04 HIV-1 viral setpoint / / 17641165 rs913998 chr1 152749891 G T 7.14E-05 Multiple complex diseases / / 17554300 rs16834495 chr1 152750800 G A 5.82E-05 Multiple complex diseases / / 17554300 rs950337 chr1 152756774 T C 6.06E-04 Multiple complex diseases / / 17554300 rs6694602 chr1 152773905 G A 7.65E-05 Insulin resistance / / 21901158 rs7411365 chr1 152780139 C T 2.75E-04 Multiple complex diseases / / 17554300 rs7411365 chr1 152780139 C T 1.80E-05 Malaria / / 19465909 rs7517755 chr1 152796449 T C 2.60E-05 Urinary metabolites / / 21572414 rs7517755 chr1 152796449 T C 8.89E-08 White blood cell count / / 21738479 rs2339392 chr1 152820248 C T 8.99E-04 Multiple complex diseases / / 17554300 rs7519200 chr1 152824413 G T 7.75E-04 Multiple complex diseases / / 17554300 rs16834715 chr1 152844585 C T 8.03E-04 Multiple complex diseases / / 17554300 rs3737861 chr1 152850938 A C 6.63E-06 White blood cell count SMCP intron 21738479 rs3737861 chr1 152850938 A C 2.10E-05 Body Mass Index SMCP intron pha002896 rs3856026 chr1 152869763 T C 3.72E-05 Cognitive test performance / / 20125193 rs11809092 chr1 152874742 C T 2.50E-04 Multiple complex diseases / / 17554300 rs1854779 chr1 152880672 T C 5.56E-05 Cortisol secretion,in saliva / / 21316860 rs34599045 chr1 152886874 G C 4.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4240864 chr1 152901477 G A 5.74E-04 Multiple complex diseases / / 17554300 rs1999885 chr1 152907785 G C 4.33E-07 Breast cancer / / 20852631 rs16834788 chr1 152944937 C T 1.68E-04 Amyotrophic lateral sclerosis (sporadic) SPRR4 UTR-3 24529757 rs2879490 chr1 152947163 A G 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4041402 chr1 152947397 T C 7.30E-05 Pericardial fat / / 22589742 rs1415972 chr1 152953552 G A 7.17E-06 White blood cell count / / 21738479 rs1611753 chr1 152956381 C T 8.81E-05 Cognitive test performance / / 20125193 rs1611760 chr1 152957573 T C 7.39E-05 Cognitive test performance SPRR1A intron 20125193 rs4845503 chr1 152959939 A G 7.70E-05 Pericardial fat / / 22589742 rs1415961 chr1 152973464 G A 7.39E-05 Cognitive test performance / / 20125193 rs6683514 chr1 152984397 A G 6.20E-05 Pericardial fat / / 22589742 rs2339491 chr1 152985322 T C 8.81E-05 Cognitive test performance / / 20125193 rs4041401 chr1 152985629 A G 8.20E-05 Pericardial fat / / 22589742 rs7548977 chr1 152987365 T C,G 1.10E-05 Pericardial fat / / 22589742 rs4845513 chr1 152998066 T C 7.80E-06 Pericardial fat / / 22589742 rs10888524 chr1 153000125 A G 7.60E-05 Pericardial fat / / 22589742 rs10888525 chr1 153000215 G A 7.60E-05 Pericardial fat / / 22589742 rs10888526 chr1 153000311 G T 6.10E-05 Pericardial fat / / 22589742 rs11205174 chr1 153001230 A G 6.00E-05 Pericardial fat / / 22589742 rs11205175 chr1 153001296 A C 6.00E-05 Pericardial fat / / 22589742 rs10788853 chr1 153002231 C T 7.70E-05 Pericardial fat / / 22589742 rs10788855 chr1 153002359 A T 6.00E-05 Pericardial fat / / 22589742 rs11205177 chr1 153002502 G A 7.30E-05 Pericardial fat / / 22589742 rs1415965 chr1 153002750 G A 5.90E-05 Pericardial fat / / 22589742 rs1415966 chr1 153002864 A G 5.80E-05 Pericardial fat / / 22589742 rs1933382 chr1 153003295 T G 5.80E-05 Pericardial fat / / 22589742 rs4845336 chr1 153003853 C T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845515 chr1 153003871 G T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845518 chr1 153003903 A G 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845519 chr1 153003916 A C 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs2070964 chr1 153004213 C T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs1334850 chr1 153004519 G T 5.10E-05 Pericardial fat SPRR1B intron 22589742 rs1334848 chr1 153004721 A T 5.10E-05 Pericardial fat SPRR1B intron 22589742 rs1108410 chr1 153005662 T C 6.50E-06 Pericardial fat / / 22589742 rs423692 chr1 153005681 T G 5.00E-05 Pericardial fat / / 22589742 rs489323 chr1 153006047 G A 4.90E-05 Pericardial fat / / 22589742 rs1415969 chr1 153006448 G T 5.40E-05 Pericardial fat / / 22589742 rs373740781 chr1 153006641 G GA 4.90E-05 Pericardial fat / / 22589742 rs382292 chr1 153006641 G A 4.90E-05 Pericardial fat / / 22589742 rs451939 chr1 153006877 C T 4.80E-05 Pericardial fat / / 22589742 rs406350 chr1 153007492 C T 4.80E-05 Pericardial fat / / 22589742 rs407448 chr1 153007504 C T 4.00E-05 Pericardial fat / / 22589742 rs557553 chr1 153010370 T G 4.80E-05 Pericardial fat / / 22589742 rs561143 chr1 153010734 C T 4.70E-05 Pericardial fat / / 22589742 rs10788856 chr1 153011517 G C 4.70E-05 Pericardial fat / / 22589742 rs1048296 chr1 153012240 A C 4.70E-05 Pericardial fat SPRR2D UTR-3 22589742 rs1750309 chr1 153013630 G A,C 4.70E-05 Pericardial fat / / 22589742 rs1995308 chr1 153014082 T A 3.50E-06 Pericardial fat / / 22589742 rs409986 chr1 153014741 C A 4.80E-05 Pericardial fat / / 22589742 rs441229 chr1 153015059 A C 5.40E-05 Pericardial fat / / 22589742 rs1890285 chr1 153015396 T C 8.70E-05 Pericardial fat / / 22589742 rs368912 chr1 153016204 C G 5.50E-05 Pericardial fat / / 22589742 rs310126 chr1 153019416 A C 4.50E-05 Pericardial fat / / 22589742 rs310105 chr1 153022253 A G 5.10E-05 Pericardial fat / / 22589742 rs12079087 chr1 153023888 T C 6.90E-06 Pericardial fat / / 22589742 rs6664380 chr1 153030365 G T 6.80E-06 Pericardial fat / / 22589742 rs12083211 chr1 153032131 T A 6.70E-06 Pericardial fat / / 22589742 rs582345 chr1 153033406 G A 4.40E-05 Pericardial fat / / 22589742 rs6675009 chr1 153033783 G A 7.00E-06 Pericardial fat / / 22589742 rs6587724 chr1 153034501 T A 7.00E-06 Pericardial fat / / 22589742 rs608509 chr1 153034650 G C 4.30E-05 Pericardial fat / / 22589742 rs821755 chr1 153036245 G C 4.30E-05 Pericardial fat / / 22589742 rs7531076 chr1 153039167 G T 7.90E-06 Pericardial fat / / 22589742 rs6673356 chr1 153041903 A G 9.20E-06 Pericardial fat / / 22589742 rs6693927 chr1 153044009 G A 9.10E-06 Pericardial fat SPRR2B intron 22589742 rs440598 chr1 153044733 T C 4.60E-05 Pericardial fat / / 22589742 rs6686526 chr1 153044996 T C 9.20E-06 Pericardial fat / / 22589742 rs1500937 chr1 153045483 G C 9.20E-06 Pericardial fat / / 22589742 rs11812015 chr1 153045584 G T 9.20E-06 Pericardial fat / / 22589742 rs11205181 chr1 153045728 C T 9.20E-06 Pericardial fat / / 22589742 rs11205182 chr1 153045748 C T 9.20E-06 Pericardial fat / / 22589742 rs7543689 chr1 153046803 A T 9.30E-06 Pericardial fat / / 22589742 rs11590835 chr1 153047166 T C 9.30E-06 Pericardial fat / / 22589742 rs662506 chr1 153048386 C A 3.80E-05 Pericardial fat / / 22589742 rs11576797 chr1 153049417 T C 9.20E-06 Pericardial fat / / 22589742 rs399550 chr1 153049917 T C 4.40E-05 Pericardial fat / / 22589742 rs201057762 chr1 153050058 A AG 4.40E-05 Pericardial fat / / 22589742 rs387930 chr1 153050058 A G 4.40E-05 Pericardial fat / / 22589742 rs10888529 chr1 153050654 G T 9.40E-06 Pericardial fat / / 22589742 rs6692062 chr1 153051729 T C 1.00E-05 Pericardial fat / / 22589742 rs383582 chr1 153084246 C T 1.89E-05 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs1119266 chr1 153097240 G A 2.30E-05 Urinary metabolites / / 21572414 rs11205209 chr1 153104182 A G 2.80E-05 Urinary metabolites / / 21572414 rs11577955 chr1 153119519 G A 5.60E-05 Pericardial fat / / 22589742 rs11578865 chr1 153126302 G A 5.00E-05 Pericardial fat / / 22589742 rs499893 chr1 153127880 T C 2.70E-05 Urinary metabolites / / 21572414 rs12068238 chr1 153136355 T C 3.25E-04 Lung function (forced vital capacity) / / 24023788 rs11585767 chr1 153142328 C T 4.40E-05 Pericardial fat / / 22589742 rs498131 chr1 153143504 C G 5.56E-06 White blood cell count / / 21738479 rs943139 chr1 153163377 A G 0.000396 Salmonella-induced pyroptosis / / 22837397 rs1831238 chr1 153169522 G A 1.43E-06 White blood cell count / / 21738479 rs1410869 chr1 153169596 A C 7.33E-07 White blood cell count / / 21738479 rs10888535 chr1 153171148 G C 2.73E-06 White blood cell count / / 21738479 rs1410858 chr1 153182116 C A 3.64E-06 White blood cell count / / 21738479 rs11205222 chr1 153182979 A G 7.27E-05 Personality dimensions / / 18957941 rs1980908 chr1 153183088 G A 5.04E-04 Smoking quantity / / 24665060 rs1980909 chr1 153183327 A C 1.85E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10788860 chr1 153184789 A G 8.99E-04 Coronary Artery Disease / / 17634449 rs10788860 chr1 153184789 A G 9.94E-05 Serum metabolites / / 19043545 rs10494294 chr1 153185017 G A 6.70E-05 Personality dimensions / / 18957941 rs11205224 chr1 153185549 C T 7.23E-05 Personality dimensions / / 18957941 rs34345817 chr1 153185549 CA C 7.23E-05 Personality dimensions / / 18957941 rs11583156 chr1 153192077 C T 4.83E-05 Personality dimensions / / 18957941 rs16835081 chr1 153197544 C T 4.98E-05 Personality dimensions / / 18957941 rs16835083 chr1 153197618 C T 3.09E-05 Personality dimensions / / 18957941 rs16835086 chr1 153206051 T A 1.72E-04 Coronary Artery Disease / / 17634449 rs4517302 chr1 153207416 G T 8.45E-05 Coronary Artery Disease / / 17634449 rs1329097 chr1 153224122 T A 3.61E-04 Type 2 diabetes / / 17463246 rs821431 chr1 153271524 C T 6.67E-06 White blood cell count PGLYRP3 intron 21738479 rs821426 chr1 153282072 C A 7.10E-05 Endometriosis PGLYRP3 intron 21151130 rs2771122 chr1 153312644 A G 5.62E-05 HIV-1 viral setpoint PGLYRP4 intron 22174851 rs2288990 chr1 153318008 C G 5.81E-05 Type 2 diabetes PGLYRP4 intron 17463246 rs12027903 chr1 153327756 G T 4.27E-04 Alcohol dependence / / 20201924 rs3006412 chr1 153390542 G C 3.12E-04 Fibrinogen S100A7A UTR-5 17255346 rs16835308 chr1 153404808 T C 4.31E-04 Fibrinogen / / 17255346 rs12047494 chr1 153446797 T C 5.39E-08 Metabolite levels / / 23281178 rs12022550 chr1 153452931 G A 5.39E-08 Metabolite levels / / 23281178 rs12025638 chr1 153456349 G A 5.39E-08 Metabolite levels / / 23281178 rs16835332 chr1 153456926 G C 5.39E-08 Metabolite levels / / 23281178 rs3014848 chr1 153457385 G A 5.39E-08 Metabolite levels / / 23281178 rs2986209 chr1 153459457 T G 5.39E-08 Metabolite levels / / 23281178 rs4845552 chr1 153479998 G A 6.00E-06 Hippocampal atrophy / / 19668339 rs138355706 chr1 153520235 G A 0.00035 Breast cancer (ER positive) S100A3 missense 23555315 rs8401 chr1 153533898 A G 1.47E-06 White blood cell count S100A2 UTR-3 21738479 rs1046379 chr1 153604029 C T 1.47E-06 White blood cell count S100A1 intron 21738479 rs10797056 chr1 153613783 A G 6.03E-04 Type 2 diabetes CHTOP intron 17463246 rs10797056 chr1 153613783 A G 1.00E-05 Lymphocyte counts CHTOP intron 22286170 rs7934 chr1 153618766 C T 7.96E-04 Type 2 diabetes CHTOP UTR-3 17463246 rs913859 chr1 153620086 A G 5.60E-04 Myocardial Infarction / / pha002883 rs913860 chr1 153620127 T A 7.28E-04 Type 2 diabetes / / 17463246 rs6427671 chr1 153637404 A G 1.81E-06 White blood cell count ILF2 intron 21738479 rs7536700 chr1 153640827 C T 4.00E-06 Multiple myeloma (IgH translocation) ILF2 intron 23502783 rs10082235 chr1 153656650 C T 5.40E-05 Carotid intima media thickness NPR1 intron 19679847 rs11264236 chr1 153658480 G A 1.93E-06 White blood cell count NPR1 intron 21738479 rs6698058 chr1 153703013 C T 2.31E-04 Type 2 diabetes INTS3 intron 17463246 rs6427183 chr1 153706699 T G 3.76E-04 Multiple complex diseases INTS3 intron 17554300 rs11264336 chr1 153708633 A G 2.57E-05 Monocyte counts INTS3 intron pha003089 rs7515716 chr1 153708906 G A 2.50E-05 Monocyte counts INTS3 intron pha003089 rs12097583 chr1 153723037 T C 2.50E-05 Monocyte counts INTS3 intron pha003089 rs10752613 chr1 153760104 T A 1.94E-04 Multiple complex diseases / / 17554300 rs9427228 chr1 153768451 C T 1.30E-05 Lipoproteins LOC343052 intron pha003079 rs12738361 chr1 153768740 C T 4.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9426935 chr1 153769400 C T 5.00E-06 Lentiform nucleus volume LOC343052 intron 22903471 rs16835600 chr1 153773429 T C 6.14E-05 Multiple complex diseases LOC343052 intron 17554300 rs4434872 chr1 153774276 T C 8.00E-06 Conduct disorder (symptom count) / / 20585324 rs4434872 chr1 153774276 T C 3.82E-04 Insulin resistance / / 21901158 rs4451582 chr1 153777669 G T 9.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B UTR-3 21844884 rs1139620 chr1 153777848 C T 9.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B UTR-3 21844884 rs6668066 chr1 153786182 G A 7.34E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs4363451 chr1 153790501 C T 8.23E-04 Multiple complex diseases GATAD2B intron 17554300 rs4596938 chr1 153794697 T C 8.60E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs6690242 chr1 153801098 C T 3.20E-05 Lipoproteins GATAD2B intron pha003079 rs6427306 chr1 153812119 C T 7.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs4845576 chr1 153825404 C T 8.09E-04 Multiple complex diseases GATAD2B intron 17554300 rs4520447 chr1 153829389 T C 4.15E-04 Multiple complex diseases GATAD2B intron 17554300 rs7414227 chr1 153848996 G A 3.00E-06 Lentiform nucleus volume GATAD2B intron 22903471 rs4845584 chr1 153885261 C A 9.39E-05 Multiple complex diseases GATAD2B intron 17554300 rs2252508 chr1 153913770 A G 5.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DENND4B intron 21844884 rs2252508 chr1 153913770 A G 5.00E-06 Lentiform nucleus volume DENND4B intron 22903471 rs10908557 chr1 153927052 C G 7.14E-04 Multiple complex diseases CRTC2 intron 17554300 rs61755890 chr1 153934820 C T 0.0008 Prostate cancer SLC39A1 missense 23555315 rs2072704 chr1 153935543 G A 2.07E-05 Lipoproteins SLC39A1 intron pha003079 rs11264736 chr1 153939130 C T 7.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC39A1 intron 21844884 rs11264736 chr1 153939130 C T 4.00E-06 Lentiform nucleus volume SLC39A1 intron 22903471 rs2494663 chr1 154092056 C A 1.12E-04 Acute lymphoblastic leukemia (childhood) NUP210L intron 22076464 rs4521985 chr1 154123523 G A 0.000722799 Hypertension (early onset hypertension) NUP210L intron 22479346 rs11265251 chr1 154157090 T C 9.84E-05 Suicide attempts in bipolar disorder TPM3 intron 21041247 rs4074015 chr1 154167626 G C 0.000000442 HDL cholesterol / / 23063622 rs6719 chr1 154179679 T C 3.95E-05 Suicide attempts in bipolar disorder C1orf43 UTR-3 21041247 rs9803857 chr1 154191791 G A 4.30E-05 Suicide attempts in bipolar disorder C1orf43 intron 21041247 rs2879788 chr1 154204310 A T 4.19E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs12062977 chr1 154211516 C T 4.06E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs10158820 chr1 154217763 C T 4.05E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs6427509 chr1 154219718 C T 4.03E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs2340473 chr1 154225344 T C 4.03E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs1194596 chr1 154238383 A G 8.16E-04 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs1194596 chr1 154238383 A G 1.39E-05 Lymphocyte counts UBAP2L intron 22286170 rs1212352 chr1 154239283 T A 1.55E-04 Acute lymphoblastic leukemia (childhood) UBAP2L intron 22076464 rs1044013 chr1 154243115 C T 7.78E-04 Suicide attempts in bipolar disorder UBAP2L UTR-3 21041247 rs1194593 chr1 154245512 A G 7.68E-04 Suicide attempts in bipolar disorder HAX1 intron 21041247 rs1760802 chr1 154259275 C G 7.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs3103309 chr1 154270877 C T 2.88E-05 HIV-1 viral setpoint / / 17641165 rs4103781 chr1 154280622 C T 3.15E-05 Self-reported allergy / / 23817569 rs3916566 chr1 154282146 C T 7.80E-05 Self-reported allergy / / 23817569 rs6427560 chr1 154287687 A G 9.06E-05 Self-reported allergy / / 23817569 rs1194610 chr1 154296076 T C 2.20E-04 Coronary heart disease AQP10 cds-synon 21966275 rs1194610 chr1 154296076 T C 7.41E-05 Soluble levels of adhesion molecules AQP10 cds-synon pha003072 rs1194588 chr1 154313232 T C 6.22E-04 Response to cytidine analogues (gemcitabine) ATP8B2 intron 24483146 rs1194587 chr1 154317153 C T 1.03E-04 Self-reported allergy ATP8B2 cds-synon 23817569 rs1194586 chr1 154317418 T C 1.03E-04 Self-reported allergy ATP8B2 intron 23817569 rs1194585 chr1 154318564 G A 1.02E-04 Self-reported allergy ATP8B2 intron 23817569 rs1194584 chr1 154319756 G T 8.70E-05 Self-reported allergy ATP8B2 intron 23817569 rs1194592 chr1 154324384 C G 7.01E-05 Self-reported allergy / / 23817569 rs2483712 chr1 154325149 A C 3.78E-05 Self-reported allergy / / 23817569 rs6688376 chr1 154326366 C T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12025518 chr1 154340789 A C 6.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs11582424 chr1 154363985 A C 6.04E-04 Alcohol dependence / / 24277619 rs11265608 chr1 154364140 G A 0.0000574 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs11265608 chr1 154364140 G A 0.000112 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs11265608 chr1 154364140 G A 2.75E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs17654071 chr1 154369252 A G 3.53E-04 Alcohol dependence / / 24277619 rs2054855 chr1 154370938 C T 8.84E-04 Multiple complex diseases / / 17554300 rs1552481 chr1 154376353 C T 5.17E-14 HDL cholesterol IL6R nearGene-5 23063622 rs12089132 chr1 154378336 T C 1.71E-31 HDL cholesterol IL6R intron 23063622 rs72698115 chr1 154379369 A C 1.26E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) IL6R intron 23603761 rs4845618 chr1 154400015 G T 0.00000059 C-reactive protein IL6R intron 23505291 rs4845618 chr1 154400015 G T 2.76E-10 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs2228144 chr1 154401679 G A 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) IL6R cds-synon 24554482 rs7553796 chr1 154404406 A C 0.0000024 C-reactive protein IL6R intron 23505291 rs7553796 chr1 154404406 A C 5.10E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7518199 chr1 154407419 A C 3.89E-07 Fibrinogen IL6R intron 20978265 rs7518199 chr1 154407419 A C 1.06E-20 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7518199 chr1 154407419 A C 1.67E-10 C-reactive protein IL6R intron 23505291 rs4845371 chr1 154408340 T C 0.00000245 C-reactive protein IL6R intron 23505291 rs4845371 chr1 154408340 T C 2.71E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs6667434 chr1 154409100 A G 0.0000025 C-reactive protein IL6R intron 23505291 rs6667434 chr1 154409100 A G 3.36E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4553185 chr1 154410955 C T 1.98E-04 Alzheimer's disease (late onset) IL6R intron 21379329 rs4553185 chr1 154410955 C T 0.00000206 C-reactive protein IL6R intron 23505291 rs4553185 chr1 154410955 C T 4.40E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4537545 chr1 154418879 C T 2.00E-14 C-reactive protein IL6R intron 19567438 rs4537545 chr1 154418879 C T 1.98E-07 Fibrinogen IL6R intron 20978265 rs4537545 chr1 154418879 C T 6.40E-04 Atrial fibrillation IL6R intron 21846873 rs4537545 chr1 154418879 C T 2.20E-11 C-reactive protein IL6R intron 23505291 rs4537545 chr1 154418879 C T 9.63E-22 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4537545 chr1 154418879 C T 5.09E-05 C-reactive protein IL6R intron 23844046 rs12730935 chr1 154419892 G A 4.87E-60 Interleukin-6R IL6R intron 23696881 rs7529229 chr1 154420778 T C 8.28E-08 Fibrinogen IL6R intron 20978265 rs7529229 chr1 154420778 T C 8.30E-04 Atrial fibrillation IL6R intron 21846873 rs7529229 chr1 154420778 T C 1.77E-21 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7529229 chr1 154420778 T C 2.28E-11 C-reactive protein IL6R intron 23505291 rs28638007 chr1 154421354 T C 4.90E-04 Atrial fibrillation IL6R intron 21846873 rs28638007 chr1 154421354 T C 0.000000369 C-reactive protein IL6R intron 23505291 rs28638007 chr1 154421354 T C 1.77E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4845625 chr1 154422067 T C 4.80E-04 Atrial fibrillation IL6R intron 21846873 rs4845625 chr1 154422067 T C 3.10E-04 Coronary heart disease IL6R intron 21966275 rs4845625 chr1 154422067 T C 0.00000043 Coronary artery disease with myocardial infarction IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.0000367 Coronary artery disease (CAD) age >50 IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.0000655 Coronary artery disease (CAD) (males) IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.000201 Coronary artery disease (CAD) age <=50 IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.000374 Coronary artery disease (CAD) (females) IL6R intron 23202125 rs4845625 chr1 154422067 T C 3.64E-10 Coronary artery disease IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.00000042 C-reactive protein IL6R intron 23505291 rs4845625 chr1 154422067 T C 1.18E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4845625 chr1 154422067 T C 1.93E-05 Coronary artery disease IL6R intron 24262325 rs4845626 chr1 154423485 G T 6.13E-04 Multiple complex diseases IL6R intron 17554300 rs4845626 chr1 154423485 G T 4.96E-04 Response to taxane treatment (placlitaxel) IL6R intron 23006423 rs4129267 chr1 154426264 C T 7.00E-06 Pulmonary function IL6R intron 17903307 rs4129267 chr1 154426264 C T 2.00E-57 Protein quantitative trait loci IL6R intron 18464913 rs4129267 chr1 154426264 C T 8.41E-07 Fibrinogen IL6R intron 20978265 rs4129267 chr1 154426264 C T 2.00E-48 C-reactive protein IL6R intron 21300955 rs4129267 chr1 154426264 C T 2.00E-08 Asthma IL6R intron 21907864 rs4129267 chr1 154426264 C T 1.63E-21 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4129267 chr1 154426264 C T 8.80E-12 C-reactive protein IL6R intron 23505291 rs4129267 chr1 154426264 C T 6.00E-27 Fibrinogen IL6R intron 23969696 rs2228145 chr1 154426970 A C,G,T 2.00E-08 C-reactive protein IL6R missense 18439548 rs2228145 chr1 154426970 A C,G,T 2.00E-11 Fibrinogen IL6R missense 20031577 rs2228145 chr1 154426970 A C,G,T 0.000000013 Rheumatoid arthritis IL6R missense 23143596 rs2228145 chr1 154426970 A C,G,T 0.00000002 Circulating C-reactive protein IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 0.0000153 Coronary heart disease IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 1.02E-21 Interleukin-6 (IL-6) levels IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 1.80E-11 Fibrinogen IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 2.00E-57 Circulating soluble interleukin-6 (sIL-6) IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 2.36E-08 Circulating interleukin-6 (IL-6) IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 4.00E-09 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 5.00E-06 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 9.20E-05 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 2.00E-08 C-reactive protein IL6R missense 18439548 rs2228145 chr1 154426970 A C,G,T 2.00E-11 Fibrinogen IL6R missense 20031577 rs2228145 chr1 154426970 A C,G,T 0.000000157 Rheumatoid arthritis (CCP positive) IL6R missense 23143596 rs2228145 chr1 154426970 A C,G,T 1.08E-11 C-reactive protein IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 8.84E-60 Interleukin-6R IL6R missense 23696881 rs11265618 chr1 154430092 C T 8.34E-04 Multiple complex diseases IL6R intron 17554300 rs11265618 chr1 154430092 C T 1.16E-06 Rheumatoid arthritis IL6R intron 19503088 rs11265618 chr1 154430092 C T 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL6R intron 20877124 rs11265618 chr1 154430092 C T 8.10E-04 Response to taxane treatment (placlitaxel) IL6R intron 23006423 rs4240872 chr1 154436195 C T 4.51E-04 Alcohol dependence IL6R intron 20201924 rs4240872 chr1 154436195 C T 7.73E-05 Alzheimer's disease (late onset) IL6R intron 21379329 rs4240872 chr1 154436195 C T 7.21E-05 Abdominal aortic aneurysm IL6R intron 24046328 rs4240872 chr1 154436195 C T 4.26E-04 Myocardial infarction IL6R intron 24916648 rs4509570 chr1 154436384 G C 8.10E-04 Coronary heart disease IL6R intron 21966275 rs4509570 chr1 154436384 G C 3.08E-08 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs2229238 chr1 154437896 T C 7.00E-07 Coronary heart disease IL6R UTR-3 22319020 rs7514452 chr1 154438084 C T 3.47E-06 Alzheimer's disease (late onset) IL6R UTR-3 21379329 rs7514452 chr1 154438084 C T 6.83E-05 Abdominal aortic aneurysm IL6R UTR-3 24046328 rs6700296 chr1 154473660 T C 6.26E-04 Multiple complex diseases SHE intron 17554300 rs12740969 chr1 154487060 T G 0.00000495 C-reactive protein TDRD10 intron 23505291 rs12740969 chr1 154487060 T G 1.20E-11 Interleukin-6 (IL-6) levels TDRD10 intron 23505291 rs6674171 chr1 154491683 A G 1.15E-05 Abdominal aortic aneurysm TDRD10 intron 22055160 rs7556449 chr1 154505886 A G 3.05E-06 Alzheimer's disease (late onset) TDRD10 intron 21379329 rs12136771 chr1 154511502 T C 9.00E-04 Multiple complex diseases TDRD10 intron 17554300 rs75323106 chr1 154511502 T TC 9.00E-04 Multiple complex diseases TDRD10 intron 17554300 rs3811448 chr1 154516578 G A 1.69E-06 Alzheimer's disease (late onset) TDRD10 missense 21379329 rs7543174 chr1 154527672 C T 9.51E-05 IgE levels UBE2Q1 intron 22075330 rs4074436 chr1 154531910 G A 3.54E-08 White blood cell count / / 21738479 rs9427089 chr1 154534766 G A 9.63E-07 White blood cell count / / 21738479 rs4845652 chr1 154538205 C T 0.0000479 Sarcoidosis / / 22952805 rs2072661 chr1 154548880 G A 1 Drug response to Nicotine CHRNB2 UTR-3 18593715 rs11264221 chr1 154551717 C T 1.13E-04 Multiple complex diseases CHRNB2 UTR-3 17554300 rs884618 chr1 154601157 A G 5.20E-07 White blood cell count ADAR nearGene-5 21738479 rs9427108 chr1 154607914 G A 5.15E-07 White blood cell count / / 21738479 rs12092890 chr1 154608570 C T 1.34E-04 Multiple complex diseases / / 17554300 rs9426831 chr1 154609657 A T 3.16E-06 White blood cell count / / 21738479 rs11264233 chr1 154625632 G A 2.69E-07 White blood cell count / / 21738479 rs9427113 chr1 154626477 A G 1.51E-08 White blood cell count / / 21738479 rs9427114 chr1 154626705 T C 1.27E-08 White blood cell count / / 21738479 rs1876304 chr1 154633513 G T 8.50E-06 Asthma / / pha003128 rs9427118 chr1 154637584 C T 4.73E-06 White blood cell count / / 21738479 rs6698385 chr1 154652572 A G 2.83E-05 Asthma / / pha003128 rs2036627 chr1 154669577 C T 7.24E-06 Smoking behavior KCNN3 nearGene-3 19188921 rs1995662 chr1 154679567 C T 8.77E-06 Smoking behavior KCNN3 UTR-3 19188921 rs1995662 chr1 154679567 C T 1.87E-04 Parkinson's disease KCNN3 UTR-3 21248740 rs4845663 chr1 154692088 T C 1.09E-06 White blood cell count KCNN3 intron 21738479 rs3738028 chr1 154698817 C A 4.60E-05 Type 2 diabetes KCNN3 intron 17460697 rs10494301 chr1 154701218 T C 5.68E-04 Obesity (extreme) KCNN3 intron 21935397 rs12402320 chr1 154701406 C T 0.000436065 Hypertension (early onset hypertension) KCNN3 intron 22479346 rs6682000 chr1 154711226 C A 1.02E-04 Amyotrophic lateral sclerosis (sporadic) KCNN3 intron 24529757 rs1506985 chr1 154713341 T C 0.0000466 post-traumatic stress disorder KCNN3 intron 22869035 rs1506985 chr1 154713341 T C 4.66E-05 Schizophrenia KCNN3 intron 22883433 rs4999127 chr1 154714006 G A 0.0000206 post-traumatic stress disorder KCNN3 intron 22869035 rs4999127 chr1 154714006 G A 2.06E-05 Schizophrenia KCNN3 intron 22883433 rs4845390 chr1 154726374 T C 5.29E-04 Multiple complex diseases KCNN3 intron 17554300 rs10494300 chr1 154726546 G C 4.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KCNN3 intron 24578207 rs10494300 chr1 154726546 G C 4.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KCNN3 intron 24578207 rs6682291 chr1 154732776 A C 4.40E-04 Alzheimer's disease KCNN3 intron 24755620 rs1131820 chr1 154744852 A G 3.55E-04 Multiple complex diseases KCNN3 cds-synon 17554300 rs6691316 chr1 154754194 C T 7.00E-06 Obesity-related traits KCNN3 intron 23251661 rs6691316 chr1 154754194 C T 9.00E-06 Obesity-related traits KCNN3 intron 23251661 rs4079531 chr1 154761265 G A 2.00E-04 Cognitive impairment induced by topiramate KCNN3 intron 22091778 rs954785 chr1 154770139 G T 3.60E-06 Non-small cell lung cancer (survival) KCNN3 intron 23704207 rs1702176 chr1 154777157 G A 1 Drug response to Etoposide KCNN3 intron 17537913 rs2798601 chr1 154779685 A G 7.96E-05 Postoperative ventricular dysfunction KCNN3 intron 21980348 rs7512194 chr1 154781889 G A 6.07E-04 Amyotrophic Lateral Sclerosis KCNN3 intron 17362836 rs1106236 chr1 154787136 T C 7.29E-05 Blood Pressure KCNN3 intron pha003048 rs1218598 chr1 154795389 G A 9.10E-05 Endometriosis KCNN3 intron 21151130 rs6681392 chr1 154796712 T C 4.73E-06 White blood cell count KCNN3 intron 21738479 rs12128882 chr1 154811435 T C 9.71E-05 Sodium levels KCNN3 intron pha003093 rs12740456 chr1 154814197 C A 9.71E-05 Coronary heart disease KCNN3 intron pha003030 rs6666258 chr1 154814268 G C 2.00E-14 Atrial fibrillation KCNN3 intron 22544366 rs13376333 chr1 154814353 C T 2.00E-21 Atrial fibrillation KCNN3 intron 20173747 rs883905 chr1 154815366 G A 4.77E-06 White blood cell count KCNN3 intron 21738479 rs4845396 chr1 154828409 G A 6.50E-05 Endometriosis KCNN3 intron 21151130 rs1218582 chr1 154834183 G A 2.00E-08 Prostate cancer KCNN3 intron 23535732 rs10796934 chr1 154849479 G C 4.53E-04 Multiple complex diseases / / 17554300 rs10908445 chr1 154849590 G A 2.81E-04 Multiple complex diseases / / 17554300 rs4845678 chr1 154853295 T C 4.84E-04 Multiple complex diseases / / 17554300 rs1630500 chr1 154855055 G A 2.00E-08 Parkinson's disease / / 24842889 rs4845679 chr1 154861187 G T 9.67E-05 Serum metabolites / / 19043545 rs4845681 chr1 154868055 G T 9.30E-04 Multiple complex diseases / / 17554300 rs4845681 chr1 154868055 G T 9.78E-05 Serum metabolites / / 19043545 rs12130132 chr1 154880386 G A 7.71E-04 Multiple complex diseases / / 17554300 rs10908448 chr1 154882544 C T 2.75E-04 Multiple complex diseases / / 17554300 rs4845690 chr1 154886817 T C 2.77E-04 Multiple complex diseases / / 17554300 rs12143679 chr1 154891287 C G 0.0000762 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16836525 chr1 154898899 C T 0.0003 Prostate cancer PMVK missense 23555315 rs16836525 chr1 154898899 C T 0.00061 Prostate cancer (non-advanced prostate cancer) PMVK missense 23555315 rs4578216 chr1 154900721 T C 4.90E-04 Atrial fibrillation PMVK intron 21846873 rs11264286 chr1 154903047 G A 5.93E-06 White blood cell count PMVK intron 21738479 rs877343 chr1 154910012 A G 5.50E-05 Coronary heart disease / / 21966275 rs4845693 chr1 154911257 C T 2.21E-04 Multiple complex diseases / / 17554300 rs3766921 chr1 154935253 G C 1.47E-06 White blood cell count SHC1 UTR-3 21738479 rs4845401 chr1 154941593 C G 3.00E-10 White blood cell count SHC1 intron 21738479 rs12075984 chr1 154943881 A G 1.02E-06 White blood cell count SHC1 intron 21738479 rs12076073 chr1 154944156 A G 3.17E-06 White blood cell count SHC1 intron 21738479 rs11585145 chr1 154947496 A T 1.94E-06 White blood cell count CKS1B intron 21738479 rs10908449 chr1 154955724 C T 9.42E-04 Multiple complex diseases / / 17554300 rs10908449 chr1 154955724 C T 2.88E-06 White blood cell count / / 21738479 rs4845700 chr1 154981708 C T 9.13E-08 White blood cell count ZBTB7B intron 21738479 rs4845405 chr1 155007302 C A 4.88E-04 Myocardial Infarction DCST1 intron pha002873 rs11264300 chr1 155019710 A C 1.36E-04 Myocardial Infarction DCST1 missense pha002873 rs7367207 chr1 155079477 C T 8.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11264329 chr1 155095158 A G 1.22E-06 Lung cancer / / 19654303 rs11264329 chr1 155095158 A G 4.40E-06 Digit length ratio / / 20303062 rs11264329 chr1 155095158 A G 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11264330 chr1 155098905 G A 5.00E-06 Obesity-related traits / / 23251661 rs4971066 chr1 155105882 T G 2.47E-05 Cervical cancer EF/1 intron 24700089 rs9297 chr1 155106550 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) EF/1 UTR-3 20708005 rs12726330 chr1 155108167 G A 5.00E-08 Parkinson's disease / / 22451204 rs4246529 chr1 155115260 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12025371 chr1 155119327 A T 5.54E-06 White blood cell count / / 21738479 rs35304908 chr1 155119327 A AT 5.54E-06 White blood cell count / / 21738479 rs63172161 chr1 155119327 A AT 5.54E-06 White blood cell count / / 21738479 rs10157801 chr1 155120012 A G 1.20E-05 Urinary metabolites / / 21572414 rs10908458 chr1 155126948 T C 2.00E-15 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs4971079 chr1 155130391 G A 5.60E-06 Urinary metabolites / / 21572414 rs4276913 chr1 155131673 A G 2.40E-05 Urinary metabolites / / 21572414 rs4971092 chr1 155143946 C T 1.14E-06 White blood cell count KRTCAP2 intron 21738479 rs4971059 chr1 155148781 G A 3.02E-09 Urate levels TRIM46 intron 23263486 rs3814316 chr1 155149718 G A 6.48E-11 Urate levels TRIM46 cds-synon 23263486 rs11264341 chr1 155151493 C T 6.00E-19 Urate levels TRIM46 intron 23263486 rs9426886 chr1 155151754 A T 1.12E-14 Urate levels TRIM46 intron 23263486 rs4971100 chr1 155155731 G A 1.82E-14 Urate levels TRIM46 intron 23263486 rs2070803 chr1 155157715 A G 1.20E-06 Gastric cancer (diffuse-type gastric cancer) TRIM46 nearGene-3 18488030 rs4072037 chr1 155162067 C T 2.00E-36 magnesium levels MUC1 cds-synon 20700443 rs4072037 chr1 155162067 C T 4.00E-07 Esophageal cancer and gastric cancer MUC1 cds-synon 20729852 rs4072037 chr1 155162067 C T 3.91E-09 Urate levels MUC1 cds-synon 23263486 rs2075570 chr1 155182164 C T 9.20E-07 Gastric cancer (diffuse-type gastric cancer) MTX1 intron 18488030 rs2049805 chr1 155194980 T C 2.00E-12 Renal function-related traits (BUN) GBAP1 intron 22797727 rs2990245 chr1 155197462 C T 2.63E-08 Urate levels GBAP1 nearGene-5 23263486 rs1142287 chr1 155230131 C T 2.00E-13 Crohn's disease SCAMP3 cds-synon 21102463 rs1142287 chr1 155230131 C T 2.00E-13 Crohn's disease SCAMP3 cds-synon 21102463 rs4971072 chr1 155273869 G A 3.14E-14 White blood cell count / / 21738479 rs2297480 chr1 155279482 T G 1 Drug response to Alendronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Ibandronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Pamidronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Risedronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Zoledronate FDPS intron 18687167 rs11264359 chr1 155282829 A G 3.80E-05 Crohn's disease FDPS intron 20570966 rs11264363 chr1 155318308 G C 5.16E-04 Type 2 diabetes ASH1L intron 17463246 rs1886905 chr1 155372672 T C 6.62E-06 White blood cell count ASH1L intron 21738479 rs570246343 chr1 155372672 T TC 6.62E-06 White blood cell count ASH1L intron 21738479 rs1325908 chr1 155413304 C A 9.65E-04 Type 2 diabetes ASH1L intron 17463246 rs1325908 chr1 155413304 C A 4.10E-06 White blood cell count ASH1L intron 21738479 rs6688636 chr1 155478897 T C 4.30E-05 Crohn's disease ASH1L intron 20570966 rs6688636 chr1 155478897 T C 2.82E-06 White blood cell count ASH1L intron 21738479 rs6696888 chr1 155508882 G A 1.30E-13 White blood cell count ASH1L intron 21738479 rs602905 chr1 155628628 C G 4.67E-06 Age-related macular degeneration / / pha000001 rs651905 chr1 155641975 A G 4.67E-06 Age-related macular degeneration YY1AP1 intron pha000001 rs821551 chr1 155688580 C A 5.07E-11 White blood cell count DAP3 intron 21738479 rs348184 chr1 155697810 A G 4.92E-04 Multiple complex diseases DAP3 intron 17554300 rs348184 chr1 155697810 A G 1.05E-22 Narcolepsy DAP3 intron 19629137 rs372780 chr1 155698028 A C 7.52E-07 White blood cell count DAP3 intron 21738479 rs394851 chr1 155719467 G T 1.63E-10 White blood cell count MSTO2P intron 21738479 rs822485 chr1 155763032 G A 2.20E-04 Multiple complex diseases GON4L intron 17554300 rs822519 chr1 155840706 C T 9.02E-04 Insulin resistance SYT11 intron 21901158 rs729022 chr1 155852123 C T 4.57E-06 White blood cell count SYT11 UTR-3 21738479 rs2282301 chr1 155868625 G A 7.00E-06 Conduct disorder (interaction) RIT1 UTR-3 18846501 rs3856261 chr1 155876613 G A 2.49E-07 White blood cell count RIT1 intron 21738479 rs670523 chr1 155878732 A G 6.00E-11 Inflammatory bowel disease RIT1 intron 23128233 rs572609 chr1 155897716 T C 3.05E-04 Multiple complex diseases KIAA0907 intron 17554300 rs11264422 chr1 155907823 T A 1.69E-08 White blood cell count / / 21738479 rs142470296 chr1 155912426 A G 0.000058 Prostate cancer (advanced) RXFP4 missense 23555315 rs2364403 chr1 155927752 G A 1.00E-06 Amyotrophic lateral sclerosis (age of onset) ARHGEF2 intron 22959728 rs6670493 chr1 155956903 C G 9.89E-06 White blood cell count / / 21738479 rs11589188 chr1 155971887 T C 6.00E-05 Alcohol dependence / / 21703634 rs34372695 chr1 156030037 C T 4.00E-12 Parkinson's disease / / 21292315 rs34372695 chr1 156030037 C T 3.60E-12 Parkinson's disease / / 22438815 rs2275075 chr1 156040310 A G 8.00E-05 Waist circumference and related phenotypes / / 18454146 rs11264432 chr1 156042915 G A 1.99E-04 Suicide attempts in bipolar disorder MEX3A UTR-3 21041247 rs12035615 chr1 156055344 C T 7.91E-04 Multiple complex diseases LM/ intron 17554300 rs10737170 chr1 156063880 C A 2.47E-04 Response to taxane treatment (placlitaxel) LM/ intron 23006423 rs10737170 chr1 156063880 C A 8.62E-08 Parkinson's disease LM/ intron 24842889 rs6661281 chr1 156074845 T C 6.12E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs915179 chr1 156078249 A G 5.97E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs915179 chr1 156078249 A G 2.37E-05 Longevity LM/ intron 22279548 rs915180 chr1 156079083 C T 4.82E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs505058 chr1 156106185 T C 2.00E-04 Alzheimer's disease (late onset) LM/ cds-synon 21460841 rs12128066 chr1 156127368 T C 2.10E-05 Bipolar disorder and schizophrenia SEMA4A intron 20889312 rs112223391 chr1 156156094 G A 3.61E-05 Intracerebral hemorrhage / / 24656865 rs7534339 chr1 156156219 T C 3.14E-05 Intracerebral hemorrhage / / 24656865 rs6427304 chr1 156156789 A G 6.80E-05 White matter hyperintensity burden / / 21681796 rs6427304 chr1 156156789 A G 4.02E-07 Intracerebral hemorrhage / / 24656865 rs11587860 chr1 156156951 G C 3.10E-07 Intracerebral hemorrhage / / 24656865 rs2758615 chr1 156158367 T C 5.08E-07 Intracerebral hemorrhage / / 24656865 rs57056972 chr1 156159064 C A 3.61E-05 Intracerebral hemorrhage / / 24656865 rs2842864 chr1 156159217 G A 5.09E-07 Intracerebral hemorrhage / / 24656865 rs2842865 chr1 156159532 G A 5.64E-07 Intracerebral hemorrhage / / 24656865 rs55910626 chr1 156159909 C G 3.57E-05 Intracerebral hemorrhage / / 24656865 rs2758616 chr1 156160358 T C 7.73E-07 Intracerebral hemorrhage / / 24656865 rs2842869 chr1 156160696 A G 5.16E-07 Intracerebral hemorrhage / / 24656865 rs10159384 chr1 156160822 C T 3.61E-05 Intracerebral hemorrhage / / 24656865 rs2758618 chr1 156160892 T C 5.16E-07 Intracerebral hemorrhage / / 24656865 rs61462713 chr1 156161682 C T 3.78E-05 Intracerebral hemorrhage / / 24656865 rs2758619 chr1 156162559 A G 5.27E-07 Intracerebral hemorrhage / / 24656865 rs41265025 chr1 156163906 C T 3.64E-05 Intracerebral hemorrhage SLC25A44 UTR-5 24656865 rs2540183 chr1 156164885 C G 8.65E-08 Intracerebral hemorrhage SLC25A44 intron 24656865 rs3001790 chr1 156165290 T G 4.71E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2984615 chr1 156165317 G C 4.71E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2842882 chr1 156165342 T G 4.70E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs55675376 chr1 156165881 C T 3.62E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2842857 chr1 156168736 T C 6.30E-05 White matter hyperintensity burden SLC25A44 intron 21681796 rs2842857 chr1 156168736 T C 5.01E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2072499 chr1 156169610 A G 3.00E-08 Testicular germ cell tumor SLC25A44 intron 23666240 rs2072499 chr1 156169610 A G 4.37E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2253677 chr1 156171296 C G 3.13E-04 Multiple complex diseases SLC25A44 intron 17554300 rs2253677 chr1 156171296 C G 6.20E-05 White matter hyperintensity burden SLC25A44 intron 21681796 rs2253677 chr1 156171296 C G 5.02E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2253809 chr1 156172125 T C 4.14E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2241109 chr1 156173082 C T 6.74E-04 Alcohol dependence SLC25A44 intron 20201924 rs2241109 chr1 156173082 C T 3.80E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2266514 chr1 156173685 T C 3.86E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2736605 chr1 156174475 T C 5.46E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2736607 chr1 156174930 G T 3.71E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs72708291 chr1 156177285 A T 3.70E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2241108 chr1 156181007 C G 5.20E-05 White matter hyperintensity burden SLC25A44 UTR-3 21681796 rs2241108 chr1 156181007 C G 4.20E-07 Intracerebral hemorrhage SLC25A44 UTR-3 24656865 rs2853641 chr1 156181770 A G 5.30E-05 White matter hyperintensity burden SLC25A44 UTR-3 21681796 rs2853641 chr1 156181770 A G 4.20E-07 Intracerebral hemorrhage SLC25A44 UTR-3 24656865 rs2075163 chr1 156181833 T G 0.00007648 Sarcoidosis SLC25A44 UTR-3 22952805 rs2241107 chr1 156182710 T C 5.40E-05 White matter hyperintensity burden / / 21681796 rs2241107 chr1 156182710 T C 4.27E-07 Intracerebral hemorrhage / / 24656865 rs1060604 chr1 156184268 T C 8.29E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs1137703 chr1 156184458 T C 4.47E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2244144 chr1 156184598 G A 8.20E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2244144 chr1 156184598 G A 8.22E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2540175 chr1 156184747 T C 5.08E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2853643 chr1 156184831 G A 8.29E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs7534434 chr1 156186615 A G 4.62E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2540173 chr1 156188214 A G 1.90E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2540173 chr1 156188214 A G 4.85E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs116902958 chr1 156188624 T A 0.0000329 Sarcoidosis PMF1 intron 22952805 rs2853646 chr1 156189626 C T 7.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs6427307 chr1 156190083 A G 5.34E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2247476 chr1 156190280 C A 3.86E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs887953 chr1 156191149 T C 8.20E-05 White matter hyperintensity burden PMF1 intron 21681796 rs887953 chr1 156191149 T C 7.55E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs909269 chr1 156192028 C T 4.16E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2758598 chr1 156194339 G A 1.20E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2758600 chr1 156195205 C T 8.32E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2540171 chr1 156195682 G A 3.54E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2248074 chr1 156195888 C T 5.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2736613 chr1 156196016 T C 5.43E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842868 chr1 156196407 T G 3.55E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2984613 chr1 156197380 C T 1.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2984613 chr1 156197380 C T 2.00E-10 Intracerebral hemorrhage PMF1 intron 24656865 rs3001789 chr1 156197614 T G 1.59E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758603 chr1 156198994 T C 1.56E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758605 chr1 156200445 G C 9.40E-06 White matter hyperintensity burden PMF1 intron 21681796 rs2758605 chr1 156200445 G C 0.0000979 white matter hyperintensity burden PMF1 intron 23674528 rs2758605 chr1 156200445 G C 1.55E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842870 chr1 156200671 T C 1.65E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs1052053 chr1 156202173 A C,G,T 9.55E-04 Multiple complex diseases PMF1 missense 17554300 rs1052053 chr1 156202173 A C,G,T 5.00E-06 White matter hyperintensity burden PMF1 missense 21681796 rs1052053 chr1 156202173 A C,G,T 0.0000605 white matter hyperintensity burden PMF1 missense 23674528 rs1052053 chr1 156202173 A C,G,T 9.24E-08 Intracerebral hemorrhage PMF1 missense 24656865 rs2736609 chr1 156202640 C T 1.82E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758607 chr1 156202759 G A 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2251636 chr1 156202809 G C 1.21E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2758608 chr1 156202860 A T 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758609 chr1 156202868 G A 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2251847 chr1 156204047 G A 1.00E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2251847 chr1 156204047 G A 1.62E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842873 chr1 156204653 C T 6.40E-06 White matter hyperintensity burden PMF1 intron 21681796 rs2842873 chr1 156204653 C T 0.00000751 white matter hyperintensity burden PMF1 intron 23674528 rs2842873 chr1 156204653 C T 1.40E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs1052067 chr1 156206121 G A 5.12E-05 Alcohol dependence PMF1 missense 20201924 rs1052067 chr1 156206121 G A 5.12E-05 Alcoholism PMF1 missense pha002891 rs182363024 chr1 156208217 G A 0.00007925 Sarcoidosis PMF1 intron 22952805 rs2842880 chr1 156232358 T C 3.00E-04 Cognitive impairment induced by topiramate SMG5 intron 22091778 rs6684514 chr1 156255456 G A 3.00E-09 Blood cell counts and other traits TMEM79 missense 20139978 rs6684514 chr1 156255456 G A 3.39E-09 Blood cell counts and other traits TMEM79 missense 20139978 rs6684514 chr1 156255456 G A 1.00E-23 Glycated hemoglobin levels TMEM79 missense 24647736 rs11264467 chr1 156273061 C T 1.07E-04 Lymphocyte counts / / 22286170 rs2249790 chr1 156287360 C T 2.00E-04 Cognitive impairment induced by topiramate CCT3 intron 22091778 rs7525133 chr1 156341494 G A 5.00E-06 Visceral adipose tissue adjusted for BMI RHBG intron 22589738 rs2245623 chr1 156347131 G A 1.61E-04 IgE levels RHBG missense 17255346 rs872120 chr1 156352396 C T 0.00000998 Polycystic ovary syndrome RHBG intron 22951595 rs872120 chr1 156352396 C T 9.98E-06 Intracranial aneurysm RHBG intron 22961961 rs6686886 chr1 156356480 G A 6.58E-04 Lymphocyte counts / / 22286170 rs6686886 chr1 156356480 G A 9.00E-06 Subcutaneous adipose tissue / / 22589738 rs16837376 chr1 156392455 A T 2.94E-04 Type 2 diabetes C1orf61 intron 17463246 rs10494305 chr1 156400060 C T 4.70E-05 Kawasaki disease / / 22446962 rs11264483 chr1 156406381 G C 1.67E-10 White blood cell count / / 21738479 rs4414033 chr1 156406853 G A 1.78E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1171663 chr1 156413502 A C 4.81E-04 Smoking cessation / / 24665060 rs1050316 chr1 156434703 G T 3.20E-10 Migraine / / 22683712 rs2274316 chr1 156446242 C A 3.60E-08 Migraine MEF2D intron 22683712 rs2274316 chr1 156446242 C A 1.00E-07 Migraine - clinic-based MEF2D intron 23793025 rs2274316 chr1 156446242 C A 1.00E-08 Migraine MEF2D intron 23793025 rs2274316 chr1 156446242 C A 2.31E-05 Migraine without aura MEF2D intron 23793025 rs1925950 chr1 156450740 G A 2.97E-08 Migraine / / 22683712 rs202206511 chr1 156456301 C CT 7.00E-11 Migraine MEF2D intron 22683712 rs202206511 chr1 156456301 C CT 1.35E-07 Migraine - clinic-based MEF2D intron 23793025 rs202206511 chr1 156456301 C CT 1.42E-05 Migraine without aura MEF2D intron 23793025 rs202206511 chr1 156456301 C CT 1.91E-08 Migraine MEF2D intron 23793025 rs3790455 chr1 156456301 C T 7.00E-11 Migraine MEF2D intron 22683712 rs3790455 chr1 156456301 C T 1.35E-07 Migraine - clinic-based MEF2D intron 23793025 rs3790455 chr1 156456301 C T 1.42E-05 Migraine without aura MEF2D intron 23793025 rs3790455 chr1 156456301 C T 1.91E-08 Migraine MEF2D intron 23793025 rs3790459 chr1 156461707 A T 2.85E-08 Migraine MEF2D intron 22683712 rs10908505 chr1 156468243 T A 5.70E-11 White blood cell count MEF2D intron 21738479 rs12136856 chr1 156473114 C G 3.90E-08 Migraine / / 22683712 rs11264489 chr1 156480831 A G 6.00E-04 Obesity (extreme) / / 21935397 rs6685228 chr1 156486009 G A 7.53E-04 Smoking initiation / / 24665060 rs6674079 chr1 156486061 A G 5.07E-04 Obesity (extreme) / / 21935397 rs1750307 chr1 156488420 T A 6.22E-04 Obesity (extreme) / / 21935397 rs1171564 chr1 156498673 T A 5.43E-04 Type 2 diabetes IQGAP3 intron 17463246 rs1609666 chr1 156502991 A G 1.34E-04 Type 2 diabetes IQGAP3 intron 17463246 rs1609666 chr1 156502991 A G 4.83E-05 Serum metabolites IQGAP3 intron 19043545 rs1609666 chr1 156502991 A G 7.14E-04 Suicide attempts in bipolar disorder IQGAP3 intron 21423239 rs744224 chr1 156518379 G A 4.30E-05 Type 2 diabetes IQGAP3 missense 17463246 rs12760461 chr1 156525023 T C 9.80E-04 Suicide attempts in bipolar disorder IQGAP3 intron 21423239 rs6682716 chr1 156551848 A G 2.98E-08 White blood cell count TTC24 missense 21738479 rs12090808 chr1 156555819 A G 3.68E-10 Triglycerides TTC24 missense 23063622 rs10796961 chr1 156556321 G A 3.05E-07 White blood cell count TTC24 cds-synon 21738479 rs879461 chr1 156567496 C T 6.28E-05 Serum metabolites GPATCH4 intron 19043545 rs879461 chr1 156567496 C T 7.70E-33 Lymphocyte counts GPATCH4 intron 22286170 rs41434645 chr1 156570715 T G 5.82E-04 Multiple complex diseases GPATCH4 intron 17554300 rs11576266 chr1 156572159 A G 1.03E-07 White blood cell count / / 21738479 rs7536235 chr1 156581534 T C 5.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1056695 chr1 156622252 G A 9.37E-05 Coronary heart disease BCAN missense pha003035 rs11360 chr1 156629037 A G 3.57E-05 stroke (ischemic) BCAN UTR-3 17434096 rs147070824 chr1 156641200 T A 0.00009 Prostate cancer (advanced) NES missense 23555315 rs12145743 chr1 156700651 T G 0.00054 Breast cancer RR/D1 intron 23555315 rs12145743 chr1 156700651 T G 2.00E-08 HDL cholesterol RR/D1 intron 24097068 rs6670122 chr1 156707775 T G 2.25E-41 Narcolepsy MRPL24 intron 19629137 rs4399146 chr1 156713558 G A 0.0006 Breast cancer HDGF missense 23555315 rs1412310 chr1 156746608 G A 1.79E-04 HIV-1 viral setpoint PRCC intron 17641165 rs2644615 chr1 156761618 C T 1.80E-05 Urinary metabolites PRCC intron 21572414 rs928392 chr1 156770816 T C 2.20E-05 Urinary metabolites PRCC nearGene-3 21572414 rs7531222 chr1 156789781 C T 8.58E-06 White blood cell count NTRK1 intron 21738479 rs12756019 chr1 156799912 G A 4.89E-08 White blood cell count NTRK1 intron 21738479 rs6337 chr1 156848995 C T 1.27E-08 White blood cell count NTRK1 cds-synon 21738479 rs2768759 chr1 156852463 A C 1 Drug response to Aspirin / / 18511696 rs2768762 chr1 156860462 G T 5.01E-14 White blood cell count / / 21738479 rs12566888 chr1 156869047 G T 4.00E-16 Platelet aggregation PEAR1 intron 20526338 rs12566888 chr1 156869047 G T 5.00E-19 Platelet aggregation PEAR1 intron 20526338 rs12041331 chr1 156869714 G A 7.70E-09 Platelet response with aspirin and clopidogrel PEAR1 intron 23392654 rs2768744 chr1 156872149 G A 1.96E-09 White blood cell count PEAR1 intron 21738479 rs749256 chr1 156884365 T C 2.12E-04 Alzheimer's disease PEAR1 intron 24755620 rs822436 chr1 156892394 T C 1.06E-06 White blood cell count LRRC71 intron 21738479 rs865239 chr1 156896164 A G 4.37E-06 White blood cell count LRRC71 intron 21738479 rs822430 chr1 156902259 G A 2.76E-05 Lipid levels LRRC71 cds-synon 19913121 rs822431 chr1 156902281 T G 0.000553649 Primary sclerosing cholangitis LRRC71 missense 23603763 rs12402294 chr1 156910488 A G 9.38E-04 Multiple complex diseases ARHGEF11 intron 17554300 rs2275201 chr1 156915038 C T 1.37E-06 White blood cell count ARHGEF11 intron 21738479 rs12138039 chr1 156918137 C T 2.23E-06 White blood cell count ARHGEF11 cds-synon 21738479 rs6655972 chr1 156929865 A G 2.17E-06 White blood cell count ARHGEF11 intron 21738479 rs6680271 chr1 156945708 C G 2.95E-06 White blood cell count ARHGEF11 intron 21738479 rs1572407 chr1 156946099 T C 2.30E-06 White blood cell count ARHGEF11 intron 21738479 rs6427339 chr1 156954267 C T 1.50E-07 White blood cell count ARHGEF11 intron 21738479 rs6427340 chr1 156954384 T C 9.72E-07 White blood cell count ARHGEF11 intron 21738479 rs1572411 chr1 156969896 G T 1.31E-06 White blood cell count ARHGEF11 intron 21738479 rs822577 chr1 156972467 T C 1.44E-06 White blood cell count ARHGEF11 intron 21738479 rs7550260 chr1 157001661 C A 4.93E-05 Intracranial aneurysm ARHGEF11 intron 20613766 rs16838014 chr1 157049635 A T 5.55E-04 Smoking initiation / / 24665060 rs7551464 chr1 157055398 G A 2.16E-07 White blood cell count / / 21738479 rs7534239 chr1 157058424 A G 9.97E-04 Multiple complex diseases / / 17554300 rs7534239 chr1 157058424 A G 0.000000233 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs7534239 chr1 157058424 A G 2.33E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1176535 chr1 157061550 G A 5.46E-06 White blood cell count / / 21738479 rs1176535 chr1 157061550 G A 0.000000913 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs1176535 chr1 157061550 G A 9.13E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1176536 chr1 157062364 G A,C,T 1.81E-10 White blood cell count ETV3L UTR-3 21738479 rs7544345 chr1 157064929 C T 1.00E-10 White blood cell count ETV3L intron 21738479 rs1571045 chr1 157066129 C T 1.10E-04 Alcohol dependence ETV3L intron 20201924 rs17404670 chr1 157066893 G A 1.28E-11 White blood cell count ETV3L intron 21738479 rs6427351 chr1 157066950 T C 7.07E-04 Type 2 diabetes ETV3L intron 17463246 rs16838099 chr1 157083542 C T 6.57E-04 Multiple complex diseases / / 17554300 rs1183449 chr1 157083817 A G 2.07E-07 White blood cell count / / 21738479 rs11264618 chr1 157090760 C G 5.72E-04 Type 2 diabetes / / 17463246 rs2231856 chr1 157095470 A G 2.52E-05 Smoking cessation ETV3 cds-synon 24665060 rs6704373 chr1 157104470 C G 6.66E-04 Type 2 diabetes ETV3 intron 17463246 rs6704373 chr1 157104470 C G 5.29E-06 White blood cell count ETV3 intron 21738479 rs6427353 chr1 157109624 G A 5.61E-06 Post-operative nausea and vomiting / / 21694509 rs10494309 chr1 157118421 T C 6.37E-05 Post-operative nausea and vomiting / / 21694509 rs11264624 chr1 157127118 G A 6.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs11264625 chr1 157128705 T C 2.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs6427356 chr1 157130566 A G 8.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6427356 chr1 157130566 A G 2.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs6657122 chr1 157130597 T A 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6657097 chr1 157130719 A G 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2148397 chr1 157131744 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6661210 chr1 157132388 A G 3.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs6675005 chr1 157132732 G A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10796971 chr1 157133121 G A 1.96E-05 Suicide attempts in bipolar disorder / / 21423239 rs10796972 chr1 157133137 G A 1.91E-05 Suicide attempts in bipolar disorder / / 21423239 rs6700498 chr1 157133150 C T 1.34E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176542 chr1 157133476 G A 1.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176543 chr1 157133595 C A 1.37E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176551 chr1 157135656 T C 1.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176555 chr1 157136541 G C 9.47E-04 Multiple complex diseases / / 17554300 rs1176555 chr1 157136541 G C 1.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs1538386 chr1 157140456 A T 1.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs16838195 chr1 157145225 T G 5.76E-67 Multiple complex diseases / / 17554300 rs2316825 chr1 157168984 C G 3.15E-04 Multiple complex diseases / / 17554300 rs7511847 chr1 157187436 G A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7511847 chr1 157187436 G A 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1338672 chr1 157187711 T C 3.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12070704 chr1 157262482 T C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6427368 chr1 157275152 T C 2.53E-08 White blood cell count / / 21738479 rs11264673 chr1 157279122 A C 1.91E-07 White blood cell count / / 21738479 rs4661028 chr1 157322310 A C 8.16E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs4661129 chr1 157322796 C T 2.03E-07 Inflammatory biomarkers / / 22291609 rs1408554 chr1 157323211 T C 4.46E-10 White blood cell count / / 21738479 rs12239592 chr1 157327571 T C 1.61E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11264696 chr1 157328953 T C 1.32E-06 White blood cell count / / 21738479 rs2224901 chr1 157331407 G A 1.98E-08 White blood cell count / / 21738479 rs9427266 chr1 157332482 G A 1.24E-06 White blood cell count / / 21738479 rs12134519 chr1 157333244 G A 2.89E-08 White blood cell count / / 21738479 rs2317049 chr1 157334428 A G 5.55E-08 White blood cell count / / 21738479 rs2317050 chr1 157334724 A G 1.96E-08 White blood cell count / / 21738479 rs2147445 chr1 157335891 C T 2.60E-05 Hypertension / / 22384028 rs1967788 chr1 157336988 C G 1.18E-07 White blood cell count / / 21738479 rs1967792 chr1 157337305 A T 3.54E-08 White blood cell count / / 21738479 rs2151157 chr1 157337663 T C 2.30E-08 White blood cell count / / 21738479 rs11264700 chr1 157338094 C T 7.66E-09 White blood cell count / / 21738479 rs12138542 chr1 157342962 G A 8.36E-06 White blood cell count / / 21738479 rs2873343 chr1 157356480 C G 9.11E-06 White blood cell count / / 21738479 rs11264714 chr1 157360752 C A 6.86E-04 Tourette syndrome / / 22889924 rs12043295 chr1 157361577 T C 3.99E-04 Multiple complex diseases / / 17554300 rs10465957 chr1 157365378 C T 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12734925 chr1 157367179 C T 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10908564 chr1 157369433 T G 4.20E-05 Cognitive performance / / 19734545 rs4246530 chr1 157378637 C A 7.84E-04 Multiple complex diseases / / 17554300 rs4246534 chr1 157383740 T C 9.40E-04 Multiple complex diseases / / 17554300 rs16838537 chr1 157385496 T C 1.32E-05 Socioeconomic Factors / / pha003066 rs12748574 chr1 157387799 C T 2.01E-05 Femoral neck bone geometry / / 22087292 rs12076935 chr1 157389398 G T 3.56E-05 Femoral neck bone geometry / / 22087292 rs4971147 chr1 157389741 T C 3.60E-05 Parkinson's disease (age of onset) / / 19772629 rs7523656 chr1 157402121 G A 7.82E-04 Type 2 diabetes / / 17463246 rs4399149 chr1 157403585 A T 5.40E-08 White blood cell count / / 21738479 rs4060884 chr1 157430425 A G 3.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4060884 chr1 157430425 A G 1.64E-06 White blood cell count / / 21738479 rs6686423 chr1 157437510 G A 8.00E-06 Renal sinus fat / / 22044751 rs12132012 chr1 157443532 C T 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12132012 chr1 157443532 C T 3.23E-08 White blood cell count / / 21738479 rs6427381 chr1 157453883 G A 7.30E-10 White blood cell count / / 21738479 rs3845582 chr1 157456260 A G 2.42E-07 White blood cell count / / 21738479 rs3845586 chr1 157484453 G A 1.19E-10 White blood cell count FCRL5 UTR-3 21738479 rs3811035 chr1 157485561 G A 5.56E-14 White blood cell count FCRL5 intron 21738479 rs6696309 chr1 157490710 G A 2.00E-10 White blood cell count FCRL5 intron 21738479 rs17416676 chr1 157503805 G A 3.79E-07 White blood cell count FCRL5 intron 21738479 rs2012199 chr1 157509025 C T 1.00E-04 Upper aerodigestive tract cancers FCRL5 missense 21437268 rs2244798 chr1 157527963 G A 1.45E-06 White blood cell count / / 21738479 rs849832 chr1 157531532 G C 1.06E-13 White blood cell count / / 21738479 rs16838818 chr1 157535159 C A 9.31E-04 Coronary heart disease / / 21606135 rs2758684 chr1 157537530 T G 7.47E-13 White blood cell count / / 21738479 rs12566695 chr1 157538363 A G 1.16E-06 White blood cell count / / 21738479 rs11264764 chr1 157538612 G A 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11264764 chr1 157538612 G A 2.69E-05 Orofacial clefts / / 22419666 rs6669223 chr1 157540981 A T 1.23E-06 White blood cell count / / 21738479 rs14335 chr1 157544850 C T 9.72E-07 White blood cell count FCRL4 UTR-3 21738479 rs10489673 chr1 157550066 T C 3.82E-07 White blood cell count FCRL4 intron 21738479 rs4246533 chr1 157552944 G C 6.26E-07 White blood cell count FCRL4 intron 21738479 rs2778003 chr1 157569194 G A 4.82E-04 Stroke / / pha002887 rs9427302 chr1 157612420 C T 9.05E-08 White blood cell count / / 21738479 rs12145148 chr1 157615261 T A 1.60E-05 Urinary metabolites / / 21572414 rs2785663 chr1 157620758 T G 3.52E-07 White blood cell count / / 21738479 rs2778010 chr1 157621513 T C 3.88E-04 Alcohol dependence / / 21314694 rs2785666 chr1 157625122 G A 4.55E-08 White blood cell count / / 21738479 rs2785657 chr1 157631311 T C 1.50E-07 White blood cell count / / 21738479 rs12082327 chr1 157634415 C T 1.85E-05 Body mass index / / 17255346 rs10908581 chr1 157638275 A G 8.98E-07 White blood cell count / / 21738479 rs6679422 chr1 157641266 C A 3.50E-07 White blood cell count / / 21738479 rs10908583 chr1 157641683 C T 1.02E-08 Graves' disease / / 21841780 rs10908584 chr1 157641758 T A 3.47E-08 White blood cell count / / 21738479 rs2210911 chr1 157643867 A G 6.28E-08 Graves' disease / / 21841780 rs11264794 chr1 157647789 C A 1.83E-07 White blood cell count FCRL3 nearGene-3 21738479 rs2282284 chr1 157648543 T C 6.82E-04 Body mass index FCRL3 missense 17255346 rs7549100 chr1 157657842 A G 2.90E-05 Urinary metabolites FCRL3 intron 21572414 rs11264798 chr1 157661848 C G 4.86E-14 Positivity for ZnT8A in Type 1 diabetes FCRL3 intron 22526605 rs12080623 chr1 157665064 A G 7.56E-05 HIV-1 control FCRL3 intron 20041166 rs7522061 chr1 157668390 T C 1.65E-08 Graves' disease FCRL3 missense 21841780 rs7522061 chr1 157668390 T C 1.13E-16 Positivity for ZnT8A in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 1.74E-11 Positivity for ZnT8RA in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 8.13E-12 Positivity for ZnT8WA in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 0.0000108 Graves' disease FCRL3 missense 22922229 rs7522061 chr1 157668390 T C 0.0000236 Graves' disease and Hashimoto's thyroiditis FCRL3 missense 22922229 rs2210913 chr1 157668993 C T 9.95E-06 White blood cell count FCRL3 intron 21738479 rs3761959 chr1 157669278 C T 3.00E-06 Multiple sclerosis FCRL3 intron 21833088 rs3761959 chr1 157669278 C T 2.00E-13 Graves' disease FCRL3 intron 21841780 rs7528684 chr1 157670816 A G 1.06E-06 White blood cell count FCRL3 nearGene-5 21738479 rs7528684 chr1 157670816 A G 1.00E-11 Type 1 diabetes autoantibodies FCRL3 nearGene-5 21829393 rs7528684 chr1 157670816 A G 0.000314 Positivity for ZnT8A in Type 1 diabetes FCRL3 nearGene-5 22526605 rs2210914 chr1 157673628 T C 1.25E-08 White blood cell count / / 21738479 rs2317230 chr1 157674997 G T 1.90E-04 Rheumatoid arthritis / / 24390342 rs2317230 chr1 157674997 G T 2.00E-07 Rheumatoid arthritis / / 24390342 rs2317230 chr1 157674997 G T 8.30E-05 Rheumatoid arthritis / / 24390342 rs17676303 chr1 157679691 C T 6.53E-04 Multiple complex diseases / / 17554300 rs17727339 chr1 157680114 T C 5.10E-04 Multiple complex diseases / / 17554300 rs2873407 chr1 157693368 G A 4.85E-04 Fibrinogen / / 17255346 rs1537948 chr1 157694094 T C 2.01E-04 Fibrinogen / / 17255346 rs1537949 chr1 157701249 T C 2.17E-06 White blood cell count / / 21738479 rs10430455 chr1 157703238 T A 9.00E-04 Rheumatoid arthritis / / 22446963 rs7517644 chr1 157717028 A G 5.59E-06 Graves' disease FCRL2 intron 21841780 rs6696643 chr1 157718283 A T 5.06E-08 White blood cell count FCRL2 intron 21738479 rs7529060 chr1 157725264 T G 8.40E-07 White blood cell count FCRL2 intron 21738479 rs12408952 chr1 157730028 T C 0.00000563 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL2 intron 23392654 rs12408952 chr1 157730028 T C 5.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL2 intron 23400010 rs12568320 chr1 157744004 A G 2.00E-04 Cognitive impairment induced by topiramate FCRL2 intron 22091778 rs6427402 chr1 157749544 C T 1.67E-06 White blood cell count / / 21738479 rs12743184 chr1 157754359 A G 1.16E-07 Graves' disease / / 21841780 rs12132140 chr1 157767362 C T 4.32E-05 Panic disorder FCRL1 intron 19165232 rs12132140 chr1 157767362 C T 8.47E-05 Body Mass Index FCRL1 intron pha003020 rs3811024 chr1 157768000 G C 6.96E-05 Lymphocyte counts FCRL1 cds-synon 22286170 rs2050568 chr1 157770241 C T 3.70E-08 Graves' disease FCRL1 intron 21841780 rs4971154 chr1 157771880 C T 3.60E-06 White blood cell count FCRL1 cds-synon 21738479 rs6689427 chr1 157780892 A G 1.13E-08 Graves' disease FCRL1 intron 21841780 rs6696137 chr1 157782581 T C 0.000000111 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs6696137 chr1 157782581 T C 1.11E-07 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs2148135 chr1 157783485 C T 4.84E-08 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs2148135 chr1 157783485 C T 4.84E-08 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs11264825 chr1 157788270 A G 0.000000081 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs11264825 chr1 157788270 A G 8.10E-08 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs2765493 chr1 157798000 G A 6.73E-08 Graves' disease / / 21841780 rs2765501 chr1 157804648 G A 7.62E-06 White blood cell count CD5L intron 21738479 rs2765502 chr1 157805107 G A 1.66E-06 Graves' disease CD5L intron 21841780 rs2260040 chr1 157811392 G A 9.13E-05 Graves' disease CD5L intron 21841780 rs2281870 chr1 157811585 G T 5.14E-05 Leukocyte Counts CD5L UTR-5 pha003091 rs4971115 chr1 157829702 G A 8.85E-04 Obesity (extreme) / / 21935397 rs17690088 chr1 157834858 C T 8.75E-04 Obesity (extreme) / / 21935397 rs11264835 chr1 157836891 T C 2.28E-08 White blood cell count / / 21738479 rs6427405 chr1 157840353 T C 3.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7537631 chr1 157848670 T C 1.56E-06 White blood cell count / / 21738479 rs7537631 chr1 157848670 T C 9.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7537631 chr1 157848670 T C 2.36E-06 Lymphocyte counts / / pha003094 rs4272616 chr1 157865663 T C 5.45E-09 White blood cell count / / 21738479 rs11264845 chr1 157871097 A G 4.19E-07 White blood cell count / / 21738479 rs7545514 chr1 157878897 G A 2.45E-06 White blood cell count / / 21738479 rs7524095 chr1 157879294 C T 9.20E-05 Premature ovarian failure / / 19508998 rs7524095 chr1 157879294 C T 9.20E-05 Other erythrocyte phenotypes / / 19862010 rs4971165 chr1 157891524 A C,G,T 5.71E-05 Blood Pressure / / pha003039 rs4971166 chr1 157891597 A G 1.70E-05 Urinary metabolites / / 21572414 rs4971166 chr1 157891597 A G 2.86E-07 White blood cell count / / 21738479 rs12022838 chr1 157891609 G A 2.19E-06 White blood cell count / / 21738479 rs7524979 chr1 157891709 G A 3.53E-09 White blood cell count / / 21738479 rs12123550 chr1 157905094 T A 5.22E-04 Multiple complex diseases / / 17554300 rs12123554 chr1 157905143 T C 5.50E-05 Alcohol dependence / / 20201924 rs12123554 chr1 157905143 T C 5.48E-05 Alcoholism / / pha002892 rs12124798 chr1 157906955 A T 5.00E-04 Multiple complex diseases / / 17554300 rs11264863 chr1 157907065 G C 5.42E-04 Multiple complex diseases / / 17554300 rs10494321 chr1 157908444 A G 2.00E-05 Type 2 diabetes / / 17903298 rs1925035 chr1 157909525 C T 1.49E-05 Neuroblastoma / / pha002895 rs6684686 chr1 157909708 A G 6.03E-04 Multiple complex diseases / / 17554300 rs6701170 chr1 157913954 T C 5.03E-04 Multiple complex diseases / / 17554300 rs4971168 chr1 157914172 C T 4.03E-04 Multiple complex diseases / / 17554300 rs927698 chr1 157926455 G A 9.85E-07 White blood cell count / / 21738479 rs720773 chr1 157934242 A G 6.61E-07 White blood cell count / / 21738479 rs12403172 chr1 157937856 C A 7.00E-05 Response to statin therapy / / 20339536 rs11580979 chr1 157969306 G T 6.76E-05 Coronary heart disease KIRREL intron pha003030 rs11585913 chr1 157976896 C T 9.30E-04 Type 2 diabetes KIRREL intron 17463246 rs3892165 chr1 157977049 A G 9.81E-04 Type 2 diabetes KIRREL intron 17463246 rs6680584 chr1 157978956 A G 2.31E-06 White blood cell count KIRREL intron 21738479 rs7519243 chr1 157992818 T C 9.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIRREL intron 23233662 rs7548850 chr1 158005274 G C 8.71E-04 Multiple complex diseases KIRREL intron 17554300 rs12045704 chr1 158008229 T C 5.55E-06 Personality dimensions KIRREL intron 23658558 rs7540377 chr1 158040767 A G 1.60E-05 Urinary metabolites KIRREL intron 21572414 rs10908615 chr1 158042153 C T 2.30E-06 Iron levels KIRREL intron 21208937 rs7364493 chr1 158056651 A G 4.43E-06 White blood cell count KIRREL intron 21738479 rs7514301 chr1 158057420 A T 7.89E-08 White blood cell count KIRREL intron 21738479 rs3820676 chr1 158057691 A C 6.96E-04 Type 2 diabetes KIRREL intron 17463246 rs3820676 chr1 158057691 A C 4.14E-07 White blood cell count KIRREL intron 21738479 rs6427419 chr1 158058109 C A 2.41E-11 White blood cell count KIRREL intron 21738479 rs6427419 chr1 158058109 C A 8.00E-06 Obesity-related traits KIRREL intron 23251661 rs3768540 chr1 158060515 C T 3.20E-11 White blood cell count KIRREL intron 21738479 rs912572 chr1 158061626 G T 2.34E-05 Post-operative nausea and vomiting KIRREL intron 21694509 rs3768538 chr1 158066042 A G 5.82E-07 White blood cell count / / 21738479 rs6427420 chr1 158066834 A G 3.80E-06 White blood cell count / / 21738479 rs874844 chr1 158067047 A C 5.00E-11 White blood cell count / / 21738479 rs3820677 chr1 158068344 A G 4.75E-11 White blood cell count / / 21738479 rs567631262 chr1 158071131 G GT 7.29E-04 Type 2 diabetes / / 17463246 rs942540 chr1 158071131 G A 7.29E-04 Type 2 diabetes / / 17463246 rs17421546 chr1 158074220 G A 6.95E-05 Left ventricular hypertrophy / / pha003052 rs17455763 chr1 158134119 T A 8.54E-08 White blood cell count / / 21738479 rs1570699 chr1 158145229 T C 2.44E-04 Heart Failure / / pha002885 rs3087210 chr1 158146028 G A 2.36E-04 Heart Failure / / pha002885 rs1690769 chr1 158158597 C T 1.60E-05 Urinary metabolites / / 21572414 rs1690778 chr1 158167760 A T 9.91E-04 Multiple complex diseases / / 17554300 rs401904 chr1 158170546 T C 3.64E-06 White blood cell count LOC100505799 intron 21738479 rs400214 chr1 158171078 T C 3.29E-04 Hearing function LOC100505799 intron 17255346 rs400214 chr1 158171078 T C 2.20E-05 Esophageal cancer (squamous cell) LOC100505799 intron 22960999 rs1748383 chr1 158173706 T C 3.89E-06 White blood cell count / / 21738479 rs440862 chr1 158175824 A G 3.96E-06 White blood cell count / / 21738479 rs384414 chr1 158179236 C T 2.51E-06 White blood cell count / / 21738479 rs402699 chr1 158179483 G A 2.32E-06 White blood cell count / / 21738479 rs449838 chr1 158182363 C T 2.30E-06 White blood cell count / / 21738479 rs594364 chr1 158182407 C T 1.60E-06 White blood cell count / / 21738479 rs607948 chr1 158183129 T C 1.25E-06 White blood cell count / / 21738479 rs12040592 chr1 158183743 C A 1.11E-06 White blood cell count / / 21738479 rs691314 chr1 158183942 G A 2.30E-06 White blood cell count / / 21738479 rs623215 chr1 158184244 T A 1.01E-06 White blood cell count / / 21738479 rs691551 chr1 158184353 T A 1.30E-06 White blood cell count / / 21738479 rs448556 chr1 158184570 C T 1.14E-06 White blood cell count / / 21738479 rs377795 chr1 158184769 A T 9.89E-06 White blood cell count / / 21738479 rs393304 chr1 158184815 G A 4.20E-06 White blood cell count / / 21738479 rs448005 chr1 158185165 G A 1.42E-06 White blood cell count / / 21738479 rs1633149 chr1 158192745 A G 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1633149 chr1 158192745 A G 3.30E-06 White blood cell count / / 21738479 rs429201 chr1 158194899 C T 3.46E-08 White blood cell count / / 21738479 rs374513 chr1 158195465 C T 3.40E-06 White blood cell count / / 21738479 rs411089 chr1 158224825 C T 8.28E-04 Parkinson's disease CD1A intron 17052657 rs411089 chr1 158224825 C T 6.30E-04 Amyotrophic Lateral Sclerosis CD1A intron 17362836 rs1230716 chr1 158232763 C G 4.17E-12 White blood cell count / / 21738479 rs12077177 chr1 158256016 G A 5.30E-05 Hearing function / / 17255346 rs7544532 chr1 158292236 C T 1.86E-06 White blood cell count / / 21738479 rs10797007 chr1 158295629 A G 2.02E-04 Parkinson's disease / / 17052657 rs10797007 chr1 158295629 A G 1.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10797007 chr1 158295629 A G 9.25E-07 White blood cell count / / 21738479 rs10158210 chr1 158311985 A G 3.02E-09 White blood cell count / / 21738479 rs2317955 chr1 158315924 G T 8.97E-05 Rheumatoid arthritis / / 19503088 rs11264960 chr1 158319787 A G 4.95E-09 White blood cell count / / 21738479 rs2873587 chr1 158324413 A G 1.49E-04 Multiple complex diseases CD1E missense 17554300 rs1065457 chr1 158324425 A G 1.94E-04 Parkinson's disease CD1E missense 17052657 rs1065457 chr1 158324425 A G 3.40E-05 Amyotrophic Lateral Sclerosis CD1E missense 17362836 rs1065457 chr1 158324425 A G 8.92E-05 Serum metabolites CD1E missense 19043545 rs1065457 chr1 158324425 A G 3.19E-09 White blood cell count CD1E missense 21738479 rs11264963 chr1 158335533 A G 5.16E-08 White blood cell count / / 21738479 rs13376124 chr1 158338434 A G 5.94E-04 Acute lung injury / / 22295056 rs7547997 chr1 158341273 G A 6.74E-08 White blood cell count / / 21738479 rs2157685 chr1 158346251 G A,T 5.94E-04 Acute lung injury / / 22295056 rs6701609 chr1 158346590 A G 5.94E-04 Acute lung injury / / 22295056 rs6704215 chr1 158346717 A G 8.65E-04 Acute lung injury / / 22295056 rs7511778 chr1 158347220 A G 8.65E-04 Acute lung injury / / 22295056 rs7545457 chr1 158347399 C T 8.65E-04 Acute lung injury / / 22295056 rs11807992 chr1 158350654 A C 8.65E-04 Acute lung injury / / 22295056 rs11808003 chr1 158350707 A T 8.65E-04 Acute lung injury / / 22295056 rs11809920 chr1 158351914 G C 8.65E-04 Acute lung injury / / 22295056 rs11808876 chr1 158351980 T C 9.78E-04 Acute lung injury / / 22295056 rs11808874 chr1 158352170 A C 9.78E-04 Acute lung injury / / 22295056 rs7553679 chr1 158353356 G A 9.78E-04 Acute lung injury / / 22295056 rs12239158 chr1 158353465 C T 9.78E-04 Acute lung injury / / 22295056 rs4656284 chr1 158381815 G A 3.44E-04 Smoking initiation / / 24665060 rs17628151 chr1 158394230 T C 7.49E-04 Smoking initiation / / 24665060 rs6427437 chr1 158414877 T A 5.84E-04 Smoking initiation / / 24665060 rs12127971 chr1 158425271 C A 1.12E-04 Smoking initiation / / 24665060 rs12728815 chr1 158431310 A C 1.77E-04 Smoking initiation / / 24665060 rs1002309 chr1 158433074 A T 1.56E-05 Smoking initiation / / 24665060 rs12403683 chr1 158441462 T C 7.77E-12 Red blood cell traits / / 23222517 rs11264980 chr1 158453439 G T 5.57E-04 Multiple complex diseases / / 17554300 rs11264980 chr1 158453439 G T 2.25E-12 Red blood cell traits / / 23222517 rs10489832 chr1 158454356 G A 2.80E-05 Sleep and circadian phenotypes / / 17903308 rs950488 chr1 158459975 C A 0.000000004 Mean corpuscular hemoglobin concentration / / 22560525 rs950488 chr1 158459975 C A 1.87E-11 Red blood cell traits / / 23222517 rs879636 chr1 158462797 C T 3.97E-09 Red blood cell traits / / 23222517 rs12041363 chr1 158475894 T C 1.82E-08 Red blood cell traits / / 23222517 rs12041363 chr1 158475894 T C 5.10E-05 Glycated hemoglobin levels / / 24405752 rs12044799 chr1 158490295 A G 1.25E-12 Red blood cell traits / / 23222517 rs11265005 chr1 158493055 C G 2.86E-11 Red blood cell traits / / 23222517 rs11265022 chr1 158512619 T A 5.63E-04 Multiple complex diseases / / 17554300 rs11265022 chr1 158512619 T A 8.12E-14 Red blood cell traits / / 23222517 rs16840314 chr1 158517353 G A 4.91E-04 Multiple complex diseases OR6Y1 cds-synon 17554300 rs16840314 chr1 158517353 G A 7.93E-13 Red blood cell traits OR6Y1 cds-synon 23222517 rs9804152 chr1 158518939 T C 5.74E-05 Longevity / / 20304771 rs12042917 chr1 158529661 G T 7.50E-13 Red blood cell traits / / 23222517 rs863343 chr1 158534385 A G 9.82E-12 Red blood cell traits / / 23222517 rs863344 chr1 158534831 G A 3.54E-04 Multiple complex diseases / / 17554300 rs863344 chr1 158534831 G A 3.07E-14 Red blood cell traits / / 23222517 rs863366 chr1 158553168 G C 7.65E-08 Red blood cell traits / / 23222517 rs863368 chr1 158553332 A G 8.18E-08 Red blood cell traits / / 23222517 rs2479861 chr1 158554142 G A 3.17E-07 Red blood cell traits / / 23222517 rs2479862 chr1 158554257 G T 7.68E-08 Red blood cell traits / / 23222517 rs2482959 chr1 158554702 C T 7.18E-08 Red blood cell traits / / 23222517 rs12119726 chr1 158556839 A G 4.30E-06 Carotenoid and tocopherol levels / / 19185284 rs857695 chr1 158558142 T A 5.10E-08 Red blood cell traits / / 23222517 rs2157690 chr1 158569486 A T 1.79E-08 Red blood cell traits / / 23222517 rs1103852 chr1 158570890 C A 1.30E-07 Red blood cell traits / / 23222517 rs857719 chr1 158573336 T A 2.76E-08 Red blood cell traits / / 23222517 rs857684 chr1 158575729 C T 8.21E-09 Other erythrocyte phenotypes / / 19862010 rs857684 chr1 158575729 C T 4.00E-16 Red blood cell traits / / 23222517 rs860772 chr1 158576100 G C 2.74E-10 Red blood cell traits / / 23222517 rs857685 chr1 158577109 A C 5.63E-16 Red blood cell traits OR10Z1 missense 23222517 rs857686 chr1 158577788 C A 2.02E-08 Red blood cell traits / / 23222517 rs857688 chr1 158578018 T C 1.25E-08 Red blood cell traits / / 23222517 rs12724903 chr1 158578865 A C 1.30E-04 Alcohol dependence / / 20201924 rs2479868 chr1 158580069 C T 1.12E-08 Other erythrocyte phenotypes SPTA1 nearGene-3 19862010 rs2479868 chr1 158580069 C T 3.60E-15 Red blood cell traits SPTA1 nearGene-3 23222517 rs12128171 chr1 158580477 A G 6.02E-08 Red blood cell traits SPTA1 nearGene-3 23222517 rs12601 chr1 158580759 G A 3.10E-04 Iris characteristics SPTA1 UTR-3 21835309 rs2157691 chr1 158582838 G C 6.05E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2157691 chr1 158582838 G C 2.73E-15 Red blood cell traits SPTA1 intron 23222517 rs2518491 chr1 158585230 C T 5.72E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2518491 chr1 158585230 C T 5.06E-15 Red blood cell traits SPTA1 intron 23222517 rs2779116 chr1 158585415 C A,G,T 5.74E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2779116 chr1 158585415 C A,G,T 3.00E-09 Glycated hemoglobin levels SPTA1 intron 20858683 rs2779116 chr1 158585415 C A,G,T 1.71E-11 Red blood cell traits SPTA1 intron 23222517 rs2022003 chr1 158586966 A T 3.68E-10 Red blood cell traits SPTA1 intron 23222517 rs7553252 chr1 158588916 C G 1.16E-07 Red blood cell traits SPTA1 intron 23222517 rs1616 chr1 158592455 G T 6.93E-04 Smoking initiation SPTA1 intron 24665060 rs12088990 chr1 158596524 A G 3.47E-08 Red blood cell traits SPTA1 intron 23222517 rs3737515 chr1 158597507 G C 8.30E-09 Red blood cell traits SPTA1 missense 23222517 rs4511106 chr1 158598499 G A 7.48E-08 Red blood cell traits SPTA1 intron 23222517 rs12138682 chr1 158600194 T C 8.48E-09 Red blood cell traits SPTA1 intron 23222517 rs6682458 chr1 158603013 C G 1.84E-07 Red blood cell traits SPTA1 intron 23222517 rs11811522 chr1 158604143 G A 6.29E-06 Serum metabolites SPTA1 intron 19043545 rs11811522 chr1 158604143 G A 7.58E-08 Red blood cell traits SPTA1 intron 23222517 rs16830483 chr1 158604391 T C 6.16E-04 Alzheimer's disease SPTA1 missense 24755620 rs3738791 chr1 158606449 G T 1.79E-07 Red blood cell traits SPTA1 cds-synon 23222517 rs857725 chr1 158607935 T G 6.97E-09 Other erythrocyte phenotypes SPTA1 missense 19862010 rs857725 chr1 158607935 T G 0.00000002 Mean corpuscular hemoglobin concentration SPTA1 missense 22560525 rs857725 chr1 158607935 T G 1.60E-13 Red blood cell traits SPTA1 missense 23222517 rs857721 chr1 158612548 T A 1.00E-10 Other erythrocyte phenotypes SPTA1 intron 19862010 rs857721 chr1 158612548 T A 7.03E-04 Blood cell counts and other traits SPTA1 intron 20139978 rs857721 chr1 158612548 T A 1.60E-15 Red blood cell traits SPTA1 intron 23222517 rs6702040 chr1 158614198 C T 2.19E-07 Red blood cell traits SPTA1 intron 23222517 rs10443907 chr1 158614667 C T 8.92E-08 Red blood cell traits SPTA1 intron 23222517 rs17635940 chr1 158615988 G T 1.99E-08 Red blood cell traits SPTA1 intron 23222517 rs12076831 chr1 158616398 C T 1.98E-08 Red blood cell traits SPTA1 intron 23222517 rs10443899 chr1 158616614 T A 1.22E-08 Red blood cell traits SPTA1 intron 23222517 rs2246434 chr1 158618455 G A 4.18E-08 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2246434 chr1 158618455 G A 6.04E-09 Glycated hemoglobin levels SPTA1 intron 22885924 rs2246434 chr1 158618455 G A 2.65E-14 Red blood cell traits SPTA1 intron 23222517 rs861409 chr1 158620477 C G 2.38E-13 Red blood cell traits SPTA1 intron 23222517 rs863327 chr1 158620647 G A 8.73E-14 Red blood cell traits SPTA1 intron 23222517 rs16840439 chr1 158622819 G T 3.92E-04 Lung function (forced expiratory volume in 1 second) SPTA1 intron 24023788 rs2276401 chr1 158624779 T C 1.64E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SPTA1 intron 24023788 rs857691 chr1 158626378 C T 5.22E-13 Red blood cell traits SPTA1 cds-synon 23222517 rs2518493 chr1 158631171 A C,G 2.04E-12 Red blood cell traits SPTA1 cds-synon 23222517 rs7519423 chr1 158635308 G T 1.49E-04 Multiple complex diseases SPTA1 intron 17554300 rs71579625 chr1 158635852 A AG 5.34E-08 White blood cell count SPTA1 intron 21738479 rs857680 chr1 158635852 A G 5.34E-08 White blood cell count SPTA1 intron 21738479 rs703115 chr1 158643037 T C 4.33E-04 Sudden cardiac arrest SPTA1 intron 21658281 rs378557 chr1 158643513 G A 1.61E-07 White blood cell count SPTA1 intron 21738479 rs703116 chr1 158644105 T A 1.92E-07 White blood cell count SPTA1 intron 21738479 rs325998 chr1 158646833 C T 2.71E-07 White blood cell count SPTA1 intron 21738479 rs325993 chr1 158648490 T C 2.19E-08 White blood cell count SPTA1 intron 21738479 rs703124 chr1 158649464 T C 3.45E-08 White blood cell count SPTA1 intron 21738479 rs413514 chr1 158649921 A G 8.36E-09 White blood cell count SPTA1 intron 21738479 rs390718 chr1 158655840 C T 5.44E-08 White blood cell count SPTA1 intron 21738479 rs7534057 chr1 158662730 T G 5.41E-08 White blood cell count / / 21738479 rs2494033 chr1 158668042 A C 2.71E-09 White blood cell count / / 21738479 rs703131 chr1 158670763 G T 2.90E-07 White blood cell count / / 21738479 rs16840675 chr1 158687031 C T 2.98E-06 White blood cell count OR6K3 missense 21738479 rs857924 chr1 158696300 G A 8.14E-09 White blood cell count / / 21738479 rs167821 chr1 158702189 A G 1.07E-04 Sudden cardiac arrest / / 21658281 rs183447 chr1 158707235 G A 4.25E-06 White blood cell count / / 21738479 rs381510 chr1 158708549 A G 6.16E-06 White blood cell count / / 21738479 rs2564856 chr1 158712627 T G 4.78E-04 Sudden cardiac arrest / / 21658281 rs425539 chr1 158719221 G C 5.84E-06 White blood cell count / / 21738479 rs454127 chr1 158720188 A G 1.45E-07 White blood cell count / / 21738479 rs10489844 chr1 158728389 C T 6.47E-04 Multiple complex diseases / / 17554300 rs10489844 chr1 158728389 C T 4.14E-09 White blood cell count / / 21738479 rs11802305 chr1 158729323 C T 4.75E-04 Sarcoidosis / / 19165924 rs1864346 chr1 158736445 C T 2.63E-04 Multiple complex diseases OR6N1 missense 17554300 rs1864346 chr1 158736445 C T 5.54E-09 White blood cell count OR6N1 missense 21738479 rs1864347 chr1 158736517 A T 2.98E-04 Multiple complex diseases / / 17554300 rs1864347 chr1 158736517 A T 6.58E-09 White blood cell count / / 21738479 rs7513257 chr1 158741903 A T 6.43E-05 Schizophrenia(age at onset) / / 21688384 rs11265070 chr1 158743995 A G 6.96E-04 Depression (quantitative trait) / / 20800221 rs2325694 chr1 158744060 G A 2.85E-04 Multiple complex diseases / / 17554300 rs857835 chr1 158747492 A G 5.25E-04 Coronary heart disease / / 21971053 rs857847 chr1 158754813 G A 9.38E-05 Waist Circumference / / pha003025 rs857849 chr1 158756914 G T 8.45E-04 Multiple complex diseases / / 17554300 rs857850 chr1 158756976 C T 5.71E-06 Multiple complex diseases / / 17554300 rs857854 chr1 158763983 T C 1.15E-08 White blood cell count / / 21738479 rs857859 chr1 158771450 T A 8.01E-11 White blood cell count / / 21738479 rs919477 chr1 158772845 C T 1.41E-04 Parkinson's disease / / 17052657 rs7550055 chr1 158778764 T G 1.34E-04 Parkinson's disease / / 17052657 rs857782 chr1 158780584 A T 5.48E-06 White blood cell count / / 21738479 rs13376489 chr1 158785647 C A 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs13376489 chr1 158785647 C A 1.34E-06 Obesity-related traits / / 23251661 rs11265075 chr1 158787438 G C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2875712 chr1 158788542 A G 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs12090080 chr1 158789208 G C 3.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs11265079 chr1 158793852 G T 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11265081 chr1 158796545 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12089272 chr1 158796905 T A 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs7545956 chr1 158803370 A T 3.31E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs7513873 chr1 158803873 G A 5.75E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs12092047 chr1 158804755 A G 4.72E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs11265085 chr1 158807011 A G 4.60E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs11805139 chr1 158816738 C G 6.76E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs2106091 chr1 158821200 T C 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2106091 chr1 158821200 T C 5.24E-06 Obesity-related traits / / 23251661 rs12568794 chr1 158846099 C T 5.67E-04 Lymphocyte counts / / 22286170 rs12088342 chr1 158871453 T G 8.86E-04 Alzheimer's disease / / 22005930 rs861319 chr1 158915917 A G 4.24E-06 White blood cell count PYHIN1 intron 21738479 rs1101999 chr1 158932555 C T 4.00E-09 Asthma PYHIN1 intron 21804549 rs10908697 chr1 158941634 A G 8.56E-05 Glucose levels PYHIN1 intron pha003058 rs856146 chr1 158959450 T C 7.22E-06 White blood cell count / / 21738479 rs4657616 chr1 158971086 A G 4.64E-11 White blood cell count / / 21738479 rs4657616 chr1 158971086 A G 5.00E-47 Hematology traits / / 23263863 rs4657618 chr1 158972490 T C 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs856064 chr1 158983285 T C 7.25E-08 White blood cell count IFI16 intron 21738479 rs1057024 chr1 158990247 A G 1.28E-08 White blood cell count IFI16 cds-synon 21738479 rs856049 chr1 158990412 A G 2.18E-11 White blood cell count IFI16 intron 21738479 rs1101993 chr1 158996895 G A 7.06E-07 White blood cell count IFI16 intron 21738479 rs1101993 chr1 158996895 G A 2.53E-06 Obesity-related traits IFI16 intron 23251661 rs12094741 chr1 158998665 G A 2.80E-06 Obesity-related traits IFI16 intron 23251661 rs856054 chr1 159001521 C T 3.31E-17 White blood cell count IFI16 intron 21738479 rs861318 chr1 159002222 A G 1.00E-06 Obesity-related traits IFI16 intron 23251661 rs1057027 chr1 159002377 C A 1.05E-06 Obesity-related traits IFI16 missense 23251661 rs1057028 chr1 159002389 T A 2.68E-04 Insulin resistance IFI16 missense 21901158 rs1772415 chr1 159002778 A G 6.49E-04 Insulin resistance IFI16 intron 21901158 rs1772413 chr1 159003409 A G 2.52E-06 White blood cell count IFI16 intron 21738479 rs1772408 chr1 159005649 A G 8.00E-07 Celiac disease and Rheumatoid arthritis IFI16 intron 21383967 rs2570916 chr1 159012646 C A,G,T 4.31E-19 White blood cell count IFI16 intron 21738479 rs2793845 chr1 159032255 G T 6.82E-06 Obesity-related traits / / 23251661 rs855871 chr1 159044651 G A 7.40E-08 White blood cell count AIM2 intron 21738479 rs855866 chr1 159052720 A G 1.43E-17 White blood cell count / / 21738479 rs855867 chr1 159052847 G A 1.33E-08 White blood cell count / / 21738479 rs2852720 chr1 159060560 T C 9.32E-08 White blood cell count / / 21738479 rs2518564 chr1 159062436 G A 4.47E-22 White blood cell count / / 21738479 rs2814764 chr1 159064568 A T 5.98E-09 White blood cell count / / 21738479 rs1894043 chr1 159069211 T C 6.81E-23 White blood cell count / / 21738479 rs2518565 chr1 159070113 A G 6.65E-06 White blood cell count / / 21738479 rs2852723 chr1 159073725 G A 4.08E-06 White blood cell count / / 21738479 rs2852727 chr1 159086986 G A 1.20E-12 White blood cell count / / 21738479 rs1894044 chr1 159088334 G C 2.45E-12 White blood cell count / / 21738479 rs2518569 chr1 159095575 T G 4.62E-09 Inflammatory biomarkers / / 22291609 rs2518570 chr1 159096902 C G 3.10E-08 White blood cell count / / 21738479 rs2814779 chr1 159098713 A G 3.07E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2814779 chr1 159098713 A G 4.13E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11265142 chr1 159099908 A G 1.28E-09 Inflammatory biomarkers / / 22291609 rs1103577 chr1 159100315 T C 5.05E-12 White blood cell count / / 21738479 rs863030 chr1 159108794 G A 1.27E-06 White blood cell count / / 21738479 rs863036 chr1 159117109 T A 1.31E-06 White blood cell count / / 21738479 rs3026935 chr1 159117690 T C 2.05E-04 Height / / 17255346 rs3026943 chr1 159131926 A C 8.15E-08 Inflammatory biomarkers / / 22291609 rs3026946 chr1 159135282 C T 4.19E-08 Inflammatory biomarkers / / 22291609 rs965358 chr1 159140349 T A 1.59E-09 Inflammatory biomarkers / / 22291609 rs3026968 chr1 159147452 C T 9.00E-14 Inflammatory biomarkers CADM3 intron 22291609 rs1474747 chr1 159148513 C T 3.00E-06 Select biomarker traits CADM3 intron 17903293 rs1474747 chr1 159148513 C T 5.74E-10 Inflammatory biomarkers CADM3 intron 22291609 rs16841832 chr1 159154312 G A 1.11E-08 Inflammatory biomarkers CADM3 intron 22291609 rs2281300 chr1 159156285 C T 3.20E-09 Inflammatory biomarkers CADM3 intron 22291609 rs3027001 chr1 159169463 C T 1.08E-07 White blood cell count CADM3 intron 21738479 rs3027001 chr1 159169463 C T 8.44E-05 IgE levels CADM3 intron 22075330 rs3027009 chr1 159173887 A G 7.00E-07 Lean body mass and age at menarche (combined) DARC UTR-5 22744181 rs3027012 chr1 159174123 C T 1.52E-09 White blood cell count DARC UTR-5 21738479 rs3027012 chr1 159174123 C T 8.92E-15 Inflammatory biomarkers DARC UTR-5 22291609 rs3027012 chr1 159174123 C T 1.74E-07 Obesity-related traits DARC UTR-5 23251661 rs2814778 chr1 159174683 T C 1.10E-13 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 1.40E-103 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 4.10E-82 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 5.50E-85 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 1.00E-08 Neutrophil count DARC UTR-5 21507922 rs2814778 chr1 159174683 T C 7.00E-55 White blood cell count DARC UTR-5 22037903 rs2814778 chr1 159174683 T C 6.48E-08 Circulating myeloperoxidase levels (serum) DARC UTR-5 23620142 rs863002 chr1 159174920 C T 8.20E-10 White blood cell count DARC intron 21738479 rs863002 chr1 159174920 C T 3.59E-13 Obesity-related traits DARC intron 23251661 rs3027016 chr1 159175193 A G 3.06E-06 Obesity-related traits DARC UTR-5 23251661 rs12075 chr1 159175354 G A 1.14E-09 White blood cell count DARC missense 21738479 rs12075 chr1 159175354 G A 5.00E-24 White blood cell count DARC missense 22037903 rs12075 chr1 159175354 G A 4.00E-51 Inflammatory biomarkers DARC missense 22291609 rs12075 chr1 159175354 G A 1.30E-29 Duffy system Fya antigen DARC missense 22611595 rs12075 chr1 159175354 G A 1.00E-21 Monocyte chemoattractant protein-1 DARC missense 23017229 rs12075 chr1 159175354 G A 4.10E-04 Type 2 diabetes DARC missense 23209189 rs12075 chr1 159175354 G A 1.00E-21 Obesity-related traits DARC missense 23251661 rs13962 chr1 159175527 G A 2.00E-11 IgE levels DARC frameshift 22075330 rs863006 chr1 159177748 G A 1.03E-16 Obesity-related traits / / 23251661 rs3027031 chr1 159178273 C G 3.97E-09 Inflammatory biomarkers / / 22291609 rs3027040 chr1 159181492 C A 9.31E-07 White blood cell count / / 21738479 rs3027041 chr1 159181560 T C 6.02E-08 White blood cell count / / 21738479 rs3027044 chr1 159181869 T C 9.14E-04 Alzheimer's disease / / 17998437 rs3027048 chr1 159183713 C T 1.99E-10 White blood cell count / / 21738479 rs12034864 chr1 159184980 A G 1.46E-10 White blood cell count / / 21738479 rs12034864 chr1 159184980 A G 6.95E-07 Inflammatory biomarkers / / 22291609 rs3027056 chr1 159186231 G A 9.45E-07 Inflammatory biomarkers / / 22291609 rs3027061 chr1 159186600 A G 2.00E-07 White blood cell count / / 21738479 rs3027063 chr1 159186781 C T 4.24E-10 White blood cell count / / 21738479 rs3027063 chr1 159186781 C T 7.42E-07 Inflammatory biomarkers / / 22291609 rs17666424 chr1 159187530 G A 3.22E-11 Inflammatory biomarkers / / 22291609 rs3027077 chr1 159191648 C T 2.71E-07 White blood cell count / / 21738479 rs863011 chr1 159194172 C T 8.26E-17 Inflammatory biomarkers / / 22291609 rs4083420 chr1 159194838 A G 3.60E-07 Inflammatory biomarkers / / 22291609 rs10489849 chr1 159196765 C T 1.00E-06 Select biomarker traits / / 17903293 rs10489849 chr1 159196765 C T 2.48E-08 Inflammatory biomarkers / / 22291609 rs863013 chr1 159200020 G T 3.32E-07 White blood cell count / / 21738479 rs863013 chr1 159200020 G T 2.43E-07 IgE levels / / 22075330 rs863013 chr1 159200020 G T 1.54E-07 Inflammatory biomarkers / / 22291609 rs863013 chr1 159200020 G T 2.92E-05 Inflammation / / pha002897 rs6660102 chr1 159211064 G T 5.14E-08 White blood cell count / / 21738479 rs6660102 chr1 159211064 G T 5.72E-13 Inflammatory biomarkers / / 22291609 rs863017 chr1 159214544 A T 1.20E-17 Inflammatory biomarkers / / 22291609 rs12072644 chr1 159215287 C T 5.70E-08 White blood cell count / / 21738479 rs12072644 chr1 159215287 C T 6.70E-13 Inflammatory biomarkers / / 22291609 rs863018 chr1 159215326 C T 2.05E-06 White blood cell count / / 21738479 rs863018 chr1 159215326 C T 5.25E-07 IgE levels / / 22075330 rs3845624 chr1 159218266 A C 2.37E-10 White blood cell count / / 21738479 rs3845624 chr1 159218266 A C 2.00E-11 Inflammatory biomarkers / / 22291609 rs11265158 chr1 159224030 T C 6.96E-15 White blood cell count / / 21738479 rs10908702 chr1 159228378 C T 5.82E-15 White blood cell count / / 21738479 rs10908702 chr1 159228378 C T 2.28E-04 Age-related macular degeneration / / 22125219 rs113854958 chr1 159230098 TA T 2.63E-08 IgE levels / / 22075330 rs2494257 chr1 159230098 T A 2.63E-08 IgE levels / / 22075330 rs2511211 chr1 159230471 T G 3.80E-09 IgE levels / / 22075330 rs2427832 chr1 159233075 A G 1.49E-04 Myopia (pathological) / / 21095009 rs2427832 chr1 159233075 A G 2.81E-18 Inflammatory biomarkers / / 22291609 rs2494258 chr1 159234579 T C 5.74E-18 Inflammatory biomarkers / / 22291609 rs12405354 chr1 159237652 A G 1.97E-12 Inflammatory biomarkers / / 22291609 rs2511212 chr1 159244893 C T 4.71E-17 Inflammatory biomarkers / / 22291609 rs2494260 chr1 159246185 T C 2.59E-16 Inflammatory biomarkers / / 22291609 rs2427834 chr1 159246523 A G 6.78E-09 Inflammatory biomarkers / / 22291609 rs2494261 chr1 159251294 G A 4.04E-19 Inflammatory biomarkers / / 22291609 rs2494262 chr1 159253672 C A 7.88E-11 White blood cell count / / 21738479 rs2494262 chr1 159253672 C A 1.51E-07 IgE levels / / 22075330 rs2427836 chr1 159254764 T C 4.30E-04 Parkinson's disease FCER1A intron 17052657 rs2427836 chr1 159254764 T C 8.72E-10 White blood cell count FCER1A intron 21738479 rs2427836 chr1 159254764 T C 6.07E-09 IgE levels FCER1A intron 22075330 rs2511214 chr1 159254866 G T 1.07E-10 White blood cell count FCER1A intron 21738479 rs2511214 chr1 159254866 G T 8.99E-08 IgE levels FCER1A intron 22075330 rs2494263 chr1 159255794 G A 1.87E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2427837 chr1 159258545 G A 1.79E-04 IgE levels FCER1A intron 17255346 rs2427837 chr1 159258545 G A 9.82E-12 IgE levels FCER1A intron 22075330 rs2427837 chr1 159258545 G A 1.28E-07 Obesity-related traits FCER1A intron 23251661 rs2247584 chr1 159259680 T G 1.39E-09 White blood cell count FCER1A intron 21738479 rs2247584 chr1 159259680 T G 3.34E-09 IgE levels FCER1A intron 22075330 rs2427824 chr1 159265062 T C 1.33E-11 Inflammatory biomarkers FCER1A intron 22291609 rs16841987 chr1 159265266 G A 1.20E-09 Inflammatory biomarkers FCER1A intron 22291609 rs3845625 chr1 159265876 C T 6.31E-09 Inflammatory biomarkers FCER1A intron 22291609 rs2427825 chr1 159266066 T C 9.46E-04 Myopia (pathological) FCER1A intron 21095009 rs2427825 chr1 159266066 T C 3.19E-12 Inflammatory biomarkers FCER1A intron 22291609 rs2494264 chr1 159266838 T A 2.20E-10 White blood cell count FCER1A intron 21738479 rs2494264 chr1 159266838 T A 1.37E-09 IgE levels FCER1A intron 22075330 rs2251746 chr1 159272060 T C 5.41E-05 IgE levels FCER1A intron 17255346 rs2251746 chr1 159272060 T C 2.00E-20 IgE levels FCER1A intron 18846228 rs2251746 chr1 159272060 T C 5.00E-26 IgE levels FCER1A intron 22075330 rs2427828 chr1 159273041 G A 7.07E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2494265 chr1 159275274 A T 7.28E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2252226 chr1 159276153 C T 6.12E-07 White blood cell count FCER1A intron 21738479 rs2252226 chr1 159276153 C T 2.49E-07 IgE levels FCER1A intron 22075330 rs7549785 chr1 159277868 G A 5.94E-09 Inflammatory biomarkers FCER1A UTR-3 22291609 rs2494250 chr1 159278251 G C 1.00E-14 Select biomarker traits / / 17903293 rs2494250 chr1 159278251 G C 5.23E-11 Inflammatory biomarkers / / 22291609 rs2494251 chr1 159281151 G A 7.24E-04 Parkinson's disease / / 17052657 rs2494251 chr1 159281151 G A 2.17E-09 White blood cell count / / 21738479 rs2494251 chr1 159281151 G A 3.12E-08 IgE levels / / 22075330 rs2427829 chr1 159282011 A G 8.36E-05 IgE levels / / 22075330 rs7522607 chr1 159285991 T C 5.78E-09 Inflammatory biomarkers / / 22291609 rs4269772 chr1 159290661 T C 8.85E-04 Myopia (pathological) / / 21095009 rs4269772 chr1 159290661 T C 1.30E-08 Inflammatory biomarkers / / 22291609 rs12724895 chr1 159291045 T A 1.57E-08 White blood cell count / / 21738479 rs12724895 chr1 159291045 T A 3.38E-08 IgE levels / / 22075330 rs4282816 chr1 159292850 G A 8.57E-05 IgE levels / / 22075330 rs4498803 chr1 159305157 C T 8.58E-05 IgE levels / / 22075330 rs12074934 chr1 159308071 T G 8.68E-12 White blood cell count / / 21738479 rs16842041 chr1 159308539 G A 9.54E-12 White blood cell count / / 21738479 rs12128960 chr1 159313447 A T 3.88E-09 White blood cell count / / 21738479 rs12128960 chr1 159313447 A T 1.22E-05 IgE levels / / 22075330 rs12132451 chr1 159313842 G A 3.75E-10 White blood cell count / / 21738479 rs12132451 chr1 159313842 G A 1.21E-05 IgE levels / / 22075330 rs10218647 chr1 159319803 G A 2.15E-04 Celiac disease / / 23936387 rs10908709 chr1 159320180 C A 3.33E-09 White blood cell count / / 21738479 rs10908709 chr1 159320180 C A 1.22E-05 IgE levels / / 22075330 rs11265174 chr1 159320359 T A 3.53E-08 White blood cell count / / 21738479 rs11265174 chr1 159320359 T A 1.15E-08 Inflammatory biomarkers / / 22291609 rs10908710 chr1 159320979 G A 8.65E-04 Parkinson's disease / / 17052657 rs10908710 chr1 159320979 G A 1.18E-10 White blood cell count / / 21738479 rs10908710 chr1 159320979 G A 1.22E-05 IgE levels / / 22075330 rs10908711 chr1 159321259 G A 1.92E-11 White blood cell count / / 21738479 rs4443888 chr1 159321675 G T 3.05E-04 Myopia (pathological) / / 21095009 rs4443888 chr1 159321675 G T 1.15E-11 White blood cell count / / 21738479 rs9782926 chr1 159323392 T A 1.42E-07 White blood cell count / / 21738479 rs9782926 chr1 159323392 T A 2.55E-09 Inflammatory biomarkers / / 22291609 rs11265177 chr1 159325834 A G 2.27E-09 Inflammatory biomarkers / / 22291609 rs4656784 chr1 159326880 A G 2.00E-16 IgE levels / / 22075330 rs4656784 chr1 159326880 A G 2.69E-07 Inflammatory biomarkers / / 22291609 rs11265178 chr1 159329046 C A 2.24E-10 White blood cell count / / 21738479 rs11265178 chr1 159329046 C A 1.23E-05 IgE levels / / 22075330 rs10494322 chr1 159336948 T C 1.73E-07 White blood cell count / / 21738479 rs4399156 chr1 159338072 G A 1.21E-13 Inflammatory biomarkers / / 22291609 rs4517343 chr1 159339006 A G 2.82E-12 White blood cell count / / 21738479 rs4517343 chr1 159339006 A G 1.25E-07 Inflammatory biomarkers / / 22291609 rs4537549 chr1 159339036 C G 2.88E-13 White blood cell count / / 21738479 rs4537549 chr1 159339036 C G 1.25E-07 Inflammatory biomarkers / / 22291609 rs6692378 chr1 159339241 T C 7.27E-14 White blood cell count / / 21738479 rs6692378 chr1 159339241 T C 8.10E-05 IgE levels / / 22075330 rs6692378 chr1 159339241 T C 4.52E-07 Inflammatory biomarkers / / 22291609 rs6677678 chr1 159339520 C T 3.73E-13 White blood cell count / / 21738479 rs6677678 chr1 159339520 C T 1.25E-07 Inflammatory biomarkers / / 22291609 rs10908713 chr1 159339559 T C 2.97E-13 White blood cell count / / 21738479 rs10908713 chr1 159339559 T C 1.82E-07 Inflammatory biomarkers / / 22291609 rs12141365 chr1 159340299 T C 7.52E-08 IgE levels / / 22075330 rs10908714 chr1 159340353 T A 4.86E-12 White blood cell count / / 21738479 rs10908714 chr1 159340353 T A 6.07E-07 IgE levels / / 22075330 rs4400605 chr1 159340416 T C 3.44E-13 White blood cell count / / 21738479 rs4400605 chr1 159340416 T C 1.78E-07 Inflammatory biomarkers / / 22291609 rs7548833 chr1 159340591 T C 3.55E-06 White blood cell count / / 21738479 rs7548736 chr1 159340686 A G 1.36E-12 White blood cell count / / 21738479 rs12142553 chr1 159341672 T C 1.12E-13 Inflammatory biomarkers / / 22291609 rs4130236 chr1 159341851 C T 1.95E-07 Inflammatory biomarkers / / 22291609 rs6687734 chr1 159342302 C T 5.78E-06 White blood cell count / / 21738479 rs6702853 chr1 159342410 T A 9.39E-08 White blood cell count / / 21738479 rs6702853 chr1 159342410 T A 3.54E-07 Inflammatory biomarkers / / 22291609 rs6687840 chr1 159342439 C T 7.00E-06 Chemerin levels / / 20237162 rs6687840 chr1 159342439 C T 3.13E-13 White blood cell count / / 21738479 rs6687840 chr1 159342439 C T 2.69E-07 Inflammatory biomarkers / / 22291609 rs11265180 chr1 159343648 G C 1.53E-09 Inflammatory biomarkers / / 22291609 rs6701545 chr1 159351967 T C 1.89E-07 Inflammatory biomarkers / / 22291609 rs4446959 chr1 159357684 T C 8.00E-06 Chemerin levels / / 20237162 rs4446959 chr1 159357684 T C 2.74E-12 White blood cell count / / 21738479 rs4446959 chr1 159357684 T C 2.69E-08 Inflammatory biomarkers / / 22291609 rs11265186 chr1 159375903 C T 3.31E-14 Inflammatory biomarkers / / 22291609 rs10908716 chr1 159376343 A G 3.31E-14 Inflammatory biomarkers / / 22291609 rs10908717 chr1 159376352 C A 3.31E-14 Inflammatory biomarkers / / 22291609 rs3122633 chr1 159377458 T C 1.94E-07 Inflammatory biomarkers / / 22291609 rs11265187 chr1 159378594 C T 2.00E-04 Myopia (pathological) / / 21095009 rs11265187 chr1 159378594 C T 3.87E-14 Inflammatory biomarkers / / 22291609 rs12034969 chr1 159384944 T C 1.13E-13 White blood cell count / / 21738479 rs12034969 chr1 159384944 T C 6.53E-05 IgE levels / / 22075330 rs12034969 chr1 159384944 T C 4.32E-07 Inflammatory biomarkers / / 22291609 rs11265190 chr1 159391401 G A 6.54E-12 White blood cell count / / 21738479 rs11265190 chr1 159391401 G A 6.45E-05 IgE levels / / 22075330 rs11265190 chr1 159391401 G A 4.13E-07 Inflammatory biomarkers / / 22291609 rs4492615 chr1 159391863 T C 3.95E-14 Inflammatory biomarkers / / 22291609 rs12118201 chr1 159396941 C T 4.69E-07 IgE levels / / 22075330 rs12118201 chr1 159396941 C T 8.76E-08 Inflammatory biomarkers / / 22291609 rs12043437 chr1 159398715 T C 2.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs11265191 chr1 159400359 C T 6.05E-05 IgE levels / / 22075330 rs11265191 chr1 159400359 C T 2.09E-07 Inflammatory biomarkers / / 22291609 rs11265193 chr1 159401656 G T 5.39E-14 Inflammatory biomarkers / / 22291609 rs11265194 chr1 159403689 G T 3.87E-08 Inflammatory biomarkers / / 22291609 rs4128725 chr1 159405959 T C 4.00E-12 Select biomarker traits / / 17903293 rs4128725 chr1 159405959 T C 5.46E-14 Inflammatory biomarkers / / 22291609 rs12145079 chr1 159406538 G A 3.28E-12 White blood cell count / / 21738479 rs12145616 chr1 159409479 T G 6.58E-07 Inflammatory biomarkers / / 22291609 rs10908721 chr1 159409533 G A 8.10E-04 Multiple complex diseases OR10J1 UTR-5 17554300 rs12048482 chr1 159409857 A G 5.64E-05 IgE levels OR10J1 missense 22075330 rs12048482 chr1 159409857 A G 1.44E-07 Inflammatory biomarkers OR10J1 missense 22291609 rs12118628 chr1 159409884 G A 1.36E-04 Myopia (pathological) OR10J1 missense 21095009 rs12118628 chr1 159409884 G A 5.64E-14 Inflammatory biomarkers OR10J1 missense 22291609 rs4656236 chr1 159410975 G A 1.44E-04 IgE levels / / 17255346 rs4656236 chr1 159410975 G A 3.58E-07 White blood cell count / / 21738479 rs4656236 chr1 159410975 G A 1.77E-07 IgE levels / / 22075330 rs4656236 chr1 159410975 G A 2.80E-07 Inflammatory biomarkers / / 22291609 rs4656236 chr1 159410975 G A 8.74E-06 Obesity-related traits / / 23251661 rs4656237 chr1 159413824 T C 5.72E-04 Myopia (pathological) / / 21095009 rs4656237 chr1 159413824 T C 4.08E-14 Inflammatory biomarkers / / 22291609 rs12410729 chr1 159414034 T C 5.07E-14 Inflammatory biomarkers / / 22291609 rs11265196 chr1 159418212 G A 1.30E-07 White blood cell count / / 21738479 rs11265196 chr1 159418212 G A 3.72E-05 IgE levels / / 22075330 rs11265196 chr1 159418212 G A 1.80E-07 Inflammatory biomarkers / / 22291609 rs11265198 chr1 159420307 G A 2.10E-07 White blood cell count / / 21738479 rs4562618 chr1 159429748 T A 6.88E-05 Alzheimer's disease / / 22832961 rs7540542 chr1 159430327 G T 1.87E-07 IgE levels / / 22075330 rs7540542 chr1 159430327 G T 1.91E-07 Inflammatory biomarkers / / 22291609 rs12565926 chr1 159431839 C T 1.59E-05 Alzheimer's disease / / 22832961 rs12133577 chr1 159432278 C T 4.47E-11 White blood cell count / / 21738479 rs12133577 chr1 159432278 C T 3.33E-07 IgE levels / / 22075330 rs11265204 chr1 159439913 A G 6.66E-04 Parkinson's disease / / 17052657 rs11265204 chr1 159439913 A G 2.06E-06 White blood cell count / / 21738479 rs11265204 chr1 159439913 A G 3.39E-07 IgE levels / / 22075330 rs12566875 chr1 159440210 C G 5.69E-05 Alzheimer's disease / / 22832961 rs12034243 chr1 159441441 G A 9.89E-12 White blood cell count / / 21738479 rs12034243 chr1 159441441 G A 3.55E-07 IgE levels / / 22075330 rs4339862 chr1 159441628 C A 1.13E-11 White blood cell count / / 21738479 rs7519020 chr1 159446104 A G 8.07E-06 White blood cell count / / 21738479 rs4233351 chr1 159446370 G A 9.12E-06 White blood cell count / / 21738479 rs6678321 chr1 159446883 G A 9.99E-06 White blood cell count / / 21738479 rs11265206 chr1 159449083 T C 5.53E-13 Inflammatory biomarkers / / 22291609 rs7541480 chr1 159449464 A G 9.26E-06 White blood cell count / / 21738479 rs10908724 chr1 159450168 G T 9.79E-13 Inflammatory biomarkers / / 22291609 rs4133289 chr1 159453937 C T 2.00E-07 Hemostatic factors and hematological phenotypes / / 17903294 rs4133289 chr1 159453937 C T 2.13E-06 White blood cell count / / 21738479 rs12132709 chr1 159454237 G A 1.20E-06 White blood cell count / / 21738479 rs12756262 chr1 159455330 A G 1.20E-06 White blood cell count / / 21738479 rs12135090 chr1 159457072 G A 1.01E-06 White blood cell count / / 21738479 rs7555008 chr1 159457808 T C 2.32E-07 White blood cell count / / 21738479 rs12141291 chr1 159460871 C T 5.68E-06 White blood cell count / / 21738479 rs4325129 chr1 159462381 A G 6.21E-06 White blood cell count / / 21738479 rs4325129 chr1 159462381 A G 6.00E-06 Obesity-related traits / / 23251661 rs12567624 chr1 159468713 T A 4.63E-07 White blood cell count / / 21738479 rs12726858 chr1 159469428 A G 4.99E-08 White blood cell count / / 21738479 rs6689654 chr1 159471321 G T 4.11E-06 White blood cell count / / 21738479 rs6699279 chr1 159473788 G C 5.91E-08 White blood cell count / / 21738479 rs12142583 chr1 159477947 A G 1.49E-12 Inflammatory biomarkers / / 22291609 rs11811256 chr1 159478230 T C 3.30E-07 Inflammatory biomarkers / / 22291609 rs6687017 chr1 159478262 T C 7.08E-06 White blood cell count / / 21738479 rs12047230 chr1 159479005 A G 1.36E-08 White blood cell count / / 21738479 rs12047230 chr1 159479005 A G 1.03E-10 Inflammatory biomarkers / / 22291609 rs12124964 chr1 159479032 C T 6.36E-07 White blood cell count / / 21738479 rs12143656 chr1 159479148 A G 1.17E-12 Inflammatory biomarkers / / 22291609 rs6689142 chr1 159483350 C A 9.63E-05 Alzheimer's disease / / 22832961 rs12564423 chr1 159486149 C T 8.29E-05 Alzheimer's disease / / 22832961 rs11265218 chr1 159486640 T C 7.67E-13 Inflammatory biomarkers / / 22291609 rs6427482 chr1 159499258 G A 7.37E-08 Inflammatory biomarkers / / 22291609 rs10908733 chr1 159504054 T A 9.86E-12 Inflammatory biomarkers / / 22291609 rs1584250 chr1 159507674 C T 2.20E-10 Inflammatory biomarkers / / 22291609 rs11265230 chr1 159515295 A G 8.98E-11 Inflammatory biomarkers / / 22291609 rs6659792 chr1 159515398 A T 2.23E-07 White blood cell count / / 21738479 rs2084257 chr1 159523486 C A 6.32E-16 White blood cell count / / 21738479 rs1584252 chr1 159523628 A T 4.09E-08 White blood cell count / / 21738479 rs1584252 chr1 159523628 A T 9.38E-05 IgE levels / / 22075330 rs1584252 chr1 159523628 A T 4.10E-10 Inflammatory biomarkers / / 22291609 rs2166587 chr1 159549993 A C,T 8.80E-04 Coronary heart disease / / 21966275 rs17457976 chr1 159580873 A G 9.68E-06 White blood cell count / / 21738479 rs2794502 chr1 159582055 T G 8.83E-05 Socioeconomic Factors / / pha003066 rs10494331 chr1 159582103 C T 1.90E-05 Type 2 diabetes / / 17903298 rs10494331 chr1 159582103 C T 2.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4233355 chr1 159582218 G A 1.73E-06 White blood cell count / / 21738479 rs4233355 chr1 159582218 G A 3.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs2592889 chr1 159584265 C T 3.28E-04 Multiple complex diseases / / 17554300 rs2794505 chr1 159584337 C G 3.43E-04 Multiple complex diseases / / 17554300 rs1446971 chr1 159585164 G A 1.04E-08 Inflammatory biomarkers / / 22291609 rs1446970 chr1 159585193 G C 5.52E-06 White blood cell count / / 21738479 rs1374485 chr1 159585282 A G 7.40E-06 White blood cell count / / 21738479 rs2794506 chr1 159585560 A G 8.28E-07 White blood cell count / / 21738479 rs2794506 chr1 159585560 A G 3.02E-07 Inflammatory biomarkers / / 22291609 rs2592879 chr1 159589734 C G 4.00E-04 Multiple complex diseases / / 17554300 rs2794509 chr1 159592810 G T 4.11E-06 White blood cell count / / 21738479 rs2794510 chr1 159592915 T C 4.58E-04 Multiple complex diseases / / 17554300 rs2794510 chr1 159592915 T C 6.30E-06 White blood cell count / / 21738479 rs983788 chr1 159595417 A G,T 1.23E-06 White blood cell count / / 21738479 rs983788 chr1 159595417 A G,T 4.76E-07 Inflammatory biomarkers / / 22291609 rs983789 chr1 159595682 G T 6.24E-11 Inflammatory biomarkers / / 22291609 rs983790 chr1 159595717 A G 5.58E-06 White blood cell count / / 21738479 rs1446954 chr1 159596129 G C 7.40E-16 Inflammatory biomarkers / / 22291609 rs1446955 chr1 159596156 G A 9.28E-11 Inflammatory biomarkers / / 22291609 rs1446956 chr1 159596721 T C 5.87E-09 Inflammatory biomarkers / / 22291609 rs1446957 chr1 159596766 C G 7.99E-13 Inflammatory biomarkers / / 22291609 rs2794514 chr1 159598303 A G 3.73E-11 Inflammatory biomarkers / / 22291609 rs12060842 chr1 159598747 G A 5.09E-13 Inflammatory biomarkers / / 22291609 rs984553 chr1 159599414 A G 2.41E-06 White blood cell count / / 21738479 rs984553 chr1 159599414 A G 2.98E-11 Inflammatory biomarkers / / 22291609 rs1446958 chr1 159599807 A G 4.76E-06 White blood cell count / / 21738479 rs1446958 chr1 159599807 A G 2.48E-11 Inflammatory biomarkers / / 22291609 rs2794525 chr1 159602515 G A 3.64E-11 White blood cell count / / 21738479 rs2794525 chr1 159602515 G A 1.73E-12 Inflammatory biomarkers / / 22291609 rs6427488 chr1 159602870 C T 6.72E-09 White blood cell count / / 21738479 rs2592881 chr1 159605100 T C 1.19E-13 Inflammatory biomarkers / / 22291609 rs1867939 chr1 159605894 A C 2.81E-11 Inflammatory biomarkers / / 22291609 rs2808651 chr1 159606226 T C 2.45E-09 White blood cell count / / 21738479 rs2808651 chr1 159606226 T C 5.65E-11 Inflammatory biomarkers / / 22291609 rs2808652 chr1 159606256 T C 3.60E-12 Inflammatory biomarkers / / 22291609 rs2808653 chr1 159606420 C T 5.64E-11 Inflammatory biomarkers / / 22291609 rs1446959 chr1 159606804 T A 2.01E-08 White blood cell count / / 21738479 rs7529729 chr1 159607351 T A 5.66E-09 White blood cell count / / 21738479 rs985472 chr1 159608945 T A 5.75E-11 Inflammatory biomarkers / / 22291609 rs4656241 chr1 159613986 T C 3.06E-07 Inflammation / / pha002897 rs2808660 chr1 159616159 G A 4.00E-08 Inflammatory biomarkers / / 22291609 rs2592900 chr1 159616629 A G 5.44E-08 Inflammatory biomarkers / / 22291609 rs2592901 chr1 159617163 C T 7.57E-08 Inflammatory biomarkers / / 22291609 rs1446977 chr1 159619356 A T 6.92E-08 Inflammatory biomarkers / / 22291609 rs41497649 chr1 159624757 G A 8.68E-04 Type 2 diabetes / / 17463246 rs41497649 chr1 159624757 G A 7.83E-11 Inflammatory biomarkers / / 22291609 rs12087465 chr1 159625299 C A 8.05E-14 Inflammatory biomarkers / / 22291609 rs2794526 chr1 159625478 G A 5.61E-07 Inflammatory biomarkers / / 22291609 rs2794526 chr1 159625478 G A 1.56E-08 C-reactive protein / / 23844046 rs16827462 chr1 159627891 G A 9.75E-08 C-reactive protein / / 22492993 rs1891186 chr1 159629021 A G 8.34E-05 Premature ovarian failure / / 19508998 rs1891186 chr1 159629021 A G 8.34E-05 Other erythrocyte phenotypes / / 19862010 rs1891186 chr1 159629021 A G 1.42E-07 Inflammatory biomarkers / / 22291609 rs1891186 chr1 159629021 A G 1.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1891186 chr1 159629021 A G 2.83E-05 Inflammation / / pha002897 rs1891187 chr1 159629053 T A 3.75E-07 Inflammatory biomarkers / / 22291609 rs1891187 chr1 159629053 T A 7.32E-09 C-reactive protein / / 23844046 rs1446976 chr1 159629194 A G 1.52E-07 Inflammatory biomarkers / / 22291609 rs1446976 chr1 159629194 A G 5.84E-09 C-reactive protein / / 23844046 rs1446975 chr1 159629342 T C 1.03E-07 Inflammatory biomarkers / / 22291609 rs1446975 chr1 159629342 T C 7.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1446974 chr1 159629384 T C 6.37E-08 Inflammatory biomarkers / / 22291609 rs2794500 chr1 159635021 C T 8.34E-05 Premature ovarian failure / / 19508998 rs2794500 chr1 159635021 C T 8.34E-05 Other erythrocyte phenotypes / / 19862010 rs2794500 chr1 159635021 C T 1.05E-07 Inflammatory biomarkers / / 22291609 rs2794500 chr1 159635021 C T 7.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2794500 chr1 159635021 C T 4.11E-05 Inflammation / / pha002897 rs2794498 chr1 159636116 G T 3.38E-08 Inflammatory biomarkers / / 22291609 rs2794498 chr1 159636116 G T 1.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs895582 chr1 159637919 G A 3.23E-08 Inflammatory biomarkers / / 22291609 rs895581 chr1 159637987 A G 2.36E-08 Inflammatory biomarkers / / 22291609 rs895581 chr1 159637987 A G 2.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11585798 chr1 159638015 T A 5.95E-06 White blood cell count / / 21738479 rs1971863 chr1 159638931 T C 6.39E-08 Inflammatory biomarkers / / 22291609 rs1971863 chr1 159638931 T C 2.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1811472 chr1 159642349 G C 1.21E-11 C-reactive protein / / 23844046 rs1811472 chr1 159642349 G C 2.27E-15 Inflammation / / pha002897 rs12567054 chr1 159644968 T G 2.22E-16 C-reactive protein / / 23844046 rs2794515 chr1 159646544 T C 6.51E-05 Glucose levels / / pha003061 rs16842484 chr1 159646924 T C 7.71E-08 Inflammatory biomarkers / / 22291609 rs12744244 chr1 159647656 C A 7.73E-06 White blood cell count / / 21738479 rs12744244 chr1 159647656 C A 8.78E-08 Inflammatory biomarkers / / 22291609 rs12744244 chr1 159647656 C A 2.50E-06 Inflammation / / pha002897 rs12093699 chr1 159647988 G A 6.00E-06 Protein quantitative trait loci / / 18464913 rs12093699 chr1 159647988 G A 1.62E-13 Inflammation / / pha002897 rs10494326 chr1 159649700 C T 4.31E-11 C-reactive protein / / 22492993 rs10494326 chr1 159649700 C T 4.00E-73 C-reactive protein / / 22939635 rs10494326 chr1 159649700 C T 4.00E-73 C-reactive protein / / 22939635 rs2592887 chr1 159652939 C T 2.80E-09 C-reactive protein / / 21647738 rs2592887 chr1 159652939 C T 2.80E-07 Metabolic syndrome phenotype / / 22022282 rs2592887 chr1 159652939 C T 8.40E-08 Metabolic syndrome phenotype / / 22022282 rs2592887 chr1 159652939 C T 7.16E-13 Inflammatory biomarkers / / 22291609 rs2592887 chr1 159652939 C T 1.38E-14 C-reactive protein / / 23844046 rs2592887 chr1 159652939 C T 1.51E-16 Inflammation / / pha002897 rs2592887 chr1 159652939 C T 8.96E-05 Weight / / pha003026 rs1470515 chr1 159653599 C T 2.10E-09 C-reactive protein / / 21647738 rs1470515 chr1 159653599 C T 6.31E-13 Inflammatory biomarkers / / 22291609 rs1470515 chr1 159653599 C T 4.33E-19 C-reactive protein / / 23844046 rs16842502 chr1 159653863 C A 4.42E-07 Inflammatory biomarkers / / 22291609 rs16842502 chr1 159653863 C A 5.56E-21 C-reactive protein / / 23844046 rs16842502 chr1 159653863 C A 9.62E-11 C-reactive protein / / 24763700 rs7531832 chr1 159654216 A G 5.94E-11 C-reactive protein / / 22492993 rs726640 chr1 159655518 G A 2.00E-13 C-reactive protein / / 22492993 rs16842520 chr1 159657850 C G 1.79E-09 C-reactive protein / / 22492993 rs12749227 chr1 159659109 C T 1.67E-06 White blood cell count / / 21738479 rs12749227 chr1 159659109 C T 1.96E-07 Inflammatory biomarkers / / 22291609 rs12739022 chr1 159659431 T C 3.58E-11 White blood cell count / / 21738479 rs12739022 chr1 159659431 T C 1.97E-07 Inflammatory biomarkers / / 22291609 rs12754915 chr1 159660869 T C 5.29E-07 White blood cell count / / 21738479 rs12754915 chr1 159660869 T C 2.24E-07 Inflammatory biomarkers / / 22291609 rs1935193 chr1 159664090 T A 1.07E-12 C-reactive protein / / 23844046 rs16842525 chr1 159664624 T C 6.79E-10 C-reactive protein / / 22492993 rs2808624 chr1 159665921 C G 2.00E-09 C-reactive protein / / 21647738 rs2808624 chr1 159665921 C G 3.17E-13 Inflammatory biomarkers / / 22291609 rs2808624 chr1 159665921 C G 2.96E-19 C-reactive protein / / 23844046 rs1341666 chr1 159667059 C G 6.84E-10 C-reactive protein / / 22492993 rs2027469 chr1 159667190 G A 1.23E-06 Inflammation / / pha002897 rs2369146 chr1 159668195 A G 3.90E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11265257 chr1 159668984 C T 1.90E-09 C-reactive protein / / 21647738 rs11265257 chr1 159668984 C T 3.80E-13 Inflammatory biomarkers / / 22291609 rs11265257 chr1 159668984 C T 2.75E-19 C-reactive protein / / 23844046 rs12741825 chr1 159670145 C T 7.51E-12 White blood cell count / / 21738479 rs12741825 chr1 159670145 C T 1.34E-07 Inflammatory biomarkers / / 22291609 rs12741825 chr1 159670145 C T 1.08E-08 C-reactive protein / / 23696881 rs12755606 chr1 159670336 C G 9.99E-08 Inflammatory biomarkers / / 22291609 rs12239267 chr1 159670928 C T 2.43E-09 C-reactive protein / / 22492993 rs1572970 chr1 159673585 G A 8.45E-07 Inflammatory biomarkers / / 22291609 rs1572970 chr1 159673585 G A 3.17E-10 C-reactive protein / / 23844046 rs876537 chr1 159674933 C T 1.00E-09 C-reactive protein / / 21647738 rs876537 chr1 159674933 C T 1.80E-19 C-reactive protein / / 23844046 rs876537 chr1 159674933 C T 1.49E-15 C-reactive protein / / 24763700 rs2808628 chr1 159676011 G A 7.30E-09 C-reactive protein / / 21647738 rs2808628 chr1 159676011 G A 4.40E-15 Inflammatory biomarkers / / 22291609 rs2808628 chr1 159676011 G A 1.07E-19 C-reactive protein / / 23844046 rs2808628 chr1 159676011 G A 7.50E-16 C-reactive protein / / 24763700 rs16842559 chr1 159676171 T C 4.05E-07 Inflammatory biomarkers / / 22291609 rs16842559 chr1 159676171 T C 4.00E-21 C-reactive protein / / 23844046 rs16842559 chr1 159676171 T C 1.99E-12 C-reactive protein / / 24763700 rs16842568 chr1 159676220 A G 4.04E-07 Inflammatory biomarkers / / 22291609 rs16842568 chr1 159676220 A G 4.15E-21 C-reactive protein / / 23844046 rs16842568 chr1 159676220 A G 1.99E-12 C-reactive protein / / 24763700 rs2808629 chr1 159676796 G A 3.20E-08 Biomarkers / / 17903293 rs2808629 chr1 159676796 G A 1.00E-08 C-reactive protein / / 21647738 rs2808629 chr1 159676796 G A 5.05E-15 Inflammatory biomarkers / / 22291609 rs2808629 chr1 159676796 G A 4.97E-20 C-reactive protein / / 23844046 rs2808629 chr1 159676796 G A 6.64E-16 C-reactive protein / / 24763700 rs6667499 chr1 159677654 G A 9.35E-10 C-reactive protein / / 22492993 rs2794520 chr1 159678816 C T 3.00E-08 Select biomarker traits / / 17903293 rs2794520 chr1 159678816 C T 3.00E-22 Metabolic traits / / 19060910 rs2794520 chr1 159678816 C T 2.00E-186 C-reactive protein / / 21300955 rs2794520 chr1 159678816 C T 1.10E-08 C-reactive protein / / 21647738 rs2794520 chr1 159678816 C T 0.00064 Rosuvastatin induced percent change in C-reactive protein (CRP) / / 22230323 rs2794520 chr1 159678816 C T 1.82E-15 Inflammatory biomarkers / / 22291609 rs2794520 chr1 159678816 C T 8.88E-16 C-reactive protein / / 23844046 rs2794520 chr1 159678816 C T 7.39E-16 C-reactive protein / / 24763700 rs2794520 chr1 159678816 C T 2.92E-22 Inflammation / / pha002897 rs3093077 chr1 159679636 A C 3.65E-07 Inflammatory biomarkers / / 22291609 rs3093077 chr1 159679636 A C 5.14E-17 C-reactive protein / / 23844046 rs3093077 chr1 159679636 A C 1.18E-11 C-reactive protein / / 24763700 rs3093075 chr1 159679913 G T 3.62E-07 Inflammatory biomarkers / / 22291609 rs3093075 chr1 159679913 G T 1.45E-20 C-reactive protein / / 23844046 rs3093075 chr1 159679913 G T 1.15E-11 C-reactive protein / / 24763700 rs2808630 chr1 159680868 C T 7.00E-06 Lung cancer / / 18385676 rs2808630 chr1 159680868 C T 7.00E-06 Nasopharyngeal carcinoma / / 20512145 rs3093068 chr1 159681364 G C 0.000712 Interleukin-6 (IL-6) levels / / 23505291 rs3093068 chr1 159681364 G C 2.73E-17 C-reactive protein / / 23505291 rs1205 chr1 159682233 C T 1.10E-08 C-reactive protein CRP UTR-3 21647738 rs1205 chr1 159682233 C T 5.42E-16 Inflammatory biomarkers CRP UTR-3 22291609 rs1205 chr1 159682233 C T 1.29E-18 C-reactive protein CRP UTR-3 23505291 rs1205 chr1 159682233 C T 2.61E-20 C-reactive protein CRP UTR-3 23844046 rs1205 chr1 159682233 C T 5.09E-16 C-reactive protein CRP UTR-3 24763700 rs1130864 chr1 159683091 G A 4.59E-17 C-reactive protein CRP UTR-3 23505291 rs1800947 chr1 159683438 C G 3.02E-14 C-reactive protein CRP cds-synon 23505291 rs3091244 chr1 159684665 G A,T 6.00E-28 C-reactive protein CRP nearGene-5 18439548 rs3091244 chr1 159684665 G A,T 3.00E-07 C-reactive protein CRP nearGene-5 21647738 rs3091244 chr1 159684665 G A,T 4.19E-35 C-reactive protein CRP nearGene-5 23505291 rs3093059 chr1 159685136 A G 4.00E-21 C-reactive protein CRP nearGene-5 21196492 rs3093059 chr1 159685136 A G 4.00E-21 Asthma CRP nearGene-5 21907864 rs3093059 chr1 159685136 A G 0.000175 Interleukin-6 (IL-6) levels CRP nearGene-5 23505291 rs3093059 chr1 159685136 A G 1.37E-18 C-reactive protein CRP nearGene-5 23505291 rs3093058 chr1 159685315 T A 7.55E-10 C-reactive protein CRP nearGene-5 22492993 rs9628671 chr1 159687972 C T 1.34E-09 C-reactive protein / / 22492993 rs2027471 chr1 159689388 T A 1.30E-07 C-reactive protein / / 21647738 rs2027471 chr1 159689388 T A 0.00011 Rosuvastatin induced percent change in C-reactive protein (CRP) / / 22230323 rs2027471 chr1 159689388 T A 2.97E-16 Inflammatory biomarkers / / 22291609 rs2027471 chr1 159689388 T A 2.30E-05 C-reactive protein / / 22492993 rs2027471 chr1 159689388 T A 3.95E-19 C-reactive protein / / 23844046 rs2027471 chr1 159689388 T A 3.92E-14 C-reactive protein / / 24763700 rs1341665 chr1 159691559 G A 1.20E-07 C-reactive protein / / 21647738 rs1341665 chr1 159691559 G A 2.00E-20 Inflammatory biomarkers / / 22291609 rs1341665 chr1 159691559 G A 2.30E-05 C-reactive protein / / 22492993 rs1341665 chr1 159691559 G A 8.84E-19 C-reactive protein / / 23505291 rs1341665 chr1 159691559 G A 3.75E-19 C-reactive protein / / 23844046 rs1341665 chr1 159691559 G A 3.76E-14 C-reactive protein / / 24763700 rs3116656 chr1 159692372 A G 1.06E-06 White blood cell count / / 21738479 rs3116656 chr1 159692372 A G 4.08E-07 Inflammatory biomarkers / / 22291609 rs12068753 chr1 159692537 T A 7.09E-07 Inflammatory biomarkers / / 22291609 rs12068753 chr1 159692537 T A 0.000261 Interleukin-6 (IL-6) levels / / 23505291 rs12068753 chr1 159692537 T A 8.02E-19 C-reactive protein / / 23505291 rs12068753 chr1 159692537 T A 4.19E-20 C-reactive protein / / 23844046 rs12068753 chr1 159692537 T A 2.18E-12 C-reactive protein / / 24763700 rs2808634 chr1 159692573 T C 3.00E-10 C-reactive protein / / 22939635 rs3116653 chr1 159696910 G C 4.63E-06 White blood cell count / / 21738479 rs3116653 chr1 159696910 G C 7.66E-07 Inflammatory biomarkers / / 22291609 rs16842599 chr1 159697475 T C 3.02E-07 Inflammatory biomarkers / / 22291609 rs16842599 chr1 159697475 T C 1.15E-20 C-reactive protein / / 23844046 rs16842599 chr1 159697475 T C 1.55E-12 C-reactive protein / / 24763700 rs3116651 chr1 159698485 C T 6.48E-06 White blood cell count / / 21738479 rs7553007 chr1 159698549 G A 8.00E-44 C-reactive protein / / 19567438 rs7553007 chr1 159698549 G A 1.20E-08 C-reactive protein / / 21647738 rs7553007 chr1 159698549 G A 1.41E-15 Inflammatory biomarkers / / 22291609 rs7553007 chr1 159698549 G A 2.90E-05 C-reactive protein / / 22492993 rs7553007 chr1 159698549 G A 1.00E-09 C-reactive protein / / 22939635 rs7553007 chr1 159698549 G A 1.00E-37 C-reactive protein / / 22939635 rs7553007 chr1 159698549 G A 5.09E-20 C-reactive protein / / 23844046 rs7553007 chr1 159698549 G A 2.00E-16 C-reactive protein / / 24763700 rs11265260 chr1 159700039 A G 7.00E-06 C-reactive protein / / 18439552 rs11265260 chr1 159700039 A G 1.50E-07 Inflammatory biomarkers / / 22291609 rs11265260 chr1 159700039 A G 1.12E-17 C-reactive protein / / 23844046 rs11265260 chr1 159700039 A G 4.45E-09 Inflammation / / pha002897 rs12727021 chr1 159702487 G A,C,T 3.57E-06 White blood cell count / / 21738479 rs12081252 chr1 159706513 T C 9.84E-08 Inflammatory biomarkers / / 22291609 rs12081252 chr1 159706513 T C 1.47E-20 C-reactive protein / / 23844046 rs12081252 chr1 159706513 T C 2.10E-12 C-reactive protein / / 24763700 rs12081264 chr1 159706560 T C 9.86E-08 Inflammatory biomarkers / / 22291609 rs12081264 chr1 159706560 T C 4.94E-20 C-reactive protein / / 23844046 rs12081264 chr1 159706560 T C 2.42E-12 C-reactive protein / / 24763700 rs12081480 chr1 159706990 T G 1.98E-20 C-reactive protein / / 23844046 rs12081480 chr1 159706990 T G 1.90E-12 C-reactive protein / / 24763700 rs4275453 chr1 159708047 C T 8.88E-13 C-reactive protein / / 23844046 rs4275453 chr1 159708047 C T 5.26E-09 C-reactive protein / / 24763700 rs12728740 chr1 159710093 C A 1.93E-10 White blood cell count / / 21738479 rs10437339 chr1 159710385 C G 3.43E-11 C-reactive protein / / 23844046 rs11265263 chr1 159710517 C A,T 3.00E-06 Vaccine-related adverse events / / 21396408 rs10437340 chr1 159710809 G C 2.64E-07 Inflammatory biomarkers / / 22291609 rs12083620 chr1 159713225 T A 2.64E-07 Inflammatory biomarkers / / 22291609 rs11265265 chr1 159713556 T C 4.74E-08 C-reactive protein / / 23844046 rs12049404 chr1 159713844 C T 1.40E-07 C-reactive protein / / 21647738 rs12049404 chr1 159713844 C T 3.68E-12 C-reactive protein / / 23844046 rs12760041 chr1 159714035 C T 5.16E-09 White blood cell count / / 21738479 rs4285692 chr1 159714149 T C 7.28E-10 C-reactive protein / / 23844046 rs11588887 chr1 159717162 G A 1.90E-07 C-reactive protein / / 21647738 rs11588887 chr1 159717162 G A 5.35E-09 C-reactive protein / / 23844046 rs12734907 chr1 159719594 A T 7.44E-10 White blood cell count / / 21738479 rs4131568 chr1 159722056 C T 3.48E-10 White blood cell count / / 21738479 rs4131568 chr1 159722056 C T 4.39E-05 Inflammation / / pha002897 rs4656849 chr1 159723521 A G 1.80E-05 Inflammation / / pha002897 rs4512645 chr1 159729047 G A 6.39E-10 White blood cell count / / 21738479 rs4364879 chr1 159736755 A G 2.91E-07 Inflammation / / pha002897 rs4406626 chr1 159743181 C A 2.06E-04 Cholesterol / / 17255346 rs3806185 chr1 159748886 C T 3.99E-08 Inflammatory biomarkers / / 22291609 rs3806185 chr1 159748886 C T 4.83E-07 Type 2 diabetes / / 23300278 rs3820099 chr1 159749188 C A 7.48E-05 Cholesterol / / 17255346 rs1129923 chr1 159752066 G A 3.90E-05 Height DUSP23 missense 21194676 rs1129923 chr1 159752066 G A 7.40E-07 Height DUSP23 missense 21194676 rs4233356 chr1 159753183 A G 9.00E-06 Interstitial lung disease / / 21787189 rs16842662 chr1 159762120 A G 2.90E-05 Monocyte counts / / pha003089 rs11265282 chr1 159774408 T C 6.71E-14 Esophageal cancer FCRL6 intron 21642993 rs2501343 chr1 159794576 G T 2.30E-05 Urinary metabolites / / 21572414 rs2501354 chr1 159815642 G A 8.10E-05 Type 2 diabetes C1orf204 intron 17463248 rs2501353 chr1 159815940 G T 2.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C1orf204 intron 24023788 rs2501351 chr1 159816313 T G 2.10E-05 Urinary metabolites C1orf204 intron 21572414 rs2501350 chr1 159817004 G C 7.00E-05 Type 2 diabetes C1orf204 intron 17463248 rs6659742 chr1 159818513 C T 7.00E-07 Multiple sclerosis (OCB status) C1orf204 intron 23472185 rs11587021 chr1 159825916 C T 2.93E-12 White blood cell count VSIG8 intron 21738479 rs2501335 chr1 159831370 A G 8.28E-14 White blood cell count VSIG8 intron 21738479 rs4074846 chr1 159831406 G A 2.24E-13 White blood cell count VSIG8 intron 21738479 rs2501334 chr1 159832915 G A 1.04E-10 White blood cell count / / 21738479 rs12409375 chr1 159833733 C T 3.85E-06 White blood cell count / / 21738479 rs3795332 chr1 159834428 T G 2.85E-06 White blood cell count / / 21738479 rs11265287 chr1 159838965 C G 2.63E-14 White blood cell count / / 21738479 rs6673451 chr1 159840131 G C 7.21E-09 White blood cell count / / 21738479 rs11265289 chr1 159842103 C T 3.51E-14 White blood cell count / / 21738479 rs4545332 chr1 159842566 T A 2.15E-08 White blood cell count CCDC19 intron 21738479 rs4460634 chr1 159842691 C G 5.34E-08 White blood cell count CCDC19 intron 21738479 rs145923860 chr1 159842779 C T 0.00011 Prostate cancer (advanced) CCDC19 missense 23555315 rs11265290 chr1 159843606 T C 5.28E-08 White blood cell count CCDC19 intron 21738479 rs6682796 chr1 159852822 G A 8.55E-08 White blood cell count CCDC19 intron 21738479 rs6671929 chr1 159853139 A G 6.84E-08 White blood cell count CCDC19 intron 21738479 rs11265291 chr1 159853321 G A 8.87E-15 White blood cell count CCDC19 intron 21738479 rs2501324 chr1 159856429 C T 2.33E-12 Bilirubin levels,in serum CCDC19 cds-synon 20639394 rs145722573 chr1 159858278 G T 0.000067 Prostate cancer (advanced) CCDC19 missense 23555315 rs4656855 chr1 159859260 T C 2.79E-13 White blood cell count CCDC19 intron 21738479 rs2501321 chr1 159859279 A G 4.29E-06 Alzheimer's disease CCDC19 intron 17998437 rs2501321 chr1 159859279 A G 2.80E-05 Urinary metabolites CCDC19 intron 21572414 rs4656856 chr1 159859392 C T 2.01E-15 White blood cell count CCDC19 intron 21738479 rs10752631 chr1 159862153 T C 2.31E-15 White blood cell count CCDC19 intron 21738479 rs2494487 chr1 159866460 A G 3.59E-10 White blood cell count CCDC19 intron 21738479 rs3806192 chr1 159871184 C G 2.61E-15 White blood cell count / / 21738479 rs11265294 chr1 159875153 C T 7.08E-15 White blood cell count / / 21738479 rs10752632 chr1 159875455 G A 2.00E-14 White blood cell count / / 21738479 rs2494481 chr1 159878126 C A 9.60E-09 White blood cell count / / 21738479 rs1320566 chr1 159903634 C T 6.73E-06 Myopia (severe) IGSF9 intron 23933737 rs4262538 chr1 159908045 C T 5.70E-04 Type 2 diabetes IGSF9 intron 17463246 rs1316275 chr1 159913388 G A 6.29E-06 White blood cell count IGSF9 UTR-5 21738479 rs2840582 chr1 159916937 A G 7.13E-07 White blood cell count / / 21738479 rs16831153 chr1 159920719 G A 3.40E-04 Response to antidepressants / / 19736353 rs2789419 chr1 159920826 T A 3.96E-06 White blood cell count / / 21738479 rs2249707 chr1 159922959 C T 3.60E-06 White blood cell count SLAMF9 intron 21738479 rs2840584 chr1 159925431 C T 1.82E-09 Multiple complex diseases / / 17554300 rs2840584 chr1 159925431 C T 2.30E-06 White blood cell count / / 21738479 rs1316963 chr1 159928711 G A 5.41E-06 White blood cell count / / 21738479 rs2840588 chr1 159931395 C A 6.47E-04 Multiple complex diseases LOC100505633 intron 17554300 rs7541727 chr1 159932319 C T 1.97E-04 Taste perception LOC100505633 intron 22132133 rs7541727 chr1 159932319 C T 3.98E-04 Response to cytadine analogues (cytosine arabinoside) LOC100505633 intron 24483146 rs2840591 chr1 159940000 G A 4.79E-04 Tourette syndrome LOC100505633 intron 22889924 rs2789424 chr1 159942456 C T 1.13E-10 White blood cell count LOC100505633 intron 21738479 rs2789425 chr1 159949651 T C 1.14E-06 White blood cell count / / 21738479 rs1317712 chr1 159954369 C T 1.10E-04 Multiple complex diseases / / 17554300 rs2494208 chr1 159973615 G A 3.17E-04 Multiple complex diseases / / 17554300 rs2185214 chr1 159976751 A G 2.50E-04 HIV-1 viral setpoint / / 17641165 rs1934078 chr1 159977049 C T 3.91E-04 Multiple complex diseases / / 17554300 rs16831234 chr1 159977732 T A 0.0000433 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12086013 chr1 159983651 G A 0.0000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7531304 chr1 159984431 T C 0.0000128 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12058277 chr1 159985517 C T 0.0000202 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2211108 chr1 159988685 G A 6.31E-04 Type 2 diabetes / / 17463246 rs6427502 chr1 159989928 C G 0.00000518 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12726002 chr1 159991096 C A 0.00000574 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12403242 chr1 159995482 C G 8.65E-06 White blood cell count / / 21738479 rs12409352 chr1 160000435 A T 9.40E-06 White blood cell count PIGM missense 21738479 rs12409352 chr1 160000435 A T 0.000071 Breast cancer PIGM missense 23555315 rs17367150 chr1 160006809 A G 0.0000139 Nonsyndromic striae distensae (stretch marks) KCNJ10 nearGene-3 23633020 rs1053074 chr1 160009121 A C 0.000083 Nonsyndromic striae distensae (stretch marks) KCNJ10 UTR-3 23633020 rs12729701 chr1 160012406 A G 0.0000146 Nonsyndromic striae distensae (stretch marks) KCNJ10 intron 23633020 rs12133079 chr1 160016464 C A 8.68E-07 White blood cell count KCNJ10 intron 21738479 rs11265313 chr1 160029456 G A 1.50E-05 Height KCNJ10 intron 21998595 rs2737703 chr1 160055932 C T 6.52E-05 Waist Circumference KCNJ9 intron pha003025 rs2753268 chr1 160058252 G A 9.43E-05 Body Mass Index KCNJ9 UTR-3 pha003015 rs2753268 chr1 160058252 G A 2.33E-05 Weight KCNJ9 UTR-3 pha003026 rs6688363 chr1 160077854 C T 2.00E-07 Response to antipsychotic treatment / / 23241943 rs3761685 chr1 160084643 T C 0.0000963 HDL cholesterol ATP1A2 nearGene-5 23063622 rs1023420 chr1 160094343 T C 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP1A2 intron 20877124 rs1321655 chr1 160094458 A G,T 1.49E-11 HDL cholesterol ATP1A2 intron 23063622 rs1321655 chr1 160094458 A G,T 2.29E-08 LDL cholesterol ATP1A2 intron 23063622 rs1321655 chr1 160094458 A G,T 4.15E-10 Cholesterol,total ATP1A2 intron 23063622 rs11265329 chr1 160095446 C T 1.52E-08 White blood cell count ATP1A2 intron 21738479 rs16831388 chr1 160095625 A G 1.19E-04 Heart rate ATP1A2 intron 23583979 rs11265332 chr1 160117195 C G 7.64E-06 White blood cell count / / 21738479 rs12138430 chr1 160123781 A G 9.22E-04 Amyotrophic Lateral Sclerosis ATP1A4 intron 17362836 rs12144820 chr1 160126188 G A 6.08E-07 White blood cell count ATP1A4 intron 21738479 rs953104 chr1 160131429 G A 9.58E-05 Potassium levels ATP1A4 intron pha003086 rs1935306 chr1 160152057 C T 8.04E-04 Tourette syndrome ATP1A4 intron 22889924 rs659235 chr1 160159156 G A 3.11E-04 Birth weight / / 17255346 rs3827532 chr1 160170731 C T 2.69E-05 Alzheimer's disease (age of onset) CASQ1 intron 22005931 rs680083 chr1 160180906 G A 1.14E-04 Fibrinogen PEA15 intron 17255346 rs1061511 chr1 160189500 C A 2.40E-04 Fibrinogen DCAF8 intron 17255346 rs16831628 chr1 160193057 G A 5.72E-04 Alzheimer's disease DCAF8 intron 17998437 rs4596880 chr1 160224700 T A 1.54E-04 Fibrinogen DCAF8 intron 17255346 rs6661197 chr1 160234691 T G 5.12E-05 Fibrinogen / / 17255346 rs2795067 chr1 160251792 A G 4.06E-05 Fibrinogen PEX19 intron 17255346 rs2820421 chr1 160256004 C A 5.63E-05 Fibrinogen PEX19 nearGene-5 17255346 rs3789042 chr1 160265515 T C 8.72E-05 Fibrinogen COPA intron 17255346 rs6699059 chr1 160278311 A G 3.62E-04 Fibrinogen COPA intron 17255346 rs4656896 chr1 160295829 C T 5.58E-05 Alzheimer's disease (age of onset) COPA intron 22005931 rs16831810 chr1 160296841 G A 4.80E-05 Alzheimer's disease (age of onset) COPA intron 22005931 rs1802778 chr1 160303416 G A 3.72E-04 Fibrinogen COPA cds-synon 17255346 rs7512872 chr1 160310363 A G 4.13E-05 Fibrinogen COPA intron 17255346 rs2147471 chr1 160311845 C A 1.01E-04 Fibrinogen COPA intron 17255346 rs10752637 chr1 160312265 T G 9.02E-05 Fibrinogen COPA intron 17255346 rs1324738 chr1 160312625 C T 1.93E-04 Multiple complex diseases COPA intron 17554300 rs6669689 chr1 160318940 A G 4.47E-04 Fibrinogen NCSTN intron 17255346 rs6664438 chr1 160321359 C T 2.18E-04 Bipolar disorder NCSTN intron 18317468 rs6664438 chr1 160321359 C T 2.50E-05 Urinary metabolites NCSTN intron 21572414 rs6664438 chr1 160321359 C T 5.32E-08 Glucose levels NCSTN intron pha003061 rs1041066 chr1 160321656 G A 6.48E-05 Alzheimer's disease (age of onset) NCSTN intron 22005931 rs6677637 chr1 160324771 C T 5.32E-08 Glucose levels NCSTN intron pha003061 rs12724113 chr1 160328804 G A 8.80E-05 Parkinson's disease (age of onset) NCSTN nearGene-3 19772629 rs12724113 chr1 160328804 G A 1.58E-07 White blood cell count NCSTN nearGene-3 21738479 rs4656256 chr1 160331019 A G 8.52E-10 White blood cell count / / 21738479 rs4656256 chr1 160331019 A G 4.48E-06 Type 2 diabetes / / 22961080 rs4656902 chr1 160333742 T G 3.77E-04 Multiple complex diseases / / 17554300 rs4656902 chr1 160333742 T G 3.64E-05 Glucose levels / / pha003061 rs10908776 chr1 160334362 C T 8.86E-06 White blood cell count / / 21738479 rs12407581 chr1 160349641 C T 8.28E-04 Lymphocyte counts / / 22286170 rs12404657 chr1 160351229 C A 6.90E-05 Menopause (age at onset) / / 22267201 rs7513382 chr1 160372109 G T 1.20E-06 White blood cell count VANGL2 intron 21738479 rs6688100 chr1 160399586 T C 7.49E-06 White blood cell count / / 21738479 rs12757461 chr1 160415924 G A 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11585691 chr1 160420036 C T 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16832015 chr1 160421916 C T 2.00E-06 Cognitive performance / / 19734545 rs1149392 chr1 160428188 A G 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1149386 chr1 160441241 G C 1.50E-08 Graves' disease / / 21900946 rs3795327 chr1 160458782 A G 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLAMF6 intron 20877124 rs1265883 chr1 160464911 C A 2.25E-04 Type 2 diabetes SLAMF6 intron 17463246 rs1265883 chr1 160464911 C A 8.06E-05 Rheumatoid arthritis SLAMF6 intron 21452313 rs1265883 chr1 160464911 C A 2.00E-18 Graves' disease SLAMF6 intron 23612905 rs1268524 chr1 160470258 C T 0.000023 Salmonella-induced pyroptosis SLAMF6 intron 22837397 rs6660233 chr1 160473163 G T 7.90E-06 Urinary metabolites SLAMF6 intron 21572414 rs6689237 chr1 160492270 G A 1.80E-05 Urinary metabolites SLAMF6 intron 21572414 rs6689237 chr1 160492270 G A 5.35E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SLAMF6 intron 24192120 rs2147466 chr1 160504157 G A 8.97E-07 White blood cell count / / 21738479 rs1408595 chr1 160506277 T A 7.13E-07 White blood cell count / / 21738479 rs11265432 chr1 160507016 T C 5.35E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12134393 chr1 160512224 G A 2.80E-07 White blood cell count CD84 UTR-3 21738479 rs10737176 chr1 160512616 G A 6.44E-07 White blood cell count CD84 UTR-3 21738479 rs1503860 chr1 160513456 G A 1.38E-07 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs6427528 chr1 160516308 A G 2.00E-06 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs6427528 chr1 160516308 A G 7.78E-08 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs3733266 chr1 160516659 C G 8.20E-06 Urinary metabolites CD84 UTR-3 21572414 rs3766389 chr1 160517214 A G 8.20E-06 Urinary metabolites CD84 UTR-3 21572414 rs10908788 chr1 160548263 A G 8.00E-06 Urinary metabolites CD84 intron 21572414 rs349250 chr1 160556144 A G 2.50E-05 Urinary metabolites / / 21572414 rs6668881 chr1 160569131 G A 2.70E-05 Urinary metabolites / / 21572414 rs111643709 chr1 160591741 C T 3.60E-11 Metabolite levels SLAMF1 intron 22286219 rs6672302 chr1 160600319 G T 6.85E-06 Telomere length SLAMF1 intron 23900074 rs2295612 chr1 160616703 G T 2.16E-04 Alzheimer's disease (late onset) SLAMF1 missense 21379329 rs10218843 chr1 160626061 A G 3.84E-06 Schizophrenia (treatment refractory) / / 22479419 rs11265461 chr1 160630143 T C 2.00E-07 Schizophrenia (treatment refractory) / / 22479419 rs11265464 chr1 160660312 T C 4.69E-04 Multiple complex diseases CD48 intron 17554300 rs11265472 chr1 160674460 T C 9.59E-05 Non-alcoholic fatty liver disease histology (other) CD48 intron 20708005 rs10489639 chr1 160679527 G A 4.90E-05 Kidney function and endocine traits CD48 intron 17903292 rs10489639 chr1 160679527 G A 9.33E-05 Sudden cardiac arrest CD48 intron 21658281 rs10908805 chr1 160679733 C T 3.41E-04 Multiple complex diseases CD48 intron 17554300 rs1503849 chr1 160680764 A G 5.56E-04 Multiple complex diseases CD48 intron 17554300 rs17313034 chr1 160713848 T C 5.93E-05 Cervical cancer SLAMF7 intron 24700089 rs489286 chr1 160722550 A G 3.39E-04 Response to cytadine analogues (cytosine arabinoside) SLAMF7 intron 24483146 rs495706 chr1 160723256 A G 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs518721 chr1 160723517 A G 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11582702 chr1 160727986 C T 1.10E-05 Cervical cancer / / 24700089 rs574491 chr1 160735814 A G 4.78E-04 Schizophrenia / / 20832056 rs574491 chr1 160735814 A G 1.20E-05 Urinary metabolites / / 21572414 rs528095 chr1 160738146 T C 3.59E-04 Schizophrenia / / 20832056 rs528095 chr1 160738146 T C 1.40E-05 Urinary metabolites / / 21572414 rs12068654 chr1 160743749 T G 5.00E-06 Cervical cancer / / 24700089 rs493644 chr1 160745399 C T 7.97E-06 White blood cell count / / 21738479 rs16832364 chr1 160746013 A C 2.54E-05 Type 2 diabetes / / 17463246 rs576523 chr1 160746076 G A 2.00E-07 Capecitabine sensitivity / / 22864933 rs7556098 chr1 160747615 C T 8.78E-05 Kawasaki disease / / 22081228 rs6427545 chr1 160770515 G A 3.97E-04 Type 2 diabetes LY9 intron 17463246 rs6656939 chr1 160773346 C G 5.30E-04 Type 2 diabetes LY9 intron 17463246 rs4656932 chr1 160779495 G A 1.80E-04 Primary sclerosing cholangitis LY9 intron 19944697 rs560681 chr1 160786670 A G 2.96E-04 Insulin resistance LY9 intron 21901158 rs3766377 chr1 160800559 A G 1.25E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses CD244 UTR-3 17903301 rs3766377 chr1 160800559 A G 2.50E-05 Psoriasis CD244 UTR-3 20953189 rs4656940 chr1 160830268 A G 6.00E-07 Crohn's disease CD244 intron 21102463 rs2274910 chr1 160852046 T C 1.00E-09 Crohn's disease ITLN1 intron 18587394 rs2274910 chr1 160852046 T C 1.00E-09 Asthma ITLN1 intron 21150878 rs2274910 chr1 160852046 T C 1.46E-09 Multiple sclerosis ITLN1 intron 22190364 rs4656958 chr1 160856964 A G 7.00E-09 Inflammatory bowel disease / / 23128233 rs11265510 chr1 160859559 A G 1.61E-04 Multiple complex diseases / / 17554300 rs11265519 chr1 160878913 C A 2.20E-04 Multiple complex diseases / / 17554300 rs11265519 chr1 160878913 C A 3.82E-07 Crohn's disease / / 18587394 rs6691672 chr1 160885530 A G 3.95E-04 Multiple complex diseases / / 17554300 rs2252389 chr1 160922195 A G 4.87E-04 Response to taxane treatment (placlitaxel) ITLN2 intron 23006423 rs4596920 chr1 160922751 C T 5.20E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) ITLN2 intron 21221126 rs12126313 chr1 160925455 C A 3.80E-05 Suicidal ideation / / 20877300 rs1556260 chr1 161014446 C T 4.08E-09 Lymphocyte counts USF1 intron 22286170 rs2774279 chr1 161017556 C T 2.39E-04 Alzheimer's disease ARHGAP30 cds-synon 22005930 rs61733353 chr1 161018422 C G 0.00028 Breast cancer ARHGAP30 missense 23555315 rs11588189 chr1 161019621 C T 4.01E-04 Alzheimer's disease ARHGAP30 intron 22005930 rs12130871 chr1 161026490 A G 7.74E-04 Alzheimer's disease ARHGAP30 intron 22005930 rs10797092 chr1 161037042 A C 1.45E-04 IgE levels ARHGAP30 intron 17255346 rs3892375 chr1 161054054 T C 3.41E-04 Schizophrenia PVRL4 intron 20832056 rs1556258 chr1 161056455 T C 0.0000377 Nonsyndromic striae distensae (stretch marks) PVRL4 intron 23633020 rs4078017 chr1 161074092 G A 1.80E-05 Urinary metabolites PFDN2 intron 21572414 rs17389237 chr1 161092761 A G 1.60E-05 Urinary metabolites NIT1 intron 21572414 rs10797093 chr1 161103445 T G 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs3813620 chr1 161145005 C T 1.60E-05 Urinary metabolites B4GALT3 cds-synon 21572414 rs3813624 chr1 161170977 C T 3.92E-04 Lung function (forced expiratory volume in 1 second) NDUFS2 intron 17255346 rs10908826 chr1 161172525 C T 1.67E-04 Lung function (forced expiratory volume in 1 second) NDUFS2 intron 17255346 rs3924264 chr1 161178684 T C 2.73E-04 Type 2 diabetes NDUFS2 intron 17463246 rs3557 chr1 161188893 T G 8.96E-04 Type 2 diabetes FCER1G UTR-3 17463246 rs6413453 chr1 161192316 G A 4.46E-05 Atrial fibrillation APOA2 intron 21846873 rs4073054 chr1 161200487 C A 1.40E-06 Type 2 diabetes NR1I3 intron 17463246 rs4073054 chr1 161200487 C A 2.00E-08 Lipid levels NR1I3 intron 19936222 rs4073054 chr1 161200487 C A 5.70E-11 Lipid levels NR1I3 intron 19936222 rs4073054 chr1 161200487 C A 9.01E-05 Telomere length NR1I3 intron 21573004 rs4073054 chr1 161200487 C A 4.00E-19 Blood metabolite levels NR1I3 intron 24816252 rs11265572 chr1 161213063 G T 5.25E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2502807 chr1 161217693 C A 9.22E-05 Cognitive test performance / / 20125193 rs10494349 chr1 161259741 T C 7.31E-05 Common variable immunodeficiency / / 21497890 rs4436408 chr1 161260215 G A 5.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs12750393 chr1 161262428 C T 8.67E-05 Smoking initiation / / 24665060 rs4657015 chr1 161272441 A G 8.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs16832790 chr1 161275943 C T 2.13E-04 Coronary heart disease MPZ cds-synon 21606135 rs17394957 chr1 161313437 C T 0.00004 Endoxifen sentivity (5 uM) SDHC intron 23508821 rs4474277 chr1 161329401 G A 0.00000119 Primary sclerosing cholangitis SDHC intron 23603763 rs16832872 chr1 161335902 G A 9.20E-04 Coronary heart disease C1orf192 intron 21606135 rs12744234 chr1 161361979 C T 3.02E-04 Lymphocyte counts / / 22286170 rs72717009 chr1 161405053 C T 1.00E-07 Rheumatoid arthritis / / 24390342 rs72717009 chr1 161405053 C T 5.00E-07 Rheumatoid arthritis / / 24390342 rs4657039 chr1 161462728 A G 2.20E-05 Ulcerative colitis / / 19915573 rs7511868 chr1 161463331 G A 5.42E-05 Ulcerative colitis / / 19915573 rs6427595 chr1 161463498 G A 8.48E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7535475 chr1 161463587 C A 3.00E-06 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs6696854 chr1 161463814 T C 3.65E-05 Ulcerative colitis / / 19915573 rs6696854 chr1 161463814 T C 8.48E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6684851 chr1 161464412 C T 3.67E-05 Ulcerative colitis / / 19915573 rs12746613 chr1 161467042 C T 5.70E-04 Rheumatoid arthritis / / 22446963 rs12746613 chr1 161467042 C T 0.00000433 Rheumatoid arthritis / / 23143596 rs12139150 chr1 161470505 G C 2.81E-06 Ulcerative colitis / / 19915573 rs10800309 chr1 161472158 A G 7.00E-04 Systemic lupus erythematosus / / 18204446 rs10800309 chr1 161472158 A G 2.22E-05 Ulcerative colitis / / 19915573 rs10800309 chr1 161472158 A G 3.00E-09 Ulcerative colitis / / 20228799 rs10800309 chr1 161472158 A G 2.80E-09 Multiple sclerosis / / 22190364 rs10494360 chr1 161475750 G A 0.00003 Rheumatoid arthritis FCGR2A intron 23143596 rs6671847 chr1 161478810 G A 8.50E-09 Ulcerative colitis FCGR2A intron 19915573 rs1801274 chr1 161479745 A G 6.78E-07 Systemic lupus erythematosus FCGR2A missense 18204446 rs1801274 chr1 161479745 A G 2.00E-12 Ulcerative colitis FCGR2A missense 19915573 rs1801274 chr1 161479745 A G 2.00E-20 Ulcerative colitis FCGR2A missense 21297633 rs1801274 chr1 161479745 A G 7.00E-11 Kawasaki disease FCGR2A missense 22081228 rs1801274 chr1 161479745 A G 3.67E-08 Cholesterol,total FCGR2A missense 23063622 rs1801274 chr1 161479745 A G 2.00E-38 Inflammatory bowel disease FCGR2A missense 23128233 rs1801274 chr1 161479745 A G 2.12E-04 Ulcerative colitis FCGR2A missense 23511034 rs1801274 chr1 161479745 A G 5.02E-04 Systemic lupus erythematosus and Systemic sclerosis FCGR2A missense 23740937 rs1801274 chr1 161479745 A G 9.00E-06 Systemic lupus erythematosus FCGR2A missense 24871463 rs12142755 chr1 161481743 A G 5.87E-04 Response to cytadine analogues (cytosine arabinoside) FCGR2A intron 24483146 rs368433 chr1 161484210 T C 2.00E-08 Helicobacter pylori serologic status FCGR2A intron 23652523 rs17400517 chr1 161485259 G T 4.95E-08 Helicobacter pylori serologic status FCGR2A intron 23652523 rs9427401 chr1 161492175 C G 4.57E-08 Helicobacter pylori serologic status / / 23652523 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 12975461 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 16609067 rs396991 chr1 161514542 A C 1 Drug response to Cetuximab FCGR3A missense 17704420 rs396991 chr1 161514542 A C 1 Drug response to Infliximab FCGR3A missense 19005160 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 19018870 rs67418890 chr1 161540857 T A 1.00E-10 Lipid metabolism phenotypes / / 22286219 rs10917688 chr1 161658780 C T 1.06E-04 Multiple complex diseases / / 17554300 rs1538972 chr1 161676557 G A 7.81E-05 Neuroblastoma / / pha002895 rs1954173 chr1 161677784 G A 6.24E-04 Rheumatoid arthritis FCRLA intron 21452313 rs1954174 chr1 161677807 C T 5.00E-06 Alcohol dependence FCRLA intron 21956439 rs1954174 chr1 161677807 C T 0.000247946 Hypertension (early onset hypertension) FCRLA intron 22479346 rs12135523 chr1 161678254 A G 6.52E-07 White blood cell count FCRLA intron 21738479 rs12134087 chr1 161678311 C T 1.06E-06 White blood cell count FCRLA intron 21738479 rs12136407 chr1 161678377 T C 1.52E-06 White blood cell count FCRLA intron 21738479 rs1934908 chr1 161680868 T C 4.20E-06 White blood cell count FCRLA intron 21738479 rs71634903 chr1 161681869 A G 0.000019 Prostate cancer (advanced) FCRLA missense 23555315 rs11746 chr1 161683136 G A 2.31E-06 White blood cell count FCRLA missense 21738479 rs1891020 chr1 161694454 A G 3.19E-06 Lymphocyte counts FCRLB intron 22286170 rs16858733 chr1 161697977 G C 8.89E-04 Alzheimer's disease / / 22005930 rs1503814 chr1 161709119 C T 4.96E-04 Multiple complex diseases / / 17554300 rs1027702 chr1 161712857 C T 5.74E-08 Neuroblastoma (low-risk) / / 21436895 rs1027702 chr1 161712857 C T 2.71E-07 Neuroblastoma / / pha002895 rs10917835 chr1 161717293 T A 3.50E-04 Type 2 diabetes / / 22158537 rs1063178 chr1 161721707 C T 2.42E-05 Neuroblastoma / / pha002895 rs3820449 chr1 161727172 G A 3.23E-06 Neuroblastoma / / pha002895 rs12745240 chr1 161728001 G A 8.04E-05 Neuroblastoma / / pha002895 rs7519514 chr1 161739190 A G 3.06E-08 White blood cell count ATF6 intron 21738479 rs7519514 chr1 161739190 A G 6.37E-06 Type 2 diabetes ATF6 intron 22158537 rs905594 chr1 161741274 T C 5.32E-08 White blood cell count ATF6 intron 21738479 rs905594 chr1 161741274 T C 3.52E-05 Type 2 diabetes ATF6 intron 22158537 rs905594 chr1 161741274 T C 3.81E-06 Diabetes Mellitus ATF6 intron pha003059 rs1027700 chr1 161757036 A T 1.15E-07 Type 2 diabetes ATF6 intron 22158537 rs6698956 chr1 161758744 T C 0.0004616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs6698956 chr1 161758744 T C 4.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs11576878 chr1 161775577 A G 2.06E-07 Type 2 diabetes ATF6 intron 22158537 rs2134697 chr1 161780979 G A 1.02E-05 Type 2 diabetes ATF6 intron 22158537 rs16849542 chr1 161786495 A G 1.77E-25 Narcolepsy ATF6 intron 19629137 rs11581556 chr1 161793612 G A 8.59E-07 Type 2 diabetes ATF6 intron 22158537 rs10918029 chr1 161795896 G A 0.0004025 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs10918029 chr1 161795896 G A 4.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs12691498 chr1 161809706 T A 0.000373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs12691498 chr1 161809706 T A 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs1006310 chr1 161811555 T C 2.61E-07 White blood cell count ATF6 intron 21738479 rs1006310 chr1 161811555 T C 5.86E-04 Type 2 diabetes ATF6 intron 22158537 rs3767635 chr1 161820904 A G 1.80E-05 Urinary metabolites ATF6 intron 21572414 rs931778 chr1 161823618 A G 1.98E-07 White blood cell count ATF6 intron 21738479 rs931778 chr1 161823618 A G 8.73E-04 Type 2 diabetes ATF6 intron 22158537 rs3767633 chr1 161826615 T A 8.00E-06 IgG glycosylation ATF6 intron 23382691 rs2340721 chr1 161849385 A C 3.46E-07 White blood cell count ATF6 intron 21738479 rs2340721 chr1 161849385 A C 7.96E-04 Type 2 diabetes ATF6 intron 22158537 rs10918137 chr1 161862555 G A 3.36E-07 White blood cell count ATF6 intron 21738479 rs12124509 chr1 161867489 G A 1.14E-07 White blood cell count ATF6 intron 21738479 rs2341475 chr1 161878608 A G 8.85E-05 Type 2 diabetes ATF6 intron 22158537 rs12079579 chr1 161880482 G A 0.00056 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs12079579 chr1 161880482 G A 5.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs4657121 chr1 161883083 G A 7.90E-07 Type 2 diabetes ATF6 intron 22158537 rs4657121 chr1 161883083 G A 4.49E-05 Neuroblastoma ATF6 intron pha002895 rs7554023 chr1 161896364 A G 1.00E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATF6 intron 24023788 rs10918270 chr1 161915501 G A 8.00E-06 Parkinson's disease (age of onset) ATF6 intron 19772629 rs3795649 chr1 161931562 G A 9.69E-05 Heart Failure ATF6 UTR-3 pha002885 rs2499844 chr1 161935361 G A,C 8.82E-07 Type 2 diabetes / / 22158537 rs2490439 chr1 161935854 G T 1.18E-06 Type 2 diabetes / / 22158537 rs2490438 chr1 161936788 G A 1.19E-06 Type 2 diabetes / / 22158537 rs2490431 chr1 161941219 T C 1.50E-08 White blood cell count / / 21738479 rs4656342 chr1 161942491 C G 1.34E-07 White blood cell count / / 21738479 rs12076482 chr1 161942885 G A 0.0007398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12076482 chr1 161942885 G A 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6693833 chr1 161943058 C T 1.81E-06 White blood cell count / / 21738479 rs2340725 chr1 161943634 T C 1.28E-07 White blood cell count / / 21738479 rs2340726 chr1 161943780 G A 3.66E-07 White blood cell count / / 21738479 rs6427642 chr1 161944753 C G 1.16E-07 White blood cell count / / 21738479 rs1962508 chr1 161945419 C A 2.51E-07 White blood cell count / / 21738479 rs1962509 chr1 161945467 C G 3.33E-07 White blood cell count / / 21738479 rs2340727 chr1 161946727 A G 8.87E-07 White blood cell count / / 21738479 rs2340727 chr1 161946727 A G 2.00E-23 Hematology traits / / 23263863 rs10918341 chr1 161950399 A G 3.24E-10 White blood cell count / / 21738479 rs10918341 chr1 161950399 A G 8.21E-05 Type 2 diabetes / / 22158537 rs10918342 chr1 161950451 G A 4.59E-11 White blood cell count / / 21738479 rs12039519 chr1 161953400 G A 7.00E-06 Parasitemia in Tripanosoma cruzi seropositivity OLFML2B UTR-3 24324551 rs16835120 chr1 161955633 C T 3.39E-04 Multiple complex diseases OLFML2B intron 17554300 rs12217099 chr1 161956109 C T 8.68E-04 Response to taxane treatment (placlitaxel) OLFML2B intron 23006423 rs2499836 chr1 161967681 A G 8.58E-05 Schizophrenia OLFML2B missense 24253340 rs2499834 chr1 161969636 T G 0.000779 Ovarian cancer OLFML2B intron 22794196 rs7523246 chr1 161972767 G A 4.79E-08 White blood cell count OLFML2B intron 21738479 rs11812028 chr1 161974641 A T 7.93E-11 White blood cell count OLFML2B intron 21738479 rs16838789 chr1 161981845 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OLFML2B intron 22628534 rs12119861 chr1 161985004 C T 7.83E-05 HIV-1 control OLFML2B intron 20041166 rs16839677 chr1 161987385 G A 3.91E-05 Odorant perception OLFML2B intron 23910658 rs12072417 chr1 162000045 T G 7.62E-04 Multiple complex diseases / / 17554300 rs7551221 chr1 162000398 T C 5.80E-06 Major depressive disorder / / 21042317 rs1415268 chr1 162006451 A T 1.00E-06 QT interval / / 16648850 rs2880058 chr1 162014632 A G 2.00E-10 QT interval / / 20031603 rs2880058 chr1 162014632 A G 6.70E-09 Electrocardiographic traits / / 20062061 rs12036340 chr1 162015740 A G 4.12E-08 QT interval / / 23166209 rs4657139 chr1 162029907 A T 1.00E-10 QT interval / / 16648850 rs10918594 chr1 162030688 C G 1 Drug response to Isradipine / / 19247217 rs10918594 chr1 162030688 C G 1 Drug response to Verapamil / / 19247217 rs12143842 chr1 162033890 C T 2.00E-78 QT interval / / 19305408 rs12143842 chr1 162033890 C T 2.00E-78 QT interval / / 19305409 rs12143842 chr1 162033890 C T 1.00E-83 QT interval / / 19587794 rs12143842 chr1 162033890 C T 1.20E-08 Electrocardiographic traits / / 20062061 rs12143842 chr1 162033890 C T 2.00E-15 QT interval / / 23166209 rs12143842 chr1 162033890 C T 4.58E-05 Heart Rate / / pha003053 rs16847548 chr1 162035274 T C 2.34E-07 QT interval / / 19587794 rs16847548 chr1 162035274 T C 1.84E-10 QT interval / / 23166209 rs10918602 chr1 162037700 T C 4.97E-08 QT interval NOS1AP nearGene-5 23166209 rs12090585 chr1 162038776 G A 7.80E-10 Electrocardiographic traits NOS1AP nearGene-5 20062061 rs16849413 chr1 162043629 C T 3.03E-04 Multiple complex diseases NOS1AP intron 17554300 rs4656349 chr1 162049824 G A 4.10E-09 Electrocardiographic traits NOS1AP intron 20062061 rs6670339 chr1 162055806 C T 3.70E-10 Electrocardiographic traits NOS1AP intron 20062061 rs4657140 chr1 162061265 T C 1.60E-09 Electrocardiographic traits NOS1AP intron 20062061 rs4657140 chr1 162061265 T C 8.79E-05 Neutrophil count NOS1AP intron pha003095 rs1415257 chr1 162062044 C T 9.45E-05 Neutrophil count NOS1AP intron pha003095 rs12036529 chr1 162070706 A T 6.12E-06 White blood cell count NOS1AP intron 21738479 rs12757771 chr1 162076521 C T 4.89E-04 Coronary heart disease NOS1AP intron 21971053 rs76078015 chr1 162079688 G A 0.0000217 Menopause (age at onset) NOS1AP intron 23424626 rs1415259 chr1 162085309 C T 7.00E-10 Electrocardiographic traits NOS1AP intron 20062061 rs1415259 chr1 162085309 C T 8.38E-05 Neutrophil count NOS1AP intron pha003095 rs10494366 chr1 162085685 G T 1.00E-10 QT interval NOS1AP intron 16648850 rs10494366 chr1 162085685 G T 9.00E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs10494366 chr1 162085685 G T 1 Drug response to Isradipine NOS1AP intron 19247217 rs10494366 chr1 162085685 G T 1 Drug response to Verapamil NOS1AP intron 19247217 rs10494366 chr1 162085685 G T 5.00E-22 Electrocardiographic traits NOS1AP intron 20062063 rs10494366 chr1 162085685 G T 8.38E-05 Neutrophil count NOS1AP intron pha003095 rs76662883 chr1 162089318 G A,C,T 9.00E-06 Obesity-related traits NOS1AP intron 23251661 rs10753758 chr1 162089331 A G 7.98E-04 Type 2 diabetes NOS1AP intron 17463246 rs12140791 chr1 162091284 C T 0.0000638 Major depressive disorder NOS1AP intron 23149448 rs12140791 chr1 162091284 C T 5.12E-05 Schizophrenia NOS1AP intron pha002857 rs10458392 chr1 162092110 T G 3.30E-08 Electrocardiographic traits NOS1AP intron 20062061 rs1572495 chr1 162099301 G A 4.43E-06 White blood cell count NOS1AP intron 21738479 rs12084985 chr1 162099951 G A 6.71E-06 White blood cell count NOS1AP intron 21738479 rs16856782 chr1 162100112 C T 6.62E-06 White blood cell count NOS1AP intron 21738479 rs16856785 chr1 162100287 G C 6.73E-06 White blood cell count NOS1AP intron 21738479 rs12093845 chr1 162101829 A G 8.22E-06 White blood cell count NOS1AP intron 21738479 rs10494367 chr1 162103178 G A 8.88E-06 White blood cell count NOS1AP intron 21738479 rs4657154 chr1 162108119 A G 6.30E-09 Electrocardiographic traits NOS1AP intron 20062061 rs4657155 chr1 162108265 C A 3.38E-05 Bipolar disorder and schizophrenia NOS1AP intron 20889312 rs16857031 chr1 162112910 C G 1.00E-34 QT interval NOS1AP intron 19305408 rs1932933 chr1 162118046 T C 4.30E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs1932933 chr1 162118046 T C 1.30E-09 Electrocardiographic traits NOS1AP intron 20062061 rs1932933 chr1 162118046 T C 8.40E-04 Alcohol dependence NOS1AP intron 20201924 rs1932933 chr1 162118046 T C 0.00000582 Alcohol dependence NOS1AP intron 23691058 rs1932932 chr1 162120579 C G 7.45E-07 White blood cell count NOS1AP intron 21738479 rs4656355 chr1 162123797 A G 4.62E-07 White blood cell count NOS1AP intron 21738479 rs10918790 chr1 162128822 G A 1.09E-06 White blood cell count NOS1AP intron 21738479 rs12029454 chr1 162133117 G A 3.00E-45 QT interval NOS1AP intron 19305408 rs12029454 chr1 162133117 G A 1.10E-05 Electrocardiographic traits NOS1AP intron 20062061 rs12029454 chr1 162133117 G A 4.37E-09 QT interval NOS1AP intron 23166209 rs1337068 chr1 162133146 G A 8.31E-08 Triglycerides NOS1AP intron 23063622 rs10918796 chr1 162133343 C A 3.50E-07 White blood cell count NOS1AP intron 21738479 rs6427656 chr1 162134638 G A 7.75E-07 White blood cell count NOS1AP intron 21738479 rs945713 chr1 162135670 G A 2.82E-05 QT interval NOS1AP intron 16648850 rs945713 chr1 162135670 G A 2.40E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs945713 chr1 162135670 G A 2.45E-07 White blood cell count NOS1AP intron 21738479 rs11805598 chr1 162140336 A G 5.10E-07 White blood cell count NOS1AP intron 21738479 rs7549718 chr1 162140862 A G 2.12E-07 White blood cell count NOS1AP intron 21738479 rs7534004 chr1 162146709 G A 3.11E-09 QT interval NOS1AP intron 23166209 rs12135795 chr1 162149765 A G 1.57E-07 White blood cell count NOS1AP intron 21738479 rs12724220 chr1 162152998 A G 2.98E-08 White blood cell count NOS1AP intron 21738479 rs6671817 chr1 162153226 A G 1.17E-08 White blood cell count NOS1AP intron 21738479 rs10127719 chr1 162156170 T C 1.75E-08 QT interval NOS1AP intron 23166209 rs7546234 chr1 162156304 G A 7.30E-06 Coffee consumption NOS1AP intron 21357676 rs12087800 chr1 162161940 G A 7.03E-06 QT interval NOS1AP intron 23166209 rs1415263 chr1 162166043 C T 1.48E-05 QT interval NOS1AP intron 16648850 rs12567315 chr1 162166646 G A 1.82E-09 QT interval NOS1AP intron 23166209 rs6663969 chr1 162166919 G C 5.38E-06 White blood cell count NOS1AP intron 21738479 rs6692381 chr1 162167884 C T 1.23E-09 QT interval NOS1AP intron 23166209 rs6667431 chr1 162167921 G A 1.85E-09 QT interval NOS1AP intron 23166209 rs4306106 chr1 162171994 G A 5.07E-09 QT interval NOS1AP intron 23166209 rs10800352 chr1 162172689 A G 4.69E-09 QT interval NOS1AP intron 23166209 rs4480335 chr1 162173377 A C 4.32E-09 QT interval NOS1AP intron 23166209 rs12116744 chr1 162180456 G A 3.56E-09 QT interval NOS1AP intron 23166209 rs12027785 chr1 162181145 T A 3.45E-09 QT interval NOS1AP intron 23166209 rs3934467 chr1 162182677 C T 2.58E-09 QT interval NOS1AP intron 23166209 rs4657173 chr1 162185546 G T 4.60E-07 QT interval NOS1AP intron 23166209 rs4391647 chr1 162186931 A G 7.73E-10 QT interval NOS1AP intron 23166209 rs16858527 chr1 162187715 A G 5.84E-05 Nephrolithiasis NOS1AP intron 22396660 rs6683968 chr1 162191412 T G 1.00E-04 QT interval NOS1AP intron 16648850 rs6683968 chr1 162191412 T G 1.00E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs16858695 chr1 162193738 C T 5.45E-05 Nephrolithiasis NOS1AP intron 22396660 rs12734991 chr1 162194576 C T 9.99E-07 White blood cell count NOS1AP intron 21738479 rs4657175 chr1 162195738 T G 1.00E-09 QT interval NOS1AP intron 22726844 rs4657175 chr1 162195738 T G 7.24E-10 QT interval NOS1AP intron 23166209 rs4657175 chr1 162195738 T G 7.24E-10 Schizophrenia NOS1AP intron 23212062 rs12123267 chr1 162199351 C T 1.67E-09 QT interval NOS1AP intron 23166209 rs4424487 chr1 162199362 T A 5.58E-07 White blood cell count NOS1AP intron 21738479 rs6664702 chr1 162204907 T C 5.46E-08 QT interval NOS1AP intron 23166209 rs4431825 chr1 162210471 A G 6.03E-06 White blood cell count NOS1AP intron 21738479 rs4657178 chr1 162210610 C T 7.00E-33 QT interval NOS1AP intron 19305409 rs10919021 chr1 162235390 C T 2.33E-10 Triglycerides NOS1AP intron 23063622 rs4497188 chr1 162235513 T C 5.83E-04 Multiple complex diseases NOS1AP intron 17554300 rs6427667 chr1 162244026 G C 4.97E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7511679 chr1 162247404 C T 4.91E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7525777 chr1 162247439 T C 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7528328 chr1 162247779 T C 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7528328 chr1 162247779 T C 1.10E-06 Urinary metabolites NOS1AP intron 21572414 rs7525955 chr1 162247832 A G 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7525955 chr1 162247832 A G 1.30E-06 Urinary metabolites NOS1AP intron 21572414 rs11800645 chr1 162248078 T G 4.89E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs6670958 chr1 162249715 G A 8.26E-05 Cognitive impairment induced by topiramate NOS1AP intron 22091778 rs2819325 chr1 162283511 G A 3.36E-08 Cholesterol,total NOS1AP intron 23063622 rs2819325 chr1 162283511 G A 5.76E-13 HDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 1.55E-16 Cholesterol,total NOS1AP intron 23063622 rs370911 chr1 162293305 A G 1.61E-14 LDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 2.60E-14 HDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 2.81E-08 Triglycerides NOS1AP intron 23063622 rs425820 chr1 162293664 G A 0.000000527 HDL cholesterol NOS1AP intron 23063622 rs12048222 chr1 162294094 A G 1.20E-05 Urinary metabolites NOS1AP intron 21572414 rs1912439 chr1 162294145 A G 2.63E-08 HDL cholesterol NOS1AP intron 23063622 rs1858232 chr1 162303838 A G 7.88E-04 Type 2 diabetes NOS1AP intron 17463246 rs347311 chr1 162303907 G C 7.62E-06 Cognitive decline NOS1AP intron 22054870 rs1858233 chr1 162303999 C T 6.22E-04 Response to cytadine analogues (cytosine arabinoside) NOS1AP intron 24483146 rs347313 chr1 162304276 A G 8.23E-04 Rheumatoid arthritis NOS1AP intron 21452313 rs10919200 chr1 162305160 G A 5.07E-04 Type 2 diabetes NOS1AP intron 17463246 rs347273 chr1 162317513 G A 1.75E-05 Word reading NOS1AP intron 23738518 rs347272 chr1 162318498 A G 1.57E-05 Word reading NOS1AP intron 23738518 rs11577628 chr1 162319524 A G 5.00E-06 Word reading NOS1AP intron 23738518 rs2661814 chr1 162320006 G A 1.05E-09 LDL cholesterol NOS1AP intron 23063622 rs12745104 chr1 162327313 C T 8.52E-05 Lipid levels NOS1AP intron pha003082 rs1510291 chr1 162328061 C T 0.000000473 HDL cholesterol NOS1AP intron 23063622 rs6681981 chr1 162331621 A G 5.70E-04 Alcohol dependence NOS1AP intron 20201924 rs16860953 chr1 162333917 G A 3.86E-08 LDL cholesterol NOS1AP UTR-5 23063622 rs10919293 chr1 162347618 A G 2.54E-04 Smoking quantity / / 24665060 rs4657188 chr1 162347877 G C 7.69E-07 White blood cell count / / 21738479 rs10494369 chr1 162357035 A G 8.48E-05 Taste perception / / 22132133 rs164420 chr1 162359746 T C 9.42E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs164423 chr1 162360279 A G 1.43E-04 Lung function (forced vital capacity) / / 24023788 rs2655732 chr1 162363732 A G 1.13E-04 Heart Failure / / pha002884 rs11804223 chr1 162412492 G C 8.67E-04 Multiple complex diseases / / 17554300 rs469726 chr1 162417107 G A 2.38E-04 Multiple complex diseases / / 17554300 rs6673387 chr1 162458412 C T 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17471292 chr1 162509510 T A 7.90E-07 Red blood cell traits / / 23222517 rs7545344 chr1 162540329 T C 0.000641 Salmonella-induced pyroptosis UAP1 intron 22837397 rs11585602 chr1 162551783 T C 1.02E-08 Metabolite levels UAP1 intron 23281178 rs10917570 chr1 162556810 C T 1.02E-08 Metabolite levels UAP1 intron 23281178 rs6672561 chr1 162559479 A G 2.27E-04 Type 2 diabetes UAP1 intron 17463246 rs10494372 chr1 162571578 G A 1.73E-04 Type 2 diabetes / / 17463246 rs7528465 chr1 162578873 T C 9.41E-05 Glucose levels / / pha003061 rs6668320 chr1 162580337 G C 2.06E-04 Type 2 diabetes / / 17463246 rs6702652 chr1 162597545 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7544972 chr1 162600119 T C 3.25E-04 Type 2 diabetes / / 17463246 rs10494373 chr1 162619362 A C 1.74E-05 Brain structure DDR2 intron 22504417 rs4233391 chr1 162639552 T C 2.20E-04 Multiple complex diseases DDR2 intron 17554300 rs4657219 chr1 162639774 G T 1.55E-04 Multiple complex diseases DDR2 intron 17554300 rs4657222 chr1 162644317 G C 8.88E-04 Multiple complex diseases DDR2 intron 17554300 rs10799862 chr1 162644411 T C 6.78E-04 Multiple complex diseases DDR2 intron 17554300 rs10917587 chr1 162661463 A G 1.29E-07 White blood cell count DDR2 intron 21738479 rs17433759 chr1 162673705 C T 5.95E-04 Type 2 diabetes DDR2 intron 17463246 rs16843850 chr1 162685018 C T 6.24E-04 Smoking initiation DDR2 intron 24665060 rs16843853 chr1 162685303 G A 6.24E-04 Smoking initiation DDR2 intron 24665060 rs10047103 chr1 162702302 C G 1.44E-04 Smoking initiation DDR2 intron 24665060 rs2684866 chr1 162726281 A C 4.55E-07 White blood cell count DDR2 intron 21738479 rs2805025 chr1 162732491 G A 5.68E-07 White blood cell count DDR2 intron 21738479 rs1779991 chr1 162733409 C T 1.52E-04 Smoking initiation DDR2 intron 24665060 rs1780007 chr1 162748025 A C 4.35E-07 White blood cell count DDR2 intron 21738479 rs1779999 chr1 162753092 C T 2.47E-06 White blood cell count / / 21738479 rs4656381 chr1 162776137 G A 3.93E-04 Colorectal cancer HSD17B7 intron 23266556 rs2684879 chr1 162802615 C A 4.11E-04 Colorectal cancer / / 23266556 rs2805042 chr1 162803754 G A 3.43E-04 Colorectal cancer / / 23266556 rs2684880 chr1 162810754 C T 3.23E-04 Colorectal cancer / / 23266556 rs6699770 chr1 162813432 G A 2.40E-04 Colorectal cancer / / 23266556 rs6691351 chr1 162813583 A G 1.71E-04 Colorectal cancer / / 23266556 rs6679069 chr1 162813651 C T 5.78E-04 Colorectal cancer / / 23266556 rs10737489 chr1 162813950 T C 1.24E-04 Colorectal cancer / / 23266556 rs1892124 chr1 162816583 A G 2.56E-06 Colorectal cancer / / 23266556 rs10753591 chr1 162817400 C T 8.17E-06 Colorectal cancer / / 23266556 rs1858236 chr1 162818421 A G 2.61E-04 Colorectal cancer / / 23266556 rs1912453 chr1 162821291 A G 9.00E-06 Colorectal cancer / / 23266556 rs11800473 chr1 162836981 C T 4.37E-05 HDL cholesterol C1orf110 intron pha003074 rs7555990 chr1 162841904 C T 1.73E-05 Cognitive test performance / / 20125193 rs12047510 chr1 162842202 T C 5.54E-05 Cleft lip / / 20436469 rs12047510 chr1 162842202 T C 5.36E-05 Orofacial clefts / / 22863734 rs7541250 chr1 162862158 C G 6.90E-05 Insulin resistance / / 21901158 rs12124253 chr1 162862846 A C 7.72E-04 Depression (quantitative trait) / / 20800221 rs12124253 chr1 162862846 A C 2.39E-06 White blood cell count / / 21738479 rs4657236 chr1 162864403 A T 1.76E-04 Depression (quantitative trait) / / 20800221 rs10917632 chr1 162864476 C T 2.41E-04 Depression (quantitative trait) / / 20800221 rs2343485 chr1 162864623 C T 9.79E-04 Insulin resistance / / 21901158 rs10917633 chr1 162865197 T C 3.40E-04 Depression (quantitative trait) / / 20800221 rs12730805 chr1 162873220 C A 7.90E-04 Alcohol dependence / / 20201924 rs16846622 chr1 162875195 G A 3.85E-04 Multiple complex diseases / / 17554300 rs17489752 chr1 162877069 G T 2.70E-05 Urinary metabolites / / 21572414 rs4657238 chr1 162880984 T C 2.00E-05 Urinary metabolites / / 21572414 rs10917638 chr1 162881137 T C 5.56E-05 Cervical cancer / / 24700089 rs6681091 chr1 162905434 T G 2.40E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1961879 chr1 162914749 C T 2.61E-04 Heart Failure / / pha002885 rs12021880 chr1 162920421 T C 8.22E-07 Glaucoma-related traits / / 22058429 rs2343331 chr1 162930820 C T 2.49E-05 Crohn's disease / / 17435756 rs2880605 chr1 162932038 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12403644 chr1 162936636 T A 1.30E-05 Urinary metabolites / / 21572414 rs17438400 chr1 162938179 C T 5.57E-08 Metabolite levels / / 23281178 rs12126781 chr1 162940693 A G 1.30E-08 Metabolite levels / / 23281178 rs16847292 chr1 162944464 T C 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11580679 chr1 162944573 A G 8.30E-06 Urinary metabolites / / 21572414 rs7340068 chr1 162946949 G A 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2661322 chr1 162961560 G C,T 7.22E-08 Metabolite levels / / 23281178 rs2842006 chr1 163009498 T C 7.71E-06 Schizophrenia / / 19197363 rs2661339 chr1 163018934 T G 1.31E-04 Age-related macular degeneration / / 22125219 rs2661275 chr1 163031580 T C 6.66E-05 Type 2 diabetes / / 17463246 rs2661275 chr1 163031580 T C 3.72E-05 Schizophrenia / / 20832056 rs2661274 chr1 163031621 C T 6.98E-05 Type 2 diabetes / / 17463246 rs2661274 chr1 163031621 C T 2.83E-05 Schizophrenia / / 20832056 rs10917670 chr1 163032842 C T 1 Drug response to Risperidone / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Perphenazine RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Quetiapine RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Risperidone RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Ziprasidone RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Perphenazine RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Quetiapine RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Risperidone RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Ziprasidone RGS4 intron 18204343 rs2842030 chr1 163040495 G T 1 Drug response to Perphenazine RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Quetiapine RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Risperidone RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Ziprasidone RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Perphenazine RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Quetiapine RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Risperidone RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Ziprasidone RGS4 intron 17588543 rs10759 chr1 163046351 G T 2.67E-04 Smoking initiation RGS4 UTR-3 24665060 rs2841957 chr1 163053018 C T 4.45E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2063142 chr1 163053289 A G 4.00E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2841959 chr1 163058194 T C 5.70E-05 Telomere length / / 23900074 rs1507740 chr1 163075021 C T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1507740 chr1 163075021 C T 0.00000464 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress / / 22550155 rs2841984 chr1 163086196 G C 1.32E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1507739 chr1 163087085 G A 1.31E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6691456 chr1 163090421 A G 0.0008 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs6691456 chr1 163090421 A G 2.33E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2841993 chr1 163111066 C T 2.36E-05 Monocyte counts / / pha003089 rs3806368 chr1 163113878 G A 5.39E-04 Multiple complex diseases RGS5 UTR-3 17554300 rs1054943 chr1 163114096 G C 6.69E-06 Multiple complex diseases RGS5 UTR-3 17554300 rs7540909 chr1 163132634 C T 7.07E-04 Heart Failure RGS5 intron pha002884 rs12035879 chr1 163142555 G A 4.00E-06 Liver enzyme levels (alanine transaminase) RGS5 intron 24124411 rs10917693 chr1 163145664 T C 5.72E-04 Smoking initiation RGS5 intron 24665060 rs4657247 chr1 163151897 C T 2.96E-05 Bipolar disorder RGS5 intron 19488044 rs4657247 chr1 163151897 C T 1.05E-05 Bipolar Disorder RGS5 intron pha002863 rs12566267 chr1 163153168 T G 2.48E-05 Bipolar disorder RGS5 intron 19488044 rs12566267 chr1 163153168 T G 8.82E-06 Bipolar Disorder RGS5 intron pha002863 rs4132246 chr1 163154369 A C,G 4.90E-05 Bipolar Disorder RGS5 intron pha002863 rs7513108 chr1 163163777 T G 4.54E-05 Erythrocyte counts RGS5 intron pha003101 rs937925 chr1 163228151 T C 9.41E-06 Tunica Media RGS5 intron pha003034 rs937925 chr1 163228151 T C 2.39E-05 Tunica Media RGS5 intron pha003036 rs3010367 chr1 163258354 T C 4.58E-05 Serum metabolites RGS5 intron 19043545 rs16852030 chr1 163260844 A G 1.02E-05 Tunica Media RGS5 intron pha003034 rs16852030 chr1 163260844 A G 4.71E-05 Tunica Media RGS5 intron pha003036 rs3010370 chr1 163282358 G A 6.82E-05 Serum metabolites RGS5 intron 19043545 rs2136241 chr1 163289571 C T 7.76E-05 Cognitive test performance RGS5 intron 20125193 rs2136241 chr1 163289571 C T 6.90E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines RGS5 intron 21844884 rs12408485 chr1 163289988 G A 2.80E-05 Urinary metabolites RGS5 intron 21572414 rs3806364 chr1 163290473 G C 2.20E-05 Urinary metabolites RGS5 intron 21572414 rs2292275 chr1 163292217 T C 1.60E-05 Urinary metabolites NUF2 intron 21572414 rs2292275 chr1 163292217 T C 4.81E-04 Body mass index NUF2 intron 21701565 rs2292275 chr1 163292217 T C 5.11E-06 White blood cell count NUF2 intron 21738479 rs12735996 chr1 163296293 C G 2.40E-05 Urinary metabolites NUF2 intron 21572414 rs2136243 chr1 163302789 T C 3.74E-04 Body mass index NUF2 intron 21701565 rs2136243 chr1 163302789 T C 6.72E-07 White blood cell count NUF2 intron 21738479 rs11802875 chr1 163313539 C T 9.09E-04 Multiple complex diseases NUF2 missense 17554300 rs17362993 chr1 163313880 G A 1.70E-04 Myasthenia gravis NUF2 intron 23055271 rs1396544 chr1 163330805 G A 6.57E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1995785 chr1 163332621 G A 2.10E-04 Interstitial lung disease / / 23583980 rs1995785 chr1 163332621 G A 7.84E-04 Smoking initiation / / 24665060 rs12735960 chr1 163341499 T C 9.59E-05 Bipolar disorder / / 18317468 rs3013493 chr1 163355061 A G 3.52E-05 Multiple complex diseases / / 17554300 rs6689760 chr1 163358704 C T 1.08E-04 Multiple complex diseases / / 17554300 rs17363368 chr1 163358833 A G 2.38E-04 Type 2 diabetes / / 17463246 rs6704467 chr1 163364512 A G 5.80E-05 Multiple complex diseases / / 17554300 rs6704467 chr1 163364512 A G 8.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4638099 chr1 163365521 C T 7.54E-05 Multiple complex diseases / / 17554300 rs17359359 chr1 163372030 G A 1.78E-04 Type 2 diabetes / / 17463246 rs17359359 chr1 163372030 G A 1.10E-04 Plasma trimethylamine N-oxide levels / / 24675659 rs4657270 chr1 163378647 G A 8.88E-05 Iron status biomarkers / / 19084217 rs4265409 chr1 163414559 C T 5.12E-04 Multiple complex diseases / / 17554300 rs12734758 chr1 163420695 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10917759 chr1 163435598 A G 9.65E-04 Type 2 diabetes / / 17463246 rs12139998 chr1 163441103 A C 9.22E-04 Type 2 diabetes / / 17463246 rs10917773 chr1 163449989 C T 9.32E-04 Intraocular pressure / / 23836780 rs12119063 chr1 163453573 T G 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10917775 chr1 163454111 G A 7.45E-04 Type 2 diabetes / / 17463246 rs10917775 chr1 163454111 G A 9.69E-06 Personality dimensions / / 22628180 rs1890798 chr1 163457348 T C 2.19E-05 Lung adenocarcinoma / / 19836008 rs16854856 chr1 163460730 C T 4.39E-04 Multiple complex diseases / / 17554300 rs2791136 chr1 163470515 T C 5.12E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2791138 chr1 163470851 T C 8.91E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6427740 chr1 163478748 G C 4.26E-04 Body mass index / / 21701565 rs16855237 chr1 163480472 C A 1.97E-04 Multiple complex diseases / / 17554300 rs12565565 chr1 163482240 A G 7.82E-04 Body mass index / / 21701565 rs12038132 chr1 163483608 T C 7.12E-04 Body mass index / / 21701565 rs3001089 chr1 163500711 T G 5.00E-07 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs2791131 chr1 163507977 G A 9.58E-06 Prion diseases / / 22210626 rs6679806 chr1 163528747 G A 6.31E-04 Iron levels / / pha002876 rs12034856 chr1 163544574 A G 9.33E-06 White blood cell count / / 21738479 rs16858747 chr1 163698330 C A 7.27E-04 Multiple complex diseases / / 17554300 rs1932355 chr1 163714719 A G 0.00000229 Fasting blood glucose / / 22216000 rs10494397 chr1 163735376 C T 9.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4657305 chr1 163762232 T C 1.16E-05 Osteoarthritis (knee and hip) / / 21177295 rs4657305 chr1 163762232 T C 7.16E-05 Osteoarthritis (knee and hip) / / 21177295 rs6671893 chr1 163775335 A G 2.20E-05 Urinary metabolites / / 21572414 rs1016610 chr1 163781066 T C 5.30E-05 Serum metabolites / / 19043545 rs7553942 chr1 163781591 G A 8.03E-05 Serum metabolites / / 19043545 rs12031632 chr1 163801544 A G 4.86E-05 Serum metabolites / / 19043545 rs10917866 chr1 163810259 C G 9.22E-05 Serum metabolites / / 19043545 rs796694 chr1 163829349 C A 1.00E-05 Prostate cancer / / 21743057 rs10494400 chr1 163830144 T C 1.07E-04 Type 2 diabetes / / 17463246 rs781934 chr1 163838187 C T 1.00E-05 Prostate cancer / / 21743057 rs16861608 chr1 163855085 C T 1.90E-06 Urinary metabolites / / 21572414 rs6669526 chr1 163857031 C T 9.52E-04 Obesity (extreme) / / 21935397 rs2346102 chr1 163857585 G T 2.06E-09 LDL cholesterol / / 23063622 rs6661534 chr1 163859805 G A 6.60E-06 Urinary metabolites / / 21572414 rs1441178 chr1 163864334 C T 7.53E-05 Stroke / / pha002887 rs1441178 chr1 163864334 C T 6.76E-05 Cholesterol / / pha003083 rs1816756 chr1 163866023 C T 2.93E-05 Cholesterol / / pha003083 rs2881310 chr1 163887606 G A 5.80E-05 Personality dimensions / / 18957941 rs2881310 chr1 163887606 G A 3.30E-06 Urinary metabolites / / 21572414 rs1961041 chr1 163906277 T C 1.27E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs16823121 chr1 163912475 T C 9.20E-06 Urinary metabolites / / 21572414 rs4657319 chr1 163912523 G C,T 7.14E-04 Bipolar disorder / / 19259986 rs4657319 chr1 163912523 G C,T 1.96E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12033122 chr1 163917950 C A 9.44E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12027802 chr1 163919788 G A 3.38E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1444439 chr1 163950439 A G 8.39E-04 Myocardial Infarction / / pha002873 rs424950 chr1 163956503 G C 5.00E-06 Sex hormone-binding globulin levels / / 22675492 rs260913 chr1 163968414 T C 3.26E-04 Smoking quantity / / 24665060 rs7551501 chr1 164011540 C T 4.92E-04 Multiple complex diseases / / 17554300 rs3929860 chr1 164085202 T A 4.39E-04 Multiple complex diseases / / 17554300 rs10800006 chr1 164120948 A T 2.79E-05 Body mass (lean) / / 19268274 rs7539840 chr1 164127511 G A 3.27E-05 Body mass (lean) / / 19268274 rs7551656 chr1 164127702 T C 2.75E-05 Body mass (lean) / / 19268274 rs6686539 chr1 164131343 A T 4.18E-05 Body mass (lean) / / 19268274 rs803441 chr1 164183831 G A 2.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6697445 chr1 164211914 G C 1.63E-04 Lipid levels / / 19016617 rs6697445 chr1 164211914 G C 5.02E-04 Lipid levels / / 19016617 rs16826875 chr1 164212053 G A 7.42E-04 Multiple complex diseases / / 17554300 rs10494412 chr1 164212480 T C 1.63E-04 Lipid levels / / 19016617 rs10494412 chr1 164212480 T C 7.00E-04 Lipid levels / / 19016617 rs10494413 chr1 164213652 G A 1.45E-04 Lipid levels / / 19016617 rs10494413 chr1 164213652 G A 6.56E-04 Lipid levels / / 19016617 rs4142895 chr1 164226999 T A 2.40E-05 Urinary metabolites / / 21572414 rs6682660 chr1 164227437 C A 3.96E-04 Type 2 diabetes / / 17463246 rs11809129 chr1 164229645 T C 6.58E-04 Type 2 diabetes / / 17463246 rs10917967 chr1 164230383 A G 4.97E-04 Type 2 diabetes / / 17463246 rs10917967 chr1 164230383 A G 1.80E-05 Urinary metabolites / / 21572414 rs1934038 chr1 164242726 T C 7.29E-06 White blood cell count / / 21738479 rs1578087 chr1 164244096 T A,G 7.71E-06 White blood cell count / / 21738479 rs16828112 chr1 164284812 G A 4.40E-04 Multiple complex diseases / / 17554300 rs9287061 chr1 164328387 T C 2.03E-06 Statin-induced myopathy / / 21826682 rs769305 chr1 164331903 A C 4.68E-04 Multiple complex diseases / / 17554300 rs16829156 chr1 164332201 G A 1.99E-05 Multiple complex diseases / / 17554300 rs12566285 chr1 164400183 C A 7.52E-04 Type 2 diabetes / / 17463246 rs1289726 chr1 164412847 G T 1.74E-04 Schizophrenia / / 19197363 rs10918010 chr1 164426985 C T 6.96E-04 Alzheimer's disease / / 17998437 rs12723400 chr1 164440415 G A 7.02E-05 stroke (ischemic) / / 17434096 rs1538370 chr1 164447212 A G 2.69E-05 Multiple sclerosis (age of onset) / / 19010793 rs10494417 chr1 164447438 A G 9.44E-05 Post-operative nausea and vomiting / / 21694509 rs7550193 chr1 164452742 G C 1.47E-04 Nicotine dependence / / 17158188 rs7517505 chr1 164453373 T C 1.58E-04 Nicotine dependence / / 17158188 rs2027290 chr1 164454550 A C 1.42E-04 Nicotine dependence / / 17158188 rs10800021 chr1 164454649 C G 1.86E-04 Nicotine dependence / / 17158188 rs10800030 chr1 164491497 A G 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12038282 chr1 164534207 A G 5.70E-05 Diabetic retinopathy PBX1 intron 21441570 rs12039194 chr1 164537228 G A 5.40E-05 Diabetic retinopathy PBX1 intron 21441570 rs2800791 chr1 164563425 A G 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PBX1 intron 20031582 rs16833167 chr1 164580108 T C 1.57E-04 Multiple complex diseases PBX1 intron 17554300 rs2800785 chr1 164583573 G C 3.18E-04 Coronary Artery Disease PBX1 intron 17634449 rs16833488 chr1 164609582 C T 7.25E-04 Amyotrophic Lateral Sclerosis PBX1 intron 17362836 rs16833488 chr1 164609582 C T 1.22E-05 Orofacial clefts PBX1 intron 22419666 rs2800780 chr1 164611689 A G 6.00E-07 Urinary metabolites PBX1 intron 21572414 rs10494419 chr1 164611901 T G 2.12E-04 Alcohol dependence PBX1 intron 21314694 rs2800779 chr1 164612150 T G 4.79E-04 Multiple complex diseases PBX1 intron 17554300 rs10800040 chr1 164618913 T C 3.49E-04 Body mass index PBX1 intron 21701565 rs1387390 chr1 164628310 C T 3.78E-04 Body mass index PBX1 intron 21701565 rs41515147 chr1 164636953 G A 1.06E-04 Multiple complex diseases PBX1 intron 17554300 rs1552560 chr1 164656976 T C 1.09E-04 Acute lung injury PBX1 intron 22295056 rs1780352 chr1 164663211 C T 4.24E-05 Monocyte chemoattractant protein-1 PBX1 intron pha003071 rs2800798 chr1 164666253 G A 4.83E-05 Monocyte chemoattractant protein-1 PBX1 intron pha003071 rs10494420 chr1 164683116 G A 1.04E-05 Varicose Veins PBX1 intron pha001411 rs1489333 chr1 164683738 A G 9.73E-05 Aging (time to event) PBX1 intron 21782286 rs1387389 chr1 164689762 G A 4.00E-06 Breast cancer (prognosis) PBX1 intron 23319801 rs1489331 chr1 164690183 A G 7.20E-04 Multiple complex diseases PBX1 intron 17554300 rs10494421 chr1 164738727 C T 1.50E-05 Urinary metabolites PBX1 intron 21572414 rs6670655 chr1 164739171 T C 3.00E-06 Height PBX1 intron 20966902 rs12736383 chr1 164739573 A G 1.50E-05 Urinary metabolites PBX1 intron 21572414 rs10494422 chr1 164781015 A C 5.09E-04 Nicotine smoking PBX1 intron 19268276 rs3767367 chr1 164782006 A G 4.82E-04 Parkinson's disease PBX1 intron 17052657 rs956409 chr1 164786799 G A 1.03E-05 Taste perception PBX1 intron 22132133 rs3767364 chr1 164790534 A G 1.84E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer PBX1 intron 21483023 rs9887944 chr1 164800483 A G 6.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PBX1 intron 20877124 rs1107533 chr1 164807125 A G 9.29E-05 Body mass (lean) PBX1 intron 19268274 rs12081132 chr1 164809687 A G 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PBX1 intron 20877124 rs10918081 chr1 164825891 T C 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs4345787 chr1 164828928 T C 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1890535 chr1 164829035 A G 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1890535 chr1 164829035 A G 3.32E-05 Coronary restenosis / / 21878436 rs10918083 chr1 164837493 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11580794 chr1 164856772 A G 3.53E-04 Hearing function / / 17255346 rs1936078 chr1 164879202 G A 3.51E-04 Fibrinogen / / 17255346 rs1936078 chr1 164879202 G A 3.29E-04 White matter integrity / / 22425255 rs1419067 chr1 164922847 G A 7.74E-05 Chronic Hepatitis C infection / / 21725309 rs1891737 chr1 164928753 A C 5.03E-04 White matter integrity / / 22425255 rs1936085 chr1 164931749 A G 1.10E-04 Type 2 diabetes / / 17463246 rs4275431 chr1 164934462 G A 1.50E-05 Schizophrenia / / 19571808 rs1954402 chr1 164935156 A T 8.51E-05 Multiple complex diseases / / 17554300 rs7516582 chr1 164936976 T C 1.18E-04 Multiple complex diseases / / 17554300 rs7516582 chr1 164936976 T C 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10800062 chr1 164940608 A C 9.10E-05 Type 2 diabetes / / 23209189 rs1573182 chr1 164958641 A G 3.20E-05 Schizophrenia / / 19571808 rs1419070 chr1 164968421 A C 9.30E-05 Schizophrenia / / 19571808 rs6702388 chr1 164970360 T C 8.49E-05 Neuroticism / / 23229837 rs723821 chr1 165016712 C A 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs723821 chr1 165016712 C A 7.80E-04 Coronary heart disease / / 21606135 rs723821 chr1 165016712 C A 2.60E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs723822 chr1 165016732 A T 7.44E-04 Coronary heart disease / / 21606135 rs12049436 chr1 165032101 T C 1.80E-05 Urinary metabolites / / 21572414 rs12049436 chr1 165032101 T C 7.89E-05 Cognitive decline / / 23732972 rs10494430 chr1 165036995 T C 5.99E-05 Schizophrenia / / 19571809 rs12119600 chr1 165038271 G A 4.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs6426897 chr1 165102499 G A 7.86E-04 Tourette syndrome / / 22889924 rs60624478 chr1 165107979 G A 6.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs60950492 chr1 165110832 A G 4.05E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs1394443 chr1 165128583 A G 7.20E-06 Urinary metabolites / / 21572414 rs1343546 chr1 165137227 A G 2.00E-05 Urinary metabolites / / 21572414 rs903339 chr1 165137560 G A 1.50E-05 Urinary metabolites / / 21572414 rs1891927 chr1 165138246 G A 5.83E-05 Myopia (pathological) / / 21640322 rs968853 chr1 165146572 G A 2.60E-05 Urinary metabolites / / 21572414 rs1891931 chr1 165160578 G T 9.70E-07 Urinary metabolites / / 21572414 rs1891931 chr1 165160578 G T 9.70E-06 Obesity-related traits / / 23251661 rs989335 chr1 165161763 A G 7.44E-05 Heart Rate / / pha003053 rs7416223 chr1 165170050 C T 0.00000781 Inter-adventitial common carotid artery diameter / / 23246012 rs4656435 chr1 165175374 G A 5.05E-04 Response to cytidine analogues (gemcitabine) LMX1A intron 24483146 rs1354510 chr1 165175515 A G 7.78E-05 Response to acetaminophen (hepatotoxicity) LMX1A intron 21177773 rs1532815 chr1 165180089 T A 6.00E-07 Response to acetaminophen (hepatotoxicity) LMX1A intron 21177773 rs10494436 chr1 165196400 A G 1.90E-05 Urinary metabolites LMX1A intron 21572414 rs10494438 chr1 165199023 G A 6.92E-05 Body Fat Distribution LMX1A intron pha003017 rs1394439 chr1 165213822 G A 8.48E-04 Response to TNF antagonist treatment LMX1A intron 21061259 rs10918143 chr1 165222368 C T 3.11E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMX1A intron 20877124 rs10918143 chr1 165222368 C T 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMX1A intron 20877124 rs6656615 chr1 165241580 T A 1.25E-04 Insulin resistance LMX1A intron 21901158 rs6662186 chr1 165264733 A C 1.20E-04 Pulmonary function LMX1A intron 23932459 rs875822 chr1 165286563 T G 2.80E-05 Urinary metabolites LMX1A intron 21572414 rs1395548 chr1 165313427 A C 1.22E-06 Bone mass and geometry LMX1A intron 17903296 rs10918148 chr1 165317732 C T 1.90E-05 Urinary metabolites LMX1A intron 21572414 rs12081765 chr1 165341849 A G 7.52E-04 Response to TNF antagonist treatment / / 21061259 rs1506942 chr1 165341896 G C 1.08E-12 Multiple complex diseases / / 17554300 rs17469292 chr1 165365379 A G 7.30E-05 Response to ximelagatran treatment / / 17505501 rs2134095 chr1 165377552 G A 5.10E-04 Major depressive disorder RXRG cds-synon 22472876 rs3767339 chr1 165378064 A C 6.42E-04 Major depressive disorder RXRG intron 22472876 rs10489744 chr1 165380623 G A 6.86E-04 Major depressive disorder RXRG intron 22472876 rs466639 chr1 165394882 T C 1.00E-13 Menarche (age at onset) RXRG intron 21102462 rs466639 chr1 165394882 T C 4.80E-06 Urinary metabolites RXRG intron 21572414 rs157879 chr1 165398844 T G 9.30E-06 Urinary metabolites RXRG intron 21572414 rs285480 chr1 165403903 G A 4.00E-07 Personality dimensions RXRG intron 21368711 rs10800098 chr1 165409095 G A 4.00E-06 AIDS RXRG intron 19754311 rs285482 chr1 165410723 G T 3.03E-04 Multiple complex diseases RXRG intron 17554300 rs752739 chr1 165412959 G A 6.72E-04 Suicide attempts in bipolar disorder RXRG intron 21423239 rs285428 chr1 165422559 T C 0.00089 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs12402931 chr1 165423287 C A 2.60E-05 Urinary metabolites / / 21572414 rs7519141 chr1 165425536 A G 3.98E-04 Multiple complex diseases / / 17554300 rs7519629 chr1 165425966 A G 2.46E-04 Multiple complex diseases / / 17554300 rs2859731 chr1 165436058 T G 3.72E-05 Psoriasis / / 18364390 rs4657443 chr1 165436331 G A 8.30E-05 Personality dimensions / / 18957941 rs10800102 chr1 165438912 T C 8.90E-05 Personality dimensions / / 18957941 rs962979 chr1 165440058 G A 8.90E-05 Personality dimensions / / 18957941 rs10918196 chr1 165448157 T C 9.00E-06 Lentiform nucleus volume LOC400794 intron 22903471 rs285483 chr1 165454213 G A 5.30E-04 Alzheimer's disease LOC400794 intron 24755620 rs184041 chr1 165462091 G C 5.29E-04 Response to taxane treatment (placlitaxel) LOC400794 intron 23006423 rs184043 chr1 165464051 G A 8.01E-04 Type 2 diabetes LOC400794 intron 17463246 rs184043 chr1 165464051 G A 3.82E-04 Coronary heart disease LOC400794 intron 21971053 rs285477 chr1 165483326 T G 9.55E-04 Multiple complex diseases LOC400794 intron 17554300 rs285463 chr1 165486905 T C 3.40E-04 Taste perception LOC400794 intron 22132133 rs285461 chr1 165497692 T C 9.56E-05 Pulmonary function in asthmatics LOC400794 intron 23541324 rs2254782 chr1 165505504 A G 5.55E-04 Multiple complex diseases LOC400794 intron 17554300 rs285439 chr1 165517729 C T 3.50E-08 Lymphocyte counts LOC400794 intron 22286170 rs952375 chr1 165559225 A G 3.17E-04 Tourette syndrome / / 22889924 rs1337441 chr1 165573850 A G 3.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1337446 chr1 165576753 C T 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6690679 chr1 165597321 C T 8.38E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6657788 chr1 165599804 A G 1.13E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4147592 chr1 165600146 G A 3.20E-06 Fasting plasma glucose MGST3 UTR-5 19060907 rs6686643 chr1 165616588 T C 7.00E-06 Total ventricular volume MGST3 intron 21116278 rs2297765 chr1 165622207 C T 6.84E-05 Meningococcal disease MGST3 intron 20694013 rs11506 chr1 165631506 A G 8.48E-05 Melanoma ALDH9A1 UTR-3 21926416 rs12080699 chr1 165639043 C G 9.90E-05 Response to statin therapy ALDH9A1 intron 20339536 rs2882006 chr1 165651153 T A 6.10E-07 Lymphocyte counts ALDH9A1 intron 22286170 rs1913844 chr1 165651502 G C 0.0000699 Panic disorder ALDH9A1 intron 23149450 rs1913844 chr1 165651502 G C 6.99E-05 Serum tamsulosin hydrochloride concentration ALDH9A1 intron 23151678 rs17452017 chr1 165684677 C T 3.00E-04 Bipolar disorder / / 24387768 rs4656461 chr1 165687205 G A 6.00E-14 Glaucoma / / 21532571 rs4656461 chr1 165687205 G A 9.60E-06 Intraocular pressure / / 22570627 rs4656461 chr1 165687205 G A 8.30E-07 Intraocular pressure / / 24002674 rs7524755 chr1 165694897 T C 7.80E-06 Intraocular pressure TMCO1 UTR-3 22570627 rs1913845 chr1 165695579 C T 1.16E-05 Serum metabolites TMCO1 UTR-3 19043545 rs6660601 chr1 165695855 C T 7.50E-06 Intraocular pressure TMCO1 UTR-3 22570627 rs10918271 chr1 165704732 C T 8.89E-06 Blood Pressure TMCO1 intron pha003043 rs6696454 chr1 165707923 T C 6.40E-06 Intraocular pressure TMCO1 intron 22570627 rs7555523 chr1 165718979 C A 2.00E-08 Intraocular pressure TMCO1 intron 22570627 rs7555523 chr1 165718979 C A 1.88E-04 Intraocular pressure TMCO1 intron 23836780 rs17418864 chr1 165732482 T C 7.25E-04 Multiple complex diseases TMCO1 intron 17554300 rs17418864 chr1 165732482 T C 1.40E-05 Urinary metabolites TMCO1 intron 21572414 rs4657476 chr1 165732661 C T 6.40E-06 Intraocular pressure TMCO1 intron 22570627 rs7518099 chr1 165736880 C T 2.14E-05 Glaucoma TMCO1 intron 21532571 rs7518099 chr1 165736880 C T 7.80E-06 Intraocular pressure TMCO1 intron 22570627 rs7518099 chr1 165736880 C T 1.04E-04 Intraocular pressure TMCO1 intron 23836780 rs7518099 chr1 165736880 C T 8.00E-08 Intraocular pressure TMCO1 intron 24002674 rs2790053 chr1 165737704 C G 7.70E-06 Intraocular pressure TMCO1 intron 22570627 rs2251768 chr1 165738311 A T 7.70E-06 Intraocular pressure / / 22570627 rs2790052 chr1 165738463 G C 7.60E-06 Intraocular pressure / / 22570627 rs2814471 chr1 165739598 C T 7.40E-06 Intraocular pressure LOC100147773 intron 22570627 rs12562047 chr1 165829156 T G 0.000027 Aging UCK2 intron 22445811 rs4657482 chr1 165831649 A G 2.00E-06 Testicular germ cell tumor UCK2 intron 19483681 rs4657482 chr1 165831649 A G 2.00E-06 Nasopharyngeal carcinoma UCK2 intron 20512145 rs4657482 chr1 165831649 A G 4.67E-06 Statin-induced myopathy UCK2 intron 21826682 rs4657482 chr1 165831649 A G 6.00E-06 Testicular germ cell tumor UCK2 intron 23666239 rs3790672 chr1 165873392 T C 2.00E-08 Testicular germ cell tumor UCK2 intron 23666240 rs3790674 chr1 165873619 A G 6.37E-04 Multiple complex diseases UCK2 intron 17554300 rs12118019 chr1 165887138 G C 1.50E-05 Urinary metabolites / / 21572414 rs561315 chr1 165887397 C G 7.00E-06 Urinary metabolites / / 21572414 rs530717 chr1 165887761 C T 2.10E-05 Urinary metabolites / / 21572414 rs505877 chr1 165893530 C T 5.40E-06 Urinary metabolites / / 21572414 rs4657493 chr1 165917109 G T 6.98E-04 Stroke / / pha002887 rs16853832 chr1 165919309 G A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs4540635 chr1 165924619 T G 4.42E-04 White matter integrity / / 22425255 rs7524799 chr1 165935581 T C 6.74E-06 Chronic obstructive pulmonary disease / / 19300482 rs7522756 chr1 165961938 A G 1.44E-05 Chronic obstructive pulmonary disease / / 19300482 rs732285 chr1 165967420 G A 4.86E-05 Chronic obstructive pulmonary disease / / 19300482 rs732285 chr1 165967420 G A 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6426962 chr1 165996331 A C 1.94E-05 Chronic obstructive pulmonary disease / / 19300482 rs12139648 chr1 166004371 G T 8.38E-05 Sudden cardiac arrest / / 21658281 rs1319898 chr1 166007024 C T 5.99E-05 Lung adenocarcinoma / / 19836008 rs6426968 chr1 166083488 T G 4.62E-05 Serum metabolites FAM78B intron 19043545 rs7513325 chr1 166084296 A G 4.11E-05 Serum metabolites FAM78B intron 19043545 rs4074897 chr1 166086171 G A 0.000012 Chronic kidney disease FAM78B intron 23539754 rs4656479 chr1 166107783 A G 9.57E-04 Multiple complex diseases FAM78B intron 17554300 rs9787101 chr1 166118896 C T 9.99E-05 Serum metabolites FAM78B intron 19043545 rs9651038 chr1 166128406 A G 8.74E-10 Multiple complex diseases FAM78B intron 17554300 rs2116519 chr1 166130218 G A 0.0000011 Chronic kidney disease FAM78B intron 23539754 rs12144426 chr1 166152034 T A 0.000035 Primary sclerosing cholangitis / / 22521342 rs6658513 chr1 166166695 G A 7.50E-06 Primary sclerosing cholangitis / / 19944697 rs7552225 chr1 166170361 C G 1.10E-05 Primary sclerosing cholangitis / / 19944697 rs1451606 chr1 166174572 G A 8.42E-06 Serum metabolites / / 19043545 rs1451606 chr1 166174572 G A 1.70E-05 Primary sclerosing cholangitis / / 19944697 rs10753713 chr1 166174854 C T 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10753714 chr1 166174940 C G 8.30E-06 Primary sclerosing cholangitis / / 19944697 rs896403 chr1 166176043 T C 1.50E-06 Primary sclerosing cholangitis / / 21151127 rs4391646 chr1 166177384 T C 8.80E-07 Primary sclerosing cholangitis / / 21151127 rs6678400 chr1 166177760 G T 9.50E-07 Primary sclerosing cholangitis / / 21151127 rs1432122 chr1 166226118 A G 9.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs2599513 chr1 166235714 T C 2.03E-04 Vaspin levels / / 22907691 rs2599513 chr1 166235714 T C 0.0002028 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs16856830 chr1 166251769 C T 5.76E-04 Multiple complex diseases / / 17554300 rs16856830 chr1 166251769 C T 5.20E-05 Primary sclerosing cholangitis / / 19944697 rs2568106 chr1 166264243 C T 1.12E-04 Vaspin levels / / 22907691 rs2568106 chr1 166264243 C T 0.0001063 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2568106 chr1 166264243 C T 0.0001122 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs4575063 chr1 166271612 T C 8.85E-04 Multiple complex diseases / / 17554300 rs10800212 chr1 166302712 A G 1.30E-05 Urinary metabolites / / 21572414 rs7523538 chr1 166317814 A G 6.70E-05 Femoral neck bone geometry / / 22087292 rs7523538 chr1 166317814 A G 0.00029 Fasting blood glucose / / 22216000 rs16857044 chr1 166348632 G A 9.67E-04 Myopia (pathological) / / 21095009 rs16857044 chr1 166348632 G A 3.90E-04 Insulin resistance / / 21901158 rs12746568 chr1 166356784 T C 2.06E-04 Celiac disease / / 23936387 rs16857179 chr1 166448963 A C 2.02E-05 Coronary heart disease / / pha003032 rs7552571 chr1 166456476 T G 3.75E-04 Multiple complex diseases / / 17554300 rs4002 chr1 166540210 G A 4.04E-04 Tourette syndrome / / 22889924 rs10918532 chr1 166545275 C T 6.98E-04 Tourette syndrome / / 22889924 rs17431003 chr1 166545748 A G 2.28E-04 Tourette syndrome / / 22889924 rs10494467 chr1 166550436 G A 8.68E-04 Sarcoidosis / / 21540310 rs7539202 chr1 166552723 T C 5.48E-05 Serum metabolites / / 19043545 rs472652 chr1 166564305 C T 3.17E-04 Alzheimer's disease (late onset) / / 21379329 rs12741275 chr1 166593754 T C 9.85E-06 Obesity-related traits FMO9P intron 23251661 rs714339 chr1 166595209 C T 8.91E-05 Stroke / / pha002886 rs12120439 chr1 166601757 C T 3.01E-04 Tourette syndrome / / 22889924 rs491814 chr1 166607463 C T 1.76E-04 Vaspin levels / / 22907691 rs491814 chr1 166607463 C T 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3125821 chr1 166610608 G A 1.76E-04 Vaspin levels / / 22907691 rs3125821 chr1 166610608 G A 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3845541 chr1 166618118 T G 6.25E-04 Bipolar disorder,schizoaffective / / 19567891 rs565064 chr1 166628260 C T 1.76E-04 Vaspin levels / / 22907691 rs565064 chr1 166628260 C T 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs577317 chr1 166631034 A G 2.28E-04 Substance dependence / / 21818250 rs579089 chr1 166631859 T C 1.76E-04 Vaspin levels / / 22907691 rs579089 chr1 166631859 T C 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3904701 chr1 166634268 G C 6.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs190191518 chr1 166656404 C T 9.71E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11807188 chr1 166656798 T C 5.88E-04 Stroke / / pha002886 rs7517690 chr1 166662705 C T 8.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs540656 chr1 166669237 G A 2.73E-05 Stroke / / pha002886 rs579100 chr1 166674289 A C 2.63E-04 Insulin resistance / / 21901158 rs1856091 chr1 166686630 G A 7.14E-04 Insulin resistance / / 21901158 rs4657594 chr1 166706135 C T 1.04E-04 Insulin resistance / / 21901158 rs1815531 chr1 166717206 T C 2.12E-05 Cognitive test performance / / 20125193 rs563244 chr1 166730775 A C 2.85E-04 Stroke / / pha002886 rs480820 chr1 166758542 A C 4.03E-04 Alzheimer's disease (late onset) / / 21379329 rs858796 chr1 166765794 T C 6.47E-04 Smoking initiation / / 24665060 rs858798 chr1 166766242 T C 4.68E-04 Smoking initiation / / 24665060 rs858814 chr1 166772579 T C 7.41E-04 Smoking initiation / / 24665060 rs6667673 chr1 166777148 A G 1.13E-05 Bilirubin levels,in serum / / 19389676 rs16858093 chr1 166777544 T C 5.58E-04 Multiple complex diseases / / 17554300 rs2205647 chr1 166778754 C A 1.12E-05 Bilirubin levels,in serum / / 19389676 rs10157620 chr1 166794977 G T 4.42E-04 Smoking initiation / / 24665060 rs4656517 chr1 166856059 G A 5.12E-05 Major depressive disorder / / 21621269 rs4656517 chr1 166856059 G A 8.80E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17331190 chr1 166857963 C G 2.10E-05 Pericardial fat / / 22589742 rs6427044 chr1 166870475 A C 4.10E-07 Urinary metabolites / / 21572414 rs1053407 chr1 166882737 C T 6.24E-04 Alcohol consumption (maxi-drinks) ILDR2 UTR-3 24277619 rs10489574 chr1 166910831 A G 3.90E-05 Pericardial fat ILDR2 intron 22589742 rs393025 chr1 166944928 C A 1.32E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7545911 chr1 166947681 G A 7.52E-06 Hemoglobin / / pha003098 rs7545911 chr1 166947681 G A 1.55E-05 Erythrocyte counts / / pha003099 rs402031 chr1 166950458 A G 1.18E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7528849 chr1 166954870 A G 6.53E-04 Lymphocyte counts / / 22286170 rs10918607 chr1 166957803 T C 5.86E-05 Hemoglobin / / pha003098 rs10918607 chr1 166957803 T C 7.04E-05 Erythrocyte counts / / pha003099 rs11578336 chr1 166958710 T G 5.86E-06 Hemoglobin MAEL missense pha003098 rs11578336 chr1 166958710 T G 1.37E-05 Erythrocyte counts MAEL missense pha003099 rs1041238 chr1 166974420 T C 6.08E-05 Atopy MAEL intron 21625490 rs12133327 chr1 166982285 A G 5.63E-05 Atopy MAEL intron 21625490 rs6661553 chr1 167005881 A G 4.85E-04 Smoking initiation / / 24665060 rs12410568 chr1 167015496 G A 1.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4233414 chr1 167021041 T C 5.31E-04 Multiple complex diseases / / 17554300 rs10918613 chr1 167037025 G A 2.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPA33 intron 24023788 rs12133648 chr1 167044527 G T 6.62E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918616 chr1 167045333 A G 7.23E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918618 chr1 167045512 G A 4.91E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs73028893 chr1 167046455 A G 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity GPA33 intron 24324551 rs10918619 chr1 167048067 C G 7.23E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918620 chr1 167048120 A G 4.18E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918621 chr1 167051092 C A 8.09E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs2281964 chr1 167059336 C T 0.00000639 Panic disorder GPA33 intron 23149450 rs2281964 chr1 167059336 C T 6.39E-06 Serum tamsulosin hydrochloride concentration GPA33 intron 23151678 rs2281962 chr1 167059760 A G 3.78E-05 Insulin Resistance GPA33 UTR-5 pha003062 rs2281962 chr1 167059760 A G 1.26E-05 Insulin-related traits GPA33 UTR-5 pha003063 rs10918625 chr1 167063520 A G 1.90E-05 Pericardial fat / / 22589742 rs12042641 chr1 167065025 G A 2.10E-05 Pericardial fat DUSP27 intron 22589742 rs12042641 chr1 167065025 G A 3.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DUSP27 intron 24023788 rs10918626 chr1 167065837 T G 2.00E-05 Pericardial fat DUSP27 intron 22589742 rs10127714 chr1 167066609 A C 2.20E-05 Pericardial fat DUSP27 intron 22589742 rs10127745 chr1 167066742 T G 2.00E-05 Pericardial fat DUSP27 intron 22589742 rs12044569 chr1 167066796 G A 1.90E-05 Pericardial fat DUSP27 intron 22589742 rs11590638 chr1 167070558 G C 2.40E-05 Pericardial fat DUSP27 intron 22589742 rs267746 chr1 167096931 A C 4.61E-04 Type 2 diabetes DUSP27 missense 17463246 rs11806848 chr1 167102492 C A 5.54E-04 Multiple complex diseases / / 17554300 rs4656525 chr1 167121665 G A 5.98E-04 Stroke / / pha002887 rs1532482 chr1 167124465 A T 8.10E-05 Personality dimensions / / 18957941 rs869714 chr1 167126250 C T 1.54E-05 Parkinson's disease / / pha002868 rs7527143 chr1 167127354 G A 2.65E-05 Parkinson's disease / / pha002868 rs12021649 chr1 167135333 C T 6.86E-04 Multiple complex diseases / / 17554300 rs2861445 chr1 167136353 G C 6.55E-04 Multiple complex diseases / / 17554300 rs6691080 chr1 167140959 A G 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10918653 chr1 167143896 G A 1.18E-05 Parkinson's disease (motor and cognition) / / 22658654 rs1391295 chr1 167151280 C A 3.48E-04 Smoking quantity / / 24665060 rs9803659 chr1 167156500 T C 4.00E-06 Liver enzyme levels / / 18940312 rs10494472 chr1 167159608 C G 3.36E-05 Type 2 diabetes / / 17463246 rs10494472 chr1 167159608 C G 1.09E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6675659 chr1 167169509 T A 5.95E-04 Obesity (extreme) / / 21935397 rs10800292 chr1 167172438 G A 5.57E-04 Obesity (extreme) / / 21935397 rs1021621 chr1 167198536 A G 3.60E-05 Celiac disease POU2F1 intron 17558408 rs10494474 chr1 167199180 C G 2.60E-04 Statin-induced myopathy POU2F1 intron 21826682 rs1391294 chr1 167211472 A G 2.47E-05 Multiple complex diseases POU2F1 intron 17554300 rs2814036 chr1 167228298 G A 3.11E-05 Multiple complex diseases POU2F1 intron 17554300 rs1359059 chr1 167234166 G A 9.31E-04 Alzheimer's disease POU2F1 intron 17998437 rs4656538 chr1 167259755 A G 9.11E-04 Alzheimer's disease POU2F1 intron 17998437 rs1028703 chr1 167270716 A C 5.33E-04 Fibrinogen POU2F1 intron 17255346 rs2177692 chr1 167317798 G A 1.43E-05 Multiple complex diseases POU2F1 intron 17554300 rs12742052 chr1 167334349 G A 1.03E-04 Multiple complex diseases POU2F1 intron 17554300 rs2949666 chr1 167392702 A G 5.70E-05 Celiac disease POU2F1 UTR-3 17558408 rs1917534 chr1 167397271 G A 1.81E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs1917534 chr1 167397271 G A 5.02E-05 Erythrocyte counts / / pha003099 rs953809 chr1 167403625 A G 6.90E-05 Cognitive test performance CD247 intron 20125193 rs2480679 chr1 167407517 A G 6.92E-05 Cognitive test performance CD247 intron 20125193 rs840016 chr1 167408670 C T 2.00E-06 Rheumatoid arthritis CD247 intron 20453842 rs1404567 chr1 167408874 A G 6.09E-05 Cognitive test performance CD247 intron 20125193 rs864537 chr1 167411384 A G 4.00E-07 Celiac disease CD247 intron 20190752 rs864537 chr1 167411384 A G 2.00E-11 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs864537 chr1 167411384 A G 2.20E-11 Rheumatoid arthritis CD247 intron 23143596 rs2056626 chr1 167420425 T G 3.00E-09 Systemic sclerosis CD247 intron 20383147 rs2056626 chr1 167420425 T G 1.66E-07 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs2056626 chr1 167420425 T G 1.00E-06 Systemic sclerosis CD247 intron 21750679 rs2056626 chr1 167420425 T G 3.00E-06 Systemic sclerosis CD247 intron 21779181 rs2056626 chr1 167420425 T G 0.000239004 Primary sclerosing cholangitis CD247 intron 23603763 rs7523907 chr1 167427247 C T 4.06E-07 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs12737372 chr1 167451115 C T 1.84E-05 Orofacial clefts CD247 intron 22419666 rs2949655 chr1 167451850 G A 3.55E-05 Orofacial clefts CD247 intron 22419666 rs863455 chr1 167457824 C T 8.41E-04 Coronary heart disease CD247 intron 21971053 rs858543 chr1 167467298 A G 8.37E-04 Systemic lupus erythematosus CD247 intron 22004975 rs858543 chr1 167467298 A G 4.00E-04 Systemic lupus erythematosus CD247 intron 23273568 rs704853 chr1 167468864 G T 2.47E-07 Systemic lupus erythematosus CD247 intron 22004975 rs704853 chr1 167468864 G T 1.79E-04 Systemic lupus erythematosus CD247 intron 23273568 rs10918708 chr1 167499290 G A 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs858492 chr1 167502112 T C 3.76E-05 Hearing function / / 17255346 rs10918710 chr1 167503235 G A 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12038219 chr1 167503917 G C 5.05E-04 Multiple complex diseases / / 17554300 rs10489191 chr1 167505895 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs932398 chr1 167506663 T C 9.81E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs16859159 chr1 167507857 A G 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs16859165 chr1 167508118 T C 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2064294 chr1 167510182 G A 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860662 chr1 167510837 T C 6.00E-04 Response to taxane treatment (placlitaxel) CREG1 UTR-3 23006423 rs2143300 chr1 167510996 G A 6.00E-04 Response to taxane treatment (placlitaxel) CREG1 UTR-3 23006423 rs2031131 chr1 167511256 T C 6.41E-06 Suicide attempts in bipolar disorder CREG1 UTR-3 21423239 rs3820392 chr1 167512531 C T 8.73E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs1229430 chr1 167513418 C T 8.00E-05 Alcoholism (heaviness of drinking) CREG1 intron 21529783 rs12042693 chr1 167513723 G A 6.91E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs12022039 chr1 167514197 C G 7.99E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs2982475 chr1 167514919 G C 1.51E-05 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs4657669 chr1 167521425 C T 6.90E-05 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs1737487 chr1 167523387 T C 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1737487 chr1 167523387 T C 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2984801 chr1 167526473 G A 1.10E-06 Urinary metabolites / / 21572414 rs11577169 chr1 167526508 C G 7.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs2902346 chr1 167526823 G A 3.70E-07 Urinary metabolites / / 21572414 rs2902347 chr1 167526972 C T 5.00E-07 Urinary metabolites / / 21572414 rs1737480 chr1 167528912 C T 3.60E-06 Urinary metabolites / / 21572414 rs1773548 chr1 167529639 G A 5.18E-04 Myopia (pathological) / / 21095009 rs1773548 chr1 167529639 G A 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs909935 chr1 167533014 C T 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4657670 chr1 167534270 T C 6.70E-05 Type 2 diabetes / / 17463246 rs7543683 chr1 167542337 A G 4.10E-05 Personality dimensions / / 18957941 rs7554445 chr1 167554337 T G 3.80E-05 Personality dimensions / / 18957941 rs12124252 chr1 167557852 A C 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6666091 chr1 167563012 T C 1.94E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4657679 chr1 167572558 C T 5.40E-05 Personality dimensions / / 18957941 rs1013057 chr1 167580349 T C 7.00E-06 Personality dimensions / / 18957941 rs11809621 chr1 167585884 G T 6.00E-04 Tourette syndrome / / 22889924 rs1229403 chr1 167589943 T C 4.78E-05 Osteoarthritis (knee and hip) / / 21177295 rs1890131 chr1 167597473 C T 5.10E-07 Coronary spasm / / 18075462 rs3738222 chr1 167600220 T C 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCSD1 intron 20877124 rs3738222 chr1 167600220 T C 9.79E-04 Tourette syndrome RCSD1 intron 22889924 rs12760768 chr1 167619333 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) RCSD1 intron 20708005 rs1022538 chr1 167625652 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) RCSD1 intron 20708005 rs12131752 chr1 167632361 G T 5.00E-04 Coronary heart disease RCSD1 intron 21971053 rs1229358 chr1 167640711 T A 4.50E-06 Urinary metabolites RCSD1 intron 21572414 rs12066500 chr1 167666218 C T 1.60E-05 Urinary metabolites RCSD1 intron 21572414 rs4657699 chr1 167679477 T C 6.17E-05 Bladder cancer / / 19648920 rs4657699 chr1 167679477 T C 4.00E-06 Urinary metabolites / / 21572414 rs1933077 chr1 167680498 C G 7.19E-06 Personality dimensions / / 18957941 rs16859491 chr1 167699295 C T 3.08E-04 Type 2 diabetes MPZL1 intron 17463246 rs16859491 chr1 167699295 C T 4.00E-06 Urinary metabolites MPZL1 intron 21572414 rs4145462 chr1 167718499 A G 1.00E-06 Alzheimer's disease (late onset) MPZL1 intron 22881374 rs12757250 chr1 167739355 T C 2.28E-04 Amyotrophic Lateral Sclerosis MPZL1 intron 17362836 rs4472738 chr1 167739821 C A 6.87E-05 Left ventricular hypertrophy MPZL1 intron pha003052 rs3752606 chr1 167758784 A G 6.35E-05 Myopia (pathological) MPZL1 UTR-3 21640322 rs10918774 chr1 167777775 G A 8.37E-04 Acute lung injury / / 22295056 rs10918774 chr1 167777775 G A 6.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12060498 chr1 167787265 C T 3.24E-04 Fibrinogen ADCY10 intron 17255346 rs4656560 chr1 167790618 T C 1.00E-04 Information processing speed ADCY10 intron 21130836 rs1476075 chr1 167794406 G A 9.95E-05 Information processing speed ADCY10 intron 21130836 rs17482924 chr1 167801355 G A 2.66E-04 Lymphocyte counts ADCY10 intron 22286170 rs16859735 chr1 167803349 T A 1.68E-04 Multiple complex diseases ADCY10 intron 17554300 rs3752608 chr1 167803823 G T 7.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ADCY10 intron 23648065 rs204262 chr1 167814468 A G 4.46E-04 Fibrinogen ADCY10 intron 17255346 rs204262 chr1 167814468 A G 8.34E-04 Suicide attempts in bipolar disorder ADCY10 intron 21041247 rs7512378 chr1 167825134 A G 9.60E-05 Attention deficit hyperactivity disorder ADCY10 intron 22420046 rs7512378 chr1 167825134 A G 6.21E-05 Hepatocellular carcinoma ADCY10 intron 22807686 rs203812 chr1 167837285 A C 8.40E-04 Taste perception ADCY10 intron 22132133 rs203849 chr1 167849414 A G 1.18E-05 Breast cancer ADCY10 cds-synon 24143190 rs10489202 chr1 167903079 G T 7.39E-04 Type 2 diabetes BRP44 intron 17463246 rs10489202 chr1 167903079 G T 1.70E-04 Type 2 diabetes and 6 quantitative traits BRP44 intron 17848626 rs10489202 chr1 167903079 G T 1.00E-08 Schizophrenia BRP44 intron 22037555 rs16828104 chr1 168090899 C T 7.10E-04 Multiple complex diseases GPR161 intron 17554300 rs10489208 chr1 168094709 C T 7.08E-04 Multiple complex diseases GPR161 intron 17554300 rs10489208 chr1 168094709 C T 2.29E-15 Lymphocyte counts GPR161 intron 22286170 rs4657739 chr1 168142489 C T 2.98E-04 Celiac disease / / 23936387 rs4657741 chr1 168149142 G A 1.97E-04 Celiac disease TIPRL intron 23936387 rs2294253 chr1 168156627 C T 4.87E-05 Celiac disease TIPRL intron 23936387 rs2235207 chr1 168159262 C T 2.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs2235207 chr1 168159262 C T 1.26E-04 Celiac disease TIPRL intron 23936387 rs1040404 chr1 168159890 G A 9.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs1040404 chr1 168159890 G A 8.24E-05 Celiac disease TIPRL intron 23936387 rs1040403 chr1 168164197 T G 6.21E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs2072778 chr1 168168750 A G 1.30E-05 Urinary metabolites TIPRL intron 21572414 rs2072776 chr1 168169452 G A 3.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL UTR-3 22566498 rs10157201 chr1 168172624 A G 3.78E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2075976 chr1 168269338 A C 6.03E-04 Breast cancer TBX19 intron 21060860 rs6427122 chr1 168274691 C T 7.75E-05 Multiple complex diseases TBX19 intron 17554300 rs2239613 chr1 168284327 A G 7.61E-06 Glycemic traits (pregnancy) / / 23903356 rs10753772 chr1 168295144 A G 2.38E-06 Glycemic traits (pregnancy) / / 23903356 rs10800353 chr1 168295203 T C 2.16E-06 Glycemic traits (pregnancy) / / 23903356 rs982702 chr1 168296436 T C 1.85E-06 Glycemic traits (pregnancy) / / 23903356 rs982702 chr1 168296436 T C 5.61E-04 Smoking cessation / / 24665060 rs1005423 chr1 168297451 C T 4.38E-06 Glycemic traits (pregnancy) / / 23903356 rs6674077 chr1 168299478 C T 3.36E-07 Glycemic traits (pregnancy) / / 23903356 rs2179184 chr1 168300075 A G 1.83E-06 Glycemic traits (pregnancy) / / 23903356 rs1040412 chr1 168300722 C A 2.88E-07 Glycemic traits (pregnancy) / / 23903356 rs2103570 chr1 168302975 C G 5.65E-07 Glycemic traits (pregnancy) / / 23903356 rs6685637 chr1 168303347 G A 2.75E-06 Glycemic traits (pregnancy) / / 23903356 rs6688030 chr1 168303543 C T 1.98E-06 Glycemic traits (pregnancy) / / 23903356 rs7512951 chr1 168309388 C T 6.23E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1886004 chr1 168332753 A G 8.80E-04 Type 2 diabetes / / 17846125 rs16860520 chr1 168380748 A G 6.42E-04 Type 2 diabetes LOC100505918 intron 17463246 rs12740293 chr1 168381150 A G 0.000264 Salmonella-induced pyroptosis LOC100505918 intron 22837397 rs2300564 chr1 168391067 T C 8.67E-04 Alzheimer's disease LOC100505918 intron 17998437 rs7417366 chr1 168463587 A G 0.000122 Lumbar spine bone mineral density (females) / / 22692763 rs7417366 chr1 168463587 A G 0.000575 Lumbar spine bone mineral density (males) / / 22692763 rs7417366 chr1 168463587 A G 7.42E-08 Lumbar spine bone mineral density / / 22692763 rs16860688 chr1 168463868 T G 1.34E-04 Progressive supranuclear palsy / / 21685912 rs10918916 chr1 168490420 A C 2.48E-04 Multiple complex diseases / / 17554300 rs12759385 chr1 168494126 G A 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1323532 chr1 168496272 G T 6.19E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1040508 chr1 168500750 C T 7.66E-05 Serum metabolites / / 19043545 rs1040509 chr1 168500984 G T 8.45E-04 Multiple complex diseases / / 17554300 rs1040509 chr1 168500984 G T 2.04E-05 Serum metabolites / / 19043545 rs12049040 chr1 168521615 G A 2.73E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1933107 chr1 168524895 A G 2.23E-04 Premature ovarian failure / / 19508998 rs1933105 chr1 168526394 T G 1.82E-05 Serum metabolites / / 19043545 rs6427130 chr1 168549422 C T 2.09E-04 Multiple complex diseases XCL1 intron 17554300 rs6700487 chr1 168549885 T C 6.82E-04 Suicide attempts in bipolar disorder XCL1 intron 21423239 rs2143312 chr1 168556301 T A 2.60E-05 Urinary metabolites / / 21572414 rs7556321 chr1 168560132 G A 3.80E-05 Malaria / / 19465909 rs10918931 chr1 168562091 T C 9.29E-10 Narcolepsy / / 19629137 rs7533545 chr1 168566976 G A 1.79E-05 Smoking cessation / / 24665060 rs2419117 chr1 168589182 T G 1.73E-05 Alzheimer's disease (late onset) / / 21379329 rs11580561 chr1 168599216 C T 1.03E-04 Alzheimer's disease (late onset) / / 21379329 rs11580561 chr1 168599216 C T 4.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7551639 chr1 168608152 G A 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7551639 chr1 168608152 G A 2.20E-04 Dental caries / / 21940522 rs1412337 chr1 168618641 G A 2.00E-09 Morbidity-free survival / / 17903295 rs16861246 chr1 168623309 G A 6.73E-04 Multiple complex diseases / / 17554300 rs16861250 chr1 168623998 C T 9.67E-05 Multiple complex diseases / / 17554300 rs1538173 chr1 168642062 T C 2.80E-06 Bone mass and geometry / / 17903296 rs12116794 chr1 168666850 A C 3.12E-05 Amyotrophic lateral sclerosis (sporadic) DPT intron 24529757 rs545833 chr1 168689940 C T 5.19E-07 QT interval DPT intron 19305409 rs545833 chr1 168689940 C T 7.09E-05 Lactate dehydrogenase levels DPT intron 20981236 rs545833 chr1 168689940 C T 2.19E-04 Vaspin levels DPT intron 22907691 rs545833 chr1 168689940 C T 0.0002193 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPT intron 22907730 rs11590043 chr1 168692615 C A 7.71E-06 Waist Circumference DPT intron pha003023 rs6427150 chr1 168725876 A G 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs926431 chr1 168734730 G A 3.00E-06 Urinary metabolites / / 21572414 rs2744666 chr1 168737147 A G 1.40E-06 Urinary metabolites / / 21572414 rs2786765 chr1 168741270 C T 1.80E-06 Urinary metabolites / / 21572414 rs2786767 chr1 168742357 C T 6.70E-06 Urinary metabolites / / 21572414 rs6659944 chr1 168779469 G A 9.47E-05 Height / / pha003011 rs41370344 chr1 168787307 T C 8.83E-04 Type 2 diabetes / / 17463246 rs41370344 chr1 168787307 T C 1.29E-04 Body mass index / / 21701565 rs41370344 chr1 168787307 T C 4.32E-04 Body mass index / / 21701565 rs857633 chr1 168833962 C T 6.97E-04 Smoking cessation / / 24665060 rs1322496 chr1 168842658 C G 7.93E-05 Hypertension / / 19609347 rs2419391 chr1 168849228 C G 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2146204 chr1 168874099 A C 2.97E-06 Hypertension / / 19609347 rs17514217 chr1 168889407 T A 4.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514217 chr1 168889407 T A 6.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514245 chr1 168889557 A G 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514245 chr1 168889557 A G 5.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs7530207 chr1 168890420 G C 4.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs7530207 chr1 168890420 G C 6.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs6427160 chr1 168892181 T C 4.80E-04 Intelligence (childhood) / / 23358156 rs2010667 chr1 168902339 C G 4.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs34429748 chr1 168927684 C CA 9.10E-06 Urinary metabolites / / 21572414 rs6702394 chr1 168927684 C T 9.10E-06 Urinary metabolites / / 21572414 rs41351446 chr1 168933987 C T 4.44E-04 Multiple complex diseases / / 17554300 rs10489373 chr1 168939789 G A 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10489376 chr1 168961407 G A 9.20E-04 Multiple complex diseases / / 17554300 rs16861846 chr1 168961568 A C 5.08E-04 Multiple complex diseases / / 17554300 rs16861846 chr1 168961568 A C 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6665379 chr1 168982164 G A 1.26E-05 Schizophrenia(age at onset) / / 21688384 rs12095831 chr1 168989553 T C 4.80E-04 Multiple complex diseases / / 17554300 rs4656640 chr1 168996958 T G 4.09E-05 Cholesterol / / 17255346 rs1320975 chr1 169022734 C T 4.58E-04 Alzheimer's disease / / 24755620 rs114101204 chr1 169026054 G A 2.86E-10 Venous thrombosis / / 22675575 rs114964168 chr1 169032877 C T 2.26E-10 Venous thrombosis / / 22675575 rs12061601 chr1 169070450 T C 5.03E-07 Venous thromboembolism / / 22672568 rs12061601 chr1 169070450 T C 5.88E-10 QT interval / / 23166209 rs12061601 chr1 169070450 T C 5.88E-10 Schizophrenia / / 23212062 rs1320976 chr1 169073346 G A 2.00E-10 QT interval / / 23166209 rs2032045 chr1 169078076 G A 3.51E-04 Multiple complex diseases ATP1B1 intron 17554300 rs1200131 chr1 169078859 G A 9.29E-04 Multiple complex diseases ATP1B1 intron 17554300 rs77977611 chr1 169081792 T G 5.13E-13 Venous thrombosis ATP1B1 intron 22675575 rs75112989 chr1 169099137 G A 3.59E-20 Venous thrombosis ATP1B1 intron 22675575 rs10919071 chr1 169099483 A G 1.00E-15 QT interval ATP1B1 intron 19305409 rs1138486 chr1 169101935 C T 4.23E-06 QT interval ATP1B1 UTR-3 23166209 rs77979353 chr1 169115022 T C 2.66E-22 Venous thrombosis NME7 intron 22675575 rs3766053 chr1 169126401 A C 2.70E-05 Urinary metabolites NME7 intron 21572414 rs1200164 chr1 169126895 G C 9.84E-06 QT interval NME7 intron 23166209 rs16861990 chr1 169135127 A C 2.00E-06 D-dimer levels NME7 intron 21502573 rs16861990 chr1 169135127 A C 4.90E-20 Venous thromboembolism NME7 intron 21980494 rs16861990 chr1 169135127 A C 2.00E-12 Venous thromboembolism NME7 intron 22672568 rs16861990 chr1 169135127 A C 4.71E-20 Venous thrombosis NME7 intron 22675575 rs12029857 chr1 169151228 T C 9.39E-06 Venous thromboembolism NME7 intron 22672568 rs144737447 chr1 169160458 C T 2.10E-28 Venous thrombosis NME7 intron 22675575 rs3766074 chr1 169163017 G A 3.59E-04 Stroke NME7 intron pha002886 rs10800418 chr1 169183385 A C,T 8.90E-06 Urinary metabolites NME7 intron 21572414 rs2227246 chr1 169208179 C T 2.77E-27 Venous thrombosis NME7 intron 22675575 rs10800427 chr1 169272451 A T 4.01E-23 Venous thrombosis NME7 intron 22675575 rs10800428 chr1 169272453 G A 2.33E-23 Venous thrombosis NME7 intron 22675575 rs12125501 chr1 169273808 G A 0.000149 Coronary artery disease NME7 intron 23202125 rs1208327 chr1 169296864 C T 1.45E-22 Venous thromboembolism NME7 intron 21980494 rs1208327 chr1 169296864 C T 7.96E-13 Venous thromboembolism NME7 intron 22672568 rs1208327 chr1 169296864 C T 8.44E-21 Venous thrombosis NME7 intron 22675575 rs1200063 chr1 169314430 T C 5.21E-22 Venous thrombosis NME7 intron 22675575 rs10919147 chr1 169315527 A G 5.82E-04 Stroke NME7 intron pha002886 rs1209731 chr1 169324793 T C 4.68E-27 Venous thrombosis NME7 intron 22675575 rs7538157 chr1 169351544 A C 9.03E-25 Venous thromboembolism BLZF1 intron 21980494 rs7538157 chr1 169351544 A C 1.04E-14 Venous thromboembolism BLZF1 intron 22672568 rs10919158 chr1 169357144 C T 4.51E-04 Stroke BLZF1 intron pha002886 rs10919164 chr1 169384437 T C 2.26E-04 Amyotrophic lateral sclerosis (sporadic) C1orf114 intron 24529757 rs16862153 chr1 169393888 C T 6.51E-04 Type 2 diabetes C1orf114 intron 17463246 rs10919168 chr1 169394226 A G 7.66E-06 Venous thromboembolism C1orf114 intron 22672568 rs12092506 chr1 169405517 A G 2.13E-04 Epilepsy / / 22116939 rs1208135 chr1 169424098 A G 2.12E-20 Venous thromboembolism / / 21980494 rs1208135 chr1 169424098 A G 4.26E-11 Venous thromboembolism / / 22672568 rs1208135 chr1 169424098 A G 1.39E-20 Venous thrombosis / / 22675575 rs1208134 chr1 169428944 C T 2.12E-20 Venous thromboembolism / / 21980494 rs1208134 chr1 169428944 C T 4.46E-11 Venous thromboembolism / / 22672568 rs1208134 chr1 169428944 C T 7.13E-21 Venous thrombosis / / 22675575 rs2678166 chr1 169435027 C T 1.46E-32 Venous thrombosis SLC19A2 UTR-3 22675575 rs1983546 chr1 169446183 A G 1.00E-06 Urinary metabolites SLC19A2 intron 21572414 rs2038024 chr1 169455982 C A 1.12E-08 Venous thromboembolism / / 22672568 rs2038024 chr1 169455982 C A 1.75E-09 Activated protein C resistance / / 23188048 rs2901092 chr1 169456393 A G 7.81E-07 Venous thromboembolism / / 22672568 rs10800448 chr1 169460406 A G 4.95E-09 Venous thrombosis / / 22675575 rs6696217 chr1 169460726 A G 1.38E-13 Venous thromboembolism / / 21980494 rs6696217 chr1 169460726 A G 6.33E-14 Venous thromboembolism / / 22672568 rs6696217 chr1 169460726 A G 3.02E-17 Venous thrombosis / / 22675575 rs4656682 chr1 169463518 A G 9.98E-11 Venous thrombosis / / 22675575 rs67150165 chr1 169463518 AT AAT,AGC 9.98E-11 Venous thrombosis / / 22675575 rs4656683 chr1 169463519 T C 9.01E-11 Venous thrombosis / / 22675575 rs1894692 chr1 169467654 G A 1.79E-13 Venous thromboembolism / / 21980494 rs1894692 chr1 169467654 G A 2.85E-21 Venous thromboembolism / / 22672568 rs1894692 chr1 169467654 G A 2.72E-34 Venous thrombosis / / 22675575 rs4264045 chr1 169470748 T G 4.02E-26 Venous thrombosis / / 22675575 rs6670848 chr1 169472899 A G 7.25E-25 Venous thrombosis / / 22675575 rs10737547 chr1 169476052 A G 1.49E-22 Venous thromboembolism / / 21980494 rs10737547 chr1 169476052 A G 6.25E-17 Venous thromboembolism / / 22672568 rs10737547 chr1 169476052 A G 7.31E-25 Venous thrombosis / / 22675575 rs6687813 chr1 169477574 A C 2.00E-14 D-dimer levels / / 21502573 rs6687813 chr1 169477574 A C 8.61E-23 Venous thromboembolism / / 21980494 rs6687813 chr1 169477574 A C 6.24E-17 Venous thromboembolism / / 22672568 rs6687813 chr1 169477574 A C 2.24E-25 Venous thrombosis / / 22675575 rs970740 chr1 169479974 C T 4.47E-26 Venous thromboembolism / / 21980494 rs970740 chr1 169479974 C T 4.35E-17 Venous thromboembolism / / 22672568 rs970740 chr1 169479974 C T 5.01E-26 Venous thrombosis / / 22675575 rs6427194 chr1 169481121 T A 5.06E-26 Venous thromboembolism F5 nearGene-3 21980494 rs6427194 chr1 169481121 T A 4.30E-17 Venous thromboembolism F5 nearGene-3 22672568 rs6427194 chr1 169481121 T A 5.02E-25 Venous thrombosis F5 nearGene-3 22675575 rs6427195 chr1 169481176 A T 5.06E-26 Venous thromboembolism F5 nearGene-3 21980494 rs6427195 chr1 169481176 A T 4.28E-17 Venous thromboembolism F5 nearGene-3 22672568 rs6427195 chr1 169481176 A T 5.24E-25 Venous thrombosis F5 nearGene-3 22675575 rs6427196 chr1 169481223 C G 5.29E-26 Venous thromboembolism F5 UTR-3 21980494 rs6427196 chr1 169481223 C G 4.24E-17 Venous thromboembolism F5 UTR-3 22672568 rs6427196 chr1 169481223 C G 6.04E-25 Venous thrombosis F5 UTR-3 22675575 rs6427196 chr1 169481223 C G 2.11E-28 Activated protein C resistance F5 UTR-3 23188048 rs6427196 chr1 169481223 C G 4.00E-51 Venous thromboembolism F5 UTR-3 23650146 rs2213865 chr1 169486128 G A 5.58E-05 Cognitive impairment induced by topiramate F5 intron 22091778 rs2420370 chr1 169490392 G C 4.15E-26 Venous thromboembolism F5 intron 21980494 rs2420370 chr1 169490392 G C 8.47E-17 Venous thromboembolism F5 intron 22672568 rs6682179 chr1 169490401 T C 5.63E-25 Venous thrombosis F5 intron 22675575 rs6682179 chr1 169490401 T C 1.43E-28 Activated protein C resistance F5 intron 23188048 rs2420371 chr1 169491555 G A 1.20E-12 Venous thromboembolism F5 intron 19278955 rs2420371 chr1 169491555 G A 4.02E-26 Venous thromboembolism F5 intron 21980494 rs2420371 chr1 169491555 G A 4.00E-80 Hemostatic factors and hematological phenotypes F5 intron 22443383 rs2420371 chr1 169491555 G A 9.61E-17 Venous thromboembolism F5 intron 22672568 rs2420371 chr1 169491555 G A 6.09E-26 Venous thrombosis F5 intron 22675575 rs9332637 chr1 169494996 G A 3.06E-08 HDL cholesterol F5 intron 23063622 rs2420372 chr1 169498056 A G 3.39E-26 Venous thromboembolism F5 intron 21980494 rs2420372 chr1 169498056 A G 7.47E-17 Venous thromboembolism F5 intron 22672568 rs2420372 chr1 169498056 A G 2.19E-25 Venous thrombosis F5 intron 22675575 rs6009 chr1 169498834 T C 3.96E-26 Venous thromboembolism F5 intron 21980494 rs6009 chr1 169498834 T C 7.26E-17 Venous thromboembolism F5 intron 22672568 rs6009 chr1 169498834 T C 1.93E-25 Venous thrombosis F5 intron 22675575 rs6009 chr1 169498834 T C 1.24E-27 Activated protein C resistance F5 intron 23188048 rs6030 chr1 169498975 T C 3.00E-06 Uric acid levels F5 missense 23703922 rs6427197 chr1 169500590 C A 3.75E-26 Venous thromboembolism F5 intron 21980494 rs6427197 chr1 169500590 C A 6.92E-17 Venous thromboembolism F5 intron 22672568 rs6427197 chr1 169500590 C A 2.08E-25 Venous thrombosis F5 intron 22675575 rs1557570 chr1 169507844 G T 9.51E-06 Venous thromboembolism F5 intron 22672568 rs6031 chr1 169511903 G A 0.00000152 HDL cholesterol F5 missense 23063622 rs1018827 chr1 169514006 A G 2.00E-26 Venous thromboembolism F5 intron 21980494 rs1018827 chr1 169514006 A G 4.24E-17 Venous thromboembolism F5 intron 22672568 rs1018827 chr1 169514006 A G 1.36E-25 Venous thrombosis F5 intron 22675575 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 10225605 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 11583312 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 15799206 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 16113779 rs6025 chr1 169519049 T C 3.73E-15 Venous thromboembolism / / 21980494 rs6025 chr1 169519049 T C 2.00E-22 Venous thromboembolism / / 22672568 rs6025 chr1 169519049 T C 4.23E-35 Venous thrombosis / / 22675575 rs6025 chr1 169519049 T C 4.20E-104 Activated protein C resistance / / 23188048 rs6020 chr1 169519112 C T 1.88E-04 Type 2 diabetes F5 missense 17463246 rs6020 chr1 169519112 C T 0.000047 Prostate cancer F5 missense 23555315 rs2213868 chr1 169521553 G A 3.35E-27 Venous thrombosis F5 intron 22675575 rs6035 chr1 169521849 T C 9.15E-05 Cognitive impairment induced by topiramate F5 cds-synon 22091778 rs9332579 chr1 169525312 C T 0.000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332570 chr1 169528075 C G 0.0000011 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332569 chr1 169528180 C A 1.40E-09 Cholesterol,total F5 intron 23063622 rs6427203 chr1 169529031 A C 0.0000018 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs7545236 chr1 169530070 A C 0.0000012 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs1894701 chr1 169530586 T C 0.0000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332552 chr1 169537036 G A 0.00000125 Triglycerides F5 intron 23063622 rs2298908 chr1 169538544 C T 0.0000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs6663533 chr1 169539348 T G 4.21E-04 Multiple complex diseases F5 intron 17554300 rs6663533 chr1 169539348 T G 0.00026 Coronary artery calcification F5 intron 23727086 rs6019 chr1 169541513 C G 0.00026 Coronary artery calcification F5 missense 23727086 rs6703865 chr1 169550963 G A 1.00E-09 Hippocampal atrophy F5 intron 22745009 rs6028 chr1 169551682 T C 3.00E-09 Activated partial thromboplastin time F5 cds-synon 22703881 rs9332492 chr1 169553110 A C 1.41E-08 Cholesterol,total F5 intron 23063622 rs9332682 chr1 169553860 G A 1.35E-10 HDL cholesterol F5 intron 23063622 rs6128 chr1 169562904 C T 0.0000031 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP cds-synon 21873659 rs6128 chr1 169562904 C T 0.00056 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP cds-synon 21873659 rs6128 chr1 169562904 C T 0.00043 Coronary artery calcification SELP cds-synon 23727086 rs3917831 chr1 169562949 A G 2.43E-11 Cholesterol,total SELP cds-synon 23063622 rs6136 chr1 169563951 T G 4.00E-61 Soluble levels of adhesion molecules SELP missense 20167578 rs3917820 chr1 169564745 G A 2.71E-04 Type 2 diabetes SELP intron 17463246 rs3917820 chr1 169564745 G A 5.47E-06 Cardiovascular disease SELP intron 18179892 rs6133 chr1 169565346 C A,G 0.000011 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP missense 21873659 rs6133 chr1 169565346 C A,G 0.00023 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP missense 21873659 rs6127 chr1 169566313 C T 3.91E-04 Smoking quantity SELP missense 24665060 rs3917793 chr1 169567545 C A 4.70E-04 Coronary heart disease SELP intron 21966275 rs3917781 chr1 169569733 A G 9.25E-04 Multiple complex diseases SELP intron 17554300 rs3917781 chr1 169569733 A G 1.03E-08 HDL cholesterol SELP intron 23063622 rs3917779 chr1 169570848 G A 0.000016 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP intron 21873659 rs3917779 chr1 169570848 G A 0.00029 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP intron 21873659 rs3917770 chr1 169572179 G A 5.99E-04 Multiple complex diseases SELP intron 17554300 rs2235302 chr1 169580290 C T 4.00E-16 Soluble levels of adhesion molecules SELP intron 20167578 rs3917693 chr1 169589370 C T 8.04E-10 Venous thrombosis SELP intron 22675575 rs3917683 chr1 169591373 T C 4.18E-06 Total ventricular volume SELP intron 21116278 rs3917862 chr1 169593113 A G 4.35E-06 Venous thromboembolism SELP intron 22672568 rs732314 chr1 169599254 T C 5.49E-06 Total ventricular volume SELP intron 21116278 rs1569476 chr1 169608917 C T 3.00E-07 Total ventricular volume / / 21116278 rs7531806 chr1 169651044 G A 1.00E-08 Acne (severe) / / 24399259 rs4987381 chr1 169661180 C A 7.72E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987345 chr1 169668608 A G 8.59E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987343 chr1 169668856 T C 7.44E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987340 chr1 169669143 C T 7.16E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs964555 chr1 169671088 A C 2.34E-05 Alcohol dependence SELL intron 20201924 rs964555 chr1 169671088 A C 2.34E-05 Alcoholism SELL intron pha002891 rs4987325 chr1 169671217 T G 6.43E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987324 chr1 169671237 A C 1.74E-04 Type 2 diabetes SELL intron 17463246 rs4987324 chr1 169671237 A C 9.99E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987323 chr1 169671277 G C 1.85E-04 Type 2 diabetes SELL intron 17463246 rs4987323 chr1 169671277 G C 9.99E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987395 chr1 169671386 T A 7.35E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987314 chr1 169672343 C T 1.23E-05 Alcohol dependence SELL intron 20201924 rs4987314 chr1 169672343 C T 1.23E-05 Alcoholism SELL intron pha002891 rs12137905 chr1 169672867 C T 9.32E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs2229569 chr1 169673838 G A 9.88E-06 Alcoholism SELL missense pha002891 rs4987308 chr1 169674116 C G 6.82E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987307 chr1 169674403 G T 5.25E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987304 chr1 169674561 A C 6.42E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987302 chr1 169674983 G A 6.92E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987299 chr1 169675349 T C 1.64E-04 Type 2 diabetes SELL intron 17463246 rs2205847 chr1 169676223 G T 1.94E-04 Alcohol dependence SELL intron 20201924 rs1131498 chr1 169676486 A G 4.00E-06 Amyotrophic lateral sclerosis SELL missense 19451621 rs1131498 chr1 169676486 A G 4.00E-06 Amyotrophic lateral sclerosis SELL missense 19451621 rs1051091 chr1 169677709 A G 2.11E-04 Alcohol dependence SELL cds-synon 20201924 rs4987285 chr1 169678024 T C 6.00E-05 Alcohol dependence SELL intron 20201924 rs4987285 chr1 169678024 T C 6.00E-05 Alcoholism SELL intron pha002891 rs1569457 chr1 169680074 G A 6.01E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs2205849 chr1 169681357 T C 1.40E-05 Alcohol dependence SELL nearGene-5 20201924 rs2205849 chr1 169681357 T C 1.40E-05 Alcoholism SELL nearGene-5 pha002891 rs4656703 chr1 169688135 A C 4.48E-05 Alcohol dependence / / 20201924 rs4656703 chr1 169688135 A C 4.48E-05 Alcoholism / / pha002891 rs12133642 chr1 169689800 A G 1.87E-04 Type 2 diabetes / / 17463246 rs12133642 chr1 169689800 A G 9.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs12133666 chr1 169689832 A T 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs3917449 chr1 169691219 G A 5.35E-05 Alcohol dependence / / 20201924 rs3917449 chr1 169691219 G A 5.35E-05 Alcoholism / / pha002891 rs3917462 chr1 169691667 T C 0.000093 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELE nearGene-3 21873659 rs3917441 chr1 169692121 G C 3.00E-04 Suicide attempts in bipolar disorder SELE UTR-3 21423239 rs4786 chr1 169692132 T C 1.21E-04 Alcohol dependence SELE UTR-3 20201924 rs5359 chr1 169692522 T C 6.98E-06 Alcohol dependence SELE UTR-3 20201924 rs5359 chr1 169692522 T C 6.98E-06 Alcoholism SELE UTR-3 pha002891 rs5357 chr1 169692713 A G 4.25E-04 Suicide attempts in bipolar disorder SELE UTR-3 21423239 rs3917427 chr1 169696033 A G 9.73E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs3917425 chr1 169696754 A T 2.72E-04 Type 2 diabetes SELE intron 17463246 rs3917425 chr1 169696754 A T 9.99E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs5367 chr1 169697076 A G 9.55E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs1076637 chr1 169697444 C T 1.89E-05 Alcohol dependence SELE intron 20201924 rs1076637 chr1 169697444 C T 1.89E-05 Alcoholism SELE intron pha002891 rs5364 chr1 169698647 C T 5.27E-09 Lipid levels SELE missense 19913121 rs5363 chr1 169698789 A G 9.53E-04 Suicide attempts in bipolar disorder SELE cds-synon 21423239 rs3917419 chr1 169699819 G A 2.43E-05 Alcohol dependence SELE intron 20201924 rs3917419 chr1 169699819 G A 2.43E-05 Alcoholism SELE intron pha002891 rs3917411 chr1 169700756 A T 1.74E-04 Type 2 diabetes SELE intron 17463246 rs3917411 chr1 169700756 A T 9.73E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs3917410 chr1 169701108 A G 1.48E-04 Type 2 diabetes SELE intron 17463246 rs932307 chr1 169702705 G A 3.96E-04 Alcohol dependence SELE intron 20201924 rs1805193 chr1 169702772 C A 9.95E-04 Suicide attempts in bipolar disorder SELE UTR-5 21423239 rs3917400 chr1 169702899 G A 9.94E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs5353 chr1 169702974 T C 5.11E-05 Alcohol dependence SELE intron 20201924 rs5353 chr1 169702974 T C 5.11E-05 Alcoholism SELE intron pha002891 rs3917392 chr1 169704335 T C 1.05E-04 Type 2 diabetes SELE nearGene-5 17463246 rs10489181 chr1 169712597 T C 7.70E-05 Malaria / / 19465909 rs17527744 chr1 169721968 A C 5.03E-05 Type 2 diabetes / / 17463246 rs12145504 chr1 169722279 A G 9.63E-04 Type 2 diabetes / / 17463246 rs4537624 chr1 169725425 G T 5.03E-05 Type 2 diabetes / / 17463246 rs2420505 chr1 169728137 A G 1.16E-04 Type 2 diabetes / / 17463246 rs12128695 chr1 169729450 C T 5.39E-04 Type 2 diabetes / / 17463246 rs17593568 chr1 169734937 T A 4.40E-04 Type 2 diabetes / / 17463246 rs12121606 chr1 169735197 G A 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs12121681 chr1 169735399 G C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12122781 chr1 169736514 G A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12027035 chr1 169738202 T G 0.000691631 Hypertension (early onset hypertension) / / 22479346 rs2205851 chr1 169739650 C T 1.86E-04 Attention deficit hyperactivity disorder / / 22420046 rs12125023 chr1 169746015 T A 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17593862 chr1 169748286 C T 5.03E-05 Type 2 diabetes / / 17463246 rs17593862 chr1 169748286 C T 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs12132633 chr1 169756215 G A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs12130372 chr1 169757316 A G 3.80E-04 Type 2 diabetes / / 17463246 rs12132222 chr1 169758564 A G 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145417 chr1 169760895 C T 5.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145574 chr1 169761370 C T 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs12135361 chr1 169761591 A G 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs10489177 chr1 169762807 T G 2.67E-04 Celiac disease METTL18 missense 23936387 rs3766135 chr1 169768500 C T 4.28E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12141572 chr1 169769566 G C 4.04E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs10489176 chr1 169770637 C T 4.27E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766138 chr1 169773160 T C 8.60E-04 Type 2 diabetes C1orf112 intron 17463246 rs12143161 chr1 169779664 A G 4.64E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17529304 chr1 169781291 A G 4.24E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2420510 chr1 169788584 T C 0.000404 Breast cancer early age of onset C1orf112 intron 18463975 rs12122767 chr1 169790668 G A 3.60E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12121443 chr1 169792642 A T 3.72E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766141 chr1 169792692 T C 3.54E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2272920 chr1 169799880 G T 8.81E-04 Suicide attempts in bipolar disorder C1orf112 missense 21423239 rs10489174 chr1 169800090 C T 8.82E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17601631 chr1 169800690 A G 8.79E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17529791 chr1 169803690 A C 8.82E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766143 chr1 169803717 C T 8.84E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs9645329 chr1 169804720 T A 7.73E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12119635 chr1 169805549 T C 7.67E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12123432 chr1 169807095 G A 7.50E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12133074 chr1 169808651 C T 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12126591 chr1 169809974 G C 7.48E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17602051 chr1 169811877 C T 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2272919 chr1 169811966 T G 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17602072 chr1 169812534 C A 7.32E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs1046058 chr1 169822543 A G 7.49E-04 Suicide attempts in bipolar disorder SCYL3 UTR-3 21423239 rs12143301 chr1 169823790 C G 7.09E-04 Suicide attempts in bipolar disorder SCYL3 missense 21423239 rs12132384 chr1 169824068 A G 7.10E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12135726 chr1 169824104 G A 7.04E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12128929 chr1 169826080 A G 8.77E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17602701 chr1 169828327 G A 7.49E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12136425 chr1 169830104 G C 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17543611 chr1 169836175 T C 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12134837 chr1 169836765 A G 7.48E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12135642 chr1 169836946 T C 7.46E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17543730 chr1 169838715 C T 7.44E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12119368 chr1 169840213 C T 7.47E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12122419 chr1 169843017 C T 7.45E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12141317 chr1 169843436 A G 9.69E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12142093 chr1 169843609 A G 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12145458 chr1 169843623 G A 7.48E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12143057 chr1 169844093 T C 7.46E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12127500 chr1 169853190 C T 6.11E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17603570 chr1 169854113 T C 6.11E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12124032 chr1 169855107 C T 5.87E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17603666 chr1 169856028 T C 5.86E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12144624 chr1 169856622 A T 4.41E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12144683 chr1 169856743 A G 3.65E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17544586 chr1 169857490 C T 4.40E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12131357 chr1 169862064 C G 2.40E-05 Urinary metabolites SCYL3 intron 21572414 rs12124561 chr1 169875679 T C 7.00E-04 Type 2 diabetes / / 17463246 rs12125595 chr1 169876537 T C 7.93E-04 Smoking cessation / / 24665060 rs12125679 chr1 169876817 T A 2.30E-05 Urinary metabolites / / 21572414 rs10919271 chr1 169905053 G A 2.39E-04 Celiac disease KIFAP3 intron 23936387 rs673789 chr1 169908455 G C 5.37E-04 Multiple complex diseases KIFAP3 intron 17554300 rs2806385 chr1 169909254 T G 9.31E-04 Type 2 diabetes KIFAP3 intron 17463246 rs545963 chr1 169937418 C T 2.30E-06 Urinary metabolites KIFAP3 intron 21572414 rs41496844 chr1 169945664 A G 6.61E-04 Multiple complex diseases KIFAP3 intron 17554300 rs654664 chr1 169946436 C T 1.80E-05 Urinary metabolites KIFAP3 intron 21572414 rs12124907 chr1 169980811 C A 2.30E-05 Urinary metabolites KIFAP3 intron 21572414 rs12123693 chr1 169985324 C T 9.46E-05 Celiac disease KIFAP3 intron 23936387 rs1541160 chr1 169995802 C T 2.00E-08 Amyotrophic lateral sclerosis KIFAP3 intron 19451621 rs10800495 chr1 169998200 C T 7.18E-05 Celiac disease KIFAP3 intron 23936387 rs1415551 chr1 170002212 T C 1.77E-04 Celiac disease KIFAP3 intron 23936387 rs16862968 chr1 170002561 T C 1.30E-05 Urinary metabolites KIFAP3 intron 21572414 rs4656732 chr1 170004722 G A 1.46E-04 Multiple complex diseases KIFAP3 intron 17554300 rs1928887 chr1 170007869 A C 6.75E-04 Type 2 diabetes KIFAP3 intron 17463246 rs1928887 chr1 170007869 A C 6.39E-05 Multiple complex diseases KIFAP3 intron 17554300 rs10494479 chr1 170027498 G A 1.50E-05 Urinary metabolites KIFAP3 intron 21572414 rs12146137 chr1 170037624 C T 9.64E-05 Celiac disease KIFAP3 UTR-5 23936387 rs12141613 chr1 170044163 A G 2.40E-05 Urinary metabolites KIFAP3 nearGene-5 21572414 rs10919298 chr1 170064344 T C 9.24E-06 Waist-hip ratio / / 20935629 rs16863031 chr1 170070827 G A 1.89E-06 Waist-hip ratio / / 20935629 rs12042109 chr1 170085453 C A 6.15E-04 Alzheimer's disease / / 17998437 rs16863069 chr1 170126741 A C 2.80E-05 Cognitive function METTL11B intron 24684796 rs495524 chr1 170128608 A T 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) METTL11B intron 19901119 rs551042 chr1 170132339 C T 8.49E-06 C-reactive protein METTL11B intron 22492993 rs10158534 chr1 170172417 T G 4.61E-04 Alcohol dependence / / 20201924 rs10919328 chr1 170177483 G C 5.70E-06 Urinary metabolites / / 21572414 rs12116424 chr1 170186354 G A 2.50E-05 Urinary metabolites / / 21572414 rs3936027 chr1 170187033 G T 1.04E-11 Multiple complex diseases / / 17554300 rs1412787 chr1 170208724 C T 4.10E-04 Alcohol dependence / / 20201924 rs12122745 chr1 170210475 T C 2.96E-04 Multiple complex diseases / / 17554300 rs10919335 chr1 170213020 C G 1.90E-07 Urinary metabolites / / 21572414 rs6701383 chr1 170312674 A G 8.06E-04 Multiple complex diseases / / 17554300 rs1412795 chr1 170319649 G A 7.05E-05 Blood Pressure / / pha003040 rs1930538 chr1 170330773 C T 9.88E-06 Waist-hip ratio / / 20935629 rs6427247 chr1 170380480 A G 4.92E-04 Diabetic retinopathy / / 20871662 rs6427260 chr1 170517184 A G 6.36E-04 Multiple complex diseases GORAB intron 17554300 rs3903239 chr1 170569317 A G 8.00E-14 Atrial fibrillation / / 22544366 rs17549441 chr1 170592126 C A 8.02E-04 Smoking quantity / / 24665060 rs659580 chr1 170633896 T C 1.00E-06 Response to angiotensin II receptor blocker therapy PRRX1 intron 22566498 rs489090 chr1 170661764 C A 7.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs2187895 chr1 170684431 G C 7.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs6701640 chr1 170696474 A C 5.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs12409048 chr1 170699149 G A 7.10E-05 HIV-1 control PRRX1 intron 20041166 rs3820416 chr1 170707675 T C 6.02E-05 HIV-1 control PRRX1 UTR-3 20041166 rs4656797 chr1 170708637 C G 5.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 nearGene-3 22566498 rs16863548 chr1 170709358 T C 5.71E-04 Multiple complex diseases / / 17554300 rs6679313 chr1 170715110 A G 1.68E-04 Body mass index / / 17255346 rs2421494 chr1 170715531 G A 8.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs991230 chr1 170719187 G A 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10800542 chr1 170764915 T G 1.48E-04 Body mass index / / 17255346 rs2143109 chr1 170773031 A G 2.48E-04 Body mass index / / 17255346 rs10737555 chr1 170795855 A C 9.79E-04 Multiple complex diseases / / 17554300 rs6677161 chr1 170797204 C T 6.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10489239 chr1 170856852 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs10489241 chr1 170858095 T C 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs12038181 chr1 170860531 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs6681815 chr1 170894922 T C 6.06E-04 Type 2 diabetes / / 17463246 rs139086068 chr1 170965700 G A 0.00067 Prostate cancer C1orf129 missense 23555315 rs16863938 chr1 170984413 T C 0.000619 Salmonella-induced pyroptosis C1orf129 intron 22837397 rs2204792 chr1 170987278 T C 6.14E-05 HIV-1 viral setpoint C1orf129 intron 22174851 rs16864042 chr1 171079005 G T 8.71E-06 Schizophrenia FMO3 intron 20185149 rs7051320 chr1 171079700 C T 4.98E-04 Alcohol dependence FMO3 intron 21314694 rs7061710 chr1 171080615 G C 8.00E-14 Blood metabolite levels FMO3 intron 24816252 rs2266780 chr1 171083242 A G 1.13E-05 Schizophrenia FMO3 missense 20185149 rs12089338 chr1 171088560 T C 1.21E-05 Prion diseases / / 22210626 rs1795240 chr1 171091875 A G 5.00E-08 Lentiform nucleus volume / / 22903471 rs2281006 chr1 171110869 G T 2.10E-05 Schizophrenia FMO6P intron 20185149 rs7063044 chr1 171116760 C T 9.00E-06 Schizophrenia FMO6P intron 20185149 rs6608452 chr1 171117113 C T 9.73E-06 Schizophrenia FMO6P intron 20185149 rs7879557 chr1 171117341 A T 5.51E-06 Schizophrenia FMO6P intron 20185149 rs16864136 chr1 171133889 C A 4.86E-04 Lymphocyte counts / / 22286170 rs7545752 chr1 171148521 G A 9.02E-04 Alzheimer's disease / / 22005930 rs12752688 chr1 171151638 C T 3.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7512785 chr1 171179287 C T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMO2 UTR-3 20877124 rs10912593 chr1 171188057 C T 3.00E-05 Anger / / 24489884 rs7551531 chr1 171214880 G A 5.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7551531 chr1 171214880 G A 8.88E-05 Potassium levels / / pha003086 rs16864314 chr1 171251196 A G 1.55E-04 Multiple complex diseases FMO1 missense 17554300 rs10798304 chr1 171258642 C T 6.73E-05 Bipolar Disorder / / pha002863 rs6660565 chr1 171261193 G A 2.00E-06 Sudden cardiac arrest / / 21658281 rs11576306 chr1 171312508 A G 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs1018391 chr1 171340430 T C 2.16E-05 Sudden cardiac arrest / / 21658281 rs10912887 chr1 171364141 C T 7.31E-05 Lipoproteins / / pha003079 rs10737306 chr1 171366426 A T 1.80E-06 Urinary metabolites / / 21572414 rs7523796 chr1 171391273 C A 4.63E-04 Myopia (pathological) / / 21095009 rs17644596 chr1 171393826 G C 1.20E-05 Urinary metabolites / / 21572414 rs12122751 chr1 171394149 A G 3.54E-04 Coronary heart disease / / 21606135 rs10912988 chr1 171400498 C T 5.53E-04 Multiple complex diseases / / 17554300 rs960845 chr1 171413250 A G 3.13E-04 Alzheimer's disease / / 17998437 rs4916386 chr1 171449207 T C 7.96E-05 Myopia (severe) / / 23933737 rs10913149 chr1 171472188 A G 2.17E-05 Lung function (forced expiratory volume in 1 second) PRRC2C intron pha003102 rs4384265 chr1 171478523 G A 5.43E-06 Myopia (severe) PRRC2C intron 23933737 rs2038042 chr1 171481592 G A 6.13E-06 Myopia (severe) PRRC2C intron 23933737 rs10913157 chr1 171486912 G A 0.00073 Prostate cancer PRRC2C missense 23555315 rs10913157 chr1 171486912 G A 2.17E-05 Lung function (forced expiratory volume in 1 second) PRRC2C missense pha003102 rs2272810 chr1 171511442 A G 2.47E-04 Multiple complex diseases PRRC2C intron 17554300 rs2421847 chr1 171557600 A G 9.00E-07 Alzheimer's disease (cognitive decline) PRRC2C missense 23535033 rs929115 chr1 171591189 T G 6.88E-04 Type 2 diabetes / / 20818381 rs12035960 chr1 171615206 C T 8.11E-05 Height MYOC intron pha003011 rs235913 chr1 171618656 T G 6.71E-04 White matter integrity MYOC intron 22425255 rs11800109 chr1 171639099 T C 1.46E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs11576221 chr1 171653696 A G 9.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12081515 chr1 171680631 A G 8.70E-05 Bipolar disorder and schizophrenia VAMP4 intron 20889312 rs1001373 chr1 171684506 G A 9.77E-05 Erythrocyte counts VAMP4 intron pha003099 rs10913582 chr1 171715585 G A 6.50E-04 Smoking initiation / / 24665060 rs17649250 chr1 171720586 G C 5.93E-07 Lymphocyte counts / / 22286170 rs17650204 chr1 171755071 A G 7.76E-04 Iron levels METTL13 cds-synon pha002876 rs6668165 chr1 171794638 G C 5.13E-04 Multiple complex diseases / / 17554300 rs10753196 chr1 171797810 A G 3.12E-06 Cognitive test performance / / 20125193 rs6683945 chr1 171840264 G A 1.45E-05 Insulin-related traits DNM3 intron 19902172 rs12121064 chr1 171863472 T G 7.03E-05 Body Mass Index DNM3 intron pha003015 rs10798751 chr1 171889347 T G 9.72E-04 Multiple complex diseases DNM3 intron 17554300 rs2093184 chr1 171892085 G A 9.61E-04 Alzheimer's disease DNM3 intron 17998437 rs6673413 chr1 171896950 T C 7.01E-06 Lipid traits DNM3 intron 21777205 rs2038479 chr1 171939290 C A 1.34E-09 Metabolite levels DNM3 intron 23281178 rs6425521 chr1 171942783 C A 1.32E-06 Kawasaki disease DNM3 intron 21221998 rs10914127 chr1 171943948 A G 1.07E-09 Metabolite levels DNM3 intron 23281178 rs2180748 chr1 171947018 T G 2.00E-08 Mean platelet volume DNM3 intron 24026423 rs10914141 chr1 171947316 G T 1.05E-05 Multiple complex diseases DNM3 intron 17554300 rs10914144 chr1 171949750 T C 2.00E-14 Mean platelet volume DNM3 intron 19820697 rs10914144 chr1 171949750 T C 1.00E-24 Mean platelet volume DNM3 intron 22139419 rs10914144 chr1 171949750 T C 2.00E-12 Platelet counts DNM3 intron 22139419 rs10914144 chr1 171949750 T C 2.10E-14 Mean platelet volume DNM3 intron 22423221 rs10914144 chr1 171949750 T C 1.49E-08 Metabolite levels DNM3 intron 23281178 rs10914144 chr1 171949750 T C 2.00E-08 Mean platelet volume DNM3 intron 24026423 rs2208370 chr1 171955331 G A 2.00E-04 Cognitive impairment induced by topiramate DNM3 intron 22091778 rs17346452 chr1 172053287 T C 1.00E-23 Height DNM3 intron 20881960 rs4244192 chr1 172072635 A G 6.37E-04 Alzheimer's disease DNM3 intron 17998437 rs4604727 chr1 172090738 C G 1 Drug response to Etoposide DNM3 intron 17537913 rs2421987 chr1 172100831 G A 3.50E-05 Endometriosis DNM3 intron 21151130 rs2421987 chr1 172100831 G A 9.10E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs10911111 chr1 172117680 A G 3.90E-04 Alzheimer's disease DNM3 intron 17998437 rs10911112 chr1 172118780 G A 6.59E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs2146901 chr1 172119559 T C 1.60E-04 Endometriosis DNM3 intron 21151130 rs2146901 chr1 172119559 T C 3.78E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs2181624 chr1 172119582 C G 1.43E-04 Alzheimer's disease DNM3 intron 17998437 rs10797791 chr1 172121859 G A 6.16E-04 Alzheimer's disease DNM3 intron 17998437 rs10797791 chr1 172121859 G A 6.78E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs650169 chr1 172188062 C T 7.12E-04 Type 2 diabetes DNM3 intron 17463246 rs678962 chr1 172189889 T G 3.00E-08 Height DNM3 intron 18391951 rs678962 chr1 172189889 T G 6.97E-05 Cognitive test performance DNM3 intron 20125193 rs479336 chr1 172199573 T G 9.00E-15 Bone mineral density DNM3 intron 22504420 rs12075079 chr1 172219995 A G 8.24E-05 Cognitive test performance DNM3 intron 20125193 rs12075079 chr1 172219995 A G 7.00E-12 Height DNM3 intron 23563607 rs10489290 chr1 172223403 C A 4.86E-05 Cognitive test performance DNM3 intron 20125193 rs2421992 chr1 172241251 C T 5.00E-08 Height DNM3 intron 20881960 rs12139001 chr1 172241820 G C 1.14E-05 Smoking behavior DNM3 intron 20418889 rs4619005 chr1 172257261 C A 1.38E-05 Smoking behavior DNM3 intron 20418889 rs2757490 chr1 172264401 C T 7.08E-04 Depression (quantitative trait) DNM3 intron 20800221 rs2757493 chr1 172267419 T C 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DNM3 intron 20877124 rs16844255 chr1 172271050 C T 5.16E-05 Cognitive test performance DNM3 intron 20125193 rs17368984 chr1 172318558 T C 2.20E-05 Urinary metabolites DNM3 intron 21572414 rs6676665 chr1 172346174 C A 6.29E-04 Type 2 diabetes DNM3 intron 17463246 rs6676665 chr1 172346174 C A 0.00000016 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs4916251 chr1 172346396 T A 4.10E-04 Type 2 diabetes DNM3 intron 17463246 rs4916251 chr1 172346396 T A 0.000000188 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs4916251 chr1 172346396 T A 0.00065 Abdominal aortic aneurysm DNM3 intron 23246012 rs1011731 chr1 172346548 G A 9.58E-05 Multiple sclerosis DNM3 intron 17660530 rs1011731 chr1 172346548 G A 1.00E-17 Waist-hip ratio DNM3 intron 20935629 rs3213564 chr1 172349921 G A 0.000000327 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs9425586 chr1 172351052 T C 6.40E-04 Type 2 diabetes DNM3 intron 17463246 rs9425586 chr1 172351052 T C 0.000000158 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs1023479 chr1 172355132 G A 7.02E-04 Type 2 diabetes DNM3 intron 17463246 rs1023479 chr1 172355132 G A 0.000000159 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs2213731 chr1 172359815 C A 0.000000208 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs2227198 chr1 172360164 A G 2.21E-04 Substance dependence DNM3 intron 21818250 rs3768445 chr1 172362949 G T 8.15E-08 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs10489284 chr1 172367062 A G 6.19E-04 Suicide attempts in bipolar disorder DNM3 intron 21041247 rs4471302 chr1 172367137 T C 6.13E-04 Suicide attempts in bipolar disorder DNM3 intron 21041247 rs6698987 chr1 172368967 T C 5.41E-04 Type 2 diabetes DNM3 intron 17463246 rs6698987 chr1 172368967 T C 1.76E-04 Alcohol dependence DNM3 intron 21314694 rs1063412 chr1 172410967 G A 0.000000014 Soluble CD14 PIGC missense 23162014 rs4916266 chr1 172450795 C A 1.66E-04 Multiple complex diseases / / 17554300 rs16844585 chr1 172453197 T G 0.00000855 Inter-adventitial common carotid artery diameter / / 23246012 rs2213736 chr1 172464497 C T 6.97E-04 Multiple complex diseases / / 17554300 rs10489279 chr1 172498216 G A 0.000789097 Hypertension (early onset hypertension) / / 22479346 rs7518180 chr1 172583137 C T 0.000000176 Triglycerides / / 23063622 rs2859242 chr1 172624864 C T 6.73E-05 Alcohol dependence / / 20201924 rs2859242 chr1 172624864 C T 6.73E-05 Alcoholism / / pha002891 rs10458360 chr1 172633975 G C 4.27E-04 Type 2 diabetes FASLG intron 17463246 rs6673027 chr1 172645898 C T 7.09E-05 Blood Pressure / / pha003049 rs859670 chr1 172673322 C A 6.08E-04 Multiple complex diseases / / 17554300 rs12068671 chr1 172681031 T C 1.40E-10 Celiac disease / / 22057235 rs859637 chr1 172711000 T C 2.00E-06 Celiac disease / / 20190752 rs859624 chr1 172730829 T C 2.70E-05 Allergic sensitization / / 23817571 rs11810332 chr1 172789765 A G 1.58E-05 Asthma / / pha003128 rs10912477 chr1 172795995 A C 1.49E-04 Type 2 diabetes / / 17463246 rs10912477 chr1 172795995 A C 7.78E-04 Tourette syndrome / / 22889924 rs10912477 chr1 172795995 A C 1.57E-05 Asthma / / pha003128 rs12037853 chr1 172852403 A G 9.46E-05 Multiple complex diseases / / 17554300 rs7517810 chr1 172853460 C T 2.00E-15 Crohn's disease / / 21102463 rs9286879 chr1 172862234 A G 2.00E-09 Crohn's disease / / 18587394 rs9286879 chr1 172862234 A G 2.00E-09 Asthma / / 21150878 rs9286879 chr1 172862234 A G 1.53E-09 Multiple sclerosis / / 22190364 rs9286879 chr1 172862234 A G 6.00E-22 Crohn's disease / / 23128233 rs9286879 chr1 172862234 A G 8.25E-07 Celiac disease / / 24999842 rs10489276 chr1 172862939 C T 3.98E-05 Multiple complex diseases / / 17554300 rs10489276 chr1 172862939 C T 9.01E-08 Crohn's disease / / 18587394 rs2157453 chr1 172863948 G A 8.00E-07 Celiac disease / / 24999842 rs12142280 chr1 172864652 T A 8.30E-09 Celiac disease / / 22057235 rs4145469 chr1 172874991 C G 1.60E-06 Multiple complex diseases / / 17554300 rs6688532 chr1 172892952 A C 8.16E-07 Multiple complex diseases / / 17554300 rs12035082 chr1 172898377 T C 2.00E-07 Crohn's disease / / 17554261 rs12035082 chr1 172898377 T C 3.97E-07 Multiple complex diseases / / 17554300 rs12037606 chr1 172898402 G A 3.37E-07 Multiple complex diseases / / 17554300 rs7517726 chr1 172913577 C G 1.99E-06 Multiple complex diseases / / 17554300 rs4916290 chr1 172914284 G C 2.14E-05 Multiple complex diseases / / 17554300 rs16845215 chr1 172942014 G A 1.90E-05 Multiple complex diseases / / 17554300 rs6693531 chr1 172948860 C T 3.02E-04 Multiple complex diseases / / 17554300 rs6697964 chr1 172962496 G A 5.82E-04 Multiple complex diseases / / 17554300 rs2092357 chr1 172973645 G A 9.45E-05 Panic disorder / / 19165232 rs6425196 chr1 172981545 A G 8.19E-04 Diabetic retinopathy / / 20871662 rs12122495 chr1 172982715 C G 1.54E-04 Multiple complex diseases / / 17554300 rs12117214 chr1 172985389 G A 1.34E-04 Multiple complex diseases / / 17554300 rs1033465 chr1 172987730 T A 1.56E-04 Multiple complex diseases / / 17554300 rs16845306 chr1 173008568 T C 7.14E-04 Multiple complex diseases / / 17554300 rs9286880 chr1 173018680 T G 2.62E-08 Metabolite levels TNFSF18 intron 23281178 rs7537126 chr1 173021349 T C 5.66E-04 Diabetic retinopathy / / 20871662 rs4916297 chr1 173037763 C T 9.83E-09 Metabolite levels / / 23281178 rs2422272 chr1 173049073 G A 1.41E-08 Metabolite levels / / 23281178 rs202148845 chr1 173050272 G GA 2.91E-08 Metabolite levels / / 23281178 rs2223833 chr1 173050272 G A 2.91E-08 Metabolite levels / / 23281178 rs2207060 chr1 173055263 A C 6.17E-09 Metabolite levels / / 23281178 rs6425203 chr1 173064279 C T 1.25E-08 Metabolite levels / / 23281178 rs974363 chr1 173071389 G T 8.11E-09 Metabolite levels / / 23281178 rs6674831 chr1 173075630 G A 9.43E-09 Metabolite levels / / 23281178 rs10912533 chr1 173079943 C T 7.93E-09 Metabolite levels / / 23281178 rs4916306 chr1 173085211 T G 9.41E-09 Metabolite levels / / 23281178 rs12034497 chr1 173092191 A G 7.99E-09 Metabolite levels / / 23281178 rs6663179 chr1 173110953 A G 4.20E-04 Multiple complex diseases / / 17554300 rs10912551 chr1 173119967 G T 9.91E-04 Acute lung injury / / 22295056 rs7553711 chr1 173131908 T C 4.08E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10157163 chr1 173132965 C T 9.67E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6665456 chr1 173140765 T C 0.000000074 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16845506 chr1 173141800 T A,G 0.0000049 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6676785 chr1 173145017 A G 8.08E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs4916312 chr1 173146357 G A 0.000000099 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs4090391 chr1 173147090 C T 7.73E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10127495 chr1 173148671 A C 8.49E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs11811788 chr1 173150727 C G 4.23E-04 Acute lung injury / / 22295056 rs11811788 chr1 173150727 C G 0.00003 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10127727 chr1 173150964 G A 0.00000561 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6691738 chr1 173152036 T G 9.88E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs7514229 chr1 173154304 G T 1.92E-04 Acute lung injury TNFSF4 UTR-3 22295056 rs3861950 chr1 173156292 T C 2.71E-04 Acute lung injury TNFSF4 intron 22295056 rs3861950 chr1 173156292 T C 5.42E-08 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs4081545 chr1 173159516 T C 2.94E-04 Acute lung injury TNFSF4 intron 22295056 rs4081545 chr1 173159516 T C 0.000000073 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10465507 chr1 173162439 C A 0.00000633 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10798264 chr1 173163357 G A 0.00000726 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912560 chr1 173164457 A G 0.0000139 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912561 chr1 173164565 C T 0.00000657 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs4916313 chr1 173164787 T C 0.000000157 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs13343108 chr1 173168230 T C 0.0000171 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs7525284 chr1 173168397 G A 4.69E-04 Acute lung injury TNFSF4 intron 22295056 rs7525284 chr1 173168397 G A 0.0000119 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912564 chr1 173170618 C T 3.76E-04 Acute lung injury TNFSF4 intron 22295056 rs11811856 chr1 173171673 C G 7.02E-04 Acute lung injury TNFSF4 intron 22295056 rs11811856 chr1 173171673 C G 0.0000287 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs2205960 chr1 173191475 G T 3.00E-32 Systemic lupus erythematosus / / 19838193 rs2205960 chr1 173191475 G T 6.30E-09 Multiple sclerosis / / 22190364 rs2205960 chr1 173191475 G T 3.00E-12 Systemic lupus erythematosus / / 23273568 rs2205960 chr1 173191475 G T 7.82E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1012507 chr1 173219471 G T 1.60E-10 Systemic lupus erythematosus LOC100506023 intron 23273568 rs844648 chr1 173223863 G A 7.90E-08 Systemic lupus erythematosus LOC100506023 intron 23273568 rs704840 chr1 173226195 T G 1.90E-10 Systemic lupus erythematosus LOC100506023 intron 23273568 rs704840 chr1 173226195 T G 4.00E-07 Systemic lupus erythematosus and Systemic sclerosis LOC100506023 intron 23740937 rs844656 chr1 173235835 T G 7.90E-05 Alcoholism (heaviness of drinking) LOC100506023 intron 21529783 rs10489265 chr1 173236065 A C 7.60E-12 Systemic lupus erythematosus LOC100506023 intron 23273568 rs10798267 chr1 173266444 T C 3.77E-05 Diabetes Mellitus LOC100506023 intron pha003059 rs6685520 chr1 173278169 G A 4.30E-05 Personality dimensions LOC100506023 intron 18957941 rs6685520 chr1 173278169 G A 9.91E-05 Blood pressure (response to calcium channel blocker) LOC100506023 intron 24192120 rs4916321 chr1 173284199 G T 7.00E-06 Multiple sclerosis LOC100506023 intron 23412934 rs61828284 chr1 173299743 C T 0.00000547 Rheumatoid arthritis (CCP positive) LOC100506023 intron 23143596 rs61828284 chr1 173299743 C T 0.0000568 Rheumatoid arthritis LOC100506023 intron 23143596 rs17346536 chr1 173300840 A G 4.10E-06 Diabetic retinopathy LOC100506023 intron 21441570 rs1342038 chr1 173301516 G A 4.00E-06 Diabetic retinopathy LOC100506023 intron 21441570 rs10798269 chr1 173309713 A G 1.00E-07 Systemic lupus erythematosus LOC100506023 intron 18204446 rs1539259 chr1 173312501 T G 8.58E-04 Amyotrophic Lateral Sclerosis LOC100506023 intron 17362836 rs1857066 chr1 173332629 A C 2.32E-09 Systemic lupus erythematosus and Systemic sclerosis LOC100506023 intron 23740937 rs17350697 chr1 173333916 C T 1.90E-04 Attention deficit hyperactivity disorder LOC100506023 intron pha002875 rs2105325 chr1 173349725 A C 3.00E-11 Rheumatoid arthritis LOC100506023 intron 24390342 rs2105325 chr1 173349725 A C 7.00E-13 Rheumatoid arthritis LOC100506023 intron 24390342 rs6701588 chr1 173353159 G A 4.21E-05 Asthma LOC100506023 intron 22561531 rs1557121 chr1 173353881 T C 7.70E-06 Myasthenia gravis LOC100506023 intron 23055271 rs4294450 chr1 173389640 C T 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs3934576 chr1 173398436 T C 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs3934575 chr1 173398533 T C 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs6660804 chr1 173438399 C A 7.89E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs912767 chr1 173456445 A G 6.59E-04 Response to taxane treatment (placlitaxel) PRDX6 intron 23006423 rs7521536 chr1 173465265 T C 3.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12065426 chr1 173470105 A G 3.61E-04 Response to taxane treatment (placlitaxel) SLC9A11 UTR-3 23006423 rs12037210 chr1 173474773 C T 7.85E-04 Smoking quantity SLC9A11 intron 24665060 rs16846125 chr1 173497712 A G 3.85E-04 Multiple complex diseases SLC9A11 intron 17554300 rs6425246 chr1 173516245 A G 9.16E-04 Multiple complex diseases SLC9A11 intron 17554300 rs12027862 chr1 173532805 G A 5.01E-04 Multiple complex diseases SLC9A11 intron 17554300 rs898658 chr1 173541768 T C 7.69E-04 Multiple complex diseases SLC9A11 intron 17554300 rs898657 chr1 173542017 G T 6.60E-04 Multiple complex diseases SLC9A11 intron 17554300 rs6691482 chr1 173542864 T C 2.17E-06 Cognition,early reading ability SLC9A11 intron 17684495 rs6691482 chr1 173542864 T C 4.00E-05 Breast cancer and prostate cancer SLC9A11 intron 17903305 rs6684491 chr1 173551720 A T 1.38E-05 Age-related macular degeneration SLC9A11 intron pha000001 rs6678784 chr1 173574871 A G 4.80E-06 Age-related macular degeneration / / pha000001 rs12065033 chr1 173579034 C T 3.39E-06 Age-related macular degeneration ANKRD45 UTR-3 pha000001 rs7550036 chr1 173682365 G A 1.44E-05 Age-related macular degeneration / / pha000001 rs10912671 chr1 173689891 A G 1.87E-04 Type 2 diabetes KLHL20 intron 17463246 rs6425256 chr1 173722545 A G 5.62E-04 Multiple complex diseases KLHL20 intron 17554300 rs16846395 chr1 173725101 G A 1.28E-05 Multiple complex diseases KLHL20 cds-synon 17554300 rs16846398 chr1 173725376 C G 5.65E-04 Multiple complex diseases KLHL20 intron 17554300 rs7536773 chr1 173735378 T C 1.44E-05 Age-related macular degeneration KLHL20 cds-synon pha000001 rs6692452 chr1 173754505 A G 1.44E-05 Age-related macular degeneration KLHL20 UTR-3 pha000001 rs2144708 chr1 173780119 A G 7.02E-05 Type 2 diabetes CENPL intron 17463246 rs3791020 chr1 173813197 G A 5.71E-07 Type 2 diabetes DARS2 intron 17463246 rs6691327 chr1 173813448 T G 4.10E-04 Multiple complex diseases DARS2 intron 17554300 rs6691327 chr1 173813448 T G 1.44E-05 Age-related macular degeneration DARS2 intron pha000001 rs2295366 chr1 173825692 T G 1.17E-06 Type 2 diabetes DARS2 intron 17463246 rs2065170 chr1 173845232 T C 9.26E-05 Cholesterol ZBTB37 intron 17255346 rs35571466 chr1 173852874 A G 3.92E-04 Type 2 diabetes ZBTB37 intron 17463246 rs9425766 chr1 173853127 T C 4.62E-04 Type 2 diabetes ZBTB37 intron 17463246 rs16846526 chr1 173856237 G A 9.10E-05 Cholesterol / / 17255346 rs9425430 chr1 173857283 A G 4.85E-04 Type 2 diabetes / / 17463246 rs16846546 chr1 173860182 T C 8.55E-05 Cholesterol / / 17255346 rs10489894 chr1 173866024 A G 2.81E-04 Type 2 diabetes / / 17463246 rs6691053 chr1 173868955 C T 2.37E-05 Educational attainment / / 21694764 rs9425436 chr1 173870364 G A 3.30E-04 Type 2 diabetes / / 17463246 rs2227611 chr1 173875467 A G 4.06E-08 LDL cholesterol SERPINC1 intron 23063622 rs2759328 chr1 173876705 C T 1.44E-04 Cholesterol SERPINC1 intron 17255346 rs5878 chr1 173878832 T C 6.24E-04 Type 2 diabetes SERPINC1 cds-synon 17463246 rs5878 chr1 173878832 T C 4.05E-04 Multiple complex diseases SERPINC1 cds-synon 17554300 rs941989 chr1 173881871 C T 7.39E-04 Type 2 diabetes SERPINC1 intron 17463246 rs941988 chr1 173881893 C T 7.77E-05 Cholesterol SERPINC1 intron 17255346 rs2227589 chr1 173886216 C T 7.11E-05 Cholesterol SERPINC1 intron 17255346 rs1951627 chr1 173891817 G A 5.44E-05 Lymphocyte counts / / 22286170 rs10912711 chr1 173961992 T C 8.37E-04 Multiple complex diseases RC3H1 cds-synon 17554300 rs10912742 chr1 174160343 C T 1.89E-07 Multiple complex diseases RABGAP1L intron 17554300 rs16846809 chr1 174219398 A G 6.70E-04 Asthma RABGAP1L intron 20698975 rs6670617 chr1 174246712 C A 8.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs4650989 chr1 174258877 G A 3.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs7555067 chr1 174266642 C T 8.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs17301013 chr1 174312813 C T 5.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs12094364 chr1 174356463 C A 1.38E-04 Multiple complex diseases RABGAP1L intron 17554300 rs10489257 chr1 174359128 G A 1.40E-04 Multiple complex diseases RABGAP1L intron 17554300 rs17373189 chr1 174369767 A G 3.90E-05 Anger RABGAP1L intron 24489884 rs10489261 chr1 174440683 C T 1.10E-04 Asthma RABGAP1L intron 20698975 rs12088073 chr1 174497642 A C 5.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6425284 chr1 174499977 G A 3.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6425284 chr1 174499977 G A 7.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) RABGAP1L intron 23648065 rs17301853 chr1 174552811 C T 1.00E-06 Migraine without aura RABGAP1L intron 23793025 rs17301853 chr1 174552811 C T 7.00E-06 Migraine - clinic-based RABGAP1L intron 23793025 rs6664864 chr1 174592050 A G 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6692753 chr1 174737457 G T 4.20E-04 Asthma RABGAP1L intron 20698975 rs3018410 chr1 174818547 A G 3.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs3753563 chr1 174923346 T C 7.70E-05 Alcoholism (heaviness of drinking) RABGAP1L intron 21529783 rs6686962 chr1 174953569 C A 2.63E-04 Birth weight RABGAP1L intron 17255346 rs10912870 chr1 174988016 C T 7.25E-04 Response to taxane treatment (placlitaxel) MRPS14 intron 23006423 rs12409660 chr1 175022207 G C 1.79E-05 Suicide attempts in bipolar disorder / / 21041247 rs1009418 chr1 175029547 A T 7.12E-05 Birth weight / / 17255346 rs10798331 chr1 175034437 A G 4.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs10912878 chr1 175034643 A T 1.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs16847812 chr1 175049379 G A 8.16E-04 Fibrinogen TNN missense 17255346 rs7521981 chr1 175091151 G A 2.60E-05 Urinary metabolites TNN intron 21572414 rs2072041 chr1 175092840 T C 8.34E-04 Rheumatoid arthritis TNN intron 21452313 rs12094153 chr1 175094025 G A 5.49E-05 Alcohol dependence TNN intron 21703634 rs4651322 chr1 175104719 T C 7.98E-04 Rheumatoid arthritis TNN intron 21452313 rs2072038 chr1 175105778 T C 3.40E-05 HIV-1 control TNN intron 20041166 rs2157588 chr1 175107826 C T 7.16E-05 Alcohol dependence TNN intron 21703634 rs12135071 chr1 175117548 C T 7.44E-05 Epilepsy (remission after treatment) / / 23962720 rs6701037 chr1 175120079 A C 1.75E-06 Alcohol dependence / / 20202923 rs6701037 chr1 175120079 A C 2.00E-07 Alcohol dependence / / 21703634 rs6701037 chr1 175120079 A C 2.30E-04 Alcohol dependence / / 21956439 rs6701037 chr1 175120079 A C 0.0000331 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg / / 22661486 rs73032636 chr1 175122587 C T 7.30E-05 Epilepsy (remission after treatment) / / 23962720 rs56237830 chr1 175124377 C T 8.70E-05 Epilepsy (remission after treatment) / / 23962720 rs6425323 chr1 175125036 C T 2.27E-06 Alcohol dependence / / 20202923 rs6425323 chr1 175125036 C T 3.13E-07 Alcohol dependence / / 21703634 rs6425323 chr1 175125036 C T 2.80E-04 Alcohol dependence / / 21956439 rs1057302 chr1 175126423 A G 1.94E-06 Alcohol dependence KIAA0040 UTR-3 20202923 rs1057302 chr1 175126423 A G 5.12E-07 Alcohol dependence KIAA0040 UTR-3 21703634 rs1057302 chr1 175126423 A G 6.20E-04 Alcohol dependence KIAA0040 UTR-3 21956439 rs1057285 chr1 175126845 T C 2.86E-05 Epilepsy (remission after treatment) KIAA0040 UTR-3 23962720 rs4650716 chr1 175128711 C A 2.57E-05 Alcohol dependence KIAA0040 UTR-3 21703634 rs1057239 chr1 175130204 G A 2.01E-06 Alcohol dependence KIAA0040 UTR-5 20202923 rs1057239 chr1 175130204 G A 1.93E-06 Alcohol dependence KIAA0040 UTR-5 21703634 rs1057239 chr1 175130204 G A 3.10E-04 Alcohol dependence KIAA0040 UTR-5 21956439 rs1057239 chr1 175130204 G A 1.20E-06 Alcohol and nictotine co-dependence KIAA0040 UTR-5 22488850 rs1894709 chr1 175132371 G T 2.78E-06 Alcohol dependence KIAA0040 intron 20202923 rs1894709 chr1 175132371 G T 2.12E-06 Alcohol dependence KIAA0040 intron 21703634 rs1894709 chr1 175132371 G T 4.30E-04 Alcohol dependence KIAA0040 intron 21956439 rs1894709 chr1 175132371 G T 1.60E-06 Alcohol and nictotine co-dependence KIAA0040 intron 22488850 rs10489327 chr1 175134314 C T 2.70E-05 Urinary metabolites KIAA0040 intron 21572414 rs10489326 chr1 175134677 A G 4.90E-05 Alcohol dependence KIAA0040 intron 21703634 rs760486 chr1 175137376 G T 2.48E-04 Alzheimer's disease KIAA0040 intron 17998437 rs12136973 chr1 175140319 T C 3.50E-07 Amyotrophic Lateral Sclerosis KIAA0040 intron 17362836 rs1008459 chr1 175151183 T C 1.00E-07 Amyotrophic Lateral Sclerosis KIAA0040 intron 17362836 rs3766685 chr1 175156428 G C 3.10E-04 Alzheimer's disease KIAA0040 intron 17998437 rs3766682 chr1 175157838 A G 6.10E-05 Response to antidepressants KIAA0040 intron 19736353 rs760489 chr1 175172539 G A 8.84E-05 Glycosylated haemoglobin levels / / 17255346 rs760489 chr1 175172539 G A 1.05E-04 Heart Failure / / pha002884 rs875326 chr1 175289399 C T 2.10E-05 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs875326 chr1 175289399 C T 2.51E-05 Bipolar disorder / / 21926972 rs875326 chr1 175289399 C T 0.000500808 Hypertension (early onset hypertension) / / 22479346 rs7551235 chr1 175294275 G A 0.000146117 Hypertension (early onset hypertension) TNR intron 22479346 rs3766680 chr1 175296448 T C 4.00E-06 Tonometry TNR intron 17903302 rs10489319 chr1 175320746 T C 8.46E-06 Stroke (ischemic) TNR intron 22941190 rs2236886 chr1 175321636 C G,T 8.29E-06 Stroke (ischemic) TNR intron 22941190 rs16848281 chr1 175322842 T C 9.95E-04 Obesity (extreme) TNR intron 21935397 rs10912966 chr1 175323386 G A 7.90E-04 Obesity (extreme) TNR intron 21935397 rs10798390 chr1 175326303 A G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs16848304 chr1 175336185 G C 9.39E-04 Obesity (extreme) TNR intron 21935397 rs16848329 chr1 175339089 A G 7.85E-06 Stroke (ischemic) TNR intron 22941190 rs16848353 chr1 175341548 G A 8.01E-06 Stroke (ischemic) TNR intron 22941190 rs12730963 chr1 175342485 T C 8.15E-06 Stroke (ischemic) TNR intron 22941190 rs7534171 chr1 175358778 G T 1.68E-04 Multiple complex diseases TNR intron 17554300 rs859468 chr1 175381926 C T 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs6666777 chr1 175391741 C T 7.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) TNR intron 23648065 rs2105913 chr1 175410119 G A 2.19E-05 Hypertension TNR intron 19609347 rs873525 chr1 175419201 G A 7.35E-04 Coronary heart disease TNR intron 21606135 rs7548041 chr1 175440469 C T 6.12E-05 Bipolar disorder and schizophrenia TNR intron 20889312 rs12081663 chr1 175476197 G T 4.90E-04 Type 2 diabetes TNR intron 17463246 rs7515041 chr1 175505966 A G 9.82E-07 Obesity and osteoporosis TNR intron 19714249 rs7515041 chr1 175505966 A G 1.30E-05 Urinary metabolites TNR intron 21572414 rs1534901 chr1 175511784 G A 4.80E-06 Urinary metabolites TNR intron 21572414 rs7540211 chr1 175528957 T G 2.88E-04 Age-related macular degeneration TNR intron 22125219 rs10913008 chr1 175531634 G A 2.99E-04 Schizophrenia TNR intron 19197363 rs7539708 chr1 175569473 A G 1.42E-05 HIV-1 viral setpoint TNR intron 17641165 rs1323127 chr1 175579354 A C 5.34E-04 Type 2 diabetes TNR intron 17463246 rs1359047 chr1 175582788 T C 6.67E-06 Rheumatoid arthritis TNR intron 19503088 rs1359047 chr1 175582788 T C 8.12E-05 Attention deficit hyperactivity disorder TNR intron 22420046 rs10798406 chr1 175586033 A C 4.79E-04 Aortic root size TNR intron 21223598 rs12030347 chr1 175587531 G C 5.97E-04 Aortic root size TNR intron 21223598 rs12037583 chr1 175593305 C T 8.26E-05 HIV-1 viral setpoint TNR intron 17641165 rs998677 chr1 175642887 G A 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs7544659 chr1 175647041 A G 2.47E-04 Coronary Artery Disease TNR intron 17634449 rs12401659 chr1 175652529 T C 7.15E-04 Multiple complex diseases TNR intron 17554300 rs12404663 chr1 175658531 G A 9.80E-06 Urinary metabolites TNR intron 21572414 rs12404663 chr1 175658531 G A 7.80E-04 Alzheimer's disease TNR intron 22005930 rs1535578 chr1 175664240 G C 3.11E-04 Alzheimer's disease TNR intron 22005930 rs1155910 chr1 175664892 C T 3.21E-04 Alzheimer's disease TNR intron 22005930 rs12034759 chr1 175667600 G A 2.83E-05 Alzheimer's disease TNR intron 22005930 rs7539097 chr1 175669902 A G 2.93E-05 Alzheimer's disease TNR intron 22005930 rs7527642 chr1 175670134 C A 2.91E-05 Alzheimer's disease TNR intron 22005930 rs4652109 chr1 175670201 T C 3.70E-04 Response to cytadine analogues (cytosine arabinoside) TNR intron 24483146 rs16848982 chr1 175671241 T A 2.65E-05 Alzheimer's disease TNR intron 22005930 rs12408049 chr1 175671536 C T 3.70E-06 Urinary metabolites TNR intron 21572414 rs12408049 chr1 175671536 C T 2.59E-05 Alzheimer's disease TNR intron 22005930 rs12404438 chr1 175671940 A G 2.56E-05 Alzheimer's disease TNR intron 22005930 rs10913061 chr1 175672947 G C 3.51E-05 Alzheimer's disease TNR intron 22005930 rs12034220 chr1 175675281 T G 2.55E-05 Alzheimer's disease TNR intron 22005930 rs10913063 chr1 175675596 G A 6.52E-04 Multiple complex diseases TNR intron 17554300 rs12038088 chr1 175678789 T G 2.13E-05 Alzheimer's disease TNR intron 22005930 rs12038088 chr1 175678789 T G 2.97E-04 Smoking initiation TNR intron 24665060 rs12049604 chr1 175680596 C A 5.40E-06 Urinary metabolites TNR intron 21572414 rs12049604 chr1 175680596 C A 2.29E-05 Alzheimer's disease TNR intron 22005930 rs12042335 chr1 175680758 G C 4.12E-05 Alzheimer's disease TNR intron 22005930 rs17377915 chr1 175712027 G A 7.30E-04 Obesity (extreme) TNR intron 21935397 rs17312292 chr1 175715606 G C 7.00E-06 Corneal astigmatism / / 23322567 rs12127628 chr1 175719996 G A 8.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs535335 chr1 175728110 T C 3.10E-06 Personality dimensions / / 23658558 rs16849103 chr1 175729733 G T 1.55E-04 Multiple complex diseases / / 17554300 rs671000 chr1 175731846 T C 4.21E-06 Personality dimensions / / 23658558 rs501915 chr1 175732289 C T 5.71E-06 Personality dimensions / / 23658558 rs6425361 chr1 175756706 T C 5.65E-06 Personality dimensions / / 23658558 rs491132 chr1 175832906 A G 4.10E-06 Iron levels / / 21208937 rs6656281 chr1 175886511 A G 6.28E-04 Tourette syndrome / / 22889924 rs6687849 chr1 175904809 C T 6.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs1357338 chr1 175930886 A G 9.15E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs1357337 chr1 175930937 C T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs6704250 chr1 175932662 G C 3.00E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs4622022 chr1 176014340 C A 5.61E-04 Type 2 diabetes RFWD2 intron 17846125 rs12033847 chr1 176027978 C T 2.68E-05 HIV-1 control RFWD2 intron 20041166 rs2502826 chr1 176043797 C T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs2481653 chr1 176044121 A C 5.65E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs2481627 chr1 176092167 T G 5.71E-05 Elbow pain RFWD2 intron pha003008 rs10913150 chr1 176172795 G T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs191606 chr1 176241018 A G 2.19E-05 Serum metabolites / / 19043545 rs2455738 chr1 176291703 C T 3.10E-04 Lung function (forced vital capacity) / / 24023788 rs4471226 chr1 176423140 C T 2.96E-04 Fractional exhaled nitric oxide (childhood) / / 24315451 rs4471226 chr1 176423140 C T 3.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs7553073 chr1 176429600 A G 5.59E-06 Stroke (ischemic) / / 22941190 rs7531549 chr1 176434044 G A 3.91E-07 Stroke (ischemic) PAPPA2 intron 22941190 rs7515586 chr1 176435567 C T 4.36E-07 Stroke (ischemic) PAPPA2 intron 22941190 rs7536647 chr1 176440645 G T 1.48E-04 Smoking initiation PAPPA2 intron 24665060 rs6671694 chr1 176520317 C T 9.65E-04 Response to taxane treatment (placlitaxel) PAPPA2 intron 23006423 rs1506780 chr1 176550847 T C 1.16E-04 Multiple complex diseases PAPPA2 intron 17554300 rs10913209 chr1 176554443 G A 3.78E-04 Age-related macular degeneration PAPPA2 intron 22125219 rs10798473 chr1 176646383 A G 9.45E-05 Serum metabolites PAPPA2 intron 19043545 rs4507975 chr1 176684432 A G 4.00E-09 Venous thromboembolism (gene x gene interaction) PAPPA2 intron 23509962 rs1555070 chr1 176772958 T C 1.71E-04 Multiple complex diseases PAPPA2 intron 17554300 rs1555070 chr1 176772958 T C 0.000244 Oxaliplatin induced neuropathy in response to colorectal cancer treatment PAPPA2 intron 22310351 rs6656137 chr1 176775678 C T 4.55E-04 Type 2 diabetes PAPPA2 intron 17463246 rs10913257 chr1 176778610 G T 3.70E-04 Type 2 diabetes PAPPA2 intron 17463246 rs1022523 chr1 176788394 G A 8.40E-05 Coronary heart disease PAPPA2 intron pha003032 rs1325598 chr1 176792249 A G 1.00E-09 Height PAPPA2 intron 20881960 rs12118034 chr1 176809368 C T 7.33E-04 Type 2 diabetes PAPPA2 cds-synon 17463246 rs2294494 chr1 176812620 T C 7.79E-04 Multiple complex diseases / / 17554300 rs1883431 chr1 176812896 C T 2.39E-04 Type 2 diabetes / / 17463246 rs16850248 chr1 176813430 C T 9.69E-05 Multiple complex diseases / / 17554300 rs16850255 chr1 176818541 T C 1.18E-05 Longevity / / 20304771 rs12094387 chr1 176819875 T C 1.23E-05 Longevity / / 20304771 rs1534957 chr1 176821057 G A 1.26E-05 Longevity / / 20304771 rs10913265 chr1 176832273 C T 5.09E-04 Multiple complex diseases ASTN1 UTR-3 17554300 rs17313104 chr1 176852976 G C 8.13E-04 Type 2 diabetes ASTN1 intron 17463246 rs6664879 chr1 176871637 G T 8.47E-04 Type 2 diabetes ASTN1 intron 17463246 rs10913275 chr1 176878265 G A 8.12E-04 Type 2 diabetes ASTN1 intron 17463246 rs10913281 chr1 176942706 C T 4.94E-04 Multiple complex diseases ASTN1 intron 17554300 rs12135256 chr1 176975445 C G 9.76E-04 Alcohol dependence ASTN1 intron 21314694 rs12135256 chr1 176975445 C G 5.50E-04 QT interval ASTN1 intron 22726844 rs2861887 chr1 177041997 C T 1.10E-25 Narcolepsy ASTN1 intron 19629137 rs6425412 chr1 177073727 A G 0.0002 Migraine ASTN1 intron 22678113 rs227519 chr1 177089904 A G 6.99E-04 Type 2 diabetes ASTN1 intron 17463246 rs12090000 chr1 177152360 A G 4.12E-04 Type 2 diabetes FAM5B intron 17463246 rs12090000 chr1 177152360 A G 0.0002 Migraine FAM5B intron 22678113 rs1521442 chr1 177164539 C T 8.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FAM5B intron 20031582 rs760689 chr1 177194569 C G 1.80E-05 Urinary metabolites FAM5B intron 21572414 rs6683060 chr1 177196068 G T 9.64E-05 Multiple complex diseases FAM5B intron 17554300 rs6674725 chr1 177198818 G T 6.67E-05 Postoperative ventricular dysfunction FAM5B intron 21980348 rs926319 chr1 177204137 C A 7.25E-04 Multiple complex diseases FAM5B intron 17554300 rs6699955 chr1 177214110 T C 4.60E-04 Multiple complex diseases FAM5B intron 17554300 rs12744134 chr1 177223673 G A 8.85E-05 Postoperative ventricular dysfunction FAM5B intron 21980348 rs12083865 chr1 177230782 C T 1.32E-05 Telomere length FAM5B intron 20139977 rs10798508 chr1 177232064 C T 7.21E-04 Multiple complex diseases FAM5B intron 17554300 rs2139876 chr1 177237394 C T 8.03E-04 Multiple complex diseases FAM5B intron 17554300 rs2139876 chr1 177237394 C T 3.22E-05 Serum metabolites FAM5B intron 19043545 rs11587000 chr1 177261108 G A 5.52E-05 Cholesterol / / pha003073 rs16851037 chr1 177271313 G A 7.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs2861972 chr1 177274018 A G 7.92E-04 Type 2 diabetes / / 17463246 rs1123317 chr1 177300379 C T 4.05E-06 Cholesterol / / pha003073 rs1123317 chr1 177300379 C T 2.86E-05 ldl cholesterol / / pha003076 rs1123317 chr1 177300379 C T 1.82E-05 Cholesterol / / pha003078 rs4652245 chr1 177302972 G T 5.50E-04 Type 2 diabetes / / 17463246 rs4140633 chr1 177304940 A G 4.38E-04 Type 2 diabetes / / 17463246 rs3946142 chr1 177305858 C T 4.96E-04 Type 2 diabetes / / 17463246 rs6425419 chr1 177309473 G A 3.75E-04 Multiple complex diseases / / 17554300 rs4650963 chr1 177309490 G T 1.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6658794 chr1 177314198 G A 1.19E-04 Type 2 diabetes / / 17463246 rs1107923 chr1 177332967 C A 2.13E-04 Multiple complex diseases / / 17554300 rs2902103 chr1 177341802 T G 1.80E-04 Multiple complex diseases / / 17554300 rs2902103 chr1 177341802 T G 1.70E-04 Insulin resistance / / 21901158 rs7513623 chr1 177346429 C A 2.41E-04 Multiple complex diseases / / 17554300 rs10429832 chr1 177355133 C T 1.93E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs10913317 chr1 177355420 G A 3.76E-04 Multiple complex diseases / / 17554300 rs12117677 chr1 177358514 T C 2.58E-04 Multiple complex diseases / / 17554300 rs16851156 chr1 177360312 A G 4.80E-04 Multiple complex diseases / / 17554300 rs736840 chr1 177363013 A G 9.55E-05 Type 2 diabetes LOC100506128 intron 17463246 rs736840 chr1 177363013 A G 0.000649 Salmonella-induced pyroptosis LOC100506128 intron 22837397 rs6657693 chr1 177367162 T C 4.16E-04 Multiple complex diseases LOC100506128 intron 17554300 rs10913331 chr1 177380428 G A 1.87E-04 Multiple complex diseases LOC100506128 intron 17554300 rs10913334 chr1 177383617 G A 2.30E-04 Multiple complex diseases LOC100506128 intron 17554300 rs17609581 chr1 177384135 C T 1.57E-04 Multiple complex diseases LOC100506128 intron 17554300 rs12141778 chr1 177387794 C T 4.98E-04 Multiple complex diseases LOC100506128 intron 17554300 rs12026256 chr1 177433576 A G 1.67E-11 Alcohol consumption LOC100506128 intron pha001398 rs7521346 chr1 177434054 C T 7.74E-05 Smoking initiation LOC100506128 intron 24665060 rs12140698 chr1 177446916 C T 4.98E-06 Cardiovascular disease LOC100506128 intron 18179892 rs1885020 chr1 177451209 C T 1.01E-04 Celiac disease LOC100506128 intron 23936387 rs10913355 chr1 177455532 G A 9.79E-04 Multiple complex diseases LOC100506128 intron 17554300 rs16851585 chr1 177568799 C G 5.00E-06 Age-related macular degeneration / / 23326517 rs2862033 chr1 177583180 G C 9.57E-05 Serum metabolites / / 19043545 rs1252070 chr1 177600210 A C 2.85E-04 Type 2 diabetes / / 17463246 rs1252068 chr1 177602068 C T 3.02E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1252077 chr1 177615594 C T 4.53E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1252076 chr1 177617650 T C 6.13E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1572511 chr1 177621201 T C 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7529907 chr1 177639015 A G 4.08E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12035381 chr1 177648733 A G 8.29E-04 Type 2 diabetes / / 17463246 rs16851688 chr1 177648870 C T 1.73E-07 Type 2 diabetes / / 17463246 rs2104212 chr1 177651210 G A 4.91E-04 Insulin resistance / / 21901158 rs1885646 chr1 177652462 A G 1.01E-04 Schizophrenia / / 21674006 rs12140439 chr1 177722907 C A 1.00E-06 Schizophrenia / / 23894747 rs12046610 chr1 177755681 T C 5.68E-04 Coronary heart disease / / 21971053 rs4618929 chr1 177772715 T C 5.16E-04 Obesity (extreme) / / 21935397 rs4442331 chr1 177772815 G A 7.28E-04 Obesity (extreme) / / 21935397 rs4532784 chr1 177773099 G C 7.11E-04 Obesity (extreme) / / 21935397 rs4650976 chr1 177777450 C G 1.03E-04 Obesity (extreme) / / 21935397 rs4650977 chr1 177777608 G C 1.02E-04 Obesity (extreme) / / 21935397 rs6668375 chr1 177781284 C T 8.11E-04 Obesity (extreme) / / 21935397 rs76020919 chr1 177781293 C A 0.0000397 Menopause (age at onset) / / 23424626 rs6674700 chr1 177782904 C T 1.11E-04 Multiple complex diseases / / 17554300 rs4081366 chr1 177784137 C T 1.37E-06 Body mass index / / 23669352 rs74703854 chr1 177784203 A G 0.0000397 Menopause (age at onset) / / 23424626 rs116881786 chr1 177787323 A G 0.0000397 Menopause (age at onset) / / 23424626 rs10798570 chr1 177788008 T G 7.26E-04 Obesity (extreme) / / 21935397 rs10798571 chr1 177788180 T C 7.22E-04 Obesity (extreme) / / 21935397 rs78937547 chr1 177788728 T G 0.00000189 Menopause (age at onset) / / 23424626 rs4081367 chr1 177790062 T C 6.87E-04 Obesity (extreme) / / 21935397 rs10913435 chr1 177790711 T A 6.75E-04 Obesity (extreme) / / 21935397 rs79775735 chr1 177792041 C A 0.0000397 Menopause (age at onset) / / 23424626 rs117217277 chr1 177792712 A G 0.0000397 Menopause (age at onset) / / 23424626 rs12039449 chr1 177798421 T C 5.45E-04 Alzheimer's disease / / 22005930 rs4132288 chr1 177802710 G A 7.14E-04 Telomere length / / 23900074 rs7525646 chr1 177802872 A G 6.94E-04 Alzheimer's disease / / 22005930 rs76571116 chr1 177805878 T C 0.0000157 Menopause (age at onset) / / 23424626 rs76471454 chr1 177806598 G A 0.0000397 Menopause (age at onset) / / 23424626 rs2902200 chr1 177806838 A G 6.83E-04 Telomere length / / 23900074 rs12043001 chr1 177807335 T C 5.68E-04 Alzheimer's disease / / 22005930 rs7537762 chr1 177808463 G A 3.77E-04 Multiple complex diseases / / 17554300 rs10913445 chr1 177809560 G C 3.64E-04 Telomere length / / 23900074 rs10913446 chr1 177809861 T C 7.83E-05 Lung function (forced vital capacity) / / pha003104 rs117674205 chr1 177810653 G C 0.0000397 Menopause (age at onset) / / 23424626 rs12143390 chr1 177811306 T G 2.20E-05 Urinary metabolites / / 21572414 rs12143390 chr1 177811306 T G 6.28E-04 Alzheimer's disease / / 22005930 rs3886720 chr1 177812017 G A 6.94E-04 Alzheimer's disease / / 22005930 rs117260315 chr1 177815766 C T 0.0000397 Menopause (age at onset) / / 23424626 rs12757638 chr1 177815769 G A 6.82E-04 Obesity (extreme) / / 21935397 rs6689521 chr1 177818786 A G 7.96E-05 Lung function (forced vital capacity) / / pha003104 rs3131312 chr1 177820480 C T 4.86E-04 Obesity (extreme) / / 21935397 rs3131313 chr1 177821366 T C 6.62E-05 Multiple complex diseases / / 17554300 rs3131315 chr1 177823179 T A 4.90E-04 Obesity (extreme) / / 21935397 rs3131318 chr1 177825403 A C 4.77E-04 Obesity (extreme) / / 21935397 rs3131319 chr1 177825832 T G 9.89E-04 Obesity (extreme) / / 21935397 rs79468804 chr1 177827154 C T 0.0000397 Menopause (age at onset) / / 23424626 rs1571347 chr1 177827338 C T 9.75E-04 Obesity (extreme) / / 21935397 rs1410410 chr1 177828736 A G 4.74E-04 Obesity (extreme) / / 21935397 rs3131321 chr1 177829458 A G 4.70E-04 Obesity (extreme) / / 21935397 rs3131322 chr1 177830530 T C 8.95E-04 Obesity (extreme) / / 21935397 rs116923068 chr1 177831176 C G 0.0000397 Menopause (age at onset) / / 23424626 rs4142027 chr1 177833576 C T 9.04E-04 Obesity (extreme) / / 21935397 rs1536669 chr1 177834077 T C 4.91E-04 Obesity (extreme) / / 21935397 rs943763 chr1 177836264 A C 4.57E-04 Obesity (extreme) / / 21935397 rs633715 chr1 177852580 T C 2.00E-08 Menarche (age at onset) / / 21102462 rs633715 chr1 177852580 T C 5.70E-05 Obesity (extreme) / / 21935397 rs633715 chr1 177852580 T C 4.00E-19 Obesity / / 23563607 rs633715 chr1 177852580 T C 5.00E-12 Body mass index / / 23563607 rs633715 chr1 177852580 T C 7.00E-20 Obesity / / 23563607 rs633715 chr1 177852580 T C 9.00E-23 Obesity / / 23563607 rs10913454 chr1 177852789 C A 6.03E-06 Type 2 diabetes / / 17463246 rs10913454 chr1 177852789 C A 1.80E-04 Obesity (extreme) / / 21935397 rs10798577 chr1 177853220 C G 7.57E-06 Type 2 diabetes / / 17463246 rs10798577 chr1 177853220 C G 1.81E-04 Obesity (extreme) / / 21935397 rs516636 chr1 177855517 C A 3.00E-09 Body mass index / / 22344221 rs10798578 chr1 177856925 C T 1.96E-05 Type 2 diabetes / / 17463246 rs10798578 chr1 177856925 C T 3.93E-04 Obesity (extreme) / / 21935397 rs1336785 chr1 177859642 G C 3.96E-04 Obesity (extreme) / / 21935397 rs527065 chr1 177868882 G T 2.04E-06 Obesity (extreme) / / 21935397 rs685233 chr1 177869941 A G 4.99E-04 Type 2 diabetes / / 17463246 rs685233 chr1 177869941 A G 2.07E-06 Obesity (extreme) / / 21935397 rs623130 chr1 177871886 T C 2.12E-06 Obesity (extreme) / / 21935397 rs574367 chr1 177873210 G T 6.76E-05 Obesity (extreme) / / 21935397 rs574367 chr1 177873210 G T 9.47E-20 Body mass index / / 22344219 rs574367 chr1 177873210 G T 2.00E-19 Body mass index / / 24861553 rs10157480 chr1 177873333 A G 1.92E-04 Obesity (extreme) / / 21935397 rs576101 chr1 177873383 T A 2.20E-06 Obesity (extreme) / / 21935397 rs527248 chr1 177875514 A G 6.97E-05 Obesity (extreme) / / 21935397 rs589500 chr1 177876946 C T 7.04E-05 Obesity (extreme) / / 21935397 rs604388 chr1 177877979 T C 2.21E-06 Obesity (extreme) / / 21935397 rs693232 chr1 177881651 C G 7.22E-05 Obesity (extreme) / / 21935397 rs617763 chr1 177885238 C T 2.35E-06 Obesity (extreme) / / 21935397 rs618759 chr1 177885488 A G 2.61E-06 Obesity (extreme) / / 21935397 rs630372 chr1 177885762 G A 4.52E-05 Obesity (extreme) / / 21935397 rs10913461 chr1 177887117 C G 2.51E-04 Obesity (extreme) / / 21935397 rs512898 chr1 177888429 T C 3.64E-06 Obesity (extreme) / / 21935397 rs543874 chr1 177889480 A G 4.00E-23 Body mass index / / 20935630 rs543874 chr1 177889480 A G 6.51E-05 Obesity (extreme) / / 21935397 rs543874 chr1 177889480 A G 3.56E-23 Body mass index / / 23001569 rs543874 chr1 177889480 A G 2.00E-13 Body mass index / / 23583978 rs543874 chr1 177889480 A G 4.90E-04 Menarche (age at onset) / / 23599027 rs543874 chr1 177889480 A G 4.00E-11 Body mass index / / 23669352 rs506589 chr1 177894287 T C 6.57E-05 Obesity (extreme) / / 21935397 rs8030 chr1 177897975 C T 6.34E-06 Obesity (extreme) / / 21935397 rs545608 chr1 177899121 G C 6.61E-05 Obesity (extreme) SEC16B intron 21935397 rs575908 chr1 177900098 T C 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEC16B intron 20877124 rs575908 chr1 177900098 T C 7.31E-06 Obesity (extreme) SEC16B intron 21935397 rs591120 chr1 177902753 G C 1.11E-08 Body mass index SEC16B missense 23669352 rs10489882 chr1 177904495 T C 8.85E-04 Obesity (extreme) SEC16B intron 21935397 rs2902210 chr1 177905174 T C 1.13E-04 Type 2 diabetes SEC16B intron 17463246 rs2902210 chr1 177905174 T C 4.20E-04 Obesity (extreme) SEC16B intron 21935397 rs10913469 chr1 177913519 T C 1.00E-08 Weight SEC16B intron 19079260 rs10913469 chr1 177913519 T C 6.00E-08 Body mass index SEC16B intron 19079260 rs10913469 chr1 177913519 T C 4.20E-06 Smoking behavior SEC16B intron 20418888 rs10913469 chr1 177913519 T C 2.40E-08 Menarche (age at onset) SEC16B intron 21102462 rs10913469 chr1 177913519 T C 3.92E-04 Obesity (extreme) SEC16B intron 21935397 rs10913469 chr1 177913519 T C 3.18E-08 Obesity SEC16B intron 22484627 rs116071515 chr1 177929074 G T 0.0000306 Menopause (age at onset) SEC16B intron 23424626 rs12137761 chr1 177936525 A G 5.24E-05 Cytomegalovirus antibody response SEC16B intron 21993531 rs2152716 chr1 177962184 G A 6.48E-04 Insulin resistance / / 21901158 rs12409266 chr1 177970998 C T 3.13E-05 Telomere length / / 23001564 rs7340104 chr1 177971866 C T 7.24E-05 HDL cholesterol / / pha003074 rs17360705 chr1 177989198 A C 3.15E-04 Amyotrophic lateral sclerosis (sporadic) LOC730102 intron 24529757 rs946817 chr1 177997709 A G 6.39E-04 Rheumatoid arthritis LOC730102 intron 21452313 rs16852409 chr1 178041772 A G 6.75E-04 Multiple complex diseases / / 17554300 rs316274 chr1 178142208 G A 8.00E-07 Immune response to smallpox vaccine (IL-6) RASAL2 intron 22542470 rs12036491 chr1 178163651 C A 7.35E-05 Amyotrophic lateral sclerosis (sporadic) RASAL2 intron 24529757 rs608656 chr1 178201147 A G 3.12E-05 Cognitive test performance RASAL2 intron 20125193 rs2225586 chr1 178204132 G A 0.000082 Sarcoidosis RASAL2 intron 22952805 rs1412784 chr1 178206664 A G 0.00002185 Sarcoidosis RASAL2 intron 22952805 rs116375667 chr1 178387833 T C 0.000072 Nonsyndromic striae distensae (stretch marks) RASAL2 intron 23633020 rs2017349 chr1 178419417 A G 7.52E-05 Cognitive test performance RASAL2 intron 20125193 rs6672334 chr1 178454768 G A 9.92E-05 Cognitive test performance / / 20125193 rs74441626 chr1 178460785 C A 0.0000961 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2746325 chr1 178463591 C T 2.65E-05 Cognitive test performance / / 20125193 rs2746325 chr1 178463591 C T 1.70E-05 Urinary metabolites / / 21572414 rs10158298 chr1 178470865 C A 9.90E-06 Urinary metabolites / / 21572414 rs12760731 chr1 178471222 C T 5.00E-06 Obesity-related traits / / 23251661 rs12754916 chr1 178484065 A G 1.83E-05 Brain derived neurotrophic factor levels,in serum C1orf49 intron 22047184 rs12023718 chr1 178491879 T C 6.00E-06 Obesity-related traits C1orf49 intron 23251661 rs12033565 chr1 178491966 C T 7.64E-06 Obesity-related traits C1orf49 intron 23251661 rs4457535 chr1 178497186 A G 8.50E-04 Type 2 diabetes / / 17463246 rs4650994 chr1 178515312 G A 7.00E-09 HDL cholesterol C1orf220 intron 24097068 rs4233175 chr1 178517591 A G 3.78E-06 Alcohol dependence / / 20202923 rs10913569 chr1 178518008 A G 9.22E-07 Alcohol dependence / / 20202923 rs10798618 chr1 178519124 A C 7.41E-04 Type 2 diabetes / / 17463246 rs2811297 chr1 178551472 C T 5.50E-04 Type 2 diabetes / / 17463246 rs2811302 chr1 178552875 C T 6.65E-04 Type 2 diabetes / / 17463246 rs3922812 chr1 178659933 G A 8.80E-04 Type 2 diabetes / / 17846124 rs16853243 chr1 178661341 C T 4.32E-05 Meningococcal disease / / 20694013 rs7543277 chr1 178679194 T C 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811280 chr1 178686247 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs2811280 chr1 178686247 A G 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs16853302 chr1 178686331 A C 4.03E-04 Schizophrenia / / 19197363 rs16853302 chr1 178686331 A C 4.39E-05 Meningococcal disease / / 20694013 rs10913619 chr1 178691366 T C 1.45E-05 Serum metabolites / / 19043545 rs2773080 chr1 178696750 T C 8.00E-04 Type 2 diabetes RALGPS2 intron 17846124 rs4651005 chr1 178719306 C T 8.94E-04 Response to taxane treatment (placlitaxel) RALGPS2 intron 23006423 rs16853350 chr1 178765148 T G 7.50E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs965558 chr1 178782625 A G 9.40E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs3766642 chr1 178813531 G A 9.57E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs2297687 chr1 178820327 G A 1.93E-10 Triglycerides ANGPTL1 cds-synon 23063622 rs12565332 chr1 178824416 C G 9.05E-04 Suicide attempts in bipolar disorder ANGPTL1 intron 21423239 rs6696204 chr1 178841980 A G 9.92E-05 Insulin-related traits RALGPS2 intron pha003063 rs2184464 chr1 178849489 G A 2.67E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs4652341 chr1 178956553 C T 1.86E-04 Body mass index / / 21701565 rs10913672 chr1 178981416 G A 8.30E-06 Urinary metabolites / / 21572414 rs3813638 chr1 178994644 C T 2.01E-05 Body Mass Index / / pha002896 rs6425512 chr1 179000143 G A 1.27E-05 Body Mass Index FAM20B intron pha002896 rs6425513 chr1 179006462 G A 6.98E-05 Body Mass Index FAM20B intron pha002896 rs3766635 chr1 179016483 T C 8.79E-04 Acute lung injury FAM20B intron 22295056 rs16853590 chr1 179020377 C G 8.79E-04 Acute lung injury FAM20B intron 22295056 rs12131503 chr1 179034229 T A 3.26E-04 Body mass index FAM20B intron 21701565 rs10798652 chr1 179061427 C T 4.98E-04 Lymphocyte counts TOR3A intron 22286170 rs1128952 chr1 179065125 C T 8.84E-05 Erythrocyte counts TOR3A UTR-3 pha003101 rs1325195 chr1 179071756 G A 5.00E-06 IgE grass sensitization ABL2 UTR-3 22036096 rs17277288 chr1 179077613 T C 2.70E-04 Atrial fibrillation ABL2 missense 21846873 rs3818433 chr1 179079190 T C 3.92E-05 Body Mass Index ABL2 intron pha002896 rs2274230 chr1 179084080 T G 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 cds-synon 23006423 rs9724754 chr1 179084408 C A 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 intron 23006423 rs17277358 chr1 179100710 C T 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 intron 23006423 rs9650996 chr1 179124290 G A 3.76E-06 Left ventricular mass ABL2 intron 21212386 rs12080991 chr1 179242140 T C 4.63E-05 Smoking initiation / / 24665060 rs1004959 chr1 179251673 G C 7.39E-04 Smoking initiation / / 24665060 rs12143460 chr1 179273031 A G 7.91E-04 Suicide attempts in bipolar disorder SOAT1 intron 21423239 rs17277834 chr1 179293079 C A 8.49E-04 Suicide attempts in bipolar disorder SOAT1 intron 21423239 rs4651024 chr1 179312102 T C 3.30E-05 Bone mineral density (BMD),in women SOAT1 intron 20164292 rs2152319 chr1 179315357 C A 2.30E-05 Bone mineral density (BMD),in women SOAT1 intron 20164292 rs13306729 chr1 179316687 A G 7.18E-04 Smoking initiation SOAT1 intron 24665060 rs1044925 chr1 179323738 C A 2.26E-04 Sudden cardiac arrest SOAT1 UTR-3 21658281 rs10913753 chr1 179400260 A G 8.61E-04 Multiple complex diseases AXDND1 intron 17554300 rs4651028 chr1 179407523 A G 9.46E-04 Multiple complex diseases AXDND1 intron 17554300 rs4130266 chr1 179415532 T G 8.81E-04 Multiple complex diseases AXDND1 intron 17554300 rs10494520 chr1 179452275 G A 6.74E-04 Schizophrenia AXDND1 cds-synon 21674006 rs12047808 chr1 179469314 A G 6.00E-06 Multiple sclerosis (age of onset) AXDND1 intron 19010793 rs10913801 chr1 179471750 T G 2.22E-06 Esophageal cancer (squamous cell) AXDND1 intron 22960999 rs1410587 chr1 179516072 C T 6.00E-04 Alcohol dependence AXDND1 intron 20201924 rs16854304 chr1 179518459 G T 7.48E-04 Body mass index AXDND1 intron 21701565 rs2274626 chr1 179521932 G T 1.40E-04 Breast cancer and prostate cancer NPHS2 intron 17903305 rs2274626 chr1 179521932 G T 7.80E-04 Alcohol dependence NPHS2 intron 20201924 rs745317 chr1 179525311 C T 2.88E-05 Multiple sclerosis (age of onset) NPHS2 intron 19010793 rs7517766 chr1 179547750 A G 5.11E-04 Multiple complex diseases / / 17554300 rs12403885 chr1 179548291 T G 1.10E-05 Urinary metabolites / / 21572414 rs4652420 chr1 179562143 G A 2.60E-05 Urinary metabolites TDRD5 intron 21572414 rs4652421 chr1 179563717 G A 4.60E-05 Biliary atresia TDRD5 intron 20460270 rs10753200 chr1 179564144 G A 4.02E-04 Body mass index TDRD5 intron 21701565 rs10753200 chr1 179564144 G A 5.82E-04 Body mass index TDRD5 intron 21701565 rs4652424 chr1 179569088 C G 9.31E-04 Alzheimer's disease TDRD5 intron 17998437 rs4652424 chr1 179569088 C G 5.01E-04 Body mass index TDRD5 intron 21701565 rs4652424 chr1 179569088 C G 6.63E-04 Body mass index TDRD5 intron 21701565 rs10913839 chr1 179593166 G A 5.63E-04 Multiple complex diseases TDRD5 intron 17554300 rs16854429 chr1 179609589 G T 7.29E-05 Alcohol dependence TDRD5 intron 21703634 rs1498122 chr1 179682093 A T 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504057 chr1 179687259 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1052447 chr1 179711649 T G 1.00E-04 Prostate cancer / / 21743057 rs10913876 chr1 179721771 G T 1.00E-04 Prostate cancer FAM163A intron 21743057 rs2454199 chr1 179729554 A G 3.70E-04 Insulin resistance FAM163A intron 21901158 rs17370180 chr1 179742819 A C 1.30E-05 Urinary metabolites FAM163A intron 21572414 rs4448484 chr1 179748514 T C 3.80E-04 Type 2 diabetes FAM163A intron 17463246 rs12756748 chr1 179757855 T G 4.78E-05 ldl cholesterol FAM163A intron pha003077 rs12756748 chr1 179757855 T G 3.72E-05 Cholesterol FAM163A intron pha003083 rs10798724 chr1 179766086 C T 8.55E-05 Information processing speed FAM163A intron 21130836 rs10913892 chr1 179786385 T C 1.40E-05 Urinary metabolites / / 21572414 rs10913893 chr1 179790518 G A 2.00E-05 Urinary metabolites / / 21572414 rs16854795 chr1 179790833 A G 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1048418 chr1 179831248 G A 3.44E-05 Cognitive test performance TOR1AIP2 UTR-3 20125193 rs1300068 chr1 179858333 C T 3.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TOR1AIP1 intron 24023788 rs3845388 chr1 179882095 G A 2.27E-05 Cognitive test performance TOR1AIP1 intron 20125193 rs6689160 chr1 179891565 A G 5.80E-08 Glaucoma (primary open-angle) / / 22428042 rs474258 chr1 179895764 A G 4.75E-05 Height / / 22021425 rs475233 chr1 179895861 T C 4.26E-05 Height / / 22021425 rs585355 chr1 179900644 T C 1.50E-05 Urinary metabolites / / 21572414 rs2281805 chr1 179909076 T C 8.87E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2501618 chr1 179958809 T C 1.30E-07 Atopy CEP350 intron 19961619 rs2501618 chr1 179958809 T C 1.49E-05 Malignant pleural mesothelioma CEP350 intron 23626673 rs2501618 chr1 179958809 T C 1.52E-04 Malignant pleural mesothelioma CEP350 intron 23626673 rs4076449 chr1 179997018 T C 1.00E-04 Cognitive impairment induced by topiramate CEP350 intron 22091778 rs12125245 chr1 180000542 G T 2.71E-05 Cognitive test performance CEP350 missense 20125193 rs6425603 chr1 180018254 C T 6.49E-04 Lymphocyte counts CEP350 intron 22286170 rs10913927 chr1 180039137 C T 1.05E-04 Lymphocyte counts CEP350 intron 22286170 rs111829180 chr1 180053531 G A 1.98E-11 Metabolite levels CEP350 intron 22286219 rs6685965 chr1 180110092 C A,G,T 5.36E-08 Metabolite levels / / 23281178 rs3845391 chr1 180119544 T G 8.72E-06 Cognitive test performance / / 20125193 rs55946907 chr1 180130723 C T 9.00E-06 Anorexia nervosa QSOX1 intron 23568457 rs16855395 chr1 180150719 T G 9.46E-05 Multiple complex diseases QSOX1 intron 17554300 rs10913943 chr1 180162364 C T 1.00E-04 Information processing speed QSOX1 intron 21130836 rs3767165 chr1 180165091 A G 1.37E-05 Triglycerides QSOX1 intron 19074352 rs3767165 chr1 180165091 A G 1.37E-05 Polyunsaturated fatty acid levels,in plasma QSOX1 intron 19148276 rs12145255 chr1 180169367 C T 8.78E-04 Body mass index / / 21701565 rs7521602 chr1 180177266 G T 0.00031 Salmonella-induced pyroptosis / / 22837397 rs10913949 chr1 180178695 T G 3.47E-04 White matter integrity / / 22425255 rs355623 chr1 180194443 A G 2.77E-04 Type 2 diabetes / / 17463246 rs355621 chr1 180194672 C G 5.55E-04 Type 2 diabetes / / 17463246 rs357050 chr1 180234729 T C 3.56E-04 Smoking initiation LHX4 intron 24665060 rs2290478 chr1 180238495 A G 5.62E-04 Smoking quantity LHX4 intron 24665060 rs1925339 chr1 180261070 G T 2.34E-05 Personality dimensions ACBD6 intron 22628180 rs10798745 chr1 180291777 T C 2.34E-05 Personality dimensions ACBD6 intron 22628180 rs4642852 chr1 180356025 C A 2.37E-05 Personality dimensions ACBD6 intron 22628180 rs6661208 chr1 180361630 T C 2.37E-05 Personality dimensions ACBD6 intron 22628180 rs7542223 chr1 180420271 T C,G 1.46E-05 Tuberculosis ACBD6 intron 22306650 rs1538620 chr1 180489737 G A 8.70E-05 Personality dimensions / / 18957941 rs4651067 chr1 180494062 G A 4.84E-05 Odorant perception / / 23910658 rs12039331 chr1 180501196 A G 2.18E-05 Personality dimensions / / 22628180 rs4652519 chr1 180549164 G A 6.73E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6661325 chr1 180597577 T C 9.89E-05 Serum metabolites / / 19043545 rs7527074 chr1 180645441 C T 9.00E-06 Asthma (childhood onset) XPR1 intron 23829686 rs6681878 chr1 180674565 A T 3.27E-04 Multiple complex diseases XPR1 intron 17554300 rs16856409 chr1 180699554 A G 4.82E-04 Response to cytidine analogues (gemcitabine) XPR1 intron 24483146 rs12401315 chr1 180706924 C A 9.60E-06 Urinary metabolites XPR1 intron 21572414 rs6700926 chr1 180722353 G A 2.34E-04 Alzheimer's disease XPR1 intron 22005930 rs7556592 chr1 180753483 G T 2.60E-05 Urinary metabolites XPR1 intron 21572414 rs7544774 chr1 180757628 T C 3.34E-04 Bone mass and geometry XPR1 intron 17903296 rs12080611 chr1 180766896 G A 2.31E-04 Multiple complex diseases XPR1 intron 17554300 rs12075809 chr1 180772435 A G 3.25E-04 Multiple complex diseases XPR1 intron 17554300 rs3789373 chr1 180774130 C T 9.52E-04 Alcohol dependence XPR1 intron 21314694 rs2271668 chr1 180849081 A G 8.82E-04 Response to cytidine analogues (gemcitabine) XPR1 intron 24483146 rs10914123 chr1 180849494 T C 2.90E-04 Alzheimer's disease XPR1 intron 22005930 rs10494535 chr1 180858459 C T 7.40E-04 Response to cytidine analogues (gemcitabine) XPR1 UTR-3 24483146 rs10914134 chr1 180891542 A C 9.89E-05 Waist Circumference KIAA1614 intron pha003023 rs10753229 chr1 180920226 G T 3.23E-04 Multiple complex diseases LOC100509205 intron 17554300 rs1411478 chr1 180962282 A G 4.00E-11 Progressive supranuclear palsy STX6 intron 21685912 rs1411479 chr1 181006930 A G 5.46E-04 Premature ovarian failure MR1 intron 19508998 rs1411479 chr1 181006930 A G 4.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MR1 intron 24023788 rs10797666 chr1 181018799 A C 2.00E-04 Cognitive impairment induced by topiramate MR1 intron 22091778 rs2282348 chr1 181027925 G T 6.91E-05 Body Mass Index MR1 UTR-3 pha003022 rs10797668 chr1 181035754 A G 9.09E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6682093 chr1 181042889 G A 9.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6682093 chr1 181042889 G A 1.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs3856068 chr1 181046368 A C 9.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3856068 chr1 181046368 A C 1.67E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4651082 chr1 181050713 T C 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3892275 chr1 181054522 G A 9.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6662507 chr1 181056160 G A 0.0006803 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6662507 chr1 181056160 G A 6.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6662507 chr1 181056160 G A 1.42E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2275470 chr1 181065807 G A 0.0007103 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2275470 chr1 181065807 G A 7.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2275470 chr1 181065807 G A 1.79E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4652563 chr1 181088058 T C 1.83E-05 Multiple complex diseases / / 17554300 rs6700566 chr1 181095552 C A 5.05E-04 Alzheimer's disease / / 17998437 rs4652564 chr1 181104869 C G 3.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4652565 chr1 181109008 C G 5.99E-04 Alzheimer's disease / / 17998437 rs881964 chr1 181109478 C T 2.51E-05 Osteoarthritis (knee and hip) / / 21177295 rs881964 chr1 181109478 C T 4.79E-04 Osteoarthritis (knee and hip) / / 21177295 rs3856075 chr1 181110097 T G 7.10E-04 Alzheimer's disease / / 17998437 rs12127075 chr1 181127902 T A 9.08E-04 Multiple complex diseases / / 17554300 rs4652572 chr1 181128206 T C 3.84E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs946645 chr1 181154177 A G 8.46E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4048562 chr1 181261712 G A 3.76E-06 Phospholipid levels (plasma) / / 21829377 rs3911590 chr1 181262158 A G 3.52E-06 Phospholipid levels (plasma) / / 21829377 rs3845427 chr1 181262438 T A 9.51E-07 Phospholipid levels (plasma) / / 21829377 rs10910917 chr1 181265245 A G 3.54E-06 Phospholipid levels (plasma) / / 21829377 rs2332203 chr1 181266420 G A 1.61E-06 Phospholipid levels (plasma) / / 21829377 rs2332206 chr1 181273842 A G 4.10E-06 Phospholipid levels (plasma) / / 21829377 rs7523745 chr1 181274415 T C 3.90E-06 Phospholipid levels (plasma) / / 21829377 rs6658112 chr1 181280106 C G 1.82E-06 Phospholipid levels (plasma) / / 21829377 rs3894266 chr1 181289937 C G 2.25E-06 Phospholipid levels (plasma) / / 21829377 rs7525299 chr1 181296112 A G 9.00E-05 Height / / pha003011 rs12119916 chr1 181307883 A G 6.07E-05 Cognitive test performance / / 20125193 rs12408625 chr1 181329186 C T 4.78E-04 Type 2 diabetes / / 17463246 rs4517314 chr1 181339616 C T 1.25E-06 Type 2 diabetes / / 21799836 rs16857239 chr1 181377529 A C 5.15E-04 Type 2 diabetes / / 17463246 rs16857248 chr1 181378036 C A 8.45E-04 Type 2 diabetes / / 17463246 rs591650 chr1 181384078 T G 2.05E-05 Blood Pressure / / pha003044 rs4287138 chr1 181399618 G T 5.52E-04 Sarcoidosis / / 19165924 rs12566751 chr1 181417812 T C 1.30E-05 Blood Pressure / / pha003046 rs3856086 chr1 181422435 T G 4.44E-07 Lymphocyte counts / / 22286170 rs3856087 chr1 181424533 G A 2.00E-05 Blood Pressure / / pha003046 rs2332267 chr1 181426910 C T 8.00E-06 Coronary artery calcification / / 23870195 rs12066616 chr1 181428761 C T 3.44E-05 Blood Pressure / / pha003046 rs6424813 chr1 181433468 G A 8.61E-05 Schizophrenia / / 24253340 rs644796 chr1 181436054 T C 1.01E-05 C-reactive protein / / 22492993 rs16857380 chr1 181443599 A G 1.70E-05 Urinary metabolites / / 21572414 rs146609419 chr1 181453509 T TC 9.76E-05 Lung function (forced expiratory volume in 1 second) CAC/1E intron pha003103 rs556321 chr1 181453509 T C 9.76E-05 Lung function (forced expiratory volume in 1 second) CAC/1E intron pha003103 rs517209 chr1 181488212 T G 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1E intron 20877124 rs16857512 chr1 181494835 A G 2.14E-08 Multiple complex diseases CAC/1E intron 17554300 rs7512415 chr1 181508622 A G 6.94E-04 Type 2 diabetes CAC/1E intron 17463246 rs6682262 chr1 181524561 T A 9.87E-04 Obesity (extreme) CAC/1E intron 21935397 rs17495655 chr1 181526354 G A 2.60E-06 Urinary metabolites CAC/1E intron 21572414 rs10910960 chr1 181532332 G A 1.15E-04 Progressive supranuclear palsy CAC/1E intron 21685912 rs1953690 chr1 181534435 G A 1.30E-05 Urinary metabolites CAC/1E intron 21572414 rs10494540 chr1 181549547 T G 3.58E-05 Cognitive impairment induced by topiramate CAC/1E intron 22091778 rs2877652 chr1 181553797 T C 1.07E-04 HIV-1 viral setpoint CAC/1E intron 21490045 rs3856094 chr1 181561783 C T 4.73E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAC/1E intron 24023788 rs199960 chr1 181579231 G A 2.42E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAC/1E intron 24023788 rs199960 chr1 181579231 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAC/1E intron 24023788 rs4271174 chr1 181582350 G T 4.28E-06 HIV-1 viral setpoint CAC/1E intron 21490045 rs175338 chr1 181605165 A G 1.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAC/1E intron 24023788 rs17742601 chr1 181618101 C G 6.53E-05 Alzheimer's disease CAC/1E intron 17998437 rs4083386 chr1 181622824 T C 1.36E-04 Prion diseases CAC/1E intron 22210626 rs3820260 chr1 181638511 C T 3.90E-05 Breast cancer CAC/1E intron 17529974 rs3753737 chr1 181645227 G A 7.00E-05 Iris characteristics CAC/1E intron 21835309 rs3845441 chr1 181655752 C A,G,T 7.00E-06 IgG glycosylation CAC/1E intron 23382691 rs576602 chr1 181754059 A C 2.56E-04 Multiple complex diseases CAC/1E intron 17554300 rs638132 chr1 181768985 G A 0.0000492 Polycystic ovary syndrome CAC/1E UTR-3 22951595 rs638132 chr1 181768985 G A 4.92E-05 Intracranial aneurysm CAC/1E UTR-3 22961961 rs695072 chr1 181816509 T C 0.000735988 Hypertension (early onset hypertension) / / 22479346 rs4465155 chr1 181821407 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs525867 chr1 181828097 A G 2.40E-05 Urinary metabolites / / 21572414 rs6691114 chr1 181842049 G C 2.94E-04 Multiple complex diseases / / 17554300 rs535607 chr1 181848014 A G 1.18E-05 Serum metabolites / / 19043545 rs79066418 chr1 181887010 G A 0.00007204 Sarcoidosis / / 22952805 rs74560931 chr1 181902708 A G 0.00007557 Sarcoidosis / / 22952805 rs78555787 chr1 181939630 G A 0.0000871 Sarcoidosis / / 22952805 rs115469509 chr1 181948224 G A 0.00006038 Sarcoidosis / / 22952805 rs145761963 chr1 182012460 G A 0.00009604 Sarcoidosis / / 22952805 rs12565808 chr1 182013486 G A 7.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2452905 chr1 182018765 A G 4.53E-04 Body mass index / / 21701565 rs7554182 chr1 182021283 C T 6.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs8179259 chr1 182052276 C G 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs3856106 chr1 182054977 C T 1.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10797754 chr1 182055497 G C 1.38E-04 Multiple complex diseases / / 17554300 rs3856108 chr1 182056046 A T 1.04E-04 Multiple complex diseases / / 17554300 rs7537211 chr1 182058556 A G 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs7537211 chr1 182058556 A G 9.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7545241 chr1 182063963 T G 2.32E-04 Multiple complex diseases / / 17554300 rs10911019 chr1 182064484 C T 3.16E-04 Multiple complex diseases / / 17554300 rs10911021 chr1 182081960 C T 2.00E-08 Cardiovascular heart disease in diabetics / / 23982368 rs3856111 chr1 182084976 A G 6.62E-04 Type 2 diabetes / / 17463246 rs12409614 chr1 182085441 A G 9.69E-04 Coronary Artery Disease / / 17634449 rs12409614 chr1 182085441 A G 8.66E-05 Serum metabolites / / 19043545 rs12407822 chr1 182087214 G A 4.50E-04 Multiple complex diseases / / 17554300 rs10911024 chr1 182114569 G A 5.11E-04 Coronary Artery Disease / / 17634449 rs12564594 chr1 182116368 A G 3.92E-04 Alcohol dependence / / 20201924 rs4121149 chr1 182118604 G A 5.62E-07 Blood pressure / / 21996601 rs1779826 chr1 182131540 A G 1.64E-04 Multiple complex diseases / / 17554300 rs1689800 chr1 182168885 A G 3.00E-10 HDL cholesterol / / 20686565 rs1689800 chr1 182168885 A G 5.00E-20 HDL cholesterol / / 24097068 rs1779819 chr1 182178482 A G 1.53E-04 Multiple complex diseases / / 17554300 rs4113814 chr1 182178847 C T 1.00E-04 Multiple complex diseases / / 17554300 rs1419326 chr1 182182651 A C 2.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10911032 chr1 182185360 T C 8.51E-05 Coronary Artery Disease / / 17634449 rs113154036 chr1 182191448 G A 0.00009703 Sarcoidosis / / 22952805 rs10911042 chr1 182205415 T C 1.27E-04 Coronary Artery Disease / / 17634449 rs1018611 chr1 182224790 G A 5.12E-04 Type 2 diabetes / / 17463246 rs11802583 chr1 182237758 A G 5.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2256917 chr1 182249873 A G 4.64E-04 Multiple complex diseases / / 17554300 rs12031309 chr1 182255948 A G 9.63E-04 Coronary Artery Disease / / 17634449 rs12024291 chr1 182280599 C T 1.20E-04 Major depressive disorder / / 21042317 rs16858833 chr1 182283571 G C 8.00E-04 Major depressive disorder / / 21042317 rs6703548 chr1 182291435 T G 7.40E-04 Major depressive disorder / / 21042317 rs10797766 chr1 182291545 G A 4.20E-04 Major depressive disorder / / 21042317 rs2985441 chr1 182305147 T C 9.52E-05 Type 2 diabetes / / 17463246 rs2985441 chr1 182305147 T C 7.40E-06 Glioma (high-grade) / / 19578366 rs2246475 chr1 182312757 C T 2.77E-04 Alzheimer's disease / / 17998437 rs2256956 chr1 182319935 G A 1.56E-07 Iris color / / 18252221 rs17509621 chr1 182366278 T C 2.34E-06 Type 2 diabetes / / 17463246 rs3818458 chr1 182376260 C T 2.68E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12568218 chr1 182404479 C G 8.90E-04 Type 2 diabetes / / 17463246 rs497915 chr1 182406654 A G 2.60E-05 Urinary metabolites / / 21572414 rs677739 chr1 182407610 A G 2.60E-05 Urinary metabolites / / 21572414 rs267866 chr1 182420448 G A 6.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) RGSL1 intron 23648065 rs16859058 chr1 182456423 T A 2.70E-04 Blood pressure RGSL1 intron 17255346 rs12024567 chr1 182457029 G A,C,T 2.59E-04 Blood pressure RGSL1 intron 17255346 rs17568993 chr1 182537494 C T 2.63E-07 Lymphocyte counts / / 22286170 rs12034992 chr1 182538063 G A 1.49E-05 Blood pressure / / 17255346 rs12723593 chr1 182538582 C G 2.40E-05 Urinary metabolites / / 21572414 rs627839 chr1 182542081 G T 3.21E-04 Fasting insulin (interaction) / / 24204828 rs627839 chr1 182542081 G T 4.93E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs11072 chr1 182543331 A G 5.00E-05 Iris characteristics R/SEL UTR-3 21835309 rs11072 chr1 182543331 A G 6.29E-04 Smoking cessation R/SEL UTR-3 24665060 rs533259 chr1 182549019 A G 6.00E-09 Multiple sclerosis R/SEL intron 23412934 rs682585 chr1 182559510 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes R/SEL nearGene-5 22628534 rs12041623 chr1 182561633 T C 3.90E-04 Alzheimer's disease / / 17998437 rs10489966 chr1 182575376 T G 2.73E-04 Alzheimer's disease / / 17998437 rs10752878 chr1 182582375 T G 3.62E-06 Postoperative ventricular dysfunction / / 21980348 rs602988 chr1 182586203 C T 1.05E-04 Multiple complex diseases / / 17554300 rs1287820 chr1 182589331 C G 5.08E-05 Postoperative ventricular dysfunction / / 21980348 rs528846 chr1 182592336 C T 4.98E-04 Multiple complex diseases / / 17554300 rs528846 chr1 182592336 C T 7.79E-05 Lung adenocarcinoma / / 19836008 rs488735 chr1 182609461 A G 2.60E-05 Multiple complex diseases / / 17554300 rs529502 chr1 182614303 A G 5.64E-04 Multiple complex diseases / / 17554300 rs12409524 chr1 182625258 T C 7.41E-04 Type 2 diabetes RGS8 intron 17463246 rs4652741 chr1 182626738 C A 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS8 intron 20877124 rs567397 chr1 182640638 A G 2.40E-04 Smoking initiation RGS8 intron 24665060 rs680277 chr1 182640864 T C 1.81E-04 Smoking initiation RGS8 missense 24665060 rs7512765 chr1 182672104 G A 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1287968 chr1 182672251 T C 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs621071 chr1 182682811 T C 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2482806 chr1 182684087 A C 2.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2482806 chr1 182684087 A C 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs542324 chr1 182684489 T A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs595289 chr1 182696117 C G 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2482808 chr1 182700570 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1287982 chr1 182701073 T G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6663553 chr1 182714585 C T 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10797792 chr1 182717434 A G 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12031590 chr1 182722554 A G 3.50E-05 Suicide attempts in bipolar disorder / / 21423239 rs9787058 chr1 182724185 C G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9787061 chr1 182724241 C A 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7540658 chr1 182744205 A C 3.23E-04 Schizophrenia / / 21926974 rs6692387 chr1 182754545 T C 4.28E-05 Multiple complex diseases / / 17554300 rs6677418 chr1 182820248 T A 1.24E-04 Multiple complex diseases DHX9 intron 17554300 rs10797794 chr1 182858008 G A 1.19E-04 Cocaine dependence / / 23958962 rs78487548 chr1 182922215 G T 0.00042 Breast cancer SHCBP1L missense 23555315 rs16859878 chr1 182938992 C T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10911180 chr1 182959364 C A 1.40E-04 IgE levels in asthmatics / / 23967269 rs12753817 chr1 182970337 T A 4.12E-04 Type 2 diabetes / / 17463246 rs4233192 chr1 182970837 G T 8.74E-04 Type 2 diabetes / / 17463246 rs4233192 chr1 182970837 G T 4.42E-04 Lymphocyte counts / / 22286170 rs10752881 chr1 182973491 A G 5.00E-06 Colorectal cancer / / 24836286 rs4487994 chr1 182982173 T A 8.92E-05 Colorectal cancer / / 23266556 rs4454510 chr1 182982303 G A 9.94E-05 Colorectal cancer / / 23266556 rs10752885 chr1 182982878 G C 1.57E-04 Colorectal cancer / / 23266556 rs10911191 chr1 182984524 T C 9.45E-04 Type 2 diabetes / / 17463246 rs10911191 chr1 182984524 T C 9.32E-05 Colorectal cancer / / 23266556 rs10797812 chr1 182984597 G A 2.40E-04 Neuroticism / / 17667963 rs12126434 chr1 182988414 G A 8.96E-05 Colorectal cancer / / 23266556 rs10737236 chr1 182988608 T C 9.01E-04 Type 2 diabetes / / 17463246 rs10737236 chr1 182988608 T C 8.99E-05 Colorectal cancer / / 23266556 rs10737237 chr1 182989269 A G 8.99E-05 Colorectal cancer / / 23266556 rs10797813 chr1 182989366 C T 8.82E-05 Colorectal cancer / / 23266556 rs10797814 chr1 182990929 C A 8.48E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs6695746 chr1 182991355 T C 8.77E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs6695837 chr1 182991462 T C 7.01E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs4652763 chr1 182994084 A G 8.74E-05 Colorectal cancer LAMC1 intron 23266556 rs4652764 chr1 182994115 G A 4.34E-04 Colorectal cancer LAMC1 intron 23266556 rs4642853 chr1 182996242 C T 8.92E-05 Colorectal cancer LAMC1 intron 23266556 rs4651138 chr1 183001312 C A 8.29E-05 Colorectal cancer LAMC1 intron 23266556 rs6678517 chr1 183002639 A G 2.82E-06 Colorectal cancer LAMC1 intron 23266556 rs10911203 chr1 183004076 G A 6.53E-05 IgE levels in asthmatics LAMC1 intron 23967269 rs10797819 chr1 183006911 A G 1.03E-04 Colorectal cancer LAMC1 intron 23266556 rs12043805 chr1 183008150 T A 2.34E-06 Colorectal cancer LAMC1 intron 23266556 rs4652769 chr1 183009196 T C 1.05E-04 Colorectal cancer LAMC1 intron 23266556 rs10911205 chr1 183009277 C A 2.57E-06 Colorectal cancer LAMC1 intron 23266556 rs10911206 chr1 183012423 A G 1.12E-04 Colorectal cancer LAMC1 intron 23266556 rs4366285 chr1 183013672 T G 2.13E-05 Colorectal cancer LAMC1 intron 23266556 rs10911209 chr1 183013988 T G 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs6660111 chr1 183014289 G A 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs6664995 chr1 183017345 T C 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs10797822 chr1 183017769 A G 1.09E-04 Colorectal cancer LAMC1 intron 23266556 rs4422969 chr1 183020762 G A 9.14E-05 Colorectal cancer LAMC1 intron 23266556 rs10752890 chr1 183021910 A G 1.45E-04 Colorectal cancer LAMC1 intron 23266556 rs10911211 chr1 183022299 A T 2.56E-06 Colorectal cancer LAMC1 intron 23266556 rs4652772 chr1 183023696 G C 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs10911212 chr1 183024469 C T 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs4546885 chr1 183025555 G C 1.61E-05 Colorectal cancer LAMC1 intron 23266556 rs3934579 chr1 183027432 G A 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs3934697 chr1 183027512 A G 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs10797828 chr1 183028430 G A 9.41E-06 Colorectal cancer LAMC1 intron 23266556 rs3935384 chr1 183028970 C T 2.58E-04 Smoking cessation LAMC1 intron 18519826 rs3935384 chr1 183028970 C T 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs4266836 chr1 183029070 T G 1.02E-04 Colorectal cancer LAMC1 intron 23266556 rs10797829 chr1 183033228 A G 1.25E-04 Colorectal cancer LAMC1 intron 23266556 rs6424883 chr1 183037695 T C 8.71E-05 Non-alcoholic fatty liver disease histology (other) LAMC1 intron 20708005 rs6424883 chr1 183037695 T C 2.20E-06 Colorectal cancer LAMC1 intron 23266556 rs12120747 chr1 183042531 G A 2.58E-06 Colorectal cancer LAMC1 intron 23266556 rs10797832 chr1 183044034 A G 1.23E-04 Colorectal cancer LAMC1 intron 23266556 rs10911222 chr1 183047363 G A 1.25E-04 Colorectal cancer LAMC1 intron 23266556 rs10911229 chr1 183050368 C G 1.26E-04 Colorectal cancer LAMC1 intron 23266556 rs10911232 chr1 183052533 C T 2.16E-04 Type 2 diabetes LAMC1 intron 17463246 rs10911232 chr1 183052533 C T 3.35E-06 Colorectal cancer LAMC1 intron 23266556 rs10911233 chr1 183052585 G A 2.84E-06 Colorectal cancer LAMC1 intron 23266556 rs4397624 chr1 183053131 C T 2.43E-04 Colorectal cancer LAMC1 intron 23266556 rs10911235 chr1 183053746 G A 1.34E-04 Colorectal cancer LAMC1 intron 23266556 rs4652773 chr1 183054827 A C,G 1.33E-04 Colorectal cancer LAMC1 intron 23266556 rs2151669 chr1 183055398 T G 1.33E-04 Colorectal cancer LAMC1 intron 23266556 rs6672306 chr1 183058898 G A 6.54E-04 Colorectal cancer LAMC1 intron 23266556 rs4233194 chr1 183060917 G C 7.87E-05 Colorectal cancer LAMC1 intron 23266556 rs7525917 chr1 183065406 A G 6.25E-05 Colorectal cancer LAMC1 intron 23266556 rs6424885 chr1 183066254 T G 6.37E-05 Colorectal cancer LAMC1 intron 23266556 rs10752897 chr1 183071024 C T 9.67E-05 Colorectal cancer LAMC1 intron 23266556 rs2296288 chr1 183072590 T C 7.79E-05 Colorectal cancer LAMC1 cds-synon 23266556 rs10797835 chr1 183072908 T C 5.79E-05 Colorectal cancer LAMC1 intron 23266556 rs2027075 chr1 183073266 A G 6.61E-05 Colorectal cancer LAMC1 intron 23266556 rs2027078 chr1 183073478 G A 6.43E-05 Colorectal cancer LAMC1 intron 23266556 rs2027080 chr1 183074415 C T 6.46E-05 Colorectal cancer LAMC1 intron 23266556 rs10797837 chr1 183075121 C G 6.65E-05 Colorectal cancer LAMC1 intron 23266556 rs2333622 chr1 183075456 T C 6.70E-05 Colorectal cancer LAMC1 intron 23266556 rs12091137 chr1 183075732 A G 9.35E-04 Type 2 diabetes LAMC1 intron 17463246 rs12091137 chr1 183075732 A G 4.76E-05 Smoking cessation LAMC1 intron 18519826 rs12091137 chr1 183075732 A G 6.51E-05 Colorectal cancer LAMC1 intron 23266556 rs12086466 chr1 183075778 T C 9.66E-04 Type 2 diabetes LAMC1 intron 17463246 rs12086466 chr1 183075778 T C 5.79E-05 Smoking cessation LAMC1 intron 18519826 rs12086466 chr1 183075778 T C 7.42E-05 Colorectal cancer LAMC1 intron 23266556 rs723015 chr1 183076581 C T 6.93E-05 Smoking cessation LAMC1 intron 18519826 rs10911247 chr1 183076993 A G 6.43E-05 Colorectal cancer LAMC1 intron 23266556 rs10797838 chr1 183077020 A G 1.01E-04 Smoking cessation LAMC1 intron 18519826 rs10797838 chr1 183077020 A G 6.22E-05 Colorectal cancer LAMC1 intron 23266556 rs10797839 chr1 183077797 T C 2.05E-05 Smoking cessation LAMC1 intron 18519826 rs10797839 chr1 183077797 T C 6.35E-05 Colorectal cancer LAMC1 intron 23266556 rs10752898 chr1 183077896 T C 9.66E-05 Smoking cessation LAMC1 intron 18519826 rs10752898 chr1 183077896 T C 7.67E-05 Colorectal cancer LAMC1 intron 23266556 rs3768625 chr1 183078712 G T 8.58E-05 Colorectal cancer LAMC1 intron 23266556 rs3768624 chr1 183079252 C T 6.44E-05 Colorectal cancer LAMC1 intron 23266556 rs2296290 chr1 183079412 C T 6.31E-05 Colorectal cancer LAMC1 intron 23266556 rs2296291 chr1 183079509 C T 6.58E-05 Colorectal cancer LAMC1 intron 23266556 rs6672093 chr1 183079853 T C 6.30E-05 Colorectal cancer LAMC1 intron 23266556 rs10911249 chr1 183080690 G A 6.77E-05 Colorectal cancer LAMC1 intron 23266556 rs10911251 chr1 183081194 A C 9.00E-08 Colorectal cancer LAMC1 intron 23266556 rs10797842 chr1 183081867 G A 4.49E-04 Type 2 diabetes LAMC1 intron 17463246 rs10797842 chr1 183081867 G A 1.15E-04 Colorectal cancer LAMC1 intron 23266556 rs1537520 chr1 183084229 C T 8.84E-05 Colorectal cancer LAMC1 intron 23266556 rs6692207 chr1 183085304 T C 7.84E-05 Colorectal cancer LAMC1 intron 23266556 rs6424888 chr1 183085696 A G 8.07E-05 Colorectal cancer LAMC1 intron 23266556 rs20563 chr1 183085755 A G 6.08E-04 Colorectal cancer LAMC1 missense 23266556 rs2296292 chr1 183086757 A C 7.92E-05 Colorectal cancer LAMC1 cds-synon 23266556 rs10797848 chr1 183087727 A G 8.60E-05 Colorectal cancer LAMC1 intron 23266556 rs10797849 chr1 183088988 A G 8.53E-05 Colorectal cancer LAMC1 intron 23266556 rs3768622 chr1 183090011 G A 7.98E-05 Colorectal cancer LAMC1 intron 23266556 rs10752902 chr1 183090265 T A 8.50E-05 Colorectal cancer LAMC1 intron 23266556 rs6424889 chr1 183091796 G C 8.54E-05 Colorectal cancer LAMC1 intron 23266556 rs4652776 chr1 183091920 G A 8.51E-05 Colorectal cancer LAMC1 intron 23266556 rs4651139 chr1 183091963 C T 8.52E-05 Colorectal cancer LAMC1 intron 23266556 rs4652777 chr1 183091992 T G 8.59E-05 Colorectal cancer LAMC1 intron 23266556 rs3768620 chr1 183092237 G A 8.55E-05 Colorectal cancer LAMC1 intron 23266556 rs3768619 chr1 183092404 C G 8.55E-05 Colorectal cancer LAMC1 intron 23266556 rs3768617 chr1 183092500 C T 2.86E-06 Colorectal cancer LAMC1 intron 23266556 rs7518957 chr1 183093028 A T 8.59E-05 Colorectal cancer LAMC1 intron 23266556 rs2093982 chr1 183094191 T C 4.40E-05 Colorectal cancer LAMC1 intron 23266556 rs2093983 chr1 183094210 T C 8.68E-05 Colorectal cancer LAMC1 intron 23266556 rs2093985 chr1 183094322 C T 3.55E-04 Colorectal cancer LAMC1 intron 23266556 rs20558 chr1 183094547 T C 6.33E-04 Colorectal cancer LAMC1 missense 23266556 rs1886499 chr1 183095024 C T 3.08E-05 Colorectal cancer LAMC1 intron 23266556 rs2296293 chr1 183095477 G A 8.26E-05 Colorectal cancer LAMC1 intron 23266556 rs2296294 chr1 183095596 T C 1.94E-04 Colorectal cancer LAMC1 intron 23266556 rs2224933 chr1 183095765 A G 1.13E-04 Colorectal cancer LAMC1 intron 23266556 rs1413390 chr1 183096634 G A 9.26E-05 Colorectal cancer LAMC1 intron 23266556 rs1413389 chr1 183096668 C T 9.84E-05 Colorectal cancer LAMC1 intron 23266556 rs1413387 chr1 183096774 G A 9.89E-05 Colorectal cancer LAMC1 intron 23266556 rs7529465 chr1 183096880 A G 9.86E-05 Colorectal cancer LAMC1 intron 23266556 rs4651140 chr1 183096952 G T 9.90E-05 Colorectal cancer LAMC1 intron 23266556 rs4651141 chr1 183096969 A G 9.89E-05 Colorectal cancer LAMC1 intron 23266556 rs4651143 chr1 183097398 A G 9.82E-05 Colorectal cancer LAMC1 intron 23266556 rs1360704 chr1 183099380 T C 2.76E-06 Colorectal cancer LAMC1 intron 23266556 rs2296300 chr1 183099701 G A 8.18E-05 Colorectal cancer LAMC1 intron 23266556 rs6691755 chr1 183099821 G A 9.08E-05 Colorectal cancer LAMC1 intron 23266556 rs2333620 chr1 183100555 T C 9.01E-05 Colorectal cancer LAMC1 intron 23266556 rs10752903 chr1 183100863 A G 9.23E-05 Colorectal cancer LAMC1 intron 23266556 rs10737245 chr1 183100884 G A 9.22E-05 Colorectal cancer LAMC1 intron 23266556 rs10752904 chr1 183101038 A G 9.19E-05 Colorectal cancer LAMC1 intron 23266556 rs10797852 chr1 183101302 C T 9.35E-05 Colorectal cancer LAMC1 intron 23266556 rs12061219 chr1 183101471 G A 9.05E-05 Colorectal cancer LAMC1 intron 23266556 rs12095664 chr1 183101686 G A 7.29E-05 Colorectal cancer LAMC1 intron 23266556 rs3768616 chr1 183103551 T C 8.88E-05 Colorectal cancer LAMC1 intron 23266556 rs3768615 chr1 183103604 A G 8.72E-05 Colorectal cancer LAMC1 intron 23266556 rs10911260 chr1 183106230 C A 6.53E-04 Colorectal cancer LAMC1 intron 23266556 rs2274984 chr1 183107446 G T 8.75E-04 Type 2 diabetes LAMC1 intron 17463246 rs2274984 chr1 183107446 G T 1.29E-04 Colorectal cancer LAMC1 intron 23266556 rs2027085 chr1 183108611 T G 7.23E-05 Smoking cessation LAMC1 intron 18519826 rs2027085 chr1 183108611 T G 1.34E-04 Colorectal cancer LAMC1 intron 23266556 rs729819 chr1 183109034 G A 1.27E-04 Colorectal cancer LAMC1 intron 23266556 rs1062044 chr1 183112412 A G 1.59E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs944971 chr1 183112505 T C 2.65E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs944970 chr1 183112566 T C 1.58E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs3738829 chr1 183113862 C T 1.31E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1547715 chr1 183113952 A G 1.46E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1547714 chr1 183114119 C T 1.51E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1051473 chr1 183114146 T C 1.40E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs7473 chr1 183114634 G A 1.43E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs12034436 chr1 183114797 A G 1.24E-04 Colorectal cancer LAMC1 nearGene-3 23266556 rs10911262 chr1 183114956 A G 8.45E-04 Colorectal cancer LAMC1 nearGene-3 23266556 rs12565776 chr1 183116531 A G 5.00E-06 Systemic lupus erythematosus / / 24871463 rs17479287 chr1 183143422 G A 1.10E-04 IgE levels in asthmatics / / 23967269 rs479994 chr1 183161729 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) LAMC2 intron 20708005 rs1028771 chr1 183170948 A C 4.00E-06 Coronary heart disease LAMC2 intron 21347282 rs10494560 chr1 183172548 C T 5.70E-04 Type 2 diabetes and 6 quantitative traits LAMC2 intron 17848626 rs525410 chr1 183176430 A G 6.00E-07 Systemic lupus erythematosus LAMC2 intron 21408207 rs16860537 chr1 183180260 A G 5.00E-06 Systemic lupus erythematosus and Systemic sclerosis LAMC2 intron 23740937 rs10911279 chr1 183182188 C G 3.89E-05 Type 2 diabetes LAMC2 intron 17463246 rs875794 chr1 183184848 T G 2.92E-05 Type 2 diabetes LAMC2 intron 17463246 rs875795 chr1 183184960 C T 3.76E-05 Type 2 diabetes LAMC2 intron 17463246 rs942617 chr1 183185406 G C 3.43E-05 Type 2 diabetes LAMC2 intron 17463246 rs3768600 chr1 183186096 G A 5.71E-05 Type 2 diabetes LAMC2 intron 17463246 rs16860582 chr1 183190451 T C 2.97E-04 Alcohol dependence LAMC2 intron 20201924 rs12044752 chr1 183193694 C T 3.76E-05 Type 2 diabetes LAMC2 intron 17463246 rs16860609 chr1 183196217 C A 8.28E-04 Multiple complex diseases LAMC2 intron 17554300 rs3768597 chr1 183198013 C T 3.20E-04 Response to cytidine analogues (gemcitabine) LAMC2 intron 24483146 rs1047981 chr1 183206573 G A 3.18E-05 Type 2 diabetes LAMC2 cds-synon 17463246 rs3768593 chr1 183212548 T G 2.62E-05 Type 2 diabetes LAMC2 UTR-3 17463246 rs549191 chr1 183220937 A G 8.32E-06 Type 2 diabetes NM/T2 UTR-3 17463246 rs503243 chr1 183222013 G A 7.36E-06 Type 2 diabetes NM/T2 intron 17463246 rs9660718 chr1 183241736 T A 7.74E-05 Multiple complex diseases NM/T2 intron 17554300 rs4652795 chr1 183266182 C T 5.00E-06 Obesity-related traits NM/T2 intron 23251661 rs16860763 chr1 183270797 G T 2.53E-05 Acute lymphoblastic leukemia (childhood) NM/T2 intron 19684603 rs6687056 chr1 183272295 T C 8.52E-04 Schizophrenia NM/T2 intron 19197363 rs17483344 chr1 183273348 G A 6.23E-04 Type 2 diabetes NM/T2 intron 17463246 rs602182 chr1 183279029 G T 9.06E-04 Heart Failure NM/T2 intron pha002884 rs634375 chr1 183327866 C T 7.03E-04 Multiple complex diseases NM/T2 intron 17554300 rs2022013 chr1 183353853 C T 1.08E-07 Systemic lupus erythematosus NM/T2 intron 18204446 rs2078087 chr1 183358405 C T 4.66E-04 Sudden cardiac arrest NM/T2 intron 21658281 rs2078087 chr1 183358405 C T 1.00E-06 Obesity-related traits NM/T2 intron 23251661 rs1819628 chr1 183358440 T C 2.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NM/T2 intron 20877124 rs10494563 chr1 183376980 G T 4.99E-06 Obesity-related traits NM/T2 intron 23251661 rs2788048 chr1 183389877 A G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2788056 chr1 183400890 T C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2702199 chr1 183401880 T C 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2226099 chr1 183449357 C T 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SMG7 intron 20877124 rs2226099 chr1 183449357 C T 8.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SMG7 intron 20877124 rs3842897 chr1 183503664 A G 5.05E-05 Cognitive impairment induced by topiramate SMG7 intron 22091778 rs699246 chr1 183516100 G C 8.94E-30 Lymphocyte counts SMG7 intron 22286170 rs16861259 chr1 183593328 C T 8.12E-04 Type 2 diabetes / / 17463246 rs2231241 chr1 183596703 G A 8.80E-05 Systemic lupus erythematosus ARPC5 cds-synon 23273568 rs11811536 chr1 183604258 C A 1.10E-04 Systemic lupus erythematosus ARPC5 intron 23273568 rs10911390 chr1 183616884 C T 6.00E-06 Systemic lupus erythematosus APOBEC4 missense 23273568 rs1174657 chr1 183616926 T C 1.70E-04 Asperger disorder APOBEC4 missense 21182207 rs1174658 chr1 183617105 A G 1.70E-04 Asperger disorder APOBEC4 missense 21182207 rs10911398 chr1 183646886 A C 7.43E-04 Type 2 diabetes RGL1 intron 17463246 rs4507976 chr1 183666920 G A 2.86E-04 Multiple complex diseases RGL1 intron 17554300 rs6424904 chr1 183668132 A G 3.90E-04 Asperger disorder RGL1 intron 21182207 rs10911419 chr1 183675931 G A 6.07E-04 Multiple complex diseases RGL1 intron 17554300 rs3820689 chr1 183711483 C T 3.10E-04 Type 2 diabetes and 6 quantitative traits RGL1 intron 17848626 rs6664373 chr1 183737203 T C 9.45E-04 Multiple complex diseases RGL1 intron 17554300 rs1926834 chr1 183739363 C T 6.05E-04 Multiple complex diseases RGL1 intron 17554300 rs4388664 chr1 183804680 C T 8.18E-04 Myopia (pathological) RGL1 intron 21095009 rs2491439 chr1 183807275 A G 6.48E-04 Type 2 diabetes RGL1 intron 17463246 rs11806497 chr1 183812807 G A,C,T 5.41E-04 Substance dependence RGL1 intron 21818250 rs3010058 chr1 183820769 A G 2.50E-08 Metabolite levels RGL1 intron 23281178 rs9425321 chr1 183830901 C T 7.00E-06 Urinary metabolites RGL1 intron 21572414 rs9425322 chr1 183834061 G A 2.76E-06 Response to antidepressants RGL1 intron 20360315 rs9425323 chr1 183834276 C T 1.53E-06 Response to antidepressants RGL1 intron 20360315 rs4651156 chr1 183837032 A G 3.00E-06 Response to antidepressants RGL1 intron 20360315 rs9425326 chr1 183839005 T C 4.22E-06 Response to antidepressants RGL1 intron 20360315 rs9425616 chr1 183841103 G C 2.21E-06 Response to antidepressants RGL1 intron 20360315 rs9425617 chr1 183841784 T A 2.14E-06 Response to antidepressants RGL1 intron 20360315 rs10797917 chr1 183841796 T G 4.34E-06 Response to antidepressants RGL1 intron 20360315 rs10797919 chr1 183852914 G C 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder RGL1 intron 18951430 rs12562685 chr1 183885270 C T 6.96E-04 Type 2 diabetes RGL1 intron 17463246 rs10911469 chr1 183888858 G A 2.37E-04 Lymphocyte counts RGL1 intron 22286170 rs12563980 chr1 183889552 C T 8.45E-04 Type 2 diabetes RGL1 intron 17463246 rs7554987 chr1 183889607 T C 7.90E-04 Type 2 diabetes RGL1 intron 17463246 rs17503785 chr1 183903789 C G 2.49E-04 Birth weight / / 17255346 rs2986574 chr1 183906614 G A 6.00E-06 Parkinson's disease GLT25D2 UTR-3 17052657 rs3010040 chr1 183908222 C T 1.20E-05 Parkinson's disease GLT25D2 intron 17052657 rs2296713 chr1 183909717 G A 1.20E-05 Parkinson's disease GLT25D2 cds-synon 17052657 rs1887279 chr1 183910160 C T 6.00E-06 Parkinson's disease GLT25D2 intron 17052657 rs1887277 chr1 183932459 A C 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLT25D2 intron 20877124 rs149948023 chr1 183938537 G A 0.00024 Prostate cancer (non-advanced prostate cancer) GLT25D2 missense 23555315 rs724427 chr1 183939985 A T 8.60E-05 White matter hyperintensity burden GLT25D2 intron 21681796 rs10911491 chr1 183984495 T C 2.00E-05 Urinary metabolites GLT25D2 intron 21572414 rs12077047 chr1 183984717 T A 2.20E-05 Urinary metabolites GLT25D2 intron 21572414 rs756199 chr1 184002874 A G 7.00E-06 Height GLT25D2 intron 20189936 rs3814333 chr1 184007119 C T 2.00E-13 Height / / 23563607 rs2274432 chr1 184020945 G A 8.00E-09 Height TSEN15 missense 18391951 rs2274432 chr1 184020945 G A 3.87E-05 Height TSEN15 missense 19570815 rs1046934 chr1 184023529 A C 2.00E-31 Height TSEN15 missense 20881960 rs1926921 chr1 184032403 G A 4.96E-04 White matter integrity TSEN15 intron 22425255 rs12411231 chr1 184049394 C T 9.73E-04 Multiple complex diseases / / 17554300 rs1327144 chr1 184051573 A C 4.09E-05 Height / / pha003011 rs10752931 chr1 184067280 T C 8.03E-04 White matter integrity / / 22425255 rs971572 chr1 184068508 C A 9.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs16822455 chr1 184070494 G A 2.64E-04 Multiple complex diseases / / 17554300 rs1887296 chr1 184072250 C T 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1887296 chr1 184072250 C T 8.33E-04 White matter integrity / / 22425255 rs6424925 chr1 184128264 G A 3.98E-04 White matter integrity / / 22425255 rs6694958 chr1 184149821 A G 5.23E-04 Smoking initiation / / 24665060 rs2194698 chr1 184171449 C A 6.10E-06 Urinary metabolites / / 21572414 rs1863155 chr1 184177245 C T 7.00E-06 Urinary metabolites / / 21572414 rs1863155 chr1 184177245 C T 3.46E-05 Erythrocyte counts / / pha003099 rs16822576 chr1 184180060 A C 2.46E-04 Smoking initiation / / 24665060 rs35605894 chr1 184180060 A AC 2.46E-04 Smoking initiation / / 24665060 rs1409808 chr1 184189782 A G 7.40E-04 Smoking initiation / / 24665060 rs1409810 chr1 184190439 G A 4.49E-04 Smoking initiation / / 24665060 rs12132917 chr1 184192775 T C 4.23E-04 Smoking initiation / / 24665060 rs1854085 chr1 184192838 C T 7.63E-04 Smoking initiation / / 24665060 rs1930294 chr1 184195232 G T 2.23E-05 Smoking initiation / / 24665060 rs10494576 chr1 184197960 C G 7.94E-05 Smoking initiation / / 24665060 rs10494577 chr1 184205173 C A 7.01E-04 Smoking initiation / / 24665060 rs7528912 chr1 184205246 G C 1.77E-04 Smoking initiation / / 24665060 rs2378840 chr1 184219848 C T 4.77E-04 Smoking initiation / / 24665060 rs12117439 chr1 184261349 C T 1.19E-04 Smoking initiation / / 24665060 rs10911556 chr1 184283376 G A 1.99E-04 Smoking initiation / / 24665060 rs12096575 chr1 184288820 G A 1.66E-04 Smoking initiation / / 24665060 rs10911560 chr1 184292242 A G 6.73E-04 Obesity (extreme) / / 21935397 rs1930293 chr1 184294167 T C 6.68E-04 Obesity (extreme) / / 21935397 rs1930293 chr1 184294167 T C 5.69E-04 Smoking initiation / / 24665060 rs12074351 chr1 184300413 A G 6.73E-04 Obesity (extreme) / / 21935397 rs12059311 chr1 184302494 G A 6.36E-04 Obesity (extreme) / / 21935397 rs12083933 chr1 184304868 C T 1.10E-05 Urinary metabolites / / 21572414 rs4390140 chr1 184324403 C T 1.10E-05 Urinary metabolites / / 21572414 rs10911583 chr1 184332991 G A 7.59E-05 Insulin Resistance / / pha003062 rs10911593 chr1 184358935 A G 2.00E-05 Urinary metabolites C1orf21 intron 21572414 rs4326589 chr1 184358996 C T 8.30E-06 Urinary metabolites C1orf21 intron 21572414 rs4631655 chr1 184361316 G C 5.30E-05 Coronary heart disease C1orf21 intron 21966275 rs7415961 chr1 184363103 T C 1.70E-05 Urinary metabolites C1orf21 intron 21572414 rs6424950 chr1 184363837 T C 1.40E-05 Urinary metabolites C1orf21 intron 21572414 rs11799574 chr1 184391279 C A 5.16E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs12145326 chr1 184394956 C T 5.16E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs41470944 chr1 184402229 C A 1.53E-04 Multiple complex diseases C1orf21 intron 17554300 rs16823149 chr1 184402508 A G 5.50E-08 Colorectal cancer C1orf21 intron 20610541 rs16823195 chr1 184430842 G A 5.10E-05 Multiple complex diseases C1orf21 intron 17554300 rs6684430 chr1 184433058 T A 2.46E-04 Multiple complex diseases C1orf21 intron 17554300 rs10489724 chr1 184440480 T C 5.56E-05 Multiple complex diseases C1orf21 intron 17554300 rs10489725 chr1 184440541 T C 3.07E-04 Blood pressure C1orf21 intron 17255346 rs10489725 chr1 184440541 T C 2.16E-04 Multiple complex diseases C1orf21 intron 17554300 rs10489726 chr1 184440620 C T 2.91E-04 Blood pressure C1orf21 intron 17255346 rs10489726 chr1 184440620 C T 2.77E-04 Multiple complex diseases C1orf21 intron 17554300 rs4651208 chr1 184442054 T C 6.34E-05 Pulmonary function in asthmatics C1orf21 intron 23541324 rs6683932 chr1 184447624 C A 7.41E-05 Multiple complex diseases C1orf21 intron 17554300 rs2001270 chr1 184493884 A G 1.00E-04 Alcoholism (heaviness of drinking) C1orf21 intron 21529783 rs10911611 chr1 184537821 T C 1.00E-04 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs10911611 chr1 184537821 T C 1.00E-04 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs10911611 chr1 184537821 T C 2.73E-05 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs17255321 chr1 184560541 C A 4.19E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs12032371 chr1 184563169 C T 2.33E-04 Alzheimer's disease (late onset) C1orf21 intron 21379329 rs6695173 chr1 184577317 T G 4.29E-04 Blood pressure C1orf21 intron 17255346 rs10797981 chr1 184609820 G A 8.68E-05 Body Mass Index / / pha003009 rs73046798 chr1 184619002 C T 1.03E-04 Acne (severe) / / 24927181 rs4651229 chr1 184623559 G A 8.58E-05 Multiple complex diseases / / 17554300 rs73046800 chr1 184624354 G A 1.05E-04 Acne (severe) / / 24927181 rs10911628 chr1 184649503 C A 2.00E-13 Systemic lupus erythematosus / / 24871463 rs6663178 chr1 184661642 G A 6.88E-06 Obesity-related traits EDEM3 UTR-3 23251661 rs3736757 chr1 184677464 G A 6.00E-06 Obesity-related traits EDEM3 cds-synon 23251661 rs1040666 chr1 184694583 C A 9.05E-06 Obesity-related traits EDEM3 intron 23251661 rs861588 chr1 184738494 G A 4.50E-06 Urinary metabolites / / 21572414 rs861601 chr1 184745264 G A 4.44E-06 Obesity-related traits / / 23251661 rs570441 chr1 184760001 T C 7.23E-06 Obesity-related traits / / 23251661 rs7360 chr1 184760433 C T 4.27E-06 Obesity-related traits FAM129A UTR-3 23251661 rs682331 chr1 184761365 A G 4.00E-06 Obesity-related traits FAM129A UTR-3 23251661 rs35704242 chr1 184764824 C T 6.32E-05 Major depressive disorder FAM129A missense 21621269 rs338563 chr1 184776403 C T 7.04E-04 Obesity (extreme) FAM129A intron 21935397 rs338565 chr1 184777101 G A 7.05E-04 Obesity (extreme) FAM129A intron 21935397 rs543912 chr1 184777177 C A 7.04E-04 Obesity (extreme) FAM129A intron 21935397 rs338566 chr1 184777467 A T 6.30E-04 Obesity (extreme) FAM129A intron 21935397 rs338567 chr1 184777813 T C 7.03E-04 Obesity (extreme) FAM129A intron 21935397 rs338568 chr1 184777880 C A 7.03E-04 Obesity (extreme) FAM129A intron 21935397 rs10797988 chr1 184783699 C T 6.38E-04 Obesity (extreme) FAM129A intron 21935397 rs10797988 chr1 184783699 C T 8.43E-06 Obesity-related traits FAM129A intron 23251661 rs10797989 chr1 184794386 C G 6.73E-04 Obesity (extreme) FAM129A intron 21935397 rs520605 chr1 184795779 C T 5.30E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM129A intron 24023788 rs4651234 chr1 184799343 C T 7.59E-04 Obesity (extreme) FAM129A intron 21935397 rs481215 chr1 184800395 T G 9.19E-04 Obesity (extreme) FAM129A intron 21935397 rs906285 chr1 184800630 G A 7.47E-04 Obesity (extreme) FAM129A intron 21935397 rs484847 chr1 184800757 T C 9.26E-04 Obesity (extreme) FAM129A intron 21935397 rs671114 chr1 184812433 A C 5.95E-04 Type 2 diabetes FAM129A intron 17846126 rs685595 chr1 184813262 A G 5.58E-04 Type 2 diabetes FAM129A intron 17846126 rs580869 chr1 184813775 G A 6.03E-04 Type 2 diabetes FAM129A intron 17846126 rs688292 chr1 184813885 C T 6.03E-04 Type 2 diabetes FAM129A intron 17846126 rs688292 chr1 184813885 C T 3.86E-05 Bladder cancer FAM129A intron 19648920 rs234654 chr1 184849148 T C 3.01E-05 Insulin Resistance FAM129A intron pha003062 rs234654 chr1 184849148 T C 5.82E-05 Insulin-related traits FAM129A intron pha003063 rs10911659 chr1 184905261 C T 9.44E-04 Multiple complex diseases FAM129A intron 17554300 rs234091 chr1 184919549 T A 2.00E-05 Schizophrenia(treatment response to risperidone) FAM129A intron 19850283 rs7512071 chr1 184921581 T C 1.10E-05 Urinary metabolites FAM129A intron 21572414 rs4651243 chr1 184922863 G A 2.29E-04 Multiple complex diseases FAM129A intron 17554300 rs7355169 chr1 184923061 C G 1.10E-05 Urinary metabolites FAM129A intron 21572414 rs234110 chr1 184943837 A G 1.04E-04 Hearing function / / 17255346 rs3753573 chr1 185014002 G A 2.00E-06 Obesity-related traits / / 23251661 rs34982714 chr1 185071735 A AC 3.50E-08 Urinary metabolites RNF2 UTR-3 21572414 rs12096987 chr1 185201061 T C 8.87E-05 Obsessive-compulsive disorder SWT1 intron 24821223 rs10798004 chr1 185265149 G A 1.81E-04 Celiac disease / / 23936387 rs11803823 chr1 185298185 T G 1.32E-04 Multiple complex diseases LOC100288079 intron 17554300 rs6424976 chr1 185317357 T C 6.28E-04 Type 2 diabetes / / 17463246 rs6689206 chr1 185325547 T G 9.31E-04 Type 2 diabetes / / 17463246 rs7545878 chr1 185326860 T G 9.62E-05 Postoperative ventricular dysfunction / / 21980348 rs7512337 chr1 185335532 T C 9.59E-05 Postoperative ventricular dysfunction / / 21980348 rs7548599 chr1 185336295 G A 4.89E-04 Type 2 diabetes / / 17463246 rs4651254 chr1 185341597 T C 6.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10911713 chr1 185347488 C T 8.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10911717 chr1 185369231 C T 7.85E-05 Postoperative ventricular dysfunction / / 21980348 rs10911722 chr1 185381591 C T 8.26E-05 Postoperative ventricular dysfunction / / 21980348 rs10752951 chr1 185383982 G A 5.68E-04 Multiple complex diseases / / 17554300 rs7552672 chr1 185413074 C T 7.69E-05 Serum metabolites / / 19043545 rs4323662 chr1 185430494 G T 6.78E-06 Odorant perception / / 23910658 rs4323662 chr1 185430494 G T 1.89E-05 Celiac disease / / 23936387 rs12039912 chr1 185438634 A G 2.69E-05 Sleep duration / / 22105623 rs17643861 chr1 185440175 G A 7.09E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16824178 chr1 185456941 G A 2.97E-04 Multiple complex diseases / / 17554300 rs6663267 chr1 185464267 A G 2.76E-04 Type 2 diabetes / / 17463246 rs2181006 chr1 185465874 G T 3.55E-04 Type 2 diabetes / / 17463246 rs958564 chr1 185468919 A G 7.99E-04 Type 2 diabetes / / 17463246 rs7542383 chr1 185510221 C T 2.38E-04 Multiple complex diseases / / 17554300 rs1321996 chr1 185515461 A G 6.56E-05 Type 2 diabetes / / 17463246 rs534817 chr1 185520600 G A 1.55E-05 Type 2 diabetes / / 17463246 rs10798019 chr1 185522687 A C 9.76E-04 Alzheimer's disease / / 24755620 rs1321999 chr1 185524918 A G 2.15E-04 Type 2 diabetes / / 17463246 rs1321999 chr1 185524918 A G 2.07E-04 Insulin resistance / / 21901158 rs1321999 chr1 185524918 A G 8.02E-04 Obesity (extreme) / / 21935397 rs2821436 chr1 185525592 C G 1.28E-04 Type 2 diabetes / / 17463246 rs10911755 chr1 185526043 A C 3.89E-04 Type 2 diabetes / / 17463246 rs10911755 chr1 185526043 A C 4.83E-04 Insulin resistance / / 21901158 rs10911755 chr1 185526043 A C 7.90E-04 Obesity (extreme) / / 21935397 rs41453048 chr1 185529717 T C 4.61E-04 Type 2 diabetes / / 17463246 rs41453048 chr1 185529717 T C 5.70E-04 Insulin resistance / / 21901158 rs516040 chr1 185530242 A T 6.70E-05 Type 2 diabetes / / 17463246 rs11586588 chr1 185533305 G A 2.21E-04 Type 2 diabetes / / 17463246 rs11586588 chr1 185533305 G A 9.19E-04 Obesity (extreme) / / 21935397 rs556035 chr1 185533785 T C 3.14E-04 Alzheimer's disease / / 24755620 rs472975 chr1 185534476 A G 3.83E-05 Educational attainment / / 21694764 rs2842580 chr1 185536609 C A 3.39E-04 Alzheimer's disease / / 24755620 rs11583193 chr1 185540618 C A 6.49E-04 Obesity (extreme) / / 21935397 rs12402607 chr1 185543875 A G 6.66E-04 Obesity (extreme) / / 21935397 rs193087 chr1 185551100 G A 0.00001051 Sarcoidosis / / 22952805 rs12090554 chr1 185552348 G A 7.89E-07 Ventricular fibrillation in acute MI / / 20622880 rs12048982 chr1 185553146 T G 6.90E-04 Obesity (extreme) / / 21935397 rs12046138 chr1 185553524 G A 6.92E-04 Obesity (extreme) / / 21935397 rs193088 chr1 185554476 T C 9.24E-04 Alzheimer's disease / / 24755620 rs179776 chr1 185554489 T C 6.12E-05 Type 2 diabetes / / 17463246 rs333711 chr1 185561895 A G 7.81E-05 Type 2 diabetes / / 17463246 rs333713 chr1 185563418 G A 7.82E-05 Type 2 diabetes / / 17463246 rs333713 chr1 185563418 G A 8.12E-05 Insulin resistance / / 21901158 rs1407273 chr1 185578272 T C 3.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10798024 chr1 185603772 T G 9.59E-04 Multiple complex diseases / / 17554300 rs74133262 chr1 185684623 C T 1.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs11589747 chr1 185715394 C T 1.21E-05 Postoperative ventricular dysfunction HMCN1 intron 21980348 rs10489713 chr1 185724616 C T 0.00000292 Internal carotid artery thickness (near walls) HMCN1 intron 23487405 rs13375391 chr1 185794883 G A 9.00E-06 QRS duration HMCN1 intron 23534349 rs16824658 chr1 185864512 A G 3.76E-07 Gallstones HMCN1 intron 17632509 rs60502467 chr1 185878632 A G 0.00081 Breast cancer HMCN1 missense 23555315 rs6425015 chr1 186034964 C A 3.14E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911810 chr1 186036398 T C 0.000000148 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2064790 chr1 186037691 A T 4.37E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2064789 chr1 186037769 G A 4.41E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383430 chr1 186037949 C T 7.41E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs970578 chr1 186038467 C T 4.25E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761905 chr1 186039006 C T 3.98E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761904 chr1 186039340 G A 4.03E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761903 chr1 186039428 G A 0.000000129 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911811 chr1 186040062 G C 1.49E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383431 chr1 186042623 C T 1.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10752960 chr1 186043232 G T 1.46E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs975398 chr1 186044237 G A 1.13E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10752961 chr1 186044847 T C 4.85E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7550425 chr1 186045280 C G 1.21E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383432 chr1 186046748 G A 6.93E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911812 chr1 186048208 T G 1.18E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10798035 chr1 186050417 A G 3.52E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 missense 23633020 rs7530133 chr1 186051168 A T 9.35E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10798036 chr1 186052962 C G 6.90E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911814 chr1 186053440 A G 1.07E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651295 chr1 186054055 A G 1.11E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911815 chr1 186054796 A G 1.48E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425016 chr1 186055177 A G 2.28E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425017 chr1 186055371 A G 1.61E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6687977 chr1 186059551 A G 6.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1998088 chr1 186061099 G A 2.01E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651297 chr1 186061950 G A 1.87E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2073308 chr1 186063143 A T 3.16E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651298 chr1 186063863 T C 3.50E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2180480 chr1 186064781 A T 2.82E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs61831302 chr1 186064858 A C 0.0000287 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1022670 chr1 186064868 A G 3.90E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2891228 chr1 186065216 C T 4.40E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2891229 chr1 186065382 C T 4.46E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2038601 chr1 186065539 T G 8.38E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1853249 chr1 186067296 A C 2.57E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1590273 chr1 186067895 A G 2.65E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1830627 chr1 186068248 A G 2.73E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1923460 chr1 186068597 A G 2.76E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911819 chr1 186069140 C T 0.000000164 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383433 chr1 186070778 A G 9.82E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs716756 chr1 186070902 A G 5.50E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs716755 chr1 186071053 T G 3.71E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911820 chr1 186073181 C A 5.34E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7527490 chr1 186074918 A G 2.53E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7552781 chr1 186075520 C T 6.81E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6701244 chr1 186076291 C T 0.000000197 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7511761 chr1 186077302 C A 2.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1555495 chr1 186077463 A G 3.92E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911821 chr1 186080269 G C 7.69E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7555520 chr1 186081918 C T 1.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7555906 chr1 186082316 C G 2.35E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651299 chr1 186082509 C T 1.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4233125 chr1 186082632 G A 5.21E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12078938 chr1 186083534 C T 0.000000136 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12078939 chr1 186083536 C A 0.000000136 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs720971 chr1 186085768 T C 1.74E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs720972 chr1 186085897 C A 2.01E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10157742 chr1 186086578 G A 1.42E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10157924 chr1 186087544 G C 1.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7543494 chr1 186093558 T G 3.27E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs77123846 chr1 186101317 G A 0.0000128 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911827 chr1 186101964 C T 0.0000797 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10489753 chr1 186108672 G A 2.90E-04 Stroke HMCN1 intron pha002887 rs17531405 chr1 186113852 G C 4.69E-04 Type 2 diabetes HMCN1 intron 17463246 rs6703518 chr1 186116797 G T 0.000000881 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7512168 chr1 186119056 T C 0.000000709 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1322376 chr1 186120139 T G 0.000000507 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7545010 chr1 186126099 A G 0.00000076 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7525679 chr1 186126793 G A 0.0000171 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6673026 chr1 186132451 G C 0.00000784 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2208692 chr1 186133290 C A 0.00000499 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs72707469 chr1 186134561 C T 0.00000793 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6680616 chr1 186135081 C G 0.00000961 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs78002252 chr1 186135231 A C 0.0000488 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425021 chr1 186135236 G A 0.000000237 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7549613 chr1 186136289 T C 0.00000468 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383457 chr1 186136572 T C 0.00000956 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs11582026 chr1 186140907 A G 0.00000447 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651302 chr1 186141301 G A 0.000000785 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12120763 chr1 186141836 G T 0.0000142 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12123389 chr1 186142073 A G 0.00000492 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7554865 chr1 186143052 T C 0.00000602 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7554872 chr1 186143082 T C 0.0000109 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs911743 chr1 186144104 A C 0.00000668 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs61831358 chr1 186146175 A G 0.0000723 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs11579683 chr1 186149017 G A 0.0000127 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1407434 chr1 186149032 G A 3.59E-04 Lung function (forced vital capacity) HMCN1 intron 24023788 rs10911836 chr1 186149235 C T 0.00000726 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs16825040 chr1 186151493 C G 0.00000401 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs680638 chr1 186156514 C T 1.26E-04 Bipolar disorder,schizoaffective HMCN1 intron 19567891 rs1322375 chr1 186163076 T C 3.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1885522 chr1 186172443 C A 4.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs676236 chr1 186173178 A G 2.77E-04 Bipolar disorder,schizoaffective / / 19567891 rs595888 chr1 186174823 C T 6.71E-04 Bipolar disorder,schizoaffective / / 19567891 rs13375677 chr1 186178238 T C 6.34E-05 Personality dimensions / / 18957941 rs1743664 chr1 186190201 T G 6.87E-05 Personality dimensions / / 18957941 rs586281 chr1 186199484 G A 6.18E-06 Personality dimensions / / 18957941 rs586281 chr1 186199484 G A 6.20E-06 Personality dimensions / / 21173776 rs6671112 chr1 186232656 A C 7.90E-05 Response to statin therapy / / 20339536 rs6671112 chr1 186232656 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1285115 chr1 186237510 C T 8.90E-05 Response to statin therapy / / 20339536 rs857584 chr1 186241738 T C 8.00E-05 Response to statin therapy / / 20339536 rs704308 chr1 186242675 A C 5.70E-05 Response to statin therapy / / 20339536 rs704308 chr1 186242675 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3820182 chr1 186290333 G A 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TPR intron 20877124 rs58030082 chr1 186313108 C T 0.000013 Breast cancer TPR missense 23555315 rs11806304 chr1 186372865 A G 9.60E-04 Response to cytidine analogues (gemcitabine) C1orf27 intron 24483146 rs6665157 chr1 186379265 G A 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C1orf27 intron 20877124 rs6665157 chr1 186379265 G A 9.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C1orf27 intron 20877124 rs6665157 chr1 186379265 G A 8.00E-06 Hypertension C1orf27 intron 22384028 rs6425029 chr1 186406546 G T 5.69E-04 Multiple complex diseases / / 17554300 rs1882926 chr1 186411579 C A 4.22E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6672638 chr1 186417484 T C 1.86E-05 Response to tocilizumab in rheumatoid arthritis PDC intron 22491018 rs12062743 chr1 186447591 C T 2.58E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs497285 chr1 186454429 C A 2.94E-05 Serum alpha1-antitrypsin levels / / 23990791 rs480075 chr1 186456336 A G 9.91E-04 Type 2 diabetes / / 17463246 rs480075 chr1 186456336 A G 3.20E-04 Type 2 diabetes / / 17463249 rs480075 chr1 186456336 A G 3.24E-04 Multiple complex diseases / / 17554300 rs480075 chr1 186456336 A G 2.76E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10911877 chr1 186506612 G A 7.88E-04 Insulin resistance / / 21901158 rs7542810 chr1 186532231 G A 5.84E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1569879 chr1 186547952 C T 9.01E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1013665 chr1 186548140 C T 1.05E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4140432 chr1 186550535 T G 7.28E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10798052 chr1 186577925 C T 7.20E-04 Insulin resistance / / 21901158 rs11584662 chr1 186580824 G T 4.92E-05 Male-pattern baldness / / 18849994 rs17520924 chr1 186593131 C T 4.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10489396 chr1 186598211 C T 5.88E-04 Insulin resistance / / 21901158 rs10489397 chr1 186598610 C A 3.31E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7514491 chr1 186599018 T C 1.19E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2383513 chr1 186599524 T C 1.73E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs11811047 chr1 186601141 G A 5.99E-04 Insulin resistance / / 21901158 rs12405141 chr1 186623470 A G 8.24E-04 Type 2 diabetes / / 17463246 rs12405141 chr1 186623470 A G 3.04E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10911901 chr1 186624006 A C 1.03E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9783017 chr1 186627831 C T 9.56E-04 Type 2 diabetes / / 17463246 rs10911902 chr1 186632317 C T 6.54E-04 Type 2 diabetes / / 17463246 rs10911902 chr1 186632317 C T 2.00E-06 Schizophrenia / / 18347602 rs4648310 chr1 186640525 T C 5.90E-06 Blood pressure PTGS2 nearGene-3 21060006 rs4648310 chr1 186640525 T C 5.90E-06 Blood pressure PTGS2 nearGene-3 21060006 rs2206593 chr1 186642429 A G 4.60E-06 Serum alpha1-antitrypsin levels PTGS2 UTR-3 23990791 rs5275 chr1 186643058 A G 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTGS2 UTR-3 20877124 rs2745557 chr1 186649221 A G 2.43E-05 Serum alpha1-antitrypsin levels PTGS2 intron 23990791 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15138244 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15150618 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15767339 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 16678543 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 17495879 rs2745559 chr1 186652002 A C 3.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10911905 chr1 186652395 T G 2.23E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs34093265 chr1 186652395 T TG 2.23E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2143417 chr1 186653787 G T 3.65E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1119065 chr1 186658072 C T 1.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2383529 chr1 186669092 A G 7.19E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6665419 chr1 186674561 C A 2.51E-04 Multiple complex diseases / / 17554300 rs12401885 chr1 186682875 T C 3.57E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2205953 chr1 186692562 T C 7.78E-04 Alcohol dependence / / 21314694 rs12088741 chr1 186718317 T A 3.92E-04 Multiple complex diseases / / 17554300 rs4140564 chr1 186725003 G A 3.00E-06 Knee osteoarthritis / / 18471798 rs10489401 chr1 186742947 A G 6.32E-05 Urate levels / / 23263486 rs4651330 chr1 186816650 C A 4.96E-04 Alzheimer's disease PLA2G4A intron 17998437 rs10752979 chr1 186835995 A G 9.05E-04 Alzheimer's disease PLA2G4A intron 17998437 rs2223307 chr1 186844926 C T 7.33E-04 Response to taxane treatment (placlitaxel) PLA2G4A intron 23006423 rs2223309 chr1 186848093 G A 5.80E-04 Insulin resistance PLA2G4A intron 21901158 rs1980444 chr1 186850960 T C 2.10E-06 Glioma (high-grade) PLA2G4A intron 19578366 rs12042344 chr1 186858135 T C 9.20E-04 Insulin resistance PLA2G4A intron 21901158 rs12720541 chr1 186870072 G T 9.00E-06 Epilepsy (generalized) PLA2G4A intron 22949513 rs6698103 chr1 186870546 G C 7.87E-04 Suicide attempts in bipolar disorder PLA2G4A intron 21423239 rs10798069 chr1 186875459 G T 8.41E-05 Partial epilepsies PLA2G4A intron 20522523 rs10798069 chr1 186875459 G T 1.00E-04 Cognitive impairment induced by topiramate PLA2G4A intron 22091778 rs6686848 chr1 186887107 C A 1.11E-04 Suicide attempts in bipolar disorder PLA2G4A intron 21423239 rs6674263 chr1 186936162 A T 6.63E-07 Red blood cell traits PLA2G4A intron 23222517 rs6672835 chr1 186940756 A T 9.91E-07 Red blood cell traits PLA2G4A intron 23222517 rs12720690 chr1 186948221 G T 0.000000869 Cholesterol,total PLA2G4A intron 23063622 rs10489410 chr1 186954195 T G 5.44E-07 Lipoproteins PLA2G4A intron pha003079 rs761516 chr1 186961326 T G 5.15E-05 Alcohol dependence / / 21314694 rs1474797 chr1 186967193 A G 1.13E-04 Opioid sensitivity / / 23183491 rs6689013 chr1 186980818 A C 7.40E-06 Urinary metabolites / / 21572414 rs10752993 chr1 186981339 C T 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2207215 chr1 186985141 C T 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4233126 chr1 186999604 A T 1.19E-04 Type 2 diabetes / / 17463246 rs4233126 chr1 186999604 A T 8.27E-05 Serum metabolites / / 19043545 rs1884022 chr1 187002419 A C 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7540422 chr1 187005310 A G 6.07E-05 Information processing speed / / 21130836 rs1297676 chr1 187041011 T C 9.90E-05 Serum metabolites / / 19043545 rs2144438 chr1 187054897 T C 6.70E-06 Urinary metabolites / / 21572414 rs7511950 chr1 187055561 A G 7.96E-05 Arthritis (juvenile idiopathic) / / 22354554 rs10911998 chr1 187057847 C T 4.49E-05 Autism / / 24189344 rs1008407 chr1 187062807 A G 1.00E-04 Information processing speed / / 21130836 rs10798085 chr1 187066811 T G 3.40E-06 Urinary metabolites / / 21572414 rs118654 chr1 187070355 G T 4.30E-06 Urinary metabolites / / 21572414 rs230611 chr1 187093666 T A 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs230607 chr1 187096481 C A 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs230607 chr1 187096481 C A 9.91E-05 Body Composition / / pha003012 rs230607 chr1 187096481 C A 3.28E-05 Body Mass Index / / pha003021 rs12564176 chr1 187130516 A G 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12133085 chr1 187135612 C A 2.66E-06 Carotenoid and tocopherol levels / / 19185284 rs10494592 chr1 187158604 T G 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs330746 chr1 187233123 T C 5.29E-05 Body Composition / / pha003012 rs330746 chr1 187233123 T C 6.89E-05 Body Mass Index / / pha003021 rs330749 chr1 187237164 G A 5.58E-05 Body Composition / / pha003012 rs330749 chr1 187237164 G A 7.23E-05 Body Mass Index / / pha003021 rs4651370 chr1 187239092 T A 0.00000528 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4651370 chr1 187239092 T A 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11807539 chr1 187243386 G A 9.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2453727 chr1 187247150 C T 4.72E-04 Schizophrenia / / 19197363 rs7523591 chr1 187261732 T A 0.000195 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7523591 chr1 187261732 T A 1.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7532843 chr1 187264446 T C 0.0001919 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7532843 chr1 187264446 T C 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12143542 chr1 187266802 G A 4.03E-05 Body Composition / / pha003012 rs12143542 chr1 187266802 G A 8.26E-05 Body Mass Index / / pha003021 rs12118757 chr1 187267705 T C 0.0001454 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12118757 chr1 187267705 T C 1.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12117650 chr1 187275669 G A 0.0001029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12117650 chr1 187275669 G A 1.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12733231 chr1 187276220 A G 0.0001016 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12733231 chr1 187276220 A G 1.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12739992 chr1 187277743 G A 0.00009412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12739992 chr1 187277743 G A 9.41E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12125797 chr1 187279673 T C 0.00009253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12125797 chr1 187279673 T C 9.25E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10752999 chr1 187279690 A C 2.82E-05 Body Composition / / pha003012 rs10752999 chr1 187279690 A C 5.69E-05 Body Mass Index / / pha003021 rs12134274 chr1 187289832 A C 0.0003694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12134274 chr1 187289832 A C 3.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12142623 chr1 187290406 C A 0.00001358 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12142623 chr1 187290406 C A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6683451 chr1 187292608 A C 9.77E-05 Lipoproteins / / pha003079 rs1032538 chr1 187295508 C T 1.37E-05 Body Composition / / pha003012 rs1032538 chr1 187295508 C T 7.90E-05 Body Mass Index / / pha003021 rs1285496 chr1 187295740 C A 1.14E-05 Body Composition / / pha003012 rs1285496 chr1 187295740 C A 6.57E-05 Body Mass Index / / pha003021 rs1148757 chr1 187320698 G A 3.76E-04 Taste perception / / 22132133 rs2802475 chr1 187327396 A G 3.02E-05 Body Composition / / pha003012 rs2489646 chr1 187329086 A C 6.42E-05 Body Composition / / pha003012 rs931590 chr1 187341438 T C 3.09E-07 Body Composition / / pha003012 rs931590 chr1 187341438 T C 1.12E-06 Body Mass Index / / pha003021 rs4409608 chr1 187353527 A G 2.63E-07 Body Composition / / pha003012 rs4409608 chr1 187353527 A G 1.09E-06 Body Mass Index / / pha003021 rs11583351 chr1 187355994 A G 1.94E-05 Body Composition / / pha003012 rs11583351 chr1 187355994 A G 7.56E-05 Body Mass Index / / pha003021 rs4651377 chr1 187381112 G A 2.23E-05 Glycosylated haemoglobin levels / / 17255346 rs7552942 chr1 187382298 T C 1.37E-05 Glycosylated haemoglobin levels / / 17255346 rs7516204 chr1 187389942 T C 8.95E-05 Glycosylated haemoglobin levels / / 17255346 rs12142409 chr1 187390668 G A 2.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2244067 chr1 187412042 A T 7.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs1938512 chr1 187422872 C A 3.45E-04 Alcohol dependence / / 24277619 rs12137534 chr1 187428231 A G 5.43E-04 Type 2 diabetes / / 17463246 rs12088162 chr1 187429753 A T 2.44E-04 Type 2 diabetes / / 17463246 rs10798113 chr1 187432059 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1892543 chr1 187434767 C T 5.23E-05 Serum metabolites / / 19043545 rs1938522 chr1 187435580 G T 5.27E-05 Serum metabolites / / 19043545 rs2249494 chr1 187435909 G T 8.16E-04 Type 2 diabetes / / 17463246 rs10732980 chr1 187440916 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4651390 chr1 187445049 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16827144 chr1 187467969 A T 2.17E-04 Multiple complex diseases / / 17554300 rs12028808 chr1 187478809 T G 7.04E-05 Type 2 diabetes / / 23300278 rs7555613 chr1 187479735 A C 0.0008761 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7555613 chr1 187479735 A C 8.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912086 chr1 187490224 A C 0.0008598 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912086 chr1 187490224 A C 8.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12130665 chr1 187495140 T C 0.0008718 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12130665 chr1 187495140 T C 8.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12134218 chr1 187495399 A G 0.0008694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12134218 chr1 187495399 A G 8.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1538481 chr1 187498000 T A 0.0008852 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1538481 chr1 187498000 T A 8.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912090 chr1 187500052 C T 0.0008782 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912090 chr1 187500052 C T 8.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912092 chr1 187509488 C T 0.00088 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912092 chr1 187509488 C T 8.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2891285 chr1 187522674 T C 8.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2383655 chr1 187533238 G A 5.51E-04 Multiple complex diseases / / 17554300 rs10494599 chr1 187534561 A G 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs1339083 chr1 187552665 T C 3.24E-05 Orofacial clefts / / 22419666 rs12127474 chr1 187557096 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs12075120 chr1 187573295 G A 2.67E-05 Orofacial clefts / / 22419666 rs12075120 chr1 187573295 G A 1.44E-05 Creatinine levels / / pha003069 rs1416478 chr1 187574028 G A 3.92E-05 Psoriasis / / 18364390 rs2383658 chr1 187581303 G A 7.37E-05 Orofacial clefts / / 22419666 rs12746529 chr1 187588239 T C 9.01E-06 Creatinine levels / / pha003069 rs16827381 chr1 187599437 G A 7.25E-05 Type 2 diabetes / / 17463246 rs6686371 chr1 187607131 C A 1.20E-05 Urinary metabolites / / 21572414 rs6686651 chr1 187607223 G A 2.34E-04 Smoking initiation / / 24665060 rs10753015 chr1 187611232 G A 7.90E-06 Urinary metabolites / / 21572414 rs12749748 chr1 187623971 T C 1.10E-05 Urinary metabolites / / 21572414 rs12749748 chr1 187623971 T C 2.85E-05 Creatinine levels / / pha003069 rs10494602 chr1 187628458 C T 4.07E-05 Creatinine levels / / pha003069 rs17613702 chr1 187651919 C T 8.41E-05 Smoking initiation / / 24665060 rs2891292 chr1 187652296 C T 7.85E-04 Smoking initiation / / 24665060 rs3120952 chr1 187656368 C T 6.50E-07 Urinary metabolites / / 21572414 rs3127494 chr1 187657248 G A 5.30E-07 Urinary metabolites / / 21572414 rs953554 chr1 187661530 T C 6.00E-06 Smoking initiation / / 24665060 rs3120959 chr1 187662571 A G 1.92E-04 Fibrinogen / / 17255346 rs16827441 chr1 187668728 T C 5.06E-04 Smoking initiation / / 24665060 rs6685655 chr1 187677162 G A 7.80E-05 Smoking initiation / / 24665060 rs4501794 chr1 187677281 G T 8.29E-04 Multiple complex diseases / / 17554300 rs6425114 chr1 187681358 A C 7.48E-05 Creatinine levels / / pha003069 rs4233130 chr1 187685344 A G 8.96E-05 Smoking initiation / / 24665060 rs4498762 chr1 187689619 A G 4.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6671961 chr1 187690536 A T 2.10E-05 Urinary metabolites / / 21572414 rs147535159 chr1 187692731 T C 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs151023900 chr1 187693831 A G 0.00000439 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117260858 chr1 187696963 T C 0.00000433 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117232653 chr1 187702935 T C 0.0000044 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs79918766 chr1 187703615 C T 0.0000044 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6701697 chr1 187707768 C G 3.08E-04 Smoking initiation / / 24665060 rs75445209 chr1 187707926 G A 0.00000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6673165 chr1 187710134 T A 0.00000435 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10912159 chr1 187711459 G A 8.55E-05 Socioeconomic Factors / / pha003066 rs10912160 chr1 187711717 G A 9.28E-08 Metabolite levels / / 23281178 rs6697553 chr1 187713440 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10912162 chr1 187715179 G C 8.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs118069725 chr1 187721126 G T 0.00000545 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117902173 chr1 187721954 C A 0.00000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10753026 chr1 187724610 G A 1.10E-06 Urinary metabolites / / 21572414 rs77850287 chr1 187725322 G A 0.00000254 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs114735216 chr1 187725506 G A 0.00000262 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs139733258 chr1 187726488 C T 0.00000255 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs116411447 chr1 187729331 T C 0.00000272 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3095425 chr1 187729787 T G 1.20E-05 Urinary metabolites / / 21572414 rs3127511 chr1 187730546 G C 6.40E-07 Urinary metabolites / / 21572414 rs147066159 chr1 187736279 A G 0.00000247 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1158512 chr1 187744623 C T 1.41E-04 Smoking initiation / / 24665060 rs3123045 chr1 187747787 T C 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3123045 chr1 187747787 T C 7.92E-04 Smoking initiation / / 24665060 rs117122963 chr1 187747891 G A 0.00000259 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs967778 chr1 187748399 C T 1.85E-04 Smoking initiation / / 24665060 rs10912174 chr1 187749447 T C 6.57E-04 Smoking initiation / / 24665060 rs116883766 chr1 187752522 G A 0.00000151 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs116229031 chr1 187754464 C A 0.00000186 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1476901 chr1 187760345 T C 8.88E-05 Schizophrenia / / 19571809 rs10798148 chr1 187779509 T C 9.20E-05 Personality dimensions / / 18957941 rs2495474 chr1 187813938 T G 5.94E-05 Serum metabolites / / 19043545 rs2430149 chr1 187821262 C T 8.72E-05 Serum metabolites / / 19043545 rs2215698 chr1 187822931 A G 6.52E-06 Serum metabolites / / 19043545 rs2430144 chr1 187823537 A G 7.83E-05 Body Mass Index / / pha003014 rs2430129 chr1 187840553 C T 9.68E-06 Serum metabolites / / 19043545 rs800820 chr1 187846268 T C 1.59E-05 Serum metabolites / / 19043545 rs776797 chr1 187888914 G A 8.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs655167 chr1 187902981 A G 7.00E-06 Hypothyroidism / / 22493691 rs1432437 chr1 187908413 A G 5.41E-04 Type 2 diabetes / / 17463246 rs1159069 chr1 187912258 C T 6.95E-04 Type 2 diabetes / / 17463246 rs1159069 chr1 187912258 C T 8.86E-04 Multiple complex diseases / / 17554300 rs2195856 chr1 187922876 A C 3.21E-04 Type 2 diabetes / / 17463246 rs7539069 chr1 187940867 A G 6.60E-05 HIV-1 control / / 20041166 rs12404590 chr1 187984417 C A 2.76E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4650751 chr1 188012281 T G 6.02E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs7544859 chr1 188013287 A G 2.53E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs12131117 chr1 188015078 T C 6.50E-04 Acute lung injury / / 22295056 rs1323012 chr1 188037933 G A,C,T 4.59E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs10798164 chr1 188048096 T G 4.03E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs7523908 chr1 188048430 G C 4.03E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs1407709 chr1 188062679 T C 4.00E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs6676981 chr1 188075597 C A 7.12E-04 Multiple complex diseases / / 17554300 rs10489764 chr1 188085833 T C 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12756923 chr1 188097356 T C 7.59E-04 Multiple complex diseases / / 17554300 rs10912249 chr1 188098441 A G 7.72E-04 Multiple complex diseases / / 17554300 rs1923808 chr1 188102053 C T 8.94E-04 HIV-1 viral setpoint / / 17641165 rs1323004 chr1 188108625 G A 8.94E-04 HIV-1 viral setpoint / / 17641165 rs12129062 chr1 188117353 C T 1.04E-05 Major depressive disorder / / 19107115 rs7554161 chr1 188124782 T C 8.91E-04 Multiple complex diseases / / 17554300 rs354252 chr1 188129116 G C 8.00E-04 Multiple complex diseases / / 17554300 rs12040679 chr1 188134928 C T 9.47E-04 Multiple complex diseases / / 17554300 rs10494612 chr1 188155305 C T 2.95E-04 Multiple complex diseases / / 17554300 rs1487492 chr1 188162030 A G 5.69E-04 HIV-1 viral setpoint / / 17641165 rs12128431 chr1 188162228 G A 6.97E-05 Acute lung injury / / 22295056 rs12143302 chr1 188162327 C A 6.97E-05 Acute lung injury / / 22295056 rs7414437 chr1 188169106 A G 5.81E-05 Heart Rate / / pha003053 rs10494611 chr1 188171319 C G 5.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12140374 chr1 188175132 T C 7.45E-04 Acute lung injury / / 22295056 rs11810998 chr1 188178381 T G 2.81E-05 Major depressive disorder / / 19107115 rs11810998 chr1 188178381 T G 7.31E-04 Acute lung injury / / 22295056 rs12143522 chr1 188187052 G C 6.64E-04 Acute lung injury / / 22295056 rs6425147 chr1 188192177 G A 3.17E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3010654 chr1 188248649 T C 7.27E-05 Response to methylphenidate treatment / / 21130132 rs12136061 chr1 188275062 C T 1.10E-04 IgE levels in asthmatics / / 23967269 rs10494608 chr1 188285804 T C 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10912319 chr1 188297287 C T 7.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4463623 chr1 188300868 C T 1.00E-06 Hypertension / / 22384028 rs4434808 chr1 188308289 C T 3.00E-06 Hypertension / / 22384028 rs12126176 chr1 188314941 C G 3.18E-04 Insulin resistance / / 21901158 rs1387343 chr1 188328650 C T 8.00E-06 Hypertension / / 22384028 rs12031313 chr1 188352158 T C 2.00E-05 Urinary metabolites / / 21572414 rs12125250 chr1 188379428 C A 4.00E-06 Economic and political preferences / / 22566634 rs12569034 chr1 188381951 A C 2.20E-05 Urinary metabolites / / 21572414 rs12142669 chr1 188383316 T C 3.00E-06 Obesity-related traits / / 23251661 rs10798210 chr1 188384464 T C 2.65E-06 Obesity-related traits / / 23251661 rs1472002 chr1 188390606 T G 8.19E-05 Cognitive performance / / 19734545 rs1472002 chr1 188390606 T G 2.00E-05 HIV-1 control / / 20041166 rs284046 chr1 188425733 A C 6.28E-04 Nicotine dependence / / 17158188 rs10912417 chr1 188457478 G A 7.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2170561 chr1 188463044 T A 0.0000034 Amygdala reactivity / / 22856363 rs12048929 chr1 188465070 G A 5.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12038869 chr1 188469106 C T 5.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs284113 chr1 188477749 G T 1.10E-05 Hypertension / / 22384028 rs12123962 chr1 188478589 G A 9.33E-04 Aortic root size / / 21223598 rs1906768 chr1 188490214 A C 5.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12022365 chr1 188509218 A G 5.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs900334 chr1 188512442 C A 6.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10912450 chr1 188533300 G A 8.97E-05 Multiple complex diseases / / 17554300 rs2312283 chr1 188629757 A G 7.96E-05 Insulin resistance / / 21901158 rs34906964 chr1 188629757 A AT 7.96E-05 Insulin resistance / / 21901158 rs10921075 chr1 188678917 C A,T 7.50E-05 Progressive supranuclear palsy / / 21685912 rs4551597 chr1 188764543 T C 9.54E-05 Alzheimer's disease (late onset) / / 21379329 rs12029028 chr1 188788576 G T 6.69E-04 Taste perception / / 22132133 rs16829481 chr1 188852259 C T 2.93E-05 Multiple complex diseases / / 17554300 rs16829586 chr1 188876279 C T 8.45E-05 Orofacial clefts / / 22419666 rs9651064 chr1 188929353 T C 0.0008608 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9651064 chr1 188929353 T C 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9651065 chr1 188930161 A G 0.0008638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9651065 chr1 188930161 A G 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1373936 chr1 188961641 A C 6.45E-05 ldl cholesterol / / pha003076 rs2053675 chr1 188967356 A G 6.58E-05 ldl cholesterol / / pha003076 rs10921102 chr1 188994596 G A 8.98E-05 ldl cholesterol / / pha003076 rs10921112 chr1 188997868 C A 6.27E-05 Serum metabolites / / 19043545 rs7528687 chr1 189007626 A G 0.0007254 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7528687 chr1 189007626 A G 7.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6428096 chr1 189010340 T C 3.65E-05 Serum metabolites / / 19043545 rs6428096 chr1 189010340 T C 8.13E-04 Response to TNF antagonist treatment / / 21061259 rs12046366 chr1 189022599 G T 4.55E-05 Serum metabolites / / 19043545 rs12046366 chr1 189022599 G T 7.97E-04 Response to TNF antagonist treatment / / 21061259 rs10921184 chr1 189029198 C T 7.88E-05 Parkinson's disease / / 21812969 rs4508010 chr1 189034273 G A 7.62E-05 Serum metabolites / / 19043545 rs4508010 chr1 189034273 G A 9.11E-04 Response to TNF antagonist treatment / / 21061259 rs1912910 chr1 189047232 G C 9.18E-04 Response to TNF antagonist treatment / / 21061259 rs2175550 chr1 189079402 C T 2.63E-05 Serum metabolites / / 19043545 rs2175550 chr1 189079402 C T 5.58E-04 Response to TNF antagonist treatment / / 21061259 rs10754040 chr1 189079982 C T 2.69E-05 Serum metabolites / / 19043545 rs10754040 chr1 189079982 C T 6.95E-04 Response to TNF antagonist treatment / / 21061259 rs12138517 chr1 189138755 T G 4.40E-05 Iron levels / / 21208937 rs1539388 chr1 189147180 T G 8.28E-05 Serum metabolites / / 19043545 rs1342553 chr1 189180993 A G 9.33E-05 Serum metabolites / / 19043545 rs1342553 chr1 189180993 A G 1.27E-04 Progressive supranuclear palsy / / 21685912 rs1342554 chr1 189181078 C T 8.57E-05 Serum metabolites / / 19043545 rs4313401 chr1 189384373 A G 6.41E-05 Serum metabolites / / 19043545 rs11800563 chr1 189432044 C G 8.46E-05 Serum metabolites / / 19043545 rs578175605 chr1 189432044 C CAAATCACTT 8.46E-05 Serum metabolites / / 19043545 rs10922227 chr1 189520505 G A 4.34E-05 Serum metabolites / / 19043545 rs12132580 chr1 189523652 T C 4.98E-05 Orofacial clefts / / 22419666 rs12127810 chr1 189526779 C T 1.93E-04 Insulin resistance / / 21901158 rs10489759 chr1 189589339 C T 8.00E-08 Immune response to smallpox vaccine (IL-6) / / 22542470 rs10737562 chr1 189723623 A G 7.00E-06 Systemic lupus erythematosus / / 21408207 rs12566065 chr1 189736833 T C 1.26E-05 Serum metabolites / / 19043545 rs12742200 chr1 189758533 G A 5.77E-04 Tourette syndrome / / 22889924 rs11578153 chr1 189758772 C T 6.05E-05 Serum albumin level / / pha003084 rs2418508 chr1 189761051 A G 1.71E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1517100 chr1 189786171 G A 8.18E-04 Schizophrenia / / 21674006 rs10800667 chr1 189788319 A G 5.02E-04 Depression (quantitative trait) / / 20800221 rs12138327 chr1 189791316 C T 5.08E-04 Heart Failure / / pha002884 rs1568133 chr1 189822612 G A 2.18E-04 Multiple complex diseases / / 17554300 rs2944697 chr1 189830133 G T 3.85E-05 Cognitive performance / / 19734545 rs3005708 chr1 189835520 G A 1.39E-04 Multiple complex diseases / / 17554300 rs1356344 chr1 189837106 C G 4.42E-04 Multiple complex diseases / / 17554300 rs1400544 chr1 189861404 A T 6.00E-06 Subclinical atherosclerosis / / 17903303 rs10920278 chr1 189970400 T G 8.53E-05 Serum metabolites / / 19043545 rs10737578 chr1 189983720 T C 2.92E-05 Body Mass Index / / pha002896 rs4845211 chr1 189986745 C A 3.51E-05 Body Mass Index / / pha002896 rs4845214 chr1 189990412 G A 5.96E-05 Body Mass Index / / pha002896 rs9970628 chr1 189994233 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1935881 chr1 190066386 T C 6.00E-06 Echocardiographic traits / / 17903301 rs17375108 chr1 190070919 T C 4.89E-04 Alzheimer's disease (late onset) FAM5C intron 21379329 rs7540848 chr1 190096421 A G 0.0000231 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs1418808 chr1 190104227 C T 0.0000284 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs10920654 chr1 190131750 C T 4.94E-05 Brain structure FAM5C intron 22504417 rs16832159 chr1 190146211 T A 4.25E-04 Multiple complex diseases FAM5C intron 17554300 rs12041138 chr1 190149198 G A 0.0000239 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs815330 chr1 190164775 C T 5.13E-05 Body Mass Index FAM5C intron pha003015 rs6681246 chr1 190186387 G A 0.0000423 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs2419063 chr1 190256835 A G 8.96E-05 Orofacial clefts FAM5C intron 22419666 rs567393 chr1 190259941 T C 4.80E-04 Atrial fibrillation FAM5C intron 21846873 rs655598 chr1 190287713 G A 1.32E-04 Stroke FAM5C intron pha002887 rs1540513 chr1 190301532 C T 9.10E-04 Multiple complex diseases FAM5C intron 17554300 rs1540513 chr1 190301532 C T 4.07E-05 Orofacial clefts FAM5C intron 22419666 rs718609 chr1 190307072 G A 0.0000311 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs980180 chr1 190317108 A G 3.88E-04 Multiple complex diseases FAM5C intron 17554300 rs1148613 chr1 190337300 A C 2.94E-04 Alzheimer's disease FAM5C intron 17998437 rs725106 chr1 190347665 G A 4.35E-04 Alzheimer's disease FAM5C intron 17998437 rs17377331 chr1 190369508 G C 1.32E-04 Coronary Artery Disease FAM5C intron 17634449 rs17377331 chr1 190369508 G C 7.77E-05 Cytomegalovirus antibody response FAM5C intron 21993531 rs2490271 chr1 190442971 G A 3.44E-04 Crohn's disease FAM5C intron 17435756 rs1093016 chr1 190458764 C T 3.10E-04 Intelligence (childhood) / / 23358156 rs1093016 chr1 190458764 C T 8.16E-04 Iron levels / / pha002876 rs1604355 chr1 190459007 C G 1.29E-04 Cardiovascular disease / / 17903304 rs814941 chr1 190466822 G A 1.22E-05 Serum metabolites / / 19043545 rs814942 chr1 190467230 G A 1.31E-05 Serum metabolites / / 19043545 rs814948 chr1 190470311 A G 1.22E-05 Serum metabolites / / 19043545 rs814950 chr1 190470470 C G 1.22E-05 Serum metabolites / / 19043545 rs17378957 chr1 190501099 T C 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs755805 chr1 190503966 C T 4.63E-04 Iron levels / / pha002876 rs814958 chr1 190514183 T C 6.77E-04 Iron levels / / pha002876 rs814953 chr1 190522976 T G 4.12E-04 Type 2 diabetes / / 17463246 rs12072620 chr1 190528074 T C 3.26E-06 Adiponectin levels / / 20887962 rs1501501 chr1 190528445 C T 3.26E-06 Adiponectin levels / / 20887962 rs814951 chr1 190531999 C T 5.88E-04 Response to gemcitabine in pancreatic cancer / / 22142827 rs749390 chr1 190560021 C T 7.27E-04 Smoking quantity / / 24665060 rs520227 chr1 190569312 G C 4.00E-04 Type 2 diabetes / / 17463246 rs520227 chr1 190569312 G C 0.0000846 Oxaliplatin induced mucositis in response to colorectal cancer treatment / / 22310351 rs598359 chr1 190569947 G A 5.54E-04 Type 2 diabetes / / 17463246 rs2149028 chr1 190570848 C A 6.38E-06 Vitiligo / / 22561518 rs584161 chr1 190577336 T G 4.48E-04 Premature ovarian failure / / 19508998 rs720630 chr1 190588300 G A 4.13E-04 Type 2 diabetes / / 17463246 rs1590496 chr1 190641200 T C 1.90E-05 Urinary metabolites LOC440704 intron 21572414 rs6678095 chr1 190647315 T C 6.96E-05 Serum metabolites LOC440704 intron 19043545 rs4845171 chr1 190653611 A G 1.10E-05 Urinary metabolites LOC440704 intron 21572414 rs1998710 chr1 190670884 C T 2.80E-06 Urinary metabolites LOC440704 intron 21572414 rs4845172 chr1 190671884 A G 6.65E-05 Monocyte chemoattractant protein-1 LOC440704 intron pha003071 rs1408839 chr1 190681784 A G 2.30E-06 Urinary metabolites LOC440704 intron 21572414 rs573068 chr1 190713300 G A 2.95E-05 Alzheimer's disease LOC440704 intron 24755620 rs490184 chr1 190713980 G A 4.50E-06 Urinary metabolites LOC440704 intron 21572414 rs10494642 chr1 190745969 T C 8.60E-04 Type 2 diabetes and 6 quantitative traits LOC440704 intron 17848626 rs10494642 chr1 190745969 T C 7.65E-05 Cognitive impairment induced by topiramate LOC440704 intron 22091778 rs16832771 chr1 190760788 C T 9.05E-05 Myopia (pathological) LOC440704 intron 21640322 rs527579 chr1 190768685 T C 2.80E-05 Urinary metabolites LOC440704 intron 21572414 rs568537 chr1 190780134 T A 1.50E-05 Urinary metabolites / / 21572414 rs2438406 chr1 190800881 C G 1.70E-05 Response to statin therapy / / 20339536 rs10920808 chr1 190813083 A C 5.30E-06 Response to statin therapy / / 20339536 rs10494649 chr1 190813289 T C 2.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs4845251 chr1 190815260 G T 1.30E-05 Response to statin therapy / / 20339536 rs12146125 chr1 190818105 G T 1.40E-05 Response to statin therapy / / 20339536 rs10920810 chr1 190818216 A C 1.50E-05 Response to statin therapy / / 20339536 rs10800972 chr1 190818256 A C 1.40E-05 Response to statin therapy / / 20339536 rs2419925 chr1 190819195 A T 1.30E-05 Response to statin therapy / / 20339536 rs2118650 chr1 190823688 G T 8.00E-06 Response to statin therapy / / 20339536 rs1936992 chr1 190825536 G A 8.30E-06 Response to statin therapy / / 20339536 rs2105423 chr1 190832971 A G 7.70E-06 Response to statin therapy / / 20339536 rs1438533 chr1 190833559 C T 6.40E-06 Response to statin therapy / / 20339536 rs1370882 chr1 190833695 T C 6.30E-06 Response to statin therapy / / 20339536 rs7521393 chr1 190833868 C T 6.20E-06 Response to statin therapy / / 20339536 rs1438532 chr1 190834267 T G 6.10E-06 Response to statin therapy / / 20339536 rs1438531 chr1 190834358 T C 6.00E-06 Response to statin therapy / / 20339536 rs1438530 chr1 190834375 A G 6.30E-06 Response to statin therapy / / 20339536 rs1156627 chr1 190835000 G A 6.40E-06 Response to statin therapy / / 20339536 rs1156626 chr1 190835135 T G 6.40E-06 Response to statin therapy / / 20339536 rs1156625 chr1 190835394 T C 6.30E-06 Response to statin therapy / / 20339536 rs1370880 chr1 190836891 G A 4.20E-06 Response to statin therapy / / 20339536 rs1370879 chr1 190837105 G A 4.00E-06 Response to statin therapy / / 20339536 rs1170703 chr1 190837514 T C 4.10E-06 Response to statin therapy / / 20339536 rs2053302 chr1 190841673 T C 4.00E-06 Response to statin therapy / / 20339536 rs2118652 chr1 190841987 T C 4.40E-06 Response to statin therapy / / 20339536 rs6684247 chr1 190847263 G A 3.90E-06 Response to statin therapy / / 20339536 rs10800986 chr1 190848743 T C 3.90E-06 Response to statin therapy / / 20339536 rs1025717 chr1 190851794 G T 5.60E-06 Response to statin therapy / / 20339536 rs7535458 chr1 190853596 C T 6.10E-06 Response to statin therapy / / 20339536 rs1030922 chr1 190854351 G A 6.70E-06 Response to statin therapy / / 20339536 rs1170712 chr1 190855787 A T 8.00E-06 Response to statin therapy / / 20339536 rs10800989 chr1 190855881 C T 7.00E-06 Response to statin therapy / / 20339536 rs6686343 chr1 190856627 A C 7.10E-06 Response to statin therapy / / 20339536 rs10920829 chr1 190857871 C A 7.50E-06 Response to statin therapy / / 20339536 rs1936993 chr1 190860403 A G 1.80E-05 Response to statin therapy / / 20339536 rs6699971 chr1 190860691 A G 1.20E-05 Response to statin therapy / / 20339536 rs10920831 chr1 190862150 C T 8.20E-06 Response to statin therapy / / 20339536 rs12039354 chr1 190862268 G A 8.60E-06 Response to statin therapy / / 20339536 rs12135498 chr1 190863011 G A 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1936980 chr1 190876141 T C 2.50E-05 Response to statin therapy / / 20339536 rs4845175 chr1 190879904 T C 2.00E-05 Response to statin therapy / / 20339536 rs11588821 chr1 190886773 T C 3.76E-05 Alzheimer's disease / / 17998437 rs11588831 chr1 190886816 T G 6.68E-05 Alzheimer's disease / / 17998437 rs1936987 chr1 190889685 T C 8.40E-06 Alzheimer's disease / / 17998437 rs12145615 chr1 190891132 A T 2.90E-05 Response to statin therapy / / 20339536 rs10920836 chr1 190891339 C G 3.10E-05 Response to statin therapy / / 20339536 rs10920837 chr1 190893221 G C 2.70E-05 Response to statin therapy / / 20339536 rs4845257 chr1 190893913 T G 2.60E-05 Response to statin therapy / / 20339536 rs2420144 chr1 190900121 T A 7.21E-06 Alzheimer's disease / / 17998437 rs12025636 chr1 190901190 A G 1.40E-05 Response to statin therapy / / 20339536 rs12403605 chr1 190903993 A G 1.07E-05 Alzheimer's disease / / 17998437 rs12403877 chr1 190904400 A T 8.57E-06 Alzheimer's disease / / 17998437 rs12738693 chr1 190912603 A C 6.11E-05 Alzheimer's disease / / 17998437 rs12567544 chr1 190913478 C A 6.70E-06 Response to statin therapy / / 20339536 rs7549733 chr1 190916669 G A 7.00E-06 Response to statin therapy / / 20339536 rs10753960 chr1 190919126 C T 7.10E-06 Response to statin therapy / / 20339536 rs1431137 chr1 190923645 T C 6.80E-06 Response to statin therapy / / 20339536 rs1924720 chr1 190929421 G T 1.70E-05 Response to statin therapy / / 20339536 rs1431141 chr1 190934017 T C 1.30E-05 Response to statin therapy / / 20339536 rs10800994 chr1 190934888 G C 1.30E-05 Response to statin therapy / / 20339536 rs6666860 chr1 190949620 C A 3.60E-05 Response to statin therapy / / 20339536 rs10753970 chr1 191005777 A G 2.54E-05 Serum metabolites / / 19043545 rs10753970 chr1 191005777 A G 7.10E-05 Response to statin therapy / / 20339536 rs7555707 chr1 191013299 G A 7.00E-04 Smoking initiation / / 24665060 rs1454353 chr1 191093816 T C 9.50E-05 Response to statin therapy / / 20339536 rs2168081 chr1 191095755 T C 8.30E-05 Response to statin therapy / / 20339536 rs1073289 chr1 191097285 A G 7.60E-05 Response to statin therapy / / 20339536 rs4845268 chr1 191102082 T G 3.07E-05 Serum metabolites / / 19043545 rs4845268 chr1 191102082 T G 7.60E-05 Response to statin therapy / / 20339536 rs10920895 chr1 191102174 G C 7.49E-05 Serum metabolites / / 19043545 rs1993302 chr1 191110795 T C 5.30E-05 Response to statin therapy / / 20339536 rs6675143 chr1 191112084 C T 6.20E-05 Response to statin therapy / / 20339536 rs10753973 chr1 191113703 C T 5.78E-04 Type 2 diabetes / / 17463246 rs10753973 chr1 191113703 C T 1.84E-05 Serum metabolites / / 19043545 rs10753973 chr1 191113703 C T 5.40E-05 Response to statin therapy / / 20339536 rs10753974 chr1 191115638 C T 5.30E-05 Response to statin therapy / / 20339536 rs1563191 chr1 191117749 A G 6.50E-05 Response to statin therapy / / 20339536 rs1454356 chr1 191133789 C A 8.90E-05 Response to statin therapy / / 20339536 rs1454356 chr1 191133789 C A 0.0000642 Uterine leiomyomata / / 23040493 rs7528993 chr1 191145878 G C 5.71E-04 Multiple complex diseases / / 17554300 rs10494652 chr1 191150439 C T 3.05E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs1246813 chr1 191220906 T C 3.29E-05 F-cell distribution / / 21326311 rs1931204 chr1 191277082 C T 3.83E-05 Serum metabolites / / 19043545 rs6690512 chr1 191340943 G A 7.68E-04 Alcohol dependence / / 24277619 rs6700152 chr1 191397516 A G 1.55E-05 F-cell distribution / / 21326311 rs524646 chr1 191401978 G A 1.67E-04 Multiple complex diseases / / 17554300 rs16833511 chr1 191410505 T G 2.10E-05 Non-small cell lung cancer / / 21866343 rs491685 chr1 191423124 T A 1.83E-04 Acute lung injury / / 22295056 rs650957 chr1 191429227 C T 1.23E-04 Attention deficit hyperactivity disorder / / 22012869 rs11800005 chr1 191430223 A G 9.97E-05 Glucose levels / / pha003058 rs562619 chr1 191438525 A G 1.20E-05 Urinary metabolites / / 21572414 rs634828 chr1 191459679 A G 4.14E-05 Femoral neck bone geometry / / 22087292 rs620765 chr1 191460132 G A 5.90E-06 Urinary metabolites / / 21572414 rs10920957 chr1 191462474 A C 6.21E-05 Alzheimer's disease (late onset) / / 21379329 rs637642 chr1 191478482 G A 6.59E-05 Alzheimer's disease (late onset) / / 21379329 rs1338029 chr1 191491194 T G 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs658232 chr1 191497548 C T 2.35E-04 Coronary Artery Disease / / 17634449 rs658232 chr1 191497548 C T 2.10E-06 Urinary metabolites / / 21572414 rs6657109 chr1 191499342 A G 3.16E-04 Multiple complex diseases / / 17554300 rs655205 chr1 191499720 T C 4.30E-06 Urinary metabolites / / 21572414 rs1892294 chr1 191502099 C T 9.41E-05 Alzheimer's disease (late onset) / / 21379329 rs629563 chr1 191505973 G A 2.89E-04 Coronary Artery Disease / / 17634449 rs631450 chr1 191506986 C T 9.50E-06 Urinary metabolites / / 21572414 rs633095 chr1 191513228 A G 6.84E-04 Type 2 diabetes / / 17463246 rs633095 chr1 191513228 A G 1.30E-05 Urinary metabolites / / 21572414 rs12751302 chr1 191546574 C T 1.61E-06 Major depression (suicidal thoughts and behavior) / / 21750702 rs1954602 chr1 191558022 G T 5.95E-04 Type 2 diabetes / / 17463246 rs10801047 chr1 191559356 A T 3.00E-08 Crohn's disease / / 17554261 rs10801047 chr1 191559356 A T 8.15E-05 Multiple complex diseases / / 17554300 rs10801047 chr1 191559356 A T 2.70E-05 Urinary metabolites / / 21572414 rs1890232 chr1 191564481 A G 5.81E-04 Type 2 diabetes / / 17463246 rs6698540 chr1 191622277 A T 7.30E-09 Urinary metabolites / / 21572414 rs6698540 chr1 191622277 A T 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1338035 chr1 191627004 C T 9.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10494658 chr1 191689375 T G 2.00E-05 Urinary metabolites / / 21572414 rs6428063 chr1 191694194 C T 1.30E-05 Urinary metabolites / / 21572414 rs2814623 chr1 191695246 A G 2.20E-05 Urinary metabolites / / 21572414 rs2785761 chr1 191719427 T G 8.50E-06 Urinary metabolites / / 21572414 rs10494659 chr1 191719473 A G 5.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7536312 chr1 191727360 G A 6.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10494661 chr1 191728182 A T 1.20E-05 Urinary metabolites / / 21572414 rs1509702 chr1 191741681 G C 9.60E-06 Urinary metabolites / / 21572414 rs6696942 chr1 191804265 T C 9.00E-05 Cognitive test performance / / 20125193 rs16833847 chr1 191819881 A G 4.30E-04 Nicotine dependence / / 17158188 rs4845294 chr1 191848287 A G 1.77E-04 Smoking initiation / / 24665060 rs12082046 chr1 191866249 A C 4.95E-04 Coronary heart disease / / 21971053 rs17403780 chr1 191939788 T A 1.00E-06 IgG glycosylation / / 23382691 rs17403780 chr1 191939788 T A 6.00E-06 IgG glycosylation / / 23382691 rs17403780 chr1 191939788 T A 7.00E-06 IgG glycosylation / / 23382691 rs10921053 chr1 191968069 A G 3.21E-04 Obesity (extreme) / / 21935397 rs7367454 chr1 191979895 A T 8.68E-04 Multiple complex diseases / / 17554300 rs7349065 chr1 191980100 G A 9.94E-04 Multiple complex diseases / / 17554300 rs6428079 chr1 191983858 A C 3.28E-04 Obesity (extreme) / / 21935397 rs12040845 chr1 191998251 T C 4.41E-04 Multiple complex diseases / / 17554300 rs7529541 chr1 191999509 A C 1.20E-05 Urinary metabolites / / 21572414 rs12040119 chr1 192037153 C T 6.61E-04 Type 2 diabetes / / 17463246 rs12033842 chr1 192048703 G A 4.55E-04 Type 2 diabetes / / 17463246 rs2999599 chr1 192049086 T C 8.05E-04 Multiple complex diseases / / 17554300 rs3012198 chr1 192050674 C A 6.56E-04 Obesity (extreme) / / 21935397 rs4399135 chr1 192056067 G A 8.84E-04 Multiple complex diseases / / 17554300 rs10921078 chr1 192059022 G A 0.0000717 Gains in maximal O2 uptake response / / 21183627 rs4360506 chr1 192059386 T C 4.48E-04 Multiple complex diseases / / 17554300 rs10921079 chr1 192060886 A G 7.90E-04 Multiple complex diseases / / 17554300 rs4620521 chr1 192074537 A G 9.05E-04 Multiple complex diseases / / 17554300 rs12736318 chr1 192091291 A G 7.90E-04 Obesity (extreme) / / 21935397 rs1578102 chr1 192170251 C G 9.21E-04 Type 2 diabetes / / 17463246 rs876582 chr1 192174155 T C 6.60E-04 Type 2 diabetes / / 17463246 rs1175128 chr1 192199554 T C 4.71E-04 Hemoglobin concentration / / 20534544 rs1175106 chr1 192208913 C T 2.51E-04 Hemoglobin concentration / / 20534544 rs946421 chr1 192211842 C T 1.35E-05 Hemoglobin concentration / / 20534544 rs1175154 chr1 192230089 G A 1.11E-05 Hemoglobin concentration / / 20534544 rs1175126 chr1 192236376 A G 1.11E-05 Hemoglobin concentration / / 20534544 rs17523810 chr1 192245030 C T 7.96E-04 Type 2 diabetes / / 17463246 rs1175121 chr1 192246590 G A 4.66E-05 Hemoglobin concentration / / 20534544 rs1175119 chr1 192249116 C A 2.31E-04 Hemoglobin concentration / / 20534544 rs1339129 chr1 192283229 T C 3.22E-05 Hemoglobin concentration / / 20534544 rs6663865 chr1 192296038 T C 3.22E-05 Hemoglobin concentration RGS21 intron 20534544 rs12126995 chr1 192315253 A G 5.64E-04 Type 2 diabetes RGS21 intron 17463246 rs9645337 chr1 192322860 A G 5.64E-04 Type 2 diabetes RGS21 intron 17463246 rs1936671 chr1 192323753 G A 5.87E-04 Type 2 diabetes RGS21 intron 17463246 rs12048512 chr1 192353005 T C 2.74E-04 Myopia (pathological) / / 21095009 rs9988643 chr1 192362674 C T 2.30E-06 Urinary metabolites / / 21572414 rs6428099 chr1 192369866 T C 1.10E-06 Urinary metabolites / / 21572414 rs2369810 chr1 192370110 T C 1.60E-06 Urinary metabolites / / 21572414 rs1936701 chr1 192375206 A G 4.10E-06 Urinary metabolites / / 21572414 rs4658007 chr1 192378406 G A 1.60E-06 Urinary metabolites / / 21572414 rs7545141 chr1 192384797 C A 1.10E-06 Urinary metabolites / / 21572414 rs10754006 chr1 192390633 G A 1.90E-06 Urinary metabolites / / 21572414 rs1936692 chr1 192391249 G C 1.10E-06 Urinary metabolites / / 21572414 rs1317165 chr1 192419760 C T 2.20E-05 Urinary metabolites / / 21572414 rs4378188 chr1 192420005 A T 3.70E-04 Type 2 diabetes / / 17463246 rs10921152 chr1 192420060 A G 2.90E-05 Urinary metabolites / / 21572414 rs10494666 chr1 192421227 C T 2.20E-05 Urinary metabolites / / 21572414 rs10921159 chr1 192424634 T C 2.00E-05 Urinary metabolites / / 21572414 rs12067906 chr1 192431998 T C 9.00E-07 Blood pressure / / 22763476 rs10921164 chr1 192439681 G A 1.55E-04 Multiple complex diseases / / 17554300 rs10801121 chr1 192478874 G A 2.91E-04 Multiple complex diseases / / 17554300 rs10801121 chr1 192478874 G A 6.05E-05 Type 1 diabetes / / 18978792 rs10754012 chr1 192492895 A G 1.96E-06 Multiple sclerosis / / 17660530 rs10754012 chr1 192492895 A G 3.42E-05 Type 1 diabetes / / 18978792 rs2209014 chr1 192506082 G A 2.16E-04 Type 1 diabetes / / 21980299 rs10489868 chr1 192511183 T C 7.61E-04 Multiple complex diseases / / 17554300 rs72734930 chr1 192512559 G A 3.70E-04 Celiac disease / / 22057235 rs2760524 chr1 192530548 A G 5.17E-06 Multiple sclerosis / / 17660530 rs2760524 chr1 192530548 A G 9.77E-06 Multiple sclerosis / / 19525953 rs2760524 chr1 192530548 A G 1.60E-06 Multiple sclerosis / / 21833088 rs2816316 chr1 192536813 C A 3.00E-11 Celiac disease / / 18311140 rs2816316 chr1 192536813 C A 2.00E-17 Celiac disease / / 20190752 rs2816316 chr1 192536813 C A 2.00E-17 Asthma / / 21150878 rs2816316 chr1 192536813 C A 2.20E-17 Celiac disease and Rheumatoid arthritis / / 21383967 rs2816316 chr1 192536813 C A 2.20E-17 Multiple sclerosis / / 22190364 rs1323296 chr1 192537508 A G 1.90E-05 Urinary metabolites / / 21572414 rs10489870 chr1 192540520 C G 0.00000133 HDL cholesterol / / 23063622 rs1323292 chr1 192541021 G A 2.00E-08 Multiple sclerosis / / 21833088 rs1359062 chr1 192541472 C G 5.88E-05 Multiple sclerosis / / 17660530 rs1359062 chr1 192541472 C G 2.50E-25 Celiac disease / / 22057235 rs10921202 chr1 192547052 G T 3.96E-05 Celiac disease RGS1 intron 23936387 rs2760535 chr1 192549912 G A 6.50E-04 Schizophrenia / / 19197363 rs2984921 chr1 192551624 G A 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2984921 chr1 192551624 G A 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16834472 chr1 192553685 G C 5.83E-05 Type 2 diabetes / / 17463246 rs6428106 chr1 192554431 G T 2.95E-07 Chronic kidney disease / / 21931561 rs6428109 chr1 192554617 A C 1.09E-04 Type 2 diabetes / / 17463246 rs10489873 chr1 192559646 G A 2.15E-04 Acute lung injury / / 22295056 rs10489873 chr1 192559646 G A 7.42E-06 Crohn's disease and psoriasis / / 22482804 rs1407818 chr1 192561712 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10921206 chr1 192567674 T C 8.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10921216 chr1 192583913 T C 6.94E-04 Multiple complex diseases / / 17554300 rs6673310 chr1 192597985 G C 5.52E-04 Multiple complex diseases / / 17554300 rs4147220 chr1 192598515 T G 4.10E-06 Urinary metabolites / / 21572414 rs4147220 chr1 192598515 T G 0.0000904 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7511974 chr1 192599633 C A 0.0000137 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6428126 chr1 192603046 C G 0.0000163 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3795618 chr1 192603657 G T 0.0000274 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10921224 chr1 192604314 C A 0.0000297 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4338337 chr1 192609256 A T 0.0000369 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs4357510 chr1 192612394 A C,T 0.0000722 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs4658062 chr1 192616195 G A 1.20E-05 stroke (ischemic) RGS13 intron 17434096 rs4658064 chr1 192618028 G C 3.73E-04 Type 2 diabetes RGS13 intron 17463246 rs4658064 chr1 192618028 G C 9.00E-04 Acute lymphoblastic leukemia (childhood) RGS13 intron 20189245 rs4658064 chr1 192618028 G C 1.00E-05 Urinary metabolites RGS13 intron 21572414 rs6700053 chr1 192618413 T G 1.34E-04 Type 2 diabetes RGS13 intron 17463246 rs6700053 chr1 192618413 T G 7.05E-05 Multiple complex diseases RGS13 intron 17554300 rs116406040 chr1 192623389 A G 0.0000804 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs7544449 chr1 192625901 C T 2.58E-04 Type 2 diabetes RGS13 intron 17463246 rs7544449 chr1 192625901 C T 2.61E-04 Multiple complex diseases RGS13 intron 17554300 rs17585105 chr1 192697412 A G 4.95E-04 Multiple complex diseases / / 17554300 rs10801153 chr1 192763948 G A 2.10E-06 Malaria / / 19465909 rs4657836 chr1 192777178 C A 0.000000196 HDL cholesterol RGS2 nearGene-5 23063622 rs4606 chr1 192781172 C G 1 Drug response to Clozapine RGS2 UTR-3 18347610 rs4606 chr1 192781172 C G 1 Drug response to Olanzapine RGS2 UTR-3 18347610 rs4606 chr1 192781172 C G 1 Drug response to Risperidone RGS2 UTR-3 18347610 rs7550636 chr1 192806241 T C 4.00E-06 Coronary artery calcification / / 23870195 rs16834927 chr1 192835293 T C 3.58E-05 Multiple complex diseases / / 17554300 rs10921286 chr1 192889452 C T 1.85E-04 Lymphocyte counts / / 22286170 rs842796 chr1 192902415 T C 4.28E-05 Parkinson's disease / / 17052657 rs842796 chr1 192902415 T C 2.24E-06 Substance dependence phenotypes / / 24832863 rs842814 chr1 192911972 G T 2.32E-05 Multiple complex diseases / / 17554300 rs10921295 chr1 192937049 A G 7.58E-04 Multiple complex diseases / / 17554300 rs12025826 chr1 192940642 G A 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9427573 chr1 192995213 C T 5.00E-06 Cannabis dependence UCHL5 intron 21668797 rs6661522 chr1 193010623 T C 8.57E-04 Parkinson's disease UCHL5 intron 17052657 rs2887640 chr1 193027834 A C 6.91E-04 Multiple complex diseases UCHL5 intron 17554300 rs12123511 chr1 193083501 G T 1.66E-04 Multiple complex diseases / / 17554300 rs10801186 chr1 193143779 A G 6.44E-04 Multiple complex diseases CDC73 intron 17554300 rs28930674 chr1 193150219 A G 9.39E-04 Multiple complex diseases B3GALT2 cds-synon 17554300 rs10494675 chr1 193150873 T C 4.07E-04 Multiple complex diseases B3GALT2 intron 17554300 rs12122868 chr1 193158483 G A 3.14E-04 Smoking initiation CDC73 intron 24665060 rs817137 chr1 193275029 G A 6.41E-05 Multiple complex diseases / / 17554300 rs1749432 chr1 193291244 T A 4.51E-08 Narcolepsy / / 19629137 rs17601491 chr1 193367233 A G 2.80E-04 Multiple complex diseases / / 17554300 rs12758913 chr1 193437106 G A 7.00E-04 Multiple complex diseases / / 17554300 rs7516749 chr1 193439175 G A 4.51E-04 Multiple complex diseases / / 17554300 rs11808338 chr1 193443701 G A 2.20E-05 Urinary metabolites / / 21572414 rs7554157 chr1 193489169 C T 6.71E-05 Parkinson's disease / / 17052657 rs1007460 chr1 193510827 T C 1.70E-07 Urinary metabolites / / 21572414 rs10801204 chr1 193531058 C T 1.10E-06 Urinary metabolites / / 21572414 rs10801205 chr1 193531084 A G 2.60E-06 Urinary metabolites / / 21572414 rs6668266 chr1 193584062 T C 2.00E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6668266 chr1 193584062 T C 0.0000306 Panic disorder / / 23149450 rs6668266 chr1 193584062 T C 3.06E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1339307 chr1 193589444 A G 7.00E-06 Asthma / / 21790008 rs6678275 chr1 193625233 G C 3.00E-07 Alzheimer's disease (late onset) / / 24162737 rs6695669 chr1 193630577 G A 3.52E-04 Alzheimer's disease / / 17998437 rs16835685 chr1 193663276 A G 2.52E-04 Multiple complex diseases / / 17554300 rs16835697 chr1 193682630 A G 2.30E-05 Urinary metabolites / / 21572414 rs12122818 chr1 193686395 A C 3.88E-04 Esophageal adenocarcinoma / / 24121790 rs6691652 chr1 193717698 G T 8.16E-04 Alzheimer's disease / / 17998437 rs6691652 chr1 193717698 G T 1.02E-04 Insulin resistance / / 21901158 rs6697313 chr1 193722284 A G 1.43E-04 Insulin resistance / / 21901158 rs2025934 chr1 193734900 G A 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs1326851 chr1 193736204 G A 9.47E-04 Bipolar disorder / / 19259986 rs6664259 chr1 193737549 A G 7.10E-05 Insulin resistance / / 21901158 rs1160521 chr1 193738279 G A 7.38E-04 Bipolar disorder / / 19259986 rs968309 chr1 193752801 C T 9.42E-04 Bipolar disorder / / 19259986 rs1328179 chr1 193753223 C T 5.61E-05 Type 2 diabetes and other traits / / 19734900 rs10921443 chr1 193783317 G T 3.33E-05 Job-related exhaustion / / 23620144 rs9287130 chr1 193830644 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs578374 chr1 193883832 C A 1.94E-04 Multiple complex diseases / / 17554300 rs7542605 chr1 193884958 T C 8.72E-09 Metabolite levels / / 23281178 rs10921464 chr1 193889533 C T 6.68E-06 Major depressive disorder / / 20516156 rs10921464 chr1 193889533 C T 8.72E-09 Metabolite levels / / 23281178 rs10801266 chr1 193893686 G A 8.72E-09 Metabolite levels / / 23281178 rs4255367 chr1 193895092 A G 8.72E-09 Metabolite levels / / 23281178 rs4409629 chr1 193895239 T C 8.72E-09 Metabolite levels / / 23281178 rs4330903 chr1 193895333 C T 8.72E-09 Metabolite levels / / 23281178 rs606149 chr1 193921548 C T 3.00E-06 Major depressive disorder / / 20516156 rs606149 chr1 193921548 C T 0.00000219 Major depressive disorder age at onset>25 / / 22915352 rs7541634 chr1 193944200 T C 5.70E-06 Urinary metabolites / / 21572414 rs1442421 chr1 194025452 C T 8.55E-05 Schizophrenia / / 19571809 rs634899 chr1 194035948 T C 1.80E-05 Meningococcal disease / / 20694013 rs2506058 chr1 194106280 C T 1.90E-04 Telomere length / / 23900074 rs2506058 chr1 194106280 C T 9.09E-05 Socioeconomic Factors / / pha003067 rs16836478 chr1 194157661 T C 4.94E-04 Multiple complex diseases / / 17554300 rs302211 chr1 194172222 A G 8.07E-04 Type 2 diabetes / / 17463246 rs16836545 chr1 194203301 T C 1.96E-05 Multiple complex diseases / / 17554300 rs2029250 chr1 194254120 G A 2.00E-05 Urinary metabolites / / 21572414 rs2506048 chr1 194258816 T C 5.60E-04 Multiple complex diseases / / 17554300 rs12090292 chr1 194265219 T C 2.20E-05 Urinary metabolites / / 21572414 rs16836639 chr1 194268571 T C 1.30E-05 Urinary metabolites / / 21572414 rs1018626 chr1 194269455 G A 2.61E-05 Partial epilepsies / / 20522523 rs6428217 chr1 194304659 G C 6.06E-04 Type 2 diabetes / / 17463246 rs6664256 chr1 194308977 T C 9.97E-04 Type 2 diabetes / / 17463246 rs4276898 chr1 194320639 A G 2.34E-05 Information processing speed / / 21130836 rs4261097 chr1 194322244 T A 6.01E-04 Type 2 diabetes / / 17463246 rs17622017 chr1 194341208 C T 6.69E-04 Tuberculosis / / 22239941 rs12121745 chr1 194412218 A G 5.30E-04 White matter integrity / / 22425255 rs10494705 chr1 194436341 G T 5.30E-04 White matter integrity / / 22425255 rs6673013 chr1 194461499 C T 2.20E-04 Multiple complex diseases / / 17554300 rs4266861 chr1 194486776 C T 1.72E-04 Multiple complex diseases / / 17554300 rs11586374 chr1 194491453 C A 1.02E-04 Multiple complex diseases / / 17554300 rs3001167 chr1 194530914 A G 3.00E-06 Obesity-related traits / / 23251661 rs3001156 chr1 194550938 C A 1.97E-04 Parkinson's disease / / 17052657 rs3001156 chr1 194550938 C A 9.20E-06 Glioma (high-grade) / / 19578366 rs3001156 chr1 194550938 C A 9.46E-05 Asthma / / 20159242 rs10494709 chr1 194584977 T C 2.05E-04 Scoliosis / / 21216876 rs13376197 chr1 194591753 T C 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10801343 chr1 194639330 T G 6.71E-04 Multiple complex diseases / / 17554300 rs4253903 chr1 194648188 T C 9.71E-04 Multiple complex diseases / / 17554300 rs7520494 chr1 194660182 G A 8.70E-04 Multiple complex diseases / / 17554300 rs6428261 chr1 194679640 T A 9.90E-04 Multiple complex diseases / / 17554300 rs4446945 chr1 194713204 G A 1.38E-04 Multiple complex diseases / / 17554300 rs7550967 chr1 194783067 T C 2.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1011550 chr1 194801684 G A 4.05E-04 Body mass index / / 21701565 rs4657943 chr1 194846016 G A 7.37E-04 Taste perception / / 22132133 rs339626 chr1 194853172 G T 1.70E-04 IgE levels / / 17255346 rs6695766 chr1 194910364 G A 4.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10494716 chr1 194915839 A T 0.0000639 Sarcoidosis / / 22952805 rs1032828 chr1 194916701 C A 9.02E-04 Obesity (extreme) / / 21935397 rs11583374 chr1 194965856 T C 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs12569023 chr1 194987069 G A 1.60E-05 Urinary metabolites / / 21572414 rs4657796 chr1 195052937 T A,C,G 6.14E-04 Type 2 diabetes / / 17463246 rs696392 chr1 195053221 T C 4.95E-05 Suicidal ideation / / 20877300 rs12755016 chr1 195166911 A C 4.23E-04 Alzheimer's disease / / 17998437 rs687523 chr1 195170004 A G 5.53E-06 Asthma / / 21790008 rs4657976 chr1 195265767 A G 8.25E-04 Multiple complex diseases / / 17554300 rs6428282 chr1 195267072 C A 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1359381 chr1 195310452 C T 7.61E-04 Smoking quantity / / 24665060 rs12731553 chr1 195316969 T G 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1348101 chr1 195322984 T A 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs16838299 chr1 195343282 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs17668176 chr1 195343788 C T 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs16838301 chr1 195347168 G A 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12729977 chr1 195348938 C T 5.14E-07 Multiple complex diseases / / 17554300 rs1987929 chr1 195367222 T C 9.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1324713 chr1 195376935 C T 2.09E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6702266 chr1 195376972 C T 1.00E-04 Adverse response to radiation therapy / / 23719583 rs6702266 chr1 195376972 C T 3.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs3845556 chr1 195439716 C T 7.28E-04 Acute lung injury / / 22295056 rs10801420 chr1 195457300 C A 1.50E-05 Urinary metabolites / / 21572414 rs1548286 chr1 195516792 C G 9.48E-04 Multiple complex diseases / / 17554300 rs2400604 chr1 195531171 C T 6.86E-04 Multiple complex diseases / / 17554300 rs1890645 chr1 195531423 T C 4.00E-06 Neonatal lupus / / 20662065 rs11804696 chr1 195600211 C G 4.92E-05 Serum metabolites / / 19043545 rs1556455 chr1 195629083 G A 9.69E-05 Personality dimensions / / 18957941 rs1159275 chr1 195649242 G T 8.67E-06 Personality dimensions / / 18957941 rs1159275 chr1 195649242 G T 3.64E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1159275 chr1 195649242 G T 8.70E-06 Personality dimensions / / 21173776 rs10754146 chr1 195659214 A C 3.64E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10754147 chr1 195672584 A G 4.35E-04 Multiple complex diseases / / 17554300 rs17672688 chr1 195686601 G A 1.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10801449 chr1 195708999 T C 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10218626 chr1 195790084 G A 4.98E-04 Multiple complex diseases / / 17554300 rs6677435 chr1 195790658 G A 9.00E-06 Cocaine dependence / / 23958962 rs4488010 chr1 195807493 T C 7.18E-04 Smoking initiation / / 24665060 rs6679891 chr1 195826738 G A 1.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16838980 chr1 195832253 T G 1.67E-05 Anxiety in major depressive disorder / / 24047446 rs12140768 chr1 195836268 T C 1.73E-04 Multiple complex diseases / / 17554300 rs12140768 chr1 195836268 T C 2.29E-04 Cognitive decline / / 23732972 rs3008578 chr1 195864604 A T 6.30E-04 Smoking initiation / / 24665060 rs3010144 chr1 195867138 G T 6.30E-04 Smoking initiation / / 24665060 rs3008576 chr1 195869123 T C 6.30E-04 Smoking initiation / / 24665060 rs3010150 chr1 195873063 C T 4.13E-04 Smoking initiation / / 24665060 rs1451920 chr1 195874790 T A 7.21E-04 Type 2 diabetes / / 17463246 rs3008572 chr1 195876292 C T 4.50E-04 Smoking initiation / / 24665060 rs16839109 chr1 195877256 A G 7.16E-04 Multiple complex diseases / / 17554300 rs2923911 chr1 195883861 A C 3.43E-04 Smoking initiation / / 24665060 rs10921984 chr1 195891127 C T 7.51E-05 Waist-Hip Ratio / / pha003013 rs10921984 chr1 195891127 C T 7.52E-05 Waist-Hip Ratio / / pha003028 rs41373250 chr1 195900235 C G,T 1.10E-05 Urinary metabolites / / 21572414 rs7517337 chr1 195914273 A G 2.00E-06 Total ventricular volume / / 21116278 rs4295871 chr1 195916887 A G 8.60E-06 Urinary metabolites / / 21572414 rs4483387 chr1 195917003 G T 1.70E-05 Urinary metabolites / / 21572414 rs4658011 chr1 195932083 G A 0.000279 Salmonella-induced pyroptosis / / 22837397 rs12043048 chr1 195934306 C T 0.00035 Salmonella-induced pyroptosis / / 22837397 rs10921998 chr1 195934627 G A 1.83E-04 Multiple complex diseases / / 17554300 rs979769 chr1 195940328 C G 3.20E-05 Cognitive function / / 24684796 rs17686400 chr1 195951286 C T 1.41E-04 Obesity (extreme) / / 21935397 rs1562943 chr1 195963926 C A 9.88E-04 Multiple complex diseases / / 17554300 rs17686963 chr1 195974790 G A 8.31E-05 Obesity (extreme) / / 21935397 rs17687163 chr1 195985385 A C 7.38E-05 Obesity (extreme) / / 21935397 rs12737611 chr1 195987589 C T 7.26E-05 Obesity (extreme) / / 21935397 rs12735954 chr1 195990946 A G 6.89E-05 Obesity (extreme) / / 21935397 rs1008082 chr1 195997563 T C 5.08E-06 Serum metabolites / / 19043545 rs1008082 chr1 195997563 T C 8.75E-06 Bleomycin sensitivity / / 21106707 rs12128800 chr1 196004403 T A 1.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs1451916 chr1 196024294 A C 7.38E-05 Left ventricular hypertrophy / / pha003052 rs375562694 chr1 196024294 A AT 7.38E-05 Left ventricular hypertrophy / / pha003052 rs549773131 chr1 196024294 A AT 7.38E-05 Left ventricular hypertrophy / / pha003052 rs10922013 chr1 196027872 G T 9.92E-06 Bipolar disorder / / 19488044 rs10922013 chr1 196027872 G T 4.23E-05 Bipolar Disorder / / pha002858 rs7512769 chr1 196042662 T A 8.39E-05 Bipolar disorder / / 19488044 rs7512769 chr1 196042662 T A 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs11579497 chr1 196061711 G A 2.60E-05 Alcohol dependence / / 19581569 rs11579497 chr1 196061711 G A 3.10E-07 Urinary metabolites / / 21572414 rs10922025 chr1 196068493 A C 2.00E-07 Urinary metabolites / / 21572414 rs6678032 chr1 196069199 T C 1.80E-07 Urinary metabolites / / 21572414 rs6696438 chr1 196084492 C T 5.86E-05 Schizophrenia / / 19197363 rs12036795 chr1 196089818 A C 3.94E-05 Alcohol dependence / / 19581569 rs12136161 chr1 196098354 A T 7.99E-04 Multiple complex diseases / / 17554300 rs12136161 chr1 196098354 A T 7.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs6676015 chr1 196099926 A G 5.95E-04 Multiple complex diseases / / 17554300 rs12087473 chr1 196100216 A G 4.12E-04 Multiple complex diseases / / 17554300 rs12087473 chr1 196100216 A G 7.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs7535849 chr1 196101014 A G 3.66E-04 Alzheimer's disease / / 17998437 rs7535849 chr1 196101014 A G 7.50E-07 Urinary metabolites / / 21572414 rs7535849 chr1 196101014 A G 2.36E-04 Alzheimer's disease / / pha002879 rs7534836 chr1 196105786 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10754180 chr1 196136924 A G 4.51E-05 Cognitive performance / / 19734545 rs2094027 chr1 196150447 T A 1.70E-05 Urinary metabolites / / 21572414 rs2094028 chr1 196150496 C T 1.34E-05 Serum metabolites / / 19043545 rs1325307 chr1 196151387 C G 1.70E-05 Urinary metabolites / / 21572414 rs10922047 chr1 196152634 A G 1.60E-05 Urinary metabolites / / 21572414 rs1886629 chr1 196154898 C T 0.00000553 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs1886630 chr1 196155111 G A 2.70E-05 Urinary metabolites / / 21572414 rs7511738 chr1 196155872 G T 1.70E-05 Urinary metabolites / / 21572414 rs1925327 chr1 196163629 C A 1.70E-05 Urinary metabolites / / 21572414 rs1325300 chr1 196167779 C A 3.06E-04 Alzheimer's disease (late onset) / / 21379329 rs1325301 chr1 196167828 A G 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs1925334 chr1 196170958 C T 1.60E-05 Urinary metabolites / / 21572414 rs10922049 chr1 196172936 C T 4.62E-05 Multiple complex diseases / / 17554300 rs10922049 chr1 196172936 C T 2.10E-05 Urinary metabolites / / 21572414 rs1925335 chr1 196180344 A G 9.91E-24 Narcolepsy / / 19629137 rs1998712 chr1 196187665 G A 4.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10157380 chr1 196187709 G T 7.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10158703 chr1 196187968 C G 6.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7529369 chr1 196208890 C T 5.67E-05 Age-related macular degeneration KCNT2 intron pha002890 rs12727325 chr1 196223735 G A 1.99E-04 Rheumatoid arthritis KCNT2 intron 21452313 rs2477354 chr1 196239368 A G 3.94E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs2477357 chr1 196251522 T C 7.40E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs12058062 chr1 196256498 G A 3.94E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs12407399 chr1 196291977 T C 5.19E-05 Age-related macular degeneration KCNT2 intron pha002890 rs7554267 chr1 196304863 G T 7.80E-13 Age-related macular degeneration KCNT2 intron pha002869 rs7554267 chr1 196304863 G T 7.93E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10494742 chr1 196346553 A G 4.52E-05 Age-related macular degeneration KCNT2 intron pha002890 rs2027368 chr1 196351150 A C 3.60E-08 Age-related macular degeneration KCNT2 intron 23326517 rs2027368 chr1 196351150 A C 5.66E-24 Age-related macular degeneration KCNT2 intron pha002869 rs2027368 chr1 196351150 A C 1.54E-23 Age-related macular degeneration KCNT2 intron pha002890 rs1769996 chr1 196353041 C T 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs1769996 chr1 196353041 C T 4.44E-08 End-stage coagulation KCNT2 intron 23381943 rs10737670 chr1 196357746 A G 2.30E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10737670 chr1 196357746 A G 9.84E-09 End-stage coagulation KCNT2 intron 23381943 rs10801530 chr1 196361497 G T 2.40E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801530 chr1 196361497 G T 9.89E-09 End-stage coagulation KCNT2 intron 23381943 rs10801531 chr1 196363544 G A 2.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801531 chr1 196363544 G A 5.20E-09 End-stage coagulation KCNT2 intron 23381943 rs10801532 chr1 196364176 A G 2.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801532 chr1 196364176 A G 9.92E-09 End-stage coagulation KCNT2 intron 23381943 rs7535696 chr1 196371432 T C 2.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs7535696 chr1 196371432 T C 1.15E-08 End-stage coagulation KCNT2 intron 23381943 rs7535696 chr1 196371432 T C 8.60E-25 Age-related macular degeneration KCNT2 intron pha002869 rs7535696 chr1 196371432 T C 2.97E-24 Age-related macular degeneration KCNT2 intron pha002890 rs16839884 chr1 196375060 G A 2.58E-06 Age-related macular degeneration KCNT2 intron pha002869 rs16839884 chr1 196375060 G A 1.57E-05 Age-related macular degeneration KCNT2 intron pha002890 rs16839886 chr1 196376474 T G 7.26E-06 Age-related macular degeneration KCNT2 intron pha002869 rs16839886 chr1 196376474 T G 4.01E-05 Age-related macular degeneration KCNT2 intron pha002890 rs3928857 chr1 196383601 T C 2.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3928857 chr1 196383601 T C 1.01E-08 End-stage coagulation KCNT2 intron 23381943 rs3855964 chr1 196384116 T G 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3855964 chr1 196384116 T G 1.01E-08 End-stage coagulation KCNT2 intron 23381943 rs3927686 chr1 196385649 T C 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3927686 chr1 196385649 T C 1.54E-08 End-stage coagulation KCNT2 intron 23381943 rs3927686 chr1 196385649 T C 4.28E-25 Age-related macular degeneration KCNT2 intron pha002869 rs3927686 chr1 196385649 T C 1.85E-24 Age-related macular degeneration KCNT2 intron pha002890 rs12729649 chr1 196387632 G A 3.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12729649 chr1 196387632 G A 1.56E-08 End-stage coagulation KCNT2 intron 23381943 rs12069983 chr1 196387741 C A 3.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12069983 chr1 196387741 C A 1.56E-08 End-stage coagulation KCNT2 intron 23381943 rs12069983 chr1 196387741 C A 2.07E-06 Age-related macular degeneration KCNT2 intron 23577725 rs12069990 chr1 196387809 C T 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12069990 chr1 196387809 C T 1.34E-08 End-stage coagulation KCNT2 intron 23381943 rs16839906 chr1 196391866 T C 5.33E-05 Age-related macular degeneration KCNT2 intron pha002890 rs10801533 chr1 196395871 G A 2.46E-04 Scoliosis KCNT2 intron 21216876 rs10801533 chr1 196395871 G A 4.39E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10801533 chr1 196395871 G A 1.21E-11 Age-related macular degeneration KCNT2 intron pha002890 rs1538687 chr1 196397775 C T 8.72E-04 Type 2 diabetes KCNT2 intron 17463246 rs1538687 chr1 196397775 C T 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs1538687 chr1 196397775 C T 6.67E-09 End-stage coagulation KCNT2 intron 23381943 rs1538687 chr1 196397775 C T 1.17E-06 Age-related macular degeneration KCNT2 intron 23577725 rs1538686 chr1 196397819 G A 5.96E-04 Type 2 diabetes KCNT2 intron 17463246 rs1538686 chr1 196397819 G A 9.64E-05 Body Mass Index KCNT2 intron pha003019 rs1538686 chr1 196397819 G A 8.43E-05 Body Mass Index KCNT2 intron pha003020 rs2878557 chr1 196402773 T C 4.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs2878557 chr1 196402773 T C 1.50E-08 End-stage coagulation KCNT2 intron 23381943 rs2878557 chr1 196402773 T C 5.80E-25 Age-related macular degeneration KCNT2 intron pha002869 rs2878557 chr1 196402773 T C 5.19E-24 Age-related macular degeneration KCNT2 intron pha002890 rs7531611 chr1 196405652 T C 8.27E-04 Type 2 diabetes KCNT2 intron 17463246 rs7531611 chr1 196405652 T C 3.10E-08 End-stage coagulation KCNT2 intron 23381943 rs10754187 chr1 196416252 A G 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10754187 chr1 196416252 A G 1.62E-08 End-stage coagulation KCNT2 intron 23381943 rs10494743 chr1 196425133 A G 2.15E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10494743 chr1 196425133 A G 6.58E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10494743 chr1 196425133 A G 6.96E-05 Body Mass Index KCNT2 intron pha003019 rs10494743 chr1 196425133 A G 7.53E-05 Body Mass Index KCNT2 intron pha003020 rs10801537 chr1 196426841 A G 1.70E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801537 chr1 196426841 A G 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs11807331 chr1 196427811 T C 1.60E-08 Age-related macular degeneration KCNT2 intron 23326517 rs11807331 chr1 196427811 T C 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs10922071 chr1 196433870 G A 1.30E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10922071 chr1 196433870 G A 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs10801538 chr1 196438949 A G 3.05E-04 Scoliosis KCNT2 intron 21216876 rs10801538 chr1 196438949 A G 2.02E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10801538 chr1 196438949 A G 6.25E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10801538 chr1 196438949 A G 7.52E-05 Body Mass Index KCNT2 intron pha003019 rs10801538 chr1 196438949 A G 7.77E-05 Body Mass Index KCNT2 intron pha003020 rs12065463 chr1 196464754 T C 8.60E-09 Age-related macular degeneration KCNT2 intron 23326517 rs12065463 chr1 196464754 T C 3.72E-08 End-stage coagulation KCNT2 intron 23381943 rs1339951 chr1 196482357 C A 4.86E-05 Age-related macular degeneration KCNT2 intron pha002890 rs12743252 chr1 196493740 A G 3.15E-05 Relative hand skill KCNT2 intron 24068947 rs4388642 chr1 196494547 T C 4.60E-09 Age-related macular degeneration KCNT2 intron 23326517 rs12043743 chr1 196502836 T A 8.70E-06 Urinary metabolites KCNT2 intron 21572414 rs10922082 chr1 196513694 G A 1.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10922082 chr1 196513694 G A 3.47E-06 Age-related macular degeneration (extreme sampling) KCNT2 intron 23577725 rs10922082 chr1 196513694 G A 7.18E-07 Age-related macular degeneration KCNT2 intron 23577725 rs6704166 chr1 196514176 A T 3.30E-09 Age-related macular degeneration KCNT2 intron 23326517 rs10922083 chr1 196516398 C T 1.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10754192 chr1 196519023 T C 4.96E-05 Age-related macular degeneration KCNT2 intron pha002890 rs10922084 chr1 196525314 A C 1.40E-08 Age-related macular degeneration KCNT2 intron 23326517 rs4515738 chr1 196540893 T C 5.30E-04 Multiple complex diseases KCNT2 intron 17554300 rs10494744 chr1 196542567 T C 4.40E-12 Age-related macular degeneration KCNT2 intron pha002869 rs10494744 chr1 196542567 T C 1.35E-11 Age-related macular degeneration KCNT2 intron pha002890 rs4294368 chr1 196547688 C T 5.30E-05 Age-related macular degeneration KCNT2 intron pha002890 rs16840224 chr1 196569681 C T 2.80E-09 Age-related macular degeneration KCNT2 intron 23326517 rs16840224 chr1 196569681 C T 3.08E-06 Age-related macular degeneration (extreme sampling) KCNT2 intron 23577725 rs16840224 chr1 196569681 C T 7.74E-07 Age-related macular degeneration KCNT2 intron 23577725 rs10754196 chr1 196570706 A G 3.50E-09 Age-related macular degeneration KCNT2 intron 23326517 rs10754196 chr1 196570706 A G 4.44E-27 Age-related macular degeneration KCNT2 intron pha002869 rs10754196 chr1 196570706 A G 2.45E-26 Age-related macular degeneration KCNT2 intron pha002890 rs10754198 chr1 196573505 A T 1.10E-11 Age-related macular degeneration KCNT2 intron 23326517 rs10801551 chr1 196580039 G A 9.00E-09 Age-related macular degeneration / / 23326517 rs10801551 chr1 196580039 G A 2.80E-11 End-stage coagulation / / 23381943 rs10801551 chr1 196580039 G A 1.04E-14 Age-related macular degeneration / / 23577725 rs10801551 chr1 196580039 G A 8.19E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs4657825 chr1 196584321 A G 8.70E-10 Age-related macular degeneration / / 23326517 rs4657825 chr1 196584321 A G 5.29E-13 End-stage coagulation / / 23381943 rs12061508 chr1 196584468 G A 3.70E-09 Age-related macular degeneration / / 23326517 rs12061508 chr1 196584468 G A 1.46E-12 End-stage coagulation / / 23381943 rs12061508 chr1 196584468 G A 1.28E-14 Age-related macular degeneration / / 23577725 rs12061508 chr1 196584468 G A 8.13E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs944041 chr1 196585217 A G 5.21E-04 Multiple complex diseases / / 17554300 rs12029571 chr1 196603302 A G 1.10E-10 Age-related macular degeneration / / 23326517 rs12029571 chr1 196603302 A G 1.52E-11 End-stage coagulation / / 23381943 rs17573790 chr1 196609396 A C 2.40E-08 Age-related macular degeneration / / 23326517 rs505102 chr1 196619502 T C 2.28E-06 Age-related macular degeneration CFH nearGene-5 22125219 rs505102 chr1 196619502 T C 1.05E-08 Circulating myeloperoxidase levels (serum) CFH nearGene-5 23620142 rs505102 chr1 196619502 T C 9.09E-46 Age-related macular degeneration CFH nearGene-5 pha002869 rs505102 chr1 196619502 T C 1.07E-40 Age-related macular degeneration CFH nearGene-5 pha002890 rs3753394 chr1 196620917 C T 7.00E-11 Complement C3 and C4 levels CFH nearGene-5 23028341 rs7524776 chr1 196623337 T C 8.10E-09 Age-related macular degeneration CFH intron 23326517 rs6680396 chr1 196632470 A G 3.10E-11 Age-related macular degeneration CFH intron 23326517 rs6680396 chr1 196632470 A G 2.60E-12 End-stage coagulation CFH intron 23381943 rs6680396 chr1 196632470 A G 6.65E-43 Circulating myeloperoxidase levels (serum) CFH intron 23620142 rs529825 chr1 196635106 G A 3.20E-12 Age-related macular degeneration CFH intron 23326517 rs529825 chr1 196635106 G A 6.91E-13 End-stage coagulation CFH intron 23381943 rs800292 chr1 196642233 G A 4.90E-07 Age-related macular degeneration CFH missense 20861866 rs800292 chr1 196642233 G A 4.23E-15 Age-related macular degeneration CFH missense 21909106 rs800292 chr1 196642233 G A 1.37E-06 Age-related macular degeneration CFH missense 22125219 rs800292 chr1 196642233 G A 1.20E-12 Age-related macular degeneration CFH missense 23326517 rs800292 chr1 196642233 G A 1.46E-12 End-stage coagulation CFH missense 23381943 rs800292 chr1 196642233 G A 1.65E-10 Age-related macular degeneration (extreme sampling) CFH missense 23577725 rs800292 chr1 196642233 G A 4.41E-15 Age-related macular degeneration CFH missense 23577725 rs800292 chr1 196642233 G A 5.00E-41 Circulating myeloperoxidase levels (serum) CFH missense 23620142 rs800292 chr1 196642233 G A 5.05E-11 Age-related macular degeneration CFH missense pha000001 rs800292 chr1 196642233 G A 1.68E-07 Age-related macular degeneration CFH missense pha002856 rs800292 chr1 196642233 G A 2.21E-47 Age-related macular degeneration CFH missense pha002869 rs800292 chr1 196642233 G A 9.78E-42 Age-related macular degeneration CFH missense pha002890 rs1329424 chr1 196646176 T G 6.00E-16 Age-related macular degeneration CFH intron 20385819 rs1329424 chr1 196646176 T G 2.00E-31 Age-related macular degeneration CFH intron 23326517 rs572515 chr1 196646261 A G 5.40E-15 Age-related macular degeneration CFH intron 20861866 rs572515 chr1 196646261 A G 2.80E-31 Age-related macular degeneration CFH intron 23326517 rs572515 chr1 196646261 A G 1.18E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs572515 chr1 196646261 A G 4.07E-30 Age-related macular degeneration CFH intron 23577725 rs572515 chr1 196646261 A G 4.10E-21 Age-related macular degeneration CFH intron pha000001 rs572515 chr1 196646261 A G 1.22E-15 Age-related macular degeneration CFH intron pha002856 rs12127759 chr1 196648613 C T 6.30E-11 Age-related macular degeneration CFH intron 23326517 rs16840419 chr1 196651745 A G 6.60E-11 Age-related macular degeneration CFH intron 23326517 rs3766404 chr1 196651832 T C 1.80E-05 Nephropathy CFH intron 21399633 rs3766404 chr1 196651832 T C 7.60E-11 Age-related macular degeneration CFH intron 23326517 rs3766404 chr1 196651832 T C 2.50E-23 Age-related macular degeneration CFH intron pha002869 rs3766404 chr1 196651832 T C 2.44E-21 Age-related macular degeneration CFH intron pha002890 rs16840422 chr1 196652834 C T 7.80E-11 Age-related macular degeneration CFH intron 23326517 rs1061147 chr1 196654324 A C 7.00E-32 Age-related macular degeneration CFH cds-synon 23326517 rs1329422 chr1 196655280 C G 2.90E-31 Age-related macular degeneration CFH intron 23326517 rs2300430 chr1 196655713 T C 6.10E-31 Age-related macular degeneration CFH intron 23326517 rs10801553 chr1 196655743 A C 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs10801553 chr1 196655743 A C 2.44E-29 Age-related macular degeneration CFH intron 23577725 rs10801553 chr1 196655743 A C 7.04E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1329421 chr1 196656205 A T 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs10801554 chr1 196657655 C T 3.40E-31 Age-related macular degeneration CFH intron 23326517 rs7529589 chr1 196658279 T C 1.50E-14 Age-related macular degeneration CFH intron 20861866 rs7529589 chr1 196658279 T C 5.00E-31 Age-related macular degeneration CFH intron 23326517 rs7529589 chr1 196658279 T C 2.67E-19 Age-related macular degeneration CFH intron pha000001 rs7529589 chr1 196658279 T C 1.60E-14 Age-related macular degeneration CFH intron pha002856 rs482934 chr1 196658497 G T 5.00E-31 Age-related macular degeneration CFH intron 23326517 rs1061170 chr1 196659237 C T 4.00E-117 Age-related macular degeneration CFH missense 20385826 rs1061170 chr1 196659237 C T 1.00E-261 Age-related macular degeneration CFH missense 21665990 rs1061170 chr1 196659237 C T 1.88E-05 Age-related macular degeneration CFH missense 21909106 rs1061170 chr1 196659237 C T 1.00E-108 Age-related macular degeneration (CNV) CFH missense 22705344 rs1061170 chr1 196659237 C T 5.00E-67 Age-related macular degeneration (GA) CFH missense 22705344 rs1061170 chr1 196659237 C T 2.40E-28 Age-related macular degeneration CFH missense 23326517 rs10801555 chr1 196660261 A G 2.75E-05 Type 2 diabetes CFH intron 17463246 rs10801555 chr1 196660261 A G 2.14E-08 Age-related macular degeneration CFH intron 22125219 rs10801555 chr1 196660261 A G 2.00E-47 Age-related macular degeneration CFH intron 22694956 rs10801555 chr1 196660261 A G 6.10E-31 Age-related macular degeneration CFH intron 23326517 rs10801555 chr1 196660261 A G 1.52E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10801555 chr1 196660261 A G 7.63E-30 Age-related macular degeneration CFH intron 23577725 rs10801555 chr1 196660261 A G 3.74E-84 Age-related macular degeneration CFH intron pha002869 rs10801555 chr1 196660261 A G 1.33E-71 Age-related macular degeneration CFH intron pha002890 rs10801556 chr1 196660464 A G 1.20E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10801556 chr1 196660464 A G 1.38E-29 Age-related macular degeneration CFH intron 23577725 rs10922094 chr1 196661505 G C 4.30E-31 Age-related macular degeneration CFH intron 23326517 rs12124794 chr1 196661538 A T 4.50E-10 Age-related macular degeneration CFH intron 23326517 rs12124794 chr1 196661538 A T 4.38E-12 End-stage coagulation CFH intron 23381943 rs10922096 chr1 196662459 T C 6.80E-12 Age-related macular degeneration CFH intron 23326517 rs12041668 chr1 196663047 C T 3.60E-10 Age-related macular degeneration CFH intron 23326517 rs12041668 chr1 196663047 C T 1.53E-11 End-stage coagulation CFH intron 23381943 rs514943 chr1 196663913 C T 1.32E-29 Age-related macular degeneration CFH intron 23577725 rs514943 chr1 196663913 C T 6.00E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10922102 chr1 196668287 C T 3.50E-31 Age-related macular degeneration CFH intron 23326517 rs2860102 chr1 196668319 A T 3.60E-31 Age-related macular degeneration CFH intron 23326517 rs4658046 chr1 196670757 C T 2.10E-29 Age-related macular degeneration CFH intron 23326517 rs10754199 chr1 196670839 A G 3.16E-08 Age-related macular degeneration CFH intron 22125219 rs10754199 chr1 196670839 A G 1.17E-85 Age-related macular degeneration CFH intron pha002869 rs10754199 chr1 196670839 A G 7.71E-73 Age-related macular degeneration CFH intron pha002890 rs12038333 chr1 196672454 G A 1.10E-14 Age-related macular degeneration CFH intron 20861866 rs12038333 chr1 196672454 G A 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs12038333 chr1 196672454 G A 2.77E-20 Age-related macular degeneration CFH intron pha000001 rs12038333 chr1 196672454 G A 4.47E-15 Age-related macular degeneration CFH intron pha002856 rs12045503 chr1 196672473 C T 2.90E-31 Age-related macular degeneration CFH intron 23326517 rs9970784 chr1 196673802 C T 4.20E-30 Age-related macular degeneration CFH intron 23326517 rs1831282 chr1 196673993 A C 7.55E-04 Type 2 diabetes CFH intron 17463246 rs1831282 chr1 196673993 A C 4.10E-05 Age-related macular degeneration CFH intron 20861866 rs1831282 chr1 196673993 A C 4.50E-30 Age-related macular degeneration CFH intron 23326517 rs1831282 chr1 196673993 A C 1.00E-31 Age-related macular degeneration CFH intron 23577725 rs1831282 chr1 196673993 A C 9.00E-24 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs203687 chr1 196674270 C T 4.00E-30 Age-related macular degeneration CFH intron 23326517 rs203687 chr1 196674270 C T 2.11E-30 Age-related macular degeneration CFH intron 23577725 rs203687 chr1 196674270 C T 3.52E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs2019727 chr1 196674714 T A 1.40E-09 Age-related macular degeneration CFH intron 20861866 rs2019727 chr1 196674714 T A 1.00E-10 Age-related macular degeneration CFH intron 23326517 rs2019727 chr1 196674714 T A 1.39E-12 Age-related macular degeneration CFH intron 23577725 rs2019727 chr1 196674714 T A 4.39E-11 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs2019727 chr1 196674714 T A 2.99E-12 Age-related macular degeneration CFH intron pha000002 rs2019724 chr1 196674917 T C 5.27E-09 Age-related macular degeneration CFH intron 22125219 rs2019724 chr1 196674917 T C 3.60E-30 Age-related macular degeneration CFH intron 23326517 rs2019724 chr1 196674917 T C 2.07E-88 Age-related macular degeneration CFH intron pha002869 rs2019724 chr1 196674917 T C 9.52E-75 Age-related macular degeneration CFH intron pha002890 rs1887973 chr1 196675179 G A,C 3.90E-30 Age-related macular degeneration CFH intron 23326517 rs6428357 chr1 196675571 A G 3.80E-05 Age-related macular degeneration CFH intron 20861866 rs6428357 chr1 196675571 A G 7.36E-09 Age-related macular degeneration CFH intron 22125219 rs6428357 chr1 196675571 A G 4.20E-30 Age-related macular degeneration CFH intron 23326517 rs6428357 chr1 196675571 A G 2.20E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs6428357 chr1 196675571 A G 2.20E-31 Age-related macular degeneration CFH intron 23577725 rs6695321 chr1 196675861 A G 3.70E-10 Age-related macular degeneration CFH intron 23326517 rs6695321 chr1 196675861 A G 1.73E-13 Age-related macular degeneration CFH intron 23577725 rs6695321 chr1 196675861 A G 2.47E-09 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10733086 chr1 196676935 A T 6.46E-04 Type 2 diabetes CFH intron 17463246 rs10733086 chr1 196676935 A T 2.20E-05 Age-related macular degeneration CFH intron 20861866 rs10733086 chr1 196676935 A T 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs10733086 chr1 196676935 A T 1.04E-29 Age-related macular degeneration CFH intron 23577725 rs10733086 chr1 196676935 A T 7.89E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1410997 chr1 196677163 C A 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs203685 chr1 196677945 C A 1.20E-29 Age-related macular degeneration CFH intron 23326517 rs10737680 chr1 196679455 A C 2.00E-76 Age-related macular degeneration CFH intron 20385819 rs10737680 chr1 196679455 A C 8.70E-26 Age-related macular degeneration CFH intron 23326517 rs10737680 chr1 196679455 A C 1.33E-09 End-stage coagulation CFH intron 23381943 rs10737680 chr1 196679455 A C 1E-434 Age-related macular degeneration CFH intron 23455636 rs10737680 chr1 196679455 A C 1.38E-26 Age-related macular degeneration CFH intron 23577725 rs10737680 chr1 196679455 A C 1.81E-21 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1831281 chr1 196680814 C T 3.60E-10 Age-related macular degeneration CFH intron 23326517 rs1831281 chr1 196680814 C T 7.20E-13 End-stage coagulation CFH intron 23381943 rs203674 chr1 196684625 G T 1.50E-17 Age-related macular degeneration CFH intron 20861866 rs203674 chr1 196684625 G T 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs203674 chr1 196684625 G T 1.29E-25 Age-related macular degeneration CFH intron pha000001 rs203674 chr1 196684625 G T 6.04E-18 Age-related macular degeneration CFH intron pha002856 rs3753395 chr1 196686652 A T 1.00E-25 Age-related macular degeneration CFH intron 23326517 rs3753395 chr1 196686652 A T 1.33E-09 End-stage coagulation CFH intron 23381943 rs6677604 chr1 196686918 G A 3.00E-10 Nephropathy CFH intron 21399633 rs6677604 chr1 196686918 G A 2.30E-10 Age-related macular degeneration CFH intron 23326517 rs6677604 chr1 196686918 G A 9.46E-38 Age-related macular degeneration CFH intron pha002869 rs6677604 chr1 196686918 G A 1.65E-32 Age-related macular degeneration CFH intron pha002890 rs10922106 chr1 196691464 A G 1.00E-25 Age-related macular degeneration CFH intron 23326517 rs10922106 chr1 196691464 A G 1.33E-09 End-stage coagulation CFH intron 23381943 rs393955 chr1 196692470 C A 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs381974 chr1 196692672 A G 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs381974 chr1 196692672 A G 1.35E-05 Schizophrenia CFH intron 24043878 rs379489 chr1 196693451 A G 4.75E-09 Age-related macular degeneration CFH intron 22125219 rs379489 chr1 196693451 A G 1.49E-21 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs379489 chr1 196693451 A G 5.64E-29 Age-related macular degeneration CFH intron 23577725 rs403846 chr1 196696737 T C 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs403846 chr1 196696737 T C 1.74E-31 Age-related macular degeneration CFH intron 23577725 rs403846 chr1 196696737 T C 9.09E-24 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs419137 chr1 196696875 G T 1.06E-10 Age-related macular degeneration CFH intron pha002869 rs419137 chr1 196696875 G T 2.33E-09 Age-related macular degeneration CFH intron pha002890 rs1410996 chr1 196696933 G A 2.00E-111 Age-related macular degeneration CFH intron 20385826 rs1410996 chr1 196696933 G A 1.10E-25 Age-related macular degeneration CFH intron 23326517 rs1410996 chr1 196696933 G A 1.00E-09 End-stage coagulation CFH intron 23381943 rs395544 chr1 196698272 A G 7.60E-04 Type 2 diabetes CFH intron 17463246 rs395544 chr1 196698272 A G 3.80E-05 Age-related macular degeneration CFH intron 20861866 rs395544 chr1 196698272 A G 1.20E-29 Age-related macular degeneration CFH intron 23326517 rs395544 chr1 196698272 A G 1.74E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs395544 chr1 196698272 A G 2.61E-31 Age-related macular degeneration CFH intron 23577725 rs1576340 chr1 196698711 G T 5.40E-10 Age-related macular degeneration CFH intron 23326517 rs1576340 chr1 196698711 G T 6.68E-09 End-stage coagulation CFH intron 23381943 rs12144939 chr1 196698945 G A,T 2.40E-11 Age-related macular degeneration CFH intron 23326517 rs380390 chr1 196701051 G C 4.00E-08 Age-related macular degeneration CFH intron 15761122 rs380390 chr1 196701051 G C 3.40E-14 Age-related macular degeneration CFH intron 20861866 rs380390 chr1 196701051 G C 5.50E-30 Age-related macular degeneration CFH intron 23326517 rs380390 chr1 196701051 G C 1.75E-19 Age-related macular degeneration CFH intron pha000002 rs7540032 chr1 196701284 C T 1.70E-25 Age-related macular degeneration CFH intron 23326517 rs7540032 chr1 196701284 C T 9.02E-10 End-stage coagulation CFH intron 23381943 rs2284664 chr1 196702525 C T 3.89E-04 Hemoglobin concentration CFH intron 20534544 rs2284664 chr1 196702525 C T 4.27E-05 Age-related macular degeneration CFH intron 22125219 rs2284664 chr1 196702525 C T 5.00E-10 Age-related macular degeneration CFH intron 23326517 rs2284664 chr1 196702525 C T 2.38E-13 End-stage coagulation CFH intron 23381943 rs2284664 chr1 196702525 C T 2.81E-41 Age-related macular degeneration CFH intron pha002869 rs2284664 chr1 196702525 C T 2.28E-36 Age-related macular degeneration CFH intron pha002890 rs1329428 chr1 196702810 C T 1.40E-06 Age-related macular degeneration CFH intron 15761122 rs1329428 chr1 196702810 C T 3.00E-64 Age-related macular degeneration CFH intron 20861866 rs1329428 chr1 196702810 C T 1.02E-08 Age-related macular degeneration CFH intron 22125219 rs1329428 chr1 196702810 C T 2.10E-25 Age-related macular degeneration CFH intron 23326517 rs1329428 chr1 196702810 C T 6.89E-10 End-stage coagulation CFH intron 23381943 rs1329428 chr1 196702810 C T 1.35E-16 Age-related macular degeneration CFH intron pha000002 rs1329428 chr1 196702810 C T 8.92E-92 Age-related macular degeneration CFH intron pha002869 rs1329428 chr1 196702810 C T 6.93E-76 Age-related macular degeneration CFH intron pha002890 rs434536 chr1 196705167 C T 9.83E-04 Multiple complex diseases CFH intron 17554300 rs424535 chr1 196709223 A T 9.90E-05 Age-related macular degeneration CFH intron 20861866 rs424535 chr1 196709223 A T 3.80E-09 Age-related macular degeneration CFH intron 23326517 rs424535 chr1 196709223 A T 1.56E-14 Age-related macular degeneration CFH intron 23577725 rs424535 chr1 196709223 A T 2.38E-11 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1065489 chr1 196709774 G T 4.74E-05 Meningococcal disease CFH missense 20694013 rs11582939 chr1 196710157 C T 6.13E-05 Meningococcal disease CFH intron 20694013 rs16840522 chr1 196710916 T C 2.00E-10 Age-related macular degeneration CFH intron 23326517 rs10801560 chr1 196714600 C A 2.50E-10 Age-related macular degeneration CFH intron 23326517 rs10801560 chr1 196714600 C A 2.80E-13 End-stage coagulation CFH intron 23381943 rs10801561 chr1 196714670 T A 2.50E-10 Age-related macular degeneration CFH intron 23326517 rs10801561 chr1 196714670 T A 2.80E-13 End-stage coagulation CFH intron 23381943 rs402032 chr1 196718214 C G 5.90E-09 Age-related macular degeneration / / 23326517 rs395998 chr1 196739837 C T 9.10E-30 Age-related macular degeneration / / 23326517 rs426736 chr1 196760417 A G 5.00E-13 Meningococcal disease CFHR3 intron 20694013 rs411854 chr1 196762117 A G 4.00E-12 Age-related macular degeneration CFHR3 intron 23326517 rs9427913 chr1 196765467 T G 1.40E-26 Age-related macular degeneration / / 23326517 rs436719 chr1 196787744 T G 5.40E-09 Age-related macular degeneration CFHR1 nearGene-5 23326517 rs432007 chr1 196792464 A C 8.90E-27 Age-related macular degeneration CFHR1 intron 23326517 rs438781 chr1 196796240 T A 1.90E-25 Age-related macular degeneration CFHR1 intron 23326517 rs1738740 chr1 196808640 A T 1.40E-26 Age-related macular degeneration / / 23326517 rs6679884 chr1 196817998 G A 3.60E-10 Age-related macular degeneration / / 23326517 rs503002 chr1 196820287 A G 6.10E-09 Age-related macular degeneration / / 23326517 rs10754206 chr1 196820924 T G 6.80E-27 Age-related macular degeneration / / 23326517 rs1964645 chr1 196822014 T C 4.20E-10 Age-related macular degeneration / / 23326517 rs1964645 chr1 196822014 T C 2.76E-13 End-stage coagulation / / 23381943 rs1963605 chr1 196822168 C A 3.30E-10 Age-related macular degeneration / / 23326517 rs1963605 chr1 196822168 C A 1.75E-13 End-stage coagulation / / 23381943 rs16840607 chr1 196823030 T G 2.10E-08 Age-related macular degeneration / / 23326517 rs10922144 chr1 196823300 C A,G,T 2.07E-04 Age-related macular degeneration / / 22125219 rs10922144 chr1 196823300 C A,G,T 4.10E-10 Age-related macular degeneration / / 23326517 rs10922144 chr1 196823300 C A,G,T 1.21E-13 End-stage coagulation / / 23381943 rs10922144 chr1 196823300 C A,G,T 3.90E-37 Age-related macular degeneration / / pha002869 rs10922144 chr1 196823300 C A,G,T 1.53E-32 Age-related macular degeneration / / pha002890 rs7542235 chr1 196823613 A G 8.30E-11 Age-related macular degeneration / / 23326517 rs7542235 chr1 196823613 A G 1.08E-12 Age-related macular degeneration / / 23577725 rs7542235 chr1 196823613 A G 6.80E-12 Age-related macular degeneration (extreme sampling) / / 23577725 rs16840639 chr1 196824773 T C 8.50E-11 Age-related macular degeneration / / 23326517 rs7519758 chr1 196825287 C T 8.10E-11 Age-related macular degeneration / / 23326517 rs7412359 chr1 196832925 G A 1.80E-09 Age-related macular degeneration / / 23326517 rs10922146 chr1 196834636 C T 6.10E-10 Age-related macular degeneration / / 23326517 rs10922146 chr1 196834636 C T 1.44E-13 End-stage coagulation / / 23381943 rs12047098 chr1 196835106 T C 6.20E-10 Age-related macular degeneration / / 23326517 rs12047098 chr1 196835106 T C 1.44E-13 End-stage coagulation / / 23381943 rs7552547 chr1 196836999 T G 2.10E-09 Age-related macular degeneration / / 23326517 rs6657442 chr1 196838060 T C 1.92E-04 Age-related macular degeneration / / 22125219 rs6657442 chr1 196838060 T C 6.90E-10 Age-related macular degeneration / / 23326517 rs6657442 chr1 196838060 T C 3.77E-13 End-stage coagulation / / 23381943 rs6657442 chr1 196838060 T C 1.30E-38 Age-related macular degeneration / / pha002869 rs6657442 chr1 196838060 T C 2.07E-33 Age-related macular degeneration / / pha002890 rs7413265 chr1 196839163 G T 6.60E-10 Age-related macular degeneration / / 23326517 rs7413265 chr1 196839163 G T 1.44E-13 End-stage coagulation / / 23381943 rs7413265 chr1 196839163 G T 1.05E-11 Age-related macular degeneration / / 23577725 rs7413265 chr1 196839163 G T 1.75E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs7516560 chr1 196839430 T C 1.70E-09 Age-related macular degeneration / / 23326517 rs7516560 chr1 196839430 T C 2.39E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs7516560 chr1 196839430 T C 6.02E-08 Age-related macular degeneration / / 23577725 rs7514704 chr1 196839991 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs7519492 chr1 196840125 T C 1.80E-09 Age-related macular degeneration / / 23326517 rs7517126 chr1 196840272 A G 1.60E-09 Age-related macular degeneration / / 23326517 rs7517126 chr1 196840272 A G 5.99E-20 Age-related macular degeneration / / pha002890 rs7517587 chr1 196840765 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs13375144 chr1 196841690 C T 1.80E-09 Age-related macular degeneration / / 23326517 rs13375144 chr1 196841690 C T 5.05E-19 Age-related macular degeneration / / pha002890 rs13375150 chr1 196841839 C T 1.90E-09 Age-related macular degeneration / / 23326517 rs13374399 chr1 196842006 G A 2.00E-09 Age-related macular degeneration / / 23326517 rs13375236 chr1 196842271 C T 1.00E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs13375236 chr1 196842271 C T 2.01E-08 Age-related macular degeneration / / 23577725 rs2336502 chr1 196842574 T C 2.40E-08 Age-related macular degeneration / / 23326517 rs2133138 chr1 196843171 G A 2.00E-09 Age-related macular degeneration / / 23326517 rs2133138 chr1 196843171 G A 3.36E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs2133138 chr1 196843171 G A 6.04E-08 Age-related macular degeneration / / 23577725 rs2336503 chr1 196843420 C A 1.50E-09 Age-related macular degeneration / / 23326517 rs2336503 chr1 196843420 C A 3.85E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs2336503 chr1 196843420 C A 4.52E-08 Age-related macular degeneration / / 23577725 rs6428363 chr1 196843711 G A 1.74E-10 Age-related macular degeneration / / 23577725 rs6428363 chr1 196843711 G A 2.06E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428364 chr1 196844049 C T 1.50E-09 Age-related macular degeneration / / 23326517 rs6428364 chr1 196844049 C T 5.13E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428364 chr1 196844049 C T 7.80E-08 Age-related macular degeneration / / 23577725 rs6428365 chr1 196844131 C A 1.70E-09 Age-related macular degeneration / / 23326517 rs6428366 chr1 196844167 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs6428366 chr1 196844167 A G 1.40E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428366 chr1 196844167 A G 4.13E-08 Age-related macular degeneration / / 23577725 rs6428367 chr1 196844192 T C 1.80E-09 Age-related macular degeneration / / 23326517 rs6428367 chr1 196844192 T C 1.12E-07 Age-related macular degeneration / / 23577725 rs6428367 chr1 196844192 T C 3.37E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428368 chr1 196844310 T C 1.90E-09 Age-related macular degeneration / / 23326517 rs6428369 chr1 196844335 T C 1.90E-09 Age-related macular degeneration / / 23326517 rs6428369 chr1 196844335 T C 3.45E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428369 chr1 196844335 T C 9.57E-08 Age-related macular degeneration / / 23577725 rs6428370 chr1 196844593 A G 7.00E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6428370 chr1 196844593 A G 7.00E-06 Nasopharyngeal carcinoma / / 20512145 rs6428370 chr1 196844593 A G 1.60E-08 Age-related macular degeneration / / 23326517 rs6428370 chr1 196844593 A G 3.99E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428370 chr1 196844593 A G 4.22E-10 Age-related macular degeneration / / 23577725 rs12240143 chr1 196845017 T C 1.60E-08 Age-related macular degeneration / / 23326517 rs1021636 chr1 196845273 A G 2.13E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs1021636 chr1 196845273 A G 5.17E-12 Age-related macular degeneration / / 23577725 rs12240148 chr1 196845307 T C 2.30E-09 Age-related macular degeneration / / 23326517 rs6695525 chr1 196845521 T G 2.70E-25 Age-related macular degeneration / / 23326517 rs10801575 chr1 196852781 T C 1.20E-09 Age-related macular degeneration / / 20861866 rs10801575 chr1 196852781 T C 8.31E-14 Age-related macular degeneration / / pha000001 rs10801575 chr1 196852781 T C 7.31E-11 Age-related macular degeneration / / pha002856 rs10801575 chr1 196852781 T C 1.13E-19 Age-related macular degeneration / / pha002890 rs7366238 chr1 196860797 A G 1.70E-09 Age-related macular degeneration CFHR4 intron 23326517 rs7366238 chr1 196860797 A G 7.29E-16 End-stage coagulation CFHR4 intron 23381943 rs6685931 chr1 196867233 T C 2.13E-10 Age-related macular degeneration CFHR4 intron 22125219 rs6685931 chr1 196867233 T C 5.50E-27 Age-related macular degeneration CFHR4 intron 23326517 rs6685931 chr1 196867233 T C 2.61E-73 Age-related macular degeneration CFHR4 intron pha002869 rs6685931 chr1 196867233 T C 1.42E-61 Age-related macular degeneration CFHR4 intron pha002890 rs10922147 chr1 196877689 C G 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs10922147 chr1 196877689 C G 3.88E-19 End-stage coagulation CFHR4 intron 23381943 rs1409153 chr1 196880005 C T 3.60E-27 Age-related macular degeneration CFHR4 intron 23326517 rs1853883 chr1 196881600 G C 3.41E-18 Age-related macular degeneration CFHR4 intron 21197116 rs1853883 chr1 196881600 G C 2.20E-23 Age-related macular degeneration CFHR4 intron 23326517 rs1853883 chr1 196881600 G C 3.34E-17 Age-related macular degeneration (extreme sampling) CFHR4 intron 23577725 rs1853883 chr1 196881600 G C 8.16E-23 Age-related macular degeneration CFHR4 intron 23577725 rs1853883 chr1 196881600 G C 1.08E-22 Age-related macular degeneration CFHR4 intron pha000001 rs1853883 chr1 196881600 G C 4.85E-15 Age-related macular degeneration CFHR4 intron pha002856 rs7522952 chr1 196882344 A G 2.34E-17 Age-related macular degeneration CFHR4 intron pha002869 rs7522952 chr1 196882344 A G 5.97E-16 Age-related macular degeneration CFHR4 intron pha002890 rs7525447 chr1 196882436 T C 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs7533270 chr1 196882503 G A 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs1853882 chr1 196885344 C G 5.90E-08 Age-related macular degeneration CFHR4 intron 20861866 rs1853882 chr1 196885344 C G 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs1853882 chr1 196885344 C G 4.26E-11 Age-related macular degeneration CFHR4 intron pha000002 rs10801580 chr1 196885685 T C 1.34E-07 Age-related macular degeneration (extreme sampling) CFHR4 intron 23577725 rs10801580 chr1 196885685 T C 1.72E-11 Age-related macular degeneration CFHR4 intron 23577725 rs4915559 chr1 196886770 T C 1.20E-08 Age-related macular degeneration CFHR4 intron 23326517 rs4915559 chr1 196886770 T C 7.00E-19 End-stage coagulation CFHR4 intron 23381943 rs1971579 chr1 196887181 T G 3.40E-10 Age-related macular degeneration CFHR4 intron 20861866 rs1971579 chr1 196887181 T G 3.43E-10 Age-related macular degeneration CFHR4 intron pha000002 rs10494745 chr1 196887457 G A 3.30E-09 Age-related macular degeneration CFHR4 missense 23326517 rs7548070 chr1 196892322 G A 4.93E-21 Age-related macular degeneration / / pha002869 rs7548070 chr1 196892322 G A 2.60E-19 Age-related macular degeneration / / pha002890 rs4086175 chr1 196894326 T C 9.60E-09 Age-related macular degeneration / / 23326517 rs4915318 chr1 196897088 C A 3.99E-05 Age-related macular degeneration / / 22125219 rs4915318 chr1 196897088 C A 1.00E-08 Age-related macular degeneration / / 23326517 rs4915318 chr1 196897088 C A 2.53E-18 End-stage coagulation / / 23381943 rs4915318 chr1 196897088 C A 5.91E-34 Age-related macular degeneration / / pha002869 rs4915318 chr1 196897088 C A 5.49E-30 Age-related macular degeneration / / pha002890 rs7538501 chr1 196901753 C T 1.10E-08 Age-related macular degeneration / / 23326517 rs7538501 chr1 196901753 C T 2.02E-20 Age-related macular degeneration / / pha002869 rs7538501 chr1 196901753 C T 7.55E-19 Age-related macular degeneration / / pha002890 rs2986127 chr1 196904671 T C 4.40E-10 Age-related macular degeneration / / 23326517 rs432366 chr1 196912191 C G 3.60E-08 Age-related macular degeneration / / 23326517 rs1853881 chr1 196915745 A C 3.10E-11 Age-related macular degeneration CFHR2 intron 23326517 rs6674522 chr1 196916359 G C 4.91E-06 Age-related macular degeneration CFHR2 intron 23577725 rs6674522 chr1 196916359 G C 5.00E-06 Age-related macular degeneration (extreme sampling) CFHR2 intron 23577725 rs12066959 chr1 196917899 G A 1.19E-18 End-stage coagulation CFHR2 intron 23381943 rs201886468 chr1 196917899 G GTA 1.19E-18 End-stage coagulation CFHR2 intron 23381943 rs4085749 chr1 196920148 C T 1.18E-18 End-stage coagulation CFHR2 cds-synon 23381943 rs3828032 chr1 196920178 C T 2.90E-08 Age-related macular degeneration CFHR2 intron 23326517 rs3790414 chr1 196920299 T A 1.00E-05 Age-related macular degeneration CFHR2 intron 20861866 rs3790414 chr1 196920299 T A 1.17E-18 End-stage coagulation CFHR2 intron 23381943 rs3790414 chr1 196920299 T A 2.51E-06 Age-related macular degeneration CFHR2 intron pha000001 rs3790414 chr1 196920299 T A 6.21E-05 Age-related macular degeneration CFHR2 intron pha002856 rs9427934 chr1 196922860 G A 3.10E-08 Age-related macular degeneration CFHR2 intron 23326517 rs7531555 chr1 196929310 C T 4.30E-05 Age-related macular degeneration / / 20861866 rs7531555 chr1 196929310 C T 1.01E-18 End-stage coagulation / / 23381943 rs7531555 chr1 196929310 C T 4.87E-06 Age-related macular degeneration / / pha000001 rs9427938 chr1 196933245 C T 4.10E-08 Age-related macular degeneration / / 23326517 rs6428379 chr1 196937536 T C 5.05E-09 Age-related macular degeneration / / 22125219 rs6428379 chr1 196937536 T C 1.90E-22 Age-related macular degeneration / / 23326517 rs6667243 chr1 196941493 T C 1.92E-08 Age-related macular degeneration / / 22125219 rs6667243 chr1 196941493 T C 5.50E-20 Age-related macular degeneration / / 23326517 rs6667243 chr1 196941493 T C 1.10E-16 Age-related macular degeneration (extreme sampling) / / 23577725 rs6667243 chr1 196941493 T C 2.16E-21 Age-related macular degeneration / / 23577725 rs6667243 chr1 196941493 T C 3.34E-66 Age-related macular degeneration / / pha002869 rs6667243 chr1 196941493 T C 1.13E-57 Age-related macular degeneration / / pha002890 rs6675769 chr1 196941661 G A 4.10E-20 Age-related macular degeneration / / 23326517 rs10801582 chr1 196944357 G A 1.99E-18 End-stage coagulation / / 23381943 rs12755054 chr1 196947030 T C 1.70E-09 Age-related macular degeneration CFHR5 intron 23326517 rs12755054 chr1 196947030 T C 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs12755054 chr1 196947030 T C 1.13E-09 Age-related macular degeneration CFHR5 intron 23577725 rs12755054 chr1 196947030 T C 8.69E-09 Age-related macular degeneration (extreme sampling) CFHR5 intron 23577725 rs12731209 chr1 196947139 C T 2.00E-05 Age-related macular degeneration CFHR5 intron 20861866 rs12731209 chr1 196947139 C T 3.35E-08 Age-related macular degeneration CFHR5 intron pha000001 rs12731209 chr1 196947139 C T 1.30E-05 Age-related macular degeneration CFHR5 intron pha002856 rs1759016 chr1 196952498 C T 1.60E-06 Age-related macular degeneration CFHR5 intron 20861866 rs1759016 chr1 196952498 C T 2.00E-09 Age-related macular degeneration CFHR5 intron 23326517 rs1759016 chr1 196952498 C T 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs1759016 chr1 196952498 C T 2.07E-09 Age-related macular degeneration CFHR5 intron pha000001 rs1759016 chr1 196952498 C T 4.71E-07 Age-related macular degeneration CFHR5 intron pha002856 rs1750311 chr1 196954225 C A 2.00E-09 Age-related macular degeneration CFHR5 intron 23326517 rs1750311 chr1 196954225 C A 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs10922152 chr1 196963006 T A 2.60E-12 Age-related macular degeneration CFHR5 intron 20861866 rs10922152 chr1 196963006 T A 2.20E-16 Age-related macular degeneration CFHR5 intron 23326517 rs10922152 chr1 196963006 T A 2.63E-17 Age-related macular degeneration CFHR5 intron pha000001 rs10922152 chr1 196963006 T A 5.21E-12 Age-related macular degeneration CFHR5 intron pha002856 rs12116643 chr1 196973183 T C 5.00E-30 End-stage coagulation CFHR5 intron 23381943 rs10922153 chr1 196978615 T G 3.80E-12 Age-related macular degeneration CFHR5 UTR-3 20861866 rs10922153 chr1 196978615 T G 2.80E-16 Age-related macular degeneration CFHR5 UTR-3 23326517 rs10922153 chr1 196978615 T G 2.63E-17 Age-related macular degeneration CFHR5 UTR-3 pha000001 rs10922153 chr1 196978615 T G 5.21E-12 Age-related macular degeneration CFHR5 UTR-3 pha002856 rs6663083 chr1 196980660 T C 2.40E-12 Age-related macular degeneration / / 20861866 rs6663083 chr1 196980660 T C 2.90E-16 Age-related macular degeneration / / 23326517 rs6663083 chr1 196980660 T C 2.70E-17 Age-related macular degeneration / / pha000001 rs6663083 chr1 196980660 T C 5.47E-12 Age-related macular degeneration / / pha002856 rs7555070 chr1 196982154 C T 3.08E-04 Age-related macular degeneration / / 22125219 rs7555070 chr1 196982154 C T 2.60E-09 Age-related macular degeneration / / 23326517 rs7555070 chr1 196982154 C T 6.40E-10 End-stage coagulation / / 23381943 rs7555070 chr1 196982154 C T 5.69E-24 Age-related macular degeneration / / pha002869 rs7555070 chr1 196982154 C T 5.60E-22 Age-related macular degeneration / / pha002890 rs1332666 chr1 196984679 A G 1.93E-07 Age-related macular degeneration / / 22125219 rs1332666 chr1 196984679 A G 9.46E-04 Tourette syndrome / / 22889924 rs1332666 chr1 196984679 A G 3.90E-16 Age-related macular degeneration / / 23326517 rs1332666 chr1 196984679 A G 1.19E-50 Age-related macular degeneration / / pha002869 rs1332666 chr1 196984679 A G 3.74E-45 Age-related macular degeneration / / pha002890 rs12125782 chr1 196993119 A T 2.43E-09 End-stage coagulation / / 23381943 rs2336597 chr1 196993339 A G 3.61E-04 Multiple complex diseases / / 17554300 rs1360558 chr1 196993973 G A 4.27E-13 End-stage coagulation / / 23381943 rs2336596 chr1 196995092 G A 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1332667 chr1 196995848 G T 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1332667 chr1 196995848 G T 1.29E-21 End-stage coagulation / / 23381943 rs12075161 chr1 197001099 T A 5.90E-30 End-stage coagulation / / 23381943 rs10737685 chr1 197004484 A G 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10737685 chr1 197004484 A G 1.29E-21 End-stage coagulation / / 23381943 rs6702252 chr1 197005212 G A 1.29E-21 End-stage coagulation / / 23381943 rs1332668 chr1 197005736 C T 1.29E-21 End-stage coagulation / / 23381943 rs200940460 chr1 197005736 C CT 1.29E-21 End-stage coagulation / / 23381943 rs698859 chr1 197008365 C T 2.27E-12 End-stage coagulation F13B UTR-3 23381943 rs5990 chr1 197008597 A C 1.29E-21 End-stage coagulation F13B intron 23381943 rs12134960 chr1 197009508 G C 5.90E-30 End-stage coagulation F13B intron 23381943 rs5998 chr1 197009798 A G 1.29E-21 End-stage coagulation F13B cds-synon 23381943 rs10484502 chr1 197010475 G A 1.29E-21 End-stage coagulation F13B intron 23381943 rs857025 chr1 197010795 C T 2.27E-12 End-stage coagulation F13B intron 23381943 rs10754209 chr1 197011577 T A 1.29E-21 End-stage coagulation F13B intron 23381943 rs7518773 chr1 197011636 A G 1.22E-21 End-stage coagulation F13B intron 23381943 rs10754210 chr1 197012111 G A 7.22E-14 Age-related macular degeneration F13B intron pha002869 rs10754210 chr1 197012111 G A 1.56E-14 Age-related macular degeneration F13B intron pha002890 rs2990510 chr1 197020658 T G 4.30E-06 Age-related macular degeneration F13B intron 20861866 rs2990510 chr1 197020658 T G 6.00E-06 Erectile dysfunction F13B intron 22704111 rs2990510 chr1 197020658 T G 4.24E-07 Age-related macular degeneration F13B intron pha000001 rs2990510 chr1 197020658 T G 4.80E-06 Age-related macular degeneration F13B intron pha000002 rs2990510 chr1 197020658 T G 9.94E-06 Age-related macular degeneration F13B intron pha002856 rs10801586 chr1 197021189 C T 1.96E-30 End-stage coagulation F13B intron 23381943 rs1611982 chr1 197022768 G A 1.29E-21 End-stage coagulation F13B intron 23381943 rs1412635 chr1 197023048 G A 7.72E-22 End-stage coagulation F13B intron 23381943 rs2298883 chr1 197028634 A G 1.91E-30 End-stage coagulation F13B intron 23381943 rs1615413 chr1 197030317 A G 1.29E-21 End-stage coagulation F13B intron 23381943 rs6003 chr1 197031021 C T 6.80E-05 Age-related macular degeneration F13B missense 20861866 rs6003 chr1 197031021 C T 3.65E-09 Age-related macular degeneration F13B missense pha000001 rs6003 chr1 197031021 C T 5.97E-06 Age-related macular degeneration F13B missense pha002856 rs6003 chr1 197031021 C T 4.16E-11 Age-related macular degeneration F13B missense pha002869 rs6003 chr1 197031021 C T 2.53E-10 Age-related macular degeneration F13B missense pha002890 rs1759006 chr1 197031664 T C 2.30E-05 Age-related macular degeneration F13B intron 20861866 rs1759006 chr1 197031664 T C 6.06E-09 Age-related macular degeneration F13B intron pha000002 rs5996 chr1 197032345 C A,G 1.89E-12 End-stage coagulation F13B intron 23381943 rs2298882 chr1 197034826 T G 1.29E-21 End-stage coagulation F13B intron 23381943 rs1412632 chr1 197036868 G A 7.20E-05 Age-related macular degeneration F13B nearGene-5 20861866 rs1412632 chr1 197036868 G A 1.42E-08 Age-related macular degeneration F13B nearGene-5 pha000001 rs1412632 chr1 197036868 G A 9.67E-06 Age-related macular degeneration F13B nearGene-5 pha002856 rs1412631 chr1 197037237 T C 5.50E-05 Age-related macular degeneration F13B nearGene-5 20861866 rs1412631 chr1 197037237 T C 2.17E-09 Age-related macular degeneration F13B nearGene-5 pha000001 rs1412631 chr1 197037237 T C 4.76E-06 Age-related macular degeneration F13B nearGene-5 pha002856 rs1332660 chr1 197053141 T C 6.07E-30 End-stage coagulation ASPM nearGene-3 23381943 rs12677 chr1 197053373 G A 6.80E-05 Age-related macular degeneration ASPM UTR-3 20861866 rs12677 chr1 197053373 G A 3.65E-09 Age-related macular degeneration ASPM UTR-3 pha000001 rs12677 chr1 197053373 G A 5.97E-06 Age-related macular degeneration ASPM UTR-3 pha002856 rs955927 chr1 197060783 A T 2.87E-11 End-stage coagulation ASPM intron 23381943 rs6700180 chr1 197064496 G A 1.32E-20 End-stage coagulation ASPM intron 23381943 rs10737686 chr1 197068200 C T 1.58E-30 End-stage coagulation ASPM intron 23381943 rs3762271 chr1 197070442 G T 1.05E-11 End-stage coagulation ASPM missense 23381943 rs12138336 chr1 197070521 C G 4.79E-10 End-stage coagulation ASPM missense 23381943 rs10922162 chr1 197070776 C T 8.90E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs10922162 chr1 197070776 C T 2.00E-30 End-stage coagulation ASPM cds-synon 23381943 rs10801589 chr1 197076194 C T 3.83E-21 End-stage coagulation ASPM intron 23381943 rs10922163 chr1 197077391 T C 4.15E-21 End-stage coagulation ASPM intron 23381943 rs12034362 chr1 197077516 T C 1.55E-30 End-stage coagulation ASPM intron 23381943 rs12034362 chr1 197077516 T C 4.45E-14 Age-related macular degeneration ASPM intron pha002869 rs12034362 chr1 197077516 T C 7.46E-13 Age-related macular degeneration ASPM intron pha002890 rs2026429 chr1 197079671 C A 7.66E-12 Age-related macular degeneration ASPM intron pha002869 rs2026429 chr1 197079671 C A 6.24E-11 Age-related macular degeneration ASPM intron pha002890 rs12085377 chr1 197081682 G A 1.55E-30 End-stage coagulation ASPM intron 23381943 rs10922168 chr1 197086130 T C 1.55E-30 End-stage coagulation ASPM intron 23381943 rs4915337 chr1 197091537 A T 6.80E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs4915337 chr1 197091537 A T 3.65E-09 Age-related macular degeneration ASPM cds-synon pha000001 rs4915337 chr1 197091537 A T 5.97E-06 Age-related macular degeneration ASPM cds-synon pha002856 rs12042442 chr1 197096135 T C 1.54E-30 End-stage coagulation ASPM intron 23381943 rs3737110 chr1 197101303 C A 1.14E-12 End-stage coagulation ASPM intron 23381943 rs4915344 chr1 197102745 A G 1.54E-30 End-stage coagulation ASPM intron 23381943 rs1888991 chr1 197110822 A G 6.80E-05 Age-related macular degeneration ASPM intron 20861866 rs1888991 chr1 197110822 A G 3.65E-09 Age-related macular degeneration ASPM intron pha000001 rs1888991 chr1 197110822 A G 5.97E-06 Age-related macular degeneration ASPM intron pha002856 rs6677082 chr1 197112533 G A 7.40E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs6677082 chr1 197112533 G A 3.99E-09 Age-related macular degeneration ASPM cds-synon pha000001 rs6677082 chr1 197112533 G A 4.57E-09 Age-related macular degeneration ASPM cds-synon pha000002 rs6677082 chr1 197112533 G A 6.47E-06 Age-related macular degeneration ASPM cds-synon pha002856 rs1127661 chr1 197123043 T C 6.41E-11 End-stage coagulation ZBTB41 UTR-3 23381943 rs4639796 chr1 197126649 G A 8.90E-05 Age-related macular degeneration ZBTB41 UTR-3 20861866 rs4639796 chr1 197126649 G A 8.09E-28 End-stage coagulation ZBTB41 UTR-3 23381943 rs12028827 chr1 197127491 A C 8.09E-28 End-stage coagulation ZBTB41 UTR-3 23381943 rs12724106 chr1 197127578 A G 7.80E-05 Diabetic retinopathy ZBTB41 UTR-3 21441570 rs12128631 chr1 197128726 G A 1.32E-27 End-stage coagulation ZBTB41 cds-synon 23381943 rs12137359 chr1 197129981 C T 1.02E-27 End-stage coagulation ZBTB41 intron 23381943 rs12137359 chr1 197129981 C T 2.05E-13 Age-related macular degeneration ZBTB41 intron pha002869 rs12137359 chr1 197129981 C T 2.68E-12 Age-related macular degeneration ZBTB41 intron pha002890 rs4244139 chr1 197131374 G A 9.62E-20 End-stage coagulation ZBTB41 intron 23381943 rs6677930 chr1 197135466 C A 1.35E-19 End-stage coagulation ZBTB41 intron 23381943 rs4520444 chr1 197141988 G T 3.64E-11 Age-related macular degeneration ZBTB41 intron pha002869 rs4520444 chr1 197141988 G T 8.05E-12 Age-related macular degeneration ZBTB41 intron pha002890 rs6656448 chr1 197143278 C T 7.60E-05 Age-related macular degeneration ZBTB41 intron 20861866 rs6656448 chr1 197143278 C T 8.77E-09 Age-related macular degeneration ZBTB41 intron pha000001 rs6656448 chr1 197143278 C T 5.63E-06 Age-related macular degeneration ZBTB41 intron pha002856 rs10922177 chr1 197153767 T C 4.24E-09 End-stage coagulation ZBTB41 intron 23381943 rs7410943 chr1 197155021 A G 3.00E-19 End-stage coagulation ZBTB41 intron 23381943 rs10494747 chr1 197163928 A T 6.98E-12 End-stage coagulation ZBTB41 intron 23381943 rs10754218 chr1 197165014 G A 7.79E-12 End-stage coagulation ZBTB41 intron 23381943 rs10801596 chr1 197165267 G A 2.13E-13 End-stage coagulation ZBTB41 intron 23381943 rs7516246 chr1 197165712 C T 2.11E-13 End-stage coagulation ZBTB41 intron 23381943 rs6690022 chr1 197170027 A G 1.15E-10 End-stage coagulation / / 23381943 rs6690022 chr1 197170027 A G 5.06E-05 Age-related macular degeneration / / pha002856 rs7544067 chr1 197179710 C T 1.15E-10 End-stage coagulation CRB1 intron 23381943 rs1415216 chr1 197185649 C T 1.15E-10 End-stage coagulation CRB1 intron 23381943 rs10922187 chr1 197187605 C T 1.60E-10 End-stage coagulation CRB1 intron 23381943 rs4915406 chr1 197195650 C T 7.85E-11 End-stage coagulation CRB1 intron 23381943 rs1764629 chr1 197216632 A G 7.20E-05 Age-related macular degeneration CRB1 intron 20861866 rs1764629 chr1 197216632 A G 5.01E-06 Age-related macular degeneration CRB1 intron pha000002 rs17616836 chr1 197216681 G A 6.47E-04 Type 2 diabetes CRB1 intron 17463246 rs10754220 chr1 197244290 G A 2.85E-10 Age-related macular degeneration CRB1 intron pha002869 rs10754220 chr1 197244290 G A 4.20E-11 Age-related macular degeneration CRB1 intron pha002890 rs7542212 chr1 197245860 A G 5.60E-04 Coronary Artery Disease CRB1 intron 17634449 rs7542212 chr1 197245860 A G 8.54E-11 End-stage coagulation CRB1 intron 23381943 rs3790380 chr1 197246968 C A 1.18E-10 End-stage coagulation CRB1 intron 23381943 rs1009188 chr1 197257090 T C 7.11E-04 Type 2 diabetes CRB1 intron 17463246 rs482526 chr1 197268763 A C 5.07E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs664767 chr1 197280295 A C 5.07E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1415214 chr1 197283185 C T 5.92E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1415214 chr1 197283185 C T 9.74E-05 Age-related macular degeneration CRB1 intron pha002890 rs1764623 chr1 197288308 G T 4.64E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs550098 chr1 197297408 A G 2.87E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs580067 chr1 197298373 T C 2.77E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1615444 chr1 197299315 C T 2.72E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1764786 chr1 197300496 A G 2.65E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2821131 chr1 197302402 T G 1.99E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786115 chr1 197302690 A G 7.07E-06 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786113 chr1 197304081 T G 1.18E-04 Type 2 diabetes CRB1 intron 17463246 rs2786113 chr1 197304081 T G 1.87E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786111 chr1 197306099 C T 5.00E-06 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786106 chr1 197311228 T C 9.32E-04 Alzheimer's disease CRB1 intron 24755620 rs949571 chr1 197313189 C T 3.31E-05 Age-related macular degeneration CRB1 intron pha002890 rs2786098 chr1 197325908 T A,C,G 2.00E-13 Asthma CRB1 intron 20032318 rs12083773 chr1 197343763 T C 5.88E-04 Insulin resistance CRB1 intron 21901158 rs2759662 chr1 197361571 G A 8.44E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs10922215 chr1 197363948 G A 6.78E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs2476020 chr1 197368281 T G 1.01E-05 Post-operative nausea and vomiting CRB1 intron 21694509 rs11802794 chr1 197372250 C A 1.11E-07 Post-operative nausea and vomiting CRB1 intron 21694509 rs11802794 chr1 197372250 C A 6.78E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs11799515 chr1 197372437 G T 8.60E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs9659183 chr1 197438606 G T 7.94E-05 Post-operative nausea and vomiting CRB1 intron 21694509 rs4915551 chr1 197508901 G A 2.80E-05 Body mass index (asthmatics) DENND1B intron 23517042 rs10754224 chr1 197512789 A C 3.19E-04 Height DENND1B intron 17255346 rs2111931 chr1 197529218 C T 2.90E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs2111932 chr1 197530550 T C 5.82E-04 Multiple complex diseases DENND1B intron 17554300 rs11583319 chr1 197555860 A G 8.40E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs41340645 chr1 197613888 A C 2.09E-04 Multiple complex diseases DENND1B intron 17554300 rs6688289 chr1 197615058 C T 2.92E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs1775453 chr1 197629342 C T 2.00E-07 Serum protein levels (sST2) DENND1B intron 23999434 rs2488389 chr1 197631141 G A 8.00E-13 Inflammatory bowel disease DENND1B intron 23128233 rs2488411 chr1 197658799 C T 3.83E-04 Height DENND1B intron 17255346 rs1891497 chr1 197659555 A G 5.11E-04 Height DENND1B intron 17255346 rs12092948 chr1 197689967 T C 3.39E-07 Post-operative nausea and vomiting DENND1B intron 21694509 rs41322944 chr1 197695793 C G 3.25E-04 Multiple complex diseases DENND1B intron 17554300 rs16841904 chr1 197701992 C T 2.07E-09 Primary biliary cirrhosis DENND1B intron 21399635 rs2488401 chr1 197702401 C T 1.88E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs2488393 chr1 197722240 C T 4.29E-12 Primary biliary cirrhosis DENND1B intron 22961000 rs10922273 chr1 197725373 C T 6.61E-05 Coronary heart disease DENND1B intron pha003031 rs1998598 chr1 197727642 A G 9.00E-09 Crohn's disease DENND1B intron 21102463 rs35511146 chr1 197729087 T TA 2.80E-04 Urinary metabolites DENND1B intron 21572414 rs1775456 chr1 197733055 G A 3.00E-07 Asthma DENND1B intron 21907864 rs1775456 chr1 197733055 G A 5.20E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1924518 chr1 197738327 A G 2.90E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1775444 chr1 197740690 T C 5.80E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1539414 chr1 197743506 G A 4.70E-05 Crohn's disease DENND1B intron 20570966 rs1539414 chr1 197743506 G A 2.32E-09 Primary biliary cirrhosis DENND1B intron 21399635 rs1539414 chr1 197743506 G A 9.79E-05 Post-operative nausea and vomiting DENND1B intron 21694509 rs1539414 chr1 197743506 G A 0.0000023 Primary biliary cirrhosis (anti-mitochondrial antibody positive) DENND1B intron 22936693 rs1539414 chr1 197743506 G A 0.00000346 Primary biliary cirrhosis DENND1B intron 22936693 rs1539414 chr1 197743506 G A 0.0000345 Primary biliary cirrhosis in females DENND1B intron 22936693 rs1539414 chr1 197743506 G A 2.01E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs9427672 chr1 197754741 A G 0.000267 Primary biliary cirrhosis / / 22936693 rs12134279 chr1 197781198 C T 2.00E-14 Primary biliary cirrhosis / / 21399635 rs12121863 chr1 197785420 A G 7.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10754233 chr1 197816787 G A 5.13E-05 Multiple complex diseases / / 17554300 rs10922306 chr1 197823360 A G 7.55E-07 Age-related macular degeneration / / pha002869 rs10922306 chr1 197823360 A G 1.79E-06 Age-related macular degeneration / / pha002890 rs10922313 chr1 197836347 T C 3.56E-06 Age-related macular degeneration / / pha002869 rs10922313 chr1 197836347 T C 4.57E-06 Age-related macular degeneration / / pha002890 rs10801629 chr1 197844367 C T 2.70E-04 Alcohol dependence / / 20201924 rs10801629 chr1 197844367 C T 0.00000413 Alcohol dependence / / 23691058 rs10922323 chr1 197862321 T C 3.60E-04 Alcohol dependence / / 20201924 rs10922323 chr1 197862321 T C 0.00000646 Alcohol dependence / / 23691058 rs12138550 chr1 197866357 C T 2.60E-05 Urinary metabolites / / 21572414 rs545711 chr1 197939323 A T 3.96E-04 Multiple complex diseases / / 17554300 rs3850618 chr1 197946606 A G 5.84E-04 Multiple complex diseases / / 17554300 rs10922349 chr1 197964577 A T 1.70E-05 Urinary metabolites / / 21572414 rs12404040 chr1 197967676 C T 1.70E-05 Urinary metabolites / / 21572414 rs1543511 chr1 197968019 T C 9.44E-05 Height / / 17255346 rs1543511 chr1 197968019 T C 5.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12064633 chr1 197974876 T A 9.00E-04 Type 2 diabetes / / 17463246 rs11580655 chr1 197988761 T C 7.59E-04 Alzheimer's disease / / 17998437 rs2359378 chr1 198022138 C T 1.65E-04 Multiple complex diseases / / 17554300 rs1233839 chr1 198034569 C T 6.80E-04 Telomere length / / 23900074 rs12141081 chr1 198069359 C T 2.77E-04 Multiple complex diseases / / 17554300 rs12141081 chr1 198069359 C T 6.04E-04 Aortic root size / / 21223598 rs12135790 chr1 198079359 T A 1.92E-04 Multiple complex diseases / / 17554300 rs1938378 chr1 198146240 T A 2.60E-05 Urinary metabolites NEK7 intron 21572414 rs10494765 chr1 198215042 T G 4.74E-04 Nicotine dependence NEK7 intron 17158188 rs1475423 chr1 198223490 A T 1.88E-04 Nicotine dependence NEK7 intron 17158188 rs1927252 chr1 198233907 C A 3.60E-07 Bipolar disorder NEK7 intron 21738484 rs16842730 chr1 198273889 G A 1.26E-04 Nicotine dependence NEK7 intron 17158188 rs16842733 chr1 198274100 A G 4.42E-04 Nicotine dependence NEK7 intron 17158188 rs10494769 chr1 198274361 A G 2.84E-04 Nicotine dependence NEK7 intron 17158188 rs12407433 chr1 198274908 A T 7.33E-04 Nicotine dependence NEK7 intron 17158188 rs16842754 chr1 198277135 C A 5.25E-04 Nicotine dependence NEK7 intron 17158188 rs1139949 chr1 198289927 G C 3.61E-04 Body mass index NEK7 UTR-3 17255346 rs1139949 chr1 198289927 G C 5.80E-04 Type 2 diabetes NEK7 UTR-3 17463246 rs6660793 chr1 198311960 C T 3.03E-04 Body mass index / / 17255346 rs6660793 chr1 198311960 C T 3.98E-04 Type 2 diabetes / / 17463246 rs1556016 chr1 198315826 A T 6.56E-04 Bipolar disorder / / 19259986 rs16842856 chr1 198317345 C T 4.01E-04 Multiple complex diseases / / 17554300 rs6428453 chr1 198325457 G T 2.61E-04 Body mass index / / 17255346 rs6428453 chr1 198325457 G T 6.56E-04 Type 2 diabetes / / 17463246 rs963564 chr1 198334894 G A 5.01E-04 Type 2 diabetes / / 17463246 rs963564 chr1 198334894 G A 5.45E-04 Multiple complex diseases / / 17554300 rs16842978 chr1 198369123 A T 2.11E-04 Body mass index / / 17255346 rs16842978 chr1 198369123 A T 8.21E-04 Type 2 diabetes / / 17463246 rs7550723 chr1 198373152 C T 2.81E-04 Body mass index / / 17255346 rs7550723 chr1 198373152 C T 9.79E-04 Type 2 diabetes / / 17463246 rs16843001 chr1 198373326 T C 2.21E-04 Nicotine dependence / / 17158188 rs4915286 chr1 198379069 A T 5.21E-04 Type 2 diabetes / / 17463246 rs7554576 chr1 198392334 G A 5.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12078566 chr1 198393815 G A 2.95E-04 Atopic dermatitis / / 21666691 rs12078566 chr1 198393815 G A 5.49E-04 Heart Failure / / pha002885 rs12036304 chr1 198407610 A T 3.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16843093 chr1 198416675 A G 1.64E-04 Nicotine dependence / / 17158188 rs12085366 chr1 198417004 T C 1.46E-05 Atopic dermatitis / / 21666691 rs10922421 chr1 198417152 G T 0.0000502 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2813164 chr1 198421408 A G 8.30E-07 Bipolar disorder / / 19416921 rs4351678 chr1 198435983 A G 4.95E-04 Type 2 diabetes / / 17463246 rs16843150 chr1 198450275 T G 3.66E-05 Smoking initiation / / 24665060 rs10158064 chr1 198457080 T G 3.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4915292 chr1 198461064 C T 0.0000668 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12041939 chr1 198462661 C T 0.00000363 Femoral neck bone mineral density (premenopausal) / / 23074152 rs16843188 chr1 198466351 G A 1.20E-04 Multiple complex diseases / / 17554300 rs10922438 chr1 198469162 G A 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12058080 chr1 198481371 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2359847 chr1 198484209 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs16843226 chr1 198484784 A G 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12083381 chr1 198485706 T C 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10494777 chr1 198489457 T C 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10922446 chr1 198494473 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ATP6V1G3 intron 23648065 rs6428467 chr1 198511122 A C 2.00E-04 Interstitial lung disease ATP6V1G3 nearGene-5 23583980 rs16843298 chr1 198518546 C A 2.90E-06 Body mass index / / 19584900 rs16843298 chr1 198518546 C A 9.90E-05 Body mass index / / 19584900 rs17659788 chr1 198521135 A G 9.20E-05 Parkinson's disease (age of onset) / / 19772629 rs12144380 chr1 198564497 T C 7.75E-05 Leukocyte Counts / / pha003091 rs4915310 chr1 198580255 G A 1.51E-04 Alzheimer's disease (late onset) / / 21379329 rs12127588 chr1 198595506 G A 6.76E-10 Blood cell counts and other traits / / 20139978 rs12127588 chr1 198595506 G A 7.00E-10 Blood cell counts and other traits / / 20139978 rs34090688 chr1 198595506 G GA 6.76E-10 Blood cell counts and other traits / / 20139978 rs34090688 chr1 198595506 G GA 7.00E-10 Blood cell counts and other traits / / 20139978 rs11582374 chr1 198596234 G T 0.000698627 Primary sclerosing cholangitis / / 23603763 rs1409362 chr1 198618500 A G 7.81E-04 Alzheimer's disease PTPRC intron 22005930 rs1326271 chr1 198619759 G A 7.85E-04 Alzheimer's disease PTPRC intron 22005930 rs7522020 chr1 198637853 G T 3.50E-04 Alzheimer's disease PTPRC intron 22005930 rs17668708 chr1 198640488 C T 1.70E-05 Rheumatoid arthritis PTPRC intron 24390342 rs17668708 chr1 198640488 C T 1.80E-05 Rheumatoid arthritis PTPRC intron 24390342 rs2359952 chr1 198656407 A G 4.00E-07 Ulcerative colitis PTPRC intron 24837172 rs12127625 chr1 198656771 C T 0.0000381 Primary sclerosing cholangitis PTPRC intron 23603763 rs2182419 chr1 198660143 G A 8.63E-04 Multiple complex diseases PTPRC intron 17554300 rs10919560 chr1 198690691 A G 8.49E-05 Self-reported allergy PTPRC intron 23817569 rs1011338 chr1 198692364 T C 2.00E-04 Multiple complex diseases PTPRC intron 17554300 rs10919563 chr1 198700442 G A 1.08E-04 Multiple complex diseases PTPRC intron 17554300 rs10919563 chr1 198700442 G A 3.30E-04 Rheumatoid arthritis PTPRC intron 22446963 rs10919563 chr1 198700442 G A 1.25E-10 Rheumatoid arthritis PTPRC intron 23143596 rs10919563 chr1 198700442 G A 7.18E-05 Rheumatoid arthritis PTPRC intron 24449572 rs11589894 chr1 198705081 A G 7.79E-05 Self-reported allergy PTPRC intron 23817569 rs874909 chr1 198719973 T C 1.07E-04 Alzheimer's disease PTPRC intron 22005930 rs874909 chr1 198719973 T C 5.32E-04 Self-reported allergy PTPRC intron 23817569 rs17670373 chr1 198722841 A G 2.70E-04 Alzheimer's disease PTPRC intron 22005930 rs17670373 chr1 198722841 A G 5.20E-04 Self-reported allergy PTPRC intron 23817569 rs4915157 chr1 198730501 C T 2.88E-04 Insulin resistance / / 21901158 rs6696533 chr1 198733567 T C 2.51E-04 Alzheimer's disease / / 22005930 rs12568099 chr1 198750422 C T 3.74E-04 Multiple complex diseases / / 17554300 rs12568099 chr1 198750422 C T 9.80E-06 Bipolar disorder / / 19416921 rs2784103 chr1 198760554 T C 7.82E-04 Alzheimer's disease / / 22005930 rs2759643 chr1 198764636 A T 7.00E-05 Asthma and hay fever / / 24388013 rs2759646 chr1 198768756 G A 5.61E-04 Alzheimer's disease / / 22005930 rs2759647 chr1 198768785 A T 5.58E-04 Alzheimer's disease / / 22005930 rs2784114 chr1 198771170 C T 9.96E-05 Self-reported allergy / / 23817569 rs1452 chr1 198771400 A G 7.90E-05 Self-reported allergy / / 23817569 rs2784113 chr1 198773703 G T 7.74E-05 Self-reported allergy / / 23817569 rs12043681 chr1 198775474 T C 6.17E-04 Coronary heart disease / / 21606135 rs9427431 chr1 198777472 T C 5.52E-04 Coronary heart disease LOC100131234 intron 21606135 rs1407684 chr1 198777754 T C 5.35E-04 Coronary heart disease LOC100131234 intron 21606135 rs2014863 chr1 198809601 C T 0.000021 Rheumatoid arthritis LOC100131234 intron 23143596 rs1322916 chr1 198876258 T C 1.35E-05 Asthma LOC100131234 intron 23181788 rs10489689 chr1 198889074 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100131234 intron 22628534 rs6658650 chr1 198921640 G A 8.83E-05 Serum metabolites / / 19043545 rs1892432 chr1 198940624 T C 9.47E-04 White matter integrity / / 22425255 rs1892433 chr1 198961568 G A 2.60E-05 Urinary metabolites / / 21572414 rs10919614 chr1 198974825 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10919615 chr1 198974904 C T 8.47E-07 Red blood cell traits / / 23222517 rs1124025 chr1 198979818 C G 4.51E-04 Type 2 diabetes / / 17463246 rs1124025 chr1 198979818 C G 3.73E-07 Red blood cell traits / / 23222517 rs12757682 chr1 198981241 T C 2.59E-05 Hypertension / / 19609347 rs12748299 chr1 198983324 C G 1.66E-05 Hypertension / / 19609347 rs2186188 chr1 198991093 A G 4.76E-04 Smoking quantity / / 24665060 rs12125200 chr1 198992043 A G 2.33E-07 Red blood cell traits / / 23222517 rs2360962 chr1 199004709 A T 1.16E-08 Red blood cell traits / / 23222517 rs7529925 chr1 199007208 C T 8.00E-09 Red blood cell traits / / 23222517 rs1434282 chr1 199010721 C T 1.48E-08 Red blood cell traits / / 23222517 rs1036332 chr1 199012478 A C 1.67E-07 Red blood cell traits / / 23222517 rs962793 chr1 199034906 A G 5.30E-05 Kawasaki disease / / 22081228 rs322921 chr1 199058893 A T 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs322895 chr1 199093876 T C 0.00016 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs10800612 chr1 199139429 C T 2.62E-05 Serum metabolites / / 19043545 rs6684332 chr1 199150453 C T 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10800613 chr1 199158242 C A 1.38E-05 Serum metabolites / / 19043545 rs10494785 chr1 199161762 T C 3.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12402922 chr1 199171803 C T 4.12E-05 Serum metabolites / / 19043545 rs6684754 chr1 199171827 T A 1.14E-05 Serum metabolites / / 19043545 rs10494786 chr1 199195892 T C 1.56E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs10494787 chr1 199213194 C G 3.64E-17 Multiple complex diseases / / 17554300 rs11579522 chr1 199266874 A G 5.31E-05 Autism spectrum disorders (language delay) / / 21519539 rs1561144 chr1 199298683 T C 4.50E-05 Diabetic retinopathy / / 21441570 rs6677813 chr1 199303910 G C 4.80E-05 Diabetic retinopathy / / 21441570 rs1325184 chr1 199312280 C T 2.83E-04 Type 2 diabetes / / 17463246 rs1327067 chr1 199314285 G A 4.86E-04 Multiple complex diseases / / 17554300 rs576141 chr1 199329274 A G 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs16844716 chr1 199356516 A C 9.00E-06 Dialysis-related mortality / / 21546767 rs693911 chr1 199357586 G C 6.26E-05 Major depressive disorder (broad) / / 20038947 rs595113 chr1 199359440 C A 6.02E-05 Major depressive disorder (broad) / / 20038947 rs493474 chr1 199360977 C T 4.13E-05 Major depressive disorder (broad) / / 20038947 rs638079 chr1 199362153 C T 5.86E-05 Major depressive disorder (broad) / / 20038947 rs571609 chr1 199362216 C T 5.84E-05 Major depressive disorder (broad) / / 20038947 rs4562659 chr1 199364111 G T 5.83E-05 Major depressive disorder (broad) / / 20038947 rs543505 chr1 199373716 T C 1.80E-05 Bipolar disorder and schizophrenia / / 20889312 rs661480 chr1 199374488 C A 7.43E-05 Major depressive disorder (broad) / / 20038947 rs661480 chr1 199374488 C A 1.26E-05 Bipolar disorder and schizophrenia / / 20889312 rs585476 chr1 199377000 A C 7.64E-05 Major depressive disorder (broad) / / 20038947 rs628061 chr1 199378212 C T 5.94E-05 Major depressive disorder (broad) / / 20038947 rs528227 chr1 199386880 T C 7.65E-05 Major depressive disorder (broad) / / 20038947 rs516182 chr1 199395968 G A 8.07E-05 Major depressive disorder (broad) / / 20038947 rs826937 chr1 199396278 A G 8.08E-05 Major depressive disorder (broad) / / 20038947 rs580169 chr1 199407512 T C 8.06E-05 Major depressive disorder (broad) / / 20038947 rs729439 chr1 199422097 C G 7.83E-05 Major depressive disorder (broad) / / 20038947 rs1337730 chr1 199429509 G A 2.63E-05 Major depressive disorder (broad) / / 20038947 rs7535498 chr1 199431121 T C 9.32E-05 Major depressive disorder (broad) / / 20038947 rs4915175 chr1 199431778 G C 9.39E-05 Major depressive disorder (broad) / / 20038947 rs7542074 chr1 199435387 A C 6.65E-05 Bipolar disorder and schizophrenia / / 20889312 rs1572565 chr1 199441665 A G 0.00005 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs12045830 chr1 199513565 G A 9.00E-05 Diabetic retinopathy / / 21441570 rs945877 chr1 199519005 G A 4.07E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs2786742 chr1 199558644 T A 5.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10919737 chr1 199644492 A G 5.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17162624 chr1 199655861 T C 1.32E-04 Birth weight / / 17255346 rs2435241 chr1 199690834 C G 3.25E-04 Type 2 diabetes / / 17463246 rs1030519 chr1 199715370 A G 5.90E-06 Urinary metabolites / / 21572414 rs17162712 chr1 199717132 T A 3.04E-05 Multiple complex diseases / / 17554300 rs17162712 chr1 199717132 T A 7.54E-04 Insulin resistance / / 21901158 rs1346680 chr1 199772234 A G 7.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs9427689 chr1 199782481 C G 7.40E-06 Urinary metabolites / / 21572414 rs987648 chr1 199783024 T C 1.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs12027362 chr1 199792844 G A 9.26E-04 Coronary heart disease / / 21971053 rs12096427 chr1 199822974 A G 2.91E-05 Cognitive test performance / / 20125193 rs12096427 chr1 199822974 A G 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1425791 chr1 199832023 A G 2.79E-05 Cognitive test performance / / 20125193 rs17664308 chr1 199839998 T C 1.48E-05 Pancreatic cancer / / pha002889 rs10919761 chr1 199858391 G A 2.91E-05 Cognitive test performance / / 20125193 rs6677214 chr1 199889671 T G 3.87E-04 Coronary heart disease / / 21971053 rs12029406 chr1 199905828 C T 4.59E-04 Smoking initiation / / 24665060 rs12029406 chr1 199905828 C T 1.04E-07 Pancreatic cancer / / pha002889 rs1991245 chr1 199925306 G A 4.01E-04 Smoking initiation / / 24665060 rs10737565 chr1 199953766 A G 8.05E-04 Multiple complex diseases / / 17554300 rs4465241 chr1 199963622 T C 4.79E-07 Pancreatic cancer / / pha002889 rs10919791 chr1 199965168 G A 6.37E-10 Pancreatic cancer / / pha002889 rs4244145 chr1 199971261 G A 1.98E-05 Pancreatic cancer / / pha002889 rs4379703 chr1 199974728 A G 1.75E-04 Multiple complex diseases / / 17554300 rs2816939 chr1 199985700 T C 4.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2816939 chr1 199985700 T C 9.58E-06 Pancreatic cancer / / pha002889 rs2821347 chr1 199985792 C T 4.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2821347 chr1 199985792 C T 1.16E-05 Pancreatic cancer / / pha002889 rs2737621 chr1 199997403 T C 3.42E-05 Pancreatic cancer NR5A2 intron pha002889 rs2737660 chr1 200002067 T G 1.48E-05 Pancreatic cancer NR5A2 intron pha002874 rs2737660 chr1 200002067 T G 2.64E-05 Pancreatic cancer NR5A2 intron pha002889 rs3790844 chr1 200007432 A G 2.00E-10 Pancreatic cancer NR5A2 intron 20101243 rs3790844 chr1 200007432 A G 2.00E-10 Nasopharyngeal carcinoma NR5A2 intron 20512145 rs3790844 chr1 200007432 A G 2.45E-10 Pancreatic cancer NR5A2 intron pha002889 rs3790843 chr1 200010824 C T 9.00E-05 Cognitive function NR5A2 intron 24684796 rs3790843 chr1 200010824 C T 6.69E-09 Pancreatic cancer NR5A2 intron pha002889 rs4495736 chr1 200013513 T G 2.82E-04 Suicide attempts in bipolar disorder NR5A2 intron 21423239 rs2821367 chr1 200016146 T C 1.89E-06 Pancreatic cancer NR5A2 intron pha002889 rs2737640 chr1 200020261 C T 4.62E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NR5A2 intron 24023788 rs2737641 chr1 200022667 G A 3.30E-05 Creatinine levels NR5A2 intron pha003069 rs2821378 chr1 200023141 G A 5.03E-04 Insulin resistance NR5A2 intron 21901158 rs2821379 chr1 200024300 G A 5.33E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2737645 chr1 200025886 T C 2.52E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2821384 chr1 200031716 G A 3.91E-05 Insulin resistance NR5A2 intron 21901158 rs3006246 chr1 200032080 C A 0.0000526 Type 2 diabetes NR5A2 intron 22325160 rs2821388 chr1 200033769 A G 7.63E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2816916 chr1 200034969 A G 7.97E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs3828112 chr1 200042031 T C 3.78E-05 Neuroblastoma NR5A2 intron pha002895 rs2821319 chr1 200061056 C T 0.00029 Coronary artery calcification NR5A2 intron 23727086 rs2253771 chr1 200068658 C T 7.00E-05 Orofacial clefts NR5A2 intron 22419666 rs3762398 chr1 200090120 G A 9.89E-05 Height NR5A2 intron pha003011 rs3762397 chr1 200090219 C T 2.78E-07 Bone mass and geometry NR5A2 intron 17903296 rs2816958 chr1 200101920 A G 2.00E-17 Ulcerative colitis NR5A2 intron 23128233 rs2737618 chr1 200107425 G A 6.68E-06 Uric acid levels NR5A2 intron 21294900 rs2816953 chr1 200107550 A G 1.60E-05 Urinary metabolites NR5A2 intron 21572414 rs10919819 chr1 200112916 C T 9.06E-05 Epilepsy (remission after treatment) NR5A2 intron 23962720 rs2737627 chr1 200114642 G A 7.89E-05 Epilepsy (remission after treatment) NR5A2 intron 23962720 rs3790794 chr1 200119079 A T 4.18E-04 Smoking quantity NR5A2 intron 24665060 rs10494809 chr1 200132084 C T 0.000003 Stressful life events NR5A2 intron 23237013 rs10494810 chr1 200136582 G A 6.00E-04 Type 2 diabetes and 6 quantitative traits NR5A2 intron 17848626 rs10494810 chr1 200136582 G A 4.30E-04 Obesity-related traits NR5A2 intron 17903300 rs7556640 chr1 200142532 C T 7.19E-05 Multiple complex diseases NR5A2 intron 17554300 rs41348946 chr1 200150164 G A 5.71E-04 Multiple complex diseases / / 17554300 rs12562944 chr1 200162670 C T 4.79E-05 Hemoglobin / / pha003098 rs12562944 chr1 200162670 C T 5.64E-05 Erythrocyte counts / / pha003099 rs12128246 chr1 200197618 A C 1.58E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10800685 chr1 200213790 G A 2.40E-05 Urinary metabolites / / 21572414 rs10800686 chr1 200218981 T C 2.40E-05 Urinary metabolites / / 21572414 rs12562086 chr1 200219020 C T 1.20E-05 Urinary metabolites / / 21572414 rs12047019 chr1 200222777 A G 2.20E-05 Urinary metabolites / / 21572414 rs12047019 chr1 200222777 A G 7.23E-04 Smoking cessation / / 24665060 rs10919870 chr1 200234381 A C 1.13E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10919870 chr1 200234381 A C 2.05E-04 Lung function (forced vital capacity) / / 24023788 rs41377147 chr1 200243838 C T 3.93E-05 Multiple complex diseases / / 17554300 rs10919876 chr1 200247025 T C 2.00E-04 Lung function (forced vital capacity) / / 24023788 rs10919876 chr1 200247025 T C 3.05E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2185277 chr1 200263870 C T 5.59E-04 Multiple complex diseases / / 17554300 rs6427818 chr1 200267231 T C 9.91E-04 Multiple complex diseases / / 17554300 rs940398 chr1 200269369 T C 6.20E-04 Multiple complex diseases / / 17554300 rs2790125 chr1 200285880 T C 4.46E-04 Multiple complex diseases / / 17554300 rs2790125 chr1 200285880 T C 9.08E-05 Serum metabolites / / 19043545 rs2808489 chr1 200286485 C T 4.17E-04 Multiple complex diseases / / 17554300 rs2808473 chr1 200293042 C T 2.22E-04 Depression (quantitative trait) / / 20800221 rs10919897 chr1 200300037 C A 1.82E-04 Multiple complex diseases / / 17554300 rs2808477 chr1 200300299 G A 3.42E-04 Multiple complex diseases / / 17554300 rs2808477 chr1 200300299 G A 2.32E-05 Serum metabolites / / 19043545 rs2790109 chr1 200311868 C G 3.28E-04 Glycosylated haemoglobin levels / / 17255346 rs2808484 chr1 200318170 C T 2.50E-05 Urinary metabolites C1orf98 intron 21572414 rs2808500 chr1 200330479 A G 2.40E-05 Urinary metabolites C1orf98 intron 21572414 rs2808502 chr1 200331702 A G 1.34E-04 Multiple complex diseases C1orf98 intron 17554300 rs2808502 chr1 200331702 A G 2.64E-05 Serum metabolites C1orf98 intron 19043545 rs1572768 chr1 200368352 G T 1.30E-05 Urinary metabolites / / 21572414 rs12117955 chr1 200425433 C A 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs12058730 chr1 200437506 A G 2.69E-05 Anxiety in major depressive disorder / / 24047446 rs9287107 chr1 200438701 A G 9.51E-05 Body mass (lean) / / 19268274 rs12146113 chr1 200443118 G A 4.90E-05 Parkinson's disease (age of onset) / / 19772629 rs16846760 chr1 200446986 G A 1.90E-05 Urinary metabolites / / 21572414 rs6427833 chr1 200469505 T C 3.59E-04 Type 2 diabetes / / 17463246 rs6680807 chr1 200471464 C A 9.97E-05 Left ventricular hypertrophy / / pha003052 rs10919966 chr1 200502569 T C 1.58E-04 Type 2 diabetes / / 17463246 rs6682828 chr1 200507096 G A 7.03E-04 Multiple complex diseases / / 17554300 rs6686605 chr1 200508568 C T 2.94E-04 Type 2 diabetes / / 17463246 rs10919973 chr1 200520443 G C 8.78E-04 Type 2 diabetes / / 17463246 rs6693825 chr1 200531923 T C 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs7518491 chr1 200534009 A G 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs7543730 chr1 200534248 C T 9.12E-04 Type 2 diabetes KIF14 cds-synon 17463246 rs10753877 chr1 200549590 T C 9.12E-04 Type 2 diabetes KIF14 intron 17463246 rs6699100 chr1 200552388 C T 9.12E-04 Type 2 diabetes KIF14 intron 17463246 rs4504918 chr1 200557767 C T 2.76E-04 Type 2 diabetes KIF14 intron 17463246 rs6665951 chr1 200558363 T C 1.84E-04 Type 2 diabetes KIF14 cds-synon 17463246 rs12117521 chr1 200560094 C T 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2808238 chr1 200574959 T C 4.21E-04 Smoking initiation KIF14 intron 24665060 rs2794410 chr1 200575794 A G 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2794410 chr1 200575794 A G 5.47E-04 Smoking initiation KIF14 intron 24665060 rs10800716 chr1 200580709 A T 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2808241 chr1 200583380 T G 2.48E-04 Smoking initiation KIF14 intron 24665060 rs201051794 chr1 200592547 A AACT 4.13E-04 Type 2 diabetes / / 17463246 rs2808250 chr1 200592547 A T 4.13E-04 Type 2 diabetes / / 17463246 rs12744758 chr1 200593138 G A 7.51E-04 Type 2 diabetes / / 17463246 rs4915447 chr1 200593468 T A 9.04E-04 Type 2 diabetes / / 17463246 rs2808257 chr1 200594005 C T 0.0000013 Inter-adventitial common carotid artery diameter / / 23246012 rs12728040 chr1 200595879 G A 7.51E-04 Type 2 diabetes / / 17463246 rs7529962 chr1 200596977 T C 2.56E-04 Type 2 diabetes / / 17463246 rs2809361 chr1 200622353 C T 1.36E-04 Amyotrophic lateral sclerosis (sporadic) DDX59 intron 24529757 rs6656619 chr1 200640792 T C 5.09E-04 Type 2 diabetes / / 17463246 rs6656619 chr1 200640792 T C 4.71E-04 Schizophrenia / / 20832056 rs4387211 chr1 200645938 A T 4.23E-04 Schizophrenia / / 20832056 rs6700559 chr1 200646073 C T 6.18E-04 Type 2 diabetes / / 17463246 rs6700559 chr1 200646073 C T 3.58E-04 Schizophrenia / / 20832056 rs6700559 chr1 200646073 C T 0.000000765 Coronary artery disease / / 23202125 rs7535122 chr1 200672699 A G 7.10E-06 Electrocardiographic conduction measures / / 19389651 rs7512898 chr1 200672906 G T 5.00E-06 Electrocardiographic conduction measures / / 19389651 rs6660197 chr1 200703541 C T 6.78E-05 Epilepsy / / 22116939 rs10449265 chr1 200703906 T A 4.91E-04 Multiple complex diseases / / 17554300 rs10494819 chr1 200704754 C T 3.17E-04 Type 2 diabetes / / 17463246 rs17750695 chr1 200721265 A G 1.50E-05 Anxiety in major depressive disorder CAMSAP2 intron 24047446 rs6658596 chr1 200748921 C T 7.92E-04 Multiple complex diseases CAMSAP2 intron 17554300 rs12742404 chr1 200811765 A G 6.39E-06 Epilepsy CAMSAP2 intron 22116939 rs16830092 chr1 200823498 T C 8.17E-04 Insulin resistance CAMSAP2 intron 21901158 rs2292096 chr1 200826769 A G 1.00E-08 Epilepsy CAMSAP2 intron 22116939 rs2292096 chr1 200826769 A G 0.0000589 Coronary artery disease CAMSAP2 intron 23202125 rs6702767 chr1 200844547 A G 0.00000097 Myopia (Age of onset) / / 23468642 rs3753955 chr1 200857774 T C 7.70E-04 Type 2 diabetes / / 17463246 rs3767494 chr1 200871216 G A 5.50E-04 Coronary Artery Disease C1orf106 intron 17634449 rs7554511 chr1 200877562 C A 1.89E-07 Multiple complex diseases C1orf106 intron 17554300 rs7554511 chr1 200877562 C A 1.00E-06 Ulcerative colitis C1orf106 intron 19915572 rs7554511 chr1 200877562 C A 2.00E-07 Crohn's disease C1orf106 intron 21102463 rs7554511 chr1 200877562 C A 2.00E-13 Ulcerative colitis C1orf106 intron 21297633 rs7554511 chr1 200877562 C A 1.00E-32 Inflammatory bowel disease C1orf106 intron 23128233 rs4915463 chr1 200879302 A G 6.34E-04 Amyotrophic Lateral Sclerosis C1orf106 intron 17362836 rs10800746 chr1 200881392 C T 2.60E-08 Celiac disease C1orf106 intron 22057235 rs7522462 chr1 200881595 G A 5.68E-07 Multiple complex diseases C1orf106 intron 17554300 rs7522462 chr1 200881595 G A 2.00E-09 Multiple sclerosis C1orf106 intron 21833088 rs7522462 chr1 200881595 G A 8.30E-04 Multiple sclerosis C1orf106 intron 24234648 rs378672 chr1 200886333 C G 1.52E-04 Multiple complex diseases / / 17554300 rs378672 chr1 200886333 C G 3.60E-05 Ankylosing spondylitis / / 21743469 rs404339 chr1 200886891 C G 4.30E-06 Multiple complex diseases / / 17554300 rs296543 chr1 200889833 T C 6.52E-05 Age-related macular degeneration / / pha000002 rs296547 chr1 200892137 T C 4.00E-09 Celiac disease / / 20190752 rs296547 chr1 200892137 T C 4.00E-09 Asthma / / 21150878 rs296547 chr1 200892137 T C 4.11E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs296547 chr1 200892137 T C 4.11E-09 Multiple sclerosis / / 22190364 rs296513 chr1 200906473 G A 1.65E-04 Multiple complex diseases / / 17554300 rs11579874 chr1 200920362 G A 7.90E-06 Multiple complex diseases / / 17554300 rs1572789 chr1 200932305 G A 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11584383 chr1 200935866 T C 4.21E-04 Type 2 diabetes / / 17463246 rs11584383 chr1 200935866 T C 2.90E-05 Multiple complex diseases / / 17554300 rs11584383 chr1 200935866 T C 1.00E-11 Crohn's disease / / 18587394 rs11584383 chr1 200935866 T C 2.00E-07 Ulcerative colitis / / 20228799 rs11584383 chr1 200935866 T C 1.00E-11 Asthma / / 21150878 rs11584383 chr1 200935866 T C 1.43E-11 Multiple sclerosis / / 22190364 rs11584383 chr1 200935866 T C 4.54E-05 Smoking quantity / / 24665060 rs10494828 chr1 200957032 G A 5.13E-05 Age-related macular degeneration KIF21B intron pha000002 rs2297909 chr1 200960307 G A 8.10E-10 Crohn's disease KIF21B intron 18587394 rs2297909 chr1 200960307 G A 5.00E-12 Ankylosing spondylitis KIF21B intron 21743469 rs2297909 chr1 200960307 G A 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) KIF21B intron 23453885 rs6687260 chr1 200980698 A G 5.60E-04 Multiple complex diseases KIF21B intron 17554300 rs6700264 chr1 200984022 A G 6.66E-04 Multiple complex diseases KIF21B intron 17554300 rs12122721 chr1 200984480 G A 9.90E-06 Multiple complex diseases KIF21B intron 17554300 rs12122721 chr1 200984480 G A 1.00E-06 Multiple sclerosis KIF21B intron 21833088 rs17419032 chr1 200998531 C T 1.21E-05 Multiple complex diseases / / 17554300 rs11583328 chr1 201002173 G A 6.06E-05 Multiple complex diseases / / 17554300 rs3767498 chr1 201020727 A G 6.89E-04 Smoking initiation CAC/1S intron 24665060 rs2297903 chr1 201031307 A C 9.77E-04 Suicide attempts in bipolar disorder CAC/1S intron 21423239 rs9427712 chr1 201041198 G A 3.70E-04 Response to taxane treatment (placlitaxel) CAC/1S intron 23006423 rs9427713 chr1 201041364 G A 2.66E-04 Response to taxane treatment (placlitaxel) CAC/1S intron 23006423 rs2886329 chr1 201041480 A G 1.50E-05 Response to antidepressants CAC/1S intron 19736353 rs3820422 chr1 201045473 A G 3.34E-07 Schizophrenia CAC/1S intron 21926974 rs2365293 chr1 201075245 T C 2.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1S intron 20877124 rs2281845 chr1 201081943 C T 8.00E-17 Permanent tooth development CAC/1S nearGene-5 21931568 rs1536127 chr1 201086894 C A 8.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs7547762 chr1 201088245 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs942703 chr1 201092979 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs6704363 chr1 201096383 A G 3.80E-06 Primary tooth development (number of teeth) / / 23704328 rs2057579 chr1 201099275 T C 2.60E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs10800760 chr1 201100439 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs12025414 chr1 201100496 A G 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs11589642 chr1 201100748 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs6697303 chr1 201101413 C T 3.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs6694122 chr1 201121523 T C 2.04E-04 Substance dependence TMEM9 intron 21818250 rs7542768 chr1 201125326 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6413916 chr1 201139616 G A 2.07E-04 Multiple complex diseases / / 17554300 rs831768 chr1 201149033 C T 4.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs16847994 chr1 201156566 C T 3.08E-04 Coronary Artery Disease / / 17634449 rs831752 chr1 201157146 C A 2.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs1107128 chr1 201163191 G T 2.00E-04 Cognitive impairment induced by topiramate IGFN1 intron 22091778 rs4915221 chr1 201166383 G A 1.00E-04 Cognitive impairment induced by topiramate IGFN1 missense 22091778 rs2365299 chr1 201169554 T G 2.00E-04 Cognitive impairment induced by topiramate IGFN1 intron 22091778 rs832159 chr1 201173150 C A 4.28E-04 Multiple complex diseases IGFN1 intron 17554300 rs832159 chr1 201173150 C A 6.23E-04 Alzheimer's disease IGFN1 intron 17998437 rs4396148 chr1 201174822 C A 7.07E-04 Multiple complex diseases IGFN1 intron 17554300 rs4396148 chr1 201174822 C A 5.58E-04 Alzheimer's disease IGFN1 intron 17998437 rs3738268 chr1 201187828 T C 2.00E-04 Information processing speed IGFN1 intron 21130836 rs2039959 chr1 201188739 T G 8.98E-04 Multiple complex diseases IGFN1 intron 17554300 rs4915224 chr1 201190307 A G 2.00E-04 Information processing speed IGFN1 intron 21130836 rs6687300 chr1 201193499 G T 3.86E-04 Amyotrophic Lateral Sclerosis IGFN1 intron 17362836 rs6687494 chr1 201193668 G T 7.52E-05 Information processing speed IGFN1 intron 21130836 rs2365642 chr1 201235086 A G 4.11E-06 Waist circumference / / 19557197 rs7517345 chr1 201256533 G A 6.79E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs16848229 chr1 201257373 A G 9.80E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs832174 chr1 201258519 A T 8.95E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs860554 chr1 201262432 C T 5.00E-08 Panic disorder PKP1 intron 19165232 rs832147 chr1 201269687 C G 6.81E-05 Asthma PKP1 intron 11022011 rs34626929 chr1 201282334 G A 0.000000594 Triglycerides PKP1 missense 23063622 rs6690976 chr1 201305625 C T 0.000603 Salmonella-induced pyroptosis / / 22837397 rs12126907 chr1 201312033 A G 3.81E-05 Psoriasis / / 20953187 rs16848403 chr1 201315182 A G 0.00057 Salmonella-induced pyroptosis / / 22837397 rs2275863 chr1 201328824 G A 7.40E-05 Alcoholism (heaviness of drinking) TNNT2 intron 21529783 rs3729842 chr1 201337170 A G 3.04E-04 Type 2 diabetes TNNT2 intron 17846125 rs6427901 chr1 201340813 G A 9.70E-04 Amyotrophic lateral sclerosis (sporadic) TNNT2 intron 24529757 rs868407 chr1 201341341 C T 6.70E-05 Coronary heart disease TNNT2 intron 21966275 rs6663175 chr1 201341850 C T 7.25E-10 Triglycerides TNNT2 intron 23063622 rs3020556 chr1 201343115 C G 5.51E-08 Cardiac Troponin-T levels TNNT2 intron 23247143 rs12564445 chr1 201345487 G A 5.00E-08 Cardiac Troponin-T levels TNNT2 intron 23247143 rs2799686 chr1 201347315 A G 1.60E-05 Alcoholism (heaviness of drinking) TNNT2 nearGene-5 21529783 rs3738281 chr1 201358304 C A 2.11E-04 Height LAD1 missense 17255346 rs12408988 chr1 201410585 A G 1.56E-04 Alzheimer's disease (late onset) / / 21379329 rs7525711 chr1 201419375 G A 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs7553988 chr1 201421082 A G 9.53E-04 Alzheimer's disease / / 24755620 rs10920205 chr1 201422201 G A 7.30E-05 Memory performance / / 22105620 rs10753902 chr1 201422348 T C 4.60E-04 Alzheimer's disease (late onset) / / 21379329 rs371169997 chr1 201422348 TAA T 4.60E-04 Alzheimer's disease (late onset) / / 21379329 rs16848610 chr1 201423658 A C 1.93E-05 Asthma / / 11022011 rs3887566 chr1 201423940 G C 3.10E-05 Memory performance / / 22105620 rs12090950 chr1 201429381 G A 1.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12090950 chr1 201429381 G A 4.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs6669318 chr1 201431075 A G 4.75E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs515384 chr1 201464807 T C 1.42E-04 Scoliosis CSRP1 intron 21216876 rs603836 chr1 201465839 T C 6.73E-04 Amyotrophic Lateral Sclerosis CSRP1 intron 17362836 rs10800784 chr1 201466057 A G 1.10E-04 Aortic root size CSRP1 intron 21223598 rs623791 chr1 201475209 C T 0.000042 Colorectal adenoma (excluding hyperplasic) CSRP1 intron 23677573 rs623791 chr1 201475209 C T 0.000042 Colorectal adenoma (including hyperplasic) CSRP1 intron 23677573 rs2038972 chr1 201475727 A C 0.0000375 Colorectal adenoma (excluding hyperplasic) CSRP1 intron 23677573 rs2038972 chr1 201475727 A C 0.0000375 Colorectal adenoma (including hyperplasic) CSRP1 intron 23677573 rs4915235 chr1 201490926 T G 4.71E-05 Blood pressure / / 17255346 rs7552162 chr1 201496207 A G 7.75E-04 Type 2 diabetes / / 17463246 rs4915537 chr1 201500825 C T 3.08E-04 Blood pressure / / 17255346 rs17469306 chr1 201503355 T C 8.09E-04 Type 2 diabetes / / 17463246 rs633696 chr1 201547000 T C 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs1267131 chr1 201547094 A C 5.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1267131 chr1 201547094 A C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs617053 chr1 201547532 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs617053 chr1 201547532 G A 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs511201 chr1 201549296 A G 4.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs511201 chr1 201549296 A G 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs516701 chr1 201549933 A G 8.54E-12 Narcolepsy / / 19629137 rs585041 chr1 201551007 T A 5.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs585041 chr1 201551007 T A 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs677390 chr1 201551788 A G 5.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs608356 chr1 201560163 A G 5.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs625436 chr1 201561675 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs685982 chr1 201562604 T A 5.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs2068824 chr1 201594665 T C 6.00E-06 Celiac disease / / 23936387 rs495198 chr1 201606116 G A 2.19E-06 Asthma / / 11022011 rs724220 chr1 201630461 T G 2.46E-05 Blood Pressure /V1 intron pha002903 rs586688 chr1 201630955 G A 8.00E-06 Obesity-related traits /V1 intron 23251661 rs492563 chr1 201631471 T C 1.81E-04 Alzheimer's disease /V1 intron 17998437 rs647130 chr1 201637982 C T 2.87E-04 Alzheimer's disease /V1 intron 17998437 rs7523519 chr1 201647654 G T 6.35E-04 Alzheimer's disease /V1 intron 24755620 rs602668 chr1 201657709 C T 8.18E-06 Alzheimer's disease /V1 intron 17998437 rs654631 chr1 201658449 A G 1.30E-05 Alzheimer's disease /V1 intron 17998437 rs606114 chr1 201664101 T C 3.24E-05 Alzheimer's disease /V1 intron 17998437 rs12034680 chr1 201667862 G A 6.16E-04 Alzheimer's disease /V1 intron 24755620 rs239967 chr1 201692871 G A 5.80E-08 Metabolite levels /V1 intron 23281178 rs7535989 chr1 201732694 T G 1.70E-04 Amyotrophic lateral sclerosis (sporadic) /V1 intron 24529757 rs7551784 chr1 201767249 C T 4.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) /V1 intron 22566498 rs4379719 chr1 201775746 G A 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) /V1 intron 23648065 rs1043823 chr1 201845432 C T 5.64E-05 Caffeine consumption IPO9 UTR-3 21490707 rs2820315 chr1 201872264 C T 0.00000168 Coronary artery disease LMOD1 intron 23202125 rs2819346 chr1 201882087 A C 9.82E-04 Type 2 diabetes LMOD1 intron 17463246 rs2819346 chr1 201882087 A C 1.56E-04 Multiple complex diseases LMOD1 intron 17554300 rs4494199 chr1 201884668 A G 2.90E-04 Coronary heart disease LMOD1 intron 21966275 rs2819348 chr1 201884952 T C 3.00E-06 Breast size LMOD1 intron 22747683 rs2820300 chr1 201908678 A G 7.45E-04 Multiple complex diseases LMOD1 intron 17554300 rs2820300 chr1 201908678 A G 2.53E-10 LDL cholesterol LMOD1 intron 23063622 rs2819368 chr1 201910563 C T 9.84E-15 LDL cholesterol LMOD1 intron 23063622 rs2820301 chr1 201912822 G A 1.19E-10 LDL cholesterol LMOD1 intron 23063622 rs2819371 chr1 201915658 A C 1.60E-12 LDL cholesterol / / 23063622 rs2820304 chr1 201918527 T G 5.57E-05 Parkinson's disease / / 17052657 rs2820306 chr1 201923805 A G 7.91E-04 Myopia (pathological) / / 21095009 rs12090635 chr1 201936324 A G 5.87E-04 Suicide attempts in bipolar disorder TIMM17A intron 21423239 rs12754196 chr1 201940216 C T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7529387 chr1 201950038 G A 9.70E-15 Butyrylcholinesterase levels / / 21862451 rs4950806 chr1 201952574 T C 9.00E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs11590299 chr1 201953596 T A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs6689324 chr1 201954697 C T 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs11586632 chr1 201955614 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs4950752 chr1 201956427 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs10800805 chr1 201959738 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs2819358 chr1 201976402 T G 5.58E-04 Osteoarthritis (knee and hip) LOC100289488 intron 21177295 rs2819358 chr1 201976402 T G 6.13E-05 Osteoarthritis (knee and hip) LOC100289488 intron 21177295 rs2819358 chr1 201976402 T G 1.39E-04 Pancreatic cancer LOC100289488 intron pha002874 rs2819361 chr1 201980119 C G 2.90E-04 Obesity (extreme) ELF3 intron 21935397 rs2819365 chr1 201983242 C T 6.98E-05 Lung adenocarcinoma ELF3 intron 19836008 rs6661833 chr1 202037007 C A 7.53E-05 Waist Circumference / / pha003023 rs9427727 chr1 202038945 T C 9.77E-05 Schizophrenia / / 19197363 rs4436440 chr1 202052013 T A 5.16E-07 Asthma / / 11022011 rs10800812 chr1 202055938 A G 1.62E-08 Asthma / / 11022011 rs4329563 chr1 202090641 C G 1.35E-04 Response to TNF antagonist treatment / / 21061259 rs6701064 chr1 202093735 G T 6.28E-04 Response to TNF antagonist treatment GPR37L1 intron 21061259 rs12069950 chr1 202101443 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17435204 chr1 202106996 T C 2.67E-04 Nicotine dependence ARL8A intron 17158188 rs10920357 chr1 202151566 A G 2.75E-04 Response to taxane treatment (placlitaxel) PTPRVP intron 23006423 rs1823696 chr1 202167176 C T 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LGR6 intron 20877124 rs17489300 chr1 202179042 A C 9.52E-04 Multiple complex diseases LGR6 intron 17554300 rs116439821 chr1 202184821 C T 1.55E-05 Cocaine dependence LGR6 intron 23958962 rs6678914 chr1 202187176 G A 1.00E-08 Breast cancer LGR6 intron 23535733 rs896549 chr1 202205323 A G 5.17E-05 Cognitive performance LGR6 intron 19734545 rs2993444 chr1 202239771 C T 1.00E-04 Information processing speed LGR6 intron 21130836 rs2924100 chr1 202243688 A G 1.00E-04 Information processing speed LGR6 intron 21130836 rs788829 chr1 202265521 G A 2.00E-04 Information processing speed LGR6 intron 21130836 rs705768 chr1 202281006 G T 9.43E-05 Erythrocyte counts LGR6 intron pha003101 rs11583656 chr1 202370997 C T 6.86E-04 Multiple complex diseases PPP1R12B intron 17554300 rs12734001 chr1 202390914 C T 2.79E-07 Asthma PPP1R12B intron 21790008 rs12734001 chr1 202390914 C T 4.03E-05 Parkinson's disease PPP1R12B intron 21812969 rs12734001 chr1 202390914 C T 3.51E-09 Prion diseases PPP1R12B intron 22210626 rs12734001 chr1 202390914 C T 6.06E-15 Gender PPP1R12B intron 22362730 rs12734001 chr1 202390914 C T 2.32E-05 Celiac disease PPP1R12B intron 23936387 rs12739262 chr1 202391743 C T 1.00E-06 Obesity-related traits PPP1R12B intron 23251661 rs805911 chr1 202440419 C T 1.91E-04 Multiple complex diseases PPP1R12B intron 17554300 rs3817222 chr1 202464760 C T 2.18E-07 Asthma PPP1R12B missense 21790008 rs3817222 chr1 202464760 C T 1.02E-30 Gender PPP1R12B missense 22362730 rs3817227 chr1 202464842 A G 6.06E-15 Gender PPP1R12B intron 22362730 rs12734338 chr1 202469723 T C 8.98E-04 Amyotrophic Lateral Sclerosis PPP1R12B intron 17362836 rs12734338 chr1 202469723 T C 1.46E-05 HIV-1 viral setpoint PPP1R12B intron 17641165 rs12734338 chr1 202469723 T C 2.60E-05 HIV-1 control PPP1R12B intron 20041166 rs12734338 chr1 202469723 T C 1.70E-06 Asthma PPP1R12B intron 20698975 rs12734338 chr1 202469723 T C 3.57E-31 Gender PPP1R12B intron 22362730 rs12734338 chr1 202469723 T C 3.00E-07 Celiac disease PPP1R12B intron 23936387 rs12734338 chr1 202469723 T C 3.00E-07 Coronary heart disease PPP1R12B intron 24778558 rs12741415 chr1 202474774 G A 1.76E-25 Gender PPP1R12B intron 22362730 rs12743401 chr1 202476648 T C 9.13E-04 Amyotrophic Lateral Sclerosis PPP1R12B intron 17362836 rs12743401 chr1 202476648 T C 1.46E-05 HIV-1 viral setpoint PPP1R12B intron 17641165 rs12743401 chr1 202476648 T C 4.20E-06 Asthma PPP1R12B intron 20698975 rs12743401 chr1 202476648 T C 1.02E-30 Gender PPP1R12B intron 22362730 rs4084639 chr1 202510164 G C 6.06E-15 Gender PPP1R12B intron 22362730 rs3881953 chr1 202528021 G A 5.53E-04 Amyotrophic Lateral Sclerosis PPP1R12B missense 17362836 rs3881953 chr1 202528021 G A 4.26E-31 Gender PPP1R12B missense 22362730 rs585658 chr1 202573179 C T 0.000032 Mean arterial pressure SYT2 intron 22510845 rs16830648 chr1 202595153 A G 2.91E-04 Multiple complex diseases SYT2 intron 17554300 rs10494835 chr1 202602197 C T 3.30E-04 Heroin addiction SYT2 intron 20520587 rs12404969 chr1 202622426 C T 2.00E-05 Urinary metabolites SYT2 intron 21572414 rs2153441 chr1 202628576 T C 7.68E-05 Bipolar disorder and schizophrenia SYT2 intron 20889312 rs7517181 chr1 202629745 T C 2.60E-05 Urinary metabolites SYT2 intron 21572414 rs10920452 chr1 202641340 G A 7.54E-04 Type 2 diabetes SYT2 intron 17463246 rs11588808 chr1 202667492 A G 2.30E-05 Urinary metabolites SYT2 intron 21572414 rs7529811 chr1 202688077 A G 6.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs3820153 chr1 202725286 A G 5.09E-04 Type 2 diabetes KDM5B intron 17463246 rs12132801 chr1 202726145 G A 2.00E-04 Cognitive impairment induced by topiramate KDM5B intron 22091778 rs7519148 chr1 202734579 A G 5.13E-05 Bipolar disorder and schizophrenia KDM5B intron 20889312 rs12132992 chr1 202761823 C G 2.13E-04 Type 2 diabetes KDM5B intron 17463246 rs17497724 chr1 202808605 A G 5.75E-05 Cognitive test performance / / 20125193 rs6699298 chr1 202853593 C T 9.19E-04 Obesity (extreme) RABIF intron 21935397 rs3806346 chr1 202859600 A G 8.99E-04 Obesity (extreme) / / 21935397 rs3766572 chr1 202860067 T C 8.87E-04 Obesity (extreme) / / 21935397 rs12089566 chr1 202861342 A G 1.39E-04 Smoking initiation / / 24665060 rs10920519 chr1 202866331 A C 8.84E-04 Obesity (extreme) KLHL12 intron 21935397 rs7542125 chr1 202871238 T C 8.79E-04 Obesity (extreme) KLHL12 intron 21935397 rs10800877 chr1 202884063 C T 4.81E-04 Smoking initiation KLHL12 intron 24665060 rs10800880 chr1 202892917 T C 9.61E-04 Obesity (extreme) KLHL12 intron 21935397 rs10800891 chr1 202947596 T C 1.98E-05 Multiple complex diseases / / 17554300 rs16850854 chr1 202956588 G T 8.83E-04 Multiple complex diseases / / 17554300 rs1046529 chr1 202992954 T C 9.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TMEM183A UTR-3 21844884 rs10920553 chr1 203008286 C G 4.80E-06 Urinary metabolites LOC100507405 cds-synon 21572414 rs3820151 chr1 203046534 A G 2.40E-05 Brain structure PPFIA4 UTR-3 22504417 rs115855025 chr1 203054980 C T 0.00089 Breast cancer MYOG missense 23555315 rs58592594 chr1 203058476 C T 3.64E-04 Alcohol consumption / / 23743675 rs1038984 chr1 203058842 G A 3.32E-04 Alcohol consumption / / 23743675 rs7549561 chr1 203106390 A G 0.000163432 Hypertension (early onset hypertension) ADORA1 intron 22479346 rs10800901 chr1 203111304 A G 5.97E-04 Multiple complex diseases ADORA1 intron 17554300 rs3766560 chr1 203118394 C T 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA1 intron 20877124 rs17465037 chr1 203130671 G A 6.27E-04 Amyotrophic lateral sclerosis (sporadic) ADORA1 intron 24529757 rs3753472 chr1 203131533 T C 8.17E-04 Amyotrophic Lateral Sclerosis ADORA1 intron 17362836 rs16851020 chr1 203133652 G T 4.14E-05 Asthma ADORA1 intron 11022011 rs16851020 chr1 203133652 G T 1.90E-05 Urinary metabolites ADORA1 intron 21572414 rs16851020 chr1 203133652 G T 9.96E-05 Blood pressure (response to angiotensin II receptor blocker) ADORA1 intron 24192120 rs2250509 chr1 203138970 A G 1.80E-04 Type 2 diabetes MYBPH intron 17463246 rs2071580 chr1 203149154 C T 6.50E-05 Schizophrenia(age at onset) CHI3L1 intron 21688384 rs4950928 chr1 203155882 G C 1.00E-13 YKL-40 levels CHI3L1 UTR-5 18403759 rs6691378 chr1 203157122 G A 3.76E-05 Asthma CHI3L1 nearGene-5 11022011 rs4950929 chr1 203160126 G T 1.32E-12 Asthma / / 11022011 rs946263 chr1 203165381 G A 9.74E-13 Asthma / / 11022011 rs2153101 chr1 203168474 A T 9.74E-13 Asthma / / 11022011 rs946264 chr1 203169492 A C 4.90E-04 Multiple complex diseases / / 17554300 rs2486949 chr1 203173356 T C 4.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs2486949 chr1 203173356 T C 2.19E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12042412 chr1 203173656 C T 0.000121631 Hypertension (early onset hypertension) / / 22479346 rs2244385 chr1 203191262 C G 7.40E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486067 chr1 203191866 C T 5.29E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486961 chr1 203191904 C T 5.22E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486962 chr1 203191920 G A 2.00E-04 Cognitive impairment induced by topiramate CHIT1 intron 22091778 rs2486068 chr1 203193134 T G 3.85E-04 Alzheimer's disease CHIT1 intron 22005930 rs137852607 chr1 203194834 C T 0.00076 Breast cancer CHIT1 missense 23555315 rs2486070 chr1 203195689 G A 2.93E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486071 chr1 203196479 A C 1.98E-04 Alzheimer's disease CHIT1 intron 22005930 rs17533071 chr1 203200196 T C 4.50E-05 Response to Vitamin E supplementation CHIT1 nearGene-5 22437554 rs2494283 chr1 203202902 T C 1.10E-05 Urinary metabolites / / 21572414 rs2494286 chr1 203206709 T A 1.20E-05 Urinary metabolites / / 21572414 rs2494287 chr1 203207520 T C 1.50E-05 Urinary metabolites / / 21572414 rs2494292 chr1 203215064 A T 2.50E-05 Urinary metabolites / / 21572414 rs2486925 chr1 203234037 T G 1.50E-05 Urinary metabolites / / 21572414 rs884926 chr1 203295794 G A 1.42E-05 Height / / pha003010 rs884926 chr1 203295794 G A 9.02E-06 Height / / pha003011 rs6665383 chr1 203299849 G C 2.27E-04 Multiple complex diseases / / 17554300 rs6665383 chr1 203299849 G C 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6428000 chr1 203300916 C T 2.60E-05 Urinary metabolites / / 21572414 rs2364940 chr1 203307072 T G 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7543493 chr1 203308406 T C 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12739111 chr1 203308801 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12757745 chr1 203308968 G A 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12757745 chr1 203308968 G A 7.16E-05 Height / / pha003010 rs12757745 chr1 203308968 G A 3.12E-05 Height / / pha003011 rs12723309 chr1 203309028 G A 2.50E-05 Urinary metabolites / / 21572414 rs3738020 chr1 203309512 G T 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs3738021 chr1 203309616 T C 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2886220 chr1 203309752 T C 2.14E-04 Suicide attempts in bipolar disorder FMOD UTR-3 21423239 rs7208 chr1 203309880 G A 2.16E-04 Suicide attempts in bipolar disorder FMOD UTR-3 21423239 rs10800912 chr1 203312960 G A 7.52E-04 Suicide attempts in bipolar disorder FMOD intron 21423239 rs10800913 chr1 203315893 G A 8.54E-04 Alcohol consumption (maxi-drinks) FMOD intron 24277619 rs1891174 chr1 203323636 G A 4.92E-04 Multiple complex diseases / / 17554300 rs12756933 chr1 203338525 G T 6.50E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6697045 chr1 203347210 A G 4.82E-05 Cognitive test performance / / 20125193 rs7543408 chr1 203352135 G C 6.03E-04 Type 2 diabetes / / 17463246 rs6428009 chr1 203361173 G C 6.92E-05 Schizophrenia / / pha002859 rs10920631 chr1 203367047 T C 5.06E-05 Cognitive test performance / / 20125193 rs879446 chr1 203371570 C T 1.20E-05 Urinary metabolites / / 21572414 rs1539143 chr1 203372485 G A 1.00E-06 Obesity-related traits / / 23251661 rs13328676 chr1 203377559 G C 5.40E-05 Pericardial fat / / 22589742 rs1417925 chr1 203403117 T G 4.30E-06 Urinary metabolites / / 21572414 rs6681328 chr1 203404635 G A 4.90E-05 Pericardial fat / / 22589742 rs999051 chr1 203411859 T C 5.60E-06 Urinary metabolites / / 21572414 rs9439 chr1 203455902 A C 0.00019 Breast cancer PRELP missense 23555315 rs2242204 chr1 203457961 T C 8.50E-06 Urinary metabolites PRELP UTR-3 21572414 rs2242203 chr1 203458037 A T 6.10E-06 Urinary metabolites PRELP UTR-3 21572414 rs16851713 chr1 203460673 T C 4.30E-06 Urinary metabolites PRELP nearGene-3 21572414 rs2279127 chr1 203472941 A G 5.28E-05 Nephrolithiasis OPTC intron 22396660 rs2279127 chr1 203472941 A G 4.30E-06 Pericardial fat OPTC intron 22589742 rs13303252 chr1 203485142 C T 8.16E-04 Body mass index / / 21701565 rs6688116 chr1 203492121 A G 1.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13303128 chr1 203492720 C T 9.00E-06 Metabolite levels (MHPG) / / 23319000 rs2802782 chr1 203571766 T G 2.17E-04 Obesity (extreme) / / 21935397 rs6593903 chr1 203584850 C T 0.0000273 Height (Pygmy height) / / 22570615 rs9645427 chr1 203587406 G C 9.12E-04 Obesity (extreme) / / 21935397 rs12120868 chr1 203587538 G T 4.71E-04 Obesity (extreme) / / 21935397 rs4951276 chr1 203599192 T A 8.17E-04 Lymphocyte counts ATP2B4 intron 22286170 rs10736845 chr1 203650786 T C 2.10E-07 Red blood cell traits ATP2B4 intron 23222517 rs10751451 chr1 203650978 C T 2.75E-07 Red blood cell traits ATP2B4 intron 23222517 rs11240734 chr1 203651824 C T 1.18E-11 Red blood cell traits ATP2B4 intron 23222517 rs1541252 chr1 203651927 T C 5.13E-07 Red blood cell traits ATP2B4 UTR-5 23222517 rs1541252 chr1 203651927 T C 9.00E-08 Mean corpuscular hemoglobin concentration ATP2B4 UTR-5 23263863 rs1541253 chr1 203652040 T C 3.05E-07 Red blood cell traits ATP2B4 UTR-5 23222517 rs1541254 chr1 203652140 C G 2.33E-11 Red blood cell traits ATP2B4 UTR-5 23222517 rs1419114 chr1 203652444 A G 4.61E-11 Red blood cell traits ATP2B4 cds-synon 23222517 rs4951070 chr1 203652698 T C 2.46E-07 Red blood cell traits ATP2B4 intron 23222517 rs10900585 chr1 203654024 G T 2.00E-10 Malaria ATP2B4 intron 22895189 rs6658130 chr1 203654568 G A 2.10E-07 Red blood cell traits ATP2B4 intron 23222517 rs6594006 chr1 203654738 A G 1.17E-11 Red blood cell traits ATP2B4 intron 23222517 rs6594007 chr1 203654772 A G 9.97E-12 Red blood cell traits ATP2B4 intron 23222517 rs6594008 chr1 203654851 T C 1.77E-07 Red blood cell traits ATP2B4 intron 23222517 rs7539122 chr1 203655043 C T 9.90E-12 Red blood cell traits ATP2B4 intron 23222517 rs7551442 chr1 203655121 A G 9.72E-12 Red blood cell traits ATP2B4 intron 23222517 rs7551560 chr1 203655270 A G 1.00E-11 Red blood cell traits ATP2B4 intron 23222517 rs7554335 chr1 203655743 A G 2.29E-07 Red blood cell traits ATP2B4 intron 23222517 rs4951375 chr1 203655785 T G 1.80E-07 Red blood cell traits ATP2B4 intron 23222517 rs2365860 chr1 203656230 G T 1.37E-11 Red blood cell traits ATP2B4 intron 23222517 rs10900588 chr1 203656814 G A 8.85E-07 Red blood cell traits ATP2B4 intron 23222517 rs10900589 chr1 203656974 A T 2.47E-11 Red blood cell traits ATP2B4 intron 23222517 rs2365858 chr1 203657749 C G 1.49E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951377 chr1 203658471 A G 1.05E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951378 chr1 203658782 A G 1.36E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951074 chr1 203660781 A G 1.80E-08 Malaria ATP2B4 intron 22895189 rs4951074 chr1 203660781 A G 6.33E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951381 chr1 203660838 A G 2.26E-11 Red blood cell traits ATP2B4 intron 23222517 rs2228445 chr1 203667409 T C 2.65E-07 Red blood cell traits ATP2B4 cds-synon 23222517 rs4951107 chr1 203687154 T G 3.74E-05 Parkinson's disease (motor and cognition) ATP2B4 intron 22658654 rs4951107 chr1 203687154 T G 3.74E-05 Immune response to anthrax vaccine ATP2B4 intron 22658931 rs11808688 chr1 203689314 A G 4.27E-05 Parkinson's disease (motor and cognition) ATP2B4 intron 22658654 rs11808688 chr1 203689314 A G 4.27E-05 Immune response to anthrax vaccine ATP2B4 intron 22658931 rs970 chr1 203712996 T C 6.52E-04 Iron levels ATP2B4 UTR-3 pha002876 rs3820195 chr1 203740462 G A 4.98E-04 Alzheimer's disease LAX1 intron 22005930 rs3737975 chr1 203740803 G C 7.72E-04 Alzheimer's disease LAX1 intron 22005930 rs3737973 chr1 203741368 C A 5.15E-04 Multiple complex diseases LAX1 intron 17554300 rs2185079 chr1 203747772 G A 7.80E-04 Smoking cessation / / 24665060 rs12240088 chr1 203752854 A G 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs13375815 chr1 203754922 C T 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2365866 chr1 203758129 A C 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6697388 chr1 203767822 T G 5.35E-04 Response to cytidine analogues (gemcitabine) ZBED6 missense 24483146 rs7552670 chr1 203768328 T C 0.000439 Breast cancer early age of onset ZBED6 missense 18463975 rs7511676 chr1 203770210 T G 5.35E-04 Response to cytidine analogues (gemcitabine) ZC3H11A intron 24483146 rs12145049 chr1 203777741 C T 2.41E-05 Height ZC3H11A intron pha003011 rs7547408 chr1 203784788 C T 4.37E-04 Multiple complex diseases ZC3H11A intron 17554300 rs16830289 chr1 203802051 G A 3.89E-04 Multiple complex diseases ZC3H11A intron 17554300 rs12723861 chr1 203807500 A G 0.0000958 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity ZC3H11A intron 22945461 rs12723861 chr1 203807500 A G 5.95E-05 Height ZC3H11A intron pha003011 rs11240620 chr1 203881082 C T 9.31E-04 Alzheimer's disease / / 17998437 rs6685964 chr1 203906128 A T 9.56E-04 Insulin resistance / / 21901158 rs1935588 chr1 203910220 G A 6.14E-04 Bone mass and geometry / / 17903296 rs2886616 chr1 203912438 C T 8.03E-05 Blood Pressure / / pha003045 rs12064551 chr1 203924763 C T 9.48E-04 Insulin resistance / / 21901158 rs4434893 chr1 203928412 G A 9.03E-04 Multiple complex diseases / / 17554300 rs2096196 chr1 203932993 C A,T 9.30E-05 Height / / 18391952 rs12408223 chr1 203948660 A G 2.34E-04 Cholesterol / / 17255346 rs4301679 chr1 204005018 C T 9.05E-04 Obesity (extreme) LINC00303 intron 21935397 rs4951290 chr1 204006104 T G 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs4951291 chr1 204006538 T C 5.30E-06 Colorectal cancer LINC00303 intron 19011631 rs4951291 chr1 204006538 T C 1.32E-05 Bone mineral density LINC00303 intron 19181680 rs4951039 chr1 204006597 G A 5.80E-06 Colorectal cancer / / 19011631 rs4951039 chr1 204006597 G A 6.47E-05 Bone mineral density / / 19181680 rs12133634 chr1 204014607 T C 3.44E-04 Obesity (extreme) / / 21935397 rs12133665 chr1 204014693 T C 3.40E-04 Obesity (extreme) / / 21935397 rs10900544 chr1 204015718 A G 1.66E-05 Bone mineral density / / 19181680 rs6673836 chr1 204031363 G A 1.00E-04 Smoking quantity / / 24665060 rs12046258 chr1 204039160 G A 4.93E-05 Prostate cancer / / 18264096 rs17404350 chr1 204057142 C G 6.50E-07 Urinary metabolites SOX13 intron 21572414 rs3795579 chr1 204069838 G T 6.28E-04 Smoking initiation SOX13 intron 24665060 rs3795579 chr1 204069838 G T 8.36E-04 Iron levels SOX13 intron pha002876 rs2293336 chr1 204082002 C T 5.61E-05 Serum metabolites SOX13 intron 19043545 rs2037679 chr1 204082938 C T 4.97E-04 Response to cytidine analogues (gemcitabine) SOX13 intron 24483146 rs1917540 chr1 204101681 C T 6.45E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs2293335 chr1 204103618 G A 5.00E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs11240680 chr1 204109473 G A 7.94E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs3795578 chr1 204112984 G A 7.00E-06 Response to acetaminophen (hepatotoxicity) ETNK2 intron 21177773 rs940651 chr1 204115586 G C 2.20E-05 Urinary metabolites ETNK2 intron 21572414 rs1997034 chr1 204118360 T C 2.17E-04 Multiple complex diseases ETNK2 intron 17554300 rs1997034 chr1 204118360 T C 6.95E-04 Bipolar disorder,schizoaffective ETNK2 intron 19567891 rs1997034 chr1 204118360 T C 0.000104004 Hypertension (early onset hypertension) ETNK2 intron 22479346 rs11571093 chr1 204123671 G C 2.67E-04 Multiple complex diseases REN nearGene-3 17554300 rs11571087 chr1 204126245 A T 0.0000013 HDL cholesterol REN intron 23236364 rs11571111 chr1 204130233 C A 2.95E-10 Cholesterol,total REN intron 23063622 rs11571111 chr1 204130233 C A 4.79E-08 Triglycerides REN intron 23063622 rs11571111 chr1 204130233 C A 8.78E-17 HDL cholesterol REN intron 23063622 rs6676670 chr1 204132816 G A,T 1.24E-04 Hearing function REN intron 17255346 rs6668858 chr1 204135788 G A 0.000000206 Cholesterol,total REN nearGene-5 23063622 rs6668858 chr1 204135788 G A 2.66E-08 Triglycerides REN nearGene-5 23063622 rs6668858 chr1 204135788 G A 6.19E-13 HDL cholesterol REN nearGene-5 23063622 rs16853062 chr1 204140218 T A 1.18E-04 Multiple complex diseases / / 17554300 rs11240692 chr1 204149077 C G 8.41E-04 Parkinson's disease / / 16252231 rs12040249 chr1 204158228 G A 7.23E-04 Parkinson's disease / / 16252231 rs7538038 chr1 204161026 A G 3.78E-04 Hearing function KISS1 intron 17255346 rs4951316 chr1 204161490 T C 3.18E-04 Hearing function KISS1 intron 17255346 rs2510 chr1 204161591 T C 1.53E-04 Hearing function KISS1 intron 17255346 rs12097666 chr1 204162212 T C 2.87E-04 Hearing function KISS1 intron 17255346 rs4951319 chr1 204162230 T C 2.51E-04 Hearing function KISS1 intron 17255346 rs3924586 chr1 204166043 C T 1.88E-04 Hearing function KISS1 nearGene-5 17255346 rs4534452 chr1 204185184 A G 6.81E-04 Alzheimer's disease / / 17998437 rs7546241 chr1 204193774 G A 2.20E-05 Urinary metabolites PLEKHA6 intron 21572414 rs11240700 chr1 204195956 T C 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4581328 chr1 204196327 A C 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4614318 chr1 204196482 C T 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4434894 chr1 204203651 C A 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs6702751 chr1 204211793 A C 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4951056 chr1 204232972 C T 1.80E-06 Urinary metabolites PLEKHA6 intron 21572414 rs10793760 chr1 204238403 G A 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs7551075 chr1 204239603 T C 4.00E-06 Urinary metabolites PLEKHA6 intron 21572414 rs11240713 chr1 204244886 C G 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4951059 chr1 204258019 T C 1.38E-04 Multiple complex diseases PLEKHA6 intron 17554300 rs16853233 chr1 204261060 A G 2.80E-05 Personality dimensions PLEKHA6 intron 18957941 rs7534537 chr1 204274519 T C 3.00E-06 Palmitoleic acid (16:1n-7) plasma levels PLEKHA6 intron 23362303 rs57159858 chr1 204280535 C T 3.63E-12 Metabolite levels PLEKHA6 intron 22286219 rs4245727 chr1 204283624 C G 1.40E-05 Malaria PLEKHA6 intron 19465909 rs4951067 chr1 204318983 C T 3.43E-04 Schizophrenia PLEKHA6 intron 20832056 rs4951068 chr1 204318997 C T 3.43E-04 Schizophrenia PLEKHA6 intron 20832056 rs16853492 chr1 204326479 G A 7.54E-04 Multiple complex diseases PLEKHA6 intron 17554300 rs1398152 chr1 204334076 C A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11240732 chr1 204345392 T C 5.33E-05 Hypertension / / 19609347 rs3106364 chr1 204355244 T G 6.03E-05 Hemoglobin / / pha003098 rs1512113 chr1 204359597 T C 0.000295709 Hypertension (early onset hypertension) / / 22479346 rs11240738 chr1 204367303 A G 4.05E-04 Multiple complex diseases / / 17554300 rs3014622 chr1 204367668 G C 1.09E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs12119503 chr1 204386463 T C 1.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12061474 chr1 204389314 C T 1.27E-05 Multiple complex diseases / / 17554300 rs4951373 chr1 204392257 G A 1.60E-04 Alcohol dependence PIK3C2B UTR-3 20201924 rs4951373 chr1 204392257 G A 6.40E-05 Alcohol dependence PIK3C2B UTR-3 20201924 rs4951373 chr1 204392257 G A 0.000594232 Hypertension (early onset hypertension) PIK3C2B UTR-3 22479346 rs4951373 chr1 204392257 G A 6.42E-05 Alcoholism PIK3C2B UTR-3 pha002892 rs16853737 chr1 204425826 G A 8.90E-05 HIV-1 control PIK3C2B intron 20041166 rs2137255 chr1 204426373 C T 4.57E-04 Alcohol dependence PIK3C2B intron 21314694 rs1553920 chr1 204445035 T C 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2B intron 20877124 rs6594014 chr1 204449434 A G 4.90E-05 Cognitive performance PIK3C2B intron 19734545 rs10494852 chr1 204457786 C T 1.98E-04 Alzheimer's disease PIK3C2B intron 24755620 rs11240751 chr1 204462050 A G 2.05E-04 Alzheimer's disease / / 24755620 rs10900594 chr1 204470129 G C 3.54E-08 Lymphocyte counts / / 22286170 rs2926537 chr1 204472279 C T 6.99E-05 Multiple complex diseases / / 17554300 rs4951393 chr1 204489557 C A 4.85E-04 Alzheimer's disease MDM4 intron 24755620 rs4252685 chr1 204496856 C A 3.51E-04 Alzheimer's disease MDM4 intron 24755620 rs898388 chr1 204500257 G A 9.82E-04 Multiple complex diseases MDM4 intron 17554300 rs10458588 chr1 204505487 T C 9.48E-05 Cognitive performance MDM4 intron 19734545 rs4252725 chr1 204513256 A G 3.70E-04 Alzheimer's disease MDM4 intron 24755620 rs2369244 chr1 204515299 G C 2.02E-04 Alzheimer's disease MDM4 intron 24755620 rs2290854 chr1 204516025 A G 1.00E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 1.21E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 1.39E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 2.15E-04 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 3.58E-05 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 3.91E-04 Alzheimer's disease MDM4 intron 24755620 rs1563828 chr1 204516577 A G 2.25E-04 Alzheimer's disease MDM4 intron 24755620 rs4245739 chr1 204518842 C A 2.00E-11 Prostate cancer MDM4 UTR-3 23535732 rs4245739 chr1 204518842 C A 2.00E-12 Breast cancer MDM4 UTR-3 23535733 rs4245739 chr1 204518842 C A 4.00E-06 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) MDM4 UTR-3 24325915 rs4245739 chr1 204518842 C A 8.01E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs10900596 chr1 204522457 T C 4.11E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs10900597 chr1 204522489 C T 2.20E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs12039454 chr1 204542580 T C 2.34E-04 Alzheimer's disease / / 24755620 rs10793766 chr1 204549496 C T 1.70E-04 Alzheimer's disease / / 24755620 rs16854023 chr1 204551830 T C 2.33E-04 Multiple complex diseases / / 17554300 rs6679717 chr1 204560677 A G 2.85E-04 Alzheimer's disease / / 24755620 rs4951409 chr1 204560990 T A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs7532236 chr1 204561617 C T 2.96E-04 Alzheimer's disease / / 24755620 rs6682208 chr1 204566183 T C 1.64E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 2.65E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 4.00E-07 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 4.25E-07 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 5.43E-06 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 5.06E-04 Alzheimer's disease / / 24755620 rs10900601 chr1 204572050 A G 7.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs12143943 chr1 204572071 G A 5.00E-06 Cognitive performance / / 19734545 rs11584700 chr1 204576983 A G 8.00E-12 Educational attainment / / 23722424 rs898387 chr1 204579373 G A 4.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs898386 chr1 204579697 A G 3.81E-05 Cognitive performance / / 19734545 rs898386 chr1 204579697 A G 4.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs2045624 chr1 204584385 G C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs3789043 chr1 204589150 C T 1.83E-04 Multiple complex diseases LRRN2 UTR-5 17554300 rs884108 chr1 204591237 A G 7.24E-04 Suicide attempts in bipolar disorder LRRN2 intron 21041247 rs12094388 chr1 204592174 A G 2.86E-04 Alzheimer's disease (late onset) LRRN2 intron 21379329 rs4951084 chr1 204606974 C G 1.75E-04 Suicide attempts in bipolar disorder LRRN2 intron 21041247 rs4951087 chr1 204609194 A G 1.25E-05 Psoriasis LRRN2 intron 18364390 rs10900418 chr1 204614166 T C 7.61E-04 Type 2 diabetes LRRN2 intron 17463246 rs11801229 chr1 204614475 A G 5.28E-04 Alcohol dependence LRRN2 intron 21314694 rs17335469 chr1 204632163 T C 4.05E-05 ldl cholesterol LRRN2 intron pha003076 rs2149819 chr1 204632333 T C 2.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRRN2 intron 20031582 rs17413714 chr1 204633340 A C 2.23E-04 Obesity (extreme) LRRN2 intron 21935397 rs16854208 chr1 204675641 C A,G 1.44E-04 Multiple complex diseases / / 17554300 rs868506 chr1 204682411 T G 4.11E-04 Type 2 diabetes / / 17463246 rs12239515 chr1 204703480 A G 4.70E-05 Parkinson's disease (familial) / / 18985386 rs12239515 chr1 204703480 A G 0.000551351 Hypertension (early onset hypertension) / / 22479346 rs1329632 chr1 204705517 C T 0.000551351 Hypertension (early onset hypertension) / / 22479346 rs2012130 chr1 204717211 C T 2.47E-05 Odorant perception / / 23910658 rs7551603 chr1 204734495 G A 1.10E-05 Urinary metabolites / / 21572414 rs7544209 chr1 204734807 T C 4.90E-06 Urinary metabolites / / 21572414 rs11240266 chr1 204743826 T C 1.30E-05 Urinary metabolites / / 21572414 rs6593907 chr1 204746302 T C 1.30E-05 Urinary metabolites / / 21572414 rs4951117 chr1 204778847 T A 2.10E-05 Urinary metabolites / / 21572414 rs7552806 chr1 204784018 A C 3.00E-06 Dental caries / / 23064961 rs7552806 chr1 204784018 A C 3.00E-06 Dental caries / / 23064961 rs4483476 chr1 204788353 T C 5.12E-04 Multiple complex diseases / / 17554300 rs2208843 chr1 204789624 G A 5.83E-05 Crohn's disease and psoriasis / / 22482804 rs10458589 chr1 204792001 T C 6.16E-04 Multiple complex diseases / / 17554300 rs10458591 chr1 204792210 T C 5.13E-04 Multiple complex diseases / / 17554300 rs7525016 chr1 204792995 C T 6.41E-04 Multiple complex diseases / / 17554300 rs4951129 chr1 204796564 A T 2.05E-04 Multiple complex diseases NFASC nearGene-5 17554300 rs750087 chr1 204810161 G A 9.36E-04 Response to taxane treatment (placlitaxel) NFASC intron 23006423 rs4951135 chr1 204815612 T C 8.37E-04 Schizophrenia NFASC intron 19197363 rs12239394 chr1 204825794 A C 2.38E-05 Cognitive impairment induced by topiramate NFASC intron 22091778 rs12043259 chr1 204828041 C G 2.00E-11 Addiction NFASC intron 23533358 rs2759281 chr1 204866365 T C 2.98E-04 Alzheimer's disease (late onset) NFASC intron 21379329 rs12025272 chr1 204869559 A G 3.12E-04 Myopia (pathological) NFASC intron 21095009 rs2247208 chr1 204877652 G A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) NFASC intron 24529757 rs2887480 chr1 204881338 C T 3.60E-04 Iron levels NFASC intron pha002876 rs6593917 chr1 204890731 A G 1.61E-04 Blood pressure NFASC intron 17255346 rs2802814 chr1 204906922 T C 5.48E-04 Multiple complex diseases NFASC intron 17554300 rs2802814 chr1 204906922 T C 4.59E-05 Erythrocyte counts NFASC intron pha003099 rs12044157 chr1 204917271 G A 6.43E-04 Type 2 diabetes NFASC intron 17463246 rs4951147 chr1 204919232 G A 1.83E-05 Hemoglobin NFASC intron pha003098 rs4951147 chr1 204919232 G A 1.00E-04 Erythrocyte counts NFASC intron pha003099 rs6696330 chr1 204946387 C T 8.57E-04 Multiple complex diseases NFASC intron 17554300 rs2802841 chr1 204975735 G A 1.50E-04 Endometriosis NFASC intron 21151130 rs2802837 chr1 204993935 A G 6.67E-05 Attention deficit hyperactivity disorder / / 23728934 rs2794867 chr1 204994110 C A 5.87E-05 Height / / pha003010 rs2794867 chr1 204994110 C A 4.91E-05 Height / / pha003011 rs10793722 chr1 205019380 G T 2.10E-05 Urinary metabolites CNTN2 intron 21572414 rs3753855 chr1 205040726 A G 8.80E-04 Multiple complex diseases CNTN2 intron 17554300 rs12117194 chr1 205040943 C G 2.79E-04 Blood pressure CNTN2 intron 17255346 rs6662930 chr1 205041465 T C 1.88E-07 Red blood cell traits CNTN2 intron 23222517 rs6696846 chr1 205041952 C T 2.68E-07 Red blood cell traits CNTN2 intron 23222517 rs1042831 chr1 205043250 G C 3.06E-07 Red blood cell traits CNTN2 UTR-3 23222517 rs1572993 chr1 205045087 G A 6.63E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain CNTN2 UTR-3 20154673 rs7523477 chr1 205048383 T C 2.00E-04 Stroke / / pha002886 rs7523477 chr1 205048383 T C 7.71E-05 Waist Circumference / / pha003024 rs11240352 chr1 205051711 G C 8.83E-07 Red blood cell traits / / 23222517 rs4950979 chr1 205052939 G A 9.92E-05 Weight TMEM81 cds-synon pha003026 rs7520752 chr1 205054114 A G 9.13E-07 Red blood cell traits / / 23222517 rs2369526 chr1 205054406 C T 1.97E-04 Blood pressure / / 17255346 rs12139373 chr1 205054879 A C 9.42E-08 Red blood cell traits / / 23222517 rs10158848 chr1 205061192 C T 8.74E-07 Red blood cell traits RBBP5 intron 23222517 rs3738154 chr1 205063949 C T 4.11E-04 Insulin resistance RBBP5 intron 21901158 rs11577406 chr1 205065733 G T 4.73E-07 Red blood cell traits RBBP5 intron 23222517 rs11240357 chr1 205070522 C T 8.89E-04 Multiple complex diseases RBBP5 intron 17554300 rs11240358 chr1 205070573 G A 4.12E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain RBBP5 intron 20154673 rs11240358 chr1 205070573 G A 8.91E-04 Response to taxane treatment (placlitaxel) RBBP5 intron 23006423 rs3738155 chr1 205074424 C T 3.24E-07 Red blood cell traits RBBP5 intron 23222517 rs12125465 chr1 205074854 C A 3.13E-07 Red blood cell traits RBBP5 intron 23222517 rs4950982 chr1 205078247 T C 7.95E-04 Stroke RBBP5 intron pha002886 rs4950982 chr1 205078247 T C 8.24E-05 Waist Circumference RBBP5 intron pha003024 rs11240360 chr1 205083865 T C 2.05E-07 Red blood cell traits RBBP5 intron 23222517 rs7515178 chr1 205084120 G A 8.51E-05 IgE levels in asthmatics (D.p. specific) RBBP5 intron 23967269 rs6700182 chr1 205092374 A G 8.24E-05 Waist Circumference / / pha003024 rs3862948 chr1 205099959 C A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6675633 chr1 205100480 G A 3.82E-07 Red blood cell traits / / 23222517 rs3862949 chr1 205103070 A T 5.66E-07 Red blood cell traits / / 23222517 rs10900450 chr1 205106238 C G 6.07E-04 Multiple complex diseases / / 17554300 rs10900450 chr1 205106238 C G 5.50E-07 Red blood cell traits / / 23222517 rs4394715 chr1 205108393 T G 2.42E-07 Red blood cell traits / / 23222517 rs11240368 chr1 205110929 T C 9.01E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs11240368 chr1 205110929 T C 8.24E-05 Waist Circumference / / pha003024 rs2836 chr1 205111761 A C 2.25E-04 Blood pressure DSTYK UTR-3 17255346 rs2836 chr1 205111761 A C 5.18E-08 Red blood cell traits DSTYK UTR-3 23222517 rs11240369 chr1 205115099 G A 2.21E-07 Red blood cell traits DSTYK UTR-3 23222517 rs11240370 chr1 205118336 T G 8.15E-07 Red blood cell traits DSTYK intron 23222517 rs12142514 chr1 205122529 A G 2.68E-05 Glaucoma (primary open-angle) DSTYK intron 22605921 rs12142514 chr1 205122529 A G 5.15E-07 Red blood cell traits DSTYK intron 23222517 rs10751431 chr1 205128059 C T 1.41E-07 Red blood cell traits DSTYK intron 23222517 rs4951172 chr1 205137578 G A 1.21E-07 Red blood cell traits DSTYK intron 23222517 rs10900456 chr1 205145005 C T 2.31E-07 Red blood cell traits DSTYK intron 23222517 rs11240376 chr1 205146460 A G 1.72E-07 Red blood cell traits DSTYK intron 23222517 rs10900461 chr1 205153208 C T 3.78E-07 Red blood cell traits DSTYK intron 23222517 rs10900462 chr1 205153312 G A 1.80E-07 Red blood cell traits DSTYK intron 23222517 rs3851285 chr1 205155753 C T 2.25E-07 Red blood cell traits DSTYK intron 23222517 rs10900464 chr1 205157100 T C 1.73E-07 Red blood cell traits DSTYK intron 23222517 rs12042196 chr1 205157759 C T 8.36E-05 Schizophrenia DSTYK intron 19571811 rs10900465 chr1 205158183 C T 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs6692706 chr1 205158561 G T 2.93E-07 Red blood cell traits DSTYK intron 23222517 rs10900468 chr1 205163057 A G 2.71E-07 Red blood cell traits DSTYK intron 23222517 rs10900468 chr1 205163057 A G 5.30E-05 Blood Pressure DSTYK intron pha003046 rs10900468 chr1 205163057 A G 9.14E-05 Blood Pressure DSTYK intron pha003048 rs11588199 chr1 205164580 C T 2.19E-07 Red blood cell traits DSTYK intron 23222517 rs12129162 chr1 205164650 A G 2.96E-07 Red blood cell traits DSTYK intron 23222517 rs4333898 chr1 205169613 C T 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs11240384 chr1 205172175 C T 2.66E-07 Red blood cell traits DSTYK intron 23222517 rs11240385 chr1 205173101 A G 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs6682400 chr1 205173519 T G 1.28E-07 Red blood cell traits DSTYK intron 23222517 rs11240388 chr1 205177617 G A 1.49E-07 Red blood cell traits DSTYK intron 23222517 rs11240390 chr1 205179457 A G 2.34E-07 Red blood cell traits DSTYK intron 23222517 rs76872152 chr1 205180410 C T 5.00E-06 Obesity-related traits DSTYK missense 23251661 rs10900472 chr1 205181526 T C 6.61E-04 Multiple complex diseases / / 17554300 rs10900472 chr1 205181526 T C 1.89E-07 Red blood cell traits / / 23222517 rs6659069 chr1 205182031 A G 7.98E-08 Red blood cell traits / / 23222517 rs6664706 chr1 205182563 T C 4.75E-08 Red blood cell traits / / 23222517 rs12140422 chr1 205187981 G A 7.94E-09 Red blood cell traits / / 23222517 rs7531256 chr1 205191202 T G 2.26E-04 Blood pressure / / 17255346 rs7531256 chr1 205191202 T G 1.87E-09 Red blood cell traits / / 23222517 rs7513642 chr1 205195831 C T 4.42E-04 Multiple complex diseases / / 17554300 rs896320 chr1 205205347 T C 1.10E-07 Red blood cell traits TMCC2 intron 23222517 rs1172161 chr1 205206495 C T 1.76E-04 Blood pressure TMCC2 intron 17255346 rs1172161 chr1 205206495 C T 1.23E-08 Red blood cell traits TMCC2 intron 23222517 rs1172159 chr1 205207512 T C 1.51E-07 Red blood cell traits TMCC2 intron 23222517 rs1078362 chr1 205209530 A G 8.41E-08 Red blood cell traits TMCC2 intron 23222517 rs1172140 chr1 205213024 G A 1.01E-08 Red blood cell traits TMCC2 intron 23222517 rs1172139 chr1 205213962 G A 1.28E-04 Blood pressure TMCC2 intron 17255346 rs1172139 chr1 205213962 G A 4.84E-09 Red blood cell traits TMCC2 intron 23222517 rs748012 chr1 205216573 G A 6.76E-09 Red blood cell traits TMCC2 intron 23222517 rs4400674 chr1 205218425 C A 9.40E-08 Red blood cell traits TMCC2 intron 23222517 rs1172156 chr1 205220087 G A 1.39E-07 Red blood cell traits TMCC2 intron 23222517 rs1172154 chr1 205220639 T G 2.10E-08 Red blood cell traits TMCC2 intron 23222517 rs1172153 chr1 205220661 T C 2.56E-08 Red blood cell traits TMCC2 intron 23222517 rs1172152 chr1 205220718 T A 1.80E-08 Red blood cell traits TMCC2 intron 23222517 rs1172151 chr1 205221659 T G 2.93E-07 Red blood cell traits TMCC2 intron 23222517 rs1172150 chr1 205221861 A G 3.18E-08 Red blood cell traits TMCC2 intron 23222517 rs1172149 chr1 205224758 A G 2.00E-08 Red blood cell traits TMCC2 intron 23222517 rs1172147 chr1 205225457 G A 2.15E-08 Red blood cell traits TMCC2 intron 23222517 rs1151785 chr1 205232299 C T 6.01E-08 Red blood cell traits TMCC2 intron 23222517 rs1151784 chr1 205232447 C T 1.76E-08 Red blood cell traits TMCC2 intron 23222517 rs1172111 chr1 205232980 G A 3.03E-08 Red blood cell traits TMCC2 intron 23222517 rs1177720 chr1 205234428 C T 3.29E-07 Red blood cell traits TMCC2 intron 23222517 rs7367930 chr1 205235512 A G 4.08E-08 Red blood cell traits TMCC2 intron 23222517 rs1668873 chr1 205235990 G A 1.00E-20 Mean platelet volume TMCC2 intron 19820697 rs1668873 chr1 205235990 G A 1.40E-20 Mean platelet volume TMCC2 intron 22423221 rs1668873 chr1 205235990 G A 3.24E-09 Red blood cell traits TMCC2 intron 23222517 rs4951182 chr1 205236233 A C 3.03E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMCC2 intron 20154673 rs1768587 chr1 205236432 C T 1.07E-08 Red blood cell traits TMCC2 intron 23222517 rs1668871 chr1 205237137 T C 1.78E-05 Blood pressure TMCC2 intron 17255346 rs1668871 chr1 205237137 T C 3.00E-14 Platelet counts TMCC2 intron 22139419 rs1668871 chr1 205237137 T C 1.26E-08 Red blood cell traits TMCC2 intron 23222517 rs1768586 chr1 205238275 A G 1.75E-04 Blood pressure TMCC2 cds-synon 17255346 rs1768586 chr1 205238275 A G 6.89E-09 Red blood cell traits TMCC2 cds-synon 23222517 rs1779411 chr1 205238530 C T 4.64E-08 Red blood cell traits TMCC2 cds-synon 23222517 rs1768585 chr1 205239121 C G 2.30E-08 Red blood cell traits TMCC2 intron 23222517 rs1668869 chr1 205239779 G C 9.52E-09 Red blood cell traits TMCC2 intron 23222517 rs1668867 chr1 205240251 C T 1.81E-08 Red blood cell traits TMCC2 cds-synon 23222517 rs4951184 chr1 205240659 T A 1.91E-08 Red blood cell traits TMCC2 intron 23222517 rs1172132 chr1 205242901 A G 4.04E-07 Red blood cell traits / / 23222517 rs1172130 chr1 205244953 G A 4.00E-27 Mean platelet volume / / 22139419 rs1172130 chr1 205244953 G A 7.03E-09 Red blood cell traits / / 23222517 rs1172130 chr1 205244953 G A 6.00E-13 Mean platelet volume / / 24026423 rs1172129 chr1 205244972 T A 3.23E-08 Red blood cell traits / / 23222517 rs1172137 chr1 205246061 G T 7.84E-07 Red blood cell traits / / 23222517 rs1172136 chr1 205247097 T G 7.12E-09 Red blood cell traits / / 23222517 rs1779410 chr1 205248759 A G 8.21E-10 Red blood cell traits / / 23222517 rs9660992 chr1 205249450 A G 1.27E-05 Blood pressure / / 17255346 rs9660992 chr1 205249450 A G 7.08E-10 Red blood cell traits / / 23222517 rs9660992 chr1 205249450 A G 3.00E-13 Mean platelet volume / / 24026423 rs12092492 chr1 205251880 T C 4.07E-08 Red blood cell traits / / 23222517 rs1151787 chr1 205254238 G A 5.04E-09 Red blood cell traits / / 23222517 rs1180734 chr1 205255438 T C 1.33E-08 Red blood cell traits / / 23222517 rs1562866 chr1 205257338 T C 7.30E-04 Asthma / / 20698975 rs1562866 chr1 205257338 T C 3.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1172122 chr1 205261174 T C 5.65E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10157145 chr1 205261963 T C 4.12E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10157145 chr1 205261963 T C 4.72E-05 Waist-Hip Ratio / / pha003029 rs17345816 chr1 205262868 A T 1.40E-08 Red blood cell traits / / 23222517 rs12128254 chr1 205268097 C T 2.26E-08 Red blood cell traits / / 23222517 rs17345997 chr1 205279612 C T 7.21E-06 Acute lymphoblastic leukemia (childhood) NUAK2 intron 19684603 rs963550 chr1 205330243 A C 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1984292 chr1 205336543 C G 6.68E-05 Relative hand skill / / 24068947 rs6676552 chr1 205336875 C T 6.10E-05 Relative hand skill / / 24068947 rs16855560 chr1 205389460 T C 6.01E-04 Coronary Artery Disease LEMD1 intron 17634449 rs12145634 chr1 205398564 G A 6.48E-04 Common variable immunodeficiency / / 21497890 rs10900493 chr1 205423893 G A 2.49E-05 F-cell distribution / / 21326311 rs6682726 chr1 205426620 G A 4.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4279903 chr1 205439769 G A 4.85E-04 Smoking initiation / / 24665060 rs12041346 chr1 205442885 T C 2.62E-04 Multiple complex diseases / / 17554300 rs12041346 chr1 205442885 T C 2.98E-05 Smoking initiation / / 24665060 rs2027288 chr1 205444187 A G 1.53E-04 Smoking initiation / / 24665060 rs6680582 chr1 205458163 T A 5.00E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2027286 chr1 205459511 T C 4.23E-04 Alzheimer's disease / / 17998437 rs2867890 chr1 205469756 A G 6.10E-06 Urinary metabolites / / 21572414 rs12127944 chr1 205483595 C G 4.00E-06 IgG glycosylation CDK18 intron 23382691 rs12127944 chr1 205483595 C G 6.00E-06 IgG glycosylation CDK18 intron 23382691 rs12042887 chr1 205499355 C A 3.45E-04 Lung function (forced expiratory volume in 1 second) CDK18 intron 17255346 rs12759507 chr1 205546615 C T 9.21E-04 Depression (quantitative trait) MFSD4 intron 20800221 rs7526132 chr1 205554085 G C 3.87E-05 Response to acetaminophen (hepatotoxicity) MFSD4 missense 21177773 rs7515820 chr1 205554095 A C 8.95E-04 Alcohol dependence MFSD4 cds-synon 21314694 rs10900518 chr1 205607514 C T 6.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2153903 chr1 205616849 G A 8.04E-06 Triglycerides / / 19074352 rs2153903 chr1 205616849 G A 8.04E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs12409639 chr1 205638222 G A 2.00E-19 Prostate-specific antigen levels SLC45A3 intron 23269536 rs16856139 chr1 205638464 C T 2.49E-08 Parkinson's disease SLC45A3 intron 22438815 rs16856139 chr1 205638464 C T 2.00E-11 Prostate-specific antigen levels SLC45A3 intron 24919509 rs12132270 chr1 205660940 C T 3.03E-05 Parkinson's disease / / 21738487 rs1172198 chr1 205662718 G A 1.58E-09 Lymphocyte counts / / 22286170 rs12748961 chr1 205676263 T C 4.00E-08 White blood cell types / / 21738478 rs16856186 chr1 205678126 T G 9.00E-06 Pulmonary function decline / / 22424883 rs951366 chr1 205685352 T C 7.10E-04 Multiple complex diseases NUCKS1 UTR-3 17554300 rs823094 chr1 205689807 T G 2.00E-07 Pubertal anthropometrics NUCKS1 intron 23449627 rs188212039 chr1 205712530 G A 5.00E-06 Serum dimethylarginine levels (symmetric) NUCKS1 intron 24159190 rs823128 chr1 205713378 G A 7.00E-08 Parkinson's disease NUCKS1 intron 19915575 rs823128 chr1 205713378 G A 1.38E-11 Parkinson's disease NUCKS1 intron 22438815 rs823114 chr1 205719532 G A 2.12E-06 Parkinson's disease NUCKS1 nearGene-5 21738487 rs823114 chr1 205719532 G A 3.00E-06 Parkinson's disease NUCKS1 nearGene-5 24842889 rs823121 chr1 205724302 G A 8.27E-06 Multiple complex diseases / / 17554300 rs823122 chr1 205725028 C T 3.59E-08 Parkinson's disease / / 22438815 rs823122 chr1 205725028 C T 7.51E-05 Tuberculosis / / 24057671 rs823123 chr1 205725346 C T 6.53E-05 Tuberculosis / / 24057671 rs708723 chr1 205739266 C T 6.68E-05 Parkinson's disease RAB7L1 UTR-3 22451204 rs947211 chr1 205752665 A G 2.00E-12 Parkinson's disease / / 19915576 rs947211 chr1 205752665 A G 2.55E-05 Parkinson's disease / / 21738487 rs947211 chr1 205752665 A G 1.52E-12 Prion diseases / / 22210626 rs947211 chr1 205752665 A G 9.61E-11 Parkinson's disease / / 22438815 rs947211 chr1 205752665 A G 6.68E-04 Parkinson's disease / / 24842889 rs10494874 chr1 205754688 G C 3.03E-04 Coronary heart disease / / 21606135 rs12565968 chr1 205755046 G A 5.57E-05 Schizophrenia(age at onset) / / 21688384 rs6679073 chr1 205756484 C A 1.13E-04 Coronary heart disease / / 21606135 rs6679073 chr1 205756484 C A 7.90E-04 Alzheimer's disease / / 22005930 rs823154 chr1 205762406 C T 1.73E-05 Multiple complex diseases SLC41A1 intron 17554300 rs823156 chr1 205764640 G A 1.00E-07 Parkinson's disease SLC41A1 intron 21738487 rs823156 chr1 205764640 G A 2.09E-12 Parkinson's disease SLC41A1 intron 22438815 rs2224 chr1 205769551 G A 5.07E-04 Multiple complex diseases SLC41A1 intron 17554300 rs823066 chr1 205771173 A G 8.90E-05 Parkinson's disease SLC41A1 intron 21738487 rs708730 chr1 205777780 G A 2.10E-07 Parkinson's disease SLC41A1 intron 21738487 rs708730 chr1 205777780 G A 2.07E-07 Parkinson's disease SLC41A1 intron 22438815 rs823091 chr1 205792836 T C 7.69E-04 Multiple complex diseases / / 17554300 rs823088 chr1 205794175 C T 4.28E-04 Multiple complex diseases / / 17554300 rs16856400 chr1 205803724 A C 9.05E-04 Multiple complex diseases PM20D1 intron 17554300 rs954206 chr1 205807504 C T 7.91E-04 Alzheimer's disease PM20D1 intron 22005930 rs11240572 chr1 205808013 C A 6.11E-07 Parkinson's disease PM20D1 intron 19915575 rs11240572 chr1 205808013 C A 2.25E-17 Parkinson's disease PM20D1 intron 22438815 rs11240574 chr1 205813672 T C 4.83E-04 Alzheimer's disease (late onset) PM20D1 intron 21379329 rs7517009 chr1 205815992 C T 7.49E-06 Response to statin treatment (atorvastatin),change in cholesterol levels PM20D1 intron 20031582 rs12028467 chr1 205859798 G C 6.86E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LOC284581 intron 24236485 rs7365031 chr1 205867013 T C 9.29E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12757540 chr1 205887389 C A 1.90E-05 Urinary metabolites SLC26A9 intron 21572414 rs3811429 chr1 205887774 A G 6.54E-05 Serum albumin level SLC26A9 intron pha003084 rs12727528 chr1 205894602 G A 1.70E-04 Multiple complex diseases SLC26A9 intron 17554300 rs11240594 chr1 205896235 G A 1.00E-07 Response to antipsychotic treatment SLC26A9 intron 21107309 rs7512462 chr1 205899595 T C 9.33E-04 Myopia (pathological) SLC26A9 intron 21095009 rs7512462 chr1 205899595 T C 2.03E-08 Cystic fibrosis (meconium ileus) SLC26A9 intron 22466613 rs7512462 chr1 205899595 T C 2.90E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7512462 chr1 205899595 T C 6.86E-05 Tunica Media SLC26A9 intron pha003034 rs7521316 chr1 205907796 T C 5.34E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs2036100 chr1 205907872 C G 7.40E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1874361 chr1 205908186 A C 1.60E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs11240598 chr1 205908630 C G 1.28E-06 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7555534 chr1 205908867 C T 8.80E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6593975 chr1 205909276 C T 6.57E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6593976 chr1 205909285 A C 6.16E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs61814953 chr1 205910080 T C 8.04E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6673820 chr1 205910604 A G 2.40E-05 Response to statin therapy SLC26A9 intron 20339536 rs6673820 chr1 205910604 A G 2.41E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6661355 chr1 205910631 C T 2.30E-05 Response to statin therapy SLC26A9 intron 20339536 rs6661355 chr1 205910631 C T 1.48E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7415921 chr1 205910883 G T 1.80E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1342061 chr1 205911385 T A 1.09E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1342062 chr1 205912786 G T 1.70E-06 Cystic fibrosis-related diabetes / / 23670970 rs1342063 chr1 205912859 C T 2.96E-08 Cystic fibrosis-related diabetes / / 23670970 rs1342064 chr1 205913073 T C 3.27E-08 Cystic fibrosis-related diabetes / / 23670970 rs4951030 chr1 205913747 T A 5.56E-07 Cystic fibrosis-related diabetes / / 23670970 rs4951271 chr1 205913848 A G 1.73E-08 Cystic fibrosis-related diabetes / / 23670970 rs4077468 chr1 205914757 A G 9.44E-09 Cystic fibrosis (meconium ileus) / / 22466613 rs4077468 chr1 205914757 A G 1.00E-09 Cystic fibrosis-related diabetes / / 23670970 rs4077469 chr1 205914885 C T 2.50E-08 Cystic fibrosis-related diabetes / / 23670970 rs12047830 chr1 205916699 G A 3.26E-06 Cystic fibrosis (meconium ileus) / / 22466613 rs7419153 chr1 205917309 G A 9.00E-05 Response to statin therapy / / 20339536 rs7419153 chr1 205917309 G A 1.22E-07 Cystic fibrosis (meconium ileus) / / 22466613 rs7419153 chr1 205917309 G A 2.00E-06 Cystic fibrosis-related diabetes / / 23670970 rs7419153 chr1 205917309 G A 4.44E-05 Tunica Media / / pha003034 rs7418300 chr1 205918020 C G 1.65E-06 Cystic fibrosis-related diabetes / / 23670970 rs28373064 chr1 206223556 A G 9.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs28607590 chr1 206230548 G C 2.00E-04 Cognitive impairment induced by topiramate AVPR1B intron 22091778 rs2244510 chr1 206595069 T C 1.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11120040 chr1 206601326 C T 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2297539 chr1 206603535 G A 2.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4845104 chr1 206609320 T C 3.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2483064 chr1 206614772 A G 5.06E-05 Heart Rate / / pha003053 rs6701879 chr1 206617766 T C 3.30E-04 Mathematical ability / / 20039944 rs2336938 chr1 206618799 A C 1.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2336938 chr1 206618799 A C 7.09E-05 Heart Rate / / pha003053 rs10158553 chr1 206621247 T G 0.00000877 Femoral neck bone mineral density (premenopausal) / / 23074152 rs10158553 chr1 206621247 T G 0.000455 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs2480408 chr1 206624018 G A 8.19E-30 Narcolepsy / / 19629137 rs2483058 chr1 206626828 C G 4.10E-04 Atrial fibrillation / / 21846873 rs2483058 chr1 206626828 C G 9.00E-07 Cholesterol and Triglycerides / / 23031429 rs3813982 chr1 206629674 A G 2.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3813982 chr1 206629674 A G 5.14E-05 Heart Rate / / pha003053 rs7546842 chr1 206630721 G A 3.00E-04 Multiple complex diseases / / 17554300 rs41303986 chr1 206643795 C T 3.46E-04 Taste perception IKBKE UTR-5 22132133 rs2297546 chr1 206648037 C G 8.10E-05 Parkinson's disease (age of onset) IKBKE intron 19772629 rs11118087 chr1 206656577 G A 0.00039 Coronary artery calcification IKBKE intron 23727086 rs944775 chr1 206668593 T C 5.81E-05 Celiac disease IKBKE intron 23936387 rs15672 chr1 206669958 G A 6.81E-05 Celiac disease IKBKE UTR-3 23936387 rs3860295 chr1 206676331 G A 1.16E-04 Celiac disease / / 23936387 rs11118968 chr1 206698249 G A 2.45E-07 Autism RASSF5 intron 22843504 rs9661909 chr1 206714818 C T 2.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) RASSF5 intron 23648065 rs11811181 chr1 206724737 G A 1.81E-05 Brain structure RASSF5 intron 22504417 rs12569261 chr1 206727260 A G 1.10E-05 Brain structure RASSF5 intron 22504417 rs2210517 chr1 206729593 G A 2.04E-05 Brain structure RASSF5 intron 22504417 rs10442694 chr1 206733417 C T 6.92E-05 Migraine RASSF5 intron 23793025 rs3813973 chr1 206775390 G A 1.60E-05 Urinary metabolites EIF2D intron 21572414 rs6685813 chr1 206784809 T C 1.82E-05 Cognitive test performance EIF2D intron 20125193 rs6677934 chr1 206788458 A G 8.11E-05 Alcohol withdrawal symptoms / / 22072270 rs7546458 chr1 206797993 A C 3.81E-04 Multiple complex diseases / / 17554300 rs12140898 chr1 206846600 T C 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10863787 chr1 206876797 C G 8.93E-04 Suicide attempts in bipolar disorder MAPKAPK2 intron 21423239 rs12060808 chr1 206877337 C T 6.61E-04 Suicide attempts in bipolar disorder MAPKAPK2 intron 21423239 rs4548444 chr1 206890138 A G 8.27E-05 Blood Pressure MAPKAPK2 intron pha002898 rs4147011 chr1 206912501 A G 5.44E-05 Taste perception / / 22132133 rs4845133 chr1 206915334 C G 9.11E-04 Alcohol dependence / / 21314694 rs11119451 chr1 206925681 G C 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs3024505 chr1 206939904 G A 1.00E-12 Ulcerative colitis / / 18836448 rs3024505 chr1 206939904 G A 2.00E-09 Type 1 diabetes / / 19430480 rs3024505 chr1 206939904 G A 1.00E-08 Ulcerative colitis / / 20228799 rs3024505 chr1 206939904 G A 2.00E-14 Crohn's disease / / 21102463 rs3024505 chr1 206939904 G A 6.00E-17 Ulcerative colitis / / 21297633 rs3024505 chr1 206939904 G A 5.00E-10 Type 1 diabetes autoantibodies / / 21829393 rs3024505 chr1 206939904 G A 4.00E-08 Multiple sclerosis / / 22190364 rs3024505 chr1 206939904 G A 7.00E-42 Inflammatory bowel disease / / 23128233 rs3024493 chr1 206943968 C A 8.00E-08 Ulcerative colitis IL10 intron 19915572 rs3024493 chr1 206943968 C A 1.00E-12 Ulcerative colitis IL10 intron 20228798 rs3024493 chr1 206943968 C A 2.01E-08 Type 1 diabetes IL10 intron 21980299 rs1554286 chr1 206944233 A G 8.28E-04 Coronary Artery Disease IL10 intron 17634449 rs1554286 chr1 206944233 A G 3.48E-04 Lymphocyte counts IL10 intron 22286170 rs1518111 chr1 206944645 T C 4.00E-18 Behcet's disease IL10 intron 20622878 rs3024490 chr1 206945311 A C 3.02E-07 Behcet's disease IL10 intron 23291587 rs3024490 chr1 206945311 A C 2.22E-07 Behcet's disease IL10 intron pha002888 rs1800871 chr1 206946634 A G 1.00E-14 Behcet's disease IL10 nearGene-5 20622879 rs1800871 chr1 206946634 A G 3.02E-07 Behcet's disease IL10 nearGene-5 23291587 rs1800894 chr1 206946666 C T 0.000851 Colorectal cancer vs. adenoma controls (females) IL10 nearGene-5 22532847 rs17351243 chr1 206959527 G A 8.42E-05 Ulcerative colitis / / 19915573 rs12075255 chr1 206961628 A G 1.87E-05 Ulcerative colitis / / 19915573 rs885334 chr1 206962416 C T 1.98E-05 Ulcerative colitis / / 19915573 rs11583394 chr1 206968893 C T 5.60E-06 Ulcerative colitis / / 19915573 rs2243173 chr1 207011458 T A 8.67E-04 Multiple complex diseases IL19 intron 17554300 rs4845144 chr1 207016648 G A 3.72E-04 Multiple complex diseases / / 17554300 rs574773 chr1 207032751 C T 2.00E-06 Economic and political preferences / / 22566634 rs2981573 chr1 207040577 G A 1.01E-04 Multiple complex diseases IL20 intron 17554300 rs291089 chr1 207059121 G A 1.16E-08 Metabolite levels / / 23281178 rs1713235 chr1 207061772 C T 1.12E-08 Metabolite levels / / 23281178 rs372258579 chr1 207061772 CT CCT,CTG 1.12E-08 Metabolite levels / / 23281178 rs12022348 chr1 207064400 A G 1.95E-08 Metabolite levels / / 23281178 rs3860300 chr1 207064918 C G 1.95E-08 Metabolite levels / / 23281178 rs6540701 chr1 207065770 T C 1.95E-08 Metabolite levels / / 23281178 rs6540703 chr1 207065806 T A 1.95E-08 Metabolite levels / / 23281178 rs4845147 chr1 207066383 C T 1.95E-08 Metabolite levels / / 23281178 rs1856748 chr1 207067840 T C 2.07E-08 Metabolite levels / / 23281178 rs1150253 chr1 207071595 G A 9.04E-08 Metabolite levels IL24 intron 23281178 rs291109 chr1 207072151 T C 2.82E-08 Metabolite levels IL24 intron 23281178 rs1150254 chr1 207072515 T C 9.17E-08 Metabolite levels IL24 intron 23281178 rs1150256 chr1 207073133 G A 9.50E-08 Metabolite levels IL24 intron 23281178 rs1150258 chr1 207074905 T A,C,G 9.50E-08 Metabolite levels IL24 missense 23281178 rs291107 chr1 207075171 T C 2.82E-08 Metabolite levels IL24 intron 23281178 rs94872 chr1 207086845 T C 2.26E-08 Metabolite levels FAIM3 intron 23281178 rs483850 chr1 207089971 T A 5.57E-09 Metabolite levels FAIM3 intron 23281178 rs1356495 chr1 207093202 C A,G,T 0.000384 Salmonella-induced pyroptosis FAIM3 intron 22837397 rs291100 chr1 207104813 T C 6.50E-04 IgA nephropathy PIGR intron 12740691 rs291102 chr1 207106478 G A 3.00E-04 IgA nephropathy PIGR missense 12740691 rs291102 chr1 207106478 G A 6.84E-05 stroke (ischemic) PIGR missense 17434096 rs503746 chr1 207109425 A G 3.00E-04 IgA nephropathy PIGR intron 12740691 rs291097 chr1 207110888 G A 6.84E-05 stroke (ischemic) PIGR cds-synon 17434096 rs291096 chr1 207110936 T C 3.00E-04 IgA nephropathy PIGR cds-synon 12740691 rs291092 chr1 207113230 T G 4.42E-04 Type 2 diabetes PIGR intron 17463246 rs291092 chr1 207113230 T G 3.96E-04 Multiple complex diseases PIGR intron 17554300 rs291091 chr1 207113679 T C 6.78E-09 Metabolite levels PIGR intron 23281178 rs12136238 chr1 207118422 G A 5.50E-04 IgA nephropathy PIGR intron 12740691 rs2275529 chr1 207119853 C A 5.50E-04 IgA nephropathy PIGR nearGene-5 12740691 rs4844555 chr1 207120930 C T 6.66E-09 Metabolite levels PIGR nearGene-5 23281178 rs11119938 chr1 207141792 C G 2.27E-04 Multiple complex diseases FCAMR intron 17554300 rs1856746 chr1 207143422 A G 8.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) FCAMR intron 23648065 rs12066378 chr1 207144619 T C 4.19E-04 Multiple complex diseases / / 17554300 rs2353550 chr1 207146837 A G 2.90E-06 Glioma (high-grade) / / 19578366 rs6687771 chr1 207156274 T C 4.14E-04 Multiple complex diseases / / 17554300 rs2791708 chr1 207162433 T C 7.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2054780 chr1 207221612 C T 9.69E-05 Age-related macular degeneration YOD1 UTR-3 21197116 rs2054780 chr1 207221612 C T 4.60E-05 Age-related macular degeneration YOD1 UTR-3 pha002856 rs2243816 chr1 207241281 G A 9.18E-05 Age-related macular degeneration PFKFB2 intron pha002856 rs17258746 chr1 207252647 T A 1.24E-04 Body mass index PFKFB2 UTR-3 21701565 rs17258746 chr1 207252647 T A 1.88E-04 Body mass index PFKFB2 UTR-3 21701565 rs12088135 chr1 207252911 C T 6.19E-04 Alcohol dependence PFKFB2 UTR-3 21314694 rs6673422 chr1 207253487 A G 2.94E-04 Body mass index PFKFB2 UTR-3 21701565 rs6673422 chr1 207253487 A G 6.24E-05 Body mass index PFKFB2 UTR-3 21701565 rs4142863 chr1 207255654 C T 3.06E-04 Body mass index / / 21701565 rs4142863 chr1 207255654 C T 7.66E-04 Body mass index / / 21701565 rs12045707 chr1 207256205 C T 5.29E-04 Body mass index / / 21701565 rs2353545 chr1 207261196 A G 3.42E-04 Body mass index C4BPB nearGene-5 21701565 rs2353545 chr1 207261196 A G 9.53E-05 Body mass index C4BPB nearGene-5 21701565 rs3813948 chr1 207269858 T C 4.00E-10 C4b binding protein levels C4BPB intron 20212171 rs2842704 chr1 207289436 G A 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C4BPA intron 20877124 rs9943077 chr1 207295298 T C 1.59E-04 Body mass index C4BPA intron 21701565 rs9943077 chr1 207295298 T C 4.57E-05 Body mass index C4BPA intron 21701565 rs891373 chr1 207414244 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs7545125 chr1 207424727 A G 5.60E-04 Addiction / / 17099884 rs2564978 chr1 207494416 T C 5.00E-05 Asthma (aspirin-intolerant) CD55 nearGene-5 21072201 rs2564978 chr1 207494416 T C 0.0005 H1N1 influenza A virus infection CD55 nearGene-5 22693232 rs6667140 chr1 207570177 A G 8.57E-05 Coronary heart disease / / pha003030 rs12734973 chr1 207596652 T C 3.08E-06 Elbow pain / / pha003008 rs17045328 chr1 207652176 A G 7.00E-06 Type 2 diabetes CR2 intron 21490949 rs4317805 chr1 207652992 A G 7.73E-04 Suicide attempts in bipolar disorder CR2 intron 21423239 rs4317805 chr1 207652992 A G 7.25E-05 Hypertension CR2 intron pha003042 rs2182912 chr1 207660344 T A 6.19E-05 Alzheimer's disease CR2 intron 19734903 rs2182912 chr1 207660344 T A 5.30E-05 Alzheimer's disease (late onset) CR2 intron 21460841 rs7519408 chr1 207661289 G C 3.10E-06 Urinary metabolites CR2 intron 21572414 rs11117913 chr1 207668235 C T 8.65E-04 Multiple complex diseases CR1 nearGene-5 17554300 rs4844597 chr1 207671269 C T 5.79E-05 Alzheimer's disease CR1 intron 19734903 rs4844597 chr1 207671269 C T 4.70E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4274065 chr1 207671476 C T 5.90E-05 Alzheimer's disease CR1 intron 19734903 rs4274065 chr1 207671476 C T 4.70E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4310446 chr1 207676604 C T 3.07E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs9429945 chr1 207676768 T C 8.99E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4844599 chr1 207679229 T G 1.63E-10 Inflammatory biomarkers CR1 intron 22291609 rs12567973 chr1 207681501 C G,T 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs12567990 chr1 207681685 C T 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs11117956 chr1 207684359 T G 2.56E-10 Inflammatory biomarkers CR1 intron 22291609 rs11117959 chr1 207684519 A G 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs10863358 chr1 207690871 G C 3.57E-10 Inflammatory biomarkers CR1 intron 22291609 rs6656401 chr1 207692049 A G 3.00E-10 Alzheimer's disease CR1 intron 19734903 rs6656401 chr1 207692049 A G 5.16E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs6656401 chr1 207692049 A G 6.00E-24 Alzheimer's disease (late onset) CR1 intron 24162737 rs3886100 chr1 207739127 A G 7.93E-10 Inflammatory biomarkers CR1 intron 22291609 rs17046851 chr1 207747984 A G 2.84E-10 Inflammatory biomarkers CR1 intron 22291609 rs650877 chr1 207748793 A G 8.98E-10 Inflammatory biomarkers CR1 intron 22291609 rs12757487 chr1 207749188 G A 6.19E-10 Inflammatory biomarkers CR1 intron 22291609 rs599948 chr1 207752239 T C 2.22E-09 Inflammatory biomarkers CR1 intron 22291609 rs601356 chr1 207752550 T G 3.71E-09 Inflammatory biomarkers CR1 intron 22291609 rs614709 chr1 207753275 T C 3.69E-09 Inflammatory biomarkers CR1 intron 22291609 rs2274566 chr1 207753345 C T 7.66E-10 Inflammatory biomarkers CR1 intron 22291609 rs2274567 chr1 207753621 A G 1.72E-10 Inflammatory biomarkers CR1 missense 22291609 rs12034598 chr1 207757515 A G 9.00E-14 Inflammatory biomarkers CR1 intron 22291609 rs646817 chr1 207757936 A G 3.74E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118131 chr1 207761196 C T 3.00E-10 Inflammatory biomarkers CR1 intron 22291609 rs3738468 chr1 207762358 G A 3.03E-10 Inflammatory biomarkers CR1 intron 22291609 rs10779330 chr1 207762674 G A 3.04E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118135 chr1 207770428 A G 4.03E-10 Inflammatory biomarkers CR1 intron 22291609 rs12141045 chr1 207772154 T C 4.10E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118136 chr1 207772408 A G 4.12E-10 Inflammatory biomarkers CR1 intron 22291609 rs7539922 chr1 207773339 G A 6.05E-10 Inflammatory biomarkers CR1 intron 22291609 rs677066 chr1 207773991 T C 1.08E-09 Inflammatory biomarkers CR1 intron 22291609 rs11118157 chr1 207778319 C A 1.09E-09 Inflammatory biomarkers CR1 intron 22291609 rs11118166 chr1 207781995 A G 7.75E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118167 chr1 207782154 T C 6.83E-10 Inflammatory biomarkers CR1 intron 22291609 rs6691117 chr1 207782931 A G 1.01E-09 Inflammatory biomarkers CR1 missense 22291609 rs12032275 chr1 207783507 C T 1.42E-09 Inflammatory biomarkers CR1 intron 22291609 rs3818361 chr1 207784968 A G 9.18E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs3818361 chr1 207784968 A G 3.00E-10 Alzheimer's disease CR1 intron 19734903 rs3818361 chr1 207784968 A G 4.00E-14 Alzheimer's disease CR1 intron 21460840 rs3818361 chr1 207784968 A G 3.53E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs3818361 chr1 207784968 A G 9.20E-06 Prion diseases CR1 intron 22210626 rs7519119 chr1 207786152 G A 5.87E-10 Inflammatory biomarkers CR1 intron 22291609 rs7542544 chr1 207786223 C A 1.07E-09 Inflammatory biomarkers CR1 intron 22291609 rs6701713 chr1 207786289 A G 8.71E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs6701713 chr1 207786289 A G 6.39E-06 Alzheimer's disease CR1 intron 19734903 rs6701713 chr1 207786289 A G 5.00E-10 Alzheimer's disease (late onset) CR1 intron 21460841 rs10429953 chr1 207788578 A G 7.07E-10 Inflammatory biomarkers CR1 intron 22291609 rs12734030 chr1 207793964 C T 1.84E-09 Inflammatory biomarkers CR1 intron 22291609 rs36066893 chr1 207793964 C CT 1.84E-09 Inflammatory biomarkers CR1 intron 22291609 rs2296160 chr1 207795320 A G 3.40E-06 Alzheimer's disease CR1 missense 19734903 rs2296160 chr1 207795320 A G 8.03E-09 Alzheimer's disease (late onset) CR1 missense 21460841 rs1408078 chr1 207800555 T C 3.40E-06 Alzheimer's disease CR1 intron 19734903 rs1408078 chr1 207800555 T C 8.03E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs4844610 chr1 207802552 A C 9.29E-06 Alzheimer's disease CR1 intron 19734903 rs4844610 chr1 207802552 A C 8.27E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs11803956 chr1 207803021 T C 7.49E-10 Inflammatory biomarkers CR1 intron 22291609 rs12041437 chr1 207803264 C A 7.47E-10 Inflammatory biomarkers CR1 intron 22291609 rs12034383 chr1 207803595 G A 2.00E-28 Erythrocyte sedimentation rate CR1 intron 21700265 rs12034383 chr1 207803595 G A 7.41E-10 Inflammatory biomarkers CR1 intron 22291609 rs12034383 chr1 207803595 G A 1.65E-05 LDL lipoproteins CR1 intron pha002902 rs1408077 chr1 207804141 A C 8.32E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs1408077 chr1 207804141 A C 9.05E-06 Alzheimer's disease CR1 intron 19734903 rs1408077 chr1 207804141 A C 1.91E-08 Alzheimer's disease (late onset) CR1 intron 21460841 rs1408077 chr1 207804141 A C 7.24E-04 Response to cytadine analogues (cytosine arabinoside) CR1 intron 24483146 rs11803366 chr1 207806989 T C 1.47E-09 Inflammatory biomarkers CR1 intron 22291609 rs1323720 chr1 207823161 T C 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs1323722 chr1 207823405 C T 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs10863461 chr1 207840776 G A 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs7527798 chr1 207872290 T C 2.00E-09 Erythrocyte sedimentation rate CR1L intron 21700265 rs4844614 chr1 207875175 G T 2.00E-07 LDL cholesterol CR1L intron 19060910 rs4844614 chr1 207875175 G T 2.00E-07 Coronary heart disease CR1L intron 21347282 rs4844614 chr1 207875175 G T 2.38E-07 LDL lipoproteins CR1L intron pha002902 rs2724387 chr1 207932617 T G 3.32E-04 Amyotrophic lateral sclerosis (sporadic) CD46 intron 24529757 rs17006738 chr1 207936103 G A 1.62E-04 IgE levels CD46 intron 17255346 rs7545126 chr1 207938236 C T 9.00E-06 Obesity-related traits CD46 intron 23251661 rs11118555 chr1 207940853 T A 4.00E-26 Heart rate CD46 intron 23583979 rs2724375 chr1 207997973 C A 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12731740 chr1 208024820 C T 3.00E-09 Biomedical quantitative traits / / 19396169 rs2796241 chr1 208027459 C A 2.20E-05 Urinary metabolites / / 21572414 rs1967689 chr1 208039471 G C 5.00E-06 Age-related macular degeneration / / 23326517 rs2952 chr1 208049077 C T 2.33E-05 Osteoarthritis (knee and hip) / / 21177295 rs2952 chr1 208049077 C T 4.74E-05 Osteoarthritis (knee and hip) / / 21177295 rs2556 chr1 208060359 G A 2.35E-04 Suicide attempts in bipolar disorder CD34 UTR-3 21041247 rs2262269 chr1 208067651 A C 2.00E-04 Schizophrenia (treatment refractory) CD34 intron 22479419 rs2488250 chr1 208069877 G A 0.0006409 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CD34 intron 23233654 rs2488250 chr1 208069877 G A 6.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) CD34 intron 23233662 rs11118918 chr1 208095688 G T 1.43E-05 Diabetic nephropathy / / 21150874 rs11118918 chr1 208095688 G T 5.51E-04 Type 2 diabetes / / 22238593 rs2745960 chr1 208095701 T A 0.0004795 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2745960 chr1 208095701 T A 4.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12041505 chr1 208097796 G A 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473653 chr1 208101656 C T 0.0004845 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2473653 chr1 208101656 C T 4.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs560752 chr1 208106568 T C 9.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11580454 chr1 208124349 G A 0.0001566 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11580454 chr1 208124349 G A 1.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11118958 chr1 208125204 G C 0.000415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11118958 chr1 208125204 G C 4.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2745967 chr1 208128722 G A 7.00E-08 Resting heart rate / / 20639392 rs11578508 chr1 208129065 A G 4.00E-10 Heart rate / / 23583979 rs12023412 chr1 208165338 C G 1.10E-05 Urinary metabolites / / 21572414 rs651480 chr1 208171368 C T 2.06E-05 Hearing function / / 17255346 rs3901316 chr1 208178218 T C 8.20E-06 Urinary metabolites / / 21572414 rs556625 chr1 208195981 C T 1.13E-04 Intracranial aneurysm PLX/2 UTR-3 22286173 rs591305 chr1 208197882 G C 1.23E-05 Response to methylphenidate treatment PLX/2 UTR-3 21130132 rs7520548 chr1 208205643 C A 0.000384 Salmonella-induced pyroptosis PLX/2 intron 22837397 rs2785622 chr1 208214504 T C 8.43E-04 Coronary Artery Disease PLX/2 intron 17634449 rs2274446 chr1 208252456 C T 7.37E-05 Lactate dehydrogenase levels PLX/2 intron 20981236 rs12083980 chr1 208278877 C T 8.71E-05 Multiple sclerosis (age of onset) PLX/2 intron 19010793 rs11118986 chr1 208279228 G A 5.89E-05 Multiple sclerosis (age of onset) PLX/2 intron 19010793 rs6671923 chr1 208325802 G A 5.19E-04 Multiple complex diseases PLX/2 intron 17554300 rs6671923 chr1 208325802 G A 3.50E-06 Fasting plasma glucose PLX/2 intron 19060907 rs1262049 chr1 208332650 T A 9.07E-04 Multiple complex diseases PLX/2 intron 17554300 rs2801201 chr1 208338095 G A 8.34E-08 Multiple complex diseases PLX/2 intron 17554300 rs2801201 chr1 208338095 G A 8.02E-06 Telomere length PLX/2 intron 20139977 rs11118997 chr1 208339601 G A 9.47E-04 Multiple complex diseases PLX/2 intron 17554300 rs4406633 chr1 208350952 G A 6.90E-04 Schizophrenia (treatment refractory) PLX/2 intron 22479419 rs2489774 chr1 208361527 C T 4.44E-04 Multiple complex diseases PLX/2 intron 17554300 rs2489774 chr1 208361527 C T 8.67E-04 Coronary Artery Disease PLX/2 intron 17634449 rs11590686 chr1 208368201 C T 2.30E-05 Schizophrenia (treatment refractory) PLX/2 intron 22479419 rs7525987 chr1 208373312 T C 2.47E-04 Multiple complex diseases PLX/2 intron 17554300 rs3748735 chr1 208390469 C T 2.12E-04 Amyotrophic Lateral Sclerosis PLX/2 missense 17362836 rs1262046 chr1 208400492 C T 1.87E-06 Cognitive decline PLX/2 intron 23207651 rs2782934 chr1 208408503 A G 6.12E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PLX/2 intron 20031582 rs2782934 chr1 208408503 A G 7.05E-04 Myocardial Infarction PLX/2 intron pha002883 rs1272623 chr1 208410635 T G 5.67E-05 Cognitive test performance PLX/2 intron 20125193 rs11588788 chr1 208442000 G A 5.50E-05 Parkinson's disease (age of onset) / / 19772629 rs2590691 chr1 208445800 C T 6.70E-06 Urinary metabolites / / 21572414 rs2590691 chr1 208445800 C T 7.79E-05 Blood Pressure / / pha003044 rs2440902 chr1 208446359 G A 4.20E-06 Urinary metabolites / / 21572414 rs1781026 chr1 208463935 A G 4.53E-05 Blood Pressure / / pha003044 rs718242 chr1 208464910 A C 5.45E-05 Blood Pressure / / pha003044 rs7515725 chr1 208470708 T C 7.64E-05 Blood Pressure / / pha003044 rs6540465 chr1 208479203 T C 5.14E-06 Multiple complex diseases / / 17554300 rs6702300 chr1 208485874 G A 0.000278861 Hypertension (early onset hypertension) / / 22479346 rs17259513 chr1 208510207 T C 9.33E-04 Multiple complex diseases / / 17554300 rs6695225 chr1 208513728 G A 8.87E-05 Blood Pressure / / pha003044 rs17012410 chr1 208517277 G A 3.76E-04 Rheumatoid arthritis / / 21452313 rs6694253 chr1 208518783 G C 0.0001518 Sarcoidosis / / 22952805 rs12406933 chr1 208525983 C T 6.25E-04 Smoking initiation / / 24665060 rs6677524 chr1 208535774 T G 2.59E-04 Multiple complex diseases / / 17554300 rs10779476 chr1 208543562 C T 1.00E-04 Prostate cancer / / 21743057 rs696985 chr1 208547582 G T 1.00E-05 Prostate cancer / / 21743057 rs696984 chr1 208548174 T C 5.00E-06 Prostate cancer / / 21743057 rs696983 chr1 208548223 T C 1.00E-04 Prostate cancer / / 21743057 rs696981 chr1 208549846 C T 3.00E-05 Prostate cancer / / 21743057 rs701642 chr1 208551533 C T 3.00E-05 Prostate cancer / / 21743057 rs698993 chr1 208553707 A T 5.30E-06 Urinary metabolites / / 21572414 rs701641 chr1 208554185 C T 5.30E-06 Urinary metabolites / / 21572414 rs12409730 chr1 208555807 G A 2.00E-05 Urinary metabolites / / 21572414 rs12409730 chr1 208555807 G A 3.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs696979 chr1 208558547 T C 3.04E-04 Premature ovarian failure / / 19508998 rs710417 chr1 208578200 G A 7.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs696948 chr1 208589905 C T 2.03E-04 Multiple complex diseases / / 17554300 rs12124696 chr1 208591203 T C 1.88E-04 HIV-1 viral setpoint / / 17641165 rs17012564 chr1 208629207 A G 6.70E-07 Urinary metabolites / / 21572414 rs696958 chr1 208634002 G A 8.88E-05 Parkinson's disease / / 21248740 rs1392096 chr1 208635549 A G 0.00000742 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs841503 chr1 208662959 C A 2.50E-07 Multiple sclerosis / / 17660530 rs17259784 chr1 208757586 G C 6.00E-06 Cardiac hypertrophy / / 21348951 rs2185383 chr1 208779683 C A 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17012951 chr1 208798145 C A 6.87E-04 Multiple complex diseases / / 17554300 rs17012953 chr1 208798856 A G 1.68E-71 Multiple complex diseases / / 17554300 rs17012962 chr1 208800712 A G 4.28E-04 Multiple complex diseases / / 17554300 rs17012964 chr1 208801107 A G 4.18E-04 Multiple complex diseases / / 17554300 rs2275515 chr1 208801568 T C 2.43E-04 Multiple complex diseases / / 17554300 rs12145940 chr1 208818206 C A 4.93E-05 Neuroblastoma / / pha002895 rs6680293 chr1 208830499 T C 2.25E-04 Coronary Artery Disease / / 17634449 rs1166879 chr1 208897416 C T 5.01E-05 Brain lesion load / / 19010793 rs4844438 chr1 208914856 A G 9.20E-04 Alcohol dependence / / 24277619 rs12403851 chr1 208922357 A G 4.40E-05 Height / / pha003010 rs11803397 chr1 208929786 A C 6.81E-04 Multiple complex diseases / / 17554300 rs12565978 chr1 208935416 T C 4.09E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs17259916 chr1 208937403 G T 4.01E-04 Smoking initiation / / 24665060 rs11585869 chr1 208938237 C T 2.16E-04 Smoking initiation / / 24665060 rs11119132 chr1 208992432 C A,G,T 9.60E-04 Type 2 diabetes / / 17463246 rs11119132 chr1 208992432 C A,G,T 1.26E-04 Multiple complex diseases / / 17554300 rs12408989 chr1 209007778 C A 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs2225933 chr1 209054831 C T 0.00000107 Common carotid artery thickness (far walls) / / 23487405 rs17260000 chr1 209057061 A G 3.63E-04 Tourette syndrome / / 22889924 rs11119150 chr1 209065259 T C 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12566014 chr1 209081485 T C 9.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10157571 chr1 209092473 C T 2.24E-04 Celiac disease / / 23936387 rs11577857 chr1 209105367 G A 2.00E-04 Information processing speed / / 21130836 rs11582344 chr1 209105966 C G 1.70E-05 Urinary metabolites / / 21572414 rs12037214 chr1 209146127 T C 7.67E-05 Parent of origin effect on language impairment (child trend) LOC100506899 intron 24571439 rs1924252 chr1 209153924 T C 2.13E-04 Parkinson's disease / / 16252231 rs1924251 chr1 209160036 A G 7.11E-04 Multiple complex diseases / / 17554300 rs7549301 chr1 209162412 C T 7.17E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs4844743 chr1 209192139 C T 3.45E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12030256 chr1 209203866 T C 2.44E-04 Alcohol dependence / / 20201924 rs12037818 chr1 209209120 G C 5.45E-05 Odorant perception / / 23910658 rs17014015 chr1 209237451 C T 9.10E-05 Diabetic nephropathy / / 21150874 rs17014015 chr1 209237451 C T 2.05E-04 Type 2 diabetes / / 22238593 rs7534677 chr1 209240296 C G 4.90E-04 Obesity (extreme) / / 21935397 rs1411406 chr1 209258715 G T 4.10E-06 Urinary metabolites / / 21572414 rs6540507 chr1 209269627 A G 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10494917 chr1 209273939 A G 1.30E-05 Urinary metabolites / / 21572414 rs35577903 chr1 209277772 G T 2.20E-05 Urinary metabolites / / 21572414 rs11119220 chr1 209283460 A G 0.000866 Salmonella-induced pyroptosis / / 22837397 rs4424511 chr1 209316630 C T 5.75E-06 Recombination rate / / 21698098 rs4382726 chr1 209334217 G A 4.00E-06 Response to amphetamines / / 22952603 rs17014126 chr1 209335997 C T 7.35E-04 Multiple complex diseases / / 17554300 rs4844776 chr1 209342457 C A 6.37E-06 Response to amphetamines / / 22952603 rs1933612 chr1 209342622 G A 1.68E-04 Type 2 diabetes / / 17463246 rs17014148 chr1 209362100 G A 4.15E-04 Multiple complex diseases / / 17554300 rs6657861 chr1 209365397 A G 0.000478 Salmonella-induced pyroptosis / / 22837397 rs2153043 chr1 209426304 T C 2.20E-05 Urinary metabolites / / 21572414 rs2788151 chr1 209435926 T C 6.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2265733 chr1 209446729 C T 2.60E-05 Urinary metabolites / / 21572414 rs2660648 chr1 209449439 A G 1.10E-05 Urinary metabolites / / 21572414 rs2843171 chr1 209456475 T C 8.20E-06 Urinary metabolites / / 21572414 rs1553623 chr1 209460346 T C 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6665154 chr1 209577743 G A 7.94E-05 Post-operative nausea and vomiting / / 21694509 rs1988163 chr1 209581483 C A 3.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs7531215 chr1 209589686 A G 1.89E-04 Type 2 diabetes / / 17463246 rs7531215 chr1 209589686 A G 1.26E-04 Multiple complex diseases / / 17554300 rs6691406 chr1 209590546 G A 3.36E-05 Multiple complex diseases / / 17554300 rs17014465 chr1 209600258 A C 8.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10779506 chr1 209603360 G C 7.50E-04 Multiple complex diseases MIR205HG intron 17554300 rs2294938 chr1 209603996 A G 4.79E-04 Multiple complex diseases MIR205HG intron 17554300 rs2294938 chr1 209603996 A G 2.90E-06 Glioma (high-grade) MIR205HG intron 19578366 rs1157819 chr1 209604734 T A 6.00E-04 Chronic fatigue syndrome MIR205HG intron 21912186 rs2249632 chr1 209605102 A G 6.14E-04 Multiple complex diseases MIR205HG intron 17554300 rs12045481 chr1 209621687 G A 6.17E-05 Body Mass Index / / pha003020 rs7526722 chr1 209632204 C T 3.15E-04 Amyotrophic lateral sclerosis / / 23624525 rs742254 chr1 209652946 A C 6.67E-06 Waist-Hip Ratio / / pha003013 rs742254 chr1 209652946 A C 9.41E-05 Waist Circumference / / pha003025 rs742254 chr1 209652946 A C 3.56E-06 Waist-Hip Ratio / / pha003028 rs2092253 chr1 209670324 G A 3.51E-04 Sarcoidosis / / 19165924 rs2092253 chr1 209670324 G A 1.67E-05 Waist-Hip Ratio / / pha003013 rs2092253 chr1 209670324 G A 8.59E-06 Waist-Hip Ratio / / pha003028 rs1120599 chr1 209670782 T C 3.84E-05 Amyotrophic lateral sclerosis / / 23624525 rs12750212 chr1 209682096 G A 1.00E-05 Tanning / / 19340012 rs2356932 chr1 209706685 A G 2.40E-04 Amyotrophic lateral sclerosis / / 23624525 rs6703183 chr1 209712889 T C 3.00E-08 Amyotrophic lateral sclerosis / / 23624525 rs6703522 chr1 209713138 T C 2.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs996146 chr1 209720842 C T 1.65E-05 Bone mineral traits,in men / / 21427758 rs996146 chr1 209720842 C T 5.19E-05 Bone mineral traits,in men / / 21427758 rs996146 chr1 209720842 C T 6.39E-05 Bone mineral traits,in men / / 21427758 rs6673693 chr1 209723420 T G 6.00E-04 Crohn's disease / / 17684544 rs12130212 chr1 209727257 T A 2.00E-06 Obesity (extreme) / / 21935397 rs10746420 chr1 209728590 T C 5.50E-06 Urinary metabolites / / 21572414 rs880782 chr1 209779953 G A 9.11E-05 Meningococcal disease CAMK1G intron 20694013 rs880782 chr1 209779953 G A 2.18E-05 Tunica Media CAMK1G intron pha003038 rs1049607 chr1 209788703 T C 4.15E-04 Type 2 diabetes LAMB3 cds-synon 17463246 rs2076227 chr1 209789086 G A 3.97E-04 Type 2 diabetes LAMB3 intron 17463246 rs742372 chr1 209828912 A T 3.60E-06 Urinary metabolites / / 21572414 rs11580294 chr1 209839374 G A 1.07E-04 Multiple complex diseases / / 17554300 rs11808911 chr1 209871977 C T 3.29E-04 Response to taxane treatment (placlitaxel) HSD11B1 intron 23006423 rs11119328 chr1 209885318 C A 8.12E-05 Orofacial clefts HSD11B1 intron 22863734 rs846906 chr1 209887718 T C 1.41E-05 Bladder cancer (smoking interaction) HSD11B1 intron 24662972 rs17015076 chr1 209912593 C T 8.94E-06 Cleft lip / / 20436469 rs3765240 chr1 209918151 G A 6.18E-05 Cognitive test performance / / 20125193 rs3765240 chr1 209918151 G A 8.00E-06 Orofacial clefts / / 22863734 rs3817821 chr1 209918503 A T 9.14E-04 Multiple complex diseases / / 17554300 rs627670 chr1 209929299 G A 9.95E-05 Cognitive test performance / / 20125193 rs627670 chr1 209929299 G A 1.04E-05 Orofacial clefts / / 22863734 rs909710 chr1 209930694 G A 8.79E-06 Orofacial clefts TRAF3IP3 intron 22863734 rs10489341 chr1 209932121 C T 9.20E-05 Asthma TRAF3IP3 intron 20698975 rs17015169 chr1 209936914 C T 1.66E-07 Cleft lip TRAF3IP3 cds-synon 20436469 rs17015169 chr1 209936914 C T 8.14E-09 Orofacial clefts TRAF3IP3 cds-synon 22863734 rs590223 chr1 209946707 G A 1.92E-06 Orofacial clefts TRAF3IP3 intron 22863734 rs1044516 chr1 209959614 G T 3.93E-07 Cleft lip IRF6 UTR-3 20436469 rs2235372 chr1 209960436 G A 1.00E-05 Urinary metabolites IRF6 UTR-3 21572414 rs2235372 chr1 209960436 G A 1.31E-04 Insulin resistance IRF6 UTR-3 21901158 rs742215 chr1 209961023 T A 1.40E-05 Urinary metabolites IRF6 UTR-3 21572414 rs2073485 chr1 209962794 G A 6.11E-11 Cleft lip IRF6 intron 20436469 rs2073485 chr1 209962794 G A 2.12E-10 Orofacial clefts IRF6 intron 22863734 rs674433 chr1 209964875 G T 1.81E-04 Insulin resistance IRF6 intron 21901158 rs17015218 chr1 209967915 A G 2.24E-04 Insulin resistance IRF6 intron 21901158 rs2013196 chr1 209968411 C T 8.31E-04 Multiple complex diseases IRF6 intron 17554300 rs2013196 chr1 209968411 C T 3.08E-05 Calcium intake levels and metabolic syndrome IRF6 intron 22170361 rs2013162 chr1 209968684 C A 2.24E-11 Cleft lip IRF6 cds-synon 20436469 rs17015226 chr1 209970096 C G 3.98E-04 Insulin resistance IRF6 intron 21901158 rs7555285 chr1 209970355 G C 2.74E-04 Insulin resistance IRF6 intron 21901158 rs861020 chr1 209977111 A G 8.20E-05 Orofacial clefts IRF6 intron 20023658 rs861020 chr1 209977111 A G 1.32E-09 Cleft lip IRF6 intron 20436469 rs861020 chr1 209977111 A G 3.00E-12 Orofacial clefts IRF6 intron 22863734 rs6540560 chr1 209982073 C T 2.80E-05 Urinary metabolites / / 21572414 rs6540560 chr1 209982073 C T 7.37E-04 Insulin resistance / / 21901158 rs6696825 chr1 209982372 A G 2.00E-05 Urinary metabolites / / 21572414 rs10863790 chr1 209988047 A C 1.00E-14 Cleft lip / / 20436469 rs642961 chr1 209989270 A G 6.83E-04 Type 2 diabetes / / 17463246 rs642961 chr1 209989270 A G 2.00E-06 Orofacial clefts / / 19270707 rs3753513 chr1 209999790 G A 3.99E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs9308411 chr1 210005713 C T 6.92E-04 Type 2 diabetes DIEXF intron 17463246 rs17015309 chr1 210007218 C T 2.16E-05 Post-operative nausea and vomiting DIEXF intron 21694509 rs126280 chr1 210019824 A G 1.09E-08 Cleft lip DIEXF intron 20436469 rs126280 chr1 210019824 A G 8.11E-11 Orofacial clefts DIEXF intron 22863734 rs11119354 chr1 210024097 G A 4.81E-05 Calcium intake levels and metabolic syndrome DIEXF intron 22170361 rs6689839 chr1 210027026 G A 9.30E-05 Cleft lip DIEXF UTR-3 20436469 rs6689839 chr1 210027026 G A 1.98E-05 Orofacial clefts DIEXF UTR-3 22863734 rs2049998 chr1 210031154 G A 6.77E-04 Type 2 diabetes / / 17463246 rs2064163 chr1 210048819 G T 2.44E-08 Cleft lip / / 20436469 rs2064163 chr1 210048819 G T 2.08E-08 Orofacial clefts / / 22863734 rs12063989 chr1 210049893 T C 1.06E-09 Cleft lip / / 20436469 rs7540457 chr1 210053549 C G 3.09E-05 Multiple complex diseases / / 17554300 rs932347 chr1 210055630 C T 3.07E-05 Cleft lip / / 20436469 rs932347 chr1 210055630 C T 1.38E-06 Orofacial clefts / / 22863734 rs4844913 chr1 210068117 G A 1.87E-06 Cleft lip / / 20436469 rs4844913 chr1 210068117 G A 7.99E-07 Orofacial clefts / / 22863734 rs9429830 chr1 210110537 T C 1.74E-06 Cleft lip SYT14 nearGene-5 20436469 rs9429830 chr1 210110537 T C 2.20E-07 Orofacial clefts SYT14 nearGene-5 22863734 rs10863800 chr1 210123774 A G 5.37E-04 Smoking initiation SYT14 intron 24665060 rs11590161 chr1 210165928 G C 2.30E-05 Urinary metabolites SYT14 intron 21572414 rs7543650 chr1 210170975 A T 2.50E-05 Urinary metabolites SYT14 intron 21572414 rs11119388 chr1 210174417 A G 4.57E-09 Cleft lip SYT14 intron 20436469 rs227193 chr1 210212424 T C 8.94E-04 Multiple complex diseases SYT14 intron 17554300 rs12561877 chr1 210215414 C T 2.39E-05 Smoking initiation SYT14 intron 24665060 rs227178 chr1 210216946 C T 9.64E-04 Multiple complex diseases SYT14 intron 17554300 rs227178 chr1 210216946 C T 2.96E-06 Cleft lip SYT14 intron 20436469 rs227178 chr1 210216946 C T 1.01E-06 Orofacial clefts SYT14 intron 22863734 rs701948 chr1 210233610 C T 9.01E-04 Multiple complex diseases SYT14 intron 17554300 rs170555 chr1 210241616 T C 2.05E-04 Schizophrenia SYT14 intron 21674006 rs17318744 chr1 210244470 A G 7.30E-04 Response to cytadine analogues (cytosine arabinoside) SYT14 intron 24483146 rs227201 chr1 210247816 A G 9.85E-04 Multiple complex diseases SYT14 intron 17554300 rs227200 chr1 210249486 G C 9.09E-04 Multiple complex diseases SYT14 intron 17554300 rs11119409 chr1 210293333 C T 8.14E-04 Multiple complex diseases SYT14 intron 17554300 rs923561 chr1 210302595 G A 2.90E-05 Monocyte chemoattractant protein-1 SYT14 intron pha003071 rs11119414 chr1 210305881 A G 6.77E-04 Multiple complex diseases SYT14 intron 17554300 rs1002382 chr1 210312760 G A 1.02E-04 Myocardial Infarction SYT14 intron pha002873 rs4537554 chr1 210331585 C T 2.79E-04 Myocardial Infarction SYT14 intron pha002873 rs17188190 chr1 210337726 G A 2.18E-05 Monocyte chemoattractant protein-1 SYT14 nearGene-3 pha003071 rs2485893 chr1 210348155 A G 9.85E-07 Cleft lip / / 20436469 rs2485893 chr1 210348155 A G 8.86E-07 Orofacial clefts / / 22863734 rs2485893 chr1 210348155 A G 7.87E-05 Glucose levels / / pha003061 rs10779526 chr1 210352196 T C 8.70E-07 Cleft lip / / 20436469 rs10779526 chr1 210352196 T C 8.18E-07 Orofacial clefts / / 22863734 rs10779526 chr1 210352196 T C 7.10E-05 Glucose levels / / pha003061 rs12567108 chr1 210354442 G A 2.26E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs2485885 chr1 210356013 G A 3.92E-04 Type 2 diabetes / / 17463246 rs1014370 chr1 210356238 G A 2.37E-04 Type 2 diabetes / / 17463246 rs12094311 chr1 210369136 A G 1.24E-07 Cleft lip / / 20436469 rs12094311 chr1 210369136 A G 8.89E-08 Orofacial clefts / / 22863734 rs12060567 chr1 210370590 G A 3.17E-07 Cleft lip / / 20436469 rs12060567 chr1 210370590 G A 1.62E-07 Orofacial clefts / / 22863734 rs2485901 chr1 210370761 T G 3.00E-06 Glioma (high-grade) / / 19578366 rs2494183 chr1 210386585 G A 2.09E-04 Multiple complex diseases / / 17554300 rs2494184 chr1 210386892 T C 8.35E-04 Acne (severe) / / 24399259 rs590380 chr1 210463071 G A 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs689248 chr1 210463122 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs588197 chr1 210463515 A T 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs587203 chr1 210463786 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs608791 chr1 210464638 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12739013 chr1 210468160 A G 8.16E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs12138216 chr1 210480361 G A 7.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12138216 chr1 210480361 G A 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs615285 chr1 210484981 G A 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4844997 chr1 210486895 T C 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4430327 chr1 210499394 C T 9.61E-05 Cholesterol / / pha003073 rs3765886 chr1 210516146 G A 3.20E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs1338289 chr1 210519658 G A 3.97E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs17016002 chr1 210522686 C T 4.46E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10863822 chr1 210528535 C G 3.51E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs7527939 chr1 210536025 C T 6.00E-09 Schizophrenia HHAT intron 23142968 rs12141780 chr1 210536722 C T 9.83E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765877 chr1 210537625 C T 4.11E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10489386 chr1 210541178 A T 5.58E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12087955 chr1 210547489 A C 4.98E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12062126 chr1 210547517 C T 5.14E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12120970 chr1 210548548 C G 7.02E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12143463 chr1 210556982 T A 7.58E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765866 chr1 210559105 G A 7.68E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765865 chr1 210559381 A G 6.30E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12145699 chr1 210561861 G A 6.10E-04 Multiple complex diseases HHAT intron 17554300 rs12046133 chr1 210562168 A G 8.24E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs2294843 chr1 210566557 A G 8.10E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs1997783 chr1 210567820 C T 5.38E-05 Cholesterol HHAT intron pha003073 rs12024862 chr1 210569102 A G 9.94E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10489385 chr1 210572437 C T 3.79E-04 Multiple complex diseases HHAT intron 17554300 rs10489385 chr1 210572437 C T 5.98E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3753230 chr1 210575444 G A 6.22E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10863825 chr1 210577134 T C 4.38E-04 Multiple complex diseases HHAT intron 17554300 rs10863825 chr1 210577134 T C 8.86E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs11119485 chr1 210577359 A G 8.46E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs11119496 chr1 210605675 C T 1.80E-05 Urinary metabolites HHAT intron 21572414 rs926576 chr1 210608164 C T 1.81E-04 Multiple complex diseases HHAT intron 17554300 rs11119499 chr1 210611316 G A 4.06E-04 Response to cytadine analogues (cytosine arabinoside) HHAT intron 24483146 rs11119499 chr1 210611316 G A 9.17E-04 Response to cytidine analogues (gemcitabine) HHAT intron 24483146 rs3819985 chr1 210622790 C T 2.60E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HHAT intron 24023788 rs17260438 chr1 210662875 G A 2.22E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HHAT intron 24023788 rs17416565 chr1 210669415 T G 1.19E-04 Multiple complex diseases HHAT intron 17554300 rs17016468 chr1 210736837 C T 3.49E-04 Multiple complex diseases HHAT intron 17554300 rs2501909 chr1 210738604 C G 2.80E-05 Urinary metabolites HHAT intron 21572414 rs12133319 chr1 210794866 G A 4.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4504959 chr1 210801879 T G 6.02E-05 Information processing speed HHAT intron 21130836 rs4951687 chr1 210807047 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4951687 chr1 210807047 A G 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4951488 chr1 210808270 G A 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs12096661 chr1 210819646 A C 5.44E-04 Response to taxane treatment (placlitaxel) HHAT intron 23006423 rs4951508 chr1 210829477 T C 2.25E-04 Vaspin levels HHAT intron 22907691 rs4951508 chr1 210829477 T C 0.0002249 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit HHAT intron 22907730 rs4472816 chr1 210830320 T C 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4472816 chr1 210830320 T C 5.89E-04 Response to taxane treatment (placlitaxel) HHAT intron 23006423 rs4472816 chr1 210830320 T C 9.91E-05 HDL cholesterol HHAT intron pha003075 rs10746432 chr1 210837691 A G 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs11119565 chr1 210839684 C T 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4366378 chr1 210847740 A C 2.13E-05 stroke (ischemic) HHAT UTR-3 17434096 rs10863850 chr1 210848224 A G 2.04E-04 Schizophrenia(treatment response to risperidone) HHAT UTR-3 19850283 rs1135317 chr1 210857457 A G 3.88E-04 Multiple complex diseases KCNH1 cds-synon 17554300 rs2357921 chr1 210858222 C T 8.04E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs4628571 chr1 210858403 C T 1.70E-04 Multiple complex diseases KCNH1 intron 17554300 rs4628571 chr1 210858403 C T 5.87E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs4628571 chr1 210858403 C T 1.00E-05 Anger KCNH1 intron 24489884 rs12141923 chr1 210860558 C T 6.24E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs17260690 chr1 210871341 C A 4.14E-04 Smoking initiation KCNH1 intron 24665060 rs1934620 chr1 210898263 A G 8.00E-06 Smooth-surface caries KCNH1 intron 23470693 rs10863854 chr1 210913912 C T 8.47E-05 Serum metabolites KCNH1 intron 19043545 rs4951563 chr1 210923061 A G 1.73E-05 Chronic obstructive pulmonary disease KCNH1 intron 19300482 rs4951563 chr1 210923061 A G 1.73E-05 Response to statin treatment (atorvastatin),change in cholesterol levels KCNH1 intron 20031582 rs1934636 chr1 210929893 C A 0.000045 Prostate cancer KCNH1 intron 22532847 rs2185385 chr1 210930809 A G 8.49E-05 Serum metabolites KCNH1 intron 19043545 rs1418973 chr1 210994339 G A 7.09E-04 Stroke KCNH1 intron pha002887 rs4951669 chr1 211032696 C G 2.70E-05 Parkinson's disease (age of onset) KCNH1 intron 19772629 rs1343144 chr1 211043895 A C 5.78E-04 Multiple complex diseases KCNH1 intron 17554300 rs7552646 chr1 211069694 A G 2.76E-05 Cognitive performance KCNH1 intron 19734545 rs1501562 chr1 211072392 C T 1.60E-05 Inflammatory demyelinating disease KCNH1 intron 19850125 rs6656271 chr1 211081403 A G 3.61E-04 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs1777242 chr1 211087197 G C 7.20E-07 Red blood cell traits KCNH1 intron 23222517 rs12121565 chr1 211098815 G T 9.00E-06 Urinary metabolites KCNH1 intron 21572414 rs6702809 chr1 211114607 C T 5.90E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) KCNH1 intron 24192120 rs1501558 chr1 211126407 G A 3.06E-04 Alcohol dependence KCNH1 intron 20201924 rs33985151 chr1 211166032 T C 2.30E-05 Urinary metabolites KCNH1 intron 21572414 rs1501550 chr1 211168759 G A 2.00E-06 Circulating vasoactive peptide levels KCNH1 intron 23381795 rs1501551 chr1 211176922 C T 2.92E-04 Premature ovarian failure KCNH1 intron 19508998 rs1501551 chr1 211176922 C T 6.18E-04 Alcohol dependence KCNH1 intron 20201924 rs6662529 chr1 211222705 C T 7.75E-05 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs4072301 chr1 211225288 C T 7.40E-06 Urinary metabolites KCNH1 intron 21572414 rs11119672 chr1 211228477 C T 3.90E-06 Urinary metabolites KCNH1 intron 21572414 rs4628570 chr1 211239659 C T 2.40E-05 Urinary metabolites KCNH1 intron 21572414 rs17267442 chr1 211272818 C T 7.16E-04 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs6687686 chr1 211275293 C T 1.08E-04 Parkinson's disease KCNH1 intron 21248740 rs1538287 chr1 211311244 C T 2.64E-05 Longevity / / 21612516 rs6540664 chr1 211331893 G A 4.45E-05 Longevity / / 21612516 rs3120780 chr1 211348635 A G 1.91E-05 Non-word repetition / / 23738518 rs12134651 chr1 211351513 A G 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs12731366 chr1 211378802 G A 9.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3111253 chr1 211412408 C G 0.0001744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3111253 chr1 211412408 C G 1.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3111257 chr1 211420319 T C 5.89E-05 Sodium levels / / pha003093 rs17267491 chr1 211463815 C T 9.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12729996 chr1 211469497 A C,T 9.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12754607 chr1 211470727 C G 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12754747 chr1 211470827 C T 0.0008509 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs12754747 chr1 211470827 C T 8.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs17188937 chr1 211475333 A C 0.0008027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs17188937 chr1 211475333 A C 8.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12041498 chr1 211485060 A T 0.0002083 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs12041498 chr1 211485060 A T 2.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs6540681 chr1 211493573 A G 6.80E-04 Alcohol dependence / / 20201924 rs12723208 chr1 211510894 A G 4.40E-07 Glioma (high-grade) TRAF5 intron 19578366 rs12723208 chr1 211510894 A G 0.0006104 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs12723208 chr1 211510894 A G 6.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs2280079 chr1 211517202 G A 0.0006086 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs2280079 chr1 211517202 G A 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs4951522 chr1 211527481 G A 0.00002317 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs4951522 chr1 211527481 G A 2.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs10494936 chr1 211528806 T C 0.00002319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs10494936 chr1 211528806 T C 2.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs12752670 chr1 211530480 G A 0.000609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs12752670 chr1 211530480 G A 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs6684874 chr1 211532060 A T 0.00002565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs6684874 chr1 211532060 A T 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs2292483 chr1 211533027 G A 0.00002572 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs2292483 chr1 211533027 G A 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs17267554 chr1 211540144 C T 2.60E-05 Lymphocyte counts TRAF5 intron 22286170 rs17267554 chr1 211540144 C T 0.0006538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs17267554 chr1 211540144 C T 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs17267561 chr1 211540941 G A 0.0006549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs17267561 chr1 211540941 G A 6.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs12124008 chr1 211643872 T C 1.46E-04 Myocardial Infarction / / pha002883 rs11119748 chr1 211652185 C G 9.20E-04 Multiple complex diseases RD3 UTR-3 17554300 rs17017536 chr1 211656238 G A 2.08E-04 Multiple complex diseases RD3 intron 17554300 rs10863899 chr1 211666218 A G 2.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) RD3 UTR-5 23648065 rs7527396 chr1 211667857 G A 7.21E-04 Multiple complex diseases RD3 nearGene-5 17554300 rs1578838 chr1 211671118 T G 8.37E-05 Cognitive test performance / / 20125193 rs755448 chr1 211672506 G A 2.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs11119754 chr1 211678947 T C 9.90E-05 Cognitive test performance / / 20125193 rs2166104 chr1 211690818 A T 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2166104 chr1 211690818 A T 7.13E-06 Retinopathy in non-diabetics / / 23393555 rs2120671 chr1 211690993 A C 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7553035 chr1 211691706 G T 4.00E-06 Retinopathy in non-diabetics / / 23393555 rs6669700 chr1 211697052 G A 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1614866 chr1 211700658 G A 1.00E-06 Coronary heart disease / / 21347282 rs1614866 chr1 211700658 G A 1.00E-06 Coronary heart disease / / 21347282 rs7527626 chr1 211705386 T C 6.16E-04 Aortic root size / / 21223598 rs1777826 chr1 211709083 A G 1.40E-05 Post-operative nausea and vomiting / / 21694509 rs1285978 chr1 211718203 C T 8.74E-05 Alzheimer's disease (age of onset) / / 22005931 rs12041727 chr1 211727371 T A 2.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs7530862 chr1 211736470 T C 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17017750 chr1 211738180 G C 9.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs2278652 chr1 211751025 A G 9.03E-04 Suicide attempts in bipolar disorder SLC30A1 intron 21423239 rs12030478 chr1 211755204 C T 1.69E-06 Rheumatoid arthritis / / 19503088 rs17017782 chr1 211763053 A G 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs9429874 chr1 211767738 A C 8.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12727395 chr1 211769306 T C 8.58E-06 Alzheimer's disease / / 22832961 rs4951536 chr1 211776439 A C 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4951536 chr1 211776439 A C 3.42E-05 Weight / / pha003026 rs4951536 chr1 211776439 A C 8.80E-05 Weight / / pha003027 rs894853 chr1 211807505 C G 7.36E-04 Multiple complex diseases / / 17554300 rs10158309 chr1 211813550 C T 7.97E-04 Multiple complex diseases / / 17554300 rs2028706 chr1 211831380 A C 8.32E-04 Obesity (extreme) NEK2 nearGene-3 21935397 rs12027312 chr1 211832965 T G 5.10E-04 Alzheimer's disease NEK2 intron 22005930 rs12037104 chr1 211833095 C T 3.74E-04 Alzheimer's disease NEK2 intron 22005930 rs1373292 chr1 211833926 G A 9.31E-04 Amyotrophic Lateral Sclerosis NEK2 intron 17827064 rs12039766 chr1 211835267 C A 3.80E-04 Alzheimer's disease NEK2 intron 22005930 rs12031285 chr1 211836789 T C 7.98E-04 Obesity (extreme) NEK2 cds-synon 21935397 rs11119789 chr1 211837396 C T 4.39E-04 Obesity (extreme) NEK2 intron 21935397 rs10159325 chr1 211838131 G C 6.64E-04 Obesity (extreme) NEK2 intron 21935397 rs6698450 chr1 211844020 C G 6.95E-04 Obesity (extreme) NEK2 intron 21935397 rs11119792 chr1 211849969 C T 5.64E-04 Obesity (extreme) NEK2 nearGene-5 21935397 rs701924 chr1 211854180 T C 6.75E-04 Sarcoidosis / / 19165924 rs7551769 chr1 211856410 G A 4.80E-04 Obesity (extreme) / / 21935397 rs10494939 chr1 211856495 T C 6.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10494939 chr1 211856495 T C 4.55E-04 Obesity (extreme) / / 21935397 rs7516751 chr1 211859913 G A 4.78E-04 Alzheimer's disease / / 22005930 rs6661565 chr1 211859925 G A 8.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7553543 chr1 211865655 A G 4.81E-04 Alzheimer's disease / / 22005930 rs7540628 chr1 211891444 A G 1.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11119805 chr1 211918244 T A 3.00E-09 Stearic acid (18:0) plasma levels LPGAT1 UTR-3 23362303 rs6673226 chr1 211934111 G A 2.29E-04 Body mass index LPGAT1 intron 21701565 rs6673226 chr1 211934111 G A 5.10E-04 Body mass index LPGAT1 intron 21701565 rs12023263 chr1 211943879 C T 3.55E-04 Body mass index LPGAT1 intron 21701565 rs12023263 chr1 211943879 C T 5.82E-04 Body mass index LPGAT1 intron 21701565 rs4951552 chr1 211979135 A C 1.53E-04 Body mass index LPGAT1 intron 21701565 rs4951552 chr1 211979135 A C 2.62E-04 Body mass index LPGAT1 intron 21701565 rs11119813 chr1 211979205 T G 1.68E-04 Type 2 diabetes LPGAT1 intron 17463246 rs6540709 chr1 211990542 A G 1.14E-04 Type 2 diabetes LPGAT1 intron 17463246 rs7534335 chr1 212008445 T G 2.76E-04 Type 2 diabetes / / 17463246 rs12058008 chr1 212046447 A G 1.67E-04 Body mass index / / 21701565 rs12058008 chr1 212046447 A G 2.21E-04 Body mass index / / 21701565 rs11119822 chr1 212056593 G A 1.28E-04 Body mass index / / 21701565 rs11119822 chr1 212056593 G A 1.43E-04 Body mass index / / 21701565 rs7540019 chr1 212079778 A G 8.66E-04 Myopia (pathological) / / 21095009 rs2808382 chr1 212091948 G C 4.90E-06 Urinary metabolites / / 21572414 rs2788135 chr1 212125260 G A 2.80E-04 Stroke INTS7 intron pha002886 rs17018280 chr1 212125430 T G 6.53E-04 Multiple complex diseases INTS7 intron 17554300 rs2788131 chr1 212133675 A C 3.74E-04 Type 2 diabetes INTS7 intron 17463246 rs34836942 chr1 212148999 C T 7.53E-04 Multiple complex diseases INTS7 intron 17554300 rs34836942 chr1 212148999 C T 8.64E-04 Alzheimer's disease INTS7 intron 17998437 rs17018311 chr1 212155008 T C 2.00E-08 Temperament (bipolar disorder) INTS7 intron 22365631 rs2993535 chr1 212155192 A G 1.30E-06 Urinary metabolites INTS7 intron 21572414 rs3010029 chr1 212197844 A G 1.80E-06 Urinary metabolites INTS7 intron 21572414 rs17018378 chr1 212210027 G A 4.92E-04 Multiple complex diseases DTL intron 17554300 rs10863936 chr1 212237798 G A 2.00E-09 Height DTL intron 20881960 rs10863938 chr1 212262467 T C 2.68E-04 Stroke DTL intron pha002886 rs1586660 chr1 212266531 C G 1.80E-06 Urinary metabolites DTL intron 21572414 rs3135474 chr1 212273639 C T 2.41E-04 Stroke DTL missense pha002886 rs7545292 chr1 212279058 G T 4.65E-04 Stroke / / pha002886 rs11119860 chr1 212332294 T C 5.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11119861 chr1 212338360 A G 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs11119865 chr1 212344323 C T 4.69E-04 Type 2 diabetes / / 17463246 rs11119865 chr1 212344323 C T 5.90E-04 Multiple complex diseases / / 17554300 rs11119866 chr1 212344489 A G 7.96E-04 Multiple complex diseases / / 17554300 rs7550051 chr1 212345669 G A 8.16E-04 Myocardial Infarction / / pha002883 rs6680653 chr1 212347352 C T 5.18E-05 Relative hand skill / / 24068947 rs4325202 chr1 212351181 C T 4.73E-05 Relative hand skill / / 24068947 rs1472224 chr1 212351319 T C 4.66E-05 Relative hand skill / / 24068947 rs10436976 chr1 212360408 A G 8.73E-05 Hypertension (essential hypertension) / / 22184326 rs1967114 chr1 212375336 G A 7.95E-04 Multiple complex diseases / / 17554300 rs11119881 chr1 212379741 A C 1.98E-05 Major depressive disorder / / 19107115 rs6540731 chr1 212392163 G A 9.00E-06 Intelligence (childhood) / / 23358156 rs7519168 chr1 212393385 A C 6.05E-04 Multiple complex diseases / / 17554300 rs3816912 chr1 212399849 G A 6.04E-04 Multiple complex diseases / / 17554300 rs11119887 chr1 212407562 C T 4.00E-04 Multiple complex diseases / / 17554300 rs12145451 chr1 212425291 C A 5.74E-04 Heart Failure / / pha002884 rs10494951 chr1 212429259 G A 6.83E-04 Type 2 diabetes / / 17463246 rs12728266 chr1 212430756 A G 1.10E-04 Type 2 diabetes / / 17463246 rs903119 chr1 212434241 A G 1.15E-04 Height / / 17255346 rs351393 chr1 212476519 A G 1.80E-05 Urinary metabolites PPP2R5A intron 21572414 rs1473321 chr1 212579055 T C 2.80E-05 Urinary metabolites TMEM206 intron 21572414 rs612414 chr1 212602176 G T 0.000010661 Alcohol dependence / / 23089632 rs583058 chr1 212610755 T C 0.0000142 Alcohol dependence NENF intron 23089632 rs4804 chr1 212619339 T C 0.000715 Alcohol dependence NENF cds-synon 23089632 rs4804 chr1 212619339 T C 8.36E-06 Alcohol dependence NENF cds-synon 23089632 rs483954 chr1 212620214 A G 0.0000039 Alcohol dependence / / 23089632 rs483954 chr1 212620214 A G 0.00063 Alcohol dependence / / 23089632 rs675065 chr1 212634583 A G 4.26E-04 Alcohol dependence / / 24277619 rs1021379 chr1 212700204 C T 9.09E-06 Lymphocyte counts / / 22286170 rs2942354 chr1 212708371 A C 8.12E-04 Multiple complex diseases / / 17554300 rs631569 chr1 212717106 G A 3.86E-04 Type 2 diabetes / / 17463246 rs1195474 chr1 212738202 A T 6.16E-05 Multiple complex diseases ATF3 nearGene-5 17554300 rs1195474 chr1 212738202 A T 1.43E-05 Serum metabolites ATF3 nearGene-5 19043545 rs10863981 chr1 212756363 G A 4.06E-04 Alzheimer's disease (late onset) ATF3 intron 21379329 rs4543871 chr1 212757658 T C 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ATF3 intron 23648065 rs4543871 chr1 212757658 T C 5.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ATF3 intron 23648065 rs1105899 chr1 212758604 C T 1.80E-05 Urinary metabolites ATF3 intron 21572414 rs1567710 chr1 212768428 C T 8.77E-04 HIV-1 viral setpoint ATF3 intron 17641165 rs11119986 chr1 212769955 G A 4.07E-04 Multiple complex diseases ATF3 intron 17554300 rs10494954 chr1 212778507 T C 8.46E-04 Multiple complex diseases ATF3 intron 17554300 rs3123536 chr1 212809606 C T 0.000525 Salmonella-induced pyroptosis / / 22837397 rs17019510 chr1 212816729 A G 8.69E-05 Bipolar disorder / / 18317468 rs2501846 chr1 212841934 T C 9.24E-04 Tourette syndrome / / 22889924 rs4951633 chr1 212842330 G T 2.50E-05 Urinary metabolites / / 21572414 rs12128789 chr1 212852832 T C 5.28E-04 Multiple complex diseases / / 17554300 rs17019567 chr1 212855923 A G 4.33E-07 IgE levels / / 22075330 rs3768547 chr1 212871081 T A 3.14E-04 Lung function (forced expiratory volume in 1 second) BATF3 intron 17255346 rs3768547 chr1 212871081 T A 2.96E-04 Multiple complex diseases BATF3 intron 17554300 rs9658807 chr1 212876902 A G 6.33E-05 IgE levels / / 22075330 rs7555918 chr1 212885805 A G 2.94E-04 Insulin resistance / / 21901158 rs6681171 chr1 212892113 T G 1.41E-05 Type 1 diabetes / / 21980299 rs10863988 chr1 212894474 G A 2.12E-04 Multiple complex diseases / / 17554300 rs10863988 chr1 212894474 G A 3.50E-06 Urinary metabolites / / 21572414 rs11800991 chr1 212894578 C T 1.00E-04 Insulin resistance / / 21901158 rs11800642 chr1 212909744 A G 3.23E-06 HIV-1 control NSL1 UTR-3 20041166 rs2271148 chr1 212913168 T C 7.68E-04 Response to taxane treatment (placlitaxel) NSL1 intron 23006423 rs6702101 chr1 212913590 C T 7.86E-06 HIV-1 control NSL1 intron 20041166 rs12125867 chr1 212917980 G A 2.44E-04 Multiple complex diseases NSL1 intron 17554300 rs12125867 chr1 212917980 G A 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs1507358 chr1 212925361 T C 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs1507357 chr1 212925429 C A 4.92E-04 Multiple complex diseases NSL1 intron 17554300 rs6540762 chr1 212925857 C T 8.97E-06 HIV-1 control NSL1 intron 20041166 rs12404618 chr1 212927009 A G 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs12404885 chr1 212927167 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs11120014 chr1 212933545 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs11808846 chr1 212943581 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs6687672 chr1 212944877 C G 6.64E-04 Multiple complex diseases NSL1 intron 17554300 rs7516312 chr1 212946919 T C 5.32E-04 Multiple complex diseases NSL1 intron 17554300 rs10863997 chr1 212947520 G A 2.62E-05 HIV-1 control NSL1 intron 20041166 rs3738798 chr1 212965469 C T 8.97E-06 HIV-1 control TATDN3 intron 20041166 rs17019726 chr1 212969128 A G 2.69E-04 Multiple complex diseases TATDN3 intron 17554300 rs10494955 chr1 212971978 C G 2.51E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) TATDN3 intron 17982456 rs12128410 chr1 212972599 C T 7.55E-04 Multiple complex diseases TATDN3 intron 17554300 rs12128410 chr1 212972599 C T 1.17E-05 HIV-1 control TATDN3 intron 20041166 rs12128410 chr1 212972599 C T 2.70E-05 Urinary metabolites TATDN3 intron 21572414 rs1532951 chr1 212978197 T G 3.40E-05 HIV-1 control TATDN3 intron 20041166 rs7515115 chr1 212986554 T C 5.07E-04 Multiple complex diseases TATDN3 intron 17554300 rs7515115 chr1 212986554 T C 1.23E-05 HIV-1 control TATDN3 intron 20041166 rs6694190 chr1 213005012 G A 2.13E-04 Multiple complex diseases C1orf227 intron 17554300 rs6694190 chr1 213005012 G A 1.20E-05 Urinary metabolites C1orf227 intron 21572414 rs963328 chr1 213037661 G T 5.00E-05 Type 2 diabetes FLVCR1 intron 17903298 rs963328 chr1 213037661 G T 3.01E-05 Blood Pressure and Arterial Stiffness FLVCR1 intron 17903302 rs963328 chr1 213037661 G T 3.52E-04 Lymphocyte counts FLVCR1 intron 22286170 rs1587175 chr1 213065262 A T 8.10E-04 Type 2 diabetes and 6 quantitative traits FLVCR1 intron 17848626 rs1284852 chr1 213073013 C T 2.60E-06 Urinary metabolites FLVCR1 nearGene-3 21572414 rs12760321 chr1 213083261 T C 2.79E-04 Type 2 diabetes / / 17463246 rs1284864 chr1 213094034 G A 6.75E-05 Prostate cancer / / pha002878 rs1890933 chr1 213097217 A C 1.50E-05 Urinary metabolites / / 21572414 rs6663614 chr1 213097941 C A 4.01E-04 Insulin resistance / / 21901158 rs6656706 chr1 213120103 C T 9.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs3002288 chr1 213126565 G A 7.00E-08 Eye color VASH2 intron 23548203 rs3738804 chr1 213134651 C T 9.72E-05 Parent of origin effect on language impairment (paternal) VASH2 intron 24571439 rs6679892 chr1 213138075 C A 7.53E-04 Amyotrophic Lateral Sclerosis VASH2 intron 17362836 rs6679892 chr1 213138075 C A 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VASH2 intron 20877124 rs7511930 chr1 213146944 A G 7.22E-04 Amyotrophic Lateral Sclerosis VASH2 intron 17362836 rs7511930 chr1 213146944 A G 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VASH2 intron 20877124 rs6688043 chr1 213160145 T C 2.28E-04 Multiple complex diseases VASH2 intron 17554300 rs3002284 chr1 213181916 T C 8.70E-04 Iris characteristics ANGEL2 intron 21835309 rs74825882 chr1 213186688 C G 0.000076 Breast cancer (ER positive) ANGEL2 missense 23555315 rs4951477 chr1 213232555 A C 2.77E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs11120089 chr1 213278325 A G 4.88E-04 Schizophrenia RPS6KC1 intron 19197363 rs6692144 chr1 213307456 T C 6.57E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1391549 chr1 213371127 C T 6.06E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs2817978 chr1 213373306 G A 8.54E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1498356 chr1 213382584 T G 3.77E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs3924768 chr1 213401648 T C 3.98E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs17020327 chr1 213420895 T C 7.02E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1187802 chr1 213456220 A G 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11576637 chr1 213503630 T A,C,G 7.95E-04 Schizophrenia / / 19197363 rs1187768 chr1 213511147 G A 9.94E-04 Type 2 diabetes / / 17463246 rs10864043 chr1 213521433 A G 8.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1187767 chr1 213524560 T G 8.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1656023 chr1 213525900 T C 2.53E-04 Obesity (extreme) / / 21935397 rs1656022 chr1 213527242 G A 2.45E-14 Multiple complex diseases / / 17554300 rs1656022 chr1 213527242 G A 2.59E-04 Obesity (extreme) / / 21935397 rs1656021 chr1 213527588 C T 2.60E-04 Obesity (extreme) / / 21935397 rs1699196 chr1 213529216 T A 6.52E-05 Cytomegalovirus antibody response / / 21993531 rs1187782 chr1 213545274 A T 1.40E-05 Urinary metabolites / / 21572414 rs1187780 chr1 213547278 C T 1.60E-05 Urinary metabolites / / 21572414 rs2359700 chr1 213548789 C T 6.05E-04 Multiple complex diseases / / 17554300 rs1434890 chr1 213556162 G A 5.80E-06 Urinary metabolites / / 21572414 rs11809986 chr1 213558937 A G 0.00019 Coronary artery calcification / / 23727086 rs1187770 chr1 213563818 C A 2.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs320462 chr1 213586276 G C 5.99E-05 Response to citalopram treatment / / 19846067 rs12045355 chr1 213603105 G A 3.64E-04 Smoking cessation / / 24665060 rs320451 chr1 213617738 C T 9.20E-05 Smoking cessation / / 24665060 rs1158048 chr1 213629388 G A 7.52E-04 Body mass index / / 21701565 rs1158048 chr1 213629388 G A 2.30E-04 Smoking cessation / / 24665060 rs12036568 chr1 213636801 C T 6.94E-04 Body mass index / / 21701565 rs12036568 chr1 213636801 C T 4.51E-05 Smoking cessation / / 24665060 rs6667442 chr1 213638762 T A 2.60E-05 Smoking cessation / / 24665060 rs320466 chr1 213651724 T C 4.92E-04 Fat body mass / / 24064335 rs17702239 chr1 213659876 G A 0.000104 Breast cancer early age of onset / / 18463975 rs12137618 chr1 213659901 G T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2165130 chr1 213666824 G T 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2173482 chr1 213666889 C G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1561499 chr1 213709450 C A 6.69E-05 Serum metabolites / / 19043545 rs967352 chr1 213721111 C T 3.84E-04 Smoking initiation / / 24665060 rs2218115 chr1 213724325 G T 2.83E-05 Serum metabolites / / 19043545 rs320391 chr1 213725260 T C 2.30E-05 Serum metabolites / / 19043545 rs412878 chr1 213729352 T A 9.68E-05 Serum metabolites / / 19043545 rs4073191 chr1 213747787 T C 8.37E-24 Varicose Veins / / pha001412 rs17021056 chr1 213769092 T C 5.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6692095 chr1 213776884 C T 4.56E-04 Smoking quantity / / 24665060 rs11120170 chr1 213779196 G A 3.60E-04 Alcohol dependence / / 20201924 rs12135768 chr1 213798251 G A 1.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4655454 chr1 213805502 A G 1.90E-05 Glioma (high-grade) / / 19578366 rs7529857 chr1 213811721 T G 7.64E-04 Pemphigus vulgaris / / 22437316 rs12144639 chr1 213817311 G A 5.70E-06 Orofacial clefts / / 22419666 rs6693655 chr1 213827269 T C 7.18E-04 Myopia (pathological) / / 21095009 rs7526094 chr1 213833093 G A 2.70E-05 Urinary metabolites / / 21572414 rs4655303 chr1 213834643 A T 5.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs1509865 chr1 213840987 C G 1.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17706439 chr1 213855588 G A 3.00E-06 RR interval (heart rate) / / 20031603 rs4655461 chr1 213864971 G A 9.52E-06 C-reactive protein / / 22492993 rs10864064 chr1 213877776 T G 7.38E-06 C-reactive protein / / 22492993 rs6540801 chr1 213887376 G C 9.85E-05 Formal thought disorder in schizophrenia / / 22648509 rs6540801 chr1 213887376 G C 7.70E-04 Smoking quantity / / 24665060 rs6657203 chr1 213893501 G T 6.56E-05 Formal thought disorder in schizophrenia / / 22648509 rs1704198 chr1 213910494 T G 4.00E-07 Obesity / / 23818313 rs11803653 chr1 213914914 G A 9.57E-05 Formal thought disorder in schizophrenia / / 22648509 rs2664687 chr1 213915461 G A 2.10E-06 Urinary metabolites / / 21572414 rs12041173 chr1 213932821 T C 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1891058 chr1 213937382 G A 8.09E-05 Smoking initiation / / 24665060 rs17759253 chr1 213941794 G A 4.75E-04 Alzheimer's disease (late onset) / / 21379329 rs12117411 chr1 213952992 T C 1.70E-05 Urinary metabolites / / 21572414 rs12724110 chr1 213962023 C T 2.66E-04 Insulin resistance / / 21901158 rs12058083 chr1 213968815 A G 2.80E-05 Urinary metabolites / / 21572414 rs1891060 chr1 213969354 C T 1.41E-05 HIV-1 viral setpoint / / 17641165 rs12758106 chr1 213991265 T C 2.66E-04 Insulin resistance / / 21901158 rs2236580 chr1 214026324 C T 8.69E-05 Major depressive disorder PROX1-AS1 intron 21621269 rs853750 chr1 214044159 A C 7.26E-05 Post-operative nausea and vomiting PROX1-AS1 intron 21694509 rs9662330 chr1 214069479 C T 3.46E-04 HIV-1 viral setpoint PROX1-AS1 intron 17641165 rs1073570 chr1 214095944 C T 9.40E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs7550337 chr1 214099716 T C 8.15E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs1159179 chr1 214108641 T C 9.06E-04 Insulin resistance PROX1-AS1 intron 21901158 rs11120231 chr1 214110152 C A 4.66E-04 Rheumatoid arthritis PROX1-AS1 intron 21452313 rs7554295 chr1 214110402 C T 6.45E-04 Insulin resistance PROX1-AS1 intron 21901158 rs340849 chr1 214118090 C A 8.00E-06 Alzheimer's disease PROX1-AS1 intron 22159054 rs340846 chr1 214121096 T C 4.84E-04 Rheumatoid arthritis PROX1-AS1 intron 21452313 rs17762150 chr1 214124818 C T 3.64E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs6665854 chr1 214125024 C A 5.93E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs17762192 chr1 214125127 G C 7.13E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs1367951 chr1 214125513 A G 6.69E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs6698217 chr1 214130413 A C 4.90E-06 Urinary metabolites PROX1-AS1 intron 21572414 rs17712208 chr1 214150445 T A 0.0000039 Type 2 diabetes / / 22885922 rs17712208 chr1 214150445 T A 3.22E-12 Fasting blood glucose / / 22885924 rs17021749 chr1 214150482 C T 1.10E-06 Cognitive impairment induced by topiramate / / 22091778 rs2075423 chr1 214154719 G T 0.0000071 Fasting blood glucose / / 22885922 rs2075423 chr1 214154719 G T 0.0000093 Type 2 diabetes (males) / / 22885922 rs2075423 chr1 214154719 G T 0.00001 Type 2 diabetes (females) / / 22885922 rs2075423 chr1 214154719 G T 0.00039 HOMA-B / / 22885922 rs2075423 chr1 214154719 G T 8.10E-09 Type 2 diabetes / / 22885922 rs2075423 chr1 214154719 G T 2.00E-06 Type 2 diabetes / / 24509480 rs13376660 chr1 214154985 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs340878 chr1 214157049 G C 0.00000094 Fasting blood glucose / / 22885924 rs340874 chr1 214159256 T C 7.11E-04 HIV-1 viral setpoint / / 17641165 rs340874 chr1 214159256 T C 5.00E-06 Fasting glucose-related traits / / 20081858 rs340874 chr1 214159256 T C 7.00E-12 Fasting insulin-related traits / / 20081858 rs340874 chr1 214159256 T C 4.00E-09 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs340874 chr1 214159256 T C 4.10E-10 Type 2 diabetes / / 22885922 rs340874 chr1 214159256 T C 0.0000435 Fasting insulin-related traits / / 22885924 rs340874 chr1 214159256 T C 1.78E-11 Fasting blood glucose / / 22885924 rs340835 chr1 214163675 G A 2.73E-04 Multiple complex diseases PROX1 intron 17554300 rs340835 chr1 214163675 G A 9.61E-04 Stroke PROX1 intron pha002887 rs11120251 chr1 214239318 G A 6.25E-04 Schizophrenia(age at onset) / / 21688384 rs1440620 chr1 214261350 T C 1.00E-06 Dietary macronutrient intake / / 23372041 rs1440620 chr1 214261350 T C 9.98E-04 Alcohol dependence / / 24277619 rs920489 chr1 214287420 T C 1.20E-05 Urinary metabolites / / 21572414 rs1795040 chr1 214288429 A G 7.72E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1660383 chr1 214288897 G A 1.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660382 chr1 214289118 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660381 chr1 214289767 T C 2.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660380 chr1 214289779 A G 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660378 chr1 214290242 T C 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660377 chr1 214290301 T A 2.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795037 chr1 214290542 G A 2.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1440619 chr1 214291051 G A 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs12568811 chr1 214291944 A G 2.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795036 chr1 214292309 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795035 chr1 214292353 C T 2.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795034 chr1 214292589 T C 2.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795033 chr1 214293994 T G 3.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1660375 chr1 214294554 G A 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs7550684 chr1 214305863 T C 2.78E-04 Multiple complex diseases / / 17554300 rs1223802 chr1 214348346 G A 7.83E-04 Type 2 diabetes / / 22158537 rs2218196 chr1 214350457 A G 5.99E-04 Multiple complex diseases / / 17554300 rs11589520 chr1 214350621 A G 7.38E-04 Multiple complex diseases / / 17554300 rs2196944 chr1 214359057 C G 3.20E-04 Multiple complex diseases / / 17554300 rs6699206 chr1 214368330 G A 1.78E-05 Cognitive performance / / 19734545 rs1660367 chr1 214406939 T C 1.39E-05 Cognitive performance / / 19734545 rs6665548 chr1 214416824 A G 3.92E-04 Multiple complex diseases / / 17554300 rs6665548 chr1 214416824 A G 6.04E-04 Alcohol dependence / / 21314694 rs6682783 chr1 214418139 G T 7.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs766499 chr1 214439328 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs766499 chr1 214439328 A C 7.09E-05 Creatinine levels / / pha003069 rs9308433 chr1 214457009 T C 2.00E-06 IgG glycosylation SMYD2 intron 23382691 rs9308433 chr1 214457009 T C 4.00E-06 IgG glycosylation SMYD2 intron 23382691 rs9970083 chr1 214457286 G T 2.80E-05 Creatinine levels SMYD2 intron pha003069 rs11120288 chr1 214462988 A G 9.97E-05 Lipid levels SMYD2 intron pha003082 rs6677732 chr1 214490228 A G 8.09E-04 Multiple complex diseases SMYD2 intron 17554300 rs12124666 chr1 214491961 C T 7.95E-04 Multiple complex diseases SMYD2 intron 17554300 rs12124666 chr1 214491961 C T 4.05E-05 Creatinine levels SMYD2 intron pha003069 rs1134647 chr1 214492286 G A 4.00E-05 Creatinine levels SMYD2 missense pha003069 rs7419021 chr1 214502374 T C 9.87E-04 Multiple complex diseases SMYD2 intron 17554300 rs1472441 chr1 214527252 G A 3.42E-06 Statin-induced myopathy PTPN14 UTR-3 21826682 rs7543972 chr1 214529786 A G 1.85E-05 Multiple complex diseases PTPN14 UTR-3 17554300 rs7543972 chr1 214529786 A G 3.53E-06 Height PTPN14 UTR-3 22021425 rs3002309 chr1 214544632 A C 4.29E-05 Statin-induced myopathy PTPN14 intron 21826682 rs3013444 chr1 214559440 C T 7.05E-06 Height PTPN14 intron 22021425 rs6657368 chr1 214567378 A G 3.19E-04 Multiple complex diseases PTPN14 intron 17554300 rs12748605 chr1 214571527 C G 0.000144 Salmonella-induced pyroptosis PTPN14 intron 22837397 rs6657749 chr1 214576513 C T 2.99E-05 Attention deficit hyperactivity disorder PTPN14 intron 18980221 rs6657749 chr1 214576513 C T 4.68E-06 Attention deficit hyperactivity disorder PTPN14 intron pha002875 rs11120313 chr1 214581206 C A 4.53E-06 Blood pressure PTPN14 intron 21378095 rs17732428 chr1 214610504 A G 5.87E-05 Blood Pressure PTPN14 intron pha003048 rs6698007 chr1 214624286 T G 2.92E-04 Bipolar disorder PTPN14 intron 18317468 rs12757404 chr1 214629616 A G 2.00E-06 Lipid traits PTPN14 intron 24386095 rs17734395 chr1 214673445 C T 3.87E-04 Multiple complex diseases PTPN14 intron 17554300 rs17042140 chr1 214674925 T C 4.00E-06 Thyroid stimulating hormone PTPN14 intron 24722205 rs6540844 chr1 214680378 C T 2.00E-06 Urinary metabolites PTPN14 intron 21572414 rs4326598 chr1 214710841 C T 3.10E-07 Urinary metabolites PTPN14 intron 21572414 rs12747035 chr1 214719346 G A 2.00E-05 Urinary metabolites PTPN14 intron 21572414 rs7535253 chr1 214744893 T C 8.31E-04 Aortic root size / / 21223598 rs7535253 chr1 214744893 T C 8.13E-04 Alzheimer's disease / / 22005930 rs7523691 chr1 214745193 C T 1.95E-05 Multiple complex diseases / / 17554300 rs2807644 chr1 214747257 A C 2.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs2807644 chr1 214747257 A C 6.38E-04 Stroke / / pha002886 rs12097854 chr1 214817364 T C 5.39E-04 Type 2 diabetes CENPF intron 17463246 rs12097854 chr1 214817364 T C 5.26E-04 Multiple complex diseases CENPF intron 17554300 rs3748697 chr1 214820099 A G 7.92E-05 Cognitive impairment induced by topiramate CENPF missense 22091778 rs3748697 chr1 214820099 A G 8.50E-04 Stroke CENPF missense pha002886 rs3748698 chr1 214820299 A G 2.55E-04 Amyotrophic Lateral Sclerosis CENPF cds-synon 17362836 rs438034 chr1 214830617 A G 5.00E-06 Response to antineoplastic agents CENPF missense 21659360 rs438034 chr1 214830617 A G 3.76E-05 Cognitive impairment induced by topiramate CENPF missense 22091778 rs438034 chr1 214830617 A G 8.93E-04 Stroke CENPF missense pha002886 rs417774 chr1 214833425 G A 6.68E-05 Cognitive impairment induced by topiramate CENPF intron 22091778 rs335561 chr1 214865123 C T 3.52E-04 Multiple complex diseases / / 17554300 rs7553478 chr1 214870992 C T 1.68E-04 Multiple complex diseases / / 17554300 rs1858650 chr1 214939861 G A 2.88E-05 Weight loss (gastric bypass surgery) / / 23633212 rs6695352 chr1 214954939 T C 4.00E-06 Migraine without aura / / 23793025 rs6695352 chr1 214954939 T C 5.81E-04 Migraine / / 23793025 rs11805072 chr1 214984422 G A 4.90E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11807086 chr1 215064388 G A 8.95E-04 Iron levels / / pha002876 rs1336948 chr1 215068688 C T 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6540871 chr1 215095284 T C 8.76E-04 HIV-1 viral setpoint / / 17641165 rs7534785 chr1 215102422 G A 5.29E-04 Alcohol dependence / / 21314694 rs6684902 chr1 215113661 G A 8.46E-05 Blood Pressure / / pha003039 rs1377185 chr1 215120353 C T 4.56E-05 Major depressive disorder / / 21621269 rs1377185 chr1 215120353 C T 3.16E-05 Major depressive disorder / / pha002850 rs556648 chr1 215120596 G A 9.05E-05 Major depressive disorder / / 21621269 rs556648 chr1 215120596 G A 3.84E-05 Major depressive disorder / / pha002850 rs549523 chr1 215127770 A G 5.97E-05 Blood Pressure / / pha003039 rs1452628 chr1 215139887 A T 2.10E-05 Urinary metabolites / / 21572414 rs61819972 chr1 215167654 T G 0.00008829 Sarcoidosis / / 22952805 rs56152266 chr1 215168036 A G 0.00008829 Sarcoidosis / / 22952805 rs61819973 chr1 215168874 T G 0.00008829 Sarcoidosis / / 22952805 rs61819974 chr1 215169703 T C 0.00008589 Sarcoidosis / / 22952805 rs10494989 chr1 215188239 G A 2.40E-05 Lipid traits KCNK2 intron 17903299 rs12064317 chr1 215227041 G T 6.10E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs12066755 chr1 215231442 A T 7.70E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs6665177 chr1 215231468 A G 6.20E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs12088480 chr1 215246836 C T 7.80E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs11120483 chr1 215247294 A G 7.70E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs7528988 chr1 215248417 C T 9.78E-04 Obesity (extreme) KCNK2 intron 21935397 rs11120504 chr1 215307777 G T 8.68E-05 Melanoma KCNK2 intron 21926416 rs12567520 chr1 215329267 G A 3.31E-04 Alzheimer's disease (late onset) KCNK2 intron 21379329 rs17024342 chr1 215342573 C T 1.42E-04 Multiple complex diseases KCNK2 cds-synon 17554300 rs12038695 chr1 215377957 C A 7.35E-05 Melanoma KCNK2 intron 21926416 rs12753507 chr1 215380352 G A 7.51E-05 Melanoma KCNK2 intron 21926416 rs12753507 chr1 215380352 G A 8.91E-05 Receptive language ability KCNK2 intron 24687471 rs6540886 chr1 215398012 A G 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK2 intron 20877124 rs946487 chr1 215415383 A G 6.49E-04 Multiple complex diseases / / 17554300 rs10494997 chr1 215460047 G A 1.36E-05 Triglycerides / / pha002904 rs11120550 chr1 215491234 G A 5.25E-04 Multiple complex diseases / / 17554300 rs6678266 chr1 215507774 G C 3.17E-05 Multiple complex diseases / / 17554300 rs11120565 chr1 215516983 T C 5.04E-04 Multiple complex diseases / / 17554300 rs2089427 chr1 215570581 A G 7.82E-05 Melanoma / / 21926416 rs1319603 chr1 215631500 T C 6.28E-04 Multiple complex diseases / / 17554300 rs1911546 chr1 215649097 C T 3.66E-04 Alcohol dependence / / 21314694 rs2677112 chr1 215825167 T G 8.56E-04 Alcohol dependence USH2A intron 21314694 rs4655413 chr1 215828499 C T 4.56E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) USH2A intron 24023788 rs11120594 chr1 215839090 G A 1.00E-05 Alcoholism (heaviness of drinking) USH2A intron 21529783 rs2797234 chr1 215848587 T C 1.20E-04 Alzheimer's disease USH2A cds-synon 24755620 rs2797235 chr1 215848641 T C 1.88E-05 Cognitive test performance / / 20125193 rs11120597 chr1 215850892 G A 8.89E-04 Depression (quantitative trait) USH2A intron 20800221 rs1857226 chr1 215888712 G T 7.36E-04 Alzheimer's disease USH2A intron 17998437 rs2797218 chr1 215893303 A G 3.55E-05 Erythrocyte counts USH2A intron pha003099 rs2820710 chr1 215897099 T G 1.90E-05 Erythrocyte counts USH2A intron pha003099 rs17025239 chr1 215898222 G A 9.87E-04 Myopia (pathological) USH2A intron 21095009 rs12406638 chr1 215902239 G A 8.37E-05 Hemoglobin USH2A intron pha003098 rs12406638 chr1 215902239 G A 1.34E-05 Erythrocyte counts USH2A intron pha003099 rs4330896 chr1 215904873 G A 8.03E-05 Glucose levels USH2A intron pha002899 rs4330896 chr1 215904873 G A 2.24E-05 Erythrocyte counts USH2A intron pha003099 rs2797221 chr1 215912642 T C 8.30E-05 Blood pressure USH2A intron 21060006 rs2797221 chr1 215912642 T C 8.60E-07 Blood pressure USH2A intron 21060006 rs2820727 chr1 215928321 C T 5.59E-05 Hemoglobin USH2A intron pha003098 rs11120620 chr1 215928483 T C 1.90E-05 Glucose levels USH2A intron pha002899 rs17025389 chr1 215941805 C T 4.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels USH2A intron 20031582 rs6540910 chr1 215949580 T A 9.39E-04 Multiple complex diseases USH2A intron 17554300 rs6665799 chr1 215955937 T G 1.98E-04 Lung function (forced expiratory volume in 1 second) USH2A intron 24023788 rs12063584 chr1 216053570 C G 5.24E-06 Height USH2A intron 20400458 rs7513600 chr1 216054304 T G 4.12E-04 Acute lung injury USH2A intron 22295056 rs12136954 chr1 216055493 T C 5.97E-04 Insulin resistance USH2A intron 21901158 rs17025548 chr1 216056348 A G 8.00E-06 IgG glycosylation USH2A intron 23382691 rs1556940 chr1 216056779 T C 8.96E-05 Monocyte counts USH2A intron pha003089 rs1325523 chr1 216074957 C A 8.81E-06 Response to citalopram treatment USH2A intron 19846067 rs11120695 chr1 216080130 G T 5.91E-04 Celiac disease USH2A intron 23936387 rs942837 chr1 216099194 T C 1.39E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs513746 chr1 216102796 T C 1.41E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs517577 chr1 216103270 A G 1.41E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs662355 chr1 216103777 G C 1.43E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs647908 chr1 216104726 A C 1.45E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs498911 chr1 216104980 A C 2.38E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs646576 chr1 216105016 A G 1.45E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs492474 chr1 216112208 T G 1.51E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs772713 chr1 216113287 A C 1.76E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs6690523 chr1 216139575 A C 8.54E-04 Coronary heart disease USH2A intron 21971053 rs1992099 chr1 216167644 T C 5.75E-04 Insulin resistance USH2A intron 21901158 rs10864219 chr1 216172380 A G 6.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A missense 21844884 rs12126638 chr1 216175696 T C 9.56E-05 Nicotine smoking USH2A intron 19268276 rs7541086 chr1 216176250 G A 3.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs6696269 chr1 216181197 T C 3.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs17645898 chr1 216215944 G A 1.38E-05 Bipolar disorder USH2A intron 17486107 rs17026081 chr1 216269176 C T 4.94E-04 Lung function (forced vital capacity) USH2A intron 24023788 rs421821 chr1 216282495 A G 8.06E-05 Height USH2A intron pha003011 rs301734 chr1 216292566 G T 1.89E-04 Type 2 diabetes USH2A intron 17463246 rs637374 chr1 216293543 A G 2.40E-14 Health and aging,CVD and cancer age of onset USH2A intron 22174011 rs637374 chr1 216293543 A G 3.00E-09 Health and aging,CVD and cancer age of onset USH2A intron 22174011 rs532342 chr1 216298635 T C 1.00E-04 Information processing speed USH2A intron 21130836 rs17026130 chr1 216298733 C G 4.78E-04 Type 2 diabetes USH2A intron 17463246 rs10495017 chr1 216300399 G A 6.74E-04 Type 2 diabetes USH2A intron 17463246 rs448588 chr1 216313208 G A 4.32E-05 Information processing speed USH2A intron 21130836 rs17026170 chr1 216314566 C T 2.51E-04 Type 2 diabetes USH2A intron 17463246 rs594799 chr1 216317495 T C 4.32E-05 Information processing speed USH2A intron 21130836 rs301755 chr1 216332012 C T 1.35E-05 Information processing speed USH2A intron 21130836 rs1805049 chr1 216348764 C T 1.58E-05 Height / / pha003011 rs2274117 chr1 216363137 G A 1.72E-05 Height USH2A intron pha003011 rs407590 chr1 216368414 T C 6.23E-05 Height USH2A intron pha003010 rs407590 chr1 216368414 T C 4.64E-07 Height USH2A intron pha003011 rs148135241 chr1 216373416 A C 0.000038 Prostate cancer (advanced) USH2A missense 23555315 rs3754064 chr1 216384908 G T 4.55E-07 Height USH2A intron pha003011 rs2669057 chr1 216400022 C T 2.49E-05 Height USH2A intron pha003010 rs2669057 chr1 216400022 C T 4.38E-08 Height USH2A intron pha003011 rs773498 chr1 216400158 C T 4.01E-05 Height USH2A intron pha003011 rs600535 chr1 216403499 A G 2.49E-05 Height USH2A intron pha003010 rs600535 chr1 216403499 A G 4.38E-08 Height USH2A intron pha003011 rs3767693 chr1 216410939 T G 4.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs6703090 chr1 216431593 G A 6.53E-04 Insulin resistance USH2A intron 21901158 rs386654 chr1 216431962 G A 3.21E-05 Height USH2A intron pha003010 rs386654 chr1 216431962 G A 8.18E-08 Height USH2A intron pha003011 rs700022 chr1 216435996 T C 5.66E-06 Height USH2A intron pha003011 rs11120747 chr1 216438500 G A 2.23E-05 Height USH2A intron pha003011 rs2168924 chr1 216440105 G A 6.03E-04 Type 2 diabetes USH2A intron 17463246 rs2168924 chr1 216440105 G A 2.90E-06 Urinary metabolites USH2A intron 21572414 rs10779667 chr1 216452846 G A 6.39E-05 Height USH2A intron pha003011 rs1159143 chr1 216454483 T G 9.72E-07 Height USH2A intron pha003011 rs700025 chr1 216461304 T C 1.54E-05 Glycosylated haemoglobin levels USH2A intron 17255346 rs17042212 chr1 216473745 A G 8.75E-07 Height USH2A intron pha003011 rs11801737 chr1 216492391 A G 2.00E-05 Height USH2A intron pha003011 rs7532570 chr1 216504269 A G 6.00E-06 IgG glycosylation USH2A intron 23382691 rs1606357 chr1 216521091 C T 2.93E-05 Height USH2A intron pha003011 rs2809299 chr1 216540541 T C 0.00013 Coronary artery calcification USH2A intron 23727086 rs1588656 chr1 216549082 C A 8.04E-04 Type 2 diabetes USH2A intron 17463246 rs17026635 chr1 216552367 C T 6.33E-07 Lipid traits USH2A intron 21777205 rs7545826 chr1 216612801 C T 4.24E-04 Type 2 diabetes / / 17463246 rs4548509 chr1 216630824 A G 9.49E-08 Metabolite levels / / 23281178 rs10495024 chr1 216632948 T C 6.00E-06 Testosterone levels / / 22675492 rs4338426 chr1 216649667 C T 2.20E-05 Response to antidepressants / / 19736353 rs7548662 chr1 216656646 G A 2.93E-04 Blood pressure / / 17255346 rs7548662 chr1 216656646 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11582478 chr1 216670203 T G 9.18E-04 Myopia (pathological) / / 21095009 rs4360581 chr1 216671992 C T 8.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11117608 chr1 216701242 G A 4.15E-04 Suicide attempts in bipolar disorder ESRRG intron 21423239 rs4846514 chr1 216702685 T C 7.31E-04 Type 2 diabetes ESRRG intron 17463246 rs6696225 chr1 216705965 T C 1.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs1833036 chr1 216707012 G T 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs6694260 chr1 216712891 C A 5.40E-04 Schizophrenia ESRRG intron 19197363 rs2377098 chr1 216715514 G T 3.33E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs12145418 chr1 216716320 G T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs12757165 chr1 216716537 A G 1.00E-07 Cardiac hypertrophy ESRRG intron 21348951 rs6658528 chr1 216722090 C T 4.65E-06 Statin-induced myopathy ESRRG intron 21826682 rs73089908 chr1 216725230 T G 5.64E-14 Metabolite levels ESRRG intron 22286219 rs10442688 chr1 216726333 T C 6.60E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs4846528 chr1 216727323 C T 3.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs7553212 chr1 216738788 A C,G,T 7.00E-06 Alcohol consumption ESRRG intron 23743675 rs1984137 chr1 216745245 A G 1.48E-04 Lung function (forced vital capacity) ESRRG intron 24023788 rs1984137 chr1 216745245 A G 3.59E-05 Height ESRRG intron pha003010 rs1984137 chr1 216745245 A G 8.71E-05 Height ESRRG intron pha003011 rs17669622 chr1 216756821 G A 9.00E-07 Mean arterial pressure (alcohol consumption interaction) ESRRG intron 24376456 rs4124653 chr1 216785099 G A 4.68E-04 Acute lung injury ESRRG intron 22295056 rs7553463 chr1 216788184 G A 4.68E-04 Acute lung injury ESRRG intron 22295056 rs1498276 chr1 216788927 T C 4.68E-04 Acute lung injury ESRRG intron 22295056 rs6673566 chr1 216789386 T G 4.68E-04 Acute lung injury ESRRG intron 22295056 rs6673588 chr1 216789443 T G 3.83E-05 Ulcerative colitis ESRRG intron 19915573 rs6673588 chr1 216789443 T G 4.68E-04 Acute lung injury ESRRG intron 22295056 rs1857413 chr1 216812324 C T 6.91E-04 Response to cytadine analogues (cytosine arabinoside) ESRRG intron 24483146 rs1817998 chr1 216813244 C T 7.28E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ESRRG intron 24023788 rs12023399 chr1 216819427 C G 7.17E-05 Schizophrenia ESRRG intron 20832056 rs946465 chr1 216840371 C T 2.05E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs10779275 chr1 216843588 C T 1.80E-05 Urinary metabolites ESRRG intron 21572414 rs10127480 chr1 216844423 T C 2.67E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs10779276 chr1 216857387 A G 9.01E-05 Height ESRRG intron pha003010 rs2813711 chr1 216879911 A G 2.36E-05 Bone mineral traits,in men ESRRG intron 21427758 rs2813711 chr1 216879911 A G 3.68E-05 Bone mineral traits,in men ESRRG intron 21427758 rs2813711 chr1 216879911 A G 7.13E-05 Bone mineral traits,in men ESRRG intron 21427758 rs1416617 chr1 216910472 G A 7.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ESRRG intron 20031582 rs10779279 chr1 216925972 G A 3.98E-05 Multiple complex diseases ESRRG intron 17554300 rs6604643 chr1 216927468 A G 4.71E-04 Multiple complex diseases ESRRG intron 17554300 rs6604644 chr1 216940621 A G 7.74E-05 Creatinine levels ESRRG intron pha003069 rs2813694 chr1 216942781 A C 6.00E-05 Prostate cancer ESRRG intron 21743057 rs6702277 chr1 216956685 C T 7.70E-05 Fasting plasma glucose ESRRG intron 19060907 rs7355008 chr1 216966601 T C 9.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ESRRG intron 23648065 rs12723353 chr1 216984496 T G 7.31E-05 HIV-1 control ESRRG intron 20041166 rs3738490 chr1 216998464 A G 3.25E-04 White matter integrity ESRRG intron 22425255 rs2164613 chr1 217003419 C T 5.98E-05 HIV-1 control ESRRG intron 20041166 rs1561186 chr1 217007348 C T 2.83E-04 Tourette syndrome ESRRG intron 22889924 rs10492953 chr1 217009575 A G 1.68E-04 Tourette syndrome ESRRG intron 22889924 rs10492953 chr1 217009575 A G 4.87E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs1542003 chr1 217019565 T C 2.22E-04 Tourette syndrome ESRRG intron 22889924 rs11117697 chr1 217021466 G A 8.19E-04 Tourette syndrome ESRRG intron 22889924 rs11117697 chr1 217021466 G A 1.89E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs12086350 chr1 217025695 T C 1.35E-04 Multiple complex diseases ESRRG intron 17554300 rs7537872 chr1 217028528 T C 9.30E-04 Multiple complex diseases ESRRG intron 17554300 rs11572550 chr1 217040549 C A 4.91E-04 Multiple complex diseases ESRRG intron 17554300 rs1436899 chr1 217057482 A G 7.12E-04 Nicotine smoking ESRRG intron 19268276 rs1436900 chr1 217058479 C T 7.00E-06 optic disc size (cup) ESRRG intron 20395239 rs12029460 chr1 217064861 A C 2.48E-05 Multiple complex diseases ESRRG intron 17554300 rs4436447 chr1 217070040 A C 2.09E-04 Amyotrophic lateral sclerosis (sporadic) ESRRG intron 24529757 rs2576206 chr1 217071322 G A 7.00E-06 Urinary metabolites ESRRG intron 21572414 rs1025652 chr1 217082139 T A 9.59E-05 Cervical cancer ESRRG intron 24700089 rs4348786 chr1 217082283 C T 1.57E-05 Esophageal cancer (squamous cell) ESRRG intron 22960999 rs4348786 chr1 217082283 C T 9.59E-05 Cervical cancer ESRRG intron 24700089 rs1436879 chr1 217082385 C T 9.14E-04 Depression (quantitative trait) ESRRG intron 20800221 rs11572505 chr1 217094044 T C 1.10E-04 Alcohol dependence ESRRG intron 20201924 rs4335430 chr1 217100231 C T 4.31E-06 Brain infarcts,covert MRI-defined ESRRG intron 20044523 rs2818781 chr1 217136773 C T 2.20E-04 Type 2 diabetes ESRRG intron 17846126 rs11117745 chr1 217173648 T G 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG UTR-5 20877124 rs2789567 chr1 217177525 C T 3.60E-09 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs2789571 chr1 217180432 G T 9.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs17686866 chr1 217185265 C A 0.0000038 Preeclampsia ESRRG intron 22748001 rs17686866 chr1 217185265 C A 8.99E-06 Preeclampsia ESRRG intron 23551011 rs2818752 chr1 217185558 G A 4.77E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs6604651 chr1 217195463 A G 7.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs2377360 chr1 217200883 G A 9.00E-06 Major depressive disorder ESRRG intron 23377640 rs7527281 chr1 217203091 C A 2.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs4846811 chr1 217246640 T G 5.77E-04 Multiple complex diseases ESRRG intron 17554300 rs6696046 chr1 217253266 T C 1.40E-05 Urinary metabolites ESRRG intron 21572414 rs1339220 chr1 217265073 G T 1.13E-04 Multiple complex diseases ESRRG intron 17554300 rs830307 chr1 217270667 A C 3.52E-05 Brain derived neurotrophic factor levels,in serum ESRRG intron 22047184 rs830307 chr1 217270667 A C 3.02E-05 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs12033461 chr1 217272629 T C 1.00E-04 Information processing speed ESRRG intron 21130836 rs12026424 chr1 217274676 G C 9.00E-04 Acute lymphoblastic leukemia (childhood) ESRRG intron 20189245 rs11117772 chr1 217281640 T C 4.59E-04 Depression (quantitative trait) ESRRG intron 20800221 rs987445 chr1 217282499 G T 4.56E-04 Depression (quantitative trait) ESRRG intron 20800221 rs987445 chr1 217282499 G T 2.98E-07 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs1354221 chr1 217285309 A G 6.78E-05 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs11576806 chr1 217290281 C T 6.67E-05 Bipolar disorder ESRRG intron 20451256 rs11576172 chr1 217324654 G A 7.53E-04 Coronary heart disease / / 21971053 rs7555255 chr1 217350383 T C 3.88E-05 Receptive language ability / / 24687471 rs11117791 chr1 217355588 G A 3.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17045405 chr1 217356154 T C 4.00E-05 Coffee consumption / / 21357676 rs1827438 chr1 217359640 A T 8.66E-05 Personality dimensions / / 23903073 rs1393385 chr1 217368088 T C 1.14E-04 Multiple complex diseases / / 17554300 rs1502342 chr1 217376665 T G 4.22E-04 Type 2 diabetes / / 17463246 rs1502342 chr1 217376665 T G 4.39E-04 Multiple complex diseases / / 17554300 rs12049257 chr1 217377070 A C 4.38E-04 Type 2 diabetes / / 17463246 rs12049257 chr1 217377070 A C 9.07E-04 Multiple complex diseases / / 17554300 rs1502367 chr1 217396359 C G 9.79E-04 Type 2 diabetes / / 17463246 rs11117808 chr1 217396792 C A 1.00E-06 Urinary metabolites / / 21572414 rs11117811 chr1 217398583 G A 3.49E-04 Type 2 diabetes / / 17463246 rs11117811 chr1 217398583 G A 3.12E-04 Multiple complex diseases / / 17554300 rs4131971 chr1 217423490 G C 3.02E-04 Type 2 diabetes / / 17463246 rs4846828 chr1 217429631 G A 1.47E-04 Smoking cessation / / 18519826 rs4846828 chr1 217429631 G A 2.29E-05 Smoking cessation / / 18519826 rs4146799 chr1 217435636 G A 8.05E-06 Asthma / / 21790008 rs4498862 chr1 217439859 A G 2.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs11117833 chr1 217447992 T C 8.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs6604543 chr1 217452415 A G 8.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs4846406 chr1 217453219 G A 8.05E-06 Asthma / / 21790008 rs4846411 chr1 217461144 C A 8.05E-06 Asthma / / 21790008 rs12758898 chr1 217471995 C T 6.52E-06 Parkinson's disease / / 21738487 rs34588585 chr1 217478881 A AT 4.47E-04 Multiple complex diseases / / 17554300 rs6671908 chr1 217478881 A T 4.47E-04 Multiple complex diseases / / 17554300 rs2646806 chr1 217479640 T C 1.79E-04 Smoking cessation / / 18519826 rs2815205 chr1 217486452 C T 6.62E-04 Type 2 diabetes / / 17463246 rs2815206 chr1 217489760 G A 8.77E-04 Type 2 diabetes / / 17463246 rs12354289 chr1 217490684 A C 5.65E-05 Multiple complex diseases / / 17554300 rs2173289 chr1 217510208 T A 3.37E-04 Gallstones / / 17632509 rs17046085 chr1 217522491 A G 9.63E-04 Multiple complex diseases / / 17554300 rs1497828 chr1 217527024 C G 4.00E-06 Dialysis-related mortality / / 21546767 rs2646821 chr1 217528236 C T 5.69E-05 Smoking cessation / / 18519826 rs11809557 chr1 217563420 G A 2.04E-04 Multiple complex diseases / / 17554300 rs17046325 chr1 217572751 T C 4.78E-05 Smoking cessation / / 18519826 rs2646849 chr1 217584106 A T 5.90E-06 Urinary metabolites / / 21572414 rs12128013 chr1 217599330 G C 6.65E-05 Serum metabolites / / 19043545 rs7520483 chr1 217604777 G A 8.03E-05 Serum metabolites GPATCH2 intron 19043545 rs265130 chr1 217616105 T C 1.20E-05 Urinary metabolites GPATCH2 intron 21572414 rs265128 chr1 217616760 T A 8.31E-05 Response to metformin GPATCH2 intron 21186350 rs4846415 chr1 217680035 C T 2.46E-04 Heart Failure GPATCH2 intron pha002884 rs2059397 chr1 217718132 C G 6.00E-06 Visceral adipose tissue adjusted for BMI GPATCH2 intron 22589738 rs2042525 chr1 217739036 T C 9.02E-05 Hypertension (essential hypertension) GPATCH2 intron 22184326 rs6704368 chr1 217775681 A T 8.77E-04 Alzheimer's disease GPATCH2 intron 24755620 rs10495065 chr1 217833200 C G 4.34E-04 Type 2 diabetes SPATA17 intron 17463246 rs6692477 chr1 217842129 A G 1.50E-05 Lipid levels SPATA17 intron 18193043 rs10863335 chr1 217842887 A G 9.12E-05 Suicide attempts in bipolar disorder SPATA17 intron 21423239 rs4347270 chr1 217888972 A G 4.40E-05 Coronary heart disease SPATA17 intron 21606135 rs4347270 chr1 217888972 A G 8.85E-04 Alzheimer's disease SPATA17 intron 24755620 rs4846429 chr1 217890974 T A 3.17E-04 Suicide attempts in bipolar disorder SPATA17 intron 21423239 rs10495072 chr1 217892890 T C 8.84E-04 Alzheimer's disease SPATA17 intron 24755620 rs6673733 chr1 217916357 A G 4.54E-04 Alzheimer's disease SPATA17 intron 24755620 rs10495074 chr1 217931665 A G 5.32E-05 Alzheimer's disease SPATA17 intron 24755620 rs17726462 chr1 217951156 A G 1.12E-04 Alzheimer's disease SPATA17 intron 24755620 rs11578620 chr1 217985428 T C 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPATA17 intron 20877124 rs6674883 chr1 218008788 G A 3.18E-04 Type 2 diabetes SPATA17 intron 17463246 rs6674883 chr1 218008788 G A 5.62E-04 Response to taxane treatment (placlitaxel) SPATA17 intron 23006423 rs12409486 chr1 218016827 A G 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPATA17 intron 20877124 rs1567449 chr1 218018956 C T 6.80E-04 Alcohol consumption (maxi-drinks) SPATA17 intron 24277619 rs12759918 chr1 218021137 C T 6.67E-04 Alcohol consumption (maxi-drinks) SPATA17 intron 24277619 rs12748013 chr1 218024308 G A 3.60E-06 Urinary metabolites SPATA17 intron 21572414 rs11117953 chr1 218036817 G A 7.11E-05 Left ventricular hypertrophy SPATA17 intron pha003052 rs17739539 chr1 218054687 C T 4.66E-05 Tuberculosis / / 22306650 rs17739539 chr1 218054687 C T 2.70E-04 Tuberculosis / / 24057671 rs11117970 chr1 218072745 A C 5.38E-05 Serum metabolites / / 19043545 rs4846446 chr1 218075115 G A 9.58E-05 Serum metabolites / / 19043545 rs10495084 chr1 218079260 G C 3.76E-04 Smoking quantity / / 24665060 rs871378 chr1 218085255 G A 1.74E-04 Heart Failure / / pha002884 rs6685632 chr1 218090414 A G 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6604568 chr1 218094151 G A 2.33E-05 Eating disorders / / 22911880 rs10495085 chr1 218105019 C T 1.40E-04 IgE levels in asthmatics / / 23967269 rs17691163 chr1 218128141 G A 8.00E-06 Urinary metabolites / / 21572414 rs17691163 chr1 218128141 G A 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs7546897 chr1 218147287 C T 4.60E-04 Alzheimer's disease / / 22005930 rs7546902 chr1 218147297 C T 7.09E-04 Alzheimer's disease / / 22005930 rs2171963 chr1 218169961 G A 8.67E-04 Myocardial Infarction / / pha002873 rs1490331 chr1 218198027 T C 5.10E-04 Myocardial Infarction / / pha002873 rs17047227 chr1 218198395 C T 4.40E-06 Phospholipid levels (plasma) / / 21829377 rs11118018 chr1 218215033 A T 5.36E-04 Type 2 diabetes / / 17463246 rs4846459 chr1 218230035 C T 6.99E-04 Type 2 diabetes / / 17463246 rs12127278 chr1 218248260 A G 1.99E-04 Amyotrophic lateral sclerosis / / 20801718 rs10863373 chr1 218251692 G T 4.08E-04 Longevity / / 22279548 rs2130586 chr1 218254376 A C 5.29E-04 Smoking initiation / / 24665060 rs10157529 chr1 218263870 T C 7.79E-04 Type 2 diabetes / / 17463246 rs6658076 chr1 218347150 T C 3.22E-05 Type 2 diabetes / / 17463246 rs10495096 chr1 218348909 T C 3.45E-04 Hearing function / / 17255346 rs10495096 chr1 218348909 T C 4.81E-04 Type 2 diabetes / / 17463246 rs10495096 chr1 218348909 T C 3.65E-05 Schizophrenia / / 20832056 rs10863379 chr1 218354793 G T 9.50E-04 Alzheimer's disease / / 17998437 rs7553207 chr1 218370200 T C 1.24E-05 Bone mineral density / / 19181680 rs11118052 chr1 218379881 G A 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10863384 chr1 218428101 A C 4.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1338445 chr1 218439928 T C 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs11118070 chr1 218465933 A C 2.64E-04 Alzheimer's disease (late onset) RRP15 intron 21379329 rs1933641 chr1 218468961 T C 2.38E-188 Multiple complex diseases RRP15 intron 17554300 rs11118083 chr1 218500591 G A 2.69E-04 Alzheimer's disease (late onset) RRP15 intron 21379329 rs17047682 chr1 218523025 A G 9.20E-05 Lung adenocarcinoma TGFB2 intron 22797724 rs17047703 chr1 218525588 C A 2.17E-04 Hearing function TGFB2 intron 17255346 rs3892225 chr1 218553297 A G 3.41E-05 Response to tocilizumab in rheumatoid arthritis TGFB2 intron 22491018 rs10482751 chr1 218556297 T C 2.32E-04 Celiac disease TGFB2 intron 23936387 rs12029576 chr1 218559475 C A 1.99E-04 Celiac disease TGFB2 intron 23936387 rs1342586 chr1 218597859 C T 4.96E-05 Heart Rate TGFB2 intron pha003053 rs4846480 chr1 218598469 A T 8.00E-09 Chronic obstructive pulmonary disease (severe) TGFB2 intron 24621683 rs6684205 chr1 218609702 A G 2.00E-12 Height TGFB2 intron 20881960 rs10482821 chr1 218610434 C A 9.31E-06 Multiple complex diseases TGFB2 intron 17554300 rs900 chr1 218614905 A T 5.20E-08 Height TGFB2 UTR-3 21194676 rs900 chr1 218614905 A T 6.00E-10 Height TGFB2 UTR-3 21194676 rs623356 chr1 218647386 T C 6.15E-05 Magnesium levels / / pha003092 rs6665024 chr1 218690577 G A 8.01E-04 Taste perception / / 22132133 rs11118120 chr1 218705761 A C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1018040 chr1 218705814 T A 1.24E-04 Body mass index / / 17255346 rs1018040 chr1 218705814 T A 5.28E-04 Multiple complex diseases / / 17554300 rs1018040 chr1 218705814 T A 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs1018040 chr1 218705814 T A 8.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs12563275 chr1 218706772 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12563275 chr1 218706772 T C 3.37E-05 Alzheimer's disease (age of onset) / / 22005931 rs512589 chr1 218708110 A G 8.50E-06 Bipolar disorder / / 20451256 rs2047163 chr1 218708603 C A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2047163 chr1 218708603 C A 3.42E-05 Alzheimer's disease (age of onset) / / 22005931 rs987074 chr1 218715320 G C 3.91E-05 Alzheimer's disease (age of onset) / / 22005931 rs4846489 chr1 218718037 T C 4.38E-05 Alzheimer's disease (age of onset) / / 22005931 rs11118121 chr1 218719755 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11118121 chr1 218719755 T C 4.74E-05 Alzheimer's disease (age of onset) / / 22005931 rs11118123 chr1 218720002 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10863400 chr1 218723535 T C 2.80E-05 Urinary metabolites / / 21572414 rs1603059 chr1 218727857 T C 7.00E-04 Bipolar disorder / / 19259986 rs259474 chr1 218759983 A G 1.74E-04 Type 2 diabetes / / 17463246 rs259474 chr1 218759983 A G 5.33E-04 Multiple complex diseases / / 17554300 rs17048238 chr1 218761681 C T 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs996221 chr1 218788434 A C 5.14E-04 Type 2 diabetes / / 17463246 rs6690218 chr1 218832257 T C 5.70E-06 Urinary metabolites / / 21572414 rs11485142 chr1 218833214 A C 1.41E-06 Hearing function / / 21493956 rs11485142 chr1 218833214 A C 2.10E-05 Urinary metabolites / / 21572414 rs1159268 chr1 218844906 G A 4.00E-08 Acne (severe) / / 24927181 rs28463616 chr1 218854635 T C 0.0000889 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28627122 chr1 218855367 A G 0.0000852 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696363 chr1 218855636 T C 0.0000958 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs993925 chr1 218860068 C T 1.00E-08 Pulmonary function / / 21946350 rs1383756 chr1 218872624 C T 4.71E-05 Aging (time to event) / / 21782286 rs17571465 chr1 218890658 A T 7.77E-04 Multiple complex diseases / / 17554300 rs2378002 chr1 218922358 G T 1.99E-07 Esophageal cancer (squamous cell) / / 22960999 rs12037343 chr1 218931905 G T 3.00E-06 Smooth-surface caries / / 24556642 rs7542694 chr1 218931976 C T 1.20E-05 Urinary metabolites / / 21572414 rs17048517 chr1 218934929 C A 2.95E-06 Smooth-surface caries / / 24556642 rs6541199 chr1 218938961 C T 2.12E-05 Prion diseases / / 22210626 rs10495107 chr1 218970504 G A 2.38E-04 Type 2 diabetes / / 17846124 rs12033283 chr1 218992800 G A 7.42E-06 Smooth-surface caries / / 24556642 rs7552186 chr1 218995273 C T 3.00E-08 Height / / 23563607 rs642836 chr1 219023654 G A 2.19E-04 Multiple complex diseases / / 17554300 rs17048805 chr1 219065882 G T 0.0006807 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048805 chr1 219065882 G T 6.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17048811 chr1 219067810 C T 0.0006763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048811 chr1 219067810 C T 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9661984 chr1 219083060 T G 7.42E-04 Alcohol dependence / / 24277619 rs2275335 chr1 219086396 T C 7.10E-07 Iron levels / / 21208937 rs11118175 chr1 219089313 A G 5.67E-04 Iron levels / / pha002876 rs12728902 chr1 219095005 G C 1.28E-05 Reading and spelling / / 23738518 rs626518 chr1 219101848 C T 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs2788271 chr1 219117743 T G 2.35E-05 Alzheimer's disease (late onset) / / 21379329 rs11118180 chr1 219117863 A C 1.94E-04 Alzheimer's disease (late onset) / / 21379329 rs10495117 chr1 219135058 C T 9.85E-06 Bilirubin levels,in serum / / 19389676 rs618171 chr1 219149298 A G 2.00E-07 Bilirubin levels,in serum / / 19389676 rs11581158 chr1 219150622 C T 1.54E-06 Alzheimer's disease (late onset) / / 21379329 rs7540160 chr1 219176608 A G 9.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10495127 chr1 219208920 T C 1.38E-04 Alzheimer's disease (late onset) / / 21379329 rs1625084 chr1 219217875 C T 5.71E-04 Smoking cessation / / 24665060 rs1256682 chr1 219222502 A G 7.55E-04 Smoking cessation / / 24665060 rs945761 chr1 219235064 T C 3.85E-04 Coronary heart disease / / 21971053 rs1256598 chr1 219243302 A T 4.73E-04 Smoking cessation / / 24665060 rs17579646 chr1 219248069 T G 2.27E-06 Alzheimer's disease (late onset) / / 21379329 rs1256638 chr1 219248086 A G 6.06E-04 Smoking cessation / / 24665060 rs1256617 chr1 219257488 G T 8.03E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256623 chr1 219261001 C G 7.19E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256567 chr1 219265380 T A 9.95E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256568 chr1 219265915 C T 7.35E-04 Alzheimer's disease LOC643723 intron 22005930 rs1146772 chr1 219273409 C T 7.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs12141207 chr1 219273881 A G 1.01E-05 Mammographic density LOC643723 intron 22532574 rs10863427 chr1 219283784 A G 6.45E-04 Alzheimer's disease LOC643723 intron 22005930 rs17049050 chr1 219294927 G C 9.56E-04 Multiple complex diseases LOC643723 intron 17554300 rs7545152 chr1 219298539 G A 7.06E-05 Cognitive impairment induced by topiramate LOC643723 intron 22091778 rs10863429 chr1 219299794 T C 4.74E-04 Obesity (extreme) LOC643723 intron 21935397 rs11118219 chr1 219301677 T G 3.87E-04 Alzheimer's disease LOC643723 intron 22005930 rs12119171 chr1 219305114 T C 5.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs12067803 chr1 219306923 A G 7.08E-04 Obesity (extreme) LOC643723 intron 21935397 rs7543820 chr1 219307899 G A 7.73E-04 Obesity (extreme) LOC643723 intron 21935397 rs6657093 chr1 219308575 A T 2.52E-04 Alzheimer's disease LOC643723 intron 22005930 rs6655927 chr1 219312063 G C 2.51E-04 Alzheimer's disease LOC643723 intron 22005930 rs12119303 chr1 219314550 G T 2.84E-04 Alzheimer's disease LOC643723 intron 22005930 rs12134260 chr1 219314816 C T 2.51E-04 Alzheimer's disease LOC643723 intron 22005930 rs1404360 chr1 219318128 A G 7.36E-04 Alzheimer's disease LOC643723 intron 22005930 rs7523306 chr1 219320846 G A 8.02E-04 Obesity (extreme) LOC643723 intron 21935397 rs7539768 chr1 219321179 T G 8.06E-04 Obesity (extreme) LOC643723 intron 21935397 rs12079503 chr1 219323278 T C 8.10E-04 Obesity (extreme) LOC643723 intron 21935397 rs12128311 chr1 219325068 T C 2.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs6692337 chr1 219325343 C G 3.27E-04 Alzheimer's disease LOC643723 intron 22005930 rs11118226 chr1 219326056 A C 2.23E-04 Alzheimer's disease LOC643723 intron 22005930 rs1404361 chr1 219326734 T A 2.22E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846532 chr1 219329357 G A 2.67E-04 Alzheimer's disease LOC643723 intron 22005930 rs6657059 chr1 219332058 T G 8.55E-04 Obesity (extreme) LOC643723 intron 21935397 rs6660443 chr1 219332903 T C 2.36E-04 Alzheimer's disease LOC643723 intron 22005930 rs11118229 chr1 219333297 C T 8.62E-04 Obesity (extreme) LOC643723 intron 21935397 rs11590608 chr1 219335219 C T 6.13E-04 Alzheimer's disease LOC643723 intron 22005930 rs3748633 chr1 219337051 C G 2.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs3748635 chr1 219337088 A T 8.83E-04 Obesity (extreme) LOC643723 intron 21935397 rs9308387 chr1 219337294 C T 2.24E-04 Alzheimer's disease LOC643723 intron 22005930 rs3849291 chr1 219338066 A G 2.23E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846533 chr1 219338934 C T 2.21E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846534 chr1 219338962 C T 2.20E-04 Alzheimer's disease LOC643723 intron 22005930 rs1847661 chr1 219343805 C A 6.07E-04 Alzheimer's disease LOC643723 intron 22005930 rs1524633 chr1 219345242 T C 2.22E-04 Alzheimer's disease LOC643723 intron 22005930 rs1505257 chr1 219347790 T A 2.26E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs7536671 chr1 219350309 T C 2.78E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs12140499 chr1 219350848 G A 2.26E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs6699816 chr1 219355789 A G 9.31E-04 Obesity (extreme) LYPLAL1 intron 21935397 rs12119484 chr1 219360387 T C 2.19E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs11118233 chr1 219361486 T C 6.65E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs2049423 chr1 219364661 T G 3.12E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs11118234 chr1 219367962 A G 3.99E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs12093892 chr1 219368348 G T 9.84E-04 Obesity (extreme) LYPLAL1 intron 21935397 rs1474375 chr1 219382194 T A 2.52E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs6692892 chr1 219383192 T C 6.92E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs1568804 chr1 219391205 T C 1.91E-04 Alzheimer's disease / / 22005930 rs4846539 chr1 219392381 G A 2.84E-04 Alzheimer's disease / / 22005930 rs10863439 chr1 219394080 A C 4.54E-04 Alzheimer's disease / / 22005930 rs17588395 chr1 219412715 G A 1.71E-06 Mammographic density / / 22532574 rs885533 chr1 219415464 A G 3.37E-04 Alzheimer's disease / / 22005930 rs869543 chr1 219416279 A C 9.32E-04 Alzheimer's disease / / 22005930 rs11118246 chr1 219419437 A G 2.52E-04 Alzheimer's disease / / 22005930 rs2177625 chr1 219423223 C A 1.53E-04 Alzheimer's disease / / 22005930 rs6690356 chr1 219430484 C T 1.52E-04 Alzheimer's disease / / 22005930 rs4339871 chr1 219433030 G A 4.02E-04 Parkinson's disease / / 17052657 rs6695675 chr1 219436911 C T 1.46E-04 Alzheimer's disease / / 22005930 rs7543459 chr1 219438661 G C 1.05E-04 Alzheimer's disease / / 22005930 rs7554977 chr1 219439134 C T 1.04E-04 Alzheimer's disease / / 22005930 rs12033194 chr1 219441669 A G 1.01E-04 Alzheimer's disease / / 22005930 rs7524519 chr1 219442625 A G 2.57E-04 Longevity / / 22279548 rs12138304 chr1 219443893 C T 7.98E-04 Alzheimer's disease / / 22005930 rs6679287 chr1 219444769 A G 7.87E-04 Alzheimer's disease / / 22005930 rs12740853 chr1 219445621 C T 9.34E-05 Alzheimer's disease / / 22005930 rs11118250 chr1 219446253 G A 9.07E-05 Alzheimer's disease / / 22005930 rs10495125 chr1 219446991 C G 4.89E-05 Alzheimer's disease / / 22005930 rs6541215 chr1 219447464 G A 1.14E-04 Alzheimer's disease / / 22005930 rs12137855 chr1 219448378 C T 1.06E-04 Nonalcoholic fatty liver disease / / 21423719 rs11118251 chr1 219448564 C T 1.16E-04 Alzheimer's disease / / 22005930 rs11118252 chr1 219448632 C T 1.16E-04 Alzheimer's disease / / 22005930 rs17589136 chr1 219454837 T C 1.44E-04 Alzheimer's disease / / 22005930 rs2186259 chr1 219455914 A C 1.10E-04 Alzheimer's disease / / 22005930 rs6699635 chr1 219456604 A T 1.47E-04 Alzheimer's disease / / 22005930 rs10779348 chr1 219459871 G T 5.35E-04 Alzheimer's disease / / 22005930 rs12080335 chr1 219459987 T C 6.01E-04 Obesity (extreme) / / 21935397 rs10863443 chr1 219460657 A T 1.35E-04 Alzheimer's disease / / 22005930 rs2186256 chr1 219460925 A G 1.35E-04 Alzheimer's disease / / 22005930 rs12238967 chr1 219461975 C T 1.54E-04 Alzheimer's disease / / 22005930 rs11118258 chr1 219462603 C G 1.35E-04 Alzheimer's disease / / 22005930 rs11809367 chr1 219462839 A G 1.04E-04 Alzheimer's disease / / 22005930 rs17523824 chr1 219463061 G A 1.54E-04 Alzheimer's disease / / 22005930 rs17005229 chr1 219463484 G A 6.16E-04 Obesity (extreme) / / 21935397 rs10863444 chr1 219464144 T C 1.34E-04 Alzheimer's disease / / 22005930 rs12029233 chr1 219465099 G A 3.86E-04 Alzheimer's disease / / 22005930 rs12078797 chr1 219465410 A G 5.15E-06 ldl cholesterol / / pha003077 rs6665677 chr1 219470417 T G 1.23E-05 Sleep duration / / 22105623 rs12135929 chr1 219474601 A G 1.98E-04 Alzheimer's disease (late onset) / / 21460841 rs9943060 chr1 219478193 G A 2.09E-04 Blood pressure / / 17255346 rs9943060 chr1 219478193 G A 9.29E-06 Sleep duration / / 22105623 rs11118262 chr1 219479112 T C 1.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6675063 chr1 219479214 A T 7.14E-06 Sleep duration / / 22105623 rs7538186 chr1 219480797 T C 6.52E-06 Sleep duration / / 22105623 rs10157397 chr1 219484329 G A 6.36E-04 Multiple complex diseases / / 17554300 rs12122774 chr1 219488567 C T 4.94E-04 Multiple complex diseases / / 17554300 rs11118271 chr1 219488759 A T 6.12E-06 Sleep duration / / 22105623 rs7552206 chr1 219492898 C A 8.81E-04 Multiple complex diseases / / 17554300 rs7514670 chr1 219493082 T A 7.54E-06 Sleep duration / / 22105623 rs7539990 chr1 219497545 G A 7.30E-06 Sleep duration / / 22105623 rs1455703 chr1 219500145 C T 5.10E-04 Multiple complex diseases / / 17554300 rs10495124 chr1 219502193 G A 2.78E-06 Diabetes Mellitus / / pha003059 rs11118277 chr1 219507866 G A 1.60E-05 Sleep duration / / 22105623 rs11118283 chr1 219523445 A T 1.83E-05 Sleep duration / / 22105623 rs1340092 chr1 219523477 G A 1.91E-04 Blood pressure / / 17255346 rs1340092 chr1 219523477 G A 1.01E-04 Type 2 diabetes / / 17463246 rs1340092 chr1 219523477 G A 1.84E-05 Sleep duration / / 22105623 rs6541220 chr1 219529395 G A 1.93E-05 Sleep duration / / 22105623 rs12137276 chr1 219530826 A G 6.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17591522 chr1 219533768 G A 3.42E-06 Diabetes Mellitus / / pha003059 rs1856716 chr1 219534574 T C 1.60E-04 Blood pressure / / 17255346 rs17005330 chr1 219535477 G C 1.19E-04 Multiple complex diseases / / 17554300 rs6704463 chr1 219547825 G T 3.42E-06 Diabetes Mellitus / / pha003059 rs6671991 chr1 219557811 G T 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10863456 chr1 219562683 G A 8.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1547502 chr1 219564357 T C 9.60E-05 ldl cholesterol / / pha003077 rs1598472 chr1 219571519 T C 9.60E-04 Multiple complex diseases / / 17554300 rs12032159 chr1 219586415 G A 5.46E-05 Alzheimer's disease / / 21098978 rs11118298 chr1 219588105 A G 5.53E-05 Serum metabolites / / 19043545 rs2124328 chr1 219588237 A C 5.07E-05 Alzheimer's disease / / 21098978 rs2791559 chr1 219588803 A G 4.13E-05 Multiple complex diseases / / 17554300 rs2791559 chr1 219588803 A G 2.52E-05 Alzheimer's disease / / 21098978 rs2791559 chr1 219588803 A G 9.29E-05 ldl cholesterol / / pha003077 rs2820455 chr1 219596070 C T 1.03E-04 Smoking cessation / / 24665060 rs2791563 chr1 219596488 A G 6.96E-05 Smoking cessation / / 24665060 rs7523871 chr1 219596699 T C 3.18E-04 Type 2 diabetes / / 17463246 rs7514932 chr1 219608812 T G 8.69E-04 Multiple complex diseases / / 17554300 rs2168333 chr1 219616208 T G 2.52E-05 Type 2 diabetes / / 17463246 rs2605082 chr1 219619538 A G 1.55E-04 Type 2 diabetes / / 17463246 rs17005614 chr1 219634811 T G 5.00E-05 Sarcoidosis / / 19165924 rs2820436 chr1 219640680 A C 0.00055 Fasting blood glucose / / 22885924 rs2820436 chr1 219640680 A C 2.10E-09 Fasting insulin-related traits / / 22885924 rs2605100 chr1 219644224 A G 4.39E-04 HIV-1 viral setpoint / / 17641165 rs2605100 chr1 219644224 A G 3.00E-08 Adiposity / / 19557161 rs12022722 chr1 219651133 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs12022722 chr1 219651133 C T 4.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1563355 chr1 219653101 T C 1.34E-04 Type 2 diabetes / / 17846124 rs2605110 chr1 219654392 C T 5.00E-05 Type 2 diabetes / / 17846124 rs4623705 chr1 219654722 G A 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11118316 chr1 219657163 G A 3.00E-09 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs1417066 chr1 219673828 G A 1.00E-06 Osteoarthritis / / 22763110 rs1417066 chr1 219673828 G A 1.00E-06 Cortical thickness / / 22792071 rs2791553 chr1 219676042 A G 5.00E-07 Adiponectin levels / / 22479202 rs6672377 chr1 219678736 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2820464 chr1 219693220 G A 7.00E-09 Waist-hip ratio / / 23563607 rs2785980 chr1 219700519 T C 3.70E-05 Kidney function and endocine traits / / 17903292 rs2785980 chr1 219700519 T C 2.00E-08 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs78696400 chr1 219715108 A G 0.0000896 Menopause (age at onset) / / 23424626 rs4846565 chr1 219722104 G A 1.76E-09 Fasting insulin-related traits / / 22885924 rs3001032 chr1 219727779 T C 4.00E-08 Adiponectin levels / / 22479202 rs11118343 chr1 219739907 T G 8.43E-11 Axial length / / 24144296 rs4428898 chr1 219739966 G A 9.13E-09 Myopia (pathological) / / 22685421 rs4428898 chr1 219739966 G A 9.40E-06 Myopia (severe) / / 23933737 rs4428898 chr1 219739966 G A 4.32E-10 Axial length / / 24144296 rs12046004 chr1 219741333 G C 8.93E-11 Axial length / / 24144296 rs10779361 chr1 219742744 C T 9.35E-11 Axial length / / 24144296 rs11118346 chr1 219743719 C T 2.00E-12 Height / / 20881960 rs11118346 chr1 219743719 C T 2.71E-10 Axial length / / 24144296 rs11118347 chr1 219744249 G T 2.62E-10 Axial length / / 24144296 rs2050595 chr1 219746646 T A 1.63E-10 Axial length / / 24144296 rs2820446 chr1 219748818 C G 2.00E-06 Type 2 diabetes / / 24509480 rs2494192 chr1 219749261 G A 1.51E-06 Waist-hip ratio / / 20935629 rs4846567 chr1 219750717 G T 5.00E-33 Waist-hip ratio / / 20935629 rs2820443 chr1 219753509 T C 7.00E-16 Sexual dimorphism in anthropometric traits / / 23754948 rs6677960 chr1 219754982 G A 4.05E-11 Axial length / / 24144296 rs4373767 chr1 219759682 C T 6.14E-08 Myopia (pathological) / / 22685421 rs4373767 chr1 219759682 C T 7.46E-06 Myopia (severe) / / 23933737 rs4373767 chr1 219759682 C T 1.66E-11 Axial length / / 24144296 rs994767 chr1 219775432 A G 1.00E-11 Axial length / / 24144296 rs11118356 chr1 219777110 C T 1.12E-11 Axial length / / 24144296 rs10863469 chr1 219777468 T C 1.11E-11 Axial length / / 24144296 rs11118358 chr1 219778115 T C 3.16E-11 Axial length / / 24144296 rs10779363 chr1 219786890 C T 1.47E-07 Myopia (pathological) / / 22685421 rs10779363 chr1 219786890 C T 5.15E-06 Myopia (severe) / / 23933737 rs10779363 chr1 219786890 C T 5.13E-11 Axial length / / 24144296 rs10746387 chr1 219787214 A G 4.49E-11 Axial length / / 24144296 rs10746388 chr1 219787322 T A 3.75E-11 Axial length / / 24144296 rs10779364 chr1 219787413 G C 5.35E-11 Axial length / / 24144296 rs10779365 chr1 219787507 A T 3.88E-11 Axial length / / 24144296 rs11118365 chr1 219788166 T G 3.89E-11 Axial length / / 24144296 rs7525202 chr1 219788519 G A 3.89E-11 Axial length / / 24144296 rs7541594 chr1 219789435 A G 8.59E-11 Axial length / / 24144296 rs7544369 chr1 219789462 T C 2.46E-07 Myopia (pathological) / / 22685421 rs7544369 chr1 219789462 T C 5.93E-11 Axial length / / 24144296 rs11118367 chr1 219790221 C T 8.36E-11 Axial length / / 24144296 rs1009859 chr1 219791822 G A 1.52E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10458468 chr1 219821478 C T 1.50E-06 Urinary metabolites / / 21572414 rs10779377 chr1 219881894 C T 9.39E-04 Multiple complex diseases / / 17554300 rs6700439 chr1 219893091 A G 4.66E-06 Uric acid levels / / 21294900 rs12035718 chr1 219926135 G A 2.30E-05 Urinary metabolites / / 21572414 rs17006538 chr1 219926717 C T 9.89E-05 Multiple complex diseases / / 17554300 rs17006539 chr1 219926845 G C 4.74E-05 Multiple complex diseases / / 17554300 rs4846589 chr1 219931859 T C 8.20E-06 Urinary metabolites / / 21572414 rs946109 chr1 219934317 C T 5.42E-05 Orofacial clefts / / 22419666 rs7535102 chr1 219947840 A G 7.72E-06 White blood cell count / / 21738479 rs2066418 chr1 219980552 G A 2.35E-08 Response to tamoxifen in breast cancer / / 22180457 rs1891561 chr1 220008024 T C 1.56E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs10863513 chr1 220075257 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2378331 chr1 220078828 A G 5.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs4846607 chr1 220093188 G A 8.45E-04 Aortic root size SLC30A10 intron 21223598 rs138775009 chr1 220098929 C G 1.97E-04 Acne (severe) SLC30A10 intron 24927181 rs12129498 chr1 220107917 A G 2.71E-05 Alcohol and nictotine co-dependence / / 20158304 rs950455 chr1 220108918 G A 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7530353 chr1 220111321 T C 7.54E-05 Glycosylated haemoglobin levels / / 17255346 rs11118465 chr1 220119384 A C 2.20E-04 Response to antidepressants / / 19736353 rs1391565 chr1 220128228 C G 1.67E-05 IgE levels / / 22075330 rs10779390 chr1 220137006 G A 7.59E-04 Type 2 diabetes / / 17463246 rs2027504 chr1 220140714 T C 8.54E-04 Type 2 diabetes / / 17463246 rs148551457 chr1 220180562 T C 0.00042 Prostate cancer EPRS missense 23555315 rs2789788 chr1 220275378 G A 7.80E-05 Brain derived neurotrophic factor levels,in serum IARS2 intron 22047184 rs79314046 chr1 220364850 C T 0.00003554 Sarcoidosis RAB3GAP2 intron 22952805 rs6541128 chr1 220489544 C T 6.27E-05 Height / / pha003011 rs6541130 chr1 220491151 A G 6.31E-05 Height / / pha003011 rs7524270 chr1 220500958 A C 3.60E-05 Personality dimensions / / 18957941 rs7534648 chr1 220501017 G T 2.25E-05 Personality dimensions / / 18957941 rs11118527 chr1 220504423 C T 4.87E-04 Multiple complex diseases / / 17554300 rs9970755 chr1 220510703 T C 2.41E-04 Multiple complex diseases / / 17554300 rs9803782 chr1 220523521 T G 6.77E-04 Type 2 diabetes / / 23300278 rs12041182 chr1 220544573 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs975639 chr1 220582320 G A 2.37E-05 Multiple complex diseases / / 17554300 rs975639 chr1 220582320 G A 0.000613 Salmonella-induced pyroptosis / / 22837397 rs1856430 chr1 220582970 A T 0.000451 Salmonella-induced pyroptosis / / 22837397 rs1578049 chr1 220590437 G T 8.30E-05 Personality dimensions / / 18957941 rs1578049 chr1 220590437 G T 1.56E-05 Bipolar disorder / / 20451256 rs7512221 chr1 220601623 C T 7.44E-07 Alcohol and nictotine co-dependence / / 20158304 rs7512221 chr1 220601623 C T 6.60E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs12042936 chr1 220604517 G A 2.48E-04 Type 2 diabetes / / 17463246 rs7553380 chr1 220626086 A G 5.29E-06 Alcohol and nictotine co-dependence / / 20158304 rs12563333 chr1 220658234 C T 6.00E-08 Bipolar disorder / / 22205951 rs7530302 chr1 220664952 G A 1.90E-09 Alcohol and nictotine co-dependence / / 20158304 rs7530302 chr1 220664952 G A 3.70E-04 Alcohol and nictotine co-dependence / / 20158304 rs7530302 chr1 220664952 G A 6.87E-06 Alcohol and nictotine co-dependence / / 20158304 rs6704108 chr1 220692822 A G 3.82E-06 White blood cell count / / 21738479 rs17008084 chr1 220793423 C T 3.91E-06 White blood cell count MARK1 intron 21738479 rs6670387 chr1 220796478 T C 4.12E-06 White blood cell count MARK1 intron 21738479 rs3849285 chr1 220799606 T A 6.41E-06 White blood cell count MARK1 intron 21738479 rs7523054 chr1 220817281 A G 3.10E-06 White blood cell count MARK1 intron 21738479 rs3897868 chr1 220846039 C T 5.25E-06 White blood cell count / / 21738479 rs3897869 chr1 220846080 T C 8.44E-06 White blood cell count / / 21738479 rs425437 chr1 220868508 A G 1.86E-13 Lymphocyte counts C1orf115 intron 22286170 rs796486 chr1 220885612 C A 3.00E-04 White blood cell types / / 21738478 rs12127880 chr1 220903765 G A 2.19E-06 Cognitive test performance / / 20125193 rs337161 chr1 220914920 G T 3.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs12133663 chr1 220920083 G A 3.34E-04 Body mass index / / 17255346 rs371348 chr1 220928376 T C 4.98E-04 Smoking initiation MARCH2 cds-synon 24665060 rs1494373 chr1 220929356 T C 6.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) MARCH2 intron 19875103 rs6659246 chr1 220931227 C A 2.37E-04 Alcohol dependence MARCH2 intron 20201924 rs10779415 chr1 220935808 C T 8.31E-04 Alcohol dependence MARCH2 intron 20201924 rs3795536 chr1 220935977 G A 6.19E-04 Alcohol dependence MARCH2 intron 20201924 rs3795535 chr1 220936372 G A 7.16E-05 Smoking initiation MARCH2 missense 24665060 rs11118597 chr1 220936568 G A 4.46E-04 Alcohol dependence MARCH2 intron 20201924 rs1874115 chr1 220964639 T C 2.09E-11 Multiple complex diseases MARCH1 intron 17554300 rs2642438 chr1 220970028 A G 4.20E-06 Phospholipid levels (plasma) MARCH1 missense 21829377 rs2642442 chr1 220973563 C T 5.00E-13 Cholesterol,total MARCH1 intron 20686565 rs2642442 chr1 220973563 C T 6.00E-11 LDL cholesterol MARCH1 intron 20686565 rs2642442 chr1 220973563 C T 3.00E-11 Cholesterol,total MARCH1 intron 24097068 rs2642442 chr1 220973563 C T 5.00E-11 LDL cholesterol MARCH1 intron 24097068 rs2642444 chr1 220974218 A G 2.43E-04 Parkinson's disease MARCH1 intron 21044948 rs6693017 chr1 220977333 T G 3.00E-07 Monocyte early outgrowth colony forming units MARCH1 intron 21493818 rs2642420 chr1 220977650 C A 1.03E-04 IgE levels MARCH1 intron 17255346 rs17649913 chr1 220983402 T C 2.30E-05 Urinary metabolites MARCH1 intron 21572414 rs11118607 chr1 220984364 C T 2.85E-04 Alcohol dependence MARCH1 intron 21314694 rs4143772 chr1 220988346 G A 1.12E-05 F-cell distribution / / 21326311 rs17596947 chr1 220993464 G T 1.50E-05 Urinary metabolites / / 21572414 rs2279638 chr1 221001787 G A 7.49E-06 F-cell distribution / / 21326311 rs12073837 chr1 221010205 C T 2.00E-06 F-cell distribution / / 21326311 rs11118618 chr1 221011546 C T 9.30E-04 Parkinson's disease / / 21044948 rs1577545 chr1 221020746 T C 1.72E-04 Lymphocyte counts / / 22286170 rs11118620 chr1 221028508 T C 7.00E-06 Heart failure / / 20445134 rs1389750 chr1 221040171 T G 4.10E-04 Type 2 diabetes / / 17463246 rs2807880 chr1 221043003 T C 1.10E-05 Urinary metabolites / / 21572414 rs2807857 chr1 221052640 T C 9.01E-05 Alzheimer's disease / / 22832961 rs17597773 chr1 221054761 C G 3.97E-05 Telomere length HLX intron 20139977 rs868058 chr1 221056390 A T 9.12E-05 Alzheimer's disease HLX intron 22832961 rs11578466 chr1 221057739 C G 3.31E-04 Hearing function HLX missense 17255346 rs2807862 chr1 221064481 G T 3.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6541166 chr1 221069370 A C 1.06E-04 Hearing function / / 17255346 rs4846672 chr1 221079666 A G 6.86E-05 Multiple complex diseases / / 17554300 rs7542375 chr1 221111780 T G 2.00E-06 Obesity-related traits / / 23251661 rs4846676 chr1 221152602 T C 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4846676 chr1 221152602 T C 2.74E-05 Height / / pha003011 rs2784262 chr1 221153278 G A 2.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2784264 chr1 221155819 A G 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2808219 chr1 221157900 T C 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17009262 chr1 221200503 G A 4.73E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13375635 chr1 221228069 C T 5.05E-04 Multiple complex diseases / / 17554300 rs12125058 chr1 221277508 C T 4.65E-05 Major depressive disorder (broad) / / 20038947 rs1442459 chr1 221287861 C A 5.56E-05 Major depressive disorder (broad) / / 20038947 rs4846689 chr1 221377435 A C 0.0000436 Uterine leiomyomata / / 23040493 rs17578266 chr1 221401679 C G 9.52E-05 Obesity (extreme) / / 21935397 rs4415570 chr1 221472909 T C 6.59E-04 Parkinson's disease / / 16252231 rs12402910 chr1 221495487 T C 2.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2996005 chr1 221496601 T C 7.24E-04 Multiple complex diseases / / 17554300 rs2996003 chr1 221500943 T C 4.85E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6704281 chr1 221507646 C T 4.94E-04 Suicide attempts in bipolar disorder C1orf140 intron 21041247 rs6704281 chr1 221507646 C T 3.74E-04 Smoking cessation C1orf140 intron 24665060 rs6704485 chr1 221507861 C G 4.94E-04 Suicide attempts in bipolar disorder C1orf140 intron 21041247 rs6704485 chr1 221507861 C G 2.48E-04 Smoking cessation C1orf140 intron 24665060 rs4313406 chr1 221511715 T C 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs4313406 chr1 221511715 T C 4.70E-04 Smoking cessation / / 24665060 rs6690986 chr1 221513236 T C 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs6671621 chr1 221517472 C G 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs4465211 chr1 221518582 A G 4.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs10863604 chr1 221521421 C G 4.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs10863605 chr1 221523403 A G 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs12044275 chr1 221526452 A G 1.60E-05 Urinary metabolites / / 21572414 rs12733856 chr1 221551539 C A 3.00E-06 Heart failure / / 20400778 rs3123736 chr1 221553536 G C 1.78E-04 Multiple complex diseases / / 17554300 rs3131543 chr1 221554800 A G 5.31E-04 Multiple complex diseases / / 17554300 rs1380251 chr1 221569175 G A 1.64E-06 Personality dimensions / / 18957941 rs1380251 chr1 221569175 G A 1.60E-06 Personality dimensions / / 21173776 rs1903136 chr1 221577849 G A 7.20E-07 Urinary metabolites / / 21572414 rs1993629 chr1 221578009 A G 1.00E-06 Urinary metabolites / / 21572414 rs3131533 chr1 221579628 A G 2.14E-05 F-cell distribution / / 21326311 rs1459222 chr1 221581795 G T 1.50E-05 Urinary metabolites / / 21572414 rs9726422 chr1 221604980 A G 1.80E-05 Personality dimensions / / 18957941 rs10465658 chr1 221606691 A G 6.13E-06 Personality dimensions / / 18957941 rs12032381 chr1 221617076 A C 6.00E-06 Dupuytren's disease / / 20971583 rs12032381 chr1 221617076 A C 0.00041 Prostate cancer / / 23555315 rs4846348 chr1 221702709 T C 1.27E-04 Amyotrophic lateral sclerosis / / 20801718 rs11118748 chr1 221715136 C T 4.99E-04 Type 2 diabetes / / 17463246 rs11118748 chr1 221715136 C T 1.84E-05 Alcohol and nictotine co-dependence / / 20158304 rs12025878 chr1 221843191 C T 3.86E-04 Lung function (forced vital capacity) / / 24023788 rs13376254 chr1 221849425 T C 3.86E-04 Lung function (forced vital capacity) / / 24023788 rs10863647 chr1 221856899 A G 2.80E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2090649 chr1 221867157 T C 8.65E-04 Multiple complex diseases / / 17554300 rs6655992 chr1 221868913 A C 2.90E-05 Urinary metabolites / / 21572414 rs11118832 chr1 221884371 T C 6.70E-04 Schizophrenia DUSP10 intron 19197363 rs11118838 chr1 221897346 A C 9.48E-04 Multiple complex diseases DUSP10 intron 17554300 rs6604668 chr1 221901624 T C 8.47E-04 Multiple complex diseases DUSP10 intron 17554300 rs11118858 chr1 221952958 G T 3.70E-05 Multiple complex diseases / / 17554300 rs10495178 chr1 221960438 G C 8.04E-05 Multiple complex diseases / / 17554300 rs10495179 chr1 221969368 C T 8.26E-05 Asthma / / 11022011 rs11118864 chr1 221979367 C T 2.88E-05 Asthma / / 11022011 rs3934724 chr1 221979762 T C 8.95E-04 Multiple complex diseases / / 17554300 rs4584399 chr1 221984235 T C 1.30E-04 Multiple complex diseases / / 17554300 rs4317815 chr1 221985915 A C 2.91E-04 Multiple complex diseases / / 17554300 rs12125690 chr1 222010866 A G 9.20E-04 Endometriosis / / 21151130 rs4579763 chr1 222012950 A C 7.53E-05 Multiple complex diseases / / 17554300 rs10495182 chr1 222027431 T C 7.73E-04 Multiple complex diseases / / 17554300 rs10495182 chr1 222027431 T C 6.07E-04 Bipolar disorder / / 19259986 rs12144971 chr1 222032485 C T 6.26E-05 Celiac disease / / 23936387 rs7551298 chr1 222037066 T C 4.50E-04 Multiple complex diseases / / 17554300 rs12130910 chr1 222038372 G A 5.04E-06 Mathematical ability / / 24801482 rs4240931 chr1 222039055 C T 6.26E-05 Celiac disease / / 23936387 rs4846732 chr1 222045181 T C 4.05E-04 Multiple complex diseases / / 17554300 rs6691170 chr1 222045446 G T 1.00E-09 Colorectal cancer / / 20972440 rs11811613 chr1 222055403 A G 2.16E-04 Celiac disease / / 23936387 rs11118883 chr1 222061022 G A 1.27E-04 Colorectal cancer / / 24737748 rs4846734 chr1 222072998 A G 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11118885 chr1 222075459 T C 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2378489 chr1 222076208 A C 9.48E-05 Alzheimer's disease (age of onset) / / 22005931 rs2378493 chr1 222076840 G A 9.10E-05 Alzheimer's disease (age of onset) / / 22005931 rs7520703 chr1 222084187 C A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2260032 chr1 222105479 G A 8.86E-04 White matter integrity / / 22425255 rs2790760 chr1 222109518 G A 3.77E-05 Celiac disease / / 23936387 rs6687758 chr1 222164948 A G 2.00E-09 Colorectal cancer / / 20972440 rs6687758 chr1 222164948 A G 6.00E-08 Progressive supranuclear palsy / / 21685912 rs6687758 chr1 222164948 A G 9.00E-09 Colorectal cancer / / 24836286 rs2970199 chr1 222177454 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2800860 chr1 222183226 C T 8.01E-04 Taste perception / / 22132133 rs12139468 chr1 222183756 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17442148 chr1 222187794 T C 1.20E-05 Kawasaki disease / / 22446962 rs2584315 chr1 222206887 G A 9.27E-05 Prostate cancer / / pha002877 rs2584316 chr1 222211329 A G 6.35E-05 Prostate cancer / / pha002877 rs1442440 chr1 222239534 T C 2.28E-04 Obesity (extreme) / / 21935397 rs7513781 chr1 222239932 T C 5.85E-04 Obesity (extreme) / / 21935397 rs7556050 chr1 222239992 A G 5.77E-04 Obesity (extreme) / / 21935397 rs1339875 chr1 222240322 T G 7.59E-04 Obesity (extreme) / / 21935397 rs1856620 chr1 222240379 T C 7.49E-04 Obesity (extreme) / / 21935397 rs1339876 chr1 222240418 A T 7.38E-04 Obesity (extreme) / / 21935397 rs7548749 chr1 222241688 G A 5.61E-04 Obesity (extreme) / / 21935397 rs12038701 chr1 222242777 G A 7.32E-04 Obesity (extreme) / / 21935397 rs11118934 chr1 222243455 T C 2.77E-04 Obesity (extreme) / / 21935397 rs12134885 chr1 222244380 T C 2.73E-04 Obesity (extreme) / / 21935397 rs10863680 chr1 222244880 T C 2.72E-04 Obesity (extreme) / / 21935397 rs10863681 chr1 222245258 A G 6.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs12135862 chr1 222245387 T C 5.53E-06 Metabolite levels (MHPG) / / 23319000 rs10863682 chr1 222247975 T C 3.61E-05 Obesity (extreme) / / 21935397 rs1890757 chr1 222248682 A C 1.11E-04 Obesity (extreme) / / 21935397 rs1890758 chr1 222248823 A G 1.14E-04 Obesity (extreme) / / 21935397 rs12096184 chr1 222250435 A G 1.11E-04 Obesity (extreme) / / 21935397 rs11118936 chr1 222251043 A G 1.11E-04 Obesity (extreme) / / 21935397 rs10863684 chr1 222251332 G A 3.67E-05 Obesity (extreme) / / 21935397 rs11118937 chr1 222251427 T C 3.67E-05 Obesity (extreme) / / 21935397 rs7525314 chr1 222251508 C T 1.10E-04 Obesity (extreme) / / 21935397 rs12138480 chr1 222252021 G A 3.60E-05 Obesity (extreme) / / 21935397 rs1890759 chr1 222254624 T A 1.45E-04 Obesity (extreme) / / 21935397 rs10863685 chr1 222255923 A G 1.45E-04 Obesity (extreme) / / 21935397 rs1591912 chr1 222256140 A G 1.45E-04 Obesity (extreme) / / 21935397 rs10495184 chr1 222259677 C A 3.28E-05 Obesity (extreme) / / 21935397 rs12561821 chr1 222261229 T C 6.16E-05 Obesity (extreme) / / 21935397 rs11118942 chr1 222265553 G A 3.01E-04 Obesity (extreme) / / 21935397 rs11118943 chr1 222266606 G A 3.23E-04 Obesity (extreme) / / 21935397 rs12125086 chr1 222268856 C T 3.37E-04 Obesity (extreme) / / 21935397 rs6702063 chr1 222270724 C T 3.42E-04 Obesity (extreme) / / 21935397 rs873549 chr1 222271767 C T 6.00E-23 Keloid / / 20711176 rs6678715 chr1 222277283 G C 1.30E-04 Obesity (extreme) / / 21935397 rs10863689 chr1 222282485 T C 2.59E-04 Obesity (extreme) / / 21935397 rs10779468 chr1 222282882 T C 2.60E-04 Obesity (extreme) / / 21935397 rs291906 chr1 222388787 T C 2.55E-04 Alzheimer's disease (late onset) / / 21379329 rs158710 chr1 222396017 G A 3.23E-04 Alzheimer's disease (late onset) / / 21379329 rs1155471 chr1 222504752 A G 4.03E-05 Anxiety in major depressive disorder / / 24047446 rs1386579 chr1 222574834 T C 6.65E-04 Aortic root size / / 21223598 rs10495191 chr1 222694436 A T 1.46E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs4481859 chr1 222732656 T G 9.43E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs10495194 chr1 222733971 C T 8.20E-05 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs2936032 chr1 222751791 C T 5.40E-05 Alcohol dependence TAF1A intron 22096494 rs3008647 chr1 222759007 T C 1.27E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17464836 chr1 222762128 A C 9.68E-05 Smoking quantity TAF1A intron 24665060 rs17464857 chr1 222762709 T G 1.40E-05 Multiple complex diseases TAF1A intron 17554300 rs17464857 chr1 222762709 T G 9.12E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17464857 chr1 222762709 T G 0.000877 Coronary artery disease with myocardial infarction TAF1A intron 23202125 rs2936041 chr1 222762773 T A 1.03E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17511318 chr1 222762958 A G 9.12E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs2936040 chr1 222763661 T A 1.45E-04 Multiple sclerosis / / 17660530 rs3008653 chr1 222764791 G C 1.11E-04 Response to taxane treatment (placlitaxel) LOC100506161 intron 23006423 rs3008654 chr1 222766609 A G 3.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1909194 chr1 222770703 A G 6.83E-04 Multiple complex diseases / / 17554300 rs1909194 chr1 222770703 A G 9.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1909194 chr1 222770703 A G 1.97E-04 Smoking quantity / / 24665060 rs3002130 chr1 222772139 C T 3.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3008598 chr1 222779948 T C 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4846770 chr1 222795569 C G 7.21E-08 Multiple complex diseases MIA3 intron 17554300 rs3008621 chr1 222804046 G A 1.00E-04 Multiple complex diseases MIA3 intron 17554300 rs3008621 chr1 222804046 G A 1.92E-06 Coronary Artery Disease MIA3 intron 17634449 rs2133188 chr1 222813753 G T 1.68E-04 Multiple complex diseases MIA3 intron 17554300 rs2133189 chr1 222814442 C T 1.37E-05 Multiple complex diseases MIA3 intron 17554300 rs2133189 chr1 222814442 C T 1.38E-05 Coronary Artery Disease MIA3 intron 17634449 rs2133189 chr1 222814442 C T 2.73E-07 Coronary heart disease MIA3 intron 22319020 rs17465637 chr1 222823529 A C 1.00E-05 Multiple complex diseases MIA3 intron 17554300 rs17465637 chr1 222823529 A C 1.00E-06 Coronary heart disease MIA3 intron 17634449 rs17465637 chr1 222823529 A C 1.00E-09 Myocardial infarction (early onset) MIA3 intron 19198609 rs17465637 chr1 222823529 A C 1.00E-09 Coronary heart disease MIA3 intron 21347282 rs17465637 chr1 222823529 A C 1.00E-08 Coronary heart disease MIA3 intron 21378990 rs17465637 chr1 222823529 A C 1.36E-08 Pericardial fat MIA3 intron 22589742 rs2291832 chr1 222826481 G A 4.90E-07 Coronary heart disease MIA3 intron 21966275 rs4240934 chr1 222904298 T C 1.57E-04 Multiple complex diseases BROX intron 17554300 rs9286760 chr1 222919682 G A 6.68E-05 Age-related macular degeneration FAM177B intron pha000002 rs6683071 chr1 222923351 A G 4.00E-06 Cognitive performance FAM177B missense 19734545 rs77190419 chr1 222947382 A T 0.00004694 Sarcoidosis / / 22952805 rs17163573 chr1 223089435 C T 7.34E-04 Type 2 diabetes DISP1 intron 17463246 rs10495205 chr1 223123348 G A 4.39E-04 Type 2 diabetes DISP1 intron 17846124 rs2789909 chr1 223171725 G T 1.53E-10 Multiple complex diseases DISP1 intron 17554300 rs851193 chr1 223294851 T C 7.51E-04 Multiple complex diseases TLR5 intron 17554300 rs851192 chr1 223295254 G C 9.64E-04 Multiple complex diseases TLR5 intron 17554300 rs851191 chr1 223308965 A C 6.51E-04 Multiple complex diseases TLR5 intron 17554300 rs1341987 chr1 223309213 C G 4.34E-05 Multiple complex diseases TLR5 intron 17554300 rs2096142 chr1 223311845 T C 3.78E-05 Multiple complex diseases TLR5 intron 17554300 rs2096141 chr1 223311940 A T 3.86E-05 Multiple complex diseases TLR5 intron 17554300 rs851171 chr1 223349020 G A 5.88E-04 Alcohol dependence / / 21314694 rs4661250 chr1 223399328 A G 3.84E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 17255346 rs851212 chr1 223417224 C T 0.0000431 Nonsyndromic striae distensae (stretch marks) SUSD4 intron 23633020 rs712856 chr1 223468336 A G 2.64E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 24023788 rs17163777 chr1 223468732 C T 4.66E-04 Multiple complex diseases SUSD4 intron 17554300 rs17163777 chr1 223468732 C T 8.96E-05 Amyotrophic lateral sclerosis (sporadic) SUSD4 intron 24529757 rs17161994 chr1 223469434 C G 9.46E-05 Chronic obstructive pulmonary disease SUSD4 intron 19300482 rs17161994 chr1 223469434 C G 9.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SUSD4 intron 20031582 rs825113 chr1 223498145 G A 4.57E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 24023788 rs1772283 chr1 223553189 T C 2.35E-04 Myocardial Infarction / / pha002873 rs1772290 chr1 223579329 C A,G,T 1.70E-05 Urinary metabolites / / 21572414 rs1095174 chr1 223581572 T C 9.67E-05 Body Mass Index / / pha003015 rs17162072 chr1 223594970 G A 6.33E-04 Insulin resistance / / 21901158 rs825148 chr1 223595240 C T 1.25E-77 Multiple complex diseases / / 17554300 rs825134 chr1 223603882 G T 3.08E-05 Multiple complex diseases / / 17554300 rs4233518 chr1 223636166 C T 8.46E-04 Multiple complex diseases / / 17554300 rs6671793 chr1 223637721 G T 3.78E-05 Coronary heart disease / / pha003055 rs6604713 chr1 223641831 G T 6.21E-04 Multiple complex diseases / / 17554300 rs4285687 chr1 223653432 G A 2.58E-05 Longevity / / 22279548 rs11261291 chr1 223656191 T A 7.29E-04 Smoking cessation / / 24665060 rs10495209 chr1 223656537 C T 4.49E-05 Smoking cessation / / 24665060 rs7527013 chr1 223662541 G A 1.46E-04 Smoking cessation / / 24665060 rs6690293 chr1 223663505 A G 2.30E-04 Smoking cessation / / 24665060 rs6685694 chr1 223663555 C T 2.63E-04 Smoking cessation / / 24665060 rs4623692 chr1 223663828 C T 3.04E-04 Smoking cessation / / 24665060 rs12046541 chr1 223663935 T G 2.45E-04 Smoking cessation / / 24665060 rs4661273 chr1 223665468 G A 4.82E-04 Smoking cessation / / 24665060 rs6682926 chr1 223665536 G A 5.70E-04 Smoking cessation / / 24665060 rs6604719 chr1 223670323 T G 3.30E-04 Smoking cessation / / 24665060 rs4512641 chr1 223673932 A G 3.43E-04 Smoking cessation / / 24665060 rs4511103 chr1 223680537 G A 1.55E-04 Smoking cessation / / 24665060 rs4325124 chr1 223682051 T C 6.87E-05 Smoking cessation / / 24665060 rs4603130 chr1 223686766 G A 1.90E-04 Smoking cessation / / 24665060 rs7554045 chr1 223687990 A T 8.91E-05 Smoking cessation / / 24665060 rs17162209 chr1 223693162 G A 8.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2404354 chr1 223840398 C T 9.60E-04 Type 2 diabetes / / 22238593 rs7525504 chr1 223867631 G A 6.50E-04 Interstitial lung disease / / 23583980 rs17596 chr1 223905532 G A 3.75E-06 Interstitial lung disease CAPN2 cds-synon 23583980 rs12066704 chr1 223931068 C T 2.55E-04 Glycosylated haemoglobin levels CAPN2 intron 17255346 rs1222138 chr1 223931411 G A 1.82E-04 Glycosylated haemoglobin levels CAPN2 intron 17255346 rs17598 chr1 223933079 C T 2.38E-04 Glycosylated haemoglobin levels CAPN2 cds-synon 17255346 rs1153942 chr1 223970745 T G 2.74E-04 Response to cytidine analogues (gemcitabine) TP53BP2 intron 24483146 rs41345146 chr1 224020068 G T 3.07E-05 Multiple complex diseases TP53BP2 intron 17554300 rs17319010 chr1 224089383 A C 6.06E-15 Gender / / 22362730 rs10916197 chr1 224230307 T C 4.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10916197 chr1 224230307 T C 3.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4551564 chr1 224237716 C A 5.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6604882 chr1 224240939 C A 2.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6604882 chr1 224240939 C A 8.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6663154 chr1 224246746 T G 9.60E-05 Major depressive disorder / / 22472876 rs7531519 chr1 224251838 A C 8.04E-04 Type 2 diabetes / / 17463246 rs7513964 chr1 224255757 G A 4.85E-04 Tourette syndrome / / 22889924 rs10916248 chr1 224256348 A T 5.00E-06 QT interval (interaction) / / 23459443 rs10916260 chr1 224264382 C T 2.35E-04 Smoking cessation / / 24665060 rs10799505 chr1 224351023 C T 3.66E-08 Lymphocyte counts / / 22286170 rs7530205 chr1 224487290 T C 9.10E-04 Heart Failure NVL intron pha002884 rs4653579 chr1 224518354 T C 5.30E-26 Progranulin levels NVL nearGene-5 21087763 rs4653579 chr1 224518354 T C 5.30E-26 Myocardial infarction NVL nearGene-5 21211798 rs11579964 chr1 224538940 C T 4.00E-06 Major depressive disorder / / 21042317 rs11579964 chr1 224538940 C T 1.01E-07 Major depressive disorder / / 22472876 rs11579964 chr1 224538940 C T 4.40E-06 Depression (quantitative trait) / / 23290196 rs12121977 chr1 224599977 G T 3.81E-04 Premature ovarian failure WDR26 intron 19508998 rs10799576 chr1 224644549 C T 4.05E-06 Pulmonary function LOC100506354 intron 20010835 rs12731630 chr1 224650947 T C 8.69E-05 HIV-1 viral setpoint LOC100506354 intron 22174851 rs2404785 chr1 224659778 G A 3.56E-05 Elbow pain LOC100506354 intron pha003008 rs2405028 chr1 224673659 A G 3.56E-05 Elbow pain LOC100506354 intron pha003008 rs10916625 chr1 224682884 A G 3.72E-05 Elbow pain LOC100506354 intron pha003008 rs791504 chr1 224694877 A T 3.41E-04 Multiple complex diseases LOC100506354 intron 17554300 rs7541917 chr1 224707101 G A 1.69E-04 Multiple complex diseases LOC100506354 intron 17554300 rs7550648 chr1 224707177 C T 3.15E-05 Multiple complex diseases LOC100506354 intron 17554300 rs10916631 chr1 224708052 C T 1.82E-04 Multiple complex diseases LOC100506354 intron 17554300 rs3738367 chr1 224708588 C T 2.50E-04 Multiple complex diseases LOC100506354 intron 17554300 rs72760323 chr1 224767537 G A 0.00006681 Sarcoidosis / / 22952805 rs16849891 chr1 224777150 A G 1.09E-05 Panic disorder / / 19165232 rs16850250 chr1 224804649 G A 2.32E-04 Smoking cessation CNIH3 UTR-5 24665060 rs6695864 chr1 224820292 G T 7.54E-05 Major depressive disorder (broad) CNIH3 intron 20038947 rs924362 chr1 224821550 C T 6.93E-04 Myopia (pathological) CNIH3 intron 21095009 rs10429870 chr1 224840799 C T 4.83E-04 Coronary heart disease CNIH3 intron 21606135 rs298730 chr1 224841244 A G 1.16E-04 Aortic root size CNIH3 intron 21223598 rs298733 chr1 224842251 C A 6.90E-04 Aortic root size CNIH3 intron 21223598 rs930323 chr1 224865790 C G 1.20E-04 Blood Phenotypes CNIH3 intron 17903294 rs930323 chr1 224865790 C G 3.10E-04 Alzheimer's disease CNIH3 intron 17998437 rs17573714 chr1 224875392 G A 2.77E-04 Alzheimer's disease CNIH3 intron 17998437 rs12025142 chr1 224876101 C A 8.45E-04 Coronary heart disease CNIH3 intron 21606135 rs4653593 chr1 224881970 A G 4.72E-04 Alzheimer's disease CNIH3 intron 17998437 rs6679040 chr1 224910507 G A 9.07E-08 Metabolite levels CNIH3 intron 23281178 rs1010735 chr1 224915429 T G 4.18E-05 Soluble levels of adhesion molecules CNIH3 intron pha003072 rs6660579 chr1 224916592 C T 2.63E-05 Cognitive test performance CNIH3 intron 20125193 rs6660579 chr1 224916592 C T 0.0000078 Preeclampsia CNIH3 intron 22432041 rs6660579 chr1 224916592 C T 4.69E-05 Amyotrophic lateral sclerosis (sporadic) CNIH3 intron 24529757 rs2802561 chr1 224948813 T C 3.71E-04 Multiple complex diseases / / 17554300 rs2802562 chr1 224950129 C T 9.54E-04 Multiple complex diseases / / 17554300 rs2997477 chr1 224984367 G C 7.13E-08 Narcolepsy / / 19629137 rs12081821 chr1 224991534 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11810181 chr1 225008581 T C 1.02E-05 Erythrocyte counts / / pha003101 rs2662928 chr1 225011642 A G 8.79E-05 Asthma / / 11022011 rs1892121 chr1 225018101 A G 6.78E-05 Asthma / / 11022011 rs10799281 chr1 225079770 A G 9.29E-05 Coronary restenosis / / 21878436 rs12563323 chr1 225084219 C T 8.70E-06 Urinary metabolites / / 21572414 rs16857749 chr1 225088095 T C 2.30E-05 Urinary metabolites / / 21572414 rs2449266 chr1 225108715 A G 9.67E-05 Smoking quantity / / 24665060 rs6686694 chr1 225310170 G A 4.60E-04 Blood pressure D/H14 intron 21422096 rs16844054 chr1 225311160 G C 8.80E-04 Type 2 diabetes D/H14 intron 17463246 rs12754230 chr1 225392252 C T 3.65E-04 Type 2 diabetes D/H14 intron 17463246 rs10495234 chr1 225493583 G A 3.21E-04 Multiple complex diseases D/H14 intron 17554300 rs648011 chr1 225508712 C T 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) D/H14 intron 23648065 rs3856145 chr1 225528183 C A 2.76E-04 Celiac disease D/H14 missense 23936387 rs12753933 chr1 225528648 T A 2.05E-04 Multiple complex diseases D/H14 intron 17554300 rs16844799 chr1 225549008 T C 0.00005446 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H14 intron 23233654 rs16844799 chr1 225549008 T C 5.45E-05 Methotrexate clearance (acute lymphoblastic leukemia) D/H14 intron 23233662 rs3856154 chr1 225565015 T C 7.29E-04 Common variable immunodeficiency D/H14 missense 21497890 rs6661263 chr1 225575588 C G 6.85E-04 Multiple complex diseases D/H14 intron 17554300 rs16844841 chr1 225590675 A C 4.00E-06 IgG glycosylation LBR UTR-3 23382691 rs16844846 chr1 225592927 T G 4.00E-06 IgG glycosylation LBR intron 23382691 rs16844846 chr1 225592927 T G 6.00E-06 IgG glycosylation LBR intron 23382691 rs17557867 chr1 225598855 G A 2.70E-05 Urinary metabolites LBR intron 21572414 rs4653637 chr1 225624016 G A 2.90E-04 Asthma / / 20698975 rs6702538 chr1 225624513 A C 1.30E-04 Multiple complex diseases / / 17554300 rs6426075 chr1 225637606 A G 1.00E-05 Urinary metabolites / / 21572414 rs6426075 chr1 225637606 A G 0.000759 Salmonella-induced pyroptosis / / 22837397 rs947034 chr1 225647649 G A 5.87E-05 Psoriasis / / 20953190 rs10799312 chr1 225653150 A G 0.000316 Salmonella-induced pyroptosis / / 22837397 rs3893032 chr1 225656388 A C 0.000235 Salmonella-induced pyroptosis / / 22837397 rs10799316 chr1 225668031 G A 5.00E-04 Multiple complex diseases / / 17554300 rs9804142 chr1 225673847 C T 6.57E-05 Multiple complex diseases / / 17554300 rs3795443 chr1 225675003 A G 4.56E-05 Alcohol and nictotine co-dependence E/H UTR-3 20158304 rs954534 chr1 225676330 T C 6.30E-04 Amyotrophic lateral sclerosis (sporadic) E/H UTR-3 24529757 rs1629896 chr1 225685928 A G 4.82E-06 Osteoarthritis E/H intron 22763110 rs10799319 chr1 225703485 A G 5.12E-05 Multiple complex diseases E/H intron 17554300 rs7555139 chr1 225716241 G A 4.31E-05 Multiple complex diseases E/H intron 17554300 rs510293 chr1 225732239 A T 3.53E-05 Multiple complex diseases E/H intron 17554300 rs499782 chr1 225768228 C T 3.59E-04 Multiple complex diseases E/H intron 17554300 rs17502774 chr1 225775962 A G 7.14E-04 Type 2 diabetes E/H intron 17463246 rs526201 chr1 225780166 C T 6.98E-04 Parkinson's disease E/H intron 17052657 rs2840958 chr1 225805043 A G 5.05E-05 Multiple complex diseases E/H intron 17554300 rs12140001 chr1 225809414 T A 6.07E-05 Personality dimensions E/H intron 18957941 rs2639703 chr1 225812911 T C 8.46E-06 Multiple complex diseases E/H intron 17554300 rs2840967 chr1 225824028 C T 3.70E-04 Asthma E/H intron 20698975 rs2615060 chr1 225873612 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs10915864 chr1 225901006 A G 2.00E-06 Obesity-related traits / / 23251661 rs12044217 chr1 225902582 C T 1.78E-04 Longevity / / 22279548 rs12044217 chr1 225902582 C T 4.00E-04 Myasthenia gravis / / 23055271 rs16845221 chr1 225924178 C T 2.42E-04 Multiple complex diseases / / 17554300 rs16845250 chr1 225946690 T C 9.81E-05 Smoking initiation / / 24665060 rs12118223 chr1 225951441 A T 6.34E-04 Bulimia nervosa / / 23568457 rs12403575 chr1 225961384 A G 2.53E-04 Taste perception / / 22132133 rs4653433 chr1 225974531 A G 5.44E-07 Asthma SRP9 intron 21804549 rs10157103 chr1 225988818 C T 2.04E-04 Multiple complex diseases / / 17554300 rs10799324 chr1 225994515 C A 7.18E-04 Multiple complex diseases / / 17554300 rs4653436 chr1 225995211 G A 1 Drug response to Warfarin / / 19794411 rs868966 chr1 226006098 G A 7.50E-05 Calcium levels EPHX1 intron pha003085 rs3753658 chr1 226012686 G T 4.11E-04 Response to taxane treatment (placlitaxel) EPHX1 intron 23006423 rs3753661 chr1 226014342 T G 2.42E-04 Birth weight EPHX1 intron 17255346 rs3766934 chr1 226015017 G T 3.28E-04 Birth weight EPHX1 intron 17255346 rs1051740 chr1 226019633 T C 1 Drug response to Carbamazepine EPHX1 missense 15692831 rs1051740 chr1 226019633 T C 1 Drug response to Warfarin EPHX1 missense 19794411 rs1051740 chr1 226019633 T C 1 Drug response to Phenytoin EPHX1 missense 19952982 rs1131873 chr1 226019653 G A 1 Drug response to Warfarin EPHX1 cds-synon 19794411 rs2260863 chr1 226019774 G C 1 Drug response to Warfarin EPHX1 intron 19794411 rs2740170 chr1 226024797 T C 1.51E-05 Prion diseases EPHX1 intron 22210626 rs2234922 chr1 226026406 A G 1 Drug response to Carbamazepine EPHX1 missense 15692831 rs2234922 chr1 226026406 A G 1 Drug response to Warfarin EPHX1 missense 19794411 rs2234922 chr1 226026406 A G 1 Drug response to Phenytoin EPHX1 missense 19952982 rs4149227 chr1 226032530 C A 8.21E-04 Response to cytidine analogues (gemcitabine) EPHX1 intron 24483146 rs4149230 chr1 226033030 G C 8.21E-04 Response to cytidine analogues (gemcitabine) EPHX1 cds-synon 24483146 rs10158985 chr1 226050609 C A 0.000137 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment TMEM63A intron 22310351 rs360094 chr1 226064846 A G 7.33E-05 Serum metabolites TMEM63A intron 19043545 rs360098 chr1 226066690 G C 4.08E-05 Serum metabolites TMEM63A intron 19043545 rs1223245 chr1 226082425 A G 5.00E-06 Preschool internalizing problems / / 24839885 rs14868 chr1 226107787 T C 3.62E-05 Basophils PYCR2 UTR-3 pha003087 rs12754943 chr1 226228627 C T 7.67E-05 Type 2 diabetes / / 17463246 rs6664668 chr1 226255954 G A 6.96E-06 Alcohol and nictotine co-dependence H3F3A intron 20158304 rs10915928 chr1 226266440 G A 3.93E-04 Type 2 diabetes / / 17463246 rs11577282 chr1 226287622 T G 3.91E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12136759 chr1 226321051 A G 3.67E-04 Type 2 diabetes / / 17463246 rs12136759 chr1 226321051 A G 4.65E-04 Coronary Artery Disease / / 17634449 rs1043641 chr1 226332993 C T 1.33E-05 Iron status biomarkers ACBD3 UTR-3 19084217 rs2306121 chr1 226353521 T A 6.13E-04 Coronary Artery Disease ACBD3 intron 17634449 rs10915955 chr1 226363155 G A 1.69E-05 Multiple complex diseases ACBD3 intron 17554300 rs9660924 chr1 226371939 C T 2.19E-04 Coronary Artery Disease ACBD3 intron 17634449 rs16860148 chr1 226376731 A G 1.09E-04 Multiple complex diseases / / 17554300 rs10753415 chr1 226385623 T C 5.08E-05 Crohn's disease / / 18587394 rs10495244 chr1 226387618 G A 4.02E-05 Multiple complex diseases / / 17554300 rs41357249 chr1 226397002 T C 1.30E-04 Alzheimer's disease / / 17998437 rs10915971 chr1 226508645 C T 8.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3219142 chr1 226552068 G A 7.86E-05 Longevity PARP1 intron 20304771 rs1136410 chr1 226555302 A G 9.97E-04 Multiple complex diseases PARP1 missense 17554300 rs3219123 chr1 226555348 G A 6.23E-06 Alcohol and nictotine co-dependence PARP1 intron 20158304 rs2027440 chr1 226563859 C T 3.50E-04 Type 2 diabetes and 6 quantitative traits PARP1 intron 17848626 rs3219090 chr1 226564691 T C 9.00E-08 Melanoma PARP1 intron 21983785 rs3219060 chr1 226572483 G T 5.63E-08 LDL cholesterol PARP1 intron 23063622 rs6426461 chr1 226613233 T C 2.58E-04 Smoking quantity / / 24665060 rs10799353 chr1 226662799 G A 1.53E-05 Femoral neck bone geometry / / 22087292 rs7551258 chr1 226671906 T C 7.61E-04 Multiple complex diseases / / 17554300 rs7551258 chr1 226671906 T C 2.10E-05 Urinary metabolites / / 21572414 rs7551258 chr1 226671906 T C 3.46E-04 Smoking quantity / / 24665060 rs506128 chr1 226702300 G A 9.64E-05 Blood Pressure / / pha003040 rs584297 chr1 226708481 T C 3.26E-05 F-cell distribution / / 21326311 rs708741 chr1 226737202 A G 0.00001502 Sarcoidosis C1orf95 intron 22952805 rs837748 chr1 226737845 A G 0.00007737 Sarcoidosis C1orf95 intron 22952805 rs603609 chr1 226738546 C T 3.38E-06 Multiple complex diseases C1orf95 intron 17554300 rs708743 chr1 226739447 C T 0.00001323 Sarcoidosis C1orf95 intron 22952805 rs650932 chr1 226740876 C A 0.00002543 Sarcoidosis C1orf95 intron 22952805 rs708745 chr1 226743163 A G 0.00006972 Sarcoidosis C1orf95 intron 22952805 rs588782 chr1 226744139 T C 0.0000632 Sarcoidosis C1orf95 intron 22952805 rs660449 chr1 226748670 T C 0.00002907 Sarcoidosis C1orf95 intron 22952805 rs7525939 chr1 226755971 C T 4.62E-04 Alzheimer's disease C1orf95 intron 21059989 rs7525939 chr1 226755971 C T 5.29E-06 Alzheimer's disease C1orf95 intron 21059989 rs654318 chr1 226760438 C G 7.42E-04 Acute lung injury C1orf95 intron 22295056 rs17580122 chr1 226778586 G T 8.75E-06 Type 2 diabetes C1orf95 intron 17463246 rs1050492 chr1 226820500 G A 8.29E-04 Alcohol dependence ITPKB UTR-3 21314694 rs10495246 chr1 226826484 C A 1.93E-06 Glaucoma (primary open-angle) ITPKB intron 22605921 rs1288934 chr1 226828038 A G 6.79E-05 Prion diseases ITPKB intron 22210626 rs3768373 chr1 226836036 C T 2.77E-05 Multiple complex diseases ITPKB intron 17554300 rs3768373 chr1 226836036 C T 4.67E-05 Cognitive impairment induced by topiramate ITPKB intron 22091778 rs200050925 chr1 226837127 T A 2.10E-12 Metabolite levels ITPKB intron 22286219 rs10916025 chr1 226855889 G C 6.00E-06 Subcutaneous adipose tissue ITPKB intron 22589738 rs708766 chr1 226865254 A C 8.59E-05 Orofacial clefts ITPKB intron 22419666 rs3768408 chr1 226910340 C T 1.00E-04 Cognitive impairment induced by topiramate ITPKB intron 22091778 rs708772 chr1 226912891 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITPKB intron 20877124 rs10495249 chr1 226919119 A G 9.48E-04 Multiple complex diseases ITPKB intron 17554300 rs6667260 chr1 226923938 A C 0.00008 Coronary artery calcification ITPKB missense 23727086 rs10916034 chr1 226952315 T C 5.96E-04 Obesity (extreme) / / 21935397 rs12729579 chr1 226956181 C T 2.89E-04 White matter integrity / / 22425255 rs835673 chr1 226960025 T C 2.40E-04 White matter integrity / / 22425255 rs12033364 chr1 226965174 G A 4.87E-04 White matter integrity / / 22425255 rs10495250 chr1 226973381 G A 3.57E-05 Gaucher disease severity / / 22388998 rs7547071 chr1 227014390 C T 3.97E-04 Aortic root size / / 21223598 rs1150896 chr1 227047256 T C 9.88E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6687807 chr1 227111521 A G 4.07E-04 Multiple complex diseases / / 17554300 rs6660932 chr1 227124660 C T 6.37E-05 Cognitive performance / / 19734545 rs12593 chr1 227172290 C T 2.85E-04 Suicide attempts in bipolar disorder ADCK3 cds-synon 21041247 rs141270350 chr1 227174318 C T 1.20E-09 Breast cancer(er negative) ADCK3 cds-synon 23555315 rs1186 chr1 227177731 A T 3.55E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3768425 chr1 227178127 A G 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045290 chr1 227178700 A G 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045289 chr1 227178713 C T 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045287 chr1 227178962 T C 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045285 chr1 227179054 G A 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1062908 chr1 227181554 C G 3.57E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs373548817 chr1 227181554 CA CCA,CGG 3.57E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045252 chr1 227181555 A G 3.58E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3795449 chr1 227181838 T G 3.58E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3795451 chr1 227181923 C T 3.59E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1343743 chr1 227183125 C T 3.65E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs10495273 chr1 227183359 T G 3.65E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs10916075 chr1 227184074 G A 3.67E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs11587443 chr1 227187896 T C 3.68E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs7541033 chr1 227188371 C A 3.48E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12409428 chr1 227189969 T C 3.72E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6684821 chr1 227190233 G A 3.74E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2297418 chr1 227192579 A C 3.80E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6426559 chr1 227195876 T C 3.71E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs11588904 chr1 227196211 T C 3.72E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12403236 chr1 227196502 C G 3.74E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12409755 chr1 227196949 A T 3.66E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6693535 chr1 227197685 G A 3.49E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6659424 chr1 227197875 A G 3.31E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs1929862 chr1 227199718 G A 3.30E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6704144 chr1 227201030 G C 3.29E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6665290 chr1 227201106 C T 3.03E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs17600669 chr1 227201871 A G 6.55E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs17600725 chr1 227204231 A G 6.90E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2104861 chr1 227208621 C T 6.27E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2104861 chr1 227208621 C T 6.67E-06 Monocyte counts CDC42BPA intron pha003089 rs12122759 chr1 227217340 T C 2.00E-04 Multiple complex diseases CDC42BPA intron 17554300 rs1319103 chr1 227219314 A G 8.57E-04 Parkinson's disease CDC42BPA intron 17052657 rs7521639 chr1 227223736 T C 1.90E-05 HIV-1 control CDC42BPA intron 20041166 rs6681959 chr1 227241676 C G 1.35E-04 Multiple complex diseases CDC42BPA intron 17554300 rs10495266 chr1 227247016 G C 5.19E-04 Sarcoidosis CDC42BPA intron 21540310 rs7526822 chr1 227263491 C T 1.89E-04 Multiple complex diseases CDC42BPA intron 17554300 rs9426545 chr1 227302912 A G 6.98E-04 Heart Failure CDC42BPA intron pha002885 rs629571 chr1 227304838 T C 7.04E-04 Heart Failure CDC42BPA intron pha002885 rs16847143 chr1 227308031 G A 7.91E-05 Multiple complex diseases CDC42BPA intron 17554300 rs10495256 chr1 227342798 G T 3.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC42BPA intron 20031582 rs1913342 chr1 227361072 G A 2.98E-04 Multiple complex diseases CDC42BPA intron 17554300 rs12035998 chr1 227374760 G A 7.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC42BPA intron 20031582 rs1877619 chr1 227401170 T C 2.93E-04 Multiple complex diseases CDC42BPA intron 17554300 rs16847490 chr1 227421999 T A 2.90E-12 Multiple complex diseases CDC42BPA intron 17554300 rs2813950 chr1 227426072 G A 2.30E-05 Urinary metabolites CDC42BPA intron 21572414 rs16847561 chr1 227469549 C T 2.69E-05 Amyotrophic lateral sclerosis CDC42BPA intron 19193627 rs10495252 chr1 227471891 T C 2.21E-04 Multiple complex diseases CDC42BPA intron 17554300 rs7549619 chr1 227506948 C A 2.30E-04 Multiple complex diseases / / 17554300 rs12047613 chr1 227544843 T A 9.97E-06 Response to amphetamines / / 22952603 rs3014268 chr1 227558822 G A 1.95E-04 Multiple complex diseases / / 17554300 rs7533453 chr1 227576220 C A 1.40E-05 Coffee consumption / / 21357676 rs3000777 chr1 227584651 G A 5.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11799974 chr1 227624312 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16847830 chr1 227626402 G T 6.97E-04 Multiple complex diseases / / 17554300 rs2819513 chr1 227630987 G A 2.34E-05 Hemoglobin / / pha003096 rs2819513 chr1 227630987 G A 2.45E-05 Hematocrit / / pha003097 rs10495275 chr1 227642119 T C 1.89E-06 Pancreatic cancer / / 22158540 rs953537 chr1 227655222 T C 1.00E-04 Asperger disorder / / 21182207 rs953537 chr1 227655222 T C 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10916150 chr1 227655314 G A 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs9628651 chr1 227661082 A C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs12410462 chr1 227667790 G A 4.00E-07 Major depressive disorder / / 23377640 rs2819522 chr1 227668181 G A 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs2814086 chr1 227669393 G C 3.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1495850 chr1 227669682 T A 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1390403 chr1 227673227 C A 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7549565 chr1 227679714 G T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1390401 chr1 227797950 A G 5.00E-09 Height ZNF678 intron 18391952 rs12070036 chr1 227819514 G A 9.89E-05 Multiple complex diseases ZNF678 intron 17554300 rs1045407 chr1 227847233 A G 3.38E-04 Type 2 diabetes ZNF678 UTR-3 17463246 rs6671682 chr1 227880275 C T 9.18E-05 Attention deficit hyperactivity disorder / / 22420046 rs10799445 chr1 227911883 A C 2.00E-13 Height / / 20881960 rs3087908 chr1 227920103 G A 2.22E-05 B cell non-Hodgkin lymphoma JMJD4 missense 23749188 rs2236359 chr1 227935444 A G 3.70E-05 Hypothyroidism S/P47 missense 22493691 rs12077397 chr1 227940738 C T 1.47E-04 Type 2 diabetes S/P47 intron 17463246 rs10916205 chr1 227957591 C T 8.20E-05 Hypothyroidism S/P47 intron 22493691 rs754224 chr1 227963491 G T 2.08E-05 Bladder cancer S/P47 intron 19648920 rs11590137 chr1 227981505 G A 3.05E-04 Multiple complex diseases / / 17554300 rs6679942 chr1 227992928 C T 7.18E-05 Multiple complex diseases / / 17554300 rs4341357 chr1 227995023 T A 0.000658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4341357 chr1 227995023 T A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1582114 chr1 228016370 A G 5.25E-04 Multiple complex diseases PRSS38 intron 17554300 rs12047364 chr1 228023201 C G 2.45E-04 Multiple complex diseases PRSS38 intron 17554300 rs11589239 chr1 228037278 C T 6.25E-04 Multiple complex diseases / / 17554300 rs10157777 chr1 228068143 G A 1.15E-05 Response to methylphenidate treatment / / 21130132 rs945699 chr1 228093319 A G 2.00E-08 Amyotrophic lateral sclerosis / / 17671248 rs12725747 chr1 228106921 G A 2.71E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10127943 chr1 228110064 G A 7.26E-05 Body Mass Index WNT9A intron pha003014 rs7529664 chr1 228122132 C T 8.96E-04 Multiple complex diseases WNT9A intron 17554300 rs7529664 chr1 228122132 C T 7.56E-04 Taste perception WNT9A intron 22132133 rs681239 chr1 228139672 A G 9.43E-05 Fibrinogen / / pha003068 rs708121 chr1 228208257 A G 4.90E-04 Endometriosis WNT3A intron 23104006 rs3121310 chr1 228224824 A G 1.70E-04 Endometriosis WNT3A intron 21151130 rs3768331 chr1 228282695 C T 5.48E-04 Suicide attempts in bipolar disorder ARF1 intron 21423239 rs16848404 chr1 228412537 G A 7.50E-04 Rheumatoid arthritis OBSCN intron 21452313 rs947087 chr1 228415594 G A 0.000896857 Hypertension (early onset hypertension) OBSCN intron 22479346 rs4653935 chr1 228474817 G A 0.000378548 Hypertension (early onset hypertension) OBSCN intron 22479346 rs564636 chr1 228483369 C T 1.39E-06 Recombination rate OBSCN intron 21698098 rs287614 chr1 228489101 C A 8.59E-05 Age-related macular degeneration OBSCN intron 21197116 rs1150910 chr1 228492044 G A 7.33E-05 Age-related macular degeneration OBSCN intron 21197116 rs435776 chr1 228494790 G A 5.30E-06 Age-related macular degeneration OBSCN missense pha000001 rs113376653 chr1 228505275 C T 0.000072 Prostate cancer (advanced) OBSCN missense 23555315 rs3795801 chr1 228505739 G A 0.000486527 Hypertension (early onset hypertension) OBSCN missense 22479346 rs4653549 chr1 228529606 G A 0.000644782 Hypertension (early onset hypertension) OBSCN intron 22479346 rs11578798 chr1 228543303 T A 8.75E-04 Alcohol dependence OBSCN intron 21314694 rs147709306 chr1 228548255 G C 0.000015 Prostate cancer (advanced) OBSCN missense 23555315 rs472594 chr1 228601638 T C 4.04E-05 Blood Pressure TRIM17 intron pha002898 rs4653551 chr1 228627913 G A 3.01E-06 Non-obstructive azoospermia / / 22541561 rs16848614 chr1 228633197 T C 0.000896046 Hypertension (early onset hypertension) / / 22479346 rs16848614 chr1 228633197 T C 7.33E-06 Body Mass Index / / pha003007 rs16848614 chr1 228633197 T C 4.62E-05 Waist Circumference / / pha003025 rs16848614 chr1 228633197 T C 2.97E-05 Weight / / pha003027 rs10733022 chr1 228660501 C A 0.00089 Prostate cancer / / 23555315 rs1925714 chr1 228703289 A G 2.00E-07 Tuberculosis / / 24057671 rs11586639 chr1 228715705 A G 7.54E-05 Kawasaki disease / / 22446961 rs10916338 chr1 228715923 G A 4.74E-06 Tuberculosis / / 24057671 rs2182200 chr1 228716166 C A 1.82E-05 Tuberculosis / / 24057671 rs7415895 chr1 228741147 A G 8.30E-05 Type 1 diabetes / / 18978792 rs12044139 chr1 228807528 A T 2.20E-04 Multiple complex diseases RHOU intron 17554300 rs12144495 chr1 228810937 T G 8.38E-04 Acute lung injury RHOU intron 22295056 rs2295256 chr1 228874049 C T 5.60E-04 Acute lung injury RHOU intron 22295056 rs4391637 chr1 228878379 A C 5.47E-04 Acute lung injury RHOU intron 22295056 rs1062060 chr1 228880021 C T 4.20E-05 Crohn's disease RHOU UTR-3 20570966 rs1062060 chr1 228880021 C T 4.76E-04 Acute lung injury RHOU UTR-3 22295056 rs11578216 chr1 228880098 T A 6.06E-04 Acute lung injury RHOU UTR-3 22295056 rs6426514 chr1 228880115 G A 2.00E-06 Type 2 diabetes RHOU UTR-3 23300278 rs11580020 chr1 228880466 G A 8.60E-04 Acute lung injury RHOU UTR-3 22295056 rs4654650 chr1 228895860 T C 2.44E-04 Type 2 diabetes / / 17463246 rs9426534 chr1 228896420 T A 2.69E-04 Type 2 diabetes / / 17463246 rs6691235 chr1 228901242 T G 4.09E-05 Body mass index / / 17255346 rs6688686 chr1 228901263 A G 3.77E-05 Body mass index / / 17255346 rs728370 chr1 228903818 C T 2.60E-04 Myasthenia gravis / / 23055271 rs241324 chr1 228916634 A G 2.80E-04 Myasthenia gravis / / 23055271 rs12749124 chr1 228945692 T C 2.91E-05 Hemoglobin / / pha003096 rs241301 chr1 228962427 T C 3.05E-06 Basophils / / pha003087 rs2639760 chr1 228966621 A G 4.58E-06 Basophils / / pha003087 rs2748092 chr1 228968757 G A 2.42E-05 Response to methylphenidate treatment / / 21130132 rs801112 chr1 228996622 T C 5.00E-06 Endometriosis / / 20844546 rs801114 chr1 228997835 T G 6.00E-12 Basal cell carcinoma / / 18849993 rs801114 chr1 228997835 T G 6.00E-12 Nasopharyngeal carcinoma / / 20512145 rs801114 chr1 228997835 T G 2.00E-13 Basal cell carcinoma / / 24403052 rs71074 chr1 229003739 T C 2.43E-05 Basophils / / pha003087 rs1341715 chr1 229018916 A G 4.04E-06 Basophils / / pha003087 rs11585386 chr1 229019148 C T 5.00E-06 Aging / / 22773346 rs6674543 chr1 229021947 T G 8.15E-04 Insulin resistance / / 21901158 rs2236591 chr1 229039470 C T 4.41E-05 Basophils / / pha003087 rs12078733 chr1 229041874 T C 6.41E-05 Basophils / / pha003087 rs603404 chr1 229105145 A G 7.80E-05 Alcohol dependence / / 20201924 rs603404 chr1 229105145 A G 9.00E-05 Alcohol dependence / / 20201924 rs603404 chr1 229105145 A G 7.84E-05 Alcoholism / / pha002892 rs603404 chr1 229105145 A G 9.02E-05 Alcoholism / / pha002893 rs778381 chr1 229106195 G A 8.30E-06 Urinary metabolites / / 21572414 rs10916397 chr1 229110404 T G 1.52E-15 Multiple complex diseases / / 17554300 rs7529576 chr1 229114198 G A 5.30E-05 Glioma (high-grade) / / 19578366 rs10916399 chr1 229118735 G A 4.49E-04 Multiple complex diseases / / 17554300 rs10916407 chr1 229149821 G A 1.24E-04 Parkinson's disease / / 17052657 rs1458762 chr1 229157752 T C 3.46E-04 Parkinson's disease / / 17052657 rs4654712 chr1 229195093 T A 4.06E-05 Vaspin levels / / 22907691 rs10916422 chr1 229227923 G A 4.12E-04 Body mass index / / 21701565 rs17140127 chr1 229243687 C T 2.23E-04 Body mass index / / 21701565 rs17583896 chr1 229250187 T C 1.67E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1551623 chr1 229256752 C T 3.44E-04 Alzheimer's disease / / 17998437 rs11809337 chr1 229258221 G A 6.93E-05 Inflammation / / pha002897 rs10916424 chr1 229262842 G A 2.96E-04 Hearing function / / 17255346 rs9726077 chr1 229272490 G A 2.40E-04 Primary sclerosing cholangitis / / 19944697 rs10916434 chr1 229282011 C T 2.40E-04 Primary sclerosing cholangitis / / 19944697 rs9793739 chr1 229285858 G A 4.00E-06 Dental caries / / 23259602 rs9793739 chr1 229285858 G A 5.00E-07 Dental caries / / 23259602 rs9287024 chr1 229291651 T G 4.14E-06 Asthma / / 11022011 rs365684 chr1 229305602 C T 2.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12023401 chr1 229334294 A G 6.73E-04 Prostate cancer / / 23023329 rs16849553 chr1 229336846 T C 7.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs16849568 chr1 229339670 T C 2.08E-07 Multiple complex diseases / / 17554300 rs2988738 chr1 229360505 T C 0.00000448 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) / / 23091423 rs932927 chr1 229362876 G A 3.41E-05 Creatinine levels / / pha003069 rs365462 chr1 229372577 A G 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435863 chr1 229372913 T C 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435864 chr1 229372934 A G 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435865 chr1 229377014 T C 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs201183839 chr1 229396071 AC A,AAA 9.94E-05 Parkinson's disease / / 17052657 rs201820188 chr1 229396071 A C 9.94E-05 Parkinson's disease / / 17052657 rs2036773 chr1 229396071 A AA,AC 9.94E-05 Parkinson's disease / / 17052657 rs237779 chr1 229435276 A G 8.75E-05 Blood Pressure RAB4A intron pha003049 rs9435840 chr1 229461882 A C 5.60E-04 Multiple complex diseases C1orf96 intron 17554300 rs163771 chr1 229469350 G A 6.80E-05 Eating disorders (purging via substances) C1orf96 intron 23568457 rs238098 chr1 229508716 T C 1.67E-04 Cholesterol / / 17255346 rs1002063 chr1 229537513 A G 3.23E-05 HIV-1 viral setpoint / / 21490045 rs41307728 chr1 229594003 C T 0.00068 Prostate cancer NUP133 missense 23555315 rs446924 chr1 229666990 C T 4.32E-05 IgE levels in asthmatics (D.p. specific) ABCB10 intron 23967269 rs10916517 chr1 229702505 G A 3.50E-04 Multiple complex diseases / / 17554300 rs12049351 chr1 229718001 C G 1.00E-06 Circulating myeloperoxidase levels (plasma) / / 23620142 rs35065129 chr1 229722395 A AG 1.10E-06 Urinary metabolites / / 21572414 rs6701445 chr1 229724800 T C 2.24E-05 Longevity / / 21612516 rs2295625 chr1 229730452 G A 7.54E-05 Prion diseases TAF5L cds-synon 22210626 rs10916527 chr1 229746970 T C 2.00E-05 Urinary metabolites TAF5L intron 21572414 rs2273574 chr1 229750343 T G 6.98E-04 Stroke TAF5L intron pha002886 rs3811473 chr1 229772693 T G 1.87E-04 Attention deficit hyperactivity disorder URB2 missense pha002875 rs3955545 chr1 229776053 C T 1.50E-05 Urinary metabolites URB2 intron 21572414 rs3955545 chr1 229776053 C T 1.80E-04 Attention deficit hyperactivity disorder URB2 intron pha002875 rs6704530 chr1 229797040 A C 1.40E-04 Type 2 diabetes / / 17463246 rs12403112 chr1 229798874 C T 2.09E-04 Type 2 diabetes / / 17463246 rs12738647 chr1 229803654 C T 7.67E-04 Smoking initiation / / 24665060 rs12062780 chr1 229804873 G A 3.15E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10495285 chr1 229804995 C G 4.00E-07 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4925506 chr1 229811989 C T 2.95E-08 Autism / / 22935194 rs17595207 chr1 229888090 G T 1.79E-04 Multiple complex diseases / / 17554300 rs670054 chr1 229888337 C A 3.52E-05 Insulin Resistance / / pha003062 rs670054 chr1 229888337 C A 5.01E-05 Insulin-related traits / / pha003063 rs643009 chr1 229910737 G A 9.41E-04 Iron levels / / pha002876 rs640333 chr1 229913100 G A 5.23E-05 Multiple complex diseases / / 17554300 rs557208 chr1 229916660 T C 1.44E-05 Multiple complex diseases / / 17554300 rs527081 chr1 229917648 C G 1.77E-05 Multiple complex diseases / / 17554300 rs481515 chr1 229921700 T C 2.71E-05 Multiple complex diseases / / 17554300 rs479531 chr1 229921927 T C 2.10E-05 Multiple complex diseases / / 17554300 rs2780629 chr1 229929298 A G 3.18E-05 Multiple complex diseases / / 17554300 rs541010 chr1 229935677 A G 2.94E-05 Multiple complex diseases / / 17554300 rs603991 chr1 229956480 C T 5.10E-05 Multiple complex diseases / / 17554300 rs16850412 chr1 229984950 G A 2.70E-05 Urinary metabolites / / 21572414 rs2780623 chr1 230013938 G A 6.64E-05 HIV-1 viral setpoint / / 21490045 rs12117248 chr1 230076169 T C 4.19E-05 Cytomegalovirus antibody response / / 21993531 rs10779848 chr1 230136986 T C 7.56E-04 Multiple complex diseases / / 17554300 rs12410483 chr1 230146177 A G 5.37E-04 Coronary heart disease / / 21606135 rs4411137 chr1 230146467 C A 2.81E-04 Coronary heart disease / / 21606135 rs4295887 chr1 230152083 G A 5.84E-05 Cognitive test performance / / 20125193 rs11122617 chr1 230161993 C T 2.29E-04 Multiple complex diseases / / 17554300 rs7529252 chr1 230206891 G A 8.56E-06 Multiple complex diseases GALNT2 intron 17554300 rs1474926 chr1 230207406 C A 0.000043 Body mass index GALNT2 intron 23001569 rs6684432 chr1 230209790 T C 1.36E-05 Serum vitamin D-binding protein levels GALNT2 intron 24740207 rs6673349 chr1 230211398 G A 8.70E-04 Multiple complex diseases GALNT2 intron 17554300 rs11122275 chr1 230212533 G A 3.92E-04 Multiple complex diseases GALNT2 intron 17554300 rs7520640 chr1 230228980 G T 6.97E-04 Multiple complex diseases GALNT2 intron 17554300 rs7519655 chr1 230229324 A C 3.85E-04 Multiple complex diseases GALNT2 intron 17554300 rs10779824 chr1 230231256 C T 5.72E-05 Alcohol consumption GALNT2 intron 23743675 rs7529009 chr1 230232080 A G 5.62E-05 Multiple complex diseases GALNT2 intron 17554300 rs910821 chr1 230232241 T A 1.06E-04 Alcohol consumption GALNT2 intron 23743675 rs12726525 chr1 230235032 G A 6.58E-05 Alcohol consumption GALNT2 intron 23743675 rs10746509 chr1 230237282 C T 6.77E-05 Multiple complex diseases GALNT2 intron 17554300 rs10864690 chr1 230237540 T A 9.11E-05 Multiple complex diseases GALNT2 intron 17554300 rs1998068 chr1 230238063 C G 7.73E-05 Multiple complex diseases GALNT2 intron 17554300 rs1998067 chr1 230238507 A G 4.74E-04 Multiple complex diseases GALNT2 intron 17554300 rs1998066 chr1 230238569 T C 2.02E-04 Multiple complex diseases GALNT2 intron 17554300 rs12035297 chr1 230238821 C T 7.69E-05 Alcohol consumption GALNT2 intron 23743675 rs1474839 chr1 230241400 G A 6.82E-04 Multiple complex diseases GALNT2 intron 17554300 rs1967707 chr1 230241456 G A 1.54E-04 Multiple complex diseases GALNT2 intron 17554300 rs12751815 chr1 230242580 C T 4.52E-04 Multiple complex diseases GALNT2 intron 17554300 rs12751815 chr1 230242580 C T 1.01E-04 Alcohol consumption GALNT2 intron 23743675 rs12732392 chr1 230244966 A G 1.09E-04 Alcohol consumption GALNT2 intron 23743675 rs1022663 chr1 230245200 T C 0.0000062 Coronary artery calcification GALNT2 intron 23727086 rs11585739 chr1 230245900 T C 1.42E-04 Multiple complex diseases GALNT2 intron 17554300 rs12724775 chr1 230247123 G A 9.70E-05 Alcohol consumption GALNT2 intron 23743675 rs6659923 chr1 230247564 A G 9.72E-04 Multiple complex diseases GALNT2 intron 17554300 rs7550262 chr1 230248739 G A 2.40E-05 Urinary metabolites GALNT2 intron 21572414 rs12086347 chr1 230263373 G A,T 1.05E-04 Alcohol consumption GALNT2 intron 23743675 rs11122361 chr1 230263959 G A 8.06E-04 Amyotrophic Lateral Sclerosis GALNT2 intron 17362836 rs10864699 chr1 230264607 G A 1.83E-04 Alcohol consumption GALNT2 intron 23743675 rs7541570 chr1 230265342 T C 2.44E-04 Alcohol consumption GALNT2 intron 23743675 rs4846904 chr1 230279410 G A 1.00E-06 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 3.90E-04 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 5.40E-05 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 5.50E-06 Lipid levels GALNT2 intron 19936222 rs4846908 chr1 230285056 G A 4.80E-05 Lipid levels GALNT2 intron 19936222 rs4846908 chr1 230285056 G A 0.000000759 HDL cholesterol GALNT2 intron 23063622 rs1998064 chr1 230287128 T G 7.20E-06 Urinary metabolites GALNT2 intron 21572414 rs2144300 chr1 230294916 C T 6.56E-05 Type 2 diabetes GALNT2 intron 17463246 rs2144300 chr1 230294916 C T 3.00E-14 HDL cholesterol GALNT2 intron 18193043 rs2144300 chr1 230294916 C T 8.00E-07 Triglycerides GALNT2 intron 18193043 rs2144300 chr1 230294916 C T 6.32E-05 Smoking cessation GALNT2 intron 18519826 rs2144300 chr1 230294916 C T 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs2144300 chr1 230294916 C T 3.00E-14 Coronary heart disease GALNT2 intron 21347282 rs2144300 chr1 230294916 C T 3.37E-16 HDL cholesterol GALNT2 intron 23063622 rs2144300 chr1 230294916 C T 6.39E-09 Triglycerides GALNT2 intron 23063622 rs2144300 chr1 230294916 C T 0.0000467 HDL cholesterol GALNT2 intron 23236364 rs2144300 chr1 230294916 C T 3.00E-06 Circulating myeloperoxidase levels (serum) GALNT2 intron 23620142 rs17315646 chr1 230295307 C G 8.94E-05 Type 2 diabetes GALNT2 intron 17463246 rs17315646 chr1 230295307 C G 5.71E-05 Smoking cessation GALNT2 intron 18519826 rs17315646 chr1 230295307 C G 7.50E-05 Response to statin therapy GALNT2 intron 20339536 rs17315646 chr1 230295307 C G 6.99E-12 HDL cholesterol GALNT2 intron 23063622 rs17315646 chr1 230295307 C G 8.57E-08 Triglycerides GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 8.53E-05 Type 2 diabetes GALNT2 intron 17463246 rs4846914 chr1 230295691 G A 2.50E-09 Lipid levels GALNT2 intron 18193043 rs4846914 chr1 230295691 G A 2.00E-13 HDL cholesterol GALNT2 intron 18193044 rs4846914 chr1 230295691 G A 7.00E-15 Triglycerides GALNT2 intron 18193044 rs4846914 chr1 230295691 G A 1.80E-04 Smoking cessation GALNT2 intron 18519826 rs4846914 chr1 230295691 G A 4.00E-08 HDL cholesterol GALNT2 intron 19060906 rs4846914 chr1 230295691 G A 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs4846914 chr1 230295691 G A 2.00E-14 Triglycerides GALNT2 intron 20686565 rs4846914 chr1 230295691 G A 4.00E-21 HDL cholesterol GALNT2 intron 20686565 rs4846914 chr1 230295691 G A 2.00E-13 Coronary heart disease GALNT2 intron 21347282 rs4846914 chr1 230295691 G A 8.91E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) GALNT2 intron 21541012 rs4846914 chr1 230295691 G A 3.96E-08 Triglycerides GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 4.28E-16 HDL cholesterol GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 4.00E-41 HDL cholesterol GALNT2 intron 24097068 rs4846914 chr1 230295691 G A 7.00E-31 Triglycerides GALNT2 intron 24097068 rs10127775 chr1 230295789 A G,T 8.61E-05 Type 2 diabetes GALNT2 intron 17463246 rs10127775 chr1 230295789 A G,T 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs10127775 chr1 230295789 A G,T 1.00E-09 Metabolite levels (atherosclerosis) GALNT2 intron 22916037 rs2281719 chr1 230297659 C T 3.73E-04 Type 2 diabetes GALNT2 intron 17463246 rs2281719 chr1 230297659 C T 8.10E-05 Response to statin therapy GALNT2 intron 20339536 rs2281719 chr1 230297659 C T 8.51E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) GALNT2 intron 21541012 rs2281719 chr1 230297659 C T 0.00000013 Triglycerides GALNT2 intron 23063622 rs2281719 chr1 230297659 C T 3.77E-15 HDL cholesterol GALNT2 intron 23063622 rs10779835 chr1 230299949 T C 1.60E-06 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 3.50E-05 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 5.30E-04 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 8.30E-05 Response to statin therapy GALNT2 intron 20339536 rs4846918 chr1 230300586 C T 3.20E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs4846918 chr1 230300586 C T 0.000000422 HDL cholesterol GALNT2 intron 22629316 rs4846918 chr1 230300586 C T 0.000019 HDL cholesterol (female) GALNT2 intron 22629316 rs4846918 chr1 230300586 C T 2.71E-12 HDL cholesterol GALNT2 intron 23063622 rs4846918 chr1 230300586 C T 6.65E-08 Triglycerides GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 3.80E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs2296065 chr1 230301776 G A 0.000000415 Triglycerides in females GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 0.000288 HDL cholesterol (male) GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 1.36E-09 HDL cholesterol (female) GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 4.37E-08 Triglycerides GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 9.61E-13 HDL cholesterol GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 3.86E-05 HDL particle features GALNT2 intron pha002900 rs10489615 chr1 230304988 A G 7.00E-05 Response to statin therapy GALNT2 intron 20339536 rs10489615 chr1 230304988 A G 4.00E-09 HDL cholesterol GALNT2 intron 20864672 rs1321257 chr1 230305312 G A 6.40E-05 Response to statin therapy GALNT2 intron 20339536 rs4846922 chr1 230307182 T C 4.00E-08 Metabolic syndrome GALNT2 intron 22399527 rs609526 chr1 230308906 T A 2.63E-04 Type 2 diabetes GALNT2 intron 17463246 rs609526 chr1 230308906 T A 2.49E-05 Smoking cessation GALNT2 intron 18519826 rs609526 chr1 230308906 T A 2.61E-12 HDL cholesterol GALNT2 intron 23063622 rs609526 chr1 230308906 T A 2.25E-04 Blood pressure (response to calcium channel blocker) GALNT2 intron 24192120 rs611841 chr1 230309481 C A 3.54E-08 HDL cholesterol GALNT2 intron 23063622 rs611841 chr1 230309481 C A 5.57E-08 Triglycerides GALNT2 intron 23063622 rs611229 chr1 230324067 T G 1.53E-09 HDL cholesterol GALNT2 intron 23063622 rs611229 chr1 230324067 T G 4.93E-06 HDL particle features GALNT2 intron pha002900 rs612577 chr1 230324364 T C 3.72E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs6703306 chr1 230351829 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs12076454 chr1 230378663 C T 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs3789630 chr1 230387498 C T 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs3761944 chr1 230388989 G C 8.00E-06 Hematology traits GALNT2 intron 23303382 rs12139970 chr1 230406460 G T 2.86E-06 HDL particle features GALNT2 intron pha002900 rs12030266 chr1 230427458 A C 4.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1386584 chr1 230436520 A G 2.48E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs11586112 chr1 230454674 C A 9.56E-04 Alzheimer's disease / / 17998437 rs7523232 chr1 230462848 C G 4.97E-05 Type 2 diabetes PGBD5 intron 17463246 rs828463 chr1 230513128 G A 5.28E-04 Smoking quantity PGBD5 intron 24665060 rs701170 chr1 230517993 C A 9.93E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PGBD5 intron 24023788 rs270851 chr1 230535437 G A 7.15E-05 Blood pressure PGBD5 intron 17255346 rs11122509 chr1 230551909 T C 0.000855417 Hypertension (early onset hypertension) PGBD5 intron 22479346 rs4846967 chr1 230575433 A C 7.69E-04 Smoking quantity / / 24665060 rs853010 chr1 230631025 T G 1.27E-04 Blood pressure / / 17255346 rs853006 chr1 230652782 T G 1.60E-05 Urinary metabolites / / 21572414 rs701157 chr1 230674826 T C 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs853444 chr1 230682813 A G 1.40E-06 Urinary metabolites / / 21572414 rs853444 chr1 230682813 A G 4.59E-04 Obesity (extreme) / / 21935397 rs853448 chr1 230686473 A C 6.74E-06 Body Mass Index / / pha003015 rs11122534 chr1 230688466 A G 2.77E-05 Celiac disease / / 23936387 rs11804015 chr1 230704291 T C 8.01E-05 Body Mass Index / / pha003015 rs10779846 chr1 230706208 C T 7.08E-04 Type 2 diabetes / / 17463246 rs200591 chr1 230706923 G A 4.54E-06 Body Mass Index / / pha003015 rs200591 chr1 230706923 G A 3.05E-05 Weight / / pha003027 rs740492 chr1 230711435 C T 1.54E-05 Body Mass Index / / pha003015 rs11122546 chr1 230719896 C A 9.95E-05 Myocardial Infarction / / pha002873 rs16852057 chr1 230724960 G A 4.81E-04 Multiple complex diseases / / 17554300 rs11122547 chr1 230725720 T C 4.64E-05 Myocardial Infarction / / pha002873 rs17659489 chr1 230749245 C T 2.20E-05 Urinary metabolites / / 21572414 rs853464 chr1 230749646 G A 2.81E-05 Body Mass Index / / pha003015 rs853464 chr1 230749646 G A 9.05E-05 Weight / / pha003027 rs11122556 chr1 230752309 C G 1.60E-04 Multiple complex diseases / / 17554300 rs853469 chr1 230759310 T C 5.49E-05 Body Mass Index / / pha003015 rs1078198 chr1 230774477 T C 8.49E-05 ldl cholesterol / / pha003077 rs1078197 chr1 230774851 T C 3.99E-05 ldl cholesterol / / pha003077 rs1359866 chr1 230795177 T C 5.49E-04 Smoking cessation COG2 intron 24665060 rs12143647 chr1 230808246 C T 3.20E-04 Suicidal ideation COG2 intron 22030708 rs2479131 chr1 230818841 G T 4.09E-04 Alzheimer's disease COG2 intron 17998437 rs41342047 chr1 230821996 C T 1.44E-04 Multiple complex diseases COG2 intron 17554300 rs143526339 chr1 230822832 C G 0.00015 Breast cancer COG2 missense 23555315 rs943580 chr1 230837044 G A 2.10E-08 Blood pressure / / 22100073 rs3789670 chr1 230843714 C T 5.40E-05 Blood pressure AGT intron 22100073 rs3789671 chr1 230843800 G T 1.10E-07 Blood pressure AGT intron 22100073 rs2478543 chr1 230844310 T C 1.20E-08 Blood pressure AGT intron 22100073 rs6687360 chr1 230844992 C T 8.20E-09 Blood pressure AGT intron 22100073 rs699 chr1 230845794 A G 1 Drug response to Atenolol AGT missense 11593098 rs699 chr1 230845794 A G 1 Drug response to Losartan AGT missense 11593098 rs699 chr1 230845794 A G 1.10E-08 Blood pressure AGT missense 22100073 rs699 chr1 230845794 A G 1 Drug response to Atenolol AGT missense 8728305 rs699 chr1 230845794 A G 1 Drug response to Lisinopril AGT missense 8728305 rs699 chr1 230845794 A G 1 Drug response to Nifedipine AGT missense 8728305 rs4762 chr1 230845977 G A 1 Drug response to Atenolol AGT missense 11593098 rs4762 chr1 230845977 G A 1 Drug response to Losartan AGT missense 11593098 rs11568026 chr1 230847523 A G 0.000000663 HDL cholesterol AGT intron 23063622 rs11568023 chr1 230848179 G A 7.16E-05 Multiple complex diseases AGT intron 17554300 rs2004776 chr1 230848702 C T 1.21E-06 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 6.70E-14 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 7.10E-10 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 9.03E-13 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 1.40E-04 Blood pressure (age interaction) AGT intron 24954895 rs2493134 chr1 230849359 T C 7.00E-09 Blood pressure AGT intron 22100073 rs2148582 chr1 230849799 A G 1.60E-08 Blood pressure AGT intron 22100073 rs5051 chr1 230849872 C T 2.30E-08 Blood pressure AGT UTR-5 22100073 rs5049 chr1 230850083 C T 5.90E-06 Blood pressure AGT UTR-5 22100073 rs5046 chr1 230850398 G A 5.20E-06 Blood pressure AGT nearGene-5 22100073 rs2071405 chr1 230850658 C T 5.70E-06 Blood pressure AGT nearGene-5 22100073 rs2071404 chr1 230850940 C A 6.00E-06 Blood pressure AGT nearGene-5 22100073 rs1977414 chr1 230852551 C T 2.40E-06 Blood pressure / / 22100073 rs16852515 chr1 230877144 A C 1.50E-05 Multiple complex diseases / / 17554300 rs16852515 chr1 230877144 A C 4.20E-05 Personality dimensions / / 18957941 rs6541330 chr1 230884363 T C 5.22E-05 Platelet counts CAPN9 intron pha003100 rs28359608 chr1 230895340 C A 9.85E-04 Amyotrophic lateral sclerosis (sporadic) CAPN9 missense 24529757 rs12038826 chr1 230922951 T C 7.00E-06 Myopia (pathological) CAPN9 intron 23049088 rs4477283 chr1 230932442 C T 1.25E-04 Amyotrophic lateral sclerosis CAPN9 intron 20801718 rs12139410 chr1 230933107 A G 5.14E-05 Insulin Resistance CAPN9 intron pha003062 rs1202524 chr1 230951172 G A 0.000023 Endometrial cancer / / 22426144 rs1202529 chr1 230955097 G C 0.000032 Endometrial cancer (Type 1 endometrial cancer) / / 22426144 rs1202529 chr1 230955097 G C 0.000055 Endometrial cancer / / 22426144 rs4847021 chr1 230959298 C T 2.22E-04 Multiple complex diseases / / 17554300 rs11122614 chr1 230967445 G A 9.71E-05 Insulin Resistance / / pha003062 rs11122614 chr1 230967445 G A 7.42E-05 Insulin-related traits / / pha003063 rs11122616 chr1 230978726 A G 1.10E-05 Urinary metabolites C1orf198 intron 21572414 rs1202558 chr1 230983656 C T 4.32E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202570 chr1 230992134 A G 2.90E-05 Urinary metabolites C1orf198 intron 21572414 rs1202570 chr1 230992134 A G 9.24E-05 Orofacial clefts C1orf198 intron 22419666 rs1202577 chr1 230998112 T C 9.50E-06 Urinary metabolites C1orf198 intron 21572414 rs1202580 chr1 231000791 A G 7.34E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202582 chr1 231001233 T C 6.07E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202584 chr1 231002150 A G 9.53E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs185614261 chr1 231004221 G A 0.000021 Breast cancer C1orf198 missense 23555315 rs9431872 chr1 231018941 A C 1.10E-05 Cognitive function / / 24684796 rs7550054 chr1 231062006 G A 6.97E-04 Multiple complex diseases TTC13 intron 17554300 rs4846886 chr1 231087400 G T 4.24E-05 HIV-1 viral setpoint TTC13 intron 22174851 rs6541240 chr1 231090578 G A 5.20E-05 Type 2 diabetes TTC13 intron 17293876 rs10864649 chr1 231132597 G C 6.30E-05 Multiple complex diseases ARV1 intron 17554300 rs12032403 chr1 231149298 A G 1.36E-04 Taste perception / / 22132133 rs10864659 chr1 231187053 T C 3.98E-04 Multiple complex diseases / / 17554300 rs6696857 chr1 231198028 C T 6.38E-04 Multiple complex diseases / / 17554300 rs4369216 chr1 231198332 A C 2.23E-05 Hirschsprung's disease / / 19196962 rs4463650 chr1 231199849 T G 6.58E-04 Multiple complex diseases / / 17554300 rs4388693 chr1 231220364 G A 3.06E-06 Leprosy / / pha002872 rs12043426 chr1 231241824 A C 3.50E-06 Primary sclerosing cholangitis / / 21151127 rs2883720 chr1 231255113 C T 5.07E-05 Multiple complex diseases / / 17554300 rs7514972 chr1 231262876 T C 2.30E-04 Multiple complex diseases / / 17554300 rs7514972 chr1 231262876 T C 2.82E-04 Lymphocyte counts / / 22286170 rs12023396 chr1 231270636 A G 4.00E-07 Obesity-related traits / / 23251661 rs9431646 chr1 231273550 G A 7.35E-04 Obesity (extreme) / / 21935397 rs9431933 chr1 231273656 C T 9.08E-04 Obesity (extreme) / / 21935397 rs9431934 chr1 231274460 C T 9.06E-04 Obesity (extreme) / / 21935397 rs6689582 chr1 231284128 G A 5.08E-04 Alzheimer's disease / / 22005930 rs1321132 chr1 231291359 G A 1.87E-04 Smoking initiation / / 24665060 rs9431660 chr1 231311867 A G 7.19E-05 White matter integrity TRIM67 intron 22425255 rs1406869 chr1 231313859 T C 8.84E-05 Heart Rate TRIM67 intron pha003054 rs9431663 chr1 231314221 A G 1.20E-04 Neuroticism TRIM67 intron 17667963 rs12563076 chr1 231327666 T A 3.19E-04 Smoking initiation TRIM67 intron 24665060 rs491182 chr1 231362923 G A 2.50E-05 Urinary metabolites C1orf131 intron 21572414 rs16854120 chr1 231504359 C T 5.79E-04 Multiple complex diseases EGLN1 intron 17554300 rs12030600 chr1 231605379 G A 9.10E-06 Urinary metabolites / / 21572414 rs1769800 chr1 231620545 T C 1.89E-04 Self-reported allergy / / 23817569 rs1769801 chr1 231622949 T C 2.63E-04 Self-reported allergy / / 23817569 rs1765774 chr1 231628292 A G 1.30E-05 Urinary metabolites / / 21572414 rs1765794 chr1 231656418 G A 8.98E-04 Self-reported allergy / / 23817569 rs1059595 chr1 231658301 A G 7.14E-04 Alcohol dependence / / 21314694 rs1059595 chr1 231658301 A G 2.50E-05 Urinary metabolites / / 21572414 rs766288 chr1 231693688 G T 9.16E-05 Self-reported allergy TS/X intron 23817569 rs1655304 chr1 231731343 G C 4.89E-04 Self-reported allergy LOC100287814 intron 23817569 rs1765778 chr1 231732356 G A 6.10E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655297 chr1 231733687 C T 2.54E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655296 chr1 231733795 G T 2.88E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655295 chr1 231734001 T A 2.46E-04 Self-reported allergy LOC100287814 intron 23817569 rs6656071 chr1 231737700 C T 3.01E-04 Self-reported allergy LOC100287814 intron 23817569 rs6679985 chr1 231737829 G C 3.37E-04 Self-reported allergy LOC100287814 intron 23817569 rs6674294 chr1 231738385 T C 3.18E-04 Self-reported allergy LOC100287814 intron 23817569 rs6683094 chr1 231738565 G A 3.18E-04 Self-reported allergy LOC100287814 intron 23817569 rs1025527 chr1 231749845 A G 2.26E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs1025526 chr1 231750641 C T 1.78E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs9661331 chr1 231752306 C T 1.41E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6541275 chr1 231752942 A G 1.89E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6541279 chr1 231753463 G C 2.31E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs4603118 chr1 231754600 A G 2.26E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6656080 chr1 231755265 G A 2.19E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs1030711 chr1 231755461 A T 5.92E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs9659663 chr1 231757060 A G 1.02E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs823167 chr1 231767230 G A 8.37E-04 Self-reported allergy DISC1 intron 23817569 rs823165 chr1 231769446 T A 6.43E-05 Self-reported allergy DISC1 intron 23817569 rs823163 chr1 231771108 A G 1.31E-04 Self-reported allergy DISC1 intron 23817569 rs1094656 chr1 231773675 T C 2.04E-04 Self-reported allergy DISC1 intron 23817569 rs1094655 chr1 231774362 A G 1.48E-04 Self-reported allergy DISC1 intron 23817569 rs823161 chr1 231775017 G A 1.56E-04 Self-reported allergy DISC1 intron 23817569 rs980394 chr1 231779507 G A 9.02E-05 Self-reported allergy DISC1 intron 23817569 rs11122318 chr1 231806852 T C 2.30E-04 Self-reported allergy DISC1 intron 23817569 rs12030517 chr1 231808385 T C 1.52E-04 Self-reported allergy DISC1 intron 23817569 rs12042938 chr1 231816842 C T 4.00E-36 Neuranatomic and neurocognitive phenotypes DISC1 intron 21483430 rs12042938 chr1 231816842 C T 9.93E-04 Self-reported allergy DISC1 intron 23817569 rs12044355 chr1 231844347 A C 8.34E-04 Multiple complex diseases DISC1 intron 17554300 rs12044355 chr1 231844347 A C 9.00E-06 Alzheimer's disease DISC1 intron 19118814 rs12044355 chr1 231844347 A C 9.20E-06 Alzheimer's disease (late onset) DISC1 intron 21460841 rs11122324 chr1 231859181 G A 1.87E-04 Multiple complex diseases DISC1 UTR-3 17554300 rs2793086 chr1 231899704 T G 9.00E-06 Response to antineoplastic agents DISC1 intron 21659360 rs16854954 chr1 231912592 T C 7.72E-05 Schizophrenia DISC1 intron 20185149 rs10495310 chr1 231918776 A C 2.34E-04 Alzheimer's disease (late onset) DISC1 intron 21379329 rs17817356 chr1 231920221 G A 1.86E-04 Fibrinogen DISC1 intron 17255346 rs11590192 chr1 231922845 T C 8.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) DISC1 intron 23648065 rs4459095 chr1 231985580 A G 1.27E-04 Smoking cessation DISC1 intron 18519826 rs9432024 chr1 232007219 T C 0.00000167 Schizophrenia DISC1 intron 22440650 rs10864698 chr1 232017889 G A 9.83E-04 Type 2 diabetes DISC1 intron 17463246 rs9431714 chr1 232021248 G A 1.60E-05 Urinary metabolites DISC1 intron 21572414 rs16855598 chr1 232054181 T C 3.85E-04 Multiple complex diseases DISC1 intron 17554300 rs701158 chr1 232073128 A G 8.85E-04 Alzheimer's disease DISC1 intron 24755620 rs872624 chr1 232074900 G A 2.01E-04 Smoking cessation DISC1 intron 18519826 rs872624 chr1 232074900 G A 7.03E-05 Smoking cessation DISC1 intron 18519826 rs1094401 chr1 232083585 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) DISC1 intron 20189245 rs16855725 chr1 232088232 G T 4.80E-04 Multiple complex diseases DISC1 intron 17554300 rs821597 chr1 232102264 G A 1.53E-04 Smoking quantity DISC1 intron 24665060 rs821600 chr1 232117026 G A 3.04E-04 Smoking quantity DISC1 intron 24665060 rs821662 chr1 232121135 T C 1.97E-04 Smoking quantity DISC1 intron 24665060 rs821663 chr1 232121222 C T 2.46E-04 Smoking quantity DISC1 intron 24665060 rs16855881 chr1 232124689 T C 3.60E-04 Multiple complex diseases DISC1 intron 17554300 rs821654 chr1 232127354 A G 7.47E-04 Smoking quantity DISC1 intron 24665060 rs3121910 chr1 232137193 T G 7.34E-04 Smoking quantity DISC1 intron 24665060 rs1754605 chr1 232137674 T C 6.51E-04 Smoking quantity DISC1 intron 24665060 rs866596 chr1 232146930 A G 3.95E-04 Smoking quantity DISC1 intron 24665060 rs821627 chr1 232147168 C T 2.96E-05 Smoking quantity DISC1 intron 24665060 rs866055 chr1 232147568 A G 9.06E-05 Smoking quantity DISC1 intron 24665060 rs1475514 chr1 232153793 G A 4.76E-04 Smoking quantity DISC1 intron 24665060 rs16856202 chr1 232155151 T G 8.00E-06 Amyotrophic lateral sclerosis DISC1 intron 19451621 rs1411771 chr1 232174775 T C 0.0000206 Antithrombin DISC1 UTR-3 23705025 rs2026298 chr1 232232335 C T 8.47E-04 Multiple complex diseases / / 17554300 rs1576618 chr1 232244331 C T 1.40E-06 Response to statin therapy / / 20339536 rs9729778 chr1 232246001 C T 4.30E-04 Alzheimer's disease (late onset) / / 21379329 rs10746514 chr1 232246027 G A 1.00E-06 Response to statin therapy / / 20339536 rs9308486 chr1 232246418 A G 1.90E-05 Response to statin therapy / / 20339536 rs9308486 chr1 232246418 A G 4.42E-05 Bleomycin sensitivity / / 21106707 rs9724918 chr1 232248087 C T 5.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9724918 chr1 232248087 C T 2.50E-05 Response to statin therapy / / 20339536 rs17832313 chr1 232266181 T C 8.05E-05 Orofacial clefts / / 22419666 rs867844 chr1 232266278 T A 4.30E-05 Response to statin therapy / / 20339536 rs1888601 chr1 232266922 C T 4.30E-05 Response to statin therapy / / 20339536 rs11122432 chr1 232270985 A G 3.99E-04 Multiple complex diseases / / 17554300 rs10864720 chr1 232271232 C T 4.00E-05 Response to statin therapy / / 20339536 rs12039526 chr1 232272599 C T 5.10E-05 Response to statin therapy / / 20339536 rs9662589 chr1 232277611 A C 7.40E-04 Multiple complex diseases / / 17554300 rs9308490 chr1 232308565 G C 7.84E-06 Serum metabolites / / 19043545 rs9727900 chr1 232311020 C T 2.50E-05 Weight / / pha003026 rs12754490 chr1 232312344 T C 6.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs1571755 chr1 232314505 C T 1.00E-04 Information processing speed / / 21130836 rs16856660 chr1 232321591 C T 7.10E-05 Multiple complex diseases / / 17554300 rs6605044 chr1 232349755 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4649384 chr1 232394263 T G 2.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9286807 chr1 232403070 T C 2.06E-04 Smoking quantity / / 24665060 rs11803212 chr1 232415093 G A 1.29E-04 Celiac disease / / 23936387 rs16856730 chr1 232422283 T C 3.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9725031 chr1 232444455 C T 8.00E-06 Post-traumatic stress disorder / / 24677629 rs4649292 chr1 232463715 G A 2.41E-04 HIV-1 viral setpoint / / 17641165 rs789367 chr1 232472932 G T 4.86E-05 Sarcoidosis / / 19165924 rs662242 chr1 232477392 T C 5.97E-05 Smoking quantity / / 24665060 rs607869 chr1 232484231 T A 4.46E-04 Smoking quantity / / 24665060 rs592557 chr1 232489950 C T 4.00E-04 Nicotine dependence / / 17407593 rs16856874 chr1 232494124 G A 6.63E-05 Pancreatic cancer / / pha002874 rs645925 chr1 232496302 G A 0.0000714 Tuberculosis with early age of onset / / 22551897 rs644690 chr1 232505285 T C 4.40E-04 Myasthenia gravis / / 23055271 rs3120768 chr1 232512873 A G 7.84E-05 Smoking quantity / / 24665060 rs789357 chr1 232516302 C T 4.50E-07 Urinary metabolites / / 21572414 rs669408 chr1 232519150 A C 1.00E-06 Immunoglobulin A / / 20694011 rs612191 chr1 232522748 T C 4.74E-04 Sarcoidosis / / 19165924 rs612191 chr1 232522748 T C 1.30E-06 Urinary metabolites / / 21572414 rs647578 chr1 232523442 A G 1.30E-06 Urinary metabolites / / 21572414 rs10158347 chr1 232529744 A G 9.37E-04 Type 2 diabetes / / 22158537 rs12043279 chr1 232540311 G A 9.90E-04 Alzheimer's disease SIPA1L2 intron 17998437 rs946132 chr1 232553739 C T 8.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SIPA1L2 intron 20877124 rs12758343 chr1 232566207 C T 1.09E-04 Lung function (forced expiratory volume in 1 second) SIPA1L2 intron 17255346 rs1547741 chr1 232568293 A G 2.40E-04 HIV-1 viral setpoint SIPA1L2 intron 17641165 rs6664207 chr1 232575539 G A 1.00E-04 Cognitive impairment induced by topiramate SIPA1L2 intron 22091778 rs6664207 chr1 232575539 G A 2.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SIPA1L2 intron 24023788 rs573140 chr1 232577281 T G 0.00000658 Bipolar disorder SIPA1L2 intron 23637625 rs17794366 chr1 232583916 G A 6.90E-04 Myopia (pathological) SIPA1L2 intron 21095009 rs6674092 chr1 232638409 G A 2.40E-05 Urinary metabolites SIPA1L2 intron 21572414 rs4649382 chr1 232641169 T C 4.12E-04 Multiple complex diseases SIPA1L2 intron 17554300 rs3795366 chr1 232650750 A G 9.47E-05 Waist-Hip Ratio SIPA1L2 cds-synon pha003029 rs12753793 chr1 232657870 T C 3.07E-04 Multiple complex diseases / / 17554300 rs6666357 chr1 232667977 C T 8.24E-04 Multiple complex diseases / / 17554300 rs789633 chr1 232673154 C T 6.61E-05 Waist-Hip Ratio / / pha003029 rs16857596 chr1 232673626 A G 1.39E-04 Aortic root size / / 21223598 rs789666 chr1 232686897 G A 5.11E-05 Paget's disease / / 20436471 rs16857696 chr1 232704719 T G 5.81E-04 Multiple complex diseases / / 17554300 rs16857696 chr1 232704719 T G 2.83E-04 Coronary heart disease / / 21606135 rs10797579 chr1 232718667 G T 9.19E-04 Type 2 diabetes / / 17463246 rs12036860 chr1 232725909 C G 5.10E-05 Body mass (lean) / / 19268274 rs16857720 chr1 232726069 A G 4.37E-05 Body mass (lean) / / 19268274 rs16857721 chr1 232726276 G T 3.69E-05 Body mass (lean) / / 19268274 rs4649274 chr1 232735234 G A 2.88E-04 Type 2 diabetes / / 17463246 rs10495332 chr1 232756026 T C 8.00E-06 Smooth-surface caries / / 24556642 rs7527321 chr1 232767895 T C 8.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10797586 chr1 232769870 T C 6.78E-04 Multiple complex diseases / / 17554300 rs6672248 chr1 232773900 A G 2.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17807087 chr1 232787894 A C 0.00000614 Transmission distortion / / 22377632 rs2184345 chr1 232811111 T C 1.64E-05 Myopia (pathological) / / 21640322 rs6699751 chr1 232811429 T C 5.00E-04 Alcohol dependence / / 20201924 rs4308924 chr1 232827343 T C 7.97E-05 Asthma / / 11022011 rs6676329 chr1 232859200 T C 2.04E-04 Multiple complex diseases / / 17554300 rs2644465 chr1 232895309 T G 1.49E-04 Type 2 diabetes / / 17463246 rs974935 chr1 232906829 C G 1.40E-05 Urinary metabolites / / 21572414 rs2814501 chr1 232911400 G A 0.000774 Salmonella-induced pyroptosis / / 22837397 rs2201591 chr1 232917823 C A 1.60E-05 Urinary metabolites / / 21572414 rs2644469 chr1 232921039 T C 9.81E-04 Multiple complex diseases / / 17554300 rs2644473 chr1 232924699 A T 2.10E-05 Urinary metabolites / / 21572414 rs2795467 chr1 232930057 A G 7.38E-04 Multiple complex diseases / / 17554300 rs2795467 chr1 232930057 A G 0.000466 Salmonella-induced pyroptosis / / 22837397 rs2795463 chr1 232932567 G A 2.10E-05 Urinary metabolites / / 21572414 rs1948529 chr1 232933687 G A 2.10E-05 Urinary metabolites / / 21572414 rs12567597 chr1 232941354 G T 2.94E-04 Suicide attempts in bipolar disorder KIAA1383 cds-synon 21423239 rs1874400 chr1 232990563 G A 2.60E-04 Heart Failure / / pha002884 rs2753393 chr1 233005854 A G 8.00E-06 Urinary metabolites / / 21572414 rs12062989 chr1 233011667 T A,C 6.00E-04 Multiple complex diseases / / 17554300 rs9424490 chr1 233021870 C G 3.62E-05 Nicotine smoking / / 19268276 rs7515204 chr1 233024567 T G 4.03E-04 Multiple complex diseases / / 17554300 rs10465473 chr1 233036385 C T 2.95E-04 Cholesterol / / 17255346 rs1073282 chr1 233039521 A G 9.13E-04 Type 2 diabetes / / 17463246 rs9424612 chr1 233040857 T C 1.18E-04 Cholesterol / / 17255346 rs2104042 chr1 233045461 A G 1.17E-04 Cholesterol / / 17255346 rs2104043 chr1 233045499 A G 1.18E-04 Cholesterol / / 17255346 rs714576 chr1 233046240 A G 2.67E-04 Cholesterol / / 17255346 rs714576 chr1 233046240 A G 8.13E-04 Type 2 diabetes / / 17463246 rs2224402 chr1 233052341 A G 3.10E-04 Breast cancer and prostate cancer / / 17903305 rs2224402 chr1 233052341 A G 8.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4141442 chr1 233098875 T C 7.55E-04 Alcohol dependence NTPCR intron 20201924 rs7523847 chr1 233100404 C A 6.14E-04 Alcohol dependence NTPCR intron 20201924 rs41309639 chr1 233122127 C T 0.000027 Breast cancer PCNXL2 missense 23555315 rs11579920 chr1 233163578 C T 5.20E-06 Urinary metabolites PCNXL2 intron 21572414 rs6676202 chr1 233171297 A G 5.90E-06 Urinary metabolites PCNXL2 intron 21572414 rs3820118 chr1 233173456 G A 1.22E-04 Lymphocyte counts PCNXL2 intron 22286170 rs6424271 chr1 233176596 T C 2.70E-05 HIV-1 control PCNXL2 intron 20041166 rs12082991 chr1 233268087 G A 1.46E-04 Sudden cardiac arrest PCNXL2 intron 21658281 rs1016405 chr1 233272372 C T 4.04E-06 Telomere length PCNXL2 intron 23900074 rs1125642 chr1 233279349 G A 3.61E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PCNXL2 intron 24236485 rs1125642 chr1 233279349 G A 9.76E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PCNXL2 intron 24236485 rs2477859 chr1 233281297 T C 8.97E-04 Nicotine smoking PCNXL2 intron 19268276 rs12036544 chr1 233312157 C A 3.04E-05 Waist-Hip Ratio PCNXL2 intron pha003013 rs12036544 chr1 233312157 C A 7.61E-05 Waist-Hip Ratio PCNXL2 intron pha003028 rs4649444 chr1 233339211 C A 1.00E-06 Homeostasis model assessment of beta-cell function (interaction) PCNXL2 intron 24204828 rs16858849 chr1 233339427 A G 9.19E-06 Homeostasis model assessment of beta-cell function (interaction) PCNXL2 intron 24204828 rs12027542 chr1 233340154 A G 4.00E-07 Type 2 diabetes PCNXL2 intron 21490949 rs701177 chr1 233357608 T C 8.32E-05 Coronary heart disease PCNXL2 intron pha003055 rs701177 chr1 233357608 T C 2.23E-05 Eosinophil counts PCNXL2 intron pha003088 rs701176 chr1 233362930 G A 4.74E-05 Longevity PCNXL2 intron 22279548 rs701173 chr1 233368289 A G 1.41E-06 Eosinophil counts PCNXL2 intron pha003088 rs10489808 chr1 233397267 G A 5.16E-04 Multiple complex diseases PCNXL2 intron 17554300 rs1033322 chr1 233400424 A G 9.61E-04 Stroke PCNXL2 intron pha002886 rs12135534 chr1 233407177 C A 9.84E-06 Insulin resistance PCNXL2 intron 21901158 rs11583596 chr1 233410047 G A 3.19E-05 Insulin resistance PCNXL2 intron 21901158 rs1294327 chr1 233426676 G T 3.78E-05 Stroke PCNXL2 intron pha002886 rs6667845 chr1 233429825 G A 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCNXL2 intron 20877124 rs1294338 chr1 233438952 G T 5.10E-05 Parkinson's disease (age of onset) / / 19772629 rs1294338 chr1 233438952 G T 3.69E-06 Brain structure / / 22504417 rs7513538 chr1 233475385 T C 7.91E-04 Amyotrophic Lateral Sclerosis KIAA1804 intron 17362836 rs6665230 chr1 233477868 A C 4.35E-04 Amyotrophic Lateral Sclerosis KIAA1804 intron 17362836 rs6665230 chr1 233477868 A C 5.03E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs7526011 chr1 233479064 T C 7.06E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs1533777 chr1 233479355 T C 2.26E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs926007 chr1 233483006 A G 7.32E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6678607 chr1 233483731 G C 7.67E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6703635 chr1 233483754 C G,T 7.77E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10797448 chr1 233484687 C T 8.88E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6424180 chr1 233489308 A T 9.45E-04 Obesity (extreme) KIAA1804 intron 21935397 rs7539016 chr1 233489499 A G 4.27E-04 Parkinson's disease KIAA1804 intron 17052657 rs7539016 chr1 233489499 A G 9.49E-04 Obesity (extreme) KIAA1804 intron 21935397 rs7549137 chr1 233489529 G A 9.50E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10910133 chr1 233489993 G A 9.50E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10797449 chr1 233490138 G A 9.51E-04 Obesity (extreme) KIAA1804 intron 21935397 rs2049183 chr1 233490408 T A 9.53E-04 Obesity (extreme) KIAA1804 intron 21935397 rs1294255 chr1 233501358 G C 1.90E-05 Breast cancer and prostate cancer KIAA1804 intron 17903305 rs4649309 chr1 233522265 T C 6.07E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10910153 chr1 233530532 G T 7.21E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6673933 chr1 233545582 A G 3.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17205291 chr1 233548331 C G 6.86E-05 Cardiovascular disease / / 22029572 rs12119248 chr1 233571079 C T 4.26E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12139945 chr1 233573008 A G 8.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4233060 chr1 233624614 G A 2.57E-05 Multiple sclerosis (age of onset) / / 19010793 rs4129547 chr1 233628771 A G 3.56E-04 Alzheimer's disease / / 24755620 rs10797464 chr1 233633797 G T 6.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10797465 chr1 233633819 G T 5.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10910200 chr1 233643856 G C 6.00E-06 Diabetic retinopathy / / 21441570 rs4649325 chr1 233644713 T C 5.71E-04 Acute lung injury / / 22295056 rs10910204 chr1 233653024 C A 4.01E-04 Multiple complex diseases / / 17554300 rs6693442 chr1 233653780 G C 1.23E-04 Multiple complex diseases / / 17554300 rs780212 chr1 233654847 T C 5.69E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1497090 chr1 233659290 G A 1.30E-05 Multiple complex diseases / / 17554300 rs780222 chr1 233661003 A G 9.50E-05 HIV-1 viral setpoint / / 22174851 rs2000179 chr1 233663942 C T 5.81E-05 Cognitive test performance / / 20125193 rs12731522 chr1 233679176 A G 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1390969 chr1 233690105 T A 5.47E-04 Multiple complex diseases / / 17554300 rs12740439 chr1 233695394 G A 6.77E-04 Multiple complex diseases / / 17554300 rs11800854 chr1 233719984 G A 3.00E-07 Periodontal microbiota / / 22699663 rs11800854 chr1 233719984 G A 4.00E-06 Periodontal microbiota / / 22699663 rs1773950 chr1 233735468 C T 5.22E-05 Creatinine levels / / pha003069 rs12119367 chr1 233738404 A C 9.36E-04 Stroke / / pha002887 rs12071360 chr1 233744579 T C 3.56E-05 Cocaine dependence / / 23958962 rs12071360 chr1 233744579 T C 8.33E-11 Cocaine dependence / / 23958962 rs41495154 chr1 233754237 G A 2.70E-04 Multiple complex diseases KCNK1 intron 17554300 rs701206 chr1 233757721 C T 3.58E-05 Multiple complex diseases KCNK1 intron 17554300 rs701228 chr1 233768990 G C 1.60E-04 Multiple complex diseases KCNK1 intron 17554300 rs6667354 chr1 233784222 T G 7.90E-05 Cognitive impairment induced by topiramate KCNK1 intron 22091778 rs2282428 chr1 233786170 C T 5.75E-05 QT interval KCNK1 intron 16648850 rs12144885 chr1 233788316 T C 1.60E-05 Cognitive impairment induced by topiramate KCNK1 intron 22091778 rs10732966 chr1 233794839 T C 3.64E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs544750 chr1 233799509 G A 2.07E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs630938 chr1 233800484 C T 3.28E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs701234 chr1 233803982 C G 3.69E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs532657 chr1 233813072 G T 5.09E-04 Multiple complex diseases / / 17554300 rs659340 chr1 233815677 C A 3.85E-04 Multiple complex diseases / / 17554300 rs595191 chr1 233823925 A G 2.50E-04 Asperger disorder / / 21182207 rs595191 chr1 233823925 A G 1.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs651185 chr1 233871030 C T 7.55E-04 Multiple complex diseases / / 17554300 rs680337 chr1 233874633 A G 4.17E-05 Cognitive test performance / / 20125193 rs587531 chr1 233878427 T A 5.67E-04 Multiple complex diseases / / 17554300 rs6676367 chr1 233887113 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6687540 chr1 233893329 G C 1.41E-04 Cognitive decline / / 23732972 rs16859591 chr1 233927721 A G 1.91E-04 Multiple complex diseases / / 17554300 rs16859594 chr1 233927868 T C 6.95E-04 Insulin resistance / / 21901158 rs7539340 chr1 234021539 A G 9.20E-05 Multiple complex diseases / / 17554300 rs10157596 chr1 234023144 T C 7.23E-04 Multiple complex diseases / / 17554300 rs6702789 chr1 234064302 G A 3.17E-04 Type 2 diabetes SLC35F3 intron 17463246 rs6702789 chr1 234064302 G A 1.57E-04 Lymphocyte counts SLC35F3 intron 22286170 rs9435539 chr1 234142548 T C 1.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs6586363 chr1 234143175 A G 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs9435540 chr1 234143998 G A 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs748910 chr1 234177506 G A 5.26E-04 Aortic root size SLC35F3 intron 21223598 rs9435500 chr1 234198222 G A 9.86E-05 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4281379 chr1 234210250 C G 2.21E-04 White matter integrity SLC35F3 intron 22425255 rs9435557 chr1 234217852 A G 2.17E-04 White matter integrity SLC35F3 intron 22425255 rs12032360 chr1 234218147 A C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs12032360 chr1 234218147 A C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs2045518 chr1 234230388 A G 9.20E-04 Alcohol dependence SLC35F3 intron 21314694 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs10797527 chr1 234250281 A G 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs12071173 chr1 234280906 T C 1.41E-04 Multiple complex diseases SLC35F3 intron 17554300 rs12074312 chr1 234285974 G T 1.00E-04 Information processing speed SLC35F3 intron 21130836 rs16842714 chr1 234316313 T C 1.18E-04 Multiple complex diseases SLC35F3 intron 17554300 rs1543468 chr1 234348425 T C 2.50E-05 Kidney function and endocine traits SLC35F3 intron 17903292 rs10910389 chr1 234364285 C A 7.90E-04 Endometriosis SLC35F3 intron 21151130 rs12119646 chr1 234382599 T C 4.25E-05 Left ventricular hypertrophy SLC35F3 intron pha003052 rs12024374 chr1 234384658 G A 4.80E-05 Left ventricular hypertrophy SLC35F3 intron pha003052 rs7552485 chr1 234415806 T C 7.26E-04 Myocardial Infarction SLC35F3 intron pha002873 rs594349 chr1 234427534 A C 3.55E-06 Substance dependence phenotypes SLC35F3 intron 24832863 rs1570105 chr1 234429727 G A 6.23E-05 Blood Pressure SLC35F3 intron pha003049 rs517527 chr1 234431320 T C 4.35E-05 Job-related exhaustion SLC35F3 intron 23620144 rs16842939 chr1 234448530 G T 1.50E-05 Urinary metabolites SLC35F3 intron 21572414 rs1407149 chr1 234452980 G A 1.46E-04 Amyotrophic Lateral Sclerosis SLC35F3 intron 17827064 rs12133361 chr1 234461183 C T 5.04E-04 Depression (quantitative trait) / / 20800221 rs3001707 chr1 234481678 A G 0.0000704 Tuberculosis with early age of onset / / 22551897 rs2991957 chr1 234493015 A G 2.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3001702 chr1 234493686 A G 2.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6693224 chr1 234503369 G C 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6702834 chr1 234507000 A C 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6698335 chr1 234507382 C T 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4300255 chr1 234510262 A G 3.89E-04 Multiple complex diseases C1orf31 intron 17554300 rs6586385 chr1 234511213 G C 7.46E-04 Alzheimer's disease C1orf31 intron 17998437 rs6586385 chr1 234511213 G C 9.94E-04 Suicide attempts in bipolar disorder C1orf31 intron 21423239 rs6695813 chr1 234515608 A C 3.57E-04 Suicide attempts in bipolar disorder C1orf31 intron 21423239 rs6669190 chr1 234525940 T C 7.56E-04 Alzheimer's disease / / 17998437 rs2175594 chr1 234529552 C T 5.43E-04 Multiple complex diseases TARBP1 cds-synon 17554300 rs2175593 chr1 234529570 G A 8.22E-04 Multiple complex diseases TARBP1 cds-synon 17554300 rs1039993 chr1 234529879 T C 2.44E-04 Suicide attempts in bipolar disorder TARBP1 intron 21423239 rs17576781 chr1 234537924 T C 1.74E-04 Suicide attempts in bipolar disorder TARBP1 intron 21423239 rs12073170 chr1 234541801 A G 8.25E-04 Myopia (pathological) TARBP1 cds-synon 21095009 rs4920180 chr1 234572637 G A 0.000791 Salmonella-induced pyroptosis TARBP1 intron 22837397 rs2273875 chr1 234573357 G C 2.14E-04 Smoking quantity TARBP1 intron 24665060 rs3768286 chr1 234581891 C T 4.05E-04 Response to taxane treatment (placlitaxel) TARBP1 intron 23006423 rs10489896 chr1 234583618 C T 6.00E-06 Cognitive test performance TARBP1 intron 17903297 rs1334814 chr1 234584926 A C 7.60E-04 Response to taxane treatment (placlitaxel) TARBP1 intron 23006423 rs270504 chr1 234601586 G A 5.50E-05 Major depressive disorder TARBP1 intron 21042317 rs544470 chr1 234613050 T C 2.44E-04 Lymphocyte counts TARBP1 intron 22286170 rs12082553 chr1 234613114 T C 6.43E-04 Multiple complex diseases TARBP1 intron 17554300 rs271738 chr1 234662890 G A 5.00E-06 Bipolar disorder / / 22688191 rs271742 chr1 234666319 T C 4.41E-04 Response to taxane treatment (placlitaxel) LOC100506795 intron 23006423 rs79169886 chr1 234691374 T C 0.00004709 Sarcoidosis / / 22952805 rs4362021 chr1 234696177 T A 4.84E-04 Type 2 diabetes / / 17463246 rs9970996 chr1 234701910 G A 0.000654682 Hypertension (early onset hypertension) / / 22479346 rs9970996 chr1 234701910 G A 9.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs138621343 chr1 234703342 G A 0.00004061 Sarcoidosis / / 22952805 rs744487 chr1 234726012 A C 5.00E-06 Coronary heart disease / / 21347282 rs11581667 chr1 234726356 C T 4.00E-06 IgG glycosylation / / 23382691 rs17578989 chr1 234737989 T C 2.23E-05 Esophageal cancer (squamous cell) / / 22960999 rs1329125 chr1 234740880 C T 3.05E-05 Prostate cancer IRF2BP2 UTR-3 22923026 rs7537526 chr1 234767290 A G 7.04E-04 Telomere length LINC00184 intron 23900074 rs9803801 chr1 234769793 C T 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12058613 chr1 234782449 A G 6.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs673283 chr1 234792524 G A 8.85E-05 Glucose levels / / pha003057 rs482329 chr1 234816554 G C 6.00E-06 Life threatening arrhythmia / / 22247754 rs588965 chr1 234820827 G T 6.61E-04 Bipolar disorder / / 19259986 rs1753579 chr1 234837359 T C 5.44E-05 Glucose levels / / pha003057 rs615086 chr1 234838501 C T 3.89E-05 Serum metabolites / / 19043545 rs7518033 chr1 234856227 A T 6.85E-04 Multiple complex diseases / / 17554300 rs514230 chr1 234858597 A T 5.00E-14 Cholesterol,total / / 20686565 rs514230 chr1 234858597 A T 9.00E-12 LDL cholesterol / / 20686565 rs514230 chr1 234858597 A T 5.00E-14 Cholesterol,total / / 24097068 rs514230 chr1 234858597 A T 9.00E-12 LDL cholesterol / / 24097068 rs7554650 chr1 234874740 C G 1.67E-04 Bone mass and geometry / / 17903296 rs2587531 chr1 234892797 C T 7.91E-04 Type 2 diabetes / / 17463246 rs2587529 chr1 234903271 G T 3.97E-04 Smoking initiation / / 24665060 rs10910502 chr1 234906812 T A 5.36E-04 Smoking initiation / / 24665060 rs2439500 chr1 234906829 C T 4.54E-05 Hodgkin's lymphoma / / 24149102 rs3914503 chr1 234956342 A G 6.23E-05 Alzheimer's disease / / 17998437 rs2796160 chr1 234966277 A C 7.36E-04 Heart Failure / / pha002885 rs2673949 chr1 234976206 A G 2.82E-04 Multiple complex diseases / / 17554300 rs2069084 chr1 234984988 G A 6.00E-06 HIV-1 control / / 20041166 rs2802955 chr1 235015199 C T 3.65E-06 LDL lipoproteins / / pha002902 rs11586083 chr1 235090973 T C 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs908327 chr1 235092600 A C 5.00E-10 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs2802928 chr1 235094931 A G 4.90E-04 Alcohol dependence / / 20201924 rs10910536 chr1 235097045 C A 1.94E-06 Height / / pha003011 rs6586361 chr1 235119382 G T 3.02E-05 Coronary Artery Disease / / 17634449 rs3924208 chr1 235130526 C T 2.54E-04 Coronary Artery Disease / / 17634449 rs9662936 chr1 235248412 C T 7.77E-05 HIV-1 control / / 20041166 rs11577354 chr1 235267127 G A 7.00E-06 Obesity-related traits / / 23251661 rs7411516 chr1 235272357 C T 1.23E-04 Vaspin levels / / 22907691 rs7411516 chr1 235272357 C T 0.0001228 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs4329572 chr1 235290922 C A 1.00E-04 Alcoholism (heaviness of drinking) TOMM20 intron 21529783 rs12117563 chr1 235384838 G A 1.22E-04 Multiple complex diseases ARID4B intron 17554300 rs13374091 chr1 235582924 T G 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs16832594 chr1 235583589 T C 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs16832599 chr1 235586331 T A 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs6429082 chr1 235600129 T C 3.00E-07 Adiposity TBCE intron 19557161 rs10925824 chr1 235645079 T C 6.23E-06 Carotenoid and tocopherol levels B3GALNT2 intron 19185284 rs10802790 chr1 235701864 G C 5.00E-05 Iris characteristics / / 21835309 rs291353 chr1 235720898 C T 6.00E-06 Aging traits GNG4 intron 17903295 rs2481094 chr1 235732496 C T 2.79E-05 Triglycerides GNG4 intron pha003080 rs6674438 chr1 235738515 T C 1.04E-04 HIV-1 viral setpoint GNG4 intron 17641165 rs2841880 chr1 235738814 T C 2.71E-06 Triglycerides GNG4 intron pha003080 rs2841873 chr1 235743992 T G 1.46E-05 Triglycerides GNG4 intron pha003080 rs2774316 chr1 235754243 G C 3.58E-06 Hirschsprung's disease GNG4 intron 19196962 rs881070 chr1 235756737 C T 5.25E-04 Smoking initiation GNG4 intron 24665060 rs10926189 chr1 235760817 C T 9.95E-05 Chronic obstructive pulmonary disease GNG4 intron 19300482 rs10926189 chr1 235760817 C T 5.20E-05 IgE levels in asthmatics (D.f. specific) GNG4 intron 23967269 rs17547995 chr1 235766162 C T 8.95E-05 Post-operative nausea and vomiting GNG4 intron 21694509 rs6429207 chr1 235798334 A C 2.39E-04 Birth weight GNG4 intron 17255346 rs6429207 chr1 235798334 A C 3.03E-05 Cytomegalovirus antibody response GNG4 intron 21993531 rs1891978 chr1 235809170 G A 2.75E-04 Alzheimer's disease GNG4 intron 17998437 rs1891978 chr1 235809170 G A 8.70E-07 Urinary metabolites GNG4 intron 21572414 rs11810173 chr1 235832555 C T 9.37E-05 Body Composition LYST intron pha003012 rs13373917 chr1 235838759 C T 2.16E-04 Multiple complex diseases LYST intron 17554300 rs7517694 chr1 235840294 G A 2.69E-04 Multiple complex diseases LYST intron 17554300 rs16848869 chr1 235890146 T C 4.70E-04 Multiple complex diseases LYST intron 17554300 rs1078859 chr1 235912025 C A 0.000114217 Hypertension (early onset hypertension) LYST intron 22479346 rs12089846 chr1 235959705 A C 7.83E-04 Heart Failure LYST intron pha002885 rs2385029 chr1 236044714 G A 1.40E-05 Urinary metabolites / / 21572414 rs6683202 chr1 236051938 G A 2.70E-07 Urinary metabolites / / 21572414 rs6659936 chr1 236055605 A C 9.66E-04 Multiple complex diseases / / 17554300 rs6657655 chr1 236055833 C T 8.83E-04 Longevity / / 22279548 rs6665519 chr1 236066472 T G 7.03E-04 Alzheimer's disease / / 17998437 rs4660126 chr1 236077778 A G 4.77E-04 HIV-1 viral setpoint / / 17641165 rs17616115 chr1 236118351 A G 7.91E-06 Height / / pha003010 rs17616115 chr1 236118351 A G 3.20E-05 Height / / pha003011 rs17616115 chr1 236118351 A G 2.33E-06 Lung function (forced expiratory volume in 1 second) / / pha003102 rs17616115 chr1 236118351 A G 5.23E-06 Lung function (forced vital capacity) / / pha003104 rs4659618 chr1 236150459 A G 8.70E-05 Diabetic retinopathy NID1 intron 21441570 rs3754237 chr1 236177182 A G 4.44E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NID1 intron 24023788 rs3768080 chr1 236179869 A G 7.00E-08 Cutaneous nevi NID1 intron 21478494 rs17552351 chr1 236181854 T C 4.06E-05 Cytomegalovirus antibody response NID1 intron 21993531 rs12411075 chr1 236182924 C T 0.0008027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs12411075 chr1 236182924 C T 8.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs10754833 chr1 236184931 T C 4.33E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NID1 intron 24023788 rs12024223 chr1 236185054 A G 1.45E-04 Multiple complex diseases NID1 intron 17554300 rs12401457 chr1 236186697 G A 0.0007991 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs12401457 chr1 236186697 G A 7.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs3738533 chr1 236187365 T C 0.0007969 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs3738533 chr1 236187365 T C 7.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs746997 chr1 236195181 A G 9.69E-04 Type 2 diabetes NID1 intron 17463246 rs1570828 chr1 236206080 A G 3.42E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs10803248 chr1 236206443 T C 3.00E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs10803248 chr1 236206443 T C 8.98E-04 Telomere length NID1 intron 23900074 rs6702978 chr1 236224569 A G 7.41E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs12093542 chr1 236229347 C A 2.74E-06 Multiple complex diseases / / 17554300 rs12093542 chr1 236229347 C A 6.42E-04 Aortic root size / / 21223598 rs10754850 chr1 236234626 C A 1.70E-05 Bipolar disorder and schizophrenia / / 20889312 rs6682352 chr1 236272711 C T 4.16E-05 Cognitive performance / / 19734545 rs6688981 chr1 236295833 A G 9.03E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6689258 chr1 236296079 A G 3.40E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10802285 chr1 236311886 T C 5.58E-05 Alzheimer's disease (late onset) GPR137B intron 21379329 rs7520258 chr1 236313127 T C 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) GPR137B intron 21107309 rs10924380 chr1 236315070 G A 1.10E-04 Intelligence (childhood) GPR137B intron 23358156 rs2094045 chr1 236328010 T G 9.67E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPR137B intron 24023788 rs7537965 chr1 236329513 T C 2.68E-04 Rheumatoid arthritis GPR137B intron 21452313 rs7537965 chr1 236329513 T C 8.11E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPR137B intron 24023788 rs6702348 chr1 236335567 A G 2.99E-05 Rheumatoid arthritis GPR137B intron 21452313 rs4659635 chr1 236338226 G A 5.70E-05 Erythrocyte counts GPR137B intron pha003090 rs2385203 chr1 236346213 C T 8.29E-04 Type 2 diabetes GPR137B intron 17463246 rs188136623 chr1 236389655 C A 0.000029 Prostate cancer (advanced) ERO1LB missense 23555315 rs1405630 chr1 236420117 G T 2.21E-04 Lung function (forced expiratory volume in 1 second) ERO1LB intron 24023788 rs6662005 chr1 236439916 G A 1.26E-05 Pancreatic cancer ERO1LB intron 23180869 rs11587363 chr1 236444658 T C 2.53E-05 Major depressive disorder ERO1LB intron 22472876 rs16833556 chr1 236450108 C T 6.70E-04 Multiple complex diseases / / 17554300 rs10924993 chr1 236459785 T G 7.00E-07 Asthma (childhood onset) / / 17611496 rs34210603 chr1 236474797 T TC 5.98E-04 Stroke / / pha002887 rs7554436 chr1 236474797 T C 5.98E-04 Stroke / / pha002887 rs12040004 chr1 236494471 G A 0.000314083 Hypertension (early onset hypertension) / / 22479346 rs12404278 chr1 236510995 C T 0.0007395 Hypertension (early onset hypertension) / / 22479346 rs10925109 chr1 236521008 C T 0.000668143 Hypertension (early onset hypertension) / / 22479346 rs12027455 chr1 236534653 A G 0.000240634 Hypertension (early onset hypertension) / / 22479346 rs6673040 chr1 236545893 T G 7.89E-06 Major depressive disorder / / 22472876 rs4659657 chr1 236546142 G A 6.09E-06 Major depressive disorder / / 22472876 rs1025977 chr1 236547422 T G 8.00E-06 Major depressive disorder / / 22472876 rs4659660 chr1 236552530 A G 6.42E-06 Major depressive disorder / / 22472876 rs4659664 chr1 236555310 A T 2.39E-05 Major depressive disorder / / 22472876 rs10802533 chr1 236557412 T G 1.02E-05 Major depressive disorder EDARADD nearGene-5 22472876 rs966365 chr1 236557771 G A 7.80E-06 Major depressive disorder EDARADD missense 22472876 rs966364 chr1 236557928 G A 9.55E-06 Major depressive disorder EDARADD intron 22472876 rs608825 chr1 236568770 C T 5.50E-04 Volumetric brain MRI EDARADD intron 17903297 rs648236 chr1 236605833 G C 4.77E-04 Multiple complex diseases EDARADD intron 17554300 rs646040 chr1 236606292 A G 2.39E-04 Multiple complex diseases EDARADD intron 17554300 rs17582358 chr1 236616134 G A 2.60E-04 Acute lung injury EDARADD intron 22295056 rs4659456 chr1 236657887 C G 1.60E-04 Type 2 diabetes / / 17463246 rs6689881 chr1 236672004 T C 2.49E-04 Myocardial Infarction / / pha002883 rs16833729 chr1 236673695 A G 3.77E-04 Multiple complex diseases / / 17554300 rs10925154 chr1 236676682 C T 8.94E-05 Multiple complex diseases / / 17554300 rs1266379 chr1 236681719 T C 0.000124 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs4659682 chr1 236682248 A G 0.00000103 Attention deficit-hyperactivity disorder (ADHD) DSM-IV scale,preschool edition LGALS8 intron 23049896 rs819415 chr1 236694490 C T 4.10E-04 Multiple complex diseases LGALS8 intron 17554300 rs1891241 chr1 236698470 G A 0.000245 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs1041934 chr1 236700823 T C 0.000296 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs2737706 chr1 236700982 T C 0.000315 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs16833819 chr1 236701492 T C 0.000297 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs16833820 chr1 236701525 C T 0.000282 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2472126 chr1 236702374 G A,C 0.000506 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs2758994 chr1 236703767 C T 0.000142 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2799410 chr1 236707007 C T 0.000191 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs1124907 chr1 236707816 C T 0.000205 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2243963 chr1 236708940 T C 0.000257 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs15701 chr1 236711323 T C 0.000221 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs1160 chr1 236711586 G A 0.0002 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs1041940 chr1 236711882 G T 0.000233 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs1041944 chr1 236711981 C T 0.000214 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2758998 chr1 236713828 G A 0.000341 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs6989 chr1 236714064 A C 0.000275 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2254487 chr1 236714335 C T 0.00013 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2540 chr1 236714916 T C 0.000451 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2275685 chr1 236716959 C T 0.000182 Salmonella-induced pyroptosis HEATR1 cds-synon 22837397 rs2275687 chr1 236717926 T C 0.000128 Salmonella-induced pyroptosis HEATR1 missense 22837397 rs6668926 chr1 236718561 G A 0.000131 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs1126627 chr1 236718620 T C 0.000166 Salmonella-induced pyroptosis HEATR1 missense 22837397 rs2759005 chr1 236720833 C T 0.000136 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs6661946 chr1 236723108 C T 4.11E-06 Nicotine smoking HEATR1 missense 19268276 rs10754577 chr1 236723178 C A 0.000217 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs1407519 chr1 236724974 A C 5.98E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs1358959 chr1 236725048 A G 6.50E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs7544230 chr1 236729834 G A 3.95E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs2799430 chr1 236732054 A G 6.24E-04 Multiple complex diseases HEATR1 intron 17554300 rs2799428 chr1 236736564 T A 0.000735 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs2853599 chr1 236736751 T A 0.000676 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs16833940 chr1 236736997 A G 1.84E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs10495379 chr1 236737396 T C 8.72E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs16833958 chr1 236742166 A G 8.77E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs3738541 chr1 236749626 C T 7.74E-04 Endometrial cancer HEATR1 cds-synon 24096698 rs2794753 chr1 236757507 A G 0.0000807 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs965399 chr1 236768404 A G 0.00000749 LDL cholesterol particle diameter / / 23263444 rs10925170 chr1 236775649 G T 0.00000402 HDL cholesterol particle diameter / / 23263444 rs1743998 chr1 236794970 A G 6.53E-04 Multiple complex diseases / / 17554300 rs577193 chr1 236802016 C G 8.91E-05 Multiple complex diseases / / 17554300 rs1998352 chr1 236803020 T C 2.00E-04 Information processing speed / / 21130836 rs10925178 chr1 236803753 G A 3.83E-05 Dental caries / / 21940522 rs10925185 chr1 236817010 T C 1.89E-05 Dental caries / / 21940522 rs568851 chr1 236817124 A G 9.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs475488 chr1 236821847 G A 1.60E-04 Nicotine dependence / / 17407593 rs3905125 chr1 236864459 C T 1.52E-04 Multiple complex diseases ACTN2 intron 17554300 rs1366990 chr1 236881703 T A,C,G 7.27E-04 Body mass index ACTN2 intron 21701565 rs819639 chr1 236893599 G A 2.20E-04 Type 2 diabetes ACTN2 intron 17846124 rs7542508 chr1 236900018 G A 7.89E-04 Multiple complex diseases ACTN2 intron 17554300 rs4659711 chr1 236902364 C T 5.40E-04 Multiple complex diseases ACTN2 intron 17554300 rs12048046 chr1 236912057 T C 3.00E-06 Periodontitis (CDC/AAP) ACTN2 intron 24024966 rs2297956 chr1 236912286 G A 4.99E-05 Autism ACTN2 intron 19812673 rs2297955 chr1 236912597 A G 3.42E-06 Periodontitis (CDC/AAP) ACTN2 intron 24024966 rs4659713 chr1 236915207 G A 0.000307601 Hypertension (early onset hypertension) ACTN2 intron 22479346 rs10737811 chr1 236916352 G A 0.000307601 Hypertension (early onset hypertension) ACTN2 intron 22479346 rs6687802 chr1 236938367 A G 2.83E-05 Post-operative nausea and vomiting / / 21694509 rs7526063 chr1 236971998 C T 4.42E-06 Alcohol and nictotine co-dependence MTR intron 20158304 rs4659727 chr1 237006914 A G 5.20E-05 Response to lithium treatment in bipolar disorder MTR intron 19448189 rs1805087 chr1 237048500 A G 1 Drug response to Ethanol MTR missense 10498402 rs1805087 chr1 237048500 A G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MTR missense 21239504 rs2275565 chr1 237048676 G T 2.00E-10 Homocysteine levels MTR intron 23824729 rs10158822 chr1 237050176 T G 6.30E-05 Response to lithium treatment in bipolar disorder MTR intron 19448189 rs11806016 chr1 237069315 C T 3.87E-06 Dental caries / / 21940522 rs12068674 chr1 237077363 T C 6.70E-06 Personality dimensions / / 21173776 rs4006371 chr1 237077657 C T 6.70E-06 Personality dimensions / / 21173776 rs4006372 chr1 237077815 C T 6.60E-06 Personality dimensions / / 21173776 rs16834552 chr1 237079692 C T 6.60E-06 Personality dimensions / / 21173776 rs7548398 chr1 237081002 A G 4.90E-06 Personality dimensions / / 21173776 rs6701337 chr1 237081727 T C 2.10E-06 Personality dimensions / / 21173776 rs6698815 chr1 237081792 A G 6.80E-06 Personality dimensions / / 21173776 rs6686536 chr1 237081844 C T 6.90E-06 Personality dimensions / / 21173776 rs6661736 chr1 237082203 G C 7.00E-06 Personality dimensions / / 21173776 rs10495388 chr1 237093109 A C,G,T 8.00E-06 Personality dimensions / / 21173776 rs7411668 chr1 237093697 C T 5.70E-06 Personality dimensions / / 21173776 rs736759 chr1 237093840 G A 5.80E-06 Personality dimensions / / 21173776 rs7545717 chr1 237110626 A G 2.58E-04 Telomere length / / 23900074 rs16834612 chr1 237114288 T G 1.28E-04 Telomere length / / 23900074 rs1252112 chr1 237114552 T C 1.00E-04 Multiple complex diseases / / 17554300 rs1252114 chr1 237116376 T A 6.88E-04 Multiple complex diseases / / 17554300 rs1252131 chr1 237132873 G A 1.10E-04 Multiple complex diseases / / 17554300 rs1252138 chr1 237140960 T G 2.86E-05 Nonalcoholic fatty liver disease / / 21423719 rs1252171 chr1 237144513 T G 9.20E-06 Urinary metabolites / / 21572414 rs16848861 chr1 237144914 A G 4.73E-06 Blood pressure / / 21378095 rs575297527 chr1 237144914 A ACGCGCCG 4.73E-06 Blood pressure / / 21378095 rs4659485 chr1 237145918 T C 1.90E-05 Type 2 diabetes / / 22238593 rs1625040 chr1 237146379 A G 2.60E-05 Longevity (90 years and older) / / 24688116 rs1625040 chr1 237146379 A G 3.50E-04 Longevity (85 years and older) / / 24688116 rs1252145 chr1 237153919 A G 2.85E-05 Orofacial clefts / / 22419666 rs12047281 chr1 237161467 C T 2.20E-04 Scoliosis / / 21216876 rs1252160 chr1 237165077 A G 7.01E-04 HIV-1 viral setpoint / / 17641165 rs12410379 chr1 237166773 C T 5.26E-04 Alzheimer's disease / / 22005930 rs12724972 chr1 237177572 T C 7.90E-04 Myocardial Infarction / / pha002883 rs12239401 chr1 237194523 C T 5.24E-05 Weight / / pha003026 rs41445947 chr1 237194728 G T 2.28E-04 Alzheimer's disease / / 17998437 rs10802580 chr1 237194922 A G 2.87E-05 Alzheimer's disease / / 17998437 rs10802581 chr1 237198593 G A 5.33E-04 Alzheimer's disease / / 17998437 rs11583513 chr1 237199183 C T 5.35E-04 Heart Failure / / pha002885 rs2385576 chr1 237199775 T G 2.31E-05 Weight / / pha003026 rs1881548 chr1 237207189 A G 5.81E-05 Body Mass Index RYR2 intron pha003006 rs1881548 chr1 237207189 A G 4.24E-05 Waist Circumference RYR2 intron pha003024 rs6678625 chr1 237210003 C T 9.37E-04 Multiple complex diseases RYR2 intron 17554300 rs10925299 chr1 237213764 C T 6.45E-04 Suicide attempts in bipolar disorder RYR2 intron 21423239 rs4659488 chr1 237215263 T C 0.0000478 Panic disorder RYR2 intron 23149450 rs4659488 chr1 237215263 T C 4.78E-05 Serum tamsulosin hydrochloride concentration RYR2 intron 23151678 rs4659488 chr1 237215263 T C 0.00024 Coronary artery calcification RYR2 intron 23727086 rs1124814 chr1 237216056 A G 0.0000436 Panic disorder RYR2 intron 23149450 rs1124814 chr1 237216056 A G 4.36E-05 Serum tamsulosin hydrochloride concentration RYR2 intron 23151678 rs9428374 chr1 237248102 C A 2.90E-06 Urinary metabolites RYR2 intron 21572414 rs10802587 chr1 237248454 G A 1.46E-04 Multiple complex diseases RYR2 intron 17554300 rs6428989 chr1 237248703 A G 7.70E-06 Urinary metabolites RYR2 intron 21572414 rs10925310 chr1 237251005 T C 2.03E-05 Glycosylated haemoglobin levels RYR2 intron 17255346 rs12131634 chr1 237257824 C T 1.62E-04 Lung function (forced vital capacity) RYR2 intron 24023788 rs16834810 chr1 237258799 G A 1.38E-04 Schizophrenia(age at onset) RYR2 intron 21688384 rs16834810 chr1 237258799 G A 3.30E-06 Stroke (ischemic) RYR2 intron 22384361 rs7551249 chr1 237261761 G A 4.76E-04 Hemoglobin concentration RYR2 intron 20534544 rs6701985 chr1 237266311 A G 8.21E-04 Multiple complex diseases RYR2 intron 17554300 rs7554607 chr1 237266603 A G 2.00E-06 Acute lymphoblastic leukemia (childhood) RYR2 intron 19684603 rs7554607 chr1 237266603 A G 2.00E-06 Nasopharyngeal carcinoma RYR2 intron 20512145 rs16834822 chr1 237267334 G T 2.10E-06 Schizophrenia(age at onset) RYR2 intron 21688384 rs16834824 chr1 237267370 C T 2.33E-06 Schizophrenia(age at onset) RYR2 intron 21688384 rs1980798 chr1 237272139 T G 4.66E-06 Glycemic traits (pregnancy) RYR2 intron 23903356 rs2485558 chr1 237278525 G C 1.53E-05 Psoriasis RYR2 intron 20953188 rs41454545 chr1 237282751 C G 2.12E-04 Multiple complex diseases RYR2 intron 17554300 rs2485570 chr1 237285607 G T 2.08E-26 Narcolepsy RYR2 intron 19629137 rs10754593 chr1 237326348 G C 3.00E-04 Asthma (childhood onset) RYR2 intron 21359210 rs1106159 chr1 237348427 A G 5.21E-06 Obesity-related traits RYR2 intron 23251661 rs6668069 chr1 237349657 C T 4.76E-06 Obesity-related traits RYR2 intron 23251661 rs6683225 chr1 237349738 T C 2.00E-06 Obesity-related traits RYR2 intron 23251661 rs268786 chr1 237355985 C A 8.00E-06 Obesity-related traits RYR2 intron 23251661 rs187910 chr1 237359988 A G 3.10E-06 Obesity-related traits RYR2 intron 23251661 rs6683160 chr1 237390732 A C 3.31E-05 IgE levels in asthmatics RYR2 intron 23967269 rs679735 chr1 237405093 T C 4.24E-05 Serum metabolites RYR2 intron 19043545 rs918241 chr1 237420086 C A 4.52E-05 Leukocyte Counts RYR2 intron pha003091 rs10495392 chr1 237422989 C T 4.33E-05 Alcohol and nictotine co-dependence RYR2 intron 20158304 rs4659491 chr1 237433239 T C 5.78E-06 Leukocyte Counts RYR2 intron pha003091 rs11802494 chr1 237460954 T C 4.11E-05 Cognitive test performance RYR2 intron 20125193 rs12066348 chr1 237462804 G A 6.11E-07 Lipid levels RYR2 intron 19913121 rs7514372 chr1 237478709 A G 9.41E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs6670163 chr1 237536584 T G 2.00E-05 Type 2 diabetes RYR2 intron 17293876 rs17682073 chr1 237547223 A G 0.000069 Coronary artery calcification RYR2 intron 23727086 rs10925402 chr1 237559453 G A 1.02E-04 Body mass index RYR2 intron 17255346 rs10925405 chr1 237561361 C T 1.20E-05 Response to antidepressants RYR2 intron 19736353 rs7537614 chr1 237597309 A G 2.70E-05 Urinary metabolites RYR2 intron 21572414 rs7529251 chr1 237598416 C T 3.00E-07 IgG glycosylation RYR2 intron 23382691 rs17633019 chr1 237599023 G A 3.30E-04 Atrial fibrillation RYR2 intron 21846873 rs12087410 chr1 237605491 C G 7.80E-05 Malaria RYR2 intron 19465909 rs2100969 chr1 237613274 A G 1.35E-05 Serum metabolites RYR2 intron 19043545 rs2100969 chr1 237613274 A G 5.08E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs2086209 chr1 237613571 C T 5.85E-05 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs16835265 chr1 237617365 G A,T 0.00000062 Cholesterol,total RYR2 intron 23063622 rs4258212 chr1 237617399 A C 1.35E-05 Serum metabolites RYR2 intron 19043545 rs4258212 chr1 237617399 A C 5.59E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs3765097 chr1 237617757 C T 4.99E-04 Response to taxane treatment (placlitaxel) RYR2 cds-synon 23006423 rs2045955 chr1 237620049 T C 1.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs11588591 chr1 237620954 G A 1.23E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs1478912 chr1 237621239 T C 6.00E-06 Response to taxane treatment (docetaxel) RYR2 intron 23006423 rs3753617 chr1 237624783 A C 4.13E-05 HDL particle features RYR2 intron pha002900 rs4436381 chr1 237635103 A C 5.76E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4329502 chr1 237635303 C A 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4397648 chr1 237635321 T C 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4625270 chr1 237635416 T C 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4329503 chr1 237635564 C T 8.57E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs16835307 chr1 237648143 C T 2.24E-05 Multiple complex diseases RYR2 intron 17554300 rs16835307 chr1 237648143 C T 2.12E-04 Blood pressure (response to angiotensin II receptor blocker) RYR2 intron 24192120 rs2805429 chr1 237684278 C G 4.10E-05 Personality dimensions RYR2 intron 18957941 rs2805434 chr1 237686126 A G 3.50E-05 Personality dimensions RYR2 intron 18957941 rs2805446 chr1 237693190 T C 2.50E-05 Orofacial clefts RYR2 intron 22419666 rs2805446 chr1 237693190 T C 1.60E-04 Intelligence (childhood) RYR2 intron 23358156 rs10925451 chr1 237702709 A G 2.90E-05 Electrocardiographic conduction measures RYR2 intron 19389651 rs2257101 chr1 237703314 T G 4.20E-04 Insulin resistance RYR2 intron 21901158 rs2257096 chr1 237703401 A G 8.05E-04 Suicide attempts in bipolar disorder RYR2 intron 21423239 rs2257096 chr1 237703401 A G 6.61E-04 Insulin resistance RYR2 intron 21901158 rs2618672 chr1 237704539 C T 2.12E-04 Multiple complex diseases RYR2 intron 17554300 rs2779383 chr1 237713081 A G 2.00E-05 Prostate cancer RYR2 intron 21743057 rs3766851 chr1 237713312 T A 7.32E-06 Sleep duration RYR2 intron 22105623 rs2127148 chr1 237723828 T G 9.63E-04 Multiple complex diseases RYR2 intron 17554300 rs2805396 chr1 237732395 G A 1.67E-05 Sleep duration RYR2 intron 22105623 rs6683048 chr1 237788786 G A 3.90E-11 Autism,gender differences RYR2 intron 21151189 rs7531957 chr1 237789656 T G 0.0000642 Gains in maximal O2 uptake response RYR2 intron 21183627 rs939698 chr1 237790680 G A 3.60E-04 Cardiovascular disease RYR2 intron 17903304 rs476078 chr1 237796092 T C 5.59E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs10802626 chr1 237796837 G A 9.07E-05 Non-alcoholic fatty liver disease histology (other) RYR2 intron 20708005 rs10925480 chr1 237797757 A G 9.18E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs7526807 chr1 237797973 C T 8.42E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs7538471 chr1 237797997 A G 3.21E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs1023214 chr1 237802065 A G 1.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RYR2 intron 24023788 rs10495399 chr1 237812083 T G 4.39E-15 LDL cholesterol RYR2 intron 23063622 rs16835603 chr1 237818049 A G 0.00000177 Cholesterol,total RYR2 intron 23063622 rs3766882 chr1 237819869 G A 1.51E-04 Multiple complex diseases RYR2 intron 17554300 rs1571980 chr1 237827504 T C 4.35E-19 LDL cholesterol RYR2 intron 23063622 rs6657332 chr1 237830895 G T 6.92E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer RYR2 intron 21483023 rs876793 chr1 237852083 T C 3.00E-07 Lipid traits RYR2 intron 24386095 rs12040571 chr1 237869704 C A 4.80E-05 Iron levels RYR2 intron 21208937 rs10925500 chr1 237892645 C A 1.42E-04 Alzheimer's disease RYR2 intron 17998437 rs10925500 chr1 237892645 C A 2.58E-05 Alzheimer's disease RYR2 intron pha002879 rs16835702 chr1 237908488 A G 2.70E-06 Lipid traits RYR2 intron 24386095 rs16835705 chr1 237908911 G A 4.20E-06 Lipid traits RYR2 intron 24386095 rs2685289 chr1 237909539 C T 0.000001 Triglycerides RYR2 intron 23063622 rs2819770 chr1 237911004 C T 4.00E-06 Exercise treadmill test traits RYR2 intron 17903301 rs2056387 chr1 237924112 C A 5.17E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses RYR2 intron 17903301 rs2056387 chr1 237924112 C A 1.10E-04 Breast cancer and prostate cancer RYR2 intron 17903305 rs2249287 chr1 237937874 C T 1.46E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs12737847 chr1 237945870 T C 4.39E-04 Alcohol dependence RYR2 intron 20201924 rs2275690 chr1 237949456 T C 6.92E-05 Blood Pressure RYR2 intron pha003039 rs12043362 chr1 237960958 G A 1.20E-04 Gallstones RYR2 intron 17632509 rs2819742 chr1 237990122 A G 2.00E-07 Response to cerivastatin RYR2 intron 21386754 rs2275692 chr1 237993724 C T 1.20E-05 Urinary metabolites RYR2 intron 21572414 rs16835894 chr1 237996594 C T 6.56E-04 Glycemic traits (pregnancy) RYR2 UTR-3 23903356 rs1316429 chr1 238001895 G C 1.19E-04 Diabetic nephropathy / / 21150874 rs1316429 chr1 238001895 G C 2.75E-04 Type 2 diabetes / / 22238593 rs1539208 chr1 238012770 C T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs16835926 chr1 238013174 A G 3.69E-04 Multiple complex diseases / / 17554300 rs7525233 chr1 238013507 T A 8.24E-04 Multiple complex diseases / / 17554300 rs2819751 chr1 238015523 C A 2.52E-04 Alzheimer's disease / / 24755620 rs6680230 chr1 238015805 T C 5.81E-04 Multiple complex diseases / / 17554300 rs547984 chr1 238096886 A C 6.00E-05 Glaucoma (primary open-angle) / / 19625618 rs540782 chr1 238097039 C G 6.00E-05 Glaucoma (primary open-angle) / / 19625618 rs693421 chr1 238099090 T G 4.00E-05 Glaucoma (primary open-angle) / / 19625618 rs2499604 chr1 238103501 C T 2.00E-06 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs2499601 chr1 238104895 C T 9.00E-05 Glaucoma (primary open-angle) / / 19625618 rs9428707 chr1 238215702 A C 6.69E-04 Acute lung injury / / 22295056 rs16836337 chr1 238264117 C T 7.17E-04 Aortic root size / / 21223598 rs16836338 chr1 238264227 A G 7.58E-04 Aortic root size / / 21223598 rs12078672 chr1 238274904 T C 2.51E-06 Sickle cell anemia (severity) / / 20029952 rs16836366 chr1 238281405 C T 8.61E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16836376 chr1 238285307 T C 2.10E-05 Urinary metabolites / / 21572414 rs1338924 chr1 238295979 C T 6.53E-04 Acute lung injury / / 22295056 rs10925572 chr1 238297453 G A 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs16836417 chr1 238299841 C A 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs11799391 chr1 238300172 A C 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10925573 chr1 238300214 T G 2.09E-05 Response to citalopram treatment / / 19846067 rs10925573 chr1 238300214 T G 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs16836421 chr1 238300737 A G 8.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1338926 chr1 238305858 A G 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1572706 chr1 238307309 A C 7.18E-04 Acute lung injury / / 22295056 rs1416386 chr1 238307856 A G 9.26E-04 Acute lung injury / / 22295056 rs1416385 chr1 238307907 C T 8.69E-04 Acute lung injury / / 22295056 rs1361277 chr1 238308602 C T 6.82E-04 Acute lung injury / / 22295056 rs1361277 chr1 238308602 C T 2.00E-08 White matter microstructure (global fractional anisotropy) / / 24736177 rs1933980 chr1 238310901 A G 4.05E-04 Acute lung injury / / 22295056 rs2392788 chr1 238311490 T A 3.49E-04 Acute lung injury / / 22295056 rs7547681 chr1 238311680 G A 4.16E-04 Acute lung injury / / 22295056 rs10925576 chr1 238312176 T C 3.52E-04 Acute lung injury / / 22295056 rs1338927 chr1 238317672 G A 3.34E-04 Acute lung injury / / 22295056 rs7555833 chr1 238322892 A G 3.93E-04 Acute lung injury / / 22295056 rs6668206 chr1 238326067 T G 4.11E-04 Acute lung injury / / 22295056 rs11582096 chr1 238326284 A G 3.93E-04 Acute lung injury / / 22295056 rs4659514 chr1 238329027 A C 4.33E-04 Acute lung injury / / 22295056 rs6429059 chr1 238331873 G T 1.03E-04 Acute lung injury / / 22295056 rs7542442 chr1 238334913 G C 5.96E-04 Acute lung injury / / 22295056 rs2392790 chr1 238336236 G C 6.32E-04 Acute lung injury / / 22295056 rs1572703 chr1 238339110 A G 2.80E-06 Digit length ratio / / 20303062 rs7533568 chr1 238339776 T C 8.20E-04 Acute lung injury / / 22295056 rs1338922 chr1 238346577 C T 5.31E-04 Acute lung injury / / 22295056 rs4998092 chr1 238353122 T C 6.57E-04 Acute lung injury / / 22295056 rs1287293 chr1 238367608 A G 5.42E-04 Multiple complex diseases / / 17554300 rs1976011 chr1 238369006 T C 1.39E-04 Progressive supranuclear palsy / / 21685912 rs551741 chr1 238374449 A G 5.53E-04 Acute lung injury / / 22295056 rs10495406 chr1 238380730 G A 5.70E-04 Acute lung injury / / 22295056 rs1481139 chr1 238382824 A T 7.90E-04 Acute lung injury / / 22295056 rs12757674 chr1 238383960 G A 6.84E-04 Acute lung injury / / 22295056 rs10925593 chr1 238386808 T A 6.58E-04 Acute lung injury / / 22295056 rs970522 chr1 238424735 T C 6.62E-05 Post-operative nausea and vomiting / / 21694509 rs6672666 chr1 238432884 T C 5.14E-05 Post-operative nausea and vomiting / / 21694509 rs10495407 chr1 238439308 G A 2.10E-04 Statin-induced myopathy / / 21826682 rs12094201 chr1 238442713 A G 6.22E-04 Major depressive disorder / / 22472876 rs16836693 chr1 238474019 A C 6.00E-07 Urinary metabolites / / 21572414 rs16836698 chr1 238474457 C A 2.70E-06 Urinary metabolites / / 21572414 rs259603 chr1 238480079 G A 1.57E-11 Multiple complex diseases / / 17554300 rs16836768 chr1 238509470 T G 8.36E-04 Heart Failure / / pha002885 rs11583706 chr1 238521637 G T 9.20E-08 Glioma (high-grade) / / 19578366 rs7531928 chr1 238540226 T C 5.45E-05 Triglycerides / / pha003080 rs1021358 chr1 238544006 A G 3.46E-06 Alzheimer's disease / / 17998437 rs6678429 chr1 238549714 C T 5.07E-04 Heart Failure / / pha002884 rs923542 chr1 238559897 C A 2.12E-05 Alcohol consumption / / 23953852 rs7417996 chr1 238562060 A C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1021356 chr1 238573691 A G 0.0000049 post-traumatic stress disorder / / 22869035 rs1021356 chr1 238573691 A G 4.93E-06 Schizophrenia / / 22883433 rs6662339 chr1 238574814 C T 0.0000423 post-traumatic stress disorder / / 22869035 rs6662339 chr1 238574814 C T 4.23E-05 Schizophrenia / / 22883433 rs6689284 chr1 238575717 G A 0.0000315 post-traumatic stress disorder / / 22869035 rs6689284 chr1 238575717 G A 3.15E-05 Schizophrenia / / 22883433 rs6665978 chr1 238575867 C T 0.0000315 post-traumatic stress disorder / / 22869035 rs6665978 chr1 238575867 C T 3.15E-05 Schizophrenia / / 22883433 rs12118091 chr1 238576614 T G 0.0000049 post-traumatic stress disorder / / 22869035 rs12118091 chr1 238576614 T G 4.93E-06 Schizophrenia / / 22883433 rs113508478 chr1 238576715 C T 0.0000074 post-traumatic stress disorder / / 22869035 rs113508478 chr1 238576715 C T 0.00000735 post-traumatic stress disorder / / 22869035 rs1418211 chr1 238582307 C G 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1418210 chr1 238582365 C A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12077464 chr1 238605552 A C 2.20E-04 Multiple complex diseases / / 17554300 rs12096077 chr1 238620372 G T 6.72E-06 C-reactive protein / / 22492993 rs6701617 chr1 238668477 T C 1.54E-06 Serum selenium levels / / 23698163 rs6692700 chr1 238669776 C A 1.51E-06 Serum selenium levels / / 23698163 rs6692700 chr1 238669776 C A 2.00E-06 Serum selenium levels / / 23698163 rs10925672 chr1 238669969 G C 1.54E-06 Serum selenium levels / / 23698163 rs6429079 chr1 238672294 A G 2.34E-06 Serum selenium levels / / 23698163 rs12045395 chr1 238675402 C G 2.56E-06 Serum selenium levels / / 23698163 rs10802701 chr1 238675515 G A 2.61E-06 Serum selenium levels / / 23698163 rs10754644 chr1 238724741 A G 7.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs646969 chr1 238729943 T G 1.90E-06 Urinary metabolites / / 21572414 rs624912 chr1 238741253 T C 3.35E-05 Cholesterol / / pha003073 rs624912 chr1 238741253 T C 6.84E-05 Cholesterol / / pha003078 rs535914 chr1 238763098 T C 1.02E-05 Socioeconomic Factors / / pha003067 rs614831 chr1 238766807 G A 1.22E-05 Socioeconomic Factors / / pha003067 rs7517092 chr1 238771226 T C 1.59E-04 Alcohol dependence / / 20201924 rs474167 chr1 238773561 A G 5.89E-05 Diabetes Mellitus / / pha003059 rs574819 chr1 238777528 T C 5.89E-05 Diabetes Mellitus / / pha003059 rs6678175 chr1 238817430 A G 7.77E-05 Cardiovascular disease / / pha003065 rs16837283 chr1 238818794 T C 9.69E-04 Alcohol dependence / / 24277619 rs7547641 chr1 238822032 A G 3.60E-05 Cardiovascular disease / / pha003065 rs10159091 chr1 238890311 G C 2.00E-04 Multiple complex diseases / / 17554300 rs2689154 chr1 238908353 C G 6.00E-06 Pancreatic cancer / / 22158540 rs2689171 chr1 238918413 A T 4.56E-04 Type 2 diabetes / / 17463246 rs10925756 chr1 238919928 G T 9.23E-04 Multiple complex diseases / / 17554300 rs3001438 chr1 238920004 G A 4.41E-04 Type 2 diabetes / / 17463246 rs3011571 chr1 238921903 T C 2.74E-04 Type 2 diabetes / / 17463246 rs2841409 chr1 238923765 G C 9.49E-04 Major depressive disorder / / 22472876 rs2689128 chr1 238931277 T C 7.92E-04 Tourette syndrome / / 22889924 rs16837451 chr1 238947387 A G 1.20E-05 Urinary metabolites / / 21572414 rs10495421 chr1 238952622 C T 2.46E-05 Diabetes Mellitus / / pha003060 rs869035 chr1 239003522 G A 7.99E-04 Tourette syndrome / / 22889924 rs9428739 chr1 239034512 T C 5.89E-04 Multiple complex diseases / / 17554300 rs1915279 chr1 239075714 A G 2.00E-06 Treatment response for severe sepsis / / 22310353 rs7513289 chr1 239093239 G A 1.05E-05 Diabetes Mellitus / / pha003060 rs10925783 chr1 239097333 C T 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1915260 chr1 239109813 G A 8.64E-06 Diabetes Mellitus / / pha003060 rs9428791 chr1 239121351 A G 3.84E-04 Body mass index / / 17255346 rs2883158 chr1 239124181 C T 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2883158 chr1 239124181 C T 4.69E-05 Diabetes Mellitus / / pha003060 rs17621797 chr1 239130988 C A 2.23E-04 Multiple complex diseases / / 17554300 rs16837650 chr1 239164093 C T 3.95E-04 Smoking cessation / / 24665060 rs1915250 chr1 239183774 C T 3.05E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs7550941 chr1 239191297 G C 4.86E-05 Personality dimensions / / 18957941 rs10754661 chr1 239201173 C T 3.50E-04 Multiple complex diseases / / 17554300 rs6667563 chr1 239203938 T C 2.12E-04 Multiple complex diseases / / 17554300 rs2883159 chr1 239204302 C T 1.98E-04 Multiple complex diseases / / 17554300 rs1915252 chr1 239206398 G A 1.86E-04 Multiple complex diseases / / 17554300 rs10925809 chr1 239230295 A G 6.29E-05 Lipoproteins / / pha003079 rs1509691 chr1 239253606 T G 1.50E-05 Urinary metabolites / / 21572414 rs12410287 chr1 239261262 C T 5.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7541537 chr1 239313573 C A 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4659904 chr1 239317135 A G 1.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10754667 chr1 239336071 A C 2.09E-05 Hypertension (early onset hypertension) / / 22479346 rs6703086 chr1 239343728 A G 0.000152712 Hypertension (early onset hypertension) / / 22479346 rs6703086 chr1 239343728 A G 7.55E-05 Body Fat Distribution / / pha003017 rs6703086 chr1 239343728 A G 3.87E-05 Body Fat Distribution / / pha003018 rs2039801 chr1 239356155 T G 5.71E-05 Type 2 diabetes / / 17463246 rs1339738 chr1 239397104 C T 7.00E-06 IgG glycosylation / / 23382691 rs2820026 chr1 239423724 C T 2.51E-04 Type 2 diabetes / / 17463246 rs2820026 chr1 239423724 C T 3.38E-06 Multiple complex diseases / / 17554300 rs9428826 chr1 239430497 C T 1.44E-04 Type 2 diabetes / / 17463246 rs9428826 chr1 239430497 C T 2.25E-06 Multiple complex diseases / / 17554300 rs2790622 chr1 239436135 A C 1.89E-04 Type 2 diabetes / / 17463246 rs2790622 chr1 239436135 A C 9.45E-07 Multiple complex diseases / / 17554300 rs2820037 chr1 239436542 A T 2.53E-04 Type 2 diabetes / / 17463246 rs2820037 chr1 239436542 A T 8.00E-07 Hypertension / / 17554300 rs2820037 chr1 239436542 A T 8.00E-07 Coronary heart disease / / 21347282 rs2820038 chr1 239436607 C T 2.53E-04 Type 2 diabetes / / 17463246 rs2820038 chr1 239436607 C T 9.13E-07 Multiple complex diseases / / 17554300 rs2820038 chr1 239436607 C T 2.80E-05 Urinary metabolites / / 21572414 rs2820046 chr1 239439310 T A 3.14E-04 Type 2 diabetes / / 17463246 rs2820046 chr1 239439310 T A 1.12E-06 Multiple complex diseases / / 17554300 rs4634896 chr1 239485654 A C 4.79E-04 Multiple complex diseases / / 17554300 rs12049599 chr1 239496469 A G 6.44E-05 Lymphocyte counts / / pha003094 rs10925871 chr1 239506077 G A 6.38E-05 Systemic sclerosis / / 21750679 rs12036333 chr1 239519066 G A 0.00000131 Cytarabine sensitivity / / 23538338 rs6429135 chr1 239523874 G A 4.04E-04 Multiple complex diseases / / 17554300 rs6678395 chr1 239575774 C T 8.58E-05 Bone mineral density LOC100505872 intron 19181680 rs6671410 chr1 239597345 G T 2.30E-06 Intelligence LOC100505872 intron 21826061 rs6677208 chr1 239601969 A C 3.00E-06 Platelet counts LOC100505872 intron 21507922 rs2354398 chr1 239608049 A T 3.40E-06 Urinary metabolites LOC100505872 intron 21572414 rs10754671 chr1 239632055 T C 6.42E-05 Intelligence LOC100505872 intron 21826061 rs13373941 chr1 239644171 T G 8.00E-06 Obesity-related traits LOC100505872 intron 23251661 rs12139491 chr1 239685723 A G 1.81E-05 Insulin-related traits LOC100505872 intron pha003063 rs10925917 chr1 239717119 A G 7.88E-05 Sudden cardiac arrest / / 21658281 rs12406060 chr1 239720458 T C 7.87E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1984207 chr1 239726247 A G 7.85E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12135445 chr1 239743257 G A 4.71E-04 Alcohol dependence / / 24277619 rs12135445 chr1 239743257 G A 9.97E-05 Body Mass Index / / pha003020 rs12135445 chr1 239743257 G A 5.03E-05 Insulin Resistance / / pha003062 rs12135445 chr1 239743257 G A 3.87E-05 Insulin-related traits / / pha003063 rs1899617 chr1 239748949 G A 3.46E-04 Multiple complex diseases / / 17554300 rs10802779 chr1 239760713 T C 4.36E-05 Fibrinogen / / pha003068 rs16838569 chr1 239776089 G A 6.00E-04 Obesity (extreme) / / 21935397 rs10925928 chr1 239777139 T G 2.77E-04 Obesity (extreme) / / 21935397 rs12080951 chr1 239778660 C T 2.64E-04 Alcohol dependence / / 24277619 rs6690612 chr1 239781166 T C 3.48E-04 Multiple complex diseases / / 17554300 rs2355230 chr1 239785165 C A 9.16E-10 Post-operative nausea and vomiting / / 21694509 rs2165870 chr1 239785420 A G 5.50E-05 Post-operative nausea and vomiting / / 21694509 rs10754677 chr1 239833100 G A 4.62E-04 Sudden cardiac arrest CHRM3 intron 21658281 rs1867266 chr1 239839305 T G 4.46E-04 Smoking initiation CHRM3 intron 24665060 rs7523711 chr1 239854977 A T 5.85E-04 Multiple complex diseases CHRM3 intron 17554300 rs6694025 chr1 239862101 C T 3.57E-04 Multiple complex diseases CHRM3 intron 17554300 rs7527723 chr1 239907420 A G 6.23E-04 Multiple complex diseases CHRM3 intron 17554300 rs645248 chr1 239907731 G C 1.69E-04 Multiple complex diseases CHRM3 intron 17554300 rs685550 chr1 239924408 G A 8.27E-04 Obesity (extreme) CHRM3 intron 21935397 rs12059546 chr1 239970097 A G 4.00E-08 Epilepsy (generalized) CHRM3 intron 22949513 rs4463655 chr1 239984294 T C 6.47E-04 Type 2 diabetes CHRM3 intron 17463246 rs7548522 chr1 239998625 C T 5.45E-04 Suicide attempts in bipolar disorder CHRM3 intron 21423239 rs10925985 chr1 240000988 T C 0.0005996 Sarcoidosis CHRM3 intron 22952805 rs6682181 chr1 240040098 A G 2.16E-04 Multiple complex diseases CHRM3 intron 17554300 rs536477 chr1 240045908 A G 3.00E-09 Venous thromboembolism (gene x gene interaction) CHRM3 intron 23509962 rs10495448 chr1 240055473 G A 1.30E-04 Response to taxane treatment (placlitaxel) CHRM3 intron 23006423 rs6666471 chr1 240091765 G A 5.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7531091 chr1 240094975 G A 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1471351 chr1 240114540 C T 2.97E-04 Type 2 diabetes / / 17463246 rs1984165 chr1 240118265 T C 9.94E-04 Type 2 diabetes / / 17463246 rs10495451 chr1 240137811 C T 2.03E-04 Premature ovarian failure / / 19508998 rs6677092 chr1 240173282 T C 1.24E-07 Multiple complex diseases RPS7P5 intron 17554300 rs6677092 chr1 240173282 T C 8.21E-05 Serum metabolites RPS7P5 intron 19043545 rs10926064 chr1 240173998 C T 2.57E-05 Melanoma RPS7P5 intron 21926416 rs10802825 chr1 240176600 A G 6.68E-05 Serum metabolites / / 19043545 rs1891230 chr1 240187633 A G 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs922307 chr1 240190387 G A 8.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12088486 chr1 240195776 C A 8.83E-06 Longevity / / 21612516 rs12733694 chr1 240218134 T C 9.15E-05 Melanoma / / 21926416 rs7548944 chr1 240228959 C G 2.80E-05 Urinary metabolites / / 21572414 rs4659562 chr1 240240025 A G 5.89E-04 Type 2 diabetes / / 17463246 rs12143985 chr1 240258525 C T 1.30E-05 Urinary metabolites FMN2 intron 21572414 rs11810574 chr1 240283736 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients FMN2 intron 23400010 rs1982530 chr1 240298817 T C 2.34E-04 Birth weight FMN2 intron 17255346 rs10926141 chr1 240308382 C A 2.59E-04 Type 2 diabetes FMN2 intron 17463246 rs10926145 chr1 240314586 A G 9.46E-04 Type 2 diabetes FMN2 intron 17463246 rs1891231 chr1 240315515 G A 2.67E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs12092459 chr1 240338133 A C 3.64E-06 Left ventricular mass FMN2 intron 21212386 rs7511696 chr1 240339918 T C 4.79E-04 Type 2 diabetes FMN2 intron 17463246 rs11591010 chr1 240340616 T C 7.85E-04 Type 2 diabetes FMN2 intron 17463246 rs2124724 chr1 240354069 G T 3.16E-05 IgE levels FMN2 intron 17255346 rs2124724 chr1 240354069 G T 1.41E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs12057575 chr1 240357637 A G 8.67E-04 HIV-1 viral setpoint FMN2 intron 17641165 rs1037666 chr1 240358485 C T 4.00E-06 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs140911005 chr1 240370313 G A 0.000006 Prostate cancer (advanced) FMN2 missense 23555315 rs6429189 chr1 240382784 C T 5.45E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs17626030 chr1 240435787 T C 2.90E-05 Urinary metabolites FMN2 intron 21572414 rs4659953 chr1 240439717 C T 8.84E-04 Type 2 diabetes FMN2 intron 17463246 rs4659568 chr1 240441142 A G 9.70E-07 Urinary metabolites FMN2 intron 21572414 rs4659568 chr1 240441142 A G 2.05E-05 Body Mass Index FMN2 intron pha003006 rs4659568 chr1 240441142 A G 1.49E-06 Body Mass Index FMN2 intron pha003014 rs4659568 chr1 240441142 A G 5.32E-05 Weight FMN2 intron pha003026 rs10495462 chr1 240442817 T C 3.71E-05 Body Mass Index FMN2 intron pha003014 rs17672135 chr1 240445596 T C 2.00E-06 Coronary heart disease FMN2 intron 17554300 rs17672135 chr1 240445596 T C 1.04E-04 Coronary Artery Disease FMN2 intron 17634449 rs17672135 chr1 240445596 T C 2.00E-06 Coronary heart disease FMN2 intron 21347282 rs1456648 chr1 240445712 T G 4.44E-05 Multiple complex diseases FMN2 intron 17554300 rs1542400 chr1 240446096 T G 2.40E-06 Urinary metabolites FMN2 intron 21572414 rs6673167 chr1 240448434 G T 1.09E-04 Multiple complex diseases FMN2 intron 17554300 rs6664907 chr1 240448468 T C 2.08E-08 Triglycerides FMN2 intron 23063622 rs1456649 chr1 240451605 G C 1.66E-31 HDL cholesterol FMN2 intron 23063622 rs1456649 chr1 240451605 G C 6.08E-86 Triglycerides FMN2 intron 23063622 rs1456649 chr1 240451605 G C 7.36E-11 LDL cholesterol FMN2 intron 23063622 rs988832 chr1 240456022 T C 8.47E-04 Rheumatoid arthritis FMN2 intron 21452313 rs988832 chr1 240456022 T C 9.81E-05 Body Mass Index FMN2 intron pha003006 rs6659900 chr1 240456751 T C 3.81E-05 Body Mass Index FMN2 intron pha003006 rs6659900 chr1 240456751 T C 5.98E-06 Body Mass Index FMN2 intron pha003014 rs7526497 chr1 240457973 G T 4.88E-04 Alzheimer's disease FMN2 intron 22005930 rs16839760 chr1 240461521 C A 3.75E-04 Alzheimer's disease FMN2 intron 22005930 rs1598676 chr1 240470604 T G 5.42E-04 Alzheimer's disease FMN2 intron 22005930 rs994277 chr1 240472692 G A 1.00E-05 Urinary metabolites FMN2 intron 21572414 rs6701541 chr1 240475346 A G 1.42E-54 Multiple complex diseases FMN2 intron 17554300 rs6701541 chr1 240475346 A G 0.00000149 Triglycerides FMN2 intron 23063622 rs6701177 chr1 240477294 G A 1.06E-05 Body Mass Index FMN2 intron pha003006 rs6701177 chr1 240477294 G A 4.09E-06 Body Mass Index FMN2 intron pha003014 rs6701177 chr1 240477294 G A 6.10E-05 Weight FMN2 intron pha003026 rs4433380 chr1 240478385 A G 3.23E-04 Alzheimer's disease FMN2 intron 22005930 rs4233480 chr1 240479065 A G 5.80E-06 Urinary metabolites FMN2 intron 21572414 rs12240157 chr1 240480132 A G 4.62E-04 Alzheimer's disease FMN2 intron 22005930 rs13376476 chr1 240484422 T A 5.03E-04 Alzheimer's disease FMN2 intron 22005930 rs13374744 chr1 240486721 C T 3.03E-04 Alzheimer's disease FMN2 intron 22005930 rs6664970 chr1 240489585 A G 4.56E-04 Alzheimer's disease FMN2 intron 22005930 rs4330908 chr1 240489952 G C 5.55E-09 Triglycerides FMN2 intron 23063622 rs6686353 chr1 240492543 G A,C,T 9.10E-07 Urinary metabolites FMN2 intron 21572414 rs12122068 chr1 240497598 T C 2.10E-05 Urinary metabolites FMN2 intron 21572414 rs10926223 chr1 240498247 T C 2.30E-05 Urinary metabolites FMN2 intron 21572414 rs16839838 chr1 240500388 T C 7.69E-04 Alzheimer's disease FMN2 intron 22005930 rs16839844 chr1 240500412 G A 7.76E-04 Alzheimer's disease FMN2 intron 22005930 rs12406544 chr1 240503031 C A 7.64E-04 Alzheimer's disease FMN2 intron 22005930 rs12407532 chr1 240505407 C T 2.84E-04 Alzheimer's disease FMN2 intron 22005930 rs12406031 chr1 240514103 G T 3.96E-04 Alzheimer's disease FMN2 intron 22005930 rs2068307 chr1 240516361 G T 5.70E-05 Body Mass Index FMN2 intron pha003014 rs9725819 chr1 240519677 T C 3.64E-04 Alzheimer's disease FMN2 intron 22005930 rs12095342 chr1 240524580 C T 1.90E-05 Urinary metabolites FMN2 intron 21572414 rs9660912 chr1 240527029 G T 8.33E-04 Stroke FMN2 intron pha002886 rs12723298 chr1 240527080 C T 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMN2 intron 20877124 rs10926234 chr1 240532005 T C 8.33E-05 Orofacial clefts FMN2 intron 22419666 rs9662927 chr1 240538952 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs10802866 chr1 240541011 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs9661599 chr1 240548069 A T 1 Drug response to Etoposide FMN2 intron 17537913 rs9662388 chr1 240552223 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs1537849 chr1 240554447 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs2184711 chr1 240554988 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs9730073 chr1 240556035 T C 1 Drug response to Etoposide FMN2 intron 17537913 rs12562192 chr1 240559446 A C,T 1 Drug response to Etoposide FMN2 intron 17537913 rs10926240 chr1 240559938 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs10802867 chr1 240564513 A G 2.80E-04 Alcohol dependence FMN2 intron 20201924 rs10802867 chr1 240564513 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs9287234 chr1 240566373 G A 7.90E-06 Bone mass and geometry FMN2 intron 17903296 rs1889869 chr1 240583596 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs1889869 chr1 240583596 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs9287237 chr1 240597214 G T 2.00E-09 Bone mineral density FMN2 intron 23437003 rs10926254 chr1 240599099 A G 6.30E-04 Alcohol dependence FMN2 intron 20201924 rs2356386 chr1 240601269 A G 4.93E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FMN2 intron 21844884 rs12091371 chr1 240605052 G A 7.00E-08 Alzheimer's disease (cognitive decline) FMN2 intron 23535033 rs11590081 chr1 240612986 G T 2.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FMN2 intron 20031582 rs10754705 chr1 240613766 G T 1.21E-04 Acute lymphoblastic leukemia (childhood) FMN2 intron 22076464 rs10754705 chr1 240613766 G T 1.36E-04 Amyotrophic lateral sclerosis (sporadic) FMN2 intron 24529757 rs16840114 chr1 240625431 A G 9.00E-06 Anger FMN2 intron 24489884 rs16840114 chr1 240625431 A G 9.10E-06 Anger FMN2 intron 24489884 rs16840117 chr1 240625834 A G 3.01E-04 Fibrinogen FMN2 intron 17255346 rs9287243 chr1 240633273 A G 9.41E-04 Alzheimer's disease FMN2 intron 22005930 rs9727156 chr1 240633672 T C 9.72E-04 Alzheimer's disease FMN2 intron 22005930 rs879081 chr1 240639558 C T 3.64E-04 Alzheimer's disease (late onset) / / 21379329 rs9729366 chr1 240639611 A G 2.62E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs11578184 chr1 240643167 A C 2.89E-04 Alzheimer's disease (late onset) / / 21379329 rs12734326 chr1 240644644 C T 0.0000071 Asthma / / 23040885 rs1414654 chr1 240649079 T G 8.10E-04 Body mass index / / 21701565 rs16840259 chr1 240666644 T G 4.60E-04 Multiple complex diseases GREM2 intron 17554300 rs12143400 chr1 240679670 T C 4.87E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GREM2 intron 24236485 rs3748540 chr1 240693711 C T 7.88E-05 Pulmonary function in asthmatics GREM2 intron 23541324 rs12129547 chr1 240695255 C T 1.99E-04 IgE levels GREM2 intron 17255346 rs4587552 chr1 240698245 C T 6.04E-05 Insulin-related traits GREM2 intron 19902172 rs10495471 chr1 240706107 A G 2.00E-07 Immune response to smallpox vaccine (IL-6) GREM2 intron 22542470 rs12069813 chr1 240712898 A G 9.26E-04 Alzheimer's disease GREM2 intron 24755620 rs1320590 chr1 240716710 A G 5.62E-05 Bipolar disorder and schizophrenia GREM2 intron 20889312 rs10737846 chr1 240718920 C T 3.03E-04 Alzheimer's disease (late onset) GREM2 intron 21379329 rs10737846 chr1 240718920 C T 4.16E-04 Alzheimer's disease GREM2 intron 24755620 rs7543336 chr1 240736355 C T 3.25E-04 Alzheimer's disease GREM2 intron 22005930 rs10926301 chr1 240736540 A G 9.54E-04 Alzheimer's disease GREM2 intron 22005930 rs12126125 chr1 240783716 A G 6.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6689991 chr1 240786782 C T 9.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16840459 chr1 240810197 C T 4.53E-04 Type 2 diabetes / / 17463246 rs7526951 chr1 240819499 G A 3.94E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4659996 chr1 240846124 G A 7.00E-06 ankle-brachial index / / 22199011 rs4660000 chr1 240848817 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs16840493 chr1 240867476 C T 5.74E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs6678643 chr1 240885642 G A 7.98E-04 Depression (quantitative trait) / / 20800221 rs7531849 chr1 240894583 A C 3.08E-06 Longevity / / 20304771 rs7531849 chr1 240894583 A C 3.04E-05 Pancreatic cancer / / pha002874 rs4443878 chr1 240904418 C T 1.33E-06 Longevity LOC100506929 intron 20304771 rs4611001 chr1 240904628 A G 1.33E-06 Longevity LOC100506929 intron 20304771 rs4611001 chr1 240904628 A G 3.09E-05 Aging (time to event) LOC100506929 intron 21782286 rs6679652 chr1 240908767 C T 6.55E-05 Rheumatoid arthritis / / 21452313 rs16848948 chr1 240919970 T C 5.41E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs12097299 chr1 240943132 C T 3.23E-05 Hypertension RGS7 intron 19609347 rs16840647 chr1 240963070 A G 4.02E-07 Creutzfeldt-Jakob disease (variant) RGS7 intron 22137330 rs16840647 chr1 240963070 A G 4.56E-04 Smoking initiation RGS7 intron 24665060 rs7544372 chr1 240987754 C T 9.00E-06 Obesity-related traits RGS7 intron 23251661 rs785970 chr1 241003474 G A 1.41E-05 Aging (time to event) RGS7 intron 21782286 rs4660010 chr1 241039187 G A 6.42E-04 Schizophrenia RGS7 intron 19197363 rs261833 chr1 241046905 T C 1.30E-05 Urinary metabolites RGS7 intron 21572414 rs3856237 chr1 241047490 A C 1.30E-05 Urinary metabolites RGS7 intron 21572414 rs12083487 chr1 241047702 C T 5.00E-06 Urinary metabolites RGS7 intron 21572414 rs2446621 chr1 241050218 T C 2.86E-04 Bipolar disorder RGS7 intron 18317468 rs2446621 chr1 241050218 T C 6.70E-06 Urinary metabolites RGS7 intron 21572414 rs17698283 chr1 241050375 G A 4.08E-06 Glucose levels RGS7 intron pha003058 rs17698283 chr1 241050375 G A 2.46E-05 Glucose levels RGS7 intron pha003061 rs187783 chr1 241053122 C T 4.30E-06 Urinary metabolites RGS7 intron 21572414 rs12751419 chr1 241058174 A G 6.31E-05 Glucose levels RGS7 intron pha003058 rs261858 chr1 241096756 T C 1.57E-04 Schizophrenia RGS7 intron 19197363 rs6697598 chr1 241105515 T C 9.52E-05 Amyotrophic lateral sclerosis (sporadic) RGS7 intron 24529757 rs4660017 chr1 241139151 C T 1.28E-04 Multiple complex diseases RGS7 intron 17554300 rs4659586 chr1 241139692 A T 2.42E-04 Multiple complex diseases RGS7 intron 17554300 rs2502448 chr1 241164526 T C 0.0001 High platelet reactivity in patients with type 2 diabetes during acetylsalicylic acid (ASA) treatment (defined as CEPI-CT score of <193 s) RGS7 intron 23054467 rs2502448 chr1 241164526 T C 0.00025 Coronary artery calcification RGS7 intron 23727086 rs628208 chr1 241170977 A G 5.62E-04 Type 2 diabetes RGS7 intron 17463246 rs601675 chr1 241183612 A G 0.000332 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) RGS7 intron 23527081 rs938927 chr1 241215740 G A 3.52E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer RGS7 intron 21483023 rs2493010 chr1 241236721 A G 5.12E-05 Multiple complex diseases RGS7 intron 17554300 rs9428859 chr1 241239862 G A 6.84E-05 Post-operative nausea and vomiting RGS7 intron 21694509 rs2492990 chr1 241255581 T G 7.20E-04 Response to taxane treatment (placlitaxel) RGS7 intron 23006423 rs2492988 chr1 241257765 G A 8.47E-04 Response to taxane treatment (placlitaxel) RGS7 intron 23006423 rs2492987 chr1 241259007 T C 2.07E-05 Post-operative nausea and vomiting RGS7 intron 21694509 rs12086317 chr1 241264216 A G 8.53E-04 Alcohol dependence RGS7 intron 24277619 rs10158567 chr1 241288510 G A 7.16E-04 Alcohol dependence RGS7 intron 21314694 rs10158567 chr1 241288510 G A 1.60E-05 Urinary metabolites RGS7 intron 21572414 rs4131804 chr1 241288878 G T 6.70E-06 Urinary metabolites RGS7 intron 21572414 rs4660034 chr1 241329258 G A 7.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7 intron 20877124 rs4660035 chr1 241329693 C T 0.000452 Salmonella-induced pyroptosis RGS7 intron 22837397 rs7527775 chr1 241338661 G A 0.000717 Salmonella-induced pyroptosis RGS7 intron 22837397 rs4266869 chr1 241339787 C G 2.70E-05 Urinary metabolites RGS7 intron 21572414 rs4659592 chr1 241372527 C A 3.09E-07 Post-operative nausea and vomiting RGS7 intron 21694509 rs72760508 chr1 241376522 A T 0.00009449 Sarcoidosis RGS7 intron 22952805 rs12566189 chr1 241377328 G T 0.0000916 Sarcoidosis RGS7 intron 22952805 rs2140065 chr1 241390758 C T 3.61E-05 Coronary heart disease RGS7 intron pha003031 rs2815859 chr1 241394043 C G 8.03E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815858 chr1 241394361 C T 7.10E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815856 chr1 241395193 A G 2.39E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2686230 chr1 241395328 G A 2.19E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815854 chr1 241395811 T G 2.25E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs9428500 chr1 241397089 T C 2.19E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815851 chr1 241397662 G A 2.07E-05 Triglycerides RGS7 intron pha003080 rs1915886 chr1 241398598 A G 3.63E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs1915888 chr1 241398712 C T 3.18E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4290050 chr1 241399513 G A 3.31E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4378194 chr1 241399532 T C 1.93E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs9428866 chr1 241399554 T C 2.69E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815842 chr1 241399761 A G 2.05E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815841 chr1 241399845 G A 2.56E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2686240 chr1 241400004 C T 1.99E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815834 chr1 241401288 G A 1.77E-05 Triglycerides RGS7 intron pha003080 rs4359023 chr1 241403497 G A 2.90E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4359023 chr1 241403497 G A 3.14E-05 Triglycerides RGS7 intron pha003081 rs4359023 chr1 241403497 G A 6.09E-05 Lipid levels RGS7 intron pha003082 rs2880130 chr1 241415658 T C 6.56E-04 Smoking initiation RGS7 intron 24665060 rs61553648 chr1 241418981 A G 0.00009448 Sarcoidosis RGS7 intron 22952805 rs10926441 chr1 241421106 G C 9.05E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10754721 chr1 241421370 G A 8.07E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10802938 chr1 241421610 A G 8.29E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10926443 chr1 241421911 A G 6.72E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10926444 chr1 241421976 A T 6.83E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10802939 chr1 241423655 G A 7.21E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10754722 chr1 241425762 A G 6.87E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs1996806 chr1 241433465 C T 7.39E-04 Multiple complex diseases RGS7 intron 17554300 rs10926448 chr1 241434468 C A 3.10E-04 Multiple complex diseases RGS7 intron 17554300 rs10926448 chr1 241434468 C A 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RGS7 intron 21844884 rs12090898 chr1 241452500 C T 7.31E-05 Major depressive disorder RGS7 intron 19107115 rs7550277 chr1 241454335 T C 8.60E-04 Suicidal ideation RGS7 intron 22030708 rs10737858 chr1 241455974 A G 3.69E-04 Smoking initiation RGS7 intron 24665060 rs6684760 chr1 241458229 G C 4.86E-04 Insulin resistance RGS7 intron 21901158 rs7355007 chr1 241459462 A G 1.61E-05 Insulin-related traits RGS7 intron 19902172 rs6668091 chr1 241511550 A G 2.60E-05 Anger RGS7 intron 24489884 rs10737863 chr1 241513635 T C 3.37E-04 Multiple complex diseases RGS7 intron 17554300 rs7554279 chr1 241523480 G A 1.10E-06 Urinary metabolites / / 21572414 rs2185627 chr1 241530588 G A 8.90E-04 Multiple complex diseases / / 17554300 rs1592072 chr1 241539109 T C 8.80E-04 Multiple complex diseases / / 17554300 rs1341446 chr1 241541888 G A 3.71E-05 Bipolar disorder / / 21771265 rs4660080 chr1 241542793 G A 1.11E-05 Bipolar disorder / / 21771265 rs1557078 chr1 241550350 C T 2.95E-05 Bipolar disorder / / 21771265 rs1935094 chr1 241569327 C T 1.36E-05 Esophageal cancer (squamous cell) / / 22960999 rs2341942 chr1 241570018 C T 8.21E-05 Erythrocyte counts / / pha003101 rs1341449 chr1 241576302 C A 8.16E-04 Heart Failure / / pha002885 rs1539100 chr1 241586018 C T 2.35E-04 Type 2 diabetes / / 17463246 rs1891129 chr1 241586687 T C 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4659607 chr1 241667244 G T 3.45E-04 Parkinson's disease FH intron 17052657 rs6678986 chr1 241684831 A G 9.33E-04 Alcohol dependence FH nearGene-5 24277619 rs4659609 chr1 241697084 G A 6.80E-04 Multiple complex diseases KMO intron 17554300 rs10802970 chr1 241702689 A C 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KMO intron 20877124 rs6677357 chr1 241706007 G A 9.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KMO intron 20877124 rs6661244 chr1 241709304 T C 8.92E-04 Multiple complex diseases KMO intron 17554300 rs3007737 chr1 241720559 T C 7.43E-04 Multiple complex diseases KMO intron 17554300 rs3753214 chr1 241724922 T C 2.20E-04 Asthma KMO intron 20698975 rs2275163 chr1 241730054 C T 9.42E-04 Response to alcohol consumption (flushing response) KMO intron 24277619 rs850678 chr1 241747139 A T 2.93E-05 Personality dimensions KMO intron 22628180 rs648708 chr1 241747838 T C 2.93E-05 Personality dimensions KMO intron 22628180 rs659887 chr1 241748003 T C 2.95E-05 Personality dimensions KMO intron 22628180 rs655970 chr1 241754836 A G 2.96E-05 Personality dimensions KMO intron 22628180 rs1053221 chr1 241755567 T C 1.00E-06 Obesity-related traits KMO UTR-3 23251661 rs640718 chr1 241755925 A G 1.00E-04 Prostate cancer KMO UTR-3 21743057 rs3193688 chr1 241758566 G C 1.13E-06 Obesity-related traits KMO UTR-3 23251661 rs1053183 chr1 241758631 A G 2.97E-05 Personality dimensions KMO UTR-3 22628180 rs6413960 chr1 241830086 A G 5.58E-05 Serum metabolites WDR64 intron 19043545 rs6413960 chr1 241830086 A G 9.71E-05 Insulin resistance WDR64 intron 21901158 rs6429287 chr1 241830538 T C 7.32E-05 Body Mass Index WDR64 intron pha003006 rs9428890 chr1 241868349 G A 2.49E-04 Alcohol dependence WDR64 intron 21314694 rs12569163 chr1 241878547 T G 2.00E-06 Radiation response WDR64 intron 20923822 rs7519667 chr1 241885307 C T 2.71E-05 Response to taxane treatment (placlitaxel) WDR64 intron 23006423 rs9782914 chr1 241892235 T C 4.30E-04 Non-substance related behavioral disinhibition WDR64 intron 23942779 rs9782914 chr1 241892235 T C 8.00E-06 Behavioural disinhibition (generation interaction) WDR64 intron 23942779 rs9782914 chr1 241892235 T C 9.40E-06 Illicit drug use WDR64 intron 23942779 rs10926554 chr1 241894086 C A 1.80E-04 Non-substance related behavioral disinhibition WDR64 intron 23942779 rs10926554 chr1 241894086 C A 3.00E-06 Illicit drug use WDR64 intron 23942779 rs10926554 chr1 241894086 C A 5.90E-05 Nicotine use WDR64 intron 23942779 rs10926556 chr1 241897899 T A 4.50E-05 Personality dimensions WDR64 intron 18957941 rs4658506 chr1 241945917 C T 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy WDR64 intron 23834954 rs3902093 chr1 241995903 C A 9.34E-04 Alzheimer's disease / / 17998437 rs4149868 chr1 242016838 T C 8.04E-05 Bipolar disorder and schizophrenia EXO1 intron 20889312 rs148510810 chr1 242030355 G A 0.00028 Prostate cancer EXO1 missense 23555315 rs4149967 chr1 242035574 G C 0.00000102 Cholesterol,total EXO1 missense 23063622 rs1635502 chr1 242039382 A G 0.00028 Coronary artery calcification EXO1 intron 23727086 rs1635501 chr1 242040775 C T 8.00E-10 Menopause (age at onset) EXO1 intron 22267201 rs1776148 chr1 242042545 A G 9.20E-05 Amyotrophic lateral sclerosis EXO1 missense 20801717 rs4408133 chr1 242049649 G C 0.0000074 Type 2 diabetes EXO1 intron 22325160 rs4658535 chr1 242059221 G A 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5009401 chr1 242076590 G A 3.26E-05 Squamous cell carcinoma / / 23341777 rs4658573 chr1 242094314 A C 4.59E-05 Brain structure / / 22504417 rs112610111 chr1 242159566 C T 0.00041 Prostate cancer MAP1LC3C missense 23555315 rs6673338 chr1 242200884 G A 1.34E-04 Multiple complex diseases / / 17554300 rs10754748 chr1 242208009 G A 0.000356 Antisocial behavior / / 23077488 rs1589263 chr1 242235655 A G 1.60E-05 Major depressive disorder / / 21621269 rs7528333 chr1 242238751 T C 1.38E-05 HIV-1 viral setpoint / / 22174851 rs2164422 chr1 242266434 T C 3.08E-04 Type 2 diabetes PLD5 intron 17463246 rs984985 chr1 242269283 C T 9.04E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs4658619 chr1 242271323 T G 1.90E-05 Glioma (high-grade) PLD5 intron 19578366 rs10803016 chr1 242274908 G T 2.58E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs10803016 chr1 242274908 G T 7.00E-06 Coronary artery calcification PLD5 intron 23870195 rs6663013 chr1 242276117 A G 1.60E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs2574669 chr1 242281003 A C 3.99E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs2574669 chr1 242281003 A C 1.12E-05 Socioeconomic Factors PLD5 intron pha003067 rs2636254 chr1 242282285 T C 4.55E-04 Multiple complex diseases PLD5 intron 17554300 rs2217881 chr1 242318471 A G 1.72E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316838 chr1 242320660 G A 1.21E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316838 chr1 242320660 G A 2.09E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs12124834 chr1 242323886 A T 8.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLD5 intron 21844884 rs316850 chr1 242327693 A G 6.77E-04 Multiple complex diseases PLD5 intron 17554300 rs695021 chr1 242328222 C T 2.08E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs695021 chr1 242328222 C T 3.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs1393299 chr1 242329791 C T 8.69E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs316896 chr1 242329814 C T 1.85E-04 Multiple complex diseases PLD5 intron 17554300 rs316895 chr1 242331083 G A 8.61E-05 Multiple complex diseases PLD5 intron 17554300 rs12139740 chr1 242332976 C T 3.79E-04 Multiple complex diseases PLD5 intron 17554300 rs316871 chr1 242342884 G A 4.14E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316871 chr1 242342884 G A 4.20E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs376621 chr1 242345821 C T 3.42E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs12135329 chr1 242347587 T C 2.08E-04 Multiple complex diseases PLD5 intron 17554300 rs316833 chr1 242347608 G A 3.69E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316823 chr1 242356028 T C 2.88E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316823 chr1 242356028 T C 4.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs420194 chr1 242357360 C T 7.66E-05 Multiple complex diseases PLD5 intron 17554300 rs427498 chr1 242357455 A C 4.43E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs402098 chr1 242363698 C G 2.88E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs402098 chr1 242363698 C G 4.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs2653165 chr1 242366282 G A 9.00E-06 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs400838 chr1 242398159 G A 2.97E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs390956 chr1 242398403 G A 5.94E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs380005 chr1 242400313 A T 3.62E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs2259017 chr1 242455489 G A 2.19E-04 Multiple complex diseases PLD5 intron 17554300 rs7521223 chr1 242499648 C T 1.06E-04 Multiple complex diseases PLD5 intron 17554300 rs2919024 chr1 242522042 A G 7.00E-06 IgG glycosylation PLD5 intron 23382691 rs1439523 chr1 242531654 T C 4.00E-06 IgG glycosylation PLD5 intron 23382691 rs2809985 chr1 242562721 A G 3.81E-04 Nicotine smoking PLD5 intron 19268276 rs12410712 chr1 242567214 T C 1.61E-05 Brain structure PLD5 intron 22504417 rs2055538 chr1 242602516 T C 9.82E-04 Multiple complex diseases PLD5 intron 17554300 rs2055536 chr1 242603059 A G 0.0000996 post-traumatic stress disorder PLD5 intron 22869035 rs2055536 chr1 242603059 A G 9.96E-05 Schizophrenia PLD5 intron 22883433 rs2810030 chr1 242603249 G A 0.0000971 post-traumatic stress disorder PLD5 intron 22869035 rs2810030 chr1 242603249 G A 9.71E-05 Schizophrenia PLD5 intron 22883433 rs2810034 chr1 242606388 T C 4.87E-04 Response to TNF antagonist treatment PLD5 intron 21061259 rs10926745 chr1 242621027 T C 5.85E-04 Response to TNF antagonist treatment PLD5 intron 21061259 rs6673239 chr1 242627621 T A 2.00E-04 Nonalcoholic fatty liver disease PLD5 intron 21423719 rs872216 chr1 242635682 G A 6.67E-04 Multiple complex diseases PLD5 intron 17554300 rs872216 chr1 242635682 G A 5.85E-04 Smoking quantity PLD5 intron 24665060 rs2809987 chr1 242659943 T C 8.45E-04 Myopia (pathological) PLD5 intron 21095009 rs2654856 chr1 242669380 C T 8.27E-04 Alzheimer's disease PLD5 intron 24755620 rs7551349 chr1 242695639 C T 7.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7551349 chr1 242695639 C T 5.62E-04 Multiple complex diseases / / 17554300 rs10926781 chr1 242758744 A G 8.86E-04 Multiple complex diseases / / 17554300 rs12123434 chr1 242761026 C T 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12123434 chr1 242761026 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7527225 chr1 242765473 G A 6.77E-04 Schizophrenia / / 19197363 rs6674901 chr1 242798937 T A 6.88E-04 Multiple complex diseases / / 17554300 rs10926800 chr1 242801209 C T 9.46E-05 Telomere length / / 21573004 rs10926800 chr1 242801209 C T 1.48E-04 Tourette syndrome / / 22889924 rs1413214 chr1 242805821 G A 3.82E-04 Tourette syndrome / / 22889924 rs1413213 chr1 242805900 C T 3.52E-04 Tourette syndrome / / 22889924 rs6692131 chr1 242854431 T C 2.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10803073 chr1 242859680 C T 4.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10803073 chr1 242859680 C T 1.10E-05 Urinary metabolites / / 21572414 rs10803074 chr1 242864143 A T 3.93E-05 Bipolar disorder / / 22925353 rs1413202 chr1 242872032 A C 8.02E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1413202 chr1 242872032 A C 2.80E-05 Cognitive test performance / / 20125193 rs1413202 chr1 242872032 A C 4.62E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10926828 chr1 242873595 T C 2.30E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs6657754 chr1 242873955 C A 4.10E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs6676375 chr1 242874885 T C 8.00E-07 Tuberculosis / / 24057671 rs10803075 chr1 242874959 G A 7.21E-04 Multiple complex diseases / / 17554300 rs2019842 chr1 242917941 C T 4.47E-04 Alzheimer's disease / / 17998437 rs2184186 chr1 242918428 A G 8.35E-04 Alzheimer's disease / / 17998437 rs9943068 chr1 242946169 C T 9.66E-04 Multiple complex diseases / / 17554300 rs914951 chr1 242952078 T G 8.79E-06 Bone mass and geometry / / 17903296 rs12752277 chr1 242955437 C T 1.23E-06 Obesity-related traits / / 23251661 rs12751297 chr1 242955563 G A 1.00E-06 Obesity-related traits / / 23251661 rs2809867 chr1 242956230 A G 1.34E-06 Obesity-related traits / / 23251661 rs1556557 chr1 242980016 G A 1.77E-24 Gender / / 22362730 rs12739153 chr1 242982864 G T 6.06E-15 Gender / / 22362730 rs4658859 chr1 242996817 T G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2027040 chr1 242997944 G C 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658860 chr1 243000992 G T 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9428546 chr1 243002546 C T 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs914945 chr1 243003189 A C 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs914944 chr1 243003522 C T 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs914942 chr1 243003907 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803092 chr1 243004286 A G 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926882 chr1 243004326 T C 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926883 chr1 243004424 G T 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658862 chr1 243004714 A G 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658863 chr1 243004789 T C 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429381 chr1 243005376 T C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333692 chr1 243005814 T G 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333691 chr1 243005986 T C 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs12023105 chr1 243006334 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10127533 chr1 243006696 T C 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12143316 chr1 243007084 C T 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs12737815 chr1 243008648 A T 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429382 chr1 243009528 C G 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1413217 chr1 243009592 C T 2.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10737885 chr1 243010342 A G 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658500 chr1 243017513 G C 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658867 chr1 243019476 C T 6.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs4658868 chr1 243019840 C G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs7549075 chr1 243021165 T G 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926895 chr1 243023342 T G 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429385 chr1 243024869 G A 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs12024121 chr1 243025115 G T 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926897 chr1 243027762 A G 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926898 chr1 243027814 G T 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12074294 chr1 243032018 C G 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658504 chr1 243041047 T C 2.64E-04 Schizophrenia / / 19197363 rs10157714 chr1 243044002 T C 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6429388 chr1 243044281 A C 1.50E-04 Multiple complex diseases / / 17554300 rs10926906 chr1 243049874 C G 2.09E-05 Schizophrenia / / 19571811 rs4658507 chr1 243056401 G A 5.70E-04 Sarcoidosis / / 19165924 rs2502344 chr1 243070731 G A 6.81E-15 Gender / / 22362730 rs3003542 chr1 243087106 T C 5.53E-04 Fibrinogen / / 17255346 rs10803102 chr1 243114662 G A 1.58E-04 Vaspin levels / / 22907691 rs10803102 chr1 243114662 G A 0.0001579 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs3013386 chr1 243117502 A T 1.20E-05 Urinary metabolites / / 21572414 rs12723357 chr1 243118512 T C 1.87E-14 Gender / / 22362730 rs1081091 chr1 243121042 G C 7.92E-06 Multiple complex diseases / / 17554300 rs3013398 chr1 243142966 C T 8.60E-14 Gender / / 22362730 rs2105146 chr1 243290642 G A 3.00E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs2105146 chr1 243290642 G A 3.20E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs55716084 chr1 243290642 G A 3.00E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs55716084 chr1 243290642 G A 3.20E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs3753542 chr1 243304012 T C 9.70E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs4658538 chr1 243309191 A G 9.50E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs7531823 chr1 243394551 T C 9.23E-04 Response to cytadine analogues (cytosine arabinoside) CEP170 intron 24483146 rs6669104 chr1 243396119 C T 7.86E-04 Response to alcohol consumption (flushing response) CEP170 intron 24277619 rs12741781 chr1 243428152 T G 4.92E-06 Nasopharyngeal carcinoma SDCCAG8 intron 23209447 rs3818802 chr1 243449881 G A 2.44E-05 Schizophrenia SDCCAG8 intron 21926974 rs11807162 chr1 243454680 G A 0.000136 Salmonella-induced pyroptosis SDCCAG8 intron 22837397 rs10926984 chr1 243462153 T G 3.94E-06 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs12145833 chr1 243483754 T G 5.00E-07 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs2802723 chr1 243498312 T C 1.34E-05 Nasopharyngeal carcinoma SDCCAG8 intron 23209447 rs2783963 chr1 243501583 A G 8.68E-06 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs2490393 chr1 243522906 A G 9.58E-05 HIV-1 viral setpoint SDCCAG8 intron 21490045 rs1538774 chr1 243544827 C G 3.00E-08 Schizophrenia SDCCAG8 intron 23974872 rs10927013 chr1 243589156 G T 8.09E-09 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs10803142 chr1 243598234 G A 3.80E-05 Intelligence (childhood) SDCCAG8 intron 23358156 rs2039839 chr1 243598670 A G 1.28E-08 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs7551067 chr1 243606579 T A 8.56E-04 Multiple complex diseases SDCCAG8 intron 17554300 rs6703335 chr1 243608967 A G 4.70E-04 Primary sclerosing cholangitis SDCCAG8 intron 19944697 rs6703335 chr1 243608967 A G 5.00E-08 Schizophrenia SDCCAG8 intron 21926974 rs6703335 chr1 243608967 A G 4.00E-09 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs3006925 chr1 243609927 T C 8.39E-05 HIV-1 viral setpoint SDCCAG8 intron 21490045 rs10803143 chr1 243615589 C T 4.23E-05 Body Composition SDCCAG8 intron pha003012 rs10927025 chr1 243639218 C T 1.40E-05 Urinary metabolites SDCCAG8 intron 21572414 rs2994339 chr1 243641420 A G 5.48E-04 Multiple complex diseases SDCCAG8 intron 17554300 rs2994329 chr1 243647921 C T 2.00E-04 Cognitive impairment induced by topiramate SDCCAG8 intron 22091778 rs6429427 chr1 243657201 T C 2.40E-09 LDL cholesterol AKT3 intron 23063622 rs6429427 chr1 243657201 T C 8.04E-10 Cholesterol,total AKT3 intron 23063622 rs3006927 chr1 243657399 C T 7.16E-04 Type 2 diabetes AKT3 intron 17463246 rs14403 chr1 243663893 C T 2.00E-08 Schizophrenia AKT3 UTR-3 23974872 rs7523742 chr1 243688150 A G 6.75E-05 Type 2 diabetes AKT3 intron 17463246 rs320309 chr1 243781174 A G 8.14E-05 stroke (ischemic) AKT3 intron 17434096 rs320320 chr1 243835186 A G 1.00E-07 Menarche (age at onset) AKT3 intron 23599027 rs320320 chr1 243835186 A G 1.18E-07 Menarche (age at onset) AKT3 intron 23599027 rs320320 chr1 243835186 A G 5.00E-06 Menarche (age at onset) AKT3 intron 23599027 rs10803155 chr1 243894782 A G 1.33E-05 stroke (ischemic) AKT3 intron 17434096 rs1545654 chr1 243916478 A T 1.33E-05 stroke (ischemic) AKT3 intron 17434096 rs897960 chr1 243933568 G A 3.83E-05 stroke (ischemic) AKT3 intron 17434096 rs4132509 chr1 243943084 C A 2.00E-06 RR interval (heart rate) AKT3 intron 20031603 rs4593807 chr1 244004392 G A 3.12E-05 stroke (ischemic) AKT3 intron 17434096 rs4430311 chr1 244015993 C T 6.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs2953331 chr1 244024268 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2953329 chr1 244025999 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7553354 chr1 244044810 A C 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4658601 chr1 244056489 C T 9.71E-04 Tourette syndrome / / 22889924 rs4658405 chr1 244061500 A G 8.99E-04 Tourette syndrome / / 22889924 rs10927088 chr1 244064564 A G 5.78E-04 Type 2 diabetes / / 17463246 rs11584607 chr1 244069010 A G 7.40E-05 Diabetic retinopathy / / 21441570 rs2454224 chr1 244143789 T A 7.30E-05 Diabetic retinopathy LOC339529 intron 21441570 rs4658609 chr1 244155726 G T 4.57E-05 Glucose levels LOC339529 intron pha003058 rs4658609 chr1 244155726 G T 3.71E-05 Hemoglobin LOC339529 intron pha003096 rs4658609 chr1 244155726 G T 3.67E-05 Hematocrit LOC339529 intron pha003097 rs6671359 chr1 244157930 G A 8.77E-04 Type 2 diabetes LOC339529 intron 17463246 rs479338 chr1 244159143 G A 4.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs536441 chr1 244160904 G A 1.50E-05 Diabetic retinopathy LOC339529 intron 21441570 rs10927097 chr1 244161794 A G 7.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs1711347 chr1 244161982 G A 8.50E-07 Diabetic retinopathy LOC339529 intron 21441570 rs520971 chr1 244162694 T C 8.10E-06 Diabetic retinopathy LOC339529 intron 21441570 rs523878 chr1 244163092 G A 1.50E-05 Diabetic retinopathy LOC339529 intron 21441570 rs551361 chr1 244163731 A T 7.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs12119867 chr1 244164997 T C 2.39E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1009375 chr1 244167131 T C 7.00E-05 Diabetic retinopathy LOC339529 intron 21441570 rs12126763 chr1 244167170 C T 6.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12126831 chr1 244167389 C A 6.16E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12119931 chr1 244167665 G T 5.92E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12127679 chr1 244167801 C T 1.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1319790 chr1 244168236 C T 6.11E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1156644 chr1 244168335 G A,T 5.64E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs11582480 chr1 244169011 C A 5.70E-05 Diabetic retinopathy LOC339529 intron 21441570 rs10927099 chr1 244169756 T C 5.55E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs512825 chr1 244170194 A G 6.20E-07 Diabetic retinopathy LOC339529 intron 21441570 rs12122270 chr1 244170455 G T 3.19E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs11580734 chr1 244173339 G C 1.10E-05 Diabetic retinopathy / / 21441570 rs10927101 chr1 244173872 C A 2.00E-06 Diabetic retinopathy LOC339529 intron 21441570 rs10927102 chr1 244174161 T A 7.30E-06 Diabetic retinopathy / / 21441570 rs476141 chr1 244176424 G T 1.00E-07 Diabetic retinopathy LOC339529 intron 21441570 rs10927113 chr1 244198499 G A 5.73E-04 Multiple complex diseases LOC339529 intron 17554300 rs2454234 chr1 244256545 C G 7.38E-04 Type 2 diabetes / / 17463246 rs2454234 chr1 244256545 C G 3.10E-05 Primary sclerosing cholangitis / / 19944697 rs6695226 chr1 244309299 A G 5.07E-04 Schizophrenia / / 19197363 rs12239526 chr1 244312700 G A 2.07E-04 Acute lung injury / / 22295056 rs913992 chr1 244314476 C T 1.30E-04 Alcohol dependence / / 20201924 rs913992 chr1 244314476 C T 4.40E-04 Alcohol dependence / / 20201924 rs12087666 chr1 244334507 T C 5.32E-04 Multiple complex diseases / / 17554300 rs7522710 chr1 244377850 T C 6.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12048859 chr1 244389589 C T 2.31E-05 ldl cholesterol / / pha003076 rs12048859 chr1 244389589 C T 4.41E-05 Cholesterol / / pha003078 rs10429923 chr1 244390492 C A 1.93E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10429924 chr1 244390564 C T 1.00E-06 Schizophrenia / / 22885689 rs879065 chr1 244392845 A G 5.08E-04 Iron levels / / pha002876 rs4297276 chr1 244403107 C T 7.26E-04 Smoking cessation / / 24665060 rs12025435 chr1 244482404 G A 1.08E-05 Smoking initiation / / 24665060 rs12403791 chr1 244498500 T C 1.33E-05 Cognitive performance / / 19734545 rs10927198 chr1 244505481 A T 1.00E-05 Urinary metabolites / / 21572414 rs4658624 chr1 244508697 A G 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4658627 chr1 244511176 G A 9.60E-06 Male-pattern baldness / / 18849994 rs4658627 chr1 244511176 G A 6.00E-06 Asthma (childhood onset) / / 22560479 rs10803199 chr1 244515378 C T 5.41E-05 Alzheimer's disease (age of onset) / / 22005931 rs4658635 chr1 244529403 A G 6.06E-04 Iron levels C1orf100 intron pha002876 rs3101457 chr1 244533214 G A 3.00E-07 Smoking behavior C1orf100 intron 22832964 rs10927230 chr1 244564283 C T 6.50E-06 Urinary metabolites / / 21572414 rs12404398 chr1 244564738 T C 3.40E-06 Urinary metabolites / / 21572414 rs2306084 chr1 244573030 C A 8.51E-06 Obesity-related traits ADSS intron 23251661 rs10927232 chr1 244576507 T C 4.10E-06 Urinary metabolites ADSS intron 21572414 rs10927232 chr1 244576507 T C 6.50E-06 Obesity-related traits ADSS intron 23251661 rs3102460 chr1 244576717 C T 4.00E-06 Obesity-related traits ADSS intron 23251661 rs3101468 chr1 244577558 G A 2.41E-04 Type 2 diabetes ADSS intron 17463246 rs12087973 chr1 244578462 C T 5.92E-06 Obesity-related traits ADSS intron 23251661 rs12408001 chr1 244591695 A G 1.40E-05 Urinary metabolites ADSS intron 21572414 rs4132572 chr1 244592435 T C 6.13E-06 Obesity-related traits ADSS intron 23251661 rs3127462 chr1 244597892 C T 2.84E-04 Stroke ADSS intron pha002886 rs6695703 chr1 244598159 A G 2.20E-06 Urinary metabolites ADSS intron 21572414 rs3003212 chr1 244612252 A G 6.47E-04 Stroke ADSS intron pha002886 rs3003211 chr1 244612984 T C 1.61E-04 Stroke ADSS intron pha002886 rs3006009 chr1 244630447 C T 1.35E-05 Cognitive test performance C1orf101 intron 20125193 rs10927277 chr1 244767326 G C 2.13E-04 Obesity (extreme) C1orf101 intron 21935397 rs7540302 chr1 244775026 C T 4.76E-05 Soluble levels of adhesion molecules C1orf101 intron pha003072 rs10803228 chr1 244777718 A G 2.40E-05 Urinary metabolites C1orf101 intron 21572414 rs1995391 chr1 244809662 A G 1.00E-05 Urinary metabolites / / 21572414 rs987179 chr1 244809936 G A 6.23E-06 Osteoarthritis / / 22763110 rs6429499 chr1 244812498 T C 1.00E-05 Urinary metabolites / / 21572414 rs10927306 chr1 244885285 G A 3.90E-04 Sarcoidosis / / 19165924 rs12119043 chr1 244924191 C G 2.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12088062 chr1 244974586 C T 1.50E-07 Glioma (high-grade) / / 19578366 rs12088062 chr1 244974586 C T 2.75E-05 Personality dimensions / / 23903073 rs11801533 chr1 245002430 C A 5.61E-05 Bipolar Disorder COX20 intron pha002863 rs11579106 chr1 245008115 C T 5.52E-04 Celiac disease COX20 UTR-3 23936387 rs4658673 chr1 245042312 G A 1.24E-04 Parkinson's disease / / 17052657 rs4658673 chr1 245042312 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs756034 chr1 245099499 G A 5.83E-04 Multiple complex diseases / / 17554300 rs2050632 chr1 245159567 C T 3.70E-04 Cognition,early reading ability EFCAB2 intron 17684495 rs11580510 chr1 245205876 C G,T 1.84E-04 Alzheimer's disease EFCAB2 intron 24755620 rs638797 chr1 245217530 T G 2.33E-04 Type 2 diabetes EFCAB2 intron 17463246 rs4658693 chr1 245239342 T C 6.57E-04 Multiple complex diseases EFCAB2 intron 17554300 rs6429521 chr1 245246340 G A 0.0000221 Polycystic ovary syndrome EFCAB2 intron 22951595 rs6429521 chr1 245246340 G A 2.21E-05 Intracranial aneurysm EFCAB2 intron 22961961 rs2886208 chr1 245271418 G A 3.63E-04 Smoking initiation EFCAB2 intron 24665060 rs3897400 chr1 245282154 C T 7.30E-04 Smoking initiation EFCAB2 intron 24665060 rs6693918 chr1 245283910 C T 4.52E-05 Monocyte chemoattractant protein-1 EFCAB2 intron pha003071 rs4658702 chr1 245290111 G A 7.00E-06 Urinary metabolites / / 21572414 rs4233443 chr1 245307601 C T 7.60E-05 Diabetic retinopathy / / 21441570 rs6671796 chr1 245358619 G A 2.59E-05 Telomere length KIF26B intron 21573004 rs6428904 chr1 245363423 A G 4.48E-06 HDL cholesterol KIF26B intron pha003074 rs6428904 chr1 245363423 A G 5.02E-06 HDL cholesterol KIF26B intron pha003075 rs7527554 chr1 245371026 A G 1.22E-05 HDL cholesterol KIF26B intron pha003075 rs4465244 chr1 245381632 T A 2.72E-04 Multiple complex diseases KIF26B intron 17554300 rs10924125 chr1 245388149 C T 8.57E-04 Stroke KIF26B intron pha002886 rs4658732 chr1 245418431 C G 3.48E-04 Aortic root size KIF26B intron 21223598 rs10802205 chr1 245449935 C T 1.89E-05 Hearing impairment KIF26B intron 19047183 rs11811491 chr1 245477121 A G 6.78E-05 IgE levels KIF26B intron 17255346 rs4658748 chr1 245481432 G A 3.69E-05 Height KIF26B intron pha003011 rs6428914 chr1 245486835 C A 5.34E-05 Insulin-related traits KIF26B intron pha003063 rs4658753 chr1 245491406 C T 0.0000911 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KIF26B intron 22628534 rs1148917 chr1 245528415 G A 0.000228901 Hypertension (early onset hypertension) KIF26B intron 22479346 rs1173847 chr1 245528780 A C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) KIF26B intron 24529757 rs1093961 chr1 245576457 T C 4.79E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KIF26B intron 17982456 rs1704415 chr1 245593672 G A 3.77E-05 Sarcoidosis KIF26B intron 19165924 rs1093937 chr1 245608819 G A 3.59E-04 Alzheimer's disease (late onset) KIF26B intron 21379329 rs12094249 chr1 245612896 G A 1.32E-04 Alzheimer's disease (late onset) KIF26B intron 21379329 rs12035552 chr1 245621118 C T 3.42E-06 Triglycerides KIF26B intron 19074352 rs12035552 chr1 245621118 C T 3.42E-06 Polyunsaturated fatty acid levels,in plasma KIF26B intron 19148276 rs669314 chr1 245625652 C T 2.34E-04 Smoking quantity KIF26B intron 24665060 rs1173657 chr1 245626039 A G 2.40E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1093932 chr1 245626278 T C 9.70E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1173658 chr1 245626920 C T 2.40E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1538472 chr1 245636059 A G 4.54E-05 Breast cancer KIF26B intron pha002853 rs6662923 chr1 245641061 G A 0.0006211 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs6662923 chr1 245641061 G A 6.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs6687098 chr1 245641147 A G 0.000609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs6687098 chr1 245641147 A G 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs10924209 chr1 245645242 T G 0.0004823 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs10924209 chr1 245645242 T G 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs7520037 chr1 245646929 C A 2.83E-04 Cholesterol KIF26B intron 17255346 rs7520037 chr1 245646929 C A 0.000774 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs7520037 chr1 245646929 C A 7.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs12121903 chr1 245647361 G A 0.0007766 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs12121903 chr1 245647361 G A 7.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs12136713 chr1 245647425 C T 0.0006586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs12136713 chr1 245647425 C T 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs2363902 chr1 245654625 C T 1.60E-04 Statin-induced myopathy KIF26B intron 21826682 rs1416472 chr1 245677320 C T 2.21E-05 Coronary restenosis KIF26B intron 21878436 rs6662614 chr1 245681650 G A 6.43E-05 Smoking quantity KIF26B intron 24665060 rs9919234 chr1 245703990 G T 3.02E-04 Taste perception KIF26B intron 22132133 rs9919234 chr1 245703990 G T 3.77E-06 Hippocampal volume in schizophrenia KIF26B intron 23805179 rs10924245 chr1 245733608 G T 7.00E-06 Schizophrenia KIF26B intron 23212062 rs1715794 chr1 245768212 C T 1.75E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) KIF26B intron 24236485 rs1715794 chr1 245768212 C T 3.90E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) KIF26B intron 24236485 rs10924249 chr1 245770642 G T 5.22E-05 Alzheimer's disease (age of onset) KIF26B intron 22005931 rs7555351 chr1 245772529 A G 4.72E-05 Smoking cessation KIF26B intron 24665060 rs10754458 chr1 245774993 A G 3.75E-05 Coronary heart disease KIF26B intron pha003056 rs10924254 chr1 245776322 G T 1.40E-04 Smoking cessation KIF26B intron 24665060 rs1715789 chr1 245779716 A G 1.54E-04 Type 2 diabetes KIF26B intron 17463246 rs1715784 chr1 245781414 G A 2.90E-05 Urinary metabolites KIF26B intron 21572414 rs1715783 chr1 245781591 G T 2.20E-05 Urinary metabolites KIF26B intron 21572414 rs1771513 chr1 245786747 A G 1.80E-05 Urinary metabolites KIF26B intron 21572414 rs7527246 chr1 245816347 T C 1.27E-04 Type 2 diabetes KIF26B intron 17463246 rs3737920 chr1 245830019 G A 1.35E-04 Type 2 diabetes KIF26B intron 17463246 rs10924303 chr1 245847034 C T 6.50E-09 Glioma (high-grade) KIF26B intron 19578366 rs6700721 chr1 245854173 G A 2.69E-04 Multiple complex diseases KIF26B intron 17554300 rs6701023 chr1 245854503 G C 4.15E-04 Multiple complex diseases KIF26B intron 17554300 rs10924306 chr1 245857065 G A 7.21E-04 Multiple complex diseases KIF26B intron 17554300 rs2185368 chr1 245915582 A G 2.71E-04 Response to taxane treatment (placlitaxel) SMYD3 intron 23006423 rs12088988 chr1 245926038 T G 6.50E-04 Multiple complex diseases SMYD3 intron 17554300 rs2817506 chr1 245926485 C T 4.47E-04 Multiple complex diseases SMYD3 intron 17554300 rs2791380 chr1 245928778 G C 3.00E-04 Multiple complex diseases SMYD3 intron 17554300 rs2247524 chr1 245932792 G A 3.01E-04 Response to taxane treatment (placlitaxel) SMYD3 intron 23006423 rs2817478 chr1 245960086 T C 8.82E-05 Insulin resistance SMYD3 intron 21901158 rs2791393 chr1 245960306 G A 7.20E-06 Urinary metabolites SMYD3 intron 21572414 rs2791393 chr1 245960306 G A 4.53E-05 Insulin resistance SMYD3 intron 21901158 rs2817475 chr1 245962202 C T 4.67E-04 Nicotine smoking SMYD3 intron 19268276 rs10924342 chr1 245989211 C G 4.04E-05 Multiple complex diseases SMYD3 intron 17554300 rs7537586 chr1 245997603 A G 8.96E-05 Multiple complex diseases SMYD3 intron 17554300 rs6689627 chr1 245997919 T C 3.35E-04 Multiple complex diseases SMYD3 intron 17554300 rs9728248 chr1 246005798 C A 1.84E-04 Substance dependence SMYD3 intron 21818250 rs10924366 chr1 246027410 T C 9.35E-04 Multiple complex diseases SMYD3 intron 17554300 rs4654164 chr1 246054787 G T 3.52E-04 Lung function (forced vital capacity) SMYD3 intron 24023788 rs9728343 chr1 246057046 C T 2.87E-04 Lung function (forced vital capacity) SMYD3 intron 24023788 rs4654068 chr1 246058909 T C 1.79E-05 Height SMYD3 intron pha003010 rs4654068 chr1 246058909 T C 7.99E-07 Height SMYD3 intron pha003011 rs4654068 chr1 246058909 T C 3.34E-05 Waist Circumference SMYD3 intron pha003023 rs6426327 chr1 246089811 G A 8.41E-05 Bipolar disorder SMYD3 intron 19488044 rs2275312 chr1 246090818 C T 5.28E-05 Bipolar disorder and schizophrenia SMYD3 intron 20889312 rs2275313 chr1 246091115 C G 6.74E-05 Bipolar disorder SMYD3 intron 19488044 rs2275313 chr1 246091115 C G 6.18E-05 Bipolar disorder and schizophrenia SMYD3 intron 20889312 rs2275313 chr1 246091115 C G 6.98E-05 Bipolar Disorder SMYD3 intron pha002858 rs7355113 chr1 246097984 T C 9.30E-05 Response to statin therapy SMYD3 intron 20339536 rs12131373 chr1 246098014 C T 4.74E-04 Obesity (extreme) SMYD3 intron 21935397 rs12562286 chr1 246099686 G A 9.40E-05 Response to statin therapy SMYD3 intron 20339536 rs1544149 chr1 246125283 C T 1.82E-04 HIV-1 viral setpoint SMYD3 intron 17641165 rs4654179 chr1 246144436 C T 6.53E-05 Diabetic nephropathy SMYD3 intron pha002864 rs1538294 chr1 246146328 A G 7.53E-04 HIV-1 viral setpoint SMYD3 intron 17641165 rs4654180 chr1 246148791 C A 3.68E-05 Diabetic nephropathy SMYD3 intron pha002864 rs10802308 chr1 246152478 C T 1.29E-04 Multiple complex diseases SMYD3 intron 17554300 rs2105158 chr1 246162256 C A 2.06E-05 Diabetic nephropathy SMYD3 intron pha002864 rs12084862 chr1 246203214 G A 8.20E-06 Migraine SMYD3 intron 20802479 rs6693295 chr1 246223120 C T 6.00E-06 Migraine with aura SMYD3 intron 23793025 rs6693295 chr1 246223120 C T 9.00E-06 Migraine - clinic-based SMYD3 intron 23793025 rs61839075 chr1 246241574 G T 0.00003939 Sarcoidosis SMYD3 intron 22952805 rs6692380 chr1 246310748 T G 6.11E-04 Type 2 diabetes SMYD3 intron 17463246 rs4654092 chr1 246319482 A G 1.74E-05 Prostate cancer SMYD3 intron pha002877 rs4654216 chr1 246330176 C T 7.70E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924545 chr1 246364592 T C 9.15E-04 Multiple complex diseases SMYD3 intron 17554300 rs7539358 chr1 246369599 A G 7.08E-04 Multiple complex diseases SMYD3 intron 17554300 rs10802346 chr1 246372880 G C 7.17E-05 Fractional exhaled nitric oxide (childhood) SMYD3 intron 24315451 rs10802346 chr1 246372880 G C 8.00E-06 Fractional exhaled nitric oxide (childhood) SMYD3 intron 24315451 rs10924556 chr1 246378041 A G 4.88E-04 Multiple complex diseases SMYD3 intron 17554300 rs4636424 chr1 246393636 A G 4.59E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924576 chr1 246394175 T C 2.25E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924577 chr1 246394232 T C 3.85E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924579 chr1 246394320 G A 3.41E-04 Multiple complex diseases SMYD3 intron 17554300 rs2027372 chr1 246454368 A G 2.40E-06 Glioma (high-grade) SMYD3 intron 19578366 rs10924690 chr1 246483783 G A 3.40E-08 Glioma (high-grade) SMYD3 intron 19578366 rs10924692 chr1 246489492 C T 5.85E-04 Multiple complex diseases SMYD3 intron 17554300 rs4654103 chr1 246525619 T G 1.60E-05 Glioma (high-grade) SMYD3 intron 19578366 rs1339965 chr1 246550861 A G 5.92E-04 Heart Failure SMYD3 intron pha002885 rs10924727 chr1 246586841 A C 9.05E-06 Creatinine levels SMYD3 intron pha003069 rs10924730 chr1 246602240 C T 2.28E-05 Multiple complex diseases SMYD3 intron 17554300 rs7517207 chr1 246657606 A G 7.85E-04 Smoking initiation SMYD3 intron 24665060 rs11800820 chr1 246661236 C T 4.00E-06 Obesity-related traits SMYD3 intron 23251661 rs6668455 chr1 246664442 T G 7.82E-04 Suicide attempts in bipolar disorder SMYD3 intron 21423239 rs7520453 chr1 246670481 C G 7.27E-04 Suicide attempts in bipolar disorder SMYD3 missense 21423239 rs3120701 chr1 246706139 C T 1.86E-05 Alcohol and nictotine co-dependence TFB2M intron 20158304 rs4545307 chr1 246708846 G A 3.46E-04 Type 2 diabetes TFB2M intron 17463246 rs6663956 chr1 246757449 T C 2.27E-04 Multiple complex diseases CNST intron 17554300 rs6663956 chr1 246757449 T C 1.64E-04 Lymphocyte counts CNST intron 22286170 rs3129539 chr1 246801648 G A 9.61E-04 Parkinson's disease CNST intron 17052657 rs3129539 chr1 246801648 G A 1.07E-04 Multiple complex diseases CNST intron 17554300 rs7534740 chr1 246823857 G A 1.24E-05 Femoral neck bone geometry CNST intron 22087292 rs4130648 chr1 246829616 T C 2.45E-04 Type 2 diabetes CNST UTR-3 17463246 rs4335342 chr1 246830488 T C 4.91E-04 Type 2 diabetes CNST UTR-3 17463246 rs6657743 chr1 246893948 C T 4.95E-05 Post-operative nausea and vomiting SCCPDH intron 21694509 rs7526237 chr1 246898134 C T 1.23E-04 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs7526237 chr1 246898134 C T 3.76E-04 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs7526237 chr1 246898134 C T 4.53E-05 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs4130317 chr1 246919472 C T 8.09E-04 Myocardial Infarction SCCPDH intron pha002873 rs6685364 chr1 246939943 T C 7.04E-04 Myocardial Infarction LOC100130097 missense pha002873 rs11584835 chr1 246973094 A G 7.10E-04 White matter integrity / / 22425255 rs7515514 chr1 246973156 G A 7.78E-04 White matter integrity / / 22425255 rs7524529 chr1 246973158 C T 7.78E-04 White matter integrity / / 22425255 rs7531852 chr1 246973283 T C 8.63E-04 White matter integrity / / 22425255 rs3007302 chr1 246992317 G A 7.37E-04 Multiple complex diseases / / 17554300 rs2996550 chr1 247000748 A G 1.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6685066 chr1 247001166 A G 7.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs5021094 chr1 247006160 G T 7.27E-05 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs6688227 chr1 247010734 C T 6.85E-05 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs6426183 chr1 247012724 T C 4.60E-06 Ankle-brachial index AHCTF1 intron 22199011 rs7530860 chr1 247018184 A G 4.35E-04 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs1630829 chr1 247023866 C T 6.56E-04 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs2642990 chr1 247048834 T C 5.26E-04 Suicide attempts in bipolar disorder AHCTF1 missense 21423239 rs1779969 chr1 247069949 T C 0.00079 Erectile dysfunction after radiotherapy for prostate cancer AHCTF1 intron 23021708 rs1039010 chr1 247081383 A G 8.42E-04 Suicide attempts in bipolar disorder AHCTF1 intron 21423239 rs6673828 chr1 247139343 G A 1.91E-04 Response to taxane treatment (placlitaxel) ZNF695 intron 23006423 rs1691228 chr1 247142532 C T 8.10E-06 Digit length ratio ZNF695 intron 20303062 rs34759714 chr1 247146733 G GT 5.50E-04 Urinary metabolites ZNF695 intron 21572414 rs4971307 chr1 247188448 C T 2.40E-05 Urinary metabolites ZNF670-ZNF695 intron 21572414 rs10924897 chr1 247202032 G T 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7547915 chr1 247203606 T C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs12141355 chr1 247204494 G C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7549105 chr1 247205056 A G 4.42E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4925540 chr1 247214878 A C 2.00E-06 Response to taxane treatment (docetaxel) ZNF670 intron 23006423 rs1573897 chr1 247215054 T C 2.00E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4634944 chr1 247225034 T C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs10924899 chr1 247226344 G A 4.47E-04 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7542852 chr1 247226986 T G 4.34E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4925622 chr1 247240863 T C 6.69E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs12135374 chr1 247251453 A G 3.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6669242 chr1 247251482 A G 1.74E-04 Alzheimer's disease (late onset) / / 21379329 rs6426220 chr1 247276394 A G 4.17E-05 Heart Rate / / pha003051 rs12093759 chr1 247305873 C T 4.91E-05 Alzheimer's disease (late onset) ZNF124 intron 21379329 rs7521596 chr1 247308691 T C 6.20E-05 Alzheimer's disease (late onset) ZNF124 intron 21379329 rs11806327 chr1 247320868 G A 2.41E-05 Multiple complex diseases ZNF124 intron 17554300 rs6659481 chr1 247344204 A T 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs3738443 chr1 247348189 C T 4.00E-06 Alcohol dependence / / 21314694 rs10754538 chr1 247352621 T C 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10924967 chr1 247390862 G A 3.51E-04 Multiple complex diseases / / 17554300 rs1192835 chr1 247409018 A C 1.16E-04 Hearing function / / 17255346 rs1771928 chr1 247438521 C T 2.93E-05 Hearing function / / 17255346 rs12023478 chr1 247450565 C T 1.63E-04 Celiac disease / / 23936387 rs1057996 chr1 247459414 C T 2.27E-05 Hearing function / / 17255346 rs875883 chr1 247460356 C T 1.40E-05 Urinary metabolites / / 21572414 rs2153631 chr1 247462048 A G 5.70E-06 Urinary metabolites / / 21572414 rs9725334 chr1 247462273 A G 5.60E-06 Urinary metabolites / / 21572414 rs1616299 chr1 247462701 C T 1.70E-05 Urinary metabolites / / 21572414 rs12023326 chr1 247471121 T C 2.13E-04 Celiac disease ZNF496 intron 23936387 rs139561401 chr1 247471846 G A 0.000058 Breast cancer ZNF496 missense 23555315 rs10924984 chr1 247485932 A G 3.46E-05 Hearing function ZNF496 intron 17255346 rs6692645 chr1 247486421 G C 7.90E-06 Urinary metabolites ZNF496 intron 21572414 rs6426239 chr1 247486736 C T 2.13E-04 Celiac disease ZNF496 intron 23936387 rs6690864 chr1 247490707 G A 2.15E-04 Celiac disease ZNF496 intron 23936387 rs10924987 chr1 247491143 C T 9.91E-05 Celiac disease ZNF496 intron 23936387 rs10924990 chr1 247507908 C T 1.70E-05 Urinary metabolites / / 21572414 rs10399672 chr1 247536083 C T 9.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11802371 chr1 247542838 A G 1.11E-04 Diabetic nephropathy / / pha002866 rs7555997 chr1 247547334 C A 3.46E-05 Depression (quantitative trait) / / 23290196 rs7529058 chr1 247575768 G A 6.65E-04 Type 2 diabetes / / 17463246 rs7529058 chr1 247575768 G A 8.11E-04 Alzheimer's disease / / 17998437 rs10925015 chr1 247583677 G C 8.00E-06 Word reading NLRP3 intron 23738518 rs4925650 chr1 247584075 G A 8.40E-06 Word reading NLRP3 intron 23738518 rs1539019 chr1 247600301 A C 1.00E-08 Fibrinogen NLRP3 intron 20031576 rs1539019 chr1 247600301 A C 7.74E-07 Fibrinogen NLRP3 intron 20978265 rs12143966 chr1 247601357 G A 1.10E-05 Urinary metabolites NLRP3 intron 21572414 rs12239046 chr1 247601595 T C 3.26E-07 Fibrinogen NLRP3 intron 20978265 rs12239046 chr1 247601595 T C 1.00E-15 C-reactive protein NLRP3 intron 21300955 rs4925659 chr1 247603463 G A 5.26E-08 Fibrinogen NLRP3 intron 20978265 rs10157379 chr1 247605599 C T 1.00E-19 Fibrinogen NLRP3 intron 23969696 rs12065526 chr1 247614407 G A 7.51E-04 Smoking cessation OR2B11 missense 24665060 rs12745508 chr1 247617979 G A,C,T 4.20E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10754561 chr1 247622800 T C 4.11E-04 Multiple complex diseases / / 17554300 rs4604732 chr1 247623872 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6663238 chr1 247624971 C T 2.70E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4472786 chr1 247636518 G A 6.20E-05 Gallbladder cancer / / 22318345 rs10754564 chr1 247662398 T C 6.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4472787 chr1 247666165 A G 2.43E-04 Multiple complex diseases / / 17554300 rs7550918 chr1 247675559 C T 3.00E-11 Platelet counts / / 22139419 rs7550918 chr1 247675559 C T 4.00E-05 Platelet counts / / 24026423 rs1881797 chr1 247689532 C T 7.00E-06 Acute lymphoblastic leukemia (childhood) LOC148824 intron 19684603 rs1881797 chr1 247689532 C T 7.00E-06 Nasopharyngeal carcinoma LOC148824 intron 20512145 rs1105489 chr1 247710867 G A 2.36E-04 White matter integrity / / 22425255 rs3844081 chr1 247723670 C T 7.84E-05 Body Fat Distribution C1orf150 intron pha003017 rs1151694 chr1 247728962 C T 2.53E-05 ldl cholesterol C1orf150 intron pha003077 rs1151694 chr1 247728962 C T 2.89E-05 Cholesterol C1orf150 intron pha003083 rs10925083 chr1 247745227 C T 1.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10802523 chr1 247745313 G T 2.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1176046 chr1 247748235 C T 5.53E-05 ldl cholesterol / / pha003077 rs1176046 chr1 247748235 C T 5.32E-05 Cholesterol / / pha003083 rs868724 chr1 247753207 G T 3.50E-05 Response to statin therapy / / 20339536 rs1151685 chr1 247753334 A G 3.50E-05 Response to statin therapy / / 20339536 rs4002806 chr1 247761306 T C 4.00E-05 Response to statin therapy / / 20339536 rs7523061 chr1 247762328 C T 4.20E-05 Response to statin therapy / / 20339536 rs7523061 chr1 247762328 C T 8.74E-05 Myopia (pathological) / / 21640322 rs4925690 chr1 247764393 A G 7.60E-05 Response to statin therapy / / 20339536 rs147517990 chr1 247769412 C A 0.00081 Breast cancer OR2G3 missense 23555315 rs1144815 chr1 247781569 C T 8.90E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1144812 chr1 247785143 T C 5.52E-04 Multiple complex diseases / / 17554300 rs61115794 chr1 247795252 C A,G 1.11E-13 Metabolite levels / / 22286219 rs28503794 chr1 247802038 G C 9.67E-05 Cognitive test performance / / 20125193 rs1176067 chr1 247849862 G C 2.90E-05 Urinary metabolites / / 21572414 rs7553300 chr1 247896286 G A 1.90E-05 Urinary metabolites / / 21572414 rs2892286 chr1 247967505 G A 9.11E-04 Type 2 diabetes / / 17463246 rs2892286 chr1 247967505 G A 1.13E-04 Multiple complex diseases / / 17554300 rs10788727 chr1 247999379 T C 6.82E-04 Aortic root size / / 21223598 rs10888255 chr1 248004687 C G 2.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs10888256 chr1 248004775 C T 3.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs4607924 chr1 248004848 G C 2.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs6690724 chr1 248008668 C T 3.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1339847 chr1 248039294 G A 1.99E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy TRIM58 missense 23834954 rs3811444 chr1 248039451 C T 6.00E-09 Platelet counts TRIM58 missense 22139419 rs3811444 chr1 248039451 C T 5.00E-10 Red blood cell traits TRIM58 missense 23222517 rs4925753 chr1 248040104 C T 5.36E-05 Hypertension TRIM58 UTR-3 pha003041 rs11204538 chr1 248046272 C T 2.00E-08 Blood cell counts and other traits / / 20139978 rs11204538 chr1 248046272 C T 2.33E-08 Blood cell counts and other traits / / 20139978 rs10888267 chr1 248059423 C T 9.66E-06 Longevity OR2W3 missense 20304771 rs6695104 chr1 248060894 C A 3.90E-05 HDL particle features / / pha002900 rs2225891 chr1 248111078 T C 6.17E-04 Smoking quantity OR2L13 intron 24665060 rs10888287 chr1 248117416 T G 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OR2L13 intron 20877124 rs10888287 chr1 248117416 T G 5.53E-05 Diabetic nephropathy OR2L13 intron 21150874 rs10888287 chr1 248117416 T G 5.03E-04 Type 2 diabetes OR2L13 intron 22238593 rs10888307 chr1 248124660 G T 7.78E-05 Post-operative nausea and vomiting OR2L13 intron 21694509 rs11204575 chr1 248124858 G A 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OR2L13 intron 20877124 rs12041241 chr1 248134289 C A 1.67E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs12041241 chr1 248134289 C A 1.67E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs4451578 chr1 248138217 T G 3.18E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs4451578 chr1 248138217 T G 3.18E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs4268383 chr1 248138520 A G 3.17E-04 Sudden cardiac arrest OR2L13 intron 21658281 rs4268383 chr1 248138520 A G 3.18E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs4268383 chr1 248138520 A G 3.18E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs11576203 chr1 248148188 C T 1.07E-04 Lung function (forced expiratory volume in 1 second) OR2L13 intron 24023788 rs11576203 chr1 248148188 C T 3.96E-04 Lung function (forced vital capacity) OR2L13 intron 24023788 rs1933162 chr1 248179029 C T 3.69E-04 Lung function (forced vital capacity) OR2L13 intron 24023788 rs7531785 chr1 248210872 C T 0.000636 Salmonella-induced pyroptosis OR2L13 intron 22837397 rs7527770 chr1 248227201 A C 6.28E-05 Hemoglobin OR2L13 intron pha003098 rs7527770 chr1 248227201 A C 1.37E-05 Erythrocyte counts OR2L13 intron pha003099 rs10749643 chr1 248264018 C T 9.14E-05 HIV-1 control / / 20041166 rs4523547 chr1 248341792 C A 6.18E-05 Erythrocyte counts / / pha003099 rs7537031 chr1 248342837 C A 9.77E-07 Common traits (Other) / / 20585627 rs9435891 chr1 248344598 T C 1.95E-09 Common traits (Other) / / 20585627 rs4615870 chr1 248349215 C T 4.29E-05 Panic disorder / / 19165232 rs10788759 chr1 248350776 A G 1.78E-09 Common traits (Other) / / 20585627 rs7550630 chr1 248362311 C T 2.04E-15 Common traits (Other) / / 20585627 rs4916113 chr1 248377292 C T 3.09E-15 Common traits (Other) / / 20585627 rs7349159 chr1 248386242 C T 6.03E-14 Common traits (Other) / / 20585627 rs4642918 chr1 248411057 G T 1.60E-05 Glioma (high-grade) / / 19578366 rs4642918 chr1 248411057 G T 7.59E-14 Common traits (Other) / / 20585627 rs6587440 chr1 248415662 A G 3.50E-05 Glioma (high-grade) / / 19578366 rs6587440 chr1 248415662 A G 1.41E-20 Common traits (Other) / / 20585627 rs10888354 chr1 248455512 G A 3.35E-05 Glucose levels / / pha003057 rs4309013 chr1 248480768 C T 1.10E-05 Glioma (high-grade) / / 19578366 rs4309013 chr1 248480768 C T 5.37E-23 Common traits (Other) / / 20585627 rs7555310 chr1 248487638 A G 5.60E-05 Glioma (high-grade) OR2M7 missense 19578366 rs7555310 chr1 248487638 A G 1.91E-22 Common traits (Other) OR2M7 missense 20585627 rs4559542 chr1 248489980 C T 1.78E-08 Common traits (Other) / / 20585627 rs4244187 chr1 248493511 T C 9.55E-23 Common traits (Other) / / 20585627 rs4481887 chr1 248496863 A G 7.00E-24 Common traits (Other) / / 20585627 rs1538703 chr1 248519821 T G 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs946761 chr1 248521032 T C 6.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1544175 chr1 248524262 G A 7.94E-09 Common traits (Other) / / 20585627 rs6587475 chr1 248578622 C T 9.14E-05 Cognitive decline / / 22054870 rs4916176 chr1 248860641 A C 5.06E-09 Longevity,exceptional / / 20595579 rs14851 chr1 249104845 G T 0.000493 Salmonella-induced pyroptosis SH3BP5L UTR-3 22837397 rs11205415 chr1 249120684 T G 1.10E-06 Urinary metabolites / / 21572414 rs12032643 chr1 249168436 G A 1.00E-09 Myopia (pathological) / / 23049088 rs11542478 chr2 38938 A C 9.00E-06 Information processing speed FAM110C UTR-3 21130836 rs11542478 chr2 38938 A C 6.16E-04 Suicide attempts in bipolar disorder FAM110C UTR-3 21423239 rs436446 chr2 106409 T C 1.92E-06 Suicide attempts in bipolar disorder / / 21423239 rs300797 chr2 107140 G A 1.93E-06 Suicide attempts in bipolar disorder / / 21423239 rs300780 chr2 110819 C T 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs300778 chr2 111964 C A 1.91E-06 Suicide attempts in bipolar disorder / / 21423239 rs300774 chr2 112496 A C 2.99E-05 Type 2 diabetes / / 17463246 rs300774 chr2 112496 A C 5.00E-08 Suicide attempts in bipolar disorder / / 21423239 rs300773 chr2 115035 C T 1.60E-05 Type 2 diabetes / / 17463246 rs300773 chr2 115035 C T 5.79E-06 Suicide attempts in bipolar disorder / / 21423239 rs393008 chr2 125639 A G 5.73E-06 Suicide attempts in bipolar disorder / / 21423239 rs441469 chr2 129028 G A 6.33E-05 Type 2 diabetes / / 17463246 rs441469 chr2 129028 G A 6.90E-06 Suicide attempts in bipolar disorder / / 21423239 rs375613 chr2 130618 G A,C 6.54E-05 Type 2 diabetes / / 17463246 rs375613 chr2 130618 G A,C 7.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs300729 chr2 131788 G C 3.84E-05 Type 2 diabetes / / 17463246 rs300729 chr2 131788 G C 7.97E-06 Suicide attempts in bipolar disorder / / 21423239 rs300728 chr2 131828 G A 7.98E-06 Suicide attempts in bipolar disorder / / 21423239 rs300727 chr2 132469 C A 1.02E-05 Suicide attempts in bipolar disorder / / 21423239 rs300726 chr2 132490 C G 1.04E-05 Suicide attempts in bipolar disorder / / 21423239 rs300723 chr2 134131 C T 1.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs300722 chr2 134249 A C 2.18E-05 Type 2 diabetes / / 17463246 rs300722 chr2 134249 A C 8.92E-06 Suicide attempts in bipolar disorder / / 21423239 rs300721 chr2 134436 A T 1.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs300720 chr2 134472 A G 1.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs300719 chr2 136203 C T 9.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs300717 chr2 136638 G A 1.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs300715 chr2 137962 T C 1.03E-05 Suicide attempts in bipolar disorder / / 21423239 rs300712 chr2 138903 A T 9.00E-06 Suicide attempts in bipolar disorder / / 21423239 rs300710 chr2 139574 T C 6.33E-05 Type 2 diabetes / / 17463246 rs300710 chr2 139574 T C 7.60E-06 Suicide attempts in bipolar disorder / / 21423239 rs300709 chr2 139743 A G 6.66E-05 Type 2 diabetes / / 17463246 rs300709 chr2 139743 A G 2.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs300709 chr2 139743 A G 2.00E-05 Urinary metabolites / / 21572414 rs300708 chr2 140449 A G 6.34E-06 Suicide attempts in bipolar disorder / / 21423239 rs300707 chr2 141324 G T 6.37E-06 Suicide attempts in bipolar disorder / / 21423239 rs437409 chr2 142137 G A 8.61E-06 Suicide attempts in bipolar disorder / / 21423239 rs405258 chr2 145646 T A 8.47E-06 Suicide attempts in bipolar disorder / / 21423239 rs6732024 chr2 148410 A G 5.26E-06 Suicide attempts in bipolar disorder / / 21423239 rs409572 chr2 153302 A G 5.22E-06 Suicide attempts in bipolar disorder / / 21423239 rs300739 chr2 161605 A G 1.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs10460597 chr2 165976 T C 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707786 chr2 166224 T G 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707786 chr2 166224 T G 0.00065 Endometrial cancer / / 22426144 rs300732 chr2 166725 A G 9.68E-06 Suicide attempts in bipolar disorder / / 21423239 rs300734 chr2 167167 T G 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs6708206 chr2 167187 A C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs300735 chr2 167739 C G 1.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs300737 chr2 170576 T C 7.23E-04 Type 2 diabetes / / 17463246 rs300737 chr2 170576 T C 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs1810329 chr2 176395 A T 7.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs300692 chr2 181415 C T 3.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs300701 chr2 187396 C G 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs440617 chr2 189818 C T 1.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs384526 chr2 193882 A G 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs385909 chr2 199678 A G 6.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs453447 chr2 205446 C A 5.80E-06 Urinary metabolites / / 21572414 rs300703 chr2 239416 C T 2.70E-05 Type 2 diabetes SH3YL1 intron 17903298 rs10181051 chr2 242800 T C 5.38E-05 Neuroblastoma SH3YL1 intron pha002895 rs10167992 chr2 263270 T C 6.90E-04 Response to TNF antagonist treatment SH3YL1 intron 21061259 rs6742672 chr2 301784 G A 7.11E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4643574 chr2 315215 A G 5.00E-06 Cognitive performance / / 20125193 rs1858308 chr2 354241 T G 3.98E-05 Serum metabolites / / 19043545 rs6740249 chr2 355800 T C 4.37E-05 Alcohol dependence / / 21314694 rs4639527 chr2 416815 A G 3.31E-04 Multiple complex diseases / / 17554300 rs10460598 chr2 429880 T G 7.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4854307 chr2 443281 T C 2.00E-06 Body mass index / / 24861553 rs971999 chr2 469266 C T 9.96E-05 Body mass index / / 23669352 rs2724913 chr2 481504 G A 1.31E-04 Age-related macular degeneration / / 22125219 rs4854313 chr2 483114 G A 1.15E-04 Type 2 diabetes / / 20818381 rs2974256 chr2 535043 C T 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17041996 chr2 550338 A G 1.70E-04 Multiple complex diseases / / 17554300 rs17042043 chr2 581414 A C 2.25E-04 Smoking initiation / / 24665060 rs6712649 chr2 584523 G A 1.16E-04 Age-related macular degeneration / / 22125219 rs11686772 chr2 584563 C T 1.16E-04 Age-related macular degeneration / / 22125219 rs17042062 chr2 585129 C T 9.69E-05 Age-related macular degeneration / / 22125219 rs4402801 chr2 585333 G A 9.69E-05 Age-related macular degeneration / / 22125219 rs2683992 chr2 600575 G A,C,T 8.75E-04 Obesity (extreme) / / 21935397 rs2683992 chr2 600575 G A,C,T 0.0000554 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867105 chr2 601905 T G 8.75E-04 Obesity (extreme) / / 21935397 rs2867105 chr2 601905 T G 0.0000518 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12996547 chr2 602036 C T 1.00E-09 Obesity / / 23563607 rs12996547 chr2 602036 C T 5.10E-11 Obesity / / 23563607 rs2903497 chr2 607049 C T 4.87E-04 Multiple complex diseases / / 17554300 rs2947415 chr2 609177 A G 0.0000389 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17728164 chr2 609326 C T 9.76E-04 Prostate cancer mortality / / 20978177 rs2867131 chr2 610603 T C 1.05E-06 Body mass index / / 19557197 rs2867131 chr2 610603 T C 1.08E-04 Obesity (extreme) / / 21935397 rs2867131 chr2 610603 T C 0.0000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2947411 chr2 614168 A G 2.32E-06 Body mass index / / 19557197 rs2947411 chr2 614168 A G 2.00E-08 Menarche (age at onset) / / 21102462 rs2947411 chr2 614168 A G 1.91E-04 Obesity (extreme) / / 21935397 rs2947411 chr2 614168 A G 0.000000301 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2860323 chr2 614210 A G 2.26E-06 Body mass index / / 19557197 rs2860323 chr2 614210 A G 1.91E-04 Obesity (extreme) / / 21935397 rs2860323 chr2 614210 A G 0.00000029 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567570 chr2 615140 T C 2.23E-06 Body mass index / / 19557197 rs7567570 chr2 615140 T C 1.91E-04 Obesity (extreme) / / 21935397 rs7567570 chr2 615140 T C 0.000000342 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559547 chr2 615627 C T 0.000000283 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7563362 chr2 620297 A G 0.000000135 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570232 chr2 621185 T C 0.000000236 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548237 chr2 621461 A C 1.02E-06 Body mass index / / 19557197 rs6548237 chr2 621461 A C 2.97E-04 Obesity (extreme) / / 21935397 rs6548237 chr2 621461 A C 0.000000279 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939584 chr2 621558 C T 7.18E-05 Obesity (extreme) / / 21935397 rs6717005 chr2 621910 A C 0.00000023 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320332 chr2 621954 T C 0.000000229 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320331 chr2 622161 G C 1.12E-06 Body mass index / / 19557197 rs1320331 chr2 622161 G C 3.82E-04 Obesity (extreme) / / 21935397 rs1320331 chr2 622161 G C 0.000000226 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320330 chr2 622225 T G 1.06E-06 Body mass index / / 19557197 rs1320330 chr2 622225 T G 3.29E-04 Obesity (extreme) / / 21935397 rs1320330 chr2 622225 T G 0.000000224 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939583 chr2 622531 C T 1.16E-06 Body mass index / / 19557197 rs939583 chr2 622531 C T 4.06E-04 Obesity (extreme) / / 21935397 rs939583 chr2 622531 C T 0.00000022 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939583 chr2 622531 C T 1.00E-07 Body mass index / / 24064335 rs939582 chr2 622723 A G 1.20E-06 Body mass index / / 19557197 rs939582 chr2 622723 A G 4.13E-04 Obesity (extreme) / / 21935397 rs939582 chr2 622723 A G 0.000000214 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867125 chr2 622827 T C 1.15E-06 Body mass index / / 19557197 rs2867125 chr2 622827 T C 1.10E-10 Smoking behavior / / 20418888 rs2867125 chr2 622827 T C 3.00E-49 Body mass index / / 20935630 rs2867125 chr2 622827 T C 4.19E-04 Obesity (extreme) / / 21935397 rs2867125 chr2 622827 T C 2.77E-49 Body mass index / / 23001569 rs2867125 chr2 622827 T C 0.00000015 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867124 chr2 622857 A G 0.000000239 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854339 chr2 623212 T C 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854340 chr2 623216 G A 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939581 chr2 623224 C T 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127483 chr2 623691 G A 1.88E-06 Body mass index / / 19557197 rs11127483 chr2 623691 G A 2.26E-04 Obesity (extreme) / / 21935397 rs11687052 chr2 623740 A G 0.000000211 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127484 chr2 623798 T C 1.18E-06 Body mass index / / 19557197 rs11127484 chr2 623798 T C 3.70E-04 Obesity (extreme) / / 21935397 rs11127484 chr2 623798 T C 0.000000159 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6719518 chr2 623935 C T 1.17E-06 Body mass index / / 19557197 rs6719518 chr2 623935 C T 3.50E-04 Obesity (extreme) / / 21935397 rs6719518 chr2 623935 C T 0.000000205 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6728726 chr2 623976 T C 1.74E-06 Body mass index / / 19557197 rs6728726 chr2 623976 T C 0.000000198 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6711012 chr2 624034 G C 1.15E-06 Body mass index / / 19557197 rs6711012 chr2 624034 G C 3.43E-04 Obesity (extreme) / / 21935397 rs6711012 chr2 624034 G C 3.00E-40 Obesity / / 23563607 rs6711012 chr2 624034 G C 6.00E-35 Obesity / / 23563607 rs6711012 chr2 624034 G C 0.0000002 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731872 chr2 624205 T G 0.000000198 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867123 chr2 624524 G C 1.13E-06 Body mass index / / 19557197 rs2867123 chr2 624524 G C 3.35E-04 Obesity (extreme) / / 21935397 rs2867123 chr2 624524 G C 0.00000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867122 chr2 624581 A C 1.12E-06 Body mass index / / 19557197 rs2867122 chr2 624581 A C 3.30E-04 Obesity (extreme) / / 21935397 rs2867122 chr2 624581 A C 0.00000017 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903492 chr2 624678 G A 1.12E-06 Body mass index / / 19557197 rs2903492 chr2 624678 G A 3.27E-04 Obesity (extreme) / / 21935397 rs2903492 chr2 624678 G A 6.00E-15 Body mass index / / 23563607 rs2903492 chr2 624678 G A 0.00000017 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7576624 chr2 625029 C T 1.12E-06 Body mass index / / 19557197 rs7576624 chr2 625029 C T 1.21E-04 Obesity (extreme) / / 21935397 rs7576624 chr2 625029 C T 0.000000155 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112863468 chr2 625057 C CT 1.05E-06 Body mass index / / 19557197 rs112863468 chr2 625057 C CT 1.19E-04 Obesity (extreme) / / 21935397 rs112863468 chr2 625057 C CT 0.000000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7576635 chr2 625057 C T 1.05E-06 Body mass index / / 19557197 rs7576635 chr2 625057 C T 1.19E-04 Obesity (extreme) / / 21935397 rs7576635 chr2 625057 C T 0.000000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12476198 chr2 625347 T C 9.61E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6744646 chr2 628504 A G 1.07E-06 Body mass index / / 19557197 rs6744646 chr2 628504 A G 1.18E-04 Obesity (extreme) / / 21935397 rs6744646 chr2 628504 A G 0.000000092 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6744653 chr2 628524 A G 1.07E-06 Body mass index / / 19557197 rs6744653 chr2 628524 A G 1.17E-04 Obesity (extreme) / / 21935397 rs6744653 chr2 628524 A G 9.14E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6739303 chr2 628749 C T 7.48E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12463617 chr2 629244 A C 2.95E-04 Obesity (extreme) / / 21935397 rs12463617 chr2 629244 A C 2.00E-13 Obesity (early onset extreme) / / 23563609 rs12463617 chr2 629244 A C 8.52E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12463617 chr2 629244 A C 3.00E-17 Body mass index / / 23669352 rs12463617 chr2 629244 A C 2.00E-12 Body mass index / / 24861553 rs6743060 chr2 629510 C A 1.03E-06 Body mass index / / 19557197 rs6743060 chr2 629510 C A 1.15E-04 Obesity (extreme) / / 21935397 rs6743060 chr2 629510 C A 6.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6748821 chr2 629601 A G 6.23E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6752470 chr2 629694 T A 1.07E-06 Body mass index / / 19557197 rs6752470 chr2 629694 T A 1.14E-04 Obesity (extreme) / / 21935397 rs6752470 chr2 629694 T A 5.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732341 chr2 629817 G C 4.49E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6749087 chr2 629818 A T 6.86E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6752706 chr2 629831 T C 1.16E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12995480 chr2 629881 T C 1.15E-06 Body mass index / / 19557197 rs12995480 chr2 629881 T C 1.12E-04 Obesity (extreme) / / 21935397 rs12995480 chr2 629881 T C 4.35E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732471 chr2 629914 G A 1.16E-06 Body mass index / / 19557197 rs6732471 chr2 629914 G A 1.11E-04 Obesity (extreme) / / 21935397 rs6732471 chr2 629914 G A 0.000000042 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12995666 chr2 629959 T C 5.02E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13007080 chr2 630024 A C 1.15E-06 Body mass index / / 19557197 rs13007080 chr2 630024 A C 1.10E-04 Obesity (extreme) / / 21935397 rs13007080 chr2 630024 A C 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13007086 chr2 630034 A T 1.15E-06 Body mass index / / 19557197 rs13007086 chr2 630034 A T 1.09E-04 Obesity (extreme) / / 21935397 rs13007086 chr2 630034 A T 5.94E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66906321 chr2 630070 T C 5.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73139123 chr2 630075 C T 0.00000005 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731225 chr2 630224 A T 4.15E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6725549 chr2 630323 C A 1.28E-06 Body mass index / / 19557197 rs6725549 chr2 630323 C A 9.59E-05 Obesity (extreme) / / 21935397 rs6725549 chr2 630323 C A 3.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731348 chr2 630339 A C 1.33E-06 Body mass index / / 19557197 rs6731348 chr2 630339 A C 9.47E-05 Obesity (extreme) / / 21935397 rs6731348 chr2 630339 A C 3.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6725686 chr2 630436 C A 3.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6735024 chr2 630509 T C 3.75E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6735049 chr2 630569 T C 1.12E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731688 chr2 630662 A C 1.35E-06 Body mass index / / 19557197 rs6731688 chr2 630662 A C 9.42E-05 Obesity (extreme) / / 21935397 rs6731688 chr2 630662 A C 3.67E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13008590 chr2 630788 A G 3.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017305 chr2 630902 A T 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs202116406 chr2 630903 A ATG 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017304 chr2 630903 A G 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017303 chr2 630995 T G 1.36E-06 Body mass index / / 19557197 rs5017303 chr2 630995 T G 9.31E-05 Obesity (extreme) / / 21935397 rs5017303 chr2 630995 T G 6.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017300 chr2 631099 C G 1.39E-06 Body mass index / / 19557197 rs5017300 chr2 631099 C G 9.26E-05 Obesity (extreme) / / 21935397 rs7579427 chr2 631183 C A 3.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7588007 chr2 631255 T C 3.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7569102 chr2 631335 G T 0.000000037 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7569210 chr2 631462 G A 2.78E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7585056 chr2 631528 A G 1.42E-06 Body mass index / / 19557197 rs7585056 chr2 631528 A G 9.21E-05 Obesity (extreme) / / 21935397 rs7585056 chr2 631528 A G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7579971 chr2 631603 C T 5.18E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865548 chr2 631606 A G 2.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865549 chr2 631759 G A 0.000000028 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127485 chr2 632028 C T 1.39E-06 Body mass index / / 19557197 rs11127485 chr2 632028 C T 2.00E-07 Obesity (early onset extreme) / / 20421936 rs11127485 chr2 632028 C T 9.10E-05 Obesity (extreme) / / 21935397 rs11127485 chr2 632028 C T 1.16E-06 Body mass index / / 22344219 rs11127485 chr2 632028 C T 0.000000036 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127486 chr2 632101 C T 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12623218 chr2 632146 T A 1.40E-06 Body mass index / / 19557197 rs12623218 chr2 632146 T A 8.95E-05 Obesity (extreme) / / 21935397 rs12623218 chr2 632146 T A 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12992154 chr2 632300 G T 1.38E-06 Body mass index / / 19557197 rs12992154 chr2 632300 G T 8.90E-05 Obesity (extreme) / / 21935397 rs12992154 chr2 632300 G T 2.93E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13021737 chr2 632348 A G 1.36E-06 Body mass index / / 19557197 rs13021737 chr2 632348 A G 8.79E-05 Obesity (extreme) / / 21935397 rs13021737 chr2 632348 A G 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13027828 chr2 632379 T G 2.65E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028252 chr2 632529 T C 1.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13022164 chr2 632536 A G 1.47E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13012571 chr2 632550 C T 1.35E-06 Body mass index / / 19557197 rs13012571 chr2 632550 C T 8.70E-05 Obesity (extreme) / / 21935397 rs13012571 chr2 632550 C T 1.42E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028310 chr2 632591 T C 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028310 chr2 632591 T C 1.63E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13022337 chr2 632609 A G 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13013021 chr2 632723 C T 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34119520 chr2 632760 T C 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12993295 chr2 632808 G T 2.44E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35802221 chr2 632904 A G 2.43E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105303 chr2 632922 G A 2.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105304 chr2 632925 A G 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854342 chr2 634476 G C 0.000000115 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548238 chr2 634905 T C 1.00E-18 Body mass index / / 19079261 rs6548238 chr2 634905 T C 1.40E-18 Smoking behavior / / 20418888 rs6548238 chr2 634905 T C 7.10E-07 Menarche (age at onset) / / 21102462 rs6548238 chr2 634905 T C 4.48E-04 Obesity (extreme) / / 21935397 rs6548238 chr2 634905 T C 2.27E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548239 chr2 635154 G A 2.29E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6734363 chr2 635200 G A 1.27E-06 Body mass index / / 19557197 rs6734363 chr2 635200 G A 8.50E-05 Obesity (extreme) / / 21935397 rs6734363 chr2 635200 G A 4.31E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6755502 chr2 635721 T C 1.27E-06 Body mass index / / 19557197 rs6755502 chr2 635721 T C 8.45E-05 Obesity (extreme) / / 21935397 rs6755502 chr2 635721 T C 2.41E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6746275 chr2 635857 C A 0.000000116 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6751993 chr2 635864 A G 0.000000114 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6751994 chr2 635866 A G 0.000000115 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6749375 chr2 636017 C T 1.62E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35142762 chr2 636790 T C 2.61E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35796073 chr2 636819 C A 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548240 chr2 636929 C A 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13387939 chr2 637498 C A 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13396119 chr2 637508 T C 3.08E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13388043 chr2 637597 C T 9.17E-07 Body mass index / / 19557197 rs13388043 chr2 637597 C T 8.36E-05 Obesity (extreme) / / 21935397 rs13388043 chr2 637597 C T 0.000000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13393304 chr2 637830 A G 9.91E-07 Body mass index / / 19557197 rs13393304 chr2 637830 A G 8.27E-05 Obesity (extreme) / / 21935397 rs13393304 chr2 637830 A G 0.000000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854344 chr2 638144 G T 9.61E-07 Body mass index / / 19557197 rs4854344 chr2 638144 G T 5.00E-05 Weight / / 19851299 rs4854344 chr2 638144 G T 2.90E-10 Smoking behavior / / 20418888 rs4854344 chr2 638144 G T 8.22E-05 Obesity (extreme) / / 21935397 rs4854344 chr2 638144 G T 7.36E-13 Obesity / / 22484627 rs4854344 chr2 638144 G T 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854345 chr2 638190 A G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7561556 chr2 638560 T C 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7606023 chr2 638566 C G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854346 chr2 638918 A C 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7564708 chr2 639055 T C 2.91E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105327 chr2 639060 T A 4.01E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7564711 chr2 639061 T G 1.27E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127487 chr2 639900 C T 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10166979 chr2 640701 A G 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865550 chr2 641718 T G 2.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865551 chr2 641863 T A 2.98E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714413 chr2 642253 T C 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7601028 chr2 642499 C G 2.49E-04 Obesity (extreme) / / 21935397 rs7601028 chr2 642499 C G 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7591067 chr2 642846 G A 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7604609 chr2 643303 C G 9.89E-07 Body mass index / / 19557197 rs7604609 chr2 643303 C G 8.15E-05 Obesity (extreme) / / 21935397 rs7604609 chr2 643303 C G 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7560127 chr2 643315 T C 3.05E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7594220 chr2 643320 G A 9.77E-09 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7604752 chr2 643428 C A 0.000000031 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7560246 chr2 643469 T C 3.12E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7561317 chr2 644953 A G 2.00E-18 Weight / / 19079260 rs7561317 chr2 644953 A G 4.00E-17 Body mass index / / 19079260 rs7561317 chr2 644953 A G 9.43E-07 Body mass index / / 19557197 rs7561317 chr2 644953 A G 2.40E-10 Smoking behavior / / 20418888 rs7561317 chr2 644953 A G 8.04E-05 Obesity (extreme) / / 21935397 rs7561317 chr2 644953 A G 3.15E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567368 chr2 645082 T C 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7558910 chr2 645122 C G 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559018 chr2 645203 C T 2.86E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567710 chr2 645372 T G 2.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559447 chr2 645646 C T 2.71E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127488 chr2 646061 T C 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127489 chr2 646081 C T 2.33E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127490 chr2 646110 C T 2.32E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127491 chr2 646145 T C 1.01E-06 Body mass index / / 19557197 rs11127491 chr2 646145 T C 8.01E-05 Obesity (extreme) / / 21935397 rs11127491 chr2 646145 T C 2.48E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10172769 chr2 646345 G A 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10189761 chr2 646364 T A 2.72E-06 Body mass index / / 19557197 rs10189761 chr2 646364 T A 1.27E-04 Obesity (extreme) / / 21935397 rs10189761 chr2 646364 T A 6.00E-24 Obesity / / 23563607 rs10189761 chr2 646364 T A 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190052 chr2 646674 T C 1.02E-06 Body mass index / / 19557197 rs10190052 chr2 646674 T C 7.80E-05 Obesity (extreme) / / 21935397 rs10190052 chr2 646674 T C 2.94E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190052 chr2 646674 T C 2.00E-07 Type 2 diabetes / / 24509480 rs10173167 chr2 646767 G A 9.97E-07 Body mass index / / 19557197 rs10173167 chr2 646767 G A 7.74E-05 Obesity (extreme) / / 21935397 rs10173167 chr2 646767 G A 2.31E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7571957 chr2 646803 T C 9.63E-07 Body mass index / / 19557197 rs7571957 chr2 646803 T C 7.68E-05 Obesity (extreme) / / 21935397 rs7571957 chr2 646803 T C 2.41E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7571967 chr2 646839 T G 2.28E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190313 chr2 647577 A G 8.01E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10193244 chr2 647580 T C 1.00E-06 Body mass index / / 19557197 rs10193244 chr2 647580 T C 7.65E-05 Obesity (extreme) / / 21935397 rs10193244 chr2 647580 T C 8.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854348 chr2 647760 A G 9.90E-07 Body mass index / / 19557197 rs4854348 chr2 647760 A G 7.62E-05 Obesity (extreme) / / 21935397 rs4854348 chr2 647760 A G 2.38E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854349 chr2 647861 T C 9.62E-07 Body mass index / / 19557197 rs4854349 chr2 647861 T C 7.59E-05 Obesity (extreme) / / 21935397 rs4854349 chr2 647861 T C 2.39E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570198 chr2 648198 C T 9.43E-07 Body mass index / / 19557197 rs7570198 chr2 648198 C T 7.52E-05 Obesity (extreme) / / 21935397 rs7570198 chr2 648198 C T 2.38E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4407278 chr2 648607 C T 0.000000336 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4423631 chr2 648758 T C 8.90E-07 Body mass index / / 19557197 rs4423631 chr2 648758 T C 7.43E-05 Obesity (extreme) / / 21935397 rs4423631 chr2 648758 T C 2.81E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4452188 chr2 648810 A G 8.69E-07 Body mass index / / 19557197 rs4452188 chr2 648810 A G 7.37E-05 Obesity (extreme) / / 21935397 rs4452188 chr2 648810 A G 3.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320338 chr2 649347 T G 8.29E-07 Body mass index / / 19557197 rs1320338 chr2 649347 T G 7.70E-05 Obesity (extreme) / / 21935397 rs1320338 chr2 649347 T G 3.16E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903489 chr2 649638 C T 3.45E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320337 chr2 649867 A T 8.39E-07 Body mass index / / 19557197 rs1320337 chr2 649867 A T 7.77E-05 Obesity (extreme) / / 21935397 rs1320337 chr2 649867 A T 3.18E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320336 chr2 650012 G A 8.36E-07 Body mass index / / 19557197 rs1320336 chr2 650012 G A 7.84E-05 Obesity (extreme) / / 21935397 rs1320336 chr2 650012 G A 0.000000034 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867108 chr2 650143 T C 8.43E-07 Body mass index / / 19557197 rs2867108 chr2 650143 T C 8.00E-05 Obesity (extreme) / / 21935397 rs2867108 chr2 650143 T C 5.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386517 chr2 650479 G C 8.47E-07 Body mass index / / 19557197 rs13386517 chr2 650479 G C 8.08E-05 Obesity (extreme) / / 21935397 rs13386517 chr2 650479 G C 5.69E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13401686 chr2 650519 A G 8.37E-07 Body mass index / / 19557197 rs13401686 chr2 650519 A G 8.16E-05 Obesity (extreme) / / 21935397 rs13401686 chr2 650519 A G 1.71E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386627 chr2 650560 G C 8.28E-07 Body mass index / / 19557197 rs13386627 chr2 650560 G C 8.23E-05 Obesity (extreme) / / 21935397 rs13386627 chr2 650560 G C 0.000000036 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4613321 chr2 650647 A G 8.22E-07 Body mass index / / 19557197 rs4613321 chr2 650647 A G 8.39E-05 Obesity (extreme) / / 21935397 rs4613321 chr2 650647 A G 3.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386964 chr2 650828 G A 8.21E-07 Body mass index / / 19557197 rs13386964 chr2 650828 G A 8.56E-05 Obesity (extreme) / / 21935397 rs13386964 chr2 650828 G A 3.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13387091 chr2 650980 G A 0.000000039 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867109 chr2 651030 T G 8.18E-07 Body mass index / / 19557197 rs2867109 chr2 651030 T G 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2867109 chr2 651030 T G 8.74E-05 Obesity (extreme) / / 21935397 rs2867109 chr2 651030 T G 3.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867110 chr2 651105 G C 8.54E-07 Body mass index / / 19557197 rs2867110 chr2 651105 G C 8.82E-05 Obesity (extreme) / / 21935397 rs2867110 chr2 651105 G C 3.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867111 chr2 651286 A C 0.000000125 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903490 chr2 651290 A G 0.000000136 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867112 chr2 651349 T G 8.00E-07 Body mass index / / 19557197 rs2867112 chr2 651349 T G 9.66E-05 Obesity (extreme) / / 21935397 rs2867112 chr2 651349 T G 0.000000131 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867113 chr2 651365 G A 8.02E-07 Body mass index / / 19557197 rs2867113 chr2 651365 G A 9.86E-05 Obesity (extreme) / / 21935397 rs2867113 chr2 651365 G A 8.49E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867114 chr2 651380 C T 0.00000296 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867115 chr2 651382 T C 0.00000358 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714414 chr2 651407 T C 8.11E-07 Body mass index / / 19557197 rs12714414 chr2 651407 T C 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714414 chr2 651407 T C 1.01E-04 Obesity (extreme) / / 21935397 rs12714414 chr2 651407 T C 5.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714415 chr2 651430 T C 8.14E-07 Body mass index / / 19557197 rs12714415 chr2 651430 T C 1.03E-04 Obesity (extreme) / / 21935397 rs12714415 chr2 651430 T C 5.89E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6719980 chr2 651507 T C 8.12E-07 Body mass index / / 19557197 rs6719980 chr2 651507 T C 1.05E-04 Obesity (extreme) / / 21935397 rs6719980 chr2 651507 T C 0.00000007 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1879523 chr2 651599 A T 7.77E-09 Obesity / / 23563607 rs7608050 chr2 652247 G A 8.13E-07 Body mass index / / 19557197 rs7608050 chr2 652247 G A 1.08E-04 Obesity (extreme) / / 21935397 rs7608050 chr2 652247 G A 0.000000025 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6760274 chr2 652272 G A 3.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7574359 chr2 652542 T C 8.23E-07 Body mass index / / 19557197 rs7574359 chr2 652542 T C 1.12E-04 Obesity (extreme) / / 21935397 rs7574359 chr2 652542 T C 7.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570993 chr2 652565 A G 0.000000119 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4429506 chr2 652576 C A 0.000000167 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10192350 chr2 652607 T C 0.000000131 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13415094 chr2 653093 T C 8.13E-07 Body mass index / / 19557197 rs13415094 chr2 653093 T C 1.16E-04 Obesity (extreme) / / 21935397 rs13415094 chr2 653093 T C 0.000000065 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13396935 chr2 653195 G A 8.10E-07 Body mass index / / 19557197 rs13396935 chr2 653195 G A 1.19E-04 Obesity (extreme) / / 21935397 rs13396935 chr2 653195 G A 0.000000069 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13412194 chr2 653245 A C 3.78E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13412197 chr2 653250 A G 3.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13397165 chr2 653354 G A 8.13E-07 Body mass index / / 19557197 rs13397165 chr2 653354 G A 1.22E-04 Obesity (extreme) / / 21935397 rs13397165 chr2 653354 G A 7.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35913461 chr2 653575 C T 7.13E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35628463 chr2 653581 G A 0.000000071 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10188118 chr2 653623 C G 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10188334 chr2 653874 C T 8.11E-07 Body mass index / / 19557197 rs10188334 chr2 653874 C T 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs10188334 chr2 653874 C T 1.27E-04 Obesity (extreme) / / 21935397 rs10188334 chr2 653874 C T 2.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12999373 chr2 663483 G A 2.00E-06 Uric acid levels / / 22229870 rs12999373 chr2 663483 G A 3.00E-06 Response to fenofibrate (adiponectin levels) / / 23149075 rs11673780 chr2 664719 A G 3.30E-04 Type 2 diabetes / / 17463246 rs1320333 chr2 679179 C T 8.00E-06 Obesity-related traits / / 23251661 rs1320333 chr2 679179 C T 5.70E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4372938 chr2 716503 T C 3.05E-05 Body Mass Index / / pha003019 rs4372938 chr2 716503 T C 1.46E-05 Body Mass Index / / pha003022 rs3924384 chr2 726564 T C 1.50E-05 Sickle cell anemia (severity) / / 20029952 rs7580986 chr2 729948 G T 2.35E-06 Sickle cell anemia (severity) / / 20029952 rs4335978 chr2 750078 A G 9.77E-05 Atopic dermatitis / / 23042114 rs4380275 chr2 773278 C T 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs6729766 chr2 824614 T A 0.000797 Salmonella-induced pyroptosis LOC339822 intron 22837397 rs12466616 chr2 877633 G A 9.88E-05 Smoking initiation / / 24665060 rs6744291 chr2 941020 C G 6.29E-12 Multiple complex diseases / / 17554300 rs4971347 chr2 943636 C T 0.000027 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs6710556 chr2 969866 T C 9.72E-04 Multiple complex diseases SNTG2 intron 17554300 rs11127542 chr2 1004430 T C 2.20E-04 Multiple complex diseases SNTG2 intron 17554300 rs10201045 chr2 1025239 A G 9.62E-04 Type 2 diabetes SNTG2 intron 17463246 rs10203650 chr2 1025268 T C 7.50E-04 Type 2 diabetes SNTG2 intron 17463246 rs4971371 chr2 1076684 C T 5.57E-04 Alcohol dependence SNTG2 intron 21314694 rs13389243 chr2 1099654 C T 7.08E-04 Depression (quantitative trait) SNTG2 intron 20800221 rs7579535 chr2 1150095 A C 1.12E-05 Eosinophil counts SNTG2 intron pha003088 rs4971396 chr2 1153552 T G 7.93E-06 Eosinophil counts SNTG2 intron pha003088 rs7579446 chr2 1206464 G C 3.22E-04 Height SNTG2 intron 17255346 rs7579446 chr2 1206464 G C 8.86E-04 Type 2 diabetes SNTG2 intron 17463246 rs4971418 chr2 1216394 A G 5.56E-04 Multiple complex diseases SNTG2 intron 17554300 rs6548209 chr2 1228487 T G 3.29E-04 Cognitive decline SNTG2 intron 23732972 rs10192365 chr2 1231315 A G 7.26E-05 Cognitive decline SNTG2 intron 23732972 rs11674954 chr2 1283031 T G 3.55E-04 Amyotrophic Lateral Sclerosis SNTG2 intron 17362836 rs7424980 chr2 1284020 T C 4.52E-04 Tourette syndrome SNTG2 intron 22889924 rs13411595 chr2 1287872 T C 6.40E-05 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs11211641 chr2 1287922 T A,G 9.33E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs6738955 chr2 1288297 C T 1.76E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs7421044 chr2 1291096 G A 9.26E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs12467819 chr2 1293260 G A 9.30E-06 Urinary metabolites SNTG2 intron 21572414 rs11211670 chr2 1367035 G C 1.60E-05 Urinary metabolites SNTG2 intron 21572414 rs13387242 chr2 1376021 G A 1.80E-05 Urinary metabolites / / 21572414 rs9326164 chr2 1393107 A G 2.85E-04 Multiple complex diseases / / 17554300 rs11675434 chr2 1407815 C T 2.00E-16 Thyroid peroxidase antibody positivity / / 24586183 rs11675434 chr2 1407815 C T 7.00E-13 Thyroid peroxidase antibody levels / / 24586183 rs2071403 chr2 1417244 A G 1.00E-10 Thyroid peroxidase antibody positivity TPO UTR-5 24722205 rs1514687 chr2 1437988 T G 2.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) TPO intron 24554482 rs1126797 chr2 1497803 C A,G,T 2.48E-05 Major depressive disorder TPO missense 20516156 rs11896517 chr2 1518112 T C 2.00E-09 Health and aging,CVD and cancer age of onset TPO intron 22174011 rs17732233 chr2 1519064 C T 4.97E-05 Alcohol and nictotine co-dependence TPO intron 20158304 rs1126799 chr2 1520676 T C 2.31E-04 Alzheimer's disease (late onset) TPO missense 21379329 rs4927594 chr2 1525558 C T 3.32E-05 Major depressive disorder TPO intron 20516156 rs4927632 chr2 1545110 G A 2.04E-05 Alcohol and nictotine co-dependence TPO intron 20158304 rs6705087 chr2 1550309 T C 4.80E-06 Alcohol and nictotine co-dependence / / 20158304 rs10206020 chr2 1557927 T C 8.96E-04 Type 2 diabetes / / 17463246 rs10206020 chr2 1557927 T C 3.00E-06 IgG glycosylation / / 23382691 rs10206020 chr2 1557927 T C 4.00E-06 IgG glycosylation / / 23382691 rs6721243 chr2 1580250 A G 2.05E-04 Cholesterol / / 17255346 rs7564265 chr2 1582242 A G 2.31E-05 Gaucher disease severity / / 22388998 rs11127330 chr2 1621676 C T 2.40E-05 Urinary metabolites / / 21572414 rs11692295 chr2 1623765 T C 9.80E-06 Urinary metabolites / / 21572414 rs9309692 chr2 1625121 C A 4.20E-05 Response to statin therapy / / 20339536 rs1544846 chr2 1676388 C T 5.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDN intron 20877124 rs6548062 chr2 1698030 A G 8.87E-04 Type 2 diabetes PXDN intron 17463246 rs7588729 chr2 1708502 C A 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDN intron 20877124 rs13401942 chr2 1711624 A G 1.95E-04 Multiple complex diseases PXDN intron 17554300 rs10469992 chr2 1760091 C T 2.50E-05 Urinary metabolites / / 21572414 rs2382560 chr2 1762828 T C 1.70E-05 Urinary metabolites / / 21572414 rs7563388 chr2 1773193 G A 0.000749763 Hypertension (early onset hypertension) / / 22479346 rs6745451 chr2 1776761 C T 8.23E-05 Hypertension (early onset hypertension) / / 22479346 rs6735179 chr2 1777150 A G 6.85E-05 Personality dimensions / / 18957941 rs6735179 chr2 1777150 A G 1.00E-07 Response to antipsychotic treatment / / 20195266 rs6548056 chr2 1813322 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYT1L intron 20877124 rs6548056 chr2 1813322 C T 4.26E-04 Common variable immunodeficiency MYT1L intron 21497890 rs6548056 chr2 1813322 C T 3.69E-04 Coronary heart disease MYT1L intron 21971053 rs4645032 chr2 1820060 T C 2.97E-04 Obesity (extreme) MYT1L intron 21935397 rs7560247 chr2 1883389 T C 4.44E-05 Hypertension MYT1L intron pha003041 rs11127306 chr2 1887049 G A 5.24E-05 Hypertension MYT1L intron pha003041 rs11885419 chr2 1891930 A G 0.0000313 Colorectal adenoma (excluding hyperplasic) MYT1L intron 23677573 rs11885419 chr2 1891930 A G 0.0000313 Colorectal adenoma (including hyperplasic) MYT1L intron 23677573 rs10184726 chr2 1924946 C T 1.60E-05 Urinary metabolites MYT1L intron 21572414 rs2241685 chr2 1925993 C T 8.00E-06 Attention deficit hyperactivity disorder MYT1L intron 18839057 rs13389573 chr2 1936113 T G 4.19E-04 Type 2 diabetes MYT1L intron 17463246 rs11687068 chr2 1948949 T C 6.98E-04 Type 2 diabetes MYT1L intron 17463246 rs11687068 chr2 1948949 T C 8.50E-04 Multiple complex diseases MYT1L intron 17554300 rs13417303 chr2 1950897 C T 6.33E-04 Insulin resistance MYT1L intron 21901158 rs1991773 chr2 1957476 C T 2.21E-04 Multiple complex diseases MYT1L intron 17554300 rs6733654 chr2 1963271 G A 3.51E-05 Soluble levels of adhesion molecules MYT1L intron pha003072 rs10185662 chr2 1964906 C T 9.56E-04 Multiple complex diseases MYT1L intron 17554300 rs891878 chr2 1992624 T G 1.47E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs1560625 chr2 1993024 T G 6.23E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs13389846 chr2 1996027 T C 9.57E-05 Pulmonary function MYT1L intron 20010835 rs17039313 chr2 2084964 T C 7.16E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs1643413 chr2 2104124 A G 2.60E-05 Urinary metabolites MYT1L intron 21572414 rs1620250 chr2 2128585 T C 1.55E-05 Pulmonary function MYT1L intron 20010835 rs12998803 chr2 2129071 T C 4.42E-04 Aortic root size MYT1L intron 21223598 rs17247373 chr2 2135309 C A 3.24E-04 Aortic root size MYT1L intron 21223598 rs11687473 chr2 2165519 C A 6.63E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs17039365 chr2 2197239 T C 4.59E-04 Hypertension (young onset) MYT1L intron 24892410 rs10495483 chr2 2198752 G C 9.70E-04 Bipolar disorder MYT1L intron 19259986 rs7596980 chr2 2199705 C T 7.52E-04 Hypertension (young onset) MYT1L intron 24892410 rs6748501 chr2 2204179 T C 1.00E-04 Cognitive impairment induced by topiramate MYT1L intron 22091778 rs1582414 chr2 2216368 G T 2.88E-04 Type 2 diabetes MYT1L intron 17846125 rs10184190 chr2 2233492 A C 1.79E-04 Amyotrophic lateral sclerosis (sporadic) MYT1L intron 24529757 rs4853946 chr2 2236281 T C 2.73E-04 Abdominal aortic aneurysm MYT1L intron 22055160 rs10168134 chr2 2257724 T C 7.88E-04 Alzheimer's disease MYT1L intron 17998437 rs6753548 chr2 2268764 C G 7.65E-04 Alzheimer's disease MYT1L intron 17998437 rs10190125 chr2 2294426 G A 1.68E-04 Longevity MYT1L intron 22279548 rs12612846 chr2 2381297 G A 6.24E-04 Multiple complex diseases / / 17554300 rs11884676 chr2 2381613 G A 8.27E-05 Orofacial clefts / / 22419666 rs11884676 chr2 2381613 G A 1.93E-05 Glucose levels / / pha003061 rs17720273 chr2 2390619 C G 0.00000474 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs17720273 chr2 2390619 C G 4.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs13411814 chr2 2399524 G A 4.10E-05 Glucose levels / / pha003057 rs1567675 chr2 2403590 C A 1.18E-04 Multiple complex diseases / / 17554300 rs6741513 chr2 2417721 A G 2.48E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs7577250 chr2 2437074 A G 3.71E-05 Body Mass Index / / pha003019 rs7577250 chr2 2437074 A G 6.72E-06 Body Mass Index / / pha003020 rs7577250 chr2 2437074 A G 8.02E-06 Insulin Resistance / / pha003062 rs7577250 chr2 2437074 A G 1.96E-05 Insulin-related traits / / pha003063 rs12616839 chr2 2438630 C A 5.61E-05 Body Mass Index / / pha003019 rs12616839 chr2 2438630 C A 9.92E-06 Body Mass Index / / pha003020 rs12616839 chr2 2438630 C A 1.21E-05 Insulin Resistance / / pha003062 rs12616839 chr2 2438630 C A 2.71E-05 Insulin-related traits / / pha003063 rs13013201 chr2 2473647 G A 8.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs823538 chr2 2493770 A G 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7593925 chr2 2512230 A G 9.02E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs823557 chr2 2512660 T C 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10199521 chr2 2519513 C T 3.00E-06 Diabetic retinopathy / / 21441570 rs10199521 chr2 2519513 C T 5.44E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10199516 chr2 2519521 C T 3.40E-06 Diabetic retinopathy / / 21441570 rs10199516 chr2 2519521 C T 5.46E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13023303 chr2 2520359 G T 9.50E-06 Urinary metabolites / / 21572414 rs2668843 chr2 2521301 G A 3.70E-06 Diabetic retinopathy / / 21441570 rs938141 chr2 2521840 G A 4.10E-06 Diabetic retinopathy / / 21441570 rs10495489 chr2 2532159 T A 9.78E-04 Multiple complex diseases / / 17554300 rs11676482 chr2 2533488 C G 1.44E-05 Response to citalopram treatment / / 19846067 rs2037148 chr2 2540292 A C 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2037147 chr2 2540386 T C 1.06E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1980145 chr2 2540775 A G 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7568276 chr2 2545078 A G 2.69E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs181867028 chr2 2545734 A T 8.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2037146 chr2 2564549 A G 9.68E-04 Type 2 diabetes / / 17463246 rs11127343 chr2 2564992 C T 9.12E-04 Type 2 diabetes / / 17463246 rs869759 chr2 2571142 C T 4.39E-05 Alzheimer's disease (late onset) / / 21379329 rs13004123 chr2 2577912 C A,G,T 1.89E-04 Alzheimer's disease (late onset) / / 21379329 rs2598592 chr2 2590381 C T 7.00E-06 White matter integrity / / 23218918 rs12995456 chr2 2594614 A C 7.60E-05 Glioma (high-grade) / / 19578366 rs4853911 chr2 2601765 G A 7.69E-05 Smoking initiation / / 24665060 rs7556672 chr2 2605757 G T 6.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1584644 chr2 2606830 G C 6.16E-04 Alzheimer's disease / / 17998437 rs752787 chr2 2609713 T A 8.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2891741 chr2 2613960 A G 3.69E-04 Alzheimer's disease / / 17998437 rs13031108 chr2 2633258 T C 3.76E-05 Eosinophil counts / / pha003088 rs3814051 chr2 2640865 G T 0.000324532 Hypertension (early onset hypertension) / / 22479346 rs4853887 chr2 2650131 G A 1.25E-05 Multiple complex diseases / / 17554300 rs10202240 chr2 2666966 G A 4.01E-05 Cognitive performance / / 19734545 rs6714525 chr2 2699840 T A 7.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1993081 chr2 2701665 T C 2.32E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1993082 chr2 2705929 G A 7.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1993082 chr2 2705929 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6548077 chr2 2718978 G A,C,T 8.29E-05 Alzheimer's disease (late onset) / / 21379329 rs12466602 chr2 2742748 C T 3.15E-04 Multiple complex diseases / / 17554300 rs2053908 chr2 2750095 T A 1.20E-04 Type 2 diabetes / / 17463246 rs17038881 chr2 2754703 T C 0.0002049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17038881 chr2 2754703 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13389878 chr2 2757162 G A 0.00013 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs11693002 chr2 2761323 G C 0.000031 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs13431590 chr2 2761577 A G 8.19E-04 Tourette syndrome / / 22889924 rs1031348 chr2 2764201 C A 2.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs934555 chr2 2811664 T C 8.40E-06 Urinary metabolites / / 21572414 rs823220 chr2 2827276 C T 1.10E-05 Urinary metabolites / / 21572414 rs823220 chr2 2827276 C T 4.13E-04 Insulin resistance / / 21901158 rs823221 chr2 2827345 A G 1.10E-05 Urinary metabolites / / 21572414 rs823223 chr2 2827974 G A 1.10E-05 Urinary metabolites / / 21572414 rs823223 chr2 2827974 G A 7.87E-04 Insulin resistance / / 21901158 rs823224 chr2 2828104 T C 1.20E-05 Urinary metabolites / / 21572414 rs823231 chr2 2831484 C T 7.32E-04 Smoking initiation / / 24665060 rs10200599 chr2 2838270 G A 2.30E-05 Memory performance / / 22105620 rs10200599 chr2 2838270 G A 3.10E-05 Smoking initiation / / 24665060 rs935630 chr2 2839594 C T 2.00E-05 Memory performance / / 22105620 rs13403149 chr2 2843308 G A 7.00E-06 Smoking initiation / / 24665060 rs10202957 chr2 2844858 A T 1.34E-04 Smoking initiation / / 24665060 rs13401708 chr2 2845963 C T 8.35E-05 Smoking initiation / / 24665060 rs823243 chr2 2848102 T C 8.00E-04 Alcohol dependence / / 20201924 rs13022869 chr2 2879216 G T 0.0005812 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13022869 chr2 2879216 G T 5.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1656326 chr2 2880229 A G 0.000232 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1656326 chr2 2880229 A G 2.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11694272 chr2 2892309 T C 0.0004301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11694272 chr2 2892309 T C 4.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7569351 chr2 2892642 G A 0.0005114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7569351 chr2 2892642 G A 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11691324 chr2 2895033 C T 0.0005864 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11691324 chr2 2895033 C T 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17040523 chr2 2895193 C T 0.00000055 Independent stressful life events / / 23237013 rs17040523 chr2 2895193 C T 0.0000013 Stressful life events / / 23237013 rs17491951 chr2 2926013 G A 7.00E-06 White matter integrity (interaction) / / 23218918 rs7594094 chr2 2942376 G A 3.06E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7594094 chr2 2942376 G A 3.06E-05 Immune response to anthrax vaccine / / 22658931 rs1667059 chr2 2946331 C T 1.89E-04 Parkinson's disease / / 17052657 rs1667029 chr2 2950289 T C 1.54E-04 Parkinson's disease / / 17052657 rs1463147 chr2 2970688 C A 6.70E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17437842 chr2 2978905 C T 8.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17490371 chr2 3011244 C G 4.30E-06 Urinary metabolites / / 21572414 rs2031028 chr2 3012290 A G 3.00E-06 Urinary metabolites / / 21572414 rs12470135 chr2 3012947 C T 1.80E-05 Urinary metabolites / / 21572414 rs1406534 chr2 3029935 A C 2.40E-06 Urinary metabolites / / 21572414 rs7371570 chr2 3067917 G A 8.62E-04 Schizophrenia / / 19197363 rs11902160 chr2 3068334 C T 5.26E-05 Cognitive performance / / 19734545 rs7420489 chr2 3071419 A G 5.35E-05 Cognitive performance / / 19734545 rs6709268 chr2 3079139 C A 8.60E-06 Type 2 diabetes / / 21647700 rs62119855 chr2 3079363 C T 9.09E-06 Stroke (ischemic) / / 21957438 rs7371392 chr2 3083625 A G 8.49E-06 Stroke (ischemic) / / 21957438 rs10169682 chr2 3086833 C T 2.63E-06 Stroke (ischemic) / / 21957438 rs12714371 chr2 3087454 T A 9.03E-06 Stroke (ischemic) / / 21957438 rs4854189 chr2 3098843 G A 2.09E-06 Stroke (ischemic) / / 21957438 rs1453822 chr2 3099075 T G 6.18E-06 Stroke (ischemic) / / 21957438 rs13023918 chr2 3116598 A G 6.74E-05 HDL cholesterol / / pha003075 rs13023918 chr2 3116598 A G 7.78E-05 Lipid levels / / pha003082 rs4854192 chr2 3120184 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs7565101 chr2 3127370 A G 3.27E-04 Blood pressure / / 17255346 rs2887312 chr2 3152466 G A 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11677255 chr2 3153038 C A 7.53E-04 Aortic root size / / 21223598 rs6730025 chr2 3163738 G A 0.0008131 Hypertension (early onset hypertension) / / 22479346 rs13021132 chr2 3172438 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13021132 chr2 3172438 C T 1.34E-05 Insulin Resistance / / pha003062 rs13021132 chr2 3172438 C T 2.22E-06 Insulin-related traits / / pha003063 rs10208086 chr2 3175992 G A 3.04E-06 Insulin Resistance / / pha003062 rs10208086 chr2 3175992 G A 6.73E-08 Insulin-related traits / / pha003063 rs4854106 chr2 3213822 A G 9.03E-05 Amyotrophic lateral sclerosis (sporadic) TSSC1 intron 24529757 rs7595382 chr2 3220709 G A 4.10E-05 Insulin Resistance TSSC1 intron pha003062 rs7595382 chr2 3220709 G A 9.54E-07 Insulin-related traits TSSC1 intron pha003063 rs2694103 chr2 3243238 G A 1.62E-04 Response to taxane treatment (placlitaxel) TSSC1 intron 23006423 rs1869417 chr2 3249933 T C 9.97E-05 Insulin-related traits TSSC1 intron pha003063 rs2694093 chr2 3258174 C T 8.23E-04 Multiple complex diseases TSSC1 intron 17554300 rs2694074 chr2 3265710 T A 1.80E-06 Nasopharyngeal carcinoma TSSC1 intron 23209447 rs2694075 chr2 3265893 T C 9.23E-04 Multiple complex diseases TSSC1 intron 17554300 rs2694079 chr2 3277639 G A 9.26E-04 Multiple complex diseases TSSC1 intron 17554300 rs10206606 chr2 3305635 G A 8.75E-05 Serum metabolites TSSC1 intron 19043545 rs7563810 chr2 3322170 A G 1.00E-04 Coronary heart disease TSSC1 intron 21378986 rs6548153 chr2 3326045 C A 0.0000901 Nicotine dependence (smoking) TSSC1 intron 22377092 rs12623730 chr2 3334003 C T 0.0000859 Nicotine dependence (smoking) TSSC1 intron 22377092 rs2324582 chr2 3339350 G A 1.92E-04 Schizophrenia TSSC1 intron 20832056 rs6712776 chr2 3352449 A G 2.90E-05 Hypertension TSSC1 intron 19609347 rs6712776 chr2 3352449 A G 8.29E-04 Aortic root size TSSC1 intron 21223598 rs4854182 chr2 3366890 C T 2.50E-05 Urinary metabolites TSSC1 intron 21572414 rs10865541 chr2 3392075 T A,C 6.00E-06 Obesity-related traits TRAPPC12 cds-synon 23251661 rs10865541 chr2 3392075 T A,C 5.23E-05 Receptive language ability TRAPPC12 cds-synon 24687471 rs10165099 chr2 3402591 T C 3.43E-05 Receptive language ability TRAPPC12 intron 24687471 rs4627605 chr2 3411923 G A 4.73E-05 Receptive language ability TRAPPC12 intron 24687471 rs4971502 chr2 3414029 A G 9.40E-05 Receptive language ability TRAPPC12 intron 24687471 rs13020433 chr2 3417577 G A 7.06E-05 Receptive language ability TRAPPC12 intron 24687471 rs6739163 chr2 3419011 G A 7.13E-05 HIV-1 control TRAPPC12 intron 20041166 rs7558487 chr2 3425514 G C 6.67E-05 Receptive language ability TRAPPC12 intron 24687471 rs10206964 chr2 3425948 T C 6.63E-05 Receptive language ability TRAPPC12 intron 24687471 rs7579868 chr2 3431157 T G 5.85E-05 Receptive language ability TRAPPC12 intron 24687471 rs4971505 chr2 3432550 T G 5.62E-05 Receptive language ability TRAPPC12 intron 24687471 rs7585799 chr2 3464810 C T 4.57E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRAPPC12 intron 20877124 rs9678657 chr2 3497167 G A 9.73E-04 Multiple complex diseases / / 17554300 rs4591372 chr2 3503566 T A 5.81E-04 Smoking quantity ADI1 intron 24665060 rs9798096 chr2 3508994 C T 2.50E-04 Celiac disease ADI1 intron 23936387 rs4595985 chr2 3581514 T C 6.62E-05 Longevity LOC100506014 intron 20304771 rs10153531 chr2 3589803 A G 8.05E-05 Longevity / / 20304771 rs7589966 chr2 3696636 T C 1.30E-05 Urinary metabolites / / 21572414 rs4849975 chr2 3701336 G A 7.83E-05 Intelligence / / 21826061 rs11894441 chr2 3701972 G A 9.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17445240 chr2 3703041 A G 2.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17445240 chr2 3703041 A G 5.49E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs17445240 chr2 3703041 A G 5.01E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs13418767 chr2 3704830 G T 5.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13418767 chr2 3704830 G T 2.77E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs6754459 chr2 3707423 C T 1.92E-04 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs6754459 chr2 3707423 C T 5.73E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) ALLC intron 24792382 rs17017879 chr2 3713658 G C 3.40E-04 Fibrinogen ALLC intron 17255346 rs17017879 chr2 3713658 G C 4.52E-05 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs11687349 chr2 3717496 T G 5.68E-04 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs11123610 chr2 3723026 G A 4.00E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) ALLC intron 24792382 rs6743352 chr2 3732546 T C 2.80E-05 Amyotrophic Lateral Sclerosis ALLC intron 17827064 rs6730148 chr2 3748971 T C 2.00E-06 Obesity-related traits ALLC intron 23251661 rs6730396 chr2 3749119 T C 1.40E-13 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs6730396 chr2 3749119 T C 1.90E-32 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs6730396 chr2 3749119 T C 2.90E-28 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs11682163 chr2 3749546 T C 0.0000076 Primary sclerosing cholangitis ALLC intron 22521342 rs6542651 chr2 3759830 T C 2.84E-05 Parkinson's disease DCDC2C intron 19915575 rs6542651 chr2 3759830 T C 3.34E-06 Parkinson's disease DCDC2C intron pha002868 rs17017928 chr2 3769141 G A 4.96E-23 Narcolepsy DCDC2C intron 19629137 rs357957 chr2 3783688 G A 6.49E-04 Multiple complex diseases DCDC2C intron 17554300 rs357958 chr2 3783716 A G 6.14E-04 Multiple complex diseases DCDC2C intron 17554300 rs17017966 chr2 3792530 T C 0.0001101 Sarcoidosis DCDC2C intron 22952805 rs357973 chr2 3798725 A G 9.30E-05 Type 2 diabetes DCDC2C intron 17463248 rs357971 chr2 3799594 C G 9.10E-05 Type 2 diabetes DCDC2C intron 17463248 rs357968 chr2 3800496 C T 8.51E-04 Parkinson's disease DCDC2C intron 17052657 rs6761325 chr2 3812539 T G 9.80E-04 Acute lung injury DCDC2C intron 22295056 rs10195488 chr2 3824135 T C 5.62E-05 Height / / pha003011 rs13021385 chr2 3826387 T C 4.49E-05 Height / / pha003011 rs17018026 chr2 3836760 G A 3.42E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11886534 chr2 3837303 A G 7.87E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11677370 chr2 3841420 T A 3.00E-06 Type 2 diabetes / / 21490949 rs2034730 chr2 3882177 A G 2.77E-04 Schizophrenia / / 20832056 rs897067 chr2 3891792 T C 2.56E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs897065 chr2 3892049 A G 1.79E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4850000 chr2 3918124 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4850005 chr2 3953682 G A 4.65E-05 Type 2 diabetes / / 17463246 rs1565806 chr2 3970561 C T 9.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11123630 chr2 4123851 C T 7.53E-05 Multiple complex diseases / / 17554300 rs4849943 chr2 4124656 C A 4.28E-04 Smoking quantity / / 24665060 rs12478345 chr2 4135272 A G 2.74E-04 Smoking quantity / / 24665060 rs1024026 chr2 4135981 C T 6.80E-04 Smoking quantity / / 24665060 rs12464429 chr2 4136781 A G 1.70E-05 Urinary metabolites / / 21572414 rs6759055 chr2 4137992 T G 3.88E-04 Alzheimer's disease / / 24755620 rs12476453 chr2 4140215 C A 1.20E-04 Multiple complex diseases / / 17554300 rs6709996 chr2 4160920 G A 5.65E-04 Multiple complex diseases / / 17554300 rs1437700 chr2 4170619 A G 2.38E-04 Fibrinogen / / 17255346 rs7601231 chr2 4176692 G T 4.30E-04 Sudden cardiac arrest / / 21658281 rs11692873 chr2 4183357 G A 5.92E-04 Multiple complex diseases / / 17554300 rs6714273 chr2 4188698 C T 6.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4850057 chr2 4220499 T C 2.48E-05 Multiple complex diseases / / 17554300 rs17018897 chr2 4290344 A G 3.11E-05 Multiple complex diseases / / 17554300 rs11686135 chr2 4318976 T C 4.00E-06 Pulmonary function decline / / 22424883 rs6716364 chr2 4325172 C T 2.23E-05 Atopy / / 21625490 rs11123636 chr2 4327104 G T 7.31E-05 Post-operative nausea and vomiting / / 21694509 rs7586198 chr2 4327339 T C 2.34E-04 Schizophrenia / / 19197363 rs6760082 chr2 4329378 G A 6.87E-05 Serum metabolites / / 19043545 rs10171541 chr2 4344241 A G 6.88E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2030265 chr2 4349367 C T 2.60E-05 Urinary metabolites / / 21572414 rs4585039 chr2 4353141 C A 2.20E-04 Schizophrenia / / 19197363 rs11123646 chr2 4377723 A C 4.97E-05 Post-operative nausea and vomiting / / 21694509 rs4328647 chr2 4379490 T A 6.57E-05 Serum metabolites / / 19043545 rs6542705 chr2 4402182 A C 7.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3908110 chr2 4416841 C A,T 1.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs637295 chr2 4429392 C T 0.0002 Coronary artery calcification / / 23727086 rs619773 chr2 4449917 G A 4.21E-04 White matter integrity / / 22425255 rs9973340 chr2 4469132 C T 3.40E-04 Height / / 17255346 rs2677912 chr2 4471138 A G 3.68E-05 Height / / 17255346 rs634273 chr2 4474196 G A 9.86E-04 Response to alcohol consumption (flushing response) / / 24277619 rs631806 chr2 4485914 A G 5.85E-04 Alzheimer's disease / / 17998437 rs7596238 chr2 4492173 G A 9.06E-06 Personality dimensions / / 23658558 rs1453592 chr2 4516591 G A 5.06E-05 Multiple complex diseases / / 17554300 rs648196 chr2 4517511 G T 3.06E-04 Alcohol dependence / / 20201924 rs648196 chr2 4517511 G T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17555205 chr2 4541099 A G 1.64E-05 Coronary heart disease / / pha003031 rs6750002 chr2 4567844 A G 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1453600 chr2 4583424 G A 6.77E-04 Type 2 diabetes / / 17463246 rs1670530 chr2 4592241 C T 4.10E-04 Alcohol dependence / / 20201924 rs1479234 chr2 4593371 T C 1.00E-04 Information processing speed / / 21130836 rs10495505 chr2 4601562 C T 2.71E-04 Type 2 diabetes / / 17463246 rs6712089 chr2 4602607 A G 8.47E-04 Type 2 diabetes / / 17463246 rs2169943 chr2 4679290 G A 4.32E-05 Bipolar disorder LOC727982 intron 18317468 rs2619192 chr2 4700632 T G 4.52E-05 Bipolar disorder LOC727982 intron 18317468 rs17019595 chr2 4704141 A G 1.25E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs9308788 chr2 4711095 T A 3.94E-04 Bipolar disorder / / 19259986 rs10495507 chr2 4734920 C A 8.20E-04 Bipolar disorder / / 19259986 rs2218537 chr2 4737590 G A 6.51E-04 Type 2 diabetes / / 22158537 rs2592086 chr2 4805579 A G 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs825941 chr2 4807167 A T 2.18E-04 Type 2 diabetes / / 17463246 rs17019777 chr2 4807209 A G 9.20E-06 Urinary metabolites / / 21572414 rs825939 chr2 4807737 T C 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs825937 chr2 4808027 C A 4.07E-04 Multiple complex diseases / / 17554300 rs825937 chr2 4808027 C A 2.00E-07 Blood pressure / / 24954895 rs825932 chr2 4811626 A G 9.14E-04 Multiple complex diseases / / 17554300 rs825915 chr2 4818674 A G 1.44E-05 Bilirubin levels,in serum / / 19389676 rs12711955 chr2 4832338 A G 7.84E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17582650 chr2 4855471 A G 4.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1975386 chr2 4855697 A G 6.91E-04 Prostate cancer mortality / / 20978177 rs735671 chr2 4860237 C T 6.67E-04 Coronary heart disease / / 21971053 rs1866608 chr2 4865185 A G 2.24E-06 Rheumatoid arthritis / / 19503088 rs1371473 chr2 4878144 T C 6.95E-04 Coronary heart disease / / 21971053 rs1821990 chr2 4882122 C T 6.21E-04 Coronary heart disease / / 21971053 rs934993 chr2 4886084 C T 4.33E-04 Coronary heart disease / / 21971053 rs13002818 chr2 4889204 T C 2.46E-04 Telomere length / / 23900074 rs6747617 chr2 4889925 G A 7.58E-05 Coronary heart disease / / 21971053 rs6754512 chr2 4894603 A G 6.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7600533 chr2 4897836 C T 3.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10495513 chr2 4916939 G A 2.09E-04 Coronary heart disease / / 21971053 rs6542644 chr2 4930330 T C 1.94E-04 Coronary heart disease / / 21971053 rs6746310 chr2 4952797 A C 1.30E-08 Urinary metabolites / / 21572414 rs17586945 chr2 4956957 G A 7.30E-06 Urinary metabolites / / 21572414 rs934989 chr2 4957344 A G 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2255816 chr2 4958322 A T 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2620437 chr2 4958988 G A 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12615696 chr2 4962469 A G 9.19E-04 Coronary heart disease / / 21971053 rs12464103 chr2 4974780 G A 2.63E-05 Brain lesion load / / 19010793 rs28668317 chr2 5166220 G A 1.54E-05 Smoking initiation / / 24665060 rs8179663 chr2 5173840 A G 6.52E-04 Smoking initiation / / 24665060 rs4552162 chr2 5181373 G A 7.14E-04 Smoking initiation / / 24665060 rs4669203 chr2 5197986 G C 1.00E-04 Prostate cancer / / 21743057 rs12613788 chr2 5215885 C T 8.00E-05 Prostate cancer / / 21743057 rs16863306 chr2 5218148 G C 8.00E-05 Prostate cancer / / 21743057 rs12997987 chr2 5222191 C T 9.50E-04 Multiple complex diseases / / 17554300 rs10187299 chr2 5241031 A T 4.21E-04 Alzheimer's disease / / 17998437 rs10187299 chr2 5241031 A T 7.53E-05 Aortic root size / / 21223598 rs10181839 chr2 5241229 T C 4.44E-04 Alzheimer's disease / / 17998437 rs10181839 chr2 5241229 T C 7.98E-05 Aortic root size / / 21223598 rs1584832 chr2 5253424 A C 3.17E-04 Gallstones / / 17632509 rs1075309 chr2 5253598 C T 7.00E-07 Tuberculosis / / 24057671 rs4670034 chr2 5271928 C T 4.31E-04 Alzheimer's disease / / 17998437 rs17331611 chr2 5293171 C A 2.80E-05 Urinary metabolites / / 21572414 rs7609160 chr2 5326832 T A 7.71E-04 Alzheimer's disease / / 17998437 rs9287678 chr2 5340675 A G 9.32E-04 Alzheimer's disease / / 17998437 rs10210050 chr2 5344984 G A 7.96E-04 Alzheimer's disease / / 17998437 rs13419667 chr2 5412077 G A 1.14E-06 Multiple complex diseases / / 17554300 rs13385805 chr2 5413937 C T 2.24E-04 Multiple complex diseases / / 17554300 rs13004938 chr2 5437543 A G 9.00E-06 Obesity-related traits / / 23251661 rs10190732 chr2 5464761 G T 1.57E-05 Alzheimer's disease / / 21627779 rs9287696 chr2 5465154 G A 3.55E-05 Aging (time to event) / / 21782286 rs955146 chr2 5494048 T C 4.17E-05 Smoking initiation / / 24665060 rs940515 chr2 5494291 A G 1.77E-04 Smoking initiation / / 24665060 rs940516 chr2 5494701 T A 4.51E-04 Smoking initiation / / 24665060 rs11677035 chr2 5495963 C T 7.78E-04 Smoking initiation / / 24665060 rs1524490 chr2 5508545 C A 8.65E-05 Post-operative nausea and vomiting / / 21694509 rs700952 chr2 5510754 C T 8.57E-06 Type 2 diabetes / / 23300278 rs17356557 chr2 5512416 T C 1.38E-06 Type 2 diabetes / / 23300278 rs10170790 chr2 5515545 C T 2.31E-05 Post-operative nausea and vomiting / / 21694509 rs10170790 chr2 5515545 C T 7.74E-05 Insulin-related traits / / pha003063 rs1524483 chr2 5559013 T G 9.59E-04 Major depressive disorder / / 22472876 rs792087 chr2 5576619 T A 3.45E-04 Multiple complex diseases / / 17554300 rs792083 chr2 5579202 T C 5.76E-04 Multiple complex diseases / / 17554300 rs2462394 chr2 5579420 G A 5.51E-04 Multiple complex diseases / / 17554300 rs4644991 chr2 5588753 T C 8.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs813779 chr2 5590257 T C 5.81E-05 Heart Failure / / pha002885 rs10929584 chr2 5611872 A G 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4669393 chr2 5623567 C T 1.82E-04 Alzheimer's disease / / 24755620 rs11894081 chr2 5664008 G T 4.00E-09 Crohn's disease / / 23266558 rs920185 chr2 5679036 C A 9.69E-05 Response to methylphenidate treatment / / 21130132 rs920185 chr2 5679036 C A 2.50E-05 Urinary metabolites / / 21572414 rs13409347 chr2 5680264 G T 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10929647 chr2 5688365 C A 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs10929647 chr2 5688365 C A 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2882274 chr2 5688981 T C 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs13432623 chr2 5689218 C T 2.70E-05 Urinary metabolites / / 21572414 rs13390174 chr2 5689457 T C 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs13390174 chr2 5689457 T C 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17363613 chr2 5733431 C A 8.41E-05 Pancreatic cancer / / pha002874 rs16864022 chr2 5795413 A G 2.90E-05 Urinary metabolites / / 21572414 rs6740618 chr2 5818277 T G 6.42E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6740458 chr2 5818713 A T 6.58E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6735027 chr2 5818895 C A 3.52E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12621309 chr2 5819288 G A 7.04E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10929756 chr2 5819517 C T 6.38E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4547512 chr2 5821748 G T 6.61E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6734206 chr2 5824158 C G 7.51E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10206204 chr2 5825923 G T 6.56E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6432221 chr2 5828702 T G 7.74E-04 Type 2 diabetes / / 17463246 rs7604153 chr2 5852483 A G 2.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7604153 chr2 5852483 A G 3.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16864067 chr2 5860331 G A 3.50E-06 Urinary metabolites / / 21572414 rs1864263 chr2 5860402 T A 0.000194 Breast cancer early age of onset / / 18463975 rs1366733 chr2 5890171 C T 7.02E-04 Multiple complex diseases / / 17554300 rs13391560 chr2 5891097 A G 6.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2722602 chr2 5891437 C T 3.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16864170 chr2 5907880 T C 2.00E-07 Chronic kidney disease / / 20383146 rs1560238 chr2 5925857 C T 0.0000174 post-traumatic stress disorder / / 22869035 rs1560238 chr2 5925857 C T 1.74E-05 Schizophrenia / / 22883433 rs16864200 chr2 5926156 C T 0.0000169 post-traumatic stress disorder / / 22869035 rs16864200 chr2 5926156 C T 1.69E-05 Schizophrenia / / 22883433 rs16864209 chr2 5928093 T C 0.0000169 post-traumatic stress disorder / / 22869035 rs16864209 chr2 5928093 T C 1.69E-05 Schizophrenia / / 22883433 rs10495524 chr2 5931302 G A 8.88E-04 Schizophrenia / / 19197363 rs2722583 chr2 5942145 C A 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1429238 chr2 5958708 C T 7.13E-04 Type 2 diabetes / / 17463246 rs1366740 chr2 5966363 G A 4.51E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1864261 chr2 5967398 T C 7.81E-04 Type 2 diabetes / / 17463246 rs2709447 chr2 5973504 A C 3.36E-04 Schizophrenia / / 19197363 rs2709464 chr2 5985695 T C 8.90E-05 Coffee consumption / / 21357676 rs1346612 chr2 5985923 C T 2.05E-04 Type 2 diabetes / / 17846124 rs7583513 chr2 5992237 G A 1.40E-05 Multiple complex diseases / / 17554300 rs2564024 chr2 6005500 T A 1.56E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2564024 chr2 6005500 T A 2.94E-04 Type 2 diabetes / / 17463246 rs2564024 chr2 6005500 T A 2.11E-04 Alzheimer's disease / / 17998437 rs2564024 chr2 6005500 T A 6.97E-05 Serum metabolites / / 19043545 rs12617498 chr2 6010582 G C 7.94E-04 Alzheimer's disease / / 17998437 rs2564032 chr2 6020651 T C 7.54E-04 Multiple complex diseases / / 17554300 rs2564039 chr2 6029014 T C 7.18E-04 Alzheimer's disease / / 17998437 rs16864476 chr2 6039064 G T 7.75E-04 Multiple complex diseases / / 17554300 rs16864477 chr2 6039177 G A 3.75E-04 Multiple complex diseases / / 17554300 rs4257373 chr2 6052307 A G 4.24E-04 Multiple complex diseases / / 17554300 rs7586540 chr2 6052751 G A 5.00E-06 Coronary artery calcification / / 23870195 rs10495528 chr2 6057847 T C 7.28E-05 Diabetic retinopathy / / 20871662 rs10495528 chr2 6057847 T C 1.19E-05 Body Mass Index / / pha003007 rs10495528 chr2 6057847 T C 9.72E-05 Body Fat Distribution / / pha003016 rs4293540 chr2 6060989 T C 7.94E-06 Coronary artery calcification / / 23870195 rs7563310 chr2 6061966 A G 7.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs6748570 chr2 6073449 C T 2.62E-05 Bipolar disorder,schizoaffective LOC150622 intron 19567891 rs4349325 chr2 6078420 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) LOC150622 intron 20708005 rs34648212 chr2 6081657 A T 9.74E-04 Multiple complex diseases LOC150622 intron 17554300 rs13432692 chr2 6085200 C T 7.02E-06 Prostate cancer LOC150622 intron 24185611 rs12470944 chr2 6100997 A G 4.24E-05 Serum metabolites LOC150622 intron 19043545 rs6432462 chr2 6122449 T C 1.82E-05 Multiple complex diseases / / 17554300 rs1405262 chr2 6134940 T C 6.00E-06 HIV-1 control / / 20041166 rs941009 chr2 6141286 T C 6.05E-04 Stroke / / pha002887 rs2609186 chr2 6160591 G A 2.00E-04 Dietary macronutrient intake / / 23636237 rs7566764 chr2 6169727 C T 1.79E-05 Body mass (lean) / / 19268274 rs1918043 chr2 6175170 T A 2.04E-05 Body mass (lean) / / 19268274 rs1918043 chr2 6175170 T A 6.06E-04 Insulin resistance / / 21901158 rs1918041 chr2 6175506 G A 1.92E-05 Body mass (lean) / / 19268274 rs751051 chr2 6177737 G A 3.34E-05 Body mass (lean) / / 19268274 rs2609103 chr2 6181855 G A 8.07E-05 Body mass (lean) / / 19268274 rs2693818 chr2 6204508 C T 5.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12052388 chr2 6224960 T G 0.000244 Salmonella-induced pyroptosis / / 22837397 rs2693871 chr2 6234129 A G 6.22E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2249724 chr2 6235208 A C 6.22E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2350906 chr2 6249264 G A 9.11E-05 Multiple complex diseases / / 17554300 rs1852319 chr2 6252585 A G 1.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1852319 chr2 6252585 A G 5.64E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2693889 chr2 6254752 A G 6.33E-05 Blood Pressure / / pha002903 rs16864796 chr2 6295756 A G 2.57E-04 Multiple complex diseases / / 17554300 rs6722570 chr2 6300140 C T 8.79E-04 Heart Failure / / pha002885 rs10168477 chr2 6330449 T G 3.38E-05 Coronary heart disease / / pha003033 rs10495535 chr2 6381852 G A 3.40E-06 Urinary metabolites / / 21572414 rs2351100 chr2 6396424 T C 1.71E-05 Insulin-related traits / / 19902172 rs10193208 chr2 6398203 C T 1.18E-04 Multiple complex diseases / / 17554300 rs4669054 chr2 6398413 T A 4.48E-05 Body mass (lean) / / 19268274 rs10208141 chr2 6398527 T C 2.15E-04 Multiple complex diseases / / 17554300 rs4538171 chr2 6402296 C T 5.66E-04 Multiple complex diseases / / 17554300 rs16865007 chr2 6419606 C T 2.74E-04 Multiple complex diseases / / 17554300 rs6761025 chr2 6433173 G A 2.70E-05 Urinary metabolites / / 21572414 rs4337447 chr2 6434587 T C 4.37E-04 Intracranial aneurysm / / 20613766 rs2044652 chr2 6441964 G C 4.77E-04 Multiple complex diseases / / 17554300 rs16865017 chr2 6449121 A G 4.82E-04 Multiple complex diseases / / 17554300 rs7591996 chr2 6461421 A C 1.00E-08 Osteosarcoma / / 23727862 rs13403411 chr2 6478838 G A 5.20E-06 Osteosarcoma / / 23727862 rs13394549 chr2 6495748 G A 1.43E-04 Gallstones / / 17632509 rs16865088 chr2 6512470 G C 4.91E-04 Multiple complex diseases / / 17554300 rs11899039 chr2 6515225 T A 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6739653 chr2 6522333 G A 7.80E-04 Alcohol dependence / / 20201924 rs10208273 chr2 6523994 A G 2.93E-07 Osteosarcoma / / 23727862 rs11692553 chr2 6528496 A T 6.36E-05 Serum metabolites / / 19043545 rs1564032 chr2 6529504 T C 6.60E-04 Alcohol dependence / / 20201924 rs6713599 chr2 6533326 C T 2.80E-05 Urinary metabolites / / 21572414 rs6723180 chr2 6551857 A G 5.90E-04 Alcohol dependence / / 20201924 rs6726264 chr2 6551873 T C 5.90E-04 Alcohol dependence / / 20201924 rs13027881 chr2 6555933 G A 3.76E-06 Parkinson's disease / / pha002868 rs6734894 chr2 6556781 G A 4.63E-06 Parkinson's disease / / pha002868 rs7577180 chr2 6561446 C T 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4669069 chr2 6570758 T C 0.00003 Follicular lymphoma / / 23025665 rs1462061 chr2 6606787 G A 3.45E-04 Alzheimer's disease / / 17998437 rs306196 chr2 6627807 A G 7.59E-04 Multiple complex diseases / / 17554300 rs4668498 chr2 6641549 T G 7.72E-04 Insulin resistance / / 21901158 rs16865301 chr2 6657760 C T 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs17386094 chr2 6661264 A C 2.60E-05 Urinary metabolites / / 21572414 rs12465667 chr2 6661877 T C 1.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4669075 chr2 6679793 C A 7.33E-04 Alzheimer's disease / / 24755620 rs10495537 chr2 6694519 C T 5.00E-07 Visceral adipose tissue adjusted for BMI / / 22589738 rs1870131 chr2 6695161 C T 2.63E-05 stroke (ischemic) / / 17434096 rs962528 chr2 6697088 C T 8.00E-06 Visceral fat / / 22589738 rs1350342 chr2 6703089 G A 3.09E-04 Atopy / / 21625490 rs12998104 chr2 6729633 C T 5.08E-04 Depression (quantitative trait) / / 20800221 rs12998104 chr2 6729633 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs13401852 chr2 6733673 G A 4.78E-04 Depression (quantitative trait) / / 20800221 rs13401852 chr2 6733673 G A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs13393305 chr2 6734181 A G 4.69E-04 Depression (quantitative trait) / / 20800221 rs13383761 chr2 6735155 C T 5.52E-04 Depression (quantitative trait) / / 20800221 rs13383761 chr2 6735155 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6732257 chr2 6739006 C A 3.91E-04 Depression (quantitative trait) / / 20800221 rs6732257 chr2 6739006 C A 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1461312 chr2 6743067 A T 3.87E-04 Depression (quantitative trait) / / 20800221 rs1461312 chr2 6743067 A T 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6717016 chr2 6747503 G A 3.81E-04 Depression (quantitative trait) / / 20800221 rs6717016 chr2 6747503 G A 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13387837 chr2 6754148 G A 4.13E-04 Depression (quantitative trait) / / 20800221 rs13387837 chr2 6754148 G A 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10204937 chr2 6758874 A G 5.95E-04 Depression (quantitative trait) / / 20800221 rs10204937 chr2 6758874 A G 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs4668504 chr2 6758957 G A 2.74E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7575004 chr2 6761631 C T 5.96E-04 Depression (quantitative trait) / / 20800221 rs7584788 chr2 6769318 C T 5.19E-04 Bone mass and geometry / / 17903296 rs7584788 chr2 6769318 C T 4.54E-04 Depression (quantitative trait) / / 20800221 rs7584788 chr2 6769318 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12692323 chr2 6772729 T A 4.30E-04 Depression (quantitative trait) / / 20800221 rs12692323 chr2 6772729 T A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs376286195 chr2 6774326 C CTTA 1.69E-04 Depression (quantitative trait) / / 20800221 rs376286195 chr2 6774326 C CTTA 0.0000073 Cytarabine sensitivity / / 23538338 rs6714052 chr2 6774326 C A,T 1.69E-04 Depression (quantitative trait) / / 20800221 rs6714052 chr2 6774326 C A,T 0.0000073 Cytarabine sensitivity / / 23538338 rs76628858 chr2 6774326 C CTTA 1.69E-04 Depression (quantitative trait) / / 20800221 rs76628858 chr2 6774326 C CTTA 0.0000073 Cytarabine sensitivity / / 23538338 rs13421943 chr2 6777264 C T 3.93E-04 Depression (quantitative trait) / / 20800221 rs7561212 chr2 6781149 G A 1.95E-04 Depression (quantitative trait) / / 20800221 rs7561212 chr2 6781149 G A 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505696 chr2 6851269 T C 9.40E-05 Longevity / / 22279548 rs307992 chr2 6851976 T C 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs307993 chr2 6852369 G A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs307995 chr2 6852972 T C 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs307996 chr2 6853387 T C 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs307997 chr2 6853468 T C 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs13413734 chr2 6866483 A G 9.30E-06 Brachial circumference / / 22479309 rs1870744 chr2 6871849 T C 9.74E-04 Alzheimer's disease / / 24755620 rs11681428 chr2 6880984 T C 9.95E-04 Alzheimer's disease LINC00487 intron 24755620 rs17650774 chr2 6913020 A G 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11683777 chr2 6922783 C T 5.77E-05 Depression (quantitative trait) / / 23290196 rs905968 chr2 6935239 C T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs16865587 chr2 6935623 C T 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4668508 chr2 6936085 G A 7.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs7588087 chr2 6936616 T A 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2174519 chr2 6937310 T C 4.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200467 chr2 6937593 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs6742876 chr2 6937744 T C 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6742989 chr2 6937849 T C 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4613245 chr2 6938163 C T 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4458187 chr2 6938308 A G 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs16865600 chr2 6939346 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505695 chr2 6940217 T C 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs113498426 chr2 6940819 A AT 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1847735 chr2 6940819 A T 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505694 chr2 6940956 C T 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7600900 chr2 6941288 A C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7606696 chr2 6941519 T C 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6712193 chr2 6942043 G A 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1448871 chr2 6942690 A G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10495544 chr2 6956133 A C 6.51E-05 Serum metabolites / / 19043545 rs113470953 chr2 6976394 T C 3.57E-05 Intracerebral hemorrhage / / 24656865 rs10495545 chr2 6990020 C T 8.88E-05 AIDS progression CMPK2 cds-synon 19115949 rs4669112 chr2 7028652 C T 1.62E-04 Smoking cessation RSAD2 intron 18519826 rs16865717 chr2 7032618 T C 9.00E-09 Venous thromboembolism (gene x gene interaction) RSAD2 intron 23509962 rs4669114 chr2 7036621 A G 2.11E-05 Sudden cardiac arrest RSAD2 UTR-3 21658281 rs1013864 chr2 7051171 G A 1.21E-05 Graves' disease / / 21841780 rs3806609 chr2 7056183 T C 2.00E-05 Graves' disease LOC386597 intron 21841780 rs771274 chr2 7060629 C T 2.22E-04 Graves' disease RNF144A intron 21841780 rs10495547 chr2 7062123 G A 4.12E-05 Schizophrenia RNF144A intron 20832056 rs720388 chr2 7068927 T C 1.80E-04 Aortic root size RNF144A intron 21223598 rs1797557 chr2 7080792 C T 4.65E-04 Aortic root size RNF144A intron 21223598 rs3772022 chr2 7085569 C T 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF144A intron 20877124 rs3772019 chr2 7096989 A G 8.60E-06 Urinary metabolites RNF144A intron 21572414 rs771315 chr2 7097523 T C 4.76E-05 Smoking cessation RNF144A intron 18519826 rs3772017 chr2 7097845 C G 1.20E-04 Smoking cessation RNF144A intron 18519826 rs3772017 chr2 7097845 C G 2.20E-05 Urinary metabolites RNF144A intron 21572414 rs3772016 chr2 7098007 C G 2.50E-05 Urinary metabolites RNF144A intron 21572414 rs771318 chr2 7101720 A G 4.92E-04 Multiple complex diseases RNF144A intron 17554300 rs771319 chr2 7101811 C T 4.94E-04 Multiple complex diseases RNF144A intron 17554300 rs771320 chr2 7104166 A C 2.22E-04 Smoking quantity RNF144A intron 24665060 rs3772002 chr2 7111899 G T 5.76E-04 Smoking quantity RNF144A intron 24665060 rs3836204 chr2 7111899 G GT 5.76E-04 Smoking quantity RNF144A intron 24665060 rs543410060 chr2 7111899 G GT 5.76E-04 Smoking quantity RNF144A intron 24665060 rs3771997 chr2 7119618 G A 7.84E-04 Smoking quantity RNF144A intron 24665060 rs11685858 chr2 7142180 G C 6.89E-04 Multiple complex diseases RNF144A intron 17554300 rs6741819 chr2 7147973 C T 9.50E-04 Multiple complex diseases RNF144A intron 17554300 rs6741819 chr2 7147973 C T 2.00E-07 Response to antipsychotic treatment RNF144A intron 20195266 rs2460405 chr2 7149509 A G 1.37E-04 Body mass index RNF144A intron 21701565 rs447721 chr2 7150330 C T 3.49E-04 Lung function (forced expiratory volume in 1 second) RNF144A intron 17255346 rs447721 chr2 7150330 C T 1.35E-04 Body mass index RNF144A intron 21701565 rs445411 chr2 7150527 T C 2.05E-04 Body mass index RNF144A intron 21701565 rs381214 chr2 7150654 C T 1.35E-04 Body mass index RNF144A intron 21701565 rs388773 chr2 7150758 G A,C,T 3.34E-04 Body mass index RNF144A intron 21701565 rs412098 chr2 7151074 A G 4.98E-04 Amyotrophic lateral sclerosis (sporadic) RNF144A intron 24529757 rs420013 chr2 7161586 C A 1.21E-04 Stroke RNF144A intron pha002887 rs16865853 chr2 7171364 C T 7.19E-05 Blood pressure (response to angiotensin II receptor blocker) RNF144A intron 24192120 rs16865867 chr2 7186608 G A 7.40E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs6722170 chr2 7187199 A G 7.40E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs309295 chr2 7188238 G A 4.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs89983 chr2 7195192 C A 4.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs309271 chr2 7202496 T G 9.04E-04 Stroke / / pha002887 rs6746899 chr2 7203328 A G 7.14E-04 Multiple complex diseases / / 17554300 rs6431850 chr2 7248419 C T 1.78E-04 Cholesterol / / 17255346 rs7557365 chr2 7346878 C T 8.41E-04 Multiple complex diseases / / 17554300 rs4669156 chr2 7350916 C A 2.91E-04 Multiple complex diseases / / 17554300 rs1404845 chr2 7353714 C A 1.16E-04 Multiple complex diseases / / 17554300 rs1016516 chr2 7371689 A G 1.97E-04 Multiple complex diseases / / 17554300 rs2140855 chr2 7387447 C T 5.20E-04 Body mass index / / 21701565 rs7599262 chr2 7396577 G T 6.35E-05 Body Fat Distribution / / pha003017 rs7599262 chr2 7396577 G T 5.55E-05 Body Fat Distribution / / pha003018 rs10182781 chr2 7431359 T C 4.66E-06 Coronary heart disease / / 22319020 rs17681533 chr2 7439390 C T 3.11E-04 Multiple complex diseases / / 17554300 rs4669177 chr2 7445627 T C 2.43E-04 Multiple complex diseases / / 17554300 rs1430289 chr2 7454360 T C 7.49E-05 Multiple complex diseases / / 17554300 rs10179297 chr2 7460260 T C 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11682970 chr2 7477186 T C 4.81E-05 Post-operative nausea and vomiting / / 21694509 rs2352714 chr2 7490156 A G 8.20E-05 Major depressive disorder / / pha002850 rs12469647 chr2 7502642 A G 2.30E-05 Urinary metabolites / / 21572414 rs13030633 chr2 7517620 C T 9.87E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs12623931 chr2 7520946 A C 1.70E-06 Urinary metabolites / / 21572414 rs1367272 chr2 7561886 C T 1.77E-04 adolescent idiopathic scoliosis LOC100506274 intron 24023777 rs8179776 chr2 7564293 T G 7.50E-05 Temporomandibular joint disorders LOC100506274 intron 23746317 rs7608732 chr2 7583311 A C 2.40E-04 Celiac disease LOC100506274 intron 23936387 rs12692335 chr2 7606695 C T 0.000069 Uterine leiomyomata / / 23040493 rs6431885 chr2 7656440 T C 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6431885 chr2 7656440 T C 5.79E-05 Blood Pressure / / pha003049 rs10519830 chr2 7657807 A G 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7604664 chr2 7659087 G A 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs985268 chr2 7659201 G A 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7589284 chr2 7702036 C T 8.52E-05 Femoral neck bone geometry / / 22087292 rs11682922 chr2 7794936 G T 3.45E-07 Insulin-related traits / / 22791750 rs1720971 chr2 7822218 T C 7.78E-04 Insulin resistance / / 21901158 rs812811 chr2 7829406 A G 4.98E-04 Type 2 diabetes / / 17463246 rs772438 chr2 7831600 C G 2.62E-04 Type 2 diabetes / / 17463246 rs11676467 chr2 7833261 C T 5.46E-05 Cognitive test performance / / 20125193 rs10495558 chr2 7836151 T C 2.84E-04 Type 2 diabetes / / 17463246 rs10495558 chr2 7836151 T C 5.30E-05 Response to statin therapy / / 20339536 rs2948927 chr2 7856399 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2948926 chr2 7862742 G T 7.94E-05 Smoking initiation / / 24665060 rs41506246 chr2 7873892 G C 2.84E-05 Smoking initiation / / 24665060 rs12692341 chr2 7883907 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs812810 chr2 7886879 C T 8.09E-04 Iron levels / / pha002876 rs10206339 chr2 7891122 A G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13395925 chr2 7893850 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs772428 chr2 7897634 G A 1.32E-04 Body mass index / / 21701565 rs13386694 chr2 7899580 A G 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs13386820 chr2 7899688 A C 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10929497 chr2 7899972 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13392332 chr2 7899987 T A 8.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2140456 chr2 7921457 G A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs954498 chr2 7922920 G T 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200068 chr2 7928447 C T 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6760840 chr2 7930884 G T 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11683873 chr2 7931803 G A 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs867399 chr2 7933490 C T 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs17440033 chr2 7934583 C T 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12105768 chr2 7942739 G A 3.00E-06 Urinary metabolites / / 21572414 rs7561052 chr2 7949693 C T 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10166962 chr2 7950796 G A 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12692343 chr2 7951843 C T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1014431 chr2 7957112 T A 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs798443 chr2 7968275 G A 4.65E-05 Serum metabolites / / 19043545 rs2193071 chr2 8036260 G A 4.00E-06 Obesity-related traits / / 23251661 rs4669226 chr2 8053597 A G 5.00E-06 Multiple sclerosis / / 23412934 rs41009 chr2 8095158 A G 7.74E-04 Type 2 diabetes LOC339788 intron 17463246 rs6431912 chr2 8097807 C T 4.65E-05 Multiple complex diseases LOC339788 intron 17554300 rs193932 chr2 8107383 T C 8.75E-05 Type 2 diabetes LOC339788 intron 17463246 rs193931 chr2 8107435 G A 8.02E-05 Type 2 diabetes LOC339788 intron 17463246 rs193929 chr2 8107620 G T 6.55E-05 Type 2 diabetes LOC339788 intron 17463246 rs41007 chr2 8109043 C T 7.87E-05 Type 2 diabetes LOC339788 intron 17463246 rs13430914 chr2 8114648 G A 2.51E-05 Type 2 diabetes LOC339788 intron 17463246 rs17433703 chr2 8115300 C T 2.17E-05 Type 2 diabetes LOC339788 intron 17463246 rs1974696 chr2 8115782 G A 8.12E-05 Type 2 diabetes LOC339788 intron 17463246 rs6736759 chr2 8158653 A G 1.16E-04 Multiple complex diseases LINC00299 intron 17554300 rs7579823 chr2 8160356 C T 5.70E-05 HIV-1 control LINC00299 intron 20041166 rs6752439 chr2 8162049 T C 5.70E-05 HIV-1 control LINC00299 intron 20041166 rs6431918 chr2 8166518 G A 2.98E-04 Multiple complex diseases LINC00299 intron 17554300 rs7600576 chr2 8229484 C G 7.30E-05 Personality dimensions LINC00299 intron 18957941 rs6712604 chr2 8235239 T C 2.14E-05 Partial epilepsies LINC00299 intron 20522523 rs12479058 chr2 8278854 G T 3.73E-06 Schizophrenia LINC00299 intron 22037555 rs7591430 chr2 8287950 T C 6.53E-05 Schizophrenia LINC00299 intron 19571809 rs7591430 chr2 8287950 T C 5.64E-05 Schizophrenia LINC00299 intron pha002859 rs4669243 chr2 8302971 T C 1.43E-06 Nasopharyngeal carcinoma LINC00299 intron 23209447 rs4668564 chr2 8308813 C T 6.23E-06 Nasopharyngeal carcinoma LINC00299 intron 23209447 rs17389911 chr2 8365872 A G 4.40E-04 Multiple complex diseases LINC00299 intron 17554300 rs7595804 chr2 8424313 T C 3.54E-04 Suicide attempts in bipolar disorder LINC00299 intron 21423239 rs6747626 chr2 8424848 T C 2.07E-04 Suicide attempts in bipolar disorder LINC00299 intron 21423239 rs3097276 chr2 8432132 C T 3.16E-05 IgE levels LINC00299 intron 22075330 rs3102947 chr2 8434185 G C 2.00E-07 IgE levels LINC00299 intron 22075330 rs2931130 chr2 8434948 A G 2.34E-04 Glycosylated haemoglobin levels / / 17255346 rs2931130 chr2 8434948 A G 3.27E-05 IgE levels / / 22075330 rs346835 chr2 8438693 C T 2.30E-07 Self-reported allergy LINC00299 intron 23817569 rs10165200 chr2 8439629 G A 4.43E-04 Self-reported allergy LINC00299 intron 23817569 rs13416555 chr2 8441735 C G 1.19E-07 Self-reported allergy LINC00299 intron 23817569 rs10174949 chr2 8442248 G A 1.00E-07 Self-reported allergy LINC00299 intron 23817569 rs891058 chr2 8442547 G A 1.41E-07 Self-reported allergy LINC00299 intron 23817569 rs10178845 chr2 8443803 G A 1.31E-07 Self-reported allergy LINC00299 intron 23817569 rs3111414 chr2 8443859 C G 1.68E-04 Self-reported allergy LINC00299 intron 23817569 rs4315494 chr2 8446377 A G 1.18E-04 Obesity (early onset extreme) LINC00299 intron 23563609 rs4315494 chr2 8446377 A G 8.69E-04 Amyotrophic lateral sclerosis (sporadic) LINC00299 intron 24529757 rs367023 chr2 8450123 A G 2.02E-07 Self-reported allergy LINC00299 intron 23817569 rs439614 chr2 8451479 C T 3.74E-04 Self-reported allergy LINC00299 intron 23817569 rs13395467 chr2 8451498 A G 3.66E-07 Self-reported allergy LINC00299 intron 23817569 rs404236 chr2 8456003 A G 4.88E-05 IgE levels LINC00299 intron 22075330 rs3097289 chr2 8459193 T C 4.65E-05 IgE levels LINC00299 intron 22075330 rs3856439 chr2 8459404 C T 2.69E-07 Self-reported allergy LINC00299 intron 23817569 rs2562016 chr2 8459808 G C 4.58E-05 IgE levels LINC00299 intron 22075330 rs10210006 chr2 8466486 C G 4.07E-07 Self-reported allergy LINC00299 intron 23817569 rs2914424 chr2 8466915 T A 3.72E-05 IgE levels LINC00299 intron 22075330 rs3102956 chr2 8467444 A G 3.68E-05 IgE levels LINC00299 intron 22075330 rs7567352 chr2 8471236 C T 2.36E-06 Self-reported allergy / / 23817569 rs2931136 chr2 8481299 A T 5.74E-06 Self-reported allergy / / 23817569 rs9287698 chr2 8487296 C T 9.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs9287698 chr2 8487296 C T 5.51E-06 Self-reported allergy / / 23817569 rs1807241 chr2 8488143 G C 9.96E-06 Self-reported allergy / / 23817569 rs41403046 chr2 8497069 C T 3.56E-04 Multiple complex diseases / / 17554300 rs6431935 chr2 8501473 A C 2.76E-04 Self-reported allergy / / 23817569 rs4669253 chr2 8502239 G A 2.04E-04 Self-reported allergy / / 23817569 rs12623235 chr2 8508080 G A 2.36E-04 Type 2 diabetes / / 17463246 rs6761309 chr2 8520508 G A 2.92E-05 Serum metabolites / / 19043545 rs7425561 chr2 8521327 T A 8.51E-05 Serum metabolites / / 19043545 rs13008689 chr2 8530256 G A 4.35E-05 Serum metabolites / / 19043545 rs13008689 chr2 8530256 G A 1.00E-06 Longevity / / 20834067 rs4076706 chr2 8531037 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs409169 chr2 8556084 A G 3.17E-04 Self-reported allergy / / 23817569 rs1017920 chr2 8559180 G A 5.48E-04 Stroke / / pha002887 rs1032840 chr2 8560247 A G 3.00E-05 Cognitive function / / 24684796 rs1872602 chr2 8561695 T G 1.80E-05 Odorant perception / / 23910658 rs2630720 chr2 8571477 G A 3.06E-04 Testicular dysgenesis syndrome / / 22140272 rs6715753 chr2 8577361 A T 9.70E-04 Insulin resistance / / 21901158 rs10929532 chr2 8684458 T C 9.45E-05 Insulin resistance / / 21901158 rs11680487 chr2 8684540 G T 1.22E-04 Insulin resistance / / 21901158 rs345901 chr2 8691839 A G 9.80E-06 Urinary metabolites / / 21572414 rs3856444 chr2 8745998 C G 1.65E-07 Red blood cell traits / / 23222517 rs13398673 chr2 8753026 A G 2.80E-05 Urinary metabolites / / 21572414 rs12993630 chr2 8753269 C T 3.81E-07 Red blood cell traits / / 23222517 rs3896594 chr2 8762414 T G 8.19E-07 Red blood cell traits / / 23222517 rs4669318 chr2 8770564 G A 5.70E-04 Obesity (extreme) / / 21935397 rs1344807 chr2 8775493 G A 9.98E-05 Cognitive performance / / 19734545 rs4442969 chr2 8809061 C T 4.79E-05 Orofacial clefts / / 22419666 rs10188643 chr2 8810425 C T 2.06E-05 Orofacial clefts / / 22419666 rs10189304 chr2 8828645 G A 2.60E-05 Urinary metabolites / / 21572414 rs4668589 chr2 8850817 G A 3.53E-04 Aortic root size / / 21223598 rs9789497 chr2 8858736 T C 4.24E-04 Type 2 diabetes / / 17463246 rs6753855 chr2 8863392 A G 2.14E-06 Platelet counts / / 21507922 rs1550250 chr2 8917977 G A 2.51E-04 Type 2 diabetes KIDINS220 intron 17463246 rs12329306 chr2 8926883 C T 2.60E-04 Type 2 diabetes KIDINS220 intron 17463246 rs7587928 chr2 8949070 T C 2.00E-07 Neutrophil count KIDINS220 intron 21507922 rs13008971 chr2 8980472 A C 6.00E-07 Schizophrenia / / 21926974 rs11894892 chr2 8981020 C A 9.70E-05 Basophils / / pha003087 rs10495560 chr2 8989184 C T 7.77E-04 Type 2 diabetes / / 17463246 rs2221868 chr2 9177204 T C 5.32E-04 Type 2 diabetes / / 17463246 rs16866900 chr2 9247025 A C 6.72E-04 Type 2 diabetes / / 17463246 rs907159 chr2 9250007 T C 2.50E-05 Urinary metabolites / / 21572414 rs1109670 chr2 9250038 C A 9.00E-06 Multiple sclerosis / / 19010793 rs1109670 chr2 9250038 C A 8.04E-04 Body mass index / / 21701565 rs2015061 chr2 9256210 T C 1.14E-27 Narcolepsy / / 19629137 rs9636252 chr2 9259598 T C 3.00E-06 IgG glycosylation / / 23382691 rs6743450 chr2 9269554 A G 6.05E-04 Rheumatoid arthritis / / 21452313 rs6743450 chr2 9269554 A G 7.86E-04 Body mass index / / 21701565 rs6743450 chr2 9269554 A G 8.05E-04 Body mass index / / 21701565 rs6736097 chr2 9281704 C T 9.17E-04 Rheumatoid arthritis / / 21452313 rs1344185 chr2 9290324 A G 4.53E-04 Alzheimer's disease (late onset) / / 21379329 rs10198885 chr2 9307900 C G 1.37E-04 Multiple complex diseases / / 17554300 rs6431983 chr2 9310604 A C 1.00E-04 Information processing speed / / 21130836 rs4669378 chr2 9315483 T C 7.10E-05 Obesity,menopause / / 21424828 rs41359346 chr2 9320577 G A 4.74E-04 Multiple complex diseases / / 17554300 rs12692379 chr2 9324513 C T 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6743148 chr2 9340227 A C 5.95E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16866958 chr2 9352517 G A 2.64E-04 Alzheimer's disease (late onset) ASAP2 intron 21379329 rs9287705 chr2 9353255 G T 1.05E-05 Coronary heart disease ASAP2 intron pha003035 rs12479189 chr2 9354669 G A 8.89E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs12479189 chr2 9354669 G A 1.38E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs11897394 chr2 9357533 T C 3.34E-05 Coronary heart disease ASAP2 intron pha003035 rs2666219 chr2 9403822 C T 2.13E-04 Alzheimer's disease (late onset) ASAP2 intron 21379329 rs7605582 chr2 9416090 G A 2.00E-04 Cognitive impairment induced by topiramate ASAP2 intron 22091778 rs10192751 chr2 9419106 G T 4.08E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10193254 chr2 9419583 G A 6.79E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs4669381 chr2 9422788 A G 1.77E-05 Waist Circumference ASAP2 intron pha003025 rs4669381 chr2 9422788 A G 9.91E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs12472609 chr2 9427591 A G 5.18E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs7588636 chr2 9430778 G A 9.82E-05 Body Mass Index ASAP2 intron pha003007 rs7588636 chr2 9430778 G A 7.98E-06 Waist Circumference ASAP2 intron pha003025 rs7588636 chr2 9430778 G A 8.08E-05 Weight ASAP2 intron pha003027 rs7588636 chr2 9430778 G A 7.83E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs3811600 chr2 9437413 C T 4.89E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10203328 chr2 9459986 T G 9.19E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs10203328 chr2 9459986 T G 1.48E-05 Waist Circumference ASAP2 intron pha003025 rs10203328 chr2 9459986 T G 6.42E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs12475160 chr2 9463454 C T 5.87E-05 Body Mass Index ASAP2 intron pha003007 rs12475160 chr2 9463454 C T 5.29E-06 Waist Circumference ASAP2 intron pha003025 rs12475160 chr2 9463454 C T 2.87E-05 Weight ASAP2 intron pha003027 rs12475160 chr2 9463454 C T 7.05E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10181704 chr2 9465687 G T 3.24E-05 Waist Circumference ASAP2 intron pha003025 rs10181704 chr2 9465687 G T 9.97E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs7569295 chr2 9467815 C T 9.98E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs7569295 chr2 9467815 C T 1.68E-05 Waist Circumference ASAP2 intron pha003025 rs7569295 chr2 9467815 C T 6.93E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs116567340 chr2 9485625 G A 9.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ASAP2 intron 24159190 rs116252892 chr2 9489788 G A 9.65E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ASAP2 intron 24159190 rs2709580 chr2 9514573 T C 4.48E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs2709586 chr2 9517647 A G 5.82E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10186062 chr2 9542286 G A 6.94E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs10186062 chr2 9542286 G A 2.53E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10929579 chr2 9547171 G A 4.40E-04 Lymphocyte counts ITGB1BP1 intron 22286170 rs12474647 chr2 9554280 A T 2.49E-04 Coronary heart disease ITGB1BP1 intron 21606135 rs12151757 chr2 9595145 T C 8.00E-04 Type 2 diabetes CPSF3 intron 17463246 rs116264366 chr2 9618822 G A 8.44E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) IAH1 intron 24159190 rs56237316 chr2 9637331 A G 0.000023 Prostate cancer ADAM17 cds-synon 23555315 rs56237316 chr2 9637331 A G 0.000029 Prostate cancer (non-advanced prostate cancer) ADAM17 cds-synon 23555315 rs12467921 chr2 9643688 A G 9.12E-06 Stroke (ischemic) ADAM17 intron 22941190 rs55794209 chr2 9645632 C A 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ADAM17 intron 24159190 rs2276338 chr2 9645789 C T 8.66E-06 Stroke (ischemic) ADAM17 intron 22941190 rs7580419 chr2 9646388 C T 8.93E-06 Stroke (ischemic) ADAM17 intron 22941190 rs10211522 chr2 9648215 C T 9.25E-06 Stroke (ischemic) ADAM17 intron 22941190 rs17590793 chr2 9648374 G C 9.65E-06 Stroke (ischemic) ADAM17 intron 22941190 rs10929587 chr2 9662820 T A 8.60E-04 Primary sclerosing cholangitis ADAM17 intron 19944697 rs2230818 chr2 9667930 T A,C 8.63E-09 Triglycerides ADAM17 STOP-GAIN 23063622 rs17362650 chr2 9676413 T C 8.00E-06 Alcohol dependence (age at onset) ADAM17 intron 24962325 rs17525614 chr2 9679854 T C 7.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADAM17 intron 20031582 rs10179642 chr2 9683696 T C 2.00E-04 Cognitive impairment induced by topiramate ADAM17 intron 22091778 rs6432018 chr2 9721896 C A 8.00E-07 Heart rate variability traits / / 22174390 rs10495572 chr2 9734859 G C 6.74E-04 Multiple complex diseases YWHAQ intron 17554300 rs10495571 chr2 9736066 A G 6.05E-04 Multiple complex diseases YWHAQ intron 17554300 rs74416513 chr2 9745256 C T 4.63E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) YWHAQ intron 24159190 rs16867083 chr2 9767441 T C 4.88E-04 Multiple complex diseases YWHAQ intron 17554300 rs17362902 chr2 9768564 A G 1.23E-04 Multiple complex diseases YWHAQ intron 17554300 rs4669402 chr2 9779413 G C 5.45E-04 Coronary heart disease / / 21606135 rs4669403 chr2 9782132 C A,T 3.91E-04 Smoking initiation / / 24665060 rs868095 chr2 9783689 G A 0.000798 Salmonella-induced pyroptosis / / 22837397 rs16867116 chr2 9815766 C T 4.36E-04 Insulin resistance / / 21901158 rs13422603 chr2 9823306 G C 8.03E-04 Multiple complex diseases / / 17554300 rs6741886 chr2 9832407 G A 7.77E-05 Major depressive disorder / / 21621269 rs1877947 chr2 9881989 G A 1.59E-04 Multiple complex diseases / / 17554300 rs4668644 chr2 9890804 A G 6.77E-05 Major depressive disorder / / 19107115 rs13412895 chr2 9893454 T C 6.24E-05 Major depressive disorder / / 19107115 rs16867155 chr2 9902902 A G 1.63E-04 Smoking initiation / / 24665060 rs4145374 chr2 9903788 T A,C 2.14E-04 Smoking initiation / / 24665060 rs13395893 chr2 9913515 T G 9.90E-04 Type 2 diabetes / / 23209189 rs4669458 chr2 9922283 T C 4.11E-05 Anxiety and major depressive disorder / / 24047446 rs2357266 chr2 9924387 A G 4.00E-06 Self-rated health / / 20707712 rs17363477 chr2 9931094 A G 5.67E-05 Recombination rate / / 21698098 rs4669466 chr2 9937035 A G 1.31E-05 Type 2 diabetes / / 17463246 rs16867169 chr2 9941529 T A 4.80E-06 Urinary metabolites / / 21572414 rs16867170 chr2 9948475 T G 2.27E-04 Multiple complex diseases / / 17554300 rs16867173 chr2 9948737 T C 1.94E-04 Multiple complex diseases / / 17554300 rs908296 chr2 9954768 T C 6.60E-04 Multiple complex diseases / / 17554300 rs4027379 chr2 9964370 C T 9.61E-05 Cognitive decline / / 22054870 rs287980 chr2 9971366 G A 5.88E-05 Cholesterol / / 17255346 rs1469544 chr2 9988348 T G 5.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs16867195 chr2 9989442 A G 6.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs1014509 chr2 9996156 T C 5.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs438762 chr2 10035870 T A 1.71E-05 Lymphocyte counts TAF1B intron 22286170 rs112736747 chr2 10059654 C G 7.16E-06 Osteoarthritis TAF1B intron 21871595 rs3828260 chr2 10094442 C A 6.79E-05 Lipoproteins GRHL1 intron pha003079 rs2303918 chr2 10094992 A G 6.18E-04 Multiple complex diseases GRHL1 intron 17554300 rs6708858 chr2 10098227 T C 3.03E-05 Serum metabolites GRHL1 intron 19043545 rs1897164 chr2 10111901 T C 3.42E-05 Bilirubin levels,in serum GRHL1 intron 19389676 rs11902236 chr2 10117868 C T 3.00E-08 Prostate cancer GRHL1 intron 23535732 rs3791760 chr2 10118424 T C 0.00087 Salmonella-induced pyroptosis GRHL1 intron 22837397 rs2011516 chr2 10120605 A G 3.54E-04 Alzheimer's disease GRHL1 intron 22005930 rs6756056 chr2 10160082 C T 8.27E-05 Femoral neck bone geometry / / 22087292 rs6727702 chr2 10175442 C A 9.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4669519 chr2 10179042 A G 8.27E-04 Parkinson's disease / / 17052657 rs4233877 chr2 10241915 T G 0.000399401 Hypertension (early onset hypertension) / / 22479346 rs6741290 chr2 10264709 T C 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RRM2 intron 20877124 rs2241113 chr2 10275746 A C 2.73E-04 Type 2 diabetes / / 17463246 rs2241113 chr2 10275746 A C 1.40E-10 Blood pressure / / 21996601 rs717886 chr2 10275814 T C 1.98E-04 Type 2 diabetes / / 17463246 rs2110641 chr2 10291414 G C 3.10E-08 Blood pressure C2orf48 intron 21996601 rs10197121 chr2 10293689 C T 5.93E-04 Type 2 diabetes C2orf48 intron 17463246 rs10197121 chr2 10293689 C T 3.27E-07 Blood pressure C2orf48 intron 21996601 rs13424629 chr2 10296486 T C 3.83E-07 Blood pressure C2orf48 intron 21996601 rs4668669 chr2 10348018 C T 0.0000404 Placental abruption C2orf48 intron 23205182 rs7566637 chr2 10422939 C T 3.20E-05 Major depressive disorder (broad) / / 20038947 rs2884208 chr2 10440987 T C 1.42E-05 Cognitive test performance / / 20125193 rs6734475 chr2 10450398 G A 6.19E-04 Amyotrophic lateral sclerosis (sporadic) HPCAL1 intron 24529757 rs11694489 chr2 10462852 C T 5.81E-06 Response to tocilizumab in rheumatoid arthritis HPCAL1 intron 22491018 rs16856119 chr2 10467823 C T 3.58E-06 Response to tocilizumab in rheumatoid arthritis HPCAL1 intron 22491018 rs1003652 chr2 10468296 A C 0.00089889 Hypertension (early onset hypertension) HPCAL1 intron 22479346 rs6745569 chr2 10476532 T C 1.49E-05 Hemoglobin HPCAL1 intron pha003096 rs6745569 chr2 10476532 T C 4.41E-05 Hematocrit HPCAL1 intron pha003097 rs1558628 chr2 10478422 T C 9.96E-06 Hemoglobin HPCAL1 intron pha003096 rs1558628 chr2 10478422 T C 3.68E-05 Hematocrit HPCAL1 intron pha003097 rs4669573 chr2 10478936 A G 2.46E-04 Multiple complex diseases HPCAL1 intron 17554300 rs4669573 chr2 10478936 A G 3.67E-06 Alzheimer's disease HPCAL1 intron 21059989 rs4669573 chr2 10478936 A G 5.26E-05 Alzheimer's disease HPCAL1 intron 21059989 rs6758633 chr2 10480201 T C 3.03E-06 Hemoglobin HPCAL1 intron pha003096 rs6758633 chr2 10480201 T C 2.02E-05 Hematocrit HPCAL1 intron pha003097 rs6743846 chr2 10480415 C T 3.03E-06 Hemoglobin HPCAL1 intron pha003096 rs6743846 chr2 10480415 C T 2.02E-05 Hematocrit HPCAL1 intron pha003097 rs10197851 chr2 10485409 A G 1.02E-04 Alzheimer's disease HPCAL1 intron 21059989 rs10197851 chr2 10485409 A G 7.13E-06 Alzheimer's disease HPCAL1 intron 21059989 rs10181190 chr2 10489290 C T 2.30E-05 Urinary metabolites HPCAL1 intron 21572414 rs2884210 chr2 10501681 G T 8.20E-06 Magnesium levels HPCAL1 intron pha003092 rs11677361 chr2 10502733 A G 6.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6755271 chr2 10510040 A G 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6721270 chr2 10521126 A G 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6721270 chr2 10521126 A G 7.37E-04 Response to taxane treatment (placlitaxel) HPCAL1 intron 23006423 rs10198351 chr2 10524780 C T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs10198351 chr2 10524780 C T 6.45E-04 Response to taxane treatment (placlitaxel) HPCAL1 intron 23006423 rs11888704 chr2 10530325 G T 3.63E-05 Cognitive decline HPCAL1 intron 22054870 rs4142237 chr2 10530550 A G 1 Drug response to Etoposide HPCAL1 intron 17537913 rs13383253 chr2 10557093 G A 8.21E-05 HDL cholesterol HPCAL1 intron pha003074 rs3755256 chr2 10566414 G A 4.50E-07 Biliary atresia HPCAL1 intron 20460270 rs6432097 chr2 10595578 T C 3.87E-04 Multiple complex diseases / / 17554300 rs11890785 chr2 10619702 C T 0.000133 Salmonella-induced pyroptosis / / 22837397 rs818185 chr2 10648857 T C 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17436529 chr2 10655141 A G 4.31E-06 Bleomycin sensitivity / / 21106707 rs10185605 chr2 10656284 C T 2.78E-04 Taste perception / / 22132133 rs13013488 chr2 10657025 A T 6.12E-05 Aortic root size / / 21223598 rs2540275 chr2 10667749 G A 1.92E-04 Alcohol dependence / / 20201924 rs2270308 chr2 10675371 C T 1.18E-04 Multiple complex diseases / / 17554300 rs736725 chr2 10689889 G C 7.07E-05 Type 1 diabetes / / 18978792 rs6736915 chr2 10700239 T C 7.92E-05 Body mass (lean) / / 19268274 rs4668690 chr2 10713932 G A 5.12E-04 Type 2 diabetes NOL10 intron 17463246 rs4668690 chr2 10713932 G A 8.05E-05 Systemic sclerosis NOL10 intron 21750679 rs10490187 chr2 10737673 G A 6.80E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) NOL10 intron 17982456 rs12476937 chr2 10761985 C T 3.53E-05 Intracerebral hemorrhage NOL10 intron 24656865 rs7422405 chr2 10850929 G A 4.55E-05 Systemic sclerosis / / 21750679 rs4669621 chr2 10886098 C T 2.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1C2 intron 20877124 rs1198872 chr2 10903412 C T 2.00E-06 Cardiac Troponin-T levels ATP6V1C2 intron 23247143 rs6432144 chr2 10916958 C T 7.02E-04 Aortic root size ATP6V1C2 intron 21223598 rs1106184 chr2 10963527 T C 8.80E-05 Longevity and age-related phenotypes / / 17903295 rs4669638 chr2 11021731 T A,C,G 5.89E-04 Response to TNF antagonist treatment / / 21061259 rs1317768 chr2 11024620 G A 2.55E-05 Bipolar disorder / / 20451256 rs7576288 chr2 11025705 G A 6.99E-04 Taste perception / / 22132133 rs7580382 chr2 11026953 G A 5.03E-05 Bipolar disorder / / 20451256 rs1317760 chr2 11031056 G A 2.13E-05 Bipolar disorder / / 20451256 rs16856887 chr2 11064628 A T 5.60E-06 Serum metabolites / / 19043545 rs16856924 chr2 11083596 G C 6.57E-04 Multiple complex diseases / / 17554300 rs7594176 chr2 11083972 T A 6.80E-04 Multiple complex diseases / / 17554300 rs2003298 chr2 11086150 T C 0.000121 Gains in maximal O2 uptake response / / 21183627 rs6730326 chr2 11091780 G T 2.00E-05 Urinary metabolites / / 21572414 rs10202936 chr2 11093401 T C 8.71E-05 Lymphocyte counts / / 22286170 rs4669654 chr2 11103496 G T 4.31E-04 Multiple complex diseases / / 17554300 rs13390165 chr2 11118836 C T 1.29E-05 Body mass (lean) / / 19268274 rs6432159 chr2 11127974 A G 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs10195742 chr2 11135890 C T 4.74E-04 Multiple complex diseases / / 17554300 rs13022057 chr2 11151452 C T 2.70E-05 Urinary metabolites / / 21572414 rs12472523 chr2 11154270 C A 1.30E-04 Type 2 diabetes / / 17463246 rs6432163 chr2 11159080 A C 9.20E-05 HIV-1 control / / 20041166 rs17456970 chr2 11169028 G A 8.14E-04 Lymphocyte counts / / 22286170 rs11677588 chr2 11189849 G A 2.64E-04 Cholesterol / / 17255346 rs2357889 chr2 11199971 C T 4.14E-04 Schizophrenia / / 19197363 rs6432168 chr2 11215734 A G 1.94E-05 Cognitive test performance / / 20125193 rs6739054 chr2 11220562 A G 2.00E-06 Cognitive performance / / 20125193 rs4668712 chr2 11226507 G A 4.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4669687 chr2 11229946 A G 4.84E-04 Myopia (pathological) / / 21095009 rs925748 chr2 11247813 T C 3.92E-05 Alzheimer's disease FLJ33534 intron 17998437 rs12478033 chr2 11248242 T C 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ33534 intron 20877124 rs12692432 chr2 11255340 C T 6.00E-06 Metabolite levels (HVA/MHPG ratio) FLJ33534 intron 23319000 rs9287725 chr2 11257494 C T 2.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ33534 intron 20877124 rs16857178 chr2 11257505 G A 9.00E-06 Obesity-related traits FLJ33534 intron 23251661 rs7608117 chr2 11265972 T G 8.91E-05 Pulmonary function FLJ33534 intron 20010835 rs13002429 chr2 11267366 T C 5.53E-05 Pulmonary function FLJ33534 intron 20010835 rs17366322 chr2 11272784 G T 7.26E-05 Pulmonary function / / 20010835 rs12470798 chr2 11281101 C G 8.93E-05 Pulmonary function C2orf50 intron 20010835 rs1828930 chr2 11291036 C T 9.15E-05 Pulmonary function / / 20010835 rs7581322 chr2 11293336 T G 8.16E-05 Pulmonary function / / 20010835 rs12996399 chr2 11313839 G A 8.75E-05 Pulmonary function PQLC3 intron 20010835 rs17366517 chr2 11320668 A G 2.69E-04 Multiple complex diseases / / 17554300 rs13423864 chr2 11347249 T C 9.57E-04 Alzheimer's disease ROCK2 intron 22005930 rs2056103 chr2 11364756 T A 9.28E-04 Alzheimer's disease ROCK2 intron 22005930 rs13393192 chr2 11368666 T C 8.93E-04 Alzheimer's disease ROCK2 intron 22005930 rs13397757 chr2 11370768 A G 8.94E-04 Alzheimer's disease ROCK2 intron 22005930 rs13404430 chr2 11381113 C A 6.36E-04 Alzheimer's disease ROCK2 intron 22005930 rs12479227 chr2 11394353 C T 3.03E-05 Sudden cardiac arrest ROCK2 intron 21658281 rs16857307 chr2 11397128 T C 5.82E-04 Multiple complex diseases ROCK2 intron 17554300 rs6743710 chr2 11501680 C T 2.92E-04 Alzheimer's disease LOC650157 intron 22005930 rs10189756 chr2 11503081 T C 4.00E-04 Alzheimer's disease LOC650157 intron 22005930 rs6716724 chr2 11510948 A G 6.00E-07 Sudden cardiac arrest LOC650157 intron 21658281 rs4260216 chr2 11535523 G T 1.36E-05 Odorant perception / / 23910658 rs11687681 chr2 11572815 G A 1.62E-04 Longevity / / 22279548 rs13407457 chr2 11655487 G T 3.60E-05 Endometriosis / / 21151130 rs13407457 chr2 11655487 G T 2.50E-05 Endometriosis / / 23104006 rs6758730 chr2 11677449 A G 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GREB1 intron 20877124 rs6758730 chr2 11677449 A G 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GREB1 intron 20877124 rs4669749 chr2 11692664 C A 2.00E-05 Electrocardiographic traits and heart rate variability GREB1 intron 17903306 rs4669751 chr2 11706693 T C 1.36E-04 Height GREB1 missense 17255346 rs7578132 chr2 11718858 T C 1.00E-05 Urinary metabolites GREB1 intron 21572414 rs12470971 chr2 11725241 G A 8.10E-06 Endometriosis GREB1 intron 23104006 rs13394619 chr2 11727507 G A 6.00E-09 Endometriosis GREB1 splice-3 23104006 rs12476319 chr2 11748406 T C 5.00E-04 Alcohol dependence GREB1 intron 21314694 rs73175262 chr2 11758431 G A 7.00E-08 Obesity-related traits GREB1 missense 23251661 rs73175262 chr2 11758431 G A 9.00E-06 Obesity-related traits GREB1 missense 23251661 rs7562399 chr2 11767282 G A 3.75E-04 Alzheimer's disease GREB1 intron 17998437 rs7562399 chr2 11767282 G A 7.74E-04 Alcohol dependence GREB1 intron 20201924 rs3792034 chr2 11768174 G A 3.53E-04 Multiple complex diseases GREB1 intron 17554300 rs7564647 chr2 11770685 A G 1.43E-04 Type 2 diabetes GREB1 intron 17463246 rs7567094 chr2 11787239 A C 8.87E-05 Type 2 diabetes / / 17463246 rs11676470 chr2 11815723 G T 1.11E-04 Smoking initiation / / 24665060 rs6721977 chr2 11823437 A C 1.41E-04 Coronary heart disease / / 21606135 rs11889370 chr2 11855096 T C 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12692445 chr2 11855712 A G 5.30E-05 Iron levels / / 21208937 rs11894146 chr2 11879174 T C 8.51E-05 Cognitive test performance / / 20125193 rs4076055 chr2 11889385 G T 0.000330734 Hypertension (early onset hypertension) LPIN1 intron 22479346 rs10192566 chr2 11890428 C G 1 Drug response to Rosiglitazone LPIN1 intron 18693052 rs7595221 chr2 11896975 G A 0.000251703 Hypertension (early onset hypertension) LPIN1 intron 22479346 rs2118403 chr2 11986791 A G 5.08E-05 Platelet counts / / pha003100 rs2716640 chr2 11987932 G A 3.11E-04 Insulin resistance / / 21901158 rs6735995 chr2 11991593 T C 4.68E-04 Multiple complex diseases / / 17554300 rs10495585 chr2 11992128 A C 9.42E-05 Cleft lip / / 20436469 rs373256169 chr2 11992128 AG AAG,ACC 9.42E-05 Cleft lip / / 20436469 rs10929773 chr2 12029322 G A 7.70E-05 Response to statin therapy / / 20339536 rs17605562 chr2 12037179 C T 9.00E-06 Hair morphology / / 19896111 rs4027132 chr2 12037492 G A 3.12E-06 Multiple complex diseases / / 17554300 rs4027132 chr2 12037492 G A 6.63E-06 Bipolar disorder,schizoaffective / / 19567891 rs4027132 chr2 12037492 G A 3.00E-06 Bipolar disorder / / 21254220 rs10183830 chr2 12038710 T G 7.80E-05 Response to statin therapy / / 20339536 rs4668743 chr2 12039694 T C 7.82E-04 Obesity (extreme) / / 21935397 rs16857996 chr2 12041594 C T 5.50E-05 Response to statin therapy / / 20339536 rs12472797 chr2 12045272 C T 1.78E-05 Multiple complex diseases / / 17554300 rs10204395 chr2 12045457 A C 6.02E-04 Multiple complex diseases / / 17554300 rs10204395 chr2 12045457 A C 5.40E-05 Response to statin therapy / / 20339536 rs10207016 chr2 12045540 T C 5.30E-05 Response to statin therapy / / 20339536 rs7607539 chr2 12048160 C T 2.11E-05 Elbow pain / / pha003008 rs12468031 chr2 12081764 C T 1.22E-04 Birth weight / / 17255346 rs2716625 chr2 12089229 T C 8.39E-05 Orofacial clefts / / 22419666 rs2033877 chr2 12095888 G A 5.93E-05 Orofacial clefts / / 22419666 rs1036668 chr2 12132638 G T 9.71E-04 Alcohol dependence / / 24277619 rs10210269 chr2 12144035 G A 4.07E-04 Coronary Artery Disease / / 17634449 rs12692450 chr2 12147176 G C 8.49E-05 Serum metabolites / / 19043545 rs41378155 chr2 12149681 A G 3.38E-04 Type 2 diabetes / / 17463246 rs12472165 chr2 12150406 C G 7.24E-04 Type 2 diabetes / / 17463246 rs11690527 chr2 12181825 C T 0.000000899 Asthma / / 22694930 rs6432254 chr2 12196768 A G 5.24E-04 Multiple complex diseases / / 17554300 rs7562854 chr2 12199218 T C 7.52E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs10495588 chr2 12203273 G A 8.70E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs16858228 chr2 12212445 A G 1.00E-06 Obesity-related traits / / 23251661 rs10803743 chr2 12221688 C A 3.92E-04 Multiple complex diseases / / 17554300 rs10166582 chr2 12225930 C A 7.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6711682 chr2 12229669 A G 1.50E-04 Multiple complex diseases / / 17554300 rs6432261 chr2 12229926 A G 2.83E-04 Multiple complex diseases / / 17554300 rs6731006 chr2 12239782 A G 8.21E-04 Multiple complex diseases / / 17554300 rs6731006 chr2 12239782 A G 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2278550 chr2 12247311 C G 8.72E-04 Multiple complex diseases LOC100506457 intron 17554300 rs6432264 chr2 12247650 C G 9.82E-04 Type 2 diabetes LOC100506457 intron 17463246 rs6432264 chr2 12247650 C G 3.38E-04 Multiple complex diseases LOC100506457 intron 17554300 rs1470013 chr2 12248589 A G 3.20E-05 Amyotrophic lateral sclerosis (sporadic) LOC100506457 intron 24529757 rs17551536 chr2 12252350 A G 5.00E-06 Bronchopulmonary dysplasia LOC100506457 intron 23897914 rs6741502 chr2 12256332 C A 1.19E-04 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs10929785 chr2 12264126 T C 8.75E-05 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs7601706 chr2 12265210 C A 2.06E-04 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs17551939 chr2 12268748 A C 8.49E-05 Bipolar Disorder LOC100506457 intron pha002863 rs16858314 chr2 12269747 A G 4.10E-06 Urinary metabolites LOC100506457 intron 21572414 rs916522 chr2 12279879 C A 6.82E-05 Nephrolithiasis / / 22396660 rs916524 chr2 12280396 T C 1.90E-04 Multiple complex diseases / / 17554300 rs916524 chr2 12280396 T C 8.18E-04 Coronary heart disease / / 21606135 rs1821897 chr2 12283275 G C 7.05E-04 Type 2 diabetes / / 17463246 rs16858333 chr2 12285268 T C 1.50E-05 Urinary metabolites / / 21572414 rs1971516 chr2 12291656 A G 3.71E-04 Alzheimer's disease (late onset) / / 21379329 rs13399680 chr2 12295638 C T 4.66E-05 Serum metabolites / / 19043545 rs731395 chr2 12296582 G A 1.58E-05 Vaspin levels / / 22907691 rs731395 chr2 12296582 G A 0.0000158 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3954862 chr2 12304753 T C 1.30E-05 Vaspin levels / / 22907691 rs3954862 chr2 12304753 T C 0.000013 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3954862 chr2 12304753 T C 0.0001575 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3906767 chr2 12305222 C T 1.30E-05 Vaspin levels / / 22907691 rs3906767 chr2 12305222 C T 0.000013 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3906767 chr2 12305222 C T 0.0001575 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10197240 chr2 12307205 A G 2.81E-04 Multiple complex diseases / / 17554300 rs4669821 chr2 12315199 T G 5.55E-05 Height / / pha003010 rs6432267 chr2 12318466 G A 1.03E-04 Type 2 diabetes / / 17463246 rs6432267 chr2 12318466 G A 4.25E-05 Multiple complex diseases / / 17554300 rs10172170 chr2 12319000 A G 1.51E-04 Multiple complex diseases / / 17554300 rs7558139 chr2 12322604 T C 3.11E-05 Serum metabolites / / 19043545 rs10803744 chr2 12323369 G A 9.92E-05 Vaspin levels / / 22907691 rs10803744 chr2 12323369 G A 0.0000992 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17618039 chr2 12326837 A T 2.10E-05 Urinary metabolites / / 21572414 rs10495593 chr2 12329347 G T 5.10E-05 Lipid traits / / 17903299 rs10495594 chr2 12330399 G A 5.10E-05 Lipid traits / / 17903299 rs1225214 chr2 12335338 G A 2.55E-05 Serum metabolites / / 19043545 rs1542327 chr2 12354664 T C 5.84E-04 Heart Failure / / pha002884 rs1453488 chr2 12366908 C T 4.35E-05 Pulmonary function in asthmatics / / 23541324 rs4669834 chr2 12369870 A G 5.13E-05 Pulmonary function in asthmatics / / 23541324 rs4669835 chr2 12372623 A G 2.02E-05 Height / / pha003010 rs12992291 chr2 12387305 T C 8.15E-04 Parkinson's disease / / 16252231 rs12992291 chr2 12387305 T C 3.30E-06 Urinary metabolites / / 21572414 rs10803746 chr2 12397133 G A 8.14E-04 Smoking initiation / / 24665060 rs1020605 chr2 12397435 T C 1.21E-04 Aortic root size / / 21223598 rs1020605 chr2 12397435 T C 7.54E-04 Smoking initiation / / 24665060 rs2380426 chr2 12399050 C T 1.58E-04 Aortic root size / / 21223598 rs2380426 chr2 12399050 C T 2.25E-04 Vaspin levels / / 22907691 rs2380426 chr2 12399050 C T 0.0002247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1901851 chr2 12401923 A C 1.85E-04 Aortic root size / / 21223598 rs6720800 chr2 12401985 T C 1.73E-04 Aortic root size / / 21223598 rs12623366 chr2 12402467 G T 1.41E-04 Aortic root size / / 21223598 rs16858543 chr2 12403280 G A 1.79E-04 Aortic root size / / 21223598 rs10495595 chr2 12406806 T C 3.72E-05 Aortic root size / / 21223598 rs12989835 chr2 12409041 G T 1.88E-04 Aortic root size / / 21223598 rs10205200 chr2 12409153 T C 1.00E-04 Bipolar disorder / / 18317468 rs10205200 chr2 12409153 T C 8.43E-05 Aortic root size / / 21223598 rs10164492 chr2 12411048 T G 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2034680 chr2 12414595 C G 6.96E-05 Aortic root size / / 21223598 rs7567643 chr2 12415940 C T 1.29E-04 Aortic root size / / 21223598 rs10754960 chr2 12418070 A G 1.30E-04 Aortic root size / / 21223598 rs6432275 chr2 12418532 C T 1.83E-04 Aortic root size / / 21223598 rs7578740 chr2 12418752 C T 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12105920 chr2 12420336 C T 2.09E-04 Aortic root size / / 21223598 rs10188552 chr2 12420990 G A 2.06E-04 Aortic root size / / 21223598 rs9287745 chr2 12421602 G A 2.10E-04 Aortic root size / / 21223598 rs11681455 chr2 12421708 T G 2.16E-04 Aortic root size / / 21223598 rs11681455 chr2 12421708 T G 4.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2164876 chr2 12430628 A G 1.86E-04 Aortic root size / / 21223598 rs723504 chr2 12431440 T C 2.14E-04 Aortic root size / / 21223598 rs723504 chr2 12431440 T C 5.43E-05 Tunica Media / / pha003034 rs4669836 chr2 12433491 A G 2.13E-04 Aortic root size / / 21223598 rs6761842 chr2 12434250 A C 2.15E-04 Aortic root size / / 21223598 rs6761857 chr2 12434277 A G 2.18E-04 Aortic root size / / 21223598 rs6710595 chr2 12434358 T C 4.78E-04 Multiple complex diseases / / 17554300 rs6710595 chr2 12434358 T C 2.14E-04 Aortic root size / / 21223598 rs2380431 chr2 12438193 T C 1.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16858622 chr2 12440201 G A 1.87E-04 Aortic root size / / 21223598 rs1031455 chr2 12442537 T C 6.28E-05 Multiple complex diseases / / 17554300 rs6733870 chr2 12445505 T C 2.85E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1002296 chr2 12450707 A G 4.77E-04 Multiple complex diseases / / 17554300 rs1002297 chr2 12450840 A T 2.60E-05 Urinary metabolites / / 21572414 rs10929800 chr2 12452560 A G 2.20E-05 Urinary metabolites / / 21572414 rs11684242 chr2 12453068 T C 1.20E-05 Urinary metabolites / / 21572414 rs16858693 chr2 12475214 A G 1.14E-04 Multiple complex diseases / / 17554300 rs6432284 chr2 12485992 C T 4.26E-04 Multiple complex diseases / / 17554300 rs11690119 chr2 12511957 C T 7.55E-04 HIV-1 viral setpoint / / 17641165 rs10929808 chr2 12568996 G A 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs10176670 chr2 12585727 T G 7.38E-05 Circulating vasoactive peptide levels / / 23381795 rs7592226 chr2 12611100 G A 1.28E-04 Multiple complex diseases / / 17554300 rs1547587 chr2 12619109 A G 4.16E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6757329 chr2 12625305 G C 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534422 chr2 12640741 G A 2.00E-06 Type 1 diabetes / / 19430480 rs1534422 chr2 12640741 G A 0.000000176 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs1534422 chr2 12640741 G A 0.00000469 Graves' disease / / 22922229 rs13013085 chr2 12676426 G A 3.75E-05 Multiple sclerosis / / 17660530 rs6432315 chr2 12720311 T C 3.40E-05 HIV-1 control / / 20041166 rs4668771 chr2 12727616 T C 4.84E-05 Multiple complex diseases / / 17554300 rs4538172 chr2 12728266 A G 1.19E-21 Varicose Veins / / pha001412 rs11675322 chr2 12735727 G A 1.85E-05 Mammographic density / / 22532574 rs2139380 chr2 12741369 T G 3.49E-04 Smoking quantity / / 24665060 rs11677151 chr2 12759532 C T 3.98E-06 Mammographic density / / 22532574 rs16859166 chr2 12760843 G A 6.18E-04 Type 2 diabetes / / 17463246 rs7568831 chr2 12763243 A G 8.86E-05 Information processing speed / / 21130836 rs6432321 chr2 12778345 T C 2.25E-04 Alcohol dependence / / 24277619 rs11694463 chr2 12781621 T C 6.10E-05 Nicotine dependence / / 17158188 rs11694463 chr2 12781621 T C 6.28E-05 Mammographic density / / 22532574 rs559703 chr2 12787237 A G 2.35E-05 Information processing speed / / 21130836 rs559703 chr2 12787237 A G 7.86E-04 Smoking quantity / / 24665060 rs2113810 chr2 12789884 G A 2.97E-05 Myopia (severe) / / 23933737 rs6432322 chr2 12794840 T C 2.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs654004 chr2 12827258 C T 4.64E-05 Telomere length / / 20139977 rs625842 chr2 12828973 A C 6.24E-04 Schizophrenia / / 19197363 rs624895 chr2 12829246 T A 2.48E-05 Telomere length / / 20139977 rs501596 chr2 12833928 A G 8.11E-04 Schizophrenia / / 19197363 rs477599 chr2 12834170 G A 2.88E-05 Telomere length / / 20139977 rs645490 chr2 12841445 T G 5.00E-04 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs6719434 chr2 12862905 T C 5.50E-05 Pericardial fat TRIB2 intron 22589742 rs2278117 chr2 12863770 G A 2.30E-05 Pericardial fat TRIB2 intron 22589742 rs2042567 chr2 12878642 T C 6.90E-05 Pericardial fat TRIB2 intron 22589742 rs2042566 chr2 12878668 C T 6.70E-05 Pericardial fat TRIB2 intron 22589742 rs1469215 chr2 12886320 G T 5.80E-05 Pericardial fat / / 22589742 rs1974923 chr2 12887702 T C 2.60E-07 Pericardial fat / / 22589742 rs2113818 chr2 12890860 T C 3.60E-07 Pericardial fat / / 22589742 rs2059428 chr2 12892929 C T 6.40E-05 Pericardial fat / / 22589742 rs2059427 chr2 12893977 C T 4.40E-05 Pericardial fat / / 22589742 rs12616457 chr2 12896713 G A 2.10E-06 Pericardial fat / / 22589742 rs2380453 chr2 12897291 C G 1.90E-06 Pericardial fat / / 22589742 rs5022058 chr2 12897548 C G 1.90E-06 Pericardial fat / / 22589742 rs7562714 chr2 12898382 G A 1.90E-06 Pericardial fat / / 22589742 rs4669869 chr2 12898460 T C 6.20E-08 Pericardial fat / / 22589742 rs13011003 chr2 12901052 C A 1.80E-06 Pericardial fat / / 22589742 rs4669872 chr2 12901482 G C 3.30E-05 Pericardial fat / / 22589742 rs973977 chr2 12905490 C T 3.30E-05 Pericardial fat / / 22589742 rs890075 chr2 12910044 T C 8.30E-08 Pericardial fat / / 22589742 rs890074 chr2 12910084 G A 8.30E-08 Pericardial fat / / 22589742 rs4669873 chr2 12914541 A G 4.20E-07 Pericardial fat / / 22589742 rs4669874 chr2 12915120 T C 4.20E-07 Pericardial fat / / 22589742 rs4669875 chr2 12915867 G C 1.20E-05 Pericardial fat / / 22589742 rs7581972 chr2 12916919 T C 4.70E-07 Pericardial fat / / 22589742 rs2161996 chr2 12917543 A T 4.10E-07 Pericardial fat / / 22589742 rs4669876 chr2 12918300 C T 3.50E-05 Pericardial fat / / 22589742 rs10200958 chr2 12919215 C T 4.00E-07 Pericardial fat / / 22589742 rs6432331 chr2 12924111 A G 3.80E-07 Pericardial fat / / 22589742 rs6432334 chr2 12928927 T G 3.80E-07 Pericardial fat / / 22589742 rs1863176 chr2 12931092 G C 4.20E-07 Pericardial fat / / 22589742 rs6727552 chr2 12932307 G T 4.10E-05 Pericardial fat / / 22589742 rs10200527 chr2 12933917 T C 2.70E-05 Pericardial fat / / 22589742 rs10198180 chr2 12936190 G A 4.00E-05 Pericardial fat / / 22589742 rs7580835 chr2 12938819 G A 4.00E-07 Pericardial fat / / 22589742 rs2194724 chr2 12942042 T C 4.90E-06 Pericardial fat / / 22589742 rs12692486 chr2 12948146 T C 3.90E-07 Pericardial fat / / 22589742 rs732805 chr2 12948901 G A 3.90E-07 Pericardial fat / / 22589742 rs4583433 chr2 12949571 G T 3.90E-07 Pericardial fat / / 22589742 rs1469218 chr2 12950092 C G 3.90E-07 Pericardial fat / / 22589742 rs1469217 chr2 12950124 T C 3.90E-07 Pericardial fat / / 22589742 rs6730819 chr2 12951196 C T 3.90E-07 Pericardial fat / / 22589742 rs12623251 chr2 12951321 C T 4.60E-06 Pericardial fat / / 22589742 rs10175345 chr2 12951414 T G 3.90E-07 Pericardial fat / / 22589742 rs2113815 chr2 12951705 G A 3.90E-07 Pericardial fat / / 22589742 rs2113814 chr2 12951752 C T 4.00E-07 Pericardial fat / / 22589742 rs2113813 chr2 12951767 C T 4.00E-07 Pericardial fat / / 22589742 rs2113812 chr2 12951779 A G 4.00E-07 Pericardial fat / / 22589742 rs6432336 chr2 12951950 G A 4.00E-07 Pericardial fat / / 22589742 rs7597914 chr2 12952193 A G 4.00E-07 Pericardial fat / / 22589742 rs2113811 chr2 12952494 A G 5.30E-07 Pericardial fat / / 22589742 rs11685678 chr2 12953264 G A 2.50E-05 Pericardial fat / / 22589742 rs4668789 chr2 12954404 G A 4.10E-07 Pericardial fat / / 22589742 rs13000123 chr2 12954826 C T 4.10E-07 Pericardial fat / / 22589742 rs10929832 chr2 12955682 C T 4.10E-07 Pericardial fat / / 22589742 rs1544853 chr2 12955770 A C 4.10E-07 Pericardial fat / / 22589742 rs1544852 chr2 12955849 T C 4.10E-07 Pericardial fat / / 22589742 rs1544851 chr2 12955898 C T 4.10E-07 Pericardial fat / / 22589742 rs7598770 chr2 12956329 T C 4.10E-07 Pericardial fat / / 22589742 rs6751241 chr2 12957120 T C 4.40E-07 Pericardial fat / / 22589742 rs7586442 chr2 12957620 C G 4.40E-07 Pericardial fat / / 22589742 rs7586563 chr2 12957754 C T 4.40E-07 Pericardial fat / / 22589742 rs4668792 chr2 12959810 C T 4.50E-07 Pericardial fat / / 22589742 rs10191751 chr2 12962315 A G 8.80E-05 Pericardial fat / / 22589742 rs10194305 chr2 12962365 T A 2.80E-07 Pericardial fat / / 22589742 rs10179809 chr2 12962585 C A 2.70E-07 Pericardial fat / / 22589742 rs10192149 chr2 12962678 A G 2.90E-08 Pericardial fat / / 22589742 rs17465721 chr2 12962818 C T 8.00E-05 Pericardial fat / / 22589742 rs6432340 chr2 12963117 T C 2.80E-08 Pericardial fat / / 22589742 rs12621238 chr2 12964066 T C 2.70E-08 Pericardial fat / / 22589742 rs10186351 chr2 12964428 C T 2.70E-08 Pericardial fat / / 22589742 rs10198628 chr2 12964497 A G 5.00E-14 Pericardial fat / / 22589742 rs10164960 chr2 12965159 G A 4.70E-08 Pericardial fat / / 22589742 rs10204312 chr2 12965413 T C 2.90E-08 Pericardial fat / / 22589742 rs6432341 chr2 12965814 C G 4.00E-08 Pericardial fat / / 22589742 rs7572835 chr2 12966506 G A 4.10E-08 Pericardial fat / / 22589742 rs2098823 chr2 12968025 C A 8.20E-08 Pericardial fat / / 22589742 rs4669884 chr2 12968885 C T 1.70E-05 Pericardial fat / / 22589742 rs10180496 chr2 12968900 A G 1.00E-07 Dental caries / / 23064961 rs7558700 chr2 12969893 C G 1.50E-07 Pericardial fat / / 22589742 rs7558818 chr2 12969972 C T 1.30E-07 Pericardial fat / / 22589742 rs7584581 chr2 12969987 G C 1.80E-07 Pericardial fat / / 22589742 rs7559029 chr2 12970155 C A 1.80E-07 Pericardial fat / / 22589742 rs10184321 chr2 12970372 A C 6.30E-08 Pericardial fat / / 22589742 rs12617714 chr2 12971271 A G 1.30E-05 Pericardial fat / / 22589742 rs4669885 chr2 12973019 C A,G 6.30E-08 Pericardial fat / / 22589742 rs12999821 chr2 12973540 A G 6.30E-08 Pericardial fat / / 22589742 rs4669886 chr2 12974244 A G 7.50E-06 Pericardial fat / / 22589742 rs4669887 chr2 12976179 T G 1.00E-04 Schizophrenia / / 19197363 rs4669887 chr2 12976179 T G 3.30E-05 Pericardial fat / / 22589742 rs4669889 chr2 12980591 T C 6.40E-08 Pericardial fat / / 22589742 rs6732344 chr2 12984438 G A 5.80E-08 Pericardial fat / / 22589742 rs12468536 chr2 12984962 G A 7.50E-08 Pericardial fat / / 22589742 rs10929833 chr2 12984999 T C 6.20E-08 Pericardial fat / / 22589742 rs890070 chr2 12985129 G T 6.30E-08 Pericardial fat / / 22589742 rs950612 chr2 12990034 G C 8.00E-05 Pericardial fat / / 22589742 rs1554443 chr2 12991744 C G 2.20E-06 Pericardial fat / / 22589742 rs10188224 chr2 12995782 T G 4.80E-06 Pericardial fat / / 22589742 rs4669892 chr2 12997563 G C 2.90E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs4669893 chr2 12998152 G C 3.20E-06 Pericardial fat / / 22589742 rs7556962 chr2 13000040 T C 3.30E-06 Pericardial fat / / 22589742 rs6747537 chr2 13000397 C T 4.60E-05 Pericardial fat / / 22589742 rs1357060 chr2 13002998 T C 3.60E-06 Pericardial fat / / 22589742 rs1521249 chr2 13008754 T C 4.10E-06 Pericardial fat / / 22589742 rs17465771 chr2 13016168 G C 2.60E-05 Pericardial fat / / 22589742 rs10182783 chr2 13021683 G A 3.37E-05 Serum alpha1-antitrypsin levels / / 23990791 rs6432342 chr2 13022260 A G 3.50E-05 Pericardial fat / / 22589742 rs1879543 chr2 13024831 C T 6.30E-05 Pericardial fat / / 22589742 rs1949631 chr2 13027074 A G 5.85E-04 Multiple complex diseases / / 17554300 rs956596 chr2 13027660 A G 3.90E-05 Pericardial fat / / 22589742 rs6739633 chr2 13028547 C T 8.00E-05 HIV-1 viral setpoint / / 22174851 rs1357061 chr2 13035974 T C 6.52E-04 Multiple complex diseases / / 17554300 rs1521246 chr2 13037918 A C 4.70E-05 Pericardial fat / / 22589742 rs6432343 chr2 13039946 A G 5.70E-05 Pericardial fat / / 22589742 rs6728142 chr2 13041090 T C 4.54E-05 Serum alpha1-antitrypsin levels / / 23990791 rs1521247 chr2 13041412 C G 5.50E-05 Pericardial fat / / 22589742 rs13430556 chr2 13042709 T C 3.82E-05 Serum alpha1-antitrypsin levels / / 23990791 rs13388631 chr2 13042823 G C 3.56E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10172921 chr2 13042870 G A 3.30E-05 Serum alpha1-antitrypsin levels / / 23990791 rs779339 chr2 13043884 A G 5.20E-05 Pericardial fat / / 22589742 rs13390247 chr2 13045563 T C 4.20E-05 Serum alpha1-antitrypsin levels / / 23990791 rs779343 chr2 13049099 T C 6.80E-05 Pericardial fat / / 22589742 rs13400830 chr2 13054564 A G 7.83E-06 Serum alpha1-antitrypsin levels / / 23990791 rs16859504 chr2 13055358 G A 8.38E-06 Serum alpha1-antitrypsin levels / / 23990791 rs983037 chr2 13080220 A C 9.59E-06 Schizophrenia / / 19197363 rs779379 chr2 13080607 A G 1.49E-04 Acute lung injury / / 22295056 rs779388 chr2 13085166 C T 3.44E-05 Coronary heart disease / / pha003031 rs7584450 chr2 13089072 A G 7.85E-05 Serum metabolites / / 19043545 rs711870 chr2 13089226 C A 6.51E-04 Acute lung injury / / 22295056 rs999059 chr2 13102424 T C 6.91E-04 Schizophrenia / / 19197363 rs779406 chr2 13102613 A G 3.66E-04 Acute lung injury / / 22295056 rs779409 chr2 13104553 C G 3.34E-04 Acute lung injury / / 22295056 rs779411 chr2 13105269 T C 3.34E-04 Acute lung injury / / 22295056 rs2459337 chr2 13108712 G C 2.80E-04 Acute lung injury LOC100506474 intron 22295056 rs12692488 chr2 13134803 A G 3.06E-04 Iron levels LOC100506474 intron pha002876 rs4668795 chr2 13167258 A C 3.60E-05 Coronary heart disease / / pha003031 rs1818595 chr2 13168232 A G 7.01E-04 Schizophrenia / / 19197363 rs4346352 chr2 13222498 C T 7.05E-05 Coronary heart disease / / pha003031 rs4669910 chr2 13289018 C T 3.40E-05 HIV-1 control / / 20041166 rs16859919 chr2 13300659 G T 2.70E-04 Multiple complex diseases / / 17554300 rs10203818 chr2 13367633 G A 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13403000 chr2 13368225 C T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13403000 chr2 13368225 C T 5.28E-05 Coronary heart disease / / pha003031 rs9678154 chr2 13384186 A G 5.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16860506 chr2 13663029 T C 9.53E-04 Multiple complex diseases / / 17554300 rs16860575 chr2 13722414 T C 2.90E-05 Urinary metabolites / / 21572414 rs16860590 chr2 13722980 T G 2.40E-05 Urinary metabolites / / 21572414 rs2048401 chr2 13836169 T C 1.40E-05 Urinary metabolites / / 21572414 rs2175342 chr2 13839480 G T 2.50E-05 Urinary metabolites / / 21572414 rs1446542 chr2 13846734 T C 2.33E-05 Progressive supranuclear palsy / / 21685912 rs1588477 chr2 13892092 A C 7.45E-05 Multiple complex diseases / / 17554300 rs6432417 chr2 13951524 A G 4.74E-04 Acne (severe) / / 24927181 rs1000826 chr2 13984302 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10495625 chr2 13986304 T C 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1598106 chr2 14029748 C G 2.00E-07 IgG glycosylation / / 23382691 rs6752124 chr2 14040624 G A 4.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6752124 chr2 14040624 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11900844 chr2 14041017 C T 0.000199 Salmonella-induced pyroptosis / / 22837397 rs17312849 chr2 14059424 C T 8.73E-04 Multiple complex diseases / / 17554300 rs747193 chr2 14081761 A G 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs91166 chr2 14081905 T C 9.79E-05 Serum metabolites / / 19043545 rs401974 chr2 14082017 T C 3.02E-04 Longevity / / 22279548 rs549213 chr2 14094791 T C 9.10E-04 Type 2 diabetes / / 17463246 rs10495619 chr2 14153031 C G 1.70E-05 Urinary metabolites / / 21572414 rs391769 chr2 14162065 A G 1.70E-05 Urinary metabolites / / 21572414 rs16861159 chr2 14212802 C T 4.83E-04 Multiple complex diseases / / 17554300 rs360474 chr2 14227970 G A 7.32E-05 Height / / 17255346 rs16861195 chr2 14254307 T A 7.78E-04 Alzheimer's disease / / 17998437 rs16861198 chr2 14254391 G A 6.33E-04 Alzheimer's disease / / 17998437 rs6432444 chr2 14258368 A G 6.45E-05 Blood Pressure / / pha003050 rs10174530 chr2 14271246 T C 1.44E-04 Alzheimer's disease / / 17998437 rs7572783 chr2 14287044 G A 4.33E-04 Alzheimer's disease / / 17998437 rs10179956 chr2 14294926 G T 1.15E-04 Alzheimer's disease / / 17998437 rs13384764 chr2 14303716 C T 3.79E-04 Alzheimer's disease / / 17998437 rs10495633 chr2 14312862 T C 7.17E-04 Diabetic retinopathy / / 20871662 rs7571070 chr2 14334195 C T 3.36E-05 Cortisol secretion,in saliva / / 21316860 rs1839208 chr2 14365186 G T 3.85E-05 Personality dimensions / / 22628180 rs12692521 chr2 14366696 C A,G,T 3.85E-05 Personality dimensions / / 22628180 rs10200546 chr2 14382112 G C 2.64E-04 Multiple complex diseases / / 17554300 rs16861531 chr2 14398052 G C 7.00E-07 Response to antidepressant treatment / / 22041458 rs1900855 chr2 14416772 A C 7.89E-04 Multiple complex diseases / / 17554300 rs7585523 chr2 14432623 C T 5.80E-04 Multiple complex diseases / / 17554300 rs13385301 chr2 14473903 C A 6.97E-05 IgE levels / / 22075330 rs10495639 chr2 14475689 C T 7.02E-05 IgE levels / / 22075330 rs11888369 chr2 14477599 T C 8.63E-05 IgE levels / / 22075330 rs13416263 chr2 14481038 G A 8.80E-05 IgE levels / / 22075330 rs13419213 chr2 14485156 A G 8.98E-05 IgE levels / / 22075330 rs13410836 chr2 14487799 T C 9.01E-05 IgE levels / / 22075330 rs10203925 chr2 14491335 T C 9.06E-05 IgE levels / / 22075330 rs13428704 chr2 14492900 A T 9.06E-05 IgE levels / / 22075330 rs1850135 chr2 14510134 C A 3.20E-05 Multiple complex diseases / / 17554300 rs11884512 chr2 14526931 G C 3.73E-05 IgE levels / / 22075330 rs4145975 chr2 14571744 T C 7.70E-05 Obesity,menopause / / 21424828 rs4426508 chr2 14580815 C G 3.90E-06 Urinary metabolites / / 21572414 rs2056150 chr2 14603290 A G 1.03E-05 Prostate cancer / / 24185611 rs2865931 chr2 14610061 G A 8.40E-05 Glucose levels / / pha003061 rs10929915 chr2 14651888 G A 2.39E-04 Multiple complex diseases / / 17554300 rs12473205 chr2 14658053 C A 4.15E-05 Prostate cancer / / 22923026 rs13408950 chr2 14682175 T G 5.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2380614 chr2 14685560 C T 6.93E-05 Serum metabolites / / 19043545 rs4670003 chr2 14686152 G A 1.28E-04 Type 2 diabetes / / 17463246 rs4670003 chr2 14686152 G A 7.90E-05 Serum metabolites / / 19043545 rs16861832 chr2 14687525 C T 9.07E-04 Multiple complex diseases / / 17554300 rs10188924 chr2 14687890 A C 2.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6724180 chr2 14691935 A G 8.66E-05 Serum metabolites / / 19043545 rs2380619 chr2 14710487 A T 1.14E-04 Type 2 diabetes / / 17463246 rs7602441 chr2 14801501 G A 8.62E-05 Stroke / / 22306652 rs7602441 chr2 14801501 G A 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs1434975 chr2 14805442 G A 2.46E-05 HIV-1 progression to AIDS and death / / 21811574 rs1369242 chr2 14827944 T C 1.60E-06 Urinary metabolites / / 21572414 rs7607607 chr2 14881995 A C 8.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs188141385 chr2 14975369 A G 4.16E-10 TNF-alpha (TNF-a) / / 23696881 rs2679421 chr2 14985079 A C 2.52E-05 Fibrinogen / / 17255346 rs1540790 chr2 15002176 C G 4.18E-05 Fibrinogen / / 17255346 rs10176935 chr2 15004104 T C 3.00E-05 Fibrinogen / / 17255346 rs1878847 chr2 15006960 C T 1.40E-06 Urinary metabolites / / 21572414 rs11886100 chr2 15008308 A C 2.00E-06 Urinary metabolites / / 21572414 rs10173791 chr2 15033404 T C 1.20E-05 Urinary metabolites / / 21572414 rs10173791 chr2 15033404 T C 7.33E-04 Tourette syndrome / / 22889924 rs17433057 chr2 15036267 C T 4.02E-05 Aging (time to event) / / 21782286 rs1518793 chr2 15036358 T C 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12622607 chr2 15053752 T C 3.88E-04 Smoking quantity / / 24665060 rs1568282 chr2 15066177 C T 6.78E-05 Longevity / / 22279548 rs10200717 chr2 15068315 A C 8.75E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11887847 chr2 15074706 A G 5.94E-04 Multiple complex diseases / / 17554300 rs10172951 chr2 15079571 A G 2.53E-04 Multiple complex diseases / / 17554300 rs793824 chr2 15081118 G T 5.46E-06 Odorant perception / / 23910658 rs715121 chr2 15082832 T C 1.83E-04 Multiple complex diseases / / 17554300 rs13411450 chr2 15084108 T C 9.05E-05 Multiple complex diseases / / 17554300 rs6432494 chr2 15102839 C T 6.90E-06 Urinary metabolites / / 21572414 rs4670047 chr2 15106804 C T 6.02E-05 Epilepsy / / 22116939 rs7587023 chr2 15110323 C T 4.37E-05 Epilepsy / / 22116939 rs1344741 chr2 15125286 C T 3.89E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6737611 chr2 15131647 A G 4.00E-05 Prostate cancer / / 21743057 rs6748326 chr2 15148338 C T 9.48E-05 Post-operative nausea and vomiting / / 21694509 rs4668845 chr2 15162318 G A 7.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2890484 chr2 15176554 C G 6.26E-04 Type 2 diabetes / / 17463246 rs1816319 chr2 15212093 G A 2.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1178199 chr2 15217710 T G 1.62E-04 Insulin resistance / / 21901158 rs13391879 chr2 15229630 T C 9.73E-05 Left ventricular hypertrophy / / pha003052 rs1346874 chr2 15246192 G A 6.74E-04 Insulin resistance / / 21901158 rs11695054 chr2 15254827 G A 7.60E-04 Type 2 diabetes / / 17463246 rs7598924 chr2 15255532 A G 5.11E-05 Tunica Media / / pha003037 rs9287654 chr2 15256140 T A 4.50E-04 Type 2 diabetes / / 17463246 rs1990851 chr2 15256606 A G 1.74E-06 Renal cell carcinoma / / 23184150 rs2216537 chr2 15263472 C T 6.84E-04 Type 2 diabetes / / 17463246 rs11688502 chr2 15278561 A G 4.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10192667 chr2 15284746 C T 2.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7572179 chr2 15295998 G C 1.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4294976 chr2 15297306 G T 6.66E-04 Premature ovarian failure / / 19508998 rs4668880 chr2 15303803 C T 7.25E-04 Acute lung injury / / 22295056 rs1469017 chr2 15311954 A G 2.99E-05 Information processing speed NBAS intron 21130836 rs6730450 chr2 15322577 G A 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBAS intron 20877124 rs13007229 chr2 15342428 T C 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBAS intron 20877124 rs10183588 chr2 15353916 A C 8.43E-05 Serum metabolites NBAS intron 19043545 rs4668885 chr2 15357213 T C 8.69E-05 Information processing speed NBAS intron 21130836 rs12616994 chr2 15373675 T C 4.20E-05 Information processing speed NBAS intron 21130836 rs2042144 chr2 15393316 T C 0.0004293 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs2042144 chr2 15393316 T C 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6711181 chr2 15400577 A G 0.0007672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6711181 chr2 15400577 A G 7.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs4668891 chr2 15401476 C T 0.000763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs4668891 chr2 15401476 C T 7.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10929356 chr2 15402016 T G 0.0005329 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10929356 chr2 15402016 T G 5.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs929735 chr2 15403932 C T 0.0007583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs929735 chr2 15403932 C T 7.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1989380 chr2 15404109 G C 0.0007569 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1989380 chr2 15404109 G C 7.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6431689 chr2 15404546 T C 0.000752 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6431689 chr2 15404546 T C 7.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs16862470 chr2 15405213 G A 4.89E-04 Multiple complex diseases NBAS intron 17554300 rs6738994 chr2 15405663 G T 0.000743 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6738994 chr2 15405663 G T 7.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs11904632 chr2 15406044 C A 0.0007415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs11904632 chr2 15406044 C A 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs11904635 chr2 15406061 C A 0.0007403 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs11904635 chr2 15406061 C A 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7605754 chr2 15406506 T A 0.000701 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7605754 chr2 15406506 T A 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10929357 chr2 15410107 A G 0.0003826 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10929357 chr2 15410107 A G 3.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs4465744 chr2 15410130 A G 0.0005373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs4465744 chr2 15410130 A G 5.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs962616 chr2 15413179 G A 0.0006686 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs962616 chr2 15413179 G A 6.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs962617 chr2 15413276 G A 0.0006676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs962617 chr2 15413276 G A 6.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs3805093 chr2 15418054 A C 0.000343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs3805093 chr2 15418054 A C 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs721858 chr2 15419856 T A 0.0004689 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs721858 chr2 15419856 T A 4.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs3828463 chr2 15419945 A C 0.0003412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs3828463 chr2 15419945 A C 3.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10193783 chr2 15420523 G A 0.0006446 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10193783 chr2 15420523 G A 6.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7575687 chr2 15421848 G C 0.0006373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7575687 chr2 15421848 G C 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7340328 chr2 15425781 T G 0.0004549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7340328 chr2 15425781 T G 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10199552 chr2 15427592 G T 0.0004546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10199552 chr2 15427592 G T 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs12613488 chr2 15433328 G T 0.0006299 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs12613488 chr2 15433328 G T 6.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7598652 chr2 15434967 T C 0.0004818 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7598652 chr2 15434967 T C 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7584861 chr2 15435181 C G 0.0004815 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7584861 chr2 15435181 C G 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs12993786 chr2 15437707 C T 0.0006368 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs12993786 chr2 15437707 C T 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10181295 chr2 15441492 G A 0.0003352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10181295 chr2 15441492 G A 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1076509 chr2 15441821 C T 0.0003356 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1076509 chr2 15441821 C T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs741570 chr2 15442041 G A 0.0003387 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs741570 chr2 15442041 G A 3.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10199885 chr2 15443121 T C 0.000251 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10199885 chr2 15443121 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6431690 chr2 15443525 T C 0.0002513 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6431690 chr2 15443525 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6708720 chr2 15447902 C T 0.0003362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6708720 chr2 15447902 C T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1318102 chr2 15448311 A T 0.0004764 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1318102 chr2 15448311 A T 4.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10206116 chr2 15450646 T C 0.0003546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10206116 chr2 15450646 T C 3.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs888636 chr2 15456209 G A 0.0005074 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs888636 chr2 15456209 G A 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10803672 chr2 15464726 A G 0.0005284 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10803672 chr2 15464726 A G 5.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7599455 chr2 15468791 G A 0.0007033 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7599455 chr2 15468791 G A 7.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs13405125 chr2 15479175 T C 5.10E-04 Aortic root size NBAS intron 21223598 rs7572081 chr2 15509146 A G 5.14E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines NBAS intron 21844884 rs2049718 chr2 15518589 C T 1.66E-04 Smoking cessation NBAS intron 18519826 rs16862653 chr2 15542352 C T 7.35E-04 Type 2 diabetes NBAS missense 17463246 rs2031011 chr2 15548390 T C 1.36E-04 Smoking cessation NBAS intron 18519826 rs2031011 chr2 15548390 T C 4.83E-05 Serum metabolites NBAS intron 19043545 rs7568678 chr2 15596203 C T 1.39E-04 Smoking cessation NBAS intron 18519826 rs2241237 chr2 15656157 T A 1.00E-04 Smoking cessation NBAS intron 18519826 rs2241237 chr2 15656157 T A 3.85E-04 Smoking cessation NBAS intron 18519826 rs7581919 chr2 15664756 C T 8.00E-06 Conduct disorder (symptom count) NBAS intron 20585324 rs7581919 chr2 15664756 C T 7.44E-04 Iron levels NBAS intron pha002876 rs6710456 chr2 15669939 T C 6.85E-05 Smoking cessation NBAS intron 18519826 rs11694485 chr2 15676154 C T 5.05E-06 Smoking cessation NBAS intron 18519826 rs3755130 chr2 15729583 G A 1.20E-05 Urinary metabolites / / 21572414 rs3755132 chr2 15729820 T G 1.00E-14 Wilms tumor / / 22544364 rs2302930 chr2 15737343 A G 3.10E-06 Wilms tumor DDX1 intron 22544364 rs2302931 chr2 15737480 C A 3.10E-06 Wilms tumor DDX1 intron 22544364 rs4668942 chr2 15750443 T C 3.10E-06 Wilms tumor DDX1 intron 22544364 rs7594193 chr2 15750640 A G 3.10E-06 Wilms tumor DDX1 intron 22544364 rs3770466 chr2 15758293 T C 3.10E-06 Wilms tumor DDX1 intron 22544364 rs3770467 chr2 15762935 G A 3.14E-06 Wilms tumor DDX1 intron 22544364 rs41264163 chr2 15763788 C T 3.14E-06 Wilms tumor DDX1 intron 22544364 rs4668945 chr2 15764078 G C 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6734471 chr2 15765425 C T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6743036 chr2 15767761 G A 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6743630 chr2 15768256 G A 3.34E-06 Wilms tumor DDX1 intron 22544364 rs3770470 chr2 15770507 G T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs3770471 chr2 15770775 C T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs4668948 chr2 15771586 A C 2.55E-06 Wilms tumor / / 22544364 rs4668949 chr2 15771615 C T 1.51E-06 Wilms tumor / / 22544364 rs976015 chr2 15772546 C G 3.14E-06 Wilms tumor / / 22544364 rs16862822 chr2 15772958 G A 3.34E-06 Wilms tumor / / 22544364 rs976233 chr2 15774115 C T 3.34E-06 Wilms tumor / / 22544364 rs16862823 chr2 15775210 T C 3.14E-06 Wilms tumor / / 22544364 rs807624 chr2 15782471 G T 1.00E-14 Wilms tumor / / 22544364 rs6724800 chr2 15786243 A G 1.86E-06 Wilms tumor / / 22544364 rs16862838 chr2 15788191 C T 1.71E-06 Wilms tumor / / 22544364 rs4668458 chr2 15789441 G A 2.22E-06 Wilms tumor / / 22544364 rs6431721 chr2 15791937 C T 2.66E-06 Wilms tumor / / 22544364 rs807571 chr2 15809109 G A 3.30E-04 Age-related macular degeneration / / 22125219 rs7579979 chr2 15812261 A G 1.31E-05 IgE levels / / 22075330 rs10929380 chr2 15812577 G A 1.34E-05 IgE levels / / 22075330 rs7593726 chr2 15813840 C T 1.72E-05 IgE levels / / 22075330 rs7582338 chr2 15818041 A G 5.88E-05 Insulin resistance / / 21901158 rs6739656 chr2 15832258 G C 4.31E-04 Coronary heart disease / / 21606135 rs6754458 chr2 15834052 A G 4.72E-04 Coronary heart disease / / 21606135 rs1862101 chr2 15843840 T C 8.11E-06 Ulcerative colitis / / 19915573 rs1862101 chr2 15843840 T C 5.80E-05 Lipid traits / / 22028671 rs6746441 chr2 15856372 A G 2.72E-06 Ulcerative colitis / / 19915573 rs7591368 chr2 15862330 C A 6.07E-07 Ulcerative colitis / / 19915573 rs6431731 chr2 15863002 C T 4.00E-08 Chronic kidney disease / / 22479191 rs2380671 chr2 15867707 A G 9.14E-05 Bipolar disorder and schizophrenia / / 20889312 rs2080799 chr2 15872327 T C 6.74E-05 Chronic obstructive pulmonary disease / / 19300482 rs2080799 chr2 15872327 T C 6.74E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2080798 chr2 15872385 T C 1.63E-05 Chronic obstructive pulmonary disease / / 19300482 rs2080798 chr2 15872385 T C 1.63E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1345564 chr2 15895707 C A 6.59E-05 Prostate cancer / / 22923026 rs2693010 chr2 15902138 G A 2.27E-05 Cognitive impairment induced by topiramate / / 22091778 rs2112101 chr2 15902679 T C 2.90E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs12464087 chr2 15902912 G A 7.68E-04 Type 2 diabetes / / 17463246 rs2544531 chr2 15904041 A G 6.39E-04 Type 2 diabetes / / 17463246 rs6728667 chr2 15904705 G A 1.32E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs6728750 chr2 15904734 G A 1.10E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544534 chr2 15906466 T C 2.23E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs1477253 chr2 15910457 T C 1.18E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693008 chr2 15913019 G C 2.23E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544523 chr2 15920323 T C 1.00E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693019 chr2 15922288 T C 1.36E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs1363058 chr2 15923441 C T 1.60E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544527 chr2 15926168 T C 9.00E-06 Pulmonary function / / 21946350 rs2544527 chr2 15926168 T C 2.00E-07 Pulmonary function (interaction) / / 23284291 rs2544527 chr2 15926168 T C 9.89E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2544527 chr2 15926168 T C 1.85E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693026 chr2 15926593 A G 5.72E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2380674 chr2 15931387 T C 9.30E-04 Multiple complex diseases / / 17554300 rs11894034 chr2 15940948 T C 1.90E-06 Urinary metabolites / / 21572414 rs4668996 chr2 15953381 T C 6.42E-04 Type 2 diabetes / / 17463246 rs2380694 chr2 15958803 T C 6.42E-06 Hair morphology / / 19896111 rs7586898 chr2 15961599 G C 2.00E-06 Hair morphology / / 19896111 rs7595922 chr2 15965628 T C 3.30E-04 Rheumatoid arthritis / / 21452313 rs11678237 chr2 15986586 C A 1.36E-04 Multiple complex diseases / / 17554300 rs2890494 chr2 15992495 G A 4.76E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11688136 chr2 16010659 A C 6.61E-04 Alzheimer's disease / / 17998437 rs2380707 chr2 16012630 A G 5.22E-04 Bone mass and geometry / / 17903296 rs10929397 chr2 16020019 T A,C 1.90E-05 Urinary metabolites / / 21572414 rs4669011 chr2 16029727 G A 1.99E-04 Multiple complex diseases / / 17554300 rs755915 chr2 16030231 A G 7.02E-04 Multiple complex diseases / / 17554300 rs2254328 chr2 16030567 A G 2.71E-04 Multiple complex diseases / / 17554300 rs746104 chr2 16031027 C T 2.28E-04 Multiple complex diseases / / 17554300 rs10495647 chr2 16035256 A G 3.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11676479 chr2 16036368 T C 5.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11676479 chr2 16036368 T C 9.30E-05 Iron levels / / 21208937 rs10803675 chr2 16056139 G A 1.62E-04 Type 2 diabetes / / 17463246 rs10803675 chr2 16056139 G A 8.23E-04 Multiple complex diseases / / 17554300 rs11886063 chr2 16080157 C G 5.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6719419 chr2 16127922 G A 1.94E-04 Multiple complex diseases / / 17554300 rs6706117 chr2 16131782 A G 5.34E-04 Alcohol dependence / / 20201924 rs3815884 chr2 16137572 C T 7.54E-04 Multiple complex diseases / / 17554300 rs2114802 chr2 16137611 C T 1.80E-05 Urinary metabolites / / 21572414 rs13396055 chr2 16142703 G A 4.67E-04 Multiple complex diseases / / 17554300 rs13396055 chr2 16142703 G A 2.90E-05 Urinary metabolites / / 21572414 rs41459549 chr2 16169350 C T 6.48E-04 Multiple complex diseases / / 17554300 rs6716719 chr2 16169371 A C 1.25E-04 Multiple complex diseases / / 17554300 rs11896089 chr2 16171139 T A 7.30E-05 Response to statin therapy / / 20339536 rs11896089 chr2 16171139 T A 0.00000472 HDL cholesterol particle diameter / / 23263444 rs10194143 chr2 16176894 T C 1.00E-04 Prostate cancer / / 21743057 rs55678912 chr2 16191545 C T 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7569161 chr2 16193273 A G 3.93E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7579022 chr2 16193461 G C 4.90E-04 Multiple complex diseases / / 17554300 rs72770595 chr2 16196085 A G 6.04E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770598 chr2 16197939 T A 4.58E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770600 chr2 16198363 T C 4.58E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770601 chr2 16198672 C T 5.94E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7608858 chr2 16201566 C T 1.51E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4668486 chr2 16243192 A C 4.33E-05 Multiple sclerosis / / 19525953 rs4047461 chr2 16358715 T G 4.92E-04 Multiple complex diseases / / 17554300 rs340718 chr2 16403550 G A 7.68E-04 Type 2 diabetes / / 17463246 rs12474170 chr2 16405448 G A 2.50E-05 Urinary metabolites / / 21572414 rs2163063 chr2 16430070 G A 4.84E-05 Blood Pressure / / pha003049 rs1429405 chr2 16433074 G A 6.69E-05 Blood Pressure / / pha003049 rs7569508 chr2 16433908 T C 4.07E-04 Alzheimer's disease / / 24755620 rs340738 chr2 16438076 A G 1.92E-06 Blood Pressure / / pha003049 rs1567967 chr2 16469070 G C 7.13E-04 Type 2 diabetes / / 17463246 rs340742 chr2 16471243 C A 4.58E-04 Smoking cessation / / 24665060 rs629526 chr2 16475090 T C 5.45E-04 Smoking cessation / / 24665060 rs680603 chr2 16488267 C T 2.47E-05 Sleep duration / / 22105623 rs13385414 chr2 16546282 A G 6.69E-04 Smoking initiation / / 24665060 rs1156704 chr2 16557140 C T 6.53E-05 Orofacial clefts / / 22419666 rs16982292 chr2 16589611 G T 8.06E-04 Multiple complex diseases / / 17554300 rs1367158 chr2 16590965 T A,C 3.23E-05 Weight / / pha003026 rs1367158 chr2 16590965 T A,C 5.18E-05 Weight / / pha003027 rs11884584 chr2 16598521 C A 1.64E-05 Height / / pha003011 rs2115849 chr2 16600041 T C 1.03E-05 Height / / pha003011 rs4832591 chr2 16606596 A G 7.21E-05 Height / / pha003010 rs4832591 chr2 16606596 A G 6.04E-06 Height / / pha003011 rs2115850 chr2 16609693 A G 8.72E-05 Height / / pha003010 rs2115850 chr2 16609693 A G 8.25E-06 Height / / pha003011 rs934224 chr2 16613889 C T 8.29E-05 Elbow pain / / pha003008 rs934224 chr2 16613889 C T 6.37E-05 Height / / pha003010 rs934224 chr2 16613889 C T 2.27E-06 Height / / pha003011 rs934224 chr2 16613889 C T 2.80E-05 Weight / / pha003026 rs6746008 chr2 16621135 G T 6.60E-07 Height / / pha003010 rs6746008 chr2 16621135 G T 6.24E-08 Height / / pha003011 rs7563815 chr2 16624337 C T 2.95E-06 Height / / pha003010 rs7563815 chr2 16624337 C T 2.11E-07 Height / / pha003011 rs4832615 chr2 16630784 T C 3.77E-05 Height / / pha003010 rs4832615 chr2 16630784 T C 2.49E-06 Height / / pha003011 rs13012094 chr2 16631289 C T 7.70E-06 Height / / pha003010 rs13012094 chr2 16631289 C T 2.15E-06 Height / / pha003011 rs10185113 chr2 16632751 A G 6.03E-05 Height / / pha003010 rs10185113 chr2 16632751 A G 1.32E-05 Height / / pha003011 rs1346751 chr2 16639566 C T 8.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs4832633 chr2 16648888 G A 1.90E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4832633 chr2 16648888 G A 5.80E-05 Height / / pha003010 rs4832633 chr2 16648888 G A 6.15E-06 Height / / pha003011 rs4393752 chr2 16652659 T C 7.61E-05 Height / / pha003011 rs16982439 chr2 16655641 C T 3.66E-04 Type 2 diabetes / / 17463246 rs1346752 chr2 16676846 T C 2.88E-05 Height / / pha003011 rs1430054 chr2 16680691 A G 2.86E-05 Height / / pha003011 rs1430055 chr2 16680789 G A 2.79E-07 Esophageal cancer (squamous cell) / / 22960999 rs12463697 chr2 16686128 A G 6.68E-05 Height / / pha003010 rs12463697 chr2 16686128 A G 1.68E-06 Height / / pha003011 rs4240228 chr2 16688759 G T 3.04E-05 Height / / pha003011 rs6705856 chr2 16698235 C T 9.94E-05 Height / / pha003011 rs4560110 chr2 16702136 A G 2.96E-05 Height / / pha003011 rs4832647 chr2 16705396 A G 9.40E-05 Orofacial clefts / / 22863734 rs4497881 chr2 16706891 C A 7.63E-05 Cleft lip / / 20436469 rs4497881 chr2 16706891 C A 1.77E-06 Orofacial clefts / / 22863734 rs4441471 chr2 16715408 A G 3.37E-05 Cleft lip / / 20436469 rs4441471 chr2 16715408 A G 8.00E-07 Orofacial clefts / / 22863734 rs6761778 chr2 16717466 C T 2.87E-07 Facial morphology / / 22341974 rs2067702 chr2 16718894 A G 2.87E-07 Facial morphology / / 22341974 rs6752432 chr2 16720447 C T 2.01E-04 Type 2 diabetes / / 17463246 rs6741506 chr2 16720735 G C 1.52E-04 Type 2 diabetes / / 17463246 rs4832657 chr2 16726739 C T 2.68E-07 Facial morphology / / 22341974 rs10168963 chr2 16729410 C T 5.43E-05 Cognitive test performance / / 20125193 rs15653 chr2 16731510 G A 5.35E-06 Orofacial clefts FAM49A UTR-3 22863734 rs555725386 chr2 16731510 G GT 5.35E-06 Orofacial clefts FAM49A UTR-3 22863734 rs5007483 chr2 16733525 G T 4.42E-07 Facial morphology FAM49A UTR-3 22341974 rs7552 chr2 16733928 A G 3.25E-07 Facial morphology FAM49A UTR-3 22341974 rs12997119 chr2 16734284 T C 2.52E-07 Facial morphology FAM49A intron 22341974 rs6743040 chr2 16734999 T C 1.92E-04 Type 2 diabetes FAM49A intron 17463246 rs7573656 chr2 16735432 G A 3.01E-07 Facial morphology FAM49A intron 22341974 rs7586823 chr2 16741442 C T 8.51E-05 Intelligence FAM49A intron 21826061 rs6743717 chr2 16791265 G A 4.57E-05 Amyotrophic Lateral Sclerosis FAM49A intron 17827064 rs11679606 chr2 16795418 A G 1.30E-04 Type 2 diabetes FAM49A intron 17463249 rs11679606 chr2 16795418 A G 1.29E-04 Multiple complex diseases FAM49A intron 17554300 rs6723770 chr2 16795666 T C 1.35E-04 Multiple complex diseases FAM49A intron 17554300 rs11897395 chr2 16807587 C A 4.53E-04 Parkinson's disease FAM49A intron 17052657 rs9306896 chr2 16813028 G C 8.77E-05 Multiple complex diseases FAM49A intron 17554300 rs41347856 chr2 16867615 G A 8.98E-04 Multiple complex diseases / / 17554300 rs17645454 chr2 16896822 C T 7.18E-05 Type 2 diabetes / / 17463246 rs1722426 chr2 16907892 C A 3.94E-04 Heart Failure / / pha002885 rs6732082 chr2 16909022 A G 4.20E-07 Urinary metabolites / / 21572414 rs11674035 chr2 16921112 T C 0.0001 Migraine / / 22678113 rs1862059 chr2 16926228 C T 0.0001 Migraine / / 22678113 rs16982730 chr2 16946721 T G 9.02E-04 Type 2 diabetes / / 17463246 rs11096693 chr2 16949116 G C 9.28E-04 Type 2 diabetes / / 17463246 rs11690985 chr2 16949922 C T 5.28E-04 Type 2 diabetes / / 17463246 rs11693345 chr2 16950112 A G 5.85E-04 Type 2 diabetes / / 17463246 rs16982758 chr2 16950440 A C 7.69E-04 Type 2 diabetes / / 17463246 rs11682177 chr2 16956880 T C 6.25E-04 Type 2 diabetes / / 17463246 rs2341997 chr2 16971986 T C 3.30E-05 Anger / / 24489884 rs2341997 chr2 16971986 T C 4.29E-05 Heart Rate / / pha003051 rs2160938 chr2 16995726 G C 4.95E-04 Multiple complex diseases / / 17554300 rs4140716 chr2 17015790 C T 7.16E-04 Aortic root size / / 21223598 rs2042077 chr2 17019622 G A 4.91E-05 Erythrocyte counts / / pha003101 rs34823620 chr2 17021774 T C 9.52E-04 Multiple complex diseases / / 17554300 rs2216451 chr2 17024097 C A 3.40E-05 Erythrocyte counts / / pha003101 rs11096709 chr2 17103115 C G 5.82E-04 Type 2 diabetes / / 17463246 rs2042079 chr2 17105852 C T 4.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2042079 chr2 17105852 C T 2.85E-06 Bipolar disorder / / 17486107 rs2042079 chr2 17105852 C T 1.20E-05 Parkinson's disease / / 19915575 rs2042079 chr2 17105852 C T 3.40E-05 Parkinson's disease / / pha002868 rs4832481 chr2 17122737 A C 3.61E-05 Erythrocyte counts / / pha003101 rs6707000 chr2 17128879 A G 8.15E-04 Rheumatoid arthritis / / 21452313 rs1515966 chr2 17216459 T C 4.72E-04 Parkinson's disease / / 17052657 rs1515966 chr2 17216459 T C 6.92E-04 HIV-1 viral setpoint / / 17641165 rs1356186 chr2 17227509 A G 2.76E-05 Bipolar disorder / / 17486107 rs11690007 chr2 17258880 T C 4.29E-04 Type 2 diabetes / / 17463246 rs7340478 chr2 17271133 G A 1.91E-04 Aortic root size / / 21223598 rs10495658 chr2 17303288 T G 0.0000399 Schizophrenia / / 23637625 rs13006099 chr2 17305810 G A 3.77E-04 Body mass index / / 21701565 rs2342551 chr2 17314547 C T 6.40E-04 Multiple complex diseases / / 17554300 rs12987450 chr2 17344959 G C 5.71E-04 Multiple complex diseases / / 17554300 rs1588173 chr2 17346118 C A 6.89E-04 Multiple complex diseases / / 17554300 rs12620480 chr2 17353506 G C 5.62E-04 Body mass index / / 21701565 rs484687 chr2 17359400 T C 8.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195119 chr2 17365709 C T 3.99E-04 Multiple complex diseases / / 17554300 rs13401551 chr2 17373951 G A 3.89E-04 Multiple complex diseases / / 17554300 rs10182258 chr2 17379728 G A,C,T 3.42E-04 Multiple complex diseases / / 17554300 rs12467252 chr2 17384658 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs11898524 chr2 17386806 T C 5.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs11893015 chr2 17387162 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs13031560 chr2 17388290 T C 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1589272 chr2 17389900 G A 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10495660 chr2 17396548 T G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11674840 chr2 17397895 A G 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs1519969 chr2 17399452 T A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1519968 chr2 17399486 A C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs7419572 chr2 17399740 G A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs16983357 chr2 17399921 G C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11693140 chr2 17400070 A T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2030358 chr2 17400329 T C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2030357 chr2 17400393 A G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11673738 chr2 17401389 T A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11677772 chr2 17401741 G T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1507986 chr2 17402996 C T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2174865 chr2 17403582 C G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13020402 chr2 17403829 C T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13018947 chr2 17403887 G C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11889338 chr2 17427585 G A 9.00E-06 Alzheimer's disease / / 22159054 rs6740500 chr2 17430803 C T 2.50E-04 White matter integrity / / 22425255 rs7602088 chr2 17530815 A G 3.67E-06 Asthma / / 21790008 rs3112233 chr2 17556532 A C 2.90E-05 Orofacial clefts / / 22419666 rs12185578 chr2 17609239 T A 9.00E-06 Subcutaneous adipose tissue / / 22589738 rs17380100 chr2 17681504 T C 5.75E-05 Cognitive test performance / / 20125193 rs17380121 chr2 17683231 G T 7.81E-05 Alcohol consumption / / 23953852 rs446947 chr2 17712696 A T 6.65E-05 Serum metabolites / / 19043545 rs426590 chr2 17738199 C T 6.65E-05 Serum metabolites VSNL1 intron 19043545 rs16983673 chr2 17766142 C T 6.81E-04 Amyotrophic Lateral Sclerosis VSNL1 intron 17362836 rs16983681 chr2 17768968 C T 6.43E-04 Alzheimer's disease VSNL1 intron 22005930 rs1033301 chr2 17773998 A C 9.73E-07 Alzheimer's disease VSNL1 intron 22005930 rs4038129 chr2 17774746 A G 9.58E-07 Alzheimer's disease VSNL1 intron 22005930 rs4038131 chr2 17775032 A G 6.00E-07 Alzheimer's disease VSNL1 intron 22005930 rs1949510 chr2 17778129 C T 2.16E-06 Alzheimer's disease VSNL1 intron 22005930 rs1426510 chr2 17782556 A T 4.36E-05 Serum metabolites VSNL1 intron 19043545 rs13006235 chr2 17790442 C G 7.72E-04 Alzheimer's disease VSNL1 intron 22005930 rs7560823 chr2 17879411 T C 4.06E-05 Post-operative nausea and vomiting SMC6 intron 21694509 rs11897477 chr2 17902381 C G 7.81E-04 Alzheimer's disease SMC6 intron 22005930 rs7574887 chr2 17948649 T C 0.00019 Cognitive impairment (no dementia) GEN1 intron 23042215 rs2615048 chr2 17958762 G A 9.24E-21 Lymphocyte counts GEN1 intron 22286170 rs13394205 chr2 17986027 C A 1.08E-05 Multiple complex diseases / / 17554300 rs214034 chr2 17988658 A C 7.00E-06 Response to amphetamines / / 22952603 rs12710647 chr2 17989466 T A,C,G 1.05E-04 Gallstones / / 17632509 rs1564010 chr2 17991857 A G 2.69E-04 Multiple complex diseases / / 17554300 rs4302214 chr2 18016788 C T 3.59E-04 Multiple complex diseases / / 17554300 rs1063 chr2 18026245 G A 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11680328 chr2 18037807 T A 5.00E-05 Obesity (extreme) / / 21935397 rs6758546 chr2 18038812 A G 9.24E-06 Obesity (extreme) / / 21935397 rs6758546 chr2 18038812 A G 4.70E-05 Body Mass Index / / pha003009 rs7583266 chr2 18083850 G A 7.44E-05 Rheumatoid arthritis KCNS3 intron 17804836 rs1564004 chr2 18098857 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNS3 intron 20877124 rs1564004 chr2 18098857 C T 6.00E-04 Bipolar disorder KCNS3 intron 24387768 rs1461949 chr2 18102223 G A 7.45E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs1461946 chr2 18106179 G A 6.66E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs2045720 chr2 18110711 T C 6.72E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs4832524 chr2 18113623 A G 6.50E-04 Suicide attempts in bipolar disorder KCNS3 missense 21423239 rs3747515 chr2 18113789 G A 3.60E-04 Suicide attempts in bipolar disorder KCNS3 UTR-3 21423239 rs1031771 chr2 18114932 C T 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs6712999 chr2 18115305 C G 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs6713395 chr2 18115603 C G 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs6713633 chr2 18115776 C A 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11889711 chr2 18117236 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832526 chr2 18117419 C T 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1471342 chr2 18122198 C T 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11689375 chr2 18129524 T C 8.98E-04 Multiple complex diseases / / 17554300 rs7590044 chr2 18178394 C G 4.70E-06 Urinary metabolites / / 21572414 rs12052676 chr2 18189056 T G 1.95E-05 Smoking initiation / / 24665060 rs2710005 chr2 18214457 G A 4.89E-04 Smoking initiation / / 24665060 rs16984191 chr2 18223548 C T 5.33E-05 Odorant perception / / 23910658 rs4832534 chr2 18227620 G A 3.34E-04 Smoking initiation / / 24665060 rs2345089 chr2 18230779 A G 1.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16984239 chr2 18234446 C A 2.00E-06 Amyotrophic lateral sclerosis / / 17362836 rs16984239 chr2 18234446 C A 1.70E-06 Amyotrophic lateral sclerosis (sporadic) / / 19740415 rs4832537 chr2 18235029 C A 7.06E-05 QT interval / / 22726844 rs1962539 chr2 18235611 C A 2.38E-04 Iron levels / / pha002876 rs3924803 chr2 18235971 T G 4.00E-05 Temperament (bipolar disorder) / / 22365631 rs7560267 chr2 18239971 T G 2.50E-05 Temperament (bipolar disorder) / / 22365631 rs4075511 chr2 18243534 A C 3.00E-06 Temperament (bipolar disorder) / / 22365631 rs6748095 chr2 18247868 G C 2.20E-05 Temperament (bipolar disorder) / / 22365631 rs6748095 chr2 18247868 G C 8.30E-06 QT interval / / 22726844 rs13015992 chr2 18256919 A C 3.78E-04 Type 2 diabetes / / 17463246 rs7580025 chr2 18265521 C T 5.45E-04 Iron levels / / pha002876 rs11899855 chr2 18268451 G A 1.60E-05 Urinary metabolites / / 21572414 rs7578543 chr2 18270135 C T 2.60E-05 Urinary metabolites / / 21572414 rs4832407 chr2 18271334 G A 6.87E-04 Type 2 diabetes / / 17463246 rs13395500 chr2 18275620 G C 8.77E-05 Serum metabolites / / 19043545 rs17388890 chr2 18276766 T C 8.61E-04 Multiple complex diseases / / 17554300 rs2345493 chr2 18292201 G T 5.22E-05 Pulmonary function / / 20010834 rs12471785 chr2 18314546 G A 7.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs11684345 chr2 18316158 T C 7.73E-05 Femoral neck bone geometry / / 22087292 rs2345496 chr2 18316641 A G 7.31E-04 Multiple complex diseases / / 17554300 rs1377068 chr2 18329769 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10495679 chr2 18352405 G T 5.36E-04 Diabetic retinopathy / / 20871662 rs1993163 chr2 18360228 T C 1.01E-04 Body mass index / / 17255346 rs13023396 chr2 18361283 A G 6.85E-05 Type 2 diabetes / / 17463246 rs2345513 chr2 18366716 A C 5.46E-05 Body mass index / / 17255346 rs1377085 chr2 18367133 A G 2.21E-04 Body mass index / / 17255346 rs4832549 chr2 18368355 G A 1.74E-04 Body mass index / / 17255346 rs4832551 chr2 18371880 A G 2.53E-04 Body mass index / / 17255346 rs1013260 chr2 18381993 T C 7.18E-05 Orofacial clefts / / 22419666 rs16984512 chr2 18413287 C G 3.67E-04 Blood pressure / / 17255346 rs12710680 chr2 18422013 A G 7.20E-05 Cognitive function / / 24684796 rs16984594 chr2 18451111 A G 1.07E-04 Body mass index / / 17255346 rs16984606 chr2 18451405 T C 1.34E-04 Body mass index / / 17255346 rs16984606 chr2 18451405 T C 3.80E-04 Multiple complex diseases / / 17554300 rs1452420 chr2 18470759 C A 3.45E-04 Type 2 diabetes / / 17463246 rs7606861 chr2 18484044 G A 3.46E-04 Body mass index / / 17255346 rs10205974 chr2 18486802 A G 1.90E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6721414 chr2 18494495 G C 8.00E-04 Chronic fatigue syndrome / / 21912186 rs16984751 chr2 18520021 G A 3.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16984751 chr2 18520021 G A 4.32E-04 Myopia (pathological) / / 21095009 rs1489694 chr2 18533217 A G 1.40E-05 Urinary metabolites / / 21572414 rs7580332 chr2 18540644 A G 9.00E-06 Amyotrophic lateral sclerosis / / 18084291 rs876030 chr2 18544954 G A 5.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11096532 chr2 18551509 G A 5.97E-06 Hearing function / / 17255346 rs12104719 chr2 18565886 T C 0.00008648 Sarcoidosis / / 22952805 rs6761216 chr2 18567007 C G 0.0005101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6761216 chr2 18567007 C G 5.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832576 chr2 18569545 C G 9.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832433 chr2 18569645 A C 0.0006666 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4832433 chr2 18569645 A C 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832578 chr2 18571007 C T 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13393337 chr2 18571609 T G 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13397559 chr2 18573398 A T 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4240217 chr2 18573767 T C 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7570270 chr2 18576488 C A 9.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10191509 chr2 18576516 T G 9.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7584064 chr2 18576603 A C 9.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6531096 chr2 18576647 C T 9.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7584173 chr2 18576687 A T 9.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4510230 chr2 18576980 A G 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4335948 chr2 18577104 C T 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6723572 chr2 18578097 T C 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1356321 chr2 18578853 C T 0.00005212 Sarcoidosis / / 22952805 rs1356320 chr2 18578880 A G 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6728574 chr2 18579741 T G 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6710668 chr2 18579818 C T 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6710757 chr2 18579846 C T 9.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6731646 chr2 18579967 T G 0.0008982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6731646 chr2 18579967 T G 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6728709 chr2 18580069 A G 0.0008972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6728709 chr2 18580069 A G 8.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6731858 chr2 18580130 T C 0.0008975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6731858 chr2 18580130 T C 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9678808 chr2 18580434 G C 0.0004236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9678808 chr2 18580434 G C 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs969030 chr2 18582725 G A 8.25E-05 Hearing function / / 17255346 rs969030 chr2 18582725 G A 0.00008658 Sarcoidosis / / 22952805 rs17690910 chr2 18585657 T C 0.0008314 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1489680 chr2 18590088 G A 0.00003777 Sarcoidosis / / 22952805 rs13432451 chr2 18590537 G A 0.0004508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13432451 chr2 18590537 G A 4.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4372901 chr2 18590974 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7558548 chr2 18594360 A G 9.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16984968 chr2 18603773 A G 7.60E-06 Urinary metabolites / / 21572414 rs6732003 chr2 18610381 T C 5.07E-04 Aortic root size / / 21223598 rs9808546 chr2 18621953 T C 2.20E-05 Urinary metabolites / / 21572414 rs13428828 chr2 18626184 C T 2.70E-05 Urinary metabolites / / 21572414 rs7589253 chr2 18648687 A G 1.10E-05 Urinary metabolites / / 21572414 rs6745120 chr2 18681809 G A 1.89E-05 Cognitive test performance / / 20125193 rs2345724 chr2 18685074 A G 9.04E-06 Alopecia areata / / 22027810 rs16985182 chr2 18699750 A G 3.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2272519 chr2 18711750 C T 7.20E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs4462780 chr2 18725175 C A 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16985278 chr2 18734072 C T 4.97E-04 Stroke / / pha002887 rs2252736 chr2 18787470 T C 8.27E-05 Glucose levels / / pha003058 rs16985374 chr2 18828102 C G 6.31E-06 Odorant perception / / 23910658 rs12053481 chr2 18832346 C A 4.87E-05 Stroke / / pha002887 rs1445130 chr2 18834651 A G 1.00E-07 Bulimia nervosa / / 23568457 rs4602226 chr2 18839561 C G 0.0008627 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4602226 chr2 18839561 C G 8.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1550771 chr2 18860375 T C 5.40E-04 Alcohol dependence / / 20201924 rs4832620 chr2 18953108 C T 5.47E-04 Coronary Artery Disease / / 17634449 rs11892969 chr2 18973451 G A 5.35E-04 Alzheimer's disease / / 17998437 rs6531119 chr2 18993027 C T 5.85E-04 Stroke / / pha002887 rs7570667 chr2 19074654 A G 6.95E-04 Rheumatoid arthritis / / 21452313 rs7602667 chr2 19096952 C A 3.17E-05 Cognitive performance / / 19734545 rs1876040 chr2 19134748 A G 6.00E-08 Cognitive performance / / 20125193 rs1317019 chr2 19140546 G A 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1343785 chr2 19163825 A G 2.10E-05 Urinary metabolites / / 21572414 rs17704720 chr2 19170212 C T 9.09E-04 Alzheimer's disease / / 22005930 rs17755914 chr2 19183676 G A 3.41E-04 Alzheimer's disease / / 22005930 rs884895 chr2 19184996 G A 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4832642 chr2 19249694 T C 7.40E-05 Hematology traits / / 23303382 rs16985872 chr2 19257397 T C 7.12E-04 Coronary heart disease / / 21606135 rs4666451 chr2 19286943 G A 2.00E-07 Breast cancer / / 17529967 rs12710696 chr2 19320803 T C 6.06E-04 Multiple complex diseases / / 17554300 rs12710696 chr2 19320803 T C 5.00E-08 Breast cancer / / 23535733 rs12464722 chr2 19341657 C T 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12710701 chr2 19344757 T C 1.76E-05 Serum metabolites / / 19043545 rs12105891 chr2 19354741 T G 5.18E-04 Multiple complex diseases / / 17554300 rs12105891 chr2 19354741 T G 8.01E-05 Serum metabolites / / 19043545 rs11904265 chr2 19358483 T C 8.00E-04 Smoking cessation / / 24665060 rs2118381 chr2 19368078 G A 7.55E-05 Serum metabolites / / 19043545 rs851340 chr2 19369285 A T 6.74E-05 Serum metabolites / / 19043545 rs16981939 chr2 19376903 T C 5.48E-05 Cocaine dependence / / 23958962 rs16981939 chr2 19376903 T C 5.55E-04 Cocaine dependence / / 23958962 rs13034680 chr2 19435346 C A 4.36E-05 Vitiligo / / 19890347 rs851365 chr2 19469209 T C 1.40E-05 Urinary metabolites / / 21572414 rs851357 chr2 19473075 C T 1.58E-05 Coronary Artery Disease / / 17634449 rs851357 chr2 19473075 C T 1.60E-05 Urinary metabolites / / 21572414 rs17439558 chr2 19473547 T C 9.51E-06 Bipolar disorder and schizophrenia / / 20889312 rs17439558 chr2 19473547 T C 8.84E-04 Response to TNF antagonist treatment / / 21061259 rs851352 chr2 19475331 C T 8.30E-06 Urinary metabolites / / 21572414 rs984899 chr2 19485726 G C 1.60E-05 Urinary metabolites / / 21572414 rs1965786 chr2 19486628 T C 1.70E-05 Urinary metabolites / / 21572414 rs703323 chr2 19489081 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1727177 chr2 19492579 T C 5.94E-08 Corneal structure / / 22003120 rs10514626 chr2 19497993 G A 4.65E-06 Longevity / / 21612516 rs703315 chr2 19501213 T A 5.40E-06 Urinary metabolites / / 21572414 rs6725667 chr2 19524172 T G 3.14E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs6735941 chr2 19524457 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6531166 chr2 19540002 A G 8.61E-05 Cognitive impairment induced by topiramate / / 22091778 rs17441606 chr2 19568435 C A 5.25E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs7603289 chr2 19582775 T C 1.66E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs1522493 chr2 19598472 A G 2.26E-04 Stroke / / pha002886 rs16986388 chr2 19616496 C T 3.96E-04 Multiple complex diseases / / 17554300 rs2198161 chr2 19625636 G A 6.86E-05 Nephrolithiasis / / 22396660 rs703297 chr2 19625818 C T 4.11E-05 Nephrolithiasis / / 22396660 rs703297 chr2 19625818 C T 6.60E-04 Stroke / / pha002886 rs13398721 chr2 19629304 T C 2.00E-07 non-small cell lung cancer / / 23478653 rs17495469 chr2 19629832 A G 2.00E-04 Polycystic ovary syndrome / / 22178785 rs7596217 chr2 19650271 C T 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13386398 chr2 19665118 C T 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4666491 chr2 19705084 G A 9.11E-04 Depression (quantitative trait) / / 20800221 rs10208877 chr2 19723280 C T 5.28E-04 Multiple complex diseases / / 17554300 rs824506 chr2 19730376 T C 4.23E-05 Post-operative nausea and vomiting / / 21694509 rs1427547 chr2 19739976 T C 1.04E-04 Blood pressure / / 21909110 rs11897302 chr2 19774399 T C 0.00000778 Carotid intima media thickness / / 23152477 rs1344650 chr2 19776038 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7586564 chr2 19788211 C T 3.28E-04 Iron levels / / pha002876 rs1427540 chr2 19790551 A T 4.58E-04 Type 2 diabetes / / 17463246 rs1427540 chr2 19790551 A T 3.55E-04 Alzheimer's disease / / 17998437 rs7573038 chr2 19800918 A T 8.92E-04 Multiple complex diseases / / 17554300 rs1453194 chr2 19872803 G A,C,T 3.93E-04 Multiple complex diseases / / 17554300 rs6531190 chr2 19878796 T C 1.64E-04 Multiple complex diseases / / 17554300 rs6531193 chr2 19889227 C T 6.69E-04 Iron levels / / pha002876 rs17562209 chr2 19911287 C T 6.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2167796 chr2 19915600 C A 2.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16986953 chr2 19942473 G A 0.000000896 Coronary artery disease / / 23202125 rs16986953 chr2 19942473 G A 0.00000406 Coronary artery disease with myocardial infarction / / 23202125 rs16986953 chr2 19942473 G A 0.000552 Coronary artery disease (CAD) age >50 / / 23202125 rs16986953 chr2 19942473 G A 1.67E-08 Coronary artery disease (CAD) age <=50 / / 23202125 rs16986953 chr2 19942473 G A 1.89E-08 Coronary artery disease (CAD) (males) / / 23202125 rs2123536 chr2 19945577 T C 7.00E-11 Coronary heart disease / / 22751097 rs4666562 chr2 19948931 G A 7.25E-05 Multiple complex diseases / / 17554300 rs7569689 chr2 19951724 G A 7.61E-04 Coronary Artery Disease / / 17634449 rs1453200 chr2 19952128 T C 8.45E-04 Multiple complex diseases / / 17554300 rs16987000 chr2 19952459 A G 2.12E-04 Multiple complex diseases / / 17554300 rs17621899 chr2 19952635 A T 2.49E-04 Coronary Artery Disease / / 17634449 rs17564315 chr2 19958496 G A 8.56E-04 Multiple complex diseases / / 17554300 rs17564315 chr2 19958496 G A 7.00E-07 Inflammatory biomarkers / / 22228203 rs9306885 chr2 19988832 T C 3.80E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs6728440 chr2 19999346 G A 2.00E-07 Inflammatory biomarkers / / 22228203 rs11694666 chr2 20014876 T C 3.73E-04 Multiple complex diseases / / 17554300 rs1866182 chr2 20022983 T A 1.20E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs1866183 chr2 20023099 T A 1.02E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10200435 chr2 20034313 G A 8.96E-05 Smoking initiation / / 24665060 rs6725359 chr2 20035911 C T 5.58E-04 Multiple complex diseases / / 17554300 rs16987151 chr2 20043254 A G 1.66E-05 Personality dimensions / / 18957941 rs11096623 chr2 20046065 A G 8.27E-04 Multiple complex diseases / / 17554300 rs2083141 chr2 20050793 C G 5.99E-04 Multiple complex diseases / / 17554300 rs2083141 chr2 20050793 C G 3.22E-04 Smoking initiation / / 24665060 rs6750471 chr2 20052298 C T 0.0000134 Circulating PCSK9 levels / / 22460556 rs10184466 chr2 20054057 G A 1.15E-04 Gallstones / / 17632509 rs964864 chr2 20059031 G A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs964864 chr2 20059031 G A 2.05E-04 Lung function (forced vital capacity) / / 24023788 rs11676372 chr2 20072512 C T 3.60E-04 Aortic root size FLJ12334 intron 21223598 rs1370586 chr2 20090469 G A 7.24E-04 Multiple complex diseases / / 17554300 rs2304589 chr2 20101487 G A 1.80E-05 Lipid traits TTC32 cds-synon 17903299 rs2304589 chr2 20101487 G A 6.35E-04 Bipolar disorder TTC32 cds-synon 19259986 rs2278528 chr2 20101832 C G 2.00E-05 Lipid traits / / 17903299 rs3731661 chr2 20110856 G A 1.00E-04 Cognitive impairment induced by topiramate WDR35 UTR-3 22091778 rs1381817 chr2 20179220 C T 1.87E-07 Lymphocyte counts WDR35 intron 22286170 rs11674251 chr2 20216509 T C 9.01E-42 Non-small cell lung cancer / / 21866343 rs1191812 chr2 20224999 A C 1.00E-05 Information processing speed LOC100506455 intron 21130836 rs12471796 chr2 20256192 G A 1.40E-05 Major depressive disorder / / 19065144 rs12471796 chr2 20256192 G A 2.77E-06 Major depressive disorder / / 21621269 rs12471796 chr2 20256192 G A 1.51E-05 Major depressive disorder / / pha002850 rs12472043 chr2 20256838 G A 0.00000519 Major depressive disorder / / 23149448 rs1513831 chr2 20256856 G T 7.00E-06 Information processing speed / / 21130836 rs1513831 chr2 20256856 G T 0.0000418 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11694170 chr2 20260512 T C 7.00E-06 Information processing speed / / 21130836 rs11694170 chr2 20260512 T C 0.0000418 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7565124 chr2 20261685 G A 1.10E-05 Major depressive disorder / / 19065144 rs7565124 chr2 20261685 G A 2.00E-06 Major depressive disorder / / 21621269 rs7565124 chr2 20261685 G A 1.38E-05 Major depressive disorder / / pha002850 rs2126551 chr2 20270027 A G 0.0000217 Major depressive disorder / / 23149448 rs878983 chr2 20277748 C T 8.60E-05 Information processing speed / / 21130836 rs11689490 chr2 20281927 T C 1.00E-04 Information processing speed / / 21130836 rs13384258 chr2 20322005 T C 3.44E-05 Orofacial clefts / / 22419666 rs13384258 chr2 20322005 T C 1.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13384258 chr2 20322005 T C 5.68E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6531209 chr2 20334723 G T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4666360 chr2 20335709 G A 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4666360 chr2 20335709 G A 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4666360 chr2 20335709 G A 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4666366 chr2 20340155 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs981396 chr2 20346651 G A 4.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs981395 chr2 20346774 T G 2.91E-05 HIV-1 control / / 20041166 rs10495703 chr2 20350783 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs977130 chr2 20351391 A C 0.0000854 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11899121 chr2 20367973 G C 3.50E-06 Parkinson's disease (age of onset) / / 19772629 rs11894335 chr2 20368196 A G 3.35E-06 Triglycerides / / pha003080 rs870526 chr2 20369562 C T 7.70E-06 Parkinson's disease (age of onset) / / 19772629 rs2090033 chr2 20372497 C T 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6419087 chr2 20377392 C A 2.90E-05 Urinary metabolites / / 21572414 rs13428318 chr2 20378882 T G 1.00E-04 Information processing speed / / 21130836 rs13428318 chr2 20378882 T G 4.47E-05 Triglycerides / / pha003080 rs6742663 chr2 20395160 A G 6.68E-06 Hearing function / / 21493956 rs6756290 chr2 20395611 G T 7.98E-06 Hearing function / / 21493956 rs2348475 chr2 20397114 C T 8.28E-06 Hearing function / / 21493956 rs11895809 chr2 20399054 A G 8.30E-06 Hearing function / / 21493956 rs4666374 chr2 20399764 A T 1.21E-04 Acne (severe) / / 24927181 rs4350703 chr2 20400269 T A 7.35E-06 Hearing function / / 21493956 rs1043419 chr2 20448561 A G 4.16E-05 Attention deficit hyperactivity disorder PUM2 UTR-3 pha002875 rs10164749 chr2 20472847 G A 9.95E-05 Premature ovarian failure PUM2 intron 19508998 rs10164749 chr2 20472847 G A 9.95E-05 Other erythrocyte phenotypes PUM2 intron 19862010 rs10195153 chr2 20551993 G A 7.46E-04 Multiple complex diseases / / 17554300 rs4666383 chr2 20572094 T C 4.43E-05 Myocardial Infarction / / pha002873 rs10514649 chr2 20582635 G A 6.49E-06 Job-related exhaustion / / 23620144 rs343155 chr2 20592798 G A 1.50E-05 Breast cancer / / 17529974 rs343155 chr2 20592798 G A 2.71E-05 Brain structure / / 22504417 rs16987610 chr2 20605249 A G 8.91E-04 Alzheimer's disease / / 17998437 rs16987610 chr2 20605249 A G 3.53E-05 Brain structure / / 22504417 rs343140 chr2 20605810 C A 5.74E-04 Type 2 diabetes / / 17463246 rs1010415 chr2 20627875 G A 6.56E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3892295 chr2 20628882 T G 3.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs6531240 chr2 20665361 C T 1.36E-04 Insulin resistance / / 21901158 rs11901246 chr2 20665400 G T 3.48E-04 Multiple complex diseases / / 17554300 rs959058 chr2 20675601 T C 6.73E-05 Bipolar disorder,affective / / 20528957 rs959058 chr2 20675601 T C 3.02E-04 White matter integrity / / 22425255 rs2084919 chr2 20678496 T C 6.23E-05 Depression (quantitative trait) / / 23290196 rs12997261 chr2 20682303 T G 3.62E-04 Rheumatoid arthritis / / 21452313 rs342070 chr2 20685471 C T 1.04E-05 Systemic sclerosis / / 21750679 rs13021401 chr2 20688519 C T 3.00E-06 Systemic sclerosis / / 21750679 rs931257 chr2 20688941 A C 4.69E-04 Rheumatoid arthritis / / 21452313 rs4666412 chr2 20695707 T C 8.04E-05 Height / / pha003010 rs4666412 chr2 20695707 T C 3.82E-07 Height / / pha003011 rs342096 chr2 20696256 G T 0.000314 Schizophrenia / / 22440650 rs342136 chr2 20709989 C T 6.14E-04 Lymphocyte counts / / 22286170 rs7568542 chr2 20719241 T C 8.95E-04 Multiple complex diseases / / 17554300 rs4666415 chr2 20720237 A G 0.000539 Height (Pygmy height) / / 22570615 rs10495705 chr2 20741344 T C 4.64E-05 Serum metabolites / / 19043545 rs2348868 chr2 20751009 G A 5.74E-04 Multiple complex diseases / / 17554300 rs2117842 chr2 20761069 G A,C 6.75E-04 Obesity (early onset extreme) / / 23563609 rs16987836 chr2 20763911 T C 2.35E-04 Multiple complex diseases / / 17554300 rs16987893 chr2 20806453 G T 0.000848 Height (Pygmy height) / / 22570615 rs4666441 chr2 20813657 G A 3.51E-04 Type 2 diabetes / / 17463246 rs1047163 chr2 20817812 A G 8.20E-05 Multiple complex diseases HS1BP3 UTR-3 17554300 rs896733 chr2 20819316 G T 2.87E-05 Asthma HS1BP3 intron 22561531 rs7570901 chr2 20861207 A G 2.02E-04 Cocaine dependence / / 23958962 rs1013363 chr2 20863286 C T 2.08E-04 Cocaine dependence / / 23958962 rs13394027 chr2 20882056 G A 8.17E-04 Multiple complex diseases / / 17554300 rs13394027 chr2 20882056 G A 3.68E-12 Lymphocyte counts / / 22286170 rs13385191 chr2 20888265 A G 8.00E-08 Prostate cancer C2orf43 intron 20676098 rs340600 chr2 20892006 G T 1.80E-07 Digit length ratio C2orf43 intron 20303062 rs6724513 chr2 20892483 A G 1.60E-07 Digit length ratio C2orf43 intron 20303062 rs12467020 chr2 20894422 C G 1.44E-04 Type 2 diabetes C2orf43 intron 17463246 rs4971516 chr2 20903015 T C 3.36E-04 Type 2 diabetes C2orf43 intron 17463246 rs4971516 chr2 20903015 T C 2.00E-40 LDL cholesterol C2orf43 intron 21059979 rs4971516 chr2 20903015 T C 2.00E-52 LDL cholesterol C2orf43 intron 21059979 rs6729843 chr2 20927997 T C 2.28E-05 Heart Rate C2orf43 intron pha003051 rs4971546 chr2 20934623 T C 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C2orf43 intron 20877124 rs4971546 chr2 20934623 T C 4.93E-05 Cognitive impairment induced by topiramate C2orf43 intron 22091778 rs4971547 chr2 20945762 G A 6.42E-07 Brachial circumference C2orf43 intron 22479309 rs17721572 chr2 20962670 C T 6.47E-07 Brachial circumference C2orf43 intron 22479309 rs17665125 chr2 20963639 T A 2.13E-07 Brachial circumference C2orf43 intron 22479309 rs564896 chr2 20977533 T C 8.20E-04 Type 2 diabetes and 6 quantitative traits C2orf43 intron 17848626 rs1898432 chr2 21053915 C T 4.44E-05 Multiple complex diseases / / 17554300 rs7573184 chr2 21059262 G C 2.10E-05 Serum metabolites / / 19043545 rs12619737 chr2 21076149 C T 7.50E-05 Response to statin therapy / / 20339536 rs880973 chr2 21078879 A G 8.70E-05 Response to statin therapy / / 20339536 rs1437401 chr2 21084166 C G,T 8.40E-05 Response to statin therapy / / 20339536 rs7569328 chr2 21100778 C T 1.00E-07 Coronary heart disease / / 21347282 rs6722139 chr2 21101382 C A 2.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs12994068 chr2 21118983 A C 9.38E-04 Alzheimer's disease / / 17998437 rs6711016 chr2 21123352 C A 1.94E-04 Type 2 diabetes / / 17463246 rs6711016 chr2 21123352 C A 2.17E-14 Metabolite levels / / 22286219 rs6711016 chr2 21123352 C A 6.24E-04 Acute lung injury / / 22295056 rs6711016 chr2 21123352 C A 4.00E-08 Metabolic syndrome / / 22399527 rs6711016 chr2 21123352 C A 0.00000246 VLDL cholesterol particle diameter / / 23263444 rs10198175 chr2 21133883 A G 2.38E-08 Triglycerides / / 19060911 rs10198175 chr2 21133883 A G 4.58E-07 LDL lipoproteins / / pha002902 rs56296027 chr2 21134011 T C 1.83E-15 Metabolite levels / / 22286219 rs4341893 chr2 21135577 A G 1.90E-07 LDL lipoproteins / / pha002902 rs13414987 chr2 21141832 C A 1.10E-13 Metabolic syndrome phenotype / / 22022282 rs13414987 chr2 21141832 C A 2.40E-10 Metabolic syndrome phenotype / / 22022282 rs4296389 chr2 21142994 C T 3.70E-11 Metabolite levels / / 22286219 rs4426495 chr2 21143982 C T 5.86E-13 Metabolite levels / / 22286219 rs10180633 chr2 21144829 G T 5.88E-13 Metabolite levels / / 22286219 rs10183548 chr2 21145499 G A 6.97E-13 Metabolite levels / / 22286219 rs6732011 chr2 21146521 G T 6.22E-11 Metabolite levels / / 22286219 rs3923037 chr2 21148274 A C 3.97E-04 Alzheimer's disease (late onset) / / 21379329 rs3923037 chr2 21148274 A C 7.64E-13 Metabolite levels / / 22286219 rs3923037 chr2 21148274 A C 2.29E-07 LDL lipoproteins / / pha002902 rs3923037 chr2 21148274 A C 2.34E-06 Triglycerides / / pha002904 rs4665639 chr2 21186891 A G 2.60E-05 LDL lipoproteins / / pha002902 rs7604788 chr2 21190024 C T 8.98E-12 Metabolite levels / / 22286219 rs6728178 chr2 21193946 G A 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs6728178 chr2 21193946 G A 1.70E-17 Metabolite levels / / 22286219 rs6728178 chr2 21193946 G A 0.000000019 VLDL cholesterol particle diameter / / 23263444 rs6728178 chr2 21193946 G A 2.02E-06 HDL particle features / / pha002900 rs6728178 chr2 21193946 G A 2.13E-08 LDL lipoproteins / / pha002902 rs6728178 chr2 21193946 G A 3.70E-08 Triglycerides / / pha002904 rs17041676 chr2 21194905 A G 6.26E-04 Multiple complex diseases / / 17554300 rs10495712 chr2 21196112 A G 1.15E-08 Triglycerides / / 19060911 rs10495712 chr2 21196112 A G 1.03E-07 LDL lipoproteins / / pha002902 rs6733447 chr2 21198136 G A 3.93E-05 LDL lipoproteins / / pha002902 rs11902417 chr2 21198900 G A 3.57E-04 Type 2 diabetes / / 17463246 rs11902417 chr2 21198900 G A 4.00E-07 HDL cholesterol / / 20864672 rs11902417 chr2 21198900 G A 1.61E-17 Metabolite levels / / 22286219 rs11902417 chr2 21198900 G A 0.00000023 Triglycerides in females / / 23063622 rs11902417 chr2 21198900 G A 1.07E-11 Triglycerides in males / / 23063622 rs11902417 chr2 21198900 G A 1.23E-14 HDL cholesterol / / 23063622 rs11902417 chr2 21198900 G A 2.11E-14 Cholesterol,total / / 23063622 rs11902417 chr2 21198900 G A 4.00E-20 Triglycerides / / 23063622 rs11902417 chr2 21198900 G A 4.56E-12 LDL cholesterol / / 23063622 rs11902417 chr2 21198900 G A 2.07E-08 VLDL cholesterol particle diameter / / 23263444 rs10184054 chr2 21203877 C G 1.51E-17 Metabolite levels / / 22286219 rs10184054 chr2 21203877 C G 1.88E-08 VLDL cholesterol particle diameter / / 23263444 rs6544366 chr2 21204025 G T 3.10E-04 Type 2 diabetes / / 17463246 rs6544366 chr2 21204025 G T 2.00E-07 Triglycerides / / 20864672 rs6544366 chr2 21204025 G T 1.59E-17 Metabolite levels / / 22286219 rs6544366 chr2 21204025 G T 1.88E-08 VLDL cholesterol particle diameter / / 23263444 rs4564803 chr2 21205502 G T 1.48E-17 Metabolite levels / / 22286219 rs4564803 chr2 21205502 G T 1.86E-08 VLDL cholesterol particle diameter / / 23263444 rs6754295 chr2 21206183 T G 3.00E-08 Triglycerides / / 19060911 rs6754295 chr2 21206183 T G 4.00E-08 HDL cholesterol / / 19060911 rs6754295 chr2 21206183 T G 3.90E-47 Lipid levels / / 19936222 rs6754295 chr2 21206183 T G 4.00E-08 Coronary heart disease / / 21347282 rs6754295 chr2 21206183 T G 1.49E-04 Alzheimer's disease (late onset) / / 21379329 rs6754295 chr2 21206183 T G 1.28E-17 Metabolite levels / / 22286219 rs6754295 chr2 21206183 T G 1.81E-08 VLDL cholesterol particle diameter / / 23263444 rs6754295 chr2 21206183 T G 3.78E-06 HDL particle features / / pha002900 rs6754295 chr2 21206183 T G 1.40E-08 LDL lipoproteins / / pha002902 rs6754295 chr2 21206183 T G 9.47E-08 Triglycerides / / pha002904 rs7557067 chr2 21208211 A G 9.00E-12 Triglycerides / / 19060906 rs7557067 chr2 21208211 A G 1.47E-17 Metabolite levels / / 22286219 rs7557067 chr2 21208211 A G 0.000000017 VLDL cholesterol particle diameter / / 23263444 rs62122481 chr2 21216815 C A 3.03E-13 Metabolite levels / / 22286219 rs13392272 chr2 21217490 C T 6.98E-14 Metabolite levels / / 22286219 rs6725189 chr2 21219001 G T 4.01E-05 ldl cholesterol / / pha003076 rs4665710 chr2 21221035 A C 9.17E-18 Metabolite levels / / 22286219 rs952275 chr2 21221399 T G 1.50E-14 Metabolite levels / / 22286219 rs1801695 chr2 21224853 C G,T 0.0000458 HDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 4.96E-06 Lipoprotein-associated phospholipase A2 activity and mass APOB missense 20442857 rs1042034 chr2 21225281 C T 1.00E-30 HDL cholesterol APOB missense 20686565 rs1042034 chr2 21225281 C T 1.00E-45 Triglycerides APOB missense 20686565 rs1042034 chr2 21225281 C T 9.80E-18 Metabolite levels APOB missense 22286219 rs1042034 chr2 21225281 C T 0.000000971 Triglycerides (females) APOB missense 22629316 rs1042034 chr2 21225281 C T 0.0000154 Triglycerides (males) APOB missense 22629316 rs1042034 chr2 21225281 C T 2.23E-10 Triglycerides APOB missense 22629316 rs1042034 chr2 21225281 C T 1.78E-28 Triglycerides APOB missense 23063622 rs1042034 chr2 21225281 C T 1.96E-24 Triglycerides APOB missense 23063622 rs1042034 chr2 21225281 C T 2.07E-11 LDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 6.60E-13 Cholesterol,total APOB missense 23063622 rs1042034 chr2 21225281 C T 8.05E-20 HDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 0.000000252 VLDL cholesterol particle diameter APOB missense 23263444 rs1042031 chr2 21225753 C T 1.88E-11 Cholesterol,total APOB missense 23063622 rs1042031 chr2 21225753 C T 5.60E-12 LDL cholesterol APOB missense 23063622 rs2678379 chr2 21226560 A G 1.05E-17 Metabolite levels APOB intron 22286219 rs2678379 chr2 21226560 A G 1.23E-15 HDL cholesterol APOB intron 23063622 rs2678379 chr2 21226560 A G 2.92E-10 LDL cholesterol APOB intron 23063622 rs2678379 chr2 21226560 A G 5.05E-22 Triglycerides APOB intron 23063622 rs2678379 chr2 21226560 A G 9.35E-12 Cholesterol,total APOB intron 23063622 rs2678379 chr2 21226560 A G 0.000000254 VLDL cholesterol particle diameter APOB intron 23263444 rs1800479 chr2 21227383 C G 3.15E-11 LDL cholesterol APOB intron 23063622 rs1800479 chr2 21227383 C G 6.51E-10 Cholesterol,total APOB intron 23063622 rs12713558 chr2 21229039 C T 5.80E-05 Multiple complex diseases APOB cds-synon 17554300 rs5742904 chr2 21229160 C T 7.53E-14 LDL cholesterol APOB missense 22629316 rs5742904 chr2 21229160 C T 1.04E-46 LDL cholesterol APOB missense 23063622 rs5742904 chr2 21229160 C T 1.21E-11 Cholesterol,total APOB missense 23063622 rs676210 chr2 21231524 G A 4.40E-04 Response to ximelagatran treatment APOB missense 17505501 rs676210 chr2 21231524 G A 1.00E-08 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 1.50E-09 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 2.05E-10 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 3.70E-64 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 8.60E-56 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 5.93E-06 Lipoprotein-associated phospholipase A2 activity and mass APOB missense 20442857 rs676210 chr2 21231524 G A 4.08E-12 Metabolite levels APOB missense 22286219 rs676210 chr2 21231524 G A 2.97E-10 LDL cholesterol APOB missense 23063622 rs676210 chr2 21231524 G A 3.23E-24 Triglycerides APOB missense 23063622 rs676210 chr2 21231524 G A 5.34E-20 HDL cholesterol APOB missense 23063622 rs676210 chr2 21231524 G A 6.14E-12 Cholesterol,total APOB missense 23063622 rs676210 chr2 21231524 G A 3.00E-47 LDL (oxidized) APOB missense 23247145 rs676210 chr2 21231524 G A 0.000000256 VLDL cholesterol particle diameter APOB missense 23263444 rs676210 chr2 21231524 G A 4.05E-30 LDL cholesterol (Oxidized) APOB missense 23696881 rs676210 chr2 21231524 G A 4.78E-06 HDL particle features APOB missense pha002900 rs676210 chr2 21231524 G A 2.60E-07 LDL lipoproteins APOB missense pha002902 rs676210 chr2 21231524 G A 3.36E-08 Triglycerides APOB missense pha002904 rs6413458 chr2 21231592 G A 2.00E-07 Lipoprotein-associated phospholipase A2 activity and mass APOB cds-synon 23118302 rs693 chr2 21232195 G A 7.00E-07 Triglycerides APOB cds-synon 17463246 rs693 chr2 21232195 G A 3.10E-09 Lipid levels APOB cds-synon 18193043 rs693 chr2 21232195 G A 1.00E-21 LDL cholesterol APOB cds-synon 18193044 rs693 chr2 21232195 G A 2.00E-07 Triglycerides APOB cds-synon 18193044 rs693 chr2 21232195 G A 4.40E-08 LDL cholesterol APOB cds-synon 18262040 rs693 chr2 21232195 G A 3.00E-11 LDL cholesterol APOB cds-synon 19060910 rs693 chr2 21232195 G A 4.00E-17 LDL cholesterol APOB cds-synon 19060911 rs693 chr2 21232195 G A 9.00E-23 Cholesterol,total APOB cds-synon 19060911 rs693 chr2 21232195 G A 4.10E-08 Lipid levels APOB cds-synon 19802338 rs693 chr2 21232195 G A 3.86E-08 Lipid levels APOB cds-synon 19913121 rs693 chr2 21232195 G A 5.69E-06 Lipid levels APOB cds-synon 19913121 rs693 chr2 21232195 G A 1.00E-21 Coronary heart disease APOB cds-synon 21347282 rs693 chr2 21232195 G A 3.06E-08 Cardiovascular disease risk factors APOB cds-synon 21943158 rs693 chr2 21232195 G A 2.30E-14 Metabolite levels APOB cds-synon 22286219 rs693 chr2 21232195 G A 0.00000102 Triglycerides APOB cds-synon 23063622 rs693 chr2 21232195 G A 2.69E-44 Cholesterol,total APOB cds-synon 23063622 rs693 chr2 21232195 G A 5.84E-47 LDL cholesterol APOB cds-synon 23063622 rs693 chr2 21232195 G A 0.00028 LDL cholesterol APOB cds-synon 23100282 rs693 chr2 21232195 G A 2.99E-11 LDL lipoproteins APOB cds-synon pha002902 rs1041968 chr2 21232804 G A 6.20E-08 Lipid levels APOB cds-synon 19802338 rs1041968 chr2 21232804 G A 5.32E-08 Lipid levels APOB cds-synon 19913121 rs1041968 chr2 21232804 G A 7.80E-06 Lipid levels APOB cds-synon 19913121 rs1041968 chr2 21232804 G A 2.19E-14 Metabolite levels APOB cds-synon 22286219 rs1041968 chr2 21232804 G A 1.75E-32 Cholesterol,total APOB cds-synon 23063622 rs1041968 chr2 21232804 G A 3.88E-33 LDL cholesterol APOB cds-synon 23063622 rs533617 chr2 21233972 T C 0.0000618 Type 2 diabetes APOB missense 22325160 rs533617 chr2 21233972 T C 1.19E-12 Triglycerides APOB missense 23063622 rs533617 chr2 21233972 T C 3.85E-11 HDL cholesterol APOB missense 23063622 rs533617 chr2 21233972 T C 7.00E-19 LDL cholesterol APOB missense 23063622 rs533617 chr2 21233972 T C 9.42E-21 Cholesterol,total APOB missense 23063622 rs12720847 chr2 21235375 G A 0.00000046 Triglycerides APOB cds-synon 23063622 rs3749054 chr2 21237238 A T 1.93E-11 LDL cholesterol APOB intron 23063622 rs3749054 chr2 21237238 A T 7.80E-11 Cholesterol,total APOB intron 23063622 rs673548 chr2 21237544 G A 2.00E-08 Metabolic traits APOB intron 19060910 rs673548 chr2 21237544 G A 1.10E-08 Triglycerides APOB intron 19060911 rs673548 chr2 21237544 G A 1.60E-22 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 1.70E-14 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 1.70E-18 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.00E-19 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.28E-10 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.40E-08 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.80E-42 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 2.47E-12 Metabolite levels APOB intron 22286219 rs673548 chr2 21237544 G A 1.00E-10 Metabolic syndrome APOB intron 22399527 rs673548 chr2 21237544 G A 0.0000111 HDL cholesterol (female) APOB intron 22629316 rs673548 chr2 21237544 G A 0.0000799 HDL cholesterol (male) APOB intron 22629316 rs673548 chr2 21237544 G A 6.45E-09 HDL cholesterol APOB intron 22629316 rs673548 chr2 21237544 G A 1.00E-13 Metabolite levels (atherosclerosis) APOB intron 22916037 rs673548 chr2 21237544 G A 1.61E-24 Triglycerides APOB intron 23063622 rs673548 chr2 21237544 G A 1.84E-10 LDL cholesterol APOB intron 23063622 rs673548 chr2 21237544 G A 5.64E-12 Cholesterol,total APOB intron 23063622 rs673548 chr2 21237544 G A 6.24E-18 HDL cholesterol APOB intron 23063622 rs673548 chr2 21237544 G A 8.59E-29 Triglycerides APOB intron 23063622 rs673548 chr2 21237544 G A 0.000000354 VLDL cholesterol particle diameter APOB intron 23263444 rs673548 chr2 21237544 G A 3.40E-06 HDL particle features APOB intron pha002900 rs673548 chr2 21237544 G A 2.28E-07 LDL lipoproteins APOB intron pha002902 rs673548 chr2 21237544 G A 2.01E-08 Triglycerides APOB intron pha002904 rs2854725 chr2 21237786 T G 3.53E-09 LDL cholesterol APOB intron 23063622 rs2854725 chr2 21237786 T G 4.64E-10 Cholesterol,total APOB intron 23063622 rs11680233 chr2 21240031 A C 1.77E-12 Metabolite levels APOB intron 22286219 rs11126598 chr2 21240364 A G 1.54E-12 Metabolite levels APOB intron 22286219 rs12713956 chr2 21241505 A G 2.21E-04 Cholesterol APOB intron 17255346 rs12713956 chr2 21241505 A G 2.27E-12 LDL cholesterol APOB intron 23063622 rs12713956 chr2 21241505 A G 9.75E-12 Cholesterol,total APOB intron 23063622 rs12713956 chr2 21241505 A G 4.00E-08 LDL cholesterol APOB intron 23726366 rs12720828 chr2 21241744 C T 7.07E-12 Cholesterol,total APOB intron 23063622 rs12720828 chr2 21241744 C T 7.08E-12 LDL cholesterol APOB intron 23063622 rs10199768 chr2 21244000 G T 1.61E-04 Lipid levels APOB intron 19913121 rs10199768 chr2 21244000 G T 6.58E-07 Lipid levels APOB intron 19913121 rs10199768 chr2 21244000 G T 8.00E-15 Cardiovascular disease risk factors APOB intron 21943158 rs10199768 chr2 21244000 G T 9.79E-12 Metabolite levels APOB intron 22286219 rs10199768 chr2 21244000 G T 1.23E-48 Cholesterol,total APOB intron 23063622 rs10199768 chr2 21244000 G T 3.50E-49 LDL cholesterol APOB intron 23063622 rs3791980 chr2 21245329 G T 2.93E-11 Metabolite levels APOB intron 22286219 rs1801700 chr2 21245813 G A 0.0000169 Triglycerides APOB cds-synon 23063622 rs12720838 chr2 21247211 C T 1.88E-13 LDL cholesterol APOB intron 23063622 rs12720838 chr2 21247211 C T 2.78E-13 Cholesterol,total APOB intron 23063622 rs12691202 chr2 21249716 C T 1.32E-12 LDL cholesterol APOB missense 23063622 rs12691202 chr2 21249716 C T 2.05E-14 Cholesterol,total APOB missense 23063622 rs679899 chr2 21250914 G A 1.13E-20 LDL cholesterol APOB missense 23063622 rs679899 chr2 21250914 G A 3.32E-22 Cholesterol,total APOB missense 23063622 rs679899 chr2 21250914 G A 0.00014 LDL cholesterol APOB missense 23100282 rs679899 chr2 21250914 G A 9.04E-05 LDL lipoproteins APOB missense pha002902 rs570877 chr2 21251040 T G 1.54E-14 Cholesterol,total APOB intron 23063622 rs570877 chr2 21251040 T G 2.14E-15 LDL cholesterol APOB intron 23063622 rs12714214 chr2 21251367 G A 5.78E-04 Multiple complex diseases APOB missense 17554300 rs1469513 chr2 21259562 T C 2.72E-04 Type 2 diabetes APOB intron 17463246 rs1469513 chr2 21259562 T C 3.05E-11 Metabolite levels APOB intron 22286219 rs520354 chr2 21259612 A G 1.23E-21 Cholesterol,total APOB intron 23063622 rs520354 chr2 21259612 A G 9.57E-21 LDL cholesterol APOB intron 23063622 rs550619 chr2 21260601 G A 6.90E-04 Atrial fibrillation APOB intron 21846873 rs550619 chr2 21260601 G A 1.14E-15 LDL cholesterol APOB intron 23063622 rs550619 chr2 21260601 G A 5.06E-15 Cholesterol,total APOB intron 23063622 rs597331 chr2 21262427 G A 3.59E-13 LDL cholesterol APOB intron 23063622 rs597331 chr2 21262427 G A 6.88E-14 Cholesterol,total APOB intron 23063622 rs12720788 chr2 21262871 A T 0.0000238 LDL cholesterol APOB intron 23063622 rs531819 chr2 21263639 T G 3.21E-07 Lipid levels APOB intron 19913121 rs531819 chr2 21263639 T G 4.91E-08 Lipid levels APOB intron 19913121 rs531819 chr2 21263639 T G 5.80E-05 Response to statin therapy APOB intron 20339536 rs531819 chr2 21263639 T G 3.12E-45 LDL cholesterol APOB intron 23063622 rs531819 chr2 21263639 T G 3.16E-27 LDL cholesterol (female) APOB intron 23063622 rs531819 chr2 21263639 T G 4.59E-15 LDL cholesterol (male) APOB intron 23063622 rs531819 chr2 21263639 T G 9.60E-45 Cholesterol,total APOB intron 23063622 rs9282603 chr2 21263886 A G 0.00002 Breast cancer(er negative) APOB missense 23555315 rs1367117 chr2 21263900 G A 1 Drug response to Atenolol APOB missense 15453913 rs1367117 chr2 21263900 G A 1 Drug response to Irbesartan APOB missense 15453913 rs1367117 chr2 21263900 G A 2.63E-08 Lipid levels APOB missense 19913121 rs1367117 chr2 21263900 G A 2.94E-05 Lipid levels APOB missense 19913121 rs1367117 chr2 21263900 G A 2.10E-17 Lipid levels APOB missense 19936222 rs1367117 chr2 21263900 G A 6.46E-25 Lipid levels APOB missense 19936222 rs1367117 chr2 21263900 G A 4.00E-114 LDL cholesterol APOB missense 20686565 rs1367117 chr2 21263900 G A 4.00E-96 Cholesterol,total APOB missense 20686565 rs1367117 chr2 21263900 G A 0.000685 HDL cholesterol APOB missense 23063622 rs1367117 chr2 21263900 G A 0.000692 Triglycerides APOB missense 23063622 rs1367117 chr2 21263900 G A 3.97E-58 LDL cholesterol APOB missense 23063622 rs1367117 chr2 21263900 G A 8.84E-62 Cholesterol,total APOB missense 23063622 rs1367117 chr2 21263900 G A 1.00E-182 LDL cholesterol APOB missense 24097068 rs1367117 chr2 21263900 G A 3.00E-139 Cholesterol,total APOB missense 24097068 rs12720841 chr2 21264734 T C 0.00000112 Triglycerides APOB intron 23063622 rs12714264 chr2 21265518 A T 3.04E-05 Type 2 diabetes APOB intron 17463246 rs12714264 chr2 21265518 A T 1.23E-07 Lipid levels APOB intron 19913121 rs12714264 chr2 21265518 A T 1.60E-07 Lipid levels APOB intron 19913121 rs12714264 chr2 21265518 A T 9.50E-05 Response to statin therapy APOB intron 20339536 rs12714264 chr2 21265518 A T 7.00E-04 Coronary heart disease APOB intron 21966275 rs12720826 chr2 21265695 T C 4.26E-08 LDL cholesterol APOB intron 23236364 rs12720826 chr2 21265695 T C 5.20E-09 Cholesterol,total APOB intron 23236364 rs12720799 chr2 21266164 C T 0.00000112 Triglycerides APOB intron 23063622 rs1800481 chr2 21267210 A G 4.95E-08 Lipid levels APOB nearGene-5 19913121 rs1800481 chr2 21267210 A G 7.41E-07 Lipid levels APOB nearGene-5 19913121 rs1800481 chr2 21267210 A G 2.24E-28 LDL cholesterol APOB nearGene-5 23063622 rs1800481 chr2 21267210 A G 4.24E-28 Cholesterol,total APOB nearGene-5 23063622 rs934197 chr2 21267461 G A 2.53E-05 Lipid levels APOB nearGene-5 19913121 rs934197 chr2 21267461 G A 3.43E-08 Lipid levels APOB nearGene-5 19913121 rs934197 chr2 21267461 G A 2.88E-34 LDL cholesterol APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 3.11E-14 LDL cholesterol (male) APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 8.51E-24 LDL cholesterol (female) APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 2.81E-61 Cholesterol,total APOB nearGene-5 23063622 rs934197 chr2 21267461 G A 7.69E-59 LDL cholesterol APOB nearGene-5 23063622 rs617314 chr2 21268219 A C 0.000371 Cholesterol,total APOB nearGene-5 23063622 rs585967 chr2 21270554 A C 2.48E-07 Lipid levels / / 19913121 rs585967 chr2 21270554 A C 3.28E-08 Lipid levels / / 19913121 rs585967 chr2 21270554 A C 4.00E-05 Response to statin therapy / / 20339536 rs585967 chr2 21270554 A C 2.49E-46 LDL cholesterol / / 23063622 rs585967 chr2 21270554 A C 3.49E-45 Cholesterol,total / / 23063622 rs17398765 chr2 21270751 A G 1.39E-17 Cholesterol,total / / 23063622 rs17398765 chr2 21270751 A G 7.17E-19 LDL cholesterol / / 23063622 rs1713222 chr2 21271323 A G 1.00E-08 LDL cholesterol / / 18262040 rs1713222 chr2 21271323 A G 3.18E-17 Triglycerides / / 19060911 rs1713222 chr2 21271323 A G 5.10E-12 Lipid levels / / 19802338 rs1713222 chr2 21271323 A G 5.70E-08 Lipid levels / / 19802338 rs1713222 chr2 21271323 A G 1.80E-13 Lipid levels / / 19936222 rs1713222 chr2 21271323 A G 7.08E-11 Lipid levels / / 19936222 rs1713222 chr2 21271323 A G 4.40E-05 Response to statin therapy / / 20339536 rs1713222 chr2 21271323 A G 6.10E-13 Metabolic syndrome phenotype / / 22022282 rs1713222 chr2 21271323 A G 8.70E-13 Metabolic syndrome phenotype / / 22022282 rs1713222 chr2 21271323 A G 9.33E-08 LDL lipoproteins / / pha002902 rs1713222 chr2 21271323 A G 3.30E-05 ldl cholesterol / / pha003076 rs7575840 chr2 21273490 G T 1.24E-04 Type 2 diabetes / / 17463246 rs7575840 chr2 21273490 G T 5.40E-14 Lipid levels / / 18193043 rs7575840 chr2 21273490 G T 1.90E-09 LDL cholesterol / / 18262040 rs7575840 chr2 21273490 G T 1.54E-05 Lipid levels / / 19913121 rs7575840 chr2 21273490 G T 7.84E-08 Lipid levels / / 19913121 rs7575840 chr2 21273490 G T 1.35E-47 Cholesterol,total / / 23063622 rs7575840 chr2 21273490 G T 2.37E-39 LDL cholesterol / / 23063622 rs515135 chr2 21286057 T C 3.10E-14 Lipid levels / / 18193043 rs515135 chr2 21286057 T C 5.00E-29 LDL cholesterol / / 19060906 rs515135 chr2 21286057 T C 1.10E-05 Response to statin therapy / / 20339536 rs515135 chr2 21286057 T C 2.00E-20 LDL cholesterol / / 20864672 rs515135 chr2 21286057 T C 5.00E-29 Coronary heart disease / / 21347282 rs515135 chr2 21286057 T C 0.000257 Coronary artery disease (CAD) age <=50 / / 23202125 rs515135 chr2 21286057 T C 0.000666 Triglycerides / / 23202125 rs515135 chr2 21286057 T C 1.80E-10 Coronary artery disease / / 23202125 rs515135 chr2 21286057 T C 1.96E-09 Coronary artery disease with myocardial infarction / / 23202125 rs515135 chr2 21286057 T C 2.93E-09 Coronary artery disease (CAD) (males) / / 23202125 rs515135 chr2 21286057 T C 3.14E-109 LDL cholesterol / / 23202125 rs515135 chr2 21286057 T C 5.42E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs515135 chr2 21286057 T C 8.38E-92 Cholesterol,total / / 23202125 rs515135 chr2 21286057 T C 9.12E-04 Coronary artery disease / / 24262325 rs563290 chr2 21288226 G A 7.60E-18 Lipid levels / / 18193043 rs563290 chr2 21288226 G A 1.33E-11 Lipid levels / / 19913121 rs563290 chr2 21288226 G A 7.38E-13 Lipid levels / / 19913121 rs563290 chr2 21288226 G A 1.10E-05 Response to statin therapy / / 20339536 rs563290 chr2 21288226 G A 3.96E-32 LDL cholesterol / / 23063622 rs563290 chr2 21288226 G A 6.18E-30 Cholesterol,total / / 23063622 rs562338 chr2 21288321 A G 9.77E-05 Cholesterol / / 17255346 rs562338 chr2 21288321 A G 2.28E-08 Type 2 diabetes / / 17463246 rs562338 chr2 21288321 A G 8.58E-13 Cardiovascular disease / / 18179892 rs562338 chr2 21288321 A G 6.00E-22 LDL cholesterol / / 18193043 rs562338 chr2 21288321 A G 1.00E-09 LDL cholesterol / / 18262040 rs562338 chr2 21288321 A G 1.21E-11 Lipid levels / / 19913121 rs562338 chr2 21288321 A G 6.00E-13 Lipid levels / / 19913121 rs562338 chr2 21288321 A G 1.10E-05 Response to statin therapy / / 20339536 rs562338 chr2 21288321 A G 6.00E-22 Coronary heart disease / / 21347282 rs562338 chr2 21288321 A G 1.10E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs562338 chr2 21288321 A G 3.81E-16 LDL cholesterol (male) / / 22629316 rs562338 chr2 21288321 A G 7.60E-34 LDL cholesterol / / 22629316 rs562338 chr2 21288321 A G 9.28E-21 LDL cholesterol (female) / / 22629316 rs562338 chr2 21288321 A G 1.21E-51 LDL cholesterol / / 23063622 rs562338 chr2 21288321 A G 4.03E-53 Cholesterol,total / / 23063622 rs562338 chr2 21288321 A G 0.0000002 Cholesterol,total / / 23236364 rs562338 chr2 21288321 A G 6.54E-08 LDL cholesterol / / 23236364 rs581411 chr2 21289432 G A 1.10E-05 Response to statin therapy / / 20339536 rs668948 chr2 21291529 G A 1.10E-05 Response to statin therapy / / 20339536 rs541041 chr2 21294975 G A 1.27E-04 Cholesterol / / 17255346 rs541041 chr2 21294975 G A 1.46E-08 Triglycerides / / 19060911 rs541041 chr2 21294975 G A 8.00E-06 Response to statin therapy / / 20339536 rs541041 chr2 21294975 G A 5.48E-10 Cholesterol,total / / 23063622 rs478588 chr2 21297149 A G 1.40E-05 Response to statin therapy / / 20339536 rs565202 chr2 21297447 A G 1.70E-04 Response to antidepressants / / 19736353 rs1429974 chr2 21300770 C A 4.93E-15 Triglycerides / / 19060911 rs1429974 chr2 21300770 C A 2.18E-06 LDL lipoproteins / / pha002902 rs7567217 chr2 21303470 T C 9.50E-06 Response to statin therapy / / 20339536 rs568938 chr2 21303616 C T 1.00E-05 Response to statin therapy / / 20339536 rs568938 chr2 21303616 C T 1.62E-07 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs754524 chr2 21311541 T G 3.48E-11 Triglycerides / / 19060911 rs754524 chr2 21311541 T G 1.69E-07 Lipid levels / / 19913121 rs754524 chr2 21311541 T G 3.11E-05 Lipid levels / / 19913121 rs754524 chr2 21311541 T G 4.09E-42 Cholesterol,total / / 23063622 rs754524 chr2 21311541 T G 5.69E-41 LDL cholesterol / / 23063622 rs754524 chr2 21311541 T G 2.03E-07 LDL lipoproteins / / pha002902 rs754523 chr2 21311691 A G 8.30E-12 Lipid levels / / 18193043 rs754523 chr2 21311691 A G 1.25E-15 Triglycerides / / 19060911 rs754523 chr2 21311691 A G 1.11E-06 Lipid levels / / 19913121 rs754523 chr2 21311691 A G 2.86E-09 Lipid levels / / 19913121 rs754523 chr2 21311691 A G 1.05E-14 Total cholesterol in males / / 23063622 rs754523 chr2 21311691 A G 3.44E-30 Total cholesterol in females / / 23063622 rs754523 chr2 21311691 A G 3.83E-47 Cholesterol,total / / 23063622 rs754523 chr2 21311691 A G 4.29E-42 LDL cholesterol / / 23063622 rs754523 chr2 21311691 A G 0.00025 LDL cholesterol / / 23100282 rs754523 chr2 21311691 A G 1.12E-06 LDL lipoproteins / / pha002902 rs614303 chr2 21313577 G A 9.80E-06 Response to statin therapy / / 20339536 rs312944 chr2 21325188 A T 1.10E-05 Response to statin therapy / / 20339536 rs17399838 chr2 21368217 A G 4.20E-05 Response to statin therapy / / 20339536 rs17399838 chr2 21368217 A G 4.94E-04 Smoking quantity / / 24665060 rs312970 chr2 21369815 A T 1.84E-05 Type 2 diabetes / / 17463246 rs312970 chr2 21369815 A T 2.70E-05 Response to statin therapy / / 20339536 rs312970 chr2 21369815 A T 2.33E-05 Smoking quantity / / 24665060 rs11687710 chr2 21371068 T C 3.51E-04 Type 2 diabetes / / 17463246 rs837137 chr2 21377935 A G 2.70E-05 Response to statin therapy / / 20339536 rs111826230 chr2 21378453 A G 0.0000547 Menopause (age at onset) / / 23424626 rs312985 chr2 21378805 A G 8.37E-05 Cholesterol / / 17255346 rs312985 chr2 21378805 A G 1.69E-10 Triglycerides / / 19060911 rs312985 chr2 21378805 A G 2.20E-08 Lipid levels / / 19802338 rs312985 chr2 21378805 A G 2.40E-13 Lipid levels / / 19802338 rs312985 chr2 21378805 A G 1.18E-17 Lipid levels / / 19936222 rs312985 chr2 21378805 A G 2.50E-05 Response to statin therapy / / 20339536 rs312985 chr2 21378805 A G 1.41E-04 Smoking quantity / / 24665060 rs532300 chr2 21381608 C A 2.00E-05 Response to statin therapy / / 20339536 rs527034 chr2 21382786 C A 2.08E-04 Cholesterol / / 17255346 rs527034 chr2 21382786 C A 4.35E-06 Type 2 diabetes / / 17463246 rs527034 chr2 21382786 C A 2.00E-05 Response to statin therapy / / 20339536 rs527034 chr2 21382786 C A 1.03E-04 Smoking quantity / / 24665060 rs4560142 chr2 21383717 C T 1.16E-04 Cholesterol / / 17255346 rs4560142 chr2 21383717 C T 1.01E-05 Type 2 diabetes / / 17463246 rs4560142 chr2 21383717 C T 8.30E-09 LDL cholesterol / / 18262040 rs4560142 chr2 21383717 C T 2.00E-05 Response to statin therapy / / 20339536 rs4560142 chr2 21383717 C T 7.87E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4560142 chr2 21383717 C T 5.85E-05 Smoking quantity / / 24665060 rs4591370 chr2 21383742 A G 1.16E-04 Cholesterol / / 17255346 rs4591370 chr2 21383742 A G 8.72E-06 Type 2 diabetes / / 17463246 rs4591370 chr2 21383742 A G 8.20E-09 LDL cholesterol / / 18262040 rs4591370 chr2 21383742 A G 2.00E-05 Response to statin therapy / / 20339536 rs4591370 chr2 21383742 A G 6.92E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4591370 chr2 21383742 A G 0.000000029 Cholesterol,total / / 23063622 rs4591370 chr2 21383742 A G 4.79E-05 Smoking quantity / / 24665060 rs1652421 chr2 21383848 A G 1.70E-05 Response to statin therapy / / 20339536 rs1652420 chr2 21383881 A T 1.60E-05 Response to statin therapy / / 20339536 rs1712247 chr2 21383951 C T 1.16E-04 Cholesterol / / 17255346 rs1712247 chr2 21383951 C T 1.36E-05 Type 2 diabetes / / 17463246 rs1712247 chr2 21383951 C T 1.50E-05 Response to statin therapy / / 20339536 rs1712247 chr2 21383951 C T 6.06E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs1712247 chr2 21383951 C T 4.26E-05 Smoking quantity / / 24665060 rs548506 chr2 21385541 A G 1.50E-05 Response to statin therapy / / 20339536 rs1652419 chr2 21385649 C T 1.00E-05 Response to statin therapy / / 20339536 rs1712250 chr2 21386058 C T 1.00E-05 Response to statin therapy / / 20339536 rs1367120 chr2 21386304 T C 1.00E-05 Response to statin therapy / / 20339536 rs1367119 chr2 21386375 A C,G,T 1.00E-05 Response to statin therapy / / 20339536 rs522963 chr2 21386957 T C 1.00E-05 Response to statin therapy / / 20339536 rs522250 chr2 21387113 T C 1.20E-05 Response to statin therapy / / 20339536 rs529697 chr2 21387948 G T 1.80E-05 Response to statin therapy / / 20339536 rs1652418 chr2 21388456 T C 2.20E-05 Response to statin therapy / / 20339536 rs538928 chr2 21389019 A G 1.01E-04 Cholesterol / / 17255346 rs538928 chr2 21389019 A G 8.75E-06 Type 2 diabetes / / 17463246 rs538928 chr2 21389019 A G 2.70E-08 LDL cholesterol / / 18262040 rs538928 chr2 21389019 A G 1.90E-05 Response to statin therapy / / 20339536 rs538928 chr2 21389019 A G 7.33E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs560844 chr2 21389108 A G 3.00E-05 Response to statin therapy / / 20339536 rs563696 chr2 21389430 T A 2.90E-05 Response to statin therapy / / 20339536 rs4635554 chr2 21389659 T G 6.40E-05 Response to statin therapy / / 20339536 rs4635554 chr2 21389659 T G 2.00E-07 Hypertriglyceridemia / / 20657596 rs479545 chr2 21389897 T C 3.20E-05 Response to statin therapy / / 20339536 rs501863 chr2 21390000 G A 2.90E-05 Response to statin therapy / / 20339536 rs480732 chr2 21390149 A T 3.10E-05 Response to statin therapy / / 20339536 rs480787 chr2 21390169 A C,G,T 2.50E-05 Response to statin therapy / / 20339536 rs483436 chr2 21390407 G A 3.20E-05 Response to statin therapy / / 20339536 rs486139 chr2 21390674 G A 2.30E-05 Response to statin therapy / / 20339536 rs538528 chr2 21391740 T C 2.20E-05 Response to statin therapy / / 20339536 rs540439 chr2 21391978 C T 2.20E-05 Response to statin therapy / / 20339536 rs563280 chr2 21392153 T G 2.20E-05 Response to statin therapy / / 20339536 rs576203 chr2 21393623 A G 1.01E-04 Cholesterol / / 17255346 rs576203 chr2 21393623 A G 8.88E-06 Type 2 diabetes / / 17463246 rs576203 chr2 21393623 A G 9.00E-09 LDL cholesterol / / 18262040 rs576203 chr2 21393623 A G 2.20E-05 Response to statin therapy / / 20339536 rs576203 chr2 21393623 A G 8.45E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs576203 chr2 21393623 A G 3.61E-05 Smoking quantity / / 24665060 rs488507 chr2 21393689 G T 9.50E-05 Cholesterol / / 17255346 rs488507 chr2 21393689 G T 2.00E-08 LDL cholesterol / / 18262040 rs488507 chr2 21393689 G T 2.00E-05 Response to statin therapy / / 20339536 rs488507 chr2 21393689 G T 6.37E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs578095 chr2 21393866 A G 1.60E-05 Response to statin therapy / / 20339536 rs496100 chr2 21394614 A G 1.40E-05 Response to statin therapy / / 20339536 rs553523 chr2 21394798 T G 1.30E-05 Response to statin therapy / / 20339536 rs554414 chr2 21394892 T C 1.10E-05 Response to statin therapy / / 20339536 rs556504 chr2 21395261 C G 1.10E-05 Response to statin therapy / / 20339536 rs559967 chr2 21395598 A G 1.20E-05 Response to statin therapy / / 20339536 rs561850 chr2 21395805 A G 1.20E-05 Response to statin therapy / / 20339536 rs473269 chr2 21395830 T C 1.10E-05 Response to statin therapy / / 20339536 rs477146 chr2 21396334 A G 1.00E-05 Response to statin therapy / / 20339536 rs1652417 chr2 21396517 T C 1.00E-05 Response to statin therapy / / 20339536 rs1712251 chr2 21396551 G A 1.00E-05 Response to statin therapy / / 20339536 rs1652416 chr2 21396609 A G 1.10E-05 Response to statin therapy / / 20339536 rs483621 chr2 21397035 T A 1.10E-05 Response to statin therapy / / 20339536 rs506585 chr2 21397182 G A 8.13E-05 Cholesterol / / 17255346 rs506585 chr2 21397182 G A 9.01E-06 Type 2 diabetes / / 17463246 rs506585 chr2 21397182 G A 1.00E-08 LDL cholesterol / / 18262040 rs506585 chr2 21397182 G A 6.33E-11 Triglycerides / / 19060911 rs506585 chr2 21397182 G A 7.70E-14 Lipid levels / / 19802338 rs506585 chr2 21397182 G A 9.30E-09 Lipid levels / / 19802338 rs506585 chr2 21397182 G A 1.20E-25 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 1.50E-22 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 2.80E-31 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 1.30E-05 Response to statin therapy / / 20339536 rs506585 chr2 21397182 G A 6.84E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs506585 chr2 21397182 G A 7.84E-05 Smoking quantity / / 24665060 rs507616 chr2 21397321 G C 1.20E-05 Response to statin therapy / / 20339536 rs531380 chr2 21397561 C G 1.20E-05 Response to statin therapy / / 20339536 rs532225 chr2 21397637 T C 1.30E-05 Response to statin therapy / / 20339536 rs560408 chr2 21398379 T C 1.30E-05 Response to statin therapy / / 20339536 rs541569 chr2 21398768 G A 1.30E-05 Response to statin therapy / / 20339536 rs544039 chr2 21398985 C A 1.30E-05 Response to statin therapy / / 20339536 rs478442 chr2 21399216 G T 9.09E-05 Cholesterol / / 17255346 rs478442 chr2 21399216 G T 9.84E-06 Type 2 diabetes / / 17463246 rs478442 chr2 21399216 G T 8.10E-09 LDL cholesterol / / 18262040 rs478442 chr2 21399216 G T 1.40E-05 Response to statin therapy / / 20339536 rs478442 chr2 21399216 G T 8.50E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs478442 chr2 21399216 G T 1.08E-04 Smoking quantity / / 24665060 rs570033 chr2 21399567 C G 1.40E-05 Response to statin therapy / / 20339536 rs574438 chr2 21399961 T C 1.40E-05 Response to statin therapy / / 20339536 rs5002500 chr2 21399974 C G 1.70E-05 Response to statin therapy / / 20339536 rs574461 chr2 21400013 A G 1.40E-05 Response to statin therapy / / 20339536 rs494315 chr2 21400950 C T 1.30E-05 Response to statin therapy / / 20339536 rs494465 chr2 21401010 C T 1.20E-05 Response to statin therapy / / 20339536 rs567071 chr2 21405790 G A 7.70E-10 Lipid levels / / 19802338 rs567071 chr2 21405790 G A 7.39E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs486246 chr2 21406751 G A 9.70E-06 Response to statin therapy / / 20339536 rs504616 chr2 21414020 C G 9.90E-06 Response to statin therapy / / 20339536 rs503662 chr2 21414142 T C 6.93E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs10221876 chr2 21419809 A T 1.20E-05 Response to statin therapy / / 20339536 rs1878512 chr2 21420358 C A 1.61E-04 Cholesterol / / 17255346 rs1878512 chr2 21420358 C A 1.50E-05 Response to statin therapy / / 20339536 rs1878512 chr2 21420358 C A 9.95E-05 Smoking quantity / / 24665060 rs17041988 chr2 21420697 A G 1.40E-05 Response to statin therapy / / 20339536 rs10206521 chr2 21420828 T C 7.80E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs7578527 chr2 21422403 G A 1.50E-05 Response to statin therapy / / 20339536 rs17042000 chr2 21422928 C T 1.50E-05 Response to statin therapy / / 20339536 rs10169543 chr2 21423989 T C 6.64E-05 Cholesterol / / 17255346 rs10169543 chr2 21423989 T C 2.00E-05 Response to statin therapy / / 20339536 rs12712940 chr2 21426743 C A 2.00E-05 Response to statin therapy / / 20339536 rs312051 chr2 21429055 G C 9.70E-05 Response to statin therapy / / 20339536 rs7605304 chr2 21445569 G A 0.000509 Height (Pygmy height) / / 22570615 rs949790 chr2 21449987 G A 2.37E-09 Triglycerides / / 19060911 rs386397 chr2 21451827 A G 3.52E-04 Smoking quantity / / 24665060 rs7566040 chr2 21454424 G T 3.16E-04 Smoking quantity / / 24665060 rs13398007 chr2 21469336 C T 6.74E-10 Triglycerides / / 19060911 rs13398007 chr2 21469336 C T 2.30E-09 Lipid levels / / 19802338 rs13398007 chr2 21469336 C T 9.30E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs11689154 chr2 21473385 A G 5.57E-04 Smoking initiation / / 24665060 rs312049 chr2 21475944 T C 7.12E-04 Smoking quantity / / 24665060 rs17397220 chr2 21501219 C A 5.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs10199484 chr2 21513546 T C 9.56E-05 Bipolar disorder / / 19488044 rs10199484 chr2 21513546 T C 8.89E-05 Alzheimer's disease (age of onset) / / 22005931 rs10171175 chr2 21515070 G A 1.78E-04 Body mass index / / 17255346 rs721064 chr2 21518442 A G 2.59E-05 Bipolar disorder / / 18317468 rs721064 chr2 21518442 A G 1.11E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs418451 chr2 21521637 G T 8.12E-05 Bipolar disorder / / 19488044 rs423277 chr2 21526322 T G 8.76E-05 Alzheimer's disease (age of onset) / / 22005931 rs219531 chr2 21528396 G C 9.86E-05 Bipolar disorder / / 19488044 rs219543 chr2 21535673 A G 0.000014 Height (Pygmy height) / / 22570615 rs13427673 chr2 21536873 G A 1.80E-04 Body mass index / / 17255346 rs2337901 chr2 21537251 C T 0.000000103 Cholesterol,total / / 23063622 rs4665702 chr2 21538345 G A 2.09E-05 Alzheimer's disease (age of onset) / / 22005931 rs219550 chr2 21539585 A G 2.71E-04 Iron levels / / pha002876 rs219553 chr2 21577743 G A 7.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs892459 chr2 21584340 G C 8.64E-05 Serum metabolites / / 19043545 rs6706688 chr2 21612470 G A 3.26E-05 Multiple complex diseases / / 17554300 rs17042324 chr2 21674321 T C 5.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs17042333 chr2 21675325 G C 7.91E-05 Multiple complex diseases / / 17554300 rs17042410 chr2 21688064 A G 1.09E-08 Multiple complex diseases / / 17554300 rs890082 chr2 21693244 T C 2.21E-05 Cognitive performance / / 19734545 rs979572 chr2 21696409 T G 1.20E-04 Type 2 diabetes / / 17846124 rs13392037 chr2 21703101 C T 6.42E-05 Schizophrenia / / 20832056 rs17042457 chr2 21703314 C G 6.42E-05 Schizophrenia / / 20832056 rs10490611 chr2 21707203 A G 6.42E-05 Schizophrenia / / 20832056 rs2194560 chr2 21768741 A G 3.00E-04 Hearing function / / 17255346 rs2194562 chr2 21769639 G A 2.08E-04 White matter integrity / / 22425255 rs4665932 chr2 21785061 C A 8.34E-06 Hearing function / / 17255346 rs970127 chr2 21793966 C T 1.70E-05 Hearing function / / 17255346 rs17042603 chr2 21798418 A G 0.0000018 Confectionary intake / / 23408455 rs918897 chr2 21825860 A G 2.46E-05 Gallbladder cancer / / 22318345 rs1117324 chr2 21840093 C T 3.00E-07 Response to antipsychotic treatment / / 20195266 rs10495717 chr2 21925067 T C 1.31E-04 Stroke LOC645949 intron pha002887 rs7568769 chr2 21943231 C T 1.12E-04 Age-related macular degeneration / / 22125219 rs6733000 chr2 21952204 C T 3.03E-04 Crohn's disease / / 17435756 rs10180600 chr2 22283986 T C 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs7600502 chr2 22297003 A G 3.00E-09 C-reactive protein and white blood cell count / / 22788528 rs7561156 chr2 22335940 A G 1.00E-04 Prostate cancer / / 21743057 rs7576134 chr2 22336150 G A 1.00E-04 Prostate cancer / / 21743057 rs4533497 chr2 22336757 A G 1.00E-04 Prostate cancer / / 21743057 rs2138885 chr2 22336964 G A 1.00E-04 Prostate cancer / / 21743057 rs7601596 chr2 22348539 G T 3.00E-05 Prostate cancer / / 21743057 rs1554268 chr2 22431110 C T 7.61E-04 Multiple complex diseases / / 17554300 rs1554268 chr2 22431110 C T 1.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10193722 chr2 22439514 A C 9.73E-05 Schizophrenia / / 24253340 rs10164909 chr2 22517197 G A 9.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4665502 chr2 22547633 C G 0.0001118 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4665502 chr2 22547633 C G 1.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10188288 chr2 22567357 T C 0.000114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10188288 chr2 22567357 T C 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17391760 chr2 22568159 G T 2.00E-04 Information processing speed / / 21130836 rs17043657 chr2 22568473 T C 0.0001113 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17043657 chr2 22568473 T C 1.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7569716 chr2 22568713 A T 1.00E-07 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs10192983 chr2 22569908 A G 0.0001137 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10192983 chr2 22569908 A G 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1509379 chr2 22576085 A C 6.75E-05 Schizophrenia / / 19571809 rs1509379 chr2 22576085 A C 3.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs1605834 chr2 22576100 A G 1.61E-05 Schizophrenia / / 19571809 rs1605834 chr2 22576100 A G 8.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1605834 chr2 22576100 A G 5.11E-05 Schizophrenia / / pha002857 rs13424767 chr2 22612275 T C 1.02E-05 Schizophrenia / / 19571809 rs1396725 chr2 22612638 G A 2.54E-05 Schizophrenia / / 19571809 rs1509355 chr2 22613819 C T 2.72E-05 Schizophrenia / / 19571809 rs13413863 chr2 22615313 A G 5.96E-05 Schizophrenia / / 19571809 rs6741194 chr2 22616209 G T 1.73E-05 Schizophrenia / / 19571809 rs1949038 chr2 22616534 T C 2.58E-05 Schizophrenia / / 19571809 rs1509360 chr2 22616777 G A 2.63E-04 Multiple complex diseases / / 17554300 rs1509360 chr2 22616777 G A 1.80E-05 Schizophrenia / / 19571809 rs6749647 chr2 22618537 G T 4.72E-05 Schizophrenia / / 19571809 rs1509384 chr2 22644836 A G 8.50E-04 Lipid traits / / 17903299 rs1876766 chr2 22665048 C T 4.74E-04 Multiple complex diseases / / 17554300 rs4533498 chr2 22688256 A G 5.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2339516 chr2 22704855 G A 7.95E-04 Multiple complex diseases / / 17554300 rs882012 chr2 22711827 G A 5.40E-04 Multiple complex diseases / / 17554300 rs937932 chr2 22712316 T G 8.17E-04 Multiple complex diseases / / 17554300 rs937932 chr2 22712316 T G 5.62E-04 Premature ovarian failure / / 19508998 rs17043947 chr2 22736987 C T 2.00E-07 Self-rated health / / 20707712 rs13006508 chr2 22741939 A G 3.57E-05 Schizophrenia / / 19571809 rs6735294 chr2 22742356 T C 7.12E-05 Schizophrenia / / 19571809 rs6544021 chr2 22753225 T C 2.93E-04 Diabetic retinopathy / / 20871662 rs4988826 chr2 22756232 A G 6.02E-05 Multiple complex diseases / / 17554300 rs1703818 chr2 22764544 T G 9.40E-05 Temperament (bipolar disorder) / / 22365631 rs2062339 chr2 22777008 A G 2.40E-05 Temperament (bipolar disorder) / / 22365631 rs6748330 chr2 22778763 G A 3.30E-05 Temperament (bipolar disorder) / / 22365631 rs2220153 chr2 22779339 A G 2.10E-05 Temperament (bipolar disorder) / / 22365631 rs1032114 chr2 22789633 G A 3.80E-05 Temperament (bipolar disorder) / / 22365631 rs12052295 chr2 22806507 C T 7.00E-05 Temperament (bipolar disorder) / / 22365631 rs11688379 chr2 22816936 A T 6.70E-05 Temperament (bipolar disorder) / / 22365631 rs13015955 chr2 22822159 G A 4.00E-07 Coronary heart disease / / 21347282 rs7588192 chr2 22828898 C T 8.74E-04 Multiple complex diseases / / 17554300 rs1466556 chr2 22896073 T C 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534608 chr2 22903486 G A 7.92E-04 Multiple complex diseases / / 17554300 rs1534608 chr2 22903486 G A 7.55E-05 HIV-1 viral setpoint / / 22174851 rs3849399 chr2 22911727 T C 2.61E-04 Type 2 diabetes / / 17463246 rs719503 chr2 22918437 G A 4.00E-04 Premature ovarian failure / / 19508998 rs2204727 chr2 22975606 T C 8.31E-04 Coronary Artery Disease / / 17634449 rs13421717 chr2 23052800 C T 6.37E-05 Multiple complex diseases / / 17554300 rs4389355 chr2 23068640 G A 6.54E-05 Coronary heart disease / / pha003031 rs7560236 chr2 23076783 C T 1.15E-07 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs17321444 chr2 23108116 C T 3.90E-05 Triglycerides / / pha002904 rs2001795 chr2 23115536 T C 1.12E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10189050 chr2 23124558 C A 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10189050 chr2 23124558 C A 4.00E-06 Obesity-related traits / / 23251661 rs1542190 chr2 23149442 T C 3.90E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6718432 chr2 23169705 T C 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17393543 chr2 23171228 A G 2.10E-05 Urinary metabolites / / 21572414 rs10187446 chr2 23174168 T G 4.23E-05 Monocyte counts / / pha003089 rs713514 chr2 23175970 C T 3.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6737109 chr2 23179531 T C 4.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1348864 chr2 23182262 A C 1.80E-05 Vitamin D concentrations / / 20600896 rs1348864 chr2 23182262 A C 1.80E-05 Vitamin D concentrations / / 20600896 rs2681019 chr2 23187504 C A 8.00E-08 Dialysis-related mortality / / 21546767 rs2592768 chr2 23196362 A G 3.91E-04 Smoking initiation / / 24665060 rs17044558 chr2 23219872 A T 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1446881 chr2 23223292 A G 9.18E-04 Myocardial Infarction / / pha002883 rs13004805 chr2 23227284 C T 3.72E-04 Multiple complex diseases / / 17554300 rs13427835 chr2 23231002 G C 1.72E-04 Hearing function / / 17255346 rs13427835 chr2 23231002 G C 1.10E-05 Urinary metabolites / / 21572414 rs13015418 chr2 23231787 T G 7.78E-05 Personality dimensions / / 18957941 rs2681035 chr2 23234259 C T 7.29E-04 Multiple complex diseases / / 17554300 rs41458646 chr2 23238943 A G 8.00E-06 Alzheimer's disease (late onset) / / 22881374 rs2121450 chr2 23241481 G A 7.07E-06 Height / / 22021425 rs12466477 chr2 23242926 T C 4.54E-05 Height / / 22021425 rs1473333 chr2 23243972 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17044682 chr2 23260912 T C 1.08E-04 Aortic root size / / 21223598 rs11689205 chr2 23282771 G A 4.30E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1446875 chr2 23300822 T C 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs13036116 chr2 23302096 G A 3.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11689706 chr2 23340784 C T 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7591791 chr2 23345329 A T 1.50E-05 Urinary metabolites / / 21572414 rs1817020 chr2 23360557 G T 2.50E-05 Urinary metabolites / / 21572414 rs1562751 chr2 23360855 T A 5.44E-04 Depression (quantitative trait) / / 20800221 rs1562752 chr2 23361001 C A 5.46E-04 Depression (quantitative trait) / / 20800221 rs1449965 chr2 23364711 G A 8.24E-05 Depression (quantitative trait) / / 20800221 rs10194644 chr2 23369473 C T 5.54E-04 Depression (quantitative trait) / / 20800221 rs10197888 chr2 23370317 C T 5.54E-04 Depression (quantitative trait) / / 20800221 rs6716929 chr2 23402150 C T 8.28E-04 Depression (quantitative trait) / / 20800221 rs6721782 chr2 23403834 C G 7.42E-04 Depression (quantitative trait) / / 20800221 rs1562755 chr2 23409862 A G 4.91E-05 Gallstones / / 17632509 rs1375864 chr2 23410734 G C 9.27E-05 Depression (quantitative trait) / / 20800221 rs1449984 chr2 23414651 A G 7.00E-06 Depression (quantitative trait) / / 20800221 rs1449984 chr2 23414651 A G 6.60E-06 Depression (quantitative trait) / / 23290196 rs10495740 chr2 23431541 T G 2.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10495741 chr2 23432044 A G 2.80E-04 Multiple complex diseases / / 17554300 rs1449968 chr2 23442158 T G 2.91E-05 Depression (quantitative trait) / / 20800221 rs9789344 chr2 23476896 A G 8.00E-04 Depression (quantitative trait) / / 20800221 rs2577734 chr2 23494356 C A 9.27E-04 Depression (quantitative trait) / / 20800221 rs1438131 chr2 23506782 G A 8.06E-10 Multiple sclerosis / / 17660530 rs17726419 chr2 23520112 C T 1.47E-05 Sudden cardiac arrest / / 21658281 rs10187596 chr2 23520587 G A 3.78E-04 Depression (quantitative trait) / / 20800221 rs1469974 chr2 23522173 G A 5.06E-05 Depression (quantitative trait) / / 20800221 rs17675487 chr2 23522489 A G 5.19E-05 Depression (quantitative trait) / / 20800221 rs9789743 chr2 23524378 C G 5.48E-05 Depression (quantitative trait) / / 20800221 rs9789522 chr2 23524674 G C 5.52E-05 Depression (quantitative trait) / / 20800221 rs1002159 chr2 23538632 C A 9.43E-05 Obesity (extreme) / / 21935397 rs1002158 chr2 23538843 T G 6.83E-06 Obesity (extreme) / / 21935397 rs2033768 chr2 23542578 T C 6.20E-04 Obesity (extreme) / / 21935397 rs2577720 chr2 23548614 A C 4.41E-04 Alzheimer's disease / / 17998437 rs2577720 chr2 23548614 A C 8.00E-06 F-cell distribution / / 21326311 rs2723120 chr2 23548656 T C 4.93E-04 Type 2 diabetes / / 17463246 rs2723120 chr2 23548656 T C 1.57E-04 Alzheimer's disease / / 17998437 rs2723120 chr2 23548656 T C 6.27E-04 Obesity (extreme) / / 21935397 rs6720873 chr2 23551770 G A 5.16E-04 Obesity (extreme) / / 21935397 rs998157 chr2 23553314 G A 6.02E-06 White blood cell count / / 21738479 rs1122899 chr2 23555150 T C 6.07E-04 Obesity (extreme) / / 21935397 rs2723124 chr2 23558014 C A 6.28E-04 Obesity (extreme) / / 21935397 rs2577711 chr2 23571849 C T 6.34E-04 Obesity (extreme) / / 21935397 rs2723140 chr2 23572757 A G 6.36E-04 Obesity (extreme) / / 21935397 rs6749822 chr2 23581558 C T 9.49E-04 Obesity (extreme) / / 21935397 rs6720565 chr2 23581619 G A 9.63E-04 Alzheimer's disease / / 17998437 rs6720565 chr2 23581619 G A 9.46E-04 Obesity (extreme) / / 21935397 rs2577705 chr2 23589439 A G 4.30E-05 Obesity (extreme) / / 21935397 rs2577704 chr2 23592145 G A 3.00E-06 IgG glycosylation / / 23382691 rs2577704 chr2 23592145 G A 5.00E-06 IgG glycosylation / / 23382691 rs2577703 chr2 23592219 C T 5.80E-05 Obesity (extreme) / / 21935397 rs2577756 chr2 23601556 A G 2.34E-05 Obesity (extreme) / / 21935397 rs13397583 chr2 23606030 C T 2.20E-05 Celiac disease / / 17558408 rs11125011 chr2 23610838 G A 4.14E-04 Multiple complex diseases KLHL29 intron 17554300 rs1030907 chr2 23615027 T C 2.59E-05 Obesity (extreme) KLHL29 intron 21935397 rs6742888 chr2 23616057 T C 4.07E-04 Multiple complex diseases KLHL29 intron 17554300 rs920271 chr2 23620246 T C 3.21E-04 Obesity (extreme) KLHL29 intron 21935397 rs2577748 chr2 23624262 T C 4.15E-04 Obesity (extreme) KLHL29 intron 21935397 rs2577744 chr2 23628311 T A 4.59E-04 Obesity (extreme) KLHL29 intron 21935397 rs12621454 chr2 23633569 A G 4.83E-04 Obesity (extreme) KLHL29 intron 21935397 rs2723111 chr2 23634300 A G 7.70E-04 Obesity (extreme) KLHL29 intron 21935397 rs6544822 chr2 23635949 C T 3.98E-04 Obesity (extreme) KLHL29 intron 21935397 rs737565 chr2 23651204 C A 9.29E-04 Multiple complex diseases KLHL29 intron 17554300 rs6544861 chr2 23676505 C A 2.13E-04 Multiple complex diseases KLHL29 intron 17554300 rs6742202 chr2 23716694 A C 7.09E-04 Body mass index KLHL29 intron 21701565 rs1653763 chr2 23724991 T G 1.27E-05 Major depressive disorder KLHL29 intron 19107115 rs1653765 chr2 23729232 A G 6.93E-05 Major depressive disorder KLHL29 intron 19107115 rs17045504 chr2 23733781 A G 2.55E-05 Height KLHL29 intron 22021425 rs1613177 chr2 23743160 G A 6.33E-04 Body mass index KLHL29 intron 21701565 rs748860 chr2 23754948 C T 7.40E-05 Hypothyroidism KLHL29 intron 22493691 rs4665609 chr2 23774752 A C 4.20E-06 Prostate cancer (early onset) KLHL29 intron 24740154 rs10165828 chr2 23781787 C T 8.60E-05 Diabetic retinopathy KLHL29 intron 21441570 rs1709339 chr2 23783753 A G 2.00E-05 Smoking behavior KLHL29 intron 20418888 rs1560591 chr2 23784121 A G 8.90E-05 Diabetic retinopathy KLHL29 intron 21441570 rs17045705 chr2 23829271 C T 2.90E-04 Cholesterol KLHL29 intron 17255346 rs3795933 chr2 23878191 G A 2.20E-04 Primary sclerosing cholangitis KLHL29 intron 19944697 rs1991083 chr2 23887437 C T 3.60E-05 Height KLHL29 intron 21998595 rs6715626 chr2 23891551 G A 6.02E-04 Amyotrophic Lateral Sclerosis KLHL29 intron 17827064 rs889862 chr2 23897996 C T 4.48E-05 Amyotrophic Lateral Sclerosis KLHL29 intron 17827064 rs4665630 chr2 23898317 C T 1.00E-07 Coronary heart disease KLHL29 intron 21347282 rs3795942 chr2 23919375 C T 4.79E-06 Obesity-related traits KLHL29 cds-synon 23251661 rs3795948 chr2 23926659 T C 9.68E-06 Obesity-related traits KLHL29 cds-synon 23251661 rs2712102 chr2 23932461 C T 8.40E-05 Crohn's disease / / 20570966 rs12478744 chr2 23947589 A G 1.10E-06 Obesity-related traits / / 23251661 rs7608623 chr2 23948953 G T 6.00E-07 Obesity-related traits / / 23251661 rs2551324 chr2 23978800 C G 6.80E-06 Urinary metabolites ATAD2B intron 21572414 rs35379186 chr2 24044352 T C 1.70E-05 Urinary metabolites ATAD2B intron 21572414 rs2339928 chr2 24049453 G A 7.90E-05 Serum metabolites ATAD2B intron 19043545 rs2712089 chr2 24080274 A G 3.20E-06 Urinary metabolites ATAD2B intron 21572414 rs17711796 chr2 24123539 C T 2.20E-05 Urinary metabolites ATAD2B intron 21572414 rs11674248 chr2 24154192 A C 3.00E-06 Obesity-related traits / / 23251661 rs7572949 chr2 24162018 T C 4.92E-06 Obesity-related traits / / 23251661 rs7561273 chr2 24247514 A G 4.48E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7561273 chr2 24247514 A G 6.00E-06 Quantitative traits / / 19197348 rs7561273 chr2 24247514 A G 0.0000609 Coronary artery disease / / 23202125 rs2339940 chr2 24251787 G T 6.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11902184 chr2 24281484 G A 1.55E-04 Lung function (forced expiratory volume in 1 second) FKBP1B intron 17255346 rs2303289 chr2 24342242 C G 4.60E-04 Lymphocyte counts PFN4 intron 22286170 rs6754391 chr2 24369019 T C 4.86E-04 Type 2 diabetes LOC375190 intron 17463246 rs6754391 chr2 24369019 T C 5.85E-04 Multiple complex diseases LOC375190 intron 17554300 rs6723962 chr2 24391733 A G 6.60E-04 Multiple complex diseases LOC375190 intron 17554300 rs2288073 chr2 24413298 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) C2orf84 missense 23509962 rs7564420 chr2 24414002 A G 3.28E-04 Multiple complex diseases / / 17554300 rs2303291 chr2 24431184 C T 8.84E-05 Parkinson's disease ITSN2 missense 17052657 rs2303296 chr2 24432839 A G 2.64E-04 Parkinson's disease ITSN2 cds-synon 17052657 rs2303297 chr2 24432937 C T 2.64E-04 Parkinson's disease ITSN2 intron 17052657 rs6746005 chr2 24434345 G A 9.88E-04 Alzheimer's disease ITSN2 intron 22005930 rs2551182 chr2 24440417 C T 4.75E-05 Male-pattern baldness ITSN2 intron 18849994 rs6707781 chr2 24441883 T G 8.41E-04 Alzheimer's disease ITSN2 intron 22005930 rs2543662 chr2 24443271 C A 2.96E-05 Parkinson's disease ITSN2 UTR-3 17052657 rs1203 chr2 24443330 A G 8.51E-04 Alzheimer's disease ITSN2 UTR-3 22005930 rs10495747 chr2 24514996 T C 3.78E-05 Male-pattern baldness ITSN2 intron 18849994 rs6707600 chr2 24521766 C T 3.00E-06 Response to antipsychotic treatment in schizophrenia (working memory) ITSN2 intron 21107309 rs2702042 chr2 24546542 C T 5.76E-04 Type 2 diabetes ITSN2 intron 17463246 rs2702042 chr2 24546542 C T 7.28E-04 Multiple complex diseases ITSN2 intron 17554300 rs12470303 chr2 24619883 A G 3.84E-04 Multiple complex diseases / / 17554300 rs7595372 chr2 24632122 T G 8.07E-04 Alzheimer's disease / / 22005930 rs729921 chr2 24633124 T G 8.35E-04 Alzheimer's disease / / 22005930 rs894466 chr2 24633771 T C 7.46E-04 Alzheimer's disease / / 22005930 rs4581852 chr2 24638256 C A 6.60E-04 Alzheimer's disease / / 22005930 rs2584940 chr2 24641639 T G 7.36E-04 Alzheimer's disease / / 22005930 rs2702089 chr2 24643291 C T 5.12E-04 Alzheimer's disease / / 22005930 rs11125582 chr2 24646213 G A 4.52E-04 Alzheimer's disease / / 22005930 rs11125583 chr2 24646278 C A 4.92E-04 Alzheimer's disease / / 22005930 rs2249387 chr2 24649801 C G 4.59E-04 Alzheimer's disease / / 22005930 rs6705716 chr2 24651341 C T 3.42E-04 Alzheimer's disease / / 22005930 rs2702050 chr2 24652464 T C 3.79E-04 Alzheimer's disease / / 22005930 rs2702051 chr2 24652896 C A 3.61E-04 Alzheimer's disease / / 22005930 rs2584944 chr2 24652999 T C 3.51E-04 Alzheimer's disease / / 22005930 rs10200838 chr2 24656627 G A 6.39E-05 Alzheimer's disease / / 22005930 rs2012222 chr2 24658162 G A 5.66E-05 Alzheimer's disease / / 22005930 rs1545257 chr2 24658794 G A 2.11E-04 Alzheimer's disease / / 22005930 rs2584937 chr2 24674385 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1031092 chr2 24680249 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1031089 chr2 24692010 G A 1.75E-05 Heart Rate / / pha003054 rs2165738 chr2 24692809 C G 1.11E-04 Multiple complex diseases / / 17554300 rs2165738 chr2 24692809 C G 4.00E-06 Type 1 diabetes / / 18978792 rs2702132 chr2 24698726 G A 5.31E-05 Heart Rate / / pha003054 rs17734306 chr2 24722438 A G 1.42E-04 Glycosylated haemoglobin levels / / 17255346 rs1545255 chr2 24739410 A G 6.41E-04 Multiple complex diseases / / 17554300 rs1545255 chr2 24739410 A G 3.70E-04 Myasthenia gravis / / 23055271 rs6723622 chr2 24789640 G A 9.05E-04 Multiple complex diseases / / 17554300 rs995647 chr2 24810255 G A 5.70E-05 Heart Rate NCOA1 intron pha003054 rs6720514 chr2 24826619 T C 8.75E-05 Glycosylated haemoglobin levels NCOA1 intron 17255346 rs6545667 chr2 24874502 C G 0.000000565 Triglycerides NCOA1 intron 23063622 rs17791703 chr2 24881271 T C 2.16E-05 Multiple complex diseases NCOA1 intron 17554300 rs2119115 chr2 24886781 A C 1.46E-04 Glycosylated haemoglobin levels NCOA1 intron 17255346 rs17046499 chr2 24954055 T C 9.72E-04 Suicide attempts in bipolar disorder NCOA1 intron 21423239 rs6761875 chr2 24972217 T C 6.45E-04 Lymphocyte counts NCOA1 intron 22286170 rs9309308 chr2 24994570 T C 1.25E-04 Multiple complex diseases / / 17554300 rs9309308 chr2 24994570 T C 8.62E-05 Caffeine consumption / / 21490707 rs2891409 chr2 25017357 G T 2.29E-04 Heart rate CENPO intron 23583979 rs41523444 chr2 25017708 G C 1.63E-05 Bipolar Disorder CENPO intron pha002858 rs35213472 chr2 25018509 T C 6.98E-05 Bipolar Disorder CENPO intron pha002858 rs11895026 chr2 25036858 C A 1.00E-13 Height CENPO intron 23563607 rs11125797 chr2 25037626 G T 7.18E-05 Multiple complex diseases CENPO intron 17554300 rs2082881 chr2 25038268 G A 3.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CENPO intron 23648065 rs2278483 chr2 25040082 C T 7.49E-05 Caffeine consumption CENPO intron 21490707 rs1550115 chr2 25041620 C T 3.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CENPO intron 23648065 rs17799872 chr2 25044957 G A 8.21E-04 Obesity (extreme) CENPO UTR-3 21935397 rs13390269 chr2 25068793 G A 6.81E-04 Obesity (extreme) ADCY3 intron 21935397 rs17046666 chr2 25070351 G C 6.92E-04 Obesity (extreme) ADCY3 intron 21935397 rs6545758 chr2 25074874 T C 7.01E-04 Alzheimer's disease ADCY3 intron 22005930 rs6760328 chr2 25077991 T C 3.20E-05 Major depressive disorder ADCY3 intron 21042317 rs1541984 chr2 25082414 G A 3.20E-05 Major depressive disorder ADCY3 intron 21042317 rs7597157 chr2 25089166 C T 6.50E-05 Major depressive disorder ADCY3 intron 21042317 rs13407913 chr2 25097644 A G 3.00E-06 Body mass index (non-asthmatics) ADCY3 intron 23517042 rs2033655 chr2 25101092 G A 1.90E-05 Major depressive disorder ADCY3 intron 21042317 rs2033654 chr2 25103108 C A 2.00E-06 Body mass index (non-asthmatics) ADCY3 intron 23517042 rs12986610 chr2 25106265 C T 5.80E-05 Major depressive disorder ADCY3 intron 21042317 rs7586879 chr2 25116977 C T 4.00E-08 Body mass index ADCY3 intron 23583978 rs6545800 chr2 25118885 C T 9.34E-04 Multiple complex diseases ADCY3 intron 17554300 rs6545800 chr2 25118885 C T 6.00E-16 Inflammatory bowel disease ADCY3 intron 23128233 rs7565468 chr2 25130092 C T 7.40E-05 Major depressive disorder ADCY3 intron 21042317 rs6545814 chr2 25131316 A G 1.87E-04 Smoking cessation ADCY3 intron 18519826 rs6545814 chr2 25131316 A G 1.00E-13 Body mass index ADCY3 intron 22344219 rs6545814 chr2 25131316 A G 1.00E-10 Body mass index ADCY3 intron 24861553 rs11900505 chr2 25131986 A C 8.91E-04 Multiple complex diseases ADCY3 intron 17554300 rs2384061 chr2 25135620 G A 7.96E-06 Smoking cessation ADCY3 intron 18519826 rs2384061 chr2 25135620 G A 8.75E-06 Smoking cessation ADCY3 intron 18519826 rs2384061 chr2 25135620 G A 6.30E-06 Major depressive disorder ADCY3 intron 21042317 rs11676272 chr2 25141538 A G 5.88E-10 Body mass index ADCY3 missense 22344219 rs6752378 chr2 25150116 C A 2.81E-11 Obesity / / 22484627 rs10182181 chr2 25150296 A G 3.43E-05 Height / / 22021425 rs10182181 chr2 25150296 A G 1.00E-17 Obesity / / 23563607 rs10182181 chr2 25150296 A G 3.00E-14 Obesity / / 23563607 rs713586 chr2 25158008 T C 6.00E-22 Body mass index / / 20935630 rs713586 chr2 25158008 T C 6.69E-04 Type 2 diabetes / / 22238593 rs713586 chr2 25158008 T C 1.02E-05 Body mass index / / 22344219 rs713586 chr2 25158008 T C 6.17E-22 Body mass index / / 23001569 rs713586 chr2 25158008 T C 2.56E-05 Age-related macular degeneration / / 23577725 rs713587 chr2 25158281 C T 4.00E-06 Body mass index (non-asthmatics) / / 23517042 rs17046742 chr2 25165825 G A 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1172294 chr2 25169200 A G 1.00E-08 Pubertal anthropometrics D/JC27 UTR-3 23449627 rs4665736 chr2 25187599 C T 7.00E-16 Height D/JC27 intron 20881960 rs6749646 chr2 25193998 A T 6.93E-04 Obesity (extreme) D/JC27 intron 21935397 rs13388020 chr2 25196266 G C 6.83E-04 Obesity (extreme) D/JC27-AS1 intron 21935397 rs6733301 chr2 25276284 G A 8.00E-07 Height EFR3B intron 18391951 rs478222 chr2 25301755 A T 4.00E-09 Type 1 diabetes EFR3B intron 21980299 rs567359 chr2 25304574 A G 3.64E-04 Multiple complex diseases EFR3B intron 17554300 rs1530016 chr2 25305756 C T 3.00E-06 Body mass index (non-asthmatics) EFR3B intron 23517042 rs12233132 chr2 25328703 C T 3.24E-05 Height EFR3B intron pha003011 rs12233134 chr2 25329016 C T 4.39E-04 Type 2 diabetes EFR3B intron 22238593 rs4665284 chr2 25339658 G A 2.76E-05 Height EFR3B intron pha003011 rs7575363 chr2 25342914 A G 5.66E-04 Obesity (extreme) EFR3B intron 21935397 rs6718083 chr2 25362194 G A 8.77E-04 Parkinson's disease EFR3B intron 17052657 rs6718083 chr2 25362194 G A 1.80E-05 Height EFR3B intron pha003011 rs1561288 chr2 25369002 C T 5.00E-08 Body mass index EFR3B intron 23669352 rs1561288 chr2 25369002 C T 1.48E-05 Height EFR3B intron pha003011 rs1561289 chr2 25369040 C T 8.77E-04 Parkinson's disease EFR3B intron 17052657 rs1561289 chr2 25369040 C T 1.48E-05 Height EFR3B intron pha003011 rs13428823 chr2 25373298 G A 6.00E-12 Height EFR3B intron 23563607 rs1866146 chr2 25380573 G A 5.86E-04 Multiple complex diseases EFR3B UTR-3 17554300 rs1866146 chr2 25380573 G A 1.40E-07 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 2.50E-12 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 3.30E-06 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 9.33E-04 Obesity (extreme) EFR3B UTR-3 21935397 rs934778 chr2 25389224 A G 9.05E-04 Obesity (extreme) POMC intron 21935397 rs934778 chr2 25389224 A G 3.75E-05 Triglycerides POMC intron pha002904 rs874401 chr2 25402280 G A 8.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs4665771 chr2 25404327 T C 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665773 chr2 25404975 C A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665774 chr2 25404982 T G 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665775 chr2 25407121 A G 8.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs10186053 chr2 25410190 A G 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665777 chr2 25410896 C T 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665778 chr2 25410970 A T 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs17046917 chr2 25412032 T G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665779 chr2 25412672 A G 9.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs12619868 chr2 25412845 T C 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665287 chr2 25413309 C T 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665287 chr2 25413309 C T 3.66E-05 Body Mass Index / / pha002896 rs12617514 chr2 25419691 C T 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12617514 chr2 25419691 C T 3.66E-05 Body Mass Index / / pha002896 rs10202360 chr2 25420865 A C 2.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs12619264 chr2 25421803 C T 3.36E-05 Suicide attempts in bipolar disorder / / 21423239 rs12612413 chr2 25426846 G T 7.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs12468449 chr2 25432277 T C 9.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs12624309 chr2 25437885 C A 7.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs4665783 chr2 25448050 A G 7.35E-05 Suicide attempts in bipolar disorder / / 21423239 rs2164411 chr2 25452906 G A 4.66E-13 Multiple complex diseases / / 17554300 rs2164411 chr2 25452906 G A 9.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs13420827 chr2 25453968 C G 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs13420827 chr2 25453968 C G 1.10E-04 Iris characteristics / / 21835309 rs11681447 chr2 25472784 C T 1.12E-04 Multiple complex diseases DNMT3A intron 17554300 rs1465825 chr2 25478453 C T 1.52E-04 Multiple complex diseases DNMT3A intron 17554300 rs11694842 chr2 25482970 A G 4.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) DNMT3A intron 23648065 rs13428812 chr2 25492467 A G 9.00E-10 Crohn's disease DNMT3A intron 21102463 rs12999687 chr2 25512438 T G 0.000000683 Body mass index DNMT3A intron 22885924 rs6546071 chr2 25532021 C T 4.78E-04 Multiple complex diseases DNMT3A intron 17554300 rs10196664 chr2 25589466 A G 6.06E-04 Multiple complex diseases / / 17554300 rs1010658 chr2 25595194 T C 4.72E-05 Multiple myeloma / / 22120009 rs1010658 chr2 25595194 T C 4.00E-06 Multiple myeloma / / 23955597 rs1010659 chr2 25595397 C T 3.83E-05 Multiple myeloma / / 22120009 rs11126027 chr2 25596144 G C 6.18E-06 Multiple myeloma / / 22120009 rs562908097 chr2 25596322 TG T 6.07E-06 Multiple myeloma / / 22120009 rs562908097 chr2 25596322 TG T 2.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7586928 chr2 25596322 T C 6.07E-06 Multiple myeloma / / 22120009 rs7586928 chr2 25596322 T C 2.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs732075 chr2 25596431 T G 6.00E-06 Multiple myeloma / / 22120009 rs732076 chr2 25596509 A C 5.95E-06 Multiple myeloma / / 22120009 rs2304426 chr2 25602142 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DTNB intron 20877124 rs2304426 chr2 25602142 G A 7.77E-04 Multiple myeloma DTNB intron 22120009 rs2304427 chr2 25602310 C T 8.95E-04 White matter integrity DTNB intron 22425255 rs55924491 chr2 25605023 C G 1.28E-07 Multiple myeloma DTNB intron 22120009 rs6761076 chr2 25607758 T C 1.81E-07 Multiple myeloma DTNB intron 22120009 rs62131107 chr2 25612725 G T 1.15E-04 Multiple myeloma DTNB intron 22120009 rs7558082 chr2 25612814 C T 5.39E-07 Multiple myeloma DTNB intron 22120009 rs7577599 chr2 25613146 T C 3.37E-07 Multiple myeloma DTNB intron 22120009 rs7577599 chr2 25613146 T C 6.00E-06 Multiple myeloma (IgH translocation) DTNB intron 23502783 rs7577599 chr2 25613146 T C 1.00E-08 Multiple myeloma DTNB intron 23955597 rs1865693 chr2 25620477 G A 1.21E-04 Multiple myeloma DTNB intron 22120009 rs17046986 chr2 25620900 C T 1.22E-04 Multiple myeloma DTNB intron 22120009 rs7571570 chr2 25621530 C T 1.47E-04 Multiple myeloma DTNB intron 22120009 rs7571570 chr2 25621530 C T 4.00E-07 Multiple myeloma DTNB intron 23955597 rs6724910 chr2 25622439 C T 1.12E-04 Multiple myeloma DTNB intron 22120009 rs1369704 chr2 25623590 T C 7.30E-05 Multiple myeloma DTNB intron 22120009 rs2384232 chr2 25623749 G A 8.85E-05 Multiple myeloma DTNB intron 22120009 rs2384232 chr2 25623749 G A 3.00E-07 Multiple myeloma DTNB intron 23955597 rs10206012 chr2 25624186 G A 6.97E-05 Multiple myeloma DTNB intron 22120009 rs6546148 chr2 25625005 A G 6.87E-05 Multiple myeloma DTNB intron 22120009 rs7583617 chr2 25625859 T C 9.58E-05 Multiple myeloma DTNB intron 22120009 rs7570164 chr2 25626236 C T 6.75E-05 Multiple myeloma DTNB intron 22120009 rs7586918 chr2 25626385 T C 8.78E-05 Multiple myeloma DTNB intron 22120009 rs7586918 chr2 25626385 T C 2.00E-07 Multiple myeloma DTNB intron 23955597 rs12622767 chr2 25627916 A G 7.74E-06 Multiple myeloma DTNB intron 22120009 rs6756177 chr2 25628897 G A 3.24E-05 Multiple myeloma DTNB intron 22120009 rs6546149 chr2 25629438 C G 2.24E-05 Multiple myeloma DTNB intron 22120009 rs60462983 chr2 25629525 A G 5.26E-06 Multiple myeloma DTNB intron 22120009 rs10180663 chr2 25633242 T C 1.10E-05 Multiple myeloma DTNB intron 22120009 rs10180663 chr2 25633242 T C 2.00E-06 Multiple myeloma (IgH translocation) DTNB intron 23502783 rs10180663 chr2 25633242 T C 9.00E-08 Multiple myeloma DTNB intron 23955597 rs10189164 chr2 25633368 G C 4.92E-04 Multiple myeloma DTNB intron 22120009 rs6731296 chr2 25634827 C T 5.87E-05 Multiple myeloma DTNB intron 22120009 rs7605235 chr2 25654049 G A 7.47E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines DTNB intron 21844884 rs7605235 chr2 25654049 G A 7.58E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DTNB intron 21844884 rs6746082 chr2 25659244 A C 4.00E-07 Multiple myeloma DTNB intron 22120009 rs6746082 chr2 25659244 A C 7.00E-09 Multiple myeloma DTNB intron 23955597 rs7589394 chr2 25661744 C G 4.65E-07 Multiple myeloma DTNB intron 22120009 rs1006752 chr2 25663991 C T 7.10E-06 Multiple myeloma DTNB intron 22120009 rs1006752 chr2 25663991 C T 7.00E-07 Multiple myeloma DTNB intron 23955597 rs2036653 chr2 25666969 A T 2.57E-07 Multiple myeloma DTNB intron 22120009 rs6721434 chr2 25669517 G A 9.82E-04 Iron levels DTNB intron pha002876 rs6712045 chr2 25669973 T G 2.90E-06 Multiple myeloma DTNB intron 22120009 rs13390436 chr2 25670777 C T 2.28E-07 Multiple myeloma DTNB intron 22120009 rs6546183 chr2 25671806 G A 4.87E-07 Multiple myeloma DTNB intron 22120009 rs6546183 chr2 25671806 G A 1.00E-07 Multiple myeloma DTNB intron 23955597 rs6546184 chr2 25672469 C T 2.84E-07 Multiple myeloma DTNB intron 22120009 rs13397493 chr2 25672692 C T 2.86E-07 Multiple myeloma DTNB intron 22120009 rs6733060 chr2 25677997 G C 3.54E-06 Multiple myeloma DTNB intron 22120009 rs113288889 chr2 25681552 C T 6.91E-06 Multiple myeloma DTNB intron 22120009 rs13387987 chr2 25682416 G A 3.11E-07 Multiple myeloma DTNB intron 22120009 rs6546199 chr2 25683447 A G 5.18E-04 Alzheimer's disease DTNB intron 24755620 rs2384235 chr2 25684118 T C 4.50E-04 Alzheimer's disease DTNB intron 24755620 rs13386804 chr2 25692112 G T 9.23E-04 Alzheimer's disease DTNB intron 24755620 rs6737282 chr2 25697403 A G 5.70E-04 Alzheimer's disease DTNB intron 24755620 rs4665791 chr2 25698847 G A 2.58E-06 Multiple myeloma DTNB intron 22120009 rs504855 chr2 25700434 G A 9.31E-04 Alzheimer's disease DTNB intron 24755620 rs6751254 chr2 25705428 T C 3.97E-04 Lung function (forced vital capacity) DTNB intron 24023788 rs2055718 chr2 25710090 G A 9.80E-04 Alzheimer's disease DTNB intron 24755620 rs1507705 chr2 25714916 C T 6.03E-04 Multiple myeloma DTNB intron 22120009 rs7577573 chr2 25716597 G A 7.31E-06 Multiple myeloma DTNB intron 22120009 rs679112 chr2 25718052 G A 7.23E-06 Multiple myeloma DTNB intron 22120009 rs6728820 chr2 25724886 T C 1.21E-04 Multiple myeloma DTNB intron 22120009 rs6725828 chr2 25725057 A C 8.46E-05 Multiple myeloma DTNB intron 22120009 rs545065 chr2 25726123 T C 3.73E-04 Multiple myeloma DTNB intron 22120009 rs9309386 chr2 25727910 G A 9.80E-04 Type 2 diabetes DTNB intron 17846124 rs551405 chr2 25729007 G C 1.56E-04 Multiple myeloma DTNB intron 22120009 rs1965239 chr2 25729721 A G 1.52E-04 Multiple myeloma DTNB intron 22120009 rs671826 chr2 25730069 T C 1.54E-04 Multiple myeloma DTNB intron 22120009 rs683662 chr2 25730344 A G 1.53E-04 Multiple myeloma DTNB intron 22120009 rs517506 chr2 25730404 A G 1.53E-04 Multiple myeloma DTNB intron 22120009 rs517403 chr2 25730439 G A 1.51E-04 Multiple myeloma DTNB intron 22120009 rs2384237 chr2 25731389 A C 3.17E-04 Multiple myeloma DTNB intron 22120009 rs2384238 chr2 25731413 A T 3.17E-04 Multiple myeloma DTNB intron 22120009 rs372492988 chr2 25731413 A ATT 3.17E-04 Multiple myeloma DTNB intron 22120009 rs56398912 chr2 25731413 A ATT 3.17E-04 Multiple myeloma DTNB intron 22120009 rs503169 chr2 25735072 A G 1.54E-04 Multiple myeloma DTNB intron 22120009 rs519177 chr2 25737041 A G 1.67E-04 Multiple myeloma DTNB intron 22120009 rs596173 chr2 25740991 C T 6.04E-04 Multiple myeloma DTNB intron 22120009 rs498963 chr2 25741061 T G 6.06E-04 Multiple myeloma DTNB intron 22120009 rs670343 chr2 25744731 G A 6.55E-04 Multiple myeloma DTNB intron 22120009 rs6546237 chr2 25749376 T C 3.25E-04 Multiple myeloma DTNB intron 22120009 rs1848307 chr2 25752181 C T 7.44E-04 Multiple myeloma DTNB intron 22120009 rs624622 chr2 25752979 C T 7.85E-04 Multiple myeloma DTNB intron 22120009 rs537986 chr2 25754005 A G 7.92E-04 Multiple myeloma DTNB intron 22120009 rs539879 chr2 25754235 T C 7.74E-04 Multiple myeloma DTNB intron 22120009 rs636586 chr2 25754670 C A 7.83E-04 Multiple myeloma DTNB intron 22120009 rs6731902 chr2 25755200 T G 8.25E-04 Multiple myeloma DTNB intron 22120009 rs936012 chr2 25755848 C T 7.19E-04 Multiple myeloma DTNB intron 22120009 rs483490 chr2 25756264 A G 8.07E-04 Multiple myeloma DTNB intron 22120009 rs3100636 chr2 25757080 G C 8.45E-04 Multiple myeloma DTNB intron 22120009 rs3105720 chr2 25757091 C T 8.45E-04 Multiple myeloma DTNB intron 22120009 rs682888 chr2 25757709 T C 8.57E-04 Multiple myeloma DTNB intron 22120009 rs503594 chr2 25757803 C T 8.57E-04 Multiple myeloma DTNB intron 22120009 rs670576 chr2 25758132 A G 8.59E-04 Multiple myeloma DTNB intron 22120009 rs80307750 chr2 25758677 C T 8.62E-04 Multiple myeloma DTNB intron 22120009 rs111628494 chr2 25758974 G A 8.91E-04 Multiple myeloma DTNB intron 22120009 rs637519 chr2 25760891 G A 7.97E-04 Multiple myeloma DTNB intron 22120009 rs508262 chr2 25761044 G A 8.66E-04 Multiple myeloma DTNB intron 22120009 rs840001 chr2 25763590 C G 7.19E-04 Multiple myeloma DTNB intron 22120009 rs486217 chr2 25767561 A G 8.00E-04 Multiple myeloma DTNB intron 22120009 rs659323 chr2 25771379 A T 8.35E-04 Multiple myeloma DTNB intron 22120009 rs658414 chr2 25771561 C T 7.75E-04 Multiple myeloma DTNB intron 22120009 rs478237 chr2 25775885 A G 8.36E-04 Multiple myeloma DTNB intron 22120009 rs76471080 chr2 25778179 C A 8.25E-04 Multiple myeloma DTNB intron 22120009 rs12473635 chr2 25778637 T C 8.22E-04 Multiple myeloma DTNB intron 22120009 rs61712781 chr2 25779495 T C 8.20E-04 Multiple myeloma DTNB intron 22120009 rs6737159 chr2 25781453 T C 8.16E-04 Multiple myeloma DTNB intron 22120009 rs2123826 chr2 25789144 A G 7.86E-05 Multiple myeloma DTNB intron 22120009 rs11678268 chr2 25837156 T C 4.14E-06 Cognitive impairment induced by topiramate DTNB intron 22091778 rs858648 chr2 25867203 G T 1.57E-07 Cognitive impairment induced by topiramate DTNB intron 22091778 rs704789 chr2 25874261 C T 2.84E-07 Cognitive impairment induced by topiramate DTNB intron 22091778 rs11684202 chr2 25887558 A G 6.00E-06 Coronary heart disease DTNB intron 21347282 rs11684202 chr2 25887558 A G 1.30E-05 Urinary metabolites DTNB intron 21572414 rs6738958 chr2 25892403 T G 7.30E-06 Urinary metabolites DTNB intron 21572414 rs11676342 chr2 25923407 G T 4.60E-06 Nasopharyngeal carcinoma / / 23209447 rs2384259 chr2 25929371 T G 8.40E-06 Urinary metabolites / / 21572414 rs41521945 chr2 25938077 A T 1.67E-04 Multiple complex diseases / / 17554300 rs1076000 chr2 25977356 G A 8.40E-04 Multiple complex diseases ASXL2 intron 17554300 rs7581916 chr2 25988915 G C 7.99E-05 Hearing function ASXL2 intron 17255346 rs17680828 chr2 25990640 T C 9.56E-05 Multiple complex diseases ASXL2 intron 17554300 rs17047144 chr2 26018106 G A 2.28E-04 Hearing function ASXL2 intron 17255346 rs12713741 chr2 26207421 G A 8.93E-05 Serum metabolites / / 19043545 rs112288323 chr2 26228207 C T 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6734513 chr2 26232521 G C 7.20E-06 Urinary metabolites / / 21572414 rs68184094 chr2 26249899 T A 2.00E-06 Metabolite levels (HVA) / / 23319000 rs68184094 chr2 26249899 T A 4.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs13388915 chr2 26272602 G A 8.00E-06 Immune response to smallpox vaccine (IL-6) RAB10 intron 22542470 rs13395488 chr2 26280029 G A 9.43E-06 Multiple complex diseases RAB10 intron 17554300 rs10048683 chr2 26320519 G A 6.36E-05 Lymphocyte counts RAB10 intron 22286170 rs9332419 chr2 26322040 A G 0.00000617 Preeclampsia RAB10 intron 22432041 rs34792425 chr2 26341570 A C 6.52E-06 Metabolite levels (MHPG) RAB10 intron 23319000 rs11126375 chr2 26344787 G A 0.00000913 Preeclampsia RAB10 intron 22432041 rs1025543 chr2 26385788 T C 1.14E-04 Body mass index / / 21701565 rs1025542 chr2 26385849 G A 1.60E-04 Body mass index / / 21701565 rs17593512 chr2 26417829 G A 1.22E-04 Type 2 diabetes HADHA intron 17463246 rs137852769 chr2 26418053 C G 0.0000052 Breast cancer (ER positive) HADHA missense 23555315 rs137852769 chr2 26418053 C G 0.00044 Breast cancer HADHA missense 23555315 rs4665319 chr2 26424583 A C 1.80E-05 Coronary heart disease HADHA intron 21966275 rs17527979 chr2 26428132 C T 4.57E-04 Alzheimer's disease HADHA intron 17998437 rs6745226 chr2 26493597 C A 8.58E-04 Body mass index HADHB intron 21701565 rs6753473 chr2 26526419 T G 2.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753473 chr2 26526419 T G 4.00E-06 Non-small cell lung cancer / / 23144319 rs13000148 chr2 26526763 T C 4.95E-04 Alzheimer's disease / / 17998437 rs11902679 chr2 26527798 C T 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs1897115 chr2 26554063 C T 5.87E-04 Tourette syndrome GPR113 intron 22889924 rs11899781 chr2 26580137 C T 1.91E-04 Multiple complex diseases EPT1 intron 17554300 rs3820937 chr2 26616624 G C 2.27E-05 Sudden cardiac arrest EPT1 UTR-3 21658281 rs10179397 chr2 26635328 A C 5.78E-04 Response to taxane treatment (placlitaxel) CCDC164 intron 23006423 rs17529722 chr2 26635442 G A 5.10E-04 Type 2 diabetes CCDC164 intron 17463246 rs13409838 chr2 26638983 A C 2.44E-04 Multiple complex diseases CCDC164 intron 17554300 rs4450561 chr2 26653457 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) CCDC164 intron 20708005 rs3795958 chr2 26667130 A G 2.00E-06 Metabolite levels (HVA) CCDC164 missense 23319000 rs3795958 chr2 26667130 A G 4.00E-06 Metabolite levels (HVA/MHPG ratio) CCDC164 missense 23319000 rs2280515 chr2 26677303 G T 2.68E-04 Alcohol dependence CCDC164 intron 21314694 rs4416176 chr2 26682646 T C 4.00E-04 Multiple complex diseases OTOF intron 17554300 rs13031842 chr2 26711136 C T 5.97E-04 Type 2 diabetes OTOF intron 17463246 rs13029647 chr2 26731244 T C 6.51E-04 Type 2 diabetes OTOF intron 17463246 rs4665865 chr2 26738696 C A 1.32E-04 Acute lymphoblastic leukemia (childhood) OTOF intron 22076464 rs11682534 chr2 26762046 A G 4.00E-05 Lipid levels OTOF intron 18193043 rs6547102 chr2 26773867 C T 8.79E-04 Obesity (extreme) OTOF intron 21935397 rs10192160 chr2 26778638 C G 3.72E-05 Non-word repetition OTOF intron 23738518 rs1011108 chr2 26782621 C T 2.00E-06 Periodontal microbiota OTOF nearGene-5 22699663 rs1148949 chr2 26796919 G A 4.06E-05 Non-word repetition C2orf70 intron 23738518 rs2272464 chr2 26799031 G A 8.73E-04 Amyotrophic Lateral Sclerosis C2orf70 cds-synon 17362836 rs6727852 chr2 26840492 T C 6.30E-05 Vitiligo CIB4 intron 22951725 rs1662992 chr2 26848046 T C 2.23E-05 Vitiligo CIB4 intron 22951725 rs11694917 chr2 26864607 C T 5.35E-04 Type 2 diabetes / / 17463246 rs1275953 chr2 26880402 C T 7.50E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275951 chr2 26883482 C T 6.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275945 chr2 26886068 C T 4.61E-05 Bipolar disorder and schizophrenia / / 20889312 rs1731227 chr2 26886523 G A 7.96E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275964 chr2 26892931 G A 3.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs1009221 chr2 26894589 A G 1.81E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1275985 chr2 26911745 C T 1.02E-05 Multiple complex diseases / / 17554300 rs1275986 chr2 26912079 C A 6.51E-06 Multiple complex diseases / / 17554300 rs1275986 chr2 26912079 C A 3.09E-06 Kawasaki disease / / 21221998 rs1275988 chr2 26914364 C T 7.97E-06 Multiple complex diseases / / 17554300 rs1275988 chr2 26914364 C T 3.18E-06 Kawasaki disease / / 21221998 rs1275982 chr2 26919089 C T 6.97E-06 Multiple complex diseases KCNK3 intron 17554300 rs11126666 chr2 26928811 G A 9.80E-04 Type 2 diabetes KCNK3 intron 17463246 rs11126666 chr2 26928811 G A 1.35E-05 Multiple complex diseases KCNK3 intron 17554300 rs11126666 chr2 26928811 G A 3.85E-06 Kawasaki disease KCNK3 intron 21221998 rs11126666 chr2 26928811 G A 5.23E-05 Insulin-related traits KCNK3 intron pha003063 rs1275935 chr2 26961857 G T 2.56E-04 Smoking initiation / / 24665060 rs11126681 chr2 26963378 A G 3.39E-04 Multiple complex diseases / / 17554300 rs870535 chr2 26964015 T C 5.73E-04 Multiple complex diseases / / 17554300 rs870535 chr2 26964015 T C 4.53E-04 Smoking initiation / / 24665060 rs828273 chr2 26972205 G A 3.76E-04 Multiple complex diseases / / 17554300 rs3845684 chr2 26979671 T C 8.28E-05 Smoking initiation / / 24665060 rs2060390 chr2 27024478 G A 8.60E-05 Glioma (high-grade) / / 19578366 rs999087 chr2 27033604 C T 1.32E-04 Smoking initiation / / 24665060 rs2117275 chr2 27043309 G A 1.11E-04 Smoking initiation / / 24665060 rs7606808 chr2 27044227 C T 3.10E-05 Smoking initiation / / 24665060 rs7602471 chr2 27050727 G A 4.13E-04 Smoking initiation / / 24665060 rs1368892 chr2 27054551 A G 1.24E-04 Smoking initiation / / 24665060 rs4513249 chr2 27058451 G T 2.79E-04 Multiple complex diseases / / 17554300 rs3885083 chr2 27058657 A G 9.08E-05 Smoking initiation / / 24665060 rs4665360 chr2 27059011 T C 4.90E-04 Smoking initiation / / 24665060 rs1560860 chr2 27061253 T C 9.99E-05 Smoking initiation / / 24665060 rs6547275 chr2 27064577 T C 2.25E-04 Smoking initiation / / 24665060 rs11887277 chr2 27083269 T C 5.00E-06 Obesity-related traits DPYSL5 intron 23251661 rs6756245 chr2 27083489 T C 5.76E-06 Obesity-related traits DPYSL5 intron 23251661 rs827884 chr2 27094842 C G 6.67E-04 Multiple complex diseases DPYSL5 intron 17554300 rs12618836 chr2 27137616 G A 9.07E-05 Gallstones DPYSL5 intron 17632509 rs9309559 chr2 27141515 A C 6.16E-04 Aortic root size DPYSL5 intron 21223598 rs10196501 chr2 27147272 A G 4.78E-04 Smoking initiation DPYSL5 intron 24665060 rs1371614 chr2 27152874 C T 2.00E-12 Fasting glucose-related traits (interaction with BMI) DPYSL5 intron 22581228 rs1371614 chr2 27152874 C T 7.09E-11 Fasting blood glucose DPYSL5 intron 22885924 rs1371614 chr2 27152874 C T 4.79E-04 Lung function (forced expiratory volume in 1 second) DPYSL5 intron 24023788 rs7564363 chr2 27191473 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6716275 chr2 27227707 A G 8.06E-05 Gallstones MAPRE3 intron 17632509 rs1124649 chr2 27260469 G A 0.000000516 Fasting blood glucose TMEM214 missense 22885924 rs3754734 chr2 27299598 G T 1.59E-04 Coronary Artery Disease / / 17634449 rs1866559 chr2 27335586 T C 5.30E-05 Electrocardiographic traits and heart rate variability CGREF1 intron 17903306 rs7588926 chr2 27342894 C T 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2304678 chr2 27353507 G C 1.67E-07 Hirschsprung's disease ABHD1 missense 19196962 rs1275512 chr2 27371203 A G 5.00E-05 Prostate cancer / / 21743057 rs6709602 chr2 27405497 C T 3.23E-05 F-cell distribution / / 21326311 rs6709602 chr2 27405497 C T 7.23E-05 Hypertension (essential hypertension) / / 22184326 rs1659700 chr2 27414134 T C 1.32E-04 Cholesterol / / 17255346 rs1275501 chr2 27419282 T G 6.92E-05 Hypertension (essential hypertension) / / 22184326 rs1659685 chr2 27420690 C T 4.08E-05 Hypertension (essential hypertension) / / 22184326 rs140443329 chr2 27424304 C T 0.00023 Breast cancer SLC5A6 missense 23555315 rs1395 chr2 27424636 G A 2.92E-08 Urate levels SLC5A6 missense 23263486 rs1395 chr2 27424636 G A 8.00E-11 Blood metabolite levels SLC5A6 missense 24816252 rs2580761 chr2 27426362 G A 2.60E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs1275522 chr2 27426878 C T 6.33E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs1275528 chr2 27430781 A G 8.79E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs11608 chr2 27435374 G A 7.01E-05 Hypertension (essential hypertension) C2orf28 UTR-5 22184326 rs11126918 chr2 27438710 G A 3.70E-05 Hypertension (essential hypertension) C2orf28 intron 22184326 rs4665958 chr2 27443196 A G 9.54E-05 Hypertension (essential hypertension) CAD intron 22184326 rs7593448 chr2 27449293 C G 5.87E-11 Triglycerides CAD intron 23063622 rs3769143 chr2 27450724 G A 6.20E-05 Hypertension (essential hypertension) CAD intron 22184326 rs13399758 chr2 27455726 T C 2.73E-05 Cholesterol CAD intron 17255346 rs4665960 chr2 27467598 C T 2.03E-05 Hypertension (essential hypertension) / / 22184326 rs1561535 chr2 27471025 C T 2.18E-05 Hypertension (essential hypertension) / / 22184326 rs9653564 chr2 27472618 G A 3.26E-05 Hypertension (essential hypertension) / / 22184326 rs1992291 chr2 27504312 A G 1.38E-05 Hypertension (essential hypertension) / / 22184326 rs11686131 chr2 27508710 C T 5.93E-06 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665376 chr2 27509032 T C 4.15E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665962 chr2 27515105 A G 7.09E-06 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404327 chr2 27519153 G T 4.43E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404327 chr2 27519153 G T 1.35E-09 Urate levels TRIM54 intron 23263486 rs13404446 chr2 27519254 G A 3.39E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404446 chr2 27519254 G A 1.87E-04 Lymphocyte counts TRIM54 intron 22286170 rs13404446 chr2 27519254 G A 3.09E-09 Fasting blood glucose TRIM54 intron 22885924 rs13404446 chr2 27519254 G A 1.36E-09 Urate levels TRIM54 intron 23263486 rs7575245 chr2 27527321 G A 4.75E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665963 chr2 27528692 T C 4.73E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665963 chr2 27528692 T C 4.06E-13 Triglycerides TRIM54 intron 23063622 rs4665963 chr2 27528692 T C 1.21E-09 Urate levels TRIM54 intron 23263486 rs4665965 chr2 27536380 T C 5.68E-05 Hypertension (essential hypertension) MPV17 intron 22184326 rs4665965 chr2 27536380 T C 1.83E-09 Fasting blood glucose MPV17 intron 22885924 rs4665965 chr2 27536380 T C 9.18E-10 Urate levels MPV17 intron 23263486 rs1975384 chr2 27542041 C T 8.15E-06 Hypertension (essential hypertension) MPV17 intron 22184326 rs1122227 chr2 27544285 C T 2.32E-05 Hypertension (essential hypertension) MPV17 intron 22184326 rs1122227 chr2 27544285 C T 9.44E-11 Triglycerides MPV17 intron 23063622 rs1049817 chr2 27550967 A G 1.45E-06 Lipid levels GTF3C2 cds-synon 19913121 rs1049817 chr2 27550967 A G 3.10E-06 Response to statin therapy GTF3C2 cds-synon 20339536 rs1049817 chr2 27550967 A G 1.20E-07 Urate levels GTF3C2 cds-synon 20884846 rs1049817 chr2 27550967 A G 9.70E-30 Triglycerides GTF3C2 cds-synon 23063622 rs1049817 chr2 27550967 A G 1.05E-16 Urate levels GTF3C2 cds-synon 23263486 rs3739095 chr2 27556721 G A 2.90E-07 Response to statin therapy GTF3C2 intron 20339536 rs3739095 chr2 27556721 G A 1.40E-10 Urate levels GTF3C2 intron 20884846 rs3739095 chr2 27556721 G A 4.54E-21 Urate levels GTF3C2 intron 23263486 rs11684134 chr2 27558252 A G 2.10E-06 Response to statin therapy GTF3C2 intron 20339536 rs11684134 chr2 27558252 A G 7.10E-09 Urate levels GTF3C2 intron 20884846 rs11684134 chr2 27558252 A G 5.51E-18 Urate levels GTF3C2 intron 23263486 rs11689803 chr2 27566520 T A 8.50E-06 Response to statin therapy GTF3C2 intron 20339536 rs11689803 chr2 27566520 T A 4.87E-13 Urate levels GTF3C2 intron 23263486 rs6743819 chr2 27567407 G T 3.60E-06 Response to statin therapy GTF3C2 intron 20339536 rs6743819 chr2 27567407 G T 1.40E-07 Urate levels GTF3C2 intron 20884846 rs6743819 chr2 27567407 G T 5.50E-17 Urate levels GTF3C2 intron 23263486 rs10205219 chr2 27568565 T C 3.70E-06 Response to statin therapy GTF3C2 intron 20339536 rs10205219 chr2 27568565 T C 1.40E-07 Urate levels GTF3C2 intron 20884846 rs10205219 chr2 27568565 T C 5.45E-17 Urate levels GTF3C2 intron 23263486 rs4665969 chr2 27574953 T C 3.60E-06 Response to statin therapy GTF3C2 intron 20339536 rs4665969 chr2 27574953 T C 1.30E-07 Urate levels GTF3C2 intron 20884846 rs4665969 chr2 27574953 T C 1.15E-16 Urate levels GTF3C2 intron 23263486 rs6760828 chr2 27579231 T C 3.70E-06 Response to statin therapy GTF3C2 intron 20339536 rs6760828 chr2 27579231 T C 1.20E-07 Urate levels GTF3C2 intron 20884846 rs6760828 chr2 27579231 T C 9.10E-17 Urate levels GTF3C2 intron 23263486 rs55795546 chr2 27580983 A G 4.51E-05 Intracerebral hemorrhage / / 24656865 rs7586601 chr2 27584666 A G 1.40E-07 Response to statin therapy / / 20339536 rs7586601 chr2 27584666 A G 2.80E-10 Urate levels / / 20884846 rs7586601 chr2 27584666 A G 3.72E-37 Triglycerides / / 23063622 rs7586601 chr2 27584666 A G 7.52E-20 Urate levels / / 23263486 rs1058065 chr2 27587724 G A 4.00E-06 IgG glycosylation EIF2B4 cds-synon 23382691 rs2280737 chr2 27589810 T C 1.30E-05 Response to statin therapy EIF2B4 intron 20339536 rs2280737 chr2 27589810 T C 2.50E-07 Urate levels EIF2B4 intron 20884846 rs2280737 chr2 27589810 T C 4.31E-16 Urate levels EIF2B4 intron 23263486 rs56402945 chr2 27591708 G A 4.37E-05 Intracerebral hemorrhage EIF2B4 intron 24656865 rs7602534 chr2 27592423 C T 1.50E-05 Response to statin therapy EIF2B4 intron 20339536 rs7602534 chr2 27592423 C T 3.40E-07 Urate levels EIF2B4 intron 20884846 rs7602534 chr2 27592423 C T 4.17E-16 Urate levels EIF2B4 intron 23263486 rs1528533 chr2 27595756 G C 1.40E-05 Response to statin therapy SNX17 intron 20339536 rs1528533 chr2 27595756 G C 1.90E-07 Urate levels SNX17 intron 20884846 rs1528533 chr2 27595756 G C 2.11E-22 Triglycerides SNX17 intron 23063622 rs1528533 chr2 27595756 G C 1.58E-15 Urate levels SNX17 intron 23263486 rs4665972 chr2 27598097 T C 3.62E-14 Metabolite levels SNX17 intron 22286219 rs4665972 chr2 27598097 T C 1.00E-06 Breast size SNX17 intron 22747683 rs4665972 chr2 27598097 T C 1.00E-08 Triglycerides SNX17 intron 23726366 rs4665972 chr2 27598097 T C 1.05E-08 Triglycerides SNX17 intron 23726366 rs13472 chr2 27600239 G A 1.40E-05 Response to statin therapy ZNF513 UTR-3 20339536 rs13472 chr2 27600239 G A 2.20E-07 Urate levels ZNF513 UTR-3 20884846 rs13472 chr2 27600239 G A 9.21E-29 Triglycerides ZNF513 UTR-3 23063622 rs13472 chr2 27600239 G A 5.06E-16 Urate levels ZNF513 UTR-3 23263486 rs4582 chr2 27604279 A G 1.30E-05 Response to statin therapy PPM1G UTR-3 20339536 rs4582 chr2 27604279 A G 6.64E-13 Urate levels PPM1G UTR-3 23263486 rs2384629 chr2 27606098 A G 3.74E-09 Urate levels PPM1G intron 23263486 rs1647284 chr2 27608115 C T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs1647284 chr2 27608115 C T 1.70E-07 Urate levels PPM1G intron 20884846 rs1647284 chr2 27608115 C T 1.54E-15 Urate levels PPM1G intron 23263486 rs76823937 chr2 27611154 T C 4.83E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs7594812 chr2 27611469 A G 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs7594812 chr2 27611469 A G 1.60E-07 Urate levels PPM1G intron 20884846 rs7594812 chr2 27611469 A G 1.36E-15 Urate levels PPM1G intron 23263486 rs12476704 chr2 27613031 C A 1.40E-05 Response to statin therapy PPM1G intron 20339536 rs12476704 chr2 27613031 C A 1.60E-07 Urate levels PPM1G intron 20884846 rs12476704 chr2 27613031 C A 5.67E-16 Urate levels PPM1G intron 23263486 rs11891554 chr2 27613617 G A 0.000000224 Fasting blood glucose PPM1G intron 22885924 rs11891554 chr2 27613617 G A 4.77E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs2911712 chr2 27626945 A T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs2911712 chr2 27626945 A T 1.30E-07 Urate levels PPM1G intron 20884846 rs2911712 chr2 27626945 A T 1.62E-15 Urate levels PPM1G intron 23263486 rs62131866 chr2 27627704 G A 3.87E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs7563162 chr2 27631191 C T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs7563162 chr2 27631191 C T 1.30E-07 Urate levels PPM1G intron 20884846 rs7563162 chr2 27631191 C T 2.30E-15 Urate levels PPM1G intron 23263486 rs62131868 chr2 27631558 T C 3.72E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs6717803 chr2 27634511 A G 3.75E-05 Intracerebral hemorrhage / / 24656865 rs1728918 chr2 27635463 A G 5.11E-13 Metabolite levels / / 22286219 rs1728918 chr2 27635463 A G 5.00E-16 Crohn's disease / / 23128233 rs1060525 chr2 27635582 A G 1.30E-05 Response to statin therapy / / 20339536 rs1060525 chr2 27635582 A G 1.60E-07 Urate levels / / 20884846 rs1060525 chr2 27635582 A G 1.70E-15 Urate levels / / 23263486 rs2010087 chr2 27637235 C T 1.50E-05 Response to statin therapy / / 20339536 rs2010087 chr2 27637235 C T 1.30E-07 Urate levels / / 20884846 rs2010087 chr2 27637235 C T 5.72E-16 Urate levels / / 23263486 rs4665976 chr2 27640325 A G 1.30E-05 Response to statin therapy / / 20339536 rs4665976 chr2 27640325 A G 1.30E-07 Urate levels / / 20884846 rs4665976 chr2 27640325 A G 1.58E-15 Urate levels / / 23263486 rs11675428 chr2 27642734 A C 5.86E-04 Parkinson's disease / / 17052657 rs11675428 chr2 27642734 A C 1.94E-08 Urate levels / / 23263486 rs1728922 chr2 27644464 A C 1.30E-05 Response to statin therapy / / 20339536 rs1728922 chr2 27644464 A C 1.20E-07 Urate levels / / 20884846 rs1728922 chr2 27644464 A C 1.99E-15 Urate levels / / 23263486 rs6547626 chr2 27646770 C T 1.30E-05 Response to statin therapy / / 20339536 rs6547626 chr2 27646770 C T 1.10E-07 Urate levels / / 20884846 rs6547626 chr2 27646770 C T 1.92E-15 Urate levels / / 23263486 rs62131869 chr2 27647453 G A 4.37E-05 Intracerebral hemorrhage / / 24656865 rs4665978 chr2 27648726 T C 1.30E-07 Response to statin therapy / / 20339536 rs4665978 chr2 27648726 T C 1.80E-10 Urate levels / / 20884846 rs4665978 chr2 27648726 T C 1.16E-19 Urate levels / / 23263486 rs780100 chr2 27652153 G T 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs780100 chr2 27652153 G T 3.40E-08 Urate levels NRBP1 intron 20884846 rs780100 chr2 27652153 G T 1.84E-15 Urate levels NRBP1 intron 23263486 rs704791 chr2 27657167 T C 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs704791 chr2 27657167 T C 3.90E-08 Urate levels NRBP1 intron 20884846 rs704791 chr2 27657167 T C 2.16E-15 Urate levels NRBP1 intron 23263486 rs780102 chr2 27659491 T C 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs780102 chr2 27659491 T C 3.30E-08 Urate levels NRBP1 intron 20884846 rs780102 chr2 27659491 T C 2.24E-15 Urate levels NRBP1 intron 23263486 rs1260341 chr2 27663215 T A 1.40E-05 Response to statin therapy NRBP1 intron 20339536 rs1260341 chr2 27663215 T A 3.20E-08 Urate levels NRBP1 intron 20884846 rs1260341 chr2 27663215 T A 1.88E-15 Urate levels NRBP1 intron 23263486 rs1260342 chr2 27663416 G T 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs1260342 chr2 27663416 G T 3.20E-08 Urate levels NRBP1 intron 20884846 rs1260342 chr2 27663416 G T 1.95E-15 Urate levels NRBP1 intron 23263486 rs62131871 chr2 27667184 G A 2.83E-05 Intracerebral hemorrhage KRTCAP3 intron 24656865 rs11541994 chr2 27667297 A AA,AG 9.40E-06 Response to statin therapy IFT172 UTR-3 20339536 rs11541994 chr2 27667297 A AA,AG 2.90E-08 Urate levels IFT172 UTR-3 20884846 rs11541994 chr2 27667297 A AA,AG 2.03E-15 Urate levels IFT172 UTR-3 23263486 rs4803 chr2 27667297 A G 9.40E-06 Response to statin therapy IFT172 UTR-3 20339536 rs4803 chr2 27667297 A G 2.90E-08 Urate levels IFT172 UTR-3 20884846 rs4803 chr2 27667297 A G 2.03E-15 Urate levels IFT172 UTR-3 23263486 rs780104 chr2 27677691 G A 1.20E-05 Response to statin therapy IFT172 intron 20339536 rs780104 chr2 27677691 G A 2.90E-08 Urate levels IFT172 intron 20884846 rs780104 chr2 27677691 G A 2.24E-15 Urate levels IFT172 intron 23263486 rs6734392 chr2 27677778 C T 2.83E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs780106 chr2 27681598 A C 8.50E-06 Response to statin therapy IFT172 intron 20339536 rs780106 chr2 27681598 A C 3.10E-08 Urate levels IFT172 intron 20884846 rs780106 chr2 27681598 A C 1.17E-15 Urate levels IFT172 intron 23263486 rs780107 chr2 27684734 A G 9.20E-06 Response to statin therapy IFT172 intron 20339536 rs780107 chr2 27684734 A G 2.90E-08 Urate levels IFT172 intron 20884846 rs780107 chr2 27684734 A G 1.25E-15 Urate levels IFT172 intron 23263486 rs780110 chr2 27685388 G A 4.30E-08 Response to statin therapy IFT172 intron 20339536 rs780110 chr2 27685388 G A 3.80E-11 Urate levels IFT172 intron 20884846 rs780110 chr2 27685388 G A 0.00000172 Body mass index IFT172 intron 22885924 rs780110 chr2 27685388 G A 3.82E-20 Fasting blood glucose IFT172 intron 22885924 rs780110 chr2 27685388 G A 9.11E-20 Urate levels IFT172 intron 23263486 rs1647276 chr2 27688601 C T 8.70E-06 Response to statin therapy IFT172 intron 20339536 rs1647276 chr2 27688601 C T 2.70E-08 Urate levels IFT172 intron 20884846 rs1647276 chr2 27688601 C T 1.39E-15 Urate levels IFT172 intron 23263486 rs1647266 chr2 27693485 T C 6.30E-06 Response to statin therapy IFT172 intron 20339536 rs1647266 chr2 27693485 T C 2.80E-08 Urate levels IFT172 intron 20884846 rs1647266 chr2 27693485 T C 1.42E-15 Urate levels IFT172 intron 23263486 rs780117 chr2 27698343 C G 8.50E-06 Response to statin therapy IFT172 intron 20339536 rs780117 chr2 27698343 C G 2.60E-08 Urate levels IFT172 intron 20884846 rs780117 chr2 27698343 C G 1.16E-15 Urate levels IFT172 intron 23263486 rs56047188 chr2 27699789 C T 4.56E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs1260345 chr2 27703495 A G 3.10E-05 Response to statin therapy IFT172 intron 20339536 rs1260345 chr2 27703495 A G 7.03E-13 Urate levels IFT172 intron 23263486 rs2272417 chr2 27706640 T C 4.50E-05 Response to statin therapy IFT172 intron 20339536 rs2272417 chr2 27706640 T C 7.05E-06 Schizophrenia IFT172 intron 21926974 rs2272417 chr2 27706640 T C 3.39E-13 Urate levels IFT172 intron 23263486 rs58979173 chr2 27711157 A C 4.88E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs7583698 chr2 27712408 C T 4.72E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs8395 chr2 27715207 T A 8.30E-06 Response to statin therapy FNDC4 UTR-3 20339536 rs8395 chr2 27715207 T A 7.73E-13 Urate levels FNDC4 UTR-3 23263486 rs2303369 chr2 27715416 C T 6.80E-06 Response to statin therapy FNDC4 intron 20339536 rs2303369 chr2 27715416 C T 2.30E-08 Urate levels FNDC4 intron 20884846 rs2303369 chr2 27715416 C T 2.00E-12 Menopause (age at onset) FNDC4 intron 22267201 rs2303369 chr2 27715416 C T 5.17E-16 Urate levels FNDC4 intron 23263486 rs704795 chr2 27716494 G A 6.00E-06 Response to statin therapy FNDC4 intron 20339536 rs704795 chr2 27716494 G A 1.90E-08 Urate levels FNDC4 intron 20884846 rs704795 chr2 27716494 G A 1.50E-15 Urate levels FNDC4 intron 23263486 rs780090 chr2 27718474 T C 0.000000563 Cholesterol,total GCKR nearGene-5 23063622 rs780090 chr2 27718474 T C 9.30E-16 Triglycerides GCKR nearGene-5 23063622 rs780090 chr2 27718474 T C 6.01E-16 Urate levels GCKR nearGene-5 23263486 rs813592 chr2 27721971 T C 1.50E-06 Response to statin therapy GCKR intron 20339536 rs813592 chr2 27721971 T C 1.30E-08 Urate levels GCKR intron 20884846 rs813592 chr2 27721971 T C 4.96E-28 Triglycerides GCKR intron 23063622 rs813592 chr2 27721971 T C 2.70E-15 Urate levels GCKR intron 23263486 rs813592 chr2 27721971 T C 0.0000271 Schizophrenia GCKR intron 23637625 rs1260320 chr2 27722416 G A 1.40E-06 Response to statin therapy GCKR intron 20339536 rs1260320 chr2 27722416 G A 1.20E-08 Urate levels GCKR intron 20884846 rs1260320 chr2 27722416 G A 1.53E-15 Urate levels GCKR intron 23263486 rs2293572 chr2 27728777 C G 2.80E-06 Response to statin therapy GCKR intron 20339536 rs2293572 chr2 27728777 C G 1.10E-08 Urate levels GCKR intron 20884846 rs2293572 chr2 27728777 C G 3.75E-27 Triglycerides GCKR intron 23063622 rs2293572 chr2 27728777 C G 4.94E-16 Urate levels GCKR intron 23263486 rs2293571 chr2 27729480 G A 2.80E-06 Response to statin therapy GCKR intron 20339536 rs2293571 chr2 27729480 G A 1.30E-08 Urate levels GCKR intron 20884846 rs2293571 chr2 27729480 G A 3.21E-04 Lymphocyte counts GCKR intron 22286170 rs2293571 chr2 27729480 G A 6.40E-16 Urate levels GCKR intron 23263486 rs8179219 chr2 27730817 G A 4.87E-05 Intracerebral hemorrhage GCKR intron 24656865 rs1260326 chr2 27730940 T C 5.60E-22 Lipid levels GCKR missense 18193043 rs1260326 chr2 27730940 T C 4.00E-08 Waist circumference and related phenotypes GCKR missense 18454146 rs1260326 chr2 27730940 T C 2.30E-06 Crohn's disease GCKR missense 18587394 rs1260326 chr2 27730940 T C 2.00E-31 Triglycerides GCKR missense 19060906 rs1260326 chr2 27730940 T C 4.00E-10 Metabolic traits GCKR missense 19060910 rs1260326 chr2 27730940 T C 5.17E-17 Triglycerides GCKR missense 19060911 rs1260326 chr2 27730940 T C 1.82E-09 Uric acid levels GCKR missense 19503597 rs1260326 chr2 27730940 T C 1.30E-16 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 1.60E-06 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 9.90E-07 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 1.83E-07 Lipid levels GCKR missense 19913121 rs1260326 chr2 27730940 T C 1.00E-37 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.79E-28 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.87E-11 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.90E-35 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.40E-09 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.48E-29 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.60E-24 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.67E-17 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 4.45E-32 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.10E-15 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.20E-14 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.30E-36 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.20E-10 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.60E-16 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.78E-17 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 8.00E-28 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 8.39E-21 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.00E-10 Two-hour glucose challenge GCKR missense 20081857 rs1260326 chr2 27730940 T C 1.11E-11 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 4.00E-09 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 4.36E-09 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 7.30E-05 Response to statin therapy GCKR missense 20339536 rs1260326 chr2 27730940 T C 3.00E-14 Chronic kidney disease GCKR missense 20383146 rs1260326 chr2 27730940 T C 7.00E-09 Hypertriglyceridemia GCKR missense 20657596 rs1260326 chr2 27730940 T C 6.00E-133 Triglycerides GCKR missense 20686565 rs1260326 chr2 27730940 T C 7.00E-27 Cholesterol,total GCKR missense 20686565 rs1260326 chr2 27730940 T C 2.04E-17 Protein C levels GCKR missense 20802025 rs1260326 chr2 27730940 T C 5.90E-17 Urate levels GCKR missense 20884846 rs1260326 chr2 27730940 T C 5.00E-40 C-reactive protein GCKR missense 21300955 rs1260326 chr2 27730940 T C 1.70E-28 FVII levels GCKR missense 21676895 rs1260326 chr2 27730940 T C 5.60E-25 FVII levels GCKR missense 21676895 rs1260326 chr2 27730940 T C 4.36E-09 Hepatitis B GCKR missense 21750111 rs1260326 chr2 27730940 T C 7.66E-14 Urate levels GCKR missense 21768215 rs1260326 chr2 27730940 T C 1.44E-08 Phospholipid levels (plasma) GCKR missense 21829377 rs1260326 chr2 27730940 T C 2.00E-08 Cardiovascular disease risk factors GCKR missense 21943158 rs1260326 chr2 27730940 T C 4.00E-13 Liver enzyme levels (gamma-glutamyl transferase) GCKR missense 22001757 rs1260326 chr2 27730940 T C 1.20E-08 Metabolic syndrome phenotype GCKR missense 22022282 rs1260326 chr2 27730940 T C 8.10E-16 Metabolic syndrome phenotype GCKR missense 22022282 rs1260326 chr2 27730940 T C 9.00E-10 Platelet counts GCKR missense 22139419 rs1260326 chr2 27730940 T C 2.61E-04 Triglycerides GCKR missense 22171074 rs1260326 chr2 27730940 T C 3.00E-18 Metabolite levels GCKR missense 22286219 rs1260326 chr2 27730940 T C 4.48E-12 Chronic kidney disease GCKR missense 22479191 rs1260326 chr2 27730940 T C 3.00E-09 Non-albumin protein levels GCKR missense 22558069 rs1260326 chr2 27730940 T C 1.27E-18 Triglycerides (males) GCKR missense 22629316 rs1260326 chr2 27730940 T C 1.75E-20 Triglycerides (females) GCKR missense 22629316 rs1260326 chr2 27730940 T C 6.79E-35 Triglycerides GCKR missense 22629316 rs1260326 chr2 27730940 T C 2.17E-41 Fasting blood glucose GCKR missense 22885924 rs1260326 chr2 27730940 T C 2.74E-22 Fasting insulin-related traits GCKR missense 22885924 rs1260326 chr2 27730940 T C 9.04E-15 2-hour glucose tolerance test GCKR missense 22885924 rs1260326 chr2 27730940 T C 1.00E-12 Metabolite levels (atherosclerosis) GCKR missense 22916037 rs1260326 chr2 27730940 T C 2.00E-08 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 3.00E-14 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 4.00E-06 Serum total protein level GCKR missense 23022100 rs1260326 chr2 27730940 T C 4.00E-19 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 6.00E-08 Serum total protein level GCKR missense 23022100 rs1260326 chr2 27730940 T C 1.17E-42 Triglycerides in males GCKR missense 23063622 rs1260326 chr2 27730940 T C 2.33E-19 Cholesterol,total GCKR missense 23063622 rs1260326 chr2 27730940 T C 3.90E-38 Triglycerides in females GCKR missense 23063622 rs1260326 chr2 27730940 T C 4.05E-88 Triglycerides GCKR missense 23063622 rs1260326 chr2 27730940 T C 5.08E-98 Triglycerides GCKR missense 23063622 rs1260326 chr2 27730940 T C 5.00E-06 Lipoprotein-associated phospholipase A2 activity and mass GCKR missense 23118302 rs1260326 chr2 27730940 T C 1.34E-08 Triglycerides GCKR missense 23236364 rs1260326 chr2 27730940 T C 1.00E-44 Urate levels GCKR missense 23263486 rs1260326 chr2 27730940 T C 5.41E-09 C-reactive protein GCKR missense 23505291 rs1260326 chr2 27730940 T C 2.00E-13 Hypertriglyceridemia GCKR missense 23505323 rs1260326 chr2 27730940 T C 1.30E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 1.50E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.00E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.30E-05 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.70E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 3.70E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 4.30E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 5.00E-07 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 8.90E-05 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 1.45E-08 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.31E-07 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.62E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.94E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 3.73E-04 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 6.00E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 6.00E-13 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 7.38E-05 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.00E-239 Triglycerides GCKR missense 24097068 rs1260326 chr2 27730940 T C 3.00E-42 Cholesterol,total GCKR missense 24097068 rs1260326 chr2 27730940 T C 3.00E-07 Lipid traits GCKR missense 24386095 rs1260326 chr2 27730940 T C 1.00E-77 Blood metabolite levels GCKR missense 24816252 rs1260326 chr2 27730940 T C 3.00E-148 Blood metabolite ratios GCKR missense 24816252 rs1260326 chr2 27730940 T C 6.00E-14 Blood metabolite levels GCKR missense 24816252 rs1260326 chr2 27730940 T C 3.56E-10 Triglycerides GCKR missense pha002904 rs1260326 chr2 27730940 T C 1.80E-05 Cholesterol GCKR missense pha003073 rs1260326 chr2 27730940 T C 3.35E-05 Cholesterol GCKR missense pha003078 rs1260326 chr2 27730940 T C 3.89E-05 Triglycerides GCKR missense pha003080 rs3817588 chr2 27731212 T C 4.10E-08 Non-albumin protein levels GCKR intron 22558069 rs3817588 chr2 27731212 T C 1.70E-10 Urate levels GCKR intron 23263486 rs4425043 chr2 27733452 G A 2.70E-06 Response to statin therapy GCKR intron 20339536 rs4425043 chr2 27733452 G A 1.20E-08 Urate levels GCKR intron 20884846 rs4425043 chr2 27733452 G A 2.89E-04 FVII levels GCKR intron 21676895 rs4425043 chr2 27733452 G A 9.30E-06 FVII levels GCKR intron 21676895 rs4425043 chr2 27733452 G A 8.55E-16 Urate levels GCKR intron 23263486 rs6547692 chr2 27734972 G A 1.11E-11 Metabolite levels GCKR intron 22286219 rs62131877 chr2 27740328 C T 2.95E-05 Intracerebral hemorrhage GCKR intron 24656865 rs780096 chr2 27741072 C G 6.22E-13 Metabolite levels GCKR intron 22286219 rs780095 chr2 27741105 A G 6.25E-13 Metabolite levels GCKR intron 22286219 rs780094 chr2 27741237 T C 1.00E-15 Type 2 diabetes GCKR intron 17463246 rs780094 chr2 27741237 T C 1.88E-05 Multiple complex diseases GCKR intron 17554300 rs780094 chr2 27741237 T C 5.00E-07 LDL cholesterol GCKR intron 18179892 rs780094 chr2 27741237 T C 6.00E-32 Triglycerides GCKR intron 18193043 rs780094 chr2 27741237 T C 3.00E-14 Triglycerides GCKR intron 18193044 rs780094 chr2 27741237 T C 7.00E-15 C-reactive protein GCKR intron 18439548 rs780094 chr2 27741237 T C 1.50E-07 Crohn's disease GCKR intron 18587394 rs780094 chr2 27741237 T C 3.00E-20 Triglycerides GCKR intron 19060911 rs780094 chr2 27741237 T C 1.00E-09 Uric acid levels GCKR intron 19503597 rs780094 chr2 27741237 T C 1.50E-15 Lipid levels GCKR intron 19802338 rs780094 chr2 27741237 T C 1.07E-17 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 1.56E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 1.70E-09 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.60E-19 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.67E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.87E-16 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.10E-17 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.30E-12 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.79E-19 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 4.50E-08 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 6.98E-10 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 8.60E-18 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 9.80E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.06E-06 Response to statin treatment (atorvastatin),change in cholesterol levels GCKR intron 20031582 rs780094 chr2 27741237 T C 3.00E-24 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 4.00E-20 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 6.00E-38 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 5.00E-06 Blood cell counts and other traits GCKR intron 20139978 rs780094 chr2 27741237 T C 5.12E-06 Blood cell counts and other traits GCKR intron 20139978 rs780094 chr2 27741237 T C 3.80E-07 Fasting glucose-related traits GCKR intron 20152958 rs780094 chr2 27741237 T C 1.20E-14 Response to statin therapy GCKR intron 20339536 rs780094 chr2 27741237 T C 9.30E-06 Calcium levels GCKR intron 20705733 rs780094 chr2 27741237 T C 1.89E-16 Protein C levels GCKR intron 20802025 rs780094 chr2 27741237 T C 4.70E-17 Urate levels GCKR intron 20884846 rs780094 chr2 27741237 T C 1.00E-05 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 1.50E-05 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 2.20E-11 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 5.00E-07 Coronary heart disease GCKR intron 21347282 rs780094 chr2 27741237 T C 2.56E-04 Nonalcoholic fatty liver disease GCKR intron 21423719 rs780094 chr2 27741237 T C 6.44E-13 Urate levels GCKR intron 21768215 rs780094 chr2 27741237 T C 9.00E-09 Phospholipid levels (plasma) GCKR intron 21829377 rs780094 chr2 27741237 T C 1.20E-04 Type 2 diabetes GCKR intron 21874001 rs780094 chr2 27741237 T C 6.00E-53 Metabolic traits GCKR intron 21886157 rs780094 chr2 27741237 T C 7.10E-04 Urate (in serum),gout GCKR intron 21983786 rs780094 chr2 27741237 T C 2.04E-16 Metabolite levels GCKR intron 22286219 rs780094 chr2 27741237 T C 0.000000212 Type 2 diabetes GCKR intron 22325160 rs780094 chr2 27741237 T C 6.00E-20 Metabolic syndrome GCKR intron 22399527 rs780094 chr2 27741237 T C 3.00E-10 Fasting insulin-related traits (interaction with BMI) GCKR intron 22581228 rs780094 chr2 27741237 T C 4.00E-24 Fasting glucose-related traits (interaction with BMI) GCKR intron 22581228 rs780094 chr2 27741237 T C 0.00000076 HOMA-IR GCKR intron 22885922 rs780094 chr2 27741237 T C 0.000047 Type 2 diabetes (males) GCKR intron 22885922 rs780094 chr2 27741237 T C 7.10E-14 Fasting insulin-related traits GCKR intron 22885922 rs780094 chr2 27741237 T C 1.04E-10 2-hour glucose tolerance test GCKR intron 22885924 rs780094 chr2 27741237 T C 2.58E-37 Fasting blood glucose GCKR intron 22885924 rs780094 chr2 27741237 T C 7.37E-20 Fasting insulin-related traits GCKR intron 22885924 rs780094 chr2 27741237 T C 1.80E-13 Cholesterol,total GCKR intron 23063622 rs780094 chr2 27741237 T C 3.00E-78 Triglycerides GCKR intron 23063622 rs780094 chr2 27741237 T C 6.52E-39 Urate levels GCKR intron 23263486 rs780094 chr2 27741237 T C 0.000000039 C-reactive protein GCKR intron 23505291 rs780094 chr2 27741237 T C 7.00E-09 Triglycerides GCKR intron 23726366 rs780094 chr2 27741237 T C 2.09E-04 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 2.53E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 3.30E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 3.42E-11 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 1.00E-10 Calcium levels GCKR intron 24068962 rs780094 chr2 27741237 T C 1.00E-05 Type 2 diabetes GCKR intron 24509480 rs780094 chr2 27741237 T C 5.03E-09 Triglycerides GCKR intron pha002904 rs780094 chr2 27741237 T C 5.59E-05 Cholesterol GCKR intron pha003073 rs780094 chr2 27741237 T C 9.61E-05 Cholesterol GCKR intron pha003078 rs780093 chr2 27742603 T C 1.50E-17 Lipid levels GCKR intron 18193043 rs780093 chr2 27742603 T C 2.94E-09 Uric acid levels GCKR intron 19503597 rs780093 chr2 27742603 T C 1.30E-14 Response to statin therapy GCKR intron 20339536 rs780093 chr2 27742603 T C 7.00E-06 Calcium levels GCKR intron 20705733 rs780093 chr2 27742603 T C 5.63E-17 Protein C levels GCKR intron 20802025 rs780093 chr2 27742603 T C 4.00E-17 Urate levels GCKR intron 20884846 rs780093 chr2 27742603 T C 5.00E-11 Crohn's disease GCKR intron 21102463 rs780093 chr2 27742603 T C 2.00E-12 Waist Circumference - Triglycerides (WC-TG) GCKR intron 21386085 rs780093 chr2 27742603 T C 3.00E-10 Triglycerides-Blood Pressure (TG-BP) GCKR intron 21386085 rs780093 chr2 27742603 T C 7.49E-13 Urate levels GCKR intron 21768215 rs780093 chr2 27742603 T C 2.04E-08 Phospholipid levels (plasma) GCKR intron 21829377 rs780093 chr2 27742603 T C 8.20E-04 Urate (in serum),gout GCKR intron 21983786 rs780093 chr2 27742603 T C 1.64E-16 Metabolite levels GCKR intron 22286219 rs780093 chr2 27742603 T C 5.00E-06 Breast size GCKR intron 22747683 rs780093 chr2 27742603 T C 2.00E-16 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 7.00E-08 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 9.00E-11 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 2.41E-78 Triglycerides GCKR intron 23063622 rs780093 chr2 27742603 T C 2.52E-13 Cholesterol,total GCKR intron 23063622 rs780093 chr2 27742603 T C 3.65E-39 Urate levels GCKR intron 23263486 rs780093 chr2 27742603 T C 1.00E-09 Palmitoleic acid (16:1n-7) plasma levels GCKR intron 23362303 rs780093 chr2 27742603 T C 3.00E-06 Palmitic acid (16:0) plasma levels GCKR intron 23362303 rs780093 chr2 27742603 T C 6.79E-08 C-reactive protein GCKR intron 23505291 rs780093 chr2 27742603 T C 3.37E-07 Glycemic traits (pregnancy) GCKR intron 23903356 rs780093 chr2 27742603 T C 8.85E-10 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 5.00E-18 Metabolite levels GCKR intron 21909109 rs780092 chr2 27743154 A G 5.00E-27 Triglycerides GCKR intron 21909109 rs780092 chr2 27743154 A G 2.84E-07 Non-albumin protein levels GCKR intron 22558069 rs780092 chr2 27743154 A G 8.46E-10 Urate levels GCKR intron 23263486 rs780092 chr2 27743154 A G 2.85E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 6.63E-07 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 2.00E-09 Lipid traits GCKR intron 24023260 rs814295 chr2 27743215 A G 3.11E-07 Non-albumin protein levels GCKR intron 22558069 rs814295 chr2 27743215 A G 0.000000281 Cholesterol,total GCKR intron 23063622 rs814295 chr2 27743215 A G 4.97E-15 Triglycerides GCKR intron 23063622 rs814295 chr2 27743215 A G 3.23E-09 Urate levels GCKR intron 23263486 rs814295 chr2 27743215 A G 1.23E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs11681351 chr2 27743423 G A 1.40E-06 Response to statin therapy GCKR intron 20339536 rs11681351 chr2 27743423 G A 1.60E-08 Urate levels GCKR intron 20884846 rs11681351 chr2 27743423 G A 0.000077 post-traumatic stress disorder GCKR intron 22869035 rs11681351 chr2 27743423 G A 7.70E-05 Schizophrenia GCKR intron 22883433 rs11681351 chr2 27743423 G A 2.22E-25 Triglycerides GCKR intron 23063622 rs11681351 chr2 27743423 G A 7.62E-15 Urate levels GCKR intron 23263486 rs704790 chr2 27746410 G A 2.28E-08 Triglycerides GCKR UTR-3 23063622 rs8179252 chr2 27746832 A C 8.82E-04 Multiple complex diseases GCKR nearGene-3 17554300 rs8179252 chr2 27746832 A C 1.60E-06 Response to statin therapy GCKR nearGene-3 20339536 rs8179252 chr2 27746832 A C 0.000077 post-traumatic stress disorder GCKR nearGene-3 22869035 rs8179252 chr2 27746832 A C 7.70E-05 Schizophrenia GCKR nearGene-3 22883433 rs8179252 chr2 27746832 A C 1.02E-14 Urate levels GCKR nearGene-3 23263486 rs1260334 chr2 27748597 C A 1.37E-12 Metabolite levels / / 22286219 rs1260333 chr2 27748624 A G 3.19E-08 Uric acid levels / / 19503597 rs1260333 chr2 27748624 A G 7.20E-10 Lipid levels / / 19802338 rs1260333 chr2 27748624 A G 1.40E-11 Response to statin therapy / / 20339536 rs1260333 chr2 27748624 A G 1.57E-13 Protein C levels / / 20802025 rs1260333 chr2 27748624 A G 2.00E-19 Triglycerides / / 20864672 rs1260333 chr2 27748624 A G 4.30E-13 Urate levels / / 20884846 rs1260333 chr2 27748624 A G 6.36E-12 Urate levels / / 21768215 rs1260333 chr2 27748624 A G 7.67E-07 Phospholipid levels (plasma) / / 21829377 rs1260333 chr2 27748624 A G 1.35E-11 Metabolite levels / / 22286219 rs1260333 chr2 27748624 A G 5.02E-33 Urate levels / / 23263486 rs1260333 chr2 27748624 A G 2.87E-06 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 3.33E-10 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 4.71E-07 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 7.81E-10 Glycemic traits (pregnancy) / / 23903356 rs1313566 chr2 27748904 G A 1.36E-12 Metabolite levels / / 22286219 rs200826320 chr2 27750545 AT A 1.81E-12 Metabolite levels / / 22286219 rs2950835 chr2 27750545 A G 1.81E-12 Metabolite levels / / 22286219 rs2911711 chr2 27750546 T A 1.40E-11 Response to statin therapy / / 20339536 rs2911711 chr2 27750546 T A 1.53E-13 Protein C levels / / 20802025 rs2911711 chr2 27750546 T A 4.10E-13 Urate levels / / 20884846 rs2911711 chr2 27750546 T A 6.99E-12 Urate levels / / 21768215 rs2911711 chr2 27750546 T A 7.65E-07 Phospholipid levels (plasma) / / 21829377 rs2911711 chr2 27750546 T A 2.43E-12 Metabolite levels / / 22286219 rs2911711 chr2 27750546 T A 4.55E-33 Urate levels / / 23263486 rs2911711 chr2 27750546 T A 2.53E-09 Glycemic traits (pregnancy) / / 23903356 rs2911711 chr2 27750546 T A 5.66E-07 Glycemic traits (pregnancy) / / 23903356 rs6753534 chr2 27752871 C T 1.33E-13 Metabolite levels / / 22286219 rs4665987 chr2 27755825 G A 4.70E-08 Response to statin therapy / / 20339536 rs4665987 chr2 27755825 G A 1.38E-10 Protein C levels / / 20802025 rs4665987 chr2 27755825 G A 3.90E-07 Urate levels / / 20884846 rs4665987 chr2 27755825 G A 4.55E-08 Urate levels / / 21768215 rs4665987 chr2 27755825 G A 1.66E-12 Metabolite levels / / 22286219 rs4665987 chr2 27755825 G A 8.80E-05 Renal function-related traits (urea) / / 22797727 rs4665987 chr2 27755825 G A 4.35E-13 Urate levels / / 23263486 rs12473139 chr2 27765587 T C 1.61E-12 Metabolite levels / / 22286219 rs4665991 chr2 27766284 G A 1.00E-07 Response to statin therapy / / 20339536 rs4665991 chr2 27766284 G A 1.83E-10 Protein C levels / / 20802025 rs4665991 chr2 27766284 G A 6.48E-08 Urate levels / / 21768215 rs4665991 chr2 27766284 G A 1.34E-12 Metabolite levels / / 22286219 rs4665991 chr2 27766284 G A 7.11E-13 Urate levels / / 23263486 rs12995461 chr2 27778167 A C 1.63E-12 Metabolite levels / / 22286219 rs10169065 chr2 27778560 A G 9.14E-11 Metabolite levels / / 22286219 rs10179872 chr2 27778572 G A 9.14E-11 Metabolite levels / / 22286219 rs4665382 chr2 27783801 T C 1.10E-07 Response to statin therapy / / 20339536 rs4665382 chr2 27783801 T C 2.12E-10 Protein C levels / / 20802025 rs4665382 chr2 27783801 T C 7.92E-08 Urate levels / / 21768215 rs4665382 chr2 27783801 T C 1.56E-12 Metabolite levels / / 22286219 rs4665382 chr2 27783801 T C 6.13E-13 Urate levels / / 23263486 rs4665382 chr2 27783801 T C 1.93E-06 Glycemic traits (pregnancy) / / 23903356 rs7570476 chr2 27784658 C T 1.63E-12 Metabolite levels / / 22286219 rs10208529 chr2 27786188 A T 9.20E-08 Response to statin therapy / / 20339536 rs10208529 chr2 27786188 A T 2.18E-10 Protein C levels / / 20802025 rs10208529 chr2 27786188 A T 8.74E-08 Urate levels / / 21768215 rs10208529 chr2 27786188 A T 2.26E-11 Metabolite levels / / 22286219 rs10208529 chr2 27786188 A T 6.28E-13 Urate levels / / 23263486 rs4665383 chr2 27791555 C G 9.20E-08 Response to statin therapy / / 20339536 rs4665383 chr2 27791555 C G 8.78E-11 Protein C levels / / 20802025 rs4665383 chr2 27791555 C G 9.24E-08 Urate levels / / 21768215 rs4665383 chr2 27791555 C G 1.66E-12 Metabolite levels / / 22286219 rs4665383 chr2 27791555 C G 6.35E-13 Urate levels / / 23263486 rs7577311 chr2 27793921 G T 1.65E-12 Metabolite levels / / 22286219 rs10205364 chr2 27794233 C T 0.0000912 post-traumatic stress disorder / / 22869035 rs10205364 chr2 27794233 C T 9.12E-05 Schizophrenia / / 22883433 rs1919125 chr2 27801403 C G 0.000093 post-traumatic stress disorder C2orf16 missense 22869035 rs1919125 chr2 27801403 C G 9.30E-05 Schizophrenia C2orf16 missense 22883433 rs1919126 chr2 27801418 C A 0.0000902 post-traumatic stress disorder C2orf16 missense 22869035 rs1919126 chr2 27801418 C A 9.02E-05 Schizophrenia C2orf16 missense 22883433 rs1919126 chr2 27801418 C A 4.24E-09 Triglycerides C2orf16 missense 23063622 rs1919127 chr2 27801493 T C 1.24E-08 Triglycerides C2orf16 missense 19060911 rs1919127 chr2 27801493 T C 2.00E-07 Response to statin therapy C2orf16 missense 20339536 rs1919127 chr2 27801493 T C 2.27E-10 Protein C levels C2orf16 missense 20802025 rs1919127 chr2 27801493 T C 1.17E-07 Urate levels C2orf16 missense 21768215 rs1919127 chr2 27801493 T C 2.20E-12 Metabolite levels C2orf16 missense 22286219 rs1919127 chr2 27801493 T C 7.33E-13 Urate levels C2orf16 missense 23263486 rs1919127 chr2 27801493 T C 5.24E-06 Glycemic traits (pregnancy) C2orf16 missense 23903356 rs1919127 chr2 27801493 T C 5.76E-05 Triglycerides C2orf16 missense pha002904 rs1919128 chr2 27801759 A G 8.70E-08 Response to statin therapy C2orf16 missense 20339536 rs1919128 chr2 27801759 A G 2.24E-10 Protein C levels C2orf16 missense 20802025 rs1919128 chr2 27801759 A G 2.00E-09 Waist Circumference - Triglycerides (WC-TG) C2orf16 missense 21386085 rs1919128 chr2 27801759 A G 9.29E-08 Urate levels C2orf16 missense 21768215 rs1919128 chr2 27801759 A G 1.75E-12 Metabolite levels C2orf16 missense 22286219 rs1919128 chr2 27801759 A G 1.22E-33 Triglycerides C2orf16 missense 23063622 rs1919128 chr2 27801759 A G 5.85E-13 Urate levels C2orf16 missense 23263486 rs1919128 chr2 27801759 A G 0.00001 C-reactive protein C2orf16 missense 23505291 rs1919128 chr2 27801759 A G 6.38E-06 Glycemic traits (pregnancy) C2orf16 missense 23903356 rs13026621 chr2 27807624 G A 0.0000902 post-traumatic stress disorder ZNF512 intron 22869035 rs13026621 chr2 27807624 G A 9.02E-05 Schizophrenia ZNF512 intron 22883433 rs12478841 chr2 27811722 A G 8.30E-08 Response to statin therapy ZNF512 intron 20339536 rs12478841 chr2 27811722 A G 2.11E-10 Protein C levels ZNF512 intron 20802025 rs12478841 chr2 27811722 A G 1.17E-07 Urate levels ZNF512 intron 21768215 rs12478841 chr2 27811722 A G 1.65E-12 Metabolite levels ZNF512 intron 22286219 rs12478841 chr2 27811722 A G 6.85E-13 Urate levels ZNF512 intron 23263486 rs12478841 chr2 27811722 A G 3.16E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs6760250 chr2 27812252 G A 8.80E-08 Response to statin therapy ZNF512 intron 20339536 rs6760250 chr2 27812252 G A 2.08E-10 Protein C levels ZNF512 intron 20802025 rs6760250 chr2 27812252 G A 1.18E-07 Urate levels ZNF512 intron 21768215 rs6760250 chr2 27812252 G A 1.70E-12 Metabolite levels ZNF512 intron 22286219 rs6760250 chr2 27812252 G A 6.73E-13 Urate levels ZNF512 intron 23263486 rs6760250 chr2 27812252 G A 2.72E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs13022873 chr2 27815510 A C 8.20E-08 Response to statin therapy ZNF512 intron 20339536 rs13022873 chr2 27815510 A C 1.99E-10 Protein C levels ZNF512 intron 20802025 rs13022873 chr2 27815510 A C 5.00E-09 Waist Circumference - Triglycerides (WC-TG) ZNF512 intron 21386085 rs13022873 chr2 27815510 A C 1.16E-07 Urate levels ZNF512 intron 21768215 rs13022873 chr2 27815510 A C 1.50E-12 Metabolite levels ZNF512 intron 22286219 rs13022873 chr2 27815510 A C 6.22E-11 Urate levels ZNF512 intron 23263486 rs13022873 chr2 27815510 A C 3.32E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12467476 chr2 27825715 T C 7.90E-08 Response to statin therapy ZNF512 intron 20339536 rs12467476 chr2 27825715 T C 1.88E-10 Protein C levels ZNF512 intron 20802025 rs12467476 chr2 27825715 T C 1.17E-07 Urate levels ZNF512 intron 21768215 rs12467476 chr2 27825715 T C 1.69E-12 Metabolite levels ZNF512 intron 22286219 rs12467476 chr2 27825715 T C 5.52E-13 Urate levels ZNF512 intron 23263486 rs12467476 chr2 27825715 T C 3.25E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12464616 chr2 27827092 C T 1.70E-12 Metabolite levels ZNF512 intron 22286219 rs6547735 chr2 27831607 T C 0.000000019 Triglycerides ZNF512 intron 23063622 rs2384656 chr2 27832055 A G 5.50E-08 Response to statin therapy ZNF512 intron 20339536 rs2384656 chr2 27832055 A G 1.71E-10 Protein C levels ZNF512 intron 20802025 rs2384656 chr2 27832055 A G 1.16E-07 Urate levels ZNF512 intron 21768215 rs2384656 chr2 27832055 A G 2.97E-12 Metabolite levels ZNF512 intron 22286219 rs2384656 chr2 27832055 A G 7.07E-13 Urate levels ZNF512 intron 23263486 rs2384656 chr2 27832055 A G 4.42E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12987055 chr2 27834152 T C 1.72E-12 Metabolite levels ZNF512 intron 22286219 rs13020949 chr2 27836605 C T 1.57E-12 Metabolite levels ZNF512 intron 22286219 rs4666000 chr2 27839369 T C 5.10E-07 Response to statin therapy ZNF512 intron 20339536 rs4666000 chr2 27839369 T C 5.95E-10 Protein C levels ZNF512 intron 20802025 rs4666000 chr2 27839369 T C 6.12E-08 Urate levels ZNF512 intron 21768215 rs4666000 chr2 27839369 T C 2.99E-11 Metabolite levels ZNF512 intron 22286219 rs4666000 chr2 27839369 T C 4.17E-11 Urate levels ZNF512 intron 23263486 rs4666000 chr2 27839369 T C 3.79E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs2068834 chr2 27839539 T C 8.30E-07 Response to statin therapy ZNF512 intron 20339536 rs2068834 chr2 27839539 T C 7.16E-10 Protein C levels ZNF512 intron 20802025 rs2068834 chr2 27839539 T C 6.35E-08 Urate levels ZNF512 intron 21768215 rs2068834 chr2 27839539 T C 2.68E-11 Metabolite levels ZNF512 intron 22286219 rs2068834 chr2 27839539 T C 0.000006444 2-hour glucose tolerance test ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 1.24E-09 Body mass index ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 9.68E-20 Fasting blood glucose ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 8.98E-33 Triglycerides ZNF512 intron 23063622 rs2068834 chr2 27839539 T C 4.28E-11 Urate levels ZNF512 intron 23263486 rs2068834 chr2 27839539 T C 0.000028 C-reactive protein ZNF512 intron 23505291 rs2068834 chr2 27839539 T C 3.01E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs4666002 chr2 27840640 G C 6.30E-08 Response to statin therapy ZNF512 intron 20339536 rs4666002 chr2 27840640 G C 1.07E-10 Protein C levels ZNF512 intron 20802025 rs4666002 chr2 27840640 G C 1.90E-12 Metabolite levels ZNF512 intron 22286219 rs4666002 chr2 27840640 G C 7.00E-11 Phospholipid levels (plasma) ZNF512 intron 22359512 rs4666002 chr2 27840640 G C 3.52E-10 Urate levels ZNF512 intron 23263486 rs1881396 chr2 27844601 T G 3.80E-05 Mathematical ability ZNF512 UTR-3 20039944 rs1528404 chr2 27846603 T C 1.70E-04 Lymphocyte counts / / 22286170 rs4665384 chr2 27848397 A G 0.000000108 Triglycerides / / 23063622 rs12615690 chr2 27851120 T C 7.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCDC121 intron 20031582 rs3749147 chr2 27851918 G A 3.30E-08 Response to statin therapy GPN1 missense 20339536 rs3749147 chr2 27851918 G A 3.04E-11 Protein C levels GPN1 missense 20802025 rs3749147 chr2 27851918 G A 1.00E-09 Waist Circumference - Triglycerides (WC-TG) GPN1 missense 21386085 rs3749147 chr2 27851918 G A 2.56E-07 Urate levels GPN1 missense 21768215 rs3749147 chr2 27851918 G A 1.11E-12 Metabolite levels GPN1 missense 22286219 rs3749147 chr2 27851918 G A 1.62E-09 Urate levels GPN1 missense 23263486 rs13002853 chr2 27853245 C G 3.20E-08 Response to statin therapy GPN1 intron 20339536 rs13002853 chr2 27853245 C G 3.39E-11 Protein C levels GPN1 intron 20802025 rs13002853 chr2 27853245 C G 2.76E-07 Urate levels GPN1 intron 21768215 rs13002853 chr2 27853245 C G 1.20E-12 Metabolite levels GPN1 intron 22286219 rs13002853 chr2 27853245 C G 8.92E-12 Urate levels GPN1 intron 23263486 rs6547740 chr2 27854369 G A 7.87E-04 Prostate cancer mortality GPN1 intron 20978177 rs34502053 chr2 27854524 G A 8.78E-13 Metabolite levels GPN1 intron 22286219 rs4666005 chr2 27855239 A G 7.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GPN1 intron 20031582 rs4666005 chr2 27855239 A G 0.0000683 post-traumatic stress disorder GPN1 intron 22869035 rs4666005 chr2 27855239 A G 6.83E-05 Schizophrenia GPN1 intron 22883433 rs1528402 chr2 27857517 G A 0.0000298 post-traumatic stress disorder GPN1 intron 22869035 rs1528402 chr2 27857517 G A 2.98E-05 Schizophrenia GPN1 intron 22883433 rs111571364 chr2 27859317 G T 8.00E-06 Periodontitis (CDC/AAP) GPN1 intron 24024966 rs114940462 chr2 27861618 G T 3.98E-05 Intracerebral hemorrhage GPN1 intron 24656865 rs2272406 chr2 27892023 A T 8.40E-06 Response to statin therapy SLC4A1AP intron 20339536 rs2272406 chr2 27892023 A T 1.89E-08 Protein C levels SLC4A1AP intron 20802025 rs2272406 chr2 27892023 A T 5.80E-09 Urate levels SLC4A1AP intron 23263486 rs2178198 chr2 27895073 C T 1.58E-12 Urate levels SLC4A1AP intron 23263486 rs17006206 chr2 27907473 A G 2.00E-06 Alzheimer's disease SLC4A1AP intron 22159054 rs13023094 chr2 27910706 A C 1.70E-05 Response to statin therapy SLC4A1AP intron 20339536 rs13023094 chr2 27910706 A C 2.52E-08 Protein C levels SLC4A1AP intron 20802025 rs13023094 chr2 27910706 A C 7.05E-05 Nephrolithiasis SLC4A1AP intron 22396660 rs13023094 chr2 27910706 A C 0.000021 Endometrial cancer SLC4A1AP intron 22426144 rs13023094 chr2 27910706 A C 8.12E-09 Urate levels SLC4A1AP intron 23263486 rs13030973 chr2 27928797 T C 5.90E-06 Response to statin therapy / / 20339536 rs13030973 chr2 27928797 T C 4.77E-08 Protein C levels / / 20802025 rs13030973 chr2 27928797 T C 1.62E-08 Urate levels / / 23263486 rs6727388 chr2 27932587 A G 6.30E-06 Response to statin therapy / / 20339536 rs6727388 chr2 27932587 A G 4.80E-08 Protein C levels / / 20802025 rs6727388 chr2 27932587 A G 1.49E-08 Urate levels / / 23263486 rs4616435 chr2 27933642 C T 6.20E-06 Response to statin therapy / / 20339536 rs4616435 chr2 27933642 C T 4.82E-08 Protein C levels / / 20802025 rs4616435 chr2 27933642 C T 1.48E-08 Urate levels / / 23263486 rs6727215 chr2 27934731 G A 6.20E-06 Response to statin therapy / / 20339536 rs6727215 chr2 27934731 G A 4.84E-08 Protein C levels / / 20802025 rs6727215 chr2 27934731 G A 1.65E-08 Urate levels / / 23263486 rs867282 chr2 27951658 T C 9.06E-08 Body mass index / / 22885924 rs2384655 chr2 27952235 A T 1.10E-12 Metabolite levels / / 22286219 rs12994085 chr2 27952406 C T 3.14E-11 Metabolite levels / / 22286219 rs12993377 chr2 27952767 G C 1.86E-11 Metabolite levels / / 22286219 rs6753736 chr2 27958855 C G 1.49E-11 Metabolite levels / / 22286219 rs13023194 chr2 27967260 G C 5.40E-06 Response to statin therapy / / 20339536 rs13023194 chr2 27967260 G C 1.04E-15 Fasting blood glucose / / 22885924 rs13023194 chr2 27967260 G C 1.89E-09 Urate levels / / 23263486 rs9967838 chr2 27968454 A C 2.85E-11 Metabolite levels / / 22286219 rs9677663 chr2 27972445 G A 4.74E-11 Metabolite levels / / 22286219 rs12104449 chr2 27972833 A G 6.10E-13 Urate levels / / 23263486 rs57238885 chr2 27974260 C G,T 1.52E-10 Metabolite levels / / 22286219 rs10201247 chr2 27974971 A G 2.72E-11 Metabolite levels / / 22286219 rs6547796 chr2 27975394 T C 4.75E-11 Metabolite levels / / 22286219 rs10209020 chr2 27980944 C T 6.60E-11 Metabolite levels / / 22286219 rs12471347 chr2 27981655 G C 2.13E-11 Metabolite levels / / 22286219 rs12477908 chr2 27987046 A C 1.65E-11 Metabolite levels / / 22286219 rs13013484 chr2 27988821 G A 1.92E-11 Metabolite levels / / 22286219 rs13013484 chr2 27988821 G A 0.000000109 Body mass index / / 22885924 rs3736594 chr2 27995781 A C 1.91E-11 Metabolite levels MRPL33 intron 22286219 rs3736594 chr2 27995781 A C 1.00E-15 Fasting glucose-related traits (interaction with BMI) MRPL33 intron 22581228 rs3736594 chr2 27995781 A C 9.68E-04 Response to cytadine analogues (cytosine arabinoside) MRPL33 intron 24483146 rs3792253 chr2 28002002 T C 9.97E-10 Triglycerides MRPL33 intron 23063622 rs13030345 chr2 28003174 G T 7.60E-06 Response to statin therapy / / 20339536 rs13030345 chr2 28003174 G T 0.0000041 Endometrial cancer / / 22426144 rs13030345 chr2 28003174 G T 0.000002507 2-hour glucose tolerance test / / 22885924 rs13030345 chr2 28003174 G T 5.00E-25 Triglycerides / / 23063622 rs13030345 chr2 28003174 G T 1.44E-08 Urate levels / / 23263486 rs4666014 chr2 28019175 G A 2.03E-09 Triglycerides RBKS intron 23063622 rs4666014 chr2 28019175 G A 8.12E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11127125 chr2 28023120 T C 2.10E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs4665392 chr2 28029649 A G 2.66E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs12617171 chr2 28038799 C T 1.30E-05 Lipid levels RBKS intron 18193043 rs4666020 chr2 28046028 G A 4.60E-04 Amyotrophic Lateral Sclerosis RBKS intron 17362836 rs4666022 chr2 28057823 T C 3.71E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11901133 chr2 28069713 T G 8.73E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11127129 chr2 28076708 C G 4.70E-07 Lipid levels RBKS intron 18193043 rs11127129 chr2 28076708 C G 0.000000126 Triglycerides RBKS intron 23063622 rs898034 chr2 28090820 T C 2.36E-09 Triglycerides RBKS intron 23063622 rs6708889 chr2 28107692 C T 3.29E-10 Triglycerides RBKS intron 23063622 rs2305929 chr2 28113911 A G 1.30E-05 Response to statin therapy BRE intron 20339536 rs2305929 chr2 28113911 A G 1.00E-10 Fasting blood glucose BRE intron 22885924 rs2305929 chr2 28113911 A G 5.38E-21 Triglycerides BRE intron 23063622 rs1458396 chr2 28136351 A G 7.52E-04 Response to cytadine analogues (cytosine arabinoside) BRE intron 24483146 rs898031 chr2 28203294 C T 7.19E-04 Myopia (pathological) BRE intron 21095009 rs7577342 chr2 28205581 C T 4.09E-04 Type 2 diabetes BRE intron 17463246 rs73923981 chr2 28235764 G A 0.0000732 Menopause (age at onset) BRE intron 23424626 rs10495761 chr2 28235955 T C 9.13E-04 Amyotrophic Lateral Sclerosis BRE intron 17362836 rs10173528 chr2 28288392 C T 6.15E-04 Myopia (pathological) BRE intron 21095009 rs17006489 chr2 28304630 A G 7.37E-11 Metabolite levels BRE intron 22286219 rs2337700 chr2 28306943 G A 1.29E-04 Response to cholinesterase inhibitors in Alzheimer's disease BRE intron 23374588 rs3863 chr2 28319134 A G 6.53E-04 Alzheimer's disease BRE intron 24755620 rs7572644 chr2 28320033 T C 5.10E-05 Multiple sclerosis BRE intron 17660530 rs6705961 chr2 28325201 C T 8.53E-04 Alzheimer's disease BRE intron 17998437 rs1948922 chr2 28342153 A G 5.26E-04 Multiple complex diseases BRE intron 17554300 rs1948922 chr2 28342153 A G 4.76E-05 Hemoglobin BRE intron pha003096 rs4401177 chr2 28344285 G A 2.77E-09 Urate levels BRE intron 23263486 rs7601155 chr2 28347682 C T 2.00E-07 Waist circumference BRE intron 23966867 rs12053063 chr2 28350611 A G 5.41E-04 Multiple complex diseases BRE intron 17554300 rs2048047 chr2 28358981 C T 2.96E-04 Glaucoma (primary open-angle) BRE intron 22605921 rs1038694 chr2 28373552 A G 2.08E-05 Hemoglobin BRE intron pha003096 rs1038694 chr2 28373552 A G 9.18E-05 Hematocrit BRE intron pha003097 rs13405885 chr2 28375772 G A 9.57E-05 Hematocrit BRE intron pha003097 rs4666040 chr2 28380295 A G 8.34E-05 Multiple sclerosis BRE intron 17660530 rs17006590 chr2 28389846 A C 9.58E-04 Prostate cancer mortality BRE intron 20978177 rs17759746 chr2 28394293 T C 0.000123 Ovarian cancer BRE intron 22794196 rs4666042 chr2 28421461 G A 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BRE intron 20877124 rs17709034 chr2 28424472 C T 6.16E-09 Urate levels BRE intron 23263486 rs6732163 chr2 28428466 A G 4.60E-04 Longevity BRE intron 22279548 rs7349418 chr2 28443050 C T 1.59E-08 Urate levels BRE intron 23263486 rs6711937 chr2 28497276 C T 6.78E-05 Glaucoma (primary open-angle) BRE intron 22605921 rs10495763 chr2 28510347 A G 5.40E-04 Type 2 diabetes and 6 quantitative traits BRE intron 17848626 rs10189899 chr2 28520083 A G 5.82E-05 Major depressive disorder BRE intron pha002850 rs4666052 chr2 28530720 A G 7.97E-04 Amyotrophic Lateral Sclerosis BRE intron 17827064 rs1546029 chr2 28542934 A G 3.78E-04 Prostate cancer mortality BRE intron 20978177 rs884437 chr2 28570398 A G 6.49E-05 Cognitive test performance / / 20125193 rs10184619 chr2 28582597 C T 5.85E-06 Crohn's disease and psoriasis / / 22482804 rs7602568 chr2 28584315 T C 3.02E-05 Cognitive test performance / / 20125193 rs906805 chr2 28604879 A G 5.98E-08 Multiple complex diseases / / 17554300 rs13392378 chr2 28607344 G A 2.90E-05 Urinary metabolites / / 21572414 rs925255 chr2 28614794 C T 3.00E-15 Inflammatory bowel disease FLJ31356 intron 23128233 rs7606480 chr2 28632377 G A 6.41E-06 Multiple complex diseases FOSL2 intron 17554300 rs1396733 chr2 28642747 C A 2.23E-06 Multiple complex diseases / / 17554300 rs7590263 chr2 28645802 C T 9.49E-06 Multiple complex diseases / / 17554300 rs12478126 chr2 28645948 C T 1.11E-05 Multiple complex diseases / / 17554300 rs6547853 chr2 28646801 G A 8.00E-07 Type 1 diabetes / / 21980299 rs6547854 chr2 28655788 T C 6.32E-04 Type 2 diabetes / / 17463246 rs2879177 chr2 28658231 A C 3.32E-04 Type 2 diabetes / / 17463246 rs2338013 chr2 28662264 G A 6.39E-05 Multiple complex diseases / / 17554300 rs2972052 chr2 28662493 A G 0.00033 Salmonella-induced pyroptosis / / 22837397 rs2940787 chr2 28663333 G T 3.36E-05 Parkinson's disease / / 17052657 rs2940799 chr2 28669749 C G 3.65E-04 Alzheimer's disease / / 17998437 rs2972050 chr2 28671048 A G 0.000716 Salmonella-induced pyroptosis / / 22837397 rs1581035 chr2 28686332 G A 4.45E-04 Longevity / / 22279548 rs11127158 chr2 28690849 A C 8.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7579759 chr2 28693648 A C 1.97E-08 Narcolepsy / / 19629137 rs875789 chr2 28700759 G A 5.02E-04 Smoking quantity / / 24665060 rs10203313 chr2 28714750 C T 6.20E-06 Urinary metabolites / / 21572414 rs10203313 chr2 28714750 C T 3.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11127160 chr2 28716955 C A 5.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12621347 chr2 28726440 G C 2.00E-05 Urinary metabolites PLB1 intron 21572414 rs12621347 chr2 28726440 G C 4.26E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs4398231 chr2 28728254 A G 2.40E-05 Urinary metabolites PLB1 intron 21572414 rs4398231 chr2 28728254 A G 4.26E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs12478824 chr2 28731702 T C 4.50E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs6748157 chr2 28733361 A G 1.80E-05 Urinary metabolites PLB1 intron 21572414 rs6748157 chr2 28733361 A G 9.79E-05 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs13023754 chr2 28735998 T C 4.04E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs6547856 chr2 28744077 G A 1.13E-04 Acute lung injury PLB1 intron 22295056 rs9309663 chr2 28768427 C T 2.28E-05 Suicidal ideation PLB1 intron 20877300 rs10170463 chr2 28773874 C A 3.59E-04 Multiple complex diseases PLB1 intron 17554300 rs1997267 chr2 28774319 C T 3.74E-05 Waist-Hip Ratio PLB1 intron pha003029 rs11679308 chr2 28786640 T C 9.54E-05 Waist-Hip Ratio PLB1 intron pha003029 rs10186460 chr2 28789643 T C 7.20E-05 Body Composition PLB1 intron pha003012 rs2338545 chr2 28799775 A G 6.30E-05 Type 2 diabetes PLB1 intron 17463248 rs2338545 chr2 28799775 A G 2.95E-04 Alzheimer's disease PLB1 intron 22005930 rs7595633 chr2 28803240 A G 5.79E-05 Coronary heart disease PLB1 intron pha003035 rs10171857 chr2 28807342 G A 8.24E-05 HIV-1 viral setpoint PLB1 intron 22174851 rs6547861 chr2 28831271 A G 5.62E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) PLB1 intron 21541012 rs11127182 chr2 28851116 A G 2.77E-04 Nicotine smoking PLB1 intron 19268276 rs4530322 chr2 28852926 A G 4.30E-06 Glaucoma (primary open-angle) PLB1 intron 20835238 rs6719289 chr2 28856801 A G 5.13E-04 Multiple complex diseases PLB1 intron 17554300 rs6719289 chr2 28856801 A G 2.82E-04 Nicotine smoking PLB1 intron 19268276 rs6738334 chr2 28866928 A G 4.58E-04 Type 2 diabetes / / 17463246 rs11682523 chr2 28898837 C T 3.60E-05 Basophils / / pha003087 rs11887648 chr2 28920335 C T 2.17E-04 Multiple complex diseases / / 17554300 rs4233728 chr2 28977274 A G 9.16E-04 HIV-1 viral setpoint PPP1CB intron 17641165 rs13399528 chr2 28982827 C G 5.67E-04 Multiple complex diseases PPP1CB intron 17554300 rs10191120 chr2 28997936 A G 1.60E-04 Multiple complex diseases PPP1CB intron 17554300 rs3768666 chr2 29005870 C T 4.74E-04 Lymphocyte counts PPP1CB intron 22286170 rs10210252 chr2 29017870 C T 3.37E-04 Multiple complex diseases PPP1CB intron 17554300 rs6737027 chr2 29070805 C T 4.60E-05 Multiple complex diseases SPDYA intron 17554300 rs7589735 chr2 29099752 G A 8.80E-06 Urinary metabolites / / 21572414 rs4632299 chr2 29112102 G A 8.50E-06 Urinary metabolites / / 21572414 rs13014379 chr2 29112852 T C 6.10E-06 Chronic kidney disease / / 22479191 rs6547889 chr2 29128322 T C 2.40E-05 Urinary metabolites WDR43 intron 21572414 rs1140697 chr2 29152456 A G 7.56E-05 Serum metabolites WDR43 cds-synon 19043545 rs4666143 chr2 29172991 T C 5.87E-05 Weight / / pha003026 rs6714085 chr2 29184267 A G 2.39E-04 Obesity (extreme) / / 21935397 rs4666156 chr2 29196713 G C 1.04E-04 Obesity (extreme) / / 21935397 rs4666157 chr2 29196785 T C 1.03E-04 Obesity (extreme) / / 21935397 rs17007459 chr2 29247845 C A 2.52E-10 Narcolepsy FAM179A intron 19629137 rs13008299 chr2 29247997 T G 7.00E-08 Diastolic blood pressure (alcohol consumption interaction) FAM179A intron 24376456 rs17007460 chr2 29251134 C T 4.99E-06 Multiple sclerosis (brain glutamate levels) FAM179A intron 20802204 rs6734543 chr2 29273583 T A 8.20E-06 Urinary metabolites FAM179A intron 21572414 rs882632 chr2 29280761 C T 2.00E-06 Major depressive disorder / / 20125088 rs10182566 chr2 29287708 C T 7.18E-04 Suicide attempts in bipolar disorder C2orf71 UTR-3 21041247 rs13031086 chr2 29288481 C T 8.61E-04 Suicide attempts in bipolar disorder C2orf71 intron 21041247 rs17744052 chr2 29289411 A G 6.01E-04 Suicide attempts in bipolar disorder C2orf71 intron 21041247 rs17744093 chr2 29294754 G C 5.69E-04 Suicide attempts in bipolar disorder C2orf71 missense 21041247 rs10200693 chr2 29295016 A G 8.02E-04 Suicide attempts in bipolar disorder C2orf71 cds-synon 21041247 rs13385188 chr2 29295676 G A 7.90E-04 Suicide attempts in bipolar disorder C2orf71 cds-synon 21041247 rs7562696 chr2 29303600 A G 7.30E-04 Multiple complex diseases / / 17554300 rs3213947 chr2 29366830 A G 6.42E-06 Glucose levels CLIP4 intron pha003057 rs3100239 chr2 29375902 T C 8.25E-04 Parkinson's disease CLIP4 intron 17052657 rs3112920 chr2 29380711 C T 2.60E-05 Urinary metabolites CLIP4 intron 21572414 rs2123443 chr2 29382038 C T 3.09E-05 Glucose levels CLIP4 intron pha003057 rs2305450 chr2 29383374 G A 3.69E-05 Major depression (suicidal thoughts and behavior) CLIP4 intron 21750702 rs12620500 chr2 29392680 C T 9.80E-04 Depression (quantitative trait) CLIP4 intron 20800221 rs12620500 chr2 29392680 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLIP4 intron 20877124 rs4622670 chr2 29446202 G A 2.00E-04 Amyotrophic lateral sclerosis ALK intron 17671248 rs7572088 chr2 29481036 C G 8.08E-05 Serum metabolites ALK intron 19043545 rs2339379 chr2 29481537 T C 6.16E-05 Serum metabolites ALK intron 19043545 rs17007760 chr2 29486702 G A 3.02E-04 Alzheimer's disease ALK intron 24755620 rs12617579 chr2 29489620 C T 3.81E-05 Nicotine smoking ALK intron 19268276 rs35228363 chr2 29497967 G A 0.00025 Prostate cancer ALK missense 23555315 rs4666189 chr2 29502690 T C 9.93E-04 Multiple complex diseases ALK intron 17554300 rs10432706 chr2 29534165 C A 6.08E-05 Cognitive test performance ALK intron 20125193 rs17007869 chr2 29535061 G A 9.04E-05 Formal thought disorder in schizophrenia ALK intron 22648509 rs2276549 chr2 29541104 C T 3.22E-05 Serum metabolites ALK intron 19043545 rs17007916 chr2 29562741 G A 7.75E-04 Multiple complex diseases ALK intron 17554300 rs17007920 chr2 29570906 T C 4.98E-05 Height ALK intron pha003011 rs10204572 chr2 29580466 T C 6.61E-05 Amyotrophic lateral sclerosis (sporadic) ALK intron 24529757 rs4146673 chr2 29582433 T C 8.85E-08 Metabolite levels ALK intron 23281178 rs1534544 chr2 29596488 G T 8.52E-06 Insulin-related traits ALK intron pha003063 rs10186332 chr2 29607480 G A 5.87E-05 Insulin-related traits ALK intron pha003063 rs4666212 chr2 29613214 C T 2.30E-05 Urinary metabolites ALK intron 21572414 rs11127220 chr2 29618678 C A 3.48E-04 Body mass index ALK intron 17255346 rs7421353 chr2 29641874 T C 7.49E-05 HDL cholesterol ALK intron pha003075 rs4128317 chr2 29659854 A C 0.0000735 Oxaliplatin induced mucositis in response to colorectal cancer treatment ALK intron 22310351 rs6547929 chr2 29666856 C T 1.60E-05 Urinary metabolites ALK intron 21572414 rs4322797 chr2 29666976 T C 9.20E-06 Urinary metabolites ALK intron 21572414 rs4322797 chr2 29666976 T C 0.000420356 Hypertension (early onset hypertension) ALK intron 22479346 rs4408683 chr2 29667326 G A 8.30E-06 Urinary metabolites ALK intron 21572414 rs4456659 chr2 29670834 A G 3.55E-04 Obesity (extreme) ALK intron 21935397 rs4497832 chr2 29670877 T C 4.43E-04 Obesity (extreme) ALK intron 21935397 rs4341891 chr2 29671104 T G 5.64E-04 Obesity (extreme) ALK intron 21935397 rs4589706 chr2 29671127 T C 5.48E-04 Obesity (extreme) ALK intron 21935397 rs10779969 chr2 29671801 A C 5.14E-04 Obesity (extreme) ALK intron 21935397 rs4366858 chr2 29672547 C T 4.18E-04 Obesity (extreme) ALK intron 21935397 rs4299298 chr2 29672756 T C 4.12E-04 Obesity (extreme) ALK intron 21935397 rs6547930 chr2 29672940 C T 4.10E-04 Obesity (extreme) ALK intron 21935397 rs11127225 chr2 29673607 T C 4.07E-04 Obesity (extreme) ALK intron 21935397 rs4233736 chr2 29676965 T C 3.76E-04 Obesity (extreme) ALK intron 21935397 rs4233737 chr2 29677036 C G 9.70E-04 Obesity (extreme) ALK intron 21935397 rs4602182 chr2 29677522 T C 6.84E-04 Obesity (extreme) ALK intron 21935397 rs7580476 chr2 29683558 C T 6.33E-04 Alcohol consumption (maxi-drinks) ALK intron 24277619 rs3923028 chr2 29685596 C T 2.00E-05 Major depressive disorder ALK intron 19065144 rs3923028 chr2 29685596 C T 3.11E-05 Major depressive disorder ALK intron 21621269 rs3923028 chr2 29685596 C T 3.80E-05 Major depressive disorder ALK intron pha002850 rs12714281 chr2 29691960 T C 0.000810007 Hypertension (early onset hypertension) ALK intron 22479346 rs12714281 chr2 29691960 T C 1.87E-04 Homeostasis model assessment of insulin resistance (interaction) ALK intron 24204828 rs12714281 chr2 29691960 T C 2.73E-04 Fasting insulin (interaction) ALK intron 24204828 rs4493213 chr2 29698164 T C 0.000458398 Hypertension (early onset hypertension) ALK intron 22479346 rs4503951 chr2 29698383 G A 1.70E-05 Urinary metabolites ALK intron 21572414 rs6547933 chr2 29700165 T C 0.00047798 Hypertension (early onset hypertension) ALK intron 22479346 rs7426089 chr2 29702682 A G 2.35E-04 Schizophrenia ALK intron 19197363 rs7426089 chr2 29702682 A G 3.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALK intron 20877124 rs4299297 chr2 29705020 A C 0.000466927 Hypertension (early onset hypertension) ALK intron 22479346 rs4665461 chr2 29707986 C T 5.13E-04 Obesity (extreme) ALK intron 21935397 rs11684392 chr2 29725676 C T 3.00E-06 Asthma ALK intron 21790008 rs6719507 chr2 29733801 G A 4.95E-04 Obesity (extreme) ALK intron 21935397 rs4468777 chr2 29743581 T G 3.63E-04 Obesity (extreme) ALK intron 21935397 rs7578465 chr2 29743733 T C 4.87E-04 Obesity (extreme) ALK intron 21935397 rs7578465 chr2 29743733 T C 0.0005799 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7578465 chr2 29743733 T C 5.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs7562040 chr2 29743822 C G 3.35E-04 Obesity (extreme) ALK intron 21935397 rs7562040 chr2 29743822 C G 0.0005739 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7562040 chr2 29743822 C G 5.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs10168427 chr2 29744983 C T 3.75E-04 Obesity (extreme) ALK intron 21935397 rs12467802 chr2 29747174 C T 7.40E-05 Alcohol dependence ALK intron 21703634 rs12467802 chr2 29747174 C T 6.54E-05 Schizophrenia (cytomegalovirus infection interaction) ALK intron 23358160 rs7571895 chr2 29751631 C A 0.000247 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7571895 chr2 29751631 C A 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs7592571 chr2 29767894 C A 8.53E-06 Alcohol dependence ALK intron 21703634 rs6547946 chr2 29780633 C G 0.0000056 Mean arterial pressure ALK intron 22510845 rs4280415 chr2 29783021 T C 0.0000197 Migraine ALK intron 22678113 rs4280415 chr2 29783021 T C 1.97E-05 Migraine ALK intron 22683712 rs10193521 chr2 29785679 G A 5.27E-05 Alcohol dependence ALK intron 21703634 rs12473275 chr2 29785781 G A 6.11E-05 Alcohol dependence ALK intron 21703634 rs12473275 chr2 29785781 G A 9.24E-05 Schizophrenia (cytomegalovirus infection interaction) ALK intron 23358160 rs6547949 chr2 29791841 A G 9.61E-04 Obesity (extreme) ALK intron 21935397 rs13014477 chr2 29795988 T G 7.50E-05 Vaspin levels ALK intron 22907691 rs13014477 chr2 29795988 T G 0.0000264 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit ALK intron 22907730 rs13014477 chr2 29795988 T G 0.000075 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks ALK intron 22907730 rs12621412 chr2 29796202 A G 0.000017 Mean arterial pressure ALK intron 22510845 rs6709634 chr2 29814009 C T 8.78E-05 Insulin Resistance ALK intron pha003062 rs6547957 chr2 29816800 G A 1.30E-05 Diabetes Mellitus ALK intron pha003059 rs6547957 chr2 29816800 G A 1.54E-05 Insulin Resistance ALK intron pha003062 rs6547957 chr2 29816800 G A 8.70E-05 Insulin-related traits ALK intron pha003063 rs6733973 chr2 29820586 T C 7.21E-06 Insulin Resistance ALK intron pha003062 rs6733973 chr2 29820586 T C 4.38E-05 Insulin-related traits ALK intron pha003063 rs4666255 chr2 29823652 A G 6.02E-06 Insulin Resistance ALK intron pha003062 rs4666255 chr2 29823652 A G 2.90E-05 Insulin-related traits ALK intron pha003063 rs6547960 chr2 29830234 T C 1.43E-05 Insulin Resistance ALK intron pha003062 rs6547960 chr2 29830234 T C 7.77E-05 Insulin-related traits ALK intron pha003063 rs2879504 chr2 29861246 A G 7.86E-05 Insulin Resistance ALK intron pha003062 rs13392455 chr2 29871128 C T 1.08E-04 Smoking cessation ALK intron 24665060 rs7577363 chr2 29876343 G A 7.37E-05 Multiple sclerosis ALK intron 17660530 rs6547967 chr2 29880877 C T 7.80E-05 HIV-1 control ALK intron 20041166 rs2631962 chr2 29922364 A G 9.68E-04 Type 2 diabetes ALK intron 17463246 rs2541194 chr2 29947235 A G 6.76E-04 Type 2 diabetes ALK intron 17463246 rs2257135 chr2 29948698 G A 2.84E-04 Type 2 diabetes ALK intron 17463246 rs2631955 chr2 29954416 T C 4.37E-04 Type 2 diabetes ALK intron 17463246 rs12998454 chr2 29954652 A C 9.91E-04 Type 2 diabetes ALK intron 17463246 rs4666270 chr2 29989203 T G 1.00E-04 Cognitive impairment induced by topiramate ALK intron 22091778 rs2339478 chr2 29995801 C T 9.19E-05 ldl cholesterol ALK intron pha003077 rs11694445 chr2 30034279 A G 4.48E-04 Prostate cancer mortality ALK intron 20978177 rs10187657 chr2 30042217 A G 2.65E-04 Multiple complex diseases ALK intron 17554300 rs10187657 chr2 30042217 A G 4.70E-06 Urinary metabolites ALK intron 21572414 rs4132594 chr2 30045521 G A 4.90E-05 Heart Rate ALK intron pha003053 rs4264531 chr2 30048387 C T 3.75E-04 Multiple complex diseases ALK intron 17554300 rs13012046 chr2 30068116 T G 2.15E-05 Coronary heart disease ALK intron pha003031 rs4075920 chr2 30075051 G A 4.03E-05 Suicidal ideation ALK intron 20877300 rs12616992 chr2 30080818 C T 2.67E-05 Receptive language ability ALK intron 24687471 rs12613938 chr2 30087465 C T 1.91E-05 Receptive language ability ALK intron 24687471 rs12620548 chr2 30090341 T C 7.82E-05 Cognitive impairment induced by topiramate ALK intron 22091778 rs12620548 chr2 30090341 T C 3.23E-05 Receptive language ability ALK intron 24687471 rs7574859 chr2 30094209 T G 1.80E-05 Urinary metabolites ALK intron 21572414 rs4280420 chr2 30106142 C T 7.91E-05 Type 2 diabetes ALK intron 17463246 rs4280420 chr2 30106142 C T 2.49E-04 Multiple complex diseases ALK intron 17554300 rs4520995 chr2 30118386 T C 4.23E-04 Alcohol consumption (maxi-drinks) ALK intron 24277619 rs6754787 chr2 30141950 C G 1.05E-04 Multiple complex diseases ALK intron 17554300 rs11693432 chr2 30180109 G C 3.21E-04 Multiple complex diseases / / 17554300 rs4359705 chr2 30200798 T C 2.15E-05 Coronary heart disease / / pha003030 rs4952125 chr2 30210861 A G 3.73E-05 Coronary heart disease / / pha003030 rs7575487 chr2 30237620 T G 7.21E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs12465875 chr2 30272550 G A 7.74E-04 Acute lung injury / / 22295056 rs2009666 chr2 30273188 C T 7.74E-04 Acute lung injury / / 22295056 rs2290052 chr2 30273535 G A 7.06E-04 Acute lung injury / / 22295056 rs12464374 chr2 30273759 T C 7.06E-04 Acute lung injury / / 22295056 rs12475473 chr2 30273791 C T 6.83E-04 Acute lung injury / / 22295056 rs7584886 chr2 30275074 T C 6.83E-04 Acute lung injury / / 22295056 rs12477758 chr2 30276651 T C 6.83E-04 Acute lung injury / / 22295056 rs12473767 chr2 30277205 C T 6.83E-04 Acute lung injury / / 22295056 rs1108288 chr2 30277518 C G 8.82E-04 Acute lung injury / / 22295056 rs17009105 chr2 30278431 A G 6.33E-04 Acute lung injury / / 22295056 rs935482 chr2 30279202 C A 4.78E-04 Acute lung injury / / 22295056 rs12468948 chr2 30280388 G A 7.17E-04 Acute lung injury / / 22295056 rs1447524 chr2 30282981 G A 6.97E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1597036 chr2 30283564 C T 3.37E-04 Acute lung injury / / 22295056 rs6731342 chr2 30284800 T G 5.45E-04 Acute lung injury / / 22295056 rs12465311 chr2 30287512 G A 6.48E-04 Acute lung injury / / 22295056 rs1900589 chr2 30292775 A G 9.70E-04 Acute lung injury / / 22295056 rs1137288 chr2 30381505 T C 2.00E-04 Cognitive impairment induced by topiramate YPEL5 cds-synon 22091778 rs961440 chr2 30398039 C T 5.25E-05 Multiple complex diseases / / 17554300 rs11681599 chr2 30426437 G A 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17736058 chr2 30426554 T C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952108 chr2 30429735 C T 1.16E-07 Primary biliary cirrhosis / / 21399635 rs7579944 chr2 30445026 T C 1.00E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs1355208 chr2 30445322 A G 3.40E-05 Celiac disease / / 17558408 rs1355208 chr2 30445322 A G 3.48E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs955214 chr2 30445926 G A 4.17E-04 Obesity (extreme) / / 21935397 rs1396836 chr2 30446083 T C 4.54E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs906868 chr2 30448344 G T 7.19E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs10175798 chr2 30449594 G A 1.00E-09 Rheumatoid arthritis / / 24390342 rs10175798 chr2 30449594 G A 4.00E-08 Rheumatoid arthritis / / 24390342 rs2362540 chr2 30452959 C A 1.27E-04 Parkinson's disease / / 21248740 rs3738863 chr2 30457561 A G 1.82E-06 Primary biliary cirrhosis LBH intron 21399635 rs1473591 chr2 30462979 A C 5.86E-05 Lung adenocarcinoma LBH intron 19836008 rs11676884 chr2 30466066 C T 2.23E-04 Multiple complex diseases LBH intron 17554300 rs4384829 chr2 30466802 G A 3.90E-04 Multiple complex diseases LBH intron 17554300 rs4564821 chr2 30474255 C T 1.79E-04 Multiple complex diseases LBH intron 17554300 rs13386455 chr2 30480865 A G 6.36E-05 Asthma LBH UTR-3 pha003128 rs12467407 chr2 30507340 C T 5.84E-04 Multiple complex diseases / / 17554300 rs6708166 chr2 30526780 G A 1.00E-06 vWF and FVIII levels / / 21810271 rs13014895 chr2 30540833 T C 8.80E-06 Urinary metabolites / / 21572414 rs13014895 chr2 30540833 T C 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6730942 chr2 30540988 A T 8.80E-06 Urinary metabolites / / 21572414 rs7578949 chr2 30569355 T C 2.58E-05 Serum albumin level / / pha003084 rs6740257 chr2 30577757 T C 6.48E-05 Cognitive test performance / / 20125193 rs829586 chr2 30626447 A C 5.89E-04 Alzheimer's disease / / 17998437 rs829604 chr2 30635580 C G 6.84E-05 Self-reported allergy / / 23817569 rs17394352 chr2 30638988 T A 5.03E-05 Self-reported allergy / / 23817569 rs829699 chr2 30643811 T C 5.96E-05 Self-reported allergy / / 23817569 rs829584 chr2 30677275 A G 2.13E-04 Aortic root size LCLAT1 intron 21223598 rs829573 chr2 30682630 T A 1.92E-04 Aortic root size LCLAT1 intron 21223598 rs1357849 chr2 30696207 A G 7.44E-05 Serum metabolites LCLAT1 intron 19043545 rs829642 chr2 30699970 T C 4.80E-05 Alcohol dependence LCLAT1 intron 20201924 rs829642 chr2 30699970 T C 4.80E-05 Alcoholism LCLAT1 intron pha002892 rs829646 chr2 30719326 T C 6.30E-05 Alcohol dependence LCLAT1 intron 20201924 rs829646 chr2 30719326 T C 6.34E-05 Alcoholism LCLAT1 intron pha002892 rs4952147 chr2 30776270 G A 2.20E-04 Alcohol dependence LCLAT1 intron 20201924 rs4952152 chr2 30797350 G A 4.26E-04 Aortic root size LCLAT1 intron 21223598 rs12052683 chr2 30857850 G T 3.51E-04 Multiple complex diseases LCLAT1 intron 17554300 rs12613783 chr2 30858736 A G 1.27E-04 Multiple complex diseases LCLAT1 intron 17554300 rs12613783 chr2 30858736 A G 9.41E-05 Cognitive impairment induced by topiramate LCLAT1 intron 22091778 rs12467646 chr2 30863092 C T 9.22E-04 Aortic root size LCLAT1 cds-synon 21223598 rs2609954 chr2 30871808 G A 1.00E-04 Alcohol dependence / / 20201924 rs7583600 chr2 30872064 T G 8.83E-05 Multiple complex diseases / / 17554300 rs6548026 chr2 30872366 C T 9.39E-05 Multiple complex diseases / / 17554300 rs2602777 chr2 30879524 G A 7.05E-04 Tourette syndrome / / 22889924 rs2602772 chr2 30885263 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1562417 chr2 30910849 C T 2.06E-04 Alzheimer's disease (late onset) / / 21379329 rs543134 chr2 30917735 T G 2.75E-05 Serum metabolites / / 19043545 rs2681686 chr2 30925674 T A 1.80E-05 Urinary metabolites / / 21572414 rs2681687 chr2 30926706 C T 1.40E-05 Urinary metabolites / / 21572414 rs7599134 chr2 30927012 T C 7.00E-06 Urinary metabolites / / 21572414 rs11887038 chr2 30955086 G A 1.00E-04 Cognitive impairment induced by topiramate CAPN13 intron 22091778 rs7607943 chr2 30956721 G T 3.61E-05 Cognitive impairment induced by topiramate CAPN13 intron 22091778 rs509380 chr2 30959262 G T 9.13E-04 Multiple complex diseases CAPN13 intron 17554300 rs509380 chr2 30959262 G T 2.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAPN13 intron 20877124 rs1879276 chr2 30959827 C T 5.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAPN13 intron 20877124 rs2609914 chr2 30961997 C A 9.07E-04 Alzheimer's disease CAPN13 intron 17998437 rs10153751 chr2 30962675 T G 7.46E-05 Body Mass Index CAPN13 intron pha003020 rs35438878 chr2 30962675 T TG 7.46E-05 Body Mass Index CAPN13 intron pha003020 rs765716 chr2 30971264 C G 7.23E-04 Type 2 diabetes CAPN13 intron 17463246 rs765716 chr2 30971264 C G 5.15E-04 Multiple complex diseases CAPN13 intron 17554300 rs17010141 chr2 30974575 A C 5.57E-05 Iron levels CAPN13 intron 19880490 rs17010141 chr2 30974575 A C 5.57E-05 Iron levels CAPN13 intron pha002876 rs12052795 chr2 30983696 G A 5.82E-04 Alzheimer's disease CAPN13 intron 17998437 rs17324662 chr2 30986645 C T 4.75E-05 Alzheimer's disease CAPN13 intron 17998437 rs6548032 chr2 30988375 A G 2.36E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs13003439 chr2 30990328 G T 3.21E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs7592480 chr2 30990941 A G 3.18E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010236 chr2 30992719 G T 2.36E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010236 chr2 30992719 G T 3.15E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17324843 chr2 30992877 G A 2.91E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17324843 chr2 30992877 G A 3.16E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs200944264 chr2 30993308 T A 0.00076 Prostate cancer CAPN13 missense 23555315 rs4952179 chr2 30995027 T C 6.86E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs1568403 chr2 31001167 A G 2.20E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs1568403 chr2 31001167 A G 9.64E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010264 chr2 31001605 G C 1.86E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010264 chr2 31001605 G C 9.70E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6754923 chr2 31002130 C G 1.53E-04 Multiple complex diseases CAPN13 intron 17554300 rs6754923 chr2 31002130 C G 4.99E-05 Serum metabolites CAPN13 intron 19043545 rs6754923 chr2 31002130 C G 2.61E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4952181 chr2 31002221 T A 1.41E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4952181 chr2 31002221 T A 9.82E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17041560 chr2 31003019 G A 2.68E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030383 chr2 31005078 T A,G 2.40E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030384 chr2 31005079 T G 2.50E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030385 chr2 31005129 C T 1.17E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030385 chr2 31005129 C T 2.34E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4597573 chr2 31005176 T C 2.88E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4597574 chr2 31005297 T C 8.68E-05 Colorectal cancer CAPN13 intron 19723657 rs4597574 chr2 31005297 T C 2.91E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030386 chr2 31005412 G A 4.56E-05 Serum metabolites CAPN13 intron 19043545 rs2030386 chr2 31005412 G A 1.26E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030386 chr2 31005412 G A 1.96E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548034 chr2 31005484 A G 2.95E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548035 chr2 31005871 A G 1.24E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548035 chr2 31005871 A G 2.26E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6710242 chr2 31006133 T C 1.18E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6710242 chr2 31006133 T C 2.20E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs11675229 chr2 31006239 C T 2.87E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010271 chr2 31006636 C T 2.87E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548036 chr2 31006724 C G 1.29E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548036 chr2 31006724 C G 7.37E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2090734 chr2 31007389 A T 2.81E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6754455 chr2 31007679 C T 2.80E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6732918 chr2 31009479 G A 8.01E-05 Lung function (forced vital capacity) CAPN13 intron 24023788 rs17010323 chr2 31022617 G A 8.17E-04 Parkinson's disease CAPN13 intron 17052657 rs17010323 chr2 31022617 G A 1.50E-04 Amyotrophic Lateral Sclerosis CAPN13 intron 17362836 rs6735205 chr2 31027576 C G 1.90E-07 Urinary metabolites CAPN13 intron 21572414 rs10173959 chr2 31028945 T C 5.90E-06 Urinary metabolites CAPN13 intron 21572414 rs10176484 chr2 31029096 T A 1.70E-05 Urinary metabolites CAPN13 intron 21572414 rs1879282 chr2 31029835 C T 4.00E-06 Urinary metabolites CAPN13 intron 21572414 rs7592727 chr2 31030024 C T 5.10E-06 Urinary metabolites CAPN13 intron 21572414 rs6548038 chr2 31037485 T C 6.30E-06 Urinary metabolites / / 21572414 rs939370 chr2 31048782 C T 3.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs939370 chr2 31048782 C T 1.00E-04 Erythrocyte counts / / pha003090 rs939369 chr2 31048811 C T 2.60E-05 Urinary metabolites / / 21572414 rs2194448 chr2 31064313 C T 1.17E-04 Gallstones / / 17632509 rs10490517 chr2 31086198 C A 2.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10490517 chr2 31086198 C A 8.66E-05 Erythrocyte counts / / pha003090 rs2194452 chr2 31093502 A G 8.94E-04 Acute lung injury / / 22295056 rs2216824 chr2 31094245 C A 8.94E-04 Acute lung injury / / 22295056 rs13429869 chr2 31099832 C T 8.35E-04 Acute lung injury / / 22295056 rs10167990 chr2 31101646 C A 8.35E-04 Acute lung injury / / 22295056 rs10191298 chr2 31101982 G A 8.96E-04 Acute lung injury / / 22295056 rs2042491 chr2 31103730 C T 8.31E-04 Acute lung injury / / 22295056 rs2042490 chr2 31103788 G A 8.31E-04 Acute lung injury / / 22295056 rs10175111 chr2 31103996 C A 9.73E-05 Bipolar disorder / / 20451256 rs10175111 chr2 31103996 C A 5.63E-04 Acute lung injury / / 22295056 rs17010429 chr2 31105974 C A 6.30E-04 Acute lung injury / / 22295056 rs3755527 chr2 31107154 A G 9.40E-05 Glioma (high-grade) / / 19578366 rs10184608 chr2 31107181 T C 4.85E-04 Acute lung injury / / 22295056 rs3732337 chr2 31114972 C T 6.41E-04 Coronary heart disease / / 21971053 rs17321093 chr2 31117795 C T 1.61E-04 Myopia (pathological) / / 21095009 rs4952192 chr2 31122598 C T 5.64E-04 Coronary heart disease / / 21971053 rs17010471 chr2 31142852 T C 2.42E-05 Prostate cancer GALNT14 intron 22923026 rs10205350 chr2 31146497 G T 3.94E-07 Autism GALNT14 intron 22843504 rs2010334 chr2 31236491 G A 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT14 intron 20877124 rs17010574 chr2 31243964 G C 3.67E-06 Asthma (childhood onset) GALNT14 intron 23829686 rs10209881 chr2 31246249 T C 1.90E-05 Urinary metabolites GALNT14 intron 21572414 rs10197865 chr2 31246546 C T 5.48E-05 IgE levels in asthmatics GALNT14 intron 23967269 rs6752303 chr2 31247485 T C 1.90E-05 Urinary metabolites GALNT14 intron 21572414 rs9679162 chr2 31247514 G T 1.60E-05 Urinary metabolites GALNT14 intron 21572414 rs5009910 chr2 31249014 T C 2.80E-05 Urinary metabolites GALNT14 intron 21572414 rs4952029 chr2 31249105 C G 4.49E-05 Brain derived neurotrophic factor levels,in serum GALNT14 intron 22047184 rs7608731 chr2 31249974 T C 8.15E-05 IgE levels in asthmatics GALNT14 intron 23967269 rs1862968 chr2 31254348 C T 1.10E-04 IgE levels in asthmatics GALNT14 intron 23967269 rs9308914 chr2 31263433 C A 1.00E-04 IgE levels in asthmatics GALNT14 intron 23967269 rs11681174 chr2 31278254 A G 9.24E-05 Acute lung injury GALNT14 intron 22295056 rs10211370 chr2 31280917 C T 1.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT14 intron 20877124 rs4630806 chr2 31292715 C T 2.20E-05 Urinary metabolites GALNT14 intron 21572414 rs2098787 chr2 31296644 A G 0.00000726 Otitis media (children 3 years old or younger) GALNT14 intron 23133572 rs1862981 chr2 31297524 T G 9.67E-05 Non-alcoholic fatty liver disease histology (other) GALNT14 intron 20708005 rs1862981 chr2 31297524 T G 0.0000051 Otitis media (children 3 years old or younger) GALNT14 intron 23133572 rs1000916 chr2 31314555 T C 9.00E-06 HIV-1 viral setpoint GALNT14 intron 22174851 rs10193546 chr2 31315414 G A 1.35E-04 Lymphocyte counts GALNT14 intron 22286170 rs4561706 chr2 31316509 C T 2.51E-05 HIV-1 viral setpoint GALNT14 intron 22174851 rs10490519 chr2 31318351 T C 0.000524663 Hypertension (early onset hypertension) GALNT14 intron 22479346 rs2216831 chr2 31318838 G A 4.66E-05 HIV-1 viral setpoint GALNT14 intron 22174851 rs11888670 chr2 31320834 T C 0.000210111 Hypertension (early onset hypertension) GALNT14 intron 22479346 rs11687856 chr2 31340646 G A 1.16E-22 Narcolepsy GALNT14 intron 19629137 rs10165977 chr2 31344193 A G 0.0000192 Polycystic ovary syndrome GALNT14 intron 22951595 rs10165977 chr2 31344193 A G 1.92E-05 Intracranial aneurysm GALNT14 intron 22961961 rs2216832 chr2 31348390 A G 4.60E-05 Smoking initiation GALNT14 intron 24665060 rs956747 chr2 31374733 A G 2.10E-05 Urinary metabolites / / 21572414 rs956747 chr2 31374733 A G 1.36E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6543610 chr2 31376654 G C 1.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs17010768 chr2 31377294 C T 7.44E-04 Multiple complex diseases / / 17554300 rs6747497 chr2 31380113 G C 8.54E-04 Type 2 diabetes / / 17463246 rs1443712 chr2 31392316 C A 8.36E-05 Cognitive performance / / 19734545 rs17010928 chr2 31415054 G A 0.0000985 Otitis media (children 3 years old or younger) CAPN14 intron 23133572 rs17010928 chr2 31415054 G A 2.65E-04 Celiac disease CAPN14 intron 23936387 rs10192210 chr2 31415077 G A 5.58E-05 Schizophrenia CAPN14 intron 19571809 rs10192210 chr2 31415077 G A 3.52E-05 Schizophrenia CAPN14 intron pha002859 rs34438079 chr2 31426449 T TG 2.42E-04 Myopia (pathological) CAPN14 intron 21095009 rs7559123 chr2 31426449 T G 2.42E-04 Myopia (pathological) CAPN14 intron 21095009 rs6728152 chr2 31431651 T C 0.000175 Otitis media (children 3 years old or younger) CAPN14 intron 23133572 rs6736278 chr2 31442875 C T 9.80E-05 Myopia (pathological) / / 21095009 rs13408922 chr2 31444826 C A 0.00000132 Otitis media (children 3 years old or younger) / / 23133572 rs13386745 chr2 31445615 A G 0.00000163 Otitis media (children 3 years old or younger) / / 23133572 rs13386850 chr2 31445691 A C 0.00000132 Otitis media (children 3 years old or younger) / / 23133572 rs13386968 chr2 31445795 A G 8.18E-04 Myopia (pathological) / / 21095009 rs601255 chr2 31452231 G A 1.52E-04 Multiple complex diseases / / 17554300 rs590557 chr2 31461395 G A 1.40E-04 Testosterone levels EHD3 intron 22675492 rs649729 chr2 31464385 T A 1.00E-12 Mean platelet volume EHD3 intron 22139419 rs649729 chr2 31464385 T A 4.00E-06 Mean platelet volume EHD3 intron 24026423 rs647316 chr2 31464829 A G 3.00E-11 Mean platelet volume EHD3 intron 19820697 rs647316 chr2 31464829 A G 3.20E-11 Mean platelet volume EHD3 intron 22423221 rs649509 chr2 31465278 C A 7.03E-05 Testosterone levels EHD3 intron 22675492 rs597800 chr2 31474242 G C 5.00E-07 Estradiol levels EHD3 intron 22675492 rs611076 chr2 31474903 G A 7.94E-05 Testosterone levels EHD3 intron 22675492 rs654091 chr2 31477589 G A 7.87E-05 Testosterone levels EHD3 intron 22675492 rs671403 chr2 31479234 G A 5.01E-05 Testosterone levels EHD3 intron 22675492 rs672364 chr2 31479425 G A 3.35E-05 Testosterone levels EHD3 intron 22675492 rs622107 chr2 31481640 T C 9.43E-05 Testosterone levels EHD3 intron 22675492 rs625132 chr2 31482300 A G 9.00E-14 Platelet counts EHD3 intron 22139419 rs625132 chr2 31482300 A G 8.00E-05 Platelet counts EHD3 intron 24026423 rs669292 chr2 31485332 T C 1.40E-04 Testosterone levels EHD3 intron 22675492 rs617163 chr2 31488554 C T 3.92E-05 Testosterone levels EHD3 intron 22675492 rs644503 chr2 31489826 G C 3.41E-05 Testosterone levels EHD3 UTR-3 22675492 rs1560268 chr2 31537931 T C 2.00E-04 Glycosylated haemoglobin levels / / 17255346 rs2064816 chr2 31541391 T C 2.58E-04 Type 2 diabetes / / 17463246 rs207420 chr2 31544724 T C 8.00E-06 Personality dimensions / / 21173776 rs12478111 chr2 31550180 G A 8.35E-05 Socioeconomic Factors / / pha003066 rs10490361 chr2 31553549 G C 8.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6543626 chr2 31556986 C T 6.62E-05 Major depressive disorder (broad) XDH nearGene-3 20038947 rs4952085 chr2 31570689 G A 9.34E-04 Longevity XDH intron 22279548 rs4952085 chr2 31570689 G A 5.18E-05 Left ventricular hypertrophy XDH intron pha003052 rs1884725 chr2 31571786 A G 6.81E-05 Left ventricular hypertrophy XDH cds-synon pha003052 rs17011353 chr2 31588437 C T 9.43E-04 Type 2 diabetes XDH intron 17463246 rs2295475 chr2 31589847 G A 5.22E-06 Obesity-related traits XDH cds-synon 23251661 rs761926 chr2 31590785 C G 4.00E-06 Obesity-related traits XDH intron 23251661 rs13398137 chr2 31594789 A C 5.59E-04 Type 2 diabetes XDH intron 17463246 rs2163059 chr2 31603134 A G 9.99E-06 Colorectal cancer XDH intron 21242260 rs206846 chr2 31610311 C G 3.49E-05 Serum metabolites XDH intron 19043545 rs11678276 chr2 31665108 G A 7.62E-04 Smoking quantity / / 24665060 rs4952218 chr2 31731120 A T 9.60E-04 Multiple complex diseases / / 17554300 rs2281546 chr2 31757024 T G 2.85E-05 Lung adenocarcinoma SRD5A2 intron 19836008 rs4952220 chr2 31765556 C A 2.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SRD5A2 intron 24023788 rs2268797 chr2 31783752 C T 2.80E-17 Inflammatory biomarkers SRD5A2 intron 24182552 rs2300701 chr2 31787008 A G 1.35E-05 Serum metabolites SRD5A2 intron 19043545 rs2300702 chr2 31788018 C G 1.60E-17 Inflammatory biomarkers SRD5A2 intron 24182552 rs806645 chr2 31807940 T C 6.60E-05 Serum metabolites SRD5A2 nearGene-5 19043545 rs559555 chr2 31810974 T A 1.00E-44 Blood metabolite ratios / / 24816252 rs559555 chr2 31810974 T A 4.00E-22 Blood metabolite levels / / 24816252 rs559555 chr2 31810974 T A 7.00E-19 Blood metabolite levels / / 24816252 rs13027103 chr2 31891571 G A 3.98E-05 Major depressive disorder (broad) / / 20038947 rs7567093 chr2 31891733 A G 2.69E-05 Lung adenocarcinoma / / 19836008 rs223655 chr2 32011895 T C 3.08E-05 Lung adenocarcinoma / / 19836008 rs223657 chr2 32014315 G A 2.37E-05 Lung adenocarcinoma / / 19836008 rs10490358 chr2 32082097 G C 9.20E-04 Multiple complex diseases / / 17554300 rs974229 chr2 32084711 C T 7.06E-04 Multiple complex diseases / / 17554300 rs160802 chr2 32105386 A G 3.57E-05 Lung adenocarcinoma MEMO1 intron 19836008 rs17011668 chr2 32110725 T C 5.00E-05 Prostate cancer MEMO1 intron 21743057 rs2064813 chr2 32212935 T G 3.76E-04 Lung function (forced expiratory volume in 1 second) MEMO1 intron 24023788 rs6748621 chr2 32262201 T C 1.10E-16 Inflammatory biomarkers DPY30 intron 24182552 rs6737500 chr2 32263087 C T 1.10E-16 Inflammatory biomarkers DPY30 intron 24182552 rs12989936 chr2 32268586 T C 2.30E-17 Inflammatory biomarkers / / 24182552 rs7577696 chr2 32278782 A G 3.00E-19 Inflammatory biomarkers / / 24182552 rs2280967 chr2 32289746 T C 3.20E-16 Inflammatory biomarkers SPAST intron 24182552 rs6760105 chr2 32307386 A G 3.60E-16 Inflammatory biomarkers SPAST intron 24182552 rs11691939 chr2 32339561 C T 5.80E-04 Lymphocyte counts SPAST intron 22286170 rs7580118 chr2 32398134 T C 8.11E-04 Type 2 diabetes SLC30A6 intron 17463246 rs17011863 chr2 32407674 C G 6.19E-05 Schizophrenia SLC30A6 intron 19571809 rs212745 chr2 32412832 C G 2.10E-15 Inflammatory biomarkers SLC30A6 intron 24182552 rs212679 chr2 32431107 C A 1.90E-15 Inflammatory biomarkers SLC30A6 intron 24182552 rs212701 chr2 32444054 T C 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SLC30A6 intron 23648065 rs177083 chr2 32447718 C T 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SLC30A6 UTR-3 23648065 rs212704 chr2 32450348 C T 3.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) NLRC4 intron 23648065 rs212713 chr2 32457537 C T 1.50E-10 Inflammatory biomarkers NLRC4 intron 24182552 rs455060 chr2 32475109 G A 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) NLRC4 cds-synon 23648065 rs479333 chr2 32489158 C G 1.30E-15 Inflammatory biomarkers NLRC4 intron 24182552 rs390480 chr2 32510072 G T 5.80E-04 Response to taxane treatment (placlitaxel) YIPF4 intron 23006423 rs2366894 chr2 32713706 A T 9.43E-04 Parkinson's disease BIRC6 missense 17052657 rs1031261 chr2 32865521 G C 2.00E-06 Hippocampal atrophy TTC27 intron 22745009 rs17012044 chr2 32881702 G A 9.46E-05 Schizophrenia TTC27 intron 20832056 rs2295730 chr2 32897147 G T 3.42E-05 Eosinophil counts TTC27 intron pha003088 rs7594173 chr2 32900330 A G 1.23E-05 Blood pressure TTC27 intron 24001895 rs13009977 chr2 32915597 A C 1.72E-05 Calcium levels TTC27 intron pha003085 rs3769589 chr2 32918720 G A 1.81E-06 Orofacial clefts TTC27 intron 19270707 rs6743661 chr2 32933095 T G 1.10E-04 Alcohol dependence TTC27 intron 20201924 rs11124288 chr2 32937182 C A 4.89E-05 Calcium levels TTC27 intron pha003085 rs3769583 chr2 32968121 C T 5.01E-04 Bipolar disorder TTC27 intron 19259986 rs1448225 chr2 32970453 T C 3.13E-05 Orofacial clefts TTC27 intron 19270707 rs3769578 chr2 32976251 G T 9.46E-04 Multiple complex diseases TTC27 intron 17554300 rs2839744 chr2 32981163 G A 3.79E-05 Orofacial clefts TTC27 intron 19270707 rs2273665 chr2 32983526 C T 3.79E-05 Orofacial clefts TTC27 cds-synon 19270707 rs2218898 chr2 32985073 T C 7.22E-04 Multiple complex diseases TTC27 intron 17554300 rs7558757 chr2 32994874 T C 8.70E-04 Multiple complex diseases TTC27 intron 17554300 rs4952294 chr2 33013440 T A 1.48E-05 Lipoprotein-associated phospholipase A2 activity and mass TTC27 intron 20442857 rs3769567 chr2 33034057 A C 1.37E-05 Orofacial clefts TTC27 intron 19270707 rs927088 chr2 33037217 G A 2.17E-04 Glycemic traits (pregnancy) TTC27 intron 23903356 rs927088 chr2 33037217 G A 8.10E-04 Glycemic traits (pregnancy) TTC27 intron 23903356 rs3820915 chr2 33045629 G C 2.77E-04 Hearing function TTC27 intron 17255346 rs3820915 chr2 33045629 G C 0.000031 Mean arterial pressure TTC27 intron 22510845 rs13033415 chr2 33054282 G A 5.74E-06 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs13033415 chr2 33054282 G A 6.99E-06 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs10173066 chr2 33057305 C G 3.15E-04 Hearing function LINC00486 intron 17255346 rs10173066 chr2 33057305 C G 5.87E-04 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs10173352 chr2 33057389 G A 2.17E-06 Orofacial clefts LINC00486 intron 19270707 rs10173352 chr2 33057389 G A 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LINC00486 intron 24023788 rs6707573 chr2 33058768 C T 7.74E-05 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs6543679 chr2 33062481 C T 2.37E-04 Hearing function LINC00486 intron 17255346 rs7565366 chr2 33065405 C G 9.33E-04 Multiple complex diseases LINC00486 intron 17554300 rs897510 chr2 33081584 G A 9.94E-05 Hearing function LINC00486 intron 17255346 rs35070884 chr2 33107259 T C 5.38E-04 Multiple complex diseases LINC00486 intron 17554300 rs4952315 chr2 33108465 T G 4.49E-05 Lymphocyte counts LINC00486 intron 22286170 rs13033107 chr2 33119383 A G 1.36E-04 Body mass index LINC00486 intron 17255346 rs6752373 chr2 33120234 G A 2.26E-04 Body mass index LINC00486 intron 17255346 rs6728021 chr2 33121504 A G 4.00E-08 Immune response to smallpox vaccine (IL-6) LINC00486 intron 22610502 rs6716986 chr2 33127080 T C 6.81E-04 Multiple complex diseases LINC00486 intron 17554300 rs17012387 chr2 33178646 A G 8.01E-04 Multiple complex diseases LTBP1 intron 17554300 rs219145 chr2 33211514 C G 3.94E-06 Brachial circumference LTBP1 intron 22479309 rs219157 chr2 33217287 T C 9.99E-05 Relative hand skill LTBP1 intron 24068947 rs219158 chr2 33218037 A G 9.70E-05 Relative hand skill LTBP1 intron 24068947 rs219159 chr2 33218120 C T 9.71E-05 Relative hand skill LTBP1 intron 24068947 rs219186 chr2 33242555 C T 8.14E-04 Stroke LTBP1 intron pha002887 rs2123917 chr2 33248411 G A 1.84E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LTBP1 intron 24023788 rs7423562 chr2 33272454 A C 4.18E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs7423562 chr2 33272454 A C 9.41E-05 Orofacial clefts LTBP1 intron 22419666 rs368929 chr2 33296836 G A 3.19E-04 Multiple complex diseases LTBP1 intron 17554300 rs11896749 chr2 33297929 C T 2.60E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs11896749 chr2 33297929 C T 7.29E-05 Orofacial clefts LTBP1 intron 22419666 rs11896749 chr2 33297929 C T 1.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LTBP1 intron 24023788 rs542631 chr2 33301947 T G 7.34E-05 Cognitive performance LTBP1 intron 19734545 rs542631 chr2 33301947 T G 1.00E-07 Immune reponse to smallpox (secreted IFN-alpha) LTBP1 intron 22610502 rs17397408 chr2 33333871 A G 2.40E-05 Urinary metabolites LTBP1 intron 21572414 rs218193 chr2 33344570 T G 1.20E-04 Multiple complex diseases LTBP1 intron 17554300 rs1545552 chr2 33360338 A G 2.00E-10 Height LTBP1 intron 23563607 rs6714546 chr2 33361425 A G 2.00E-09 Height LTBP1 intron 20881960 rs6705263 chr2 33362643 T G 1.83E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs6737948 chr2 33365244 G A 1.40E-04 Vaspin levels LTBP1 intron 22907691 rs6737948 chr2 33365244 G A 0.00014 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LTBP1 intron 22907730 rs10432656 chr2 33375032 C T 5.40E-05 HIV-1 control LTBP1 intron 20041166 rs10432656 chr2 33375032 C T 1.43E-05 Cholesterol LTBP1 intron pha003073 rs10432656 chr2 33375032 C T 1.42E-05 Cholesterol LTBP1 intron pha003078 rs10432656 chr2 33375032 C T 2.63E-05 Triglycerides LTBP1 intron pha003080 rs7572753 chr2 33387540 T C 4.20E-04 Intelligence (childhood) LTBP1 intron 23358156 rs17012623 chr2 33390188 T G 9.60E-04 Iron levels LTBP1 intron pha002876 rs4670307 chr2 33432201 A G 7.80E-05 Cognitive function LTBP1 intron 24684796 rs4671024 chr2 33445658 G A 8.40E-05 Diabetic retinopathy LTBP1 intron 21441570 rs2290448 chr2 33447202 C T 8.10E-05 Diabetic retinopathy LTBP1 cds-synon 21441570 rs17642074 chr2 33447979 A G 8.40E-05 Diabetic retinopathy LTBP1 intron 21441570 rs4671035 chr2 33449367 C G 8.00E-05 Diabetic retinopathy LTBP1 intron 21441570 rs4670322 chr2 33455742 A G 5.13E-05 Parkinson's disease LTBP1 intron pha002865 rs4630744 chr2 33461375 A G 8.60E-05 Diabetic retinopathy LTBP1 intron 21441570 rs3769528 chr2 33471192 A G 8.00E-08 Height LTBP1 intron 20189936 rs3769528 chr2 33471192 A G 3.49E-06 Orofacial clefts LTBP1 intron 22419666 rs3731575 chr2 33477964 C T 3.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LTBP1 intron 24023788 rs1453845 chr2 33496281 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) LTBP1 intron 20189245 rs817531 chr2 33498044 T G 1.56E-04 Type 2 diabetes LTBP1 intron 17463246 rs6739506 chr2 33506363 C T 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs4670408 chr2 33516152 C T 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs41464348 chr2 33527299 G A 9.16E-04 Type 2 diabetes LTBP1 intron 17463246 rs41464348 chr2 33527299 G A 7.00E-06 Height LTBP1 intron 19893584 rs1453842 chr2 33536962 A T 7.55E-04 Type 2 diabetes LTBP1 intron 17463246 rs723042 chr2 33541702 A G 6.41E-05 Lactate dehydrogenase levels LTBP1 intron 20981236 rs2167972 chr2 33556839 T C 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs2167972 chr2 33556839 T C 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs10495786 chr2 33559429 T C 1.18E-04 Response to cholinesterase inhibitors in Alzheimer's disease LTBP1 intron 23374588 rs17012889 chr2 33598217 A C 4.93E-04 Multiple complex diseases LTBP1 intron 17554300 rs17012898 chr2 33601649 A C 3.79E-04 Multiple complex diseases LTBP1 intron 17554300 rs6719824 chr2 33604048 A C 3.69E-05 Cortisol secretion,in saliva LTBP1 intron 21316860 rs6719824 chr2 33604048 A C 3.46E-05 Orofacial clefts LTBP1 intron 22419666 rs6742198 chr2 33607071 G A 4.10E-05 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs6757228 chr2 33616240 C A 6.43E-05 Amyotrophic lateral sclerosis (sporadic) LTBP1 intron 24529757 rs602622 chr2 33658226 C G 9.09E-04 Multiple complex diseases / / 17554300 rs6543714 chr2 33682603 T G 8.94E-05 Lung adenocarcinoma RASGRP3 intron 19836008 rs6543714 chr2 33682603 T G 3.20E-06 Urinary metabolites RASGRP3 intron 21572414 rs2124437 chr2 33682737 G T 7.78E-04 Oral cancers (chewing tobacco related) RASGRP3 intron 22503698 rs10779917 chr2 33686494 G A 2.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs17013034 chr2 33688129 C T 1.10E-05 Blood Pressure RASGRP3 intron pha003045 rs17013034 chr2 33688129 C T 8.58E-06 Blood Pressure RASGRP3 intron pha003047 rs13385731 chr2 33701890 T C 1.00E-15 Systemic lupus erythematosus RASGRP3 intron 19838193 rs13385731 chr2 33701890 T C 4.00E-06 Systemic lupus erythematosus RASGRP3 intron 23273568 rs1378725 chr2 33708414 T C 4.23E-04 Multiple complex diseases RASGRP3 intron 17554300 rs17013126 chr2 33709961 T C 7.97E-04 Multiple complex diseases RASGRP3 intron 17554300 rs7561821 chr2 33715742 T G 1.88E-04 Alcohol consumption (maxi-drinks) RASGRP3 intron 24277619 rs10495789 chr2 33719109 A G 9.81E-06 Multiple complex diseases RASGRP3 intron 17554300 rs6761582 chr2 33733554 T C 1.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs6746494 chr2 33733719 C G 6.59E-06 Serum metabolites RASGRP3 intron 19043545 rs2305576 chr2 33745208 T C 8.34E-05 Taste perception RASGRP3 intron 22132133 rs4258776 chr2 33772525 G A 2.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs11690827 chr2 33773739 A T 9.94E-04 Type 2 diabetes RASGRP3 intron 17463246 rs6543722 chr2 33832523 C A 8.47E-05 Height / / pha003011 rs1839158 chr2 33855431 C G 1 Drug response to Etoposide / / 17537913 rs10200581 chr2 33861293 C A 7.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2012014 chr2 33862493 T A 9.34E-05 Aortic root size / / 21223598 rs2004037 chr2 33862803 A T 7.85E-04 Acute lung injury / / 22295056 rs6711516 chr2 33895267 G T 1.77E-04 Taste perception / / 22132133 rs11904039 chr2 33897454 A G 1.83E-04 Acute lung injury / / 22295056 rs1550992 chr2 33931075 A G 3.42E-04 Gallstones / / 17632509 rs12988770 chr2 33940918 G A 4.33E-04 Taste perception / / 22132133 rs6706223 chr2 33944002 G A 1.25E-04 Taste perception / / 22132133 rs4670906 chr2 33946932 G A 3.80E-06 Parkinson's disease (familial) / / 18985386 rs17338665 chr2 33947012 A G 2.18E-04 Multiple complex diseases / / 17554300 rs11684598 chr2 33952621 G A 4.58E-05 Taste perception / / 22132133 rs4257379 chr2 33965251 G T 3.19E-04 Taste perception / / 22132133 rs6749326 chr2 33975365 G A 8.96E-05 LDL lipoproteins / / pha002902 rs6758248 chr2 33977878 G A 2.10E-04 Taste perception / / 22132133 rs4670279 chr2 33991952 A G 7.08E-04 Taste perception / / 22132133 rs4313958 chr2 34023020 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17013939 chr2 34036757 C A 6.38E-04 Multiple complex diseases / / 17554300 rs7579548 chr2 34056734 T G 8.51E-06 Glycemic traits (pregnancy) / / 23903356 rs773828 chr2 34103546 A C 4.70E-04 Schizophrenia / / 19197363 rs773823 chr2 34115251 T C 7.10E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs773820 chr2 34116688 G T 7.33E-05 Leukocyte Counts / / pha003091 rs2687208 chr2 34136251 C G 7.94E-04 Multiple complex diseases / / 17554300 rs11675822 chr2 34147919 C T 9.84E-04 Multiple complex diseases / / 17554300 rs7561310 chr2 34150347 G A 2.26E-04 Multiple complex diseases / / 17554300 rs9284729 chr2 34237001 T G 4.00E-05 Pericardial fat / / 22589742 rs2216963 chr2 34259736 A G 8.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6720882 chr2 34264101 A G 2.14E-04 Aortic root size / / 21223598 rs6728854 chr2 34273136 C A 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6543803 chr2 34273293 C T 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1425005 chr2 34283170 G A 4.93E-04 Premature ovarian failure / / 19508998 rs9308945 chr2 34284852 A G 3.00E-10 Hypertension (young onset) / / 19421330 rs6711736 chr2 34284984 G A 3.00E-10 Hypertension (young onset) / / 19421330 rs6729869 chr2 34285194 T A 3.00E-10 Hypertension (young onset) / / 19421330 rs17339029 chr2 34285885 A G 6.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1593293 chr2 34289199 A G 2.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1816151 chr2 34291679 A G 2.00E-05 Urinary metabolites / / 21572414 rs13393038 chr2 34293353 T A 2.60E-05 Urinary metabolites / / 21572414 rs9308946 chr2 34302827 T G 0.000895778 Hypertension (early onset hypertension) / / 22479346 rs10495809 chr2 34305257 G A 3.00E-10 Hypertension (young onset) / / 19421330 rs17014711 chr2 34326938 G A 6.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6708860 chr2 34333297 G A 5.59E-05 Cognitive test performance / / 20125193 rs17470247 chr2 34381971 A G 1.91E-04 Vaspin levels / / 22907691 rs17470247 chr2 34381971 A G 0.0001914 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2193800 chr2 34390610 G A 2.27E-05 Blood Pressure / / pha003043 rs1541636 chr2 34427633 A G 7.28E-04 Taste perception / / 22132133 rs1541636 chr2 34427633 A G 2.24E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1541636 chr2 34427633 A G 9.44E-06 Blood Pressure / / pha003043 rs1988964 chr2 34429224 A G 6.34E-05 Multiple complex diseases / / 17554300 rs1988964 chr2 34429224 A G 2.20E-05 Urinary metabolites / / 21572414 rs6543818 chr2 34445158 C A 9.16E-05 Response to methylphenidate treatment / / 21130132 rs2161025 chr2 34453722 C T 2.50E-05 Urinary metabolites / / 21572414 rs972053 chr2 34458232 G C 2.50E-05 Urinary metabolites / / 21572414 rs7574426 chr2 34460541 A G 9.40E-06 Urinary metabolites / / 21572414 rs11124366 chr2 34467962 C T 3.20E-06 Urinary metabolites / / 21572414 rs2371922 chr2 34474517 C T 4.47E-05 Blood Pressure / / pha003043 rs11687656 chr2 34475820 T G 2.80E-05 Urinary metabolites / / 21572414 rs13407683 chr2 34477438 G A 4.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6733379 chr2 34480075 G T 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6719309 chr2 34499749 A C 2.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1978414 chr2 34505480 C T 2.66E-04 Type 2 diabetes / / 17463246 rs249084 chr2 34515140 C A 6.71E-04 Type 2 diabetes / / 17463246 rs111344 chr2 34516450 T C 5.28E-04 Type 2 diabetes / / 17463246 rs9967777 chr2 34517688 C G 3.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs9967777 chr2 34517688 C G 1.10E-05 Urinary metabolites / / 21572414 rs12613086 chr2 34519779 A G 1.20E-05 Multiple complex diseases / / 17554300 rs6721933 chr2 34542730 G T 9.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs249103 chr2 34548229 A T 6.45E-04 Type 2 diabetes / / 17463246 rs10495813 chr2 34564586 T C 8.84E-05 Body Mass Index / / pha003020 rs10495813 chr2 34564586 T C 8.64E-05 Waist Circumference / / pha003024 rs12712380 chr2 34566647 C T 3.44E-04 Type 2 diabetes / / 17463246 rs41319450 chr2 34567302 C G 2.98E-04 Type 2 diabetes / / 17463246 rs12623550 chr2 34599529 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1583366 chr2 34601927 A G 4.78E-04 Multiple complex diseases / / 17554300 rs1434126 chr2 34610836 C T 9.24E-04 Alzheimer's disease / / 22005930 rs1434126 chr2 34610836 C T 6.88E-04 Tourette syndrome / / 22889924 rs6543833 chr2 34631032 C G 8.00E-08 Ovarian reserve / / 22116950 rs17248142 chr2 34638921 A T 7.74E-04 Multiple complex diseases / / 17554300 rs2887971 chr2 34644109 T C 8.86E-04 Multiple complex diseases / / 17554300 rs892458 chr2 34667749 T C 1.30E-04 Heart Failure / / pha002884 rs10495822 chr2 34672921 G T 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1519911 chr2 34685280 C T 2.10E-05 Urinary metabolites / / 21572414 rs4670084 chr2 34691069 G C 5.40E-06 Urinary metabolites / / 21572414 rs7583467 chr2 34691083 G A 4.99E-04 Heart Failure / / pha002884 rs11889782 chr2 34722626 A G 1.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10495824 chr2 34750545 A G 1.10E-05 Urinary metabolites / / 21572414 rs1022390 chr2 34751803 A C 6.60E-06 Urinary metabolites / / 21572414 rs2371401 chr2 34803638 A C 4.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs41495350 chr2 34817771 G T 5.64E-04 Multiple complex diseases / / 17554300 rs41431451 chr2 34868864 T C 1.76E-04 Multiple complex diseases / / 17554300 rs1358358 chr2 34891689 G A 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7575839 chr2 34902177 A G 8.35E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1527616 chr2 34909001 C T 3.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11683103 chr2 34912850 G A 8.60E-06 Alzheimer's disease (late onset) / / 20885792 rs11683103 chr2 34912850 G A 8.60E-06 Alzheimer's disease (late onset) / / 21460841 rs3856481 chr2 34946284 C G 6.13E-04 Alzheimer's disease / / 17998437 rs380322 chr2 35043996 C T 8.60E-04 Taste perception / / 22132133 rs72795093 chr2 35054313 T C 8.97E-06 Response to amphetamines / / 22952603 rs6725256 chr2 35055879 C T 7.39E-06 Response to amphetamines / / 22952603 rs7559552 chr2 35058421 A C 8.55E-06 Response to amphetamines / / 22952603 rs7608287 chr2 35069807 G T 2.48E-06 Response to amphetamines / / 22952603 rs280691 chr2 35073607 T C 1.66E-05 Creatinine levels / / pha003069 rs72796913 chr2 35074300 T C 1.74E-06 Response to amphetamines / / 22952603 rs72796914 chr2 35075575 C G 1.63E-06 Response to amphetamines / / 22952603 rs72796917 chr2 35078778 C T 1.26E-06 Response to amphetamines / / 22952603 rs72796929 chr2 35090946 T C 1.09E-06 Response to amphetamines / / 22952603 rs280754 chr2 35092762 C T 6.17E-05 Creatinine levels / / pha003069 rs7600259 chr2 35093293 T G 1.00E-06 Response to amphetamines / / 22952603 rs6727092 chr2 35103218 A G 6.80E-06 Response to amphetamines / / 22952603 rs12467773 chr2 35107431 T C 7.98E-06 Response to amphetamines / / 22952603 rs72778810 chr2 35117772 T C 3.38E-06 Response to amphetamines / / 22952603 rs1911544 chr2 35143864 T C 1.58E-04 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs1395697 chr2 35144127 A C 9.02E-04 Type 2 diabetes / / 17463246 rs6543889 chr2 35197402 T A 1.02E-04 Cholesterol / / 17255346 rs11124408 chr2 35198305 T C 5.74E-05 Cholesterol / / 17255346 rs11124408 chr2 35198305 T C 7.15E-05 Gallstones / / 17632509 rs11124408 chr2 35198305 T C 5.40E-04 Coronary heart disease / / 21606135 rs10184960 chr2 35201802 G C 1.17E-04 Cholesterol / / 17255346 rs10184960 chr2 35201802 G C 9.08E-04 Type 2 diabetes / / 17463246 rs1377421 chr2 35213052 G C 5.86E-04 Multiple complex diseases / / 17554300 rs1377421 chr2 35213052 G C 7.40E-04 Smoking initiation / / 24665060 rs17387182 chr2 35224451 C T 7.75E-04 Alcohol dependence / / 20201924 rs17398711 chr2 35235120 C T 7.54E-05 Alcohol dependence / / 20201924 rs17398711 chr2 35235120 C T 7.54E-05 Alcoholism / / pha002891 rs896824 chr2 35237370 A G 1.58E-04 Cholesterol / / 17255346 rs6710736 chr2 35248047 A G 3.02E-04 Cholesterol / / 17255346 rs6710736 chr2 35248047 A G 8.92E-04 Type 2 diabetes / / 17463246 rs6739609 chr2 35248062 G A 3.02E-04 Cholesterol / / 17255346 rs6739609 chr2 35248062 G A 6.03E-04 Type 2 diabetes / / 17463246 rs1453266 chr2 35250422 T C 3.04E-04 Cholesterol / / 17255346 rs1453266 chr2 35250422 T C 9.58E-04 Type 2 diabetes / / 17463246 rs1453267 chr2 35250716 A G 7.66E-04 Type 2 diabetes / / 17463246 rs3920465 chr2 35292658 C A 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12712411 chr2 35293343 T G 9.30E-04 Myocardial Infarction / / pha002873 rs1955381 chr2 35295078 G A 6.02E-04 Type 2 diabetes / / 17463246 rs13005421 chr2 35298411 G A 5.46E-04 Smoking initiation / / 24665060 rs1922357 chr2 35304850 A T 3.70E-04 Type 2 diabetes / / 17463246 rs17016225 chr2 35370851 A G 4.19E-04 Serum selenium levels / / 23698163 rs1439845 chr2 35411425 G A 2.00E-04 Smoking behavior / / 20418888 rs4670450 chr2 35435104 G A 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17016345 chr2 35447145 G A 2.71E-08 Multiple complex diseases / / 17554300 rs726698 chr2 35455341 A T 1.15E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs726698 chr2 35455341 A T 2.20E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs12712425 chr2 35465744 G A 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6750486 chr2 35526918 C T 6.00E-06 Conduct disorder (symptom count) / / 20585324 rs6543930 chr2 35572015 T C 1.61E-04 Alzheimer's disease / / 22005930 rs7586043 chr2 35572711 G A 2.94E-04 Alzheimer's disease / / 22005930 rs7590763 chr2 35575340 T C 3.66E-04 Alzheimer's disease / / 22005930 rs7584802 chr2 35577771 C T 2.76E-04 Alzheimer's disease / / 22005930 rs6751791 chr2 35581997 G A 2.21E-04 Alzheimer's disease / / 22005930 rs17016489 chr2 35585929 C A 2.43E-04 Multiple complex diseases / / 17554300 rs7587787 chr2 35588953 C G 2.83E-04 Alzheimer's disease / / 22005930 rs6756976 chr2 35589317 T A 2.61E-04 Alzheimer's disease / / 22005930 rs17823215 chr2 35589972 A G 2.27E-04 Alzheimer's disease / / 22005930 rs17772161 chr2 35590409 C G 2.62E-04 Alzheimer's disease / / 22005930 rs7598399 chr2 35591234 G A 2.25E-04 Alzheimer's disease / / 22005930 rs12993283 chr2 35592405 C T 3.86E-04 Alzheimer's disease / / 22005930 rs17399446 chr2 35600932 T A 4.91E-04 Alzheimer's disease / / 22005930 rs4577259 chr2 35607078 A G 4.50E-04 Alzheimer's disease / / 22005930 rs17016558 chr2 35614444 T C 1.28E-04 Schizophrenia / / 19197363 rs4670466 chr2 35622544 A T 2.13E-04 Type 2 diabetes / / 17463246 rs4670467 chr2 35622660 G A 2.06E-04 Type 2 diabetes / / 17463246 rs6756157 chr2 35624746 T C 7.35E-04 Schizophrenia / / 19197363 rs4254484 chr2 35643579 A G 8.98E-04 Multiple complex diseases / / 17554300 rs13012972 chr2 35644367 T C 7.59E-04 Type 2 diabetes / / 17463246 rs11885690 chr2 35654708 T C 1.33E-05 Biliary atresia / / 20460270 rs4513272 chr2 35659858 A G 3.51E-05 Weight / / pha003026 rs13402855 chr2 35662797 C T 2.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs2719085 chr2 35674924 G A 3.55E-05 Weight / / pha003026 rs4297857 chr2 35675611 C A 8.94E-05 Body Mass Index / / pha003006 rs4297857 chr2 35675611 C A 6.29E-05 Body Mass Index / / pha003014 rs4297857 chr2 35675611 C A 1.01E-06 Waist Circumference / / pha003024 rs4297857 chr2 35675611 C A 4.87E-07 Weight / / pha003026 rs2714589 chr2 35676713 C T 3.67E-05 Weight / / pha003026 rs2719121 chr2 35713309 G A 8.23E-05 Body Mass Index / / pha003014 rs11681520 chr2 35737252 C G 7.82E-04 Alzheimer's disease / / 17998437 rs1583756 chr2 35753511 T C 9.03E-05 Height / / pha003011 rs1439706 chr2 35764414 T C 5.75E-06 Asthma (childhood onset) / / 23829686 rs7591339 chr2 35825598 C T 6.40E-04 Type 2 diabetes / / 17463246 rs1371418 chr2 35830334 G A 6.58E-04 Type 2 diabetes / / 17463246 rs1371419 chr2 35833642 T C 5.19E-04 Body mass index / / 21701565 rs7570146 chr2 35844752 G T 8.96E-04 Type 2 diabetes / / 17463246 rs1439691 chr2 35851282 A C 6.67E-04 Type 2 diabetes / / 17463246 rs10495843 chr2 35859342 G T 7.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1439693 chr2 35859748 T C 9.52E-04 Parkinson's disease / / 17052657 rs17328874 chr2 35863393 A G 8.59E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1439697 chr2 35880978 T C 1.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6744761 chr2 35933774 A G 4.97E-05 Type 2 diabetes / / 17463246 rs9308980 chr2 35937722 G C 1.90E-05 Urinary metabolites / / 21572414 rs1401220 chr2 35944694 A G 9.99E-05 Type 2 diabetes / / 17463246 rs1401220 chr2 35944694 A G 2.30E-05 Urinary metabolites / / 21572414 rs1401219 chr2 35944777 G A 1.24E-04 Type 2 diabetes / / 17463246 rs1401219 chr2 35944777 G A 2.30E-05 Urinary metabolites / / 21572414 rs6737499 chr2 35945993 T C 1.20E-05 Urinary metabolites / / 21572414 rs4016189 chr2 35967123 G C 2.70E-06 Urinary metabolites / / 21572414 rs17017391 chr2 36001197 C A 2.14E-05 Tunica Media / / pha003036 rs7557606 chr2 36014002 A G 2.80E-05 Urinary metabolites / / 21572414 rs10166465 chr2 36020005 T C 7.24E-05 Menopause (age at onset) / / 19448619 rs7592322 chr2 36077340 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6751249 chr2 36079256 T C 1.23E-05 Bladder cancer / / 24163127 rs17017699 chr2 36084515 T C 1.52E-04 Multiple complex diseases / / 17554300 rs10173700 chr2 36097070 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1401775 chr2 36098961 T C 8.83E-05 Panic disorder / / 19165232 rs2968576 chr2 36123261 T G 4.95E-04 Taste perception / / 22132133 rs1533969 chr2 36125308 G A 2.14E-05 Parkinson's disease / / 19915575 rs2949065 chr2 36132943 C T 3.61E-05 Parkinson's disease / / 19915575 rs12712470 chr2 36135030 C T 9.58E-05 Elbow pain / / pha003008 rs12712470 chr2 36135030 C T 5.95E-05 Waist Circumference / / pha003024 rs12712470 chr2 36135030 C T 4.12E-05 Weight / / pha003026 rs1533971 chr2 36136638 G A 9.78E-05 Elbow pain / / pha003008 rs1533971 chr2 36136638 G A 5.52E-05 Waist Circumference / / pha003024 rs1533971 chr2 36136638 G A 3.68E-05 Weight / / pha003026 rs11900940 chr2 36150624 C T 2.14E-05 Waist Circumference / / pha003024 rs11900940 chr2 36150624 C T 6.10E-05 Weight / / pha003026 rs2968624 chr2 36162477 A G 2.53E-04 Smoking initiation / / 24665060 rs2968625 chr2 36163832 A G 4.03E-04 Alcohol dependence / / 20201924 rs17017873 chr2 36166844 G C 2.14E-04 Obesity (early onset extreme) / / 23563609 rs2949081 chr2 36169533 G T 4.03E-04 Alcohol dependence / / 20201924 rs2968629 chr2 36170939 C T 9.63E-05 Body Mass Index / / pha003019 rs13409385 chr2 36176752 C T 1.67E-05 Alzheimer's disease (late onset) / / 21379329 rs13016974 chr2 36180191 C G 8.01E-04 Multiple complex diseases / / 17554300 rs2020327 chr2 36193739 T C 8.67E-04 Type 2 diabetes / / 17463246 rs2020327 chr2 36193739 T C 4.70E-04 Multiple complex diseases / / 17554300 rs833764 chr2 36194180 T C 1.95E-05 Body Mass Index / / pha003019 rs833764 chr2 36194180 T C 9.09E-05 Body Mass Index / / pha003022 rs1705046 chr2 36211712 A G 6.82E-05 Body Mass Index / / pha003019 rs833787 chr2 36224052 T C 4.94E-06 Body Mass Index / / pha003019 rs833787 chr2 36224052 T C 6.49E-05 Body Mass Index / / pha003020 rs833787 chr2 36224052 T C 9.05E-06 Body Mass Index / / pha003022 rs305188 chr2 36251327 G C 4.69E-04 Type 2 diabetes / / 17463246 rs7566742 chr2 36257825 C A 1.35E-04 Type 2 diabetes / / 17463246 rs2251598 chr2 36261471 G T 2.74E-04 Taste perception / / 22132133 rs1873117 chr2 36263467 T C 3.84E-04 Nicotine dependence / / 17158188 rs4670135 chr2 36270756 C T 3.90E-05 HIV-1 control / / 20041166 rs305208 chr2 36274603 G A 4.25E-04 Type 2 diabetes / / 17463246 rs305205 chr2 36276269 G T 9.97E-04 Type 2 diabetes / / 17463246 rs305204 chr2 36276750 T C 8.08E-04 Type 2 diabetes / / 17463246 rs305203 chr2 36277969 G A 9.05E-04 Type 2 diabetes / / 17463246 rs305202 chr2 36278224 G A 7.98E-04 Type 2 diabetes / / 17463246 rs177541 chr2 36283088 G A 5.79E-04 Type 2 diabetes / / 17463246 rs2666128 chr2 36287452 C T 3.46E-05 Parkinson's disease / / pha002868 rs10495863 chr2 36288320 G A 9.88E-04 Type 2 diabetes / / 17463246 rs10495863 chr2 36288320 G A 6.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2666138 chr2 36331157 G A 3.00E-07 Alopecia areata / / 22027810 rs1686103 chr2 36354621 A C 3.26E-05 Parkinson's disease / / pha002868 rs17018354 chr2 36383466 G A 5.42E-04 Type 2 diabetes / / 17463246 rs12614272 chr2 36386902 T C 4.13E-05 Lymphocyte counts / / pha003094 rs12614272 chr2 36386902 T C 2.29E-05 Neutrophil count / / pha003095 rs11674150 chr2 36447481 G A 6.62E-04 Multiple complex diseases / / 17554300 rs11124503 chr2 36455837 G A 3.11E-04 Multiple complex diseases / / 17554300 rs1529267 chr2 36464050 T C 4.64E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1919818 chr2 36480422 T C 4.95E-04 Insulin resistance / / 21901158 rs2246009 chr2 36483942 A G 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699168 chr2 36484948 A G 7.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552000 chr2 36489670 C G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2551999 chr2 36489820 T C 7.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6704972 chr2 36490624 G T 6.38E-04 Alzheimer's disease / / 17998437 rs12104793 chr2 36491004 G A 5.77E-04 Alzheimer's disease / / 17998437 rs2552046 chr2 36491041 A C 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699179 chr2 36493401 G T 8.55E-04 Alzheimer's disease / / 17998437 rs1881777 chr2 36494095 C G 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881778 chr2 36494176 C T 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881778 chr2 36494176 C T 8.59E-04 Acute lung injury / / 22295056 rs2699181 chr2 36495030 C T 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194577 chr2 36496233 C T 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194577 chr2 36496233 C T 7.54E-04 Acute lung injury / / 22295056 rs726946 chr2 36497171 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs726947 chr2 36497312 C T 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17387739 chr2 36498265 C T 2.02E-04 Alzheimer's disease / / 17998437 rs2699184 chr2 36500798 T C 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699184 chr2 36500798 T C 9.01E-04 Acute lung injury / / 22295056 rs2699185 chr2 36501147 C T 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699185 chr2 36501147 C T 9.01E-04 Acute lung injury / / 22295056 rs2552037 chr2 36505165 A C 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552035 chr2 36507300 G A 5.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs2552034 chr2 36507357 C T 5.61E-05 Suicide attempts in bipolar disorder / / 21423239 rs2552029 chr2 36509516 A C 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552028 chr2 36510643 A G 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552028 chr2 36510643 A G 7.54E-04 Acute lung injury / / 22295056 rs2699190 chr2 36510725 A T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552027 chr2 36511930 C G 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552027 chr2 36511930 C G 7.54E-04 Acute lung injury / / 22295056 rs2243925 chr2 36513791 G A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2161905 chr2 36516173 G A 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699193 chr2 36516663 A G 1.25E-04 Alzheimer's disease / / 17998437 rs2699193 chr2 36516663 A G 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6544004 chr2 36518699 A G 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6733100 chr2 36520350 A G 8.02E-05 Alzheimer's disease / / 17998437 rs6733100 chr2 36520350 A G 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699187 chr2 36521759 A G 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1863080 chr2 36526436 T G 8.00E-06 Anthropometric traits / / 19260139 rs4670143 chr2 36549966 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10490672 chr2 36571139 A C 6.14E-04 Alcohol dependence / / 21314694 rs4670544 chr2 36580631 C T 0.000681658 Hypertension (early onset hypertension) / / 22479346 rs9308991 chr2 36596663 C G 9.38E-04 Multiple complex diseases CRIM1 intron 17554300 rs11124511 chr2 36602368 C T 1.60E-05 Urinary metabolites CRIM1 intron 21572414 rs3770939 chr2 36617528 G A 7.72E-04 Response to taxane treatment (placlitaxel) CRIM1 intron 23006423 rs12466450 chr2 36620953 C T 1.00E-04 Anxiety spectrum disorders CRIM1 intron 20368705 rs3770935 chr2 36625388 C T 4.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRIM1 intron 23648065 rs4670145 chr2 36627725 A G 8.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRIM1 intron 23648065 rs3770924 chr2 36631779 A G 1.30E-04 IgE levels in asthmatics CRIM1 intron 23967269 rs7562790 chr2 36673555 T G 8.00E-09 Ventricular conduction CRIM1 intron 21076409 rs7562790 chr2 36673555 T G 4.90E-06 Urinary metabolites CRIM1 intron 21572414 rs7562790 chr2 36673555 T G 6.00E-04 Taste perception CRIM1 intron 22132133 rs848512 chr2 36675530 A G 1.00E-06 IgE levels in asthmatics CRIM1 intron 23967269 rs3770876 chr2 36679028 T G 8.40E-06 Urinary metabolites CRIM1 intron 21572414 rs711254 chr2 36680848 A G 6.73E-06 IgE levels in asthmatics CRIM1 intron 23967269 rs3770866 chr2 36690093 C T 4.50E-04 Insulin resistance CRIM1 intron 21901158 rs4670560 chr2 36702052 C T 6.81E-04 Insulin resistance CRIM1 intron 21901158 rs3770839 chr2 36717620 G A 0.0000806 Salmonella-induced pyroptosis CRIM1 intron 22837397 rs3899034 chr2 36717819 G A 0.0000955 Salmonella-induced pyroptosis CRIM1 intron 22837397 rs848529 chr2 36732171 T C 0.0002711 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs848529 chr2 36732171 T C 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs884215 chr2 36742955 A G 2.69E-05 Bipolar disorder CRIM1 intron 19488044 rs884215 chr2 36742955 A G 2.34E-05 Bipolar Disorder CRIM1 intron pha002863 rs2287082 chr2 36745012 C A 1.20E-05 Urinary metabolites CRIM1 intron 21572414 rs17480811 chr2 36745949 C A 0.0002713 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17480811 chr2 36745949 C A 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848523 chr2 36747656 T C 2.10E-05 Blood Phenotypes CRIM1 intron 17903294 rs17018986 chr2 36751421 A G 0.0002827 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17018986 chr2 36751421 A G 2.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs3821153 chr2 36753122 T G 8.05E-04 Insulin resistance CRIM1 intron 21901158 rs17019000 chr2 36755937 T C 0.0002869 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17019000 chr2 36755937 T C 2.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs17019002 chr2 36756196 G A 0.0002866 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17019002 chr2 36756196 G A 2.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs11681392 chr2 36758100 G T 1.60E-05 Urinary metabolites CRIM1 intron 21572414 rs882842 chr2 36758284 A C 0.0003078 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs882842 chr2 36758284 A C 3.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848516 chr2 36764402 A G 0.000246 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs848516 chr2 36764402 A G 2.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848607 chr2 36770192 G A 1.86E-04 Alzheimer's disease CRIM1 intron 22005930 rs981355 chr2 36770401 C T 3.23E-05 Lipoproteins CRIM1 intron pha003079 rs848606 chr2 36770736 G T 1.28E-04 Alzheimer's disease CRIM1 intron 22005930 rs12712508 chr2 36771309 A G 8.20E-04 Alzheimer's disease CRIM1 intron 22005930 rs848605 chr2 36773260 G A 2.39E-04 Alzheimer's disease CRIM1 intron 22005930 rs848603 chr2 36773868 C T 2.17E-04 Alzheimer's disease CRIM1 intron 22005930 rs10189344 chr2 36778887 A C 1.33E-04 Lymphocyte counts / / 22286170 rs1533948 chr2 36781138 A G 1.53E-05 Lipoproteins FEZ2 intron pha003079 rs848641 chr2 36785169 C T 8.00E-04 Body mass index FEZ2 intron 24827717 rs13406184 chr2 36791226 T C 4.07E-05 Lipoproteins FEZ2 intron pha003079 rs848619 chr2 36810769 T C 4.35E-05 Lipoproteins FEZ2 intron pha003079 rs12105545 chr2 36814201 G A 2.85E-05 Lipoproteins FEZ2 intron pha003079 rs918066 chr2 36838600 T C 9.92E-05 Lipoproteins / / pha003079 rs10164588 chr2 36839723 T A 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs4670153 chr2 36848313 G C 2.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12464610 chr2 36849808 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7422754 chr2 36851079 A G 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11124523 chr2 36851264 C T 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7600979 chr2 36854548 C T 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4595955 chr2 36882586 T C 3.98E-05 Parkinson's disease (motor and cognition) / / 22658654 rs4595955 chr2 36882586 T C 3.98E-05 Immune response to anthrax vaccine / / 22658931 rs13021543 chr2 36883858 A G 9.80E-05 Parkinson's disease (motor and cognition) / / 22658654 rs13021543 chr2 36883858 A G 9.80E-05 Immune response to anthrax vaccine / / 22658931 rs6755881 chr2 36895652 C G 2.76E-04 Multiple complex diseases / / 17554300 rs6713334 chr2 36904442 C A 1.34E-04 Multiple complex diseases / / 17554300 rs11124529 chr2 36913267 C T 9.32E-04 Insulin resistance / / 21901158 rs6544028 chr2 36928030 T C 2.62E-04 Age-related macular degeneration VIT intron 22125219 rs9308994 chr2 36930788 G C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) VIT intron 17982456 rs10460526 chr2 36932843 C T 9.43E-04 Stroke VIT intron pha002887 rs4670165 chr2 36942266 C A 2.79E-04 Multiple complex diseases VIT intron 17554300 rs4670165 chr2 36942266 C A 1.10E-05 Urinary metabolites VIT intron 21572414 rs1015695 chr2 36959885 A G 2.80E-05 Urinary metabolites VIT intron 21572414 rs2372711 chr2 36962557 A G 4.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines VIT intron 21844884 rs12469652 chr2 36977116 A G 3.95E-05 Parkinson's disease VIT intron 21812969 rs4670600 chr2 36979512 A G 3.41E-05 Triglycerides VIT intron pha002904 rs12997998 chr2 36980698 A C 1.20E-05 Urinary metabolites VIT intron 21572414 rs1468811 chr2 36993811 T C 3.64E-04 Multiple complex diseases VIT intron 17554300 rs4670605 chr2 36996398 A G 3.43E-04 Type 2 diabetes VIT intron 17463246 rs17494117 chr2 37015371 C T 4.10E-05 Serum albumin level VIT intron pha003084 rs974966 chr2 37048522 A G 2.00E-05 Hypothyroidism / / 22493691 rs2372715 chr2 37049287 G A 7.84E-04 Multiple complex diseases / / 17554300 rs888053 chr2 37049563 A T 6.00E-05 Hypothyroidism / / 22493691 rs3770781 chr2 37078839 A G 5.08E-04 Myopia (pathological) STRN intron 21095009 rs2540923 chr2 37094945 A G 1.50E-05 HIV-1 control STRN intron 20041166 rs2691111 chr2 37102129 G A 1.50E-05 HIV-1 control STRN intron 20041166 rs13430716 chr2 37136517 A G 1.50E-05 HIV-1 control STRN intron 20041166 rs11124552 chr2 37142754 A G 2.68E-05 Multiple complex diseases STRN intron 17554300 rs11124555 chr2 37176213 G A 2.01E-05 HIV-1 viral setpoint STRN intron 22174851 rs3770775 chr2 37180207 C A 3.50E-04 Lipopolysaccharide induced cytokine levels STRN intron 23823136 rs3770770 chr2 37192866 C T 9.80E-04 Multiple complex diseases STRN intron 17554300 rs3770770 chr2 37192866 C T 9.65E-04 Response to cytidine analogues (gemcitabine) STRN intron 24483146 rs1007823 chr2 37230728 T A,C,G 6.01E-05 Kawasaki disease HEATR5B cds-synon 22081228 rs17038861 chr2 37233265 T G 2.34E-04 Multiple complex diseases HEATR5B intron 17554300 rs17020136 chr2 37248015 T C 2.00E-09 Ventricular conduction HEATR5B intron 21076409 rs1008838 chr2 37252235 A G 7.81E-04 Alzheimer's disease HEATR5B intron 24755620 rs7581702 chr2 37252852 G C 2.05E-04 Multiple complex diseases HEATR5B intron 17554300 rs2372914 chr2 37264675 T C 9.28E-06 Stroke HEATR5B intron 22306652 rs13423928 chr2 37277811 A G 6.80E-04 Alzheimer's disease HEATR5B intron 24755620 rs4233920 chr2 37336720 A G 4.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) EIF2AK2 intron 24023788 rs4648195 chr2 37363968 CG C 7.79E-04 Type 2 diabetes EIF2AK2 intron 17463246 rs4648196 chr2 37363968 C G 7.79E-04 Type 2 diabetes EIF2AK2 intron 17463246 rs2254958 chr2 37376291 G A 9.13E-05 Cardiovascular disease EIF2AK2 UTR-5 pha003065 rs11124565 chr2 37410316 T G 2.61E-05 Schizophrenia SULT6B1 intron 20832056 rs11895771 chr2 37412935 T G 7.97E-06 Schizophrenia SULT6B1 intron 20832056 rs11895771 chr2 37412935 T G 3.95E-04 Alcohol dependence SULT6B1 intron 21314694 rs6724820 chr2 37414431 A C 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SULT6B1 intron 20877124 rs7340131 chr2 37416494 G A,C 4.95E-04 Multiple complex diseases / / 17554300 rs2239650 chr2 37438764 A G 8.22E-04 Acute lung injury CEBPZ intron 22295056 rs2041840 chr2 37467264 T C 9.00E-06 Chronic lymphocytic leukemia C2orf56 intron 24292274 rs1056021 chr2 37480249 A G 3.28E-04 Lung function (forced expiratory volume in 1 second) PRKD3 UTR-3 17255346 rs3770764 chr2 37489877 G A 1.98E-04 Height PRKD3 intron 17255346 rs2300885 chr2 37496276 T A,C,G 1.50E-05 Urinary metabolites PRKD3 intron 21572414 rs2160394 chr2 37499406 C T 1.40E-05 Urinary metabolites PRKD3 intron 21572414 rs141998414 chr2 37513340 C T 0.000058 Breast cancer(er negative) PRKD3 missense 23555315 rs141998414 chr2 37513340 C T 0.0002 Breast cancer PRKD3 missense 23555315 rs2287091 chr2 37513586 A G 1.27E-04 Multiple complex diseases PRKD3 intron 17554300 rs10204434 chr2 37513670 A G 1.96E-04 Multiple complex diseases PRKD3 intron 17554300 rs10181140 chr2 37513763 G T 7.70E-05 Personality dimensions PRKD3 intron 18957941 rs10181140 chr2 37513763 G T 7.59E-04 Suicide attempts in bipolar disorder PRKD3 intron 21041247 rs6754376 chr2 37527164 A G 6.91E-05 Panic disorder PRKD3 intron 19165232 rs4670688 chr2 37541060 A G 4.00E-06 Urinary metabolites PRKD3 intron 21572414 rs1158219 chr2 37546820 T A 3.51E-05 Bipolar disorder / / 19488044 rs1158219 chr2 37546820 T A 3.60E-05 Bipolar Disorder / / pha002858 rs6734118 chr2 37559355 C A 3.35E-05 Type 1 diabetes / / 18978792 rs6734118 chr2 37559355 C A 0.00018856 Primary sclerosing cholangitis / / 23603763 rs6708524 chr2 37572687 G A 9.58E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs3821142 chr2 37575287 C T 9.78E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs10179447 chr2 37578208 G A 9.80E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs2373000 chr2 37592628 C T 7.00E-09 Schizophrenia QPCT intron 23974872 rs3770748 chr2 37595525 A G 5.86E-04 Response to cytidine analogues (gemcitabine) QPCT intron 24483146 rs3770745 chr2 37596089 C T 1.68E-08 Chronic lymphocytic leukemia QPCT intron 23770605 rs7582749 chr2 37599337 C G 3.70E-04 Crohn's disease QPCT intron 17684544 rs6544071 chr2 37600793 G A 8.04E-04 Insulin resistance / / 21901158 rs1024816 chr2 37601208 A G 1.72E-06 Osteoarthritis / / 22763110 rs6713585 chr2 37624938 G A 3.54E-04 Insulin resistance / / 21901158 rs10173794 chr2 37629222 A G 7.50E-05 Major depressive disorder / / 21621269 rs13002028 chr2 37646632 A C 4.40E-04 Major depressive disorder / / 21042317 rs4490163 chr2 37655077 T C 5.36E-04 Tourette syndrome / / 22889924 rs888098 chr2 37684741 C T 5.87E-05 Cognitive test performance / / 20125193 rs2192947 chr2 37690633 T C 4.59E-04 Smoking quantity / / 24665060 rs6724538 chr2 37728018 G T 5.20E-06 Urinary metabolites / / 21572414 rs960902 chr2 37731665 G A 8.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs10178620 chr2 37743379 G T 3.86E-05 Cognitive test performance / / 20125193 rs4352210 chr2 37750980 A G 2.00E-06 RR interval (heart rate) / / 20031603 rs6730320 chr2 37804964 G T 8.24E-05 Serum metabolites / / 19043545 rs4140806 chr2 37831162 T C 3.80E-04 Type 2 diabetes / / 17463249 rs917732 chr2 37831553 A G 4.81E-05 Sudden cardiac arrest / / 21658281 rs10490281 chr2 37848297 G A 8.31E-04 Multiple complex diseases / / 17554300 rs6729121 chr2 37855222 T C 6.44E-05 Inflammation / / pha002897 rs17021160 chr2 37864069 G T 2.80E-05 Urinary metabolites / / 21572414 rs2079998 chr2 37865070 C T 2.40E-05 Urinary metabolites / / 21572414 rs12475180 chr2 37888538 A G 5.15E-04 Alzheimer's disease CDC42EP3 intron 17998437 rs6757232 chr2 37904904 A T 2.71E-04 Multiple complex diseases / / 17554300 rs10195538 chr2 37917363 A G 1.38E-04 Multiple complex diseases / / 17554300 rs4670766 chr2 37940542 T C 2.00E-06 Total ventricular volume / / 21116278 rs12616929 chr2 37947741 T G 0.0002132 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12616929 chr2 37947741 T G 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1035025 chr2 37949160 T C 8.89E-06 Coronary heart disease / / pha003031 rs1476873 chr2 37949251 A G 6.98E-04 Schizophrenia / / 19197363 rs13012266 chr2 37957480 T C 7.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6725186 chr2 37958369 G A 8.15E-04 Insulin resistance / / 21901158 rs6733157 chr2 37960368 C T 1.91E-06 Coronary heart disease / / pha003031 rs17511102 chr2 37960613 A T 2.00E-18 Height / / 20881960 rs17511102 chr2 37960613 A T 2.00E-08 Height / / 23563607 rs604381 chr2 37977017 G T 8.00E-06 Conduct disorder (interaction) / / 18846501 rs2373298 chr2 37987192 G T 2.26E-06 Esophageal cancer (squamous cell) / / 22960999 rs7593725 chr2 37996799 A G 2.75E-04 Acute lung injury / / 22295056 rs13410013 chr2 37998488 C T 2.72E-04 Acute lung injury / / 22295056 rs9973697 chr2 37999684 G A 6.38E-04 Acute lung injury / / 22295056 rs10209437 chr2 38000571 T C 5.07E-04 Acute lung injury / / 22295056 rs10197084 chr2 38000588 C G 5.93E-04 Acute lung injury / / 22295056 rs10495872 chr2 38003615 A G 3.02E-05 Pulmonary function / / 17903307 rs6727100 chr2 38004431 G T 3.26E-04 Multiple complex diseases / / 17554300 rs13404698 chr2 38009280 A G 5.83E-04 Acute lung injury / / 22295056 rs6718541 chr2 38009492 A G 7.49E-04 Acute lung injury / / 22295056 rs6544107 chr2 38009648 C T 6.23E-04 Acute lung injury / / 22295056 rs10165941 chr2 38010925 G A 7.43E-05 Coronary heart disease / / pha003031 rs934222 chr2 38012814 C A 6.44E-05 Coronary heart disease / / pha003031 rs877053 chr2 38012935 G A 5.45E-04 HIV-1 viral setpoint / / 17641165 rs13007266 chr2 38018438 C T 1.12E-08 Metabolite levels / / 23281178 rs1579491 chr2 38018661 G A 6.77E-04 Coronary heart disease / / 21606135 rs1579491 chr2 38018661 G A 1.48E-04 Major depressive disorder / / 22472876 rs867574 chr2 38021498 T C 4.42E-05 Multiple sclerosis / / 20598377 rs1367150 chr2 38035290 T G 0.000773 Salmonella-induced pyroptosis / / 22837397 rs4670779 chr2 38044344 C T 4.00E-06 Bone mineral density (spine) / / 19079262 rs11899949 chr2 38049069 A G 6.70E-05 Diabetic retinopathy / / 21441570 rs10191189 chr2 38053651 C T 6.14E-05 Alzheimer's disease / / 22832961 rs10167502 chr2 38053726 A T 5.00E-05 Alzheimer's disease / / 22832961 rs1430014 chr2 38060583 T G 5.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1864432 chr2 38064671 C T 7.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17411119 chr2 38066683 T C 7.59E-05 Prostate cancer / / pha002877 rs7598641 chr2 38066716 T C 6.12E-05 Prostate cancer / / pha002877 rs766231 chr2 38067593 T C 3.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2707243 chr2 38071114 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9967771 chr2 38092624 C T 6.94E-04 Multiple complex diseases / / 17554300 rs2707237 chr2 38095622 G A 5.40E-06 Urinary metabolites / / 21572414 rs17021567 chr2 38108094 A C 5.63E-04 Coronary heart disease / / 21606135 rs1430023 chr2 38110077 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6706045 chr2 38115194 T C 5.70E-06 Urinary metabolites / / 21572414 rs1991582 chr2 38125923 C G,T 1.80E-05 Urinary metabolites / / 21572414 rs884342 chr2 38128777 T G 0.0000956 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1430035 chr2 38133608 A G 4.76E-05 Prion diseases / / 22210626 rs4670791 chr2 38146418 G A 1.45E-04 Prion diseases / / 22210626 rs6716296 chr2 38174964 A G 8.89E-06 Brain structure FAM82A1 intron 22504417 rs2197561 chr2 38178362 T C 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) FAM82A1 intron 23648065 rs1446296 chr2 38216416 T G 7.14E-04 White matter integrity FAM82A1 intron 22425255 rs10181021 chr2 38221095 A C,G 8.66E-04 White matter integrity FAM82A1 intron 22425255 rs2373327 chr2 38222086 A G 2.40E-04 Endometriosis FAM82A1 intron 21151130 rs1374196 chr2 38228668 A G 7.26E-05 Age-related macular degeneration FAM82A1 intron pha000002 rs17021897 chr2 38272813 A G 4.86E-05 HDL cholesterol FAM82A1 intron pha003075 rs6741148 chr2 38277832 T G 4.00E-06 Erectile dysfunction and prostate cancer treatment FAM82A1 intron 20932654 rs1800440 chr2 38298139 T C 1.30E-05 Systemic lupus erythematosus CYP1B1 missense pha002867 rs1056836 chr2 38298203 C G 1 Drug response to Docetaxel / / 18187806 rs1056836 chr2 38298203 C G 1 Drug response to Paclitaxel / / 19474787 rs4646430 chr2 38306415 C G 8.52E-06 Duodenal ulcer / / 22387998 rs162556 chr2 38306454 G A 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4646429 chr2 38306935 C T 8.25E-06 Duodenal ulcer / / 22387998 rs10175338 chr2 38307643 G T 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10175338 chr2 38307643 G T 9.25E-06 Duodenal ulcer / / 22387998 rs17022010 chr2 38331931 A T 5.30E-04 Coronary heart disease / / 21606135 rs232535 chr2 38332303 C T 1.61E-04 Coronary heart disease / / 21606135 rs3795980 chr2 38350814 G T 6.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs3795980 chr2 38350814 G T 6.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10204598 chr2 38351969 G A 2.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2432662 chr2 38352174 C T 8.57E-04 Coronary heart disease / / 21606135 rs17491111 chr2 38353487 T C 3.63E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs232620 chr2 38358664 A G 4.03E-04 Coronary heart disease / / 21606135 rs10469900 chr2 38367083 T C 5.51E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs10188379 chr2 38371476 G C 7.19E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs918804 chr2 38373364 A T 6.72E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs170818 chr2 38374567 C T 2.50E-04 Coronary heart disease CYP1B1-AS1 intron 21606135 rs10196846 chr2 38379110 C A 0.0000569 Amyotrophic lateral sclerosis CYP1B1-AS1 intron 23587638 rs232576 chr2 38386220 A G 4.18E-06 Coronary heart disease CYP1B1-AS1 intron 21606135 rs232574 chr2 38387227 C A 4.54E-04 Lung function (forced vital capacity) CYP1B1-AS1 intron 24023788 rs232569 chr2 38394363 C T 4.89E-05 Coronary heart disease CYP1B1-AS1 intron 21606135 rs2194381 chr2 38404795 T C 9.17E-04 Type 2 diabetes CYP1B1-AS1 intron 17463246 rs13385748 chr2 38405869 G A 4.11E-04 Type 2 diabetes CYP1B1-AS1 intron 17463246 rs2447738 chr2 38411167 C T 3.66E-05 Coronary heart disease / / 21606135 rs183487 chr2 38414541 T C 6.45E-04 Substance dependence / / 21818250 rs232587 chr2 38420853 T A 6.36E-05 Coronary heart disease / / 21606135 rs17022251 chr2 38431991 T C 1.98E-06 Multiple complex diseases / / 17554300 rs13432312 chr2 38490324 T C 8.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12468478 chr2 38509407 G A 1.64E-05 Smoking cessation / / 18519826 rs12468478 chr2 38509407 G A 6.80E-05 Personality dimensions / / 18957941 rs875653 chr2 38512522 C T 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs875654 chr2 38512710 T C 4.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs13417898 chr2 38516428 T C 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs11883614 chr2 38517488 A C 5.42E-05 Smoking cessation / / 18519826 rs11894455 chr2 38517515 C T 8.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs4670861 chr2 38520856 T C 8.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs3755025 chr2 38521058 T C 8.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs2305245 chr2 38537626 A C 3.42E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs12712583 chr2 38542573 T C 3.30E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10202238 chr2 38542790 T C 6.37E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs1022076 chr2 38544049 C T 3.29E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6544157 chr2 38546918 G A 8.24E-05 Cognitive test performance ATL2 intron 20125193 rs7593981 chr2 38549537 T A 3.25E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs7606701 chr2 38549847 A C 3.36E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs9808407 chr2 38550413 C A 3.23E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6745929 chr2 38553453 C T 1.06E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs4589732 chr2 38555830 C G 9.25E-05 Smoking cessation ATL2 intron 18519826 rs4589732 chr2 38555830 C G 7.19E-05 Serum metabolites ATL2 intron 19043545 rs4589732 chr2 38555830 C G 2.64E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs1375010 chr2 38557660 G A 2.62E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10177042 chr2 38563527 C G 1.26E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs13431831 chr2 38565044 G C 3.78E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11884107 chr2 38565390 C T 3.75E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11679270 chr2 38568808 C A 2.32E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11679271 chr2 38568827 C T 2.31E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10198323 chr2 38571255 T C 8.87E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11687138 chr2 38573690 G A 2.87E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6737169 chr2 38577701 T C 8.86E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6716350 chr2 38586074 C T 8.99E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11900967 chr2 38588138 T A 2.91E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11687878 chr2 38589747 G T 2.92E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6760123 chr2 38602511 C T 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATL2 intron 20877124 rs6760123 chr2 38602511 C T 2.91E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6760123 chr2 38602511 C T 8.28E-05 Body Mass Index ATL2 intron pha002896 rs3806552 chr2 38605393 A C 3.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3806551 chr2 38606219 G C 2.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs10182455 chr2 38611011 G A 2.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs10198160 chr2 38611930 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10197684 chr2 38620569 C T 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10197684 chr2 38620569 C T 1.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1027880 chr2 38626307 T C 8.86E-04 Parkinson's disease / / 17052657 rs13392984 chr2 38634844 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17022657 chr2 38657595 G A 2.50E-05 Urinary metabolites / / 21572414 rs12997019 chr2 38682719 T C 3.40E-04 Alcohol dependence / / 21314694 rs17022787 chr2 38702122 T C 8.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13424546 chr2 38723049 G A 6.33E-05 Celiac disease / / 23936387 rs4670257 chr2 38726650 G A 8.60E-04 Parkinson's disease / / 17052657 rs4490160 chr2 38728911 G A 9.21E-04 Parkinson's disease / / 17052657 rs12622497 chr2 38749083 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs3731843 chr2 38749920 C A 3.27E-05 Serum metabolites / / 19043545 rs10164547 chr2 38760294 C T 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs17421399 chr2 38769087 A C 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17493321 chr2 38772507 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7571463 chr2 38772915 C T 4.91E-04 Gallstones / / 17632509 rs7571463 chr2 38772915 C T 2.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574556 chr2 38773108 G T 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12328034 chr2 38789682 A G 4.69E-04 Acute lung injury / / 22295056 rs10495880 chr2 38799896 G A 9.09E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs17493538 chr2 38806329 A C 1.10E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs4268910 chr2 38807177 C G 4.24E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6544169 chr2 38814517 G A 5.88E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6721860 chr2 38818221 C T 2.02E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6544170 chr2 38820522 T C 7.16E-05 Multiple sclerosis HNRPLL intron 20598377 rs6544170 chr2 38820522 T C 4.46E-05 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs1864828 chr2 38824781 T A 4.21E-05 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs17421743 chr2 38825407 G C 5.12E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6757844 chr2 38832850 C G 6.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs7578356 chr2 38862223 A C 7.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13384427 chr2 38901790 C T 9.37E-04 Parkinson's disease GALM intron 16252231 rs17576472 chr2 38903022 T A 4.57E-05 Multiple complex diseases GALM intron 17554300 rs17023042 chr2 38912786 C G 8.24E-04 Multiple complex diseases GALM intron 17554300 rs17422091 chr2 38914242 G C 9.60E-05 White matter hyperintensity burden GALM intron 21681796 rs6741892 chr2 38916970 A T 5.00E-06 5-HTT brain serotonin transporter levels GALM missense 21339755 rs1965752 chr2 38943609 G A 3.33E-04 Coronary heart disease GALM intron 21606135 rs11124646 chr2 38954419 A G 3.26E-04 Multiple complex diseases GALM intron 17554300 rs6728394 chr2 38955866 G A 4.67E-04 Multiple complex diseases GALM intron 17554300 rs3097714 chr2 38960491 A G 6.17E-04 Tourette syndrome GALM intron 22889924 rs3097713 chr2 38964531 A G 1.70E-05 Urinary metabolites / / 21572414 rs3134628 chr2 38977612 A G 8.80E-05 White matter hyperintensity burden SRSF7 intron 21681796 rs12621103 chr2 38978764 T C 8.80E-05 White matter hyperintensity burden / / 21681796 rs1562855 chr2 39008468 C T 4.70E-05 White matter hyperintensity burden GEMIN6 intron 21681796 rs1056104 chr2 39008949 G A 0.00000574 Nicotine dependence (smoking) GEMIN6 missense 23643383 rs3099968 chr2 39033590 T C 9.31E-04 Tourette syndrome DHX57 intron 22889924 rs3112215 chr2 39037813 G A 4.50E-05 White matter hyperintensity burden DHX57 intron 21681796 rs12479213 chr2 39101209 C A 9.00E-06 Obesity-related traits DHX57 intron 23251661 rs3099950 chr2 39109558 G A 8.00E-06 Amyotrophic lateral sclerosis MORN2 missense 19451621 rs368451 chr2 39166576 T C 3.75E-05 Odorant perception ARHGEF33 intron 23910658 rs12473092 chr2 39204040 C T 9.70E-06 Urinary metabolites / / 21572414 rs6704656 chr2 39210398 A T 2.10E-05 Urinary metabolites SOS1 UTR-3 21572414 rs13031871 chr2 39252851 T G 5.79E-04 Type 2 diabetes SOS1 intron 22158537 rs11674846 chr2 39271729 T C 3.74E-04 Type 2 diabetes SOS1 intron 22158537 rs2373497 chr2 39288098 G A 1.40E-05 Urinary metabolites SOS1 intron 21572414 rs6758330 chr2 39288183 T C 8.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOS1 intron 20877124 rs6758330 chr2 39288183 T C 2.10E-05 Urinary metabolites SOS1 intron 21572414 rs2060989 chr2 39293530 G A 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOS1 intron 20877124 rs7564481 chr2 39330377 G A 6.96E-04 Insulin resistance SOS1 intron 21901158 rs10184855 chr2 39361586 G A 9.02E-05 Lymphocyte counts / / 22286170 rs10171977 chr2 39373207 T C 3.76E-05 Body Mass Index / / pha003006 rs6735427 chr2 39376798 C T 7.19E-04 Multiple complex diseases / / 17554300 rs1567423 chr2 39385155 G T 4.26E-04 Tourette syndrome / / 22889924 rs11124661 chr2 39401658 A G 5.69E-04 Multiple complex diseases / / 17554300 rs2136638 chr2 39409854 T C 7.78E-04 Multiple complex diseases CDKL4 intron 17554300 rs11689688 chr2 39416457 C A 3.73E-04 Multiple complex diseases CDKL4 intron 17554300 rs12712633 chr2 39444235 C G 9.49E-04 Multiple complex diseases CDKL4 intron 17554300 rs6707666 chr2 39459570 C G 7.03E-04 Multiple complex diseases / / 17554300 rs4516411 chr2 39468676 T G 8.24E-04 Multiple complex diseases / / 17554300 rs4516411 chr2 39468676 T G 2.07E-05 Odorant perception / / 23910658 rs2058863 chr2 39580377 G A 4.01E-05 stroke (ischemic) MAP4K3 intron 17434096 rs4670934 chr2 39644134 C T 3.20E-11 Multiple complex diseases MAP4K3 intron 17554300 rs9677244 chr2 39692393 G A 4.70E-05 Coffee consumption LOC728730 intron 21357676 rs12621670 chr2 39748858 C T 7.44E-05 Cognitive impairment induced by topiramate LOC728730 intron 22091778 rs17023903 chr2 39754116 C T 2.97E-04 Multiple complex diseases LOC728730 intron 17554300 rs7597939 chr2 39814690 A G 1.20E-05 HIV-1 control LOC728730 intron 20041166 rs2716697 chr2 39841502 A G 7.06E-06 Obesity-related traits / / 23251661 rs7587205 chr2 39843197 G T 4.00E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17475620 chr2 39843875 A G 8.45E-04 Acute lung injury / / 22295056 rs885252 chr2 39850633 A C 7.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6751438 chr2 39857134 G T 6.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2540255 chr2 39900326 C T 4.73E-04 Lung function (forced expiratory volume in 1 second) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 2.98E-04 Lung function (forced expiratory volume in 1 second) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 4.70E-04 Lung function (forced vital capacity) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 6.79E-05 Elbow pain TMEM178 intron pha003008 rs13427136 chr2 39911151 T C 1.63E-04 Arthritis (juvenile idiopathic) TMEM178 intron 22354554 rs17024218 chr2 39939536 T C 2.00E-06 Obesity-related traits TMEM178 intron 23251661 rs2716734 chr2 39947721 C T 2.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs10490332 chr2 39951909 C T 9.10E-05 Multiple complex diseases / / 17554300 rs10490332 chr2 39951909 C T 3.15E-06 Obesity-related traits / / 23251661 rs2716727 chr2 39953746 T C 2.61E-05 Personality dimensions / / 18957941 rs2716727 chr2 39953746 T C 4.50E-04 Obesity (extreme) / / 21935397 rs1861243 chr2 39956836 T C 8.52E-04 Type 2 diabetes / / 17463246 rs1861243 chr2 39956836 T C 4.35E-04 Multiple complex diseases / / 17554300 rs1861243 chr2 39956836 T C 5.36E-06 Personality dimensions / / 18957941 rs2540226 chr2 39959060 A C 9.23E-04 Type 2 diabetes / / 17463246 rs2540226 chr2 39959060 A C 1.79E-04 Multiple complex diseases / / 17554300 rs2540226 chr2 39959060 A C 3.00E-06 Personality dimensions / / 18957941 rs2540226 chr2 39959060 A C 3.90E-06 Personality dimensions / / 21173776 rs4670955 chr2 39963122 T C 7.95E-05 Personality dimensions / / 18957941 rs4670958 chr2 39980724 C T 6.93E-04 Multiple complex diseases THUMPD2 intron 17554300 rs4670958 chr2 39980724 C T 9.85E-06 Personality dimensions THUMPD2 intron 18957941 rs12470473 chr2 40005290 T C 1.30E-05 Personality dimensions THUMPD2 intron 18957941 rs75820127 chr2 40013335 A G 2.46E-05 Intracerebral hemorrhage / / 24656865 rs10490333 chr2 40024643 A G 9.64E-05 Personality dimensions / / 18957941 rs1003447 chr2 40027918 A G 6.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12475386 chr2 40094081 C T 9.95E-05 Cognitive performance / / 19734545 rs7566309 chr2 40096398 A G 6.00E-04 Alcohol dependence / / 24277619 rs7603007 chr2 40111773 A T 2.70E-05 Urinary metabolites / / 21572414 rs6721181 chr2 40115696 C T 6.00E-07 Asthma (childhood onset) / / 23829686 rs4670981 chr2 40119060 T G 2.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs12469949 chr2 40121335 A G 3.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs12469949 chr2 40121335 A G 4.21E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12469949 chr2 40121335 A G 4.51E-04 Lung function (forced vital capacity) / / 24023788 rs7598492 chr2 40122972 G A 1.31E-04 Multiple complex diseases / / 17554300 rs7601303 chr2 40123232 G C 9.36E-05 Multiple complex diseases / / 17554300 rs13385459 chr2 40123904 C A 0.0000293 Tuberculosis with late age of onset / / 22551897 rs2888638 chr2 40136231 T G 1.03E-05 Osteosarcoma / / 23727862 rs17024600 chr2 40141610 T A 1.98E-04 Multiple complex diseases / / 17554300 rs12621187 chr2 40145915 T C 1.80E-05 Urinary metabolites LOC100128590 intron 21572414 rs17024612 chr2 40152867 A G 1.35E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024614 chr2 40152918 T C 1.50E-04 Multiple complex diseases LOC100128590 intron 17554300 rs10181603 chr2 40159265 T C 1.00E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024636 chr2 40166131 C T 1.12E-04 Multiple complex diseases LOC100128590 intron 17554300 rs725374 chr2 40167128 A T 3.08E-06 Multiple complex diseases LOC100128590 intron 17554300 rs11124710 chr2 40168578 G A 1.00E-04 Cognitive impairment induced by topiramate LOC100128590 intron 22091778 rs75847378 chr2 40181517 G A 7.00E-07 Alzheimer's disease LOC100128590 intron 24770881 rs10865162 chr2 40222206 C T 7.89E-05 Cognitive impairment induced by topiramate LOC100128590 intron 22091778 rs17024775 chr2 40225327 A G 4.53E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024784 chr2 40226489 T G 3.61E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024784 chr2 40226489 T G 8.89E-05 Glaucoma (primary open-angle) LOC100128590 intron 22605921 rs12476349 chr2 40264408 T C 3.26E-04 Acute lung injury LOC100128590 intron 22295056 rs2192724 chr2 40270387 A C 1.58E-04 Alzheimer's disease (late onset) LOC100128590 intron 21379329 rs6705905 chr2 40270534 T G 2.40E-05 Urinary metabolites LOC100128590 intron 21572414 rs6544307 chr2 40299464 C T 5.83E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs12614752 chr2 40316473 T G 2.94E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs12151560 chr2 40318880 T C 4.06E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs917977 chr2 40321189 T C 4.04E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs13032715 chr2 40325029 T C 2.84E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs759359 chr2 40329105 G T 3.77E-05 Height LOC100128590 intron 22021425 rs6736628 chr2 40332851 G C 2.29E-04 Smoking initiation LOC100128590 intron 24665060 rs2888655 chr2 40338067 G A 7.32E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17500300 chr2 40348737 A C 3.53E-04 Iron levels SLC8A1 intron pha002876 rs2110927 chr2 40354688 C T 5.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2160364 chr2 40357323 T C 9.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs765554 chr2 40358175 G A 2.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2110922 chr2 40363644 C A 9.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2058693 chr2 40376453 T G 8.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs435923 chr2 40377632 C A 6.72E-04 Insulin resistance SLC8A1 intron 21901158 rs409620 chr2 40378344 T C 4.67E-04 Alzheimer's disease (late onset) SLC8A1 intron 21379329 rs13425134 chr2 40381369 A G 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs452369 chr2 40384733 C T 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs1861427 chr2 40387489 A G 7.16E-05 Prostate cancer SLC8A1 intron pha002877 rs2072530 chr2 40391516 G A 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs1005213 chr2 40391789 G T 2.02E-04 Multiple complex diseases SLC8A1 intron 17554300 rs17025372 chr2 40395937 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs404005 chr2 40396078 C T 3.00E-07 HIV-associated dementia SLC8A1 intron 22628157 rs12993486 chr2 40396296 T C 8.79E-05 Cognitive decline SLC8A1 intron 22054870 rs2072529 chr2 40397165 A G 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs105288 chr2 40400127 A G 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs105287 chr2 40400179 A G 3.18E-04 Multiple complex diseases SLC8A1 intron 17554300 rs417591 chr2 40400312 A G 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs385341 chr2 40400489 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs106706 chr2 40403104 A G 8.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs446538 chr2 40403803 T C 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs581477 chr2 40406679 T C 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs581568 chr2 40406745 T C 3.02E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs379410 chr2 40410269 T C 8.15E-04 Type 2 diabetes SLC8A1 intron 17463246 rs379410 chr2 40410269 T C 2.56E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs376535 chr2 40411717 C T 4.38E-05 Cognitive decline SLC8A1 intron 22054870 rs391631 chr2 40413713 A T 1.15E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs417873 chr2 40414959 T A 1.26E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs430314 chr2 40415673 G A,T 9.10E-04 Type 2 diabetes SLC8A1 intron 17463246 rs430314 chr2 40415673 G A,T 1.32E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs389109 chr2 40416919 C T 3.26E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs12104840 chr2 40420129 G A 5.89E-04 Insulin resistance SLC8A1 intron 21901158 rs368577 chr2 40424897 C T 5.48E-04 Multiple complex diseases SLC8A1 intron 17554300 rs11674102 chr2 40429442 A G 4.95E-05 Multiple complex diseases SLC8A1 intron 17554300 rs17504446 chr2 40430611 A C 1.26E-04 Insulin resistance SLC8A1 intron 21901158 rs415695 chr2 40469240 T C 8.96E-04 Multiple complex diseases SLC8A1 intron 17554300 rs371909 chr2 40469705 G C 5.15E-05 Multiple complex diseases SLC8A1 intron 17554300 rs7593406 chr2 40475441 G T 6.31E-04 Insulin resistance SLC8A1 intron 21901158 rs405884 chr2 40482717 G C 3.35E-04 Type 2 diabetes SLC8A1 intron 17463246 rs3749056 chr2 40484945 T C 4.00E-06 QRS duration in Tripanosoma cruzi seropositivity SLC8A1 intron 24324551 rs434082 chr2 40485074 C T 5.68E-04 Type 2 diabetes SLC8A1 intron 17463246 rs434082 chr2 40485074 C T 8.51E-04 Hypertension,salt-sensitive SLC8A1 intron 21573014 rs421576 chr2 40490009 A C 5.39E-05 Acute lung injury SLC8A1 intron 22295056 rs403630 chr2 40492788 A C 1.85E-04 Acute lung injury SLC8A1 intron 22295056 rs13419087 chr2 40495934 A G 4.21E-04 Acute lung injury SLC8A1 intron 22295056 rs13021772 chr2 40497458 A T 6.59E-04 Acute lung injury SLC8A1 intron 22295056 rs7583177 chr2 40502259 G A 9.43E-04 Acute lung injury SLC8A1 intron 22295056 rs10210665 chr2 40532749 T C 9.85E-05 Cognitive impairment induced by topiramate SLC8A1 intron 22091778 rs2110743 chr2 40538968 A G 6.20E-06 Urinary metabolites SLC8A1 intron 21572414 rs2160236 chr2 40557276 G C 8.00E-04 Suicide attempts in bipolar disorder SLC8A1 intron 21041247 rs10490051 chr2 40571426 T C 9.65E-04 Multiple complex diseases SLC8A1 intron 17554300 rs10490051 chr2 40571426 T C 1.35E-05 Orofacial clefts SLC8A1 intron 22419666 rs12611608 chr2 40577162 G C 6.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC8A1 intron 21844884 rs10180986 chr2 40578171 T A 1.00E-04 Prostate cancer SLC8A1 intron 21743057 rs17025867 chr2 40578559 G A 2.00E-07 Obesity (early onset extreme) SLC8A1 intron 23563609 rs13405065 chr2 40583595 G A 7.01E-04 Multiple complex diseases SLC8A1 intron 17554300 rs6544331 chr2 40591189 C G 1.00E-07 Urinary metabolites SLC8A1 intron 21572414 rs34408472 chr2 40592311 G A 8.90E-08 Urinary metabolites SLC8A1 intron 21572414 rs6544334 chr2 40596524 A C 3.85E-07 Body mass (lean) SLC8A1 intron 19268274 rs7581611 chr2 40598884 T C 6.60E-05 Body mass (lean) SLC8A1 intron 19268274 rs12472012 chr2 40605768 C T 4.02E-04 Insulin resistance SLC8A1 intron 21901158 rs1477004 chr2 40612072 A G 9.34E-05 Orofacial clefts SLC8A1 intron 22419666 rs2373859 chr2 40617820 C T 8.85E-05 Orofacial clefts SLC8A1 intron 22419666 rs10490046 chr2 40630678 A C 7.23E-05 Alcohol consumption SLC8A1 intron 23743675 rs10490045 chr2 40631355 T C 6.40E-05 Alcohol consumption SLC8A1 intron 23743675 rs12614757 chr2 40633859 A G 8.70E-06 Urinary metabolites SLC8A1 intron 21572414 rs9789765 chr2 40634834 A T 4.58E-04 Alcohol dependence SLC8A1 intron 21314694 rs6755144 chr2 40636240 A G 4.04E-05 Alcohol consumption SLC8A1 intron 23743675 rs13017237 chr2 40639297 G A 8.47E-04 Multiple complex diseases SLC8A1 intron 17554300 rs6705173 chr2 40641699 T C 4.83E-04 Alzheimer's disease (late onset) SLC8A1 intron 21379329 rs13414307 chr2 40649084 A G 3.30E-05 Type 2 diabetes SLC8A1 intron 17460697 rs7579930 chr2 40649916 A C 6.93E-06 Obesity-related traits SLC8A1 intron 23251661 rs4629203 chr2 40662546 T C 3.00E-06 Obesity-related traits SLC8A1 intron 23251661 rs1990609 chr2 40667007 C T 8.85E-04 Iron levels SLC8A1 intron pha002876 rs17026033 chr2 40670651 G C 8.41E-04 Type 2 diabetes SLC8A1 intron 17463246 rs17026039 chr2 40670694 G C 8.39E-04 Type 2 diabetes SLC8A1 intron 17463246 rs6544340 chr2 40682153 T C 4.65E-05 Serum metabolites SLC8A1 intron 19043545 rs7597373 chr2 40687437 C A 3.85E-04 Multiple complex diseases SLC8A1 intron 17554300 rs2373864 chr2 40688262 A G 5.07E-05 Serum metabolites SLC8A1 intron 19043545 rs11679585 chr2 40691468 C A 0.0000573 Narcolepsy (non-HLA narcolepsy) SLC8A1 intron 23459209 rs17026106 chr2 40738497 T C 2.01E-04 Schizophrenia SLC8A1 intron 20832056 rs13017279 chr2 40757454 C T 1.17E-04 Schizophrenia / / 20832056 rs17026152 chr2 40757655 G A 1.30E-04 Schizophrenia / / 20832056 rs13017846 chr2 40757791 A G 2.60E-04 Schizophrenia / / 20832056 rs13017846 chr2 40757791 A G 8.00E-14 QT interval / / 22726844 rs17026155 chr2 40760283 C T 1.50E-04 Schizophrenia / / 20832056 rs17026156 chr2 40760965 T C 1.65E-04 Schizophrenia / / 20832056 rs13010889 chr2 40764015 C A 8.75E-05 Schizophrenia / / 20832056 rs7561779 chr2 40778289 T G 7.55E-05 Potassium levels / / pha003086 rs7561779 chr2 40778289 T G 9.25E-05 Eosinophil counts / / pha003088 rs17026180 chr2 40783776 A C 1.20E-05 Multiple complex diseases / / 17554300 rs10490258 chr2 40805954 C T 1.50E-05 Blood Phenotypes / / 17903294 rs42807 chr2 40835285 T G 4.29E-05 Insulin resistance / / 21901158 rs6755751 chr2 40870602 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12468195 chr2 40882419 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17026460 chr2 40884647 C T 4.53E-04 Hemoglobin concentration / / 20534544 rs6717047 chr2 40890903 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs983123 chr2 40940616 G A 5.15E-04 Hemoglobin concentration / / 20534544 rs2192820 chr2 40948842 G T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1107932 chr2 40949168 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1107932 chr2 40949168 T C 5.15E-04 Hemoglobin concentration / / 20534544 rs4952645 chr2 40949606 T G 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12105490 chr2 40959809 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12466466 chr2 40977474 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6708921 chr2 40982517 C G 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4603810 chr2 40987687 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4603810 chr2 40987687 G A 2.60E-05 Urinary metabolites / / 21572414 rs1456587 chr2 40989264 C T 2.72E-04 Type 2 diabetes / / 17463246 rs1456587 chr2 40989264 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4552230 chr2 40990316 C T 1.40E-05 Urinary metabolites / / 21572414 rs7566371 chr2 40990662 T G 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6722048 chr2 41036518 G A 7.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11124763 chr2 41037903 T C 5.89E-04 Multiple complex diseases / / 17554300 rs1456596 chr2 41078726 G A 5.54E-04 Alzheimer's disease / / 24755620 rs7592667 chr2 41087391 C T 8.99E-04 Alzheimer's disease / / 24755620 rs4952654 chr2 41093123 T C 3.34E-04 Smoking cessation / / 24665060 rs982428 chr2 41107020 G A 7.20E-04 Type 2 diabetes / / 17463246 rs1981804 chr2 41199040 G A 4.02E-04 Alzheimer's disease / / 24755620 rs11124777 chr2 41207286 C T 8.77E-04 Multiple complex diseases / / 17554300 rs12472025 chr2 41217822 T C 2.90E-05 Parkinson's disease (familial) / / 18985386 rs17027130 chr2 41273631 T C 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1991099 chr2 41304560 G C 6.48E-04 Multiple complex diseases / / 17554300 rs17027254 chr2 41391252 C T 9.18E-05 Type 2 diabetes / / 17463246 rs9646981 chr2 41403446 T C 8.05E-06 Type 2 diabetes / / 17463246 rs12712739 chr2 41416322 T A 2.00E-05 Urinary metabolites / / 21572414 rs13014596 chr2 41418224 A G 3.94E-06 Type 2 diabetes / / 17463246 rs7579184 chr2 41423097 C T 6.39E-06 Type 2 diabetes / / 17463246 rs11687208 chr2 41424692 T C 1.57E-05 Type 2 diabetes / / 17463246 rs881024 chr2 41438438 A G 3.55E-05 Type 2 diabetes / / 17463246 rs11894180 chr2 41474388 A C 3.27E-04 Type 2 diabetes / / 17463246 rs10168228 chr2 41475622 G C 4.45E-04 Type 2 diabetes / / 17463246 rs17689334 chr2 41481639 G A 1.41E-04 Type 2 diabetes / / 17463246 rs17027360 chr2 41486554 A G 3.30E-04 Alcohol dependence / / 20201924 rs4140752 chr2 41487071 G A 8.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs10490379 chr2 41503910 A C 3.93E-04 Multiple complex diseases / / 17554300 rs1441231 chr2 41505473 T C 8.20E-04 Alcohol dependence / / 20201924 rs1508116 chr2 41526122 T C 1.30E-04 Lipid traits / / 17903299 rs12612547 chr2 41528139 A C 3.46E-04 Type 2 diabetes / / 17463246 rs17027408 chr2 41529807 G A 2.64E-04 Alzheimer's disease / / 22005930 rs13385952 chr2 41531398 T C 9.00E-04 Atrial fibrillation / / 21846873 rs13385952 chr2 41531398 T C 1.24E-04 Alzheimer's disease / / 22005930 rs10490380 chr2 41532189 G T 6.13E-04 Type 2 diabetes / / 17463246 rs10490380 chr2 41532189 G T 5.40E-04 Multiple complex diseases / / 17554300 rs17027420 chr2 41534961 C A 2.05E-04 Type 2 diabetes / / 17463246 rs13415944 chr2 41535003 G C 1.25E-04 Type 2 diabetes / / 17463246 rs13415944 chr2 41535003 G C 2.89E-05 Diabetes (gestational) / / 22233651 rs4952451 chr2 41544368 G A 9.95E-04 Alzheimer's disease / / 22005930 rs2374232 chr2 41546907 T G 4.31E-04 Multiple complex diseases / / 17554300 rs2023545 chr2 41551957 C A 2.78E-04 Multiple complex diseases / / 17554300 rs7569590 chr2 41556442 C A 7.91E-05 Bipolar disorder / / 19488044 rs7569590 chr2 41556442 C A 7.17E-04 Alzheimer's disease / / 22005930 rs7569590 chr2 41556442 C A 3.30E-05 Bipolar Disorder / / pha002863 rs6750424 chr2 41560726 T C 3.08E-04 Multiple complex diseases / / 17554300 rs2048178 chr2 41561475 T A 1.23E-04 Multiple complex diseases / / 17554300 rs2048178 chr2 41561475 T A 7.08E-04 Alzheimer's disease / / 22005930 rs7565096 chr2 41562110 A C 2.53E-04 Multiple complex diseases / / 17554300 rs7565096 chr2 41562110 A C 8.07E-04 Alzheimer's disease / / 22005930 rs6745177 chr2 41564729 T A 5.28E-04 Multiple complex diseases / / 17554300 rs4952453 chr2 41569885 C T 9.13E-05 Multiple complex diseases / / 17554300 rs4952453 chr2 41569885 C T 6.86E-04 Alzheimer's disease / / 22005930 rs1508114 chr2 41572171 C T 7.20E-04 Alzheimer's disease / / 22005930 rs2063179 chr2 41574085 T C 7.95E-04 Alzheimer's disease / / 22005930 rs6727419 chr2 41579722 T C 6.83E-04 Multiple complex diseases / / 17554300 rs7584371 chr2 41581176 T C 6.62E-04 Alzheimer's disease / / 22005930 rs12465106 chr2 41583244 A C 7.46E-04 Alzheimer's disease / / 22005930 rs7577619 chr2 41593738 C T 3.09E-04 Multiple complex diseases / / 17554300 rs2068390 chr2 41603674 T C 5.22E-04 Multiple complex diseases / / 17554300 rs2068390 chr2 41603674 T C 5.00E-04 Alzheimer's disease / / 22005930 rs6544414 chr2 41615490 A C 4.36E-04 Alzheimer's disease / / 22005930 rs12052737 chr2 41616692 T C 6.59E-04 Alzheimer's disease / / 22005930 rs10495891 chr2 41617543 C T 6.54E-04 Alzheimer's disease / / 22005930 rs1396133 chr2 41617969 C T 4.59E-04 Alzheimer's disease / / 22005930 rs12616486 chr2 41620948 C G 6.53E-04 Alzheimer's disease / / 22005930 rs4245772 chr2 41633212 G A 8.69E-04 Multiple complex diseases / / 17554300 rs4281952 chr2 41633705 T C 4.74E-04 Multiple complex diseases / / 17554300 rs4952362 chr2 41636730 G C 9.84E-04 Alzheimer's disease / / 22005930 rs4952462 chr2 41636754 T G 5.28E-04 Alzheimer's disease / / 22005930 rs1995738 chr2 41637415 T G 9.78E-04 Multiple complex diseases / / 17554300 rs11124811 chr2 41638727 A T 6.33E-04 Alzheimer's disease / / 22005930 rs1508119 chr2 41640295 T C 5.63E-04 Alzheimer's disease / / 22005930 rs4952364 chr2 41641558 A C 6.13E-04 Alzheimer's disease / / 22005930 rs1354982 chr2 41641880 G C 5.19E-04 Alzheimer's disease / / 22005930 rs1354983 chr2 41642035 C G 7.52E-04 Alzheimer's disease / / 22005930 rs1354984 chr2 41642045 A C 6.72E-04 Alzheimer's disease / / 22005930 rs1508120 chr2 41643650 A C 4.55E-04 Alzheimer's disease / / 22005930 rs4952464 chr2 41646813 G A 6.07E-04 Alzheimer's disease / / 22005930 rs7589089 chr2 41650011 A G 4.93E-04 Multiple complex diseases / / 17554300 rs906549 chr2 41653824 C T 6.58E-04 Alzheimer's disease / / 22005930 rs1508123 chr2 41654633 T A 6.23E-04 Alzheimer's disease / / 22005930 rs10191557 chr2 41658224 G C 8.12E-04 Multiple complex diseases / / 17554300 rs1157103 chr2 41659303 C T 9.50E-04 Alzheimer's disease / / 22005930 rs1508128 chr2 41661763 A G 6.82E-04 Multiple complex diseases / / 17554300 rs12465424 chr2 41662810 T C 2.47E-04 Multiple complex diseases / / 17554300 rs12469176 chr2 41662827 A G 3.99E-04 Multiple complex diseases / / 17554300 rs12996069 chr2 41704150 A G 4.12E-04 Smoking initiation / / 24665060 rs4985357 chr2 41733169 G T 3.06E-04 Birth weight / / 17255346 rs13423625 chr2 41737267 G A 3.32E-04 Smoking initiation / / 24665060 rs11124821 chr2 41761764 C T 1.92E-04 Birth weight / / 17255346 rs6755297 chr2 41762080 T C 1.98E-04 Smoking initiation / / 24665060 rs12620138 chr2 41765955 G A 4.61E-05 Birth weight / / 17255346 rs11124822 chr2 41774145 G A 3.20E-04 Birth weight / / 17255346 rs10164666 chr2 41775517 C T 2.82E-04 Smoking initiation / / 24665060 rs2195495 chr2 41798912 A G 1.91E-04 Birth weight / / 17255346 rs6544449 chr2 41802979 G A 3.84E-04 Smoking initiation / / 24665060 rs12712786 chr2 41806534 C T 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12712787 chr2 41806652 A G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2163050 chr2 41826738 G A 3.93E-04 Alzheimer's disease (late onset) / / 21379329 rs10865177 chr2 41829089 G A 8.91E-04 Multiple complex diseases / / 17554300 rs7603075 chr2 41832878 T C 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7562541 chr2 41832918 A G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10205791 chr2 41839007 C T 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs7599301 chr2 41840956 C G 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028125 chr2 41853654 T C 2.79E-04 Type 2 diabetes / / 17463246 rs17028125 chr2 41853654 T C 5.86E-04 Multiple complex diseases / / 17554300 rs10197606 chr2 41878796 A G 1.95E-05 Parkinson's disease / / 16252231 rs9789345 chr2 41898188 A G 6.94E-05 Parkinson's disease / / 16252231 rs12712806 chr2 41906810 T C 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6745319 chr2 41909765 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674789 chr2 41911100 C A 3.76E-05 Parkinson's disease / / 16252231 rs6724520 chr2 41911525 A G 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1920510 chr2 41913030 G A 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490649 chr2 41913548 C T 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10210110 chr2 41915477 G A 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4493315 chr2 41917871 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952502 chr2 41921628 G A 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1920498 chr2 41925981 C T 4.19E-04 Parkinson's disease / / 16252231 rs1920498 chr2 41925981 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6746652 chr2 41927815 A G 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6734033 chr2 41931415 C T 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11685994 chr2 41934148 G C 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028447 chr2 41934802 G T 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs17610091 chr2 41934824 T G 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs13000158 chr2 41935905 C T 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs13000173 chr2 41935967 A C 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747554 chr2 41936183 T C 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761925 chr2 41936886 A G 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6733623 chr2 41937036 C A,T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6736655 chr2 41937090 G A 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952373 chr2 41941110 A C 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952508 chr2 41945351 T C 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028520 chr2 41946732 A G 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11896334 chr2 41947118 A C 1.00E-04 Information processing speed / / 21130836 rs12994941 chr2 41950726 T C 0.0000269 Colorectal cancer (males) / / 22532847 rs11692045 chr2 41950953 A G 1.54E-05 Hypertension / / 19609347 rs2141650 chr2 41953699 G A 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490643 chr2 41957014 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7568362 chr2 41957254 C A 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6749718 chr2 41962044 T C 2.50E-05 Urinary metabolites / / 21572414 rs41518745 chr2 41976511 T C 3.60E-04 Insulin resistance / / 21901158 rs4563280 chr2 41976547 A C 8.58E-06 Gaucher disease severity / / 22388998 rs7572321 chr2 41979425 T C 4.13E-04 Alzheimer's disease / / 22005930 rs17028687 chr2 41995339 A G 7.70E-04 Alzheimer's disease / / 22005930 rs4381822 chr2 41996612 A G 9.32E-05 Leukocyte Counts / / pha003091 rs4952374 chr2 41997648 T C 7.97E-05 HDL cholesterol / / pha003075 rs17465239 chr2 42004689 C T 9.90E-07 Urinary metabolites / / 21572414 rs719593 chr2 42004997 A G 5.00E-06 Conduct disorder (interaction) / / 18846501 rs7581374 chr2 42006280 C G 7.75E-05 Type 2 diabetes / / 17463246 rs6704827 chr2 42015775 T G 7.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4952513 chr2 42017861 T C 7.20E-05 Cognitive function / / 24684796 rs10211025 chr2 42028633 A G 9.70E-07 Asthma / / 24406073 rs12328045 chr2 42035110 A C 4.60E-06 Asthma / / 24406073 rs12471624 chr2 42046593 A T 1.80E-05 Urinary metabolites / / 21572414 rs4535089 chr2 42069298 T G 8.91E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs4305317 chr2 42080624 T G 2.00E-06 Rheumatoid arthritis / / 21156761 rs4305317 chr2 42080624 T G 4.00E-08 Rheumatoid arthritis / / 21156761 rs7423989 chr2 42100184 T A 8.43E-04 Body mass index / / 21701565 rs11676056 chr2 42100538 A G 3.25E-04 Body mass index / / 21701565 rs11676056 chr2 42100538 A G 7.35E-04 Body mass index / / 21701565 rs4952528 chr2 42112333 G A 1.40E-05 Urinary metabolites LOC388942 intron 21572414 rs4641988 chr2 42112720 C T 1.40E-05 Urinary metabolites LOC388942 intron 21572414 rs765678 chr2 42115621 G C 8.30E-06 Urinary metabolites LOC388942 intron 21572414 rs11886254 chr2 42118216 G C 2.70E-05 Urinary metabolites LOC388942 intron 21572414 rs7563575 chr2 42121185 G A 2.50E-05 Urinary metabolites / / 21572414 rs2374380 chr2 42122150 G C,T 8.27E-05 Major depressive disorder (broad) / / 20038947 rs4952533 chr2 42129211 G C 8.93E-05 Major depressive disorder (broad) / / 20038947 rs4952534 chr2 42129595 A C 7.70E-06 Urinary metabolites / / 21572414 rs4952535 chr2 42131523 G A 0.000101 Gains in maximal O2 uptake response / / 21183627 rs2374341 chr2 42133432 C T 1.80E-05 Urinary metabolites / / 21572414 rs2374342 chr2 42133542 A C 9.20E-04 Multiple complex diseases / / 17554300 rs2374342 chr2 42133542 A C 9.90E-06 Urinary metabolites / / 21572414 rs7580660 chr2 42136788 C T 9.60E-05 Endometriosis / / 21151130 rs2276698 chr2 42160388 G A 7.16E-05 Lung adenocarcinoma / / 19836008 rs4952548 chr2 42164215 A C 2.80E-05 Urinary metabolites C2orf91 UTR-3 21572414 rs4952548 chr2 42164215 A C 1.21E-04 Orofacial clefts C2orf91 UTR-3 22863734 rs7556683 chr2 42170854 T C 7.50E-06 Digit length ratio C2orf91 intron 20303062 rs4952561 chr2 42209530 T C 9.47E-05 Femoral neck bone geometry / / 22087292 rs7584262 chr2 42250549 C T 1.00E-09 Bone mineral density / / 22504420 rs11887431 chr2 42267462 C T 3.66E-05 Parkinson's disease / / 16252231 rs4952590 chr2 42276921 C T 2.00E-06 Atopy PKDCC intron 19961619 rs11891490 chr2 42285915 G A 6.78E-04 Type 2 diabetes / / 17463246 rs10454141 chr2 42313092 C T 2.34E-04 Lung function (forced vital capacity) / / 24023788 rs17029233 chr2 42343144 A T 3.07E-19 Varicose Veins / / pha001414 rs6733455 chr2 42350487 C T 7.08E-04 Alcohol dependence / / 21314694 rs4531983 chr2 42360204 A G 5.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4952936 chr2 42370455 T C 3.71E-05 Vitiligo / / 19890347 rs13412252 chr2 42373747 C T 6.37E-06 Intracerebral hemorrhage / / 24656865 rs17670415 chr2 42416503 C T 3.52E-04 Multiple complex diseases EML4 intron 17554300 rs997288 chr2 42525582 C G 6.31E-04 Body mass index EML4 intron 21701565 rs1874449 chr2 42667585 T G 6.30E-05 Bulimia nervosa / / 23568457 rs11685479 chr2 42694337 G A 8.70E-05 ldl cholesterol KCNG3 intron pha003077 rs2029899 chr2 42718898 G A 2.37E-04 Acute lung injury KCNG3 intron 22295056 rs17029761 chr2 42728604 A G 3.64E-04 Acute lung injury / / 22295056 rs9808148 chr2 42737734 T C 1.71E-04 Acute lung injury / / 22295056 rs924114 chr2 42739333 C T 2.61E-04 Acute lung injury / / 22295056 rs4953391 chr2 42740675 A C 6.16E-04 Acute lung injury / / 22295056 rs4953392 chr2 42740881 A G 6.83E-04 Acute lung injury / / 22295056 rs13398888 chr2 42753496 A T 1.72E-04 Acute lung injury / / 22295056 rs1874448 chr2 42761106 A G 3.19E-04 Blood pressure / / 17255346 rs12996453 chr2 42762739 G C 1.77E-04 Blood pressure / / 17255346 rs17029781 chr2 42767044 T C 4.25E-05 Longevity / / 20304771 rs17679678 chr2 42859714 G A 3.40E-05 Longevity MTA3 intron 20304771 rs6544586 chr2 42900991 G A 1.08E-04 Blood pressure MTA3 intron 17255346 rs930421 chr2 42981239 A G 6.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs6719977 chr2 42985803 T C 2.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs6719977 chr2 42985803 T C 6.10E-05 Diabetes Mellitus / / pha003060 rs2374443 chr2 43012336 C T 4.62E-05 Anxiety and major depressive disorder HAAO intron 24047446 rs12613026 chr2 43014289 C T 6.49E-06 Parkinson's disease HAAO intron 21812969 rs6717237 chr2 43043116 G A 6.65E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs1347929 chr2 43050311 C T 1.68E-05 Heart Rate / / pha003054 rs13395650 chr2 43076271 G A 8.00E-04 Body mass index / / 21701565 rs6720920 chr2 43079958 G A 9.01E-05 Multiple complex diseases / / 17554300 rs4332966 chr2 43083831 T G 2.72E-04 Systolic blood pressure / / 21909115 rs4953676 chr2 43121726 C A 3.00E-04 Obesity (extreme) / / 21935397 rs4245824 chr2 43127717 T C 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4953682 chr2 43128748 C G 5.07E-04 Obesity (extreme) / / 21935397 rs12986863 chr2 43132547 C T 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4952947 chr2 43138933 G A 1.03E-04 Obesity (extreme) / / 21935397 rs1078100 chr2 43146800 T C 2.23E-04 Substance dependence / / 21818250 rs12712870 chr2 43161180 A G 1.90E-05 Urinary metabolites / / 21572414 rs7603548 chr2 43165147 T C 9.21E-06 Intelligence / / 21826061 rs6544619 chr2 43184729 C T 3.00E-07 Diastolic blood pressure / / 19430483 rs10176316 chr2 43199311 C T 4.53E-04 Alzheimer's disease / / 22005930 rs6710906 chr2 43200107 C A 5.87E-04 Insulin resistance / / 21901158 rs9808138 chr2 43200625 G C 5.57E-04 Alzheimer's disease / / 22005930 rs6544624 chr2 43213996 G A 6.30E-06 Urinary metabolites / / 21572414 rs7593685 chr2 43215855 T C 9.40E-04 Coronary Artery Disease / / 17634449 rs11124912 chr2 43223032 A C 4.70E-04 Type 2 diabetes / / 17463246 rs17030257 chr2 43232117 C T 6.30E-04 Breast cancer / / 19330027 rs11686640 chr2 43239425 C T 2.50E-06 Urinary metabolites / / 21572414 rs921072 chr2 43242143 G C 1.13E-04 Type 2 diabetes / / 17463246 rs6748564 chr2 43246767 T G 3.10E-06 Urinary metabolites / / 21572414 rs2121355 chr2 43253242 T A 1.70E-05 Urinary metabolites / / 21572414 rs9973820 chr2 43278048 G A 5.06E-04 Insulin resistance / / 21901158 rs7582239 chr2 43286610 G T 1.61E-04 Multiple complex diseases / / 17554300 rs6711874 chr2 43288810 A G 5.09E-04 Multiple complex diseases / / 17554300 rs17030342 chr2 43299383 G A 4.23E-04 Coronary heart disease / / 21606135 rs17030347 chr2 43301017 T C 2.68E-04 Multiple complex diseases / / 17554300 rs747094 chr2 43305391 C T 2.97E-04 Alzheimer's disease / / 17998437 rs2374482 chr2 43305926 G A 9.73E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs6718520 chr2 43325570 A G 3.00E-08 Multiple sclerosis LOC100506047 intron 22190364 rs6718520 chr2 43325570 A G 1.20E-05 Multiple sclerosis LOC100506047 intron 24234648 rs4567998 chr2 43330109 C A 0.000000004 Joint damage severity in rheumatoid arthritis / / 23696630 rs4575770 chr2 43330140 C T 4.08E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs6709667 chr2 43330320 C T 4.20E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs4952660 chr2 43332143 A C 4.86E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs73925919 chr2 43334791 A G 0.00000022 Joint damage severity in rheumatoid arthritis / / 23696630 rs10199639 chr2 43347127 C G 9.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12466022 chr2 43359061 C A 6.00E-10 Multiple sclerosis / / 21833088 rs12466022 chr2 43359061 C A 4.20E-05 Multiple sclerosis / / 24234648 rs882502 chr2 43363752 T C 0.000513 Salmonella-induced pyroptosis / / 22837397 rs7568470 chr2 43424046 T G 4.11E-05 Serum metabolites / / 19043545 rs10174764 chr2 43429806 G A 2.15E-05 Multiple complex diseases / / 17554300 rs6749927 chr2 43484556 A G 2.92E-05 Orofacial clefts THADA intron 22863734 rs6712357 chr2 43494990 A C 9.40E-04 Type 2 diabetes THADA intron 17463246 rs7561670 chr2 43506259 G A 1.60E-05 Orofacial clefts THADA intron 22863734 rs11900952 chr2 43514036 G A 2.25E-05 Cleft lip THADA intron 20436469 rs11900952 chr2 43514036 G A 1.03E-06 Orofacial clefts THADA intron 22863734 rs11891936 chr2 43532302 C T 2.93E-09 Polycystic ovary syndrome THADA intron 21151128 rs7590268 chr2 43540125 T G 9.00E-08 Orofacial clefts THADA intron 20023658 rs7590268 chr2 43540125 T G 1.00E-08 Orofacial clefts THADA intron 22863734 rs7590268 chr2 43540125 T G 0.0000719 Facial morphology THADA intron 23028347 rs11690012 chr2 43542480 G C 5.90E-05 Arthritis (juvenile idiopathic) THADA intron 22354554 rs13035011 chr2 43544117 C T 3.70E-08 Orofacial clefts THADA intron 22863734 rs17030684 chr2 43548128 G A 3.46E-07 Polycystic ovary syndrome THADA intron 21151128 rs35338810 chr2 43548946 C T 6.44E-06 Orofacial clefts THADA intron 22863734 rs1465618 chr2 43553949 T C 2.00E-08 Prostate cancer THADA intron 19767753 rs1465618 chr2 43553949 T C 2.00E-08 Nasopharyngeal carcinoma THADA intron 20512145 rs1465618 chr2 43553949 T C 0.00016 Prostate cancer THADA intron 23555315 rs4340576 chr2 43555506 T C 2.71E-07 Polycystic ovary syndrome THADA intron 21151128 rs12468394 chr2 43561161 C A 1.20E-09 Polycystic ovary syndrome THADA intron 21151128 rs12468394 chr2 43561161 C A 2.45E-12 Polycystic ovary syndrome THADA intron 22885925 rs6729902 chr2 43576968 C T 2.48E-07 Orofacial clefts THADA intron 22863734 rs3901678 chr2 43587451 G T 3.97E-07 Hair morphology THADA intron 19896111 rs6732426 chr2 43587504 C T 7.96E-05 Multiple complex diseases THADA intron 17554300 rs6732426 chr2 43587504 C T 1.00E-07 Hair morphology THADA intron 19896111 rs17030720 chr2 43589094 T C 4.79E-04 Multiple complex diseases THADA intron 17554300 rs6544648 chr2 43600058 C T 1.91E-06 Orofacial clefts THADA intron 22863734 rs11899863 chr2 43618819 C T 9.50E-11 Type 2 diabetes THADA intron 22885922 rs12477823 chr2 43620320 G A 2.15E-06 Orofacial clefts THADA intron 22863734 rs7596480 chr2 43621162 C T 1.99E-06 Orofacial clefts THADA intron 22863734 rs6544652 chr2 43626212 C T 2.12E-06 Orofacial clefts THADA intron 22863734 rs7600177 chr2 43628055 C T 2.65E-06 Orofacial clefts THADA intron 22863734 rs17030752 chr2 43630493 T C 7.02E-05 Orofacial clefts THADA intron 22863734 rs6544653 chr2 43632950 C T 7.50E-04 Multiple complex diseases THADA intron 17554300 rs9677398 chr2 43634135 C A 3.78E-06 Orofacial clefts THADA intron 22863734 rs13402827 chr2 43634468 T C 6.37E-06 Response to amphetamines THADA intron 22952603 rs6544656 chr2 43635143 G A 2.27E-06 Orofacial clefts THADA intron 22863734 rs7567607 chr2 43638185 C T 1.06E-08 Polycystic ovary syndrome THADA intron 21151128 rs7567607 chr2 43638185 C T 0.000039 Prostate cancer THADA intron 23555315 rs7567607 chr2 43638185 C T 0.00062 Prostate cancer (non-advanced prostate cancer) THADA intron 23555315 rs13429458 chr2 43638838 A C 8.51E-06 Hair morphology THADA intron 19896111 rs13429458 chr2 43638838 A C 2.00E-23 Polycystic ovary syndrome THADA intron 21151128 rs13429458 chr2 43638838 A C 4.00E-13 Polycystic ovary syndrome THADA intron 22885925 rs13429458 chr2 43638838 A C 6.00E-06 Response to amphetamines THADA intron 22952603 rs7568365 chr2 43638855 C T 3.02E-08 Polycystic ovary syndrome THADA intron 21151128 rs13417665 chr2 43638888 T C 9.68E-06 Response to amphetamines THADA intron 22952603 rs7582497 chr2 43638947 T C 6.07E-08 Polycystic ovary syndrome THADA intron 21151128 rs10176241 chr2 43648176 A G 1.08E-06 Polycystic ovary syndrome THADA intron 21151128 rs10176241 chr2 43648176 A G 2.25E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs7575024 chr2 43666991 T C 8.96E-05 Type 1 diabetes THADA intron 18978792 rs7586101 chr2 43669851 T C 5.49E-04 Multiple complex diseases THADA intron 17554300 rs10445925 chr2 43670144 G C 1.40E-06 Orofacial clefts THADA intron 22863734 rs6744642 chr2 43671904 T C 1.24E-06 Polycystic ovary syndrome THADA intron 21151128 rs7556744 chr2 43672795 A G 7.44E-04 Multiple complex diseases THADA intron 17554300 rs10200833 chr2 43673316 C G 0.000471 Type 2 diabetes THADA intron 22325160 rs35114568 chr2 43675292 C A 1.73E-06 Orofacial clefts THADA intron 22863734 rs2046916 chr2 43686207 C T 3.21E-06 Orofacial clefts THADA intron 22863734 rs17030835 chr2 43686245 C G 1.30E-04 Type 2 diabetes THADA intron 17463246 rs17030845 chr2 43687879 C T 1.00E-10 Platelet counts THADA intron 22139419 rs6544660 chr2 43688496 C T 5.89E-04 Multiple complex diseases THADA intron 17554300 rs7561287 chr2 43689071 A G 6.72E-04 Type 2 diabetes THADA intron 17463246 rs7561287 chr2 43689071 A G 4.34E-04 Multiple complex diseases THADA intron 17554300 rs10203174 chr2 43690030 C T 0.0000087 Fasting blood glucose THADA intron 22885922 rs10203174 chr2 43690030 C T 0.0000098 HOMA-B THADA intron 22885922 rs10203174 chr2 43690030 C T 9.50E-12 Type 2 diabetes THADA intron 22885922 rs10203174 chr2 43690030 C T 4.80E-05 Type 2 diabetes THADA intron 24509480 rs13405158 chr2 43705286 T C 0.00064 Type 2 diabetes (females) THADA intron 22885922 rs13405158 chr2 43705286 T C 5.20E-10 Type 2 diabetes (males) THADA intron 22885922 rs12478601 chr2 43721508 C T 3.00E-23 Polycystic ovary syndrome THADA intron 21151128 rs12478601 chr2 43721508 C T 3.37E-10 Polycystic ovary syndrome THADA intron 22885925 rs13431070 chr2 43721954 G A 9.79E-04 Type 2 diabetes THADA intron 17463246 rs7578597 chr2 43732823 T C 1.00E-09 Type 2 diabetes THADA missense 18372903 rs7578597 chr2 43732823 T C 1.00E-09 Coronary heart disease THADA missense 21347282 rs7578597 chr2 43732823 T C 1.00E-09 Type 2 diabetes THADA missense 21647700 rs7578597 chr2 43732823 T C 0.000000291 Type 2 diabetes THADA missense 22325160 rs7578597 chr2 43732823 T C 1.10E-09 Type 2 diabetes THADA missense 23300278 rs1038822 chr2 43738173 T C 1.89E-08 Polycystic ovary syndrome THADA intron 21151128 rs6753942 chr2 43749436 T G 7.80E-04 Alzheimer's disease THADA intron 22005930 rs17030980 chr2 43751480 T C 9.93E-04 Alzheimer's disease THADA intron 22005930 rs17031005 chr2 43761299 A G 5.46E-05 Type 1 diabetes THADA intron 18978792 rs17031016 chr2 43764442 T C 4.04E-04 Type 2 diabetes THADA intron 17463246 rs7559891 chr2 43767039 G A 1.92E-07 Polycystic ovary syndrome THADA intron 21151128 rs1873555 chr2 43779665 T C 3.95E-07 Polycystic ovary syndrome THADA intron 21151128 rs1873555 chr2 43779665 T C 2.52E-05 Orofacial clefts THADA intron 22863734 rs7596052 chr2 43781826 G A 1.07E-04 Multiple complex diseases THADA intron 17554300 rs7596052 chr2 43781826 G A 1.23E-06 Polycystic ovary syndrome THADA intron 21151128 rs10165527 chr2 43782868 C T 1.29E-04 Multiple complex diseases THADA intron 17554300 rs10165527 chr2 43782868 C T 1.90E-06 Polycystic ovary syndrome THADA intron 21151128 rs6725776 chr2 43783141 A G 3.95E-05 Orofacial clefts THADA intron 22863734 rs6726014 chr2 43783294 A T 1.00E-06 Polycystic ovary syndrome THADA intron 21151128 rs881477 chr2 43791563 T C 9.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) THADA intron 22566498 rs17031053 chr2 43796811 T A 1.00E-04 Prostate cancer THADA intron 21743057 rs10211106 chr2 43798053 C T 7.83E-05 Orofacial clefts THADA intron 22863734 rs3752355 chr2 43799070 C T 1.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs3752355 chr2 43799070 C T 3.26E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs2374551 chr2 43802380 C G 2.06E-06 Polycystic ovary syndrome THADA intron 21151128 rs6731009 chr2 43803428 T C 2.06E-04 Type 2 diabetes THADA intron 17463246 rs6731009 chr2 43803428 T C 4.94E-07 Polycystic ovary syndrome THADA intron 21151128 rs17031076 chr2 43803468 T A,C 1.00E-04 Prostate cancer THADA intron 21743057 rs10495903 chr2 43806918 C T 1.60E-04 Multiple complex diseases THADA intron 17554300 rs10495903 chr2 43806918 C T 2.00E-14 Crohn's disease THADA intron 21102463 rs10495903 chr2 43806918 C T 8.00E-12 Inflammatory bowel disease THADA intron 23128233 rs17031088 chr2 43807090 T C 2.45E-04 Multiple complex diseases THADA intron 17554300 rs11890152 chr2 43807368 C G 1.54E-04 Type 2 diabetes THADA intron 17463246 rs10179648 chr2 43808065 C T 4.19E-08 Polycystic ovary syndrome THADA intron 21151128 rs10179648 chr2 43808065 C T 2.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs10179648 chr2 43808065 C T 2.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs10179648 chr2 43808065 C T 9.97E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs17031092 chr2 43809248 T G 3.39E-04 Multiple complex diseases THADA intron 17554300 rs11897432 chr2 43817505 G A 2.36E-06 Orofacial clefts THADA intron 22863734 rs11897432 chr2 43817505 G A 8.00E-07 DNA methylation (variation) THADA intron 23725790 rs7558302 chr2 43836687 C T 6.11E-08 Polycystic ovary syndrome / / 21151128 rs17031133 chr2 43844833 G A 1.58E-04 Multiple complex diseases / / 17554300 rs6749617 chr2 43845329 A T 2.77E-04 Multiple complex diseases / / 17554300 rs11886047 chr2 43850590 T C 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs6544678 chr2 43861551 T C 2.00E-05 Urinary metabolites / / 21572414 rs10174938 chr2 43873144 A C 7.49E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs17335631 chr2 43873505 C A 6.37E-05 Serum metabolites PLEKHH2 intron 19043545 rs17335631 chr2 43873505 C A 8.41E-05 Orofacial clefts PLEKHH2 intron 20023658 rs17335631 chr2 43873505 C A 1.44E-04 Orofacial clefts PLEKHH2 intron 22863734 rs7592384 chr2 43926465 G T 5.27E-04 Orofacial clefts PLEKHH2 intron 22863734 rs7573490 chr2 43928768 A G 0.000876 Salmonella-induced pyroptosis PLEKHH2 intron 22837397 rs4952676 chr2 43929983 G A 4.19E-04 Orofacial clefts PLEKHH2 intron 22863734 rs6759851 chr2 43930616 G C 9.87E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs4953002 chr2 43931176 T C 5.75E-04 Orofacial clefts PLEKHH2 cds-synon 22863734 rs6716551 chr2 43935725 T C 7.49E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs11695642 chr2 43952695 G T 3.10E-06 Iron levels PLEKHH2 intron 21208937 rs7561861 chr2 43962562 G T 7.64E-05 Prostate cancer PLEKHH2 intron 18264096 rs1368086 chr2 43965007 C T 7.93E-04 Bipolar disorder PLEKHH2 intron 19259986 rs17414390 chr2 43976263 T C 4.92E-04 Multiple complex diseases PLEKHH2 intron 17554300 rs10495907 chr2 43998726 G A 0.0000238 Coronary artery disease / / 23202125 rs725238 chr2 43999182 C T 3.70E-04 Myasthenia gravis / / 23055271 rs3762571 chr2 43999734 T G 3.30E-04 Myasthenia gravis / / 23055271 rs2288709 chr2 44004010 T C 5.30E-04 Type 2 diabetes DYNC2LI1 missense 23209189 rs3765000 chr2 44014301 A G 8.58E-05 Cortisol secretion,in saliva DYNC2LI1 intron 21316860 rs4953017 chr2 44024282 T A 7.37E-04 Multiple complex diseases DYNC2LI1 intron 17554300 rs3792015 chr2 44025628 T C 2.85E-22 Narcolepsy DYNC2LI1 intron 19629137 rs4952679 chr2 44029821 C T 9.82E-05 Cortisol secretion,in saliva DYNC2LI1 intron 21316860 rs4953019 chr2 44043393 G A 5.99E-05 Lipid levels ABCG5 intron 19913121 rs10205816 chr2 44044255 A G 9.70E-07 Iron levels ABCG5 intron 21208937 rs10439467 chr2 44048346 C T 0.0000482 LDL cholesterol ABCG5 intron 23063622 rs4148188 chr2 44050687 C T 4.60E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs4148187 chr2 44050888 G A 4.60E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs4289236 chr2 44054123 G A 2.67E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs17031687 chr2 44055387 C T 0.00000038 LDL cholesterol ABCG5 intron 23063622 rs17031687 chr2 44055387 C T 0.00000148 Cholesterol,total ABCG5 intron 23063622 rs6756629 chr2 44065090 G A,C,T 2.00E-11 Cholesterol,total ABCG5 missense 19060911 rs6756629 chr2 44065090 G A,C,T 3.00E-10 LDL cholesterol ABCG5 missense 19060911 rs6756629 chr2 44065090 G A,C,T 3.00E-10 Coronary heart disease ABCG5 missense 21347282 rs11887534 chr2 44066247 G C,T 1.00E-14 Gallstones ABCG8 missense 17632509 rs11887534 chr2 44066247 G C,T 2.78E-11 Lipid levels ABCG8 missense 19936222 rs11887534 chr2 44066247 G C,T 3.48E-10 Lipid levels ABCG8 missense 19936222 rs10179921 chr2 44068291 C T 8.82E-05 Cholesterol ABCG8 intron pha003078 rs17031710 chr2 44070893 A T 0.000000018 LDL cholesterol ABCG8 intron 23063622 rs17031710 chr2 44070893 A T 0.000000773 Triglycerides ABCG8 intron 23063622 rs17031710 chr2 44070893 A T 8.48E-10 Cholesterol,total ABCG8 intron 23063622 rs6748810 chr2 44070935 A G 3.19E-04 Multiple complex diseases ABCG8 intron 17554300 rs4299376 chr2 44072576 G T 1.20E-09 Gallstones ABCG8 intron 17632509 rs4299376 chr2 44072576 G T 7.60E-08 Lipid levels ABCG8 intron 19913121 rs4299376 chr2 44072576 G T 8.70E-10 Lipid levels ABCG8 intron 19913121 rs4299376 chr2 44072576 G T 9.74E-14 Lipid levels ABCG8 intron 19936222 rs4299376 chr2 44072576 G T 2.00E-47 LDL cholesterol ABCG8 intron 20686565 rs4299376 chr2 44072576 G T 4.00E-45 Cholesterol,total ABCG8 intron 20686565 rs4299376 chr2 44072576 G T 1.40E-06 Coronary heart disease ABCG8 intron 21966275 rs4299376 chr2 44072576 G T 2.25E-32 LDL cholesterol ABCG8 intron 23063622 rs4299376 chr2 44072576 G T 2.32E-30 Cholesterol,total ABCG8 intron 23063622 rs4299376 chr2 44072576 G T 0.000000015 LDL cholesterol ABCG8 intron 23100282 rs4299376 chr2 44072576 G T 0.00000013 Apolipoprotein B levels ABCG8 intron 23100282 rs4299376 chr2 44072576 G T 1.50E-08 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) ABCG8 intron 23103227 rs4299376 chr2 44072576 G T 3.00E-73 Cholesterol,total ABCG8 intron 24097068 rs4299376 chr2 44072576 G T 4.00E-72 LDL cholesterol ABCG8 intron 24097068 rs41360247 chr2 44073656 T C 4.07E-09 Gallstones ABCG8 intron 17632509 rs41360247 chr2 44073656 T C 6.00E-25 Phytosterol levels ABCG8 intron 20529992 rs6544713 chr2 44073881 T C 2.00E-20 LDL cholesterol ABCG8 intron 19060906 rs6544713 chr2 44073881 T C 2.00E-20 Coronary heart disease ABCG8 intron 21347282 rs6544713 chr2 44073881 T C 0.00000153 Coronary artery disease (CAD) age >50 ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 0.0000443 Coronary artery disease with myocardial infarction ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 0.000155 Coronary artery disease (CAD) age <=50 ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 1.17E-44 Cholesterol,total ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 1.21E-10 Coronary artery disease (CAD) (males) ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 2.37E-47 LDL cholesterol ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 2.76E-10 Coronary artery disease ABCG8 intron 23202125 rs4953023 chr2 44074000 G A 3.40E-09 Gallstones ABCG8 intron 17632509 rs4953023 chr2 44074000 G A 0.00000642 LDL cholesterol (female) ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 0.000862 LDL cholesterol (male) ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 2.41E-08 LDL cholesterol ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 0.0000023 LDL cholesterol (male) ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 0.000354 Total cholesterol in males ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 3.67E-13 LDL cholesterol (female) ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 5.43E-19 LDL cholesterol ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 6.67E-17 Cholesterol,total ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 6.93E-14 Total cholesterol in females ABCG8 intron 23063622 rs4245791 chr2 44074431 C T 1.78E-04 Multiple complex diseases ABCG8 intron 17554300 rs4245791 chr2 44074431 C T 2.90E-08 Gallstones ABCG8 intron 17632509 rs4245791 chr2 44074431 C T 3.33E-08 Lipid levels ABCG8 intron 20370913 rs4245791 chr2 44074431 C T 2.00E-50 Phytosterol levels ABCG8 intron 20529992 rs4245791 chr2 44074431 C T 1.00E-09 LDL cholesterol ABCG8 intron 23726366 rs17424122 chr2 44075217 T A 5.00E-04 Gallstones ABCG8 intron 17632509 rs4148217 chr2 44099433 C A,G,T 4.91E-11 LDL cholesterol ABCG8 missense 23063622 rs4148217 chr2 44099433 C A,G,T 6.63E-11 Cholesterol,total ABCG8 missense 23063622 rs4148218 chr2 44099582 G A 4.52E-11 LDL cholesterol ABCG8 intron 23063622 rs4148218 chr2 44099582 G A 6.08E-12 Cholesterol,total ABCG8 intron 23063622 rs2955279 chr2 44112422 C T 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12465555 chr2 44118189 A G 3.72E-04 Type 2 diabetes LRPPRC intron 17463246 rs12465555 chr2 44118189 A G 3.27E-05 Amyotrophic lateral sclerosis LRPPRC intron 19193627 rs12465555 chr2 44118189 A G 3.05E-05 Non-word repetition LRPPRC intron 23738518 rs13387221 chr2 44135314 G A 9.00E-06 Intelligence (childhood) LRPPRC intron 23358156 rs4390811 chr2 44176225 G C 4.73E-05 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10206724 chr2 44185345 G A 3.68E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs6723119 chr2 44187204 A G 5.94E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10190161 chr2 44187829 A C 9.50E-06 Urinary metabolites LRPPRC intron 21572414 rs10190161 chr2 44187829 A C 6.43E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10865195 chr2 44189607 C T 8.77E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs11124960 chr2 44215710 C T 6.23E-05 Amyotrophic lateral sclerosis LRPPRC intron 19193627 rs6730684 chr2 44231918 C G 8.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6759184 chr2 44231969 A G 6.44E-05 Nonalcoholic fatty liver disease / / 21423719 rs6759184 chr2 44231969 A G 4.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9284745 chr2 44291333 C T 7.75E-04 Schizophrenia / / 19197363 rs7565605 chr2 44292977 C T 4.83E-04 Multiple complex diseases / / 17554300 rs7565605 chr2 44292977 C T 0.00067 Salmonella-induced pyroptosis / / 22837397 rs7570865 chr2 44305057 C A,G,T 3.95E-04 Multiple complex diseases / / 17554300 rs6544738 chr2 44305240 G A 8.38E-04 Multiple complex diseases / / 17554300 rs10193534 chr2 44306584 G C 7.09E-04 Multiple complex diseases / / 17554300 rs7607908 chr2 44307450 A G 5.10E-04 Type 2 diabetes / / 17463246 rs7606187 chr2 44315927 T C 1.42E-04 Parkinson's disease / / 17052657 rs6726274 chr2 44318652 A G 1.43E-04 Schizophrenia / / 20832056 rs7355599 chr2 44322757 A G 2.34E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7355599 chr2 44322757 A G 4.54E-05 Lung function (forced vital capacity) / / 24023788 rs2333825 chr2 44326923 A G 2.68E-06 Cardiovascular disease / / 18179892 rs6732415 chr2 44337872 G A 5.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs10495913 chr2 44343676 G A 7.59E-05 AIDS / / 19754311 rs11124972 chr2 44351536 T G 7.96E-05 Glucose levels / / pha003061 rs7593878 chr2 44358504 A C 5.44E-05 Obsessive-compulsive disorder / / 24821223 rs7593878 chr2 44358504 A C 5.44E-05 Obsessive-compulsive disorder / / 24821223 rs11894015 chr2 44359828 C A,G,T 2.10E-05 Urinary metabolites / / 21572414 rs6544744 chr2 44392252 G C 2.48E-04 Alzheimer's disease / / 17998437 rs6544745 chr2 44392271 C A 4.90E-04 Type 2 diabetes / / 17463246 rs10180864 chr2 44392395 G A 1.71E-04 Type 2 diabetes / / 17463246 rs7595470 chr2 44402467 T C 8.91E-05 Alzheimer's disease PPM1B intron 17998437 rs13008237 chr2 44404902 T C 1.23E-04 Alzheimer's disease PPM1B intron 17998437 rs6544746 chr2 44407985 G A 5.20E-04 Alzheimer's disease PPM1B intron 17998437 rs2053458 chr2 44443079 C G 9.57E-04 Alcohol dependence PPM1B intron 21314694 rs11124981 chr2 44462133 T A 2.40E-05 Alzheimer's disease PPM1B nearGene-3 17998437 rs4953076 chr2 44480950 G C 4.00E-09 Height / / 23563607 rs12712916 chr2 44482099 A C 3.92E-05 Alzheimer's disease / / 17998437 rs12712916 chr2 44482099 A C 1.50E-05 Urinary metabolites / / 21572414 rs3738985 chr2 44502788 A C 3.69E-04 Alzheimer's disease SLC3A1 cds-synon 17998437 rs3738985 chr2 44502788 A C 9.00E-06 Urinary metabolites SLC3A1 cds-synon 21572414 rs3768919 chr2 44512971 G A,C,T 1.80E-06 Urinary metabolites SLC3A1 intron 21572414 rs3768919 chr2 44512971 G A,C,T 2.29E-05 Asthma SLC3A1 intron 23181788 rs6706053 chr2 44517662 T C 1.70E-06 Urinary metabolites SLC3A1 intron 21572414 rs6706053 chr2 44517662 T C 1.07E-05 Asthma SLC3A1 intron 23181788 rs3738984 chr2 44531484 C T 6.40E-06 Urinary metabolites SLC3A1 intron 21572414 rs3738983 chr2 44531635 T C 8.03E-04 Type 2 diabetes SLC3A1 intron 17463246 rs1946932 chr2 44543125 C G 8.76E-05 Bipolar disorder and schizophrenia SLC3A1 intron 20889312 rs1946932 chr2 44543125 C G 3.84E-05 Bipolar disorder SLC3A1 intron 22925353 rs1372079 chr2 44543317 C T 4.79E-05 Bipolar disorder SLC3A1 intron 22925353 rs1372078 chr2 44543389 T A 1.10E-05 Urinary metabolites SLC3A1 intron 21572414 rs1142523 chr2 44545576 T C 8.36E-05 Cognitive test performance PREPL UTR-3 20125193 rs8410 chr2 44546016 C A,G,T 8.68E-05 Bipolar disorder and schizophrenia PREPL UTR-3 20889312 rs698761 chr2 44547574 G A 2.10E-05 Urinary metabolites SLC3A1 missense 21572414 rs2241869 chr2 44549229 G A 1.80E-05 Urinary metabolites PREPL intron 21572414 rs4953085 chr2 44554724 A G 8.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PREPL intron 23648065 rs4953088 chr2 44564518 A G 7.60E-06 Urinary metabolites PREPL intron 21572414 rs4953092 chr2 44565293 G A 1.30E-05 Urinary metabolites PREPL intron 21572414 rs2289463 chr2 44565447 A T 1.70E-05 Urinary metabolites PREPL intron 21572414 rs12472538 chr2 44566872 C A 5.34E-05 Odorant perception PREPL intron 23910658 rs698774 chr2 44584314 G A 1.80E-05 Urinary metabolites PREPL intron 21572414 rs786613 chr2 44590066 G C 1.40E-05 Urinary metabolites CAMKMT intron 21572414 rs786616 chr2 44592975 G C 1.50E-05 Urinary metabolites CAMKMT intron 21572414 rs1067344 chr2 44620810 T G 3.49E-04 Alcohol dependence CAMKMT intron 21314694 rs1067386 chr2 44644257 G T 8.10E-06 Urinary metabolites CAMKMT intron 21572414 rs1067383 chr2 44645911 G A 2.20E-05 Urinary metabolites CAMKMT intron 21572414 rs1584885 chr2 44647038 G T 2.07E-05 Bipolar disorder and schizophrenia CAMKMT intron 20889312 rs17498753 chr2 44647831 A G 5.69E-05 Bipolar disorder CAMKMT intron 19488044 rs17498753 chr2 44647831 A G 1.00E-06 Bipolar disorder CAMKMT intron 21738484 rs17498753 chr2 44647831 A G 6.93E-05 Bipolar Disorder CAMKMT intron pha002858 rs13414205 chr2 44662475 C T 7.00E-08 Immune reponse to smallpox (secreted TNF-alpha) CAMKMT intron 22610502 rs1085447 chr2 44670996 A G 1.40E-05 Urinary metabolites CAMKMT intron 21572414 rs1067409 chr2 44673057 T C 8.17E-04 Multiple complex diseases CAMKMT intron 17554300 rs17498998 chr2 44674151 T C 1.47E-04 Body mass index CAMKMT intron 17255346 rs1067405 chr2 44674861 T C 2.50E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs2166453 chr2 44693424 C T 5.76E-05 Bipolar disorder and schizophrenia CAMKMT intron 20889312 rs698813 chr2 44705615 A G 1.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) CAMKMT intron 24025145 rs698822 chr2 44720752 A G 2.44E-04 Multiple complex diseases CAMKMT intron 17554300 rs17581117 chr2 44724992 G A 4.19E-04 Type 2 diabetes CAMKMT intron 17463246 rs698838 chr2 44738763 C T 5.40E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs1223222 chr2 44756361 C A 6.60E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs2341459 chr2 44768202 T C 8.00E-10 Height CAMKMT intron 20881960 rs10170837 chr2 44771535 T G 8.50E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs10201401 chr2 44810480 G A 3.27E-04 Tourette syndrome CAMKMT intron 22889924 rs786180 chr2 44900846 G A 3.65E-05 Hemoglobin CAMKMT intron pha003096 rs653231 chr2 44903040 G A 2.60E-07 Urinary metabolites CAMKMT intron 21572414 rs343975 chr2 44911681 C G 6.00E-07 Urinary metabolites CAMKMT intron 21572414 rs343978 chr2 44916344 C T 1.33E-04 IgE levels CAMKMT intron 17255346 rs343955 chr2 44944877 G A 1.13E-05 Hemoglobin CAMKMT intron pha003096 rs343955 chr2 44944877 G A 5.40E-05 Hematocrit CAMKMT intron pha003097 rs343964 chr2 44966378 A G 4.60E-05 Hemoglobin CAMKMT intron pha003096 rs12473962 chr2 44974370 C A 3.50E-04 Myasthenia gravis CAMKMT intron 23055271 rs343935 chr2 44991100 T C 9.20E-04 Type 2 diabetes and 6 quantitative traits CAMKMT intron 17848626 rs343936 chr2 44992550 T C 4.75E-05 Hemoglobin CAMKMT intron pha003096 rs11679997 chr2 44993487 C T 3.14E-05 Bone mineral traits,in men CAMKMT intron 21427758 rs11679997 chr2 44993487 C T 6.73E-05 Bone mineral traits,in men CAMKMT intron 21427758 rs10495921 chr2 45003555 A G 2.66E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10203604 chr2 45087265 C T 0.0000451 Tuberculosis with late age of onset / / 22551897 rs11674185 chr2 45095097 G A 0.0000727 Tuberculosis with late age of onset / / 22551897 rs529177 chr2 45100208 T G 1.60E-05 Urinary metabolites / / 21572414 rs737447 chr2 45106017 T G 3.29E-05 Response to metformin / / 21186350 rs4952726 chr2 45107621 T C 3.73E-05 Response to metformin / / 21186350 rs6740875 chr2 45117702 G A 6.10E-04 Multiple complex diseases / / 17554300 rs7561677 chr2 45129440 C T 1.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs518853 chr2 45141218 G A 9.69E-04 Type 2 diabetes / / 17463246 rs528301 chr2 45154908 G A 5.00E-06 Alcohol and nictotine co-dependence / / 22488850 rs1983312 chr2 45187127 G A 5.80E-04 Rheumatoid arthritis / / 21452313 rs895636 chr2 45188353 C T 1.00E-12 Metabolite levels / / 21909109 rs340514 chr2 45189011 C T 3.52E-04 Type 2 diabetes / / 17463246 rs4953156 chr2 45189763 G A 9.03E-04 Rheumatoid arthritis / / 21452313 rs6705604 chr2 45216585 G A 3.38E-04 Cognitive decline / / 23732972 rs2290030 chr2 45232686 A C 3.31E-04 Multiple complex diseases SIX2 UTR-3 17554300 rs2290030 chr2 45232686 A C 9.54E-04 Amyotrophic lateral sclerosis (sporadic) SIX2 UTR-3 24529757 rs1447106 chr2 45239021 T C 5.18E-04 Type 2 diabetes / / 17846125 rs921120 chr2 45273041 A G 8.23E-05 Coronary heart disease / / pha003030 rs4355165 chr2 45285952 G T 5.00E-04 HIV-1 viral setpoint / / 17641165 rs2959233 chr2 45311515 G A 6.01E-04 Type 2 diabetes / / 17463246 rs2959236 chr2 45312967 T C 5.47E-04 Alcohol dependence / / 20201924 rs908568 chr2 45336379 C T 9.29E-05 Serum metabolites / / 19043545 rs868714 chr2 45336859 T G 8.78E-05 Serum metabolites / / 19043545 rs868714 chr2 45336859 T G 9.67E-05 Relative hand skill in reading disability / / 24068947 rs13027491 chr2 45340575 T A 9.73E-05 Relative hand skill in reading disability / / 24068947 rs17337049 chr2 45369224 C T 7.40E-05 Memory performance / / 22105620 rs992618 chr2 45387774 C T 4.06E-05 Prostate cancer / / 23023329 rs10206235 chr2 45389301 A G 6.80E-05 HIV-1 control / / 20041166 rs12712936 chr2 45390835 G A 0.00000893 Cytarabine sensitivity / / 23538338 rs10209754 chr2 45404169 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UNQ6975 intron 20877124 rs10209754 chr2 45404169 T C 6.12E-04 Aortic root size UNQ6975 intron 21223598 rs6720296 chr2 45408269 A C 3.93E-04 Rheumatoid arthritis UNQ6975 intron 21452313 rs12476824 chr2 45413394 A G 3.10E-05 Height UNQ6975 intron pha003010 rs12476824 chr2 45413394 A G 6.08E-05 Height UNQ6975 intron pha003011 rs7569588 chr2 45420082 G T 7.00E-04 Amyotrophic lateral sclerosis UNQ6975 intron 17671248 rs7569588 chr2 45420082 G T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes UNQ6975 intron 22628534 rs11125007 chr2 45426104 G A 4.50E-04 Cocaine dependence UNQ6975 intron 23958962 rs11125007 chr2 45426104 G A 9.04E-05 Cocaine dependence UNQ6975 intron 23958962 rs4953208 chr2 45437361 A G 9.81E-04 Type 2 diabetes UNQ6975 intron 17463246 rs11125013 chr2 45465435 A G 7.18E-04 Response to taxane treatment (placlitaxel) UNQ6975 intron 23006423 rs7595329 chr2 45483869 T C 0.000634 fMRI brain tests in schizophrenia / / 22440650 rs7594273 chr2 45493703 T C 3.21E-05 IgE levels / / 17255346 rs918810 chr2 45494927 G A 1.66E-04 IgE levels / / 17255346 rs7579209 chr2 45498718 C T 3.42E-04 IgE levels / / 17255346 rs870575 chr2 45503260 G A 5.90E-07 Parkinson's disease / / 20711177 rs12476712 chr2 45506771 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs7561692 chr2 45509817 T C 8.35E-04 Iron levels / / pha002876 rs2042474 chr2 45510971 T C 4.93E-06 Vitiligo / / 22951725 rs1862890 chr2 45514154 T C 4.77E-06 Vitiligo / / 22951725 rs6737073 chr2 45530679 C G 2.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1862893 chr2 45546106 G T 8.22E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12473388 chr2 45549305 T C 3.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16909 chr2 45551530 A G 5.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4245803 chr2 45574206 G A 4.30E-04 Alcohol dependence / / 20201924 rs10167668 chr2 45582319 A G 1.12E-06 Alcohol and nictotine co-dependence / / 20158304 rs2067981 chr2 45595266 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2067981 chr2 45595266 A G 9.44E-05 Cognitive test performance / / 20125193 rs1862071 chr2 45600699 G A 2.20E-05 Urinary metabolites / / 21572414 rs4952763 chr2 45608066 C T 2.04E-04 Multiple complex diseases / / 17554300 rs2216506 chr2 45635465 T C 8.70E-04 Alcohol dependence SRBD1 intron 20201924 rs3213787 chr2 45646824 A G 3.00E-09 Glaucoma SRBD1 intron 20363506 rs3770251 chr2 45668670 T C 2.82E-05 Vitiligo SRBD1 intron 19890347 rs3755076 chr2 45669349 T C 8.71E-05 Multiple complex diseases SRBD1 intron 17554300 rs17394081 chr2 45692947 C T 1.59E-05 Type 2 diabetes SRBD1 intron 17463246 rs17394081 chr2 45692947 C T 2.40E-04 Multiple complex diseases SRBD1 intron 17554300 rs6712896 chr2 45707814 A C 1.57E-04 Smoking initiation SRBD1 intron 24665060 rs17322265 chr2 45719992 C T 2.12E-05 Common variable immunodeficiency SRBD1 intron 21497890 rs10427402 chr2 45744392 G T 2.37E-04 Multiple complex diseases SRBD1 intron 17554300 rs4476395 chr2 45748712 C A 7.99E-04 Multiple complex diseases SRBD1 intron 17554300 rs4425122 chr2 45749523 C T 5.04E-04 Type 2 diabetes SRBD1 intron 17463246 rs4425122 chr2 45749523 C T 4.59E-04 Multiple complex diseases SRBD1 intron 17554300 rs2112040 chr2 45752214 G A 8.70E-05 Glioma (high-grade) SRBD1 intron 19578366 rs2082876 chr2 45769170 C A 4.28E-05 Glaucoma (primary open-angle) SRBD1 intron 22605921 rs748573 chr2 45770394 C G 3.59E-04 Multiple complex diseases SRBD1 intron 17554300 rs6708810 chr2 45774050 G A 4.90E-04 Type 2 diabetes SRBD1 intron 17463246 rs6708810 chr2 45774050 G A 4.74E-04 Multiple complex diseases SRBD1 intron 17554300 rs6710581 chr2 45779218 C A 7.01E-04 Type 2 diabetes SRBD1 intron 17463246 rs6710581 chr2 45779218 C A 4.30E-04 Multiple complex diseases SRBD1 intron 17554300 rs718731 chr2 45831537 A G 2.00E-04 Information processing speed SRBD1 intron 21130836 rs1403450 chr2 45843275 G A 6.06E-04 Myopia (pathological) / / 21095009 rs6713298 chr2 45850077 C T 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7565326 chr2 45850809 C T 5.13E-05 Multiple complex diseases / / 17554300 rs12622230 chr2 45855315 A C 4.02E-05 Alcohol dependence / / 20201924 rs12622230 chr2 45855315 A C 4.02E-05 Alcoholism / / pha002891 rs2344662 chr2 45864710 A C 2.27E-05 Anxiety in major depressive disorder / / 24047446 rs3731949 chr2 45900565 C T 3.20E-04 Myopia (pathological) PRKCE intron 21095009 rs542413 chr2 45922031 G A 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCE intron 20877124 rs11674329 chr2 45928086 A C 0.000530036 Hypertension (early onset hypertension) PRKCE intron 22479346 rs6743119 chr2 45959960 T C 5.81E-04 Type 2 diabetes PRKCE intron 17463246 rs4953246 chr2 45980110 T C 6.51E-04 Obesity (extreme) PRKCE intron 21935397 rs938661 chr2 45981920 T C 8.30E-06 Urinary metabolites PRKCE intron 21572414 rs867286 chr2 45982030 G A 3.30E-05 Bipolar disorder and schizophrenia PRKCE intron 20889312 rs867286 chr2 45982030 G A 4.39E-04 Obesity (extreme) PRKCE intron 21935397 rs884401 chr2 45982608 T C 9.92E-04 Obesity (extreme) PRKCE intron 21935397 rs884400 chr2 45982645 T C 1.70E-05 Urinary metabolites PRKCE intron 21572414 rs884399 chr2 45982925 G T 4.22E-04 Obesity (extreme) PRKCE intron 21935397 rs4953249 chr2 45992857 G A 7.30E-06 Major depression (suicidal thoughts and behavior) PRKCE intron 21750702 rs4953251 chr2 45994586 C T 5.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCE intron 20877124 rs3924521 chr2 45995181 G A 0.00034 Breast cancer PRKCE intron 23555315 rs3924523 chr2 45995350 A G 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PRKCE intron 17982456 rs13404973 chr2 45997411 G A 1.62E-04 Autism spectrum disorders (language delay) PRKCE intron 21519539 rs13405086 chr2 45997519 G A 1.62E-04 Autism spectrum disorders (language delay) PRKCE intron 21519539 rs7558342 chr2 46015851 T G 1.13E-05 Serum metabolites PRKCE intron 19043545 rs11898074 chr2 46018223 A C 4.49E-04 Response to cholinesterase inhibitors in Alzheimer's disease PRKCE intron 23374588 rs11898209 chr2 46018533 A G 2.40E-05 Hypothyroidism PRKCE intron 22493691 rs6743144 chr2 46026901 A G 2.10E-05 Urinary metabolites PRKCE intron 21572414 rs4953260 chr2 46033719 C T 8.60E-05 Hypothyroidism PRKCE intron 22493691 rs7593800 chr2 46039147 C T 8.03E-05 Biliary atresia PRKCE intron 20460270 rs3886870 chr2 46042478 G A 2.43E-05 Hypertension PRKCE intron pha003041 rs3886870 chr2 46042478 G A 7.00E-06 Hypertension PRKCE intron pha003042 rs935672 chr2 46045959 C T 4.10E-04 Type 2 diabetes PRKCE intron 17463246 rs12328510 chr2 46051529 C G 2.30E-05 Parkinson's disease (age of onset) PRKCE intron 19772629 rs6747706 chr2 46052497 A C 7.79E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs13409215 chr2 46053362 C G 7.29E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs935661 chr2 46055357 G T 4.20E-04 Type 2 diabetes and 6 quantitative traits PRKCE intron 17848626 rs10865208 chr2 46056502 C T 8.61E-04 Type 2 diabetes PRKCE intron 17463246 rs935656 chr2 46064857 C T 1.63E-04 Coronary Artery Disease PRKCE intron 17634449 rs7593255 chr2 46074687 C T 1.53E-04 Multiple complex diseases PRKCE intron 17554300 rs1947195 chr2 46085325 C T 2.38E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs1992932 chr2 46087873 T C 9.73E-05 Progressive supranuclear palsy PRKCE intron 21685912 rs10189339 chr2 46093760 G A 1.49E-05 Progressive supranuclear palsy PRKCE intron 21685912 rs12467641 chr2 46102141 A T 3.11E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs11125041 chr2 46108945 C T 1.63E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs13431763 chr2 46110574 G A 1.34E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs878812 chr2 46133791 T C 2.51E-04 Multiple complex diseases PRKCE intron 17554300 rs13417518 chr2 46136825 G T 3.09E-06 Left ventricular mass PRKCE intron 21212386 rs6720958 chr2 46158523 C A 1.20E-05 Urinary metabolites PRKCE intron 21572414 rs13036100 chr2 46158690 G A 9.87E-04 Multiple complex diseases PRKCE intron 17554300 rs13023787 chr2 46174736 A G 5.59E-04 Smoking initiation PRKCE intron 24665060 rs11903566 chr2 46175313 G A 0.00000359 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PRKCE intron 22628534 rs6750700 chr2 46176403 C A 4.15E-04 Body mass index PRKCE intron 17255346 rs6751349 chr2 46176962 C A 8.00E-06 QT interval PRKCE intron 23166209 rs12471357 chr2 46179662 T C 6.03E-06 Response to tocilizumab in rheumatoid arthritis PRKCE intron 22491018 rs2595199 chr2 46187460 T C 3.14E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PRKCE intron 24023788 rs7607360 chr2 46194334 A G 2.00E-04 Cognitive impairment induced by topiramate PRKCE intron 22091778 rs13396424 chr2 46205039 T G 8.00E-06 Metabolite levels (X-11787) PRKCE intron 23934736 rs2595211 chr2 46206752 T G 9.02E-04 Nicotine dependence PRKCE intron 17158188 rs6705717 chr2 46207966 G A 9.94E-04 Type 2 diabetes PRKCE intron 17463246 rs2122112 chr2 46219949 T G 9.76E-05 Cognitive performance PRKCE intron 19734545 rs11903923 chr2 46258941 C T 9.26E-04 Rheumatoid arthritis PRKCE intron 21452313 rs1470598 chr2 46269567 A G 6.93E-04 Nicotine smoking PRKCE intron 19268276 rs6751805 chr2 46287743 A G 3.19E-04 Blood pressure PRKCE intron 17255346 rs12712962 chr2 46294811 T C 8.32E-04 Response to cytidine analogues (gemcitabine) PRKCE intron 24483146 rs12712963 chr2 46294981 A G 1.92E-04 Multiple complex diseases PRKCE intron 17554300 rs12712963 chr2 46294981 A G 1.32E-04 Response to cytidine analogues (gemcitabine) PRKCE intron 24483146 rs12712963 chr2 46294981 A G 4.25E-04 Response to cytadine analogues (cytosine arabinoside) PRKCE intron 24483146 rs13432276 chr2 46311960 A C 3.62E-05 Gaucher disease severity PRKCE intron 22388998 rs2345955 chr2 46320880 C T 8.20E-04 Nicotine smoking PRKCE intron 19268276 rs2345955 chr2 46320880 C T 1.69E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs2345955 chr2 46320880 C T 7.27E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12373805 chr2 46321094 G A 7.52E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12373805 chr2 46321094 G A 9.20E-06 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10167555 chr2 46321106 T G 3.47E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10167555 chr2 46321106 T G 6.95E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10202504 chr2 46321333 C G 1.60E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10202504 chr2 46321333 C G 7.89E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs4953309 chr2 46322766 C G 3.81E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs4953309 chr2 46322766 C G 6.07E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477342 chr2 46327870 C T 1.35E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477342 chr2 46327870 C T 7.30E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477409 chr2 46327960 G C 1.24E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477409 chr2 46327960 G C 7.23E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs7568264 chr2 46328552 A G 1.95E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs7568264 chr2 46328552 A G 6.66E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1116246 chr2 46329867 G A 1.31E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1116246 chr2 46329867 G A 6.87E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 1.42E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 6.78E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 7.00E-06 Pulmonary function decline PRKCE intron 22424883 rs12712970 chr2 46333694 G A 1.62E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712970 chr2 46333694 G A 8.62E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs11680282 chr2 46334021 C G 8.86E-04 Body mass index PRKCE intron 21701565 rs11684352 chr2 46334632 A G 7.09E-04 Body mass index PRKCE intron 21701565 rs1597156 chr2 46338714 C T 1.84E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1597156 chr2 46338714 C T 8.31E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375055 chr2 46340378 G A 1.81E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375055 chr2 46340378 G A 8.13E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375054 chr2 46340462 G T 8.80E-04 Body mass index PRKCE intron 21701565 rs3768752 chr2 46343003 C A 1.67E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs3768752 chr2 46343003 C A 7.88E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12619351 chr2 46343735 G T 3.01E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12619351 chr2 46343735 G T 9.83E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12616328 chr2 46345345 G A 5.84E-04 Multiple complex diseases PRKCE intron 17554300 rs3768751 chr2 46346716 T C 2.96E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs3768751 chr2 46346716 T C 1.58E-10 Red blood cell traits PRKCE intron 23222517 rs3768750 chr2 46347023 G A 3.70E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs3768750 chr2 46347023 G A 3.01E-10 Red blood cell traits PRKCE intron 23222517 rs17034581 chr2 46347196 A T 3.02E-08 Red blood cell traits PRKCE intron 23222517 rs4952800 chr2 46347606 G A 4.07E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs4952800 chr2 46347606 G A 4.89E-10 Red blood cell traits PRKCE intron 23222517 rs2218660 chr2 46347792 T G 2.58E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs2218660 chr2 46347792 T G 4.84E-10 Red blood cell traits PRKCE intron 23222517 rs17737466 chr2 46348878 C T 9.76E-04 Tourette syndrome PRKCE intron 22889924 rs3768747 chr2 46352058 A C 3.31E-09 Red blood cell traits PRKCE intron 23222517 rs3754569 chr2 46352453 G T 5.86E-11 Red blood cell traits PRKCE intron 23222517 rs10495927 chr2 46352499 A G 1.43E-07 Red blood cell traits PRKCE intron 23222517 rs10495928 chr2 46353166 A G 7.00E-13 Hemoglobin PRKCE intron 19862010 rs10495928 chr2 46353166 A G 3.81E-08 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 4.61E-06 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 5.00E-06 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 1.02E-13 Red blood cell traits PRKCE intron 23222517 rs10495928 chr2 46353166 A G 2.76E-04 Red blood cell traits PRKCE intron 23935956 rs10495928 chr2 46353166 A G 4.45E-04 Red blood cell traits PRKCE intron 23935956 rs4952801 chr2 46354245 T A,C 1.56E-08 Red blood cell traits PRKCE intron 23222517 rs4953318 chr2 46355051 A C 1.18E-12 Other erythrocyte phenotypes PRKCE intron 19862010 rs4953318 chr2 46355051 A C 3.00E-19 Red blood cell traits PRKCE intron 23222517 rs13008603 chr2 46355848 C A 1.39E-08 Other erythrocyte phenotypes PRKCE intron 19862010 rs13008603 chr2 46355848 C A 2.31E-08 Red blood cell traits PRKCE intron 23222517 rs13008603 chr2 46355848 C A 4.00E-09 Red blood cell traits PRKCE intron 23446634 rs17737768 chr2 46357133 T C 5.46E-09 Red blood cell traits PRKCE intron 23222517 rs10184620 chr2 46358535 A G 7.23E-09 Other erythrocyte phenotypes PRKCE intron 19862010 rs10184620 chr2 46358535 A G 9.92E-08 Red blood cell traits PRKCE intron 23222517 rs17034610 chr2 46359079 A G 6.90E-04 Body mass index PRKCE intron 21701565 rs10168349 chr2 46360907 G C 4.00E-15 Hematocrit PRKCE intron 19862010 rs10168349 chr2 46360907 G C 5.00E-07 Blood cell counts and other traits PRKCE intron 20139978 rs10168349 chr2 46360907 G C 5.07E-07 Blood cell counts and other traits PRKCE intron 20139978 rs10168349 chr2 46360907 G C 2.75E-14 Red blood cell traits PRKCE intron 23222517 rs12105417 chr2 46361255 A C 1.45E-10 Red blood cell traits PRKCE intron 23222517 rs10183887 chr2 46361808 T A 6.13E-09 Red blood cell traits PRKCE intron 23222517 rs10198247 chr2 46362677 A G 1.07E-10 Red blood cell traits PRKCE intron 23222517 rs13406773 chr2 46362868 T C 4.58E-09 Red blood cell traits PRKCE intron 23222517 rs13406901 chr2 46363066 T G 6.47E-09 Red blood cell traits PRKCE intron 23222517 rs11690961 chr2 46363336 A C 4.39E-09 Red blood cell traits PRKCE intron 23222517 rs6724315 chr2 46363699 T C 1.86E-08 Red blood cell traits PRKCE intron 23222517 rs13410378 chr2 46363807 T C 1.36E-07 Red blood cell traits PRKCE intron 23222517 rs12992366 chr2 46365920 G A 7.34E-09 Other erythrocyte phenotypes PRKCE intron 19862010 rs12992366 chr2 46365920 G A 5.76E-09 Red blood cell traits PRKCE intron 23222517 rs2053797 chr2 46370892 G A 6.81E-05 Multiple complex diseases PRKCE intron 17554300 rs2053797 chr2 46370892 G A 7.04E-09 Red blood cell traits PRKCE intron 23222517 rs3754568 chr2 46371214 T C 4.65E-07 Red blood cell traits PRKCE intron 23222517 rs10495929 chr2 46372174 G A 1.70E-08 Red blood cell traits PRKCE intron 23222517 rs12990867 chr2 46372411 G A 6.19E-10 Red blood cell traits PRKCE intron 23222517 rs17034641 chr2 46372644 G A 7.58E-05 Multiple complex diseases PRKCE intron 17554300 rs17034641 chr2 46372644 G A 4.61E-09 Red blood cell traits PRKCE intron 23222517 rs10495930 chr2 46372675 A G 1.72E-08 Red blood cell traits PRKCE intron 23222517 rs6544874 chr2 46374385 G A 5.99E-08 Red blood cell traits PRKCE intron 23222517 rs4953321 chr2 46383399 G T 3.51E-04 Multiple complex diseases PRKCE intron 17554300 rs10205024 chr2 46385339 A G 0.00000168 Central corneal thickness PRKCE intron 22661486 rs10205024 chr2 46385339 A G 1.68E-06 Testosterone levels PRKCE intron 22675492 rs3820729 chr2 46392775 C T 8.33E-07 Red blood cell traits PRKCE intron 23222517 rs281472 chr2 46403837 A G 4.80E-05 Cognitive test performance PRKCE intron 20125193 rs14138 chr2 46414446 G A 3.52E-05 Post-operative nausea and vomiting PRKCE UTR-3 21694509 rs281500 chr2 46417808 C G 1.70E-04 Height / / 17255346 rs281498 chr2 46419958 T C 1.20E-06 Urinary metabolites / / 21572414 rs714104 chr2 46464796 A G 9.18E-04 Multiple complex diseases / / 17554300 rs17745066 chr2 46488081 G A 5.93E-04 Tourette syndrome / / 22889924 rs1867787 chr2 46525391 G C 1.90E-07 Renal cell carcinoma EPAS1 intron 21131975 rs10211665 chr2 46526096 T C 1.90E-07 Renal cell carcinoma EPAS1 intron 21131975 rs11125068 chr2 46527816 A G 2.30E-08 Renal cell carcinoma EPAS1 intron 21131975 rs2346417 chr2 46528961 T A 8.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs1867783 chr2 46529302 G C 1.30E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11894252 chr2 46533376 T C 9.10E-09 Renal cell carcinoma EPAS1 intron 21131975 rs11894252 chr2 46533376 T C 1.80E-08 Renal cell carcinoma EPAS1 intron 22010048 rs11684885 chr2 46533552 T G 9.00E-09 Renal cell carcinoma EPAS1 intron 21131975 rs1867784 chr2 46534220 T C 6.20E-09 Renal cell carcinoma EPAS1 intron 21131975 rs1867785 chr2 46534338 A G 8.80E-09 Renal cell carcinoma EPAS1 intron 21131975 rs2121266 chr2 46535924 C A 1.40E-08 Renal cell carcinoma EPAS1 intron 21131975 rs4952818 chr2 46537056 C T 2.80E-08 Renal cell carcinoma EPAS1 intron 21131975 rs7579899 chr2 46537604 A G 2.00E-09 Renal cell carcinoma EPAS1 intron 21131975 rs17034950 chr2 46538794 G A 8.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs11689011 chr2 46541176 T C 2.60E-08 Renal cell carcinoma EPAS1 intron 21131975 rs10495932 chr2 46545818 G T 8.33E-04 Multiple complex diseases EPAS1 intron 17554300 rs2044456 chr2 46546316 A G 4.40E-07 Renal cell carcinoma EPAS1 intron 21131975 rs4953340 chr2 46548064 C G 5.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs9973653 chr2 46548109 G T 1.60E-07 Renal cell carcinoma EPAS1 intron 21131975 rs2034327 chr2 46549040 G C 7.20E-07 Renal cell carcinoma EPAS1 intron 21131975 rs2121267 chr2 46549389 T C 6.60E-05 Kidney function and endocine traits EPAS1 intron 17903292 rs2121267 chr2 46549389 T C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) EPAS1 intron 17982456 rs2121267 chr2 46549389 T C 2.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs895436 chr2 46550492 G C 6.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4952819 chr2 46550718 G C 1.83E-04 Multiple complex diseases EPAS1 intron 17554300 rs4952819 chr2 46550718 G C 6.80E-06 Renal cell carcinoma EPAS1 intron 21131975 rs7582701 chr2 46550769 G C 1.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 2.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 4.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 4.00E-06 IgG glycosylation EPAS1 intron 23382691 rs4953342 chr2 46552047 A G 3.62E-05 Brain structure EPAS1 intron 22504417 rs4953343 chr2 46552177 G C 3.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4953345 chr2 46552601 T A 9.10E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4952820 chr2 46553966 A G 4.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11125071 chr2 46554533 C G 4.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs1868089 chr2 46554646 C T 4.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12613519 chr2 46555221 A G 8.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12613526 chr2 46555263 A G 8.60E-06 Renal cell carcinoma EPAS1 intron 21131975 rs10208823 chr2 46555670 T C 3.50E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12712973 chr2 46556633 A C 8.50E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12620992 chr2 46556761 G C 5.10E-06 Renal cell carcinoma EPAS1 intron 21131975 rs6706717 chr2 46556824 A G 5.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11900910 chr2 46557600 C T 9.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs9679290 chr2 46557644 G C 3.38E-04 Multiple complex diseases EPAS1 intron 17554300 rs9679290 chr2 46557644 G C 7.30E-06 Renal cell carcinoma EPAS1 intron 21131975 rs35366004 chr2 46557962 G T 7.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4953346 chr2 46558208 T G 1.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953347 chr2 46558225 A G 1.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953348 chr2 46558432 A G 1.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6758592 chr2 46558541 T C 2.20E-05 Renal cell carcinoma EPAS1 intron 21131975 rs12617313 chr2 46559776 A T 1.90E-05 Renal cell carcinoma EPAS1 intron 21131975 rs11125072 chr2 46560084 T A 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953349 chr2 46560644 T A,G 2.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6726454 chr2 46561202 A G 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6726570 chr2 46561309 A G 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4145837 chr2 46561816 G A 1.80E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6706003 chr2 46563392 C G 3.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953351 chr2 46564583 C A 7.20E-05 Renal cell carcinoma EPAS1 intron 21131975 rs12614710 chr2 46565091 T G 2.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953352 chr2 46565522 T C 5.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4035887 chr2 46567227 A G 9.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953353 chr2 46567276 G T 3.41E-04 Hemoglobin concentration EPAS1 intron 20534544 rs2346175 chr2 46571310 T C 2.00E-04 Renal cell carcinoma EPAS1 intron 21131975 rs10191091 chr2 46573210 C T 8.15E-06 Hearing function EPAS1 intron 21493956 rs6715787 chr2 46576172 C G 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs17035010 chr2 46576488 C T 7.50E-05 Renal cell carcinoma EPAS1 intron 21131975 rs17035013 chr2 46576573 T C 1.80E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6544887 chr2 46577212 T C 2.18E-06 Hearing function EPAS1 intron 21493956 rs6544888 chr2 46577265 A C 2.19E-06 Hearing function EPAS1 intron 21493956 rs6544889 chr2 46577299 G A 2.18E-06 Hearing function EPAS1 intron 21493956 rs4953356 chr2 46578924 G T 3.79E-06 Hearing function EPAS1 intron 21493956 rs6743087 chr2 46579348 T C 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6756667 chr2 46579409 A G 6.14E-06 Hemoglobin concentration EPAS1 intron 20534544 rs6756667 chr2 46579409 A G 9.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6756667 chr2 46579409 A G 3.73E-06 Hearing function EPAS1 intron 21493956 rs6756667 chr2 46579409 A G 2.00E-04 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs6756667 chr2 46579409 A G 9.87E-05 Body Mass Index EPAS1 intron pha003006 rs6756667 chr2 46579409 A G 6.85E-05 Weight EPAS1 intron pha003026 rs1562451 chr2 46579730 C T 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs1562452 chr2 46580444 G A 2.61E-06 Hearing function EPAS1 intron 21493956 rs1562452 chr2 46580444 G A 8.60E-05 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs1562452 chr2 46580444 G A 9.76E-05 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs1562453 chr2 46580474 T C 6.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs1562453 chr2 46580474 T C 3.76E-06 Hearing function EPAS1 intron 21493956 rs6735812 chr2 46581074 C G 4.47E-06 Hearing function EPAS1 intron 21493956 rs4953358 chr2 46581453 C G 7.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953358 chr2 46581453 C G 4.56E-06 Hearing function EPAS1 intron 21493956 rs7599883 chr2 46581544 T A 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953359 chr2 46581643 C T 4.63E-06 Hearing function EPAS1 intron 21493956 rs7589621 chr2 46582382 G A 7.15E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7589621 chr2 46582382 G A 3.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6712143 chr2 46582891 A G 3.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6743991 chr2 46583235 C A 4.27E-06 Hearing function EPAS1 intron 21493956 rs2278753 chr2 46583593 G A 6.60E-04 Renal cell carcinoma EPAS1 intron 21131975 rs10176396 chr2 46584573 C T 3.20E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6707241 chr2 46584852 C T 8.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6707241 chr2 46584852 C T 7.32E-06 Hearing function EPAS1 intron 21493956 rs6740096 chr2 46585888 A T 8.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6740096 chr2 46585888 A T 7.34E-06 Hearing function EPAS1 intron 21493956 rs7583554 chr2 46587097 T C 1.93E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7583554 chr2 46587097 T C 6.80E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953360 chr2 46589179 A G 6.70E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6755594 chr2 46589295 A G 9.00E-04 Renal cell carcinoma EPAS1 intron 21131975 rs13412887 chr2 46589487 C G 0.00031 Coronary artery calcification EPAS1 intron 23727086 rs3768729 chr2 46592006 T C 9.62E-05 Hemoglobin concentration EPAS1 intron 20534544 rs3768729 chr2 46592006 T C 6.70E-04 Renal cell carcinoma EPAS1 intron 21131975 rs3768730 chr2 46592524 G T 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPAS1 intron 20877124 rs3768730 chr2 46592524 G T 3.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPAS1 intron 20877124 rs1374749 chr2 46596433 G A 1.38E-04 Hemoglobin concentration EPAS1 intron 20534544 rs1374749 chr2 46596433 G A 6.84E-05 Waist Circumference EPAS1 intron pha003024 rs1374749 chr2 46596433 G A 5.61E-05 Waist Circumference EPAS1 intron pha003025 rs1374749 chr2 46596433 G A 5.61E-05 Weight EPAS1 intron pha003026 rs6753127 chr2 46597296 T C 3.51E-05 Body Mass Index EPAS1 intron pha003014 rs1992846 chr2 46597581 C T 4.11E-04 Hemoglobin concentration EPAS1 intron 20534544 rs7583088 chr2 46603165 A G 7.30E-06 Hemoglobin concentration EPAS1 intron 20534544 rs7583088 chr2 46603165 A G 2.99E-04 Myopia (pathological) EPAS1 intron 21095009 rs7583088 chr2 46603165 A G 5.35E-05 Body Mass Index EPAS1 intron pha003006 rs7583088 chr2 46603165 A G 2.59E-05 Waist Circumference EPAS1 intron pha003024 rs7583088 chr2 46603165 A G 8.73E-05 Waist Circumference EPAS1 intron pha003025 rs7583088 chr2 46603165 A G 2.73E-05 Weight EPAS1 intron pha003026 rs17035085 chr2 46605287 A G 5.96E-06 Hair morphology EPAS1 intron 19896111 rs13019268 chr2 46610212 A C 9.76E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7577700 chr2 46610605 T G 3.93E-06 Hair morphology EPAS1 intron 19896111 rs1868092 chr2 46614202 G A 2.95E-07 Hemoglobin concentration LOC100652809 intron 20534544 rs1868092 chr2 46614202 G A 7.58E-05 Body Mass Index LOC100652809 intron pha003006 rs1868092 chr2 46614202 G A 5.72E-05 Waist Circumference LOC100652809 intron pha003024 rs1868092 chr2 46614202 G A 8.15E-05 Waist Circumference LOC100652809 intron pha003025 rs1868092 chr2 46614202 G A 5.35E-05 Weight LOC100652809 intron pha003026 rs11689694 chr2 46617182 T C 6.83E-05 Hemoglobin concentration LOC100652809 intron 20534544 rs17035106 chr2 46633478 G A,C,T 6.38E-06 Hair morphology / / 19896111 rs12623288 chr2 46634645 G A 3.00E-06 Hair morphology / / 19896111 rs13011481 chr2 46635648 T C 9.78E-06 Hemoglobin concentration / / 20534544 rs13011481 chr2 46635648 T C 2.54E-04 Myopia (pathological) / / 21095009 rs12615428 chr2 46636277 T G 2.04E-05 Hemoglobin concentration / / 20534544 rs1447563 chr2 46637364 A C 5.15E-08 Hemoglobin concentration / / 20534544 rs2346177 chr2 46642249 G A 2.00E-06 Coronary heart disease / / 21347282 rs1530623 chr2 46651680 C T 1.90E-04 Multiple complex diseases / / 17554300 rs11125075 chr2 46656344 A G,T 6.10E-08 Hemoglobin concentration / / 20534544 rs7587138 chr2 46657089 G A 2.50E-05 Urinary metabolites / / 21572414 rs7571742 chr2 46660306 A G 4.89E-05 Brain structure / / 22504417 rs7559484 chr2 46660445 T C 4.48E-05 Brain structure / / 22504417 rs12986899 chr2 46660752 A C 1.56E-05 Brain structure / / 22504417 rs7556828 chr2 46663172 G A 3.89E-05 Brain structure / / 22504417 rs1530628 chr2 46670941 T C 4.98E-05 Brain structure / / 22504417 rs7565770 chr2 46683683 A C 2.61E-05 Abdominal aortic aneurysm / / 22055160 rs7565770 chr2 46683683 A C 2.89E-05 Brain structure / / 22504417 rs1530621 chr2 46688688 T C 2.88E-05 Brain structure / / 22504417 rs2121698 chr2 46709571 C T 3.33E-05 Brain structure LOC388946 intron 22504417 rs4953388 chr2 46713201 G A 1.59E-09 Hemoglobin concentration / / 20534544 rs7590802 chr2 46723219 C A 8.56E-06 Hemoglobin concentration / / 20534544 rs6544898 chr2 46732771 A G 6.65E-05 Serum metabolites / / 19043545 rs4953396 chr2 46736794 C A 1.03E-04 Parkinson's disease / / 17052657 rs4953396 chr2 46736794 C A 7.88E-09 Hemoglobin concentration / / 20534544 rs12470532 chr2 46738846 T C 8.07E-04 Multiple complex diseases / / 17554300 rs12470532 chr2 46738846 T C 2.54E-05 Serum metabolites / / 19043545 rs3814045 chr2 46739157 A G 2.62E-05 Serum metabolites ATP6V1E2 UTR-3 19043545 rs896210 chr2 46746745 G A 5.47E-04 Amyotrophic Lateral Sclerosis ATP6V1E2 UTR-5 17362836 rs896210 chr2 46746745 G A 8.95E-08 Hemoglobin concentration ATP6V1E2 UTR-5 20534544 rs4952830 chr2 46746963 A G 0.00000674 Preeclampsia ATP6V1E2 UTR-5 22432041 rs2012022 chr2 46748395 T C 5.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs41395646 chr2 46756431 A G 7.31E-04 Multiple complex diseases / / 17554300 rs1001745 chr2 46775059 T C 6.23E-07 Lymphocyte counts RHOQ intron 22286170 rs17818399 chr2 46826026 A C 3.00E-07 Height PIGF intron 20966902 rs1451156 chr2 46832602 C T 8.89E-06 Hemoglobin concentration PIGF intron 20534544 rs6713104 chr2 46838005 T C 2.00E-04 Information processing speed PIGF intron 21130836 rs13000706 chr2 46838247 C G 2.05E-11 Lymphocyte counts PIGF intron 22286170 rs3213985 chr2 46840735 T C 2.00E-04 Information processing speed PIGF intron 21130836 rs1531133 chr2 46843631 A G 1.11E-05 Hemoglobin concentration PIGF intron 20534544 rs982414 chr2 46845576 A G 9.14E-09 Hemoglobin concentration CRIPT intron 20534544 rs6735530 chr2 46848446 T C 2.04E-07 Hemoglobin concentration CRIPT intron 20534544 rs12105006 chr2 46862586 T C 2.29E-06 Hemoglobin concentration / / 20534544 rs10495934 chr2 46874746 G A 5.48E-05 Hemoglobin concentration / / 20534544 rs6712910 chr2 46876958 G A 8.68E-05 Hemoglobin concentration / / 20534544 rs7575099 chr2 46879599 G C 2.38E-04 Multiple complex diseases / / 17554300 rs10204096 chr2 46883739 C T 5.75E-04 Body mass index / / 21701565 rs4953404 chr2 46886142 G A 1.00E-06 Pulse pressure (alcohol consumption interaction) / / 24376456 rs4953404 chr2 46886142 G A 8.00E-07 Pulse pressure (alcohol consumption interaction) / / 24376456 rs6742593 chr2 46890538 T C 6.58E-05 Cervical cancer / / 24700089 rs17035495 chr2 46898352 T C 5.48E-04 Multiple complex diseases / / 17554300 rs10178013 chr2 46902040 T C 2.80E-05 Urinary metabolites / / 21572414 rs10495936 chr2 46908199 C T 5.70E-05 Magnesium levels / / pha003092 rs3814041 chr2 46908571 C A 3.40E-05 Magnesium levels / / pha003092 rs7596521 chr2 46918665 A G 8.65E-05 Hemoglobin concentration / / 20534544 rs12474201 chr2 46921285 G A 3.00E-13 Height / / 20881960 rs11676737 chr2 46929873 T C 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs13025984 chr2 46938789 T C 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs4952843 chr2 46957845 A G 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs11695058 chr2 46978349 A G 9.96E-07 Lymphocyte counts SOCS5 intron 22286170 rs17823065 chr2 46988073 T C 6.49E-04 Multiple complex diseases SOCS5 UTR-3 17554300 rs10495938 chr2 46991159 G C 8.25E-05 Iron status biomarkers / / 19084217 rs11125091 chr2 47009746 T C 1.29E-04 Hemoglobin concentration / / 20534544 rs9309137 chr2 47011834 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs76351433 chr2 47022543 A C 2.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs17035674 chr2 47030868 T C 5.76E-04 Multiple complex diseases / / 17554300 rs10514803 chr2 47089473 T C 7.01E-04 Type 2 diabetes / / 17463246 rs10514803 chr2 47089473 T C 1.28E-05 Lipid traits / / 24023261 rs12990097 chr2 47095205 G C 1.20E-04 Major depressive disorder / / 22472876 rs4953434 chr2 47095489 G A 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6715234 chr2 47114100 T A,C,G 1.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11690921 chr2 47153762 C T 7.01E-04 Colorectal cancer MCFD2 intron 24737748 rs4300885 chr2 47159082 C T 2.95E-04 Multiple complex diseases MCFD2 intron 17554300 rs17035912 chr2 47171322 A G 3.72E-04 Smoking initiation TTC7A intron 24665060 rs7593939 chr2 47178571 A G 4.93E-04 Taste perception TTC7A intron 22132133 rs17035931 chr2 47182032 A C 2.21E-05 Major depressive disorder TTC7A intron 20516156 rs6726941 chr2 47184447 C T 7.70E-04 Major depressive disorder TTC7A intron 21042317 rs13387604 chr2 47184989 A G 9.01E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy TTC7A intron 24578207 rs13387604 chr2 47184989 A G 9.01E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy TTC7A intron 24578207 rs17540003 chr2 47221105 C T 0.00032 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540003 chr2 47221105 C T 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17481321 chr2 47224927 C A 0.0003492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17481321 chr2 47224927 C A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17481349 chr2 47225186 T C 0.0003592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17481349 chr2 47225186 T C 3.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540504 chr2 47226183 G A 6.26E-04 Alzheimer's disease TTC7A intron 22005930 rs17540504 chr2 47226183 G A 0.0003822 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540504 chr2 47226183 G A 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17036033 chr2 47227768 G A 3.90E-04 Major depressive disorder TTC7A intron 21042317 rs2007462 chr2 47229025 T C 1.79E-04 Alzheimer's disease TTC7A intron 22005930 rs2007462 chr2 47229025 T C 0.0006673 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs2007462 chr2 47229025 T C 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540615 chr2 47229380 C T 1.96E-04 Alzheimer's disease TTC7A intron 22005930 rs17540615 chr2 47229380 C T 0.0005478 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540615 chr2 47229380 C T 5.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540621 chr2 47229839 G C 2.00E-06 Response to statin therapy TTC7A intron 20339536 rs13407983 chr2 47233048 G A 1.37E-04 Smoking initiation TTC7A intron 24665060 rs10193261 chr2 47239142 G T 1.70E-05 Response to statin therapy TTC7A intron 20339536 rs13426848 chr2 47239473 T C 2.78E-04 Alzheimer's disease TTC7A intron 22005930 rs10194115 chr2 47240012 G T 5.20E-06 Response to statin therapy TTC7A intron 20339536 rs10194115 chr2 47240012 G T 5.00E-07 Erectile dysfunction and prostate cancer treatment TTC7A intron 20932654 rs7581528 chr2 47240149 G A 4.82E-04 Alzheimer's disease TTC7A intron 22005930 rs7581528 chr2 47240149 G A 0.0008638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs7581528 chr2 47240149 G A 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs10196993 chr2 47240485 G C 5.50E-06 Response to statin therapy TTC7A intron 20339536 rs17036119 chr2 47249966 C T 5.74E-04 Multiple complex diseases TTC7A intron 17554300 rs4952863 chr2 47257977 T C 5.94E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs7578472 chr2 47260839 T C 2.70E-05 Urinary metabolites TTC7A intron 21572414 rs11695952 chr2 47262695 A G 6.69E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs12712986 chr2 47273668 G A 9.33E-05 Bipolar disorder TTC7A intron 20451256 rs17036168 chr2 47279605 C T 1.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs17036168 chr2 47279605 C T 2.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs17541472 chr2 47280156 G A 3.24E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs2436772 chr2 47283557 G A 4.26E-05 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs10460536 chr2 47283793 T C 2.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs10460536 chr2 47283793 T C 8.13E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs13393256 chr2 47286759 A C 3.33E-04 Multiple complex diseases TTC7A intron 17554300 rs13393256 chr2 47286759 A C 4.89E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs6734192 chr2 47286857 C T 6.56E-04 Suicide attempts in bipolar disorder TTC7A intron 21423239 rs4953456 chr2 47290570 T C 1.33E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 4.53E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 4.56E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 2.91E-06 Systemic lupus erythematosus and Systemic sclerosis TTC7A intron 23740937 rs6704853 chr2 47293507 G A 9.17E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs6704853 chr2 47293507 G A 9.55E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs1549981 chr2 47294762 G A 7.90E-04 Lymphocyte counts TTC7A intron 22286170 rs7569495 chr2 47298430 T C 1.47E-05 Eosinophil counts TTC7A intron pha003088 rs4953463 chr2 47322330 G A 5.29E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs2347604 chr2 47323152 A C 2.02E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs371711248 chr2 47323152 AA AAA,ACC 2.02E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs17036272 chr2 47346185 C A 1.70E-05 Urinary metabolites C2orf61 intron 21572414 rs1880583 chr2 47348347 C T 4.09E-05 Body Mass Index C2orf61 intron pha002896 rs7596776 chr2 47355143 G A 1.90E-05 Urinary metabolites C2orf61 intron 21572414 rs2030772 chr2 47359666 A T 9.10E-06 Urinary metabolites C2orf61 intron 21572414 rs726117 chr2 47372425 G A 7.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) C2orf61 intron 23648065 rs815811 chr2 47377472 C T 7.00E-06 Urinary metabolites C2orf61 intron 21572414 rs815807 chr2 47381245 G A 1.50E-05 Urinary metabolites C2orf61 intron 21572414 rs17036307 chr2 47381408 T G 8.96E-05 Multiple complex diseases C2orf61 intron 17554300 rs11884600 chr2 47384601 A G 7.86E-04 Type 2 diabetes / / 22238593 rs815815 chr2 47399064 C T 7.00E-07 Dialysis-related mortality CALM2 intron 21546767 rs815815 chr2 47399064 C T 2.30E-05 Urinary metabolites CALM2 intron 21572414 rs815815 chr2 47399064 C T 0.000435 Alpha-2-adrenoceptor-mediated vasoconstriction CALM2 intron 23337848 rs1723482 chr2 47406539 C T 5.12E-04 Type 2 diabetes / / 17846125 rs1723482 chr2 47406539 C T 5.50E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs4953476 chr2 47433465 T A 1.40E-04 Obesity (extreme) / / 21935397 rs7598661 chr2 47468955 A G 2.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10191479 chr2 47469711 C T 5.80E-04 Type 2 diabetes / / 17463246 rs12620038 chr2 47476135 C G 4.00E-04 Pancreatic cancer / / 23180869 rs904160 chr2 47477584 T C 7.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs72806423 chr2 47479014 A T 9.74E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10186190 chr2 47480107 A G 0.00004874 Sarcoidosis / / 22952805 rs10209762 chr2 47480133 C T 0.00006715 Sarcoidosis / / 22952805 rs10210258 chr2 47480419 G C 0.00008367 Sarcoidosis / / 22952805 rs10190105 chr2 47481641 A G 9.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs12612772 chr2 47482167 G A 9.30E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10165172 chr2 47512078 T C 5.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4952887 chr2 47646968 C T 3.74E-05 Bone mineral density MSH2 intron 19181680 rs10514805 chr2 47679978 G A 7.30E-05 Stroke MSH2 intron pha002886 rs3771281 chr2 47692281 C T 1.97E-05 Paget's disease MSH2 intron 20436471 rs10188090 chr2 47709153 G A 5.24E-05 Paget's disease MSH2 intron 20436471 rs17036636 chr2 47721328 T C 7.72E-05 Bone mineral density / / 19181680 rs6708696 chr2 47773540 A G 2.69E-04 Multiple complex diseases KCNK12 intron 17554300 rs6708696 chr2 47773540 A G 6.10E-05 Bone mineral density KCNK12 intron 19181680 rs3814360 chr2 47800603 A T 2.35E-04 Smoking initiation LOC100652825 UTR-3 24665060 rs11682393 chr2 47804497 T A 5.76E-04 Multiple complex diseases / / 17554300 rs4245815 chr2 47819972 G A 7.07E-05 Lung cancer / / 18978787 rs4245815 chr2 47819972 G A 6.62E-04 Alcohol dependence / / 20201924 rs11694783 chr2 47826681 G A 2.49E-05 HIV-1 viral setpoint / / 22174851 rs17036703 chr2 47826830 G A 6.14E-05 HIV-1 viral setpoint / / 22174851 rs4953514 chr2 47829230 A G 4.60E-05 HIV-1 viral setpoint / / 22174851 rs12468025 chr2 47831793 C T 3.30E-08 Urinary metabolites / / 21572414 rs11676321 chr2 47834080 G A 1.90E-07 Urinary metabolites / / 21572414 rs6544997 chr2 47844505 A G 7.00E-06 Vitiligo / / 19890347 rs11892597 chr2 47856243 A C 5.18E-05 Serum metabolites / / 19043545 rs11887626 chr2 47856328 T G 1.40E-04 Pulmonary function / / 23932459 rs4952894 chr2 47857914 A G 0.0000567 Tuberculosis with late age of onset / / 22551897 rs4952894 chr2 47857914 A G 4.76E-04 Smoking quantity / / 24665060 rs4266057 chr2 47866656 C T 4.32E-04 Alzheimer's disease / / 22005930 rs1574378 chr2 47874352 T A 2.62E-04 Alzheimer's disease / / 22005930 rs1882450 chr2 47874603 G C 1.83E-04 Alzheimer's disease / / 22005930 rs1574380 chr2 47874713 C T 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2091750 chr2 47874961 T G 5.09E-05 Alzheimer's disease / / 22005930 rs13413097 chr2 47876798 G A 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1400633 chr2 47884002 G C,T 5.63E-06 Alzheimer's disease / / 22005930 rs2969775 chr2 47885476 G T 2.00E-06 Alzheimer's disease / / 22005930 rs2944778 chr2 47885601 T G 1.73E-04 Alzheimer's disease / / 22005930 rs2705766 chr2 47890331 T C 1.74E-04 Alzheimer's disease / / 22005930 rs2705766 chr2 47890331 T C 5.56E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs2969772 chr2 47894472 A G 2.86E-05 Alzheimer's disease / / 22005930 rs4588237 chr2 47942902 A G 7.66E-05 Chronic obstructive pulmonary disease / / 19300482 rs797700 chr2 47948101 C T 0.0000817 Asthma / / 22694930 rs2098242 chr2 47956819 C T 2.65E-04 Type 2 diabetes / / 17463246 rs3136279 chr2 48017768 C A 6.81E-05 Type 2 diabetes MSH6 intron 17846126 rs3136329 chr2 48024876 C T 3.33E-04 Obesity (extreme) MSH6 intron 21935397 rs3136337 chr2 48028465 C T 4.36E-04 Obesity (extreme) MSH6 intron 21935397 rs530262234 chr2 48032312 GTCTC G 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MSH6 intron 22010049 rs7562048 chr2 48032312 G A 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MSH6 intron 22010049 rs10490303 chr2 48039484 T G 2.25E-05 Lymphocyte counts FBXO11 intron pha003094 rs10490303 chr2 48039484 T G 7.11E-05 Neutrophil count FBXO11 intron pha003095 rs330787 chr2 48041377 A G 4.64E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) FBXO11 intron 23103227 rs330787 chr2 48041377 A G 0.0000464 Otitis media (children 3 years old or younger) FBXO11 intron 23133572 rs4381823 chr2 48047335 A G 6.00E-06 Schizophrenia FBXO11 intron 23894747 rs12463595 chr2 48098708 C T 3.52E-05 Schizophrenia FBXO11 intron 24253340 rs13035558 chr2 48131936 T C 8.43E-05 Schizophrenia FBXO11 intron 24253340 rs7588761 chr2 48150587 C T 1.51E-05 Lymphocyte counts / / pha003094 rs7588761 chr2 48150587 C T 8.36E-05 Neutrophil count / / pha003095 rs4552231 chr2 48167631 A C 2.24E-04 Alzheimer's disease (late onset) / / 21379329 rs34198350 chr2 48169382 C T 8.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs6729916 chr2 48174199 T C 1.71E-05 Body mass index / / 19584900 rs6729916 chr2 48174199 T C 2.06E-05 Body mass index / / 19584900 rs6729916 chr2 48174199 T C 3.77E-04 Alzheimer's disease (late onset) / / 21379329 rs6729916 chr2 48174199 T C 6.12E-05 Intelligence / / 21826061 rs6729916 chr2 48174199 T C 2.45E-05 Lymphocyte counts / / pha003094 rs6729916 chr2 48174199 T C 3.85E-05 Neutrophil count / / pha003095 rs6717617 chr2 48192962 G C 1.47E-05 Body mass index / / 19584900 rs6717617 chr2 48192962 G C 9.80E-06 Body mass index / / 19584900 rs10199698 chr2 48193108 T C 3.23E-04 Alzheimer's disease (late onset) / / 21379329 rs10199698 chr2 48193108 T C 7.15E-05 Intelligence / / 21826061 rs10199698 chr2 48193108 T C 1.50E-05 Lymphocyte counts / / pha003094 rs10199698 chr2 48193108 T C 3.19E-05 Neutrophil count / / pha003095 rs10183748 chr2 48197968 C T 1.03E-05 Body mass index / / 19584900 rs10183748 chr2 48197968 C T 1.11E-05 Body mass index / / 19584900 rs10183748 chr2 48197968 C T 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs10183748 chr2 48197968 C T 7.35E-05 Intelligence / / 21826061 rs10183748 chr2 48197968 C T 1.50E-05 Lymphocyte counts / / pha003094 rs10183748 chr2 48197968 C T 3.12E-05 Neutrophil count / / pha003095 rs10207319 chr2 48198049 A T 1.03E-05 Body mass index / / 19584900 rs10207319 chr2 48198049 A T 1.11E-05 Body mass index / / 19584900 rs11693533 chr2 48209986 G A 2.80E-04 Obesity (extreme) / / 21935397 rs11695693 chr2 48223309 A G 2.59E-04 Obesity (extreme) / / 21935397 rs11692660 chr2 48244584 C A 6.93E-04 Obesity (extreme) / / 21935397 rs6745620 chr2 48245742 C T 7.07E-04 Obesity (extreme) / / 21935397 rs17037087 chr2 48246555 G T 7.18E-04 Obesity (extreme) / / 21935397 rs11682328 chr2 48248101 T C 7.36E-04 Obesity (extreme) / / 21935397 rs11681243 chr2 48251156 G T 7.30E-04 Obesity (extreme) / / 21935397 rs11687232 chr2 48251493 T C 7.26E-04 Obesity (extreme) / / 21935397 rs11677590 chr2 48275068 T G 6.70E-04 Obesity (extreme) / / 21935397 rs11693696 chr2 48285147 C T 4.97E-04 Obesity (extreme) / / 21935397 rs11680404 chr2 48296105 G A 4.09E-04 Obesity (extreme) / / 21935397 rs11689818 chr2 48298991 T G 3.76E-04 Obesity (extreme) / / 21935397 rs6755400 chr2 48300851 A G 4.51E-04 Nicotine dependence / / 17158188 rs7561696 chr2 48303851 A G 3.73E-04 Obesity (extreme) / / 21935397 rs11687989 chr2 48306647 G A 3.71E-04 Obesity (extreme) / / 21935397 rs1878078 chr2 48318158 T C 7.80E-05 Glioma (high-grade) / / 19578366 rs7583719 chr2 48337970 G A 3.04E-04 Obesity (extreme) / / 21935397 rs17396793 chr2 48365018 G A 3.11E-04 Obesity (extreme) / / 21935397 rs7581510 chr2 48379578 A G 3.25E-04 Obesity (extreme) / / 21935397 rs6733558 chr2 48395486 A G 2.77E-04 Obesity (extreme) / / 21935397 rs11676381 chr2 48413924 G A 2.76E-04 Obesity (extreme) / / 21935397 rs11691493 chr2 48414153 C T 2.76E-04 Obesity (extreme) / / 21935397 rs11683689 chr2 48423881 C A 2.64E-04 Obesity (extreme) / / 21935397 rs13431982 chr2 48432921 T C 2.50E-04 Obesity (extreme) / / 21935397 rs10495950 chr2 48434764 T G 2.51E-04 Obesity (extreme) / / 21935397 rs17325048 chr2 48436566 A C 2.52E-04 Obesity (extreme) / / 21935397 rs11681876 chr2 48445328 A G 2.99E-04 Obesity (extreme) / / 21935397 rs11680162 chr2 48456974 C T 3.34E-04 Obesity (extreme) / / 21935397 rs3750272 chr2 48461993 A G 7.20E-04 Stroke / / pha002887 rs7574310 chr2 48465627 C T 6.29E-04 Multiple complex diseases / / 17554300 rs17397094 chr2 48467708 C G 8.60E-04 Obesity (extreme) / / 21935397 rs952468 chr2 48470132 T G 8.78E-04 Obesity (extreme) / / 21935397 rs6747738 chr2 48471369 C T 8.84E-04 Obesity (extreme) / / 21935397 rs17325209 chr2 48479210 G A 8.68E-04 Obesity (extreme) / / 21935397 rs11695923 chr2 48487207 C T 8.28E-04 Obesity (extreme) / / 21935397 rs11682838 chr2 48641155 A G 6.80E-04 Obesity (extreme) / / 21935397 rs4606978 chr2 48643436 A C 6.22E-06 Triglycerides / / pha003080 rs17397442 chr2 48644275 C T 7.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs17397442 chr2 48644275 C T 7.94E-05 Lipid levels / / pha003082 rs10454142 chr2 48646399 T C 1.00E-07 Sex hormone-binding globulin levels / / 22829776 rs17325537 chr2 48646751 C G 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17037329 chr2 48646827 A C 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs7565792 chr2 48649705 T C 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4316980 chr2 48650308 C T 5.71E-05 Triglycerides / / pha003080 rs4561709 chr2 48714938 T G 1.18E-04 Suicide attempts in bipolar disorder PPP1R21 intron 21423239 rs35284764 chr2 48777878 T C 7.48E-04 Multiple complex diseases STON1 intron 17554300 rs876968 chr2 48778865 G T 6.32E-04 Multiple complex diseases STON1 intron 17554300 rs6705602 chr2 48781222 G A 3.63E-04 Alzheimer's disease STON1 intron 22005930 rs149954327 chr2 48809144 T G 1.53E-09 Body mass index STON1 missense 23555315 rs2293276 chr2 48819197 A G 7.19E-05 Waist Circumference STON1 intron pha003023 rs2140551 chr2 48822381 G A 7.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STON1 cds-synon 20877124 rs3749146 chr2 48824501 C T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) STON1 UTR-3 24529757 rs13018198 chr2 48824698 T C 2.27E-04 Response to taxane treatment (placlitaxel) STON1 UTR-3 23006423 rs11693317 chr2 48832414 T G 9.78E-04 Response to taxane treatment (placlitaxel) STON1-GTF2A1L intron 23006423 rs7604334 chr2 48832433 A G 7.39E-04 Response to taxane treatment (placlitaxel) STON1-GTF2A1L intron 23006423 rs17326067 chr2 48847097 C T 4.89E-04 Coronary heart disease GTF2A1L intron 21606135 rs13028463 chr2 48847174 G A 5.04E-04 Response to taxane treatment (placlitaxel) GTF2A1L intron 23006423 rs1589749 chr2 48862498 A G 7.03E-04 Coronary heart disease GTF2A1L intron 21606135 rs2349099 chr2 48862902 C T 7.09E-04 Type 2 diabetes GTF2A1L intron 17463246 rs2349099 chr2 48862902 C T 9.88E-04 Coronary heart disease GTF2A1L intron 21606135 rs11689544 chr2 48909171 G A 1.12E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs17326321 chr2 48937576 G A 5.20E-04 Taste perception LHCGR intron 22132133 rs4490239 chr2 48948802 T C 4.70E-04 Stroke LHCGR intron pha002887 rs10495959 chr2 48959537 T C 6.14E-04 Multiple complex diseases LHCGR intron 17554300 rs4319975 chr2 48959603 A G 2.75E-04 Multiple complex diseases LHCGR intron 17554300 rs12471286 chr2 48966160 C G 6.20E-08 Urinary metabolites LHCGR intron 21572414 rs35960650 chr2 48974634 G T 9.00E-06 Urinary metabolites LHCGR intron 21572414 rs13405728 chr2 48978159 A G 8.00E-21 Polycystic ovary syndrome LHCGR intron 21151128 rs13405728 chr2 48978159 A G 4.00E-09 Polycystic ovary syndrome LHCGR intron 22885925 rs13405728 chr2 48978159 A G 1.44E-04 Response to cholinesterase inhibitors in Alzheimer's disease LHCGR intron 23374588 rs4073368 chr2 48982358 G A 4.60E-07 Urinary metabolites LHCGR intron 21572414 rs2301267 chr2 48984391 C T 9.33E-04 Obesity (extreme) STON1-GTF2A1L intron 21935397 rs4334540 chr2 48996317 C G 8.00E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs4245820 chr2 48996544 A G 8.84E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs11125182 chr2 48999658 G A 8.76E-04 Coronary Artery Disease STON1-GTF2A1L intron 17634449 rs13426172 chr2 48999782 A G 1.53E-04 Obesity (extreme) STON1-GTF2A1L intron 21935397 rs4507141 chr2 49000425 C A 1.10E-05 Urinary metabolites STON1-GTF2A1L intron 21572414 rs4414727 chr2 49030009 T A 3.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4482537 chr2 49052255 C T 3.18E-05 Erythrocyte counts / / pha003101 rs10490128 chr2 49093258 A G 1.40E-05 Urinary metabolites / / 21572414 rs733726 chr2 49096835 C T 6.51E-05 Cognitive performance / / 19734545 rs981273 chr2 49120549 A G 1.30E-05 Urinary metabolites / / 21572414 rs2192615 chr2 49122094 C T 8.09E-05 Hypertension / / 21082022 rs4952929 chr2 49139350 G C 2.60E-05 Urinary metabolites / / 21572414 rs11891861 chr2 49156580 T G 6.49E-05 Parkinson's disease / / 17052657 rs989373 chr2 49158325 T C 7.40E-04 Alcohol dependence / / 20201924 rs6706144 chr2 49170577 A G 2.40E-05 Urinary metabolites / / 21572414 rs7591064 chr2 49177601 C T 5.00E-06 Radiation response / / 20923822 rs2268363 chr2 49201328 A G 5.00E-08 Erectile dysfunction and prostate cancer treatment FSHR intron 20932654 rs2268361 chr2 49201612 C T 1.00E-12 Polycystic ovary syndrome FSHR intron 22885925 rs3788981 chr2 49245561 A C 0.00025 Breast cancer early age of onset FSHR intron 18463975 rs2349415 chr2 49247832 T C 2.35E-12 Polycystic ovary syndrome FSHR intron 22885925 rs3913668 chr2 49268462 A G 3.08E-04 Smoking cessation FSHR intron 24665060 rs10865238 chr2 49268804 A G 2.19E-12 Polycystic ovary syndrome FSHR intron 22885925 rs1504189 chr2 49279932 T C 3.05E-06 Cognitive test performance FSHR intron 20125193 rs4971622 chr2 49292811 A T 8.83E-04 Suicide attempts in bipolar disorder FSHR intron 21041247 rs1504155 chr2 49402250 A C 4.00E-04 Obesity-related traits / / 17903300 rs12987821 chr2 49468791 A C 7.67E-04 Smoking cessation / / 24665060 rs10495970 chr2 49491810 G A 5.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs9636436 chr2 49498006 G A 2.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs1365867 chr2 49548375 G A 4.15E-04 Smoking initiation / / 24665060 rs817088 chr2 49575829 T G 8.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1882345 chr2 49630281 T C 9.47E-04 Alzheimer's disease / / 22005930 rs1921617 chr2 49646072 T A 7.10E-06 Fasting plasma glucose / / 19060907 rs1344648 chr2 49647376 G A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs817004 chr2 49648928 T C 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs817008 chr2 49650161 G C 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6545112 chr2 49651185 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1358420 chr2 49652112 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs817010 chr2 49652176 G C 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs817012 chr2 49652722 A T 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544914 chr2 49654260 T C 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544915 chr2 49654581 G A 1.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1405969 chr2 49676328 A G 1.70E-05 Urinary metabolites / / 21572414 rs7593459 chr2 49695700 A T 1.60E-06 Bipolar disorder / / 19416921 rs12713060 chr2 49699199 C A 1.40E-05 Urinary metabolites / / 21572414 rs13005268 chr2 49699762 C G 3.00E-06 Urinary metabolites / / 21572414 rs1527912 chr2 49701071 T C 3.30E-06 Urinary metabolites / / 21572414 rs11125247 chr2 49701614 A T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs13419824 chr2 49705607 G T 2.70E-06 Urinary metabolites / / 21572414 rs11888995 chr2 49714129 T C 2.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12987465 chr2 49715021 G A 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs12987465 chr2 49715021 G A 5.33E-05 Erythrocyte counts / / pha003101 rs2098986 chr2 49718822 C G 2.50E-05 Urinary metabolites / / 21572414 rs12996690 chr2 49724966 T C 8.45E-05 Erythrocyte counts / / pha003101 rs6756236 chr2 49728396 A C 2.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7589821 chr2 49731956 G A 1.79E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1553127 chr2 49732935 T C 1.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1553127 chr2 49732935 T C 5.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1405965 chr2 49737819 A G 2.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1405965 chr2 49737819 A G 3.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs6709183 chr2 49749038 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4971621 chr2 49752589 T C 6.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1995172 chr2 49790063 C T 0.0000195 Panic disorder / / 23149450 rs1995172 chr2 49790063 C T 1.95E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs13429217 chr2 49808562 C T 9.28E-05 Height / / pha003010 rs4971624 chr2 49836326 C A 4.60E-04 Multiple complex diseases / / 17554300 rs7577053 chr2 49849708 T C 2.00E-05 Urinary metabolites / / 21572414 rs1391749 chr2 49852392 A C 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2350699 chr2 49871330 G A 1.54E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs10495981 chr2 49883809 T C 8.92E-05 Cholesterol / / pha003073 rs13383039 chr2 49885175 C G 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs12713068 chr2 49887106 A G 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2059713 chr2 49888607 T G 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6545125 chr2 49888676 G A 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs560021053 chr2 49904128 TA T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs881422 chr2 49904128 T A 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2882478 chr2 49904589 A G 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs17180320 chr2 49908670 C G 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12623969 chr2 49909418 G A 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4527245 chr2 49910253 G C 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs17180439 chr2 49914910 G C 4.50E-06 Urinary metabolites / / 21572414 rs1518826 chr2 49926570 T C 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4402808 chr2 49933279 C T 8.52E-04 Prostate cancer mortality / / 20978177 rs10200783 chr2 49936924 G C 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10196361 chr2 49942227 A C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10185615 chr2 49944565 A C 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12475071 chr2 49948420 A C 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17489085 chr2 49952622 T G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs17039212 chr2 49955497 C A 9.00E-06 Systemic lupus erythematosus / / 19165918 rs17039212 chr2 49955497 C A 2.86E-04 Prostate cancer mortality / / 20978177 rs4971626 chr2 49956426 A C 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4971627 chr2 49956489 A G 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs951840 chr2 49961169 T C 5.22E-05 Multiple complex diseases / / 17554300 rs7355306 chr2 49962464 A G 7.73E-04 Multiple complex diseases / / 17554300 rs10204924 chr2 49962785 G C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7593733 chr2 49963077 C A 9.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12328055 chr2 49971239 G A 2.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs12328060 chr2 49971406 G A 8.60E-05 Tuberculosis / / 24057671 rs11125273 chr2 49971708 C G 1.20E-06 Urinary metabolites / / 21572414 rs1914779 chr2 49986278 C T 4.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs1518823 chr2 49990368 C T 4.37E-04 Prostate cancer mortality / / 20978177 rs11903512 chr2 50005959 T C 8.58E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17039332 chr2 50022072 T C 5.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7562270 chr2 50032071 A G 9.30E-05 Height / / pha003010 rs17039367 chr2 50083603 G A 9.76E-04 Type 2 diabetes / / 17463246 rs17039375 chr2 50088431 T A 7.48E-04 Type 2 diabetes / / 17463246 rs2068489 chr2 50089009 C G 8.57E-04 Type 2 diabetes / / 17463246 rs10495985 chr2 50092761 T C 6.81E-04 Type 2 diabetes / / 17463246 rs10495985 chr2 50092761 T C 9.27E-05 Caffeine consumption / / 21490707 rs11893681 chr2 50122480 G T 8.46E-04 Type 2 diabetes / / 17463246 rs10495987 chr2 50153280 A C 5.66E-05 Bipolar disorder NRXN1 intron 20451256 rs11681792 chr2 50184394 C T 4.00E-07 Behavioural disinhibition (generation interaction) NRXN1 intron 23942779 rs11681792 chr2 50184394 C T 6.70E-04 Behavioural disinhibition (generation interaction) NRXN1 intron 23942779 rs17439001 chr2 50189443 A C 9.29E-05 Self-reported allergy NRXN1 intron 23817569 rs11889551 chr2 50202953 G T 2.96E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs2112073 chr2 50209558 C T 7.06E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs1363025 chr2 50215373 G A 7.55E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs7604754 chr2 50230334 C T 8.44E-05 Caffeine consumption NRXN1 intron 21490707 rs10196324 chr2 50236619 A T 6.42E-05 Diabetic nephropathy NRXN1 intron pha002864 rs6753833 chr2 50247149 A G 1.87E-05 Caffeine consumption NRXN1 intron 21490707 rs17494917 chr2 50250758 A G 3.78E-05 Caffeine consumption NRXN1 intron 21490707 rs9677968 chr2 50251100 A G 3.34E-05 Smoking cessation NRXN1 intron 18519826 rs1895132 chr2 50259734 G A,C 1.53E-04 Multiple complex diseases NRXN1 intron 17554300 rs10191808 chr2 50268555 T G 4.72E-05 Cognitive performance NRXN1 intron 19734545 rs17495366 chr2 50268616 T C 3.12E-05 Attention deficit hyperactivity disorder NRXN1 intron 20732627 rs2351155 chr2 50307245 G A 1.31E-05 Cognitive performance NRXN1 intron 19734545 rs2351155 chr2 50307245 G A 1.87E-05 Blood Pressure NRXN1 intron pha003040 rs970896 chr2 50308985 C A 8.90E-04 Type 2 diabetes and 6 quantitative traits NRXN1 intron 17848626 rs1523355 chr2 50328062 G T 2.90E-05 Urinary metabolites NRXN1 intron 21572414 rs13430861 chr2 50328375 C A 5.70E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs1452762 chr2 50330068 A G 6.27E-04 Coronary Artery Disease NRXN1 intron 17634449 rs17039291 chr2 50330318 T A 8.47E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs10490241 chr2 50332310 C A,G,T 6.08E-05 Cognitive performance NRXN1 intron 19734545 rs921573 chr2 50334183 C A 1.93E-04 Smoking cessation NRXN1 intron 18519826 rs7606758 chr2 50357734 T C 7.14E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs13008902 chr2 50358675 T G 3.68E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs11675607 chr2 50365727 G A 1.23E-04 Smoking cessation NRXN1 intron 18519826 rs2602003 chr2 50388284 A G 8.24E-04 Multiple complex diseases NRXN1 intron 17554300 rs7599263 chr2 50390615 T C 4.03E-05 Lipoproteins NRXN1 intron pha003079 rs9309179 chr2 50458179 G A 1.48E-04 Smoking cessation NRXN1 intron 18519826 rs1356888 chr2 50516018 T C 1.00E-06 Longevity NRXN1 intron 20834067 rs7569775 chr2 50532337 T C 8.16E-04 HIV-1 viral setpoint NRXN1 intron 17641165 rs10048731 chr2 50668760 T C 2.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs10048731 chr2 50668760 T C 3.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs1015823 chr2 50687878 C T 2.43E-05 Cognitive test performance NRXN1 intron 20125193 rs3213756 chr2 50692560 A G 8.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs6721498 chr2 50713012 G A 1 Drug response to Nicotine NRXN1 intron 18270208 rs17476669 chr2 50726471 G A 7.92E-06 Waist circumference NRXN1 intron 19557197 rs6734480 chr2 50726529 C G 3.82E-04 Type 2 diabetes NRXN1 intron 17846125 rs6734480 chr2 50726529 C G 2.90E-06 Urinary metabolites NRXN1 intron 21572414 rs6734480 chr2 50726529 C G 7.11E-04 Alzheimer's disease NRXN1 intron 22005930 rs6754640 chr2 50731318 G A 1.00E-06 Temperament NRXN1 intron 22832960 rs10176705 chr2 50744774 C T 9.00E-06 Personality dimensions NRXN1 intron 20691247 rs6750634 chr2 50760503 G A 4.00E-06 Metabolite levels (HVA/MHPG ratio) NRXN1 intron 23319000 rs12053235 chr2 50777896 T A 5.78E-06 Metabolite levels (MHPG) NRXN1 intron 23319000 rs34288758 chr2 50796550 C A 4.52E-06 Metabolite levels (MHPG) NRXN1 intron 23319000 rs725288 chr2 50805475 C T 1.41E-04 Smoking cessation NRXN1 intron 24665060 rs4467312 chr2 50826484 T C 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs12476492 chr2 50840322 A G 0.000005 Major depressive disorder age at onset<15 NRXN1 intron 22915352 rs9752732 chr2 50882657 C T 8.00E-05 Blood Pressure NRXN1 intron pha003049 rs4971689 chr2 50921932 C G 0.0000175 Skin total naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene NRXN1 intron 22391508 rs4971689 chr2 50921932 C G 0.0000276 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene NRXN1 intron 22391508 rs12618157 chr2 50937036 A G 6.10E-07 Amyotrophic Lateral Sclerosis NRXN1 intron 17362836 rs17502019 chr2 50961916 G C 6.14E-04 Multiple complex diseases NRXN1 intron 17554300 rs3842845 chr2 50976171 A C 4.19E-04 Type 2 diabetes NRXN1 intron 17463246 rs3901491 chr2 50976485 T G 1.88E-04 Parkinson's disease NRXN1 intron 17052657 rs3901491 chr2 50976485 T G 1.70E-05 Urinary metabolites NRXN1 intron 21572414 rs17502934 chr2 50994255 G T 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs3892750 chr2 50996952 C T 3.10E-06 Urinary metabolites NRXN1 intron 21572414 rs3850333 chr2 51002929 A G 6.36E-05 Schizophrenia NRXN1 intron 19571811 rs9750635 chr2 51036712 T C 1.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs3850337 chr2 51039097 A T 8.76E-04 Multiple complex diseases NRXN1 intron 17554300 rs9309201 chr2 51042342 C T 8.85E-06 Elbow pain NRXN1 intron pha003008 rs17569702 chr2 51059836 T C 3.15E-06 Multiple sclerosis (brain glutamate levels) NRXN1 intron 20802204 rs2193225 chr2 51079482 T C 1 Drug response to Nicotine NRXN1 intron 18270208 rs1558799 chr2 51095053 G A 2.65E-05 Multiple sclerosis (brain glutamate levels) NRXN1 intron 20802204 rs6545185 chr2 51125058 A G 2.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs6545185 chr2 51125058 A G 9.86E-05 Elbow pain NRXN1 intron pha003008 rs6741326 chr2 51129285 G A 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs7558540 chr2 51140228 C T 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs7558540 chr2 51140228 C T 3.91E-04 Body mass index NRXN1 intron 21701565 rs7423296 chr2 51149072 T C 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs10490165 chr2 51188566 T C 4.15E-26 Narcolepsy NRXN1 intron 19629137 rs12623467 chr2 51225089 C T 1.48E-05 Nicotine dependence NRXN1 intron 17158188 rs6749209 chr2 51238652 A G 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs12467557 chr2 51242270 A G 6.88E-05 Nicotine dependence NRXN1 intron 17158188 rs13382584 chr2 51247294 T C 7.12E-04 Alcohol dependence NRXN1 intron 20201924 rs10490162 chr2 51247657 T C 5.66E-05 Nicotine dependence NRXN1 intron 17158188 rs2352545 chr2 51266982 C T 9.33E-05 Depression (quantitative trait) / / 23290196 rs2111380 chr2 51270610 A T 8.65E-05 Depression (quantitative trait) / / 23290196 rs11889082 chr2 51272118 A G 1.22E-06 Cardiovascular disease / / 18179892 rs4971723 chr2 51279135 T C 7.79E-05 Depression (quantitative trait) / / 23290196 rs6545190 chr2 51282609 G T 9.25E-05 Depression (quantitative trait) / / 23290196 rs10180695 chr2 51292332 T C 7.78E-05 Depression (quantitative trait) / / 23290196 rs34888568 chr2 51304476 G A 3.33E-05 Multiple complex diseases / / 17554300 rs17041243 chr2 51314528 T G 5.04E-04 Multiple complex diseases / / 17554300 rs17041373 chr2 51388866 G T 7.84E-04 Multiple complex diseases / / 17554300 rs3732051 chr2 51427174 C T 7.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6718224 chr2 51468494 G A 2.52E-04 Type 2 diabetes / / 17463246 rs2098441 chr2 51476956 A G 7.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs2098446 chr2 51481255 G A 7.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs10490146 chr2 51512492 A G 3.66E-04 Birth weight / / 17255346 rs4971738 chr2 51512724 C T 5.60E-04 Alzheimer's disease / / 17998437 rs10490145 chr2 51513683 G A 0.000460588 Hypertension (early onset hypertension) / / 22479346 rs2216133 chr2 51514659 T C 9.98E-05 Rheumatoid arthritis / / 17804836 rs723713 chr2 51517775 G T 5.68E-05 Multiple complex diseases / / 17554300 rs10490144 chr2 51519281 T C 7.53E-04 Type 2 diabetes / / 17463246 rs10490142 chr2 51520327 C T 1.46E-04 Birth weight / / 17255346 rs17041533 chr2 51520800 C T 1.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13405861 chr2 51521625 A G 5.59E-05 Alzheimer's disease / / 17998437 rs7602908 chr2 51528298 G A 1.57E-04 Birth weight / / 17255346 rs17524147 chr2 51566704 T C 2.45E-04 Type 2 diabetes / / 17463246 rs17590125 chr2 51581507 G T 4.13E-04 Type 2 diabetes / / 17463246 rs1206397 chr2 51667739 C A 3.00E-07 Cognitive performance / / 19734545 rs13022923 chr2 51680339 G A 3.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs991902 chr2 51689676 T G 3.48E-05 Diabetic nephropathy / / pha002852 rs2160407 chr2 51691387 C T 7.96E-04 Multiple complex diseases / / 17554300 rs2839839 chr2 51691484 A C 7.09E-05 Diabetic nephropathy / / pha002852 rs6739884 chr2 51702486 A G 1.96E-04 Hearing function / / 17255346 rs1406428 chr2 51736994 C T 2.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1528805 chr2 51738393 C T 6.45E-04 Coronary heart disease / / 21971053 rs10495996 chr2 51743688 A G 6.08E-05 Bipolar disorder / / 17486107 rs1534611 chr2 51747186 T C 3.68E-04 Coronary heart disease / / 21971053 rs2697999 chr2 51756961 G A 8.30E-06 Cognitive impairment induced by topiramate / / 22091778 rs17864534 chr2 51764360 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs3915321 chr2 51764718 C T 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs3915322 chr2 51765008 G A 4.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs2354378 chr2 51765416 C T 4.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs11680441 chr2 51767398 G A 4.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs7592062 chr2 51768912 A G 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs2950945 chr2 51768939 G A 7.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs1997326 chr2 51769196 G T 5.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919434 chr2 51771417 T C 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528817 chr2 51771557 A G 3.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs12995836 chr2 51772064 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs13001767 chr2 51772415 G T 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698031 chr2 51772808 A G 3.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs1358580 chr2 51773028 A G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528816 chr2 51775261 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528815 chr2 51775273 G C 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528814 chr2 51775511 T C 3.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715081 chr2 51775814 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563043 chr2 51777241 C G 2.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563162 chr2 51778608 G A 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs202114406 chr2 51778608 G GT 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs372843652 chr2 51778608 GT G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs78062703 chr2 51778608 GTT G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715084 chr2 51778654 T C 2.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715086 chr2 51778721 T A 2.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715088 chr2 51778828 T C 2.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715089 chr2 51779120 C A 2.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs2222779 chr2 51780150 A G 6.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698029 chr2 51780259 G T 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715079 chr2 51781034 G A 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698028 chr2 51781853 C T 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715077 chr2 51782284 C A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698026 chr2 51782507 G A 2.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs2950942 chr2 51785617 C T 2.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715062 chr2 51786142 G A 4.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698024 chr2 51786520 G A 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698022 chr2 51787982 C A 3.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919433 chr2 51791380 G C 5.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919432 chr2 51791446 C T 3.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1569190 chr2 51791767 G T 7.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs1609361 chr2 51792223 A G 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528813 chr2 51792896 A T 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528812 chr2 51793338 G C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1406429 chr2 51794327 C T 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1581667 chr2 51794752 C T 4.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698014 chr2 51795922 T G 4.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715057 chr2 51795951 C T 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528811 chr2 51796148 C T 4.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528810 chr2 51796267 C T 5.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528809 chr2 51796413 G A 5.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698011 chr2 51797785 G T 5.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698011 chr2 51797785 G T 5.33E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2715076 chr2 51799271 C A 5.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563154 chr2 51803683 G C 3.57E-04 Multiple complex diseases / / 17554300 rs2204729 chr2 51804042 A G 1.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4971754 chr2 51804524 G A 3.24E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2354382 chr2 51826920 T C 4.54E-05 Interstitial lung disease / / 23583980 rs2459335 chr2 51838229 T C 1.40E-05 Urinary metabolites / / 21572414 rs2459335 chr2 51838229 T C 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs952893 chr2 51876227 C T 0.000141 Transmission distortion / / 22377632 rs6714367 chr2 51914354 C T 0.000836903 Hypertension (early onset hypertension) / / 22479346 rs17864603 chr2 51989400 T C 5.27E-06 Hearing function / / 21493956 rs17862772 chr2 51991896 A G 1.03E-05 Bipolar disorder and schizophrenia / / 20889312 rs10194873 chr2 52009536 T C 7.89E-06 Soluble levels of adhesion molecules / / pha003072 rs11686436 chr2 52017764 C T 1.06E-05 Leukocyte Counts / / pha003091 rs1541980 chr2 52035257 A G 9.00E-05 Psoriasis / / 20953190 rs1435808 chr2 52036315 G A 3.35E-05 Prion diseases / / 22210626 rs11563262 chr2 52040359 G T 7.00E-05 Prostate cancer / / 21743057 rs7603003 chr2 52042513 A G 3.49E-05 Psoriasis / / 20953190 rs7603003 chr2 52042513 A G 2.88E-04 Osteoarthritis (knee and hip) / / 21177295 rs7603003 chr2 52042513 A G 4.18E-05 Osteoarthritis (knee and hip) / / 21177295 rs1017418 chr2 52048162 G C 0.00006733 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1017418 chr2 52048162 G C 5.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3861566 chr2 52065162 C T 1.30E-05 Post-operative nausea and vomiting / / 21694509 rs11562986 chr2 52065967 G A 4.93E-06 Esophageal cancer (squamous cell) / / 22960999 rs1435805 chr2 52068507 T C 5.66E-05 Post-operative nausea and vomiting / / 21694509 rs1369670 chr2 52073620 A G 8.43E-05 Post-operative nausea and vomiting / / 21694509 rs13035243 chr2 52083589 A G 1.09E-05 Premature ovarian failure / / 19508998 rs13035243 chr2 52083589 A G 1.09E-05 Other erythrocyte phenotypes / / 19862010 rs11125392 chr2 52107116 A T 2.00E-05 Urinary metabolites / / 21572414 rs17042362 chr2 52223396 A G 6.84E-04 Stroke / / pha002886 rs10209646 chr2 52262658 T G 7.57E-04 Type 2 diabetes / / 17463246 rs10209646 chr2 52262658 T G 2.10E-05 Urinary metabolites / / 21572414 rs10209718 chr2 52262676 T C 2.70E-04 Type 2 diabetes / / 17463246 rs10209718 chr2 52262676 T C 1.60E-05 Urinary metabolites / / 21572414 rs7582556 chr2 52262713 G C 2.10E-05 Urinary metabolites / / 21572414 rs7582793 chr2 52262932 G A 6.46E-04 Acute lung injury / / 22295056 rs7595947 chr2 52264332 A G 6.09E-04 Type 2 diabetes / / 17463246 rs13397279 chr2 52274871 A C 5.64E-04 Response to TNF antagonist treatment / / 21061259 rs10167057 chr2 52288297 G C 3.02E-05 Multiple complex diseases / / 17554300 rs17042508 chr2 52305747 A G 2.90E-05 Urinary metabolites / / 21572414 rs13390640 chr2 52332457 A G 9.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7594573 chr2 52371363 C T 3.24E-04 Smoking cessation / / 24665060 rs13398003 chr2 52378299 T C 2.00E-05 Urinary metabolites / / 21572414 rs10180287 chr2 52382382 G T 4.31E-04 Smoking cessation / / 24665060 rs11892271 chr2 52383698 C T 6.27E-05 Myopia (pathological) / / 23049088 rs12621097 chr2 52384668 C T 2.10E-05 Urinary metabolites / / 21572414 rs12621097 chr2 52384668 C T 7.35E-04 Smoking cessation / / 24665060 rs7606800 chr2 52395370 G A 9.80E-06 Urinary metabolites / / 21572414 rs12713179 chr2 52397517 A G 4.38E-04 Smoking cessation / / 24665060 rs1922192 chr2 52401421 T C 7.93E-04 Smoking cessation / / 24665060 rs12466271 chr2 52420941 C T 1.13E-05 Smoking cessation / / 24665060 rs6710228 chr2 52427816 G T 5.87E-05 Alzheimer's disease / / 17998437 rs2141847 chr2 52430934 G A 5.51E-05 Smoking cessation / / 24665060 rs1922185 chr2 52441782 C G 4.28E-04 Smoking cessation / / 24665060 rs11679267 chr2 52451702 G A 5.74E-04 Smoking cessation / / 24665060 rs4533502 chr2 52452204 G A 3.77E-04 Smoking cessation / / 24665060 rs6726230 chr2 52461739 G A 5.21E-05 Smoking cessation / / 24665060 rs12995337 chr2 52461984 G A 4.66E-05 Smoking cessation / / 24665060 rs4303750 chr2 52463610 C T 9.48E-05 Smoking cessation / / 24665060 rs7586327 chr2 52469618 C T 6.82E-04 Smoking cessation / / 24665060 rs12622126 chr2 52476027 G T 4.76E-04 Smoking cessation / / 24665060 rs12472885 chr2 52479251 A G 1.90E-05 Iron levels / / 21208937 rs2141844 chr2 52493926 A G 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2141844 chr2 52493926 A G 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707935 chr2 52497171 C G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs10196182 chr2 52505020 T A 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs13405875 chr2 52505554 C A 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1997492 chr2 52506774 C T 3.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs2355817 chr2 52508314 G A 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs13389926 chr2 52511386 T C 4.11E-08 Metabolite levels / / 23281178 rs13389926 chr2 52511386 T C 8.26E-05 Diabetes Mellitus / / pha003060 rs17042688 chr2 52511794 G T 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs17786474 chr2 52511887 G A 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164659 chr2 52518281 C T 5.78E-08 Metabolite levels / / 23281178 rs1922210 chr2 52521126 A G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1922210 chr2 52521126 A G 7.72E-04 Alzheimer's disease / / 24755620 rs10205333 chr2 52523725 A G 7.30E-06 Urinary metabolites / / 21572414 rs12475021 chr2 52535407 T G 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12475021 chr2 52535407 T G 1.36E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs6739969 chr2 52540726 G A 7.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1424786 chr2 52546156 A G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552317 chr2 52550366 G T 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2727880 chr2 52554652 C T 1.82E-04 Type 2 diabetes / / 17463246 rs2727890 chr2 52559485 T A 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4346424 chr2 52565737 C A 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6720308 chr2 52588102 A C 7.44E-05 Serum albumin level / / pha003084 rs17788159 chr2 52599360 T C 0.0000604 Panic disorder LOC100506300 intron 23149450 rs17788159 chr2 52599360 T C 6.04E-05 Serum tamsulosin hydrochloride concentration LOC100506300 intron 23151678 rs10173797 chr2 52614168 A G 3.74E-04 Suicide attempts in bipolar disorder LOC100506300 intron 21423239 rs2552352 chr2 52615845 T C 4.03E-04 Suicide attempts in bipolar disorder LOC100506300 intron 21423239 rs1424802 chr2 52644897 T C 6.25E-06 Serum albumin level / / pha003084 rs2552347 chr2 52653026 G A 8.70E-05 Serum albumin level / / pha003084 rs10193067 chr2 52690413 A C 3.61E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10176819 chr2 52692796 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs10189311 chr2 52692942 T C 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12614961 chr2 52694381 T C 5.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7560361 chr2 52694473 T C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7599425 chr2 52694499 C G 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12611666 chr2 52694638 C T 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs11125427 chr2 52694728 A G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10191908 chr2 52695215 A G 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10168435 chr2 52695364 C T 5.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4971827 chr2 52695754 C T 7.74E-05 Coronary Artery Disease / / 17634449 rs6759941 chr2 52696996 G T 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12619788 chr2 52703590 G A 8.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs6545278 chr2 52706052 T G 8.00E-07 Conotruncal heart defects / / 24800985 rs1526687 chr2 52713807 T G 5.00E-06 Cardiac Troponin-T levels / / 23247143 rs6545286 chr2 52785456 A G 1.29E-04 Alzheimer's disease (late onset) / / 21379329 rs1526676 chr2 52790493 C T 8.90E-06 Urinary metabolites / / 21572414 rs12475183 chr2 52792937 A G 9.85E-04 Multiple complex diseases / / 17554300 rs2356194 chr2 52807474 A G 8.60E-06 Urinary metabolites / / 21572414 rs11895971 chr2 52820363 A G 1.31E-05 Waist-Hip Ratio / / pha003029 rs1021175 chr2 52824147 T C 5.00E-06 Urinary metabolites / / 21572414 rs17043120 chr2 52826401 A G 1.79E-05 Waist-Hip Ratio / / pha003029 rs10203946 chr2 52829150 A G 4.40E-05 Serum metabolites / / 19043545 rs1843032 chr2 52841312 A G 3.70E-06 Urinary metabolites / / 21572414 rs2168094 chr2 52891554 G C 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1454398 chr2 52900416 T C 8.14E-04 Coronary Artery Disease / / 17634449 rs1601166 chr2 52909704 A G 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs350779 chr2 52944722 C T 9.84E-05 Alzheimer's disease (late onset) / / 21379329 rs1349882 chr2 52949318 G T 5.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12713213 chr2 52958528 G A 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17043319 chr2 52961642 A G 3.16E-09 Metabolite levels / / 23281178 rs17043323 chr2 52963904 G A 1.27E-08 Metabolite levels / / 23281178 rs17043328 chr2 52965456 C T 1.27E-08 Metabolite levels / / 23281178 rs13404836 chr2 52966539 G C 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1319797 chr2 52969029 G A 3.40E-05 Body Mass Index / / pha003006 rs1319797 chr2 52969029 G A 3.17E-05 Waist Circumference / / pha003024 rs1319797 chr2 52969029 G A 6.00E-05 Weight / / pha003026 rs1384919 chr2 52974459 G C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs1971201 chr2 53003740 T C 8.73E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1451464 chr2 53006126 G A 2.70E-05 Urinary metabolites / / 21572414 rs1349500 chr2 53006435 T C 1.80E-05 Urinary metabolites / / 21572414 rs2603394 chr2 53007471 T C 2.40E-05 Urinary metabolites / / 21572414 rs785286 chr2 53013320 A G 1.60E-05 Urinary metabolites / / 21572414 rs7607342 chr2 53027798 C T 2.71E-05 Body Mass Index / / pha003014 rs11888200 chr2 53119838 T C 2.10E-04 Coronary Artery Disease / / 17634449 rs2839750 chr2 53129090 A C 4.02E-13 Narcolepsy / / 19629137 rs10175099 chr2 53146216 A G 2.08E-06 Serum metabolites / / 19043545 rs17043835 chr2 53154158 G C 5.92E-05 Serum metabolites / / 19043545 rs4672085 chr2 53154899 G A 3.62E-04 Rheumatoid arthritis / / 21452313 rs1510107 chr2 53160137 C G 1.00E-05 Blood Phenotypes / / 17903294 rs7577197 chr2 53174956 C T 9.09E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs17043867 chr2 53180043 A G 6.88E-04 Parkinson's disease / / 16252231 rs17043868 chr2 53180166 G T 4.02E-05 Serum metabolites / / 19043545 rs2288639 chr2 53188267 A G 5.57E-06 Serum metabolites / / 19043545 rs1446439 chr2 53219203 T C 2.09E-04 Multiple complex diseases / / 17554300 rs6545316 chr2 53223038 A G 9.73E-04 Coronary Artery Disease / / 17634449 rs17044013 chr2 53234943 A T 1.08E-05 Serum metabolites / / 19043545 rs1160297 chr2 53237320 G C 1.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs10184575 chr2 53237372 A C 7.33E-07 Red blood cell traits / / 23222517 rs1446442 chr2 53246064 T C 8.70E-05 Body Mass Index / / pha003014 rs1446445 chr2 53256694 C A 8.74E-04 Myopia (pathological) / / 21095009 rs10496010 chr2 53261856 G A 9.16E-04 Type 2 diabetes / / 17846124 rs2357013 chr2 53266129 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs2357014 chr2 53270575 T C 2.56E-04 Insulin resistance / / 21901158 rs9653536 chr2 53352630 A G 3.71E-04 Height / / 17255346 rs17044134 chr2 53358680 T G 3.57E-04 Coronary Artery Disease / / 17634449 rs2034254 chr2 53358953 A G 1.83E-04 IgE levels / / 17255346 rs17189210 chr2 53361731 T G 5.89E-04 Coronary Artery Disease / / 17634449 rs10496014 chr2 53371251 A G 6.30E-05 Glioma (high-grade) / / 19578366 rs4233969 chr2 53384500 C T 1.90E-05 Urinary metabolites / / 21572414 rs11687654 chr2 53389666 T C 3.96E-04 Multiple complex diseases / / 17554300 rs9309245 chr2 53397048 C G 1.77E-05 Type 2 diabetes / / 23945395 rs17267852 chr2 53401300 C G 7.66E-04 Multiple complex diseases / / 17554300 rs10209546 chr2 53408321 G T 4.17E-04 Multiple complex diseases / / 17554300 rs1364669 chr2 53452495 C A 1.10E-04 Multiple complex diseases / / 17554300 rs195574 chr2 53473426 T C 6.10E-04 Primary sclerosing cholangitis / / 19944697 rs996712 chr2 53502775 A C,G,T 8.00E-06 Obesity-related traits / / 23251661 rs4672305 chr2 53507604 A C 2.95E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11678259 chr2 53508689 T G 1.09E-04 Smoking initiation / / 24665060 rs10202079 chr2 53514022 A G 2.20E-05 Urinary metabolites / / 21572414 rs4671350 chr2 53518480 G A 1.30E-05 Urinary metabolites / / 21572414 rs992874 chr2 53532456 A G 3.18E-05 HIV-1 viral setpoint / / 22174851 rs993161 chr2 53538638 T C 1.60E-05 Urinary metabolites / / 21572414 rs17039520 chr2 53538850 C T 2.76E-04 Multiple complex diseases / / 17554300 rs4672329 chr2 53541547 C T 2.48E-04 Multiple complex diseases / / 17554300 rs7576932 chr2 53549075 T G 5.15E-04 Multiple complex diseases / / 17554300 rs12475695 chr2 53636324 C A 2.29E-04 Rheumatoid arthritis / / 21452313 rs12713247 chr2 53637182 C T 0.0000304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12713247 chr2 53637182 C T 3.04E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4672412 chr2 53647050 T C 2.23E-05 Reading and spelling / / 23738518 rs2172645 chr2 53647729 A C 2.00E-05 Reading and spelling / / 23738518 rs17044651 chr2 53655867 T A 7.79E-04 Multiple complex diseases / / 17554300 rs17044653 chr2 53655977 C T 3.84E-04 Multiple complex diseases / / 17554300 rs10496023 chr2 53656677 A G 4.09E-04 Multiple complex diseases / / 17554300 rs1521937 chr2 53662216 A C 4.12E-04 Parkinson's disease / / 17052657 rs1521937 chr2 53662216 A C 0.0002515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1521937 chr2 53662216 A C 2.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17189393 chr2 53663698 A G 0.0002307 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17189393 chr2 53663698 A G 2.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12713250 chr2 53666367 G C 0.000238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12713250 chr2 53666367 G C 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6545346 chr2 53667806 C T 0.0002708 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6545346 chr2 53667806 C T 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs745685 chr2 53691289 G A 0.0005099 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs745685 chr2 53691289 G A 5.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs903228 chr2 53692049 G C 2.42E-08 Multiple complex diseases / / 17554300 rs1568546 chr2 53692326 C T 0.000516 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1568546 chr2 53692326 C T 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1318578 chr2 53703155 C A 0.0003631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1318578 chr2 53703155 C A 3.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17044787 chr2 53704264 C G 9.20E-06 Left ventricular mass / / 21212386 rs10164725 chr2 53706224 T C 0.000744405 Hypertension (early onset hypertension) / / 22479346 rs4672452 chr2 53730641 G A 2.79E-04 Type 2 diabetes / / 17463246 rs7586411 chr2 53731496 G A 4.45E-04 Type 2 diabetes / / 17463246 rs7586356 chr2 53731637 C T 6.66E-04 Type 2 diabetes / / 17463246 rs17268019 chr2 53735050 A G 0.000285 Salmonella-induced pyroptosis / / 22837397 rs6743847 chr2 53738599 G A 5.17E-04 Type 2 diabetes / / 17463246 rs17268047 chr2 53747437 T A 9.99E-04 Obesity (extreme) / / 21935397 rs56148675 chr2 53756542 T C 5.00E-06 Bulimia nervosa / / 23568457 rs2357359 chr2 53756556 G A 3.96E-04 Obesity (extreme) / / 21935397 rs13407662 chr2 53782559 C T 5.00E-08 Stroke (ischemic) / / 23041239 rs10460550 chr2 53788277 T C 2.86E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs718349 chr2 53791087 G T 3.33E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7566120 chr2 53796167 G A 2.92E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17044935 chr2 53808311 T C 4.37E-04 Type 2 diabetes / / 17463246 rs6715066 chr2 53826209 G A 6.59E-04 Multiple complex diseases / / 17554300 rs759719 chr2 53829044 C G 7.89E-04 Obesity (extreme) / / 21935397 rs2357490 chr2 53832072 C T 2.35E-05 Heart Rate / / pha003053 rs10490459 chr2 53833291 G C 7.10E-04 Schizophrenia / / 21674006 rs6753258 chr2 53846547 C T 5.10E-04 Type 2 diabetes / / 17463246 rs12619100 chr2 53850382 T C 7.68E-06 Serum albumin level / / pha003084 rs11125512 chr2 53850774 A G 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7597885 chr2 53852975 A G 3.44E-04 Multiple complex diseases / / 17554300 rs17578196 chr2 53856374 T C 3.51E-04 Multiple complex diseases / / 17554300 rs6752239 chr2 53859017 A G 9.54E-04 Multiple complex diseases / / 17554300 rs1468983 chr2 53859679 C G,T 7.65E-04 Multiple complex diseases / / 17554300 rs12618833 chr2 53864413 C T 2.96E-06 Schizophrenia / / 24253340 rs997644 chr2 53867187 G T 2.49E-06 Schizophrenia / / 24253340 rs10865275 chr2 53877867 C G 6.12E-04 Alzheimer's disease / / 24755620 rs2160930 chr2 53882527 A G 2.02E-04 Alzheimer's disease (late onset) / / 21379329 rs11889094 chr2 53889867 C T 1.33E-04 Alzheimer's disease (late onset) / / 21379329 rs2287512 chr2 53898032 T C 4.90E-05 Schizophrenia ASB3 intron 24253340 rs7557799 chr2 53901897 A T 8.23E-04 Multiple complex diseases ASB3 intron 17554300 rs7556791 chr2 53906935 A G 8.53E-04 Alzheimer's disease ASB3 intron 24755620 rs7583622 chr2 53931190 G A 5.26E-05 Multiple sclerosis ASB3 intron 17660530 rs6705712 chr2 53954681 C G 8.85E-04 Multiple complex diseases ASB3 intron 17554300 rs6705712 chr2 53954681 C G 0.0000569 Panic disorder ASB3 intron 23149450 rs6705712 chr2 53954681 C G 5.69E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs6714424 chr2 53956980 C A 1.59E-05 Lymphocyte counts ASB3 intron 22286170 rs10188142 chr2 53958136 C T 7.50E-04 Multiple complex diseases ASB3 intron 17554300 rs10188142 chr2 53958136 C T 0.0000554 Panic disorder ASB3 intron 23149450 rs10188142 chr2 53958136 C T 5.54E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs3821081 chr2 53965389 G A 2.67E-04 Multiple complex diseases ASB3 intron 17554300 rs3821081 chr2 53965389 G A 0.0000803 Panic disorder ASB3 intron 23149450 rs3821081 chr2 53965389 G A 8.03E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs3770393 chr2 53972693 G A 0.0000749 Panic disorder ASB3 intron 23149450 rs3770393 chr2 53972693 G A 7.49E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs12613353 chr2 53974223 T G 0.0000898 Panic disorder ASB3 intron 23149450 rs12613353 chr2 53974223 T G 8.98E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs2542588 chr2 54018924 C T 0.0000434 Panic disorder ERLEC1 intron 23149450 rs2542588 chr2 54018924 C T 4.34E-05 Serum tamsulosin hydrochloride concentration ERLEC1 intron 23151678 rs2287344 chr2 54034251 G A 1.42E-04 Tourette syndrome ERLEC1 intron 22889924 rs2542571 chr2 54041983 G T 3.36E-05 Response to taxane treatment (placlitaxel) ERLEC1 intron 23006423 rs698853 chr2 54053872 A G 7.37E-04 Parkinson's disease GPR75-ASB3 intron 17052657 rs698853 chr2 54053872 A G 7.11E-06 Multiple sclerosis GPR75-ASB3 intron 17660530 rs805438 chr2 54056188 T A 7.39E-05 Multiple complex diseases GPR75-ASB3 intron 17554300 rs805438 chr2 54056188 T A 0.0000341 Panic disorder GPR75-ASB3 intron 23149450 rs805438 chr2 54056188 T A 3.41E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs2080721 chr2 54056270 C G 0.0000484 Panic disorder GPR75-ASB3 intron 23149450 rs2080721 chr2 54056270 C G 4.84E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs805439 chr2 54056574 C T 9.91E-05 Multiple complex diseases GPR75-ASB3 intron 17554300 rs805439 chr2 54056574 C T 0.0000215 Panic disorder GPR75-ASB3 intron 23149450 rs805439 chr2 54056574 C T 2.15E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs12617599 chr2 54058082 G C,T 0.0000737 Panic disorder GPR75-ASB3 intron 23149450 rs12617599 chr2 54058082 G C,T 7.37E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs805360 chr2 54164848 G T 1.79E-04 Alzheimer's disease (late onset) PSME4 intron 21379329 rs17045435 chr2 54174258 A G 7.58E-04 Multiple complex diseases PSME4 intron 17554300 rs1363060 chr2 54284584 G A 1.01E-05 Heart Rate LOC100506338 intron pha003051 rs41385746 chr2 54305030 T C 6.33E-05 Multiple sclerosis LOC100506338 intron 17660530 rs34498089 chr2 54308826 A G 3.13E-05 Multiple sclerosis LOC100506338 intron 17660530 rs17039547 chr2 54333729 A C 4.57E-05 Multiple sclerosis / / 17660530 rs1559040 chr2 54347750 C T 4.00E-08 Sudden cardiac arrest ACYP2 intron 21658281 rs10206954 chr2 54358517 C T 2.01E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs10186140 chr2 54362975 T C 9.45E-05 Heart Rate ACYP2 intron pha003051 rs7572559 chr2 54372118 G A 5.25E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs10201710 chr2 54372931 T C 2.66E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs13399590 chr2 54382335 A G 2.66E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs3738855 chr2 54386075 T C 3.44E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs11893929 chr2 54418017 C T 2.25E-05 Schizophrenia ACYP2 intron 24253340 rs13417493 chr2 54420617 G A 3.18E-05 Schizophrenia ACYP2 intron 24253340 rs1399513 chr2 54424601 A C 9.09E-06 Schizophrenia ACYP2 intron 24253340 rs1727504 chr2 54428134 C T 3.76E-05 Aging (time to event) ACYP2 intron 21782286 rs11886559 chr2 54437400 G T 2.34E-05 Schizophrenia ACYP2 intron 24253340 rs11894205 chr2 54442697 C T 5.17E-05 Schizophrenia ACYP2 intron 24253340 rs843652 chr2 54469703 T C 8.22E-05 Serum metabolites ACYP2 intron 19043545 rs11125529 chr2 54475866 C A 4.48E-08 Telomere length ACYP2 intron 23535734 rs10165485 chr2 54481636 T C 5.16E-05 Sodium levels TSPYL6 UTR-3 pha003093 rs13407991 chr2 54530993 A G 8.85E-04 Tourette syndrome ACYP2 intron 22889924 rs4600702 chr2 54598757 C G 1.26E-05 Aging (time to event) / / 21782286 rs13407315 chr2 54615040 T C 3.44E-05 Duodenal ulcer / / 22387998 rs6545397 chr2 54615526 A G 7.25E-04 Smoking initiation / / 24665060 rs13425775 chr2 54616446 A G 6.48E-04 Coronary heart disease / / 21971053 rs4359699 chr2 54623790 T C 4.36E-06 Bone mineral density / / 24249740 rs6743995 chr2 54625873 T G 3.49E-04 Multiple complex diseases / / 17554300 rs6734097 chr2 54651933 C T 3.00E-08 Bone mineral density (spine) / / 19801982 rs4315567 chr2 54655944 T G 3.60E-05 Bone mineral density (spine) / / 19079262 rs7607093 chr2 54659174 T G 4.00E-08 Bone mineral density (spine) / / 19801982 rs4233949 chr2 54659707 C G 4.50E-08 Bone mineral density (spine) / / 19801982 rs4233949 chr2 54659707 C G 9.10E-06 Urinary metabolites / / 21572414 rs4233949 chr2 54659707 C G 2.00E-18 Bone mineral density / / 22504420 rs4233949 chr2 54659707 C G 0.000492 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs4233949 chr2 54659707 C G 1.71E-05 Bone mineral density / / 24249740 rs4233949 chr2 54659707 C G 8.21E-04 Bone mineral density / / 24249740 rs6744982 chr2 54659980 C G 6.10E-06 Urinary metabolites / / 21572414 rs6752877 chr2 54661569 G T 2.90E-08 Bone mineral density (spine) / / 19801982 rs4558622 chr2 54664296 A C 1.70E-05 Urinary metabolites / / 21572414 rs11898505 chr2 54684557 A G 8.00E-07 Bone mineral density (spine) SPTBN1 intron 18445777 rs11898505 chr2 54684557 A G 4.00E-06 Bone mineral density (spine) SPTBN1 intron 19079262 rs11898505 chr2 54684557 A G 2.00E-08 Bone mineral density (spine) SPTBN1 intron 19801982 rs11898505 chr2 54684557 A G 4.00E-13 Bone properties (heel) SPTBN1 intron 24430505 rs11898505 chr2 54684557 A G 6.00E-06 Bone properties (heel) SPTBN1 intron 24430505 rs4557020 chr2 54718181 T C 3.00E-07 Myopia (pathological) SPTBN1 intron 22685421 rs10496031 chr2 54723203 C A 3.39E-04 Parkinson's disease SPTBN1 intron 17052657 rs17045939 chr2 54738233 A C 4.37E-04 Acute lung injury SPTBN1 intron 22295056 rs17045941 chr2 54738392 C G 3.91E-04 Insulin resistance SPTBN1 intron 21901158 rs17045949 chr2 54746887 G C 4.38E-04 Aortic root size SPTBN1 intron 21223598 rs4671950 chr2 54759730 G A 1.00E-04 Prostate cancer SPTBN1 intron 21743057 rs11895933 chr2 54767792 A G 1.00E-04 Prostate cancer SPTBN1 intron 21743057 rs3936082 chr2 54777920 T C 1.38E-04 Multiple complex diseases SPTBN1 intron 17554300 rs4455199 chr2 54792110 T C 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPTBN1 intron 20877124 rs4455199 chr2 54792110 T C 3.87E-04 Rheumatoid arthritis SPTBN1 intron 21452313 rs6734445 chr2 54797798 C T 4.44E-05 Bipolar disorder SPTBN1 intron 19488044 rs6734445 chr2 54797798 C T 8.30E-04 Asthma SPTBN1 intron 20698975 rs6734445 chr2 54797798 C T 4.13E-05 Bipolar Disorder SPTBN1 intron pha002863 rs4671961 chr2 54798596 G A 3.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPTBN1 intron 20877124 rs10204932 chr2 54799127 G A 1.83E-05 Sleep duration SPTBN1 intron 22105623 rs7584223 chr2 54818895 T C 6.40E-04 Asthma SPTBN1 intron 20698975 rs7608414 chr2 54844995 G A 9.32E-05 Calcium levels SPTBN1 intron pha003085 rs6545435 chr2 54859403 C T 1.60E-04 Asthma SPTBN1 intron 20698975 rs2941579 chr2 54861825 T C 4.11E-05 Schizophrenia SPTBN1 intron pha002857 rs3106204 chr2 54863352 T G 1.85E-04 Rheumatoid arthritis SPTBN1 intron 21452313 rs966003 chr2 54884870 C T 3.36E-04 Bipolar disorder,affective SPTBN1 intron 20528957 rs2971880 chr2 54885640 T A 2.33E-04 Bipolar disorder,affective SPTBN1 intron 20528957 rs13414727 chr2 54891126 C T 9.17E-04 Multiple complex diseases SPTBN1 intron 17554300 rs2971884 chr2 54904463 G A 7.79E-05 Attention deficit hyperactivity disorder / / pha002875 rs17046149 chr2 54910872 T C 3.06E-05 Bipolar disorder,affective / / 20528957 rs2941577 chr2 54914459 C T 7.89E-04 Type 2 diabetes / / 17463246 rs2941577 chr2 54914459 C T 9.89E-05 Attention deficit hyperactivity disorder / / pha002875 rs6717369 chr2 54915044 T C 2.46E-04 Bipolar disorder,affective / / 20528957 rs6717369 chr2 54915044 T C 8.71E-04 Rheumatoid arthritis / / 21452313 rs6717369 chr2 54915044 T C 3.01E-05 Height / / pha003010 rs6717369 chr2 54915044 T C 6.10E-06 Height / / pha003011 rs4671969 chr2 54915617 T C 1.95E-04 Bipolar disorder,affective / / 20528957 rs2666035 chr2 54938838 T A 4.88E-05 Attention deficit hyperactivity disorder / / pha002875 rs2666036 chr2 54942538 G A 6.64E-05 Height / / pha003010 rs2666036 chr2 54942538 G A 7.97E-05 Height / / pha003011 rs9309258 chr2 54943642 C T 5.97E-04 Acute lung injury / / 22295056 rs17046257 chr2 54949785 G A 4.76E-04 Acute lung injury / / 22295056 rs6732751 chr2 54957416 G A 7.22E-05 Bipolar disorder,affective EML6 intron 20528957 rs6732751 chr2 54957416 G A 6.84E-04 Acute lung injury EML6 intron 22295056 rs7582640 chr2 54957773 C T 4.77E-04 Acute lung injury EML6 intron 22295056 rs6708082 chr2 54958830 A G 1.23E-04 Bipolar disorder,affective EML6 intron 20528957 rs6708082 chr2 54958830 A G 4.77E-04 Acute lung injury EML6 intron 22295056 rs6740110 chr2 54959092 C G 1.36E-04 Bipolar disorder,affective EML6 intron 20528957 rs6740110 chr2 54959092 C G 4.77E-04 Acute lung injury EML6 intron 22295056 rs10169439 chr2 54959690 T C 4.17E-04 Acute lung injury EML6 intron 22295056 rs6545440 chr2 54959862 A T 4.77E-04 Acute lung injury EML6 intron 22295056 rs13428703 chr2 54960680 G A 4.65E-04 Acute lung injury EML6 intron 22295056 rs6752720 chr2 54962352 G A 8.29E-04 Acute lung injury EML6 intron 22295056 rs6753004 chr2 54962723 C A 8.29E-04 Acute lung injury EML6 intron 22295056 rs10194108 chr2 54964021 A G 6.20E-04 Acute lung injury EML6 intron 22295056 rs13401661 chr2 54972648 C T 8.69E-05 Pancreatic cancer EML6 intron pha002889 rs2631835 chr2 54975471 T C 9.92E-05 Multiple complex diseases EML6 intron 17554300 rs1848924 chr2 54976770 A G 2.05E-04 Multiple complex diseases EML6 intron 17554300 rs12615703 chr2 54987142 C A 3.92E-04 Multiple complex diseases EML6 intron 17554300 rs17046292 chr2 54991442 A T 6.51E-04 Multiple complex diseases EML6 intron 17554300 rs4671975 chr2 54991712 G A 4.78E-04 Multiple complex diseases EML6 intron 17554300 rs2116441 chr2 54995746 A G 1.00E-04 Multiple complex diseases EML6 intron 17554300 rs2116441 chr2 54995746 A G 8.58E-04 Taste perception EML6 intron 22132133 rs165051 chr2 55019723 C G 9.51E-04 Multiple complex diseases EML6 intron 17554300 rs2578715 chr2 55034113 C T 1.66E-06 Height EML6 intron pha003010 rs2578715 chr2 55034113 C T 2.30E-05 Height EML6 intron pha003011 rs2631837 chr2 55038830 A G 1.09E-07 Height EML6 intron pha003010 rs2631837 chr2 55038830 A G 8.19E-06 Height EML6 intron pha003011 rs2567839 chr2 55042463 A G 9.59E-05 Height EML6 intron pha003010 rs2567839 chr2 55042463 A G 7.89E-05 Height EML6 intron pha003011 rs2567840 chr2 55046042 C T 8.38E-05 Height EML6 intron pha003010 rs10197243 chr2 55052493 C T 1.50E-05 Urinary metabolites EML6 intron 21572414 rs17046387 chr2 55052949 T G 2.75E-04 Type 2 diabetes EML6 intron 17463246 rs1549840 chr2 55063113 C T 4.68E-04 Multiple complex diseases EML6 intron 17554300 rs10173697 chr2 55066310 T C 4.00E-05 Type 2 diabetes EML6 intron 17460697 rs2116435 chr2 55072474 G A 6.33E-05 Heart Rate EML6 intron pha003053 rs4613325 chr2 55073464 G A 3.07E-04 Alzheimer's disease EML6 intron 17998437 rs12465327 chr2 55074429 C A 9.38E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2165006 chr2 55075394 T C 1.64E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6545449 chr2 55076441 T C 3.05E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs12713278 chr2 55077061 A G 1.20E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs4671979 chr2 55079242 G T 9.34E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs13033818 chr2 55079388 C T 2.80E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs13033668 chr2 55079454 A G 4.56E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2033411 chr2 55079654 A T 1.12E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs12713280 chr2 55081376 C T 6.00E-06 Economic and political preferences EML6 intron 22566634 rs7596552 chr2 55082903 T G 1.44E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10496033 chr2 55084583 C T 8.00E-06 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10188555 chr2 55086183 T C 7.73E-06 Suicide attempts in bipolar disorder EML6 intron 21423239 rs1371020 chr2 55087887 C T 5.06E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs1371020 chr2 55087887 C T 0.0007356 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EML6 intron 23233654 rs1371020 chr2 55087887 C T 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) EML6 intron 23233662 rs2358155 chr2 55091029 C T 1.81E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6545450 chr2 55091223 A C 5.43E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2006878 chr2 55091375 G A 2.90E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs723975 chr2 55092926 G A 2.96E-05 Personality dimensions EML6 intron 22628180 rs17417731 chr2 55093784 T A 2.75E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs4671981 chr2 55093859 C G 2.91E-05 Personality dimensions EML6 intron 22628180 rs11677058 chr2 55097549 A G 6.76E-05 Cognitive test performance EML6 intron 20125193 rs13385982 chr2 55103265 G T 2.07E-04 Alcohol dependence EML6 intron 20201924 rs2163618 chr2 55111689 G A 3.04E-04 Alcohol dependence EML6 intron 20201924 rs10171653 chr2 55127601 A G 0.0000923 Carotid intima media thickness EML6 intron 23152477 rs7355716 chr2 55133564 G A 1.47E-04 Acute lymphoblastic leukemia (childhood) EML6 intron 22076464 rs4671992 chr2 55134309 C T 9.22E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2304685 chr2 55144103 C G 8.49E-04 Bipolar disorder EML6 intron 19259986 rs10176018 chr2 55153731 A G 3.98E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6726292 chr2 55156630 G A 1.00E-06 Obesity (extreme) EML6 intron 19553259 rs13394146 chr2 55176112 C T 5.43E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10746530 chr2 55181893 G A 1.25E-04 Scoliosis EML6 intron 21216876 rs11898145 chr2 55182968 C A 5.23E-05 Orofacial clefts EML6 intron 22419666 rs7584992 chr2 55183627 G A 1.62E-05 Height EML6 intron pha003010 rs17046514 chr2 55185862 G A 1.70E-05 Urinary metabolites EML6 intron 21572414 rs12623902 chr2 55186229 T C 7.04E-04 Obesity (extreme) EML6 intron 21935397 rs17346629 chr2 55186394 A C 7.04E-04 Obesity (extreme) EML6 cds-synon 21935397 rs6741304 chr2 55188195 G A 4.96E-04 Obesity (extreme) EML6 intron 21935397 rs2255112 chr2 55200800 T G 4.42E-04 Smoking initiation RTN4 intron 24665060 rs2580765 chr2 55204028 A C 4.29E-04 Smoking initiation RTN4 intron 24665060 rs2580770 chr2 55214912 C G 7.35E-04 Multiple complex diseases RTN4 intron 17554300 rs2580771 chr2 55215825 G A 1.64E-04 Multiple complex diseases RTN4 intron 17554300 rs2919129 chr2 55216545 C A 1.52E-04 Smoking initiation RTN4 intron 24665060 rs2580772 chr2 55218805 G T 1.64E-04 Smoking initiation RTN4 intron 24665060 rs17046570 chr2 55220584 C T 9.62E-05 Coronary heart disease RTN4 intron 24778558 rs6755468 chr2 55240026 A C 3.35E-04 Smoking initiation RTN4 intron 24665060 rs10496037 chr2 55257677 C T 4.79E-05 Triglycerides RTN4 intron pha003081 rs2968794 chr2 55290651 G C 1.45E-04 Smoking initiation / / 24665060 rs7575107 chr2 55305986 T G 7.86E-04 Acute lung injury / / 22295056 rs6724138 chr2 55314518 G A 4.05E-04 Endometrial cancer / / 24096698 rs6724138 chr2 55314518 G A 7.82E-05 Endometrial cancer / / 24096698 rs12464796 chr2 55327407 C T 2.52E-05 HDL cholesterol / / pha003075 rs12464877 chr2 55327550 G T 4.10E-06 HDL cholesterol / / pha003075 rs2968778 chr2 55338420 C T 4.18E-05 HDL cholesterol / / pha003075 rs10496039 chr2 55346785 T C 3.88E-05 HDL cholesterol / / pha003075 rs11892071 chr2 55349726 A C 7.50E-06 Hypertension / / pha003041 rs10168457 chr2 55357427 C T 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7349405 chr2 55391294 C A 2.37E-04 Insulin resistance / / 21901158 rs7349405 chr2 55391294 C A 6.94E-05 Hypertension / / pha003041 rs1133182 chr2 55402225 C T 8.43E-04 Multiple complex diseases C2orf63 UTR-3 17554300 rs7588591 chr2 55418935 C A 2.00E-06 Bipolar disorder (body mass index interaction) C2orf63 intron 24322204 rs1437391 chr2 55446356 A G 3.47E-04 IgE levels C2orf63 intron 17255346 rs1561231 chr2 55455867 T C 9.68E-04 Weight loss (gastric bypass surgery) C2orf63 intron 23643386 rs17046820 chr2 55510799 A T 2.92E-04 Multiple complex diseases / / 17554300 rs2589113 chr2 55516323 T G 2.00E-08 Height CCDC88A UTR-3 21998595 rs6746287 chr2 55538097 A G 0.0006513 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CCDC88A intron 23233654 rs6746287 chr2 55538097 A G 6.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) CCDC88A intron 23233662 rs10518764 chr2 55576469 T C 6.84E-06 Multiple complex diseases CCDC88A intron 17554300 rs3861571 chr2 55582236 G A 1.90E-05 Lipid levels CCDC88A intron 19016617 rs3861571 chr2 55582236 G A 2.84E-06 Lipid levels CCDC88A intron 19016617 rs3861571 chr2 55582236 G A 5.58E-04 Lipid levels CCDC88A intron 19016617 rs17046963 chr2 55600755 T C 3.03E-04 Multiple complex diseases CCDC88A intron 17554300 rs4672035 chr2 55636351 T C 1.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC88A intron 20877124 rs4672040 chr2 55640649 G A 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC88A intron 20877124 rs4672045 chr2 55658147 G A 4.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13028756 chr2 55668771 A C 7.80E-04 Multiple complex diseases / / 17554300 rs7593229 chr2 55680496 G A 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6719033 chr2 55684494 C T 1.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1037509 chr2 55687597 C T 2.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4671246 chr2 55688713 C T 1.96E-04 Dental caries / / 21940522 rs13032503 chr2 55739093 C T 6.57E-05 Mammographic density / / 22532574 rs12992408 chr2 55749085 T G 7.18E-05 Blood Pressure CCDC104 intron pha002903 rs10496050 chr2 55806313 C T 1.28E-05 Blood Pressure SMEK2 intron pha002903 rs782586 chr2 55836165 A C 1.20E-06 Blood Pressure SMEK2 intron pha002903 rs782588 chr2 55841640 T C 1.23E-06 Blood Pressure SMEK2 intron pha002903 rs782588 chr2 55841640 T C 9.80E-05 Weight SMEK2 intron pha003027 rs782590 chr2 55843413 C T 4.00E-08 Metabolic syndrome SMEK2 intron 22399527 rs2291336 chr2 55845351 T A,C 9.14E-05 Coronary Artery Disease / / 17634449 rs782602 chr2 55849309 A G 8.02E-07 Blood Pressure / / pha002903 rs706548 chr2 55850106 C G 4.80E-04 Height / / 21998595 rs2627759 chr2 55853341 T C 5.00E-06 Blood Pressure / / pha002903 rs782652 chr2 55862775 C A 9.38E-06 Blood Pressure PNPT1 UTR-3 pha002903 rs1373228 chr2 55871285 G A 2.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PNPT1 intron 20031582 rs2627775 chr2 55877113 C T 7.58E-05 Weight PNPT1 intron pha003027 rs2627775 chr2 55877113 C T 4.99E-05 ldl cholesterol PNPT1 intron pha003077 rs7559307 chr2 55882672 T C 8.24E-04 Multiple complex diseases PNPT1 intron 17554300 rs6545513 chr2 55884864 G A 4.94E-04 Multiple complex diseases PNPT1 intron 17554300 rs782606 chr2 55886602 T C 5.82E-06 Blood Pressure PNPT1 intron pha002903 rs782606 chr2 55886602 T C 2.70E-05 Weight PNPT1 intron pha003027 rs7575170 chr2 55886780 C T 5.42E-05 Weight PNPT1 intron pha003027 rs7575170 chr2 55886780 C T 2.66E-05 Cardiovascular disease PNPT1 intron pha003065 rs2586954 chr2 55892261 A C 1.40E-05 Blood Pressure PNPT1 intron pha002903 rs2586954 chr2 55892261 A C 2.17E-05 Weight PNPT1 intron pha003027 rs782637 chr2 55894247 T C 2.68E-05 Blood Pressure PNPT1 intron pha002903 rs12474717 chr2 55943217 G T 2.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs4672066 chr2 55956223 A G 7.17E-06 Lung function (forced vital capacity) / / 24929828 rs4672066 chr2 55956223 A G 2.93E-04 Heart Failure / / pha002884 rs10178492 chr2 55958891 T C 1.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2163237 chr2 55973732 C T 5.00E-06 IgG glycosylation / / 23382691 rs1583116 chr2 55983929 C T 3.43E-06 Left ventricular mass / / 21212386 rs1583116 chr2 55983929 C T 6.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1579496 chr2 55986436 C A,G,T 2.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4672069 chr2 55987857 C G 8.28E-06 Lung function (forced vital capacity) / / 24929828 rs4233963 chr2 55988293 T C 4.12E-05 Lung function (forced vital capacity) / / 24929828 rs11694759 chr2 55988681 T G 1.80E-05 Lung function (forced vital capacity) / / 24929828 rs11887339 chr2 55988948 A G 1.96E-05 Lung function (forced vital capacity) / / 24929828 rs1961386 chr2 55992905 A G 1.31E-05 Lung function (forced vital capacity) / / 24929828 rs934274 chr2 55994818 A G 5.85E-06 Lung function (forced vital capacity) / / 24929828 rs934275 chr2 55994856 T C 6.88E-06 Lung function (forced vital capacity) / / 24929828 rs11693187 chr2 55996787 G A 5.91E-06 Lung function (forced vital capacity) / / 24929828 rs11676678 chr2 55996959 T A 3.42E-06 Lung function (forced vital capacity) / / 24929828 rs13404193 chr2 55997646 A G 2.96E-05 Lung function (forced vital capacity) / / 24929828 rs11694790 chr2 55997871 C T 1.16E-06 Lung function (forced vital capacity) / / 24929828 rs934276 chr2 55998008 T C 1.80E-06 Lung function (forced vital capacity) / / 24929828 rs934277 chr2 55998173 C T 1.14E-06 Lung function (forced vital capacity) / / 24929828 rs12614845 chr2 55998590 T C 1.29E-06 Lung function (forced vital capacity) / / 24929828 rs11684982 chr2 55998850 A T 1.80E-06 Lung function (forced vital capacity) / / 24929828 rs4671259 chr2 56000183 A G 7.24E-06 Lung function (forced vital capacity) / / 24929828 rs7560508 chr2 56002372 C T 3.55E-05 Lung function (forced vital capacity) / / 24929828 rs1430198 chr2 56002404 G A 3.55E-05 Lung function (forced vital capacity) / / 24929828 rs1430199 chr2 56002685 G A 1.16E-06 Lung function (forced vital capacity) / / 24929828 rs1430200 chr2 56002923 T C 2.90E-06 Lung function (forced vital capacity) / / 24929828 rs9309269 chr2 56003053 G A 3.24E-06 Lung function (forced vital capacity) / / 24929828 rs6742316 chr2 56003988 A T 3.75E-05 Lung function (forced vital capacity) / / 24929828 rs6723918 chr2 56004139 A G 3.89E-05 Lung function (forced vital capacity) / / 24929828 rs7577894 chr2 56008904 T C 1.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs11125600 chr2 56009670 C G 3.50E-05 Lung function (forced vital capacity) / / 24929828 rs9309270 chr2 56010084 T C 3.33E-06 Lung function (forced vital capacity) / / 24929828 rs77406423 chr2 56010606 A C 3.56E-05 Lung function (forced vital capacity) / / 24929828 rs7602081 chr2 56020185 T C 6.59E-06 Lung function (forced vital capacity) / / 24929828 rs1430191 chr2 56033427 C T 1.05E-05 Lung function (forced vital capacity) / / 24929828 rs10196888 chr2 56036226 A G 1.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs10196888 chr2 56036226 A G 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs1346781 chr2 56037076 C T 5.73E-06 Lung function (forced vital capacity) / / 24929828 rs6723695 chr2 56038066 T C 1.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs6723695 chr2 56038066 T C 7.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7577580 chr2 56038729 T G 1.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7577580 chr2 56038729 T G 7.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs6730839 chr2 56048107 G C 1.53E-06 Height / / 22216288 rs6759150 chr2 56048194 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759150 chr2 56048194 A T 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs13394642 chr2 56049955 A G 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs13394642 chr2 56049955 A G 8.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs11903784 chr2 56052485 G T 3.87E-05 Lung function (forced vital capacity) / / 24929828 rs1594308 chr2 56054052 T G 3.65E-05 Lung function (forced vital capacity) / / 24929828 rs6733730 chr2 56054216 G C 1.92E-06 Lung function (forced vital capacity) / / 24929828 rs6545526 chr2 56055436 T G 1.90E-06 Lung function (forced vital capacity) / / 24929828 rs143080645 chr2 56059152 T C 3.11E-05 Lung function (forced vital capacity) / / 24929828 rs57692404 chr2 56060659 C T 3.00E-05 Lung function (forced vital capacity) / / 24929828 rs543949007 chr2 56061295 CT C 6.74E-06 Lung function (forced vital capacity) / / 24929828 rs7609520 chr2 56061295 C T 6.74E-06 Lung function (forced vital capacity) / / 24929828 rs148288741 chr2 56063907 A T 2.79E-05 Lung function (forced vital capacity) / / 24929828 rs116371971 chr2 56065354 C G 2.72E-05 Lung function (forced vital capacity) / / 24929828 rs1430201 chr2 56069405 T A 2.90E-05 Lung function (forced vital capacity) / / 24929828 rs934278 chr2 56070352 G A 2.56E-06 Lung function (forced vital capacity) / / 24929828 rs6545527 chr2 56073809 T C 4.05E-06 Lung function (forced vital capacity) / / 24929828 rs6743114 chr2 56074525 A G 9.28E-06 Lung function (forced vital capacity) / / 24929828 rs7607070 chr2 56078417 A T 3.36E-06 Lung function (forced vital capacity) / / 24929828 rs116212307 chr2 56078555 G A 4.23E-05 Lung function (forced vital capacity) / / 24929828 rs11694213 chr2 56088667 T A 8.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1367226 chr2 56089540 A G 4.00E-08 Height / / 20881960 rs1367226 chr2 56089540 A G 2.26E-06 Lung function (forced vital capacity) / / 24929828 rs11125607 chr2 56090113 T A 4.39E-06 Lung function (forced vital capacity) / / 24929828 rs17047272 chr2 56090337 A G 4.35E-05 Lung function (forced vital capacity) / / 24929828 rs1346787 chr2 56092612 C T 4.53E-04 Alzheimer's disease (late onset) EFEMP1 nearGene-3 21379329 rs1346787 chr2 56092612 C T 6.12E-06 Lung function (forced vital capacity) EFEMP1 nearGene-3 24929828 rs77784128 chr2 56094394 G A 2.98E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs3791679 chr2 56096892 A G 6.00E-11 Height EFEMP1 intron 18391951 rs3791679 chr2 56096892 A G 6.00E-09 Height EFEMP1 intron 20189936 rs3791679 chr2 56096892 A G 1.71E-06 Osteoarthritis EFEMP1 intron 22763110 rs3791679 chr2 56096892 A G 8.00E-16 Height EFEMP1 intron 23563607 rs17047275 chr2 56098569 G C 4.89E-04 Multiple complex diseases EFEMP1 intron 17554300 rs75943405 chr2 56099672 G A 1.09E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs17047277 chr2 56100846 C G 3.68E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs17047281 chr2 56102552 T C 2.02E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs75915915 chr2 56107760 C T 1.78E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs74968080 chr2 56107904 A G 1.64E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs78077363 chr2 56107976 C T 3.46E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs3791675 chr2 56111309 C T 2.00E-12 Height EFEMP1 intron 18391952 rs3791675 chr2 56111309 C T 2.00E-09 Height EFEMP1 intron 19396169 rs3791675 chr2 56111309 C T 4.00E-06 Height EFEMP1 intron 19893584 rs3791675 chr2 56111309 C T 3.00E-07 Height EFEMP1 intron 20397748 rs3791675 chr2 56111309 C T 3.00E-35 Height EFEMP1 intron 20881960 rs17047300 chr2 56112168 G A 1.20E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs1367228 chr2 56112440 C A 2.00E-09 Venous thromboembolism (gene x gene interaction) EFEMP1 intron 23509962 rs75000414 chr2 56113746 C T 6.24E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs10496055 chr2 56115859 G A 1.08E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs1430193 chr2 56120853 A T 2.00E-12 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs4487120 chr2 56132276 A T 5.46E-04 Multiple complex diseases EFEMP1 intron 17554300 rs7559906 chr2 56133040 C T 5.65E-04 Multiple complex diseases EFEMP1 intron 17554300 rs2033316 chr2 56140531 A G 7.30E-05 Alcoholism (heaviness of drinking) EFEMP1 intron 21529783 rs3762515 chr2 56150864 C T 9.50E-05 White matter hyperintensity burden EFEMP1 UTR-5 21681796 rs2868440 chr2 56158646 C T 3.75E-05 Lung function (forced vital capacity) / / 24929828 rs7563487 chr2 56163875 C T 3.21E-05 Lung function (forced vital capacity) / / 24929828 rs12617071 chr2 56166830 T G 2.80E-05 Lung function (forced vital capacity) / / 24929828 rs17047337 chr2 56166944 C A 3.60E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs557947133 chr2 56166944 C CT 3.60E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs17278953 chr2 56167809 G A 7.21E-04 Multiple complex diseases / / 17554300 rs11694304 chr2 56182118 G C 5.03E-07 Lung function (forced vital capacity) / / 24929828 rs72811742 chr2 56182666 C T 1.83E-05 Lung function (forced vital capacity) / / 24929828 rs6749890 chr2 56183651 C G 1.30E-05 Lung function (forced vital capacity) / / 24929828 rs17279016 chr2 56183856 C T 1.58E-06 Lung function (forced vital capacity) / / 24929828 rs2163714 chr2 56184748 C A 4.31E-05 Lung function (forced vital capacity) / / 24929828 rs17279030 chr2 56185872 A C 9.42E-04 Multiple complex diseases / / 17554300 rs1432562 chr2 56186182 G A 9.63E-07 Lung function (forced vital capacity) / / 24929828 rs1465684 chr2 56186525 C A 4.04E-05 Lung function (forced vital capacity) / / 24929828 rs62164511 chr2 56195696 A G 2.00E-07 Lung function (forced vital capacity) / / 24929828 rs17279203 chr2 56198160 T C 1.65E-04 Multiple complex diseases / / 17554300 rs17047369 chr2 56198401 A G 3.54E-04 Obesity (extreme) / / 21935397 rs6545535 chr2 56214516 A G 9.34E-05 Blood Pressure / / pha002903 rs7558150 chr2 56216904 T G 4.64E-04 Multiple complex diseases / / 17554300 rs13029542 chr2 56228351 C T 4.30E-04 Alcohol dependence / / 20201924 rs4672084 chr2 56229384 C T 1.31E-04 Alzheimer's disease (late onset) / / 21379329 rs6741589 chr2 56239995 C T 9.08E-04 Alzheimer's disease / / 22005930 rs4553860 chr2 56244096 A G 4.90E-04 Alcohol dependence / / 20201924 rs1347093 chr2 56246340 G T 4.50E-04 Alcohol dependence / / 20201924 rs1347093 chr2 56246340 G T 4.10E-04 Alzheimer's disease / / 22005930 rs10469875 chr2 56261491 G C 2.28E-05 Lung function (forced vital capacity) / / 24929828 rs1432547 chr2 56300279 A G 3.66E-04 Type 2 diabetes / / 17463246 rs10166672 chr2 56330148 A G 8.05E-04 Alzheimer's disease / / 22005930 rs10210015 chr2 56332639 T C 8.54E-04 Alzheimer's disease / / 22005930 rs2868993 chr2 56335979 C T 7.90E-05 HIV-1 control / / 20041166 rs17268563 chr2 56361233 G A 1.72E-04 Multiple complex diseases / / 17554300 rs6751715 chr2 56363377 T C 1.00E-06 HIV-1 control / / 20041166 rs2111469 chr2 56376308 C T 8.58E-05 Serum metabolites / / 19043545 rs2111469 chr2 56376308 C T 4.90E-05 HIV-1 control / / 20041166 rs11685990 chr2 56381388 T C 3.67E-05 Height / / 22021425 rs17190037 chr2 56381660 C T 3.43E-05 Type 2 diabetes / / 17463246 rs10176451 chr2 56396433 C T 8.03E-04 HIV-1 viral setpoint / / 17641165 rs13024922 chr2 56398230 A C,T 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13024922 chr2 56398230 A C,T 9.78E-04 Heart Failure / / pha002884 rs1861774 chr2 56402808 A C 5.71E-05 Information processing speed / / 21130836 rs1861774 chr2 56402808 A C 3.53E-05 Heart Rate / / pha003053 rs7423933 chr2 56415771 G A 2.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC85A intron 20877124 rs1016339 chr2 56421972 C T 2.65E-04 Alzheimer's disease (late onset) CCDC85A intron 21379329 rs1016339 chr2 56421972 C T 1.03E-04 Longevity CCDC85A intron 22279548 rs12613794 chr2 56425702 C T 8.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC85A intron 20877124 rs17190086 chr2 56435657 G T 7.89E-04 Smoking initiation CCDC85A intron 24665060 rs17047588 chr2 56436865 G C 2.17E-04 Multiple complex diseases CCDC85A intron 17554300 rs10490395 chr2 56448266 A C 4.70E-04 Crohn's disease CCDC85A intron 17684544 rs17268688 chr2 56454266 C T 7.50E-05 Major depressive disorder CCDC85A intron 21042317 rs12996636 chr2 56461523 A T 6.60E-05 Parkinson's disease (age of onset) CCDC85A intron 19772629 rs4672101 chr2 56475484 G A,C 0.0000329 Colorectal adenoma (excluding hyperplasic) CCDC85A intron 23677573 rs4672101 chr2 56475484 G A,C 0.0000329 Colorectal adenoma (including hyperplasic) CCDC85A intron 23677573 rs759615 chr2 56480571 C T 5.11E-05 Multiple complex diseases CCDC85A intron 17554300 rs1468914 chr2 56480917 G A 8.74E-05 Multiple complex diseases CCDC85A intron 17554300 rs13016868 chr2 56488460 T G 0.000164 Salmonella-induced pyroptosis CCDC85A intron 22837397 rs13004757 chr2 56490661 C A 4.10E-06 Recombination rate CCDC85A intron 21698098 rs214042 chr2 56502903 A C 1.26E-04 Major depressive disorder CCDC85A intron 22472876 rs7603700 chr2 56525027 C A 6.98E-04 Multiple complex diseases CCDC85A intron 17554300 rs9808416 chr2 56563822 C T 2.00E-05 Alcoholism (heaviness of drinking) CCDC85A intron 21529783 rs7561980 chr2 56585774 A G 1.44E-04 Lung function (forced expiratory volume in 1 second) CCDC85A intron 24023788 rs10168390 chr2 56589215 C T 4.29E-04 Multiple complex diseases CCDC85A intron 17554300 rs17268785 chr2 56592083 A G 1.00E-10 Menarche (age at onset) CCDC85A intron 21102462 rs17047854 chr2 56598309 G A 5.80E-04 Menarche (age at onset) CCDC85A intron 23599027 rs17047859 chr2 56600669 A C 1.55E-04 Alcohol dependence CCDC85A intron 21314694 rs2193488 chr2 56608816 G A 7.21E-04 Alcohol consumption (maxi-drinks) CCDC85A intron 24277619 rs17047868 chr2 56609371 G A 6.00E-05 Alcohol dependence CCDC85A intron 22096494 rs11902680 chr2 56611725 C A 5.67E-04 Alcohol consumption (maxi-drinks) CCDC85A UTR-3 24277619 rs41449651 chr2 56615699 G A 4.95E-04 Multiple complex diseases / / 17554300 rs7563921 chr2 56619366 T A 1.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4671281 chr2 56628301 A T 3.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17038123 chr2 56629071 C A 5.80E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17038122 chr2 56629093 A G 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11694963 chr2 56638627 T C 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7582028 chr2 56638856 C T 7.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7582028 chr2 56638856 C T 8.48E-05 Blood Pressure / / pha003043 rs7600814 chr2 56643955 C T 5.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1861776 chr2 56656894 A G 1.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10202807 chr2 56666949 T C 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1117260 chr2 56667121 T C 6.63E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2869826 chr2 56669447 A G 7.23E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs956157 chr2 56673449 T C 4.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs986787 chr2 56676363 G A 6.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11885335 chr2 56679612 G A 2.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17047946 chr2 56680920 G T 1.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13397156 chr2 56682547 C A 2.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13397156 chr2 56682547 C A 2.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4614971 chr2 56687629 G A 5.23E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1465360 chr2 56688264 A G 3.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1465359 chr2 56688330 A G 1.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17047975 chr2 56688397 A G 7.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs13382678 chr2 56689048 G A 1.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10193613 chr2 56695597 A C 5.21E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1017272 chr2 56696778 C T 4.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1030334 chr2 56700945 C G,T 6.66E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1030333 chr2 56701022 C A 4.59E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17047986 chr2 56701657 T C 6.00E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10490404 chr2 56702495 C T 5.98E-05 Multiple complex diseases / / 17554300 rs10490404 chr2 56702495 C T 1.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2033015 chr2 56702871 T A 2.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs879807 chr2 56708945 G A 2.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2113866 chr2 56716928 A C 9.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13406625 chr2 56722007 T C 7.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs890100 chr2 56734035 C A 6.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs890099 chr2 56734070 G A 2.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs982116 chr2 56739650 A G 9.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7605943 chr2 56741751 T A 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048045 chr2 56743132 T G 9.03E-04 Multiple complex diseases / / 17554300 rs2162025 chr2 56746396 A T 2.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10490407 chr2 56746524 C T 9.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9309282 chr2 56746631 C T 7.69E-13 Metabolite levels / / 22286219 rs17268931 chr2 56750209 C T 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs987576 chr2 56752025 A G 6.25E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1477521 chr2 56754479 T C 3.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6718973 chr2 56756857 T C 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7580218 chr2 56759264 T G 2.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7580549 chr2 56759547 T C 1.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1304899 chr2 56759863 C G 1.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2870064 chr2 56760592 A G 5.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4671282 chr2 56761626 A G 6.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672130 chr2 56761998 A G 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs996846 chr2 56764646 A G 1.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1160085 chr2 56765050 G A 8.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1156972 chr2 56765635 A C 2.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048108 chr2 56766538 C A 9.64E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1156672 chr2 56770848 C T 2.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17039629 chr2 56771307 C A 6.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17190394 chr2 56771330 T C 3.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10490411 chr2 56772337 T C 1.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10208385 chr2 56778009 C T 4.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10210929 chr2 56778360 C T 5.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6721009 chr2 56778687 A T 6.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2194794 chr2 56787100 C T 5.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6719712 chr2 56788339 A G 4.76E-04 Insulin resistance / / 21901158 rs6719808 chr2 56788428 A G 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048168 chr2 56792506 T C 2.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2162024 chr2 56798007 A G 2.51E-04 Type 2 diabetes / / 17463246 rs17048179 chr2 56798398 G A 3.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672140 chr2 56798910 G A 2.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11125642 chr2 56814463 G T 2.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2870066 chr2 56822558 C A 3.47E-04 Rheumatoid arthritis / / 21452313 rs2112027 chr2 56836621 T C 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs737030 chr2 56843605 G A 3.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6545584 chr2 56849161 G A 4.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6722231 chr2 56854346 A C 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6757997 chr2 56896324 C T 7.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6728372 chr2 56899555 T C 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17269015 chr2 56906260 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2042119 chr2 56924658 A G 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672150 chr2 56928639 G A 3.23E-05 Coronary heart disease / / pha003056 rs10200459 chr2 56940693 G A 2.51E-04 Smoking cessation / / 24665060 rs2682843 chr2 56974139 A G 2.60E-05 Urinary metabolites / / 21572414 rs17696789 chr2 57015668 T G 1.30E-05 Platelet counts / / 21507922 rs17697039 chr2 57022855 T C 3.26E-05 Brain structure / / 22504417 rs1468958 chr2 57041772 T C 8.06E-05 Schizophrenia / / pha002859 rs1023598 chr2 57051996 G A 9.64E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2111724 chr2 57091538 C T 7.60E-06 Urinary metabolites / / 21572414 rs2111724 chr2 57091538 C T 7.38E-05 Asthma / / 23181788 rs11125665 chr2 57093359 G T 1.93E-04 Parkinson's disease / / 21248740 rs768329 chr2 57098139 C T 5.44E-04 Smoking initiation / / 24665060 rs6545606 chr2 57101446 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6545606 chr2 57101446 G A 1.74E-06 Elbow pain / / pha003008 rs12479315 chr2 57107235 A G 1.86E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2216407 chr2 57110146 C A 1.92E-05 Serum alpha1-antitrypsin levels / / 23990791 rs12467061 chr2 57128280 C T 1.97E-04 Parkinson's disease / / 21248740 rs13021125 chr2 57135241 A G 1.40E-04 Parkinson's disease / / 21248740 rs7589657 chr2 57147590 C T 4.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10183114 chr2 57148302 A G 4.92E-04 Multiple complex diseases / / 17554300 rs17048515 chr2 57158169 G A 2.24E-04 Multiple complex diseases / / 17554300 rs2865267 chr2 57167414 G T 6.45E-04 Multiple complex diseases / / 17554300 rs7578236 chr2 57174489 C T 8.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs7578236 chr2 57174489 C T 8.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2865272 chr2 57178928 T C 9.38E-05 Elbow pain / / pha003008 rs17048557 chr2 57192672 C G 1.61E-04 Multiple complex diseases / / 17554300 rs2163048 chr2 57225631 A G 1.00E-04 Information processing speed / / 21130836 rs1424642 chr2 57296558 A C 1.34E-07 Type 2 diabetes / / 23945395 rs7557284 chr2 57341448 G A 6.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1424646 chr2 57345571 T G 5.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17189459 chr2 57368572 T C 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs368972698 chr2 57368572 T TTTTTAGATACTGAAAGTATGTTTCCA 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs56913484 chr2 57368572 T TTTTTAGATACTGAAAGTATGTTTCCA 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989586 chr2 57382439 A G 8.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs966115 chr2 57387855 G T 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6545625 chr2 57393245 C T 2.98E-04 Body mass index / / 17255346 rs1424626 chr2 57394885 A T 4.44E-05 Aortic root size / / 21223598 rs1424627 chr2 57396264 C T 5.93E-05 Elbow pain / / pha003008 rs6545627 chr2 57397423 T C 7.29E-05 Elbow pain / / pha003008 rs1424638 chr2 57407649 T C 5.68E-05 Body mass index / / 17255346 rs7604249 chr2 57436631 T C 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4233968 chr2 57487947 G A 3.20E-05 Cardiovascular disease / / pha003065 rs17048747 chr2 57532112 A G 0.0002066 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048747 chr2 57532112 A G 2.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10204326 chr2 57589477 A G 4.94E-04 Smoking initiation / / 24665060 rs1401257 chr2 57626992 G T 3.65E-04 Alzheimer's disease / / 24755620 rs1518684 chr2 57627453 A G 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7597800 chr2 57665438 T C 9.37E-04 Alzheimer's disease / / 17998437 rs6746641 chr2 57668829 C A 7.52E-06 Height / / 20400458 rs7589636 chr2 57690033 A G 3.98E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17048844 chr2 57696957 T C 4.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs17048844 chr2 57696957 T C 7.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1518685 chr2 57703467 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs820951 chr2 57738696 A G 1.12E-04 Alzheimer's disease / / 22005930 rs820950 chr2 57738723 G A 1.31E-04 Alzheimer's disease / / 22005930 rs820949 chr2 57738847 T A 1.92E-04 Alzheimer's disease / / 22005930 rs1881020 chr2 57739441 G A 9.19E-05 Alzheimer's disease / / 22005930 rs820984 chr2 57757646 A G 7.99E-04 Alzheimer's disease / / 22005930 rs13392012 chr2 57763213 T C 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs13392012 chr2 57763213 T C 7.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs6746753 chr2 57763858 G C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs6746753 chr2 57763858 G C 8.13E-05 Suicide attempts in bipolar disorder / / 21041247 rs13389335 chr2 57764968 A T 3.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs13389335 chr2 57764968 A T 7.60E-05 Suicide attempts in bipolar disorder / / 21041247 rs13410921 chr2 57771012 A C 3.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs13410921 chr2 57771012 A C 7.59E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309297 chr2 57771807 G C 3.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309297 chr2 57771807 G C 7.81E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309298 chr2 57772923 A G 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309298 chr2 57772923 A G 8.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309299 chr2 57775502 G C 1.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309299 chr2 57775502 G C 3.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166539 chr2 57775779 G A 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166539 chr2 57775779 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309301 chr2 57775902 G A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309301 chr2 57775902 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs10496069 chr2 57776656 A T 1.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs10496069 chr2 57776656 A T 3.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs10153799 chr2 57780042 T G 3.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs10153799 chr2 57780042 T G 3.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs6747684 chr2 57781712 A G 9.74E-05 Information processing speed / / 21130836 rs13412537 chr2 57783284 C G 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs13412537 chr2 57783284 C G 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11125721 chr2 57826028 G A 1.10E-05 Urinary metabolites / / 21572414 rs17810870 chr2 57842453 C T 3.45E-05 Basophils / / pha003087 rs1405826 chr2 57845016 T C 7.76E-05 Basophils / / pha003087 rs10496070 chr2 57848179 A T 3.73E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2612305 chr2 57858053 C T 1.02E-04 Type 2 diabetes / / 17463246 rs6728612 chr2 57859236 C T 3.81E-05 Basophils / / pha003087 rs1960633 chr2 57882582 T A 1.92E-04 Smoking initiation / / 24665060 rs2311731 chr2 57884793 T G 9.99E-04 Multiple complex diseases / / 17554300 rs10496073 chr2 57901385 A G 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17049036 chr2 57901997 G A 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6759349 chr2 57912777 C T 1.91E-05 Body Mass Index / / pha003006 rs6759349 chr2 57912777 C T 3.40E-05 Body Mass Index / / pha003014 rs6759349 chr2 57912777 C T 7.67E-05 Weight / / pha003026 rs1350691 chr2 57930971 A T 4.28E-05 Type 2 diabetes / / 17463246 rs3732135 chr2 57933881 G A 9.50E-05 Body Mass Index / / pha003006 rs13026414 chr2 57934055 C T 2.00E-09 Epilepsy (generalized) / / 22949513 rs1380703 chr2 57941287 A G 1.10E-05 Longevity and age-related phenotypes / / 17903295 rs10496077 chr2 57943044 T C 7.05E-06 Lipoproteins / / pha003079 rs17049112 chr2 57978620 T C 3.42E-04 IgE levels / / 17255346 rs11682175 chr2 57987593 T C 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs11682175 chr2 57987593 T C 4.07E-06 Schizophrenia / / 21926974 rs2717055 chr2 58044220 G A 3.25E-05 Bipolar disorder / / 19488044 rs2717055 chr2 58044220 G A 4.33E-05 Bipolar Disorder / / pha002858 rs1106090 chr2 58068741 G A 3.36E-05 Lipoproteins / / pha003079 rs2717068 chr2 58094873 A C 4.00E-07 Epilepsy (generalized) / / 22949513 rs7583473 chr2 58101921 C T 4.33E-06 Lipoproteins / / pha003079 rs1533725 chr2 58111922 T G 6.04E-04 Multiple complex diseases / / 17554300 rs2678914 chr2 58117926 C G 3.45E-04 Multiple complex diseases / / 17554300 rs2678917 chr2 58120553 T A 3.61E-04 Multiple complex diseases / / 17554300 rs2717001 chr2 58137618 C T 1.00E-04 Schizophrenia / / 21747397 rs17829368 chr2 58145771 T C 2.71E-04 Blood pressure / / 17255346 rs10189138 chr2 58153676 G T 0.000142 Schizophrenia / / 23637625 rs2717023 chr2 58161355 C T 9.21E-05 Serum metabolites / / 19043545 rs2717025 chr2 58163146 G T 1.43E-04 Multiple complex diseases / / 17554300 rs2717025 chr2 58163146 G T 2.39E-05 Brain structure / / 22504417 rs2717026 chr2 58163178 A G 2.54E-05 Brain structure / / 22504417 rs2717029 chr2 58165595 G T 1.13E-04 Multiple complex diseases / / 17554300 rs2717031 chr2 58166468 T C 4.62E-05 Bipolar disorder / / 19488044 rs2717036 chr2 58168098 T C 8.36E-05 Bipolar disorder / / 19488044 rs2717038 chr2 58168831 A G 1.40E-04 Multiple complex diseases / / 17554300 rs2717038 chr2 58168831 A G 1.81E-05 Brain structure / / 22504417 rs2717039 chr2 58169166 G T 1.48E-04 Multiple complex diseases / / 17554300 rs2717039 chr2 58169166 G T 1.35E-05 Brain structure / / 22504417 rs2678897 chr2 58169418 G A 9.31E-05 Bipolar disorder / / 19488044 rs10172295 chr2 58201202 G A 2.45E-04 Multiple complex diseases / / 17554300 rs10496084 chr2 58220320 C T 8.36E-05 Lipoproteins / / pha003079 rs2312147 chr2 58222928 T C 3.00E-07 Schizophrenia / / 19571808 rs2312147 chr2 58222928 T C 1.90E-09 Schizophrenia / / 21791550 rs2312147 chr2 58222928 T C 0.00000039 Psychosis / / 23164818 rs2312147 chr2 58222928 T C 0.00023 Schizophrenia / / 23164818 rs1016771 chr2 58335681 T C 9.11E-06 Bipolar disorder VRK2 intron 19488044 rs1016771 chr2 58335681 T C 1.26E-05 Bipolar Disorder VRK2 intron pha002858 rs2043890 chr2 58350571 G A 1.52E-05 Bipolar disorder VRK2 intron 19488044 rs2043890 chr2 58350571 G A 1.53E-05 Bipolar Disorder VRK2 intron pha002858 rs17614198 chr2 58384827 A G 9.98E-05 Insulin-related traits VRK2 intron pha003063 rs848291 chr2 58388696 A G 9.65E-06 Bipolar disorder FANCL cds-synon 19488044 rs848291 chr2 58388696 A G 3.41E-05 Bipolar Disorder FANCL cds-synon pha002858 rs848286 chr2 58394543 T C 2.79E-04 Type 2 diabetes FANCL intron 17463246 rs848280 chr2 58412472 T C 9.23E-05 Bipolar disorder FANCL intron 19488044 rs17049406 chr2 58429870 A T 1.02E-04 Multiple complex diseases FANCL intron 17554300 rs2110664 chr2 58462731 C A 8.36E-04 Cervical cancer FANCL intron 23817570 rs10490251 chr2 58498481 G A 7.36E-04 Type 2 diabetes / / 17463246 rs11885675 chr2 58522661 T A 9.48E-04 Alcohol dependence / / 21314694 rs11125750 chr2 58577971 T C 4.00E-04 Obesity (extreme) / / 21935397 rs6761469 chr2 58581018 A G 4.00E-04 Obesity (extreme) / / 21935397 rs11902397 chr2 58586412 A G 7.33E-04 Smoking cessation / / 24665060 rs887956 chr2 58597957 A C 6.32E-04 Smoking cessation / / 24665060 rs17049487 chr2 58601888 G C 8.68E-04 Alzheimer's disease / / 22005930 rs4399710 chr2 58617762 G A 3.57E-04 Obesity (extreme) / / 21935397 rs10490246 chr2 58631933 G C 3.57E-04 Alzheimer's disease / / 22005930 rs2192663 chr2 58633553 C T 4.24E-04 Obesity (extreme) / / 21935397 rs7340335 chr2 58639078 A G 4.34E-04 Obesity (extreme) / / 21935397 rs10179027 chr2 58652438 A T 7.76E-04 Obesity (extreme) / / 21935397 rs12613228 chr2 58662069 G A 4.25E-04 Alzheimer's disease / / 22005930 rs6757755 chr2 58668007 C G 5.24E-04 Bipolar disorder / / 19259986 rs1016756 chr2 58677349 G A 6.34E-04 Alzheimer's disease / / 22005930 rs17399334 chr2 58690295 A G 5.11E-05 Intelligence / / 21826061 rs12618801 chr2 58779404 G A 2.23E-05 Intelligence FLJ30838 intron 21826061 rs17269098 chr2 58779689 A G 6.03E-05 Intelligence FLJ30838 intron 21826061 rs2902140 chr2 58820417 C T 3.89E-04 Taste perception FLJ30838 intron 22132133 rs12713385 chr2 58824981 G C 5.19E-04 Alzheimer's disease FLJ30838 intron 22005930 rs7607950 chr2 58826638 A G 4.08E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049584 chr2 58828331 G C 2.15E-04 Type 2 diabetes FLJ30838 intron 17463246 rs7569678 chr2 58830445 A G 7.45E-05 Intelligence FLJ30838 intron 21826061 rs17269126 chr2 58832407 A G 2.27E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6731302 chr2 58833493 A G 2.00E-09 Obesity FLJ30838 intron 23563607 rs12619586 chr2 58838242 A G 4.30E-04 Alzheimer's disease FLJ30838 intron 22005930 rs6545694 chr2 58847953 A G 3.69E-04 Tourette syndrome FLJ30838 intron 22889924 rs13011109 chr2 58857419 G C 7.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FLJ30838 intron 20031582 rs1922786 chr2 58863573 A G 2.13E-04 Tourette syndrome FLJ30838 intron 22889924 rs10187702 chr2 58869775 T C 7.58E-04 Alzheimer's disease FLJ30838 intron 22005930 rs7591633 chr2 58872058 A G 7.98E-04 Smoking initiation FLJ30838 intron 24665060 rs1159609 chr2 58882418 T G 0.00000227 Body mass index FLJ30838 intron 23001569 rs17049635 chr2 58883053 A G 3.53E-04 Multiple complex diseases FLJ30838 intron 17554300 rs13025286 chr2 58887240 G A 7.87E-04 Type 2 diabetes FLJ30838 intron 17463246 rs1861411 chr2 58904177 A G 5.14E-04 Body mass index FLJ30838 intron 24861553 rs10204803 chr2 58904855 C T 7.58E-04 Multiple complex diseases FLJ30838 intron 17554300 rs17615494 chr2 58950363 G T 2.96E-04 Alzheimer's disease FLJ30838 intron 22005930 rs2708149 chr2 58951187 A G 2.59E-04 Tourette syndrome FLJ30838 intron 22889924 rs13428870 chr2 58956557 T G 3.42E-04 Alzheimer's disease FLJ30838 intron 22005930 rs6741951 chr2 58959112 G A 4.10E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049712 chr2 58961136 C T 4.38E-04 Alzheimer's disease FLJ30838 intron 22005930 rs12622165 chr2 58964083 C A 4.83E-04 Alzheimer's disease FLJ30838 intron 22005930 rs1641155 chr2 58965211 T G 3.05E-04 Alzheimer's disease FLJ30838 intron 22005930 rs2708147 chr2 58970323 G C 5.41E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049722 chr2 58976863 C T 2.76E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6759519 chr2 58981325 A G 1.03E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6759519 chr2 58981325 A G 9.09E-04 Tourette syndrome FLJ30838 intron 22889924 rs6759757 chr2 58981525 A G 6.42E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6731121 chr2 58991868 G T 3.55E-04 Type 2 diabetes FLJ30838 intron 17463246 rs10204566 chr2 58999505 G A 1.00E-05 Myasthenia gravis FLJ30838 intron 23055271 rs6719884 chr2 59036916 A C 3.00E-06 Myasthenia gravis FLJ30838 intron 23055271 rs12617233 chr2 59039998 T C 5.54E-09 Body mass index FLJ30838 intron 23001569 rs12386185 chr2 59042739 C G 9.01E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs2160206 chr2 59047919 T G 2.38E-04 Stroke FLJ30838 intron pha002887 rs10182324 chr2 59047973 C T 8.65E-04 Multiple complex diseases FLJ30838 intron 17554300 rs10182324 chr2 59047973 C T 9.46E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs17049763 chr2 59064879 C G 6.60E-04 Obesity (extreme) FLJ30838 intron 21935397 rs7593324 chr2 59065808 G A 6.60E-04 Obesity (extreme) FLJ30838 intron 21935397 rs7593324 chr2 59065808 G A 3.56E-04 Iron levels FLJ30838 intron pha002876 rs7592415 chr2 59072516 A G 1.56E-04 Breast cancer FLJ30838 intron pha002853 rs17552189 chr2 59072969 C T 8.50E-05 Alcohol dependence FLJ30838 intron 20201924 rs17552189 chr2 59072969 C T 4.00E-06 Cannabis dependence FLJ30838 intron 21668797 rs17552189 chr2 59072969 C T 8.46E-05 Alcoholism FLJ30838 intron pha002892 rs4140883 chr2 59079538 C T 5.91E-05 Cognitive performance FLJ30838 intron 19734545 rs4140883 chr2 59079538 C T 2.34E-04 Stroke FLJ30838 intron pha002887 rs10198586 chr2 59082438 G A 4.14E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs11125762 chr2 59091613 A G 8.68E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6719683 chr2 59094190 G A 7.98E-04 Iron levels FLJ30838 intron pha002876 rs12996396 chr2 59103234 C T 6.49E-04 Type 2 diabetes FLJ30838 intron 17463246 rs2192692 chr2 59104524 G A 1.60E-04 Stroke FLJ30838 intron pha002887 rs42846 chr2 59108940 C G 2.00E-05 Urinary metabolites FLJ30838 intron 21572414 rs42843 chr2 59110328 T G 5.88E-04 Multiple complex diseases FLJ30838 intron 17554300 rs42843 chr2 59110328 T G 1.10E-05 Urinary metabolites FLJ30838 intron 21572414 rs42836 chr2 59113179 A C 8.61E-04 Multiple complex diseases FLJ30838 intron 17554300 rs42833 chr2 59116852 A T 7.60E-06 Urinary metabolites FLJ30838 intron 21572414 rs2160091 chr2 59145840 A G 4.37E-05 Cholesterol FLJ30838 intron pha003073 rs2160091 chr2 59145840 A G 5.06E-05 Cholesterol FLJ30838 intron pha003078 rs6736768 chr2 59176413 A G 7.23E-05 Body Mass Index FLJ30838 intron pha003019 rs713457 chr2 59178687 C T 9.09E-04 Coronary Artery Disease FLJ30838 intron 17634449 rs17049848 chr2 59184123 G A 6.20E-05 Parkinson's disease FLJ30838 intron 21248740 rs17049848 chr2 59184123 G A 3.87E-05 Body Mass Index FLJ30838 intron pha003019 rs17049848 chr2 59184123 G A 4.73E-05 Body Mass Index FLJ30838 intron pha003020 rs111835151 chr2 59202029 G C 2.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs111835151 chr2 59202029 G C 9.49E-06 Serum dimethylarginine levels (asymmetric) FLJ30838 intron 24159190 rs114458406 chr2 59205731 T G 5.81E-06 Serum dimethylarginine levels (asymmetric) FLJ30838 intron 24159190 rs7577730 chr2 59205954 T G 7.42E-06 Stroke (ischemic) FLJ30838 intron 21957438 rs74618786 chr2 59214179 T C 2.74E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs59121803 chr2 59224977 T G 6.95E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs17620941 chr2 59234869 G A 2.58E-04 Type 2 diabetes FLJ30838 intron 17463246 rs7590342 chr2 59260404 A G 7.07E-04 White matter integrity FLJ30838 intron 22425255 rs991964 chr2 59282591 T C 9.00E-06 Uterine fibroids FLJ30838 intron 21460842 rs991964 chr2 59282591 T C 2.40E-05 Urinary metabolites FLJ30838 intron 21572414 rs991964 chr2 59282591 T C 3.90E-05 Cognitive function FLJ30838 intron 24684796 rs10490103 chr2 59290759 C T 1.59E-05 Alzheimer's disease (late onset) / / 21379329 rs887912 chr2 59302877 T C 2.00E-12 Body mass index / / 20935630 rs887912 chr2 59302877 T C 1.79E-12 Body mass index / / 23001569 rs887912 chr2 59302877 T C 1.00E-10 Obesity / / 23563607 rs887912 chr2 59302877 T C 6.00E-09 Obesity / / 23563607 rs2863776 chr2 59302990 A T 4.40E-05 Cognitive function / / 24684796 rs11686642 chr2 59339111 C T 5.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13402382 chr2 59354311 A G 5.66E-05 Blood Pressure / / pha003048 rs11691214 chr2 59435619 A T 2.20E-05 Urinary metabolites / / 21572414 rs2192567 chr2 59456623 G T 9.80E-06 Urinary metabolites / / 21572414 rs10177858 chr2 59465454 C T 7.29E-04 Response to TNF antagonist treatment / / 21061259 rs13403641 chr2 59467224 G C 1.80E-06 Urinary metabolites / / 21572414 rs10170742 chr2 59470345 A C 6.34E-05 Schizophrenia / / 19197363 rs2192563 chr2 59473060 G A 5.90E-06 Urinary metabolites / / 21572414 rs10490113 chr2 59499347 A C 5.00E-06 Breast cancer / / 17903305 rs10490113 chr2 59499347 A C 5.00E-06 Nasopharyngeal carcinoma / / 20512145 rs7588177 chr2 59509155 T C 7.10E-06 Urinary metabolites / / 21572414 rs10202074 chr2 59514746 T A 4.80E-06 Urinary metabolites / / 21572414 rs12464814 chr2 59515129 A G 1.20E-05 Urinary metabolites / / 21572414 rs10182747 chr2 59519869 A C 1.30E-05 Urinary metabolites / / 21572414 rs6545733 chr2 59529413 G A 1.50E-05 Urinary metabolites / / 21572414 rs2561893 chr2 59560414 T C 2.60E-05 Urinary metabolites / / 21572414 rs2540015 chr2 59565198 T C 8.60E-07 Urinary metabolites / / 21572414 rs17644588 chr2 59580326 G A 7.28E-04 Nicotine dependence / / 17158188 rs7606152 chr2 59586372 A G 3.40E-05 Response to statin therapy / / 20339536 rs13420083 chr2 59603700 T C 6.80E-06 Urinary metabolites / / 21572414 rs4432437 chr2 59605576 T C 4.22E-05 Chronic obstructive pulmonary disease / / 19300482 rs7577424 chr2 59610711 C T 4.78E-05 Response to Vitamin E supplementation / / 22437554 rs17645334 chr2 59661788 C T 1.47E-04 Alzheimer's disease (late onset) / / 21379329 rs12464531 chr2 59673530 T C 0.00019174 Hypertension (early onset hypertension) / / 22479346 rs13018470 chr2 59694749 C T 0.0000683 Panic disorder / / 23149450 rs13018470 chr2 59694749 C T 6.83E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2110565 chr2 59749401 A G 6.15E-05 Pulmonary function in asthmatics / / 23541324 rs2674061 chr2 59753331 C T 6.07E-05 Alcohol consumption / / 23743675 rs2540099 chr2 59753741 C T 6.37E-05 Alcohol consumption / / 23743675 rs2540098 chr2 59753809 C T 6.53E-05 Alcohol consumption / / 23743675 rs56093216 chr2 59753972 T C 6.78E-05 Alcohol consumption / / 23743675 rs2540097 chr2 59755664 A G 6.62E-05 Alcohol consumption / / 23743675 rs2540096 chr2 59756854 T C 5.01E-05 Alcohol consumption / / 23743675 rs2674041 chr2 59757501 G A 6.63E-05 Alcohol consumption / / 23743675 rs2540089 chr2 59762371 C T 5.45E-05 Alcohol consumption / / 23743675 rs2540088 chr2 59762560 C G 4.87E-05 Alcohol consumption / / 23743675 rs2540087 chr2 59762594 C A 5.34E-05 Alcohol consumption / / 23743675 rs2674067 chr2 59765684 A G 7.35E-05 Alcohol consumption / / 23743675 rs2674046 chr2 59768141 C T 5.61E-05 Alcohol consumption / / 23743675 rs2674047 chr2 59768685 T A 6.60E-05 Alcohol consumption / / 23743675 rs2674048 chr2 59769012 C T 7.00E-05 Alcohol consumption / / 23743675 rs2540083 chr2 59769150 G A 6.68E-05 Alcohol consumption / / 23743675 rs7571858 chr2 59769273 G T 3.48E-05 Alcohol consumption / / 23743675 rs2674050 chr2 59769317 C T 6.85E-05 Alcohol consumption / / 23743675 rs2674052 chr2 59770353 T G 6.82E-05 Alcohol consumption / / 23743675 rs2674079 chr2 59771479 A C,T 6.42E-05 Alcohol consumption / / 23743675 rs10195005 chr2 59771640 G A 4.64E-05 Alcohol consumption / / 23743675 rs996762 chr2 59772059 C G 6.38E-04 Multiple complex diseases / / 17554300 rs2418867 chr2 59772602 C T 4.59E-05 Alcohol consumption / / 23743675 rs887942 chr2 59775168 G C 2.61E-05 Alcohol consumption / / 23743675 rs2215906 chr2 59775565 C T 3.16E-05 Alcohol consumption / / 23743675 rs721250 chr2 59777016 C T 2.94E-05 Alcohol consumption / / 23743675 rs10203166 chr2 59789705 C T 4.00E-06 IgG glycosylation / / 23382691 rs2539669 chr2 59794609 A G 5.52E-06 Asthma / / 21790008 rs17050261 chr2 59804348 G C 2.46E-04 Smoking initiation / / 24665060 rs6728994 chr2 59811884 C T 7.14E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6760859 chr2 59812464 A G 2.64E-04 Parkinson's disease / / 17052657 rs2539706 chr2 59819545 G A 6.56E-04 Parkinson's disease / / 17052657 rs2539706 chr2 59819545 G A 8.87E-04 Multiple complex diseases / / 17554300 rs2539703 chr2 59831289 C T 7.62E-04 Parkinson's disease / / 17052657 rs2539684 chr2 59849513 T G 2.46E-04 Fibrinogen / / 17255346 rs2674063 chr2 59853322 T C,G 2.29E-04 Fibrinogen / / 17255346 rs2539682 chr2 59853699 A G 8.88E-05 Fibrinogen / / 17255346 rs13019632 chr2 59858364 T C 1.53E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs13019632 chr2 59858364 T C 1.59E-05 Lung function (forced vital capacity) / / 24023788 rs13019632 chr2 59858364 T C 2.51E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1005741 chr2 59859867 G A 1.22E-04 Fibrinogen / / 17255346 rs1005741 chr2 59859867 G A 8.80E-05 HIV-1 control / / 20041166 rs17596277 chr2 59888538 G A 2.95E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs17596277 chr2 59888538 G A 1.05E-04 Lung function (forced vital capacity) / / 24023788 rs17596277 chr2 59888538 G A 1.51E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2110330 chr2 59903052 A G 2.71E-04 Fibrinogen / / 17255346 rs2110330 chr2 59903052 A G 3.78E-04 Multiple complex diseases / / 17554300 rs1372878 chr2 59904565 G A 2.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17596662 chr2 59911911 G A,T 2.32E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1112604 chr2 59928561 G A 8.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7598185 chr2 59952259 C A 1.20E-05 Height / / 21998595 rs11125807 chr2 59952937 C T 1.94E-04 Self-reported allergy / / 23817569 rs17050390 chr2 59953668 G C 2.19E-04 Self-reported allergy / / 23817569 rs9309316 chr2 59955616 A C 4.95E-04 Type 2 diabetes / / 17463246 rs9309316 chr2 59955616 A C 4.61E-04 Multiple complex diseases / / 17554300 rs17050411 chr2 59979504 T C 9.96E-04 Alcohol dependence / / 24277619 rs10187463 chr2 59985441 C T 2.48E-04 Age-related macular degeneration / / 22125219 rs11125811 chr2 59987774 T C 7.02E-04 Alcohol dependence / / 24277619 rs11125813 chr2 59991047 G A 7.91E-04 Type 2 diabetes / / 17463246 rs17327578 chr2 59998044 C T 8.48E-04 Type 2 diabetes / / 17463246 rs1899491 chr2 60000394 G T 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs367668284 chr2 60009701 G GGT 1.14E-11 Metabolite levels / / 22286219 rs1019265 chr2 60012569 A G 3.94E-05 Bipolar disorder / / 20451256 rs1019264 chr2 60012802 G A 3.23E-04 Obesity (extreme) / / 21935397 rs7590023 chr2 60020374 G A 2.57E-05 Bipolar disorder / / 20451256 rs7562462 chr2 60023703 T A,C,G 7.34E-05 Bipolar disorder / / 20451256 rs1372876 chr2 60025963 A C 2.25E-05 Bipolar disorder / / 20451256 rs4671355 chr2 60029072 T C 2.59E-05 Bipolar disorder / / 20451256 rs6545754 chr2 60029857 A G 3.80E-05 Bipolar disorder / / 20451256 rs4672319 chr2 60030580 A G 2.88E-05 Bipolar disorder / / 20451256 rs4671356 chr2 60034937 T C 3.74E-05 Bipolar disorder / / 20451256 rs730402 chr2 60094706 G A 6.85E-05 Serum metabolites / / 19043545 rs730402 chr2 60094706 G A 1.03E-04 Cognitive function / / 24684796 rs17328175 chr2 60105275 A G 7.51E-05 IgE levels / / 22075330 rs11684416 chr2 60110498 C G 9.49E-04 Acute lung injury / / 22295056 rs12991146 chr2 60111222 C A 2.18E-05 Smoking initiation / / 24665060 rs6545764 chr2 60112225 C T 8.75E-05 Aging (time to event) / / 21782286 rs6728812 chr2 60112579 C T 2.10E-05 Smoking initiation / / 24665060 rs6545765 chr2 60119744 T C 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs145433814 chr2 60126311 G A 6.00E-06 Eating disorders (purging via substances) / / 23568457 rs17050481 chr2 60126601 G A 3.45E-04 Multiple complex diseases / / 17554300 rs1019614 chr2 60131157 A G 2.57E-05 Brain lesion load / / 19010793 rs1344293 chr2 60133158 G T 1.50E-05 Urinary metabolites / / 21572414 rs17050485 chr2 60133565 C T 5.12E-04 Prostate cancer mortality / / 20978177 rs13025366 chr2 60142688 T G 1.99E-05 Blood Pressure / / pha003048 rs7576017 chr2 60159532 A G 3.98E-05 Brain lesion load / / 19010793 rs12468914 chr2 60159756 T C 8.13E-05 Brain lesion load / / 19010793 rs4672333 chr2 60191297 A G 5.34E-05 Blood Pressure / / pha003048 rs6736566 chr2 60195954 A C 1.00E-04 Prostate cancer / / 21743057 rs13033133 chr2 60198537 C T 5.51E-04 Type 2 diabetes / / 17463246 rs13033133 chr2 60198537 C T 2.13E-04 Multiple complex diseases / / 17554300 rs13033133 chr2 60198537 C T 2.30E-05 Urinary metabolites / / 21572414 rs12617593 chr2 60198798 G A 7.19E-04 Type 2 diabetes / / 17463246 rs12617593 chr2 60198798 G A 2.41E-04 Multiple complex diseases / / 17554300 rs4672335 chr2 60202239 G A 1.78E-05 Brain lesion load / / 19010793 rs1863160 chr2 60202617 T C 5.00E-05 Prostate cancer / / 21743057 rs12476853 chr2 60203980 G C 4.02E-05 Multiple complex diseases / / 17554300 rs1863159 chr2 60206554 C T 3.10E-05 Body mass index / / 20818722 rs2419411 chr2 60215475 C T 7.65E-05 Blood Pressure / / pha003048 rs4672337 chr2 60217093 G T 1.70E-04 Multiple complex diseases / / 17554300 rs11896330 chr2 60235568 G A 7.59E-05 Brain lesion load / / 19010793 rs12373776 chr2 60237213 C T 6.83E-04 Smoking initiation / / 24665060 rs4672341 chr2 60241822 C A 3.98E-05 Brain lesion load / / 19010793 rs4672341 chr2 60241822 C A 7.37E-04 Smoking initiation / / 24665060 rs11888990 chr2 60255313 G A 1.39E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs13016030 chr2 60268260 G A 6.39E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6712720 chr2 60281608 G C 4.00E-06 Monocyte early outgrowth colony forming units / / 21493818 rs2192580 chr2 60290360 T C 1.50E-05 Urinary metabolites / / 21572414 rs41454851 chr2 60317395 C T 5.33E-04 Multiple complex diseases / / 17554300 rs17027385 chr2 60317433 G C 3.97E-04 Multiple complex diseases / / 17554300 rs2419643 chr2 60318058 G A 4.01E-04 Alzheimer's disease (late onset) / / 21379329 rs17027670 chr2 60321554 G A 2.10E-04 Multiple complex diseases / / 17554300 rs17027920 chr2 60324502 C T 3.74E-04 Multiple complex diseases / / 17554300 rs17028210 chr2 60328685 C G 2.70E-05 Multiple complex diseases / / 17554300 rs6726368 chr2 60330305 G C 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs972337 chr2 60331399 C T 8.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs887930 chr2 60333732 G A 3.42E-04 Alzheimer's disease (late onset) / / 21379329 rs17039713 chr2 60336589 G T 4.29E-05 Vascular dementia / / 22116812 rs10490066 chr2 60409379 C A 7.20E-06 Urinary metabolites / / 21572414 rs1473099 chr2 60449710 A G 8.83E-05 Osteoarthritis / / 19508968 rs359268 chr2 60459806 T C 1.00E-06 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs359233 chr2 60470926 A G 4.15E-04 Fibrinogen / / 17255346 rs113567488 chr2 60490322 T TG 4.96E-04 Type 2 diabetes / / 17463246 rs9309323 chr2 60490322 T G 4.96E-04 Type 2 diabetes / / 17463246 rs4671378 chr2 60494312 T C 9.21E-04 Type 2 diabetes / / 17463246 rs4671379 chr2 60495038 T C 3.52E-04 Type 2 diabetes / / 17463246 rs10202231 chr2 60500144 T A 7.00E-07 Response to antipsychotic treatment / / 20195266 rs2160067 chr2 60500415 A G 6.47E-04 Type 2 diabetes / / 17463246 rs2110398 chr2 60500484 T C 5.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2110398 chr2 60500484 T C 4.75E-06 Acne (severe) / / 24927181 rs4672381 chr2 60514946 C T 8.55E-04 Type 2 diabetes / / 17463246 rs4671386 chr2 60514993 C A 2.00E-06 Acne (severe) / / 24927181 rs6545803 chr2 60534199 G T 7.87E-05 Caffeine consumption / / 21490707 rs6545803 chr2 60534199 G T 6.00E-06 Nevirapine-induced rash / / 21810746 rs9309324 chr2 60546132 T G 1.93E-05 Multiple complex diseases / / 17554300 rs1512228 chr2 60561931 T C 9.43E-04 Multiple complex diseases / / 17554300 rs9784100 chr2 60562714 G C 2.33E-05 Multiple complex diseases / / 17554300 rs243088 chr2 60568745 A T 4.70E-10 Type 2 diabetes / / 22885922 rs243088 chr2 60568745 A T 6.50E-10 Type 2 diabetes (males) / / 22885922 rs243088 chr2 60568745 A T 3.00E-06 Type 2 diabetes / / 24509480 rs243083 chr2 60573870 A G 0.000011 Type 2 diabetes / / 22885922 rs12999941 chr2 60579624 C T 4.59E-05 Multiple complex diseases / / 17554300 rs9309325 chr2 60580831 A G 6.50E-05 Multiple complex diseases / / 17554300 rs9309325 chr2 60580831 A G 7.56E-05 Platelet counts / / 23263863 rs7573683 chr2 60581094 T C 6.82E-04 Multiple complex diseases / / 17554300 rs6731582 chr2 60583202 T C 6.90E-04 Multiple complex diseases / / 17554300 rs243023 chr2 60583727 T C 1.35E-05 Parkinson's disease / / 17052657 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 20581827 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 21647700 rs243021 chr2 60584819 G A 0.0000053 Type 2 diabetes / / 22885922 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 23300278 rs243019 chr2 60585806 T C 0.000000022 Type 2 diabetes / / 22885922 rs243018 chr2 60586707 C G 6.67E-06 Multiple complex diseases / / 17554300 rs243016 chr2 60588713 A T 9.64E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs243015 chr2 60588871 G A 5.88E-04 Multiple complex diseases / / 17554300 rs243015 chr2 60588871 G A 2.00E-05 Urinary metabolites / / 21572414 rs243052 chr2 60590257 G A 5.10E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243050 chr2 60592027 G A 2.72E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243044 chr2 60595793 G T 2.57E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243039 chr2 60597565 G A 2.98E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243037 chr2 60599100 C G 1.04E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1003690 chr2 60599988 T C 6.80E-05 Personality dimensions / / 18957941 rs243033 chr2 60603602 G C 9.40E-05 F-cell distribution / / 17767159 rs243032 chr2 60603950 G A 4.20E-07 F-cell distribution / / 17767159 rs243032 chr2 60603950 G A 2.76E-11 Other erythrocyte phenotypes / / 19862010 rs243032 chr2 60603950 G A 3.47E-09 Red blood cell traits / / 23222517 rs173373 chr2 60605919 C T 7.00E-09 F-cell distribution / / 17767159 rs173373 chr2 60605919 C T 2.86E-11 Other erythrocyte phenotypes / / 19862010 rs173373 chr2 60605919 C T 7.48E-11 Red blood cell traits / / 23222517 rs243030 chr2 60606571 C T 1.70E-08 F-cell distribution / / 17767159 rs243030 chr2 60606571 C T 3.10E-05 Subclinical atherosclerosis / / 17903303 rs243030 chr2 60606571 C T 2.61E-11 Other erythrocyte phenotypes / / 19862010 rs243030 chr2 60606571 C T 6.72E-11 Red blood cell traits / / 23222517 rs243029 chr2 60606654 C T 4.20E-08 F-cell distribution / / 17767159 rs243029 chr2 60606654 C T 2.64E-11 Other erythrocyte phenotypes / / 19862010 rs243029 chr2 60606654 C T 6.47E-10 Red blood cell traits / / 23222517 rs243027 chr2 60607007 T G 2.20E-10 F-cell distribution / / 17767159 rs243027 chr2 60607007 T G 2.26E-08 Other erythrocyte phenotypes / / 19862010 rs243027 chr2 60607007 T G 2.20E-10 F-cell distribution / / 21326311 rs243027 chr2 60607007 T G 9.50E-10 Red blood cell traits / / 23222517 rs13027161 chr2 60607728 T C 3.50E-08 F-cell distribution / / 17767159 rs13027161 chr2 60607728 T C 3.44E-08 Fetal hemoglobin levels / / 18245381 rs13027161 chr2 60607728 T C 2.21E-11 Other erythrocyte phenotypes / / 19862010 rs13027161 chr2 60607728 T C 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs13027161 chr2 60607728 T C 7.15E-12 Red blood cell traits / / 23222517 rs2668729 chr2 60608383 G A 3.20E-08 F-cell distribution / / 17767159 rs2668729 chr2 60608383 G A 2.56E-10 Other erythrocyte phenotypes / / 19862010 rs2668729 chr2 60608383 G A 1.20E-10 Red blood cell traits / / 23222517 rs2540917 chr2 60608759 T C 5.60E-09 F-cell distribution / / 17767159 rs2540917 chr2 60608759 T C 1.00E-14 Mean corpuscular volume / / 19862010 rs2540917 chr2 60608759 T C 2.46E-11 Red blood cell traits / / 23222517 rs2540916 chr2 60608930 T C 1.60E-07 F-cell distribution / / 17767159 rs2540916 chr2 60608930 T C 2.61E-10 Other erythrocyte phenotypes / / 19862010 rs2540916 chr2 60608930 T C 1.73E-10 Red blood cell traits / / 23222517 rs9967849 chr2 60609474 C T 7.60E-09 F-cell distribution / / 17767159 rs9967849 chr2 60609474 C T 3.27E-11 Other erythrocyte phenotypes / / 19862010 rs9967849 chr2 60609474 C T 6.38E-11 Red blood cell traits / / 23222517 rs1553934 chr2 60609896 G C 1.80E-08 F-cell distribution / / 17767159 rs1553934 chr2 60609896 G C 4.38E-08 Fetal hemoglobin levels / / 18245381 rs1553934 chr2 60609896 G C 3.45E-11 Other erythrocyte phenotypes / / 19862010 rs1553934 chr2 60609896 G C 3.05E-11 Red blood cell traits / / 23222517 rs2540914 chr2 60610411 A C 3.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2540913 chr2 60610812 T C 1.12E-09 Fetal hemoglobin levels / / 18245381 rs2540913 chr2 60610812 T C 2.64E-11 Other erythrocyte phenotypes / / 19862010 rs2540913 chr2 60610812 T C 9.38E-11 Red blood cell traits / / 23222517 rs925483 chr2 60611285 G A 2.60E-09 F-cell distribution / / 17767159 rs925483 chr2 60611285 G A 7.51E-08 Fetal hemoglobin levels / / 18245381 rs925483 chr2 60611285 G A 4.52E-11 Other erythrocyte phenotypes / / 19862010 rs925483 chr2 60611285 G A 1.10E-10 Red blood cell traits / / 23222517 rs925484 chr2 60611437 C G 3.10E-09 F-cell distribution / / 17767159 rs925484 chr2 60611437 C G 4.54E-11 Other erythrocyte phenotypes / / 19862010 rs925484 chr2 60611437 C G 8.45E-11 Red blood cell traits / / 23222517 rs2137281 chr2 60612008 C T 9.40E-10 F-cell distribution / / 17767159 rs2137281 chr2 60612008 C T 2.94E-08 Fetal hemoglobin levels / / 18245381 rs2137281 chr2 60612008 C T 2.70E-11 Other erythrocyte phenotypes / / 19862010 rs2137281 chr2 60612008 C T 2.92E-10 Red blood cell traits / / 23222517 rs2137282 chr2 60612070 T A 7.40E-05 F-cell distribution / / 17767159 rs2137282 chr2 60612070 T A 1.30E-08 Red blood cell traits / / 23222517 rs2244030 chr2 60612238 A G 4.84E-07 Red blood cell traits / / 23222517 rs2137283 chr2 60612457 C A 1.70E-09 F-cell distribution / / 17767159 rs2137283 chr2 60612457 C A 2.83E-11 Other erythrocyte phenotypes / / 19862010 rs2137283 chr2 60612457 C A 3.61E-11 Red blood cell traits / / 23222517 rs243082 chr2 60613123 C T 7.90E-05 F-cell distribution / / 17767159 rs243081 chr2 60613776 G A 2.50E-12 F-cell distribution / / 17767159 rs243081 chr2 60613776 G A 7.20E-09 Red blood cell traits / / 23222517 rs243080 chr2 60614572 G A 2.70E-08 F-cell distribution / / 17767159 rs243080 chr2 60614572 G A 4.02E-09 Other erythrocyte phenotypes / / 19862010 rs243080 chr2 60614572 G A 2.39E-09 Red blood cell traits / / 23222517 rs243079 chr2 60615028 A C 2.00E-09 F-cell distribution / / 17767159 rs243079 chr2 60615028 A C 1.33E-08 Fetal hemoglobin levels / / 18245381 rs243079 chr2 60615028 A C 5.32E-08 Red blood cell traits / / 23222517 rs243078 chr2 60615303 A G 1.30E-08 F-cell distribution / / 17767159 rs243078 chr2 60615303 A G 3.09E-08 Fetal hemoglobin levels / / 18245381 rs243078 chr2 60615303 A G 4.08E-10 Red blood cell traits / / 23222517 rs243077 chr2 60616682 A G 6.80E-04 F-cell distribution / / 17767159 rs243076 chr2 60617563 G A 1.40E-08 F-cell distribution / / 17767159 rs243076 chr2 60617563 G A 2.74E-11 Other erythrocyte phenotypes / / 19862010 rs243076 chr2 60617563 G A 1.39E-11 Red blood cell traits / / 23222517 rs243075 chr2 60617571 T C 6.10E-04 F-cell distribution / / 17767159 rs243074 chr2 60617761 G A 5.80E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243074 chr2 60617761 G A 2.79E-07 Red blood cell traits / / 23222517 rs243073 chr2 60618690 T C 4.50E-04 F-cell distribution / / 17767159 rs243073 chr2 60618690 T C 8.10E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243072 chr2 60618796 G C 7.20E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243072 chr2 60618796 G C 7.82E-07 Red blood cell traits / / 23222517 rs243071 chr2 60619028 A G 7.20E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243071 chr2 60619028 A G 5.26E-07 Red blood cell traits / / 23222517 rs13401861 chr2 60619814 T C 4.00E-04 F-cell distribution / / 17767159 rs243070 chr2 60620286 T A 1.70E-05 F-cell distribution / / 17767159 rs243070 chr2 60620286 T A 4.00E-13 Red blood cell traits / / 23222517 rs243069 chr2 60620834 A C 6.20E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243067 chr2 60621643 G T 1.10E-08 F-cell distribution / / 17767159 rs243067 chr2 60621643 G T 6.05E-11 Other erythrocyte phenotypes / / 19862010 rs243067 chr2 60621643 G T 7.49E-11 Red blood cell traits / / 23222517 rs243066 chr2 60621766 A G 5.40E-10 F-cell distribution / / 17767159 rs243066 chr2 60621766 A G 6.07E-11 Other erythrocyte phenotypes / / 19862010 rs243066 chr2 60621766 A G 8.20E-11 Red blood cell traits / / 23222517 rs243065 chr2 60622064 G C 3.10E-09 F-cell distribution / / 17767159 rs243065 chr2 60622064 G C 2.67E-09 Red blood cell traits / / 23222517 rs7589285 chr2 60622491 A T 5.60E-04 F-cell distribution / / 17767159 rs243063 chr2 60622899 A T 6.90E-09 F-cell distribution / / 17767159 rs243063 chr2 60622899 A T 7.44E-11 Other erythrocyte phenotypes / / 19862010 rs243063 chr2 60622899 A T 1.18E-10 Red blood cell traits / / 23222517 rs243062 chr2 60623676 G A 4.20E-10 F-cell distribution / / 17767159 rs243061 chr2 60623698 T C 2.00E-09 F-cell distribution / / 17767159 rs184839 chr2 60625400 G C 7.80E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs184839 chr2 60625400 G C 5.49E-07 Red blood cell traits / / 23222517 rs13011022 chr2 60626822 G A 1.40E-09 F-cell distribution / / 17767159 rs13011022 chr2 60626822 G A 9.36E-07 Red blood cell traits / / 23222517 rs11125841 chr2 60627565 A G 3.30E-08 F-cell distribution / / 17767159 rs888082 chr2 60629609 G A 3.10E-09 F-cell distribution / / 17767159 rs888082 chr2 60629609 G A 1.93E-09 Fetal hemoglobin levels / / 18245381 rs888082 chr2 60629609 G A 5.47E-09 Red blood cell traits / / 23222517 rs929645 chr2 60629866 C A 1.30E-04 Multiple complex diseases / / 17554300 rs12995080 chr2 60631229 G A 1.20E-05 F-cell distribution / / 17767159 rs13009393 chr2 60633364 G A 2.20E-10 F-cell distribution / / 17767159 rs13009393 chr2 60633364 G A 9.40E-11 Other erythrocyte phenotypes / / 19862010 rs13009393 chr2 60633364 G A 2.05E-10 Red blood cell traits / / 23222517 rs12464462 chr2 60636416 A G 1.90E-09 F-cell distribution / / 17767159 rs12464462 chr2 60636416 A G 4.33E-11 Other erythrocyte phenotypes / / 19862010 rs12464462 chr2 60636416 A G 3.46E-09 Red blood cell traits / / 23222517 rs12472541 chr2 60636497 C A 3.90E-04 F-cell distribution / / 17767159 rs12472541 chr2 60636497 C A 1.09E-07 Red blood cell traits / / 23222517 rs17027944 chr2 60636614 C A 1.08E-07 Red blood cell traits / / 23222517 rs10445937 chr2 60637656 G A 1.38E-04 Multiple complex diseases / / 17554300 rs10445937 chr2 60637656 G A 3.10E-09 F-cell distribution / / 17767159 rs10445937 chr2 60637656 G A 5.81E-09 Fetal hemoglobin levels / / 18245381 rs10445937 chr2 60637656 G A 3.68E-11 Other erythrocyte phenotypes / / 19862010 rs10445937 chr2 60637656 G A 3.22E-09 Red blood cell traits / / 23222517 rs17330904 chr2 60639733 T C 5.10E-04 F-cell distribution / / 17767159 rs12476132 chr2 60639904 G A 2.90E-09 F-cell distribution / / 17767159 rs12476132 chr2 60639904 G A 3.68E-11 Other erythrocyte phenotypes / / 19862010 rs12476132 chr2 60639904 G A 2.96E-09 Red blood cell traits / / 23222517 rs11125842 chr2 60640807 A G 8.30E-08 F-cell distribution / / 17767159 rs11125842 chr2 60640807 A G 1.50E-07 Red blood cell traits / / 23222517 rs13028240 chr2 60641329 G A 1.40E-05 F-cell distribution / / 17767159 rs13028240 chr2 60641329 G A 5.10E-07 Red blood cell traits / / 23222517 rs13028240 chr2 60641329 G A 3.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12463461 chr2 60642899 G T 9.23E-11 Red blood cell traits / / 23222517 rs12997266 chr2 60649143 G A 1.90E-09 F-cell distribution LOC100506891 intron 17767159 rs12104736 chr2 60650716 C G 9.00E-09 F-cell distribution LOC100506891 intron 17767159 rs12104736 chr2 60650716 C G 5.01E-07 Red blood cell traits LOC100506891 intron 23222517 rs13013119 chr2 60652061 C T 3.70E-05 F-cell distribution / / 17767159 rs1035831 chr2 60653572 T C 2.50E-05 Urinary metabolites / / 21572414 rs10490070 chr2 60655679 A G 9.60E-05 F-cell distribution / / 17767159 rs10490070 chr2 60655679 A G 6.06E-05 Cognitive test performance / / 20125193 rs10490070 chr2 60655679 A G 3.77E-10 Red blood cell traits / / 23222517 rs13011256 chr2 60656992 G A 4.50E-05 F-cell distribution / / 17767159 rs13011256 chr2 60656992 G A 6.54E-07 Red blood cell traits / / 23222517 rs11894442 chr2 60657018 T C 3.60E-08 F-cell distribution / / 17767159 rs11894442 chr2 60657018 T C 9.52E-08 Red blood cell traits / / 23222517 rs1861431 chr2 60657825 C A 2.50E-05 Urinary metabolites / / 21572414 rs6718203 chr2 60659307 C G 7.00E-04 F-cell distribution / / 17767159 rs17402905 chr2 60660308 T C 8.00E-05 F-cell distribution / / 17767159 rs17402905 chr2 60660308 T C 4.30E-07 Red blood cell traits / / 23222517 rs17402912 chr2 60660522 A G 4.60E-05 F-cell distribution / / 17767159 rs17402912 chr2 60660522 A G 7.26E-11 Red blood cell traits / / 23222517 rs17331017 chr2 60662149 C A 6.40E-05 F-cell distribution / / 17767159 rs17331017 chr2 60662149 C A 3.76E-07 Red blood cell traits / / 23222517 rs8179712 chr2 60663798 C T 6.98E-05 Schizophrenia / / 21747397 rs1011407 chr2 60665768 A G 4.10E-04 F-cell distribution / / 17767159 rs1011406 chr2 60666075 C G 6.90E-04 F-cell distribution / / 17767159 rs12474693 chr2 60668432 C T 3.68E-10 Fetal hemoglobin levels / / 18245381 rs12474693 chr2 60668432 C T 9.87E-07 Red blood cell traits / / 23222517 rs10490071 chr2 60668890 G A 5.30E-05 F-cell distribution / / 17767159 rs10490071 chr2 60668890 G A 4.40E-10 Red blood cell traits / / 23222517 rs11884411 chr2 60669494 T C 1.90E-09 F-cell distribution / / 17767159 rs11884411 chr2 60669494 T C 2.98E-09 Fetal hemoglobin levels / / 18245381 rs11884411 chr2 60669494 T C 9.84E-08 Red blood cell traits / / 23222517 rs10490072 chr2 60669931 T C 3.10E-04 F-cell distribution / / 17767159 rs10490072 chr2 60669931 T C 5.57E-11 Red blood cell traits / / 23222517 rs12468946 chr2 60670477 A G 7.30E-09 F-cell distribution / / 17767159 rs17028192 chr2 60671339 C T 3.10E-04 F-cell distribution / / 17767159 rs13034649 chr2 60672255 C T 5.70E-05 F-cell distribution / / 17767159 rs13034649 chr2 60672255 C T 4.44E-11 Red blood cell traits / / 23222517 rs13034231 chr2 60677968 C A 5.93E-07 Red blood cell traits BCL11A nearGene-3 23222517 rs2058703 chr2 60679226 G A 4.23E-06 Platelet CD36 surface expression BCL11A UTR-3 21478428 rs17331129 chr2 60679942 T C 1.00E-05 F-cell distribution BCL11A intron 17767159 rs17331129 chr2 60679942 T C 2.01E-11 Fetal hemoglobin levels BCL11A intron 18245381 rs4672393 chr2 60697654 C A 2.00E-06 Urinary metabolites BCL11A intron 21572414 rs12477097 chr2 60698397 A C 4.10E-04 F-cell distribution BCL11A intron 17767159 rs12477097 chr2 60698397 A C 2.60E-07 Urinary metabolites BCL11A intron 21572414 rs12477097 chr2 60698397 A C 4.45E-08 Fetal hemoglobin levels BCL11A intron 22936743 rs4672394 chr2 60698461 C T 1.50E-06 Urinary metabolites BCL11A intron 21572414 rs733628 chr2 60702766 T C 5.70E-04 F-cell distribution BCL11A intron 17767159 rs7581162 chr2 60704484 T A 8.76E-07 Red blood cell traits BCL11A intron 23222517 rs7593947 chr2 60704933 A T 2.60E-05 Type 2 diabetes BCL11A intron 17463246 rs7593947 chr2 60704933 A T 4.18E-05 Bipolar disorder BCL11A intron 19488044 rs7593947 chr2 60704933 A T 6.07E-08 Red blood cell traits BCL11A intron 23222517 rs7593947 chr2 60704933 A T 8.46E-05 Bipolar Disorder BCL11A intron pha002863 rs34737760 chr2 60705608 C G 2.50E-04 F-cell distribution BCL11A intron 17767159 rs45445891 chr2 60706259 T G 3.90E-04 F-cell distribution BCL11A intron 17767159 rs12992182 chr2 60707038 C A 2.50E-04 F-cell distribution BCL11A intron 17767159 rs12997966 chr2 60707182 G A 2.10E-04 F-cell distribution BCL11A intron 17767159 rs7579014 chr2 60707894 G A 1.20E-06 F-cell distribution BCL11A intron 17767159 rs7579014 chr2 60707894 G A 7.08E-14 Fetal hemoglobin levels BCL11A intron 18245381 rs35908689 chr2 60707941 C G 2.50E-04 F-cell distribution BCL11A intron 17767159 rs6732518 chr2 60708597 C T 1.10E-21 F-cell distribution BCL11A intron 17767159 rs6732518 chr2 60708597 C T 2.87E-09 F-cell distribution BCL11A intron 21326311 rs6732518 chr2 60708597 C T 2.20E-17 Fetal hemoglobin levels BCL11A intron 22936743 rs13019832 chr2 60710571 G A 7.60E-12 F-cell distribution BCL11A intron 17767159 rs13019832 chr2 60710571 G A 2.96E-09 Other erythrocyte phenotypes BCL11A intron 19862010 rs11692396 chr2 60710738 G A 7.90E-12 F-cell distribution BCL11A intron 17767159 rs10189857 chr2 60713235 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10189857 chr2 60713235 A G 5.12E-07 Red blood cell traits BCL11A intron 23222517 rs6545816 chr2 60714861 A C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6545817 chr2 60715179 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs13024177 chr2 60716308 G C 5.90E-04 F-cell distribution BCL11A intron 17767159 rs13031396 chr2 60717399 G T 2.10E-04 F-cell distribution BCL11A intron 17767159 rs1427407 chr2 60718043 T G 6.00E-31 F-cell distribution BCL11A intron 17767159 rs1427407 chr2 60718043 T G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7599488 chr2 60718347 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896293 chr2 60718848 G T 2.00E-07 F-cell distribution BCL11A intron 17767159 rs1896294 chr2 60719074 C T 1.70E-10 F-cell distribution BCL11A intron 17767159 rs1896294 chr2 60719074 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs766431 chr2 60719918 A G 2.70E-07 F-cell distribution BCL11A intron 17767159 rs766432 chr2 60719970 C A 1.80E-28 F-cell distribution BCL11A intron 17767159 rs766432 chr2 60719970 C A 1.00E-29 Fetal hemoglobin levels BCL11A intron 20018918 rs766432 chr2 60719970 C A 1.00E-10 Beta thalassemia/Hemoglobin E disease BCL11A intron 20183929 rs766432 chr2 60719970 C A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs766432 chr2 60719970 C A 5.36E-58 Fetal hemoglobin levels BCL11A intron 22936743 rs766432 chr2 60719970 C A 9.00E-07 Sickle cell anemia (haemolysis) BCL11A intron 23406172 rs11886868 chr2 60720246 C T 4.20E-11 F-cell distribution BCL11A intron 17767159 rs11886868 chr2 60720246 C T 7.00E-35 Fetal hemoglobin levels BCL11A intron 18245381 rs11886868 chr2 60720246 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10195871 chr2 60720589 A G 5.40E-11 F-cell distribution BCL11A intron 17767159 rs10195871 chr2 60720589 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10195871 chr2 60720589 A G 2.14E-49 Fetal hemoglobin levels BCL11A intron 22936743 rs10172646 chr2 60720757 G A 4.30E-11 F-cell distribution BCL11A intron 17767159 rs10172646 chr2 60720757 G A 2.85E-33 Fetal hemoglobin levels BCL11A intron 18245381 rs10172646 chr2 60720757 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs4671393 chr2 60720951 A G 2.60E-27 F-cell distribution BCL11A intron 17767159 rs4671393 chr2 60720951 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7584113 chr2 60721311 A G 2.90E-10 F-cell distribution BCL11A intron 17767159 rs7584113 chr2 60721311 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7557939 chr2 60721347 G A 4.60E-11 F-cell distribution BCL11A intron 17767159 rs7557939 chr2 60721347 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6706648 chr2 60722040 C T 9.30E-08 F-cell distribution BCL11A intron 17767159 rs6706648 chr2 60722040 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6706648 chr2 60722040 C T 3.97E-39 Fetal hemoglobin levels BCL11A intron 22936743 rs6738440 chr2 60722241 A G 6.00E-06 F-cell distribution BCL11A intron 17767159 rs6738440 chr2 60722241 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6738440 chr2 60722241 A G 2.95E-23 Fetal hemoglobin levels BCL11A intron 22936743 rs7565301 chr2 60723266 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6729815 chr2 60723672 T C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896295 chr2 60724086 T C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896296 chr2 60724087 G T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7606173 chr2 60725451 G C 4.71E-09 Other erythrocyte phenotypes BCL11A intron 19862010 rs7606173 chr2 60725451 G C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6709302 chr2 60727629 G A 1.10E-05 F-cell distribution BCL11A intron 17767159 rs6709302 chr2 60727629 G A 8.90E-10 F-cell distribution BCL11A intron 21326311 rs6709302 chr2 60727629 G A 3.42E-22 Fetal hemoglobin levels BCL11A intron 22936743 rs10184550 chr2 60729294 G A 3.83E-10 Fetal hemoglobin levels BCL11A intron 22936743 rs2556378 chr2 60762502 T G 7.00E-06 Attention deficit hyperactivity disorder BCL11A intron 22012869 rs13382983 chr2 60789053 G A 1.40E-05 Urinary metabolites / / 21572414 rs2901066 chr2 60797896 A C 2.61E-04 Insulin resistance / / 21901158 rs357002 chr2 60810195 A G 2.50E-05 Urinary metabolites / / 21572414 rs356999 chr2 60811584 A G 4.10E-04 Suicidal ideation / / 22030708 rs356998 chr2 60811719 G A 2.60E-05 Urinary metabolites / / 21572414 rs842775 chr2 60853939 C G 2.63E-04 Type 2 diabetes / / 17463246 rs6705125 chr2 60881975 C T 9.99E-04 Type 2 diabetes / / 17463246 rs2118480 chr2 60886477 G A 1.50E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17031423 chr2 60893016 T C 4.49E-05 Job-related exhaustion / / 23620144 rs2420382 chr2 60896740 A C 8.15E-06 Job-related exhaustion / / 23620144 rs7589998 chr2 60924020 A G 5.00E-06 Obesity-related traits / / 23251661 rs13395150 chr2 60975288 A C 8.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7600065 chr2 61019699 C T 5.54E-06 Rheumatoid arthritis PAPOLG intron 19503088 rs13034020 chr2 61043834 A G 3.00E-06 Hodgkin's lymphoma / / 24920014 rs13034020 chr2 61043834 A G 1.66E-05 Cardiovascular disease / / pha003065 rs1432295 chr2 61066666 G A 2.00E-08 Hodgkin's lymphoma / / 21037568 rs1432295 chr2 61066666 G A 1.00E-06 Hodgkin's lymphoma / / 24149102 rs17538840 chr2 61077817 T A 1.60E-05 Urinary metabolites FLJ16341 intron 21572414 rs702873 chr2 61081542 C T 9.30E-08 Rheumatoid arthritis FLJ16341 intron 19503088 rs702873 chr2 61081542 C T 4.00E-09 Psoriasis FLJ16341 intron 20953190 rs702873 chr2 61081542 C T 2.00E-07 Psoriatic arthritis FLJ16341 intron 22170493 rs62149416 chr2 61083506 T C 1.80E-17 Psoriasis FLJ16341 intron 23143594 rs842633 chr2 61089317 G A 1.11E-04 Multiple complex diseases FLJ16341 intron 17554300 rs842636 chr2 61091950 G A 6.00E-06 Psoriasis FLJ16341 intron 20953189 rs842639 chr2 61095245 G A 4.31E-04 Schizophrenia FLJ16341 intron 19197363 rs10203477 chr2 61104985 A T 3.18E-05 Parkinson's disease FLJ16341 intron 17052657 rs842647 chr2 61119471 G A 5.24E-04 Schizophrenia REL intron 19197363 rs6545836 chr2 61122973 G A 2.30E-05 Urinary metabolites REL intron 21572414 rs34695944 chr2 61124850 T C 1.76E-08 Rheumatoid arthritis (CCP positive) REL intron 23143596 rs34695944 chr2 61124850 T C 8.54E-11 Rheumatoid arthritis REL intron 23143596 rs34695944 chr2 61124850 T C 2.00E-15 Rheumatoid arthritis REL intron 24390342 rs34695944 chr2 61124850 T C 4.00E-16 Rheumatoid arthritis REL intron 24390342 rs13031237 chr2 61136129 G T 6.01E-10 Rheumatoid arthritis REL intron 19503088 rs13031237 chr2 61136129 G T 8.00E-07 Rheumatoid arthritis REL intron 20453842 rs13031237 chr2 61136129 G T 2.00E-12 Celiac disease and Rheumatoid arthritis REL intron 21383967 rs13031237 chr2 61136129 G T 1.30E-06 Rheumatoid arthritis REL intron 22446963 rs13031237 chr2 61136129 G T 1.26E-11 Rheumatoid arthritis (CCP positive) REL intron 23143596 rs13031237 chr2 61136129 G T 1.40E-09 Rheumatoid arthritis REL intron 23143596 rs13017599 chr2 61164331 G A 2.00E-12 Rheumatoid arthritis / / 19503088 rs13017599 chr2 61164331 G A 1.00E-08 Psoriatic arthritis / / 22170493 rs13017599 chr2 61164331 G A 2.00E-12 Multiple sclerosis / / 22190364 rs13017599 chr2 61164331 G A 0.00019 Primary sclerosing cholangitis / / 22521342 rs6726160 chr2 61164729 T G 6.37E-05 Parkinson's disease / / 17052657 rs6726160 chr2 61164729 T G 1.47E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs6706689 chr2 61171045 A G 1.50E-04 Parkinson's disease PUS10 intron 17052657 rs6706689 chr2 61171045 A G 7.18E-08 Celiac disease and Rheumatoid arthritis PUS10 intron 21383967 rs12479056 chr2 61175312 T C 0.00000076 Primary sclerosing cholangitis PUS10 cds-synon 23603763 rs10208137 chr2 61178171 G A 1.80E-05 Urinary metabolites PUS10 intron 21572414 rs10176601 chr2 61179160 T C 2.10E-05 Urinary metabolites PUS10 intron 21572414 rs13003464 chr2 61186829 A G 1.57E-07 Crohn's disease PUS10 intron 18587394 rs13003464 chr2 61186829 A G 4.00E-13 Celiac disease PUS10 intron 20190752 rs13003464 chr2 61186829 A G 7.00E-09 Ulcerative colitis PUS10 intron 20228799 rs13003464 chr2 61186829 A G 4.00E-13 Asthma PUS10 intron 21150878 rs13003464 chr2 61186829 A G 3.71E-13 Celiac disease and Rheumatoid arthritis PUS10 intron 21383967 rs13003464 chr2 61186829 A G 4.30E-16 Celiac disease PUS10 intron 22057235 rs13003464 chr2 61186829 A G 3.71E-13 Multiple sclerosis PUS10 intron 22190364 rs13003464 chr2 61186829 A G 5.00E-09 Crohn's disease PUS10 intron 22412388 rs13003464 chr2 61186829 A G 4.30E-16 Celiac disease PUS10 intron 23143596 rs1864268 chr2 61202169 C G 9.74E-06 Response to platinum-based chemotherapy in small-cell lung cancer PUS10 intron 20463552 rs7608910 chr2 61204856 A G 2.00E-14 Ulcerative colitis PUS10 intron 21297633 rs7608910 chr2 61204856 A G 9.00E-32 Inflammatory bowel disease PUS10 intron 23128233 rs10188217 chr2 61217542 T C 6.36E-08 Crohn's disease PUS10 intron 18587394 rs10188217 chr2 61217542 T C 1.00E-11 Crohn's disease and celiac disease PUS10 intron 21298027 rs10181042 chr2 61224259 C T 3.90E-05 Type 2 diabetes PUS10 intron 17463246 rs10181042 chr2 61224259 C T 2.52E-04 Multiple complex diseases PUS10 intron 17554300 rs10181042 chr2 61224259 C T 7.00E-09 Crohn's disease PUS10 intron 21102463 rs9309333 chr2 61232705 G A 6.90E-04 Alzheimer's disease PUS10 intron 17998437 rs2564118 chr2 61233289 A G 1.95E-04 Type 2 diabetes PUS10 intron 17463246 rs12713431 chr2 61249676 A G 3.46E-04 Coronary Artery Disease PEX13 intron 17634449 rs1177234 chr2 61260063 C A 2.23E-04 Type 2 diabetes PEX13 intron 17463246 rs3108630 chr2 61268160 G A 2.08E-04 Type 2 diabetes PEX13 intron 17463246 rs1177279 chr2 61295122 A G 2.82E-04 Schizophrenia KIAA1841 intron 19197363 rs1177298 chr2 61306754 C A 4.61E-04 Type 2 diabetes KIAA1841 intron 17463246 rs1177264 chr2 61340450 G T 5.06E-05 Type 2 diabetes KIAA1841 intron 17463246 rs1177290 chr2 61346133 A G 1.99E-05 Type 2 diabetes KIAA1841 intron 17463246 rs1177274 chr2 61368532 T G 5.30E-05 Cognitive test performance / / 20125193 rs720201 chr2 61376463 T C 7.18E-04 Type 2 diabetes C2orf74 intron 17463246 rs720201 chr2 61376463 T C 3.52E-04 Response to platinum-based chemotherapy in small-cell lung cancer C2orf74 intron 20463552 rs1177309 chr2 61385248 A G 8.23E-05 Type 2 diabetes C2orf74 intron 17463246 rs3889717 chr2 61390791 A G 1.05E-04 Type 2 diabetes C2orf74 intron 17463246 rs1729662 chr2 61391305 G A 7.38E-05 Cognitive test performance C2orf74 intron 20125193 rs1729662 chr2 61391305 G A 3.35E-04 Coronary heart disease C2orf74 intron 21971053 rs777585 chr2 61412559 C T 2.07E-04 Type 2 diabetes AHSA2 intron 17463246 rs1059541 chr2 61414470 C G 4.57E-05 Response to platinum-based chemotherapy in small-cell lung cancer AHSA2 UTR-3 20463552 rs777587 chr2 61427675 A G 2.25E-04 Type 2 diabetes USP34 intron 17463246 rs7591772 chr2 61462400 C G 1.50E-04 Type 2 diabetes USP34 intron 17463246 rs17007356 chr2 61465504 G T 1.69E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs78404002 chr2 61466603 C T 0.0000342 Rheumatoid arthritis USP34 intron 23143596 rs10496091 chr2 61482261 G A 9.98E-05 Body Mass Index USP34 intron pha003006 rs10496091 chr2 61482261 G A 7.22E-06 Weight USP34 intron pha003026 rs10496091 chr2 61482261 G A 7.14E-05 Weight USP34 intron pha003027 rs2167566 chr2 61519408 T G 4.90E-05 Squamous cell carcinoma USP34 intron 23341777 rs2600672 chr2 61536740 G A 9.66E-04 Type 2 diabetes USP34 intron 17463246 rs2694619 chr2 61536901 C T 2.27E-04 Type 2 diabetes USP34 intron 17463246 rs2694618 chr2 61536984 C T 2.36E-04 Type 2 diabetes USP34 intron 17463246 rs17008218 chr2 61538054 T A 0.0000439 Rheumatoid arthritis USP34 intron 23143596 rs11680679 chr2 61540612 T C 5.54E-04 Major depressive disorder USP34 intron 22472876 rs1584301 chr2 61586132 T C 7.77E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs17008755 chr2 61604429 A G 4.48E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs10196146 chr2 61605379 C A 1.07E-04 Type 2 diabetes USP34 intron 17463246 rs17008940 chr2 61618598 C T 1.10E-04 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs10496093 chr2 61618660 C T 1.10E-04 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs4387777 chr2 61629635 C T 3.40E-05 Bipolar disorder USP34 intron 21771265 rs2463100 chr2 61659199 G C 7.12E-04 Type 2 diabetes USP34 intron 17463246 rs778139 chr2 61684564 G A 9.91E-04 Alcohol consumption (maxi-drinks) USP34 intron 24277619 rs1050567 chr2 61705663 C T 1.29E-04 Response to platinum-based chemotherapy in small-cell lung cancer XPO1 UTR-3 20463552 rs1050567 chr2 61705663 C T 2.89E-05 Attention deficit hyperactivity disorder XPO1 UTR-3 22420046 rs17009924 chr2 61727985 T C 0.0000947 Rheumatoid arthritis XPO1 intron 23143596 rs7563678 chr2 61741811 T C 1.13E-04 Type 2 diabetes XPO1 intron 17463246 rs3732171 chr2 61749690 C T 1.00E-04 Type 2 diabetes XPO1 intron 17463246 rs6545883 chr2 61772257 A G 5.00E-06 Tuberculosis / / 20694014 rs78534076 chr2 61776131 G C,T 0.0000491 Rheumatoid arthritis / / 23143596 rs778753 chr2 61780200 T A 1.16E-05 Tuberculosis / / 20694014 rs778757 chr2 61782047 C T 4.05E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs778764 chr2 61785680 C T 1.25E-05 Tuberculosis / / 20694014 rs9679654 chr2 61836773 T C 9.85E-05 Waist Circumference / / pha003024 rs9679654 chr2 61836773 T C 3.72E-05 Waist Circumference / / pha003025 rs7594191 chr2 61840018 C T 3.18E-04 Type 2 diabetes / / 17463246 rs1345207 chr2 61874015 G A 8.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2421332 chr2 61876965 T C 3.00E-09 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4233975 chr2 61899141 G A 0.0000191 HDL cholesterol particle diameter / / 23263444 rs6705537 chr2 61919772 C A 9.58E-09 Multiple complex diseases / / 17554300 rs4672448 chr2 61928100 A C 4.82E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs1186868 chr2 61991238 G A 7.00E-35 Fetal Hemoglobin levels / / 18245381 rs10166783 chr2 62017085 G A 1.00E-04 Hemoglobin concentration / / 20534544 rs1534645 chr2 62027085 C A 2.62E-04 Hemoglobin concentration / / 20534544 rs2178293 chr2 62034474 A G 2.62E-04 Hemoglobin concentration / / 20534544 rs11688210 chr2 62036610 C T 3.71E-04 Hemoglobin concentration / / 20534544 rs7589969 chr2 62044253 G T 4.08E-04 Hemoglobin concentration / / 20534544 rs11125895 chr2 62069358 T C 3.71E-04 Hemoglobin concentration FAM161A missense 20534544 rs17014577 chr2 62071338 T C 1.30E-05 Urinary metabolites FAM161A intron 21572414 rs2272429 chr2 62107632 G A 5.19E-04 Hemoglobin concentration CCT4 intron 20534544 rs6756087 chr2 62118385 G A 5.23E-04 Type 2 diabetes / / 22158537 rs6722228 chr2 62159728 G A 2.07E-04 Coronary heart disease COMMD1 intron 21971053 rs7579874 chr2 62190001 C A 0.0001 Migraine COMMD1 intron 22678113 rs6755858 chr2 62197878 T C 5.50E-04 Multiple complex diseases COMMD1 intron 17554300 rs4672473 chr2 62240786 G T 0.0003 Migraine COMMD1 intron 22678113 rs17018107 chr2 62279008 C T 5.82E-04 Type 2 diabetes COMMD1 intron 17463246 rs6743108 chr2 62298745 C T 5.49E-05 Cognitive performance COMMD1 intron 19734545 rs7572994 chr2 62418558 C T 6.00E-05 Cognitive performance / / 19734545 rs7605321 chr2 62432133 G A 6.00E-04 Alcohol dependence B3GNT2 intron 20201924 rs11900673 chr2 62452661 C T 1.00E-08 Rheumatoid arthritis / / 22446963 rs13385025 chr2 62461120 G A 1.20E-05 Rheumatoid arthritis / / 24390342 rs13385025 chr2 62461120 G A 9.00E-07 Rheumatoid arthritis / / 24390342 rs11689568 chr2 62491643 C T 8.10E-06 Urinary metabolites / / 21572414 rs10200191 chr2 62497170 G A 2.10E-05 Urinary metabolites / / 21572414 rs10200191 chr2 62497170 G A 2.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10200712 chr2 62497902 C T 3.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs569393016 chr2 62497902 CGGAA C 3.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11676235 chr2 62502387 G T 2.60E-05 Urinary metabolites / / 21572414 rs4563212 chr2 62503017 C T 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4672495 chr2 62521244 G T 3.20E-09 Ankylosing spondylitis / / 20062062 rs7596545 chr2 62530227 C T 5.83E-04 Multiple complex diseases / / 17554300 rs10779949 chr2 62549445 C A 0.000244692 Primary sclerosing cholangitis / / 23603763 rs10865331 chr2 62551472 A G 5.32E-04 Multiple complex diseases / / 17554300 rs10865331 chr2 62551472 A G 2.00E-19 Ankylosing spondylitis / / 20062062 rs10865331 chr2 62551472 A G 7.00E-34 Ankylosing spondylitis / / 21743469 rs10865331 chr2 62551472 A G 4.50E-04 Myasthenia gravis / / 23055271 rs10865331 chr2 62551472 A G 1.00E-09 Crohn's disease / / 23128233 rs10865331 chr2 62551472 A G 4.70E-10 Psoriasis / / 23143594 rs4671421 chr2 62599559 A G 2.43E-05 Body Mass Index / / pha003020 rs4671421 chr2 62599559 A G 5.87E-05 Waist Circumference / / pha003024 rs75792394 chr2 62609078 G T 6.47E-06 Cocaine dependence / / 23958962 rs6545929 chr2 62610179 G A 7.82E-04 Multiple complex diseases / / 17554300 rs6706698 chr2 62706695 T C 2.40E-05 Urinary metabolites / / 21572414 rs6545944 chr2 62708186 G A 3.50E-06 Urinary metabolites / / 21572414 rs6545946 chr2 62713533 C T 7.00E-09 Crohn's disease / / 22412388 rs10202106 chr2 62720041 T C 9.95E-05 Schizophrenia / / 19571809 rs6545950 chr2 62751619 A G 1.70E-05 Urinary metabolites / / 21572414 rs1997247 chr2 62757555 G A 9.70E-07 Alcohol and nictotine co-dependence / / 20158304 rs6738968 chr2 62783777 C T 1.30E-05 Urinary metabolites / / 21572414 rs2049674 chr2 62783842 C T 7.48E-05 Multiple complex diseases / / 17554300 rs17025954 chr2 62805224 A G 0.0000074 Asthma (exacerbation) / / 23706709 rs1038570 chr2 62890171 C A 8.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7591708 chr2 63022050 T C 2.03E-05 Inflammation EHBP1 intron pha002897 rs6714241 chr2 63069112 T G 9.57E-04 Type 2 diabetes EHBP1 intron 17463246 rs1877026 chr2 63072208 A G 2.06E-05 Alcohol and nictotine co-dependence EHBP1 intron 20158304 rs11901070 chr2 63126755 T C 3.60E-05 Lung cancer EHBP1 intron 18385738 rs721048 chr2 63131731 G A 8.00E-09 Prostate cancer EHBP1 intron 18264098 rs721048 chr2 63131731 G A 8.00E-09 Nasopharyngeal carcinoma EHBP1 intron 20512145 rs2710646 chr2 63134879 C A 2.27E-06 Inflammation EHBP1 intron pha002897 rs2710642 chr2 63149557 G A 6.00E-09 LDL cholesterol EHBP1 intron 24097068 rs6545977 chr2 63301164 G A 5.00E-07 Prostate cancer / / 19767753 rs6545977 chr2 63301164 G A 5.00E-07 Nasopharyngeal carcinoma / / 20512145 rs6545977 chr2 63301164 G A 0.000006 Prostate cancer / / 23555315 rs6545977 chr2 63301164 G A 0.000017 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs13010733 chr2 63363355 T G 2.25E-04 Age-related macular degeneration WDPCP intron 22125219 rs13431765 chr2 63417729 T G 5.38E-05 Inflammation WDPCP intron pha002897 rs11125954 chr2 63474793 T C 4.34E-05 Glycosylated haemoglobin levels WDPCP intron 17255346 rs7585088 chr2 63484884 T C 6.54E-05 Glycosylated haemoglobin levels WDPCP intron 17255346 rs17474840 chr2 63485359 A G 6.70E-04 Urinary albumin excretion rate in type 1 diabetes WDPCP intron 24595857 rs1517408 chr2 63490493 A G 2.32E-04 Glycosylated haemoglobin levels WDPCP intron 17255346 rs2699393 chr2 63491438 G A 1.76E-04 Glycosylated haemoglobin levels WDPCP intron 17255346 rs2138798 chr2 63511435 G T 8.00E-07 Obesity-related traits WDPCP intron 23251661 rs7566860 chr2 63564683 T C 1.40E-04 Age-related macular degeneration WDPCP intron 22125219 rs11683229 chr2 63596836 A G 6.00E-06 Protein quantitative trait loci WDPCP intron 18464913 rs33977056 chr2 63744282 G A 0.0000224 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene WDPCP intron 22391508 rs2421954 chr2 63754275 T C 1.51E-04 Cardiovascular disease WDPCP intron 17903304 rs2278718 chr2 63815801 A C 7.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MDH1 UTR-5 23648065 rs4671070 chr2 64012860 C T 2.80E-04 Type 2 diabetes / / 17463246 rs4671072 chr2 64087027 T A 7.74E-04 Multiple complex diseases UGP2 intron 17554300 rs3934536 chr2 64089373 G T 5.77E-05 Multiple complex diseases UGP2 intron 17554300 rs4616468 chr2 64104132 C T 4.66E-04 Multiple complex diseases UGP2 intron 17554300 rs12993544 chr2 64105553 A G 6.70E-04 Alcohol dependence UGP2 intron 20201924 rs11558741 chr2 64124722 C A 2.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 missense 22047184 rs12999675 chr2 64136069 C A 8.75E-04 Multiple complex diseases VPS54 intron 17554300 rs17555655 chr2 64144829 T A 1.44E-04 Multiple complex diseases VPS54 intron 17554300 rs6736556 chr2 64180957 C T 2.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs6757168 chr2 64194247 C T 3.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs7560265 chr2 64196920 C T 7.06E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs6546043 chr2 64207445 C A 5.17E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs329478 chr2 64257746 T C 9.20E-04 Type 2 diabetes / / 17463246 rs193031 chr2 64260458 C G 9.60E-06 Aortic stiffness / / 22068335 rs13007342 chr2 64271155 T A 3.62E-04 Multiple complex diseases / / 17554300 rs17028360 chr2 64276197 A G 7.57E-05 Suicide attempts in bipolar disorder / / 21041247 rs10171434 chr2 64279606 C T 3.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171434 chr2 64279606 C T 2.50E-05 Urinary metabolites / / 21572414 rs7560803 chr2 64281498 G A 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs13429819 chr2 64283986 A G 5.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs17028375 chr2 64312142 T C 1.72E-09 Esophageal cancer / / 21642993 rs10496105 chr2 64320746 G A 8.08E-05 Type 2 diabetes and other traits PELI1 UTR-3 19734900 rs7604693 chr2 64349202 C A 2.00E-06 Kawasaki disease PELI1 intron 21221998 rs6733160 chr2 64364632 T C 7.00E-06 Allergic dermatitis (nickel) PELI1 intron 23921680 rs6710681 chr2 64413221 T C 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs6710681 chr2 64413221 T C 2.00E-04 Chronic fatigue syndrome LINC00309 intron 21912186 rs6751738 chr2 64418379 C A 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs1973848 chr2 64418456 T C 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs10496108 chr2 64419656 A G 1.10E-04 Multiple complex diseases LINC00309 intron 17554300 rs12987393 chr2 64421514 T C 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs6758601 chr2 64425094 G A 5.64E-04 Insulin resistance LINC00309 intron 21901158 rs1529102 chr2 64495627 G A 6.00E-06 Breast size / / 22747683 rs2698530 chr2 64503895 A C 1.00E-07 Iron status biomarkers / / 21483845 rs2698530 chr2 64503895 A C 2.00E-07 Iron status biomarkers / / 21483845 rs2698530 chr2 64503895 A C 4.00E-06 Iron status biomarkers / / 21483845 rs2698538 chr2 64507742 G A 8.08E-04 Type 2 diabetes / / 17463246 rs2433383 chr2 64517384 C T 6.89E-04 Depression (quantitative trait) / / 20800221 rs919123 chr2 64553440 A C 3.90E-04 Alcohol dependence / / 20201924 rs919123 chr2 64553440 A C 4.80E-04 Alcohol dependence / / 20201924 rs1365475 chr2 64559621 G A 5.75E-04 Type 2 diabetes / / 17463246 rs919122 chr2 64559966 G A 4.21E-04 Type 2 diabetes / / 17463246 rs2059630 chr2 64565907 T A 2.92E-04 Type 2 diabetes / / 17463246 rs1426698 chr2 64566825 G T 3.97E-04 Type 2 diabetes / / 17463246 rs12477412 chr2 64567680 T G 3.30E-04 Tourette syndrome / / 22889924 rs6546069 chr2 64595483 G C 1.26E-04 Smoking initiation / / 24665060 rs13411839 chr2 64607432 C G 8.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10176971 chr2 64618975 T C 7.08E-05 Smoking cessation / / 18519826 rs1426707 chr2 64619247 A C 7.53E-06 Smoking cessation / / 18519826 rs10496112 chr2 64623733 T G 3.30E-05 Blood Phenotypes / / 17903294 rs872241 chr2 64630299 A G 7.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs13391261 chr2 64656409 G A 2.38E-04 Hemoglobin concentration / / 20534544 rs4671582 chr2 64661404 T C 1.03E-04 Hemoglobin concentration / / 20534544 rs7591656 chr2 64662732 T C 2.46E-04 Hemoglobin concentration / / 20534544 rs9309360 chr2 64663169 C T 9.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs6733373 chr2 64665661 T C 2.38E-04 Hemoglobin concentration / / 20534544 rs10496113 chr2 64665970 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10496113 chr2 64665970 A G 8.23E-05 ldl cholesterol / / pha003076 rs10496114 chr2 64668253 G T 9.43E-04 Type 2 diabetes / / 17463246 rs10496114 chr2 64668253 G T 2.38E-04 Hemoglobin concentration / / 20534544 rs6761063 chr2 64672218 T A 9.43E-04 Type 2 diabetes / / 17463246 rs6729083 chr2 64680967 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs13391620 chr2 64684663 A G 9.84E-04 Type 2 diabetes LGALSL intron 17463246 rs17743505 chr2 64684755 A G 5.20E-06 Urinary metabolites LGALSL intron 21572414 rs10496117 chr2 64687665 C A 2.66E-05 Cognitive impairment induced by topiramate LGALSL UTR-3 22091778 rs10496117 chr2 64687665 C A 9.52E-05 Cognitive impairment induced by topiramate LGALSL UTR-3 22091778 rs7355543 chr2 64693013 A C 2.05E-04 Response to TNF antagonist treatment / / 21061259 rs7355543 chr2 64693013 A C 1.80E-06 Urinary metabolites / / 21572414 rs6546073 chr2 64698397 G A 4.25E-04 Multiple complex diseases / / 17554300 rs12713521 chr2 64817256 G A 4.83E-04 Lung function (forced expiratory volume in 1 second) AFTPH intron 24023788 rs9653500 chr2 64820616 A G 2.00E-04 Multiple complex diseases / / 17554300 rs13020375 chr2 64829151 G A 3.81E-04 Sudden cardiac arrest / / 21658281 rs6546090 chr2 64839984 G T 5.27E-04 Multiple complex diseases / / 17554300 rs7557491 chr2 64852557 C A 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7591336 chr2 64868170 T A 7.19E-04 Multiple complex diseases SERTAD2 intron 17554300 rs7591336 chr2 64868170 T A 7.47E-04 Aortic root size SERTAD2 intron 21223598 rs17029216 chr2 64917229 C T 5.69E-05 Multiple complex diseases / / 17554300 rs2136451 chr2 64993045 G A 5.79E-04 Smoking cessation / / 24665060 rs17608651 chr2 65004346 G A 7.36E-04 Multiple complex diseases / / 17554300 rs10469881 chr2 65007992 T C 5.20E-04 Type 2 diabetes / / 17463246 rs929698 chr2 65008756 A C 3.59E-04 Parkinson's disease / / 17052657 rs7579416 chr2 65009646 C T 6.77E-04 Smoking initiation / / 24665060 rs17029460 chr2 65026936 C T 4.07E-04 Multiple complex diseases / / 17554300 rs11683197 chr2 65027624 T C 5.00E-06 Visceral fat / / 22589738 rs17661512 chr2 65050524 C T 2.90E-06 Urinary metabolites / / 21572414 rs6738590 chr2 65059603 A G 1.40E-04 Coronary heart disease / / 21606135 rs741477 chr2 65066311 A G 3.10E-05 Alzheimer's disease (late onset) / / 21460841 rs2048262 chr2 65101579 A C 6.16E-04 Multiple complex diseases / / 17554300 rs6546108 chr2 65103983 G A 4.05E-05 Height / / pha003010 rs918197 chr2 65106350 C T 6.49E-05 Height / / pha003010 rs11126023 chr2 65113153 G A 2.20E-05 Urinary metabolites / / 21572414 rs13022383 chr2 65130948 G A 4.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13027905 chr2 65131511 A G 3.02E-04 Type 2 diabetes / / 17463246 rs4140738 chr2 65132099 G A 4.42E-04 Type 2 diabetes LOC400958 intron 17463246 rs4140738 chr2 65132099 G A 5.80E-06 Urinary metabolites LOC400958 intron 21572414 rs2008831 chr2 65132540 C T 1.23E-04 Amyotrophic Lateral Sclerosis LOC400958 intron 17362836 rs34610365 chr2 65135673 A T 1.53E-04 Type 2 diabetes LOC400958 intron 17463246 rs41537649 chr2 65138117 G T 1.78E-04 Type 2 diabetes LOC400958 intron 17463246 rs41537649 chr2 65138117 G T 6.50E-06 Urinary metabolites LOC400958 intron 21572414 rs10490210 chr2 65170482 G A 1.16E-05 Type 2 diabetes / / 17463246 rs7576477 chr2 65174146 G C 2.67E-05 Type 2 diabetes / / 17463246 rs7590631 chr2 65174408 T G 1.40E-05 Type 2 diabetes / / 17463246 rs4671635 chr2 65180817 G A 3.88E-05 Waist Circumference / / pha003023 rs2017320 chr2 65193391 C T 7.19E-05 Waist Circumference / / pha003023 rs10211524 chr2 65208074 G A 4.49E-22 Metabolite levels / / 22286219 rs10211524 chr2 65208074 G A 3.00E-10 Metabolite levels (atherosclerosis) / / 22916037 rs10211524 chr2 65208074 G A 6.00E-16 Blood metabolite levels / / 24816252 rs10194107 chr2 65213822 T C 4.02E-12 Metabolite levels / / 22286219 rs10170033 chr2 65215257 C T 3.68E-12 Metabolite levels / / 22286219 rs2007061 chr2 65219030 T C 1.51E-12 Metabolite levels SLC1A4 intron 22286219 rs2160387 chr2 65220910 T C 3.00E-22 Metabolite levels SLC1A4 intron 22286219 rs1541580 chr2 65221184 C T 9.57E-13 Metabolite levels SLC1A4 intron 22286219 rs3770707 chr2 65226461 C A 1.14E-10 Metabolite levels SLC1A4 intron 22286219 rs3770706 chr2 65226463 G A 1.14E-10 Metabolite levels SLC1A4 intron 22286219 rs3770705 chr2 65230739 T C 0.00000437 Change in depression severity with antidepressants (NRI or SRI) SLC1A4 intron 23091423 rs2422358 chr2 65231806 A T 4.77E-17 Metabolite levels SLC1A4 intron 22286219 rs6546119 chr2 65235333 T G 6.85E-04 Multiple complex diseases SLC1A4 intron 17554300 rs1058922 chr2 65250541 A T 9.00E-06 Urinary metabolites SLC1A4 UTR-3 21572414 rs2422435 chr2 65257849 G A 4.19E-04 Smoking quantity / / 24665060 rs2302647 chr2 65283174 G A 2.00E-04 Asthma (aspirin-intolerant) / / 21072201 rs2302647 chr2 65283174 G A 5.00E-05 Asthma (aspirin-intolerant) / / 21072201 rs2241161 chr2 65290842 C A 9.39E-05 Schizophrenia CEP68 intron 24253340 rs2252867 chr2 65296280 T C 7.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2252867 chr2 65296280 T C 9.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs7572857 chr2 65296798 G A 3.00E-05 Asthma (aspirin-intolerant) CEP68 missense 21072201 rs7572857 chr2 65296798 G A 6.00E-05 Asthma (aspirin-intolerant) CEP68 missense 21072201 rs2723087 chr2 65298282 T A 4.00E-04 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2723087 chr2 65298282 T A 9.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2723090 chr2 65300995 G A 5.50E-06 Urinary metabolites CEP68 intron 21572414 rs6741255 chr2 65306905 C T 1.00E-04 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs6741255 chr2 65306905 C T 5.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs1420185 chr2 65315903 G A 6.55E-04 Type 2 diabetes RAB1A intron 17463246 rs10187798 chr2 65333300 A G 1.00E-06 Urinary metabolites RAB1A intron 21572414 rs11885480 chr2 65336170 T C 4.40E-07 Urinary metabolites RAB1A intron 21572414 rs6546134 chr2 65431194 T C 7.58E-04 Type 2 diabetes / / 17463246 rs7581784 chr2 65435028 C A 9.49E-04 Type 2 diabetes / / 17463246 rs3771099 chr2 65476400 G T 6.20E-05 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs4671646 chr2 65487672 G A 0.00017526 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs268864 chr2 65489742 G A 0.000384216 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs2287064 chr2 65491802 G A 0.00017526 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs4671124 chr2 65495283 A G 7.38E-04 Amyotrophic lateral sclerosis (sporadic) ACTR2 intron 24529757 rs7561932 chr2 65545068 T C 7.71E-04 Response to cytadine analogues (cytosine arabinoside) SPRED2 intron 24483146 rs10170788 chr2 65546879 C T 4.20E-05 Response to Vitamin E supplementation SPRED2 intron 22437554 rs6546146 chr2 65556324 C A 0.000000603 Rheumatoid arthritis (CCP positive) SPRED2 intron 23143596 rs6546146 chr2 65556324 C A 0.0000008 Rheumatoid arthritis SPRED2 intron 23143596 rs6727281 chr2 65558588 C T 8.36E-04 Type 2 diabetes SPRED2 intron 17463246 rs2271198 chr2 65559027 A G 0.0000722 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2271198 chr2 65559027 A G 7.22E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs17533992 chr2 65561543 T G 1.46E-04 Type 2 diabetes SPRED2 intron 17463246 rs10186240 chr2 65577651 T G 1.22E-05 Serum metabolites SPRED2 intron 19043545 rs10186240 chr2 65577651 T G 0.000051 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs10186240 chr2 65577651 T G 5.10E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs7559283 chr2 65578368 C T 0.0000504 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs7559283 chr2 65578368 C T 5.04E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6711791 chr2 65579228 G T 0.0000118 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs6711791 chr2 65579228 G T 1.18E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs11126034 chr2 65580221 T C 9.35E-04 Multiple complex diseases SPRED2 intron 17554300 rs1396210 chr2 65584274 A G 0.0000412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1396210 chr2 65584274 A G 4.12E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6738087 chr2 65592325 T C 0.0000348 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs6738087 chr2 65592325 T C 3.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs934734 chr2 65595586 G A 3.52E-05 Serum metabolites SPRED2 intron 19043545 rs934734 chr2 65595586 G A 5.00E-10 Rheumatoid arthritis SPRED2 intron 20453842 rs934734 chr2 65595586 G A 5.30E-10 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs934734 chr2 65595586 G A 4.69E-05 Height SPRED2 intron 22021425 rs934734 chr2 65595586 G A 5.30E-10 Multiple sclerosis SPRED2 intron 22190364 rs934734 chr2 65595586 G A 5.50E-07 Rheumatoid arthritis SPRED2 intron 22446963 rs934734 chr2 65595586 G A 5.30E-10 Rheumatoid arthritis SPRED2 intron 23143596 rs934734 chr2 65595586 G A 0.0000119 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs934734 chr2 65595586 G A 1.19E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs934734 chr2 65595586 G A 2.00E-08 Rheumatoid arthritis SPRED2 intron 24782177 rs10188658 chr2 65597400 G A 1.77E-05 Height SPRED2 intron 22021425 rs11673987 chr2 65597671 A G 3.49E-08 Rheumatoid arthritis SPRED2 intron 23143596 rs17534153 chr2 65598222 C T 1.69E-05 Bipolar disorder SPRED2 intron 17486107 rs1858036 chr2 65598241 A G 7.48E-10 Rheumatoid arthritis (CCP positive) SPRED2 intron 23143596 rs1858037 chr2 65598300 T A 1.00E-08 Rheumatoid arthritis SPRED2 intron 24390342 rs1858037 chr2 65598300 T A 2.00E-09 Rheumatoid arthritis SPRED2 intron 24390342 rs1858037 chr2 65598300 T A 3.00E-15 Rheumatoid arthritis SPRED2 intron 24390342 rs268122 chr2 65602109 A T 4.20E-05 Serum metabolites SPRED2 intron 19043545 rs268122 chr2 65602109 A T 0.0000334 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268122 chr2 65602109 A T 3.34E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1866051 chr2 65602149 T C 0.00000878 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1866051 chr2 65602149 T C 8.78E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs174847 chr2 65605194 C T 0.000028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs174847 chr2 65605194 C T 2.80E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs11689314 chr2 65605408 G T 0.0000275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs11689314 chr2 65605408 G T 2.75E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1194849 chr2 65606653 T C 2.75E-08 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs1194849 chr2 65606653 T C 5.20E-04 Common variable immunodeficiency SPRED2 intron 21497890 rs1194849 chr2 65606653 T C 0.0000202 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1194849 chr2 65606653 T C 2.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268139 chr2 65606991 A C 0.0000199 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268139 chr2 65606991 A C 1.99E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs198478 chr2 65607011 A G 0.0000197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs198478 chr2 65607011 A G 1.97E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268138 chr2 65607294 A G 1.99E-05 Serum metabolites SPRED2 intron 19043545 rs268138 chr2 65607294 A G 0.0000153 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268138 chr2 65607294 A G 1.53E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268136 chr2 65607543 C A,G,T 0.0000193 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268136 chr2 65607543 C A,G,T 1.93E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs874952 chr2 65608525 G A 3.30E-04 Multiple complex diseases SPRED2 intron 17554300 rs1876518 chr2 65608909 C T 2.00E-08 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs1876518 chr2 65608909 C T 0.000019 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1876518 chr2 65608909 C T 1.90E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268133 chr2 65609550 A C 5.46E-05 Erythrocyte counts SPRED2 intron pha003101 rs268132 chr2 65609677 T C 1.12E-04 Arthritis (juvenile idiopathic) SPRED2 intron 22354554 rs268132 chr2 65609677 T C 0.0000189 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268132 chr2 65609677 T C 1.89E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268131 chr2 65610471 T A 8.27E-04 Type 2 diabetes SPRED2 intron 17463246 rs268131 chr2 65610471 T A 5.80E-05 Serum metabolites SPRED2 intron 19043545 rs268131 chr2 65610471 T A 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268131 chr2 65610471 T A 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs702875 chr2 65614197 T C 0.00000779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs702875 chr2 65614197 T C 7.79E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1039764 chr2 65614613 T C 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1039764 chr2 65614613 T C 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs17534670 chr2 65615428 G A 3.68E-05 Serum metabolites SPRED2 intron 19043545 rs17534670 chr2 65615428 G A 0.00000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs17534670 chr2 65615428 G A 7.78E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs4303705 chr2 65619710 C T 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs4303705 chr2 65619710 C T 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661796 chr2 65627406 T C 0.0000186 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661796 chr2 65627406 T C 1.86E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661797 chr2 65633190 G A 0.0000185 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661797 chr2 65633190 G A 1.85E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs10496125 chr2 65635206 C A 6.18E-14 Lymphocyte counts SPRED2 intron 22286170 rs10496125 chr2 65635206 C A 1.84E-05 Erythrocyte counts SPRED2 intron pha003101 rs2661798 chr2 65635688 A T 2.94E-05 Serum metabolites SPRED2 intron 19043545 rs2661798 chr2 65635688 A T 0.0000223 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661798 chr2 65635688 A T 2.23E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661794 chr2 65639543 C A 0.0000366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661794 chr2 65639543 C A 3.66E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6740462 chr2 65667272 C A 2.00E-08 Inflammatory bowel disease / / 23128233 rs6712418 chr2 65695395 C T 8.61E-04 Multiple complex diseases / / 17554300 rs6712418 chr2 65695395 C T 2.45E-04 Alzheimer's disease / / 17998437 rs840969 chr2 65702803 T C 8.59E-05 Crohn's disease / / 23850713 rs2244364 chr2 65710328 T C 0.0002439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244364 chr2 65710328 T C 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2244255 chr2 65710864 A G 0.0002395 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244255 chr2 65710864 A G 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2244238 chr2 65711298 T G 0.0002896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244238 chr2 65711298 T G 2.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs840943 chr2 65715832 T C 0.0006324 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs840943 chr2 65715832 T C 6.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs840944 chr2 65715983 C A 0.0006183 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs840944 chr2 65715983 C A 6.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13432799 chr2 65722087 A G 3.23E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs13432799 chr2 65722087 A G 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs840958 chr2 65726198 G C 4.26E-04 Multiple complex diseases / / 17554300 rs840962 chr2 65727567 A C 8.57E-05 Bipolar disorder / / 18317468 rs702933 chr2 65741615 T C 9.16E-05 Caffeine consumption / / 21490707 rs702938 chr2 65747442 A G 6.02E-05 Major depressive disorder / / 22472876 rs3845816 chr2 65758355 A G 2.94E-05 Major depressive disorder / / 22472876 rs702891 chr2 65758450 C G 3.55E-05 Major depressive disorder / / 22472876 rs702891 chr2 65758450 C G 4.60E-04 Pulmonary function / / 23932459 rs3845817 chr2 65758525 T C 2.00E-06 Bipolar disorder / / 21926972 rs3845817 chr2 65758525 T C 1.98E-05 Major depressive disorder / / 22472876 rs3845817 chr2 65758525 T C 0.00000145 Bipolar disorder / / 23070075 rs3911862 chr2 65759671 A G 3.09E-05 Major depressive disorder / / 22472876 rs3911862 chr2 65759671 A G 0.0000565 Bipolar disorder / / 23637625 rs702909 chr2 65767247 G T 1.89E-05 Major depressive disorder / / 22472876 rs702919 chr2 65772291 C T 2.57E-05 Major depressive disorder / / 22472876 rs13003991 chr2 65772956 C G 4.07E-07 Bipolar disorder / / 22182935 rs13003991 chr2 65772956 C G 2.09E-05 Major depressive disorder / / 22472876 rs11678288 chr2 65774687 T A 4.58E-07 Bipolar disorder / / 22182935 rs11678288 chr2 65774687 T A 2.03E-05 Major depressive disorder / / 22472876 rs1673450 chr2 65783593 A G 6.18E-05 Body mass (lean) / / 19268274 rs897876 chr2 65791581 C T 2.00E-07 Hypertension (young onset) / / 24892410 rs1673442 chr2 65793878 A G 1.68E-04 Bipolar disorder / / 18317468 rs1673441 chr2 65794114 A G 9.14E-05 Bipolar disorder / / 18317468 rs11902125 chr2 65838800 G A 1.30E-06 Cystic fibrosis-related diabetes / / 23670970 rs1457451 chr2 65862378 G A 3.00E-06 Iron status biomarkers / / 19084217 rs4671136 chr2 65869241 T C 1.80E-04 Multiple complex diseases / / 17554300 rs1345351 chr2 65902188 G A 9.93E-04 Type 2 diabetes / / 17463246 rs1019365 chr2 65924908 C T 4.70E-05 Memory performance / / 22105620 rs2860851 chr2 65932417 T C 6.00E-05 Prostate cancer / / 21743057 rs13431495 chr2 65975754 G T 6.74E-05 Progressive supranuclear palsy / / 21685912 rs3845820 chr2 65976244 T G 3.44E-04 Taste perception / / 22132133 rs6546180 chr2 66006558 T C 2.52E-04 Myopia (pathological) / / 21095009 rs10179158 chr2 66012032 T C 5.76E-04 Myopia (pathological) / / 21095009 rs11682069 chr2 66014828 A G 6.60E-05 Response to statin therapy / / 20339536 rs10198911 chr2 66019696 A G 5.60E-05 Response to statin therapy / / 20339536 rs11693109 chr2 66021675 A C 4.30E-05 Response to statin therapy / / 20339536 rs10496130 chr2 66025474 T C 4.40E-05 Response to statin therapy / / 20339536 rs13396492 chr2 66025650 G A 4.80E-05 Response to statin therapy / / 20339536 rs6727797 chr2 66026431 T C 3.70E-05 Response to statin therapy / / 20339536 rs6727797 chr2 66026431 T C 6.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13406620 chr2 66028199 C T 5.80E-05 Response to statin therapy / / 20339536 rs17030858 chr2 66035660 T A 6.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs17030866 chr2 66039793 G A 5.47E-04 Myopia (pathological) / / 21095009 rs6743363 chr2 66045064 G A 4.94E-04 Hemoglobin concentration / / 20534544 rs7595869 chr2 66066927 T C 6.76E-04 Multiple complex diseases / / 17554300 rs11686582 chr2 66077576 A T 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12995236 chr2 66077753 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13412059 chr2 66077869 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13386707 chr2 66077918 C T 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs12713551 chr2 66078147 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6716340 chr2 66078264 T C 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs13414975 chr2 66078299 A G 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490586 chr2 66081606 A G 3.43E-05 Height / / 22021425 rs10490587 chr2 66081693 T C 8.97E-04 Schizophrenia / / 19197363 rs2194782 chr2 66082204 A G 1.60E-05 Crohn's disease / / 20570966 rs6719655 chr2 66089359 T C 8.91E-05 Coronary Artery Disease / / 17634449 rs17031012 chr2 66096120 C A 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10183336 chr2 66097560 G A 4.35E-04 Multiple complex diseases / / 17554300 rs12471713 chr2 66104282 G C 4.89E-06 Melanoma / / 21926416 rs17031071 chr2 66129494 G A 2.96E-04 Cholesterol / / 17255346 rs719832 chr2 66138791 A G 4.49E-05 Serum metabolites / / 19043545 rs6717463 chr2 66140128 A G 2.15E-05 Serum metabolites / / 19043545 rs6728803 chr2 66148466 A G 6.80E-07 Type 2 diabetes / / 21647700 rs17031166 chr2 66167064 G C 4.98E-06 Testicular cancer / / 19483682 rs1549383 chr2 66167564 G A 1.01E-06 Testicular cancer / / 19483682 rs1549383 chr2 66167564 G A 3.44E-06 Testicular cancer / / 21551455 rs17604526 chr2 66172199 G A 4.79E-05 Intelligence / / 21826061 rs6716270 chr2 66201731 T C 4.24E-04 Multiple complex diseases / / 17554300 rs6546200 chr2 66204736 C G 8.64E-05 Femoral neck bone geometry / / 22087292 rs1484475 chr2 66208119 A T 4.12E-05 Femoral neck bone geometry / / 22087292 rs13395694 chr2 66208800 C A 6.18E-06 Waist-hip ratio / / 20935629 rs10203404 chr2 66209299 A G 8.08E-05 Femoral neck bone geometry / / 22087292 rs10180226 chr2 66209485 G T 7.65E-05 Femoral neck bone geometry / / 22087292 rs10199102 chr2 66211303 T C 8.06E-05 Serum metabolites / / 19043545 rs13429325 chr2 66228401 G C 3.60E-05 Parkinson's disease (familial) / / 18985386 rs17031294 chr2 66236037 T G 1.76E-04 Multiple complex diseases / / 17554300 rs2699783 chr2 66258701 T C 6.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2699783 chr2 66258701 T C 7.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs2627857 chr2 66302093 G A 7.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13409331 chr2 66305945 A G 9.11E-04 Multiple complex diseases / / 17554300 rs4671716 chr2 66358238 T C 3.73E-04 Alzheimer's disease (late onset) / / 21379329 rs11687648 chr2 66376064 T C 6.20E-04 Obesity (extreme) / / 21935397 rs1906900 chr2 66379789 G A 5.96E-04 Obesity (extreme) / / 21935397 rs10198265 chr2 66380826 C T 5.93E-04 Obesity (extreme) / / 21935397 rs6712489 chr2 66382388 A G 5.92E-04 Obesity (extreme) / / 21935397 rs7573350 chr2 66384249 T C 5.92E-04 Obesity (extreme) / / 21935397 rs13424573 chr2 66385433 A T 5.92E-04 Obesity (extreme) / / 21935397 rs6748113 chr2 66387107 A C 5.92E-04 Obesity (extreme) / / 21935397 rs7600569 chr2 66388139 A G 5.86E-04 Obesity (extreme) / / 21935397 rs2861009 chr2 66388290 T C 5.84E-04 Obesity (extreme) / / 21935397 rs6761361 chr2 66390890 A C 5.80E-04 Obesity (extreme) / / 21935397 rs12613969 chr2 66391046 A G 6.02E-04 Obesity (extreme) / / 21935397 rs1320859 chr2 66391442 C A 6.00E-04 Obesity (extreme) / / 21935397 rs10200852 chr2 66391832 G A 5.98E-04 Obesity (extreme) / / 21935397 rs10177124 chr2 66391841 A G 5.96E-04 Obesity (extreme) / / 21935397 rs2954974 chr2 66391895 G C 1.25E-04 Obesity (extreme) / / 21935397 rs1320861 chr2 66392262 T C 5.97E-04 Obesity (extreme) / / 21935397 rs1320862 chr2 66392325 G A 5.98E-04 Obesity (extreme) / / 21935397 rs1997383 chr2 66393650 T C 5.86E-04 Obesity (extreme) / / 21935397 rs1906901 chr2 66397457 G A 6.62E-04 Parkinson's disease / / 17052657 rs10496132 chr2 66397547 C T 6.62E-04 Parkinson's disease / / 17052657 rs12612632 chr2 66401580 C T 6.89E-05 Sarcoidosis / / 19165924 rs1038703 chr2 66426280 T G 0.00067 Salmonella-induced pyroptosis / / 22837397 rs2971817 chr2 66427978 A G 0.000518 Salmonella-induced pyroptosis / / 22837397 rs2971816 chr2 66428152 A G 0.000304 Salmonella-induced pyroptosis / / 22837397 rs2932245 chr2 66429851 G A 0.000746 Salmonella-induced pyroptosis / / 22837397 rs2951288 chr2 66430063 A G 0.000652 Salmonella-induced pyroptosis / / 22837397 rs2971814 chr2 66431813 T C 0.0000817 Salmonella-induced pyroptosis / / 22837397 rs6728427 chr2 66449706 C G 7.65E-04 Type 2 diabetes / / 17463246 rs11896357 chr2 66454478 C T 2.75E-04 Type 2 diabetes / / 17463246 rs1565328 chr2 66498775 A G 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11689807 chr2 66504005 A G 3.31E-05 Brain lesion load / / 19010793 rs10166869 chr2 66536557 G T 6.54E-04 Multiple complex diseases / / 17554300 rs4414666 chr2 66537344 G T 2.02E-05 Suicide attempts in bipolar disorder / / 21423239 rs4588174 chr2 66537359 A G 4.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs2971834 chr2 66546314 A G 6.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs2969694 chr2 66548543 C G 4.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs6546221 chr2 66551522 C T 5.87E-04 Multiple complex diseases / / 17554300 rs2971826 chr2 66557236 C T 3.59E-04 Multiple complex diseases / / 17554300 rs1878944 chr2 66563484 T A 9.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs1878945 chr2 66563517 G T 9.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs2946371 chr2 66566690 A G 7.42E-04 Multiple complex diseases / / 17554300 rs2860235 chr2 66567896 T C 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1519111 chr2 66571467 C G 5.05E-04 Multiple complex diseases / / 17554300 rs1401453 chr2 66581403 A C 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2971811 chr2 66583690 G T 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1401451 chr2 66584645 C G 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10865352 chr2 66586934 C T 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs10211254 chr2 66591968 T A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2946370 chr2 66592411 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2222252 chr2 66592742 C T 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741807 chr2 66593273 G C 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10182624 chr2 66602521 T G 9.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1467229 chr2 66605631 T G 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs952203 chr2 66643773 A G 1.21E-04 Alzheimer's disease (late onset) / / 21379329 rs2049019 chr2 66671858 C A 8.13E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs11126079 chr2 66676367 G C 5.96E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs1519102 chr2 66677816 G C 8.47E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs1519103 chr2 66677881 G T 5.76E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs6716792 chr2 66687843 C A 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MEIS1 intron 20877124 rs6755563 chr2 66693328 T C 5.08E-04 Type 2 diabetes MEIS1 intron 17463246 rs6755563 chr2 66693328 T C 2.10E-04 Response to alcohol consumption (flushing response) MEIS1 intron 24277619 rs10203407 chr2 66698796 G A 7.66E-05 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs6730722 chr2 66703251 A G 8.69E-04 Alzheimer's disease MEIS1 intron 24755620 rs7595378 chr2 66705785 C A 7.04E-04 Alzheimer's disease MEIS1 intron 24755620 rs17032114 chr2 66714597 A G 1.27E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs17032119 chr2 66715272 T G 8.02E-05 Type 2 diabetes MEIS1 intron 17463246 rs12471916 chr2 66715364 T G 5.04E-04 Type 2 diabetes MEIS1 intron 17463246 rs7563565 chr2 66716592 C T 1.34E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs10166707 chr2 66719503 A G 8.89E-04 Alzheimer's disease MEIS1 intron 24755620 rs2139246 chr2 66721860 G A 3.08E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs12619205 chr2 66725867 G A 4.64E-04 Aspirin exacerbated respiratory disease in asthmatics MEIS1 intron 23180272 rs13023583 chr2 66725940 T C 6.84E-04 Aspirin exacerbated respiratory disease in asthmatics MEIS1 intron 23180272 rs4300815 chr2 66746532 C A 8.87E-09 PR segment MEIS1 intron 24850809 rs4430933 chr2 66749610 A G 3.11E-08 PR segment MEIS1 intron 24850809 rs6742861 chr2 66750152 T C 8.29E-09 PR segment MEIS1 intron 24850809 rs11677371 chr2 66756413 A G 5.60E-09 PR interval MEIS1 intron 21347284 rs11677371 chr2 66756413 A G 3.24E-08 PR segment MEIS1 intron 24850809 rs3891585 chr2 66756976 A G 4.89E-09 PR interval MEIS1 intron 21347284 rs3891585 chr2 66756976 A G 1.00E-11 PR interval MEIS1 intron 23139255 rs3891585 chr2 66756976 A G 2.30E-08 PR segment MEIS1 intron 24850809 rs11693646 chr2 66759843 G A 4.92E-09 PR segment MEIS1 intron 24850809 rs11678354 chr2 66760079 T A 5.00E-09 PR segment MEIS1 intron 24850809 rs4433986 chr2 66760311 A G 5.19E-09 PR interval MEIS1 intron 21347284 rs4433986 chr2 66760311 A G 3.07E-08 PR segment MEIS1 intron 24850809 rs7603236 chr2 66762411 C T 3.93E-09 PR interval MEIS1 intron 21347284 rs7603236 chr2 66762411 C T 4.10E-08 PR segment MEIS1 intron 24850809 rs12469063 chr2 66764308 A G 6.52E-12 Restless legs syndrome MEIS1 intron 17637780 rs10865355 chr2 66764997 A G 2.94E-09 PR interval MEIS1 intron 21347284 rs10865355 chr2 66764997 A G 4.51E-08 PR segment MEIS1 intron 24850809 rs17625724 chr2 66768975 G A 9.13E-09 PR segment MEIS1 intron 24850809 rs11678796 chr2 66770035 G A 1.06E-08 PR segment MEIS1 intron 24850809 rs11897119 chr2 66772000 T C 5.00E-11 PR interval MEIS1 intron 20062060 rs3772026 chr2 66779866 G A 2.14E-08 PR segment MEIS1 intron 24850809 rs2300478 chr2 66781453 T G 7.41E-04 Type 2 diabetes MEIS1 intron 17463246 rs2300478 chr2 66781453 T G 3.00E-28 Restless legs syndrome MEIS1 intron 17637780 rs2300478 chr2 66781453 T G 3.00E-49 Restless legs syndrome MEIS1 intron 21779176 rs12614369 chr2 66792109 A G 3.60E-05 Malaria MEIS1 intron 19465909 rs10195834 chr2 66827052 G A 5.47E-05 Elbow pain / / pha003008 rs2861113 chr2 66831411 C T 1.39E-05 Elbow pain / / pha003008 rs1981736 chr2 66836319 G A 1.40E-05 Elbow pain / / pha003008 rs6756458 chr2 66868074 C T 1.68E-05 Elbow pain / / pha003008 rs11695019 chr2 66878488 A G 3.32E-05 F-cell distribution / / 21326311 rs11695019 chr2 66878488 A G 9.77E-05 Triglycerides / / pha003081 rs9941639 chr2 66896718 G T 2.86E-05 Elbow pain / / pha003008 rs7593598 chr2 66900322 C T 1.10E-05 Elbow pain / / pha003008 rs6745277 chr2 66900737 G A 7.96E-06 Elbow pain / / pha003008 rs6751774 chr2 66907476 C T 2.84E-04 Type 2 diabetes / / 17463246 rs1468817 chr2 66916737 C T 2.99E-04 Birth weight / / 17255346 rs6705424 chr2 66936494 T C 9.49E-05 Weight / / pha003026 rs10490191 chr2 66937329 G A 5.53E-05 Body Mass Index / / pha003014 rs10490191 chr2 66937329 G A 7.75E-05 Weight / / pha003026 rs12622301 chr2 66950851 T C 1.93E-05 Body Mass Index / / pha003014 rs12622301 chr2 66950851 T C 4.79E-05 Waist Circumference / / pha003024 rs12622301 chr2 66950851 T C 2.29E-05 Weight / / pha003026 rs12622301 chr2 66950851 T C 9.61E-05 Cardiovascular disease / / pha003064 rs1111233 chr2 66956502 A G 7.33E-05 Waist Circumference / / pha003024 rs1111233 chr2 66956502 A G 7.38E-05 Weight / / pha003026 rs1111233 chr2 66956502 A G 8.88E-05 Weight / / pha003027 rs1111233 chr2 66956502 A G 2.44E-05 Cardiovascular disease / / pha003064 rs2901879 chr2 66966066 C T 7.00E-07 Colorectal cancer (diet interaction) / / 24743840 rs11126097 chr2 67007492 A T 9.66E-04 Multiple complex diseases / / 17554300 rs10168064 chr2 67008311 C T 8.92E-04 Multiple complex diseases / / 17554300 rs9309394 chr2 67008629 T C 9.29E-05 Sarcoidosis / / 19165924 rs2194659 chr2 67014761 C T 6.60E-05 Multiple complex diseases / / 17554300 rs2194659 chr2 67014761 C T 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2194659 chr2 67014761 C T 5.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13018425 chr2 67050752 T C 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs3919596 chr2 67060126 A C 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4671160 chr2 67060284 T A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1559600 chr2 67061154 A G 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6704842 chr2 67061235 T C 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747693 chr2 67061831 C T 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1559604 chr2 67067641 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4671750 chr2 67071459 C T 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1126147 chr2 67090833 G A 4.76E-04 Parkinson's disease / / 17052657 rs10519071 chr2 67144798 G T 7.81E-05 Alzheimer's disease (late onset) / / 21379329 rs1420369 chr2 67155259 A G 5.66E-04 Premature ovarian failure / / 19508998 rs12471464 chr2 67204642 T C 1.74E-05 Major depressive disorder / / 20516156 rs1362486 chr2 67208563 C A 0.0000277 Tuberculosis with late age of onset / / 22551897 rs1362475 chr2 67258675 A G 5.84E-05 Myopia (severe) / / 23933737 rs10519086 chr2 67262646 T G 9.15E-05 Alzheimer's disease / / 22005930 rs13016756 chr2 67265594 C T 2.50E-05 Urinary metabolites / / 21572414 rs12619502 chr2 67266506 T C 1.69E-04 Alzheimer's disease / / 22005930 rs746784 chr2 67271291 A G 5.19E-04 Smoking cessation / / 24665060 rs990255 chr2 67279175 A C 4.69E-04 Depression (quantitative trait) / / 20800221 rs7594674 chr2 67279960 G A 6.50E-04 Neuroticism / / 17667963 rs7594674 chr2 67279960 G A 4.01E-04 Smoking cessation / / 24665060 rs17032937 chr2 67280371 A G 5.80E-04 Multiple complex diseases / / 17554300 rs11676618 chr2 67282576 G T 8.41E-06 Periodontitis (CDC/AAP) / / 24024966 rs2861317 chr2 67290263 G A 7.63E-06 Periodontitis (CDC/AAP) / / 24024966 rs17032961 chr2 67290698 A G 4.34E-04 Depression (quantitative trait) / / 20800221 rs10179160 chr2 67291715 T C 8.57E-05 Platelet counts / / pha003100 rs1420365 chr2 67294779 C T 4.81E-05 Hypertension / / pha003042 rs1833219 chr2 67297409 A C 8.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs17032968 chr2 67298283 C T 7.94E-04 Multiple complex diseases / / 17554300 rs4671772 chr2 67299855 G A 6.73E-05 Type 2 diabetes / / 17463246 rs17032971 chr2 67299931 C T 7.89E-04 Multiple complex diseases / / 17554300 rs13405122 chr2 67302866 C T 7.57E-05 Cognitive test performance / / 20125193 rs17033002 chr2 67305081 G T 4.52E-04 Depression (quantitative trait) / / 20800221 rs3821130 chr2 67307202 T C 4.53E-04 Depression (quantitative trait) / / 20800221 rs752939 chr2 67311169 G T 4.53E-04 Depression (quantitative trait) / / 20800221 rs752938 chr2 67311224 C G 4.53E-04 Depression (quantitative trait) / / 20800221 rs6741648 chr2 67313661 G A 4.53E-04 Depression (quantitative trait) / / 20800221 rs10196486 chr2 67323400 A G 5.69E-05 Blood Pressure / / pha003047 rs17033084 chr2 67332744 G C 3.86E-04 Depression (quantitative trait) / / 20800221 rs1921291 chr2 67340471 T C 7.82E-05 Blood Pressure / / pha003047 rs11897312 chr2 67340843 C T 1.39E-04 Type 2 diabetes / / 17463246 rs1921290 chr2 67341817 G T 8.76E-05 Blood Pressure / / pha003047 rs6721279 chr2 67368780 C T 7.21E-04 Smoking cessation LOC644838 intron 24665060 rs7600464 chr2 67381644 C T 7.60E-05 Hypertension LOC644838 intron pha003042 rs10199442 chr2 67387721 C A 2.12E-04 Smoking cessation LOC644838 intron 24665060 rs13403463 chr2 67402182 G A 1.11E-04 Blood pressure LOC644838 intron 17255346 rs13004577 chr2 67404326 A G 2.47E-04 Alzheimer's disease LOC644838 intron 17998437 rs13004577 chr2 67404326 A G 2.90E-06 Urinary metabolites LOC644838 intron 21572414 rs10183986 chr2 67438040 G A 8.21E-05 Cognitive performance LOC644838 intron 19734545 rs875037 chr2 67456700 T C 1.27E-04 Blood pressure / / 17255346 rs1483342 chr2 67467982 T C 1.52E-05 Blood pressure / / 17255346 rs2062204 chr2 67472545 A C 3.79E-05 Blood pressure / / 17255346 rs13012056 chr2 67472630 G A 1.06E-06 Kawasaki disease / / 21221998 rs17601386 chr2 67476026 G A 1.29E-04 Blood pressure / / 17255346 rs17033369 chr2 67506724 T C 1.60E-08 Non-obstructive azoospermia / / 22541561 rs12053284 chr2 67518237 G A 2.20E-05 Urinary metabolites / / 21572414 rs12713595 chr2 67523685 G A 1.65E-05 Blood pressure / / 17255346 rs10865359 chr2 67525436 A G 1.50E-05 Urinary metabolites / / 21572414 rs7572809 chr2 67539226 G A 9.94E-04 Depression (quantitative trait) / / 20800221 rs2128769 chr2 67542454 T C 7.88E-05 Blood pressure / / 17255346 rs6739392 chr2 67601971 A T 4.00E-06 Waist-hip ratio / / 23966867 rs2035565 chr2 67619656 C T 5.46E-07 Pancreatic cancer / / 22158540 rs6740919 chr2 67620055 C G 5.17E-05 Pulmonary function / / 17903307 rs13036061 chr2 67630476 T C 3.07E-04 Heart Failure ETAA1 missense pha002885 rs632647 chr2 67668847 G A 1.00E-04 Information processing speed / / 21130836 rs600524 chr2 67673780 G A 3.09E-04 Obesity (extreme) / / 21935397 rs600579 chr2 67673823 A T 3.12E-04 Obesity (extreme) / / 21935397 rs650129 chr2 67673930 C G 6.30E-04 Obesity (extreme) / / 21935397 rs12470994 chr2 67674506 C A 5.01E-04 Smoking initiation / / 24665060 rs13033289 chr2 67674538 A G 9.10E-04 Myocardial Infarction / / pha002883 rs6756612 chr2 67711468 A G 0.000203442 Hypertension (early onset hypertension) / / 22479346 rs1521043 chr2 67716030 T G 0.0002678 Hypertension (early onset hypertension) / / 22479346 rs4089733 chr2 67717239 A G 0.000113157 Hypertension (early onset hypertension) / / 22479346 rs7584345 chr2 67718290 C T 0.000408443 Hypertension (early onset hypertension) / / 22479346 rs17606508 chr2 67718362 T C 6.16E-09 Metabolite levels / / 23281178 rs17033681 chr2 67723565 A G 0.00089507 Hypertension (early onset hypertension) / / 22479346 rs1357011 chr2 67737672 A C 8.01E-05 HIV-1 viral setpoint / / 17641165 rs10490718 chr2 67744258 G T 4.09E-04 Type 2 diabetes / / 17463246 rs6739215 chr2 67749650 G A 4.00E-04 Primary sclerosing cholangitis / / 19944697 rs17033724 chr2 67751727 G A 8.03E-04 Multiple complex diseases / / 17554300 rs1607905 chr2 67757721 C G 2.20E-05 Urinary metabolites / / 21572414 rs2683687 chr2 67758663 A G 5.94E-04 Type 2 diabetes / / 17463246 rs2683687 chr2 67758663 A G 6.43E-04 HIV-1 viral setpoint / / 17641165 rs6546313 chr2 67771628 A C 3.10E-04 Primary sclerosing cholangitis / / 19944697 rs2861638 chr2 67776518 A C 4.50E-04 Endometriosis / / 21151130 rs13005138 chr2 67800265 G C 1.70E-05 Urinary metabolites / / 21572414 rs12997331 chr2 67804851 G C 2.80E-05 Urinary metabolites / / 21572414 rs41407847 chr2 67804935 G A 7.48E-04 Multiple complex diseases / / 17554300 rs12620828 chr2 67806472 A G,T 4.52E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17033861 chr2 67828078 G A 1.53E-04 Coronary heart disease / / 21606135 rs13398112 chr2 67828614 T C 2.09E-04 Coronary heart disease / / 21606135 rs17034013 chr2 67863024 T C 2.76E-04 Multiple complex diseases / / 17554300 rs1367477 chr2 67864013 A G 8.31E-04 Multiple complex diseases / / 17554300 rs980226 chr2 67864313 G T 1.30E-05 Urinary metabolites / / 21572414 rs9309401 chr2 67864597 C T 7.69E-04 Multiple complex diseases / / 17554300 rs4141819 chr2 67864675 C T 9.00E-08 Endometriosis / / 23104006 rs10490726 chr2 67866542 G A 1.11E-05 Calcium levels / / pha003085 rs7572685 chr2 67870225 C T 7.11E-04 Multiple complex diseases / / 17554300 rs12476951 chr2 67880148 C T 9.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs4671821 chr2 67890323 T C 8.20E-05 HIV-1 control / / 20041166 rs4671825 chr2 67908846 T C 1.68E-05 Bipolar disorder / / 19488044 rs4671825 chr2 67908846 T C 8.68E-05 Bipolar disorder and schizophrenia / / 20889312 rs4671826 chr2 67908949 C T 7.90E-06 Bipolar disorder / / 19488044 rs4671826 chr2 67908949 C T 6.60E-05 HIV-1 control / / 20041166 rs4671826 chr2 67908949 C T 2.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs9309403 chr2 67911513 A G 3.90E-05 HIV-1 control / / 20041166 rs11675008 chr2 67916875 A G 3.56E-05 Major depressive disorder (broad) / / 20038947 rs11692071 chr2 67916928 T G 2.66E-05 Major depressive disorder (broad) / / 20038947 rs4671836 chr2 67918196 A G 2.58E-05 Major depressive disorder (broad) / / 20038947 rs10165761 chr2 67919554 T C 1.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs1978657 chr2 67919897 C T 9.62E-06 Bipolar disorder and schizophrenia / / 20889312 rs4671839 chr2 67920930 T C 8.68E-05 Major depressive disorder (broad) / / 20038947 rs10169649 chr2 67921037 T A 5.69E-05 Major depressive disorder (broad) / / 20038947 rs4671840 chr2 67921216 A G 5.17E-05 Major depressive disorder (broad) / / 20038947 rs4671840 chr2 67921216 A G 0.000033 Major depressive disorder / / 23149448 rs4671841 chr2 67921411 A C 1.35E-05 Major depressive disorder (broad) / / 20038947 rs6735177 chr2 67924370 C A 1.10E-05 Iron levels / / 21208937 rs1367467 chr2 67932298 A G 1.30E-05 Major depressive disorder (broad) / / 20038947 rs989720 chr2 67932740 T C 1.48E-05 Major depressive disorder (broad) / / 20038947 rs1430770 chr2 67933079 G A 1.25E-05 Major depressive disorder (broad) / / 20038947 rs1430771 chr2 67933177 C G 4.64E-05 Major depressive disorder (broad) / / 20038947 rs13403823 chr2 67939457 C T 5.58E-06 Major depressive disorder (broad) / / 20038947 rs724566 chr2 67942202 T C 3.36E-05 Personality dimensions / / 22628180 rs724568 chr2 67942480 C A 5.00E-06 Major depressive disorder (broad) / / 20038947 rs17034213 chr2 67945022 A G 7.80E-06 Urinary metabolites / / 21572414 rs4671842 chr2 67945371 T C 7.87E-05 Major depressive disorder (broad) / / 20038947 rs1367458 chr2 67946328 C T 8.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs10865363 chr2 67946891 C T 6.96E-06 Major depressive disorder (broad) / / 20038947 rs737358 chr2 67950632 G A 6.61E-06 Major depressive disorder (broad) / / 20038947 rs737359 chr2 67950714 C T 9.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs934311 chr2 67950790 A G 3.70E-04 Hearing function / / 17255346 rs4671197 chr2 67952811 T C 7.97E-05 Major depressive disorder (broad) / / 20038947 rs4671197 chr2 67952811 T C 2.96E-04 Epilepsy / / 22116939 rs6758822 chr2 67956823 T C 7.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12477687 chr2 67957066 C T 5.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs13432159 chr2 67973887 T G 9.00E-08 Response to antidepressant treatment / / 22041458 rs6724422 chr2 67976788 C T 1.90E-05 Urinary metabolites / / 21572414 rs6724422 chr2 67976788 C T 4.00E-07 Response to antidepressant treatment / / 22041458 rs12713602 chr2 67977997 A G 3.28E-05 Coronary heart disease / / pha003056 rs17034385 chr2 68003307 T C 1.89E-04 Lung function (forced vital capacity) / / 24023788 rs17616984 chr2 68022793 C T 3.13E-05 White matter integrity / / 22425255 rs1346866 chr2 68024446 G A 7.89E-04 Insulin resistance / / 21901158 rs11126158 chr2 68031007 G C 5.16E-04 Insulin resistance / / 21901158 rs6715551 chr2 68035962 T C 2.84E-04 Parkinson's disease / / 17052657 rs6747972 chr2 68070225 A G 9.00E-11 Restless legs syndrome / / 21779176 rs17034461 chr2 68088399 C A 7.75E-04 Multiple complex diseases / / 17554300 rs1910370 chr2 68095097 G A 7.78E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17034538 chr2 68100458 C T 2.30E-05 Gaucher disease severity / / 22388998 rs17034763 chr2 68204413 C T 3.77E-04 Alcohol dependence / / 24277619 rs1921592 chr2 68207810 C A 3.94E-05 Cognitive test performance / / 20125193 rs974366 chr2 68214370 C T 5.46E-05 Cognitive test performance / / 20125193 rs6546347 chr2 68219788 G C 1.90E-04 Multiple complex diseases / / 17554300 rs1921589 chr2 68223525 G A 7.30E-05 Myopia (pathological) / / 21095009 rs1503244 chr2 68224343 T C 2.46E-04 Iron levels / / pha002876 rs17034837 chr2 68235872 G T 7.95E-04 Multiple complex diseases / / 17554300 rs146109287 chr2 68237913 T C 2.00E-07 Age-related nuclear cataracts / / 24951543 rs1921586 chr2 68241345 A G 1.49E-04 Myopia (pathological) / / 21095009 rs7558466 chr2 68250296 G T 8.58E-04 Iron levels / / pha002876 rs11681944 chr2 68322579 G A 0.0000328 Antithrombin / / 23705025 rs17034987 chr2 68338613 G A 3.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1075454 chr2 68342443 T C 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4078978 chr2 68359897 C T 2.00E-18 Immune reponse to smallpox (secreted IFN-alpha) WDR92 intron 22610502 rs6546357 chr2 68379038 G A 4.85E-05 Lymphocyte counts WDR92 intron 22286170 rs78556816 chr2 68386026 C T 1.00E-06 PR interval in Tripanosoma cruzi seropositivity PNO1 intron 24324551 rs6733029 chr2 68434157 T C 3.70E-04 Pulmonary function PPP3R1 intron 23932459 rs1822469 chr2 68454685 C T 9.00E-05 Height PPP3R1 intron 21194676 rs1822469 chr2 68454685 C T 9.30E-07 Height PPP3R1 intron 21194676 rs41427451 chr2 68492037 C T 5.42E-06 White blood cell count / / 21738479 rs2120335 chr2 68495002 G A 4.11E-05 Bipolar disorder / / 20451256 rs6546367 chr2 68495243 G A 4.27E-05 Bipolar disorder / / 20451256 rs10188159 chr2 68526730 T A 1.40E-04 Smoking initiation CNRIP1 intron 24665060 rs13025842 chr2 68546449 G A 5.72E-05 Coronary heart disease CNRIP1 cds-synon pha003030 rs9309413 chr2 68570772 G C,T 2.00E-09 Metabolite levels / / 19043545 rs7578047 chr2 68579931 A G 4.00E-06 Anger / / 24489884 rs7563924 chr2 68589234 T C 3.39E-04 Type 2 diabetes / / 17463246 rs17035378 chr2 68598955 T C 8.00E-09 Celiac disease PLEK intron 20190752 rs17035378 chr2 68598955 T C 8.00E-09 Asthma PLEK intron 21150878 rs17035378 chr2 68598955 T C 7.79E-09 Celiac disease and Rheumatoid arthritis PLEK intron 21383967 rs17035378 chr2 68598955 T C 7.79E-09 Multiple sclerosis PLEK intron 22190364 rs34515106 chr2 68607978 A C 0.000000215 Triglycerides PLEK missense 23063622 rs34515106 chr2 68607978 A C 0.000000467 Cholesterol,total PLEK missense 23063622 rs140933780 chr2 68613681 C T 0.00013 Prostate cancer (advanced) PLEK missense 23555315 rs6750761 chr2 68618216 G C 1.50E-04 Type 2 diabetes and 6 quantitative traits PLEK intron 17848626 rs10178792 chr2 68643625 T A 7.02E-04 Smoking cessation / / 24665060 rs10167650 chr2 68645560 T G 1.30E-04 Celiac disease / / 22057235 rs7592330 chr2 68646783 G A 2.00E-07 Multiple sclerosis / / 22190364 rs7595037 chr2 68647095 C T 5.00E-11 Multiple sclerosis / / 21833088 rs7595037 chr2 68647095 C T 1.60E-05 Multiple sclerosis / / 24234648 rs7602709 chr2 68649298 C T 8.38E-04 Multiple complex diseases / / 17554300 rs6759808 chr2 68650997 G A 4.00E-06 Obesity-related traits / / 23251661 rs11126184 chr2 68652174 C A 0.00000141 Obstructive sleep apnea / / 23155414 rs11126185 chr2 68652580 G A 5.00E-06 Obesity-related traits / / 23251661 rs7421154 chr2 68665945 C T 2.73E-04 Alzheimer's disease / / 22005930 rs7420089 chr2 68758389 C T 2.27E-05 Type 1 diabetes APLF intron 21980299 rs7560955 chr2 68770276 A G 7.50E-06 Urinary metabolites APLF intron 21572414 rs10193445 chr2 68804125 T A 2.10E-05 Urinary metabolites APLF intron 21572414 rs7593112 chr2 68808208 T C 2.00E-05 Urinary metabolites / / 21572414 rs12988094 chr2 68822422 T A 2.10E-05 Urinary metabolites / / 21572414 rs10179623 chr2 68823305 C G 2.80E-05 Urinary metabolites / / 21572414 rs7576538 chr2 68950454 A G 9.43E-04 Multiple complex diseases / / 17554300 rs7593402 chr2 68972726 G A 9.98E-04 Rheumatoid arthritis ARHGAP25 intron 21452313 rs4068868 chr2 68976604 G T 7.38E-04 Type 2 diabetes ARHGAP25 intron 17463246 rs13032797 chr2 69001171 C T 0.00000391 LDL cholesterol particle diameter ARHGAP25 intron 23263444 rs2311412 chr2 69010557 T C 1.70E-06 Urinary metabolites ARHGAP25 intron 21572414 rs11677065 chr2 69013007 T C 4.40E-05 Multiple complex diseases ARHGAP25 intron 17554300 rs11694733 chr2 69013166 C T 1.54E-04 Multiple complex diseases ARHGAP25 intron 17554300 rs11694785 chr2 69013251 C T 3.16E-04 Multiple complex diseases ARHGAP25 intron 17554300 rs7558602 chr2 69024789 T C 8.25E-05 HDL cholesterol ARHGAP25 intron pha003074 rs115522963 chr2 69033583 C T 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ARHGAP25 intron 24159190 rs6743599 chr2 69036054 A G 6.33E-04 Type 2 diabetes ARHGAP25 intron 17463246 rs6743599 chr2 69036054 A G 5.43E-04 Response to taxane treatment (placlitaxel) ARHGAP25 intron 23006423 rs6707620 chr2 69058599 G C 4.29E-04 Multiple complex diseases / / 17554300 rs10496166 chr2 69063909 G A 4.00E-06 RR interval (heart rate) / / 20031603 rs4605401 chr2 69111016 T C 7.30E-04 Primary sclerosing cholangitis / / 19944697 rs6747865 chr2 69154946 G A 6.06E-04 Alzheimer's disease / / 22005930 rs2871928 chr2 69155271 A G 8.66E-04 Alzheimer's disease / / 22005930 rs4254535 chr2 69198388 T C 7.05E-06 Lung cancer / / 18978787 rs4254535 chr2 69198388 T C 5.00E-06 Lung cancer / / 19654303 rs4254535 chr2 69198388 T C 5.00E-06 Nasopharyngeal carcinoma / / 20512145 rs7586849 chr2 69199829 G A,T 5.90E-04 Multiple complex diseases / / 17554300 rs4462818 chr2 69208302 T G 6.45E-05 Tunica Media / / pha003034 rs4462818 chr2 69208302 T G 9.29E-05 Tunica Media / / pha003037 rs4462818 chr2 69208302 T G 7.56E-06 Serum albumin level / / pha003084 rs6716266 chr2 69245228 T G 1.00E-08 Asthma (childhood onset) ANTXR1 intron 17611496 rs4366940 chr2 69267134 G A 1.20E-05 Response to statin therapy ANTXR1 intron 20339536 rs12465132 chr2 69269894 G A 3.20E-05 Response to statin therapy ANTXR1 intron 20339536 rs12465994 chr2 69270261 G A 2.00E-05 Response to statin therapy ANTXR1 intron 20339536 rs11126214 chr2 69272116 C T 1.60E-05 Response to statin therapy ANTXR1 intron 20339536 rs11900784 chr2 69272496 A T 0.00000309 Nicotine dependence (smoking) ANTXR1 intron 23542338 rs7579629 chr2 69282532 C G 2.70E-05 Response to statin therapy ANTXR1 intron 20339536 rs12464309 chr2 69284111 G T 5.40E-05 Response to statin therapy ANTXR1 intron 20339536 rs4315565 chr2 69287943 A G 1.00E-08 Height ANTXR1 intron 21998595 rs12473368 chr2 69292224 G C 5.60E-05 Response to statin therapy ANTXR1 intron 20339536 rs1106518 chr2 69328218 G A 5.67E-05 Asthma ANTXR1 intron 23181788 rs6710260 chr2 69330118 A G 6.64E-04 Obesity (extreme) ANTXR1 intron 21935397 rs6710260 chr2 69330118 A G 0.000262779 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs6710260 chr2 69330118 A G 2.53E-05 Age-related macular degeneration ANTXR1 intron pha002856 rs4241349 chr2 69330284 G A 9.91E-04 Obesity (extreme) ANTXR1 intron 21935397 rs4241349 chr2 69330284 G A 3.26E-05 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs10179227 chr2 69330445 A G 0.000266695 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs12611797 chr2 69333577 G T 0.0001658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANTXR1 intron 23233654 rs12611797 chr2 69333577 G T 1.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANTXR1 intron 23233662 rs11689690 chr2 69334220 C T 0.0001679 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANTXR1 intron 23233654 rs11689690 chr2 69334220 C T 1.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANTXR1 intron 23233662 rs7564112 chr2 69343149 C T 1.53E-04 Obesity (extreme) ANTXR1 intron 21935397 rs13026824 chr2 69349219 G C 3.76E-04 Fibrinogen ANTXR1 intron 17255346 rs4358156 chr2 69354700 T C 2.49E-04 Fibrinogen ANTXR1 intron 17255346 rs13016276 chr2 69391521 T G 7.21E-05 Fibrinogen ANTXR1 intron 17255346 rs7599536 chr2 69396953 A G 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANTXR1 intron 20877124 rs10182789 chr2 69410325 T G 8.40E-05 Heart Rate ANTXR1 intron pha003051 rs10189815 chr2 69414496 A G 1.89E-04 Fibrinogen ANTXR1 intron 17255346 rs4464317 chr2 69437291 C T 5.80E-06 Menarche (age at onset) ANTXR1 intron 19282985 rs4464317 chr2 69437291 C T 6.17E-05 Cortisol secretion,in saliva ANTXR1 intron 21316860 rs4384823 chr2 69437475 C T 8.26E-06 Menarche (age at onset) ANTXR1 intron 19282985 rs4484064 chr2 69444521 C T 8.19E-04 Type 2 diabetes ANTXR1 intron 17463246 rs4365492 chr2 69446251 G A 8.22E-04 Type 2 diabetes ANTXR1 intron 17463246 rs4365492 chr2 69446251 G A 5.67E-04 Multiple complex diseases ANTXR1 intron 17554300 rs11887039 chr2 69486729 G A 5.86E-04 Multiple complex diseases / / 17554300 rs6546493 chr2 69489816 A G 5.91E-04 Depression (quantitative trait) / / 20800221 rs4128633 chr2 69498192 C T 1.09E-05 Multiple complex diseases / / 17554300 rs13399511 chr2 69619363 C T 7.72E-04 Smoking initiation / / 24665060 rs10496170 chr2 69707752 A G 7.07E-04 Bipolar disorder AAK1 intron 19259986 rs41320747 chr2 69716915 G T 8.51E-04 Multiple complex diseases AAK1 intron 17554300 rs7577851 chr2 69723710 C T 9.00E-06 Parkinson's disease (age of onset) AAK1 intron 19772629 rs3771543 chr2 69784255 C T 4.30E-04 Smoking initiation AAK1 intron 24665060 rs13431612 chr2 69800579 T C 4.47E-04 Response to taxane treatment (placlitaxel) AAK1 intron 23006423 rs12987661 chr2 69813458 T C 6.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) AAK1 intron 23934736 rs2312215 chr2 69839825 T A 7.59E-04 Diabetic retinopathy AAK1 intron 20871662 rs6721715 chr2 69910110 A G 3.30E-04 Acute lung injury / / 22295056 rs12620484 chr2 69918942 A G 3.10E-04 Acute lung injury / / 22295056 rs12620484 chr2 69918942 A G 3.43E-05 Erythrocyte counts / / pha003099 rs35907069 chr2 69940780 G A 3.05E-04 Alzheimer's disease / / 22005930 rs6726789 chr2 69942011 A C 3.75E-05 Odorant perception / / 23910658 rs7597155 chr2 69985435 G A 5.00E-06 Palmitoleic acid (16:1n-7) plasma levels ANXA4 intron 23362303 rs13412112 chr2 69990290 T G 3.89E-05 Lung function (forced expiratory volume in 1 second) ANXA4 intron 24023788 rs721566 chr2 70013733 A G 2.06E-04 Smoking initiation ANXA4 intron 24665060 rs10496171 chr2 70015181 C T 9.94E-04 Multiple complex diseases ANXA4 intron 17554300 rs2228203 chr2 70033584 C T 6.10E-05 Smoking initiation ANXA4 missense 24665060 rs17037076 chr2 70033649 G A 3.50E-05 Smoking initiation ANXA4 intron 24665060 rs2124009 chr2 70034465 G C 9.08E-05 Smoking initiation ANXA4 intron 24665060 rs10173964 chr2 70043387 C T 2.00E-04 Multiple complex diseases ANXA4 intron 17554300 rs2290452 chr2 70047644 G A 1.94E-04 Smoking initiation ANXA4 intron 24665060 rs146778617 chr2 70052624 G T 0.000006 Prostate cancer ANXA4 missense 23555315 rs146778617 chr2 70052624 G T 0.000034 Prostate cancer (non-advanced prostate cancer) ANXA4 missense 23555315 rs7572381 chr2 70055042 T G 1.19E-04 Multiple complex diseases / / 17554300 rs2278933 chr2 70056365 A C 7.98E-05 Smoking initiation / / 24665060 rs4420721 chr2 70063527 C T 1.98E-04 Smoking initiation GMCL1 intron 24665060 rs17037145 chr2 70072464 A G 2.04E-04 Multiple complex diseases GMCL1 intron 17554300 rs17037193 chr2 70103504 T C 3.15E-04 Smoking initiation GMCL1 intron 24665060 rs2124007 chr2 70107409 A G 1.60E-04 Smoking initiation / / 24665060 rs7588986 chr2 70108071 C T 1.10E-04 Multiple complex diseases / / 17554300 rs1056482 chr2 70108256 T A 8.26E-05 Serum metabolites / / 19043545 rs2054046 chr2 70117074 T C 2.35E-05 Smoking initiation / / 24665060 rs10205487 chr2 70151471 A G 5.02E-04 Multiple sclerosis MXD1 intron 17660530 rs6731423 chr2 70173327 A C 1.85E-05 Erythrocyte counts / / pha003099 rs7583236 chr2 70182805 T C 4.00E-06 Obesity-related traits / / 23251661 rs140244507 chr2 70187809 G A 0.000093 Breast cancer ASPRV1 missense 23555315 rs116939658 chr2 70213304 C T 2.76E-05 Atopic dermatitis PCBP1-AS1 intron 23042114 rs117950954 chr2 70291839 G A 5.25E-05 Atopic dermatitis PCBP1-AS1 intron 23042114 rs6708331 chr2 70368923 G A 6.00E-06 Obesity-related traits / / 23251661 rs11677137 chr2 70389900 A G 1.80E-05 Urinary metabolites C2orf42 intron 21572414 rs7568216 chr2 70416197 C T 3.66E-05 HIV-1 viral setpoint C2orf42 intron 22174851 rs6750410 chr2 70417730 A G 4.84E-05 HIV-1 viral setpoint C2orf42 intron 22174851 rs7589857 chr2 70418339 T C 2.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs7575953 chr2 70418368 C G 2.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs11694045 chr2 70419373 T G 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11690691 chr2 70426325 C T 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs10210930 chr2 70429805 C T 4.47E-04 Coronary heart disease / / 21606135 rs1059408 chr2 70436818 C T 9.48E-04 Type 2 diabetes TIA1 UTR-3 17463246 rs2289920 chr2 70442792 T C 2.86E-04 Multiple complex diseases TIA1 intron 17554300 rs6546578 chr2 70493210 T C 6.47E-05 Lipid levels PCYOX1 intron 19913121 rs6546579 chr2 70493282 G T 7.84E-05 Lipid levels PCYOX1 intron 19913121 rs6751173 chr2 70505908 G A 3.53E-04 Coronary heart disease PCYOX1 UTR-3 21606135 rs14234 chr2 70524142 A G 7.26E-05 Lymphocyte counts FAM136A UTR-3 22286170 rs13399467 chr2 70545542 C G 4.57E-04 Coronary heart disease / / 21606135 rs6751950 chr2 70560939 C T 2.16E-05 Brain structure / / 22504417 rs4852161 chr2 70562650 T C 1.40E-05 Brain structure / / 22504417 rs13394815 chr2 70564002 C A 9.21E-05 Multiple complex diseases / / 17554300 rs13394815 chr2 70564002 C A 2.38E-06 Brain structure / / 22504417 rs17654413 chr2 70572108 T C 9.05E-04 Type 2 diabetes / / 17463246 rs1871238 chr2 70574318 G T 1.86E-04 Brain structure / / 22504417 rs1478644 chr2 70576997 A G 7.44E-05 Brain structure / / 22504417 rs17615746 chr2 70579074 A G 5.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11690566 chr2 70581314 C T 6.74E-04 Multiple complex diseases / / 17554300 rs1551951 chr2 70596291 C T 1.07E-04 Parkinson's disease / / 21248740 rs4852569 chr2 70639236 A G 9.00E-05 Smoking initiation / / 24665060 rs1904212 chr2 70639877 T G 3.53E-04 Smoking initiation / / 24665060 rs6546600 chr2 70640522 T C 3.53E-04 Smoking initiation / / 24665060 rs6546602 chr2 70640754 C T 3.69E-04 Smoking initiation / / 24665060 rs12713695 chr2 70641028 C T 2.83E-04 Smoking initiation / / 24665060 rs4852573 chr2 70642013 C A 3.57E-04 Smoking initiation / / 24665060 rs6546604 chr2 70642807 G A 6.77E-04 Multiple complex diseases / / 17554300 rs6724948 chr2 70643919 G C 1.99E-04 Smoking initiation / / 24665060 rs3911081 chr2 70648684 A G 9.50E-05 Glioma (high-grade) / / 19578366 rs509664 chr2 70655613 G A 8.52E-04 Alzheimer's disease / / 22005930 rs494537 chr2 70659116 G A 8.44E-04 Alzheimer's disease / / 22005930 rs2461861 chr2 70664385 G A 8.63E-04 Alzheimer's disease / / 22005930 rs187293906 chr2 70665662 C T 5.00E-06 Acne (severe) / / 24927181 rs2461522 chr2 70665675 A G 9.37E-04 Alzheimer's disease / / 22005930 rs473698 chr2 70675581 C G 9.81E-04 Alzheimer's disease TGFA UTR-3 22005930 rs538118 chr2 70676639 A G 9.67E-04 Alzheimer's disease TGFA UTR-3 22005930 rs10172814 chr2 70680950 A G 0.00018 Coronary artery calcification TGFA intron 23727086 rs2278791 chr2 70683753 T C 0.0005 Coronary artery calcification TGFA intron 23727086 rs6749533 chr2 70691766 T C 4.36E-04 Smoking cessation TGFA intron 24665060 rs3771514 chr2 70697667 G A 8.00E-06 Obesity-related traits TGFA intron 23251661 rs3771512 chr2 70697720 C A 3.10E-04 Type 2 diabetes TGFA intron 17463246 rs3771502 chr2 70717507 A G 0.0000449 Polycystic ovary syndrome TGFA intron 22951595 rs3771502 chr2 70717507 A G 4.49E-05 Intracranial aneurysm TGFA intron 22961961 rs3911080 chr2 70719919 G A 1.00E-04 Cognitive impairment induced by topiramate TGFA intron 22091778 rs404420 chr2 70733526 T C 7.39E-04 Type 2 diabetes TGFA intron 17463246 rs7582571 chr2 70733788 A C 7.25E-05 Multiple complex diseases TGFA intron 17554300 rs454305 chr2 70736219 A G 5.00E-06 Neutrophil count TGFA intron 21507922 rs10198315 chr2 70742173 T G 5.76E-04 Multiple complex diseases TGFA intron 17554300 rs4521071 chr2 70743939 T C 5.75E-04 Multiple complex diseases TGFA intron 17554300 rs13393308 chr2 70744323 C T 1.60E-04 Multiple complex diseases TGFA intron 17554300 rs428225 chr2 70759161 T C 2.00E-04 Information processing speed TGFA intron 21130836 rs432203 chr2 70764688 C A 1.00E-06 Longevity TGFA intron 20834067 rs4852650 chr2 70775085 A G 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TGFA intron 20877124 rs17040266 chr2 70789532 A C 3.80E-04 Multiple complex diseases / / 17554300 rs2215021 chr2 70796257 A G 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2190649 chr2 70796476 C T 2.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3915035 chr2 70801709 G A 3.29E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs382925 chr2 70806369 C T 5.62E-04 Fibrinogen / / 17255346 rs17005910 chr2 70809246 C T 5.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11680093 chr2 70810066 C T 1.54E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11680093 chr2 70810066 C T 3.87E-04 Iron levels / / pha002876 rs2108482 chr2 70825461 C T 2.92E-05 Sudden cardiac arrest / / 21658281 rs11678699 chr2 70830411 T C 2.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2902451 chr2 70857059 T G 2.00E-05 Urinary metabolites / / 21572414 rs11903517 chr2 70865531 G T 7.06E-04 Multiple complex diseases / / 17554300 rs740389 chr2 70896100 A T 1.60E-05 Urinary metabolites ADD2 intron 21572414 rs740390 chr2 70897322 A G 3.30E-06 Urinary metabolites ADD2 intron 21572414 rs6750771 chr2 70901548 G A 3.30E-06 Urinary metabolites ADD2 intron 21572414 rs12470211 chr2 70912868 G A 3.53E-04 Alzheimer's disease ADD2 intron 22005930 rs11682965 chr2 70933659 T A 6.14E-04 Alzheimer's disease ADD2 intron 22005930 rs17006175 chr2 70941813 C G 4.33E-05 Receptive language ability ADD2 intron 24687471 rs3755369 chr2 70942964 G A 5.23E-05 Receptive language ability ADD2 intron 24687471 rs3771450 chr2 70943138 T G 1.84E-04 Alzheimer's disease ADD2 intron 22005930 rs3771449 chr2 70943418 A G 1.71E-04 Alzheimer's disease ADD2 intron 22005930 rs7597774 chr2 70943850 A C 2.05E-07 Dilated cardiomyopathy ADD2 intron 20975947 rs3755368 chr2 70944349 T C 2.56E-04 Alzheimer's disease ADD2 intron 22005930 rs3755365 chr2 70944565 A G 5.26E-04 Alzheimer's disease ADD2 intron 22005930 rs2052273 chr2 70944880 A G 3.47E-04 Amyotrophic lateral sclerosis (sporadic) ADD2 intron 24529757 rs3755361 chr2 70945251 T C 2.43E-04 Alzheimer's disease ADD2 intron 22005930 rs3771439 chr2 70949766 T A 1.98E-05 Serum metabolites ADD2 intron 19043545 rs3771434 chr2 70951723 C T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADD2 intron 20877124 rs7584508 chr2 70952091 C A 1.28E-05 Lipoproteins ADD2 intron pha003079 rs1014592 chr2 70953985 G C 9.60E-04 Alzheimer's disease ADD2 intron 22005930 rs2192969 chr2 70956939 T C 9.59E-04 Alzheimer's disease ADD2 intron 22005930 rs3771426 chr2 70957503 A G 8.00E-05 Hypertension ADD2 intron 18003638 rs3771424 chr2 70958885 C T 4.06E-04 Smoking initiation ADD2 intron 24665060 rs3755353 chr2 70959327 G A 1.77E-06 Testicular cancer ADD2 intron 19483682 rs3771423 chr2 70959750 A G 8.00E-04 Alzheimer's disease ADD2 intron 22005930 rs3771412 chr2 70965438 A T 7.74E-04 Alzheimer's disease ADD2 intron 22005930 rs11126291 chr2 70965799 T G 5.77E-04 Suicide attempts in bipolar disorder ADD2 intron 21041247 rs3755352 chr2 70969783 A T 5.81E-04 Suicide attempts in bipolar disorder ADD2 intron 21041247 rs2052272 chr2 70970762 A T 8.12E-04 Alzheimer's disease ADD2 intron 22005930 rs6740913 chr2 70971685 A G 7.60E-04 Alzheimer's disease ADD2 intron 22005930 rs1861451 chr2 70973247 A G 4.67E-04 Smoking initiation ADD2 intron 24665060 rs3821251 chr2 70974700 T C 7.86E-04 Alzheimer's disease ADD2 intron 22005930 rs3755351 chr2 70974890 G T 1.70E-05 Hypertension ADD2 intron 18003638 rs3771409 chr2 70976012 T A 7.34E-04 Alzheimer's disease ADD2 intron 22005930 rs6741841 chr2 70980163 T C 8.21E-04 Alzheimer's disease ADD2 intron 22005930 rs3771408 chr2 70981146 A G 9.63E-05 Alzheimer's disease ADD2 intron 22005930 rs2863801 chr2 70991738 C T 1.36E-04 Multiple complex diseases ADD2 intron 17554300 rs2863801 chr2 70991738 C T 7.71E-04 Alzheimer's disease ADD2 intron 22005930 rs6707940 chr2 70998237 A G 1.72E-04 Alzheimer's disease / / 22005930 rs6749482 chr2 71001502 G A 6.04E-04 Alzheimer's disease / / 22005930 rs17655355 chr2 71005101 C G 3.62E-04 Alzheimer's disease FIGLA intron 22005930 rs12616540 chr2 71005727 A G 6.57E-04 Alzheimer's disease FIGLA intron 22005930 rs9646990 chr2 71005951 T C 6.62E-04 Alzheimer's disease FIGLA intron 22005930 rs7596564 chr2 71006246 G A 2.74E-04 Alzheimer's disease FIGLA intron 22005930 rs2024454 chr2 71006389 T C 6.15E-04 Alzheimer's disease FIGLA intron 22005930 rs6546626 chr2 71006632 G A 3.77E-04 Alzheimer's disease FIGLA intron 22005930 rs6709934 chr2 71007411 T C 6.51E-04 Alzheimer's disease FIGLA intron 22005930 rs13023269 chr2 71008396 T C 6.53E-04 Alzheimer's disease FIGLA intron 22005930 rs2080394 chr2 71009449 C T 4.12E-04 Alzheimer's disease FIGLA intron 22005930 rs6546629 chr2 71009593 G C 8.31E-04 Alzheimer's disease FIGLA intron 22005930 rs17038448 chr2 71011558 C T 7.02E-04 Alzheimer's disease FIGLA intron 22005930 rs7566700 chr2 71012946 C A 6.75E-04 Alzheimer's disease FIGLA intron 22005930 rs7566814 chr2 71013039 C T 7.74E-04 Alzheimer's disease FIGLA intron 22005930 rs10184254 chr2 71014322 T C 5.43E-04 Alzheimer's disease FIGLA intron 22005930 rs6546634 chr2 71016498 C A 6.00E-04 Alzheimer's disease FIGLA intron 22005930 rs17656087 chr2 71040352 A C 7.99E-04 Multiple complex diseases CLEC4F intron 17554300 rs2075221 chr2 71044211 C T 1.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLEC4F missense 20031582 rs2863804 chr2 71052118 T C 4.96E-04 Multiple complex diseases / / 17554300 rs2110978 chr2 71052229 T C 6.75E-05 Multiple complex diseases / / 17554300 rs741326 chr2 71058835 A G 4.14E-05 Schizophrenia / / 19571811 rs4852708 chr2 71063942 C T 9.00E-06 IgG glycosylation / / 23382691 rs17006471 chr2 71068623 T C 3.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs17006471 chr2 71068623 T C 1.11E-08 Atopic dermatitis / / 23886662 rs11889897 chr2 71076472 C T 0.0000105 Skin 2-naphthyl-keratin adduct (2NKA) levels in workers exposed to naphthalene / / 22391508 rs10167243 chr2 71090525 A G 7.88E-05 Atopic dermatitis / / 23042114 rs6723162 chr2 71102286 A T 2.18E-04 Body mass index / / 21701565 rs6723162 chr2 71102286 A T 6.99E-04 Body mass index / / 21701565 rs7594319 chr2 71118757 A G 1.81E-04 Body mass index / / 21701565 rs7594319 chr2 71118757 A G 2.61E-04 Body mass index / / 21701565 rs3771395 chr2 71133014 G A 2.00E-07 Corneal astigmatism VAX2 intron 23322567 rs10489991 chr2 71138371 C A 0.0000244 Tuberculosis with early age of onset VAX2 intron 22551897 rs11681519 chr2 71138685 T C 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VAX2 intron 20877124 rs11126309 chr2 71149293 C A 3.48E-04 Body mass index VAX2 intron 21701565 rs4852238 chr2 71152500 A C 4.19E-04 Body mass index VAX2 intron 21701565 rs6748268 chr2 71152850 T C 4.96E-05 Progressive supranuclear palsy VAX2 intron 21685912 rs10185490 chr2 71166840 A G 2.05E-04 Scoliosis ATP6V1B1 intron 21216876 rs11695103 chr2 71167025 G A 4.33E-04 Body mass index ATP6V1B1 intron 21701565 rs10165187 chr2 71167577 G A 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1B1 intron 20877124 rs10165187 chr2 71167577 G A 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1B1 intron 20877124 rs17006555 chr2 71169978 G C 0.000000361 HDL cholesterol ATP6V1B1 intron 23063622 rs10210235 chr2 71182900 T C 8.57E-05 Arthritis (juvenile idiopathic) ATP6V1B1 intron 22354554 rs3771383 chr2 71206626 G T 1.00E-04 Cognitive impairment induced by topiramate ANKRD53 intron 22091778 rs3771383 chr2 71206626 G T 4.89E-05 Glucose levels ANKRD53 intron pha003061 rs6760496 chr2 71234671 G A 5.53E-05 Weight / / pha003026 rs10196871 chr2 71235034 A G 4.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs10188275 chr2 71235122 T C 4.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs10189222 chr2 71236047 T C 4.45E-05 Suicide attempts in bipolar disorder / / 21041247 rs10179209 chr2 71236072 G A 4.51E-05 Suicide attempts in bipolar disorder / / 21041247 rs13420242 chr2 71263768 T C 8.34E-04 Insulin resistance / / 21901158 rs6724815 chr2 71285340 G A 3.23E-04 Alzheimer's disease / / 22005930 rs6725116 chr2 71285678 C T 3.97E-04 Hearing function / / 17255346 rs10167593 chr2 71285874 A C 2.10E-05 Urinary metabolites / / 21572414 rs9636399 chr2 71288912 T C 9.70E-06 Urinary metabolites / / 21572414 rs11126315 chr2 71291058 T C 1.90E-04 Multiple complex diseases / / 17554300 rs1458868 chr2 71376201 C T 2.70E-04 Birth weight MPHOSPH10 intron 17255346 rs115361918 chr2 71376471 G A 0.00032 Breast cancer (ER positive) MPHOSPH10 missense 23555315 rs357732 chr2 71381652 C T 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs370068 chr2 71403181 G C 3.04E-04 Gallstones / / 17632509 rs413693 chr2 71403616 T G 4.24E-04 Parkinson's disease / / 17052657 rs413693 chr2 71403616 T G 2.00E-06 Smoking behavior / / 20418888 rs413693 chr2 71403616 T G 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs413693 chr2 71403616 T G 1.48E-06 Left ventricular hypertrophy / / pha003052 rs450964 chr2 71408869 T C 9.79E-05 Serum metabolites / / 19043545 rs411758 chr2 71409237 A C 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10210663 chr2 71409358 A G 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs3732238 chr2 71413984 A G 7.68E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs3821248 chr2 71414007 A G 7.56E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs3187463 chr2 71414645 A G 7.86E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs17006730 chr2 71416054 G A 7.84E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs12615297 chr2 71431885 G A 2.46E-05 Monocyte counts PAIP2B intron pha003089 rs11692793 chr2 71432288 A G 4.60E-05 Monocyte counts PAIP2B intron pha003089 rs2418896 chr2 71436269 G A 1.80E-04 Rheumatoid arthritis PAIP2B intron 22446963 rs2418896 chr2 71436269 G A 2.76E-06 Left ventricular hypertrophy PAIP2B intron pha003052 rs741472 chr2 71436854 G A 8.13E-05 Alzheimer's disease PAIP2B intron 21098978 rs741472 chr2 71436854 G A 7.80E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs6724890 chr2 71440847 C T 7.36E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs4852772 chr2 71443645 A G 2.45E-04 Tourette syndrome PAIP2B intron 22889924 rs763713 chr2 71448455 G T 2.11E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs2216372 chr2 71453160 G T 1.56E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs6708352 chr2 71457571 T C 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546680 chr2 71463434 C G 5.10E-10 Non-obstructive azoospermia / / 22197933 rs6713034 chr2 71467971 G A 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7594256 chr2 71469011 A G 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17006807 chr2 71470998 T C 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1870384 chr2 71471154 C T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1870385 chr2 71471456 T C 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs6750088 chr2 71478223 T A 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2900806 chr2 71478797 C G 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12987627 chr2 71485220 G A 5.67E-05 Taste perception / / 22132133 rs2609505 chr2 71488944 G T 4.91E-04 Tourette syndrome / / 22889924 rs2542530 chr2 71489804 G T 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544698 chr2 71490153 T C 6.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741028 chr2 71495162 G T 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542532 chr2 71495639 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1585290 chr2 71497654 T C 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1458870 chr2 71505109 C G 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2058897 chr2 71518186 T A 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546681 chr2 71518537 C G 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7419694 chr2 71522113 T G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7598689 chr2 71522165 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6708788 chr2 71522879 T C 2.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs12612930 chr2 71525785 T C 2.00E-10 Height / / 23456168 rs72909550 chr2 71526524 G T 9.86E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2670746 chr2 71526624 T C 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670745 chr2 71526817 G A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542545 chr2 71528842 G T 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542546 chr2 71528850 T C 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs7609266 chr2 71530558 G C 6.35E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2542547 chr2 71531413 C T 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670740 chr2 71531856 A G 1.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542485 chr2 71533729 G A 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17743264 chr2 71534811 G C 8.62E-04 Parkinson's disease / / 16252231 rs17743264 chr2 71534811 G C 7.84E-04 Multiple complex diseases / / 17554300 rs2670734 chr2 71538826 C A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670733 chr2 71539398 G T 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1073877 chr2 71541660 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7584059 chr2 71548684 C G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542489 chr2 71558113 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2257136 chr2 71558924 G T 1.33E-04 Suicide attempts in bipolar disorder ZNF638 UTR-5 21423239 rs3771381 chr2 71560665 A T 9.68E-04 Multiple complex diseases ZNF638 intron 17554300 rs2542490 chr2 71561053 G A 1.11E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs17692517 chr2 71563549 T G 8.67E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs72909586 chr2 71567349 T C 5.70E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs1990773 chr2 71567986 C G 1.56E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs7581030 chr2 71572455 C T 3.71E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2670752 chr2 71573808 G A 4.95E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2058899 chr2 71580129 G A 2.60E-05 Urinary metabolites ZNF638 intron 21572414 rs2542501 chr2 71583191 A G 8.80E-04 Tourette syndrome ZNF638 intron 22889924 rs2542505 chr2 71587797 C T 1.24E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542508 chr2 71588442 C T 1.03E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542511 chr2 71592444 G T 8.73E-05 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs6753560 chr2 71593535 G A 7.89E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs3755335 chr2 71594219 G A 7.81E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542513 chr2 71595238 C A 1.33E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542516 chr2 71598107 G A 1.31E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs17693250 chr2 71601434 T G 2.60E-05 Urinary metabolites ZNF638 intron 21572414 rs1024890 chr2 71601522 C T 1.76E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2058900 chr2 71604238 T A 1.32E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs1990775 chr2 71610016 A G 1.10E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs7557781 chr2 71613914 A G 9.72E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs6745147 chr2 71614454 A G 1.05E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs10208242 chr2 71614947 A G 4.32E-04 Taste perception ZNF638 intron 22132133 rs2542528 chr2 71615534 C T 1.04E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13392164 chr2 71618323 A G 1.37E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs12713748 chr2 71620563 A G 1.28E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13424541 chr2 71625767 G A 1.43E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs3771371 chr2 71627539 C T 4.10E-06 Urinary metabolites ZNF638 intron 21572414 rs3732235 chr2 71631109 A G 1.45E-04 Suicide attempts in bipolar disorder ZNF638 missense 21423239 rs3732234 chr2 71631296 T C 1.22E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13032033 chr2 71657168 G A 7.70E-05 Memory performance ZNF638 intron 22105620 rs4852259 chr2 71682950 C G 9.70E-06 Bipolar disorder DYSF intron 18317468 rs56988800 chr2 71688118 C A 1.00E-07 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs80255579 chr2 71690472 C A 5.41E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs74836064 chr2 71690528 G A 1.64E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4362586 chr2 71690647 T C 1.69E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4542877 chr2 71690715 G A 1.71E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4629186 chr2 71690800 C T 1.75E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs11692280 chr2 71690860 G A 1.08E-05 Systemic sclerosis DYSF intron 21750679 rs74776753 chr2 71690944 G A 1.78E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs75252201 chr2 71691063 G A 1.80E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs111519406 chr2 71691099 G A 1.80E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs78624083 chr2 71691457 G C 1.88E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs78130680 chr2 71691604 C T 9.31E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4538230 chr2 71691896 T A 1.90E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4322872 chr2 71691899 A G 1.90E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4547553 chr2 71691940 G A 1.91E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4353676 chr2 71691942 A G 1.89E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs72896814 chr2 71692152 A G 1.11E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs80137915 chr2 71692195 G A 1.89E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs79523511 chr2 71692883 C G 1.82E-07 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs12477276 chr2 71703364 A G 4.20E-06 Left ventricular hypertrophy DYSF intron pha003052 rs7574062 chr2 71716494 C T 2.62E-04 IgE levels DYSF intron 17255346 rs4852261 chr2 71722096 A G 4.73E-05 Prostate cancer DYSF intron pha002878 rs9309455 chr2 71733764 T C 5.85E-04 Multiple complex diseases DYSF intron 17554300 rs9309457 chr2 71733941 A G 2.66E-05 Parent of origin effect on language impairment (paternal) DYSF intron 24571439 rs11903960 chr2 71743376 T C 7.35E-04 Multiple complex diseases DYSF intron 17554300 rs11675613 chr2 71759702 C T 5.70E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs4564797 chr2 71760554 G A 4.47E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs4852806 chr2 71774011 T C 6.78E-05 Parent of origin effect on language impairment (paternal) DYSF intron 24571439 rs11690146 chr2 71779115 C T 2.40E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs7568834 chr2 71806112 T C 8.95E-05 Cleft lip DYSF intron 20436469 rs1529409 chr2 71830689 T C 1.40E-05 Multiple sclerosis DYSF intron 17660530 rs13030767 chr2 71836525 T C 5.53E-05 Type 2 diabetes DYSF intron 17463246 rs1863810 chr2 71842536 G T 1.00E-04 Information processing speed DYSF intron 21130836 rs9677779 chr2 71903036 G A 2.87E-06 HIV-1 control DYSF intron 20041166 rs11126341 chr2 71916661 T C 4.78E-05 Epilepsy (remission after treatment) / / 23962720 rs7598653 chr2 71941150 A G 2.95E-06 White blood cell count / / 21738479 rs2900976 chr2 71958480 C T 1.00E-06 Protein quantitative trait loci / / 18464913 rs4123814 chr2 71975921 T G 1.10E-05 Urinary metabolites / / 21572414 rs1563740 chr2 71984140 T A 1.40E-05 Urinary metabolites / / 21572414 rs10865387 chr2 71994680 T A 2.40E-05 Urinary metabolites / / 21572414 rs12623780 chr2 71999008 C T 6.50E-06 Urinary metabolites / / 21572414 rs6754058 chr2 72005585 C T 2.90E-05 Urinary metabolites / / 21572414 rs2419778 chr2 72030760 G A 2.70E-05 Urinary metabolites / / 21572414 rs17007417 chr2 72035671 T C 9.70E-05 Creatinine levels / / pha003069 rs1471219 chr2 72066907 A G 2.27E-05 Lung adenocarcinoma / / 19836008 rs10192419 chr2 72074476 T C 1.39E-05 Lung adenocarcinoma / / 19836008 rs1380264 chr2 72101981 G C 1.62E-04 Type 2 diabetes / / 17463246 rs6716321 chr2 72110992 C G 4.33E-04 Type 2 diabetes / / 17463246 rs7584466 chr2 72111530 T C 8.11E-05 Coronary Artery Disease / / 17634449 rs2901028 chr2 72111683 T G 0.000841 Salmonella-induced pyroptosis / / 22837397 rs17486127 chr2 72111879 G C 4.15E-06 Lipid traits / / 21777205 rs7597548 chr2 72164912 G C 7.60E-06 Urinary metabolites / / 21572414 rs61220700 chr2 72181187 T C 4.57E-27 Metabolite levels / / 22286219 rs1517397 chr2 72189250 T C 9.42E-05 Tunica Media / / pha003034 rs4852833 chr2 72236929 G A 2.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs955788 chr2 72237360 G A 7.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs1878503 chr2 72251751 G A 1.69E-04 Scoliosis / / 21216876 rs4852838 chr2 72254272 C T 8.94E-05 Type 2 diabetes / / 17463246 rs13382212 chr2 72263628 T C 4.01E-04 Type 2 diabetes / / 17463246 rs4852279 chr2 72264864 A G 3.37E-04 Type 2 diabetes / / 17463246 rs741161 chr2 72268093 T A 9.21E-05 Type 2 diabetes / / 17463246 rs741161 chr2 72268093 T A 4.81E-04 Multiple complex diseases / / 17554300 rs17007727 chr2 72303473 T C 6.40E-05 HIV-1 control / / 20041166 rs13406776 chr2 72305463 G A 6.40E-05 HIV-1 control / / 20041166 rs10168803 chr2 72319253 C T 4.13E-04 Tourette syndrome / / 22889924 rs10194900 chr2 72325404 A C 1.33E-04 Tourette syndrome / / 22889924 rs2041666 chr2 72353573 G T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2420201 chr2 72356370 G A 0.0006367 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CYP26B1 UTR-3 23233654 rs2420201 chr2 72356370 G A 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) CYP26B1 UTR-3 23233662 rs6546748 chr2 72383868 C T 4.92E-05 Intracerebral hemorrhage / / 24656865 rs10202129 chr2 72385492 G A 2.99E-05 Intracerebral hemorrhage / / 24656865 rs10174010 chr2 72387539 T C 1.48E-05 Intracerebral hemorrhage / / 24656865 rs11126362 chr2 72393138 C T 0.00006108 Sarcoidosis / / 22952805 rs194243 chr2 72394749 A G 0.00005191 Sarcoidosis / / 22952805 rs194242 chr2 72394893 A G 0.0000714 Sarcoidosis / / 22952805 rs1860853 chr2 72395048 A G 0.00003531 Sarcoidosis / / 22952805 rs35934538 chr2 72395048 AG A 0.00003531 Sarcoidosis / / 22952805 rs1860852 chr2 72395049 G A 0.00003223 Sarcoidosis / / 22952805 rs41414 chr2 72405827 A T 0.00008301 Sarcoidosis / / 22952805 rs41412 chr2 72407263 T C 0.00007478 Sarcoidosis EXOC6B intron 22952805 rs41407 chr2 72415803 C A 0.00005671 Sarcoidosis EXOC6B intron 22952805 rs41405 chr2 72416489 G C 0.00006077 Sarcoidosis EXOC6B intron 22952805 rs41403 chr2 72418689 C A 0.00002379 Sarcoidosis EXOC6B intron 22952805 rs13339845 chr2 72419864 A G 9.64E-04 Multiple complex diseases EXOC6B intron 17554300 rs41400 chr2 72420204 C T 0.00003973 Sarcoidosis EXOC6B intron 22952805 rs41398 chr2 72422160 T C 0.00005376 Sarcoidosis EXOC6B intron 22952805 rs41397 chr2 72422386 C A 0.00004422 Sarcoidosis EXOC6B intron 22952805 rs41394 chr2 72424868 T C 0.00004751 Sarcoidosis EXOC6B intron 22952805 rs41393 chr2 72425292 A G 0.00002684 Sarcoidosis EXOC6B intron 22952805 rs28278 chr2 72425439 C G 0.00003801 Sarcoidosis EXOC6B intron 22952805 rs41391 chr2 72427480 C A 0.00005338 Sarcoidosis EXOC6B intron 22952805 rs41390 chr2 72427905 G C 0.00005894 Sarcoidosis EXOC6B intron 22952805 rs41389 chr2 72428379 C T 0.00005981 Sarcoidosis EXOC6B intron 22952805 rs41388 chr2 72428488 A G 0.00007119 Sarcoidosis EXOC6B intron 22952805 rs17673916 chr2 72487364 T C 1.50E-05 Urinary metabolites EXOC6B intron 21572414 rs10175915 chr2 72488160 T A 1.50E-05 Urinary metabolites EXOC6B intron 21572414 rs10175915 chr2 72488160 T A 4.28E-05 Blood pressure EXOC6B intron 21909110 rs17725024 chr2 72498920 T C 6.30E-06 Urinary metabolites EXOC6B intron 21572414 rs6719255 chr2 72500375 G A 7.20E-06 Urinary metabolites EXOC6B intron 21572414 rs10204415 chr2 72507640 T C 8.99E-04 Response to cytadine analogues (cytosine arabinoside) EXOC6B intron 24483146 rs11126370 chr2 72725947 G A 7.40E-04 Alcohol dependence EXOC6B intron 20201924 rs2138683 chr2 72735509 G A 4.90E-04 Alcohol dependence EXOC6B intron 20201924 rs10496185 chr2 72748616 A G 1.03E-05 Bilirubin levels,in serum EXOC6B intron 19389676 rs12471136 chr2 72789317 A G 8.00E-04 Alcohol dependence EXOC6B intron 20201924 rs1446890 chr2 72795730 G A 8.80E-04 Alcohol dependence EXOC6B intron 20201924 rs10203912 chr2 72933110 T C 4.14E-04 Multiple complex diseases EXOC6B intron 17554300 rs7593084 chr2 73013836 C T 5.04E-04 Multiple complex diseases EXOC6B intron 17554300 rs4852896 chr2 73073494 A C 5.90E-04 Multiple complex diseases / / 17554300 rs1161267 chr2 73122181 G A 2.69E-04 Blood pressure / / 21909110 rs768851 chr2 73378241 G A 5.55E-05 Elbow pain / / pha003008 rs2043092 chr2 73407076 C T 1.30E-04 Myasthenia gravis / / 23055271 rs11886257 chr2 73416873 C T 3.93E-06 Elbow pain / / pha003008 rs7599223 chr2 73427103 A G 7.20E-06 Elbow pain / / pha003008 rs7557285 chr2 73442812 G A 5.06E-06 Elbow pain SMYD5 intron pha003008 rs2303904 chr2 73447775 A G 7.68E-04 Nicotine smoking SMYD5 intron 19268276 rs3188114 chr2 73454256 G A 1.93E-04 Nicotine smoking SMYD5 UTR-3 19268276 rs1474298 chr2 73466592 G A 3.42E-05 Elbow pain CCT7 intron pha003008 rs7557055 chr2 73472670 G A 1.80E-06 Elbow pain CCT7 intron pha003008 rs502930 chr2 73492220 T C 9.13E-04 Myopia (pathological) FBXO41 intron 21095009 rs6718864 chr2 73574591 A G 9.03E-06 F-cell distribution / / 21326311 rs1918863 chr2 73644481 A G 1.60E-05 Urinary metabolites ALMS1 intron 21572414 rs2421549 chr2 73658573 T C 2.12E-04 Alzheimer's disease ALMS1 intron 24755620 rs7585004 chr2 73666645 G C 1.80E-05 Urinary metabolites ALMS1 intron 21572414 rs12104768 chr2 73674966 T C 3.60E-37 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs6546837 chr2 73677898 G C 3.28E-08 Chronic kidney disease ALMS1 missense 21931561 rs10496192 chr2 73679866 T C 2.53E-04 Diabetic retinopathy ALMS1 missense 20871662 rs34183407 chr2 73681179 C T 1.32E-72 Cholesterol,total ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 2.39E-78 HDL cholesterol ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 3.20E-14 Triglycerides ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 5.58E-49 LDL cholesterol ALMS1 missense 23063622 rs6749680 chr2 73685852 G A 7.00E-04 Iron levels ALMS1 intron pha002876 rs7607014 chr2 73730174 A G 6.90E-06 Urinary metabolites ALMS1 intron 21572414 rs7598660 chr2 73740425 G A 1.38E-04 Type 2 diabetes ALMS1 intron 17463246 rs9309473 chr2 73743982 A G 1.00E-11 Metabolite levels ALMS1 intron 21931564 rs11884776 chr2 73746923 C T 6.00E-17 Urinary metabolites (H-NMR features) ALMS1 cds-synon 24586186 rs10469966 chr2 73752368 G A 1.00E-51 Blood metabolite levels ALMS1 intron 24816252 rs13008860 chr2 73774019 G A 2.80E-04 Iron levels ALMS1 intron pha002876 rs6546847 chr2 73785358 A G 1.00E-17 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs6546847 chr2 73785358 A G 5.00E-161 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs13391552 chr2 73818936 G A 5.00E-252 Metabolic traits ALMS1 intron 21886157 rs1052161 chr2 73828538 G A 4.49E-04 Iron levels ALMS1 missense pha002876 rs1052162 chr2 73829372 C T 8.00E-06 Urinary metabolites ALMS1 cds-synon 21572414 rs17349853 chr2 73831714 T G 3.04E-04 Iron levels ALMS1 intron pha002876 rs6546857 chr2 73837955 A G 1.00E-23 Metabolite levels (X-11787) / / 23934736 rs6745480 chr2 73840055 G A 5.40E-06 Urinary metabolites / / 21572414 rs13538 chr2 73868328 A G 5.00E-14 Chronic kidney disease /T8 missense 20383146 rs13538 chr2 73868328 A G 6.98E-10 Chronic kidney disease /T8 missense 22479191 rs13538 chr2 73868328 A G 1.70E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 1.80E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 1.80E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 2.80E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 3.90E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 4.00E-05 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 5.10E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 5.60E-05 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 6.10E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 2.00E-23 Metabolite levels (X-11787) /T8 missense 23934736 rs13538 chr2 73868328 A G 4.00E-66 Metabolite levels /T8 missense 24625756 rs13538 chr2 73868328 A G 5E-498 Blood metabolite ratios /T8 missense 24816252 rs13538 chr2 73868328 A G 8.00E-157 Blood metabolite levels /T8 missense 24816252 rs10206899 chr2 73900900 T C 1.00E-15 Creatinine levels ALMS1P intron 20383145 rs10206899 chr2 73900900 T C 2.00E-09 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 4.00E-08 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 6.00E-09 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 2.00E-14 Blood metabolite levels ALMS1P intron 24816252 rs10206899 chr2 73900900 T C 5E-481 Blood metabolite levels ALMS1P intron 24816252 rs10206899 chr2 73900900 T C 8.00E-123 Blood metabolite levels ALMS1P intron 24816252 rs2421678 chr2 73964214 C T 8.18E-04 Alzheimer's disease TPRKB intron 24755620 rs4514898 chr2 73966271 C T 3.00E-23 Urinary metabolites (H-NMR features) / / 24586186 rs2567599 chr2 73994074 G A 2.89E-04 Alzheimer's disease DUSP11 intron 24755620 rs3813229 chr2 74056564 A G 1.40E-29 Urinary metabolites (H-NMR features) STAMBP UTR-5 24586186 rs7609273 chr2 74070843 T C 4.11E-04 Multiple complex diseases STAMBP intron 17554300 rs13384232 chr2 74087710 C A 2.29E-04 Multiple complex diseases STAMBP intron 17554300 rs571878872 chr2 74087710 CA C 2.29E-04 Multiple complex diseases STAMBP intron 17554300 rs7557701 chr2 74125550 G A 1.99E-04 Alzheimer's disease ACTG2 intron 24755620 rs7586415 chr2 74129389 T C 3.63E-04 Alzheimer's disease ACTG2 intron 24755620 rs6546878 chr2 74175324 C A 1.02E-05 Mathematical ability DGUOK intron 24801482 rs4777 chr2 74185876 A T 5.97E-04 Type 2 diabetes DGUOK UTR-3 17463246 rs10169997 chr2 74194587 A G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4852324 chr2 74202578 T C 6.00E-14 Systemic lupus erythematosus / / 23273568 rs4852324 chr2 74202578 T C 6.90E-05 Cognitive function / / 24684796 rs4852324 chr2 74202578 T C 3.84E-05 Hemoglobin / / pha003098 rs6705628 chr2 74208362 C T 7.00E-17 Systemic lupus erythematosus / / 23273568 rs6714060 chr2 74210442 C T 3.99E-05 Telomere length / / 23001564 rs6714060 chr2 74210442 C T 2.30E-05 Cognitive function / / 24684796 rs10496194 chr2 74215977 C G 1.42E-05 Telomere length / / 23001564 rs6546886 chr2 74245777 T C 3.00E-06 Dialysis-related mortality / / 21546767 rs6756474 chr2 74282706 T C 2.41E-04 Sudden cardiac arrest TET3 intron 21658281 rs12991192 chr2 74309666 T C 1.86E-04 Sudden cardiac arrest TET3 intron 21658281 rs13021880 chr2 74310787 C G 0.0006931 Sarcoidosis TET3 intron 22952805 rs828872 chr2 74313080 T C 3.36E-04 White matter integrity TET3 intron 22425255 rs13025827 chr2 74337353 T C 8.62E-04 Aortic root size / / 21223598 rs6758220 chr2 74337584 G A 6.78E-04 Aortic root size / / 21223598 rs6758220 chr2 74337584 G A 8.91E-06 Hemoglobin / / pha003096 rs6758220 chr2 74337584 G A 5.74E-06 Hematocrit / / pha003097 rs3099824 chr2 74342567 A G 6.44E-06 Carotenoid and tocopherol levels / / 19185284 rs7594992 chr2 74364946 G A 1.81E-04 Multiple complex diseases BOLA3 intron 17554300 rs828888 chr2 74372678 A C 1.08E-05 Intelligence BOLA3 intron 21826061 rs828887 chr2 74373044 G A 3.93E-04 Myopia (pathological) BOLA3 intron 21095009 rs828887 chr2 74373044 G A 7.95E-05 Intelligence BOLA3 intron 21826061 rs828884 chr2 74374641 C T 4.63E-05 Intelligence BOLA3 intron 21826061 rs828883 chr2 74375457 G A 2.42E-04 Response to TNF antagonist treatment BOLA3-AS1 intron 21061259 rs828882 chr2 74375804 C T 1.94E-04 Response to TNF antagonist treatment BOLA3-AS1 intron 21061259 rs4083173 chr2 74401657 A G 8.97E-04 Myopia (pathological) MOB1A intron 21095009 rs1667601 chr2 74406055 G T 2.30E-04 Iris characteristics / / 21835309 rs828860 chr2 74411281 G A 2.79E-04 Myopia (pathological) / / 21095009 rs7340453 chr2 74428015 T C 5.74E-05 Intelligence MTHFD2 intron 21826061 rs828903 chr2 74436721 A G 2.89E-05 Intelligence MTHFD2 intron 21826061 rs12053233 chr2 74451762 C T 1.91E-04 Tourette syndrome SLC4A5 intron 22889924 rs13006863 chr2 74463566 C T 5.00E-07 Immune reponse to smallpox (secreted TNF-alpha) SLC4A5 intron 22610502 rs13006863 chr2 74463566 C T 3.00E-06 Post-traumatic stress disorder (asjusted for relatedness) SLC4A5 intron 23726511 rs3771725 chr2 74485896 T G 5.06E-04 Smoking initiation SLC4A5 intron 24665060 rs6722230 chr2 74489062 G A 2.06E-04 Response to cytidine analogues (gemcitabine) SLC4A5 intron 24483146 rs6722230 chr2 74489062 G A 3.90E-05 Response to cytadine analogues (cytosine arabinoside) SLC4A5 intron 24483146 rs17009792 chr2 74489323 C T 7.45E-05 Type 2 diabetes SLC4A5 missense 17463246 rs17009792 chr2 74489323 C T 1.68E-04 Response to cytidine analogues (gemcitabine) SLC4A5 missense 24483146 rs17009792 chr2 74489323 C T 4.13E-05 Response to cytadine analogues (cytosine arabinoside) SLC4A5 missense 24483146 rs2109356 chr2 74490502 C T 3.03E-04 Smoking initiation SLC4A5 intron 24665060 rs6723819 chr2 74501510 A G 2.41E-04 Smoking initiation SLC4A5 intron 24665060 rs7560244 chr2 74515158 G A 1.20E-04 Response to cytidine analogues (gemcitabine) SLC4A5 intron 24483146 rs3771738 chr2 74540917 C T 9.78E-04 Multiple complex diseases SLC4A5 intron 17554300 rs7581836 chr2 74577397 T G 2.18E-04 Smoking initiation / / 24665060 rs12328185 chr2 74621660 A G 5.99E-04 Multiple complex diseases / / 17554300 rs17009922 chr2 74622037 C G 7.24E-04 Multiple complex diseases / / 17554300 rs10187051 chr2 74639591 T C 9.43E-05 Personality dimensions / / 18957941 rs10187076 chr2 74639637 T C 9.45E-05 Personality dimensions / / 18957941 rs3732293 chr2 74649934 A C 1.50E-06 Major depressive disorder WDR54 intron 21042317 rs1063588 chr2 74690378 C T 3.57E-04 IgE levels MOGS missense 17255346 rs1063588 chr2 74690378 C T 6.93E-05 Multiple complex diseases MOGS missense 17554300 rs1047911 chr2 74699778 C A 3.45E-04 IgE levels MRPL53 missense 17255346 rs6546909 chr2 74746322 A T 2.91E-05 Multiple complex diseases DQX1 cds-synon 17554300 rs10779958 chr2 74755778 A C 2.97E-06 Osteoarthritis AUP1 intron 22763110 rs17010021 chr2 74761539 T A 1.00E-05 Anorexia nervosa LOXL3 missense 23568457 rs17010022 chr2 74763258 C G 2.44E-04 Multiple complex diseases LOXL3 cds-synon 17554300 rs7569357 chr2 74778644 C T 3.34E-04 Multiple complex diseases DOK1 intron 17554300 rs11126435 chr2 74789700 A T 3.06E-05 Multiple complex diseases C2orf65 intron 17554300 rs363685 chr2 74814836 C T 5.70E-05 Volumetric brain MRI C2orf65 intron 17903297 rs363691 chr2 74841569 C T 1.95E-04 Multiple complex diseases C2orf65 intron 17554300 rs363611 chr2 74906200 C T 5.75E-04 Multiple complex diseases SEMA4F intron 17554300 rs363612 chr2 74911073 T C 6.79E-04 Multiple complex diseases / / 17554300 rs363612 chr2 74911073 T C 2.00E-04 Smoking initiation / / 24665060 rs363617 chr2 74918692 T C 2.30E-04 Multiple complex diseases / / 17554300 rs7355739 chr2 74926935 A C 4.40E-04 Multiple complex diseases / / 17554300 rs2041835 chr2 74927197 A G 5.00E-04 Multiple complex diseases / / 17554300 rs363620 chr2 74928350 C A 4.51E-04 Multiple complex diseases / / 17554300 rs11126440 chr2 74929490 A G 3.94E-04 Multiple complex diseases / / 17554300 rs363624 chr2 74930842 A G 5.48E-04 Multiple complex diseases / / 17554300 rs363625 chr2 74930899 A G 4.62E-04 Multiple complex diseases / / 17554300 rs1137 chr2 74939176 T C 4.00E-06 Myopia (pathological) / / 22685421 rs6546920 chr2 74971385 A G 5.21E-04 Acute lung injury / / 22295056 rs205611 chr2 74972081 A G 1.74E-04 Multiple complex diseases / / 17554300 rs205611 chr2 74972081 A G 1.00E-06 Iris characteristics / / 21835309 rs17739760 chr2 74990671 G A 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs3980420 chr2 75030680 T C 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546929 chr2 75031011 A G 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs3771798 chr2 75064392 T C 1.04E-05 Post-operative nausea and vomiting HK2 intron 21694509 rs28362967 chr2 75074055 G T 4.41E-04 Type 2 diabetes HK2 intron 17463246 rs28362967 chr2 75074055 G T 7.00E-04 Acute lymphoblastic leukemia (childhood) HK2 intron 20189245 rs10496195 chr2 75074932 A C 1.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HK2 intron 20877124 rs681900 chr2 75074967 T C 3.00E-06 Femoral neck bone geometry HK2 intron 22087292 rs680545 chr2 75075255 G A 5.92E-06 Sickle cell anemia (severity) HK2 intron 20029952 rs3771783 chr2 75082895 G A 1.00E-04 Bipolar disorder HK2 intron 17486107 rs3771781 chr2 75085163 C T 3.25E-05 Common variable immunodeficiency HK2 intron 21497890 rs3732300 chr2 75099381 T C 1.12E-04 Nicotine dependence HK2 intron 17158188 rs1869340 chr2 75102176 A G 5.82E-07 Schizophrenia HK2 intron 21926974 rs17741356 chr2 75113903 A G 2.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HK2 intron 20031582 rs923273 chr2 75114730 C T 4.62E-04 Insulin resistance HK2 intron 21901158 rs12989728 chr2 75138842 C A 9.11E-04 Insulin resistance / / 21901158 rs17010519 chr2 75142302 C T 1.15E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs4853081 chr2 75165905 A T 9.36E-05 Type 2 diabetes / / 17463246 rs11902447 chr2 75166777 C T 1.16E-04 Type 2 diabetes / / 17463246 rs2287102 chr2 75186337 A G 1.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) POLE4 intron 23648065 rs17040394 chr2 75187831 G A 3.76E-05 Multiple complex diseases POLE4 intron 17554300 rs3886110 chr2 75207832 G T 1.31E-04 Type 2 diabetes / / 17463246 rs7602776 chr2 75218331 T A 9.28E-05 Type 2 diabetes / / 17463246 rs7571034 chr2 75238361 C G 3.89E-04 Type 2 diabetes / / 17463246 rs4366930 chr2 75242863 G T 3.31E-04 Type 2 diabetes / / 17463246 rs13012537 chr2 75269064 T C 2.16E-05 Type 2 diabetes / / 17463246 rs13012537 chr2 75269064 T C 3.09E-06 Lymphocyte counts / / 22286170 rs754978 chr2 75271796 A C 5.42E-05 Type 2 diabetes / / 17463246 rs4439987 chr2 75287106 G A 4.70E-04 Multiple complex diseases TACR1 intron 17554300 rs4439987 chr2 75287106 G A 1.61E-04 Parkinson's disease TACR1 intron 21248740 rs13404785 chr2 75290700 A G 5.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TACR1 intron 23648065 rs3755457 chr2 75291510 G A 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TACR1 intron 23648065 rs13417600 chr2 75329306 A G 7.16E-05 Relative hand skill TACR1 intron 24068947 rs3771815 chr2 75335078 A C 7.10E-05 Relative hand skill TACR1 intron 24068947 rs3771816 chr2 75338308 T A 5.54E-05 Relative hand skill TACR1 intron 24068947 rs3771817 chr2 75338380 A G 5.56E-05 Relative hand skill TACR1 intron 24068947 rs10210154 chr2 75338843 A T 5.57E-05 Relative hand skill TACR1 intron 24068947 rs7587891 chr2 75339492 T C 7.19E-05 Relative hand skill TACR1 intron 24068947 rs10172781 chr2 75341547 A G 3.71E-05 Relative hand skill TACR1 intron 24068947 rs741418 chr2 75363186 G A 2.07E-04 Response to taxane treatment (placlitaxel) TACR1 intron 23006423 rs17010823 chr2 75372955 C G 2.48E-04 IgE levels TACR1 intron 17255346 rs17010825 chr2 75374199 C T 2.48E-04 IgE levels TACR1 intron 17255346 rs3771863 chr2 75419714 C T 3.00E-09 Brain connectivity TACR1 intron 23471985 rs10204684 chr2 75419745 C A 8.81E-04 Alzheimer's disease TACR1 intron 24755620 rs2287231 chr2 75449129 G A 1.10E-05 Urinary metabolites / / 21572414 rs1468900 chr2 75449983 A G 1.32E-04 Alcohol dependence / / 20201924 rs13406588 chr2 75451356 A G 5.12E-04 Alzheimer's disease / / 24755620 rs6546958 chr2 75452466 T C 2.30E-05 Urinary metabolites / / 21572414 rs7568535 chr2 75459144 T C 9.89E-05 Chronic Hepatitis C infection / / 21725309 rs765684 chr2 75459668 A G 9.00E-07 Sexual dimorphism in anthropometric traits / / 23754948 rs2422153 chr2 75505999 G A 1.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17040426 chr2 75512782 T C 4.95E-04 Multiple complex diseases / / 17554300 rs2192927 chr2 75518372 T C 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17011067 chr2 75546024 A T 1.31E-06 Recombination rate / / 21698098 rs10172219 chr2 75559706 G A 5.92E-04 Multiple complex diseases / / 17554300 rs4853138 chr2 75574188 T G 5.09E-04 Multiple complex diseases / / 17554300 rs6749524 chr2 75588230 T C 2.39E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7599681 chr2 75652821 G A 2.09E-04 Alzheimer's disease / / 17998437 rs10201616 chr2 75675860 T C 7.70E-05 Cognitive test performance / / 20125193 rs10208759 chr2 75681330 G A 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10208759 chr2 75681330 G A 5.51E-05 Height / / pha003010 rs11126472 chr2 75720372 C T 2.34E-05 Multiple sclerosis (brain glutamate levels) FAM176A missense 20802204 rs11126472 chr2 75720372 C T 1.97E-05 Height FAM176A missense pha003010 rs11126472 chr2 75720372 C T 9.55E-06 Height FAM176A missense pha003011 rs17011416 chr2 75744392 C T 7.53E-04 Type 2 diabetes FAM176A intron 17463246 rs6754778 chr2 75764175 C T 1.78E-04 Taste perception FAM176A intron 22132133 rs10515917 chr2 75769810 C T 1.93E-05 Taste perception FAM176A intron 22132133 rs2422173 chr2 75777968 G A 4.91E-05 Waist-Hip Ratio FAM176A intron pha003013 rs2422173 chr2 75777968 G A 8.01E-05 Waist Circumference FAM176A intron pha003024 rs2422173 chr2 75777968 G A 4.40E-05 Waist Circumference FAM176A intron pha003025 rs2422173 chr2 75777968 G A 8.08E-05 Waist-Hip Ratio FAM176A intron pha003028 rs2422173 chr2 75777968 G A 6.12E-05 Waist-Hip Ratio FAM176A intron pha003029 rs12053306 chr2 75780007 G T 2.96E-05 Body Mass Index FAM176A intron pha003020 rs11126477 chr2 75786771 A G 1.28E-05 Body Mass Index FAM176A intron pha003006 rs11126477 chr2 75786771 A G 5.33E-05 Body Mass Index FAM176A intron pha003007 rs11126477 chr2 75786771 A G 9.03E-05 Body Mass Index FAM176A intron pha003019 rs11126477 chr2 75786771 A G 9.40E-05 Waist Circumference FAM176A intron pha003024 rs759255 chr2 75788396 C A 1.44E-04 Alzheimer's disease (late onset) FAM176A intron 21379329 rs17011455 chr2 75790489 T C 5.00E-06 Presence of antiphospholipid antibodies FAM176A intron 23509613 rs17011478 chr2 75792143 C T 6.00E-06 Obesity-related traits FAM176A intron 23251661 rs10175794 chr2 75792626 T A 8.83E-04 Coronary Artery Disease FAM176A intron 17634449 rs7595746 chr2 75797440 C T 6.93E-04 Myocardial Infarction / / pha002883 rs6709627 chr2 75802151 C A 1.70E-04 Alzheimer's disease (late onset) / / 21379329 rs6709627 chr2 75802151 C A 3.86E-05 Odorant perception / / 23910658 rs12994560 chr2 75805048 C T 4.73E-05 Body Mass Index / / pha003006 rs1075860 chr2 75814139 G A 5.48E-05 Multiple complex diseases / / 17554300 rs1075860 chr2 75814139 G A 6.22E-04 Lymphocyte counts / / 22286170 rs7562126 chr2 75832877 G C 1.81E-05 Intracerebral hemorrhage / / 24656865 rs7562242 chr2 75832989 G A 1.70E-05 Intracerebral hemorrhage / / 24656865 rs35644534 chr2 75833517 C T 2.02E-05 Intracerebral hemorrhage / / 24656865 rs740270 chr2 75837011 G T 1.79E-05 Intracerebral hemorrhage / / 24656865 rs35951645 chr2 75838889 T A 1.52E-05 Intracerebral hemorrhage / / 24656865 rs6733242 chr2 75843485 C T 3.43E-04 Multiple complex diseases / / 17554300 rs875755 chr2 75844679 T C 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs886767 chr2 75844958 G A 9.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11690080 chr2 75845448 T C 2.87E-04 Blood pressure / / 17255346 rs11690080 chr2 75845448 T C 1.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10166389 chr2 75846545 A G 3.14E-04 Type 2 diabetes / / 17463246 rs7588344 chr2 75846558 T C 8.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs714479 chr2 75847704 C A 7.70E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10206430 chr2 75847993 T G 2.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2422229 chr2 75848679 A G 7.18E-04 Type 2 diabetes / / 17463246 rs6547013 chr2 75850735 T C 4.31E-04 Type 2 diabetes / / 17463246 rs10182133 chr2 75856492 A C 0.000561 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs1017051 chr2 75865277 T C 6.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12105510 chr2 75869828 T C 5.62E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7588016 chr2 75876340 T C 2.14E-05 Cognitive performance MRPL19 intron 19734545 rs13405970 chr2 75882754 A G 9.99E-04 Tourette syndrome MRPL19 UTR-3 22889924 rs17011662 chr2 75918648 T C 2.71E-05 Cognitive performance GCFC2 intron 19734545 rs2298948 chr2 75926565 T C 5.00E-08 Hippocampal atrophy GCFC2 intron 22745009 rs4355145 chr2 75956005 G A 1.00E-05 Urinary metabolites / / 21572414 rs7582041 chr2 75973757 G T 1.78E-05 Cholesterol / / 17255346 rs11675641 chr2 75977535 A C 5.27E-05 Parkinson's disease / / 21738487 rs10183217 chr2 75997264 A G 7.34E-06 Cholesterol / / 17255346 rs17011759 chr2 76000091 A G 1.01E-04 Cholesterol / / 17255346 rs17011759 chr2 76000091 A G 1.00E-05 Urinary metabolites / / 21572414 rs17011786 chr2 76003360 A T 1.40E-05 Urinary metabolites / / 21572414 rs7573143 chr2 76004385 A G 2.98E-04 Cholesterol / / 17255346 rs7573143 chr2 76004385 A G 0.000894 Salmonella-induced pyroptosis / / 22837397 rs6760389 chr2 76031113 G T 6.39E-04 Type 2 diabetes / / 17463246 rs6760389 chr2 76031113 G T 3.60E-06 Urinary metabolites / / 21572414 rs4361150 chr2 76035099 G A 1.00E-06 Urinary metabolites / / 21572414 rs6733843 chr2 76049781 C T 5.57E-04 Multiple complex diseases / / 17554300 rs6751526 chr2 76120604 T G 4.08E-04 Multiple complex diseases / / 17554300 rs6720541 chr2 76146755 G A 9.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2583527 chr2 76184281 C T 0.0001666 Sarcoidosis / / 22952805 rs2583526 chr2 76184816 C T 1.00E-06 Smoking initiation / / 24665060 rs12467779 chr2 76196574 G A 4.84E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4853182 chr2 76197787 C T 4.66E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12471016 chr2 76204989 C T 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1441655 chr2 76209508 C A 0.0005553 Sarcoidosis / / 22952805 rs1441654 chr2 76220274 C A 4.14E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs317226 chr2 76222000 G C 0.0003279 Sarcoidosis / / 22952805 rs4853189 chr2 76232326 C T 5.06E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs436000 chr2 76240361 G T 8.00E-07 Economic and political preferences (fairness) / / 22566634 rs431838 chr2 76300058 C A 4.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs406952 chr2 76307345 T C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1660568 chr2 76308359 T C 7.04E-04 Alzheimer's disease / / 24755620 rs443713 chr2 76310384 A C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs411150 chr2 76313589 A T 8.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs317294 chr2 76334174 T G 8.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10204325 chr2 76375711 C T 1.00E-07 Economic and political preferences (fairness) / / 22566634 rs12473082 chr2 76382733 T G 6.98E-04 Alzheimer's disease / / 24755620 rs4852395 chr2 76383940 T C 3.56E-04 Gallstones / / 17632509 rs6711215 chr2 76385487 A T 7.76E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13417780 chr2 76408283 G A 1.26E-06 Panic disorder / / 19165232 rs1916870 chr2 76430941 T G 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761061 chr2 76438298 A G 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10168901 chr2 76479233 C G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs17703039 chr2 76485985 A G 2.89E-05 Relative hand skill / / 24068947 rs7609022 chr2 76487107 T G 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860732 chr2 76488564 A G 5.52E-04 Smoking quantity / / 24665060 rs12464573 chr2 76494928 C T 4.62E-04 Smoking quantity / / 24665060 rs10194221 chr2 76495414 A C 3.19E-04 Smoking quantity / / 24665060 rs17754447 chr2 76495893 T C 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1526654 chr2 76498511 A G 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11684308 chr2 76500077 C A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs13012492 chr2 76500871 T G 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1524209 chr2 76503762 A G 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11126513 chr2 76506460 G T 1.28E-06 Malignant mesothelioma / / 23827383 rs10519328 chr2 76507201 C T 1.28E-06 Malignant mesothelioma / / 23827383 rs1526627 chr2 76509398 G C 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs17754897 chr2 76509864 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6743740 chr2 76511383 G A 2.64E-04 Birth weight / / 17255346 rs17012460 chr2 76513387 A G 1.30E-06 Malignant mesothelioma / / 23827383 rs17012460 chr2 76513387 A G 7.36E-04 Smoking quantity / / 24665060 rs1526620 chr2 76516021 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1526619 chr2 76517005 A G 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747727 chr2 76535474 A C 2.85E-04 Birth weight / / 17255346 rs1830149 chr2 76562339 C T 1.25E-04 Multiple complex diseases / / 17554300 rs4853241 chr2 76579521 T C 6.99E-04 Smoking quantity / / 24665060 rs6547078 chr2 76588942 C T 9.15E-04 Alzheimer's disease / / 24755620 rs17012588 chr2 76606274 A G 6.49E-04 Smoking quantity / / 24665060 rs1519894 chr2 76633531 C G 1.77E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1519894 chr2 76633531 C G 7.70E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12105972 chr2 76648560 G C 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10168327 chr2 76667565 A G 1.78E-04 Type 2 diabetes / / 17463246 rs13035292 chr2 76678784 C A 5.24E-04 Multiple complex diseases / / 17554300 rs13035292 chr2 76678784 C A 7.36E-05 Post-operative nausea and vomiting / / 21694509 rs12466278 chr2 76712612 T A 8.16E-04 Multiple complex diseases / / 17554300 rs74529274 chr2 76759575 C T 9.00E-06 Response to amphetamines / / 22952603 rs12052843 chr2 76760606 C T 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1921254 chr2 76762485 A G 2.50E-05 Urinary metabolites / / 21572414 rs7603063 chr2 76776659 T C 3.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7592517 chr2 76777279 C T 1.31E-04 Type 2 diabetes / / 20818381 rs74511629 chr2 76783069 A G 9.97E-06 Response to amphetamines / / 22952603 rs77131518 chr2 76784978 A G 9.94E-06 Response to amphetamines / / 22952603 rs2139502 chr2 76786845 C T 1.42E-04 Type 2 diabetes / / 20818381 rs6742896 chr2 76787450 G T 9.99E-06 Response to amphetamines / / 22952603 rs6716298 chr2 76860212 C A 6.72E-05 Socioeconomic Factors / / pha003066 rs13002499 chr2 76874809 C T 6.66E-05 Socioeconomic Factors / / pha003066 rs17013020 chr2 76914970 A G 7.89E-06 Hypertension / / pha003041 rs17013020 chr2 76914970 A G 3.74E-05 Blood Pressure / / pha003045 rs17013020 chr2 76914970 A G 1.86E-05 Blood Pressure / / pha003047 rs17013053 chr2 76942709 T C 4.88E-08 Multiple complex diseases / / 17554300 rs10865426 chr2 76948804 A T 0.000107679 Primary sclerosing cholangitis / / 23603763 rs12232994 chr2 76955993 T C,G 7.44E-05 Obesity (extreme) / / 21935397 rs10169851 chr2 76956494 G C 9.27E-04 Obesity (extreme) / / 21935397 rs971120 chr2 76961518 C T 2.81E-04 Type 2 diabetes / / 17463246 rs7584499 chr2 76961857 T G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs13406374 chr2 76961961 G A 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7569282 chr2 76966652 G A 4.81E-05 Obesity (extreme) / / 21935397 rs4853267 chr2 76967644 G C 4.67E-05 Obesity (extreme) / / 21935397 rs12993991 chr2 76968250 A T 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs969933 chr2 76968595 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056207 chr2 76969273 A G 4.74E-05 Obesity (extreme) / / 21935397 rs2056208 chr2 76969378 C T 4.82E-05 Obesity (extreme) / / 21935397 rs2056209 chr2 76969542 T G 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs17013121 chr2 76969799 G T 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6745704 chr2 76969818 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6730814 chr2 76969846 C T 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056210 chr2 76971440 C T 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056211 chr2 76971574 G A 9.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs13396159 chr2 76976577 A G 4.94E-04 Obesity (extreme) LRRTM4 intron 21935397 rs13403042 chr2 76978268 A T 7.81E-04 Obesity (extreme) LRRTM4 intron 21935397 rs10186864 chr2 76982894 T C 8.80E-05 White matter hyperintensity burden LRRTM4 intron 21681796 rs7601238 chr2 76990988 C T 3.78E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13030721 chr2 76994317 C G 6.50E-06 Urinary metabolites LRRTM4 intron 21572414 rs6718624 chr2 76994539 A G 2.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs13008894 chr2 76994984 T C 8.10E-07 Urinary metabolites LRRTM4 intron 21572414 rs7560515 chr2 76995467 T C 1.80E-06 Urinary metabolites LRRTM4 intron 21572414 rs12995505 chr2 76996310 G A,C,T 2.20E-06 Urinary metabolites LRRTM4 intron 21572414 rs4853272 chr2 77013724 C A 3.15E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853272 chr2 77013724 C A 3.12E-04 Obesity (extreme) LRRTM4 intron 21935397 rs6743728 chr2 77015014 T C 7.94E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6743728 chr2 77015014 T C 2.96E-04 Obesity (extreme) LRRTM4 intron 21935397 rs10207067 chr2 77018564 G C 2.10E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13428376 chr2 77018951 C T 2.07E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853274 chr2 77019490 G C 1.79E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10178612 chr2 77020219 T C 1.80E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1517781 chr2 77021031 C T 2.19E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1517782 chr2 77021226 C A 9.95E-07 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10170138 chr2 77021928 C T 9.27E-07 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10221841 chr2 77022492 A G 2.53E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10221606 chr2 77022651 C T 1.49E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11126566 chr2 77030315 A G 1.43E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11126572 chr2 77032027 T C 2.49E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17333150 chr2 77050462 C T 2.94E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7607019 chr2 77085351 A G 6.60E-06 Type 2 diabetes LRRTM4 intron 23209189 rs10520167 chr2 77093691 T G 8.75E-04 Multiple complex diseases LRRTM4 intron 17554300 rs721390 chr2 77094790 G T 6.24E-04 Type 2 diabetes LRRTM4 intron 17463246 rs17405232 chr2 77097164 T C 4.41E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17333446 chr2 77120146 A G 2.11E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4852420 chr2 77129922 T C 5.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013364 chr2 77153600 G A 5.86E-05 HIV-1 control LRRTM4 intron 20041166 rs11886263 chr2 77157183 C G 3.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4852423 chr2 77159948 T C 3.01E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13413625 chr2 77160723 T A 3.37E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13417401 chr2 77161916 T C 3.21E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9973564 chr2 77166432 C T 3.00E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9973567 chr2 77166479 C G 3.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9309507 chr2 77167848 G C 2.79E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11884377 chr2 77168745 A C 4.72E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193677 chr2 77169750 G C 5.12E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193590 chr2 77169802 C G 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs140227592 chr2 77169802 C CAGTG,CTGTGTG,CTGTGTGTGTGTGTGTG 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs61077287 chr2 77169802 C CTGTGTGTGTGTGTGTGTG 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10170002 chr2 77169883 A T 6.92E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013381 chr2 77169988 T C 6.25E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520170 chr2 77170201 A G 9.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013387 chr2 77172669 A C 4.99E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1921627 chr2 77172693 T C 1.00E-05 Type 2 diabetes LRRTM4 intron 23209189 rs10520173 chr2 77173236 G A 9.23E-04 Bipolar disorder LRRTM4 intron 19259986 rs10204605 chr2 77174354 T C 5.06E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10205089 chr2 77174845 T C 4.97E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10195940 chr2 77175595 G A 9.76E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10199630 chr2 77177049 G A 8.19E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11885408 chr2 77181715 G T 7.77E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13414920 chr2 77182065 A C 4.77E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13025838 chr2 77185856 T C 5.86E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013449 chr2 77187116 C G 4.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193253 chr2 77197919 C T 3.83E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446728 chr2 77198725 G C 5.63E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446714 chr2 77205297 T C 5.38E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6750979 chr2 77209051 G T 4.99E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547106 chr2 77209245 T C 4.07E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547107 chr2 77209379 C T 1.87E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520175 chr2 77209969 C G 6.47E-04 Bipolar disorder LRRTM4 intron 19259986 rs10520175 chr2 77209969 C G 3.42E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6758707 chr2 77210780 C G 2.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446717 chr2 77211342 G A 2.86E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547108 chr2 77211611 A G 2.08E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547109 chr2 77211682 C A 1.53E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6737296 chr2 77212204 A G 1.81E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7561189 chr2 77213066 C T 1.27E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13021476 chr2 77213436 A G 1.45E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs2044485 chr2 77214849 A T 4.05E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547111 chr2 77215023 G C 1.73E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1374392 chr2 77215388 C T 3.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446718 chr2 77215735 A C 1.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446720 chr2 77215788 T C 1.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17040496 chr2 77216522 A G 1.75E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1374394 chr2 77221590 T G 6.24E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1470504 chr2 77222810 A C 8.10E-04 Type 2 diabetes LRRTM4 intron 23209189 rs13388552 chr2 77222934 A G 4.30E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1470506 chr2 77223938 C T 4.00E-07 IgG glycosylation LRRTM4 intron 23382691 rs1470506 chr2 77223938 C T 6.00E-06 IgG glycosylation LRRTM4 intron 23382691 rs10205987 chr2 77224331 A C 1.99E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs12988557 chr2 77226087 G A 8.60E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17334184 chr2 77226747 C A 1.19E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520177 chr2 77228622 T C 9.00E-04 Type 2 diabetes and 6 quantitative traits LRRTM4 intron 17848626 rs6547113 chr2 77229227 C G,T 6.73E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6706194 chr2 77229559 A G 7.70E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853290 chr2 77232873 G A 4.44E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446706 chr2 77233822 G A 5.68E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10165789 chr2 77233847 C A 2.25E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013615 chr2 77241510 A G 4.41E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1348828 chr2 77245603 C G 2.46E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547115 chr2 77246331 A G 8.00E-06 IgG glycosylation LRRTM4 intron 23382691 rs12713890 chr2 77247271 A C 6.52E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1542187 chr2 77251959 C T 7.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13033902 chr2 77264354 T C 4.91E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1982340 chr2 77285117 C T 5.05E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7607753 chr2 77286529 C G 2.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10175781 chr2 77287190 C T 1.07E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13001302 chr2 77289484 T G 1.96E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7570003 chr2 77290609 G A 6.00E-06 Urinary metabolites LRRTM4 intron 21572414 rs10198799 chr2 77290690 T C 7.40E-06 Urinary metabolites LRRTM4 intron 21572414 rs13412552 chr2 77292449 C A 5.80E-06 Urinary metabolites LRRTM4 intron 21572414 rs6730095 chr2 77298456 G T 7.20E-04 Multiple complex diseases LRRTM4 intron 17554300 rs6730095 chr2 77298456 G T 5.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs6750737 chr2 77334007 G A 2.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs13386913 chr2 77375303 C T 0.0000027 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) LRRTM4 intron 23080225 rs10171377 chr2 77437279 T G 6.47E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6740940 chr2 77461887 C T 2.95E-05 Cocaine dependence LRRTM4 intron 23958962 rs2901836 chr2 77466517 T G 6.45E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1946879 chr2 77466683 G A 6.50E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13007978 chr2 77468373 T C 7.84E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6705164 chr2 77468540 T C 8.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13031572 chr2 77468655 A C 8.09E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6751463 chr2 77469401 G A 8.17E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs2861012 chr2 77470040 C T 8.15E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7603914 chr2 77470724 G T 8.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7563141 chr2 77494953 G T 7.20E-05 Malaria LRRTM4 intron 19465909 rs12611712 chr2 77497242 A G 4.13E-04 Multiple complex diseases LRRTM4 intron 17554300 rs7599090 chr2 77539865 C A 2.62E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs436659 chr2 77540502 G A 7.14E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7602394 chr2 77540524 C A 1.04E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs192634 chr2 77595904 G A 3.59E-04 Alzheimer's disease (late onset) LRRTM4 intron 21379329 rs2439567 chr2 77603802 A C 1.05E-05 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs415838 chr2 77612535 G A 3.98E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs443237 chr2 77626445 T C 1.11E-05 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs433156 chr2 77627119 A C 3.29E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290018 chr2 77630480 G A 1.61E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290017 chr2 77633146 G T 1.57E-07 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290016 chr2 77633888 T C 5.76E-07 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs13395897 chr2 77666733 A G 3.76E-05 Serum alpha1-antitrypsin levels LRRTM4 intron 23990791 rs6749190 chr2 77669850 C A 9.60E-04 Iron levels LRRTM4 intron pha002876 rs17594539 chr2 77672435 T G 8.05E-05 Alzheimer's disease LRRTM4 intron 22832961 rs12989961 chr2 77673919 T A 6.46E-04 Insulin resistance LRRTM4 intron 21901158 rs2861078 chr2 77697995 G A 7.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRTM4 intron 20877124 rs12997025 chr2 77711560 G T 5.15E-04 Type 2 diabetes LRRTM4 intron 22158537 rs1922817 chr2 77712607 G T 2.80E-04 Osteoarthritis LRRTM4 intron 19508968 rs11126611 chr2 77714052 T C 3.41E-04 Type 2 diabetes LRRTM4 intron 22158537 rs11126613 chr2 77722435 C T 3.47E-04 Type 2 diabetes LRRTM4 intron 22158537 rs17595137 chr2 77728001 G C 3.16E-04 Type 2 diabetes LRRTM4 intron 22158537 rs11885676 chr2 77732482 T C 2.49E-04 Type 2 diabetes LRRTM4 intron 22158537 rs689553 chr2 77735664 T C 3.12E-04 Type 2 diabetes LRRTM4 intron 22158537 rs17752074 chr2 77750589 G A 2.40E-05 Urinary metabolites / / 21572414 rs2901850 chr2 77783575 G T 4.58E-07 Facial morphology / / 22341974 rs4473409 chr2 77787896 T G 8.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs61354037 chr2 77800399 T C 2.20E-39 Metabolite levels / / 22286219 rs4558608 chr2 77850353 T C 9.85E-05 Schizophrenia / / 19571809 rs4485592 chr2 77857764 G A 2.91E-05 Body Mass Index / / pha003019 rs4485592 chr2 77857764 G A 3.73E-05 Body Mass Index / / pha003022 rs12052417 chr2 77872197 C T 5.87E-05 Body Mass Index / / pha003019 rs12052417 chr2 77872197 C T 6.38E-05 Body Mass Index / / pha003022 rs11684020 chr2 77878741 T C 3.86E-04 Smoking cessation / / 24665060 rs7598757 chr2 77928314 A G 1.42E-04 Type 2 diabetes / / 17463246 rs1994391 chr2 77989565 C T 3.10E-05 Postoperative ventricular dysfunction / / 21980348 rs13410776 chr2 77990389 T G 9.87E-06 Cognitive impairment induced by topiramate / / 22091778 rs1017931 chr2 78003283 G C 4.09E-05 Postoperative ventricular dysfunction / / 21980348 rs2054834 chr2 78013268 G T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2171325 chr2 78025576 G T 8.39E-06 Postoperative ventricular dysfunction / / 21980348 rs2861215 chr2 78046792 C T 4.70E-05 Volumetric brain MRI / / 17903297 rs7606314 chr2 78048214 C T 1.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7595103 chr2 78075244 G A 7.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs10205106 chr2 78084926 C T 2.32E-05 Sarcoidosis / / 19165924 rs11126639 chr2 78093107 T C 1.99E-04 White matter integrity / / 22425255 rs4594471 chr2 78094407 T C 2.44E-04 White matter integrity / / 22425255 rs10183550 chr2 78097679 G A 2.31E-04 White matter integrity / / 22425255 rs10865432 chr2 78117502 C A 1.93E-04 Epilepsy / / 22116939 rs1897616 chr2 78120305 C T 3.68E-04 Epilepsy / / 22116939 rs10172925 chr2 78124090 G A 1.47E-04 Epilepsy / / 22116939 rs6547168 chr2 78125714 T C 3.46E-06 Serum metabolites / / 19043545 rs7602889 chr2 78133560 T C 1.30E-05 Epilepsy / / 22116939 rs4853352 chr2 78139549 G A 5.50E-06 Epilepsy / / 22116939 rs4853355 chr2 78144479 G A 3.88E-04 Epilepsy / / 22116939 rs1433197 chr2 78145340 T C 6.06E-04 Epilepsy / / 22116939 rs1368502 chr2 78170534 G A 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs1368502 chr2 78170534 G A 2.15E-04 Epilepsy / / 22116939 rs10174468 chr2 78179866 G A 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs1074192 chr2 78199268 C T 6.97E-05 Epilepsy / / 22116939 rs1609077 chr2 78214766 T C 6.34E-04 Epilepsy / / 22116939 rs2163873 chr2 78221253 T G 8.01E-04 Epilepsy / / 22116939 rs1405588 chr2 78262099 G A 5.20E-04 Coronary heart disease / / 21971053 rs1527194 chr2 78263883 T C 7.08E-04 Epilepsy / / 22116939 rs17014915 chr2 78294642 T C 4.25E-05 Suicide attempts in bipolar disorder / / 21041247 rs17014922 chr2 78296074 T C 4.28E-05 Suicide attempts in bipolar disorder / / 21041247 rs2164851 chr2 78302215 G A 1.49E-04 Epilepsy / / 22116939 rs11126651 chr2 78304795 T G 2.70E-04 Alcohol dependence / / 20201924 rs11126651 chr2 78304795 T G 8.80E-04 Alcohol dependence / / 20201924 rs7573381 chr2 78305622 A G 6.30E-04 Alcohol dependence / / 20201924 rs1437985 chr2 78311781 T C 3.57E-04 Epilepsy / / 22116939 rs6547183 chr2 78314039 T C 3.59E-04 Epilepsy / / 22116939 rs1550248 chr2 78316507 T C 5.27E-04 Multiple complex diseases / / 17554300 rs1550248 chr2 78316507 T C 4.21E-05 Cardiovascular disease / / pha003065 rs7593405 chr2 78328532 C T 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs10173591 chr2 78332806 C T 4.93E-04 Epilepsy / / 22116939 rs1370637 chr2 78341245 C A 5.57E-04 Epilepsy / / 22116939 rs13425498 chr2 78352550 C T 2.60E-04 Alzheimer's disease / / 22005930 rs1437982 chr2 78361627 C T 2.38E-04 Alzheimer's disease / / 22005930 rs10175966 chr2 78368924 C T 3.34E-04 Alzheimer's disease / / 22005930 rs12994771 chr2 78373181 G A 3.57E-04 Alzheimer's disease / / 22005930 rs13020811 chr2 78375148 C T 3.85E-04 Alzheimer's disease / / 22005930 rs6716814 chr2 78376184 C T 3.99E-04 Alzheimer's disease / / 22005930 rs12713950 chr2 78381506 G T 5.04E-04 Alzheimer's disease / / 22005930 rs6547194 chr2 78457741 G T 8.56E-04 Multiple complex diseases / / 17554300 rs1405274 chr2 78500655 C T 4.20E-05 Major depressive disorder / / 21042317 rs1818965 chr2 78501560 A G 6.70E-05 Major depressive disorder / / 21042317 rs17015127 chr2 78521092 A G 7.70E-05 Major depressive disorder / / 21042317 rs6743486 chr2 78523914 C T 8.80E-05 Major depressive disorder / / 21042317 rs2037723 chr2 78539666 G A 2.88E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2037723 chr2 78539666 G A 3.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2037723 chr2 78539666 G A 8.91E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6754754 chr2 78562013 G A 1.29E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6754754 chr2 78562013 G A 1.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1114583 chr2 78593396 C T 2.26E-04 Cognition,early reading ability / / 17684495 rs2861609 chr2 78633880 A G 4.64E-05 Body Composition / / pha003012 rs10181697 chr2 78702648 T C 9.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17643690 chr2 78758875 C T 5.60E-06 Urinary metabolites / / 21572414 rs17585586 chr2 78993517 A G 6.82E-04 Multiple complex diseases / / 17554300 rs1521952 chr2 79013457 A G 5.40E-05 Eosinophil counts / / pha003088 rs4853413 chr2 79021429 T C 6.56E-04 Multiple complex diseases / / 17554300 rs4853414 chr2 79069569 C T 1.61E-04 Major depressive disorder / / 22472876 rs6744850 chr2 79113589 A C 1.91E-04 Type 2 diabetes / / 17463246 rs4853422 chr2 79116722 C T 8.85E-05 HIV-1 viral setpoint / / 22174851 rs10169228 chr2 79121549 A G 4.97E-04 Smoking initiation / / 24665060 rs1915751 chr2 79122483 T C 3.77E-04 Taste perception / / 22132133 rs17648900 chr2 79135349 A G 6.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7585834 chr2 79141188 A C 1.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2861680 chr2 79152922 G A 7.69E-04 Smoking initiation / / 24665060 rs9309542 chr2 79160592 G T 1.42E-05 Eosinophil counts / / pha003088 rs9309543 chr2 79160617 G A 1.42E-05 Eosinophil counts / / pha003088 rs1261226 chr2 79166443 T C 1.19E-05 Bone mass and geometry / / 17903296 rs1261226 chr2 79166443 T C 4.00E-05 Eosinophil counts / / pha003088 rs12986641 chr2 79183413 T C 1.19E-06 Contrast sensitivity / / 24152035 rs12986856 chr2 79183516 T C 3.67E-07 Contrast sensitivity / / 24152035 rs17692905 chr2 79184629 C T 3.78E-07 Contrast sensitivity / / 24152035 rs13000084 chr2 79185415 C A 5.86E-07 Contrast sensitivity / / 24152035 rs17692957 chr2 79185685 C T 3.54E-07 Contrast sensitivity / / 24152035 rs13001435 chr2 79185904 G T 5.86E-07 Contrast sensitivity / / 24152035 rs13007327 chr2 79186313 G A 5.86E-07 Contrast sensitivity / / 24152035 rs13007459 chr2 79186563 C A 3.54E-07 Contrast sensitivity / / 24152035 rs34474458 chr2 79186758 C T 5.87E-07 Contrast sensitivity / / 24152035 rs13008392 chr2 79186785 G A 5.87E-07 Contrast sensitivity / / 24152035 rs35919794 chr2 79187128 A T 5.87E-07 Contrast sensitivity / / 24152035 rs36072286 chr2 79187137 T C 3.55E-07 Contrast sensitivity / / 24152035 rs35743083 chr2 79187151 T C 5.87E-07 Contrast sensitivity / / 24152035 rs11674703 chr2 79187381 T C 5.86E-07 Contrast sensitivity / / 24152035 rs13014457 chr2 79187457 C T 5.86E-07 Contrast sensitivity / / 24152035 rs11679961 chr2 79187489 A C 5.86E-07 Contrast sensitivity / / 24152035 rs11691084 chr2 79187502 C T 5.86E-07 Contrast sensitivity / / 24152035 rs11691141 chr2 79187588 C G 5.87E-07 Contrast sensitivity / / 24152035 rs71424840 chr2 79188272 T C 5.84E-07 Contrast sensitivity / / 24152035 rs11683300 chr2 79190060 A G 2.45E-07 Contrast sensitivity / / 24152035 rs11695755 chr2 79190073 C T 2.43E-07 Contrast sensitivity / / 24152035 rs10520219 chr2 79190408 G A 8.35E-06 Contrast sensitivity / / 24152035 rs11679452 chr2 79190517 T C 1.94E-07 Contrast sensitivity / / 24152035 rs17015957 chr2 79191047 A G 7.68E-06 Contrast sensitivity / / 24152035 rs55857353 chr2 79191129 C T 1.97E-07 Contrast sensitivity / / 24152035 rs17015960 chr2 79192643 A G 8.57E-06 Contrast sensitivity / / 24152035 rs35119416 chr2 79193163 T G 3.06E-07 Contrast sensitivity / / 24152035 rs56330221 chr2 79193372 A G 9.65E-06 Contrast sensitivity / / 24152035 rs11677315 chr2 79194293 T C 9.11E-08 Contrast sensitivity / / 24152035 rs11693972 chr2 79194668 C G 2.37E-06 Contrast sensitivity / / 24152035 rs11683503 chr2 79198168 T C 1.00E-07 Contrast sensitivity / / 24152035 rs34611177 chr2 79201918 A T 2.14E-07 Contrast sensitivity / / 24152035 rs17749826 chr2 79213468 G A 4.32E-07 Contrast sensitivity / / 24152035 rs10520222 chr2 79214891 C T 9.07E-07 Contrast sensitivity / / 24152035 rs11676773 chr2 79215748 A G 1.89E-07 Contrast sensitivity / / 24152035 rs13008188 chr2 79216796 G A 4.30E-07 Contrast sensitivity / / 24152035 rs11694350 chr2 79219390 G A 3.08E-07 Contrast sensitivity / / 24152035 rs1666768 chr2 79223215 G A 0.000274 Salmonella-induced pyroptosis / / 22837397 rs811526 chr2 79227099 A C 1.93E-05 Response to hepatitis C treatment / / 19684573 rs789304 chr2 79227147 G C 1.10E-05 Urinary metabolites / / 21572414 rs10520227 chr2 79230585 G A 5.40E-06 Urinary metabolites / / 21572414 rs375644 chr2 79241810 C T 1.80E-06 Urinary metabolites / / 21572414 rs17016215 chr2 79252307 G A 5.77E-04 Multiple complex diseases / / 17554300 rs17016215 chr2 79252307 G A 6.29E-05 Femoral neck bone geometry / / 22087292 rs283838 chr2 79263703 G A 9.20E-06 Menarche (age at onset) / / 19448622 rs283843 chr2 79268213 C A 2.90E-05 Urinary metabolites / / 21572414 rs283849 chr2 79271035 T G 4.30E-06 Urinary metabolites / / 21572414 rs364446 chr2 79291934 C T 2.88E-04 Schizophrenia / / 19197363 rs6710553 chr2 79300863 C T 1.34E-04 Multiple complex diseases / / 17554300 rs1608234 chr2 79303418 T C 6.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1036392 chr2 79342811 C T 1.69E-05 Multiple complex diseases / / 17554300 rs7603333 chr2 79357595 G A,T 8.75E-05 Schizophrenia / / 19197363 rs17753959 chr2 79359874 G A 8.91E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3819315 chr2 79364601 C T 9.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs879021 chr2 79364824 C A 7.32E-05 Schizophrenia / / 19197363 rs1589614 chr2 79370426 C T 8.60E-05 Alzheimer's disease (late onset) / / 21379329 rs17016435 chr2 79405396 A G 5.53E-05 Biliary atresia / / 20460270 rs10496214 chr2 79417943 G T 6.88E-04 Schizophrenia / / 19197363 rs4853444 chr2 79450316 C A 3.69E-04 Parkinson's disease / / 17052657 rs4853451 chr2 79508165 G A 3.92E-05 Taste perception / / 22132133 rs12470852 chr2 79509022 G C 4.22E-04 Acute lung injury / / 22295056 rs11126705 chr2 79509292 C T 2.01E-04 Acute lung injury / / 22295056 rs12623159 chr2 79516586 T A 1.73E-04 Acute lung injury / / 22295056 rs11126706 chr2 79517133 A G 1.62E-04 Acute lung injury / / 22295056 rs6733601 chr2 79517346 G A 6.37E-04 Multiple complex diseases / / 17554300 rs11126707 chr2 79517637 G A 1.17E-04 Acute lung injury / / 22295056 rs732258 chr2 79518553 C T 1.35E-04 Acute lung injury / / 22295056 rs12471468 chr2 79521952 A G 1.03E-04 Acute lung injury / / 22295056 rs12465102 chr2 79525033 T A 2.83E-04 Acute lung injury / / 22295056 rs1434205 chr2 79525428 T C 8.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6760650 chr2 79529472 C T 1.74E-04 Acute lung injury / / 22295056 rs6760878 chr2 79529552 G C 3.13E-04 Acute lung injury / / 22295056 rs10200371 chr2 79530813 A G 3.05E-04 Acute lung injury / / 22295056 rs13397704 chr2 79536354 G A 8.37E-04 Acute lung injury / / 22295056 rs13427217 chr2 79537984 A T 1.34E-04 Acute lung injury / / 22295056 rs13418113 chr2 79538168 T G 1.25E-04 Acute lung injury / / 22295056 rs13418113 chr2 79538168 T G 9.14E-05 Blood Pressure / / pha003039 rs13409348 chr2 79539988 G C 3.00E-06 Bipolar disorder / / 19416921 rs13409348 chr2 79539988 G C 1.08E-04 Acute lung injury / / 22295056 rs13385415 chr2 79543430 T A 5.02E-04 Acute lung injury / / 22295056 rs10200167 chr2 79544256 T C 1.56E-04 Alzheimer's disease / / 24755620 rs1434172 chr2 79553119 C A 1.34E-04 Acute lung injury / / 22295056 rs1562886 chr2 79562459 T C 2.13E-04 Smoking cessation / / 24665060 rs1368965 chr2 79567440 C A 5.07E-05 Potassium levels / / pha003086 rs4852472 chr2 79571761 C T 6.57E-04 Alzheimer's disease / / 17998437 rs2100290 chr2 79632347 A G 2.00E-06 Alcohol consumption / / 23942779 rs2100290 chr2 79632347 A G 2.80E-04 Nicotine use / / 23942779 rs399885 chr2 79687252 A C 5.00E-07 Response to antipsychotic treatment / / 20195266 rs1864548 chr2 79689572 T C 3.70E-04 Rheumatoid arthritis / / 22446963 rs7598481 chr2 79697456 C T 9.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs1864549 chr2 79699411 C A 6.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17040658 chr2 79708518 A G 9.50E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7570469 chr2 79709354 C T 6.00E-07 Response to antipsychotic treatment / / 20195266 rs11900604 chr2 79715879 T G 3.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17017222 chr2 79733001 C T 7.34E-05 Multiple complex diseases / / 17554300 rs41503545 chr2 79735130 T A 5.89E-04 Multiple complex diseases / / 17554300 rs10206130 chr2 79750591 G T 2.80E-06 Urinary metabolites CTN/2 intron 21572414 rs10206130 chr2 79750591 G T 4.13E-05 Sudden cardiac arrest CTN/2 intron 21658281 rs6719738 chr2 79760238 T C 7.40E-06 Urinary metabolites CTN/2 intron 21572414 rs17017233 chr2 79772054 T C 8.64E-05 Multiple complex diseases CTN/2 intron 17554300 rs17017233 chr2 79772054 T C 1.06E-04 Blood pressure (response to calcium channel blocker) CTN/2 intron 24192120 rs880813 chr2 79776291 C A 8.20E-04 Alzheimer's disease CTN/2 intron 22005930 rs7597912 chr2 79778112 T C 3.17E-05 Sudden cardiac arrest CTN/2 intron 21658281 rs10520246 chr2 79781669 G T 1.50E-04 Breast cancer and prostate cancer CTN/2 intron 17903305 rs10520247 chr2 79781797 G C 2.80E-05 Breast cancer and prostate cancer CTN/2 intron 17903305 rs2685159 chr2 79782036 A G 3.19E-04 Multiple complex diseases CTN/2 intron 17554300 rs2685159 chr2 79782036 A G 1.52E-04 Blood pressure (response to calcium channel blocker) CTN/2 intron 24192120 rs2685162 chr2 79783547 T C 8.82E-04 Alzheimer's disease CTN/2 intron 22005930 rs1972755 chr2 79784187 T C 8.54E-04 Alzheimer's disease CTN/2 intron 22005930 rs1430641 chr2 79785578 C G 6.55E-04 Alzheimer's disease CTN/2 intron 22005930 rs2566540 chr2 79786393 A T 6.91E-04 Alzheimer's disease CTN/2 intron 22005930 rs2566541 chr2 79793629 C A 9.91E-04 Alzheimer's disease CTN/2 intron 22005930 rs17017285 chr2 79800992 T C 5.69E-04 Multiple complex diseases CTN/2 intron 17554300 rs2685150 chr2 79803425 A G 7.27E-04 Alzheimer's disease CTN/2 intron 22005930 rs1549761 chr2 79811084 C A 6.46E-04 Alzheimer's disease CTN/2 intron 22005930 rs11126737 chr2 79811402 G A 9.64E-04 Alzheimer's disease CTN/2 intron 22005930 rs7598670 chr2 79813622 T C 6.77E-04 Alzheimer's disease CTN/2 intron 22005930 rs6740609 chr2 79855622 C T 6.92E-05 Cognitive test performance CTN/2 intron 20125193 rs6740609 chr2 79855622 C T 4.48E-04 Hemoglobin concentration CTN/2 intron 20534544 rs12464912 chr2 79890172 T C 7.14E-05 Lung adenocarcinoma CTN/2 intron 19836008 rs6759387 chr2 79891085 T A 1.42E-04 Type 2 diabetes CTN/2 intron 17463246 rs4422182 chr2 79905813 G A 0.0005935 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CTN/2 intron 23233654 rs4422182 chr2 79905813 G A 5.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) CTN/2 intron 23233662 rs2089815 chr2 79905975 T G 0.0005893 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CTN/2 intron 23233654 rs2089815 chr2 79905975 T G 5.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) CTN/2 intron 23233662 rs12471455 chr2 79910349 G A 9.45E-06 Pancreatic cancer CTN/2 intron pha002889 rs11695685 chr2 79922802 C T 5.00E-07 Protein quantitative trait loci CTN/2 intron 18464913 rs13028762 chr2 79930269 T C 3.91E-04 Smoking cessation CTN/2 intron 24665060 rs6547265 chr2 79940319 G C 5.30E-06 Urinary metabolites CTN/2 intron 21572414 rs6547265 chr2 79940319 G C 5.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CTN/2 intron 22566498 rs11693318 chr2 79956356 C A 1.33E-05 Pancreatic cancer CTN/2 intron 23180869 rs1567532 chr2 79956550 C T 9.55E-06 Pancreatic cancer CTN/2 intron 23180869 rs7565556 chr2 79963405 G C 5.40E-04 Type 2 diabetes and 6 quantitative traits CTN/2 intron 17848626 rs6724922 chr2 79971248 C T 2.27E-05 Waist-Hip Ratio CTN/2 intron pha003029 rs4541274 chr2 79973436 T C 7.04E-04 Longevity CTN/2 intron 22279548 rs6547273 chr2 79985605 T G 1.91E-05 Heart Rate CTN/2 intron pha003054 rs7592956 chr2 79992038 C T 2.70E-05 Urinary metabolites CTN/2 intron 21572414 rs1912697 chr2 79993340 G T 1.00E-05 Urinary metabolites CTN/2 intron 21572414 rs6751684 chr2 80023852 C A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) CTN/2 intron 24529757 rs868032 chr2 80034570 T C 6.73E-04 Multiple complex diseases CTN/2 intron 17554300 rs2941752 chr2 80047419 G A 1.20E-05 Urinary metabolites CTN/2 intron 21572414 rs4852531 chr2 80049718 C T 8.23E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CTN/2 intron 24023788 rs2861914 chr2 80081182 T G 1.60E-04 Type 2 diabetes CTN/2 intron 17463246 rs713261 chr2 80095412 C T 9.90E-04 Multiple complex diseases CTN/2 intron 17554300 rs2916508 chr2 80111797 G T 3.96E-04 Age-related macular degeneration CTN/2 intron 22125219 rs986211 chr2 80112641 C T 1.06E-05 Age-related macular degeneration CTN/2 intron 22125219 rs2974173 chr2 80121731 G T 3.25E-04 Hemoglobin concentration CTN/2 intron 20534544 rs17018130 chr2 80134512 A G 4.12E-04 Multiple complex diseases CTN/2 intron 17554300 rs2974179 chr2 80138245 A G 1.67E-04 Hemoglobin concentration CTN/2 intron 20534544 rs2916530 chr2 80156246 G A 1.69E-04 Coronary Artery Disease CTN/2 intron 17634449 rs2974142 chr2 80162195 C T 4.21E-05 HDL particle features CTN/2 intron pha002900 rs2974133 chr2 80180508 G T 2.45E-05 Prion diseases CTN/2 intron 22210626 rs3905417 chr2 80181443 G A 2.20E-05 Urinary metabolites CTN/2 intron 21572414 rs4591366 chr2 80182551 C T 9.14E-05 HDL cholesterol CTN/2 intron pha003075 rs6745989 chr2 80182604 G A 5.41E-06 Panic disorder CTN/2 intron 19165232 rs6745989 chr2 80182604 G A 2.67E-25 Narcolepsy CTN/2 intron 19629137 rs747921 chr2 80185885 A G 6.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) CTN/2 intron 23648065 rs12990844 chr2 80187793 C T 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs6752828 chr2 80187969 C T 3.90E-04 Myopia (pathological) CTN/2 intron 21095009 rs2861913 chr2 80192435 A G 1.12E-04 Multiple sclerosis CTN/2 intron 17660530 rs2861913 chr2 80192435 A G 6.95E-05 Personality dimensions CTN/2 intron 18957941 rs2861913 chr2 80192435 A G 2.75E-05 Serum metabolites CTN/2 intron 19043545 rs6719499 chr2 80193386 G A 2.45E-05 Coronary heart disease CTN/2 intron pha003031 rs13001262 chr2 80194080 C T 6.40E-05 Coronary heart disease CTN/2 intron pha003031 rs13028697 chr2 80194625 T C 3.01E-05 Intelligence CTN/2 intron 21826061 rs13028697 chr2 80194625 T C 9.74E-05 Coronary heart disease CTN/2 intron pha003031 rs542255 chr2 80196736 T G 5.52E-05 Coronary heart disease CTN/2 intron pha003031 rs671772 chr2 80197462 T C 6.83E-05 Coronary heart disease CTN/2 intron pha003032 rs17261321 chr2 80197843 G T 9.60E-05 Coronary heart disease CTN/2 intron pha003030 rs598453 chr2 80214554 C T 7.55E-05 Coronary heart disease CTN/2 intron pha003030 rs556003 chr2 80216399 C T 4.75E-05 Coronary heart disease CTN/2 intron pha003032 rs491062 chr2 80218984 C A 8.58E-06 Coronary heart disease CTN/2 intron pha003032 rs571094 chr2 80220009 A C 8.50E-06 Urinary metabolites CTN/2 intron 21572414 rs1368909 chr2 80228740 T C 1.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) CTN/2 intron 23648065 rs6741085 chr2 80230424 T G 4.97E-04 Response to taxane treatment (placlitaxel) CTN/2 intron 23006423 rs423412 chr2 80236251 A G 0.00008141 Sarcoidosis CTN/2 intron 22952805 rs719487 chr2 80238531 C T 3.00E-06 Urinary metabolites CTN/2 intron 21572414 rs921637 chr2 80259424 G A 3.30E-04 Aortic root size CTN/2 intron 21223598 rs4852549 chr2 80280680 G A 1.64E-04 Multiple complex diseases CTN/2 intron 17554300 rs13394835 chr2 80280710 C A 2.81E-04 Multiple complex diseases CTN/2 intron 17554300 rs6738962 chr2 80281173 A G 1.00E-08 Alzheimer's disease (cognitive decline) CTN/2 intron 23535033 rs13427272 chr2 80285936 G A 6.10E-07 Fasting plasma glucose CTN/2 intron 19060907 rs716487 chr2 80310648 A G 1.10E-04 Rheumatoid arthritis CTN/2 intron 21673997 rs6720989 chr2 80329535 G A 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs6720989 chr2 80329535 G A 2.05E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7575007 chr2 80330233 G C 2.03E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7592938 chr2 80331554 T C 2.27E-04 Cholesterol CTN/2 intron 17255346 rs10496237 chr2 80331812 C T 2.03E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1031442 chr2 80332151 T C 1.62E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1552308 chr2 80333464 G A 1.79E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7570587 chr2 80334824 C T 9.83E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1017633 chr2 80340091 C A 8.99E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1017632 chr2 80340234 G A 9.27E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1319228 chr2 80344073 G A 5.28E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs2902111 chr2 80346212 C T 6.62E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1319241 chr2 80392892 C T 1.83E-04 Cholesterol CTN/2 intron 17255346 rs17018760 chr2 80398707 C T 7.17E-05 Cholesterol CTN/2 intron 17255346 rs11893350 chr2 80399212 C T 5.53E-05 Cholesterol CTN/2 intron 17255346 rs1530397 chr2 80415634 A C 3.70E-05 Cholesterol CTN/2 intron 17255346 rs7570531 chr2 80420696 T C 2.50E-05 Cholesterol CTN/2 intron 17255346 rs961408 chr2 80421277 A G 3.57E-05 Cholesterol CTN/2 intron 17255346 rs1446107 chr2 80434401 A G 1.53E-05 Cholesterol CTN/2 intron 17255346 rs1446108 chr2 80434636 G A 2.11E-05 Cholesterol CTN/2 intron 17255346 rs7590636 chr2 80445512 G A 1.79E-05 Cholesterol CTN/2 intron 17255346 rs1006607 chr2 80448882 A G 1.94E-05 Cholesterol CTN/2 intron 17255346 rs2120408 chr2 80450284 A G 2.16E-05 Cholesterol CTN/2 intron 17255346 rs1965834 chr2 80451078 G A 1.44E-05 Cholesterol CTN/2 intron 17255346 rs1965833 chr2 80451184 T C 3.88E-05 Cholesterol CTN/2 intron 17255346 rs2165975 chr2 80452104 G A 2.88E-05 Cholesterol CTN/2 intron 17255346 rs2587148 chr2 80463850 G A 5.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs1079319 chr2 80510040 G T 4.16E-05 Cholesterol CTN/2 intron 17255346 rs1930 chr2 80514672 C T 1.90E-04 Blood pressure CTN/2 intron 21572416 rs6733871 chr2 80529956 T C 4.69E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy LRRTM1 missense 23834954 rs12465382 chr2 80567348 A G 3.36E-04 Smoking initiation CTN/2 intron 24665060 rs1443896 chr2 80572750 G A 1.83E-04 Smoking initiation CTN/2 intron 24665060 rs6739985 chr2 80575448 G T 1.70E-04 Smoking initiation CTN/2 intron 24665060 rs13431891 chr2 80605790 A G 4.06E-08 Eye color CTN/2 intron 23486544 rs7557554 chr2 80651461 C T 6.92E-04 Type 2 diabetes CTN/2 intron 17463246 rs1444541 chr2 80656878 G A 5.57E-05 Soluble levels of adhesion molecules CTN/2 intron pha003072 rs6747004 chr2 80668722 T G 2.80E-05 Urinary metabolites CTN/2 intron 21572414 rs3290 chr2 80677131 G C 5.16E-04 Type 2 diabetes CTN/2 intron 17463246 rs17019221 chr2 80703605 A G 6.19E-05 Smoking cessation CTN/2 intron 18519826 rs11886059 chr2 80716608 T C 3.73E-04 Multiple complex diseases CTN/2 intron 17554300 rs13409724 chr2 80752502 T C 7.97E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs12611756 chr2 80761192 A C 5.88E-05 Cardiovascular disease CTN/2 intron 22029572 rs13423141 chr2 80770808 C T 8.74E-05 Alcohol dependence CTN/2 intron 20201924 rs13423141 chr2 80770808 C T 8.74E-05 Alcoholism CTN/2 intron pha002891 rs7605261 chr2 80771190 T G 5.73E-04 Alcohol dependence CTN/2 intron 20201924 rs1816456 chr2 80786499 T G 0.000393 Salmonella-induced pyroptosis CTN/2 intron 22837397 rs1434064 chr2 80798914 G C 7.35E-05 Smoking cessation CTN/2 intron 18519826 rs1560862 chr2 80800793 G A 0.0000598 Tuberculosis with late age of onset CTN/2 intron 22551897 rs3770340 chr2 80813664 G A 4.83E-04 Sarcoidosis CTN/2 intron 19165924 rs216645 chr2 80825711 A T 1.26E-04 Smoking cessation CTN/2 intron 18519826 rs216645 chr2 80825711 A T 7.93E-04 Smoking cessation CTN/2 intron 18519826 rs216645 chr2 80825711 A T 7.17E-04 Alzheimer's disease CTN/2 intron 24755620 rs17019480 chr2 80834949 G A 2.98E-04 Smoking initiation CTN/2 intron 24665060 rs17019531 chr2 80858726 C T 0.000807 Salmonella-induced pyroptosis CTN/2 intron 22837397 rs13382374 chr2 80885470 T C 7.53E-04 Depression (quantitative trait) / / 20800221 rs7574764 chr2 80898579 T C 7.43E-04 Depression (quantitative trait) / / 20800221 rs13404209 chr2 80900868 C G 7.36E-04 Depression (quantitative trait) / / 20800221 rs6718076 chr2 80900986 G A 1.44E-04 Type 2 diabetes / / 17463246 rs1370339 chr2 80915114 C T 5.68E-05 Anorexia nervosa / / 24514567 rs17019600 chr2 80915734 C A 5.10E-05 Ulcerative colitis / / 19915572 rs11684938 chr2 80924920 A G 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6757169 chr2 80939019 A G 6.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7593517 chr2 80942676 G A 2.36E-04 Multiple complex diseases / / 17554300 rs7607618 chr2 80942951 T C 3.88E-04 Multiple complex diseases / / 17554300 rs10490511 chr2 80948763 G A 7.03E-04 Multiple complex diseases / / 17554300 rs1265750 chr2 80951823 T C 9.16E-05 Blood Pressure / / pha002903 rs6547332 chr2 81018887 G A 8.69E-04 Nicotine dependence / / 17158188 rs4852592 chr2 81040532 G A 8.56E-05 Body Mass Index / / pha003006 rs6547333 chr2 81099320 A T 2.36E-04 Nicotine dependence / / 17158188 rs17019859 chr2 81125236 G A 1.81E-04 Nicotine dependence / / 17158188 rs7583676 chr2 81171004 C A 4.52E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs2862358 chr2 81180603 T G 5.80E-05 Personality dimensions / / 18957941 rs4462808 chr2 81191209 G T 1.31E-04 Osteoarthritis / / 19508968 rs4389353 chr2 81201683 C T 3.37E-04 Osteoarthritis / / 19508968 rs6547341 chr2 81241412 C T 6.69E-05 Body Composition / / pha003012 rs12465939 chr2 81241811 C A,T 3.94E-06 Socioeconomic Factors / / pha003066 rs3979242 chr2 81261916 G A 7.70E-05 Body Composition / / pha003012 rs11126794 chr2 81321126 C T 7.93E-05 Personality dimensions / / 18957941 rs1968758 chr2 81420899 G T 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13430688 chr2 81421951 A G 1.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4852611 chr2 81425437 C A 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs921963 chr2 81426483 C A 2.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2010447 chr2 81427187 C T 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6710284 chr2 81440526 T C 4.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1379387 chr2 81442038 G A 7.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7557024 chr2 81461019 A G 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7557987 chr2 81469658 T G 9.69E-05 Body Mass Index / / pha003009 rs4349373 chr2 81471682 C T 7.72E-05 Body Mass Index / / pha003009 rs6707716 chr2 81485448 T C 4.42E-28 Narcolepsy / / 19629137 rs7581118 chr2 81505707 C T 7.73E-05 Body Mass Index / / pha003009 rs13424413 chr2 81562649 G A 1.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10208516 chr2 81574758 G A 7.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12467913 chr2 81637683 A T 0.0004676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12467913 chr2 81637683 A T 4.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1435883 chr2 81642505 A G 6.14E-05 Blood Pressure / / pha002903 rs11887827 chr2 81666154 A G 8.27E-14 Multiple complex diseases / / 17554300 rs10496265 chr2 81668808 T C 1.00E-08 Aging traits / / 17903295 rs12468325 chr2 81690580 C G 9.73E-04 Multiple complex diseases LOC100507201 intron 17554300 rs6752979 chr2 81741750 G A 4.74E-05 Blood Pressure / / pha002903 rs10496262 chr2 81751124 C A 3.00E-07 Aging traits / / 17903295 rs764977 chr2 81757391 T C 8.76E-05 Blood Pressure / / pha002903 rs6756959 chr2 81772723 G A 2.20E-06 Orthostatic hypotension / / 24124408 rs6715049 chr2 81772994 T C 3.50E-06 Orthostatic hypotension / / 24124408 rs6715049 chr2 81772994 T C 6.31E-05 Blood Pressure / / pha002903 rs17020478 chr2 81818331 A G 5.25E-04 Multiple complex diseases / / 17554300 rs7570909 chr2 81819551 T C 9.77E-05 Blood Pressure / / pha002903 rs17020502 chr2 81828061 G A 2.00E-05 Urinary metabolites / / 21572414 rs17020502 chr2 81828061 G A 3.70E-06 Orthostatic hypotension / / 24124408 rs11126825 chr2 81844064 A G 2.00E-05 Urinary metabolites / / 21572414 rs6736587 chr2 81855725 A C 5.00E-08 Orthostatic hypotension / / 24124408 rs12615721 chr2 81856526 G A 8.00E-06 Pulmonary function decline / / 22424883 rs12052359 chr2 81872922 C A 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12052359 chr2 81872922 C A 7.00E-06 Bilirubin levels / / 22085899 rs11883603 chr2 81902711 T A 2.70E-05 Urinary metabolites / / 21572414 rs12612468 chr2 81935992 A C 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674927 chr2 81938574 T G 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1432187 chr2 81946409 A C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6706099 chr2 81955364 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6734974 chr2 81955456 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs17020736 chr2 81967942 T A 2.70E-05 Urinary metabolites / / 21572414 rs2705635 chr2 81991586 G A 2.60E-05 Urinary metabolites / / 21572414 rs1108797 chr2 81992578 A G 2.40E-05 Urinary metabolites / / 21572414 rs1221178 chr2 81992756 A G 2.10E-05 Urinary metabolites / / 21572414 rs1368038 chr2 82027767 T C 5.37E-04 Multiple complex diseases / / 17554300 rs10166510 chr2 82035216 A G 7.38E-04 Smoking initiation / / 24665060 rs17563144 chr2 82035849 C T 1.90E-05 Urinary metabolites / / 21572414 rs12470539 chr2 82046122 A C 8.85E-04 Multiple complex diseases / / 17554300 rs2862590 chr2 82078480 G T 6.73E-05 Otosclerosis / / 19230858 rs2862591 chr2 82078577 C A 1.30E-05 Urinary metabolites / / 21572414 rs991869 chr2 82086880 C G 3.20E-06 Urinary metabolites / / 21572414 rs1897403 chr2 82110525 G A,C 1.90E-05 Urinary metabolites / / 21572414 rs11895085 chr2 82135708 G A 8.60E-06 Urinary metabolites / / 21572414 rs10520308 chr2 82149614 T G 4.59E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2685708 chr2 82168870 A G 9.30E-05 Bipolar disorder / / 17486107 rs2862675 chr2 82224685 A G 6.87E-04 Rheumatoid arthritis / / 21452313 rs17568078 chr2 82225677 A G 3.64E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17021319 chr2 82227252 T C 6.15E-05 Intelligence / / 21826061 rs6729973 chr2 82232407 A G 6.85E-05 Intelligence / / 21826061 rs4852655 chr2 82235644 C T 8.56E-04 Schizophrenia / / 19197363 rs11687765 chr2 82325531 C A 7.80E-04 Body mass index / / 21701565 rs9309592 chr2 82331757 G T 5.55E-04 Body mass index / / 21701565 rs1529593 chr2 82372848 G A 4.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7560758 chr2 82382462 A G 4.40E-04 Multiple complex diseases / / 17554300 rs17021536 chr2 82416690 G A 5.90E-04 Multiple complex diseases / / 17554300 rs2163361 chr2 82427505 A T 8.29E-04 Multiple complex diseases / / 17554300 rs7586694 chr2 82658348 G A 1.94E-05 Post-operative nausea and vomiting / / 21694509 rs11681331 chr2 82717155 C A 6.39E-05 Lung adenocarcinoma / / 19836008 rs6706386 chr2 82741007 C G 9.26E-04 Coronary Artery Disease / / 17634449 rs17021922 chr2 82768466 C T 9.37E-04 Coronary Artery Disease / / 17634449 rs6547436 chr2 82811606 G A 8.98E-04 Coronary Artery Disease / / 17634449 rs1910233 chr2 82867347 T G 9.17E-04 Myopia (pathological) / / 21095009 rs1393503 chr2 82883841 T G 5.52E-04 Myopia (pathological) / / 21095009 rs1393504 chr2 82883860 G T 5.95E-04 Myopia (pathological) / / 21095009 rs6731289 chr2 82892794 C A 2.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6731289 chr2 82892794 C A 8.45E-04 Myopia (pathological) / / 21095009 rs6731289 chr2 82892794 C A 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10520355 chr2 82913165 T C 1.00E-06 Urinary metabolites / / 21572414 rs1393501 chr2 82921559 C A 4.36E-04 Myopia (pathological) / / 21095009 rs4852691 chr2 82924585 G C 1.40E-05 Urinary metabolites / / 21572414 rs1502598 chr2 82925182 A T 1.40E-05 Urinary metabolites / / 21572414 rs12476792 chr2 82935393 G A 2.30E-05 Urinary metabolites / / 21572414 rs2134370 chr2 82939886 A G 5.43E-04 Myopia (pathological) / / 21095009 rs13415522 chr2 82943212 T C 2.60E-05 Urinary metabolites / / 21572414 rs17022257 chr2 82947063 A G 5.16E-04 Smoking quantity / / 24665060 rs17022279 chr2 82956407 C G 9.98E-04 Self-reported allergy / / 23817569 rs17022288 chr2 82957817 C T 9.76E-05 Smoking quantity / / 24665060 rs12328118 chr2 82957950 A G 4.93E-05 Vaspin levels / / 22907691 rs12328118 chr2 82957950 A G 0.0000493 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022321 chr2 82960647 C G 9.31E-04 Self-reported allergy / / 23817569 rs6547441 chr2 82965627 G A 1.46E-04 Vaspin levels / / 22907691 rs6547441 chr2 82965627 G A 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1393509 chr2 82978565 G A 1.46E-04 Vaspin levels / / 22907691 rs1393509 chr2 82978565 G A 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11692714 chr2 82981654 T C 6.20E-05 Vaspin levels / / 22907691 rs11692714 chr2 82981654 T C 0.000062 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022382 chr2 82989156 T C 1.46E-04 Vaspin levels / / 22907691 rs17022382 chr2 82989156 T C 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022383 chr2 82991635 G A 6.20E-05 Vaspin levels / / 22907691 rs17022383 chr2 82991635 G A 0.000062 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7558379 chr2 83004733 A G 4.81E-04 Myopia (pathological) / / 21095009 rs7571839 chr2 83011373 T C 1.46E-04 Vaspin levels / / 22907691 rs7571839 chr2 83011373 T C 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs13012745 chr2 83020550 T C 4.76E-04 Myopia (pathological) / / 21095009 rs17022444 chr2 83029469 C G 1.00E-10 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs17022457 chr2 83039280 C T 4.00E-04 Self-reported allergy / / 23817569 rs972827 chr2 83040357 G A 1.20E-04 Myopia (pathological) / / 21095009 rs17022458 chr2 83040659 T C 3.94E-04 Self-reported allergy / / 23817569 rs974260 chr2 83041653 C T 2.82E-04 Myopia (pathological) / / 21095009 rs17022478 chr2 83044252 T C 3.85E-04 Self-reported allergy / / 23817569 rs7594284 chr2 83049370 A G 1.23E-04 Myopia (pathological) / / 21095009 rs17022522 chr2 83052914 C G 4.04E-04 Self-reported allergy / / 23817569 rs17022524 chr2 83053130 T C 4.24E-04 Self-reported allergy / / 23817569 rs17022543 chr2 83058079 T C 5.04E-04 Self-reported allergy / / 23817569 rs17022550 chr2 83058433 A G 4.96E-04 Self-reported allergy / / 23817569 rs17022562 chr2 83060790 C T 4.92E-04 Self-reported allergy / / 23817569 rs17022565 chr2 83061820 T A 5.72E-04 Self-reported allergy / / 23817569 rs17022569 chr2 83062465 C T 8.41E-04 Self-reported allergy / / 23817569 rs34405784 chr2 83062465 C CG 8.41E-04 Self-reported allergy / / 23817569 rs17022576 chr2 83064503 G C 6.04E-04 Self-reported allergy / / 23817569 rs17022577 chr2 83065273 T C 6.05E-04 Self-reported allergy / / 23817569 rs17022578 chr2 83065850 C T 6.36E-04 Self-reported allergy / / 23817569 rs17022583 chr2 83066047 G A 6.45E-04 Self-reported allergy / / 23817569 rs17022587 chr2 83068625 C T 6.79E-04 Self-reported allergy / / 23817569 rs10520359 chr2 83070326 T C 7.24E-04 Self-reported allergy / / 23817569 rs1609470 chr2 83077717 A T 5.98E-04 Type 2 diabetes / / 17463246 rs9917294 chr2 83082439 G A 8.20E-05 Endometriosis / / 21151130 rs11126880 chr2 83084350 A T 1.43E-04 Self-reported allergy / / 23817569 rs17022662 chr2 83085078 C T 1.44E-04 Self-reported allergy / / 23817569 rs17022668 chr2 83091427 G T 8.07E-04 Self-reported allergy / / 23817569 rs17040798 chr2 83278233 A C 4.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496288 chr2 83292565 T C 2.00E-09 Hypertension / / 21626137 rs10496289 chr2 83293380 C T 2.00E-09 Hypertension / / 21626137 rs17040804 chr2 83293667 C T 6.51E-04 Multiple complex diseases / / 17554300 rs2043074 chr2 83301097 T C 6.38E-05 Intelligence / / 21826061 rs2043074 chr2 83301097 T C 2.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs724302 chr2 83315550 C T 9.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17023156 chr2 83332983 T C 9.11E-05 Intelligence / / 21826061 rs17023156 chr2 83332983 T C 8.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs963064 chr2 83335815 A G 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1430275 chr2 83336271 A G 2.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946554 chr2 83336680 A T 6.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496292 chr2 83340360 G A 3.08E-05 Bilirubin levels,in serum / / 19389676 rs17023205 chr2 83340623 C T 2.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496293 chr2 83342154 A G 4.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17023229 chr2 83352379 T G 3.08E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17023252 chr2 83357496 A G 6.70E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1430282 chr2 83416683 C A 6.70E-05 Intelligence / / 21826061 rs1430282 chr2 83416683 C A 8.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12619752 chr2 83429829 A G 2.92E-04 Hemoglobin concentration / / 20534544 rs11126894 chr2 83436237 T G 4.08E-04 Hemoglobin concentration / / 20534544 rs7422290 chr2 83472006 C T 4.08E-04 Hemoglobin concentration / / 20534544 rs7420983 chr2 83474151 C T 4.01E-04 Hemoglobin concentration / / 20534544 rs6547469 chr2 83474832 G A 4.08E-04 Hemoglobin concentration / / 20534544 rs7595346 chr2 83484387 A T 2.16E-04 Multiple complex diseases / / 17554300 rs6547479 chr2 83515924 C A,G 2.05E-04 Hemoglobin concentration / / 20534544 rs12232909 chr2 83546161 A G 2.85E-04 Hemoglobin concentration / / 20534544 rs12232909 chr2 83546161 A G 4.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs6745924 chr2 83551072 G C 4.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs7425554 chr2 83553973 C T 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs6760584 chr2 83556740 T G 8.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs7422781 chr2 83560840 A G 6.75E-05 Hemoglobin concentration / / 20534544 rs6749875 chr2 83592850 G A 9.93E-05 Hemoglobin concentration / / 20534544 rs1991542 chr2 83601285 C T 6.63E-05 Mammographic density / / 22532574 rs1121554 chr2 83608066 A G 0.0000091 Amygdala reactivity / / 22856363 rs1035979 chr2 83614035 C T 7.31E-06 Height / / pha003010 rs1035979 chr2 83614035 C T 1.09E-06 Height / / pha003011 rs1429381 chr2 83618557 C A 7.30E-06 Height / / pha003010 rs1429381 chr2 83618557 C A 1.09E-06 Height / / pha003011 rs767504 chr2 83625349 T C 9.86E-06 Height / / pha003010 rs767504 chr2 83625349 T C 1.35E-06 Height / / pha003011 rs1896848 chr2 83633730 G T 9.18E-06 Height / / pha003010 rs1896848 chr2 83633730 G T 1.06E-06 Height / / pha003011 rs1541835 chr2 83635578 C T 4.36E-05 Height / / pha003010 rs1541835 chr2 83635578 C T 6.90E-06 Height / / pha003011 rs11887003 chr2 83656820 T C 5.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2361508 chr2 83679699 A G 2.03E-05 Height / / pha003011 rs6547499 chr2 83687160 T C 9.77E-04 Multiple complex diseases / / 17554300 rs1366828 chr2 83753456 C T 1.66E-04 Alzheimer's disease (late onset) / / 21379329 rs993735 chr2 83763856 G A 2.84E-04 Alzheimer's disease (late onset) / / 21379329 rs728849 chr2 83797177 A G 8.92E-05 Alzheimer's disease (late onset) / / 21379329 rs6722452 chr2 83807370 T A 6.60E-06 Urinary metabolites / / 21572414 rs1386306 chr2 83809305 G A 1.90E-05 Urinary metabolites / / 21572414 rs11900533 chr2 83811171 T C 6.60E-06 Urinary metabolites / / 21572414 rs6747341 chr2 83823026 G A 6.60E-06 Urinary metabolites / / 21572414 rs6739790 chr2 83838519 A G 4.52E-04 Alzheimer's disease (late onset) / / 21379329 rs2362235 chr2 83850912 A C 3.71E-04 Alzheimer's disease (late onset) / / 21379329 rs2122456 chr2 83991599 T C 3.16E-04 Multiple complex diseases / / 17554300 rs2218792 chr2 84001716 G A 1.55E-04 Lung function (forced vital capacity) / / 24023788 rs1450253 chr2 84012407 C T 5.48E-04 Multiple complex diseases / / 17554300 rs3111387 chr2 84015498 A G 3.37E-05 Lung function (forced vital capacity) / / 24023788 rs4832336 chr2 84057963 G A 5.10E-04 Alcohol dependence / / 20201924 rs13415661 chr2 84061712 A G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10211421 chr2 84064563 C T 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10084165 chr2 84065043 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832340 chr2 84065388 C T 7.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832341 chr2 84065659 G C 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832342 chr2 84065703 T A 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs9309610 chr2 84067982 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs13413484 chr2 84069655 T C 8.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574955 chr2 84072347 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs13423886 chr2 84074312 A G 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6724077 chr2 84077868 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6752715 chr2 84078006 A C 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4423611 chr2 84079690 C A 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7569405 chr2 84093827 A G 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6704961 chr2 84095691 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4476361 chr2 84097557 T G 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714113 chr2 84105498 G C 2.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2885856 chr2 84195984 T C 4.23E-08 Height / / pha003010 rs2885856 chr2 84195984 T C 8.45E-08 Height / / pha003011 rs13398848 chr2 84245168 A G 1.00E-06 Conduct disorder (symptom count) / / 20585324 rs13398848 chr2 84245168 A G 5.00E-06 Conduct disorder (symptom count) / / 20585324 rs1447537 chr2 84246586 G A 4.00E-06 RR interval (heart rate) / / 20031603 rs11885459 chr2 84349389 C G 4.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12612847 chr2 84350015 G A 4.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1534238 chr2 84350917 T A 3.00E-06 Response to antipsychotic treatment / / 20195266 rs1405384 chr2 84358932 A C 2.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12466737 chr2 84377246 T C 7.43E-04 Acute lung injury / / 22295056 rs1358193 chr2 84377388 A T 2.87E-04 Acute lung injury / / 22295056 rs12463924 chr2 84378959 C T 9.23E-04 Acute lung injury / / 22295056 rs10496308 chr2 84419732 T C 6.70E-05 Cholesterol / / pha003073 rs10496308 chr2 84419732 T C 1.78E-05 ldl cholesterol / / pha003076 rs6547537 chr2 84444886 A G 4.00E-06 IgG glycosylation / / 23382691 rs17024868 chr2 84537078 C T 5.18E-04 Multiple complex diseases / / 17554300 rs1947463 chr2 84579493 T A 9.04E-04 Multiple complex diseases / / 17554300 rs6747898 chr2 84618750 C T 5.38E-04 Multiple complex diseases / / 17554300 rs17024989 chr2 84634026 G C 4.34E-04 Type 2 diabetes / / 17463246 rs17757829 chr2 84666634 T C 4.37E-04 Multiple complex diseases SUCLG1 intron 17554300 rs1599306 chr2 84672482 A G 9.39E-04 Multiple complex diseases SUCLG1 intron 17554300 rs7561462 chr2 84686757 A G 7.59E-06 Coronary artery calcification SUCLG1 nearGene-5 23870195 rs7581224 chr2 84709215 G T 2.00E-06 Coronary artery calcification / / 23870195 rs4831979 chr2 84725380 A T 2.59E-04 Multiple complex diseases / / 17554300 rs17758259 chr2 84759082 G A 2.78E-04 Suicide attempts in bipolar disorder D/H6 intron 21423239 rs13034783 chr2 84782750 T C 1.00E-04 Cognitive impairment induced by topiramate D/H6 intron 22091778 rs7601121 chr2 84795954 G A 4.33E-04 Multiple complex diseases D/H6 intron 17554300 rs13002679 chr2 84800898 T C 2.42E-04 Vaspin levels D/H6 intron 22907691 rs13002679 chr2 84800898 T C 0.0002415 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit D/H6 intron 22907730 rs1811537 chr2 84815236 G A 2.69E-04 Multiple complex diseases D/H6 intron 17554300 rs17759625 chr2 84815684 A G 6.12E-04 Alcohol dependence D/H6 intron 21314694 rs4020077 chr2 84828002 G A 3.96E-04 Multiple complex diseases D/H6 intron 17554300 rs1460710 chr2 84830909 T A 1.75E-04 Multiple complex diseases D/H6 intron 17554300 rs7570369 chr2 84831767 G A 5.47E-04 Multiple complex diseases D/H6 intron 17554300 rs12997105 chr2 84833628 G C 5.05E-04 Multiple complex diseases D/H6 intron 17554300 rs4832104 chr2 84839270 C A 5.46E-04 Multiple complex diseases D/H6 intron 17554300 rs11889456 chr2 84846683 A G 7.13E-04 Multiple complex diseases D/H6 intron 17554300 rs11889456 chr2 84846683 A G 2.50E-05 Urinary metabolites D/H6 intron 21572414 rs11676670 chr2 84852011 C T 4.24E-04 Multiple complex diseases D/H6 intron 17554300 rs10210186 chr2 84854846 C T 1.80E-05 Urinary metabolites D/H6 intron 21572414 rs6726617 chr2 84859888 T G 6.35E-04 Multiple complex diseases D/H6 intron 17554300 rs3890771 chr2 84860330 A T 4.95E-04 Multiple complex diseases D/H6 intron 17554300 rs4313996 chr2 84862843 C A 1.75E-04 Multiple complex diseases D/H6 intron 17554300 rs7572042 chr2 84867252 C T 2.77E-04 Multiple complex diseases D/H6 intron 17554300 rs7593359 chr2 84874964 T C 2.79E-07 Multiple complex diseases D/H6 intron 17554300 rs12992282 chr2 84880695 G A 3.46E-05 Body Mass Index D/H6 cds-synon pha003015 rs17025409 chr2 84897501 A G 4.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels D/H6 missense 20031582 rs1192285 chr2 84926484 C T 7.00E-06 Urinary metabolites D/H6 intron 21572414 rs1192266 chr2 84936200 A G 7.00E-06 Urinary metabolites D/H6 intron 21572414 rs1192340 chr2 84948021 G A 2.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines D/H6 intron 21844884 rs1192324 chr2 84961735 G A 1.20E-05 Urinary metabolites D/H6 intron 21572414 rs1192380 chr2 84995108 C A 9.81E-04 Suicide attempts in bipolar disorder D/H6 intron 21423239 rs1192372 chr2 85011546 T C 9.90E-05 Longevity and age-related phenotypes D/H6 intron 17903295 rs1192316 chr2 85013202 G A 7.70E-04 Type 2 diabetes and 6 quantitative traits D/H6 intron 17848626 rs41365348 chr2 85015348 T C 5.80E-04 Multiple complex diseases D/H6 intron 17554300 rs1192367 chr2 85033835 C G 3.60E-04 Type 2 diabetes and 6 quantitative traits D/H6 intron 17848626 rs7573165 chr2 85034733 T C 0.000767 Salmonella-induced pyroptosis D/H6 intron 22837397 rs7584208 chr2 85046475 G A 4.96E-04 Multiple complex diseases D/H6 cds-synon 17554300 rs10514645 chr2 85077774 A G 3.30E-04 Stroke C2orf89 intron pha002886 rs1979403 chr2 85168571 T C 9.84E-05 Cognitive test performance / / 20125193 rs1979403 chr2 85168571 T C 0.000847 Salmonella-induced pyroptosis / / 22837397 rs7583930 chr2 85190907 T C 6.47E-05 Cognitive test performance / / 20125193 rs2272514 chr2 85286519 T G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KCMF1 UTR-3 17982456 rs2568225 chr2 85379914 T C 8.70E-04 Response to taxane treatment (placlitaxel) TCF7L1 intron 23006423 rs2583547 chr2 85414140 G A 6.54E-04 Tourette syndrome TCF7L1 intron 22889924 rs6709476 chr2 85443924 G A 5.57E-05 Nicotine smoking TCF7L1 intron 19268276 rs6547600 chr2 85447830 C T 6.77E-05 Heart Rate TCF7L1 intron pha003054 rs6758778 chr2 85471980 G A 7.72E-05 Femoral neck bone geometry TCF7L1 intron 22087292 rs6758778 chr2 85471980 G A 1.44E-05 Hemoglobin TCF7L1 intron pha003096 rs17763853 chr2 85480715 A G 1.40E-05 Urinary metabolites TCF7L1 intron 21572414 rs6736348 chr2 85506104 G A 5.54E-05 Hemoglobin TCF7L1 intron pha003096 rs10206876 chr2 85508065 C A 8.39E-06 Bipolar disorder TCF7L1 intron 17486107 rs7600828 chr2 85510295 C G 8.96E-04 Type 2 diabetes TCF7L1 intron 17463246 rs17026157 chr2 85511646 A T 8.48E-04 Multiple complex diseases TCF7L1 intron 17554300 rs4832155 chr2 85523220 G A 9.35E-05 Dengue shock syndrome TCF7L1 intron 22001756 rs4832159 chr2 85523541 T G 9.35E-05 Dengue shock syndrome TCF7L1 intron 22001756 rs6737773 chr2 85524369 A G 4.27E-08 CD8+ T cell IFN-gamma response to smallpox vaccine TCF7L1 intron 22661280 rs6741339 chr2 85532205 C G 7.73E-04 Type 2 diabetes TCF7L1 intron 17463246 rs4832163 chr2 85541083 T C 4.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1053561 chr2 85546052 A G 4.09E-04 Type 2 diabetes TGOLN2 UTR-3 17463246 rs1053561 chr2 85546052 A G 8.85E-04 Multiple complex diseases TGOLN2 UTR-3 17554300 rs1053561 chr2 85546052 A G 1.34E-04 Amyotrophic lateral sclerosis (sporadic) TGOLN2 UTR-3 24529757 rs1061782 chr2 85546615 C T 5.61E-04 Type 2 diabetes TGOLN2 UTR-3 17463246 rs1061782 chr2 85546615 C T 9.14E-04 Multiple complex diseases TGOLN2 UTR-3 17554300 rs4459734 chr2 85547429 G T 1.69E-04 Amyotrophic Lateral Sclerosis TGOLN2 UTR-3 17362836 rs4247303 chr2 85554080 G A 4.64E-04 Amyotrophic Lateral Sclerosis TGOLN2 missense 17362836 rs10460585 chr2 85555262 T G 5.82E-04 Amyotrophic Lateral Sclerosis TGOLN2 UTR-5 17362836 rs3923229 chr2 85562172 C T 3.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6747513 chr2 85565634 T C 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs15413 chr2 85569379 C T 1.09E-05 Lung function (forced expiratory volume in 1 second) RETSAT UTR-3 pha003103 rs17734981 chr2 85588447 C G 2.99E-04 Type 2 diabetes ELMOD3 intron 17463246 rs17026285 chr2 85616758 T C 2.63E-05 Type 2 diabetes ELMOD3 intron 17463246 rs7581471 chr2 85626706 T C 9.51E-04 Alzheimer's disease CAPG intron 22005930 rs11696093 chr2 85636195 T C 7.11E-04 Amyotrophic Lateral Sclerosis CAPG intron 17362836 rs7577642 chr2 85699750 C T 7.00E-06 Protein quantitative trait loci / / 18464913 rs960066 chr2 85700924 G T 9.71E-05 Body mass index / / 17255346 rs11688246 chr2 85705677 C A 1.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs11680227 chr2 85707654 A G 2.23E-04 Body mass index / / 17255346 rs6750610 chr2 85731858 T C 3.76E-04 Lung function (forced vital capacity) / / 24023788 rs17792131 chr2 85733192 C T 2.96E-06 Osteoporosis / / 20548944 rs10496316 chr2 85747371 T C 3.60E-04 Lymphocyte counts / / 22286170 rs3755015 chr2 85764041 G A 1.10E-04 Coronary heart disease / / 21966275 rs699664 chr2 85780536 C T 3.12E-04 Body mass index GGCX missense 17255346 rs12714145 chr2 85787341 C T 1 Drug response to Warfarin GGCX intron 19794411 rs10187424 chr2 85794297 T C 3.00E-15 Prostate cancer / / 21743467 rs6757263 chr2 85803542 T C 2.22E-04 Lymphocyte counts VAMP8 nearGene-5 22286170 rs1010 chr2 85808982 T A,C,G 5.70E-04 Coronary heart disease VAMP8 UTR-3 21966275 rs1561198 chr2 85809989 C T 0.000000166 Coronary artery disease (CAD) (males) / / 23202125 rs1561198 chr2 85809989 C T 0.000000177 Coronary artery disease with myocardial infarction / / 23202125 rs1561198 chr2 85809989 C T 1.22E-10 Coronary artery disease / / 23202125 rs1561198 chr2 85809989 C T 1.43E-09 Coronary artery disease (CAD) age <=50 / / 23202125 rs1561198 chr2 85809989 C T 6.05E-04 Coronary artery disease / / 24262325 rs1254901 chr2 85811229 G A 3.60E-04 Iris characteristics / / 21835309 rs12714147 chr2 85813834 A G 0.0000392 GGCX expression in mammary artery VAMP5 intron 23202125 rs6643 chr2 85824251 T C 6.58E-04 Glycosylated haemoglobin levels RNF181 missense 17255346 rs2232750 chr2 85824468 C T 7.06E-05 Lymphocyte counts RNF181 intron 22286170 rs1130866 chr2 85893741 G A 6.58E-05 Lung adenocarcinoma SFTPB missense 19836008 rs4616480 chr2 85897768 G A 9.00E-04 Type 2 diabetes SFTPB nearGene-5 17463246 rs10181739 chr2 85921552 G A 6.21E-06 Glycemic traits (pregnancy) GNLY STOP-GAIN 23903356 rs10181739 chr2 85921552 G A 6.44E-06 Glycemic traits (pregnancy) GNLY STOP-GAIN 23903356 rs13413829 chr2 85930208 G A 6.59E-06 Glycemic traits (pregnancy) / / 23903356 rs13413829 chr2 85930208 G A 6.78E-06 Glycemic traits (pregnancy) / / 23903356 rs13383848 chr2 85932617 T C 4.59E-06 Glycemic traits (pregnancy) / / 23903356 rs13383848 chr2 85932617 T C 5.42E-06 Glycemic traits (pregnancy) / / 23903356 rs13422837 chr2 85934595 T C 4.42E-06 Glycemic traits (pregnancy) / / 23903356 rs13422837 chr2 85934595 T C 5.23E-06 Glycemic traits (pregnancy) / / 23903356 rs4525696 chr2 85938000 T C 4.45E-05 Amyotrophic lateral sclerosis / / 20801718 rs6759087 chr2 85948793 G A 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11126997 chr2 85949396 A G 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs13014588 chr2 85950232 A C 5.14E-05 Suicide attempts in bipolar disorder / / 21423239 rs13030230 chr2 85953030 C A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs9677221 chr2 85968147 T A 8.40E-06 Parkinson's disease (familial) / / 18985386 rs11126998 chr2 85978786 G C 2.74E-04 Multiple complex diseases / / 17554300 rs4832198 chr2 85995648 C T 7.49E-04 Multiple complex diseases ATOH8 intron 17554300 rs869778 chr2 86010243 A G 0.00018 Coronary artery calcification ATOH8 intron 23727086 rs13386681 chr2 86013029 C T 0.00012 Coronary artery calcification ATOH8 intron 23727086 rs1518990 chr2 86079341 T C 6.34E-04 Type 2 diabetes ST3GAL5 intron 17463246 rs2366947 chr2 86088009 T C 1.54E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs1533605 chr2 86092253 T C 5.16E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs4553826 chr2 86095201 G A 2.44E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs6721125 chr2 86104729 C T 1.71E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs6753350 chr2 86105498 A G 1.78E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs2679722 chr2 86135154 G A 2.15E-04 Cognitive decline / / 23732972 rs7593080 chr2 86145787 C T 2.42E-04 Cognitive decline / / 23732972 rs2164878 chr2 86153855 C T 8.23E-05 Cognitive decline / / 23732972 rs6547647 chr2 86155271 C T 9.45E-05 Autism spectrum disorders (language delay) / / 21519539 rs6547647 chr2 86155271 C T 8.23E-05 Cognitive decline / / 23732972 rs7576135 chr2 86160562 C T 9.45E-05 Autism spectrum disorders (language delay) / / 21519539 rs7576135 chr2 86160562 C T 9.07E-05 Cognitive decline / / 23732972 rs11691934 chr2 86165443 T C 1.08E-04 Parkinson's disease / / 17052657 rs11691934 chr2 86165443 T C 0.00004 Salmonella-induced pyroptosis / / 22837397 rs13431245 chr2 86167602 T C 3.63E-05 Pancreatic cancer / / 23180869 rs2366958 chr2 86169989 T C 6.16E-04 Obesity (extreme) / / 21935397 rs2366958 chr2 86169989 T C 3.47E-04 Cognitive decline / / 23732972 rs1370699 chr2 86172274 A G 1.73E-04 Parkinson's disease / / 17052657 rs9309628 chr2 86172328 T C 5.57E-04 Obesity (extreme) / / 21935397 rs735738 chr2 86177322 T C 5.59E-04 Obesity (extreme) / / 21935397 rs11891625 chr2 86182258 C T 4.72E-04 Prostate cancer mortality / / 20978177 rs4514874 chr2 86182648 T C 4.28E-04 Prostate cancer mortality / / 20978177 rs1438155 chr2 86183897 A G 4.72E-04 Prostate cancer mortality / / 20978177 rs78239085 chr2 86260785 C T 0.00069 Prostate cancer POLR1A missense 23555315 rs34892520 chr2 86269163 C T 6.99E-04 Cocaine dependence POLR1A missense 23958962 rs311581 chr2 86282960 A G 4.10E-08 Lymphocyte counts POLR1A intron 22286170 rs2288118 chr2 86310110 C T 2.11E-04 Breast cancer POLR1A intron pha002853 rs715334 chr2 86322071 G A 9.07E-04 Parkinson's disease POLR1A intron 17052657 rs10779967 chr2 86330726 A G 5.61E-05 Breast cancer POLR1A intron pha002853 rs1075622 chr2 86337930 T C 1.59E-04 Breast cancer PTCD3 intron pha002853 rs17618119 chr2 86343316 G A 4.80E-06 Urinary metabolites PTCD3 intron 21572414 rs2367202 chr2 86345536 A G 2.09E-04 Breast cancer PTCD3 intron pha002853 rs1424520 chr2 86349004 G A 8.52E-05 Rheumatoid arthritis PTCD3 intron 17804836 rs1025104 chr2 86350664 A G 1.60E-04 Breast cancer PTCD3 intron pha002853 rs2241437 chr2 86360573 T G 3.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) PTCD3 intron 21130132 rs11395 chr2 86365607 T C 9.10E-04 Parkinson's disease PTCD3 UTR-3 17052657 rs11395 chr2 86365607 T C 7.09E-04 Multiple complex diseases PTCD3 UTR-3 17554300 rs3731818 chr2 86368804 G A 6.21E-04 Parkinson's disease PTCD3 UTR-3 17052657 rs10191567 chr2 86385397 T C 3.89E-04 Fibrinogen IMMT intron 17255346 rs9917140 chr2 86392665 T A 2.08E-04 Smoking cessation IMMT intron 18519826 rs7561888 chr2 86392768 A G 0.00000546 Antisocial behavior IMMT intron 23077488 rs10496318 chr2 86402813 C G 6.00E-04 Type 2 diabetes and 6 quantitative traits IMMT intron 17848626 rs2367204 chr2 86404411 A G 6.20E-04 Type 2 diabetes and 6 quantitative traits IMMT intron 17848626 rs10175330 chr2 86414114 C A 1.79E-04 Smoking cessation IMMT intron 18519826 rs4422155 chr2 86423019 C T 1.42E-04 Parkinson's disease / / 17052657 rs3770059 chr2 86436067 C A 5.88E-05 Tunica Media MRPL35 intron pha003034 rs17510310 chr2 86443208 C T 0.00000663 Antisocial behavior REEP1 UTR-3 23077488 rs749581 chr2 86448231 T C 0.000104 Salmonella-induced pyroptosis REEP1 intron 22837397 rs4832257 chr2 86453919 C T 0.000155 Salmonella-induced pyroptosis REEP1 intron 22837397 rs13000103 chr2 86455492 C T 0.000487 Salmonella-induced pyroptosis REEP1 intron 22837397 rs13017143 chr2 86466549 T C 2.88E-04 Cognitive decline REEP1 intron 23732972 rs6547667 chr2 86475443 T C 5.87E-04 Smoking initiation REEP1 intron 24665060 rs9677502 chr2 86480938 A C,G 9.95E-05 Cognitive test performance REEP1 intron 20125193 rs11691807 chr2 86483021 G A 4.70E-05 Smoking cessation REEP1 intron 18519826 rs17510512 chr2 86485315 T C 4.30E-05 Major depressive disorder REEP1 intron 21042317 rs13023154 chr2 86516984 G A 4.95E-05 Pulmonary function REEP1 intron 20010835 rs13023154 chr2 86516984 G A 3.46E-04 Cognitive decline REEP1 intron 23732972 rs6716825 chr2 86538070 T C 3.28E-04 Alzheimer's disease (late onset) REEP1 intron 21379329 rs11675985 chr2 86558975 T G 1.40E-05 Urinary metabolites REEP1 intron 21572414 rs12471787 chr2 86566701 A G 9.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) REEP1 nearGene-5 20877124 rs6547678 chr2 86613175 G A 3.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6713586 chr2 86632902 T A,C 1.09E-04 Vaspin levels / / 22907691 rs6713586 chr2 86632902 T A,C 0.0001088 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2030259 chr2 86683642 A G 4.14E-04 Epilepsy KDM3A missense 22116939 rs2030259 chr2 86683642 A G 9.12E-05 Glucose levels KDM3A missense pha002899 rs2367575 chr2 86720841 C T 3.19E-04 Epilepsy / / 22116939 rs17027280 chr2 86733287 C T 2.60E-05 Urinary metabolites CHMP3 intron 21572414 rs13023294 chr2 86812177 A G 2.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RNF103-CHMP3 intron 24023788 rs11127047 chr2 86826508 C T 3.14E-05 Psoriasis RNF103-CHMP3 intron 18364390 rs41368845 chr2 86835932 A G 0.0000053 Mean arterial pressure RNF103 intron 22510845 rs114532231 chr2 86860631 C T 2.00E-06 Serum dimethylarginine levels (asymmetric) RNF103-CHMP3 intron 24159190 rs1018311 chr2 86903017 C T 9.33E-04 Prostate cancer mortality RNF103-CHMP3 intron 20978177 rs1850138 chr2 86989466 A T 8.91E-07 Red blood cell traits RMND5A intron 23222517 rs938486 chr2 86994719 C T 8.39E-07 Red blood cell traits RMND5A intron 23222517 rs1193 chr2 87002229 C T 9.69E-07 Red blood cell traits RMND5A UTR-3 23222517 rs1049458 chr2 87003197 C G 6.61E-07 Red blood cell traits RMND5A UTR-3 23222517 rs938487 chr2 87009488 A G 1.61E-06 Alzheimer's disease (late onset) / / 21379329 rs3810831 chr2 87018547 A G 5.63E-05 Alzheimer's disease (late onset) CD8A UTR-5 21379329 rs6753271 chr2 87029673 T C 6.64E-05 Parent of origin effect on language impairment (child trend) CD8A intron 24571439 rs6547705 chr2 87044316 G A 1.00E-08 Progressive supranuclear palsy CD8B intron 21685912 rs13001400 chr2 87048702 T G 5.40E-06 Urinary metabolites CD8B intron 21572414 rs4832049 chr2 87053719 T C 6.90E-07 Urinary metabolites CD8B intron 21572414 rs6749703 chr2 87055249 A G 9.38E-05 Serum metabolites CD8B intron 19043545 rs4240205 chr2 87056805 A G 2.10E-05 Urinary metabolites CD8B intron 21572414 rs6709175 chr2 87108211 T C 3.62E-05 Alcohol and nictotine co-dependence LOC100286979 intron 20158304 rs3732347 chr2 88292394 C G 1.10E-06 Bilirubin levels / / 19414484 rs7609117 chr2 88297789 G A 1.60E-05 Bilirubin levels / / 19414484 rs12714206 chr2 88299844 C T 1.60E-05 Bilirubin levels / / 19414484 rs2885493 chr2 88306346 T C 5.40E-07 Bilirubin levels / / 19414484 rs12714207 chr2 88315793 C T 5.00E-07 Bilirubin levels / / 19414484 rs10192766 chr2 88315993 A G 1.50E-05 Bilirubin levels / / 19414484 rs7594862 chr2 88339743 T C 1.20E-05 Bilirubin levels KRCC1 intron 19414484 rs539337359 chr2 88344018 TAA T 1.30E-05 Bilirubin levels KRCC1 intron 19414484 rs6705301 chr2 88344018 T C 1.30E-05 Bilirubin levels KRCC1 intron 19414484 rs9309641 chr2 88355735 C T 1.20E-06 Bilirubin levels / / 19414484 rs894200 chr2 88359580 G T 9.50E-06 Bilirubin levels / / 19414484 rs2919856 chr2 88388538 A T 2.00E-06 IgG glycosylation SMYD1 intron 23382691 rs2970911 chr2 88395824 G A 7.03E-04 Alcohol dependence SMYD1 intron 21314694 rs2970888 chr2 88411793 C A 9.89E-04 Alcohol consumption (maxi-drinks) SMYD1 UTR-3 24277619 rs1372299 chr2 88416221 C T 8.61E-05 Height / / pha003011 rs2919872 chr2 88428571 C T 8.98E-05 Lipoprotein A [Lp(a)] levels in plasma / / 21592478 rs2970902 chr2 88429183 G C 0.00001992 Sarcoidosis / / 22952805 rs12470985 chr2 88432394 G T 0.00002941 Sarcoidosis / / 22952805 rs35103143 chr2 88434736 A C 0.00002167 Sarcoidosis / / 22952805 rs6735524 chr2 88436001 G A 6.74E-04 Prostate cancer mortality / / 20978177 rs34185550 chr2 88436839 T C 0.00008586 Sarcoidosis / / 22952805 rs4410295 chr2 88439557 A C 0.00003006 Sarcoidosis / / 22952805 rs7590305 chr2 88513131 C T 1.39E-04 Celiac disease / / 23936387 rs1914728 chr2 88516080 T G 9.95E-05 Post-operative nausea and vomiting / / 21694509 rs7564776 chr2 88530735 G C 5.90E-05 Parkinson's disease (age of onset) / / 19772629 rs6736170 chr2 88547402 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6547764 chr2 88550275 A G 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1258411 chr2 88618096 A G 2.29E-04 Body mass index / / 17255346 rs1258411 chr2 88618096 A G 4.94E-04 Rheumatoid arthritis / / 21452313 rs1258410 chr2 88618519 T C 3.65E-05 Body mass index / / 17255346 rs1258408 chr2 88619494 T C 4.44E-05 Multiple complex diseases / / 17554300 rs1258407 chr2 88619599 T C 3.65E-05 Body mass index / / 17255346 rs1258396 chr2 88625879 T C 2.83E-04 Body mass index / / 17255346 rs1659249 chr2 88628756 T A 4.54E-05 Body mass index / / 17255346 rs1713941 chr2 88629360 C T 2.47E-04 Multiple complex diseases / / 17554300 rs1258419 chr2 88631170 C T 4.07E-04 Body mass index / / 17255346 rs1258425 chr2 88651217 A G 3.55E-05 Body mass index / / 17255346 rs1659258 chr2 88659588 A G 2.00E-08 Visceral fat / / 22589738 rs10221815 chr2 88697965 A G 1.86E-04 Body mass index / / 17255346 rs10221875 chr2 88700165 A G 5.54E-04 Coronary heart disease / / 21606135 rs13425454 chr2 88709968 T C 1.10E-05 Urinary metabolites / / 21572414 rs13425454 chr2 88709968 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17037654 chr2 88716724 T C 2.90E-04 Multiple complex diseases / / 17554300 rs7604265 chr2 88728059 C G 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6721576 chr2 88738507 C T 9.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6722564 chr2 88739292 C T 3.03E-04 Multiple complex diseases / / 17554300 rs1438903 chr2 88743779 G A 8.35E-04 Multiple complex diseases / / 17554300 rs1016839 chr2 88770768 A G 4.08E-04 Multiple complex diseases / / 17554300 rs6759954 chr2 88784492 T C 3.98E-04 Spine bone size / / 23207799 rs11677224 chr2 88789815 T C 3.92E-05 Multiple complex diseases / / 17554300 rs7595875 chr2 88817092 T C 2.50E-05 Urinary metabolites / / 21572414 rs4449134 chr2 88846961 A G 2.42E-04 Type 2 diabetes / / 17463246 rs4449134 chr2 88846961 A G 8.53E-04 Multiple complex diseases / / 17554300 rs6739095 chr2 88880064 T A 1.10E-05 Urinary metabolites EIF2AK3 intron 21572414 rs7571971 chr2 88895351 T C 4.00E-13 Progressive supranuclear palsy EIF2AK3 intron 21685912 rs1913671 chr2 88899883 T C 1.10E-05 Urinary metabolites EIF2AK3 intron 21572414 rs867529 chr2 88913273 G C 1.40E-10 Height EIF2AK3 missense 21194676 rs867529 chr2 88913273 G C 1.50E-06 Height EIF2AK3 missense 21194676 rs867529 chr2 88913273 G C 1.70E-04 Height EIF2AK3 missense 21194676 rs11684404 chr2 88924622 T C 1.00E-13 Height EIF2AK3 intron 20881960 rs11684404 chr2 88924622 T C 9.20E-06 Urinary metabolites EIF2AK3 intron 21572414 rs13411467 chr2 88977106 T C 8.17E-04 Multiple complex diseases / / 17554300 rs938372 chr2 88999769 C T 9.92E-04 Parkinson's disease RPIA intron 17052657 rs7572313 chr2 89080394 C A 8.13E-04 Multiple complex diseases ANKRD36BP2 intron 17554300 rs1843217 chr2 89124238 T C 2.91E-05 Bipolar Disorder LOC100132330 intron pha002863 rs2847840 chr2 90077496 A G 8.82E-04 Type 2 diabetes / / 17463246 rs191753171 chr2 91697808 C G 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs10201588 chr2 95358799 C T 9.81E-04 Multiple complex diseases / / 17554300 rs10202262 chr2 95444917 C T 4.88E-05 Height ANKRD20A8P intron pha003010 rs10202262 chr2 95444917 C T 7.75E-05 Height ANKRD20A8P intron pha003011 rs12185570 chr2 95457829 T C 9.54E-04 Obesity (extreme) ANKRD20A8P intron 21935397 rs17842087 chr2 95479775 T C 9.56E-04 Obesity (extreme) ANKRD20A8P intron 21935397 rs17802433 chr2 95537630 G T 6.06E-15 Gender TEKT4 missense 22362730 rs4854239 chr2 95586249 T G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC442028 intron 22628534 rs12474195 chr2 95595941 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC442028 intron 22628534 rs4564804 chr2 95628045 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10172167 chr2 95629038 T G 3.22E-05 Alcohol dependence / / 21314694 rs10445976 chr2 95676438 C T 4.22E-04 Obesity (extreme) / / 21935397 rs1316873 chr2 95698646 C G 3.44E-04 Obesity (extreme) MAL intron 21935397 rs17119064 chr2 95721459 C T 3.39E-04 Obesity (extreme) / / 21935397 rs872580 chr2 95722909 C A 3.60E-05 HIV-1 control / / 20041166 rs3112986 chr2 95729338 A G 4.30E-05 HIV-1 control / / 20041166 rs3112996 chr2 95812372 G A 3.60E-05 HIV-1 control / / 20041166 rs3112996 chr2 95812372 G A 8.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3105104 chr2 95816365 G A 3.60E-05 HIV-1 control ZNF514 intron 20041166 rs3105104 chr2 95816365 G A 9.23E-04 Response to taxane treatment (placlitaxel) ZNF514 intron 23006423 rs3112997 chr2 95818151 G A 3.60E-05 HIV-1 control ZNF514 intron 20041166 rs3112228 chr2 95835614 C T 3.60E-05 HIV-1 control ZNF2 intron 20041166 rs3112229 chr2 95838674 A G 8.57E-04 Response to taxane treatment (placlitaxel) ZNF2 intron 23006423 rs3112230 chr2 95846158 T C 3.60E-05 HIV-1 control ZNF2 intron 20041166 rs3105105 chr2 95848018 T C 3.60E-05 HIV-1 control ZNF2 UTR-3 20041166 rs3105105 chr2 95848018 T C 9.23E-04 Response to taxane treatment (placlitaxel) ZNF2 UTR-3 23006423 rs1875402 chr2 95848354 G A 3.60E-05 HIV-1 control ZNF2 UTR-3 20041166 rs1875402 chr2 95848354 G A 6.58E-04 Response to taxane treatment (placlitaxel) ZNF2 UTR-3 23006423 rs2320624 chr2 95856611 A G 3.60E-05 HIV-1 control / / 20041166 rs2320624 chr2 95856611 A G 9.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2320625 chr2 95862736 T C 0.000619 Height (Pygmy height) / / 22570615 rs13385838 chr2 95868247 G A 4.81E-04 Obesity (extreme) / / 21935397 rs13387294 chr2 95888434 T G 6.08E-04 Obesity (extreme) / / 21935397 rs6725821 chr2 95897767 T C 3.60E-05 HIV-1 control / / 20041166 rs6748967 chr2 95914095 G A 3.60E-05 HIV-1 control / / 20041166 rs6748967 chr2 95914095 G A 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1966272 chr2 95926154 C A 3.60E-05 HIV-1 control / / 20041166 rs1966272 chr2 95926154 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1966272 chr2 95926154 C A 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4854249 chr2 95930630 A G 3.60E-05 HIV-1 control / / 20041166 rs954078 chr2 95937997 T C 0.0003123 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs954078 chr2 95937997 T C 3.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9989786 chr2 95967746 A G 5.60E-05 HIV-1 control KCNIP3 intron 20041166 rs4854251 chr2 96037247 T G 5.53E-05 Abdominal aortic aneurysm KCNIP3 intron 24046328 rs10874471 chr2 96038093 T C 5.53E-05 Abdominal aortic aneurysm KCNIP3 intron 24046328 rs10515920 chr2 96334397 G T 7.25E-05 Multiple complex diseases / / 17554300 rs11676901 chr2 96370571 A C 4.29E-05 Cognitive test performance / / 20125193 rs749458 chr2 96795857 T C 5.75E-05 IgE levels ASTL missense 22075330 rs11886999 chr2 96841793 T C 8.00E-06 Cardiac Troponin-T levels / / 23247143 rs4907304 chr2 96898296 T C 6.62E-05 IgE levels LOC285033 intron 22075330 rs12617019 chr2 96905568 T C 6.71E-04 Multiple complex diseases / / 17554300 rs1044594 chr2 96937296 G C 9.61E-04 Multiple complex diseases CIAO1 UTR-3 17554300 rs17479466 chr2 96962859 A G 6.46E-04 Multiple complex diseases SNRNP200 intron 17554300 rs4907310 chr2 96980113 C T 7.73E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs17633463 chr2 97016334 G A 6.25E-05 Multiple complex diseases NCAPH intron 17554300 rs3731935 chr2 97020049 T C 7.72E-04 Multiple complex diseases NCAPH cds-synon 17554300 rs4426565 chr2 97051981 C T 4.35E-04 Smoking initiation / / 24665060 rs687950 chr2 97069612 G C 8.46E-04 Multiple complex diseases / / 17554300 rs1870340 chr2 97116953 A G 3.29E-114 Multiple complex diseases / / 17554300 rs6753667 chr2 97160382 G A 1.75E-05 Colorectal cancer / / 21242260 rs2579502 chr2 97198800 T C 8.04E-04 Multiple complex diseases / / 17554300 rs2579502 chr2 97198800 T C 1.48E-05 Colorectal cancer / / 21242260 rs2438709 chr2 97199694 A G 0.0000741 Follicular lymphoma / / 23025665 rs4907240 chr2 97228039 G A 4.00E-06 Event-related brain oscillations / / 21184583 rs2314109 chr2 97243532 C T 6.72E-04 Multiple complex diseases / / 17554300 rs2314109 chr2 97243532 C T 1.35E-05 Colorectal cancer / / 21242260 rs17685664 chr2 97315570 C T 9.93E-06 Colorectal cancer FER1L5 intron 21242260 rs13029764 chr2 97328874 A G 4.97E-04 Multiple complex diseases FER1L5 intron 17554300 rs2280355 chr2 97366303 A G 1.02E-05 Orofacial clefts FER1L5 intron 19270707 rs2271893 chr2 97405440 G A 2.00E-10 Bipolar disorder LMAN2L intron 22182935 rs2271893 chr2 97405440 G A 2.08E-05 Major depressive disorder LMAN2L intron 22472876 rs2271893 chr2 97405440 G A 0.0000185 Bipolar disorder LMAN2L intron 23637625 rs6746896 chr2 97410949 A G 2.00E-06 Bipolar disorder / / 21926972 rs6746896 chr2 97410949 A G 3.57E-08 Bipolar disorder / / 22182935 rs6746896 chr2 97410949 A G 2.26E-05 Major depressive disorder / / 22472876 rs6746896 chr2 97410949 A G 0.000000114 Bipolar disorder / / 23070075 rs2314398 chr2 97413488 C G 3.00E-06 Bipolar disorder / / 18711365 rs2678381 chr2 97441266 G A 8.53E-04 Type 2 diabetes CNNM4 intron 17463246 rs9948 chr2 97500800 G C,T 6.00E-06 Erectile dysfunction and prostate cancer treatment CNNM3 UTR-3 20932654 rs12613171 chr2 97553747 G A 6.38E-05 Odorant perception FAM178B intron 23910658 rs17119645 chr2 97553909 T C 3.80E-04 Smoking cessation FAM178B intron 24665060 rs7603256 chr2 97567389 C T 8.30E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6576990 chr2 97572798 T C 9.68E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6734673 chr2 97577241 T C 9.73E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6717064 chr2 97577343 C A 9.99E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs7592101 chr2 97579507 T C 9.67E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs11900466 chr2 97585936 C T 1.18E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer FAM178B intron 21483023 rs3903548 chr2 97591670 T C 9.86E-05 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs3903548 chr2 97591670 T C 1.18E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer FAM178B intron 21483023 rs11889996 chr2 97594366 A T 2.65E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs11676858 chr2 97597577 A G 8.62E-04 Alzheimer's disease FAM178B intron 17998437 rs13383143 chr2 97599266 C T 7.76E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs532711393 chr2 97605748 AC A 1.57E-05 Body Mass Index FAM178B intron pha003020 rs7594227 chr2 97605748 A G 1.57E-05 Body Mass Index FAM178B intron pha003020 rs1257022 chr2 97614936 C T 7.40E-05 Breast cancer FAM178B intron 19330027 rs1796043 chr2 97623413 G A 7.24E-05 Soluble levels of adhesion molecules FAM178B intron pha003072 rs1730122 chr2 97630540 T C 0.0000881 Primary sclerosing cholangitis FAM178B intron 23603763 rs10179966 chr2 97845100 C T 6.80E-05 Body Mass Index ANKRD36 intron pha003019 rs10179966 chr2 97845100 C T 4.86E-06 Body Mass Index ANKRD36 intron pha003020 rs17842456 chr2 98014319 T C 8.53E-04 Type 2 diabetes / / 17463246 rs11901495 chr2 98017804 G A 9.48E-04 Type 2 diabetes / / 17463246 rs11901495 chr2 98017804 G A 7.97E-05 Body Mass Index / / pha003019 rs11901495 chr2 98017804 G A 6.03E-06 Body Mass Index / / pha003020 rs10207116 chr2 98018281 G A 4.22E-05 Body Mass Index / / pha003019 rs10207116 chr2 98018281 G A 2.45E-06 Body Mass Index / / pha003020 rs2922564 chr2 98152475 C T 3.00E-05 Pericardial fat ANKRD36B intron 22589742 rs11690658 chr2 98163203 G T 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs11691779 chr2 98166928 C A 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs12712056 chr2 98170122 T C 3.70E-05 Pericardial fat ANKRD36B intron 22589742 rs6718109 chr2 98175863 T C 4.00E-05 Pericardial fat ANKRD36B intron 22589742 rs3931133 chr2 98176340 G A 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs12994535 chr2 98208691 G T 4.20E-05 Pericardial fat / / 22589742 rs3906948 chr2 98225437 A G 3.50E-05 Pericardial fat / / 22589742 rs2309166 chr2 98239486 C A 2.70E-05 Pericardial fat / / 22589742 rs4069489 chr2 98239649 A G 4.70E-05 Pericardial fat / / 22589742 rs4069493 chr2 98239803 T C 2.30E-05 Pericardial fat / / 22589742 rs4069494 chr2 98239804 G A 3.60E-05 Pericardial fat / / 22589742 rs1800649 chr2 98264857 C T 9.90E-05 Pericardial fat / / 22589742 rs11692435 chr2 98275354 G A 4.06E-04 Stroke ACTR1B missense pha002887 rs11123849 chr2 98286235 T C 3.98E-04 Myocardial Infarction / / pha002883 rs2290127 chr2 98319035 C T 8.74E-04 Coronary Artery Disease LOC728537 intron 17634449 rs11687510 chr2 98334679 C T 8.10E-05 Tourette syndrome ZAP70 intron 22889924 rs13033383 chr2 98339513 C T 7.55E-04 Tourette syndrome ZAP70 intron 22889924 rs1466020 chr2 98365250 G A 7.27E-05 Multiple complex diseases / / 17554300 rs930607 chr2 98371458 G A 7.10E-05 Multiple complex diseases / / 17554300 rs5865 chr2 98373006 C T 6.33E-04 Multiple complex diseases TMEM131 UTR-3 17554300 rs17022209 chr2 98394211 A C 4.69E-05 Cognitive impairment induced by topiramate TMEM131 intron 22091778 rs2309316 chr2 98524859 A C 4.82E-05 Multiple complex diseases TMEM131 intron 17554300 rs12712174 chr2 98531455 T A 6.05E-05 Multiple complex diseases TMEM131 intron 17554300 rs6709571 chr2 98531626 C G 5.36E-05 Multiple complex diseases TMEM131 intron 17554300 rs10191101 chr2 98534065 C T 7.57E-04 Multiple complex diseases TMEM131 intron 17554300 rs11690482 chr2 98560164 A G 5.32E-05 Multiple complex diseases TMEM131 intron 17554300 rs7598116 chr2 98575891 G C 5.01E-05 Multiple complex diseases TMEM131 intron 17554300 rs6726775 chr2 98586842 C A 4.69E-05 Cognitive impairment induced by topiramate TMEM131 intron 22091778 rs2017028 chr2 98589451 G T 8.28E-05 Multiple complex diseases TMEM131 intron 17554300 rs298906 chr2 98674859 G A 5.98E-04 Smoking initiation / / 24665060 rs6705251 chr2 98714445 G A 2.62E-04 Multiple complex diseases VWA3B intron 17554300 rs2053918 chr2 98730815 A C 8.40E-05 Glioma (high-grade) VWA3B intron 19578366 rs7598069 chr2 98761391 A G 3.35E-05 Multiple complex diseases VWA3B intron 17554300 rs17426403 chr2 98763159 C T 8.74E-04 Alzheimer's disease VWA3B intron 17998437 rs13399675 chr2 98789352 G A 1.10E-04 Smoking initiation VWA3B intron 24665060 rs10187244 chr2 98816010 T A 2.38E-06 Multiple complex diseases VWA3B intron 17554300 rs7603439 chr2 98827156 T G 2.00E-04 Breast cancer VWA3B intron pha002853 rs4132466 chr2 98835962 C T 3.93E-05 Heart Rate VWA3B intron pha003054 rs7601049 chr2 98844674 C G 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) VWA3B missense 21239504 rs11889349 chr2 98853173 G A 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) VWA3B missense 21239504 rs12470615 chr2 98858308 C G 2.48E-04 Multiple complex diseases VWA3B intron 17554300 rs4608580 chr2 98861057 C T 7.91E-05 Nicotine smoking VWA3B intron 19268276 rs13395774 chr2 98880845 C A 9.74E-04 Heart Failure VWA3B intron pha002885 rs6715989 chr2 98912271 G A 1.69E-04 Breast cancer VWA3B intron pha002853 rs7571001 chr2 98949400 T C 1.95E-04 Breast cancer / / pha002853 rs7571110 chr2 98949483 T C 5.25E-04 Multiple complex diseases / / 17554300 rs17429208 chr2 98961589 A G 7.56E-04 Multiple complex diseases CNGA3 nearGene-5 17554300 rs10865016 chr2 98989304 G A 9.67E-06 Nicotine smoking CNGA3 intron 19268276 rs13424165 chr2 98993035 A T 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNGA3 intron 23233662 rs2174353 chr2 98993635 A G 4.67E-05 Obesity (extreme) CNGA3 intron 21935397 rs78303077 chr2 98998983 G C 0.0000521 Nonsyndromic striae distensae (stretch marks) CNGA3 intron 23633020 rs3769745 chr2 99001403 C T 6.71E-05 Bipolar disorder CNGA3 intron 22925353 rs3754895 chr2 99004173 G T 7.07E-04 Multiple complex diseases CNGA3 intron 17554300 rs114841490 chr2 99009030 A G 0.0000193 Nonsyndromic striae distensae (stretch marks) CNGA3 intron 23633020 rs77969922 chr2 99016808 G A 0.0000134 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112907291 chr2 99082569 C T 0.00004549 Sarcoidosis INPP4A intron 22952805 rs17032120 chr2 99082938 C T 2.32E-04 Multiple complex diseases INPP4A intron 17554300 rs17032120 chr2 99082938 C T 9.92E-05 Formal thought disorder in schizophrenia INPP4A intron 22648509 rs12617721 chr2 99083892 A C 7.00E-06 Bipolar disorder (mood-incongruent) INPP4A intron 23092984 rs17504837 chr2 99136127 A G 1.50E-05 Urinary metabolites INPP4A intron 21572414 rs3769714 chr2 99150802 G C 8.16E-04 Multiple complex diseases INPP4A intron 17554300 rs3769714 chr2 99150802 G C 5.58E-05 Insulin resistance INPP4A intron 21901158 rs3820942 chr2 99172854 G A 0.0000682 Nonsyndromic striae distensae (stretch marks) INPP4A intron 23633020 rs3754876 chr2 99185867 C T 0.0000682 Nonsyndromic striae distensae (stretch marks) INPP4A intron 23633020 rs12618769 chr2 99239931 C T 1.00E-06 Bipolar disorder MGAT4A UTR-3 21738484 rs7560357 chr2 99247820 T G 4.50E-07 Bipolar disorder MGAT4A intron 21738484 rs13021375 chr2 99254031 G A 4.21E-04 Smoking quantity MGAT4A intron 24665060 rs56386350 chr2 99264073 C T 0.00001904 Sarcoidosis MGAT4A intron 22952805 rs11679648 chr2 99272802 G A 0.00005153 Sarcoidosis MGAT4A intron 22952805 rs55634708 chr2 99284927 T C 0.00002527 Sarcoidosis MGAT4A intron 22952805 rs56371690 chr2 99287729 G A 0.00001815 Sarcoidosis MGAT4A intron 22952805 rs17448190 chr2 99290399 C T 0.00001843 Sarcoidosis MGAT4A intron 22952805 rs56305624 chr2 99290856 G A 0.00001831 Sarcoidosis MGAT4A intron 22952805 rs76909086 chr2 99295731 C T 0.0000221 Sarcoidosis MGAT4A intron 22952805 rs62158010 chr2 99307430 T C 0.0002983 Sarcoidosis MGAT4A intron 22952805 rs55633363 chr2 99308148 G C 0.0002948 Sarcoidosis MGAT4A intron 22952805 rs62158012 chr2 99309914 A C 0.000005693 Sarcoidosis MGAT4A intron 22952805 rs56027617 chr2 99311272 C T 0.0002738 Sarcoidosis MGAT4A intron 22952805 rs56945529 chr2 99311400 C G 0.00002863 Sarcoidosis MGAT4A intron 22952805 rs62158015 chr2 99312106 A G 0.0003141 Sarcoidosis MGAT4A intron 22952805 rs55646762 chr2 99312981 T C 0.0003437 Sarcoidosis MGAT4A intron 22952805 rs56354279 chr2 99313344 G A 0.0003422 Sarcoidosis MGAT4A intron 22952805 rs12467276 chr2 99315067 T C 0.0002177 Sarcoidosis MGAT4A intron 22952805 rs62158019 chr2 99316339 G A 0.00001749 Sarcoidosis MGAT4A intron 22952805 rs12464653 chr2 99317157 C A 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs12469616 chr2 99317188 T C 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs882164 chr2 99317689 T C 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs56363239 chr2 99321237 A T 0.0001095 Sarcoidosis MGAT4A intron 22952805 rs7577636 chr2 99337309 C T 1.67E-04 Multiple complex diseases MGAT4A intron 17554300 rs4851150 chr2 99339122 C T 6.92E-04 Multiple complex diseases MGAT4A intron 17554300 rs41445250 chr2 99357165 A G 1.41E-04 Multiple complex diseases / / 17554300 rs11123751 chr2 99369757 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6706340 chr2 99369845 G A 1.06E-04 Multiple complex diseases / / 17554300 rs7578035 chr2 99382892 T G 3.00E-06 Bipolar disorder / / 21926972 rs7578035 chr2 99382892 T G 0.00000413 Bipolar disorder / / 23070075 rs13000014 chr2 99383330 G A 2.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7573844 chr2 99384024 G C 2.31E-05 Multiple complex diseases / / 17554300 rs12615689 chr2 99384371 G A 4.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs35979410 chr2 99404465 G A 1.11E-04 Alzheimer's disease / / 17998437 rs1356424 chr2 99425838 C T 3.91E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs1568213 chr2 99432063 T A 2.58E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs12712034 chr2 99458933 G A 9.68E-08 Metabolite levels C2orf55 intron 23281178 rs6733011 chr2 99465502 A G 3.00E-06 Bipolar disorder C2orf55 intron 19416921 rs4851164 chr2 99480327 C T 6.89E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851164 chr2 99480327 C T 7.04E-04 Alzheimer's disease C2orf55 intron 22005930 rs4851165 chr2 99485421 C T 4.09E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs17022034 chr2 99486848 A T 6.95E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851166 chr2 99493735 C T 7.02E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851166 chr2 99493735 C T 8.14E-04 Alzheimer's disease C2orf55 intron 22005930 rs17022036 chr2 99496928 G T 7.12E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs17022036 chr2 99496928 G T 8.08E-04 Alzheimer's disease C2orf55 intron 22005930 rs1574516 chr2 99501318 C T 7.23E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs10167015 chr2 99570707 G A 6.46E-04 Multiple complex diseases / / 17554300 rs6542847 chr2 99573471 A G 1.38E-04 Major depressive disorder / / 22472876 rs9679602 chr2 99577827 A G 8.30E-04 Multiple complex diseases / / 17554300 rs13396584 chr2 99611768 T G 1.19E-04 Schizophrenia / / 20832056 rs4850895 chr2 99644472 C T 1.83E-04 Response to radiotherapy in cancer (late toxicity) TSGA10 intron 24785509 rs4850895 chr2 99644472 C T 8.24E-04 Response to radiotherapy in cancer (late toxicity) TSGA10 intron 24785509 rs896886 chr2 99652713 A G 8.90E-04 Multiple complex diseases TSGA10 intron 17554300 rs896886 chr2 99652713 A G 5.11E-06 Lymphocyte counts TSGA10 intron 22286170 rs12613624 chr2 99732741 G A 5.74E-04 Multiple complex diseases TSGA10 intron 17554300 rs4851187 chr2 99745860 A C 2.27E-04 Multiple complex diseases TSGA10 intron 17554300 rs4850896 chr2 99754442 G C 2.99E-08 Metabolite levels TSGA10 intron 23281178 rs4851189 chr2 99770044 T C 2.99E-08 Metabolite levels TSGA10 intron 23281178 rs2632277 chr2 99778985 T C 2.52E-04 Multiple complex diseases LIPT1 cds-synon 17554300 rs2309582 chr2 99784307 G A 2.87E-04 Type 2 diabetes / / 17463246 rs11689265 chr2 99799267 A G 2.40E-04 Multiple complex diseases MRPL30 intron 17554300 rs13009147 chr2 99803998 T G 7.70E-04 Iris characteristics MRPL30 intron 21835309 rs10865030 chr2 99804642 T C 2.99E-08 Metabolite levels MRPL30 cds-synon 23281178 rs17851998 chr2 99804642 T TC,TT 2.99E-08 Metabolite levels MRPL30 cds-synon 23281178 rs7586635 chr2 99827733 A G 4.64E-04 Multiple complex diseases / / 17554300 rs7579999 chr2 99857670 G A 5.67E-08 Metabolite levels / / 23281178 rs17022433 chr2 99873658 T A 9.15E-07 Major depressive disorder / / 22472876 rs2200578 chr2 99876244 C T 4.00E-07 IgG glycosylation / / 23382691 rs4850899 chr2 99877465 A G 6.76E-05 Lymphocyte counts / / 22286170 rs1955393 chr2 99886301 G A 1.20E-06 Major depressive disorder / / 22472876 rs901596 chr2 99888457 C T 1.80E-06 Major depressive disorder / / 22472876 rs12464785 chr2 99938942 A G 6.18E-07 Major depressive disorder TXNDC9 intron 22472876 rs2309617 chr2 99976291 C A 8.37E-04 Type 2 diabetes EIF5B intron 17463246 rs2290255 chr2 99999097 C A 4.17E-07 Major depressive disorder EIF5B intron 22472876 rs2290261 chr2 100021184 A G 4.63E-07 Major depressive disorder REV1 intron 22472876 rs1053544 chr2 100022270 G A 3.95E-07 Major depressive disorder REV1 intron 22472876 rs717454 chr2 100022772 T C 4.10E-07 Major depressive disorder REV1 intron 22472876 rs3792146 chr2 100051522 C T 6.11E-05 Major depressive disorder REV1 intron 22472876 rs3087386 chr2 100055506 A G 6.02E-05 Major depressive disorder REV1 missense 22472876 rs3792137 chr2 100061748 C A 4.53E-07 Major depressive disorder REV1 intron 22472876 rs11899745 chr2 100064072 A G 4.41E-07 Major depressive disorder REV1 intron 22472876 rs7594838 chr2 100067554 C T 5.51E-05 Major depressive disorder REV1 intron 22472876 rs7567674 chr2 100067578 G A 5.69E-05 Major depressive disorder REV1 intron 22472876 rs4851206 chr2 100068069 T C 4.84E-07 Major depressive disorder REV1 intron 22472876 rs10172752 chr2 100069385 T G 5.93E-05 Major depressive disorder REV1 intron 22472876 rs7585019 chr2 100077327 G C 4.78E-07 Major depressive disorder REV1 intron 22472876 rs769105 chr2 100077966 G A 4.21E-07 Major depressive disorder REV1 intron 22472876 rs1011633 chr2 100094799 C T 3.71E-07 Major depressive disorder REV1 intron 22472876 rs6714244 chr2 100105312 A G 6.11E-05 Major depressive disorder REV1 intron 22472876 rs6715321 chr2 100109001 C T 4.66E-07 Major depressive disorder / / 22472876 rs2122749 chr2 100119654 C T 5.59E-04 Taste perception / / 22132133 rs1901284 chr2 100146040 C T 9.40E-04 Multiple complex diseases / / 17554300 rs12620982 chr2 100238379 C T 5.56E-05 Body Fat Distribution AFF3 intron pha003017 rs10514777 chr2 100264229 A G 8.55E-04 Coronary Artery Disease AFF3 intron 17634449 rs11676683 chr2 100275925 A C 5.80E-04 Alcohol dependence AFF3 intron 24277619 rs4851222 chr2 100288931 G A 5.80E-04 Alcohol dependence AFF3 intron 24277619 rs12466624 chr2 100315732 C T 9.51E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs10469849 chr2 100318617 T C 8.34E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs75275885 chr2 100326745 A T 6.61E-05 Epilepsy (remission after treatment) AFF3 intron 23962720 rs17022970 chr2 100338954 C T 5.67E-05 Multiple complex diseases AFF3 intron 17554300 rs79702182 chr2 100361583 A G 2.48E-05 Epilepsy (remission after treatment) AFF3 intron 23962720 rs940458 chr2 100377774 G T 7.00E-05 Coronary heart disease AFF3 intron pha003032 rs2163042 chr2 100380563 C T 9.65E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs10185087 chr2 100424310 C T 1.34E-05 Coronary heart disease AFF3 intron pha003032 rs1366765 chr2 100441349 G A 4.87E-06 Coronary heart disease AFF3 intron pha003032 rs7425117 chr2 100445030 C T 4.67E-06 Coronary heart disease AFF3 intron pha003032 rs1346620 chr2 100452928 C T 1.09E-05 Coronary heart disease AFF3 intron pha003032 rs11677260 chr2 100455547 C T 8.23E-04 Tourette syndrome AFF3 intron 22889924 rs7583877 chr2 100460654 C T 1.00E-08 Type 1 diabetes nephropathy AFF3 intron 23028342 rs7583877 chr2 100460654 C T 3.00E-07 Type 1 diabetes nephropathy AFF3 intron 23028342 rs17436594 chr2 100480432 A G 9.51E-04 Type 2 diabetes AFF3 intron 17463246 rs11886157 chr2 100545935 T A 8.76E-05 Multiple complex diseases AFF3 intron 17554300 rs17023310 chr2 100547380 T C 4.89E-04 Multiple complex diseases AFF3 intron 17554300 rs13393937 chr2 100551588 C T 1.92E-04 Smoking initiation AFF3 intron 24665060 rs4578903 chr2 100551590 G T 2.79E-10 Multiple complex diseases AFF3 intron 17554300 rs11897706 chr2 100558451 T C 6.67E-04 Smoking initiation AFF3 intron 24665060 rs7423759 chr2 100562328 C T 1.64E-04 Type 2 diabetes AFF3 intron 17463246 rs11887597 chr2 100576807 T C 1.08E-04 Bone mineral traits,in men AFF3 intron 21427758 rs11887597 chr2 100576807 T C 2.42E-05 Bone mineral traits,in men AFF3 intron 21427758 rs11887597 chr2 100576807 T C 5.64E-04 Bone mineral traits,in men AFF3 intron 21427758 rs13383014 chr2 100578606 C T 7.29E-04 Smoking initiation AFF3 intron 24665060 rs10187195 chr2 100581325 A G 8.83E-05 Smoking initiation AFF3 intron 24665060 rs10198187 chr2 100581552 G C 5.67E-04 Smoking initiation AFF3 intron 24665060 rs7576469 chr2 100584535 T C 5.04E-04 Smoking initiation AFF3 intron 24665060 rs4129805 chr2 100586506 A G 3.70E-04 Smoking initiation AFF3 intron 24665060 rs2001722 chr2 100592415 T C 8.44E-05 Smoking initiation AFF3 intron 24665060 rs13385193 chr2 100599407 T C 3.32E-04 Smoking initiation AFF3 intron 24665060 rs17023393 chr2 100609269 A G 3.08E-04 Smoking initiation AFF3 intron 24665060 rs17437101 chr2 100615241 G A 1.25E-04 Smoking initiation AFF3 intron 24665060 rs6736239 chr2 100621265 C T 3.60E-04 Smoking initiation AFF3 intron 24665060 rs10198062 chr2 100635663 A T 5.64E-05 Smoking initiation AFF3 intron 24665060 rs11685341 chr2 100636757 C T 8.80E-04 Multiple complex diseases AFF3 intron 17554300 rs7605430 chr2 100647552 C G 5.04E-04 Multiple complex diseases AFF3 intron 17554300 rs13402289 chr2 100659389 C T 1.89E-05 Educational attainment AFF3 intron 21694764 rs13402299 chr2 100659409 C T 6.89E-05 Blood Pressure AFF3 intron pha003040 rs17352801 chr2 100664685 G A 5.51E-05 Smoking initiation AFF3 intron 24665060 rs17437338 chr2 100666351 C G 8.86E-05 Smoking initiation AFF3 intron 24665060 rs17352808 chr2 100667168 G A 4.58E-05 Smoking initiation AFF3 intron 24665060 rs4851244 chr2 100671449 T C 6.06E-05 Blood Pressure AFF3 intron pha003040 rs13392222 chr2 100672408 A C 5.35E-05 Smoking initiation AFF3 intron 24665060 rs10209110 chr2 100672692 C T 0.000000011 Rheumatoid arthritis AFF3 intron 23143596 rs10209110 chr2 100672692 C T 6.79E-08 Rheumatoid arthritis (CCP positive) AFF3 intron 23143596 rs7582731 chr2 100686486 T C 0.00063 Breast cancer AFF3 intron 23555315 rs4851250 chr2 100729293 T C 4.00E-05 Blood Pressure AFF3 intron pha003040 rs6749757 chr2 100730111 C A 9.03E-05 Multiple complex diseases AFF3 intron 17554300 rs11694875 chr2 100732845 C T 2.58E-05 Multiple complex diseases AFF3 intron 17554300 rs6743817 chr2 100735567 A G 1.87E-04 Smoking initiation AFF3 intron 24665060 rs10199628 chr2 100735856 T C 5.51E-05 Smoking initiation AFF3 intron 24665060 rs17023516 chr2 100736650 T C 6.48E-05 Smoking initiation AFF3 intron 24665060 rs6745099 chr2 100739441 C G 1.15E-04 Smoking initiation AFF3 intron 24665060 rs6748652 chr2 100740059 C T 5.12E-04 Smoking initiation AFF3 intron 24665060 rs6732141 chr2 100743492 G C 1.68E-05 Type 1 diabetes nephropathy AFF3 intron 23028342 rs11692215 chr2 100746573 C T 7.56E-04 Response to taxane treatment (placlitaxel) AFF3 intron 23006423 rs4851252 chr2 100757280 C T 4.34E-05 Multiple complex diseases AFF3 intron 17554300 rs11681966 chr2 100759457 C A 5.89E-05 Multiple complex diseases / / 17554300 rs12712065 chr2 100761105 C G 8.43E-06 Type 1 diabetes nephropathy / / 23028342 rs11690905 chr2 100761473 A G 5.35E-05 Multiple complex diseases / / 17554300 rs12712067 chr2 100763900 G T 4.81E-05 Multiple complex diseases / / 17554300 rs10496344 chr2 100764125 T C 3.39E-05 Multiple complex diseases / / 17554300 rs11123813 chr2 100765692 C T 2.08E-05 Multiple complex diseases / / 17554300 rs4851256 chr2 100775045 T C 1.49E-04 Multiple complex diseases / / 17554300 rs7593261 chr2 100789907 T C 8.73E-05 Multiple complex diseases / / 17554300 rs11902705 chr2 100795207 G A 1.23E-04 Multiple complex diseases / / 17554300 rs4851262 chr2 100796248 A C 4.99E-04 Multiple complex diseases / / 17554300 rs6722241 chr2 100803778 T C 8.85E-05 Blood Pressure / / pha003040 rs6712515 chr2 100806514 T C 2.00E-11 Rheumatoid arthritis (CCP positive) / / 23143596 rs6712515 chr2 100806514 T C 2.82E-11 Rheumatoid arthritis / / 23143596 rs11676922 chr2 100806940 T A 1.00E-14 Rheumatoid arthritis / / 20453842 rs11676922 chr2 100806940 T A 1.00E-14 Celiac disease and Rheumatoid arthritis / / 21383967 rs11676922 chr2 100806940 T A 1.00E-14 Multiple sclerosis / / 22190364 rs11676922 chr2 100806940 T A 1.10E-06 Rheumatoid arthritis / / 22446963 rs11676922 chr2 100806940 T A 2.00E-08 Rheumatoid arthritis / / 24782177 rs4851264 chr2 100810188 T C 5.00E-11 Educational attainment / / 23722424 rs7566527 chr2 100811970 C T 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6740838 chr2 100813499 T G 5.12E-06 Type 1 diabetes / / 21980299 rs6740838 chr2 100813499 T G 0.000000883 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs6740838 chr2 100813499 T G 0.00000535 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs6740838 chr2 100813499 T G 1.23E-05 Blood Pressure / / pha003040 rs893245 chr2 100814893 C T 9.43E-07 Non-albumin protein levels / / 22558069 rs4851266 chr2 100818479 C T 8.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4851266 chr2 100818479 C T 5.00E-11 Educational attainment / / 23722424 rs9653442 chr2 100825367 C T 5.00E-06 Type 1 diabetes LOC150577 intron 17554260 rs9653442 chr2 100825367 C T 4.44E-06 Multiple complex diseases LOC150577 intron 17554300 rs9653442 chr2 100825367 C T 6.38E-05 Type 1 diabetes LOC150577 intron 18978792 rs9653442 chr2 100825367 C T 1.00E-14 Rheumatoid arthritis LOC150577 intron 24390342 rs9653442 chr2 100825367 C T 2.00E-18 Rheumatoid arthritis LOC150577 intron 24390342 rs9653442 chr2 100825367 C T 2.80E-05 Rheumatoid arthritis LOC150577 intron 24390342 rs11686372 chr2 100827907 C A 1.80E-05 Blood Pressure LOC150577 intron pha003040 rs11686372 chr2 100827907 C A 3.62E-05 Blood Pressure LOC150577 intron pha003048 rs4303732 chr2 100830040 T C 2.92E-05 Blood Pressure LOC150577 intron pha003040 rs4303732 chr2 100830040 T C 4.79E-05 Blood Pressure LOC150577 intron pha003048 rs4851269 chr2 100830348 T C 7.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs4851269 chr2 100830348 T C 2.38E-05 Blood Pressure LOC150577 intron pha003040 rs1160542 chr2 100832155 G A 9.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs1160542 chr2 100832155 G A 4.46E-05 Blood Pressure LOC150577 intron pha003040 rs1160543 chr2 100832182 C T 6.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC150577 intron 20031582 rs13432804 chr2 100833898 C T 1.20E-05 Urinary metabolites LOC150577 intron 21572414 rs10194635 chr2 100834217 T A 0.00000081 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) LOC150577 intron 23603761 rs10865035 chr2 100835734 A G 2.00E-06 Rheumatoid arthritis LOC150577 intron 20453842 rs10865035 chr2 100835734 A G 1.37E-05 Rheumatoid arthritis LOC150577 intron 24449572 rs2309837 chr2 100837567 T C 3.57E-06 Multiple complex diseases LOC150577 intron 17554300 rs2871344 chr2 100839430 A G 8.65E-04 Response to taxane treatment (placlitaxel) LOC150577 intron 23006423 rs6542920 chr2 100845088 A G 7.94E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6542920 chr2 100845088 A G 3.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs4851273 chr2 100848321 A G 6.46E-07 Non-albumin protein levels LOC150577 intron 22558069 rs7597861 chr2 100853187 G A 1.00E-04 Lipid traits LOC150577 intron 17903299 rs7597861 chr2 100853187 G A 1.17E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12474386 chr2 100857017 G A 2.28E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6739695 chr2 100859622 A G 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs10865036 chr2 100860595 T C 1.25E-05 Multiple complex diseases LOC150577 intron 17554300 rs10865036 chr2 100860595 T C 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12611915 chr2 100862195 G C 9.50E-06 Urinary metabolites LOC150577 intron 21572414 rs2309811 chr2 100862359 A G 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6737502 chr2 100862903 C T 1.22E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6542921 chr2 100864498 C A 1.26E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12053126 chr2 100864646 T A 9.28E-05 Glaucoma (primary open-angle) LOC150577 intron 22605921 rs4851274 chr2 100870862 T C 1.07E-07 Non-albumin protein levels / / 22558069 rs2067783 chr2 100877370 T C 9.02E-05 Cognitive performance / / 19734545 rs10173499 chr2 100877652 T C 3.40E-06 Urinary metabolites / / 21572414 rs6724490 chr2 100880539 A G 2.80E-06 Urinary metabolites / / 21572414 rs12467008 chr2 100882451 C T 2.60E-05 Urinary metabolites / / 21572414 rs4851288 chr2 100920451 T C 6.00E-04 Type 2 diabetes LONRF2 intron 17463246 rs1437967 chr2 100929072 C G 6.00E-04 Type 2 diabetes LONRF2 intron 17463246 rs6731549 chr2 100939937 T G 9.19E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4851295 chr2 100945605 T C 4.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17023990 chr2 100951210 C T 9.44E-04 Multiple complex diseases / / 17554300 rs13031508 chr2 100952757 A G 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2164847 chr2 100958715 C T 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4850927 chr2 100969067 A G 1.32E-05 Glaucoma (primary open-angle) / / 22605921 rs11685401 chr2 100976685 A G 3.43E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4640404 chr2 100980523 A G 9.17E-04 Type 2 diabetes / / 17463246 rs6542947 chr2 100999647 C G 8.70E-04 Type 2 diabetes / / 17463246 rs7587333 chr2 101006787 T C 7.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1030901 chr2 101007314 G A 9.80E-05 Response to alcohol consumption (flushing response) / / 24277619 rs1057056 chr2 101009082 C T 3.19E-05 Amyotrophic lateral sclerosis (sporadic) CHST10 UTR-3 24529757 rs150069978 chr2 101023110 C T 0.00011 Prostate cancer (advanced) CHST10 missense 23555315 rs4149510 chr2 101023635 G A 7.25E-05 Intelligence CHST10 intron 21826061 rs4851313 chr2 101029002 G A 4.33E-04 Response to alcohol consumption (flushing response) CHST10 intron 24277619 rs1519661 chr2 101088260 G A 6.91E-05 Body Mass Index NMS intron pha003006 rs753439 chr2 101088840 T C 6.91E-05 Body Mass Index NMS intron pha003006 rs1519654 chr2 101096960 C T 1.88E-05 Body Mass Index NMS cds-synon pha003006 rs10183360 chr2 101103384 C T 9.47E-05 Body Mass Index / / pha003006 rs1519662 chr2 101143618 C T 2.41E-05 Body Mass Index / / pha003006 rs12469806 chr2 101191950 G A 2.56E-04 Obesity (extreme) PDCL3 intron 21935397 rs2970991 chr2 101322193 C G 3.23E-04 Type 2 diabetes / / 17463246 rs6741485 chr2 101388261 C T 3.90E-04 Multiple complex diseases / / 17554300 rs7565981 chr2 101424331 G A 4.00E-08 Creutzfeldt-Jakob disease (variant) / / 22137330 rs7580771 chr2 101428119 G T 7.84E-05 Heart Rate / / pha003054 rs13028398 chr2 101440837 T C 9.32E-04 Coronary Artery Disease NPAS2 intron 17634449 rs3849381 chr2 101451819 T C 6.13E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs7585886 chr2 101517465 C T 3.35E-05 Amyotrophic lateral sclerosis (sporadic) NPAS2 intron 24529757 rs2117714 chr2 101521777 G A 7.99E-04 Sleep quality NPAS2 intron 23728906 rs356653 chr2 101539790 G A 7.00E-04 Chronic fatigue syndrome NPAS2 intron 21912186 rs356652 chr2 101540415 T G 2.82E-05 Cognitive test performance NPAS2 intron 20125193 rs356652 chr2 101540415 T G 9.43E-05 Erythrocyte counts NPAS2 intron pha003099 rs3754675 chr2 101549843 T C 9.08E-05 Erythrocyte counts NPAS2 intron pha003099 rs3768984 chr2 101550987 A C 2.56E-05 Rheumatoid arthritis NPAS2 intron 17804836 rs6542999 chr2 101553757 T G 9.92E-11 Triglycerides NPAS2 intron 23063622 rs7605570 chr2 101558904 T C 8.31E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs7605434 chr2 101558984 A G 0.00009399 Sarcoidosis NPAS2 intron 22952805 rs4851384 chr2 101561638 G A 2.50E-05 Urinary metabolites NPAS2 intron 21572414 rs10191450 chr2 101570735 G A 8.11E-04 Type 2 diabetes NPAS2 intron 17463246 rs882272 chr2 101576199 G A 1.29E-04 Type 2 diabetes NPAS2 intron 17463246 rs895520 chr2 101577937 G A 1.28E-04 Type 2 diabetes NPAS2 intron 17463246 rs12622050 chr2 101579454 G A 1.04E-05 Sodium levels NPAS2 intron pha003093 rs34628006 chr2 101580552 A G 0.00000211 Triglycerides NPAS2 missense 23063622 rs7581886 chr2 101581246 C T 5.05E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs2305160 chr2 101591304 A G 0.00044 Prostate cancer NPAS2 missense 23555315 rs1542178 chr2 101595475 A G 9.50E-05 Response to treatment for acute lymphoblastic leukemia NPAS2 intron 19176441 rs3768991 chr2 101599767 T C 0.00037 Coronary artery calcification NPAS2 intron 23727086 rs2278729 chr2 101668857 G A 7.15E-04 Multiple complex diseases TBC1D8 intron 17554300 rs2278729 chr2 101668857 G A 2.00E-05 Memory (short-term) TBC1D8 intron 20038948 rs2278729 chr2 101668857 G A 1.00E-07 Osteoporosis TBC1D8 intron 20548944 rs2278729 chr2 101668857 G A 1.47E-04 Response to TNF antagonist treatment TBC1D8 intron 21061259 rs2121367 chr2 101683487 C G 4.39E-05 Response to TNF antagonist treatment TBC1D8 intron 21061259 rs4851400 chr2 101696649 G A 4.96E-04 Type 2 diabetes TBC1D8 intron 17463246 rs7608232 chr2 101699063 C A 6.09E-04 Alcohol dependence TBC1D8 intron 21314694 rs2309938 chr2 101699594 A C 7.40E-05 Lung adenocarcinoma TBC1D8 intron 19836008 rs732136 chr2 101740231 T G 6.70E-04 Multiple complex diseases TBC1D8 intron 17554300 rs17025300 chr2 101759350 T C 5.44E-05 Stroke (ischemic) TBC1D8 intron 22941190 rs733830 chr2 101778319 T C 7.33E-04 Response to TNF antagonist treatment / / 21061259 rs1192817 chr2 101826261 G T 4.28E-05 Orofacial clefts / / 22419666 rs6724417 chr2 101830675 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13015194 chr2 101881980 T G 1.50E-04 Iris characteristics C2orf29 intron 21835309 rs6713930 chr2 101890427 G A 3.70E-06 Urinary metabolites / / 21572414 rs1192793 chr2 101897871 C T 5.21E-05 Glucose levels RNF149 intron pha003058 rs935065 chr2 101899130 T C 5.20E-05 Glucose levels RNF149 intron pha003058 rs6711606 chr2 101922170 T G 4.00E-06 Pancreatic cancer RNF149 intron 20686608 rs4851422 chr2 101958295 G A 3.13E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs4851423 chr2 101958326 G T 2.52E-05 Glucose levels / / pha003061 rs11677377 chr2 101973286 G T 4.74E-05 Glucose levels CREG2 intron pha003058 rs11677377 chr2 101973286 G T 4.87E-06 Glucose levels CREG2 intron pha003061 rs4850969 chr2 101985733 T C 7.55E-06 Multiple complex diseases CREG2 intron 17554300 rs7591123 chr2 101993105 T A 3.50E-05 Coffee consumption CREG2 intron 21357676 rs12712097 chr2 101994030 C T 7.94E-04 Multiple complex diseases CREG2 intron 17554300 rs12620464 chr2 102029646 T C 1.40E-05 Urinary metabolites RFX8 intron 21572414 rs12620464 chr2 102029646 T C 4.09E-05 Neuroticism RFX8 intron 23229837 rs12620464 chr2 102029646 T C 1.00E-06 Estradiol plasma levels (breast cancer) RFX8 intron 23518928 rs7565429 chr2 102036455 C T 1.80E-05 Urinary metabolites RFX8 intron 21572414 rs7583866 chr2 102064729 G A 4.04E-04 Aortic root size RFX8 intron 21223598 rs12712105 chr2 102065250 C G 2.36E-04 Aortic root size RFX8 intron 21223598 rs4850977 chr2 102065944 A G 4.47E-04 Aortic root size RFX8 intron 21223598 rs4850978 chr2 102066005 C A 4.43E-04 Aortic root size RFX8 intron 21223598 rs7574003 chr2 102081119 G A 8.64E-04 Type 2 diabetes RFX8 intron 17463246 rs1995826 chr2 102129420 C T 0.000702508 Hypertension (early onset hypertension) / / 22479346 rs11687533 chr2 102178726 C T 2.54E-05 Anxiety and major depressive disorder / / 24047446 rs6720988 chr2 102234065 T C 7.16E-05 Height / / 17255346 rs6720988 chr2 102234065 T C 4.37E-05 Cholesterol / / pha003078 rs2310128 chr2 102235312 A T 3.56E-05 Serum metabolites / / 19043545 rs10496357 chr2 102255114 T C 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10496357 chr2 102255114 T C 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10194088 chr2 102274615 T A 2.33E-04 Multiple complex diseases / / 17554300 rs41330544 chr2 102292519 C T 2.72E-05 Multiple complex diseases / / 17554300 rs7559442 chr2 102378381 G A 8.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs6744704 chr2 102385820 C T 3.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs17026045 chr2 102387089 A G 4.83E-04 Multiple complex diseases MAP4K4 intron 17554300 rs10175849 chr2 102389708 A G 6.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs3771903 chr2 102479029 G A 2.80E-04 Iris characteristics MAP4K4 intron 21835309 rs7568226 chr2 102534237 T A 1.10E-04 Iris characteristics / / 21835309 rs1019031 chr2 102574838 G T 2.00E-05 Iris characteristics / / 21835309 rs191222274 chr2 102576839 G A 4.99E-05 Acne (severe) / / 24927181 rs1990146 chr2 102579754 G A 7.32E-04 Multiple complex diseases / / 17554300 rs2190359 chr2 102580363 A G 4.34E-04 Multiple complex diseases / / 17554300 rs12468239 chr2 102605161 C T 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4321386 chr2 102613013 C G 9.00E-08 Follicle stimulating hormone IL1R2 intron 24049095 rs4851526 chr2 102618370 A G 5.20E-05 Psoriasis IL1R2 intron 20953189 rs4851526 chr2 102618370 A G 4.39E-05 Behcet's disease IL1R2 intron pha002888 rs4851527 chr2 102622376 A G 2.26E-05 Crohn's disease and psoriasis IL1R2 intron 22482804 rs3218872 chr2 102628509 T C 1.63E-04 Alzheimer's disease IL1R2 intron 17998437 rs3218873 chr2 102628561 G A 1.70E-04 Alzheimer's disease IL1R2 intron 17998437 rs28385681 chr2 102633524 T G 0.000000731 Cholesterol,total IL1R2 intron 23063622 rs2072478 chr2 102636526 A T 7.00E-04 Alzheimer's disease IL1R2 intron 17998437 rs4851531 chr2 102648609 C T 3.70E-04 Iris characteristics / / 21835309 rs2310173 chr2 102663628 T G 5.00E-07 Ankylosing spondylitis / / 20062062 rs2310173 chr2 102663628 T G 3.00E-12 Ulcerative colitis / / 21297633 rs2310173 chr2 102663628 T G 3.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4851536 chr2 102671681 T G 9.13E-04 Major depressive disorder / / 22472876 rs9967745 chr2 102676129 C T 4.81E-04 Type 2 diabetes / / 17463246 rs868251 chr2 102683386 C T 1.13E-05 Cognitive performance / / 19734545 rs13427957 chr2 102689031 C T 2.34E-04 Self-reported allergy / / 23817569 rs12624116 chr2 102690727 C T 7.37E-05 Left ventricular hypertrophy / / pha003052 rs1558644 chr2 102691310 A G 5.20E-05 Left ventricular hypertrophy / / pha003052 rs58340896 chr2 102691535 G C 0.0000774 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs871376 chr2 102711172 T C 8.19E-05 Self-reported allergy / / 23817569 rs12991050 chr2 102712652 A G 4.74E-04 Self-reported allergy / / 23817569 rs10490571 chr2 102717337 C T 9.79E-05 Inflammation / / pha002897 rs13029804 chr2 102723017 A C 4.81E-04 Self-reported allergy / / 23817569 rs11679849 chr2 102726012 A G 3.40E-04 Intelligence (childhood) / / 23358156 rs11679849 chr2 102726012 A G 5.54E-04 Self-reported allergy / / 23817569 rs12712127 chr2 102726661 A G 3.00E-08 Fibrinogen / / 23969696 rs10208542 chr2 102732315 G C 1.80E-13 Serum protein levels (sST2) / / 23999434 rs13007967 chr2 102732778 A G 3.34E-11 Serum protein levels (sST2) / / 23999434 rs12712129 chr2 102733585 G A 3.39E-11 Serum protein levels (sST2) / / 23999434 rs1465325 chr2 102734551 A G 2.05E-09 Self-reported allergy / / 23817569 rs871195 chr2 102734837 C A 2.07E-13 Serum protein levels (sST2) / / 23999434 rs1465324 chr2 102735612 G A 1.43E-10 Self-reported allergy / / 23817569 rs13029169 chr2 102735741 G A 2.19E-13 Serum protein levels (sST2) / / 23999434 rs13012334 chr2 102736020 A G 2.23E-13 Serum protein levels (sST2) / / 23999434 rs7557377 chr2 102736588 C T 2.25E-13 Serum protein levels (sST2) / / 23999434 rs12328681 chr2 102736867 G T 6.30E-10 Self-reported allergy / / 23817569 rs6712813 chr2 102738026 C T 2.36E-13 Serum protein levels (sST2) / / 23999434 rs6727859 chr2 102738164 A G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs6727985 chr2 102738275 A G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs10172039 chr2 102738785 C A 1.57E-10 Self-reported allergy / / 23817569 rs12619383 chr2 102741718 A G 0.0000255 Asthma / / 22694930 rs12619383 chr2 102741718 A G 1.87E-09 Self-reported allergy / / 23817569 rs12620132 chr2 102742115 A G 1.41E-09 Self-reported allergy / / 23817569 rs2310186 chr2 102743180 T G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs12470623 chr2 102744015 A T 2.26E-13 Serum protein levels (sST2) / / 23999434 rs6752379 chr2 102746705 G A 6.58E-14 Serum protein levels (sST2) / / 23999434 rs13387400 chr2 102750020 G A 1.51E-09 Self-reported allergy / / 23817569 rs2310187 chr2 102750428 G T 5.61E-14 Serum protein levels (sST2) / / 23999434 rs6706048 chr2 102754809 G C 4.60E-06 Urinary metabolites / / 21572414 rs13035227 chr2 102763837 T C 1.72E-13 Serum protein levels (sST2) / / 23999434 rs2110727 chr2 102764294 G A 0.00054756 Primary sclerosing cholangitis / / 23603763 rs2110727 chr2 102764294 G A 2.63E-10 Self-reported allergy / / 23817569 rs6754776 chr2 102764778 C G 2.16E-15 Serum protein levels (sST2) / / 23999434 rs1558641 chr2 102765865 G A 2.84E-10 Self-reported allergy / / 23817569 rs1558640 chr2 102765878 G A 3.18E-10 Self-reported allergy / / 23817569 rs949963 chr2 102769786 C T 8.32E-07 Asthma / / 21804549 rs949963 chr2 102769786 C T 4.04E-10 Self-reported allergy / / 23817569 rs2287049 chr2 102770738 A G 5.50E-07 Urinary metabolites IL1R1 intron 21572414 rs871657 chr2 102771341 C T 7.08E-07 Asthma IL1R1 intron 21804549 rs871657 chr2 102771341 C T 4.50E-10 Self-reported allergy IL1R1 intron 23817569 rs3917237 chr2 102772451 G A 5.26E-08 Cholesterol,total IL1R1 intron 23063622 rs2287048 chr2 102773999 C T 1.86E-10 Self-reported allergy IL1R1 intron 23817569 rs2287047 chr2 102774054 G A 1.35E-05 Aging (time to event) IL1R1 intron 21782286 rs13019803 chr2 102776202 C T 6.00E-20 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917254 chr2 102776518 G A 1.14E-15 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917273 chr2 102779719 A T 6.29E-05 Self-reported allergy IL1R1 intron 23817569 rs3917285 chr2 102781166 T A 3.07E-13 Self-reported allergy IL1R1 intron 23817569 rs3917291 chr2 102782166 G A 1.20E-14 Serum protein levels (sST2) IL1R1 intron 23999434 rs997049 chr2 102782433 T A 6.99E-05 Self-reported allergy IL1R1 intron 23817569 rs2160227 chr2 102783355 G T 1.93E-05 Cognitive impairment induced by topiramate IL1R1 intron 22091778 rs2160227 chr2 102783355 G T 2.00E-04 Cognitive impairment induced by topiramate IL1R1 intron 22091778 rs2160227 chr2 102783355 G T 5.03E-05 Self-reported allergy IL1R1 intron 23817569 rs13020778 chr2 102784574 T C 1.20E-04 Self-reported allergy IL1R1 intron 23817569 rs3917296 chr2 102784833 A G 7.15E-12 Serum protein levels (sST2) IL1R1 intron 23999434 rs951192 chr2 102785854 A C 1.26E-05 Self-reported allergy IL1R1 intron 23817569 rs3917304 chr2 102788125 G T 1.58E-05 Self-reported allergy IL1R1 intron 23817569 rs3771200 chr2 102788774 G A 4.26E-05 Self-reported allergy IL1R1 intron 23817569 rs3917314 chr2 102790863 A C 1.98E-14 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917318 chr2 102792760 A G 1.15E-05 Self-reported allergy IL1R1 intron 23817569 rs3917320 chr2 102792875 A C 2.13E-14 Serum protein levels (sST2) IL1R1 cds-synon 23999434 rs3917325 chr2 102793907 T G 2.21E-14 Serum protein levels (sST2) IL1R1 UTR-3 23999434 rs3732134 chr2 102794217 C G 9.34E-04 Type 2 diabetes IL1R1 UTR-3 17463246 rs2110726 chr2 102794282 G A 3.41E-05 Self-reported allergy IL1R1 UTR-3 23817569 rs3917328 chr2 102794541 C T 2.21E-14 Serum protein levels (sST2) IL1R1 UTR-3 23999434 rs7582198 chr2 102799834 A G 1.13E-05 Self-reported allergy / / 23817569 rs1030021 chr2 102801478 A C 9.93E-06 Self-reported allergy / / 23817569 rs10181869 chr2 102801852 C A 1.02E-05 Self-reported allergy / / 23817569 rs10184597 chr2 102802255 C T 9.43E-06 Self-reported allergy / / 23817569 rs2241132 chr2 102804035 C A 2.68E-15 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1558648 chr2 102810168 T G 4.00E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12987222 chr2 102814116 G T 1.19E-15 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3771195 chr2 102816022 C T 2.62E-04 Self-reported allergy IL1RL2 intron 23817569 rs3771192 chr2 102816140 C A 1.95E-04 Self-reported allergy IL1RL2 intron 23817569 rs11123912 chr2 102816536 G A 1.13E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12474258 chr2 102816695 C T 4.71E-08 Self-reported allergy IL1RL2 intron 23817569 rs12474258 chr2 102816695 C T 1.65E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs11678651 chr2 102817154 G T 8.46E-04 Type 2 diabetes IL1RL2 intron 17463246 rs1922302 chr2 102819049 T G 4.65E-08 Self-reported allergy IL1RL2 intron 23817569 rs1922302 chr2 102819049 T G 1.58E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2310239 chr2 102824201 G A 6.93E-04 Type 2 diabetes IL1RL2 intron 17463246 rs13021607 chr2 102824726 G A 8.86E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs11123913 chr2 102825479 T C 1.07E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs10490570 chr2 102827739 C T 8.15E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1922291 chr2 102828817 A G 6.43E-08 Self-reported allergy IL1RL2 intron 23817569 rs1922291 chr2 102828817 A G 1.57E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12989930 chr2 102829822 T C 7.87E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12996377 chr2 102830478 T A 1.32E-12 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13002813 chr2 102831280 T C 7.74E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6743219 chr2 102831711 T C 7.67E-08 Self-reported allergy IL1RL2 intron 23817569 rs6743219 chr2 102831711 T C 1.54E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13028635 chr2 102832284 C T 7.65E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1922294 chr2 102835909 G A 4.20E-04 Parkinson's disease IL1RL2 intron 17052657 rs917994 chr2 102837414 G A 4.71E-08 Self-reported allergy IL1RL2 intron 23817569 rs917994 chr2 102837414 G A 1.52E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12992518 chr2 102837598 C T 7.06E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3771185 chr2 102840507 T C 2.07E-06 Self-reported allergy IL1RL2 intron 23817569 rs12473710 chr2 102840979 T C 6.58E-06 Self-reported allergy IL1RL2 intron 23817569 rs12472862 chr2 102840994 A G 6.35E-06 Self-reported allergy IL1RL2 intron 23817569 rs17637748 chr2 102841715 A G 1.86E-06 Self-reported allergy IL1RL2 intron 23817569 rs2310241 chr2 102841949 A C 2.00E-06 Self-reported allergy IL1RL2 intron 23817569 rs2302621 chr2 102842124 G T 3.40E-08 Self-reported allergy IL1RL2 intron 23817569 rs2302621 chr2 102842124 G T 1.48E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13033782 chr2 102843833 G A 5.31E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3755285 chr2 102844020 T C 0.00000513 Asthma IL1RL2 intron 22694930 rs3755285 chr2 102844020 T C 1.20E-12 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3755285 chr2 102844020 T C 1.42E-05 Asthma IL1RL2 intron pha003127 rs1997502 chr2 102844249 A G 5.08E-11 Self-reported allergy IL1RL2 intron 23817569 rs1997502 chr2 102844249 A G 2.92E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12995229 chr2 102846907 A G 9.24E-18 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6758443 chr2 102848062 G T 5.82E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs955754 chr2 102849081 T C 3.58E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12987900 chr2 102849348 G A 1.30E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6709635 chr2 102850439 G A 2.30E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6754556 chr2 102850924 A T 2.22E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2302612 chr2 102851708 T C 2.00E-11 Serum protein levels (sST2) IL1RL2 missense 23999434 rs13002972 chr2 102851861 G A 9.30E-17 Serum protein levels (sST2) IL1RL2 intron 23999434 rs10167431 chr2 102852802 T C 5.04E-07 Self-reported allergy IL1RL2 intron 23817569 rs10167431 chr2 102852802 T C 1.04E-08 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2287040 chr2 102852980 C T 7.28E-04 Type 2 diabetes IL1RL2 intron 17463246 rs13017475 chr2 102853208 C T 7.83E-17 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13014084 chr2 102854765 A G 4.09E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12993937 chr2 102855831 G A,C,T 3.33E-19 Serum protein levels (sST2) / / 23999434 rs10178214 chr2 102858921 G T 2.57E-11 Self-reported allergy / / 23817569 rs13027294 chr2 102860074 G C 1.77E-11 Self-reported allergy / / 23817569 rs1558625 chr2 102862164 A G 1.40E-08 Serum protein levels (sST2) / / 23999434 rs1035131 chr2 102862641 T G 2.63E-04 Height / / 17255346 rs1035131 chr2 102862641 T G 9.00E-08 Urinary metabolites / / 21572414 rs2110661 chr2 102863221 G A 8.90E-08 Urinary metabolites / / 21572414 rs13018912 chr2 102864310 G T 2.86E-20 Serum protein levels (sST2) / / 23999434 rs12997225 chr2 102864748 A C 2.82E-20 Serum protein levels (sST2) / / 23999434 rs11677452 chr2 102865236 A T 3.42E-11 Self-reported allergy / / 23817569 rs9646944 chr2 102865875 G C 2.78E-11 Self-reported allergy / / 23817569 rs12712133 chr2 102866273 A G 2.70E-05 Urinary metabolites / / 21572414 rs10186746 chr2 102866377 G A 0.0000236 Primary biliary cirrhosis in females / / 22936693 rs10186746 chr2 102866377 G A 0.000024 Primary biliary cirrhosis / / 22936693 rs10186746 chr2 102866377 G A 0.0000662 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs10200410 chr2 102870871 G A 2.08E-05 Self-reported allergy / / 23817569 rs1345301 chr2 102875587 A G 1.88E-05 Self-reported allergy / / 23817569 rs1345301 chr2 102875587 A G 5.00E-06 Waist circumference / / 23966867 rs2310243 chr2 102877560 A G 1.95E-05 Self-reported allergy / / 23817569 rs13405355 chr2 102878206 C T 1.95E-05 Self-reported allergy / / 23817569 rs12475055 chr2 102878891 A C 6.00E-06 Urinary metabolites / / 21572414 rs12475055 chr2 102878891 A C 1.95E-05 Self-reported allergy / / 23817569 rs10189629 chr2 102879464 C A 2.48E-07 Asthma / / 21804549 rs10189629 chr2 102879464 C A 2.00E-16 Self-reported allergy / / 23817569 rs12995644 chr2 102880027 C A 3.97E-22 Serum protein levels (sST2) / / 23999434 rs11123915 chr2 102880823 G T 1.76E-12 Serum protein levels (sST2) / / 23999434 rs1882510 chr2 102883618 C T 9.03E-23 Serum protein levels (sST2) / / 23999434 rs1882511 chr2 102883721 G A 1.29E-23 Serum protein levels (sST2) / / 23999434 rs11692065 chr2 102883975 C T 1.56E-07 Asthma / / 21804549 rs11692065 chr2 102883975 C T 2.07E-16 Self-reported allergy / / 23817569 rs10200945 chr2 102884757 A T 1.60E-12 Serum protein levels (sST2) / / 23999434 rs4851563 chr2 102885535 A T 2.20E-05 Urinary metabolites / / 21572414 rs11674302 chr2 102887128 T C 1.69E-06 Asthma / / 20860503 rs11674302 chr2 102887128 T C 7.75E-07 Asthma / / 21804549 rs11674302 chr2 102887128 T C 2.29E-16 Self-reported allergy / / 23817569 rs13015695 chr2 102888441 C A,T 2.17E-22 Serum protein levels (sST2) / / 23999434 rs1922288 chr2 102888565 T C 2.04E-23 Serum protein levels (sST2) / / 23999434 rs10469856 chr2 102888829 A T 8.87E-13 Serum protein levels (sST2) / / 23999434 rs9308855 chr2 102890795 A G 1.09E-23 Serum protein levels (sST2) / / 23999434 rs1115281 chr2 102891107 C G 6.95E-13 Serum protein levels (sST2) / / 23999434 rs9308856 chr2 102895442 A G 2.58E-04 Multiple complex diseases / / 17554300 rs12469892 chr2 102895784 G A 7.05E-23 Serum protein levels (sST2) / / 23999434 rs12989419 chr2 102900754 A C 4.72E-37 Serum protein levels (sST2) / / 23999434 rs13024772 chr2 102902173 G A 2.59E-37 Serum protein levels (sST2) / / 23999434 rs6747153 chr2 102903827 A G 8.03E-23 Serum protein levels (sST2) / / 23999434 rs13407644 chr2 102905351 A G 1.97E-37 Serum protein levels (sST2) / / 23999434 rs13017541 chr2 102906176 C T 1.25E-37 Serum protein levels (sST2) / / 23999434 rs13024003 chr2 102907761 G C 1.17E-37 Serum protein levels (sST2) / / 23999434 rs4851003 chr2 102909277 T C 1.83E-04 Height / / 17255346 rs13009757 chr2 102912174 C T 2.67E-34 Serum protein levels (sST2) / / 23999434 rs1476984 chr2 102912269 C T 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs951774 chr2 102912664 C A 3.78E-24 Serum protein levels (sST2) / / 23999434 rs11690644 chr2 102914214 A G 3.59E-16 Self-reported allergy / / 23817569 rs10515922 chr2 102914654 A G 5.12E-09 Serum protein levels (sST2) / / 23999434 rs7600901 chr2 102915571 A G 2.74E-20 Serum protein levels (sST2) / / 23999434 rs11693697 chr2 102915662 T C 7.00E-11 Serum protein levels (sST2) / / 23999434 rs4399750 chr2 102917788 T C 1.04E-67 Serum protein levels (sST2) / / 23999434 rs1362347 chr2 102919585 C T 1.14E-31 Serum protein levels (sST2) / / 23999434 rs4090473 chr2 102922987 C G 9.95E-68 Serum protein levels (sST2) / / 23999434 rs11685424 chr2 102926981 G A 4.15E-66 Serum protein levels (sST2) / / 23999434 rs1558622 chr2 102930147 G A 9.75E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10189711 chr2 102930881 A G 9.68E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12712135 chr2 102930948 A G 2.70E-70 Serum protein levels (sST2) IL1RL1 intron 23999434 rs953934 chr2 102932293 C T 5.00E-04 Bone mass and geometry IL1RL1 intron 17903296 rs953934 chr2 102932293 C T 2.56E-70 Serum protein levels (sST2) IL1RL1 intron 23999434 rs950881 chr2 102932512 G T 2.04E-14 Self-reported allergy IL1RL1 intron 23817569 rs950880 chr2 102932562 C A 1.11E-09 Self-reported allergy IL1RL1 intron 23817569 rs950880 chr2 102932562 C A 7.00E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123918 chr2 102935237 T C 8.88E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10182639 chr2 102935805 C A 8.99E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11690443 chr2 102936131 T A 9.18E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs974389 chr2 102936981 G A 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4142132 chr2 102937482 G A 9.43E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12987782 chr2 102937966 G A 1.47E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13001301 chr2 102938998 C T 1.49E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13001325 chr2 102939036 C T 1.33E-09 Self-reported allergy IL1RL1 intron 23817569 rs13001325 chr2 102939036 C T 8.64E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420088 chr2 102939434 T C 9.45E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123920 chr2 102939833 C T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6706844 chr2 102940412 T C 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12996772 chr2 102947201 A T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17695648 chr2 102948181 A G 1.59E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420103 chr2 102948632 A C 1.00E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420102 chr2 102948819 C T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12466380 chr2 102948939 A G 9.45E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12479210 chr2 102949161 C T 2.51E-09 Self-reported allergy IL1RL1 intron 23817569 rs12479210 chr2 102949161 C T 9.42E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13019081 chr2 102950822 A C 2.51E-09 Self-reported allergy IL1RL1 intron 23817569 rs13019081 chr2 102950822 A C 9.47E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1997467 chr2 102951073 A G 1.06E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1997466 chr2 102951467 C G 1.21E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1362350 chr2 102951798 G C 1.43E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs200540641 chr2 102951851 G GA 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs2310220 chr2 102951851 G A 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs397969654 chr2 102951851 G GA 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1362349 chr2 102951972 G C 9.54E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3755278 chr2 102952217 T C 1.52E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17026974 chr2 102952360 G A 6.99E-04 Alzheimer's disease IL1RL1 intron 17998437 rs17026974 chr2 102952360 G A 3.57E-06 Self-reported allergy IL1RL1 intron 23817569 rs17026974 chr2 102952360 G A 3.26E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12712141 chr2 102953067 T C 1.06E-66 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17639215 chr2 102953444 G A 2.00E-30 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3771180 chr2 102953617 G T 2.00E-15 Asthma IL1RL1 intron 21804549 rs3771180 chr2 102953617 G T 1.65E-13 Self-reported allergy IL1RL1 intron 23817569 rs3771179 chr2 102953892 T G 1.51E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs985523 chr2 102954376 G A 6.56E-28 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13431828 chr2 102954653 C T 2.00E-04 Asthma IL1RL1 UTR-5 19910030 rs13431828 chr2 102954653 C T 1.26E-07 Asthma IL1RL1 UTR-5 20860503 rs13431828 chr2 102954653 C T 2.77E-08 Asthma IL1RL1 UTR-5 21804549 rs13431828 chr2 102954653 C T 1.51E-15 Self-reported allergy IL1RL1 UTR-5 23817569 rs13408569 chr2 102955056 G C 3.79E-08 Asthma IL1RL1 intron 21804549 rs13408569 chr2 102955056 G C 1.83E-15 Self-reported allergy IL1RL1 intron 23817569 rs13408661 chr2 102955082 G A 3.78E-08 Asthma IL1RL1 intron 21804549 rs13408661 chr2 102955082 G A 1.00E-09 Asthma IL1RL1 intron 23028483 rs13408661 chr2 102955082 G A 1.91E-15 Self-reported allergy IL1RL1 intron 23817569 rs1041973 chr2 102955468 C A 3.50E-04 Asthma IL1RL1 missense 19910030 rs1041973 chr2 102955468 C A 3.00E-05 Upper aerodigestive tract cancers IL1RL1 missense 21437268 rs1041973 chr2 102955468 C A 1.43E-06 Self-reported allergy IL1RL1 missense 23817569 rs873022 chr2 102955683 G T 3.29E-06 Self-reported allergy IL1RL1 intron 23817569 rs873022 chr2 102955683 G T 5.40E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3771177 chr2 102955860 G T 3.29E-06 Self-reported allergy IL1RL1 intron 23817569 rs3771177 chr2 102955860 G T 5.55E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13029918 chr2 102957291 A G 2.00E-39 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10173081 chr2 102957348 C T 1.42E-08 Asthma IL1RL1 intron 21804549 rs10173081 chr2 102957348 C T 2.19E-15 Self-reported allergy IL1RL1 intron 23817569 rs3732129 chr2 102957532 T C 3.20E-06 Self-reported allergy IL1RL1 intron 23817569 rs3732129 chr2 102957532 T C 6.35E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420101 chr2 102957716 C T 5.00E-14 Eosinophil counts IL1RL1 intron 19198610 rs1420101 chr2 102957716 C T 3.25E-09 Self-reported allergy IL1RL1 intron 23817569 rs1420101 chr2 102957716 C T 4.33E-92 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420101 chr2 102957716 C T 6.00E-04 Ulcerative colitis IL1RL1 intron 24837172 rs6719130 chr2 102958236 C T 1.07E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13016771 chr2 102959080 G A 1.53E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12999517 chr2 102959260 T C 3.12E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12905 chr2 102960007 G A 2.52E-06 Self-reported allergy IL1RL1 UTR-3 23817569 rs12905 chr2 102960007 G A 1.04E-39 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs3771175 chr2 102960210 T A 1.87E-15 Self-reported allergy IL1RL1 UTR-3 23817569 rs3771175 chr2 102960210 T A 5.00E-11 Allergic sensitization IL1RL1 UTR-3 23817571 rs3821204 chr2 102960281 C G 2.35E-06 Self-reported allergy IL1RL1 UTR-3 23817569 rs3821204 chr2 102960281 C G 8.01E-38 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs12712142 chr2 102960584 C A 2.22E-10 Self-reported allergy IL1RL1 UTR-3 23817569 rs12712142 chr2 102960584 C A 1.68E-84 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs2160203 chr2 102960824 A G 3.29E-09 Self-reported allergy IL1RL1 UTR-3 23817569 rs1946131 chr2 102961929 C T 2.21E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs62152663 chr2 102962346 C G 0.00012 Schizophrenia IL1RL1 intron 22440650 rs12989197 chr2 102962739 G A 2.20E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6543119 chr2 102963072 A T 3.55E-84 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12996097 chr2 102963628 G A 2.17E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13028993 chr2 102963949 T C 2.17E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13017455 chr2 102964742 C T 1.36E-10 Self-reported allergy IL1RL1 intron 23817569 rs13017455 chr2 102964742 C T 6.92E-84 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17027006 chr2 102965332 G C 1.80E-06 Self-reported allergy IL1RL1 intron 23817569 rs17027006 chr2 102965332 G C 1.36E-36 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12999542 chr2 102965392 A C 2.00E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12469506 chr2 102965871 C T 6.10E-07 Self-reported allergy IL1RL1 intron 23817569 rs12469506 chr2 102965871 C T 1.05E-41 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1921622 chr2 102966067 G A 5.18E-11 Self-reported allergy IL1RL1 intron 23817569 rs1921622 chr2 102966067 G A 6.06E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1921622 chr2 102966067 G A 6.58E-05 Blood Pressure IL1RL1 intron pha003045 rs1921622 chr2 102966067 G A 4.41E-05 Blood Pressure IL1RL1 intron pha003047 rs10208293 chr2 102966310 G A 2.80E-09 Self-reported allergy IL1RL1 intron 23817569 rs10208293 chr2 102966310 G A 2.28E-24 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10197862 chr2 102966549 A G 6.31E-08 Asthma IL1RL1 intron 21804549 rs10197862 chr2 102966549 A G 2.81E-15 Self-reported allergy IL1RL1 intron 23817569 rs10197862 chr2 102966549 A G 4.00E-11 Asthma and hay fever IL1RL1 intron 24388013 rs1861245 chr2 102966906 C T 2.94E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13424006 chr2 102967236 T C 5.68E-07 Self-reported allergy IL1RL1 intron 23817569 rs13424006 chr2 102967236 T C 3.25E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6751967 chr2 102967413 T C 5.87E-07 Self-reported allergy IL1RL1 intron 23817569 rs6751967 chr2 102967413 T C 3.39E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs552531342 chr2 102967587 A AT 2.62E-07 Self-reported allergy IL1RL1 intron 23817569 rs552531342 chr2 102967587 A AT 3.54E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6749114 chr2 102967587 A C 2.62E-07 Self-reported allergy IL1RL1 intron 23817569 rs6749114 chr2 102967587 A C 3.54E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123923 chr2 102967844 C A 1.07E-10 Self-reported allergy IL1RL1 intron 23817569 rs11123923 chr2 102967844 C A 4.89E-81 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4988955 chr2 102967928 A G 4.41E-07 Self-reported allergy IL1RL1 intron 23817569 rs4988955 chr2 102967928 A G 3.67E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4988956 chr2 102968007 G A 6.88E-07 Self-reported allergy IL1RL1 missense 23817569 rs4988956 chr2 102968007 G A 3.66E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs4988957 chr2 102968075 T C 4.87E-07 Self-reported allergy IL1RL1 cds-synon 23817569 rs4988957 chr2 102968075 T C 3.66E-17 Serum protein levels (sST2) IL1RL1 cds-synon 23999434 rs10204137 chr2 102968212 A G 1.40E-08 Asthma IL1RL1 missense 20860503 rs10204137 chr2 102968212 A G 3.66E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs4988958 chr2 102968285 T C 4.01E-07 Self-reported allergy IL1RL1 cds-synon 23817569 rs4988958 chr2 102968285 T C 3.84E-17 Serum protein levels (sST2) IL1RL1 cds-synon 23999434 rs10192157 chr2 102968356 C T 2.11E-08 Asthma IL1RL1 missense 20860503 rs10192157 chr2 102968356 C T 4.01E-07 Self-reported allergy IL1RL1 missense 23817569 rs10192157 chr2 102968356 C T 4.06E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs10206753 chr2 102968362 T C 1.54E-08 Asthma IL1RL1 missense 20860503 rs10206753 chr2 102968362 T C 4.01E-07 Self-reported allergy IL1RL1 missense 23817569 rs10206753 chr2 102968362 T C 4.33E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs9807989 chr2 102971200 T C 6.00E-08 Asthma / / 22561531 rs13015714 chr2 102971865 G T 4.00E-09 Celiac disease / / 18311140 rs13015714 chr2 102971865 G T 1.63E-04 Crohn's disease and Celiac disease / / 21298027 rs13015714 chr2 102971865 G T 8.00E-18 Atopic dermatitis / / 23042114 rs13015714 chr2 102971865 G T 4.47E-33 Serum protein levels (sST2) / / 23999434 rs7603730 chr2 102974371 A C 1.61E-07 Self-reported allergy / / 23817569 rs7603730 chr2 102974371 A C 6.09E-17 Serum protein levels (sST2) / / 23999434 rs12998521 chr2 102974417 G T 5.22E-11 Self-reported allergy / / 23817569 rs12998521 chr2 102974417 G T 1.27E-80 Serum protein levels (sST2) / / 23999434 rs10170583 chr2 102974764 G A 1.59E-07 Self-reported allergy / / 23817569 rs10170583 chr2 102974764 G A 1.13E-16 Serum protein levels (sST2) / / 23999434 rs10176664 chr2 102976172 G A 3.65E-07 Self-reported allergy / / 23817569 rs10176664 chr2 102976172 G A 5.15E-17 Serum protein levels (sST2) / / 23999434 rs3755276 chr2 102978459 C T 8.10E-07 Asthma / / 21804549 rs3755276 chr2 102978459 C T 3.94E-07 Self-reported allergy / / 23817569 rs3755276 chr2 102978459 C T 4.88E-17 Serum protein levels (sST2) / / 23999434 rs2287037 chr2 102979028 C T 4.83E-11 Self-reported allergy / / 23817569 rs2287037 chr2 102979028 C T 1.26E-80 Serum protein levels (sST2) / / 23999434 rs10515921 chr2 102981018 T G 1.85E-25 Serum protein levels (sST2) IL18R1 intron 23999434 rs1362348 chr2 102984624 C G 8.46E-07 Asthma IL18R1 intron 21804549 rs1362348 chr2 102984624 C G 3.93E-07 Self-reported allergy IL18R1 intron 23817569 rs1362348 chr2 102984624 C G 4.11E-17 Serum protein levels (sST2) IL18R1 intron 23999434 rs2058622 chr2 102985424 A G 2.88E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771172 chr2 102985812 C T 2.47E-07 Self-reported allergy IL18R1 intron 23817569 rs3771172 chr2 102985812 C T 1.27E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771171 chr2 102985950 T C 1.39E-07 Self-reported allergy IL18R1 intron 23817569 rs3771171 chr2 102985950 T C 1.28E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771170 chr2 102985980 T A 2.91E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs2160202 chr2 102986154 G A 2.47E-07 Self-reported allergy IL18R1 intron 23817569 rs2160202 chr2 102986154 G A 1.29E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs2058623 chr2 102986170 C T 2.95E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771167 chr2 102986188 A G 6.07E-23 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771166 chr2 102986222 G A 3.00E-09 Asthma IL18R1 intron 20860503 rs3771166 chr2 102986222 G A 3.40E-09 Asthma IL18R1 intron 21907864 rs3771166 chr2 102986222 G A 3.40E-09 Asthma IL18R1 intron 22561531 rs3771166 chr2 102986222 G A 3.82E-07 Self-reported allergy IL18R1 intron 23817569 rs3771166 chr2 102986222 G A 3.43E-16 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771166 chr2 102986222 G A 2.80E-04 Asthma (childhood,severe) IL18R1 intron 24241537 rs1974675 chr2 102986375 G A 3.55E-07 Self-reported allergy IL18R1 intron 23817569 rs1974675 chr2 102986375 G A 3.52E-16 Serum protein levels (sST2) IL18R1 intron 23999434 rs6728945 chr2 102986471 T C 6.86E-23 Serum protein levels (sST2) IL18R1 intron 23999434 rs1465321 chr2 102986618 T C 3.03E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs11465596 chr2 102987093 C A 2.70E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs11465597 chr2 102987213 A G 4.34E-04 Multiple complex diseases IL18R1 intron 17554300 rs11465597 chr2 102987213 A G 1.10E-05 Urinary metabolites IL18R1 intron 21572414 rs11465597 chr2 102987213 A G 6.02E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs7579737 chr2 102987361 A G 3.52E-04 Multiple complex diseases IL18R1 intron 17554300 rs7579737 chr2 102987361 A G 1.20E-05 Urinary metabolites IL18R1 intron 21572414 rs17027029 chr2 102990648 G C 0.0000997 Asthma IL18R1 intron 23666277 rs17027029 chr2 102990648 G C 5.17E-11 Self-reported allergy IL18R1 intron 23817569 rs3771164 chr2 102991786 A T 3.73E-11 Self-reported allergy IL18R1 intron 23817569 rs2270297 chr2 102992675 T C 1.45E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs7558013 chr2 102992806 G T 2.81E-09 Serum protein levels (sST2) IL18R1 intron 23999434 rs6753717 chr2 102993161 A C 1.49E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs6750020 chr2 102994714 G A 1.51E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs17027037 chr2 102994884 A G 1.18E-07 Self-reported allergy IL18R1 intron 23817569 rs17027037 chr2 102994884 A G 7.14E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs2080289 chr2 102995020 G A 1.17E-07 Self-reported allergy IL18R1 intron 23817569 rs2080289 chr2 102995020 G A 7.36E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs11683700 chr2 102996805 C T 9.63E-08 Self-reported allergy IL18R1 intron 23817569 rs11683700 chr2 102996805 C T 8.58E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs3213733 chr2 102997884 C A 6.26E-05 Prion diseases IL18R1 intron 22210626 rs3213733 chr2 102997884 C A 4.34E-10 Self-reported allergy IL18R1 intron 23817569 rs1035130 chr2 103001402 C T 1.26E-07 Self-reported allergy IL18R1 cds-synon 23817569 rs1035130 chr2 103001402 C T 1.15E-33 Serum protein levels (sST2) IL18R1 cds-synon 23999434 rs2241116 chr2 103003265 C A 2.38E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771161 chr2 103003961 C A 4.65E-10 Self-reported allergy IL18R1 intron 23817569 rs4851570 chr2 103006387 A G 1.27E-07 Self-reported allergy IL18R1 intron 23817569 rs4851570 chr2 103006387 A G 1.44E-33 Serum protein levels (sST2) IL18R1 intron 23999434 rs4851004 chr2 103009537 C T 1.41E-06 Asthma IL18R1 intron 20860503 rs3771158 chr2 103009894 A G 4.45E-10 Self-reported allergy IL18R1 intron 23817569 rs2287034 chr2 103010588 C A 7.75E-07 Self-reported allergy IL18R1 intron 23817569 rs2287034 chr2 103010588 C A 2.22E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs2287033 chr2 103011237 T C 1.24E-06 Asthma IL18R1 intron 20860503 rs4851005 chr2 103011552 C T 7.61E-07 Esophageal cancer (squamous cell) IL18R1 intron 22960999 rs4851005 chr2 103011552 C T 6.06E-07 Self-reported allergy IL18R1 intron 23817569 rs4851005 chr2 103011552 C T 2.30E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3732127 chr2 103013750 G C 4.62E-10 Self-reported allergy IL18R1 UTR-3 23817569 rs1135354 chr2 103014302 T G 1.80E-07 Self-reported allergy IL18R1 UTR-3 23817569 rs1135354 chr2 103014302 T G 1.93E-33 Serum protein levels (sST2) IL18R1 UTR-3 23999434 rs1420094 chr2 103015687 C T 1.18E-06 Asthma / / 20860503 rs17027087 chr2 103015918 C T 7.82E-07 Self-reported allergy / / 23817569 rs17027087 chr2 103015918 C T 8.44E-33 Serum protein levels (sST2) / / 23999434 rs3732123 chr2 103018077 C G 8.63E-04 Alzheimer's disease / / 17998437 rs3732123 chr2 103018077 C G 2.32E-07 Self-reported allergy / / 23817569 rs3732123 chr2 103018077 C G 4.92E-33 Serum protein levels (sST2) / / 23999434 rs12991737 chr2 103018128 T A 5.04E-08 Self-reported allergy / / 23817569 rs10202813 chr2 103019740 G T 7.48E-10 Self-reported allergy / / 23817569 rs1035127 chr2 103019919 A G 1.23E-04 Crohn's disease and Celiac disease / / 21298027 rs1035127 chr2 103019919 A G 5.65E-31 Serum protein levels (sST2) / / 23999434 rs10197310 chr2 103020030 T A 5.25E-10 Self-reported allergy / / 23817569 rs4851007 chr2 103024813 T G 2.11E-04 Crohn's disease and Celiac disease / / 21298027 rs4851007 chr2 103024813 T G 5.63E-31 Serum protein levels (sST2) / / 23999434 rs4851575 chr2 103025203 G A 5.15E-31 Serum protein levels (sST2) / / 23999434 rs10181785 chr2 103025274 C T 6.68E-10 Self-reported allergy / / 23817569 rs12712148 chr2 103025547 G A 7.47E-10 Self-reported allergy / / 23817569 rs11687768 chr2 103025738 A G 6.68E-10 Self-reported allergy / / 23817569 rs7586983 chr2 103028066 C T 6.20E-10 Self-reported allergy / / 23817569 rs11693955 chr2 103029165 A T 2.04E-07 Self-reported allergy / / 23817569 rs11693955 chr2 103029165 A T 4.38E-33 Serum protein levels (sST2) / / 23999434 rs1807782 chr2 103033147 C T 4.08E-31 Serum protein levels (sST2) / / 23999434 rs11465670 chr2 103034440 T C 3.37E-16 Serum protein levels (sST2) IL18RAP nearGene-5 23999434 rs1420106 chr2 103035044 A G 2.53E-04 Crohn's disease and Celiac disease IL18RAP nearGene-5 21298027 rs1420106 chr2 103035044 A G 4.04E-31 Serum protein levels (sST2) IL18RAP nearGene-5 23999434 rs7600961 chr2 103035455 G A 3.25E-16 Serum protein levels (sST2) IL18RAP intron 23999434 rs2293223 chr2 103035468 C T 6.67E-10 Self-reported allergy IL18RAP intron 23817569 rs2293225 chr2 103035889 C T 8.02E-24 Serum protein levels (sST2) IL18RAP intron 23999434 rs3771156 chr2 103036677 C T 3.08E-07 Self-reported allergy IL18RAP intron 23817569 rs3771156 chr2 103036677 C T 4.56E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755268 chr2 103038527 C G 4.04E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755267 chr2 103038587 T G 1.49E-04 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs3755267 chr2 103038587 T G 4.04E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3817465 chr2 103039584 A T 3.42E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2272127 chr2 103039873 C G 4.09E-10 Self-reported allergy IL18RAP intron 23817569 rs2272128 chr2 103039929 G A 3.00E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6759479 chr2 103040047 A C 4.80E-05 Allergic sensitization IL18RAP intron 23817571 rs6759588 chr2 103040159 A G 3.00E-17 Serum protein levels (sST2) IL18RAP intron 23999434 rs887972 chr2 103040945 G A 6.07E-08 Self-reported allergy IL18RAP intron 23817569 rs887972 chr2 103040945 G A 7.31E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs887971 chr2 103041167 T C 9.94E-08 Self-reported allergy IL18RAP intron 23817569 rs887971 chr2 103041167 T C 7.00E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755266 chr2 103042712 G A 8.71E-07 Asthma IL18RAP intron 20860503 rs11694658 chr2 103045020 A G 4.18E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2160232 chr2 103046880 G A 4.27E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6716784 chr2 103048467 T G 4.42E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2310300 chr2 103049074 A G 8.92E-07 Asthma IL18RAP intron 20860503 rs2041756 chr2 103049910 A G 5.24E-04 Multiple complex diseases IL18RAP intron 17554300 rs2041756 chr2 103049910 A G 3.25E-05 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs2041756 chr2 103049910 A G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10166330 chr2 103050390 C T 5.17E-10 Self-reported allergy IL18RAP intron 23817569 rs6543134 chr2 103050458 T G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2110735 chr2 103050925 A G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11681718 chr2 103051144 A G 1.34E-06 Self-reported allergy IL18RAP intron 23817569 rs11681718 chr2 103051144 A G 1.26E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs4851582 chr2 103051558 T C 5.37E-06 Self-reported allergy IL18RAP intron 23817569 rs4851582 chr2 103051558 T C 1.25E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs2110734 chr2 103052206 C T 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6746271 chr2 103052995 G C 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10176820 chr2 103054420 T C 4.40E-10 Self-reported allergy IL18RAP intron 23817569 rs2058660 chr2 103054449 G A 2.00E-12 Crohn's disease IL18RAP intron 21102463 rs2058660 chr2 103054449 G A 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465698 chr2 103054577 T C 6.65E-16 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465699 chr2 103054767 G A 2.00E-08 Serum protein levels (sST2) IL18RAP intron 23999434 rs2058658 chr2 103054803 T C 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027166 chr2 103055420 G A 7.25E-07 Self-reported allergy IL18RAP intron 23817569 rs17027166 chr2 103055420 G A 1.28E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs4851009 chr2 103055644 G A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10490204 chr2 103056534 A C 1.16E-06 Self-reported allergy IL18RAP intron 23817569 rs10490204 chr2 103056534 A C 1.28E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027173 chr2 103057043 G A 6.88E-09 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027179 chr2 103057159 C T 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs17027179 chr2 103057159 C T 1.29E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs2075186 chr2 103057251 G T 5.29E-10 Self-reported allergy IL18RAP intron 23817569 rs10490203 chr2 103059237 T G 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs10490203 chr2 103059237 T G 1.30E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs1558650 chr2 103060024 T A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs13401597 chr2 103060818 C G 3.92E-08 Triglycerides IL18RAP intron 23063622 rs3771150 chr2 103060851 G A 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs3771150 chr2 103060851 G A 1.31E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs11694360 chr2 103061147 G A 2.14E-06 Self-reported allergy IL18RAP intron 23817569 rs11694360 chr2 103061147 G A 1.40E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs11123928 chr2 103061286 G A 1.83E-06 Self-reported allergy IL18RAP intron 23817569 rs11123928 chr2 103061286 G A 1.40E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs7597017 chr2 103062116 A G 1.84E-06 Self-reported allergy IL18RAP intron 23817569 rs7597017 chr2 103062116 A G 1.41E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs6543135 chr2 103062406 C T 9.89E-09 Serum protein levels (sST2) IL18RAP intron 23999434 rs6734736 chr2 103062880 C T 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6708413 chr2 103063369 G A 6.22E-04 Multiple complex diseases IL18RAP intron 17554300 rs6708413 chr2 103063369 G A 1.45E-06 Crohn's disease IL18RAP intron 18587394 rs6708413 chr2 103063369 G A 2.05E-05 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs6708413 chr2 103063369 G A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465724 chr2 103063855 C T 1.47E-04 Type 2 diabetes IL18RAP intron 17463246 rs11465730 chr2 103066858 A G 5.13E-38 Serum protein levels (sST2) IL18RAP intron 23999434 rs7559479 chr2 103068787 G A 7.18E-04 Multiple complex diseases IL18RAP UTR-3 17554300 rs7559479 chr2 103068787 G A 3.03E-05 Crohn's disease and Celiac disease IL18RAP UTR-3 21298027 rs7559479 chr2 103068787 G A 3.42E-31 Serum protein levels (sST2) IL18RAP UTR-3 23999434 rs6741230 chr2 103069631 C T 7.55E-16 Serum protein levels (sST2) / / 23999434 rs917997 chr2 103070568 T C 6.80E-05 Celiac disease / / 17558408 rs917997 chr2 103070568 T C 1.11E-05 Crohn's disease / / 18587394 rs917997 chr2 103070568 T C 1.00E-15 Celiac disease / / 20190752 rs917997 chr2 103070568 T C 1.00E-15 Asthma / / 21150878 rs917997 chr2 103070568 T C 2.17E-05 Crohn's disease and Celiac disease / / 21298027 rs917997 chr2 103070568 T C 1.11E-15 Celiac disease and Rheumatoid arthritis / / 21383967 rs917997 chr2 103070568 T C 1.11E-15 Multiple sclerosis / / 22190364 rs917997 chr2 103070568 T C 3.00E-20 Inflammatory bowel disease / / 23128233 rs917997 chr2 103070568 T C 3.36E-31 Serum protein levels (sST2) / / 23999434 rs4070554 chr2 103074493 A G 3.16E-31 Serum protein levels (sST2) / / 23999434 rs6761825 chr2 103075561 T C 3.11E-31 Serum protein levels (sST2) / / 23999434 rs6705001 chr2 103076210 A G 3.08E-31 Serum protein levels (sST2) / / 23999434 rs6543141 chr2 103076351 G A 3.06E-31 Serum protein levels (sST2) / / 23999434 rs11690532 chr2 103076426 C T 9.03E-23 Serum protein levels (sST2) / / 23999434 rs6705385 chr2 103076569 A C 6.48E-38 Serum protein levels (sST2) / / 23999434 rs6705498 chr2 103076670 A G 6.52E-38 Serum protein levels (sST2) / / 23999434 rs6719196 chr2 103076888 G T 6.59E-38 Serum protein levels (sST2) / / 23999434 rs4851589 chr2 103077145 A G 6.18E-04 Multiple complex diseases / / 17554300 rs4241210 chr2 103078740 G A 2.97E-31 Serum protein levels (sST2) / / 23999434 rs6720564 chr2 103079297 T C 2.95E-31 Serum protein levels (sST2) / / 23999434 rs17027230 chr2 103079330 C T 1.70E-06 Self-reported allergy / / 23817569 rs17027230 chr2 103079330 C T 2.85E-33 Serum protein levels (sST2) / / 23999434 rs10210176 chr2 103079516 C A 5.85E-10 Self-reported allergy / / 23817569 rs6717915 chr2 103079619 A C 2.92E-31 Serum protein levels (sST2) / / 23999434 rs6718157 chr2 103079814 A T 2.92E-31 Serum protein levels (sST2) / / 23999434 rs917996 chr2 103082273 C A 2.91E-31 Serum protein levels (sST2) / / 23999434 rs741284 chr2 103083324 G C 4.47E-10 Self-reported allergy / / 23817569 rs12463588 chr2 103085257 C G 3.21E-37 Serum protein levels (sST2) / / 23999434 rs2310302 chr2 103086049 G C 3.62E-37 Serum protein levels (sST2) / / 23999434 rs12469887 chr2 103086758 T C 4.08E-37 Serum protein levels (sST2) / / 23999434 rs990171 chr2 103086770 A C 1.20E-16 Celiac disease / / 22057235 rs990171 chr2 103086770 A C 5.02E-31 Serum protein levels (sST2) / / 23999434 rs10172116 chr2 103087573 C T 5.48E-10 Self-reported allergy / / 23817569 rs4140786 chr2 103088176 G T 5.70E-37 Serum protein levels (sST2) / / 23999434 rs1403552 chr2 103088777 C T 5.62E-10 Self-reported allergy / / 23817569 rs10201184 chr2 103089078 G C 7.08E-37 Serum protein levels (sST2) / / 23999434 rs4851011 chr2 103089678 C T 7.24E-04 Lymphocyte counts / / 22286170 rs4851011 chr2 103089678 C T 2.45E-06 Self-reported allergy / / 23817569 rs4851011 chr2 103089678 C T 1.23E-32 Serum protein levels (sST2) / / 23999434 rs17027255 chr2 103090127 C T 2.54E-06 Self-reported allergy SLC9A4 UTR-5 23817569 rs17027255 chr2 103090127 C T 1.24E-32 Serum protein levels (sST2) SLC9A4 UTR-5 23999434 rs17027258 chr2 103091540 A G 7.00E-06 White blood cell types SLC9A4 intron 21738478 rs17027258 chr2 103091540 A G 2.63E-06 Self-reported allergy SLC9A4 intron 23817569 rs17027258 chr2 103091540 A G 1.31E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13030642 chr2 103091585 C A 7.34E-10 Self-reported allergy SLC9A4 intron 23817569 rs1468791 chr2 103092021 A G 3.11E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13018263 chr2 103092270 T C 6.33E-05 Prion diseases SLC9A4 intron 22210626 rs13018263 chr2 103092270 T C 5.84E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468790 chr2 103092441 G C 7.43E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468790 chr2 103092441 G C 6.78E-13 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1468788 chr2 103092513 C T 7.48E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468788 chr2 103092513 C T 6.80E-13 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7597819 chr2 103092906 A G 3.51E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6737668 chr2 103093081 C T 3.56E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10469840 chr2 103093243 T C 2.34E-29 Serum protein levels (sST2) SLC9A4 intron 23999434 rs759382 chr2 103094213 G T 8.84E-04 Multiple complex diseases SLC9A4 intron 17554300 rs759382 chr2 103094213 G T 2.03E-04 Crohn's disease and Celiac disease SLC9A4 intron 21298027 rs759382 chr2 103094213 G T 5.35E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs759381 chr2 103094323 A T 4.62E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11692304 chr2 103095404 G A 2.20E-12 Serum protein levels (sST2) SLC9A4 cds-synon 23999434 rs6543146 chr2 103096695 T G 8.53E-18 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1030026 chr2 103098178 A C 1.27E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523198 chr2 103098474 C T 2.17E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6751666 chr2 103098571 A G 8.54E-04 Type 2 diabetes SLC9A4 intron 17463246 rs2140316 chr2 103098676 T A 1.94E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs17027293 chr2 103098840 A G 8.76E-04 Type 2 diabetes SLC9A4 intron 17463246 rs17027295 chr2 103098871 G A 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs6543148 chr2 103100219 A G 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs7566613 chr2 103100495 G A 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs10175045 chr2 103103232 T C 2.16E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10207579 chr2 103103289 C T 6.87E-11 Serum protein levels (sST2) SLC9A4 intron 23999434 rs41348650 chr2 103104199 G A 6.72E-04 Type 2 diabetes SLC9A4 intron 17463246 rs7567885 chr2 103108852 T G 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403548 chr2 103110375 C T 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712153 chr2 103111761 C T 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11687071 chr2 103111920 G A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7566063 chr2 103112565 C A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7591872 chr2 103112641 G C 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7591878 chr2 103112658 G A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12987295 chr2 103115838 G A 1.82E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs17772203 chr2 103115860 C G 3.77E-04 Type 2 diabetes SLC9A4 intron 17463246 rs4851012 chr2 103115915 C T 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851600 chr2 103116223 C G 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851014 chr2 103116276 C T 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851602 chr2 103116305 G A 8.97E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12995030 chr2 103116466 C G 1.81E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6728288 chr2 103117268 A T 1.80E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075193 chr2 103118027 G A 1.78E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075192 chr2 103118228 A G 1.77E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075191 chr2 103118299 G T 1.77E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075190 chr2 103118559 A T 1.76E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851604 chr2 103118881 G A 9.85E-11 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11690932 chr2 103119029 G A 1.73E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075187 chr2 103120311 G A 1.62E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851016 chr2 103120400 C T 1.60E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851017 chr2 103120769 C A 1.55E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851605 chr2 103120868 A G 1.11E-10 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851606 chr2 103120889 G A 1.10E-10 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7605606 chr2 103121536 G A 1.08E-15 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13019784 chr2 103123301 A G 9.84E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs9989842 chr2 103123633 C G 1.11E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs9989749 chr2 103123642 G A 9.57E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6708949 chr2 103123965 G C 9.36E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6724109 chr2 103125018 C G 4.05E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6751949 chr2 103125138 G A 4.08E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6724322 chr2 103125182 C T 4.13E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851607 chr2 103125632 C T 4.16E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10195948 chr2 103125736 T C 4.19E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851608 chr2 103125984 C T 1.79E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712155 chr2 103127963 A T 1.71E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851609 chr2 103128866 T C 1.72E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11676371 chr2 103129692 G C 1.75E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1476999 chr2 103131679 G A 1.86E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2192758 chr2 103132269 C G 1.81E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2192757 chr2 103132378 C T 1.84E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2216000 chr2 103132640 G C 1.90E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6714379 chr2 103133310 A G 1.73E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851610 chr2 103134652 C G,T 4.23E-12 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523204 chr2 103135637 G A 1.94E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523203 chr2 103135759 A G 1.99E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851611 chr2 103135938 A T 2.02E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403550 chr2 103136309 T C 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403551 chr2 103136446 T G 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2058656 chr2 103137026 T G 1.80E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851612 chr2 103137880 C G 1.80E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851613 chr2 103137990 T C 2.12E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6750851 chr2 103138761 A G 2.14E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6750971 chr2 103138825 A G 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10193407 chr2 103139298 C T 1.73E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11123935 chr2 103139751 A G 1.64E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851614 chr2 103140398 C T 2.49E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1357471 chr2 103140472 C T 2.02E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2015478 chr2 103141447 A G 1.35E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1024798 chr2 103141651 G C 1.14E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4241211 chr2 103143159 T G 9.24E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712156 chr2 103144020 A C 5.42E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs3849364 chr2 103144242 T C 4.85E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs3849365 chr2 103144391 G A 2.61E-34 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1005042 chr2 103145359 A G 2.88E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1005043 chr2 103145426 A G 2.62E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851018 chr2 103146615 C T 2.62E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851615 chr2 103146999 G T 8.39E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs741285 chr2 103148169 C T 2.61E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1014286 chr2 103149100 G A 3.00E-33 Serum protein levels (sST2) SLC9A4 missense 23999434 rs2008159 chr2 103149162 A G 2.61E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs2008157 chr2 103149182 A G 2.61E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs1829849 chr2 103149698 A C 2.89E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs6737119 chr2 103151109 G A 3.05E-33 Serum protein levels (sST2) / / 23999434 rs6709284 chr2 103151164 C G 3.22E-33 Serum protein levels (sST2) / / 23999434 rs6724213 chr2 103151219 A C 6.41E-22 Serum protein levels (sST2) / / 23999434 rs2177317 chr2 103151319 A G 3.73E-33 Serum protein levels (sST2) / / 23999434 rs2871474 chr2 103151441 G A 5.95E-21 Serum protein levels (sST2) / / 23999434 rs4851616 chr2 103151862 C T 6.30E-22 Serum protein levels (sST2) / / 23999434 rs4851617 chr2 103152060 C T 6.62E-33 Serum protein levels (sST2) / / 23999434 rs10172553 chr2 103152975 C T 1.54E-21 Serum protein levels (sST2) / / 23999434 rs4292112 chr2 103153780 G A 1.24E-32 Serum protein levels (sST2) / / 23999434 rs6761291 chr2 103155069 C T 1.75E-21 Serum protein levels (sST2) / / 23999434 rs11685483 chr2 103159093 A C 3.18E-21 Serum protein levels (sST2) / / 23999434 rs6739426 chr2 103160443 A G 4.64E-21 Serum protein levels (sST2) / / 23999434 rs10490202 chr2 103160832 C G,T 5.15E-32 Serum protein levels (sST2) / / 23999434 rs11899041 chr2 103161053 T A 7.64E-21 Serum protein levels (sST2) / / 23999434 rs12712157 chr2 103165129 T C 5.59E-20 Serum protein levels (sST2) / / 23999434 rs10194822 chr2 103165504 T G 3.05E-21 Serum protein levels (sST2) / / 23999434 rs1303960 chr2 103165832 G A 5.17E-20 Serum protein levels (sST2) / / 23999434 rs2215998 chr2 103166043 A G 2.95E-21 Serum protein levels (sST2) / / 23999434 rs7581853 chr2 103167724 C T 6.23E-31 Serum protein levels (sST2) / / 23999434 rs10193009 chr2 103168977 C T 6.23E-31 Serum protein levels (sST2) / / 23999434 rs11123937 chr2 103169682 G A 6.52E-31 Serum protein levels (sST2) / / 23999434 rs12712159 chr2 103169982 G A 7.02E-31 Serum protein levels (sST2) / / 23999434 rs10196579 chr2 103170181 C T 3.48E-21 Serum protein levels (sST2) / / 23999434 rs997056 chr2 103170919 A G 8.39E-31 Serum protein levels (sST2) / / 23999434 rs2310295 chr2 103171066 G A 4.21E-21 Serum protein levels (sST2) / / 23999434 rs2110737 chr2 103172263 T A 1.09E-30 Serum protein levels (sST2) / / 23999434 rs2005881 chr2 103173059 G A 1.05E-19 Serum protein levels (sST2) / / 23999434 rs10210658 chr2 103175749 T G 1.86E-30 Serum protein levels (sST2) / / 23999434 rs4851619 chr2 103176411 C T 1.67E-19 Serum protein levels (sST2) / / 23999434 rs6761871 chr2 103176797 A C 1.51E-19 Serum protein levels (sST2) / / 23999434 rs6711140 chr2 103177295 T C 9.80E-12 Multiple complex diseases / / 17554300 rs10202404 chr2 103177414 C T 7.61E-21 Serum protein levels (sST2) / / 23999434 rs4851019 chr2 103177565 T A 7.61E-21 Serum protein levels (sST2) / / 23999434 rs12469973 chr2 103182273 A G 2.80E-05 Urinary metabolites / / 21572414 rs9308860 chr2 103207959 C G 3.50E-04 Self-reported allergy / / 23817569 rs6725806 chr2 103216172 T A,G 3.21E-08 Serum protein levels (sST2) / / 23999434 rs2192665 chr2 103216578 G C 2.99E-04 Type 2 diabetes / / 17463246 rs17774619 chr2 103216776 C T 1.09E-04 Type 2 diabetes / / 17463246 rs873625 chr2 103219213 A G 7.30E-04 Type 2 diabetes / / 17463246 rs3806581 chr2 103235312 T C 4.27E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1016160 chr2 103245025 A G 4.68E-14 Serum protein levels (sST2) SLC9A2 intron 23999434 rs2192669 chr2 103251554 T C 1.91E-22 Serum protein levels (sST2) SLC9A2 intron 23999434 rs17775170 chr2 103251927 G A 3.50E-12 Serum protein levels (sST2) SLC9A2 intron 23999434 rs17775237 chr2 103253943 G T 2.83E-04 Type 2 diabetes SLC9A2 intron 17463246 rs17775404 chr2 103257932 G A 2.04E-04 Type 2 diabetes SLC9A2 intron 17463246 rs4851622 chr2 103260445 T G 8.79E-04 Multiple complex diseases SLC9A2 intron 17554300 rs4140834 chr2 103268442 T C 6.33E-04 White matter integrity SLC9A2 intron 22425255 rs10178585 chr2 103272957 G A 6.60E-06 Personality dimensions SLC9A2 intron 21173776 rs13400836 chr2 103287261 A C 7.97E-04 Tourette syndrome SLC9A2 intron 22889924 rs6726894 chr2 103296936 C G 1.01E-04 Alcohol dependence SLC9A2 intron 21314694 rs33993717 chr2 103335441 A G 5.00E-06 Response to amphetamines MFSD9 missense 22952603 rs2732824 chr2 103347857 A G 2.20E-05 Temperament (bipolar disorder) MFSD9 intron 22365631 rs2540317 chr2 103349807 A G 3.40E-04 Type 2 diabetes MFSD9 intron 17846126 rs2540317 chr2 103349807 A G 7.40E-05 Temperament (bipolar disorder) MFSD9 intron 22365631 rs2540316 chr2 103350040 C T 1.00E-04 Temperament (bipolar disorder) MFSD9 intron 22365631 rs955916 chr2 103351779 A G 1.30E-04 Attention deficit hyperactivity disorder MFSD9 intron pha002875 rs12465996 chr2 103388594 C T 5.00E-06 IgG glycosylation TMEM182 intron 23382691 rs12052617 chr2 103478635 G A 2.92E-05 Alcohol and nictotine co-dependence / / 20158304 rs1024787 chr2 103487128 C T 1.18E-04 Glycosylated haemoglobin levels / / 17255346 rs10188760 chr2 103511907 G C 5.58E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs13402330 chr2 103512292 T A 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11691730 chr2 103561126 G A 4.65E-05 Alcohol and nictotine co-dependence / / 20158304 rs17206765 chr2 103565013 C T 1.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2310351 chr2 103572929 T G 4.10E-05 Major depressive disorder / / 21042317 rs1878530 chr2 103573730 G A 5.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12105421 chr2 103576088 C T 5.00E-07 Psychosis (atypical) / / 24132900 rs10496361 chr2 103583057 T C 2.64E-04 Cognition,early reading ability / / 17684495 rs10496361 chr2 103583057 T C 3.02E-05 Tunica Media / / pha003036 rs17812637 chr2 103585664 G A 1.60E-06 Urinary metabolites / / 21572414 rs7587833 chr2 103617979 G T 7.44E-04 Premature ovarian failure / / 19508998 rs9308861 chr2 103619483 T C 8.66E-04 Premature ovarian failure / / 19508998 rs10187137 chr2 103674434 C G 7.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1528063 chr2 103675293 T C 8.24E-04 Multiple complex diseases / / 17554300 rs817742 chr2 103728170 A G 1.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3915280 chr2 103757033 A G 8.36E-04 Body mass index / / 21701565 rs17028262 chr2 103760153 T C 3.33E-04 Multiple complex diseases / / 17554300 rs1528066 chr2 103762222 A G 7.98E-04 Multiple complex diseases / / 17554300 rs6735786 chr2 103770238 C T 2.00E-06 Bone mineral density (hip) / / 19079262 rs4319952 chr2 103773825 C T 5.07E-05 Blood Pressure / / pha003048 rs10496366 chr2 103787192 A T 2.69E-04 Multiple complex diseases / / 17554300 rs10469858 chr2 103979257 A G 2.85E-06 Orofacial clefts / / 22419666 rs1901480 chr2 104253005 G A 2.60E-05 Urinary metabolites / / 21572414 rs264943 chr2 104298541 C A 7.00E-06 HIV-1 viral setpoint / / 22174851 rs17343583 chr2 104302099 A G 5.56E-04 Schizophrenia / / 19197363 rs17029130 chr2 104420998 T C 3.58E-04 Alzheimer's disease / / 22005930 rs17029138 chr2 104422253 G A 1.95E-04 Alzheimer's disease / / 22005930 rs938872 chr2 104427959 G A 8.40E-04 Alzheimer's disease / / 22005930 rs11675380 chr2 104429265 A G 3.46E-04 Alzheimer's disease / / 22005930 rs11691973 chr2 104429441 C T 3.48E-04 Alzheimer's disease / / 22005930 rs11889814 chr2 104432494 A C 2.03E-04 Alzheimer's disease / / 22005930 rs17029167 chr2 104433462 G A 2.00E-04 Alzheimer's disease / / 22005930 rs17029176 chr2 104434484 T C 8.59E-04 Alzheimer's disease / / 22005930 rs2067640 chr2 104436997 C T 1.80E-04 Alzheimer's disease / / 22005930 rs17029187 chr2 104437560 G A 1.73E-04 Alzheimer's disease / / 22005930 rs17029204 chr2 104441663 A T 1.86E-04 Alzheimer's disease / / 22005930 rs17029208 chr2 104441685 C T 1.71E-04 Alzheimer's disease / / 22005930 rs11686245 chr2 104443126 G A 1.85E-04 Alzheimer's disease / / 22005930 rs2678665 chr2 104443637 A G 8.78E-04 Alzheimer's disease / / 22005930 rs2570494 chr2 104445272 T G 8.78E-04 Alzheimer's disease / / 22005930 rs11694523 chr2 104446668 C T 1.54E-04 Alzheimer's disease / / 22005930 rs2610700 chr2 104447239 C T 8.80E-04 Alzheimer's disease / / 22005930 rs2610696 chr2 104449526 C T 9.09E-04 Alzheimer's disease / / 22005930 rs1837714 chr2 104450445 C A,G 8.89E-04 Alzheimer's disease / / 22005930 rs1441100 chr2 104450471 A G 8.89E-04 Alzheimer's disease / / 22005930 rs2570491 chr2 104450970 G A 8.94E-04 Alzheimer's disease / / 22005930 rs1550536 chr2 104451134 C G 6.94E-04 Alzheimer's disease / / 22005930 rs2570490 chr2 104451549 T C 8.92E-04 Alzheimer's disease / / 22005930 rs2570489 chr2 104451881 A G 9.83E-04 Alzheimer's disease / / 22005930 rs7559425 chr2 104463080 T C 5.17E-04 Alzheimer's disease / / 22005930 rs2007689 chr2 104472913 A T 2.66E-04 Alzheimer's disease / / 22005930 rs17029303 chr2 104475374 C T 5.04E-04 Alzheimer's disease / / 22005930 rs12616008 chr2 104554763 A G 8.22E-05 Erythrocyte counts / / pha003099 rs2119507 chr2 104573005 C T 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs2570483 chr2 104575444 A G 4.03E-04 Iron levels / / pha002876 rs1036736 chr2 104578533 T C 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs2582974 chr2 104578923 T C 6.00E-05 Multiple myeloma / / 23955597 rs12613775 chr2 104580503 C T 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs10193430 chr2 104587351 T A 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs11903187 chr2 104589138 G A 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs6758152 chr2 104667738 T G 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs7567271 chr2 104671174 T A 4.65E-04 Multiple complex diseases / / 17554300 rs2889276 chr2 104714131 C T 7.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2889277 chr2 104714865 G A 3.57E-05 Type 2 diabetes / / 17846125 rs9308872 chr2 104734791 C T 1.32E-06 Myocardial Infarction / / pha002873 rs10189155 chr2 104736252 C G 5.03E-06 Suicide attempts in bipolar disorder / / 21423239 rs13404302 chr2 104742560 G A 5.29E-06 Suicide attempts in bipolar disorder / / 21423239 rs10188554 chr2 104743617 G A 7.91E-07 Myocardial Infarction / / pha002873 rs2376062 chr2 104751980 C T 6.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs7369597 chr2 104758840 C T 6.69E-06 Myocardial Infarction / / pha002873 rs4402785 chr2 104766351 C T 1.95E-05 Myocardial Infarction / / pha002873 rs12712184 chr2 104781580 T C 7.00E-05 Glioma (high-grade) / / 19578366 rs4851671 chr2 104798368 A G 5.08E-04 Multiple complex diseases / / 17554300 rs11890236 chr2 104808712 T C 9.00E-06 Obesity-related traits / / 23251661 rs12712185 chr2 104827991 A T 4.82E-05 Major depressive disorder (broad) / / 20038947 rs4450624 chr2 104846492 T C 5.44E-04 Parkinson's disease / / 16252231 rs4851675 chr2 104856148 C A 6.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10176377 chr2 104970824 C T 2.26E-04 Multiple complex diseases / / 17554300 rs17029726 chr2 104972046 T A 1.54E-04 Multiple complex diseases / / 17554300 rs12469405 chr2 104972131 C G 3.35E-04 Multiple complex diseases / / 17554300 rs17029753 chr2 104981980 A G 8.10E-05 Multiple complex diseases / / 17554300 rs17029754 chr2 104982118 G A 1.29E-05 Multiple complex diseases / / 17554300 rs7570682 chr2 104983267 G A 3.11E-06 Multiple complex diseases / / 17554300 rs7570682 chr2 104983267 G A 3.00E-06 Bipolar disorder / / 21254220 rs6732355 chr2 104984277 C A 4.00E-05 Multiple complex diseases / / 17554300 rs12620263 chr2 105008715 A G 3.93E-05 Multiple complex diseases LOC100287010 intron 17554300 rs13423425 chr2 105009335 T G 3.64E-05 Multiple complex diseases LOC100287010 intron 17554300 rs908916 chr2 105012664 C T 4.61E-05 Multiple complex diseases LOC100287010 intron 17554300 rs7425226 chr2 105019418 C A 6.00E-04 Acute lymphoblastic leukemia (childhood) LOC100287010 intron 20189245 rs12622294 chr2 105019902 C G 4.00E-04 Acute lymphoblastic leukemia (childhood) LOC100287010 intron 20189245 rs13396253 chr2 105027124 A G 9.62E-05 Endometrial cancer LOC100287010 intron 24096698 rs1033302 chr2 105093698 G A 3.16E-05 Elbow pain LOC150568 intron pha003008 rs9646956 chr2 105101407 C T 5.99E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12616824 chr2 105103068 C T 6.83E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10184670 chr2 105103344 C T 1.21E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6743147 chr2 105105033 G T 2.25E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6743263 chr2 105105148 G A 2.29E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs11889267 chr2 105106375 C T 6.36E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs11123992 chr2 105106747 G A 1.91E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10203249 chr2 105107335 G A 1.43E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10187071 chr2 105109288 C T 8.31E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6753471 chr2 105110002 T C 7.76E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10166195 chr2 105110550 G A 1.29E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12620665 chr2 105114879 A G 1.84E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs1439671 chr2 105116184 T C 7.65E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs7564645 chr2 105117317 G A 5.20E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs1439670 chr2 105118594 C T 4.02E-04 Multiple complex diseases LOC150568 intron 17554300 rs734849 chr2 105120553 G A 8.97E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12104638 chr2 105129022 C T 2.74E-04 Multiple complex diseases / / 17554300 rs1866555 chr2 105141788 C T 7.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6738747 chr2 105144490 G A 6.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17029922 chr2 105147650 G A 1.20E-06 Urinary metabolites / / 21572414 rs17624303 chr2 105148418 C T 9.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946878 chr2 105153455 G A 2.10E-05 Urinary metabolites / / 21572414 rs13429262 chr2 105154379 G A 2.10E-05 Urinary metabolites / / 21572414 rs13429262 chr2 105154379 G A 9.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13405030 chr2 105154863 C T 7.25E-04 Alzheimer's disease / / 22005930 rs7608295 chr2 105158182 A T 8.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17624523 chr2 105158638 A G 8.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs17029932 chr2 105158776 G A 9.91E-05 Alcohol dependence / / 21703634 rs17670403 chr2 105160828 C T 4.30E-06 Urinary metabolites / / 21572414 rs17670403 chr2 105160828 C T 2.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1530129 chr2 105163835 C T 2.87E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1530128 chr2 105164449 A G 2.78E-04 Coronary heart disease / / 21606135 rs2083350 chr2 105165756 C A 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs714753 chr2 105167888 G A 2.20E-05 Urinary metabolites / / 21572414 rs714753 chr2 105167888 G A 3.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6733728 chr2 105170353 T C 3.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1530126 chr2 105172500 G C 1.60E-05 Urinary metabolites / / 21572414 rs1561513 chr2 105173128 C A 2.10E-05 Urinary metabolites / / 21572414 rs1561513 chr2 105173128 C A 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1439675 chr2 105175815 A G 5.17E-04 Multiple complex diseases / / 17554300 rs1439675 chr2 105175815 A G 1.10E-05 Urinary metabolites / / 21572414 rs7586619 chr2 105176835 T A 1.40E-05 Urinary metabolites / / 21572414 rs7586619 chr2 105176835 T A 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17029958 chr2 105177640 C T 5.71E-04 Multiple complex diseases / / 17554300 rs13005764 chr2 105184355 A G 2.15E-04 Coronary heart disease / / 21606135 rs6716044 chr2 105188004 G T 4.79E-05 Type 2 diabetes and other traits / / 19734900 rs13422332 chr2 105189283 C T 1.20E-05 Urinary metabolites / / 21572414 rs13422332 chr2 105189283 C T 0.000399 Salmonella-induced pyroptosis / / 22837397 rs7598356 chr2 105189350 C A 0.000669 Salmonella-induced pyroptosis / / 22837397 rs10496386 chr2 105190420 G A 6.51E-04 Multiple complex diseases / / 17554300 rs1517862 chr2 105300588 G A 2.95E-04 Gallstones / / 17632509 rs6543265 chr2 105306305 T C 2.74E-04 Type 2 diabetes / / 17463246 rs1517860 chr2 105324489 G T 2.84E-04 Type 2 diabetes / / 17463246 rs6732043 chr2 105341106 A C 3.49E-04 Type 2 diabetes / / 22158537 rs6735165 chr2 105341214 T C 3.52E-04 Type 2 diabetes / / 22158537 rs4851712 chr2 105354926 C A 8.85E-05 Post-operative nausea and vomiting / / 21694509 rs3811547 chr2 105363267 T C 4.22E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6543267 chr2 105365247 T C 2.52E-04 Multiple complex diseases LOC284998 intron 17554300 rs6758786 chr2 105367587 C T 6.58E-04 Suicide attempts in bipolar disorder LOC284998 intron 21423239 rs12615966 chr2 105378957 C T 7.00E-06 Pancreatic cancer / / 20686608 rs1349512 chr2 105435369 T C 6.13E-04 Amyotrophic Lateral Sclerosis LOC100506421 intron 17362836 rs6714493 chr2 105436880 T G 6.13E-04 Amyotrophic Lateral Sclerosis LOC100506421 intron 17362836 rs3739154 chr2 105455303 T C 9.99E-04 Tourette syndrome LOC100506421 intron 22889924 rs6725560 chr2 105475330 A G 0.00000094 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) / / 22383894 rs2060783 chr2 105490397 A C 7.22E-04 Alzheimer's disease / / 24755620 rs7579394 chr2 105500046 T G 2.55E-04 Alzheimer's disease / / 24755620 rs1026220 chr2 105504322 A G 7.94E-04 Alzheimer's disease / / 24755620 rs715197 chr2 105512925 C T 2.50E-05 Urinary metabolites / / 21572414 rs6714749 chr2 105521412 T G 9.38E-05 Serum metabolites / / 19043545 rs1005999 chr2 105523791 C T 1.98E-07 Primary biliary cirrhosis / / 23000144 rs1005999 chr2 105523791 C T 0.000000198 Facial morphology / / 23028347 rs12611661 chr2 105589679 T C 3.33E-05 Hypertension / / 21082022 rs4266037 chr2 105730749 A G 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4567954 chr2 105730986 T G 8.93E-05 Multiple complex diseases / / 17554300 rs4567954 chr2 105730986 T G 7.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6760606 chr2 105735837 A G 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3923277 chr2 105737154 A G 9.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7567068 chr2 105742131 C T 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4378828 chr2 105745533 C T 5.50E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12616980 chr2 105746795 T C 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10191425 chr2 105754747 A C 2.73E-04 Depression (quantitative trait) / / 20800221 rs7597760 chr2 105766388 C T 9.71E-04 Multiple complex diseases / / 17554300 rs4605389 chr2 105771650 T C 3.31E-04 Depression (quantitative trait) / / 20800221 rs7583476 chr2 105778288 A T 3.16E-04 Depression (quantitative trait) / / 20800221 rs7569958 chr2 105778430 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs13411784 chr2 105779411 A C 3.62E-04 Depression (quantitative trait) / / 20800221 rs1437400 chr2 105787410 G A 3.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2679882 chr2 105791078 T C 1.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13388299 chr2 105791914 T C 5.86E-04 Depression (quantitative trait) / / 20800221 rs2679870 chr2 105792850 G A 8.34E-05 Basophils / / pha003087 rs6710490 chr2 105797265 A G 2.77E-04 Multiple complex diseases / / 17554300 rs6710490 chr2 105797265 A G 2.65E-04 Smoking cessation / / 24665060 rs2679851 chr2 105798292 A G 4.84E-04 Alzheimer's disease (late onset) / / 21379329 rs7584136 chr2 105833093 A C 7.13E-05 Pancreatic cancer / / pha002889 rs6712932 chr2 105837598 T C 6.00E-06 Type 2 diabetes / / 17668382 rs6712932 chr2 105837598 T C 6.00E-06 Coronary heart disease / / 21347282 rs17636747 chr2 105877870 C T 4.00E-06 Preeclampsia / / 23551011 rs2460255 chr2 105882061 G A 1.67E-08 Lymphocyte counts / / 22286170 rs3816133 chr2 105890632 T C 1.63E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs1020064 chr2 105897740 T G 7.00E-06 AIDS TGFBRAP1 intron 19754311 rs2576742 chr2 105898822 T A 3.19E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2576742 chr2 105898822 T A 3.77E-04 Insulin resistance TGFBRAP1 intron 21901158 rs3792044 chr2 105899702 A C 8.35E-04 Body mass index TGFBRAP1 intron 21701565 rs3792048 chr2 105901673 C T 2.13E-07 Multiple complex diseases TGFBRAP1 intron 17554300 rs920217 chr2 105904662 T C 4.44E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2679895 chr2 105906480 C G 3.79E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2679895 chr2 105906480 C G 7.05E-04 Insulin resistance TGFBRAP1 intron 21901158 rs1030877 chr2 105910513 G A 6.00E-06 Obesity-related traits TGFBRAP1 intron 23251661 rs2576748 chr2 105911258 C A 6.75E-05 Insulin resistance TGFBRAP1 intron 21901158 rs2679892 chr2 105918066 G A 1.68E-04 Body mass index TGFBRAP1 intron 21701565 rs2679892 chr2 105918066 G A 3.54E-04 Body mass index TGFBRAP1 intron 21701565 rs17689220 chr2 105918129 T C 2.84E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs893249 chr2 105925311 T C 1.90E-04 Alzheimer's disease TGFBRAP1 intron 17998437 rs6727677 chr2 105935166 A G 1.56E-04 Body mass index TGFBRAP1 intron 21701565 rs6727677 chr2 105935166 A G 4.17E-05 Body mass index TGFBRAP1 intron 21701565 rs2679874 chr2 105939430 C T 1.12E-04 Body mass index TGFBRAP1 intron 21701565 rs2679874 chr2 105939430 C T 4.38E-04 Body mass index TGFBRAP1 intron 21701565 rs2033727 chr2 105953909 G C 6.09E-04 Multiple complex diseases / / 17554300 rs2033727 chr2 105953909 G C 1.30E-05 Urinary metabolites / / 21572414 rs10190186 chr2 105997385 A G 3.44E-04 Multiple complex diseases FHL2 intron 17554300 rs4374396 chr2 106024451 A G 2.50E-05 Urinary metabolites FHL2 intron 21572414 rs10203748 chr2 106076110 T C 1.17E-05 Celiac disease / / 23936387 rs13425033 chr2 106076625 T G 1.43E-103 Multiple complex diseases / / 17554300 rs7604966 chr2 106077691 T C 4.33E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13385109 chr2 106080007 A T 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6711988 chr2 106080746 T C 3.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs9989768 chr2 106081221 T C 3.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6725019 chr2 106086944 G A 4.21E-05 Alzheimer's disease / / 17998437 rs17030964 chr2 106094387 C A 6.36E-04 Alzheimer's disease / / 17998437 rs1518614 chr2 106103606 A C 2.50E-05 Urinary metabolites / / 21572414 rs11897323 chr2 106104410 A G 4.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17030992 chr2 106119090 A G 9.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17030997 chr2 106119878 A T 2.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs112811927 chr2 106126543 C CTAGTTCTCTCT 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17031034 chr2 106126543 C G,T 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs71823776 chr2 106126543 C CTAGTTCTCTCT 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs939008 chr2 106133488 G A 7.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10203692 chr2 106155992 C T 3.23E-04 Multiple complex diseases / / 17554300 rs2122961 chr2 106157527 C A 9.55E-04 Multiple complex diseases / / 17554300 rs2889452 chr2 106158126 C G 4.91E-04 Multiple complex diseases / / 17554300 rs6726692 chr2 106160606 A G 1.12E-04 Asthma / / 23181788 rs6742097 chr2 106166317 G A 7.84E-05 Blood Pressure / / pha003050 rs17031236 chr2 106172001 T G 3.10E-04 Type 2 diabetes / / 21874001 rs10496397 chr2 106184438 C T 6.17E-04 Parkinson's disease / / 17052657 rs7601184 chr2 106216861 C A 3.81E-05 Hypertension LOC285000 intron pha003042 rs12474808 chr2 106237751 G A 7.20E-05 Lung adenocarcinoma / / 22797724 rs7597575 chr2 106238347 G A 3.53E-04 Multiple complex diseases / / 17554300 rs6543324 chr2 106244673 G A 9.07E-04 Alzheimer's disease / / 17998437 rs4851821 chr2 106260780 C T 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851823 chr2 106261304 T C 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851080 chr2 106262152 C G 8.70E-04 Multiple complex diseases / / 17554300 rs4851080 chr2 106262152 C G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7572653 chr2 106263078 C T 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164674 chr2 106264353 C G 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs369074322 chr2 106264353 CG C 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10180552 chr2 106265647 A T 4.19E-05 Multiple complex diseases / / 17554300 rs10180552 chr2 106265647 A T 1.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851824 chr2 106266677 A G 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851825 chr2 106266695 T C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851826 chr2 106267064 A G 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7581613 chr2 106267227 A G 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs12477950 chr2 106273727 A T 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7563743 chr2 106287156 A C 1.52E-05 Psoriasis / / 20953190 rs12478876 chr2 106288854 C G 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10179463 chr2 106294462 T C 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1823645 chr2 106301594 G A 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1037381 chr2 106303243 A G 5.57E-04 Multiple complex diseases / / 17554300 rs1037381 chr2 106303243 A G 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1037381 chr2 106303243 A G 0.0000399 Aging / / 22445811 rs11884955 chr2 106310212 T C 5.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs13019064 chr2 106311180 C T 1.32E-04 Multiple complex diseases / / 17554300 rs13429323 chr2 106343072 T C 1.92E-04 Height / / 17255346 rs6752668 chr2 106347216 T C 1.03E-04 Height / / 17255346 rs6739767 chr2 106348958 C G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs6743613 chr2 106349806 C T 4.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs6746639 chr2 106350031 C T 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs997522 chr2 106366232 G A 4.10E-05 Inflammatory demyelinating disease NCK2 intron 19850125 rs997522 chr2 106366232 G A 7.12E-05 Calcium levels NCK2 intron pha003085 rs12987484 chr2 106367561 T C 1.17E-04 Arthritis (juvenile idiopathic) NCK2 intron 22354554 rs11687998 chr2 106384133 C T 7.35E-04 Type 2 diabetes NCK2 intron 17463246 rs1367404 chr2 106386865 G T 3.66E-04 Alzheimer's disease NCK2 intron 17998437 rs7589589 chr2 106391154 G C 1.20E-04 Alzheimer's disease NCK2 intron 17998437 rs7589589 chr2 106391154 G C 8.13E-05 Serum metabolites NCK2 intron 19043545 rs4851864 chr2 106391338 G A 9.24E-04 Multiple complex diseases NCK2 intron 17554300 rs10198057 chr2 106392799 G T 2.08E-04 Alzheimer's disease NCK2 intron 17998437 rs17201484 chr2 106394809 G C 3.04E-04 Alzheimer's disease NCK2 intron 17998437 rs17201484 chr2 106394809 G C 8.95E-05 Serum metabolites NCK2 intron 19043545 rs1897169 chr2 106397624 A G 3.97E-04 Alzheimer's disease NCK2 intron 17998437 rs6732799 chr2 106401954 C T 4.18E-05 Prion diseases NCK2 intron 22210626 rs7588033 chr2 106408233 C T 3.79E-05 Prion diseases NCK2 intron 22210626 rs4851090 chr2 106411386 T C 9.36E-05 Multiple complex diseases NCK2 intron 17554300 rs17031793 chr2 106413031 C T 5.22E-04 Suicide attempts in bipolar disorder NCK2 intron 21423239 rs2047699 chr2 106413077 C T 5.34E-05 Prion diseases NCK2 intron 22210626 rs6719896 chr2 106428404 C G 3.42E-04 Alzheimer's disease NCK2 intron 17998437 rs1549769 chr2 106429319 A C 2.87E-04 Multiple complex diseases NCK2 intron 17554300 rs7589790 chr2 106433909 C G 3.53E-04 Type 2 diabetes NCK2 intron 17463246 rs7589790 chr2 106433909 C G 1.54E-04 Alzheimer's disease NCK2 intron 17998437 rs12995333 chr2 106436366 G T 4.43E-04 Type 2 diabetes NCK2 intron 17463246 rs12995333 chr2 106436366 G T 9.90E-05 Alzheimer's disease NCK2 intron 17998437 rs6725519 chr2 106445209 C T 2.42E-04 Alzheimer's disease NCK2 intron 17998437 rs3954042 chr2 106453347 T C 3.97E-04 Multiple complex diseases NCK2 intron 17554300 rs7589561 chr2 106454085 C T 2.02E-05 Osteoarthritis (knee and hip) NCK2 intron 21177295 rs7589561 chr2 106454085 C T 5.53E-04 Osteoarthritis (knee and hip) NCK2 intron 21177295 rs4851877 chr2 106455387 A C 3.26E-04 Multiple complex diseases NCK2 intron 17554300 rs4851095 chr2 106455549 T C 7.10E-04 Multiple complex diseases NCK2 intron 17554300 rs2377339 chr2 106457291 A G 2.24E-04 Fibrinogen NCK2 intron 17255346 rs2377339 chr2 106457291 A G 1.00E-11 Addiction NCK2 intron 23533358 rs2377339 chr2 106457291 A G 2.00E-08 Addiction NCK2 intron 23533358 rs6543344 chr2 106467506 C G 8.26E-04 Multiple complex diseases NCK2 intron 17554300 rs6543344 chr2 106467506 C G 0.00006658 Sarcoidosis NCK2 intron 22952805 rs3754807 chr2 106469333 A T 8.89E-05 Serum metabolites NCK2 intron 19043545 rs3769504 chr2 106477092 A G 9.03E-04 Type 2 diabetes NCK2 intron 17463246 rs3769503 chr2 106477285 T C 9.93E-04 Multiple complex diseases NCK2 intron 17554300 rs6704555 chr2 106477781 G A 1.74E-04 Multiple complex diseases NCK2 intron 17554300 rs9646946 chr2 106477946 A G 4.84E-04 Multiple complex diseases NCK2 intron 17554300 rs3769501 chr2 106479806 C G 5.46E-06 Kawasaki disease NCK2 intron 21221998 rs3769497 chr2 106490021 C A 7.01E-04 Multiple complex diseases NCK2 intron 17554300 rs3754801 chr2 106493191 G A 6.12E-05 Serum metabolites NCK2 intron 19043545 rs6729522 chr2 106527661 A T 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477515 chr2 106530293 T C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477516 chr2 106533298 G A 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs13428604 chr2 106533687 T C 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477517 chr2 106533914 C G 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs17031993 chr2 106535038 G A 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281921 chr2 106535966 C T 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11895604 chr2 106536134 G A 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1465491 chr2 106549469 A G 1.20E-05 Urinary metabolites / / 21572414 rs10490696 chr2 106551322 T C 8.21E-05 Blood Pressure / / pha003043 rs17665024 chr2 106555857 A G 5.24E-05 Cognitive impairment induced by topiramate / / 22091778 rs10490697 chr2 106558545 A G 1.47E-04 Hemoglobin concentration / / 20534544 rs11892293 chr2 106567399 A G 8.68E-04 Alzheimer's disease / / 22005930 rs7605392 chr2 106584728 T C 6.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7609295 chr2 106586012 A G 1.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1111513 chr2 106587548 T C 8.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1109164 chr2 106605186 G A 3.20E-04 Hemoglobin concentration / / 20534544 rs1109164 chr2 106605186 G A 9.11E-05 Depression (quantitative trait) / / 20800221 rs1669539 chr2 106615274 T C 1.00E-06 Systolic blood pressure in sickle cell anemia / / 24058526 rs4851109 chr2 106617615 G C 5.45E-05 Sudden cardiac arrest / / 21658281 rs17032192 chr2 106644772 T G 1.09E-06 Obesity and osteoporosis / / 19714249 rs1869058 chr2 106670527 G A 7.65E-05 Multiple complex diseases / / 17554300 rs17032247 chr2 106674925 G A 3.98E-05 Gaucher disease severity / / 22388998 rs17271098 chr2 106692818 G A 4.16E-04 Smoking initiation C2orf40 intron 24665060 rs7573766 chr2 106705717 C A 9.50E-04 Multiple complex diseases / / 17554300 rs10206195 chr2 106714038 T C 9.10E-04 Alcohol dependence UXS1 intron 21314694 rs17032398 chr2 106722953 T C 6.90E-06 Urinary metabolites UXS1 intron 21572414 rs17213510 chr2 106742778 T C 3.75E-04 Alzheimer's disease (late onset) UXS1 intron 21379329 rs17032647 chr2 106822764 C T 2.45E-04 Stroke / / pha002887 rs11124097 chr2 106878601 A G 3.73E-05 Alzheimer's disease (late onset) / / 21379329 rs11694824 chr2 106886684 A G 2.78E-04 Alzheimer's disease (late onset) / / 21379329 rs11673736 chr2 106886935 T C 1.55E-04 Smoking initiation / / 24665060 rs7419384 chr2 106887870 A G 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs6746840 chr2 106932170 T C 3.69E-04 Type 2 diabetes / / 17463246 rs4574118 chr2 106948443 C G 3.99E-04 Type 2 diabetes / / 17463246 rs4574118 chr2 106948443 C G 1.80E-07 Colorectal cancer / / 20610541 rs11677201 chr2 106951208 C T 6.76E-04 Type 2 diabetes / / 17463246 rs4384785 chr2 107121966 G A 2.67E-04 Heart rate / / 23583979 rs12472491 chr2 107189537 A C 4.72E-08 Metabolite levels / / 23281178 rs2035030 chr2 107203992 C T 4.84E-04 Response to alcohol consumption (flushing response) / / 24277619 rs13017273 chr2 107210805 A G 0.0000872 Panic disorder / / 23149450 rs13017273 chr2 107210805 A G 8.72E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17033012 chr2 107241221 A G 0.000045 Panic disorder / / 23149450 rs17033012 chr2 107241221 A G 4.50E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs13025573 chr2 107243678 G A 2.90E-05 Malaria / / 19465909 rs17033088 chr2 107258436 T G 0.0000814 Panic disorder / / 23149450 rs17033088 chr2 107258436 T G 8.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1006472 chr2 107329516 A C 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs1006472 chr2 107329516 A C 4.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs898457 chr2 107339458 A G 1.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs898457 chr2 107339458 A G 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs898456 chr2 107339629 G A 1.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs898456 chr2 107339629 G A 5.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs13393451 chr2 107341293 G A 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs13393451 chr2 107341293 G A 4.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs13391600 chr2 107343100 T C 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs13391600 chr2 107343100 T C 5.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs11124131 chr2 107349612 A C 1.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs11124131 chr2 107349612 A C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs2377685 chr2 107387872 T G 3.02E-05 Suicide attempts in bipolar disorder / / 21041247 rs1349065 chr2 107388308 C G 3.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs1349065 chr2 107388308 C G 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11894298 chr2 107388503 T C 3.20E-05 Suicide attempts in bipolar disorder / / 21041247 rs11894451 chr2 107388822 T C 3.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs11887836 chr2 107388889 C G 3.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs11888992 chr2 107389053 C G 3.44E-05 Suicide attempts in bipolar disorder / / 21041247 rs6747891 chr2 107389951 G A 3.46E-05 Suicide attempts in bipolar disorder / / 21041247 rs1448103 chr2 107391080 G A 3.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs17033251 chr2 107393541 T C 3.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs1448105 chr2 107395235 T A 3.86E-05 Suicide attempts in bipolar disorder / / 21041247 rs728241 chr2 107398133 G A 4.84E-05 Suicide attempts in bipolar disorder / / 21041247 rs728239 chr2 107398255 T C 4.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs728240 chr2 107398456 G T 5.23E-05 Suicide attempts in bipolar disorder / / 21041247 rs10202530 chr2 107420011 G T 6.41E-04 Type 2 diabetes ST6GAL2 UTR-3 17463246 rs10191793 chr2 107425876 A G 6.05E-07 Esophageal cancer (squamous cell) ST6GAL2 intron 22960999 rs7607635 chr2 107446918 A C 6.41E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs6712885 chr2 107448206 T C 1.10E-04 Type 2 diabetes and 6 quantitative traits ST6GAL2 intron 17848626 rs7608410 chr2 107450390 C T 1.17E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs7608410 chr2 107450390 C T 2.34E-05 Gallstones ST6GAL2 intron 17632509 rs2034357 chr2 107454575 G A 7.77E-05 stroke (ischemic) ST6GAL2 intron 17434096 rs2377689 chr2 107465840 C A 1.70E-05 Type 2 diabetes ST6GAL2 intron 17903298 rs2377690 chr2 107466177 G A 9.97E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs1448113 chr2 107467932 A G 9.40E-04 Type 2 diabetes and 6 quantitative traits ST6GAL2 intron 17848626 rs11679344 chr2 107477619 G A 7.58E-04 Suicide attempts in bipolar disorder ST6GAL2 intron 21423239 rs12712262 chr2 107516533 C A 8.02E-04 Type 2 diabetes / / 17463246 rs2012505 chr2 107517229 C T 8.91E-04 Coronary heart disease / / 21971053 rs11684876 chr2 107581130 G A 2.38E-04 Smoking initiation / / 24665060 rs724841 chr2 107620242 G A 5.96E-06 Alopecia areata / / 22027810 rs2971635 chr2 107636446 A C 6.29E-04 Myocardial Infarction / / pha002873 rs2949214 chr2 107644525 T G 4.82E-04 Myocardial Infarction / / pha002873 rs1357692 chr2 107678488 G T 9.00E-06 Alzheimer's disease / / 22832961 rs1357694 chr2 107678669 A G 1.33E-05 Alzheimer's disease / / 22832961 rs1916920 chr2 107678998 G C 1.79E-05 Alzheimer's disease / / 22832961 rs2030674 chr2 107679236 G A 2.31E-05 Alzheimer's disease / / 22832961 rs1916921 chr2 107679295 G A 2.90E-05 Alzheimer's disease / / 22832961 rs2030675 chr2 107679474 C T 4.15E-05 Alzheimer's disease / / 22832961 rs2030676 chr2 107679548 G T 7.09E-04 Acute lung injury / / 22295056 rs2030677 chr2 107679740 G A 4.16E-05 Alzheimer's disease / / 22832961 rs2971646 chr2 107680611 C T 9.19E-05 Coronary heart disease / / pha003031 rs2971892 chr2 107684059 G A 4.16E-05 Alzheimer's disease / / 22832961 rs2971650 chr2 107684415 A G 4.18E-05 Alzheimer's disease / / 22832961 rs2971894 chr2 107684957 T C 4.32E-05 Alzheimer's disease / / 22832961 rs1524288 chr2 107685863 T G 4.34E-05 Alzheimer's disease / / 22832961 rs1029864 chr2 107784393 T C 1.20E-04 Myasthenia gravis / / 23055271 rs1990410 chr2 107786595 G T 1.40E-05 Urinary metabolites / / 21572414 rs2079917 chr2 107790491 C T 3.60E-04 Myasthenia gravis / / 23055271 rs17033948 chr2 107795589 G A 5.82E-04 Multiple complex diseases / / 17554300 rs2889744 chr2 107796734 T C 6.39E-05 Intelligence / / 21826061 rs6708562 chr2 107800965 G A 1.47E-04 Myocardial Infarction / / pha002883 rs2079918 chr2 107804217 T G 4.80E-05 Myocardial Infarction / / pha002883 rs2191586 chr2 107805650 A T 1.44E-04 Progressive supranuclear palsy / / 21685912 rs3922303 chr2 107812973 C T 3.75E-04 Myocardial Infarction / / pha002883 rs7584779 chr2 107836502 A G 6.80E-06 Urinary metabolites / / 21572414 rs4676115 chr2 107873999 T C 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs9308906 chr2 107877680 C G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707325 chr2 107878129 T C 1.80E-05 Urinary metabolites / / 21572414 rs6713136 chr2 107880580 A T 2.50E-05 Urinary metabolites / / 21572414 rs10174248 chr2 107880858 T G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6543500 chr2 107882272 G A 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7587131 chr2 107883105 G A 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2109591 chr2 107887371 T C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12712283 chr2 107890207 G A 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2191581 chr2 107896351 A G 3.50E-05 Intelligence / / 21826061 rs7578096 chr2 107898194 C G 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747330 chr2 107908592 C T 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1990406 chr2 107909895 T C 2.00E-05 Urinary metabolites / / 21572414 rs4133137 chr2 107919607 G T 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7597997 chr2 107921929 G T 2.00E-05 Urinary metabolites / / 21572414 rs266177 chr2 108051515 T C 8.77E-04 Alzheimer's disease / / 17998437 rs266153 chr2 108108336 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs962954 chr2 108207340 G C 2.40E-04 Acute lung injury / / 22295056 rs10174350 chr2 108212733 A T 1.99E-04 Acute lung injury / / 22295056 rs17034491 chr2 108215198 C T 1.95E-04 Acute lung injury / / 22295056 rs13394586 chr2 108218010 A C 3.55E-04 Acute lung injury / / 22295056 rs1516208 chr2 108223574 C T 3.55E-04 Acute lung injury / / 22295056 rs973012 chr2 108223896 C T 3.51E-04 Acute lung injury / / 22295056 rs13430109 chr2 108226258 C A 3.51E-04 Acute lung injury / / 22295056 rs1516212 chr2 108230222 T C 4.26E-04 Acute lung injury / / 22295056 rs12476210 chr2 108234761 G A 4.26E-04 Acute lung injury / / 22295056 rs13404416 chr2 108236884 A T 4.26E-04 Acute lung injury / / 22295056 rs13392942 chr2 108240403 C T 4.26E-04 Acute lung injury / / 22295056 rs10187339 chr2 108240740 T C 4.26E-04 Acute lung injury / / 22295056 rs1400119 chr2 108246961 C A 4.26E-04 Acute lung injury / / 22295056 rs4676143 chr2 108247679 A G 4.26E-04 Acute lung injury / / 22295056 rs10199917 chr2 108252979 G C,T 6.50E-04 Acute lung injury / / 22295056 rs7584635 chr2 108255727 C A 1.53E-04 Acute lung injury / / 22295056 rs7587729 chr2 108255977 G A 1.53E-04 Acute lung injury / / 22295056 rs12162388 chr2 108257811 G A 1.53E-04 Acute lung injury / / 22295056 rs7560475 chr2 108259662 T C 1.53E-04 Acute lung injury / / 22295056 rs17021589 chr2 108266984 A C 1.49E-04 Acute lung injury / / 22295056 rs11890899 chr2 108268872 T C 1.58E-04 Acute lung injury / / 22295056 rs10204774 chr2 108272629 A G 3.43E-04 Acute lung injury / / 22295056 rs1158610 chr2 108273375 T C 4.59E-04 Acute lung injury / / 22295056 rs13403714 chr2 108273515 C T 4.59E-04 Acute lung injury / / 22295056 rs4586601 chr2 108276459 C A 4.64E-04 Acute lung injury / / 22295056 rs13409811 chr2 108280266 G A 3.85E-04 Acute lung injury / / 22295056 rs11123669 chr2 108286602 T C 4.98E-04 Acute lung injury / / 22295056 rs10205519 chr2 108290016 G A 5.43E-04 Acute lung injury / / 22295056 rs1516200 chr2 108303380 C T 7.84E-06 Multiple complex diseases / / 17554300 rs832182 chr2 108326760 G A 3.11E-05 Bipolar disorder / / 19488044 rs832182 chr2 108326760 G A 3.68E-05 Bipolar disorder / / 22925353 rs700844 chr2 108327724 A G 4.39E-05 Bipolar disorder / / 19488044 rs700844 chr2 108327724 A G 5.88E-05 Bipolar disorder / / 22925353 rs831983 chr2 108379520 C A 5.43E-04 Myocardial Infarction / / pha002883 rs328026 chr2 108380531 C T 5.60E-06 Alcohol and nictotine co-dependence / / 22488850 rs1583938 chr2 108411119 A C 8.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542736 chr2 108415702 G A 8.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542736 chr2 108415702 G A 0.00000731 Preeclampsia / / 22432041 rs13414755 chr2 108417526 C A 8.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs13415031 chr2 108417601 G C 7.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs17021776 chr2 108424627 T C 2.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs6734993 chr2 108556518 C T 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs7594860 chr2 108564754 C T 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs13020302 chr2 108599710 T C 1.60E-05 Urinary metabolites / / 21572414 rs3806536 chr2 108602755 T C 3.44E-04 Alzheimer's disease (late onset) / / 21379329 rs333238 chr2 108603628 A G 4.20E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333236 chr2 108603967 G A 4.24E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333236 chr2 108603967 G A 6.47E-06 Asthma SLC5A7 intron 22561531 rs333235 chr2 108607100 C T 4.47E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333234 chr2 108607394 T C 2.49E-04 Alzheimer's disease (late onset) SLC5A7 intron 21379329 rs2450280 chr2 108608018 T C 4.67E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333217 chr2 108610264 A G 8.12E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs10496417 chr2 108631729 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1467280 chr2 108685905 G T 9.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1486179 chr2 108739564 G T 8.00E-05 Tunica Media / / pha003034 rs750523 chr2 108746221 T C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17035697 chr2 108761525 G A 8.60E-05 Cognitive test performance / / 20125193 rs11677324 chr2 108771042 G A 2.08E-05 Cognitive performance / / 19734545 rs1563119 chr2 108785867 C T 6.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs855044 chr2 108816273 T C 3.39E-04 Obesity (extreme) / / 21935397 rs2219078 chr2 108875198 G A 1.20E-07 Longevity,exceptional SULT1C3 missense 20595579 rs4638749 chr2 108884042 G A 6.00E-07 Blood pressure / / 24954895 rs2100405 chr2 108891096 C T 8.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4149425 chr2 108917596 T C 4.83E-04 Response to alcohol consumption (flushing response) SULT1C2 intron 24277619 rs1879494 chr2 108938515 C A 1.25E-06 Hemoglobin concentration / / 20534544 rs12477830 chr2 108938735 A G 4.33E-05 Hemoglobin concentration / / 20534544 rs12477830 chr2 108938735 A G 7.00E-06 Asthma / / 21790008 rs7598552 chr2 108940070 T C 2.70E-06 Hemoglobin concentration SULT1C2P1 intron 20534544 rs12476238 chr2 108940336 T C 1.47E-04 Hemoglobin concentration SULT1C2P1 intron 20534544 rs10173535 chr2 108965694 G T 3.46E-04 Smoking cessation SULT1C2P1 intron 24665060 rs10167564 chr2 108988625 G A 5.48E-05 Hemoglobin concentration / / 20534544 rs1402467 chr2 108994808 C G 1 Drug response to Docetaxel SULT1C4 missense 20038957 rs1402467 chr2 108994808 C G 1 Drug response to Thalidomide SULT1C4 missense 20038957 rs4149432 chr2 108995325 T G 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs4149436 chr2 108999786 T C 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs4149437 chr2 109001623 T C 2.47E-04 Hemoglobin concentration SULT1C4 intron 20534544 rs4149438 chr2 109002048 C A 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs13390901 chr2 109025011 G T 4.45E-04 Hemoglobin concentration / / 20534544 rs6755756 chr2 109028656 A G 4.45E-04 Hemoglobin concentration / / 20534544 rs4395219 chr2 109034995 C T 3.89E-04 Smoking cessation / / 24665060 rs6708372 chr2 109053818 C T 7.27E-04 Smoking cessation / / 24665060 rs7601939 chr2 109080914 G T 6.38E-04 Smoking cessation GCC2 intron 24665060 rs2577620 chr2 109089952 A G 5.91E-04 Smoking cessation GCC2 intron 24665060 rs2577594 chr2 109105194 A G 9.96E-04 Multiple complex diseases GCC2 intron 17554300 rs6754683 chr2 109156275 G A 8.84E-06 Osteoarthritis LIMS1 intron 22763110 rs826686 chr2 109239407 C T 5.18E-04 Multiple complex diseases LIMS1 intron 17554300 rs12478500 chr2 109414103 T C 1.21E-04 Hemoglobin concentration CCDC138 intron 20534544 rs1073893 chr2 109489365 A G 2.30E-04 Type 2 diabetes and 6 quantitative traits CCDC138 intron 17848626 rs765089 chr2 109498997 T C 6.40E-05 Glaucoma (primary open-angle) / / 20835238 rs1478515 chr2 109500929 C T 4.76E-04 Hemoglobin concentration / / 20534544 rs1478515 chr2 109500929 C T 5.40E-05 Glaucoma (primary open-angle) / / 20835238 rs1478516 chr2 109501066 A C 5.30E-05 Glaucoma (primary open-angle) / / 20835238 rs1478516 chr2 109501066 A C 2.11E-04 Glaucoma (primary open-angle) / / 22419738 rs260633 chr2 109525530 C T 2.50E-05 Colorectal cancer EDAR intron 21242260 rs6732336 chr2 109541853 C T 5.16E-04 Multiple complex diseases EDAR intron 17554300 rs260705 chr2 109571440 G A 8.04E-06 Arthritis (juvenile idiopathic) EDAR intron 22354554 rs13427084 chr2 109582678 G A 1.04E-05 Tunica Media EDAR intron pha003038 rs260693 chr2 109582711 C T 3.40E-04 Iron levels EDAR intron pha002876 rs10496426 chr2 109584780 G C 3.31E-04 Multiple complex diseases EDAR intron 17554300 rs10174201 chr2 109585248 A T 5.19E-05 IgE levels EDAR intron 22075330 rs11691107 chr2 109586437 C T 5.08E-05 IgE levels EDAR intron 22075330 rs11694335 chr2 109588356 C T 5.00E-05 IgE levels EDAR intron 22075330 rs260695 chr2 109588375 G C 4.58E-05 IgE levels EDAR intron 22075330 rs11676729 chr2 109591409 G A 4.43E-05 IgE levels EDAR intron 22075330 rs183780 chr2 109595182 T C 6.30E-07 Primary tooth development (number of teeth) EDAR intron 23704328 rs11690981 chr2 109616111 G A 3.52E-05 IgE levels / / 22075330 rs260617 chr2 109623949 A G 7.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4676049 chr2 109635257 C T 4.00E-08 Alzheimer's disease (late onset) / / 20885792 rs17034806 chr2 109635905 A G 5.14E-08 Alzheimer's disease (late onset) / / 20885792 rs13428296 chr2 109649394 T C 5.71E-05 Response to methylphenidate treatment / / 21130132 rs375099 chr2 109660277 G A 4.62E-07 Common variable immunodeficiency / / 21497890 rs4676060 chr2 109662043 C T 2.02E-04 Multiple complex diseases / / 17554300 rs6737482 chr2 109669494 T C 1.34E-05 Coronary heart disease / / pha003035 rs417999 chr2 109678210 A G 4.62E-04 Prostate cancer mortality / / 20978177 rs260659 chr2 109682341 C T 6.67E-04 Prostate cancer mortality / / 20978177 rs260654 chr2 109685399 G T 8.68E-04 Prostate cancer mortality / / 20978177 rs7565363 chr2 109755441 A G 1.12E-04 Sarcoidosis / / 19165924 rs7561185 chr2 109782233 T C 3.80E-04 Major depressive disorder / / 21042317 rs4676070 chr2 109788623 C T 5.02E-04 Multiple complex diseases / / 17554300 rs4676070 chr2 109788623 C T 3.40E-04 Major depressive disorder / / 21042317 rs4676258 chr2 109798726 C T 1.70E-04 Major depressive disorder / / 21042317 rs11893469 chr2 109807143 C T 4.70E-04 Major depressive disorder / / 21042317 rs11893469 chr2 109807143 C T 2.34E-04 Tourette syndrome / / 22889924 rs1430306 chr2 109807885 G A 3.80E-04 Major depressive disorder / / 21042317 rs10184308 chr2 109824220 A G 9.50E-06 Urinary metabolites / / 21572414 rs11893925 chr2 109825067 A G 1.80E-05 Urinary metabolites / / 21572414 rs12328666 chr2 109825516 A G 2.70E-05 Urinary metabolites / / 21572414 rs752272 chr2 109830103 T G 4.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7355687 chr2 109833540 T C 1.10E-05 Urinary metabolites / / 21572414 rs10204703 chr2 109848994 T C 6.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6760953 chr2 109856486 T C 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10177036 chr2 109869452 G T 2.00E-05 Urinary metabolites / / 21572414 rs12474431 chr2 109928591 A C 4.71E-04 Multiple complex diseases / / 17554300 rs11123739 chr2 109934924 C T 6.10E-04 Type 2 diabetes / / 17463246 rs6707697 chr2 109940324 T G 2.29E-07 Information processing speed / / 21130836 rs4676274 chr2 109948720 C T 7.27E-04 Alzheimer's disease / / 17998437 rs4676275 chr2 109953626 A T 2.10E-05 Urinary metabolites / / 21572414 rs12614506 chr2 109957204 C T 8.78E-04 Multiple complex diseases / / 17554300 rs4676283 chr2 109996227 C T 4.92E-05 Coronary heart disease / / pha003030 rs6737952 chr2 109997436 G A 4.76E-05 Coronary heart disease / / pha003030 rs6745464 chr2 110029298 C T 3.50E-05 Personality dimensions / / 18957941 rs10202141 chr2 110030964 C A 3.40E-05 Personality dimensions / / 18957941 rs9330310 chr2 110265558 G T 1.58E-05 Lymphocyte counts / / 22286170 rs9330311 chr2 110273380 C T 7.36E-06 Sleep duration / / 22105623 rs11692886 chr2 110274179 C T 0.000105 Schizophrenia / / 23637625 rs9711994 chr2 110278908 C T 1.93E-05 Prostate cancer / / 22923026 rs9330321 chr2 110290160 T C 7.78E-04 Schizophrenia / / 19197363 rs11541143 chr2 110302464 G A 8.13E-05 Schizophrenia (cytomegalovirus infection interaction) SEPT10 intron 23358160 rs4953788 chr2 110336043 A C 1.77E-04 Schizophrenia SEPT10 intron 19197363 rs892464 chr2 110343913 G T 6.24E-04 Schizophrenia SEPT10 intron 19197363 rs7601026 chr2 110439949 G A 2.01E-04 Acute lung injury / / 22295056 rs13384147 chr2 110448229 G A 3.48E-05 Height / / pha003011 rs17842650 chr2 110872851 G A 7.64E-04 Multiple complex diseases MALL intron 17554300 rs17463266 chr2 110958329 C T 9.06E-04 Amyotrophic lateral sclerosis (sporadic) NPHP1 intron 24529757 rs145479679 chr2 110959008 T G 0.000000084 Breast cancer(er negative) NPHP1 missense 23555315 rs7572507 chr2 111490731 C T 9.38E-04 Alcohol consumption (maxi-drinks) ACOXL intron 24277619 rs4290670 chr2 111543487 C T 2.33E-05 Triglycerides ACOXL intron pha003080 rs17464100 chr2 111567781 C T 2.00E-05 Urinary metabolites ACOXL intron 21572414 rs2612699 chr2 111586214 C T 7.03E-05 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs4494791 chr2 111587016 T C 6.83E-04 Amyotrophic Lateral Sclerosis ACOXL intron 17827064 rs2175824 chr2 111592407 G T 4.70E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs13417566 chr2 111592606 C A 4.72E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs12463442 chr2 111595489 A G 5.57E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs12463526 chr2 111595738 A G 5.95E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1533295 chr2 111597991 A G 3.03E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs10210955 chr2 111599282 G C 2.20E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs4849121 chr2 111599706 G A 6.41E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs4849121 chr2 111599706 G A 4.00E-07 IgA nephropathy ACOXL intron 22197929 rs10180446 chr2 111601942 C G 3.37E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1554006 chr2 111604113 A G 2.20E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1554006 chr2 111604113 A G 8.63E-05 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs1554006 chr2 111604113 A G 8.76E-04 Response to cytadine analogues (cytosine arabinoside) ACOXL intron 24483146 rs13019266 chr2 111604642 T C 3.41E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs13019266 chr2 111604642 T C 2.41E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs9917154 chr2 111606591 G C 3.50E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs7576541 chr2 111607401 C T 3.57E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs6732565 chr2 111607832 A G 3.00E-08 Rheumatoid arthritis ACOXL intron 24390342 rs6732565 chr2 111607832 A G 9.00E-09 Rheumatoid arthritis ACOXL intron 24390342 rs12151613 chr2 111609385 C T 7.20E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs10197140 chr2 111609943 T C 5.03E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs17465162 chr2 111613145 T C 6.41E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs4849134 chr2 111615015 A G 2.32E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs4849135 chr2 111615079 T G 3.03E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs13401811 chr2 111616104 G A 2.00E-18 Chronic lymphocytic leukemia ACOXL intron 23770605 rs1533298 chr2 111616304 C T 2.41E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs1002016 chr2 111616912 G A 7.54E-04 Suicide attempts in bipolar disorder ACOXL intron 21423239 rs7596265 chr2 111617015 A G 4.30E-06 Urinary metabolites ACOXL intron 21572414 rs880506 chr2 111627300 G A 2.67E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs1872062 chr2 111630489 G T 4.92E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs6542190 chr2 111638063 T G 8.96E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs4849162 chr2 111639235 T C 8.56E-07 Red blood cell traits ACOXL intron 23222517 rs4849165 chr2 111639589 T C 8.82E-07 Red blood cell traits ACOXL intron 23222517 rs9308691 chr2 111641138 T C 2.67E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs10188079 chr2 111644475 C T 2.69E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs12622400 chr2 111657888 G T 3.90E-05 Pulmonary function ACOXL intron 20010835 rs323640 chr2 111659098 G C 7.27E-05 Multiple complex diseases ACOXL intron 17554300 rs12612914 chr2 111666929 G A 6.60E-05 Pulmonary function ACOXL intron 20010835 rs4849256 chr2 111685899 G T 5.03E-05 Pulmonary function ACOXL intron 20010835 rs3761708 chr2 111691530 G C 2.25E-05 Pulmonary function ACOXL intron 20010835 rs3789119 chr2 111707405 C T 4.00E-06 Economic and political preferences (immigration/crime) ACOXL intron 22566634 rs17041661 chr2 111721964 A G 5.86E-04 Type 2 diabetes ACOXL intron 17463246 rs4849303 chr2 111728482 C T 1.00E-06 Colorectal cancer (diet interaction) ACOXL intron 24743840 rs11123271 chr2 111740221 A G 6.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs6542248 chr2 111753228 C A 2.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs1483533 chr2 111757918 T C 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1384795 chr2 111771647 A G 6.50E-04 Schizophrenia ACOXL intron 19197363 rs1384795 chr2 111771647 A G 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1561476 chr2 111787027 C T 3.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs10194898 chr2 111792302 C A 6.96E-04 Aortic root size ACOXL intron 21223598 rs11123312 chr2 111796039 G A 1.98E-05 Blood pressure ACOXL intron 24001895 rs17549227 chr2 111796195 T C 1.06E-05 Brain structure ACOXL intron 22504417 rs17549227 chr2 111796195 T C 8.84E-05 Hematocrit ACOXL intron pha003097 rs6706577 chr2 111796833 A G 3.00E-05 Type 1 diabetes ACOXL intron 18978792 rs6706577 chr2 111796833 A G 8.50E-05 Serum metabolites ACOXL intron 19043545 rs17483466 chr2 111797458 A G 2.00E-10 Chronic lymphocytic leukemia ACOXL intron 18758461 rs17483466 chr2 111797458 A G 2.00E-10 Nasopharyngeal carcinoma ACOXL intron 20512145 rs17483466 chr2 111797458 A G 1.31E-05 Brain structure ACOXL intron 22504417 rs17483466 chr2 111797458 A G 5.00E-09 Chronic lymphocytic leukemia ACOXL intron 22700719 rs17483466 chr2 111797458 A G 4.96E-09 Erectile dysfunction ACOXL intron 22704111 rs17483466 chr2 111797458 A G 4.00E-17 Chronic lymphocytic leukemia ACOXL intron 23770605 rs17483466 chr2 111797458 A G 8.39E-05 Hematocrit ACOXL intron pha003097 rs3789080 chr2 111797531 C T 4.00E-06 Prostate cancer (gene x gene interaction) ACOXL intron 22219177 rs754352 chr2 111797920 A G 1.40E-05 Brain structure ACOXL intron 22504417 rs752834 chr2 111798658 G A 1.05E-05 Brain structure ACOXL intron 22504417 rs3827538 chr2 111807303 T C 5.30E-05 Oral cancers (chewing tobacco related) ACOXL intron 22503698 rs10187034 chr2 111812617 T C 1.76E-04 Multiple complex diseases ACOXL intron 17554300 rs875063 chr2 111813085 A C 9.68E-07 Red blood cell traits ACOXL intron 23222517 rs4849360 chr2 111815871 C T 1.74E-06 Bilirubin levels,in serum ACOXL intron 19389676 rs7599513 chr2 111823276 A C 3.34E-07 Red blood cell traits ACOXL intron 23222517 rs4849381 chr2 111834381 G C 6.13E-07 Red blood cell traits ACOXL intron 23222517 rs10181102 chr2 111835489 T C 4.68E-04 Smoking cessation ACOXL intron 24665060 rs7578982 chr2 111836538 T C 4.00E-07 White blood cell types ACOXL intron 21738478 rs7578982 chr2 111836538 T C 2.20E-07 Red blood cell traits ACOXL intron 23222517 rs7575878 chr2 111836664 A T 6.25E-08 Red blood cell traits ACOXL intron 23222517 rs1866493 chr2 111847078 A T 3.20E-07 Red blood cell traits ACOXL intron 23222517 rs10207392 chr2 111849659 A G 4.00E-11 Red blood cell traits ACOXL intron 23222517 rs11691193 chr2 111854524 C T 6.35E-04 Smoking cessation ACOXL intron 24665060 rs2018707 chr2 111856773 T C 4.52E-05 Hematocrit ACOXL intron pha003097 rs17040529 chr2 111859774 A G 1.61E-04 Multiple complex diseases ACOXL intron 17554300 rs11681263 chr2 111868010 C A 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1439287 chr2 111871897 G A 5.00E-15 Chronic lymphocytic leukemia ACOXL intron 24292274 rs2015454 chr2 111872148 A G 2.75E-04 Myocardial Infarction ACOXL intron pha002873 rs1837369 chr2 111874276 C T 6.78E-04 Multiple complex diseases ACOXL intron 17554300 rs10204044 chr2 111895544 C G 1.90E-05 Urinary metabolites BCL2L11 intron 21572414 rs17041869 chr2 111896243 A G 6.07E-05 Coronary heart disease BCL2L11 intron pha003055 rs724710 chr2 111907691 T C 0.000337267 Primary sclerosing cholangitis BCL2L11 cds-synon 23603763 rs724710 chr2 111907691 T C 1.79E-05 Tuberculosis BCL2L11 cds-synon 24057671 rs10169613 chr2 111934977 C T 6.30E-05 Immunoglobulin A / / 20694011 rs17558117 chr2 111940996 T A 5.98E-05 Attention deficit hyperactivity disorder / / 23728934 rs633605 chr2 111945241 C T 8.84E-05 Type 2 diabetes / / 17463246 rs6738028 chr2 111949327 G C 2.00E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs3747653 chr2 111966540 T C 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505634 intron 20877124 rs3747653 chr2 111966540 T C 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505634 intron 20877124 rs3747653 chr2 111966540 T C 2.30E-04 Stroke (pediatric) LOC100505634 intron 22990015 rs6720394 chr2 111989372 T G 4.00E-08 Primary sclerosing cholangitis LOC100505634 intron 21151127 rs13395957 chr2 112000058 T C 7.45E-05 Body Mass Index LOC100505634 intron pha003022 rs2271404 chr2 112003867 T C 3.00E-07 Atopic dermatitis LOC100505634 intron 23042114 rs17040893 chr2 112068777 C T 5.71E-05 Insulin resistance / / 21901158 rs1900710 chr2 112213244 C T 8.96E-07 Red blood cell traits LOC541471 intron 23222517 rs1900710 chr2 112213244 C T 2.50E-04 Celiac disease LOC541471 intron 23936387 rs12623041 chr2 112263142 C T 3.82E-05 Body Mass Index / / pha003006 rs12623041 chr2 112263142 C T 5.13E-05 Weight / / pha003026 rs17842119 chr2 112277492 T G 8.82E-04 White matter integrity / / 22425255 rs4616487 chr2 112319781 G A 3.88E-05 Cholesterol / / 17255346 rs1448190 chr2 112375963 A C 8.00E-06 Obesity-related traits / / 23251661 rs4848611 chr2 112388229 T C 7.26E-06 Erythrocyte counts / / pha003099 rs7593992 chr2 112395534 T C 8.11E-06 Erythrocyte counts / / pha003099 rs9308627 chr2 112397505 T C 6.45E-05 Erythrocyte counts / / pha003099 rs7596295 chr2 112400597 C T 6.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1399665 chr2 112425540 A G 3.24E-05 Self-reported allergy / / 23817569 rs1399665 chr2 112425540 A G 6.66E-04 Alcohol dependence / / 24277619 rs1399665 chr2 112425540 A G 1.41E-04 Smoking initiation / / 24665060 rs6754001 chr2 112428409 A G 0.0000152 Nicotine dependence (smoking) / / 22377092 rs1533380 chr2 112438826 C T 5.82E-05 Self-reported allergy / / 23817569 rs2311554 chr2 112440878 G C 5.29E-05 Self-reported allergy / / 23817569 rs9308631 chr2 112442431 G A 8.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9308631 chr2 112442431 G A 0.00000725 Nicotine dependence (smoking) / / 22377092 rs9308632 chr2 112442561 T C 0.0000107 Nicotine dependence (smoking) / / 22377092 rs9308632 chr2 112442561 T C 5.64E-05 Self-reported allergy / / 23817569 rs9308632 chr2 112442561 T C 9.00E-05 Smoking initiation / / 24665060 rs11122895 chr2 112470155 C T 2.00E-06 Allergic sensitization / / 23817571 rs6541824 chr2 112475467 G A 4.87E-05 Self-reported allergy / / 23817569 rs17040773 chr2 112500035 A C 2.00E-09 Bone mineral density / / 22504420 rs17040773 chr2 112500035 A C 8.53E-05 Tuberculosis / / 24057671 rs4848208 chr2 112624327 G A 3.97E-05 Self-reported allergy A/PC1 intron 23817569 rs4848819 chr2 112624436 C T 5.23E-05 Self-reported allergy A/PC1 intron 23817569 rs6742515 chr2 112625575 T C 0.00000769 Nicotine dependence (smoking) A/PC1 intron 22377092 rs4848209 chr2 112626638 A G 2.85E-05 Self-reported allergy A/PC1 intron 23817569 rs10197222 chr2 112627223 A G 0.00000899 Nicotine dependence (smoking) A/PC1 intron 22377092 rs1516637 chr2 112634339 C T 2.53E-05 Self-reported allergy A/PC1 intron 23817569 rs9653414 chr2 112634737 G A 0.00000799 Nicotine dependence (smoking) A/PC1 intron 22377092 rs9653414 chr2 112634737 G A 2.17E-05 Self-reported allergy A/PC1 intron 23817569 rs10175926 chr2 112636685 G A 5.35E-05 Self-reported allergy A/PC1 intron 23817569 rs3814026 chr2 112641666 T C 0.00016 Nicotine dependence (smoking) A/PC1 UTR-5 22377092 rs13016143 chr2 112649472 C T 3.30E-05 Personality dimensions / / 18957941 rs13016143 chr2 112649472 C T 8.62E-04 Depression (quantitative trait) / / 20800221 rs6736093 chr2 112655242 A G 6.08E-05 Cognitive decline MERTK nearGene-5 23732972 rs17174870 chr2 112665201 C T 1.00E-08 Multiple sclerosis MERTK intron 21833088 rs17174870 chr2 112665201 C T 1.20E-04 Multiple sclerosis MERTK intron 24234648 rs17779482 chr2 112665677 C T 6.31E-05 Cognitive decline MERTK intron 23732972 rs4374383 chr2 112770770 A G 1.00E-09 Hepatitis C induced liver fibrosis MERTK intron 22841784 rs4848967 chr2 112788418 G A 5.04E-05 Type 1 diabetes / / 21980299 rs11684476 chr2 112793981 T C 2.31E-04 Cognitive decline / / 23732972 rs77088208 chr2 112811013 C T 3.27E-06 Tuberculosis / / 22306650 rs4848979 chr2 112816236 G T 8.70E-05 Cognitive decline TMEM87B intron 23732972 rs4632347 chr2 112822084 A G 8.76E-05 Aging (time to event) TMEM87B intron 21782286 rs10165845 chr2 112843244 A G 6.88E-04 Amyotrophic lateral sclerosis (sporadic) TMEM87B intron 24529757 rs10204140 chr2 112859194 T C 5.80E-05 Relative hand skill TMEM87B intron 24068947 rs7591702 chr2 112860934 C G 7.41E-04 Type 2 diabetes TMEM87B intron 17463246 rs9308669 chr2 112864369 C G 6.73E-05 Serum metabolites TMEM87B intron 19043545 rs13431260 chr2 112866597 A T 9.99E-05 Relative hand skill TMEM87B intron 24068947 rs10180018 chr2 112868426 G A 5.39E-05 Heart Rate TMEM87B intron pha003054 rs12711736 chr2 112943070 C T 8.90E-04 Multiple complex diseases FBLN7 intron 17554300 rs10183121 chr2 112953542 A G 2.75E-05 Height / / pha003010 rs2254860 chr2 112995810 A G 7.07E-04 Response to alcohol consumption (flushing response) ZC3H8 intron 24277619 rs12465398 chr2 113009021 T C 7.71E-04 Response to alcohol consumption (flushing response) ZC3H8 intron 24277619 rs12622246 chr2 113021804 G A 7.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4352239 chr2 113083283 A C 4.85E-05 Major depressive disorder (broad) ZC3H6 intron 20038947 rs7601200 chr2 113089267 T C 8.07E-04 White matter integrity ZC3H6 cds-synon 22425255 rs4299347 chr2 113098812 T C 5.96E-05 Major depressive disorder (broad) / / 20038947 rs4299347 chr2 113098812 T C 7.94E-04 White matter integrity / / 22425255 rs3811038 chr2 113240183 T C 1.77E-04 Height TTL intron 17255346 rs4849073 chr2 113300658 C G 1.07E-04 Smoking cessation POLR1B intron 18519826 rs4849073 chr2 113300658 C G 8.05E-04 Smoking cessation POLR1B intron 18519826 rs4849074 chr2 113301237 C G 1.83E-04 Smoking cessation POLR1B intron 18519826 rs719667 chr2 113342682 C T 9.67E-05 Body Fat Distribution CHCHD5 intron pha003016 rs3849317 chr2 113373950 C T 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17587043 chr2 113382134 C T 4.79E-04 Alzheimer's disease / / 17998437 rs885346 chr2 113415550 G T 9.20E-04 Type 2 diabetes and 6 quantitative traits SLC20A1 intron 17848626 rs6728935 chr2 113442808 T C 9.48E-05 Schizophrenia / / 24253340 rs4849101 chr2 113444837 C T 2.22E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4849101 chr2 113444837 C T 4.91E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4337479 chr2 113453206 A G 6.42E-04 Multiple complex diseases / / 17554300 rs10211073 chr2 113457049 A G 2.50E-05 Asthma (bronchodilator response) / / 22792082 rs908547 chr2 113470159 G A 9.67E-05 Cognitive test performance / / 20125193 rs908547 chr2 113470159 G A 1.69E-05 Caffeine consumption / / 21490707 rs908547 chr2 113470159 G A 3.64E-05 Waist-Hip Ratio / / pha003013 rs908547 chr2 113470159 G A 9.66E-05 Waist-Hip Ratio / / pha003028 rs4849113 chr2 113476596 C T 4.62E-05 Cognitive test performance / / 20125193 rs4849113 chr2 113476596 C T 5.52E-05 Waist-Hip Ratio / / pha003013 rs4849114 chr2 113476642 G A 6.79E-04 Multiple complex diseases / / 17554300 rs13386452 chr2 113479614 G A 2.77E-05 Waist-Hip Ratio / / pha003013 rs13386452 chr2 113479614 G A 9.04E-05 Body Fat Distribution / / pha003016 rs13386452 chr2 113479614 G A 3.37E-05 Waist-Hip Ratio / / pha003028 rs908551 chr2 113486079 C T 7.80E-05 Waist-Hip Ratio NT5DC4 intron pha003028 rs2048874 chr2 113523967 C T 2.35E-05 Type 2 diabetes / / 17463246 rs4848300 chr2 113527906 T C 4.08E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6542095 chr2 113529183 C T 3.00E-06 Endometriosis / / 20844546 rs6542095 chr2 113529183 C T 8.01E-04 Body mass index / / 21701565 rs11677416 chr2 113529240 T C 7.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs3783550 chr2 113532885 G T 7.93E-04 Body mass index IL1A intron 21701565 rs17561 chr2 113537223 C A 2.87E-04 Amyotrophic Lateral Sclerosis IL1A missense 17827064 rs17561 chr2 113537223 C A 2.00E-04 Cognitive impairment induced by topiramate IL1A missense 22091778 rs142134831 chr2 113539232 G T 0.000000013 Breast cancer(er negative) IL1A missense 23555315 rs142134831 chr2 113539232 G T 0.0000082 Breast cancer IL1A missense 23555315 rs3783525 chr2 113541819 T A 7.93E-04 Body mass index IL1A intron 21701565 rs3783516 chr2 113545678 T C 5.41E-04 Type 2 diabetes / / 17463246 rs3783567 chr2 113545955 G A 0.00000143 Triglycerides / / 23063622 rs3783567 chr2 113545955 G A 0.00000163 LDL cholesterol / / 23063622 rs3783567 chr2 113545955 G A 4.41E-16 Cholesterol,total / / 23063622 rs3783567 chr2 113545955 G A 7.10E-14 HDL cholesterol / / 23063622 rs6746923 chr2 113553426 A G 1.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs11687733 chr2 113555788 C T 9.54E-06 Type 2 diabetes / / 17463246 rs12471565 chr2 113569920 A T 7.51E-04 Body mass index / / 21701565 rs6542097 chr2 113570581 G T 8.33E-06 Type 2 diabetes / / 17463246 rs12469600 chr2 113572357 T C 6.12E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4849124 chr2 113576902 A G 0.000867451 Hypertension (early onset hypertension) / / 22479346 rs4849124 chr2 113576902 A G 5.40E-04 Endometriosis / / 23104006 rs4849124 chr2 113576902 A G 5.95E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs4849125 chr2 113576915 G A 5.97E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3917385 chr2 113580094 G A 1.40E-04 Atrial fibrillation / / 21846873 rs3917365 chr2 113586469 A G 5.92E-04 Type 2 diabetes / / 17463246 rs16944 chr2 113594867 A G 1 Drug response to Clodronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Etidronic Acid IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Risedronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Tiludronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 2.73E-04 Parkinson's disease IL1B nearGene-5 22438815 rs13032029 chr2 113600415 C T 7.40E-04 Alzheimer's disease / / 17998437 rs13032029 chr2 113600415 C T 4.78E-05 Lymphocyte counts / / 22286170 rs2708914 chr2 113627234 T G 4.47E-04 Alcohol dependence / / 20201924 rs17042517 chr2 113639584 A G 3.34E-04 Alcohol dependence / / 21314694 rs2708973 chr2 113663873 A G 3.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs10864907 chr2 113683875 C T 4.84E-04 Multiple complex diseases / / 17554300 rs10864907 chr2 113683875 C T 3.90E-04 Pulmonary function / / 23932459 rs10864907 chr2 113683875 C T 7.00E-06 Pulmonary function / / 23932459 rs12467810 chr2 113691060 T C 8.17E-06 Response to amphetamines / / 22952603 rs12467847 chr2 113691404 A G 5.00E-06 Response to amphetamines / / 22952603 rs3923566 chr2 113706171 T C 3.43E-05 Amyotrophic lateral sclerosis / / 20801717 rs12468164 chr2 113712783 A G 9.45E-04 Multiple complex diseases / / 17554300 rs1374284 chr2 113753583 C T 1.30E-06 Urinary metabolites / / 21572414 rs6542108 chr2 113755190 T C 1.30E-06 Urinary metabolites / / 21572414 rs1446511 chr2 113762543 T C 0.000809 Salmonella-induced pyroptosis / / 22837397 rs4849142 chr2 113779875 G A 1.20E-06 Urinary metabolites IL36B UTR-3 21572414 rs6710007 chr2 113780930 G A 1.80E-06 Urinary metabolites IL36B intron 21572414 rs10496447 chr2 113782059 A G 4.05E-04 Amyotrophic Lateral Sclerosis IL36B intron 17827064 rs4849143 chr2 113787356 G C 6.44E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2305150 chr2 113789316 C T 7.72E-04 Suicide attempts in bipolar disorder IL36B UTR-5 21041247 rs6724667 chr2 113789641 G A 5.97E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2862772 chr2 113791482 G C 8.13E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs1900287 chr2 113797565 G A 7.97E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2862774 chr2 113797677 A C 9.27E-05 Cytomegalovirus antibody response IL36B intron 21993531 rs2862774 chr2 113797677 A C 6.05E-04 Smoking quantity IL36B intron 24665060 rs2862776 chr2 113797924 G A 7.58E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs7557928 chr2 113797968 T G 7.54E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs4849144 chr2 113800049 A G 7.53E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs4849144 chr2 113800049 A G 1.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IL36B intron 24023788 rs4849144 chr2 113800049 A G 3.03E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) IL36B intron 24023788 rs7569284 chr2 113803563 G A 7.53E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs9678578 chr2 113810947 T A 6.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs990524 chr2 113816481 C T 7.30E-04 Suicide attempts in bipolar disorder IL36RN intron 21041247 rs28938777 chr2 113819725 A G 0.00046 Prostate cancer IL36RN missense 23555315 rs2472188 chr2 113820814 C G 8.72E-06 Alcohol and nictotine co-dependence IL36RN UTR-3 20158304 rs12475161 chr2 113823626 T C 1.50E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs7558672 chr2 113825303 G A 2.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1446521 chr2 113827396 G A 5.93E-04 Suicide attempts in bipolar disorder IL1F10 intron 21041247 rs4849147 chr2 113829236 A T 5.72E-04 Suicide attempts in bipolar disorder IL1F10 intron 21041247 rs4849148 chr2 113829522 T C 1.74E-04 Multiple complex diseases IL1F10 intron 17554300 rs12711749 chr2 113829709 G A 1.00E-05 Urinary metabolites IL1F10 intron 21572414 rs12469822 chr2 113830563 G A 3.80E-05 Obesity,menopause IL1F10 intron 21424828 rs6761276 chr2 113832312 T C 7.00E-06 Protein quantitative trait loci IL1F10 missense 18464913 rs6761276 chr2 113832312 T C 4.56E-25 Inflammatory biomarkers IL1F10 missense 24182552 rs6743376 chr2 113832333 C A 2.00E-26 Inflammatory biomarkers IL1F10 missense 24182552 rs13386602 chr2 113834820 A C 6.12E-25 Inflammatory biomarkers / / 24182552 rs11678375 chr2 113835691 T C 6.19E-25 Inflammatory biomarkers / / 24182552 rs6759676 chr2 113836348 C T 6.15E-25 Inflammatory biomarkers / / 24182552 rs7574787 chr2 113837416 T G 4.12E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12711751 chr2 113837765 T G 2.00E-05 Response to statin therapy / / 20339536 rs13409371 chr2 113838145 G A 4.36E-04 Multiple complex diseases / / 17554300 rs10181720 chr2 113838608 A G 3.80E-05 Response to statin therapy / / 20339536 rs10184259 chr2 113838628 T C 2.70E-05 Response to statin therapy / / 20339536 rs10184259 chr2 113838628 T C 4.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10169599 chr2 113838652 C T 2.80E-05 Response to statin therapy / / 20339536 rs1867829 chr2 113839151 G A 1.94E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10176274 chr2 113840575 C G 1.43E-04 Multiple complex diseases / / 17554300 rs17042828 chr2 113840934 T C 1.20E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6734238 chr2 113841030 A G 2.00E-17 C-reactive protein / / 21300955 rs6734238 chr2 113841030 A G 7.41E-06 White blood cell count / / 21738479 rs6734238 chr2 113841030 A G 1.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6734238 chr2 113841030 A G 9.00E-10 C-reactive protein / / 22939635 rs6734238 chr2 113841030 A G 6.00E-19 Fibrinogen / / 23969696 rs6722922 chr2 113841515 C T 5.88E-05 Multiple complex diseases / / 17554300 rs6750559 chr2 113841532 G A 2.16E-04 Multiple complex diseases / / 17554300 rs17042833 chr2 113842279 C T 1.10E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs17042842 chr2 113843481 A G 1.20E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs4496335 chr2 113844475 C T 2.13E-04 Multiple complex diseases / / 17554300 rs12328368 chr2 113847144 C G 1.69E-04 Multiple complex diseases / / 17554300 rs6738239 chr2 113850792 C A 1.75E-04 Multiple complex diseases / / 17554300 rs1446510 chr2 113851517 C T 1.40E-04 Multiple complex diseases / / 17554300 rs13404928 chr2 113866525 G A 3.44E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs315921 chr2 113872051 G A 2.60E-06 Fibrinogen / / 20978265 rs315920 chr2 113873018 C T 7.81E-05 Bipolar disorder / / 20451256 rs4251961 chr2 113874467 T C 1.80E-05 Fibrinogen IL1RN nearGene-5 20978265 rs4251961 chr2 113874467 T C 0.0000254 Interleukin-6 (IL-6) levels IL1RN nearGene-5 23505291 rs4251961 chr2 113874467 T C 0.00014 C-reactive protein IL1RN nearGene-5 23505291 rs2637988 chr2 113876779 G A 1.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IL1RN intron 24023788 rs928940 chr2 113877495 G T 1.65E-05 Lymphocyte counts IL1RN intron 22286170 rs3213448 chr2 113879297 G A 6.96E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) IL1RN intron 24023788 rs2232352 chr2 113885094 C T 0.00032 Coronary artery calcification IL1RN intron 23727086 rs4252040 chr2 113889541 T G 9.62E-27 HDL cholesterol IL1RN intron 23063622 rs4252023 chr2 113890373 C T 2.00E-06 Obesity-related traits IL1RN cds-synon 23251661 rs397211 chr2 113892141 T C 4.00E-04 Psoriasis / / 20953187 rs315958 chr2 113900851 G T 3.12E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6760120 chr2 113932431 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs6760120 chr2 113932431 T C 4.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs4849163 chr2 113935028 T C 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs4849163 chr2 113935028 T C 4.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs6753019 chr2 113948159 G A 5.89E-04 Alcohol dependence PSD4 intron 24277619 rs11123169 chr2 113967075 C T 8.06E-04 Multiple complex diseases / / 17554300 rs11123170 chr2 113978940 C G 3.00E-10 Renal function-related traits (BUN) PAX8 intron 22797727 rs11123172 chr2 113984303 T C 9.50E-06 Urinary metabolites PAX8 intron 21572414 rs2241975 chr2 113984503 C T 5.97E-04 Colorectal cancer PAX8 intron 24836286 rs4849179 chr2 113985170 C T 6.07E-04 Premature ovarian failure PAX8 intron 19508998 rs2863243 chr2 113989267 T C 2.30E-05 Urinary metabolites PAX8 intron 21572414 rs2863244 chr2 114000866 A G 5.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs3768768 chr2 114001363 A G 2.32E-05 F-cell distribution PAX8 intron 21326311 rs4848320 chr2 114010791 C T 6.52E-05 Cognitive performance PAX8 intron 19734545 rs6734610 chr2 114017029 A G 1.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs6734610 chr2 114017029 A G 6.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs6542127 chr2 114022658 T C 9.25E-05 Chronic obstructive pulmonary disease PAX8 intron 19300482 rs6542127 chr2 114022658 T C 9.25E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs12476056 chr2 114050323 A G 7.18E-05 Personality dimensions / / 18957941 rs1191695 chr2 114083363 T C 7.20E-04 Alcohol dependence / / 20201924 rs1191680 chr2 114098412 C A 3.43E-04 Type 2 diabetes / / 17463246 rs1807281 chr2 114110054 G A 9.14E-04 Type 2 diabetes / / 17463246 rs12474753 chr2 114128721 C T 8.87E-06 Glucose levels / / pha003061 rs1823124 chr2 114136588 C A 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1968616 chr2 114136781 A G 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1968615 chr2 114137598 C A 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4848334 chr2 114137966 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4439970 chr2 114138771 T C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2121374 chr2 114142218 G A 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11123183 chr2 114145320 C T 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11123184 chr2 114145327 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6717693 chr2 114146326 C G 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11680681 chr2 114148097 C G 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10197232 chr2 114148961 T C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12711768 chr2 114154369 A G 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12711769 chr2 114154486 A G 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs13387994 chr2 114157319 G A 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7604877 chr2 114161384 C T 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1867870 chr2 114163647 A T 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899852 chr2 114260095 C T 3.91E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs761647 chr2 114273105 T C 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1597245 chr2 114448217 G C 6.25E-05 Body mass (lean) / / 19268274 rs1044836 chr2 114464777 C T 3.16E-05 Waist Circumference / / pha003023 rs3762491 chr2 114489252 G A 7.69E-08 Coronary arterial lesions in patients with Kawasaki disease SLC35F5 intron 23677057 rs12329244 chr2 114516494 A T 2.15E-04 Multiple complex diseases / / 17554300 rs17633451 chr2 114528877 T G 1.70E-04 Multiple complex diseases / / 17554300 rs17633527 chr2 114530525 C G 7.10E-04 Smoking initiation / / 24665060 rs2140263 chr2 114616865 T A 2.90E-04 Type 2 diabetes LOC100506762 intron 17463246 rs7567097 chr2 114635685 C T 6.15E-05 Alzheimer's disease (age of onset) LOC100506762 intron 22005931 rs6720853 chr2 114637231 C T 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LOC100506762 intron 23648065 rs11681425 chr2 114655601 G A 4.45E-04 Parkinson's disease ACTR3 intron 16252231 rs12618683 chr2 114672304 A G 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) ACTR3 intron 23648065 rs1825738 chr2 114708728 C T 9.80E-04 Type 2 diabetes ACTR3 intron 17463246 rs901466 chr2 114724122 C G 1.40E-05 Urinary metabolites / / 21572414 rs3912541 chr2 114725960 G A 4.87E-06 Blood Pressure / / pha003044 rs17046767 chr2 114757209 G C 1.93E-04 Bipolar disorder,schizoaffective LOC440900 intron 19567891 rs3982224 chr2 114759881 T C 6.53E-04 Acute lung injury LOC440900 intron 22295056 rs276828 chr2 114766658 G A 6.83E-04 Acute lung injury / / 22295056 rs276830 chr2 114767984 T C 8.68E-04 Acute lung injury / / 22295056 rs276835 chr2 114769417 G C 8.88E-04 Acute lung injury / / 22295056 rs276836 chr2 114770212 A G 9.16E-04 Acute lung injury / / 22295056 rs7581421 chr2 114770236 C T 7.99E-04 Acute lung injury / / 22295056 rs156726 chr2 114779558 T C 8.24E-04 Acute lung injury / / 22295056 rs156728 chr2 114780669 A G 7.85E-04 Acute lung injury / / 22295056 rs465316 chr2 114784936 A C 7.41E-04 Acute lung injury / / 22295056 rs400960 chr2 114785397 T G 7.87E-04 Acute lung injury / / 22295056 rs275419 chr2 114788869 C T 9.14E-04 Acute lung injury / / 22295056 rs1564856 chr2 114797318 T G 5.90E-04 Acute lung injury / / 22295056 rs6724135 chr2 114804521 A G 3.76E-04 Multiple complex diseases / / 17554300 rs923229 chr2 114830803 C A 3.00E-04 Acute lung injury / / 22295056 rs3912544 chr2 114840339 G T 2.82E-04 Acute lung injury / / 22295056 rs4089089 chr2 114846282 G A 2.36E-04 Acute lung injury / / 22295056 rs10460468 chr2 114851190 T C 2.36E-04 Acute lung injury / / 22295056 rs10191770 chr2 114937335 T C 9.30E-09 Mean arterial pressure / / 22510845 rs17759541 chr2 114937429 A G 7.22E-04 Smoking initiation / / 24665060 rs3132032 chr2 114979092 A T 4.86E-04 Acute lung injury / / 22295056 rs3105491 chr2 114980967 G T 2.00E-06 Systolic blood pressure in sickle cell anemia / / 24058526 rs3105489 chr2 114984090 T G 4.13E-05 Multiple complex diseases / / 17554300 rs17048253 chr2 114985292 C T 3.11E-04 Multiple complex diseases / / 17554300 rs3132039 chr2 114998082 G C 9.40E-04 Multiple complex diseases / / 17554300 rs4513299 chr2 115049818 C G 4.00E-06 Inflammatory biomarkers / / 22228203 rs6737251 chr2 115213675 T C 7.28E-05 C-Reactive Protein DPP10 intron pha003070 rs4849335 chr2 115217554 A C 6.01E-05 C-Reactive Protein DPP10 intron pha003070 rs4849336 chr2 115218922 C G 6.80E-07 Urinary metabolites DPP10 intron 21572414 rs4849337 chr2 115218975 C T 9.60E-07 Urinary metabolites DPP10 intron 21572414 rs1820924 chr2 115270207 C T 3.85E-05 Height DPP10 intron pha003011 rs10187644 chr2 115271841 C T 1.70E-04 Diabetic nephropathy DPP10 intron 20347642 rs1430108 chr2 115292826 T C 4.67E-04 Acute lung injury DPP10 intron 22295056 rs6542214 chr2 115294661 T C 1.09E-04 Acute lung injury DPP10 intron 22295056 rs4848368 chr2 115295816 G A 1.36E-04 Acute lung injury DPP10 intron 22295056 rs6741327 chr2 115303633 A T 8.29E-04 Obesity (extreme) DPP10 intron 21935397 rs6729737 chr2 115341833 G T 1.80E-05 Urinary metabolites DPP10 intron 21572414 rs17048495 chr2 115351504 T C 6.06E-04 Multiple complex diseases DPP10 intron 17554300 rs12996109 chr2 115394527 C T 3.98E-05 HDL particle features DPP10 intron pha002900 rs17783638 chr2 115408177 T C 2.73E-04 Hearing function DPP10 intron 17255346 rs17783638 chr2 115408177 T C 4.53E-04 Alzheimer's disease (late onset) DPP10 intron 21379329 rs13022574 chr2 115410964 C A 8.90E-05 Epilepsy (remission after treatment) DPP10 intron 23962720 rs17043351 chr2 115443094 T C 9.76E-04 Obesity (extreme) DPP10 intron 21935397 rs13032740 chr2 115453185 C T 8.21E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs7605779 chr2 115472604 T G 3.63E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs1435879 chr2 115492887 A G 3.05E-06 Asthma DPP10 intron 19910028 rs1435879 chr2 115492887 A G 1.02E-04 Obesity (extreme) DPP10 intron 21935397 rs11890570 chr2 115524203 T C 6.95E-05 Schizophrenia (cytomegalovirus infection interaction) DPP10 intron 23358160 rs319857 chr2 115530826 A G 6.67E-05 Blood Pressure DPP10 intron pha003045 rs12711807 chr2 115569596 C A 0.000043 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs12476637 chr2 115570313 C T 0.0000663 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs2420449 chr2 115573050 A G 8.17E-06 Neutrophil count DPP10 intron pha003095 rs12999750 chr2 115576519 A G 0.0000263 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs2102901 chr2 115578511 C G 0.0000364 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs6732028 chr2 115586939 A G 3.00E-06 Obesity-related traits DPP10 intron 23251661 rs1879124 chr2 115613577 A G 1.36E-05 Cardiovascular disease DPP10 intron pha003065 rs13007523 chr2 115622199 G A 5.78E-05 Celiac disease DPP10 intron 23936387 rs13000828 chr2 115638290 G A 1.40E-04 Celiac disease DPP10 intron 23936387 rs980316 chr2 115710826 T C 4.00E-04 Asthma DPP10 intron 19910030 rs980316 chr2 115710826 T C 3.66E-04 Myopia (pathological) DPP10 intron 21095009 rs980316 chr2 115710826 T C 5.08E-06 Inflammation DPP10 intron pha002897 rs980317 chr2 115710936 T C 1.60E-04 Asthma DPP10 intron 19910030 rs7421482 chr2 115716385 G T 2.70E-04 Asthma DPP10 intron 19910030 rs2175176 chr2 115720896 G T 6.55E-04 Myopia (pathological) DPP10 intron 21095009 rs12469474 chr2 115723034 G A 4.50E-04 Asthma DPP10 intron 19910030 rs1396932 chr2 115741748 A C 3.39E-04 Myopia (pathological) DPP10 intron 21095009 rs949577 chr2 115743547 A G 4.10E-04 Asthma DPP10 intron 19910030 rs949577 chr2 115743547 A G 8.34E-04 Stroke DPP10 intron pha002887 rs17043899 chr2 115757709 G T 6.11E-04 White matter integrity DPP10 intron 22425255 rs966859 chr2 115828493 T C 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs10167935 chr2 115855507 C T 2.10E-06 Urinary metabolites DPP10 intron 21572414 rs4624391 chr2 115871266 A C 8.50E-06 Urinary metabolites DPP10 intron 21572414 rs958457 chr2 115897734 G A 9.71E-05 Serum metabolites DPP10 intron 19043545 rs17687793 chr2 115908178 T C 2.80E-05 Diabetic retinopathy DPP10 intron 21441570 rs17636812 chr2 115914194 A G 2.80E-05 Diabetic retinopathy DPP10 intron 21441570 rs11123288 chr2 115964006 G A 4.79E-04 Multiple complex diseases DPP10 intron 17554300 rs13386690 chr2 116023110 A G 5.14E-05 Multiple complex diseases DPP10 intron 17554300 rs11885726 chr2 116086938 C T 2.70E-05 Urinary metabolites DPP10 intron 21572414 rs10496489 chr2 116110269 A G 1.60E-05 Urinary metabolites DPP10 intron 21572414 rs17823359 chr2 116118583 G A 1.00E-05 Urinary metabolites DPP10 intron 21572414 rs17044256 chr2 116126879 T C 4.93E-04 Multiple complex diseases DPP10 intron 17554300 rs12478263 chr2 116145068 T A 1.60E-05 Urinary metabolites DPP10 intron 21572414 rs9308712 chr2 116148108 A G 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs9308712 chr2 116148108 A G 7.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs13022199 chr2 116154002 G A 8.94E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs6542260 chr2 116163121 C T 1.80E-05 Urinary metabolites DPP10 intron 21572414 rs2677290 chr2 116164570 C G 5.46E-09 Narcolepsy DPP10 intron 19629137 rs1717038 chr2 116165658 C T 1.40E-05 Urinary metabolites DPP10 intron 21572414 rs1717040 chr2 116168800 T C 1.37E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1402446 chr2 116169391 A G 1.36E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843393 chr2 116173796 G A 1.17E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843390 chr2 116175152 G C 1.16E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs11675299 chr2 116177551 A G 4.28E-04 Multiple complex diseases DPP10 intron 17554300 rs843385 chr2 116177579 T C 1.20E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843394 chr2 116188083 T G 1.34E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs7581748 chr2 116188604 A T 2.06E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1717054 chr2 116189549 C T 1.37E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1712005 chr2 116189892 G A 1.38E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs708647 chr2 116197757 G A 3.01E-05 Multiple complex diseases DPP10 intron 17554300 rs1517368 chr2 116230314 G T 1.43E-04 Multiple complex diseases DPP10 intron 17554300 rs11123306 chr2 116231781 A G 2.78E-06 Multiple complex diseases DPP10 intron 17554300 rs1375144 chr2 116241186 G A 2.43E-06 Multiple complex diseases DPP10 intron 17554300 rs1375144 chr2 116241186 G A 2.00E-06 Bipolar disorder DPP10 intron 21254220 rs2421104 chr2 116242265 G T 9.53E-06 Multiple complex diseases DPP10 intron 17554300 rs10496495 chr2 116243444 T C 2.42E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs17362720 chr2 116254100 G A 6.20E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs34559324 chr2 116255490 G A 1.89E-04 Multiple complex diseases DPP10 intron 17554300 rs6712054 chr2 116257658 C T 6.22E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs2166906 chr2 116261081 C T 2.14E-04 Multiple complex diseases DPP10 intron 17554300 rs7421696 chr2 116261143 C T 2.33E-04 Multiple complex diseases DPP10 intron 17554300 rs4538209 chr2 116261292 T G 2.64E-04 Multiple complex diseases DPP10 intron 17554300 rs13002945 chr2 116261621 A G 2.05E-04 Multiple complex diseases DPP10 intron 17554300 rs17044597 chr2 116267032 G A 2.95E-04 Multiple complex diseases DPP10 intron 17554300 rs17044605 chr2 116277985 A G 2.22E-04 Multiple complex diseases DPP10 intron 17554300 rs984066 chr2 116283668 G A 3.27E-04 Multiple complex diseases DPP10 intron 17554300 rs4849404 chr2 116284135 T C 3.23E-04 Multiple complex diseases DPP10 intron 17554300 rs4849406 chr2 116301591 G A 1.90E-04 Multiple complex diseases DPP10 intron 17554300 rs6741692 chr2 116303931 C G 4.64E-06 Multiple complex diseases DPP10 intron 17554300 rs6738130 chr2 116327375 C T 5.15E-04 Multiple complex diseases DPP10 intron 17554300 rs17454262 chr2 116366107 T C 2.85E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs17044776 chr2 116370016 A G 9.22E-05 Multiple complex diseases DPP10 intron 17554300 rs4849413 chr2 116373882 T C 1.30E-04 Multiple complex diseases DPP10 intron 17554300 rs13012337 chr2 116396780 A G 3.26E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs7568150 chr2 116422900 C A 9.80E-04 Multiple complex diseases DPP10 intron 17554300 rs7593933 chr2 116422975 G A 9.84E-04 Multiple complex diseases DPP10 intron 17554300 rs4075701 chr2 116429790 T C 1.63E-05 Blood Pressure and Arterial Stiffness DPP10 intron 17903302 rs10173996 chr2 116467283 T G 4.22E-04 Multiple complex diseases DPP10 intron 17554300 rs4849421 chr2 116473019 A T 4.93E-04 Multiple complex diseases DPP10 intron 17554300 rs13019180 chr2 116481940 T C 7.54E-05 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs12621324 chr2 116484040 G A 9.57E-06 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs13033400 chr2 116486451 G A 7.76E-05 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs1545359 chr2 116494716 A G 7.01E-04 Multiple complex diseases DPP10 intron 17554300 rs2901396 chr2 116517742 A G 2.00E-04 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs1374271 chr2 116534922 A G 1.15E-04 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs1374268 chr2 116548326 G A 9.27E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs6735355 chr2 116548526 A G 3.24E-04 Multiple complex diseases DPP10 intron 17554300 rs17044974 chr2 116550715 T G 4.23E-04 Multiple complex diseases DPP10 intron 17554300 rs736335 chr2 116594221 G C 6.38E-04 Acute lung injury DPP10 intron 22295056 rs272038 chr2 116635862 T C 9.36E-06 Coronary heart disease / / pha003033 rs272020 chr2 116644461 C T 2.22E-05 Coronary heart disease / / pha003033 rs272000 chr2 116655795 G C 9.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs11890985 chr2 116668062 G A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7581538 chr2 116669356 G A 5.16E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1447241 chr2 116696434 C T 4.11E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1447241 chr2 116696434 C T 7.79E-04 Stroke / / pha002887 rs17045635 chr2 116932105 C T 8.76E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7598656 chr2 116968121 C T 4.33E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2035324 chr2 116968656 T C 4.54E-05 Bipolar disorder / / 19488044 rs2010823 chr2 116976066 C T 9.25E-05 Erythrocyte counts / / pha003099 rs6735305 chr2 117054882 T C 6.27E-05 Erythrocyte counts / / pha003099 rs10496515 chr2 117071213 T C 3.92E-05 Alcohol and nictotine co-dependence / / 20158304 rs10496515 chr2 117071213 T C 6.59E-05 Erythrocyte counts / / pha003099 rs7586235 chr2 117080187 T C 2.31E-04 Multiple complex diseases / / 17554300 rs6751658 chr2 117100160 A G 7.66E-05 Partial epilepsies / / 20522523 rs11123348 chr2 117126557 G A 7.03E-05 Partial epilepsies / / 20522523 rs11674077 chr2 117147179 C G 3.39E-04 Type 2 diabetes / / 17463246 rs10864945 chr2 117154934 C T 1.86E-04 Type 2 diabetes / / 17463246 rs4849472 chr2 117179890 G T 2.81E-04 Type 2 diabetes / / 17463246 rs4849476 chr2 117183690 T C 9.14E-04 Type 2 diabetes / / 17463246 rs1388407 chr2 117183853 C T 3.57E-04 Type 2 diabetes / / 17463246 rs17045920 chr2 117183972 G A 1.44E-04 Type 2 diabetes / / 17463246 rs17550669 chr2 117197204 C T 9.48E-06 Bipolar disorder / / 20451256 rs2421599 chr2 117231442 A G 1.91E-05 Body Mass Index / / pha003014 rs2901472 chr2 117231705 C A 1.44E-05 Body Mass Index / / pha003014 rs2901472 chr2 117231705 C A 9.62E-05 Waist Circumference / / pha003024 rs2421604 chr2 117254763 G A 7.57E-04 Aortic root size / / 21223598 rs10208988 chr2 117258826 G C 5.12E-04 Aortic root size / / 21223598 rs10208991 chr2 117258847 G T 6.74E-04 Aortic root size / / 21223598 rs7597707 chr2 117259370 A G 4.85E-04 Aortic root size / / 21223598 rs1948365 chr2 117259824 G C 4.28E-04 Aortic root size / / 21223598 rs2421608 chr2 117297533 T A 1.80E-05 Biomarkers / / 17903293 rs6542326 chr2 117307471 T G 5.81E-04 Multiple complex diseases / / 17554300 rs17046130 chr2 117316787 C G 5.82E-04 Multiple complex diseases / / 17554300 rs1442772 chr2 117352829 G A 1.70E-04 Multiple complex diseases / / 17554300 rs7604050 chr2 117420021 A G 7.54E-04 Parkinson's disease / / 17052657 rs7584028 chr2 117473782 T C 3.38E-05 Lactate dehydrogenase levels / / 20981236 rs6705249 chr2 117521855 A G 6.75E-05 Postoperative ventricular dysfunction / / 21980348 rs11674647 chr2 117695131 G C 2.10E-05 Urinary metabolites / / 21572414 rs4305291 chr2 117721773 A G 6.51E-04 Multiple complex diseases / / 17554300 rs6726455 chr2 117822575 C T 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1437434 chr2 117844244 A G 2.71E-04 Body mass index / / 17255346 rs17046639 chr2 117846628 T C 5.59E-04 Multiple complex diseases / / 17554300 rs332880 chr2 117867857 C T 9.26E-05 LDL lipoproteins / / pha002902 rs332925 chr2 117899586 T C 2.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2035171 chr2 117911357 A G 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2035171 chr2 117911357 A G 3.62E-04 Rheumatoid arthritis / / 21452313 rs10192798 chr2 117912256 A C 3.89E-04 Alzheimer's disease / / 24755620 rs332885 chr2 117922305 G A 5.02E-04 Alzheimer's disease / / 24755620 rs6725378 chr2 117922791 C G 9.91E-04 Multiple complex diseases / / 17554300 rs17046690 chr2 117937229 C A 6.29E-04 Multiple complex diseases / / 17554300 rs1350986 chr2 117941086 G A 7.96E-04 Alzheimer's disease / / 24755620 rs7578803 chr2 117944522 A G 5.28E-04 Alzheimer's disease / / 24755620 rs10179218 chr2 117946885 C A 0.000000774 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs10179218 chr2 117946885 C A 1.85E-08 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs10179218 chr2 117946885 C A 1.85E-08 Airflow obstruction / / 22837378 rs1869309 chr2 118067708 G A 1.39E-04 Multiple complex diseases / / 17554300 rs10496537 chr2 118081209 A C 4.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10496537 chr2 118081209 A C 7.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4849549 chr2 118101770 G A 3.00E-04 Multiple complex diseases / / 17554300 rs6742148 chr2 118103005 C A 9.30E-04 Multiple complex diseases / / 17554300 rs4308131 chr2 118110978 C T 2.74E-04 Multiple complex diseases / / 17554300 rs10177579 chr2 118111305 C A 9.84E-04 Multiple complex diseases / / 17554300 rs334826 chr2 118131773 C T 5.52E-04 Multiple complex diseases / / 17554300 rs334828 chr2 118132313 C G 5.50E-04 Multiple complex diseases / / 17554300 rs334829 chr2 118132332 T C 8.48E-04 Multiple complex diseases / / 17554300 rs334830 chr2 118132422 A G 7.60E-04 Multiple complex diseases / / 17554300 rs6723614 chr2 118138788 A G 3.85E-04 Multiple complex diseases / / 17554300 rs2138480 chr2 118142725 A G 1.19E-04 Cholesterol / / 17255346 rs1516236 chr2 118148428 C T 8.17E-04 Multiple complex diseases / / 17554300 rs1400127 chr2 118152277 G C 8.84E-04 Multiple complex diseases / / 17554300 rs2421933 chr2 118152322 G A 9.51E-04 Multiple complex diseases / / 17554300 rs1516240 chr2 118152405 A G 7.15E-04 Multiple complex diseases / / 17554300 rs6754148 chr2 118153550 G A 9.84E-04 Multiple complex diseases / / 17554300 rs1516232 chr2 118157316 T G 1.13E-04 Cholesterol / / 17255346 rs1356216 chr2 118162561 T G 4.61E-05 Cholesterol / / 17255346 rs2901595 chr2 118178076 A T 7.32E-04 Acute lung injury / / 22295056 rs6753313 chr2 118180523 T C 5.26E-05 Cholesterol / / 17255346 rs6706581 chr2 118181078 G A 3.63E-04 Multiple complex diseases / / 17554300 rs2421931 chr2 118181548 T C 1.80E-04 Cholesterol / / 17255346 rs6760213 chr2 118187490 T C 0.0000997 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1996290 chr2 118195566 G T 0.0000713 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11884677 chr2 118196387 G A 3.01E-04 Multiple complex diseases / / 17554300 rs6741941 chr2 118197899 C A 0.0000735 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6745193 chr2 118198312 C A,T 0.0000373 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2421930 chr2 118201104 C G 1.56E-04 Multiple complex diseases / / 17554300 rs1581200 chr2 118203404 G A 0.0000753 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6542370 chr2 118205154 A T 0.0000742 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4337486 chr2 118205547 T C 0.0000957 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs949917 chr2 118207795 G A 4.92E-04 Multiple complex diseases / / 17554300 rs6716125 chr2 118211048 C T 0.0000734 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4410306 chr2 118212353 T C 1.50E-04 Multiple complex diseases / / 17554300 rs6706078 chr2 118213631 C T 0.0000788 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6542373 chr2 118214397 C T 0.0000764 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1121106 chr2 118223350 A G 4.47E-04 Multiple complex diseases / / 17554300 rs290890 chr2 118255036 A G 2.51E-04 Multiple complex diseases / / 17554300 rs11892804 chr2 118272407 G T 4.17E-04 Multiple complex diseases / / 17554300 rs4849561 chr2 118274002 T C 4.35E-04 Coronary heart disease / / 21606135 rs1515991 chr2 118279545 C T 8.12E-08 Metabolite levels / / 23281178 rs7606639 chr2 118280239 G C 4.41E-04 Multiple complex diseases / / 17554300 rs10496542 chr2 118280812 C G 6.59E-04 Multiple complex diseases / / 17554300 rs1515993 chr2 118281020 G C 5.48E-04 Multiple complex diseases / / 17554300 rs17766363 chr2 118314622 C T 2.65E-04 Cholesterol / / 17255346 rs17766737 chr2 118318454 G A 5.92E-05 Cholesterol / / 17255346 rs1606944 chr2 118355063 C A 7.21E-05 Multiple complex diseases / / 17554300 rs1515998 chr2 118356097 A T 1.73E-04 Multiple complex diseases / / 17554300 rs13034275 chr2 118364695 A G 1.10E-06 Iron levels / / 21208937 rs3849326 chr2 118371828 A G 7.73E-04 Multiple complex diseases / / 17554300 rs2244671 chr2 118396232 A G 2.00E-04 Information processing speed / / 21130836 rs10490637 chr2 118416015 G A 9.74E-05 Blood Pressure / / pha003045 rs10490637 chr2 118416015 G A 2.43E-05 Blood Pressure / / pha003047 rs17047229 chr2 118422427 G A 8.22E-04 Multiple complex diseases / / 17554300 rs12475536 chr2 118448025 C T 4.94E-06 Blood Pressure / / pha003045 rs12475536 chr2 118448025 C T 3.34E-06 Blood Pressure / / pha003047 rs1477450 chr2 118448486 G A 2.06E-07 Schizophrenia / / 22037555 rs918860 chr2 118455405 G A 6.77E-06 Blood Pressure / / pha003045 rs918860 chr2 118455405 G A 1.69E-06 Blood Pressure / / pha003047 rs999496 chr2 118468300 G A 3.17E-06 Blood Pressure / / pha003045 rs999496 chr2 118468300 G A 7.96E-07 Blood Pressure / / pha003047 rs4849613 chr2 118474016 C T 7.20E-05 LDL lipoproteins / / pha002902 rs12477316 chr2 118484690 C T 6.29E-06 Blood Pressure / / pha003045 rs12477316 chr2 118484690 C T 4.36E-06 Blood Pressure / / pha003047 rs7579150 chr2 118485871 G A 6.29E-06 Blood Pressure / / pha003045 rs7579150 chr2 118485871 G A 4.36E-06 Blood Pressure / / pha003047 rs10490635 chr2 118486980 G A 7.19E-05 Multiple complex diseases / / 17554300 rs6753213 chr2 118491813 G A 2.05E-04 Coronary heart disease / / 21606135 rs1433527 chr2 118534387 C A 5.10E-05 Volumetric brain MRI / / 17903297 rs2422047 chr2 118535538 A G 9.42E-05 Waist-Hip Ratio / / pha003029 rs41385550 chr2 118549036 A C 8.00E-04 Multiple complex diseases / / 17554300 rs7581935 chr2 118557033 G T 9.79E-04 Stroke / / pha002886 rs6737733 chr2 118575468 C T 4.70E-04 Multiple complex diseases DDX18 intron 17554300 rs6737733 chr2 118575468 C T 8.11E-05 Schizophrenia DDX18 intron 19197363 rs6737733 chr2 118575468 C T 2.84E-05 Lymphocyte counts DDX18 intron 22286170 rs17508045 chr2 118576719 T C 6.49E-05 Cognitive impairment induced by topiramate DDX18 intron 22091778 rs6731372 chr2 118586360 G A 5.94E-04 Parkinson's disease DDX18 intron 16252231 rs9973563 chr2 118596118 G C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6718141 chr2 118597049 A G 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6542399 chr2 118601340 A G 3.10E-06 Urinary metabolites / / 21572414 rs6712766 chr2 118611789 G A 8.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1072231 chr2 118634348 T C 4.20E-07 Urinary metabolites / / 21572414 rs6739723 chr2 118666956 T C 3.75E-04 Type 2 diabetes / / 17463246 rs13020654 chr2 118679847 C T 8.77E-04 Alzheimer's disease CCDC93 intron 22005930 rs17583214 chr2 118702952 G C 8.93E-04 Alzheimer's disease CCDC93 intron 22005930 rs7589588 chr2 118711354 C T 8.97E-04 Alzheimer's disease CCDC93 intron 22005930 rs4142224 chr2 118716190 C T 1.83E-04 Alcohol dependence CCDC93 intron 21314694 rs10490628 chr2 118730290 C T 4.19E-04 Smoking initiation CCDC93 intron 24665060 rs10173849 chr2 118765370 C A 5.94E-04 Smoking initiation CCDC93 intron 24665060 rs6542423 chr2 118771872 T C 1.86E-04 Multiple complex diseases / / 17554300 rs1547999 chr2 118778628 A G 9.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17047645 chr2 118797340 T C 1.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17047648 chr2 118804752 T C 2.99E-04 Multiple complex diseases / / 17554300 rs1808457 chr2 118820268 T C 2.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1808457 chr2 118820268 T C 2.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17586455 chr2 118825726 T A 8.04E-04 Alzheimer's disease / / 22005930 rs17047697 chr2 118827810 G A 1.90E-06 Urinary metabolites / / 21572414 rs4849674 chr2 118827859 A G 3.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4849674 chr2 118827859 A G 9.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10490626 chr2 118835841 G A 2.00E-12 LDL cholesterol / / 24097068 rs10490626 chr2 118835841 G A 6.00E-09 Cholesterol,total / / 24097068 rs7566605 chr2 118836025 C G 7.43E-04 Type 2 diabetes / / 17463246 rs17047733 chr2 118841325 T C 2.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17047733 chr2 118841325 T C 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464355 chr2 118849850 A G 1.19E-08 Cholesterol,total INSIG2 intron 23063622 rs17528324 chr2 118856156 G A 4.13E-06 Migraine INSIG2 intron 20802479 rs11889497 chr2 118862464 T G 4.27E-05 Suicide attempts in bipolar disorder INSIG2 intron 21423239 rs13409050 chr2 118863770 G A 4.18E-05 Suicide attempts in bipolar disorder INSIG2 intron 21423239 rs11902948 chr2 118871510 T C 6.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs10207953 chr2 118871901 T C 3.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2113485 chr2 118874146 G A 4.42E-04 Heart Failure / / pha002885 rs11673894 chr2 118876072 G T 9.71E-05 Chronic obstructive pulmonary disease / / 19300482 rs11673894 chr2 118876072 G T 9.71E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11673894 chr2 118876072 G T 5.15E-04 Alzheimer's disease / / 22005930 rs17047778 chr2 118878300 A G 7.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs13396907 chr2 118880093 G A 5.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs13390830 chr2 118880329 T C 7.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs17047787 chr2 118881068 G A 8.20E-05 Suicide attempts in bipolar disorder / / 21423239 rs10168587 chr2 118884724 T C 5.02E-04 Multiple complex diseases / / 17554300 rs17047801 chr2 118887503 C T 5.11E-05 Cervical cancer / / 24700089 rs6726538 chr2 118889229 T A 3.00E-06 Cervical cancer / / 24700089 rs17047805 chr2 118891996 C T 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200637 chr2 118892254 G A 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17047806 chr2 118892531 G A 5.00E-05 Cognitive function / / 24684796 rs4084828 chr2 118893347 C T 0.0005858 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4084828 chr2 118893347 C T 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11123477 chr2 118927760 C T 0.000185 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs12613995 chr2 118986516 T C 4.60E-04 Multiple complex diseases / / 17554300 rs10864971 chr2 119000652 C T 8.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2422239 chr2 119029079 G A 2.54E-07 Primary biliary cirrhosis / / 23000144 rs2422239 chr2 119029079 G A 0.000000254 Facial morphology / / 23028347 rs4077791 chr2 119037954 G A 3.31E-04 Height / / 17255346 rs1878526 chr2 119038598 G A 1.00E-10 Bone mineral density / / 22504420 rs2422241 chr2 119043036 G A 9.23E-08 Primary biliary cirrhosis / / 23000144 rs2422241 chr2 119043036 G A 9.22E-08 Facial morphology / / 23028347 rs9308765 chr2 119043209 G A 5.10E-05 Kidney function and endocine traits / / 17903292 rs12622690 chr2 119086841 C T 0.0005542 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12622690 chr2 119086841 C T 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12986939 chr2 119089007 G A 0.0005452 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12986939 chr2 119089007 G A 5.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13400406 chr2 119104699 T C 6.80E-05 Creatinine levels / / pha003069 rs4276037 chr2 119104977 G A 0.00001152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4276037 chr2 119104977 G A 4.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4560125 chr2 119106057 A G 2.54E-05 Creatinine levels / / pha003069 rs12711904 chr2 119107986 A T 0.0004636 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12711904 chr2 119107986 A T 4.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4128289 chr2 119108415 A G 0.0004724 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4128289 chr2 119108415 A G 4.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7587899 chr2 119108916 A G 0.0004975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7587899 chr2 119108916 A G 4.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4613284 chr2 119110676 A G 0.0005538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4613284 chr2 119110676 A G 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs566437806 chr2 119110676 AT A 0.0005538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs566437806 chr2 119110676 AT A 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4849697 chr2 119110846 A G 9.41E-05 Creatinine levels / / pha003069 rs4594452 chr2 119112560 C T 4.95E-05 Creatinine levels / / pha003069 rs4470352 chr2 119113791 G C 0.0006135 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4470352 chr2 119113791 G C 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4470353 chr2 119113876 G A 0.0006341 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4470353 chr2 119113876 G A 6.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4641945 chr2 119124162 C T 0.0007785 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4641945 chr2 119124162 C T 7.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12467546 chr2 119129071 A G 0.0008588 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12467546 chr2 119129071 A G 8.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6542456 chr2 119138025 A G 2.90E-05 Urinary metabolites / / 21572414 rs6708595 chr2 119147509 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6708595 chr2 119147509 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6708595 chr2 119147509 G T 4.75E-06 Creatinine levels / / pha003069 rs7599033 chr2 119150692 C T 1.47E-05 Aging (time to event) / / 21782286 rs4073566 chr2 119161638 C A 0.0000861 Percentage fat mass / / 23436924 rs6711863 chr2 119166256 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6711863 chr2 119166256 C T 3.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs1437690 chr2 119218881 C T 5.02E-04 Prostate cancer mortality / / 20978177 rs1965130 chr2 119220906 T C 0.000177 Salmonella-induced pyroptosis / / 22837397 rs1370509 chr2 119269428 C T 2.85E-04 Smoking cessation / / 24665060 rs12711907 chr2 119272649 T C 6.97E-04 Smoking cessation / / 24665060 rs1000950 chr2 119279230 A C 4.09E-04 Smoking cessation / / 24665060 rs7594303 chr2 119279975 C T 5.83E-04 Smoking cessation / / 24665060 rs6758889 chr2 119284856 A G 6.44E-04 Smoking cessation / / 24665060 rs1437684 chr2 119286308 T C 9.78E-05 Smoking cessation / / 24665060 rs11674141 chr2 119293076 C T 1.00E-05 Urinary metabolites / / 21572414 rs7571800 chr2 119296554 C T 7.50E-04 Smoking cessation / / 24665060 rs7598288 chr2 119297173 G A 4.20E-06 Urinary metabolites / / 21572414 rs7601764 chr2 119297984 G A 1.40E-05 Urinary metabolites / / 21572414 rs7601764 chr2 119297984 G A 6.51E-04 Smoking cessation / / 24665060 rs6733132 chr2 119305178 C T 4.60E-05 Serum metabolites / / 19043545 rs6733132 chr2 119305178 C T 1.90E-06 Urinary metabolites / / 21572414 rs4849710 chr2 119307659 G A 7.65E-04 Type 2 diabetes / / 17463246 rs4849710 chr2 119307659 G A 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10427226 chr2 119315217 G C 8.60E-07 Urinary metabolites / / 21572414 rs10496549 chr2 119327151 A G 5.34E-04 Multiple complex diseases / / 17554300 rs7604059 chr2 119331523 A G 1.10E-06 Urinary metabolites / / 21572414 rs1437689 chr2 119335378 T C 9.84E-04 Type 2 diabetes / / 17463246 rs536979 chr2 119343455 T C 3.65E-04 Self-reported allergy / / 23817569 rs13017945 chr2 119344750 C T 7.59E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs511923 chr2 119345850 G A 2.97E-04 Self-reported allergy / / 23817569 rs538554 chr2 119359591 A G 3.30E-04 Self-reported allergy / / 23817569 rs651477 chr2 119395691 T C 7.00E-06 Multiple sclerosis / / 19010793 rs162679 chr2 119407150 T C 8.86E-04 White matter integrity / / 22425255 rs11891602 chr2 119424298 A C 3.90E-06 Urinary metabolites / / 21572414 rs17050305 chr2 119462837 T C 1.99E-05 Multiple complex diseases / / 17554300 rs455682 chr2 119469401 G A 8.47E-04 Multiple complex diseases / / 17554300 rs1551133 chr2 119536884 C A 2.38E-05 Chronic obstructive pulmonary disease / / 19300482 rs1551133 chr2 119536884 C A 8.63E-04 Schizophrenia / / 21747397 rs4849721 chr2 119544022 G T 4.50E-05 Iron levels / / 21208937 rs41466144 chr2 119553132 G A 5.80E-05 Cognitive function / / 24684796 rs4849724 chr2 119568625 G C 6.28E-04 Multiple complex diseases / / 17554300 rs6759783 chr2 119639040 A G 8.22E-04 Type 2 diabetes / / 17463246 rs6759783 chr2 119639040 A G 9.14E-04 Multiple complex diseases / / 17554300 rs2083244 chr2 119661221 T C 3.23E-05 Melanoma / / 21926416 rs4849731 chr2 119661546 G A 1.44E-04 Multiple complex diseases / / 17554300 rs41408750 chr2 119665464 G A 4.32E-04 Insulin resistance / / 21901158 rs1898705 chr2 119665962 G A 2.84E-04 Schizophrenia / / 19197363 rs1898705 chr2 119665962 G A 1.76E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs11693199 chr2 119732042 T C 2.86E-05 Triglycerides MARCO intron pha003080 rs1371562 chr2 119732948 G T 3.23E-05 Triglycerides MARCO intron pha003080 rs3731611 chr2 119742611 G T 9.70E-07 Non-obstructive azoospermia MARCO intron 22541561 rs12987402 chr2 119748796 C T 7.76E-04 Type 2 diabetes MARCO intron 17463246 rs7573929 chr2 119764127 C A 1.15E-04 Multiple complex diseases / / 17554300 rs1124830 chr2 119764462 G C 5.81E-04 Type 2 diabetes / / 17463246 rs1124830 chr2 119764462 G C 4.80E-05 Cognitive function / / 24684796 rs13031336 chr2 119765265 C T 9.09E-05 Insulin resistance / / 21901158 rs6542491 chr2 119765660 C G 7.40E-05 Cognitive function / / 24684796 rs17010531 chr2 119781128 G C 2.16E-04 Multiple complex diseases / / 17554300 rs111583672 chr2 119784066 A AG 8.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2422392 chr2 119798273 A G 9.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12479083 chr2 119809478 A T 1.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13410962 chr2 119812759 C T 6.56E-04 Smoking initiation / / 24665060 rs17011073 chr2 119814011 A G 6.27E-05 Panic disorder / / 19165232 rs12616925 chr2 119826388 A G 4.93E-04 Multiple complex diseases / / 17554300 rs1439950 chr2 119827462 G A 9.48E-04 Multiple complex diseases / / 17554300 rs17189298 chr2 119845317 G A 3.00E-07 T-tau levels / / 20932310 rs330763 chr2 119864163 A G 0.000511492 Hypertension (early onset hypertension) / / 22479346 rs330768 chr2 119865356 C T 2.70E-05 Urinary metabolites / / 21572414 rs895403 chr2 119868412 A C 4.73E-04 Multiple complex diseases / / 17554300 rs921047 chr2 119870766 G A 1.80E-05 Urinary metabolites / / 21572414 rs11674898 chr2 119879640 C T 9.25E-04 Response to TNF antagonist treatment / / 21061259 rs7557802 chr2 119894965 C T 3.61E-04 Depression (quantitative trait) / / 20800221 rs7597287 chr2 119903969 G C 1.98E-05 Cocaine dependence / / 23958962 rs13020121 chr2 119904953 G A 4.08E-06 Cocaine dependence / / 23958962 rs13020121 chr2 119904953 G A 5.37E-04 Cocaine dependence / / 23958962 rs745884 chr2 119909385 C A 3.74E-05 Cocaine dependence / / 23958962 rs745888 chr2 119910314 C T 6.30E-05 Cocaine dependence / / 23958962 rs745888 chr2 119910314 C T 6.63E-05 Stroke / / pha002887 rs6758051 chr2 119914101 T G 5.10E-06 Cocaine dependence C1QL2 UTR-3 23958962 rs7579840 chr2 119921881 A G 1.96E-05 Multiple complex diseases / / 17554300 rs7584975 chr2 119942569 C T 5.74E-05 Lymphocyte counts / / pha003094 rs11123504 chr2 119942886 G A 1.46E-04 Alcohol dependence / / 21314694 rs4849770 chr2 119957026 G A 1.88E-04 Alcohol dependence / / 21314694 rs838090 chr2 119997159 T C 3.96E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs838086 chr2 120001502 C A 3.44E-05 Cognitive test performance STEAP3 intron 20125193 rs17805141 chr2 120005569 C T 1.84E-05 Cocaine dependence STEAP3 cds-synon 23958962 rs734846 chr2 120008556 T G 6.09E-04 Depression (quantitative trait) STEAP3 intron 20800221 rs734845 chr2 120008735 A C 6.06E-04 Depression (quantitative trait) STEAP3 intron 20800221 rs895406 chr2 120009220 C T 9.78E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs895405 chr2 120009327 C G,T 2.94E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs72840936 chr2 120023692 G C 3.00E-06 Cocaine dependence / / 23958962 rs3816343 chr2 120063684 C T 2.00E-04 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs7578714 chr2 120096359 T C 0.000161045 Hypertension (early onset hypertension) C2orf76 intron 22479346 rs11893035 chr2 120121834 T C 9.22E-05 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs12613135 chr2 120122340 T C 9.22E-05 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs3731607 chr2 120125058 C T 0.00068 Prostate cancer DBI missense 23555315 rs956309 chr2 120128482 C T 1.64E-04 Schizophrenia DBI intron 24043878 rs1374313 chr2 120145655 T C 9.00E-07 Obesity-related traits / / 23251661 rs2422465 chr2 120166000 G A 7.40E-06 Urinary metabolites / / 21572414 rs2579643 chr2 120217456 T C 3.08E-05 Post-operative nausea and vomiting SCTR intron 21694509 rs17016143 chr2 120226549 T G 1.19E-04 Multiple complex diseases SCTR intron 17554300 rs2918939 chr2 120226922 G A 8.40E-04 Suicide attempts in bipolar disorder SCTR intron 21423239 rs10200558 chr2 120264821 G A 9.86E-04 Multiple complex diseases SCTR intron 17554300 rs2579612 chr2 120271783 C T 1.14E-06 Hepatitis B SCTR intron 24162738 rs2579621 chr2 120294700 A C 7.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2587695 chr2 120321817 A G 9.69E-04 Multiple complex diseases PCDP1 intron 17554300 rs2587695 chr2 120321817 A G 3.00E-07 Attention deficit hyperactivity disorder PCDP1 intron 18839057 rs4586634 chr2 120328072 C A 1.21E-04 Type 2 diabetes PCDP1 intron 22158537 rs7596441 chr2 120329410 C G 1.30E-04 Type 2 diabetes PCDP1 intron 22158537 rs11676752 chr2 120330571 T A 5.24E-04 Multiple complex diseases PCDP1 intron 17554300 rs721791 chr2 120335484 A C 2.83E-05 Type 2 diabetes PCDP1 intron 22158537 rs17049444 chr2 120337094 A G 1.29E-04 Type 2 diabetes PCDP1 intron 22158537 rs6706143 chr2 120338999 C T 1.36E-04 Type 2 diabetes PCDP1 intron 22158537 rs4340526 chr2 120339740 A C 2.94E-05 Type 2 diabetes PCDP1 intron 22158537 rs13403341 chr2 120342697 G C 3.63E-05 Type 2 diabetes PCDP1 intron 22158537 rs11684429 chr2 120343559 G C 1.18E-04 Type 2 diabetes PCDP1 intron 22158537 rs10187631 chr2 120343832 G A 1.38E-04 Type 2 diabetes PCDP1 intron 22158537 rs6726971 chr2 120344873 T A 1.42E-04 Type 2 diabetes PCDP1 intron 22158537 rs10189169 chr2 120346507 T C 1.02E-04 Type 2 diabetes PCDP1 intron 22158537 rs17049538 chr2 120346763 C T 1.31E-04 Type 2 diabetes PCDP1 intron 22158537 rs17049543 chr2 120347102 A G 1.43E-04 Type 2 diabetes PCDP1 intron 22158537 rs2001656 chr2 120347226 G A,C 3.23E-05 Type 2 diabetes PCDP1 intron 22158537 rs11123528 chr2 120348676 G A 6.24E-05 Type 2 diabetes PCDP1 intron 22158537 rs11681601 chr2 120348766 C G 1.47E-04 Type 2 diabetes PCDP1 intron 22158537 rs4260253 chr2 120350266 A G 1.37E-04 Type 2 diabetes PCDP1 intron 22158537 rs4480991 chr2 120350391 C T 1.35E-04 Type 2 diabetes PCDP1 intron 22158537 rs6756018 chr2 120355007 G A 1.49E-04 Type 2 diabetes PCDP1 intron 22158537 rs2860875 chr2 120364042 T C 1.72E-04 Type 2 diabetes PCDP1 intron 22158537 rs13004936 chr2 120401427 T A 1.03E-04 Type 2 diabetes PCDP1 intron 22158537 rs939775 chr2 120408400 T C 1.04E-04 Type 2 diabetes PCDP1 intron 22158537 rs1521911 chr2 120409351 C T 1.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCDP1 intron 20877124 rs1521911 chr2 120409351 C T 9.38E-05 Type 2 diabetes PCDP1 intron 22158537 rs11686014 chr2 120409616 G T 1.20E-04 Type 2 diabetes PCDP1 missense 22158537 rs10186515 chr2 120411247 T A 3.83E-04 Type 2 diabetes PCDP1 intron 22158537 rs6711244 chr2 120415348 C T 1.27E-04 Type 2 diabetes / / 22158537 rs11678053 chr2 120416787 C T 2.27E-04 Type 2 diabetes / / 22158537 rs7596716 chr2 120418222 G A 4.27E-04 Alzheimer's disease (late onset) / / 21379329 rs7596716 chr2 120418222 G A 1.88E-04 Type 2 diabetes / / 22158537 rs1879711 chr2 120418594 C A 2.84E-04 Type 2 diabetes / / 22158537 rs112839760 chr2 120435557 G GG,GT 1.64E-04 Alzheimer's disease (late onset) / / 21379329 rs1568538 chr2 120435557 G T 1.64E-04 Alzheimer's disease (late onset) / / 21379329 rs10183197 chr2 120440653 A C 4.51E-04 Multiple complex diseases / / 17554300 rs6708153 chr2 120462953 G A 5.84E-04 Type 2 diabetes / / 22158537 rs4849798 chr2 120465494 G T 5.94E-04 Type 2 diabetes / / 22158537 rs4849799 chr2 120465777 T G 6.91E-04 Type 2 diabetes / / 22158537 rs6542543 chr2 120466940 G A 8.76E-04 Type 2 diabetes / / 22158537 rs10167582 chr2 120490901 A G 3.28E-04 Multiple complex diseases / / 17554300 rs13401620 chr2 120513133 G A 2.00E-06 Breast size / / 22747683 rs61012141 chr2 120513133 G GTGCA 2.00E-06 Breast size / / 22747683 rs17667952 chr2 120577816 A G 1.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PTPN4 intron 24023788 rs6730447 chr2 120682525 A C 5.80E-05 Kawasaki disease PTPN4 intron 22446962 rs6722377 chr2 120938032 G A 2.06E-04 Multiple complex diseases / / 17554300 rs4848580 chr2 121001117 C T 4.00E-04 Response to antidepressants / / 19736353 rs3980213 chr2 121004979 A G 6.10E-04 Alcohol dependence / / 20201924 rs4849842 chr2 121012666 T A 8.99E-04 Multiple complex diseases RALB intron 17554300 rs1370379 chr2 121014589 C T 5.00E-04 Alcohol dependence RALB intron 20201924 rs3931841 chr2 121041314 A G 1.64E-04 Multiple complex diseases RALB intron 17554300 rs3931840 chr2 121041347 A C 6.40E-04 Alcohol dependence RALB intron 20201924 rs3931840 chr2 121041347 A C 5.00E-04 Body mass index RALB intron 24827717 rs2289172 chr2 121046116 C G 4.06E-04 Multiple complex diseases RALB intron 17554300 rs4849849 chr2 121046573 T C 9.35E-04 Multiple complex diseases RALB intron 17554300 rs11689112 chr2 121049166 G T 2.30E-05 Lymphocyte counts RALB intron 22286170 rs12477565 chr2 121081260 G T 2.25E-06 Prostate cancer / / 24185611 rs17625845 chr2 121089731 T C 5.00E-10 Breast size / / 22747683 rs7576192 chr2 121118031 A G 0.000000148 Preeclampsia / / 22432041 rs7579169 chr2 121118124 T C 0.000000358 Preeclampsia / / 22432041 rs12711941 chr2 121123383 T G 0.000000426 Preeclampsia / / 22432041 rs11887035 chr2 121124076 C T 3.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4366914 chr2 121135655 A G 1.60E-05 Urinary metabolites / / 21572414 rs10048787 chr2 121155192 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4456710 chr2 121175888 C T 2.96E-04 Iron levels / / pha002876 rs7563732 chr2 121193756 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7581710 chr2 121195181 A G 2.00E-07 Obesity / / 21552555 rs4300832 chr2 121197341 C A 7.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4504000 chr2 121214402 C T 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4848596 chr2 121226137 G A 5.77E-04 Multiple complex diseases / / 17554300 rs6542599 chr2 121228177 C T 3.79E-04 Smoking quantity / / 24665060 rs4848597 chr2 121231350 C T 8.74E-05 Hypertension / / pha003041 rs940677 chr2 121235399 G T 2.37E-06 Hypertension / / pha003041 rs4849887 chr2 121245122 T C 3.00E-11 Breast size / / 22747683 rs4849887 chr2 121245122 T C 4.00E-11 Breast cancer / / 23535729 rs4849898 chr2 121261473 C T 2.29E-04 Multiple complex diseases / / 17554300 rs17050244 chr2 121282630 A G 5.00E-07 Age-related macular degeneration / / 23326517 rs940683 chr2 121284956 T C 4.92E-05 Body Mass Index / / pha003009 rs6721654 chr2 121301911 C T 7.00E-06 Age-related macular degeneration / / 23326517 rs2311597 chr2 121305771 A G 1.59E-08 Urate levels / / 23263486 rs17050272 chr2 121306440 G A 2.00E-10 Urate levels / / 23263486 rs2030746 chr2 121309488 C T 3.38E-08 Urate levels / / 23263486 rs2030746 chr2 121309488 C T 4.00E-08 Cholesterol,total / / 24097068 rs2030746 chr2 121309488 C T 9.00E-09 LDL cholesterol / / 24097068 rs6706968 chr2 121310269 A C 1.48E-08 Urate levels / / 23263486 rs11677557 chr2 121317747 A G 6.81E-05 Type 2 diabetes / / 17463246 rs3860374 chr2 121348224 C T 2.01E-04 Type 2 diabetes / / 17463246 rs3860374 chr2 121348224 C T 5.20E-06 Urinary metabolites / / 21572414 rs6746992 chr2 121348472 G A 5.20E-06 Urinary metabolites / / 21572414 rs10460460 chr2 121349814 G A 1.00E-05 Urinary metabolites / / 21572414 rs7568190 chr2 121353658 A C 3.56E-04 Type 2 diabetes / / 17463246 rs1568836 chr2 121357095 A G 2.03E-04 Multiple complex diseases / / 17554300 rs7570994 chr2 121357915 T C 8.02E-04 Multiple complex diseases / / 17554300 rs13395978 chr2 121387909 T C 8.50E-05 Triglycerides / / 19074352 rs1979165 chr2 121445220 C T 7.54E-06 Bone mineral density / / 19181680 rs1109002 chr2 121460980 G A 2.96E-07 Bone mineral density / / 19181680 rs1078382 chr2 121462747 G T 9.94E-04 Multiple complex diseases / / 17554300 rs2871636 chr2 121465200 C A 8.35E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4848104 chr2 121466356 C A 9.05E-04 Multiple complex diseases / / 17554300 rs4848106 chr2 121466496 T C 6.70E-04 Multiple complex diseases / / 17554300 rs4848107 chr2 121466599 C A 5.43E-04 Multiple complex diseases / / 17554300 rs4848107 chr2 121466599 C A 9.82E-04 Alzheimer's disease / / 24755620 rs10496562 chr2 121469965 T C 8.72E-04 Alzheimer's disease / / 24755620 rs12463908 chr2 121470971 A C 8.16E-04 Alzheimer's disease / / 24755620 rs930727 chr2 121478431 G C 6.99E-04 Multiple complex diseases / / 17554300 rs4848624 chr2 121518479 C T 9.91E-04 Myopia (pathological) / / 21095009 rs4848115 chr2 121526871 T C 6.32E-04 Heart Failure / / pha002884 rs10169929 chr2 121553197 A T 4.95E-05 Brain derived neurotrophic factor levels,in serum GLI2 nearGene-5 22047184 rs4848637 chr2 121579245 G A 7.82E-05 Post-operative nausea and vomiting GLI2 intron 21694509 rs3943552 chr2 121582057 C T 6.20E-05 Tardive dyskinesia GLI2 intron 20939080 rs277554 chr2 121631384 T C 5.53E-04 Alzheimer's disease GLI2 intron 17998437 rs277552 chr2 121632454 G A 9.46E-04 Response to taxane treatment (placlitaxel) GLI2 intron 23006423 rs277536 chr2 121652747 C T 3.26E-04 Schizophrenia GLI2 intron 19197363 rs935428 chr2 121674413 A G 2.30E-07 Facial morphology GLI2 intron 22341974 rs10206938 chr2 121675238 A G 2.20E-07 Facial morphology GLI2 intron 22341974 rs895547 chr2 121676655 T C 3.45E-04 Gallstones GLI2 intron 17632509 rs2166565 chr2 121692477 A G 5.96E-04 Type 2 diabetes GLI2 intron 17463246 rs2166565 chr2 121692477 A G 1.10E-07 Facial morphology GLI2 intron 22341974 rs11122834 chr2 121701289 T C 5.00E-06 Erectile dysfunction and prostate cancer treatment GLI2 intron 20932654 rs1466042 chr2 121702919 A G 7.16E-04 Type 2 diabetes GLI2 intron 17463246 rs1466042 chr2 121702919 A G 1.00E-07 Facial morphology GLI2 intron 22341974 rs1107445 chr2 121703133 G C 1.40E-04 Multiple complex diseases GLI2 intron 17554300 rs2311803 chr2 121703623 A G 2.87E-04 Multiple complex diseases GLI2 intron 17554300 rs4848658 chr2 121707390 C T 1.00E-07 Facial morphology GLI2 intron 22341974 rs11122835 chr2 121708159 T G 1.00E-07 Facial morphology GLI2 intron 22341974 rs10864866 chr2 121708663 A G 9.90E-08 Facial morphology GLI2 intron 22341974 rs11681136 chr2 121709091 G A 9.90E-08 Facial morphology GLI2 intron 22341974 rs17005499 chr2 121709441 G A 8.07E-04 Multiple complex diseases GLI2 intron 17554300 rs12711535 chr2 121709536 C T 6.09E-04 Type 2 diabetes GLI2 intron 17463246 rs12711535 chr2 121709536 C T 1.00E-07 Facial morphology GLI2 intron 22341974 rs12711536 chr2 121709786 C T 9.70E-08 Facial morphology GLI2 intron 22341974 rs2084234 chr2 121710855 T G 9.70E-08 Facial morphology GLI2 intron 22341974 rs11122837 chr2 121711860 G A 9.60E-08 Facial morphology GLI2 intron 22341974 rs11689760 chr2 121712260 A C 9.60E-08 Facial morphology GLI2 intron 22341974 rs280199 chr2 121733476 T C 1.73E-04 Amyotrophic Lateral Sclerosis GLI2 intron 17827064 rs149091975 chr2 121744056 G A 0.00025 Prostate cancer (non-advanced prostate cancer) GLI2 missense 23555315 rs735370 chr2 121762093 C T 2.45E-04 Taste perception / / 22132133 rs13399257 chr2 121786460 A G 9.73E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs280213 chr2 121788630 G T 1.00E-04 Prostate cancer / / 21743057 rs7608862 chr2 121788901 C T 1.00E-04 Prostate cancer / / 21743057 rs280215 chr2 121789026 T C 1.00E-04 Prostate cancer / / 21743057 rs1867907 chr2 121790225 C T 1.00E-04 Prostate cancer / / 21743057 rs1446847 chr2 121795010 T C 5.42E-06 Left ventricular mass / / 21212386 rs2249979 chr2 121807776 G A 7.04E-06 Multiple complex diseases / / 17554300 rs4848143 chr2 121812224 A G 9.00E-06 Capecitabine sensitivity / / 22864933 rs2677510 chr2 121824898 T C 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs4848683 chr2 121826718 T C 1.65E-04 Alzheimer's disease (late onset) / / 21379329 rs13384487 chr2 121829977 G A 5.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13404741 chr2 121831765 T C 4.65E-04 Alzheimer's disease (late onset) / / 21379329 rs1105064 chr2 121836157 T A 1.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12464700 chr2 121856450 T C 1.52E-04 Alzheimer's disease (late onset) / / 21379329 rs17005883 chr2 121882281 G A 7.52E-04 Multiple complex diseases / / 17554300 rs4848687 chr2 121923127 A G 4.92E-04 Multiple complex diseases / / 17554300 rs11694438 chr2 121933873 C T 9.54E-05 Type 2 diabetes / / 17463246 rs11679589 chr2 121935057 T A 2.27E-04 Type 2 diabetes / / 17463246 rs11679589 chr2 121935057 T A 8.08E-05 Alzheimer's disease / / 17998437 rs4848692 chr2 121940001 G A 1.71E-04 Type 2 diabetes / / 17463246 rs4848692 chr2 121940001 G A 2.83E-05 Alzheimer's disease / / 17998437 rs17006044 chr2 121942844 A G 8.41E-04 Multiple complex diseases / / 17554300 rs12467309 chr2 121943357 C T 2.38E-04 Alzheimer's disease / / 17998437 rs12467309 chr2 121943357 C T 2.59E-04 Alzheimer's disease / / pha002879 rs11682545 chr2 121945825 C T 3.95E-06 Alzheimer's disease / / 17998437 rs11122849 chr2 121945933 A G 2.68E-05 Type 2 diabetes / / 17463246 rs12478773 chr2 121946407 A G 5.21E-05 Blood Pressure / / pha003047 rs7570949 chr2 121968685 C T 2.98E-04 Type 2 diabetes / / 17463246 rs1078442 chr2 121988924 C A 0.0000793 Percentage fat mass,diabetics removed TFCP2L1 intron 23436924 rs17006292 chr2 122018763 C A 5.00E-09 Behcet's disease TFCP2L1 intron 23001997 rs6712340 chr2 122031769 C T 1.44E-05 Gallstones TFCP2L1 intron 17632509 rs6717937 chr2 122043586 C A 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7576294 chr2 122045545 G A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2713245 chr2 122046743 G T 7.67E-04 Multiple complex diseases / / 17554300 rs2713243 chr2 122047043 C A 9.19E-04 Multiple complex diseases / / 17554300 rs2580337 chr2 122053982 A G 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2580333 chr2 122054963 C G 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2580330 chr2 122058534 A G 1.43E-04 Multiple complex diseases / / 17554300 rs2580360 chr2 122063744 A T 4.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs2919051 chr2 122095640 C T 4.28E-05 Coronary heart disease CLASP1 UTR-3 pha003055 rs12622810 chr2 122103861 C T 5.40E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs9653407 chr2 122120270 A G 4.19E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs10496565 chr2 122148174 A G 3.32E-04 Lung function (forced expiratory volume in 1 second) CLASP1 intron 24023788 rs12711551 chr2 122163006 T C 8.43E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs934760 chr2 122286442 A G 6.30E-05 Weight loss (gastric bypass surgery) CLASP1 intron 23643386 rs11122861 chr2 122353610 G A 7.50E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs7558771 chr2 122391833 A G 8.35E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs6723029 chr2 122419911 T G 1.65E-04 Multiple complex diseases LOC254128 intron 17554300 rs7562021 chr2 122511856 T C 2.87E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11122867 chr2 122515214 G T 1.63E-04 Obesity (extreme) TSN intron 21935397 rs12328818 chr2 122520557 A T 2.26E-04 Multiple complex diseases TSN intron 17554300 rs12618503 chr2 122537773 C T 5.09E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7577075 chr2 122578042 A G 6.92E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7577075 chr2 122578042 A G 3.99E-04 Stroke / / pha002887 rs6761482 chr2 122594780 G A 7.74E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10460462 chr2 122599806 G T 7.86E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6724570 chr2 122599911 G A 2.31E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6753114 chr2 122600116 A G 2.32E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10460453 chr2 122601302 T C 2.32E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7595430 chr2 122610306 C G 6.67E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13028433 chr2 122615008 T C 6.81E-04 Type 2 diabetes / / 17463246 rs4267513 chr2 122615926 C T 7.85E-04 Type 2 diabetes / / 17463246 rs4267514 chr2 122616181 C T 8.46E-04 Type 2 diabetes / / 17463246 rs4848163 chr2 122616961 G C 3.25E-04 Type 2 diabetes / / 17463246 rs4848163 chr2 122616961 G C 2.41E-04 Multiple complex diseases / / 17554300 rs4848733 chr2 122647656 C T 7.61E-05 Bipolar disorder / / 20451256 rs4848733 chr2 122647656 C T 8.06E-08 Metabolite levels / / 23281178 rs6754238 chr2 122647744 G A 6.90E-04 Multiple complex diseases / / 17554300 rs4368337 chr2 122662107 C T 8.43E-05 Bipolar disorder / / 19488044 rs4241112 chr2 122662212 T C 6.06E-05 Attention deficit hyperactivity disorder / / 18980221 rs4241112 chr2 122662212 T C 9.25E-06 Attention deficit hyperactivity disorder / / pha002875 rs7594821 chr2 122710665 G A 8.30E-04 Multiple complex diseases / / 17554300 rs7594821 chr2 122710665 G A 3.58E-04 Alzheimer's disease / / 17998437 rs1517712 chr2 122734147 C T 3.90E-04 Multiple complex diseases / / 17554300 rs4848739 chr2 122755302 A C 1.06E-04 Multiple complex diseases / / 17554300 rs17779391 chr2 122776465 C T 3.76E-05 Attention deficit hyperactivity disorder / / pha002875 rs2678160 chr2 122783985 T C 1.47E-04 Multiple complex diseases / / 17554300 rs1712861 chr2 122786238 G A 3.95E-04 Multiple complex diseases / / 17554300 rs1517711 chr2 122812115 G A 4.75E-04 Multiple complex diseases / / 17554300 rs1712842 chr2 122819883 A G 1.38E-04 Multiple complex diseases / / 17554300 rs6734612 chr2 122820360 A T 3.10E-04 Multiple complex diseases / / 17554300 rs908678 chr2 122832639 T A 6.13E-05 Multiple complex diseases / / 17554300 rs1922179 chr2 122847139 C T 3.20E-04 Alcohol dependence / / 20201924 rs12623552 chr2 122854657 G A 2.89E-04 Multiple complex diseases / / 17554300 rs1560603 chr2 122870285 T C 1.53E-04 Multiple complex diseases / / 17554300 rs7596715 chr2 122871314 G A 1.75E-04 Multiple complex diseases / / 17554300 rs1922182 chr2 122884594 C A 2.49E-04 Multiple complex diseases / / 17554300 rs11685781 chr2 122909011 G T 1.31E-04 Attention deficit hyperactivity disorder / / pha002875 rs6731435 chr2 122928698 T C 1.99E-04 Multiple complex diseases / / 17554300 rs1545015 chr2 122930682 A G 3.67E-04 Type 2 diabetes / / 17463246 rs1545016 chr2 122932022 C A 5.76E-05 Coronary restenosis / / 21878436 rs1897439 chr2 122936000 A G 4.04E-04 Multiple complex diseases / / 17554300 rs1432312 chr2 122936737 T C 4.22E-05 Information processing speed / / 21130836 rs1432312 chr2 122936737 T C 7.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4848174 chr2 122943468 C T 1.93E-04 Vaspin levels / / 22907691 rs4848174 chr2 122943468 C T 0.0001934 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs2163656 chr2 122951824 C T 7.71E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7597014 chr2 122952356 C T 4.56E-04 Aortic root size / / 21223598 rs1432302 chr2 122953150 C T 3.96E-05 Prostate-specific antigen levels / / 23359319 rs1079949 chr2 122955771 G T 3.26E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10496584 chr2 123126479 A G 4.00E-06 Lentiform nucleus volume / / 22903471 rs2037892 chr2 123127789 G A 5.00E-06 Lentiform nucleus volume / / 22903471 rs33920762 chr2 123135010 T C 6.80E-05 Multiple complex diseases / / 17554300 rs1919922 chr2 123136890 C T 5.00E-06 Lentiform nucleus volume / / 22903471 rs4848768 chr2 123141545 A G 6.00E-06 Lentiform nucleus volume / / 22903471 rs6720918 chr2 123157046 T A 1.90E-04 Breast cancer and prostate cancer / / 17903305 rs4848180 chr2 123170441 C T 4.36E-04 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs10496586 chr2 123186585 C T 3.90E-04 Crohn's disease / / 17684544 rs1580069 chr2 123200413 G A 6.10E-04 Smoking cessation / / 24665060 rs13419434 chr2 123208669 T A 9.10E-05 Age-related macular degeneration / / 20861866 rs17007761 chr2 123225623 C A 1.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs1527243 chr2 123291022 C T 1.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs10201094 chr2 123306329 C G 2.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs10201094 chr2 123306329 C G 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2091427 chr2 123307057 C G 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs2091427 chr2 123307057 C G 3.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs1080548 chr2 123308174 C T 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs1080548 chr2 123308174 C T 3.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs11695611 chr2 123314768 C T 2.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11695611 chr2 123314768 C T 3.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308637 chr2 123315041 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308637 chr2 123315041 C T 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs1561552 chr2 123319001 T G 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1561552 chr2 123319001 T G 2.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs7573865 chr2 123319451 G C 1.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs7573865 chr2 123319451 G C 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308638 chr2 123320028 T G 1.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308638 chr2 123320028 T G 2.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs766757 chr2 123320715 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs766757 chr2 123320715 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7581875 chr2 123321994 C T 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs7581875 chr2 123321994 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527255 chr2 123322387 C A 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527255 chr2 123322387 C A 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs6541834 chr2 123324533 G T 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs6541834 chr2 123324533 G T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs11122916 chr2 123326143 C T 1.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs11122916 chr2 123326143 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759289 chr2 123326947 A C 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759289 chr2 123326947 A C 2.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs13425998 chr2 123328891 T C 1.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs13425998 chr2 123328891 T C 2.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195812 chr2 123329724 C T 1.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195812 chr2 123329724 C T 2.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527253 chr2 123331847 T C 1.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527253 chr2 123331847 T C 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs999492 chr2 123332354 A C 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs999492 chr2 123332354 A C 2.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs2272315 chr2 123334253 A G 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs2272315 chr2 123334253 A G 9.55E-05 Suicide attempts in bipolar disorder / / 21041247 rs1439838 chr2 123335740 A T 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs1439838 chr2 123335740 A T 7.70E-05 Suicide attempts in bipolar disorder / / 21041247 rs10445851 chr2 123336313 T G 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10445851 chr2 123336313 T G 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs10864879 chr2 123342393 G C 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10864879 chr2 123342393 G C 8.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs1304771 chr2 123345060 G A 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1304771 chr2 123345060 G A 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171928 chr2 123352317 C T 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171928 chr2 123352317 C T 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418570 chr2 123352917 A G 1.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418570 chr2 123352917 A G 9.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs1405604 chr2 123354282 A G 1.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1405604 chr2 123354282 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753885 chr2 123358926 T A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753885 chr2 123358926 T A 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs2043940 chr2 123366899 T C 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2043940 chr2 123366899 T C 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1595755 chr2 123371222 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs1595755 chr2 123371222 T C 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1918273 chr2 123375001 G T 1.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs1918273 chr2 123375001 G T 6.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs1371489 chr2 123381819 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs1371489 chr2 123381819 C T 6.06E-05 Suicide attempts in bipolar disorder / / 21041247 rs11684281 chr2 123382031 G T 1.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs11684281 chr2 123382031 G T 1.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs11897702 chr2 123389709 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11897702 chr2 123389709 C T 4.73E-05 Suicide attempts in bipolar disorder / / 21041247 rs987707 chr2 123392303 C T 2.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs987707 chr2 123392303 C T 9.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs17039782 chr2 123393571 T C 1.96E-05 Suicide attempts in bipolar disorder / / 21041247 rs17039782 chr2 123393571 T C 9.31E-05 Suicide attempts in bipolar disorder / / 21041247 rs4848185 chr2 123394405 A G 1.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs4848185 chr2 123394405 A G 9.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs9646894 chr2 123395432 A G 7.64E-05 Aging (time to event) / / 21782286 rs13400652 chr2 123395877 C T 5.72E-05 Nicotine smoking / / 19268276 rs7582802 chr2 123397312 G A 8.39E-04 Depression (quantitative trait) / / 20800221 rs7594595 chr2 123401043 C A 8.71E-04 Depression (quantitative trait) / / 20800221 rs7608903 chr2 123401189 T C 8.79E-04 Depression (quantitative trait) / / 20800221 rs1595757 chr2 123403621 T C 9.20E-04 Depression (quantitative trait) / / 20800221 rs10166255 chr2 123407250 T C 9.24E-04 Depression (quantitative trait) / / 20800221 rs11893130 chr2 123414629 A G 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10201125 chr2 123431555 C T 8.41E-04 Depression (quantitative trait) / / 20800221 rs7598320 chr2 123431921 G A 9.70E-04 Alzheimer's disease / / 17998437 rs7598320 chr2 123431921 G A 3.06E-06 Recombination rate / / 21698098 rs6541846 chr2 123432820 A G 8.53E-04 Depression (quantitative trait) / / 20800221 rs2418650 chr2 123438579 C A 9.19E-04 Depression (quantitative trait) / / 20800221 rs10166571 chr2 123440796 C T 9.56E-04 Depression (quantitative trait) / / 20800221 rs4528763 chr2 123451593 C G 6.23E-04 Alzheimer's disease / / 17998437 rs893743 chr2 123451795 A G 3.57E-05 Cognitive test performance / / 20125193 rs12619304 chr2 123472119 A G 5.26E-04 Alzheimer's disease / / 17998437 rs7604792 chr2 123490225 T C 8.05E-05 Cognitive test performance / / 20125193 rs10496595 chr2 123502497 C T 1.95E-04 HIV-1 viral setpoint / / 17641165 rs6749889 chr2 123503566 T C 2.00E-04 HIV-1 viral setpoint / / 17641165 rs6541855 chr2 123506815 T C 2.00E-04 HIV-1 viral setpoint / / 17641165 rs12327981 chr2 123512526 T G 2.01E-04 HIV-1 viral setpoint / / 17641165 rs296034 chr2 123602800 C T 0.000316 Breast cancer early age of onset / / 18463975 rs17008837 chr2 123639466 A G 4.82E-05 Bipolar disorder,affective / / 20528957 rs17367118 chr2 123641611 G A 9.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs17008879 chr2 123655136 G T 4.92E-05 Bipolar disorder,affective / / 20528957 rs1850585 chr2 123663290 T C 4.88E-04 Premature ovarian failure / / 19508998 rs1850585 chr2 123663290 T C 1.06E-04 Bipolar disorder,affective / / 20528957 rs17008943 chr2 123684959 C G 1.08E-04 Bipolar disorder,affective / / 20528957 rs1527978 chr2 123704606 C T 4.88E-04 Premature ovarian failure / / 19508998 rs17008994 chr2 123720609 T C 6.20E-05 Bipolar disorder,affective / / 20528957 rs17009003 chr2 123721422 C T 2.01E-05 Bipolar disorder,affective / / 20528957 rs17009017 chr2 123727810 A G 1.29E-04 Bipolar disorder,affective / / 20528957 rs17009035 chr2 123732130 C A 7.89E-05 Bipolar disorder,affective / / 20528957 rs7571273 chr2 123796040 G A 9.00E-05 Serum metabolites / / 19043545 rs299566 chr2 123802996 T A 5.37E-04 Multiple complex diseases / / 17554300 rs12470896 chr2 123803856 G A 6.93E-05 Cognitive decline / / 22054870 rs299575 chr2 123808961 A G 1.00E-05 Smoking behavior / / 20418888 rs299584 chr2 123810650 C T 6.00E-04 Multiple complex diseases / / 17554300 rs1507666 chr2 123815985 A T 2.00E-04 Type 2 diabetes / / 17846126 rs1395931 chr2 123818973 A G 2.90E-05 Type 2 diabetes / / 17846126 rs17039820 chr2 123825356 C A 8.02E-06 Personality dimensions / / 23658558 rs299541 chr2 123826562 G A 3.02E-05 Vascular dementia / / 22116812 rs13011089 chr2 123828854 T G 4.98E-05 HIV-1 control / / 20041166 rs10183651 chr2 123857742 C T 8.33E-05 Vascular dementia / / 22116812 rs7608162 chr2 123888744 A C 9.72E-04 Alzheimer's disease / / 22005930 rs11122943 chr2 123898116 C T 8.82E-04 Alzheimer's disease / / 22005930 rs6709545 chr2 123906154 A G 9.21E-04 Alzheimer's disease / / 22005930 rs1515155 chr2 123925670 T G 8.00E-04 Alzheimer's disease / / 22005930 rs1515156 chr2 123925693 T C 7.60E-04 Alzheimer's disease / / 22005930 rs10168304 chr2 124000929 A T 9.07E-04 Type 2 diabetes / / 17463246 rs1519277 chr2 124018799 C T 5.10E-04 Taste perception / / 22132133 rs17184604 chr2 124050854 G A 9.24E-04 Multiple complex diseases / / 17554300 rs2030833 chr2 124075367 G A 7.25E-20 Varicose Veins / / pha001412 rs2030833 chr2 124075367 G A 7.47E-07 Pure-tone audiometry / / pha001968 rs1607514 chr2 124090707 G A 5.31E-04 Type 2 diabetes / / 17463246 rs993934 chr2 124109213 A G 7.38E-04 Type 2 diabetes / / 17463246 rs7604683 chr2 124128700 A G 3.94E-04 Type 2 diabetes / / 17463246 rs6541897 chr2 124154449 G A 9.43E-05 Multiple complex diseases / / 17554300 rs6541898 chr2 124154796 G A 8.80E-05 Multiple complex diseases / / 17554300 rs1980357 chr2 124155289 G C 3.44E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs12475652 chr2 124156469 A C 7.86E-05 Multiple complex diseases / / 17554300 rs5029700 chr2 124156844 G A 7.20E-05 Multiple complex diseases / / 17554300 rs12468931 chr2 124157877 G A 9.13E-05 Multiple complex diseases / / 17554300 rs6743440 chr2 124158880 T A 6.53E-05 Multiple complex diseases / / 17554300 rs6723718 chr2 124163193 G A 8.44E-05 Multiple complex diseases / / 17554300 rs1405093 chr2 124169595 A G 2.11E-04 Multiple complex diseases / / 17554300 rs6751285 chr2 124169811 C T 5.52E-05 Multiple complex diseases / / 17554300 rs13000960 chr2 124172605 A G 7.17E-05 Multiple complex diseases / / 17554300 rs11122979 chr2 124174155 G C 5.24E-05 Multiple complex diseases / / 17554300 rs1358053 chr2 124177870 T C 7.80E-05 Multiple complex diseases / / 17554300 rs2419737 chr2 124187984 G A 6.04E-05 Multiple complex diseases / / 17554300 rs7585580 chr2 124190566 C T 4.01E-05 Multiple complex diseases / / 17554300 rs2900971 chr2 124191768 T A 5.29E-05 Multiple complex diseases / / 17554300 rs7581320 chr2 124220901 T C 9.07E-05 Multiple complex diseases / / 17554300 rs6725855 chr2 124224582 T C 2.65E-04 Multiple complex diseases / / 17554300 rs4848866 chr2 124242210 G A 3.29E-04 Multiple complex diseases / / 17554300 rs12185746 chr2 124246717 C T 2.72E-04 Multiple complex diseases / / 17554300 rs11122985 chr2 124250217 C T 7.12E-04 Multiple complex diseases / / 17554300 rs10496614 chr2 124276444 T C 3.52E-05 Waist-Hip Ratio / / pha003028 rs2419976 chr2 124280149 T C 6.39E-04 Stroke / / pha002887 rs9678660 chr2 124291689 C A 5.93E-08 Metabolite levels / / 23281178 rs7556991 chr2 124301185 G A 8.64E-08 Metabolite levels / / 23281178 rs6748146 chr2 124302649 G A 1.83E-04 Obesity (extreme) / / 21935397 rs11890814 chr2 124311198 G T 5.93E-08 Metabolite levels / / 23281178 rs11899792 chr2 124332702 G A 5.22E-08 Metabolite levels / / 23281178 rs2419986 chr2 124336412 G A 2.08E-05 Waist-Hip Ratio / / pha003013 rs2419986 chr2 124336412 G A 2.72E-06 Waist-Hip Ratio / / pha003028 rs4848873 chr2 124357086 C G 9.66E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs17010303 chr2 124361576 A G 4.23E-05 Waist-Hip Ratio / / pha003013 rs17010303 chr2 124361576 A G 5.47E-06 Waist-Hip Ratio / / pha003028 rs2707549 chr2 124403557 C A 2.30E-04 Pulmonary function / / 23932459 rs2670610 chr2 124429542 G A 2.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2256248 chr2 124433560 G A 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2256248 chr2 124433560 G A 9.90E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs2670605 chr2 124436630 A G 9.66E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7593488 chr2 124481347 G A 5.84E-04 Tourette syndrome / / 22889924 rs12620260 chr2 124481367 C T 6.10E-06 Urinary metabolites / / 21572414 rs13006237 chr2 124515041 G A 9.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs1513788 chr2 124526322 G A 1.00E-04 Information processing speed / / 21130836 rs925796 chr2 124665077 A G 6.86E-04 Smoking initiation / / 24665060 rs12469604 chr2 124678253 G A 4.46E-04 Alzheimer's disease (late onset) / / 21379329 rs7577143 chr2 124706091 A G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1214060 chr2 124718604 C G 1.60E-05 Urinary metabolites / / 21572414 rs1214045 chr2 124723224 A C 9.82E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1400064 chr2 124729011 A C,G,T 6.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11123013 chr2 124739150 G T 4.80E-06 Urinary metabolites / / 21572414 rs1921817 chr2 124749962 T C 1.07E-05 Orofacial clefts / / 22419666 rs4848905 chr2 124754515 C T 6.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13431665 chr2 124754742 A G 5.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17010780 chr2 124814804 T G 5.97E-04 Type 2 diabetes CNT/P5 intron 17463246 rs17010827 chr2 124835210 C T 9.30E-05 Psoriasis CNT/P5 intron 19169255 rs7571072 chr2 124841261 G A 3.28E-04 Schizophrenia (cytomegalovirus infection interaction) CNT/P5 intron 23358160 rs7571072 chr2 124841261 G A 5.01E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs1347876 chr2 124847337 C A 3.51E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17278676 chr2 124849389 T G 4.40E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs12105596 chr2 124858946 G A 3.30E-04 Smoking initiation CNT/P5 intron 24665060 rs12105790 chr2 124860820 G A 2.36E-04 Smoking initiation CNT/P5 intron 24665060 rs7577916 chr2 124869709 T C 9.49E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17010871 chr2 124874645 G A 1.79E-07 Multiple complex diseases CNT/P5 intron 17554300 rs17010872 chr2 124875274 C T 8.68E-04 Multiple complex diseases CNT/P5 intron 17554300 rs7592198 chr2 124879107 T C 6.78E-04 Smoking initiation CNT/P5 intron 24665060 rs10496628 chr2 124892592 C T 7.65E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17010907 chr2 124893260 C G 9.10E-05 Response to statin therapy CNT/P5 intron 20339536 rs4456715 chr2 124894409 G C 3.92E-04 Smoking initiation CNT/P5 intron 24665060 rs960537 chr2 124913517 G A 5.61E-04 Multiple complex diseases CNT/P5 intron 17554300 rs1529289 chr2 124915643 G T 4.40E-05 Serum metabolites CNT/P5 intron 19043545 rs1530104 chr2 124922297 A G 9.65E-05 Serum metabolites CNT/P5 intron 19043545 rs2699367 chr2 124922818 C T 9.65E-05 Serum metabolites CNT/P5 intron 19043545 rs4848917 chr2 124925587 G A 2.00E-04 Cognitive impairment induced by topiramate CNT/P5 intron 22091778 rs7558429 chr2 124944244 C T 2.45E-04 Major depressive disorder CNT/P5 intron 22472876 rs17011049 chr2 124944824 C T 7.44E-04 Multiple complex diseases CNT/P5 intron 17554300 rs7569367 chr2 124946945 C T 2.19E-04 Major depressive disorder CNT/P5 intron 22472876 rs1170612 chr2 124983056 T C 6.00E-06 Schizophrenia CNT/P5 intron 22885689 rs1170612 chr2 124983056 T C 9.00E-06 Schizophrenia CNT/P5 intron 22885689 rs1367248 chr2 124998364 G T 3.00E-06 Tonometry CNT/P5 intron 17903302 rs779985 chr2 125004689 T C 3.87E-05 Psoriasis CNT/P5 intron 18364390 rs17011309 chr2 125044669 C T 3.40E-04 Multiple complex diseases CNT/P5 intron 17554300 rs780020 chr2 125051230 C T 0.00041 Endometrial cancer CNT/P5 intron 22426144 rs780023 chr2 125052071 C T 8.13E-04 Stroke CNT/P5 intron pha002886 rs733112 chr2 125061838 C A 7.60E-05 Information processing speed CNT/P5 intron 21130836 rs733112 chr2 125061838 C A 1.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) CNT/P5 intron 23648065 rs2553634 chr2 125068032 G A 8.58E-05 ldl cholesterol CNT/P5 intron pha003077 rs779979 chr2 125078104 A C 2.49E-04 Alzheimer's disease CNT/P5 intron 22005930 rs2553628 chr2 125083298 G A 5.94E-04 Alzheimer's disease CNT/P5 intron 22005930 rs2565748 chr2 125086667 C T 6.08E-04 Alzheimer's disease CNT/P5 intron 22005930 rs7582767 chr2 125108364 A G 1.53E-06 Telomere length CNT/P5 intron 23001564 rs7578650 chr2 125112975 A G 1.40E-05 Cognitive performance CNT/P5 intron 19734545 rs2565763 chr2 125143493 G A,T 7.72E-05 Fibrinogen CNT/P5 intron pha003068 rs2059980 chr2 125146329 C T 5.00E-06 Cognitive test performance CNT/P5 intron 20125193 rs780005 chr2 125147162 C T 8.00E-06 Urinary metabolites CNT/P5 intron 21572414 rs4848931 chr2 125148667 C T 4.87E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1864468 chr2 125150792 G A 4.54E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1367244 chr2 125154334 G A 4.86E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1835353 chr2 125163827 G T 8.30E-05 Lipid traits CNT/P5 intron 17903299 rs2420864 chr2 125217386 T C 2.77E-08 Meningococcal disease CNT/P5 intron 20694013 rs2421083 chr2 125246092 G A 4.92E-05 Attention deficit hyperactivity disorder CNT/P5 intron 22420046 rs11899928 chr2 125256736 T C 3.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs11899928 chr2 125256736 T C 8.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs11899928 chr2 125256736 T C 9.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs17727261 chr2 125281910 C T 5.00E-07 Response to antipsychotic treatment CNT/P5 missense 19721433 rs13021885 chr2 125291837 C T 8.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs12464032 chr2 125297608 G A 3.79E-05 Parkinson's disease CNT/P5 intron 21738487 rs12470517 chr2 125299661 T C 4.07E-05 Parkinson's disease CNT/P5 intron 21738487 rs1504009 chr2 125303280 T C 3.83E-05 Parkinson's disease CNT/P5 intron 21738487 rs2047877 chr2 125317108 G A 7.39E-04 Parkinson's disease CNT/P5 intron 16252231 rs17392176 chr2 125322648 C T 4.70E-05 Response to statin therapy CNT/P5 intron 20339536 rs17392197 chr2 125324525 A G 9.00E-06 Urinary metabolites CNT/P5 intron 21572414 rs2901331 chr2 125327950 G A 6.00E-06 Response to statin therapy CNT/P5 intron 20339536 rs17320299 chr2 125327962 G A 1.67E-06 Tunica Media CNT/P5 intron pha003034 rs6739605 chr2 125329041 A C 1.40E-05 Response to statin therapy CNT/P5 intron 20339536 rs17320347 chr2 125329445 G A 1.40E-05 Response to statin therapy CNT/P5 intron 20339536 rs6757796 chr2 125344186 A G 7.20E-04 Multiple complex diseases CNT/P5 intron 17554300 rs4355122 chr2 125346337 C T 3.93E-06 Fibrinogen CNT/P5 intron pha003068 rs1454133 chr2 125383348 G T 9.78E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs4848252 chr2 125385662 A G 7.62E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs1587788 chr2 125391317 T C 9.84E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs2219107 chr2 125391574 T G 8.50E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs7599787 chr2 125391858 A G 9.84E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs12995183 chr2 125392103 T C 8.16E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs11675141 chr2 125394477 T G 7.80E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs70996085 chr2 125394477 T TTCTCTTTTTCTCCTCTCCTCTG 7.80E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs4848966 chr2 125426455 T G 7.55E-04 Crohn's disease CNT/P5 intron 23266558 rs13386176 chr2 125428294 G A 2.30E-05 Coffee consumption CNT/P5 intron 21357676 rs13002390 chr2 125451034 T C 3.32E-07 White blood cell count CNT/P5 intron 21738479 rs1454134 chr2 125453333 G A 9.23E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1454134 chr2 125453333 G A 3.14E-06 White blood cell count CNT/P5 intron 21738479 rs10178249 chr2 125454396 A G 7.19E-07 White blood cell count CNT/P5 intron 21738479 rs1993273 chr2 125455265 A G 6.48E-07 White blood cell count CNT/P5 intron 21738479 rs1993272 chr2 125455299 T C 1.57E-06 White blood cell count CNT/P5 intron 21738479 rs11902093 chr2 125455912 C G 2.03E-06 White blood cell count CNT/P5 intron 21738479 rs6755119 chr2 125456247 C G 3.69E-06 White blood cell count CNT/P5 intron 21738479 rs7580383 chr2 125457240 A G 2.59E-06 White blood cell count CNT/P5 intron 21738479 rs7580383 chr2 125457240 A G 4.79E-04 Iron levels CNT/P5 intron pha002876 rs13407611 chr2 125457258 A G,T 6.62E-07 White blood cell count CNT/P5 intron 21738479 rs12619535 chr2 125530115 A G 2.42E-05 Bipolar disorder,affective CNT/P5 intron 20528957 rs922863 chr2 125533271 G A 2.74E-05 Bipolar disorder,affective CNT/P5 intron 20528957 rs10170205 chr2 125556113 T C 8.73E-04 Coronary heart disease CNT/P5 intron 21606135 rs1840201 chr2 125648688 C T 8.44E-04 Alzheimer's disease CNT/P5 intron 17998437 rs10190995 chr2 125741700 C T 7.95E-04 Acute lung injury / / 22295056 rs4622728 chr2 125806843 T C 6.62E-05 Cognitive test performance / / 20125193 rs4622728 chr2 125806843 T C 6.22E-06 Osteoarthritis / / 22763110 rs4459741 chr2 125861848 C T 5.30E-04 Multiple complex diseases / / 17554300 rs17012349 chr2 125966414 A T 6.12E-04 Multiple complex diseases / / 17554300 rs313252 chr2 126025268 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1903127 chr2 126030322 C T 7.90E-06 Urinary metabolites / / 21572414 rs1459166 chr2 126034009 G A 9.75E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs6735587 chr2 126038422 T G 7.90E-06 Urinary metabolites / / 21572414 rs6735587 chr2 126038422 T G 6.13E-04 Smoking quantity / / 24665060 rs313289 chr2 126069381 G A 6.60E-04 Cognition,early reading ability / / 17684495 rs191115 chr2 126092815 G A 1.23E-04 Bone mass and geometry / / 17903296 rs313262 chr2 126105052 C A 6.19E-04 Smoking quantity / / 24665060 rs1369523 chr2 126139282 C T 1.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1836676 chr2 126142204 G A 1.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9308661 chr2 126193494 G A 4.65E-05 Tunica Media / / pha003037 rs12469322 chr2 126207171 T G 7.17E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10490484 chr2 126249714 A C 1.32E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs13001190 chr2 126273115 A G 7.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6542008 chr2 126361391 A T 2.90E-04 Type 2 diabetes / / 17463246 rs6728958 chr2 126365222 C T 4.88E-04 Type 2 diabetes / / 17463246 rs13432902 chr2 126393876 G A 5.67E-04 Type 2 diabetes / / 17463246 rs1863680 chr2 126398345 C T 5.61E-04 Type 2 diabetes / / 17463246 rs1863681 chr2 126398388 A C 4.82E-04 Type 2 diabetes / / 17463246 rs6542010 chr2 126412342 C T 1.78E-08 Multiple complex diseases / / 17554300 rs11890262 chr2 126495166 T C 2.29E-06 White blood cell count / / 21738479 rs17634652 chr2 126568436 C T 3.99E-04 Multiple complex diseases / / 17554300 rs6744897 chr2 126609672 G C 5.69E-04 Multiple complex diseases / / 17554300 rs13390236 chr2 126626867 C T 5.87E-04 Multiple complex diseases / / 17554300 rs2124311 chr2 126667866 T C 7.40E-04 Multiple complex diseases / / 17554300 rs12621193 chr2 126670324 G A 3.48E-04 Longevity / / 22279548 rs7557872 chr2 126679292 G A 6.23E-06 C-reactive protein / / 22492993 rs17013251 chr2 126728027 G A 3.60E-05 HIV-1 control / / 20041166 rs10496652 chr2 126736747 A G 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542033 chr2 126761171 C T 3.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs1455620 chr2 126788428 G A 5.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs4144048 chr2 126793525 G A,T 6.20E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2219206 chr2 126793798 G A 1.56E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7581039 chr2 126794403 A G 9.31E-05 Cognitive impairment induced by topiramate / / 22091778 rs4375873 chr2 126828247 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1484448 chr2 126962441 G A 7.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs17013423 chr2 126968866 A G 5.82E-04 Multiple complex diseases / / 17554300 rs360252 chr2 127012268 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360235 chr2 127044904 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360290 chr2 127080061 T C 1.65E-04 Cardiovascular disease risk factors / / 21239051 rs360292 chr2 127080267 A G 1.50E-04 Cardiovascular disease risk factors / / 21239051 rs360293 chr2 127080509 G A 1.42E-04 Cardiovascular disease risk factors / / 21239051 rs360295 chr2 127080649 T C 1.42E-04 Cardiovascular disease risk factors / / 21239051 rs360296 chr2 127080693 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360297 chr2 127080768 C G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360299 chr2 127081160 G A 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360300 chr2 127081235 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360301 chr2 127081303 G A 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360302 chr2 127081339 G A 1.92E-04 Cardiovascular disease risk factors / / 21239051 rs360303 chr2 127081480 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360307 chr2 127082208 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360308 chr2 127082310 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360309 chr2 127082816 C A 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360312 chr2 127083064 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360313 chr2 127083091 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360316 chr2 127083873 T A 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360317 chr2 127083960 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360318 chr2 127083982 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360319 chr2 127084247 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360320 chr2 127084470 C G 1.88E-04 Cardiovascular disease risk factors / / 21239051 rs360321 chr2 127085132 C T 1.71E-04 Cardiovascular disease risk factors / / 21239051 rs360322 chr2 127085528 C T 1.88E-04 Cardiovascular disease risk factors / / 21239051 rs11684492 chr2 127090306 C T 1.80E-04 Cardiovascular disease risk factors / / 21239051 rs359687 chr2 127115202 C T 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360370 chr2 127118187 G A 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360376 chr2 127119787 G T 8.30E-04 Cognition,early reading ability / / 17684495 rs11684427 chr2 127122556 G A 1.01E-04 Cardiovascular disease risk factors / / 21239051 rs11690602 chr2 127123871 C A 9.45E-05 Cardiovascular disease risk factors / / 21239051 rs11695746 chr2 127124573 T C 8.15E-05 Cardiovascular disease risk factors / / 21239051 rs12999792 chr2 127125038 G A 8.16E-05 Cardiovascular disease risk factors / / 21239051 rs17013755 chr2 127127222 A G 8.75E-04 Multiple complex diseases / / 17554300 rs359708 chr2 127127934 A G 4.29E-05 Cardiovascular disease risk factors / / 21239051 rs13034238 chr2 127130382 T C 4.30E-05 Cardiovascular disease risk factors / / 21239051 rs359706 chr2 127131081 T C 3.63E-05 Cardiovascular disease risk factors / / 21239051 rs359688 chr2 127137005 G A 7.48E-04 Premature ovarian failure / / 19508998 rs359688 chr2 127137005 G A 4.16E-05 Cardiovascular disease risk factors / / 21239051 rs13002032 chr2 127147760 G A 5.14E-05 Cardiovascular disease risk factors / / 21239051 rs13001771 chr2 127148980 A G 4.72E-05 Cardiovascular disease risk factors / / 21239051 rs2896866 chr2 127177054 C T 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12621460 chr2 127187736 A G 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs715915 chr2 127233566 G A 1.00E-04 Prostate cancer / / 21743057 rs10928884 chr2 127234126 T C 1.00E-04 Prostate cancer / / 21743057 rs7606197 chr2 127240800 A G 9.82E-04 Insulin resistance / / 21901158 rs6750543 chr2 127299285 A G 9.72E-04 Multiple complex diseases / / 17554300 rs10201742 chr2 127328773 A C 8.00E-07 Bone mineral density (BMD),in women / / 20164292 rs1550404 chr2 127330954 T G 1.00E-06 Intelligence / / 22449649 rs10211158 chr2 127341354 T C 9.40E-05 Parkinson's disease / / 21738487 rs7590496 chr2 127357688 C A 3.93E-04 Alcohol dependence / / 20201924 rs6747825 chr2 127372728 G T 1.60E-04 Smoking initiation / / 24665060 rs6711490 chr2 127372889 T A,G 4.72E-04 Smoking initiation / / 24665060 rs10180510 chr2 127376329 T C 7.24E-04 Multiple complex diseases / / 17554300 rs6723263 chr2 127378514 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3811541 chr2 127413135 A G 1.81E-04 Vaspin levels GYPC nearGene-5 22907691 rs3811541 chr2 127413135 A G 0.0000314 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GYPC nearGene-5 22907730 rs3811541 chr2 127413135 A G 0.0001811 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GYPC nearGene-5 22907730 rs13008888 chr2 127414593 G C 7.75E-05 Femoral neck bone geometry GYPC intron 22087292 rs6729097 chr2 127414661 C T 5.50E-05 Femoral neck bone geometry GYPC intron 22087292 rs11894065 chr2 127415578 C T 3.78E-04 Multiple complex diseases GYPC intron 17554300 rs10928979 chr2 127420228 A G 1.28E-05 Femoral neck bone geometry GYPC intron 22087292 rs7599354 chr2 127443771 G T 9.19E-06 Hemoglobin GYPC UTR-5 pha003098 rs7599354 chr2 127443771 G T 5.62E-05 Erythrocyte counts GYPC UTR-5 pha003101 rs935019 chr2 127446489 A G 1.43E-12 Multiple complex diseases GYPC intron 17554300 rs7597899 chr2 127457760 T C 9.64E-06 Panic disorder / / 19165232 rs1000858 chr2 127459321 C T 8.66E-06 Tunica Media / / pha003034 rs2203724 chr2 127472032 G A 8.63E-05 Sodium levels / / pha003093 rs10164664 chr2 127473880 C A 8.63E-05 Sodium levels / / pha003093 rs10210965 chr2 127497136 A G 6.20E-05 Personality dimensions / / 18957941 rs10206681 chr2 127497422 C G 6.90E-05 Personality dimensions / / 18957941 rs11690317 chr2 127503370 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674717 chr2 127503457 A G 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7419450 chr2 127507256 G A 8.15E-04 Parkinson's disease / / 16252231 rs1914458 chr2 127515846 C T 3.56E-05 Suicide attempts in bipolar disorder / / 21423239 rs6732878 chr2 127516475 C G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6732888 chr2 127516506 C A 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1914460 chr2 127531518 A C 4.48E-04 Multiple complex diseases / / 17554300 rs4322791 chr2 127556548 A G 7.32E-04 Multiple complex diseases / / 17554300 rs6745340 chr2 127558480 A G 8.39E-04 Multiple complex diseases / / 17554300 rs10167103 chr2 127578744 A G 0.00005 Pancreatic cancer and survival / / 22665904 rs10197495 chr2 127587337 T C 8.00E-05 Schizophrenia / / 19571809 rs4413107 chr2 127621402 T C 7.53E-04 Depression (quantitative trait) / / 20800221 rs6733840 chr2 127659981 T C 6.02E-05 Panic disorder / / 19165232 rs13418717 chr2 127662897 T A 3.00E-06 Heart failure / / 20445134 rs10496658 chr2 127663497 C T 1.53E-04 Multiple complex diseases / / 17554300 rs13382758 chr2 127667403 T C 2.32E-05 Waist-Hip Ratio / / pha003013 rs13382758 chr2 127667403 T C 4.60E-05 Waist-Hip Ratio / / pha003028 rs4662692 chr2 127696077 T C 8.94E-04 Multiple complex diseases / / 17554300 rs11896939 chr2 127701950 G C 8.56E-04 Multiple complex diseases / / 17554300 rs11889584 chr2 127707412 A G 4.98E-04 Multiple complex diseases / / 17554300 rs10168813 chr2 127711477 C A 5.13E-04 Multiple complex diseases / / 17554300 rs1510528 chr2 127712231 C T 4.55E-04 Multiple complex diseases / / 17554300 rs11888349 chr2 127713065 C G 3.84E-04 Multiple complex diseases / / 17554300 rs12053575 chr2 127726891 T C 2.95E-04 Multiple complex diseases / / 17554300 rs7556956 chr2 127727338 T C 5.31E-04 Multiple complex diseases / / 17554300 rs7557069 chr2 127727448 T C 6.27E-04 Multiple complex diseases / / 17554300 rs12999411 chr2 127732462 G A 7.17E-05 Cognitive performance / / 19734545 rs831360 chr2 127737632 A C,G 3.46E-04 Multiple complex diseases / / 17554300 rs546230 chr2 127739268 G T 5.98E-04 Multiple complex diseases / / 17554300 rs496421 chr2 127743858 C T 4.65E-04 Multiple complex diseases / / 17554300 rs472489 chr2 127744101 C G 4.27E-04 Multiple complex diseases / / 17554300 rs518477 chr2 127749274 T C 1.00E-04 Information processing speed / / 21130836 rs12993006 chr2 127758448 C T 4.00E-06 Systemic lupus erythematosus / / 24871463 rs9287568 chr2 127771006 A G 5.64E-04 Multiple complex diseases / / 17554300 rs11899372 chr2 127773880 G T 1.86E-08 Autism / / 22935194 rs1137845 chr2 127821207 G A 1.20E-04 Alcohol dependence BIN1 cds-synon 20201924 rs1060743 chr2 127826533 A G 5.95E-04 Alzheimer's disease BIN1 cds-synon 17998437 rs1060743 chr2 127826533 A G 1.11E-05 Alzheimer's disease (late onset) BIN1 cds-synon 21460841 rs17014873 chr2 127830219 A C 0.0000501 Amyotrophic lateral sclerosis BIN1 intron 23587638 rs10194375 chr2 127839781 C A 7.91E-05 Alzheimer's disease (late onset) BIN1 intron 21379329 rs10200967 chr2 127841769 C T 5.86E-05 Alzheimer's disease (late onset) BIN1 intron 21460841 rs17014923 chr2 127841930 C T 4.72E-04 Multiple complex diseases BIN1 intron 17554300 rs11678252 chr2 127851697 A G 4.29E-04 White matter integrity BIN1 intron 22425255 rs10207628 chr2 127852021 G A,C 4.01E-04 Multiple complex diseases BIN1 intron 17554300 rs10207628 chr2 127852021 G A,C 1.00E-06 Alzheimer's disease BIN1 intron 22005930 rs873270 chr2 127859418 T C 9.94E-04 Alzheimer's disease BIN1 intron 24755620 rs754107 chr2 127860830 C G 5.45E-05 Type 2 diabetes BIN1 intron 17463246 rs754107 chr2 127860830 C G 4.62E-04 Alzheimer's disease BIN1 intron 17998437 rs754107 chr2 127860830 C G 1.60E-09 Progranulin levels BIN1 intron 21087763 rs754107 chr2 127860830 C G 1.60E-09 Myocardial infarction BIN1 intron 21211798 rs3856378 chr2 127872347 G C 1.62E-04 Alzheimer's disease (late onset) / / 21460841 rs4663098 chr2 127873035 T C 2.46E-07 Alzheimer's disease (late onset) / / 21460841 rs4663098 chr2 127873035 T C 5.31E-04 Alzheimer's disease / / 24755620 rs3845674 chr2 127875389 T G 2.43E-07 Alzheimer's disease (late onset) / / 21460841 rs4663100 chr2 127878438 C G 2.41E-07 Alzheimer's disease (late onset) / / 21460841 rs13004848 chr2 127887560 T C 2.04E-04 Alzheimer's disease (late onset) / / 21460841 rs11689089 chr2 127887865 T C 1.53E-05 Alzheimer's disease (late onset) / / 21460841 rs12989701 chr2 127887985 C A 3.00E-10 Alzheimer's disease (late onset) / / 21390209 rs12989701 chr2 127887985 C A 1.86E-04 Alzheimer's disease (late onset) / / 21460841 rs12989701 chr2 127887985 C A 0.00065 Breast cancer / / 23555315 rs12989701 chr2 127887985 C A 6.47E-04 Alzheimer's disease / / 24755620 rs11685593 chr2 127888121 C T 5.92E-05 Alzheimer's disease (late onset) / / 21379329 rs11685593 chr2 127888121 C T 1.66E-05 Alzheimer's disease (late onset) / / 21460841 rs11680911 chr2 127888757 A C 8.46E-11 Alzheimer's disease (late onset) / / 21460841 rs11680911 chr2 127888757 A C 6.31E-11 Alzheimer's disease / / 22832961 rs7561528 chr2 127889637 G A 3.01E-06 Type 2 diabetes and other traits / / 19734900 rs7561528 chr2 127889637 G A 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs7561528 chr2 127889637 G A 4.00E-14 Alzheimer's disease (late onset) / / 21460841 rs7561528 chr2 127889637 G A 1.13E-07 Alzheimer's disease / / 21627779 rs7561528 chr2 127889637 G A 6.00E-11 Alzheimer's disease / / 22832961 rs7561528 chr2 127889637 G A 5.47E-05 Alzheimer's disease / / 24755620 rs6710467 chr2 127889932 G A 1.81E-04 Alzheimer's disease (late onset) / / 21460841 rs4663104 chr2 127890786 G C 1.64E-05 Alzheimer's disease (late onset) / / 21460841 rs6733839 chr2 127892810 C T 7.00E-44 Alzheimer's disease (late onset) / / 24162737 rs744373 chr2 127894615 A G 3.20E-06 Type 2 diabetes and other traits / / 19734900 rs744373 chr2 127894615 A G 1.00E-10 Alzheimer's disease (late onset) / / 21390209 rs744373 chr2 127894615 A G 3.00E-14 Alzheimer's disease / / 21460840 rs744373 chr2 127894615 A G 3.61E-10 Alzheimer's disease (late onset) / / 21460841 rs744373 chr2 127894615 A G 2.00E-09 Alzheimer's disease / / 21627779 rs744373 chr2 127894615 A G 1.59E-11 Prion diseases / / 22210626 rs744373 chr2 127894615 A G 1.39E-04 Alzheimer's disease (late onset) / / 23565137 rs744373 chr2 127894615 A G 6.88E-06 Alzheimer's disease / / 24755620 rs6431223 chr2 127895487 G A 8.94E-07 Alzheimer's disease (late onset) / / 21460841 rs1469980 chr2 127896023 C T 3.94E-05 Potassium levels / / pha003086 rs2118507 chr2 127903692 T C 9.72E-05 ldl cholesterol / / pha003076 rs4663109 chr2 127922292 A G 2.89E-08 Protein C levels / / 20802025 rs7587554 chr2 127924191 C T 6.85E-06 Depression (quantitative trait) / / 23290196 rs12620339 chr2 127930976 C T 1.36E-04 Type 2 diabetes / / 17463246 rs10171361 chr2 127935585 A G 2.39E-05 Multiple complex diseases / / 17554300 rs4510165 chr2 127936284 C T 1.40E-08 Protein C levels / / 20802025 rs13035268 chr2 127937551 G A 6.47E-05 Insulin Resistance / / pha003062 rs4662573 chr2 127941798 T C 1.60E-06 Retinopathy in non-diabetics CYP27C1 UTR-3 23393555 rs4284778 chr2 127946326 T C 7.24E-09 Protein C levels CYP27C1 intron 20802025 rs1566821 chr2 127946431 T G 7.67E-04 Type 2 diabetes CYP27C1 intron 17463246 rs1566821 chr2 127946431 T G 9.79E-04 Alzheimer's disease CYP27C1 intron 17998437 rs4284779 chr2 127946500 T C 9.50E-09 Protein C levels CYP27C1 intron 20802025 rs4321325 chr2 127950997 C T 9.59E-15 Protein C levels CYP27C1 intron 20802025 rs2102237 chr2 127951834 G A 2.84E-22 Varicose Veins CYP27C1 intron pha001412 rs7568070 chr2 127953054 A C 3.66E-14 Protein C levels CYP27C1 cds-synon 20802025 rs11683427 chr2 127956543 A G 2.09E-15 Protein C levels CYP27C1 intron 20802025 rs11890243 chr2 127958041 C A 2.02E-17 Protein C levels CYP27C1 intron 20802025 rs7585314 chr2 127962493 T C 3.83E-21 Protein C levels CYP27C1 intron 20802025 rs12463909 chr2 127971738 G C 6.21E-04 Type 2 diabetes / / 17463246 rs4560059 chr2 127972228 T C 9.01E-09 Protein C levels / / 20802025 rs4662710 chr2 127976817 C G 2.08E-08 Protein C levels / / 20802025 rs1504136 chr2 127977118 T C 8.52E-23 Protein C levels / / 20802025 rs7567389 chr2 127982645 A T 2.00E-06 Self-rated health / / 20707712 rs7567389 chr2 127982645 A T 9.70E-21 Protein C levels / / 20802025 rs4359587 chr2 127987049 G A 4.14E-04 Type 2 diabetes / / 17463246 rs1566822 chr2 127987391 A G 1.95E-08 Protein C levels / / 20802025 rs4300780 chr2 127989971 A G 7.66E-04 Type 2 diabetes / / 17463246 rs4300780 chr2 127989971 A G 0.000832 Height (Pygmy height) / / 22570615 rs6738690 chr2 127992725 T C 5.44E-22 Protein C levels / / 20802025 rs4662713 chr2 127994103 C T 1.34E-21 Protein C levels / / 20802025 rs1604817 chr2 127999921 C T 9.87E-26 Protein C levels / / 20802025 rs4536600 chr2 128002572 G A 3.03E-26 Protein C levels / / 20802025 rs2174270 chr2 128006078 C T 6.76E-09 Protein C levels / / 20802025 rs12465955 chr2 128007074 A T 7.07E-09 Protein C levels / / 20802025 rs6430936 chr2 128007686 A C 5.83E-22 Protein C levels / / 20802025 rs4662717 chr2 128013504 C T 7.26E-09 Protein C levels / / 20802025 rs4662717 chr2 128013504 C T 7.31E-05 Waist-Hip Ratio / / pha003013 rs4662718 chr2 128015367 C T 7.04E-22 Protein C levels ERCC3 intron 20802025 rs1566823 chr2 128018192 A G 7.03E-13 Protein C levels ERCC3 intron 20802025 rs1143407 chr2 128023884 T C 0.000562 Height (Pygmy height) ERCC3 intron 22570615 rs4150496 chr2 128029503 C T 6.78E-14 Protein C levels ERCC3 intron 20802025 rs4150496 chr2 128029503 C T 7.16E-05 ldl cholesterol ERCC3 intron pha003076 rs2134794 chr2 128030879 A C 5.62E-15 Lymphocyte counts ERCC3 intron 22286170 rs4150479 chr2 128032386 G C 7.39E-04 Smoking initiation ERCC3 intron 24665060 rs4150477 chr2 128032546 G A 7.65E-14 Protein C levels ERCC3 intron 20802025 rs4150474 chr2 128033327 C A 2.71E-21 Protein C levels ERCC3 intron 20802025 rs4150471 chr2 128034539 A G 2.66E-21 Protein C levels ERCC3 intron 20802025 rs1011019 chr2 128037560 A G 2.55E-21 Protein C levels ERCC3 intron 20802025 rs4150454 chr2 128038544 T C 6.32E-13 Protein C levels ERCC3 intron 20802025 rs4150441 chr2 128040915 T C 5.98E-13 Protein C levels ERCC3 intron 20802025 rs3768866 chr2 128045415 G A 3.37E-14 Protein C levels ERCC3 intron 20802025 rs4150407 chr2 128049631 T C 1.72E-08 Protein C levels ERCC3 intron 20802025 rs4150402 chr2 128050134 T C 8.33E-22 Protein C levels ERCC3 intron 20802025 rs7556675 chr2 128053747 C T 7.11E-20 Protein C levels ERCC3 nearGene-5 20802025 rs4233583 chr2 128060068 C A 3.77E-14 Protein C levels MAP3K2 UTR-3 20802025 rs3088374 chr2 128062048 T C 3.81E-10 Protein C levels MAP3K2 UTR-3 20802025 rs6731176 chr2 128071003 C T 1.78E-09 Protein C levels MAP3K2 intron 20802025 rs9636237 chr2 128076022 T C 6.44E-13 Protein C levels MAP3K2 intron 20802025 rs4662720 chr2 128076607 T C 3.17E-21 Protein C levels MAP3K2 intron 20802025 rs3732209 chr2 128079806 A G 1.01E-21 Protein C levels MAP3K2 cds-synon 20802025 rs12622436 chr2 128081682 C A 3.42E-14 Protein C levels MAP3K2 intron 20802025 rs6430937 chr2 128082232 C T 3.19E-04 Type 2 diabetes MAP3K2 intron 17463246 rs6430937 chr2 128082232 C T 0.00041 Coronary artery calcification MAP3K2 intron 23727086 rs12613413 chr2 128086354 C T 0.00036 Coronary artery calcification MAP3K2 intron 23727086 rs6732279 chr2 128089540 G T 3.30E-14 Protein C levels MAP3K2 intron 20802025 rs10496661 chr2 128090144 G T 3.41E-21 Protein C levels MAP3K2 intron 20802025 rs4662722 chr2 128102569 T C 4.98E-13 Protein C levels / / 20802025 rs4662580 chr2 128102806 C A 5.59E-13 Protein C levels / / 20802025 rs6716392 chr2 128107470 T C 0.000675 Height (Pygmy height) / / 22570615 rs12479003 chr2 128118553 C T 3.10E-14 Protein C levels / / 20802025 rs12479003 chr2 128118553 C T 7.16E-05 ldl cholesterol / / pha003076 rs11680949 chr2 128123562 C G 3.59E-21 Protein C levels / / 20802025 rs7589451 chr2 128128775 T C 5.13E-13 Protein C levels / / 20802025 rs11691088 chr2 128131853 A G 1.15E-21 Protein C levels / / 20802025 rs9789510 chr2 128137012 G A 2.90E-14 Protein C levels / / 20802025 rs7607907 chr2 128144286 T C 8.15E-21 Protein C levels / / 20802025 rs13029237 chr2 128147854 C T 2.79E-14 Protein C levels / / 20802025 rs8179521 chr2 128150924 A G 8.00E-07 Asthma (childhood onset) / / 17611496 rs11679414 chr2 128151003 G A 8.15E-22 Protein C levels / / 20802025 rs7580658 chr2 128159261 G A 2.10E-14 Protein C levels / / 20802025 rs7580658 chr2 128159261 G A 5.83E-05 ldl cholesterol / / pha003076 rs6430938 chr2 128162623 C T 3.45E-22 Protein C levels / / 20802025 rs6430938 chr2 128162623 C T 7.80E-04 Aortic root size / / 21223598 rs7599210 chr2 128164177 G A 1.20E-31 Protein C levels / / 20802025 rs6753288 chr2 128169899 G A 1.13E-31 Protein C levels / / 20802025 rs6753288 chr2 128169899 G A 9.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2069898 chr2 128174227 T C 2.26E-24 Protein C levels PROC nearGene-5 20802025 rs2069904 chr2 128175779 G A 2.29E-24 Protein C levels PROC nearGene-5 20802025 rs1799808 chr2 128175862 C T 6.03E-17 Protein C levels PROC nearGene-5 20802025 rs1799810 chr2 128176040 A T 9.00E-06 Self-rated health PROC UTR-5 20707712 rs1799810 chr2 128176040 A T 4.36E-36 Protein C levels PROC UTR-5 20802025 rs1158867 chr2 128177377 C T 4.00E-36 Protein C levels PROC intron 20802025 rs1158867 chr2 128177377 C T 4.00E-36 Asthma PROC intron 21907864 rs2069916 chr2 128178415 C T 7.14E-15 Protein C levels PROC intron 20802025 rs2069916 chr2 128178415 C T 5.88E-05 Waist-Hip Ratio PROC intron pha003013 rs2069916 chr2 128178415 C T 9.46E-05 Waist-Hip Ratio PROC intron pha003028 rs2069916 chr2 128178415 C T 3.72E-05 ldl cholesterol PROC intron pha003076 rs2069919 chr2 128179553 G A 1 Drug response to Warfarin PROC intron 19794411 rs6710535 chr2 128190960 C G 1.70E-14 Protein C levels / / 20802025 rs12468304 chr2 128193812 C T 1.28E-13 Protein C levels / / 20802025 rs6754772 chr2 128195244 G A 2.38E-12 Protein C levels / / 20802025 rs6754999 chr2 128195387 G A 2.73E-14 Protein C levels / / 20802025 rs6754999 chr2 128195387 G A 1.60E-05 Waist-Hip Ratio / / pha003013 rs6754999 chr2 128195387 G A 1.65E-05 Waist-Hip Ratio / / pha003028 rs6755028 chr2 128195442 G A 4.81E-26 Protein C levels / / 20802025 rs1473623 chr2 128196220 T C 4.83E-26 Protein C levels / / 20802025 rs11683986 chr2 128196398 C T 5.41E-21 Protein C levels / / 20802025 rs6749002 chr2 128196424 T G 4.67E-26 Protein C levels / / 20802025 rs12994586 chr2 128218364 T C 4.07E-06 Height / / pha003010 rs17261845 chr2 128223757 T A 1.66E-09 Protein C levels / / 20802025 rs17261859 chr2 128224791 T G 5.21E-09 Protein C levels / / 20802025 rs7590705 chr2 128225228 A G 2.13E-06 Height / / pha003010 rs7590705 chr2 128225228 A G 2.02E-06 Height / / pha003011 rs4662582 chr2 128226841 G A 7.73E-11 Protein C levels / / 20802025 rs777569 chr2 128229148 A T 1.55E-09 Protein C levels / / 20802025 rs334160 chr2 128243335 T C 1.84E-09 Protein C levels IWS1 intron 20802025 rs334159 chr2 128243462 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334158 chr2 128246152 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334156 chr2 128247640 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334152 chr2 128249441 C T 1.61E-09 Protein C levels IWS1 intron 20802025 rs6722447 chr2 128252234 G A 6.48E-11 Protein C levels IWS1 intron 20802025 rs334151 chr2 128253571 C T 1.61E-09 Protein C levels IWS1 intron 20802025 rs334146 chr2 128258208 C A 1.60E-09 Protein C levels IWS1 intron 20802025 rs1549767 chr2 128259371 C T 6.01E-11 Protein C levels IWS1 intron 20802025 rs334144 chr2 128259657 A C 1.63E-09 Protein C levels IWS1 intron 20802025 rs334143 chr2 128263476 C T 1.60E-09 Protein C levels IWS1 intron 20802025 rs12621149 chr2 128266844 A C 7.02E-11 Protein C levels IWS1 intron 20802025 rs2679409 chr2 128270109 C T 1.58E-09 Protein C levels IWS1 intron 20802025 rs334138 chr2 128272468 A G 1.59E-09 Protein C levels IWS1 intron 20802025 rs334137 chr2 128272674 A G 1.67E-09 Protein C levels IWS1 intron 20802025 rs2460106 chr2 128273004 T A 1.54E-09 Protein C levels IWS1 intron 20802025 rs777554 chr2 128279047 C A 1.51E-09 Protein C levels IWS1 intron 20802025 rs7582598 chr2 128289856 G A 2.10E-08 Protein C levels / / 20802025 rs7570609 chr2 128289963 A C 2.57E-05 Basophils / / pha003087 rs9287540 chr2 128297727 T G 1.67E-08 Protein C levels MYO7B intron 20802025 rs2052954 chr2 128299017 C T 3.03E-08 Protein C levels MYO7B intron 20802025 rs2163348 chr2 128299079 A G 1.79E-08 Protein C levels MYO7B intron 20802025 rs1864552 chr2 128299527 C A 1.89E-08 Protein C levels MYO7B intron 20802025 rs1019842 chr2 128305196 T C 2.84E-08 Protein C levels MYO7B intron 20802025 rs6727506 chr2 128308167 G T 4.80E-09 Protein C levels MYO7B intron 20802025 rs10803588 chr2 128328375 C T 4.90E-12 Protein C levels MYO7B intron 20802025 rs10803588 chr2 128328375 C T 7.05E-05 Waist-Hip Ratio MYO7B intron pha003013 rs10803588 chr2 128328375 C T 9.58E-05 Waist-Hip Ratio MYO7B intron pha003028 rs968756 chr2 128334470 C T 9.56E-04 Suicide attempts in bipolar disorder MYO7B intron 21423239 rs12477670 chr2 128334526 A G 5.72E-11 Protein C levels MYO7B intron 20802025 rs13407823 chr2 128338714 A G 1.37E-11 Protein C levels MYO7B intron 20802025 rs4662739 chr2 128339226 G C 1.39E-11 Protein C levels MYO7B intron 20802025 rs4662740 chr2 128339456 G T 1.40E-11 Protein C levels MYO7B intron 20802025 rs11693296 chr2 128340855 G A 7.00E-06 Asthma MYO7B intron 21790008 rs10928772 chr2 128341603 T G 2.20E-10 Protein C levels MYO7B intron 20802025 rs4662743 chr2 128350808 C T 5.28E-09 Protein C levels MYO7B intron 20802025 rs4662744 chr2 128350965 C T 5.44E-09 Protein C levels MYO7B intron 20802025 rs7558838 chr2 128351346 T C 5.72E-09 Protein C levels MYO7B intron 20802025 rs6715608 chr2 128353705 A T 1.01E-08 Protein C levels MYO7B intron 20802025 rs777437 chr2 128357647 C T 1.45E-10 Protein C levels MYO7B intron 20802025 rs11691981 chr2 128364684 G A 1.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MYO7B intron 24023788 rs777433 chr2 128368235 T C 6.81E-05 White matter integrity MYO7B intron 22425255 rs777435 chr2 128369896 A G 3.35E-08 Protein C levels MYO7B intron 20802025 rs930139 chr2 128370466 C T 1.34E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MYO7B intron 24023788 rs2288657 chr2 128395498 C T 0.000000036 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2288657 chr2 128395498 C T 7.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs78022502 chr2 128396167 A C 2.00E-06 Alzheimer's disease (cognitive decline) LIMS2 UTR-3 23535033 rs2244871 chr2 128398840 T C 1.17E-04 White matter integrity LIMS2 intron 22425255 rs3771295 chr2 128404860 A G 1.00E-04 Renal cell carcinoma GPR17 intron 22010048 rs17015535 chr2 128502585 A T 6.00E-06 Coronary artery calcification WDR33 intron 23870195 rs13013415 chr2 128519797 T C 2.82E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WDR33 intron 24023788 rs13013415 chr2 128519797 T C 3.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WDR33 intron 24023788 rs11557685 chr2 128522383 T C 7.48E-05 Amyotrophic lateral sclerosis (sporadic) WDR33 cds-synon 24529757 rs17600177 chr2 128524807 T C 7.21E-05 Alzheimer's disease (late onset) WDR33 intron 21379329 rs3771291 chr2 128527705 C A 9.17E-05 Alzheimer's disease (late onset) WDR33 intron 21379329 rs6722353 chr2 128552970 G A 2.92E-05 Post-operative nausea and vomiting WDR33 intron 21694509 rs6430952 chr2 128554348 G T 7.73E-04 Multiple complex diseases WDR33 intron 17554300 rs335136 chr2 128567755 T C 3.44E-05 Hearing function WDR33 intron 17255346 rs335136 chr2 128567755 T C 1.10E-04 Taste perception WDR33 intron 22132133 rs2109312 chr2 128575831 C T 3.00E-05 Breast cancer and prostate cancer / / 17903305 rs7562358 chr2 128587317 C T 1.64E-04 Taste perception / / 22132133 rs1045832 chr2 128621094 A G 3.89E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-3 21041247 rs13411546 chr2 128622491 G A 7.11E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-3 21041247 rs2118204 chr2 128624111 T C 5.99E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs7572242 chr2 128625164 C T 5.42E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs7566163 chr2 128635987 G A 2.32E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs2405635 chr2 128637225 A G 2.28E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs10183605 chr2 128642367 C G 2.77E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-5 21041247 rs10496665 chr2 128668557 A G 1.39E-12 Alcohol consumption / / pha001402 rs10754933 chr2 128841017 C T 8.52E-04 Multiple complex diseases / / 17554300 rs13387889 chr2 128888208 C T 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10194565 chr2 128897455 A G 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs7423842 chr2 128906495 C A 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs6430995 chr2 128918538 C T 2.30E-05 Urinary metabolites UGGT1 intron 21572414 rs6720058 chr2 128930582 C G 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs6738050 chr2 128930836 T C 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10175339 chr2 128941073 G A 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10496667 chr2 128998223 G A 8.10E-04 Lipid traits / / 24386095 rs13414154 chr2 129012073 G A 3.10E-05 Psychosis (methamphetamine induced) / / 23594818 rs2290113 chr2 129024313 A G 1 Drug response to Etoposide HS6ST1 UTR-3 17537913 rs1375347 chr2 129050909 A G 8.11E-05 Cleft lip HS6ST1 intron 20436469 rs12986656 chr2 129059084 A G 8.20E-06 Urinary metabolites HS6ST1 intron 21572414 rs840875 chr2 129068234 T C 7.60E-04 Multiple complex diseases HS6ST1 intron 17554300 rs10496668 chr2 129104968 C T 0.0006563 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10496668 chr2 129104968 C T 6.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17016161 chr2 129108613 C T 0.0003175 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17016161 chr2 129108613 C T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs882275 chr2 129125972 C A 9.78E-06 Monocyte chemoattractant protein-1 / / pha003071 rs4534993 chr2 129129169 T A 1.30E-05 Urinary metabolites / / 21572414 rs13418523 chr2 129131075 C T 7.40E-05 Monocyte chemoattractant protein-1 / / pha003071 rs880713 chr2 129131614 A G 1.11E-05 Pulmonary function / / 17903307 rs17016212 chr2 129134764 C T 9.50E-05 Response to statin therapy / / 20339536 rs17216354 chr2 129161203 C A 9.27E-04 Multiple complex diseases / / 17554300 rs4662810 chr2 129181780 T A 2.80E-05 Urinary metabolites / / 21572414 rs4662814 chr2 129189563 G T 9.22E-04 Type 2 diabetes / / 17463246 rs4662814 chr2 129189563 G T 1.40E-05 Urinary metabolites / / 21572414 rs714527 chr2 129204472 C T 8.80E-06 Urinary metabolites / / 21572414 rs17283348 chr2 129222649 T G 0.000315394 Hypertension (early onset hypertension) / / 22479346 rs4662827 chr2 129226743 C T 0.000315394 Hypertension (early onset hypertension) / / 22479346 rs1992249 chr2 129230661 T G 0.000733389 Hypertension (early onset hypertension) / / 22479346 rs2011526 chr2 129235584 G A 9.19E-05 Hypertension (early onset hypertension) / / 22479346 rs4662830 chr2 129374229 G A 1.10E-06 Urinary metabolites / / 21572414 rs6747443 chr2 129397486 C T 2.81E-04 Type 2 diabetes / / 17463246 rs10176941 chr2 129406233 A G 2.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs10928826 chr2 129444023 C A 3.32E-04 Multiple complex diseases / / 17554300 rs10928827 chr2 129457798 A G 8.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4662834 chr2 129478842 A G 5.00E-06 Bleomycin sensitivity / / 21106707 rs12996713 chr2 129483106 C T 9.72E-05 Biliary atresia / / 20460270 rs6744496 chr2 129489556 G A 1.37E-04 Multiple sclerosis / / 17660530 rs10496671 chr2 129493459 T C 2.67E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7561966 chr2 129504351 A G 3.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs7425326 chr2 129540093 T C 8.50E-06 Iron levels / / 21208937 rs11678720 chr2 129542628 G A 2.42E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11690223 chr2 129542735 C A 3.07E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11690256 chr2 129542767 C T 2.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs59424068 chr2 129546527 G A 7.94E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2406272 chr2 129561915 C A 5.09E-06 Cognitive impairment induced by topiramate / / 22091778 rs10496673 chr2 129594921 C A 8.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1251101 chr2 129623137 G T 1.59E-04 IgE levels / / 17255346 rs1562319 chr2 129628406 C T 4.62E-04 Taste perception / / 22132133 rs10803597 chr2 129647350 T G 4.67E-04 IgE levels / / 17255346 rs920280 chr2 129652413 G A 6.03E-05 Serum metabolites / / 19043545 rs2264824 chr2 129688698 A G 1.10E-05 Urinary metabolites / / 21572414 rs2246289 chr2 129700617 T C 1.60E-05 Urinary metabolites / / 21572414 rs2465821 chr2 129717684 G A 1.20E-05 Urinary metabolites / / 21572414 rs10187505 chr2 129739813 C T 8.50E-06 Urinary metabolites / / 21572414 rs17048943 chr2 129746292 C T 9.30E-06 Urinary metabolites / / 21572414 rs17048958 chr2 129752049 C G 9.60E-06 Urinary metabolites / / 21572414 rs17049003 chr2 129766337 T C 1.70E-06 Urinary metabolites / / 21572414 rs17049005 chr2 129766414 G A 7.10E-07 Urinary metabolites / / 21572414 rs1519441 chr2 129785207 A G 6.87E-05 Height / / pha003011 rs11682667 chr2 129819469 T C 7.06E-06 Alcohol dependence / / 23089632 rs1401630 chr2 129847487 A G 7.25E-06 Height / / pha003011 rs13428187 chr2 129864132 G A 7.30E-05 Waist Circumference / / pha003023 rs10496676 chr2 129915151 A G 6.02E-05 Body Mass Index / / pha003022 rs908849 chr2 129921407 G A 4.53E-04 Stroke / / pha002886 rs2919747 chr2 129965276 A G 6.01E-04 Type 2 diabetes / / 17463246 rs1251207 chr2 129981872 G T 4.79E-05 Alcohol withdrawal symptoms / / 22072270 rs1251207 chr2 129981872 G T 5.44E-05 Leukocyte Counts / / pha003091 rs13033188 chr2 129982956 C T 8.33E-06 Alcohol dependence (age at onset) / / 24962325 rs1251209 chr2 129983014 A G 6.50E-06 Alcohol dependence (age at onset) / / 24962325 rs2119515 chr2 129983131 G A 9.42E-06 Alcohol dependence (age at onset) / / 24962325 rs1251210 chr2 129983541 G A 9.42E-06 Alcohol dependence (age at onset) / / 24962325 rs1270481 chr2 129983664 T C 5.12E-06 Alcohol dependence (age at onset) / / 24962325 rs735987 chr2 129984402 G A 1.22E-06 Alcohol dependence (age at onset) / / 24962325 rs1251214 chr2 129985114 C A 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251215 chr2 129985154 C T 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1268546 chr2 129985182 T C 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251216 chr2 129985210 G C 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs2406641 chr2 129985425 A G 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251205 chr2 129987520 T A 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs12472824 chr2 129989847 C T 8.18E-06 Alcohol dependence (age at onset) / / 24962325 rs4662907 chr2 129990197 G A 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs13033217 chr2 129990869 T C 5.38E-04 Substance dependence phenotypes / / 24832863 rs13033217 chr2 129990869 T C 7.18E-06 Substance dependence phenotypes / / 24832863 rs13033217 chr2 129990869 T C 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs1078826 chr2 129991012 G A 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs1660895 chr2 129994332 A T 7.00E-07 Alcohol dependence (age at onset) / / 24962325 rs35878075 chr2 129995501 G A 6.78E-06 Alcohol dependence (age at onset) / / 24962325 rs879533 chr2 129996746 T A 7.46E-07 Alcohol dependence (age at onset) / / 24962325 rs1734330 chr2 129996988 A T 7.46E-07 Alcohol dependence (age at onset) / / 24962325 rs3856372 chr2 129997083 T A 6.04E-06 Alcohol dependence (age at onset) / / 24962325 rs894110 chr2 129997543 C G 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs935085 chr2 129998033 T C 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs2952621 chr2 129998443 T C 9.51E-06 Alcohol dependence / / 23089632 rs2952621 chr2 129998443 T C 1.77E-08 Substance dependence phenotypes / / 24832863 rs2952621 chr2 129998443 T C 3.85E-05 Substance dependence phenotypes / / 24832863 rs2952621 chr2 129998443 T C 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs1251172 chr2 129999190 G A 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs4662640 chr2 129999796 A C 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs4662641 chr2 130000272 G A 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs10167178 chr2 130001725 C T 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs1441141 chr2 130002073 A G 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs6708498 chr2 130002186 C T 5.97E-06 Alcohol dependence (age at onset) / / 24962325 rs1441142 chr2 130003278 G A 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs1251179 chr2 130003735 A G 1.25E-06 Alcohol dependence (age at onset) / / 24962325 rs837827 chr2 130004151 G A 9.77E-07 Alcohol dependence (age at onset) / / 24962325 rs6756671 chr2 130007175 G A 9.70E-06 Alcohol dependence (age at onset) / / 24962325 rs2197022 chr2 130007750 G T 1.97E-04 Substance dependence phenotypes / / 24832863 rs2197022 chr2 130007750 G T 2.53E-06 Substance dependence phenotypes / / 24832863 rs11681435 chr2 130023641 G T 9.41E-06 Periodontitis (PAL4Q3) / / 24024966 rs837899 chr2 130024033 G A 6.21E-05 Alcohol withdrawal symptoms / / 22072270 rs837898 chr2 130024589 A G 9.33E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs12474348 chr2 130033707 G A 6.40E-04 Type 2 diabetes / / 17463246 rs837841 chr2 130034012 C A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7567687 chr2 130034326 C T 8.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs7567687 chr2 130034326 C T 8.00E-07 Periodontitis (PAL4Q3) / / 24024966 rs7567687 chr2 130034326 C T 8.64E-06 Substance dependence phenotypes / / 24832863 rs12471876 chr2 130034680 A C 6.40E-04 Type 2 diabetes / / 17463246 rs1251193 chr2 130051445 A G 4.22E-05 Type 2 diabetes / / 17463246 rs2582998 chr2 130054847 T C 3.95E-05 Type 2 diabetes / / 17463246 rs755569 chr2 130077270 G A 1.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs755569 chr2 130077270 G A 3.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs837857 chr2 130086211 G A 3.15E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2165437 chr2 130098870 G A 8.00E-05 Personality dimensions / / 18957941 rs837891 chr2 130104550 G A 1.50E-05 Urinary metabolites / / 21572414 rs6751134 chr2 130106089 G A 6.10E-06 Urinary metabolites / / 21572414 rs4387734 chr2 130107101 T C 4.00E-06 Urinary metabolites / / 21572414 rs4662917 chr2 130111078 T C 1.40E-05 Urinary metabolites / / 21572414 rs1568765 chr2 130119905 G A 2.20E-05 Urinary metabolites / / 21572414 rs1097701 chr2 130147336 G A 0.000188 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs11685900 chr2 130190199 C T 1.63E-04 Multiple complex diseases / / 17554300 rs10205941 chr2 130191184 A G 0.0001972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10205941 chr2 130191184 A G 1.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10205941 chr2 130191184 A G 1.66E-04 Smoking quantity / / 24665060 rs17518713 chr2 130191927 C T 0.0003592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17518713 chr2 130191927 C T 3.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17578014 chr2 130191969 T A 0.0003091 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17578014 chr2 130191969 T A 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406819 chr2 130194452 G A 0.0003954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406819 chr2 130194452 G A 3.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs876890 chr2 130195492 A T 0.000274 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs876890 chr2 130195492 A T 2.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs876890 chr2 130195492 A T 9.00E-05 Smoking quantity / / 24665060 rs10174187 chr2 130200925 A G 0.0000806 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10174187 chr2 130200925 A G 8.06E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10174187 chr2 130200925 A G 3.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10174187 chr2 130200925 A G 4.18E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10496679 chr2 130201113 G A 0.0002619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10496679 chr2 130201113 G A 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17049483 chr2 130201986 C T 9.00E-04 Nicotine dependence / / 17158188 rs17049483 chr2 130201986 C T 0.0003429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17049483 chr2 130201986 C T 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453139 chr2 130203714 A C,T 0.000345 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453139 chr2 130203714 A C,T 3.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11893564 chr2 130203864 T A 0.0003472 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11893564 chr2 130203864 T A 3.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12993231 chr2 130206377 A G 0.0002634 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12993231 chr2 130206377 A G 2.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11897269 chr2 130207348 A G 0.0003522 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406820 chr2 130208064 T C 6.55E-05 Cognitive performance / / 19734545 rs6431079 chr2 130210384 G A 0.0007313 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6431079 chr2 130210384 G A 7.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12473149 chr2 130211900 A T 0.0003901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12473149 chr2 130211900 A T 3.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12475156 chr2 130212942 T A 0.0003467 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12475156 chr2 130212942 T A 3.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12475298 chr2 130213293 T A 0.0002811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12475298 chr2 130213293 T A 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12474448 chr2 130213420 A G 0.0002811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12474448 chr2 130213420 A G 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1982452 chr2 130213585 T C 0.000281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1982452 chr2 130213585 T C 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10803605 chr2 130213965 C T 0.0002816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10803605 chr2 130213965 C T 2.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453159 chr2 130215047 G A 0.000281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453159 chr2 130215047 G A 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453158 chr2 130215115 G T 0.0003138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453158 chr2 130215115 G T 3.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662941 chr2 130215877 A G 0.0000602 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662941 chr2 130215877 A G 6.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662942 chr2 130215888 T C 0.0000601 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662942 chr2 130215888 T C 6.01E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662945 chr2 130216043 A G 0.00006 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662945 chr2 130216043 A G 6.00E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662945 chr2 130216043 A G 3.00E-06 Response to cytidine analogues (gemcitabine) / / 24483146 rs4662945 chr2 130216043 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4662945 chr2 130216043 A G 4.71E-04 Smoking quantity / / 24665060 rs7603887 chr2 130216073 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7603887 chr2 130216073 A G 3.37E-04 Smoking quantity / / 24665060 rs17519343 chr2 130217568 G A 0.0002824 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17519343 chr2 130217568 G A 2.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406822 chr2 130218178 C T 0.0002407 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406822 chr2 130218178 C T 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406822 chr2 130218178 C T 2.71E-04 Smoking quantity / / 24665060 rs4427966 chr2 130221148 G A 0.0002523 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4427966 chr2 130221148 G A 2.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1377387 chr2 130221208 T C 0.000284 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1377387 chr2 130221208 T C 2.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11889563 chr2 130225962 T C 0.0002849 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11889563 chr2 130225962 T C 2.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1031429 chr2 130226437 T C 0.0002561 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1031429 chr2 130226437 T C 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12463574 chr2 130231715 C G 0.0005546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12463574 chr2 130231715 C G 5.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12996362 chr2 130233480 C T 0.00000671 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs11888580 chr2 130235218 C T 0.0005763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11888580 chr2 130235218 C T 5.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12478202 chr2 130240631 C T 0.0005917 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12478202 chr2 130240631 C T 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12479366 chr2 130241743 C A 0.0005915 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12479366 chr2 130241743 C A 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11680033 chr2 130245943 C T 9.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs4662951 chr2 130256272 C T 7.63E-05 Femoral neck bone geometry / / 22087292 rs10200446 chr2 130258186 C T 9.49E-05 Femoral neck bone geometry / / 22087292 rs11692339 chr2 130259988 T C 6.14E-05 Cognitive test performance / / 20125193 rs10172641 chr2 130270113 T C 4.74E-04 Smoking initiation / / 24665060 rs1349734 chr2 130271206 C T 2.48E-05 Bilirubin levels,in serum / / 19389676 rs13026874 chr2 130300787 G A 3.41E-04 Smoking initiation / / 24665060 rs2214271 chr2 130323107 C T 0.0008277 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2214271 chr2 130323107 C T 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs739659 chr2 130326385 G A 6.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2247277 chr2 130326644 C T 6.19E-05 Insulin resistance / / 21901158 rs2188910 chr2 130336129 G T 9.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2188909 chr2 130336225 C G 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2704565 chr2 130336741 T C 6.40E-05 Insulin resistance / / 21901158 rs1859063 chr2 130363731 T C 3.34E-04 Attention deficit hyperactivity disorder / / 22012869 rs17049647 chr2 130377385 C A 0.00000712 Aging / / 22445811 rs3109315 chr2 130384718 C T 1.63E-05 Personality dimensions / / 22628180 rs3109315 chr2 130384718 C T 0.0000176 VLDL cholesterol particle diameter / / 23263444 rs3094428 chr2 130400856 C T 7.81E-04 Multiple complex diseases / / 17554300 rs11681113 chr2 130407220 C G 2.70E-04 Multiple complex diseases / / 17554300 rs3109270 chr2 130425068 A C 5.75E-04 Smoking initiation / / 24665060 rs3109276 chr2 130428389 T G 2.48E-04 Smoking initiation / / 24665060 rs3108978 chr2 130431535 A G 4.24E-04 Smoking initiation / / 24665060 rs2407015 chr2 130432067 T C 5.19E-04 Smoking initiation / / 24665060 rs6725384 chr2 130433313 T C 0.0000415 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs10928920 chr2 130437195 A C 3.68E-04 Smoking initiation / / 24665060 rs4662981 chr2 130460115 A G 2.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10928927 chr2 130468366 C T 3.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs4233595 chr2 130483910 G A 0.0002 Migraine / / 22678113 rs6710206 chr2 130491622 G A 0.0002 Migraine / / 22678113 rs7578253 chr2 130534281 T C 7.20E-04 Multiple complex diseases / / 17554300 rs7575461 chr2 130534330 A G 6.05E-04 Coronary heart disease / / 21606135 rs6431110 chr2 130535743 A G 1.53E-04 Multiple complex diseases / / 17554300 rs3924460 chr2 130539467 A G 7.40E-04 Multiple complex diseases / / 17554300 rs3990701 chr2 130547748 A G 3.55E-05 Panic disorder / / 19165232 rs2464786 chr2 130550135 G A 2.59E-05 Alcohol dependence / / 21703634 rs2707653 chr2 130562942 C T 6.09E-05 Alcohol dependence / / 21703634 rs7591571 chr2 130583859 A G 8.15E-05 Hematocrit / / pha003097 rs7421552 chr2 130603995 A G 2.40E-05 Myasthenia gravis / / 23055271 rs4662999 chr2 130616955 G T 5.97E-05 LDL lipoproteins / / pha002902 rs7566086 chr2 130618373 G T 1.10E-05 Urinary metabolites / / 21572414 rs6724110 chr2 130628425 T C 9.49E-05 Squamous cell carcinoma / / 23341777 rs4662667 chr2 130643612 G A 3.56E-04 Type 2 diabetes / / 17463246 rs4662667 chr2 130643612 G A 1.49E-04 Vaspin levels / / 22907691 rs4662667 chr2 130643612 G A 0.0001493 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11687226 chr2 130645042 G A 1.81E-04 Fibrinogen / / 17255346 rs11687226 chr2 130645042 G A 8.02E-04 Type 2 diabetes / / 17463246 rs4233600 chr2 130646173 T C 1.81E-04 Fibrinogen / / 17255346 rs10197035 chr2 130646434 G C 1.23E-04 Type 2 diabetes / / 17463246 rs1316468 chr2 130647012 G A 1.51E-04 Type 2 diabetes / / 17463246 rs7558713 chr2 130664784 A G 7.10E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10445703 chr2 130667081 T A 6.00E-05 Prostate cancer / / 21743057 rs10192960 chr2 130674793 G T 6.00E-05 Prostate cancer / / 21743057 rs10928942 chr2 130683344 G A 4.75E-04 Alzheimer's disease (late onset) LOC389033 intron 21379329 rs10496681 chr2 130683532 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits LOC389033 intron 17848626 rs6431119 chr2 130693921 C A 1.17E-04 Smoking initiation / / 24665060 rs6760544 chr2 130694072 A C 6.22E-05 Smoking initiation / / 24665060 rs1922633 chr2 130701189 G A 6.95E-05 Smoking initiation / / 24665060 rs6707259 chr2 130703962 C T 1.13E-04 Smoking initiation / / 24665060 rs4381734 chr2 130761737 C T 5.12E-04 Smoking initiation / / 24665060 rs2084784 chr2 130916415 A G 0.000272 Antisocial behavior SMPD4 intron 23077488 rs10198499 chr2 130943513 T C 1.60E-04 HDL particle features MZT2B intron 21283740 rs13000721 chr2 130952038 G A 0.000077 Antisocial behavior TUBA3E missense 23077488 rs7559051 chr2 131050872 G A 9.50E-04 Insulin resistance / / 21901158 rs2292850 chr2 131102538 A C 5.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IMP4 intron 20877124 rs3739122 chr2 131131525 C T 6.35E-04 Alzheimer's disease PTPN18 UTR-3 24755620 rs272128 chr2 131487673 A C 4.87E-05 Blood Pressure GPR148 missense pha003047 rs13400337 chr2 131489113 C T 6.10E-06 Iris characteristics / / 21835309 rs272146 chr2 131537733 C A 7.73E-04 Alcohol dependence / / 24277619 rs13395546 chr2 131545192 A G 1.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs272111 chr2 131546505 A C 3.45E-05 Aortic root size / / 21223598 rs272112 chr2 131546685 T C 2.82E-05 Aortic root size / / 21223598 rs1430706 chr2 131565647 G A 5.51E-04 Aortic root size / / 21223598 rs1542604 chr2 131593045 G A 6.85E-05 Body mass (lean) / / 19268274 rs6715179 chr2 131623166 A C 6.28E-04 Taste perception / / 22132133 rs11887132 chr2 131678879 G T 3.95E-05 Coronary restenosis ARHGEF4 intron 21878436 rs11687441 chr2 131701797 A C,G,T 4.92E-04 Multiple complex diseases ARHGEF4 intron 17554300 rs13021106 chr2 131741691 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ARHGEF4 intron 22628534 rs4569521 chr2 131747953 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ARHGEF4 intron 22628534 rs2313160 chr2 131837242 C A 8.05E-04 Type 2 diabetes FAM168B intron 17463246 rs7597771 chr2 131852643 G T 1.97E-04 Multiple complex diseases / / 17554300 rs1852556 chr2 132095028 T C 3.36E-05 Statin-induced myopathy / / 21826682 rs2272355 chr2 132164854 T C 8.98E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6430791 chr2 132166208 C T 6.56E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs7573518 chr2 132166387 G A 7.29E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs7584315 chr2 132166606 C T 8.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs7589111 chr2 132170888 G A 3.06E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs6739473 chr2 132171917 A C 4.89E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs941332 chr2 132188005 C T 5.25E-04 Smoking quantity / / 24665060 rs12472079 chr2 132298468 C A 9.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10928743 chr2 132346663 C G 5.47E-05 Lymphocyte counts / / 22286170 rs4850224 chr2 132410986 T C 3.72E-05 Calcium levels / / pha003085 rs7585022 chr2 132497214 T C 6.27E-04 Type 2 diabetes C2orf27A intron 17463246 rs4080478 chr2 132648802 G C 3.45E-14 Multiple complex diseases / / 17554300 rs16848400 chr2 132751852 G T 1.38E-04 Multiple complex diseases / / 17554300 rs16848398 chr2 132755417 G A 1.87E-04 Multiple complex diseases / / 17554300 rs16831128 chr2 133144392 A G 4.00E-07 Conduct disorder (symptom count) / / 20585324 rs16831128 chr2 133144392 A G 5.00E-06 Conduct disorder (symptom count) / / 20585324 rs41334446 chr2 133148734 G T 4.91E-04 Multiple complex diseases / / 17554300 rs11684939 chr2 133152621 G A 0.0006351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11684939 chr2 133152621 G A 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11690367 chr2 133158276 T G 4.12E-06 Multiple complex diseases / / 17554300 rs2315377 chr2 133159427 C T 8.68E-04 Psoriasis / / 20953187 rs6720935 chr2 133165560 C T 6.90E-04 Pulmonary function / / 23932459 rs7592134 chr2 133173065 A G 4.39E-04 Fibrinogen / / 17255346 rs13420028 chr2 133188106 T G 1.00E-10 Hypertension GPR39 intron 21626137 rs10188442 chr2 133189239 C T 1.00E-10 Hypertension GPR39 intron 21626137 rs3748861 chr2 133196452 C A 2.63E-05 Smoking initiation GPR39 intron 24665060 rs4417767 chr2 133205288 A C 6.73E-04 Type 2 diabetes GPR39 intron 17463246 rs4953981 chr2 133216079 T C 4.18E-04 Type 2 diabetes GPR39 intron 17463246 rs7605278 chr2 133216314 A C 6.96E-04 Multiple complex diseases GPR39 intron 17554300 rs4508654 chr2 133216413 A G 8.71E-04 Type 2 diabetes GPR39 intron 17463246 rs4525746 chr2 133220163 C T 7.69E-04 Type 2 diabetes GPR39 intron 17463246 rs13030799 chr2 133267847 A G 2.70E-05 Urinary metabolites GPR39 intron 21572414 rs10496687 chr2 133269261 G A 5.67E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR39 intron 22566498 rs4395295 chr2 133277683 C T 4.05E-05 Orofacial clefts GPR39 intron 22419666 rs16833598 chr2 133283250 C T 6.33E-04 Multiple complex diseases GPR39 intron 17554300 rs6710643 chr2 133283943 T C 5.31E-04 Heart Failure GPR39 intron pha002884 rs9287421 chr2 133313845 C T 1.69E-04 Dental caries GPR39 intron 21940522 rs3109144 chr2 133320414 C T 1.90E-05 Urinary metabolites GPR39 intron 21572414 rs3109154 chr2 133342529 C T 7.78E-05 Heart Failure GPR39 intron pha002884 rs3109157 chr2 133348083 A G 3.58E-05 Body Fat Distribution GPR39 intron pha003017 rs3109157 chr2 133348083 A G 2.74E-05 Body Fat Distribution GPR39 intron pha003018 rs4547577 chr2 133393808 A C 1.30E-05 Urinary metabolites GPR39 intron 21572414 rs10166009 chr2 133471789 C T 8.70E-06 Urinary metabolites NCKAP5 intron 21572414 rs10166009 chr2 133471789 C T 3.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) NCKAP5 intron 23648065 rs6736839 chr2 133478977 T C 4.28E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs4953986 chr2 133482699 T C 2.66E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs11692408 chr2 133484964 A G 2.76E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs7596376 chr2 133487103 A C 1.30E-05 Urinary metabolites NCKAP5 intron 21572414 rs4953987 chr2 133491425 A G 3.08E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs17397163 chr2 133491553 A G 8.15E-05 Hypertension NCKAP5 intron pha003042 rs560418667 chr2 133492750 A AT 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs560418667 chr2 133492750 A AT 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs61240058 chr2 133492750 A AT 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs61240058 chr2 133492750 A AT 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs984521 chr2 133492750 A G,T 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs984521 chr2 133492750 A G,T 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs16840576 chr2 133494705 C G 5.40E-06 Urinary metabolites NCKAP5 intron 21572414 rs7606532 chr2 133505873 A C 0.0002 Migraine NCKAP5 intron 22678113 rs10496693 chr2 133532709 G A 3.24E-06 Cardiovascular disease NCKAP5 intron 18179892 rs17325719 chr2 133542585 C G 4.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) NCKAP5 missense 21239504 rs1026076 chr2 133602119 A G 4.16E-05 Type 2 diabetes NCKAP5 intron 17463246 rs16842572 chr2 133612814 C G 1.80E-05 Iron levels NCKAP5 intron 21208937 rs12464177 chr2 133627136 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NCKAP5 intron 22628534 rs1037173 chr2 133630242 T C 4.04E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13005482 chr2 133635429 A G 2.73E-04 Type 2 diabetes NCKAP5 intron 17463246 rs17326398 chr2 133635545 C A 8.39E-04 Type 2 diabetes NCKAP5 intron 17463246 rs1020429 chr2 133661411 T C 5.80E-04 Premature ovarian failure NCKAP5 intron 19508998 rs13016800 chr2 133698894 C A 2.27E-04 Type 2 diabetes NCKAP5 intron 17463246 rs7589684 chr2 133735222 C G 2.00E-04 Type 2 diabetes and 6 quantitative traits NCKAP5 intron 17848626 rs6727803 chr2 133739616 G A 7.07E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21423239 rs6704839 chr2 133742332 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits NCKAP5 intron 17848626 rs1437898 chr2 133746630 A C 8.00E-06 Multiple sclerosis (age of onset) NCKAP5 intron 19010793 rs12475645 chr2 133754360 A G 2.53E-04 Alzheimer's disease (late onset) NCKAP5 intron 21379329 rs4953868 chr2 133769673 G A 5.78E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs1437903 chr2 133771658 C A 6.60E-06 Orofacial clefts NCKAP5 intron 22419666 rs13395693 chr2 133806124 T C 6.18E-04 Amyotrophic Lateral Sclerosis NCKAP5 intron 17362836 rs13395693 chr2 133806124 T C 5.49E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13395811 chr2 133806232 T C 3.72E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13413161 chr2 133822742 A G 0.0000044 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs10174856 chr2 133830379 T C 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NCKAP5 intron 20877124 rs16847317 chr2 133841199 T C 7.63E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1370596 chr2 133851844 T C 3.70E-06 Thyroid function NCKAP5 intron 20826269 rs1437895 chr2 133852801 G A 5.00E-06 Thyroid function NCKAP5 intron 20826269 rs1476150 chr2 133876395 G C 3.66E-05 Menarche (age at onset) NCKAP5 intron 23599027 rs1476150 chr2 133876395 G C 4.51E-05 Menarche (age at onset) NCKAP5 intron 23599027 rs16857192 chr2 133897009 G C 2.56E-04 Multiple complex diseases NCKAP5 intron 17554300 rs13427795 chr2 133901426 T C 0.00000087 Internal carotid artery thickness (far walls) NCKAP5 intron 23487405 rs13427795 chr2 133901426 T C 0.00000105 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs13427795 chr2 133901426 T C 0.00000275 Internal carotid artery thickness (near walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000039 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000041 Internal carotid artery thickness (far walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000079 Internal carotid artery thickness (near walls) NCKAP5 intron 23487405 rs12691834 chr2 133952040 G A 2.38E-05 Tuberculosis NCKAP5 intron 24057671 rs13029552 chr2 133957689 A C 7.43E-05 Aging (time to event) NCKAP5 intron 21782286 rs1836216 chr2 133966177 C T 4.23E-04 Diabetic retinopathy NCKAP5 intron 20871662 rs10496699 chr2 133977005 A G 7.19E-04 Parkinson's disease NCKAP5 intron 17052657 rs6749561 chr2 134000064 A G 4.91E-05 Bipolar disorder NCKAP5 intron 19488044 rs6749561 chr2 134000064 A G 1.72E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs6749561 chr2 134000064 A G 3.67E-05 Bipolar Disorder NCKAP5 intron pha002858 rs17800749 chr2 134003754 C T 9.11E-06 Bipolar disorder NCKAP5 intron 19488044 rs17800749 chr2 134003754 C T 1.81E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs17800749 chr2 134003754 C T 1.81E-05 Bipolar Disorder NCKAP5 intron pha002858 rs10496702 chr2 134005569 G A 7.83E-04 Type 2 diabetes NCKAP5 intron 17463246 rs10496702 chr2 134005569 G A 1.22E-05 Bipolar disorder NCKAP5 intron 19488044 rs10496702 chr2 134005569 G A 7.00E-07 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs10496702 chr2 134005569 G A 1.20E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13430905 chr2 134011993 C T 8.41E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13430905 chr2 134011993 C T 1.11E-05 Bipolar disorder NCKAP5 intron 19488044 rs13430905 chr2 134011993 C T 1.42E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13430905 chr2 134011993 C T 1.07E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13431418 chr2 134012499 C T 8.09E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13431418 chr2 134012499 C T 1.18E-05 Bipolar disorder NCKAP5 intron 19488044 rs13431418 chr2 134012499 C T 1.03E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13431418 chr2 134012499 C T 1.15E-05 Bipolar Disorder NCKAP5 intron pha002858 rs7600871 chr2 134014961 C T 1.16E-05 Bipolar disorder NCKAP5 intron 19488044 rs7600871 chr2 134014961 C T 8.79E-07 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs7600871 chr2 134014961 C T 1.20E-05 Bipolar Disorder NCKAP5 intron pha002858 rs10193871 chr2 134017053 T C 4.18E-06 Bipolar disorder NCKAP5 intron 19488044 rs10193871 chr2 134017053 T C 6.33E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs10193871 chr2 134017053 T C 6.98E-06 Bipolar Disorder NCKAP5 intron pha002858 rs1985935 chr2 134028503 C T 2.58E-05 Alzheimer's disease NCKAP5 intron 22005930 rs1430170 chr2 134033399 T C 1.99E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1367207 chr2 134035868 A G 1.10E-04 Alzheimer's disease NCKAP5 intron 22005930 rs6430407 chr2 134039363 G C 6.18E-04 Alzheimer's disease NCKAP5 intron 22005930 rs7577925 chr2 134040519 G A 3.00E-06 Attention deficit hyperactivity disorder NCKAP5 intron 18821565 rs7577925 chr2 134040519 G A 6.87E-04 Alzheimer's disease NCKAP5 intron 22005930 rs13399558 chr2 134043215 T A 1.89E-05 Bipolar disorder NCKAP5 intron 19488044 rs13399558 chr2 134043215 T A 4.99E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13399558 chr2 134043215 T A 1.34E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13412008 chr2 134044193 G T 4.04E-05 Bipolar disorder NCKAP5 intron 19488044 rs13412008 chr2 134044193 G T 4.53E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13412008 chr2 134044193 G T 2.65E-05 Bipolar Disorder NCKAP5 intron pha002858 rs12469282 chr2 134044781 A T 6.76E-05 Type 2 diabetes NCKAP5 intron 17463246 rs12469282 chr2 134044781 A T 2.71E-05 Bipolar disorder NCKAP5 intron 19488044 rs12469282 chr2 134044781 A T 2.57E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs12469282 chr2 134044781 A T 2.24E-05 Bipolar Disorder NCKAP5 intron pha002858 rs1549739 chr2 134044803 G C 2.08E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1344726 chr2 134046163 A G 2.20E-04 Alzheimer's disease NCKAP5 intron 22005930 rs16823369 chr2 134053137 G A 5.16E-04 Aortic root size NCKAP5 intron 21223598 rs2289076 chr2 134128159 G A 5.07E-05 Atopy NCKAP5 intron 21625490 rs9287428 chr2 134196068 T C 2.00E-04 Type 2 diabetes NCKAP5 intron 17846126 rs2012254 chr2 134201563 T C 2.60E-04 Multiple complex diseases NCKAP5 intron 17554300 rs7604549 chr2 134206763 T C 2.00E-04 Type 2 diabetes NCKAP5 intron 17846126 rs6430419 chr2 134210040 T C 2.03E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16825174 chr2 134213436 C T 9.95E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16825174 chr2 134213436 C T 2.72E-04 Lung function (forced vital capacity) NCKAP5 intron 24023788 rs1821625 chr2 134230217 G T 7.00E-06 Multiple sclerosis NCKAP5 intron 23412934 rs1865585 chr2 134238128 G C 9.98E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16826005 chr2 134266001 A G 1.00E-07 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs16826050 chr2 134271218 T A,C 3.72E-05 Cognitive impairment induced by topiramate NCKAP5 intron 22091778 rs12471007 chr2 134273472 G C 1.09E-07 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs2043234 chr2 134314782 C T 4.46E-06 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs13412991 chr2 134323037 T C 0.0002 Migraine NCKAP5 intron 22678113 rs11675147 chr2 134327168 G A 5.19E-05 Post-operative nausea and vomiting / / 21694509 rs6430432 chr2 134344666 G A 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17817136 chr2 134349496 C T 2.00E-05 Parkinson's disease (age of onset) / / 19772629 rs6715224 chr2 134350570 C T 4.33E-04 Gallbladder cancer / / 22318345 rs17817190 chr2 134351648 T G 2.50E-06 Parkinson's disease (age of onset) / / 19772629 rs7588567 chr2 134363032 T C 4.00E-07 Glaucoma (primary open-angle) / / 22419738 rs4347888 chr2 134424634 T A 1.70E-04 Multiple complex diseases / / 17554300 rs16827706 chr2 134427207 A G 8.41E-04 Taste perception / / 22132133 rs16827735 chr2 134428450 G T 3.13E-04 Multiple complex diseases / / 17554300 rs7567288 chr2 134434824 T C 2.00E-12 Height / / 20881960 rs7571689 chr2 134436669 A G 2.90E-05 Urinary metabolites / / 21572414 rs1901439 chr2 134437471 T C 0.0000267 Alcohol craving with or without dependence / / 22481050 rs1901440 chr2 134437959 C A 3.00E-06 Response to gemcitabine in pancreatic cancer / / 22293537 rs6430443 chr2 134442532 A G 8.61E-04 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4522658 chr2 134487163 G A 3.40E-05 Type 2 diabetes / / 21647700 rs6414015 chr2 134513100 C T 8.47E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1446750 chr2 134513621 G A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4425130 chr2 134514686 G A 1.35E-04 Attention deficit hyperactivity disorder / / 22420046 rs4425130 chr2 134514686 G A 5.52E-05 Body Mass Index / / pha003014 rs12472557 chr2 134528080 G A 6.36E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6722456 chr2 134529091 G A 4.00E-08 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs1446741 chr2 134529661 G T 2.49E-04 Schizophrenia / / 19197363 rs16829231 chr2 134531622 T C 7.70E-05 Glioma (high-grade) / / 19578366 rs16829231 chr2 134531622 T C 8.00E-06 Smoking behavior / / 20418888 rs16829241 chr2 134532622 C A 8.30E-05 Endometriosis / / 21151130 rs7585252 chr2 134540328 A G 1.74E-05 Wegener's granulomatosis / / 23740775 rs4589813 chr2 134549860 T G 0.000224485 Hypertension (early onset hypertension) / / 22479346 rs16829491 chr2 134563476 C T 2.30E-05 Urinary metabolites / / 21572414 rs10928460 chr2 134563712 C A 2.60E-05 Urinary metabolites / / 21572414 rs895535 chr2 134565505 G A 9.52E-05 Hypertension (early onset hypertension) / / 22479346 rs11896627 chr2 134567325 A G 3.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17770239 chr2 134584179 A G 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17770239 chr2 134584179 A G 1.64E-04 Alzheimer's disease / / 22005930 rs1446746 chr2 134586564 C G 4.93E-04 Alzheimer's disease / / 22005930 rs2197604 chr2 134594234 C T 5.80E-05 Alzheimer's disease / / 22005930 rs41343844 chr2 134618121 A G 9.28E-06 Type 2 diabetes / / 23209189 rs6711228 chr2 134644096 C T 6.58E-05 Breast cancer / / pha002853 rs13429789 chr2 134644309 G T 3.62E-06 Personality dimensions / / 22628180 rs7582472 chr2 134644794 T C 1.59E-06 Personality dimensions / / 22628180 rs7594893 chr2 134645345 G C 1.89E-04 Smoking quantity / / 24665060 rs12464286 chr2 134651226 G A 8.40E-04 Alzheimer's disease / / 17998437 rs1446732 chr2 134657740 C A 7.38E-05 Type 2 diabetes / / 17846126 rs1446732 chr2 134657740 C A 5.87E-04 Alzheimer's disease / / 17998437 rs10803542 chr2 134678803 C G 7.99E-04 Alzheimer's disease / / 17998437 rs13389356 chr2 134695073 T A 5.30E-04 Depression (quantitative trait) / / 20800221 rs930621 chr2 134702078 C T 8.74E-05 Type 2 diabetes / / 17846126 rs16829861 chr2 134729700 A G 2.61E-05 Postoperative ventricular dysfunction / / 21980348 rs10208875 chr2 134753056 A G 2.79E-05 Sodium levels / / pha003093 rs7561901 chr2 134768634 C G,T 7.03E-05 Sodium levels / / pha003093 rs2046475 chr2 134775344 T C 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6719360 chr2 134788709 G A 4.65E-05 Sodium levels / / pha003093 rs11899367 chr2 134794256 C T 8.86E-04 Type 2 diabetes / / 17463246 rs11899367 chr2 134794256 C T 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3891480 chr2 134800060 T C 2.03E-05 Sodium levels / / pha003093 rs1519305 chr2 134813786 G A 4.61E-05 Sodium levels / / pha003093 rs1715008 chr2 134817016 C T 6.41E-05 Cleft lip / / 20436469 rs1715008 chr2 134817016 C T 1.66E-06 Sodium levels / / pha003093 rs11688332 chr2 134830720 G T 2.96E-07 Sodium levels / / pha003093 rs1257370 chr2 134831118 C A 3.57E-05 Sodium levels / / pha003093 rs200893282 chr2 134831119 A AG 2.96E-07 Sodium levels / / pha003093 rs4953900 chr2 134831119 A G 2.96E-07 Sodium levels / / pha003093 rs10175819 chr2 134832158 T C 2.09E-07 Sodium levels / / pha003093 rs11684754 chr2 134833871 G A 2.66E-07 Sodium levels / / pha003093 rs1466567 chr2 134846788 G A 8.00E-04 Multiple complex diseases / / 17554300 rs1879019 chr2 134872037 A G 4.89E-04 Alzheimer's disease / / 17998437 rs1879018 chr2 134872561 T C 8.82E-04 Type 2 diabetes / / 17463246 rs4600717 chr2 134889971 G A 8.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7601756 chr2 134893447 G A 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2139310 chr2 134912172 C T 7.27E-04 Multiple complex diseases / / 17554300 rs11692586 chr2 134917005 A G 9.70E-04 Multiple complex diseases / / 17554300 rs10496721 chr2 134932459 G T 8.13E-05 Cholesterol / / pha003083 rs4953906 chr2 134955210 C T 2.53E-04 Smoking cessation / / 24665060 rs13017917 chr2 134961089 G A 1.59E-06 Rheumatoid arthritis / / 19503088 rs2593708 chr2 134979415 C T 2.79E-05 Alzheimer's disease / / 21098978 rs2593708 chr2 134979415 C T 9.42E-07 Sodium levels / / pha003093 rs1965183 chr2 134979966 A G 4.05E-05 Recombination rate / / 21698098 rs16830230 chr2 134983770 A G 5.61E-04 Alzheimer's disease / / 24755620 rs1257220 chr2 135015347 A G 1.80E-10 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 1.86E-10 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 2.65E-09 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 3.46E-09 N-glycan levels,in plasma MGAT5 intron 21908519 rs16830280 chr2 135017417 A T 3.57E-05 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791259 chr2 135018065 C T 2.06E-04 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791259 chr2 135018065 C T 3.18E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791261 chr2 135018206 T G 4.60E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791266 chr2 135018736 C G 3.42E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3828175 chr2 135018797 A G 3.52E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3828176 chr2 135022328 A T 9.16E-06 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3828176 chr2 135022328 A T 3.69E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs373081440 chr2 135022365 CA CCA,CTG 2.17E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs373081440 chr2 135022365 CA CCA,CTG 3.90E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791269 chr2 135022365 C T 2.17E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791269 chr2 135022365 C T 3.90E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791271 chr2 135022414 T C 3.93E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs6735741 chr2 135022906 A G 8.33E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs6735741 chr2 135022906 A G 4.09E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791273 chr2 135024482 G C 1.40E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791273 chr2 135024482 G C 4.20E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791275 chr2 135024680 A G 4.16E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791276 chr2 135024716 A C 4.15E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791278 chr2 135025868 G A 6.05E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs4953911 chr2 135068794 T A 2.00E-07 Multiple sclerosis (severity) MGAT5 intron 20117844 rs10172155 chr2 135094416 G A 1.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MGAT5 intron 24023788 rs2290049 chr2 135114889 A G 2.26E-04 Myopia (pathological) MGAT5 intron 21095009 rs12613306 chr2 135127474 A G 3.69E-04 Myopia (pathological) MGAT5 intron 21095009 rs12467609 chr2 135143287 C T 7.00E-06 Subcutaneous adipose tissue MGAT5 intron 22589738 rs3748900 chr2 135160755 G A 1.07E-04 Parkinson's disease MGAT5 intron 17052657 rs4954142 chr2 135161934 A G 8.52E-04 Parkinson's disease MGAT5 intron 17052657 rs2118844 chr2 135167600 G A 3.56E-05 Parkinson's disease MGAT5 intron 17052657 rs3791316 chr2 135183298 C T 9.88E-04 Response to cytidine analogues (gemcitabine) MGAT5 intron 24483146 rs610624 chr2 135213762 T C 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM163 UTR-3 20877124 rs10179686 chr2 135214570 C T 9.43E-04 Obesity (extreme) TMEM163 intron 21935397 rs10179686 chr2 135214570 C T 8.00E-06 Large artery stroke TMEM163 intron 24262325 rs1840413 chr2 135236250 T C 4.34E-04 Gallstones TMEM163 intron 17632509 rs494905 chr2 135240324 G A 1.41E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs507968 chr2 135253960 T A 3.53E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs16830708 chr2 135254442 C G,T 0.000885 Salmonella-induced pyroptosis TMEM163 intron 22837397 rs491200 chr2 135257289 C T 2.92E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs662438 chr2 135260903 C T 4.46E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs540053 chr2 135261737 C T 3.39E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs579076 chr2 135266560 C T 9.86E-05 Non-alcoholic fatty liver disease histology (other) TMEM163 intron 20708005 rs624817 chr2 135278207 T C 3.40E-05 Type 2 diabetes TMEM163 intron 23209189 rs637993 chr2 135278886 G A 1.06E-04 Cognitive function TMEM163 intron 24684796 rs512375 chr2 135285279 G T 1.30E-04 Coronary Artery Disease TMEM163 intron 17634449 rs655472 chr2 135290221 T C 8.86E-07 Coronary Artery Disease TMEM163 intron 17634449 rs666614 chr2 135290453 G C 1.19E-06 Coronary Artery Disease TMEM163 intron 17634449 rs621341 chr2 135295180 T C 3.84E-04 Parkinson's disease TMEM163 intron 22438815 rs621341 chr2 135295180 T C 6.90E-07 Type 2 diabetes TMEM163 intron 23209189 rs2924943 chr2 135300482 G A 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM163 intron 20877124 rs17498551 chr2 135323853 A G 1.34E-04 Multiple complex diseases TMEM163 intron 17554300 rs842362 chr2 135341120 G A 1.17E-04 Alzheimer's disease (late onset) TMEM163 intron 21379329 rs6750788 chr2 135362981 A G 3.28E-04 Alzheimer's disease (late onset) TMEM163 intron 21379329 rs35564151 chr2 135372951 G A 1.08E-05 Type 2 diabetes TMEM163 intron 23209189 rs6430527 chr2 135386581 C T 2.80E-04 Coronary Artery Disease TMEM163 intron 17634449 rs7560738 chr2 135419163 A G 2.60E-05 Urinary metabolites TMEM163 intron 21572414 rs998451 chr2 135429288 G A 9.22E-07 Type 2 diabetes TMEM163 intron 23209189 rs6745983 chr2 135430709 G A 2.75E-04 Coronary Artery Disease TMEM163 intron 17634449 rs10171677 chr2 135446390 A G 8.23E-05 Type 2 diabetes TMEM163 intron 23209189 rs10928513 chr2 135456759 C T 5.69E-05 Type 2 diabetes TMEM163 intron 23209189 rs6747870 chr2 135469769 A G 9.98E-04 Multiple complex diseases TMEM163 intron 17554300 rs6723108 chr2 135479980 G T 1.93E-05 Amyotrophic lateral sclerosis / / 19193627 rs6723108 chr2 135479980 G T 7.02E-06 Parkinson's disease / / 22438815 rs6723108 chr2 135479980 G T 7.00E-08 Type 2 diabetes / / 23209189 rs4346444 chr2 135486894 T G 4.56E-04 Multiple complex diseases / / 17554300 rs4346444 chr2 135486894 T G 8.05E-04 Smoking cessation / / 24665060 rs1942055 chr2 135498924 G C 1.84E-05 Lung function (forced vital capacity) / / 24929828 rs16831005 chr2 135537332 T C 1.64E-06 Body mass index / / 19584900 rs16831005 chr2 135537332 T C 6.38E-06 Body mass index / / 19584900 rs6430538 chr2 135539967 C T 2.00E-07 Parkinson's disease / / 22451204 rs7599054 chr2 135540546 A G 5.45E-04 Parkinson's disease / / 17052657 rs6710823 chr2 135592381 G A 7.00E-09 Parkinson's disease / / 21292315 rs6710823 chr2 135592381 G A 1.91E-05 Parkinson's disease / / 22438815 rs6710823 chr2 135592381 G A 1.35E-09 Parkinson's disease / / 22451204 rs10198552 chr2 135599876 T C 7.00E-07 Obesity-related traits ACMSD intron 23251661 rs6430553 chr2 135631400 C T 6.00E-12 Blood metabolite levels ACMSD intron 24816252 rs2166480 chr2 135637338 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ACMSD intron 17982456 rs10928525 chr2 135736138 C G 8.50E-04 Response to cytadine analogues (cytosine arabinoside) YSK4 intron 24483146 rs16831235 chr2 135745129 G A 7.01E-04 Response to cytadine analogues (cytosine arabinoside) YSK4 missense 24483146 rs1530559 chr2 135755629 A G 3.37E-08 Fasting insulin-related traits YSK4 intron 22885924 rs6754977 chr2 135756378 C T 1.44E-05 Age-related macular degeneration YSK4 cds-synon pha000001 rs16831243 chr2 135762344 C T 3.91E-05 Paget's disease YSK4 intron 20436471 rs7582173 chr2 135763318 G A 4.10E-05 Paget's disease YSK4 intron 20436471 rs16831256 chr2 135781035 C T 8.46E-04 Depression (quantitative trait) YSK4 intron 20800221 rs4954218 chr2 135803425 G T 8.23E-05 Serum metabolites / / 19043545 rs4954218 chr2 135803425 G T 1.00E-09 Corneal structure / / 21979947 rs61369044 chr2 135808469 A C 1.95E-35 Metabolite levels RAB3GAP1 nearGene-5 22286219 rs16831311 chr2 135816439 A G 5.07E-04 Multiple complex diseases RAB3GAP1 intron 17554300 rs16831315 chr2 135825074 T C 8.35E-04 Multiple complex diseases RAB3GAP1 intron 17554300 rs16831315 chr2 135825074 T C 2.70E-05 Personality dimensions RAB3GAP1 intron 18957941 rs7570971 chr2 135837906 C A 1.00E-08 Cholesterol,total RAB3GAP1 intron 20686565 rs7570971 chr2 135837906 C A 2.00E-08 Type 2 diabetes RAB3GAP1 intron 23209189 rs7570971 chr2 135837906 C A 1.00E-13 Cholesterol,total RAB3GAP1 intron 24097068 rs7570971 chr2 135837906 C A 8.00E-45 Blood metabolite levels RAB3GAP1 intron 24816252 rs6728452 chr2 135839805 C T 7.57E-04 Depression (quantitative trait) RAB3GAP1 intron 20800221 rs1869829 chr2 135877562 A G 7.42E-06 Paget's disease RAB3GAP1 intron 20436471 rs7603310 chr2 135902220 C T 3.40E-04 Sudden cardiac arrest RAB3GAP1 intron 21658281 rs6730157 chr2 135907088 A G 2.16E-08 Lipid levels RAB3GAP1 intron 20370913 rs6730157 chr2 135907088 A G 1.69E-05 Paget's disease RAB3GAP1 intron 20436471 rs6730157 chr2 135907088 A G 4.93E-12 Sudden cardiac death RAB3GAP1 intron 23593153 rs3739028 chr2 135907846 T C 5.28E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) RAB3GAP1 intron 24192120 rs6430563 chr2 135967778 A G 5.19E-05 Personality dimensions ZRANB3 intron 18957941 rs1900741 chr2 136002500 C T 3.13E-05 Paget's disease ZRANB3 intron 20436471 rs1561277 chr2 136092061 C A 4.95E-06 Paget's disease ZRANB3 intron 20436471 rs1469950 chr2 136128254 A G 7.06E-05 Personality dimensions ZRANB3 intron 18957941 rs16831601 chr2 136151774 C T 9.76E-05 Personality dimensions ZRANB3 intron 18957941 rs16831751 chr2 136264631 A G 4.54E-05 Personality dimensions ZRANB3 intron 18957941 rs16831751 chr2 136264631 A G 8.78E-04 Depression (quantitative trait) ZRANB3 intron 20800221 rs3806502 chr2 136288273 C T 7.59E-05 Triglycerides ZRANB3 intron pha003080 rs4954265 chr2 136324225 A G 1.00E-04 Cognitive impairment induced by topiramate R3HDM1 intron 22091778 rs4954265 chr2 136324225 A G 7.95E-05 Triglycerides R3HDM1 intron pha003080 rs6723890 chr2 136366433 A G 9.56E-04 Prostate cancer mortality R3HDM1 intron 20978177 rs12465802 chr2 136381348 G A 7.98E-09 Lipid levels R3HDM1 intron 20370913 rs10187054 chr2 136388473 T C 3.83E-04 Multiple complex diseases R3HDM1 intron 17554300 rs12466487 chr2 136407078 T C 2.49E-06 Multiple complex diseases R3HDM1 intron 17554300 rs1446585 chr2 136407479 A G 8.16E-06 Paget's disease R3HDM1 intron 20436471 rs1446584 chr2 136419961 A G 8.09E-04 Multiple complex diseases R3HDM1 intron 17554300 rs4954280 chr2 136420690 A G 7.20E-04 Multiple complex diseases R3HDM1 intron 17554300 rs4954280 chr2 136420690 A G 5.87E-08 Lipid levels R3HDM1 intron 20370913 rs1374330 chr2 136420908 A C 4.74E-05 Paget's disease R3HDM1 intron 20436471 rs313519 chr2 136439517 A C 2.64E-05 Paget's disease R3HDM1 intron 20436471 rs313528 chr2 136445869 G A 5.02E-06 Paget's disease R3HDM1 intron 20436471 rs7570283 chr2 136447707 T C 4.22E-04 Response to cytidine analogues (gemcitabine) R3HDM1 intron 24483146 rs7592050 chr2 136459227 A G 4.36E-07 Multiple complex diseases R3HDM1 intron 17554300 rs6739713 chr2 136488978 A G 6.25E-06 Paget's disease / / 20436471 rs1438307 chr2 136499166 G T 2.33E-05 Paget's disease / / 20436471 rs6430585 chr2 136506927 A C 7.99E-04 Multiple complex diseases UBXN4 intron 17554300 rs6430585 chr2 136506927 A C 1.78E-06 Paget's disease UBXN4 intron 20436471 rs6430585 chr2 136506927 A C 1.00E-06 Corneal structure UBXN4 intron 21979947 rs16831992 chr2 136509460 G C 1.90E-06 Phospholipid levels (plasma) UBXN4 intron 21829377 rs9287442 chr2 136522710 A G 2.25E-06 Paget's disease UBXN4 intron 20436471 rs10496736 chr2 136536113 C G 1.60E-12 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs10496736 chr2 136536113 C G 3.60E-14 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs10496736 chr2 136536113 C G 4.80E-11 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs1469996 chr2 136542560 A G 3.75E-06 Paget's disease UBXN4 UTR-3 20436471 rs16832011 chr2 136545299 A G 3.00E-07 Phospholipid levels (plasma) LCT nearGene-3 21829377 rs1042712 chr2 136545844 C G 5.54E-13 Multiple complex diseases LCT UTR-3 17554300 rs4954633 chr2 136546635 C T 9.78E-05 Serum albumin level LCT intron pha003084 rs2015532 chr2 136555525 T G 6.53E-05 Multiple complex diseases LCT intron 17554300 rs2322659 chr2 136555659 T C 3.34E-04 Multiple complex diseases LCT missense 17554300 rs2322659 chr2 136555659 T C 8.60E-05 Celiac disease LCT missense 17558408 rs2322659 chr2 136555659 T C 8.88E-06 Waist circumference LCT missense 19557197 rs2322659 chr2 136555659 T C 5.31E-06 Paget's disease LCT missense 20436471 rs2322659 chr2 136555659 T C 9.80E-05 Coronary heart disease LCT missense 21966275 rs3769013 chr2 136556182 T C 5.84E-04 Multiple complex diseases LCT intron 17554300 rs3769012 chr2 136556480 G A 7.04E-04 Multiple complex diseases LCT intron 17554300 rs3769012 chr2 136556480 G A 8.14E-04 Alzheimer's disease LCT intron 17998437 rs872151 chr2 136556805 C T 7.70E-05 Personality dimensions LCT intron 18957941 rs2322660 chr2 136557319 C T 9.82E-06 Waist circumference LCT intron 19557197 rs2322660 chr2 136557319 C T 7.08E-09 Lipid levels LCT intron 20370913 rs748841 chr2 136558157 C T 9.85E-06 Waist circumference LCT intron 19557197 rs2304371 chr2 136561557 G A 7.38E-04 Multiple complex diseases LCT cds-synon 17554300 rs12988076 chr2 136569848 C A 8.41E-04 Response to cytidine analogues (gemcitabine) LCT intron 24483146 rs4954445 chr2 136571982 T A 8.10E-05 Personality dimensions LCT intron 18957941 rs892715 chr2 136576577 T C 8.50E-06 Waist circumference LCT intron 19557197 rs7579771 chr2 136580260 T A 9.14E-06 Waist circumference LCT intron 19557197 rs2164210 chr2 136580287 T C 8.44E-06 Waist circumference LCT intron 19557197 rs745500 chr2 136583192 G A 9.71E-06 Waist circumference LCT intron 19557197 rs2236783 chr2 136594158 G A 4.02E-06 Waist circumference LCT cds-synon 19557197 rs4988218 chr2 136613461 T C 8.05E-04 Depression (quantitative trait) MCM6 intron 20800221 rs309180 chr2 136614255 G A 8.39E-09 Lipid levels MCM6 intron 20370913 rs4988163 chr2 136628121 G T 2.19E-04 Multiple complex diseases MCM6 intron 17554300 rs16832138 chr2 136637350 G A 2.90E-05 Personality dimensions / / 18957941 rs632632 chr2 136638216 T C 1.03E-08 Lipid levels / / 20370913 rs632632 chr2 136638216 T C 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7561565 chr2 136640787 T G 8.70E-05 Multiple complex diseases / / 17554300 rs7581814 chr2 136641593 C G 1.03E-04 Multiple complex diseases / / 17554300 rs309168 chr2 136670298 C T 8.80E-06 Waist circumference DARS intron 19557197 rs309160 chr2 136685228 C T 8.33E-06 Waist circumference DARS intron 19557197 rs309160 chr2 136685228 C T 1.99E-05 Paget's disease DARS intron 20436471 rs309161 chr2 136688749 G A 4.16E-04 Sudden cardiac arrest DARS intron 21658281 rs309164 chr2 136691825 T C 3.90E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs7573555 chr2 136694905 T C 5.70E-05 Multiple complex diseases DARS intron 17554300 rs7573555 chr2 136694905 T C 9.79E-04 Alzheimer's disease DARS intron 17998437 rs6743537 chr2 136702601 G A 1.82E-04 Multiple complex diseases DARS intron 17554300 rs6754311 chr2 136707982 T C 4.56E-06 Waist circumference DARS intron 19557197 rs6430594 chr2 136719173 A G 1.00E-05 Multiple complex diseases DARS intron 17554300 rs3768998 chr2 136720344 G T 5.82E-04 Asparaginase sensitivity in blood cell lines DARS intron 21072045 rs12615624 chr2 136721603 A G 5.13E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs13404551 chr2 136721995 T C 6.01E-06 Waist circumference DARS intron 19557197 rs13404551 chr2 136721995 T C 2.94E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs689002 chr2 136734614 A G 1.55E-04 Multiple complex diseases DARS intron 17554300 rs689002 chr2 136734614 A G 6.03E-06 White blood cell count DARS intron 21738479 rs834734 chr2 136735998 C T 1.23E-06 White blood cell count DARS intron 21738479 rs687670 chr2 136740900 T C 5.55E-06 Waist circumference DARS intron 19557197 rs309134 chr2 136755684 G A 5.40E-06 Waist circumference LOC100131316 intron 19557197 rs309134 chr2 136755684 G A 6.99E-04 Response to cytidine analogues (gemcitabine) LOC100131316 intron 24483146 rs309137 chr2 136765951 T C 3.48E-06 Waist circumference / / 19557197 rs309137 chr2 136765951 T C 5.45E-05 Paget's disease / / 20436471 rs12471781 chr2 136770509 G A 6.25E-05 Multiple complex diseases / / 17554300 rs6714750 chr2 136783169 A G 1.93E-06 Waist circumference / / 19557197 rs12475139 chr2 136786651 T A 9.80E-06 Waist circumference / / 19557197 rs6716536 chr2 136787402 C T 5.85E-06 Waist circumference / / 19557197 rs7371606 chr2 136806774 G A 4.85E-04 Multiple complex diseases / / 17554300 rs11693502 chr2 136808949 C T 5.43E-04 Multiple complex diseases / / 17554300 rs1533649 chr2 136814109 G A 0.00061 Endometrial cancer / / 22426144 rs2011946 chr2 136817616 C A 4.15E-06 Alcohol dependence / / 20202923 rs2011946 chr2 136817616 C A 2.00E-06 Smoking behavior / / 20418888 rs2011946 chr2 136817616 C A 6.73E-05 Alcohol dependence / / 21703634 rs932206 chr2 136825272 C T 3.90E-07 Type 2 diabetes / / 17293876 rs932206 chr2 136825272 C T 3.90E-07 Type 2 diabetes / / 19184112 rs932206 chr2 136825272 C T 1.31E-06 Paget's disease / / 20436471 rs2734871 chr2 136869873 G A 7.08E-04 Multiple complex diseases / / 17554300 rs10191360 chr2 136884679 T C 8.20E-04 Coronary heart disease / / 21966275 rs6710778 chr2 136886141 C T 6.28E-05 Multiple complex diseases / / 17554300 rs62160907 chr2 136889725 G A 0.0000926 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7574456 chr2 136890059 C T 2.70E-04 Coronary heart disease / / 21966275 rs17382303 chr2 136893225 T G 8.40E-05 Multiple complex diseases / / 17554300 rs17382303 chr2 136893225 T G 0.0000763 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4954564 chr2 136895508 A G 5.37E-05 Caffeine consumption / / 21490707 rs62160908 chr2 136896864 C T 0.0000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11683586 chr2 136897386 C T 0.0000447 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2176717 chr2 136899859 C T 5.86E-04 Schizophrenia / / 19197363 rs953387 chr2 136907170 A C 7.17E-05 Caffeine consumption / / 21490707 rs11691305 chr2 136907854 C G 0.000033 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160909 chr2 136913134 A G 0.0000362 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs80238030 chr2 136914692 T A 0.0000296 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160911 chr2 136919509 A G 0.0000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17382372 chr2 136921761 G A 6.81E-05 Multiple complex diseases / / 17554300 rs17382372 chr2 136921761 G A 0.0000431 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11687597 chr2 136926146 A G 0.000049 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17466923 chr2 136927678 G T 0.0000485 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16833150 chr2 136927857 A G 4.11E-04 Alzheimer's disease / / 17998437 rs62160934 chr2 136941539 T A 0.0000576 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160935 chr2 136941699 T C 0.0000307 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1123848 chr2 136945029 C T 2.46E-05 Caffeine consumption / / 21490707 rs1519529 chr2 136974257 C G 1.60E-04 Multiple complex diseases / / 17554300 rs882300 chr2 136976255 T C 3.00E-07 Electrocardiographic traits / / 17903306 rs882300 chr2 136976255 T C 1.00E-07 Multiple sclerosis / / 19525953 rs6430612 chr2 137006198 C T 2.66E-05 Elbow pain / / pha003008 rs4477975 chr2 137009006 A G 9.68E-05 Alcohol dependence / / 21703634 rs9677195 chr2 137013195 A G 8.22E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10221893 chr2 137013606 C T 2.66E-05 Elbow pain / / pha003008 rs6430614 chr2 137013930 G A 3.09E-05 Height / / pha003011 rs4452212 chr2 137015991 G A 2.00E-06 Telomere length / / 20421499 rs4074120 chr2 137026587 T C 7.41E-05 Height / / pha003010 rs4074120 chr2 137026587 T C 9.52E-06 Height / / pha003011 rs6725197 chr2 137031229 T C 2.02E-04 Multiple complex diseases / / 17554300 rs4516492 chr2 137055404 G A 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4516492 chr2 137055404 G A 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13003740 chr2 137087324 A G 8.76E-05 Atopic dermatitis / / 23042114 rs5011377 chr2 137087576 A G 9.95E-05 Atopic dermatitis / / 23042114 rs12614381 chr2 137091269 A C 1.48E-05 Schizophrenia / / 19571811 rs16833840 chr2 137116544 G A 0.000034 Salmonella-induced pyroptosis / / 22837397 rs6430635 chr2 137148547 A G 8.58E-04 Multiple complex diseases / / 17554300 rs13032229 chr2 137149254 A G 9.93E-04 Multiple complex diseases / / 17554300 rs16833988 chr2 137149620 A T 2.50E-05 Urinary metabolites / / 21572414 rs16834001 chr2 137152113 C T 4.15E-04 Multiple complex diseases / / 17554300 rs635018 chr2 137159866 A G 5.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs543721 chr2 137161557 G T 4.23E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6706755 chr2 137162063 C G 5.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9646660 chr2 137164476 A G 9.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6430637 chr2 137184835 G A 7.58E-05 Monocyte counts / / pha003089 rs16834223 chr2 137194436 A G 4.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs7561441 chr2 137197151 C G 3.02E-04 Multiple complex diseases / / 17554300 rs10496746 chr2 137207082 C T 2.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2033172 chr2 137240304 A G 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12465885 chr2 137269312 T C 8.53E-04 Obesity (extreme) / / 21935397 rs876338 chr2 137289147 T C 9.46E-04 Obesity (extreme) / / 21935397 rs10496749 chr2 137305977 T C 5.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16835520 chr2 137316141 A G 1.54E-04 Sudden cardiac arrest / / 21658281 rs934299 chr2 137338940 G T 9.00E-06 Cognitive test performance / / 17903297 rs7576758 chr2 137391962 A G 9.20E-04 Multiple complex diseases / / 17554300 rs6711718 chr2 137407012 T C 5.14E-05 Left ventricular hypertrophy / / pha003052 rs16836044 chr2 137418255 A C 4.33E-04 Type 2 diabetes / / 17463246 rs7606972 chr2 137456700 G T 2.08E-05 Cognitive decline / / 22054870 rs4618106 chr2 137463721 C T 9.48E-05 Aortic root size / / 21223598 rs10496752 chr2 137465223 C T 1.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16836162 chr2 137465622 A G 0.0000126 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1593762 chr2 137476801 A G 2.39E-05 Cognitive decline / / 22054870 rs12622368 chr2 137483980 T C 0.0000189 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4603825 chr2 137484231 G C 0.0000721 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427617 chr2 137487339 T C 0.0000502 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427616 chr2 137487498 G A 0.0000714 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11683556 chr2 137489778 G A 0.0000442 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1582861 chr2 137491121 C T 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs12476818 chr2 137493912 T C 9.60E-05 Left ventricular hypertrophy / / pha003052 rs16836228 chr2 137495620 C T 7.78E-04 Type 2 diabetes / / 17463246 rs16836228 chr2 137495620 C T 2.45E-04 Multiple complex diseases / / 17554300 rs12479021 chr2 137495815 T G 7.44E-05 Left ventricular hypertrophy / / pha003052 rs59556655 chr2 137501797 A G 0.0000395 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72617041 chr2 137502939 C T 0.0000448 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1991413 chr2 137507257 G T 0.0000275 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16836383 chr2 137508441 A G 0.0000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1896477 chr2 137508544 C T 0.00000295 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10496753 chr2 137509024 T G 0.0000154 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732148 chr2 137509604 G T 0.000049 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1346369 chr2 137511278 A G 0.0000157 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6430669 chr2 137516790 G A 0.0000846 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2001872 chr2 137522044 A G 1.91E-04 Vaspin levels / / 22907691 rs2001872 chr2 137522044 A G 0.000191 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2001872 chr2 137522044 A G 0.0000063 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3863015 chr2 137522567 G A 0.000016 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62161461 chr2 137522814 G T 0.0000876 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs77055332 chr2 137522867 G C 0.0000188 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427602 chr2 137529247 T C 5.24E-05 Paget's disease / / 20436471 rs16836631 chr2 137539487 C G 3.27E-04 Type 2 diabetes / / 17463246 rs1427593 chr2 137555224 T C 7.00E-06 Pancreatic cancer / / 20686608 rs2435389 chr2 137586694 A G 6.90E-06 Iron levels / / 21208937 rs2059973 chr2 137598039 G A 4.42E-05 Cognitive decline / / 22054870 rs12613655 chr2 137601781 G A 4.20E-06 Iron levels / / 21208937 rs10496759 chr2 137603404 C G 4.20E-05 Cognitive decline / / 22054870 rs13015892 chr2 137610035 G A 1.50E-05 Cognitive decline / / 22054870 rs1560359 chr2 137619887 C A 2.06E-04 Coronary heart disease / / 21971053 rs10928576 chr2 137629096 A G 4.38E-04 Multiple complex diseases / / 17554300 rs16837222 chr2 137629273 G A 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs518743 chr2 137662855 T C 7.54E-04 Multiple complex diseases / / 17554300 rs12469179 chr2 137704727 G A 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs524398 chr2 137715259 T C 2.45E-05 Cognitive decline / / 22054870 rs16837695 chr2 137719415 A C 6.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7585449 chr2 137719956 A G 7.00E-04 Multiple complex diseases / / 17554300 rs7591845 chr2 137720806 T G 7.42E-04 Multiple complex diseases / / 17554300 rs1344712 chr2 137729014 A G 7.70E-04 Multiple complex diseases / / 17554300 rs1030622 chr2 137744509 T C 6.67E-05 Cognitive decline / / 22054870 rs6750400 chr2 137767548 C T 2.28E-04 Obesity (extreme) THSD7B intron 21935397 rs979976 chr2 137768702 A C 8.00E-06 Corneal astigmatism THSD7B intron 23761726 rs2116538 chr2 137769420 G A 4.44E-04 Longevity THSD7B intron 22279548 rs2116538 chr2 137769420 G A 1.63E-05 Corneal astigmatism THSD7B intron 23761726 rs1432237 chr2 137808507 A G 4.44E-06 Osteoarthritis THSD7B intron 22763110 rs1368061 chr2 137868769 G A 9.30E-05 Personality dimensions THSD7B intron 18957941 rs1368061 chr2 137868769 G A 7.74E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs1432219 chr2 137868836 A C 8.77E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs974528 chr2 137870582 T C 6.80E-05 Personality dimensions THSD7B intron 18957941 rs974528 chr2 137870582 T C 4.61E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs892877 chr2 137873347 A G 4.00E-06 Liver enzyme levels (aspartate transaminase) THSD7B intron 24124411 rs1469622 chr2 137875875 T C 4.50E-05 Tooth agenesis (maxillary third molar) THSD7B intron 24172245 rs1469622 chr2 137875875 T C 8.00E-06 Tooth agenesis (third molar) THSD7B intron 24172245 rs35019443 chr2 137875875 T TC 4.50E-05 Tooth agenesis (maxillary third molar) THSD7B intron 24172245 rs35019443 chr2 137875875 T TC 8.00E-06 Tooth agenesis (third molar) THSD7B intron 24172245 rs1432205 chr2 137896264 C A 2.40E-05 Tooth agenesis (third molar) THSD7B intron 24172245 rs984295 chr2 137898753 G A 5.86E-06 Liver enzyme levels (aspartate transaminase) THSD7B intron 24124411 rs1991735 chr2 137904014 G A 5.61E-04 Obesity (extreme) THSD7B intron 21935397 rs7573893 chr2 137916325 T C 1.54E-04 Attention deficit hyperactivity disorder THSD7B intron 22420046 rs4954474 chr2 137917922 T A 8.32E-06 White blood cell count THSD7B missense 21738479 rs11899922 chr2 137919366 A G 2.00E-04 Spine bone size THSD7B intron 21947420 rs12987197 chr2 137970642 A G 7.19E-04 Suicide attempts in bipolar disorder THSD7B intron 21423239 rs4610107 chr2 137980318 G A 7.76E-06 Serum metabolites THSD7B intron 19043545 rs17197674 chr2 137984147 G A 1.70E-05 Serum metabolites THSD7B intron 19043545 rs10200345 chr2 137998775 C A 2.31E-05 Cognitive performance THSD7B intron 19734545 rs10207592 chr2 138002133 A G 4.70E-04 Alzheimer's disease (late onset) THSD7B intron 21379329 rs17346940 chr2 138011809 A G 8.45E-04 Obesity (extreme) THSD7B intron 21935397 rs10490733 chr2 138038497 T C 3.20E-05 Blood Phenotypes THSD7B intron 17903294 rs11688662 chr2 138048340 A G 5.84E-04 Obesity (extreme) THSD7B intron 21935397 rs6730418 chr2 138048455 T C 9.81E-05 Serum metabolites THSD7B intron 19043545 rs6749316 chr2 138073500 C T 4.54E-05 Attention deficit hyperactivity disorder THSD7B intron 22420046 rs17738873 chr2 138073795 A G 4.74E-04 Obesity (extreme) THSD7B intron 21935397 rs10496769 chr2 138081065 A G 2.15E-04 Blood pressure THSD7B intron 17255346 rs10204990 chr2 138096989 A G 4.77E-04 Alzheimer's disease THSD7B intron 22005930 rs718632 chr2 138102805 C T 9.21E-04 Bipolar disorder THSD7B intron 19259986 rs13405020 chr2 138142164 G C 7.00E-06 Non-small cell lung cancer THSD7B intron 23144319 rs2889092 chr2 138179576 A G 4.83E-05 Insulin resistance THSD7B intron 21901158 rs10190462 chr2 138201585 C T 2.40E-04 Blood pressure THSD7B intron 17255346 rs1869324 chr2 138227442 G A 5.40E-04 Alcohol dependence THSD7B intron 20201924 rs1869324 chr2 138227442 G A 4.71E-07 Alcohol dependence THSD7B intron 21703634 rs1869324 chr2 138227442 G A 3.68E-04 Alzheimer's disease THSD7B intron 22005930 rs2375511 chr2 138249452 C A 6.10E-04 Alcohol dependence THSD7B intron 20201924 rs13419109 chr2 138294928 T C 5.16E-04 Insulin resistance THSD7B intron 21901158 rs17742691 chr2 138321018 G C 4.66E-04 Alzheimer's disease THSD7B intron 22005930 rs7597076 chr2 138364637 T C 3.25E-04 Suicide attempts in bipolar disorder THSD7B intron 21423239 rs881639 chr2 138398906 T C 9.26E-04 Stroke THSD7B intron pha002887 rs10496784 chr2 138412985 G T 3.63E-05 Bilirubin levels,in serum THSD7B intron 19389676 rs12053559 chr2 138416391 T G 5.54E-05 Serum metabolites THSD7B intron 19043545 rs12994131 chr2 138418875 A G 3.39E-06 Recombination rate THSD7B intron 21698098 rs12617524 chr2 138468383 C T 4.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7561701 chr2 138472227 C G,T 1.48E-06 Asthma (childhood onset) / / 23829686 rs16839623 chr2 138579212 A G 8.77E-04 Multiple complex diseases / / 17554300 rs6730857 chr2 138600801 G A 6.19E-04 Multiple complex diseases / / 17554300 rs6430755 chr2 138644649 G A 7.78E-04 Type 2 diabetes / / 17463246 rs6430755 chr2 138644649 G A 5.90E-04 Multiple complex diseases / / 17554300 rs7590072 chr2 138650882 C T 3.65E-04 Multiple complex diseases / / 17554300 rs7590072 chr2 138650882 C T 7.52E-04 Body mass index / / 21701565 rs7590072 chr2 138650882 C T 7.70E-04 Body mass index / / 21701565 rs7557873 chr2 138654786 G C 8.50E-04 Type 2 diabetes / / 17463246 rs7557873 chr2 138654786 G C 3.82E-04 Multiple complex diseases / / 17554300 rs7557873 chr2 138654786 G C 7.81E-04 Body mass index / / 21701565 rs964203 chr2 138655271 C T 2.22E-04 Multiple complex diseases / / 17554300 rs964203 chr2 138655271 C T 7.64E-04 Body mass index / / 21701565 rs964203 chr2 138655271 C T 8.89E-04 Body mass index / / 21701565 rs1840647 chr2 138656320 T G 1.58E-04 Multiple complex diseases / / 17554300 rs1840647 chr2 138656320 T G 8.72E-04 Body mass index / / 21701565 rs7596424 chr2 138657891 C T 6.77E-04 Multiple complex diseases / / 17554300 rs6727027 chr2 138667408 T C 7.51E-04 Body mass index / / 21701565 rs897525 chr2 138670221 C T 7.91E-04 Multiple complex diseases / / 17554300 rs897525 chr2 138670221 C T 8.08E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 8.79E-04 Type 2 diabetes / / 17463246 rs1840658 chr2 138673651 T G 2.40E-04 Multiple complex diseases / / 17554300 rs1840658 chr2 138673651 T G 3.39E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 4.15E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 7.07E-04 Body mass index / / 21701565 rs13419499 chr2 138674287 A G 3.88E-04 Body mass index / / 21701565 rs13419499 chr2 138674287 A G 5.64E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 3.41E-04 Multiple complex diseases / / 17554300 rs6724601 chr2 138676851 C A 3.25E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 4.63E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 8.39E-04 Body mass index / / 21701565 rs4564833 chr2 138681621 T C 1.65E-06 Telomere length / / 23001564 rs1973077 chr2 138686213 A G 1.74E-04 Attention deficit hyperactivity disorder / / 22420046 rs921858 chr2 138691067 A G 4.30E-04 Body mass index / / 21701565 rs921858 chr2 138691067 A G 4.97E-04 Body mass index / / 21701565 rs3113210 chr2 138704063 C G 3.91E-04 Bipolar disorder,schizoaffective / / 19567891 rs3113240 chr2 138709568 A G 7.63E-04 Parkinson's disease / / 17052657 rs6755148 chr2 138717628 G C 2.09E-04 Parkinson's disease / / 17052657 rs3791244 chr2 138731765 G A 7.00E-10 Asthma (childhood onset) HNMT intron 17611496 rs3100700 chr2 138732194 G C 6.73E-04 Multiple complex diseases HNMT intron 17554300 rs3113205 chr2 138732281 C G 3.80E-05 Malaria HNMT intron 19465909 rs1996872 chr2 138818601 T C 0.0000353 Breast cancer early age of onset / / 18463975 rs1996872 chr2 138818601 T C 5.90E-05 Personality dimensions / / 18957941 rs1996873 chr2 138818642 G A 9.54E-04 Multiple complex diseases / / 17554300 rs10205475 chr2 138838295 G C 5.50E-05 Personality dimensions / / 18957941 rs1533906 chr2 138861772 C T 1.71E-04 Multiple complex diseases / / 17554300 rs1522909 chr2 138871234 G A 1.61E-04 Multiple complex diseases / / 17554300 rs2204181 chr2 138898229 G T 3.09E-04 Alzheimer's disease / / 22005930 rs2204181 chr2 138898229 G T 3.68E-05 Coronary heart disease / / pha003032 rs28569024 chr2 139008811 C T 9.36E-04 White matter integrity / / 22425255 rs4643591 chr2 139020862 A G 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11885046 chr2 139022658 G A 8.40E-06 Urinary metabolites / / 21572414 rs4399769 chr2 139049380 C T 1.40E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4276077 chr2 139076753 C G 4.78E-04 Multiple complex diseases / / 17554300 rs11904825 chr2 139116542 G A 9.52E-05 Blood Pressure / / pha003043 rs145745331 chr2 139116542 GA G 9.52E-05 Blood Pressure / / pha003043 rs13405108 chr2 139258603 G A 6.29E-05 Nephrolithiasis / / 22396660 rs6720716 chr2 139268802 A G 6.14E-05 Fibrinogen SPOPL intron pha003068 rs10170310 chr2 139278922 G A 1.00E-07 Response to antipsychotic treatment SPOPL intron 23241943 rs10803568 chr2 139290914 T C 7.41E-05 Fibrinogen SPOPL intron pha003068 rs13388206 chr2 139332931 A G 2.23E-04 Fibrinogen / / 17255346 rs7584853 chr2 139344740 G A,C,T 1.20E-04 Multiple complex diseases / / 17554300 rs58938945 chr2 139399354 A G 8.00E-06 Metabolite levels (MHPG) / / 23319000 rs10496799 chr2 139427669 T C 1.40E-05 Longevity and age-related phenotypes NXPH2 UTR-3 17903295 rs4954946 chr2 139442521 T C 4.90E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs7594476 chr2 139447600 C G 5.48E-05 Hypertension NXPH2 intron 19609347 rs7594562 chr2 139447623 C T 2.55E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs12691954 chr2 139465406 C T 4.26E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs10496800 chr2 139488901 C T 7.20E-04 Heart Failure NXPH2 intron pha002884 rs10928663 chr2 139489417 C T 7.46E-04 Multiple complex diseases NXPH2 intron 17554300 rs11692663 chr2 139490568 T A 9.93E-04 Multiple complex diseases NXPH2 intron 17554300 rs11686876 chr2 139502153 T A 1.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NXPH2 intron 20031582 rs10193564 chr2 139512134 C T 3.19E-04 Amyotrophic lateral sclerosis (sporadic) NXPH2 intron 24529757 rs17599328 chr2 139516703 A G 3.98E-05 Prion diseases NXPH2 intron 22210626 rs10200922 chr2 139530239 A G 2.51E-04 Suicide attempts in bipolar disorder NXPH2 intron 21423239 rs4954956 chr2 139544577 C T 8.00E-06 Breast cancer / / 17529967 rs13399914 chr2 139603975 C T 2.70E-05 Urinary metabolites / / 21572414 rs10192531 chr2 139612158 C T 2.40E-05 Urinary metabolites / / 21572414 rs17659751 chr2 139615945 A G 2.90E-05 Urinary metabolites / / 21572414 rs1485069 chr2 139636679 T A 5.03E-04 Multiple complex diseases / / 17554300 rs10496802 chr2 139644872 C A 4.00E-05 Type 2 diabetes / / 17903298 rs10496803 chr2 139651484 T G 0.000386 Salmonella-induced pyroptosis / / 22837397 rs11886636 chr2 139655616 C T 7.83E-04 Type 2 diabetes / / 17463246 rs11886636 chr2 139655616 C T 8.85E-04 Multiple complex diseases / / 17554300 rs1601352 chr2 139661244 A C 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs9636231 chr2 139671955 G A 8.00E-06 Alcohol dependence / / 21956439 rs1485058 chr2 139675535 C T 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs6738511 chr2 139676195 C A 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6757538 chr2 139677323 A C 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1872385 chr2 139681884 G C 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1872384 chr2 139682249 A G 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs936760 chr2 139682405 G A 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1385413 chr2 139683585 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4954976 chr2 139685716 T C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1485057 chr2 139686312 C T 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2062362 chr2 139686409 G T 6.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1485055 chr2 139686615 G T 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1471784 chr2 139688324 T C 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10460247 chr2 139694251 A G 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6730163 chr2 139699780 T C 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs936764 chr2 139705705 G A 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1351924 chr2 139708230 T C 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803574 chr2 139710863 G A 9.52E-06 Alcohol dependence / / 21703634 rs10803574 chr2 139710863 G A 1.80E-04 Alcohol dependence / / 21956439 rs1485086 chr2 139722479 G C 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs4954643 chr2 139722786 T C 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7563596 chr2 139729909 C A 2.72E-04 Aortic root size / / 21223598 rs3922799 chr2 139758906 G A 6.48E-05 Alcohol dependence / / 21703634 rs1351916 chr2 139763448 T A 2.00E-04 Type 2 diabetes / / 17846126 rs647111 chr2 139775063 A T 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505846 chr2 139778282 C T 9.39E-06 Alcohol dependence / / 21703634 rs1505846 chr2 139778282 C T 2.00E-04 Alcohol dependence / / 21956439 rs16841529 chr2 139801479 C T 5.17E-06 Multiple complex diseases / / 17554300 rs1605136 chr2 139804141 A G 7.51E-05 Alcohol dependence / / 21703634 rs11688290 chr2 139808906 C T 3.18E-05 Alcohol dependence / / 21703634 rs9287508 chr2 139815873 C T 5.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9287508 chr2 139815873 C T 9.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16841575 chr2 139823059 C T 5.54E-04 Multiple complex diseases / / 17554300 rs924952 chr2 139832149 G T 5.24E-04 Multiple complex diseases / / 17554300 rs4954647 chr2 139859202 T G 3.62E-05 Amyotrophic lateral sclerosis / / 19193627 rs2099575 chr2 139866554 T C 4.55E-05 Amyotrophic lateral sclerosis / / 19193627 rs12465063 chr2 139870976 T C,G 8.15E-04 Multiple complex diseases / / 17554300 rs12613183 chr2 139876065 T C 3.18E-04 Multiple complex diseases / / 17554300 rs1437329 chr2 139886095 T C 9.35E-05 Cognitive test performance / / 20125193 rs10196730 chr2 139914818 C A 1.91E-05 Major depressive disorder / / 22472876 rs10196730 chr2 139914818 C A 6.94E-05 Cervical cancer / / 24700089 rs1437296 chr2 139938408 G A 2.64E-05 Major depressive disorder / / 22472876 rs10181724 chr2 139959808 C T 1.59E-05 Major depressive disorder / / 22472876 rs1437305 chr2 139961825 G A 1.97E-05 Major depressive disorder / / 22472876 rs934707 chr2 139976061 G T 3.17E-05 Major depressive disorder / / 22472876 rs736666 chr2 140031202 G A 2.31E-04 Alzheimer's disease / / 22005930 rs6742944 chr2 140036852 G A 5.68E-04 Aortic root size / / 21223598 rs11675037 chr2 140046970 A T 2.62E-04 Alzheimer's disease / / 22005930 rs11675255 chr2 140050223 C T 9.76E-05 Alzheimer's disease / / 22005930 rs1371110 chr2 140056052 A G 4.65E-05 Bone mineral density / / 19181680 rs1399645 chr2 140147832 C T 9.00E-07 Male infertility / / 19478329 rs13033247 chr2 140203973 A G 5.60E-04 Multiple complex diseases / / 17554300 rs7421449 chr2 140205110 A C,G,T 0.0000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11890914 chr2 140220527 T C 0.0000919 Polycystic ovary syndrome / / 22951595 rs11890914 chr2 140220527 T C 9.19E-05 Intracranial aneurysm / / 22961961 rs10496820 chr2 140224777 C T 5.71E-04 Multiple complex diseases / / 17554300 rs10496821 chr2 140272019 G A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376446 chr2 140301222 C T 0.000743 Salmonella-induced pyroptosis / / 22837397 rs345619 chr2 140308150 C T 0.000417 Salmonella-induced pyroptosis / / 22837397 rs345618 chr2 140309392 C T 0.000533 Salmonella-induced pyroptosis / / 22837397 rs6430841 chr2 140318199 A G 2.73E-04 Multiple complex diseases / / 17554300 rs1347729 chr2 140323265 C A 0.000729 Salmonella-induced pyroptosis / / 22837397 rs11896674 chr2 140393064 T C 5.71E-04 Multiple complex diseases / / 17554300 rs7574941 chr2 140448156 T C 4.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs11897599 chr2 140449566 A G 4.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs7562605 chr2 140491257 A C 0.00064 Salmonella-induced pyroptosis / / 22837397 rs76747997 chr2 140511671 T C 0.0000223 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4954663 chr2 140559497 A G 0.000675 Salmonella-induced pyroptosis / / 22837397 rs1464300 chr2 140594138 C T 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17731496 chr2 140605034 C T 9.30E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16842994 chr2 140626731 C G 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs1520086 chr2 140627411 C T 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1607666 chr2 140627913 G A 9.47E-04 Parkinson's disease / / 17052657 rs10928729 chr2 140629263 G A 3.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10928730 chr2 140631904 T G 5.82E-04 Smoking initiation / / 24665060 rs9287528 chr2 140655121 G T 0.000013 Antisocial behavior / / 23077488 rs12620585 chr2 140655950 T C 6.34E-04 Coronary heart disease / / 21971053 rs11901615 chr2 140657370 T C 0.0000158 Antisocial behavior / / 23077488 rs7591869 chr2 140659840 A G 2.56E-05 Iron status biomarkers / / 19084217 rs1401941 chr2 140678237 C A 4.49E-04 Type 2 diabetes / / 17463246 rs12469257 chr2 140681274 A G 1.22E-04 Coronary heart disease / / 21971053 rs11682155 chr2 140695463 C T 4.84E-05 Cognitive performance / / 19734545 rs12479038 chr2 140699470 T C 1.36E-04 Coronary heart disease / / 21971053 rs16843075 chr2 140705119 G A 2.50E-04 Type 2 diabetes / / 17463246 rs13035203 chr2 140709142 C T 8.60E-06 Urinary metabolites / / 21572414 rs10174598 chr2 140713355 T C 2.74E-05 Interstitial lung disease / / 23583980 rs1920523 chr2 140722815 A T 1.30E-05 Urinary metabolites / / 21572414 rs7586146 chr2 140772874 C T 6.13E-04 Multiple complex diseases / / 17554300 rs1527853 chr2 140799875 T C 5.14E-04 Body mass index / / 21701565 rs16843268 chr2 140820905 G A 0.0000039 Mean arterial pressure / / 22510845 rs4954821 chr2 140892675 C G 7.37E-04 Type 2 diabetes / / 17463246 rs2950613 chr2 140913383 C G 3.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6715982 chr2 140945164 G A 8.19E-04 Smoking initiation / / 24665060 rs11883474 chr2 141041323 T G 1.95E-05 Panic disorder LRP1B intron 19165232 rs10496839 chr2 141049869 C T 1.01E-05 Myopia (pathological) LRP1B intron 23049088 rs17477276 chr2 141079858 T C 9.27E-05 Response to methylphenidate treatment LRP1B intron 21130132 rs11897270 chr2 141190436 C T 3.54E-04 Smoking quantity LRP1B intron 24665060 rs10496844 chr2 141195126 C T 4.92E-04 Multiple complex diseases LRP1B intron 17554300 rs1518444 chr2 141197873 C T 2.84E-04 Smoking quantity LRP1B intron 24665060 rs1518443 chr2 141197983 T C 5.43E-04 Smoking quantity LRP1B intron 24665060 rs1878741 chr2 141199904 C T 2.89E-04 Smoking quantity LRP1B intron 24665060 rs6747180 chr2 141212126 T C 4.67E-04 Smoking quantity LRP1B intron 24665060 rs72899866 chr2 141226309 T A 5.00E-06 Periodontitis (CDC/AAP) LRP1B intron 24024966 rs3923350 chr2 141239598 G T 5.00E-04 Obesity-related traits LRP1B intron 17903300 rs3923350 chr2 141239598 G T 5.89E-04 Nicotine smoking LRP1B intron 19268276 rs183373550 chr2 141269442 C G 7.00E-06 Serum dimethylarginine levels (symmetric) LRP1B intron 24159190 rs1905925 chr2 141296612 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) LRP1B intron 20708005 rs13032617 chr2 141312831 A G 6.02E-04 Multiple complex diseases LRP1B intron 17554300 rs2380887 chr2 141321183 C A 7.57E-05 IgE levels LRP1B intron 22075330 rs6723267 chr2 141330806 C G 4.27E-05 IgE levels LRP1B intron 22075330 rs17806210 chr2 141332832 A G 5.48E-05 IgE levels LRP1B intron 22075330 rs6732761 chr2 141334737 A C 2.65E-05 IgE levels LRP1B intron 22075330 rs10928758 chr2 141343336 A C 8.74E-05 Monocyte counts LRP1B intron pha003089 rs492190 chr2 141355107 A G 4.79E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs16844322 chr2 141361994 A G 7.08E-04 Response to alcohol consumption (flushing response) LRP1B intron 24277619 rs491391 chr2 141362058 A C 3.00E-07 optic disc size (disc) LRP1B intron 20395239 rs491391 chr2 141362058 A C 2.96E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs493102 chr2 141362222 G T 8.50E-05 Cognitive function LRP1B intron 24684796 rs487419 chr2 141377607 T C 3.89E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs547663 chr2 141382827 A C 5.30E-04 Multiple complex diseases LRP1B intron 17554300 rs10166217 chr2 141398489 T G 4.33E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs514478 chr2 141409166 A G 7.64E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs16844441 chr2 141424422 C T 6.99E-05 Tuberculosis LRP1B intron 24057671 rs2165506 chr2 141448312 A G 1.10E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs1441460 chr2 141466384 G A 3.40E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs436323 chr2 141478468 C T 3.84E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs9287300 chr2 141532786 G A 3.43E-05 Neuroblastoma LRP1B intron pha002895 rs6735489 chr2 141551350 A C 2.27E-05 Neuroblastoma LRP1B intron pha002895 rs13432282 chr2 141572109 G T 5.13E-05 Neuroblastoma LRP1B intron pha002895 rs13420111 chr2 141581332 A G 3.90E-05 Neuroblastoma LRP1B intron pha002895 rs6725365 chr2 141592580 T C 9.56E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs2200488 chr2 141600366 C T 1.09E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs12467730 chr2 141604351 A G 1.44E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs11901880 chr2 141605983 G A 1.07E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs10496855 chr2 141638380 T G 4.90E-05 Asthma LRP1B intron 20159242 rs10496856 chr2 141639391 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LRP1B intron 17982456 rs12691579 chr2 141640478 T G 1.86E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs12691580 chr2 141647612 T A 3.82E-04 Multiple complex diseases LRP1B intron 17554300 rs2016582 chr2 141652239 C T 9.49E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs12987986 chr2 141655736 A G 8.59E-06 Post-operative nausea and vomiting LRP1B intron 21694509 rs2033290 chr2 141657878 A C 5.98E-04 Response to cytidine analogues (gemcitabine) LRP1B intron 24483146 rs1366801 chr2 141660295 A G 6.09E-04 Multiple complex diseases LRP1B intron 17554300 rs10170474 chr2 141662215 A C 3.27E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs1469481 chr2 141664879 G A 2.80E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs2380945 chr2 141668323 A G 1.41E-05 Bladder cancer (smoking interaction) LRP1B intron 24662972 rs10496859 chr2 141668678 A C 4.26E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs10496860 chr2 141671250 T C 8.77E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs2052910 chr2 141713645 A C 7.10E-05 Psoriasis LRP1B intron 18364390 rs16845018 chr2 141714746 G A 7.96E-05 Cognitive test performance LRP1B intron 20125193 rs16845018 chr2 141714746 G A 5.64E-04 Smoking cessation LRP1B intron 24665060 rs16845023 chr2 141717063 G C 9.82E-06 Multiple complex diseases LRP1B intron 17554300 rs13016717 chr2 141717646 A G 4.03E-05 Cognitive test performance LRP1B intron 20125193 rs1346641 chr2 141718996 G T 7.82E-05 Cognitive test performance LRP1B intron 20125193 rs12474609 chr2 141721142 A T 6.00E-09 Aging LRP1B intron 19367585 rs4954683 chr2 141741590 T C 9.00E-06 IgG glycosylation LRP1B intron 23382691 rs10928087 chr2 141742103 A G 1.13E-04 Response to cytadine analogues (cytosine arabinoside) LRP1B intron 24483146 rs16845089 chr2 141743077 C T 2.88E-05 Response to cytadine analogues (cytosine arabinoside) LRP1B intron 24483146 rs12624219 chr2 141755731 A C 3.69E-04 Type 2 diabetes LRP1B intron 17463246 rs16845115 chr2 141756592 A C 3.69E-04 Type 2 diabetes LRP1B intron 17463246 rs1474407 chr2 141757246 C T 7.46E-05 Cognitive test performance LRP1B intron 20125193 rs1474407 chr2 141757246 C T 1.48E-04 Alzheimer's disease (late onset) LRP1B intron 21379329 rs1525590 chr2 141769764 G A 4.12E-04 Schizophrenia(treatment response to risperidone) LRP1B intron 19850283 rs17521615 chr2 141776841 C T 2.22E-04 Type 2 diabetes LRP1B intron 17463246 rs6429856 chr2 141779955 G A 5.92E-04 Alcohol consumption (maxi-drinks) LRP1B intron 24277619 rs10210358 chr2 141795620 A G 2.00E-06 Erectile dysfunction and prostate cancer treatment LRP1B intron 20932654 rs16845177 chr2 141797709 T G 7.08E-04 Multiple complex diseases LRP1B intron 17554300 rs1474406 chr2 141800073 C T 7.38E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs13422816 chr2 141805232 C A 6.16E-04 Taste perception LRP1B intron 22132133 rs6755234 chr2 141809737 C A 2.86E-05 Parkinson's disease LRP1B intron 21738487 rs2380922 chr2 141810244 T C 8.56E-06 Parkinson's disease LRP1B intron 21738487 rs16845233 chr2 141813216 C A 8.11E-04 Depression (quantitative trait) LRP1B intron 20800221 rs1525583 chr2 141819422 G A 1.99E-05 Parkinson's disease LRP1B intron 21738487 rs16845274 chr2 141826995 T A 9.22E-04 Depression (quantitative trait) LRP1B intron 20800221 rs4954687 chr2 141832339 T C 2.82E-05 Parkinson's disease LRP1B intron 21738487 rs1357966 chr2 141833621 G A 2.82E-05 Parkinson's disease LRP1B intron 21738487 rs2140872 chr2 141841860 T C 2.18E-05 Parkinson's disease LRP1B intron 21738487 rs3856355 chr2 141843386 G C 6.50E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs4954880 chr2 141846346 T C 8.05E-06 Parkinson's disease LRP1B intron 21738487 rs12996731 chr2 141857090 G A 9.84E-05 Parkinson's disease LRP1B intron 21738487 rs1882642 chr2 141861910 A G 6.27E-06 Parkinson's disease LRP1B intron 21738487 rs12691592 chr2 141878501 C A 3.54E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs2222233 chr2 141919943 C T 1.35E-05 Hepatocellular carcinoma LRP1B intron 22807686 rs1249458 chr2 141929225 G A 8.34E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs1714259 chr2 141932472 C T 1.06E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs7424161 chr2 141942235 C T 8.76E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs300373 chr2 141976620 G A 1.20E-04 Multiple complex diseases LRP1B intron 17554300 rs7558514 chr2 141977173 G A 1.12E-04 Alcohol dependence LRP1B intron 21314694 rs9283437 chr2 141998560 C A 4.18E-05 Height LRP1B intron pha003010 rs434276 chr2 142013959 C A 6.90E-05 Height LRP1B intron pha003010 rs300397 chr2 142030590 C A 1.02E-04 Schizophrenia LRP1B intron 20832056 rs2683815 chr2 142078003 C T 1.19E-04 Multiple complex diseases LRP1B intron 17554300 rs11886422 chr2 142146201 G A 1.84E-05 Telomere length LRP1B intron 23001564 rs4422109 chr2 142165632 T A 4.84E-04 Smoking initiation LRP1B intron 24665060 rs4954702 chr2 142172366 G A 4.52E-04 White matter integrity LRP1B intron 22425255 rs4954702 chr2 142172366 G A 7.39E-04 Smoking cessation LRP1B intron 24665060 rs11892609 chr2 142180729 C T 5.32E-04 Parkinson's disease LRP1B intron 17052657 rs12105292 chr2 142187915 C T 9.21E-05 Waist-Hip Ratio LRP1B intron pha003029 rs4507038 chr2 142188957 G A 9.21E-05 Waist-Hip Ratio LRP1B intron pha003029 rs4352181 chr2 142195346 G A 8.19E-04 White matter integrity LRP1B intron 22425255 rs4401160 chr2 142227602 A G 4.35E-04 Tourette syndrome LRP1B intron 22889924 rs12472911 chr2 142228509 C T 2.00E-07 Menarche (age at onset) LRP1B intron 21102462 rs6745352 chr2 142229279 T A 5.44E-04 Multiple complex diseases LRP1B intron 17554300 rs10496880 chr2 142237435 T C 8.73E-06 Blood Pressure LRP1B intron pha003049 rs10496881 chr2 142244913 G T 1.94E-04 Birth weight LRP1B intron 17255346 rs16846274 chr2 142251849 C T 2.22E-04 Birth weight LRP1B intron 17255346 rs11677666 chr2 142277072 G A 0.00007403 Sarcoidosis LRP1B intron 22952805 rs16846416 chr2 142290687 C T 3.23E-04 Type 2 diabetes LRP1B intron 17463246 rs13007647 chr2 142293363 A C 5.74E-04 Multiple complex diseases LRP1B intron 17554300 rs16855058 chr2 142307179 C T 5.90E-04 Age at menarche,age at menopause LRP1B intron 22131368 rs2381190 chr2 142342699 A G 4.25E-04 Multiple complex diseases LRP1B intron 17554300 rs16855065 chr2 142363641 C A 6.44E-05 Blood Pressure LRP1B intron pha003050 rs16855067 chr2 142363876 T C 6.24E-04 Type 2 diabetes LRP1B intron 17463246 rs2890601 chr2 142404955 A G 4.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LRP1B intron 24023788 rs16846817 chr2 142430307 A C 9.44E-08 Metabolite levels LRP1B intron 23281178 rs354856 chr2 142433670 T C 9.44E-08 Metabolite levels LRP1B intron 23281178 rs164979 chr2 142436459 C T 4.42E-07 Post-operative nausea and vomiting LRP1B intron 21694509 rs7560557 chr2 142437151 G A 4.58E-04 Lung function (forced expiratory volume in 1 second) LRP1B intron 17255346 rs7560557 chr2 142437151 G A 4.00E-04 Premature ovarian failure LRP1B intron 19508998 rs7560557 chr2 142437151 G A 9.44E-08 Metabolite levels LRP1B intron 23281178 rs9653179 chr2 142446465 T C 7.31E-05 Serum metabolites LRP1B intron 19043545 rs16846925 chr2 142467266 C T 6.55E-05 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs17801458 chr2 142468472 C T 4.71E-04 Type 2 diabetes LRP1B intron 17463246 rs17801458 chr2 142468472 C T 2.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRP1B intron 20031582 rs17801458 chr2 142468472 C T 1.40E-05 Urinary metabolites LRP1B intron 21572414 rs978601 chr2 142470905 T G 3.96E-04 Type 2 diabetes LRP1B intron 17463246 rs16846962 chr2 142475665 C T 4.47E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1347659 chr2 142478064 A G 9.71E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1898422 chr2 142495019 C A 1.30E-05 Urinary metabolites LRP1B intron 21572414 rs1898422 chr2 142495019 C A 3.24E-04 Longevity LRP1B intron 22279548 rs2217963 chr2 142495229 T C 8.10E-06 Urinary metabolites LRP1B intron 21572414 rs10803486 chr2 142495805 G A 2.60E-05 Urinary metabolites LRP1B intron 21572414 rs1036506 chr2 142504546 C T 2.00E-05 Urinary metabolites LRP1B intron 21572414 rs10496894 chr2 142506366 C T 3.41E-05 Corneal structure LRP1B intron 22003120 rs10928122 chr2 142530120 G T 6.63E-04 Alcohol dependence LRP1B intron 20201924 rs6429923 chr2 142578483 T C 1.94E-04 Cognitive decline LRP1B intron 23732972 rs13431583 chr2 142594611 T C 5.38E-06 C-reactive protein LRP1B intron 22492993 rs13004344 chr2 142606736 A G 2.40E-05 Urinary metabolites LRP1B intron 21572414 rs13018903 chr2 142608963 A G 1.71E-06 C-reactive protein LRP1B intron 22492993 rs1898016 chr2 142609604 G A 2.46E-04 Amyotrophic Lateral Sclerosis LRP1B intron 17827064 rs16847370 chr2 142612131 T C 7.24E-06 C-reactive protein LRP1B intron 22492993 rs13430058 chr2 142615596 A G 2.98E-05 C-reactive protein LRP1B intron 22492993 rs7586153 chr2 142616136 T A 9.73E-06 C-reactive protein LRP1B intron 22492993 rs13385804 chr2 142617164 A C 5.59E-06 C-reactive protein LRP1B intron 22492993 rs16847412 chr2 142618914 T C 1.20E-05 C-reactive protein LRP1B intron 22492993 rs10496905 chr2 142636460 A G 6.40E-05 Glioma (high-grade) LRP1B intron 19578366 rs10496905 chr2 142636460 A G 6.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRP1B intron 20877124 rs983540 chr2 142658129 T C 3.95E-04 Type 2 diabetes LRP1B intron 17463246 rs7564502 chr2 142739121 G A 8.49E-04 Multiple complex diseases LRP1B intron 17554300 rs16847914 chr2 142765005 C T 5.22E-04 Type 2 diabetes LRP1B intron 17463246 rs1191974 chr2 142768518 C T 8.51E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1449479 chr2 142830294 C T 6.54E-04 Type 2 diabetes LRP1B intron 17463246 rs7583748 chr2 142855291 G A 1.00E-04 Body mass index LRP1B intron 24348519 rs1001628 chr2 142868147 T G 6.10E-05 Glioma (high-grade) LRP1B intron 19578366 rs1375613 chr2 142874253 T A 3.75E-04 Multiple complex diseases LRP1B intron 17554300 rs970600 chr2 142878897 C T 6.73E-05 Response to hepatitis C treatment LRP1B intron 19684573 rs12477787 chr2 142933399 G A 3.54E-05 Telomere length / / 23001564 rs13408409 chr2 142947513 G A 1.20E-06 Urinary metabolites / / 21572414 rs2890652 chr2 142959931 T C 1.00E-10 Body mass index / / 20935630 rs2890652 chr2 142959931 T C 1.35E-10 Body mass index / / 23001569 rs1523704 chr2 142963976 T C 3.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4473327 chr2 142989440 G A 4.49E-04 Depression (quantitative trait) / / 20800221 rs4297822 chr2 142994927 T G 4.32E-04 Depression (quantitative trait) / / 20800221 rs6744481 chr2 143052039 A G 6.87E-04 Smoking initiation / / 24665060 rs4662491 chr2 143110338 A C 6.61E-04 Acute lung injury / / 22295056 rs4355053 chr2 143220554 C T 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4311004 chr2 143220907 A G 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs13416800 chr2 143222005 T C 7.41E-05 Kawasaki disease / / 22081228 rs13407187 chr2 143223382 C T 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7601564 chr2 143224339 A T 6.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs13006196 chr2 143226133 A G 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10172919 chr2 143231156 A G 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs4330055 chr2 143231622 A G 9.33E-05 Kawasaki disease / / 22081228 rs1900539 chr2 143235183 C G 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs4386266 chr2 143236253 T C 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs41320848 chr2 143448194 C T 6.49E-05 Multiple complex diseases / / 17554300 rs7598800 chr2 143475728 T G 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7598800 chr2 143475728 T G 5.85E-05 Sodium levels / / pha003093 rs7598906 chr2 143475832 T C 5.37E-05 Sodium levels / / pha003093 rs6712291 chr2 143550868 T C 5.25E-04 Eye color / / 23118974 rs13023887 chr2 143600166 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1439876 chr2 143638594 G A 1.46E-04 Lung function (forced expiratory volume in 1 second) KYNU intron 17255346 rs16858223 chr2 143650771 C T 8.39E-04 Bipolar disorder,schizoaffective KYNU intron 19567891 rs164732 chr2 143667100 C T 3.69E-04 Lung function (forced expiratory volume in 1 second) KYNU intron 17255346 rs351694 chr2 143704314 T C 7.32E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs351696 chr2 143705360 G A 6.38E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs12997823 chr2 143709091 A G 4.34E-04 Multiple complex diseases KYNU intron 17554300 rs12997823 chr2 143709091 A G 8.63E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs13024113 chr2 143711005 A G 7.66E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs16855215 chr2 143724281 T G 4.14E-05 Aortic root size KYNU intron 21223598 rs1050950 chr2 143746849 C A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs1371514 chr2 143749073 G A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs12466715 chr2 143751071 A G 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs352892 chr2 143757925 C A 2.80E-05 Response to lithium treatment in bipolar disorder KYNU intron 19448189 rs352892 chr2 143757925 C A 3.43E-05 Schizophrenia KYNU intron 19571809 rs352892 chr2 143757925 C A 5.04E-05 Schizophrenia KYNU intron pha002859 rs7425446 chr2 143777498 T A 4.10E-05 Iron levels KYNU intron 21208937 rs2304700 chr2 143791014 G T 2.06E-04 Multiple complex diseases KYNU intron 17554300 rs12477146 chr2 143793814 G A 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs2043931 chr2 143795681 C A 1.04E-05 Statin-induced myopathy KYNU intron 21826682 rs7598467 chr2 143796057 G A 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs3768844 chr2 143796694 A G 1.38E-05 Multiple complex diseases KYNU intron 17554300 rs3845642 chr2 143799003 G A 0.0003734 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KYNU intron 23233654 rs3845642 chr2 143799003 G A 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs3816193 chr2 143799907 G A 1.45E-05 Multiple complex diseases KYNU nearGene-3 17554300 rs354707 chr2 143886437 T A 4.10E-04 Type 2 diabetes / / 17463246 rs16858596 chr2 143890281 G A 5.30E-04 Alcohol dependence ARHGAP15 intron 20201924 rs827219 chr2 143892794 C T 7.14E-04 Schizophrenia ARHGAP15 intron 19197363 rs6430004 chr2 143893576 G A 5.89E-04 Tourette syndrome ARHGAP15 intron 22889924 rs9917392 chr2 143895878 C T 3.66E-07 Type 2 diabetes ARHGAP15 intron 17463246 rs10189773 chr2 143896500 A G 6.62E-07 Type 2 diabetes ARHGAP15 intron 17463246 rs354694 chr2 143925517 G A 5.87E-04 Obesity (extreme) ARHGAP15 intron 21935397 rs354696 chr2 143931505 G A 4.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) ARHGAP15 intron 23648065 rs1869009 chr2 143934549 G A 3.03E-04 Body mass index ARHGAP15 intron 17255346 rs7595079 chr2 143951325 T C 6.36E-04 Response to cytadine analogues (cytosine arabinoside) ARHGAP15 intron 24483146 rs11681284 chr2 144057444 T C 2.00E-04 Cognitive impairment induced by topiramate ARHGAP15 intron 22091778 rs12691674 chr2 144093331 T C 2.23E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs17229397 chr2 144095037 T A 1.97E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs10176394 chr2 144096374 T C 2.00E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs10496946 chr2 144102594 C T 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs532311971 chr2 144102594 CAAT C 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs562827965 chr2 144102594 CAAT C 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs11676611 chr2 144128555 G C 6.57E-04 Response to taxane treatment (placlitaxel) ARHGAP15 intron 23006423 rs2381466 chr2 144133509 A G 5.29E-04 Multiple complex diseases ARHGAP15 intron 17554300 rs13405986 chr2 144161734 A G 9.37E-04 Multiple complex diseases ARHGAP15 intron 17554300 rs13405986 chr2 144161734 A G 2.37E-05 Hemoglobin ARHGAP15 intron pha003098 rs13405986 chr2 144161734 A G 2.89E-05 Erythrocyte counts ARHGAP15 intron pha003099 rs11897813 chr2 144167920 T C 4.25E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs16822484 chr2 144177579 T C 1.00E-04 Prostate cancer ARHGAP15 intron 21743057 rs10180461 chr2 144263033 T C 4.95E-05 Erythrocyte counts ARHGAP15 intron pha003099 rs6731747 chr2 144308396 T A 8.63E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs4662339 chr2 144318832 T C 7.23E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs12992706 chr2 144363659 C T 4.46E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs6716352 chr2 144368257 G A 9.82E-06 Liver disease in chronic hepatitis B virus infection ARHGAP15 intron 24065354 rs10496950 chr2 144372973 C G 3.85E-04 Nicotine smoking ARHGAP15 intron 19268276 rs2731553 chr2 144373941 A C 4.26E-05 Intracerebral hemorrhage ARHGAP15 intron 24656865 rs11693600 chr2 144380542 C T 1.68E-04 Nicotine smoking ARHGAP15 intron 19268276 rs13422906 chr2 144398052 T A 0.0007186 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ARHGAP15 intron 23233654 rs13422906 chr2 144398052 T A 7.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARHGAP15 intron 23233662 rs13430960 chr2 144409949 C T 6.69E-04 Heart Failure ARHGAP15 intron pha002885 rs6750487 chr2 144415905 G A 8.22E-04 Heart Failure ARHGAP15 intron pha002885 rs10928195 chr2 144428608 C G 4.00E-06 Quantitative traits ARHGAP15 intron 19197348 rs12999020 chr2 144501505 T C 7.54E-05 Cognitive test performance ARHGAP15 intron 20125193 rs13420376 chr2 144572005 C T 1.37E-05 Response to metformin / / 21186350 rs13018437 chr2 144613766 G A 0.000000853 Nicotine dependence (smoking) / / 23542338 rs1257351 chr2 144631168 G T 1.20E-04 Sudden cardiac arrest / / 21658281 rs17834780 chr2 144638809 G A 5.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6713567 chr2 144647829 T C 7.85E-04 Multiple complex diseases / / 17554300 rs787151 chr2 144655836 A G 2.75E-05 Nicotine smoking / / 19268276 rs787176 chr2 144668249 C T 0.000000605 Nicotine dependence (smoking) / / 23542338 rs768145 chr2 144684875 C T 6.67E-04 Schizophrenia / / 21674006 rs1011397 chr2 144690117 C T 8.00E-06 Obesity-related traits / / 23251661 rs16823406 chr2 144781851 T C 6.67E-04 Multiple complex diseases GTDC1 intron 17554300 rs16823411 chr2 144783214 T C 4.55E-04 Body mass index GTDC1 intron 21701565 rs16823411 chr2 144783214 T C 5.39E-04 Body mass index GTDC1 intron 21701565 rs12615549 chr2 144796925 C G 4.54E-04 Body mass index GTDC1 intron 21701565 rs12615549 chr2 144796925 C G 5.64E-04 Body mass index GTDC1 intron 21701565 rs7602624 chr2 144805815 A G 4.96E-04 Body mass index GTDC1 intron 21701565 rs7602624 chr2 144805815 A G 7.22E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 2.03E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 2.25E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 9.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GTDC1 intron 24236485 rs10496957 chr2 144854774 G C 4.61E-04 Body mass index GTDC1 intron 21701565 rs10496957 chr2 144854774 G C 7.03E-04 Body mass index GTDC1 intron 21701565 rs1429098 chr2 144889825 C A 4.48E-04 Body mass index GTDC1 intron 21701565 rs1429098 chr2 144889825 C A 5.39E-04 Body mass index GTDC1 intron 21701565 rs3731958 chr2 144899559 C A 0.000011 Prostate cancer GTDC1 missense 23555315 rs12463773 chr2 144908230 T A 3.41E-09 Schizophrenia GTDC1 intron 22037555 rs6760118 chr2 144912781 A G 1.21E-04 Multiple complex diseases GTDC1 intron 17554300 rs4662368 chr2 144919040 C G 6.18E-04 Body mass index GTDC1 intron 21701565 rs4662368 chr2 144919040 C G 6.67E-04 Body mass index GTDC1 intron 21701565 rs13415860 chr2 144919272 A T 7.79E-04 Body mass index GTDC1 intron 21701565 rs1344628 chr2 144919995 A G 3.49E-04 Body mass index GTDC1 intron 21701565 rs1344628 chr2 144919995 A G 4.04E-04 Body mass index GTDC1 intron 21701565 rs6716723 chr2 144963831 G A 4.19E-04 Body mass index GTDC1 intron 21701565 rs6716723 chr2 144963831 G A 4.35E-04 Body mass index GTDC1 intron 21701565 rs10928206 chr2 144965236 G C 2.40E-06 Body mass index GTDC1 intron 21701565 rs10928206 chr2 144965236 G C 3.89E-06 Body mass index GTDC1 intron 21701565 rs16823583 chr2 144969618 T C 4.17E-04 Body mass index GTDC1 intron 21701565 rs16823583 chr2 144969618 T C 4.70E-04 Body mass index GTDC1 intron 21701565 rs1012272 chr2 144993201 C T 2.01E-04 Multiple complex diseases GTDC1 intron 17554300 rs997840 chr2 145058077 A G 4.15E-04 Body mass index GTDC1 intron 21701565 rs997840 chr2 145058077 A G 4.70E-04 Body mass index GTDC1 intron 21701565 rs10496963 chr2 145079065 T C 1.65E-06 Cognitive test performance GTDC1 intron 20125193 rs2081776 chr2 145080938 T C 1.00E-04 Information processing speed GTDC1 intron 21130836 rs12991836 chr2 145141541 A C 1.10E-06 Schizophrenia ZEB2 nearGene-3 21791550 rs12991836 chr2 145141541 A C 0.0000011 Psychosis ZEB2 nearGene-3 23164818 rs12991836 chr2 145141541 A C 1.00E-08 Schizophrenia ZEB2 nearGene-3 23974872 rs11888238 chr2 145152235 T C 5.03E-05 Renal cell carcinoma ZEB2 intron 23184150 rs10185359 chr2 145155731 T C 4.63E-04 Renal cell carcinoma ZEB2 intron 23184150 rs7560525 chr2 145169563 A G 2.07E-05 Renal cell carcinoma ZEB2 intron 23184150 rs72858437 chr2 145171259 T C 4.80E-04 Renal cell carcinoma ZEB2 intron 23184150 rs10210063 chr2 145182957 C G 1.70E-06 Renal cell carcinoma ZEB2 intron 23184150 rs10192562 chr2 145184316 A G 2.38E-06 Renal cell carcinoma ZEB2 intron 23184150 rs10164806 chr2 145193326 C T 1.92E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13401103 chr2 145198623 G A 6.10E-07 Renal cell carcinoma ZEB2 intron 23184150 rs72858474 chr2 145198889 G A 4.89E-07 Renal cell carcinoma ZEB2 intron 23184150 rs6708471 chr2 145202600 G C 6.70E-04 Multiple complex diseases ZEB2 intron 17554300 rs16823732 chr2 145204758 G A 1.44E-04 Sudden cardiac arrest ZEB2 intron 21658281 rs16823732 chr2 145204758 G A 1.58E-06 Renal cell carcinoma ZEB2 intron 23184150 rs16823732 chr2 145204758 G A 3.55E-05 Amyotrophic lateral sclerosis (sporadic) ZEB2 intron 24529757 rs10187892 chr2 145205693 G C 9.03E-05 Smoking initiation ZEB2 intron 24665060 rs12105918 chr2 145208193 T C 2.00E-08 Renal cell carcinoma ZEB2 intron 23184150 rs12105521 chr2 145208336 G A,T 7.28E-07 Renal cell carcinoma ZEB2 intron 23184150 rs72858496 chr2 145209916 C T 5.76E-07 Renal cell carcinoma ZEB2 intron 23184150 rs731108 chr2 145213638 G C 1.34E-06 Renal cell carcinoma ZEB2 intron 23184150 rs993765 chr2 145214761 C T 1.48E-04 Multiple complex diseases ZEB2 intron 17554300 rs13389578 chr2 145216048 T C 3.58E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13401515 chr2 145216132 A T 2.43E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13382811 chr2 145223620 C T 6.00E-10 Myopia (severe) ZEB2 intron 23933737 rs6755392 chr2 145242122 A G 3.55E-05 Myopia (severe) ZEB2 intron 23933737 rs13398550 chr2 145245815 A G 2.60E-05 Urinary metabolites ZEB2 intron 21572414 rs2052807 chr2 145296263 A C 2.08E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4662376 chr2 145297016 A T 2.27E-04 Fibrinogen / / 17255346 rs4662377 chr2 145297087 A T 1.80E-04 Fibrinogen / / 17255346 rs1365778 chr2 145305277 A G 6.73E-04 Tourette syndrome / / 22889924 rs7355746 chr2 145351821 T C 5.00E-07 Obesity-related traits / / 23251661 rs10496964 chr2 145359909 C T 9.00E-09 Epilepsy (generalized) / / 22949513 rs10496965 chr2 145381331 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs980772 chr2 145442190 G T 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs2195115 chr2 145446205 G A 9.52E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs10496966 chr2 145458762 A G 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs4471836 chr2 145475145 G A 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs1351734 chr2 145486593 T C 9.42E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs7603516 chr2 145504693 T G 3.10E-04 Crohn's disease DKFZp686O1327 intron 17435756 rs11883829 chr2 145519623 A G 7.98E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs10496968 chr2 145524246 C T 7.98E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs17479071 chr2 145602015 A G 2.13E-04 White matter integrity DKFZp686O1327 intron 22425255 rs11690035 chr2 145603306 C T 6.90E-04 Multiple complex diseases DKFZp686O1327 intron 17554300 rs1534482 chr2 145716881 G A 7.02E-05 Multiple complex diseases DKFZp686O1327 intron 17554300 rs17408036 chr2 145752599 T C 2.71E-04 Self-reported allergy DKFZp686O1327 intron 23817569 rs2252641 chr2 145801461 T C 1.87E-05 Type 2 diabetes DKFZp686O1327 intron 17463246 rs2252641 chr2 145801461 T C 5.63E-07 Esophageal cancer (squamous cell) DKFZp686O1327 intron 22960999 rs2252641 chr2 145801461 T C 0.00000419 Coronary artery disease (CAD) (males) DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 0.0000644 Coronary artery disease (CAD) age >50 DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 0.000503 Coronary artery disease with myocardial infarction DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 2.53E-08 Coronary artery disease DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 1.19E-05 Coronary artery disease DKFZp686O1327 intron 24262325 rs955944 chr2 145813161 A C 2.84E-04 Substance dependence DKFZp686O1327 intron 21818250 rs4662414 chr2 145818432 A G 3.05E-05 Type 2 diabetes DKFZp686O1327 intron 17463246 rs1852682 chr2 145833813 C T 4.35E-04 Multiple complex diseases LOC100505498 intron 17554300 rs16824481 chr2 145852801 G T 6.03E-05 Type 2 diabetes LOC100505498 intron 17463246 rs1997287 chr2 145875289 C T 4.29E-05 Duodenal ulcer LOC100505498 intron 22387998 rs41443345 chr2 145898342 A G 9.93E-04 Multiple complex diseases LOC100505498 intron 17554300 rs1085638 chr2 145909831 T C 5.84E-04 Multiple complex diseases LOC100505498 intron 17554300 rs2044369 chr2 145925068 A G 6.70E-05 Multiple complex diseases LOC100505498 intron 17554300 rs2197361 chr2 145978802 A C 3.49E-04 Multiple complex diseases / / 17554300 rs1445300 chr2 146015947 A G 2.70E-04 Heart Failure / / pha002885 rs1822881 chr2 146044052 A G 4.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs11687420 chr2 146045565 A T 4.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs10180522 chr2 146071853 A C 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7590923 chr2 146087653 T C 2.21E-04 Fibrinogen / / 17255346 rs13407123 chr2 146092756 T C 8.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs10445672 chr2 146105254 T C 8.00E-06 Obesity-related traits / / 23251661 rs1996289 chr2 146108380 A G 5.69E-04 Stroke / / pha002886 rs4422110 chr2 146114898 C T 2.63E-11 Common traits (Other) / / 20585627 rs1040173 chr2 146120511 C T 2.88E-09 Common traits (Other) / / 20585627 rs10427255 chr2 146125523 C T 1.00E-11 Common traits (Other) / / 20585627 rs17410058 chr2 146134774 T C 1.02E-08 Common traits (Other) / / 20585627 rs1006134 chr2 146135619 A G 3.80E-09 Common traits (Other) / / 20585627 rs16824898 chr2 146153407 G A 9.08E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1516140 chr2 146156141 G A 2.59E-04 Fibrinogen / / 17255346 rs1516140 chr2 146156141 G A 8.19E-05 Lung adenocarcinoma / / 19836008 rs1516140 chr2 146156141 G A 1.40E-05 Cognitive test performance / / 20125193 rs6721116 chr2 146156197 G A 1.62E-10 Common traits (Other) / / 20585627 rs2840149 chr2 146257174 T A 5.28E-04 Multiple complex diseases / / 17554300 rs10185841 chr2 146261295 C T 7.75E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10496982 chr2 146308114 A C 3.00E-04 Chronic fatigue syndrome / / 21912186 rs6715269 chr2 146346812 T C 5.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6430090 chr2 146347459 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6430091 chr2 146349378 C T 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1484917 chr2 146349854 A G 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7577837 chr2 146352036 A C 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7571848 chr2 146353184 T A 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10175928 chr2 146353440 C T 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12468287 chr2 146354294 C A 2.52E-05 Multiple complex diseases / / 17554300 rs12468287 chr2 146354294 C A 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2381750 chr2 146382236 G T 8.60E-04 Alcohol dependence / / 20201924 rs4632277 chr2 146404349 T C 9.48E-05 Height / / pha003010 rs2704788 chr2 146511295 G T 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11901196 chr2 146516614 T C 1.10E-06 Urinary metabolites / / 21572414 rs13426482 chr2 146522210 T G 2.60E-07 Urinary metabolites / / 21572414 rs12614611 chr2 146524499 A C 3.69E-04 Alzheimer's disease (late onset) / / 21379329 rs16825480 chr2 146529549 T C 1.10E-07 Urinary metabolites / / 21572414 rs11904072 chr2 146557524 G T 4.70E-07 Urinary metabolites / / 21572414 rs16855387 chr2 146558543 A C 2.10E-06 Urinary metabolites / / 21572414 rs1228065 chr2 146567912 C T 2.90E-07 Urinary metabolites / / 21572414 rs1228054 chr2 146572097 C T 2.10E-06 Urinary metabolites / / 21572414 rs10221780 chr2 146588323 A G 7.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1228080 chr2 146602659 T C 1.30E-05 White blood cell types / / 21738478 rs1228075 chr2 146608872 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16825695 chr2 146642195 G A 1.15E-06 Multiple complex diseases / / 17554300 rs11902459 chr2 146644346 A G 2.32E-04 Alzheimer's disease (late onset) / / 21379329 rs1317530 chr2 146660741 T C 1.10E-05 Hepatocellular carcinoma / / 22807686 rs997033 chr2 146672778 A G 8.60E-05 Arthritis (juvenile idiopathic) / / 22354554 rs1515238 chr2 146679403 C T 2.45E-05 Hepatocellular carcinoma / / 22807686 rs17412774 chr2 146773948 A C 1.10E-12 Myopia (Age of onset) / / 23468642 rs222816 chr2 146888064 G T 9.20E-04 Type 2 diabetes / / 17463246 rs222811 chr2 146891073 A G 2.42E-15 Varicose Veins / / pha001416 rs2113773 chr2 146924233 C T 4.08E-05 Blood Pressure / / pha003044 rs2194675 chr2 146932243 A G 6.70E-05 Blood Pressure / / pha003044 rs7608936 chr2 146933934 T G 4.78E-05 Multiple complex diseases / / 17554300 rs11692798 chr2 146997640 C T 5.08E-04 Alcohol dependence / / 24277619 rs987214 chr2 147004927 G A 1.69E-04 Multiple complex diseases / / 17554300 rs987214 chr2 147004927 G A 2.70E-05 Age-related macular degeneration / / pha000002 rs10490590 chr2 147017856 C G 6.51E-05 Age-related macular degeneration / / pha000002 rs13013481 chr2 147026018 A G 3.30E-04 Smoking initiation / / 24665060 rs4662459 chr2 147083675 G A 5.84E-06 Myopia (pathological) / / 21640322 rs13017430 chr2 147093298 T C 6.81E-04 Smoking cessation / / 24665060 rs2381936 chr2 147094369 C T 3.43E-05 Serum metabolites / / 19043545 rs2381936 chr2 147094369 C T 3.49E-04 Smoking cessation / / 24665060 rs6752130 chr2 147100152 G A 2.57E-04 Smoking cessation / / 24665060 rs1074530 chr2 147108688 T C 3.77E-05 Serum metabolites / / 19043545 rs10184605 chr2 147116314 G A 7.07E-04 Multiple complex diseases / / 17554300 rs2381870 chr2 147118058 G A 2.42E-04 Smoking cessation / / 24665060 rs13007824 chr2 147173705 C T 5.26E-04 Smoking cessation / / 24665060 rs13033055 chr2 147182442 A G 1.11E-04 Smoking cessation / / 24665060 rs4362505 chr2 147189398 A G 3.92E-04 Smoking cessation / / 24665060 rs12990755 chr2 147218495 A C 7.00E-05 Glioma (high-grade) / / 19578366 rs10928296 chr2 147232233 G A 1.42E-04 Multiple complex diseases / / 17554300 rs34072689 chr2 147235262 G A 6.76E-04 Smoking cessation / / 24665060 rs6715004 chr2 147242774 T C 1.74E-04 Smoking cessation / / 24665060 rs9967847 chr2 147262167 C A 4.56E-04 Type 2 diabetes / / 17463246 rs72864420 chr2 147273313 G A 1.63E-15 Blood pressure / / 21909110 rs10191269 chr2 147294113 C T 3.25E-04 Type 2 diabetes / / 17463246 rs6720072 chr2 147365709 A G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11895389 chr2 147366942 A G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12617086 chr2 147368035 T C 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707771 chr2 147369819 G C 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928302 chr2 147372024 C T 8.00E-06 HIV-1 control / / 20041166 rs10928302 chr2 147372024 C T 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928304 chr2 147380400 G C 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12475739 chr2 147383718 T G 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7579221 chr2 147385255 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7591307 chr2 147389019 G A 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs6705842 chr2 147393723 T G 7.80E-06 HIV-1 control / / 20041166 rs6739325 chr2 147398530 A G 9.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7559942 chr2 147415821 A T 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12328053 chr2 147416456 T G 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4662263 chr2 147422813 C T 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs4233576 chr2 147428977 A G 1.15E-06 Multiple complex diseases / / 17554300 rs12691747 chr2 147437780 C T 5.71E-04 Multiple complex diseases / / 17554300 rs12691747 chr2 147437780 C T 9.18E-05 Body mass (lean) / / 19268274 rs6726569 chr2 147455149 A G 9.36E-04 Multiple complex diseases / / 17554300 rs6726569 chr2 147455149 A G 4.65E-05 Body mass (lean) / / 19268274 rs10184858 chr2 147465195 G A 9.73E-04 Multiple complex diseases / / 17554300 rs12691748 chr2 147465721 G A 8.79E-04 Multiple complex diseases / / 17554300 rs4525630 chr2 147509889 C G 2.05E-04 Nicotine dependence / / 17158188 rs7588130 chr2 147512772 T C 0.000539275 Hypertension (early onset hypertension) / / 22479346 rs12479440 chr2 147524052 C T 6.07E-05 Kawasaki disease / / 22446961 rs7568410 chr2 147530335 G T 4.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5000314 chr2 147531594 T A 6.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6430138 chr2 147541992 C T 8.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4539741 chr2 147587955 G A 9.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs2037109 chr2 147626142 T C 8.42E-05 HDL cholesterol / / pha003075 rs75638626 chr2 147708864 T C 8.00E-06 Age-related nuclear cataracts / / 24951543 rs1515263 chr2 147750175 T C 1.37E-04 Prion diseases / / 22210626 rs1546602 chr2 147766421 C A 1.67E-04 Prion diseases / / 22210626 rs12467678 chr2 147795055 T C 9.38E-04 Multiple complex diseases / / 17554300 rs1515264 chr2 147795431 G A 8.59E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1515264 chr2 147795431 G A 8.59E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1499919 chr2 147862399 G C 8.39E-04 Insulin resistance / / 21901158 rs16827224 chr2 148105737 T C 2.27E-04 Sarcoidosis / / 19165924 rs1996848 chr2 148106509 G C 4.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16827299 chr2 148148960 A G 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16827303 chr2 148150029 G T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1371040 chr2 148165153 A G 6.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6708612 chr2 148165723 C T 3.92E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1438887 chr2 148166428 A C 1.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1438889 chr2 148174697 G C 0.0008391 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1438889 chr2 148174697 G C 8.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs728621 chr2 148175799 T C 7.48E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1550312 chr2 148183865 C A 3.26E-05 Alzheimer's disease (age of onset) / / 22005931 rs1371031 chr2 148185872 T G 9.81E-04 Multiple complex diseases / / 17554300 rs12998722 chr2 148203843 C T 2.77E-05 Alzheimer's disease (age of onset) / / 22005931 rs1438877 chr2 148213063 G A 6.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs1438880 chr2 148214367 C T 5.82E-04 Multiple complex diseases / / 17554300 rs4662505 chr2 148215682 C T 3.53E-09 Narcolepsy / / 19629137 rs7557911 chr2 148217792 A T 5.45E-05 Alzheimer's disease (age of onset) / / 22005931 rs7609293 chr2 148222332 A T 5.26E-05 Alzheimer's disease (age of onset) / / 22005931 rs4662515 chr2 148267476 A G 3.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs723529 chr2 148276923 G A 2.24E-05 Obesity (extreme) / / 21935397 rs6757820 chr2 148279693 T C 1.51E-05 Neuroticism / / 23229837 rs10197459 chr2 148282050 C T 2.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6753791 chr2 148287864 C G 6.11E-05 Serum metabolites / / 19043545 rs12691757 chr2 148291965 G A 4.02E-05 Serum metabolites / / 19043545 rs12691758 chr2 148292124 T G 5.52E-05 Serum metabolites / / 19043545 rs41409647 chr2 148295775 C A 5.20E-04 Multiple complex diseases / / 17554300 rs16827511 chr2 148305357 C A 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs12464146 chr2 148318521 T C 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs12464146 chr2 148318521 T C 2.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs10497013 chr2 148319755 C T 6.14E-04 Multiple complex diseases / / 17554300 rs10181805 chr2 148337163 C A 2.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4427955 chr2 148377892 T C 3.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4425033 chr2 148389870 A G 8.96E-05 Serum metabolites / / 19043545 rs11679403 chr2 148390620 G A 8.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs13410698 chr2 148403641 G A 7.03E-05 Serum metabolites / / 19043545 rs11896365 chr2 148416474 A G 8.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs951910 chr2 148421180 A G 2.43E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4662290 chr2 148431885 G T 2.19E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4662539 chr2 148432679 T C 2.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1919445 chr2 148454344 T C 6.54E-04 Multiple complex diseases / / 17554300 rs12104985 chr2 148455068 G A 3.76E-04 Type 2 diabetes / / 17463246 rs10497018 chr2 148457312 A T 8.27E-04 Parkinson's disease / / 17052657 rs7584099 chr2 148478336 A G 5.00E-07 Response to statin therapy / / 20339536 rs10177533 chr2 148484063 C T 4.65E-05 Sudden cardiac arrest / / 21658281 rs4641882 chr2 148503815 T G 9.61E-04 Multiple complex diseases / / 17554300 rs13026223 chr2 148517019 T C 9.80E-05 Cognitive function / / 24684796 rs7605932 chr2 148517301 C T 2.28E-04 Parkinson's disease / / 17052657 rs7605932 chr2 148517301 C T 2.00E-05 Cognitive function / / 24684796 rs1919440 chr2 148520066 A G 5.80E-05 Cognitive function / / 24684796 rs10170800 chr2 148522847 C T 4.60E-05 Cognitive function / / 24684796 rs10497022 chr2 148530745 C T 7.60E-05 Cognitive function / / 24684796 rs1528839 chr2 148531200 A C 4.80E-05 Cognitive function / / 24684796 rs1424949 chr2 148542963 T G 3.99E-08 Urate levels / / 23263486 rs12479193 chr2 148557911 A G 4.99E-08 Urate levels / / 23263486 rs12472058 chr2 148558041 C T 4.72E-08 Urate levels / / 23263486 rs4972326 chr2 148558848 A G 4.65E-08 Urate levels / / 23263486 rs7605029 chr2 148559921 A G 4.29E-08 Urate levels / / 23263486 rs986508 chr2 148562031 T C 3.17E-08 Urate levels / / 23263486 rs13032660 chr2 148562909 C A 3.59E-08 Urate levels / / 23263486 rs1863153 chr2 148564193 T C 3.60E-08 Urate levels / / 23263486 rs1863152 chr2 148564405 A G 3.79E-08 Urate levels / / 23263486 rs6734998 chr2 148566321 G A 4.18E-08 Urate levels / / 23263486 rs1991169 chr2 148566919 T C 3.70E-08 Urate levels / / 23263486 rs12990959 chr2 148572160 T C 3.71E-08 Urate levels / / 23263486 rs11894371 chr2 148575872 A C 2.43E-08 Urate levels / / 23263486 rs1364658 chr2 148607808 G C 2.73E-04 Parkinson's disease ACVR2A intron 17052657 rs1014064 chr2 148612154 A G 3.76E-08 Urate levels ACVR2A intron 23263486 rs10803523 chr2 148615831 T G 2.74E-08 Urate levels ACVR2A intron 23263486 rs2113793 chr2 148623453 T G 4.76E-08 Urate levels ACVR2A intron 23263486 rs929939 chr2 148627528 C A 6.15E-04 Parkinson's disease ACVR2A intron 17052657 rs929939 chr2 148627528 C A 3.16E-08 Urate levels ACVR2A intron 23263486 rs6711673 chr2 148643259 A C 3.10E-08 Urate levels ACVR2A intron 23263486 rs13033696 chr2 148645327 A G 4.55E-08 Urate levels ACVR2A intron 23263486 rs2161983 chr2 148649386 G A 2.95E-08 Urate levels ACVR2A intron 23263486 rs13019809 chr2 148650473 G A 2.44E-08 Urate levels ACVR2A intron 23263486 rs1128919 chr2 148657117 G A 3.68E-08 Urate levels ACVR2A cds-synon 23263486 rs12987286 chr2 148663568 G T 3.27E-04 Parkinson's disease ACVR2A intron 17052657 rs3768689 chr2 148669774 G C 8.47E-04 Parkinson's disease ACVR2A intron 17052657 rs13026650 chr2 148674201 G A 2.87E-08 Urate levels ACVR2A intron 23263486 rs3764955 chr2 148674797 G C 3.15E-08 Urate levels ACVR2A intron 23263486 rs2303392 chr2 148680427 G C 9.16E-04 Parkinson's disease ACVR2A intron 17052657 rs12620026 chr2 148683919 A T 4.63E-05 Panic disorder ACVR2A intron 19165232 rs1345994 chr2 148695126 T G 1.93E-08 Urate levels ORC4 intron 23263486 rs10460259 chr2 148704721 A C 6.15E-04 Parkinson's disease ORC4 intron 17052657 rs13012311 chr2 148707032 C T 1.54E-08 Urate levels ORC4 intron 23263486 rs13027200 chr2 148709653 A G 2.41E-08 Urate levels ORC4 intron 23263486 rs12463798 chr2 148716099 G T 1.45E-08 Urate levels ORC4 intron 23263486 rs2307394 chr2 148716428 T C 8.39E-04 Parkinson's disease ORC4 missense 17052657 rs2307394 chr2 148716428 T C 2.00E-08 Urate levels ORC4 missense 23263486 rs6729465 chr2 148723126 A C 1.64E-08 Urate levels ORC4 intron 23263486 rs11901963 chr2 148726771 A T 1.34E-08 Urate levels ORC4 intron 23263486 rs13027706 chr2 148732703 A G 2.11E-08 Urate levels ORC4 intron 23263486 rs7594075 chr2 148739823 G C 1.85E-08 Urate levels ORC4 intron 23263486 rs13004041 chr2 148741621 C T 2.38E-08 Urate levels ORC4 intron 23263486 rs17693310 chr2 148747978 G A 5.86E-05 Sudden cardiac arrest ORC4 intron 21658281 rs12463554 chr2 148751612 C T 3.33E-08 Urate levels ORC4 intron 23263486 rs13008838 chr2 148754825 A G 2.89E-08 Urate levels ORC4 intron 23263486 rs13035475 chr2 148754862 T G 1.72E-08 Urate levels ORC4 intron 23263486 rs13014936 chr2 148755237 C T 1.71E-08 Urate levels ORC4 intron 23263486 rs13022962 chr2 148756624 G A 1.46E-08 Urate levels ORC4 intron 23263486 rs12053401 chr2 148756668 A T 1.58E-08 Urate levels ORC4 intron 23263486 rs13028348 chr2 148757144 A G 1.51E-08 Urate levels ORC4 intron 23263486 rs1598207 chr2 148757870 A G 1.76E-08 Urate levels ORC4 intron 23263486 rs7598361 chr2 148758479 A G 3.22E-08 Urate levels ORC4 intron 23263486 rs2382201 chr2 148765496 C T 3.34E-08 Urate levels ORC4 intron 23263486 rs12989250 chr2 148776438 G A 3.19E-08 Urate levels ORC4 intron 23263486 rs1975748 chr2 148776859 A C 2.06E-08 Urate levels ORC4 intron 23263486 rs897172 chr2 148778272 A G 6.09E-04 Parkinson's disease ORC4 UTR-5 17052657 rs1015096 chr2 148782358 T C 2.64E-08 Urate levels MBD5 intron 23263486 rs13007770 chr2 148784324 C T 3.26E-08 Urate levels MBD5 intron 23263486 rs2890915 chr2 148789543 C T 3.88E-08 Urate levels MBD5 intron 23263486 rs13013887 chr2 148825780 A G 5.65E-04 Parkinson's disease MBD5 intron 17052657 rs1234413 chr2 148844369 C T 9.50E-05 Parkinson's disease MBD5 intron 21738487 rs10928374 chr2 148852035 A G 9.31E-05 Parkinson's disease MBD5 intron 21738487 rs41477845 chr2 148875566 C T 6.35E-04 Prostate cancer mortality MBD5 intron 20978177 rs10497031 chr2 148918835 A G 3.73E-04 Stroke MBD5 intron pha002887 rs16828443 chr2 148971603 C T 7.32E-04 Multiple complex diseases MBD5 intron 17554300 rs2044760 chr2 148989731 T C 6.90E-07 Urinary metabolites MBD5 intron 21572414 rs2044761 chr2 148989742 A G 7.00E-07 Urinary metabolites MBD5 intron 21572414 rs6746932 chr2 149012777 T C 2.00E-06 Urinary metabolites MBD5 intron 21572414 rs2890917 chr2 149015704 T A 6.10E-07 Urinary metabolites MBD5 intron 21572414 rs6731657 chr2 149019793 A G 1.04E-04 Self-reported allergy MBD5 intron 23817569 rs2656318 chr2 149075242 G A 5.86E-04 Multiple complex diseases MBD5 intron 17554300 rs17276501 chr2 149087536 C T 2.37E-04 Multiple complex diseases MBD5 intron 17554300 rs12617242 chr2 149164048 C T 2.93E-05 Heart Rate MBD5 intron pha003054 rs1404184 chr2 149268503 T A 5.05E-04 Smoking cessation MBD5 intron 24665060 rs1404183 chr2 149268931 G A 4.09E-04 Alzheimer's disease (late onset) MBD5 intron 21379329 rs16828726 chr2 149271642 G A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs10928399 chr2 149277896 C T 7.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756002 chr2 149284523 C T 4.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs12997473 chr2 149284887 A G 3.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs13003024 chr2 149285093 C T 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs764386 chr2 149285506 G A 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972369 chr2 149287440 C T 3.28E-05 Suicide attempts in bipolar disorder / / 21423239 rs4284768 chr2 149290719 T G 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2382231 chr2 149290943 C T 1.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs7599758 chr2 149293880 C T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs13003132 chr2 149295930 C T 1.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs13009428 chr2 149296505 C A 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs16828791 chr2 149296887 C T 4.42E-05 Suicide attempts in bipolar disorder / / 21423239 rs16828816 chr2 149305525 A T 2.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs7578059 chr2 149312470 G A 8.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs16828836 chr2 149312728 T C 6.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs930652 chr2 149317494 C T 1.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7597133 chr2 149317833 G A 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972375 chr2 149324132 C A 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs7606475 chr2 149325251 C T 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs13010027 chr2 149326704 G A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs13010027 chr2 149326704 G A 7.73E-04 Smoking initiation / / 24665060 rs10928406 chr2 149329952 G T 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928407 chr2 149329961 C G 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6746352 chr2 149352353 C T 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10172817 chr2 149380586 C T 3.76E-04 Multiple complex diseases / / 17554300 rs10191411 chr2 149387968 T C 4.00E-06 Protein quantitative trait loci / / 18464913 rs2121433 chr2 149557860 T C 1.00E-06 Alzheimer's disease biomarkers / / 21123754 rs4499362 chr2 149568396 C T 1.00E-06 Alzheimer's disease biomarkers / / 21123754 rs10171238 chr2 149568729 C T 2.99E-05 AIDS progression / / 19115949 rs7606125 chr2 149589885 T C 3.19E-04 Multiple complex diseases / / 17554300 rs17296534 chr2 149590486 G A 5.64E-05 Type 2 diabetes / / 17463246 rs6710001 chr2 149816918 A G 4.86E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6738277 chr2 149853960 A G 5.14E-04 Iron levels / / pha002876 rs6736802 chr2 149858734 A C 1.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6721330 chr2 149858906 C A 6.51E-05 Hepatocellular carcinoma / / 22807686 rs6435220 chr2 149861679 G A 4.18E-04 Iron levels / / pha002876 rs6435387 chr2 149865250 A G 3.40E-04 Schizophrenia / / 21926974 rs6435387 chr2 149865250 A G 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6435387 chr2 149865250 A G 0.0000428 Schizophrenia / / 23637625 rs7577450 chr2 149875961 A G 8.32E-05 Alcoholism / / pha002893 rs17347194 chr2 149888184 C T 3.05E-04 Iron levels / / pha002876 rs4667369 chr2 149891845 G C 3.05E-05 Schizophrenia / / 19571811 rs10929935 chr2 149892614 T C 6.30E-04 Alcohol dependence / / 20201924 rs10929935 chr2 149892614 T C 7.30E-05 Alcohol dependence / / 20201924 rs10929935 chr2 149892614 T C 5.43E-04 Iron levels / / pha002876 rs10929935 chr2 149892614 T C 7.26E-05 Alcoholism / / pha002893 rs16822509 chr2 149894724 T C 3.20E-05 Alcohol dependence / / 20201924 rs16822509 chr2 149894724 T C 3.22E-05 Alcoholism / / pha002893 rs10201643 chr2 149905641 T G 2.00E-05 Alcohol dependence LYPD6B intron 20201924 rs10201643 chr2 149905641 T G 1.96E-05 Alcoholism LYPD6B intron pha002893 rs10803789 chr2 149932430 C A 7.05E-04 Myopia (pathological) LYPD6B intron 21095009 rs6432716 chr2 149940220 A G 3.18E-04 Multiple complex diseases LYPD6B intron 17554300 rs13406443 chr2 149941679 G A 1.42E-04 Multiple complex diseases LYPD6B intron 17554300 rs13005197 chr2 149946582 T C 9.24E-04 Myopia (pathological) LYPD6B intron 21095009 rs10497052 chr2 149954253 G A 4.09E-04 Myopia (pathological) LYPD6B intron 21095009 rs1404683 chr2 149988911 G T 5.05E-06 Lipid levels LYPD6B intron 19016617 rs6737636 chr2 149990087 C T 1.74E-04 Substance dependence LYPD6B intron 21818250 rs7584841 chr2 150097468 G A 8.46E-05 Longevity / / 20304771 rs17529158 chr2 150101440 C G 9.82E-05 Type 2 diabetes / / 17463246 rs6433988 chr2 150143750 T C 3.57E-04 Type 2 diabetes / / 17463246 rs10432496 chr2 150147278 C T 6.00E-08 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs1420356 chr2 150188932 A G 3.18E-05 Longevity LYPD6 intron 20304771 rs10206766 chr2 150194002 G T 6.58E-05 Serum metabolites LYPD6 intron 19043545 rs1196698 chr2 150212010 A G 5.29E-04 Myopia (pathological) LYPD6 intron 21095009 rs13027838 chr2 150233741 C T 0.0000273 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LYPD6 intron 22628534 rs1196686 chr2 150242490 A G 1.55E-04 Type 2 diabetes LYPD6 intron 17463246 rs13035027 chr2 150382765 C A 4.49E-04 Multiple complex diseases / / 17554300 rs7578361 chr2 150397218 G T 8.00E-06 Acute lymphoblastic leukemia (childhood) / / 23007406 rs7578361 chr2 150397218 G T 9.89E-05 Asthma / / 23181788 rs7578361 chr2 150397218 G T 9.89E-05 Cognitive decline / / 23207651 rs10170236 chr2 150457624 G A 4.00E-06 Acute lymphoblastic leukemia (childhood) / / 23007406 rs4667413 chr2 150477548 C T 5.95E-04 Aortic root size / / 21223598 rs12474343 chr2 150491821 G T 3.40E-04 Aortic root size / / 21223598 rs711892 chr2 150504096 C G 7.36E-04 Multiple complex diseases / / 17554300 rs1526284 chr2 150508359 T G 1.71E-04 Celiac disease / / 23936387 rs16827293 chr2 150509332 C T 5.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs6734346 chr2 150509388 G A 9.71E-05 Multiple complex diseases / / 17554300 rs17801127 chr2 150564484 C T 2.00E-07 Liver enzyme levels (alanine transaminase) / / 24124411 rs7560430 chr2 150572567 A G 9.60E-05 Erythrocyte counts / / pha003099 rs10490076 chr2 150600709 T G 2.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs17745212 chr2 150603989 C T 3.87E-05 Bipolar disorder and schizophrenia / / 20889312 rs1012307 chr2 150655221 A C 8.00E-07 Asthma (sex interaction) FLJ32955 intron 24824216 rs13000594 chr2 150667047 A C 2.62E-05 Cognitive performance FLJ32955 intron 19734545 rs10201238 chr2 150668782 A G 5.68E-04 Multiple complex diseases FLJ32955 intron 17554300 rs2068460 chr2 150674955 T G 9.30E-05 Bipolar disorder and schizophrenia FLJ32955 intron 20889312 rs12990176 chr2 150677076 T G 4.85E-05 Femoral neck bone geometry FLJ32955 intron 22087292 rs9288698 chr2 150683337 T G 5.84E-04 Suicide attempts in bipolar disorder FLJ32955 intron 21041247 rs11889862 chr2 150697148 A G 2.00E-06 Menopause (age at onset) FLJ32955 intron 19448619 rs17296897 chr2 150718561 G A 2.92E-05 Personality dimensions / / 22628180 rs1437949 chr2 150726008 A G 3.07E-05 Personality dimensions / / 22628180 rs1437960 chr2 150727220 A T 3.09E-05 Personality dimensions / / 22628180 rs10171287 chr2 150729453 G A 3.65E-05 Personality dimensions / / 22628180 rs967618 chr2 150735158 G A 3.01E-05 Personality dimensions / / 22628180 rs1437940 chr2 150738516 A T 3.00E-05 Personality dimensions / / 22628180 rs11902738 chr2 150740332 T C 2.99E-05 Personality dimensions / / 22628180 rs1437959 chr2 150773549 A G 2.24E-05 Prostate cancer / / pha002878 rs1437956 chr2 150782730 A T 4.46E-04 Multiple complex diseases / / 17554300 rs1437956 chr2 150782730 A T 3.09E-05 Vaspin levels / / 22907691 rs331125 chr2 150870450 T C 0.0000454 Asthma / / 22694930 rs331124 chr2 150870860 C T 2.19E-05 Prostate cancer / / pha002878 rs732227 chr2 150877992 T C 0.000049 Asthma / / 22694930 rs4533492 chr2 150891651 A G 1.20E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330646 chr2 150903121 C T 8.71E-05 Arthritis (juvenile idiopathic) / / 22354554 rs108136 chr2 150909115 T G 1.49E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330625 chr2 150911159 A G 3.13E-05 Arthritis (juvenile idiopathic) / / 22354554 rs330624 chr2 150912703 A G 1.54E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330630 chr2 150948703 T C 3.00E-06 Alcohol dependence / / 21956439 rs11903537 chr2 150966084 A G 1.69E-05 Telomere length / / 23001564 rs494023 chr2 150977990 G C 8.42E-04 Type 2 diabetes / / 17463246 rs3106778 chr2 150979368 T C 7.17E-04 Type 2 diabetes / / 17463246 rs16827839 chr2 150987418 G A 9.91E-04 Major depressive disorder / / 22472876 rs492161 chr2 150991740 G C 1.10E-05 Urinary metabolites / / 21572414 rs13013440 chr2 151063726 A G 3.23E-04 Body mass index / / 17255346 rs971810 chr2 151064165 C A 1.04E-04 Type 2 diabetes / / 17463246 rs13024803 chr2 151077809 A G 8.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs6716455 chr2 151126403 G A 7.00E-07 Alcoholism (alcohol use disorder factor score) / / 21529783 rs6716455 chr2 151126403 G A 9.00E-06 Alcoholism (alcohol dependence factor score) / / 21529783 rs13002889 chr2 151148928 G A 3.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16828065 chr2 151188117 A C 6.94E-04 Multiple complex diseases / / 17554300 rs1441974 chr2 151201613 A G 0.0000356 Breast cancer early age of onset / / 18463975 rs12994436 chr2 151210898 G A 6.40E-05 Body mass index / / 17255346 rs6760903 chr2 151218033 G A 3.97E-05 Body mass index / / 17255346 rs6760903 chr2 151218033 G A 3.57E-05 Atopic dermatitis / / 21666691 rs2119753 chr2 151224579 A G 0.000227 Salmonella-induced pyroptosis / / 22837397 rs7564866 chr2 151237763 C T 0.000461 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7564866 chr2 151237763 C T 4.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17434952 chr2 151278840 A G 1.30E-05 Urinary metabolites / / 21572414 rs17435000 chr2 151289661 G T 4.69E-04 Aortic root size / / 21223598 rs17435000 chr2 151289661 G T 5.60E-06 Urinary metabolites / / 21572414 rs2334310 chr2 151291604 A C 5.37E-05 Multiple sclerosis (age of onset) / / 19010793 rs816889 chr2 151325295 A G 0.000102 Coronary artery disease RND3 UTR-3 23202125 rs2222760 chr2 151345113 G A 5.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1533664 chr2 151548341 A G 8.04E-05 Glucose levels / / pha003057 rs1125937 chr2 151606387 T C 8.47E-05 Multiple complex diseases / / 17554300 rs6734792 chr2 151624882 C T 6.04E-05 Bipolar disorder / / 17486107 rs6757804 chr2 151635832 C T 6.00E-08 Endometriosis / / 23472165 rs7560163 chr2 151637936 C G 7.00E-09 Type 2 diabetes / / 22238593 rs12475182 chr2 151638802 C T 2.56E-04 Schizophrenia / / 21747397 rs1519764 chr2 151639218 C G 8.10E-06 Urinary metabolites / / 21572414 rs962052 chr2 151644203 C T 8.60E-07 Urinary metabolites / / 21572414 rs1010330 chr2 151646872 G C 1.50E-05 Urinary metabolites / / 21572414 rs2190375 chr2 151650314 G A 2.45E-04 Parkinson's disease / / 17052657 rs1519772 chr2 151667708 C T 1.00E-05 Urinary metabolites / / 21572414 rs10489979 chr2 151682012 G A 9.39E-05 Coronary heart disease / / 21971053 rs2097935 chr2 151691144 G A 1.48E-04 Coronary heart disease / / 21971053 rs6433010 chr2 151718133 C T 0.000656595 Hypertension (early onset hypertension) / / 22479346 rs10195263 chr2 151725792 G A 3.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs12467192 chr2 151726959 C T 0.000345115 Hypertension (early onset hypertension) / / 22479346 rs1005274 chr2 151728377 G A 0.000273704 Hypertension (early onset hypertension) / / 22479346 rs1005274 chr2 151728377 G A 5.21E-05 Calcium levels / / pha003085 rs6433018 chr2 151729571 G A 0.00046308 Hypertension (early onset hypertension) / / 22479346 rs6433018 chr2 151729571 G A 3.27E-05 Calcium levels / / pha003085 rs12618428 chr2 151732979 A G 7.72E-07 Osteoarthritis / / 22763110 rs960615 chr2 151733201 C T 3.20E-05 Hypothyroidism / / 22493691 rs7585613 chr2 151741365 C T 7.08E-05 Pulmonary function / / 19300500 rs7558214 chr2 151741406 G A 7.09E-05 Pulmonary function / / 19300500 rs16828833 chr2 151743498 G T 7.10E-05 Pulmonary function / / 19300500 rs16828835 chr2 151744452 T A 7.12E-05 Pulmonary function / / 19300500 rs2190367 chr2 151749834 C T 7.16E-05 Pulmonary function / / 19300500 rs7570251 chr2 151752329 T C 7.26E-05 Pulmonary function / / 19300500 rs16828857 chr2 151753548 C A 7.19E-05 Pulmonary function / / 19300500 rs10188669 chr2 151753903 G A 1.70E-05 Urinary metabolites / / 21572414 rs16828865 chr2 151754602 T C 7.91E-05 Pulmonary function / / 19300500 rs16828883 chr2 151756711 C T 8.49E-05 Pulmonary function / / 19300500 rs7601783 chr2 151758242 G A 8.46E-05 Pulmonary function / / 19300500 rs7602001 chr2 151758422 G A 8.46E-05 Pulmonary function / / 19300500 rs11687663 chr2 151758445 T C 8.86E-04 Stroke / / pha002887 rs917237 chr2 151764512 G A 1.37E-05 Bone mineral density / / 19181680 rs917238 chr2 151773679 C G 8.62E-04 Acute lung injury / / 22295056 rs1548632 chr2 151776216 C T 6.91E-05 Bone mineral density / / 19181680 rs12692888 chr2 151781053 T C 1.60E-05 Urinary metabolites / / 21572414 rs1019035 chr2 151802844 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2062365 chr2 151835990 T C 4.21E-05 Bone mineral density / / 19181680 rs1905744 chr2 151836205 T G 2.57E-05 Bone mineral density / / 19181680 rs16829215 chr2 151871445 C T 2.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4664875 chr2 151871888 T C 4.06E-04 Substance dependence / / 21818250 rs7603077 chr2 151885556 A G 5.21E-06 Bone mineral density / / 19181680 rs1463609 chr2 151895088 A G 6.36E-06 Bone mineral density / / 19181680 rs2880167 chr2 151898262 T C 1.17E-04 Multiple complex diseases / / 17554300 rs13034178 chr2 151902601 A T 9.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6433132 chr2 151908948 T C 1.20E-27 Narcolepsy / / 19629137 rs1994256 chr2 151919436 C G 4.72E-04 Type 2 diabetes / / 17463246 rs10169306 chr2 151926472 G A 8.33E-05 Height / / pha003011 rs13026867 chr2 151931439 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2046422 chr2 151938118 T C 9.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13034554 chr2 151940137 A G 1.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs720066 chr2 151946149 G A 1.44E-05 Height / / pha003010 rs720066 chr2 151946149 G A 6.60E-06 Height / / pha003011 rs749691 chr2 151954166 G A 3.09E-04 Multiple complex diseases / / 17554300 rs749691 chr2 151954166 G A 5.54E-06 Height / / pha003010 rs749691 chr2 151954166 G A 2.67E-06 Height / / pha003011 rs1485099 chr2 151960452 T C 5.93E-05 Height / / pha003010 rs1485099 chr2 151960452 T C 1.28E-05 Height / / pha003011 rs816710 chr2 151984277 C T 3.91E-05 Height / / pha003010 rs816710 chr2 151984277 C T 5.44E-05 Height / / pha003011 rs289932 chr2 152006025 C T 5.42E-07 Autism / / 22843504 rs289932 chr2 152006025 C T 9.25E-05 Cervical cancer / / 24700089 rs289851 chr2 152023517 G A 8.56E-05 Height / / pha003011 rs16829682 chr2 152024706 G A 1.46E-04 Multiple complex diseases / / 17554300 rs112116 chr2 152035710 T C 1.03E-05 Height / / pha003010 rs112116 chr2 152035710 T C 5.44E-07 Height / / pha003011 rs289854 chr2 152050243 G A 1.03E-05 Height / / pha003010 rs289854 chr2 152050243 G A 5.44E-07 Height / / pha003011 rs289858 chr2 152052326 G A 2.81E-07 Autism / / 22843504 rs289858 chr2 152052326 G A 1.83E-05 Height / / pha003010 rs289858 chr2 152052326 G A 4.05E-06 Height / / pha003011 rs389797 chr2 152059484 G A 9.48E-04 Acute lung injury / / 22295056 rs289864 chr2 152061883 C A 8.81E-04 Acute lung injury / / 22295056 rs289871 chr2 152065396 C A 7.42E-05 Height / / pha003010 rs289871 chr2 152065396 C A 5.71E-06 Height / / pha003011 rs289827 chr2 152070336 G T 1.41E-05 Height / / pha003011 rs289903 chr2 152084705 G A 3.57E-05 Height / / pha003010 rs289903 chr2 152084705 G A 3.56E-06 Height / / pha003011 rs2218880 chr2 152099885 G A 2.89E-05 Height / / pha003011 rs11683285 chr2 152111965 G A 7.46E-04 Acute lung injury RBM43 intron 22295056 rs2271811 chr2 152117780 T C 2.30E-05 Height RBM43 intron pha003011 rs16829835 chr2 152123703 A C 7.83E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6433327 chr2 152154732 A G 2.34E-05 Height / / pha003011 rs6726634 chr2 152159880 G A 6.50E-05 Height / / pha003011 rs3771891 chr2 152218185 T G 2.03E-05 Height TNFAIP6 intron pha003010 rs3771891 chr2 152218185 T G 1.05E-07 Height TNFAIP6 intron pha003011 rs3771895 chr2 152224339 G A 6.17E-04 Suicide attempts in bipolar disorder TNFAIP6 intron 21041247 rs10432476 chr2 152225088 T C 6.09E-04 Suicide attempts in bipolar disorder TNFAIP6 intron 21041247 rs10432476 chr2 152225088 T C 0.000422 Height (Pygmy height) TNFAIP6 intron 22570615 rs1046668 chr2 152226570 A G 8.16E-05 Coronary Artery Disease TNFAIP6 missense 17634449 rs10197940 chr2 152253918 T C 5.00E-06 Lung cancer / / 23143601 rs2444263 chr2 152311570 G A 2.65E-04 Multiple complex diseases RIF1 missense 17554300 rs7422009 chr2 152313539 C T 6.78E-04 White matter integrity RIF1 intron 22425255 rs2444274 chr2 152324789 G C 4.42E-04 Multiple complex diseases RIF1 intron 17554300 rs16830061 chr2 152330148 A G 4.71E-04 White matter integrity RIF1 intron 22425255 rs16830067 chr2 152331745 T G 8.85E-04 Multiple complex diseases RIF1 UTR-3 17554300 rs16830067 chr2 152331745 T G 5.29E-04 White matter integrity RIF1 UTR-3 22425255 rs16830086 chr2 152338989 C T 3.80E-04 Multiple complex diseases / / 17554300 rs11680579 chr2 152340685 G A 8.42E-04 Type 2 diabetes / / 17463246 rs16830090 chr2 152342481 A G 4.45E-04 White matter integrity NEB intron 22425255 rs13031275 chr2 152346494 A C 5.63E-06 Waist Circumference NEB cds-synon pha003023 rs13031275 chr2 152346494 A C 1.01E-05 Waist-Hip Ratio NEB cds-synon pha003029 rs34368668 chr2 152363484 G A 0.000000577 LDL cholesterol NEB missense 23063622 rs12996964 chr2 152393422 T C 9.00E-05 Fibrinogen NEB intron 17255346 rs11902616 chr2 152467001 C T 3.43E-05 Serum selenium levels NEB intron 23698163 rs6717213 chr2 152476130 C T 3.23E-05 Serum selenium levels NEB cds-synon 23698163 rs10186482 chr2 152481977 A G 6.87E-05 Response to acetaminophen (hepatotoxicity) NEB intron 21177773 rs76767949 chr2 152499355 T C 0.00032 Prostate cancer NEB missense 23555315 rs11885813 chr2 152511515 T A 1.71E-05 Sleep duration NEB intron 22105623 rs10192459 chr2 152517979 T C 2.53E-05 Sleep duration NEB intron 22105623 rs117271684 chr2 152521983 A G 0.00069 Prostate cancer NEB missense 23555315 rs117048449 chr2 152534545 T C 0.00069 Prostate cancer NEB missense 23555315 rs13025954 chr2 152585020 C T 1.66E-04 Birth weight NEB intron 17255346 rs12472627 chr2 152633114 C T 4.82E-04 Alcohol dependence / / 21314694 rs17198087 chr2 152681044 G C 1.42E-04 Multiple complex diseases ARL5A intron 17554300 rs35017924 chr2 152685966 G A 9.10E-11 Urinary metabolites / / 21572414 rs2344734 chr2 152691829 C G 3.61E-05 Neuroticism CACNB4 UTR-3 23229837 rs3754533 chr2 152697463 G T 9.56E-04 Multiple complex diseases CACNB4 intron 17554300 rs13424831 chr2 152707252 C T 1.10E-04 Bladder cancer CACNB4 intron 19648920 rs9646794 chr2 152710431 T A 9.49E-04 Coronary heart disease CACNB4 intron 21606135 rs2461835 chr2 152741984 C T 1.50E-07 Urinary metabolites CACNB4 intron 21572414 rs12471646 chr2 152775308 G A 4.10E-06 Urinary metabolites CACNB4 intron 21572414 rs6729612 chr2 152780167 C T 1.40E-05 Urinary metabolites CACNB4 intron 21572414 rs6734642 chr2 152806855 T C 2.80E-05 Urinary metabolites CACNB4 intron 21572414 rs7558481 chr2 152817193 G C 1.80E-05 Urinary metabolites CACNB4 intron 21572414 rs2345160 chr2 152819262 G A 2.20E-07 Urinary metabolites CACNB4 intron 21572414 rs11893938 chr2 152836455 A G 9.60E-08 Urinary metabolites CACNB4 intron 21572414 rs17270394 chr2 152844074 A C 2.87E-04 Depression (quantitative trait) CACNB4 intron 20800221 rs1519708 chr2 152872455 A G 2.45E-05 Statin-induced myopathy CACNB4 intron 21826682 rs13421383 chr2 152879348 C T 3.19E-04 Type 2 diabetes CACNB4 intron 17463246 rs16830608 chr2 152880509 A C 6.08E-06 Multiple complex diseases CACNB4 intron 17554300 rs4664076 chr2 152921491 G A 2.19E-05 Hypertension CACNB4 intron 22384028 rs10930910 chr2 152930618 T C 3.83E-04 Obesity (extreme) CACNB4 intron 21935397 rs2345633 chr2 152946604 T C 7.54E-04 Type 2 diabetes CACNB4 intron 17463246 rs3820706 chr2 152957411 T C 2.00E-09 Adverse response to chemotherapy in breast cancer (alopecia) CACNB4 nearGene-5 24025145 rs12472524 chr2 152972696 A G 7.90E-04 Obesity (extreme) / / 21935397 rs10200655 chr2 152974960 T A 7.28E-04 Obesity (extreme) STAM2 UTR-3 21935397 rs10497095 chr2 152977988 G A 7.63E-04 Obesity (extreme) STAM2 intron 21935397 rs3820702 chr2 152980853 T A 6.97E-04 Obesity (extreme) STAM2 intron 21935397 rs16830728 chr2 152981335 G T 3.00E-08 Adverse response to chemotherapy in breast cancer (alopecia) STAM2 intron 24025145 rs17398246 chr2 152981827 G A 2.25E-04 Response to taxane treatment (placlitaxel) STAM2 intron 23006423 rs4664531 chr2 152986041 T C 3.31E-04 Obesity (extreme) STAM2 intron 21935397 rs12623355 chr2 152986593 C T 5.56E-04 Obesity (extreme) STAM2 intron 21935397 rs12613984 chr2 152987546 A C 5.91E-04 Obesity (extreme) STAM2 intron 21935397 rs3768651 chr2 152990721 T A,C,G 1.96E-04 Schizophrenia STAM2 intron 19197363 rs3768651 chr2 152990721 T A,C,G 6.30E-04 Obesity (extreme) STAM2 intron 21935397 rs3768650 chr2 152990932 A G 6.31E-04 Obesity (extreme) STAM2 intron 21935397 rs12612031 chr2 152992237 G A 7.29E-04 Obesity (extreme) STAM2 intron 21935397 rs12621378 chr2 152995177 C T 1.60E-04 Schizophrenia STAM2 intron 19197363 rs12621378 chr2 152995177 C T 6.43E-04 Obesity (extreme) STAM2 intron 21935397 rs12612557 chr2 152995261 T G 6.42E-04 Obesity (extreme) STAM2 intron 21935397 rs11893841 chr2 152998552 G A 1.61E-04 Schizophrenia STAM2 intron 19197363 rs11893841 chr2 152998552 G A 5.91E-04 Obesity (extreme) STAM2 intron 21935397 rs12617139 chr2 153000337 T A 8.92E-04 Obesity (extreme) STAM2 intron 21935397 rs3768649 chr2 153003104 G C 9.05E-04 Obesity (extreme) STAM2 intron 21935397 rs3768648 chr2 153003412 T C 5.11E-04 Obesity (extreme) STAM2 intron 21935397 rs4664535 chr2 153004253 G A 8.99E-04 Obesity (extreme) STAM2 intron 21935397 rs4664536 chr2 153004385 C A 8.66E-04 Obesity (extreme) STAM2 intron 21935397 rs10184862 chr2 153005844 A G 6.55E-04 Obesity (extreme) STAM2 intron 21935397 rs13003423 chr2 153006452 G C 8.87E-04 Obesity (extreme) STAM2 intron 21935397 rs6650779 chr2 153007034 A G 8.85E-04 Obesity (extreme) STAM2 intron 21935397 rs6650771 chr2 153009131 A G 8.42E-04 Obesity (extreme) STAM2 intron 21935397 rs10930958 chr2 153009409 C T 8.39E-04 Obesity (extreme) STAM2 intron 21935397 rs10930959 chr2 153009469 A G 8.81E-04 Obesity (extreme) STAM2 intron 21935397 rs6731625 chr2 153020612 A G 8.82E-04 Obesity (extreme) STAM2 intron 21935397 rs4664084 chr2 153022071 C T 8.77E-04 Obesity (extreme) STAM2 intron 21935397 rs6738680 chr2 153024113 G A 8.62E-04 Obesity (extreme) STAM2 intron 21935397 rs4611639 chr2 153025030 G C 2.83E-04 Obesity (extreme) STAM2 intron 21935397 rs12328733 chr2 153029067 G A 4.92E-04 Obesity (extreme) STAM2 intron 21935397 rs10497097 chr2 153030869 G A 4.93E-04 Obesity (extreme) STAM2 intron 21935397 rs2345639 chr2 153031113 T C 9.15E-04 Obesity (extreme) STAM2 intron 21935397 rs4368329 chr2 153032593 G A 8.82E-04 Obesity (extreme) / / 21935397 rs6740224 chr2 153032790 A C 6.19E-04 Obesity (extreme) / / 21935397 rs10803946 chr2 153033517 C A 4.93E-04 Obesity (extreme) / / 21935397 rs4664089 chr2 153045036 A G 4.38E-04 Obesity (extreme) / / 21935397 rs6713219 chr2 153079708 T C 6.77E-04 Multiple complex diseases / / 17554300 rs11883562 chr2 153083897 T C 5.42E-04 Multiple complex diseases / / 17554300 rs10497098 chr2 153090971 T A 5.70E-04 Multiple complex diseases / / 17554300 rs4664544 chr2 153092375 C T 3.96E-05 Schizophrenia / / 24253340 rs11679305 chr2 153102914 T C 6.57E-04 Obesity (extreme) / / 21935397 rs6433928 chr2 153110731 T A 4.93E-04 Multiple complex diseases / / 17554300 rs12988834 chr2 153129366 G A 5.72E-05 Schizophrenia / / 24253340 rs12997179 chr2 153147789 G A 4.39E-04 Obesity (extreme) / / 21935397 rs2345814 chr2 153150197 A T 4.28E-04 Obesity (extreme) / / 21935397 rs2881225 chr2 153150727 C T 5.68E-04 Obesity (extreme) / / 21935397 rs4308089 chr2 153153159 A G 6.00E-04 Obesity (extreme) / / 21935397 rs17326775 chr2 153153555 A G 5.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4664560 chr2 153153733 T C 7.91E-04 Obesity (extreme) / / 21935397 rs7568759 chr2 153154612 G A 8.71E-04 Obesity (extreme) / / 21935397 rs11674860 chr2 153154680 T G 7.93E-04 Obesity (extreme) / / 21935397 rs12693313 chr2 153157043 G A 6.15E-04 Obesity (extreme) / / 21935397 rs5005667 chr2 153162835 T C 7.32E-04 Obesity (extreme) / / 21935397 rs2345876 chr2 153164514 G A 5.64E-04 Obesity (extreme) / / 21935397 rs2345877 chr2 153164790 C T 8.00E-04 Obesity (extreme) / / 21935397 rs12693320 chr2 153166172 T A 7.08E-04 Obesity (extreme) / / 21935397 rs16830964 chr2 153208493 A C 1.13E-06 Schizophrenia FMNL2 intron 24253340 rs4254462 chr2 153219836 T C 0.000706191 Hypertension (early onset hypertension) FMNL2 intron 22479346 rs4664574 chr2 153221287 G T 1.39E-06 Schizophrenia FMNL2 intron 24253340 rs11674872 chr2 153225799 A G 3.44E-04 Bipolar disorder,schizoaffective FMNL2 intron 19567891 rs16831009 chr2 153232345 A G 2.44E-06 Schizophrenia FMNL2 intron 24253340 rs16831018 chr2 153237345 C T 1.31E-04 Multiple complex diseases FMNL2 intron 17554300 rs16831028 chr2 153241206 G A 5.16E-04 Bipolar disorder,schizoaffective FMNL2 intron 19567891 rs16831043 chr2 153248346 C T 7.23E-04 Type 2 diabetes FMNL2 intron 17463246 rs2345875 chr2 153253445 A G 7.23E-04 Type 2 diabetes FMNL2 intron 17463246 rs7586834 chr2 153282226 C T 4.40E-06 Lipid levels FMNL2 intron 18193043 rs7600624 chr2 153282375 A G 5.65E-06 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs3811575 chr2 153282883 A G 9.05E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6434028 chr2 153287902 T C 8.54E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6727037 chr2 153292174 G A 6.18E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6727037 chr2 153292174 G A 8.50E-04 Response to cytadine analogues (cytosine arabinoside) FMNL2 intron 24483146 rs7582905 chr2 153296210 T C 2.94E-04 Type 2 diabetes FMNL2 intron 17463246 rs12623070 chr2 153318339 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2068886 chr2 153339823 T C 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs16831263 chr2 153371873 T G 4.28E-05 Bipolar disorder and schizophrenia FMNL2 intron 20889312 rs6434081 chr2 153373267 G A 9.67E-05 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs7591606 chr2 153373875 T C 2.66E-06 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs4664593 chr2 153378652 G A 5.96E-05 Bone mineral density FMNL2 intron 19181680 rs16831280 chr2 153379527 C T 8.81E-04 Multiple complex diseases FMNL2 intron 17554300 rs9288108 chr2 153386833 C A 2.18E-04 Cholesterol FMNL2 intron 17255346 rs9288108 chr2 153386833 C A 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs17327752 chr2 153388487 G A 8.85E-04 Prostate cancer mortality FMNL2 intron 20978177 rs2346182 chr2 153388948 G T 5.79E-05 Bone mineral density FMNL2 intron 19181680 rs12474927 chr2 153391582 A G 4.58E-04 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs2577182 chr2 153393747 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2577181 chr2 153393766 C G 7.40E-06 Urinary metabolites FMNL2 intron 21572414 rs2577180 chr2 153393947 C T 1.14E-04 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs10172230 chr2 153398476 A C 1.34E-04 Cholesterol FMNL2 intron 17255346 rs10172230 chr2 153398476 A C 5.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2083098 chr2 153407808 T C 0.00001827 Sarcoidosis FMNL2 intron 22952805 rs2083099 chr2 153407834 A G 0.00001827 Sarcoidosis FMNL2 intron 22952805 rs10497104 chr2 153408076 A G 7.24E-04 Response to alcohol consumption (flushing response) FMNL2 intron 24277619 rs11675841 chr2 153436570 C T 5.00E-06 IgG glycosylation FMNL2 intron 23382691 rs11675841 chr2 153436570 C T 6.00E-06 IgG glycosylation FMNL2 intron 23382691 rs11675841 chr2 153436570 C T 8.00E-06 IgG glycosylation FMNL2 intron 23382691 rs16823807 chr2 153438660 C G 9.20E-05 Pulmonary function FMNL2 intron 23932459 rs2304556 chr2 153473794 T G 1.10E-04 Stroke (ischemic) FMNL2 intron 22384361 rs2304556 chr2 153473794 T G 1.20E-07 Stroke (ischemic) FMNL2 intron 22384361 rs4664599 chr2 153492765 T C 6.16E-04 Multiple complex diseases FMNL2 intron 17554300 rs2272535 chr2 153493286 G A 4.46E-04 Insulin resistance FMNL2 intron 21901158 rs11883762 chr2 153493435 G T 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs3762503 chr2 153522963 T C 7.58E-04 Multiple complex diseases PRPF40A intron 17554300 rs3762503 chr2 153522963 T C 1.68E-04 Bipolar disorder,schizoaffective PRPF40A intron 19567891 rs9288125 chr2 153523111 A C 9.10E-06 Biomarkers PRPF40A intron 17903293 rs4664604 chr2 153573408 C G 8.40E-06 Biomarkers PRPF40A intron 17903293 rs2450 chr2 153584421 T G 1.28E-04 Blood pressure ARL6IP6 intron 21422096 rs2450 chr2 153584421 T G 1.77E-04 Blood pressure ARL6IP6 intron 21422096 rs2450 chr2 153584421 T G 3.26E-05 Blood pressure ARL6IP6 intron 21422096 rs1986743 chr2 153586899 A G 1.60E-05 Biomarkers ARL6IP6 intron 17903293 rs1986743 chr2 153586899 A G 2.70E-07 Stroke (ischemic) ARL6IP6 intron 22384361 rs1986743 chr2 153586899 A G 3.90E-04 Stroke (ischemic) ARL6IP6 intron 22384361 rs1427404 chr2 153675372 A G 2.80E-05 Urinary metabolites / / 21572414 rs6728402 chr2 153696433 T C 2.48E-26 Narcolepsy / / 19629137 rs11692152 chr2 153721508 G A 2.12E-06 Primary biliary cirrhosis / / 21399635 rs11692152 chr2 153721508 G A 9.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10497117 chr2 153723217 A T 9.93E-04 Bipolar disorder / / 19259986 rs16831902 chr2 153733371 A G 3.21E-06 Primary biliary cirrhosis / / 21399635 rs77197937 chr2 153741268 A G 5.44E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs78683678 chr2 153749368 C T 5.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs1427399 chr2 153750590 C T 5.48E-04 Multiple complex diseases / / 17554300 rs2347039 chr2 153803234 C T 3.29E-04 Type 2 diabetes / / 17463246 rs1357643 chr2 153804455 C T 2.08E-05 Multiple complex diseases / / 17554300 rs1357643 chr2 153804455 C T 4.47E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11688483 chr2 153804944 A G 5.80E-04 Type 2 diabetes / / 17463246 rs4664633 chr2 153811011 C T 1.70E-05 Personality dimensions / / 18957941 rs7601781 chr2 153814233 A C 8.00E-06 Personality dimensions / / 18957941 rs4664635 chr2 153830935 C G 4.10E-05 Personality dimensions / / 18957941 rs1347395 chr2 153872845 A G 1.82E-04 Substance dependence / / 21818250 rs11680004 chr2 153881415 G C 2.80E-05 Urinary metabolites / / 21572414 rs7586868 chr2 153886686 T C 1.89E-05 Sleep duration / / 22105623 rs12618138 chr2 153887010 T C 1.86E-05 Sleep duration / / 22105623 rs12618169 chr2 153887095 T C 1.67E-05 Sleep duration / / 22105623 rs12618194 chr2 153887190 T G 1.85E-05 Sleep duration / / 22105623 rs16832055 chr2 153888496 A G 1.81E-05 Sleep duration / / 22105623 rs1897163 chr2 153921054 G A 1.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13415190 chr2 153931617 G A 8.23E-06 Personality dimensions / / 22628180 rs2347399 chr2 153943546 A G 8.21E-06 Personality dimensions / / 22628180 rs1158394 chr2 153947283 A G 8.73E-06 Personality dimensions / / 22628180 rs7424363 chr2 153959957 A G 3.40E-05 Cognitive test performance / / 20125193 rs13008859 chr2 153960537 T C 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2347343 chr2 153984022 A G 7.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2007857 chr2 153987922 G A 5.38E-04 Coronary heart disease / / 21606135 rs13025412 chr2 153989587 C T 9.53E-04 Coronary heart disease / / 21606135 rs7562599 chr2 154003158 G A 0.0000214 Ovarian cancer / / 22794196 rs11679885 chr2 154024363 T G 9.80E-05 Cognitive test performance / / 20125193 rs11679885 chr2 154024363 T G 5.15E-04 White matter integrity / / 22425255 rs13414678 chr2 154029978 A G 8.24E-05 Glucose levels / / pha003061 rs892747 chr2 154032484 A G 6.27E-05 Glucose levels / / pha003061 rs13402721 chr2 154061956 A T 2.81E-05 Nonalcoholic fatty liver disease / / 21423719 rs967496 chr2 154084952 C T 6.04E-04 Schizophrenia / / 21674006 rs2141799 chr2 154092871 G A 4.40E-05 Bipolar disorder / / 18317468 rs1921765 chr2 154138237 A G 0.000177071 Hypertension (early onset hypertension) / / 22479346 rs1074167 chr2 154188996 G A 3.58E-05 Personality dimensions / / 22628180 rs10176073 chr2 154195066 A G 2.71E-04 Hearing function / / 17255346 rs11682518 chr2 154223946 G T 8.55E-04 Antisocial behavior / / 20345837 rs13397414 chr2 154231414 A G 3.00E-04 Alzheimer's disease (late onset) / / 21460841 rs13398643 chr2 154235295 C T 5.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs10196515 chr2 154240309 C A 2.93E-05 Type 1 diabetes / / 18978792 rs13415573 chr2 154245354 C T 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10497122 chr2 154245633 A G 8.78E-04 Tourette syndrome / / 22889924 rs10196785 chr2 154271299 T C 7.16E-05 Smoking cessation / / 24665060 rs13418009 chr2 154272542 A G 7.90E-04 Alcohol dependence / / 20201924 rs11673716 chr2 154273475 G A 2.06E-05 Osteosarcoma / / 23727862 rs7567863 chr2 154283374 T C 9.00E-05 Schizophrenia / / 19571811 rs11684991 chr2 154308037 C G 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11675619 chr2 154317201 T G 7.77E-04 Acute lung injury / / 22295056 rs3910524 chr2 154317387 T G 7.77E-04 Acute lung injury / / 22295056 rs3910523 chr2 154317529 C T 7.77E-04 Acute lung injury / / 22295056 rs11692573 chr2 154318295 C A 7.77E-04 Acute lung injury / / 22295056 rs3910522 chr2 154330785 C A 2.97E-04 Major depressive disorder / / 22472876 rs12466830 chr2 154348863 T C 5.80E-05 Diabetic retinopathy / / 21441570 rs1658555 chr2 154367348 C T 4.31E-05 Blood pressure / / 17255346 rs12615845 chr2 154371198 C T 6.50E-05 Diabetic retinopathy / / 21441570 rs1221754 chr2 154372766 T C 6.83E-05 Major depressive disorder (broad) / / 20038947 rs1221754 chr2 154372766 T C 4.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9784007 chr2 154374874 G A 2.00E-04 Multiple complex diseases / / 17554300 rs1370674 chr2 154375056 A C 1.51E-05 Major depressive disorder (broad) / / 20038947 rs10189720 chr2 154405080 A C 2.48E-04 Blood pressure / / 17255346 rs13013028 chr2 154419722 T C 6.50E-05 Diabetic retinopathy / / 21441570 rs7589528 chr2 154420012 A G 6.40E-05 Diabetic retinopathy / / 21441570 rs7589528 chr2 154420012 A G 9.46E-04 White matter integrity / / 22425255 rs7589528 chr2 154420012 A G 7.70E-04 Tourette syndrome / / 22889924 rs12612002 chr2 154422529 T C 6.50E-05 Diabetic retinopathy / / 21441570 rs7593582 chr2 154423542 G T 6.30E-05 Diabetic retinopathy / / 21441570 rs1940268 chr2 154436735 G A 7.87E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12693773 chr2 154456308 A G 1.40E-05 Urinary metabolites / / 21572414 rs4335901 chr2 154460874 A G 1.70E-05 Urinary metabolites / / 21572414 rs713119 chr2 154507989 A G 0.000172209 Hypertension (early onset hypertension) / / 22479346 rs1546676 chr2 154509239 G A 0.00011652 Hypertension (early onset hypertension) / / 22479346 rs1519643 chr2 154519448 G A 0.000161315 Hypertension (early onset hypertension) / / 22479346 rs7591719 chr2 154540911 T C 6.40E-06 Urinary metabolites / / 21572414 rs7591719 chr2 154540911 T C 8.91E-06 Odorant perception / / 23910658 rs12995533 chr2 154545453 C T 9.20E-06 Urinary metabolites / / 21572414 rs12995533 chr2 154545453 C T 0.000279122 Hypertension (early onset hypertension) / / 22479346 rs1401743 chr2 154546923 G A 2.52E-05 IgE levels / / 22075330 rs4664152 chr2 154549105 C T 0.0005111 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4664152 chr2 154549105 C T 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10209743 chr2 154552031 A C 0.0006648 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10209743 chr2 154552031 A C 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13013240 chr2 154553429 G A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10931753 chr2 154568757 G C 5.00E-06 Blood trace element (Zn levels) / / 23720494 rs1022386 chr2 154582806 C T 6.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1372393 chr2 154692811 A G 5.70E-06 Urinary metabolites / / 21572414 rs1372393 chr2 154692811 A G 4.26E-04 White matter integrity / / 22425255 rs11893783 chr2 154732137 G C 2.12E-05 Multiple complex diseases GALNT13 intron 17554300 rs17585462 chr2 154743167 T C 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs16834756 chr2 154745009 A G 4.89E-05 Partial epilepsies GALNT13 intron 20522523 rs16834756 chr2 154745009 A G 3.68E-06 Epilepsy GALNT13 intron 22116939 rs7591589 chr2 154745902 C A,G 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs17585476 chr2 154746555 T C 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs9636324 chr2 154750741 A G 4.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs12612456 chr2 154751502 G A 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs13030825 chr2 154816802 T C 1.82E-04 Vaspin levels GALNT13 intron 22907691 rs13030825 chr2 154816802 T C 0.0001815 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GALNT13 intron 22907730 rs10931861 chr2 154824970 C G 1.12E-04 Smoking cessation GALNT13 intron 18519826 rs10931862 chr2 154830754 A G 3.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs6761233 chr2 154837081 A G 1.48E-04 Vaspin levels GALNT13 intron 22907691 rs6761233 chr2 154837081 A G 0.0001484 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GALNT13 intron 22907730 rs12693888 chr2 154842662 G A 1.11E-04 Smoking cessation GALNT13 intron 18519826 rs1013694 chr2 154861348 A G 1.45E-04 Smoking cessation GALNT13 intron 18519826 rs7565078 chr2 154889520 G T 4.47E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GALNT13 intron 24236485 rs7608978 chr2 154889809 A G 1.77E-06 Smoking cessation GALNT13 intron 18519826 rs10490534 chr2 154937930 T G 9.08E-05 Tuberculosis GALNT13 intron 20694014 rs12615781 chr2 154951309 T C 5.64E-04 Type 2 diabetes GALNT13 intron 17846124 rs12693918 chr2 154961754 G T 9.75E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GALNT13 intron 24236485 rs16836124 chr2 155002847 T C 6.00E-06 Obesity-related traits GALNT13 intron 23251661 rs12995536 chr2 155016816 C T 1.85E-04 Multiple complex diseases GALNT13 intron 17554300 rs1468995 chr2 155017425 C A 6.07E-04 Multiple complex diseases GALNT13 intron 17554300 rs958672 chr2 155070567 A T 2.00E-06 Aging traits GALNT13 intron 17903295 rs11892473 chr2 155077962 A G 4.00E-06 Coronary heart disease GALNT13 intron 21971053 rs16836327 chr2 155100016 G C 7.42E-04 Type 2 diabetes GALNT13 intron 17463246 rs7593783 chr2 155120573 C T 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs7593783 chr2 155120573 C T 2.81E-05 Telomere length GALNT13 intron 23001564 rs16836453 chr2 155165241 G A 2.72E-05 Response to methylphenidate treatment GALNT13 intron 21130132 rs16836472 chr2 155170821 G A 4.79E-04 Multiple complex diseases GALNT13 intron 17554300 rs12693973 chr2 155171139 T G 2.00E-06 Body mass index GALNT13 intron 24348519 rs3856384 chr2 155173891 A C 3.92E-04 Type 2 diabetes GALNT13 intron 17463246 rs2348924 chr2 155190478 G T 1.10E-04 Statin-induced myopathy GALNT13 intron 21826682 rs707040 chr2 155226677 T C 6.00E-06 Sudden cardiac arrest GALNT13 intron 21658281 rs12617950 chr2 155234278 C A 7.34E-04 Alzheimer's disease GALNT13 intron 17998437 rs12621256 chr2 155234318 A G 4.00E-06 Liver enzyme levels (alanine transaminase) GALNT13 intron 24124411 rs707050 chr2 155248550 G T 9.67E-05 Non-alcoholic fatty liver disease histology (other) GALNT13 intron 20708005 rs13026208 chr2 155252653 T C 4.26E-04 Oral cancers (chewing tobacco related) GALNT13 intron 22503698 rs13420537 chr2 155298395 T C 9.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GALNT13 intron 21844884 rs17815112 chr2 155314294 G A 0.000752 Salmonella-induced pyroptosis / / 22837397 rs17815112 chr2 155314294 G A 8.74E-04 Tourette syndrome / / 22889924 rs10932055 chr2 155322559 T C 9.64E-06 Coronary heart disease / / pha003031 rs707107 chr2 155322696 T G 3.36E-05 Multiple complex diseases / / 17554300 rs707107 chr2 155322696 T G 1.31E-05 Coronary heart disease / / pha003031 rs12470887 chr2 155324303 T C 3.97E-05 Multiple complex diseases / / 17554300 rs11899646 chr2 155330994 G A 2.69E-05 Multiple complex diseases / / 17554300 rs11899646 chr2 155330994 G A 3.05E-05 Coronary heart disease / / pha003031 rs1429261 chr2 155342678 C T 3.69E-05 Tunica Media / / pha003034 rs249693 chr2 155345145 T C 1.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs1366748 chr2 155362422 A G 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10497139 chr2 155368924 C G 6.19E-04 Multiple complex diseases / / 17554300 rs16837781 chr2 155370777 T C 7.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16837790 chr2 155372611 A G 9.76E-04 Multiple complex diseases / / 17554300 rs12328466 chr2 155375036 G A 9.67E-06 Bipolar disorder and schizophrenia / / 20889312 rs2691795 chr2 155391135 C T 0.0000779 Polycystic ovary syndrome / / 22951595 rs2691795 chr2 155391135 C T 7.79E-05 Intracranial aneurysm / / 22961961 rs1220526 chr2 155460781 G A 2.21E-04 Multiple complex diseases / / 17554300 rs774505 chr2 155471901 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1429252 chr2 155476165 C G 1.49E-05 Aortic root size / / 21223598 rs10497142 chr2 155538402 A T 8.80E-05 Coffee consumption / / 21357676 rs16838055 chr2 155590364 T C 2.88E-04 Smoking quantity KCNJ3 intron 24665060 rs2121089 chr2 155609387 C A 3.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KCNJ3 intron 20031582 rs17640676 chr2 155647819 G T 2.09E-05 Response to acetaminophen (hepatotoxicity) KCNJ3 intron 21177773 rs1037091 chr2 155652357 C T 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) KCNJ3 intron 23648065 rs13005001 chr2 155661146 G T 2.87E-06 Lung adenocarcinoma KCNJ3 intron 19836008 rs2652461 chr2 155687982 T G 0.000656679 Hypertension (early onset hypertension) KCNJ3 intron 22479346 rs2937600 chr2 155702768 A G 4.04E-04 Suicide attempts in bipolar disorder KCNJ3 intron 21041247 rs1900132 chr2 155703068 A G 4.05E-04 Suicide attempts in bipolar disorder KCNJ3 intron 21041247 rs4467223 chr2 155706411 T A 5.00E-05 Prostate cancer KCNJ3 intron 21743057 rs17642086 chr2 155711357 T C 4.00E-05 Prostate cancer KCNJ3 cds-synon 21743057 rs1979004 chr2 155713421 T A 4.00E-05 Prostate cancer / / 21743057 rs765439 chr2 155750882 C T 1.65E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs977869 chr2 155757249 G A 2.37E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs13011654 chr2 155844952 C T 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12986694 chr2 155941970 G A 4.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17644050 chr2 155946659 G C 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13004840 chr2 155996947 C T 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13014709 chr2 156023943 T C 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7576616 chr2 156066815 T C 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs949781 chr2 156069998 T C 9.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10497148 chr2 156083344 A G 5.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10497148 chr2 156083344 A G 7.65E-05 Alcohol consumption / / pha001399 rs1486073 chr2 156163802 G A 9.10E-04 Multiple complex diseases / / 17554300 rs2046502 chr2 156229886 G A 8.62E-04 Multiple complex diseases / / 17554300 rs4544377 chr2 156256701 G A 8.70E-04 Schizophrenia / / 19197363 rs4544377 chr2 156256701 G A 2.00E-06 Systemic lupus erythematosus / / 24871463 rs1601527 chr2 156261310 A C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2350797 chr2 156283312 G A 7.24E-07 Height / / pha003010 rs2350797 chr2 156283312 G A 5.18E-06 Height / / pha003011 rs1524909 chr2 156381959 A G 2.10E-05 Urinary metabolites / / 21572414 rs877055 chr2 156401129 T A 2.30E-05 Urinary metabolites / / 21572414 rs16839220 chr2 156403868 G C 5.23E-04 Multiple complex diseases / / 17554300 rs2691775 chr2 156434090 A G 6.60E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs278879 chr2 156441981 A G 2.57E-04 Multiple complex diseases / / 17554300 rs843229 chr2 156444948 C T 7.80E-04 Multiple complex diseases / / 17554300 rs843220 chr2 156449681 G A 6.90E-04 Multiple complex diseases / / 17554300 rs10932616 chr2 156450256 G A 1.12E-04 Smoking initiation / / 24665060 rs10432531 chr2 156461906 A G 3.32E-04 Smoking initiation / / 24665060 rs2691787 chr2 156466403 G A 7.63E-04 Multiple complex diseases / / 17554300 rs13033671 chr2 156480214 C T 0.000191922 Hypertension (early onset hypertension) / / 22479346 rs843236 chr2 156483829 C A 6.66E-05 Personality dimensions / / 18957941 rs7571452 chr2 156502613 T C 8.69E-04 Multiple complex diseases / / 17554300 rs4407211 chr2 156506516 T C 3.24E-06 Alcohol consumption / / 23953852 rs2677485 chr2 156535156 T C 5.50E-07 Alcohol consumption / / 23953852 rs35349447 chr2 156574981 T C 3.93E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12373770 chr2 156579123 T A 7.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2350817 chr2 156579598 T A 4.29E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4664774 chr2 156579660 T G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2139035 chr2 156584446 T A 6.70E-04 Type 2 diabetes / / 17463246 rs1980211 chr2 156586568 G A 7.68E-05 White matter integrity / / 22425255 rs2056242 chr2 156594333 G A 7.99E-04 White matter integrity / / 22425255 rs4429429 chr2 156598046 T C 4.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs13026792 chr2 156616143 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2882513 chr2 156625848 A G 1.68E-04 White matter integrity / / 22425255 rs1914650 chr2 156636709 G A 5.58E-04 Stroke / / pha002887 rs1316293 chr2 156659919 A G 2.21E-04 White matter integrity / / 22425255 rs13028096 chr2 156663777 A G 8.20E-06 Urinary metabolites / / 21572414 rs13033779 chr2 156686079 C T 2.80E-05 Urinary metabolites / / 21572414 rs11885215 chr2 156711077 T C 8.15E-04 Multiple complex diseases / / 17554300 rs10193997 chr2 156754055 T C 1.59E-05 stroke (ischemic) / / 17434096 rs10198409 chr2 156756235 A G 1.59E-05 stroke (ischemic) / / 17434096 rs1402071 chr2 156759291 C T 8.45E-05 stroke (ischemic) / / 17434096 rs3843321 chr2 156762304 G C 0.00038 Coronary artery calcification / / 23727086 rs2141234 chr2 156819295 C T 2.84E-06 Rheumatoid arthritis / / 19503088 rs17238525 chr2 156819585 T C 9.37E-05 Cognitive performance / / 19734545 rs17238525 chr2 156819585 T C 0.0000362 Amyotrophic lateral sclerosis / / 23587638 rs4664191 chr2 156852749 T C 4.22E-04 Alzheimer's disease / / 24755620 rs13026547 chr2 156856257 G A 4.06E-04 Alzheimer's disease / / 24755620 rs6436115 chr2 156856880 A G 3.74E-04 Alzheimer's disease / / 24755620 rs11680065 chr2 156862613 A G 2.40E-05 Urinary metabolites / / 21572414 rs7570959 chr2 156885750 T C 4.17E-05 Multiple complex diseases / / 17554300 rs1918172 chr2 156888500 C G 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs2882618 chr2 156893877 C A 7.47E-04 Multiple complex diseases / / 17554300 rs7560427 chr2 156900299 G T 3.10E-05 Type 2 diabetes / / 17463246 rs7560427 chr2 156900299 G T 9.53E-04 Multiple complex diseases / / 17554300 rs17244395 chr2 156916525 T C 1.02E-04 Type 2 diabetes / / 17463246 rs7578557 chr2 156917835 T C 2.71E-04 Type 2 diabetes / / 17463246 rs7578557 chr2 156917835 T C 8.85E-05 Serum metabolites / / 19043545 rs17244514 chr2 156918824 A C 8.24E-05 Type 2 diabetes / / 17463246 rs2204584 chr2 156919338 A G 1.76E-04 Type 2 diabetes / / 17463246 rs10497175 chr2 156924881 C A 2.80E-05 Triglycerides / / 19074352 rs10497175 chr2 156924881 C A 2.80E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs16839962 chr2 156925286 A T 9.00E-06 Response to statin therapy / / 20339536 rs10497174 chr2 156926773 C T 3.34E-04 Premature ovarian failure / / 19508998 rs13032427 chr2 156926963 C T 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12471552 chr2 156933377 G A 8.50E-05 Response to statin therapy / / 20339536 rs10177924 chr2 156933553 A G 3.00E-06 Smoking initiation / / 24665060 rs1113061 chr2 156948356 A G 5.20E-06 Urinary metabolites / / 21572414 rs13426050 chr2 156968533 G A 1.00E-05 Urinary metabolites / / 21572414 rs10196668 chr2 156970611 G T 2.09E-05 Body Mass Index / / pha003014 rs10196668 chr2 156970611 G T 2.19E-05 Insulin-related traits / / pha003063 rs12694551 chr2 156990306 C A 8.51E-05 Prion diseases / / 22210626 rs10167400 chr2 157003970 C G 7.50E-06 Urinary metabolites / / 21572414 rs4664800 chr2 157011778 G A 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11678568 chr2 157024097 G A 4.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10932915 chr2 157049799 G A 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2351535 chr2 157094848 G A 6.30E-06 Urinary metabolites / / 21572414 rs17188434 chr2 157096776 T C 1.00E-09 Menarche (age at onset) / / 21102462 rs4369815 chr2 157126964 T G 9.65E-05 Coronary heart disease / / pha003032 rs16840221 chr2 157168951 G C 5.40E-06 Urinary metabolites / / 21572414 rs707130 chr2 157197583 T C 4.13E-04 Type 2 diabetes / / 17463246 rs707130 chr2 157197583 T C 3.08E-06 Lipid traits / / 24023261 rs9288592 chr2 157383945 C G 8.88E-04 Multiple complex diseases GPD2 intron 17554300 rs2288760 chr2 157427322 A T 3.87E-04 Multiple complex diseases GPD2 intron 17554300 rs1368246 chr2 157449118 T G 3.78E-04 Smoking quantity / / 24665060 rs6706895 chr2 157452216 G C 7.90E-05 Chronic obstructive pulmonary disease / / 19300482 rs6706895 chr2 157452216 G C 7.90E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6729636 chr2 157475254 C A 1.80E-05 Urinary metabolites / / 21572414 rs16840621 chr2 157505920 A G 3.61E-04 Multiple complex diseases / / 17554300 rs7602743 chr2 157529654 G A 9.86E-05 Vascular dementia / / 22116812 rs7601713 chr2 157552860 A C 2.00E-06 QT interval / / 20031603 rs1543932 chr2 157565192 G A 7.12E-05 Gallstones / / 17632509 rs6436652 chr2 157649957 T C 7.10E-05 Bone mineral density (BMD),in women / / 20164292 rs9288624 chr2 157650780 C T 7.90E-05 Bone mineral density (BMD),in women / / 20164292 rs11683474 chr2 157672828 A T 1.51E-06 Alcohol and nictotine co-dependence / / 20158304 rs11683474 chr2 157672828 A T 2.00E-06 Alcohol and nictotine co-dependence / / 20158304 rs723802 chr2 157676466 A C 0.0002 Coronary artery calcification / / 23727086 rs10175224 chr2 157686431 G A 4.41E-04 Multiple complex diseases / / 17554300 rs295796 chr2 157753371 A T 8.53E-04 Blood pressure / / 21422096 rs295796 chr2 157753371 A T 9.65E-06 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 1.24E-06 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 1.68E-04 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 3.76E-04 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 4.77E-06 Blood pressure / / 21422096 rs10497160 chr2 157785404 T C 8.34E-04 Multiple complex diseases / / 17554300 rs1033225 chr2 157806151 T C 3.16E-06 Blood pressure / / 21422096 rs1033225 chr2 157806151 T C 3.39E-04 Blood pressure / / 21422096 rs1033224 chr2 157806453 A T 6.82E-04 Blood pressure / / 21422096 rs1033224 chr2 157806453 A T 8.29E-06 Blood pressure / / 21422096 rs1600754 chr2 157815667 G A 6.40E-05 Personality dimensions / / 18957941 rs7562882 chr2 157849626 C T 3.36E-04 Stroke / / pha002887 rs6747313 chr2 157873775 C A 1.95E-04 Birth weight / / 17255346 rs16841208 chr2 157889223 A G 8.44E-06 Multiple complex diseases / / 17554300 rs1481385 chr2 157906208 A G 8.30E-05 Diabetic nephropathy / / pha002866 rs1225828 chr2 157930736 C T 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs13403315 chr2 157935103 C T 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13401572 chr2 157947400 G A 6.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2623033 chr2 158086901 G A 9.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs834135 chr2 158094105 A G 2.60E-05 Urinary metabolites / / 21572414 rs16841426 chr2 158117300 C T 6.16E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs16841428 chr2 158117405 T C 6.16E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs16841450 chr2 158123570 G A 8.12E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs1156560 chr2 158137003 C T 9.83E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs2289940 chr2 158141186 C G 9.90E-07 Urinary metabolites GALNT5 intron 21572414 rs13422538 chr2 158141687 T A 3.00E-06 Urinary metabolites GALNT5 intron 21572414 rs2121347 chr2 158141753 T C 6.30E-06 Urinary metabolites GALNT5 intron 21572414 rs2353292 chr2 158158514 C T 2.99E-04 Oral cancers (chewing tobacco related) GALNT5 intron 22503698 rs2166488 chr2 158159836 A G 2.10E-04 Blood pressure GALNT5 intron 21422096 rs2166488 chr2 158159836 A G 2.80E-04 Blood pressure GALNT5 intron 21422096 rs12623628 chr2 158211662 G A 5.30E-04 Multiple complex diseases / / 17554300 rs16841822 chr2 158324190 A G 5.54E-07 Odorant perception / / 23910658 rs6707470 chr2 158346570 A G 4.50E-05 Urate levels / / 23263486 rs6714869 chr2 158377885 A T 3.85E-05 Multiple complex diseases / / 17554300 rs7568889 chr2 158393020 C T 1.60E-05 Urinary metabolites ACVR1C intron 21572414 rs12328809 chr2 158409104 C T 5.71E-04 Response to cytadine analogues (cytosine arabinoside) ACVR1C intron 24483146 rs747282 chr2 158549742 C T 0.00039789 Hypertension (early onset hypertension) / / 22479346 rs3017019 chr2 158570520 A C 0.000499229 Hypertension (early onset hypertension) / / 22479346 rs6756623 chr2 158574077 T C 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6756623 chr2 158574077 T C 7.93E-05 Hypertension (early onset hypertension) / / 22479346 rs17182166 chr2 158596197 G T 5.23E-05 Response to hepatitis C treatment ACVR1 intron 19684573 rs16842025 chr2 158624661 T A 2.61E-04 Multiple complex diseases ACVR1 intron 17554300 rs10497192 chr2 158671700 C T 1.79E-05 Height ACVR1 intron pha003010 rs16842130 chr2 158687087 C T 2.22E-04 Multiple complex diseases ACVR1 intron 17554300 rs10933443 chr2 158694121 C T 1.47E-05 Height ACVR1 intron pha003010 rs13398650 chr2 158694380 G A 8.49E-04 Tourette syndrome ACVR1 intron 22889924 rs9288700 chr2 158735265 G A 1.69E-05 Lung function (forced vital capacity) / / pha003104 rs16842228 chr2 158736061 G T 6.08E-04 Multiple complex diseases / / 17554300 rs16842228 chr2 158736061 G T 6.67E-05 Lung function (forced vital capacity) / / pha003104 rs16842230 chr2 158737086 A G 5.72E-05 Lung function (forced vital capacity) / / pha003104 rs4363980 chr2 158750040 T G 5.74E-04 Longevity / / 22279548 rs16842252 chr2 158753577 A G 9.16E-05 Lung function (forced vital capacity) / / pha003104 rs1441134 chr2 158757201 G A 1.21E-05 Cognitive performance / / 19734545 rs12472133 chr2 158765030 T C 9.37E-05 Cognitive performance / / 19734545 rs10183640 chr2 158780204 G A 5.00E-07 Sudden cardiac arrest / / 21658281 rs6720264 chr2 158791560 A G 6.69E-05 Chronic obstructive pulmonary disease / / 19300482 rs12694942 chr2 158810435 G T 8.89E-04 Type 2 diabetes / / 17463246 rs17420138 chr2 158876913 C T 2.30E-09 Autism,gender differences UPP2 intron 21151189 rs6759948 chr2 158889593 A G 2.89E-04 Multiple complex diseases UPP2 intron 17554300 rs6731503 chr2 158891190 C T 1.83E-05 Cognitive impairment induced by topiramate UPP2 intron 22091778 rs7605276 chr2 158893323 T G 7.11E-06 Leprosy UPP2 intron 22019778 rs2098044 chr2 158894887 C G 4.51E-05 Serum metabolites UPP2 intron 19043545 rs2355164 chr2 158899542 C T 1.17E-04 HIV-1 viral setpoint UPP2 intron 17641165 rs10206564 chr2 158925959 G T 1.90E-05 Urinary metabolites UPP2 intron 21572414 rs6713742 chr2 158972155 T C 2.29E-05 Alzheimer's disease UPP2 intron 17998437 rs2074955 chr2 158977794 A G 1.00E-07 P-tau181p levels UPP2 intron 20932310 rs7595811 chr2 159020696 T C 7.80E-05 Monocyte counts / / pha003089 rs17193070 chr2 159031448 A G 3.40E-05 Multiple complex diseases CCDC148 intron 17554300 rs1357182 chr2 159032245 T C 6.06E-04 Multiple complex diseases CCDC148 intron 17554300 rs7591479 chr2 159039836 A T 5.30E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs11692534 chr2 159043307 C G 1.92E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs16842723 chr2 159044634 C G 8.71E-04 Multiple complex diseases CCDC148 intron 17554300 rs7592105 chr2 159047406 G A 5.89E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs4233674 chr2 159058679 G A 5.47E-04 Rheumatoid arthritis CCDC148 intron 21452313 rs12104564 chr2 159066643 T C 0.00002987 Sarcoidosis CCDC148 intron 22952805 rs6723111 chr2 159070404 A G 9.20E-04 Rheumatoid arthritis CCDC148 intron 21452313 rs4664932 chr2 159071260 C T 6.02E-04 Response to taxane treatment (placlitaxel) CCDC148 intron 23006423 rs4664935 chr2 159072395 A G 5.80E-04 Multiple complex diseases CCDC148 intron 17554300 rs57622652 chr2 159074856 T A 0.00002125 Sarcoidosis CCDC148 intron 22952805 rs1521875 chr2 159075504 G C 0.0001218 Sarcoidosis CCDC148 intron 22952805 rs4664936 chr2 159075984 T C 0.0001048 Sarcoidosis CCDC148 intron 22952805 rs958671 chr2 159077019 A C 0.0001016 Sarcoidosis CCDC148 intron 22952805 rs4126019 chr2 159079471 G A 0.0000387 Sarcoidosis CCDC148 intron 22952805 rs113153326 chr2 159080566 C G 0.0001805 Sarcoidosis CCDC148 intron 22952805 rs62175430 chr2 159080781 G A 0.00001673 Sarcoidosis CCDC148 intron 22952805 rs149273273 chr2 159081022 T C 0.00005484 Sarcoidosis CCDC148 intron 22952805 rs139670759 chr2 159081040 G A 0.0001183 Sarcoidosis CCDC148 intron 22952805 rs76492695 chr2 159082873 T A 0.0000462 Sarcoidosis CCDC148 intron 22952805 rs147670480 chr2 159082954 C G 0.00002175 Sarcoidosis CCDC148 intron 22952805 rs111613161 chr2 159082976 C A 0.00007599 Sarcoidosis CCDC148 intron 22952805 rs2204087 chr2 159085798 T C 0.0000663 Sarcoidosis CCDC148 intron 22952805 rs4315473 chr2 159085899 T C 0.0000309 Sarcoidosis CCDC148 intron 22952805 rs2204088 chr2 159086035 G A 0.00007109 Sarcoidosis CCDC148 intron 22952805 rs6730499 chr2 159086525 C T 0.00001314 Sarcoidosis CCDC148 intron 22952805 rs35432923 chr2 159091148 A G 0.000004362 Sarcoidosis CCDC148 intron 22952805 rs2356081 chr2 159118048 T A 1.07E-04 Tuberculosis CCDC148 intron 22306650 rs2602189 chr2 159141224 A C 2.20E-04 Alcohol dependence CCDC148 intron 20201924 rs2602189 chr2 159141224 A C 7.40E-04 Alcohol dependence CCDC148 intron 20201924 rs9288710 chr2 159151010 T C 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC148 intron 20877124 rs13391688 chr2 159244723 A T 2.93E-05 Multiple complex diseases CCDC148 intron 17554300 rs10190089 chr2 159249741 A G 4.35E-04 Multiple complex diseases CCDC148 intron 17554300 rs10190089 chr2 159249741 A G 7.10E-05 Personality dimensions CCDC148 intron 18957941 rs2111880 chr2 159339424 G A 2.46E-04 Alzheimer's disease (late onset) PKP4 intron 21379329 rs16842973 chr2 159370243 G A 2.63E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs6730686 chr2 159374984 G A 9.11E-05 Serum metabolites PKP4 intron 19043545 rs16843004 chr2 159387110 A G 2.79E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs3771603 chr2 159411420 G A 3.90E-04 Depression (quantitative trait) PKP4 intron 20800221 rs3771604 chr2 159414979 A G 6.16E-05 Serum metabolites PKP4 intron 19043545 rs2214903 chr2 159429406 A G 6.26E-04 Smoking initiation PKP4 intron 24665060 rs3755413 chr2 159436702 A G 1.40E-05 Serum metabolites PKP4 intron 19043545 rs2051946 chr2 159454789 T G 4.63E-05 Serum metabolites PKP4 intron 19043545 rs17421757 chr2 159458601 G A 8.40E-04 Alcohol dependence PKP4 intron 20201924 rs2007493 chr2 159464191 C G 5.11E-04 Smoking initiation PKP4 intron 24665060 rs3771643 chr2 159466149 T C 2.31E-05 Serum metabolites PKP4 intron 19043545 rs3771645 chr2 159467028 C T 7.34E-05 Serum metabolites PKP4 intron 19043545 rs7607370 chr2 159469727 C T 1.03E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs3771651 chr2 159483540 T G 1.73E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs11893227 chr2 159483770 T G 4.21E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs2528635 chr2 159496390 G A 6.65E-06 Serum metabolites PKP4 intron 19043545 rs10180408 chr2 159496587 C A 9.18E-04 Insulin resistance PKP4 intron 21901158 rs2711070 chr2 159502533 G C 1.43E-05 Serum metabolites PKP4 intron 19043545 rs2528582 chr2 159511163 A G 3.10E-04 Smoking initiation PKP4 intron 24665060 rs2711072 chr2 159523803 C G 6.71E-06 Serum metabolites PKP4 intron 19043545 rs2158831 chr2 159525930 C T 2.34E-05 Serum metabolites PKP4 intron 19043545 rs2528593 chr2 159531909 A G 1.15E-04 Self-reported allergy PKP4 intron 23817569 rs16843194 chr2 159532354 A G 5.67E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs2711040 chr2 159534889 C T 1.97E-04 Self-reported allergy PKP4 intron 23817569 rs2528609 chr2 159558658 A C 4.41E-05 Self-reported allergy / / 23817569 rs757928 chr2 159577391 T C 3.95E-05 Taste perception / / 22132133 rs2528630 chr2 159586588 G C 3.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13007462 chr2 159591062 T C 6.77E-06 Obesity-related traits / / 23251661 rs4664262 chr2 159593394 C T 2.68E-06 Obesity-related traits / / 23251661 rs6705792 chr2 159602186 T C 9.23E-06 Obesity-related traits / / 23251661 rs6437198 chr2 159613196 T C 4.04E-06 Obesity-related traits / / 23251661 rs1515926 chr2 159622208 T C 2.39E-06 Obesity-related traits / / 23251661 rs2356507 chr2 159639345 C T 5.81E-06 Obesity-related traits / / 23251661 rs2356508 chr2 159644006 A C 1.00E-05 Cognitive function / / 24684796 rs17810584 chr2 159664703 C T 1.50E-05 Urinary metabolites DAPL1 intron 21572414 rs6716178 chr2 159667328 G A 7.81E-06 Obesity-related traits DAPL1 intron 23251661 rs4665011 chr2 159668758 A C 4.19E-06 Obesity-related traits DAPL1 intron 23251661 rs16843372 chr2 159670449 T C 1.00E-06 Obesity-related traits DAPL1 intron 23251661 rs6757197 chr2 159723506 G T 7.36E-07 Parkinson's disease / / 17052657 rs13035632 chr2 159750298 T C 6.11E-06 Alcohol consumption / / 23953852 rs13035632 chr2 159750298 T C 7.37E-04 Smoking initiation / / 24665060 rs17727768 chr2 159762132 A G 4.51E-04 Smoking initiation / / 24665060 rs939998 chr2 159770970 C T 1.03E-05 Alcohol consumption / / 23953852 rs6738420 chr2 159785940 T C 5.79E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6725288 chr2 159787453 C T 2.70E-04 Multiple complex diseases / / 17554300 rs1719079 chr2 159841372 G A 8.14E-04 Amyotrophic Lateral Sclerosis TANC1 intron 17362836 rs1719079 chr2 159841372 G A 7.37E-05 Coronary heart disease TANC1 intron pha003030 rs10497203 chr2 159851423 A C 8.84E-11 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs16843534 chr2 159851549 G A 7.43E-04 Alzheimer's disease TANC1 intron 22005930 rs16843536 chr2 159857642 A G 7.82E-04 Alzheimer's disease TANC1 UTR-5 22005930 rs6735689 chr2 159870038 C T 7.25E-04 Alzheimer's disease TANC1 intron 22005930 rs264607 chr2 159888711 G A 7.53E-05 Body mass (lean) TANC1 intron 19268274 rs7582141 chr2 159899489 G T 5.00E-11 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs6432512 chr2 159899913 C T 1.97E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs16843641 chr2 159918378 T C 1.28E-09 Gallstones TANC1 intron 17632509 rs264588 chr2 159936391 C A 3.08E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs264631 chr2 159950865 C G 6.40E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs13414916 chr2 159954420 C T 3.78E-04 Type 2 diabetes TANC1 intron 17463246 rs10198413 chr2 159955575 C T 3.86E-04 Type 2 diabetes TANC1 intron 17463246 rs171935 chr2 159956520 C T 3.26E-05 Waist Circumference TANC1 intron pha003023 rs264591 chr2 159975516 T C 9.48E-04 Lymphocyte counts TANC1 intron 22286170 rs4665026 chr2 159984702 G A 2.00E-05 Urinary metabolites TANC1 intron 21572414 rs6754934 chr2 159990664 G A 2.19E-04 Age-related macular degeneration TANC1 intron 22125219 rs1421385 chr2 159994048 G A 1.52E-05 Response to hepatitis C treatment TANC1 intron 19684573 rs3796105 chr2 160025639 A C 7.14E-04 Response to taxane treatment (placlitaxel) TANC1 intron 23006423 rs17494000 chr2 160041993 C T 1.30E-05 Urinary metabolites TANC1 intron 21572414 rs12617786 chr2 160047009 G A 8.27E-04 Suicide attempts in bipolar disorder TANC1 intron 21041247 rs6432515 chr2 160054932 G A 3.63E-04 Myopia (pathological) TANC1 intron 21095009 rs6754390 chr2 160061217 G C 1.00E-06 Urinary metabolites TANC1 intron 21572414 rs4233678 chr2 160061429 A G 9.22E-04 Type 2 diabetes TANC1 intron 17463246 rs13022357 chr2 160069756 A G 1.00E-06 Sudden cardiac arrest TANC1 intron 21658281 rs3815475 chr2 160114315 G A 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDSUB1 cds-synon 20877124 rs10490001 chr2 160139048 C T 7.28E-04 Tourette syndrome WDSUB1 intron 22889924 rs174244 chr2 160164187 A C 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs174240 chr2 160164716 C T 8.36E-05 Alzheimer's disease (late onset) / / 21379329 rs174230 chr2 160175310 T C 2.98E-07 Sudden cardiac arrest / / 21738491 rs4665058 chr2 160190209 A C 2.00E-10 Sudden cardiac arrest BAZ2B intron 21738491 rs11884022 chr2 160201955 T C 3.74E-04 Alzheimer's disease (late onset) BAZ2B intron 21379329 rs3771684 chr2 160202268 C T 0.00000871 Antisocial behavior BAZ2B intron 23077488 rs1011770 chr2 160238718 A G 1.25E-07 Gallstones BAZ2B intron 17632509 rs11690975 chr2 160247739 T C 2.75E-04 Multiple complex diseases BAZ2B intron 17554300 rs7585587 chr2 160251665 C T 4.35E-04 Multiple complex diseases BAZ2B intron 17554300 rs3755436 chr2 160282783 A G 0.000644 Height (Pygmy height) BAZ2B intron 22570615 rs3755437 chr2 160282976 C T 0.000644 Height (Pygmy height) BAZ2B intron 22570615 rs10207442 chr2 160285473 T C 2.66E-04 Fibrinogen BAZ2B intron 17255346 rs10187471 chr2 160289911 A G 7.40E-05 HIV-1 control BAZ2B intron 20041166 rs13417010 chr2 160295732 C T 7.40E-05 HIV-1 control BAZ2B intron 20041166 rs10202670 chr2 160310246 A G 7.80E-05 HIV-1 control BAZ2B missense 20041166 rs918970 chr2 160340922 A C 3.10E-27 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 3.90E-15 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 4.10E-33 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 5.30E-09 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs4665075 chr2 160343075 A C 8.59E-04 Multiple complex diseases BAZ2B intron 17554300 rs4665077 chr2 160402769 G A 3.24E-04 Smoking initiation BAZ2B intron 24665060 rs10489997 chr2 160405498 C T 1.94E-04 Response to gemcitabine in pancreatic cancer BAZ2B intron 22142827 rs1549386 chr2 160414526 C A 2.18E-04 Smoking initiation BAZ2B intron 24665060 rs2113861 chr2 160441744 T C 9.60E-04 Type 2 diabetes BAZ2B intron 17463246 rs12991516 chr2 160442065 G A 4.41E-04 Type 2 diabetes BAZ2B intron 17463246 rs357027 chr2 160491675 T C 1.35E-04 Multiple complex diseases / / 17554300 rs12466258 chr2 160514481 G A 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17814581 chr2 160616232 A G 6.02E-04 Smoking initiation MARCH7 intron 24665060 rs17815029 chr2 160626898 T C 5.55E-04 Smoking initiation CD302 UTR-3 24665060 rs3771720 chr2 160630922 C T 5.16E-05 Multiple complex diseases CD302 intron 17554300 rs1896270 chr2 160658739 T G 4.85E-05 Cognitive impairment induced by topiramate LY75-CD302 intron 22091778 rs13307 chr2 160659996 G A 6.89E-04 Smoking initiation LY75 UTR-3 24665060 rs12463589 chr2 160663435 T C 2.64E-04 Smoking initiation LY75 intron 24665060 rs2114630 chr2 160664459 A G 6.63E-05 Cognitive impairment induced by topiramate LY75 intron 22091778 rs2556088 chr2 160664907 T G 9.51E-04 Response to alcohol consumption (flushing response) LY75 intron 24277619 rs2556086 chr2 160708446 C A 2.98E-04 Multiple complex diseases LY75 intron 17554300 rs2357691 chr2 160725139 C T 8.10E-04 Multiple complex diseases LY75 intron 17554300 rs12692570 chr2 160726599 G A 6.08E-05 Bipolar disorder LY75 intron 22925353 rs2292387 chr2 160734722 C T 3.23E-04 Multiple complex diseases LY75 intron 17554300 rs2292388 chr2 160735008 C T 2.17E-04 Multiple complex diseases LY75 intron 17554300 rs1511224 chr2 160750861 T C 2.70E-04 Multiple complex diseases LY75 intron 17554300 rs1511224 chr2 160750861 T C 4.54E-05 Bipolar disorder LY75 intron 22925353 rs16844494 chr2 160770425 G A 1.24E-04 Multiple complex diseases / / 17554300 rs6715456 chr2 160773499 C T 1.66E-04 Multiple complex diseases / / 17554300 rs7566824 chr2 160790774 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs769369 chr2 160795256 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3828322 chr2 160807597 A T 1.25E-04 Multiple complex diseases PLA2R1 intron 17554300 rs6432570 chr2 160808314 T C 8.74E-04 Multiple complex diseases PLA2R1 intron 17554300 rs12692578 chr2 160829503 T C 4.45E-05 Cognitive impairment induced by topiramate PLA2R1 intron 22091778 rs3828324 chr2 160834991 T C 7.46E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3828324 chr2 160834991 T C 2.24E-04 Smoking initiation PLA2R1 intron 24665060 rs979129 chr2 160840151 T A,C,G 2.53E-04 Smoking initiation PLA2R1 intron 24665060 rs12692579 chr2 160841139 G A 4.02E-04 Multiple complex diseases PLA2R1 intron 17554300 rs1546512 chr2 160841307 C T 1.74E-05 Intelligence PLA2R1 intron 21826061 rs6757188 chr2 160843623 T C 3.01E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3792167 chr2 160845582 G C 7.62E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3792168 chr2 160846472 T C 4.93E-04 Smoking initiation PLA2R1 intron 24665060 rs1397712 chr2 160866165 C A 5.48E-05 Type 2 diabetes PLA2R1 intron 17463246 rs2667011 chr2 160867059 G A 3.34E-14 Bilirubin levels,in serum PLA2R1 intron 20639394 rs2667012 chr2 160867553 C A 2.34E-04 Multiple complex diseases PLA2R1 intron 17554300 rs2666997 chr2 160876151 G A 8.33E-04 Multiple complex diseases PLA2R1 intron 17554300 rs17830558 chr2 160878364 T G 4.80E-04 Breast cancer (survival) PLA2R1 intron 22232737 rs3792185 chr2 160878783 T G 5.96E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3749117 chr2 160885442 T C 1.00E-04 Information processing speed PLA2R1 missense 21130836 rs3749117 chr2 160885442 T C 1.70E-05 Waist-Hip Ratio PLA2R1 missense pha003029 rs3792189 chr2 160885872 C A 7.17E-05 Serum metabolites PLA2R1 intron 19043545 rs3792189 chr2 160885872 C A 7.15E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs3792192 chr2 160886875 G A 9.47E-05 Information processing speed PLA2R1 intron 21130836 rs3792192 chr2 160886875 G A 3.59E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs17241282 chr2 160891009 T C 8.97E-05 Information processing speed PLA2R1 intron 21130836 rs6722275 chr2 160893260 C T 1.85E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs10929965 chr2 160906931 A G 9.47E-04 Type 2 diabetes PLA2R1 intron 17463246 rs2715928 chr2 160913599 A G 8.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PLA2R1 intron 20031582 rs2667033 chr2 160913693 A G 1.48E-04 Stroke PLA2R1 intron pha002887 rs16844715 chr2 160915106 C T 4.26E-04 Type 2 diabetes PLA2R1 intron 17463246 rs4664308 chr2 160917497 A G 9.00E-29 Nephropathy (idiopathic membranous) PLA2R1 intron 21323541 rs2667026 chr2 160921555 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13403826 chr2 160963372 T C 1.69E-05 Cognitive impairment induced by topiramate ITGB6 intron 22091778 rs10497212 chr2 160964700 T G 7.70E-04 Crohn's disease ITGB6 intron 17684544 rs6432593 chr2 160965146 G A 3.40E-04 Stroke ITGB6 intron pha002887 rs6432594 chr2 160965335 A G 2.94E-05 Cognitive impairment induced by topiramate ITGB6 intron 22091778 rs6729540 chr2 160965347 G C 9.85E-04 Type 2 diabetes ITGB6 intron 17463246 rs7583743 chr2 160983889 A G 7.65E-04 Type 2 diabetes ITGB6 intron 17463246 rs7569555 chr2 160987608 G T 8.31E-04 Type 2 diabetes ITGB6 intron 17463246 rs6432603 chr2 161000343 T C 6.92E-04 Type 2 diabetes ITGB6 intron 17463246 rs983916 chr2 161015066 T G 1.00E-04 Information processing speed ITGB6 intron 21130836 rs2925763 chr2 161016776 A C 3.09E-04 Type 2 diabetes ITGB6 intron 17463246 rs2305818 chr2 161029218 G A 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ITGB6 cds-synon 20031582 rs2925758 chr2 161071031 G A 7.66E-04 Type 2 diabetes / / 17463246 rs10205184 chr2 161074672 T C 4.53E-05 Cognitive test performance / / 20125193 rs17242280 chr2 161080519 T C 9.28E-04 Type 2 diabetes / / 17463246 rs10181181 chr2 161087411 T C 1.57E-06 Type 2 diabetes / / 20418489 rs2925757 chr2 161101169 G A 2.10E-04 Crohn's disease / / 17684544 rs2925757 chr2 161101169 G A 7.94E-08 Type 2 diabetes / / 20418489 rs10170600 chr2 161118687 T C 8.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs3772070 chr2 161133471 T C 3.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs7572970 chr2 161136656 A G 3.26E-05 Multiple complex diseases RBMS1 intron 17554300 rs7572970 chr2 161136656 A G 2.61E-07 Type 2 diabetes RBMS1 intron 20418489 rs1020731 chr2 161144055 G A 9.42E-05 Multiple complex diseases RBMS1 intron 17554300 rs1020731 chr2 161144055 G A 9.44E-08 Type 2 diabetes RBMS1 intron 20418489 rs1020732 chr2 161144239 G A 2.18E-04 Multiple complex diseases RBMS1 intron 17554300 rs12692590 chr2 161153197 C G 3.19E-04 Multiple complex diseases RBMS1 intron 17554300 rs12692592 chr2 161163381 G T 1.03E-06 Multiple complex diseases RBMS1 intron 17554300 rs12692592 chr2 161163381 G T 1.01E-07 Type 2 diabetes RBMS1 intron 20418489 rs4077463 chr2 161166234 A G 7.17E-07 Multiple complex diseases RBMS1 intron 17554300 rs4077463 chr2 161166234 A G 6.41E-08 Type 2 diabetes RBMS1 intron 20418489 rs4077463 chr2 161166234 A G 6.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs7593730 chr2 161171454 T C 2.02E-07 Multiple complex diseases RBMS1 intron 17554300 rs7593730 chr2 161171454 T C 4.00E-08 Type 2 diabetes RBMS1 intron 20418489 rs7593730 chr2 161171454 T C 4.00E-08 Type 2 diabetes RBMS1 intron 21647700 rs7593730 chr2 161171454 T C 0.0000015 Type 2 diabetes RBMS1 intron 22885922 rs7593730 chr2 161171454 T C 4.70E-04 Type 2 diabetes RBMS1 intron 24509480 rs4589705 chr2 161176136 T A 9.85E-04 Type 2 diabetes RBMS1 intron 17463246 rs4589705 chr2 161176136 T A 3.66E-07 Multiple complex diseases RBMS1 intron 17554300 rs4589705 chr2 161176136 T A 7.24E-08 Type 2 diabetes RBMS1 intron 20418489 rs4664013 chr2 161184164 G C 2.47E-04 Multiple complex diseases RBMS1 intron 17554300 rs4410242 chr2 161192070 A G 6.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs10165319 chr2 161192805 T C 1.62E-04 Multiple complex diseases RBMS1 intron 17554300 rs7425274 chr2 161203395 T C 8.18E-04 Depression (quantitative trait) RBMS1 intron 20800221 rs7425274 chr2 161203395 T C 5.23E-04 Taste perception RBMS1 intron 22132133 rs9287795 chr2 161209788 C G 5.56E-07 Multiple complex diseases RBMS1 intron 17554300 rs6718526 chr2 161214175 T C 2.40E-06 Type 2 diabetes RBMS1 intron 17463249 rs6718526 chr2 161214175 T C 4.43E-07 Multiple complex diseases RBMS1 intron 17554300 rs6718526 chr2 161214175 T C 2.10E-04 Coronary heart disease RBMS1 intron 21966275 rs6718526 chr2 161214175 T C 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs6755940 chr2 161220126 A C 4.22E-04 Tourette syndrome RBMS1 intron 22889924 rs11693602 chr2 161224658 C T 4.00E-07 Multiple complex diseases RBMS1 intron 17554300 rs10929982 chr2 161236277 C T 9.84E-07 Multiple complex diseases RBMS1 intron 17554300 rs12998587 chr2 161242295 T C 7.21E-04 Multiple complex diseases RBMS1 intron 17554300 rs4664323 chr2 161259685 C T 2.97E-04 Cholesterol RBMS1 intron 17255346 rs7423892 chr2 161329644 C T 3.91E-04 Parkinson's disease RBMS1 intron 17052657 rs10178094 chr2 161336406 C A 5.99E-04 Parkinson's disease RBMS1 intron 17052657 rs7569522 chr2 161346447 A G 3.01E-05 Multiple complex diseases RBMS1 intron 17554300 rs7569522 chr2 161346447 A G 0.000041 Type 2 diabetes RBMS1 intron 22885922 rs7569522 chr2 161346447 A G 0.000095 Type 2 diabetes (females) RBMS1 intron 22885922 rs10192369 chr2 161380888 G A 9.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs13382644 chr2 161386729 G A 2.10E-04 Alcohol dependence / / 20201924 rs6432628 chr2 161395188 C T 9.10E-05 Alcohol dependence / / 20201924 rs6432628 chr2 161395188 C T 9.13E-05 Alcoholism / / pha002892 rs7598938 chr2 161406793 C T 5.00E-04 Alcohol dependence / / 20201924 rs13034284 chr2 161409559 C T 1.80E-05 Alcohol dependence / / 20201924 rs13034284 chr2 161409559 C T 1.85E-05 Alcoholism / / pha002892 rs4622746 chr2 161409668 C G 4.37E-04 Multiple complex diseases / / 17554300 rs13410476 chr2 161410542 G A 1.20E-04 Alcohol dependence / / 20201924 rs9967749 chr2 161420179 A G 8.10E-05 Alcohol dependence / / 20201924 rs9967749 chr2 161420179 A G 8.13E-05 Alcoholism / / pha002892 rs11681327 chr2 161424684 A G 4.80E-05 Alcohol dependence / / 20201924 rs11681327 chr2 161424684 A G 4.77E-05 Alcoholism / / pha002892 rs4420713 chr2 161425657 G C 2.39E-04 Insulin resistance / / 21901158 rs7603576 chr2 161431604 A G 4.70E-05 Alcohol dependence / / 20201924 rs7603576 chr2 161431604 A G 4.65E-05 Alcoholism / / pha002892 rs13010247 chr2 161432066 T C 2.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4533480 chr2 161437980 A G 8.75E-04 Cocaine dependence / / 23958962 rs13408402 chr2 161509693 G A 2.35E-04 Tourette syndrome / / 22889924 rs4664354 chr2 161544316 G T 9.84E-05 Post-operative nausea and vomiting / / 21694509 rs4664354 chr2 161544316 G T 1.59E-05 Coronary heart disease / / pha003056 rs6718138 chr2 161555610 T C 9.39E-04 Stroke / / pha002886 rs7608578 chr2 161573231 A C 4.03E-06 Post-operative nausea and vomiting / / 21694509 rs10497216 chr2 161588479 A T 1.98E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1480577 chr2 161598210 C A 3.36E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1480577 chr2 161598210 C A 3.25E-05 Coronary heart disease / / pha003056 rs4664366 chr2 161600547 A G 1.62E-05 Coronary heart disease / / pha003056 rs17220405 chr2 161608769 C T 4.90E-04 Alcohol dependence / / 20201924 rs558692 chr2 161667127 C A 8.90E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs270981 chr2 161684107 A G 7.21E-04 Multiple complex diseases / / 17554300 rs555332203 chr2 161686114 TG T 3.57E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs6720147 chr2 161686114 T A 3.57E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs16845258 chr2 161722879 G C 7.67E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12052592 chr2 161724866 A G 3.68E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs270952 chr2 161727711 T G 8.20E-05 Cognitive function / / 24684796 rs13403103 chr2 161739579 C T 4.92E-05 Tourette syndrome / / 22889924 rs10208407 chr2 161757129 G A 2.00E-06 Obesity-related traits / / 23251661 rs13406739 chr2 161770575 G A 9.15E-05 Relative hand skill / / 24068947 rs12470772 chr2 161775489 C T 1.78E-07 Post-operative nausea and vomiting / / 21694509 rs12470772 chr2 161775489 C T 4.40E-05 Kawasaki disease / / 22446962 rs13015721 chr2 161776405 T C 3.02E-05 Post-operative nausea and vomiting / / 21694509 rs1722636 chr2 161781773 C T 6.00E-07 Subcutaneous adipose tissue / / 22589738 rs1829975 chr2 161785169 C T 6.00E-06 Treatment response for severe sepsis / / 22310353 rs10208511 chr2 161863052 A G 2.34E-04 Depression (quantitative trait) / / 20800221 rs4664393 chr2 161884425 T A 3.11E-04 Alzheimer's disease / / 22005930 rs16845445 chr2 161885696 A G 2.92E-04 Alzheimer's disease / / 22005930 rs7422349 chr2 161885827 C T 3.07E-04 Alzheimer's disease / / 22005930 rs2884354 chr2 161885862 G A 3.07E-04 Alzheimer's disease / / 22005930 rs7425907 chr2 161885981 A C 3.07E-04 Alzheimer's disease / / 22005930 rs2357982 chr2 161886103 C G 3.11E-04 Alzheimer's disease / / 22005930 rs2357982 chr2 161886103 C G 3.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs2674942 chr2 161888612 C T 3.26E-04 Alzheimer's disease / / 22005930 rs2674943 chr2 161888650 A G 3.27E-04 Alzheimer's disease / / 22005930 rs2674944 chr2 161889038 G A 3.28E-04 Alzheimer's disease / / 22005930 rs2551691 chr2 161889193 T C 3.14E-04 Alzheimer's disease / / 22005930 rs2551691 chr2 161889193 T C 0.00000295 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2551691 chr2 161889193 T C 9.03E-05 Breast cancer / / pha002853 rs2551688 chr2 161890305 T C 3.25E-04 Alzheimer's disease / / 22005930 rs2551689 chr2 161891144 G T 3.22E-04 Alzheimer's disease / / 22005930 rs2113521 chr2 161891928 A T 1.99E-04 Alzheimer's disease / / 22005930 rs2113523 chr2 161892055 G C 3.20E-04 Alzheimer's disease / / 22005930 rs197271 chr2 161893148 C G 3.18E-04 Alzheimer's disease / / 22005930 rs197272 chr2 161894556 G T 2.47E-04 Alzheimer's disease / / 22005930 rs197273 chr2 161894663 A G 1.00E-07 Dietary macronutrient intake / / 23372041 rs197275 chr2 161896152 T C 2.65E-04 Alzheimer's disease / / 22005930 rs197275 chr2 161896152 T C 0.0000122 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs197275 chr2 161896152 T C 4.42E-05 Breast cancer / / pha002853 rs197276 chr2 161897009 A T 3.11E-04 Alzheimer's disease / / 22005930 rs197277 chr2 161897159 T A,C 2.89E-04 Alzheimer's disease / / 22005930 rs4664396 chr2 161901650 A G 4.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4664397 chr2 161901948 G A 3.32E-05 Cortisol secretion,in saliva / / 21316860 rs197265 chr2 161902484 G A 3.97E-04 Alzheimer's disease / / 22005930 rs197265 chr2 161902484 G A 0.000000823 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs197264 chr2 161903399 T C 7.37E-04 Alzheimer's disease / / 22005930 rs197260 chr2 161905151 G T 8.56E-04 Alzheimer's disease / / 22005930 rs197266 chr2 161905590 G C 9.42E-04 Alzheimer's disease / / 22005930 rs197269 chr2 161908132 A C 9.18E-04 Alzheimer's disease / / 22005930 rs197270 chr2 161908442 T C 9.58E-04 Alzheimer's disease / / 22005930 rs13399728 chr2 161909369 A G 9.53E-04 Alzheimer's disease / / 22005930 rs10803775 chr2 161912187 A T 9.67E-04 Alzheimer's disease / / 22005930 rs9287806 chr2 161913992 G A 9.74E-04 Alzheimer's disease / / 22005930 rs9287806 chr2 161913992 G A 0.0000175 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2216847 chr2 161914280 T G 0.00000422 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs889922 chr2 161917192 C T 0.0000215 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1025105 chr2 161922656 A G 0.0000238 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6432670 chr2 161938839 T C 9.90E-04 Alzheimer's disease / / 22005930 rs6432670 chr2 161938839 T C 0.0000954 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7564141 chr2 161943290 T C 0.0000706 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7591506 chr2 161960925 T G 6.74E-04 Parkinson's disease / / 17052657 rs7591506 chr2 161960925 T G 9.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2194505 chr2 161963254 C T 0.0000706 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10221957 chr2 161971984 T G 2.20E-05 Tourette syndrome / / 22889924 rs1267070 chr2 161988483 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7568498 chr2 162029113 T G 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) TANK intron 24554482 rs889916 chr2 162032662 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TANK intron 22628534 rs10183710 chr2 162057981 C T 6.27E-05 Tourette syndrome TANK intron 22889924 rs1267075 chr2 162059817 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TANK intron 22628534 rs7309 chr2 162092640 G A 5.58E-04 Parkinson's disease TANK UTR-3 17052657 rs7309 chr2 162092640 G A 4.00E-08 Educational attainment TANK UTR-3 23722424 rs1267043 chr2 162125294 A C 3.01E-05 Coronary heart disease / / pha003030 rs2113480 chr2 162186610 T C 6.18E-05 Suicide attempts in bipolar disorder PSMD14 intron 21423239 rs1559496 chr2 162215094 C G 3.73E-04 Multiple complex diseases PSMD14 intron 17554300 rs1116173 chr2 162226838 A G 7.34E-05 Suicide attempts in bipolar disorder PSMD14 intron 21423239 rs3769959 chr2 162249206 A G 1.89E-05 Multiple complex diseases PSMD14 intron 17554300 rs2216941 chr2 162258705 T A 9.75E-04 Multiple complex diseases PSMD14 intron 17554300 rs1110587 chr2 162264277 T C 1.22E-05 Coronary heart disease PSMD14 intron pha003030 rs13432654 chr2 162300286 A G 4.35E-05 Information processing speed / / 21130836 rs6432689 chr2 162379760 C T 8.22E-05 Coronary heart disease / / pha003030 rs2020027 chr2 162425878 G A 1.10E-05 Urinary metabolites / / 21572414 rs2389549 chr2 162462209 T C 5.50E-06 Urinary metabolites / / 21572414 rs1567420 chr2 162475601 T C 4.70E-06 Urinary metabolites / / 21572414 rs1567421 chr2 162475617 G T 4.70E-06 Urinary metabolites / / 21572414 rs16846050 chr2 162563553 G A 1.30E-05 Urinary metabolites SLC4A10 intron 21572414 rs12476631 chr2 162566936 T C 1.10E-05 Urinary metabolites SLC4A10 intron 21572414 rs16846073 chr2 162586548 C G 7.80E-06 Urinary metabolites SLC4A10 intron 21572414 rs7581747 chr2 162615115 T C 7.00E-07 Urinary metabolites SLC4A10 intron 21572414 rs13022437 chr2 162622285 G A 1.80E-06 Urinary metabolites SLC4A10 intron 21572414 rs9636284 chr2 162680512 C T 2.61E-05 Hypertension SLC4A10 intron 21082022 rs2084543 chr2 162696414 C T 6.47E-06 Hypertension SLC4A10 cds-synon 21082022 rs16846179 chr2 162749056 T G 2.14E-05 Hypertension SLC4A10 intron 21082022 rs16846221 chr2 162820220 G T 4.90E-04 Alcohol dependence SLC4A10 intron 20201924 rs12986853 chr2 162825174 C T 2.72E-04 Smoking initiation SLC4A10 intron 24665060 rs12617656 chr2 162851147 T C 1.00E-08 Rheumatoid arthritis DPP4 intron 24782177 rs12617656 chr2 162851147 T C 2.00E-21 Rheumatoid arthritis DPP4 intron 24782177 rs2970933 chr2 162854276 T C 4.00E-06 Dietary macronutrient intake DPP4 intron 23372041 rs2909448 chr2 162866255 C T 0.0000414 LDL cholesterol DPP4 intron 23063622 rs2268888 chr2 162885450 C T 7.90E-04 Alcohol dependence DPP4 intron 20201924 rs6741949 chr2 162910223 G C 3.00E-07 Hippocampal volume DPP4 intron 22504421 rs10490422 chr2 162916413 G T 1.19E-04 Coronary Artery Disease DPP4 intron 17634449 rs10490422 chr2 162916413 G T 5.92E-18 Gallbladder disease DPP4 intron pha001404 rs2300753 chr2 162928465 C A 1.99E-04 Response to cholinesterase inhibitors in Alzheimer's disease DPP4 intron 23374588 rs2270447 chr2 162959748 T C 8.00E-07 Common traits (Other) / / 20585627 rs2160711 chr2 162977965 A G 7.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2111485 chr2 163110536 A G 5.00E-15 Vitiligo / / 22561518 rs2111485 chr2 163110536 A G 2.00E-08 Inflammatory bowel disease / / 23128233 rs2111485 chr2 163110536 A G 0.000833548 Primary sclerosing cholangitis / / 23603763 rs1990760 chr2 163124051 C T 2.00E-11 Type 1 diabetes IFIH1 missense 17554260 rs1990760 chr2 163124051 C T 7.00E-09 Type 1 diabetes IFIH1 missense 19430480 rs1990760 chr2 163124051 C T 7.00E-10 Immunoglobulin A IFIH1 missense 20694011 rs1990760 chr2 163124051 C T 2.00E-14 Type 1 diabetes autoantibodies IFIH1 missense 21829393 rs1990760 chr2 163124051 C T 2.21E-08 Type 1 diabetes IFIH1 missense 21980299 rs1990760 chr2 163124051 C T 2.00E-11 Multiple sclerosis IFIH1 missense 22190364 rs1990760 chr2 163124051 C T 2.55E-04 Vitiligo IFIH1 missense 22561518 rs3747517 chr2 163128824 T C 2.34E-05 Multiple complex diseases IFIH1 missense 17554300 rs10930046 chr2 163137983 T C 4.68E-05 Neuroticism IFIH1 missense 23229837 rs3788964 chr2 163207480 T C 3.03E-04 Nicotine smoking GCA intron 19268276 rs3788964 chr2 163207480 T C 1.46E-05 Fibrinogen GCA intron pha003068 rs16846675 chr2 163260410 A G 5.31E-04 Multiple complex diseases KCNH7 intron 17554300 rs17716942 chr2 163260691 T C 1.00E-13 Psoriasis KCNH7 intron 20953190 rs17716942 chr2 163260691 T C 3.30E-18 Psoriasis KCNH7 intron 23143594 rs12464272 chr2 163305723 T A 8.32E-04 Obesity (extreme) KCNH7 intron 21935397 rs6734436 chr2 163311202 T C 8.12E-04 Obesity (extreme) KCNH7 intron 21935397 rs16846727 chr2 163316843 G A 8.10E-04 Obesity (extreme) KCNH7 intron 21935397 rs16846732 chr2 163319131 T A 7.08E-04 Obesity (extreme) KCNH7 intron 21935397 rs13403568 chr2 163320513 C G 4.92E-04 Multiple complex diseases KCNH7 intron 17554300 rs16846743 chr2 163321014 C T 6.88E-04 Obesity (extreme) KCNH7 intron 21935397 rs6758303 chr2 163325803 G C 5.97E-04 Obesity (extreme) KCNH7 intron 21935397 rs7594587 chr2 163330094 A T 5.56E-04 Obesity (extreme) KCNH7 intron 21935397 rs6715546 chr2 163331395 T G 5.55E-04 Obesity (extreme) KCNH7 intron 21935397 rs985621 chr2 163339633 G A 5.48E-04 Obesity (extreme) KCNH7 intron 21935397 rs1485978 chr2 163345284 G A 4.80E-04 Obesity (extreme) KCNH7 intron 21935397 rs12052788 chr2 163346563 T C 3.65E-04 Obesity (extreme) KCNH7 intron 21935397 rs1352070 chr2 163357883 A G 4.71E-04 Obesity (extreme) KCNH7 intron 21935397 rs1026992 chr2 163368279 C T 3.66E-05 Multiple complex diseases KCNH7 intron 17554300 rs16846856 chr2 163396985 T C 6.80E-06 Urinary metabolites KCNH7 intron 21572414 rs13422156 chr2 163397521 T G 2.30E-05 Urinary metabolites KCNH7 intron 21572414 rs12471221 chr2 163401685 G A 6.90E-06 Urinary metabolites KCNH7 intron 21572414 rs11884875 chr2 163403303 A G 7.10E-06 Urinary metabolites KCNH7 intron 21572414 rs901303 chr2 163416447 G A 4.28E-04 Obesity (extreme) KCNH7 intron 21935397 rs10439292 chr2 163417299 G A 9.58E-05 Atopic dermatitis KCNH7 intron 23042114 rs17401811 chr2 163420104 A T 5.62E-05 Atopic dermatitis KCNH7 intron 23042114 rs13002126 chr2 163420361 T C 6.14E-05 Atopic dermatitis KCNH7 intron 23042114 rs1843553 chr2 163420535 C T 6.16E-05 Atopic dermatitis KCNH7 intron 23042114 rs10497226 chr2 163421016 G C 6.18E-05 Atopic dermatitis KCNH7 intron 23042114 rs13403935 chr2 163422403 T C 8.55E-05 Atopic dermatitis KCNH7 intron 23042114 rs10930065 chr2 163558854 C T 1.51E-05 Multiple complex diseases KCNH7 intron 17554300 rs10168953 chr2 163604529 A C 8.51E-05 Orofacial clefts KCNH7 intron 22419666 rs1434996 chr2 163625587 A G 1.00E-04 Cognitive impairment induced by topiramate KCNH7 intron 22091778 rs1017406 chr2 163643407 C A 2.70E-05 Urinary metabolites KCNH7 intron 21572414 rs184270 chr2 163710934 A T 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4461275 chr2 163732409 C T 1.40E-06 Urinary metabolites / / 21572414 rs10203602 chr2 163734130 T C 1.10E-06 Urinary metabolites / / 21572414 rs10451557 chr2 163739071 C T 5.96E-04 Rheumatoid arthritis / / 21452313 rs1364562 chr2 163741726 T C 9.20E-07 Urinary metabolites / / 21572414 rs307869 chr2 163761591 T A 1.70E-06 Urinary metabolites / / 21572414 rs1424760 chr2 163781787 C T 4.00E-08 Phospholipid levels (plasma) / / 22359512 rs307861 chr2 163782427 T G 6.27E-04 Type 2 diabetes / / 17463246 rs1424762 chr2 163819564 C A 1.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10930082 chr2 163820529 A G 2.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1834224 chr2 163821538 C T 2.42E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7585233 chr2 163821969 C T 2.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12692664 chr2 163822494 T A 4.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs201294656 chr2 163822494 T TAA 4.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6739611 chr2 163822855 G A 1.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2113698 chr2 163823516 G A 1.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1424763 chr2 163824857 A G 1.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1424764 chr2 163825082 C T 1.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6756025 chr2 163827128 C A 3.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6432742 chr2 163838586 T C 9.95E-04 Type 2 diabetes / / 17463246 rs4390782 chr2 163865002 G A 0.000803 Salmonella-induced pyroptosis / / 22837397 rs918932 chr2 163894302 C T 5.08E-05 Osteoarthritis (knee and hip) / / 21177295 rs10178838 chr2 163895823 A G 3.22E-05 Type 2 diabetes / / 17463246 rs12471596 chr2 163904571 A G 8.17E-04 Multiple complex diseases / / 17554300 rs1546031 chr2 163918006 T C 4.60E-04 Multiple complex diseases / / 17554300 rs16848037 chr2 163921145 A C 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12468570 chr2 163943612 G T 1.72E-05 Type 2 diabetes / / 17463246 rs12692684 chr2 163966971 G A 6.80E-04 Multiple complex diseases / / 17554300 rs12692684 chr2 163966971 G A 3.42E-04 Bipolar disorder / / 18317468 rs35862965 chr2 163975466 AT A 3.39E-04 Multiple complex diseases / / 17554300 rs3956504 chr2 163975466 A C 3.39E-04 Multiple complex diseases / / 17554300 rs1586627 chr2 163977186 A G 5.62E-04 Multiple complex diseases / / 17554300 rs13400223 chr2 163990193 T C 2.05E-04 Multiple complex diseases / / 17554300 rs4575739 chr2 163992253 G T 4.11E-05 Type 2 diabetes / / 17463246 rs4462794 chr2 163993331 C T 1.43E-05 Type 2 diabetes / / 17463246 rs12477351 chr2 163997527 C T 1.02E-04 Type 2 diabetes / / 17463246 rs12465028 chr2 164041305 C T 9.20E-05 Type 2 diabetes / / 17463246 rs16848135 chr2 164041560 A G 8.80E-04 Type 2 diabetes / / 17463246 rs41423844 chr2 164047646 T A 7.92E-05 Type 2 diabetes / / 17463246 rs13389923 chr2 164048659 A G 8.17E-04 Myocardial Infarction / / pha002883 rs6730724 chr2 164068919 C G 7.80E-05 Type 2 diabetes / / 17463246 rs16848219 chr2 164104566 G A 2.97E-05 Multiple complex diseases / / 17554300 rs7559172 chr2 164145941 A G 8.94E-04 Type 2 diabetes / / 17463246 rs1221517 chr2 164173070 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1922092 chr2 164209580 C T 3.35E-04 Multiple complex diseases / / 17554300 rs16848321 chr2 164212164 T C 9.09E-05 Multiple complex diseases / / 17554300 rs16848323 chr2 164212362 A C 5.43E-04 Multiple complex diseases / / 17554300 rs4668300 chr2 164295936 C A 7.99E-05 Basophils / / pha003087 rs9287831 chr2 164300859 C T 1.76E-04 Gallstones / / 17632509 rs9287831 chr2 164300859 C T 4.59E-05 Basophils / / pha003087 rs12476047 chr2 164317876 T C 3.00E-06 Response to antipsychotic treatment / / 19680635 rs6732555 chr2 164330382 C T 9.31E-05 Basophils / / pha003087 rs7598913 chr2 164373280 A G 5.01E-04 Body mass index / / 21701565 rs10175821 chr2 164373852 G A 8.38E-04 Multiple complex diseases / / 17554300 rs13018106 chr2 164375202 G C 6.85E-04 Type 2 diabetes / / 17463246 rs13018106 chr2 164375202 G C 3.14E-04 Body mass index / / 21701565 rs6761831 chr2 164388639 G A 4.07E-04 Body mass index / / 21701565 rs1440465 chr2 164390510 A G 1.98E-04 Multiple complex diseases / / 17554300 rs2952065 chr2 164395131 A G 4.51E-04 Body mass index / / 21701565 rs2704357 chr2 164405728 T C 4.48E-04 Body mass index / / 21701565 rs16848648 chr2 164434950 A C 5.20E-06 Urinary metabolites / / 21572414 rs17806246 chr2 164435741 A C 4.30E-06 Urinary metabolites / / 21572414 rs12692697 chr2 164441947 A C 1.49E-04 Fibrinogen / / 17255346 rs12692700 chr2 164444305 T C 1.30E-05 Urinary metabolites / / 21572414 rs7572130 chr2 164460947 A G 2.03E-04 Type 2 diabetes / / 17463246 rs6731290 chr2 164488243 A G 1.80E-05 Urinary metabolites FIGN intron 21572414 rs982393 chr2 164490529 A T 8.00E-08 Folate pathway vitamin levels FIGN intron 19744961 rs16848743 chr2 164496367 T C 4.65E-04 Multiple complex diseases FIGN intron 17554300 rs1371827 chr2 164501773 C A,G 2.00E-05 Urinary metabolites FIGN intron 21572414 rs10177481 chr2 164506159 T C 1.40E-05 Urinary metabolites FIGN intron 21572414 rs1460665 chr2 164587447 A G 2.80E-05 Urinary metabolites FIGN intron 21572414 rs1460675 chr2 164600455 G A 1.60E-05 Urinary metabolites / / 21572414 rs10202492 chr2 164621524 A G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16848941 chr2 164675913 T C 8.04E-05 Major depressive disorder / / 21621269 rs1370493 chr2 164701057 T C 6.64E-05 Tunica Media / / pha003034 rs12994524 chr2 164720199 C T 4.78E-05 Major depressive disorder / / 21621269 rs10930111 chr2 164725276 A C 8.24E-05 Major depressive disorder / / 21621269 rs10497248 chr2 164752462 T C 2.00E-05 Urinary metabolites / / 21572414 rs10184708 chr2 164768717 T C 8.66E-05 Major depressive disorder / / 21621269 rs768017 chr2 164791764 G C 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs165274 chr2 164830609 A G 9.85E-04 Type 2 diabetes / / 17463246 rs6724503 chr2 164884641 T C 2.76E-04 Smoking initiation / / 24665060 rs2176241 chr2 164885707 T G 7.59E-04 Depression (quantitative trait) / / 20800221 rs2176241 chr2 164885707 T G 3.66E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12624028 chr2 164891028 T C 7.01E-04 Smoking initiation / / 24665060 rs12692709 chr2 164894561 T C 5.75E-06 Major depressive disorder / / 21621269 rs16849225 chr2 164906820 C T 4.00E-11 Blood pressure / / 21572416 rs13002573 chr2 164915208 A G 2.00E-08 Blood pressure / / 21909110 rs393093 chr2 164926908 G A 3.30E-05 Major depressive disorder / / 22472876 rs12470735 chr2 164933379 T C 3.70E-04 Myocardial Infarction / / pha002873 rs268269 chr2 164941139 C A 6.47E-04 Smoking initiation / / 24665060 rs1446468 chr2 164963486 T C 6.00E-12 Blood pressure / / 21909110 rs13014943 chr2 164973229 T C 1.20E-04 Multiple complex diseases / / 17554300 rs12473215 chr2 164990257 T A 4.44E-05 Sarcoidosis / / 19165924 rs7601389 chr2 165002610 T G 9.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs967184 chr2 165019579 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1446465 chr2 165035811 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1121308 chr2 165042064 T C 8.01E-04 Prostate cancer mortality / / 20978177 rs4667731 chr2 165047345 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13027527 chr2 165078704 G A 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11891401 chr2 165086747 T A 2.00E-06 Blood pressure / / 24954895 rs13398947 chr2 165090463 C T 9.88E-05 Hemoglobin / / pha003096 rs13398947 chr2 165090463 C T 3.22E-05 Hematocrit / / pha003097 rs13000630 chr2 165093965 T G 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs375188791 chr2 165093965 T TAG 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4667736 chr2 165100379 A G 2.33E-06 Cognitive impairment induced by topiramate / / 22091778 rs4667736 chr2 165100379 A G 2.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs9287843 chr2 165107298 C T 2.50E-06 Cognitive impairment induced by topiramate / / 22091778 rs9287843 chr2 165107298 C T 3.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs16849404 chr2 165130868 G A 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2165094 chr2 165173034 A T 4.12E-06 Blood pressure / / 21909110 rs561673 chr2 165314131 T C 3.37E-04 Type 2 diabetes / / 17463246 rs12466514 chr2 165320390 T C 3.35E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1521526 chr2 165329726 A C 4.85E-05 Coronary Artery Disease / / 17634449 rs17353055 chr2 165334869 G A 3.32E-04 Coronary Artery Disease / / 17634449 rs670757 chr2 165352165 C T 7.31E-05 Erythrocyte counts GRB14 intron pha003099 rs671689 chr2 165352405 G A 8.21E-05 Erythrocyte counts GRB14 intron pha003099 rs570657 chr2 165356343 A G 3.52E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs4667463 chr2 165358672 A G 3.52E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs582447 chr2 165366592 A C 2.74E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs17437781 chr2 165424837 A G 5.04E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs1521527 chr2 165427825 G C 3.95E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs11677541 chr2 165429235 G A,C,T 6.15E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs1521522 chr2 165437544 C G 7.36E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs4423615 chr2 165438230 G A 5.29E-05 Nicotine smoking GRB14 intron 19268276 rs4423615 chr2 165438230 G A 6.78E-05 Nicotine smoking GRB14 intron 19268276 rs4319945 chr2 165452742 C T 0.0000962 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity GRB14 intron 22945461 rs3923113 chr2 165501849 A C 1.00E-08 Type 2 diabetes / / 21874001 rs3923113 chr2 165501849 A C 1.80E-09 Type 2 diabetes (females) / / 22885922 rs3923113 chr2 165501849 A C 2.60E-10 Type 2 diabetes / / 22885922 rs3923113 chr2 165501849 A C 1.00E-08 Type 2 diabetes / / 23300278 rs3923113 chr2 165501849 A C 2.00E-06 Type 2 diabetes / / 24509480 rs12692735 chr2 165504565 G T 1.10E-06 Type 2 diabetes / / 21874001 rs10930133 chr2 165506724 T A 1.20E-06 Type 2 diabetes / / 21874001 rs6713419 chr2 165508300 T C 1.10E-06 Type 2 diabetes / / 21874001 rs10184004 chr2 165508389 C T 3.50E-06 Type 2 diabetes / / 21874001 rs7607886 chr2 165509579 G A 4.23E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs10179126 chr2 165511794 C G 1.50E-06 Type 2 diabetes / / 21874001 rs10195252 chr2 165513091 T C 2.00E-10 Triglycerides / / 20686565 rs10195252 chr2 165513091 T C 4.00E-34 Waist-hip ratio / / 20935629 rs10195252 chr2 165513091 T C 2.60E-06 Type 2 diabetes / / 21874001 rs10195252 chr2 165513091 T C 4.20E-13 Type 2 diabetes / / 22885922 rs10195252 chr2 165513091 T C 1.26E-16 Fasting insulin-related traits / / 22885924 rs7592412 chr2 165526338 T C 1.10E-06 Type 2 diabetes / / 21874001 rs13432797 chr2 165526587 G C 3.00E-06 Type 2 diabetes / / 21874001 rs1128249 chr2 165528624 G T 0.000000017 Type 2 diabetes / / 22885922 rs13389219 chr2 165528876 C T 3.60E-06 Type 2 diabetes / / 21874001 rs13389219 chr2 165528876 C T 0.0000002 HDL cholesterol / / 22885922 rs13389219 chr2 165528876 C T 0.000005 LDL cholesterol / / 22885922 rs13389219 chr2 165528876 C T 0.000034 Cholesterol,total / / 22885922 rs13389219 chr2 165528876 C T 0.00027 Fasting insulin-related traits / / 22885922 rs13389219 chr2 165528876 C T 1.10E-10 Type 2 diabetes / / 22885922 rs13389219 chr2 165528876 C T 3.10E-10 Triglycerides / / 22885922 rs13389219 chr2 165528876 C T 3.00E-08 Waist-hip ratio / / 23563607 rs13389219 chr2 165528876 C T 9.50E-05 Waist-hip ratio / / 23966867 rs6717858 chr2 165539661 T C 6.00E-16 Sexual dimorphism in anthropometric traits / / 23754948 rs12328675 chr2 165540800 T C 6.80E-05 Response to statin therapy / / 20339536 rs12328675 chr2 165540800 T C 3.00E-10 HDL cholesterol / / 20686565 rs12328675 chr2 165540800 T C 2.00E-15 HDL cholesterol / / 24097068 rs3769869 chr2 165543199 A G 1.43E-05 Lung function (forced expiratory volume in 1 second) COBLL1 intron pha003102 rs10490694 chr2 165548569 G A 4.78E-09 Lipid levels COBLL1 intron 19936222 rs10490694 chr2 165548569 G A 6.70E-05 Response to statin therapy COBLL1 intron 20339536 rs7607980 chr2 165551201 T C 4.00E-20 Fasting insulin-related traits (interaction with BMI) COBLL1 missense 22581228 rs150990193 chr2 165552167 T C 0.000021 Breast cancer(er negative) COBLL1 missense 23555315 rs3769870 chr2 165564484 A G 0.000462193 Hypertension (early onset hypertension) COBLL1 intron 22479346 rs3769871 chr2 165565319 C T 7.88E-04 Type 2 diabetes COBLL1 intron 17463246 rs3769872 chr2 165565548 C T 0.000536011 Hypertension (early onset hypertension) COBLL1 intron 22479346 rs10221833 chr2 165577164 G C 6.00E-06 Response to statin therapy COBLL1 intron 20339536 rs13410987 chr2 165580775 C T 1.60E-05 Response to statin therapy COBLL1 intron 20339536 rs369788854 chr2 165580775 CGTT C 1.60E-05 Response to statin therapy COBLL1 intron 20339536 rs1122004 chr2 165585585 C T 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COBLL1 intron 20877124 rs7574791 chr2 165590459 C T 1.43E-04 Stroke COBLL1 intron pha002887 rs10178921 chr2 165603512 T C 6.20E-05 Response to statin therapy COBLL1 intron 20339536 rs427059 chr2 165606954 T C 6.80E-05 Response to statin therapy COBLL1 intron 20339536 rs1509099 chr2 165628004 A C 2.10E-05 Urinary metabolites COBLL1 intron 21572414 rs355900 chr2 165638070 T C 8.65E-04 Amyotrophic Lateral Sclerosis COBLL1 intron 17362836 rs11691338 chr2 165640188 T G 2.60E-05 Urinary metabolites COBLL1 intron 21572414 rs718573 chr2 165652687 T C 9.76E-04 Schizophrenia (cytomegalovirus infection interaction) COBLL1 intron 23358160 rs10930136 chr2 165663986 T G 1.00E-06 Urinary metabolites COBLL1 intron 21572414 rs16849792 chr2 165664637 C T 1.50E-05 Urinary metabolites COBLL1 intron 21572414 rs6736779 chr2 165665144 T C 1.60E-05 Urinary metabolites COBLL1 intron 21572414 rs10173063 chr2 165665490 G A 2.14E-04 Type 2 diabetes COBLL1 intron 17463246 rs10173063 chr2 165665490 G A 1.00E-06 Urinary metabolites COBLL1 intron 21572414 rs355810 chr2 165685646 G A 5.46E-04 Amyotrophic Lateral Sclerosis COBLL1 intron 17362836 rs7569506 chr2 165710110 T C 8.20E-04 Type 2 diabetes / / 17463246 rs7569506 chr2 165710110 T C 1.00E-06 Urinary metabolites / / 21572414 rs13396952 chr2 165737057 G A 3.89E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10497251 chr2 165739014 T C 3.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13424957 chr2 165750390 C T 3.00E-06 Coronary heart disease / / 21347282 rs13424957 chr2 165750390 C T 2.63E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs3817135 chr2 165753118 A G 1.77E-04 Glycosylated haemoglobin levels / / 17255346 rs6432806 chr2 165821681 G A 5.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2077846 chr2 165855130 G A 2.68E-06 Bilirubin levels,in serum / / 19389676 rs776488 chr2 165890733 A C 2.00E-07 Common traits (Other) / / 20585627 rs776495 chr2 165895586 T G 0.00000351 Fetal hemoglobin levels / / 22936743 rs62174866 chr2 165928113 A T 6.65E-06 Osteoarthritis / / 21871595 rs62174867 chr2 165929310 C T 6.65E-06 Osteoarthritis / / 21871595 rs62174869 chr2 165930578 C G 3.44E-06 Osteoarthritis / / 21871595 rs62174894 chr2 165936973 G A 6.54E-06 Osteoarthritis / / 21871595 rs3816195 chr2 165956508 T G 5.29E-04 Alcohol dependence SCN3A intron 24277619 rs62174897 chr2 165958651 A G 1.41E-06 Osteoarthritis SCN3A intron 21871595 rs1347992 chr2 165961865 T C 4.85E-04 Alcohol dependence SCN3A intron 24277619 rs17829596 chr2 165985503 T C 5.70E-05 Crohn's disease SCN3A intron 20570966 rs17829596 chr2 165985503 T C 3.63E-05 Brain structure SCN3A intron 22504417 rs62174901 chr2 165988343 T C 9.01E-07 Osteoarthritis SCN3A intron 21871595 rs62174906 chr2 166008357 A G 6.66E-07 Osteoarthritis SCN3A intron 21871595 rs7556825 chr2 166020649 T C 3.60E-05 Multiple complex diseases SCN3A intron 17554300 rs12615864 chr2 166031792 G A 1.00E-04 Prostate cancer SCN3A intron 21743057 rs139585434 chr2 166032837 G A 0.000000161 Prostate-specific antigen SCN3A missense 23555315 rs2028891 chr2 166067658 T G 1.40E-04 Alcohol dependence / / 24277619 rs6718960 chr2 166095728 A G 0.0000196 LDL cholesterol particle diameter SCN2A nearGene-5 23263444 rs17182784 chr2 166100967 C T 0.0000196 LDL cholesterol particle diameter SCN2A intron 23263444 rs1439805 chr2 166106557 C A 5.93E-05 Coronary heart disease SCN2A intron pha003031 rs2119067 chr2 166127283 C T 4.40E-05 Alzheimer's disease (late onset) SCN2A intron 20885792 rs2119067 chr2 166127283 C T 4.40E-05 Alzheimer's disease (late onset) SCN2A intron 21460841 rs2119067 chr2 166127283 C T 1.53E-05 Coronary heart disease SCN2A intron pha003030 rs2119067 chr2 166127283 C T 8.34E-07 Coronary heart disease SCN2A intron pha003031 rs10184275 chr2 166127928 G A 2.20E-05 Alzheimer's disease (late onset) SCN2A intron 20885792 rs10184275 chr2 166127928 G A 2.20E-05 Alzheimer's disease (late onset) SCN2A intron 21460841 rs10184275 chr2 166127928 G A 4.34E-07 Coronary heart disease SCN2A intron pha003030 rs10184275 chr2 166127928 G A 1.11E-07 Coronary heart disease SCN2A intron pha003031 rs353121 chr2 166129323 G A 2.58E-05 Coronary heart disease SCN2A intron pha003030 rs353121 chr2 166129323 G A 3.43E-07 Coronary heart disease SCN2A intron pha003031 rs353119 chr2 166130379 C T 2.58E-05 Coronary heart disease SCN2A intron pha003030 rs353119 chr2 166130379 C T 3.43E-07 Coronary heart disease SCN2A intron pha003031 rs353111 chr2 166137029 T G 1.07E-05 Coronary heart disease SCN2A intron pha003031 rs16850317 chr2 166144414 T G 5.00E-06 Periodontitis (DPAL) SCN2A intron 24024966 rs7607897 chr2 166156941 A G 7.11E-04 Response to cytidine analogues (gemcitabine) SCN2A intron 24483146 rs2116658 chr2 166166672 C T 1.48E-05 Parkinson's disease SCN2A intron pha002868 rs2304016 chr2 166168503 A G 1 Drug response to Carbamazepine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Lamotrigine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Oxcarbazepine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Phenytoin SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Topiramate SCN2A intron 18784617 rs13025009 chr2 166170073 A G 2.16E-05 Parkinson's disease SCN2A intron pha002868 rs13387970 chr2 166193965 C A 8.26E-04 Response to cytidine analogues (gemcitabine) SCN2A intron 24483146 rs3910176 chr2 166205485 G T 6.48E-04 Smoking cessation SCN2A intron 24665060 rs764660 chr2 166213297 T G 7.83E-06 Parkinson's disease SCN2A intron pha002868 rs12692769 chr2 166258977 C T 2.30E-05 Urinary metabolites / / 21572414 rs1432546 chr2 166260790 A G 1.30E-05 Urinary metabolites / / 21572414 rs6432823 chr2 166263130 C T 6.72E-04 Smoking cessation / / 24665060 rs16850599 chr2 166266634 G T 9.62E-04 Rheumatoid arthritis / / 21452313 rs13385399 chr2 166269095 T G 7.86E-04 Smoking cessation / / 24665060 rs1355995 chr2 166274594 A G 5.54E-04 Rheumatoid arthritis / / 21452313 rs11683781 chr2 166288740 C T 4.33E-04 Smoking cessation / / 24665060 rs687415 chr2 166303598 C T 3.66E-04 HIV-1 viral setpoint / / 17641165 rs687415 chr2 166303598 C T 0.0000315 Alcohol craving with or without dependence / / 22481050 rs13413326 chr2 166332752 T C 3.11E-04 Multiple complex diseases CSRNP3 intron 17554300 rs6432832 chr2 166370826 A C 9.00E-06 Longevity (85 years and older) CSRNP3 intron 24688116 rs6432834 chr2 166374932 A C 4.49E-04 Multiple complex diseases CSRNP3 intron 17554300 rs10427253 chr2 166399158 G T 0.0006544 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSRNP3 intron 23233654 rs10427253 chr2 166399158 G T 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSRNP3 intron 23233662 rs7588295 chr2 166407511 A G 0.00000624 Bisphosphonate-induced osteonecrosis of the jaw CSRNP3 intron 22267851 rs10803799 chr2 166440547 A C 1.16E-04 Substance dependence CSRNP3 intron 21818250 rs13389345 chr2 166455078 G A 2.64E-04 Multiple complex diseases CSRNP3 intron 17554300 rs1869473 chr2 166491207 G A 8.71E-05 Alzheimer's disease (late onset) CSRNP3 intron 21379329 rs1820325 chr2 166534206 A G 1.57E-04 Vaspin levels CSRNP3 intron 22907691 rs1820325 chr2 166534206 A G 0.0001568 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks CSRNP3 intron 22907730 rs777346 chr2 166535918 C T 2.40E-08 Bone mineral density (paediatric,total body less head) CSRNP3 cds-synon 24945404 rs2194754 chr2 166539042 A G 4.80E-08 Bone mineral density (paediatric,total body less head) CSRNP3 UTR-3 24945404 rs777355 chr2 166554037 G A 2.70E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs777355 chr2 166554037 G A 4.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs1863196 chr2 166557510 A G 2.70E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs12185748 chr2 166576956 C T 1.10E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs12185748 chr2 166576956 C T 3.90E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs7586085 chr2 166577489 A G 1.30E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7586085 chr2 166577489 A G 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6726821 chr2 166578114 T G 1.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6726821 chr2 166578114 T G 2.00E-06 Bone mineral density (paediatric,upper limb) / / 24945404 rs6726821 chr2 166578114 T G 4.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6726821 chr2 166578114 T G 7.00E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs6710388 chr2 166583141 C T 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6710388 chr2 166583141 C T 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6710518 chr2 166583244 C T 5.00E-10 Bone mineral density / / 21533022 rs6710518 chr2 166583244 C T 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6710518 chr2 166583244 C T 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346003 chr2 166597357 C G 4.50E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 4.00E-30 Bone mineral density / / 22504420 rs1346004 chr2 166601046 G A 1.83E-05 Bone mineral density / / 24249740 rs1346004 chr2 166601046 G A 1.09E-07 Bone mineral density (paediatric,upper limb) / / 24945404 rs1346004 chr2 166601046 G A 4.50E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 4.51E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 5.00E-07 Bone mineral density (paediatric,lower limb) / / 24945404 rs1895701 chr2 166603087 T C 1.04E-05 Bone mineral density / / 24249740 rs1895701 chr2 166603087 T C 4.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs13430211 chr2 166622598 C G 4.40E-08 Bone mineral density (paediatric,total body less head) GALNT3 intron 24945404 rs16851009 chr2 166630707 C T 4.17E-05 Parkinson's disease GALNT3 intron 16252231 rs6745114 chr2 166658586 T C 2.19E-04 Smoking initiation / / 24665060 rs10497268 chr2 166664256 T C 8.16E-04 Alzheimer's disease / / 17998437 rs10930182 chr2 166688188 T C 6.19E-05 Melanoma / / 21926416 rs2060167 chr2 166689342 T C 5.33E-05 Melanoma / / 21926416 rs1560594 chr2 166699798 A G 6.23E-05 Melanoma / / 21926416 rs2304003 chr2 166714081 T C 9.11E-05 Melanoma / / 21926416 rs2304003 chr2 166714081 T C 9.00E-06 Social communication problems / / 24564958 rs16851169 chr2 166715698 G A 9.55E-04 Alzheimer's disease LOC100506124 intron 17998437 rs3762550 chr2 166736005 T G 5.41E-04 Multiple complex diseases TTC21B intron 17554300 rs714705 chr2 166750639 G A 4.68E-04 Multiple complex diseases TTC21B intron 17554300 rs714705 chr2 166750639 G A 6.53E-04 Alzheimer's disease TTC21B intron 17998437 rs13022554 chr2 166752432 A G 3.45E-04 Smoking initiation TTC21B intron 24665060 rs3749030 chr2 166774101 T C 1.00E-04 Information processing speed TTC21B intron 21130836 rs6731900 chr2 166811765 A G 4.00E-06 Memory (short-term) TTC21B nearGene-5 20038948 rs6731900 chr2 166811765 A G 4.61E-04 Smoking initiation TTC21B nearGene-5 24665060 rs12612363 chr2 166838065 C T 1.32E-04 Multiple complex diseases / / 17554300 rs565348 chr2 166873299 A C 1.00E-05 Memory (short-term) SCN1A intron 20038948 rs13383881 chr2 166885387 A G 9.73E-06 Personality dimensions SCN1A intron 23658558 rs3812718 chr2 166909544 C T 1 Drug response to Carbamazepine SCN1A intron 17436242 rs3812718 chr2 166909544 C T 1 Drug response to Phenytoin SCN1A intron 17436242 rs545331 chr2 166913962 G A 4.62E-05 Partial epilepsies SCN1A intron 20522523 rs10930201 chr2 166915335 C A 3.00E-05 Memory (short-term) SCN1A intron 20038948 rs13405797 chr2 166919162 G A 1.30E-06 Personality dimensions SCN1A intron 23658558 rs1841548 chr2 166920430 A G 1.09E-06 Personality dimensions SCN1A intron 23658558 rs13397210 chr2 166922028 C T 1.17E-06 Personality dimensions SCN1A intron 23658558 rs11692675 chr2 166926428 T C 4.78E-06 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs11692675 chr2 166926428 T C 4.87E-07 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs1020852 chr2 166927659 C T 1.68E-06 Personality dimensions SCN1A intron 23658558 rs13406905 chr2 166937368 A C 8.66E-04 Multiple complex diseases SCN1A intron 17554300 rs16851485 chr2 166937561 G A 3.74E-04 Multiple complex diseases SCN1A intron 17554300 rs12998106 chr2 166938753 C T 8.92E-06 Response to amphetamines SCN1A intron 22952603 rs11903891 chr2 166941733 G T 9.69E-06 Response to amphetamines SCN1A intron 22952603 rs11904006 chr2 166942140 C T 6.00E-06 Response to amphetamines SCN1A intron 22952603 rs11890028 chr2 166943277 T G 4.00E-06 Epilepsy (generalized) SCN1A intron 22949513 rs7587026 chr2 166978750 C A 3.00E-09 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs7587026 chr2 166978750 C A 4.00E-08 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs533202 chr2 166983181 A C 0.000205 Salmonella-induced pyroptosis SCN1A intron 22837397 rs534798 chr2 166985056 G A 0.000179 Salmonella-induced pyroptosis SCN1A intron 22837397 rs490463 chr2 166985967 T C 0.000577 Salmonella-induced pyroptosis SCN1A intron 22837397 rs514358 chr2 166987922 T C 0.000106 Salmonella-induced pyroptosis SCN1A intron 22837397 rs11681716 chr2 167017706 G A 7.13E-04 Tourette syndrome / / 22889924 rs10210369 chr2 167028525 T C 1.50E-05 Urinary metabolites / / 21572414 rs4667510 chr2 167028720 G A 9.64E-04 Type 2 diabetes / / 17463246 rs4667510 chr2 167028720 G A 1.20E-05 Urinary metabolites / / 21572414 rs16851722 chr2 167033344 G T 9.11E-04 Prostate cancer mortality / / 20978177 rs9917323 chr2 167046309 A G 5.30E-04 Type 2 diabetes / / 17463246 rs9917323 chr2 167046309 A G 2.20E-05 Urinary metabolites / / 21572414 rs4303728 chr2 167056428 G A 7.20E-04 Prostate cancer mortality SCN9A intron 20978177 rs16851785 chr2 167063771 G A 1.06E-04 Multiple complex diseases SCN9A intron 17554300 rs6725008 chr2 167076378 C T 8.58E-04 Type 2 diabetes SCN9A intron 17463246 rs6725008 chr2 167076378 C T 1.60E-05 Urinary metabolites SCN9A intron 21572414 rs7600169 chr2 167080979 A G 2.90E-06 Urinary metabolites SCN9A intron 21572414 rs6746030 chr2 167099158 A G 5.11E-04 Multiple complex diseases / / 17554300 rs4286289 chr2 167161711 C A 6.89E-04 Smoking initiation SCN9A intron 24665060 rs4438497 chr2 167177359 T C 7.00E-06 Dental caries SCN9A intron 23259602 rs6432908 chr2 167217864 G A 2.63E-05 Longevity SCN9A intron 20304771 rs17766561 chr2 167218821 G T 1.60E-05 Gaucher disease severity SCN9A intron 22388998 rs1540874 chr2 167220024 G A 2.64E-05 Longevity SCN9A intron 20304771 rs7590179 chr2 167220868 G T 2.62E-05 Longevity SCN9A intron 20304771 rs16852031 chr2 167223238 C A 4.34E-04 Multiple complex diseases SCN9A intron 17554300 rs6721003 chr2 167223512 A G 2.44E-05 Longevity SCN9A intron 20304771 rs4384809 chr2 167224518 G T 3.13E-05 Longevity SCN9A intron 20304771 rs17766807 chr2 167224695 T C 3.38E-05 Gaucher disease severity SCN9A intron 22388998 rs10930218 chr2 167228744 T G 2.40E-04 Iris characteristics SCN9A intron 21835309 rs10179640 chr2 167240987 A G 4.49E-05 Longevity / / 20304771 rs6710634 chr2 167243437 G A 4.64E-05 Longevity / / 20304771 rs1406275 chr2 167264978 G T 4.15E-04 Cognitive impairment induced by topiramate SCN7A intron 22091778 rs3791253 chr2 167286044 A G 7.99E-04 Type 2 diabetes SCN7A intron 17463246 rs7597971 chr2 167288172 G A 7.00E-04 Bipolar disorder SCN7A intron 24387768 rs11680374 chr2 167310925 A T 4.50E-05 Type 2 diabetes SCN7A intron 17463246 rs11680374 chr2 167310925 A T 9.37E-04 Multiple complex diseases SCN7A intron 17554300 rs11888208 chr2 167313451 T C 7.69E-04 Glycosylated haemoglobin levels SCN7A missense 17255346 rs11888208 chr2 167313451 T C 4.98E-06 Response to tocilizumab in rheumatoid arthritis SCN7A missense 22491018 rs13017982 chr2 167326652 T C 4.98E-06 Response to tocilizumab in rheumatoid arthritis SCN7A intron 22491018 rs11893208 chr2 167337735 A G 5.28E-04 Cognitive impairment induced by topiramate SCN7A intron 22091778 rs10930226 chr2 167346017 A T 8.12E-04 Lymphocyte counts / / 22286170 rs10497287 chr2 167372934 G A 9.20E-05 Type 2 diabetes / / 17463246 rs16852235 chr2 167377808 A T 5.19E-05 Multiple complex diseases / / 17554300 rs13015447 chr2 167377978 A C 7.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs4233808 chr2 167475482 G A 8.20E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs9287871 chr2 167506317 G A 9.56E-04 Type 2 diabetes / / 17463246 rs10497293 chr2 167515013 A C 4.44E-05 Information processing speed / / 21130836 rs2390416 chr2 167549402 C A 9.34E-05 Information processing speed / / 21130836 rs16852625 chr2 167607932 A G 2.69E-04 Type 2 diabetes / / 17463246 rs17774426 chr2 167620243 C G 2.40E-06 Urinary metabolites / / 21572414 rs7557536 chr2 167632838 G A 1.90E-04 Type 2 diabetes / / 17463246 rs7420023 chr2 167669615 C T 8.20E-04 Type 2 diabetes / / 17463246 rs12617566 chr2 167727209 G A 1.30E-04 Suicidal ideation / / 22030708 rs10930260 chr2 167842657 A C 3.22E-04 Type 2 diabetes XIRP2 intron 17463246 rs4493277 chr2 167844513 C T 5.96E-04 Multiple complex diseases XIRP2 intron 17554300 rs16852938 chr2 167926937 C A 4.14E-05 Type 2 diabetes XIRP2 intron 17463246 rs11888129 chr2 167949138 A C 1.79E-04 Insulin resistance XIRP2 intron 21901158 rs6432978 chr2 167989231 A T 5.71E-05 Type 2 diabetes XIRP2 intron 17463246 rs10497310 chr2 168009405 A G 2.22E-05 Parkinson's disease XIRP2 intron 21248740 rs6432983 chr2 168062531 G T 8.58E-04 Myocardial Infarction XIRP2 intron pha002873 rs7602119 chr2 168084857 C T 4.69E-04 Myocardial Infarction XIRP2 intron pha002873 rs10497323 chr2 168099738 T C 0.000008 Apolipoprotein B levels response after 40mg daily simvastatin treatment XIRP2 cds-synon 23100282 rs10497323 chr2 168099738 T C 0.000099 LDL cholesterol response after 40mg daily simvastatin treatment XIRP2 cds-synon 23100282 rs10497323 chr2 168099738 T C 5.06E-04 Myocardial Infarction XIRP2 cds-synon pha002873 rs3749004 chr2 168107491 A G 0.000038 LDL cholesterol response after 40mg daily simvastatin treatment XIRP2 missense 23100282 rs3749004 chr2 168107491 A G 0.000047 Apolipoprotein B levels response after 40mg daily simvastatin treatment XIRP2 missense 23100282 rs10497324 chr2 168159351 A G 2.00E-09 DNA methylation (parent-of-origin) / / 23725790 rs6726067 chr2 168180484 A G 8.51E-04 Multiple complex diseases / / 17554300 rs6756322 chr2 168286361 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6759323 chr2 168292597 C T 5.95E-04 Multiple complex diseases / / 17554300 rs16853644 chr2 168352843 G A 5.30E-04 Type 2 diabetes / / 17463246 rs1227126 chr2 168396016 T C 9.10E-04 Insulin resistance / / 21901158 rs16853726 chr2 168396030 A G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs16853735 chr2 168396526 A G 4.99E-04 Multiple complex diseases / / 17554300 rs16853738 chr2 168402076 C T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1227136 chr2 168403680 T C 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1897339 chr2 168408438 T G 3.50E-04 Alcohol dependence / / 20201924 rs1897339 chr2 168408438 T G 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1147147 chr2 168494937 T C 2.98E-05 Serum metabolites / / 19043545 rs16854016 chr2 168508395 A C 8.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1448837 chr2 168514672 A G 1.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs935638 chr2 168516699 G A 6.06E-06 Cardiac Troponin-T levels / / 23247143 rs7605048 chr2 168544776 A C 4.73E-04 Acute lung injury / / 22295056 rs13408808 chr2 168565693 A G 8.00E-06 Obesity-related traits / / 23251661 rs2044682 chr2 168574523 C A 2.34E-04 Major depressive disorder / / 22472876 rs4667970 chr2 168596313 G A 7.54E-04 Multiple complex diseases / / 17554300 rs11691258 chr2 168639838 A G 8.78E-06 Obesity-related traits / / 23251661 rs13410278 chr2 168641637 A G 1.78E-05 HIV-1 viral setpoint / / 21490045 rs1004368 chr2 168641970 A G 2.00E-06 Obesity-related traits / / 23251661 rs836692 chr2 168645406 C T 3.22E-04 Bipolar disorder / / 19259986 rs6740435 chr2 168648612 C T 9.12E-04 HIV-1 viral setpoint / / 17641165 rs6740435 chr2 168648612 C T 8.81E-06 HIV-1 viral setpoint / / 21490045 rs12992718 chr2 168649399 C A 2.91E-04 HIV-1 viral setpoint / / 17641165 rs12992718 chr2 168649399 C A 3.88E-06 HIV-1 viral setpoint / / 21490045 rs836664 chr2 168772522 A G 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7576460 chr2 168775061 C A 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs11894600 chr2 168784354 C A 1.69E-04 Cognitive decline / / 23732972 rs935381 chr2 168824134 C T 7.47E-05 Chronic obstructive pulmonary disease STK39 intron 19300482 rs9287889 chr2 168840454 C T 9.00E-04 Response to interferon beta in multiple sclerosis STK39 intron 18195134 rs16854534 chr2 168868236 C T 1.43E-04 Multiple complex diseases STK39 intron 17554300 rs16854674 chr2 168935864 A G 4.92E-04 Multiple complex diseases STK39 intron 17554300 rs6712819 chr2 168954776 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes STK39 intron 22628534 rs2278785 chr2 168996775 T C 8.40E-05 Blood pressure STK39 intron 19114657 rs3769402 chr2 168999344 A T 8.83E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs1517331 chr2 169002591 T C 5.36E-05 Hypertension (essential hypertension) STK39 intron 22184326 rs1850438 chr2 169002622 G A 5.13E-05 Blood Pressure STK39 intron pha003043 rs3769396 chr2 169002934 T C 4.35E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs3769395 chr2 169004125 C T 4.37E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs3769394 chr2 169005378 A C 1.10E-05 Blood pressure STK39 intron 19114657 rs3769392 chr2 169013674 T C 3.70E-05 Blood pressure STK39 intron 19114657 rs3754781 chr2 169015476 G A 1.70E-05 Blood pressure STK39 intron 19114657 rs3754777 chr2 169015914 C T 1.30E-05 Blood pressure STK39 intron 19114657 rs3754776 chr2 169016171 G C 2.24E-04 Multiple complex diseases STK39 intron 17554300 rs1400644 chr2 169022613 A G 9.10E-06 Blood pressure STK39 intron 19114657 rs1400645 chr2 169022981 G A 8.90E-06 Blood pressure STK39 intron 19114657 rs10497337 chr2 169027149 G A 6.30E-05 Blood pressure STK39 intron 19114657 rs11890527 chr2 169031488 T C 7.48E-04 Smoking initiation STK39 intron 24665060 rs6749447 chr2 169041386 T G 2.00E-07 Blood pressure STK39 intron 19114657 rs6734514 chr2 169041559 C T 8.40E-05 Blood pressure STK39 intron 19114657 rs4668044 chr2 169041770 A G 9.10E-05 Blood pressure STK39 intron 19114657 rs4667570 chr2 169047506 T C 8.81E-04 Multiple complex diseases STK39 intron 17554300 rs7605161 chr2 169059591 A C 6.74E-04 Multiple complex diseases STK39 intron 17554300 rs4438452 chr2 169071348 C T 9.97E-06 Lung cancer STK39 intron 19414679 rs11675180 chr2 169076787 T C 3.56E-04 Smoking initiation STK39 intron 24665060 rs2271741 chr2 169078534 A C 0.0000684 Migraine STK39 intron 22678113 rs2271741 chr2 169078534 A C 6.84E-05 Migraine STK39 intron 22683712 rs10176669 chr2 169084859 T C 1.74E-06 Lung cancer STK39 intron 19414679 rs2390669 chr2 169091942 A C 1.37E-09 Parkinson's disease STK39 intron 22438815 rs950535 chr2 169095854 G A 9.56E-05 Intelligence STK39 intron 21826061 rs16855187 chr2 169108932 A G 7.26E-04 Multiple complex diseases / / 17554300 rs2102808 chr2 169117025 G T 4.00E-10 Parkinson's disease / / 21292315 rs2102808 chr2 169117025 G T 9.97E-08 Parkinson's disease / / 22438815 rs2102808 chr2 169117025 G T 3.31E-11 Parkinson's disease / / 22451204 rs1400637 chr2 169136489 C A 4.92E-05 Parkinson's disease / / 21738487 rs9917256 chr2 169143035 G A 3.72E-06 Parkinson's disease / / 21738487 rs9917256 chr2 169143035 G A 3.00E-06 Parkinson's disease / / 22451204 rs4668059 chr2 169166282 T C 4.45E-05 Bipolar disorder / / 21926972 rs4668059 chr2 169166282 T C 0.00023 Bipolar disorder / / 23070075 rs16855271 chr2 169176370 G A 2.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs16855271 chr2 169176370 G A 9.00E-06 Schizophrenia / / pha002857 rs13421263 chr2 169182294 C T 7.49E-05 Erythrocyte counts / / pha003099 rs10186996 chr2 169185199 A G 4.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2246881 chr2 169209915 G A 4.96E-04 Smoking quantity / / 24665060 rs2044958 chr2 169220101 C A 6.78E-04 Type 2 diabetes / / 17463246 rs10497339 chr2 169226124 G C 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12475373 chr2 169252269 C A 5.07E-05 Hypertension / / 19609347 rs17806793 chr2 169299532 T C 3.08E-04 Multiple complex diseases / / 17554300 rs1124893 chr2 169300048 G A 3.82E-04 Multiple complex diseases / / 17554300 rs1124893 chr2 169300048 G A 6.40E-06 Urinary metabolites / / 21572414 rs1377504 chr2 169303242 A G 4.26E-04 Multiple complex diseases / / 17554300 rs16855373 chr2 169338808 G C 8.43E-04 Multiple complex diseases CERS6 intron 17554300 rs16855373 chr2 169338808 G C 1.89E-04 Major depressive disorder CERS6 intron 22472876 rs1901836 chr2 169361038 C T 5.03E-04 Multiple complex diseases CERS6 intron 17554300 rs7599295 chr2 169367516 T A 4.11E-04 Multiple complex diseases CERS6 intron 17554300 rs13393173 chr2 169389091 G A 4.00E-06 Response to TNF antagonist treatment CERS6 intron 18615156 rs11682385 chr2 169407091 G C 1.90E-08 Metabolite levels CERS6 intron 23281178 rs16855460 chr2 169407912 A G 5.74E-06 Left ventricular mass CERS6 intron 21212386 rs989106 chr2 169428016 T C 4.44E-04 Multiple complex diseases CERS6 intron 17554300 rs16855517 chr2 169428063 G A 3.20E-07 Left ventricular mass CERS6 intron 21212386 rs41345348 chr2 169433030 C A 8.80E-04 Multiple complex diseases CERS6 intron 17554300 rs1002666 chr2 169478018 T C 1.04E-04 Cognition,early reading ability CERS6 intron 17684495 rs4294968 chr2 169498212 T C 6.87E-05 ldl cholesterol CERS6 intron pha003076 rs1806328 chr2 169506879 G A 5.47E-04 Coronary heart disease CERS6 intron 21606135 rs6707065 chr2 169509692 C A,G 3.52E-04 Depression (quantitative trait) CERS6 intron 20800221 rs16855658 chr2 169511104 A G 3.98E-05 HDL cholesterol CERS6 intron pha003074 rs7565629 chr2 169516830 G T 3.40E-05 Sphingolipid levels CERS6 intron 19798445 rs10930335 chr2 169530546 G A 9.60E-05 Diabetic nephropathy CERS6 intron pha002866 rs7601307 chr2 169537411 C T 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CERS6 intron 20877124 rs1863144 chr2 169547991 A G 6.14E-04 Suicide attempts in bipolar disorder CERS6 intron 21423239 rs4668100 chr2 169587361 T C 0.0004132 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CERS6 intron 23233654 rs4668100 chr2 169587361 T C 4.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) CERS6 intron 23233662 rs6717260 chr2 169593638 G T 0.00000329 Common carotid artery thickness (average of near and far wall measures) CERS6 intron 23487405 rs4668102 chr2 169597668 C T 6.11E-04 Type 2 diabetes CERS6 intron 17463246 rs7584527 chr2 169602748 C G 1.13E-04 Type 2 diabetes CERS6 intron 17463246 rs2390732 chr2 169605967 G A 7.10E-13 Fasting blood glucose CERS6 intron 22885924 rs16855775 chr2 169613939 G A 1.90E-06 Multiple complex diseases CERS6 intron 17554300 rs829957 chr2 169658834 G T 6.06E-04 Type 2 diabetes NOSTRIN intron 17463246 rs17265949 chr2 169664458 A C 6.37E-04 Multiple complex diseases NOSTRIN intron 17554300 rs830031 chr2 169669031 T C 4.37E-05 Hemoglobin NOSTRIN intron pha003098 rs482435 chr2 169676045 G A 0.0000173 LDL cholesterol particle diameter NOSTRIN intron 23263444 rs10198693 chr2 169683061 G A 2.61E-05 Hemoglobin NOSTRIN intron pha003098 rs481067 chr2 169692369 G T 4.51E-04 Response to taxane treatment (placlitaxel) NOSTRIN intron 23006423 rs532779 chr2 169703751 T A 3.20E-07 Fasting glucose-related traits NOSTRIN intron 20152958 rs16856065 chr2 169719329 C T 3.50E-04 Multiple complex diseases NOSTRIN intron 17554300 rs12993143 chr2 169719500 T G 8.71E-05 Schizophrenia(age at onset) NOSTRIN intron 21688384 rs3931 chr2 169721381 A G 3.95E-04 Alzheimer's disease (late onset) NOSTRIN cds-synon 21379329 rs853770 chr2 169749841 T C 3.45E-05 Schizophrenia / / 19571809 rs13431652 chr2 169753415 T C 2.58E-12 Metabolite levels / / 22286219 rs13431652 chr2 169753415 T C 1.82E-07 Glycemic traits (pregnancy) / / 23903356 rs13431652 chr2 169753415 T C 6.99E-08 Glycemic traits (pregnancy) / / 23903356 rs12475700 chr2 169753676 G A 6.63E-15 Metabolite levels / / 22286219 rs12623237 chr2 169756058 G A 4.51E-04 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs1402837 chr2 169757354 C T 5.00E-10 Glycated Hemoglobin levels G6PC2 nearGene-5 19096518 rs1402837 chr2 169757354 C T 4.19E-08 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs1402837 chr2 169757354 C T 9.28E-07 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs573225 chr2 169757541 G A 6.50E-06 Fasting plasma glucose G6PC2 nearGene-5 19060907 rs573225 chr2 169757541 G A 1.34E-15 Metabolite levels G6PC2 nearGene-5 22286219 rs573225 chr2 169757541 G A 1.09E-07 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs573225 chr2 169757541 G A 1.31E-06 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs560887 chr2 169763148 T C 4.00E-23 Fasting plasma glucose G6PC2 intron 18451265 rs560887 chr2 169763148 T C 1.00E-57 Fasting plasma glucose G6PC2 intron 19060907 rs560887 chr2 169763148 T C 6.00E-10 Metabolic traits G6PC2 intron 19060910 rs560887 chr2 169763148 T C 2.00E-66 Fasting glucose-related traits G6PC2 intron 20081858 rs560887 chr2 169763148 T C 9.00E-218 Fasting insulin-related traits G6PC2 intron 20081858 rs560887 chr2 169763148 T C 1.30E-15 Fasting glucose-related traits G6PC2 intron 20152958 rs560887 chr2 169763148 T C 2.00E-17 Metabolite levels G6PC2 intron 22286219 rs560887 chr2 169763148 T C 5.00E-26 Metabolic syndrome G6PC2 intron 22399527 rs560887 chr2 169763148 T C 2.00E-06 Fasting plasma glucose G6PC2 intron 22508271 rs560887 chr2 169763148 T C 2.00E-113 Fasting glucose-related traits (interaction with BMI) G6PC2 intron 22581228 rs560887 chr2 169763148 T C 1.04E-17 Glycated hemoglobin levels G6PC2 intron 22885924 rs560887 chr2 169763148 T C 1.40E-178 Fasting blood glucose G6PC2 intron 22885924 rs560887 chr2 169763148 T C 4.00E-15 Metabolite levels (atherosclerosis) G6PC2 intron 22916037 rs560887 chr2 169763148 T C 2.00E-16 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 2.56E-13 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 7.61E-14 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 1.00E-17 Glycated hemoglobin levels G6PC2 intron 24405752 rs560887 chr2 169763148 T C 5.69E-10 Glucose levels G6PC2 intron pha002899 rs10166439 chr2 169763560 C T 6.51E-05 Progressive supranuclear palsy G6PC2 intron 21685912 rs146779637 chr2 169764368 C T 0.0003 Breast cancer (ER positive) G6PC2 STOP-GAIN 23555315 rs563694 chr2 169774071 C A 4.00E-07 Fasting plasma glucose / / 18521185 rs563694 chr2 169774071 C A 1.40E-06 Fasting plasma glucose / / 19060907 rs563694 chr2 169774071 C A 1.90E-15 Fasting glucose-related traits / / 20152958 rs563694 chr2 169774071 C A 3.35E-13 Metabolite levels / / 22286219 rs563694 chr2 169774071 C A 2.22E-09 Glycemic traits (pregnancy) / / 23903356 rs563694 chr2 169774071 C A 8.25E-10 Glycemic traits (pregnancy) / / 23903356 rs563694 chr2 169774071 C A 1.17E-07 Glucose levels / / pha002899 rs537183 chr2 169774646 C T 5.32E-13 Metabolite levels / / 22286219 rs537183 chr2 169774646 C T 2.14E-04 Glycemic traits (pregnancy) / / 23903356 rs537183 chr2 169774646 C T 2.27E-05 Glycemic traits (pregnancy) / / 23903356 rs502570 chr2 169774959 A G 5.35E-13 Metabolite levels / / 22286219 rs502570 chr2 169774959 A G 1.33E-04 Glycemic traits (pregnancy) / / 23903356 rs502570 chr2 169774959 A G 3.45E-04 Glycemic traits (pregnancy) / / 23903356 rs580670 chr2 169776121 T A 2.97E-12 Metabolite levels / / 22286219 rs580613 chr2 169776140 T A 4.72E-12 Metabolite levels / / 22286219 rs578763 chr2 169776360 G T 7.01E-13 Metabolite levels / / 22286219 rs475612 chr2 169776746 T C 1.04E-12 Metabolite levels / / 22286219 rs475612 chr2 169776746 T C 2.63E-04 Glycemic traits (pregnancy) / / 23903356 rs475612 chr2 169776746 T C 6.47E-04 Glycemic traits (pregnancy) / / 23903356 rs518598 chr2 169776914 T C 7.20E-12 Metabolite levels / / 22286219 rs557462 chr2 169777595 C T 5.02E-13 Metabolite levels / / 22286219 rs557462 chr2 169777595 C T 4.69E-05 Glycemic traits (pregnancy) / / 23903356 rs557462 chr2 169777595 C T 5.01E-06 Glycemic traits (pregnancy) / / 23903356 rs473351 chr2 169779896 T A,C,G 5.58E-12 Metabolite levels ABCB11 UTR-3 22286219 rs575671 chr2 169780818 A G 3.46E-12 Metabolite levels ABCB11 intron 22286219 rs486981 chr2 169782149 A G 2.86E-12 Metabolite levels ABCB11 intron 22286219 rs485094 chr2 169782353 A C 2.50E-12 Metabolite levels ABCB11 intron 22286219 rs484066 chr2 169782481 A T 5.90E-04 Coronary heart disease ABCB11 intron 21966275 rs483234 chr2 169782574 T C 3.70E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs483234 chr2 169782574 T C 6.19E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs569829 chr2 169782869 T C 2.09E-12 Metabolite levels ABCB11 intron 22286219 rs569805 chr2 169782880 A T 9.00E-08 Metabolic syndrome (bivariate traits) ABCB11 intron 21386085 rs569805 chr2 169782880 A T 2.09E-12 Metabolite levels ABCB11 intron 22286219 rs579060 chr2 169783039 G T 2.40E-10 Metabolic syndrome phenotype ABCB11 intron 22022282 rs579060 chr2 169783039 G T 4.10E-06 Metabolic syndrome phenotype ABCB11 intron 22022282 rs579060 chr2 169783039 G T 2.47E-12 Metabolite levels ABCB11 intron 22286219 rs579060 chr2 169783039 G T 4.22E-05 Amyotrophic lateral sclerosis (sporadic) ABCB11 intron 24529757 rs566879 chr2 169783209 A G 2.07E-12 Metabolite levels ABCB11 intron 22286219 rs16856247 chr2 169784413 C T 2.00E-15 Metabolite levels ABCB11 intron 21909109 rs508506 chr2 169784955 A C 1.10E-14 Fasting glucose-related traits ABCB11 intron 20152958 rs508506 chr2 169784955 A C 1.51E-12 Metabolite levels ABCB11 intron 22286219 rs508506 chr2 169784955 A C 1.47E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs508506 chr2 169784955 A C 6.36E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs494874 chr2 169789306 T C 1.18E-12 Metabolite levels ABCB11 intron 22286219 rs494874 chr2 169789306 T C 1.29E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs494874 chr2 169789306 T C 4.07E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs552976 chr2 169791438 A G 3.30E-16 Fasting glucose-related traits ABCB11 intron 20152958 rs552976 chr2 169791438 A G 8.00E-18 Glycated Hemoglobin levels ABCB11 intron 20858683 rs552976 chr2 169791438 A G 1.61E-12 Metabolite levels ABCB11 intron 22286219 rs552976 chr2 169791438 A G 8.16E-18 Glycated hemoglobin levels ABCB11 intron 22885924 rs552976 chr2 169791438 A G 3.78E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs3755157 chr2 169792171 C T 3.00E-11 Glycated hemoglobin levels ABCB11 intron 24647736 rs472614 chr2 169792421 A G 9.10E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs565412 chr2 169794283 G A 3.00E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs567074 chr2 169794431 C T 8.20E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2544367 chr2 169796288 T C 1.30E-04 HDL particle features ABCB11 intron 21283740 rs2685805 chr2 169797060 A G 4.00E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2685812 chr2 169798171 A G 1.20E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs2685813 chr2 169798439 T C 8.00E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2685814 chr2 169798619 T C 6.86E-05 Glucose levels ABCB11 intron pha002899 rs11568373 chr2 169801403 T C 2.85E-10 Cholesterol,total ABCB11 cds-synon 23063622 rs11568373 chr2 169801403 T C 3.41E-09 LDL cholesterol ABCB11 cds-synon 23063622 rs853789 chr2 169801488 A G 4.00E-16 Fasting glucose-related traits ABCB11 intron 20152958 rs853789 chr2 169801488 A G 5.06E-12 Metabolite levels ABCB11 intron 22286219 rs853789 chr2 169801488 A G 1.95E-66 Fasting blood glucose ABCB11 intron 22885924 rs853789 chr2 169801488 A G 2.42E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853789 chr2 169801488 A G 5.35E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853787 chr2 169802252 G T 1.50E-10 Fasting plasma glucose ABCB11 intron 19060907 rs853787 chr2 169802252 G T 1.65E-13 Metabolite levels ABCB11 intron 22286219 rs853787 chr2 169802252 G T 4.30E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853784 chr2 169803674 C T 1.80E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853780 chr2 169807482 C G 1.70E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs853779 chr2 169809672 G T 3.30E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853778 chr2 169811224 T C 4.70E-13 Fasting plasma glucose ABCB11 intron 19060907 rs853778 chr2 169811224 T C 3.50E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853778 chr2 169811224 T C 1.45E-05 Glucose levels ABCB11 intron pha002899 rs853777 chr2 169812217 T C 5.94E-12 Metabolite levels ABCB11 intron 22286219 rs853776 chr2 169813353 C T 3.80E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853774 chr2 169813396 G A 1.92E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853774 chr2 169813396 G A 2.89E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853773 chr2 169814347 A G 1.20E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853772 chr2 169814655 G T 1.40E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs16856314 chr2 169823092 G A 0.00000088 Cholesterol,total ABCB11 intron 23063622 rs16856314 chr2 169823092 G A 3.78E-12 LDL cholesterol ABCB11 intron 23063622 rs2287623 chr2 169830155 G A 4.00E-12 Cholesterol,total ABCB11 intron 24097068 rs3770596 chr2 169840142 A T 3.67E-05 Cognitive test performance ABCB11 intron 20125193 rs16856332 chr2 169840574 T G 2.00E-09 Liver enzyme levels (alkaline phosphatase) ABCB11 intron 22001757 rs11568377 chr2 169853220 G A 4.00E-06 Systolic blood pressure in sickle cell anemia ABCB11 cds-synon 24058526 rs10211329 chr2 169858910 A C 1.17E-04 Multiple complex diseases ABCB11 intron 17554300 rs10200158 chr2 169860718 A G 7.87E-05 Multiple complex diseases ABCB11 intron 17554300 rs6709971 chr2 169867573 T C 1.74E-09 LDL cholesterol ABCB11 intron 23063622 rs6709971 chr2 169867573 T C 4.23E-09 Cholesterol,total ABCB11 intron 23063622 rs4148777 chr2 169869901 A G 9.07E-05 Chronic obstructive pulmonary disease ABCB11 cds-synon 19300482 rs3770601 chr2 169872644 C T 0.00000189 Fasting blood glucose ABCB11 intron 22885924 rs4148765 chr2 169889579 C T 5.79E-04 Type 2 diabetes ABCB11 nearGene-5 17463246 rs12620980 chr2 169931343 A G 3.04E-04 Smoking initiation DHRS9 intron 24665060 rs16856444 chr2 169953341 C T 9.03E-05 Multiple complex diseases / / 17554300 rs10515932 chr2 169954185 A G 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6750251 chr2 169967174 C G 7.71E-04 Multiple complex diseases / / 17554300 rs6746604 chr2 169996556 G C 1.91E-05 Serum metabolites LRP2 intron 19043545 rs990627 chr2 169996654 C T 1.34E-05 Serum metabolites LRP2 intron 19043545 rs990626 chr2 169997051 G A 1.65E-05 Serum metabolites LRP2 cds-synon 19043545 rs2268380 chr2 169997399 G A 1.36E-05 Serum metabolites LRP2 intron 19043545 rs6733122 chr2 169999715 A G 9.55E-05 Serum metabolites LRP2 intron 19043545 rs2284681 chr2 170000522 C A 7.97E-05 Serum metabolites LRP2 intron 19043545 rs2075252 chr2 170010985 T C 1 Drug response to Cisplatin LRP2 missense 17457342 rs16856558 chr2 170046653 G A 2.61E-04 Type 2 diabetes LRP2 intron 17463246 rs10490131 chr2 170051167 A G 2.94E-04 Tuberculosis LRP2 intron 22239941 rs7578722 chr2 170052876 T C 7.16E-06 Interstitial lung disease LRP2 intron 23583980 rs2228171 chr2 170053505 C A,G,T 7.42E-06 Interstitial lung disease LRP2 missense 23583980 rs2228171 chr2 170053505 C A,G,T 7.42E-06 Interstitial lung disease LRP2 missense 23583980 rs2302696 chr2 170053580 C T 1.02E-05 Interstitial lung disease LRP2 intron 23583980 rs16856594 chr2 170054212 G T 0.000000538 LDL cholesterol LRP2 intron 23063622 rs16856594 chr2 170054212 G T 0.00000129 HDL cholesterol LRP2 intron 23063622 rs11898106 chr2 170055432 A G 0.00000211 LDL cholesterol LRP2 intron 23063622 rs11687903 chr2 170057722 T G 3.61E-05 Interstitial lung disease LRP2 intron 23583980 rs2239600 chr2 170058852 C T 3.86E-05 Serum metabolites LRP2 intron 19043545 rs2284675 chr2 170058959 G A 1.75E-05 Interstitial lung disease LRP2 intron 23583980 rs6709670 chr2 170059537 A G 7.85E-05 Self-reported allergy LRP2 intron 23817569 rs2052297 chr2 170071166 C T 6.95E-04 Type 2 diabetes LRP2 intron 17463246 rs2193193 chr2 170076081 G A 8.71E-05 Coronary heart disease LRP2 intron 21606135 rs2268370 chr2 170077563 A C 3.20E-04 Coronary heart disease LRP2 intron 21606135 rs143413559 chr2 170090014 T C 0.000056 Breast cancer LRP2 missense 23555315 rs2239594 chr2 170090331 C T 3.18E-05 Coronary heart disease LRP2 intron 21606135 rs10490130 chr2 170099111 A C 0.0000028 Glomerular filtration rate LRP2 intron 22962313 rs10490130 chr2 170099111 A C 9.32E-05 Cholesterol LRP2 intron pha003073 rs830957 chr2 170112098 C T 6.35E-05 Coronary heart disease LRP2 intron 21606135 rs830959 chr2 170113098 C T 7.76E-05 Coronary heart disease LRP2 intron 21606135 rs830960 chr2 170113396 C T 8.28E-05 Coronary heart disease LRP2 intron 21606135 rs2241190 chr2 170115588 T C 7.70E-04 Asthma LRP2 cds-synon 20698975 rs830994 chr2 170129528 G A 7.64E-04 Response to taxane treatment (placlitaxel) LRP2 cds-synon 23006423 rs830998 chr2 170133086 A C 9.00E-06 Anorexia nervosa LRP2 intron 21079607 rs831002 chr2 170133752 T C 3.01E-04 Coronary heart disease LRP2 intron 21606135 rs831004 chr2 170135742 C T 3.21E-06 Coronary heart disease LRP2 intron 21606135 rs831007 chr2 170138506 T C 4.58E-05 Coronary heart disease LRP2 intron 21606135 rs831008 chr2 170138896 C T 3.56E-04 Coronary heart disease LRP2 intron 21606135 rs111704488 chr2 170139387 A C 0.00022 Prostate cancer LRP2 missense 23555315 rs111704488 chr2 170139387 A C 0.00065 Prostate cancer (non-advanced prostate cancer) LRP2 missense 23555315 rs831017 chr2 170145426 G A 3.37E-04 Alzheimer's disease (late onset) LRP2 intron 21379329 rs831022 chr2 170149613 C T 2.99E-04 Alzheimer's disease (late onset) LRP2 intron 21379329 rs11887007 chr2 170149854 C A 2.30E-05 Urinary metabolites LRP2 intron 21572414 rs861239 chr2 170175109 T C 4.87E-05 Nephrolithiasis LRP2 intron 22396660 rs2229263 chr2 170175334 T C 4.51E-05 Nephrolithiasis LRP2 missense 22396660 rs10930352 chr2 170196990 T C 4.59E-05 Nephrolithiasis LRP2 intron 22396660 rs2673172 chr2 170204800 G T 8.10E-05 Renal function-related traits (urea) LRP2 intron 22797727 rs2544390 chr2 170204846 C T 3.74E-08 Blood cell counts and other traits LRP2 intron 20139978 rs2544390 chr2 170204846 C T 4.00E-08 Blood cell counts and other traits LRP2 intron 20139978 rs3770641 chr2 170205126 A T 4.11E-05 Personality dimensions LRP2 intron 22628180 rs6730118 chr2 170205350 A G 4.09E-05 Personality dimensions LRP2 intron 22628180 rs1990842 chr2 170208035 A C 3.29E-05 Personality dimensions LRP2 intron 22628180 rs10199676 chr2 170208975 G T 0.00086 Endometrial cancer LRP2 intron 22426144 rs2389557 chr2 170211377 G A 2.00E-05 Urinary metabolites LRP2 intron 21572414 rs830948 chr2 170214764 G A 2.44E-08 Cholesterol,total LRP2 intron 23063622 rs830948 chr2 170214764 G A 9.06E-11 LDL cholesterol LRP2 intron 23063622 rs2544371 chr2 170227070 A G 8.76E-05 Cognitive test performance / / 20125193 rs4233826 chr2 170233924 A G 1.96E-10 Multiple complex diseases / / 17554300 rs1399634 chr2 170244607 T A 4.20E-06 Diabetic retinopathy / / 23562823 rs4233828 chr2 170245307 A G 8.34E-04 Tourette syndrome / / 22889924 rs4668142 chr2 170264277 G T 3.60E-04 Diabetic retinopathy / / 23562823 rs4668142 chr2 170264277 G T 4.80E-06 Diabetic retinopathy / / 23562823 rs12465476 chr2 170285339 G T 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs16823058 chr2 170317904 T C 3.01E-04 Multiple complex diseases / / 17554300 rs16856972 chr2 170336797 G A 3.68E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16856977 chr2 170337823 G C 2.98E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16823068 chr2 170338986 C A 2.99E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16856981 chr2 170341710 A G 1.92E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs12465387 chr2 170350067 G A 3.50E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs12619026 chr2 170354790 A G 1.69E-06 Systemic lupus erythematosus and Systemic sclerosis BBS5 intron 23740937 rs2293058 chr2 170370976 T C 1.79E-04 Suicide attempts in bipolar disorder KBTBD10 intron 21423239 rs13417370 chr2 170373591 G A 0.0007219 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KBTBD10 intron 23233654 rs13417370 chr2 170373591 G A 7.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) KBTBD10 intron 23233662 rs7349274 chr2 170386294 G A 3.44E-05 Alcohol consumption FASTKD1 UTR-3 23953852 rs6708481 chr2 170460536 A C 0.00029 Breast cancer PPIG UTR-5 23555315 rs12470910 chr2 170594091 A G 6.40E-06 Urinary metabolites KLHL23 intron 21572414 rs6725295 chr2 170599690 A C 8.29E-08 Lymphocyte counts KLHL23 intron 22286170 rs2114646 chr2 170624221 C A,T 6.00E-06 Obesity-related traits / / 23251661 rs12692925 chr2 170631928 G A 5.13E-05 Type 2 diabetes and other traits / / 19734900 rs10930375 chr2 170632807 C T 2.35E-04 Multiple complex diseases / / 17554300 rs11894266 chr2 170636642 C T 6.85E-07 Type 2 diabetes and other traits / / 19734900 rs11894266 chr2 170636642 C T 6.85E-07 Alzheimer's disease (late onset) / / 21460841 rs10930379 chr2 170644549 G A 1.56E-04 Multiple complex diseases / / 17554300 rs10930381 chr2 170652057 A G 4.81E-04 Multiple complex diseases / / 17554300 rs16823091 chr2 170670059 G A 2.74E-04 Multiple complex diseases METTL5 intron 17554300 rs3769769 chr2 170675765 C T 9.80E-06 Alcoholism (heaviness of drinking) METTL5 intron 21529783 rs17554448 chr2 170754854 A G 8.56E-05 Pulmonary function in asthmatics UBR3 intron 23541324 rs1031773 chr2 170771022 G A 3.80E-05 Parent of origin effect on language impairment (paternal) UBR3 intron 24571439 rs10189398 chr2 170882181 T C 5.10E-05 Acute lymphoblastic leukemia (childhood) UBR3 intron 19684603 rs10204475 chr2 170932522 T G 6.52E-04 Amyotrophic Lateral Sclerosis UBR3 intron 17362836 rs1381471 chr2 170954406 T C 3.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10497352 chr2 170955771 G A 3.60E-05 Volumetric brain MRI / / 17903297 rs11883608 chr2 170961512 A G 4.70E-04 Type 2 diabetes / / 17463246 rs7576155 chr2 170982191 G C 2.25E-04 Obesity (extreme) / / 21935397 rs6711421 chr2 170988776 T C 2.24E-04 Obesity (extreme) / / 21935397 rs4667620 chr2 171000799 C T 2.89E-04 Smoking cessation / / 24665060 rs10930407 chr2 171026184 C T 6.01E-04 Body mass index / / 21701565 rs7580243 chr2 171030735 A C,T 9.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7561753 chr2 171033147 C G 1.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12692944 chr2 171033265 C G 9.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7599599 chr2 171036288 A G 1.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6433172 chr2 171037018 T C 9.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6755273 chr2 171037286 A G 9.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs7591238 chr2 171037558 T C 1.22E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11893658 chr2 171038152 A G 9.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2052633 chr2 171038286 A C 1.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2032965 chr2 171040180 G T 1.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs533162322 chr2 171040180 G GT 1.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11676415 chr2 171040453 C T 1.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11687537 chr2 171040506 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2355342 chr2 171041500 G A 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6705705 chr2 171042445 G C 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs1593240 chr2 171043087 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6742388 chr2 171044510 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs12465008 chr2 171045237 G A 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs4668218 chr2 171048425 C T 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2161915 chr2 171049486 T C 2.16E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2113653 chr2 171049550 A C 2.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6738892 chr2 171060729 C T 8.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6739145 chr2 171060783 G A 1.90E-05 Urinary metabolites MYO3B intron 21572414 rs2355343 chr2 171064562 G A 6.09E-05 Height MYO3B intron pha003011 rs12476819 chr2 171066245 C T 8.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6433178 chr2 171067956 C A 8.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs1820292 chr2 171070175 G A 1.20E-05 Urinary metabolites MYO3B intron 21572414 rs4667626 chr2 171071369 C T 1.50E-05 Urinary metabolites MYO3B intron 21572414 rs6730459 chr2 171078637 G A 0.0000313 Migraine MYO3B intron 22678113 rs6730459 chr2 171078637 G A 3.13E-05 Migraine MYO3B intron 22683712 rs6721083 chr2 171081652 G C 7.43E-04 Coronary heart disease MYO3B intron 21606135 rs1401283 chr2 171135046 A G 6.26E-05 Hypertension (essential hypertension) MYO3B intron 22184326 rs1401286 chr2 171168630 A C 7.75E-05 Body Mass Index MYO3B intron pha003014 rs10930419 chr2 171168682 G A 6.07E-04 Insulin resistance MYO3B intron 21901158 rs11681687 chr2 171172273 A C 6.06E-04 Type 2 diabetes MYO3B intron 17463246 rs12613772 chr2 171172604 T C 6.08E-04 Type 2 diabetes MYO3B intron 17463246 rs1568269 chr2 171173261 T G 6.60E-04 Type 2 diabetes MYO3B intron 17463246 rs11696033 chr2 171173948 C T 4.85E-04 Type 2 diabetes MYO3B intron 17463246 rs9677051 chr2 171174236 C G 5.54E-04 Type 2 diabetes MYO3B intron 17463246 rs2113650 chr2 171176392 T C 3.73E-04 Multiple complex diseases MYO3B intron 17554300 rs2113650 chr2 171176392 T C 9.80E-05 Orofacial clefts MYO3B intron 22419666 rs2176593 chr2 171182976 A T 4.36E-04 Type 2 diabetes MYO3B intron 17463246 rs2176592 chr2 171183010 T C 1.45E-04 Type 2 diabetes MYO3B intron 17463246 rs10930420 chr2 171183104 A G 1.82E-04 Type 2 diabetes MYO3B intron 17463246 rs10930422 chr2 171208242 A C,G,T 8.12E-05 Type 2 diabetes MYO3B intron 17463246 rs876751 chr2 171221115 C A 9.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MYO3B intron 21844884 rs6761096 chr2 171223111 T C 0.00008973 Sarcoidosis MYO3B intron 22952805 rs17425473 chr2 171223154 A C 1.00E-05 Urinary metabolites MYO3B intron 21572414 rs12471833 chr2 171226982 C A 6.96E-06 Carotenoid and tocopherol levels MYO3B intron 19185284 rs17497539 chr2 171236060 G C 2.20E-05 Urinary metabolites MYO3B intron 21572414 rs17579512 chr2 171240711 T A 5.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MYO3B intron 20031582 rs7561268 chr2 171256597 A C 2.00E-04 Information processing speed MYO3B intron 21130836 rs7561268 chr2 171256597 A C 2.00E-06 Obesity-related traits MYO3B intron 23251661 rs12477031 chr2 171287677 T C 7.14E-05 Serum metabolites MYO3B intron 19043545 rs17426142 chr2 171287710 A G 7.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO3B intron 20877124 rs17426191 chr2 171292972 C T 0.000484 Salmonella-induced pyroptosis MYO3B intron 22837397 rs2118674 chr2 171318894 A T 2.43E-04 Multiple complex diseases MYO3B intron 17554300 rs2118674 chr2 171318894 A T 4.00E-07 Palmitoleic acid (16:1n-7) plasma levels MYO3B intron 23362303 rs934861 chr2 171340688 G A 3.68E-05 Hemoglobin MYO3B intron pha003096 rs7583952 chr2 171343360 A C 9.59E-05 Parkinson's disease MYO3B intron 17052657 rs4668261 chr2 171344289 T C 2.00E-04 Information processing speed MYO3B intron 21130836 rs10185178 chr2 171356274 G A 1.03E-07 Multiple complex diseases MYO3B missense 17554300 rs10176755 chr2 171365889 A G 7.00E-06 Visceral fat MYO3B intron 22589738 rs10189774 chr2 171375497 A G 8.15E-04 Myopia (pathological) MYO3B intron 21095009 rs12466567 chr2 171393087 C T 0.0000133 Colorectal adenoma (excluding hyperplasic) MYO3B intron 23677573 rs12466567 chr2 171393087 C T 0.0000133 Colorectal adenoma (including hyperplasic) MYO3B intron 23677573 rs6730101 chr2 171409269 G A 5.37E-05 Height MYO3B intron pha003010 rs4482446 chr2 171409832 C T 2.30E-05 Urinary metabolites MYO3B intron 21572414 rs6752681 chr2 171412997 A G 8.20E-06 Urinary metabolites MYO3B intron 21572414 rs7578629 chr2 171414261 C A 7.60E-05 Height MYO3B intron pha003010 rs2192754 chr2 171418907 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MYO3B intron 22628534 rs16858767 chr2 171429351 C T 3.80E-04 Lung function (forced expiratory volume in 1 second) MYO3B intron 17255346 rs13425835 chr2 171450161 A C 6.45E-06 Obesity-related traits MYO3B intron 23251661 rs6749331 chr2 171461132 T C 3.00E-06 Obesity-related traits MYO3B intron 23251661 rs6433223 chr2 171461637 A G 1.90E-05 Urinary metabolites MYO3B intron 21572414 rs2160231 chr2 171478402 C A 3.63E-04 Schizophrenia MYO3B intron 19197363 rs1861288 chr2 171499887 T C 3.93E-04 Obesity (extreme) MYO3B intron 21935397 rs10803851 chr2 171500167 C T 9.11E-04 Obesity (extreme) MYO3B intron 21935397 rs10192049 chr2 171534221 C T 4.95E-06 Vitiligo / / 22951725 rs2080401 chr2 171540823 A C 7.00E-06 Coronary heart disease / / 21347282 rs2080401 chr2 171540823 A C 6.85E-06 Vitiligo / / 22951725 rs7574074 chr2 171548493 C T 1.48E-05 Vitiligo / / 22951725 rs6704610 chr2 171559628 T G 6.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs11680066 chr2 171566925 A G 4.08E-04 Multiple complex diseases / / 17554300 rs11895153 chr2 171575671 A G 5.81E-04 Smoking initiation / / 24665060 rs7608898 chr2 171598217 C T 3.07E-04 Smoking initiation / / 24665060 rs9973711 chr2 171635393 C T 4.67E-06 Insulin-related traits / / 22791750 rs1362487 chr2 171640942 T C 2.92E-04 Smoking initiation LOC285141 intron 24665060 rs3764916 chr2 171649402 C T 2.92E-04 Sudden cardiac arrest LOC285141 cds-synon 21658281 rs6736129 chr2 171662339 G A 1.37E-04 Sudden cardiac arrest / / 21658281 rs10191129 chr2 171688593 C G,T 6.19E-05 Sudden cardiac arrest GAD1 intron 21658281 rs3791853 chr2 171695070 A G 2.93E-04 Alcohol dependence GAD1 intron 21314694 rs4668338 chr2 171733225 G C 3.00E-06 Uric acid levels / / 18759275 rs2676145 chr2 171790387 A G 2.36E-05 Cognitive performance GORASP2 intron 19734545 rs1035839 chr2 171809485 C T 7.78E-04 Tourette syndrome GORASP2 intron 22889924 rs4668356 chr2 171822466 C G,T 1.00E-06 Cognitive performance GORASP2 cds-synon 19734545 rs4668356 chr2 171822466 C G,T 7.25E-04 Tourette syndrome GORASP2 cds-synon 22889924 rs2723253 chr2 171833910 C T 2.12E-05 Cognitive performance / / 19734545 rs2723253 chr2 171833910 C T 8.72E-04 Tourette syndrome / / 22889924 rs1045327 chr2 171849612 T C 8.36E-04 Multiple complex diseases TLK1 UTR-3 17554300 rs2883940 chr2 171853359 G A 8.13E-05 Cognitive performance TLK1 intron 19734545 rs2883940 chr2 171853359 G A 3.91E-04 Tourette syndrome TLK1 intron 22889924 rs1991370 chr2 171916120 C G 5.83E-04 Multiple complex diseases TLK1 intron 17554300 rs16823191 chr2 171930818 A G 6.49E-04 Tourette syndrome TLK1 intron 22889924 rs6761759 chr2 171944915 A G 5.83E-04 Multiple complex diseases TLK1 intron 17554300 rs10183486 chr2 171990971 C T 2.00E-14 Menopause (age at onset) TLK1 intron 22267201 rs7579424 chr2 171995065 T C 7.65E-04 Smoking initiation TLK1 intron 24665060 rs16859177 chr2 172006576 C T 4.04E-04 Alcohol dependence TLK1 intron 21314694 rs16859177 chr2 172006576 C T 1.88E-04 Tourette syndrome TLK1 intron 22889924 rs719548 chr2 172015052 G A 6.41E-04 Multiple complex diseases TLK1 intron 17554300 rs7572477 chr2 172026956 C A 1.00E-04 Cognitive impairment induced by topiramate TLK1 intron 22091778 rs218311 chr2 172057864 T C 5.72E-05 Cortisol secretion,in saliva TLK1 intron 21316860 rs218311 chr2 172057864 T C 8.98E-05 Rheumatoid arthritis TLK1 intron 21452313 rs6713640 chr2 172065645 C T 9.67E-04 Type 2 diabetes TLK1 intron 17463246 rs6713640 chr2 172065645 C T 8.70E-06 Urinary metabolites TLK1 intron 21572414 rs7568175 chr2 172066068 G T 8.94E-04 Type 2 diabetes TLK1 intron 17463246 rs1035250 chr2 172069140 T C 8.59E-05 Alzheimer's disease TLK1 intron 22832961 rs4668374 chr2 172069491 G T 4.80E-06 Urinary metabolites TLK1 intron 21572414 rs4668374 chr2 172069491 G T 3.80E-04 Sudden cardiac arrest TLK1 intron 21658281 rs4668374 chr2 172069491 G T 6.19E-04 Insulin resistance TLK1 intron 21901158 rs6724085 chr2 172073186 C T 5.10E-06 Urinary metabolites TLK1 intron 21572414 rs11674962 chr2 172077806 A C 8.53E-05 Alzheimer's disease TLK1 intron 22832961 rs10490605 chr2 172118473 C T 1.80E-05 Urinary metabolites / / 21572414 rs4667682 chr2 172127920 C T 5.00E-06 Hippocampal atrophy / / 22745009 rs4667682 chr2 172127920 C T 7.75E-05 Lipoproteins / / pha003079 rs17218608 chr2 172142609 T C 2.20E-05 Urinary metabolites / / 21572414 rs7564482 chr2 172160433 C T 5.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7564482 chr2 172160433 C T 2.84E-05 Waist-Hip Ratio / / pha003013 rs7564482 chr2 172160433 C T 2.33E-05 Waist Circumference / / pha003025 rs7564482 chr2 172160433 C T 3.30E-05 Waist-Hip Ratio / / pha003028 rs10460358 chr2 172295794 A G 8.18E-05 Alzheimer's disease DCAF17 intron 17998437 rs10515933 chr2 172325162 C T 9.46E-04 Bipolar disorder DCAF17 intron 19259986 rs12692966 chr2 172395221 C T 6.95E-06 Serum metabolites CYBRD1 intron 19043545 rs1399959 chr2 172432306 C T 1.99E-05 Suicidal ideation / / 20877300 rs1473995 chr2 172442904 C A 7.37E-06 Suicidal ideation / / 20877300 rs2356798 chr2 172456040 G T 3.90E-06 Personality dimensions / / 21173776 rs6433309 chr2 172518151 A G 6.95E-05 Tunica Media / / pha003036 rs10803863 chr2 172535337 T C 2.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs11678984 chr2 172535848 T G 2.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs17614941 chr2 172541378 T C 2.60E-05 Urinary metabolites / / 21572414 rs1554166 chr2 172541609 T G 7.39E-04 Multiple complex diseases / / 17554300 rs1554166 chr2 172541609 T G 2.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs6721680 chr2 172543913 G T 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs6757773 chr2 172549630 T A,C 2.50E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs2138348 chr2 172558172 G T 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs12185567 chr2 172560729 A C 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312925 chr2 172563922 G A 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312924 chr2 172564021 A T 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312918 chr2 172569587 G C 2.51E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs17427473 chr2 172576011 A G 5.32E-04 Nicotine dependence DYNC1I2 intron 17158188 rs7597387 chr2 172577116 T C 2.66E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs10206062 chr2 172577276 A T 2.68E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs973889 chr2 172579954 A G 2.74E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs10207085 chr2 172585885 T G 2.76E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs2292815 chr2 172586651 C G 2.80E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs6722757 chr2 172591963 A G 2.96E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs6710698 chr2 172596078 G C 4.99E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs4667694 chr2 172605399 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166005 chr2 172607294 C T 2.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs10184866 chr2 172608956 T G 2.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs4668412 chr2 172619770 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs4668412 chr2 172619770 A G 6.89E-05 Height / / pha003010 rs10194102 chr2 172626143 G C 3.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs11904009 chr2 172627343 T G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10174525 chr2 172635697 T C 3.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs6705200 chr2 172637600 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs10497374 chr2 172640623 A G 3.16E-04 Suicide attempts in bipolar disorder SLC25A12 UTR-3 21041247 rs11757 chr2 172641045 C G 3.21E-04 Suicide attempts in bipolar disorder SLC25A12 UTR-3 21041247 rs12692973 chr2 172642057 C T 3.27E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs7608403 chr2 172646765 A C 3.63E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs10167419 chr2 172649826 A G 3.85E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6758704 chr2 172655097 T C 3.88E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6754817 chr2 172663394 C T 3.65E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770452 chr2 172668682 A G 3.58E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770451 chr2 172668715 T G 3.58E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs7586207 chr2 172671094 A G 3.60E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs1400816 chr2 172680678 A C 1.00E-06 Amyotrophic lateral sclerosis (sporadic) SLC25A12 intron 24529757 rs6759575 chr2 172689068 C T 3.64E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs908670 chr2 172690180 T C 3.73E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs908671 chr2 172690265 C G 3.74E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs4668414 chr2 172704291 A C 3.74E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770445 chr2 172708919 T C 3.81E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs1878583 chr2 172725301 A G 2.50E-06 Urinary metabolites SLC25A12 cds-synon 21572414 rs12692978 chr2 172725981 C T 3.89E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6725388 chr2 172730015 G C 8.99E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6724337 chr2 172735329 C T 3.72E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs10202823 chr2 172780132 T C 7.10E-04 Suicide attempts in bipolar disorder HAT1 intron 21041247 rs6750058 chr2 172786909 G T 3.68E-05 Multiple complex diseases HAT1 intron 17554300 rs73976541 chr2 172841213 C T 0.00082 Prostate cancer HAT1 missense 23555315 rs6752812 chr2 172851502 C A 7.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs17428076 chr2 172851936 C G 2.80E-09 Myopia (Age of onset) / / 23468642 rs2028671 chr2 172852839 C T 5.70E-06 Urinary metabolites / / 21572414 rs7584187 chr2 172866105 G A 7.09E-04 Multiple complex diseases METAP1D intron 17554300 rs17428174 chr2 172886148 T C 4.62E-04 Response to TNF antagonist treatment METAP1D intron 21061259 rs7606918 chr2 172895449 A G 2.89E-08 Menopause (age at onset) METAP1D intron 22267201 rs12052246 chr2 172895606 C A 5.05E-04 Multiple complex diseases METAP1D intron 17554300 rs788164 chr2 172913390 C G 7.02E-04 Multiple complex diseases METAP1D intron 17554300 rs788160 chr2 172946315 T G 5.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2016394 chr2 172972971 G A 1.00E-08 Breast cancer / / 23535729 rs4972600 chr2 172981645 A G 8.22E-06 Cardiovascular disease / / pha003064 rs4972623 chr2 172994091 G A 8.01E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs6726793 chr2 173010595 T A 5.20E-04 Multiple complex diseases / / 17554300 rs2884155 chr2 173019144 A G 7.23E-05 Lymphocyte counts / / pha003094 rs4972740 chr2 173108443 C T 1.71E-04 Prostate cancer mortality / / 20978177 rs7574002 chr2 173124183 C T 2.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs7574225 chr2 173124237 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs7588418 chr2 173127669 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs4349318 chr2 173142480 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4349318 chr2 173142480 G T 7.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs4316910 chr2 173150235 T C 3.18E-04 Multiple complex diseases / / 17554300 rs7574709 chr2 173152508 A C 9.94E-04 Prostate cancer mortality / / 20978177 rs7574709 chr2 173152508 A C 9.50E-06 Urinary metabolites / / 21572414 rs6749293 chr2 173166803 T C 4.56E-07 Primary biliary cirrhosis / / 23000144 rs6749293 chr2 173166803 T C 0.000000456 Facial morphology / / 23028347 rs6758468 chr2 173169580 T G 2.85E-04 Multiple complex diseases / / 17554300 rs6718565 chr2 173193070 G T 2.21E-04 Multiple complex diseases / / 17554300 rs6755520 chr2 173195634 A C 1.06E-04 Multiple complex diseases / / 17554300 rs4972809 chr2 173217091 A G 2.16E-04 Celiac disease / / 23936387 rs4972810 chr2 173217889 A G 1.93E-04 Celiac disease / / 23936387 rs10930551 chr2 173225814 T G 9.43E-04 Type 2 diabetes / / 17463246 rs4283388 chr2 173239722 C T 1.18E-07 Esophageal cancer (squamous cell) / / 22960999 rs13005010 chr2 173259273 G A 8.42E-04 Multiple complex diseases / / 17554300 rs10497382 chr2 173265462 T C 7.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6707676 chr2 173273546 A C 1.01E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6711466 chr2 173274130 A G 2.69E-04 Type 2 diabetes / / 17463246 rs16860330 chr2 173278794 A T 1.22E-05 Glycosylated haemoglobin levels / / 17255346 rs17726737 chr2 173279650 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4972831 chr2 173282051 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7608097 chr2 173300053 T C 5.98E-04 Response to taxane treatment (placlitaxel) ITGA6 intron 23006423 rs12621278 chr2 173311553 A G 9.00E-23 Prostate cancer ITGA6 intron 19767753 rs12621278 chr2 173311553 A G 9.00E-23 Nasopharyngeal carcinoma ITGA6 intron 20512145 rs12621278 chr2 173311553 A G 0.000054 Prostate cancer ITGA6 intron 23555315 rs12621278 chr2 173311553 A G 0.00022 Prostate cancer (non-advanced prostate cancer) ITGA6 intron 23555315 rs12621278 chr2 173311553 A G 5.20E-05 Prostate cancer (early onset) ITGA6 intron 24740154 rs6726739 chr2 173320380 G A 6.79E-04 Multiple complex diseases ITGA6 intron 17554300 rs16860458 chr2 173331957 A G 3.44E-05 Parkinson's disease ITGA6 intron 21738487 rs2701268 chr2 173351199 G A 5.38E-04 Suicide attempts in bipolar disorder ITGA6 intron 21423239 rs2701268 chr2 173351199 G A 2.22E-04 Stroke ITGA6 intron pha002886 rs2737085 chr2 173352507 G T 0.000000203 Triglycerides ITGA6 missense 23063622 rs1574257 chr2 173373190 A G 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs11688498 chr2 173382300 C T 9.22E-05 Body Mass Index / / pha003020 rs7562865 chr2 173382865 T C 7.91E-05 Alzheimer's disease (late onset) / / 21379329 rs12052479 chr2 173404804 C A 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs3765065 chr2 173420254 T A 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972842 chr2 173429033 T A 2.04E-05 Telomere length PDK1 intron 23001564 rs3769321 chr2 173432354 A G 6.98E-04 Stroke PDK1 intron pha002886 rs13394924 chr2 173435757 C T 1.77E-04 Alzheimer's disease (late onset) PDK1 intron 21379329 rs6738196 chr2 173444462 C T 6.86E-04 Stroke PDK1 intron pha002886 rs16860693 chr2 173453278 T C 2.70E-04 Coronary heart disease PDK1 intron 21966275 rs12693005 chr2 173460640 T C 2.28E-04 Alzheimer's disease (late onset) PDK1 cds-synon 21379329 rs836589 chr2 173493078 A G 2.00E-06 Erectile dysfunction / / 22704111 rs74426112 chr2 173577908 C T 2.79E-04 Cocaine dependence / / 23958962 rs1349497 chr2 173592663 G C 3.98E-05 Response to taxane treatment (placlitaxel) LOC91149 intron 23006423 rs6755658 chr2 173635380 T C 5.22E-05 Bipolar disorder RAPGEF4 intron 19488044 rs16860884 chr2 173665907 A C 1.24E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs3820852 chr2 173680085 C A 7.22E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs6715990 chr2 173694029 G A 9.59E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2676510 chr2 173719520 G A 1.46E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs3769292 chr2 173726259 G A 8.44E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2676517 chr2 173749682 C T 5.64E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs13030842 chr2 173765808 T C 1.53E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2553011 chr2 173779775 G A 1.37E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2113807 chr2 173784658 A G 2.66E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2042561 chr2 173792625 G A 1.85E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs2592941 chr2 173817340 G A 1.75E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2592941 chr2 173817340 G A 1.88E-05 Telomere length RAPGEF4 intron 20139977 rs3769247 chr2 173832803 A G 5.71E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs750374 chr2 173834077 T C 4.34E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs6752140 chr2 173834665 T C 4.43E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs1026290 chr2 173841435 G A 4.60E-04 Myasthenia gravis RAPGEF4 intron 23055271 rs11685193 chr2 173864492 G A 6.26E-05 Serum metabolites RAPGEF4 intron 19043545 rs3769234 chr2 173867468 T C 7.11E-05 Serum metabolites RAPGEF4 intron 19043545 rs7604728 chr2 173867808 C T 0.0000153 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RAPGEF4 intron 22628534 rs16861206 chr2 173892146 C T 4.10E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2305462 chr2 173895285 A G 7.67E-04 Amyotrophic Lateral Sclerosis RAPGEF4 intron 17827064 rs4972527 chr2 173915007 G A 5.99E-04 Smoking initiation RAPGEF4 intron 24665060 rs10187560 chr2 173925051 T C 8.98E-05 Breast cancer / / pha002853 rs11692252 chr2 173929607 T C 8.77E-04 Multiple complex diseases / / 17554300 rs989531 chr2 173933618 C T 2.87E-04 Multiple complex diseases / / 17554300 rs9636294 chr2 173954787 A G 1.75E-04 Multiple complex diseases ZAK intron 17554300 rs3769203 chr2 173955062 A G 9.02E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs6758859 chr2 173965056 T C 1.19E-04 Multiple complex diseases ZAK intron 17554300 rs3754744 chr2 174002064 T C 3.80E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs3754743 chr2 174002092 G T 4.12E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs3769185 chr2 174013499 A G 7.08E-05 Amyotrophic lateral sclerosis ZAK intron 20801717 rs3769185 chr2 174013499 A G 0.0000453 Amyotrophic lateral sclerosis ZAK intron 23587638 rs3769185 chr2 174013499 A G 0.0000623 Amyotrophic lateral sclerosis ZAK intron 23587638 rs3769185 chr2 174013499 A G 7.31E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769185 chr2 174013499 A G 8.96E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs7575189 chr2 174015168 G A 6.98E-04 Multiple complex diseases ZAK intron 17554300 rs3769184 chr2 174019920 A G 1.68E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769184 chr2 174019920 A G 2.84E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769184 chr2 174019920 A G 4.19E-04 Stroke ZAK intron pha002886 rs7560960 chr2 174027123 T A 5.96E-04 Multiple complex diseases ZAK intron 17554300 rs1837470 chr2 174048371 A G 2.92E-05 Glycemic traits (pregnancy) ZAK intron 23903356 rs1837470 chr2 174048371 A G 4.04E-05 Glycemic traits (pregnancy) ZAK intron 23903356 rs3754741 chr2 174053219 A G 3.24E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs2289399 chr2 174055731 A G 3.24E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs8446 chr2 174090542 T C 5.17E-05 Parkinson's disease ZAK UTR-3 21248740 rs10182247 chr2 174094145 T C 1.24E-04 Parkinson's disease ZAK intron 21248740 rs3820831 chr2 174103428 C A 3.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZAK intron 20877124 rs6761224 chr2 174125960 T C 6.99E-04 Alcohol dependence ZAK intron 20201924 rs16861477 chr2 174135843 T A 6.86E-04 Suicide attempts in bipolar disorder MLK7-AS1 intron 21423239 rs1816811 chr2 174163320 G C 6.18E-04 Coronary heart disease / / 21606135 rs6712331 chr2 174165043 A C 5.54E-04 Coronary heart disease / / 21606135 rs7595292 chr2 174184206 A G 1.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1550623 chr2 174212894 G A 3.00E-08 Breast cancer / / 23535729 rs2288993 chr2 174230153 C G 6.63E-04 Lymphocyte counts CDCA7 intron 22286170 rs3816061 chr2 174232076 G A 7.19E-05 Multiple complex diseases CDCA7 intron 17554300 rs1047885 chr2 174233041 A G 3.06E-04 Multiple complex diseases CDCA7 UTR-3 17554300 rs6747034 chr2 174238868 A G 5.99E-04 Depression (quantitative trait) / / 20800221 rs1007833 chr2 174243438 A G 6.03E-05 Hemoglobin / / pha003098 rs7591287 chr2 174247919 A G 4.69E-05 Hemoglobin / / pha003098 rs10497394 chr2 174297659 C T 2.00E-08 Otitis media (chronic/recurrent) / / 23974705 rs1435767 chr2 174299698 A G 4.68E-05 Intracerebral hemorrhage / / 24656865 rs7574876 chr2 174315778 G T 2.30E-05 Urinary metabolites / / 21572414 rs2163960 chr2 174316051 C T 4.40E-05 Serum metabolites / / 19043545 rs10930597 chr2 174326845 C T 1.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 4.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 4.00E-08 Blood pressure measurement (low sodium intervention) / / 24165912 rs10930597 chr2 174326845 C T 5.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs10930597 chr2 174326845 C T 6.00E-06 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 7.00E-06 Blood pressure measurement (low sodium intervention) / / 24165912 rs1992013 chr2 174329983 T G 6.13E-06 White blood cell count / / 21738479 rs7349190 chr2 174336177 C T 7.45E-04 Multiple complex diseases / / 17554300 rs4597485 chr2 174337508 T A 8.20E-04 Multiple complex diseases / / 17554300 rs2358259 chr2 174348043 A G 1.39E-05 Age-related macular degeneration / / pha000001 rs7590983 chr2 174362349 T C 6.00E-06 Anthropometric traits / / 19260139 rs7581219 chr2 174363574 G A 1.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7584596 chr2 174450397 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs577687 chr2 174451691 A G 3.22E-05 Tunica Media / / pha003037 rs4972593 chr2 174462854 T A 4.00E-08 End-stage renal disease in Type 1 diabetics / / 24029427 rs6711114 chr2 174477802 G A 9.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs755816 chr2 174480881 T C 2.50E-04 Multiple complex diseases / / 17554300 rs12476327 chr2 174490915 C A 8.10E-06 Urinary metabolites / / 21572414 rs13028485 chr2 174504924 G A 2.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs554934 chr2 174508541 C G 1.30E-05 Urinary metabolites / / 21572414 rs13001922 chr2 174516818 T C 1.70E-06 Urinary metabolites / / 21572414 rs6739381 chr2 174541290 G A 3.58E-05 Parkinson's disease / / 24842889 rs752280 chr2 174553435 A C 6.94E-05 Body Mass Index / / pha003009 rs752280 chr2 174553435 A C 8.13E-05 Waist Circumference / / pha003025 rs7575459 chr2 174587180 C T 8.54E-05 Cognitive decline / / 22054870 rs7602424 chr2 174705545 G T 4.97E-04 Type 2 diabetes / / 17463246 rs6433441 chr2 174706535 T C 2.00E-05 Type 2 diabetes / / 17463246 rs1024125 chr2 174708199 T C 2.25E-05 Type 2 diabetes / / 17463246 rs1024125 chr2 174708199 T C 8.54E-04 Response to TNF antagonist treatment / / 21061259 rs2137804 chr2 174733318 A G 4.98E-04 Smoking quantity / / 24665060 rs4972416 chr2 174737068 A G 8.70E-04 Type 2 diabetes / / 17463246 rs2048666 chr2 174748572 T C 3.87E-05 Type 2 diabetes / / 17463246 rs2048666 chr2 174748572 T C 1.55E-04 Multiple complex diseases / / 17554300 rs9287966 chr2 174755423 G A 1.34E-04 Type 2 diabetes / / 17463246 rs7589313 chr2 174771911 C A 3.35E-04 Multiple complex diseases SP3 UTR-3 17554300 rs6718080 chr2 174785819 C G 6.90E-04 Multiple complex diseases SP3 intron 17554300 rs12474886 chr2 174798136 C G 6.27E-04 Type 2 diabetes SP3 intron 17463246 rs1446572 chr2 174803714 T C 8.71E-04 Type 2 diabetes SP3 intron 17463246 rs4972622 chr2 174808216 C T 8.63E-04 Type 2 diabetes SP3 intron 17463246 rs7572596 chr2 174837877 T C 6.73E-04 Type 2 diabetes / / 17463246 rs12466262 chr2 174839747 C T 1.60E-05 Urinary metabolites / / 21572414 rs10497424 chr2 174840107 T C 8.32E-05 Cognitive test performance / / 20125193 rs16862246 chr2 174850890 G A 0.0000685 Panic disorder / / 23149450 rs16862246 chr2 174850890 G A 6.85E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10497422 chr2 174852785 G T 1.58E-05 Alcohol dependence / / 19581569 rs2121362 chr2 174865857 C T 2.91E-04 Obesity (extreme) / / 21935397 rs7601227 chr2 174879174 T G 6.05E-04 Multiple complex diseases / / 17554300 rs1374315 chr2 174883399 G A 0.0000469 Migraine / / 22678113 rs1374315 chr2 174883399 G A 4.69E-05 Migraine / / 22683712 rs3813817 chr2 174891414 C T 9.27E-05 Cognitive impairment induced by topiramate LOC100128905 UTR-3 22091778 rs6756828 chr2 174919189 C T 4.23E-06 Hearing function / / 21493956 rs2044471 chr2 174931957 G A 6.79E-05 Information processing speed / / 21130836 rs6737629 chr2 174939168 C T 5.60E-08 Breast cancer OLA1 UTR-3 20852631 rs10930640 chr2 174997017 C T 7.21E-05 Bipolar disorder OLA1 intron 22925353 rs1595796 chr2 174998583 A G 6.40E-05 Schizophrenia OLA1 intron 19571808 rs4972431 chr2 174999188 C T 1.38E-07 Meningococcal disease OLA1 intron 20694013 rs11674895 chr2 175013963 C A 8.07E-05 Bipolar disorder OLA1 intron 22925353 rs2119137 chr2 175017714 A G 1.83E-04 Schizophrenia OLA1 intron 19197363 rs17319260 chr2 175026635 T A 1.50E-05 Urinary metabolites OLA1 intron 21572414 rs16862445 chr2 175026805 C T 7.12E-04 Multiple complex diseases OLA1 intron 17554300 rs4350713 chr2 175127653 A G 7.55E-04 Premature ovarian failure / / 19508998 rs13035792 chr2 175185780 C A 4.19E-05 Multiple complex diseases / / 17554300 rs7582977 chr2 175205513 T C 2.78E-04 Alzheimer's disease / / 24755620 rs7580375 chr2 175231574 A G 2.30E-05 Urinary metabolites CIR1 intron 21572414 rs6716400 chr2 175265912 T C 0.00018 Breast cancer SCRN3 missense 23555315 rs17255817 chr2 175289314 T C 7.05E-05 Cognitive test performance SCRN3 cds-synon 20125193 rs4972663 chr2 175316379 T C 7.37E-05 Hearing function GPR155 intron 17255346 rs7424769 chr2 175363694 C A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs13008567 chr2 175422978 A T 4.19E-04 Multiple complex diseases / / 17554300 rs4972450 chr2 175436940 G A 0.0005859 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 missense 23233654 rs4972450 chr2 175436940 G A 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 missense 23233662 rs1367217 chr2 175446734 C T 0.0006024 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 intron 23233654 rs1367217 chr2 175446734 C T 6.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 intron 23233662 rs1430182 chr2 175457155 C T 9.98E-05 Bone mineral density WIPF1 intron 19181680 rs1430181 chr2 175459021 G T 0.0007225 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 intron 23233654 rs1430181 chr2 175459021 G T 7.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 intron 23233662 rs13427312 chr2 175463793 T G 2.62E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs10221651 chr2 175466160 A G 1.29E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs6756690 chr2 175466441 G A 1.48E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs4595937 chr2 175471607 G T 1.08E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs6745914 chr2 175475851 A G 1.68E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs1991600 chr2 175495311 C T 8.06E-05 Insulin-related traits WIPF1 intron pha002901 rs6716254 chr2 175542474 T C 8.05E-06 Osteoarthritis WIPF1 intron 22763110 rs6738929 chr2 175562223 G T 9.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12620150 chr2 175565552 C T 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12472540 chr2 175575649 A G 5.61E-04 Stroke / / pha002886 rs2646143 chr2 175594381 A G 2.54E-04 Disc degeneration (lumbar) / / 24216480 rs2646179 chr2 175598518 C T 0.000018 Migraine / / 22678113 rs2646179 chr2 175598518 C T 1.80E-05 Migraine / / 22683712 rs7575145 chr2 175599106 T C 0.0000359 Migraine / / 22678113 rs7575145 chr2 175599106 T C 3.59E-05 Migraine / / 22683712 rs2123117 chr2 175602014 T C 9.60E-04 Multiple complex diseases / / 17554300 rs733187 chr2 175602377 G A 5.75E-06 Asthma (childhood onset) / / 23829686 rs6708544 chr2 175604194 G A 0.0000449 Migraine / / 22678113 rs6708544 chr2 175604194 G A 4.49E-05 Migraine / / 22683712 rs2600685 chr2 175627048 T C 0.0000519 Migraine CHR/1 intron 22678113 rs2600685 chr2 175627048 T C 5.19E-05 Migraine CHR/1 intron 22683712 rs1376872 chr2 175641528 A G 7.51E-04 Multiple complex diseases / / 17554300 rs2646157 chr2 175724102 G A 6.68E-06 Tuberculosis CHN1 intron 22306650 rs3771910 chr2 175747467 C T 9.96E-04 Parkinson's disease CHN1 intron 17052657 rs3771917 chr2 175836843 T C 5.25E-05 Statin-induced myopathy CHN1 intron 21826682 rs1150186 chr2 175893333 T C 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1406752 chr2 175898417 A G 1.34E-05 Aging (time to event) / / 21782286 rs1153717 chr2 175906278 T C 3.37E-04 Age-related macular degeneration / / 22125219 rs1145068 chr2 175924184 C G 2.49E-04 Cholesterol / / 17255346 rs212373 chr2 175928683 C T 1.37E-04 Cholesterol / / 17255346 rs212371 chr2 175930305 C A 2.98E-04 Multiple complex diseases / / 17554300 rs1153697 chr2 175934881 T A 1.75E-04 Cholesterol / / 17255346 rs12615750 chr2 175935264 T C 9.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs212349 chr2 175944398 T C 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs35522805 chr2 175952130 G A 2.36E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs2072538 chr2 175962664 C T 2.36E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs1153681 chr2 175964587 G A 6.58E-04 Multiple complex diseases ATF2 intron 17554300 rs1153676 chr2 175980994 C A 3.36E-05 Lymphocyte counts ATF2 intron 22286170 rs1153676 chr2 175980994 C A 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs1153672 chr2 175986973 G A 6.07E-04 Multiple complex diseases ATF2 intron 17554300 rs13388308 chr2 176006027 C T 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs11888507 chr2 176012621 C T 2.82E-04 Cholesterol ATF2 intron 17255346 rs11894840 chr2 176017065 G C 7.22E-04 Multiple complex diseases ATF2 intron 17554300 rs17270532 chr2 176017196 A C 6.68E-04 Multiple complex diseases ATF2 intron 17554300 rs21818 chr2 176035845 G A 1.55E-04 Cholesterol / / 17255346 rs10497436 chr2 176175847 A G 5.89E-04 Multiple complex diseases / / 17554300 rs4972755 chr2 176239849 G A 3.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs16863160 chr2 176241475 C T 1.61E-05 Multiple complex diseases / / 17554300 rs2461772 chr2 176273267 T C 7.60E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2461771 chr2 176277378 T C 7.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2437910 chr2 176277484 G T 7.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2461751 chr2 176289319 G A 8.00E-06 Electrocardiographic conduction measures / / 19389651 rs10930700 chr2 176320079 C T 8.88E-04 Type 2 diabetes / / 17463246 rs6736485 chr2 176381919 C T 9.53E-04 Multiple complex diseases / / 17554300 rs9646737 chr2 176389860 C T 1.00E-04 Prostate cancer / / 21743057 rs7603466 chr2 176391679 G A 6.02E-04 Multiple complex diseases / / 17554300 rs6723304 chr2 176398354 G A 1.00E-04 Prostate cancer / / 21743057 rs13024746 chr2 176403883 C T 5.00E-07 Urinary metabolites / / 21572414 rs7581058 chr2 176488243 A T 2.00E-04 Multiple complex diseases / / 17554300 rs4344900 chr2 176488944 G A 0.0000622 Primary sclerosing cholangitis / / 23603763 rs6720081 chr2 176502826 C T 1.80E-05 Urinary metabolites / / 21572414 rs7563215 chr2 176541561 G A 7.28E-04 Type 2 diabetes / / 17463246 rs10170575 chr2 176543105 C T 1.20E-06 Urinary metabolites / / 21572414 rs6734627 chr2 176552192 G T 1.50E-06 Urinary metabolites / / 21572414 rs1446825 chr2 176601473 T C 1.50E-05 Urinary metabolites / / 21572414 rs7604880 chr2 176613859 T C 5.39E-04 Multiple complex diseases / / 17554300 rs11685409 chr2 176618964 C T 3.31E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1348844 chr2 176631320 G T 9.54E-04 Parkinson's disease / / 17052657 rs10497444 chr2 176652167 A G 2.35E-05 Information processing speed / / 21130836 rs16863399 chr2 176653490 C A 6.12E-04 Multiple complex diseases / / 17554300 rs7566934 chr2 176654738 A G 7.00E-06 Information processing speed / / 21130836 rs6755005 chr2 176675516 A G 2.08E-05 Information processing speed / / 21130836 rs1446829 chr2 176677084 A G 7.09E-06 Information processing speed / / 21130836 rs1446797 chr2 176689882 G A 6.34E-04 Tourette syndrome / / 22889924 rs6737825 chr2 176707805 G A,T 9.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9287989 chr2 176717741 T C 4.00E-06 Periodontal microbiota / / 22699663 rs1816920 chr2 176723746 A G 0.0008976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1816920 chr2 176723746 A G 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10165932 chr2 176727921 T A 0.0008816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10165932 chr2 176727921 T A 8.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2884887 chr2 176730467 C T 9.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2034282 chr2 176733910 T C 9.49E-05 Monocyte counts / / pha003089 rs4972489 chr2 176734598 A C 8.00E-06 Obesity-related traits / / 23251661 rs1020410 chr2 176784138 T C 6.00E-07 Obesity-related traits / / 23251661 rs12621733 chr2 176791642 G A 5.47E-05 Monocyte chemoattractant protein-1 KIAA1715 UTR-3 pha003071 rs2166528 chr2 176806653 C T 3.87E-06 Heart Rate KIAA1715 intron pha003054 rs4369827 chr2 176809605 T C 8.48E-07 Obesity-related traits KIAA1715 intron 23251661 rs12613466 chr2 176817947 T C 9.16E-05 Monocyte chemoattractant protein-1 KIAA1715 intron pha003071 rs34897061 chr2 176829117 G C 0.00054 Breast cancer KIAA1715 missense 23555315 rs9646792 chr2 176838145 A C 3.65E-05 Interstitial lung disease KIAA1715 intron 23583980 rs12464144 chr2 176850319 G A 5.47E-05 Monocyte chemoattractant protein-1 KIAA1715 intron pha003071 rs4972801 chr2 176883266 G C 1.73E-05 Urate levels / / 23263486 rs12465451 chr2 176893529 T C 3.30E-07 Multiple complex diseases / / 17554300 rs974699 chr2 176900090 C T 2.97E-04 Bipolar disorder / / 18317468 rs1099941 chr2 176907320 C A 1.54E-05 Serum metabolites / / 19043545 rs1099942 chr2 176923881 C T 6.30E-06 Monocyte chemoattractant protein-1 / / pha003071 rs847126 chr2 176936834 A G 4.46E-05 Parkinson's disease / / 17052657 rs7601234 chr2 176981343 G T 1.00E-06 Amyotrophic lateral sclerosis (sporadic) HOXD10 nearGene-5 24529757 rs2592394 chr2 176991779 A G 5.00E-07 Magnesium levels / / 20700443 rs1348808 chr2 177000616 T C 1.63E-10 Narcolepsy HOXD-AS2 intron 19629137 rs1348807 chr2 177005757 C T 8.24E-05 Longevity / / 20304771 rs4972806 chr2 177012578 C T 8.00E-06 IgG glycosylation / / 23382691 rs7606110 chr2 177028551 T C 5.26E-04 Depression (quantitative trait) / / 20800221 rs2301301 chr2 177032267 T C 4.45E-04 Depression (quantitative trait) HOXD3 intron 20800221 rs13017511 chr2 177035395 A G 6.26E-04 Depression (quantitative trait) HOXD3 intron 20800221 rs711830 chr2 177037311 A C,G,T 2.20E-05 Urinary metabolites HOXD3 UTR-3 21572414 rs9141 chr2 177037970 T C 7.36E-04 Depression (quantitative trait) / / 20800221 rs2072590 chr2 177042633 A C 5.00E-14 Ovarian cancer HOXD-AS1 intron 20852632 rs2072590 chr2 177042633 A C 3.00E-10 Ovarian cancer HOXD-AS1 intron 23535730 rs2072590 chr2 177042633 A C 5.00E-11 Ovarian cancer HOXD-AS1 intron 23535730 rs1374325 chr2 177043971 G A 9.52E-04 Depression (quantitative trait) HOXD-AS1 intron 20800221 rs1374326 chr2 177058316 G A 9.68E-04 Alzheimer's disease / / 17998437 rs1026028 chr2 177070756 C A 3.41E-06 Alcohol dependence / / 23089632 rs2166512 chr2 177071181 T C 4.89E-06 Alcohol dependence / / 23089632 rs6714226 chr2 177076890 T G 2.50E-05 Urinary metabolites / / 21572414 rs973406 chr2 177109731 C A 4.26E-04 Multiple complex diseases / / 17554300 rs970797 chr2 177111819 T G 7.60E-08 Facial morphology / / 22341974 rs4346418 chr2 177198249 C T 8.89E-04 Taste perception MTX2 intron 22132133 rs2689949 chr2 177199125 A G 2.53E-04 Taste perception MTX2 intron 22132133 rs818361 chr2 177210511 T C 2.27E-11 Narcolepsy / / 19629137 rs16863736 chr2 177233102 G A 5.83E-04 Multiple complex diseases / / 17554300 rs17338026 chr2 177258204 A G 4.74E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs16863792 chr2 177281955 G A 3.65E-04 Smoking quantity / / 24665060 rs6712002 chr2 177307266 T C 7.43E-04 Smoking quantity / / 24665060 rs6433589 chr2 177308941 G A 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6731638 chr2 177313675 A C 1.03E-04 Smoking quantity / / 24665060 rs6747963 chr2 177318061 A G 3.30E-04 Smoking quantity / / 24665060 rs13416965 chr2 177321586 C A 2.14E-22 Narcolepsy / / 19629137 rs3898818 chr2 177340813 T C 2.00E-04 Smoking initiation / / 24665060 rs10497446 chr2 177376868 T C 4.38E-04 Alzheimer's disease / / 24755620 rs2969344 chr2 177382589 G A 2.63E-06 Insulin-related traits / / pha002901 rs17400244 chr2 177390453 T G 4.29E-04 Alzheimer's disease / / 17998437 rs1037222 chr2 177401438 G A 3.47E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1037222 chr2 177401438 G A 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1448539 chr2 177411799 T C 5.93E-05 Blood Pressure / / pha002903 rs1448537 chr2 177429661 A T 9.50E-05 Acute lung injury / / 22295056 rs2922336 chr2 177430878 A C 1.42E-04 Acute lung injury / / 22295056 rs2922338 chr2 177431607 T C 5.44E-06 Acute lung injury / / 22295056 rs1448522 chr2 177442640 G A 7.88E-07 Acute lung injury / / 22295056 rs2922346 chr2 177445709 A G 8.14E-07 Acute lung injury / / 22295056 rs12473379 chr2 177446323 C G 2.12E-07 Acute lung injury / / 22295056 rs4893896 chr2 177452904 A G 2.00E-06 Acute lung injury / / 22295056 rs4893900 chr2 177456444 G A 3.39E-06 Acute lung injury / / 22295056 rs4894166 chr2 177459411 A G 2.49E-04 Acute lung injury / / 22295056 rs7588541 chr2 177464995 T C 1.73E-04 Acute lung injury / / 22295056 rs4893907 chr2 177471223 T C 3.37E-06 Acute lung injury / / 22295056 rs1075120 chr2 177471457 C T 2.35E-06 Acute lung injury / / 22295056 rs4378837 chr2 177471763 T C 2.91E-06 Acute lung injury / / 22295056 rs1448528 chr2 177476850 A G 2.91E-06 Acute lung injury / / 22295056 rs11693766 chr2 177479968 C G 2.27E-04 Acute lung injury / / 22295056 rs2922309 chr2 177480054 A G 5.82E-04 Alzheimer's disease / / 17998437 rs2922309 chr2 177480054 A G 1.25E-04 Acute lung injury / / 22295056 rs2969363 chr2 177483123 G A 7.80E-05 Bipolar disorder / / 19488044 rs2969363 chr2 177483123 G A 3.13E-04 Alzheimer's disease (late onset) / / 21379329 rs2969363 chr2 177483123 G A 7.66E-05 Bipolar Disorder / / pha002858 rs16864122 chr2 177511440 C T 0.000000252 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs6433602 chr2 177519429 C T 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4893912 chr2 177523894 A G 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17345806 chr2 177531742 A G 7.70E-04 Acute lung injury / / 22295056 rs2710024 chr2 177532212 T C 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10497448 chr2 177532513 A C,G,T 7.70E-04 Acute lung injury / / 22295056 rs12991707 chr2 177533063 G C 7.70E-04 Acute lung injury / / 22295056 rs12997926 chr2 177533880 A G 7.83E-04 Acute lung injury / / 22295056 rs2362866 chr2 177538266 G A 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1513879 chr2 177558110 A G 9.81E-04 Acute lung injury / / 22295056 rs7567249 chr2 177558340 C T 9.81E-04 Acute lung injury / / 22295056 rs16864246 chr2 177559549 G A 5.02E-04 Smoking initiation / / 24665060 rs16864246 chr2 177559549 G A 8.57E-05 Body Mass Index / / pha003014 rs713285 chr2 177595862 A G 7.65E-05 Serum metabolites / / 19043545 rs1355847 chr2 177597274 C A 1.65E-05 Serum metabolites / / 19043545 rs4893916 chr2 177616216 A G 8.70E-06 Urinary metabolites / / 21572414 rs13021051 chr2 177616426 T C 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6758766 chr2 177630608 T G 1.70E-05 Urinary metabolites / / 21572414 rs11889984 chr2 177633313 T C 6.40E-06 Urinary metabolites / / 21572414 rs1533303 chr2 177677487 C T 8.18E-05 Cognitive performance / / 19734545 rs1534472 chr2 177677940 A G 3.08E-04 Multiple complex diseases / / 17554300 rs1534472 chr2 177677940 A G 8.39E-05 Cognitive performance / / 19734545 rs16864480 chr2 177680063 A G 4.92E-04 Tourette syndrome / / 22889924 rs840690 chr2 177681805 A C 7.31E-05 Multiple complex diseases / / 17554300 rs13032587 chr2 177683404 T C 3.82E-06 Post-operative nausea and vomiting / / 21694509 rs16864519 chr2 177687534 G A 1.13E-06 Post-operative nausea and vomiting / / 21694509 rs840706 chr2 177692572 A G 6.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1866131 chr2 177710534 T C 7.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6723196 chr2 177713373 A G 4.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1513870 chr2 177716131 A G 6.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs874416 chr2 177752461 C T 8.75E-04 Multiple complex diseases / / 17554300 rs6724100 chr2 177756733 T C 3.73E-04 Multiple complex diseases / / 17554300 rs10497473 chr2 177768589 C T 6.45E-04 Multiple complex diseases / / 17554300 rs11890791 chr2 177773103 C T 7.09E-04 Multiple complex diseases / / 17554300 rs16864700 chr2 177775920 G A 2.94E-04 Multiple complex diseases / / 17554300 rs16864702 chr2 177776684 G C 3.68E-04 Multiple complex diseases / / 17554300 rs10497471 chr2 177789538 A G 4.20E-04 Multiple complex diseases / / 17554300 rs6717501 chr2 177819209 C T 4.95E-06 Post-operative nausea and vomiting / / 21694509 rs16864835 chr2 177869199 G T 5.81E-04 Type 2 diabetes / / 17463246 rs4894230 chr2 177876027 A T 6.07E-04 Type 2 diabetes / / 17463246 rs4894232 chr2 177882193 G A 1.40E-05 Urinary metabolites / / 21572414 rs9287995 chr2 177884232 C T 6.02E-05 Pulmonary function in asthmatics / / 23541324 rs1104779 chr2 177890113 G A 9.00E-05 Coffee consumption / / 21357676 rs16864871 chr2 177902066 C G 6.24E-04 Multiple complex diseases / / 17554300 rs4894236 chr2 177905572 C T 1.27E-04 Telomere length / / 21573004 rs1529093 chr2 177909595 T C 2.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1529098 chr2 177914806 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12105278 chr2 177929191 C G 5.99E-04 Depression (quantitative trait) / / 20800221 rs17683237 chr2 177929684 C T 5.16E-04 Multiple complex diseases / / 17554300 rs1534682 chr2 177932237 T C 1.72E-04 Aortic root size / / 21223598 rs1529090 chr2 177935071 G A 9.02E-05 Aging (time to event) / / 21782286 rs4894243 chr2 177962141 C T 7.46E-05 Alcohol dependence / / 19581569 rs2706137 chr2 177991618 G A 3.82E-04 Gallstones / / 17632509 rs2706123 chr2 178029850 C T 6.60E-05 Hypothyroidism / / 22493691 rs12693115 chr2 178041663 T C 7.96E-04 Multiple complex diseases / / 17554300 rs13029183 chr2 178087851 A G 5.44E-05 Kawasaki disease HNRNPA3 UTR-3 22081228 rs1806686 chr2 178146269 C T 7.08E-04 Type 2 diabetes / / 17463246 rs1806686 chr2 178146269 C T 8.40E-04 Multiple complex diseases / / 17554300 rs1806686 chr2 178146269 C T 7.90E-06 Urinary metabolites / / 21572414 rs1806686 chr2 178146269 C T 3.66E-04 Smoking cessation / / 24665060 rs7568033 chr2 178148288 C G 2.30E-04 Gallstones / / 17632509 rs12105484 chr2 178172511 G T 0.00000193 Triglycerides LOC100130691 intron 23063622 rs4893825 chr2 178298687 T C 6.95E-04 Type 2 diabetes AGPS intron 17463246 rs17326999 chr2 178360075 G A 1.13E-04 Aortic root size AGPS intron 21223598 rs6433672 chr2 178378175 C A 5.80E-04 Multiple complex diseases AGPS intron 17554300 rs7588049 chr2 178390778 T C 6.56E-04 Multiple complex diseases AGPS intron 17554300 rs16865334 chr2 178398479 A G 1.65E-04 Multiple complex diseases AGPS intron 17554300 rs13004955 chr2 178398923 T A 6.22E-04 Type 2 diabetes AGPS intron 17463246 rs4893829 chr2 178399810 C T 6.03E-04 Multiple complex diseases AGPS intron 17554300 rs10803912 chr2 178407176 C A 3.89E-04 Multiple complex diseases AGPS UTR-3 17554300 rs2293475 chr2 178407897 T C 5.64E-04 Multiple complex diseases AGPS UTR-3 17554300 rs12988366 chr2 178417945 G T 3.73E-04 Multiple complex diseases / / 17554300 rs1348851 chr2 178418677 A G 9.04E-04 Multiple complex diseases / / 17554300 rs11889488 chr2 178426793 C T 8.98E-04 Multiple complex diseases / / 17554300 rs41493944 chr2 178454764 C T 4.03E-24 Narcolepsy / / 19629137 rs11689550 chr2 178456298 A G 8.28E-04 Type 2 diabetes / / 17463246 rs4893966 chr2 178470138 T C 6.62E-04 Type 2 diabetes / / 17463246 rs763757 chr2 178474768 C T 1.86E-04 Alzheimer's disease (late onset) / / 21379329 rs3731802 chr2 178475599 C T 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs2293471 chr2 178487729 T G 8.10E-04 Response to taxane treatment (placlitaxel) PDE11A nearGene-3 23006423 rs12618542 chr2 178494520 A G 1.00E-04 Information processing speed PDE11A intron 21130836 rs10469714 chr2 178498015 A G 9.02E-05 Information processing speed PDE11A intron 21130836 rs3770016 chr2 178540293 A G 1.28E-05 Information processing speed PDE11A intron 21130836 rs6739583 chr2 178553569 A T 2.58E-04 Prostate cancer mortality PDE11A intron 20978177 rs17400325 chr2 178565913 T C 1.90E-09 Myopia (Age of onset) PDE11A missense 23468642 rs13428806 chr2 178576681 G A 2.68E-07 Asthma PDE11A intron 20920776 rs13428806 chr2 178576681 G A 9.81E-04 Response to taxane treatment (placlitaxel) PDE11A intron 23006423 rs7573820 chr2 178586608 G A 9.26E-04 Multiple complex diseases PDE11A intron 17554300 rs3754993 chr2 178603588 G C 9.05E-05 Asthma PDE11A intron 20920776 rs4893839 chr2 178604146 T C 3.27E-06 Asthma PDE11A intron 20920776 rs11684634 chr2 178605770 C A 2.42E-08 Asthma PDE11A intron 20920776 rs11684634 chr2 178605770 C A 6.00E-05 Asthma PDE11A intron 20920776 rs1866210 chr2 178607273 G C 6.23E-05 Asthma PDE11A intron 20920776 rs1866209 chr2 178607359 G A 5.79E-06 Asthma PDE11A intron 20920776 rs998059 chr2 178612270 A C 1.31E-05 Asthma PDE11A intron 20920776 rs934798 chr2 178632479 A G 9.89E-04 Suicide attempts in bipolar disorder PDE11A intron 21423239 rs934798 chr2 178632479 A G 9.56E-05 Glucose levels PDE11A intron pha003058 rs41397549 chr2 178656825 T C 4.87E-04 Type 2 diabetes PDE11A intron 17463246 rs1946814 chr2 178679676 C T 4.43E-04 Aortic root size PDE11A intron 21223598 rs13413635 chr2 178680431 A G 3.00E-07 Heart rate PDE11A intron 23583979 rs6433698 chr2 178681534 C T 9.38E-05 Body Composition PDE11A intron pha003012 rs3821009 chr2 178682471 C T 5.16E-73 Multiple complex diseases PDE11A intron 17554300 rs3821010 chr2 178682655 A G 9.89E-05 Body Composition PDE11A intron pha003012 rs7567851 chr2 178684720 G C 3.00E-08 Height PDE11A intron 20881960 rs3770047 chr2 178685534 A G 8.66E-04 Suicide attempts in bipolar disorder PDE11A intron 21423239 rs934803 chr2 178690786 T C 0.000016 Coronary artery calcification PDE11A intron 23727086 rs934803 chr2 178690786 T C 7.01E-05 Eosinophil counts PDE11A intron pha003088 rs1438062 chr2 178695730 C T 6.15E-05 Body Composition PDE11A intron pha003012 rs753346 chr2 178697917 C T 1.05E-04 Lung function (forced vital capacity) PDE11A intron 24023788 rs753346 chr2 178697917 C T 2.68E-04 Lung function (forced expiratory volume in 1 second) PDE11A intron 24023788 rs6756606 chr2 178700057 G A 5.74E-05 Eosinophil counts PDE11A intron pha003088 rs17401468 chr2 178768683 T C 4.00E-04 Multiple complex diseases PDE11A intron 17554300 rs17401468 chr2 178768683 T C 8.22E-05 Basophils PDE11A intron pha003087 rs10497484 chr2 178776181 A G 1.02E-06 Paclitaxel sensitivity in NCI60 cancer cell lines PDE11A intron 21314952 rs1880916 chr2 178795430 G A 8.45E-05 Myopia (pathological) PDE11A intron 23049088 rs13389574 chr2 178808867 C A 9.85E-05 Cognitive test performance PDE11A intron 20125193 rs13390014 chr2 178809106 G A 9.85E-05 Cognitive test performance PDE11A intron 20125193 rs2573088 chr2 178836629 T C 1.06E-05 Asthma PDE11A intron 20920776 rs1546813 chr2 178873782 T G 9.84E-04 White matter integrity PDE11A intron 22425255 rs10206282 chr2 178883104 A AA,AG 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs374700253 chr2 178883104 A ACTTGACTTTAACTTGGCACA,ACTTGACTTTAACTTGGCACG 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs75997819 chr2 178883104 A G 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs2117740 chr2 178890329 A G 6.43E-06 Alcohol dependence (age at onset) PDE11A intron 24962325 rs11692993 chr2 178983208 A G 8.51E-04 Tourette syndrome RBM45 intron 22889924 rs16866133 chr2 179022610 T G 1.33E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs334102 chr2 179060313 A G 0.00006155 Sarcoidosis OSBPL6 intron 22952805 rs334103 chr2 179061110 T C 0.00009808 Sarcoidosis OSBPL6 intron 22952805 rs6719178 chr2 179087081 A T 6.06E-04 Coronary Artery Disease OSBPL6 intron 17634449 rs551368 chr2 179103588 A C 3.86E-04 Lung function (forced expiratory volume in 1 second) OSBPL6 intron 24023788 rs34479159 chr2 179104298 T C 6.00E-06 Breast size OSBPL6 intron 22747683 rs334601 chr2 179175022 T C 6.77E-06 Multiple complex diseases OSBPL6 intron 17554300 rs334595 chr2 179178506 A G 2.69E-04 Multiple complex diseases OSBPL6 intron 17554300 rs993598 chr2 179182695 G A 4.96E-04 Suicide attempts in bipolar disorder OSBPL6 intron 21423239 rs993598 chr2 179182695 G A 2.75E-05 Alcohol consumption OSBPL6 intron 23953852 rs12478760 chr2 179185051 A G 8.71E-04 Multiple complex diseases OSBPL6 UTR-5 17554300 rs7592114 chr2 179186529 G T 8.00E-05 Platelet counts OSBPL6 intron pha003100 rs1434087 chr2 179203797 G A 9.60E-04 Multiple complex diseases OSBPL6 cds-synon 17554300 rs1434091 chr2 179232560 A G 1.30E-05 Urinary metabolites OSBPL6 intron 21572414 rs1434094 chr2 179236048 T C 7.20E-06 Age-related macular degeneration OSBPL6 intron 20861866 rs10167053 chr2 179238993 C T 5.20E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs6706354 chr2 179239068 A G 1.70E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs6706354 chr2 179239068 A G 5.05E-05 Hemoglobin OSBPL6 intron pha003096 rs6706330 chr2 179242526 C T 5.60E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs7580640 chr2 179248420 C T 3.00E-06 QT interval OSBPL6 intron 23166209 rs6736173 chr2 179251077 T C 5.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL6 intron 20877124 rs1434095 chr2 179254330 T C 1.00E-04 Intelligence (childhood) OSBPL6 intron 23358156 rs9283487 chr2 179296271 T C 3.00E-07 Multiple sclerosis (OCB status) PRKRA UTR-3 23472185 rs17225700 chr2 179336600 T C 2.45E-05 ldl cholesterol FKBP7 intron pha003077 rs2303536 chr2 179358665 A G 3.72E-04 Coronary heart disease PLEKHA3 cds-synon 21606135 rs3820979 chr2 179368982 A C 4.00E-04 Type 2 diabetes and 6 quantitative traits PLEKHA3 UTR-3 17848626 rs2366751 chr2 179427186 A G 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN cds-synon 20877124 rs3829746 chr2 179427536 T C 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN missense 20877124 rs10497518 chr2 179469386 A G 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN intron 20877124 rs12614435 chr2 179489726 A G 9.00E-04 Atrial fibrillation TTN intron 21846873 rs6723526 chr2 179498042 T C 6.90E-08 Health and aging,CVD and cancer age of onset TTN missense 22174011 rs2562832 chr2 179581835 C A 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2627043 chr2 179582537 G T 0.000597 5-fluorouracil induced mucositis in response to colorectal cancer treatment TTN missense 22310351 rs17355446 chr2 179589241 G A 1.38E-05 Nicotine smoking TTN missense 19268276 rs72648951 chr2 179593761 T C 0.00021 Prostate cancer TTN missense 23555315 rs1883085 chr2 179604160 T G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2562829 chr2 179604366 T G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2627037 chr2 179606538 G A 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs10171049 chr2 179621864 G A 2.60E-05 Urinary metabolites TTN intron 21572414 rs12476289 chr2 179641975 C T 2.00E-06 QT interval TTN missense 20031603 rs2029395 chr2 179680221 T C 4.90E-05 Volumetric brain MRI / / 17903297 rs1489483 chr2 179688455 C T 4.58E-04 Alzheimer's disease / / 17998437 rs17362588 chr2 179721046 G A 4.00E-26 Heart rate CCDC141 missense 23583979 rs17362588 chr2 179721046 G A 4.75E-07 QRS duration CCDC141 missense 23583979 rs4894057 chr2 179735372 C T 2.00E-05 Urinary metabolites CCDC141 intron 21572414 rs1565287 chr2 179735946 A G 2.00E-05 Urinary metabolites CCDC141 intron 21572414 rs12693170 chr2 179737144 C A 1.90E-04 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs12693170 chr2 179737144 C A 3.76E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs11693319 chr2 179738269 C T 2.00E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs4894058 chr2 179738505 T C 2.90E-05 Triglycerides CCDC141 intron pha003080 rs6716304 chr2 179746322 G A 8.93E-04 Schizophrenia CCDC141 intron 19197363 rs6716304 chr2 179746322 G A 2.72E-05 Triglycerides CCDC141 intron pha003080 rs12693171 chr2 179748447 T C 1.80E-05 Urinary metabolites CCDC141 intron 21572414 rs1016799 chr2 179749332 C T 4.71E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs13403584 chr2 179842062 T A 2.90E-04 Suicidal ideation CCDC141 intron 22030708 rs12474600 chr2 179884886 G A 4.57E-07 Receptive language ability CCDC141 intron 24687471 rs17362909 chr2 179900673 A G 7.85E-04 Response to cytadine analogues (cytosine arabinoside) CCDC141 intron 24483146 rs17362972 chr2 179909467 C T 5.43E-07 Receptive language ability CCDC141 intron 24687471 rs6709090 chr2 179923685 C T 8.45E-06 Receptive language ability / / 24687471 rs10497530 chr2 179924203 A G 8.31E-06 Receptive language ability / / 24687471 rs7575047 chr2 179932910 G A 9.85E-06 Receptive language ability / / 24687471 rs6433748 chr2 179933324 G A 9.93E-06 Receptive language ability / / 24687471 rs6433749 chr2 179933371 A C 9.94E-06 Receptive language ability / / 24687471 rs6433750 chr2 179933518 G A 9.97E-06 Receptive language ability / / 24687471 rs6433751 chr2 179933575 T C 9.98E-06 Receptive language ability / / 24687471 rs6433752 chr2 179933642 A T 1.00E-05 Receptive language ability / / 24687471 rs7578521 chr2 179933815 C T 1.00E-05 Receptive language ability / / 24687471 rs7579263 chr2 179934274 G A 1.02E-05 Receptive language ability / / 24687471 rs11893153 chr2 179934543 A G 9.48E-06 Receptive language ability / / 24687471 rs11903793 chr2 179934583 C G 1.09E-05 Receptive language ability / / 24687471 rs10497531 chr2 179935124 A T 1.09E-05 Receptive language ability / / 24687471 rs10497532 chr2 179935156 A G 1.23E-05 Receptive language ability / / 24687471 rs7582862 chr2 179935235 G C 1.04E-05 Receptive language ability / / 24687471 rs7609150 chr2 179935305 A G 9.95E-06 Receptive language ability / / 24687471 rs7596842 chr2 179935364 T C 9.62E-06 Receptive language ability / / 24687471 rs11885227 chr2 179935847 G A 7.38E-06 Receptive language ability / / 24687471 rs11896002 chr2 179935887 A C 7.19E-06 Receptive language ability / / 24687471 rs17363057 chr2 179936172 T G 5.22E-06 Receptive language ability / / 24687471 rs11885400 chr2 179936237 G T 5.61E-06 Receptive language ability / / 24687471 rs16866624 chr2 179936770 G C 5.96E-06 Receptive language ability / / 24687471 rs11897059 chr2 179939876 T C 1.36E-06 Receptive language ability / / 24687471 rs3816345 chr2 179974885 C T 2.85E-04 Height SESTD1 intron 17255346 rs10497534 chr2 180036775 G A 7.89E-05 Gallstones SESTD1 intron 17632509 rs10208593 chr2 180088968 C A 3.13E-04 Lymphocyte counts SESTD1 intron 22286170 rs1158446 chr2 180124327 A C 5.59E-05 Multiple complex diseases SESTD1 intron 17554300 rs17454527 chr2 180134018 C G 6.08E-06 Receptive language ability / / 24687471 rs10166788 chr2 180136431 G A 3.39E-04 Alzheimer's disease / / 22005930 rs10172996 chr2 180137861 G A 9.97E-04 Alzheimer's disease / / 22005930 rs6733818 chr2 180146275 G A 2.22E-04 Migraine / / 23793025 rs6733818 chr2 180146275 G A 7.00E-06 Migraine without aura / / 23793025 rs4365493 chr2 180173318 T C 6.50E-06 Urinary metabolites / / 21572414 rs10930865 chr2 180201455 A C 0.0001 Migraine / / 22678113 rs13403289 chr2 180216731 C A 6.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs13403289 chr2 180216731 C A 4.10E-05 Crohn's disease (time to surgery) / / 23665963 rs13403289 chr2 180216731 C A 4.60E-05 Crohn's disease (need for surgery) / / 23665963 rs7425027 chr2 180220868 C T 7.31E-05 Hypertension (early onset hypertension) / / 22479346 rs13009904 chr2 180232128 C T 7.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7586173 chr2 180233627 T G 3.09E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7586173 chr2 180233627 T G 5.58E-05 Cholesterol / / pha003078 rs964327 chr2 180244477 A G 3.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs964327 chr2 180244477 A G 9.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1850523 chr2 180258493 T C 0.000016 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity / / 22945461 rs17363868 chr2 180272423 A G 2.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3856411 chr2 180286557 G A 2.56E-05 Personality dimensions / / 22628180 rs13390691 chr2 180326427 A T 7.10E-04 Multiple complex diseases ZNF385B intron 17554300 rs1517707 chr2 180330401 C G 7.11E-04 Multiple complex diseases ZNF385B intron 17554300 rs1517710 chr2 180336583 G A 5.99E-04 Type 2 diabetes ZNF385B intron 17463246 rs9973399 chr2 180338192 C A 3.41E-04 Multiple complex diseases ZNF385B intron 17554300 rs9973399 chr2 180338192 C A 2.30E-06 Parkinson's disease (familial) ZNF385B intron 18985386 rs6718486 chr2 180342873 C T 1.77E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs2271759 chr2 180348245 T G 2.05E-04 Prostate cancer mortality ZNF385B intron 20978177 rs2271759 chr2 180348245 T G 1.06E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs6708300 chr2 180352726 A G 1.23E-04 Prostate cancer mortality ZNF385B intron 20978177 rs12471789 chr2 180354193 C A 1.25E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs1517702 chr2 180366691 T A 3.83E-05 Attention deficit hyperactivity disorder ZNF385B intron pha002875 rs9288035 chr2 180370044 G A 4.04E-04 Suicide attempts in bipolar disorder ZNF385B intron 21423239 rs9288038 chr2 180374761 T G 9.50E-06 Urinary metabolites ZNF385B intron 21572414 rs13003114 chr2 180377479 T C 5.11E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs13003114 chr2 180377479 T C 8.92E-05 Parkinson's disease ZNF385B intron 21812969 rs17816020 chr2 180394948 A G 3.56E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs6715181 chr2 180396787 C T 1.10E-06 Prostate cancer mortality ZNF385B intron 20978177 rs6715297 chr2 180396869 C T 7.64E-04 Type 2 diabetes ZNF385B intron 17463246 rs6715297 chr2 180396869 C T 1.52E-06 Prostate cancer mortality ZNF385B intron 20978177 rs6715297 chr2 180396869 C T 9.65E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs1400822 chr2 180397455 C A,G,T 4.80E-05 Orofacial clefts ZNF385B intron 20023658 rs1400822 chr2 180397455 C A,G,T 1.71E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs16866767 chr2 180399670 G A 7.73E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs6709838 chr2 180400813 C T 6.33E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs11884072 chr2 180403128 T C 5.34E-04 Parkinson's disease ZNF385B intron 17052657 rs11884072 chr2 180403128 T C 5.12E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs1546603 chr2 180435707 G A 5.60E-07 Urinary metabolites ZNF385B intron 21572414 rs1515308 chr2 180443444 T C 5.70E-05 Partial epilepsies ZNF385B intron 20522523 rs2138196 chr2 180452188 G A 5.97E-05 Partial epilepsies ZNF385B intron 20522523 rs11683314 chr2 180453399 C T 5.34E-05 Serum metabolites ZNF385B intron 19043545 rs16866832 chr2 180456562 T A 2.40E-04 Smoking cessation ZNF385B intron 24665060 rs16866836 chr2 180457484 A G 3.33E-05 Diabetes Mellitus ZNF385B intron pha003060 rs2887110 chr2 180464847 T A 3.50E-04 Smoking cessation ZNF385B intron 24665060 rs7608208 chr2 180481889 A G 3.44E-04 Body mass index ZNF385B intron 17255346 rs3112959 chr2 180492678 A G 0.000822 Salmonella-induced pyroptosis ZNF385B intron 22837397 rs925753 chr2 180492704 G C 3.10E-05 Serum metabolites ZNF385B intron 19043545 rs3112945 chr2 180501314 C T 7.54E-05 Coronary heart disease ZNF385B intron pha003035 rs2138193 chr2 180506934 T A 1.05E-05 Uric acid levels ZNF385B intron 21294900 rs10930879 chr2 180507781 T C 6.92E-06 Body mass index ZNF385B intron 17255346 rs6743733 chr2 180511629 T C 8.62E-04 Response to taxane treatment (placlitaxel) ZNF385B intron 23006423 rs2056109 chr2 180538442 A G 8.50E-04 Obesity (extreme) ZNF385B intron 21935397 rs7424112 chr2 180546233 T G 6.50E-04 Obesity (extreme) ZNF385B intron 21935397 rs932116 chr2 180555019 G C 7.38E-04 Obesity (extreme) ZNF385B intron 21935397 rs2222033 chr2 180556229 A C 3.60E-07 Urinary metabolites ZNF385B intron 21572414 rs2222033 chr2 180556229 A C 7.33E-04 Obesity (extreme) ZNF385B intron 21935397 rs16866933 chr2 180566678 G A 6.00E-14 Sudden cardiac arrest ZNF385B intron 21658281 rs2008230 chr2 180568986 A C 2.37E-05 Relative hand skill in reading disability ZNF385B intron 24068947 rs881737 chr2 180580275 T C 5.10E-04 Smoking initiation ZNF385B intron 24665060 rs1964081 chr2 180591421 T C 3.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF385B intron 20877124 rs4556941 chr2 180626921 T G 1.12E-04 Parkinson's disease ZNF385B intron 17052657 rs4556941 chr2 180626921 T G 8.00E-05 Amyotrophic Lateral Sclerosis ZNF385B intron 17362836 rs16866996 chr2 180658729 G C 1.05E-04 Multiple complex diseases ZNF385B intron 17554300 rs357708 chr2 180664033 A G 4.64E-05 HIV-1 control ZNF385B intron 20041166 rs6733426 chr2 180830958 A G 4.59E-05 Hemoglobin CWC22 intron pha003096 rs6733426 chr2 180830958 A G 4.30E-05 Hematocrit CWC22 intron pha003097 rs262302 chr2 180931461 T C 8.34E-04 Multiple complex diseases / / 17554300 rs4125973 chr2 180946075 T C 9.41E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12623675 chr2 180972595 A G 5.69E-04 Alzheimer's disease / / 17998437 rs16867190 chr2 180976481 G T 3.47E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17793860 chr2 180979913 T C 4.68E-04 Multiple complex diseases / / 17554300 rs17793860 chr2 180979913 T C 1.70E-05 Urinary metabolites / / 21572414 rs1518430 chr2 180989284 C G 1.16E-04 Alzheimer's disease / / 17998437 rs10497560 chr2 180995313 G A 6.37E-05 Information processing speed / / 21130836 rs16867209 chr2 180999625 C T 3.88E-05 Type 2 diabetes / / 17463246 rs6758849 chr2 181001230 A C 1.09E-05 Glycemic traits (pregnancy) / / 23903356 rs13404412 chr2 181003750 T C 3.66E-04 Glycemic traits (pregnancy) / / 23903356 rs982813 chr2 181005674 G C 5.29E-04 Glycemic traits (pregnancy) / / 23903356 rs11900518 chr2 181008960 T C 2.81E-04 Glycemic traits (pregnancy) / / 23903356 rs11900565 chr2 181009003 T C 1.60E-04 Glycemic traits (pregnancy) / / 23903356 rs11900565 chr2 181009003 T C 6.95E-04 Glycemic traits (pregnancy) / / 23903356 rs17180327 chr2 181016133 A G 6.80E-07 Schizophrenia / / 21926974 rs17180327 chr2 181016133 A G 0.0000129 Schizophrenia / / 23637625 rs11689740 chr2 181016851 C G 1.25E-04 Glycemic traits (pregnancy) / / 23903356 rs11689740 chr2 181016851 C G 4.41E-04 Glycemic traits (pregnancy) / / 23903356 rs16867220 chr2 181020320 G A 1.20E-04 Type 2 diabetes / / 17463246 rs1401105 chr2 181025248 A G 9.71E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6433833 chr2 181027688 T C 3.14E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs2887172 chr2 181034436 G A 8.30E-06 Lipid traits / / 21777205 rs2887173 chr2 181036060 G A 2.10E-04 Alzheimer's disease (late onset) / / 21379329 rs16867225 chr2 181041286 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs7597201 chr2 181042370 T G 4.31E-04 Multiple sclerosis (OCB status) / / 23785401 rs6433837 chr2 181069983 C T 3.92E-04 Glycemic traits (pregnancy) / / 23903356 rs13418455 chr2 181076749 C T 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs7580896 chr2 181083696 A G 1.30E-04 Breast cancer / / 22452962 rs7580896 chr2 181083696 A G 1.12E-05 Glycemic traits (pregnancy) / / 23903356 rs7580896 chr2 181083696 A G 6.42E-06 Glycemic traits (pregnancy) / / 23903356 rs10497564 chr2 181086493 C T 5.06E-05 Glycemic traits (pregnancy) / / 23903356 rs2368139 chr2 181090941 C T 9.39E-08 Glycemic traits (pregnancy) / / 23903356 rs2368141 chr2 181092024 T A 4.77E-06 Glycemic traits (pregnancy) / / 23903356 rs7578753 chr2 181100938 C A 5.43E-06 Glycemic traits (pregnancy) / / 23903356 rs2368110 chr2 181115711 G A 5.42E-04 Type 2 diabetes / / 17463246 rs3936728 chr2 181121917 A G 9.31E-06 Glycemic traits (pregnancy) / / 23903356 rs6755569 chr2 181177756 C T 2.01E-06 Glycemic traits (pregnancy) / / 23903356 rs2176588 chr2 181261617 A G 4.86E-05 Blood Pressure / / pha002898 rs934882 chr2 181339431 G A 4.30E-05 Crohn's disease / / 20570966 rs1072038 chr2 181349830 A G 3.86E-05 Asthma / / 11022011 rs1072038 chr2 181349830 A G 8.35E-05 Multiple complex diseases / / 17554300 rs1453054 chr2 181359907 T G 1.04E-04 Multiple complex diseases / / 17554300 rs16867321 chr2 181362379 C A,G,T 2.00E-06 Obesity / / 21552555 rs11888446 chr2 181370895 G A 7.01E-07 Multiple complex diseases / / 17554300 rs10497567 chr2 181403464 G A 4.00E-04 Type 2 diabetes / / 17846126 rs991055 chr2 181468010 G A 1.73E-04 Multiple complex diseases / / 17554300 rs7595450 chr2 181481806 G C 7.82E-04 Multiple complex diseases / / 17554300 rs11896300 chr2 181492024 C T 4.90E-05 Hypertension (early onset hypertension) / / 22479346 rs933784 chr2 181511500 T C 4.62E-04 Multiple complex diseases / / 17554300 rs918959 chr2 181513729 G A 2.00E-06 Systemic lupus erythematosus / / 21408207 rs13029379 chr2 181586726 C T 5.36E-04 Coronary Artery Disease / / 17634449 rs13029379 chr2 181586726 C T 5.56E-04 Stroke / / pha002887 rs4362518 chr2 181625664 A G 6.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11676386 chr2 181659620 C A 3.95E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6758984 chr2 181698136 A G 3.81E-05 Major depressive disorder / / 22472876 rs4233776 chr2 181718781 G A 9.62E-04 HIV-1 viral setpoint / / 17641165 rs7559620 chr2 181734782 A C 3.96E-04 Myocardial Infarction / / pha002873 rs4666644 chr2 181755429 G C 1.23E-05 Major depressive disorder / / 22472876 rs13031974 chr2 181757693 A G 1.73E-05 Major depressive disorder / / 22472876 rs10178015 chr2 181773176 G A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263076 chr2 181779679 C T 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263076 chr2 181779679 C T 2.76E-05 Major depressive disorder / / 22472876 rs7578218 chr2 181855823 C G 5.44E-04 Type 2 diabetes UBE2E3 intron 17463246 rs7569991 chr2 181975252 T G 5.48E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6433894 chr2 181977227 A G 2.75E-06 White blood cell count / / 21738479 rs6731186 chr2 181977953 T C 7.15E-06 White blood cell count / / 21738479 rs7588217 chr2 181988909 C T 3.39E-06 White blood cell count / / 21738479 rs13010713 chr2 181996045 A G 5.00E-11 Celiac disease / / 20190752 rs13010713 chr2 181996045 A G 5.00E-11 Asthma / / 21150878 rs13010713 chr2 181996045 A G 4.74E-11 Celiac disease and Rheumatoid arthritis / / 21383967 rs13010713 chr2 181996045 A G 4.74E-11 Multiple sclerosis / / 22190364 rs1018326 chr2 182007800 T C 2.00E-06 Ankylosing spondylitis / / 20062062 rs1018326 chr2 182007800 T C 3.91E-06 White blood cell count / / 21738479 rs1018326 chr2 182007800 T C 3.10E-16 Celiac disease / / 22057235 rs13025711 chr2 182019461 T C 2.47E-05 Asthma / / 23181788 rs11693055 chr2 182033294 A G 6.80E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs4233792 chr2 182062313 T C 6.27E-04 Type 2 diabetes / / 17463246 rs4667158 chr2 182091564 T C 8.38E-04 Type 2 diabetes / / 17463246 rs16867404 chr2 182174452 G A 3.22E-04 Common variable immunodeficiency / / 21497890 rs16867406 chr2 182189405 C T 6.10E-05 Obsessive-compulsive disorder / / 24821223 rs16867406 chr2 182189405 C T 6.10E-05 Obsessive-compulsive disorder / / 24821223 rs17198619 chr2 182190558 G T 5.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs16867410 chr2 182201746 G A 1.22E-04 Multiple complex diseases / / 17554300 rs16867420 chr2 182226778 T C 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7602460 chr2 182261869 A G 6.00E-06 Atrioventricular conduction / / 21041692 rs12328393 chr2 182291035 A T 3.13E-06 Insulin-related traits / / 22791750 rs13389861 chr2 182291620 T C 4.67E-06 Insulin-related traits / / 22791750 rs1449263 chr2 182319301 C T 3.00E-23 White blood cell count / / 21738480 rs12988934 chr2 182323665 C T 2.00E-14 White blood cell types ITGA4 intron 21738478 rs1375493 chr2 182323766 G A 5.10E-07 Blood cell counts and traits,in red and white blood cells ITGA4 intron 21153663 rs2124440 chr2 182328214 G A 5.00E-17 Monocyte counts ITGA4 intron 23314186 rs1449264 chr2 182336474 T C 7.60E-04 Coronary heart disease ITGA4 intron 21966275 rs11694175 chr2 182338027 T C 1.96E-04 Alzheimer's disease ITGA4 intron 22005930 rs3770123 chr2 182344221 A C 5.21E-06 Osteoarthritis ITGA4 intron 21871595 rs155100 chr2 182350087 T A 2.20E-04 Alzheimer's disease ITGA4 intron 22005930 rs155104 chr2 182351216 T C 2.13E-04 Alzheimer's disease ITGA4 intron 22005930 rs155106 chr2 182351352 G T 2.87E-04 Alzheimer's disease ITGA4 intron 22005930 rs10172410 chr2 182352568 T C 2.90E-07 Osteoarthritis ITGA4 intron 21871595 rs2198731 chr2 182369945 A T 7.08E-04 Multiple complex diseases ITGA4 intron 17554300 rs3770112 chr2 182377541 G A 4.93E-08 Testicular cancer ITGA4 intron 19483682 rs1026404 chr2 182379191 A G 5.24E-04 Multiple complex diseases ITGA4 intron 17554300 rs3770110 chr2 182382367 G T 8.57E-04 Parkinson's disease ITGA4 intron 16252231 rs10514624 chr2 182418293 T C 1.21E-04 Multiple complex diseases CERKL intron 17554300 rs10490688 chr2 182422458 C A 2.84E-05 Multiple complex diseases CERKL intron 17554300 rs6706370 chr2 182427920 T A 4.35E-05 Multiple complex diseases CERKL intron 17554300 rs10427270 chr2 182436295 G C 7.93E-05 Multiple complex diseases CERKL intron 17554300 rs895901 chr2 182437094 T A 1.40E-05 Multiple complex diseases CERKL intron 17554300 rs993648 chr2 182455994 C T 3.00E-06 Response to iloperidone treatment (QT prolongation) CERKL intron 18521091 rs1116329 chr2 182465301 G A 7.40E-04 Aortic root size CERKL intron 21223598 rs10497581 chr2 182493051 T C 3.72E-04 Stroke (pediatric) CERKL intron 22990015 rs1441147 chr2 182511856 T C 3.00E-06 Lung function (forced expiratory volume in 1 second) CERKL intron 24023788 rs1441147 chr2 182511856 T C 9.00E-06 Lung function (forced vital capacity) CERKL intron 24023788 rs10207791 chr2 182522862 G A 1.35E-04 Multiple complex diseases CERKL nearGene-5 17554300 rs3755022 chr2 182536951 G A 1.60E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs3755022 chr2 182536951 G A 3.44E-04 Lung function (forced vital capacity) / / 24023788 rs12053195 chr2 182540683 T C 2.96E-04 Multiple complex diseases NEUROD1 nearGene-3 17554300 rs4666794 chr2 182554073 T C 2.04E-05 Iron status biomarkers / / 19084217 rs4666795 chr2 182554108 G A 2.30E-05 Iron status biomarkers / / 19084217 rs4666795 chr2 182554108 G A 0.0000377 Body mass index / / 23001569 rs4666572 chr2 182555564 C T 6.44E-05 Multiple complex diseases / / 17554300 rs2583008 chr2 182572502 T G 4.50E-04 Multiple complex diseases / / 17554300 rs2696328 chr2 182572614 G T 6.20E-04 Multiple complex diseases / / 17554300 rs1441158 chr2 182581409 A T 6.04E-04 Multiple complex diseases / / 17554300 rs11904490 chr2 182584021 C A 4.63E-05 Lipoproteins / / pha003079 rs12611771 chr2 182594588 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16867495 chr2 182622603 A G 5.46E-04 Multiple complex diseases / / 17554300 rs10183527 chr2 182623490 A G 2.73E-04 Multiple complex diseases / / 17554300 rs13424337 chr2 182629582 A G 2.49E-04 Multiple complex diseases / / 17554300 rs13424337 chr2 182629582 A G 6.42E-04 Insulin resistance / / 21901158 rs6718469 chr2 182716326 G A 9.97E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1157595 chr2 182749568 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13419647 chr2 182781419 C T 4.16E-04 Multiple complex diseases SSFA2 intron 17554300 rs2303554 chr2 182792984 T A 7.48E-09 Statin-induced myopathy SSFA2 missense 21826682 rs6433943 chr2 182815579 A G 8.91E-05 Body Mass Index / / pha003022 rs1153744 chr2 182859734 C A 3.80E-04 Alzheimer's disease (late onset) PPP1R1C intron 21379329 rs1196185 chr2 182884959 T A 7.90E-05 Schizophrenia PPP1R1C intron 19571809 rs12989378 chr2 182896104 G A 1.68E-05 Telomere length PPP1R1C intron 23001564 rs6732434 chr2 182901257 A G 2.73E-04 Attention deficit hyperactivity disorder PPP1R1C intron 22012869 rs16822370 chr2 182906711 G T 5.55E-04 Alcohol dependence PPP1R1C intron 21314694 rs1882211 chr2 182981846 G C 7.98E-04 Type 2 diabetes PPP1R1C intron 17463246 rs2217616 chr2 182999648 T G 5.79E-04 Multiple complex diseases / / 17554300 rs1196058 chr2 183012930 A C 1.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs1432523 chr2 183023484 A G 2.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs1196067 chr2 183029612 A G 9.35E-04 Obesity (extreme) PDE1A intron 21935397 rs1432534 chr2 183057446 A C 8.75E-05 Chronic obstructive pulmonary disease PDE1A intron 19300482 rs1432534 chr2 183057446 A C 8.75E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs12467526 chr2 183065122 A G 2.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs7578466 chr2 183113238 C T 3.63E-04 Multiple complex diseases PDE1A intron 17554300 rs6758334 chr2 183122038 T C 8.55E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs10193166 chr2 183133434 C A 9.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs833142 chr2 183163148 A C 6.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs2623410 chr2 183172364 T C 4.10E-06 Blood pressure PDE1A intron 21060006 rs2623410 chr2 183172364 T C 4.30E-05 Blood pressure PDE1A intron 21060006 rs2623410 chr2 183172364 T C 7.30E-04 Blood pressure PDE1A intron 21060006 rs11679657 chr2 183183111 G T 0.0000573 Tuberculosis with early age of onset PDE1A intron 22551897 rs12988258 chr2 183202412 G A 6.84E-04 Multiple complex diseases PDE1A intron 17554300 rs16823106 chr2 183216650 G T 7.47E-04 Multiple complex diseases PDE1A intron 17554300 rs16823120 chr2 183220865 A G 4.49E-04 Multiple complex diseases PDE1A intron 17554300 rs833115 chr2 183235574 C A 9.74E-04 Response to cytadine analogues (cytosine arabinoside) PDE1A intron 24483146 rs1898591 chr2 183242968 T G 0.000000793 LDL cholesterol PDE1A intron 23063622 rs2195611 chr2 183256567 C A 0.0001 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 PDE1A intron 21873659 rs1430148 chr2 183272699 C T 0.0000167 HDL cholesterol particle diameter PDE1A intron 23263444 rs1430147 chr2 183272945 C T 0.0000167 HDL cholesterol particle diameter PDE1A intron 23263444 rs10497600 chr2 183280294 T A 0.00000953 HDL cholesterol particle diameter PDE1A intron 23263444 rs41371048 chr2 183281664 G A 3.27E-04 Multiple complex diseases PDE1A intron 17554300 rs17343416 chr2 183286689 T C 6.93E-05 Smoking initiation PDE1A intron 24665060 rs10931012 chr2 183290028 G A 2.34E-04 Smoking initiation PDE1A intron 24665060 rs17356152 chr2 183292692 A G 0.0000087 HDL cholesterol particle diameter PDE1A intron 23263444 rs17265027 chr2 183293413 G A 0.00000269 HDL cholesterol particle diameter PDE1A intron 23263444 rs11686025 chr2 183293971 T C 0.00000732 HDL cholesterol particle diameter PDE1A intron 23263444 rs1946815 chr2 183298160 A G 0.00000209 HDL cholesterol particle diameter PDE1A intron 23263444 rs1583114 chr2 183299209 T G 0.00000228 HDL cholesterol particle diameter PDE1A intron 23263444 rs10207132 chr2 183300646 A G 0.00000299 HDL cholesterol particle diameter PDE1A intron 23263444 rs17356166 chr2 183300759 T C 0.00000633 HDL cholesterol particle diameter PDE1A intron 23263444 rs13407156 chr2 183302191 G C 0.00000273 HDL cholesterol particle diameter PDE1A intron 23263444 rs1992183 chr2 183303754 T C 1.96E-04 IgE levels PDE1A intron 17255346 rs17356207 chr2 183307827 A G 0.00000158 HDL cholesterol particle diameter PDE1A intron 23263444 rs16823254 chr2 183309282 T G 0.0000055 HDL cholesterol particle diameter PDE1A intron 23263444 rs16823257 chr2 183311380 A G 0.00000231 HDL cholesterol particle diameter PDE1A intron 23263444 rs1367203 chr2 183311523 A G 0.00000158 HDL cholesterol particle diameter PDE1A intron 23263444 rs6740889 chr2 183313207 T G 4.14E-04 IgE levels PDE1A intron 17255346 rs1125184 chr2 183320846 G A 0.00000563 HDL cholesterol particle diameter PDE1A intron 23263444 rs10497603 chr2 183336468 T C 5.11E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy PDE1A intron 23834954 rs7601804 chr2 183353582 A T 1.50E-04 Primary sclerosing cholangitis PDE1A intron 19944697 rs6433976 chr2 183376081 T C 4.06E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE1A intron 24023788 rs2887208 chr2 183380753 T C 3.00E-04 Primary sclerosing cholangitis PDE1A intron 19944697 rs10182788 chr2 183400730 G A 3.31E-05 Serum metabolites / / 19043545 rs1430154 chr2 183401789 C G 3.32E-05 Serum metabolites / / 19043545 rs6758080 chr2 183442443 G A 1.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1527878 chr2 183446535 G A 1.98E-05 Serum metabolites / / 19043545 rs1527878 chr2 183446535 G A 6.30E-04 Smoking initiation / / 24665060 rs10497607 chr2 183458192 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10497607 chr2 183458192 C T 4.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1527882 chr2 183461956 G A 1.92E-05 Bipolar disorder / / 20451256 rs1405945 chr2 183482466 T C 6.13E-06 Cognitive impairment induced by topiramate / / 22091778 rs7608820 chr2 183493891 T C 5.89E-04 Alzheimer's disease / / 17998437 rs10931027 chr2 183494672 T G 3.89E-04 Alzheimer's disease / / 17998437 rs17356672 chr2 183512335 A G 4.83E-04 Myocardial Infarction / / pha002883 rs288293 chr2 183631520 G A 1.20E-05 Coronary spasm D/JC10 intron 18075462 rs16823704 chr2 183667233 A C 7.45E-05 Type 2 diabetes / / 17463246 rs16823704 chr2 183667233 A C 1.03E-04 Progressive supranuclear palsy / / 21685912 rs10931041 chr2 183685562 C T 9.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs17265803 chr2 183696519 T C 0.0000657 Schizophrenia / / 22440650 rs7606391 chr2 183760854 A C 8.13E-05 Brain lesion load / / 19010793 rs10164916 chr2 183767134 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1022337 chr2 183906786 T C 6.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4666885 chr2 183939173 C T 5.32E-04 Type 2 diabetes / / 17463246 rs4666885 chr2 183939173 C T 1.03E-04 Hemoglobin concentration / / 20534544 rs2675043 chr2 183941444 T C 6.48E-05 Hemoglobin concentration / / 20534544 rs10460378 chr2 183957860 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DUSP19 intron 22628534 rs11883456 chr2 183959461 G A 3.32E-05 Hemoglobin concentration DUSP19 intron 20534544 rs2138484 chr2 183977942 G A 4.44E-04 Type 2 diabetes / / 17463246 rs2138484 chr2 183977942 G A 1.67E-04 Hemoglobin concentration / / 20534544 rs2675058 chr2 183978549 A G 6.19E-06 Hemoglobin concentration / / 20534544 rs17704982 chr2 183981176 G A 2.77E-04 Lymphocyte counts / / 22286170 rs16823994 chr2 183981448 T C 8.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16824004 chr2 183985969 C T 7.54E-04 Insulin resistance / / 21901158 rs2251775 chr2 183988599 T C 8.58E-05 Hemoglobin concentration / / 20534544 rs2251775 chr2 183988599 T C 9.11E-04 Myocardial Infarction / / pha002873 rs1473617 chr2 183989863 C T 1.83E-05 Hemoglobin concentration NUP35 intron 20534544 rs10497622 chr2 183997890 A G 1.90E-04 Cholesterol NUP35 intron 17255346 rs2675098 chr2 184005606 G A 4.59E-04 Eye color NUP35 intron 23118974 rs2887233 chr2 184015089 G T 1.87E-04 Multiple complex diseases NUP35 intron 17554300 rs13410455 chr2 184023295 G A 2.44E-04 Cholesterol NUP35 intron 17255346 rs6434006 chr2 184024702 T C 8.58E-05 Hemoglobin concentration NUP35 intron 20534544 rs1882443 chr2 184046119 C T 8.58E-05 Hemoglobin concentration / / 20534544 rs6434019 chr2 184066858 C T 0.0008515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6434019 chr2 184066858 C T 8.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10497624 chr2 184069020 C T 4.69E-04 Hemoglobin concentration / / 20534544 rs987607 chr2 184069487 A G 8.52E-04 Coronary Artery Disease / / 17634449 rs987607 chr2 184069487 A G 4.69E-04 Hemoglobin concentration / / 20534544 rs987607 chr2 184069487 A G 5.96E-06 Uric acid levels / / 21294900 rs987607 chr2 184069487 A G 3.51E-04 Myocardial Infarction / / pha002873 rs10931070 chr2 184084153 C G 1.95E-04 Birth weight / / 17255346 rs17758247 chr2 184085788 T C 6.99E-05 Height / / pha003011 rs4666621 chr2 184097520 A G 5.01E-04 Type 2 diabetes / / 17463246 rs1462529 chr2 184141848 A G 2.95E-05 Height / / pha003010 rs1462529 chr2 184141848 A G 1.67E-05 Height / / pha003011 rs842547 chr2 184262562 T C 8.17E-04 Multiple complex diseases / / 17554300 rs16824418 chr2 184275365 A C 8.78E-04 Type 2 diabetes / / 17463246 rs842565 chr2 184290177 T A 8.28E-04 Multiple complex diseases / / 17554300 rs1625832 chr2 184299168 A G 3.66E-04 Multiple complex diseases / / 17554300 rs1992179 chr2 184353455 T C 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13409979 chr2 184353810 G A 6.65E-06 Rheumatoid arthritis / / 19503088 rs13409979 chr2 184353810 G A 9.44E-06 Alopecia areata / / 22027810 rs4666630 chr2 184358804 G A 6.10E-06 Digit length ratio / / 20303062 rs1898582 chr2 184364553 G A 1.74E-04 Multiple complex diseases / / 17554300 rs1898582 chr2 184364553 G A 3.39E-04 Taste perception / / 22132133 rs9288091 chr2 184371403 G A 7.98E-05 Vaspin levels / / 22907691 rs9288091 chr2 184371403 G A 0.0000798 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs13426853 chr2 184391717 A G 2.95E-04 Multiple complex diseases / / 17554300 rs6712313 chr2 184392292 T C 2.67E-04 Multiple complex diseases / / 17554300 rs2368446 chr2 184407963 T C 5.30E-04 Alcohol dependence / / 20201924 rs2368423 chr2 184458832 G T 6.73E-05 Major depressive disorder (broad) / / 20038947 rs1406337 chr2 184476015 A G 7.60E-05 Height / / 17255346 rs13384559 chr2 184479350 A G 6.24E-05 Major depressive disorder (broad) / / 20038947 rs6737900 chr2 184483143 C T 6.16E-05 Major depressive disorder (broad) / / 20038947 rs6742026 chr2 184484253 C T 6.14E-05 Major depressive disorder (broad) / / 20038947 rs1463328 chr2 184502493 G A 4.09E-05 Coronary heart disease / / pha003030 rs4666636 chr2 184527836 T C 5.14E-05 Coronary heart disease / / pha003030 rs10931091 chr2 184533968 T C 3.45E-06 Heart Failure / / pha002885 rs7588905 chr2 184538604 G A 1.90E-04 Birth weight / / 17255346 rs10803967 chr2 184540102 G A 8.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13016089 chr2 184551466 A G 1.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1377767 chr2 184586627 G A 7.08E-04 Coronary heart disease / / 21606135 rs1733497 chr2 184623742 T C 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs826116 chr2 184750869 T C 9.85E-04 Multiple complex diseases / / 17554300 rs826140 chr2 184771169 C G 5.85E-05 Multiple complex diseases / / 17554300 rs826130 chr2 184793800 C T 3.79E-04 Birth weight / / 17255346 rs2165172 chr2 184800983 A G 0.00000908 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs10205814 chr2 184818243 G A 1.36E-04 Lung function (forced vital capacity) / / 24023788 rs4413128 chr2 184880887 C A 1.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4505485 chr2 184882169 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6434057 chr2 184901392 G A 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12693368 chr2 184919967 C T 4.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1002331 chr2 184923473 T G 4.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1405193 chr2 184938401 C T 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1007465 chr2 184971481 A G 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1568958 chr2 184971569 G A 1.05E-04 Multiple complex diseases / / 17554300 rs2369200 chr2 184976536 T G 5.55E-04 Multiple complex diseases / / 17554300 rs1526208 chr2 185021912 G A 9.81E-06 Total ventricular volume / / 21116278 rs2887422 chr2 185033177 C A 1.40E-05 Urinary metabolites / / 21572414 rs1526197 chr2 185050101 A G 5.90E-06 Urinary metabolites / / 21572414 rs12471114 chr2 185067733 C T 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6738298 chr2 185093719 T G 1.88E-04 Type 2 diabetes / / 17846124 rs12621296 chr2 185099836 A G 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1455882 chr2 185107332 A G 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs985365 chr2 185111854 T C 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12988831 chr2 185114368 C T 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7558999 chr2 185127554 A T 2.59E-04 Multiple complex diseases / / 17554300 rs2198715 chr2 185212246 T C 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs17429535 chr2 185223403 T C 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs10203961 chr2 185224396 C T 8.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs7602691 chr2 185225038 A G 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10200357 chr2 185230499 A T 8.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs13015290 chr2 185232216 T A 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12693375 chr2 185243700 C T 8.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs12623744 chr2 185282393 T A 9.03E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10931139 chr2 185289177 A G 1.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11691711 chr2 185293916 G A 2.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12472209 chr2 185375265 G T 5.46E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12477814 chr2 185400705 C T 6.71E-04 Alzheimer's disease / / 24755620 rs2033136 chr2 185405704 A C 5.26E-07 Multiple complex diseases / / 17554300 rs17430279 chr2 185436262 A G 4.00E-06 Obesity-related traits / / 23251661 rs181701 chr2 185445430 C T 5.81E-04 Multiple complex diseases / / 17554300 rs12693382 chr2 185467661 G A 0.0000692 Primary sclerosing cholangitis ZNF804A intron 23603763 rs17508595 chr2 185483108 C G 5.86E-04 Multiple complex diseases ZNF804A intron 17554300 rs359884 chr2 185486334 T C 9.70E-04 Alzheimer's disease ZNF804A intron 24755620 rs12613195 chr2 185489221 C G 1.01E-04 Multiple complex diseases ZNF804A intron 17554300 rs7597593 chr2 185533580 T C 8.77E-04 White matter integrity ZNF804A intron 22425255 rs7597593 chr2 185533580 T C 2.04E-06 Major depressive disorder ZNF804A intron 22472876 rs7597593 chr2 185533580 T C 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ZNF804A intron 23453885 rs17508767 chr2 185535807 A G 5.21E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs2369595 chr2 185626426 C T 9.77E-04 White matter integrity ZNF804A intron 22425255 rs77224444 chr2 185627257 C G 0.0000929 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs72901884 chr2 185629709 A C 0.0000998 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs72905792 chr2 185726138 G A 0.0000803 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs1820847 chr2 185742474 A G 4.46E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs7590852 chr2 185766912 T C 4.16E-06 Malaria ZNF804A intron 23717212 rs10497662 chr2 185769921 T C 4.11E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs17431742 chr2 185773401 C G 6.83E-04 Multiple complex diseases ZNF804A intron 17554300 rs725617 chr2 185778262 G A 4.60E-06 Malaria ZNF804A intron 23717212 rs1344706 chr2 185778428 A C 2.87E-04 Multiple complex diseases ZNF804A intron 17554300 rs1344706 chr2 185778428 A C 2.00E-07 Schizophrenia ZNF804A intron 18677311 rs1344706 chr2 185778428 A C 2.76E-04 Major depressive disorder ZNF804A intron 22472876 rs1583048 chr2 185783141 T C 2.93E-05 Information processing speed ZNF804A intron 21130836 rs1583048 chr2 185783141 T C 3.12E-04 Major depressive disorder ZNF804A intron 22472876 rs1583049 chr2 185792818 A G 1.74E-04 Type 2 diabetes ZNF804A intron 17463246 rs6726421 chr2 185796842 C G 9.20E-05 Multiple complex diseases ZNF804A intron 17554300 rs6755404 chr2 185797228 A C 1.00E-06 Malaria ZNF804A intron 23717212 rs4667002 chr2 185801755 A G 1.83E-04 Smoking quantity ZNF804A cds-synon 24665060 rs12693402 chr2 185808079 C T 7.81E-05 Response to lithium treatment in bipolar disorder / / 21961650 rs4380187 chr2 185811940 A C 6.00E-08 Schizophrenia / / 23974872 rs2163065 chr2 185853355 C T 7.90E-05 Multiple complex diseases / / 17554300 rs13386401 chr2 185865400 A G 9.57E-05 HIV-1 viral setpoint / / 17641165 rs13416716 chr2 185912017 C T 1.37E-05 HIV-1 viral setpoint / / 17641165 rs13392265 chr2 185994883 C T 9.73E-04 Multiple complex diseases / / 17554300 rs1483232 chr2 185995792 G A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11678036 chr2 186024735 C T 6.00E-06 IgG glycosylation / / 23382691 rs9288109 chr2 186025368 T C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9288109 chr2 186025368 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9288110 chr2 186025482 T C 1.85E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1038361 chr2 186031490 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2369929 chr2 186101208 G A 9.79E-04 Multiple complex diseases / / 17554300 rs7577666 chr2 186116077 G A 2.02E-04 Smoking cessation / / 24665060 rs4487060 chr2 186148230 G A 2.99E-04 Smoking cessation / / 24665060 rs2113493 chr2 186152716 C T 8.45E-05 Smoking cessation / / 24665060 rs7608802 chr2 186162731 A G 3.06E-04 Smoking cessation / / 24665060 rs7608891 chr2 186162774 A G 3.00E-04 Smoking cessation / / 24665060 rs1364477 chr2 186184030 A G 6.00E-06 IgG glycosylation / / 23382691 rs13023579 chr2 186190812 G A 2.58E-04 Alzheimer's disease / / 24755620 rs850880 chr2 186205189 T C 0.00000009 Brain microstructure and intellectual performance / / 22723713 rs850906 chr2 186218867 T G 7.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1424528 chr2 186239607 A G 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs28801070 chr2 186244817 G A,C 7.26E-07 Multiple myeloma / / 22120009 rs62195162 chr2 186244945 A G 0.0000578 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10931170 chr2 186247637 C T 4.80E-05 Kawasaki disease / / 22446962 rs17403226 chr2 186253296 T C 1.00E-06 Urinary metabolites / / 21572414 rs16826790 chr2 186255088 C G 9.60E-07 Urinary metabolites / / 21572414 rs17403547 chr2 186291818 T G 4.82E-04 Parkinson's disease / / 17052657 rs16826853 chr2 186303297 A G 2.00E-05 Urinary metabolites / / 21572414 rs767036 chr2 186303487 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2059357 chr2 186325949 C G 1.14E-04 Gallstones / / 17632509 rs2059357 chr2 186325949 C G 5.20E-05 Mathematical ability / / 20039944 rs2081326 chr2 186338274 A G 3.50E-06 Urinary metabolites / / 21572414 rs2081326 chr2 186338274 A G 2.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4309546 chr2 186394606 A T 5.40E-06 Urinary metabolites / / 21572414 rs10445775 chr2 186423207 C T 3.10E-06 Urinary metabolites / / 21572414 rs2193612 chr2 186486890 A G 3.11E-04 Gallstones / / 17632509 rs11686018 chr2 186536737 C T 2.90E-05 Urinary metabolites / / 21572414 rs11693975 chr2 186538392 T A 9.15E-04 Multiple complex diseases / / 17554300 rs11693975 chr2 186538392 T A 2.20E-05 Urinary metabolites / / 21572414 rs4334457 chr2 186583961 T C 1.20E-05 Urinary metabolites / / 21572414 rs10202023 chr2 186591557 C T 8.48E-04 Multiple complex diseases / / 17554300 rs2193820 chr2 186693608 G A 5.29E-05 Multiple complex diseases FSIP2 intron 17554300 rs12616304 chr2 186756214 T C 9.06E-04 Acute lung injury / / 22295056 rs13021558 chr2 186777129 G A 1.48E-04 Acute lung injury / / 22295056 rs964744 chr2 186882149 C T 7.91E-05 Alcohol withdrawal symptoms / / 22072270 rs875161 chr2 186896504 A C 6.33E-04 Type 2 diabetes / / 17463246 rs6434158 chr2 186897066 A C 4.16E-04 Alzheimer's disease / / 17998437 rs10184559 chr2 186939737 T C 7.09E-04 Type 2 diabetes / / 17463246 rs10184559 chr2 186939737 T C 1.60E-05 Urinary metabolites / / 21572414 rs10189482 chr2 186960817 G A 8.30E-04 Type 2 diabetes / / 17463246 rs10189482 chr2 186960817 G A 1.20E-05 Urinary metabolites / / 21572414 rs10197403 chr2 186979237 T C 9.55E-04 Type 2 diabetes / / 17463246 rs4552153 chr2 186991136 T A 8.25E-04 Type 2 diabetes / / 17463246 rs4264536 chr2 186991571 A C 8.99E-04 Type 2 diabetes / / 17463246 rs4442964 chr2 186993455 T C 8.24E-04 Type 2 diabetes / / 17463246 rs12693436 chr2 187001076 G A 3.65E-04 Type 2 diabetes / / 17463246 rs16827526 chr2 187040829 T G 4.30E-05 Alcohol withdrawal symptoms / / 22072270 rs10497667 chr2 187043858 C G 1.40E-05 Urinary metabolites / / 21572414 rs34133588 chr2 187054504 A G 1.80E-05 Urinary metabolites / / 21572414 rs35942256 chr2 187055061 A G 1.80E-05 Urinary metabolites / / 21572414 rs2370672 chr2 187066334 C T 1.80E-05 Urinary metabolites / / 21572414 rs2370671 chr2 187066503 A G 2.50E-05 Urinary metabolites / / 21572414 rs7584724 chr2 187069917 T C 1.80E-05 Urinary metabolites / / 21572414 rs4461230 chr2 187071775 G A,T 1.80E-05 Urinary metabolites / / 21572414 rs16827602 chr2 187072508 T C 5.50E-06 Urinary metabolites / / 21572414 rs16827614 chr2 187079652 A C 1.90E-06 Urinary metabolites / / 21572414 rs3107174 chr2 187084689 C T 1.00E-05 Urinary metabolites / / 21572414 rs10931232 chr2 187125310 A G 1.20E-05 Urinary metabolites / / 21572414 rs13421948 chr2 187126560 T C 7.00E-05 Major depressive disorder / / 21042317 rs4522568 chr2 187149967 A C 7.20E-05 Major depressive disorder / / 21042317 rs4530331 chr2 187150058 G A 4.50E-05 Major depressive disorder / / 21042317 rs6744814 chr2 187156914 G A 5.60E-05 Major depressive disorder / / 21042317 rs10497668 chr2 187213730 T C 9.48E-05 Alcohol withdrawal symptoms / / 22072270 rs10497669 chr2 187225386 G A 7.59E-05 Brain lesion load / / 19010793 rs12467212 chr2 187264986 A G 6.50E-05 Major depressive disorder / / 21042317 rs3911238 chr2 187470344 G C 9.65E-05 Serum metabolites ITGAV intron 19043545 rs12620429 chr2 187489647 C A 9.55E-05 Brain lesion load ITGAV intron 19010793 rs7585471 chr2 187498562 A G 5.42E-05 Orofacial clefts ITGAV intron 22419666 rs1448427 chr2 187526672 G A 3.80E-05 Orofacial clefts ITGAV intron 22419666 rs3816386 chr2 187528635 A G 6.96E-04 Suicide attempts in bipolar disorder ITGAV intron 21423239 rs11685758 chr2 187533368 C T 8.49E-04 Suicide attempts in bipolar disorder ITGAV intron 21423239 rs4666713 chr2 187602188 T G 8.42E-07 Serum metabolites FAM171B intron 19043545 rs17750683 chr2 187620297 A T 1.53E-04 Suicide attempts in bipolar disorder FAM171B intron 21423239 rs13026081 chr2 187626338 C T 4.53E-04 Suicide attempts in bipolar disorder FAM171B cds-synon 21423239 rs4589713 chr2 187685145 C T 2.32E-04 Type 2 diabetes / / 17463246 rs10497673 chr2 187731384 T C 3.27E-05 stroke (ischemic) / / 17434096 rs17700953 chr2 187754997 C A 9.10E-05 Diabetic retinopathy / / 21441570 rs16828441 chr2 187784740 G T 2.50E-05 Bipolar disorder,affective / / 20528957 rs1562893 chr2 187802572 C T 5.60E-05 Diabetic retinopathy / / 21441570 rs4563188 chr2 187807952 G A 1.70E-05 Diabetic retinopathy / / 21441570 rs2370736 chr2 187880937 C A 1.90E-04 Prion diseases / / 22210626 rs17576323 chr2 188003118 T C 9.20E-05 Diabetic retinopathy / / 21441570 rs6712198 chr2 188119621 C T 3.60E-04 Multiple complex diseases / / 17554300 rs6721057 chr2 188131849 C A 3.63E-04 Multiple complex diseases / / 17554300 rs840616 chr2 188196469 T C 7.00E-07 Coronary heart disease / / 21378988 rs3771095 chr2 188211112 C T 6.80E-05 White matter hyperintensity burden CALCRL cds-synon 21681796 rs1706287 chr2 188224057 A G 2.10E-05 Urinary metabolites CALCRL intron 21572414 rs696574 chr2 188228516 T C 6.70E-05 White matter hyperintensity burden CALCRL intron 21681796 rs840617 chr2 188230333 A T 8.80E-05 White matter hyperintensity burden CALCRL intron 21681796 rs17464221 chr2 188278203 C T 2.23E-04 Gallstones CALCRL intron 17632509 rs113727256 chr2 188332602 T C 0.000011 Breast cancer (ER positive) TFPI missense 23555315 rs113727256 chr2 188332602 T C 0.00019 Breast cancer TFPI missense 23555315 rs4140885 chr2 188333064 G A 5.00E-08 Heart rate TFPI intron 23583979 rs7586970 chr2 188343497 T C 9.00E-06 Coronary heart disease TFPI missense 21378988 rs8176445 chr2 188362807 T C 5.53E-29 Cholesterol,total TFPI intron 23063622 rs8176445 chr2 188362807 T C 7.63E-13 LDL cholesterol TFPI intron 23063622 rs8176445 chr2 188362807 T C 8.38E-11 Triglycerides TFPI intron 23063622 rs8176433 chr2 188364825 C G 1.57E-19 Cholesterol,total TFPI intron 23063622 rs8176433 chr2 188364825 C G 1.89E-27 LDL cholesterol TFPI intron 23063622 rs2192825 chr2 188390819 C T 7.57E-05 Cognitive test performance TFPI intron 20125193 rs6434225 chr2 188461438 T C 1.46E-05 Menopause (age at onset) / / 19448619 rs12469114 chr2 188475822 G A 9.72E-04 Type 2 diabetes / / 17463246 rs7561970 chr2 188482933 A G 2.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs6712217 chr2 188500930 G A 2.29E-04 Coronary heart disease / / 21606135 rs13034939 chr2 188511096 A G 3.01E-04 Coronary heart disease / / 21606135 rs13388743 chr2 188573244 C T 8.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11675507 chr2 188594997 A G 3.54E-04 Parkinson's disease / / 17052657 rs11675507 chr2 188594997 A G 4.81E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2349872 chr2 188600305 G A 3.06E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1520475 chr2 188601258 C T 1.22E-04 Parkinson's disease / / 17052657 rs1402145 chr2 188601710 A C 3.49E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1402144 chr2 188607403 A G 3.64E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9288147 chr2 188609736 A G 4.00E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1520477 chr2 188611039 T C 3.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4667192 chr2 188616978 T C 3.43E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13032640 chr2 188618150 G A 3.33E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6748449 chr2 188620681 C T 3.13E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6715141 chr2 188623152 T C 2.70E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6434236 chr2 188664170 C T 6.25E-05 Multiple complex diseases / / 17554300 rs4471853 chr2 188684507 A G 7.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6728009 chr2 188700615 G T 2.64E-05 Coronary heart disease / / 21606135 rs12615952 chr2 188722417 C T 5.98E-04 Multiple complex diseases / / 17554300 rs1040172 chr2 188761539 T C 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1040172 chr2 188761539 T C 6.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16829362 chr2 188764415 A T 2.70E-05 Urinary metabolites / / 21572414 rs1317323 chr2 188798760 T C 1.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317323 chr2 188798760 T C 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12469465 chr2 188800394 C T 1.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10170218 chr2 188814444 A C 5.10E-08 Post-traumatic stress disorder / / 24080187 rs17263610 chr2 188881350 C A 7.50E-06 Urinary metabolites / / 21572414 rs7569881 chr2 188953427 T C 5.76E-04 Acute lung injury / / 22295056 rs1439912 chr2 188957640 T C 2.09E-04 Vaspin levels / / 22907691 rs1439912 chr2 188957640 T C 0.0002087 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs893745 chr2 189088249 A G 2.53E-04 Smoking initiation / / 24665060 rs6759766 chr2 189113345 G A 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7582137 chr2 189122229 T C 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11688935 chr2 189175905 G A 2.10E-05 Type 2 diabetes GULP1 intron 17463249 rs11688935 chr2 189175905 G A 2.13E-05 Multiple complex diseases GULP1 intron 17554300 rs4128404 chr2 189179247 A G 9.96E-04 Type 2 diabetes GULP1 intron 17463246 rs10931347 chr2 189182307 A G 2.42E-05 Multiple complex diseases GULP1 intron 17554300 rs7566619 chr2 189199195 A G 2.00E-04 Cognitive impairment induced by topiramate GULP1 intron 22091778 rs10804020 chr2 189202876 A G 9.64E-04 Multiple complex diseases GULP1 intron 17554300 rs4274570 chr2 189266823 G A 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GULP1 intron 20877124 rs10931358 chr2 189270581 G C,T 4.68E-04 Type 2 diabetes GULP1 intron 17463246 rs10170220 chr2 189298118 C T 3.37E-04 Type 2 diabetes GULP1 intron 17463246 rs4667227 chr2 189306009 T C 4.35E-04 Type 2 diabetes GULP1 intron 17463246 rs13034731 chr2 189414364 C T 2.86E-04 Lung function (forced vital capacity) GULP1 intron 24023788 rs7425417 chr2 189425279 A G 6.26E-05 Type 2 diabetes GULP1 intron 17463246 rs3935690 chr2 189485156 T G 8.23E-04 Type 2 diabetes / / 17463246 rs3935690 chr2 189485156 T G 5.83E-04 Alzheimer's disease / / 17998437 rs11683183 chr2 189495871 A T 6.24E-04 Type 2 diabetes / / 17463246 rs1395868 chr2 189543514 G A 6.14E-04 Type 2 diabetes / / 17463246 rs10497681 chr2 189551707 A G 6.07E-04 Type 2 diabetes / / 17846124 rs10497681 chr2 189551707 A G 6.78E-05 Type 2 diabetes / / 17846125 rs10173369 chr2 189564693 G A 7.60E-04 Type 2 diabetes / / 17463246 rs1996987 chr2 189588449 T A 8.05E-04 Multiple complex diseases / / 17554300 rs1395864 chr2 189588880 A G 4.80E-04 Iris characteristics / / 21835309 rs10931378 chr2 189594624 C A,T 4.96E-04 Multiple complex diseases / / 17554300 rs781241 chr2 189607681 A G 6.82E-04 Multiple complex diseases DIRC1 intron 17554300 rs1400945 chr2 189614336 G A 4.47E-04 Type 2 diabetes DIRC1 intron 17463246 rs1589133 chr2 189644222 G C 1.81E-04 Multiple complex diseases DIRC1 intron 17554300 rs10166484 chr2 189648684 T C 3.43E-04 Multiple complex diseases DIRC1 intron 17554300 rs781288 chr2 189654868 A G 1.10E-04 Alzheimer's disease DIRC1 nearGene-5 17998437 rs940461 chr2 189670082 G A 5.44E-04 Type 2 diabetes / / 17463246 rs2708198 chr2 189671182 C T 8.25E-04 Type 2 diabetes / / 17463246 rs2690759 chr2 189671216 A G 5.77E-04 Alzheimer's disease / / 17998437 rs1518006 chr2 189697095 G A 6.52E-04 Multiple complex diseases / / 17554300 rs2675399 chr2 189718962 A G 6.00E-06 Obesity-related traits / / 23251661 rs4667253 chr2 189799682 T C 9.46E-04 Depression (quantitative trait) / / 20800221 rs7591905 chr2 189890114 C T 4.65E-06 Alzheimer's disease / / 21627779 rs10166301 chr2 189947814 C T 3.96E-05 Multiple complex diseases COL5A2 intron 17554300 rs17270952 chr2 190004843 C T 8.97E-04 Alzheimer's disease COL5A2 intron 17998437 rs1878085 chr2 190073366 A G 8.36E-04 Type 2 diabetes / / 17463246 rs1878085 chr2 190073366 A G 2.67E-04 Gallstones / / 17632509 rs4667272 chr2 190106465 T C 8.36E-04 Type 2 diabetes / / 17463246 rs10207860 chr2 190146586 C T 5.50E-05 Leukocyte Counts / / pha003091 rs1949604 chr2 190215928 G A 7.24E-04 Type 2 diabetes / / 17463246 rs10931414 chr2 190216503 G C 6.11E-04 Type 2 diabetes / / 17463246 rs10931418 chr2 190265035 C T 7.25E-04 Type 2 diabetes / / 17463246 rs11695159 chr2 190283215 C A 6.05E-04 Type 2 diabetes / / 17463246 rs13032853 chr2 190309412 T C 7.02E-04 Type 2 diabetes WDR75 intron 17463246 rs12693540 chr2 190352568 C T 9.80E-05 Parkinson's disease (familial) / / 18985386 rs11692009 chr2 190376388 G A 4.82E-04 Depression (quantitative trait) / / 20800221 rs10206036 chr2 190376873 G A 5.87E-04 Depression (quantitative trait) / / 20800221 rs17271148 chr2 190402222 G A 3.40E-04 Alcohol dependence / / 20201924 rs11539983 chr2 190425474 T C 5.70E-04 Alcohol dependence SLC40A1 UTR-3 20201924 rs10188230 chr2 190432613 T C 5.30E-04 Alcohol dependence SLC40A1 intron 20201924 rs930373 chr2 190443583 T C 6.95E-04 Type 2 diabetes SLC40A1 intron 17463246 rs11678005 chr2 190487106 C A,T 3.44E-04 Type 2 diabetes / / 17463246 rs11678005 chr2 190487106 C A,T 5.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4372939 chr2 190487474 G T 5.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6434355 chr2 190501523 C T 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756040 chr2 190502081 T C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756913 chr2 190505766 G C 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761923 chr2 190507599 G C 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7568449 chr2 190521054 C T 3.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11679767 chr2 190546300 A G 6.70E-05 Glioma (high-grade) ANKAR intron 19578366 rs7557519 chr2 190583187 C T 1.23E-04 Lymphocyte counts ANKAR intron 22286170 rs12053254 chr2 190607153 T C 6.00E-06 Obesity-related traits ANKAR intron 23251661 rs7606224 chr2 190643649 T C 1.28E-08 Bilirubin levels,in serum ORMDL1 intron 20639394 rs1899025 chr2 190649582 C T 8.40E-05 Glioma (high-grade) PMS1 intron 19578366 rs1899025 chr2 190649582 C T 1.80E-05 Hypertension PMS1 intron 22384028 rs5742967 chr2 190653750 C T 5.96E-06 Obesity-related traits PMS1 intron 23251661 rs5743030 chr2 190678545 G A 5.00E-06 Subcutaneous adipose tissue PMS1 intron 22589738 rs1233276 chr2 190684782 A G 8.98E-04 Suicide attempts in bipolar disorder PMS1 intron 21423239 rs5743185 chr2 190737838 G A 2.09E-11 Blood pressure PMS1 intron 21378095 rs5743185 chr2 190737838 G A 2.30E-10 Interleukin levels (IL10,IL1Ra,IL6),in plasma PMS1 intron 22205395 rs62184315 chr2 190771945 T C 4.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7563391 chr2 190779803 G C 3.81E-06 Alcohol dependence (age at onset) / / 24962325 rs62184317 chr2 190781764 C T 3.81E-06 Alcohol dependence (age at onset) / / 24962325 rs7603201 chr2 190794653 A G 7.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs2164252 chr2 190818454 G T 2.50E-05 Urinary metabolites / / 21572414 rs2168058 chr2 190818878 G A 2.80E-05 Urinary metabolites / / 21572414 rs6745182 chr2 190825226 T C 8.74E-06 Schizophrenia / / 21747397 rs16832254 chr2 190889261 G A 1.00E-05 Urinary metabolites / / 21572414 rs13010250 chr2 190900963 T C 2.10E-05 Urinary metabolites / / 21572414 rs2115552 chr2 190972205 G T 3.64E-04 Multiple complex diseases / / 17554300 rs13034723 chr2 190985680 G A 2.00E-08 Body mass index / / 22344221 rs13012077 chr2 191000031 C A,T 6.10E-04 Alzheimer's disease / / 22005930 rs2562817 chr2 191008125 T C 4.63E-04 Multiple complex diseases C2orf88 intron 17554300 rs4853684 chr2 191062951 A G 7.14E-05 Cytomegalovirus antibody response C2orf88 intron 21993531 rs16832420 chr2 191063071 G C 7.08E-05 Cytomegalovirus antibody response C2orf88 intron 21993531 rs11684995 chr2 191102249 G T 4.54E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs2099127 chr2 191102796 A C 4.50E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs11692448 chr2 191112241 G A 4.20E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs1072975 chr2 191121182 A T 8.18E-05 Aging (time to event) HIBCH intron 21782286 rs3791800 chr2 191149069 A C 4.22E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs4853689 chr2 191153014 A C 4.21E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs6752703 chr2 191164969 G A 4.13E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs2136569 chr2 191167414 T C 9.46E-04 Multiple complex diseases HIBCH intron 17554300 rs3791805 chr2 191172784 C G 3.98E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs291449 chr2 191177467 C T 7.03E-04 Multiple complex diseases HIBCH intron 17554300 rs4853693 chr2 191179508 T G 9.68E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs3791806 chr2 191182081 C T 3.96E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs291472 chr2 191190605 T C 6.76E-04 Multiple complex diseases / / 17554300 rs1882892 chr2 191213664 A G 7.99E-04 Alzheimer's disease INPP1 UTR-5 17998437 rs1882892 chr2 191213664 A G 8.90E-05 Serum metabolites INPP1 UTR-5 19043545 rs1882892 chr2 191213664 A G 7.18E-04 Lymphocyte counts INPP1 UTR-5 22286170 rs972689 chr2 191227492 A G 5.08E-04 Alzheimer's disease INPP1 intron 17998437 rs10931458 chr2 191390126 G A 4.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEM194B intron 24023788 rs10737936 chr2 191469731 T C 7.17E-04 HIV-1 viral setpoint / / 17641165 rs1023568 chr2 191515442 A T 1.20E-05 Subclinical atherosclerosis /B1 intron 17903303 rs2286896 chr2 191535576 T C 1.09E-11 Primary biliary cirrhosis /B1 intron 21399635 rs10931468 chr2 191538562 C A 2.00E-19 Primary biliary cirrhosis /B1 intron 21399635 rs3771317 chr2 191543962 T C 1.61E-12 Primary biliary cirrhosis /B1 intron 21399635 rs10202868 chr2 191563991 T C 2.70E-05 Urinary metabolites / / 21572414 rs7602459 chr2 191579425 A G 3.39E-04 Multiple complex diseases / / 17554300 rs7590384 chr2 191579573 T C 5.91E-04 Multiple complex diseases / / 17554300 rs6741418 chr2 191723719 C T 5.62E-05 Celiac disease / / 23936387 rs2355575 chr2 191728404 T G 6.13E-04 Myopia (pathological) / / 21095009 rs6734110 chr2 191838342 T C 4.92E-05 Acute lung injury STAT1 intron 21257790 rs2280232 chr2 191850766 C A 1.00E-04 Blood pressure STAT1 intron 21060006 rs2280232 chr2 191850766 C A 5.70E-05 Blood pressure STAT1 intron 21060006 rs12693591 chr2 191860502 C A 1.00E-04 Cognitive impairment induced by topiramate STAT1 intron 22091778 rs41382444 chr2 191880214 C T 5.01E-10 Primary biliary cirrhosis STAT1 nearGene-5 22936693 rs3024896 chr2 191896716 C T 6.19E-05 Insulin-related traits STAT4 intron pha002901 rs925847 chr2 191897540 C T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STAT4 intron 20877124 rs925847 chr2 191897540 C T 8.17E-05 Pulmonary function in asthmatics STAT4 intron 23541324 rs3821236 chr2 191902758 G A 8.00E-11 Systemic lupus erythematosus STAT4 intron 19165918 rs3821236 chr2 191902758 G A 3.00E-09 Systemic sclerosis STAT4 intron 20383147 rs3821236 chr2 191902758 G A 5.20E-13 Systemic lupus erythematosus STAT4 intron 21408207 rs3821236 chr2 191902758 G A 9.00E-08 Systemic sclerosis STAT4 intron 21779181 rs3821236 chr2 191902758 G A 8.49E-11 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs6715106 chr2 191913034 A G 8.40E-09 Celiac disease STAT4 intron 22057235 rs6715106 chr2 191913034 A G 8.40E-09 Celiac disease STAT4 intron 23143596 rs16833215 chr2 191913799 A G 3.94E-06 Basophils STAT4 intron pha003087 rs11893432 chr2 191921874 C G 1.53E-11 Rheumatoid arthritis (CCP positive) STAT4 intron 23143596 rs1356381 chr2 191924413 G A 4.02E-05 Multiple complex diseases STAT4 intron 17554300 rs1517352 chr2 191931464 A C 5.90E-07 Systemic lupus erythematosus STAT4 intron 21408207 rs1517352 chr2 191931464 A C 3.00E-11 Inflammatory bowel disease STAT4 intron 23128233 rs1517352 chr2 191931464 A C 5.90E-07 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs13426947 chr2 191933254 G A 7.19E-10 Rheumatoid arthritis STAT4 intron 23143596 rs13426947 chr2 191933254 G A 7.50E-09 Rheumatoid arthritis (CCP positive) STAT4 intron 23143596 rs10168266 chr2 191935804 C T 3.20E-08 Rheumatoid arthritis STAT4 intron 23028356 rs10168266 chr2 191935804 C T 9.61E-09 Rheumatoid arthritis STAT4 intron 23143596 rs10168266 chr2 191935804 C T 2.30E-20 Systemic lupus erythematosus STAT4 intron 23273568 rs10168266 chr2 191935804 C T 2.00E-17 Sjogren's syndrome STAT4 intron 24097066 rs7594501 chr2 191938600 G A 1.60E-09 Systemic lupus erythematosus STAT4 intron 23273568 rs16833239 chr2 191940260 G A 1.20E-09 Systemic lupus erythematosus STAT4 intron 23273568 rs7601754 chr2 191940451 G A 3.70E-06 Systemic lupus erythematosus STAT4 intron 18204446 rs7601754 chr2 191940451 G A 6.70E-05 Systemic lupus erythematosus STAT4 intron 19838193 rs7601754 chr2 191940451 G A 2.30E-06 Systemic lupus erythematosus STAT4 intron 21408207 rs7601754 chr2 191940451 G A 6.80E-10 Systemic lupus erythematosus STAT4 intron 23273568 rs7601754 chr2 191940451 G A 3.00E-11 Systemic lupus erythematosus and Systemic sclerosis STAT4 intron 23740937 rs3024921 chr2 191943272 A T 0.000000033 Primary biliary cirrhosis in females STAT4 intron 22936693 rs3024921 chr2 191943272 A T 2.39E-11 Primary biliary cirrhosis (anti-mitochondrial antibody positive) STAT4 intron 22936693 rs3024921 chr2 191943272 A T 4.45E-11 Primary biliary cirrhosis STAT4 intron 22936693 rs3024921 chr2 191943272 A T 2.59E-18 Primary biliary cirrhosis STAT4 intron 22961000 rs3024921 chr2 191943272 A T 0.00000666 Rheumatoid arthritis STAT4 intron 23143596 rs3024921 chr2 191943272 A T 5.76E-08 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs11889341 chr2 191943742 C T 1.00E-12 Rheumatoid arthritis STAT4 intron 24390342 rs11889341 chr2 191943742 C T 2.00E-08 Rheumatoid arthritis STAT4 intron 24390342 rs11889341 chr2 191943742 C T 4.00E-19 Rheumatoid arthritis STAT4 intron 24390342 rs12998748 chr2 191948637 G A,C,T 2.60E-04 Celiac disease STAT4 intron 22057235 rs12998748 chr2 191948637 G A,C,T 0.00026 Celiac disease STAT4 intron 23143596 rs10931480 chr2 191954047 G A 1.88E-04 Arthritis (juvenile idiopathic) STAT4 intron 22354554 rs10931481 chr2 191954852 G A 8.10E-10 Systemic lupus erythematosus STAT4 intron 21408207 rs10931481 chr2 191954852 G A 8.10E-10 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs7574865 chr2 191964633 T G 9.00E-14 Systemic lupus erythematosus STAT4 intron 18204098 rs7574865 chr2 191964633 T G 2.80E-09 Systemic lupus erythematosus STAT4 intron 18204446 rs7574865 chr2 191964633 T G 5.00E-42 Systemic lupus erythematosus STAT4 intron 19838193 rs7574865 chr2 191964633 T G 2.00E-06 Rheumatoid arthritis STAT4 intron 20453841 rs7574865 chr2 191964633 T G 3.00E-07 Rheumatoid arthritis STAT4 intron 20453842 rs7574865 chr2 191964633 T G 4.00E-10 Celiac disease and Rheumatoid arthritis STAT4 intron 21383967 rs7574865 chr2 191964633 T G 2.00E-20 Systemic lupus erythematosus STAT4 intron 21408207 rs7574865 chr2 191964633 T G 8.00E-06 Systemic lupus erythematosus STAT4 intron 21408207 rs7574865 chr2 191964633 T G 2.00E-13 Systemic sclerosis STAT4 intron 21750679 rs7574865 chr2 191964633 T G 1.40E-41 Multiple sclerosis STAT4 intron 22190364 rs7574865 chr2 191964633 T G 4.90E-07 Rheumatoid arthritis STAT4 intron 22446963 rs7574865 chr2 191964633 T G 1.00E-06 Primary biliary cirrhosis STAT4 intron 23000144 rs7574865 chr2 191964633 T G 4.00E-14 Systemic lupus erythematosus STAT4 intron 23053960 rs7574865 chr2 191964633 T G 9.61E-09 Rheumatoid arthritis STAT4 intron 23143596 rs7574865 chr2 191964633 T G 2.00E-10 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs7574865 chr2 191964633 T G 1.00E-21 Systemic lupus erythematosus STAT4 intron 23273568 rs7574865 chr2 191964633 T G 6.64E-04 Rheumatoid arthritis STAT4 intron 24449572 rs7574865 chr2 191964633 T G 5.00E-09 Systemic lupus erythematosus STAT4 intron 24871463 rs10181656 chr2 191969879 G C 2.34E-13 Rheumatoid arthritis STAT4 intron 23143596 rs10174238 chr2 191973034 G A 0.00000239 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis STAT4 intron 23603761 rs10174238 chr2 191973034 G A 1.28E-13 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) STAT4 intron 23603761 rs10174238 chr2 191973034 G A 1.81E-10 Oligoarticular juvenile idiopathic arthritis STAT4 intron 23603761 rs6752770 chr2 191973563 A G 2.03E-06 Celiac disease and Rheumatoid arthritis STAT4 intron 21383967 rs6752770 chr2 191973563 A G 1.30E-06 Celiac disease STAT4 intron 22057235 rs6752770 chr2 191973563 A G 4.20E-04 Myasthenia gravis STAT4 intron 23055271 rs6752770 chr2 191973563 A G 0.0000013 Celiac disease STAT4 intron 23143596 rs9967792 chr2 191974435 T C 7.13E-05 Multiple complex diseases STAT4 intron 17554300 rs9967792 chr2 191974435 T C 1.84E-05 Type 1 diabetes STAT4 intron 18978792 rs4853543 chr2 191976634 A G 1.61E-04 Multiple complex diseases STAT4 intron 17554300 rs4853543 chr2 191976634 A G 2.24E-05 Type 1 diabetes STAT4 intron 18978792 rs10931483 chr2 191989250 A G 1.51E-04 Multiple complex diseases STAT4 intron 17554300 rs10931483 chr2 191989250 A G 3.62E-05 Type 1 diabetes STAT4 intron 18978792 rs6738544 chr2 191989356 A C 1.67E-04 Multiple complex diseases STAT4 intron 17554300 rs1551443 chr2 191996518 T C 1.70E-04 Multiple complex diseases STAT4 intron 17554300 rs1551443 chr2 191996518 T C 3.44E-05 Type 1 diabetes STAT4 intron 18978792 rs1584945 chr2 191998552 C T 2.88E-05 Multiple complex diseases STAT4 intron 17554300 rs1584945 chr2 191998552 C T 2.34E-05 Type 1 diabetes STAT4 intron 18978792 rs6744380 chr2 192001538 A G 1.22E-04 Type 1 diabetes STAT4 intron 21980299 rs2356350 chr2 192002538 G A 5.92E-05 Multiple complex diseases STAT4 intron 17554300 rs2356350 chr2 192002538 G A 8.87E-05 Type 1 diabetes STAT4 intron 18978792 rs7574070 chr2 192010488 A C 4.00E-08 Behcet's disease STAT4 intron 23001997 rs7574070 chr2 192010488 A C 1.00E-09 Behcet's disease STAT4 intron 23291587 rs7572482 chr2 192015072 A G 4.00E-08 Behcet's disease STAT4 intron 23001997 rs7572482 chr2 192015072 A G 2.92E-05 Behcet's disease STAT4 intron 23291587 rs7572482 chr2 192015072 A G 3.18E-05 Behcet's disease STAT4 intron pha002888 rs897200 chr2 192017771 T C 6.00E-09 Behcet's disease STAT4 nearGene-5 23001997 rs6741818 chr2 192053184 G T 3.51E-04 Alzheimer's disease / / 17998437 rs16833498 chr2 192069042 C T 4.75E-04 Type 2 diabetes / / 17463246 rs16833504 chr2 192077437 T C 2.00E-05 Multiple complex diseases / / 17554300 rs6434455 chr2 192085141 A G 3.30E-04 Alzheimer's disease (late onset) / / 21379329 rs13030978 chr2 192117238 C T 1.00E-11 Liver enzyme levels (gamma-glutamyl transferase) MYO1B intron 22001757 rs1823913 chr2 192118047 T C 9.00E-06 Obesity-related traits MYO1B intron 23251661 rs17439519 chr2 192130220 A G 1.35E-04 Lung function (forced vital capacity) MYO1B intron 24023788 rs17439519 chr2 192130220 A G 4.43E-04 Lung function (forced expiratory volume in 1 second) MYO1B intron 24023788 rs11688994 chr2 192130968 G A 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs13427761 chr2 192133982 C G 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs1378156 chr2 192137192 T A 3.45E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs17511445 chr2 192144557 G A 1.85E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs13002286 chr2 192150352 C T 1.85E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs17412635 chr2 192159560 G A 3.45E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs4853575 chr2 192160875 C T 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B cds-synon 24192120 rs4853578 chr2 192161941 G A 2.60E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs10497714 chr2 192167280 A G 3.32E-04 Acute lung injury MYO1B intron 22295056 rs13032780 chr2 192222600 G A 5.31E-04 Alzheimer's disease MYO1B intron 22005930 rs16833765 chr2 192340920 A G 6.38E-05 Attention deficit hyperactivity disorder / / 22420046 rs12618512 chr2 192366684 A C 6.82E-04 Type 2 diabetes / / 17463246 rs10497719 chr2 192377594 G A 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17351803 chr2 192390014 T C 6.47E-05 Multiple complex diseases / / 17554300 rs2203748 chr2 192397191 T C 4.61E-04 Intracranial aneurysm / / 20613766 rs1517843 chr2 192405450 G A 5.21E-04 Alzheimer's disease / / 17998437 rs7596196 chr2 192461297 C A 5.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6706693 chr2 192465598 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4134381 chr2 192469816 G A 2.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4318338 chr2 192470385 C T 2.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4853629 chr2 192473543 C T 4.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs3935827 chr2 192479007 A G 4.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4401164 chr2 192479674 A G 4.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs11899661 chr2 192490640 A G 4.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6434494 chr2 192491453 A G 4.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6434497 chr2 192506225 G T 9.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs5008133 chr2 192510265 T C 3.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4592792 chr2 192532017 A G 7.53E-04 Alcohol dependence / / 24277619 rs12464838 chr2 192567912 G T 3.66E-06 Colorectal cancer / / 23266556 rs12469001 chr2 192567931 T A 3.42E-06 Colorectal cancer / / 23266556 rs6730901 chr2 192572805 T C 4.14E-06 Colorectal cancer / / 23266556 rs10931515 chr2 192575111 C G 9.09E-04 Colorectal cancer / / 23266556 rs10190843 chr2 192579683 G A 3.66E-06 Colorectal cancer / / 23266556 rs4425034 chr2 192580611 T C 3.63E-06 Colorectal cancer / / 23266556 rs4299283 chr2 192580887 A G 5.10E-06 Colorectal cancer / / 23266556 rs4477849 chr2 192580929 C T 3.48E-06 Colorectal cancer / / 23266556 rs4076769 chr2 192584206 G A 3.96E-06 Colorectal cancer / / 23266556 rs10202549 chr2 192585015 T C 3.56E-06 Colorectal cancer / / 23266556 rs13416906 chr2 192586829 G A 3.50E-06 Colorectal cancer / / 23266556 rs11903757 chr2 192587204 T C 4.00E-08 Colorectal cancer / / 23266556 rs12475675 chr2 192588314 G A 8.39E-06 Colorectal cancer / / 23266556 rs12463776 chr2 192588334 T C 3.00E-06 Colorectal cancer / / 23266556 rs6717663 chr2 192589385 T C 3.10E-06 Colorectal cancer / / 23266556 rs6717668 chr2 192589399 T C 3.39E-06 Colorectal cancer / / 23266556 rs6731095 chr2 192589442 A G 3.54E-06 Colorectal cancer / / 23266556 rs6759665 chr2 192589454 C A 1.72E-06 Colorectal cancer / / 23266556 rs12475230 chr2 192598024 C G 5.39E-04 Colorectal cancer / / 23266556 rs7568376 chr2 192621416 A G 9.19E-04 Acute lung injury / / 22295056 rs7593737 chr2 192640624 G A 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4366844 chr2 192663220 A G 7.06E-04 Acute lung injury / / 22295056 rs4853645 chr2 192704044 A T 0.0000417 Major depressive disorder SDPR intron 23149448 rs7583029 chr2 192712723 G A 8.50E-05 Major depressive disorder / / 21042317 rs6710083 chr2 192772592 G T 1.19E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11896499 chr2 192797035 A C 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7604868 chr2 192819448 C T 1.41E-05 Lung function (forced expiratory volume in 1 second) TMEFF2 intron 17255346 rs11680872 chr2 192830249 G A 2.90E-05 Lobular breast cancer (menopausal hormone therapy interaction) TMEFF2 intron 24080446 rs10497721 chr2 192914362 C A 6.68E-07 Type 2 diabetes and 6 quantitative traits TMEFF2 intron 17848626 rs10497721 chr2 192914362 C A 7.00E-07 Diabetes (incident) TMEFF2 intron 17903298 rs2356764 chr2 192927160 G A 4.90E-04 Tourette syndrome TMEFF2 intron 22889924 rs7556774 chr2 192954320 G A 6.67E-04 Type 2 diabetes TMEFF2 intron 17463246 rs13007495 chr2 192955505 T C 4.00E-06 Sudden cardiac arrest TMEFF2 intron 21658281 rs16834204 chr2 192966789 C G 1.07E-04 Bipolar disorder,schizoaffective TMEFF2 intron 19567891 rs7557901 chr2 192972529 A C 3.73E-04 Bipolar disorder,schizoaffective TMEFF2 intron 19567891 rs10497723 chr2 192992323 T C 8.45E-06 Type 2 diabetes TMEFF2 intron 17846124 rs10497723 chr2 192992323 T C 8.50E-06 Type 2 diabetes TMEFF2 intron 21647700 rs11888985 chr2 193035248 C T 4.94E-04 Multiple complex diseases TMEFF2 intron 17554300 rs10191803 chr2 193035723 T C 5.80E-06 Stroke (ischemic) TMEFF2 intron 22384361 rs2356960 chr2 193041060 G A 6.54E-05 Orofacial clefts TMEFF2 intron 22419666 rs12693642 chr2 193042710 T C 3.69E-04 Type 2 diabetes TMEFF2 intron 17463246 rs10931531 chr2 193046999 A C 9.64E-04 Type 2 diabetes TMEFF2 intron 17463246 rs10497726 chr2 193051320 C A 1.98E-05 Cardiovascular disease TMEFF2 intron 17903304 rs1113932 chr2 193052353 T C 5.01E-04 Type 2 diabetes TMEFF2 intron 17463246 rs1446397 chr2 193232686 G A 4.76E-04 Premature ovarian failure / / 19508998 rs1446397 chr2 193232686 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7581266 chr2 193257756 T C 5.04E-04 Multiple complex diseases / / 17554300 rs2357135 chr2 193261854 A G 7.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs1017895 chr2 193284475 T C 5.10E-04 Multiple complex diseases / / 17554300 rs1038472 chr2 193300851 A T 5.50E-04 Multiple complex diseases / / 17554300 rs5837312 chr2 193302111 G T 7.88E-04 Multiple complex diseases / / 17554300 rs10931548 chr2 193302483 C A 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10931550 chr2 193302629 G A 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1385351 chr2 193333903 C T 4.00E-06 HIV-1 control / / 20041166 rs1601324 chr2 193337095 A G 1.34E-05 Type 2 diabetes / / 17463246 rs6713179 chr2 193345479 A G 4.30E-05 HIV-1 control / / 20041166 rs1994245 chr2 193360531 T C 1.00E-04 Prostate cancer / / 21743057 rs11896590 chr2 193364043 A G 1.48E-05 Type 2 diabetes / / 17463246 rs6723499 chr2 193420290 C T 7.62E-04 Taste perception / / 22132133 rs12617505 chr2 193427323 A G 4.30E-04 Taste perception / / 22132133 rs717622 chr2 193440645 T C 3.03E-04 Obesity (extreme) / / 21935397 rs1515349 chr2 193458579 A G 6.77E-05 Type 2 diabetes / / 17463246 rs17442387 chr2 193482971 A T 4.38E-04 Obesity (extreme) / / 21935397 rs7608493 chr2 193510649 C T 3.53E-04 Coronary heart disease / / 21971053 rs1946877 chr2 193528836 T C 1.86E-04 Multiple complex diseases / / 17554300 rs1898917 chr2 193538820 C T 9.02E-04 Type 2 diabetes / / 17463246 rs1898917 chr2 193538820 C T 2.04E-04 Multiple complex diseases / / 17554300 rs1898917 chr2 193538820 C T 4.32E-04 Coronary heart disease / / 21971053 rs13394988 chr2 193541827 C T 8.79E-04 Type 2 diabetes / / 17463246 rs13394988 chr2 193541827 C T 2.30E-04 Multiple complex diseases / / 17554300 rs1439664 chr2 193559014 C A 1.44E-04 Multiple complex diseases / / 17554300 rs1439664 chr2 193559014 C A 5.01E-04 Coronary heart disease / / 21971053 rs1439663 chr2 193559142 G T 8.89E-04 Type 2 diabetes / / 17463246 rs1439663 chr2 193559142 G T 3.08E-04 Multiple complex diseases / / 17554300 rs16834819 chr2 193559261 C T 5.73E-04 Multiple complex diseases / / 17554300 rs1595720 chr2 193567692 T C 9.64E-04 Type 2 diabetes / / 17463246 rs1595720 chr2 193567692 T C 2.49E-04 Multiple complex diseases / / 17554300 rs6730654 chr2 193602930 G C 3.79E-04 Multiple complex diseases / / 17554300 rs6730696 chr2 193603096 C T 2.71E-04 Multiple complex diseases / / 17554300 rs11686149 chr2 193629044 A C 1.17E-04 Multiple complex diseases PCGEM1 intron 17554300 rs16834896 chr2 193634064 G A 8.70E-04 Type 2 diabetes PCGEM1 intron 17463246 rs16834896 chr2 193634064 G A 1.16E-04 Multiple complex diseases PCGEM1 intron 17554300 rs16834896 chr2 193634064 G A 3.84E-04 Coronary heart disease PCGEM1 intron 21971053 rs1439652 chr2 193639244 C T 2.23E-04 Multiple complex diseases PCGEM1 intron 17554300 rs1439651 chr2 193639542 A C 2.51E-04 Multiple complex diseases PCGEM1 intron 17554300 rs1439651 chr2 193639542 A C 9.32E-05 Coronary heart disease PCGEM1 intron 21971053 rs7567586 chr2 193640080 T C 2.71E-04 Multiple complex diseases PCGEM1 intron 17554300 rs13419834 chr2 193640476 T C 2.37E-04 Multiple complex diseases / / 17554300 rs1125174 chr2 193675766 T G 2.94E-04 Multiple complex diseases / / 17554300 rs11894222 chr2 193681377 C T 2.43E-04 Multiple complex diseases / / 17554300 rs1596754 chr2 193693359 C A 3.26E-04 Multiple complex diseases / / 17554300 rs10176429 chr2 193694766 A T 4.76E-04 Multiple complex diseases / / 17554300 rs12328398 chr2 193695871 A G 5.02E-04 Multiple complex diseases / / 17554300 rs17654201 chr2 193724080 C T 3.50E-05 Celiac disease / / 17558408 rs10174573 chr2 193742173 C T 2.00E-06 Major depressive disorder / / 23377640 rs13014947 chr2 193742999 G A 2.20E-05 Urinary metabolites / / 21572414 rs12617870 chr2 193746283 G T 3.27E-04 Body mass index / / 17255346 rs1979001 chr2 193749305 C A 2.10E-06 Urinary metabolites / / 21572414 rs9288210 chr2 193764898 G A 3.59E-04 Blood pressure / / 17255346 rs9288210 chr2 193764898 G A 2.00E-05 Urinary metabolites / / 21572414 rs2197471 chr2 193797343 G A 8.83E-04 Obesity (extreme) / / 21935397 rs2203204 chr2 193797403 A G 8.82E-04 Obesity (extreme) / / 21935397 rs10203662 chr2 193799679 T G 8.77E-04 Obesity (extreme) / / 21935397 rs7585105 chr2 193801489 T C 8.76E-04 Obesity (extreme) / / 21935397 rs1596748 chr2 193802991 A G 8.74E-04 Obesity (extreme) / / 21935397 rs1596749 chr2 193803201 A G 8.73E-04 Obesity (extreme) / / 21935397 rs10931581 chr2 193803703 G A 8.68E-04 Obesity (extreme) / / 21935397 rs765278 chr2 193805824 T C 8.68E-04 Obesity (extreme) / / 21935397 rs12613154 chr2 193806575 A G 8.74E-04 Obesity (extreme) / / 21935397 rs13006519 chr2 193807276 G C 8.98E-04 Obesity (extreme) / / 21935397 rs1596751 chr2 193807860 C T 1.90E-05 Urinary metabolites / / 21572414 rs10931584 chr2 193808370 C T 9.08E-04 Obesity (extreme) / / 21935397 rs10204100 chr2 193809193 C G 9.15E-04 Obesity (extreme) / / 21935397 rs4850844 chr2 193810226 G A 9.22E-04 Obesity (extreme) / / 21935397 rs13010260 chr2 193812656 G A 9.43E-04 Obesity (extreme) / / 21935397 rs13011989 chr2 193813425 G A 1.90E-05 Urinary metabolites / / 21572414 rs13011989 chr2 193813425 G A 9.51E-04 Obesity (extreme) / / 21935397 rs986652 chr2 193815404 A T 9.58E-04 Obesity (extreme) / / 21935397 rs12995239 chr2 193817686 A G 2.80E-05 Urinary metabolites / / 21572414 rs12995239 chr2 193817686 A G 9.66E-04 Obesity (extreme) / / 21935397 rs10174037 chr2 193821132 T A 9.73E-04 Obesity (extreme) / / 21935397 rs1512755 chr2 193821255 T C 9.92E-04 Obesity (extreme) / / 21935397 rs10497737 chr2 193824185 G A 1.00E-05 Urinary metabolites / / 21572414 rs1979002 chr2 193838929 G T 2.80E-05 Urinary metabolites / / 21572414 rs7574968 chr2 193846114 T C 1.88E-04 Body mass index / / 17255346 rs2198962 chr2 193941673 A G 1.87E-04 Multiple complex diseases / / 17554300 rs10170968 chr2 193954551 G A 3.29E-10 Multiple complex diseases / / 17554300 rs7577834 chr2 193956481 C T 2.30E-05 Urinary metabolites / / 21572414 rs17662626 chr2 193984621 A G 5.00E-08 Schizophrenia / / 21926974 rs17662626 chr2 193984621 A G 5.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs17662626 chr2 193984621 A G 0.0000779 Schizophrenia / / 23637625 rs17662759 chr2 193989223 T C 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs973885 chr2 193994278 G A 9.12E-04 Multiple complex diseases / / 17554300 rs973885 chr2 193994278 G A 6.74E-04 Tourette syndrome / / 22889924 rs1379470 chr2 193995316 A T 6.71E-04 Multiple complex diseases / / 17554300 rs1037709 chr2 193999951 T A 9.46E-04 Multiple complex diseases / / 17554300 rs1037710 chr2 193999991 C T 8.56E-04 Multiple complex diseases / / 17554300 rs1902745 chr2 194017714 C A 2.43E-04 Blood pressure / / 17255346 rs10189659 chr2 194236059 C T 1.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs6434605 chr2 194244603 T G 5.95E-04 Type 2 diabetes / / 17463246 rs2247944 chr2 194254130 G A 7.29E-04 Type 2 diabetes / / 17463246 rs1530155 chr2 194257494 A G 9.87E-04 Type 2 diabetes / / 17463246 rs2251929 chr2 194316224 C G 8.87E-04 Type 2 diabetes / / 17463246 rs11893801 chr2 194426679 T A 1.98E-05 Multiple complex diseases / / 17554300 rs6757627 chr2 194518477 A G 2.46E-05 Smoking initiation / / 24665060 rs13018978 chr2 194652248 C A 5.02E-04 Depression (quantitative trait) / / 20800221 rs4473398 chr2 194660331 T G 5.12E-04 Depression (quantitative trait) / / 20800221 rs1358626 chr2 194663490 T C 5.13E-04 Depression (quantitative trait) / / 20800221 rs10497745 chr2 194679200 C A 4.91E-04 Depression (quantitative trait) / / 20800221 rs16835330 chr2 194706556 A G 4.80E-04 Depression (quantitative trait) / / 20800221 rs12991562 chr2 194707606 C T 4.79E-04 Depression (quantitative trait) / / 20800221 rs12991562 chr2 194707606 C T 5.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs10209427 chr2 194715328 T C 4.76E-04 Depression (quantitative trait) / / 20800221 rs1358625 chr2 194716457 T C 4.78E-04 Depression (quantitative trait) / / 20800221 rs10931625 chr2 194722073 C T 4.80E-04 Depression (quantitative trait) / / 20800221 rs6740862 chr2 194727038 C T 4.82E-04 Depression (quantitative trait) / / 20800221 rs6434632 chr2 194730749 C T 4.86E-04 Depression (quantitative trait) / / 20800221 rs1534690 chr2 194733623 C T 4.53E-04 Depression (quantitative trait) / / 20800221 rs4850493 chr2 194735679 A T 4.80E-04 Depression (quantitative trait) / / 20800221 rs10184447 chr2 194736257 C T 4.88E-04 Depression (quantitative trait) / / 20800221 rs4850495 chr2 194739062 A G 2.89E-04 Depression (quantitative trait) / / 20800221 rs4850496 chr2 194739622 A G 1.61E-04 Depression (quantitative trait) / / 20800221 rs1529108 chr2 194739945 A G 2.90E-04 Depression (quantitative trait) / / 20800221 rs13029940 chr2 194744710 T C 3.03E-04 Depression (quantitative trait) / / 20800221 rs4402780 chr2 194746880 A G 3.14E-04 Depression (quantitative trait) / / 20800221 rs10179597 chr2 194747064 A G 2.55E-04 Depression (quantitative trait) / / 20800221 rs7561862 chr2 194749514 C T 7.58E-04 Depression (quantitative trait) / / 20800221 rs4468836 chr2 194785328 C A 9.84E-04 Depression (quantitative trait) / / 20800221 rs6750903 chr2 194805093 G A 8.12E-04 Depression (quantitative trait) / / 20800221 rs11892785 chr2 194810279 T C 6.30E-04 Depression (quantitative trait) / / 20800221 rs2176528 chr2 194872183 C G 4.00E-06 Bipolar disorder / / 21926972 rs2358004 chr2 195038817 G A 8.75E-04 Type 2 diabetes / / 17463246 rs10931639 chr2 195095507 G A 2.80E-04 Multiple complex diseases / / 17554300 rs10193826 chr2 195128137 C T 1.07E-04 Multiple complex diseases / / 17554300 rs4578878 chr2 195151349 C T 2.60E-05 Urinary metabolites / / 21572414 rs7577996 chr2 195198744 T C 7.97E-04 Multiple complex diseases / / 17554300 rs10931642 chr2 195259731 T C 3.81E-04 Multiple complex diseases / / 17554300 rs2360090 chr2 195344783 C T 5.38E-04 Multiple complex diseases / / 17554300 rs4404290 chr2 195461795 A G 9.64E-05 Triglycerides / / pha003081 rs12993717 chr2 195476042 C T 7.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1371555 chr2 195494177 T C 6.82E-05 Triglycerides / / pha003081 rs12613573 chr2 195499851 A T 2.58E-04 Multiple complex diseases / / 17554300 rs1595771 chr2 195518247 A C 3.64E-04 Multiple complex diseases / / 17554300 rs801350 chr2 195547393 G A 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs801378 chr2 195559997 A C 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs801301 chr2 195579293 T C 4.37E-04 Rheumatoid arthritis / / 21452313 rs801298 chr2 195581699 T C 5.49E-04 Celiac disease / / 23936387 rs1439937 chr2 195583436 C T 6.69E-04 Rheumatoid arthritis / / 21452313 rs13385784 chr2 195628811 A C 2.42E-04 Smoking initiation / / 24665060 rs13394699 chr2 195720651 T G 9.67E-04 Rheumatoid arthritis / / 21452313 rs12611555 chr2 195791620 A G 1.93E-04 Multiple complex diseases / / 17554300 rs11891594 chr2 195857383 A G 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs17821284 chr2 195857628 C G 1.89E-04 Acute lung injury / / 22295056 rs919538 chr2 195863427 G A 7.44E-05 Type 2 diabetes / / 17463246 rs1430692 chr2 195864023 C A 9.07E-05 Obesity (extreme) / / 21935397 rs6727001 chr2 195864232 T C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1430690 chr2 195864806 T C 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10174127 chr2 195867032 C T 1.86E-04 Obesity (extreme) / / 21935397 rs1014395 chr2 195867099 A T 2.29E-04 Type 2 diabetes / / 17463246 rs2068896 chr2 195869035 T G 4.62E-04 Obesity (extreme) / / 21935397 rs10172965 chr2 195871819 C T 1.33E-04 Type 2 diabetes / / 17463246 rs10172965 chr2 195871819 C T 6.00E-06 Temperament / / 22832960 rs12472928 chr2 195874246 T C 6.87E-04 Type 2 diabetes / / 17463246 rs7584610 chr2 195875175 G A 6.67E-04 Type 2 diabetes / / 17463246 rs963653 chr2 195882875 T C 6.82E-04 Type 2 diabetes / / 17463246 rs1430678 chr2 195884021 C T 7.33E-05 Obesity (extreme) / / 21935397 rs12478266 chr2 195884251 T C 2.46E-04 Type 2 diabetes / / 17463246 rs6434727 chr2 195893626 A T 2.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13391145 chr2 195903474 T C 5.60E-05 Personality dimensions / / 18957941 rs1835437 chr2 195914706 C T 3.20E-05 Personality dimensions / / 18957941 rs1835437 chr2 195914706 C T 2.70E-05 Urinary metabolites / / 21572414 rs11687841 chr2 195914876 T C 3.20E-05 Personality dimensions / / 18957941 rs11687841 chr2 195914876 T C 2.40E-05 Urinary metabolites / / 21572414 rs1599755 chr2 195974363 C T 1.10E-04 Multiple complex diseases / / 17554300 rs777733 chr2 195993166 G A 1.17E-04 Multiple complex diseases / / 17554300 rs777734 chr2 195993306 C A 4.39E-05 IgE levels in asthmatics / / 23967269 rs938066 chr2 196001454 T C 8.29E-04 Alzheimer's disease / / 17998437 rs777740 chr2 196001701 G A 3.10E-04 Alzheimer's disease / / 17998437 rs2217469 chr2 196002614 A G 3.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2130344 chr2 196011944 C A 3.04E-04 Smoking initiation / / 24665060 rs2063452 chr2 196012052 G A 2.00E-05 Blood pressure / / 19114657 rs7558137 chr2 196014263 T C 5.07E-04 Smoking initiation / / 24665060 rs7597587 chr2 196014587 G A 7.79E-04 Smoking initiation / / 24665060 rs10497749 chr2 196018044 T A 5.80E-05 Blood pressure / / 19114657 rs6736088 chr2 196018369 A G 2.00E-05 Blood pressure / / 19114657 rs7423326 chr2 196026920 T C 6.73E-04 Type 2 diabetes / / 17463246 rs1397746 chr2 196027829 C A 3.94E-04 Smoking initiation / / 24665060 rs6434742 chr2 196036903 A G 4.33E-07 Type 2 diabetes / / 17463246 rs1397744 chr2 196045183 T C 2.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7422772 chr2 196045499 G T 2.16E-04 Type 2 diabetes / / 17463246 rs7424669 chr2 196045518 T C 3.64E-05 Type 2 diabetes / / 17463246 rs6434746 chr2 196045676 A T 3.64E-05 Type 2 diabetes / / 17463246 rs6434754 chr2 196060439 A G 2.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1858305 chr2 196100505 C G 2.14E-04 Type 2 diabetes / / 17463246 rs16838948 chr2 196103245 A C 2.11E-05 Multiple complex diseases / / 17554300 rs2037597 chr2 196136553 G A 5.00E-05 Blood pressure / / 19114657 rs16839316 chr2 196162042 A C,G 1.59E-04 Multiple complex diseases / / 17554300 rs1489769 chr2 196164984 A C 1.60E-05 Blood pressure / / 19114657 rs12996090 chr2 196279513 A G 6.64E-05 Blood Pressure / / pha003040 rs4505549 chr2 196288136 T C 4.83E-06 Neuroblastoma / / pha002895 rs4505549 chr2 196288136 T C 1.20E-05 Blood Pressure / / pha003048 rs11674207 chr2 196305753 G A 6.62E-04 Type 2 diabetes / / 17463246 rs1542865 chr2 196309536 C A 7.20E-05 Celiac disease / / 17558408 rs7559362 chr2 196319300 G A 1.33E-06 Blood Pressure / / pha003048 rs16841230 chr2 196325214 T C 8.37E-04 Type 2 diabetes / / 17463246 rs6434780 chr2 196335282 G A 4.28E-04 Smoking initiation / / 24665060 rs7571836 chr2 196340492 A T 9.09E-05 Smoking initiation / / 24665060 rs1500608 chr2 196346799 G A 2.48E-04 Smoking initiation / / 24665060 rs4591358 chr2 196365890 T C 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs17177580 chr2 196373150 T C 9.41E-05 Blood Pressure / / pha003040 rs13002794 chr2 196381899 T C 7.35E-05 Blood Pressure / / pha003040 rs6434787 chr2 196449477 A G 2.70E-06 Urinary metabolites / / 21572414 rs10460389 chr2 196505964 C A 4.37E-04 Alcohol dependence / / 21314694 rs11682521 chr2 196517509 G A 3.40E-04 Alcohol dependence / / 20201924 rs11889699 chr2 196528101 A G 6.30E-06 Urinary metabolites SLC39A10 intron 21572414 rs7562020 chr2 196531031 G C 1.10E-05 Urinary metabolites SLC39A10 intron 21572414 rs41416845 chr2 196531667 T C 1.65E-08 Brain activation patterns in response to human facial expressions-for the negative faces task SLC39A10 intron 22828495 rs41416845 chr2 196531667 T C 1.65E-08 Airflow obstruction SLC39A10 intron 22837378 rs7424415 chr2 196536150 T C 1.00E-04 Alcohol dependence SLC39A10 intron 20201924 rs1866452 chr2 196536505 A G 1.90E-04 Alcohol dependence SLC39A10 intron 20201924 rs10178320 chr2 196542002 T C 1.50E-04 Alcohol dependence SLC39A10 intron 20201924 rs1561451 chr2 196549436 A G 8.90E-05 Alcohol dependence SLC39A10 intron 20201924 rs1561451 chr2 196549436 A G 8.86E-05 Alcoholism SLC39A10 intron pha002892 rs13029941 chr2 196553228 G A 5.40E-06 Urinary metabolites SLC39A10 intron 21572414 rs6706771 chr2 196565241 G T 1.90E-04 Alcohol dependence SLC39A10 intron 20201924 rs6714748 chr2 196566912 G A 1.98E-05 Neuroblastoma SLC39A10 intron pha002895 rs6714748 chr2 196566912 G A 9.67E-05 Body Fat Distribution SLC39A10 intron pha003017 rs2118839 chr2 196567176 C T 1.20E-05 Urinary metabolites SLC39A10 intron 21572414 rs16842044 chr2 196579896 A G 1.76E-04 Type 2 diabetes SLC39A10 intron 17463246 rs6756374 chr2 196587670 C A 1.10E-04 Alcohol dependence SLC39A10 intron 20201924 rs2118840 chr2 196594951 T C 6.30E-06 Urinary metabolites SLC39A10 intron 21572414 rs16840019 chr2 196661664 G T 8.53E-04 Type 2 diabetes D/H7 intron 17463246 rs6434799 chr2 196665083 C T 4.80E-04 Alcohol dependence D/H7 intron 20201924 rs6743998 chr2 196676489 T C 7.57E-04 Alcohol dependence D/H7 intron 21314694 rs16840255 chr2 196684883 C T 3.86E-04 Multiple complex diseases D/H7 intron 17554300 rs4850376 chr2 196696633 T C 2.00E-06 Urinary metabolites D/H7 intron 21572414 rs10497770 chr2 196715003 G A 1.88E-04 Vaspin levels D/H7 intron 22907691 rs10497770 chr2 196715003 G A 0.0001883 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs13028172 chr2 196732301 T G 1.70E-05 Urinary metabolites D/H7 intron 21572414 rs12469956 chr2 196739009 T A 5.76E-05 Type 2 diabetes D/H7 intron 17463246 rs16841387 chr2 196742920 C A 4.84E-06 Neuroblastoma D/H7 intron pha002895 rs341951 chr2 196747752 C G 4.66E-04 Multiple complex diseases D/H7 intron 17554300 rs419784 chr2 196762836 C T 8.58E-04 Multiple complex diseases D/H7 intron 17554300 rs6434804 chr2 196764393 T G 2.40E-05 Kidney function and endocine traits D/H7 intron 17903292 rs382397 chr2 196765294 G A 1.52E-04 Smoking quantity D/H7 intron 24665060 rs186895 chr2 196766509 C T 4.24E-05 Neuroblastoma D/H7 intron pha002895 rs16841838 chr2 196769109 A G 3.81E-04 Multiple complex diseases D/H7 intron 17554300 rs341933 chr2 196779131 A G 6.00E-06 Neuroblastoma D/H7 intron pha002895 rs1489802 chr2 196791276 T G 9.35E-05 Neuroblastoma D/H7 cds-synon pha002895 rs7570606 chr2 196791792 A G 7.53E-04 Multiple complex diseases D/H7 intron 17554300 rs1489800 chr2 196800091 A G 3.34E-04 Multiple complex diseases D/H7 intron 17554300 rs16842717 chr2 196810367 G A 7.79E-05 Neuroblastoma D/H7 intron pha002895 rs6719500 chr2 196825402 T C 2.39E-05 Neuroblastoma D/H7 missense pha002895 rs192646926 chr2 196825573 G A 0.0003 Prostate cancer D/H7 missense 23555315 rs17363011 chr2 196849453 C T 9.45E-05 Vaspin levels D/H7 intron 22907691 rs17363011 chr2 196849453 C T 0.0000945 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs1519616 chr2 196894380 G C 3.10E-06 Urinary metabolites D/H7 intron 21572414 rs6414150 chr2 196894770 A G 3.90E-06 Urinary metabolites D/H7 intron 21572414 rs6414150 chr2 196894770 A G 4.98E-05 Vaspin levels D/H7 intron 22907691 rs6414150 chr2 196894770 A G 0.0000498 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs4500968 chr2 196905455 A G 8.00E-07 Urinary metabolites D/H7 intron 21572414 rs12475846 chr2 196907795 T C 1.90E-06 Urinary metabolites D/H7 intron 21572414 rs4850381 chr2 196912067 A G 8.42E-05 Vaspin levels D/H7 intron 22907691 rs4850381 chr2 196912067 A G 0.0000842 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs6434817 chr2 196914283 A G 7.50E-07 Urinary metabolites D/H7 intron 21572414 rs16844650 chr2 196945385 C T 6.00E-06 Urinary metabolites / / 21572414 rs13414745 chr2 196945439 C T 6.70E-06 Urinary metabolites / / 21572414 rs4850654 chr2 196950670 T G 1.30E-06 Urinary metabolites / / 21572414 rs1401720 chr2 196961600 T C 4.88E-05 Body Fat Distribution / / pha003016 rs1401720 chr2 196961600 T C 6.04E-05 Body Fat Distribution / / pha003018 rs6725435 chr2 196964433 C G 4.00E-06 Urinary metabolites / / 21572414 rs12329286 chr2 196969777 T G 1.00E-06 Urinary metabolites / / 21572414 rs1568366 chr2 196976853 T C 2.50E-06 Urinary metabolites / / 21572414 rs2090671 chr2 196990913 C T 4.57E-05 Multiple complex diseases / / 17554300 rs6741307 chr2 196998315 C A,G,T 1.20E-06 Urinary metabolites STK17B UTR-3 21572414 rs7595582 chr2 197017505 A T 2.60E-06 Urinary metabolites STK17B intron 21572414 rs7586917 chr2 197018402 T C 6.70E-06 Urinary metabolites STK17B intron 21572414 rs4850669 chr2 197019260 G A 2.60E-06 Urinary metabolites STK17B intron 21572414 rs1519602 chr2 197027792 T G 1.50E-06 Urinary metabolites STK17B intron 21572414 rs4850676 chr2 197033562 C T 1.30E-06 Urinary metabolites STK17B intron 21572414 rs13001220 chr2 197057862 C T 2.99E-05 Neuroblastoma / / pha002895 rs4850679 chr2 197061152 C T 0.000429 Salmonella-induced pyroptosis / / 22837397 rs4850679 chr2 197061152 C T 5.83E-05 Neuroblastoma / / pha002895 rs4524133 chr2 197062707 A G 7.10E-05 Body Fat Distribution / / pha003016 rs2290512 chr2 197085823 C T 4.80E-04 Multiple complex diseases HECW2 intron 17554300 rs4241188 chr2 197097950 G A 0.00000077 Joint damage severity in rheumatoid arthritis HECW2 intron 23696630 rs10185953 chr2 197104208 T C 7.24E-04 Multiple complex diseases HECW2 intron 17554300 rs10185953 chr2 197104208 T C 5.20E-06 Bipolar disorder HECW2 intron 18317468 rs7575017 chr2 197109893 T G 4.90E-04 Multiple complex diseases HECW2 intron 17554300 rs6746308 chr2 197134790 G A 8.95E-04 Myopia (pathological) HECW2 intron 21095009 rs4850693 chr2 197135806 T C 7.98E-04 Myopia (pathological) HECW2 intron 21095009 rs4850695 chr2 197153259 G A 4.62E-06 Aging (time to event) HECW2 intron 21782286 rs6730618 chr2 197156918 T C 9.15E-05 Serum metabolites HECW2 intron 19043545 rs11888904 chr2 197164694 G A 5.15E-05 Serum metabolites HECW2 intron 19043545 rs11888904 chr2 197164694 G A 4.57E-04 Smoking initiation HECW2 intron 24665060 rs13394918 chr2 197164952 C T 6.20E-04 Smoking initiation HECW2 intron 24665060 rs13016354 chr2 197170701 G A 0.000000792 Left atrial diameter HECW2 intron 23275298 rs6713102 chr2 197174387 A G 3.51E-04 Lymphocyte counts HECW2 intron 22286170 rs2168369 chr2 197197092 A G 1.20E-05 Urinary metabolites HECW2 intron 21572414 rs16849755 chr2 197197233 C A,G,T 2.30E-05 Urinary metabolites HECW2 intron 21572414 rs4296447 chr2 197202607 C G 5.30E-06 Urinary metabolites HECW2 intron 21572414 rs11888148 chr2 197247574 A T 3.56E-06 Phospholipid levels (plasma) HECW2 intron 21829377 rs17831149 chr2 197263337 C T 1.10E-05 Urinary metabolites HECW2 intron 21572414 rs1528398 chr2 197311265 T C 2.59E-04 Smoking initiation HECW2 intron 24665060 rs1528398 chr2 197311265 T C 6.81E-05 Smoking quantity HECW2 intron 24665060 rs6721157 chr2 197315114 T C 6.13E-04 Schizophrenia HECW2 intron 19197363 rs1405886 chr2 197318105 T C 4.22E-04 Schizophrenia HECW2 intron 19197363 rs6728749 chr2 197322628 T C 7.57E-05 Cognitive impairment induced by topiramate HECW2 intron 22091778 rs6728749 chr2 197322628 T C 3.40E-04 Smoking initiation HECW2 intron 24665060 rs9677260 chr2 197327735 G T 1.76E-05 Amyotrophic lateral sclerosis (sporadic) HECW2 intron 24529757 rs16852469 chr2 197352884 A G 3.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HECW2 intron 20031582 rs4341955 chr2 197404714 G A 2.87E-04 Coronary heart disease HECW2 intron 21971053 rs16855046 chr2 197470459 G A 6.10E-04 Taste perception / / 22132133 rs16855610 chr2 197504764 C A 3.40E-04 Taste perception CCDC150 intron 22132133 rs6434875 chr2 197522130 G C 4.57E-04 Schizophrenia(treatment response to risperidone) CCDC150 intron 19850283 rs10197202 chr2 197522966 G A 1.30E-05 Alcoholism (heaviness of drinking) CCDC150 intron 21529783 rs80346810 chr2 197576939 G A 0.0009 Breast cancer CCDC150 missense 23555315 rs3806507 chr2 197666152 G A 2.51E-04 Rheumatoid arthritis GTF3C3 nearGene-5 21452313 rs2289380 chr2 197669189 C T 3.02E-04 Gallbladder cancer C2orf66 UTR-3 22318345 rs7580839 chr2 197673035 C T 9.65E-05 Gallbladder cancer C2orf66 intron 22318345 rs1866186 chr2 197715078 G A 9.65E-05 Gallbladder cancer PGAP1 intron 22318345 rs636258 chr2 197747960 C T 9.69E-05 Gallbladder cancer PGAP1 intron 22318345 rs12693800 chr2 197777589 C T 3.58E-04 Type 2 diabetes PGAP1 intron 17463246 rs6733360 chr2 197833680 G A 7.32E-04 Multiple complex diseases / / 17554300 rs16860099 chr2 197850176 T C 2.31E-06 Personality dimensions / / 23658558 rs11888210 chr2 197850652 T C 2.23E-06 Personality dimensions / / 23658558 rs7595528 chr2 197860406 G C 1.20E-05 Urinary metabolites ANKRD44 intron 21572414 rs4850742 chr2 197863851 C T 4.29E-06 Systemic lupus erythematosus and Systemic sclerosis ANKRD44 intron 23740937 rs7584406 chr2 197878584 T A 6.41E-04 Multiple complex diseases ANKRD44 intron 17554300 rs10497802 chr2 197882236 G T 2.58E-06 Personality dimensions ANKRD44 intron 23658558 rs4850746 chr2 197883010 C T 0.0008885 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANKRD44 intron 23233654 rs4850746 chr2 197883010 C T 8.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANKRD44 intron 23233662 rs16860886 chr2 197897885 T C 1.32E-06 Personality dimensions ANKRD44 intron 23658558 rs16860949 chr2 197904195 C T 2.58E-06 Personality dimensions ANKRD44 intron 23658558 rs4850409 chr2 197915534 T C 4.57E-05 Cognitive test performance ANKRD44 intron 20125193 rs4850410 chr2 197920169 C T 6.06E-05 Cognitive test performance ANKRD44 intron 20125193 rs4850410 chr2 197920169 C T 2.60E-05 Urinary metabolites ANKRD44 intron 21572414 rs4372926 chr2 197926353 G A 8.13E-04 Schizophrenia ANKRD44 intron 19197363 rs12464023 chr2 197947389 C T 1.30E-05 Urinary metabolites ANKRD44 intron 21572414 rs930372 chr2 197947823 A C 0.0000687 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity ANKRD44 intron 22945461 rs12467303 chr2 197950027 G A 2.00E-05 Urinary metabolites ANKRD44 intron 21572414 rs7559008 chr2 197970654 C T 8.56E-06 Glaucoma (primary open-angle) ANKRD44 intron 22605921 rs2579398 chr2 197987782 A G 3.85E-05 Multiple complex diseases ANKRD44 intron 17554300 rs2697264 chr2 197997831 T C 9.04E-06 Multiple complex diseases ANKRD44 intron 17554300 rs2579382 chr2 198021089 C T 6.13E-04 Response to cytadine analogues (cytosine arabinoside) ANKRD44 intron 24483146 rs1534540 chr2 198026894 C T 9.59E-04 Response to cytadine analogues (cytosine arabinoside) ANKRD44 intron 24483146 rs6725302 chr2 198032683 A G 1.73E-15 Gallbladder disease ANKRD44 intron pha001404 rs2697239 chr2 198041518 C T 4.66E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697236 chr2 198045646 C G 8.17E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697235 chr2 198046264 G A 8.20E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697234 chr2 198047017 C T 8.20E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2579409 chr2 198061658 G T 8.54E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2579409 chr2 198061658 G T 1.00E-04 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs2579408 chr2 198068879 G A 8.71E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2712900 chr2 198069854 C T 8.74E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697306 chr2 198075674 G A 9.44E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs2697299 chr2 198081078 A G 4.35E-04 Body mass index ANKRD44 intron 21701565 rs2697299 chr2 198081078 A G 7.80E-04 Body mass index ANKRD44 intron 21701565 rs2697299 chr2 198081078 A G 4.39E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs6715021 chr2 198082707 G A 9.16E-04 Alzheimer's disease ANKRD44 intron 24755620 rs1881401 chr2 198087907 G A 8.87E-06 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs1881400 chr2 198088063 G A 2.67E-05 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs2697318 chr2 198092910 A C 3.80E-04 Body mass index ANKRD44 intron 17255346 rs2252542 chr2 198093900 C T 5.48E-04 Body mass index ANKRD44 intron 21701565 rs17390362 chr2 198094771 C T 4.47E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs2697290 chr2 198113157 A G 9.80E-06 Crohn's disease ANKRD44 intron 20570966 rs6434921 chr2 198120197 G A 1.34E-05 Serum metabolites ANKRD44 intron 19043545 rs2697276 chr2 198130354 A G 3.74E-05 Psoriasis ANKRD44 intron 20953190 rs4850776 chr2 198132451 G A 1.39E-05 Serum metabolites ANKRD44 intron 19043545 rs4850776 chr2 198132451 G A 5.00E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs4850777 chr2 198132524 G A 1.37E-05 Serum metabolites ANKRD44 intron 19043545 rs4850777 chr2 198132524 G A 9.57E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs12617121 chr2 198134059 G A 1.13E-05 Serum metabolites ANKRD44 intron 19043545 rs4850779 chr2 198134188 G A 1.46E-05 Serum metabolites ANKRD44 intron 19043545 rs4850779 chr2 198134188 G A 5.49E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs4850780 chr2 198134535 G A 1.39E-05 Serum metabolites ANKRD44 intron 19043545 rs2712867 chr2 198135412 T C 4.08E-05 Psoriasis ANKRD44 intron 20953190 rs11693873 chr2 198142210 T C 7.70E-06 Urinary metabolites ANKRD44 intron 21572414 rs10931777 chr2 198143591 C T 1.23E-07 Prostate cancer ANKRD44 intron 22923026 rs6727480 chr2 198143871 A G 3.79E-07 Prostate cancer ANKRD44 intron 22923026 rs2043016 chr2 198146381 C T 9.16E-05 Self-reported allergy ANKRD44 intron 23817569 rs12619296 chr2 198148767 A G 2.50E-05 Self-reported allergy ANKRD44 intron 23817569 rs1429419 chr2 198154547 G A 1.58E-05 Self-reported allergy ANKRD44 intron 23817569 rs1429418 chr2 198158151 G C 2.25E-04 Self-reported allergy ANKRD44 intron 23817569 rs1366837 chr2 198160501 T C 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs2195510 chr2 198161195 A G 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs1429414 chr2 198162430 G A 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs1896857 chr2 198164530 A G 8.00E-06 Alcohol dependence (age at onset) ANKRD44 intron 24962325 rs6741380 chr2 198165121 G A 1.37E-04 Self-reported allergy ANKRD44 intron 23817569 rs6741380 chr2 198165121 G A 4.43E-05 Body Fat Distribution ANKRD44 intron pha003017 rs919433 chr2 198166565 G A 1.78E-04 Self-reported allergy ANKRD44 intron 23817569 rs2195507 chr2 198172336 T C 1.59E-05 Self-reported allergy ANKRD44 intron 23817569 rs13033821 chr2 198173536 T G 2.06E-04 Self-reported allergy ANKRD44 intron 23817569 rs4850429 chr2 198178409 G A 2.02E-04 Self-reported allergy / / 23817569 rs4850786 chr2 198178608 C T 2.19E-04 Self-reported allergy / / 23817569 rs6738721 chr2 198182334 A G 6.31E-06 Self-reported allergy / / 23817569 rs1560277 chr2 198187903 T C 4.45E-05 Self-reported allergy / / 23817569 rs2059922 chr2 198188903 C G 7.23E-06 Self-reported allergy / / 23817569 rs13032495 chr2 198189346 C T 2.93E-05 Self-reported allergy / / 23817569 rs1429412 chr2 198190894 A G 2.91E-05 Self-reported allergy / / 23817569 rs3843857 chr2 198195965 T C 3.04E-05 Self-reported allergy / / 23817569 rs7575389 chr2 198198489 A G 1.31E-05 Self-reported allergy / / 23817569 rs3097385 chr2 198199297 G A 1.02E-05 Self-reported allergy / / 23817569 rs2914982 chr2 198202793 G C 1.10E-05 Self-reported allergy / / 23817569 rs6759834 chr2 198204860 C T 4.01E-05 Self-reported allergy / / 23817569 rs12472355 chr2 198205840 C A 4.71E-05 Self-reported allergy / / 23817569 rs6711624 chr2 198207607 C G 5.27E-05 Self-reported allergy / / 23817569 rs13013049 chr2 198208664 C T 4.89E-05 Self-reported allergy / / 23817569 rs10931782 chr2 198211579 G A 4.75E-05 Self-reported allergy / / 23817569 rs788001 chr2 198213720 C T 4.54E-05 Self-reported allergy / / 23817569 rs17405525 chr2 198214183 G C 3.51E-06 Self-reported allergy / / 23817569 rs787997 chr2 198216271 A G 4.10E-05 Self-reported allergy / / 23817569 rs787995 chr2 198216853 T G 3.48E-05 Self-reported allergy / / 23817569 rs788004 chr2 198219032 C T 2.22E-05 Self-reported allergy / / 23817569 rs787994 chr2 198223121 T C 2.08E-05 Self-reported allergy / / 23817569 rs788011 chr2 198230771 A G 1.14E-05 Self-reported allergy / / 23817569 rs788010 chr2 198230949 T C 1.06E-05 Self-reported allergy / / 23817569 rs788008 chr2 198232639 C T 4.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs788007 chr2 198233676 T G 1.00E-05 Self-reported allergy / / 23817569 rs787980 chr2 198239225 C T 9.87E-06 Self-reported allergy / / 23817569 rs11888760 chr2 198243749 A T 7.45E-06 Self-reported allergy / / 23817569 rs4685 chr2 198257795 T C 6.61E-06 Self-reported allergy SF3B1 cds-synon 23817569 rs16865262 chr2 198263146 T C 1.30E-05 Prostate cancer SF3B1 intron 22923026 rs12621129 chr2 198265350 T C 8.38E-06 Self-reported allergy SF3B1 intron 23817569 rs788018 chr2 198265526 A G 8.68E-06 Self-reported allergy SF3B1 cds-synon 23817569 rs788018 chr2 198265526 A G 7.00E-04 Ulcerative colitis SF3B1 cds-synon 24837172 rs12151767 chr2 198274929 G A 1.10E-06 Self-reported allergy SF3B1 intron 23817569 rs3097384 chr2 198278834 T A 1.03E-05 Self-reported allergy SF3B1 intron 23817569 rs699319 chr2 198281776 C A 1.03E-05 Self-reported allergy SF3B1 intron 23817569 rs788023 chr2 198283305 T C 1.51E-05 Self-reported allergy SF3B1 cds-synon 23817569 rs2564372 chr2 198307813 C T 1.19E-06 Self-reported allergy / / 23817569 rs3849362 chr2 198308260 G A 1.24E-06 Self-reported allergy / / 23817569 rs2564383 chr2 198310862 A G 1.30E-05 Self-reported allergy / / 23817569 rs11902195 chr2 198316370 C G 8.41E-07 Self-reported allergy / / 23817569 rs3731570 chr2 198317783 C T 1.55E-06 Self-reported allergy / / 23817569 rs3754822 chr2 198327314 G A 1.84E-06 Prostate cancer COQ10B cds-synon 22923026 rs3754822 chr2 198327314 G A 4.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) COQ10B cds-synon 24023788 rs787983 chr2 198345797 G A 1.05E-05 Self-reported allergy / / 23817569 rs6745660 chr2 198349536 A G 8.72E-07 Self-reported allergy / / 23817569 rs788016 chr2 198352293 G A 8.69E-07 Self-reported allergy HSPD1 intron 23817569 rs2565163 chr2 198354414 T C 9.42E-06 Self-reported allergy HSPD1 intron 23817569 rs8539 chr2 198362018 T C 1.28E-05 Self-reported allergy HSPD1 cds-synon 23817569 rs17730989 chr2 198362524 C T 9.81E-07 Self-reported allergy HSPD1 intron 23817569 rs2605039 chr2 198362851 C A 2.06E-05 Self-reported allergy HSPD1 intron 23817569 rs6434930 chr2 198369370 T C 1.45E-05 Self-reported allergy HSPE1-MOB4 intron 23817569 rs6434930 chr2 198369370 T C 3.00E-04 Ulcerative colitis HSPE1-MOB4 intron 24837172 rs7601800 chr2 198395099 T C 1.49E-05 Self-reported allergy MOB4 intron 23817569 rs3792159 chr2 198403697 C T 1.44E-05 Self-reported allergy MOB4 intron 23817569 rs3792159 chr2 198403697 C T 1.00E-04 Ulcerative colitis MOB4 intron 24837172 rs3792158 chr2 198407177 A G 8.76E-07 Self-reported allergy MOB4 intron 23817569 rs7568250 chr2 198409611 G A 5.85E-06 Self-reported allergy MOB4 intron 23817569 rs1563340 chr2 198414713 A T 1.85E-05 Self-reported allergy MOB4 intron 23817569 rs17787829 chr2 198419798 T C 7.33E-07 Self-reported allergy / / 23817569 rs7582536 chr2 198436103 A G 1.07E-05 Self-reported allergy RFTN2 UTR-3 23817569 rs6434934 chr2 198437386 C G 1.55E-05 Self-reported allergy RFTN2 intron 23817569 rs10178946 chr2 198463090 G T 9.34E-06 Self-reported allergy RFTN2 intron 23817569 rs17731449 chr2 198465840 T C 6.54E-07 Self-reported allergy RFTN2 intron 23817569 rs11900232 chr2 198466273 T C 9.78E-06 Self-reported allergy RFTN2 intron 23817569 rs13411968 chr2 198467141 C T 9.78E-06 Self-reported allergy RFTN2 intron 23817569 rs6719483 chr2 198472886 A G 6.19E-06 Self-reported allergy RFTN2 intron 23817569 rs1455653 chr2 198478320 G A 4.95E-06 Self-reported allergy RFTN2 intron 23817569 rs6719729 chr2 198480072 G A 5.12E-06 Self-reported allergy RFTN2 intron 23817569 rs6719729 chr2 198480072 G A 9.33E-05 Body Fat Distribution RFTN2 intron pha003017 rs2045245 chr2 198485341 A C 5.83E-06 Self-reported allergy RFTN2 intron 23817569 rs6728904 chr2 198492837 C T 1.34E-07 Self-reported allergy RFTN2 intron 23817569 rs13396312 chr2 198493703 T A 9.66E-05 Insulin resistance RFTN2 intron 21901158 rs13396312 chr2 198493703 T A 3.31E-07 Self-reported allergy RFTN2 intron 23817569 rs3828317 chr2 198495431 G C 2.58E-07 Self-reported allergy RFTN2 intron 23817569 rs970552 chr2 198497512 T G 2.82E-07 Self-reported allergy RFTN2 intron 23817569 rs2045244 chr2 198506466 C T 2.68E-06 Prostate cancer RFTN2 intron 22923026 rs10497806 chr2 198508951 G A 1.53E-05 Self-reported allergy RFTN2 cds-synon 23817569 rs16866970 chr2 198511086 G A 2.84E-07 Self-reported allergy RFTN2 intron 23817569 rs10166328 chr2 198511917 A G 1.72E-05 Self-reported allergy RFTN2 intron 23817569 rs13413470 chr2 198512849 G A 2.90E-07 Self-reported allergy RFTN2 intron 23817569 rs7564924 chr2 198513877 C T 1.78E-05 Self-reported allergy RFTN2 intron 23817569 rs10196961 chr2 198513930 G A 3.08E-07 Self-reported allergy RFTN2 intron 23817569 rs11690491 chr2 198514924 C T 3.33E-07 Self-reported allergy RFTN2 intron 23817569 rs1598469 chr2 198515658 T C 1.67E-05 Self-reported allergy RFTN2 intron 23817569 rs13427590 chr2 198516821 C T 3.19E-07 Self-reported allergy RFTN2 intron 23817569 rs1902249 chr2 198521356 T C 1.52E-05 Self-reported allergy RFTN2 intron 23817569 rs13000656 chr2 198522126 T C 1.32E-05 Self-reported allergy RFTN2 intron 23817569 rs6708239 chr2 198525084 A G 1.46E-05 Self-reported allergy RFTN2 intron 23817569 rs6741314 chr2 198526088 G A 1.51E-05 Self-reported allergy RFTN2 intron 23817569 rs6757632 chr2 198530266 C T 1.81E-05 Self-reported allergy RFTN2 intron 23817569 rs6757852 chr2 198530293 G A 2.17E-07 Self-reported allergy RFTN2 intron 23817569 rs6757669 chr2 198530355 C T 1.50E-05 Self-reported allergy RFTN2 intron 23817569 rs6719832 chr2 198533369 A G 1.41E-05 Self-reported allergy RFTN2 intron 23817569 rs6748788 chr2 198533606 G T 2.07E-07 Self-reported allergy RFTN2 intron 23817569 rs7603839 chr2 198534708 G A 2.73E-07 Self-reported allergy RFTN2 intron 23817569 rs7340470 chr2 198545462 G A 7.54E-09 Self-reported allergy / / 23817569 rs12622674 chr2 198551812 G A 6.58E-09 Self-reported allergy / / 23817569 rs2341510 chr2 198558679 T C 5.73E-09 Self-reported allergy / / 23817569 rs6743671 chr2 198563642 T C 4.47E-09 Self-reported allergy / / 23817569 rs4850437 chr2 198569051 T G 9.63E-09 Self-reported allergy / / 23817569 rs10931791 chr2 198573612 A C 8.08E-07 Self-reported allergy / / 23817569 rs4850807 chr2 198575975 G A 7.74E-07 Self-reported allergy / / 23817569 rs4850808 chr2 198576142 T C 7.00E-09 Self-reported allergy / / 23817569 rs10931793 chr2 198577585 G A 8.02E-07 Self-reported allergy / / 23817569 rs4850809 chr2 198583403 C T 6.58E-07 Self-reported allergy / / 23817569 rs2037590 chr2 198584775 T A 6.67E-07 Self-reported allergy / / 23817569 rs10497807 chr2 198585087 G C 8.54E-09 Self-reported allergy / / 23817569 rs12472359 chr2 198587865 T C 2.27E-08 Self-reported allergy / / 23817569 rs700640 chr2 198590886 C T 2.91E-08 Self-reported allergy / / 23817569 rs700642 chr2 198600730 T G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700643 chr2 198601370 A G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700645 chr2 198605514 A G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700646 chr2 198608511 C T 4.11E-07 Self-reported allergy BOLL intron 23817569 rs770666 chr2 198611897 T A 2.88E-08 Self-reported allergy BOLL intron 23817569 rs2293255 chr2 198621506 T C 7.48E-07 Prostate cancer BOLL intron 22923026 rs700648 chr2 198622636 C T 2.66E-08 Self-reported allergy BOLL intron 23817569 rs700649 chr2 198622752 G A 2.43E-08 Self-reported allergy BOLL intron 23817569 rs700650 chr2 198624285 G A 2.33E-08 Self-reported allergy BOLL intron 23817569 rs771013 chr2 198625237 G A 2.33E-08 Self-reported allergy BOLL intron 23817569 rs700651 chr2 198631714 G A 4.00E-08 Intracranial aneurysm BOLL intron 18997786 rs700651 chr2 198631714 G A 0.00027 Prostate cancer BOLL intron 23555315 rs700651 chr2 198631714 G A 1.05E-06 Self-reported allergy BOLL intron 23817569 rs700653 chr2 198637433 A G 2.44E-08 Self-reported allergy BOLL intron 23817569 rs700654 chr2 198643421 G A 2.54E-08 Self-reported allergy BOLL intron 23817569 rs700655 chr2 198643631 G A 5.71E-08 Self-reported allergy BOLL intron 23817569 rs1851779 chr2 198647108 C T 5.41E-07 Prostate cancer BOLL intron 22923026 rs700658 chr2 198655007 A T 2.71E-06 Self-reported allergy / / 23817569 rs700659 chr2 198659923 T C 7.95E-08 Self-reported allergy / / 23817569 rs771016 chr2 198665520 C T 7.35E-08 Self-reported allergy / / 23817569 rs770657 chr2 198674184 C A 2.44E-06 Self-reported allergy PLCL1 intron 23817569 rs700667 chr2 198677508 T C 2.17E-06 Self-reported allergy PLCL1 intron 23817569 rs16824376 chr2 198684342 C T 5.00E-07 Prostate cancer PLCL1 intron 22923026 rs996427 chr2 198685609 G A 5.51E-07 Prostate cancer PLCL1 intron 22923026 rs700670 chr2 198687284 T C 2.31E-06 Self-reported allergy PLCL1 intron 23817569 rs696815 chr2 198688084 A C 2.21E-06 Self-reported allergy PLCL1 intron 23817569 rs700671 chr2 198690001 T C 2.28E-06 Self-reported allergy PLCL1 intron 23817569 rs771010 chr2 198691006 C G 5.91E-08 Self-reported allergy PLCL1 intron 23817569 rs4550664 chr2 198691405 A G 1.91E-06 Self-reported allergy PLCL1 intron 23817569 rs700672 chr2 198691455 G A 2.05E-06 Self-reported allergy PLCL1 intron 23817569 rs700674 chr2 198693703 C T 2.32E-06 Self-reported allergy PLCL1 intron 23817569 rs700675 chr2 198700216 G A 2.20E-06 Self-reported allergy PLCL1 intron 23817569 rs700677 chr2 198702424 C A 6.84E-07 Self-reported allergy PLCL1 intron 23817569 rs2574832 chr2 198704818 T G 2.18E-06 Self-reported allergy PLCL1 intron 23817569 rs700678 chr2 198705820 T C 2.66E-06 Self-reported allergy PLCL1 intron 23817569 rs700679 chr2 198706916 C T 6.89E-08 Self-reported allergy PLCL1 intron 23817569 rs700680 chr2 198707950 A T 2.07E-06 Self-reported allergy PLCL1 intron 23817569 rs700681 chr2 198711502 C A 2.00E-06 Self-reported allergy PLCL1 intron 23817569 rs700683 chr2 198712332 G A 1.86E-06 Self-reported allergy PLCL1 intron 23817569 rs700684 chr2 198713099 C T 2.00E-06 Self-reported allergy PLCL1 intron 23817569 rs6707521 chr2 198713231 G A 5.47E-07 Prostate cancer PLCL1 intron 22923026 rs700685 chr2 198715972 A G 1.87E-06 Self-reported allergy PLCL1 intron 23817569 rs7604700 chr2 198718630 A G 1.81E-06 Self-reported allergy PLCL1 intron 23817569 rs1435569 chr2 198718667 G C 1.82E-06 Self-reported allergy PLCL1 intron 23817569 rs700686 chr2 198721054 G A 1.82E-06 Self-reported allergy PLCL1 intron 23817569 rs700687 chr2 198721560 A T 1.83E-06 Self-reported allergy PLCL1 intron 23817569 rs696817 chr2 198722225 A G 1.77E-06 Self-reported allergy PLCL1 intron 23817569 rs700688 chr2 198723833 G A 1.78E-06 Self-reported allergy PLCL1 intron 23817569 rs770661 chr2 198725444 A G 1.73E-06 Self-reported allergy PLCL1 intron 23817569 rs700690 chr2 198727626 A G 1.68E-06 Self-reported allergy PLCL1 intron 23817569 rs700691 chr2 198727852 A G 5.48E-08 Self-reported allergy PLCL1 intron 23817569 rs700692 chr2 198728500 T C 1.70E-06 Self-reported allergy PLCL1 intron 23817569 rs1436131 chr2 198731230 T G 1.38E-06 Self-reported allergy PLCL1 intron 23817569 rs6753450 chr2 198735031 C T 4.05E-08 Self-reported allergy PLCL1 intron 23817569 rs10192466 chr2 198738019 G A 4.90E-08 Self-reported allergy PLCL1 intron 23817569 rs4850812 chr2 198743655 G T 1.54E-06 Self-reported allergy PLCL1 intron 23817569 rs1369511 chr2 198746115 G C 4.49E-08 Self-reported allergy PLCL1 intron 23817569 rs2060488 chr2 198751637 T G 1.50E-06 Self-reported allergy PLCL1 intron 23817569 rs1865586 chr2 198758868 A G 1.10E-06 Self-reported allergy PLCL1 intron 23817569 rs6734781 chr2 198759973 G A 1.52E-06 Self-reported allergy PLCL1 intron 23817569 rs6434943 chr2 198762192 T G 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs1435568 chr2 198762879 T C 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs6729473 chr2 198763928 G A 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs1369512 chr2 198767132 T A 4.29E-08 Self-reported allergy PLCL1 intron 23817569 rs10198606 chr2 198769739 C G,T 3.57E-08 Self-reported allergy PLCL1 intron 23817569 rs4850813 chr2 198775982 C T 1.25E-06 Self-reported allergy PLCL1 intron 23817569 rs1401095 chr2 198779867 C T 1.08E-06 Self-reported allergy PLCL1 intron 23817569 rs938929 chr2 198780860 A G 2.67E-08 Self-reported allergy PLCL1 intron 23817569 rs938929 chr2 198780860 A G 8.32E-05 Dermatomyositis PLCL1 intron 23983088 rs1589162 chr2 198782692 C T 1.29E-06 Self-reported allergy PLCL1 intron 23817569 rs4850816 chr2 198789765 C A 2.41E-08 Self-reported allergy PLCL1 intron 23817569 rs1401091 chr2 198790423 T G 1.34E-06 Self-reported allergy PLCL1 intron 23817569 rs1401092 chr2 198792320 C A 1.17E-06 Self-reported allergy PLCL1 intron 23817569 rs7557203 chr2 198795650 A G 1.25E-06 Self-reported allergy PLCL1 intron 23817569 rs11692344 chr2 198795863 T G 1.31E-08 Self-reported allergy PLCL1 intron 23817569 rs6434945 chr2 198797960 G C 1.36E-08 Self-reported allergy PLCL1 intron 23817569 rs1464211 chr2 198798630 G A 1.41E-06 Self-reported allergy PLCL1 intron 23817569 rs1607373 chr2 198800532 G A 4.43E-05 Smoking cessation PLCL1 intron 18519826 rs1607373 chr2 198800532 G A 1.53E-08 Self-reported allergy PLCL1 intron 23817569 rs4369854 chr2 198800630 T C 1.45E-06 Self-reported allergy PLCL1 intron 23817569 rs2880389 chr2 198801707 T C 1.57E-08 Self-reported allergy PLCL1 intron 23817569 rs1983359 chr2 198805098 C T 1.44E-06 Self-reported allergy PLCL1 intron 23817569 rs11887138 chr2 198805838 T A 1.39E-06 Self-reported allergy PLCL1 intron 23817569 rs10207433 chr2 198805930 G T 1.19E-08 Self-reported allergy PLCL1 intron 23817569 rs1401090 chr2 198808578 G A 1.30E-08 Self-reported allergy PLCL1 intron 23817569 rs1518366 chr2 198809196 G A 1.47E-08 Self-reported allergy PLCL1 intron 23817569 rs1914690 chr2 198809368 G A 1.45E-08 Self-reported allergy PLCL1 intron 23817569 rs1518365 chr2 198809410 T C 1.39E-06 Self-reported allergy PLCL1 intron 23817569 rs1518364 chr2 198809975 G A 1.43E-08 Self-reported allergy PLCL1 intron 23817569 rs1518364 chr2 198809975 G A 5.11E-05 Dermatomyositis PLCL1 intron 23983088 rs1518363 chr2 198810131 C T 1.46E-06 Self-reported allergy PLCL1 intron 23817569 rs1518361 chr2 198812874 A G 1.79E-06 Self-reported allergy PLCL1 intron 23817569 rs10189897 chr2 198813410 A G 1.52E-08 Self-reported allergy PLCL1 intron 23817569 rs1518360 chr2 198815303 C T 3.05E-05 Smoking cessation PLCL1 intron 18519826 rs1518360 chr2 198815303 C T 1.51E-08 Self-reported allergy PLCL1 intron 23817569 rs4410288 chr2 198819824 C T 1.32E-08 Self-reported allergy PLCL1 intron 23817569 rs1401096 chr2 198823828 A G 1.28E-06 Self-reported allergy PLCL1 intron 23817569 rs13408411 chr2 198825462 G A 1.43E-06 Self-reported allergy PLCL1 intron 23817569 rs10497809 chr2 198825668 G A 1.18E-08 Self-reported allergy PLCL1 intron 23817569 rs1356542 chr2 198835702 G T 1.10E-06 Self-reported allergy PLCL1 intron 23817569 rs7581202 chr2 198836777 A G 7.60E-06 Prostate cancer PLCL1 intron 22923026 rs7571869 chr2 198841615 T C 8.90E-09 Self-reported allergy PLCL1 intron 23817569 rs7587043 chr2 198841729 A C 8.47E-09 Self-reported allergy PLCL1 intron 23817569 rs13394871 chr2 198846337 G A 8.68E-09 Self-reported allergy PLCL1 intron 23817569 rs6726506 chr2 198846486 G T 1.42E-06 Self-reported allergy PLCL1 intron 23817569 rs1518359 chr2 198847383 C T 5.66E-09 Self-reported allergy PLCL1 intron 23817569 rs6434949 chr2 198855510 T A 7.09E-07 Self-reported allergy PLCL1 intron 23817569 rs10177758 chr2 198858917 A G 2.29E-04 Smoking cessation PLCL1 intron 18519826 rs10177758 chr2 198858917 A G 5.69E-09 Self-reported allergy PLCL1 intron 23817569 rs1866664 chr2 198860428 T C 5.44E-09 Self-reported allergy PLCL1 intron 23817569 rs1976772 chr2 198868201 G T 9.13E-07 Self-reported allergy PLCL1 intron 23817569 rs1440088 chr2 198871417 T G 6.45E-04 Type 2 diabetes PLCL1 intron 17463246 rs1595824 chr2 198874006 C A,T 3.59E-09 Self-reported allergy PLCL1 intron 23817569 rs1595825 chr2 198875464 G A 1.47E-06 Prostate cancer PLCL1 intron 22923026 rs976179 chr2 198880378 A T 2.27E-09 Self-reported allergy PLCL1 intron 23817569 rs976180 chr2 198880443 A G 1.59E-06 Self-reported allergy PLCL1 intron 23817569 rs1318867 chr2 198880481 C A 2.37E-09 Self-reported allergy PLCL1 intron 23817569 rs1025549 chr2 198881183 G A 1.05E-05 Alcohol consumption PLCL1 intron 23743675 rs1016883 chr2 198881668 G A 2.56E-06 Prostate cancer PLCL1 intron 22923026 rs1016883 chr2 198881668 G A 3.00E-08 Ulcerative colitis PLCL1 intron 23128233 rs11681663 chr2 198882952 G A 1.09E-05 Alcohol consumption PLCL1 intron 23743675 rs34692727 chr2 198883513 C T 1.13E-05 Alcohol consumption PLCL1 intron 23743675 rs11683222 chr2 198884028 C G 1.16E-05 Alcohol consumption PLCL1 intron 23743675 rs11683222 chr2 198884028 C G 2.77E-09 Self-reported allergy PLCL1 intron 23817569 rs2139049 chr2 198887660 G A 1.21E-05 Alcohol consumption PLCL1 intron 23743675 rs1978888 chr2 198889245 T C 1.15E-05 Alcohol consumption PLCL1 intron 23743675 rs2196171 chr2 198889807 T G 1.24E-05 Alcohol consumption PLCL1 intron 23743675 rs2196172 chr2 198889893 T G 2.17E-05 Alcohol consumption PLCL1 intron 23743675 rs2196172 chr2 198889893 T G 1.59E-09 Self-reported allergy PLCL1 intron 23817569 rs7592556 chr2 198891021 G A 7.08E-07 Self-reported allergy PLCL1 intron 23817569 rs1595823 chr2 198891799 C T 1.62E-05 Alcohol consumption PLCL1 intron 23743675 rs1595823 chr2 198891799 C T 3.82E-09 Self-reported allergy PLCL1 intron 23817569 rs10196612 chr2 198894139 T C 1.18E-05 Alcohol consumption PLCL1 intron 23743675 rs10196612 chr2 198894139 T C 2.19E-09 Self-reported allergy PLCL1 intron 23817569 rs10184395 chr2 198894285 G A 6.10E-07 Self-reported allergy PLCL1 intron 23817569 rs10184227 chr2 198894305 C T 1.11E-05 Alcohol consumption PLCL1 intron 23743675 rs10184227 chr2 198894305 C T 2.00E-09 Self-reported allergy PLCL1 intron 23817569 rs10166845 chr2 198896071 A G 1.16E-05 Alcohol consumption PLCL1 intron 23743675 rs6738825 chr2 198896895 A G 4.00E-09 Crohn's disease PLCL1 intron 21102463 rs6738825 chr2 198896895 A G 1.10E-05 Alcohol consumption PLCL1 intron 23743675 rs6738825 chr2 198896895 A G 1.93E-09 Self-reported allergy PLCL1 intron 23817569 rs6715070 chr2 198898265 G A 5.65E-07 Self-reported allergy PLCL1 intron 23817569 rs1541953 chr2 198898344 A T 1.06E-05 Alcohol consumption PLCL1 intron 23743675 rs1541953 chr2 198898344 A T 2.28E-09 Self-reported allergy PLCL1 intron 23817569 rs11889326 chr2 198899275 A C 1.05E-05 Alcohol consumption PLCL1 intron 23743675 rs1583792 chr2 198900288 C T 7.26E-06 Alcohol consumption PLCL1 intron 23743675 rs1371663 chr2 198900305 G A 2.60E-07 Self-reported allergy PLCL1 intron 23817569 rs1579695 chr2 198900363 G A 1.12E-05 Alcohol consumption PLCL1 intron 23743675 rs1579695 chr2 198900363 G A 1.30E-09 Self-reported allergy PLCL1 intron 23817569 rs1147169 chr2 198901395 T C 2.25E-07 Self-reported allergy PLCL1 intron 23817569 rs10190226 chr2 198901564 C T 1.86E-07 Self-reported allergy PLCL1 intron 23817569 rs962210 chr2 198902230 A T 6.11E-06 Alcohol consumption PLCL1 intron 23743675 rs10497811 chr2 198902909 A C 5.94E-06 Alcohol consumption PLCL1 intron 23743675 rs10497811 chr2 198902909 A C 7.01E-10 Self-reported allergy PLCL1 intron 23817569 rs1371664 chr2 198904465 T A 1.05E-05 Smoking cessation PLCL1 intron 18519826 rs1371664 chr2 198904465 T A 6.84E-04 Smoking cessation PLCL1 intron 18519826 rs1371664 chr2 198904465 T A 5.61E-06 Alcohol consumption PLCL1 intron 23743675 rs1371664 chr2 198904465 T A 7.65E-10 Self-reported allergy PLCL1 intron 23817569 rs2196176 chr2 198904914 A G 2.37E-07 Self-reported allergy PLCL1 intron 23817569 rs2196175 chr2 198905073 T A 6.98E-06 Alcohol consumption PLCL1 intron 23743675 rs2196174 chr2 198905172 A G 5.49E-06 Alcohol consumption PLCL1 intron 23743675 rs12329164 chr2 198905224 C G 4.49E-06 Alcohol consumption PLCL1 intron 23743675 rs892514 chr2 198905270 T C 2.19E-07 Self-reported allergy PLCL1 intron 23817569 rs10206714 chr2 198906481 C T 4.50E-06 Alcohol consumption PLCL1 intron 23743675 rs10206714 chr2 198906481 C T 7.56E-10 Self-reported allergy PLCL1 intron 23817569 rs9712275 chr2 198907143 C T 5.77E-06 Alcohol consumption PLCL1 intron 23743675 rs745899 chr2 198908040 A T 4.24E-06 Alcohol consumption PLCL1 intron 23743675 rs745899 chr2 198908040 A T 8.69E-10 Self-reported allergy PLCL1 intron 23817569 rs67031482 chr2 198911166 C T 4.00E-06 Alcohol consumption PLCL1 intron 23743675 rs10497812 chr2 198911245 G A 1.95E-07 Self-reported allergy PLCL1 intron 23817569 rs6732340 chr2 198912952 C G 4.63E-06 Alcohol consumption PLCL1 intron 23743675 rs10497813 chr2 198914072 G T 4.36E-06 Alcohol consumption PLCL1 intron 23743675 rs10497813 chr2 198914072 G T 6.00E-10 Self-reported allergy PLCL1 intron 23817569 rs2164071 chr2 198915467 T C 1.24E-07 Self-reported allergy PLCL1 intron 23817569 rs2117339 chr2 198915734 C T 4.40E-06 Alcohol consumption PLCL1 intron 23743675 rs2117339 chr2 198915734 C T 7.04E-10 Self-reported allergy PLCL1 intron 23817569 rs7420608 chr2 198915930 A T 1.06E-07 Self-reported allergy PLCL1 intron 23817569 rs11903129 chr2 198918591 A T 1.50E-07 Self-reported allergy PLCL1 intron 23817569 rs2342558 chr2 198920142 T C 1.10E-07 Self-reported allergy PLCL1 intron 23817569 rs13382697 chr2 198920560 A C 1.11E-07 Self-reported allergy PLCL1 intron 23817569 rs1837495 chr2 198921201 G A 1.12E-07 Self-reported allergy PLCL1 intron 23817569 rs11679484 chr2 198921604 C A 7.95E-08 Self-reported allergy PLCL1 intron 23817569 rs35062652 chr2 198927927 C T 6.13E-06 Alcohol consumption PLCL1 intron 23743675 rs11889006 chr2 198928647 A G 3.46E-07 Self-reported allergy PLCL1 intron 23817569 rs6434953 chr2 198929693 A G 3.48E-07 Self-reported allergy PLCL1 intron 23817569 rs6434954 chr2 198929716 T C 2.17E-07 Self-reported allergy PLCL1 intron 23817569 rs7572733 chr2 198929806 C T 6.97E-06 Alcohol consumption PLCL1 intron 23743675 rs7572733 chr2 198929806 C T 1.88E-09 Self-reported allergy PLCL1 intron 23817569 rs7572733 chr2 198929806 C T 6.00E-06 Dermatomyositis PLCL1 intron 23983088 rs7573001 chr2 198929896 G C 1.32E-07 Self-reported allergy PLCL1 intron 23817569 rs7587251 chr2 198930197 T G 6.06E-06 Alcohol consumption PLCL1 intron 23743675 rs7587251 chr2 198930197 T G 1.71E-09 Self-reported allergy PLCL1 intron 23817569 rs11690149 chr2 198933804 C T 6.18E-06 Alcohol consumption PLCL1 intron 23743675 rs11690205 chr2 198933948 C T 5.87E-06 Alcohol consumption PLCL1 intron 23743675 rs6745726 chr2 198934080 A G 2.46E-07 Self-reported allergy PLCL1 intron 23817569 rs1368989 chr2 198937082 T C 2.20E-07 Self-reported allergy PLCL1 intron 23817569 rs12105927 chr2 198937258 G A 2.85E-07 Self-reported allergy PLCL1 intron 23817569 rs7590828 chr2 198940251 C T 1.88E-07 Self-reported allergy PLCL1 intron 23817569 rs1866666 chr2 198940607 T C 7.79E-06 Alcohol consumption PLCL1 intron 23743675 rs1866666 chr2 198940607 T C 1.35E-09 Self-reported allergy PLCL1 intron 23817569 rs9973400 chr2 198941578 T C 8.29E-06 Alcohol consumption PLCL1 intron 23743675 rs1371665 chr2 198942568 C T 1.62E-04 Gallstones PLCL1 intron 17632509 rs1371665 chr2 198942568 C T 1.40E-06 Self-reported allergy PLCL1 intron 23817569 rs1036333 chr2 198943787 G T 1.11E-08 Self-reported allergy PLCL1 intron 23817569 rs6434955 chr2 198946551 G A 8.00E-06 Prostate cancer PLCL1 intron 22923026 rs1064213 chr2 198950240 G A 1.60E-04 Myasthenia gravis PLCL1 missense 23055271 rs1064213 chr2 198950240 G A 1.38E-08 Self-reported allergy PLCL1 missense 23817569 rs2033570 chr2 198952637 C T 1.20E-06 Self-reported allergy PLCL1 intron 23817569 rs11684176 chr2 198954774 C T 2.12E-08 Self-reported allergy PLCL1 intron 23817569 rs7595412 chr2 198962243 G A 2.00E-06 Hip bone size PLCL1 intron 18776929 rs1304358 chr2 198969583 C T 1.27E-05 Attention deficit hyperactivity disorder PLCL1 intron 22420046 rs4850820 chr2 198982211 C G 1.71E-04 Insulin resistance PLCL1 intron 21901158 rs10180112 chr2 198982858 C G 5.22E-04 Alcohol dependence PLCL1 intron 21314694 rs988583 chr2 198987935 C A 6.00E-06 Neutrophil count PLCL1 intron 21507922 rs16827916 chr2 199008443 C A 3.07E-04 Insulin resistance PLCL1 intron 21901158 rs1434288 chr2 199032498 C T 9.79E-05 Serum metabolites / / 19043545 rs3796096 chr2 199052600 G A 9.57E-04 Coronary Artery Disease / / 17634449 rs13429991 chr2 199067470 C A 9.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6716214 chr2 199068929 G A 5.58E-04 Taste perception / / 22132133 rs12693837 chr2 199099576 G T 4.54E-05 Birth weight / / 17255346 rs1456563 chr2 199108358 T C 6.13E-04 Alzheimer's disease / / 24755620 rs11674810 chr2 199108648 G A 6.49E-04 Alzheimer's disease / / 24755620 rs1456562 chr2 199109322 T C 6.49E-04 Alzheimer's disease / / 24755620 rs12052400 chr2 199110141 C A 6.20E-04 Alzheimer's disease / / 24755620 rs1456557 chr2 199122294 A G 8.41E-04 Insulin resistance / / 21901158 rs1379020 chr2 199137857 C T 5.51E-04 Alzheimer's disease / / 24755620 rs4850839 chr2 199148418 T C 6.98E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13398206 chr2 199169096 T C 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs16829794 chr2 199176140 G A 7.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13022622 chr2 199184007 G A 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2529663 chr2 199184482 A G 7.61E-05 Waist Circumference / / pha003025 rs2727767 chr2 199190385 A G 9.79E-05 Body Mass Index / / pha003007 rs2727767 chr2 199190385 A G 7.16E-05 Waist Circumference / / pha003025 rs12999347 chr2 199190773 G T 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804083 chr2 199368722 A G 5.27E-04 Type 2 diabetes / / 17463246 rs2054125 chr2 199385721 C T 2.00E-07 Educational attainment / / 23722424 rs1455341 chr2 199387776 A G 9.16E-04 Type 2 diabetes / / 17463246 rs1584987 chr2 199426633 C G 2.54E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10497816 chr2 199444954 C T 1.51E-08 Multiple complex diseases / / 17554300 rs1455357 chr2 199475047 G T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs16830242 chr2 199476070 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1455356 chr2 199476479 G A 0.000052 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16830272 chr2 199490528 G A 4.20E-04 Multiple complex diseases / / 17554300 rs16830272 chr2 199490528 G A 0.000022 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10497819 chr2 199504838 G A 4.21E-06 Multiple complex diseases / / 17554300 rs13393754 chr2 199518159 C T 8.24E-04 Type 2 diabetes / / 17463246 rs17229285 chr2 199523122 C T 2.00E-13 Ulcerative colitis / / 23128233 rs1455334 chr2 199542837 C A 6.43E-04 Type 2 diabetes / / 17463246 rs17826270 chr2 199558179 G A 3.08E-05 Tuberculosis / / 24057671 rs16830330 chr2 199561300 C T 1.81E-04 Multiple complex diseases / / 17554300 rs1400979 chr2 199564343 A G 4.75E-04 Obesity (extreme) / / 21935397 rs1400976 chr2 199566914 T C 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs1400976 chr2 199566914 T C 5.05E-04 Obesity (extreme) / / 21935397 rs1400975 chr2 199566963 G T 5.52E-04 Obesity (extreme) / / 21935397 rs1356485 chr2 199571750 T C 8.78E-04 Type 2 diabetes / / 17463246 rs6757941 chr2 199572092 G T 8.78E-04 Type 2 diabetes / / 17463246 rs6434980 chr2 199572550 T C 8.78E-04 Type 2 diabetes / / 17463246 rs1356494 chr2 199572896 A G 4.79E-04 Alzheimer's disease (late onset) / / 21379329 rs1356494 chr2 199572896 A G 5.21E-04 Obesity (extreme) / / 21935397 rs6434981 chr2 199573857 A C 8.78E-04 Type 2 diabetes / / 17463246 rs13020013 chr2 199575723 T C 4.61E-04 Obesity (extreme) / / 21935397 rs6434983 chr2 199576145 T C 4.85E-04 Alzheimer's disease (late onset) / / 21379329 rs6434983 chr2 199576145 T C 4.53E-04 Obesity (extreme) / / 21935397 rs1533540 chr2 199576537 T C 9.03E-04 Obesity (extreme) / / 21935397 rs1533541 chr2 199576852 A G 9.07E-04 Obesity (extreme) / / 21935397 rs1518099 chr2 199577125 G A 9.18E-04 Obesity (extreme) / / 21935397 rs6740484 chr2 199578617 T C 9.81E-04 Obesity (extreme) / / 21935397 rs16830366 chr2 199585556 C T 6.00E-06 Waist circumference / / 23966867 rs11893063 chr2 199601925 G A 2.00E-06 Brain cytoarchitecture / / 20308991 rs1400984 chr2 199609869 G A 9.56E-04 Obesity (extreme) / / 21935397 rs6705243 chr2 199620941 A G 8.19E-04 Obesity (extreme) / / 21935397 rs1533534 chr2 199623598 C T 8.31E-04 Obesity (extreme) / / 21935397 rs12617311 chr2 199632565 G A 6.00E-13 Menarche (age at onset) / / 21102462 rs1518081 chr2 199633768 T C 6.57E-04 Obesity (extreme) / / 21935397 rs16830444 chr2 199635641 G A 1.96E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1356488 chr2 199638378 T C 9.38E-04 Obesity (extreme) / / 21935397 rs12986948 chr2 199639932 A G 9.44E-04 Obesity (extreme) / / 21935397 rs11680034 chr2 199640420 T C 9.50E-04 Obesity (extreme) / / 21935397 rs7582813 chr2 199640495 C T 9.42E-04 Obesity (extreme) / / 21935397 rs12991894 chr2 199645740 G T 7.40E-04 Obesity (extreme) / / 21935397 rs1518070 chr2 199653885 C A 6.92E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17233334 chr2 199655056 T A 9.05E-04 Obesity (extreme) / / 21935397 rs1013162 chr2 199655213 A G 9.03E-04 Obesity (extreme) / / 21935397 rs1878663 chr2 199655520 T G 9.00E-04 Obesity (extreme) / / 21935397 rs7587759 chr2 199657020 C T 2.32E-04 Celiac disease / / 23936387 rs10497823 chr2 199671852 G A 1.26E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs10189905 chr2 199679110 T G 2.29E-05 Alcohol and nictotine co-dependence / / 20158304 rs10189905 chr2 199679110 T G 6.00E-07 Corneal astigmatism / / 22144915 rs12470251 chr2 199693101 T C 8.33E-04 Multiple complex diseases / / 17554300 rs3973185 chr2 199693694 G A 1.00E-06 Urinary metabolites / / 21572414 rs12614240 chr2 199753674 C T 2.40E-05 Diabetes (gestational) / / 22233651 rs1456520 chr2 199772591 C T 2.22E-06 Brain structure / / 22504417 rs6434989 chr2 199775467 C T 5.52E-05 Major depressive disorder / / 21621269 rs6650780 chr2 199797322 A G 2.38E-05 Brain structure / / 22504417 rs966744 chr2 199809716 G A 6.23E-05 Cognitive performance / / 19734545 rs1349504 chr2 199952123 C A 6.88E-04 Multiple complex diseases / / 17554300 rs1451487 chr2 199994868 T C 2.00E-04 Schizophrenia / / 19197363 rs12471454 chr2 200014483 T C 6.00E-06 Insomnia / / 23728906 rs1374360 chr2 200125150 C T 5.47E-04 Schizophrenia / / 19197363 rs2881208 chr2 200137608 T C 7.77E-05 Major depressive disorder SATB2 intron 21621269 rs2881208 chr2 200137608 T C 2.83E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 3.22E-04 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 7.01E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 7.68E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2166517 chr2 200190213 T C 9.22E-04 Multiple complex diseases SATB2 intron 17554300 rs13426349 chr2 200198964 C T 9.55E-04 Multiple complex diseases SATB2 intron 17554300 rs3828186 chr2 200214273 T C 4.30E-06 Urinary metabolites SATB2 intron 21572414 rs1348812 chr2 200236425 G A 8.02E-04 Multiple complex diseases SATB2 intron 17554300 rs4673339 chr2 200273376 A G 1.64E-05 Blood Pressure SATB2 intron pha003046 rs1992950 chr2 200290359 A G 5.00E-06 Ulcerative colitis SATB2 intron 20228799 rs6752494 chr2 200313323 T C 2.50E-05 Iron levels SATB2 intron 21208937 rs6706918 chr2 200389985 G C 1.21E-04 Multiple complex diseases / / 17554300 rs17589374 chr2 200391220 A G 2.34E-05 Multiple complex diseases / / 17554300 rs41495246 chr2 200431658 A G 1.32E-30 Multiple complex diseases / / 17554300 rs1450566 chr2 200478921 G T 1.14E-06 Multiple complex diseases / / 17554300 rs4675721 chr2 200479539 T A 7.44E-07 Multiple complex diseases / / 17554300 rs6730854 chr2 200482025 G A 1.66E-06 Multiple complex diseases / / 17554300 rs4624324 chr2 200500431 T C 1.12E-06 Multiple complex diseases / / 17554300 rs4675773 chr2 200532141 C T 8.42E-04 Type 2 diabetes / / 17463246 rs12620740 chr2 200549085 T C 2.40E-05 Urinary metabolites / / 21572414 rs10211241 chr2 200567136 C T 7.62E-05 Aging (time to event) / / 21782286 rs6748229 chr2 200569338 A G 8.95E-04 Type 2 diabetes / / 17463246 rs10804092 chr2 200577141 G T 4.87E-09 Metabolite levels / / 23281178 rs1976879 chr2 200577895 C T 2.45E-08 Metabolite levels / / 23281178 rs2049369 chr2 200577970 G A 2.25E-08 Metabolite levels / / 23281178 rs2049370 chr2 200578170 T G 2.25E-08 Metabolite levels / / 23281178 rs1996948 chr2 200598114 C T 1.20E-05 Urinary metabolites / / 21572414 rs4672548 chr2 200603517 G C 3.90E-06 Urinary metabolites / / 21572414 rs6759018 chr2 200620763 T C 5.70E-06 Urinary metabolites / / 21572414 rs4530349 chr2 200621420 C T 7.30E-06 Urinary metabolites / / 21572414 rs1523816 chr2 200632991 A G 2.80E-05 Urinary metabolites FONG intron 21572414 rs12615435 chr2 200638509 T G 7.67E-04 Type 2 diabetes FONG intron 17463246 rs12615435 chr2 200638509 T G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FONG intron 23648065 rs7605378 chr2 200676926 A C 2.00E-08 Osteoporosis FONG intron 21573128 rs2346662 chr2 200679158 C T 2.55E-04 Multiple complex diseases FONG intron 17554300 rs769954 chr2 200692159 G C 2.77E-04 Multiple complex diseases FONG intron 17554300 rs17529642 chr2 200697530 T C 5.55E-05 Parkinson's disease FONG intron 21738487 rs2689766 chr2 200697539 A T 7.78E-04 Suicide attempts in bipolar disorder FONG intron 21423239 rs10497841 chr2 200701788 A C 8.58E-04 Type 2 diabetes FONG intron 17846125 rs2949006 chr2 200715388 T G 1.00E-08 Schizophrenia FONG intron 23974872 rs769951 chr2 200731990 C G 1.88E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs6761647 chr2 200741624 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs281783 chr2 200751582 G A 1.80E-04 Multiple sclerosis / / 21833088 rs1704189 chr2 200763224 C G 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs188147 chr2 200783985 T C 2.70E-04 Suicide attempts in bipolar disorder C2orf69 intron 21423239 rs281787 chr2 200784238 A G 4.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C2orf69 intron 24023788 rs281773 chr2 200813584 T C 5.95E-04 Suicide attempts in bipolar disorder TYW5 intron 21423239 rs1704193 chr2 200815296 C G 4.50E-04 Suicide attempts in bipolar disorder TYW5 intron 21423239 rs281767 chr2 200823281 C A 2.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C2orf47 intron 24023788 rs17445724 chr2 200853425 T C 5.56E-05 Coronary heart disease / / pha003032 rs4673634 chr2 200863349 A C 4.58E-04 Schizophrenia / / 19197363 rs7565480 chr2 200868926 A G 5.20E-04 Schizophrenia / / 21674006 rs4673727 chr2 200995687 C T 1.10E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs1106399 chr2 201003837 A C 7.36E-04 Schizophrenia / / 19197363 rs1106400 chr2 201004089 T C 7.36E-04 Schizophrenia / / 19197363 rs1569175 chr2 201021954 T C 9.00E-07 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs10445792 chr2 201078821 A C 9.47E-04 Rheumatoid arthritis / / 21452313 rs4673802 chr2 201082457 A G 8.52E-05 Coronary heart disease / / pha003032 rs1729413 chr2 201086663 T G 1.69E-05 Magnesium levels / / pha003092 rs1144429 chr2 201098576 T G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs296796 chr2 201103451 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17531061 chr2 201113452 A C 3.90E-05 Asthma (bronchodilator response) / / 22792082 rs1808827 chr2 201117622 G A 3.62E-04 Multiple complex diseases / / 17554300 rs17630220 chr2 201125410 T G 8.40E-04 Type 2 diabetes / / 17463246 rs4673837 chr2 201131159 G A 1.14E-04 Alzheimer's disease / / 24755620 rs6739563 chr2 201134216 G T 6.63E-04 Rheumatoid arthritis / / 21452313 rs1347552 chr2 201137031 A G 9.57E-04 Alzheimer's disease / / 24755620 rs295136 chr2 201141002 G C 1.30E-04 Kidney function and endocine traits / / 17903292 rs11687313 chr2 201146399 G A 1.62E-04 Cholesterol / / 17255346 rs11691757 chr2 201148951 C T 5.54E-05 Alzheimer's disease / / 24755620 rs4672726 chr2 201149413 G A 6.50E-05 Alzheimer's disease / / 24755620 rs295137 chr2 201150040 C T 1.00E-06 Asthma (bronchodilator response) / / 22792082 rs12612420 chr2 201158122 G A 8.00E-06 Exercise (leisure time) / / 19727025 rs295139 chr2 201159988 T A 6.80E-06 Asthma (bronchodilator response) / / 22792082 rs4673905 chr2 201163783 A G 9.72E-06 Multiple complex diseases / / 17554300 rs159320 chr2 201187775 A G 7.70E-05 Asthma (bronchodilator response) SPATS2L intron 22792082 rs295114 chr2 201195602 C T 6.00E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs883999 chr2 201203110 T C 2.47E-04 Amyotrophic lateral sclerosis (sporadic) SPATS2L intron 24529757 rs295142 chr2 201211716 A G 4.70E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs7575286 chr2 201213507 A T 4.85E-04 Type 2 diabetes SPATS2L intron 17463246 rs1900706 chr2 201214071 C A 4.90E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs1369841 chr2 201227060 A G 5.77E-04 Multiple complex diseases SPATS2L intron 17554300 rs3769459 chr2 201234572 T G 7.92E-04 Type 2 diabetes SPATS2L intron 17463246 rs12990174 chr2 201240305 G A 2.47E-04 Multiple complex diseases SPATS2L intron 17554300 rs7598349 chr2 201247479 G A 5.10E-05 Asthma (bronchodilator response) SPATS2L intron 22792082 rs3769451 chr2 201252335 A G 4.09E-06 Creatinine levels SPATS2L intron pha003069 rs3769450 chr2 201252355 A G 3.34E-04 Suicide attempts in bipolar disorder SPATS2L intron 21041247 rs3739118 chr2 201253769 G A 0.00041 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs842825 chr2 201255134 G A 7.70E-04 Blood pressure SPATS2L intron 21228793 rs2278515 chr2 201282338 T C 0.000831 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs13004353 chr2 201313988 T C 7.93E-04 Suicide attempts in bipolar disorder SPATS2L intron 21423239 rs10197006 chr2 201314326 T C 7.72E-04 Suicide attempts in bipolar disorder SPATS2L intron 21423239 rs10497862 chr2 201315107 A T 0.000695 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs6730788 chr2 201327631 G A 0.000663794 Hypertension (early onset hypertension) SPATS2L intron 22479346 rs1561295 chr2 201330209 C A 0.000663794 Hypertension (early onset hypertension) SPATS2L intron 22479346 rs34526345 chr2 201334715 G A 2.54E-04 Taste perception SPATS2L missense 22132133 rs199940720 chr2 201337629 G T 0.000082 Prostate cancer (advanced) SPATS2L missense 23555315 rs2881745 chr2 201338052 A C,G,T 4.29E-06 Multiple complex diseases SPATS2L intron 17554300 rs733054 chr2 201344434 A G 4.18E-04 Schizophrenia SPATS2L UTR-3 20832056 rs13019534 chr2 201349631 G A 2.39E-06 Common variable immunodeficiency / / 21497890 rs10497864 chr2 201355533 A G 4.25E-04 Blood pressure KCTD18 intron 17255346 rs713397 chr2 201357624 T G 3.20E-04 HIV-1 viral setpoint KCTD18 intron 17641165 rs713397 chr2 201357624 T G 9.25E-05 Blood Pressure KCTD18 intron pha003047 rs11884301 chr2 201358423 C T 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCTD18 intron 20877124 rs12987074 chr2 201362931 C T 9.07E-05 Personality dimensions KCTD18 intron 18957941 rs17448345 chr2 201453751 G A 3.06E-04 Blood pressure AOX1 intron 17255346 rs2293525 chr2 201468732 C G 6.97E-04 Esophageal adenocarcinoma AOX1 intron 24121790 rs10187029 chr2 201469791 C G 6.29E-05 Lymphocyte counts AOX1 intron 22286170 rs6753463 chr2 201483977 G T 8.59E-04 Type 2 diabetes AOX1 intron 17463246 rs7597713 chr2 201490349 A G 4.34E-04 Smoking initiation AOX1 intron 24665060 rs3815502 chr2 201525920 C G 1.97E-04 Alcohol dependence AOX1 intron 21314694 rs55754655 chr2 201526330 A G 1 Drug response to Azathioprine AOX1 missense 19500084 rs2241080 chr2 201527239 G A 3.95E-05 Alcohol dependence AOX1 intron 21314694 rs2715898 chr2 201556388 C T 2.00E-04 Chronic fatigue syndrome / / 21912186 rs13428164 chr2 201562344 G A 2.73E-05 Fibrinogen AOX2P intron pha003068 rs2243822 chr2 201565450 G T 6.91E-05 Blood pressure AOX2P intron 17255346 rs2540055 chr2 201565685 A C 5.00E-05 Prostate cancer AOX2P intron 21743057 rs2348113 chr2 201568369 G C 5.00E-05 Prostate cancer AOX2P intron 21743057 rs2540052 chr2 201568999 C T 4.00E-05 Prostate cancer AOX2P intron 21743057 rs2540051 chr2 201571143 G A 8.60E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs2540051 chr2 201571143 G A 6.00E-08 Intelligence AOX2P intron 22449649 rs2715902 chr2 201575480 C T 7.56E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs7563911 chr2 201576284 A C,G,T 6.60E-05 Alcoholism (heaviness of drinking) AOX2P intron 21529783 rs950233 chr2 201594185 A G 5.75E-06 Non-obstructive azoospermia AOX2P intron 22541561 rs1001250 chr2 201624818 C T 5.15E-04 Parkinson's disease AOX2P intron 17052657 rs16834415 chr2 201631393 G A 2.60E-05 Urinary metabolites AOX2P intron 21572414 rs10181489 chr2 201635535 T C 2.80E-05 Lymphocyte counts AOX2P intron 22286170 rs12622452 chr2 201638647 A G 7.32E-04 Parkinson's disease / / 17052657 rs6720418 chr2 201641373 G C 7.32E-04 Parkinson's disease AOX2P intron 17052657 rs10515941 chr2 201643484 C A 3.36E-04 Type 2 diabetes AOX2P intron 17846124 rs10515941 chr2 201643484 C A 2.00E-05 Urinary metabolites AOX2P intron 21572414 rs13430864 chr2 201648639 T G 5.00E-07 Response to citalopram treatment AOX2P intron 22760553 rs10931922 chr2 201649795 T C 2.78E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs11674530 chr2 201650074 T A 3.54E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs16834587 chr2 201652048 A C 3.63E-04 Multiple complex diseases AOX2P intron 17554300 rs13423450 chr2 201652453 T C 3.33E-05 Response to citalopram treatment AOX2P intron 22760553 rs7609464 chr2 201652946 T C 3.78E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs13030323 chr2 201653966 T C 2.36E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs10931923 chr2 201659168 G A 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12465041 chr2 201660050 C G 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674449 chr2 201664304 T C 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4625890 chr2 201667523 A G 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2270280 chr2 201677791 T C 2.87E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs12475785 chr2 201679931 G T 2.94E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs2881880 chr2 201683695 T C 2.46E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs12995928 chr2 201689742 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804108 chr2 201697240 C G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7586299 chr2 201699860 G A 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6719879 chr2 201701162 G C 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs13012316 chr2 201704064 T C 7.22E-04 Multiple complex diseases / / 17554300 rs13012316 chr2 201704064 T C 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs13028326 chr2 201710305 A T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs3888610 chr2 201732117 C T 0.00004562 Sarcoidosis / / 22952805 rs7606251 chr2 201736734 T C 0.0000763 Sarcoidosis PPIL3 intron 22952805 rs11688943 chr2 201740268 T C 8.90E-08 Chronic lymphocytic leukemia PPIL3 intron 23770605 rs17467700 chr2 201745667 T C 2.70E-06 Urinary metabolites PPIL3 intron 21572414 rs16835473 chr2 201763483 C T 1.50E-04 Multiple complex diseases NIF3L1 intron 17554300 rs1912331 chr2 201783007 T C 6.36E-04 Multiple complex diseases ORC2 intron 17554300 rs16836577 chr2 201880513 C T 2.39E-04 Multiple complex diseases FAM126B intron 17554300 rs16836596 chr2 201931924 G T 4.64E-05 Multiple complex diseases FAM126B intron 17554300 rs12621441 chr2 201968940 G A 2.40E-05 Major depressive disorder / / 19065144 rs12621441 chr2 201968940 G A 3.22E-05 Major depressive disorder / / 21621269 rs12621441 chr2 201968940 G A 3.43E-05 Major depressive disorder / / pha002850 rs7583529 chr2 201988238 G A 6.45E-05 Longevity CFLAR intron 21612516 rs12620435 chr2 201995779 A G 6.14E-05 Multiple complex diseases CFLAR intron 17554300 rs4487072 chr2 202008298 C T 2.57E-04 Multiple complex diseases CFLAR intron 17554300 rs719125 chr2 202017860 G T 2.98E-04 Multiple complex diseases CFLAR intron 17554300 rs72931086 chr2 202042386 T G 0.00008672 Sarcoidosis / / 22952805 rs72931089 chr2 202042736 C A 0.00009111 Sarcoidosis / / 22952805 rs2098355 chr2 202042916 T C 0.00008672 Sarcoidosis / / 22952805 rs11900753 chr2 202044716 G A 0.00003573 Sarcoidosis / / 22952805 rs112223847 chr2 202046184 G T 0.00005836 Sarcoidosis CASP10 nearGene-5 22952805 rs41411846 chr2 202046265 T C 0.00003515 Sarcoidosis CASP10 nearGene-5 22952805 rs41332047 chr2 202046945 G A 0.00005836 Sarcoidosis CASP10 nearGene-5 22952805 rs16836789 chr2 202047833 C T 0.00003515 Sarcoidosis CASP10 UTR-5 22952805 rs17860398 chr2 202048219 C T 0.00005836 Sarcoidosis CASP10 intron 22952805 rs17468215 chr2 202049642 T C 0.00009842 Sarcoidosis CASP10 intron 22952805 rs41351447 chr2 202050153 G A 0.00004926 Sarcoidosis CASP10 intron 22952805 rs41339752 chr2 202051781 G A 7.02E-04 Multiple complex diseases CASP10 intron 17554300 rs17860400 chr2 202052617 A G 0.00003111 Sarcoidosis CASP10 intron 22952805 rs16836813 chr2 202052754 C T 0.00002886 Sarcoidosis CASP10 intron 22952805 rs56278081 chr2 202060086 C T 0.00009725 Sarcoidosis CASP10 intron 22952805 rs3731714 chr2 202060820 C T 2.94E-04 Multiple complex diseases CASP10 intron 17554300 rs13391950 chr2 202061050 C G 0.00008226 Sarcoidosis CASP10 intron 22952805 rs41343245 chr2 202061670 T C 0.00009725 Sarcoidosis CASP10 intron 22952805 rs41504752 chr2 202063350 G A 0.00009823 Sarcoidosis CASP10 intron 22952805 rs6435069 chr2 202078494 G A 5.07E-04 Multiple complex diseases CASP10 intron 17554300 rs12693932 chr2 202093395 T C 7.13E-04 Multiple complex diseases CASP10 intron 17554300 rs2037815 chr2 202101715 G A 6.83E-04 Multiple complex diseases CASP8 intron 17554300 rs3769825 chr2 202111380 A G 3.00E-09 Chronic lymphocytic leukemia CASP8 intron 23770605 rs35665714 chr2 202113552 CT C 3.93E-04 Insulin resistance CASP8 intron 21901158 rs6712381 chr2 202113552 C T 3.93E-04 Insulin resistance CASP8 intron 21901158 rs3769823 chr2 202122995 A G 0.0000488 post-traumatic stress disorder CASP8 missense 22869035 rs3769823 chr2 202122995 A G 4.88E-05 Schizophrenia CASP8 missense 22883433 rs4381764 chr2 202126863 T C 6.85E-05 Type 2 diabetes and other traits CASP8 intron 19734900 rs10084352 chr2 202127717 T C 9.35E-04 Insulin resistance CASP8 intron 21901158 rs10931936 chr2 202143928 T C 3.30E-09 Melanoma CASP8 intron 21983787 rs10931936 chr2 202143928 T C 4.74E-09 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs11681399 chr2 202145606 A G 1.76E-04 Telomere length CASP8 intron 23900074 rs10804111 chr2 202145612 C T 0.00000381 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs3769818 chr2 202151163 A G 0.00000289 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs3769818 chr2 202151163 A G 0.0000334 post-traumatic stress disorder CASP8 intron 22869035 rs3769818 chr2 202151163 A G 3.34E-05 Schizophrenia CASP8 intron 22883433 rs1035142 chr2 202153078 T G 5.40E-10 Melanoma / / 21983787 rs1035142 chr2 202153078 T G 0.00000137 Esophageal cancer (squamous cell) / / 22323360 rs1035142 chr2 202153078 T G 7.61E-05 Chronic lymphocytic leukemia / / 24292274 rs700635 chr2 202153225 C A 2.40E-09 Melanoma ALS2CR12 UTR-3 21983787 rs700635 chr2 202153225 C A 0.00000169 Esophageal cancer (squamous cell) ALS2CR12 UTR-3 22323360 rs700635 chr2 202153225 C A 0.0000334 post-traumatic stress disorder ALS2CR12 UTR-3 22869035 rs700635 chr2 202153225 C A 3.34E-05 Schizophrenia ALS2CR12 UTR-3 22883433 rs6714430 chr2 202153684 C T 0.00000158 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6714430 chr2 202153684 C T 0.0000334 post-traumatic stress disorder ALS2CR12 intron 22869035 rs6714430 chr2 202153684 C T 3.34E-05 Schizophrenia ALS2CR12 intron 22883433 rs11674814 chr2 202153846 G A 1.71E-04 Telomere length ALS2CR12 intron 23900074 rs6743068 chr2 202153920 A G 0.00000156 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6715284 chr2 202154397 C G 2.00E-09 Rheumatoid arthritis ALS2CR12 intron 24390342 rs6715284 chr2 202154397 C G 3.00E-09 Rheumatoid arthritis ALS2CR12 intron 24390342 rs13009885 chr2 202161636 G A 2.52E-04 Telomere length ALS2CR12 intron 23900074 rs11679181 chr2 202162338 C T 2.10E-04 Telomere length ALS2CR12 intron 23900074 rs13016963 chr2 202162811 A G 9.00E-10 Melanoma ALS2CR12 intron 21983787 rs13016963 chr2 202162811 A G 7.63E-10 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs9288316 chr2 202163483 G A 0.00000102 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7560328 chr2 202164837 A C 0.00000101 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6719014 chr2 202176024 T C 0.000000974 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7582362 chr2 202176294 A G 0.000000973 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs12986657 chr2 202178089 G A 1.79E-04 Telomere length ALS2CR12 intron 23900074 rs10931940 chr2 202178672 C T 2.04E-04 Telomere length ALS2CR12 intron 23900074 rs6731171 chr2 202179011 T A 0.000000964 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6735641 chr2 202180491 T C 0.000000955 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2110690 chr2 202185132 A G 0.000000843 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7570324 chr2 202185604 G T 1.93E-04 Telomere length ALS2CR12 intron 23900074 rs2080304 chr2 202186422 G C 0.000000815 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2349073 chr2 202186986 C A 0.000000808 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs11688692 chr2 202189451 T C 1.35E-04 Telomere length ALS2CR12 intron 23900074 rs9288318 chr2 202196063 C A 6.40E-04 Alcohol dependence ALS2CR12 intron 20201924 rs9288318 chr2 202196063 C A 1.35E-09 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs11898821 chr2 202199688 T C 0.000000205 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6757783 chr2 202199824 C T 0.000000203 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6435079 chr2 202200331 C G 0.000000363 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7579792 chr2 202200450 A G 0.000000195 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10186527 chr2 202200575 C T 0.000000193 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10171829 chr2 202201189 C T 4.84E-04 Insulin resistance ALS2CR12 intron 21901158 rs6745435 chr2 202202563 G A 0.000000169 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10201587 chr2 202202791 A G 8.71E-10 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7597617 chr2 202203235 G A 0.000000171 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10197246 chr2 202204741 T C 0.000000182 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10454127 chr2 202212374 G A 0.00000047 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6711127 chr2 202213515 C T 5.13E-04 Alzheimer's disease ALS2CR12 intron 22005930 rs6714736 chr2 202214148 C T 0.00000076 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6715380 chr2 202214505 G A 4.99E-04 Alzheimer's disease ALS2CR12 intron 22005930 rs13014235 chr2 202215492 C G 0.00000489 Esophageal cancer (squamous cell) ALS2CR12 missense 22323360 rs6435081 chr2 202220623 T C 0.00000866 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6737085 chr2 202221441 T A 0.0000021 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2349075 chr2 202223566 A G 0.00000732 Esophageal cancer (squamous cell) / / 22323360 rs6761514 chr2 202227549 T C 0.00000236 Esophageal cancer (squamous cell) / / 22323360 rs10178982 chr2 202227640 G C 0.00000236 Esophageal cancer (squamous cell) / / 22323360 rs11691602 chr2 202227699 A C 0.00000833 Esophageal cancer (squamous cell) / / 22323360 rs72937111 chr2 202227922 A G 0.00000239 Esophageal cancer (squamous cell) / / 22323360 rs10206231 chr2 202229225 A C 0.00000911 Esophageal cancer (squamous cell) / / 22323360 rs7578456 chr2 202235348 A G 0.000000016 Esophageal cancer (squamous cell) / / 22323360 rs10202963 chr2 202241907 T G 8.60E-04 Alcohol dependence / / 20201924 rs1914265 chr2 202417023 C T 3.52E-04 Multiple complex diseases ALS2CR11 intron 17554300 rs12693941 chr2 202423436 G A 1.15E-04 Multiple complex diseases ALS2CR11 intron 17554300 rs1208082 chr2 202497586 A C 8.49E-05 Pulmonary function in asthmatics TMEM237 intron 23541324 rs11894115 chr2 202512449 C T 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MPP4 missense 20877124 rs17384314 chr2 202531136 G C 5.10E-05 Cytomegalovirus antibody response MPP4 intron 21993531 rs17469010 chr2 202555755 T C 8.94E-04 Type 2 diabetes MPP4 intron 17463246 rs6731583 chr2 202560854 T C 2.09E-04 Type 2 diabetes MPP4 intron 17463246 rs6731583 chr2 202560854 T C 2.91E-04 Gallstones MPP4 intron 17632509 rs7598082 chr2 202569654 C A 6.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ALS2 intron 20031582 rs3731704 chr2 202603147 A G 1.91E-05 Type 2 diabetes ALS2 intron 17463246 rs7597686 chr2 202657193 A G 7.12E-04 Heart Failure / / pha002884 rs9784022 chr2 202657818 G A 1.47E-04 Lymphocyte counts / / 22286170 rs7582228 chr2 202659709 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4673210 chr2 202682736 T A 2.82E-04 Body mass index CDK15 intron 23669352 rs2072504 chr2 202741064 G A 9.00E-06 Urinary metabolites CDK15 intron 21572414 rs6708814 chr2 202742455 A C 8.79E-05 Blood Pressure CDK15 intron pha002903 rs759419 chr2 202766647 G A 1.50E-05 Urinary metabolites / / 21572414 rs6722501 chr2 202793266 G A 6.05E-05 Glucose levels / / pha003061 rs17385675 chr2 202807196 C T 3.00E-06 Response to antipsychotic treatment / / 20195266 rs7562987 chr2 202815530 G A 9.70E-05 Personality dimensions / / 18957941 rs12693955 chr2 202841545 G A 0.000385 Salmonella-induced pyroptosis / / 22837397 rs4321346 chr2 202852216 A G 8.20E-06 Urinary metabolites / / 21572414 rs13410775 chr2 202852739 T G 8.73E-06 Response to amphetamines / / 22952603 rs62193867 chr2 202854721 C T 7.84E-06 Response to amphetamines / / 22952603 rs4675242 chr2 202855194 A G 1.10E-04 Response to antidepressants / / 19736353 rs17476956 chr2 202857337 T C 9.67E-06 Response to amphetamines / / 22952603 rs6754521 chr2 202859617 G A 5.00E-06 Response to amphetamines / / 22952603 rs13402103 chr2 202869881 T C 3.14E-05 Body Composition / / pha003012 rs12185569 chr2 202875552 G A 1.54E-05 Body Composition / / pha003012 rs12185569 chr2 202875552 G A 9.69E-05 Body Mass Index / / pha003021 rs12185569 chr2 202875552 G A 8.18E-05 Insulin-related traits / / pha003063 rs12185569 chr2 202875552 G A 8.94E-05 HDL cholesterol / / pha003074 rs1477032 chr2 202875696 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10490083 chr2 202877944 C T 1.54E-05 Body Composition / / pha003012 rs10490083 chr2 202877944 C T 9.69E-05 Body Mass Index / / pha003021 rs10490083 chr2 202877944 C T 8.18E-05 Insulin-related traits / / pha003063 rs10490083 chr2 202877944 C T 8.94E-05 HDL cholesterol / / pha003074 rs7566288 chr2 202928940 G T 8.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1521882 chr2 202949851 G A 8.00E-06 Attention deficit hyperactivity disorder and conduct disorder LOC100652824 intron 18951430 rs2177083 chr2 202961665 G A 1.01E-05 Amyotrophic lateral sclerosis LOC100652824 intron 20801717 rs2177083 chr2 202961665 G A 0.00000618 Amyotrophic lateral sclerosis LOC100652824 intron 23587638 rs2177083 chr2 202961665 G A 0.0000112 Amyotrophic lateral sclerosis LOC100652824 intron 23587638 rs4675268 chr2 203014746 G C 2.10E-05 Urinary metabolites FLJ39061 intron 21572414 rs13015146 chr2 203062103 T C 9.49E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs16838988 chr2 203142338 T C 4.74E-04 Multiple complex diseases NOP58 intron 17554300 rs1105047 chr2 203202958 A G 1.88E-05 Serum metabolites / / 19043545 rs4516412 chr2 203203865 G A 8.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs12473579 chr2 203204567 G A 8.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs7589059 chr2 203313638 T C 7.75E-05 Serum metabolites BMPR2 intron 19043545 rs6747756 chr2 203315612 T C 8.37E-05 Serum metabolites BMPR2 intron 19043545 rs12468226 chr2 203337001 A G 3.00E-06 Urate levels BMPR2 intron 23263486 rs12621870 chr2 203358214 T C 9.74E-05 Monocyte counts BMPR2 intron pha003089 rs12467409 chr2 203394348 G T 2.65E-06 Lipid levels BMPR2 intron 19913121 rs10200587 chr2 203419284 A G 2.00E-11 HDL cholesterol BMPR2 intron 23063622 rs17386813 chr2 203458494 T C 5.98E-05 Alzheimer's disease (late onset) / / 21379329 rs13432396 chr2 203469588 C A 8.70E-04 Alcohol dependence / / 20201924 rs13432396 chr2 203469588 C A 5.26E-04 Smoking cessation / / 24665060 rs11694172 chr2 203532304 A G 2.00E-09 Cholesterol,total FAM117B intron 24097068 rs7577225 chr2 203550741 T C 7.10E-04 Iris characteristics FAM117B intron 21835309 rs7571219 chr2 203583254 G A 8.70E-04 Alcohol dependence FAM117B intron 20201924 rs7602496 chr2 203602207 C A 8.20E-04 Alcohol dependence FAM117B intron 20201924 rs7581854 chr2 203606754 T C 4.00E-04 Alcohol dependence FAM117B intron 20201924 rs7581854 chr2 203606754 T C 8.40E-04 Alcohol dependence FAM117B intron 20201924 rs6435163 chr2 203608742 T C 4.20E-04 Alcohol dependence FAM117B intron 20201924 rs6435163 chr2 203608742 T C 7.20E-04 Alcohol dependence FAM117B intron 20201924 rs2351116 chr2 203627311 G A 4.00E-04 Alcohol dependence FAM117B intron 20201924 rs2351116 chr2 203627311 G A 6.10E-04 Alcohol dependence FAM117B intron 20201924 rs2351117 chr2 203627412 C T 5.30E-04 Alcohol dependence FAM117B intron 20201924 rs11685819 chr2 203628757 G A 4.60E-04 Alcohol dependence FAM117B intron 20201924 rs11685819 chr2 203628757 G A 7.40E-04 Alcohol dependence FAM117B intron 20201924 rs17807135 chr2 203633245 A C 8.11E-04 Smoking cessation FAM117B UTR-3 24665060 rs6733972 chr2 203652838 T C 2.20E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs6705330 chr2 203662197 A G 5.70E-05 White matter hyperintensity burden ICA1L intron 21681796 rs11694728 chr2 203666319 T G 4.50E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs17594321 chr2 203695265 A T 2.30E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs1866423 chr2 203697790 G A 2.90E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs12053074 chr2 203699740 G C 4.30E-04 Iris characteristics ICA1L intron 21835309 rs4673238 chr2 203723989 A T 4.90E-10 Butyrylcholinesterase levels ICA1L intron 21862451 rs3845802 chr2 203740672 T G 3.30E-11 Butyrylcholinesterase levels / / 21862451 rs6725887 chr2 203745885 T C 1.00E-08 Myocardial infarction (early onset) WDR12 intron 19198609 rs6725887 chr2 203745885 T C 3.36E-05 Cardiovascular disease risk factors WDR12 intron 21239051 rs6725887 chr2 203745885 T C 1.00E-08 Coronary heart disease WDR12 intron 21347282 rs6725887 chr2 203745885 T C 1.00E-09 Coronary heart disease WDR12 intron 21378990 rs6725887 chr2 203745885 T C 1.12E-09 Pericardial fat WDR12 intron 22589742 rs6725887 chr2 203745885 T C 0.000000148 Coronary artery disease (CAD) age >50 WDR12 intron 23202125 rs6725887 chr2 203745885 T C 0.000000188 Coronary artery disease (CAD) (males) WDR12 intron 23202125 rs6725887 chr2 203745885 T C 0.00017 Coronary artery disease (CAD) age <=50 WDR12 intron 23202125 rs6725887 chr2 203745885 T C 5.51E-10 Coronary artery disease with myocardial infarction WDR12 intron 23202125 rs6725887 chr2 203745885 T C 6.55E-08 Coronary artery disease (CAD) (females) WDR12 intron 23202125 rs6725887 chr2 203745885 T C 2.00E-08 Coronary artery disease WDR12 intron 24262325 rs7582720 chr2 203753072 T C 3.00E-08 Coronary artery disease or large artery stroke WDR12 intron 24262325 rs7582720 chr2 203753072 T C 4.00E-09 Coronary artery disease or ischemic stroke WDR12 intron 24262325 rs3933629 chr2 203766367 T C 3.30E-11 Butyrylcholinesterase levels WDR12 intron 21862451 rs6719001 chr2 203777903 G A 8.80E-05 White matter hyperintensity burden ALS2CR8 intron 21681796 rs17406900 chr2 203784202 A G 1.20E-09 Butyrylcholinesterase levels ALS2CR8 intron 21862451 rs3731695 chr2 203820275 T C 4.00E-12 Butyrylcholinesterase levels ALS2CR8 intron 21862451 rs11691351 chr2 203873912 A G 4.40E-12 Butyrylcholinesterase levels / / 21862451 rs4675310 chr2 203880834 G A 1.85E-06 Coronary heart disease NBEAL1 intron 22319020 rs2351524 chr2 203880992 T C 0.000451 Cholesterol,total NBEAL1 UTR-5 23202125 rs1947983 chr2 203882593 A C 4.40E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6715752 chr2 203913552 A G 2.20E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs13396160 chr2 203913942 C T 2.20E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10439267 chr2 203923447 C T 5.70E-11 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7573079 chr2 203927551 G A 2.90E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7593917 chr2 203931012 A G 2.90E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs11690927 chr2 203944028 A G 1.30E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs1545885 chr2 203962030 A G 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs17473735 chr2 203962146 T C 4.20E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7574314 chr2 203964137 T C 3.10E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10497870 chr2 203970283 A G 3.10E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs17474056 chr2 203987554 C T 4.85E-04 Multiple complex diseases NBEAL1 intron 17554300 rs17474056 chr2 203987554 C T 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6748898 chr2 203996870 A G 1.39E-04 Multiple complex diseases NBEAL1 intron 17554300 rs17408550 chr2 203998336 C G 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10180815 chr2 204002809 A C 1.00E-04 Multiple complex diseases NBEAL1 intron 17554300 rs6751448 chr2 204006637 T G 7.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7564679 chr2 204012790 A G 7.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6435173 chr2 204013112 A G 3.64E-04 Multiple complex diseases NBEAL1 intron 17554300 rs6725247 chr2 204021436 A G 3.11E-04 Multiple complex diseases NBEAL1 intron 17554300 rs2043446 chr2 204045539 T C 2.26E-04 Multiple complex diseases NBEAL1 intron 17554300 rs2043448 chr2 204046526 A G 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10182274 chr2 204051009 G A 5.20E-04 Alcohol dependence NBEAL1 intron 20201924 rs10182274 chr2 204051009 G A 9.90E-05 Alcohol dependence NBEAL1 intron 20201924 rs10182274 chr2 204051009 G A 9.90E-05 Alcoholism NBEAL1 intron pha002893 rs6733725 chr2 204051070 G A 5.70E-06 Obesity-related traits NBEAL1 intron 23251661 rs11675464 chr2 204053742 A G 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs2117266 chr2 204060148 G T 1.60E-04 Alcohol dependence NBEAL1 intron 20201924 rs6714802 chr2 204062329 T C 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs2060388 chr2 204067268 A G 8.69E-04 Multiple complex diseases NBEAL1 intron 17554300 rs12693982 chr2 204085635 C T 2.30E-10 Butyrylcholinesterase levels / / 21862451 rs6704959 chr2 204088522 G A 8.20E-13 Butyrylcholinesterase levels / / 21862451 rs16839626 chr2 204089730 G A 2.00E-07 Obesity-related traits / / 23251661 rs16839626 chr2 204089730 G A 3.00E-06 Obesity-related traits / / 23251661 rs16839626 chr2 204089730 G A 4.00E-07 Obesity-related traits / / 23251661 rs7581515 chr2 204093040 A C 1.60E-12 Butyrylcholinesterase levels / / 21862451 rs2351774 chr2 204099222 A G 2.70E-13 Butyrylcholinesterase levels LOC100507265 intron 21862451 rs4675324 chr2 204107025 G A 9.60E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs182035689 chr2 204111603 C A 0.00007 Breast cancer(er negative) CYP20A1 missense 23555315 rs4675326 chr2 204114965 C T 1.75E-04 Multiple complex diseases CYP20A1 intron 17554300 rs11693128 chr2 204115901 A G 2.40E-13 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs3731694 chr2 204116660 A T 2.40E-13 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs10211196 chr2 204129896 G A 8.50E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs7606820 chr2 204135270 A G 8.50E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs2043444 chr2 204143126 T C 4.80E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs12693984 chr2 204152533 C T 8.00E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs11888559 chr2 204165171 T C 2.00E-06 Height CYP20A1 UTR-3 20966902 rs6435185 chr2 204213503 T C 1.10E-04 Multiple complex diseases ABI2 intron 17554300 rs12474416 chr2 204226003 G T 3.80E-08 Butyrylcholinesterase levels ABI2 intron 21862451 rs12466364 chr2 204226331 A G 3.80E-08 Butyrylcholinesterase levels ABI2 intron 21862451 rs11686036 chr2 204241639 A G 9.10E-18 Butyrylcholinesterase levels ABI2 intron 21862451 rs11675251 chr2 204249399 A G 4.00E-18 Butyrylcholinesterase levels ABI2 intron 21862451 rs3769676 chr2 204266343 T C 3.70E-15 Butyrylcholinesterase levels ABI2 intron 21862451 rs1376877 chr2 204272090 C T 4.00E-07 Subclinical atherosclerosis ABI2 intron 17903303 rs1376877 chr2 204272090 C T 1.50E-17 Butyrylcholinesterase levels ABI2 intron 21862451 rs3769678 chr2 204276327 T C 1.50E-17 Butyrylcholinesterase levels ABI2 intron 21862451 rs2255047 chr2 204287133 G A 4.90E-04 Type 2 diabetes ABI2 intron 17463246 rs2469954 chr2 204292517 T C 2.80E-15 Butyrylcholinesterase levels ABI2 UTR-3 21862451 rs2250522 chr2 204301296 G A 1.60E-15 Butyrylcholinesterase levels RAPH1 UTR-3 21862451 rs2247197 chr2 204306433 T C 1.94E-04 Multiple complex diseases RAPH1 UTR-3 17554300 rs2247097 chr2 204307003 G A 2.76E-04 Multiple complex diseases RAPH1 intron 17554300 rs2246849 chr2 204309325 G A 1.80E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11679740 chr2 204315394 G A 3.40E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2352079 chr2 204316532 C T 3.40E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11687186 chr2 204319839 C G 2.60E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2469953 chr2 204322298 T C 1.80E-14 Butyrylcholinesterase levels RAPH1 cds-synon 21862451 rs2246118 chr2 204327639 T C 2.00E-13 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2469949 chr2 204336700 C T 3.29E-04 Multiple complex diseases RAPH1 intron 17554300 rs2251317 chr2 204354823 C T 2.44E-05 Multiple complex diseases RAPH1 intron 17554300 rs2469962 chr2 204355822 G A 1.80E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2305417 chr2 204360201 A G 1.50E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2247380 chr2 204364721 C T 1.10E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2012774 chr2 204370203 A G 1.10E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11683935 chr2 204377871 C G 1.50E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs1174604 chr2 204421284 T C 1.50E-16 Butyrylcholinesterase levels / / 21862451 rs1174605 chr2 204421504 T C 1.30E-09 Butyrylcholinesterase levels / / 21862451 rs1174606 chr2 204424549 T C 6.00E-10 Butyrylcholinesterase levels / / 21862451 rs2443796 chr2 204425613 C T 6.00E-10 Butyrylcholinesterase levels / / 21862451 rs727361 chr2 204427247 T C 1.90E-10 Butyrylcholinesterase levels / / 21862451 rs4675344 chr2 204429558 C T 3.60E-10 Butyrylcholinesterase levels / / 21862451 rs11887555 chr2 204430093 T C 2.70E-10 Butyrylcholinesterase levels / / 21862451 rs6730171 chr2 204432604 T C 3.60E-10 Butyrylcholinesterase levels / / 21862451 rs2030552 chr2 204433184 C T 2.70E-10 Butyrylcholinesterase levels / / 21862451 rs1403239 chr2 204438198 A G 4.20E-10 Butyrylcholinesterase levels / / 21862451 rs7592180 chr2 204439623 C A 6.30E-10 Butyrylcholinesterase levels / / 21862451 rs7594831 chr2 204439701 C T 8.30E-10 Butyrylcholinesterase levels / / 21862451 rs7568353 chr2 204439759 A G 2.00E-09 Butyrylcholinesterase levels / / 21862451 rs7609267 chr2 204439982 T C 1.50E-09 Butyrylcholinesterase levels / / 21862451 rs7595502 chr2 204440081 G A 1.50E-09 Butyrylcholinesterase levels / / 21862451 rs16839922 chr2 204440345 T G 1.10E-09 Butyrylcholinesterase levels / / 21862451 rs13032082 chr2 204441505 A T 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs13032680 chr2 204441557 G T 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs4675348 chr2 204442447 A G 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs12989998 chr2 204442556 G C 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs7572405 chr2 204444331 G A 6.70E-09 Butyrylcholinesterase levels / / 21862451 rs17419055 chr2 204454414 G T 7.97E-05 Cognitive test performance / / 20125193 rs12618748 chr2 204455171 G A 2.54E-05 Multiple complex diseases / / 17554300 rs12618748 chr2 204455171 G A 1.02E-04 Myocardial Infarction / / pha002883 rs10191601 chr2 204455370 C T 1.02E-05 Multiple sclerosis / / 19525953 rs17478537 chr2 204459179 T C 7.55E-04 Alcohol dependence / / 21314694 rs4675350 chr2 204459206 C T 1.76E-04 Cholesterol / / 17255346 rs10207814 chr2 204459961 C T 1.30E-04 Celiac disease / / 22057235 rs10207814 chr2 204459961 C T 0.00013 Celiac disease / / 23143596 rs1879878 chr2 204465119 A G 1.82E-04 Cholesterol / / 17255346 rs7422945 chr2 204494698 A G 3.46E-05 Cholesterol / / 17255346 rs6435197 chr2 204497336 T C 4.86E-07 Cholesterol / / 17255346 rs3115961 chr2 204529949 G A 3.72E-05 Acne (severe) / / 24927181 rs4675357 chr2 204539973 G A 4.32E-05 Cognitive test performance / / 20125193 rs3181096 chr2 204570092 C T 7.12E-05 Asthma CD28 nearGene-5 20159242 rs3769683 chr2 204578797 A G 4.77E-05 Type 2 diabetes CD28 intron 17463246 rs55686954 chr2 204586515 G A 0.00000012 Rheumatoid arthritis CD28 intron 23143596 rs3181107 chr2 204593726 G A 4.57E-05 Type 2 diabetes CD28 intron 17463246 rs3181108 chr2 204593862 C T 8.76E-05 Type 2 diabetes CD28 intron 17463246 rs3116496 chr2 204594512 T C 2.07E-06 Celiac disease and Rheumatoid arthritis CD28 intron 21383967 rs4673260 chr2 204605487 C T 1.33E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs1980422 chr2 204610396 C T 1.40E-15 Celiac disease / / 22057235 rs1980422 chr2 204610396 C T 1.80E-08 Multiple sclerosis / / 22190364 rs1980422 chr2 204610396 C T 7.40E-05 Rheumatoid arthritis / / 22446963 rs1980422 chr2 204610396 C T 0.000000257 Rheumatoid arthritis (CCP positive) / / 23143596 rs1980422 chr2 204610396 C T 1.40E-15 Celiac disease / / 23143596 rs1980422 chr2 204610396 C T 2.77E-12 Rheumatoid arthritis / / 23143596 rs1980422 chr2 204610396 C T 2.00E-13 Rheumatoid arthritis / / 24390342 rs1980422 chr2 204610396 C T 3.00E-14 Rheumatoid arthritis / / 24390342 rs1980422 chr2 204610396 C T 1.75E-04 Rheumatoid arthritis / / 24449572 rs6435203 chr2 204611195 G A 7.20E-05 Immunoglobulin A / / 20694011 rs6435203 chr2 204611195 G A 1.52E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs7426056 chr2 204612058 A G 1.89E-20 Primary sclerosing cholangitis / / 23603763 rs4675366 chr2 204627793 T C 5.88E-05 Cognitive test performance / / 20125193 rs10932019 chr2 204628810 G A 6.64E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs4675367 chr2 204630692 T G 5.88E-05 Cognitive test performance / / 20125193 rs11689629 chr2 204633075 C T 5.33E-04 Type 2 diabetes / / 17463246 rs34322855 chr2 204633075 C CT 5.33E-04 Type 2 diabetes / / 17463246 rs7599230 chr2 204648661 T C 3.20E-05 Lung adenocarcinoma / / 22797724 rs3116507 chr2 204661524 G A 2.52E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs6749204 chr2 204662268 G A 1.28E-05 Cytomegalovirus antibody response / / 21993531 rs231814 chr2 204670195 G C 2.27E-04 Smoking quantity / / 24665060 rs231735 chr2 204693876 G T 6.00E-09 Rheumatoid arthritis / / 19503088 rs231790 chr2 204700574 G T 3.13E-05 Multiple complex diseases / / 17554300 rs231797 chr2 204706107 A G 4.44E-05 Multiple complex diseases / / 17554300 rs231802 chr2 204708279 T C 1.55E-05 Tuberculosis / / 24057671 rs231804 chr2 204708646 C T 8.15E-06 Rheumatoid arthritis / / 19503088 rs231804 chr2 204708646 C T 1.79E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs231804 chr2 204708646 C T 2.12E-11 Graves' disease / / 21841780 rs11571304 chr2 204708776 T A 4.35E-05 Multiple complex diseases / / 17554300 rs11571293 chr2 204717713 G T 1.56E-06 Multiple complex diseases / / 17554300 rs11571292 chr2 204720139 G A 4.51E-05 Multiple complex diseases / / 17554300 rs1024161 chr2 204721752 T C 4.00E-13 Alopecia areata / / 20596022 rs1024161 chr2 204721752 T C 2.00E-17 Graves' disease / / 21841780 rs926169 chr2 204722752 G T 8.48E-08 Graves' disease / / 21841780 rs11571316 chr2 204731089 G A 2.44E-15 Type 1 diabetes CTLA4 nearGene-5 21980299 rs16840252 chr2 204731519 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) CTLA4 nearGene-5 20189245 rs16840252 chr2 204731519 C T 1.28E-05 Antineutrophil cytoplasmic antibody-associated vasculitis CTLA4 nearGene-5 22808956 rs231774 chr2 204732223 T A 0.000000913 Cholesterol,total CTLA4 nearGene-5 23063622 rs5742909 chr2 204732347 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) CTLA4 nearGene-5 20189245 rs231775 chr2 204732714 A G 1 Drug response to Cyclosporine CTLA4 missense 18021981 rs231775 chr2 204732714 A G 9.40E-06 Hypothyroidism CTLA4 missense 22493691 rs231779 chr2 204734487 C T 7.00E-06 Hypothyroidism CTLA4 intron 22493691 rs3087243 chr2 204738919 G A 2.07E-07 Multiple complex diseases CTLA4 nearGene-3 17554300 rs3087243 chr2 204738919 G A 8.00E-11 Type 1 diabetes CTLA4 nearGene-3 18978792 rs3087243 chr2 204738919 G A 1.00E-15 Type 1 diabetes CTLA4 nearGene-3 19430480 rs3087243 chr2 204738919 G A 1.00E-08 Rheumatoid arthritis CTLA4 nearGene-3 20453842 rs3087243 chr2 204738919 G A 1.20E-08 Celiac disease and Rheumatoid arthritis CTLA4 nearGene-3 21383967 rs3087243 chr2 204738919 G A 2.00E-17 Type 1 diabetes autoantibodies CTLA4 nearGene-3 21829393 rs3087243 chr2 204738919 G A 8.00E-11 Multiple sclerosis CTLA4 nearGene-3 22190364 rs3087243 chr2 204738919 G A 2.20E-08 Rheumatoid arthritis CTLA4 nearGene-3 22446963 rs3087243 chr2 204738919 G A 6.80E-05 Hypothyroidism CTLA4 nearGene-3 22493691 rs3087243 chr2 204738919 G A 1.42E-11 Rheumatoid arthritis CTLA4 nearGene-3 23143596 rs3087243 chr2 204738919 G A 3.88E-11 Rheumatoid arthritis (CCP positive) CTLA4 nearGene-3 23143596 rs3087243 chr2 204738919 G A 1.00E-04 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs3087243 chr2 204738919 G A 3.00E-25 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs3087243 chr2 204738919 G A 4.00E-22 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs231726 chr2 204740866 C T 1.40E-06 Multiple complex diseases / / 17554300 rs231726 chr2 204740866 C T 1.16E-13 Graves' disease / / 21841780 rs1427676 chr2 204741166 C T 1.37E-06 Multiple complex diseases / / 17554300 rs11571302 chr2 204742934 G T 0.000000045 Rheumatoid arthritis / / 23143596 rs11571302 chr2 204742934 G T 4.49E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs11571297 chr2 204745003 T C 2.09E-23 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs11571297 chr2 204745003 T C 2.81E-23 Graves' disease / / 22922229 rs231757 chr2 204753487 T G 5.57E-05 Personality dimensions / / 18957941 rs231757 chr2 204753487 T G 5.07E-04 Celiac disease / / 23936387 rs6748358 chr2 204756905 C A 4.05E-05 Multiple complex diseases / / 17554300 rs6748358 chr2 204756905 C A 3.04E-06 Rheumatoid arthritis / / 19503088 rs16840307 chr2 204756999 C T 6.20E-04 Multiple complex diseases / / 17554300 rs859839 chr2 204757804 C T 2.49E-05 Personality dimensions / / 18957941 rs859839 chr2 204757804 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs13421616 chr2 204758695 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10197319 chr2 204763044 G A 2.87E-08 Graves' disease / / 21841780 rs10197319 chr2 204763044 G A 6.20E-05 Celiac disease / / 23936387 rs3096851 chr2 204763882 A C 3.69E-05 Graves' disease / / 21841780 rs7607760 chr2 204765194 G T 6.34E-05 Celiac disease / / 23936387 rs3116504 chr2 204769054 A G 3.57E-05 Graves' disease / / 21841780 rs34037980 chr2 204770054 A G 1.60E-05 Celiac disease / / 22057235 rs34037980 chr2 204770054 A G 0.000016 Celiac disease / / 23143596 rs12616245 chr2 204770803 A G 9.16E-05 Celiac disease / / 23936387 rs11890284 chr2 204777404 C T 5.66E-04 Celiac disease / / 23936387 rs6752680 chr2 204779005 T A 7.65E-05 Personality dimensions / / 18957941 rs6752680 chr2 204779005 T A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs3096866 chr2 204794952 A G 4.20E-05 Monocyte counts / / pha003089 rs3923093 chr2 204798020 T C 5.22E-05 Personality dimensions / / 18957941 rs4675374 chr2 204802578 T C 3.87E-05 Personality dimensions ICOS intron 18957941 rs4675374 chr2 204802578 T C 6.00E-09 Celiac disease ICOS intron 20190752 rs4675374 chr2 204802578 T C 6.00E-09 Asthma ICOS intron 21150878 rs4675374 chr2 204802578 T C 5.79E-09 Celiac disease and Rheumatoid arthritis ICOS intron 21383967 rs4675374 chr2 204802578 T C 5.79E-09 Multiple sclerosis ICOS intron 22190364 rs10932034 chr2 204812993 A G 1.80E-05 Urinary metabolites ICOS intron 21572414 rs1896286 chr2 204832438 G T 7.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3116534 chr2 204833769 C T 7.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1427363 chr2 204837629 T C 7.99E-05 Triglycerides / / pha003081 rs1427363 chr2 204837629 T C 4.77E-05 Lipid levels / / pha003082 rs6754914 chr2 204859514 A G 2.05E-04 Type 2 diabetes / / 17463246 rs4675397 chr2 204875234 T C 8.09E-04 Type 2 diabetes / / 17463246 rs13383369 chr2 204876709 T C 7.85E-05 Glycosylated haemoglobin levels / / 17255346 rs4675399 chr2 204877120 A G 5.00E-04 Type 2 diabetes / / 17463246 rs11884257 chr2 204886474 C T 5.27E-04 Type 2 diabetes / / 17463246 rs16840552 chr2 204888602 C T 3.51E-04 Type 2 diabetes / / 17463246 rs4675401 chr2 204889068 G A 1.58E-04 Type 2 diabetes / / 17463246 rs16824662 chr2 204895415 A G 3.11E-04 Type 2 diabetes / / 17463246 rs10206295 chr2 204918905 C T 1.59E-04 Glycosylated haemoglobin levels / / 17255346 rs961738 chr2 204951268 G A 3.49E-05 Multiple complex diseases / / 17554300 rs7588516 chr2 204967832 C G 9.01E-04 Alzheimer's disease / / 22005930 rs7562030 chr2 204967907 A G 8.48E-04 Alzheimer's disease / / 22005930 rs7588715 chr2 204967966 C G 8.74E-04 Alzheimer's disease / / 22005930 rs12465161 chr2 204969670 A C 5.85E-04 Type 2 diabetes / / 17463246 rs17214199 chr2 204969905 A C 5.85E-04 Type 2 diabetes / / 17463246 rs13419001 chr2 204981908 G A 2.52E-04 Glycosylated haemoglobin levels / / 17255346 rs16840760 chr2 204983554 T C 1.00E-06 Obesity-related traits / / 23251661 rs11673985 chr2 204986334 C T 2.49E-05 Triglycerides / / pha003081 rs11673985 chr2 204986334 C T 6.05E-05 Lipid levels / / pha003082 rs13414989 chr2 204991338 G A 1.35E-04 Glycosylated haemoglobin levels / / 17255346 rs6747093 chr2 204999862 C A 3.80E-05 Temporomandibular joint disorders / / 23746317 rs6747746 chr2 205000176 G A 2.70E-05 Temporomandibular joint disorders / / 23746317 rs10932047 chr2 205004122 T G 6.79E-04 Type 2 diabetes / / 17463246 rs10189390 chr2 205008681 C T 2.35E-05 Smoking behavior / / 19188921 rs219224 chr2 205011169 G T 1.10E-05 Temporomandibular joint disorders / / 23746317 rs7580465 chr2 205022291 T C 6.28E-05 Psoriasis / / 18364390 rs2042580 chr2 205027279 G A 2.70E-05 Temporomandibular joint disorders / / 23746317 rs6730424 chr2 205031069 G T 2.53E-05 Cognitive performance / / 19734545 rs16840880 chr2 205053197 C T 1.20E-06 Thyroid function / / 20826269 rs13401647 chr2 205057668 T C 9.60E-07 Thyroid function / / 20826269 rs6714929 chr2 205062633 G A 6.87E-05 Socioeconomic Factors / / pha003066 rs6714893 chr2 205116824 G A 1.73E-04 IgE levels / / 17255346 rs7421114 chr2 205118574 G C 9.89E-05 Age-related macular degeneration / / pha000002 rs6738181 chr2 205128021 G A 5.00E-06 Alzheimer's disease (late onset) / / 22881374 rs9288351 chr2 205131349 T C 2.63E-04 Smoking initiation / / 24665060 rs16841113 chr2 205153827 C A 4.07E-04 Alzheimer's disease (late onset) / / 21379329 rs13397660 chr2 205166492 C T 3.87E-05 Erythrocyte counts / / pha003090 rs1981913 chr2 205169149 T C 9.14E-05 Orofacial clefts / / 22419666 rs7603542 chr2 205177698 C T 9.73E-05 Erythrocyte counts / / pha003090 rs16841178 chr2 205186475 C T 3.27E-04 Alzheimer's disease (late onset) / / 21379329 rs6760579 chr2 205209449 G A 4.48E-06 Post-operative nausea and vomiting / / 21694509 rs7599719 chr2 205212629 C T 5.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6750362 chr2 205219203 A G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7608404 chr2 205232597 A G 6.41E-05 AIDS / / 19754311 rs16824671 chr2 205344693 A C 8.50E-04 Multiple complex diseases / / 17554300 rs2121681 chr2 205355892 T C 2.22E-04 Multiple complex diseases / / 17554300 rs4556959 chr2 205366339 A G 1.70E-05 Partial epilepsies / / 20522523 rs4673301 chr2 205368458 T C 3.25E-04 Lung function (forced vital capacity) / / 24023788 rs4673301 chr2 205368458 T C 4.00E-06 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9288354 chr2 205378570 A G 3.35E-04 Type 2 diabetes / / 17463246 rs7581786 chr2 205385338 A G 7.78E-04 Type 2 diabetes / / 17463246 rs12622755 chr2 205438485 A G 8.56E-04 Multiple complex diseases PARD3B intron 17554300 rs7565043 chr2 205448791 T A 3.93E-04 Multiple complex diseases PARD3B intron 17554300 rs11903539 chr2 205461753 G A 1.52E-04 Multiple complex diseases PARD3B intron 17554300 rs1978368 chr2 205501337 T G 5.88E-05 Multiple complex diseases PARD3B intron 17554300 rs13432594 chr2 205523721 T C 5.84E-04 Multiple complex diseases PARD3B intron 17554300 rs41482445 chr2 205578015 C T 2.19E-05 Multiple sclerosis PARD3B intron 17660530 rs1477179 chr2 205582870 A T 5.80E-04 Type 2 diabetes PARD3B intron 17463246 rs17113 chr2 205627933 C G 1.56E-05 Multiple sclerosis PARD3B intron 17660530 rs17638223 chr2 205643248 T C 4.77E-05 Multiple complex diseases PARD3B intron 17554300 rs17595547 chr2 205646304 T A 1.13E-04 Multiple complex diseases PARD3B intron 17554300 rs2058988 chr2 205650440 A T 1.77E-04 Multiple complex diseases PARD3B intron 17554300 rs6435252 chr2 205658016 G A 0.000510575 Hypertension (early onset hypertension) PARD3B intron 22479346 rs7580648 chr2 205668052 G A 4.39E-05 Aging (time to event) PARD3B intron 21782286 rs7580648 chr2 205668052 G A 0.000755917 Hypertension (early onset hypertension) PARD3B intron 22479346 rs7591697 chr2 205694022 A C 8.06E-05 Multiple complex diseases PARD3B intron 17554300 rs16836655 chr2 205697151 A C 7.25E-04 Multiple complex diseases PARD3B intron 17554300 rs6735981 chr2 205700834 T C 7.21E-04 Multiple complex diseases PARD3B intron 17554300 rs6747533 chr2 205744282 T G 7.54E-04 Multiple complex diseases PARD3B intron 17554300 rs7589114 chr2 205775783 C T 5.13E-05 Alcohol consumption PARD3B intron 23743675 rs7590088 chr2 205776549 G A 6.62E-05 Smoking initiation PARD3B intron 24665060 rs7572649 chr2 205783828 A C 5.74E-04 Smoking initiation PARD3B intron 24665060 rs1510775 chr2 205790839 T C 8.56E-05 Alzheimer's disease (age of onset) PARD3B intron 22005931 rs1510775 chr2 205790839 T C 1.00E-04 Smoking initiation PARD3B intron 24665060 rs2216852 chr2 205794074 C T 1.27E-04 Smoking initiation PARD3B intron 24665060 rs17535696 chr2 205799134 A T 9.08E-04 Response to cytidine analogues (gemcitabine) PARD3B intron 24483146 rs2194513 chr2 205803372 A G 4.50E-05 Glaucoma (primary open-angle) PARD3B intron 20835238 rs13390761 chr2 205809938 T G 2.73E-05 Tuberculosis PARD3B intron 20694014 rs13399116 chr2 205822633 T G 2.90E-06 Iron levels PARD3B intron 21208937 rs6731648 chr2 205853136 T C 1.74E-05 C-Reactive Protein PARD3B intron pha003070 rs2335705 chr2 205864532 C A 4.59E-06 Tuberculosis PARD3B intron 20694014 rs2335704 chr2 205864832 C A 2.00E-06 Tuberculosis PARD3B intron 20694014 rs11896055 chr2 205883547 A G 1.00E-04 Prostate cancer PARD3B intron 21743057 rs2082622 chr2 205904133 C G 4.89E-04 Nicotine smoking PARD3B intron 19268276 rs2289025 chr2 205969220 G A 3.17E-06 Smoking cessation PARD3B missense 18519826 rs2289025 chr2 205969220 G A 5.36E-04 Premature ovarian failure PARD3B missense 19508998 rs4675499 chr2 205973568 A G 3.52E-04 Type 2 diabetes PARD3B intron 17463246 rs6715145 chr2 205974111 T C 8.80E-05 Vaspin levels PARD3B intron 22907691 rs6715145 chr2 205974111 T C 0.000088 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit PARD3B intron 22907730 rs6715145 chr2 205974111 T C 0.0002364 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PARD3B intron 22907730 rs1434160 chr2 205987805 G C 1.88E-04 Smoking cessation PARD3B intron 18519826 rs10497881 chr2 205992964 C T 8.61E-04 Premature ovarian failure PARD3B intron 19508998 rs16837019 chr2 206002808 A T 6.59E-04 Type 2 diabetes PARD3B intron 17463246 rs849107 chr2 206009266 T C 6.38E-04 Type 2 diabetes PARD3B intron 17463246 rs6738364 chr2 206024264 G A 1.20E-04 Smoking cessation PARD3B intron 18519826 rs849118 chr2 206025174 G A 5.32E-04 Alcohol dependence PARD3B intron 21314694 rs13422432 chr2 206031987 A T 4.28E-04 Multiple complex diseases PARD3B intron 17554300 rs1368943 chr2 206033222 G T 5.01E-04 Multiple complex diseases PARD3B intron 17554300 rs1368944 chr2 206033290 G T 5.37E-04 Multiple complex diseases PARD3B intron 17554300 rs13415503 chr2 206037412 C T 7.04E-04 Multiple complex diseases PARD3B intron 17554300 rs17248501 chr2 206039045 A C 1.40E-05 Type 2 diabetes PARD3B intron 17463249 rs17248501 chr2 206039045 A C 1.37E-05 Multiple complex diseases PARD3B intron 17554300 rs7587983 chr2 206039704 T C 9.98E-06 Multiple complex diseases PARD3B intron 17554300 rs10170188 chr2 206048814 G A 3.30E-05 Melanoma PARD3B intron 21983785 rs10153620 chr2 206060637 G C 6.00E-06 Attention deficit hyperactivity disorder (combined symptoms) PARD3B intron 23527680 rs11681930 chr2 206063298 G A 5.00E-06 Attention deficit hyperactivity disorder (combined symptoms) PARD3B intron 23527680 rs4675502 chr2 206086171 G A 4.00E-07 Autism PARD3B intron 22843504 rs4675506 chr2 206086520 C A 5.97E-04 Multiple complex diseases PARD3B intron 17554300 rs1921797 chr2 206087119 T C 5.47E-04 Multiple complex diseases PARD3B intron 17554300 rs6730457 chr2 206087477 C T 1.76E-04 Multiple complex diseases PARD3B intron 17554300 rs6435278 chr2 206087758 A G 1.37E-04 Multiple complex diseases PARD3B intron 17554300 rs1921796 chr2 206087912 G C 1.25E-04 Multiple complex diseases PARD3B intron 17554300 rs1921795 chr2 206088079 A G 4.47E-04 Multiple complex diseases PARD3B intron 17554300 rs10182802 chr2 206088211 G A 6.30E-05 Glioma (high-grade) PARD3B intron 19578366 rs7593566 chr2 206095820 G A 1.83E-04 Smoking cessation PARD3B intron 18519826 rs11888554 chr2 206096536 C A 3.07E-04 Nicotine smoking PARD3B intron 19268276 rs2336413 chr2 206131317 A G 6.65E-05 Vaspin levels PARD3B intron 22907691 rs2336413 chr2 206131317 A G 0.0000665 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PARD3B intron 22907730 rs1540364 chr2 206132248 T C 6.82E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs10197562 chr2 206138074 G A 3.48E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs10490296 chr2 206141889 G C 2.71E-04 Prostate cancer mortality PARD3B intron 20978177 rs7606468 chr2 206144833 G A 3.78E-05 Prostate cancer mortality PARD3B intron 20978177 rs1207421 chr2 206150594 A G 6.00E-06 Knee osteoarthritis PARD3B intron 18471798 rs1211319 chr2 206156161 C T 4.95E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207433 chr2 206161433 C A 5.77E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207430 chr2 206163817 G C 5.47E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs2878692 chr2 206164173 G A 4.59E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207411 chr2 206173703 A T 8.75E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs2704643 chr2 206176140 G A 7.87E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs7567356 chr2 206184135 C G 5.02E-04 Depression (quantitative trait) PARD3B intron 20800221 rs12476682 chr2 206203291 A C 7.26E-05 Cognitive impairment induced by topiramate PARD3B intron 22091778 rs10490290 chr2 206227173 A G 7.46E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PARD3B intron 17982456 rs10490290 chr2 206227173 A G 1.00E-04 Cognitive impairment induced by topiramate PARD3B intron 22091778 rs964356 chr2 206250241 G A 7.78E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PARD3B intron 17982456 rs6711300 chr2 206260544 A G 8.47E-05 Depression (quantitative trait) PARD3B intron 20800221 rs849230 chr2 206261029 G A 6.86E-06 Type 2 diabetes PARD3B intron 21647700 rs849248 chr2 206264876 T C 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) PARD3B intron 22010049 rs10185378 chr2 206305156 C T 1.80E-05 Platelet counts PARD3B missense pha003100 rs11884476 chr2 206318593 C G 3.00E-09 AIDS progression PARD3B intron 21502085 rs6705488 chr2 206342846 T C 4.32E-05 Platelet counts PARD3B intron pha003100 rs10206532 chr2 206416848 G A 4.90E-04 Smoking cessation PARD3B intron 24665060 rs16837439 chr2 206432930 T C 2.04E-04 Type 2 diabetes PARD3B intron 17463246 rs17626122 chr2 206474012 T C 0.0000595 5-fluorouracil and oxaliplatin combined induced haematologic in response to colorectal cancer treatment PARD3B intron 22310351 rs17626122 chr2 206474012 T C 0.0000595 Oxaliplatin induced haematologic in response to colorectal cancer treatment PARD3B intron 22310351 rs17626201 chr2 206476386 C T 4.71E-05 Multiple complex diseases PARD3B intron 17554300 rs17626309 chr2 206478258 G A 7.03E-04 Multiple complex diseases PARD3B intron 17554300 rs6739327 chr2 206495714 G A 4.07E-04 Multiple complex diseases / / 17554300 rs6757529 chr2 206510949 G A 8.70E-05 Serum metabolites / / 19043545 rs849515 chr2 206512573 C G 3.88E-04 Testicular dysgenesis syndrome / / 22140272 rs3856510 chr2 206512921 C G 8.48E-05 Serum metabolites / / 19043545 rs10490287 chr2 206522975 G C 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2160327 chr2 206536329 A G 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6756429 chr2 206541927 T C 8.76E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs10207599 chr2 206543736 T A 3.25E-04 Type 2 diabetes / / 17463246 rs10171821 chr2 206544094 A G 9.43E-04 Type 2 diabetes / / 17463246 rs2192884 chr2 206545465 G A 4.13E-04 Smoking initiation NRP2 nearGene-5 24665060 rs849557 chr2 206563023 G A 7.63E-04 Insulin resistance NRP2 intron 21901158 rs3771038 chr2 206586412 G A 8.05E-04 Type 2 diabetes NRP2 intron 17463246 rs849537 chr2 206588114 T G 4.00E-04 Multiple complex diseases NRP2 intron 17554300 rs849527 chr2 206592525 A G 1.70E-05 Urinary metabolites NRP2 intron 21572414 rs849526 chr2 206592695 T C 6.20E-06 Urinary metabolites NRP2 cds-synon 21572414 rs849525 chr2 206593241 T A,C,G 2.60E-05 Urinary metabolites NRP2 intron 21572414 rs868196 chr2 206594141 G T 9.10E-06 Urinary metabolites NRP2 intron 21572414 rs849581 chr2 206602765 C T 0.00005212 Sarcoidosis NRP2 intron 22952805 rs13026243 chr2 206614091 T G 5.70E-04 Alzheimer's disease NRP2 intron 17998437 rs13026243 chr2 206614091 T G 1.79E-04 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs13026243 chr2 206614091 T G 3.18E-04 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs13026243 chr2 206614091 T G 3.37E-05 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs849560 chr2 206614160 A G 2.48E-04 Smoking cessation NRP2 intron 24665060 rs870068 chr2 206625266 C G 1.67E-04 Multiple complex diseases NRP2 intron 17554300 rs3755233 chr2 206639831 G A 2.13E-05 Alcohol and nictotine co-dependence NRP2 intron 20158304 rs4675542 chr2 206645247 G C 5.03E-05 Serum metabolites NRP2 intron 19043545 rs10932125 chr2 206652300 C G 1 Drug response to Daunorubicin NRP2 intron 18451141 rs3770990 chr2 206656185 C G 6.79E-04 Type 2 diabetes NRP2 intron 17463246 rs2041915 chr2 206669214 A G 2.79E-04 Lung function (forced vital capacity) / / 24023788 rs10182735 chr2 206690019 C T 5.45E-05 Lung adenocarcinoma / / 19836008 rs10185592 chr2 206694181 A C 3.15E-07 Autism / / 22843504 rs960705 chr2 206696300 A G 3.59E-05 Lung adenocarcinoma / / 19836008 rs955395 chr2 206718710 G A 1.40E-04 Primary sclerosing cholangitis / / 19944697 rs6745633 chr2 206719553 T C 5.70E-06 Intraocular pressure / / 22570627 rs2193227 chr2 206729306 A C 4.31E-04 Lung function (forced vital capacity) / / 24023788 rs6435307 chr2 206735656 T C 5.79E-04 Multiple complex diseases / / 17554300 rs7592297 chr2 206773502 C A 6.36E-05 Lung adenocarcinoma / / 19836008 rs7592297 chr2 206773502 C A 3.58E-04 Coronary heart disease / / 21971053 rs1420786 chr2 206776113 G A 8.69E-05 Multiple complex diseases / / 17554300 rs1861719 chr2 206779987 C T 6.56E-05 Orofacial clefts / / 22419666 rs10490682 chr2 206792412 G A 1.70E-05 Urinary metabolites / / 21572414 rs6760400 chr2 206795210 A G 7.37E-05 Lung adenocarcinoma / / 19836008 rs13384308 chr2 206795827 A G 1.30E-05 Urinary metabolites / / 21572414 rs17308259 chr2 206828161 C T 1.64E-04 Type 2 diabetes / / 17463246 rs17308259 chr2 206828161 C T 9.85E-05 Multiple complex diseases / / 17554300 rs7603514 chr2 206836612 G A 8.00E-06 Obesity (extreme) / / 19553259 rs12618490 chr2 206847296 T C 6.20E-04 Lymphocyte counts / / 22286170 rs16837908 chr2 206850155 A G 5.75E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs10192718 chr2 206862015 G A 1.07E-04 Alzheimer's disease (late onset) INO80D UTR-3 21379329 rs818026 chr2 206863874 C T 3.38E-04 Multiple complex diseases INO80D UTR-3 17554300 rs818017 chr2 206902233 A G 5.34E-04 Multiple complex diseases INO80D intron 17554300 rs17286674 chr2 206927850 G A 1.18E-04 Alzheimer's disease (late onset) INO80D intron 21379329 rs6718656 chr2 206965837 T G 6.30E-04 Iris characteristics / / 21835309 rs4147713 chr2 207015772 A C 9.24E-05 Type 1 diabetes NDUFS1 intron 18978792 rs3755227 chr2 207041933 T C 9.43E-05 Adipocyte fatty acid-binding protein concentration,in serum GPR1 cds-synon 21863005 rs16838023 chr2 207053416 G T 3.66E-05 Response to taxane treatment (placlitaxel) GPR1 intron 23006423 rs13410751 chr2 207086752 C T 4.51E-04 Menopause (age at onset) / / 22267201 rs2058710 chr2 207121782 A G 9.00E-06 Bipolar disorder and schizophrenia / / 22688191 rs146428765 chr2 207172889 C T 0.000087 Breast cancer(er negative) ZDBF2 missense 23555315 rs144699200 chr2 207173160 C T 0.00024 Breast cancer (ER positive) ZDBF2 missense 23555315 rs1031293 chr2 207229821 T C 6.65E-06 Rheumatoid arthritis / / 19503088 rs6751830 chr2 207260970 T G 1.58E-05 Serum metabolites / / 19043545 rs4675609 chr2 207267616 C T 4.97E-06 Hodgkin's lymphoma / / 24149102 rs41344245 chr2 207347917 A G 8.07E-04 Multiple complex diseases ADAM23 intron 17554300 rs2113379 chr2 207351674 C T 1.40E-05 Kidney function and endocine traits ADAM23 intron 17903292 rs2269183 chr2 207355354 G T 4.65E-04 Prostate cancer mortality ADAM23 intron 20978177 rs16838306 chr2 207393829 T C 2.82E-04 Blood pressure (response to calcium channel blocker) ADAM23 intron 24192120 rs16838318 chr2 207399907 T C 2.64E-05 Blood pressure (response to calcium channel blocker) ADAM23 intron 24192120 rs3770977 chr2 207418899 C T 1.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) ADAM23 intron 23648065 rs3770978 chr2 207441588 C G 8.28E-04 Prostate cancer mortality ADAM23 intron 20978177 rs3821170 chr2 207453310 C T 7.01E-06 Meningococcal disease ADAM23 intron 20694013 rs13420297 chr2 207457265 T C 2.88E-05 Cholesterol ADAM23 intron pha003073 rs13420297 chr2 207457265 T C 2.91E-05 Cholesterol ADAM23 intron pha003078 rs6435342 chr2 207465830 A G 2.21E-04 Type 2 diabetes ADAM23 intron 17463246 rs10490745 chr2 207466560 C T 9.51E-05 Corneal structure ADAM23 intron 22003120 rs3755226 chr2 207478649 T C 3.32E-04 Multiple complex diseases ADAM23 intron 17554300 rs3755226 chr2 207478649 T C 5.67E-04 Smoking quantity ADAM23 intron 24665060 rs13396148 chr2 207484372 G A 3.08E-06 Corneal structure / / 22003120 rs13396148 chr2 207484372 G A 1.77E-05 Cholesterol / / pha003073 rs13396148 chr2 207484372 G A 2.00E-05 Cholesterol / / pha003078 rs10186957 chr2 207486889 C T 5.87E-04 Prostate cancer mortality / / 20978177 rs10490747 chr2 207572396 C A 8.67E-04 Parkinson's disease DYTN intron 17052657 rs16838677 chr2 207581835 T C 8.35E-04 Multiple complex diseases DYTN intron 17554300 rs3828294 chr2 207629904 G A 4.64E-07 Facial morphology MDH1B intron 22341974 rs147727753 chr2 207631446 G C 0.00047 Prostate cancer FASTKD2 missense 23555315 rs3815686 chr2 207633002 A G 8.30E-05 Information processing speed FASTKD2 intron 21130836 rs2277912 chr2 207634236 T G 5.00E-06 Height FASTKD2 intron 20966902 rs12475891 chr2 207637397 C T 0.000402 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs879472 chr2 207651782 G A 0.000275 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs3791984 chr2 207654106 A G 0.000663 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs1048783 chr2 207657153 T C 8.55E-05 Information processing speed FASTKD2 UTR-3 21130836 rs6435351 chr2 207659014 T C 9.40E-05 Personality dimensions FASTKD2 UTR-3 18957941 rs17280449 chr2 207686461 G T 9.19E-04 Type 2 diabetes / / 17463246 rs35342955 chr2 207696262 G A 8.39E-04 Type 2 diabetes / / 17463246 rs6755560 chr2 207717783 T C 2.00E-06 QT interval (interaction) / / 23459443 rs2042135 chr2 207726297 G A 8.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4673364 chr2 207733111 C T 3.72E-04 Hearing function / / 17255346 rs6705071 chr2 207733838 G A 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12694063 chr2 207737751 T C 0.000135 Salmonella-induced pyroptosis / / 22837397 rs1453175 chr2 207747657 C T 5.43E-05 Hematocrit / / pha003097 rs6720430 chr2 207798923 T G 2.92E-05 Orofacial clefts / / 22419666 rs10932173 chr2 207802126 T C 0.000643 Salmonella-induced pyroptosis / / 22837397 rs17639570 chr2 207828958 C G 3.49E-05 Schizophrenia(age at onset) CPO intron 21688384 rs7582092 chr2 207833848 A G 5.20E-05 Cholesterol CPO intron pha003073 rs7582092 chr2 207833848 A G 1.96E-05 Cholesterol CPO intron pha003078 rs4675644 chr2 207840332 G C 9.00E-06 Pulmonary function decline / / 22424883 rs13391185 chr2 207841680 C A 7.02E-04 Alzheimer's disease / / 17998437 rs11695049 chr2 207851374 A G 4.14E-04 Parkinson's disease / / 17052657 rs1453160 chr2 207877465 G A 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs6732038 chr2 207890135 T C 8.80E-04 Coronary heart disease / / 21971053 rs11902322 chr2 207915477 A G 4.04E-07 Rheumatoid arthritis / / 19503088 rs6734537 chr2 207925963 T C 2.57E-06 Rheumatoid arthritis / / 19503088 rs10490478 chr2 207928063 T C 3.13E-05 Type 2 diabetes / / 17846125 rs1263600 chr2 207930673 G T 5.99E-04 Parkinson's disease / / 17052657 rs2287505 chr2 207947086 G T 3.28E-05 Blood Pressure KLF7 intron pha003043 rs13012163 chr2 207960996 C T 9.80E-04 Response to cytidine analogues (gemcitabine) KLF7 intron 24483146 rs6759901 chr2 207962456 C T 9.80E-04 Response to cytidine analogues (gemcitabine) KLF7 intron 24483146 rs1263627 chr2 207977253 A T 1.66E-04 Type 2 diabetes KLF7 intron 22238593 rs10170608 chr2 207983805 A G 6.90E-04 Breast cancer (survival) KLF7 intron 22232737 rs6727168 chr2 207989470 T C 4.73E-04 Coronary heart disease KLF7 intron 21606135 rs6743779 chr2 207990038 A C 2.40E-05 Lipid traits KLF7 intron 17903299 rs10168999 chr2 208005994 G C 2.80E-05 Urinary metabolites KLF7 intron 21572414 rs10181757 chr2 208006413 T C 9.40E-06 Urinary metabolites KLF7 intron 21572414 rs10195536 chr2 208006820 A T 1.00E-06 Urinary metabolites KLF7 intron 21572414 rs10932180 chr2 208026913 T C 5.55E-05 Major depressive disorder KLF7 intron 21621269 rs2111593 chr2 208046998 C T 5.18E-05 Major depressive disorder / / 21621269 rs7582312 chr2 208105518 C T 3.45E-04 Coronary heart disease / / 21606135 rs1012264 chr2 208115003 G A 1.99E-04 Sarcoidosis / / 19165924 rs4673368 chr2 208126719 T C 1.40E-06 Urinary metabolites / / 21572414 rs7577873 chr2 208133793 G A 2.60E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs7577873 chr2 208133793 G A 8.80E-05 Tooth agenesis (third molar) / / 24172245 rs10173558 chr2 208133995 T C 4.60E-06 Urinary metabolites / / 21572414 rs4303702 chr2 208141493 C G 4.70E-08 Urinary metabolites / / 21572414 rs10932186 chr2 208142194 C T 9.30E-07 Urinary metabolites / / 21572414 rs4675658 chr2 208145220 C T 9.20E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs16839535 chr2 208149684 G A 4.70E-08 Urinary metabolites / / 21572414 rs4673369 chr2 208155834 G T 1.10E-09 Urinary metabolites / / 21572414 rs16839580 chr2 208169592 G T 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9288382 chr2 208178532 C T 7.70E-04 Depression (quantitative trait) / / 20800221 rs11898976 chr2 208196098 G T 1.64E-05 Serum metabolites / / 19043545 rs2113383 chr2 208221168 G A 5.47E-04 Multiple complex diseases / / 17554300 rs2161767 chr2 208222261 A G 2.46E-04 Type 2 diabetes / / 17463246 rs2113385 chr2 208223028 A T 4.30E-04 Multiple complex diseases / / 17554300 rs11695858 chr2 208229699 C T 6.30E-07 Urinary metabolites / / 21572414 rs11684690 chr2 208230091 A C 5.50E-07 Urinary metabolites / / 21572414 rs17202778 chr2 208234786 T C 0.00000862 Cytarabine sensitivity / / 23538338 rs10932191 chr2 208236250 C T 5.00E-07 Urinary metabolites / / 21572414 rs7561038 chr2 208236850 A G 3.36E-05 Serum metabolites / / 19043545 rs7561038 chr2 208236850 A G 9.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs13426173 chr2 208251443 A T 4.20E-06 Urinary metabolites / / 21572414 rs11692326 chr2 208263279 C T 8.58E-04 Coronary heart disease / / 21971053 rs11682446 chr2 208263699 A C 2.70E-05 Urinary metabolites / / 21572414 rs17203403 chr2 208263990 A G 1.10E-05 Urinary metabolites / / 21572414 rs17203578 chr2 208270827 T C 7.13E-05 Hemoglobin / / pha003098 rs4510210 chr2 208298672 T C 6.99E-04 Coronary heart disease / / 21971053 rs10172070 chr2 208307761 C T 8.35E-04 Coronary heart disease / / 21971053 rs722760 chr2 208345241 T C 9.11E-04 Tuberculosis / / 22239941 rs722761 chr2 208345380 C T 9.11E-04 Tuberculosis / / 22239941 rs722761 chr2 208345380 C T 7.48E-05 Hemoglobin / / pha003098 rs10490595 chr2 208346410 C T 9.11E-04 Tuberculosis / / 22239941 rs2254137 chr2 208444028 C A 1.12E-05 Opioid sensitivity CREB1 intron 23183491 rs1806584 chr2 208466270 A G 2.00E-04 Type 2 diabetes and 6 quantitative traits CREB1 UTR-3 17848626 rs7569963 chr2 208473184 G A 1 Drug response to Citalopram / / 17548750 rs2709416 chr2 208477956 C T 9.16E-04 Insulin resistance METTL21A cds-synon 21901158 rs4234080 chr2 208489101 C A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) METTL21A UTR-5 24529757 rs2952768 chr2 208494234 T C 8.00E-07 Opioid sensitivity / / 23183491 rs2709386 chr2 208497034 G A 1.14E-06 Opioid sensitivity / / 23183491 rs12998817 chr2 208500945 C T 9.98E-04 Multiple complex diseases / / 17554300 rs7591784 chr2 208501730 A G 1.06E-06 Opioid sensitivity / / 23183491 rs7595131 chr2 208506396 T C 7.30E-04 Multiple complex diseases / / 17554300 rs4675690 chr2 208507807 C T 1 Drug response to Citalopram / / 17548750 rs2551968 chr2 208536536 C A 0.0000498 Carotid intima media thickness / / 23152477 rs2432726 chr2 208544582 A G 4.74E-04 Gallstones / / 17632509 rs2663887 chr2 208566869 G A 9.07E-07 Calcium levels / / pha003085 rs10176319 chr2 208569590 C T 2.50E-06 Calcium levels / / pha003085 rs7582078 chr2 208646851 C A 4.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2127685 chr2 208712855 A G 9.04E-04 Type 2 diabetes PLEKHM3 intron 17463246 rs2127685 chr2 208712855 A G 3.68E-04 Lymphocyte counts PLEKHM3 intron 22286170 rs7584910 chr2 208713027 G A 6.38E-04 Type 2 diabetes PLEKHM3 intron 17463246 rs6435396 chr2 208715314 G A 3.65E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs2621469 chr2 208765698 T C 1.42E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs200816436 chr2 208773279 G C 0.00031 Breast cancer PLEKHM3 missense 23555315 rs2718663 chr2 208809569 C G 1.10E-05 Urinary metabolites PLEKHM3 intron 21572414 rs6705199 chr2 208820252 G A 2.79E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs71418661 chr2 208842154 G A 0.00027 Breast cancer PLEKHM3 missense 23555315 rs10497890 chr2 208853299 T C 2.10E-05 Urinary metabolites PLEKHM3 intron 21572414 rs12464255 chr2 208926542 G A 9.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10497895 chr2 208927293 C T 9.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10932231 chr2 208929312 G C 9.67E-04 Prostate cancer mortality / / 20978177 rs896637 chr2 208957750 A G 8.11E-05 Body Mass Index / / pha003014 rs6713275 chr2 208961424 C A 7.32E-04 Multiple complex diseases / / 17554300 rs2242073 chr2 208994045 T G 8.00E-06 Attention deficit hyperactivity disorder CRYGC intron 18839057 rs796283 chr2 209011127 T C 7.84E-04 Multiple complex diseases LOC100507443 intron 17554300 rs2362790 chr2 209012367 A G 6.58E-05 Body Mass Index LOC100507443 intron pha003020 rs12468216 chr2 209023201 A G 6.91E-04 Multiple complex diseases / / 17554300 rs796280 chr2 209028191 C T 5.50E-04 Major depressive disorder CRYGA intron 21042317 rs2123291 chr2 209029192 A C 6.20E-04 Major depressive disorder CRYGA nearGene-5 21042317 rs6722000 chr2 209075957 A G 2.50E-05 Urinary metabolites / / 21572414 rs7593466 chr2 209099479 G T 5.89E-05 Cytomegalovirus antibody response / / 21993531 rs6746926 chr2 209135339 G A 4.57E-05 Brain lesion load PIKFYVE intron 19010793 rs11678092 chr2 209149617 T G 0.0000374 Polycystic ovary syndrome PIKFYVE intron 22951595 rs11678092 chr2 209149617 T G 3.74E-05 Intracranial aneurysm PIKFYVE intron 22961961 rs2289171 chr2 209204714 G A 1.17E-05 Brain lesion load PIKFYVE intron 19010793 rs4673402 chr2 209235373 G A 6.92E-05 Brain lesion load / / 19010793 rs4675764 chr2 209239742 G A 3.98E-05 Brain lesion load / / 19010793 rs1347664 chr2 209295729 C T 8.71E-04 Multiple complex diseases PTH2R intron 17554300 rs2924790 chr2 209330031 T A 4.50E-06 Urinary metabolites PTH2R intron 21572414 rs2576810 chr2 209332455 T C 7.90E-06 Urinary metabolites PTH2R intron 21572414 rs879707 chr2 209334978 A G 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTH2R intron 20877124 rs199930708 chr2 209339913 A ATG 3.55E-04 Stroke PTH2R intron pha002886 rs897082 chr2 209339913 A G 3.55E-04 Stroke PTH2R intron pha002886 rs897083 chr2 209342094 A G 9.60E-06 Urinary metabolites PTH2R intron 21572414 rs897083 chr2 209342094 A G 4.09E-04 Stroke PTH2R intron pha002886 rs3820902 chr2 209350128 G A 7.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTH2R intron 20877124 rs1057392 chr2 209359062 T C 1.50E-05 Urinary metabolites PTH2R UTR-3 21572414 rs10932263 chr2 209412884 G A 7.91E-05 Height / / 17255346 rs10932263 chr2 209412884 G A 1.86E-05 Brain lesion load / / 19010793 rs1429882 chr2 209455032 G A 2.74E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6722486 chr2 209455766 T C 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7580611 chr2 209467044 C T 3.66E-04 Stroke / / pha002886 rs13394305 chr2 209496949 T C 1.20E-05 Job-related exhaustion / / 23620144 rs1429879 chr2 209500802 A G 4.26E-05 Job-related exhaustion / / 23620144 rs2099159 chr2 209511062 C T 1.91E-04 Multiple complex diseases / / 17554300 rs2048920 chr2 209517915 T G 1.90E-05 Job-related exhaustion / / 23620144 rs17664733 chr2 209521984 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs16841676 chr2 209575924 C T 1.97E-05 Multiple complex diseases / / 17554300 rs13383928 chr2 209578600 T G 2.00E-06 Lung cancer-asbestos exposure interaction / / 22637743 rs13028604 chr2 209599808 T C 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs7593239 chr2 209605944 G A 3.77E-04 Multiple complex diseases / / 17554300 rs1356378 chr2 209622265 A T 3.45E-04 Multiple complex diseases / / 17554300 rs11897307 chr2 209635009 A G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11896599 chr2 209643445 T A 3.36E-04 Multiple complex diseases / / 17554300 rs11896599 chr2 209643445 T A 3.70E-05 Panic disorder / / 19165232 rs6414172 chr2 209748356 A G 3.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3851939 chr2 209757798 C T 6.73E-05 Hepatitis B vaccine response / / 21764829 rs1533807 chr2 209868471 T A 3.20E-06 Hearing function / / 21493956 rs2364820 chr2 209873988 A G 8.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13387460 chr2 209878841 C A 1.09E-05 Primary biliary cirrhosis / / 23000144 rs10804172 chr2 209881980 A G 5.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs4520973 chr2 209912108 G A 3.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1439736 chr2 209950995 G T 1.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs12468520 chr2 209962629 G A 1.10E-04 Multiple complex diseases / / 17554300 rs1439724 chr2 209976271 G A 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs939850 chr2 209993085 G C 3.58E-04 IgE levels / / 17255346 rs939850 chr2 209993085 G C 5.83E-05 Multiple complex diseases / / 17554300 rs1371436 chr2 210016186 T C 9.77E-05 Height / / 17255346 rs1371436 chr2 210016186 T C 2.93E-05 Multiple complex diseases / / 17554300 rs1371437 chr2 210016281 G A 3.37E-04 Height / / 17255346 rs4075133 chr2 210017298 C G 3.59E-04 IgE levels / / 17255346 rs4075133 chr2 210017298 C G 1.79E-05 Multiple complex diseases / / 17554300 rs3890028 chr2 210017891 G A 1.31E-04 Height / / 17255346 rs1079125 chr2 210017945 A C 9.79E-06 Multiple complex diseases / / 17554300 rs13392114 chr2 210026471 C T 9.12E-06 Serum metabolites / / 19043545 rs16824899 chr2 210034790 A G 4.36E-05 Serum metabolites / / 19043545 rs7560269 chr2 210037293 C G 8.66E-06 Serum metabolites / / 19043545 rs17738962 chr2 210058068 C T 1.09E-04 Height / / 17255346 rs17738962 chr2 210058068 C T 1.49E-04 Multiple complex diseases / / 17554300 rs7581212 chr2 210058383 G A 5.40E-05 Serum metabolites / / 19043545 rs1583758 chr2 210060812 T C 7.90E-05 Serum metabolites / / 19043545 rs12995006 chr2 210066993 A G 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1446607 chr2 210114896 A G 9.77E-05 Cytomegalovirus antibody response / / 21993531 rs2100078 chr2 210116243 C A 7.52E-05 Multiple complex diseases / / 17554300 rs2100078 chr2 210116243 C A 5.80E-05 Lipid levels / / 18193043 rs12465726 chr2 210122097 T A 2.03E-04 Multiple complex diseases / / 17554300 rs17740667 chr2 210122477 C T 2.91E-04 Multiple complex diseases / / 17554300 rs2028894 chr2 210138573 A T 4.39E-04 Multiple complex diseases / / 17554300 rs16842765 chr2 210156850 G A 4.86E-05 IgE levels / / 17255346 rs10176569 chr2 210175008 A G 4.33E-04 IgE levels / / 17255346 rs17674248 chr2 210204057 G A 3.48E-04 Height / / 17255346 rs17674248 chr2 210204057 G A 7.46E-06 Multiple complex diseases / / 17554300 rs17725929 chr2 210222441 G C 7.09E-07 Multiple complex diseases / / 17554300 rs17675086 chr2 210223378 C T 2.67E-04 Height / / 17255346 rs975719 chr2 210232466 T C 2.58E-05 IgE levels / / 17255346 rs975719 chr2 210232466 T C 3.47E-04 Body mass index / / 21701565 rs975719 chr2 210232466 T C 4.52E-04 Body mass index / / 21701565 rs6726105 chr2 210234774 A C 2.48E-04 Body mass index / / 21701565 rs6726105 chr2 210234774 A C 3.87E-04 Body mass index / / 21701565 rs11892351 chr2 210235426 C A 6.06E-04 Multiple complex diseases / / 17554300 rs16842863 chr2 210244181 T C 7.53E-05 IgE levels / / 17255346 rs12475149 chr2 210244866 C A 3.21E-04 Body mass index / / 21701565 rs12475149 chr2 210244866 C A 4.47E-04 Body mass index / / 21701565 rs7606091 chr2 210245922 G A 2.79E-04 Height / / 17255346 rs7606091 chr2 210245922 G A 5.63E-05 Multiple complex diseases / / 17554300 rs13017199 chr2 210246064 C G 2.01E-04 IgE levels / / 17255346 rs13017199 chr2 210246064 C G 1.90E-04 Body mass index / / 21701565 rs13017199 chr2 210246064 C G 2.30E-04 Body mass index / / 21701565 rs7355281 chr2 210248192 G T 3.16E-04 Type 2 diabetes / / 17846125 rs1446597 chr2 210250705 T G 7.11E-05 IgE levels / / 17255346 rs11676603 chr2 210261491 G C 1.55E-04 IgE levels / / 17255346 rs11677905 chr2 210261858 G T 9.64E-05 IgE levels / / 17255346 rs11677905 chr2 210261858 G T 2.14E-04 Body mass index / / 21701565 rs11677905 chr2 210261858 G T 7.66E-04 Body mass index / / 21701565 rs11889366 chr2 210263288 G A 9.00E-05 Prostate cancer / / 21743057 rs718647 chr2 210265247 C T 9.59E-05 IgE levels / / 17255346 rs12471015 chr2 210265916 G C 9.80E-05 IgE levels / / 17255346 rs12471015 chr2 210265916 G C 6.20E-04 Body mass index / / 21701565 rs11896886 chr2 210268142 G A 1.08E-04 Body mass index / / 21701565 rs11896886 chr2 210268142 G A 5.52E-04 Body mass index / / 21701565 rs10445803 chr2 210271767 C A 2.25E-04 Body mass index / / 21701565 rs10445803 chr2 210271767 C A 7.93E-04 Body mass index / / 21701565 rs10196056 chr2 210274200 C T 3.33E-04 Body mass index / / 21701565 rs1080278 chr2 210275709 G A 9.74E-05 IgE levels / / 17255346 rs1900308 chr2 210277526 A C 7.87E-05 IgE levels / / 17255346 rs1446596 chr2 210285528 C T 1.99E-04 Body mass index / / 21701565 rs6435527 chr2 210291373 A G 1.73E-04 IgE levels MAP2 intron 17255346 rs16842900 chr2 210312533 A G 6.82E-05 Multiple complex diseases MAP2 intron 17554300 rs17236116 chr2 210312769 A G 5.34E-04 Body mass index MAP2 intron 21701565 rs17236116 chr2 210312769 A G 8.19E-04 Body mass index MAP2 intron 21701565 rs16842904 chr2 210312788 C T 8.69E-04 Multiple complex diseases MAP2 intron 17554300 rs10737940 chr2 210330754 G A 1.08E-04 IgE levels MAP2 intron 17255346 rs7601095 chr2 210344871 G A 4.15E-04 IgE levels MAP2 intron 17255346 rs6728378 chr2 210346084 A G 4.38E-05 IgE levels MAP2 intron 17255346 rs7594825 chr2 210398232 G A 2.81E-05 Heart Rate MAP2 intron pha003053 rs288095 chr2 210403912 A C 2.00E-05 Prostate cancer MAP2 intron 21743057 rs6733319 chr2 210465558 G A 8.31E-04 Response to taxane treatment (placlitaxel) MAP2 intron 23006423 rs906831 chr2 210498057 G A 9.50E-04 Response to taxane treatment (placlitaxel) MAP2 intron 23006423 rs9288410 chr2 210498261 G A 5.64E-07 Age-related macular degeneration MAP2 intron pha000001 rs9288410 chr2 210498261 G A 3.28E-05 Age-related macular degeneration MAP2 intron pha000002 rs9288410 chr2 210498261 G A 2.71E-05 Age-related macular degeneration MAP2 intron pha002856 rs2663652 chr2 210508524 G A 0.000784115 Hypertension (early onset hypertension) MAP2 intron 22479346 rs16843390 chr2 210519833 A G 6.83E-04 Type 2 diabetes MAP2 intron 17463246 rs3768812 chr2 210555776 C T 9.37E-06 Taste perception MAP2 intron 22132133 rs35927101 chr2 210559865 G A 0.00027 Prostate cancer MAP2 missense 23555315 rs2191912 chr2 210606243 A G 7.87E-04 Type 2 diabetes / / 17463246 rs10932308 chr2 210642473 A T 1.90E-05 Urinary metabolites UNC80 intron 21572414 rs11692338 chr2 210643881 T C 2.80E-05 Urinary metabolites UNC80 intron 21572414 rs11680007 chr2 210646814 A C 8.70E-04 Type 2 diabetes UNC80 intron 17463246 rs11680964 chr2 210652613 A C 8.70E-04 Type 2 diabetes UNC80 intron 17463246 rs10932310 chr2 210672638 T C 2.10E-05 Urinary metabolites UNC80 intron 21572414 rs6761179 chr2 210701101 A G 9.13E-04 Myopia (pathological) UNC80 intron 21095009 rs9288414 chr2 210704200 C A 2.60E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178425 chr2 210704893 G T 2.64E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178425 chr2 210704893 G T 0.0000098 Amygdala reactivity UNC80 intron 22856363 rs10178431 chr2 210704907 G T 6.24E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178675 chr2 210705348 C G 2.81E-04 Suicide attempts in bipolar disorder UNC80 cds-synon 21041247 rs10490024 chr2 210707361 G A 2.80E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10188289 chr2 210707767 G A 2.78E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs16843780 chr2 210709033 G C 2.77E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12386218 chr2 210709793 C G 2.65E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13028068 chr2 210710406 T G 2.61E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs6752217 chr2 210711426 G T 2.49E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10194322 chr2 210715174 G A 6.11E-04 Multiple complex diseases UNC80 intron 17554300 rs10194322 chr2 210715174 G A 5.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10194322 chr2 210715174 G A 6.10E-06 Urinary metabolites UNC80 intron 21572414 rs10194333 chr2 210715307 C A 5.43E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10170708 chr2 210715357 A T 1.77E-04 Multiple complex diseases UNC80 intron 17554300 rs13013030 chr2 210716930 C G 5.58E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7584039 chr2 210717526 T C 5.60E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2191909 chr2 210718772 C G 5.64E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2159747 chr2 210718897 T C 5.75E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7579121 chr2 210721446 T C 5.87E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13010864 chr2 210722025 A G 4.24E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9631001 chr2 210725694 C T 6.13E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973787 chr2 210728999 A G 6.30E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7595063 chr2 210729517 C A,G 3.05E-04 Multiple complex diseases UNC80 intron 17554300 rs7595063 chr2 210729517 C A,G 6.45E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7598071 chr2 210729711 G C 6.51E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973848 chr2 210730560 A G 6.58E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973317 chr2 210731012 C T 6.48E-04 Multiple complex diseases UNC80 intron 17554300 rs9973317 chr2 210731012 C T 6.63E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13414802 chr2 210732686 A G 1.41E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490025 chr2 210733400 A T 3.98E-04 Multiple complex diseases UNC80 intron 17554300 rs10490025 chr2 210733400 A T 1.27E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490026 chr2 210733445 G A 4.03E-04 Multiple complex diseases UNC80 intron 17554300 rs10490026 chr2 210733445 G A 1.27E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7593426 chr2 210733835 G A 5.57E-04 Multiple complex diseases UNC80 intron 17554300 rs7593426 chr2 210733835 G A 5.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7566741 chr2 210733952 A G 5.67E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490027 chr2 210734462 T A 5.80E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328328 chr2 210734843 C T 6.29E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12329111 chr2 210734855 A C 6.34E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328346 chr2 210735086 G A 6.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490028 chr2 210735160 C T 6.55E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328869 chr2 210736168 T A 6.61E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328884 chr2 210736388 T C 6.62E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12329303 chr2 210736612 A G 6.64E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7581628 chr2 210737831 A G 6.72E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7581974 chr2 210738089 A G 6.78E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748674 chr2 210738851 T C 6.84E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748692 chr2 210738874 T C 6.93E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs1558474 chr2 210739353 C T 7.00E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs16843893 chr2 210741592 C T 7.09E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs11682914 chr2 210742033 G A 1.58E-04 Multiple complex diseases UNC80 intron 17554300 rs11682914 chr2 210742033 G A 7.12E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2109970 chr2 210742253 A G 7.17E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748818 chr2 210745855 C T 7.35E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7608462 chr2 210748646 G A 9.19E-04 Myopia (pathological) UNC80 intron 21095009 rs11688226 chr2 210770527 C T 8.68E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs11694132 chr2 210772283 A G 9.15E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs6739769 chr2 210773300 C T 9.23E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10166445 chr2 210773693 A C 1.00E-05 Urinary metabolites UNC80 intron 21572414 rs2192027 chr2 210776629 T A 2.10E-05 Urinary metabolites UNC80 intron 21572414 rs10200921 chr2 210799863 G A 5.29E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7584375 chr2 210808905 A G 5.09E-04 Multiple complex diseases UNC80 intron 17554300 rs16843977 chr2 210818971 G A 9.10E-04 Response to cytadine analogues (cytosine arabinoside) UNC80 cds-synon 24483146 rs16843990 chr2 210838759 A G 1.32E-04 Multiple complex diseases UNC80 intron 17554300 rs3738934 chr2 210874246 T C 1.00E-134 Blood metabolite levels RPE intron 24816252 rs10490029 chr2 210941899 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits KANSL1L intron 17848626 rs2160020 chr2 211001813 T C 7.82E-04 Suicide attempts in bipolar disorder KANSL1L intron 21041247 rs12613036 chr2 211007521 T C 5.34E-14 Metabolite levels KANSL1L intron 23281178 rs10932320 chr2 211009107 T C 0.0000993 Menopause (age at onset) KANSL1L intron 23424626 rs4673501 chr2 211024197 A G 2.47E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs4673501 chr2 211024197 A G 4.49E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs4673501 chr2 211024197 A G 6.29E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs263675 chr2 211037204 A G 2.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs7584317 chr2 211043102 A G 9.14E-16 Metabolite levels / / 23281178 rs1396828 chr2 211045482 T C 3.11E-04 Multiple complex diseases / / 17554300 rs1396828 chr2 211045482 T C 1.60E-11 Metabolite levels / / 23281178 rs1155845 chr2 211054599 C T 2.36E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs7601356 chr2 211056657 T C 1.40E-15 Metabolite levels ACADL intron 23281178 rs2286963 chr2 211060050 T G 3.09E-05 Serum metabolites ACADL missense 19043545 rs2286963 chr2 211060050 T G 3.00E-60 Metabolite levels ACADL missense 20037589 rs2286963 chr2 211060050 T G 1.04E-15 Metabolite levels ACADL missense 23281178 rs6739874 chr2 211061670 G T 0.000000288 Cholesterol,total ACADL intron 23236364 rs263681 chr2 211063352 G C 2.28E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs263680 chr2 211067401 G A 2.27E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509568 chr2 211069011 T C 2.24E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509572 chr2 211073337 A T 2.23E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509571 chr2 211073548 C T 2.21E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs3764913 chr2 211074909 T C 6.03E-05 Serum metabolites ACADL intron 19043545 rs3764913 chr2 211074909 T C 4.00E-29 Metabolite levels ACADL intron 23281178 rs16844213 chr2 211079166 C T 2.18E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs13415601 chr2 211080124 T A 2.19E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs13009758 chr2 211101839 T C 2.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs7558218 chr2 211103445 G T 2.10E-15 Metabolite levels / / 23281178 rs263666 chr2 211107802 A G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs12476559 chr2 211112436 G A 1.54E-11 Metabolite levels / / 23281178 rs6716836 chr2 211118337 A G 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs6760874 chr2 211118510 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1509569 chr2 211132415 A G 4.49E-14 Metabolite levels / / 23281178 rs1509569 chr2 211132415 A G 3.00E-18 Urinary metabolites (H-NMR features) / / 24586186 rs7557847 chr2 211133150 G A 9.82E-15 Metabolite levels / / 23281178 rs4558528 chr2 211134546 A T 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396830 chr2 211136612 G A 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396831 chr2 211136678 A T 2.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs7563494 chr2 211141267 T C 2.36E-08 Metabolite levels / / 23281178 rs13001183 chr2 211146773 A T 7.75E-10 Metabolite levels / / 23281178 rs7582804 chr2 211149820 G A 7.75E-10 Metabolite levels / / 23281178 rs7596691 chr2 211149926 T C 4.35E-05 Bipolar disorder / / 22925353 rs7583039 chr2 211150016 G C 2.92E-08 Metabolite levels / / 23281178 rs12999760 chr2 211150037 T C 7.75E-10 Metabolite levels / / 23281178 rs2048274 chr2 211151626 C T 7.75E-10 Metabolite levels / / 23281178 rs2048275 chr2 211151668 T C 7.75E-10 Metabolite levels / / 23281178 rs2048276 chr2 211151691 T C 7.75E-10 Metabolite levels / / 23281178 rs6734950 chr2 211151969 T G 7.75E-10 Metabolite levels / / 23281178 rs867342 chr2 211152705 A G 7.75E-10 Metabolite levels / / 23281178 rs11889646 chr2 211154128 G A 7.75E-10 Metabolite levels / / 23281178 rs6736750 chr2 211156528 G A 2.18E-09 Metabolite levels MYL1 intron 23281178 rs2136457 chr2 211157449 T C 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1995836 chr2 211159671 G A,T 7.75E-10 Metabolite levels MYL1 intron 23281178 rs6735154 chr2 211161154 G C 1.75E-09 Metabolite levels MYL1 intron 23281178 rs2063311 chr2 211163574 C A,T 7.75E-10 Metabolite levels MYL1 intron 23281178 rs12469767 chr2 211168346 A C 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1472955 chr2 211168638 A G 3.24E-05 Bipolar disorder MYL1 intron 22925353 rs6725084 chr2 211170972 A G 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1074158 chr2 211175043 A G 9.31E-05 Height MYL1 intron pha003010 rs1074158 chr2 211175043 A G 3.52E-05 Height MYL1 intron pha003011 rs6435569 chr2 211289689 G A 8.12E-04 Multiple complex diseases / / 17554300 rs3821136 chr2 211299687 G A 1.68E-04 Multiple complex diseases LANCL1 intron 17554300 rs3770699 chr2 211304138 G T 4.13E-04 Multiple complex diseases LANCL1 intron 17554300 rs2287432 chr2 211319824 T C 1.95E-04 Amyotrophic lateral sclerosis (sporadic) LANCL1 intron 24529757 rs2042049 chr2 211320374 G C 7.74E-04 Multiple complex diseases LANCL1 intron 17554300 rs4640325 chr2 211448624 G A 9.12E-04 Type 2 diabetes CPS1 intron 17463246 rs2371002 chr2 211471071 G A 6.00E-05 Prostate cancer CPS1 intron 21743057 rs12468557 chr2 211495587 C T 9.00E-06 Body mass index (asthmatics) CPS1 intron 23517042 rs2302909 chr2 211503556 G T 5.88E-06 Carotenoid and tocopherol levels CPS1 intron 19185284 rs2371007 chr2 211508194 C G 9.34E-04 Multiple complex diseases CPS1 intron 17554300 rs6435580 chr2 211523457 C T 1.06E-04 Lung function (forced expiratory volume in 1 second) CPS1 intron 24023788 rs6435580 chr2 211523457 C T 2.54E-04 Lung function (forced vital capacity) CPS1 intron 24023788 rs6726148 chr2 211526922 A T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs12997383 chr2 211529850 C T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs12997383 chr2 211529850 C T 2.35E-05 Brain structure CPS1 intron 22504417 rs16844777 chr2 211535278 C T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs1047891 chr2 211540507 C A 9.00E-09 Fibrinogen CPS1 missense 20031577 rs1047891 chr2 211540507 C A 5.00E-09 Homocysteine levels CPS1 missense 20154341 rs1047891 chr2 211540507 C A 1.00E-15 Chronic kidney disease CPS1 missense 20383146 rs1047891 chr2 211540507 C A 1.35E-10 Chronic kidney disease CPS1 missense 22479191 rs1047891 chr2 211540507 C A 5.00E-27 Homocysteine levels CPS1 missense 23824729 rs1047891 chr2 211540507 C A 9.00E-10 HDL cholesterol CPS1 missense 24097068 rs1047891 chr2 211540507 C A 9.00E-13 Plasma homocysteine levels (post-methionine load test) CPS1 missense 24651765 rs1047891 chr2 211540507 C A 9.00E-09 Fibrinogen CPS1 missense 20031577 rs1047891 chr2 211540507 C A 5.00E-09 Homocysteine levels CPS1 missense 20154341 rs1047891 chr2 211540507 C A 1.00E-15 Chronic kidney disease CPS1 missense 20383146 rs1047891 chr2 211540507 C A 5.00E-27 Homocysteine levels CPS1 missense 23824729 rs1047891 chr2 211540507 C A 3.55E-17 Homoarginine levels CPS1 missense 24047826 rs1047891 chr2 211540507 C A 4.00E-12 Metabolite levels CPS1 missense 24625756 rs715 chr2 211543055 T C 3.00E-50 Metabolite levels (Glycine metabolism) CPS1 UTR-3 23378610 rs715 chr2 211543055 T C 2.00E-11 Fibrinogen CPS1 UTR-3 23969696 rs715 chr2 211543055 T C 1.00E-24 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-147 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-16 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-19 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 3.00E-21 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 4.00E-16 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 7.00E-35 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 7.00E-58 Blood metabolite levels CPS1 UTR-3 24816252 rs2887915 chr2 211554574 C T 9.09E-08 Chronic kidney disease / / 21931561 rs2371030 chr2 211569722 G A 3.00E-06 Non-small cell lung cancer / / 23144319 rs1160096 chr2 211578483 C T 8.73E-05 Orofacial clefts / / 22419666 rs10490322 chr2 211583022 C T 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10490323 chr2 211583253 G A 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2216405 chr2 211616894 A G 1.90E-30 Serum metabolites / / 20037589 rs2216405 chr2 211616894 A G 2.00E-27 Metabolic traits / / 21886157 rs2371079 chr2 211638554 A G 1.59E-04 Aortic root size / / 21223598 rs764637 chr2 211641003 G A 3.30E-04 Diabetic retinopathy / / 20871662 rs16844916 chr2 211647290 A G 2.08E-04 Tourette syndrome / / 22889924 rs4673558 chr2 211661897 C T 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12998006 chr2 211669006 T C 7.60E-07 Bipolar disorder / / 19416921 rs16824978 chr2 211672061 C T 7.77E-06 Ankle-brachial index / / 22199011 rs986293 chr2 211672261 A G 9.98E-04 Stroke / / pha002886 rs12478788 chr2 211681243 G A 2.75E-05 Serum metabolites / / 19043545 rs12464940 chr2 211682987 G T 6.63E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2719969 chr2 211683144 G C 2.20E-04 Spine bone size / / 23207799 rs7608489 chr2 211699011 G A 5.26E-04 Parkinson's disease / / 17052657 rs7608489 chr2 211699011 G A 3.07E-04 Hearing function / / 17255346 rs13019409 chr2 211701811 A G 1.29E-04 Stroke / / pha002886 rs7580498 chr2 211703869 A C 8.74E-04 Multiple complex diseases / / 17554300 rs2542929 chr2 211711593 T G 0.0000147 LDL cholesterol particle diameter / / 23263444 rs13013804 chr2 211761578 A G 1.94E-04 Osteoarthritis / / 19508968 rs4327185 chr2 211764584 C T 2.55E-06 Glycemic traits (pregnancy) / / 23903356 rs4327185 chr2 211764584 C T 7.29E-06 Glycemic traits (pregnancy) / / 23903356 rs4362497 chr2 211772578 T A 2.84E-06 Glycemic traits (pregnancy) / / 23903356 rs4362497 chr2 211772578 T A 7.71E-06 Glycemic traits (pregnancy) / / 23903356 rs7420853 chr2 211778201 G A 2.50E-05 Urinary metabolites / / 21572414 rs7420853 chr2 211778201 G A 6.16E-06 Glycemic traits (pregnancy) / / 23903356 rs4505460 chr2 211778272 C A 8.91E-06 Glycemic traits (pregnancy) / / 23903356 rs4438425 chr2 211781209 C T 2.63E-06 Glycemic traits (pregnancy) / / 23903356 rs4438425 chr2 211781209 C T 8.23E-06 Glycemic traits (pregnancy) / / 23903356 rs4635463 chr2 211781238 C T 2.79E-06 Glycemic traits (pregnancy) / / 23903356 rs4635463 chr2 211781238 C T 8.89E-06 Glycemic traits (pregnancy) / / 23903356 rs4505461 chr2 211781269 G C 3.39E-06 Glycemic traits (pregnancy) / / 23903356 rs7566803 chr2 211782674 G A 3.31E-06 Glycemic traits (pregnancy) / / 23903356 rs7580725 chr2 211782699 T C 3.58E-06 Glycemic traits (pregnancy) / / 23903356 rs4611592 chr2 211786679 G A 2.18E-06 Glycemic traits (pregnancy) / / 23903356 rs4611592 chr2 211786679 G A 6.33E-06 Glycemic traits (pregnancy) / / 23903356 rs4425028 chr2 211799738 A G 7.02E-06 Glycemic traits (pregnancy) / / 23903356 rs4580326 chr2 211804851 C T 4.96E-06 Glycemic traits (pregnancy) / / 23903356 rs4580326 chr2 211804851 C T 8.25E-06 Glycemic traits (pregnancy) / / 23903356 rs4455102 chr2 211808697 A G 6.35E-04 Stroke / / pha002886 rs13006521 chr2 211813132 A G 4.96E-06 Glycemic traits (pregnancy) / / 23903356 rs13006521 chr2 211813132 A G 7.85E-06 Glycemic traits (pregnancy) / / 23903356 rs809949 chr2 211830196 C T 6.53E-06 Glycemic traits (pregnancy) / / 23903356 rs809949 chr2 211830196 C T 7.93E-06 Glycemic traits (pregnancy) / / 23903356 rs920212 chr2 211874950 A G 1.70E-05 Urinary metabolites / / 21572414 rs920211 chr2 211874991 T C 4.60E-06 Urinary metabolites / / 21572414 rs11688017 chr2 211880639 T C 1.70E-05 Urinary metabolites / / 21572414 rs167650 chr2 211895267 A G 4.40E-06 Urinary metabolites / / 21572414 rs1821825 chr2 211914804 C T 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1821825 chr2 211914804 C T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13016652 chr2 211927188 G A 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13016652 chr2 211927188 G A 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464316 chr2 211935990 C T 2.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464316 chr2 211935990 C T 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs697663 chr2 211943622 A C 3.86E-04 Type 2 diabetes / / 17846124 rs17737064 chr2 211981461 T A 5.54E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16845357 chr2 211989141 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11679051 chr2 212029656 T C 7.78E-05 Cardiovascular disease / / pha003064 rs35082087 chr2 212063805 T C 1.20E-05 Urinary metabolites / / 21572414 rs16845632 chr2 212080318 G C 6.87E-05 Multiple complex diseases / / 17554300 rs4632271 chr2 212157104 T C 5.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4632271 chr2 212157104 T C 7.43E-04 Rheumatoid arthritis / / 21452313 rs4632271 chr2 212157104 T C 8.49E-04 Gallbladder cancer / / 22318345 rs7557116 chr2 212158670 C T 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7557116 chr2 212158670 C T 9.33E-04 Rheumatoid arthritis / / 21452313 rs1595063 chr2 212167904 A G 9.48E-04 Rheumatoid arthritis / / 21452313 rs6728697 chr2 212169952 C A 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12694232 chr2 212194222 T C 6.52E-04 Insulin resistance / / 21901158 rs11901831 chr2 212225520 T C 1.20E-05 Melanoma / / 24980573 rs1821659 chr2 212238982 T C 5.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1595066 chr2 212241725 C T 9.47E-05 Monocyte chemoattractant protein-1 ERBB4 UTR-3 pha003071 rs10932374 chr2 212244403 G A 2.58E-05 Paclitaxel-induced neuropathy ERBB4 UTR-3 23776197 rs10932374 chr2 212244403 G A 9.42E-05 HDL cholesterol ERBB4 UTR-3 pha003075 rs17744862 chr2 212244520 A G 2.12E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ERBB4 UTR-3 24023788 rs3791682 chr2 212249706 T C 8.60E-04 Myopia (pathological) ERBB4 intron 21095009 rs3791682 chr2 212249706 T C 9.56E-05 HDL cholesterol ERBB4 intron pha003074 rs3791682 chr2 212249706 T C 2.61E-05 HDL cholesterol ERBB4 intron pha003075 rs1595062 chr2 212251070 A G 2.76E-04 Taste perception ERBB4 intron 22132133 rs149419131 chr2 212331808 C G 0.0000461 Nonsyndromic striae distensae (stretch marks) ERBB4 intron 23633020 rs13021324 chr2 212350245 T C 1.59E-04 Epilepsy ERBB4 intron 22116939 rs9941626 chr2 212351667 T G 1.23E-04 Epilepsy ERBB4 intron 22116939 rs4500888 chr2 212368188 G T 8.15E-05 Multiple complex diseases ERBB4 intron 17554300 rs6435632 chr2 212378524 G A 2.82E-05 Multiple complex diseases ERBB4 intron 17554300 rs7603778 chr2 212384650 T C 9.80E-06 Urinary metabolites ERBB4 intron 21572414 rs7597024 chr2 212386461 C T 7.60E-06 Urinary metabolites ERBB4 intron 21572414 rs11887047 chr2 212409199 G C 0.0000776 Placental abruption ERBB4 intron 23205182 rs13014132 chr2 212415917 C G 5.08E-04 Multiple complex diseases ERBB4 intron 17554300 rs13421680 chr2 212416029 A G 4.42E-04 Alcohol dependence ERBB4 intron 21314694 rs11885579 chr2 212431529 A G 9.38E-04 Alcohol dependence ERBB4 intron 21314694 rs12694242 chr2 212438861 T C 5.10E-05 HIV-1 control ERBB4 intron 20041166 rs1879532 chr2 212439312 T C,G 1.66E-07 Autism ERBB4 intron 22843504 rs4672619 chr2 212457195 C A 3.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ERBB4 intron 24023788 rs1851196 chr2 212470620 G A 2.14E-06 Schizophrenia ERBB4 intron 19571809 rs1851196 chr2 212470620 G A 5.11E-06 Schizophrenia ERBB4 intron pha002859 rs41382849 chr2 212471471 G A 6.93E-04 Multiple complex diseases ERBB4 intron 17554300 rs12616462 chr2 212490272 A C 3.65E-05 Tuberculosis ERBB4 intron 20694014 rs10180037 chr2 212508067 T C 5.50E-04 Taste perception ERBB4 intron 22132133 rs6706854 chr2 212508134 A G 2.57E-04 Type 2 diabetes ERBB4 intron 17463246 rs17335518 chr2 212526025 A G 3.10E-06 Urinary metabolites ERBB4 intron 21572414 rs10173674 chr2 212545533 C T 8.56E-04 Amyotrophic Lateral Sclerosis ERBB4 intron 17362836 rs7588792 chr2 212626917 A C 6.02E-04 Type 2 diabetes ERBB4 intron 17463246 rs1371200 chr2 212691392 G T 7.51E-04 Taste perception ERBB4 intron 22132133 rs16846917 chr2 212697542 G T 1.54E-05 Multiple sclerosis (brain glutamate levels) ERBB4 intron 20802204 rs6435678 chr2 212710468 G C 6.01E-04 Multiple complex diseases ERBB4 intron 17554300 rs6435678 chr2 212710468 G C 3.06E-04 Nicotine smoking ERBB4 intron 19268276 rs1159709 chr2 212715410 T C 1.17E-05 Multiple sclerosis (brain glutamate levels) ERBB4 intron 20802204 rs16847102 chr2 212722988 G A 7.59E-04 Multiple complex diseases ERBB4 intron 17554300 rs11679499 chr2 212729377 A T 8.50E-04 Acute lung injury ERBB4 intron 22295056 rs16847152 chr2 212736394 T C 7.92E-05 Cognitive impairment induced by topiramate ERBB4 intron 22091778 rs13390226 chr2 212739861 G A 4.24E-05 Multiple complex diseases ERBB4 intron 17554300 rs7603039 chr2 212788895 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ERBB4 intron 22628534 rs16847207 chr2 212791249 A G 0.000738 Height (Pygmy height) ERBB4 intron 22570615 rs839533 chr2 212808107 A G 0.000159 Oxaliplatin induced mucositis in response to colorectal cancer treatment ERBB4 intron 22310351 rs839511 chr2 212822242 C T 4.69E-04 Alzheimer's disease ERBB4 intron 17998437 rs839511 chr2 212822242 C T 2.58E-04 Alzheimer's disease ERBB4 intron pha002879 rs10205607 chr2 212845461 T C 0.000849 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs17415079 chr2 212856363 T C 5.73E-04 Smoking initiation ERBB4 intron 24665060 rs4673646 chr2 212860841 G A 0.000708 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs13020474 chr2 212866473 C T 0.000369 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs1879637 chr2 212868624 C T 4.00E-06 Personality dimensions ERBB4 intron 23903073 rs1521537 chr2 212885510 T C 0.0000657 Circulating PCSK9 levels ERBB4 intron 22460556 rs2139938 chr2 212891137 C A 4.90E-06 Urinary metabolites ERBB4 intron 21572414 rs1546717 chr2 212902339 A G 2.60E-05 Urinary metabolites ERBB4 intron 21572414 rs1464443 chr2 212914726 C A 1.00E-06 Amyotrophic lateral sclerosis (sporadic) ERBB4 intron 24529757 rs41422148 chr2 212967009 T C 1.98E-04 Multiple complex diseases ERBB4 intron 17554300 rs16847757 chr2 212994669 T C 2.53E-04 Multiple complex diseases ERBB4 intron 17554300 rs4673651 chr2 213004603 G A,T 0.00000608 Aging ERBB4 intron 22445811 rs13035998 chr2 213029668 T C 2.31E-05 Serum metabolites ERBB4 intron 19043545 rs6751662 chr2 213033118 T C 1.77E-05 Serum metabolites ERBB4 intron 19043545 rs1402766 chr2 213033301 A C 7.74E-06 Rheumatoid arthritis ERBB4 intron 19503088 rs12621602 chr2 213036190 A C 1.88E-07 Fibrinogen ERBB4 intron pha003068 rs939664 chr2 213038087 C G 7.85E-05 Serum metabolites ERBB4 intron 19043545 rs10497963 chr2 213065329 C T 5.42E-05 Bilirubin levels,in serum ERBB4 intron 19389676 rs1402769 chr2 213081443 T G 4.46E-05 Chronic obstructive pulmonary disease ERBB4 intron 19300482 rs1402769 chr2 213081443 T G 4.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs9288446 chr2 213082027 G C 2.30E-05 Volumetric brain MRI ERBB4 intron 17903297 rs9288449 chr2 213085996 T C 1.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs10497966 chr2 213113079 C A 9.90E-05 Psoriasis ERBB4 intron 18364390 rs1021916 chr2 213132822 A G 2.20E-05 Renal function-related traits (urea) ERBB4 intron 22797727 rs10170838 chr2 213164466 C T 9.76E-07 Type 1 diabetes nephropathy ERBB4 intron 23028342 rs1857795 chr2 213164907 A C 3.00E-05 Prostate cancer ERBB4 intron 21743057 rs17346933 chr2 213165193 A G 5.77E-05 Left ventricular hypertrophy ERBB4 intron pha003052 rs7588550 chr2 213168768 G A 2.00E-07 Type 1 diabetes nephropathy ERBB4 intron 23028342 rs7559911 chr2 213186351 C A 2.02E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs10164675 chr2 213187034 G T 8.71E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs12993440 chr2 213188013 A G 2.06E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs905883 chr2 213188470 C A,G,T 2.00E-04 Breast cancer and prostate cancer ERBB4 intron 17903305 rs16775 chr2 213189297 G A 9.06E-05 Schizophrenia ERBB4 intron 24253340 rs4673659 chr2 213189729 A C 9.00E-07 Asthma (sex interaction) ERBB4 intron 24824216 rs6719811 chr2 213194405 G A 8.27E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs1394782 chr2 213200920 G A 8.30E-05 Pericardial fat ERBB4 intron 22589742 rs1505356 chr2 213205001 C A 8.70E-05 Pericardial fat ERBB4 intron 22589742 rs1876048 chr2 213205849 G A 9.40E-05 Pericardial fat ERBB4 intron 22589742 rs1995567 chr2 213206165 T C 6.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs2135157 chr2 213206302 C T 9.40E-05 Pericardial fat ERBB4 intron 22589742 rs4630710 chr2 213211617 G A 2.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs2888089 chr2 213219281 C A 6.40E-05 Pericardial fat ERBB4 intron 22589742 rs1948877 chr2 213219641 G A 5.09E-04 Type 2 diabetes ERBB4 intron 17463246 rs11892564 chr2 213226544 A G 8.08E-04 Alzheimer's disease ERBB4 intron 24755620 rs1394799 chr2 213230879 A G 7.42E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs4511675 chr2 213233739 G T 9.30E-05 Alzheimer's disease (late onset) ERBB4 intron 21379329 rs13383860 chr2 213253930 T C 6.11E-06 Alzheimer's disease (late onset) ERBB4 intron 21379329 rs16848495 chr2 213273682 C T 3.45E-04 Type 2 diabetes ERBB4 intron 17463246 rs1283310 chr2 213273891 A G 7.64E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10197836 chr2 213274278 T C 7.76E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs4673664 chr2 213277649 T C 8.30E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10167244 chr2 213281310 A G 6.17E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10197535 chr2 213282922 G A 9.33E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs6435701 chr2 213283512 A G 7.33E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10201067 chr2 213284411 C T 8.50E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs13413590 chr2 213292329 C T 3.18E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs7569142 chr2 213294557 C T 2.83E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs13393577 chr2 213296863 T C 9.00E-14 Breast cancer ERBB4 intron 22452962 rs1505368 chr2 213297253 G A 1.00E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs1505376 chr2 213303947 T C 2.09E-04 Parkinson's disease ERBB4 intron 17052657 rs17259208 chr2 213316586 T C 3.00E-05 Kawasaki disease ERBB4 intron 22446962 rs6711080 chr2 213317329 C T 9.00E-04 Nicotine smoking ERBB4 intron 19268276 rs10168850 chr2 213334523 C T 4.90E-05 Kawasaki disease ERBB4 intron 22446962 rs16848847 chr2 213434347 A G 6.72E-04 Type 2 diabetes / / 17463246 rs984455 chr2 213453046 G C 7.54E-04 Multiple complex diseases / / 17554300 rs11693009 chr2 213486117 C T 6.57E-05 Relative hand skill / / 24068947 rs931217 chr2 213496450 C G 6.22E-05 Relative hand skill / / 24068947 rs956558 chr2 213497090 G A 6.20E-05 Relative hand skill / / 24068947 rs10179457 chr2 213500670 A G 8.30E-04 Type 2 diabetes / / 17463246 rs17331220 chr2 213510571 A G 2.95E-05 Relative hand skill / / 24068947 rs11683491 chr2 213515027 C A 3.52E-05 Relative hand skill / / 24068947 rs17331933 chr2 213545335 A C 8.75E-04 Multiple complex diseases / / 17554300 rs2371713 chr2 213547267 C G 3.37E-05 Relative hand skill / / 24068947 rs11674822 chr2 213555564 T C 3.85E-05 Sodium levels / / pha003093 rs10932444 chr2 213584688 C A 8.44E-05 Serum metabolites / / 19043545 rs7565158 chr2 213593970 G T 8.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16849204 chr2 213606762 T C 3.22E-05 Neuroblastoma / / pha002895 rs10497985 chr2 213609252 C T 4.00E-06 Cognitive decline (age-related) / / 24468470 rs16849209 chr2 213611221 G T 5.00E-04 Alcohol dependence / / 20201924 rs9288457 chr2 213676322 A C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7604632 chr2 213680645 C T 5.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4673693 chr2 213680973 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4673694 chr2 213690991 G T 2.40E-05 Urinary metabolites / / 21572414 rs4131363 chr2 213707759 A G 6.91E-04 Multiple complex diseases / / 17554300 rs7600221 chr2 213738972 G A 6.53E-05 Diabetic nephropathy / / pha002852 rs10189511 chr2 213782542 G A 0.000012 Pancreatic cancer and survival / / 22665904 rs4673710 chr2 213820871 C T 8.79E-04 Multiple complex diseases / / 17554300 rs12619285 chr2 213824045 A G 5.00E-10 Eosinophil counts / / 19198610 rs12619285 chr2 213824045 A G 4.50E-05 Information processing speed / / 21130836 rs4673714 chr2 213858157 G A 6.50E-05 Coronary heart disease / / pha003035 rs12328640 chr2 213859185 G T 5.01E-05 IgE levels / / 22075330 rs1871946 chr2 213879407 T C 3.62E-05 Response to hepatitis C treatment IKZF2 intron 19684573 rs1871946 chr2 213879407 T C 2.00E-04 Information processing speed IKZF2 intron 21130836 rs13397204 chr2 213902295 C A 1.13E-04 Self-reported allergy IKZF2 intron 23817569 rs1564612 chr2 213904322 A T 8.39E-05 Self-reported allergy IKZF2 intron 23817569 rs2220038 chr2 213905274 A G 8.95E-05 Self-reported allergy IKZF2 intron 23817569 rs10207031 chr2 213906692 T C 4.67E-04 Self-reported allergy IKZF2 intron 23817569 rs10207031 chr2 213906692 T C 4.40E-04 Smoking initiation IKZF2 intron 24665060 rs2069267 chr2 213908722 C T 1.30E-04 Self-reported allergy IKZF2 intron 23817569 rs2069266 chr2 213908979 G T 1.48E-04 Self-reported allergy IKZF2 intron 23817569 rs12622499 chr2 213910104 G A 8.93E-05 Self-reported allergy IKZF2 intron 23817569 rs1482579 chr2 213911042 G A 8.56E-05 Self-reported allergy IKZF2 intron 23817569 rs4458156 chr2 213911107 G A 8.29E-05 Self-reported allergy IKZF2 intron 23817569 rs13019839 chr2 213915104 C A 1.03E-04 Self-reported allergy IKZF2 intron 23817569 rs2035426 chr2 213915748 C G 1.10E-05 Urinary metabolites IKZF2 intron 21572414 rs2035426 chr2 213915748 C G 2.87E-04 Self-reported allergy IKZF2 intron 23817569 rs9288462 chr2 213919289 G T 1.05E-04 Self-reported allergy IKZF2 intron 23817569 rs4672669 chr2 213922773 A T 6.64E-05 Lipoprotein-associated phospholipase A2 activity and mass IKZF2 intron 20442857 rs4672670 chr2 213923059 A C 6.27E-04 Smoking initiation IKZF2 intron 24665060 rs10497990 chr2 213926508 A G 6.28E-04 Self-reported allergy IKZF2 intron 23817569 rs10186029 chr2 213929286 C T 1.92E-05 Response to hepatitis C treatment IKZF2 intron 19684573 rs16849708 chr2 213946569 G C 1.65E-04 Type 2 diabetes IKZF2 intron 17463246 rs4672676 chr2 214001948 C T 3.59E-04 Smoking initiation IKZF2 intron 24665060 rs6709554 chr2 214012508 C T 2.51E-04 Self-reported allergy IKZF2 cds-synon 23817569 rs935092 chr2 214021325 G A 2.62E-04 Multiple complex diseases / / 17554300 rs935092 chr2 214021325 G A 3.39E-05 Sudden cardiac arrest / / 21658281 rs12471471 chr2 214023052 A G 3.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs10932472 chr2 214038302 A G 3.49E-04 Multiple complex diseases / / 17554300 rs4567882 chr2 214039733 T C 2.50E-05 Urinary metabolites / / 21572414 rs16849921 chr2 214061022 C A,G,T 2.82E-05 Multiple complex diseases / / 17554300 rs2099799 chr2 214073968 G A 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1372140 chr2 214099810 G T 1.52E-04 Alzheimer's disease (late onset) / / 21379329 rs10497997 chr2 214103779 C T 1.20E-06 Fasting plasma glucose / / 19060907 rs10168433 chr2 214110416 T G 8.70E-05 Diabetic retinopathy / / 21441570 rs10181294 chr2 214115898 A G 5.56E-05 Fasting insulin (interaction) / / 24204828 rs10181294 chr2 214115898 A G 7.71E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10185045 chr2 214117303 A G 4.40E-05 Diabetic retinopathy / / 21441570 rs10208952 chr2 214117454 G A 4.40E-05 Diabetic retinopathy / / 21441570 rs16850049 chr2 214118025 G T 1.38E-07 Multiple complex diseases / / 17554300 rs17362900 chr2 214118473 C G 4.40E-05 Diabetic retinopathy / / 21441570 rs17362920 chr2 214118499 T G 5.10E-05 Diabetic retinopathy / / 21441570 rs17362983 chr2 214118592 G A 4.30E-05 Diabetic retinopathy / / 21441570 rs16850055 chr2 214118734 A G 4.30E-05 Diabetic retinopathy / / 21441570 rs10184123 chr2 214120412 T C 6.00E-05 Diabetic retinopathy / / 21441570 rs17363242 chr2 214123685 C G 3.20E-05 Diabetic retinopathy / / 21441570 rs1219984 chr2 214133382 T C 3.30E-05 Diabetic retinopathy / / 21441570 rs10198138 chr2 214134615 T C 4.30E-05 Diabetic retinopathy / / 21441570 rs10169033 chr2 214137152 A G 4.20E-05 Diabetic retinopathy / / 21441570 rs1219973 chr2 214138425 T G 3.60E-05 Diabetic retinopathy / / 21441570 rs13416683 chr2 214138559 C T 4.10E-05 Diabetic retinopathy / / 21441570 rs13393868 chr2 214138770 A G 3.50E-05 Diabetic retinopathy / / 21441570 rs7581685 chr2 214138789 T C 1.75E-05 Fasting insulin (interaction) / / 24204828 rs7581685 chr2 214138789 T C 3.04E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs1219972 chr2 214139065 A G 3.50E-05 Diabetic retinopathy / / 21441570 rs1219970 chr2 214139258 T C 3.50E-05 Diabetic retinopathy / / 21441570 rs13428264 chr2 214151720 G A 2.90E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17298252 chr2 214153802 G T 2.80E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13401350 chr2 214154634 T C 3.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs9653340 chr2 214154726 C T 2.90E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488987 chr2 214158151 A G 2.70E-05 Diabetic retinopathy SPAG16 intron 21441570 rs975956 chr2 214161773 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488988 chr2 214161849 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1219987 chr2 214162730 T G 3.78E-13 Multiple complex diseases SPAG16 intron 17554300 rs13422754 chr2 214169642 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11695933 chr2 214170625 A T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10203794 chr2 214171778 T C 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2371890 chr2 214173451 G A 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13389980 chr2 214173563 A G 2.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13418276 chr2 214173587 G A 2.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11678617 chr2 214174298 A G 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7425349 chr2 214174519 C T 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10498003 chr2 214174767 C T 2.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10498004 chr2 214175270 C T 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs766258 chr2 214176980 G A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13424627 chr2 214180831 G A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1043646 chr2 214182321 T G 2.10E-05 Diabetic retinopathy SPAG16 UTR-3 21441570 rs10210603 chr2 214183098 C A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13384459 chr2 214183769 G A 3.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11677851 chr2 214185900 C T 1.00E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1012556 chr2 214189591 C A 1.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10206666 chr2 214192212 C T 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13395064 chr2 214197366 G A 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13395079 chr2 214197488 C G 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13400851 chr2 214204084 G T 1.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11688212 chr2 214208290 C A 4.00E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7355430 chr2 214221925 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7355432 chr2 214222167 C T 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10172140 chr2 214225606 C T 4.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488982 chr2 214227945 A G 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488981 chr2 214228020 T C 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7589864 chr2 214231045 G T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13414104 chr2 214234050 T C 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13411979 chr2 214237404 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13411988 chr2 214237420 G T 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs4672679 chr2 214238530 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1387209 chr2 214241939 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10191191 chr2 214242433 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1844227 chr2 214244304 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11692490 chr2 214246268 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11682739 chr2 214247115 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488978 chr2 214248686 G A 3.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2130056 chr2 214255693 T A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750222 chr2 214256618 T G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11682093 chr2 214258901 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11690986 chr2 214269693 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17694142 chr2 214269942 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11691151 chr2 214270027 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2634482 chr2 214271199 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs16850304 chr2 214280525 A G 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750805 chr2 214280634 T G 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2035694 chr2 214282132 T A 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750895 chr2 214284096 G A 4.70E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13390905 chr2 214392651 T C 5.03E-04 Multiple complex diseases SPAG16 intron 17554300 rs12466426 chr2 214426720 G A 6.55E-05 Response to cytidine analogues (gemcitabine) SPAG16 intron 24483146 rs1400015 chr2 214462816 T G 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs11683006 chr2 214483528 A C 1.11E-05 Fasting insulin (interaction) SPAG16 intron 24204828 rs11683006 chr2 214483528 A C 2.03E-05 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs1515915 chr2 214527841 G A 8.39E-04 White matter integrity SPAG16 intron 22425255 rs2013922 chr2 214531723 C T 6.23E-06 Fasting insulin (interaction) SPAG16 intron 24204828 rs1028137 chr2 214535540 C G 3.43E-06 Fasting insulin (interaction) SPAG16 intron 24204828 rs1028137 chr2 214535540 C G 7.33E-06 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs6707387 chr2 214548537 G A 1.00E-06 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs6707387 chr2 214548537 G A 6.00E-07 Fasting insulin (interaction) SPAG16 intron 24204828 rs10165804 chr2 214575924 T G 1.11E-05 Fasting insulin (interaction) SPAG16 intron 24204828 rs10165804 chr2 214575924 T G 1.98E-05 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs7597928 chr2 214592382 A G 1.44E-04 Alcohol dependence SPAG16 intron 21314694 rs2457183 chr2 214635332 G C 3.70E-04 Type 2 diabetes SPAG16 intron 17463246 rs2662683 chr2 214639706 T A 3.01E-04 Type 2 diabetes SPAG16 intron 17463246 rs11893486 chr2 214672291 C A 1.12E-04 Type 2 diabetes SPAG16 intron 17463246 rs6705746 chr2 214678340 G A 2.42E-04 Type 2 diabetes SPAG16 intron 17463246 rs1582839 chr2 214683214 G A 7.21E-04 Type 2 diabetes SPAG16 intron 17463246 rs10932501 chr2 214700768 C A 2.60E-04 Type 2 diabetes SPAG16 intron 17463246 rs11674163 chr2 214713451 A C 3.35E-04 Type 2 diabetes SPAG16 intron 17463246 rs4503943 chr2 214714975 G A 2.01E-04 Type 2 diabetes SPAG16 intron 17463246 rs10498015 chr2 214717579 C A 1.19E-04 Type 2 diabetes SPAG16 intron 17463246 rs10179905 chr2 214726239 T A 2.11E-04 Type 2 diabetes SPAG16 intron 17463246 rs2662676 chr2 214727997 G T 1.31E-05 Multiple complex diseases SPAG16 intron 17554300 rs16851125 chr2 214789988 C T 6.61E-04 Type 2 diabetes SPAG16 intron 17463246 rs4427965 chr2 214802528 C T 3.59E-04 Type 2 diabetes SPAG16 intron 17463246 rs11678221 chr2 214803693 A T 6.89E-04 Type 2 diabetes SPAG16 intron 17463246 rs9789347 chr2 214838513 G T 8.00E-06 Obesity-related traits SPAG16 intron 23251661 rs10498012 chr2 214861233 C T 1.80E-06 Urinary metabolites SPAG16 intron 21572414 rs4673801 chr2 214862848 G A 1.90E-06 Urinary metabolites SPAG16 intron 21572414 rs1397351 chr2 214867132 A G 5.16E-04 Amyotrophic Lateral Sclerosis SPAG16 intron 17362836 rs71428314 chr2 214904957 G T 2.37E-06 Contrast sensitivity SPAG16 intron 24152035 rs9288484 chr2 214907853 C G 4.07E-06 Contrast sensitivity SPAG16 intron 24152035 rs737690 chr2 214907914 T C 4.07E-06 Contrast sensitivity SPAG16 intron 24152035 rs17207375 chr2 214914721 C T 2.22E-06 Contrast sensitivity SPAG16 intron 24152035 rs1510552 chr2 214917402 A C 1.00E-06 Contrast sensitivity SPAG16 intron 24152035 rs2058991 chr2 214932580 A G 1.37E-04 Response to taxane treatment (placlitaxel) SPAG16 intron 23006423 rs6715771 chr2 214940734 T C 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) SPAG16 intron 23648065 rs6715771 chr2 214940734 T C 6.46E-06 Contrast sensitivity SPAG16 intron 24152035 rs2080776 chr2 214956523 C T 9.03E-04 Response to cytadine analogues (cytosine arabinoside) SPAG16 intron 24483146 rs10514628 chr2 214966973 G C 5.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SPAG16 intron 21844884 rs4541202 chr2 214969001 C T 5.04E-04 Response to cytadine analogues (cytosine arabinoside) SPAG16 intron 24483146 rs2161022 chr2 214993997 G A 1.46E-04 Type 2 diabetes SPAG16 intron 17463246 rs7597126 chr2 215009358 T C 5.12E-05 Blood Pressure SPAG16 intron pha003039 rs7597126 chr2 215009358 T C 4.35E-05 Blood Pressure SPAG16 intron pha003045 rs16851532 chr2 215018724 A C 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs16851554 chr2 215024392 T G 2.46E-05 Response to acetaminophen (hepatotoxicity) SPAG16 intron 21177773 rs2372227 chr2 215034435 C A 5.34E-04 Stroke SPAG16 intron pha002887 rs2161082 chr2 215046533 A G 4.07E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs10190431 chr2 215048212 T C 1.66E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs1912196 chr2 215050520 G T 6.23E-05 Cognitive test performance SPAG16 intron 20125193 rs11887857 chr2 215052524 G A 1.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs12617276 chr2 215061093 G T 6.80E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs16851611 chr2 215081910 C T 4.03E-04 Coronary Artery Disease SPAG16 intron 17634449 rs13404035 chr2 215121966 T C 2.00E-05 Melanoma SPAG16 intron 24980573 rs10932529 chr2 215144720 G A 2.02E-04 Myocardial Infarction SPAG16 intron pha002873 rs6731110 chr2 215179277 C A 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs6731110 chr2 215179277 C A 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) SPAG16 intron 23648065 rs1912169 chr2 215181488 T G 1.00E-04 Cognitive impairment induced by topiramate SPAG16 intron 22091778 rs2216544 chr2 215182877 G A 6.29E-04 Myocardial Infarction SPAG16 intron pha002873 rs16851771 chr2 215188619 A G 2.00E-06 Obesity-related traits SPAG16 intron 23251661 rs1912185 chr2 215194668 T G 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs4673821 chr2 215243815 T C 4.45E-04 Schizophrenia(treatment response to risperidone) SPAG16 intron 19850283 rs4286276 chr2 215264826 T C 5.11E-04 Tourette syndrome SPAG16 intron 22889924 rs13428663 chr2 215285651 A G 2.86E-05 Dilated cardiomyopathy VWC2L intron 23853074 rs7563874 chr2 215325694 T C 6.24E-04 Response to taxane treatment (placlitaxel) VWC2L intron 23006423 rs4673828 chr2 215330568 C T 6.83E-05 Coronary Artery Disease VWC2L intron 17634449 rs11897844 chr2 215334760 G A 7.66E-04 Tourette syndrome VWC2L intron 22889924 rs7604827 chr2 215341890 C T 5.00E-06 PR interval VWC2L intron 23534349 rs7604827 chr2 215341890 C T 2.62E-04 Celiac disease VWC2L intron 23936387 rs13425618 chr2 215350167 A G 8.80E-04 Alcohol dependence VWC2L intron 20201924 rs4629153 chr2 215356938 C T 3.80E-04 Alcohol dependence VWC2L intron 20201924 rs4629153 chr2 215356938 C T 3.80E-04 Alcohol dependence VWC2L intron 20201924 rs9288497 chr2 215370052 A G 3.20E-04 Alcohol dependence VWC2L intron 20201924 rs9288497 chr2 215370052 A G 5.80E-04 Alcohol dependence VWC2L intron 20201924 rs11886252 chr2 215382534 C T 5.77E-04 Multiple complex diseases VWC2L intron 17554300 rs6435833 chr2 215433565 A T 1.24E-05 Biliary atresia VWC2L intron 20460270 rs7425848 chr2 215458633 T C 1.98E-05 Biliary atresia / / 20460270 rs13009173 chr2 215515382 T C 0.000103 Salmonella-induced pyroptosis / / 22837397 rs12615863 chr2 215561552 C T 6.67E-05 Alzheimer's disease / / 17998437 rs12615863 chr2 215561552 C T 4.46E-05 Alzheimer's disease / / pha002879 rs1914516 chr2 215561933 T C 3.61E-05 Alzheimer's disease / / 17998437 rs1914516 chr2 215561933 T C 1.42E-05 Alzheimer's disease / / pha002879 rs1517796 chr2 215564323 G A 5.06E-04 Alzheimer's disease / / 17998437 rs1979028 chr2 215592906 T A 1.16E-04 Multiple complex diseases BARD1 nearGene-3 17554300 rs12614960 chr2 215595512 C T 1.07E-04 Multiple complex diseases BARD1 intron 17554300 rs16852600 chr2 215595645 C T 1.92E-04 Multiple complex diseases BARD1 intron 17554300 rs16852600 chr2 215595645 C T 1.40E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs16852600 chr2 215595645 C T 6.83E-05 Neuroblastoma BARD1 intron pha002895 rs16852600 chr2 215595645 C T 3.64E-05 Coronary heart disease BARD1 intron pha003030 rs16852600 chr2 215595645 C T 5.87E-05 Coronary heart disease BARD1 intron pha003031 rs895459 chr2 215600257 G A 7.82E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs895459 chr2 215600257 G A 1.11E-05 Neuroblastoma BARD1 intron pha002895 rs10183009 chr2 215602074 G T 3.57E-04 Multiple complex diseases BARD1 intron 17554300 rs2053710 chr2 215616708 C T 5.77E-04 Amyotrophic Lateral Sclerosis BARD1 intron 17362836 rs2053710 chr2 215616708 C T 2.56E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs2053710 chr2 215616708 C T 1.62E-06 Neuroblastoma BARD1 intron pha002895 rs1374230 chr2 215618779 A G 1.34E-04 Multiple complex diseases BARD1 intron 17554300 rs1374230 chr2 215618779 A G 1.10E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs1374230 chr2 215618779 A G 1.62E-05 Neuroblastoma BARD1 intron pha002895 rs10221582 chr2 215623390 C T 2.36E-05 Multiple complex diseases BARD1 intron 17554300 rs10932572 chr2 215627397 A G 1.20E-04 Amyotrophic Lateral Sclerosis BARD1 intron 17362836 rs10932572 chr2 215627397 A G 2.80E-09 Neuroblastoma (high-risk) BARD1 intron 19412175 rs10932572 chr2 215627397 A G 2.84E-05 Neuroblastoma BARD1 intron pha002895 rs7584646 chr2 215629322 A G 2.50E-10 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7584646 chr2 215629322 A G 3.73E-05 Neuroblastoma BARD1 intron pha002895 rs6706777 chr2 215629543 G C 1.48E-05 Multiple complex diseases BARD1 intron 17554300 rs7599060 chr2 215631302 G A 3.79E-05 Multiple complex diseases BARD1 intron 17554300 rs11685215 chr2 215633624 C T 4.63E-04 Amyotrophic lateral sclerosis (sporadic) BARD1 intron 24529757 rs7557557 chr2 215634627 C T 2.79E-08 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7557557 chr2 215634627 C T 1.42E-06 Neuroblastoma BARD1 intron pha002895 rs3768716 chr2 215635794 T C 1.62E-14 Neuroblastoma (high-risk) BARD1 intron 19412175 rs3768716 chr2 215635794 T C 5.00E-13 Neuroblastoma BARD1 intron 21124317 rs3768716 chr2 215635794 T C 7.25E-13 Neuroblastoma BARD1 intron pha002895 rs17487792 chr2 215643500 C T 1.82E-14 Neuroblastoma (high-risk) BARD1 intron 19412175 rs17487792 chr2 215643500 C T 1.35E-12 Neuroblastoma BARD1 intron pha002895 rs7587476 chr2 215653887 T C 8.61E-13 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7587476 chr2 215653887 T C 4.00E-14 Neuroblastoma BARD1 intron 22941191 rs7587476 chr2 215653887 T C 3.05E-13 Neuroblastoma BARD1 intron pha002895 rs6712055 chr2 215666904 T C 5.17E-12 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6712055 chr2 215666904 T C 2.17E-09 Neuroblastoma BARD1 intron pha002895 rs16852802 chr2 215672041 T C 8.50E-04 Multiple complex diseases BARD1 intron 17554300 rs6435862 chr2 215672546 G T 9.00E-18 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6435862 chr2 215672546 G T 9.00E-18 Nasopharyngeal carcinoma BARD1 intron 20512145 rs6435862 chr2 215672546 G T 2.93E-09 Neuroblastoma BARD1 intron pha002895 rs6715570 chr2 215673440 T C 1.02E-12 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6715570 chr2 215673440 T C 1.21E-09 Neuroblastoma BARD1 intron pha002895 rs6744811 chr2 215677308 A C 1.30E-09 Neuroblastoma (high-risk) / / 19412175 rs6744811 chr2 215677308 A C 4.72E-07 Neuroblastoma / / pha002895 rs2121283 chr2 215710338 C T 4.19E-06 Neuroblastoma / / pha002895 rs1026020 chr2 215715707 A G,T 4.74E-05 Serum metabolites / / 19043545 rs11677798 chr2 215724550 C T 2.38E-06 Neuroblastoma / / pha002895 rs2592232 chr2 215725751 G A 8.87E-10 Neuroblastoma / / pha002895 rs10498025 chr2 215749256 A G 5.45E-11 Neuroblastoma / / pha002895 rs10498026 chr2 215749350 G A 9.69E-09 Neuroblastoma / / pha002895 rs7560809 chr2 215758159 A C 4.21E-04 Multiple complex diseases / / 17554300 rs1952224 chr2 215772412 G A 1.77E-05 Neuroblastoma / / pha002895 rs6737675 chr2 215780700 A G 3.20E-04 Multiple complex diseases / / 17554300 rs10204986 chr2 215790001 T G 8.07E-05 Meningococcal disease / / 20694013 rs7578759 chr2 215798408 A G 9.43E-05 Personality dimensions ABCA12 intron 18957941 rs1409612 chr2 215800710 G A 8.70E-04 Multiple complex diseases ABCA12 intron 17554300 rs1409612 chr2 215800710 G A 2.80E-05 Urinary metabolites ABCA12 intron 21572414 rs10498027 chr2 215820013 G A 1.99E-04 Multiple complex diseases ABCA12 cds-synon 17554300 rs4673925 chr2 215833415 A G 3.50E-04 Alcohol dependence ABCA12 intron 20201924 rs6756540 chr2 215833622 G T 6.10E-04 Alcohol dependence ABCA12 intron 20201924 rs1464678 chr2 215834466 A G 2.50E-04 Alcohol dependence ABCA12 intron 20201924 rs3795857 chr2 215834676 A G 3.10E-04 Alcohol dependence ABCA12 intron 20201924 rs3795857 chr2 215834676 A G 5.80E-06 Neuroblastoma ABCA12 intron pha002895 rs17493319 chr2 215840414 C A 6.95E-04 Multiple complex diseases ABCA12 intron 17554300 rs7579031 chr2 215843954 C T 7.70E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs13385378 chr2 215883362 A G 9.15E-06 PR interval in Tripanosoma cruzi seropositivity ABCA12 intron 24324551 rs10210200 chr2 215929125 G A 2.00E-06 PR interval in Tripanosoma cruzi seropositivity ABCA12 intron 24324551 rs2372479 chr2 215942490 T G 1.98E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs1880130 chr2 215947252 A G 2.38E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs13014763 chr2 216009353 C A 1.90E-05 Urinary metabolites / / 21572414 rs7557923 chr2 216009374 T C 2.20E-05 Urinary metabolites / / 21572414 rs1004301 chr2 216010390 C T 1.30E-05 Urinary metabolites / / 21572414 rs4673965 chr2 216106637 G A 1.34E-04 Age-related macular degeneration / / 22125219 rs16853680 chr2 216137978 A C 3.56E-04 Smoking quantity / / 24665060 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 15457444 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 15677700 rs2372536 chr2 216190020 C G 1 Drug response to Folic Acid ATIC missense 19016697 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 19016697 rs6757920 chr2 216205267 A G 9.60E-05 Height ATIC intron pha003011 rs6728999 chr2 216235046 C T 3.43E-10 Triglycerides FN1 missense 23063622 rs13414859 chr2 216243342 A C 0.000012 HDL cholesterol FN1 intron 23063622 rs1561302 chr2 216260298 A G 0.0000046 HDL cholesterol FN1 intron 23063622 rs17457029 chr2 216272514 G A 0.0000124 HDL cholesterol FN1 intron 23063622 rs17458018 chr2 216285375 T C 7.00E-06 Coronary heart disease FN1 intron 22319020 rs1250248 chr2 216287093 A G 1.70E-05 Endometriosis FN1 intron 21151130 rs13423742 chr2 216287796 C G 0.0000164 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1837121 chr2 216292331 G A 0.00000919 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs7609476 chr2 216294016 C A 0.0000131 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250239 chr2 216294957 C G 0.00000852 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250240 chr2 216295014 A G 0.0000118 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250241 chr2 216295312 T A 0.0000183 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs7586990 chr2 216295337 A G 0.0000275 HDL cholesterol FN1 intron 23063622 rs1250242 chr2 216296257 G C 0.00000923 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250247 chr2 216299629 C G 0.00000745 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250258 chr2 216300185 C T 0.00000151 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250259 chr2 216300482 T A 0.000000901 Nonsyndromic striae distensae (stretch marks) FN1 missense 23633020 rs4473378 chr2 216303005 T C 0.0000937 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3910516 chr2 216303053 A G 0.000000267 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250229 chr2 216304384 T C 0.000000502 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250229 chr2 216304384 T C 3.00E-08 LDL cholesterol / / 24097068 rs1250231 chr2 216305834 G A 0.000000498 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250232 chr2 216306635 C T 0.000000485 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250234 chr2 216308148 C T 0.00000353 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7423688 chr2 216308221 C T 0.0000258 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250255 chr2 216316487 C T 0.00000685 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250255 chr2 216316487 C T 3.21E-05 Breast cancer / / pha002853 rs1437787 chr2 216318237 T C 2.67E-06 Esophageal cancer (squamous cell) / / 22960999 rs10498039 chr2 216325768 C T 3.20E-04 Asthma / / 20698975 rs1561299 chr2 216339259 T C 9.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1561299 chr2 216339259 T C 4.15E-05 Relative hand skill / / 24068947 rs1437793 chr2 216364035 T C 1.84E-04 Heart Failure / / pha002885 rs1898716 chr2 216465787 C T 7.59E-04 Type 2 diabetes / / 17463246 rs10932621 chr2 216476038 G C 2.26E-04 Multiple complex diseases / / 17554300 rs11891673 chr2 216477172 G A 2.70E-06 Urinary metabolites / / 21572414 rs2579013 chr2 216517083 A G 9.72E-05 Socioeconomic Factors LOC646324 intron pha003067 rs10932623 chr2 216517945 G T 2.40E-05 Urinary metabolites LOC646324 intron 21572414 rs2678286 chr2 216526011 A G 2.40E-05 Urinary metabolites LOC646324 intron 21572414 rs869141 chr2 216534383 C G 7.17E-04 Multiple complex diseases LOC646324 intron 17554300 rs4672777 chr2 216555565 C G 5.88E-04 Type 2 diabetes LOC646324 intron 17463246 rs10932626 chr2 216627933 G T 2.93E-06 Smoking initiation LOC646324 intron 24665060 rs4674024 chr2 216631366 C T 1.52E-06 Smoking initiation LOC646324 intron 24665060 rs4674024 chr2 216631366 C T 2.00E-06 Smoking initiation LOC646324 intron 24665060 rs4257398 chr2 216758854 A G 3.99E-04 Myocardial Infarction / / pha002873 rs934152 chr2 216831098 T A 4.11E-04 Insulin resistance MREG intron 21901158 rs3770535 chr2 216838699 T C 2.07E-04 Cognitive decline MREG intron 23732972 rs3770542 chr2 216847151 A T 5.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MREG intron 22566498 rs3770549 chr2 216860550 A T 3.00E-06 Blood trace element (Se levels) MREG intron 23720494 rs3770560 chr2 216866439 G A 1.75E-04 Alzheimer's disease (late onset) MREG intron 21379329 rs13410982 chr2 216868598 C G 1.05E-05 Aging (time to event) MREG intron 21782286 rs4672790 chr2 216892446 C T 1.41E-04 Breast cancer / / 21060860 rs1344694 chr2 216893637 T G 1.47E-05 Alcohol dependence / / 19581569 rs1344694 chr2 216893637 T G 5.00E-06 Alcohol dependence / / 22004471 rs7590720 chr2 216898658 G A 1.00E-08 Alcohol dependence / / 19581569 rs934154 chr2 216901933 C T 4.20E-05 Eating disorders (purging via substances) / / 23568457 rs705648 chr2 216933792 C T 6.17E-05 Alcohol dependence PECR intron 19581569 rs17548312 chr2 216951247 A G 5.98E-05 Coronary heart disease TMEM169 intron pha003055 rs10166817 chr2 216982691 T C 7.78E-05 Cognitive test performance XRCC5 intron 20125193 rs828704 chr2 216993611 C A 6.40E-05 Coronary heart disease XRCC5 intron pha003055 rs13006837 chr2 217059254 G A 2.00E-06 Urinary metabolites XRCC5 intron 21572414 rs16855635 chr2 217067347 G T 5.71E-04 Multiple complex diseases XRCC5 intron 17554300 rs380919 chr2 217153080 C T 1.50E-05 Urinary metabolites MARCH4 intron 21572414 rs440866 chr2 217153197 G A 2.60E-05 Urinary metabolites MARCH4 intron 21572414 rs6705793 chr2 217155206 C T 4.18E-04 Type 2 diabetes MARCH4 intron 17463246 rs955816 chr2 217199624 A G 2.34E-05 Anxiety in major depressive disorder MARCH4 intron 24047446 rs6756590 chr2 217208571 C T 1.00E-06 Migraine MARCH4 intron 22683712 rs907171 chr2 217237803 A T 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs705657 chr2 217241528 G C 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11687270 chr2 217246055 G A 4.20E-05 Iron levels / / 21208937 rs2243956 chr2 217252118 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs925540 chr2 217252898 A G 8.46E-04 Multiple complex diseases / / 17554300 rs12615939 chr2 217258369 T A 1.48E-06 Multiple complex diseases / / 17554300 rs11888959 chr2 217326879 T C 4.54E-05 Serum metabolites SMARCAL1 intron 19043545 rs284531 chr2 217333174 C G 9.54E-05 Serum metabolites SMARCAL1 intron 19043545 rs3755140 chr2 217363049 C T 0.00064509 Hypertension (early onset hypertension) LOC100507554 intron 22479346 rs3755140 chr2 217363049 C T 7.14E-04 Smoking initiation LOC100507554 intron 24665060 rs2272243 chr2 217364764 G T 0.000782021 Hypertension (early onset hypertension) RPL37A intron 22479346 rs922987 chr2 217411246 T C 2.40E-04 Iris characteristics / / 21835309 rs1949872 chr2 217443802 C T 9.80E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs940794 chr2 217456567 T G 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7590938 chr2 217463442 A G 2.47E-05 Schizophrenia / / 19571809 rs10932667 chr2 217469796 A G 4.96E-05 Coronary heart disease / / pha003032 rs9288520 chr2 217481271 G A 4.00E-11 Esophageal cancer (alcohol interaction) / / 22960999 rs6733115 chr2 217488954 T C 5.30E-04 Multiple complex diseases / / 17554300 rs6733115 chr2 217488954 T C 2.43E-06 Asthma (childhood onset) / / 23829686 rs9341145 chr2 217511100 C T 3.99E-07 Glaucoma-related traits / / 22058429 rs7422089 chr2 217532139 C T 9.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2241193 chr2 217554213 T C 1.00E-07 Visceral fat IGFBP5 intron 22589738 rs888185 chr2 217570723 T G 3.88E-04 Alzheimer's disease / / 22005930 rs888184 chr2 217570766 A G 3.83E-04 Alzheimer's disease / / 22005930 rs2372865 chr2 217570995 T C 3.87E-04 Alzheimer's disease / / 22005930 rs888182 chr2 217571845 T G 4.38E-04 Alzheimer's disease / / 22005930 rs12473011 chr2 217573408 T G 7.12E-04 Alzheimer's disease / / 22005930 rs16856529 chr2 217573692 A C 6.43E-04 Alzheimer's disease / / 22005930 rs7557921 chr2 217574217 A G 7.15E-04 Alzheimer's disease / / 22005930 rs6757568 chr2 217575726 T C 7.10E-04 Alzheimer's disease / / 22005930 rs11676402 chr2 217596250 T C 6.81E-04 Aortic root size / / 21223598 rs2712170 chr2 217619858 G A,T 4.46E-04 Multiple complex diseases / / 17554300 rs13015993 chr2 217625523 G A 2.00E-07 Thyroid hormone levels / / 23408906 rs13015993 chr2 217625523 G A 3.00E-15 Thyroid hormone levels / / 23408906 rs13015993 chr2 217625523 G A 8.00E-11 Thyroid hormone levels / / 23408906 rs4674113 chr2 217638521 T C 1.14E-04 Schizophrenia / / 20832056 rs7421283 chr2 217640818 C T 2.90E-04 Alcohol dependence / / 21314694 rs16856673 chr2 217714625 T C 8.18E-04 Multiple complex diseases / / 17554300 rs10178069 chr2 217720468 A G 1.20E-05 Urinary metabolites / / 21572414 rs1179688 chr2 217749691 T G 2.80E-05 Urinary metabolites / / 21572414 rs1179683 chr2 217751546 A G 7.26E-04 Alzheimer's disease / / 17998437 rs41509447 chr2 217753980 T C 3.23E-06 Alzheimer's disease / / 17998437 rs1179697 chr2 217759516 T C 7.90E-06 Urinary metabolites / / 21572414 rs1179692 chr2 217761884 A G 3.97E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7589256 chr2 217775937 C T 2.30E-05 Urinary metabolites / / 21572414 rs1179669 chr2 217780457 G T 8.41E-04 Multiple complex diseases / / 17554300 rs10932682 chr2 217787536 C T 4.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17776232 chr2 217826219 T C 3.45E-04 Taste perception / / 22132133 rs2372928 chr2 217827849 A G 5.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10932688 chr2 217863481 C G 2.90E-04 Primary tooth development (time to first tooth eruption) / / 23704328 rs10932688 chr2 217863481 C G 3.00E-08 Primary tooth development (number of teeth) / / 23704328 rs6435957 chr2 217878209 T C 4.00E-07 Primary tooth development (number of teeth) / / 20195514 rs6435957 chr2 217878209 T C 4.66E-09 Permanent tooth development / / 21931568 rs4491709 chr2 217894756 T C 2.00E-14 Permanent tooth development / / 21931568 rs6435958 chr2 217896612 A G 1.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7564605 chr2 217898088 T C 2.29E-04 Response to TNF antagonist treatment / / 21061259 rs6735174 chr2 217900280 A C 4.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13387042 chr2 217905832 A G 1.00E-13 Breast cancer / / 17529974 rs13387042 chr2 217905832 A G 2.00E-08 Breast cancer / / 19330030 rs13387042 chr2 217905832 A G 2.00E-10 Breast cancer / / 20453838 rs13387042 chr2 217905832 A G 1.00E-13 Nasopharyngeal carcinoma / / 20512145 rs13387042 chr2 217905832 A G 9.00E-06 Breast cancer / / 20872241 rs13387042 chr2 217905832 A G 2.00E-10 Breast cancer / / 21263130 rs13387042 chr2 217905832 A G 5.49E-04 Permanent tooth development / / 21931568 rs13387042 chr2 217905832 A G 2.00E-57 Breast cancer / / 23535729 rs4621152 chr2 217908985 T C 4.58E-05 Schizophrenia / / 19571811 rs13000023 chr2 217924394 G A 3.36E-04 Type 2 diabetes / / 17463246 rs13011060 chr2 217938177 G A 1.50E-04 Breast cancer / / pha002853 rs6739040 chr2 217951726 A G 1.39E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2372965 chr2 217967717 C A 6.72E-05 Serum selenium levels / / 23698163 rs2372967 chr2 217967913 T C 6.72E-05 Serum selenium levels / / 23698163 rs3843337 chr2 217969435 A G 6.04E-05 Serum selenium levels / / 23698163 rs2372972 chr2 217971141 T C 8.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2372972 chr2 217971141 T C 3.58E-05 Serum selenium levels / / 23698163 rs9677455 chr2 217972252 A C 3.73E-05 Serum selenium levels / / 23698163 rs13015994 chr2 217974444 A C 2.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs12466929 chr2 217980433 G A 1.50E-04 Premature ovarian failure / / 19508998 rs12466929 chr2 217980433 G A 1.45E-04 Vaspin levels / / 22907691 rs12466929 chr2 217980433 G A 0.0001454 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12466929 chr2 217980433 G A 1.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1344723 chr2 218050827 A C 4.07E-04 Smoking cessation / / 24665060 rs1583111 chr2 218065917 G A 5.16E-04 Smoking cessation / / 24665060 rs12623903 chr2 218073392 T C 3.83E-04 Smoking cessation / / 24665060 rs13012936 chr2 218074070 A G 5.63E-04 Smoking cessation / / 24665060 rs13013676 chr2 218074128 G C 1.08E-04 Smoking cessation / / 24665060 rs12477810 chr2 218081443 G A 5.06E-05 Smoking cessation / / 24665060 rs2553038 chr2 218090609 C T 1.20E-05 Urinary metabolites / / 21572414 rs2115862 chr2 218095054 G C 7.00E-06 Height / / 21998595 rs2553034 chr2 218097054 G A 8.62E-05 Smoking cessation / / 24665060 rs1609871 chr2 218108789 G A 1.94E-04 Acute lung injury / / 22295056 rs2565689 chr2 218110548 T A 6.20E-06 Height / / 21998595 rs2113827 chr2 218111310 C T 9.10E-08 Height / / 21998595 rs2565688 chr2 218111701 T A 3.70E-07 Height / / 21998595 rs2553028 chr2 218117956 C G 7.30E-07 Height / / 21998595 rs1549738 chr2 218118722 G A 4.88E-05 Nicotine smoking / / 19268276 rs2553027 chr2 218121610 C T 2.60E-07 Height / / 21998595 rs11684828 chr2 218122764 A G 2.22E-04 Smoking cessation / / 24665060 rs2553026 chr2 218123648 G A 6.00E-08 Height / / 21998595 rs10490757 chr2 218126236 T C 2.77E-04 Smoking cessation / / 24665060 rs1863190 chr2 218128152 A T 1.60E-07 Height / / 21998595 rs10490758 chr2 218139894 C G 1.80E-04 Smoking cessation / / 24665060 rs2888479 chr2 218139904 G A 2.62E-04 Coronary Artery Disease / / 17634449 rs4356643 chr2 218145931 C G 9.82E-05 Coronary Artery Disease / / 17634449 rs13412710 chr2 218149159 A G 5.43E-05 Smoking cessation / / 24665060 rs1863189 chr2 218153015 C T 6.06E-04 Smoking cessation DIRC3 intron 24665060 rs2888481 chr2 218161392 G A 7.83E-04 Alzheimer's disease DIRC3 intron 22005930 rs13425869 chr2 218171660 T C 5.27E-04 Alzheimer's disease DIRC3 intron 22005930 rs4674159 chr2 218223023 T C 6.97E-04 Type 2 diabetes DIRC3 intron 17463246 rs6724073 chr2 218236786 T C 9.00E-04 Multiple complex diseases DIRC3 intron 17554300 rs16857473 chr2 218258530 T C 9.38E-04 Multiple complex diseases DIRC3 intron 17554300 rs10932715 chr2 218259783 T C 3.86E-04 Aortic root size DIRC3 intron 21223598 rs6759952 chr2 218271719 T C 6.00E-10 Thyroid cancer DIRC3 intron 23894154 rs1351164 chr2 218271898 T C 2.00E-14 Height DIRC3 intron 20881960 rs12694415 chr2 218289357 G A 7.84E-04 Multiple complex diseases DIRC3 intron 17554300 rs1478579 chr2 218291524 C T 5.89E-04 Aortic root size DIRC3 intron 21223598 rs1478581 chr2 218292652 G A 1.83E-04 Aortic root size DIRC3 intron 21223598 rs13388294 chr2 218295406 G A 4.13E-05 Thyroid cancer DIRC3 intron 23894154 rs1382435 chr2 218296003 T C 7.16E-06 Thyroid cancer DIRC3 intron 23894154 rs13004333 chr2 218296141 C G 2.72E-04 Multiple complex diseases DIRC3 intron 17554300 rs16857609 chr2 218296508 C T 1.00E-15 Breast cancer DIRC3 intron 23535729 rs16857609 chr2 218296508 C T 1.00E-04 Breast cancer DIRC3 intron 23535733 rs966423 chr2 218310340 C T 1.00E-09 Thyroid cancer DIRC3 intron 22267200 rs11689435 chr2 218314253 C T 4.00E-06 Metabolite levels (MHPG) DIRC3 intron 23319000 rs370140661 chr2 218314253 CGT C 4.00E-06 Metabolite levels (MHPG) DIRC3 intron 23319000 rs874840 chr2 218354130 C T 3.92E-04 Disc degeneration (lumbar) DIRC3 intron 24216480 rs12472818 chr2 218358312 T C 1.93E-04 Amyotrophic lateral sclerosis (sporadic) DIRC3 intron 24529757 rs4674189 chr2 218413982 C T 9.28E-05 Diabetes Mellitus DIRC3 intron pha003059 rs16857851 chr2 218418350 A G 4.91E-05 Taste perception DIRC3 intron 22132133 rs7585421 chr2 218421136 T C 7.69E-04 Aortic root size DIRC3 intron 21223598 rs4674192 chr2 218429292 C T 5.61E-04 Aortic root size DIRC3 intron 21223598 rs6714500 chr2 218438843 C T 3.25E-05 Cognitive test performance DIRC3 intron 20125193 rs6714500 chr2 218438843 C T 1.10E-05 Urinary metabolites DIRC3 intron 21572414 rs6733585 chr2 218512598 A G 5.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) DIRC3 intron 23648065 rs7578283 chr2 218517719 C T 3.20E-06 Height DIRC3 intron 21998595 rs6435999 chr2 218523162 A G 7.00E-07 Height DIRC3 intron 21998595 rs6761086 chr2 218543430 T C 1.90E-06 Height DIRC3 intron 21998595 rs934241 chr2 218563466 G A 8.40E-05 Calcium levels DIRC3 intron pha003085 rs2373146 chr2 218638176 T C 7.22E-04 Insulin resistance / / 21901158 rs11676172 chr2 218647122 T C 1.18E-04 Coronary heart disease / / 21606135 rs768921 chr2 218663979 G A 9.88E-05 Glucose levels / / pha003058 rs768921 chr2 218663979 G A 2.99E-05 Diabetes Mellitus / / pha003060 rs76043829 chr2 218677586 G A 6.00E-07 Asthma and hay fever TNS1 intron 24388013 rs2571445 chr2 218683154 A G 1.00E-12 Pulmonary function TNS1 missense 20010834 rs2571445 chr2 218683154 A G 0.0000339 Coronary artery disease TNS1 missense 23202125 rs2571445 chr2 218683154 A G 8.00E-09 Pulmonary function (interaction) TNS1 missense 23284291 rs2571445 chr2 218683154 A G 3.38E-04 Heart Failure TNS1 missense pha002885 rs11897815 chr2 218690487 T C 8.26E-04 Coronary Artery Disease TNS1 intron 17634449 rs2571440 chr2 218695686 T C 7.59E-05 Blood Pressure TNS1 intron pha003039 rs11677276 chr2 218696949 G A 3.97E-04 Blood pressure (response to calcium channel blocker) TNS1 intron 24192120 rs2059409 chr2 218720042 C T 1.08E-04 Age-related macular degeneration TNS1 intron 22125219 rs3791966 chr2 218720268 G A 2.73E-04 Age-related macular degeneration TNS1 intron 22125219 rs3791950 chr2 218729865 C A 2.00E-06 Height TNS1 intron 21998595 rs1863133 chr2 218732208 T C 4.90E-06 Height TNS1 intron 21998595 rs2042542 chr2 218736292 A G 9.25E-05 HIV-1 viral setpoint TNS1 intron 22174851 rs1424916 chr2 218739300 T C 2.60E-05 Height TNS1 intron 21998595 rs11898107 chr2 218744803 C T 3.61E-04 Multiple complex diseases TNS1 intron 17554300 rs7421896 chr2 218745862 A G 3.59E-05 Age-related macular degeneration TNS1 intron 22125219 rs10174633 chr2 218754326 T C 1.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TNS1 intron 23648065 rs16858462 chr2 218783532 G C 1.36E-04 Multiple complex diseases TNS1 intron 17554300 rs3791919 chr2 218783751 A G 8.10E-06 Urinary metabolites TNS1 intron 21572414 rs16858496 chr2 218824450 G A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs11892423 chr2 218824573 C T 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11904083 chr2 218824711 A G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs16858509 chr2 218825607 G C 1.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11688938 chr2 218827778 G A 3.07E-04 Multiple complex diseases / / 17554300 rs16858515 chr2 218828035 G T 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs881745 chr2 218846455 C G 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs934039 chr2 218853391 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1001098 chr2 218862241 C T 7.33E-04 Alcohol dependence / / 20201924 rs6712327 chr2 218864319 T C 2.75E-04 Multiple complex diseases / / 17554300 rs13389420 chr2 218866036 T C 9.73E-04 Multiple complex diseases / / 17554300 rs934036 chr2 218869388 A G 6.23E-05 Major depressive disorder (broad) / / 20038947 rs876961 chr2 218880952 A G 9.06E-05 Soluble levels of adhesion molecules / / pha003072 rs7580997 chr2 218883186 C T 1.24E-05 Colorectal cancer / / 21242260 rs1427667 chr2 218894127 C T 7.57E-07 Colorectal cancer / / 21242260 rs4672870 chr2 218941916 C T 6.57E-05 Colorectal cancer RUFY4 intron 23266556 rs12694425 chr2 218942313 C T 6.58E-05 Colorectal cancer RUFY4 intron 23266556 rs12694426 chr2 218942351 T G 6.67E-05 Colorectal cancer RUFY4 intron 23266556 rs6436025 chr2 218942848 G A 6.59E-05 Attention deficit hyperactivity disorder RUFY4 intron 22420046 rs10932745 chr2 218942976 T C 4.94E-05 Colorectal cancer RUFY4 intron 23266556 rs11687200 chr2 218944615 A G 5.60E-05 Colorectal cancer RUFY4 intron 23266556 rs11676275 chr2 218944808 G A 5.07E-05 Colorectal cancer RUFY4 intron 23266556 rs12694427 chr2 218945045 G A 5.43E-05 Colorectal cancer RUFY4 intron 23266556 rs6737563 chr2 218945674 T C 6.75E-04 Acute lung injury RUFY4 intron 22295056 rs6737563 chr2 218945674 T C 1.04E-05 Colorectal cancer RUFY4 intron 23266556 rs13013361 chr2 218947515 A T 6.97E-04 Acute lung injury RUFY4 intron 22295056 rs13013361 chr2 218947515 A T 8.94E-06 Colorectal cancer RUFY4 intron 23266556 rs4133195 chr2 218951245 C T 4.68E-04 Acute lung injury RUFY4 intron 22295056 rs4133195 chr2 218951245 C T 6.47E-06 Colorectal cancer RUFY4 intron 23266556 rs6726126 chr2 218952233 G A 4.68E-04 Acute lung injury RUFY4 intron 22295056 rs6726126 chr2 218952233 G A 9.71E-06 Colorectal cancer RUFY4 intron 23266556 rs7422358 chr2 218952778 G A 7.42E-05 Colorectal cancer RUFY4 intron 23266556 rs10804264 chr2 218955809 T C 3.77E-05 Colorectal cancer / / 23266556 rs12694428 chr2 218958820 G A 1.91E-04 Colorectal cancer / / 23266556 rs13035513 chr2 218960680 C T 1.11E-05 Colorectal cancer / / 23266556 rs13007992 chr2 218964051 G T 5.87E-05 Colorectal cancer / / 23266556 rs7426289 chr2 218966315 C T 1.56E-05 Colorectal cancer / / 23266556 rs4674250 chr2 218977531 G A 2.93E-04 Colorectal cancer / / 23266556 rs6436032 chr2 218982862 T C 9.66E-05 Colorectal cancer / / 23266556 rs4674257 chr2 218988774 A G 1.14E-05 Colorectal cancer / / 23266556 rs4674258 chr2 218990586 C T 6.92E-05 Colorectal cancer CXCR2 intron 23266556 rs4674259 chr2 218991005 G A 1.12E-05 Colorectal cancer CXCR2 UTR-5 23266556 rs6761387 chr2 218996553 C T 3.06E-05 Blood Pressure CXCR2 intron pha002903 rs6723449 chr2 218997580 T C 1.03E-05 Colorectal cancer CXCR2 intron 23266556 rs1126579 chr2 219000734 T C 1.04E-05 Colorectal cancer CXCR2 UTR-3 23266556 rs1126580 chr2 219000966 G A 2.05E-04 Colorectal cancer CXCR2 UTR-3 23266556 rs4674261 chr2 219005009 G C 2.86E-04 Colorectal cancer / / 23266556 rs11677534 chr2 219007060 T C 8.49E-06 Colorectal cancer / / 23266556 rs13009946 chr2 219007752 T G 9.97E-06 Colorectal cancer / / 23266556 rs7594532 chr2 219008000 T C 1.19E-05 Colorectal cancer / / 23266556 rs7607437 chr2 219008392 A G 1.14E-05 Colorectal cancer / / 23266556 rs11676348 chr2 219010146 C T 1.00E-10 Ulcerative colitis / / 21297633 rs11676348 chr2 219010146 C T 7.35E-05 Colorectal cancer / / 23266556 rs11676348 chr2 219010146 C T 0.000000492 Primary sclerosing cholangitis / / 23603763 rs13027120 chr2 219020914 T C 1.06E-05 Colorectal cancer / / 23266556 rs16858717 chr2 219021226 C T 8.55E-05 Bipolar disorder,affective / / 20528957 rs1008563 chr2 219026888 G A 6.39E-04 Colorectal cancer / / 23266556 rs1008562 chr2 219026972 G C 1.82E-04 Colorectal cancer / / 23266556 rs3138060 chr2 219031500 G C 8.37E-05 Bipolar disorder,affective CXCR1 intron 20528957 rs16858856 chr2 219032781 T C 8.36E-04 Multiple complex diseases CXCR1 nearGene-5 17554300 rs4674267 chr2 219046437 T C 7.29E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs13397673 chr2 219047782 G A 8.42E-05 Insulin resistance / / 21901158 rs13026485 chr2 219057984 T C 6.91E-04 Multiple complex diseases / / 17554300 rs11695623 chr2 219068115 G A 3.92E-05 Attention deficit hyperactivity disorder / / 22420046 rs6720449 chr2 219080978 G A 5.73E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs13403276 chr2 219081297 T C 3.00E-06 Obesity-related traits / / 23251661 rs13403276 chr2 219081297 T C 7.00E-06 Obesity-related traits / / 23251661 rs6733051 chr2 219084533 C T 2.00E-06 Obesity-related traits ARPC2 intron 23251661 rs7605980 chr2 219100869 C G 1.40E-04 Multiple complex diseases ARPC2 intron 17554300 rs6436047 chr2 219108913 C A 8.96E-05 Multiple complex diseases ARPC2 intron 17554300 rs6436048 chr2 219109033 A G 1.50E-04 Multiple complex diseases ARPC2 intron 17554300 rs1079204 chr2 219130514 G A 2.00E-06 Smooth-surface caries AAMP intron 23470693 rs2382817 chr2 219151218 A C 4.00E-12 Inflammatory bowel disease PNKD intron 23128233 rs1017697 chr2 219170462 G A 5.22E-05 Coronary Artery Disease PNKD intron 17634449 rs1017698 chr2 219170525 G A 8.44E-04 Multiple complex diseases PNKD intron 17554300 rs2014615 chr2 219171191 T C 6.17E-04 Multiple complex diseases PNKD intron 17554300 rs10932775 chr2 219195799 G A 2.00E-04 Information processing speed PNKD intron 21130836 rs11899020 chr2 219235224 C T 4.03E-04 Insulin resistance / / 21901158 rs11904786 chr2 219238738 G A 3.01E-04 Insulin resistance / / 21901158 rs3731863 chr2 219252208 C T 6.56E-04 Schizophrenia SLC11A1 intron 19197363 rs7580808 chr2 219271804 A C 5.16E-05 Multiple complex diseases / / 17554300 rs7607369 chr2 219279097 A G 6.08E-05 Hepatitis B vaccine response / / 21764829 rs7607369 chr2 219279097 A G 7.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs6717434 chr2 219288137 A G 1.41E-09 Triglycerides VIL1 intron 23063622 rs6720403 chr2 219294258 A C 6.89E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs3821031 chr2 219295249 C T 6.96E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs17572485 chr2 219296545 G A 7.55E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs17572485 chr2 219296545 G A 6.43E-06 Kawasaki disease VIL1 intron 21221998 rs6726798 chr2 219300855 A C 2.07E-22 HDL cholesterol VIL1 intron 23063622 rs6726798 chr2 219300855 A C 6.14E-14 Triglycerides VIL1 intron 23063622 rs1000879 chr2 219304130 G A 0.00000121 LDL cholesterol VIL1 intron 23063622 rs1000879 chr2 219304130 G A 2.04E-23 HDL cholesterol VIL1 intron 23063622 rs1000879 chr2 219304130 G A 5.41E-15 Triglycerides VIL1 intron 23063622 rs4674308 chr2 219310483 A C 7.40E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs3755042 chr2 219317248 T C 7.44E-04 Suicide attempts in bipolar disorder USP37 UTR-3 21041247 rs7601872 chr2 219319885 C G 7.45E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10189064 chr2 219327500 G A 1.01E-08 Corneal structure USP37 intron 23291589 rs664514 chr2 219329819 A G 7.34E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10200507 chr2 219335944 C A 7.49E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs3845835 chr2 219342284 T C 7.51E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7571743 chr2 219352572 C T 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10932782 chr2 219353195 C T 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs6710383 chr2 219359685 T G 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs634590 chr2 219372768 C A 6.11E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs636723 chr2 219373197 A G 7.55E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs662250 chr2 219374117 T A 7.56E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs6717433 chr2 219375711 G C 7.56E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs599973 chr2 219387273 C G 7.60E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7603816 chr2 219396255 C T 7.44E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs687747 chr2 219399627 T C 7.62E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs578450 chr2 219401237 C T 8.50E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs523305 chr2 219402691 T C 7.64E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7583449 chr2 219403022 A C 7.64E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs630858 chr2 219409689 C A 7.65E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs12619347 chr2 219419935 T C 7.66E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs4674314 chr2 219423520 T C 7.20E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs576901 chr2 219424364 A G 7.68E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs490483 chr2 219429052 A T 7.71E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs496674 chr2 219432569 G A 7.75E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs526897 chr2 219433597 G A 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs523937 chr2 219437596 G C 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs647990 chr2 219441428 T C 8.40E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs3755041 chr2 219442499 A T 7.84E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs562510 chr2 219443001 A C 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs3770216 chr2 219443717 A G 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs585185 chr2 219457741 G A 6.12E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs620596 chr2 219462419 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs832798 chr2 219464810 G A 6.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs611203 chr2 219472325 G A 1.20E-04 Height / / 21194676 rs611203 chr2 219472325 G A 1.20E-05 Height / / 21194676 rs611203 chr2 219472325 G A 5.80E-09 Height / / 21194676 rs3731867 chr2 219472734 G A 6.12E-04 Suicide attempts in bipolar disorder PLCD4 UTR-5 21041247 rs7574429 chr2 219498759 T G 6.07E-04 Suicide attempts in bipolar disorder PLCD4 intron 21041247 rs6710896 chr2 219500879 T C 9.02E-09 HDL cholesterol PLCD4 intron 23063622 rs3770213 chr2 219508372 A T 7.04E-04 Suicide attempts in bipolar disorder ZNF142 missense 21041247 rs3770214 chr2 219508988 T C 6.13E-04 Suicide attempts in bipolar disorder ZNF142 missense 21041247 rs10187066 chr2 219514759 A G 2.00E-07 Height ZNF142 intron 20881960 rs41272683 chr2 219530662 G A 0.00025 Prostate cancer (non-advanced prostate cancer) RNF25 missense 23555315 rs41272683 chr2 219530662 G A 0.00071 Prostate cancer RNF25 missense 23555315 rs2710246 chr2 219533894 T C 5.05E-04 Suicide attempts in bipolar disorder RNF25 intron 21041247 rs2241527 chr2 219537224 G A 4.10E-04 Suicide attempts in bipolar disorder STK36 intron 21041247 rs2241527 chr2 219537224 G A 1.27E-06 Statin-induced myopathy STK36 intron 21826682 rs7604319 chr2 219538799 A C 3.83E-04 Suicide attempts in bipolar disorder STK36 intron 21041247 rs2303565 chr2 219545309 T C 6.00E-07 Amyotrophic lateral sclerosis STK36 intron 22959728 rs1863704 chr2 219562675 G A 3.01E-04 Suicide attempts in bipolar disorder STK36 missense 21041247 rs10178538 chr2 219615968 T C 1.57E-06 Corneal structure TTLL4 intron 23291589 rs7603709 chr2 219642601 G A 0.0000735 Triglycerides / / 23063622 rs4674338 chr2 219647487 G A 2.60E-05 Urinary metabolites CYP27A1 intron 21572414 rs17470271 chr2 219651995 A T 2.00E-05 Urinary metabolites CYP27A1 intron 21572414 rs691960 chr2 219674004 G T 1.17E-15 HDL cholesterol CYP27A1 intron 23063622 rs691960 chr2 219674004 G T 6.88E-10 Triglycerides CYP27A1 intron 23063622 rs9973579 chr2 219697061 G C 9.29E-06 Age-related macular degeneration PRKAG3 nearGene-5 pha000001 rs10197074 chr2 219706535 C T 1.70E-05 Height / / 21998595 rs11695967 chr2 219721190 C T 7.30E-06 Urinary metabolites / / 21572414 rs10193725 chr2 219726498 T C 7.90E-06 Urinary metabolites WNT6 intron 21572414 rs6754599 chr2 219732142 C G 3.60E-04 Type 2 diabetes WNT6 intron 17463246 rs10177996 chr2 219746561 T C 3.55E-09 Common traits (Other) WNT10A intron 20585627 rs7349332 chr2 219756383 C T 1.00E-06 Hair morphology WNT10A intron 19896111 rs7349332 chr2 219756383 C T 3.00E-14 Common traits (Other) WNT10A intron 20585627 rs4674347 chr2 219759079 C G 8.48E-06 Hair morphology WNT10A nearGene-3 19896111 rs6723140 chr2 219774700 T C 1.62E-09 Common traits (Other) / / 20585627 rs6723140 chr2 219774700 T C 4.01E-05 Heart Rate / / pha003054 rs4672907 chr2 219821169 G A 5.75E-09 Common traits (Other) / / 20585627 rs359983 chr2 219823497 G A 0.0000423 Panic disorder / / 23149450 rs359983 chr2 219823497 G A 4.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs359980 chr2 219829206 T C 4.54E-04 Coronary Artery Disease / / 17634449 rs359980 chr2 219829206 T C 7.00E-06 Obesity-related traits / / 23251661 rs359965 chr2 219840891 G A 2.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs359965 chr2 219840891 G A 0.0000494 Panic disorder / / 23149450 rs359965 chr2 219840891 G A 4.94E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9967806 chr2 219878756 G A 8.69E-05 Amyotrophic lateral sclerosis (sporadic) CCDC108 missense 24529757 rs10932793 chr2 219896981 C A 9.06E-04 Type 2 diabetes CCDC108 intron 17463246 rs16859493 chr2 219898496 T C 7.81E-04 Type 2 diabetes CCDC108 UTR-3 17463246 rs6736922 chr2 219903258 T G 9.45E-04 Heart Failure CCDC108 missense pha002885 rs12470505 chr2 219908369 T G 9.00E-12 Height / / 20881960 rs1052483 chr2 219934348 G T 1.00E-06 Height / / 18391951 rs33967926 chr2 219936589 T C 4.22E-04 Multiple complex diseases / / 17554300 rs41398145 chr2 219943828 T A 9.50E-05 Multiple complex diseases NHEJ1 intron 17554300 rs6724465 chr2 219943846 G A 2.00E-08 Height NHEJ1 intron 18391952 rs7559667 chr2 219947184 A G 2.82E-04 Multiple complex diseases NHEJ1 intron 17554300 rs16859517 chr2 219949184 C T 5.00E-06 Height NHEJ1 intron 20189936 rs13419740 chr2 219969097 A G 3.83E-05 Multiple complex diseases NHEJ1 intron 17554300 rs6729662 chr2 219969798 G A 9.25E-04 Multiple complex diseases NHEJ1 intron 17554300 rs2272019 chr2 220002534 C A 3.52E-04 Multiple complex diseases NHEJ1 intron 17554300 rs6735637 chr2 220003241 T A 3.00E-04 Multiple complex diseases NHEJ1 intron 17554300 rs6761113 chr2 220006172 A G 5.58E-04 Multiple complex diseases NHEJ1 intron 17554300 rs10168553 chr2 220007414 C T 2.77E-04 Multiple complex diseases NHEJ1 intron 17554300 rs17655123 chr2 220037444 G A,C,T 1.29E-04 Amyotrophic lateral sclerosis (sporadic) CNPPD1 missense 24529757 rs73074979 chr2 220038094 G A 0.000037 Breast cancer(er negative) CNPPD1 missense 23555315 rs1127101 chr2 220040330 A G 1.57E-04 Multiple complex diseases CNPPD1 cds-synon 17554300 rs2293072 chr2 220045454 G A 4.57E-06 White blood cell count FAM134A cds-synon 21738479 rs2385394 chr2 220049290 C T 1.93E-04 Fibrinogen FAM134A UTR-3 17255346 rs2385394 chr2 220049290 C T 3.23E-04 Multiple complex diseases FAM134A UTR-3 17554300 rs6710315 chr2 220137991 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6728330 chr2 220218007 A G 2.48E-04 Multiple complex diseases / / 17554300 rs6757398 chr2 220218199 G A 2.76E-04 Multiple complex diseases / / 17554300 rs7586419 chr2 220220503 A G 1.87E-29 Narcolepsy / / 19629137 rs6717249 chr2 220243295 G A 2.00E-05 Urinary metabolites DNPEP intron 21572414 rs1132736 chr2 220250800 C T 2.27E-04 Smoking initiation DNPEP cds-synon 24665060 rs1512692 chr2 220267327 C A 8.10E-05 Height / / 21998595 rs1512693 chr2 220267512 T C 1.40E-04 Height / / 21998595 rs12466021 chr2 220268765 G A 2.90E-04 Height / / 21998595 rs4674397 chr2 220302549 C T 1.58E-04 Heart rate SPEG intron 23583979 rs748515 chr2 220311039 C A 8.89E-05 stroke (ischemic) SPEG intron 17434096 rs753974 chr2 220441067 C T 2.87E-04 Multiple complex diseases / / 17554300 rs659266 chr2 220512823 C T 2.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs628917 chr2 220521602 G T 2.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13416781 chr2 220523837 T A 8.25E-05 Multiple complex diseases / / 17554300 rs661039 chr2 220526923 A G 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4674417 chr2 220535148 G A 1.04E-05 Reading and spelling / / 23738518 rs639259 chr2 220556378 A G 2.06E-05 Reading and spelling / / 23738518 rs682699 chr2 220564839 C T 2.12E-05 Reading and spelling / / 23738518 rs605017 chr2 220566980 C T 2.12E-05 Reading and spelling / / 23738518 rs2891824 chr2 220569420 C T 6.14E-04 Multiple complex diseases / / 17554300 rs471443 chr2 220570313 G A 2.12E-05 Reading and spelling / / 23738518 rs539166 chr2 220575527 C T 2.02E-05 Reading and spelling / / 23738518 rs645999 chr2 220575854 A G 2.02E-05 Reading and spelling / / 23738518 rs674301 chr2 220577576 T C 2.02E-05 Reading and spelling / / 23738518 rs11901529 chr2 220590182 G A 2.18E-04 Multiple complex diseases / / 17554300 rs7569439 chr2 220590633 T C 2.52E-05 Reading and spelling / / 23738518 rs16860222 chr2 220592494 A G 1.20E-05 Urinary metabolites / / 21572414 rs1425029 chr2 220594539 C T 3.08E-04 Multiple complex diseases / / 17554300 rs6414197 chr2 220598195 G C 2.48E-05 Reading and spelling / / 23738518 rs6436163 chr2 220603899 C T 1.51E-05 Orofacial clefts / / 22863734 rs13389204 chr2 220606009 T A 3.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4674424 chr2 220607936 A G 1.18E-04 Amyotrophic lateral sclerosis / / 20801718 rs1477511 chr2 220621838 T G 7.42E-05 Telomere length / / 21573004 rs4674431 chr2 220632013 G A 9.73E-05 Amyotrophic lateral sclerosis / / 20801718 rs12464951 chr2 220632540 A T 2.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1035680 chr2 220634509 C T 1.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12476246 chr2 220635070 C T 1.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1364701 chr2 220657836 C T 8.33E-05 Orofacial clefts / / 22863734 rs982693 chr2 220659638 T G 6.54E-05 Orofacial clefts / / 22863734 rs1549380 chr2 220667582 G A 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs958548 chr2 220667880 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs719325 chr2 220667933 C T 5.00E-05 Orofacial clefts / / 22863734 rs1549379 chr2 220668099 T G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs3815854 chr2 220668738 C T 2.87E-05 Cleft lip / / 20436469 rs3815854 chr2 220668738 C T 7.00E-06 Orofacial clefts / / 22863734 rs2113855 chr2 220672168 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10932827 chr2 220675717 T G 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2385619 chr2 220677432 G A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7595045 chr2 220677682 T C 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7595519 chr2 220678105 T G 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2162017 chr2 220686765 A G 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674451 chr2 220687535 C T 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs890087 chr2 220689022 G A 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs992871 chr2 220689584 C T 1.29E-05 Orofacial clefts / / 22863734 rs10932828 chr2 220691684 A G 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674452 chr2 220694084 A T 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs6719949 chr2 220696298 T C 1.20E-05 Urinary metabolites / / 21572414 rs6719949 chr2 220696298 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11686815 chr2 220697170 C G 4.30E-05 Bilirubin levels / / 19414484 rs11686846 chr2 220697212 C T 3.50E-05 Bilirubin levels / / 19414484 rs11688142 chr2 220697602 C T 3.50E-05 Bilirubin levels / / 19414484 rs10498070 chr2 220698125 A C 2.00E-07 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4439946 chr2 220700665 A G 3.20E-05 Bilirubin levels / / 19414484 rs13000695 chr2 220703292 C A 2.06E-04 Alzheimer's disease (late onset) / / 21379329 rs2253615 chr2 220768879 C A 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2253615 chr2 220768879 C A 1.82E-04 Sudden cardiac arrest / / 21658281 rs7587562 chr2 220772757 A G 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804284 chr2 220773549 G T 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs750764 chr2 220781006 C T 2.34E-05 Pulmonary function in asthmatics / / 23541324 rs4672960 chr2 220783322 C T 7.45E-06 Triglycerides / / pha002904 rs731412 chr2 220789370 C T 1.30E-05 Urinary metabolites / / 21572414 rs1007684 chr2 220790637 A G 2.52E-05 Pulmonary function in asthmatics / / 23541324 rs7584117 chr2 220830207 T G 2.71E-05 Coronary heart disease / / pha003031 rs7584117 chr2 220830207 T G 6.82E-05 Coronary heart disease / / pha003033 rs10221578 chr2 220833222 G A 4.68E-06 Coronary heart disease / / pha003031 rs7608541 chr2 220848941 G A 3.89E-05 Multiple sclerosis (age of onset) / / 19010793 rs13414052 chr2 220851174 G A 2.15E-05 Triglycerides / / pha002904 rs17290560 chr2 220862496 C G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10198756 chr2 220864654 A C 3.00E-06 IgG glycosylation / / 23382691 rs2664226 chr2 220873544 A G 2.96E-04 Height / / 17255346 rs965203 chr2 220876652 T G 9.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11690874 chr2 220877631 C T 6.64E-05 Personality dimensions / / 18957941 rs1991107 chr2 220903603 C A 1.65E-04 Height / / 17255346 rs2971617 chr2 220919581 A G 9.60E-06 Coffee consumption / / 21357676 rs2911653 chr2 220921082 A C 1.17E-04 Cognitive function / / 24684796 rs17226763 chr2 220921801 C T 8.94E-05 Serum metabolites / / 19043545 rs4674493 chr2 220926429 C T 9.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2911657 chr2 220937247 A G 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs6728048 chr2 220971641 G A 2.20E-05 Urinary metabolites / / 21572414 rs13383613 chr2 220978325 T C 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs3935261 chr2 220981041 G T 6.78E-05 Schizophrenia / / pha002859 rs4073777 chr2 220997227 G A 5.93E-04 Smoking quantity / / 24665060 rs12614221 chr2 221000018 G T 3.42E-05 Major depressive disorder / / 22472876 rs12614221 chr2 221000018 G T 3.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10932834 chr2 221003489 C G 6.30E-04 Smoking quantity / / 24665060 rs7577412 chr2 221031183 G A 1.41E-04 Multiple complex diseases / / 17554300 rs4572586 chr2 221035381 G A 1.93E-04 Multiple complex diseases / / 17554300 rs4517963 chr2 221062914 A G 4.75E-04 Multiple complex diseases / / 17554300 rs6714889 chr2 221062958 G A 6.29E-04 Multiple complex diseases / / 17554300 rs4430944 chr2 221063063 T C 4.76E-04 Multiple complex diseases / / 17554300 rs6718891 chr2 221063851 G A 3.81E-04 Multiple complex diseases / / 17554300 rs10932840 chr2 221064094 T C 3.57E-04 Multiple complex diseases / / 17554300 rs10932841 chr2 221064147 A G 7.03E-04 Multiple complex diseases / / 17554300 rs6436191 chr2 221065795 T G 4.25E-04 Multiple complex diseases / / 17554300 rs7594438 chr2 221075841 C T 7.55E-04 Multiple complex diseases / / 17554300 rs4340499 chr2 221077011 C G 2.97E-04 Multiple complex diseases / / 17554300 rs17610108 chr2 221080067 A C 4.10E-04 Fibrinogen / / 17255346 rs17610130 chr2 221081421 T C 7.78E-05 Fibrinogen / / 17255346 rs17610130 chr2 221081421 T C 1.46E-06 Glucose levels / / pha003061 rs10498072 chr2 221094454 T C 2.50E-05 Urinary metabolites / / 21572414 rs1466241 chr2 221103085 G A 1.96E-04 Multiple complex diseases / / 17554300 rs17656411 chr2 221109732 C T 2.50E-05 Urinary metabolites / / 21572414 rs1551385 chr2 221110435 G A 1.50E-05 Urinary metabolites / / 21572414 rs1993313 chr2 221110780 T G 6.50E-06 Urinary metabolites / / 21572414 rs17472512 chr2 221112306 G A 1.13E-04 Fibrinogen / / 17255346 rs17472512 chr2 221112306 G A 2.65E-07 Glucose levels / / pha003061 rs10498073 chr2 221124116 C T 5.06E-04 Multiple complex diseases / / 17554300 rs16860976 chr2 221125397 G A 9.60E-04 Multiple complex diseases / / 17554300 rs2034755 chr2 221139346 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17656530 chr2 221139537 G A 1.55E-04 Multiple complex diseases / / 17554300 rs17610425 chr2 221140247 C T 7.40E-06 Urinary metabolites / / 21572414 rs10804287 chr2 221146465 G A 3.64E-05 Breast cancer / / pha002853 rs17610460 chr2 221148833 A G 1.60E-06 Urinary metabolites / / 21572414 rs6757239 chr2 221149105 G A 1.50E-06 Urinary metabolites / / 21572414 rs12468264 chr2 221166863 G A 5.50E-06 Urinary metabolites / / 21572414 rs4674516 chr2 221166925 T G 8.70E-04 Multiple complex diseases / / 17554300 rs10498076 chr2 221172135 A G 5.50E-06 Urinary metabolites / / 21572414 rs6757742 chr2 221179591 G A 1.20E-05 Urinary metabolites / / 21572414 rs6414198 chr2 221181167 T C 1.20E-05 Urinary metabolites / / 21572414 rs17657062 chr2 221183617 C A 1.60E-05 Urinary metabolites / / 21572414 rs897144 chr2 221186275 C A 2.13E-04 Breast cancer / / pha002853 rs1454552 chr2 221187549 C T 3.15E-05 Statin-induced myopathy / / 21826682 rs724158 chr2 221187667 G A 4.30E-06 Urinary metabolites / / 21572414 rs4672976 chr2 221189253 C T 1.20E-05 Urinary metabolites / / 21572414 rs12477337 chr2 221200915 G C 8.10E-06 Urinary metabolites / / 21572414 rs897141 chr2 221212147 G A 4.84E-04 Cognition,early reading ability / / 17684495 rs1378013 chr2 221221043 C T 3.50E-06 Urinary metabolites / / 21572414 rs897138 chr2 221229692 G C 2.50E-06 Urinary metabolites / / 21572414 rs6741459 chr2 221229840 G A 1.00E-05 Urinary metabolites / / 21572414 rs10498077 chr2 221238914 T C 2.75E-20 Varicose Veins / / pha001412 rs10180439 chr2 221307881 G A 5.34E-04 Type 2 diabetes / / 17463246 rs4362550 chr2 221312732 G A 3.52E-04 Type 2 diabetes / / 17463246 rs7592124 chr2 221326873 T C 6.81E-04 Multiple complex diseases / / 17554300 rs4350737 chr2 221327051 G A 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4350737 chr2 221327051 G A 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12613270 chr2 221329785 G A 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1922772 chr2 221364518 C T 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1955401 chr2 221400478 G T 4.55E-04 Taste perception / / 22132133 rs4674541 chr2 221412389 G A 1.41E-04 Taste perception / / 22132133 rs2708144 chr2 221440560 T C 3.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1796432 chr2 221447084 C T 6.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12613990 chr2 221454349 A C 6.07E-04 Obesity (extreme) / / 21935397 rs1796427 chr2 221457064 G C 3.87E-04 Type 2 diabetes / / 17463246 rs10932873 chr2 221457624 T C 5.55E-04 Obesity (extreme) / / 21935397 rs1850490 chr2 221458773 A T 5.42E-04 Obesity (extreme) / / 21935397 rs6716476 chr2 221460840 T C 9.56E-04 Obesity (extreme) / / 21935397 rs6730649 chr2 221461430 A G 5.18E-04 Obesity (extreme) / / 21935397 rs1517441 chr2 221461957 T A 9.10E-04 Obesity (extreme) / / 21935397 rs1589097 chr2 221464470 C G 8.80E-04 Obesity (extreme) / / 21935397 rs1589098 chr2 221464504 C T 8.72E-04 Obesity (extreme) / / 21935397 rs1607212 chr2 221464710 A C 8.48E-04 Obesity (extreme) / / 21935397 rs1607213 chr2 221465057 A G 8.26E-04 Obesity (extreme) / / 21935397 rs10169304 chr2 221465182 C T 6.80E-04 Obesity (extreme) / / 21935397 rs12619185 chr2 221465555 A C 7.38E-04 Obesity (extreme) / / 21935397 rs1796433 chr2 221466813 T A 2.21E-04 Type 2 diabetes / / 17463246 rs1850492 chr2 221471181 C T 3.94E-04 Obesity (extreme) / / 21935397 rs1356397 chr2 221473858 T C 7.01E-04 Obesity (extreme) / / 21935397 rs2392718 chr2 221475085 G A 3.79E-04 Obesity (extreme) / / 21935397 rs1949415 chr2 221478093 A C 6.74E-04 Obesity (extreme) / / 21935397 rs10207622 chr2 221478235 T G 6.68E-04 Obesity (extreme) / / 21935397 rs7558221 chr2 221486767 G A 6.00E-04 Obesity (extreme) / / 21935397 rs6719602 chr2 221490435 G A 6.54E-04 Obesity (extreme) / / 21935397 rs1568179 chr2 221492759 A G 3.74E-04 Obesity (extreme) / / 21935397 rs12471834 chr2 221498729 A C 6.50E-04 Obesity (extreme) / / 21935397 rs13407859 chr2 221503828 A G 7.49E-04 Multiple complex diseases / / 17554300 rs11684111 chr2 221521161 G C 4.51E-04 Obesity (extreme) / / 21935397 rs11896343 chr2 221529878 A G 2.53E-04 Obesity (extreme) / / 21935397 rs11896343 chr2 221529878 A G 7.10E-04 Alzheimer's disease / / 22005930 rs7582123 chr2 221533933 C G 2.51E-04 Obesity (extreme) / / 21935397 rs7582123 chr2 221533933 C G 6.90E-04 Alzheimer's disease / / 22005930 rs10932878 chr2 221535030 C T 2.50E-04 Obesity (extreme) / / 21935397 rs10932878 chr2 221535030 C T 5.81E-04 Alzheimer's disease / / 22005930 rs10932879 chr2 221535247 T C 2.48E-04 Obesity (extreme) / / 21935397 rs10932879 chr2 221535247 T C 7.59E-04 Alzheimer's disease / / 22005930 rs7558655 chr2 221538442 T C 2.78E-04 Obesity (extreme) / / 21935397 rs7558655 chr2 221538442 T C 4.87E-04 Alzheimer's disease / / 22005930 rs1517449 chr2 221539821 A G 2.90E-04 Obesity (extreme) / / 21935397 rs7600191 chr2 221549153 C T 3.73E-05 Hypertension / / pha003041 rs7606753 chr2 221556078 G A 2.16E-04 Kawasaki disease / / 21326860 rs7606753 chr2 221556078 G A 3.22E-05 Alzheimer's disease / / 22005930 rs1517443 chr2 221559762 T C 6.00E-05 Alzheimer's disease / / 22005930 rs1517445 chr2 221560164 A G 4.24E-05 Alzheimer's disease / / 22005930 rs12694533 chr2 221570900 C T 2.80E-06 Urinary metabolites / / 21572414 rs2893610 chr2 221571162 A G 1.04E-04 Alzheimer's disease / / 22005930 rs17578449 chr2 221574105 T C 1.20E-04 Alzheimer's disease / / 22005930 rs11690540 chr2 221576490 T C 2.23E-05 Alzheimer's disease / / 22005930 rs12694534 chr2 221576851 G T 2.42E-05 Alzheimer's disease / / 22005930 rs6705773 chr2 221578398 T C 3.04E-05 Alzheimer's disease / / 22005930 rs1996407 chr2 221579238 G A 8.69E-05 Alzheimer's disease / / 22005930 rs7599725 chr2 221584571 G A 6.17E-05 Alzheimer's disease / / 22005930 rs12694536 chr2 221585681 C T 8.63E-05 Alzheimer's disease / / 22005930 rs6712787 chr2 221594497 C T 8.90E-05 Alzheimer's disease / / 22005930 rs16861701 chr2 221596539 G A 6.98E-04 Depression (quantitative trait) / / 20800221 rs13036102 chr2 221604489 C T 1.21E-04 Alzheimer's disease / / 22005930 rs6742961 chr2 221606739 C A 1.22E-04 Alzheimer's disease / / 22005930 rs6713453 chr2 221610016 T C 1.33E-04 Alzheimer's disease / / 22005930 rs12694545 chr2 221626806 G C 1.84E-04 Alzheimer's disease / / 22005930 rs11675742 chr2 221630579 G A 1.18E-04 Alzheimer's disease / / 22005930 rs10183570 chr2 221632617 A G 1.85E-04 Alzheimer's disease / / 22005930 rs17396049 chr2 221632812 G A 6.97E-05 Alzheimer's disease / / 22005930 rs1876832 chr2 221638280 C A 4.23E-04 Myopia (pathological) / / 21095009 rs16861747 chr2 221643240 G A 2.14E-05 Cognitive test performance / / 20125193 rs7598755 chr2 221648888 C T 8.81E-06 Kawasaki disease / / 22446961 rs10804291 chr2 221651555 C T 9.71E-05 Kawasaki disease / / 22446961 rs7562441 chr2 221654925 T C 6.39E-04 Alzheimer's disease / / 22005930 rs10205272 chr2 221678075 T C 4.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1463990 chr2 221704514 G A 2.28E-04 Longevity / / 22279548 rs2136492 chr2 221704949 A C 1.97E-05 Cognitive performance / / 19734545 rs10932886 chr2 221720088 G A 1.00E-06 Brain imaging / / 20100581 rs2444838 chr2 221724838 A G 5.97E-04 Multiple complex diseases / / 17554300 rs7568936 chr2 221731360 C T 9.46E-04 Type 2 diabetes / / 17463246 rs11885719 chr2 221736049 C G 4.95E-04 Multiple complex diseases / / 17554300 rs17398519 chr2 221744435 A G 5.64E-04 Multiple complex diseases / / 17554300 rs830747 chr2 221762952 G A 1.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs17339993 chr2 221773296 A G 1.60E-04 Multiple complex diseases / / 17554300 rs749635 chr2 221786860 A C 2.79E-04 Alzheimer's disease / / 24755620 rs630054 chr2 221788172 T C 2.33E-05 Glycosylated haemoglobin levels / / 17255346 rs582085 chr2 221792364 T C 4.77E-05 Glycosylated haemoglobin levels / / 17255346 rs666274 chr2 221794326 G A 2.87E-04 Alzheimer's disease / / 24755620 rs630592 chr2 221794898 G C 7.64E-05 Glycosylated haemoglobin levels / / 17255346 rs11682003 chr2 221820913 A G 9.87E-04 Type 2 diabetes / / 17463246 rs7579067 chr2 221847734 T G 1.66E-05 Schizophrenia / / 19197363 rs897124 chr2 221862562 C T 8.95E-04 Schizophrenia / / 19197363 rs11678670 chr2 221882584 T C 2.97E-04 Smoking initiation / / 24665060 rs10498091 chr2 221899444 C T 6.00E-06 Echocardiographic traits / / 17903301 rs9808155 chr2 221927852 G T 3.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10804294 chr2 221928569 G A 2.20E-06 Schizophrenia / / 21795503 rs1991966 chr2 221938126 T C 8.49E-06 Schizophrenia / / 21795503 rs7581869 chr2 221950948 A T 1.72E-05 Personality dimensions / / 22628180 rs143917964 chr2 221951747 G A 9.78E-06 Contrast sensitivity / / 24152035 rs10498101 chr2 221954500 A G 9.70E-06 Contrast sensitivity / / 24152035 rs16862154 chr2 221954950 G A 1.41E-05 Orofacial clefts / / 22419666 rs17412073 chr2 221962096 G A 9.73E-06 Contrast sensitivity / / 24152035 rs6709919 chr2 221964881 A C 8.34E-06 Contrast sensitivity / / 24152035 rs7604236 chr2 221987040 A G 4.19E-04 Smoking initiation / / 24665060 rs4536641 chr2 222013644 A G 2.34E-04 Smoking initiation / / 24665060 rs2019083 chr2 222027666 T C 8.11E-05 Colorectal cancer / / 19723657 rs12477147 chr2 222067150 T G 7.33E-05 Orofacial clefts / / 22863734 rs17348202 chr2 222072178 T C 1.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs13029409 chr2 222105363 A G 3.91E-05 Cholesterol / / pha003073 rs13029409 chr2 222105363 A G 3.76E-05 Cholesterol / / pha003078 rs1002827 chr2 222130384 A G 4.57E-05 Cholesterol / / pha003073 rs1002827 chr2 222130384 A G 4.14E-05 Cholesterol / / pha003078 rs982757 chr2 222153932 A G 3.06E-05 Triglycerides / / pha003080 rs10498105 chr2 222157677 G T 2.60E-04 White matter integrity / / 22425255 rs10188163 chr2 222166280 C G 8.19E-04 Type 2 diabetes / / 17463246 rs10188163 chr2 222166280 C G 6.63E-04 Multiple complex diseases / / 17554300 rs1430246 chr2 222178867 A G 2.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs1346801 chr2 222180661 A G 6.91E-05 Cholesterol / / pha003073 rs1346800 chr2 222180677 G T 6.91E-05 Cholesterol / / pha003073 rs17431881 chr2 222193919 G C 1.75E-04 Attention deficit hyperactivity disorder / / pha002875 rs1897119 chr2 222208451 G C 5.05E-06 Stroke (ischemic) / / 22941190 rs1025369 chr2 222211083 T C 3.59E-05 Premature ovarian failure / / 19508998 rs1025369 chr2 222211083 T C 3.59E-05 Other erythrocyte phenotypes / / 19862010 rs4674596 chr2 222280806 C G 2.60E-04 Iris characteristics / / 21835309 rs3770205 chr2 222295760 C A 2.01E-04 Premature ovarian failure EPHA4 intron 19508998 rs1430216 chr2 222330970 T C 6.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) EPHA4 intron 23648065 rs10498114 chr2 222358909 A G 6.58E-04 Parkinson's disease EPHA4 intron 17052657 rs2710507 chr2 222380800 G A 5.62E-04 Smoking cessation EPHA4 intron 24665060 rs4302206 chr2 222394305 A G 1.44E-04 Smoking cessation EPHA4 intron 24665060 rs2250204 chr2 222400223 G A 1.78E-04 Smoking cessation EPHA4 intron 24665060 rs16862811 chr2 222401086 G T 2.65E-05 Type 2 diabetes EPHA4 intron 21647700 rs2680856 chr2 222410331 A C 4.62E-04 Smoking cessation EPHA4 intron 24665060 rs7340471 chr2 222432320 T C 2.20E-05 Urinary metabolites EPHA4 intron 21572414 rs2946558 chr2 222450800 A T 3.80E-04 Multiple complex diseases / / 17554300 rs2680837 chr2 222471516 A G 7.12E-04 Parkinson's disease / / 17052657 rs872217 chr2 222482917 A G 6.83E-04 Type 2 diabetes / / 17463246 rs13030635 chr2 222524442 G A 1.11E-04 Multiple complex diseases / / 17554300 rs10498121 chr2 222527540 G A 7.53E-04 Multiple complex diseases / / 17554300 rs12477986 chr2 222536261 A G 6.22E-04 Multiple complex diseases / / 17554300 rs1364387 chr2 222620133 G A 6.57E-04 Alzheimer's disease / / 17998437 rs2161765 chr2 222685565 A G 4.23E-06 Schizophrenia / / 21795503 rs4674616 chr2 222717778 C T 6.32E-05 HIV-1 viral setpoint / / 22174851 rs4099423 chr2 222766109 A G 7.04E-04 Multiple complex diseases / / 17554300 rs4099423 chr2 222766109 A G 9.01E-05 Insulin resistance / / 21901158 rs4085528 chr2 222771911 T C 8.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs824931 chr2 222801699 C T 3.00E-06 Body mass index / / 19851299 rs1834134 chr2 222857113 G A 2.25E-04 Type 2 diabetes / / 17463246 rs1559473 chr2 222881518 T G 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4673008 chr2 222883193 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs889837 chr2 222917491 T C 2.20E-05 Urinary metabolites / / 21572414 rs1007119 chr2 222922524 T G 9.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs348964 chr2 222933684 T C 4.63E-05 Lipoproteins / / pha003079 rs348967 chr2 222943096 T C 9.08E-04 Parkinson's disease / / 17052657 rs348970 chr2 222943945 C T 1.75E-05 Parkinson's disease / / 17052657 rs348970 chr2 222943945 C T 8.80E-05 Lipoproteins / / pha003079 rs348998 chr2 222950677 G A 4.95E-05 Lipoproteins / / pha003079 rs1424356 chr2 222957916 C T 5.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs349016 chr2 222962444 T C 1.36E-05 Lipoproteins / / pha003079 rs349020 chr2 222965299 G A 8.05E-05 Lipoproteins / / pha003079 rs9941713 chr2 222968278 C T 5.82E-04 Multiple complex diseases / / 17554300 rs2894449 chr2 222968617 C T 3.02E-05 Lipoproteins / / pha003079 rs4673012 chr2 222976013 C T 6.62E-05 Cognitive test performance / / 20125193 rs4674634 chr2 222977035 G A 7.34E-05 Cognitive test performance / / 20125193 rs4673013 chr2 222977078 C T 8.85E-05 Cognitive test performance / / 20125193 rs6757456 chr2 222986828 T C 2.75E-07 Facial morphology / / 22341974 rs16863422 chr2 222990015 A G 2.06E-08 Primary biliary cirrhosis / / 23000144 rs16863422 chr2 222990015 A G 2.06E-08 Facial morphology / / 23028347 rs11886961 chr2 222991918 C G 2.03E-07 Facial morphology / / 22341974 rs12694574 chr2 222993733 T C 2.55E-08 Primary biliary cirrhosis / / 23000144 rs12694574 chr2 222993733 T C 2.55E-08 Facial morphology / / 23028347 rs6749789 chr2 222994221 G A 1.88E-07 Facial morphology / / 22341974 rs2894450 chr2 222997104 G A 3.93E-07 Facial morphology / / 22341974 rs2894450 chr2 222997104 G A 1.55E-07 Primary biliary cirrhosis / / 23000144 rs2894450 chr2 222997104 G A 0.000000155 Facial morphology / / 23028347 rs10932943 chr2 223001061 G A 1.72E-07 Facial morphology / / 22341974 rs13385121 chr2 223002705 A G 1.62E-07 Facial morphology / / 22341974 rs974448 chr2 223005314 A G 1.57E-08 Primary biliary cirrhosis / / 23000144 rs974448 chr2 223005314 A G 1.56E-08 Facial morphology / / 23028347 rs7608778 chr2 223023579 T C 1.27E-07 Facial morphology / / 22341974 rs1370926 chr2 223030502 C G 1.88E-06 Biliary atresia / / 20460270 rs1370926 chr2 223030502 C G 1.40E-05 Urinary metabolites / / 21572414 rs1370926 chr2 223030502 C G 1.68E-09 Facial morphology / / 22341974 rs7607981 chr2 223032002 C T 1.24E-07 Facial morphology / / 22341974 rs986429 chr2 223032399 T A 1.65E-09 Facial morphology / / 22341974 rs986430 chr2 223032642 G T 1.65E-09 Facial morphology / / 22341974 rs10210971 chr2 223038895 C T 1.12E-07 Facial morphology / / 22341974 rs10176525 chr2 223039052 T A 1.37E-09 Facial morphology / / 22341974 rs10211404 chr2 223039180 G A 8.99E-08 Facial morphology / / 22341974 rs1438605 chr2 223043337 A G 1.80E-06 Urinary metabolites / / 21572414 rs1438605 chr2 223043337 A G 8.23E-08 Facial morphology / / 22341974 rs6730714 chr2 223049021 G A 9.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10169326 chr2 223051502 G A 3.59E-08 Facial morphology / / 22341974 rs11677206 chr2 223051983 C T 6.07E-10 Facial morphology / / 22341974 rs6728938 chr2 223053757 C T 3.38E-08 Facial morphology / / 22341974 rs10178871 chr2 223054001 G A 5.75E-10 Facial morphology / / 22341974 rs13023573 chr2 223055226 A C 4.86E-07 Facial morphology / / 22341974 rs10498131 chr2 223055805 G A 3.92E-07 Facial morphology / / 22341974 rs10208761 chr2 223055976 A C 3.92E-07 Facial morphology / / 22341974 rs10209141 chr2 223056368 A C 2.55E-10 Facial morphology / / 22341974 rs10209300 chr2 223056500 A G 1.07E-08 Facial morphology / / 22341974 rs6741414 chr2 223057138 C G 2.42E-10 Facial morphology / / 22341974 rs7597751 chr2 223058905 C T 9.81E-09 Facial morphology / / 22341974 rs1438607 chr2 223059951 A G 3.77E-07 Facial morphology / / 22341974 rs2855268 chr2 223066919 C G 8.77E-09 Facial morphology PAX3 intron 22341974 rs7559271 chr2 223068286 G A 4.00E-16 Facial morphology PAX3 intron 22341974 rs7588554 chr2 223074651 A G 3.72E-07 Facial morphology PAX3 intron 22341974 rs6730989 chr2 223079344 G A 8.05E-09 Facial morphology PAX3 intron 22341974 rs2578449 chr2 223080192 G A 8.07E-09 Facial morphology PAX3 intron 22341974 rs1978859 chr2 223082331 C T 3.61E-07 Primary biliary cirrhosis PAX3 intron 23000144 rs1978859 chr2 223082331 C T 0.000000361 Facial morphology PAX3 intron 23028347 rs2234675 chr2 223085955 G T 0.0001 Prostate cancer PAX3 missense 23555315 rs7590866 chr2 223087329 G A 1.11E-08 Facial morphology PAX3 intron 22341974 rs17401668 chr2 223089739 A G 1.40E-08 Facial morphology PAX3 intron 22341974 rs1013262 chr2 223090779 T G 4.67E-07 Facial morphology PAX3 intron 22341974 rs1549773 chr2 223095968 C T 1.71E-08 Facial morphology PAX3 intron 22341974 rs13410020 chr2 223102937 G A 1.22E-08 Facial morphology PAX3 intron 22341974 rs1430655 chr2 223103548 G A 3.57E-08 Facial morphology PAX3 intron 22341974 rs13388386 chr2 223104418 A G 9.08E-08 Facial morphology PAX3 intron 22341974 rs10498134 chr2 223104980 T C 3.27E-04 Tourette syndrome PAX3 intron 22889924 rs1367413 chr2 223106018 G T 3.16E-05 Asthma PAX3 intron pha003127 rs10932951 chr2 223131962 G C 8.31E-04 Multiple complex diseases PAX3 intron 17554300 rs10498137 chr2 223141438 C T 2.23E-05 Pulmonary function PAX3 intron 17903307 rs6436310 chr2 223167710 A G 7.60E-05 Asthma CCDC140 intron pha003128 rs1430666 chr2 223235543 C A 1.30E-05 Urinary metabolites / / 21572414 rs6716300 chr2 223246297 G A 2.60E-05 Urinary metabolites / / 21572414 rs1430654 chr2 223276366 T C 4.60E-05 Serum albumin level / / pha003084 rs7604173 chr2 223331920 C T 2.48E-04 Amyotrophic Lateral Sclerosis SGPP2 intron 17362836 rs735678 chr2 223339582 C A 9.50E-04 White matter integrity SGPP2 intron 22425255 rs17496827 chr2 223353446 A C 7.00E-06 Anorexia nervosa SGPP2 intron 23568457 rs1436786 chr2 223353778 T C 8.10E-05 Major depressive disorder SGPP2 intron 19107115 rs1436788 chr2 223411493 C T 7.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SGPP2 intron 20031582 rs1436788 chr2 223411493 C T 9.96E-06 Lymphocyte counts SGPP2 intron 22286170 rs11883877 chr2 223415918 C T 8.97E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs4674663 chr2 223416670 C G 6.15E-04 Type 2 diabetes SGPP2 intron 17463246 rs12614577 chr2 223419529 G C 6.32E-07 Personality dimensions SGPP2 intron 21173776 rs6751616 chr2 223422407 T G 2.61E-04 Type 2 diabetes SGPP2 intron 17463246 rs3754672 chr2 223422680 C T 7.19E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs5016700 chr2 223422720 C T 5.81E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs1347630 chr2 223427854 A G 3.32E-06 Cognitive test performance / / 20125193 rs11896566 chr2 223431383 T A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899318 chr2 223432967 T C 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7185 chr2 223436607 C T 5.25E-06 Cognitive test performance FARSB missense 20125193 rs3768976 chr2 223436860 A G 8.96E-05 Tunica Media FARSB intron pha003038 rs13030452 chr2 223474697 G A 6.27E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs2028953 chr2 223477160 A G 5.56E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs2028953 chr2 223477160 A G 2.18E-05 Tunica Media FARSB intron pha003038 rs13009500 chr2 223497633 T C 4.69E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs13410038 chr2 223499077 C T 5.22E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs921121 chr2 223505872 T C 5.32E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs1447111 chr2 223510142 A G 5.18E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs868392 chr2 223517259 C T 2.79E-05 Tunica Media FARSB intron pha003038 rs6740452 chr2 223518452 C T 1.16E-06 Personality dimensions FARSB intron 21173776 rs10180632 chr2 223526384 G A 1.03E-06 Personality dimensions / / 21173776 rs11684328 chr2 223528317 C A 1.60E-05 Cognitive test performance / / 20125193 rs4674677 chr2 223529658 G A 1.82E-06 Personality dimensions / / 21173776 rs10932966 chr2 223531739 C A 4.80E-07 Personality dimensions / / 21173776 rs1447108 chr2 223542231 A G 6.62E-06 Personality dimensions MOGAT1 intron 21173776 rs12614976 chr2 223542896 A T 6.71E-06 Personality dimensions MOGAT1 intron 21173776 rs11692810 chr2 223544096 C A 6.64E-06 Personality dimensions MOGAT1 intron 21173776 rs951997 chr2 223567016 A G 2.00E-05 Partial epilepsies MOGAT1 intron 20522523 rs951997 chr2 223567016 A G 4.53E-05 Epilepsy MOGAT1 intron 22116939 rs7562188 chr2 223588587 A G 3.92E-05 Fibrinogen / / 17255346 rs1374538 chr2 223600805 T C 3.52E-06 Fibrinogen / / 17255346 rs1374538 chr2 223600805 T C 4.20E-04 Myopia (pathological) / / 21095009 rs4312478 chr2 223616610 T C 5.01E-04 Multiple complex diseases / / 17554300 rs7589928 chr2 223655115 T C 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13408246 chr2 223664488 G A 9.32E-05 Bipolar disorder / / 19488044 rs1867802 chr2 223667882 G A 5.86E-05 Coronary heart disease / / pha003031 rs6436346 chr2 223674322 G A 2.90E-05 Adiposity / / 19461586 rs6718498 chr2 223677951 C G 4.58E-12 Multiple complex diseases / / 17554300 rs2053717 chr2 223715899 C T 3.41E-06 Coronary heart disease / / pha003031 rs795887 chr2 223758070 C T 5.69E-05 Leukocyte Counts ACSL3 intron pha003091 rs6722420 chr2 223766830 A G 7.81E-05 Leukocyte Counts ACSL3 intron pha003091 rs6756323 chr2 223785740 A G 2.49E-05 Coronary heart disease ACSL3 intron pha003031 rs6756107 chr2 223798501 G A 3.25E-06 Coronary heart disease ACSL3 intron pha003031 rs10932980 chr2 223802386 C G 9.29E-05 Serum metabolites ACSL3 intron 19043545 rs6734103 chr2 223805495 A G 2.49E-05 Coronary heart disease ACSL3 intron pha003031 rs10755042 chr2 223808401 A C 9.35E-05 Leukocyte Counts / / pha003091 rs4330101 chr2 223817023 A G 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2028383 chr2 223823132 T C 6.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1465882 chr2 223823654 G C 9.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13393781 chr2 223838190 G T 4.73E-04 Alzheimer's disease / / 22005930 rs6717772 chr2 223838450 G A 2.40E-05 Urinary metabolites / / 21572414 rs6717772 chr2 223838450 G A 9.55E-04 Alzheimer's disease / / 22005930 rs6717855 chr2 223838477 G A 9.53E-04 Alzheimer's disease / / 22005930 rs13022307 chr2 223839835 G A 7.81E-04 Alzheimer's disease / / 22005930 rs13013147 chr2 223843829 C A 7.41E-04 Alzheimer's disease / / 22005930 rs13025241 chr2 223849170 T C 5.95E-04 Alzheimer's disease / / 22005930 rs1440065 chr2 223849610 G A 1.58E-290 Multiple complex diseases / / 17554300 rs10498146 chr2 223852036 A G 7.41E-10 Schizophrenia / / 21795503 rs1440063 chr2 223852353 G A 0.00084912 Hypertension (early onset hypertension) / / 22479346 rs13033186 chr2 223852436 C T 6.58E-04 Depression (quantitative trait) / / 20800221 rs11687274 chr2 223854254 G T 6.50E-04 Depression (quantitative trait) / / 20800221 rs935028 chr2 223857554 A G 4.69E-04 Depression (quantitative trait) / / 20800221 rs1371647 chr2 223872737 G A 1.06E-05 Gallbladder cancer / / 22318345 rs1371647 chr2 223872737 G A 2.77E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs1961637 chr2 223905108 G T 2.23E-05 Serum metabolites / / 19043545 rs12621643 chr2 223917983 T G 3.00E-06 Acute lymphoblastic leukemia (childhood) KCNE4 missense 19684603 rs12621643 chr2 223917983 T G 3.00E-06 Nasopharyngeal carcinoma KCNE4 missense 20512145 rs9283536 chr2 223930506 C T 7.10E-04 Crohn's disease / / 17684544 rs1440072 chr2 223936738 C T 1.30E-04 Glycosylated haemoglobin levels / / 17255346 rs1440072 chr2 223936738 C T 4.00E-06 Body mass index / / 20966902 rs1440072 chr2 223936738 C T 8.00E-07 Waist circumference / / 20966902 rs960246 chr2 223937559 T G 1.00E-09 C-reactive protein and white blood cell count / / 22788528 rs12617270 chr2 223946634 G A 3.41E-04 Hemoglobin concentration / / 20534544 rs75419782 chr2 223946834 T C 4.17E-05 Acne (severe) / / 24927181 rs921190 chr2 223947404 G T 1.60E-04 Glycosylated haemoglobin levels / / 17255346 rs10200800 chr2 223952836 T C 1.42E-30 Narcolepsy / / 19629137 rs11884475 chr2 224006491 C T 4.05E-04 Obesity (extreme) / / 21935397 rs11894487 chr2 224010921 A T 3.21E-04 Obesity (extreme) / / 21935397 rs16864483 chr2 224012136 A G 3.20E-04 Obesity (extreme) / / 21935397 rs16864484 chr2 224012318 A C,G 3.20E-04 Obesity (extreme) / / 21935397 rs10202577 chr2 224015538 A G 7.00E-06 Urinary metabolites / / 21572414 rs1448310 chr2 224018296 T C 1.60E-05 Urinary metabolites / / 21572414 rs10432545 chr2 224018650 C T 4.94E-04 Multiple complex diseases / / 17554300 rs16864505 chr2 224018770 C T 8.26E-06 Fibrinogen / / 17255346 rs1448288 chr2 224021048 A G 5.60E-04 Multiple complex diseases / / 17554300 rs1448293 chr2 224021310 C A 1.60E-05 Urinary metabolites / / 21572414 rs11899732 chr2 224023217 T C 3.17E-04 Obesity (extreme) / / 21935397 rs895767 chr2 224023296 A C 7.00E-06 Cognitive decline (age-related) / / 24468470 rs6739367 chr2 224025078 A G 1.40E-05 Immunoglobulin A / / 20694011 rs12694596 chr2 224025984 C G 7.10E-05 Coffee consumption / / 21357676 rs10204910 chr2 224028510 G A 1.12E-06 Blood Pressure / / pha003039 rs10204910 chr2 224028510 G A 3.91E-05 Blood Pressure / / pha003045 rs11902770 chr2 224028633 C T 3.17E-04 Obesity (extreme) / / 21935397 rs10209741 chr2 224034735 G A 5.29E-04 Type 2 diabetes / / 17463246 rs6734400 chr2 224036411 C T 7.90E-04 Type 2 diabetes / / 17463246 rs2218665 chr2 224036759 G C 2.00E-05 Urinary metabolites / / 21572414 rs10172933 chr2 224038175 C A 3.63E-04 Type 2 diabetes / / 17463246 rs6713755 chr2 224038435 A C 0.0000317 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs1375084 chr2 224042628 C G 2.10E-05 Urinary metabolites / / 21572414 rs1597167 chr2 224044250 A G 3.69E-07 Asthma / / 21790008 rs6745131 chr2 224079263 C T 9.96E-04 Type 2 diabetes / / 17463246 rs1400796 chr2 224084303 C A 2.17E-04 Fibrinogen / / 17255346 rs4673054 chr2 224087862 A T 6.49E-04 Type 2 diabetes / / 17463246 rs2203733 chr2 224093101 A G 5.59E-04 Type 2 diabetes / / 17463246 rs10933000 chr2 224093410 G A 6.81E-04 Type 2 diabetes / / 17463246 rs969494 chr2 224095058 G A 4.01E-04 Type 2 diabetes / / 17463246 rs970816 chr2 224097340 G A 4.16E-04 Type 2 diabetes / / 17463246 rs1517650 chr2 224105676 A T 5.81E-04 Multiple complex diseases / / 17554300 rs2395967 chr2 224111323 T C 5.05E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10183888 chr2 224116596 G A 1.80E-05 Urinary metabolites / / 21572414 rs13424509 chr2 224151518 A G 4.20E-05 Response to statin therapy / / 20339536 rs13412714 chr2 224151579 T C 3.80E-05 Response to statin therapy / / 20339536 rs2090504 chr2 224164448 C T 3.60E-05 Response to statin therapy / / 20339536 rs6709028 chr2 224165404 G T 3.30E-05 Response to statin therapy / / 20339536 rs10168471 chr2 224167273 C G 3.60E-05 Response to statin therapy / / 20339536 rs13414858 chr2 224167716 A C 3.60E-05 Response to statin therapy / / 20339536 rs1517645 chr2 224172750 G C 7.20E-04 Type 2 diabetes / / 17846124 rs1517628 chr2 224175831 A G 4.96E-05 Coronary heart disease / / 21971053 rs1517635 chr2 224203115 T A 1.32E-05 Educational attainment / / 21694764 rs12151816 chr2 224204815 C T 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10176350 chr2 224214759 G A 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1517641 chr2 224227452 T C 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250915 chr2 224228758 T A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250920 chr2 224230626 G C 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs990296 chr2 224232297 G A 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs990297 chr2 224232396 C A 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250924 chr2 224232527 A G 8.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250939 chr2 224244634 A G 5.15E-04 Insulin resistance / / 21901158 rs6727591 chr2 224262876 A T 5.79E-04 Insulin resistance / / 21901158 rs16864755 chr2 224274622 G A 4.00E-06 Osteoporosis-related phenotypes / / 20200953 rs16864788 chr2 224300897 G A 5.77E-04 Depression (quantitative trait) / / 20800221 rs7601486 chr2 224344833 A G 9.54E-06 Obesity-related traits / / 23251661 rs2395987 chr2 224349558 C A 6.84E-04 Type 2 diabetes / / 17463246 rs755187 chr2 224350339 A G 5.00E-04 Type 2 diabetes / / 17463246 rs6731710 chr2 224351752 C T 7.28E-04 Type 2 diabetes / / 17463246 rs6436408 chr2 224352075 G C 3.62E-04 Type 2 diabetes / / 17463246 rs17230683 chr2 224406462 C T 1.83E-04 Gallstones / / 17632509 rs11675944 chr2 224408490 G T 0.000607 Salmonella-induced pyroptosis / / 22837397 rs10498152 chr2 224439486 A G 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16864968 chr2 224459683 A G 3.00E-06 Response to hepatitis C treatment / / 22095909 rs2230168 chr2 224462056 G A,C,T 1.49E-04 Stroke SCG2 UTR-3 pha002886 rs4673067 chr2 224472252 G A 1.17E-04 Hearing function / / 17255346 rs13402129 chr2 224473767 T G 4.01E-04 Schizophrenia / / 19197363 rs13402129 chr2 224473767 T G 8.56E-05 Erythrocyte counts / / pha003099 rs13385650 chr2 224508025 G A 8.00E-05 Cholesterol / / pha003073 rs7585595 chr2 224531242 A C,T 1.98E-04 Multiple complex diseases / / 17554300 rs734556 chr2 224561329 C T 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4674808 chr2 224562525 A G 2.59E-04 Multiple complex diseases / / 17554300 rs625588 chr2 224602647 T C 7.90E-06 Major depressive disorder / / 21042317 rs4673075 chr2 224610232 C T 8.00E-05 Prostate cancer / / 21743057 rs7603262 chr2 224636490 A C 9.55E-05 Blood Pressure AP1S3 intron pha003048 rs12623921 chr2 224637079 C T 9.55E-05 Blood Pressure AP1S3 intron pha003048 rs7604002 chr2 224658733 C A 1.20E-05 Urinary metabolites AP1S3 intron 21572414 rs603848 chr2 224679310 C T 6.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AP1S3 intron 21844884 rs16865241 chr2 224689660 C A 2.60E-05 Urinary metabolites AP1S3 intron 21572414 rs7558186 chr2 224696267 G T 6.50E-04 Glaucoma (primary open-angle) AP1S3 intron 22419738 rs625289 chr2 224731744 G A 3.32E-04 Myocardial Infarction / / pha002883 rs1438832 chr2 224811952 T C 4.69E-04 Smoking initiation / / 24665060 rs7608941 chr2 224854068 C A 2.81E-04 Multiple complex diseases SERPINE2 intron 17554300 rs6436459 chr2 224880336 C T 4.20E-05 Bone mineral density (BMD),in women SERPINE2 intron 20164292 rs6436459 chr2 224880336 C T 3.37E-05 Myopia (pathological) SERPINE2 intron 21095009 rs13022548 chr2 224884090 G C 8.59E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13013387 chr2 224886238 T C 7.13E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13008520 chr2 224889383 G A 7.02E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13027940 chr2 224895301 C T 8.65E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs6436462 chr2 224898155 C T 9.38E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13012418 chr2 224905555 G A 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs282265 chr2 224917560 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs13016241 chr2 224918221 G T 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6740660 chr2 224943685 G A 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs896899 chr2 224961762 T C 0.000504431 Hypertension (early onset hypertension) / / 22479346 rs6754790 chr2 224965458 A G 0.000582293 Hypertension (early onset hypertension) / / 22479346 rs12477352 chr2 224970482 T G 0.000790666 Hypertension (early onset hypertension) / / 22479346 rs6436465 chr2 224976957 A G 7.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2396057 chr2 224977216 G C 3.65E-04 Acute lung injury / / 22295056 rs958380 chr2 224999824 C T 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7607972 chr2 225005316 T C 8.30E-06 Urinary metabolites / / 21572414 rs4264554 chr2 225007071 T C 1.89E-05 Common variable immunodeficiency / / 21497890 rs13019329 chr2 225015584 T C 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13019329 chr2 225015584 T C 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13019329 chr2 225015584 T C 0.0002 Migraine / / 22678113 rs6436469 chr2 225017062 T C 9.07E-05 Epilepsy (remission after treatment) / / 23962720 rs1476205 chr2 225024332 G A 4.24E-04 Acute lung injury / / 22295056 rs1453672 chr2 225025120 A G 4.23E-04 Acute lung injury / / 22295056 rs6761041 chr2 225030129 T C 2.82E-04 Smoking initiation / / 24665060 rs2602675 chr2 225042531 T C 5.46E-04 Smoking initiation / / 24665060 rs2629046 chr2 225047744 T C 8.00E-12 Height / / 20881960 rs2602681 chr2 225070767 C T 5.96E-04 Smoking initiation / / 24665060 rs12477529 chr2 225084764 G A 9.54E-04 Multiple complex diseases / / 17554300 rs7578029 chr2 225122467 T A 4.71E-04 Multiple complex diseases / / 17554300 rs1008415 chr2 225151655 T C 9.44E-05 Cholesterol / / pha003083 rs6755111 chr2 225178583 C T 7.21E-05 Cholesterol / / pha003083 rs13024765 chr2 225180219 C T 8.11E-05 Cholesterol / / pha003083 rs2098533 chr2 225182419 T C 8.04E-05 Cholesterol / / pha003083 rs6708010 chr2 225186069 C T 2.88E-05 Cholesterol / / pha003083 rs2042086 chr2 225222900 T C 8.71E-06 Longevity,exceptional / / 20595579 rs16865908 chr2 225245151 A G 5.09E-04 Tourette syndrome FAM124B intron 22889924 rs2216460 chr2 225247487 C A 5.74E-04 Parkinson's disease FAM124B intron 17052657 rs741533 chr2 225260618 C T 2.21E-04 Myocardial Infarction FAM124B intron pha002883 rs4673104 chr2 225285539 C G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12694637 chr2 225300505 A G 7.16E-04 Multiple complex diseases / / 17554300 rs12328241 chr2 225302513 T C 6.70E-04 Multiple complex diseases / / 17554300 rs1642922 chr2 225305832 C T 5.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1523921 chr2 225308978 T C 2.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1523921 chr2 225308978 T C 5.95E-05 Anorexia nervosa / / 24514567 rs2710598 chr2 225309374 A G 1.14E-08 Metabolite levels / / 23281178 rs2462140 chr2 225310582 A G 1.14E-08 Metabolite levels / / 23281178 rs2462140 chr2 225310582 A G 4.72E-04 Myocardial Infarction / / pha002883 rs2710603 chr2 225311923 T C 3.00E-08 Metabolite levels / / 23281178 rs1721279 chr2 225314761 A G 1.14E-08 Metabolite levels / / 23281178 rs1721279 chr2 225314761 A G 4.91E-04 Myocardial Infarction / / pha002883 rs6436488 chr2 225317949 A G 1.11E-08 Metabolite levels / / 23281178 rs6733771 chr2 225318816 T G 1.11E-08 Metabolite levels / / 23281178 rs11901496 chr2 225320132 C T 1.24E-08 Metabolite levels / / 23281178 rs11677844 chr2 225323473 A T 1.11E-08 Metabolite levels / / 23281178 rs1568752 chr2 225324758 G C 1.92E-08 Metabolite levels / / 23281178 rs6436490 chr2 225326693 A C 1.11E-08 Metabolite levels / / 23281178 rs16865992 chr2 225327572 C T 1.20E-05 Urinary metabolites / / 21572414 rs16866061 chr2 225439844 A G 9.74E-04 Multiple complex diseases CUL3 intron 17554300 rs16866061 chr2 225439844 A G 8.70E-06 Serum metabolites CUL3 intron 19043545 rs10498164 chr2 225478729 C T 8.64E-04 Depression (quantitative trait) / / 20800221 rs16866105 chr2 225515527 T C 3.71E-04 Multiple complex diseases / / 17554300 rs397871951 chr2 225543748 TG T,TTG 3.12E-11 Metabolite levels / / 22286219 rs1843834 chr2 225558042 A G 4.00E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1843834 chr2 225558042 A G 9.31E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10197382 chr2 225574650 T C 5.72E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1565073 chr2 225634693 T G 6.52E-04 Multiple complex diseases DOCK10 intron 17554300 rs1565073 chr2 225634693 T G 3.31E-05 IgE levels in asthmatics (D.p. specific) DOCK10 intron 23967269 rs17271511 chr2 225643831 A G 2.40E-05 Urinary metabolites DOCK10 intron 21572414 rs6717059 chr2 225665193 C T 1.81E-05 Cognitive performance DOCK10 intron 19734545 rs6717059 chr2 225665193 C T 4.54E-05 IgE levels in asthmatics (D.p. specific) DOCK10 intron 23967269 rs4674941 chr2 225670901 G C 0.00029 Prostate cancer DOCK10 missense 23555315 rs13024433 chr2 225774612 A C 2.49E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs11694713 chr2 225787887 G A 2.85E-04 Lymphocyte counts DOCK10 intron 22286170 rs11686538 chr2 225818564 A G 1.27E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs4674953 chr2 225826811 T C 3.86E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs9967872 chr2 225845136 C G 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs4674958 chr2 225845489 C A 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs7566475 chr2 225847668 C A 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs281526 chr2 225853618 C T 1.42E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs4674964 chr2 225921137 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674965 chr2 225921569 C G 2.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7586721 chr2 225923843 C T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6721066 chr2 225927090 A G 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7598761 chr2 225927422 G A 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574966 chr2 225927736 A G 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs13418232 chr2 225928691 T C 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6748196 chr2 225931905 C T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6760820 chr2 225935261 C G 2.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741439 chr2 225952702 A G 3.53E-05 Bipolar disorder and schizophrenia / / 20889312 rs6717227 chr2 226013860 G A 5.05E-04 Hemoglobin concentration / / 20534544 rs728654 chr2 226030132 T G 5.05E-04 Hemoglobin concentration / / 20534544 rs3845841 chr2 226031280 T A 1.60E-05 Urinary metabolites / / 21572414 rs1443668 chr2 226032426 T C 7.73E-04 Multiple complex diseases / / 17554300 rs1443668 chr2 226032426 T C 1.50E-05 Urinary metabolites / / 21572414 rs1443667 chr2 226032555 T C 1.60E-05 Urinary metabolites / / 21572414 rs1596395 chr2 226035953 C T 1.30E-05 Urinary metabolites / / 21572414 rs10190539 chr2 226036157 C T 1.50E-05 Urinary metabolites / / 21572414 rs10165442 chr2 226038842 T C 1.30E-05 Urinary metabolites / / 21572414 rs13387555 chr2 226040421 T G 1.50E-05 Urinary metabolites / / 21572414 rs9288601 chr2 226045748 C A 8.44E-04 Multiple complex diseases / / 17554300 rs1348430 chr2 226047177 T C 1.30E-05 Urinary metabolites / / 21572414 rs1470328 chr2 226051978 A G 1.30E-05 Urinary metabolites / / 21572414 rs1348422 chr2 226067358 A G 7.98E-04 Alzheimer's disease / / 22005930 rs6736537 chr2 226082156 A G 8.49E-04 Alzheimer's disease / / 22005930 rs4674980 chr2 226112612 T C 7.74E-05 Serum metabolites / / 19043545 rs12694665 chr2 226148202 A G 3.75E-04 Multiple complex diseases / / 17554300 rs2044235 chr2 226157767 C A 2.70E-05 Urinary metabolites / / 21572414 rs2044236 chr2 226157800 C A 7.85E-05 Alzheimer's disease / / 17998437 rs6436551 chr2 226183487 G A 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4673141 chr2 226191730 G A 5.60E-06 Urinary metabolites / / 21572414 rs1473307 chr2 226225623 C T 3.00E-07 Menopause (age at onset) / / 23307926 rs1517484 chr2 226237910 C T 5.00E-07 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs9973944 chr2 226244129 T C 8.33E-04 Sarcoidosis / / 19165924 rs2030199 chr2 226261607 G A 2.82E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs11692499 chr2 226364402 A G 4.55E-05 Serum metabolites NYAP2 intron 19043545 rs11692499 chr2 226364402 A G 1.43E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs6706295 chr2 226364934 A C 5.87E-05 Serum metabolites NYAP2 intron 19043545 rs6706295 chr2 226364934 A C 2.05E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs6713607 chr2 226372129 A G 4.55E-05 Serum metabolites NYAP2 intron 19043545 rs6713607 chr2 226372129 A G 3.88E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs12466468 chr2 226382951 T C 8.05E-05 Serum metabolites NYAP2 intron 19043545 rs12466468 chr2 226382951 T C 1.11E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs11695839 chr2 226393981 G A 7.20E-05 Serum metabolites NYAP2 intron 19043545 rs12053018 chr2 226395276 A C,G,T 1.85E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs891585 chr2 226400416 A T 7.67E-05 Serum metabolites NYAP2 intron 19043545 rs891585 chr2 226400416 A T 3.26E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs1431082 chr2 226451269 T G 5.25E-05 Coronary heart disease NYAP2 intron 21971053 rs1993323 chr2 226456461 C A 2.89E-04 Alcohol dependence NYAP2 intron 20201924 rs1993323 chr2 226456461 C A 8.29E-05 Coronary heart disease NYAP2 intron 21971053 rs715678 chr2 226465409 T C 9.80E-05 Response to statin therapy NYAP2 intron 20339536 rs10498192 chr2 226482621 T A 7.91E-04 Type 2 diabetes NYAP2 intron 17463246 rs936070 chr2 226501136 G A 3.22E-04 Coronary heart disease NYAP2 intron 21971053 rs16866682 chr2 226504486 A C 7.00E-05 Schizophrenia NYAP2 intron 19571809 rs13400632 chr2 226504838 C T 3.84E-04 Multiple complex diseases NYAP2 intron 17554300 rs13407844 chr2 226506851 C A 3.50E-05 Response to statin therapy NYAP2 intron 20339536 rs12994235 chr2 226507838 G A 4.80E-04 Multiple complex diseases NYAP2 intron 17554300 rs12694674 chr2 226510293 G C 4.22E-04 Multiple complex diseases NYAP2 intron 17554300 rs12694674 chr2 226510293 G C 8.10E-05 Schizophrenia NYAP2 intron 19571809 rs7595617 chr2 226515698 A G 8.17E-04 Alcohol dependence NYAP2 intron 20201924 rs6736992 chr2 226538647 A G 1.42E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7558384 chr2 226568924 T C 7.75E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2017444 chr2 226596497 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs16866733 chr2 226749371 T C 4.34E-04 Multiple complex diseases / / 17554300 rs13018599 chr2 226902562 T G 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10168777 chr2 226914836 G C 9.38E-04 Multiple complex diseases / / 17554300 rs13393056 chr2 226921917 G C 9.51E-04 Multiple complex diseases / / 17554300 rs16866798 chr2 226922612 G A 9.20E-04 Multiple complex diseases / / 17554300 rs6436593 chr2 226939141 T A 9.99E-04 Multiple complex diseases / / 17554300 rs1949717 chr2 226951194 C G 2.78E-04 Multiple complex diseases / / 17554300 rs4675047 chr2 226957178 G A 3.35E-04 Multiple complex diseases / / 17554300 rs1522804 chr2 226989156 A C 4.04E-04 Multiple complex diseases / / 17554300 rs10498197 chr2 226993313 A G 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6758183 chr2 227000986 G A 3.00E-06 Corneal astigmatism / / 22144915 rs2948556 chr2 227009627 G A 1.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC646736 intron 20877124 rs2948560 chr2 227014062 A C 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC646736 intron 20877124 rs114455893 chr2 227018516 C T 0.00005295 Sarcoidosis LOC646736 intron 22952805 rs13404263 chr2 227020399 G A 2.27E-04 IgE levels LOC646736 intron 17255346 rs1522802 chr2 227020494 A C 7.05E-05 Information processing speed LOC646736 intron 21130836 rs7578326 chr2 227020653 A G 5.00E-20 Type 2 diabetes LOC646736 intron 20581827 rs7578326 chr2 227020653 A G 3.80E-10 Type 2 diabetes LOC646736 intron 22885922 rs7578326 chr2 227020653 A G 5.00E-20 Type 2 diabetes LOC646736 intron 23300278 rs952227 chr2 227062080 A G 1.05E-06 Coronary heart disease / / 22319020 rs2943634 chr2 227068080 A C,G 7.49E-06 Multiple complex diseases / / 17554300 rs2943634 chr2 227068080 A C,G 2.00E-07 Coronary heart disease / / 17634449 rs2943634 chr2 227068080 A C,G 2.00E-07 Coronary heart disease / / 21347282 rs2943634 chr2 227068080 A C,G 5.00E-05 Coronary heart disease / / 21966275 rs2943634 chr2 227068080 A C,G 0.000000432 Type 2 diabetes / / 22325160 rs2943634 chr2 227068080 A C,G 2.00E-14 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs2943634 chr2 227068080 A C,G 0.00000134 Triglycerides / / 23063622 rs2943634 chr2 227068080 A C,G 2.36E-09 HDL cholesterol / / 23063622 rs2943636 chr2 227087284 G A 2.00E-07 Sexual dimorphism in anthropometric traits / / 23754948 rs2943640 chr2 227093585 A C 5.10E-04 Multiple complex diseases / / 17554300 rs2943640 chr2 227093585 A C 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs2943640 chr2 227093585 A C 0.00000003 Type 2 diabetes (males) / / 22885922 rs2943640 chr2 227093585 A C 0.00000014 Fasting insulin-related traits / / 22885922 rs2943640 chr2 227093585 A C 1.30E-09 Type 2 diabetes (females) / / 22885922 rs2943640 chr2 227093585 A C 2.70E-14 Type 2 diabetes / / 22885922 rs2943640 chr2 227093585 A C 7.00E-09 Type 2 diabetes / / 24509480 rs2943641 chr2 227093745 T C 9.00E-12 Type 2 diabetes and other traits / / 19734900 rs2943641 chr2 227093745 T C 9.00E-12 Coronary heart disease / / 21347282 rs2943641 chr2 227093745 T C 9.00E-12 Type 2 diabetes / / 21647700 rs2943641 chr2 227093745 T C 9.28E-12 Type 2 diabetes / / 23300278 rs1515114 chr2 227098387 A G 8.13E-04 Parkinson's disease / / 17052657 rs2943645 chr2 227099180 C T 2.26E-19 Fasting insulin-related traits / / 22885924 rs2943646 chr2 227099534 A G 3.58E-04 Multiple complex diseases / / 17554300 rs2972147 chr2 227099854 T C 3.89E-04 Multiple complex diseases / / 17554300 rs2972146 chr2 227100698 G T 2.00E-08 Triglycerides / / 20686565 rs2972146 chr2 227100698 G T 2.00E-09 HDL cholesterol / / 20686565 rs2972146 chr2 227100698 G T 2.00E-17 HDL cholesterol / / 24097068 rs2972146 chr2 227100698 G T 3.00E-15 Triglycerides / / 24097068 rs2972144 chr2 227101411 A G 3.56E-04 Multiple complex diseases / / 17554300 rs2943650 chr2 227105921 C T 4.00E-11 Adiposity / / 21706003 rs2972143 chr2 227116365 A G 3.21E-19 Fasting insulin-related traits / / 22885924 rs2943656 chr2 227121918 A G 6.62E-04 Multiple complex diseases / / 17554300 rs1515110 chr2 227122216 G T 2.00E-07 Adiponectin levels / / 22479202 rs2943657 chr2 227123439 C T 7.69E-04 Multiple complex diseases / / 17554300 rs2943658 chr2 227123584 A G 7.45E-04 Multiple complex diseases / / 17554300 rs1515099 chr2 227128899 G A 7.66E-04 Multiple complex diseases / / 17554300 rs41504645 chr2 227131174 T C 9.37E-04 Multiple complex diseases / / 17554300 rs964818 chr2 227131780 C A 2.50E-04 Alcohol dependence / / 20201924 rs964818 chr2 227131780 C A 4.40E-05 Alcohol dependence / / 20201924 rs964818 chr2 227131780 C A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs964818 chr2 227131780 C A 4.37E-05 Alcoholism / / pha002893 rs186397905 chr2 227134138 C G 0.0000221 Menopause (age at onset) / / 23424626 rs2713541 chr2 227141768 A T 8.07E-04 Multiple complex diseases / / 17554300 rs4510219 chr2 227148722 A C 2.40E-04 Alcohol dependence / / 20201924 rs4510219 chr2 227148722 A C 4.90E-05 Alcohol dependence / / 20201924 rs4510219 chr2 227148722 A C 4.86E-05 Alcoholism / / pha002893 rs189110944 chr2 227149196 C A 0.0000472 Menopause (age at onset) / / 23424626 rs35660230 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs567779929 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs71410385 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs117258126 chr2 227172342 C T 0.0000218 Menopause (age at onset) / / 23424626 rs3914466 chr2 227174846 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3914465 chr2 227174909 A G 1.60E-04 Alcohol dependence / / 20201924 rs3914465 chr2 227174909 A G 1.90E-05 Alcohol dependence / / 20201924 rs3914465 chr2 227174909 A G 1.85E-05 Alcoholism / / pha002893 rs2673148 chr2 227174983 A C 8.81E-05 Multiple complex diseases / / 17554300 rs925735 chr2 227179630 C G 2.00E-08 Adiponectin levels / / 22479202 rs10933137 chr2 227184631 C T 7.33E-04 Multiple complex diseases / / 17554300 rs2894592 chr2 227226621 T G 2.07E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2396341 chr2 227253414 C T 1.60E-05 Urinary metabolites / / 21572414 rs2396342 chr2 227253518 T C 1.50E-05 Urinary metabolites / / 21572414 rs2894604 chr2 227259267 C T 4.87E-05 Coronary Artery Disease / / 17634449 rs12185566 chr2 227263777 A G 1.87E-04 IgE levels / / 17255346 rs7599722 chr2 227265046 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13032261 chr2 227268591 C A 4.53E-05 Parkinson's disease / / 17052657 rs12991594 chr2 227270422 G A 4.42E-04 IgE levels / / 17255346 rs6749681 chr2 227277006 A G 1.05E-04 IgE levels / / 17255346 rs6749681 chr2 227277006 A G 9.73E-04 Alzheimer's disease / / 17998437 rs4281890 chr2 227284206 A G 4.75E-04 Parkinson's disease / / 17052657 rs4390759 chr2 227288763 A G 5.60E-06 Urinary metabolites / / 21572414 rs4392250 chr2 227289084 T C 1.80E-05 Urinary metabolites / / 21572414 rs4129068 chr2 227294482 C T 1.27E-04 Parkinson's disease / / 17052657 rs12694698 chr2 227296072 G A 2.14E-04 IgE levels / / 17255346 rs4446065 chr2 227308257 T A 1.80E-05 Urinary metabolites / / 21572414 rs6436625 chr2 227308645 T G 1.70E-05 Urinary metabolites / / 21572414 rs4675080 chr2 227309616 C T 2.20E-05 Urinary metabolites / / 21572414 rs10186065 chr2 227339408 A G 2.80E-05 Urinary metabolites / / 21572414 rs6757297 chr2 227342038 G C 7.71E-05 Coronary Artery Disease / / 17634449 rs13425767 chr2 227342966 C T 2.90E-05 Urinary metabolites / / 21572414 rs1392841 chr2 227345365 C A 4.24E-04 Parkinson's disease / / 17052657 rs13392647 chr2 227353550 G A 0.000773446 Hypertension (early onset hypertension) / / 22479346 rs11903929 chr2 227360446 T C 4.37E-05 Attention deficit hyperactivity disorder / / pha002875 rs10933150 chr2 227361185 T A 3.50E-06 White blood cell count / / 21738479 rs7581080 chr2 227376088 T A 8.73E-04 Alzheimer's disease / / 17998437 rs6436630 chr2 227379856 C T 9.97E-04 Alzheimer's disease / / 17998437 rs11899501 chr2 227387524 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899345 chr2 227393893 A G 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12467492 chr2 227418826 C T 4.08E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12467492 chr2 227418826 C T 1.08E-05 Platelet counts / / pha003100 rs16867090 chr2 227428810 T C 5.62E-04 Insulin resistance / / 21901158 rs16867099 chr2 227447917 A C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12185555 chr2 227559317 A G 8.25E-04 HIV-1 viral setpoint / / 17641165 rs12185555 chr2 227559317 A G 9.99E-07 HIV-1 control / / 20041166 rs12185555 chr2 227559317 A G 9.69E-06 HIV-1 viral setpoint / / 21490045 rs12185556 chr2 227559414 A G 1.10E-05 Urinary metabolites / / 21572414 rs7558386 chr2 227562139 A G 1.00E-07 P-tau181p levels / / 20932310 rs1882577 chr2 227574207 C T 6.64E-04 Type 2 diabetes / / 17463246 rs2288587 chr2 227596512 T C 8.36E-04 Multiple complex diseases IRS1 UTR-3 17554300 rs16822570 chr2 227599533 T G 5.16E-04 Multiple complex diseases IRS1 UTR-3 17554300 rs10182336 chr2 227608811 A G 0.000053 Coronary artery calcification IRS1 intron 23727086 rs13431179 chr2 227610241 G A 6.14E-04 Multiple complex diseases IRS1 intron 17554300 rs13431179 chr2 227610241 G A 4.29E-04 Sudden cardiac arrest IRS1 intron 21658281 rs10205233 chr2 227614005 C T 5.73E-04 Multiple complex diseases IRS1 intron 17554300 rs10181778 chr2 227614237 A T 7.44E-04 Multiple complex diseases IRS1 intron 17554300 rs10498210 chr2 227619946 G A 1.28E-15 Varicose Veins IRS1 intron pha001416 rs12052364 chr2 227635208 A G 9.20E-05 Multiple complex diseases IRS1 intron 17554300 rs1560251 chr2 227653948 C A 2.39E-04 Lymphocyte counts IRS1 intron 22286170 rs2288586 chr2 227655390 G C 2.19E-04 Multiple complex diseases IRS1 intron 17554300 rs2229613 chr2 227660689 C T 8.20E-09 LDL cholesterol IRS1 cds-synon 23063622 rs2229613 chr2 227660689 C T 9.37E-11 Cholesterol,total IRS1 cds-synon 23063622 rs6725556 chr2 227666992 A G 9.89E-05 Monocyte chemoattractant protein-1 / / pha003071 rs13015698 chr2 227700818 C T 8.01E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs13015698 chr2 227700818 C T 6.66E-04 Response to cytadine analogues (cytosine arabinoside) RHBDD1 intron 24483146 rs16822834 chr2 227739823 A G 1.20E-06 Urinary metabolites RHBDD1 intron 21572414 rs6734566 chr2 227757492 C A 2.30E-06 Urinary metabolites RHBDD1 intron 21572414 rs2396432 chr2 227765891 C T 9.06E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs3820928 chr2 227773466 T C 5.00E-06 Pulmonary function RHBDD1 intron 17903307 rs1864271 chr2 227780266 G C 9.90E-05 White matter hyperintensity burden RHBDD1 intron 21681796 rs7560867 chr2 227780945 C A,G 9.92E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1114562 chr2 227788592 T C 4.43E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2115597 chr2 227791218 T C 9.22E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7582251 chr2 227791703 G T 4.42E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10167086 chr2 227792729 A T 4.41E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10195072 chr2 227794452 G A 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10174073 chr2 227794944 A G 4.54E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10169717 chr2 227796911 T G 4.45E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs11685983 chr2 227799853 A G 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675123 chr2 227800205 T C 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6718767 chr2 227800776 A G 9.36E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4673174 chr2 227801316 A T 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs13384342 chr2 227805010 G A 3.76E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7562776 chr2 227806550 G A 3.76E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675128 chr2 227814757 T C 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10439363 chr2 227815065 C T 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234062 chr2 227819050 C A 3.77E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10210963 chr2 227821845 A G 4.41E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10197773 chr2 227824835 G A 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234063 chr2 227828335 A T 4.29E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2177593 chr2 227833869 G A 7.36E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6718057 chr2 227834349 T G 4.38E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1917122 chr2 227835681 C T 5.01E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2177594 chr2 227836239 C G 4.77E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7421491 chr2 227839278 C A 4.79E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1996998 chr2 227840294 C A 5.48E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1917126 chr2 227840923 G T 5.60E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675132 chr2 227841792 A C 5.31E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675133 chr2 227843010 C T 5.23E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675134 chr2 227843489 C T 5.84E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4461255 chr2 227846524 A G 5.91E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6707265 chr2 227849255 T A 8.65E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6706802 chr2 227850776 A G 5.42E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6728239 chr2 227856552 A G 7.87E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234064 chr2 227857497 G T 7.44E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10210997 chr2 227859108 C T 8.73E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs12151848 chr2 227859326 G A 7.38E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10933164 chr2 227860671 G A 4.42E-04 Suicide attempts in bipolar disorder RHBDD1 UTR-3 21423239 rs10189579 chr2 227864876 A G 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1320407 chr2 227867385 G T 7.33E-04 Suicide attempts in bipolar disorder COL4A4 nearGene-3 21423239 rs1054413 chr2 227867719 G A 7.35E-04 Suicide attempts in bipolar disorder COL4A4 UTR-3 21423239 rs2228557 chr2 227872182 G A 7.33E-04 Suicide attempts in bipolar disorder COL4A4 cds-synon 21423239 rs9288618 chr2 227872617 A G 7.32E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs13419076 chr2 227873028 A G 8.61E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs4423583 chr2 227874957 C T 6.24E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs10182307 chr2 227875360 G A 8.08E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs10188770 chr2 227877037 G A 8.64E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs6740108 chr2 227889559 A C 7.29E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs2272205 chr2 227915924 T C 3.00E-09 Immune reponse to smallpox (secreted IFN-alpha) COL4A4 intron 22610502 rs4566357 chr2 227922015 A G 0.0000247 Coronary artery disease COL4A4 intron 23202125 rs11898094 chr2 227924774 C T 1.62E-05 Brain structure COL4A4 intron 22504417 rs13015629 chr2 227938880 A G 6.24E-04 Alzheimer's disease COL4A4 intron 17998437 rs7574757 chr2 227943480 C T 2.43E-05 Brain structure COL4A4 intron 22504417 rs6743614 chr2 227977893 C A 8.02E-04 Response to taxane treatment (placlitaxel) COL4A4 intron 23006423 rs6743614 chr2 227977893 C A 3.64E-04 Smoking quantity COL4A4 intron 24665060 rs2396463 chr2 228044992 C A 1.50E-06 Creatinine levels COL4A3 intron 20222955 rs2204862 chr2 228052600 A G 4.80E-05 Creatinine levels COL4A3 intron 20222955 rs4278919 chr2 228058027 G A 6.12E-04 Acute lung injury COL4A3 intron 22295056 rs17367956 chr2 228064828 A G 3.95E-05 Parent of origin effect on language impairment (maternal) COL4A3 intron 24571439 rs6739977 chr2 228065095 A G 7.60E-05 Parent of origin effect on language impairment (maternal) COL4A3 intron 24571439 rs2141831 chr2 228087689 C T 6.51E-05 Myopia (pathological) COL4A3 intron 21095009 rs13021572 chr2 228090768 G A 7.48E-05 Telomere length COL4A3 intron 21573004 rs13028299 chr2 228091661 G A 2.24E-06 White blood cell count COL4A3 intron 21738479 rs35212277 chr2 228092035 G A 9.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) COL4A3 intron 23319000 rs13424243 chr2 228102723 G C 1.80E-05 Urinary metabolites COL4A3 missense 21572414 rs10933172 chr2 228121147 T G 9.83E-05 Non-alcoholic fatty liver disease histology (other) COL4A3 intron 20708005 rs7606754 chr2 228135180 A G 1.00E-09 Corneal structure COL4A3 intron 23291589 rs4073904 chr2 228161915 A G 1.99E-05 Monocyte chemoattractant protein-1 COL4A3 intron pha003071 rs10451555 chr2 228167560 G A 2.10E-05 Monocyte chemoattractant protein-1 COL4A3 intron pha003071 rs7582023 chr2 228267108 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4344925 chr2 228271651 G A 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4344925 chr2 228271651 G A 1.20E-05 Urinary metabolites / / 21572414 rs76113735 chr2 228308820 C T 0.0006664 Sarcoidosis / / 22952805 rs4485561 chr2 228373683 G T 1.15E-05 Airway hyperresponsiveness AGFG1 intron 23984888 rs77827358 chr2 228378545 T C 0.0005882 Sarcoidosis AGFG1 intron 22952805 rs10189795 chr2 228378861 C T 2.97E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs4972983 chr2 228393168 C A 8.62E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs6731443 chr2 228397566 T G 2.00E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs13382948 chr2 228418957 A G 2.75E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs4129709 chr2 228438549 G A 2.27E-05 Airway hyperresponsiveness / / 23984888 rs11674314 chr2 228442208 C T 2.27E-05 Airway hyperresponsiveness / / 23984888 rs7595130 chr2 228443552 A G 2.24E-05 Airway hyperresponsiveness / / 23984888 rs7579157 chr2 228445730 C T 2.23E-05 Airway hyperresponsiveness / / 23984888 rs11683662 chr2 228448028 G A 2.21E-05 Airway hyperresponsiveness / / 23984888 rs7592613 chr2 228451190 T C 2.25E-05 Airway hyperresponsiveness / / 23984888 rs7581631 chr2 228458944 A T 5.15E-04 Coronary heart disease / / 21606135 rs6714320 chr2 228466832 G A 2.26E-05 Serum metabolites / / 19043545 rs16823699 chr2 228474106 A C 2.03E-04 IgE levels / / 17255346 rs2138402 chr2 228476253 C G 4.60E-04 Suicide attempts in bipolar disorder C2orf83 missense 21423239 rs16823709 chr2 228479171 T C 1.33E-04 IgE levels C2orf83 intron 17255346 rs16823719 chr2 228481316 T C 1.16E-05 IgE levels C2orf83 intron 17255346 rs11889798 chr2 228481419 C T 4.00E-07 Immune reponse to smallpox (secreted TNF-alpha) C2orf83 intron 22610502 rs12616684 chr2 228489694 A G 2.28E-04 Multiple complex diseases C2orf83 intron 17554300 rs12616684 chr2 228489694 A G 1.60E-05 Urinary metabolites C2orf83 intron 21572414 rs10179572 chr2 228504503 A G 8.99E-04 Multiple complex diseases / / 17554300 rs10179572 chr2 228504503 A G 1.31E-05 Mathematical ability / / 24801482 rs2396468 chr2 228506119 C A 1.47E-04 Bulimia nervosa / / 23568457 rs7593751 chr2 228506427 T C 6.50E-06 Urinary metabolites / / 21572414 rs997363 chr2 228509458 C T 1.00E-06 Cervical cancer / / 24700089 rs17371490 chr2 228527799 C T 9.39E-04 Type 2 diabetes / / 17463246 rs145288025 chr2 228560632 C T 0.00062 Prostate cancer (non-advanced prostate cancer) SLC19A3 missense 23555315 rs7567984 chr2 228567967 C T 3.54E-05 Response to hepatitis C treatment SLC19A3 intron 19684573 rs11691652 chr2 228584898 T G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11691652 chr2 228584898 T G 8.00E-06 Obesity-related traits / / 23251661 rs7557339 chr2 228595557 C T 4.88E-04 Parkinson's disease / / 16252231 rs10208046 chr2 228602577 T C 7.87E-06 Type 2 diabetes / / 17463246 rs10198436 chr2 228610384 A C 9.13E-04 Parkinson's disease / / 16252231 rs7595272 chr2 228615752 C T 4.02E-04 Hemoglobin concentration / / 20534544 rs9288627 chr2 228655101 G T 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9288627 chr2 228655101 G T 5.73E-05 Sodium levels / / pha003093 rs7556897 chr2 228660112 C T 0.000000324 Primary sclerosing cholangitis / / 23603763 rs13385901 chr2 228668322 C A 4.00E-06 Eating disorders (purging via substances) / / 23568457 rs367819358 chr2 228668322 CTT CAA 4.00E-06 Eating disorders (purging via substances) / / 23568457 rs13389224 chr2 228669035 C T 3.50E-04 Colorectal cancer / / 24737748 rs10175070 chr2 228670575 G A 2.00E-06 Eating disorders (purging via substances) / / 23568457 rs41397446 chr2 228692124 A G 8.01E-04 Multiple complex diseases / / 17554300 rs7591163 chr2 228715375 C T 3.00E-07 Blood pressure / / 17903302 rs13400894 chr2 228723220 G A 7.21E-04 Coronary heart disease / / 21971053 rs4973445 chr2 228750239 G T 9.06E-04 Alzheimer's disease WDR69 intron 24755620 rs1721359 chr2 228751874 G A 1.00E-05 Blood Pressure and Arterial Stiffness WDR69 intron 17903302 rs1721341 chr2 228768484 A G 0.00027599 Hypertension (early onset hypertension) WDR69 intron 22479346 rs7578514 chr2 228772961 T C 9.76E-04 Multiple complex diseases WDR69 intron 17554300 rs17197476 chr2 228773146 C T 7.77E-04 Multiple complex diseases WDR69 intron 17554300 rs11680252 chr2 228773287 T C 4.08E-04 Coronary heart disease WDR69 intron 21971053 rs10188509 chr2 228776385 T C 7.96E-04 Multiple complex diseases WDR69 intron 17554300 rs1721355 chr2 228782976 C T 0.000202413 Hypertension (early onset hypertension) WDR69 intron 22479346 rs10498224 chr2 228789581 T C 4.34E-04 Coronary heart disease / / 21971053 rs7608896 chr2 228790328 G A 2.33E-04 Coronary heart disease / / 21971053 rs11690643 chr2 228792481 C T 2.55E-04 Coronary heart disease / / 21971053 rs1916804 chr2 228808696 G T 9.98E-05 Asthma / / 20159242 rs10200894 chr2 228817132 C G 1.70E-05 Parkinson's disease / / 16252231 rs4438469 chr2 228923045 G T 3.55E-05 Neuroblastoma SPHKAP intron pha002895 rs6760875 chr2 228925898 A G 2.73E-05 Neuroblastoma SPHKAP intron pha002895 rs7561798 chr2 228973660 A G 7.86E-06 Rheumatoid arthritis SPHKAP intron 21452313 rs12615089 chr2 228989962 G A 5.12E-05 Serum metabolites SPHKAP intron 19043545 rs7577229 chr2 228991638 T C 1.62E-04 Sudden cardiac arrest SPHKAP intron 21658281 rs6436758 chr2 229000048 A G 2.06E-04 Smoking quantity SPHKAP intron 24665060 rs10171038 chr2 229028291 G A 9.04E-05 Post-operative nausea and vomiting SPHKAP intron 21694509 rs4641922 chr2 229031147 C T 2.87E-04 Stroke SPHKAP intron pha002886 rs4450587 chr2 229033765 T G 3.73E-04 Multiple complex diseases SPHKAP intron 17554300 rs6436768 chr2 229082019 C T 4.93E-04 Multiple complex diseases / / 17554300 rs7569857 chr2 229087980 C T 8.12E-04 Depression (quantitative trait) / / 20800221 rs7596305 chr2 229088071 A G 7.73E-04 Depression (quantitative trait) / / 20800221 rs7570056 chr2 229088182 C A 7.45E-04 Depression (quantitative trait) / / 20800221 rs6734910 chr2 229088564 T C 7.48E-04 Depression (quantitative trait) / / 20800221 rs4973623 chr2 229088999 A C 7.52E-04 Depression (quantitative trait) / / 20800221 rs4973077 chr2 229089087 T C 7.52E-04 Depression (quantitative trait) / / 20800221 rs7577217 chr2 229089667 G A 7.49E-04 Depression (quantitative trait) / / 20800221 rs6756442 chr2 229090591 A G 7.48E-04 Depression (quantitative trait) / / 20800221 rs11687136 chr2 229090681 C T 7.45E-04 Depression (quantitative trait) / / 20800221 rs6738921 chr2 229091495 A T 7.44E-04 Depression (quantitative trait) / / 20800221 rs6710405 chr2 229091508 C T 7.44E-04 Depression (quantitative trait) / / 20800221 rs7565432 chr2 229092221 G A 7.43E-04 Depression (quantitative trait) / / 20800221 rs12467514 chr2 229093362 A G 7.28E-04 Depression (quantitative trait) / / 20800221 rs7591756 chr2 229099320 G A 7.22E-04 Depression (quantitative trait) / / 20800221 rs7591756 chr2 229099320 G A 1.66E-04 Stroke / / pha002886 rs13394977 chr2 229100109 C A 7.31E-04 Depression (quantitative trait) / / 20800221 rs13395080 chr2 229100197 C T 7.33E-04 Depression (quantitative trait) / / 20800221 rs9989832 chr2 229100407 T C 7.42E-04 Depression (quantitative trait) / / 20800221 rs6752284 chr2 229103185 T C 7.02E-04 Depression (quantitative trait) / / 20800221 rs7593752 chr2 229104720 G A 9.16E-04 Depression (quantitative trait) / / 20800221 rs7607608 chr2 229104755 T G 9.21E-04 Depression (quantitative trait) / / 20800221 rs10804339 chr2 229106949 T C 9.23E-04 Depression (quantitative trait) / / 20800221 rs6753687 chr2 229107336 G T 8.84E-04 Depression (quantitative trait) / / 20800221 rs6711657 chr2 229107495 T C 8.90E-04 Depression (quantitative trait) / / 20800221 rs6711657 chr2 229107495 T C 2.09E-05 Stroke / / pha002886 rs1316628 chr2 229115093 T C 8.96E-04 Depression (quantitative trait) / / 20800221 rs4973079 chr2 229186057 G T 1.95E-04 Stroke / / pha002886 rs12052730 chr2 229188012 T C 2.10E-04 Sudden cardiac arrest / / 21658281 rs7582313 chr2 229193646 T C 4.77E-04 Stroke / / pha002886 rs4973082 chr2 229201398 T A 9.94E-05 Multiple complex diseases / / 17554300 rs16824782 chr2 229244723 G A 7.99E-04 Insulin resistance / / 21901158 rs7608014 chr2 229297173 A G 1.70E-05 Urinary metabolites / / 21572414 rs2216873 chr2 229297199 A G 2.00E-05 Urinary metabolites / / 21572414 rs2059390 chr2 229332491 A G 3.02E-05 Osteoarthritis (knee and hip) / / 21177295 rs2059390 chr2 229332491 A G 3.22E-05 Osteoarthritis (knee and hip) / / 21177295 rs1019599 chr2 229355615 C G 2.30E-05 Urinary metabolites / / 21572414 rs7419568 chr2 229355672 G A 1.80E-05 Urinary metabolites / / 21572414 rs7609102 chr2 229380037 C T 8.63E-04 Multiple complex diseases / / 17554300 rs16825109 chr2 229404774 T C 7.05E-04 Multiple complex diseases / / 17554300 rs16825116 chr2 229406685 G T 1.30E-05 Urinary metabolites / / 21572414 rs1435850 chr2 229430921 T C 5.88E-04 Type 2 diabetes / / 17463246 rs6752685 chr2 229478347 G A 6.82E-04 Multiple complex diseases / / 17554300 rs12616353 chr2 229485782 A T 2.20E-05 Urinary metabolites / / 21572414 rs1469837 chr2 229490307 G A 6.85E-06 Pulmonary function / / 20010835 rs16825200 chr2 229501745 A T 7.24E-08 Pulmonary function / / 20010835 rs10498230 chr2 229502503 C T 3.87E-08 Pulmonary function / / 20010835 rs1435867 chr2 229510929 T C 3.74E-08 Pulmonary function / / 20010835 rs1435867 chr2 229510929 T C 2.00E-09 Pulmonary function (interaction) / / 23284291 rs4143199 chr2 229512901 C T 4.01E-08 Pulmonary function / / 20010835 rs16825247 chr2 229524141 A G 4.38E-08 Pulmonary function / / 20010835 rs16825251 chr2 229524638 G A 4.45E-08 Pulmonary function / / 20010835 rs7574134 chr2 229531165 C A 4.76E-08 Pulmonary function / / 20010835 rs1881204 chr2 229533885 C T 9.96E-08 Pulmonary function / / 20010835 rs12613830 chr2 229548445 A G 4.54E-05 Pulmonary function / / 20010835 rs6757803 chr2 229554943 C A 5.79E-08 Pulmonary function / / 20010835 rs16825267 chr2 229569919 C G 9.40E-08 Pulmonary function / / 20010835 rs12614274 chr2 229583850 A G 1.08E-07 Pulmonary function / / 20010835 rs4973115 chr2 229590717 G A 1.10E-07 Pulmonary function / / 20010835 rs3732192 chr2 229592304 T C 6.88E-08 Pulmonary function / / 20010835 rs9631013 chr2 229611986 C A 9.75E-04 Multiple complex diseases / / 17554300 rs10181531 chr2 229626575 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11679180 chr2 229642422 G A 1.44E-05 Endometrial cancer / / 24096698 rs11679180 chr2 229642422 G A 2.37E-05 Endometrial cancer / / 24096698 rs11679180 chr2 229642422 G A 3.00E-06 Endometrial cancer / / 24096698 rs1527669 chr2 229652463 G A 3.83E-06 Basophils / / pha003087 rs1527671 chr2 229684700 C T 7.30E-04 Type 2 diabetes / / 17463246 rs4487082 chr2 229723961 A G 5.70E-06 Schizophrenia / / 19197363 rs10490037 chr2 229741332 T C 2.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs12472073 chr2 229742593 T C 6.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs7578485 chr2 229743009 G A 7.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs809616 chr2 229763919 G A 1.18E-04 IgE levels / / 17255346 rs7571792 chr2 229766101 C T 4.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs7593561 chr2 229828458 T G 5.55E-04 Type 2 diabetes / / 17463246 rs16825544 chr2 229851713 T C 3.88E-05 Personality dimensions / / 22628180 rs13410077 chr2 229866471 G A 6.58E-04 Type 2 diabetes / / 17463246 rs13419855 chr2 229902479 A T 7.72E-04 Type 2 diabetes PID1 intron 17463246 rs2215598 chr2 229908245 C T 2.13E-04 Multiple complex diseases PID1 intron 17554300 rs6739369 chr2 229912852 A C 8.22E-05 Multiple complex diseases PID1 intron 17554300 rs6739369 chr2 229912852 A C 1.20E-05 Cognitive function PID1 intron 24684796 rs16825626 chr2 229918641 T C 3.00E-05 Cognitive function PID1 intron 24684796 rs31276 chr2 229920520 C T 2.50E-05 Cognitive function PID1 intron 24684796 rs17475974 chr2 229956007 G T 9.65E-05 Cognitive impairment induced by topiramate PID1 intron 22091778 rs10200706 chr2 229965638 T C 2.00E-04 Information processing speed PID1 intron 21130836 rs6436839 chr2 229969798 A G 3.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) PID1 intron 21107309 rs17676106 chr2 229983205 G A 0.000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PID1 intron 23233654 rs17676106 chr2 229983205 G A 7.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) PID1 intron 23233662 rs1419950 chr2 229993089 T C 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) PID1 intron 23233662 rs12467995 chr2 229994369 T C 2.13E-04 Stroke PID1 intron pha002887 rs1419951 chr2 229999602 C T 8.57E-04 Nicotine smoking PID1 intron 19268276 rs7561332 chr2 230012894 G A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs7561470 chr2 230013020 G A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs7575420 chr2 230013055 T A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs10804349 chr2 230032129 G T 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PID1 intron 20877124 rs1419958 chr2 230033560 T G 2.17E-05 Cognitive performance PID1 intron 19734545 rs12623151 chr2 230077532 G A 6.01E-05 Lipoprotein-associated phospholipase A2 activity and mass PID1 intron 20442857 rs10498234 chr2 230083143 G T 5.98E-05 Cognitive test performance PID1 intron 20125193 rs1235203 chr2 230095897 G A 9.56E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs974251 chr2 230097911 C G 7.18E-05 Lipoprotein-associated phospholipase A2 activity and mass PID1 intron 20442857 rs6747101 chr2 230103371 C T 1.07E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs1226994 chr2 230104110 C T 4.91E-05 Orofacial clefts PID1 intron 22419666 rs1226997 chr2 230109580 C T 1.67E-05 Suicide attempts in bipolar disorder PID1 intron 21423239 rs1226998 chr2 230109673 T C 3.69E-05 Orofacial clefts PID1 intron 22419666 rs10933284 chr2 230115370 C T 2.22E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs6724020 chr2 230122247 G A 6.76E-05 Serum metabolites PID1 intron 19043545 rs10498236 chr2 230127085 T C 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PID1 intron 17982456 rs4321351 chr2 230129493 A G 6.76E-06 Lipoproteins PID1 intron pha003079 rs6754229 chr2 230131445 T C 5.97E-04 Suicide attempts in bipolar disorder PID1 intron 21041247 rs10185903 chr2 230132158 T C 5.81E-04 Suicide attempts in bipolar disorder PID1 intron 21041247 rs13026191 chr2 230135172 C T 5.14E-05 Lipoproteins PID1 intron pha003079 rs10498237 chr2 230141849 A G 3.39E-05 Anxiety in major depressive disorder / / 24047446 rs12988652 chr2 230142079 G A 1.46E-05 Orofacial clefts / / 22419666 rs7579884 chr2 230146591 A G 4.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226946 chr2 230148538 C T 4.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226936 chr2 230155126 T G 4.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs11676521 chr2 230155626 G T 5.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs11678426 chr2 230157108 G A 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1922458 chr2 230159931 A G 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs35134249 chr2 230159931 A AT 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1419948 chr2 230160162 A C 6.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs1419947 chr2 230160233 A G 6.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226973 chr2 230163047 C A 7.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498238 chr2 230166564 C T 4.74E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs17257436 chr2 230166970 A G 8.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs16825971 chr2 230167323 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226959 chr2 230169199 C A 8.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226954 chr2 230172176 T C 7.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs6436859 chr2 230197262 A G 7.46E-05 Lipoproteins / / pha003079 rs6728087 chr2 230211261 A C 4.29E-04 Coronary heart disease / / 21606135 rs4973190 chr2 230211434 T C 7.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs9288645 chr2 230214932 T C 2.89E-04 Glaucoma (primary open-angle) / / 22419738 rs7594321 chr2 230224031 T C 3.00E-09 Pulmonary function (interaction) DNER intron 23284291 rs7594321 chr2 230224031 T C 5.00E-11 Pulmonary function (interaction) DNER intron 23284291 rs10933295 chr2 230271297 T C 2.94E-05 Blood Pressure DNER intron pha003043 rs6731881 chr2 230276998 A G 1.40E-05 Blood Pressure DNER intron pha003043 rs2396663 chr2 230284815 T C 9.36E-04 Parkinson's disease DNER intron 17052657 rs6718937 chr2 230307418 T C 5.39E-04 Type 2 diabetes DNER intron 17463246 rs4973205 chr2 230321488 C T 5.05E-05 Coronary heart disease DNER intron pha003035 rs6733371 chr2 230325123 C T 5.79E-05 Femoral neck bone geometry DNER intron 22087292 rs11675728 chr2 230326068 C T 7.22E-05 Pulmonary function in asthmatics DNER intron 23541324 rs9967719 chr2 230327643 G T 7.41E-05 Femoral neck bone geometry DNER intron 22087292 rs6750269 chr2 230341132 T C 9.79E-04 Multiple complex diseases DNER intron 17554300 rs11890081 chr2 230349989 T C 8.00E-06 IgG glycosylation DNER intron 23382691 rs12620995 chr2 230351558 G A 9.39E-05 Information processing speed DNER intron 21130836 rs7570424 chr2 230352718 T C 4.82E-04 Multiple complex diseases DNER intron 17554300 rs7556846 chr2 230352851 G A 8.00E-04 Multiple complex diseases DNER intron 17554300 rs7570739 chr2 230352976 T C 5.02E-04 Multiple complex diseases DNER intron 17554300 rs2216531 chr2 230383471 A C 2.88E-04 Lung function (forced vital capacity) DNER intron 24023788 rs11695348 chr2 230436865 A G 9.03E-04 Amyotrophic lateral sclerosis (sporadic) DNER intron 24529757 rs888177 chr2 230461323 G A 4.60E-05 Glycosylated haemoglobin levels DNER intron 17255346 rs2052303 chr2 230461850 C T 4.66E-05 Glycosylated haemoglobin levels DNER intron 17255346 rs1861616 chr2 230462275 G A 4.18E-04 Body mass index DNER intron 17255346 rs759538 chr2 230463394 C T 4.31E-04 Body mass index DNER intron 17255346 rs6743564 chr2 230468618 C A 1.16E-04 Glycosylated haemoglobin levels DNER intron 17255346 rs6727393 chr2 230485415 T G 4.88E-04 Smoking initiation DNER intron 24665060 rs12986692 chr2 230485450 C T 2.89E-04 Parkinson's disease DNER intron 17052657 rs7605496 chr2 230506712 G T 7.04E-05 Response to cholinesterase inhibitors in Alzheimer's disease DNER intron 23374588 rs6752370 chr2 230518233 A G 8.53E-07 Autism DNER intron 22843504 rs1861612 chr2 230522398 G A 7.00E-08 Type 2 diabetes DNER intron 24101674 rs6712401 chr2 230532751 A G 4.96E-04 Multiple complex diseases DNER intron 17554300 rs6712401 chr2 230532751 A G 0.00037 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6712401 chr2 230532751 A G 3.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs6756438 chr2 230532819 T C 0.0003106 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6756438 chr2 230532819 T C 3.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs6741523 chr2 230532873 G C 0.0002448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6741523 chr2 230532873 G C 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs2216249 chr2 230545356 T C 6.00E-04 Alcohol dependence DNER intron 20201924 rs7558924 chr2 230545657 T C 6.11E-05 C-Reactive Protein DNER intron pha003070 rs2761119 chr2 230555225 A T 3.11E-05 Serum metabolites DNER intron 19043545 rs208785 chr2 230562456 G C 7.89E-04 Response to cytidine analogues (gemcitabine) DNER intron 24483146 rs6707272 chr2 230609149 C T 4.95E-18 Breast cancer (Postmenopausal women) / / 23423446 rs10432554 chr2 230666898 A G 9.27E-04 Parkinson's disease TRIP12 intron 17052657 rs1035833 chr2 230709198 A G 2.30E-04 Type 2 diabetes TRIP12 intron 19184112 rs13014061 chr2 230759699 C A 1.70E-16 Breast cancer (Postmenopausal women) TRIP12 intron 23423446 rs7607428 chr2 230796237 A C 7.35E-04 Myopia (pathological) FBXO36 intron 21095009 rs7558844 chr2 230814685 C T 0.000719 Salmonella-induced pyroptosis FBXO36 intron 22837397 rs6757156 chr2 230820600 A G 4.65E-04 Multiple complex diseases FBXO36 intron 17554300 rs560304 chr2 230822296 C T 5.66E-16 Breast cancer (Postmenopausal women) FBXO36 intron 23423446 rs12694823 chr2 230952046 G A 1.55E-05 Parkinson's disease / / 21738487 rs12162384 chr2 230959532 C A 4.68E-04 Smoking quantity / / 24665060 rs1365773 chr2 231009554 C A 7.57E-04 Alcohol dependence / / 20201924 rs4973275 chr2 231014505 C T 9.84E-05 Parkinson's disease / / 21738487 rs7424288 chr2 231018169 C T 4.05E-05 Parkinson's disease / / 21738487 rs6735555 chr2 231021064 C A 2.37E-05 Parkinson's disease / / 21738487 rs6742762 chr2 231029682 A G 2.43E-05 Personality dimensions / / 22628180 rs6436915 chr2 231034524 G T 0.0000068 Autism spectrum disorders SP110 intron 22412387 rs13004065 chr2 231035100 A G 3.63E-04 Multiple complex diseases SP110 intron 17554300 rs9784019 chr2 231035575 A G 9.72E-06 Obesity-related traits SP110 intron 23251661 rs13010639 chr2 231035745 C T 6.00E-06 Obesity-related traits SP110 intron 23251661 rs13018234 chr2 231036866 G A 9.72E-06 Obesity-related traits SP110 cds-synon 23251661 rs10498244 chr2 231037833 T C 6.24E-04 Bipolar disorder SP110 intron 19259986 rs13025520 chr2 231038029 G A 9.72E-06 Obesity-related traits SP110 intron 23251661 rs4973285 chr2 231045943 G C 8.05E-05 Schizophrenia SP110 intron 20832056 rs10804364 chr2 231047303 G A 3.54E-05 Schizophrenia SP110 intron 20832056 rs10755048 chr2 231047645 T C 4.88E-05 Schizophrenia SP110 intron 20832056 rs10755048 chr2 231047645 T C 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs6752361 chr2 231053318 A G 4.04E-04 Schizophrenia SP110 intron 20832056 rs1896259 chr2 231058869 C A 4.04E-04 Schizophrenia SP110 intron 20832056 rs1896258 chr2 231058954 C T 4.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs4973298 chr2 231060003 A G 4.04E-04 Schizophrenia SP110 intron 20832056 rs41345344 chr2 231064928 G C 4.04E-04 Schizophrenia SP110 intron 20832056 rs41423848 chr2 231065083 C A 4.04E-04 Schizophrenia SP110 intron 20832056 rs2114592 chr2 231075206 G A 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs7601299 chr2 231077994 A G 5.08E-04 Multiple complex diseases SP110 intron 17554300 rs13389060 chr2 231082124 G T 4.60E-06 Urinary metabolites SP110 intron 21572414 rs11695193 chr2 231090015 T A 1.49E-04 Multiple complex diseases SP110 intron 17554300 rs13397985 chr2 231091223 T G 7.40E-05 Multiple complex diseases SP140 intron 17554300 rs13397985 chr2 231091223 T G 9.04E-06 Crohn's disease SP140 intron 18587394 rs13397985 chr2 231091223 T G 6.00E-10 Chronic lymphocytic leukemia SP140 intron 18758461 rs13397985 chr2 231091223 T G 6.00E-10 Nasopharyngeal carcinoma SP140 intron 20512145 rs13397985 chr2 231091223 T G 3.55E-04 Lymphocyte counts SP140 intron 22286170 rs13397985 chr2 231091223 T G 2.00E-07 Chronic lymphocytic leukemia SP140 intron 22700719 rs13397985 chr2 231091223 T G 1.75E-07 Erectile dysfunction SP140 intron 22704111 rs13397985 chr2 231091223 T G 1.00E-22 Chronic lymphocytic leukemia SP140 intron 23770605 rs13397985 chr2 231091223 T G 5.00E-13 Chronic lymphocytic leukemia SP140 intron 24292274 rs13397985 chr2 231091223 T G 7.51E-06 Waist Circumference SP140 intron pha003023 rs6716753 chr2 231097129 T C 1.00E-16 Crohn's disease SP140 intron 23128233 rs10201872 chr2 231106724 C T 2.00E-10 Multiple sclerosis SP140 intron 21833088 rs10201872 chr2 231106724 C T 5.60E-04 Multiple sclerosis SP140 intron 24234648 rs10201872 chr2 231106724 C T 3.10E-06 Waist Circumference SP140 intron pha003023 rs6743984 chr2 231109329 T C 3.52E-05 Multiple complex diseases SP140 intron 17554300 rs6743984 chr2 231109329 T C 2.48E-06 Crohn's disease SP140 intron 18587394 rs6743984 chr2 231109329 T C 7.26E-04 Lymphocyte counts SP140 intron 22286170 rs10498245 chr2 231111422 A G 9.50E-04 Amyotrophic lateral sclerosis (sporadic) SP140 intron 24529757 rs9989899 chr2 231114131 G A 5.97E-06 Waist Circumference SP140 intron pha003023 rs9989808 chr2 231114180 A G 1.70E-05 Urinary metabolites SP140 intron 21572414 rs2114590 chr2 231114593 C G 1.10E-05 Urinary metabolites SP140 intron 21572414 rs2114590 chr2 231114593 C G 1.47E-04 Response to taxane treatment (placlitaxel) SP140 intron 23006423 rs9989792 chr2 231115603 T C 4.67E-04 Response to taxane treatment (placlitaxel) SP140 intron 23006423 rs7423615 chr2 231116874 C T 3.00E-13 Crohn's disease SP140 intron 21102463 rs3820975 chr2 231118041 A C 1.60E-06 Urinary metabolites SP140 missense 21572414 rs4973305 chr2 231139382 C A,T 7.30E-06 Urinary metabolites SP140 intron 21572414 rs4973306 chr2 231139777 T C 7.52E-05 Cognitive performance SP140 intron 19734545 rs11689231 chr2 231148009 A G 6.72E-05 Platelet counts SP140 intron pha003100 rs6710297 chr2 231157512 A G 1.95E-04 Multiple complex diseases SP140 intron 17554300 rs3769846 chr2 231159410 T A 4.10E-06 Urinary metabolites SP140 intron 21572414 rs16827035 chr2 231174138 G C 5.90E-05 Response to statin therapy SP140 intron 20339536 rs6707578 chr2 231174420 G A 2.20E-05 Urinary metabolites SP140 intron 21572414 rs4973310 chr2 231180915 A G 8.90E-05 Response to statin therapy / / 20339536 rs4973310 chr2 231180915 A G 7.32E-05 Kawasaki disease / / 22081228 rs4973311 chr2 231180966 A G 8.10E-05 Response to statin therapy / / 20339536 rs4973311 chr2 231180966 A G 3.20E-07 Urinary metabolites / / 21572414 rs4973312 chr2 231181285 C T 8.20E-05 Response to statin therapy / / 20339536 rs4973312 chr2 231181285 C T 1.30E-06 Urinary metabolites / / 21572414 rs12464193 chr2 231181428 G A 8.00E-05 Response to statin therapy / / 20339536 rs12464229 chr2 231181554 G A 7.40E-05 Response to statin therapy / / 20339536 rs11886029 chr2 231182472 G C 6.40E-05 Response to statin therapy / / 20339536 rs10498248 chr2 231182505 C T 5.50E-05 Response to statin therapy / / 20339536 rs10498248 chr2 231182505 C T 5.70E-07 Urinary metabolites / / 21572414 rs11887130 chr2 231182682 C T 6.60E-05 Response to statin therapy / / 20339536 rs10498249 chr2 231182893 C T 4.50E-05 Response to statin therapy / / 20339536 rs12466273 chr2 231183091 G A 4.10E-05 Response to statin therapy / / 20339536 rs720977 chr2 231183321 G A 7.54E-05 Cognitive test performance / / 20125193 rs6726527 chr2 231184106 G T 2.60E-05 Response to statin therapy / / 20339536 rs6726527 chr2 231184106 G T 6.30E-06 Urinary metabolites / / 21572414 rs16827136 chr2 231196132 C A 2.26E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SP140L intron 24023788 rs4973316 chr2 231221928 C T 3.47E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SP140L intron 24023788 rs11678791 chr2 231223975 C T 3.44E-05 Platelet counts SP140L intron pha003100 rs16827171 chr2 231224255 A G 1.00E-06 Urinary metabolites SP140L intron 21572414 rs6712333 chr2 231230171 C T 5.00E-06 Nicotine use SP140L intron 23942779 rs6712333 chr2 231230171 C T 6.10E-05 Alcohol dependence SP140L intron 23942779 rs6712333 chr2 231230171 C T 8.30E-04 Illicit drug use SP140L intron 23942779 rs12694866 chr2 231284556 T C 8.78E-04 Tourette syndrome SP100 intron 22889924 rs7595408 chr2 231320960 T G 4.49E-05 Response to mTOR inhibitor (rapamycin) SP100 intron 24009623 rs1649866 chr2 231329517 G A 2.03E-05 Bone mineral traits,in men SP100 intron 21427758 rs1649890 chr2 231337546 A C 2.00E-05 Urinary metabolites SP100 intron 21572414 rs1678211 chr2 231349111 C T 2.90E-05 Urinary metabolites SP100 intron 21572414 rs1678189 chr2 231411995 A T 4.83E-04 Multiple complex diseases / / 17554300 rs17275498 chr2 231420401 A C 8.00E-06 Cognitive performance / / 20125193 rs6759540 chr2 231428531 G A 2.60E-05 Urinary metabolites / / 21572414 rs17354508 chr2 231429977 G A 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10933342 chr2 231442359 A T 3.12E-04 Type 2 diabetes / / 17463246 rs7562389 chr2 231442496 T C 7.13E-04 Alzheimer's disease / / 17998437 rs11691070 chr2 231442959 G A 8.09E-05 Epilepsy (remission after treatment) / / 23962720 rs11674767 chr2 231443143 T C 8.14E-05 Epilepsy (remission after treatment) / / 23962720 rs73992446 chr2 231443209 T C 8.14E-05 Epilepsy (remission after treatment) / / 23962720 rs10498252 chr2 231443428 G T 4.21E-04 Type 2 diabetes / / 17463246 rs2241534 chr2 231443615 C T 8.10E-05 Epilepsy (remission after treatment) / / 23962720 rs2241536 chr2 231443924 T C 8.99E-05 Epilepsy (remission after treatment) / / 23962720 rs2241537 chr2 231444292 T C 8.06E-05 Epilepsy (remission after treatment) / / 23962720 rs56199999 chr2 231444470 C T 8.02E-05 Epilepsy (remission after treatment) / / 23962720 rs11692958 chr2 231444526 G T 8.03E-05 Epilepsy (remission after treatment) / / 23962720 rs11681649 chr2 231444531 A T 8.03E-05 Epilepsy (remission after treatment) / / 23962720 rs11694266 chr2 231444896 C T 8.05E-05 Epilepsy (remission after treatment) / / 23962720 rs11694317 chr2 231445045 C G 8.02E-05 Epilepsy (remission after treatment) / / 23962720 rs73992447 chr2 231445247 C T 7.99E-05 Epilepsy (remission after treatment) / / 23962720 rs113951959 chr2 231446036 C T 9.21E-05 Epilepsy (remission after treatment) / / 23962720 rs11676418 chr2 231447589 C G 9.46E-05 Epilepsy (remission after treatment) / / 23962720 rs11682332 chr2 231447604 T C 9.44E-05 Epilepsy (remission after treatment) / / 23962720 rs11687550 chr2 231447739 A G 9.46E-05 Epilepsy (remission after treatment) / / 23962720 rs11682484 chr2 231447937 T C 6.82E-05 Epilepsy (remission after treatment) / / 23962720 rs80252298 chr2 231448572 C T 3.44E-05 Epilepsy (remission after treatment) / / 23962720 rs79961618 chr2 231448590 G A 3.49E-05 Epilepsy (remission after treatment) / / 23962720 rs77776156 chr2 231448703 A G 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs80339554 chr2 231448713 T C 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs76024850 chr2 231448773 G A 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs77816227 chr2 231448842 C A 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs79209263 chr2 231448987 A G 3.50E-05 Epilepsy (remission after treatment) / / 23962720 rs78397825 chr2 231449008 C T 5.21E-05 Epilepsy (remission after treatment) / / 23962720 rs75634989 chr2 231449009 A G 5.21E-05 Epilepsy (remission after treatment) / / 23962720 rs4972965 chr2 231477415 G A 6.65E-05 HIV-1 viral setpoint / / 22174851 rs10168790 chr2 231492965 C A 7.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7584576 chr2 231508389 T C 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9973459 chr2 231525099 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs16827514 chr2 231546750 T C 5.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs938906 chr2 231555684 T C 4.23E-05 Cognitive performance / / 19734545 rs9973480 chr2 231573384 A C 2.90E-04 Alcohol dependence / / 20201924 rs9973480 chr2 231573384 A C 5.30E-04 Alcohol dependence / / 20201924 rs11682404 chr2 231574896 A G 2.70E-04 Alcohol dependence / / 20201924 rs11682404 chr2 231574896 A G 3.10E-04 Alcohol dependence / / 20201924 rs10933355 chr2 231582196 G A 3.10E-04 Alcohol dependence CAB39 intron 20201924 rs10933355 chr2 231582196 G A 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs6436971 chr2 231582797 T C 2.00E-05 Urinary metabolites CAB39 intron 21572414 rs13411251 chr2 231586340 T G 2.40E-04 Alcohol dependence CAB39 intron 20201924 rs13411251 chr2 231586340 T G 3.10E-04 Alcohol dependence CAB39 intron 20201924 rs6711453 chr2 231594089 A G 3.00E-04 Alcohol dependence CAB39 intron 20201924 rs6711453 chr2 231594089 A G 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs6717266 chr2 231613141 G A 3.00E-04 Alcohol dependence CAB39 intron 20201924 rs6717266 chr2 231613141 G A 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs2438296 chr2 231651832 G T 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAB39 intron 20877124 rs3792068 chr2 231673225 A G 3.40E-04 Alcohol dependence CAB39 intron 20201924 rs3792068 chr2 231673225 A G 4.00E-04 Alcohol dependence CAB39 intron 20201924 rs6436975 chr2 231701319 G A 3.62E-04 Multiple complex diseases / / 17554300 rs10182071 chr2 231709953 A G 5.14E-05 Orofacial clefts / / 19270707 rs2466149 chr2 231722128 T C 2.82E-05 Bipolar disorder / / 22925353 rs10201627 chr2 231774377 C A 0.000441 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) GPR55 UTR-3 23527081 rs3749073 chr2 231775094 C A 0.000536 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) GPR55 missense 23527081 rs3111780 chr2 231790097 T C 3.21E-04 Stroke (pediatric) / / 22990015 rs2175149 chr2 231877207 T C 1.66E-04 Bipolar disorder,schizoaffective / / 19567891 rs2136477 chr2 231877319 G A 5.20E-05 Malaria / / 19465909 rs2136477 chr2 231877319 G A 9.40E-05 Bipolar disorder,schizoaffective / / 19567891 rs4973362 chr2 231877952 G T 9.54E-05 Bipolar disorder,schizoaffective / / 19567891 rs1543061 chr2 231878496 C T 9.60E-07 Malaria / / 19465909 rs1543061 chr2 231878496 C T 9.21E-05 Bipolar disorder,schizoaffective / / 19567891 rs10192428 chr2 231878740 G A 5.10E-07 Malaria / / 19465909 rs10192428 chr2 231878740 G A 1.01E-04 Bipolar disorder,schizoaffective / / 19567891 rs6750230 chr2 231880112 G A 1.60E-05 Malaria / / 19465909 rs6750277 chr2 231880308 C T 6.60E-05 Malaria / / 19465909 rs6750277 chr2 231880308 C T 6.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs4973370 chr2 231882118 G A 1.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs4973371 chr2 231882293 A G 2.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs4973374 chr2 231885415 T C 1.15E-05 HIV-1 progression to AIDS and death / / 21811574 rs4973374 chr2 231885415 T C 1.15E-05 HIV-1 progression to AIDS and death / / 21811574 rs4973374 chr2 231885415 T C 1.80E-04 HIV-1 progression to AIDS and death / / 21811574 rs1472959 chr2 231940960 A G 9.81E-04 Alzheimer's disease PSMD1 intron 17998437 rs6736017 chr2 231973416 T C 0.000000137 LDL cholesterol HTR2B missense 23063622 rs6736017 chr2 231973416 T C 7.39E-16 Triglycerides HTR2B missense 23063622 rs6437001 chr2 232013304 G T 5.24E-05 Multiple complex diseases PSMD1 intron 17554300 rs6437002 chr2 232025284 G A 6.86E-05 HDL particle features PSMD1 intron pha002900 rs6755467 chr2 232044684 A C 1.01E-04 Multiple complex diseases / / 17554300 rs753855 chr2 232066651 T C 9.82E-06 Alzheimer's disease (age of onset) ARMC9 intron 22005931 rs5018532 chr2 232077075 A G 1.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ARMC9 intron 23648065 rs5018532 chr2 232077075 A G 6.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ARMC9 intron 23648065 rs16827863 chr2 232077670 T C 1.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ARMC9 intron 23648065 rs16827863 chr2 232077670 T C 6.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ARMC9 intron 23648065 rs3731776 chr2 232091479 C T 4.53E-04 Multiple complex diseases ARMC9 intron 17554300 rs6437008 chr2 232091948 C G 0.000096 Panic disorder ARMC9 intron 23149450 rs6437008 chr2 232091948 C G 9.60E-05 Serum tamsulosin hydrochloride concentration ARMC9 intron 23151678 rs9677476 chr2 232126290 A G 2.40E-05 Urinary metabolites ARMC9 intron 21572414 rs745962 chr2 232159212 T C 7.00E-06 Follicle stimulating hormone ARMC9 intron 24049095 rs11894854 chr2 232171968 A G 9.75E-04 Suicide attempts in bipolar disorder ARMC9 intron 21423239 rs7580717 chr2 232176541 G A 5.00E-06 Multiple myeloma ARMC9 intron 23955597 rs1868929 chr2 232183591 C T 7.67E-05 Systemic sclerosis ARMC9 intron 21779181 rs6753112 chr2 232187155 C T 5.00E-06 Multiple myeloma ARMC9 intron 23955597 rs10498225 chr2 232190985 C A 9.29E-04 Celiac disease ARMC9 intron 23936387 rs1669070 chr2 232192305 C T 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARMC9 intron 23400010 rs1729086 chr2 232208056 C T 4.72E-04 Smoking cessation ARMC9 intron 24665060 rs1729085 chr2 232208941 C G 6.15E-04 Smoking cessation ARMC9 intron 24665060 rs2595503 chr2 232252322 T G 2.60E-04 Smoking cessation / / 24665060 rs13030174 chr2 232271284 A C 1.00E-10 Heart rate / / 23583979 rs12475512 chr2 232298076 G A 7.00E-07 Eating disorders (purging via substances) / / 23568457 rs13017932 chr2 232298812 C T 9.67E-04 Acute lung injury / / 22295056 rs7563453 chr2 232301670 G A 1.90E-05 Urinary metabolites / / 21572414 rs7563453 chr2 232301670 G A 9.31E-04 Acute lung injury / / 22295056 rs16828074 chr2 232318754 C G,T 4.31E-04 Multiple complex diseases / / 17554300 rs16828074 chr2 232318754 C G,T 6.00E-09 Attention deficit hyperactivity disorder / / 23728934 rs4449121 chr2 232370059 A C 5.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs6750795 chr2 232378231 T C 2.00E-08 Height LINC00471 intron 23563607 rs1797395 chr2 232401503 T C 1.60E-05 Serum metabolites / / 19043545 rs1667305 chr2 232403829 T C 2.32E-05 Blood Pressure / / pha003043 rs1797396 chr2 232403863 G A 8.78E-04 Type 2 diabetes / / 17463246 rs1797397 chr2 232404469 A G 1.75E-05 Serum metabolites / / 19043545 rs1667313 chr2 232408018 A C 2.32E-05 Blood Pressure / / pha003043 rs1667314 chr2 232408269 A T 1.83E-05 Serum metabolites / / 19043545 rs2595506 chr2 232408841 G A 3.51E-05 Serum metabolites / / 19043545 rs2595506 chr2 232408841 G A 1.46E-07 Lymphocyte counts / / 22286170 rs1797386 chr2 232414338 C T 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs1667320 chr2 232418314 G T 2.00E-04 Dietary macronutrient intake / / 23636237 rs10165533 chr2 232419666 A C 1.92E-05 Coronary heart disease / / pha003031 rs1797392 chr2 232422257 C T 6.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs1667301 chr2 232423717 A G 6.78E-05 Cardiovascular disease / / pha003065 rs6733018 chr2 232425276 A G 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs12993888 chr2 232425763 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs4340504 chr2 232432298 A C 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs10460338 chr2 232434661 C T 4.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs6727830 chr2 232436364 G A 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498258 chr2 232437359 A G 3.37E-04 Type 2 diabetes / / 17463246 rs10498258 chr2 232437359 A G 4.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs10182727 chr2 232440737 A T 4.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13025854 chr2 232441175 C A 4.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs4973009 chr2 232461115 A G 2.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs4973462 chr2 232491289 C T 9.40E-06 Urinary metabolites / / 21572414 rs13007920 chr2 232491355 C T 2.87E-05 Body Mass Index / / pha003015 rs13007920 chr2 232491355 C T 4.10E-05 Waist Circumference / / pha003025 rs4530357 chr2 232540702 T C 5.04E-05 Hypertension / / 22384028 rs3856531 chr2 232544906 C T 2.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4973472 chr2 232550160 T A 2.87E-05 Serum metabolites / / 19043545 rs4973475 chr2 232553362 C T 4.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13398149 chr2 232564881 A C 2.15E-05 Response to methylphenidate treatment / / 21130132 rs13398149 chr2 232564881 A C 6.50E-05 Major depressive disorder / / 22472876 rs6737601 chr2 232572381 A G 1.35E-05 Major depressive disorder / / 22472876 rs6755895 chr2 232579795 T C 3.17E-05 Major depressive disorder / / 22472876 rs11695646 chr2 232584807 A G 2.02E-05 Major depressive disorder / / 22472876 rs838423 chr2 232598197 G A 1.41E-04 Fibrinogen PDE6D intron 17255346 rs4973479 chr2 232624863 C T 0.000000315 Total IFN-gamma response to smallpox vaccine PDE6D intron 22661280 rs10195385 chr2 232720739 A G 4.74E-04 Multiple complex diseases / / 17554300 rs1866599 chr2 232726300 C T 6.07E-04 Major depressive disorder / / 22472876 rs2119063 chr2 232751057 T G 7.78E-04 Coronary Artery Disease / / 17634449 rs2119061 chr2 232751260 G A 8.63E-04 Coronary Artery Disease / / 17634449 rs2679180 chr2 232756528 C T 8.16E-05 Serum metabolites / / 19043545 rs3107179 chr2 232788325 C T 9.60E-10 Height NPPC intron 21194676 rs749052 chr2 232796610 T C 1.00E-06 Height / / 18391951 rs749052 chr2 232796610 T C 5.04E-05 Bipolar disorder and schizophrenia / / 20889312 rs2679178 chr2 232797861 C T 5.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs2679178 chr2 232797861 C T 1.60E-09 Height / / 21194676 rs2679178 chr2 232797861 C T 3.80E-06 Height / / 21194676 rs2679178 chr2 232797861 C T 4.40E-14 Height / / 21194676 rs2580816 chr2 232797966 C T 6.00E-22 Height / / 20881960 rs2580817 chr2 232798723 G A 1.20E-04 Attention deficit hyperactivity disorder / / 22012869 rs2580823 chr2 232806319 G A 1.59E-05 Recombination rate / / 21698098 rs12473319 chr2 232880971 G C 2.91E-05 Multiple complex diseases DIS3L2 intron 17554300 rs3100624 chr2 232938583 C T 9.00E-04 Bipolar disorder DIS3L2 intron 17486107 rs3100584 chr2 232946290 C T 8.49E-05 Bipolar disorder and schizophrenia DIS3L2 intron 20889312 rs3116158 chr2 232955363 G A 6.62E-05 Bipolar disorder and schizophrenia DIS3L2 intron 20889312 rs3103267 chr2 232988582 A C 3.00E-08 Height DIS3L2 intron 23563607 rs3103296 chr2 233034495 T C 3.10E-05 Height DIS3L2 intron 21194676 rs3103296 chr2 233034495 T C 4.80E-09 Height DIS3L2 intron 21194676 rs3103296 chr2 233034495 T C 5.60E-05 Height DIS3L2 intron 21194676 rs4973508 chr2 233067832 T A 1.00E-05 Malaria DIS3L2 intron 19465909 rs7571816 chr2 233077064 A G 9.00E-09 Height DIS3L2 intron 20189936 rs13020779 chr2 233149600 A G 8.00E-05 Lung cancer DIS3L2 intron 18978790 rs6717918 chr2 233155110 T C 3.00E-09 Height DIS3L2 intron 19570815 rs12617170 chr2 233161765 A G 4.93E-04 Alzheimer's disease (late onset) DIS3L2 intron 21379329 rs2741311 chr2 233239743 T C 4.31E-04 Myopia (pathological) / / 21095009 rs7599982 chr2 233247873 G A 4.52E-05 Type 2 diabetes ALPP nearGene-3 22158537 rs7573222 chr2 233247934 A C 3.97E-05 Type 2 diabetes ALPP nearGene-3 22158537 rs11687072 chr2 233259466 A G 7.25E-06 Type 2 diabetes / / 17463246 rs11687072 chr2 233259466 A G 2.38E-05 Type 2 diabetes / / 22158537 rs2741321 chr2 233280239 C T 2.48E-04 Type 2 diabetes / / 17463246 rs2741321 chr2 233280239 C T 2.04E-05 Type 2 diabetes / / 22158537 rs744873 chr2 233280565 A G 1.76E-04 Type 2 diabetes / / 17463246 rs744874 chr2 233280822 G T 1.76E-04 Type 2 diabetes / / 17463246 rs2573219 chr2 233288667 A C 1.97E-05 Type 2 diabetes / / 22158537 rs2853392 chr2 233293773 A G 1.94E-05 Type 2 diabetes / / 22158537 rs2573232 chr2 233300046 T C 8.85E-05 Type 2 diabetes / / 22158537 rs790025 chr2 233303133 C A 4.49E-05 Parkinson's disease / / 17052657 rs790039 chr2 233309026 G C 3.82E-04 Type 2 diabetes / / 22158537 rs2678505 chr2 233309066 A G 3.76E-04 Type 2 diabetes / / 17463246 rs2678505 chr2 233309066 A G 1.60E-04 Type 2 diabetes / / 22158537 rs2853407 chr2 233310094 C T 1.47E-04 Type 2 diabetes / / 22158537 rs6721457 chr2 233319977 G C 6.60E-05 Aortic root size / / 21223598 rs2003780 chr2 233323177 T C 4.06E-05 Waist-Hip Ratio ALPI intron pha003013 rs2003780 chr2 233323177 T C 4.12E-05 Waist-Hip Ratio ALPI intron pha003028 rs11693163 chr2 233326446 C T 5.10E-05 Waist-Hip Ratio / / pha003013 rs11693163 chr2 233326446 C T 6.10E-05 Waist-Hip Ratio / / pha003028 rs2853425 chr2 233343228 G A 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1190468 chr2 233353904 G A 0.00023 Coronary artery calcification / / 23727086 rs2573223 chr2 233372850 A G 8.26E-06 Sleep duration / / 22105623 rs1656404 chr2 233379941 G A 8.00E-11 Refractive error / / 23396134 rs2697804 chr2 233380020 G A 4.46E-06 Sleep duration / / 22105623 rs2697800 chr2 233383416 C T 1.97E-05 Sleep duration PRSS56 nearGene-5 22105623 rs2697800 chr2 233383416 C T 1.30E-04 Smoking quantity PRSS56 nearGene-5 24665060 rs1550094 chr2 233385396 G A 1.30E-15 Myopia (Age of onset) PRSS56 missense 23468642 rs2245601 chr2 233390937 A G 4.13E-06 Sleep duration CHRND cds-synon 22105623 rs12466358 chr2 233397525 T G 1.03E-05 Arthritis (juvenile idiopathic) CHRND intron 22354554 rs1881492 chr2 233406998 T G 6.96E-04 Multiple complex diseases CHRNG intron 17554300 rs1881492 chr2 233406998 T G 5.00E-11 Refractive error CHRNG intron 23396134 rs2853462 chr2 233407120 C T 7.61E-05 Cytomegalovirus antibody response CHRNG intron 21993531 rs1190449 chr2 233418920 G T 4.07E-04 Smoking quantity EIF4E2 intron 24665060 rs1656402 chr2 233426526 C T 8.00E-08 Non-small cell lung cancer (survival) EIF4E2 intron 21079520 rs2276560 chr2 233450919 C T 9.67E-05 Femoral neck bone geometry / / 22087292 rs2140773 chr2 233513175 C A 1.00E-09 Liver enzyme levels (gamma-glutamyl transferase) EFHD1 intron 22001757 rs7578760 chr2 233533202 C T 1.03E-06 Schizophrenia EFHD1 intron 21795503 rs10207739 chr2 233684097 T C 9.19E-04 Rheumatoid arthritis GIGYF2 intron 21452313 rs6731064 chr2 233721684 A C 7.35E-04 Aortic root size GIGYF2 UTR-3 21223598 rs2675968 chr2 233736244 C T 2.58E-06 Schizophrenia C2orf82 intron 21926974 rs2675968 chr2 233736244 C T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) C2orf82 intron 23453885 rs2675968 chr2 233736244 C T 0.0000564 Schizophrenia C2orf82 intron 23637625 rs778371 chr2 233743109 A G 2.00E-08 Schizophrenia / / 23974872 rs895431 chr2 233759362 G C 1.33E-04 Sudden cardiac arrest NGEF intron 21658281 rs7355380 chr2 233772300 C T 5.63E-05 Soluble levels of adhesion molecules NGEF intron pha003072 rs809017 chr2 233774183 G A 7.72E-05 Intracranial aneurysm NGEF intron 22286173 rs778362 chr2 233780186 C T 4.19E-04 Sudden cardiac arrest NGEF intron 21658281 rs7602554 chr2 233820737 G A 7.10E-06 Urinary metabolites NGEF intron 21572414 rs7583124 chr2 233835654 C T 4.95E-04 Obesity (extreme) NGEF intron 21935397 rs11678495 chr2 233838447 A G 5.13E-04 Obesity (extreme) NGEF intron 21935397 rs6437079 chr2 233839174 G A 5.68E-04 Obesity (extreme) NGEF intron 21935397 rs954526 chr2 233840063 A G 4.55E-04 Obesity (extreme) NGEF intron 21935397 rs938572 chr2 233841300 G A 2.00E-04 Obesity (extreme) NGEF intron 21935397 rs938573 chr2 233841366 A G 1.82E-04 Obesity (extreme) NGEF intron 21935397 rs6745724 chr2 233854241 A G 2.00E-04 Adiposity NGEF intron 19461586 rs11885626 chr2 233854397 G A 6.00E-05 Prostate cancer NGEF intron 21743057 rs6437080 chr2 233855461 G A 9.14E-04 Alzheimer's disease NGEF intron 17998437 rs4973062 chr2 233858636 C T 1.30E-04 Adiposity NGEF intron 19461586 rs1104953 chr2 233870366 G C 4.59E-04 Obesity (extreme) NGEF intron 21935397 rs10169320 chr2 233871619 A G 4.54E-04 Obesity (extreme) NGEF intron 21935397 rs10169752 chr2 233872049 A G 4.83E-04 Obesity (extreme) NGEF intron 21935397 rs13383577 chr2 233874399 T C 5.00E-04 Adiposity NGEF intron 19461586 rs3811588 chr2 233875975 G A 1.66E-05 Sudden cardiac arrest NGEF intron 21658281 rs13396115 chr2 233882712 T C 6.99E-04 Obesity (extreme) / / 21935397 rs6437086 chr2 233893807 A G 2.00E-05 Lupus / / 17911428 rs4511711 chr2 233895666 A C 9.19E-05 Lung function (forced vital capacity) / / pha003104 rs2233375 chr2 233896498 C T 4.00E-06 Contrast sensitivity / / 24152035 rs2233382 chr2 233897161 A C 7.79E-04 Multiple complex diseases / / 17554300 rs11695991 chr2 233900089 A C 8.16E-06 Contrast sensitivity / / 24152035 rs62191860 chr2 233904259 C T 8.31E-06 Contrast sensitivity / / 24152035 rs4246649 chr2 233925491 A G 2.67E-07 Contrast sensitivity / / 24152035 rs11674347 chr2 233941388 A G 3.25E-04 Smoking quantity / / 24665060 rs4356648 chr2 233950265 C A 5.12E-05 Type 2 diabetes / / 17463246 rs6756729 chr2 233957253 A T 1.97E-04 Type 2 diabetes / / 17463246 rs6437090 chr2 233962551 G A 6.61E-06 Contrast sensitivity / / 24152035 rs9288685 chr2 233987114 T C 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10200271 chr2 233997057 A C 7.51E-04 Multiple complex diseases / / 17554300 rs10933434 chr2 233998108 G T 2.20E-05 Urinary metabolites / / 21572414 rs10933436 chr2 233998481 C A 7.00E-06 Coronary heart disease / / 21378990 rs35349669 chr2 234068476 C T 3.00E-08 Alzheimer's disease (late onset) / / 24162737 rs11673739 chr2 234072738 A G 9.55E-04 Obesity (extreme) / / 21935397 rs10929180 chr2 234073523 G C 9.67E-04 Obesity (extreme) / / 21935397 rs4436949 chr2 234092392 A G 6.58E-05 Obesity (extreme) / / 21935397 rs4663834 chr2 234118583 T G 1.90E-05 Urinary metabolites / / 21572414 rs12471808 chr2 234138324 A T 1.90E-05 Urinary metabolites / / 21572414 rs2083575 chr2 234145080 T C 1.78E-04 Multiple complex diseases / / 17554300 rs2083575 chr2 234145080 T C 1.00E-07 Bilirubin levels / / 19414484 rs10210302 chr2 234158839 C T 5.00E-14 Crohn's disease ATG16L1 nearGene-5 17554300 rs6752107 chr2 234161448 G A 3.80E-05 Multiple complex diseases ATG16L1 intron 17554300 rs6431654 chr2 234161769 C T 1.39E-16 Multiple complex diseases ATG16L1 intron 17554300 rs6737398 chr2 234170397 G A 1.23E-06 Multiple complex diseases ATG16L1 intron 17554300 rs12994997 chr2 234173503 G A 4.00E-70 Crohn's disease ATG16L1 intron 23128233 rs3828309 chr2 234180410 A G 7.98E-05 Multiple complex diseases ATG16L1 intron 17554300 rs3828309 chr2 234180410 A G 2.00E-32 Crohn's disease ATG16L1 intron 18587394 rs3828309 chr2 234180410 A G 2.00E-32 Asthma ATG16L1 intron 21150878 rs3828309 chr2 234180410 A G 2.36E-32 Multiple sclerosis ATG16L1 intron 22190364 rs2289473 chr2 234182025 C A,G,T 1.20E-07 Bilirubin levels ATG16L1 intron 19414484 rs2241880 chr2 234183368 A G 1.00E-13 Crohn's disease ATG16L1 missense 17435756 rs2241880 chr2 234183368 A G 8.68E-07 Crohn's disease ATG16L1 missense 17684544 rs2241880 chr2 234183368 A G 4.61E-25 Crohn's disease ATG16L1 missense 18587394 rs2241880 chr2 234183368 A G 3.00E-06 Crohn's disease ATG16L1 missense 20570966 rs2241880 chr2 234183368 A G 1.00E-12 Crohn's disease ATG16L1 missense 22412388 rs3792109 chr2 234184417 G A 7.00E-41 Crohn's disease ATG16L1 intron 21102463 rs3792109 chr2 234184417 G A 5.00E-09 Crohn's disease ATG16L1 intron 22936669 rs3792106 chr2 234190740 T C 2.60E-13 Multiple complex diseases ATG16L1 intron 17554300 rs4663396 chr2 234192251 C T 7.58E-08 Multiple complex diseases ATG16L1 intron 17554300 rs7587051 chr2 234194755 G C 3.60E-10 Bilirubin levels ATG16L1 intron 19414484 rs11890449 chr2 234199401 C T 6.13E-04 Multiple complex diseases ATG16L1 intron 17554300 rs6431262 chr2 234199537 G T 6.28E-05 Multiple complex diseases ATG16L1 intron 17554300 rs4663421 chr2 234201700 G C 1.30E-04 Multiple complex diseases ATG16L1 intron 17554300 rs4663147 chr2 234210681 G A 6.05E-05 Crohn's disease / / 23850713 rs6759896 chr2 234210972 G A 2.10E-07 Bilirubin levels / / 19414484 rs6759896 chr2 234210972 G A 1.70E-04 Eating disorders / / 23568457 rs3792104 chr2 234221935 G T 1.68E-04 Response to cytadine analogues (cytosine arabinoside) SAG intron 24483146 rs11891546 chr2 234232722 T G 2.60E-10 Bilirubin levels SAG intron 19414484 rs2304773 chr2 234235820 C T 6.26E-04 Response to cytadine analogues (cytosine arabinoside) SAG cds-synon 24483146 rs880116 chr2 234246264 C T 4.00E-05 Bilirubin levels SAG intron 19414484 rs880114 chr2 234246458 T C 3.90E-05 Bilirubin levels SAG intron 19414484 rs3828305 chr2 234246994 A G 3.90E-05 Bilirubin levels SAG intron 19414484 rs13427703 chr2 234247508 C G 1.42E-04 Response to cytadine analogues (cytosine arabinoside) SAG intron 24483146 rs13427703 chr2 234247508 C G 4.27E-04 Smoking initiation SAG intron 24665060 rs2241874 chr2 234247627 T C 1.87E-04 Multiple complex diseases SAG intron 17554300 rs2241873 chr2 234247924 G A 2.08E-04 Multiple complex diseases SAG intron 17554300 rs3792091 chr2 234251322 T G 2.30E-06 Bilirubin levels SAG intron 19414484 rs1046974 chr2 234255547 G A 3.80E-08 Bilirubin levels SAG missense 19414484 rs13014016 chr2 234257454 A G 3.50E-06 Bilirubin levels / / 19414484 rs11679046 chr2 234258101 C T 4.30E-06 Bilirubin levels / / 19414484 rs1550532 chr2 234264848 C G 2.40E-14 Bilirubin levels DGKD intron 19414484 rs1550532 chr2 234264848 C G 1.20E-07 Bilirubin levels DGKD intron 19419973 rs1550532 chr2 234264848 C G 3.08E-19 Bilirubin levels,in serum DGKD intron 20639394 rs1550532 chr2 234264848 C G 8.00E-11 Calcium levels DGKD intron 24068962 rs1441093 chr2 234272484 A G 1.50E-07 Bilirubin levels DGKD intron 19414484 rs838705 chr2 234273242 G A 3.30E-13 Bilirubin levels DGKD intron 19414484 rs838705 chr2 234273242 G A 9.00E-06 Calcium levels DGKD intron 20705733 rs838705 chr2 234273242 G A 0.00047 Prostate cancer (non-advanced prostate cancer) DGKD intron 23555315 rs7573866 chr2 234276216 T C 1.40E-14 Bilirubin levels DGKD intron 19414484 rs7576633 chr2 234279252 C G 2.30E-09 Bilirubin levels DGKD intron 19414484 rs7566221 chr2 234279295 G C 2.50E-04 Multiple complex diseases DGKD intron 17554300 rs7566221 chr2 234279295 G C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs6759246 chr2 234281439 G C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs6722763 chr2 234282210 A G 1.60E-09 Bilirubin levels DGKD intron 19414484 rs7580412 chr2 234283288 T C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs838708 chr2 234284399 G A 1.80E-15 Bilirubin levels DGKD intron 19414484 rs838708 chr2 234284399 G A 4.35E-08 Bilirubin levels DGKD intron 19419973 rs838708 chr2 234284399 G A 6.37E-18 Bilirubin levels,in serum DGKD intron 20639394 rs838709 chr2 234284744 C A 9.80E-15 Bilirubin levels DGKD intron 19414484 rs838709 chr2 234284744 C A 6.85E-18 Bilirubin levels,in serum DGKD intron 20639394 rs6726046 chr2 234287221 G A 2.50E-05 Bilirubin levels DGKD intron 19414484 rs7598771 chr2 234288048 T C 2.40E-14 Bilirubin levels DGKD intron 19414484 rs838716 chr2 234294791 G C 1.40E-15 Bilirubin levels DGKD intron 19414484 rs838717 chr2 234296444 G A 8.30E-16 Bilirubin levels DGKD intron 19414484 rs838718 chr2 234296650 G A 1.80E-16 Bilirubin levels DGKD intron 19414484 rs706848 chr2 234299919 G A 3.00E-16 Bilirubin levels DGKD intron 19414484 rs706848 chr2 234299919 G A 1.26E-08 Bilirubin levels,in serum DGKD intron 20639394 rs7584554 chr2 234308782 T G 1.60E-18 Bilirubin levels DGKD intron 19414484 rs13414407 chr2 234313158 A G 6.55E-04 Smoking initiation DGKD intron 24665060 rs838730 chr2 234314479 A T 1.80E-05 Bilirubin levels DGKD intron 19414484 rs7568534 chr2 234315079 G C 1.10E-08 Bilirubin levels DGKD intron 19414484 rs838731 chr2 234315363 C T 1.80E-05 Bilirubin levels DGKD intron 19414484 rs7422734 chr2 234315792 C T 5.79E-04 Smoking initiation DGKD intron 24665060 rs7587876 chr2 234316032 A G 9.40E-15 Bilirubin levels DGKD intron 19414484 rs838732 chr2 234321752 T C 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838733 chr2 234323261 A G 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838733 chr2 234323261 A G 2.48E-04 Lymphocyte counts DGKD intron 22286170 rs838734 chr2 234323564 G A 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838735 chr2 234324192 G C 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838736 chr2 234324232 G A 1.20E-17 Bilirubin levels DGKD intron 19414484 rs6753242 chr2 234329419 G T 7.00E-15 Bilirubin levels DGKD intron 19414484 rs2971868 chr2 234329549 T C 1.30E-05 Bilirubin levels DGKD intron 19414484 rs2924808 chr2 234329816 G C 4.90E-18 Bilirubin levels DGKD intron 19414484 rs11694406 chr2 234331810 G A 4.50E-17 Bilirubin levels DGKD intron 19414484 rs11694406 chr2 234331810 G A 5.45E-08 Metabolite levels DGKD intron 23281178 rs11689634 chr2 234338179 T C 1.70E-13 Bilirubin levels DGKD intron 19414484 rs11681604 chr2 234338227 G A 4.10E-08 Bilirubin levels DGKD intron 19414484 rs11892545 chr2 234338935 G A 6.77E-05 Multiple complex diseases DGKD intron 17554300 rs6714168 chr2 234339999 A G 3.50E-08 Bilirubin levels DGKD intron 19414484 rs2924815 chr2 234340446 A C 2.60E-05 Bilirubin levels DGKD intron 19414484 rs2305542 chr2 234354245 G A 3.40E-09 Bilirubin levels DGKD intron 19414484 rs2971859 chr2 234355898 G C 6.30E-06 Bilirubin levels DGKD intron 19414484 rs2242100 chr2 234358286 C T 2.30E-10 Bilirubin levels DGKD intron 19414484 rs3820744 chr2 234361548 T C 4.90E-15 Bilirubin levels DGKD intron 19414484 rs13391864 chr2 234362816 C T 2.40E-04 Smoking initiation DGKD intron 24665060 rs11675254 chr2 234364047 G A 3.30E-15 Bilirubin levels DGKD intron 19414484 rs2034762 chr2 234364237 T A 5.20E-15 Bilirubin levels DGKD intron 19414484 rs2290464 chr2 234368821 T C 6.30E-08 Bilirubin levels DGKD intron 19414484 rs3754595 chr2 234370425 A G 2.00E-15 Bilirubin levels DGKD intron 19414484 rs1053895 chr2 234378902 T C 8.70E-07 Bilirubin levels DGKD UTR-3 19414484 rs2026 chr2 234380666 C T 9.80E-06 Bilirubin levels DGKD UTR-3 19414484 rs2971869 chr2 234380988 G T 8.12E-04 Multiple complex diseases DGKD nearGene-3 17554300 rs10175828 chr2 234381817 G T 7.81E-08 Bilirubin levels / / 19419973 rs745155 chr2 234386803 T G 7.61E-05 Partial epilepsies USP40 intron 20522523 rs2971865 chr2 234388689 G A 8.39E-04 Multiple complex diseases USP40 intron 17554300 rs3796092 chr2 234390469 C A 1.40E-19 Bilirubin levels USP40 intron 19414484 rs3796090 chr2 234390602 T C 1.80E-18 Bilirubin levels USP40 intron 19414484 rs10929178 chr2 234396566 G C 1.20E-19 Bilirubin levels USP40 intron 19414484 rs10929178 chr2 234396566 G C 5.29E-04 Rheumatoid arthritis (ACPA-negative) USP40 intron 24532677 rs11683101 chr2 234398725 T C 7.60E-15 Bilirubin levels USP40 intron 19414484 rs6704644 chr2 234406655 G T 3.20E-20 Bilirubin levels USP40 intron 19414484 rs6704644 chr2 234406655 G T 8.00E-08 Bilirubin levels USP40 intron 21646302 rs2603545 chr2 234425051 C T 9.10E-04 Multiple complex diseases USP40 intron 17554300 rs6746234 chr2 234433081 G A 5.20E-20 Bilirubin levels USP40 intron 19414484 rs11675858 chr2 234440053 G A 5.30E-20 Bilirubin levels USP40 intron 19414484 rs4047189 chr2 234442949 G T 6.00E-23 Bilirubin levels USP40 intron 19414484 rs1597940 chr2 234446511 C T 5.70E-04 Multiple complex diseases USP40 intron 17554300 rs1453321 chr2 234446594 A T 4.83E-04 Multiple complex diseases USP40 intron 17554300 rs2167884 chr2 234449316 G A 3.72E-04 Smoking initiation USP40 cds-synon 24665060 rs1901812 chr2 234450822 T C 6.90E-04 Multiple complex diseases USP40 intron 17554300 rs10929208 chr2 234451486 C T 8.28E-04 Multiple complex diseases USP40 intron 17554300 rs11686188 chr2 234451630 G A 4.30E-20 Bilirubin levels USP40 intron 19414484 rs4047198 chr2 234454900 C G 3.90E-09 Bilirubin levels USP40 intron 19414484 rs6756068 chr2 234455898 A G 1.77E-04 Multiple complex diseases USP40 intron 17554300 rs13385018 chr2 234456256 C T 1.50E-07 Bilirubin levels USP40 intron 19414484 rs1542325 chr2 234456752 C G 9.58E-04 Multiple complex diseases USP40 intron 17554300 rs11676524 chr2 234460968 A T 3.90E-20 Bilirubin levels USP40 intron 19414484 rs12472244 chr2 234466843 A G 2.20E-14 Bilirubin levels USP40 intron 19414484 rs6720619 chr2 234468148 C A 1.43E-04 Smoking initiation USP40 intron 24665060 rs13401703 chr2 234477460 T C 2.30E-04 Multiple complex diseases / / 17554300 rs12467878 chr2 234477504 G A 8.10E-04 Multiple complex diseases / / 17554300 rs13387539 chr2 234482610 C T 1.50E-07 Bilirubin levels / / 19414484 rs4129945 chr2 234493048 A G 2.90E-08 Bilirubin levels / / 19414484 rs4129945 chr2 234493048 A G 3.40E-06 HIV-1 control / / 20041166 rs4132954 chr2 234493876 T A 2.10E-08 Bilirubin levels / / 19414484 rs13417719 chr2 234494173 G A 5.80E-08 Bilirubin levels / / 19414484 rs13430633 chr2 234494513 C A 1.70E-08 Bilirubin levels / / 19414484 rs13383300 chr2 234495469 C G 5.90E-08 Bilirubin levels / / 19414484 rs17864661 chr2 234495742 C T 1.10E-26 Bilirubin levels / / 19414484 rs17864661 chr2 234495742 C T 5.71E-08 Metabolite levels / / 23281178 rs17864662 chr2 234496534 C T 1.70E-07 Bilirubin levels / / 19414484 rs1002846 chr2 234496945 A G 7.70E-06 Bilirubin levels / / 19414484 rs17868296 chr2 234497246 A G 1.70E-08 Bilirubin levels / / 19414484 rs6757739 chr2 234498128 C T 1.90E-08 Bilirubin levels / / 19414484 rs6757739 chr2 234498128 C T 5.13E-11 Bilirubin levels,in serum / / 20639394 rs17863751 chr2 234498485 A T 2.00E-05 Bilirubin levels / / 19414484 rs17868297 chr2 234498651 C A,G,T 6.90E-09 Bilirubin levels / / 19414484 rs17868297 chr2 234498651 C A,G,T 7.20E-06 HIV-1 control / / 20041166 rs17868297 chr2 234498651 C A,G,T 2.10E-08 Bilirubin levels,in serum / / 20639394 rs13394291 chr2 234501740 T C 8.00E-09 Bilirubin levels / / 19414484 rs13394291 chr2 234501740 T C 2.10E-08 Bilirubin levels,in serum / / 20639394 rs13394720 chr2 234502121 T C 7.70E-09 Bilirubin levels / / 19414484 rs13394720 chr2 234502121 T C 5.00E-07 HIV-1 control / / 20041166 rs13394720 chr2 234502121 T C 2.10E-08 Bilirubin levels,in serum / / 20639394 rs1597944 chr2 234504098 C T 4.00E-06 Brain lesion load / / 19010793 rs1597944 chr2 234504098 C T 4.00E-06 Normalized brain volume / / 19010793 rs1115381 chr2 234505285 T C 1.90E-23 Bilirubin levels / / 19414484 rs1115381 chr2 234505285 T C 4.53E-73 Bilirubin levels,in serum / / 20639394 rs17868298 chr2 234505915 C T 5.00E-14 Bilirubin levels / / 19414484 rs17868299 chr2 234506808 C T 5.00E-14 Bilirubin levels / / 19414484 rs12618259 chr2 234506921 A T 6.00E-36 Bilirubin levels / / 19414484 rs2602385 chr2 234508075 T C 4.80E-20 Bilirubin levels / / 19414484 rs6728792 chr2 234508692 A C 8.20E-21 Bilirubin levels / / 19414484 rs1901813 chr2 234508768 A G 7.00E-37 Bilirubin levels / / 19414484 rs2741012 chr2 234508963 C T 1.87E-12 Metabolite levels / / 23281178 rs17864666 chr2 234509857 T C 5.00E-14 Bilirubin levels / / 19414484 rs2741013 chr2 234509911 C T 1.87E-12 Metabolite levels / / 23281178 rs7563478 chr2 234510446 A G 5.00E-14 Bilirubin levels / / 19414484 rs2741019 chr2 234510688 C G 4.70E-217 Bilirubin levels / / 19414484 rs2741019 chr2 234510688 C G 1.87E-12 Metabolite levels / / 23281178 rs6713902 chr2 234511864 C A 2.30E-21 Bilirubin levels / / 19414484 rs2741021 chr2 234511883 C T 1.40E-216 Bilirubin levels / / 19414484 rs2741021 chr2 234511883 C T 1.87E-12 Metabolite levels / / 23281178 rs2219067 chr2 234512005 C G 5.60E-36 Bilirubin levels / / 19414484 rs2219067 chr2 234512005 C G 6.54E-104 Bilirubin levels,in serum / / 20639394 rs2219067 chr2 234512005 C G 1.16E-10 Bilirubin levels / / 23371916 rs2269352 chr2 234512976 T C 4.70E-34 Bilirubin levels / / 19414484 rs2269352 chr2 234512976 T C 1.10E-07 Bilirubin levels / / 19419973 rs2269352 chr2 234512976 T C 4.15E-103 Bilirubin levels,in serum / / 20639394 rs2269352 chr2 234512976 T C 2.26E-10 Bilirubin levels / / 23371916 rs6707134 chr2 234513372 G A 2.30E-21 Bilirubin levels / / 19414484 rs4663754 chr2 234513720 A C 4.10E-34 Bilirubin levels / / 19414484 rs17863756 chr2 234513980 T C 6.60E-20 Bilirubin levels / / 19414484 rs2741022 chr2 234514273 C T 1.87E-12 Metabolite levels / / 23281178 rs17862835 chr2 234514513 C T 5.20E-14 Bilirubin levels / / 19414484 rs17862836 chr2 234514763 A C 2.20E-21 Bilirubin levels / / 19414484 rs1551286 chr2 234515155 C T 5.30E-14 Bilirubin levels / / 19414484 rs4402757 chr2 234516455 G C 1.40E-10 Bilirubin levels / / 19414484 rs2602362 chr2 234516548 A C 1.40E-215 Bilirubin levels / / 19414484 rs2602362 chr2 234516548 A C 1.87E-12 Metabolite levels / / 23281178 rs2741023 chr2 234516714 G A 1.01E-25 Bilirubin levels / / 19419973 rs2741023 chr2 234516714 G A 1.64E-19 Bilirubin levels,in serum / / 20639394 rs2741023 chr2 234516714 G A 1.67E-09 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 2.55E-10 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 5.00E-04 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 6.00E-04 Bilirubin levels / / 23642732 rs17862837 chr2 234516799 T A 5.30E-37 Bilirubin levels / / 19414484 rs17868303 chr2 234517082 C T 1.50E-23 Bilirubin levels / / 19414484 rs2741027 chr2 234518011 G A 2.40E-215 Bilirubin levels / / 19414484 rs2741027 chr2 234518011 G A 1.87E-12 Metabolite levels / / 23281178 rs17864668 chr2 234518422 T G 1.60E-23 Bilirubin levels / / 19414484 rs17864669 chr2 234518514 T C 5.70E-14 Bilirubin levels / / 19414484 rs2741028 chr2 234518914 G A 2.40E-215 Bilirubin levels / / 19414484 rs2741028 chr2 234518914 G A 1.87E-12 Metabolite levels / / 23281178 rs17868306 chr2 234519337 A G 6.10E-14 Bilirubin levels / / 19414484 rs2602363 chr2 234520525 T C 1.40E-215 Bilirubin levels / / 19414484 rs2602363 chr2 234520525 T C 1.87E-12 Metabolite levels / / 23281178 rs4281899 chr2 234520669 T G 3.20E-34 Bilirubin levels / / 19414484 rs4281899 chr2 234520669 T G 1.15E-113 Bilirubin levels,in serum / / 20639394 rs2602364 chr2 234524229 G A 4.90E-215 Bilirubin levels / / 19414484 rs2602364 chr2 234524229 G A 3.35E-11 Metabolite levels / / 23281178 rs10210058 chr2 234525355 C T 3.00E-34 Bilirubin levels / / 19414484 rs10210058 chr2 234525355 C T 1.15E-113 Bilirubin levels,in serum / / 20639394 rs4114768 chr2 234525824 G A 1.50E-23 Bilirubin levels / / 19414484 rs1042590 chr2 234526785 G A 3.60E-11 Bilirubin levels UGT1A8 cds-synon 19414484 rs1042590 chr2 234526785 G A 6.73E-09 Bilirubin levels,in serum UGT1A8 cds-synon 20639394 rs1042597 chr2 234526871 C G,T 2.80E-34 Bilirubin levels UGT1A8 missense 19414484 rs1042597 chr2 234526871 C G,T 1 Drug response to Cyclosporine UGT1A8 missense 19890249 rs1042597 chr2 234526871 C G,T 1 Drug response to Mycophenolate Mofetil UGT1A8 missense 19890249 rs1042597 chr2 234526871 C G,T 1 Drug response to Mycophenolic Acid UGT1A8 missense 19890249 rs1126806 chr2 234527073 A G 6.70E-06 Bilirubin levels UGT1A8 cds-synon 19414484 rs17863762 chr2 234527183 G A 3.90E-10 Bilirubin levels UGT1A8 missense 19414484 rs13027376 chr2 234527397 G A 2.70E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864670 chr2 234527398 G T 6.60E-14 Bilirubin levels UGT1A8 intron 19414484 rs10221563 chr2 234528798 G A 1.30E-05 Bilirubin levels UGT1A8 intron 19414484 rs13400017 chr2 234529391 A G 2.50E-34 Bilirubin levels UGT1A8 intron 19414484 rs13400017 chr2 234529391 A G 4.79E-107 Bilirubin levels,in serum UGT1A8 intron 20639394 rs6431558 chr2 234529643 C T 8.60E-111 Bilirubin levels UGT1A8 intron 19414484 rs2741029 chr2 234530160 T G 4.40E-216 Bilirubin levels UGT1A8 intron 19414484 rs2741029 chr2 234530160 T G 1.87E-12 Metabolite levels UGT1A8 intron 23281178 rs2741029 chr2 234530160 T G 1.16E-08 Bilirubin levels UGT1A8 intron 23642732 rs2741029 chr2 234530160 T G 2.18E-09 Bilirubin levels UGT1A8 intron 23642732 rs17862846 chr2 234534625 T C 6.50E-14 Bilirubin levels UGT1A8 intron 19414484 rs1597941 chr2 234534648 G A 2.30E-34 Bilirubin levels UGT1A8 intron 19414484 rs17863766 chr2 234535189 G A 1.00E-23 Bilirubin levels UGT1A8 intron 19414484 rs2741030 chr2 234536152 C T 1.87E-12 Metabolite levels UGT1A8 intron 23281178 rs1377460 chr2 234536637 A G 3.90E-11 Bilirubin levels UGT1A8 intron 19414484 rs1377460 chr2 234536637 A G 1.25E-69 Bilirubin levels,in serum UGT1A8 intron 20639394 rs13394704 chr2 234537447 G T 2.20E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864675 chr2 234538491 C A 6.50E-14 Bilirubin levels UGT1A8 intron 19414484 rs2741031 chr2 234538716 T C 3.80E-11 Bilirubin levels UGT1A8 intron 19414484 rs2741031 chr2 234538716 T C 4.53E-73 Bilirubin levels,in serum UGT1A8 intron 20639394 rs1823803 chr2 234539111 T C 2.80E-60 Bilirubin levels UGT1A8 intron 19414484 rs1823803 chr2 234539111 T C 2.60E-09 Bilirubin levels UGT1A8 intron 23371916 rs28969975 chr2 234539381 T A 1.80E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864678 chr2 234544610 T A 1.70E-15 Bilirubin levels UGT1A8 intron 19414484 rs11683356 chr2 234545294 G A 5.30E-43 Bilirubin levels UGT1A10 cds-synon 19414484 rs10929251 chr2 234546229 A G 1.10E-23 Bilirubin levels UGT1A10 intron 19414484 rs10929252 chr2 234546321 G C 1.10E-23 Bilirubin levels UGT1A10 intron 19414484 rs6738678 chr2 234548334 C T 1.60E-34 Bilirubin levels UGT1A10 intron 19414484 rs6738678 chr2 234548334 C T 1.19E-106 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6738678 chr2 234548334 C T 2.54E-10 Bilirubin levels UGT1A10 intron 23371916 rs17868314 chr2 234548474 T G 3.00E-11 Bilirubin levels UGT1A10 intron 19414484 rs2018609 chr2 234548576 T C 1.50E-34 Bilirubin levels UGT1A10 intron 19414484 rs2018609 chr2 234548576 T C 1.19E-106 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741034 chr2 234548814 A G 8.20E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741034 chr2 234548814 A G 1.32E-40 Bilirubin levels UGT1A10 intron 19419973 rs2741034 chr2 234548814 A G 1.16E-12 Metabolite levels UGT1A10 intron 23281178 rs2741034 chr2 234548814 A G 1.49E-09 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 2.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 3.75E-09 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 4.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs17862847 chr2 234549011 T A 1.00E-23 Bilirubin levels UGT1A10 intron 19414484 rs2602372 chr2 234553314 A C 2.70E-20 Bilirubin levels UGT1A10 intron 19414484 rs2741035 chr2 234555809 G A 6.87E-70 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862848 chr2 234556070 C G 6.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs12327959 chr2 234556326 C G 1.30E-34 Bilirubin levels UGT1A10 intron 19414484 rs1964501 chr2 234557274 T A 4.00E-28 Bilirubin levels UGT1A10 intron 19414484 rs2741036 chr2 234558802 G A 4.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741036 chr2 234558802 G A 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs1817154 chr2 234560591 C A 4.30E-11 Bilirubin levels UGT1A10 intron 19414484 rs1817154 chr2 234560591 C A 1.10E-69 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602373 chr2 234561953 T C 4.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2602373 chr2 234561953 T C 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs2741038 chr2 234563998 G A 2.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741038 chr2 234563998 G A 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs17864679 chr2 234564068 G A 4.30E-43 Bilirubin levels UGT1A10 intron 19414484 rs2924450 chr2 234564405 C G 4.50E-11 Bilirubin levels UGT1A10 intron 19414484 rs2924450 chr2 234564405 C G 4.53E-73 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2248733 chr2 234564737 A T 9.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs11893247 chr2 234565254 T G 2.10E-10 Bilirubin levels UGT1A10 intron 19414484 rs11892031 chr2 234565283 A C 2.10E-10 Bilirubin levels UGT1A10 intron 19414484 rs11892031 chr2 234565283 A C 1.00E-07 Bladder cancer UGT1A10 intron 20972438 rs11892031 chr2 234565283 A C 1.00E-07 Bladder cancer UGT1A10 intron 24163127 rs1453322 chr2 234565438 C T 8.90E-35 Bilirubin levels UGT1A10 intron 19414484 rs1453322 chr2 234565438 C T 5.04E-09 Bilirubin levels UGT1A10 intron 19419973 rs1453322 chr2 234565438 C T 5.91E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1453322 chr2 234565438 C T 3.94E-10 Bilirubin levels UGT1A10 intron 23371916 rs2741042 chr2 234565917 C T 1.50E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741042 chr2 234565917 C T 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs7571337 chr2 234566418 T C 1.70E-112 Bilirubin levels UGT1A10 intron 19414484 rs7608713 chr2 234567051 G A 6.70E-37 Bilirubin levels UGT1A10 intron 19414484 rs2741043 chr2 234567601 G A 4.80E-11 Bilirubin levels UGT1A10 intron 19414484 rs2741043 chr2 234567601 G A 6.87E-70 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1112310 chr2 234567916 G T 6.70E-104 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602374 chr2 234568964 C T 6.99E-14 Metabolite levels UGT1A10 intron 23281178 rs1113193 chr2 234569137 G A 1.38E-08 Bilirubin levels,in serum UGT1A10 intron 19389676 rs1113193 chr2 234569137 G A 1.50E-43 Bilirubin levels UGT1A10 intron 19414484 rs1113193 chr2 234569137 G A 6.30E-16 Bilirubin levels UGT1A10 intron 19419973 rs17868318 chr2 234569185 C T 7.30E-14 Bilirubin levels UGT1A10 intron 19414484 rs17862851 chr2 234570474 G A 7.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs12479240 chr2 234570829 C T 3.90E-29 Bilirubin levels UGT1A10 intron 19414484 rs7585521 chr2 234571072 G A 7.60E-14 Bilirubin levels UGT1A10 intron 19414484 rs1901815 chr2 234571814 A G 7.50E-16 Bilirubin levels UGT1A10 intron 19414484 rs6760588 chr2 234572783 A C 1.70E-36 Bilirubin levels UGT1A10 intron 19414484 rs6706988 chr2 234573623 A G 1.40E-25 Bilirubin levels UGT1A10 intron 19414484 rs17863773 chr2 234573896 T C 3.50E-24 Bilirubin levels UGT1A10 intron 19414484 rs6731242 chr2 234578693 T A,G 1.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs13418420 chr2 234578762 T C 6.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs17864683 chr2 234579209 A C 6.20E-230 Bilirubin levels UGT1A10 intron 19414484 rs17864683 chr2 234579209 A C 1.02E-12 Metabolite levels UGT1A10 intron 23281178 rs17864684 chr2 234579363 G A 1.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs17864684 chr2 234579363 G A 2.38E-05 Follicle stimulating hormone UGT1A10 intron 24049095 rs2741044 chr2 234579368 G A 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs10176426 chr2 234579915 C T 2.20E-20 Bilirubin levels UGT1A10 intron 19414484 rs2741045 chr2 234580140 C T 1.50E-300 Bilirubin levels UGT1A10 intron 19414484 rs2741045 chr2 234580140 C T 3.32E-53 Bilirubin levels UGT1A10 intron 19419973 rs2741045 chr2 234580140 C T 3.01E-24 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741045 chr2 234580140 C T 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs2741045 chr2 234580140 C T 2.02E-14 Bilirubin levels UGT1A10 intron 23642732 rs2741045 chr2 234580140 C T 4.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs2741045 chr2 234580140 C T 4.81E-13 Bilirubin levels UGT1A10 intron 23642732 rs2741046 chr2 234580249 T C 7.70E-301 Bilirubin levels UGT1A10 intron 19414484 rs2741046 chr2 234580249 T C 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs6714486 chr2 234580305 T A 4.70E-13 Bilirubin levels UGT1A10 intron 19414484 rs17868322 chr2 234580494 G A 1.00E-44 Bilirubin levels UGT1A10 intron 19414484 rs58597806 chr2 234581346 G A 1 Drug response to Propofol UGT1A9 missense 18816295 rs4663871 chr2 234581587 G A 5.20E-34 Bilirubin levels UGT1A10 intron 19414484 rs2741047 chr2 234581654 A T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741048 chr2 234581748 C A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741048 chr2 234581748 C A 1.87E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741049 chr2 234581834 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741049 chr2 234581834 T C 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7349250 chr2 234581920 A G 5.30E-08 Bilirubin levels UGT1A10 intron 19414484 rs7349250 chr2 234581920 A G 1.40E-06 Bilirubin levels UGT1A10 intron 22085899 rs2602376 chr2 234582051 C T 1.50E-300 Bilirubin levels UGT1A10 intron 19414484 rs2602376 chr2 234582051 C T 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs17862857 chr2 234582084 C T 7.00E-34 Bilirubin levels UGT1A10 intron 19414484 rs2602377 chr2 234582212 G A 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602378 chr2 234582504 A T 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602378 chr2 234582504 A T 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602379 chr2 234583062 G A 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602379 chr2 234583062 G A 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602379 chr2 234583062 G A 7.53E-18 Bilirubin levels UGT1A10 intron 23371916 rs10189426 chr2 234583490 C T 1.40E-25 Bilirubin levels UGT1A10 intron 19414484 rs10189426 chr2 234583490 C T 1.94E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10189426 chr2 234583490 C T 6.92E-07 Bilirubin levels UGT1A10 intron 22085899 rs10189426 chr2 234583490 C T 1.46E-08 Bilirubin levels UGT1A10 intron 23371916 rs12615708 chr2 234583846 G A 4.90E-08 Bilirubin levels UGT1A10 intron 19414484 rs12615708 chr2 234583846 G A 1.11E-98 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12615708 chr2 234583846 G A 6.09E-07 Bilirubin levels UGT1A10 intron 22085899 rs2602380 chr2 234584306 T C 1.00E-95 Bilirubin levels UGT1A10 intron 19414484 rs2602380 chr2 234584306 T C 7.32E-19 Bilirubin levels UGT1A10 intron 19419973 rs2602380 chr2 234584306 T C 2.53E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602380 chr2 234584306 T C 5.88E-19 Bilirubin levels UGT1A10 intron 23371916 rs2602381 chr2 234584324 T C 5.60E-111 Bilirubin levels UGT1A10 intron 19414484 rs2602381 chr2 234584324 T C 1.02E-29 Bilirubin levels UGT1A10 intron 19419973 rs2602381 chr2 234584324 T C 4.00E-06 Attention deficit hyperactivity disorder UGT1A10 intron 20732626 rs2602381 chr2 234584324 T C 3.10E-07 Bilirubin levels UGT1A10 intron 23371916 rs28948388 chr2 234586518 A T 2.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs7571915 chr2 234586574 G A 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7571915 chr2 234586574 G A 4.25E-06 Bilirubin levels UGT1A10 intron 22085899 rs4663877 chr2 234586671 G A 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7587916 chr2 234586814 A G 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs7587916 chr2 234586814 A G 1.54E-18 Bilirubin levels UGT1A10 intron 19419973 rs7587916 chr2 234586814 A G 6.17E-96 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7587916 chr2 234586814 A G 4.70E-19 Bilirubin levels UGT1A10 intron 23371916 rs10190976 chr2 234587442 G T 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12053462 chr2 234587639 A G 9.10E-34 Bilirubin levels UGT1A10 intron 19414484 rs12053462 chr2 234587639 A G 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10202865 chr2 234587707 C T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10202865 chr2 234587707 C T 4.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs10202865 chr2 234587707 C T 6.92E-19 Metabolite levels UGT1A10 intron 23281178 rs7595138 chr2 234588045 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs7595138 chr2 234588045 T C 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7579530 chr2 234588585 G A 2.50E-87 Bilirubin levels UGT1A10 intron 19414484 rs7579530 chr2 234588585 G A 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10197460 chr2 234589190 G T 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs10197460 chr2 234589190 G T 9.47E-30 Bilirubin levels UGT1A10 intron 19419973 rs10197460 chr2 234589190 G T 2.46E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10197460 chr2 234589190 G T 4.04E-06 Bilirubin levels UGT1A10 intron 22085899 rs10197460 chr2 234589190 G T 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs10197460 chr2 234589190 G T 7.70E-12 Bilirubin levels UGT1A10 intron 23371916 rs10197460 chr2 234589190 G T 3.70E-13 Bilirubin levels UGT1A10 intron 23642732 rs10197460 chr2 234589190 G T 7.64E-12 Bilirubin levels UGT1A10 intron 23642732 rs10167119 chr2 234589312 T C 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs10167119 chr2 234589312 T C 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10167119 chr2 234589312 T C 4.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs10167119 chr2 234589312 T C 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs10199293 chr2 234589504 T C 1.50E-91 Bilirubin levels UGT1A10 intron 19414484 rs10199293 chr2 234589504 T C 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12474215 chr2 234589560 A T 8.90E-34 Bilirubin levels UGT1A10 intron 19414484 rs12474215 chr2 234589560 A T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12472689 chr2 234589616 C T 9.60E-34 Bilirubin levels UGT1A10 intron 19414484 rs12472689 chr2 234589616 C T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4530361 chr2 234590041 A G 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs4530361 chr2 234590041 A G 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs28946877 chr2 234590243 C T 1.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs28946877 chr2 234590243 C T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7586110 chr2 234590527 T G 1 Drug response to Irinotecan UGT1A10 intron 18349289 rs7586110 chr2 234590527 T G 2.40E-230 Bilirubin levels UGT1A10 intron 19414484 rs7586110 chr2 234590527 T G 5.10E-29 Bilirubin levels UGT1A10 intron 19419973 rs7586110 chr2 234590527 T G 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7586110 chr2 234590527 T G 2.43E-06 Bilirubin levels UGT1A10 intron 22085899 rs7586110 chr2 234590527 T G 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs7577677 chr2 234590616 C A 1.30E-230 Bilirubin levels UGT1A7 cds-synon 19414484 rs7577677 chr2 234590616 C A 9.71E-107 Bilirubin levels,in serum UGT1A7 cds-synon 20639394 rs7577677 chr2 234590616 C A 2.43E-06 Bilirubin levels UGT1A7 cds-synon 22085899 rs7577677 chr2 234590616 C A 6.30E-16 Metabolite levels UGT1A7 cds-synon 23281178 rs17868323 chr2 234590970 T G 1 Drug response to Irinotecan UGT1A7 missense 18349289 rs17864686 chr2 234591339 G A 1.30E-33 Bilirubin levels UGT1A7 cds-synon 19414484 rs17864686 chr2 234591339 G A 6.93E-09 Bilirubin levels,in serum UGT1A7 cds-synon 20639394 rs4663888 chr2 234591987 G A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs4663888 chr2 234591987 G A 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4433994 chr2 234592635 G T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6724485 chr2 234592816 G A 8.50E-229 Bilirubin levels UGT1A10 intron 19414484 rs6724485 chr2 234592816 G A 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs6724485 chr2 234592816 G A 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4347832 chr2 234593041 T C 8.50E-229 Bilirubin levels UGT1A10 intron 19414484 rs4347832 chr2 234593041 T C 4.25E-111 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4347832 chr2 234593041 T C 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs4347832 chr2 234593041 T C 4.86E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4347832 chr2 234593041 T C 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4261716 chr2 234593117 G T 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs4261716 chr2 234593117 G T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4261716 chr2 234593117 G T 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs4261716 chr2 234593117 G T 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4261716 chr2 234593117 G T 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4583459 chr2 234593374 G T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs4583459 chr2 234593374 G T 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13002774 chr2 234593706 G A 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs13002774 chr2 234593706 G A 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13002774 chr2 234593706 G A 7.80E-08 Bilirubin levels UGT1A10 intron 22085899 rs13002774 chr2 234593706 G A 4.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs13002774 chr2 234593706 G A 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4553819 chr2 234594083 A G 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs4553819 chr2 234594083 A G 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4553819 chr2 234594083 A G 8.01E-08 Bilirubin levels UGT1A10 intron 22085899 rs4553819 chr2 234594083 A G 4.83E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4553819 chr2 234594083 A G 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs17864689 chr2 234594234 G T 1.80E-13 Bilirubin levels UGT1A10 intron 19414484 rs11902131 chr2 234594269 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs11902131 chr2 234594269 C T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11902131 chr2 234594269 C T 8.01E-08 Bilirubin levels UGT1A10 intron 22085899 rs11902131 chr2 234594269 C T 4.82E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs11902131 chr2 234594269 C T 1.42E-16 Metabolite levels UGT1A10 intron 23281178 rs17868325 chr2 234594387 T G 3.00E-33 Bilirubin levels UGT1A10 intron 19414484 rs17868325 chr2 234594387 T G 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753317 chr2 234594979 T A 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs6753317 chr2 234594979 T A 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753320 chr2 234595615 A C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6753320 chr2 234595615 A C 8.30E-19 Bilirubin levels UGT1A10 intron 19419973 rs6753320 chr2 234595615 A C 4.46E-109 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753320 chr2 234595615 A C 1.56E-09 Bilirubin levels UGT1A10 intron 22085899 rs6753320 chr2 234595615 A C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6753320 chr2 234595615 A C 4.52E-16 Metabolite levels UGT1A10 intron 23281178 rs6753320 chr2 234595615 A C 5.32E-13 Bilirubin levels UGT1A10 intron 23371916 rs6736508 chr2 234595747 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6736508 chr2 234595747 G A 2.39E-21 Bilirubin levels UGT1A10 intron 19419973 rs6736508 chr2 234595747 G A 3.67E-110 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6736508 chr2 234595747 G A 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6736508 chr2 234595747 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6736508 chr2 234595747 G A 2.07E-16 Metabolite levels UGT1A10 intron 23281178 rs6736508 chr2 234595747 G A 3.72E-13 Bilirubin levels UGT1A10 intron 23371916 rs6736508 chr2 234595747 G A 1.22E-11 Bilirubin levels UGT1A10 intron 23642732 rs6736508 chr2 234595747 G A 4.71E-13 Bilirubin levels UGT1A10 intron 23642732 rs6753569 chr2 234595817 A C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6753569 chr2 234595817 A C 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753569 chr2 234595817 A C 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6753569 chr2 234595817 A C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6753569 chr2 234595817 A C 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs6736743 chr2 234595950 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6736743 chr2 234595950 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6736743 chr2 234595950 G A 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6736743 chr2 234595950 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6736743 chr2 234595950 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs6737107 chr2 234596195 G A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6737107 chr2 234596195 G A 1.47E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6754100 chr2 234596214 A C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6754100 chr2 234596214 A C 4.85E-17 Bilirubin levels UGT1A10 intron 19419973 rs6754100 chr2 234596214 A C 3.41E-101 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6754100 chr2 234596214 A C 4.85E-18 Bilirubin levels UGT1A10 intron 23371916 rs17863781 chr2 234596515 C G 7.40E-20 Bilirubin levels UGT1A10 intron 19414484 rs10168155 chr2 234596836 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10168155 chr2 234596836 C T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168155 chr2 234596836 C T 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs10168155 chr2 234596836 C T 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10168155 chr2 234596836 C T 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10175809 chr2 234596865 T A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10175809 chr2 234596865 T A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10175809 chr2 234596865 T A 6.39E-08 Bilirubin levels UGT1A10 intron 22085899 rs10175809 chr2 234596865 T A 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10175809 chr2 234596865 T A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10168333 chr2 234596988 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10168333 chr2 234596988 C T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168333 chr2 234596988 C T 6.39E-08 Bilirubin levels UGT1A10 intron 22085899 rs10168333 chr2 234596988 C T 4.87E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10168333 chr2 234596988 C T 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10168416 chr2 234597087 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168416 chr2 234597087 C G 1.46E-06 Bilirubin levels UGT1A10 intron 22085899 rs10168416 chr2 234597087 C G 0.00058 fMRI brain tests in schizophrenia UGT1A10 intron 22440650 rs10168416 chr2 234597087 C G 1.46E-19 Metabolite levels UGT1A10 intron 23281178 rs10173355 chr2 234597321 A T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10173355 chr2 234597321 A T 2.11E-06 Bilirubin levels UGT1A10 intron 22085899 rs10173355 chr2 234597321 A T 1.46E-19 Metabolite levels UGT1A10 intron 23281178 rs11680450 chr2 234597483 T C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs11680450 chr2 234597483 T C 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11680450 chr2 234597483 T C 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs11680450 chr2 234597483 T C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs11680450 chr2 234597483 T C 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs4485562 chr2 234597566 G A 4.40E-33 Bilirubin levels UGT1A10 intron 19414484 rs4485562 chr2 234597566 G A 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10171367 chr2 234597667 C G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10171367 chr2 234597667 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10171367 chr2 234597667 C G 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs10171367 chr2 234597667 C G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10171367 chr2 234597667 C G 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10179094 chr2 234597825 T A 7.00E-231 Bilirubin levels UGT1A10 intron 19414484 rs10179094 chr2 234597825 T A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10179094 chr2 234597825 T A 2.11E-06 Bilirubin levels UGT1A10 intron 22085899 rs10179094 chr2 234597825 T A 3.55E-16 Metabolite levels UGT1A10 intron 23281178 rs17862859 chr2 234597842 G A 1.70E-14 Bilirubin levels UGT1A10 intron 19414484 rs6707947 chr2 234597915 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6707947 chr2 234597915 T C 1.62E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7563561 chr2 234598991 T G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs7563561 chr2 234598991 T G 1.69E-20 Bilirubin levels UGT1A10 intron 19419973 rs7563561 chr2 234598991 T G 6.18E-115 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7563561 chr2 234598991 T G 2.83E-09 Bilirubin levels UGT1A10 intron 22085899 rs7563561 chr2 234598991 T G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs7563561 chr2 234598991 T G 1.87E-16 Metabolite levels UGT1A10 intron 23281178 rs7563561 chr2 234598991 T G 1.10E-12 Bilirubin levels UGT1A10 intron 23371916 rs7563561 chr2 234598991 T G 2.47E-11 Bilirubin levels UGT1A10 intron 23642732 rs7563561 chr2 234598991 T G 7.18E-13 Bilirubin levels UGT1A10 intron 23642732 rs7608175 chr2 234599089 C G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs7608175 chr2 234599089 C G 1.96E-21 Bilirubin levels UGT1A10 intron 19419973 rs7608175 chr2 234599089 C G 3.23E-110 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7608175 chr2 234599089 C G 1.42E-07 Bilirubin levels UGT1A10 intron 22085899 rs7608175 chr2 234599089 C G 4.96E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs7608175 chr2 234599089 C G 2.36E-16 Metabolite levels UGT1A10 intron 23281178 rs7608175 chr2 234599089 C G 3.91E-13 Bilirubin levels UGT1A10 intron 23371916 rs7608175 chr2 234599089 C G 2.20E-11 Bilirubin levels UGT1A10 intron 23642732 rs7608175 chr2 234599089 C G 7.45E-13 Bilirubin levels UGT1A10 intron 23642732 rs12623271 chr2 234599941 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12623271 chr2 234599941 C G 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs12623271 chr2 234599941 C G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs12623271 chr2 234599941 C G 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs12474980 chr2 234600116 G A 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs12474980 chr2 234600116 G A 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10445704 chr2 234600274 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10445704 chr2 234600274 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10445704 chr2 234600274 G A 2.16E-09 Bilirubin levels UGT1A10 intron 22085899 rs10445704 chr2 234600274 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10445704 chr2 234600274 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs13015720 chr2 234600999 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs13015720 chr2 234600999 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13015720 chr2 234600999 G A 1.98E-09 Bilirubin levels UGT1A10 intron 22085899 rs13015720 chr2 234600999 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs13015720 chr2 234600999 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs12476197 chr2 234601224 G C 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs12476197 chr2 234601224 G C 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6759892 chr2 234601669 T G 5.70E-228 Bilirubin levels UGT1A6 missense 19414484 rs6759892 chr2 234601669 T G 1.47E-21 Bilirubin levels UGT1A6 missense 19419973 rs6759892 chr2 234601669 T G 1.79E-110 Bilirubin levels,in serum UGT1A6 missense 20639394 rs6759892 chr2 234601669 T G 1.98E-09 Bilirubin levels UGT1A6 missense 22085899 rs6759892 chr2 234601669 T G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A6 missense 22566498 rs6759892 chr2 234601669 T G 8.12E-17 Metabolite levels UGT1A6 missense 23281178 rs6759892 chr2 234601669 T G 3.91E-13 Bilirubin levels UGT1A6 missense 23371916 rs6759892 chr2 234601669 T G 2.51E-11 Bilirubin levels UGT1A6 missense 23642732 rs6759892 chr2 234601669 T G 7.93E-13 Bilirubin levels UGT1A6 missense 23642732 rs1105880 chr2 234601965 A G 4.98E-99 Bilirubin levels,in serum UGT1A6 cds-synon 20639394 rs1105880 chr2 234601965 A G 1.98E-09 Bilirubin levels UGT1A6 cds-synon 22085899 rs1105880 chr2 234601965 A G 0.000261 fMRI brain tests in schizophrenia UGT1A6 cds-synon 22440650 rs1105880 chr2 234601965 A G 5.50E-13 Bilirubin levels UGT1A6 cds-synon 23371916 rs2070959 chr2 234602191 A G 4.98E-99 Bilirubin levels,in serum UGT1A6 missense 20639394 rs2070959 chr2 234602191 A G 2.11E-06 Bilirubin levels UGT1A6 missense 22085899 rs2070959 chr2 234602191 A G 0.00058 fMRI brain tests in schizophrenia UGT1A6 missense 22440650 rs2070959 chr2 234602191 A G 2.33E-19 Metabolite levels UGT1A6 missense 23281178 rs2070959 chr2 234602191 A G 1.52E-12 Bilirubin levels UGT1A6 missense 23642732 rs2070959 chr2 234602191 A G 2.48E-14 Bilirubin levels UGT1A6 missense 23642732 rs1105879 chr2 234602202 A C 4.98E-99 Bilirubin levels,in serum UGT1A6 missense 20639394 rs1105879 chr2 234602202 A C 4.12E-08 Bilirubin levels UGT1A6 missense 22085899 rs1105879 chr2 234602202 A C 0.000212 fMRI brain tests in schizophrenia UGT1A6 missense 22440650 rs1105879 chr2 234602202 A C 1.21E-14 Bilirubin levels UGT1A6 missense 23642732 rs1105879 chr2 234602202 A C 1.30E-12 Bilirubin levels UGT1A6 missense 23642732 rs7592281 chr2 234602641 G T 2.70E-08 Bilirubin levels UGT1A10 intron 19414484 rs7592624 chr2 234602906 G A 2.50E-131 Bilirubin levels UGT1A10 intron 19414484 rs7592624 chr2 234602906 G A 1.03E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6761246 chr2 234603439 A C 1.00E-96 Bilirubin levels UGT1A10 intron 19414484 rs6761246 chr2 234603439 A C 5.82E-18 Bilirubin levels UGT1A10 intron 19419973 rs6761246 chr2 234603439 A C 2.69E-101 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6761246 chr2 234603439 A C 1.05E-18 Bilirubin levels UGT1A10 intron 23371916 rs28899170 chr2 234604230 C A 8.40E-19 Metabolite levels UGT1A10 intron 23281178 rs6751673 chr2 234604903 G A 5.80E-53 Bilirubin levels UGT1A10 intron 19414484 rs17864692 chr2 234605486 G A 1.80E-11 Bilirubin levels UGT1A10 intron 19414484 rs1604144 chr2 234605835 C T 1.30E-49 Bilirubin levels UGT1A10 intron 19414484 rs1604144 chr2 234605835 C T 8.93E-08 Metabolite levels UGT1A10 intron 23281178 rs1604144 chr2 234605835 C T 4.75E-05 Neuroblastoma UGT1A10 intron pha002895 rs6715829 chr2 234606162 A T 1.50E-291 Bilirubin levels UGT1A10 intron 19414484 rs6715829 chr2 234606162 A T 2.44E-16 Metabolite levels UGT1A10 intron 23281178 rs28898578 chr2 234606528 A T 6.34E-13 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12466747 chr2 234606787 G C 2.90E-34 Bilirubin levels UGT1A10 intron 19414484 rs12466747 chr2 234606787 G C 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12988520 chr2 234607394 A C 4.70E-130 Bilirubin levels UGT1A10 intron 19414484 rs12988520 chr2 234607394 A C 1.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs12471030 chr2 234607560 C T 4.70E-35 Bilirubin levels UGT1A10 intron 19414484 rs12471030 chr2 234607560 C T 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs35982104 chr2 234607560 C CT 4.70E-35 Bilirubin levels UGT1A10 intron 19414484 rs35982104 chr2 234607560 C CT 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862866 chr2 234610912 A G 6.10E-210 Bilirubin levels UGT1A10 intron 19414484 rs17862866 chr2 234610912 A G 1.35E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862866 chr2 234610912 A G 2.96E-11 Metabolite levels UGT1A10 intron 23281178 rs17863787 chr2 234611094 T G 9.27E-09 Bilirubin levels UGT1A10 intron 22085899 rs17863787 chr2 234611094 T G 3.71E-19 Metabolite levels UGT1A10 intron 23281178 rs7420193 chr2 234611523 C G 6.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs11683974 chr2 234613000 C T 2.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs6722836 chr2 234613196 A C 4.42E-10 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17863788 chr2 234614499 T C 5.00E-06 Bilirubin levels UGT1A10 intron 19414484 rs6725478 chr2 234615400 C T 4.50E-273 Bilirubin levels UGT1A10 intron 19414484 rs6725478 chr2 234615400 C T 9.02E-17 Metabolite levels UGT1A10 intron 23281178 rs4663325 chr2 234616357 C T 6.60E-07 Bilirubin levels UGT1A10 intron 19414484 rs4663326 chr2 234616571 A G 6.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs7572563 chr2 234617236 G A 1.80E-210 Bilirubin levels UGT1A10 intron 19414484 rs7572563 chr2 234617236 G A 1.35E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7572563 chr2 234617236 G A 2.03E-11 Metabolite levels UGT1A10 intron 23281178 rs7583278 chr2 234617407 C T 2.90E-274 Bilirubin levels UGT1A10 intron 19414484 rs7583278 chr2 234617407 C T 9.02E-17 Metabolite levels UGT1A10 intron 23281178 rs4663327 chr2 234617632 G A 6.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs28898589 chr2 234617750 A G 4.42E-10 Bilirubin levels,in serum UGT1A10 intron 20639394 rs28898590 chr2 234619422 G T 2.20E-16 Bilirubin levels UGT1A10 intron 19414484 rs2885295 chr2 234619866 T A 6.30E-07 Bilirubin levels UGT1A10 intron 19414484 rs4233633 chr2 234619937 G C 3.86E-08 Bilirubin levels UGT1A10 intron 23371916 rs28898593 chr2 234620171 A G 1.77E-06 Bilirubin levels UGT1A10 intron 22085899 rs28898596 chr2 234620640 G A 2.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs3893334 chr2 234620917 C T 2.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs2013030 chr2 234621040 A G 1.80E-09 Bilirubin levels UGT1A10 intron 19414484 rs2013021 chr2 234621086 C T 1.70E-07 Bilirubin levels UGT1A10 intron 19414484 rs2013018 chr2 234621157 T C 1.60E-07 Bilirubin levels UGT1A10 intron 19414484 rs5020121 chr2 234621269 C T 1.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs4556969 chr2 234621404 C T 1.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs28898600 chr2 234621436 T G 1.77E-06 Bilirubin levels UGT1A10 intron 22085899 rs11689628 chr2 234621488 C T 1.50E-40 Bilirubin levels UGT1A10 intron 19414484 rs3755321 chr2 234621825 T C 1.40E-07 Bilirubin levels UGT1A5 missense 19414484 rs28946885 chr2 234622067 A T 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs12475068 chr2 234622110 C G 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs3892170 chr2 234622412 G C 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs17862870 chr2 234622742 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs4663945 chr2 234623117 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs12477216 chr2 234623667 C T 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17868334 chr2 234624817 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17863791 chr2 234624884 T C 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17863792 chr2 234625126 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17874943 chr2 234625239 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs6744284 chr2 234625297 C T 1.56E-40 Bilirubin levels UGT1A10 intron 19419973 rs6744284 chr2 234625297 C T 1.55E-153 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6744284 chr2 234625297 C T 5.82E-14 Metabolite levels UGT1A10 intron 23281178 rs6744284 chr2 234625297 C T 7.71E-20 Bilirubin levels UGT1A10 intron 23371916 rs6744284 chr2 234625297 C T 3.26E-16 Bilirubin levels UGT1A10 intron 23642732 rs6744284 chr2 234625297 C T 3.85E-19 Bilirubin levels UGT1A10 intron 23642732 rs28898605 chr2 234625494 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs1875263 chr2 234625622 C T 3.60E-218 Bilirubin levels UGT1A10 intron 19414484 rs1875263 chr2 234625622 C T 1.66E-149 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1875263 chr2 234625622 C T 6.11E-07 Bilirubin levels UGT1A10 intron 22085899 rs1875263 chr2 234625622 C T 1.88E-12 Metabolite levels UGT1A10 intron 23281178 rs3806595 chr2 234625718 T A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs3806594 chr2 234625890 T C 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs3806593 chr2 234625919 A G 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs11676072 chr2 234625983 A G 1.60E-40 Bilirubin levels UGT1A10 intron 19414484 rs3806591 chr2 234626199 T C 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs869283 chr2 234626287 G A 1.30E-279 Bilirubin levels UGT1A10 intron 19414484 rs869283 chr2 234626287 G A 1.66E-149 Bilirubin levels,in serum UGT1A10 intron 20639394 rs869283 chr2 234626287 G A 4.57E-06 Bilirubin levels UGT1A10 intron 22085899 rs869283 chr2 234626287 G A 3.10E-16 Metabolite levels UGT1A10 intron 23281178 rs3732221 chr2 234627010 C T 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs3732220 chr2 234627048 G A 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs3732218 chr2 234627304 G A 2.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs6755571 chr2 234627536 C A 9.60E-19 Bilirubin levels UGT1A4 missense 19414484 rs2011404 chr2 234627937 T C 5.60E-50 Bilirubin levels UGT1A4 cds-synon 19414484 rs28898611 chr2 234628526 G C 3.54E-06 Bilirubin levels UGT1A10 intron 22085899 rs871514 chr2 234628529 T C 6.94E-04 Multiple complex diseases UGT1A10 intron 17554300 rs871514 chr2 234628529 T C 7.50E-262 Bilirubin levels UGT1A10 intron 19414484 rs871514 chr2 234628529 T C 7.62E-38 Bilirubin levels UGT1A10 intron 19419973 rs871514 chr2 234628529 T C 3.01E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs871514 chr2 234628529 T C 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs7597496 chr2 234630443 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs7597496 chr2 234630443 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7597496 chr2 234630443 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs6715325 chr2 234635241 T C 2.90E-201 Bilirubin levels UGT1A10 intron 19414484 rs6715325 chr2 234635241 T C 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6715325 chr2 234635241 T C 5.02E-09 Bilirubin levels UGT1A10 intron 22085899 rs6715325 chr2 234635241 T C 1.35E-08 Metabolite levels UGT1A10 intron 23281178 rs6715325 chr2 234635241 T C 1.20E-21 Bilirubin levels UGT1A10 intron 23371916 rs4294999 chr2 234635467 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs4294999 chr2 234635467 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4294999 chr2 234635467 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs4294999 chr2 234635467 A G 1.88E-21 Bilirubin levels UGT1A10 intron 23371916 rs1983023 chr2 234637022 T C 2.80E-307 Bilirubin levels UGT1A10 intron 19414484 rs1983023 chr2 234637022 T C 3.99E-15 Metabolite levels UGT1A10 intron 23281178 rs2008595 chr2 234637192 C T 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs2008595 chr2 234637192 C T 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2008595 chr2 234637192 C T 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806597 chr2 234637569 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs3806597 chr2 234637569 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3806597 chr2 234637569 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806597 chr2 234637569 A G 3.40E-21 Bilirubin levels UGT1A10 intron 23371916 rs3806596 chr2 234637707 T C 9.80E-263 Bilirubin levels UGT1A10 intron 19414484 rs3806596 chr2 234637707 T C 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3806596 chr2 234637707 T C 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806596 chr2 234637707 T C 3.51E-21 Bilirubin levels UGT1A10 intron 23371916 rs17868336 chr2 234638006 A G 8.00E-14 Bilirubin levels UGT1A3 cds-synon 19414484 rs7574296 chr2 234638249 A G 9.80E-263 Bilirubin levels UGT1A3 cds-synon 19414484 rs7574296 chr2 234638249 A G 1.04E-84 Bilirubin levels,in serum UGT1A3 cds-synon 20639394 rs7574296 chr2 234638249 A G 2.85E-12 Metabolite levels UGT1A3 cds-synon 23281178 rs11891311 chr2 234639310 G A 1.40E-235 Bilirubin levels UGT1A10 intron 19414484 rs11891311 chr2 234639310 G A 1.66E-25 Bilirubin levels UGT1A10 intron 19419973 rs11891311 chr2 234639310 G A 8.68E-157 Height UGT1A10 intron 20400458 rs11891311 chr2 234639310 G A 8.68E-157 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11891311 chr2 234639310 G A 9.85E-11 Metabolite levels UGT1A10 intron 23281178 rs11891311 chr2 234639310 G A 1.00E-41 Bilirubin levels UGT1A10 intron 23371916 rs11891311 chr2 234639310 G A 2.06E-14 Bilirubin levels UGT1A10 intron 23642732 rs11891311 chr2 234639310 G A 6.71E-17 Bilirubin levels UGT1A10 intron 23642732 rs17868337 chr2 234639656 G A 2.10E-09 Bilirubin levels UGT1A10 intron 19414484 rs7564935 chr2 234645186 G T 7.50E-236 Bilirubin levels UGT1A10 intron 19414484 rs7564935 chr2 234645186 G T 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7564935 chr2 234645186 G T 1.95E-15 Bilirubin levels UGT1A10 intron 22085899 rs7564935 chr2 234645186 G T 3.43E-10 Metabolite levels UGT1A10 intron 23281178 rs7564935 chr2 234645186 G T 1.76E-21 Bilirubin levels UGT1A10 intron 23371916 rs11902624 chr2 234646664 T C 7.90E-07 Bilirubin levels UGT1A10 intron 19414484 rs28899194 chr2 234646682 C T 5.00E-40 Bilirubin levels UGT1A10 intron 19414484 rs6722076 chr2 234647317 G A 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6431628 chr2 234647478 A G 1.30E-263 Bilirubin levels UGT1A10 intron 19414484 rs6431628 chr2 234647478 A G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs6740653 chr2 234648708 C A 5.30E-40 Bilirubin levels UGT1A10 intron 19414484 rs17862874 chr2 234648746 A G 6.40E-19 Bilirubin levels UGT1A10 intron 19414484 rs2018985 chr2 234648860 A G 2.80E-307 Bilirubin levels UGT1A10 intron 19414484 rs2018985 chr2 234648860 A G 2.90E-06 Bilirubin levels UGT1A10 intron 22085899 rs2018985 chr2 234648860 A G 3.16E-15 Metabolite levels UGT1A10 intron 23281178 rs17862875 chr2 234649302 G A 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862875 chr2 234649302 G A 1.52E-09 Bilirubin levels UGT1A10 intron 22085899 rs17862875 chr2 234649302 G A 8.26E-14 Metabolite levels UGT1A10 intron 23281178 rs4663963 chr2 234650193 T G 1.30E-263 Bilirubin levels UGT1A10 intron 19414484 rs4663963 chr2 234650193 T G 1.02E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663963 chr2 234650193 T G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs28900371 chr2 234650208 G A 5.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs4663965 chr2 234650604 T C 6.40E-264 Bilirubin levels UGT1A10 intron 19414484 rs4663965 chr2 234650604 T C 1.09E-37 Bilirubin levels UGT1A10 intron 19419973 rs4663965 chr2 234650604 T C 3.13E-85 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663965 chr2 234650604 T C 5.02E-12 Metabolite levels UGT1A10 intron 23281178 rs4663965 chr2 234650604 T C 4.18E-21 Bilirubin levels UGT1A10 intron 23371916 rs4663965 chr2 234650604 T C 1.05E-14 Bilirubin levels UGT1A10 intron 23642732 rs4663965 chr2 234650604 T C 3.90E-13 Bilirubin levels UGT1A10 intron 23642732 rs28900373 chr2 234651223 G T 5.90E-40 Bilirubin levels UGT1A10 intron 19414484 rs17863795 chr2 234651369 T C 6.40E-19 Bilirubin levels UGT1A10 intron 19414484 rs13009407 chr2 234652347 C G 7.07E-12 Metabolite levels D/JB3 cds-synon 23281178 rs17864701 chr2 234652717 C T 7.86E-14 Metabolite levels UGT1A10 intron 23281178 rs6741543 chr2 234653107 A T 6.20E-40 Bilirubin levels UGT1A10 intron 19414484 rs4663967 chr2 234653184 A C 8.30E-265 Bilirubin levels UGT1A10 intron 19414484 rs4663967 chr2 234653184 A C 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs6741669 chr2 234653192 A G 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs6741669 chr2 234653192 A G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs28899468 chr2 234653292 T C 2.10E-38 Bilirubin levels UGT1A10 intron 19414484 rs28900379 chr2 234654322 C T 6.40E-40 Bilirubin levels UGT1A10 intron 19414484 rs11695484 chr2 234654449 A G 4.82E-11 Bilirubin levels UGT1A10 intron 22085899 rs11695484 chr2 234654449 A G 1.12E-21 Bilirubin levels UGT1A10 intron 23371916 rs4663333 chr2 234655303 G T 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs4663333 chr2 234655303 G T 1.46E-86 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663333 chr2 234655303 G T 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs4663969 chr2 234655313 C A 1.50E-203 Bilirubin levels UGT1A10 intron 19414484 rs4663969 chr2 234655313 C A 3.19E-89 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663969 chr2 234655313 C A 5.32E-10 Bilirubin levels UGT1A10 intron 22085899 rs12466997 chr2 234656517 T C 3.95E-11 Bilirubin levels UGT1A10 intron 22085899 rs11888459 chr2 234656640 T C 2.80E-238 Bilirubin levels UGT1A10 intron 19414484 rs11888459 chr2 234656640 T C 8.40E-16 Bilirubin levels UGT1A10 intron 22085899 rs11888459 chr2 234656640 T C 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs17862876 chr2 234657512 G T 5.20E-54 Bilirubin levels UGT1A10 intron 19414484 rs10178992 chr2 234657877 T A 5.30E-238 Bilirubin levels UGT1A10 intron 19414484 rs10178992 chr2 234657877 T A 1.09E-16 Bilirubin levels UGT1A10 intron 22085899 rs10178992 chr2 234657877 T A 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs28900384 chr2 234657937 C G 7.20E-40 Bilirubin levels UGT1A10 intron 19414484 rs10179091 chr2 234657983 T C 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs10179091 chr2 234657983 T C 2.93E-30 Bilirubin levels UGT1A10 intron 19419973 rs10179091 chr2 234657983 T C 1.17E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10179091 chr2 234657983 T C 2.46E-14 Bilirubin levels UGT1A10 intron 22085899 rs10179091 chr2 234657983 T C 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs10179091 chr2 234657983 T C 7.73E-21 Bilirubin levels UGT1A10 intron 23371916 rs7604115 chr2 234658116 C T 2.80E-238 Bilirubin levels UGT1A10 intron 19414484 rs7604115 chr2 234658116 C T 8.84E-17 Bilirubin levels UGT1A10 intron 22085899 rs7604115 chr2 234658116 C T 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs7556676 chr2 234658250 A G 2.70E-203 Bilirubin levels UGT1A10 intron 19414484 rs7556676 chr2 234658250 A G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7556676 chr2 234658250 A G 2.45E-10 Bilirubin levels UGT1A10 intron 22085899 rs2221198 chr2 234658623 G A 9.00E-196 Bilirubin levels UGT1A10 intron 19414484 rs2221198 chr2 234658623 G A 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2221198 chr2 234658623 G A 2.07E-10 Bilirubin levels UGT1A10 intron 22085899 rs2221198 chr2 234658623 G A 3.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs28900385 chr2 234661136 T C 7.70E-40 Bilirubin levels UGT1A10 intron 19414484 rs17862878 chr2 234661948 G A 6.38E-06 Bilirubin levels UGT1A10 intron 22085899 rs28900387 chr2 234662173 T C 1.27E-06 Bilirubin levels UGT1A10 intron 22085899 rs7608038 chr2 234662263 T C 8.85E-06 Bilirubin levels UGT1A10 intron 22085899 rs1054804 chr2 234663045 C T 8.10E-40 Bilirubin levels UGT1A10 intron 19414484 rs10929301 chr2 234663649 C G 2.10E-265 Bilirubin levels UGT1A10 intron 19414484 rs10929301 chr2 234663649 C G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10929301 chr2 234663649 C G 3.66E-10 Bilirubin levels UGT1A10 intron 22085899 rs10929301 chr2 234663649 C G 3.01E-12 Metabolite levels UGT1A10 intron 23281178 rs11673726 chr2 234664060 G T 4.40E-239 Bilirubin levels UGT1A10 intron 19414484 rs11673726 chr2 234664060 G T 2.66E-18 Bilirubin levels UGT1A10 intron 22085899 rs11673726 chr2 234664060 G T 2.05E-10 Metabolite levels UGT1A10 intron 23281178 rs6747843 chr2 234664354 G A 3.26E-11 Metabolite levels UGT1A10 intron 23281178 rs11675168 chr2 234664679 G A 8.50E-40 Bilirubin levels UGT1A10 intron 19414484 rs6714634 chr2 234664765 T C 8.15E-13 Bilirubin levels UGT1A10 intron 22085899 rs6714634 chr2 234664765 T C 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs6714634 chr2 234664765 T C 4.01E-21 Bilirubin levels UGT1A10 intron 23371916 rs17874945 chr2 234664826 C T 3.90E-19 Bilirubin levels UGT1A10 intron 19414484 rs17863800 chr2 234664881 C G 3.80E-19 Bilirubin levels UGT1A10 intron 19414484 rs11568318 chr2 234665498 C A 3.80E-19 Bilirubin levels UGT1A10 intron 19414484 rs4124874 chr2 234665659 T G 6.90E-267 Bilirubin levels UGT1A10 intron 19414484 rs4124874 chr2 234665659 T G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4124874 chr2 234665659 T G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 15007088 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 17510208 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 19125129 rs10929302 chr2 234665782 G A 1.37E-11 Bilirubin levels UGT1A10 intron 22085899 rs10929302 chr2 234665782 G A 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs4399719 chr2 234666461 T G 6.90E-267 Bilirubin levels UGT1A10 intron 19414484 rs4399719 chr2 234666461 T G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4399719 chr2 234666461 T G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs3755319 chr2 234667582 A C 8.57E-04 Type 2 diabetes UGT1A10 intron 17463246 rs3755319 chr2 234667582 A C 1.40E-266 Bilirubin levels UGT1A10 intron 19414484 rs3755319 chr2 234667582 A C 5.95E-42 Bilirubin levels UGT1A10 intron 19419973 rs3755319 chr2 234667582 A C 6.99E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3755319 chr2 234667582 A C 4.11E-11 Bilirubin levels UGT1A10 intron 22085899 rs3755319 chr2 234667582 A C 1.16E-12 Metabolite levels UGT1A10 intron 23281178 rs3755319 chr2 234667582 A C 1.83E-21 Bilirubin levels UGT1A10 intron 23371916 rs3755319 chr2 234667582 A C 3.53E-14 Bilirubin levels UGT1A10 intron 23642732 rs3755319 chr2 234667582 A C 8.09E-16 Bilirubin levels UGT1A10 intron 23642732 rs28899472 chr2 234667809 C T 1.00E-39 Bilirubin levels UGT1A10 intron 19414484 rs2003569 chr2 234667937 G A 1.80E-18 Bilirubin levels UGT1A10 intron 19414484 rs2003569 chr2 234667937 G A 9.00E-06 Bilirubin levels UGT1A10 intron 22085899 rs6723506 chr2 234668025 A G 4.94E-22 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6723506 chr2 234668025 A G 5.50E-07 Bilirubin levels UGT1A10 intron 23371916 rs887829 chr2 234668570 C T 5.59E-04 Multiple complex diseases UGT1A10 intron 17554300 rs887829 chr2 234668570 C T 1.00E-69 Bilirubin levels UGT1A10 intron 19419973 rs887829 chr2 234668570 C T 1.46E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs887829 chr2 234668570 C T 3.00E-74 Metabolic traits UGT1A10 intron 21886157 rs887829 chr2 234668570 C T 2.00E-22 Bilirubin levels UGT1A10 intron 22085899 rs887829 chr2 234668570 C T 5.00E-25 Cholelithiasis-related traits in sickle cell anemia UGT1A10 intron 22558097 rs887829 chr2 234668570 C T 9.00E-25 Metabolite levels UGT1A10 intron 23281178 rs887829 chr2 234668570 C T 2.50E-20 Bilirubin levels UGT1A10 intron 23371916 rs887829 chr2 234668570 C T 6.37E-18 Bilirubin levels UGT1A10 intron 23642732 rs887829 chr2 234668570 C T 9.00E-20 Bilirubin levels UGT1A10 intron 23642732 rs887829 chr2 234668570 C T 1.00E-17 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 6.00E-13 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 8.00E-23 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 2.00E-140 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 2.00E-152 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 2.00E-56 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 3.00E-114 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 3.00E-168 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 4.00E-95 Blood metabolite levels UGT1A10 intron 24816252 rs873478 chr2 234668870 G C 5.86E-14 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148323 chr2 234669144 G A 2.64E-05 Hirschsprung's disease UGT1A1 missense 19196962 rs4148323 chr2 234669144 G A 3.08E-139 Height UGT1A1 missense 20400458 rs4148323 chr2 234669144 G A 3.08E-139 Bilirubin levels,in serum UGT1A1 missense 20639394 rs4148323 chr2 234669144 G A 2.00E-62 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 5.00E-69 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 7.00E-30 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) UGT1A1 missense 23648065 rs17868341 chr2 234669886 C T 3.50E-19 Bilirubin levels UGT1A10 intron 19414484 rs28900396 chr2 234670560 T C 1.05E-07 Bilirubin levels UGT1A10 intron 22085899 rs28900396 chr2 234670560 T C 5.14E-14 Triglycerides UGT1A10 intron 23063622 rs28946889 chr2 234671462 G T 2.80E-69 Bilirubin levels UGT1A10 intron 19414484 rs17864704 chr2 234672172 C T 9.80E-39 Bilirubin levels UGT1A10 intron 19414484 rs28900398 chr2 234672338 T G 1.27E-06 Bilirubin levels UGT1A10 intron 22085899 rs6742078 chr2 234672639 G T 5E-324 Bilirubin levels UGT1A10 intron 19414484 rs6742078 chr2 234672639 G T 1.18E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6742078 chr2 234672639 G T 8.23E-18 Bilirubin levels UGT1A10 intron 22085899 rs6742078 chr2 234672639 G T 2.00E-23 Circulating cell-free DNA UGT1A10 intron 22511988 rs6742078 chr2 234672639 G T 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs6742078 chr2 234672639 G T 1.00E-89 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 2.00E-78 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 6.00E-40 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 3.22E-18 Bilirubin levels UGT1A10 intron 23642732 rs6742078 chr2 234672639 G T 4.44E-20 Bilirubin levels UGT1A10 intron 23642732 rs6742078 chr2 234672639 G T 2.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs3771342 chr2 234672663 G T 1.80E-18 Bilirubin levels UGT1A10 intron 19414484 rs4148324 chr2 234672722 T G 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148324 chr2 234672722 T G 1.04E-16 Bilirubin levels UGT1A10 intron 22085899 rs4148324 chr2 234672722 T G 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs4148324 chr2 234672722 T G 2.00E-116 Blood metabolite levels UGT1A10 intron 24816252 rs4148324 chr2 234672722 T G 5.00E-117 Blood metabolite levels UGT1A10 intron 24816252 rs3771341 chr2 234673239 G A,T 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs4148325 chr2 234673309 C T 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148325 chr2 234673309 C T 5.00E-62 Bilirubin levels UGT1A10 intron 21646302 rs4148325 chr2 234673309 C T 3.06E-22 Bilirubin levels UGT1A10 intron 22085899 rs4148325 chr2 234673309 C T 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs4148325 chr2 234673309 C T 3.22E-18 Bilirubin levels UGT1A10 intron 23642732 rs4148325 chr2 234673309 C T 4.44E-20 Bilirubin levels UGT1A10 intron 23642732 rs4148325 chr2 234673309 C T 2.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs4148326 chr2 234673462 T C 1.80E-267 Bilirubin levels UGT1A10 intron 19414484 rs4148326 chr2 234673462 T C 2.98E-13 Bilirubin levels UGT1A10 intron 22085899 rs4148326 chr2 234673462 T C 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs4148326 chr2 234673462 T C 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs4663971 chr2 234674252 C G 3.50E-267 Bilirubin levels UGT1A10 intron 19414484 rs4663971 chr2 234674252 C G 5.22E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663971 chr2 234674252 C G 4.96E-12 Bilirubin levels UGT1A10 intron 22085899 rs4663971 chr2 234674252 C G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs929596 chr2 234674476 A G 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs929596 chr2 234674476 A G 7.42E-14 Bilirubin levels UGT1A10 intron 22085899 rs929596 chr2 234674476 A G 2.18E-11 Metabolite levels UGT1A10 intron 23281178 rs11679312 chr2 234675036 C T 2.80E-39 Bilirubin levels UGT1A10 intron 19414484 rs6708136 chr2 234675567 C T 1.50E-38 Bilirubin levels UGT1A10 intron 19414484 rs28900402 chr2 234676412 C T 2.39E-09 Triglycerides UGT1A10 intron 23063622 rs12471326 chr2 234676458 T C 1.80E-34 Bilirubin levels UGT1A10 intron 19414484 rs10445705 chr2 234676787 G A 4.05E-06 Bilirubin levels UGT1A10 intron 22085899 rs6431630 chr2 234677386 G A 1.20E-15 Bilirubin levels UGT1A10 intron 19414484 rs4148328 chr2 234677659 C T 3.50E-61 Bilirubin levels UGT1A10 intron 19414484 rs4148328 chr2 234677659 C T 1.42E-06 Bilirubin levels UGT1A10 intron 23371916 rs11563251 chr2 234679384 C T 9.60E-15 Bilirubin levels UGT1A10 intron 19414484 rs11563251 chr2 234679384 C T 2.50E-09 Cholesterol,total UGT1A10 intron 23063622 rs11563251 chr2 234679384 C T 1.00E-09 Cholesterol,total UGT1A10 intron 24097068 rs11563251 chr2 234679384 C T 5.00E-08 LDL cholesterol UGT1A10 intron 24097068 rs11888492 chr2 234679974 C G 2.90E-14 Bilirubin levels UGT1A10 intron 19414484 rs10929303 chr2 234681416 T C 2.00E-21 Bilirubin levels UGT1A10 UTR-3 19414484 rs1042640 chr2 234681544 G C 4.90E-21 Bilirubin levels UGT1A10 UTR-3 19414484 rs8330 chr2 234681645 G C 3.20E-19 Bilirubin levels UGT1A10 UTR-3 19414484 rs4148329 chr2 234682062 C T 9.20E-10 Bilirubin levels / / 19414484 rs4148329 chr2 234682062 C T 7.49E-05 Response to hepatitis C treatment / / 19684573 rs6717546 chr2 234682119 A G 1.00E-25 Bilirubin levels / / 19414484 rs6717546 chr2 234682119 A G 7.14E-05 Response to hepatitis C treatment / / 19684573 rs1500482 chr2 234683038 C T 3.20E-15 Bilirubin levels / / 19414484 rs11563250 chr2 234683350 A G 3.70E-08 Bilirubin levels / / 19414484 rs6719561 chr2 234683763 C T 6.90E-54 Bilirubin levels / / 19414484 rs28900408 chr2 234683826 G A 5.68E-06 Bilirubin levels / / 22085899 rs4663972 chr2 234683892 C T 2.30E-17 Bilirubin levels / / 19414484 rs10199882 chr2 234685264 T C 3.90E-08 Bilirubin levels HEATR7B1 intron 19414484 rs7586006 chr2 234685527 T G 3.90E-08 Bilirubin levels HEATR7B1 intron 19414484 rs10203853 chr2 234687418 A T 3.70E-79 Bilirubin levels HEATR7B1 intron 19414484 rs10209214 chr2 234687583 T C 3.90E-54 Bilirubin levels HEATR7B1 intron 19414484 rs6431631 chr2 234688036 C A 3.10E-15 Bilirubin levels HEATR7B1 missense 19414484 rs17868345 chr2 234688360 C T 2.60E-11 Bilirubin levels HEATR7B1 cds-synon 19414484 rs4663335 chr2 234689090 G A 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6728940 chr2 234689164 G A 8.40E-54 Bilirubin levels HEATR7B1 intron 19414484 rs4663973 chr2 234689189 G T 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6746002 chr2 234689421 A G 8.60E-54 Bilirubin levels HEATR7B1 intron 19414484 rs1587493 chr2 234689751 G A 3.80E-36 Bilirubin levels HEATR7B1 intron 19414484 rs9287649 chr2 234689830 C G 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6728520 chr2 234690093 A G 6.10E-54 Bilirubin levels HEATR7B1 intron 19414484 rs6431632 chr2 234690545 A G 1.20E-14 Bilirubin levels HEATR7B1 intron 19414484 rs7583811 chr2 234692539 C T 1.50E-14 Bilirubin levels HEATR7B1 intron 19414484 rs11690786 chr2 234692617 C T 8.00E-184 Bilirubin levels HEATR7B1 intron 19414484 rs6723936 chr2 234693382 G A 4.60E-30 Bilirubin levels HEATR7B1 intron 19414484 rs11903524 chr2 234693769 A G 1.50E-14 Bilirubin levels HEATR7B1 intron 19414484 rs7596785 chr2 234694177 T C 1.80E-14 Bilirubin levels HEATR7B1 intron 19414484 rs17868346 chr2 234695087 A G 1.60E-30 Bilirubin levels HEATR7B1 intron 19414484 rs17863806 chr2 234695150 C A 3.70E-45 Bilirubin levels HEATR7B1 intron 19414484 rs10929304 chr2 234695224 T G 1.40E-14 Bilirubin levels HEATR7B1 intron 19414484 rs17862885 chr2 234695549 A G 9.50E-10 Bilirubin levels HEATR7B1 intron 19414484 rs12468017 chr2 234698097 T C 2.40E-11 Bilirubin levels HEATR7B1 intron 19414484 rs2361502 chr2 234698790 T C 7.80E-178 Bilirubin levels HEATR7B1 intron 19414484 rs2361502 chr2 234698790 T C 7.00E-23 Bilirubin levels HEATR7B1 intron 21646302 rs12986677 chr2 234698976 G A 1.00E-171 Bilirubin levels HEATR7B1 intron 19414484 rs13022508 chr2 234699086 T C 1.60E-176 Bilirubin levels HEATR7B1 intron 19414484 rs10207194 chr2 234700385 C A 3.50E-16 Bilirubin levels HEATR7B1 intron 19414484 rs10170160 chr2 234700578 T C 3.70E-19 Bilirubin levels HEATR7B1 intron 19414484 rs28948069 chr2 234700865 C G 5.40E-06 Bilirubin levels HEATR7B1 intron 19414484 rs12622156 chr2 234701686 G A 5.70E-08 Bilirubin levels HEATR7B1 intron 19414484 rs6755193 chr2 234701822 A G 9.49E-05 Response to mTOR inhibitor (everolimus) HEATR7B1 intron 24009623 rs17864714 chr2 234704076 G A 1.30E-20 Bilirubin levels HEATR7B1 intron 19414484 rs2885297 chr2 234704150 T C 2.40E-13 Bilirubin levels HEATR7B1 intron 19414484 rs1076454 chr2 234704607 C T 6.20E-16 Bilirubin levels HEATR7B1 intron 19414484 rs741160 chr2 234705389 A G 3.42E-08 Schizophrenia HEATR7B1 intron 21795503 rs741159 chr2 234706167 A G 4.20E-06 Bilirubin levels HEATR7B1 intron 19414484 rs741159 chr2 234706167 A G 1.00E-05 Urinary metabolites HEATR7B1 intron 21572414 rs9808308 chr2 234707921 A G 2.90E-05 Bilirubin levels HEATR7B1 intron 19414484 rs9808231 chr2 234708152 C T 6.80E-09 Bilirubin levels HEATR7B1 intron 19414484 rs13013882 chr2 234708428 G A 5.90E-13 Bilirubin levels HEATR7B1 cds-synon 19414484 rs11563069 chr2 234708570 G A 5.80E-13 Bilirubin levels HEATR7B1 intron 19414484 rs11563245 chr2 234709000 C T 2.50E-05 Bilirubin levels HEATR7B1 intron 19414484 rs11678741 chr2 234709831 C G 2.70E-11 Bilirubin levels HEATR7B1 intron 19414484 rs17862891 chr2 234710283 G A 6.30E-13 Bilirubin levels HEATR7B1 intron 19414484 rs730673 chr2 234711677 G C 6.90E-15 Bilirubin levels HEATR7B1 intron 19414484 rs10175949 chr2 234712921 G A 6.70E-17 Bilirubin levels HEATR7B1 intron 19414484 rs6716168 chr2 234713429 C T 5.00E-15 Bilirubin levels HEATR7B1 intron 19414484 rs2041651 chr2 234713812 G T 5.80E-17 Bilirubin levels HEATR7B1 intron 19414484 rs10929307 chr2 234717239 A G 1.60E-05 Urinary metabolites HEATR7B1 intron 21572414 rs10803663 chr2 234717669 A G 1.70E-05 Urinary metabolites HEATR7B1 intron 21572414 rs11674078 chr2 234718524 T C 1.30E-11 Bilirubin levels HEATR7B1 intron 19414484 rs11674078 chr2 234718524 T C 5.49E-05 Major depressive disorder HEATR7B1 intron pha002850 rs988344 chr2 234720734 A C 1.40E-16 Bilirubin levels HEATR7B1 intron 19414484 rs10929308 chr2 234722065 T C 8.10E-06 Bilirubin levels HEATR7B1 intron 19414484 rs1580834 chr2 234724048 G A 2.22E-04 Smoking cessation HEATR7B1 intron 24665060 rs726016 chr2 234725502 T C 7.40E-06 Bilirubin levels HEATR7B1 missense 19414484 rs726017 chr2 234725819 A G 4.30E-06 Bilirubin levels HEATR7B1 intron 19414484 rs13015369 chr2 234726058 G T 4.02E-05 Nephrolithiasis HEATR7B1 intron 22396660 rs1500480 chr2 234728078 T C 1.60E-06 Bilirubin levels HEATR7B1 missense 19414484 rs6734083 chr2 234730807 G A 4.26E-04 Alzheimer's disease HEATR7B1 missense 24755620 rs17868361 chr2 234732311 G A 1.10E-05 Bilirubin levels HEATR7B1 missense 19414484 rs7557532 chr2 234733064 T G 5.29E-05 Orofacial clefts HEATR7B1 intron 22419666 rs17862900 chr2 234736311 A G 1.40E-05 Bilirubin levels HEATR7B1 intron 19414484 rs2361507 chr2 234739810 T G 3.30E-08 Bilirubin levels HEATR7B1 intron 19414484 rs879665 chr2 234740136 G A 2.80E-07 Bilirubin levels HEATR7B1 missense 19414484 rs10185631 chr2 234740490 T G 1.10E-06 Bilirubin levels HEATR7B1 intron 19414484 rs213548 chr2 234741443 G A 3.60E-05 Bilirubin levels HEATR7B1 intron 19414484 rs2270856 chr2 234741808 C T 3.10E-10 Bilirubin levels HEATR7B1 missense 19414484 rs13416326 chr2 234744661 A G 4.80E-10 Bilirubin levels / / 19414484 rs213551 chr2 234745389 A G 5.58E-04 Multiple complex diseases / / 17554300 rs213553 chr2 234745975 A C 8.50E-04 Parkinson's disease HJURP UTR-3 17052657 rs685139 chr2 234758539 T C 6.90E-04 Suicide attempts in bipolar disorder HJURP intron 21423239 rs2286430 chr2 234761225 C A,G,T 9.98E-04 Multiple complex diseases HJURP missense 17554300 rs10204079 chr2 234762099 G A 1.30E-06 Bilirubin levels HJURP intron 19414484 rs511387 chr2 234772911 G C 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs566985 chr2 234772983 G A 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs568906 chr2 234773193 C T 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs570800 chr2 234773403 A G 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs186159 chr2 234773876 G C 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs213543 chr2 234774025 C T 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs188492 chr2 234774076 A G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13384181 chr2 234775346 G A 4.80E-07 Bilirubin levels / / 19414484 rs213544 chr2 234775675 G T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs13390675 chr2 234776752 G C 4.00E-07 Bilirubin levels MSL3P1 intron 19414484 rs213541 chr2 234779644 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11890203 chr2 234780131 A G 4.60E-07 Bilirubin levels / / 19414484 rs6727154 chr2 234788734 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs28900731 chr2 234790111 A G 2.90E-09 Bilirubin levels / / 19414484 rs17862910 chr2 234790181 G A 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs17862913 chr2 234793402 G T 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs17863831 chr2 234796001 T G 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11563065 chr2 234796385 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17868375 chr2 234799231 G A 3.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs17864734 chr2 234800159 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs17864735 chr2 234801252 A C 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164928 chr2 234801785 C T 5.60E-07 Bilirubin levels / / 19414484 rs17864737 chr2 234802187 A T 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs765900 chr2 234806833 G A 4.08E-04 Smoking initiation / / 24665060 rs17868378 chr2 234808378 A C 4.70E-07 Bilirubin levels / / 19414484 rs10929317 chr2 234811911 G T 2.55E-04 Smoking initiation / / 24665060 rs10187654 chr2 234814059 C T 9.00E-06 Pulmonary function decline / / 22424883 rs11562941 chr2 234815167 G A 2.71E-04 Smoking initiation / / 24665060 rs7577262 chr2 234818869 G A 3.00E-08 Blood pressure measurement (cold pressor test) / / 24165912 rs7577262 chr2 234818869 G A 1.95E-04 Smoking initiation / / 24665060 rs10166942 chr2 234825093 T C 6.00E-12 Migraine / / 21666692 rs10166942 chr2 234825093 T C 1.00E-12 Migraine / / 22683712 rs10166942 chr2 234825093 T C 1.21E-10 Migraine without aura / / 23793025 rs10166942 chr2 234825093 T C 1.69E-06 Migraine with aura / / 23793025 rs10166942 chr2 234825093 T C 2.91E-12 Migraine / / 23793025 rs10166942 chr2 234825093 T C 6.39E-09 Migraine - clinic-based / / 23793025 rs6741751 chr2 234827661 G A 1.00E-07 Migraine with aura TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 1.00E-08 Migraine - clinic-based TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 9.00E-11 Migraine without aura TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 9.00E-14 Migraine TRPM8 intron 23793025 rs17862920 chr2 234827995 C T 1.26E-05 Migraine TRPM8 intron 20802479 rs17862920 chr2 234827995 C T 6.00E-09 Migraine TRPM8 intron 22683712 rs17862920 chr2 234827995 C T 1.96E-04 Smoking initiation TRPM8 intron 24665060 rs10803666 chr2 234838947 G C 8.70E-04 Blood pressure TRPM8 intron 21572416 rs12472151 chr2 234852692 G A 2.00E-06 Alcohol consumption TRPM8 intron 23942779 rs12992084 chr2 234855354 T C 2.40E-06 Alcohol consumption TRPM8 intron 23942779 rs4663989 chr2 234859056 G T 9.71E-04 Multiple complex diseases TRPM8 intron 17554300 rs10929321 chr2 234871343 G A 4.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRPM8 intron 20877124 rs10207672 chr2 234888161 T C 7.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TRPM8 intron 23648065 rs2362294 chr2 234900513 G A 1.81E-04 Smoking initiation TRPM8 intron 24665060 rs3732214 chr2 234923124 A C 1.00E-04 Cognitive impairment induced by topiramate TRPM8 intron 22091778 rs11563054 chr2 234924941 T C 1.50E-04 Multiple complex diseases TRPM8 intron 17554300 rs11563199 chr2 234925521 C T 5.34E-05 Cognitive performance TRPM8 intron 19734545 rs17869077 chr2 234925758 C T 5.34E-05 Cognitive performance TRPM8 intron 19734545 rs11901004 chr2 234927260 G T 4.89E-06 Hippocampal volume in schizophrenia TRPM8 UTR-3 23805179 rs1987842 chr2 234928517 G A 4.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17866592 chr2 234929686 T C 2.31E-06 Hippocampal volume in schizophrenia / / 23805179 rs603217 chr2 234931522 G C 3.05E-04 Nicotine smoking / / 19268276 rs622060 chr2 234948684 G A 1.50E-05 Urinary metabolites / / 21572414 rs620654 chr2 234949004 G A 3.68E-04 Alzheimer's disease (late onset) / / 21379329 rs7593927 chr2 234953978 T G 0.0000917 Panic disorder / / 23149450 rs7593927 chr2 234953978 T G 9.17E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs634613 chr2 234954619 G A 1.40E-05 Urinary metabolites / / 21572414 rs11563197 chr2 234960021 C T 0.000596 Salmonella-induced pyroptosis SPP2 intron 22837397 rs2267903 chr2 234962651 G A 9.20E-05 Glioma (high-grade) SPP2 intron 19578366 rs2267903 chr2 234962651 G A 2.94E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs7603271 chr2 234964316 C A 6.04E-05 Bipolar disorder and schizophrenia SPP2 intron 20889312 rs7603271 chr2 234964316 C A 2.49E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs11563194 chr2 234966165 T C 7.37E-05 Bipolar disorder and schizophrenia SPP2 intron 20889312 rs11563194 chr2 234966165 T C 3.60E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs13396164 chr2 234966238 C T 2.98E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs17865706 chr2 234966486 C T 3.60E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs17865708 chr2 234967410 G A 0.000378 Salmonella-induced pyroptosis SPP2 intron 22837397 rs2239536 chr2 234968051 C T 2.98E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs10803669 chr2 234968786 G T 2.40E-05 Urinary metabolites SPP2 intron 21572414 rs250977 chr2 234978363 G A 4.20E-05 HIV-1 control SPP2 intron 20041166 rs250975 chr2 234981061 C T 2.90E-05 HIV-1 control SPP2 intron 20041166 rs250973 chr2 234983001 G A 9.98E-04 Alzheimer's disease SPP2 intron 24755620 rs13017720 chr2 234984758 G A 4.67E-04 Alzheimer's disease (late onset) SPP2 intron 21379329 rs250962 chr2 234991336 T C 4.22E-04 Rheumatoid arthritis / / 21452313 rs250958 chr2 234992912 T C 3.51E-04 Rheumatoid arthritis / / 21452313 rs7581053 chr2 234993308 C A 3.41E-04 Alzheimer's disease (late onset) / / 21379329 rs250944 chr2 234997218 G A 0.0000218 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs250938 chr2 235002822 G A 6.45E-04 Rheumatoid arthritis / / 21452313 rs250928 chr2 235008881 G A 7.67E-04 Rheumatoid arthritis / / 21452313 rs6731887 chr2 235020980 T G 3.88E-05 Cholesterol / / 17255346 rs6710850 chr2 235036470 A T 2.20E-04 Cholesterol / / 17255346 rs16850525 chr2 235055333 A G 7.98E-05 Asthma / / pha003128 rs11884879 chr2 235078194 G A 1.11E-04 Celiac disease / / 23936387 rs2049026 chr2 235192719 G A 7.66E-05 Body mass index / / 17255346 rs6716674 chr2 235194783 G C 4.20E-05 Cognitive function / / 24684796 rs11894176 chr2 235195326 G A 5.71E-05 Cognitive test performance / / 20125193 rs12467783 chr2 235204421 C T 6.84E-05 Blood pressure / / 17255346 rs12151790 chr2 235210727 G A 5.00E-07 Osteoporosis / / 20548944 rs4663384 chr2 235216752 G T 7.90E-05 Serum metabolites / / 19043545 rs2885958 chr2 235229127 C T 3.44E-04 Prostate cancer mortality / / 20978177 rs772781 chr2 235242143 T C 7.44E-04 Type 2 diabetes / / 17463246 rs772781 chr2 235242143 T C 1.00E-05 Urinary metabolites / / 21572414 rs772780 chr2 235242416 C T 2.23E-04 Type 2 diabetes / / 17463246 rs772780 chr2 235242416 C T 4.70E-06 Urinary metabolites / / 21572414 rs1401504 chr2 235262862 A G 7.60E-05 Glioma (high-grade) / / 19578366 rs7572928 chr2 235284355 C T 8.19E-05 Vascular dementia / / 22116812 rs10205735 chr2 235288471 C T 7.60E-07 Urinary metabolites / / 21572414 rs10165917 chr2 235292064 A G 2.60E-06 Urinary metabolites / / 21572414 rs11887188 chr2 235302810 C T 1.00E-06 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs11887188 chr2 235302810 C T 2.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs11886562 chr2 235315413 G A 1.20E-05 Urinary metabolites / / 21572414 rs6743014 chr2 235350736 A G 8.99E-04 Multiple complex diseases / / 17554300 rs1876715 chr2 235364851 C T 8.10E-04 Multiple complex diseases / / 17554300 rs7584396 chr2 235383267 T C 2.38E-04 Coronary heart disease / / 21606135 rs7594052 chr2 235390834 T G 6.35E-04 Type 2 diabetes / / 17463246 rs10177805 chr2 235425433 T C 2.49E-05 Behcet's disease / / 23291587 rs4663425 chr2 235430409 G A 1.07E-04 Blood pressure / / 17255346 rs7592582 chr2 235446253 A C 1.00E-05 Crohn's disease / / 20570966 rs10803621 chr2 235458755 A C 3.95E-04 Type 2 diabetes / / 17463246 rs12469734 chr2 235469549 G A 1.45E-04 Taste perception / / 22132133 rs6738554 chr2 235481565 G A 1.48E-04 Multiple complex diseases / / 17554300 rs950834 chr2 235492499 T G 2.39E-05 Eosinophil counts / / pha003088 rs7594340 chr2 235501150 C T 4.95E-07 Eosinophil counts / / pha003088 rs4663445 chr2 235503852 T C 7.73E-04 Obesity (extreme) / / 21935397 rs4663447 chr2 235504056 T C 2.33E-06 Eosinophil counts / / pha003088 rs13013073 chr2 235505424 G C 6.73E-05 Depression (quantitative trait) / / 23290196 rs10190832 chr2 235509738 T C 7.67E-05 Glucose levels / / pha003058 rs10190832 chr2 235509738 T C 8.12E-05 Glucose levels / / pha003061 rs1917946 chr2 235517079 A C 3.30E-06 Urinary metabolites / / 21572414 rs7561154 chr2 235518737 G A 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7605520 chr2 235519242 T G 4.00E-06 Urinary metabolites / / 21572414 rs940943 chr2 235525096 G C 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386503 chr2 235525262 A T 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386502 chr2 235525579 A G 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386501 chr2 235525599 G A 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2030841 chr2 235526784 G A 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs6711637 chr2 235527499 T C 3.40E-06 Urinary metabolites / / 21572414 rs4663448 chr2 235529903 T C 8.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs10176169 chr2 235531098 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4467334 chr2 235531268 G C,T 8.30E-06 Urinary metabolites / / 21572414 rs10167927 chr2 235550321 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10167927 chr2 235550321 G A 8.69E-05 Pancreatic cancer / / pha002889 rs2119659 chr2 235593473 T C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2119659 chr2 235593473 T C 6.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663471 chr2 235594798 T A 1.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11677044 chr2 235599903 A C 1.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9287580 chr2 235600076 G A 7.99E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663476 chr2 235601064 T G 8.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs4663477 chr2 235601211 C G 4.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663478 chr2 235601276 G C 1.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1358069 chr2 235603435 G A 8.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1358070 chr2 235603599 C G 5.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6736997 chr2 235615197 A C 6.00E-06 Pancreatic cancer / / 20686608 rs4663163 chr2 235626160 A G 2.76E-05 Major depressive disorder / / 20516156 rs2218249 chr2 235628051 C T 3.20E-05 Tooth agenesis (third molar) / / 24172245 rs6730767 chr2 235635006 G A 2.10E-05 Tooth agenesis (third molar) / / 24172245 rs7586477 chr2 235639080 T C 1.77E-06 Schizophrenia / / 21795503 rs2380261 chr2 235641180 C A 2.00E-04 Diabetic retinopathy / / 23562823 rs2380261 chr2 235641180 C A 4.70E-06 Diabetic retinopathy / / 23562823 rs1441605 chr2 235647366 C G 7.50E-06 Diabetic retinopathy / / 23562823 rs13016879 chr2 235693788 G A 3.75E-04 Depression (quantitative trait) / / 20800221 rs894188 chr2 235699767 C T 1.59E-04 Depression (quantitative trait) / / 20800221 rs10201498 chr2 235706129 G A 1.31E-04 Multiple complex diseases / / 17554300 rs10929056 chr2 235714013 C A 8.17E-06 Coronary heart disease / / pha003030 rs13022629 chr2 235720850 A G 7.94E-04 Depression (quantitative trait) / / 20800221 rs1441612 chr2 235721740 G T 3.58E-05 Coronary heart disease / / pha003030 rs13016685 chr2 235723806 G T 8.52E-05 Smoking initiation / / 24665060 rs961818 chr2 235726745 A G 5.75E-05 Coronary heart disease / / pha003030 rs11681769 chr2 235730405 G A 1.17E-06 Coronary heart disease / / pha003030 rs10929060 chr2 235733155 C A 3.46E-06 Coronary heart disease / / pha003030 rs1427696 chr2 235735930 T C 9.62E-05 Sodium levels / / pha003093 rs1529413 chr2 235775041 A G 1.60E-06 Schizophrenia / / 21795503 rs1863815 chr2 235779262 G C 4.02E-04 Multiple complex diseases / / 17554300 rs6723979 chr2 235803863 G C 8.91E-04 Aortic root size / / 21223598 rs10803629 chr2 235891645 A G 3.74E-05 Type 2 diabetes SH3BP4 intron 17463246 rs11676855 chr2 235900171 T C 9.00E-06 Dialysis-related mortality SH3BP4 intron 21546767 rs12471688 chr2 235932581 G A 2.30E-05 Response to statin therapy SH3BP4 intron 20339536 rs10199034 chr2 235935809 G C 3.10E-05 Response to statin therapy SH3BP4 intron 20339536 rs2195195 chr2 235938690 T C 2.40E-05 Response to statin therapy SH3BP4 intron 20339536 rs2195195 chr2 235938690 T C 2.56E-05 Blood Pressure SH3BP4 intron pha003046 rs11898961 chr2 235938976 A G 5.61E-04 Multiple complex diseases SH3BP4 intron 17554300 rs6739712 chr2 235945879 T A 2.20E-05 Urinary metabolites SH3BP4 intron 21572414 rs3731644 chr2 235949877 T C 0.000873929 Hypertension (early onset hypertension) SH3BP4 missense 22479346 rs3731646 chr2 235950002 G A 0.000873929 Hypertension (early onset hypertension) SH3BP4 missense 22479346 rs3731648 chr2 235950284 A C 0.000873929 Hypertension (early onset hypertension) SH3BP4 cds-synon 22479346 rs1559986 chr2 235957657 T C 2.57E-04 Cholesterol SH3BP4 intron 17255346 rs4505466 chr2 235960824 C T 8.31E-05 Longevity SH3BP4 intron 21612516 rs4505466 chr2 235960824 C T 3.13E-06 Orofacial clefts SH3BP4 intron 22419666 rs10174126 chr2 235960893 T C 7.00E-07 Orofacial clefts SH3BP4 intron 22419666 rs4334446 chr2 235965403 T C 6.70E-05 Orofacial clefts / / 22419666 rs4528714 chr2 235969515 G T 4.34E-05 Magnesium levels / / pha003092 rs13407724 chr2 235985354 C T 8.61E-04 Tourette syndrome / / 22889924 rs12692159 chr2 235990320 C A 8.10E-05 Heart Rate / / pha003053 rs12692159 chr2 235990320 C A 7.84E-05 Heart Rate / / pha003054 rs7560067 chr2 235997858 T C 1.85E-04 Tourette syndrome / / 22889924 rs11680191 chr2 236030089 G A 5.93E-05 Glucose levels / / pha003058 rs6746703 chr2 236063063 C T 2.78E-05 Myopia (severe) / / 23933737 rs10221738 chr2 236085432 G A 2.50E-04 Intracranial aneurysm / / 20613766 rs4663553 chr2 236100852 A C 5.10E-04 Tourette syndrome / / 22889924 rs6741541 chr2 236104693 T C 9.55E-04 Multiple complex diseases / / 17554300 rs6724006 chr2 236104861 C G 9.81E-04 Multiple complex diseases / / 17554300 rs10929105 chr2 236104982 C T 1.10E-05 Urinary metabolites / / 21572414 rs6727347 chr2 236111180 C A 9.55E-04 Multiple complex diseases / / 17554300 rs1991705 chr2 236128951 A G 7.00E-06 Obesity-related traits / / 23251661 rs1367878 chr2 236133216 A G 1.24E-04 Intracranial aneurysm / / 20613766 rs6710111 chr2 236144476 G A 2.44E-04 Acute lung injury / / 22295056 rs7599884 chr2 236147276 C T 3.06E-04 Acute lung injury / / 22295056 rs8179638 chr2 236161371 A C 5.97E-04 Acute lung injury / / 22295056 rs13432658 chr2 236165791 T G 4.66E-04 Acute lung injury / / 22295056 rs7595069 chr2 236166480 T C 2.20E-05 Urinary metabolites / / 21572414 rs13420609 chr2 236166928 C A 2.82E-04 Acute lung injury / / 22295056 rs12052405 chr2 236167636 T G 2.80E-04 Acute lung injury / / 22295056 rs12052406 chr2 236167696 T C 5.50E-04 Acute lung injury / / 22295056 rs12052330 chr2 236167826 A G 5.32E-04 Acute lung injury / / 22295056 rs4663191 chr2 236174758 A G 3.79E-05 Height / / pha003010 rs10929115 chr2 236179761 A C 6.93E-04 Multiple complex diseases / / 17554300 rs2043194 chr2 236180672 A G 9.99E-04 Multiple complex diseases / / 17554300 rs6431360 chr2 236180811 T G 1.59E-04 Multiple complex diseases / / 17554300 rs6431360 chr2 236180811 T G 1.45E-29 Narcolepsy / / 19629137 rs4663563 chr2 236194197 C T 3.30E-04 Height / / 17255346 rs13412315 chr2 236195931 A G 2.00E-06 Urinary metabolites / / 21572414 rs4663564 chr2 236197807 C T 7.67E-04 Smoking quantity / / 24665060 rs13422090 chr2 236197888 T C 8.20E-07 Urinary metabolites / / 21572414 rs1367876 chr2 236212004 A G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13020554 chr2 236214007 G A 8.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13020554 chr2 236214007 G A 3.48E-05 Cognitive test performance / / 20125193 rs2163566 chr2 236228143 A G 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs13428584 chr2 236265539 A G 7.62E-04 Coronary Artery Disease / / 17634449 rs11691626 chr2 236267980 C T 7.60E-05 Prostate cancer / / 22923026 rs2090418 chr2 236272767 C T 7.68E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10803639 chr2 236282912 G A 7.47E-06 Personality dimensions / / 23658558 rs11691754 chr2 236340067 A C 9.51E-04 Parkinson's disease / / 17052657 rs12474898 chr2 236367367 C T 1.80E-05 Urinary metabolites / / 21572414 rs10929133 chr2 236369719 C A 1.80E-05 Urinary metabolites / / 21572414 rs2316431 chr2 236407716 T C 7.77E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs7599284 chr2 236410952 G A 8.28E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs1865951 chr2 236415339 G A 8.27E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs7595159 chr2 236478388 A G 0.0006816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGAP1 intron 23233654 rs7595159 chr2 236478388 A G 6.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGAP1 intron 23233662 rs12151399 chr2 236478656 A G 7.03E-04 Multiple complex diseases AGAP1 intron 17554300 rs11676226 chr2 236514769 A G 7.63E-04 Response to taxane treatment (placlitaxel) AGAP1 intron 23006423 rs11676226 chr2 236514769 A G 3.66E-06 Coronary heart disease AGAP1 intron pha003032 rs7564374 chr2 236516480 G A 7.16E-04 Response to taxane treatment (placlitaxel) AGAP1 intron 23006423 rs7564374 chr2 236516480 G A 8.40E-07 Coronary heart disease AGAP1 intron pha003032 rs6431393 chr2 236539307 A G 4.00E-06 Menarche (age at onset) AGAP1 intron 23667675 rs6750322 chr2 236589977 A G 3.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) AGAP1 intron 23648065 rs12992033 chr2 236605782 G A 3.56E-04 Lung function (forced expiratory volume in 1 second) AGAP1 intron 17255346 rs3754670 chr2 236617595 T C 6.31E-04 Multiple complex diseases AGAP1 intron 17554300 rs3754669 chr2 236617736 C T 8.79E-05 Lung function (forced expiratory volume in 1 second) AGAP1 intron 17255346 rs1568069 chr2 236618642 G T 1.24E-05 Parkinson's disease AGAP1 intron 21738487 rs2675124 chr2 236631040 G A 7.39E-05 Hypertension (essential hypertension) AGAP1 intron 22184326 rs2675144 chr2 236641479 C T 4.17E-04 Alzheimer's disease AGAP1 intron 22005930 rs6711814 chr2 236646486 G T 4.19E-04 Multiple complex diseases AGAP1 intron 17554300 rs3738996 chr2 236655526 G A 1.90E-05 Cognitive test performance AGAP1 intron 20125193 rs1728286 chr2 236658058 A G 4.07E-04 Alzheimer's disease AGAP1 intron 22005930 rs6760477 chr2 236709123 G A 1.74E-05 Cognitive test performance AGAP1 intron 20125193 rs7565206 chr2 236717001 G T 6.44E-05 Cognitive test performance AGAP1 intron 20125193 rs12616076 chr2 236719302 A G 1.61E-04 Type 2 diabetes AGAP1 intron 17463246 rs12616076 chr2 236719302 A G 2.60E-05 Urinary metabolites AGAP1 intron 21572414 rs12478435 chr2 236737133 T C 3.96E-04 Amyotrophic lateral sclerosis (sporadic) AGAP1 intron 24529757 rs3820776 chr2 236780457 A G 8.48E-05 Schizophrenia AGAP1 intron 19571809 rs67755945 chr2 236792769 AC AAC,ACA 2.00E-04 Cognitive impairment induced by topiramate AGAP1 intron 22091778 rs7426112 chr2 236792769 A C,T 2.00E-04 Cognitive impairment induced by topiramate AGAP1 intron 22091778 rs13025591 chr2 236795343 A C 4.59E-07 Schizophrenia AGAP1 intron 19571809 rs13025591 chr2 236795343 A C 6.00E-06 Schizophrenia AGAP1 intron 21926974 rs13025591 chr2 236795343 A C 8.00E-08 Schizophrenia AGAP1 intron 22688191 rs11688841 chr2 236795801 G A 9.89E-04 Alcohol dependence AGAP1 intron 21314694 rs4663627 chr2 236796548 C T 0.000131 Schizophrenia AGAP1 intron 23637625 rs6747286 chr2 236813557 T C 9.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs1962550 chr2 236822569 C G 1.15E-06 Schizophrenia AGAP1 intron 19571809 rs7571708 chr2 236832573 A G 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs1962299 chr2 236834160 A G 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs7583139 chr2 236835657 A G 1.13E-04 Insulin resistance AGAP1 intron 21901158 rs10200514 chr2 236849630 C A 4.20E-06 Urinary metabolites AGAP1 intron 21572414 rs11902362 chr2 236858701 G A 6.80E-06 Urinary metabolites AGAP1 intron 21572414 rs6431414 chr2 236862139 A G 1.50E-06 Urinary metabolites AGAP1 intron 21572414 rs4261675 chr2 236864057 A C,G,T 1.60E-06 Urinary metabolites AGAP1 intron 21572414 rs7601459 chr2 236890713 T C 8.00E-06 Urinary metabolites AGAP1 intron 21572414 rs1530940 chr2 236905308 C A 2.63E-05 Hemoglobin AGAP1 intron pha003096 rs10206890 chr2 236922324 C A 6.94E-04 Amyotrophic Lateral Sclerosis AGAP1 intron 17362836 rs6739594 chr2 236951982 C T 2.44E-04 Multiple complex diseases AGAP1 intron 17554300 rs3768945 chr2 236972635 G A 8.01E-05 Amyotrophic lateral sclerosis AGAP1 intron 23624525 rs3768940 chr2 236980678 A T 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs1530933 chr2 236988413 C A 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs1530932 chr2 236988590 T A 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs11889753 chr2 236988903 A C 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs3768939 chr2 236990057 G A 2.00E-04 Information processing speed AGAP1 intron 21130836 rs3768939 chr2 236990057 G A 4.20E-05 Myopia (pathological) AGAP1 intron 23049088 rs3768939 chr2 236990057 G A 8.70E-05 Cardiovascular disease AGAP1 intron pha003064 rs6709778 chr2 236999752 T C 7.40E-04 Coronary heart disease AGAP1 intron 21971053 rs7557498 chr2 237019256 A G 2.80E-05 Urinary metabolites AGAP1 intron 21572414 rs6742722 chr2 237040797 G A 1.63E-05 Body Mass Index / / pha002896 rs11687170 chr2 237058144 T A,C 3.00E-08 Educational attainment / / 23722424 rs13386897 chr2 237099410 A G 2.47E-06 Body Mass Index / / pha002896 rs13398522 chr2 237099438 G T 4.16E-04 Multiple complex diseases / / 17554300 rs10177957 chr2 237103697 G T 5.23E-06 Body Mass Index ASB18 missense pha002896 rs13401104 chr2 237105518 G A 5.00E-09 Educational attainment ASB18 intron 23722424 rs1530952 chr2 237131159 C A 2.57E-05 Body Mass Index ASB18 intron pha002896 rs13390159 chr2 237156549 G A 2.00E-07 Response to statin therapy ASB18 intron 20339536 rs10198281 chr2 237194279 A G 4.09E-04 Smoking quantity / / 24665060 rs7586359 chr2 237195419 T G 3.00E-06 Personality dimensions / / 18957941 rs7607774 chr2 237429154 G A 4.00E-07 Alcohol dependence / / 21956439 rs7577417 chr2 237450912 G A 3.30E-04 Primary sclerosing cholangitis / / 19944697 rs6431472 chr2 237451035 C G 4.40E-04 Primary sclerosing cholangitis / / 19944697 rs4571012 chr2 237453806 G T 6.10E-04 Primary sclerosing cholangitis / / 19944697 rs7585641 chr2 237488429 G C 2.45E-04 Type 2 diabetes CXCR7 intron 17463246 rs7585641 chr2 237488429 G C 2.83E-04 Multiple complex diseases CXCR7 intron 17554300 rs896543 chr2 237509207 G A 0.00000435 Alcohol dependence / / 23089632 rs896543 chr2 237509207 G A 4.75E-07 Alcohol dependence / / 23089632 rs896543 chr2 237509207 G A 1.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7565777 chr2 237516294 A G 3.60E-06 Alcohol dependence (age at onset) / / 24962325 rs6431476 chr2 237517937 T C 0.00000114 Alcohol dependence / / 23089632 rs6431476 chr2 237517937 T C 0.00000392 Alcohol dependence / / 23089632 rs7607316 chr2 237521842 C A 3.00E-06 Airflow obstruction / / 22837378 rs7588302 chr2 237531788 T C 1.78E-04 Epilepsy / / 22116939 rs7594454 chr2 237537935 C T 0.0000305 Alcohol dependence / / 23089632 rs7594454 chr2 237537935 C T 2.60E-06 Alcohol dependence / / 23089632 rs2464850 chr2 237545512 A C 9.46E-05 Serum metabolites / / 19043545 rs2600737 chr2 237561751 C A 3.26E-05 Serum metabolites / / 19043545 rs2600731 chr2 237567361 G T 8.01E-05 Serum metabolites / / 19043545 rs2720094 chr2 237629858 G C 6.75E-05 Bipolar disorder / / 18317468 rs7556982 chr2 237644199 A G 1.55E-05 Odorant perception / / 23910658 rs10207770 chr2 237703303 T C 2.48E-04 IgE levels / / 17255346 rs1344766 chr2 237704004 G T 2.08E-04 IgE levels / / 17255346 rs7598243 chr2 237705892 A C 2.95E-04 IgE levels / / 17255346 rs934397 chr2 237706939 A G 1.23E-04 IgE levels / / 17255346 rs934396 chr2 237707002 C T 3.23E-04 IgE levels / / 17255346 rs10929194 chr2 237720634 G A 3.94E-04 IgE levels / / 17255346 rs7584906 chr2 237736216 C T 0.000897 Salmonella-induced pyroptosis / / 22837397 rs11676193 chr2 237750619 C T 0.0009 Salmonella-induced pyroptosis / / 22837397 rs1000007 chr2 237752054 T C 0.0000669 Salmonella-induced pyroptosis / / 22837397 rs12991682 chr2 237757355 C T 2.03E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2164397 chr2 237791011 G C 5.26E-04 Alzheimer's disease / / 17998437 rs1435843 chr2 237798803 G A 5.39E-08 Metabolite levels / / 23281178 rs10192201 chr2 237803408 C G 4.44E-04 Type 2 diabetes / / 21647700 rs7599706 chr2 237805687 T G 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2573730 chr2 237866135 C T 1.60E-05 Urinary metabolites / / 21572414 rs10803652 chr2 237876320 C T 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9646715 chr2 237895397 A T 7.46E-04 Type 2 diabetes / / 17463246 rs9287614 chr2 237901609 G A 8.50E-04 Alzheimer's disease / / 17998437 rs7597880 chr2 237958171 G A 4.54E-05 Platelet counts / / pha003100 rs13404290 chr2 237991777 T C 1.50E-05 Tooth agenesis (third molar) / / 24172245 rs7577630 chr2 237992613 G A 3.80E-05 Tooth agenesis (third molar) / / 24172245 rs10172321 chr2 238065463 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6711456 chr2 238114043 C T 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs13023077 chr2 238117179 A G 5.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs11694263 chr2 238190389 G A 6.69E-04 Parkinson's disease / / 17052657 rs4274551 chr2 238195820 G A 5.41E-06 Height / / pha003010 rs4274551 chr2 238195820 G A 2.70E-05 Height / / pha003011 rs11676186 chr2 238205060 C T 2.04E-04 Blood pressure / / 17255346 rs11897292 chr2 238210640 G C 8.30E-04 Diabetic nephropathy / / 20347642 rs12052878 chr2 238227594 G A 1.84E-05 Blood pressure / / 21909110 rs11690358 chr2 238244781 T C 3.43E-04 Type 2 diabetes COL6A3 missense 17463246 rs6725567 chr2 238253518 C T 7.66E-04 Insulin resistance COL6A3 intron 21901158 rs7586225 chr2 238255686 C A 9.88E-05 Insulin resistance COL6A3 intron 21901158 rs7586225 chr2 238255686 C A 2.64E-05 Height COL6A3 intron pha003011 rs2646265 chr2 238257013 G A 5.87E-04 Parkinson's disease COL6A3 cds-synon 17052657 rs2646262 chr2 238258280 C T 3.16E-05 Height COL6A3 intron pha003011 rs2646254 chr2 238267717 C T 3.30E-04 Blood pressure COL6A3 cds-synon 17255346 rs10202497 chr2 238270894 C A 8.00E-06 Aging (time to event) COL6A3 intron 21782286 rs2645770 chr2 238274828 C A 1.50E-05 Urinary metabolites COL6A3 intron 21572414 rs13407339 chr2 238316137 C T 1.14E-04 Acute lung injury COL6A3 intron 22295056 rs6717825 chr2 238334279 G A 2.72E-05 Femoral neck bone geometry / / 22087292 rs937387 chr2 238348503 T C 9.94E-05 Femoral neck bone geometry / / 22087292 rs7600317 chr2 238353513 G A 2.23E-04 Smoking initiation / / 24665060 rs7598589 chr2 238355639 A T 1.30E-04 Multiple complex diseases / / 17554300 rs7595979 chr2 238364492 C A 6.38E-06 Smoking cessation / / 18519826 rs9287620 chr2 238368730 C A,T 3.33E-04 Smoking initiation / / 24665060 rs1497129 chr2 238369184 C T 2.08E-05 Smoking cessation / / 18519826 rs13398506 chr2 238374824 A G 4.33E-04 Smoking initiation / / 24665060 rs6431541 chr2 238376190 A T 1.96E-04 Smoking cessation / / 18519826 rs7584330 chr2 238387228 A G 3.00E-09 Prostate cancer / / 21743467 rs12469812 chr2 238415117 C T 7.00E-05 Prostate cancer MLPH intron 21743057 rs2292884 chr2 238443226 A G 4.00E-08 Prostate cancer MLPH missense 21743057 rs2292884 chr2 238443226 A G 7.71E-04 Alzheimer's disease MLPH missense 22005930 rs3817362 chr2 238449007 T C 4.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MLPH missense 21239504 rs6760287 chr2 238498996 A G 1.51E-05 Response to taxane treatment (placlitaxel) RAB17 intron 23006423 rs2292873 chr2 238499444 C T 8.00E-06 Obesity-related traits RAB17 UTR-5 23251661 rs34832187 chr2 238499444 C CG 8.00E-06 Obesity-related traits RAB17 UTR-5 23251661 rs6755617 chr2 238499727 G A 1.37E-04 Response to taxane treatment (placlitaxel) RAB17 UTR-5 23006423 rs6709393 chr2 238505625 A G 3.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs1316476 chr2 238508099 T C 8.75E-04 Obesity (extreme) / / 21935397 rs7585075 chr2 238509273 G A 2.00E-04 Information processing speed / / 21130836 rs11894280 chr2 238509759 G A 1.81E-05 Arthritis (juvenile idiopathic) / / 22354554 rs10929238 chr2 238509820 G A 2.40E-06 Urinary metabolites / / 21572414 rs13000086 chr2 238515227 A T 7.70E-06 Urinary metabolites / / 21572414 rs4278886 chr2 238522744 C T 3.34E-07 Schizophrenia / / 21795503 rs13414926 chr2 238524267 C T 7.73E-04 Obesity (extreme) / / 21935397 rs57673119 chr2 238524267 C CGAGT 7.73E-04 Obesity (extreme) / / 21935397 rs12464145 chr2 238526411 A C 2.80E-06 Urinary metabolites / / 21572414 rs12464145 chr2 238526411 A C 1.39E-04 Arthritis (juvenile idiopathic) / / 22354554 rs12464181 chr2 238526498 A G 9.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12464181 chr2 238526498 A G 4.40E-07 Urinary metabolites / / 21572414 rs12464181 chr2 238526498 A G 2.57E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6715815 chr2 238541938 T C 4.04E-08 Schizophrenia LRRFIP1 intron 21795503 rs12052937 chr2 238546572 C T 1.22E-11 Schizophrenia LRRFIP1 intron 21795503 rs13408642 chr2 238564791 G A 4.29E-06 Schizophrenia LRRFIP1 intron 21795503 rs6725315 chr2 238569285 T C 2.83E-06 Schizophrenia LRRFIP1 intron 21795503 rs4663779 chr2 238576444 G A 1.90E-04 Arthritis (juvenile idiopathic) LRRFIP1 intron 22354554 rs4663780 chr2 238578365 T C 2.39E-04 Response to cytidine analogues (gemcitabine) LRRFIP1 intron 24483146 rs7588573 chr2 238590702 G A 2.55E-04 Amyotrophic Lateral Sclerosis LRRFIP1 intron 17827064 rs10211393 chr2 238594788 T C 1.31E-04 Response to cytidine analogues (gemcitabine) LRRFIP1 intron 24483146 rs10211393 chr2 238594788 T C 1.44E-05 Response to cytadine analogues (cytosine arabinoside) LRRFIP1 intron 24483146 rs3213869 chr2 238668783 A G 3.30E-04 Multiple complex diseases LRRFIP1 missense 17554300 rs11680012 chr2 238672425 G C 4.00E-06 Adiposity LRRFIP1 missense 23505185 rs2289094 chr2 238680442 T C 1.60E-05 Urinary metabolites LRRFIP1 intron 21572414 rs3769047 chr2 238769892 A G 8.73E-04 Multiple complex diseases RAMP1 intron 17554300 rs12465864 chr2 238773705 A G 2.15E-04 Alzheimer's disease (late onset) RAMP1 intron 21379329 rs6728476 chr2 238792133 A G 1.54E-06 Systemic lupus erythematosus and Systemic sclerosis RAMP1 intron 23740937 rs6741923 chr2 238799206 C G 3.87E-04 Lymphocyte counts RAMP1 intron 22286170 rs11692472 chr2 238803386 C G 5.21E-04 Obesity (extreme) RAMP1 intron 21935397 rs11675972 chr2 238803478 A G 5.20E-04 Obesity (extreme) RAMP1 intron 21935397 rs4663269 chr2 238806370 T C 7.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) RAMP1 intron 23648065 rs10185142 chr2 238822331 C T 8.00E-06 Obesity-related traits / / 23251661 rs6729271 chr2 238825809 C T 0.0003 Migraine / / 22678113 rs6729271 chr2 238825809 C T 1.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6729271 chr2 238825809 C T 1.31E-05 Waist-Hip Ratio / / pha003029 rs6719401 chr2 238836195 G A 1.96E-05 Myopia (pathological) / / 21640322 rs1446930 chr2 238870879 C T 1.27E-04 Alcohol consumption / / 23743675 rs10167252 chr2 238872246 T C 1.29E-04 Alcohol consumption / / 23743675 rs1446924 chr2 238877740 A G 1.33E-04 Alcohol consumption UBE2F intron 23743675 rs10929255 chr2 238879302 G A 1.34E-04 Alcohol consumption UBE2F intron 23743675 rs7567199 chr2 238880530 G A 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs6711485 chr2 238882675 A G 1.45E-04 Alcohol consumption UBE2F intron 23743675 rs6754093 chr2 238882735 C A 1.39E-04 Alcohol consumption UBE2F intron 23743675 rs4461215 chr2 238883966 G A 1.52E-04 Alcohol consumption UBE2F intron 23743675 rs2121472 chr2 238884837 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs10187736 chr2 238887575 C T 6.41E-04 Aortic root size UBE2F intron 21223598 rs10187736 chr2 238887575 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs7572717 chr2 238890316 T A 1.50E-04 Alcohol consumption UBE2F intron 23743675 rs6726393 chr2 238891591 A G 1.47E-04 Alcohol consumption UBE2F intron 23743675 rs7422865 chr2 238892692 T C 1.47E-04 Alcohol consumption UBE2F intron 23743675 rs6755573 chr2 238895612 G A 1.38E-04 Alcohol consumption UBE2F intron 23743675 rs11690668 chr2 238896958 C T 1.43E-04 Alcohol consumption UBE2F intron 23743675 rs4663819 chr2 238897374 G A 1.38E-04 Alcohol consumption UBE2F intron 23743675 rs11692064 chr2 238897587 C G 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs11692068 chr2 238897606 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs10048814 chr2 238897755 C T 1.46E-04 Alcohol consumption UBE2F intron 23743675 rs10048643 chr2 238897934 A G 1.48E-04 Alcohol consumption UBE2F intron 23743675 rs4663276 chr2 238898809 G A 1.46E-04 Alcohol consumption UBE2F intron 23743675 rs10203101 chr2 238903310 C T 1.48E-04 Alcohol consumption UBE2F intron 23743675 rs10469607 chr2 238904792 G A 1.49E-04 Alcohol consumption UBE2F intron 23743675 rs9751676 chr2 238906315 G C 4.30E-05 Cognitive decline UBE2F intron 23732972 rs10166061 chr2 238906511 C T 1.49E-04 Alcohol consumption UBE2F intron 23743675 rs7594965 chr2 238911101 C A 1.43E-04 Alcohol consumption UBE2F intron 23743675 rs6431570 chr2 238924568 G A 1.53E-04 Alcohol consumption UBE2F intron 23743675 rs821509 chr2 238946583 C G 4.86E-04 Aortic root size UBE2F intron 21223598 rs821501 chr2 238950886 T C 4.60E-04 Aortic root size UBE2F UTR-3 21223598 rs821497 chr2 238952547 G A 3.17E-04 Aortic root size UBE2F-SCLY intron 21223598 rs843977 chr2 238958166 T C 4.85E-04 Aortic root size UBE2F-SCLY intron 21223598 rs821490 chr2 238960572 G A 1.41E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs821488 chr2 238963756 T C 1.28E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs865380 chr2 238963998 C G 1.10E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs2264165 chr2 238966048 G A 6.66E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821486 chr2 238966691 T C 6.91E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821485 chr2 238966807 A G 6.82E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs843975 chr2 238967565 A C 6.66E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821484 chr2 238967652 A T 6.30E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs1374479 chr2 238968025 C G 6.23E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs2243545 chr2 238969150 C T 6.15E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs2250045 chr2 238970862 C T 7.04E-05 Alcohol consumption SCLY intron 23743675 rs2250039 chr2 238970937 G A 6.23E-05 Alcohol consumption SCLY intron 23743675 rs2250038 chr2 238970943 G T 6.15E-05 Alcohol consumption SCLY intron 23743675 rs821482 chr2 238971111 T C 6.22E-05 Alcohol consumption SCLY intron 23743675 rs821480 chr2 238972827 T C 7.43E-05 Alcohol consumption SCLY intron 23743675 rs2249543 chr2 238974811 A G 6.73E-05 Alcohol consumption SCLY intron 23743675 rs2249434 chr2 238975753 G C 9.10E-05 Type 2 diabetes SCLY intron 17463248 rs2592585 chr2 238979621 C T 9.57E-05 Alcohol consumption SCLY intron 23743675 rs2264166 chr2 238981301 C A 1.04E-04 Alcohol consumption SCLY intron 23743675 rs7601010 chr2 238982773 C T 1.44E-04 Alcohol consumption SCLY intron 23743675 rs2252822 chr2 238983267 A G 1.32E-04 Alcohol consumption SCLY intron 23743675 rs2262425 chr2 238984129 A G 8.08E-05 Bipolar disorder SCLY intron 17486107 rs2262425 chr2 238984129 A G 8.67E-04 Aortic root size SCLY intron 21223598 rs2262425 chr2 238984129 A G 7.76E-04 Response to taxane treatment (placlitaxel) SCLY intron 23006423 rs2262425 chr2 238984129 A G 1.35E-04 Alcohol consumption SCLY intron 23743675 rs2262426 chr2 238984497 G A 1.33E-04 Alcohol consumption SCLY intron 23743675 rs4663836 chr2 238987185 A T 9.60E-05 Alcohol consumption SCLY intron 23743675 rs3210400 chr2 238990388 G A 0.0008744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SCLY missense 23233654 rs3210400 chr2 238990388 G A 8.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) SCLY missense 23233662 rs2249077 chr2 238990985 T C 9.20E-05 Alcohol consumption SCLY intron 23743675 rs2249067 chr2 238991187 G A 6.89E-05 Alcohol consumption SCLY intron 23743675 rs2278742 chr2 238991796 C T 8.01E-05 Alcohol consumption SCLY intron 23953852 rs2248825 chr2 238993045 G A 6.80E-05 Alcohol consumption SCLY intron 23743675 rs2248824 chr2 238993104 T C 6.97E-05 Alcohol consumption SCLY intron 23743675 rs2326009 chr2 238993857 C A 8.90E-05 Alcohol consumption SCLY intron 23743675 rs2264132 chr2 238994676 T C 5.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCLY intron 20877124 rs2248623 chr2 238994828 T G 1.41E-04 Alcohol consumption SCLY intron 23743675 rs2592583 chr2 238995760 G T 1.43E-04 Alcohol consumption SCLY intron 23743675 rs34049050 chr2 238998581 A G 1.27E-04 Alcohol consumption SCLY intron 23743675 rs7591078 chr2 239005014 C G 3.71E-04 Aortic root size SCLY intron 21223598 rs7591078 chr2 239005014 C G 1.06E-04 Alcohol consumption SCLY intron 23743675 rs13033964 chr2 239005586 G A 1.10E-04 Alcohol consumption SCLY intron 23743675 rs62196004 chr2 239006314 G A 1.07E-04 Alcohol consumption SCLY intron 23743675 rs41264151 chr2 239007635 G A 1.21E-04 Alcohol consumption SCLY UTR-3 23743675 rs1562337 chr2 239008203 T C 3.72E-04 Parkinson's disease / / 17052657 rs13006807 chr2 239008542 C T 1.31E-04 Alcohol consumption / / 23743675 rs62196014 chr2 239010167 C G 1.15E-04 Alcohol consumption ESPNL intron 23743675 rs34878344 chr2 239010690 C A 1.27E-04 Alcohol consumption ESPNL cds-synon 23743675 rs7565244 chr2 239013662 A G 7.61E-04 Premature ovarian failure ESPNL intron 19508998 rs4663837 chr2 239013841 C A,G,T 1.31E-04 Alcohol consumption ESPNL intron 23743675 rs62196019 chr2 239014715 G A 1.47E-04 Alcohol consumption ESPNL intron 23743675 rs4663285 chr2 239014834 G A 1.39E-04 Alcohol consumption ESPNL intron 23743675 rs878134 chr2 239016640 G T 1.28E-04 Alcohol consumption ESPNL intron 23743675 rs878133 chr2 239016933 G A 1.28E-04 Alcohol consumption ESPNL intron 23743675 rs13025510 chr2 239017140 G A 1.33E-04 Alcohol consumption ESPNL intron 23743675 rs62197363 chr2 239028740 T C 9.99E-05 Alcohol consumption ESPNL intron 23743675 rs199604026 chr2 239049718 G A 1.70E-09 Prostate cancer (advanced) KLHL30 missense 23555315 rs2880132 chr2 239082976 G A 3.11E-04 Lung function (forced expiratory volume in 1 second) ILKAP intron 24023788 rs6431587 chr2 239090042 G A 4.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ILKAP intron 24023788 rs12472274 chr2 239095422 G A 2.00E-08 Phospholipid levels (plasma) ILKAP intron 22359512 rs6722019 chr2 239128117 T C 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6722019 chr2 239128117 T C 0.000182 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs934945 chr2 239155053 C T 9.83E-05 Cognitive performance PER2 missense 19734545 rs2304674 chr2 239181904 A G 2.20E-06 Urinary metabolites PER2 intron 21572414 rs7598777 chr2 239230657 C T 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) TRAF3IP1 intron 22010049 rs13402781 chr2 239231518 T A 7.56E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs6714098 chr2 239236301 C G 5.77E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs10205543 chr2 239243117 T C 6.13E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs3739070 chr2 239306268 A C 2.00E-12 Iris characteristics TRAF3IP1 missense 21835309 rs3739070 chr2 239306268 A C 6.00E-06 Iris characteristics TRAF3IP1 missense 21835309 rs541864 chr2 239314634 T C 7.16E-04 Type 2 diabetes / / 17463246 rs541013 chr2 239336492 G A 3.76E-04 Tourette syndrome ASB1 intron 22889924 rs579861 chr2 239348995 G T 5.73E-04 Substance dependence ASB1 intron 21818250 rs3769124 chr2 239349362 G A 7.00E-08 Pulmonary function ASB1 intron 21946350 rs472357 chr2 239355454 C T 4.70E-04 Tourette syndrome ASB1 UTR-3 22889924 rs103718 chr2 239398488 G A 1.00E-04 Prostate cancer / / 21743057 rs523437 chr2 239398809 C T 1.00E-04 Prostate cancer / / 21743057 rs2878083 chr2 239416791 C A 4.67E-05 Schizophrenia / / 19571809 rs2878083 chr2 239416791 C A 4.21E-05 Schizophrenia / / pha002859 rs303037 chr2 239425904 C A,G 5.75E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs752123 chr2 239427379 C T 6.78E-04 Multiple complex diseases LOC151171 intron 17554300 rs2334004 chr2 239427579 A G 5.63E-04 Multiple complex diseases LOC151171 intron 17554300 rs10203243 chr2 239442908 T G 6.32E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs2166855 chr2 239455842 T C 7.61E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs1027928 chr2 239524082 G A 1.30E-04 Endometriosis / / 21151130 rs12614869 chr2 239554884 T C 4.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11690021 chr2 239637228 T C 3.52E-05 Esophageal cancer (squamous cell) / / 22960999 rs11690021 chr2 239637228 T C 8.77E-05 Serum albumin level / / pha003084 rs6716943 chr2 239638153 C A 9.95E-06 Carotenoid and tocopherol levels / / 19185284 rs4545955 chr2 239638300 T C 6.67E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12692245 chr2 239655737 G A 6.66E-05 Bipolar disorder / / 19488044 rs12692245 chr2 239655737 G A 6.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs12692245 chr2 239655737 G A 4.48E-05 Bipolar Disorder / / pha002858 rs4075846 chr2 239692909 A T 3.61E-09 Male-pattern baldness / / 22693459 rs9287638 chr2 239694631 C A 1.00E-12 Male-pattern baldness / / 22693459 rs9711321 chr2 239697444 T C 6.05E-11 Male-pattern baldness / / 22693459 rs11683401 chr2 239697605 T C 6.02E-11 Male-pattern baldness / / 22693459 rs10929296 chr2 239710123 A G 6.11E-04 Multiple complex diseases / / 17554300 rs9798281 chr2 239720326 T C 3.87E-05 Behcet's disease / / pha002888 rs9710693 chr2 239722254 T C 9.36E-04 Type 2 diabetes / / 17463246 rs9287645 chr2 239722506 T C 1.10E-08 Male-pattern baldness / / 22693459 rs9751357 chr2 239733773 A G 2.08E-09 Schizophrenia / / 21795503 rs9751357 chr2 239733773 A G 2.42E-04 Smoking initiation / / 24665060 rs9752491 chr2 239734678 G A 3.78E-08 Male-pattern baldness / / 22693459 rs9751918 chr2 239735812 A G 1.71E-08 Male-pattern baldness / / 22693459 rs9750952 chr2 239736364 C T 2.21E-08 Male-pattern baldness / / 22693459 rs12613833 chr2 239749411 T C 2.84E-08 Male-pattern baldness / / 22693459 rs4078407 chr2 239835244 T C 5.56E-05 Acute lung injury / / 22295056 rs7602841 chr2 239847486 C T 9.44E-04 Multiple complex diseases FLJ43879 intron 17554300 rs12477314 chr2 239877148 C T 1.00E-07 Pulmonary function / / 21946350 rs12477314 chr2 239877148 C T 2.00E-12 Pulmonary function / / 21946350 rs12477314 chr2 239877148 C T 2.00E-07 Pulmonary function (interaction) / / 23284291 rs12467854 chr2 239888758 C G 6.66E-05 Pulmonary function / / 20010835 rs4852066 chr2 239890696 G A 9.21E-04 Depression (quantitative trait) / / 20800221 rs4851977 chr2 239891296 G A 9.58E-04 Depression (quantitative trait) / / 20800221 rs6543542 chr2 239891644 T C 9.65E-04 Depression (quantitative trait) / / 20800221 rs11679161 chr2 239893009 C T 7.80E-05 Pulmonary function / / 20010835 rs4852079 chr2 239899327 A G 8.52E-04 Depression (quantitative trait) / / 20800221 rs3922831 chr2 239935543 T C 6.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4075018 chr2 239949681 G A 8.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3752755 chr2 240004245 C T 5.40E-04 Coronary heart disease HDAC4 intron 21966275 rs3791398 chr2 240025666 G A 1.80E-05 Carotid intima media thickness HDAC4 intron 19679847 rs3791399 chr2 240025761 G A 3.70E-06 Urinary metabolites HDAC4 intron 21572414 rs747787 chr2 240032319 G A 4.80E-04 Myocardial infarction HDAC4 intron 21107343 rs3791426 chr2 240039401 A G 0.000506 Salmonella-induced pyroptosis HDAC4 intron 22837397 rs3791446 chr2 240045350 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC4 intron 20877124 rs3791461 chr2 240051965 G A 3.78E-04 Multiple complex diseases HDAC4 intron 17554300 rs3791461 chr2 240051965 G A 1.40E-05 Urinary metabolites HDAC4 intron 21572414 rs12469994 chr2 240053966 G A 5.41E-04 Alzheimer's disease HDAC4 intron 24755620 rs2121980 chr2 240055553 T C 7.10E-05 Dental caries HDAC4 intron 21940522 rs2121980 chr2 240055553 T C 0.0000346 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HDAC4 intron 23233654 rs2121980 chr2 240055553 T C 3.46E-05 Methotrexate clearance (acute lymphoblastic leukemia) HDAC4 intron 23233662 rs3791511 chr2 240080540 G A 6.43E-05 Melanoma HDAC4 intron 21926416 rs7599555 chr2 240086580 C T 5.15E-04 Multiple complex diseases HDAC4 intron 17554300 rs1448430 chr2 240092739 G A 8.10E-05 Bipolar disorder HDAC4 intron 22925353 rs489806 chr2 240099456 C A 3.06E-04 Hemoglobin concentration HDAC4 intron 20534544 rs3791549 chr2 240109024 G A 4.17E-05 Multiple complex diseases HDAC4 intron 17554300 rs3828222 chr2 240109568 C T 4.55E-05 Multiple complex diseases HDAC4 intron 17554300 rs3791556 chr2 240112972 G A 2.80E-05 Diabetic retinopathy HDAC4 intron 21441570 rs3791556 chr2 240112972 G A 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) HDAC4 intron 23453885 rs753302 chr2 240114137 A G 7.04E-04 Amyotrophic Lateral Sclerosis HDAC4 intron 17827064 rs6735945 chr2 240115818 G C 6.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines HDAC4 intron 21844884 rs496316 chr2 240155231 T C 1.80E-05 Urinary metabolites HDAC4 intron 21572414 rs12151485 chr2 240176736 G A 1.62E-04 IgE levels HDAC4 intron 17255346 rs7595357 chr2 240180336 C A 1.29E-05 IgE levels HDAC4 intron 17255346 rs7595357 chr2 240180336 C A 7.04E-05 Weight HDAC4 intron pha003027 rs1403608 chr2 240181872 G A 5.86E-04 Type 2 diabetes HDAC4 intron 17463246 rs7587786 chr2 240186518 G A 6.73E-06 Body mass index HDAC4 intron 19557197 rs6742576 chr2 240187632 G A 6.56E-06 Body mass index HDAC4 intron 19557197 rs10208713 chr2 240188918 C T 4.94E-04 Hemoglobin concentration HDAC4 intron 20534544 rs6745266 chr2 240193575 G A 6.15E-06 Body mass index HDAC4 intron 19557197 rs6737742 chr2 240216021 G A 8.58E-05 Hemoglobin concentration HDAC4 intron 20534544 rs6737742 chr2 240216021 G A 5.53E-05 Response to acetaminophen (hepatotoxicity) HDAC4 intron 21177773 rs908262 chr2 240217522 C A 8.58E-05 Hemoglobin concentration HDAC4 intron 20534544 rs908262 chr2 240217522 C A 3.71E-05 Response to acetaminophen (hepatotoxicity) HDAC4 intron 21177773 rs925738 chr2 240241255 C T 4.76E-04 Hemoglobin concentration HDAC4 intron 20534544 rs950225 chr2 240258244 C T 7.90E-04 Myocardial infarction HDAC4 intron 21107343 rs908265 chr2 240262287 T C 9.27E-05 Triglycerides HDAC4 intron pha002904 rs11686104 chr2 240286146 G A 1.03E-04 Hemoglobin concentration HDAC4 intron 20534544 rs11124194 chr2 240290494 C T 5.22E-05 Response to cytadine analogues (cytosine arabinoside) HDAC4 intron 24483146 rs11124194 chr2 240290494 C T 6.62E-04 Response to cytidine analogues (gemcitabine) HDAC4 intron 24483146 rs2411843 chr2 240294969 A C 5.47E-05 Bladder cancer (smoking interaction) HDAC4 intron 24662972 rs843453 chr2 240333093 G A 1.50E-05 Urinary metabolites / / 21572414 rs6726998 chr2 240399614 A G 3.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs11894982 chr2 240401778 A G 8.40E-05 Multiple complex diseases / / 17554300 rs6743931 chr2 240418660 G A 2.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs2630755 chr2 240426236 T C 2.00E-05 Urinary metabolites / / 21572414 rs6709029 chr2 240439835 G A 3.46E-05 Serum metabolites / / 19043545 rs12612849 chr2 240442702 C T 1.11E-05 Conotruncal heart defects / / 24800985 rs6706785 chr2 240444053 G T 6.00E-06 Conotruncal heart defects / / 24800985 rs4852088 chr2 240456946 T C 8.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs731154 chr2 240457989 T G 8.73E-05 Alzheimer's disease (age of onset) / / 22005931 rs62180959 chr2 240463182 T C 9.18E-05 Atopic dermatitis / / 23042114 rs7571310 chr2 240467250 T A 8.35E-05 Atopic dermatitis / / 23042114 rs62183061 chr2 240468521 G A 8.33E-05 Atopic dermatitis / / 23042114 rs62183062 chr2 240468671 A T 8.44E-05 Atopic dermatitis / / 23042114 rs55814338 chr2 240469892 G A 9.82E-05 Atopic dermatitis / / 23042114 rs10206786 chr2 240471992 G A 2.57E-04 Alzheimer's disease (late onset) / / 21379329 rs11679505 chr2 240499376 C T 4.61E-04 Obesity (extreme) / / 21935397 rs11684324 chr2 240510908 G A 8.29E-04 Obesity (extreme) / / 21935397 rs4852097 chr2 240530881 G T 4.75E-05 Tunica Media / / pha003037 rs7604209 chr2 240537244 G A 9.23E-05 Tunica Media / / pha003037 rs1030891 chr2 240539765 A G 2.10E-04 Alcohol dependence / / 20201924 rs1030891 chr2 240539765 A G 7.40E-04 Alcohol dependence / / 20201924 rs3916020 chr2 240562386 A C 9.46E-05 Diabetes Mellitus / / pha003059 rs4852100 chr2 240571827 A G 3.80E-05 Celiac disease / / 17558408 rs10165876 chr2 240574731 G A 3.62E-05 Leukocyte Counts / / pha003091 rs7598519 chr2 240651354 A C 6.20E-08 Iron levels / / 21208937 rs4852118 chr2 240660209 G A 2.95E-04 Coronary heart disease / / 21971053 rs4852124 chr2 240680022 T C 7.41E-06 Obesity-related traits / / 23251661 rs6748389 chr2 240685573 T G 2.64E-04 Alcohol dependence LOC150935 intron 20201924 rs10207060 chr2 240687289 T G 6.00E-06 Obesity-related traits LOC150935 intron 23251661 rs11904223 chr2 240688338 T C 4.15E-04 Parkinson's disease LOC150935 intron 17052657 rs1316932 chr2 240695187 A G 4.76E-04 Parkinson's disease LOC150935 intron 17052657 rs11674512 chr2 240695511 A G 1.59E-05 Alcohol dependence LOC150935 intron 20201924 rs11674512 chr2 240695511 A G 1.59E-05 Alcoholism LOC150935 intron pha002891 rs6543581 chr2 240702308 A G 6.42E-05 Aortic root size LOC150935 intron 21223598 rs2412042 chr2 240722820 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11695034 chr2 240728640 G A 1.06E-04 Attention deficit hyperactivity disorder / / pha002875 rs4241236 chr2 240740612 C T 8.35E-04 White matter integrity / / 22425255 rs1996511 chr2 240741278 T C 4.66E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4852140 chr2 240745718 A G 8.00E-06 Obesity-related traits / / 23251661 rs12618573 chr2 240843638 G A 8.00E-06 Response to amphetamines / / 22952603 rs11900622 chr2 240862048 T C 3.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4853981 chr2 240871893 T C 7.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs4996007 chr2 240874059 T C 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4996007 chr2 240874059 T C 1.95E-04 Smoking initiation / / 24665060 rs4854071 chr2 240885050 C T 5.67E-04 Breast cancer / / 20852631 rs13424612 chr2 240900121 C T 6.00E-10 Odorant perception NDUFA10 UTR-3 23910658 rs6748327 chr2 240902511 G A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs4149556 chr2 240915307 C T 9.75E-04 Breast cancer NDUFA10 intron 20852631 rs4149556 chr2 240915307 C T 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs13848 chr2 240946766 T C 6.30E-04 Breast cancer NDUFA10 cds-synon 20852631 rs3792085 chr2 240948789 G A 5.02E-04 Coronary heart disease NDUFA10 intron 21606135 rs2289407 chr2 240954110 A G 9.78E-04 Breast cancer NDUFA10 intron 20852631 rs3792083 chr2 240954904 G A 8.65E-04 Coronary heart disease NDUFA10 intron 21606135 rs6735806 chr2 240954972 C A 3.33E-04 Hearing function NDUFA10 intron 17255346 rs4149541 chr2 240957734 G A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs10933552 chr2 240971519 T C 8.73E-05 Serum metabolites / / 19043545 rs13415895 chr2 240976581 A C 9.83E-05 Interstitial lung disease / / 23583980 rs2099727 chr2 240979959 T C 5.76E-04 Menopause (age at onset) / / 22267201 rs6731916 chr2 240981179 T C 4.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6741800 chr2 241008898 T C 7.33E-05 Hypertension / / 19609347 rs4292120 chr2 241066280 C T 8.65E-04 Response to taxane treatment (placlitaxel) MYEOV2 cds-synon 23006423 rs1866646 chr2 241070240 A G 7.82E-04 Response to taxane treatment (placlitaxel) MYEOV2 intron 23006423 rs3749078 chr2 241073450 C T 1.76E-04 IgE levels MYEOV2 intron 17255346 rs12621732 chr2 241073496 A G 2.60E-05 Iron levels MYEOV2 intron 21208937 rs4854022 chr2 241080654 C G 1.34E-05 Age-related macular degeneration / / 23577725 rs2368498 chr2 241091482 C T 8.30E-06 Urinary metabolites / / 21572414 rs6719685 chr2 241108454 G A 6.70E-06 Urinary metabolites / / 21572414 rs6719685 chr2 241108454 G A 2.92E-05 Erythrocyte counts / / pha003101 rs4853996 chr2 241109747 C T 9.72E-04 Multiple complex diseases / / 17554300 rs4854090 chr2 241168633 T C 6.80E-07 Multiple complex diseases / / 17554300 rs4854078 chr2 241182744 C A 5.15E-06 Retinopathy in non-diabetics / / 23393555 rs10170009 chr2 241213217 T G 4.29E-04 Alzheimer's disease (late onset) / / 21379329 rs7562354 chr2 241228985 C T 0.0000966 Migraine / / 22678113 rs7562354 chr2 241228985 C T 9.66E-05 Migraine / / 22683712 rs1106154 chr2 241231989 G A 3.45E-05 Triglycerides / / pha003081 rs1106154 chr2 241231989 G A 2.30E-05 Lipid levels / / pha003082 rs1105760 chr2 241232298 C G 2.95E-04 Telomere length / / 23900074 rs4854033 chr2 241233933 T C 2.46E-04 Telomere length / / 23900074 rs3935911 chr2 241247757 C T 1.70E-06 Thyroid function / / 20826269 rs12695016 chr2 241250109 A G 1.50E-06 Thyroid function / / 20826269 rs13383344 chr2 241252648 A G 1.10E-06 Thyroid function / / 20826269 rs2352816 chr2 241256135 A G 2.40E-06 Thyroid function / / 20826269 rs2352817 chr2 241256453 G A 3.40E-06 Thyroid function / / 20826269 rs4676361 chr2 241259159 C A 2.80E-06 Thyroid function / / 20826269 rs2352821 chr2 241261657 C T 1.20E-06 Thyroid function / / 20826269 rs2352821 chr2 241261657 C T 6.61E-05 Triglycerides / / pha003080 rs2352821 chr2 241261657 C T 7.20E-05 Triglycerides / / pha003081 rs2352821 chr2 241261657 C T 4.05E-05 Lipid levels / / pha003082 rs1320123 chr2 241293064 G T 8.50E-05 Bipolar disorder and schizophrenia / / 20889312 rs1574192 chr2 241308505 G A 4.00E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs28443480 chr2 241437820 G T 5.25E-04 Alzheimer's disease ANKMY1 intron 24755620 rs4676354 chr2 241456250 G A 7.74E-04 Multiple complex diseases ANKMY1 intron 17554300 rs4676432 chr2 241456297 C T 7.50E-04 Multiple complex diseases ANKMY1 intron 17554300 rs4676428 chr2 241492255 G T 4.75E-04 Insulin resistance ANKMY1 intron 21901158 rs4305276 chr2 241495013 C G 2.00E-11 Mean platelet volume ANKMY1 intron 22139419 rs11683693 chr2 241506669 C A 4.80E-06 Age-related macular degeneration / / 20861866 rs2953146 chr2 241515252 G A 2.08E-06 Multiple complex diseases RNPEPL1 intron 17554300 rs2953145 chr2 241515596 G C 7.00E-06 Bipolar disorder RNPEPL1 intron 17554300 rs2975752 chr2 241521327 T C 2.10E-04 Multiple complex diseases / / 17554300 rs1133352 chr2 241522252 C T 3.77E-05 Multiple complex diseases / / 17554300 rs1133353 chr2 241522267 A T 3.94E-06 Multiple complex diseases / / 17554300 rs1133353 chr2 241522267 A T 6.00E-06 Bipolar disorder / / 21254220 rs1133353 chr2 241522267 A T 6.00E-06 Bipolar disorder / / 21254220 rs1133354 chr2 241522450 T C 3.15E-05 Multiple complex diseases / / 17554300 rs4676420 chr2 241527673 G A 2.95E-05 HIV-1 control CAPN10 intron 20041166 rs2975760 chr2 241531163 T C 5.31E-04 Multiple complex diseases CAPN10 intron 17554300 rs3828345 chr2 241536819 C A 2.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAPN10 intron 24023788 rs4234123 chr2 241541640 C T 2.72E-05 Multiple complex diseases / / 17554300 rs5030952 chr2 241542703 C T 1 Drug response to Tacrolimus / / 19752882 rs4676348 chr2 241544190 C T 1.02E-04 Multiple complex diseases / / 17554300 rs4676410 chr2 241563739 G A 2.00E-09 Sclerosing cholangitis and ulcerative colitis (combined) GPR35 intron 22821403 rs3749171 chr2 241569692 C T 3.00E-21 Inflammatory bowel disease GPR35 missense 23128233 rs4676406 chr2 241579108 G T 8.00E-11 Ulcerative colitis / / 21297633 rs2011743 chr2 241580725 C T 0.00005 Primary sclerosing cholangitis / / 23603763 rs1864879 chr2 241581451 C G 4.20E-04 Type 2 diabetes / / 17463246 rs4676403 chr2 241583676 A G 4.34E-05 Blood Pressure / / pha003043 rs6724516 chr2 241586810 G A 0.0000595 Primary sclerosing cholangitis / / 23603763 rs6744241 chr2 241592778 A G 2.40E-05 Erythrocyte counts / / pha003099 rs2060188 chr2 241593944 T G 3.80E-04 Type 2 diabetes / / 17463246 rs2060188 chr2 241593944 T G 2.77E-04 Lymphocyte counts / / 22286170 rs10933628 chr2 241594645 G C 3.65E-04 Type 2 diabetes / / 17463246 rs6437358 chr2 241597150 G C 5.90E-07 Ulcerative colitis / / 19915572 rs1003972 chr2 241627836 G C 3.74E-05 Type 2 diabetes / / 17463246 rs7576602 chr2 241684692 C T 7.15E-04 Depression (quantitative trait) KIF1A intron 20800221 rs2288751 chr2 241713429 T C 8.93E-04 Suicide attempts in bipolar disorder KIF1A intron 21423239 rs6708456 chr2 241729993 C T 3.45E-05 Prostate cancer KIF1A intron pha002878 rs12329123 chr2 241765872 G A 1.28E-05 Multiple complex diseases / / 17554300 rs4234121 chr2 241769281 T G 2.00E-05 Pericardial fat / / 22589742 rs4234121 chr2 241769281 T G 3.25E-05 Pulmonary function in asthmatics / / 23541324 rs4234121 chr2 241769281 T G 5.32E-05 Pulmonary function in asthmatics / / 23541324 rs4676347 chr2 241770943 A T 3.90E-05 Pericardial fat / / 22589742 rs6718518 chr2 241777882 C T 3.90E-05 Pericardial fat / / 22589742 rs11680616 chr2 241792959 T G 5.89E-04 Type 2 diabetes / / 17463246 rs11679258 chr2 241793061 A G 6.02E-04 Type 2 diabetes / / 17463246 rs11679258 chr2 241793061 A G 3.43E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11686679 chr2 241803100 A G 6.96E-04 Type 2 diabetes / / 17463246 rs115014558 chr2 241808308 C A 0.00052 Breast cancer AGXT missense 23555315 rs4344931 chr2 241818527 A C 8.10E-05 Pericardial fat AGXT UTR-3 22589742 rs4675792 chr2 241819526 C T 3.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4675874 chr2 241819796 G A 3.00E-20 Blood metabolite levels / / 24816252 rs4311055 chr2 241821017 T C 9.60E-05 Pericardial fat / / 22589742 rs3936203 chr2 241834654 A G 9.50E-05 Pericardial fat C2orf54 intron 22589742 rs10206101 chr2 241835543 A C 2.03E-04 Gallbladder cancer C2orf54 UTR-5 22318345 rs4630763 chr2 241838504 G A,T 3.46E-05 Gallbladder cancer / / 22318345 rs4675847 chr2 241865156 T C 2.98E-04 Type 2 diabetes / / 17463246 rs13405273 chr2 241882747 C T 4.70E-04 Smoking initiation LOC728763 intron 24665060 rs4521036 chr2 241927477 G A 8.24E-04 Type 2 diabetes / / 17463246 rs4676003 chr2 241960749 G A 6.85E-06 Odorant perception SNED1 intron 23910658 rs4234102 chr2 241968979 A G 7.50E-05 Celiac disease SNED1 intron 23936387 rs185349960 chr2 241969887 G A 0.00035 Prostate cancer SNED1 missense 23555315 rs185349960 chr2 241969887 G A 0.00056 Prostate cancer (non-advanced prostate cancer) SNED1 missense 23555315 rs7571117 chr2 241979550 T C 7.18E-04 Type 2 diabetes SNED1 cds-synon 17463246 rs7609450 chr2 241990727 C T 1.40E-06 Urinary metabolites SNED1 intron 21572414 rs2286321 chr2 242004866 A G 0.000012 Skin 1-naphthyl-keratin adduct (1NKA) levels in workers exposed to naphthalene SNED1 cds-synon 22391508 rs2286321 chr2 242004866 A G 0.0000419 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene SNED1 cds-synon 22391508 rs2286321 chr2 242004866 A G 9.53E-05 Mammographic density SNED1 cds-synon 22532574 rs2074843 chr2 242007839 G A 6.90E-06 Urinary metabolites SNED1 intron 21572414 rs6721345 chr2 242012729 G A 3.00E-06 Sex hormone-binding globulin levels SNED1 missense 22675492 rs12694993 chr2 242014364 C T 1.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SNED1 intron 20031582 rs13411510 chr2 242015650 T C 3.01E-04 Mammographic density SNED1 intron 22532574 rs13411556 chr2 242026649 A G 8.88E-04 Amyotrophic lateral sclerosis (sporadic) SNED1 intron 24529757 rs16843242 chr2 242031281 C T 8.52E-04 Suicide attempts in bipolar disorder SNED1 UTR-3 21423239 rs16843242 chr2 242031281 C T 1.26E-04 Insulin resistance SNED1 UTR-3 21901158 rs2240538 chr2 242035146 G T 8.90E-05 Lymphocyte counts MTERFD2 UTR-3 22286170 rs17382723 chr2 242053546 C G 3.00E-07 Height PASK UTR-3 23456168 rs2270044 chr2 242056924 T C 5.70E-04 Aortic root size PASK intron 21223598 rs141663644 chr2 242065754 C T 0.00048 Prostate cancer PASK missense 23555315 rs2058062 chr2 242068968 G A 4.00E-07 Urinary metabolites PASK intron 21572414 rs2240547 chr2 242069342 C T 9.40E-07 Urinary metabolites PASK intron 21572414 rs2120853 chr2 242080418 C T 0.000724019 Hypertension (early onset hypertension) PASK intron 22479346 rs758072 chr2 242083872 G T 9.79E-05 Alzheimer's disease (late onset) PASK intron 21379329 rs12052982 chr2 242111332 A G 4.21E-04 Alzheimer's disease (late onset) PPP1R7 intron 21379329 rs12052982 chr2 242111332 A G 0.000560685 Hypertension (early onset hypertension) PPP1R7 intron 22479346 rs6710177 chr2 242113054 A G 3.86E-05 Cognitive performance PPP1R7 intron 19734545 rs7562408 chr2 242113819 A G 0.000498847 Hypertension (early onset hypertension) PPP1R7 intron 22479346 rs1540528 chr2 242118686 C T 8.96E-05 Lung function (forced vital capacity) PPP1R7 intron pha003104 rs16843438 chr2 242137702 C T 3.44E-05 Cholesterol ANO7 intron 17255346 rs16843440 chr2 242138065 G A 8.55E-04 Multiple complex diseases ANO7 intron 17554300 rs2011792 chr2 242140427 C A 8.74E-04 Suicide attempts in bipolar disorder ANO7 intron 21423239 rs13028587 chr2 242141245 C A 8.83E-04 Suicide attempts in bipolar disorder ANO7 intron 21423239 rs7590653 chr2 242163359 G A 5.68E-04 Tourette syndrome ANO7 missense 22889924 rs7355565 chr2 242165048 T C 5.70E-04 Multiple complex diseases ANO7 nearGene-3 17554300 rs11674695 chr2 242165701 G A 7.95E-04 Multiple complex diseases / / 17554300 rs7578199 chr2 242192848 T C 1.15E-04 Tourette syndrome HDLBP missense 22889924 rs7578199 chr2 242192848 T C 5.39E-07 Chronic lymphocytic leukemia HDLBP missense 23770605 rs11693230 chr2 242212917 G A 0.0000631 Nonsyndromic striae distensae (stretch marks) HDLBP intron 23633020 rs6704615 chr2 242228733 G A 3.67E-04 Multiple complex diseases HDLBP intron 17554300 rs6752050 chr2 242228780 T C 1.20E-06 Fibrinogen HDLBP intron 20978265 rs11680983 chr2 242247994 T C 2.78E-04 Multiple complex diseases HDLBP intron 17554300 rs7599888 chr2 242248033 C G,T 3.48E-05 Multiple complex diseases HDLBP intron 17554300 rs7599888 chr2 242248033 C G,T 6.82E-05 Serum metabolites HDLBP intron 19043545 rs12694997 chr2 242262986 G A 1.00E-08 Height SEPT2 intron 20881960 rs12694997 chr2 242262986 G A 5.72E-04 Tourette syndrome SEPT2 intron 22889924 rs14351 chr2 242292378 G A,C,T 5.32E-04 Acute lung injury SEPT2 UTR-3 22295056 rs1476698 chr2 242296449 A G 9.33E-05 Coronary heart disease FARP2 intron 21971053 rs1476698 chr2 242296449 A G 2.00E-09 Fibrinogen FARP2 intron 23969696 rs11684105 chr2 242310174 T C 1.64E-04 Multiple complex diseases FARP2 intron 17554300 rs6761444 chr2 242321358 C T 1.42E-04 Multiple complex diseases FARP2 intron 17554300 rs3771561 chr2 242353704 G A 3.00E-04 Diabetic nephropathy FARP2 intron 19252134 rs757978 chr2 242371101 C T 2.00E-09 Chronic lymphocytic leukemia FARP2 missense 20062064 rs757978 chr2 242371101 C T 2.00E-09 Nasopharyngeal carcinoma FARP2 missense 20512145 rs757978 chr2 242371101 C T 3.00E-06 Chronic lymphocytic leukemia FARP2 missense 22700719 rs757978 chr2 242371101 C T 3.21E-06 Erectile dysfunction FARP2 missense 22704111 rs757978 chr2 242371101 C T 1.00E-07 Chronic lymphocytic leukemia FARP2 missense 23770605 rs757978 chr2 242371101 C T 3.47E-04 Chronic lymphocytic leukemia FARP2 missense 24292274 rs11679955 chr2 242382133 C T 2.43E-04 Multiple complex diseases FARP2 intron 17554300 rs3771570 chr2 242382864 C T 5.00E-09 Prostate cancer FARP2 intron 23535732 rs10192057 chr2 242387984 A G 2.86E-05 Multiple complex diseases FARP2 intron 17554300 rs10192057 chr2 242387984 A G 8.89E-05 Tourette syndrome FARP2 intron 22889924 rs2302013 chr2 242393658 A C 8.36E-04 Tourette syndrome FARP2 intron 22889924 rs17387035 chr2 242394003 T C 7.54E-04 Multiple complex diseases FARP2 intron 17554300 rs4675812 chr2 242395674 G A 2.51E-04 Coronary heart disease FARP2 intron 21971053 rs7597299 chr2 242398074 T C 6.31E-04 Multiple complex diseases FARP2 intron 17554300 rs62190407 chr2 242405772 G A 0.000713 Sarcoidosis FARP2 intron 22952805 rs10933558 chr2 242407478 A G 8.31E-04 Multiple complex diseases FARP2 intron 17554300 rs10933559 chr2 242407746 A G 8.50E-04 Multiple complex diseases FARP2 cds-synon 17554300 rs2240480 chr2 242408219 G A 9.49E-04 Acute lung injury FARP2 intron 22295056 rs2286277 chr2 242418362 C T 1.84E-04 Tourette syndrome FARP2 intron 22889924 rs740314 chr2 242418618 T C 8.12E-04 Acute lung injury FARP2 intron 22295056 rs13408032 chr2 242490658 C T 8.62E-04 Response to taxane treatment (placlitaxel) BOK-AS1 intron 23006423 rs12479254 chr2 242502956 C T 6.00E-07 Brain structure BOK intron 20171287 rs13004470 chr2 242511083 C T 0.0000469 Ankle-brachial index BOK intron 22361517 rs1106639 chr2 242690675 G A 0.00063 Breast cancer D2HGDH missense 23555315 rs4973677 chr2 242934578 C A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12478415 chr2 242976461 G A 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12468297 chr2 242996474 T C 0.0007183 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12468297 chr2 242996474 T C 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7573042 chr2 242996589 T C 0.0006979 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7573042 chr2 242996589 T C 6.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12719765 chr2 242997202 C G 0.0007936 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12719765 chr2 242997202 C G 7.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13412492 chr2 243000583 T G 0.0006474 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13412492 chr2 243000583 T G 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6746311 chr2 243001279 A G 0.0006438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6746311 chr2 243001279 A G 6.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7421576 chr2 243007944 G A 0.0007322 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7421576 chr2 243007944 G A 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11899408 chr2 243014630 A G 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs749924 chr2 243026495 C T 1.00E-07 Coronary artery calcification / / 23870195 rs12478296 chr2 243048760 C T 8.00E-06 Obesity-related traits LOC728323 intron 23251661 rs9682794 chr3 70895 T C 1.16E-04 Scoliosis / / 21216876 rs6801472 chr3 73912 A G 6.17E-05 Scoliosis / / 21216876 rs1400174 chr3 77174 A G 6.17E-05 Scoliosis / / 21216876 rs2176251 chr3 94149 T G 8.08E-05 Scoliosis / / 21216876 rs17075507 chr3 94150 A G 8.08E-05 Scoliosis / / 21216876 rs6800996 chr3 96855 G C,T 8.62E-04 Type 2 diabetes / / 17463246 rs12487203 chr3 99083 A G 1.38E-04 Scoliosis / / 21216876 rs7630409 chr3 101192 T A 4.23E-05 Coronary heart disease / / 21606135 rs990284 chr3 104972 A G 8.20E-04 Coronary heart disease / / 21606135 rs17042708 chr3 108226 A G 6.20E-04 Alcohol dependence / / 20201924 rs6775203 chr3 108804 G A 6.70E-04 Scoliosis / / 21216876 rs9841287 chr3 108993 A G 7.00E-09 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs9852028 chr3 113534 G T 5.79E-04 Scoliosis / / 21216876 rs954824 chr3 114133 T C 5.79E-04 Scoliosis / / 21216876 rs9867864 chr3 116498 G A 5.79E-04 Scoliosis / / 21216876 rs4685781 chr3 117152 C A 5.79E-04 Scoliosis / / 21216876 rs1568095 chr3 120220 G A 5.79E-04 Scoliosis / / 21216876 rs9861004 chr3 120401 G C 5.79E-04 Scoliosis / / 21216876 rs9311804 chr3 121226 C T 5.79E-04 Scoliosis / / 21216876 rs6778252 chr3 126158 C A 5.73E-05 Orofacial clefts / / 22419666 rs2138518 chr3 126456 T G 5.49E-04 Scoliosis / / 21216876 rs2176253 chr3 126629 C T 5.79E-04 Scoliosis / / 21216876 rs9865039 chr3 127804 C G 5.79E-04 Scoliosis / / 21216876 rs17047384 chr3 127933 C A 8.88E-05 Coronary heart disease / / 21606135 rs17047384 chr3 127933 C A 4.79E-05 Recombination rate / / 21698098 rs6443038 chr3 133412 G A 2.10E-04 Alcohol dependence / / 20201924 rs1516316 chr3 142131 C G 7.19E-04 Type 2 diabetes / / 17463246 rs1516316 chr3 142131 C G 6.07E-04 Scoliosis / / 21216876 rs1016162 chr3 143982 C T 5.70E-05 Scoliosis / / 21216876 rs9856879 chr3 148725 T C 2.01E-04 Alcohol dependence / / 20201924 rs17050452 chr3 149179 T G 7.45E-05 Scoliosis / / 21216876 rs12485321 chr3 149986 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs7629216 chr3 152005 G T 2.48E-04 Coronary heart disease / / 21606135 rs9857814 chr3 152047 A G 7.24E-05 Coronary heart disease / / 21606135 rs6786696 chr3 152592 G A 1.52E-04 Coronary heart disease / / 21606135 rs11131185 chr3 157445 T C 2.51E-05 Scoliosis / / 21216876 rs1996305 chr3 158340 C T 2.70E-05 Scoliosis / / 21216876 rs1568087 chr3 160100 A G 2.51E-05 Scoliosis / / 21216876 rs1878169 chr3 165112 A T 2.92E-07 Scoliosis / / 21216876 rs9819101 chr3 166507 G A 2.92E-07 Scoliosis / / 21216876 rs965084 chr3 167098 G C 2.92E-07 Scoliosis / / 21216876 rs13070820 chr3 168827 T C 7.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1400182 chr3 170611 C G 1.81E-07 Scoliosis / / 21216876 rs1400181 chr3 170798 C G 1.44E-06 Scoliosis / / 21216876 rs1400180 chr3 170968 T G 7.91E-08 Scoliosis / / 21216876 rs6795349 chr3 172477 A G 2.00E-06 Response to antidepressant treatment / / 22041458 rs7639674 chr3 172520 A T 1.55E-07 Scoliosis / / 21216876 rs17326792 chr3 172756 A G 4.63E-07 Scoliosis / / 21216876 rs6790856 chr3 172808 C A 1.44E-06 Scoliosis / / 21216876 rs1516342 chr3 172906 G A 6.72E-04 Alzheimer's disease / / 17998437 rs1516342 chr3 172906 G A 4.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17326898 chr3 173374 T C 1.28E-06 Scoliosis / / 21216876 rs9310378 chr3 173714 G A 8.63E-04 Scoliosis / / 21216876 rs2102777 chr3 174816 A G 2.68E-05 Scoliosis / / 21216876 rs2386564 chr3 177882 A G 4.75E-04 Scoliosis / / 21216876 rs4684051 chr3 178525 A G 1.12E-07 Scoliosis / / 21216876 rs1568096 chr3 179950 A G 1.28E-06 Scoliosis / / 21216876 rs1568097 chr3 180151 T C 6.25E-07 Scoliosis / / 21216876 rs1588962 chr3 184035 T C 4.01E-07 Scoliosis / / 21216876 rs7619069 chr3 184365 T G 2.23E-04 Scoliosis / / 21216876 rs9878349 chr3 185281 C T 2.23E-04 Scoliosis / / 21216876 rs2048629 chr3 186790 C A 6.31E-04 Scoliosis / / 21216876 rs6780087 chr3 187697 A G 2.64E-04 Scoliosis / / 21216876 rs4684083 chr3 188865 T C 9.73E-06 Alzheimer's disease / / 17998437 rs17038327 chr3 190200 T A 2.19E-06 Scoliosis / / 21216876 rs9754850 chr3 190290 T C 3.01E-04 Scoliosis / / 21216876 rs9754552 chr3 190411 A G 3.01E-04 Scoliosis / / 21216876 rs10510181 chr3 191047 G A 8.00E-07 Adolescent idiopathic scoliosis / / 21216876 rs10510182 chr3 191914 G A 2.88E-05 Scoliosis / / 21216876 rs1516348 chr3 202034 T C 3.78E-04 Alzheimer's disease / / 17998437 rs6442427 chr3 211745 C T 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17262485 chr3 217541 G A 6.49E-04 Coronary Artery Disease / / 17634449 rs17262485 chr3 217541 G A 4.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809528 chr3 250758 A G 2.39E-05 Femoral neck bone geometry CHL1 intron 22087292 rs11917787 chr3 253919 A G 9.00E-06 QT interval in Tripanosoma cruzi seropositivity CHL1 intron 24324551 rs459362 chr3 261442 A G 7.40E-05 Hypothyroidism CHL1 intron 22493691 rs11707773 chr3 262775 A T 6.70E-05 White matter hyperintensity burden CHL1 intron 21681796 rs11709854 chr3 268981 G C 2.60E-05 White matter hyperintensity burden CHL1 intron 21681796 rs17264626 chr3 272256 T C 9.93E-05 Type 2 diabetes CHL1 intron 17463246 rs17264828 chr3 277219 T C 7.50E-05 White matter hyperintensity burden CHL1 intron 21681796 rs13091217 chr3 277778 T C 2.88E-04 Type 2 diabetes CHL1 intron 17463246 rs13091420 chr3 277889 T C 6.45E-05 Type 2 diabetes CHL1 intron 17463246 rs17273893 chr3 309363 C T 4.31E-04 Common variable immunodeficiency CHL1 intron 21497890 rs17016845 chr3 309858 G A 4.78E-05 Acute lung injury CHL1 intron 22295056 rs17016917 chr3 310747 C T 8.94E-04 Acute lung injury CHL1 intron 22295056 rs17017010 chr3 311851 G T 1.22E-04 Acute lung injury CHL1 intron 22295056 rs6795631 chr3 312177 G A 9.58E-05 Pulmonary function CHL1 intron 19300500 rs6764363 chr3 312349 T C 6.00E-06 Sudden cardiac arrest CHL1 intron 21658281 rs9830226 chr3 318812 T C 4.70E-06 Urinary metabolites CHL1 intron 21572414 rs4541385 chr3 329970 G C 2.00E-05 Urinary metabolites CHL1 intron 21572414 rs17021268 chr3 336454 G C 7.99E-05 Brain derived neurotrophic factor levels,in serum CHL1 intron 22047184 rs11928134 chr3 353520 G T 4.69E-05 Multiple complex diseases CHL1 intron 17554300 rs144055818 chr3 367705 A G 0.000025 Breast cancer CHL1 missense 23555315 rs4685598 chr3 373693 A C 1.60E-05 Urinary metabolites CHL1 intron 21572414 rs12494297 chr3 377792 C T 8.65E-04 Multiple complex diseases CHL1 intron 17554300 rs892295 chr3 397553 A G 1.00E-06 Obesity-related traits CHL1 intron 23251661 rs892295 chr3 397553 A G 4.00E-06 Obesity-related traits CHL1 intron 23251661 rs12637802 chr3 409221 C G 1.54E-04 Blood pressure CHL1 intron 17255346 rs3773383 chr3 416943 G A 7.44E-05 Cognitive decline CHL1 intron 23732972 rs3773379 chr3 418585 A G 2.10E-05 Urinary metabolites CHL1 intron 21572414 rs4685668 chr3 430682 T C 3.84E-04 Hearing function CHL1 intron 17255346 rs1065035 chr3 448979 A T 2.25E-04 Hearing function CHL1 UTR-3 17255346 rs1065035 chr3 448979 A T 2.02E-04 Alzheimer's disease CHL1 UTR-3 17998437 rs9819810 chr3 454777 C T 8.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs6788648 chr3 457164 C T 7.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs6805861 chr3 465476 T C 1.22E-04 Multiple complex diseases / / 17554300 rs6442890 chr3 527223 A G 9.08E-05 Diabetic nephropathy / / pha002852 rs1865160 chr3 535673 C T 9.44E-06 Glycemic traits (pregnancy) / / 23903356 rs9837987 chr3 598777 C T 6.71E-04 Multiple complex diseases / / 17554300 rs2729207 chr3 604868 T A,C 1.30E-04 Multiple complex diseases / / 17554300 rs9848984 chr3 668914 T C 0.0000352 Colorectal cancer vs. adenoma controls / / 22532847 rs1484543 chr3 671006 G C 2.65E-04 Multiple complex diseases / / 17554300 rs9846843 chr3 674171 A G 3.82E-04 Multiple complex diseases / / 17554300 rs1905605 chr3 703725 T C 7.04E-04 Aortic root size / / 21223598 rs2627963 chr3 724380 A G 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2627943 chr3 732778 T C 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2729166 chr3 733281 A T 7.87E-05 Multiple complex diseases / / 17554300 rs2729093 chr3 776321 T C 5.22E-04 Type 2 diabetes / / 17463246 rs17047538 chr3 800606 A G 8.54E-05 Neuroblastoma / / pha002895 rs11714239 chr3 809720 G T 4.10E-05 Neuroblastoma / / pha002895 rs11131099 chr3 848802 C A 2.22E-04 Alzheimer's disease (late onset) / / 20885792 rs2177444 chr3 877011 G T 3.70E-05 Response to statin therapy / / 20339536 rs1568748 chr3 877235 A G 4.00E-05 Response to statin therapy / / 20339536 rs13066217 chr3 877912 C T 3.50E-05 Response to statin therapy / / 20339536 rs13066227 chr3 877925 C A 3.60E-05 Response to statin therapy / / 20339536 rs12494851 chr3 878192 A G 3.60E-05 Response to statin therapy / / 20339536 rs13084891 chr3 878370 T C 3.30E-05 Response to statin therapy / / 20339536 rs12495737 chr3 878511 T C 4.00E-05 Response to statin therapy / / 20339536 rs17048862 chr3 878547 T C 4.00E-05 Response to statin therapy / / 20339536 rs4684585 chr3 883851 G A 9.00E-07 Response to statin therapy / / 20339536 rs6764632 chr3 887059 C T 3.50E-05 Response to statin therapy / / 20339536 rs4686247 chr3 892951 C A 2.30E-06 Response to statin therapy / / 20339536 rs7619975 chr3 894729 C T 7.20E-05 Response to statin therapy / / 20339536 rs35964523 chr3 898661 C T 8.00E-06 Response to statin therapy / / 20339536 rs11131168 chr3 998513 G A 9.87E-05 Neuroblastoma / / pha002895 rs6803398 chr3 1007443 A G 6.18E-04 Multiple complex diseases / / 17554300 rs11927325 chr3 1015397 A G 5.45E-04 Multiple complex diseases / / 17554300 rs4390915 chr3 1018544 C T 8.67E-05 Coronary Artery Disease / / 17634449 rs4367044 chr3 1029987 C G 3.12E-04 Coronary Artery Disease / / 17634449 rs6443262 chr3 1040562 A T 7.98E-04 Coronary Artery Disease / / 17634449 rs6764623 chr3 1046038 A C 2.00E-06 Venous thromboembolism / / 23650146 rs10212227 chr3 1090485 G A 0.0000022 Amygdala reactivity / / 22856363 rs1504058 chr3 1090602 A G 3.10E-05 Response to statin therapy / / 20339536 rs11719195 chr3 1122000 C A 4.01E-05 Glucose levels / / pha003061 rs2313543 chr3 1122369 A G 5.84E-04 Iron levels / / pha002876 rs2729130 chr3 1125605 A G 7.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs76090503 chr3 1129819 G A 4.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6442221 chr3 1171860 G A 7.90E-04 Type 2 diabetes and 6 quantitative traits CNTN6 intron 17848626 rs13326242 chr3 1187861 C T 2.93E-05 Orofacial clefts CNTN6 intron 22419666 rs9823028 chr3 1190111 G A 1.30E-06 Carotid intima media thickness CNTN6 intron 21909108 rs7625601 chr3 1191340 C G 2.61E-04 IgE levels CNTN6 intron 17255346 rs17034364 chr3 1191638 A C 2.10E-04 IgE levels CNTN6 intron 17255346 rs1846466 chr3 1192829 T G 1.87E-04 IgE levels CNTN6 intron 17255346 rs3772371 chr3 1204591 A C 0.0000232 Tuberculosis with late age of onset CNTN6 intron 22551897 rs6806307 chr3 1222180 G A 2.61E-04 IgE levels CNTN6 intron 17255346 rs1499097 chr3 1227382 G A 2.10E-05 Urinary metabolites CNTN6 intron 21572414 rs1353821 chr3 1238287 T C 2.21E-05 Cognitive impairment induced by topiramate CNTN6 intron 22091778 rs9850313 chr3 1255731 G C 3.55E-04 Multiple complex diseases CNTN6 intron 17554300 rs7644569 chr3 1257668 C T 6.03E-05 Multiple sclerosis (age of onset) CNTN6 intron 19010793 rs9844484 chr3 1272373 T C 5.84E-04 Multiple complex diseases CNTN6 intron 17554300 rs9844484 chr3 1272373 T C 8.02E-05 Blood Pressure CNTN6 intron pha003046 rs11925058 chr3 1276092 A C 8.94E-04 Amyotrophic Lateral Sclerosis CNTN6 intron 17362836 rs3902530 chr3 1299185 A G 4.31E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs9815195 chr3 1301130 C A 7.00E-07 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs9834544 chr3 1301197 A G 7.03E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs3872629 chr3 1304868 A C 5.29E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs17036851 chr3 1305415 G A 5.90E-04 Nicotine dependence CNTN6 intron 17407593 rs6766488 chr3 1312979 C T 9.20E-06 Urinary metabolites CNTN6 intron 21572414 rs3772325 chr3 1313419 C G 5.47E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs3772324 chr3 1313477 C T 7.26E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs10510189 chr3 1316884 A G 8.65E-04 Myocardial Infarction CNTN6 intron pha002883 rs6442316 chr3 1319698 T C 9.49E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs6442316 chr3 1319698 T C 1.14E-05 Magnesium levels CNTN6 intron pha003092 rs7638616 chr3 1321018 C T 9.13E-05 Myocardial Infarction CNTN6 intron pha002883 rs17037155 chr3 1327426 C G 5.84E-07 Multiple complex diseases CNTN6 intron 17554300 rs17271519 chr3 1336397 A G 2.72E-04 Height CNTN6 intron 17255346 rs9861887 chr3 1345425 C T 9.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio CNTN6 intron 22589738 rs4684880 chr3 1348362 T C 2.53E-04 Smoking initiation CNTN6 intron 24665060 rs155230 chr3 1357380 G A 9.39E-04 Myopia (pathological) CNTN6 intron 21095009 rs10510170 chr3 1374976 A G 5.00E-06 Alcohol dependence CNTN6 intron 21956439 rs155403 chr3 1377266 G A 9.41E-05 Gallstones CNTN6 intron 17632509 rs155399 chr3 1386467 T C 5.50E-04 Rheumatoid arthritis CNTN6 intron 22446963 rs17038032 chr3 1389117 C T 8.11E-04 Alcohol dependence CNTN6 intron 21314694 rs7653048 chr3 1396176 T C 5.11E-05 Bone mineral density CNTN6 intron 19181680 rs1499215 chr3 1397069 T C 9.82E-04 Type 2 diabetes CNTN6 intron 17463246 rs1479530 chr3 1400419 C G 4.07E-04 Type 2 diabetes CNTN6 intron 17463246 rs13063912 chr3 1408344 C T 6.32E-04 Multiple complex diseases CNTN6 intron 17554300 rs429922 chr3 1408503 A G 2.10E-05 Urinary metabolites CNTN6 intron 21572414 rs155390 chr3 1421673 C A 1.76E-05 Type 1 diabetes CNTN6 intron 18978792 rs155390 chr3 1421673 C A 2.48E-05 Bipolar disorder (mania) CNTN6 intron 23326512 rs3772274 chr3 1421885 G A 2.50E-07 Urinary metabolites CNTN6 intron 21572414 rs155391 chr3 1421900 G A 2.30E-05 Urinary metabolites CNTN6 intron 21572414 rs155391 chr3 1421900 G A 2.44E-05 Bipolar disorder (mania) CNTN6 intron 23326512 rs2291101 chr3 1424718 G A 2.00E-05 Urinary metabolites CNTN6 cds-synon 21572414 rs2291101 chr3 1424718 G A 6.14E-04 Response to cytidine analogues (gemcitabine) CNTN6 cds-synon 24483146 rs4684146 chr3 1424745 C T 3.82E-04 Multiple complex diseases CNTN6 cds-synon 17554300 rs2291100 chr3 1424850 T G 5.47E-06 Bipolar disorder (mania) CNTN6 cds-synon 23326512 rs3845158 chr3 1425506 G A 1.20E-06 Urinary metabolites CNTN6 intron 21572414 rs1532552 chr3 1462739 T C 5.82E-04 Multiple complex diseases / / 17554300 rs2167471 chr3 1469092 C T 5.35E-04 Multiple complex diseases / / 17554300 rs1037386 chr3 1478453 T C 3.00E-06 Type 2 diabetes / / 17293876 rs1037386 chr3 1478453 T C 3.00E-06 Type 2 diabetes / / 19184112 rs12488675 chr3 1492235 G T 9.57E-06 Post-operative nausea and vomiting / / 21694509 rs17039471 chr3 1494264 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12489351 chr3 1495993 T G 2.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17039498 chr3 1496493 A G 1.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17786098 chr3 1496821 T C 7.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17193526 chr3 1500657 T G 4.90E-05 Post-operative nausea and vomiting / / 21694509 rs11919047 chr3 1510310 C A 2.77E-04 Coronary heart disease / / 21971053 rs6799147 chr3 1510822 G A 1.54E-04 Coronary heart disease / / 21971053 rs9856251 chr3 1511108 A G 1.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6763848 chr3 1512587 C A 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs6795018 chr3 1515094 G A 5.39E-04 Coronary heart disease / / 21971053 rs6786404 chr3 1515274 A G 7.34E-04 Coronary heart disease / / 21971053 rs10212138 chr3 1517822 A G 9.06E-04 Coronary heart disease / / 21971053 rs12107552 chr3 1529992 T C 2.06E-04 Alzheimer's disease / / 17998437 rs7613331 chr3 1533549 T A 1.14E-06 Asthma (childhood onset) / / 23829686 rs9876109 chr3 1550301 A G 6.27E-06 Non-obstructive azoospermia / / 22541561 rs12487870 chr3 1551708 G A 3.85E-05 Major depressive disorder / / pha002850 rs11128726 chr3 1557413 G A 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs17193610 chr3 1563944 T G 7.77E-04 Multiple complex diseases / / 17554300 rs17193610 chr3 1563944 T G 9.33E-04 Alzheimer's disease / / 17998437 rs17193610 chr3 1563944 T G 9.30E-06 Urinary metabolites / / 21572414 rs9829889 chr3 1565113 T C 3.91E-04 Multiple complex diseases / / 17554300 rs9829889 chr3 1565113 T C 8.63E-05 Lung cancer / / 18978787 rs9829889 chr3 1565113 T C 9.30E-06 Urinary metabolites / / 21572414 rs400048 chr3 1587860 T C 8.10E-05 Major depressive disorder / / 21621269 rs443052 chr3 1588919 G A 2.20E-05 Urinary metabolites / / 21572414 rs450994 chr3 1589120 G T 1.90E-05 Urinary metabolites / / 21572414 rs11712183 chr3 1597057 T C 6.06E-05 Major depressive disorder / / pha002850 rs403961 chr3 1600422 A G 3.08E-04 Height / / 17255346 rs437161 chr3 1620644 C G 7.90E-04 Testosterone levels / / 22675492 rs402675 chr3 1623393 T A 6.00E-06 Estradiol levels / / 22675492 rs13320862 chr3 1631265 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4684256 chr3 1632353 C T 1.00E-07 Systemic lupus erythematosus / / 24871463 rs9310485 chr3 1641389 A G 4.36E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs417975 chr3 1655984 T C 2.09E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs4143127 chr3 1670301 T C 8.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4524263 chr3 1673354 G A 4.60E-05 Receptive language ability / / 24687471 rs7645123 chr3 1704667 C T 1.81E-05 Triglycerides / / pha003080 rs1316461 chr3 1710334 G A 9.65E-06 Metabolite levels (MHPG) / / 23319000 rs6798827 chr3 1716268 G A 8.51E-04 Acne (severe) / / 24927181 rs6442607 chr3 1718156 C T 3.02E-06 Response to amphetamines / / 22952603 rs9815216 chr3 1720667 G A 4.11E-06 Response to amphetamines / / 22952603 rs9854279 chr3 1720834 C G 4.12E-06 Response to amphetamines / / 22952603 rs6798098 chr3 1721618 G A 8.72E-06 Response to amphetamines / / 22952603 rs13084459 chr3 1723221 C G 3.42E-06 Response to amphetamines / / 22952603 rs11128802 chr3 1723272 G A 3.17E-06 Response to amphetamines / / 22952603 rs113043097 chr3 1723661 A G 4.94E-06 Response to amphetamines / / 22952603 rs111902843 chr3 1724225 G C 3.19E-06 Response to amphetamines / / 22952603 rs6800665 chr3 1725469 A G 3.11E-06 Response to amphetamines / / 22952603 rs9831634 chr3 1731173 T C 8.05E-06 Response to amphetamines / / 22952603 rs4376023 chr3 1731450 G A 9.95E-06 Response to amphetamines / / 22952603 rs4557143 chr3 1734749 C G 1.58E-06 Response to amphetamines / / 22952603 rs73001814 chr3 1738844 G A 1.79E-06 Response to amphetamines / / 22952603 rs73001827 chr3 1741765 G C 1.00E-06 Response to amphetamines / / 22952603 rs73001862 chr3 1754948 T A 1.28E-06 Response to amphetamines / / 22952603 rs6804104 chr3 1756711 A G 2.01E-06 Response to amphetamines / / 22952603 rs73013208 chr3 1762743 C A 7.12E-06 Response to amphetamines / / 22952603 rs9848738 chr3 1775892 A T 7.55E-04 Multiple complex diseases / / 17554300 rs17029209 chr3 1781625 T C 6.21E-05 Alcohol withdrawal symptoms / / 22072270 rs4594600 chr3 1791072 C G 7.48E-04 Type 2 diabetes / / 17463246 rs12633977 chr3 1808553 C T 5.62E-06 Triglycerides / / pha003080 rs9848095 chr3 1814351 C A 3.20E-05 Cognitive impairment induced by topiramate / / 22091778 rs9883145 chr3 1816980 T C 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7624354 chr3 1818056 C T 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9875417 chr3 1819843 C T 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4603939 chr3 1826067 A G 5.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9832637 chr3 1826892 T C 5.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11128846 chr3 1827768 C T 4.18E-05 Glaucoma (primary open-angle) / / 22605921 rs9310530 chr3 1827967 C T 8.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10510216 chr3 1834534 G A 6.05E-05 Cognitive test performance / / 20125193 rs10510217 chr3 1839693 G A 7.70E-05 Multiple complex diseases / / 17554300 rs10510217 chr3 1839693 G A 3.00E-06 Total ventricular volume / / 21116278 rs11927576 chr3 1839723 T C 6.19E-05 Serum metabolites / / 19043545 rs6809401 chr3 1843129 C T 1.68E-04 Amyotrophic lateral sclerosis / / 20801718 rs4234543 chr3 1854320 T C 1.23E-05 Serum metabolites / / 19043545 rs12106926 chr3 1854867 T G 2.95E-05 Waist-Hip Ratio / / pha003013 rs12106926 chr3 1854867 T G 9.24E-05 Waist-Hip Ratio / / pha003028 rs7648375 chr3 1861769 T C 7.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9838423 chr3 1865505 G A 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7621478 chr3 1882958 T A 2.46E-04 Multiple complex diseases / / 17554300 rs7625240 chr3 1884889 A G 7.87E-04 Coronary heart disease / / 21971053 rs2727943 chr3 1897973 T C 3.00E-08 Bipolar disorder / / 22205951 rs9878659 chr3 1908074 G A 1.10E-04 Bipolar disorder / / 17486107 rs17044559 chr3 1912443 A G 6.61E-05 Triglycerides / / pha003081 rs7631764 chr3 1913585 G T 5.07E-05 Triglycerides / / pha003081 rs13097461 chr3 1926105 G A 3.23E-04 Type 2 diabetes / / 17463246 rs11713534 chr3 1929666 T C 3.78E-04 Multiple complex diseases / / 17554300 rs6800691 chr3 1931258 A C 9.72E-06 Kawasaki disease / / 22446961 rs4424753 chr3 1938484 A T 8.64E-04 Multiple complex diseases / / 17554300 rs7431184 chr3 1947477 T C 3.47E-05 Multiple complex diseases / / 17554300 rs6783551 chr3 1985238 T C 3.64E-04 Alcohol dependence / / 24277619 rs6763575 chr3 1996786 G A 9.93E-04 Coronary heart disease / / 21971053 rs1488745 chr3 2001802 G T 2.72E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs116110883 chr3 2002783 T C 9.46E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11128917 chr3 2007438 C A 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1387092 chr3 2011341 T C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2729313 chr3 2034355 C T 8.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2727952 chr3 2038356 C A 9.79E-04 Multiple complex diseases / / 17554300 rs2600056 chr3 2044132 A T 5.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6793275 chr3 2053707 T G 1.61E-04 Multiple complex diseases / / 17554300 rs17786584 chr3 2057749 T C 2.81E-04 Multiple complex diseases / / 17554300 rs4593008 chr3 2059893 T G 1.26E-04 Multiple complex diseases / / 17554300 rs2729317 chr3 2063776 T C 1.39E-04 Smoking quantity / / 24665060 rs4434131 chr3 2078499 T C 9.59E-04 Multiple complex diseases / / 17554300 rs6767146 chr3 2080561 G T 5.11E-04 Aortic root size / / 21223598 rs4685480 chr3 2088751 T C 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9826632 chr3 2120011 A T 3.60E-06 Urinary metabolites / / 21572414 rs2729277 chr3 2128834 A G 1.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4129976 chr3 2169803 T C 1.00E-05 Urinary metabolites CNTN4 intron 21572414 rs4129976 chr3 2169803 T C 0.00000712 Panic disorder CNTN4 intron 23149450 rs4129976 chr3 2169803 T C 7.12E-06 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs2729017 chr3 2194392 C A,T 0.0000343 Panic disorder CNTN4 intron 23149450 rs2729017 chr3 2194392 C A,T 3.43E-05 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs2727925 chr3 2195364 C T 4.08E-05 IgE levels CNTN4 intron 17255346 rs9849406 chr3 2198715 C T 4.81E-04 Insulin resistance CNTN4 intron 21901158 rs17194161 chr3 2206173 A G 1.22E-04 Insulin resistance CNTN4 intron 21901158 rs2727927 chr3 2206373 G A 1.93E-04 IgE levels CNTN4 intron 17255346 rs2728524 chr3 2212318 A G 2.61E-04 Multiple complex diseases CNTN4 intron 17554300 rs7613165 chr3 2223722 T C 2.02E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs17009194 chr3 2227373 G A 8.69E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs9968167 chr3 2229166 C T 8.60E-05 Hypothyroidism CNTN4 intron 22493691 rs9968229 chr3 2229445 T C 4.85E-05 Multiple complex diseases CNTN4 intron 17554300 rs13324989 chr3 2230964 G A 3.25E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs7641285 chr3 2247857 C T 9.22E-04 Bone mineral density CNTN4 intron 19181680 rs12633359 chr3 2263432 A G 2.00E-05 Urinary metabolites CNTN4 intron 21572414 rs7613221 chr3 2270812 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CNTN4 intron 22628534 rs1153495 chr3 2310591 A T 8.14E-04 Response to TNF antagonist treatment CNTN4 intron 21061259 rs1014805 chr3 2335471 A G 8.49E-05 Blood Pressure CNTN4 intron pha003047 rs1145050 chr3 2354512 T C 8.26E-05 Cognitive performance CNTN4 intron 19734545 rs4684343 chr3 2391098 G A 1.80E-04 Lipid traits CNTN4 intron 17903299 rs11129117 chr3 2395843 A T 1.29E-05 Personality dimensions CNTN4 intron 22628180 rs6785626 chr3 2400967 A G 1.70E-05 Personality dimensions CNTN4 intron 22628180 rs9862494 chr3 2402673 T C 1.10E-05 Celiac disease CNTN4 intron 17558408 rs6792956 chr3 2412847 T C 1.55E-04 Nicotine smoking CNTN4 intron 19268276 rs13064317 chr3 2413859 A G 1.09E-06 Response to tocilizumab in rheumatoid arthritis CNTN4 intron 22491018 rs17013514 chr3 2421975 A G 6.59E-06 Bipolar disorder,affective CNTN4 intron 20528957 rs17013524 chr3 2423127 T G 1.51E-05 Vitiligo CNTN4 intron 22951725 rs17013524 chr3 2423127 T G 8.59E-06 Smooth-surface caries CNTN4 intron 24556642 rs1393484 chr3 2429767 T C 4.85E-05 Cognitive test performance CNTN4 intron 20125193 rs13068208 chr3 2435741 C T 3.99E-05 Cognitive test performance CNTN4 intron 20125193 rs2653492 chr3 2480438 A G 3.32E-05 Smoking initiation CNTN4 intron 24665060 rs11129148 chr3 2486763 C T 4.00E-06 Urinary metabolites CNTN4 intron 21572414 rs2221294 chr3 2487197 A G 5.25E-05 Serum metabolites CNTN4 intron 19043545 rs2174018 chr3 2487697 A G 7.62E-04 Type 2 diabetes CNTN4 intron 17463246 rs1551997 chr3 2534772 G A 1.40E-05 Urinary metabolites CNTN4 intron 21572414 rs17620999 chr3 2561556 A G 2.11E-05 Renal cell carcinoma CNTN4 intron 23184150 rs6793017 chr3 2579127 A G 6.60E-04 Suicidal ideation CNTN4 intron 22030708 rs899540 chr3 2609580 C G 3.43E-04 Multiple complex diseases CNTN4 intron 17554300 rs899540 chr3 2609580 C G 2.15E-04 Smoking initiation CNTN4 intron 24665060 rs11707897 chr3 2614626 T C 0.0000278 Nicotine dependence (smoking) CNTN4 intron 22377092 rs11707897 chr3 2614626 T C 0.0000241 Alcohol craving with or without dependence CNTN4 intron 22481050 rs11707897 chr3 2614626 T C 3.11E-05 Alcohol consumption CNTN4 intron 23953852 rs2728055 chr3 2616290 C T 1.70E-04 Alcohol dependence CNTN4 intron 20201924 rs1466459 chr3 2621687 A G 8.62E-04 Multiple complex diseases CNTN4 intron 17554300 rs2619566 chr3 2624938 G A 4.26E-05 Hirschsprung's disease CNTN4 intron 19196962 rs2619566 chr3 2624938 G A 7.00E-06 Amyotrophic lateral sclerosis CNTN4 intron 19451621 rs1479540 chr3 2629477 A G 1.74E-04 Nicotine smoking CNTN4 intron 19268276 rs1020997 chr3 2653577 C T 3.37E-04 Common variable immunodeficiency CNTN4 intron 21497890 rs4370013 chr3 2654691 A T 4.00E-06 Blood pressure CNTN4 intron 17903302 rs2600318 chr3 2670624 G A 3.85E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CNTN4 intron 24023788 rs9849237 chr3 2675189 C T 5.11E-04 Oral cancers (chewing tobacco related) CNTN4 intron 22503698 rs1600359 chr3 2690405 G A 9.44E-05 Height CNTN4 intron pha003010 rs6442743 chr3 2701863 G T 1.71E-04 Schizophrenia CNTN4 intron 19197363 rs6442743 chr3 2701863 G T 9.86E-05 Body Mass Index CNTN4 intron pha003019 rs6442743 chr3 2701863 G T 5.45E-05 Body Mass Index CNTN4 intron pha003022 rs2600274 chr3 2716743 G A 8.22E-04 Schizophrenia CNTN4 intron 19197363 rs2600274 chr3 2716743 G A 9.63E-06 Glucose levels CNTN4 intron pha003057 rs1914011 chr3 2717559 A C 7.54E-04 Insulin resistance CNTN4 intron 21901158 rs2675307 chr3 2725060 T C 6.45E-04 Schizophrenia CNTN4 intron 19197363 rs1516390 chr3 2728391 A G 9.52E-05 Alzheimer's disease CNTN4 intron 17998437 rs7646667 chr3 2731319 C T 2.77E-04 Schizophrenia CNTN4 intron 19197363 rs2675304 chr3 2733172 C T 6.66E-04 Myopia (pathological) CNTN4 intron 21095009 rs2728024 chr3 2735354 G A 7.98E-04 Myopia (pathological) CNTN4 intron 21095009 rs1949344 chr3 2738520 G A 7.50E-06 Urinary metabolites CNTN4 intron 21572414 rs7652776 chr3 2741024 G A,C 3.19E-04 Type 2 diabetes CNTN4 intron 17463246 rs7652776 chr3 2741024 G A,C 6.19E-04 Alzheimer's disease CNTN4 intron 17998437 rs7635049 chr3 2743571 A G 1.48E-04 Type 2 diabetes CNTN4 intron 17463246 rs7623658 chr3 2743593 C G 1.32E-04 Type 2 diabetes CNTN4 intron 17463246 rs7645216 chr3 2743688 G A 1.20E-04 Type 2 diabetes CNTN4 intron 17463246 rs2600294 chr3 2752024 G C 6.37E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9837487 chr3 2753872 T C 9.21E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9852788 chr3 2756368 T G 5.65E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs13324651 chr3 2756816 G A 1.98E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11714965 chr3 2757213 A C 1.98E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9845036 chr3 2759106 C A 4.23E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9868328 chr3 2759118 T G 2.43E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11129249 chr3 2759551 T C 9.53E-05 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9310831 chr3 2760139 C G 1.47E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9310832 chr3 2760177 A G 1.64E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9832509 chr3 2760298 G C 1.66E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs13077493 chr3 2761667 T G 9.15E-05 Platelet counts CNTN4 intron pha003100 rs2675283 chr3 2761728 T G 1.34E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs7434142 chr3 2763405 C T 1.80E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs17019466 chr3 2770509 G A 4.00E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs11129265 chr3 2772862 A G 1.91E-04 Alzheimer's disease CNTN4 intron 22005930 rs2320957 chr3 2780675 T C 7.40E-05 Lung adenocarcinoma CNTN4 intron 19836008 rs9880202 chr3 2782210 T C 5.26E-04 Multiple complex diseases CNTN4 intron 17554300 rs3897737 chr3 2796414 G A 8.04E-04 Tourette syndrome CNTN4 intron 22889924 rs3897737 chr3 2796414 G A 1.06E-05 Prostate cancer CNTN4 intron 22923026 rs12494784 chr3 2799942 A C 2.04E-04 Tourette syndrome CNTN4 intron 22889924 rs2320960 chr3 2802443 G C 7.34E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11129291 chr3 2812755 C G 4.06E-04 IgE levels CNTN4 intron 17255346 rs3935671 chr3 2815150 C T 8.76E-05 IgE levels CNTN4 intron 17255346 rs3935673 chr3 2815263 C T 5.07E-05 IgE levels CNTN4 intron 17255346 rs955340 chr3 2821345 C T 7.35E-05 IgE levels CNTN4 intron 17255346 rs7652782 chr3 2821616 G A 7.00E-07 Serum uric acid levels CNTN4 intron 24379826 rs6786387 chr3 2822150 C A 1.77E-04 IgE levels CNTN4 intron 17255346 rs6786387 chr3 2822150 C A 7.60E-07 Serum uric acid levels CNTN4 intron 24379826 rs954882 chr3 2826545 G A 7.67E-04 Alzheimer's disease CNTN4 intron 17998437 rs954882 chr3 2826545 G A 2.70E-05 Urinary metabolites CNTN4 intron 21572414 rs7636727 chr3 2830717 G A 8.10E-06 Urinary metabolites CNTN4 intron 21572414 rs2728090 chr3 2831511 A G 2.45E-04 Type 2 diabetes CNTN4 intron 17463246 rs41521446 chr3 2833324 C G 5.22E-05 Response to metformin CNTN4 intron 21186350 rs9847255 chr3 2835174 C T 5.16E-04 Type 2 diabetes CNTN4 intron 17463246 rs7635582 chr3 2835473 G C 6.29E-04 Type 2 diabetes CNTN4 intron 17463246 rs7628425 chr3 2836270 A G 3.20E-06 Urinary metabolites CNTN4 intron 21572414 rs1400211 chr3 2842906 G A 8.51E-04 HIV-1 viral setpoint CNTN4 intron 17641165 rs2728089 chr3 2845843 T C 2.60E-04 Amyotrophic Lateral Sclerosis CNTN4 intron 17362836 rs2728089 chr3 2845843 T C 9.61E-04 HIV-1 viral setpoint CNTN4 intron 17641165 rs975334 chr3 2846316 G A 9.00E-07 Gallbladder cancer CNTN4 intron 22318345 rs4685564 chr3 2851955 G T 6.98E-04 Coronary heart disease CNTN4 intron 21606135 rs9841434 chr3 2854988 T C 4.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN4 intron 20877124 rs9861814 chr3 2878116 C T 7.29E-04 Multiple complex diseases CNTN4 intron 17554300 rs7642309 chr3 2880210 T C 5.90E-05 Personality dimensions CNTN4 intron 18957941 rs6781149 chr3 2881575 A G 1.00E-07 Intelligence CNTN4 intron 22449649 rs17021399 chr3 2893696 A G 2.48E-05 Type 2 diabetes CNTN4 intron 17463246 rs11713158 chr3 2895684 T C 9.00E-07 Intelligence CNTN4 intron 22449649 rs7636197 chr3 2901065 G A 7.54E-04 Type 2 diabetes CNTN4 intron 17463246 rs7636197 chr3 2901065 G A 3.43E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs17584923 chr3 2902492 A G 2.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs13324783 chr3 2902809 G C 1.06E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs17021457 chr3 2902945 T C 2.66E-05 Bipolar disorder and schizophrenia CNTN4 intron 20889312 rs9872038 chr3 2903408 G T 1.80E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs9872038 chr3 2903408 G T 8.10E-05 Erythrocyte counts CNTN4 intron pha003099 rs7631834 chr3 2904908 G A 2.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs9869344 chr3 2905353 T C 2.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs7639356 chr3 2909402 T A 2.33E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs12494869 chr3 2910980 A G 2.30E-04 Multiple complex diseases CNTN4 intron 17554300 rs4608676 chr3 2912864 C T 4.47E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CNTN4 intron 24023788 rs7611373 chr3 2917437 G A 2.64E-05 Alcohol consumption CNTN4 intron 23743675 rs9882169 chr3 2917622 C G 2.03E-05 Bipolar disorder CNTN4 intron 22925353 rs7641289 chr3 2921404 A G 4.79E-04 Coronary heart disease CNTN4 intron 21971053 rs17646346 chr3 2925030 A G 6.62E-05 Intelligence CNTN4 intron 21826061 rs17022006 chr3 2938734 G A 1.38E-04 Nicotine smoking CNTN4 intron 19268276 rs17586876 chr3 2964182 A G 1.56E-05 Systolic blood pressure in sickle cell anemia CNTN4 intron 24058526 rs17586876 chr3 2964182 A G 2.00E-06 Serum uric acid levels CNTN4 intron 24379826 rs6786174 chr3 2982630 T G 1.20E-06 Serum uric acid levels CNTN4 intron 24379826 rs427502 chr3 2999019 C T 2.71E-04 Multiple complex diseases CNTN4 intron 17554300 rs751056 chr3 3000908 A G 9.92E-05 Panic disorder CNTN4 intron 19165232 rs751056 chr3 3000908 A G 0.0000527 Panic disorder CNTN4 intron 23149450 rs751056 chr3 3000908 A G 5.27E-05 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs13079652 chr3 3002447 G A 2.30E-05 Urinary metabolites CNTN4 intron 21572414 rs12715157 chr3 3006381 T C 1.21E-05 HDL cholesterol CNTN4 intron pha003075 rs12715157 chr3 3006381 T C 7.77E-05 Lipid levels CNTN4 intron pha003082 rs10510243 chr3 3006444 A G 2.94E-05 Blood Pressure CNTN4 intron pha003049 rs17595878 chr3 3027090 G A 8.84E-04 Multiple complex diseases CNTN4 intron 17554300 rs7613278 chr3 3031308 T C 4.43E-05 Type 2 diabetes CNTN4 intron 17463246 rs1499126 chr3 3035593 A G 1.17E-04 Multiple complex diseases CNTN4 intron 17554300 rs17024684 chr3 3055247 C T 2.00E-09 Brain connectivity CNTN4 intron 23471985 rs12497768 chr3 3071742 T C 2.60E-04 Primary sclerosing cholangitis CNTN4 intron 19944697 rs1039255 chr3 3073509 G A 3.40E-04 Primary sclerosing cholangitis CNTN4 intron 19944697 rs9845519 chr3 3076218 G A 6.95E-04 Taste perception CNTN4 intron 22132133 rs9820464 chr3 3078840 C T 7.99E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs7617493 chr3 3080200 T C 7.44E-04 Amyotrophic Lateral Sclerosis CNTN4 intron 17362836 rs339286 chr3 3081544 C T 6.81E-04 Smoking quantity CNTN4 intron 24665060 rs95866 chr3 3082778 C A 5.82E-04 Smoking quantity CNTN4 intron 24665060 rs7649378 chr3 3091331 C A 1.13E-05 Coronary restenosis CNTN4 intron 21878436 rs7649378 chr3 3091331 C A 8.90E-05 Hypothyroidism CNTN4 intron 22493691 rs163574 chr3 3096927 A G 6.77E-05 Chronic obstructive pulmonary disease CNTN4 intron 19300482 rs163574 chr3 3096927 A G 6.77E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CNTN4 intron 20031582 rs163579 chr3 3101065 C T 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs163582 chr3 3103110 A C 0.000426861 Hypertension (early onset hypertension) / / 22479346 rs340826 chr3 3104758 A G 2.19E-05 Hypertension (early onset hypertension) / / 22479346 rs3792424 chr3 3117700 A G 2.12E-05 Parkinson's disease IL5RA intron 21738487 rs4322988 chr3 3120571 G T 4.60E-04 Coronary heart disease IL5RA intron 21966275 rs17026370 chr3 3125441 G T 3.67E-05 Parkinson's disease IL5RA intron 21738487 rs334809 chr3 3130221 A T 1.00E-06 Oleic acid (18:1n-9) plasma levels IL5RA intron 23362303 rs3804795 chr3 3130645 T C 1.00E-06 Immune response to smallpox vaccine (IL-6) IL5RA intron 22542470 rs3856848 chr3 3147676 C T 1.84E-05 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs17879755 chr3 3147981 G A 2.00E-06 QT interval IL5RA intron 23166209 rs334782 chr3 3148458 T C 2.77E-06 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs334782 chr3 3148458 T C 5.42E-06 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs17878749 chr3 3150573 A C 3.13E-06 QT interval IL5RA intron 23166209 rs3806680 chr3 3152384 A G 6.24E-04 Obesity (extreme) IL5RA nearGene-5 21935397 rs9814648 chr3 3155229 G A 8.45E-04 Obesity (extreme) / / 21935397 rs1153459 chr3 3158485 T C 5.40E-04 Alcohol dependence / / 20201924 rs1278150 chr3 3165907 C T 2.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3762760 chr3 3188016 A G 0.000013 Endometrial cancer TRNT1 intron 22426144 rs1669342 chr3 3193676 A G 8.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRBN intron 23648065 rs17027638 chr3 3197918 A G 2.18E-04 Birth weight CRBN cds-synon 17255346 rs1669338 chr3 3199635 A C 6.00E-06 White matter integrity CRBN intron 23218918 rs698204 chr3 3205432 G C 9.04E-05 Serum metabolites CRBN intron 19043545 rs1669325 chr3 3213262 A G 1.84E-05 Word reading CRBN intron 23738518 rs9828825 chr3 3228123 G A 9.72E-06 White blood cell count / / 21738479 rs1672743 chr3 3231838 A T 6.00E-06 IgG glycosylation / / 23382691 rs967963 chr3 3236900 T C 8.70E-06 Urinary metabolites / / 21572414 rs4109078 chr3 3240356 T C 0.00038 Breast cancer / / 23555315 rs3856858 chr3 3260833 G T 2.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3856858 chr3 3260833 G T 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13065779 chr3 3261377 T C 1.00E-05 Urinary metabolites / / 21572414 rs13080820 chr3 3261438 G A 1.50E-05 Urinary metabolites / / 21572414 rs6799305 chr3 3262363 G C 2.70E-05 Urinary metabolites / / 21572414 rs4376017 chr3 3262478 C T 1.20E-05 Urinary metabolites / / 21572414 rs3914759 chr3 3265099 G A 2.50E-05 Urinary metabolites / / 21572414 rs13068305 chr3 3271778 C T 3.00E-06 Urinary metabolites / / 21572414 rs9832310 chr3 3274815 G C 3.00E-06 Urinary metabolites / / 21572414 rs12497635 chr3 3276490 C T 7.60E-06 Urinary metabolites / / 21572414 rs3843388 chr3 3280819 A C 7.48E-04 Schizophrenia / / 19197363 rs12490364 chr3 3283626 T C 4.50E-06 Urinary metabolites / / 21572414 rs7615479 chr3 3286100 T C 2.55E-15 Multiple complex diseases / / 17554300 rs11129510 chr3 3287422 T C 1.60E-05 Urinary metabolites / / 21572414 rs3914770 chr3 3288998 A C 7.90E-06 Urinary metabolites / / 21572414 rs9854706 chr3 3301678 C T 3.35E-05 Cognitive test performance / / 20125193 rs3846145 chr3 3307984 A G 3.75E-05 Cognitive test performance / / 20125193 rs771000 chr3 3342533 A G 7.52E-05 Coronary heart disease / / 21606135 rs17029949 chr3 3346910 C T 6.93E-04 Multiple complex diseases / / 17554300 rs770996 chr3 3355544 C T 6.39E-06 Pancreatic cancer / / 23180869 rs9874556 chr3 3356174 A G 4.00E-06 Pancreatic cancer / / 23180869 rs9874556 chr3 3356174 A G 9.00E-06 Alcohol dependence (age at onset) / / 24962325 rs9835812 chr3 3375784 G T 8.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs1499088 chr3 3376689 T C 3.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1499085 chr3 3378900 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 6.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs7619998 chr3 3387384 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 8.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs1508738 chr3 3414001 C T 1.20E-05 Urinary metabolites / / 21572414 rs2279977 chr3 3414586 A C 9.50E-06 Urinary metabolites / / 21572414 rs13322888 chr3 3423218 A G 6.52E-05 Coronary Artery Disease / / 17634449 rs1396433 chr3 3463376 T C 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7624675 chr3 3494748 T G 1.58E-04 Intracranial aneurysm / / 22286173 rs12492635 chr3 3501945 C T 4.11E-04 Alzheimer's disease / / 17998437 rs12486658 chr3 3502091 G A 2.91E-04 Alzheimer's disease / / 17998437 rs2220186 chr3 3505049 T A 2.72E-04 Alzheimer's disease / / 17998437 rs10212196 chr3 3545416 C T 4.01E-04 Alzheimer's disease / / 17998437 rs9876298 chr3 3556810 T C 7.63E-04 Alzheimer's disease / / 17998437 rs330243 chr3 3572242 G A 2.49E-04 Myopia (pathological) / / 21095009 rs7652928 chr3 3577113 G A 7.83E-06 Acne (severe teenage) / / 24114350 rs723168 chr3 3583063 T G 1.07E-05 Acne (severe teenage) / / 24114350 rs17684824 chr3 3588042 A C 4.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7650676 chr3 3593290 C G 8.31E-04 Depression (quantitative trait) / / 20800221 rs9811783 chr3 3599937 A C 6.09E-04 Acute lung injury / / 22295056 rs1072848 chr3 3600161 A G 7.28E-04 Depression (quantitative trait) / / 20800221 rs7626957 chr3 3602046 A G 6.82E-05 Post-operative nausea and vomiting / / 21694509 rs4684396 chr3 3614418 T C 7.00E-06 Personality dimensions / / 18957941 rs9815663 chr3 3614887 C T 5.00E-06 Personality dimensions / / 18957941 rs9815663 chr3 3614887 C T 2.00E-08 Asthma (childhood onset) / / 22560479 rs1584573 chr3 3617016 A G 1.40E-05 Personality dimensions / / 18957941 rs9829721 chr3 3622611 C T 6.83E-05 Pancreatic cancer / / pha002874 rs10865864 chr3 3628981 A G 4.00E-06 Callous-unemotional behaviour / / 23874384 rs11711298 chr3 3641794 G C 2.30E-04 Depression (quantitative trait) / / 20800221 rs9837561 chr3 3650239 A C 2.68E-04 Depression (quantitative trait) / / 20800221 rs9837561 chr3 3650239 A C 3.00E-06 Response to amphetamines / / 22952603 rs1601875 chr3 3658840 A G 1.93E-05 Bipolar disorder / / 18317468 rs1601875 chr3 3658840 A G 7.00E-06 Bipolar disorder / / 18711365 rs1488407 chr3 3659566 G C 1.30E-05 Urinary metabolites / / 21572414 rs1386948 chr3 3659605 A C 5.02E-04 Iron levels / / pha002876 rs901859 chr3 3671849 A G 9.17E-04 Depression (quantitative trait) / / 20800221 rs11129700 chr3 3672111 G T 4.32E-04 Depression (quantitative trait) / / 20800221 rs17034687 chr3 3679852 C G 2.00E-09 Disc degeneration (lumbar) / / 22993228 rs7613060 chr3 3720820 C T 2.80E-06 Urinary metabolites / / 21572414 rs711567 chr3 3725595 G T 9.76E-04 Self-reported allergy / / 23817569 rs6796108 chr3 3741831 A G 7.11E-04 Alzheimer's disease / / 22005930 rs6796414 chr3 3742077 A G 3.05E-05 Neutrophil count / / pha003095 rs1596152 chr3 3749436 A G 3.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs769784 chr3 3756970 C T 4.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7628234 chr3 3773131 A G 6.45E-05 Prostate cancer / / pha002877 rs1073657 chr3 3792945 C T 8.32E-05 Tunica Media / / pha003037 rs711548 chr3 3794591 A G 7.00E-05 Nicotine dependence / / 17407593 rs1661532 chr3 3805368 T C 4.67E-04 Multiple complex diseases / / 17554300 rs769626 chr3 3818605 T G 3.56E-05 Cervical cancer / / 24700089 rs812750 chr3 3828840 G C 1.76E-04 Coronary Artery Disease / / 17634449 rs1442211 chr3 3848714 C T 2.03E-05 Hearing function LRRN1 intron 17255346 rs1825912 chr3 3866316 A G 1.00E-04 Cognitive impairment induced by topiramate LRRN1 intron 22091778 rs1488455 chr3 3869513 A T 9.46E-08 Narcolepsy LRRN1 intron 19629137 rs10510280 chr3 3965910 G C 3.99E-05 Bipolar disorder and schizophrenia / / 20889312 rs9311205 chr3 3966355 T G 0.000529 Salmonella-induced pyroptosis / / 22837397 rs1385464 chr3 3967467 T C 0.000657 Salmonella-induced pyroptosis / / 22837397 rs9860821 chr3 3970428 T A 3.57E-05 Serum metabolites / / 19043545 rs1385457 chr3 3971379 T A 1.96E-05 Serum metabolites / / 19043545 rs1825503 chr3 3971502 G A 3.51E-05 Serum metabolites / / 19043545 rs2322357 chr3 3971538 C T 2.50E-05 Serum metabolites / / 19043545 rs2034162 chr3 3971603 C T 2.50E-05 Serum metabolites / / 19043545 rs7614075 chr3 3972228 C G 2.19E-05 Serum metabolites / / 19043545 rs1244000 chr3 3973674 G A 2.04E-05 Serum metabolites / / 19043545 rs1244001 chr3 3973807 C T 2.01E-05 Serum metabolites / / 19043545 rs1116189 chr3 3974718 G T 2.50E-05 Serum metabolites / / 19043545 rs11716390 chr3 3999670 C T 8.36E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs317544 chr3 4041690 T C 2.60E-05 Urinary metabolites / / 21572414 rs317542 chr3 4043018 T C 8.63E-05 Femoral neck bone geometry / / 22087292 rs317593 chr3 4052274 G A 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs317599 chr3 4056652 C A 3.40E-04 Multiple complex diseases / / 17554300 rs317614 chr3 4061316 T C 2.39E-04 Multiple complex diseases / / 17554300 rs317608 chr3 4075936 G A 2.22E-04 Multiple complex diseases / / 17554300 rs17039868 chr3 4136564 C T 2.48E-05 Multiple complex diseases / / 17554300 rs7612596 chr3 4139899 C A,T 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10510288 chr3 4157417 G C 9.73E-05 Suicide attempts in bipolar disorder / / 21423239 rs13084851 chr3 4157503 T C 5.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs17702174 chr3 4158345 C T 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1400167 chr3 4159402 A G 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1596472 chr3 4163562 G A 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1373341 chr3 4168251 G C 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs17702647 chr3 4168600 A C 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs952644 chr3 4181750 G A 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1843303 chr3 4185124 T C 0.0000002 Myopia (Age of onset) / / 23468642 rs17591501 chr3 4212684 A G 4.30E-04 Multiple complex diseases / / 17554300 rs1403124 chr3 4213033 C A 2.75E-05 Blood Pressure / / pha003039 rs1403124 chr3 4213033 C A 6.70E-05 Blood Pressure / / pha003045 rs2587949 chr3 4223616 C G 8.00E-06 Periodontitis (DPAL) / / 24024966 rs2600116 chr3 4224731 G A 7.93E-05 Blood Pressure / / pha003039 rs1485247 chr3 4238196 C T 7.02E-05 Blood Pressure / / pha003039 rs1444056 chr3 4239953 A C 4.37E-05 Blood Pressure / / pha003039 rs1444056 chr3 4239953 A C 7.18E-05 Blood Pressure / / pha003045 rs1153572 chr3 4275803 C T 5.66E-04 Taste perception / / 22132133 rs314416 chr3 4317445 C T 3.78E-04 Smoking quantity / / 24665060 rs310727 chr3 4336589 T C 6.22E-04 Taste perception / / 22132133 rs314439 chr3 4344303 C G 2.83E-04 Multiple complex diseases / / 17554300 rs17040374 chr3 4376778 A G 3.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2582349 chr3 4393415 A G 6.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs9811531 chr3 4400806 A T 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9867526 chr3 4400904 C G 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1688416 chr3 4402649 A C 2.30E-04 Suicide attempts in bipolar disorder SUMF1 nearGene-3 21423239 rs964403 chr3 4432033 G T 9.36E-04 Bipolar disorder SUMF1 intron 19259986 rs964403 chr3 4432033 G T 4.91E-05 Longevity SUMF1 intron 21612516 rs3864051 chr3 4432116 C T 5.49E-05 Longevity SUMF1 intron 21612516 rs794185 chr3 4437358 T C 6.00E-07 Multiple sclerosis (brain glutamate levels) SUMF1 intron 20802204 rs17040638 chr3 4451420 G A 3.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SUMF1 intron 24023788 rs1625605 chr3 4456185 G T 5.29E-04 Type 2 diabetes SUMF1 intron 17463246 rs711667 chr3 4461569 G A 0.000339279 Hypertension (early onset hypertension) SUMF1 intron 22479346 rs2582343 chr3 4467253 A G 0.000299496 Hypertension (early onset hypertension) SUMF1 intron 22479346 rs6442884 chr3 4469949 C G 1.59E-04 Aortic root size SUMF1 intron 21223598 rs17516078 chr3 4479914 A C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SUMF1 intron 20877124 rs12634249 chr3 4486303 C A 6.86E-04 Longevity SUMF1 intron 22279548 rs17040698 chr3 4489562 T C 5.08E-05 Cognitive performance SUMF1 intron 19734545 rs2259801 chr3 4513543 A G 8.63E-05 Testicular dysgenesis syndrome / / 22140272 rs304082 chr3 4527619 A C 4.99E-05 Cholesterol / / pha003073 rs2291597 chr3 4536403 G A 8.81E-04 Type 2 diabetes ITPR1 intron 17463246 rs2291597 chr3 4536403 G A 4.54E-04 Multiple complex diseases ITPR1 intron 17554300 rs11130036 chr3 4543463 A G 2.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ITPR1 intron 21844884 rs17757503 chr3 4543995 T C 3.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ITPR1 intron 21844884 rs7639802 chr3 4565559 C T 2.05E-05 Schizophrenia ITPR1 intron 20185149 rs11708874 chr3 4567628 T G 9.65E-05 Response to citalopram treatment ITPR1 intron 19846067 rs11708874 chr3 4567628 T G 1.27E-05 Schizophrenia ITPR1 intron 20185149 rs184231 chr3 4583026 G A 4.36E-05 Body Mass Index ITPR1 intron pha003021 rs10510294 chr3 4593482 T C 4.85E-04 Multiple complex diseases ITPR1 intron 17554300 rs4685758 chr3 4602498 C T 2.68E-05 Insulin Resistance ITPR1 intron pha003062 rs4685758 chr3 4602498 C T 2.42E-05 Insulin-related traits ITPR1 intron pha003063 rs4685765 chr3 4607133 C T 3.41E-04 Heart Failure ITPR1 intron pha002885 rs6774037 chr3 4615243 A G 2.18E-04 Multiple complex diseases ITPR1 intron 17554300 rs2322734 chr3 4633492 C A 8.00E-06 Airflow obstruction ITPR1 intron 22837378 rs4684427 chr3 4645916 C A 1.00E-04 Cognitive impairment induced by topiramate ITPR1 intron 22091778 rs902985 chr3 4671393 C G 7.56E-05 Aortic root size ITPR1 intron 21223598 rs4074087 chr3 4681908 C A 1.20E-05 Urinary metabolites ITPR1 intron 21572414 rs4073665 chr3 4682229 G A 3.05E-05 Depression (quantitative trait) ITPR1 intron 23290196 rs4073664 chr3 4682456 A T 1.10E-05 Urinary metabolites ITPR1 intron 21572414 rs2306870 chr3 4699776 T C 5.92E-06 Obesity-related traits ITPR1 intron 23251661 rs2306868 chr3 4699967 C G 5.92E-06 Obesity-related traits ITPR1 intron 23251661 rs7632000 chr3 4703937 C T 7.00E-07 Obesity-related traits ITPR1 intron 23251661 rs17041165 chr3 4720206 G T 2.61E-04 Response to cytidine analogues (gemcitabine) ITPR1 intron 24483146 rs3804987 chr3 4721624 C T 1.70E-05 Urinary metabolites ITPR1 intron 21572414 rs4685803 chr3 4740592 A G 8.81E-04 Type 2 diabetes ITPR1 intron 17463246 rs4685804 chr3 4740646 G A 7.54E-04 Type 2 diabetes ITPR1 intron 17463246 rs6762558 chr3 4742251 A G 4.94E-06 Systemic lupus erythematosus and Systemic sclerosis ITPR1 intron 23740937 rs6762644 chr3 4742276 A G 2.00E-12 Breast cancer ITPR1 intron 23535729 rs6802366 chr3 4743418 C G 9.05E-04 Response to cytadine analogues (cytosine arabinoside) ITPR1 intron 24483146 rs2322830 chr3 4745230 T C 4.28E-04 Type 2 diabetes ITPR1 intron 17463246 rs3804995 chr3 4751010 C T 6.89E-05 Gallstones ITPR1 intron 17632509 rs7613447 chr3 4767262 T C 2.79E-04 Aortic root size ITPR1 cds-synon 21223598 rs11920001 chr3 4776784 A G 4.39E-05 Response to cytadine analogues (cytosine arabinoside) ITPR1 intron 24483146 rs931389 chr3 4777544 T C 5.23E-04 Schizophrenia ITPR1 intron 19197363 rs13092274 chr3 4781349 T C 1.68E-04 Age-related macular degeneration ITPR1 intron 22125219 rs142774343 chr3 4783001 G T 0.00004453 Sarcoidosis ITPR1 intron 22952805 rs1866997 chr3 4794099 T C 3.79E-04 Lung function (forced vital capacity) ITPR1 intron 24023788 rs13068994 chr3 4794128 C A 8.21E-05 Height ITPR1 intron pha003011 rs3805006 chr3 4800769 T C 5.39E-86 Multiple complex diseases ITPR1 intron 17554300 rs2291863 chr3 4808703 G A 2.57E-04 HIV-1 viral setpoint ITPR1 intron 17641165 rs13060980 chr3 4826452 A G 7.74E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018107 chr3 4827309 A G 5.34E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018108 chr3 4827514 A T 6.18E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018109 chr3 4827533 A G 8.39E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs3805017 chr3 4828136 A G 6.13E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs6801569 chr3 4828703 T C 6.41E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs6809847 chr3 4828764 G C 5.28E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2633718 chr3 4828806 G A 6.40E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2633760 chr3 4829010 A G 6.35E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7611657 chr3 4829198 G C 6.33E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs4685820 chr3 4829412 A G 4.02E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7649642 chr3 4830995 A T 2.97E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7637819 chr3 4831225 T C 2.76E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2165624 chr3 4832534 T A 5.46E-04 Multiple complex diseases ITPR1 intron 17554300 rs11917686 chr3 4834409 A T 5.00E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2270748 chr3 4836462 C T 9.74E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs11713160 chr3 4837269 T G 7.00E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7612703 chr3 4852446 C T 1.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ITPR1 intron 24023788 rs3792511 chr3 4866320 T G 9.32E-05 Alzheimer's disease ITPR1 intron 22832961 rs13096481 chr3 4874498 C T 1.79E-04 Blood pressure ITPR1 intron 17255346 rs6768569 chr3 4879350 A G 4.51E-05 Psoriasis ITPR1 intron 20953190 rs876349 chr3 4928098 G T 9.38E-04 Type 2 diabetes / / 17463246 rs3856883 chr3 4928159 C T 8.39E-04 Type 2 diabetes / / 17463246 rs9836040 chr3 4941141 T C 1.19E-04 Obesity (extreme) LOC100507582 intron 21935397 rs12497445 chr3 4969763 C T 4.59E-06 Schizophrenia / / 22037555 rs7641083 chr3 4977383 C T 1.20E-05 Urinary metabolites / / 21572414 rs6442925 chr3 5013876 T C 2.00E-06 Corneal structure / / 21979947 rs1110261 chr3 5019936 G A 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs908078 chr3 5024771 T C 4.00E-06 Smoking behavior BHLHE40 cds-synon 20418888 rs2616521 chr3 5055578 T C 3.49E-05 Systemic lupus erythematosus / / pha002867 rs9858342 chr3 5078255 C T 3.10E-04 Multiple complex diseases / / 17554300 rs744230 chr3 5126013 G A 1.57E-05 Cognitive test performance / / 20125193 rs2671766 chr3 5129126 A G 2.20E-05 Urinary metabolites / / 21572414 rs2671766 chr3 5129126 A G 8.48E-04 Alzheimer's disease / / 22005930 rs2606783 chr3 5129238 A G 7.98E-04 Alzheimer's disease / / 22005930 rs3864053 chr3 5131363 T C 4.77E-05 Cognitive test performance / / 20125193 rs17735361 chr3 5131396 A G 6.84E-04 Alzheimer's disease / / 22005930 rs3930716 chr3 5132540 T C 2.46E-04 Myopia (pathological) / / 21095009 rs11918654 chr3 5188246 T C 7.00E-06 Disc degeneration (lumbar) ARL8B intron 22993228 rs459289 chr3 5225773 G T 1.47E-05 Type 2 diabetes / / 17463246 rs341974 chr3 5234726 A G 7.20E-04 Type 2 diabetes EDEM1 intron 17463246 rs341981 chr3 5245146 T G 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EDEM1 intron 20877124 rs341988 chr3 5254685 A G 7.03E-04 Type 2 diabetes EDEM1 intron 17463246 rs3846158 chr3 5273528 G A 9.40E-04 HIV-1 viral setpoint / / 17641165 rs9872393 chr3 5299769 G A 4.85E-04 Lymphocyte counts / / 22286170 rs7638397 chr3 5316622 A G 5.11E-06 Multiple complex diseases / / 17554300 rs1874971 chr3 5319518 A G 0.000531 Salmonella-induced pyroptosis / / 22837397 rs9311480 chr3 5332265 G T 3.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs407334 chr3 5351214 C T 2.03E-26 Multiple complex diseases / / 17554300 rs407334 chr3 5351214 C T 4.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1319054 chr3 5359930 A C 4.91E-04 Type 2 diabetes / / 17463246 rs9831553 chr3 5365266 A G 9.25E-04 Type 2 diabetes / / 17463246 rs11130339 chr3 5365353 A T 9.53E-04 Type 2 diabetes / / 17463246 rs343427 chr3 5365682 C T 9.53E-04 Type 2 diabetes / / 17463246 rs4485702 chr3 5389179 C T 4.72E-05 Longevity / / 20304771 rs4485702 chr3 5389179 C T 5.70E-06 Urinary metabolites / / 21572414 rs4367043 chr3 5390506 A T 4.71E-05 Longevity / / 20304771 rs4367043 chr3 5390506 A T 3.50E-06 Urinary metabolites / / 21572414 rs4234565 chr3 5400168 G A 9.60E-06 Urinary metabolites / / 21572414 rs4143244 chr3 5410364 C T 7.05E-07 Bone mass and geometry / / 17903296 rs4143244 chr3 5410364 C T 1.40E-04 Statin-induced myopathy / / 21826682 rs10510303 chr3 5410409 C T 3.72E-05 Longevity / / 20304771 rs17042380 chr3 5420067 A C 3.62E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6799552 chr3 5427290 C T 2.22E-04 Vaspin levels / / 22907691 rs6799552 chr3 5427290 C T 0.0002223 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9842582 chr3 5427679 A G 3.18E-05 Lymphocyte counts / / pha003094 rs9842582 chr3 5427679 A G 5.56E-05 Neutrophil count / / pha003095 rs6781429 chr3 5429527 G A 8.23E-05 Serum metabolites / / 19043545 rs4685921 chr3 5434536 A G 8.01E-04 Multiple complex diseases / / 17554300 rs2323142 chr3 5464641 T A 9.02E-04 Multiple complex diseases / / 17554300 rs2323142 chr3 5464641 T A 0.000123 Breast cancer early age of onset / / 18463975 rs2323142 chr3 5464641 T A 4.07E-05 Bipolar disorder / / 19488044 rs2323141 chr3 5465805 A G 8.68E-05 Bipolar disorder / / 19488044 rs6793307 chr3 5478372 G A 8.73E-04 Alzheimer's disease / / 17998437 rs10510307 chr3 5478616 T A 6.28E-04 Alzheimer's disease / / 22005930 rs17030987 chr3 5483616 G C 9.39E-04 Alzheimer's disease / / 22005930 rs17803386 chr3 5492216 T A 5.37E-04 Alzheimer's disease / / 17998437 rs7627551 chr3 5507957 T G 3.53E-04 Rheumatoid arthritis / / 21452313 rs2565612 chr3 5522945 G A 6.70E-05 Response to statin therapy / / 20339536 rs2565611 chr3 5524641 A G 1.81E-04 Body mass index / / 21701565 rs2565611 chr3 5524641 A G 3.84E-04 Body mass index / / 21701565 rs2686534 chr3 5525968 G A 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1991578 chr3 5534360 C G 7.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs11710159 chr3 5534417 C A 4.67E-04 Alzheimer's disease / / 22005930 rs11719822 chr3 5536052 G A 5.58E-04 Alzheimer's disease / / 22005930 rs2163210 chr3 5536975 G A 6.38E-04 Alzheimer's disease / / 22005930 rs17042723 chr3 5537714 C A 7.79E-04 Alzheimer's disease / / 22005930 rs9874195 chr3 5543950 T G 6.34E-04 Type 2 diabetes / / 17463246 rs9823228 chr3 5564422 A G 9.30E-06 Urinary metabolites / / 21572414 rs7635047 chr3 5592056 A G 2.20E-05 Urinary metabolites / / 21572414 rs7615007 chr3 5631528 G A 4.36E-05 Intelligence / / 21826061 rs1864428 chr3 5632123 G C 8.35E-05 Alzheimer's disease / / 17998437 rs2218972 chr3 5681597 A G 5.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6442967 chr3 5688304 T G 6.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11710433 chr3 5705052 C T 1.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs9873292 chr3 5711897 G A 8.75E-05 Cognitive test performance / / 20125193 rs13100888 chr3 5713757 G A 1.30E-05 Urinary metabolites / / 21572414 rs4283565 chr3 5714159 C T 3.96E-05 Prostate cancer / / 22923026 rs17043278 chr3 5714934 A C 0.000621 Salmonella-induced pyroptosis / / 22837397 rs6791910 chr3 5716365 T C 6.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6791910 chr3 5716365 T C 1.10E-05 Prostate cancer / / 22923026 rs7428299 chr3 5730884 T C 5.47E-04 Type 2 diabetes / / 17463246 rs11713590 chr3 5731142 G A 3.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs10212309 chr3 5741743 C T 1.69E-05 Personality dimensions / / 22628180 rs6776169 chr3 5752152 C T 1.62E-05 Personality dimensions / / 22628180 rs2123370 chr3 5754294 G T 8.73E-04 Type 2 diabetes / / 17463246 rs4143284 chr3 5760140 G A 5.83E-04 Multiple complex diseases / / 17554300 rs17043388 chr3 5760703 T A 3.89E-06 Personality dimensions / / 22628180 rs6782143 chr3 5768262 T A 1.19E-06 Personality dimensions / / 22628180 rs41322746 chr3 5772947 T C 7.41E-04 Multiple complex diseases / / 17554300 rs1811510 chr3 5775231 G T 4.06E-06 Personality dimensions / / 22628180 rs2470646 chr3 5775765 T C 2.91E-06 Personality dimensions / / 22628180 rs7621135 chr3 5776564 T A 3.07E-06 Personality dimensions / / 22628180 rs7618793 chr3 5776587 A G 5.27E-06 Personality dimensions / / 22628180 rs2470644 chr3 5776857 T C 3.37E-06 Personality dimensions / / 22628180 rs1452713 chr3 5777222 C T 5.70E-06 Personality dimensions / / 22628180 rs7632506 chr3 5785451 T G 5.25E-15 Multiple complex diseases / / 17554300 rs2444218 chr3 5796661 G T 3.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11130597 chr3 5821999 C T 3.40E-04 Parkinson's disease / / 17052657 rs6805513 chr3 5830561 C T 3.06E-06 Coronary heart disease / / pha003056 rs1897964 chr3 5831955 G C 5.28E-04 Body mass index / / 21701565 rs1836581 chr3 5832156 T C 2.38E-04 Body mass index / / 21701565 rs1836581 chr3 5832156 T C 5.51E-04 Body mass index / / 21701565 rs2437216 chr3 5835060 T C 4.81E-04 Body mass index / / 21701565 rs2437221 chr3 5840111 C T 4.55E-04 Body mass index / / 21701565 rs2437221 chr3 5840111 C T 8.09E-04 Body mass index / / 21701565 rs6785659 chr3 5842729 G A 8.68E-05 Type 2 diabetes and other traits / / 19734900 rs920063 chr3 5847660 A G 8.40E-04 Body mass index / / 21701565 rs1529860 chr3 5856373 A G 1.36E-04 Body mass index / / 17255346 rs17043640 chr3 5857133 G C 1.85E-04 Body mass index / / 17255346 rs17043640 chr3 5857133 G C 5.59E-04 Alzheimer's disease / / 17998437 rs1836583 chr3 5861205 G T 8.83E-08 Metabolite levels / / 23281178 rs4685988 chr3 5866407 G A 3.80E-08 Metabolite levels / / 23281178 rs4685989 chr3 5867227 C A 5.14E-08 Metabolite levels / / 23281178 rs1541971 chr3 5868533 A C 3.80E-08 Metabolite levels / / 23281178 rs2470649 chr3 5869470 G A 5.76E-04 Multiple complex diseases / / 17554300 rs11130617 chr3 5874245 C A 3.80E-08 Metabolite levels / / 23281178 rs2730302 chr3 5876448 C A 3.80E-08 Metabolite levels / / 23281178 rs1836574 chr3 5878521 G A 4.49E-08 Metabolite levels / / 23281178 rs4684510 chr3 5881625 T C 8.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946692 chr3 5882386 G A 3.34E-08 Metabolite levels / / 23281178 rs2572641 chr3 5883768 G A 2.96E-08 Metabolite levels / / 23281178 rs2730303 chr3 5890516 T C 6.35E-04 Multiple complex diseases / / 17554300 rs1435372 chr3 5891539 G A 3.98E-04 Multiple complex diseases / / 17554300 rs2572690 chr3 5891648 T C 5.91E-04 Common variable immunodeficiency / / 21497890 rs2730306 chr3 5891856 A G 5.11E-04 Multiple complex diseases / / 17554300 rs4685993 chr3 5895027 C T 0.00056418 Hypertension (early onset hypertension) / / 22479346 rs7427632 chr3 5897751 G T 1.75E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1961394 chr3 5900250 T A 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730313 chr3 5904553 T G 2.64E-04 Coronary heart disease / / 21606135 rs1435366 chr3 5925183 G C 1.81E-04 Type 2 diabetes / / 17463246 rs11130673 chr3 5936245 A G 0.000655 Salmonella-induced pyroptosis / / 22837397 rs12233495 chr3 5938105 C T 1.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2090350 chr3 5950921 G A 0.000356 Salmonella-induced pyroptosis / / 22837397 rs11495886 chr3 5953419 C T 0.000604 Salmonella-induced pyroptosis / / 22837397 rs1568170 chr3 5965594 C G 1.00E-04 Coronary heart disease / / 21606135 rs2222098 chr3 5986390 C A 3.35E-05 Serum metabolites / / 19043545 rs6767324 chr3 6002693 G A 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6807385 chr3 6002768 T C 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6768819 chr3 6005401 T C 2.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs17043997 chr3 6006004 A G 6.16E-05 Stroke (ischemic) / / 22941190 rs2048923 chr3 6010772 T G 2.66E-04 Hearing function / / 17255346 rs953402 chr3 6011639 A G 2.10E-05 Hearing function / / 17255346 rs953402 chr3 6011639 A G 9.10E-06 Biomarkers / / 17903293 rs10084653 chr3 6020439 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7615497 chr3 6080593 G A 3.75E-04 Acute lung injury / / 22295056 rs1033251 chr3 6081827 G A 6.13E-04 Acute lung injury / / 22295056 rs9814750 chr3 6081942 T C 6.13E-04 Acute lung injury / / 22295056 rs9858176 chr3 6092918 G C 6.70E-06 Urinary metabolites / / 21572414 rs925852 chr3 6119146 A G 7.75E-05 Magnesium levels / / pha003092 rs868243 chr3 6120442 G A 8.96E-05 Serum metabolites / / 19043545 rs10510325 chr3 6134806 G A 7.71E-05 Elbow pain / / pha003008 rs1504035 chr3 6135268 C A 6.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13078896 chr3 6141469 G C 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17215895 chr3 6179757 A G 7.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10510328 chr3 6194317 G A 3.22E-08 Pure-tone audiometry / / pha001964 rs17215933 chr3 6199813 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17215939 chr3 6201267 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4547687 chr3 6216211 C T 9.86E-05 Cleft lip / / 20436469 rs12374158 chr3 6230553 G T 1.85E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs9839456 chr3 6231998 C T 1.72E-04 Vaspin levels / / 22907691 rs9839456 chr3 6231998 C T 0.0001724 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6788599 chr3 6239264 C T 6.56E-04 Multiple complex diseases / / 17554300 rs6774280 chr3 6255997 T C 9.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6796959 chr3 6287176 C T 8.00E-06 Smoking behavior / / 20418888 rs6767746 chr3 6291637 G A 6.09E-04 Multiple complex diseases / / 17554300 rs7620588 chr3 6296931 A G 2.70E-05 Urinary metabolites / / 21572414 rs7629918 chr3 6302110 G A 4.24E-04 Body mass index / / 17255346 rs17044468 chr3 6302155 T C 4.82E-04 Multiple complex diseases / / 17554300 rs4686037 chr3 6317058 C G 2.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs17044542 chr3 6341499 A C 2.02E-29 Narcolepsy / / 19629137 rs17044542 chr3 6341499 A C 0.0000181 HDL cholesterol particle diameter / / 23263444 rs17044643 chr3 6364098 A G 2.24E-05 Multiple complex diseases / / 17554300 rs157462 chr3 6364784 C G 4.65E-05 Coronary heart disease / / 21606135 rs157544 chr3 6376084 C T 9.11E-05 Alzheimer's disease (age of onset) / / 22005931 rs271066 chr3 6377695 A T 3.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs157296 chr3 6378688 A G 1.48E-05 Alzheimer's disease (age of onset) / / 22005931 rs157297 chr3 6379792 G A 3.59E-06 Alzheimer's disease (age of onset) / / 22005931 rs6806982 chr3 6391939 T C 6.16E-04 Tourette syndrome / / 22889924 rs1435719 chr3 6421284 A G 1.42E-04 Alzheimer's disease (late onset) / / 21379329 rs7625304 chr3 6458550 A G 0.000009 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2124811 chr3 6478949 A G 1.11E-04 Osteoarthritis / / 19508968 rs17234606 chr3 6481461 A C 4.33E-05 Multiple complex diseases / / 17554300 rs17216035 chr3 6481625 C A 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs266415 chr3 6488648 T C 8.93E-05 Gallstones / / 17632509 rs9847060 chr3 6516654 G A 9.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9834048 chr3 6546891 T G 3.99E-04 Smoking initiation / / 24665060 rs6765007 chr3 6548800 T C 5.21E-04 Smoking initiation / / 24665060 rs9809045 chr3 6551706 C G 1.30E-05 Diabetic retinopathy / / 21441570 rs17045225 chr3 6553454 G A 8.11E-05 Blood pressure / / 17255346 rs17045232 chr3 6554226 C G 2.38E-04 Blood pressure / / 17255346 rs12639375 chr3 6558517 G A 1.30E-05 Diabetic retinopathy / / 21441570 rs12639378 chr3 6558567 G A 1.30E-05 Diabetic retinopathy / / 21441570 rs155206 chr3 6562331 A G 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2034871 chr3 6563099 G A 6.60E-05 Diabetic retinopathy / / 21441570 rs1456935 chr3 6564662 G T 3.99E-04 Type 2 diabetes / / 17463246 rs1456935 chr3 6564662 G T 1.40E-05 Diabetic retinopathy / / 21441570 rs17045248 chr3 6565409 A T 9.34E-05 Blood pressure / / 17255346 rs10510338 chr3 6565877 A G 3.06E-04 Blood pressure / / 17255346 rs4686069 chr3 6566412 C G 1.60E-05 Diabetic retinopathy / / 21441570 rs9880678 chr3 6568221 G A 2.20E-05 Diabetic retinopathy / / 21441570 rs12330764 chr3 6574839 A G 2.50E-05 Diabetic retinopathy / / 21441570 rs6783239 chr3 6584177 C T 6.09E-04 Smoking initiation / / 24665060 rs729008 chr3 6590865 A G 2.60E-05 Diabetic retinopathy / / 21441570 rs12633898 chr3 6591750 G T 3.10E-05 Diabetic retinopathy / / 21441570 rs9831858 chr3 6592515 A G 3.10E-05 Diabetic retinopathy / / 21441570 rs11714080 chr3 6592700 G A 3.10E-05 Diabetic retinopathy / / 21441570 rs10510340 chr3 6594461 A G 3.70E-05 Diabetic retinopathy / / 21441570 rs13321931 chr3 6595783 T G 3.70E-05 Diabetic retinopathy / / 21441570 rs11714361 chr3 6601031 A T 4.30E-05 Diabetic retinopathy / / 21441570 rs4686070 chr3 6603915 T C 4.30E-05 Diabetic retinopathy / / 21441570 rs9864053 chr3 6607460 C G 4.30E-05 Diabetic retinopathy / / 21441570 rs9311949 chr3 6615658 A G 4.20E-05 Diabetic retinopathy / / 21441570 rs17216174 chr3 6625081 A G 4.10E-05 Diabetic retinopathy / / 21441570 rs352748 chr3 6640700 C G 8.58E-04 Multiple complex diseases / / 17554300 rs7430827 chr3 6642993 A C 5.19E-05 Postoperative ventricular dysfunction / / 21980348 rs7637316 chr3 6643607 A C 2.36E-05 Postoperative ventricular dysfunction / / 21980348 rs17045412 chr3 6660474 C A 1.35E-04 Blood pressure / / 17255346 rs352283 chr3 6666083 T C 0.00002203 Sarcoidosis / / 22952805 rs352281 chr3 6666458 A G 0.00001717 Sarcoidosis / / 22952805 rs675803 chr3 6671011 G T 0.00001668 Sarcoidosis / / 22952805 rs631985 chr3 6673897 A G 0.00003048 Sarcoidosis / / 22952805 rs6766507 chr3 6674723 C T 0.00001668 Sarcoidosis / / 22952805 rs616244 chr3 6675168 T A 0.00001668 Sarcoidosis / / 22952805 rs13326304 chr3 6675541 T C 1.95E-05 HIV-1 viral setpoint / / 22174851 rs602939 chr3 6675838 T G 0.00001629 Sarcoidosis / / 22952805 rs589846 chr3 6676453 A G 0.00001629 Sarcoidosis / / 22952805 rs635098 chr3 6678415 C A 0.00001629 Sarcoidosis / / 22952805 rs632436 chr3 6679059 G A 0.00001629 Sarcoidosis / / 22952805 rs1718564 chr3 6679250 T C 0.00001629 Sarcoidosis / / 22952805 rs1698361 chr3 6679315 A G 0.00001629 Sarcoidosis / / 22952805 rs618657 chr3 6679838 C T 0.00001629 Sarcoidosis / / 22952805 rs621329 chr3 6680288 C T 0.00006677 Sarcoidosis / / 22952805 rs352275 chr3 6685140 C T 0.00001742 Sarcoidosis / / 22952805 rs9843107 chr3 6686203 G A 8.21E-05 HIV-1 viral setpoint / / 22174851 rs9843107 chr3 6686203 G A 9.92E-07 Telomere length / / 23001564 rs168460 chr3 6686606 C A 0.00001742 Sarcoidosis / / 22952805 rs624782 chr3 6687479 A G 0.00003295 Sarcoidosis / / 22952805 rs349894 chr3 6693581 G A 0.00009939 Sarcoidosis / / 22952805 rs371167 chr3 6699156 C T 0.0000761 Sarcoidosis / / 22952805 rs349898 chr3 6713095 C T 0.00009843 Sarcoidosis / / 22952805 rs349900 chr3 6716209 T G 0.00009291 Sarcoidosis / / 22952805 rs401572 chr3 6718604 A G 0.00006052 Sarcoidosis / / 22952805 rs6787150 chr3 6728385 G A 1.10E-05 Urinary metabolites / / 21572414 rs9990237 chr3 6748069 G A 8.06E-04 Alzheimer's disease / / 17998437 rs9817032 chr3 6748343 C T 3.87E-04 Alzheimer's disease / / 17998437 rs9829452 chr3 6752294 A G 3.05E-05 Telomere length / / 23001564 rs164336 chr3 6762242 T C 9.40E-04 Coronary heart disease / / 21606135 rs345244 chr3 6767906 G C 4.09E-04 Coronary heart disease / / 21606135 rs345233 chr3 6770752 T C 4.56E-04 Schizophrenia / / 19197363 rs6781770 chr3 6814988 C T 3.58E-04 Type 2 diabetes / / 17463246 rs17046124 chr3 6861866 T C 4.62E-05 Height / / 22021425 rs17288435 chr3 6863813 A C 8.13E-05 Coronary heart disease / / 21606135 rs11131055 chr3 6867518 A G 5.99E-05 Coronary heart disease / / pha003055 rs17046143 chr3 6873446 A G 1.77E-10 Multiple complex diseases / / 17554300 rs342016 chr3 6882212 G A 7.55E-05 Socioeconomic Factors / / pha003066 rs3749380 chr3 6903297 C T 2.00E-06 Panic disorder GRM7 cds-synon 19165232 rs6783840 chr3 6915723 C G 1.40E-05 Urinary metabolites GRM7 intron 21572414 rs114246623 chr3 6935066 G A 7.70E-07 Prostate cancer GRM7 intron 24185611 rs3846161 chr3 6939834 A G 8.13E-05 Serum metabolites GRM7 intron 19043545 rs339020 chr3 6973116 G T 8.43E-06 Post-operative nausea and vomiting GRM7 intron 21694509 rs802646 chr3 6978547 C T 0.0000876 Sarcoidosis GRM7 intron 22952805 rs1667850 chr3 7003531 G A 8.93E-04 Myopia (pathological) GRM7 intron 21095009 rs480409 chr3 7010081 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) GRM7 intron 23648065 rs6796324 chr3 7012842 G A 2.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) GRM7 intron 23648065 rs13317247 chr3 7026535 C T 3.93E-05 Attention deficit hyperactivity disorder GRM7 intron 23728934 rs1391950 chr3 7058417 T C 0.000027 Migraine GRM7 intron 22678113 rs1391950 chr3 7058417 T C 2.70E-05 Migraine GRM7 intron 22683712 rs11713183 chr3 7078179 T C 0.0000726 Migraine GRM7 intron 22678113 rs11713183 chr3 7078179 T C 7.26E-05 Migraine GRM7 intron 22683712 rs1353832 chr3 7083814 C T 5.06E-04 Aortic root size GRM7 intron 21223598 rs1353832 chr3 7083814 C T 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) GRM7 intron 23648065 rs6771606 chr3 7085713 T C 1.97E-04 Aortic root size GRM7 intron 21223598 rs6771606 chr3 7085713 T C 4.49E-04 Smoking initiation GRM7 intron 24665060 rs6785425 chr3 7125901 A G 6.90E-04 Schizophrenia GRM7 intron 19197363 rs6788201 chr3 7126102 T C 9.32E-05 HIV-1 viral setpoint GRM7 intron 17641165 rs9876724 chr3 7152640 G A 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) GRM7 intron 23648065 rs11928865 chr3 7155702 T A 8.67E-04 Alzheimer's disease GRM7 intron 17998437 rs9872427 chr3 7164223 T A 2.57E-04 Multiple complex diseases GRM7 intron 17554300 rs11131063 chr3 7167701 G A 1.83E-05 Iron levels GRM7 intron 19880490 rs11131063 chr3 7167701 G A 1.83E-05 Iron levels GRM7 intron pha002876 rs6443090 chr3 7168009 C G 4.10E-04 Multiple complex diseases GRM7 intron 17554300 rs6443090 chr3 7168009 C G 7.67E-04 Alzheimer's disease GRM7 intron 17998437 rs6765482 chr3 7168677 T C 7.40E-06 Urinary metabolites GRM7 intron 21572414 rs1353828 chr3 7169453 A C 1.85E-05 Iron levels GRM7 intron 19880490 rs1353828 chr3 7169453 A C 1.85E-05 Iron levels GRM7 intron pha002876 rs6766686 chr3 7170011 A G 6.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) GRM7 intron 23648065 rs9814809 chr3 7170741 G C 6.68E-04 Multiple complex diseases GRM7 intron 17554300 rs1874981 chr3 7172721 C T 2.29E-04 Multiple complex diseases GRM7 intron 17554300 rs1878164 chr3 7173002 G A 7.50E-06 Urinary metabolites GRM7 intron 21572414 rs9880404 chr3 7175878 C T 3.99E-05 Iron levels GRM7 intron 19880490 rs9880404 chr3 7175878 C T 3.99E-05 Iron levels GRM7 intron pha002876 rs17824908 chr3 7176252 A G 1.06E-04 Iron levels GRM7 intron pha002876 rs4441639 chr3 7179682 G A 9.25E-04 Alzheimer's disease GRM7 intron 17998437 rs3749448 chr3 7188116 G A 2.24E-04 Multiple complex diseases GRM7 intron 17554300 rs3749448 chr3 7188116 G A 3.46E-04 Alzheimer's disease GRM7 intron 17998437 rs17234983 chr3 7189058 A C 8.62E-04 Response to taxane treatment (placlitaxel) GRM7 intron 23006423 rs7650218 chr3 7191923 C T 3.09E-04 Multiple complex diseases GRM7 intron 17554300 rs17234990 chr3 7195141 T C 4.90E-04 Response to taxane treatment (placlitaxel) GRM7 intron 23006423 rs7621420 chr3 7196728 C T 7.70E-04 Multiple complex diseases GRM7 intron 17554300 rs9814881 chr3 7198602 A G 7.46E-04 Alzheimer's disease GRM7 intron 17998437 rs12497688 chr3 7201316 T C 8.03E-04 Multiple complex diseases GRM7 intron 17554300 rs1818033 chr3 7202533 C G 5.05E-04 Multiple complex diseases GRM7 intron 17554300 rs9864350 chr3 7202909 C T 8.00E-06 Brain size GRM7 intron 22156575 rs965170 chr3 7214563 C T 6.14E-05 Iron levels GRM7 intron 19880490 rs965170 chr3 7214563 C T 6.14E-05 Iron levels GRM7 intron pha002876 rs10866078 chr3 7215759 T C 2.74E-05 Iron levels GRM7 intron 19880490 rs10866078 chr3 7215759 T C 2.74E-05 Iron levels GRM7 intron pha002876 rs1400166 chr3 7218175 G A 5.84E-04 Iron levels GRM7 intron pha002876 rs10510351 chr3 7219432 T C 3.30E-04 Iron levels GRM7 intron pha002876 rs11715681 chr3 7222094 A G 6.17E-04 Iron levels GRM7 intron pha002876 rs6784317 chr3 7222236 G T 5.91E-04 Iron levels GRM7 intron pha002876 rs2063880 chr3 7228869 G A 2.40E-05 Urinary metabolites GRM7 intron 21572414 rs6797852 chr3 7262014 G A 3.00E-06 Breast cancer GRM7 intron 23468962 rs951557 chr3 7269035 C T 9.29E-04 Multiple complex diseases GRM7 intron 17554300 rs951557 chr3 7269035 C T 5.82E-04 Bipolar disorder,schizoaffective GRM7 intron 19567891 rs4686119 chr3 7282739 T C 6.69E-04 Type 2 diabetes GRM7 intron 17463246 rs4686119 chr3 7282739 T C 4.34E-05 Telomere length GRM7 intron 23001564 rs908465 chr3 7283715 T G 6.76E-04 Type 2 diabetes GRM7 intron 17463246 rs1605705 chr3 7290044 G A 2.18E-05 Multiple complex diseases GRM7 intron 17554300 rs4095095 chr3 7309658 G A 4.00E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 24023788 rs1876614 chr3 7321289 A G 9.74E-04 Multiple complex diseases GRM7 intron 17554300 rs7632044 chr3 7335947 C G 2.76E-04 Multiple complex diseases GRM7 intron 17554300 rs9846024 chr3 7350891 A G 8.52E-04 Multiple complex diseases GRM7 intron 17554300 rs17697853 chr3 7366195 C T 8.86E-04 Multiple complex diseases GRM7 intron 17554300 rs9990013 chr3 7366352 G T 7.96E-04 Multiple complex diseases GRM7 intron 17554300 rs6810141 chr3 7383890 T C 4.30E-04 Body mass index GRM7 intron 17255346 rs12491592 chr3 7394287 C A 2.96E-04 Common variable immunodeficiency GRM7 intron 21497890 rs13080594 chr3 7403646 C T 8.00E-07 Personality dimensions GRM7 intron 21368711 rs1499209 chr3 7418725 C T 1.90E-05 Urinary metabolites GRM7 intron 21572414 rs1499204 chr3 7437037 C G 6.30E-05 Diabetic retinopathy GRM7 intron 21441570 rs12489041 chr3 7437599 A G 5.00E-05 Diabetic retinopathy GRM7 intron 21441570 rs13066750 chr3 7438708 G A 4.70E-05 Diabetic retinopathy GRM7 intron 21441570 rs17047288 chr3 7455576 C G 4.56E-04 Alzheimer's disease GRM7 intron 17998437 rs712773 chr3 7456558 T C 4.98E-05 Longevity GRM7 intron 21612516 rs978826 chr3 7478305 C T 1.63E-04 Aortic root size GRM7 intron 21223598 rs1868616 chr3 7505487 A G 3.68E-04 Nicotine smoking GRM7 intron 19268276 rs1868616 chr3 7505487 A G 7.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) GRM7 intron 23648065 rs7623046 chr3 7510856 G A 3.55E-04 Amyotrophic Lateral Sclerosis GRM7 intron 17362836 rs779708 chr3 7512728 G A 1.56E-04 Parkinson's disease GRM7 intron 16252231 rs1391901 chr3 7517340 G A 9.51E-05 Coronary heart disease GRM7 intron pha003033 rs752300 chr3 7520084 C T 6.33E-05 Coronary heart disease GRM7 intron pha003033 rs17047422 chr3 7522152 A G 2.15E-04 Multiple complex diseases GRM7 intron 17554300 rs17047426 chr3 7522463 G A 1.85E-04 Multiple complex diseases GRM7 intron 17554300 rs9870680 chr3 7529555 C T 1.00E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs9870680 chr3 7529555 C T 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM7 intron 20877124 rs9870680 chr3 7529555 C T 0.0000837 Major depressive disorder GRM7 intron 23149448 rs9815274 chr3 7529849 A T 2.01E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs9815274 chr3 7529849 A T 6.43E-05 Major depressive disorder GRM7 intron 22472876 rs12494654 chr3 7533393 C T 2.12E-04 Multiple complex diseases GRM7 intron 17554300 rs1450100 chr3 7538202 T G 8.00E-06 Orofacial clefts GRM7 intron 22419666 rs3804945 chr3 7539974 A G 5.45E-04 Multiple complex diseases GRM7 intron 17554300 rs3804945 chr3 7539974 A G 1.93E-05 Multiple sclerosis GRM7 intron 17660530 rs1375923 chr3 7542268 C T 4.29E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs3804936 chr3 7553165 C T 6.90E-05 Orofacial clefts GRM7 intron 22419666 rs1531940 chr3 7555709 T A 1.37E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs6778646 chr3 7558907 C T 1.18E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs1106485 chr3 7562685 C G 2.25E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs779749 chr3 7576541 C T 3.51E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 17255346 rs7651961 chr3 7578273 T C 2.25E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs779746 chr3 7578531 T C 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs7652246 chr3 7578563 T G 1.99E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs6443114 chr3 7578602 A T 1.95E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs3804925 chr3 7580979 G A 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs3804925 chr3 7580979 G A 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs779742 chr3 7583058 A G 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) GRM7 intron 17982456 rs17664833 chr3 7583314 C G 1.31E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs17664833 chr3 7583314 C G 8.12E-05 Major depressive disorder GRM7 intron 21621269 rs779741 chr3 7583602 C A 1.35E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs1143740 chr3 7602077 T C 3.76E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 17255346 rs1485179 chr3 7603708 C T 6.73E-04 Alcohol dependence GRM7 intron 21314694 rs1485179 chr3 7603708 C T 7.18E-04 Smoking initiation GRM7 intron 24665060 rs17666140 chr3 7634675 G T 3.96E-05 Hypertension (early onset hypertension) GRM7 intron 22479346 rs1485171 chr3 7651185 C A 9.73E-05 Multiple complex diseases GRM7 intron 17554300 rs3792452 chr3 7666784 C T 0.000871166 Hypertension (early onset hypertension) GRM7 intron 22479346 rs3804867 chr3 7667909 C T 8.00E-04 Tourette syndrome GRM7 intron 22889924 rs1872396 chr3 7680452 A G 4.65E-05 Melanoma GRM7 intron 21926416 rs3912449 chr3 7683162 G A 6.99E-05 Melanoma GRM7 intron 21926416 rs4686148 chr3 7688662 G T 9.11E-05 Serum metabolites GRM7 intron 19043545 rs3804850 chr3 7688702 C T 2.50E-05 Urinary metabolites GRM7 intron 21572414 rs3804850 chr3 7688702 C T 4.38E-04 Non-small cell lung cancer (recurrence rate) GRM7 intron 24737549 rs9838647 chr3 7690439 A G 9.10E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs4686151 chr3 7693806 G C 9.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GRM7 intron 21844884 rs9881908 chr3 7695065 G A 3.80E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs3792439 chr3 7695640 T C 5.49E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs6782528 chr3 7721032 T A 1.37E-05 Serum metabolites GRM7 intron 19043545 rs924806 chr3 7743541 G C 1.65E-04 Multiple complex diseases GRM7 intron 17554300 rs10510371 chr3 7745206 C T 1.32E-05 Cognitive performance GRM7 intron 19734545 rs9860560 chr3 7748736 T G 5.51E-05 Stroke (ischemic) GRM7 intron 22941190 rs1504047 chr3 7748843 T G 5.51E-05 Stroke (ischemic) GRM7 intron 22941190 rs1354407 chr3 7758042 A G 5.55E-05 Stroke (ischemic) GRM7 intron 22941190 rs161885 chr3 7797492 A G 3.35E-05 Erythrocyte counts / / pha003099 rs9841316 chr3 7820659 T G 9.10E-06 Urinary metabolites / / 21572414 rs11708896 chr3 7837624 A G 6.00E-26 PR interval / / 20062060 rs6780542 chr3 7850284 T C 0.0007272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6780542 chr3 7850284 T C 7.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6443126 chr3 7851708 T G 4.00E-05 Bone mineral density (BMD),in women / / 20164292 rs161898 chr3 7856288 C A 9.44E-05 Cognitive test performance / / 20125193 rs161899 chr3 7856946 G A 7.86E-05 Body Mass Index / / pha003009 rs162216 chr3 7858048 G A 2.03E-04 Parkinson's disease / / 17052657 rs162216 chr3 7858048 G A 1.57E-06 Insulin-related traits / / 19902172 rs4686162 chr3 7858150 T C 8.80E-05 Bone mineral density (BMD),in women / / 20164292 rs162712 chr3 7865719 C T 4.15E-04 Parkinson's disease / / 17052657 rs9883082 chr3 7883963 C A 1.75E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17048056 chr3 7884798 G T 9.80E-07 Urinary metabolites / / 21572414 rs453488 chr3 7886169 C A 1.27E-05 Personality dimensions / / 22628180 rs2324413 chr3 7886455 T C 5.93E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2160954 chr3 7886502 A G 8.22E-04 Multiple complex diseases / / 17554300 rs2160954 chr3 7886502 A G 3.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2875342 chr3 7888645 T C 9.20E-07 Urinary metabolites / / 21572414 rs2875342 chr3 7888645 T C 8.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs373953 chr3 7890279 T C 1.27E-05 Personality dimensions / / 22628180 rs397592 chr3 7890939 G A 1.27E-05 Personality dimensions / / 22628180 rs399150 chr3 7891227 T G 7.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs370017 chr3 7891245 A G 1.10E-06 Urinary metabolites / / 21572414 rs7629975 chr3 7895111 G A 7.31E-05 Body Mass Index / / pha003022 rs326419 chr3 7895790 G A 8.68E-06 Personality dimensions / / 22628180 rs326417 chr3 7896492 C T 8.97E-06 Personality dimensions / / 22628180 rs326416 chr3 7897016 A G 8.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13323237 chr3 7898720 C T 9.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17740513 chr3 7902712 G A 2.20E-05 Urinary metabolites / / 21572414 rs326414 chr3 7903040 T C 4.70E-06 Urinary metabolites / / 21572414 rs1386987 chr3 7905067 G T 9.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9867817 chr3 7905524 C T 2.20E-06 Urinary metabolites / / 21572414 rs9867817 chr3 7905524 C T 7.92E-05 Body Mass Index / / pha003022 rs9829153 chr3 7905601 G A 2.10E-06 Urinary metabolites / / 21572414 rs9829153 chr3 7905601 G A 3.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs326410 chr3 7905802 A G 1.60E-05 Urinary metabolites / / 21572414 rs227 chr3 7906607 G A 2.88E-05 Acute lung injury / / 22295056 rs11720252 chr3 7907748 C T 2.40E-05 Urinary metabolites / / 21572414 rs17741012 chr3 7909163 T G 1.43E-05 Personality dimensions / / 22628180 rs10510373 chr3 7911027 G C 0.0000303 Lumbar spine bone mineral density (males) / / 22692763 rs10510373 chr3 7911027 G C 3.41E-08 Lumbar spine bone mineral density / / 22692763 rs7653216 chr3 7912970 G C 1.08E-05 Personality dimensions / / 22628180 rs438386 chr3 7913516 C T 5.59E-04 Sarcoidosis / / 19165924 rs1001254 chr3 7934333 C G 2.00E-05 Blood Phenotypes / / 17903294 rs13088386 chr3 7950430 A G 2.35E-05 Personality dimensions / / 22628180 rs10510375 chr3 7952250 C T 1.70E-14 Multiple complex diseases / / 17554300 rs10510376 chr3 7952593 A T 2.03E-05 Personality dimensions / / 22628180 rs1825924 chr3 7962284 C T 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6803927 chr3 7966137 G T 2.61E-05 Serum metabolites / / 19043545 rs6782967 chr3 7966315 C T 9.38E-04 Alzheimer's disease / / 17998437 rs17048378 chr3 7971351 A G 6.11E-04 Acute lung injury / / 22295056 rs9810651 chr3 7975633 A G 8.89E-04 Acute lung injury / / 22295056 rs2324442 chr3 7977880 A C 3.04E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4591494 chr3 7982827 T C 9.00E-06 Factor VII / / 17903294 rs4591494 chr3 7982827 T C 1.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9824002 chr3 7983000 A G 6.67E-04 Acute lung injury / / 22295056 rs3916089 chr3 7986755 C G 7.46E-04 Acute lung injury / / 22295056 rs1385437 chr3 7990493 T G 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs10510382 chr3 7997953 T C 7.96E-05 Cytomegalovirus antibody response / / 21993531 rs17048455 chr3 8017430 G C 2.04E-05 Cytomegalovirus antibody response / / 21993531 rs6769352 chr3 8018694 A G 5.05E-05 Cytomegalovirus antibody response / / 21993531 rs6780683 chr3 8018918 G A 5.04E-05 Cytomegalovirus antibody response / / 21993531 rs9985243 chr3 8020574 C T 7.24E-04 Type 2 diabetes / / 17463246 rs17048464 chr3 8022506 C T 4.30E-05 Cytomegalovirus antibody response / / 21993531 rs1385436 chr3 8024019 T G 4.29E-05 Cytomegalovirus antibody response / / 21993531 rs9859247 chr3 8030809 A G 8.45E-05 Cortisol secretion,in saliva / / 21316860 rs1485160 chr3 8031257 C T 7.51E-04 Taste perception / / 22132133 rs9834849 chr3 8039210 T C 5.36E-05 Cytomegalovirus antibody response / / 21993531 rs527498 chr3 8139779 G A 6.45E-06 Cardiovascular disease / / 18179892 rs13317787 chr3 8141952 C A 2.13E-04 Type 2 diabetes / / 17463246 rs9844587 chr3 8144234 C A 2.13E-04 Type 2 diabetes / / 17463246 rs11925840 chr3 8144902 A T 2.11E-04 Type 2 diabetes / / 17463246 rs13097609 chr3 8147718 A G 2.86E-04 Multiple complex diseases / / 17554300 rs6779176 chr3 8148696 C A 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2675247 chr3 8163253 C T 8.26E-04 Acute lung injury / / 22295056 rs1878175 chr3 8164718 G A 1.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs466663 chr3 8188766 G A 9.55E-04 Acute lung injury / / 22295056 rs320067 chr3 8194599 G A 9.26E-04 Acute lung injury / / 22295056 rs6796806 chr3 8195676 A G 3.10E-09 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs178597 chr3 8196941 C T 7.57E-04 Acute lung injury / / 22295056 rs6764798 chr3 8200271 A G 1.30E-08 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs13088606 chr3 8230904 C T 6.10E-06 Stroke (ischemic) / / 22384361 rs390783 chr3 8233002 T C 3.90E-06 Stroke (ischemic) / / 22384361 rs4684589 chr3 8239386 G A 9.80E-06 Stroke (ischemic) / / 22384361 rs6780741 chr3 8240179 A G 9.10E-06 Stroke (ischemic) / / 22384361 rs6443171 chr3 8244910 T C 2.86E-05 Basophils / / pha003087 rs9866825 chr3 8250790 A C 8.00E-06 QT interval / / 23166209 rs11131119 chr3 8256964 T C 0.000243 Salmonella-induced pyroptosis / / 22837397 rs9312006 chr3 8259491 A C,G,T 1.64E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs1873029 chr3 8266451 G A 9.80E-05 Response to lithium treatment in bipolar disorder LOC100288428 intron 19448189 rs984475 chr3 8272008 C T 1.68E-04 Multiple complex diseases LOC100288428 intron 17554300 rs2046745 chr3 8272716 C A 2.48E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1545998 chr3 8273661 G T 2.07E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1545997 chr3 8273987 T C 1.97E-04 Multiple complex diseases LOC100288428 intron 17554300 rs6762549 chr3 8274906 T C 2.61E-04 Multiple complex diseases LOC100288428 intron 17554300 rs9882964 chr3 8297505 C T 2.00E-05 Urinary metabolites LOC100288428 intron 21572414 rs2324475 chr3 8313219 G C 5.27E-04 Multiple complex diseases LOC100288428 intron 17554300 rs923381 chr3 8314924 T C 7.85E-04 Response to cytidine analogues (gemcitabine) LOC100288428 intron 24483146 rs17763297 chr3 8316110 G A 4.70E-05 Blood pressure LOC100288428 intron 21572416 rs6799462 chr3 8327085 A G 4.12E-04 Suicide attempts in bipolar disorder LOC100288428 intron 21423239 rs17048945 chr3 8330426 C T 4.20E-06 Urinary metabolites LOC100288428 intron 21572414 rs6763794 chr3 8330534 A G 4.95E-05 Serum metabolites LOC100288428 intron 19043545 rs9819127 chr3 8330829 T A 2.70E-05 Urinary metabolites LOC100288428 intron 21572414 rs4470491 chr3 8332283 C G 1.55E-05 Femoral neck bone geometry LOC100288428 intron 22087292 rs4470491 chr3 8332283 C G 9.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100288428 intron 23233662 rs10514664 chr3 8360701 G C 8.30E-04 Type 2 diabetes and 6 quantitative traits LOC100288428 intron 17848626 rs10514664 chr3 8360701 G C 1.30E-05 Urinary metabolites LOC100288428 intron 21572414 rs11712836 chr3 8375136 T C 9.62E-05 Serum metabolites LOC100288428 intron 19043545 rs359030 chr3 8403739 T C 3.51E-04 Common variable immunodeficiency LOC100288428 intron 21497890 rs2875366 chr3 8406253 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100288428 intron 22628534 rs358989 chr3 8410210 G A,T 6.57E-05 Schizophrenia LOC100288428 intron 19571811 rs9824143 chr3 8426682 T C 2.70E-05 Urinary metabolites LOC100288428 intron 21572414 rs358996 chr3 8429631 C T 7.00E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1391988 chr3 8430919 G C 7.30E-04 Multiple complex diseases LOC100288428 intron 17554300 rs359040 chr3 8438577 A G 1.60E-05 Urinary metabolites LOC100288428 intron 21572414 rs1161171 chr3 8442494 C T 7.60E-04 Type 2 diabetes and 6 quantitative traits LOC100288428 intron 17848626 rs359033 chr3 8456789 A G 8.43E-04 Type 2 diabetes LOC100288428 intron 17846125 rs1562688 chr3 8500321 G T 4.93E-05 Longevity LOC100288428 intron 21612516 rs17049174 chr3 8509497 G A 3.04E-05 Progressive supranuclear palsy LOC100288428 intron 21685912 rs7611030 chr3 8511921 A G 1.30E-05 Urinary metabolites LOC100288428 intron 21572414 rs7611030 chr3 8511921 A G 9.00E-04 Coronary heart disease LOC100288428 intron 21606135 rs11720160 chr3 8517932 T A 1.50E-05 Urinary metabolites LOC100288428 intron 21572414 rs11720160 chr3 8517932 T A 4.27E-04 Coronary heart disease LOC100288428 intron 21606135 rs17049179 chr3 8521841 T C 9.19E-04 Multiple complex diseases LOC100288428 intron 17554300 rs9882165 chr3 8548048 T A 2.60E-05 Urinary metabolites LMCD1 intron 21572414 rs6798584 chr3 8548827 G T 1.20E-05 Urinary metabolites LMCD1 intron 21572414 rs931685 chr3 8548850 G A 1.60E-05 Urinary metabolites LMCD1 intron 21572414 rs931686 chr3 8548885 T C 2.40E-05 Urinary metabolites LMCD1 intron 21572414 rs7637683 chr3 8555507 A C 1.60E-05 Urinary metabolites LMCD1 intron 21572414 rs12715650 chr3 8556784 A C 1.50E-05 Urinary metabolites LMCD1 intron 21572414 rs9312024 chr3 8561732 T C 4.40E-06 Urinary metabolites LMCD1 intron 21572414 rs1947220 chr3 8562637 A G 1.10E-05 Urinary metabolites LMCD1 intron 21572414 rs1947220 chr3 8562637 A G 5.95E-04 Smoking initiation LMCD1 intron 24665060 rs9810512 chr3 8570874 A G 2.73E-04 Smoking initiation LMCD1 intron 24665060 rs9831647 chr3 8571110 G A 1.10E-05 Urinary metabolites LMCD1 intron 21572414 rs9831647 chr3 8571110 G A 0.00000936 Preeclampsia LMCD1 intron 22748001 rs41378247 chr3 8575845 G A 7.82E-05 Type 2 diabetes LMCD1 intron 17463246 rs1027327 chr3 8606839 A G 0.00000868 Narcolepsy (non-HLA narcolepsy) LMCD1 intron 23459209 rs355136 chr3 8620012 C T 8.41E-04 Multiple complex diseases / / 17554300 rs355137 chr3 8620174 G A 7.90E-04 Multiple complex diseases / / 17554300 rs355142 chr3 8623429 C T 3.42E-04 Multiple complex diseases / / 17554300 rs3774210 chr3 8676204 A G 7.30E-05 Heart Rate C3orf32 intron pha003051 rs17049383 chr3 8680116 C T 7.08E-04 Multiple complex diseases C3orf32 intron 17554300 rs164956 chr3 8684764 A G 0.000000859 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C3orf32 intron 22628534 rs412508 chr3 8702963 A G 2.00E-05 Lung adenocarcinoma / / 19836008 rs2172557 chr3 8709205 C T 1.12E-04 Taste perception / / 22132133 rs164466 chr3 8749171 T C 7.47E-05 ldl cholesterol / / pha003076 rs12497498 chr3 8751490 G A 5.36E-04 Multiple complex diseases / / 17554300 rs1471970 chr3 8765024 A G 1.18E-04 Multiple complex diseases / / 17554300 rs237872 chr3 8780438 C T 2.50E-04 HDL particle features CAV3 intron 21283740 rs11706648 chr3 8796547 A C 6.60E-04 Asthma OXTR intron 20698975 rs2268490 chr3 8797085 C T 4.95E-05 Coronary heart disease OXTR intron pha003033 rs2268492 chr3 8800672 C T 6.42E-05 Cholesterol OXTR intron pha003078 rs2268495 chr3 8807535 G A 5.10E-06 Urinary metabolites OXTR intron 21572414 rs237899 chr3 8808515 G A 2.20E-04 Alcohol dependence OXTR intron 20201924 rs237899 chr3 8808515 G A 2.00E-06 Depression and alcohol dependence OXTR intron 22064162 rs17049528 chr3 8812862 G A 8.40E-05 Cholesterol OXTR nearGene-5 17255346 rs1488467 chr3 8813231 G C 9.97E-05 Cholesterol OXTR nearGene-5 17255346 rs6790467 chr3 8826023 A G 8.66E-05 Asthma / / pha003127 rs6793234 chr3 8826396 A G 6.86E-06 Osteoarthritis / / 22763110 rs9844525 chr3 8834445 G A 1.00E-04 Information processing speed / / 21130836 rs2544163 chr3 8854367 T C 2.76E-05 Alzheimer's disease (late onset) / / 21379329 rs2544163 chr3 8854367 T C 1.21E-05 Coronary heart disease / / pha003031 rs345069 chr3 8856126 T C 4.96E-04 Coronary heart disease / / 21606135 rs345067 chr3 8856500 T C 7.36E-04 Type 2 diabetes / / 17463246 rs173182 chr3 8858201 T C 8.85E-04 Type 2 diabetes / / 17463246 rs345065 chr3 8862925 T C 3.52E-05 Asthma / / pha003128 rs124844 chr3 8881649 A G 3.30E-06 Alzheimer's disease (late onset) / / 21379329 rs83622 chr3 8881713 T G 1.88E-04 Alzheimer's disease (late onset) / / 21379329 rs2270474 chr3 8883040 T C 4.11E-04 Coronary Artery Disease / / 17634449 rs9867782 chr3 8884204 G A 3.26E-05 Alzheimer's disease (late onset) / / 21379329 rs7632085 chr3 8890021 A G 6.27E-06 Alzheimer's disease (late onset) / / 21379329 rs11706378 chr3 8905524 C T 1.58E-04 Multiple complex diseases / / 17554300 rs11706378 chr3 8905524 C T 3.53E-04 Depression (quantitative trait) / / 20800221 rs9816708 chr3 8906295 C T 6.90E-04 Multiple complex diseases / / 17554300 rs11715042 chr3 8906866 G A 1.99E-04 Depression (quantitative trait) / / 20800221 rs17734025 chr3 8911347 T G 1.98E-04 Depression (quantitative trait) / / 20800221 rs658339 chr3 8932353 A G 7.68E-04 Suicide attempts in bipolar disorder RAD18 intron 21041247 rs250411 chr3 8942437 C G 9.00E-06 Personality dimensions RAD18 intron 18957941 rs373090 chr3 8942606 G T 7.00E-06 Personality dimensions RAD18 intron 18957941 rs11707481 chr3 8954385 G A 6.80E-05 Height RAD18 intron 21998595 rs7622068 chr3 8970377 T G 1.54E-04 Response to cytadine analogues (cytosine arabinoside) RAD18 intron 24483146 rs583509 chr3 9032897 T A 2.60E-05 Urinary metabolites SRGAP3 intron 21572414 rs413789 chr3 9034145 T G 3.42E-04 Amyotrophic Lateral Sclerosis SRGAP3 intron 17362836 rs487865 chr3 9041094 G C 1.90E-05 Urinary metabolites SRGAP3 intron 21572414 rs487865 chr3 9041094 G C 7.00E-04 Breast cancer (survival) SRGAP3 intron 22232737 rs486012 chr3 9041299 T C 9.90E-06 Urinary metabolites SRGAP3 intron 21572414 rs486012 chr3 9041299 T C 9.14E-05 Smoking quantity SRGAP3 intron 24665060 rs666743 chr3 9041346 T C 8.20E-04 Coronary heart disease SRGAP3 intron 21606135 rs571701 chr3 9041687 T C 1.70E-05 Urinary metabolites SRGAP3 intron 21572414 rs341795 chr3 9046906 T A 2.10E-05 Urinary metabolites SRGAP3 intron 21572414 rs1161765 chr3 9048152 A G 7.31E-04 Coronary heart disease SRGAP3 intron 21606135 rs341789 chr3 9050155 C G 8.18E-04 Multiple complex diseases SRGAP3 intron 17554300 rs341788 chr3 9050659 C T 9.31E-04 Coronary heart disease SRGAP3 intron 21606135 rs383563 chr3 9052494 A G 1.70E-05 Urinary metabolites SRGAP3 intron 21572414 rs399747 chr3 9052506 G T 1.30E-05 Urinary metabolites SRGAP3 intron 21572414 rs17798894 chr3 9061714 T G 9.23E-04 Multiple complex diseases SRGAP3 intron 17554300 rs1513315 chr3 9072286 T C 3.55E-04 Insulin resistance SRGAP3 intron 21901158 rs7617156 chr3 9072878 T C 6.26E-05 Triglycerides SRGAP3 intron pha003080 rs884237 chr3 9079896 T C 2.44E-04 Fibrinogen SRGAP3 intron 17255346 rs639952 chr3 9080714 T C 6.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SRGAP3 intron 20031582 rs2662090 chr3 9091946 T G 3.00E-04 Suicidal ideation SRGAP3 intron 22030708 rs2662090 chr3 9091946 T G 9.95E-05 Glucose levels SRGAP3 intron pha002899 rs2664095 chr3 9099653 T C 4.50E-07 Urinary metabolites SRGAP3 intron 21572414 rs2669989 chr3 9120004 T C 1.75E-04 Tourette syndrome SRGAP3 intron 22889924 rs17050039 chr3 9157737 A C 8.42E-04 Taste perception SRGAP3 intron 22132133 rs17050048 chr3 9160213 G A 7.39E-05 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs12634676 chr3 9164440 G C 3.88E-05 Odorant perception SRGAP3 intron 23910658 rs2675187 chr3 9179971 C A 5.00E-04 Stroke SRGAP3 intron pha002886 rs2675186 chr3 9193324 T C 6.08E-04 Multiple complex diseases SRGAP3 intron 17554300 rs2543499 chr3 9194156 A G 5.82E-04 Multiple complex diseases SRGAP3 intron 17554300 rs17530358 chr3 9200375 G A 3.80E-04 Alcohol dependence SRGAP3 intron 24277619 rs17530358 chr3 9200375 G A 5.79E-05 Coronary heart disease SRGAP3 intron pha003031 rs2664108 chr3 9207125 A G 1.07E-04 Lung function (forced vital capacity) SRGAP3 intron 24023788 rs386011 chr3 9214397 A T 2.97E-05 Serum metabolites SRGAP3 intron 19043545 rs446975 chr3 9217383 G T 1.72E-04 Premature ovarian failure SRGAP3 intron 19508998 rs446975 chr3 9217383 G T 7.38E-05 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs10490820 chr3 9230006 G A 1.66E-04 Insulin resistance SRGAP3 intron 21901158 rs6765880 chr3 9232109 T C 2.00E-05 Urinary metabolites SRGAP3 intron 21572414 rs1145153 chr3 9234763 C T 8.04E-05 Coronary heart disease SRGAP3 intron pha003031 rs9819189 chr3 9251198 T C 6.27E-04 Myopia (pathological) SRGAP3 intron 21095009 rs9819189 chr3 9251198 T C 1.25E-04 Lung function (forced expiratory volume in 1 second) SRGAP3 intron 24023788 rs9819189 chr3 9251198 T C 1.54E-04 Lung function (forced vital capacity) SRGAP3 intron 24023788 rs12638703 chr3 9252998 C T 3.53E-06 Interstitial lung disease SRGAP3 intron 23583980 rs4684627 chr3 9256398 T C 1.45E-05 Amyotrophic lateral sclerosis SRGAP3 intron 20801717 rs4684627 chr3 9256398 T C 0.000038 Amyotrophic lateral sclerosis SRGAP3 intron 23587638 rs1154398 chr3 9258218 A G 1.00E-04 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs9853725 chr3 9273196 T C 8.81E-04 Myopia (pathological) SRGAP3 intron 21095009 rs1186291 chr3 9274570 A T 3.55E-04 Multiple complex diseases SRGAP3 intron 17554300 rs4684630 chr3 9287144 C A 3.48E-04 Nicotine smoking SRGAP3 intron 19268276 rs2137216 chr3 9288545 T C 9.80E-05 Major depressive disorder SRGAP3 intron 21042317 rs11131163 chr3 9291861 A G 3.76E-05 Amyotrophic lateral sclerosis / / 20801717 rs2600175 chr3 9294880 C T 0.000593 Salmonella-induced pyroptosis / / 22837397 rs4686337 chr3 9311215 A T 1.90E-04 Multiple complex diseases / / 17554300 rs2600163 chr3 9312283 G A 6.49E-05 Smoking initiation / / 24665060 rs4686340 chr3 9345218 A C 1.00E-06 Hypertension / / 22384028 rs17050220 chr3 9350167 C A 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17802092 chr3 9359037 G T 9.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs3930151 chr3 9373721 T C 5.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10510398 chr3 9374170 T C 8.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4053784 chr3 9374648 C G 9.76E-05 Cytomegalovirus antibody response / / 21993531 rs2600169 chr3 9375147 C T 9.38E-05 Alzheimer's disease (late onset) / / 21379329 rs2728945 chr3 9418510 A G 8.42E-04 Body mass index THUMPD3 intron 21701565 rs2596917 chr3 9421024 C T 9.73E-05 Alzheimer's disease (late onset) THUMPD3 intron 21379329 rs2600193 chr3 9425743 A G 9.97E-05 Alzheimer's disease (late onset) THUMPD3 intron 21379329 rs6443238 chr3 9449055 C T 5.10E-08 Alcohol dependence SETD5 intron 22096494 rs11915826 chr3 9451377 T A 2.60E-05 Response to statin therapy SETD5 intron 20339536 rs4258956 chr3 9455051 T A 2.70E-05 Response to statin therapy SETD5 intron 20339536 rs11922615 chr3 9458307 A G 2.60E-08 Alcohol dependence SETD5 intron 22096494 rs4078527 chr3 9463688 A G 3.00E-05 Response to statin therapy SETD5 intron 20339536 rs3872706 chr3 9464092 A G 3.20E-05 Response to statin therapy SETD5 intron 20339536 rs7613389 chr3 9473202 A C 2.72E-04 Coronary Artery Disease SETD5 intron 17634449 rs7613389 chr3 9473202 A C 7.10E-05 Response to statin therapy SETD5 intron 20339536 rs3912330 chr3 9474061 A G 7.20E-05 Response to statin therapy SETD5 intron 20339536 rs17050346 chr3 9481593 A G 7.40E-05 Response to statin therapy SETD5 intron 20339536 rs6803966 chr3 9486503 G A 7.70E-05 Response to statin therapy SETD5 intron 20339536 rs2290164 chr3 9487148 T C 9.10E-05 Response to statin therapy SETD5 intron 20339536 rs7617427 chr3 9499448 A G 4.14E-04 Coronary Artery Disease SETD5 intron 17634449 rs7628780 chr3 9635563 G A 3.40E-04 Multiple complex diseases / / 17554300 rs6809387 chr3 9702755 A G 5.85E-04 Multiple complex diseases MTMR14 intron 17554300 rs3868041 chr3 9706177 A G 1.07E-04 Multiple complex diseases MTMR14 intron 17554300 rs12493353 chr3 9710307 T C 2.34E-04 Multiple complex diseases MTMR14 intron 17554300 rs10510414 chr3 9716403 A T 9.62E-05 Multiple complex diseases MTMR14 intron 17554300 rs4686369 chr3 9722566 G A 3.84E-04 Multiple complex diseases MTMR14 intron 17554300 rs159142 chr3 9730868 G C 5.11E-04 Suicide attempts in bipolar disorder MTMR14 intron 21423239 rs11131183 chr3 9735683 G A 2.60E-04 Multiple complex diseases MTMR14 intron 17554300 rs12490544 chr3 9736452 C G 6.83E-04 Multiple complex diseases MTMR14 intron 17554300 rs468056 chr3 9748636 A G 3.03E-05 Cytomegalovirus antibody response CPNE9 intron 21993531 rs293782 chr3 9819922 A C 2.80E-04 Coronary heart disease / / 21966275 rs11711241 chr3 9831970 T G 4.31E-04 Multiple complex diseases TADA3 intron 17554300 rs9879307 chr3 9870065 C T 0.0000012 Child behavior checklist/1.5-5 total problems TTLL3 intron 23049896 rs4686377 chr3 9877452 G A 6.40E-04 Type 2 diabetes TTLL3 UTR-3 17463246 rs279565 chr3 9898280 A C 3.74E-04 Stroke (pediatric) / / 22990015 rs1053239 chr3 9908749 G C 4.50E-06 Speech perception in dyslexia CIDEC UTR-3 19786962 rs17222564 chr3 9910334 T C 6.72E-04 Multiple complex diseases CIDEC intron 17554300 rs279553 chr3 9934605 T C 3.00E-05 Suicidal ideation JAGN1 cds-synon 22030708 rs279542 chr3 9935773 C G 3.00E-05 Suicidal ideation JAGN1 UTR-3 22030708 rs12053867 chr3 9939828 G A 2.86E-04 Schizophrenia / / 20832056 rs279545 chr3 9972493 G A 1.10E-04 Endometriosis IL17RC intron 21151130 rs279545 chr3 9972493 G A 2.98E-04 Alzheimer's disease IL17RC intron 24755620 rs34233937 chr3 9989107 C T 1.16E-05 Orofacial clefts PRRT3 missense 22419666 rs17050660 chr3 10001772 C T 1.33E-05 Alzheimer's disease / / 24755620 rs13063929 chr3 10010308 T C 1.55E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732968 chr3 10013273 A G 1.55E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732967 chr3 10015437 T C 1.54E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732966 chr3 10015740 C T 7.23E-06 Alzheimer's disease TMEM111 intron 24755620 rs7633769 chr3 10020622 C T 1.72E-05 Alzheimer's disease TMEM111 intron 24755620 rs3755783 chr3 10029289 A G 9.79E-06 Alzheimer's disease LOC442075 intron 24755620 rs13089863 chr3 10032259 T G 2.19E-05 Alzheimer's disease LOC442075 intron 24755620 rs13066757 chr3 10045030 C A 2.19E-05 Alzheimer's disease / / 24755620 rs6804473 chr3 10060425 C T 9.63E-05 Alzheimer's disease (late onset) CIDECP intron 21379329 rs6804473 chr3 10060425 C T 6.45E-06 Alzheimer's disease CIDECP intron 24755620 rs7611218 chr3 10063960 T C 5.12E-06 Alzheimer's disease CIDECP intron 24755620 rs3846177 chr3 10068572 G T 6.03E-06 Alzheimer's disease FANCD2 intron 24755620 rs7648104 chr3 10073311 C A 6.41E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032278 chr3 10077955 A G 6.41E-06 Alzheimer's disease FANCD2 intron 24755620 rs6442147 chr3 10078247 A G 4.73E-06 Alzheimer's disease FANCD2 intron 24755620 rs7631678 chr3 10078816 T G 6.61E-06 Alzheimer's disease FANCD2 intron 24755620 rs7637888 chr3 10080722 T C 6.61E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032283 chr3 10081545 G C 7.51E-06 Alzheimer's disease FANCD2 intron 24755620 rs9875081 chr3 10083935 G A 2.96E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs9875081 chr3 10083935 G A 1.03E-05 Alzheimer's disease FANCD2 intron 24755620 rs35625434 chr3 10084828 G A 0.00036 Prostate cancer FANCD2 missense 23555315 rs17032295 chr3 10086680 G A 1.81E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs17032295 chr3 10086680 G A 7.24E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032299 chr3 10087638 C T 7.03E-06 Alzheimer's disease FANCD2 intron 24755620 rs35782247 chr3 10089689 T G 2.39E-09 LDL cholesterol FANCD2 missense 23063622 rs7615646 chr3 10089773 A C,G 3.18E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs7615646 chr3 10089773 A C,G 7.08E-06 Alzheimer's disease FANCD2 intron 24755620 rs6781811 chr3 10121922 C T 4.62E-06 Alzheimer's disease FANCD2 intron 24755620 rs6442150 chr3 10122575 T C 5.40E-06 Alzheimer's disease FANCD2 intron 24755620 rs6789156 chr3 10124120 G A 5.77E-06 Alzheimer's disease FANCD2 intron 24755620 rs6791810 chr3 10124444 C T 5.18E-06 Alzheimer's disease FANCD2 intron 24755620 rs13319597 chr3 10126312 G T 5.42E-06 Alzheimer's disease FANCD2 intron 24755620 rs34632086 chr3 10133478 T C 3.00E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs34632086 chr3 10133478 T C 1.95E-06 Alzheimer's disease FANCD2 intron 24755620 rs9849434 chr3 10133710 G A 1.88E-06 Alzheimer's disease FANCD2 intron 24755620 rs9811771 chr3 10133949 A G 1.88E-06 Alzheimer's disease FANCD2 intron 24755620 rs12374115 chr3 10134766 C T 2.22E-06 Alzheimer's disease FANCD2 intron 24755620 rs1552244 chr3 10135577 A G 4.37E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs1552244 chr3 10135577 A G 2.00E-06 Alzheimer's disease FANCD2 intron 24755620 rs2272125 chr3 10138069 T G 4.44E-06 Alzheimer's disease FANCD2 cds-synon 24755620 rs2272124 chr3 10138189 T C 4.44E-06 Alzheimer's disease FANCD2 intron 24755620 rs2272123 chr3 10140115 G A 4.35E-06 Alzheimer's disease FANCD2 intron 24755620 rs7626117 chr3 10140671 G A 7.17E-05 Alzheimer's disease FANCD2 UTR-3 24755620 rs7647987 chr3 10140696 A G 4.60E-06 Alzheimer's disease FANCD2 UTR-3 24755620 rs12152512 chr3 10143770 C T 5.13E-06 Alzheimer's disease C3orf24 intron 24755620 rs7652935 chr3 10151138 T C 5.32E-06 Alzheimer's disease / / 24755620 rs41520445 chr3 10153141 G T 5.32E-06 Alzheimer's disease / / 24755620 rs17032396 chr3 10153559 G A 5.86E-06 Alzheimer's disease / / 24755620 rs6764068 chr3 10153842 A G 6.04E-06 Alzheimer's disease / / 24755620 rs17032414 chr3 10158302 C G 6.26E-06 Alzheimer's disease BRK1 intron 24755620 rs3774208 chr3 10164722 T G 9.57E-04 Alzheimer's disease BRK1 intron 24755620 rs713024 chr3 10181240 A G 2.30E-04 Lymphocyte counts / / 22286170 rs779803 chr3 10182562 G A 1.10E-05 Urinary metabolites VHL nearGene-5 21572414 rs457414 chr3 10202884 C A 1.83E-20 Lymphocyte counts / / 22286170 rs6779158 chr3 10203562 A G 4.31E-09 HDL cholesterol / / 23063622 rs3844278 chr3 10211918 C T 9.46E-05 Cognitive impairment induced by topiramate IRAK2 intron 22091778 rs11465886 chr3 10250783 A G 0.00041 Coronary artery calcification IRAK2 intron 23727086 rs2302862 chr3 10258493 T C 1.12E-04 Attention deficit hyperactivity disorder IRAK2 intron 22420046 rs2302862 chr3 10258493 T C 3.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) IRAK2 intron 23648065 rs778041 chr3 10272181 T G 3.99E-05 Lymphocyte counts IRAK2 intron 22286170 rs11926277 chr3 10277463 G A 4.33E-05 Bipolar disorder IRAK2 intron 22925353 rs11706450 chr3 10277866 T C 7.86E-05 Systemic sclerosis IRAK2 intron 21750679 rs11711184 chr3 10278980 A C 5.50E-05 Bipolar disorder IRAK2 intron 22925353 rs11707074 chr3 10292643 C T 7.12E-04 Alcohol dependence TATDN2 intron 21314694 rs2241312 chr3 10301300 A G 3.57E-04 Alcohol dependence TATDN2 intron 21314694 rs3732950 chr3 10334981 G A 0.000000559 Triglycerides / / 23063622 rs2619507 chr3 10335786 A G 3.83E-04 Type 2 diabetes GHRL nearGene-5 17463246 rs1629816 chr3 10336291 G A 2.20E-05 Urinary metabolites GHRL nearGene-5 21572414 rs696220 chr3 10344111 G A 1.10E-05 Urinary metabolites SEC13 intron 21572414 rs35668 chr3 10351830 G A 7.06E-05 Prion diseases SEC13 intron 22210626 rs154238 chr3 10355584 C G 7.26E-05 Serum metabolites SEC13 intron 19043545 rs1719571 chr3 10369180 A G 5.05E-04 Coronary heart disease ATP2B2 UTR-3 21606135 rs697973 chr3 10388902 G A 6.43E-05 Blood Pressure ATP2B2 intron pha003050 rs775018 chr3 10400145 A G 9.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs28113 chr3 10400643 G A 6.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs775022 chr3 10404739 C A 3.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1658704 chr3 10407045 G C 1.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs4684684 chr3 10411344 C T 4.19E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1473183 chr3 10411827 G A 7.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs2289272 chr3 10413526 G A 3.46E-04 Type 2 diabetes ATP2B2 cds-synon 17463246 rs2289273 chr3 10413601 G A 1.60E-05 Schizophrenia(treatment response to risperidone) ATP2B2 cds-synon 19850283 rs6442165 chr3 10415108 T G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs26796 chr3 10415314 G A 1.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1438168 chr3 10437280 T C 5.57E-04 Smoking initiation ATP2B2 intron 24665060 rs1438168 chr3 10437280 T C 2.82E-06 Body mass index ATP2B2 intron 24827717 rs17032820 chr3 10442539 A G 6.19E-04 Alzheimer's disease ATP2B2 intron 24755620 rs759692 chr3 10443000 C T 1.58E-04 Response to taxane treatment (placlitaxel) ATP2B2 intron 23006423 rs11710165 chr3 10443090 A C 4.77E-05 Cholesterol ATP2B2 intron pha003073 rs11710165 chr3 10443090 A C 7.43E-05 Cholesterol ATP2B2 intron pha003078 rs9839685 chr3 10448340 T C 9.53E-04 Multiple complex diseases ATP2B2 intron 17554300 rs6786239 chr3 10448772 C T 1.42E-04 Cocaine dependence ATP2B2 intron 23958962 rs6786239 chr3 10448772 C T 3.30E-06 Cocaine dependence ATP2B2 intron 23958962 rs34907 chr3 10452231 G A 2.51E-04 Taste perception ATP2B2 intron 22132133 rs34918 chr3 10460174 G A 4.21E-05 Cholesterol ATP2B2 intron pha003073 rs34918 chr3 10460174 G A 4.46E-05 Cholesterol ATP2B2 intron pha003078 rs11707511 chr3 10463507 G A 9.47E-05 Response to taxane treatment (placlitaxel) ATP2B2 intron 23006423 rs523180 chr3 10470828 C T 7.96E-05 Cholesterol ATP2B2 intron pha003073 rs523180 chr3 10470828 C T 6.78E-05 Cholesterol ATP2B2 intron pha003078 rs17032876 chr3 10470911 G A 8.83E-04 Multiple complex diseases ATP2B2 intron 17554300 rs929707 chr3 10477026 T C 8.62E-04 Stroke ATP2B2 intron pha002887 rs17603886 chr3 10484726 C T 7.00E-06 Amyotrophic lateral sclerosis (sporadic) ATP2B2 intron 24529757 rs3774135 chr3 10489487 C T 7.20E-04 Multiple complex diseases ATP2B2 intron 17554300 rs34872 chr3 10508495 T C 4.65E-05 Alzheimer's disease (age of onset) ATP2B2 intron 22005931 rs17032984 chr3 10529069 G T 0.0000459 Salmonella-induced pyroptosis ATP2B2 intron 22837397 rs799320 chr3 10533302 G T 7.70E-04 Smoking initiation ATP2B2 intron 24665060 rs6807064 chr3 10535771 C T 1.00E-07 Metabolite levels ATP2B2 intron 19043545 rs6442177 chr3 10573967 A G 2.80E-04 Multiple complex diseases / / 17554300 rs6442180 chr3 10588012 T C 9.32E-04 Multiple complex diseases / / 17554300 rs6796050 chr3 10602685 C T 4.17E-04 Acute lung injury / / 22295056 rs17509502 chr3 10605733 C T 6.51E-04 Acute lung injury / / 22295056 rs4572750 chr3 10605861 C A 6.09E-04 Acute lung injury / / 22295056 rs7629483 chr3 10611507 A G 3.29E-04 Acute lung injury / / 22295056 rs4684713 chr3 10617557 A T 5.32E-04 Acute lung injury / / 22295056 rs6803992 chr3 10622941 A C 8.07E-04 Multiple complex diseases / / 17554300 rs11920105 chr3 10627684 G T 6.80E-06 Type 2 diabetes / / 21573907 rs17033143 chr3 10630258 G A 9.20E-05 Tunica Media / / pha003037 rs4234503 chr3 10632679 C T 0.000000509 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs4234503 chr3 10632679 C T 1.95E-08 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs4234503 chr3 10632679 C T 1.95E-08 Airflow obstruction / / 22837378 rs9822272 chr3 10642523 A G 7.66E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9822272 chr3 10642523 A G 4.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17033198 chr3 10645143 T C 2.45E-04 Multiple complex diseases / / 17554300 rs6772499 chr3 10658014 A G 4.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17033245 chr3 10661289 C T 1.86E-06 Erythrocyte counts / / pha003090 rs9880149 chr3 10686437 G A 2.51E-09 Narcolepsy / / 19629137 rs892601 chr3 10732548 A C 3.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs1682825 chr3 10774759 C T 4.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs171239 chr3 10780817 T C 1.02E-06 Cognitive impairment induced by topiramate / / 22091778 rs13059249 chr3 10780904 A G 2.40E-05 Urinary metabolites / / 21572414 rs9830378 chr3 10784877 A G 2.34E-04 Multiple complex diseases / / 17554300 rs350665 chr3 10785012 C T 4.86E-04 Coronary heart disease / / 21971053 rs7627250 chr3 10785091 T C 1.44E-04 Multiple complex diseases / / 17554300 rs3900076 chr3 10801251 C T 5.99E-04 Multiple complex diseases / / 17554300 rs13078886 chr3 10801693 C A 4.54E-04 Multiple complex diseases / / 17554300 rs2581204 chr3 10815485 C T 8.90E-04 Stroke / / pha002886 rs2596834 chr3 10820067 C T 9.03E-04 Response to TNF antagonist treatment / / 21061259 rs2596834 chr3 10820067 C T 4.48E-04 Coronary heart disease / / 21971053 rs9835411 chr3 10873434 C T 1.42E-04 Multiple complex diseases SLC6A11 intron 17554300 rs1809529 chr3 10877611 C T 3.00E-07 Response to tocilizumab in rheumatoid arthritis SLC6A11 intron 22491018 rs999448 chr3 10902353 G A 3.83E-04 Tourette syndrome SLC6A11 intron 22889924 rs3774084 chr3 10958276 T C 6.50E-06 Alcohol dependence SLC6A11 intron 22096494 rs4684746 chr3 10966588 A G 1.94E-04 Substance dependence SLC6A11 intron 21818250 rs1881370 chr3 10974156 C T 9.66E-05 Multiple complex diseases SLC6A11 intron 17554300 rs751960 chr3 11016323 A G 7.90E-04 Multiple complex diseases / / 17554300 rs2930149 chr3 11021097 C T 9.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs1710885 chr3 11038807 T C 3.19E-05 Major depressive disorder SLC6A1 intron 19107115 rs1710887 chr3 11039960 T G 6.70E-04 Coronary heart disease SLC6A1 intron 21606135 rs9990174 chr3 11040439 G T 6.00E-06 Conduct disorder (interaction) SLC6A1 intron 18846501 rs1919075 chr3 11043019 G A 7.13E-04 Response to TNF antagonist treatment SLC6A1 intron 21061259 rs1710891 chr3 11049133 C T 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC6A1 intron 20877124 rs6778281 chr3 11053517 C A 7.52E-05 Attention deficit hyperactivity disorder SLC6A1 intron 20732625 rs2928079 chr3 11055114 A T 6.62E-04 Alzheimer's disease SLC6A1 intron 17998437 rs1170695 chr3 11055338 A G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC6A1 intron 20877124 rs2950798 chr3 11062934 G A 6.83E-04 Schizophrenia SLC6A1 intron 19197363 rs17033829 chr3 11065807 A C 5.53E-04 Amyotrophic Lateral Sclerosis SLC6A1 intron 17362836 rs17033829 chr3 11065807 A C 9.76E-05 Cognitive test performance SLC6A1 intron 20125193 rs9879137 chr3 11066388 T C 3.31E-04 Multiple complex diseases SLC6A1 intron 17554300 rs2675163 chr3 11075014 C T 6.00E-06 Response to Vitamin E supplementation SLC6A1 intron 22437554 rs2675163 chr3 11075014 C T 6.58E-05 Platelet counts SLC6A1 intron pha003100 rs11128537 chr3 11092828 C T 7.21E-04 Schizophrenia / / 21747397 rs7615791 chr3 11124925 T C 3.53E-05 Prion diseases / / 22210626 rs4684758 chr3 11139579 G A 0.00039 Breast cancer early age of onset / / 18463975 rs4593010 chr3 11164415 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17034071 chr3 11211338 C T 1.50E-05 Urinary metabolites HRH1 intron 21572414 rs4684059 chr3 11232779 G C 8.00E-06 IgG glycosylation HRH1 intron 23382691 rs9822871 chr3 11239366 C T 6.31E-05 Alcohol dependence HRH1 intron 21703634 rs12493961 chr3 11244825 A G 4.49E-04 Suicide attempts in bipolar disorder HRH1 intron 21041247 rs433303 chr3 11244906 C T 1.72E-06 Alcohol dependence HRH1 intron 20202923 rs433303 chr3 11244906 C T 6.90E-04 Alcohol dependence HRH1 intron 21956439 rs443137 chr3 11253721 G A 1.80E-05 Alcohol dependence HRH1 intron 21703634 rs55748939 chr3 11257378 C T 0.00007801 Sarcoidosis HRH1 intron 22952805 rs440646 chr3 11291171 G T 4.40E-05 Type 2 diabetes HRH1 intron 17463249 rs440646 chr3 11291171 G T 4.42E-05 Multiple complex diseases HRH1 intron 17554300 rs346078 chr3 11327840 G C 1.20E-04 Multiple complex diseases ATG7 intron 17554300 rs2594995 chr3 11369117 G A 4.06E-04 Nicotine dependence ATG7 intron 17158188 rs2606747 chr3 11374955 T C,G 6.67E-04 Nicotine dependence ATG7 intron 17158188 rs2594978 chr3 11383347 C A 4.13E-04 Nicotine dependence ATG7 intron 17158188 rs2606742 chr3 11391717 G A 5.80E-04 Nicotine dependence ATG7 intron 17158188 rs2606736 chr3 11400249 C T 5.00E-08 HDL cholesterol ATG7 intron 24097068 rs7621218 chr3 11442013 C T 3.27E-04 Type 2 diabetes ATG7 intron 17463246 rs9874535 chr3 11463730 A G 5.47E-04 Type 2 diabetes ATG7 intron 17463246 rs7623889 chr3 11477387 C T 8.57E-04 Suicide attempts in bipolar disorder ATG7 intron 21041247 rs9818393 chr3 11509668 C T 1.52E-04 Obesity (extreme) ATG7 intron 21935397 rs4684782 chr3 11518755 T C 6.26E-04 Type 2 diabetes ATG7 intron 17463246 rs17536147 chr3 11559102 G C 4.91E-04 Multiple complex diseases ATG7 intron 17554300 rs6442260 chr3 11590751 G A 8.69E-04 Type 2 diabetes ATG7 intron 17463246 rs7617620 chr3 11600563 C T 1.59E-05 Coronary heart disease VGLL4 intron pha003030 rs7617187 chr3 11605944 G C 1.46E-04 Obesity (extreme) VGLL4 intron 21935397 rs2574706 chr3 11615207 T C 3.00E-04 Cognitive decline VGLL4 intron 23732972 rs2004837 chr3 11617308 A G 5.56E-04 Type 2 diabetes VGLL4 intron 17463246 rs2077507 chr3 11618468 A G 7.24E-04 Type 2 diabetes VGLL4 intron 17463246 rs892932 chr3 11624211 C A 1.18E-04 Type 2 diabetes VGLL4 intron 17463246 rs892932 chr3 11624211 C A 2.92E-05 Bipolar disorder VGLL4 intron 19488044 rs892932 chr3 11624211 C A 6.66E-05 Bipolar Disorder VGLL4 intron pha002863 rs6802119 chr3 11625414 C T 2.00E-06 Metabolite levels (HVA) VGLL4 intron 23319000 rs6802119 chr3 11625414 C T 8.00E-06 Metabolite levels (HVA-5-HIAA Factor score) VGLL4 intron 23319000 rs2574726 chr3 11627978 G A 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VGLL4 intron 20877124 rs17776482 chr3 11633951 G A 3.04E-04 Alzheimer's disease VGLL4 intron 17998437 rs6780175 chr3 11638519 G C,T 1.70E-07 Urinary metabolites VGLL4 intron 21572414 rs6772112 chr3 11641535 C T 8.30E-07 Urinary metabolites VGLL4 intron 21572414 rs2574704 chr3 11655381 T C 7.22E-04 Schizophrenia VGLL4 intron 19197363 rs2574720 chr3 11660412 A C 9.88E-04 Multiple complex diseases VGLL4 intron 17554300 rs2574717 chr3 11661280 G T 8.31E-04 Multiple complex diseases VGLL4 intron 17554300 rs9871522 chr3 11663976 A G 5.00E-05 Information processing speed VGLL4 intron 21130836 rs6766610 chr3 11664859 C A 5.20E-04 Multiple complex diseases VGLL4 intron 17554300 rs6766610 chr3 11664859 C A 7.60E-05 Serum metabolites VGLL4 intron 19043545 rs2574713 chr3 11666874 G A 3.25E-05 Serum metabolites VGLL4 intron 19043545 rs6807423 chr3 11669548 A G 2.50E-06 Urinary metabolites VGLL4 intron 21572414 rs2447613 chr3 11670573 A G 2.36E-05 Serum metabolites VGLL4 intron 19043545 rs6781822 chr3 11675632 T C 2.92E-04 Obesity (extreme) VGLL4 intron 21935397 rs6782029 chr3 11675789 T C 9.00E-06 Anorexia nervosa VGLL4 intron 21079607 rs6782029 chr3 11675789 T C 3.30E-04 Alzheimer's disease (late onset) VGLL4 intron 21379329 rs13075818 chr3 11686389 G C 6.91E-04 Multiple complex diseases VGLL4 intron 17554300 rs17034986 chr3 11693869 A C 9.87E-05 Parent of origin effect on language impairment (maternal) VGLL4 intron 24571439 rs4684792 chr3 11694467 T C 9.00E-06 Relative hand skill in reading disability VGLL4 intron 24068947 rs12374138 chr3 11698796 G A 2.64E-04 Multiple complex diseases VGLL4 intron 17554300 rs11715990 chr3 11703635 G A 4.32E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs4444693 chr3 11704885 T A 4.01E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs3846116 chr3 11706197 G C 3.09E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs7644580 chr3 11721793 T C 6.28E-05 Serum metabolites VGLL4 intron 19043545 rs9854973 chr3 11727998 C T 3.77E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs1039200 chr3 11730846 C A 8.76E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs9835698 chr3 11736267 A G 5.26E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs7619252 chr3 11737145 C T 2.18E-04 Multiple complex diseases VGLL4 intron 17554300 rs7619252 chr3 11737145 C T 8.16E-05 Type 1 diabetes VGLL4 intron 18978792 rs370234 chr3 11785147 T C 2.25E-05 Insulin Resistance / / pha003062 rs370234 chr3 11785147 T C 2.31E-05 Insulin-related traits / / pha003063 rs392621 chr3 11886365 T C 6.77E-04 Type 2 diabetes TAMM41 intron 17463246 rs392621 chr3 11886365 T C 5.44E-04 Multiple complex diseases TAMM41 intron 17554300 rs392621 chr3 11886365 T C 1.57E-09 Lymphocyte counts TAMM41 intron 22286170 rs392621 chr3 11886365 T C 1.02E-04 Smoking quantity TAMM41 intron 24665060 rs440746 chr3 11888556 G T 2.97E-04 Type 2 diabetes / / 17463246 rs440746 chr3 11888556 G T 8.23E-04 Multiple complex diseases / / 17554300 rs430373 chr3 11889365 G A 1.23E-05 Smoking quantity / / 24665060 rs4684823 chr3 11889787 C T 2.50E-05 Urinary metabolites / / 21572414 rs4684823 chr3 11889787 C T 3.38E-05 Smoking quantity / / 24665060 rs732096 chr3 11893950 T C 2.28E-05 Smoking quantity / / 24665060 rs303850 chr3 11896347 A G 1.31E-04 Smoking quantity / / 24665060 rs6777876 chr3 11956598 A G 4.00E-07 Alcohol dependence / / 21314694 rs438129 chr3 12007910 T C 7.40E-05 Aging (time to event) / / 21782286 rs305506 chr3 12026709 G T 7.67E-04 Multiple complex diseases / / 17554300 rs7615580 chr3 12027240 T C 1.97E-05 White matter integrity / / 22425255 rs2618405 chr3 12038264 C A 2.03E-05 Anorexia nervosa / / 24514567 rs308971 chr3 12116620 G A 2.00E-07 Fasting insulin-related traits (interaction with BMI) SYN2 intron 22581228 rs308971 chr3 12116620 G A 2.97E-11 Body mass index SYN2 intron 22885924 rs11720130 chr3 12156316 G A 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SYN2 intron 20877124 rs4488811 chr3 12182028 C T 1.70E-05 White matter integrity SYN2 intron 22425255 rs4488811 chr3 12182028 C T 9.63E-05 Waist-Hip Ratio SYN2 intron pha003029 rs310746 chr3 12259616 C T 6.15E-05 Systemic sclerosis / / 21750679 rs7616006 chr3 12267648 A G 5.00E-08 Platelet counts / / 22139419 rs17036101 chr3 12277845 G A 2.00E-07 Type 2 diabetes / / 18372903 rs17036101 chr3 12277845 G A 2.00E-07 Coronary heart disease / / 21347282 rs17036101 chr3 12277845 G A 2.00E-07 Type 2 diabetes / / 21647700 rs13081389 chr3 12289800 A G 2.00E-07 Type 2 diabetes / / 20581827 rs13081389 chr3 12289800 A G 0.00000082 Type 2 diabetes / / 22885922 rs13081389 chr3 12289800 A G 2.00E-07 Type 2 diabetes / / 23300278 rs7641345 chr3 12296540 A G 3.10E-05 Response to statin therapy / / 20339536 rs13089415 chr3 12301360 G T 6.22E-04 White matter integrity / / 22425255 rs13089415 chr3 12301360 G T 7.79E-05 Waist-Hip Ratio / / pha003029 rs12330874 chr3 12302242 G A 7.85E-04 Alzheimer's disease / / 17998437 rs17036160 chr3 12329783 C T 0.00000787 Type 2 diabetes PPARG intron 22325160 rs17036170 chr3 12330411 G A 2.00E-08 Drug-induced liver injury PPARG intron 22968431 rs2972164 chr3 12334416 T C 0.00003 Coronary artery calcification PPARG intron 23727086 rs11709077 chr3 12336507 G A 5.10E-04 Multiple complex diseases PPARG intron 17554300 rs11709077 chr3 12336507 G A 6.98E-04 Alzheimer's disease PPARG intron 17998437 rs11709077 chr3 12336507 G A 0.000000011 Type 2 diabetes (females) PPARG intron 22885922 rs11709077 chr3 12336507 G A 0.00000015 Type 2 diabetes (males) PPARG intron 22885922 rs4684846 chr3 12338849 A G 0.00037 Coronary artery calcification PPARG intron 23727086 rs12631819 chr3 12342861 G T 0.00000835 HDL cholesterol PPARG intron 23063622 rs11128596 chr3 12343117 A C 0.00027 Coronary artery calcification PPARG intron 23727086 rs12485478 chr3 12351223 A G 0.0000359 HDL cholesterol PPARG intron 23063622 rs12496505 chr3 12356158 G A 0.00029 Coronary artery calcification PPARG intron 23727086 rs13433696 chr3 12358492 G A 0.00029 Coronary artery calcification PPARG intron 23727086 rs7646510 chr3 12363358 A G 2.05E-08 LDL cholesterol PPARG intron 23063622 rs3892175 chr3 12368038 G A 9.96E-04 Alzheimer's disease PPARG intron 22005930 rs12496005 chr3 12371082 G C 0.00021 Coronary artery calcification PPARG intron 23727086 rs12490265 chr3 12384542 G A 2.10E-05 Urinary metabolites PPARG intron 21572414 rs17036321 chr3 12384599 T C 7.44E-08 LDL cholesterol PPARG intron 23063622 rs11128603 chr3 12385828 A G 9.00E-08 Plasminogen activator inhibitor type 1 levels (PAI-1) PPARG intron 22990020 rs17036328 chr3 12390484 T C 3.46E-04 Multiple complex diseases PPARG intron 17554300 rs17036328 chr3 12390484 T C 3.59E-12 Fasting insulin-related traits PPARG intron 22885924 rs7649970 chr3 12392272 C T 0.00000454 Type 2 diabetes PPARG intron 22325160 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463246 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463248 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463249 rs1801282 chr3 12393125 C G 2.31E-04 Alzheimer's disease PPARG missense 17998437 rs1801282 chr3 12393125 C G 2.00E-06 Coronary heart disease PPARG missense 21347282 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 21647700 rs1801282 chr3 12393125 C G 0.0000215 Type 2 diabetes PPARG missense 22325160 rs1801282 chr3 12393125 C G 2.00E-07 Fasting insulin-related traits (interaction with BMI) PPARG missense 22581228 rs1801282 chr3 12393125 C G 0.00033 Fasting insulin-related traits PPARG missense 22885922 rs1801282 chr3 12393125 C G 1.10E-12 Type 2 diabetes PPARG missense 22885922 rs1801282 chr3 12393125 C G 1.40E-07 Plasminogen activator inhibitor type 1 levels (PAI-1) PPARG missense 22990020 rs1801282 chr3 12393125 C G 1.70E-06 Type 2 diabetes PPARG missense 23300278 rs1801282 chr3 12393125 C G 6.00E-10 Type 2 diabetes PPARG missense 24509480 rs1899951 chr3 12394840 C T 0.00000037 Type 2 diabetes PPARG intron 22885922 rs2938397 chr3 12408278 A G 8.30E-05 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy PPARG intron 23118302 rs73025249 chr3 12410290 G A 0.0000217 Menopause (age at onset) PPARG intron 23424626 rs13306745 chr3 12421056 G T 3.50E-17 HDL cholesterol PPARG intron 23063622 rs4135268 chr3 12437237 C G 9.20E-06 Memory performance PPARG intron 22105620 rs4135275 chr3 12443844 A G 1.35E-04 Alcohol dependence PPARG intron 20201924 rs73027210 chr3 12447268 G A 0.0000217 Menopause (age at onset) PPARG intron 23424626 rs114451007 chr3 12454621 A T 0.0000093 Menopause (age at onset) PPARG intron 23424626 rs17036700 chr3 12468627 G T 2.44E-04 Multiple complex diseases PPARG intron 17554300 rs1797912 chr3 12470239 A C 0.0000548 Type 2 diabetes PPARG intron 22325160 rs4135361 chr3 12470663 G A 5.22E-11 LDL cholesterol PPARG intron 23063622 rs7626560 chr3 12475088 C T 2.40E-05 Urinary metabolites PPARG intron 21572414 rs7650895 chr3 12475162 A C 2.40E-05 Urinary metabolites PPARG intron 21572414 rs9833097 chr3 12478817 G A 5.57E-05 Major depressive disorder / / 21621269 rs9833097 chr3 12478817 G A 6.72E-05 Major depressive disorder / / pha002850 rs4498025 chr3 12481375 C T 9.22E-04 Multiple complex diseases / / 17554300 rs13088214 chr3 12487827 T C 6.11E-05 Tunica Media / / pha003036 rs4684854 chr3 12488882 G C 4.00E-06 Sexual dimorphism in anthropometric traits / / 23754948 rs9855622 chr3 12493347 C T 3.48E-06 Systemic sclerosis / / 21750679 rs1185784 chr3 12494278 C T 0.000645 Salmonella-induced pyroptosis / / 22837397 rs1185784 chr3 12494278 C T 7.87E-04 Smoking quantity / / 24665060 rs11917039 chr3 12506675 G C 7.30E-05 Iron levels / / 21208937 rs17036788 chr3 12507401 T C 1.30E-04 Smoking quantity / / 24665060 rs709165 chr3 12514124 A G 4.97E-05 Multiple complex diseases / / 17554300 rs17036821 chr3 12533148 G T 4.42E-08 Lymphocyte counts TSEN2 intron 22286170 rs17036841 chr3 12537924 T C 4.23E-04 Smoking quantity TSEN2 intron 24665060 rs299651 chr3 12537955 T A 1.66E-04 Multiple complex diseases TSEN2 intron 17554300 rs2596827 chr3 12546172 T G 9.26E-04 Multiple complex diseases TSEN2 intron 17554300 rs299653 chr3 12548943 G C 2.28E-04 Multiple complex diseases TSEN2 intron 17554300 rs299653 chr3 12548943 G C 2.31E-04 Lymphocyte counts TSEN2 intron 22286170 rs299655 chr3 12550235 A G 3.30E-04 Multiple complex diseases TSEN2 intron 17554300 rs6766510 chr3 12551807 T C 2.00E-06 Prostate cancer (gene x gene interaction) TSEN2 intron 22219177 rs17036870 chr3 12553933 C T 3.53E-04 Multiple complex diseases TSEN2 intron 17554300 rs17036872 chr3 12559188 G A 1.92E-28 Metabolite levels TSEN2 intron 22286219 rs1618545 chr3 12560763 A T 3.18E-04 Multiple complex diseases TSEN2 intron 17554300 rs796173 chr3 12564302 A G 3.17E-04 Multiple complex diseases TSEN2 intron 17554300 rs299630 chr3 12568425 T G 3.27E-04 Multiple complex diseases TSEN2 intron 17554300 rs1552484 chr3 12580246 G C 1.34E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2596822 chr3 12596844 T C 9.26E-05 Arthritis (juvenile idiopathic) / / 22354554 rs2454422 chr3 12603900 G A 8.08E-04 Multiple complex diseases MKRN2 intron 17554300 rs2454422 chr3 12603900 G A 6.22E-05 Arthritis (juvenile idiopathic) MKRN2 intron 22354554 rs2633442 chr3 12609937 G A 3.35E-04 Multiple complex diseases MKRN2 intron 17554300 rs15997 chr3 12624070 C T 5.54E-04 Multiple complex diseases MKRN2 UTR-3 17554300 rs5746255 chr3 12624321 A G 5.85E-05 Multiple complex diseases MKRN2 UTR-3 17554300 rs13106 chr3 12624580 G A 7.96E-04 Alcohol dependence MKRN2 UTR-3 20201924 rs7956 chr3 12624763 T C 1.46E-04 Multiple complex diseases MKRN2 UTR-3 17554300 rs3729931 chr3 12626516 G A 7.00E-07 Cardiac hypertrophy RAF1 intron 21348951 rs2290159 chr3 12628920 G C 4.00E-09 Cholesterol,total RAF1 intron 20686565 rs2290159 chr3 12628920 G C 2.00E-09 Cholesterol,total RAF1 intron 24097068 rs1532533 chr3 12635706 G A 8.55E-05 Arthritis (juvenile idiopathic) RAF1 intron 22354554 rs2442809 chr3 12637675 T G 2.94E-04 Multiple complex diseases RAF1 intron 17554300 rs11705805 chr3 12662370 A G 2.62E-04 Suicide attempts in bipolar disorder RAF1 intron 21423239 rs2055312 chr3 12663250 C T 2.59E-04 Suicide attempts in bipolar disorder RAF1 intron 21423239 rs6766666 chr3 12690855 G T 8.15E-04 Multiple complex diseases RAF1 intron 17554300 rs9874315 chr3 12727962 C A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9818046 chr3 12736530 C G 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4444694 chr3 12741219 T A 8.18E-04 Type 2 diabetes / / 17463246 rs4399872 chr3 12741345 T A 8.24E-04 Type 2 diabetes / / 17463246 rs6442325 chr3 12763841 A C 7.94E-05 Orofacial clefts / / 19270707 rs17037220 chr3 12818103 T C 7.20E-04 Type 2 diabetes / / 17463246 rs6791647 chr3 12826425 A G 7.40E-04 Type 2 diabetes / / 17463246 rs9874893 chr3 12833079 C G 2.54E-04 Type 2 diabetes / / 17463246 rs4034942 chr3 12836792 C T 2.54E-04 Type 2 diabetes / / 17463246 rs2305397 chr3 12857493 C T 2.54E-04 Type 2 diabetes CAND2 missense 17463246 rs200149446 chr3 12857896 C T 0.00004 Breast cancer CAND2 missense 23555315 rs536280133 chr3 12874937 G GT 1.53E-04 Acute lung injury CAND2 intron 22295056 rs7622555 chr3 12874937 G T 1.53E-04 Acute lung injury CAND2 intron 22295056 rs7628715 chr3 12907090 C T 6.97E-05 Acute lung injury / / 22295056 rs2600228 chr3 12908510 A C 7.44E-06 Lung function (forced expiratory volume in 1 second) / / pha003102 rs434460 chr3 12917207 A G 6.08E-06 Multiple complex diseases / / 17554300 rs2569991 chr3 12923197 C A 1.00E-06 Periodontitis (DPAL) / / 24024966 rs11128623 chr3 12939829 T C 2.29E-05 Vaspin levels IQSEC1 UTR-3 22907691 rs2600322 chr3 12954868 A G 8.22E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2600221 chr3 12963216 C T 8.77E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2252275 chr3 12963445 T A 8.54E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2600328 chr3 12998180 T C 7.97E-05 Partial epilepsies IQSEC1 intron 20522523 rs3816058 chr3 13004851 T C 9.37E-04 Multiple complex diseases IQSEC1 intron 17554300 rs360834 chr3 13047002 T C 9.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC1 intron 22566498 rs360833 chr3 13047602 A G 9.43E-04 Type 2 diabetes IQSEC1 intron 17463246 rs165571 chr3 13050094 T C 5.72E-05 Fibrinogen IQSEC1 intron pha003068 rs11712537 chr3 13052644 C T 0.000214 Salmonella-induced pyroptosis IQSEC1 intron 22837397 rs11715824 chr3 13055495 G A 0.000857 Salmonella-induced pyroptosis IQSEC1 intron 22837397 rs361052 chr3 13070799 A G 3.00E-04 Pancreatic cancer IQSEC1 intron 23180869 rs444944 chr3 13117999 G A 1.30E-05 Schizophrenia / / pha002857 rs181721 chr3 13129241 C T 6.72E-06 Glycemic traits (pregnancy) / / 23903356 rs6801338 chr3 13130396 G A 8.56E-04 Multiple complex diseases / / 17554300 rs4684119 chr3 13131195 A G 7.39E-06 Glycemic traits (pregnancy) / / 23903356 rs80136581 chr3 13133587 G A 0.00008642 Sarcoidosis / / 22952805 rs2600203 chr3 13136829 C T 5.78E-06 Glycemic traits (pregnancy) / / 23903356 rs3856816 chr3 13137229 C T 6.36E-04 Multiple complex diseases / / 17554300 rs3856816 chr3 13137229 C T 9.30E-04 Response to TNF antagonist treatment / / 21061259 rs360751 chr3 13139038 T C 4.07E-06 Glycemic traits (pregnancy) / / 23903356 rs165567 chr3 13140732 A G 3.12E-06 Glycemic traits (pregnancy) / / 23903356 rs17833070 chr3 13150039 T C 1.60E-05 Urinary metabolites / / 21572414 rs9864101 chr3 13190384 C T 2.55E-07 Intracranial aneurysm / / 20613766 rs9864101 chr3 13190384 C T 5.69E-05 Post-operative nausea and vomiting / / 21694509 rs4684121 chr3 13217692 G T 3.13E-04 Multiple complex diseases / / 17554300 rs357118 chr3 13232489 G A 4.03E-05 Mammographic density / / 22532574 rs357119 chr3 13233451 G A 2.45E-04 Mammographic density / / 22532574 rs2166856 chr3 13268998 A G 9.83E-04 Multiple complex diseases / / 17554300 rs2166856 chr3 13268998 A G 1.40E-06 Urinary metabolites / / 21572414 rs9869761 chr3 13286504 G C 7.01E-05 Multiple complex diseases / / 17554300 rs357159 chr3 13308740 G C 6.33E-04 Alcohol dependence / / 21314694 rs357116 chr3 13321852 A G 2.80E-05 Urinary metabolites / / 21572414 rs749574 chr3 13330721 C T 1.05E-04 Smoking initiation / / 24665060 rs3852032 chr3 13339060 G A 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs3852032 chr3 13339060 G A 6.20E-04 Smoking initiation / / 24665060 rs17038082 chr3 13400275 G A 2.30E-15 Progranulin levels NUP210 intron 21087763 rs17038082 chr3 13400275 G A 2.30E-15 Myocardial infarction NUP210 intron 21211798 rs2046190 chr3 13404761 G A 3.71E-06 Lymphocyte counts NUP210 intron 22286170 rs6771144 chr3 13423110 G A 4.69E-05 Schizophrenia (cytomegalovirus infection interaction) NUP210 intron 23358160 rs9874760 chr3 13463133 C T 2.78E-04 Multiple complex diseases / / 17554300 rs4283554 chr3 13466117 C G 1.26E-04 Multiple complex diseases / / 17554300 rs365691 chr3 13478434 T C 8.27E-04 Multiple complex diseases / / 17554300 rs468113 chr3 13499551 G A 9.52E-04 Multiple complex diseases / / 17554300 rs59585 chr3 13501254 T C 8.33E-04 Multiple complex diseases / / 17554300 rs3846119 chr3 13505180 C T 1.45E-05 Multiple complex diseases / / 17554300 rs12635063 chr3 13508455 G A 4.24E-04 Multiple complex diseases / / 17554300 rs17029076 chr3 13508915 A C 1.34E-04 Multiple complex diseases / / 17554300 rs2675234 chr3 13517751 C T 1.36E-04 Self-reported allergy / / 23817569 rs2655215 chr3 13517761 T C 1.41E-04 Self-reported allergy / / 23817569 rs2675233 chr3 13518034 C T 1.64E-04 Self-reported allergy / / 23817569 rs2597510 chr3 13523338 C G 1.96E-04 Self-reported allergy HDAC11 intron 23817569 rs2597515 chr3 13527134 A G 1.69E-04 Self-reported allergy HDAC11 intron 23817569 rs2655222 chr3 13537240 A G 1.63E-04 Myopia (pathological) HDAC11 intron 21095009 rs1116048 chr3 13537336 T C 1.63E-04 Myopia (pathological) HDAC11 intron 21095009 rs34210830 chr3 13555017 C G 0.000023 Mean arterial pressure / / 22510845 rs2597513 chr3 13555836 C T 7.00E-10 Height / / 20881960 rs896056 chr3 13583528 G A 1.29E-05 Myopia (pathological) / / 23049088 rs4684960 chr3 13607746 C G 2.46E-04 Height FBLN2 intron 17255346 rs908813 chr3 13608182 G C 3.73E-04 Height FBLN2 intron 17255346 rs908811 chr3 13610577 T G 3.90E-04 Height FBLN2 UTR-5 17255346 rs3773283 chr3 13626592 T C 2.92E-05 Partial epilepsies FBLN2 intron 20522523 rs3773282 chr3 13630307 T C 1.08E-05 Partial epilepsies FBLN2 intron 20522523 rs1878173 chr3 13642946 A G 3.63E-04 Schizophrenia FBLN2 intron 19197363 rs3773271 chr3 13646818 T C 2.47E-04 Schizophrenia FBLN2 intron 19197363 rs17793957 chr3 13649920 C G 2.90E-04 Multiple complex diseases FBLN2 intron 17554300 rs17793957 chr3 13649920 C G 1.85E-04 Alzheimer's disease FBLN2 intron pha002879 rs1562808 chr3 13665148 T C 9.61E-05 Hemoglobin FBLN2 intron pha003096 rs6795255 chr3 13665926 C G 1.41E-05 Bipolar disorder,schizoaffective FBLN2 intron 19567891 rs3773250 chr3 13676094 C T 9.65E-05 Bipolar disorder and schizophrenia FBLN2 intron 20889312 rs7610284 chr3 13680861 C T 2.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4603942 chr3 13704113 T C 9.53E-04 Obesity (extreme) LOC285375 intron 21935397 rs6793679 chr3 13705345 C T 2.08E-05 HIV-1 viral setpoint LOC285375 intron 21490045 rs6792244 chr3 13717199 A G 6.86E-04 Obesity (extreme) LOC285375 intron 21935397 rs12495328 chr3 13717252 C T 9.57E-04 Amyotrophic lateral sclerosis (sporadic) LOC285375 intron 24529757 rs11128653 chr3 13717663 A G 6.61E-04 Obesity (extreme) LOC285375 intron 21935397 rs6775581 chr3 13720097 C T 6.41E-04 Obesity (extreme) LOC285375 intron 21935397 rs6775581 chr3 13720097 C T 8.27E-05 Taste perception LOC285375 intron 22132133 rs4557142 chr3 13722407 A C 9.97E-04 Obesity (extreme) LOC285375 intron 21935397 rs9849455 chr3 13726270 A G 4.05E-04 Obesity (extreme) LOC285375 intron 21935397 rs9849613 chr3 13726334 A G 8.28E-04 Obesity (extreme) LOC285375 intron 21935397 rs6781368 chr3 13726840 G A 9.16E-04 Obesity (extreme) LOC285375 intron 21935397 rs6794344 chr3 13726888 T C 8.54E-04 Obesity (extreme) LOC285375 intron 21935397 rs6781488 chr3 13727086 C G 8.67E-04 Obesity (extreme) LOC285375 intron 21935397 rs6795216 chr3 13730682 G T 9.23E-04 Obesity (extreme) LOC285375 intron 21935397 rs9826161 chr3 13730960 T G 8.56E-04 Obesity (extreme) LOC285375 intron 21935397 rs9830904 chr3 13731645 T C 8.95E-04 Obesity (extreme) LOC285375 intron 21935397 rs9811516 chr3 13731786 G A 3.39E-04 Multiple complex diseases LOC285375 intron 17554300 rs9848869 chr3 13731856 A G 5.65E-04 Obesity (extreme) LOC285375 intron 21935397 rs4234514 chr3 13736633 G A 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC285375 intron 20877124 rs4450798 chr3 13737000 G T 2.00E-06 Bipolar disorder (mood-incongruent) LOC285375 intron 23092984 rs12490834 chr3 13742435 G C 9.23E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs9846232 chr3 13743132 G T 1.00E-08 Personality dimensions LOC285375 intron 21368711 rs4684993 chr3 13757482 G A 2.88E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs4684995 chr3 13758474 A G 4.12E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs7631252 chr3 13803506 G A 9.64E-05 Femoral neck bone geometry / / 22087292 rs4684157 chr3 13807781 G A 9.68E-05 Femoral neck bone geometry / / 22087292 rs4685016 chr3 13808010 C T 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs9866343 chr3 13808439 T C 4.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs9284832 chr3 13810540 G C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4525847 chr3 13810670 C A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4498020 chr3 13810820 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9872360 chr3 13811824 A G 2.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs4234519 chr3 13812873 G A 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12630573 chr3 13824605 T A 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs13097641 chr3 13825666 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs13079210 chr3 13829565 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12629061 chr3 13831614 C T 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1124480 chr3 13857969 T C 9.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs4685039 chr3 13866499 G A 6.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) WNT7A intron 23648065 rs12634816 chr3 13872270 A G 2.67E-05 Blood Pressure WNT7A intron pha003049 rs10510424 chr3 13875328 C G 5.00E-04 Type 2 diabetes and 6 quantitative traits WNT7A intron 17848626 rs13321422 chr3 13884815 G A 3.90E-04 Multiple complex diseases WNT7A intron 17554300 rs1368576 chr3 13889848 G A 2.50E-04 Response to ximelagatran treatment WNT7A intron 17505501 rs9878521 chr3 13895187 C A 6.83E-04 Multiple complex diseases WNT7A intron 17554300 rs7653849 chr3 13899147 A G 3.40E-06 Schizophrenia WNT7A intron 20185149 rs1433357 chr3 13944838 C T 6.46E-04 Alzheimer's disease / / 17998437 rs9875589 chr3 13961157 T G 4.00E-06 Ovarian reserve / / 22116950 rs2731306 chr3 14080189 T C 1.03E-05 Alzheimer's disease TPRXL intron 21627779 rs2731334 chr3 14107387 C T 9.70E-04 Coronary heart disease / / 21606135 rs2731334 chr3 14107387 C T 1.03E-05 Alzheimer's disease / / 21627779 rs2607741 chr3 14147892 T C 1.03E-05 Alzheimer's disease / / 21627779 rs139590716 chr3 14180693 G C 0.00026 Breast cancer (ER positive) TMEM43 missense 23555315 rs1043953 chr3 14183758 A G 6.88E-04 Smoking initiation TMEM43 UTR-3 24665060 rs8516 chr3 14184669 T C 2.08E-04 Alcohol dependence TMEM43 UTR-3 21314694 rs8516 chr3 14184669 T C 5.68E-04 Smoking initiation TMEM43 UTR-3 24665060 rs2470458 chr3 14186823 T C 7.42E-04 Smoking initiation XPC UTR-3 24665060 rs2228001 chr3 14187449 G T 1 Drug response to Cisplatin XPC missense 19434073 rs2733533 chr3 14188700 C A 4.56E-05 Smoking initiation XPC intron 24665060 rs2733534 chr3 14188762 G C 4.83E-05 Smoking initiation XPC intron 24665060 rs2607737 chr3 14193168 C T 1.56E-04 Smoking initiation XPC intron 24665060 rs1350344 chr3 14217576 G A 1.35E-05 Smoking initiation XPC intron 24665060 rs2607744 chr3 14235285 C G 7.89E-05 Smoking initiation LSM3 intron 24665060 rs2733551 chr3 14238743 T G 2.01E-04 Smoking initiation LSM3 intron 24665060 rs4685080 chr3 14253947 C A 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12639212 chr3 14267211 A G 2.10E-05 Urinary metabolites / / 21572414 rs6442433 chr3 14275759 C G 7.22E-04 Alcohol dependence / / 21314694 rs12493406 chr3 14280171 C T 6.08E-04 Smoking initiation / / 24665060 rs6802240 chr3 14285238 A G 5.98E-05 Body Fat Distribution / / pha003016 rs6802240 chr3 14285238 A G 5.29E-06 Body Fat Distribution / / pha003017 rs6802240 chr3 14285238 A G 3.31E-06 Body Fat Distribution / / pha003018 rs10510427 chr3 14287703 G A 5.86E-05 Smoking initiation / / 24665060 rs1871856 chr3 14290893 A G 4.76E-04 Schizophrenia / / 19197363 rs2341654 chr3 14298116 T A 8.30E-05 Personality dimensions / / 18957941 rs2341654 chr3 14298116 T A 9.20E-05 Serum metabolites / / 19043545 rs9881693 chr3 14311273 T C 9.88E-05 Multiple complex diseases / / 17554300 rs9883639 chr3 14345707 C T 6.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs9837707 chr3 14347085 T C 2.50E-05 Response to alcohol consumption (flushing response) / / 24277619 rs9844272 chr3 14357848 C T 1.95E-04 Hearing function / / 17255346 rs4684207 chr3 14374615 T C 3.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs900176 chr3 14377925 A G 7.59E-05 Schizophrenia / / 19571809 rs6794796 chr3 14383632 A G 6.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs749855 chr3 14387154 T C 2.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs4684208 chr3 14389483 C T 4.53E-04 Type 2 diabetes / / 17463246 rs9878149 chr3 14402491 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1550158 chr3 14406623 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs721377 chr3 14435063 C T 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17308574 chr3 14455958 G A 9.96E-05 Kawasaki disease SLC6A6 intron 22446961 rs4331657 chr3 14459473 G A 5.74E-05 Glucose levels SLC6A6 intron pha003061 rs12638941 chr3 14460915 C T 7.05E-04 Nicotine smoking SLC6A6 intron 19268276 rs6801669 chr3 14473278 G A 4.02E-05 Response to taxane treatment (placlitaxel) SLC6A6 intron 23006423 rs4402920 chr3 14478231 C G 2.60E-05 Response to taxane treatment (placlitaxel) SLC6A6 intron 23006423 rs6790433 chr3 14480778 T C 1.00E-06 Response to taxane treatment (docetaxel) SLC6A6 intron 23006423 rs6766142 chr3 14482659 G A 8.38E-05 Body Mass Index SLC6A6 intron pha003022 rs11128699 chr3 14496162 G A 4.47E-05 Brain lesion load SLC6A6 intron 19010793 rs17237132 chr3 14499020 C T 3.61E-04 Nicotine smoking SLC6A6 intron 19268276 rs12489456 chr3 14501174 G A 4.00E-07 Alcohol dependence SLC6A6 intron 21956439 rs2289129 chr3 14508311 C T 2.02E-05 Basophils SLC6A6 intron pha003087 rs3773175 chr3 14510761 T C 4.55E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773174 chr3 14510861 T C 1.79E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773173 chr3 14510886 T C 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773172 chr3 14511699 G A 1.80E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773172 chr3 14511699 G A 5.30E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773172 chr3 14511699 G A 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773171 chr3 14512093 C T 3.20E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773171 chr3 14512093 C T 4.80E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773171 chr3 14512093 C T 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9826660 chr3 14512731 A C 4.47E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9868733 chr3 14513180 C T 4.46E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs2289128 chr3 14513695 G A 2.20E-04 Alcohol dependence SLC6A6 intron 20201924 rs2289128 chr3 14513695 G A 4.00E-04 Alcohol dependence SLC6A6 intron 20201924 rs2289128 chr3 14513695 G A 5.88E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9834678 chr3 14517115 T C 2.50E-04 Alcohol dependence SLC6A6 intron 20201924 rs9834678 chr3 14517115 T C 5.60E-05 Alcohol dependence SLC6A6 intron 20201924 rs9834678 chr3 14517115 T C 2.73E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9834678 chr3 14517115 T C 5.65E-05 Alcoholism SLC6A6 intron pha002893 rs3773167 chr3 14517282 G A 1.93E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9820113 chr3 14517999 G T 6.41E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9845444 chr3 14519102 T C 7.41E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773165 chr3 14524270 G A 1.00E-06 Alcohol dependence SLC6A6 intron 21956439 rs9036 chr3 14530721 A G 3.00E-06 Cognitive performance SLC6A6 UTR-3 19734545 rs2276756 chr3 14548208 G A 9.82E-04 Alzheimer's disease GRIP2 intron 22005930 rs4516597 chr3 14554476 T C 9.58E-04 Alzheimer's disease GRIP2 intron 22005930 rs11128703 chr3 14554608 C T 5.82E-04 Alzheimer's disease GRIP2 intron 22005930 rs11128703 chr3 14554608 C T 8.37E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIP2 intron 22566498 rs4685169 chr3 14554845 T A 5.53E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685170 chr3 14555009 C T 8.76E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685170 chr3 14555009 C T 8.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIP2 intron 22566498 rs4685171 chr3 14555216 T C 9.81E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs4685172 chr3 14555367 T C 7.35E-04 Alzheimer's disease GRIP2 intron 22005930 rs4361268 chr3 14555739 G A 5.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4613440 chr3 14555811 A G 9.92E-05 Cognitive test performance GRIP2 cds-synon 20125193 rs4613440 chr3 14555811 A G 9.26E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs4684229 chr3 14556198 T A,C,G 4.34E-04 Alzheimer's disease GRIP2 intron 22005930 rs872526 chr3 14560840 A C 3.08E-04 Nicotine smoking GRIP2 intron 19268276 rs872526 chr3 14560840 A C 8.05E-04 Alzheimer's disease GRIP2 intron 22005930 rs4234526 chr3 14563258 A G 5.90E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs200550670 chr3 14570887 CCATTTA C 6.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685180 chr3 14570887 C T 6.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4684231 chr3 14571310 G A 6.02E-04 Alzheimer's disease GRIP2 intron 22005930 rs4684232 chr3 14571669 C T 5.58E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685188 chr3 14571892 A G 5.50E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685189 chr3 14571956 T C 5.45E-04 Alzheimer's disease GRIP2 intron 22005930 rs2139505 chr3 14572596 G A 5.29E-04 Alzheimer's disease GRIP2 intron 22005930 rs2139507 chr3 14572643 C G 5.37E-04 Alzheimer's disease GRIP2 intron 22005930 rs9310449 chr3 14591346 C A 9.90E-05 Cognitive performance / / 19734545 rs4449299 chr3 14598965 C A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs1533671 chr3 14603343 T G 7.70E-05 Mammographic density / / 22532574 rs13090178 chr3 14609299 C T 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9829645 chr3 14613390 A G 2.71E-04 Type 2 diabetes / / 17463246 rs17318350 chr3 14635048 T C 2.81E-04 Type 2 diabetes / / 17463246 rs17039949 chr3 14672637 T C 8.82E-05 Multiple complex diseases / / 17554300 rs4684236 chr3 14700046 T C 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs9830735 chr3 14701635 G A 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs3773487 chr3 14706848 G A 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs3773489 chr3 14707132 A C 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs7633011 chr3 14710679 T C 3.36E-04 Lymphocyte counts C3orf19 intron 22286170 rs3773491 chr3 14712042 A G 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs11709673 chr3 14713306 A G 1.00E-04 Prostate cancer C3orf19 UTR-3 21743057 rs1432601 chr3 14731808 C T 9.66E-04 Amyotrophic Lateral Sclerosis C3orf20 intron 17362836 rs7640439 chr3 14732694 C T 6.63E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs11712257 chr3 14733230 G T 7.05E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs10470604 chr3 14737182 G T 9.06E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs7622324 chr3 14751296 G A 9.15E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs141714657 chr3 14755667 G C 0.0000093 Breast cancer C3orf20 splice-5 23555315 rs141714657 chr3 14755667 G C 0.000016 Prostate cancer C3orf20 splice-5 23555315 rs141714657 chr3 14755667 G C 0.00033 Breast cancer (ER positive) C3orf20 splice-5 23555315 rs13075489 chr3 14758055 T C 7.65E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs6442472 chr3 14765262 C T 4.19E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs2195918 chr3 14770495 A G 7.22E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs9834046 chr3 14772357 G T 9.39E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs12496846 chr3 14773267 A G 3.24E-05 Opioid sensitivity C3orf20 intron 23183491 rs17040258 chr3 14796144 C T 8.71E-04 Type 2 diabetes C3orf20 intron 17463246 rs17040258 chr3 14796144 C T 1.84E-06 White blood cell count C3orf20 intron 21738479 rs17040258 chr3 14796144 C T 4.96E-05 Lung function (forced vital capacity) C3orf20 intron 24023788 rs1347104 chr3 14800419 A C 5.15E-04 Alzheimer's disease C3orf20 intron 22005930 rs7651825 chr3 14812118 G A 3.91E-05 Parkinson's disease C3orf20 intron 19915575 rs7651825 chr3 14812118 G A 2.20E-05 Parkinson's disease C3orf20 intron pha002868 rs853334 chr3 14817654 G A 3.66E-05 Body mass (lean) / / 19268274 rs3899614 chr3 14817727 G A 2.87E-04 Alzheimer's disease / / 24755620 rs13074606 chr3 14830469 A G 9.66E-05 Type 2 diabetes / / 17463246 rs1689549 chr3 14837473 T C 1.10E-05 Urinary metabolites / / 21572414 rs10510432 chr3 14865367 A C 2.32E-07 Paclitaxel sensitivity in NCI60 cancer cell lines FGD5 intron 21314952 rs9837816 chr3 14873640 C T 6.01E-07 Red blood cell traits FGD5 intron 23222517 rs7653784 chr3 14873794 T C 8.29E-04 Parkinson's disease FGD5 intron 17052657 rs1689581 chr3 14882551 T C 2.56E-04 Fibrinogen FGD5 intron 17255346 rs3887276 chr3 14886362 T C 9.22E-04 Type 2 diabetes FGD5 intron 17463246 rs1389300 chr3 14886796 A G 3.31E-04 Fibrinogen FGD5 intron 17255346 rs1389300 chr3 14886796 A G 4.90E-04 Myasthenia gravis FGD5 intron 23055271 rs1389301 chr3 14887029 G A 3.06E-04 Fibrinogen FGD5 intron 17255346 rs1826215 chr3 14887182 T C,G 4.04E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs1826215 chr3 14887182 T C,G 2.99E-07 Red blood cell traits FGD5 intron 23222517 rs1687295 chr3 14889756 T C 6.37E-08 Blood pressure FGD5 intron 21909110 rs4685217 chr3 14894121 G A 1.98E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs4685219 chr3 14894188 A G 2.82E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs1687320 chr3 14894634 C G 1.28E-04 Nicotine smoking FGD5 intron 19268276 rs294634 chr3 14900551 T G 1.90E-04 Smoking cessation FGD5 intron 24665060 rs294634 chr3 14900551 T G 9.23E-05 Serum albumin level FGD5 intron pha003084 rs17040409 chr3 14904727 G C 3.44E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs17040409 chr3 14904727 G C 4.30E-08 Red blood cell traits FGD5 intron 23222517 rs13084708 chr3 14909380 G A 4.17E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs13064931 chr3 14911568 C T 9.13E-08 Red blood cell traits FGD5 intron 23222517 rs1602300 chr3 14914699 A G 9.55E-06 Coronary artery calcification FGD5 intron 23870195 rs6804922 chr3 14923396 A G 5.84E-08 Red blood cell traits FGD5 intron 23222517 rs4684243 chr3 14931118 T A 8.06E-04 Multiple complex diseases FGD5 intron 17554300 rs903061 chr3 14958074 T G 9.71E-05 Type 2 diabetes FGD5 intron 17463246 rs13097792 chr3 14999621 G A 7.10E-06 Elbow pain NR2C2 intron pha003008 rs13097792 chr3 14999621 G A 8.64E-05 Weight NR2C2 intron pha003026 rs10510434 chr3 15020349 A G 2.57E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs17040623 chr3 15028478 A G 2.43E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs9839660 chr3 15030545 T A 2.38E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs2164358 chr3 15051128 G A 9.57E-04 HIV-1 viral setpoint NR2C2 intron 17641165 rs11128731 chr3 15059330 T C 3.18E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs612051 chr3 15075360 A G 2.25E-05 Response to taxane treatment (placlitaxel) NR2C2 intron 23006423 rs6442494 chr3 15081352 T C 7.24E-05 Serum albumin level NR2C2 intron pha003084 rs9820676 chr3 15083784 C G 2.92E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs9825022 chr3 15084014 C T 2.89E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs3773478 chr3 15113042 C T 1.74E-04 Suicide attempts in bipolar disorder ZFYVE20 UTR-3 21041247 rs9830744 chr3 15115478 C T 2.22E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs9851219 chr3 15115723 T C 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs9868848 chr3 15115872 A G 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs746665 chr3 15118733 A T 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs2306854 chr3 15119720 A C 1.70E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs2306855 chr3 15119804 T C 1.70E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs13326820 chr3 15122978 A G 1.47E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs17040729 chr3 15129537 T G 1.34E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs17040733 chr3 15134320 C G 1.11E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs9839836 chr3 15143428 T G 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs13318013 chr3 15145487 G A 1.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9867224 chr3 15150797 A G 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs9867224 chr3 15150797 A G 7.30E-05 Cognitive function / / 24684796 rs7625117 chr3 15162577 T C 3.60E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7639618 chr3 15216429 C T 7.30E-11 Osteoarthritis (knee) / / 18622395 rs353093 chr3 15224983 C T 6.20E-05 Osteoarthritis (knee) COL6A4P1 intron 18622395 rs9864422 chr3 15227252 C T 2.40E-08 Osteoarthritis (knee) COL6A4P1 intron 18622395 rs1287464 chr3 15247796 A G 6.70E-05 Osteoarthritis (knee) CAPN7 UTR-5 18622395 rs3773475 chr3 15264563 T C 2.40E-05 Osteoarthritis (knee) CAPN7 intron 18622395 rs10510438 chr3 15273386 T C 4.94E-06 Age-related macular degeneration CAPN7 intron pha000001 rs11713836 chr3 15294811 G A 2.10E-04 Osteoarthritis (knee) / / 18622395 rs1318937 chr3 15295364 A G 1.44E-04 Substance dependence / / 21818250 rs1318937 chr3 15295364 A G 3.00E-06 Alcohol dependence / / 21956439 rs1318937 chr3 15295364 A G 4.00E-07 Alcohol and nictotine co-dependence / / 22488850 rs3732728 chr3 15297954 G C 1.53E-04 Aortic root size SH3BP5 intron 21223598 rs3773474 chr3 15299028 G C 0.00000476 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs6771876 chr3 15299227 G A 0.00000546 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9818506 chr3 15299437 T C 1.04E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs9813606 chr3 15300655 A G 0.00000859 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9817868 chr3 15301052 A T 0.00000859 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs2291853 chr3 15301363 G A 6.86E-04 Multiple complex diseases SH3BP5 intron 17554300 rs3773472 chr3 15302753 G C 6.50E-07 Osteoarthritis (knee) SH3BP5 intron 18622395 rs6442508 chr3 15304741 C G 1.96E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs6442508 chr3 15304741 C G 0.0000084 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9310472 chr3 15306599 C T 1.88E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs9310472 chr3 15306599 C T 0.00000596 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs3773469 chr3 15308240 A G 5.40E-04 Osteoarthritis (knee) SH3BP5 intron 18622395 rs6788936 chr3 15309925 G T 0.00000889 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs6808313 chr3 15314024 A G 0.00000828 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs851848 chr3 15317938 T C 3.80E-04 Response to taxane treatment (placlitaxel) SH3BP5 intron 23006423 rs7340679 chr3 15346700 C T 1.04E-05 Attention deficit hyperactivity disorder SH3BP5 intron 20732625 rs9837421 chr3 15347293 C T 1.99E-05 Waist Circumference SH3BP5 intron pha003023 rs9837421 chr3 15347293 C T 8.20E-05 Waist-Hip Ratio SH3BP5 intron pha003029 rs9990297 chr3 15348130 T C 8.57E-05 Waist Circumference SH3BP5 intron pha003023 rs10510436 chr3 15349125 T C 2.40E-04 Multiple complex diseases SH3BP5 intron 17554300 rs2688665 chr3 15354907 G C 2.80E-05 Urinary metabolites SH3BP5 intron 21572414 rs17041032 chr3 15375822 G A 8.26E-04 Type 2 diabetes SH3BP5 intron 17463246 rs3844287 chr3 15379981 T C 0.0006 Salmonella-induced pyroptosis SH3BP5 intron 22837397 rs11926124 chr3 15398047 G A 3.62E-04 Myocardial Infarction / / pha002883 rs6442522 chr3 15440556 C T 5.00E-06 Uric acid levels / / 18759275 rs2290536 chr3 15469001 A C 9.12E-04 Multiple complex diseases METTL6 UTR-5 17554300 rs9855575 chr3 15514063 A C 4.67E-04 Multiple complex diseases COLQ intron 17554300 rs17041248 chr3 15545475 C G 1.69E-04 Multiple complex diseases COLQ intron 17554300 rs76909367 chr3 15552751 C T 0.0000689 Menopause (age at onset) COLQ intron 23424626 rs12495710 chr3 15559228 C T 4.38E-05 Alcohol dependence COLQ intron 20201924 rs12495710 chr3 15559228 C T 4.38E-05 Alcoholism COLQ intron pha002891 rs17041264 chr3 15562831 C T 3.81E-04 Iron levels COLQ intron pha002876 rs905648 chr3 15565322 C T 4.58E-06 Cardiovascular disease / / 18179892 rs4685252 chr3 15568863 C T 5.61E-05 Height / / pha003010 rs4685252 chr3 15568863 C T 1.65E-05 Height / / pha003011 rs4305404 chr3 15577567 G A 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707889 chr3 15579892 C A 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7651039 chr3 15648004 T C 2.00E-06 Coronary heart disease BTD intron 21378990 rs9830528 chr3 15662606 G A 2.31E-04 Multiple complex diseases BTD intron 17554300 rs2455853 chr3 15690025 G A 1.51E-04 Multiple complex diseases / / 17554300 rs2455800 chr3 15701589 T G 6.15E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs2455801 chr3 15701857 G A 5.76E-04 Aortic root size / / 21223598 rs17041442 chr3 15719279 T C 7.50E-04 Type 2 diabetes ANKRD28 intron 17463246 rs35755845 chr3 15719279 T TG 7.50E-04 Type 2 diabetes ANKRD28 intron 17463246 rs6796083 chr3 15723586 G A 3.49E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs2455848 chr3 15771372 T C 1.92E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10865735 chr3 15802131 A T 4.08E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10865735 chr3 15802131 A T 1.70E-05 Urinary metabolites ANKRD28 intron 21572414 rs6789076 chr3 15807725 T A 6.34E-04 Aortic root size ANKRD28 intron 21223598 rs1447650 chr3 15808707 C T 6.57E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs6442550 chr3 15810309 A G 5.32E-04 Aortic root size ANKRD28 intron 21223598 rs7630373 chr3 15812085 T C 1.29E-08 Adiponectin levels ANKRD28 intron 20887962 rs1348981 chr3 15828811 G T 1.70E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10510443 chr3 15829127 A G 5.72E-04 Aortic root size ANKRD28 intron 21223598 rs6762442 chr3 15833903 C G 1.57E-04 Multiple complex diseases ANKRD28 intron 17554300 rs13078999 chr3 15834746 G A 3.06E-04 Multiple complex diseases ANKRD28 intron 17554300 rs1447649 chr3 15837784 C T 1.63E-04 Multiple complex diseases ANKRD28 intron 17554300 rs11128758 chr3 15849330 G A 7.54E-04 Multiple complex diseases ANKRD28 intron 17554300 rs7610596 chr3 15849456 T C 4.29E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs17041542 chr3 15854043 A G 4.14E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs2166759 chr3 15856285 G A 7.42E-04 Aortic root size ANKRD28 intron 21223598 rs2166760 chr3 15857465 A G 6.96E-04 Multiple complex diseases ANKRD28 intron 17554300 rs12493140 chr3 15857590 G A 8.28E-04 Multiple complex diseases ANKRD28 intron 17554300 rs17041564 chr3 15861637 T C 2.54E-04 Multiple complex diseases ANKRD28 intron 17554300 rs17041564 chr3 15861637 T C 4.27E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs1345161 chr3 15863426 A G 9.61E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs11713820 chr3 15866590 C T 1.19E-04 Aortic root size ANKRD28 intron 21223598 rs9815283 chr3 15867375 A G 1.35E-04 Multiple complex diseases ANKRD28 intron 17554300 rs9864353 chr3 15869766 C T 2.38E-04 Multiple complex diseases ANKRD28 intron 17554300 rs11128760 chr3 15873407 A G 3.62E-04 Aortic root size ANKRD28 intron 21223598 rs11128762 chr3 15883439 G A 2.94E-04 Aortic root size ANKRD28 intron 21223598 rs2121737 chr3 15907946 G C 5.20E-04 Multiple complex diseases / / 17554300 rs4685266 chr3 15908766 A G 2.72E-04 Alcohol dependence / / 20201924 rs9813577 chr3 15909323 G A 7.30E-04 Multiple complex diseases / / 17554300 rs9813577 chr3 15909323 G A 4.90E-05 Cognitive function / / 24684796 rs1869627 chr3 16004488 C A 0.0008276 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1869627 chr3 16004488 C A 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7639184 chr3 16006626 A T 0.0003376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7639184 chr3 16006626 A T 3.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1454776 chr3 16009044 G T 0.0003248 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1454776 chr3 16009044 G T 3.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9811682 chr3 16009368 C T 0.0003232 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9811682 chr3 16009368 C T 3.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4685286 chr3 16009804 C G 0.0003213 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685286 chr3 16009804 C G 3.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10510444 chr3 16010476 C T 6.60E-05 Bone mineral density / / 19181680 rs10510444 chr3 16010476 C T 0.0003197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10510444 chr3 16010476 C T 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378169 chr3 16010612 C G 3.55E-05 Brain structure / / 22504417 rs13079584 chr3 16010715 G T 0.0003165 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13079584 chr3 16010715 G T 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1563229 chr3 16011202 G T 0.0003167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1563229 chr3 16011202 G T 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9869915 chr3 16011708 C T 0.0003151 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9869915 chr3 16011708 C T 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2085149 chr3 16012131 A G 0.0003136 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2085149 chr3 16012131 A G 3.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2085151 chr3 16012191 G A 0.0003124 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2085151 chr3 16012191 G A 3.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902115 chr3 16014620 G A 0.0003125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902115 chr3 16014620 G A 3.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902116 chr3 16014736 G T 0.0003101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902116 chr3 16014736 G T 3.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902117 chr3 16014769 A C 0.0003089 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902117 chr3 16014769 A C 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6442563 chr3 16014859 T C 0.0002512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6442563 chr3 16014859 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11717117 chr3 16017665 A T 0.0002941 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11717117 chr3 16017665 A T 2.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4685294 chr3 16017905 T C 0.0002931 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685294 chr3 16017905 T C 2.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6442565 chr3 16018470 A G 4.08E-05 Bone mineral density / / 19181680 rs10510445 chr3 16022885 G T 8.32E-04 Age-related macular degeneration / / 22125219 rs1378168 chr3 16024923 G A 3.11E-05 Brain structure / / 22504417 rs7625628 chr3 16035590 T C 3.30E-05 Brain structure / / 22504417 rs6770617 chr3 16036830 G A 3.26E-05 Brain structure / / 22504417 rs17041715 chr3 16042244 A G 6.34E-04 Age-related macular degeneration / / 22125219 rs4685304 chr3 16066211 C G 0.0000488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685304 chr3 16066211 C G 4.88E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9815997 chr3 16068354 C T 0.0000481 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9815997 chr3 16068354 C T 4.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9874065 chr3 16070506 C T 0.0000347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9874065 chr3 16070506 C T 3.47E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs987858 chr3 16090920 T A 5.77E-04 Body mass index / / 21701565 rs1454768 chr3 16101186 T C 6.70E-04 Parkinson's disease / / 17052657 rs1454765 chr3 16110666 T G 2.67E-05 Brain structure / / 22504417 rs12497859 chr3 16114461 A G 6.20E-05 Orofacial clefts / / 22419666 rs9830122 chr3 16127222 T C 7.09E-05 Orofacial clefts / / 22419666 rs10865738 chr3 16133383 T C 1.41E-05 Orofacial clefts / / 22419666 rs6776952 chr3 16148056 T C 3.73E-04 Type 2 diabetes / / 17463246 rs6772516 chr3 16152118 T A 3.73E-04 Type 2 diabetes / / 17463246 rs4685307 chr3 16165418 G T 1.51E-07 Blood pressure / / 21996601 rs7624406 chr3 16169491 A G 7.47E-05 Serum metabolites / / 19043545 rs7624406 chr3 16169491 A G 2.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2657606 chr3 16176298 C T 2.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12497461 chr3 16184030 A C 8.16E-05 Serum metabolites / / 19043545 rs6771632 chr3 16192143 T C 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6775152 chr3 16196224 G A 2.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6775152 chr3 16196224 G A 4.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4685319 chr3 16207275 A G 7.62E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2047975 chr3 16222989 G A 7.95E-04 Amyotrophic Lateral Sclerosis GALNTL2 intron 17827064 rs11128786 chr3 16233242 T C 1.84E-05 Leprosy GALNTL2 intron 22019778 rs6807124 chr3 16251995 G A 9.85E-05 Triglycerides GALNTL2 intron pha003081 rs7642905 chr3 16259904 T A 9.22E-04 Multiple complex diseases GALNTL2 intron 17554300 rs2271077 chr3 16261420 C T 7.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GALNTL2 missense 20031582 rs14576 chr3 16268986 C A 6.54E-05 Aging (time to event) GALNTL2 cds-synon 21782286 rs842264 chr3 16285262 T A 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs842263 chr3 16285414 T A 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs842262 chr3 16285927 G C 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs842261 chr3 16285941 G A 6.68E-04 Depression (quantitative trait) / / 20800221 rs842247 chr3 16291822 T C 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs842246 chr3 16293425 T C 6.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2292612 chr3 16300996 C T 2.28E-04 Multiple complex diseases DPH3 UTR-3 17554300 rs483682 chr3 16365223 G A 2.71E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs542591 chr3 16391908 C A 1.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs542591 chr3 16391908 C A 1.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs542591 chr3 16391908 C A 2.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs690037 chr3 16395668 C T 6.00E-07 optic disc size (cup) RFTN1 intron 20395239 rs7634895 chr3 16397878 T C 8.88E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs17200269 chr3 16398797 G C 3.59E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs12635698 chr3 16408489 T C 5.00E-06 Obesity (extreme) RFTN1 intron 19553259 rs9310496 chr3 16422989 A G 1.02E-04 Atopy RFTN1 intron 21625490 rs12629276 chr3 16428481 C T 1.40E-05 Type 2 diabetes RFTN1 intron 17293876 rs12629276 chr3 16428481 C T 1.40E-05 Type 2 diabetes RFTN1 intron 19184112 rs690403 chr3 16432477 C T 2.22E-05 Major depressive disorder RFTN1 intron 19107115 rs842495 chr3 16439969 G C 3.72E-04 Type 2 diabetes RFTN1 intron 17463246 rs842496 chr3 16440244 G A 3.88E-04 Type 2 diabetes RFTN1 intron 17463246 rs6442600 chr3 16441428 T C 3.98E-04 Type 2 diabetes RFTN1 intron 17463246 rs2860052 chr3 16441518 G C 5.17E-04 Type 2 diabetes RFTN1 intron 17463246 rs4685335 chr3 16448636 C T 3.28E-04 Type 2 diabetes RFTN1 intron 17463246 rs6776854 chr3 16457973 C T 7.03E-04 Body mass index RFTN1 intron 21701565 rs9817739 chr3 16480827 G A 7.32E-04 Multiple complex diseases RFTN1 intron 17554300 rs9817739 chr3 16480827 G A 3.47E-05 Bipolar disorder RFTN1 intron 18317468 rs9867980 chr3 16491898 T C 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RFTN1 intron 20877124 rs7621664 chr3 16518270 T C 5.80E-06 Urinary metabolites RFTN1 intron 21572414 rs11128791 chr3 16520435 T C 2.14E-04 Vaspin levels RFTN1 intron 22907691 rs11128791 chr3 16520435 T C 0.0002136 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit RFTN1 intron 22907730 rs2881512 chr3 16543983 A G 7.81E-05 Body Mass Index RFTN1 intron pha003021 rs3856834 chr3 16581660 T C 5.28E-13 Leprosy / / 22019778 rs6797084 chr3 16584850 C T 0.000496 Salmonella-induced pyroptosis / / 22837397 rs2042826 chr3 16585132 T C 0.000276 Salmonella-induced pyroptosis / / 22837397 rs6799971 chr3 16585193 G A 0.000194 Salmonella-induced pyroptosis / / 22837397 rs6442608 chr3 16588273 T C 0.000038 Coronary artery calcification / / 23727086 rs17042395 chr3 16593431 G A 1.09E-13 Gender / / 22362730 rs4685345 chr3 16610448 C G 6.16E-10 Gender / / 22362730 rs6803924 chr3 16617065 C G 1.51E-09 Gender / / 22362730 rs10510452 chr3 16625048 A G 4.54E-05 Cognitive test performance / / 20125193 rs10510452 chr3 16625048 A G 1.00E-08 Testicular germ cell tumor / / 23666240 rs4685366 chr3 16656331 A G 6.09E-05 Lipoproteins / / pha003079 rs1469372 chr3 16664509 A G 1.01E-05 Serum metabolites / / 19043545 rs17200411 chr3 16670655 C T 2.44E-04 Substance dependence / / 21818250 rs7631231 chr3 16673075 T C 4.59E-04 Body mass index / / 21701565 rs12107998 chr3 16693232 T C 3.90E-04 Body mass index / / 21701565 rs12106804 chr3 16693266 A T 3.90E-04 Body mass index / / 21701565 rs12494691 chr3 16700334 G A 6.61E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs9860475 chr3 16749024 C T 4.05E-04 Alcohol dependence / / 20201924 rs7618461 chr3 16762185 C T 9.58E-06 Serum metabolites / / 19043545 rs13322151 chr3 16763573 G T 7.27E-05 Serum metabolites / / 19043545 rs17272677 chr3 16783341 A C 2.77E-05 Serum metabolites / / 19043545 rs1449531 chr3 16840813 C T 2.39E-04 Schizophrenia / / 21674006 rs7625233 chr3 16852736 A G 5.56E-06 Hirschsprung's disease / / 19196962 rs6778524 chr3 16855953 T C 9.00E-08 Alcohol dependence / / 21956439 rs6796955 chr3 16885602 C T 4.14E-05 Major depressive disorder / / 22472876 rs6797038 chr3 16885685 C A 8.33E-05 Major depressive disorder / / 22472876 rs13081010 chr3 16899947 T C 2.10E-05 Urinary metabolites / / 21572414 rs2252086 chr3 16924645 T C 8.00E-06 Urinary metabolites / / 21572414 rs10510468 chr3 16938623 G T 6.68E-04 Type 2 diabetes PLCL2 intron 17463246 rs11917952 chr3 16943878 C T 8.89E-04 Type 2 diabetes PLCL2 intron 17463246 rs1372072 chr3 16955259 G A 2.00E-08 Primary biliary cirrhosis PLCL2 intron 21399635 rs11928330 chr3 16958367 C T 4.07E-05 Primary biliary cirrhosis PLCL2 intron 21399635 rs1025818 chr3 16965021 T C 0.0000353 Primary biliary cirrhosis PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.0000406 Primary biliary cirrhosis in females PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.000106 Primary biliary cirrhosis (anti-mitochondrial antibody positive) PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.000189 Primary biliary cirrhosis PLCL2 intron 22961000 rs7637568 chr3 16965216 T C 0.0000614 Primary biliary cirrhosis PLCL2 intron 22936693 rs9821630 chr3 16970938 A G 4.00E-06 Multiple sclerosis PLCL2 intron 21833088 rs17042882 chr3 16971876 C A,T 2.51E-177 Multiple complex diseases PLCL2 intron 17554300 rs4684305 chr3 17001165 T G 2.80E-05 Urinary metabolites PLCL2 intron 21572414 rs6769249 chr3 17002619 G A 3.75E-05 Intelligence PLCL2 intron 21826061 rs6769249 chr3 17002619 G A 9.35E-04 Heart Failure PLCL2 intron pha002884 rs6769249 chr3 17002619 G A 3.55E-05 Neutrophil count PLCL2 intron pha003095 rs4452313 chr3 17047032 A T 2.00E-10 Rheumatoid arthritis PLCL2 intron 24390342 rs4452313 chr3 17047032 A T 5.00E-11 Rheumatoid arthritis PLCL2 intron 24390342 rs9876768 chr3 17049965 T C 5.05E-04 Alcohol dependence PLCL2 intron 20201924 rs9876768 chr3 17049965 T C 9.41E-05 Response to taxane treatment (placlitaxel) PLCL2 intron 23006423 rs7653834 chr3 17051328 T C 0.000438 Salmonella-induced pyroptosis PLCL2 cds-synon 22837397 rs4383507 chr3 17073032 T C 2.40E-05 Urinary metabolites PLCL2 intron 21572414 rs12108065 chr3 17074871 A G 0.000655 Salmonella-induced pyroptosis PLCL2 intron 22837397 rs7648912 chr3 17076560 C G 0.000863 Salmonella-induced pyroptosis PLCL2 intron 22837397 rs3796299 chr3 17109339 C T 9.70E-06 Urinary metabolites PLCL2 intron 21572414 rs4685424 chr3 17117747 A T 1.50E-05 Urinary metabolites PLCL2 intron 21572414 rs4618210 chr3 17124384 A G 3.00E-09 Myocardial infarction PLCL2 intron 24916648 rs4618210 chr3 17124384 A G 5.62E-04 Heart Failure PLCL2 intron pha002884 rs4077616 chr3 17173415 A G 2.20E-05 Urinary metabolites / / 21572414 rs4234541 chr3 17182697 T C 8.28E-04 Multiple complex diseases / / 17554300 rs4685442 chr3 17213357 A G 9.71E-04 Heart Failure TBC1D5 intron pha002884 rs2470584 chr3 17214070 A G 4.97E-04 Amyotrophic lateral sclerosis (sporadic) TBC1D5 intron 24529757 rs2733500 chr3 17276149 G A 8.74E-05 Type 2 diabetes TBC1D5 intron 17846125 rs2733499 chr3 17276334 C T 6.41E-04 Type 2 diabetes TBC1D5 intron 17846125 rs2596638 chr3 17287018 C T 6.96E-04 Type 2 diabetes TBC1D5 intron 17846125 rs283917 chr3 17328509 A G 6.11E-04 Type 2 diabetes TBC1D5 intron 17846125 rs283929 chr3 17359916 C T 7.06E-04 Type 2 diabetes TBC1D5 intron 17846125 rs1374197 chr3 17394615 A G 5.91E-04 Alcohol dependence TBC1D5 intron 20201924 rs7647905 chr3 17433383 T C 6.47E-04 Alcohol dependence TBC1D5 intron 20201924 rs9823767 chr3 17615737 A G 8.17E-04 Alcohol dependence TBC1D5 intron 20201924 rs6792422 chr3 17701005 G T 6.09E-04 Type 2 diabetes TBC1D5 intron 17846125 rs10510478 chr3 17730282 A G 5.99E-04 Type 2 diabetes TBC1D5 intron 17846125 rs4128509 chr3 17731099 T C 6.04E-04 Type 2 diabetes TBC1D5 intron 17846125 rs4908967 chr3 17774944 C A 7.30E-04 Alcohol dependence TBC1D5 intron 20201924 rs7627732 chr3 17784818 T C 7.82E-04 Alcohol dependence LOC100505786 intron 20201924 rs4349529 chr3 17792118 A G 5.68E-04 Alcohol dependence / / 20201924 rs4611850 chr3 17798649 T G 6.50E-04 Alcohol dependence / / 20201924 rs11921152 chr3 17812688 C A 3.99E-05 Schizophrenia / / 20185149 rs11929066 chr3 17895208 C T 1.96E-05 Multiple complex diseases / / 17554300 rs13087154 chr3 17909190 T A 3.46E-04 Type 2 diabetes / / 17463246 rs1367522 chr3 17968408 C T 6.17E-04 Myopia (pathological) / / 21095009 rs7432256 chr3 18031212 A G 1.00E-04 Prostate cancer LOC339862 intron 21743057 rs7645289 chr3 18072808 A G 1.40E-04 Suicidal ideation LOC339862 intron 22030708 rs13079656 chr3 18093080 A G 6.16E-04 Coronary Artery Disease LOC339862 intron 17634449 rs13092967 chr3 18125502 G A 3.49E-06 Paget's disease LOC339862 intron 20436471 rs4688911 chr3 18129219 T C 8.00E-05 Prostate cancer LOC339862 intron 21743057 rs938180 chr3 18133207 A C 8.00E-05 Prostate cancer LOC339862 intron 21743057 rs4688903 chr3 18160060 G A 2.48E-06 Paget's disease LOC339862 intron 20436471 rs13060927 chr3 18190493 G A 8.27E-04 Suicide attempts in bipolar disorder LOC339862 intron 21041247 rs13071948 chr3 18192240 A G 8.79E-04 Suicide attempts in bipolar disorder LOC339862 intron 21041247 rs2102623 chr3 18206165 C T 4.84E-04 Type 2 diabetes LOC339862 intron 17463246 rs13078687 chr3 18223442 G A 7.26E-04 Multiple complex diseases LOC339862 intron 17554300 rs7641175 chr3 18311412 G A 3.00E-11 Platelet counts / / 22139419 rs6577641 chr3 18397849 C T 4.00E-06 Chronic mucus hypersecretion SATB1 intron 24714607 rs7621961 chr3 18399864 G A 2.83E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs11927883 chr3 18401567 A G 2.71E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs3922895 chr3 18402591 T A 2.68E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs9713190 chr3 18408096 T C 9.60E-06 Intraocular pressure SATB1 intron 22570627 rs9837588 chr3 18408930 A G 9.40E-06 Intraocular pressure SATB1 intron 22570627 rs9879688 chr3 18409067 G A 9.20E-06 Intraocular pressure SATB1 intron 22570627 rs9841621 chr3 18409077 A G 1.00E-04 Intraocular pressure SATB1 intron 22570627 rs9879573 chr3 18409169 C T 9.20E-06 Intraocular pressure SATB1 intron 22570627 rs6762753 chr3 18465443 A G 3.66E-04 Alzheimer's disease SATB1 UTR-5 22005930 rs6550850 chr3 18507382 C T 0.0000688 Salmonella-induced pyroptosis / / 22837397 rs6550850 chr3 18507382 C T 3.80E-08 Metabolite levels / / 23281178 rs2304763 chr3 18512879 C T 4.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1553995 chr3 18516620 A T 6.40E-06 Urinary metabolites / / 21572414 rs7633075 chr3 18581848 G T 1.53E-05 Cognitive test performance / / 20125193 rs7633075 chr3 18581848 G T 6.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs17044638 chr3 18609712 A G 3.45E-04 Type 2 diabetes / / 17463246 rs334960 chr3 18610877 C T 4.30E-04 Alcohol dependence / / 20201924 rs12714959 chr3 18621091 C T 6.14E-14 Multiple complex diseases / / 17554300 rs11707806 chr3 18623123 C G 8.51E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs400432 chr3 18623278 A G 2.73E-04 Type 2 diabetes / / 17463246 rs17044664 chr3 18643821 A C 7.95E-04 Multiple complex diseases / / 17554300 rs7651512 chr3 18647513 G A 5.26E-05 Eosinophil counts / / pha003088 rs2165399 chr3 18648481 C A 1.34E-04 Multiple complex diseases / / 17554300 rs336605 chr3 18656350 G T 4.10E-04 Alcohol dependence / / 20201924 rs4280655 chr3 18674920 C T 8.40E-06 Urinary metabolites / / 21572414 rs7638294 chr3 18675418 C T 2.45E-04 Obesity (extreme) / / 21935397 rs11128892 chr3 18684046 A G 9.30E-04 Obesity (extreme) / / 21935397 rs10780005 chr3 18693179 C T 9.28E-04 Obesity (extreme) / / 21935397 rs9855153 chr3 18693223 A G 2.00E-04 Alcohol dependence / / 20201924 rs9855153 chr3 18693223 A G 8.15E-05 Coronary heart disease / / pha003035 rs11714395 chr3 18699977 G T 3.84E-05 Insulin Resistance / / pha003062 rs11914608 chr3 18704299 A G 1.40E-05 Alcohol dependence / / 20201924 rs11914608 chr3 18704299 A G 2.30E-04 Alcohol dependence / / 20201924 rs11914608 chr3 18704299 A G 1.42E-05 Alcoholism / / pha002892 rs13073817 chr3 18706858 G A 7.00E-09 Crohn's disease / / 21102463 rs13073817 chr3 18706858 G A 8.40E-04 Obesity (extreme) / / 21935397 rs11918322 chr3 18716133 T A 0.000562392 Primary sclerosing cholangitis / / 23603763 rs9845140 chr3 18728878 C A 1.70E-04 Alcohol dependence / / 20201924 rs9826966 chr3 18737796 A G 1.90E-04 Alcohol dependence / / 20201924 rs9826966 chr3 18737796 A G 6.66E-05 Coronary heart disease / / pha003035 rs13098781 chr3 18758419 A G 6.58E-05 Insulin Resistance / / pha003062 rs11711641 chr3 18760244 A G 6.58E-05 Insulin Resistance / / pha003062 rs6778301 chr3 18765029 A G 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs11713774 chr3 18765978 T C 1.59E-05 Insulin Resistance / / pha003062 rs11713774 chr3 18765978 T C 4.14E-05 Insulin-related traits / / pha003063 rs4256159 chr3 18767404 C T 9.00E-15 Inflammatory bowel disease / / 23128233 rs4256159 chr3 18767404 C T 2.71E-05 Insulin Resistance / / pha003062 rs4256159 chr3 18767404 C T 5.70E-05 Insulin-related traits / / pha003063 rs6809854 chr3 18784423 A G 1.00E-07 Psoriasis / / 20953190 rs9284846 chr3 18790702 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9824781 chr3 18800046 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9847248 chr3 18804655 G A 1.30E-04 Alcohol dependence / / 20201924 rs7644430 chr3 18812072 A G 1.35E-04 Alzheimer's disease (late onset) / / 21379329 rs4280657 chr3 18814977 C T 5.82E-04 Multiple complex diseases / / 17554300 rs4482682 chr3 18817257 A G 1.30E-04 Alzheimer's disease (late onset) / / 21379329 rs11926588 chr3 18838880 G T 2.10E-05 Urinary metabolites / / 21572414 rs7640928 chr3 18840933 A T 8.40E-04 Type 2 diabetes / / 17463246 rs4973706 chr3 18921772 T C 0.0000531 Gains in maximal O2 uptake response / / 21183627 rs9860501 chr3 18928109 T G 2.04E-04 Blood pressure / / 17255346 rs4401379 chr3 18930125 C T 2.94E-04 Blood pressure / / 17255346 rs11710762 chr3 18939227 A G 9.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs12714975 chr3 19085374 C G 8.90E-05 Adiponectin levels / / 24105470 rs7612947 chr3 19117118 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6791995 chr3 19129843 A G 3.40E-05 Multiple complex diseases / / 17554300 rs997384 chr3 19224498 G A 9.29E-05 Pancreatic cancer KCNH8 intron pha002874 rs17005751 chr3 19242993 C G 3.39E-04 Multiple complex diseases KCNH8 intron 17554300 rs1389538 chr3 19266335 A G 1.00E-04 Cognitive impairment induced by topiramate KCNH8 intron 22091778 rs1389538 chr3 19266335 A G 0.000079 Coronary artery calcification KCNH8 intron 23727086 rs2034007 chr3 19371858 A G 5.98E-04 Smoking cessation KCNH8 intron 24665060 rs2053506 chr3 19375791 G A 4.00E-06 Hip geometry KCNH8 intron 17903296 rs13316471 chr3 19384526 C T 5.50E-04 Atrial fibrillation KCNH8 intron 21846873 rs12488588 chr3 19385436 G A 7.34E-05 Multiple complex diseases KCNH8 intron 17554300 rs9310595 chr3 19410169 C T 5.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNH8 intron 20877124 rs10470605 chr3 19436270 A G 9.90E-04 Multiple complex diseases KCNH8 intron 17554300 rs1348232 chr3 19441126 G A 5.12E-06 Serum metabolites KCNH8 intron 19043545 rs9826227 chr3 19441363 T C 0.0000009 Internal carotid artery thickness (near walls) KCNH8 intron 23487405 rs7630677 chr3 19467040 A G 8.76E-04 Type 2 diabetes KCNH8 intron 17463246 rs9809140 chr3 19519043 A G 3.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNH8 intron 24023788 rs4858318 chr3 19547184 C T 4.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNH8 intron 24023788 rs33915638 chr3 19574945 A G 8.72E-05 Lipoprotein A [Lp(a)] levels in plasma KCNH8 missense 21592478 rs12108194 chr3 19582423 C A 2.54E-04 Smoking cessation / / 24665060 rs949665 chr3 19613756 T G 1.64E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10510494 chr3 19614045 A G 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17543807 chr3 19614280 A G 1.64E-05 Serum metabolites / / 19043545 rs2203428 chr3 19680408 C T 9.11E-05 Blood Pressure / / pha003046 rs17006139 chr3 19716075 T C 2.67E-04 Multiple complex diseases / / 17554300 rs10510489 chr3 19774292 T G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17006217 chr3 19783277 T C 4.52E-07 Cardiovascular disease / / 18179892 rs10510491 chr3 19788213 A G 5.46E-06 Kawasaki disease / / 21221998 rs10510492 chr3 19792397 C T 7.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7431008 chr3 19854531 C A 9.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4858725 chr3 19888048 A G 6.01E-04 Aortic root size / / 21223598 rs2929344 chr3 19980160 C G 1.44E-05 Serum metabolites / / 19043545 rs2929343 chr3 19981414 A T 7.52E-04 Coronary heart disease / / 21606135 rs2364515 chr3 19981555 G C 6.38E-04 Coronary heart disease / / 21606135 rs2170342 chr3 19982135 C T 7.48E-05 Hemoglobin concentration / / 20534544 rs2170342 chr3 19982135 C T 1.34E-04 Attention deficit hyperactivity disorder / / 22420046 rs4858660 chr3 19994475 G A 3.12E-05 Osteoarthritis (knee and hip) RAB5A intron 21177295 rs13070718 chr3 20003228 G A 1.56E-04 Type 2 diabetes RAB5A intron 17463246 rs11128930 chr3 20022050 G A 6.77E-04 Type 2 diabetes RAB5A intron 17463246 rs4103004 chr3 20042834 C T 8.32E-05 Alzheimer's disease (late onset) PP2D1 missense 21379329 rs1915919 chr3 20083881 C T 8.00E-06 Post-traumatic stress disorder KAT2B intron 24677629 rs6773122 chr3 20087221 G A 9.47E-05 Femoral neck bone geometry KAT2B intron 22087292 rs2929404 chr3 20094566 T C 2.20E-05 Response to statin therapy KAT2B intron 20339536 rs2948085 chr3 20098119 T C 5.10E-05 Response to statin therapy KAT2B intron 20339536 rs9874923 chr3 20101563 C T 4.00E-07 Mean arterial pressure (alcohol consumption interaction) KAT2B intron 24376456 rs1124376 chr3 20108546 C T 5.00E-06 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs11714225 chr3 20121828 C T 9.20E-04 Parkinson's disease KAT2B intron 17052657 rs12636856 chr3 20136959 A G 2.30E-05 Urinary metabolites KAT2B intron 21572414 rs12636856 chr3 20136959 A G 7.00E-06 Response to mTOR inhibitor (rapamycin) KAT2B intron 24009623 rs9819628 chr3 20140837 C T 1.52E-05 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs4241546 chr3 20147562 A G 8.98E-05 Asthma KAT2B intron 23181788 rs12488369 chr3 20154059 A C 1.68E-05 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs17678713 chr3 20192769 G A 5.81E-04 Alcohol dependence KAT2B intron 20201924 rs9849205 chr3 20207136 T C 5.50E-05 Temperament (bipolar disorder) SGOL1 intron 22365631 rs1052930 chr3 20212189 A G 1.30E-05 Temperament (bipolar disorder) SGOL1 UTR-3 22365631 rs3852067 chr3 20219477 A G 7.50E-04 Multiple complex diseases SGOL1 intron 17554300 rs3852067 chr3 20219477 A G 2.60E-06 Temperament (bipolar disorder) SGOL1 intron 22365631 rs6767049 chr3 20220712 G T 2.00E-06 Temperament (bipolar disorder) SGOL1 intron 22365631 rs4858166 chr3 20292978 T C 5.99E-04 Taste perception / / 22132133 rs12489472 chr3 20301354 A C 2.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12386343 chr3 20306777 G T 8.68E-05 Coronary Artery Disease / / 17634449 rs9862603 chr3 20324715 C T 3.93E-07 Glaucoma-related traits / / 22058429 rs9820730 chr3 20348723 A G 3.42E-04 Coronary Artery Disease / / 17634449 rs9871864 chr3 20352766 T C 4.40E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs9871864 chr3 20352766 T C 6.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs6809146 chr3 20362439 T C 1.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7619947 chr3 20371453 T C 3.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6550498 chr3 20372799 G A 4.10E-06 Urinary metabolites / / 21572414 rs11128951 chr3 20375546 A G 4.27E-08 Alcohol consumption / / 23953852 rs1356792 chr3 20378153 A G 3.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12489904 chr3 20384627 G A 4.98E-04 Gallstones / / 17632509 rs9854943 chr3 20414230 T G 4.47E-04 Tourette syndrome / / 22889924 rs9854943 chr3 20414230 T G 9.15E-05 Coronary heart disease / / pha003030 rs6763225 chr3 20415512 G A 1.78E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6768597 chr3 20419583 T C 5.30E-05 Coronary heart disease / / pha003031 rs11128953 chr3 20433212 C T 2.36E-04 Tourette syndrome / / 22889924 rs1401921 chr3 20436493 C T 6.55E-04 Tourette syndrome / / 22889924 rs4858191 chr3 20437608 C G 3.94E-04 Alzheimer's disease / / 17998437 rs4858191 chr3 20437608 C G 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17805724 chr3 20451350 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6793327 chr3 20465208 T A 3.06E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs13070421 chr3 20476362 C T 1.43E-05 Monocyte chemoattractant protein-1 / / pha003071 rs7629464 chr3 20493568 A G 5.26E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1520050 chr3 20500104 G A 8.39E-05 Multiple complex diseases / / 17554300 rs1523347 chr3 20512768 A C 9.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs599845 chr3 20515745 G A 6.39E-05 Bipolar disorder and schizophrenia / / 20889312 rs1520043 chr3 20518701 T G 0.0000149 Schizophrenia / / 22440650 rs648238 chr3 20527133 A G 9.63E-05 Monocyte chemoattractant protein-1 / / pha003071 rs582714 chr3 20527630 C A 4.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1523351 chr3 20577473 C T 6.18E-07 Coronary heart disease / / pha003031 rs10440098 chr3 20578998 T C 6.53E-07 Coronary heart disease / / pha003031 rs4292253 chr3 20605302 T C 3.04E-06 Coronary heart disease / / pha003031 rs1395103 chr3 20615273 G A 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs9841080 chr3 20707404 T G 8.93E-06 Bipolar disorder and schizophrenia / / 20889312 rs75430906 chr3 20717929 G A 1.00E-07 Acne (severe) / / 24927181 rs1500422 chr3 20720138 G A 6.31E-04 Alcohol dependence / / 20201924 rs7638430 chr3 20731953 A G 4.69E-04 Multiple complex diseases / / 17554300 rs931717 chr3 20736153 T G 2.08E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2173734 chr3 20736506 C T 8.81E-04 Alzheimer's disease / / 22005930 rs17809565 chr3 20738089 A G 5.24E-04 Alcohol dependence / / 20201924 rs9990219 chr3 20809206 T C 6.00E-06 Multiple complex diseases / / 17554300 rs1500415 chr3 20819623 C T 8.60E-04 Type 2 diabetes / / 17846125 rs13071397 chr3 20830711 C T 3.79E-05 Type 2 diabetes and other traits / / 19734900 rs4858270 chr3 20856539 A G 8.92E-05 Serum metabolites / / 19043545 rs6773660 chr3 20865519 C A 2.98E-04 Alzheimer's disease / / 22005930 rs2366536 chr3 20868825 A G 9.71E-04 Alzheimer's disease / / 22005930 rs375137468 chr3 20868825 A AC 9.71E-04 Alzheimer's disease / / 22005930 rs4498065 chr3 20869043 A G 4.57E-04 Alzheimer's disease / / 22005930 rs1499004 chr3 20880872 G C 7.72E-05 Multiple complex diseases / / 17554300 rs12486758 chr3 20907259 C T 3.81E-04 Alzheimer's disease / / 22005930 rs12490794 chr3 20922300 C G 2.98E-04 Alzheimer's disease / / 22005930 rs1498996 chr3 20925380 T A 6.63E-05 Serum metabolites / / 19043545 rs17811911 chr3 20931562 A G 2.43E-05 Alzheimer's disease / / 22005930 rs1580800 chr3 20939291 G A 3.94E-04 Alzheimer's disease / / 22005930 rs7427261 chr3 20939370 A G 1.37E-05 Alzheimer's disease / / 22005930 rs6787231 chr3 20957810 G C 5.00E-06 IgG glycosylation / / 23382691 rs2201910 chr3 20995849 T C 7.08E-04 Obesity (extreme) / / 21935397 rs4858283 chr3 20996215 A G 2.74E-04 Obesity (extreme) / / 21935397 rs6791186 chr3 20996399 T C 3.35E-04 Obesity (extreme) / / 21935397 rs2366681 chr3 20997613 C A 4.75E-05 Blood Pressure / / pha003048 rs13072255 chr3 21038260 A C 9.84E-05 Type 2 diabetes / / 17463246 rs2173233 chr3 21058911 A G 2.65E-04 Type 2 diabetes / / 17463246 rs2132889 chr3 21076341 G A 2.05E-04 Coronary Artery Disease / / 17634449 rs13086092 chr3 21077375 T G 8.74E-04 Type 2 diabetes / / 17463246 rs7622116 chr3 21078939 G A 5.48E-04 Type 2 diabetes / / 17463246 rs9825481 chr3 21097113 G T 2.37E-04 Type 2 diabetes / / 17463246 rs1391139 chr3 21118255 T C 3.71E-04 Birth weight / / 17255346 rs1391139 chr3 21118255 T C 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17008182 chr3 21135162 T C 6.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs9864927 chr3 21136309 T A 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs9883374 chr3 21136757 A G 3.53E-04 Birth weight / / 17255346 rs9883374 chr3 21136757 A G 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9845916 chr3 21136818 C A 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7648119 chr3 21140240 C T 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9310636 chr3 21149605 C G 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1391136 chr3 21161388 C T 7.50E-05 Type 2 diabetes / / 17463248 rs13064120 chr3 21165513 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1497502 chr3 21165530 A C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12185976 chr3 21165908 T C 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10780008 chr3 21166410 C G 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6798717 chr3 21174797 T C 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6763489 chr3 21178623 T A 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4857979 chr3 21179332 A G 9.67E-05 Type 1 diabetes / / 18978792 rs4857979 chr3 21179332 A G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800727 chr3 21179734 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1550171 chr3 21180323 C A 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6767979 chr3 21180789 A T 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs13060855 chr3 21182719 G A 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720452 chr3 21248642 C T 5.00E-06 Bipolar disorder / / 18711365 rs1347636 chr3 21271043 A T 1.69E-04 Type 2 diabetes / / 17846125 rs6785004 chr3 21290055 T C 1.15E-04 Lung function (forced vital capacity) / / 24023788 rs6785004 chr3 21290055 T C 4.66E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9815041 chr3 21301170 C A 1.60E-05 Triglycerides / / 19074352 rs9815041 chr3 21301170 C A 1.60E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs1344870 chr3 21307401 T G 5.32E-04 Type 2 diabetes / / 17846125 rs9310639 chr3 21308534 G T 2.30E-04 Type 2 diabetes / / 17846125 rs10514675 chr3 21308756 G T 3.56E-04 Type 2 diabetes / / 17846125 rs10514676 chr3 21309839 C G 2.47E-04 Type 2 diabetes / / 17846125 rs1344868 chr3 21311150 C G 1.29E-04 Type 2 diabetes / / 17846125 rs9876170 chr3 21353382 G A 6.87E-05 Self-reported allergy / / 23817569 rs9816785 chr3 21356372 G A 6.83E-05 Self-reported allergy / / 23817569 rs13059346 chr3 21361784 T C 2.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs1395993 chr3 21369586 T C 3.49E-05 Parkinson's disease / / pha002868 rs1605524 chr3 21376648 G A 9.16E-04 Type 2 diabetes / / 17463246 rs1605524 chr3 21376648 G A 2.65E-04 Type 2 diabetes / / 17846125 rs2731943 chr3 21380677 C T 2.63E-05 Major depressive disorder / / 20516156 rs7650051 chr3 21383764 A G 9.91E-05 Schizophrenia / / 19571809 rs6770065 chr3 21392307 A G 6.17E-06 Longevity,exceptional / / 20595579 rs341859 chr3 21433365 T C 2.31E-05 HDL cholesterol / / pha003074 rs423879 chr3 21442468 G C 4.24E-05 Serum metabolites / / 19043545 rs409974 chr3 21447336 G A 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs440905 chr3 21447834 C T 5.57E-05 Serum metabolites / / 19043545 rs341865 chr3 21449227 G C 1.01E-04 Multiple complex diseases / / 17554300 rs341865 chr3 21449227 G C 1.76E-05 Serum metabolites / / 19043545 rs376703 chr3 21456170 C T 6.40E-05 HDL cholesterol / / pha003074 rs3849537 chr3 21479454 C T 1.25E-04 Attention deficit hyperactivity disorder ZNF385D intron 22420046 rs17008734 chr3 21480984 C T 2.67E-04 Multiple complex diseases ZNF385D intron 17554300 rs424695 chr3 21490145 A G 5.74E-04 Multiple complex diseases ZNF385D intron 17554300 rs424695 chr3 21490145 A G 2.60E-04 Type 2 diabetes ZNF385D intron 17846125 rs365392 chr3 21490868 G A 1.38E-04 Type 2 diabetes ZNF385D intron 17846125 rs800621 chr3 21499213 T C 5.51E-04 Multiple complex diseases ZNF385D intron 17554300 rs388647 chr3 21500623 G A 5.06E-06 Bicuspid aortic valve ZNF385D intron 20098615 rs7629679 chr3 21509376 A G 8.43E-04 Type 2 diabetes ZNF385D intron 17463246 rs1457590 chr3 21555974 C T 2.07E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs1978516 chr3 21556404 C T 2.96E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs13317601 chr3 21559129 C A 3.39E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs9829496 chr3 21559633 C T 4.26E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs17008992 chr3 21582201 A C 5.74E-05 Cognitive impairment induced by topiramate ZNF385D intron 22091778 rs7650823 chr3 21601844 T A 6.01E-05 Relative hand skill ZNF385D intron 24068947 rs11919873 chr3 21602714 T G 6.05E-05 Relative hand skill ZNF385D intron 24068947 rs13072036 chr3 21603251 C T 6.26E-05 Relative hand skill ZNF385D intron 24068947 rs10460951 chr3 21603613 A G 6.27E-05 Relative hand skill ZNF385D intron 24068947 rs7626779 chr3 21613034 T C 6.59E-05 Relative hand skill ZNF385D intron 24068947 rs3860581 chr3 21616429 G C 2.75E-05 Relative hand skill ZNF385D intron 24068947 rs7637584 chr3 21617814 A T 9.04E-05 Relative hand skill ZNF385D intron 24068947 rs1457582 chr3 21618520 A G 2.53E-05 Relative hand skill ZNF385D intron 24068947 rs1841914 chr3 21623631 T C 2.85E-04 Multiple complex diseases ZNF385D intron 17554300 rs9879945 chr3 21630297 C T 6.36E-05 Tunica Media ZNF385D intron pha003034 rs6780177 chr3 21647818 C T 1.31E-05 Heart Rate ZNF385D intron pha003054 rs13316093 chr3 21654425 T C 2.35E-05 Brain structure ZNF385D intron 22504417 rs17029417 chr3 21658582 C T 3.00E-05 Prostate cancer ZNF385D intron 21743057 rs17009164 chr3 21662929 G A 3.09E-05 Multiple complex diseases ZNF385D intron 17554300 rs3860583 chr3 21670520 T C 5.41E-04 Acute lung injury ZNF385D intron 22295056 rs7649561 chr3 21670879 C T 6.53E-05 Acute lung injury ZNF385D intron 22295056 rs7649561 chr3 21670879 C T 2.40E-05 Heart Rate ZNF385D intron pha003054 rs7619318 chr3 21673600 G A 4.59E-05 Acute lung injury ZNF385D intron 22295056 rs7619318 chr3 21673600 G A 3.71E-05 Heart Rate ZNF385D intron pha003054 rs7619318 chr3 21673600 G A 4.39E-05 Lipoproteins ZNF385D intron pha003079 rs3849544 chr3 21675069 C G 7.92E-04 Acute lung injury ZNF385D intron 22295056 rs11919688 chr3 21681969 G T 6.77E-04 Type 2 diabetes ZNF385D intron 17463246 rs11919688 chr3 21681969 G T 2.23E-04 Acute lung injury ZNF385D intron 22295056 rs3936575 chr3 21682494 A G 3.07E-05 Acute lung injury ZNF385D intron 22295056 rs1387822 chr3 21686466 G A 2.92E-05 Partial epilepsies ZNF385D intron 20522523 rs1387822 chr3 21686466 G A 2.51E-05 Epilepsy ZNF385D intron 22116939 rs1387822 chr3 21686466 G A 5.23E-04 Acute lung injury ZNF385D intron 22295056 rs1021351 chr3 21689194 G A 6.47E-05 Acute lung injury ZNF385D intron 22295056 rs2335811 chr3 21689398 G T 1.79E-04 Acute lung injury ZNF385D intron 22295056 rs2335812 chr3 21689628 T C 3.03E-05 Acute lung injury ZNF385D intron 22295056 rs1352646 chr3 21689964 T G 9.20E-05 Acute lung injury ZNF385D intron 22295056 rs2335813 chr3 21694884 A G 4.27E-04 Acute lung injury ZNF385D intron 22295056 rs9881055 chr3 21695821 G A 1.04E-04 Acute lung injury ZNF385D intron 22295056 rs11129014 chr3 21696848 G T 1.56E-04 Acute lung injury ZNF385D intron 22295056 rs2054942 chr3 21698394 A C 1.38E-04 Acute lung injury ZNF385D intron 22295056 rs6762678 chr3 21698690 A G 7.59E-05 Multiple complex diseases ZNF385D intron 17554300 rs17553605 chr3 21700102 T C 4.11E-04 Acute lung injury ZNF385D intron 22295056 rs12497214 chr3 21700282 G A 1.94E-04 Acute lung injury ZNF385D intron 22295056 rs12491669 chr3 21701236 A G 7.96E-05 Acute lung injury ZNF385D intron 22295056 rs1320292 chr3 21701712 A G 1.61E-05 Partial epilepsies ZNF385D intron 20522523 rs1320292 chr3 21701712 A G 1.82E-05 Epilepsy ZNF385D intron 22116939 rs1320292 chr3 21701712 A G 1.13E-04 Acute lung injury ZNF385D intron 22295056 rs3821396 chr3 21706369 G A 5.00E-06 Bipolar disorder ZNF385D intron 18711365 rs3821396 chr3 21706369 G A 8.20E-05 Bipolar disorder and major depressive disorder (combined) ZNF385D intron 20351715 rs9839129 chr3 21712555 C T 4.33E-05 Acute lung injury ZNF385D intron 22295056 rs12491351 chr3 21713210 G C 4.23E-05 Acute lung injury ZNF385D intron 22295056 rs986503 chr3 21714103 A G 4.31E-05 Partial epilepsies ZNF385D intron 20522523 rs986503 chr3 21714103 A G 4.80E-05 Acute lung injury ZNF385D intron 22295056 rs9816269 chr3 21718841 T C 5.00E-06 Palmitic acid (16:0) plasma levels ZNF385D intron 23362303 rs1490157 chr3 21719246 C T 5.00E-06 Partial epilepsies ZNF385D intron 20522523 rs1490157 chr3 21719246 C T 2.36E-05 Epilepsy ZNF385D intron 22116939 rs1490157 chr3 21719246 C T 4.85E-05 Acute lung injury ZNF385D intron 22295056 rs1490157 chr3 21719246 C T 0.00089 Prostate cancer ZNF385D intron 23555315 rs4298061 chr3 21726363 G T 3.14E-05 Partial epilepsies ZNF385D intron 20522523 rs4298061 chr3 21726363 G T 3.45E-05 Acute lung injury ZNF385D intron 22295056 rs2054945 chr3 21731567 C T 8.54E-04 Acute lung injury ZNF385D intron 22295056 rs11710743 chr3 21732114 T C 6.40E-06 Acute lung injury ZNF385D intron 22295056 rs6800607 chr3 21734116 C G 3.28E-04 Acute lung injury ZNF385D intron 22295056 rs7644742 chr3 21734234 C T 3.67E-05 Acute lung injury ZNF385D intron 22295056 rs7628221 chr3 21736303 G C 1.68E-04 Acute lung injury ZNF385D intron 22295056 rs4488861 chr3 21736573 G A 6.90E-04 Alcohol dependence ZNF385D intron 20201924 rs4488861 chr3 21736573 G A 1.22E-04 Acute lung injury ZNF385D intron 22295056 rs6781372 chr3 21738714 T G 3.41E-04 Acute lung injury ZNF385D intron 22295056 rs6790087 chr3 21738751 G A 9.09E-05 Acute lung injury ZNF385D intron 22295056 rs6550619 chr3 21742649 G T 6.00E-06 Acute lung injury ZNF385D intron 22295056 rs2336038 chr3 21745040 C A 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs4858344 chr3 21745418 G A 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs4858345 chr3 21745505 T C 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs6784935 chr3 21745877 A C,G,T 3.01E-05 Acute lung injury ZNF385D intron 22295056 rs12106696 chr3 21756553 G A 2.24E-05 Serum metabolites ZNF385D intron 19043545 rs13318017 chr3 21763896 A G 8.78E-04 Taste perception ZNF385D intron 22132133 rs9882615 chr3 21771422 G A 8.04E-04 Acute lung injury ZNF385D intron 22295056 rs11712735 chr3 21774269 T A 2.26E-04 Nicotine smoking ZNF385D intron 19268276 rs13062599 chr3 21779621 C T 2.39E-04 Sarcoidosis ZNF385D intron 19165924 rs13340131 chr3 21794174 A G 1.60E-05 HIV-1 control / / 20041166 rs6805992 chr3 21796865 T C 7.91E-04 Smoking cessation / / 24665060 rs7641603 chr3 21798340 C T 2.09E-29 Narcolepsy / / 19629137 rs4538394 chr3 21799709 A T 3.67E-05 Male fertility / / 22633400 rs4588386 chr3 21799771 A C 1.80E-06 Coronary heart disease / / pha003030 rs7637596 chr3 21802251 C T 3.00E-04 Smoking cessation / / 24665060 rs1320288 chr3 21802296 T C 9.35E-05 Coronary heart disease / / pha003030 rs12633231 chr3 21807679 C T 2.70E-04 Orofacial clefts / / 22419666 rs11129021 chr3 21816466 T G 6.72E-05 Coronary heart disease / / pha003030 rs6798138 chr3 21816589 G A 1.60E-05 HIV-1 control / / 20041166 rs3111745 chr3 21827159 G T 2.50E-05 Urinary metabolites / / 21572414 rs1606851 chr3 21837427 G A 9.21E-05 Alcohol withdrawal symptoms / / 22072270 rs1606852 chr3 21837676 C A 5.40E-05 Coronary heart disease / / pha003030 rs13083531 chr3 21844883 T G 1.98E-04 Alzheimer's disease (late onset) / / 21379329 rs1878012 chr3 21847618 C G 4.40E-05 Anger / / 24489884 rs13098512 chr3 21871752 G C 8.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11129025 chr3 21872193 A G 3.39E-04 Type 2 diabetes / / 17463246 rs2630787 chr3 21872335 C T 2.21E-06 Type 2 diabetes / / 17463246 rs2630787 chr3 21872335 C T 5.59E-04 Multiple complex diseases / / 17554300 rs9810237 chr3 21879418 A G 8.55E-04 Type 2 diabetes / / 17463246 rs3912513 chr3 21882659 T C 5.20E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2673522 chr3 21882969 G T 2.15E-06 Type 2 diabetes / / 17463246 rs2673522 chr3 21882969 G T 6.28E-04 Multiple complex diseases / / 17554300 rs9836784 chr3 21882991 G A 7.48E-05 Alcohol dependence / / 19581569 rs3860587 chr3 21886008 T C 6.49E-04 Type 2 diabetes / / 17463246 rs3843879 chr3 21886287 A G 3.39E-04 Type 2 diabetes / / 17463246 rs2630801 chr3 21887264 G C 8.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17009800 chr3 21887582 G A 7.41E-04 Multiple complex diseases / / 17554300 rs1515452 chr3 21888146 G C 2.00E-05 Type 2 diabetes / / 17463246 rs12489919 chr3 21889995 A C 6.49E-04 Type 2 diabetes / / 17463246 rs2673515 chr3 21894748 C T 3.27E-05 Type 2 diabetes / / 17463246 rs2336055 chr3 21895087 C T 4.91E-04 Parkinson's disease / / 17052657 rs2336055 chr3 21895087 C T 5.36E-05 Alcohol dependence / / 19581569 rs9310661 chr3 21897140 G A 1.59E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9855717 chr3 21898859 A C 6.49E-04 Type 2 diabetes / / 17463246 rs2673513 chr3 21898877 C T 4.79E-04 Multiple complex diseases / / 17554300 rs9838038 chr3 21898931 T C 6.49E-04 Type 2 diabetes / / 17463246 rs9822486 chr3 21899128 G A 8.55E-04 Type 2 diabetes / / 17463246 rs12487689 chr3 21899332 G A 8.82E-04 Type 2 diabetes / / 17463246 rs12487689 chr3 21899332 G A 8.36E-04 Alzheimer's disease / / 17998437 rs12494075 chr3 21899355 A G 8.74E-04 Alzheimer's disease / / 17998437 rs1621132 chr3 21909164 A G 1.61E-05 Type 2 diabetes / / 23945395 rs259498 chr3 21936532 G A 5.58E-05 Orofacial clefts LOC100505836 intron 20023658 rs1479975 chr3 21936641 G A,C 5.56E-05 Magnesium levels LOC100505836 intron pha003092 rs17010025 chr3 21941353 G C 4.64E-04 Multiple complex diseases LOC100505836 intron 17554300 rs17010054 chr3 21947772 G A 4.16E-04 Multiple complex diseases LOC100505836 intron 17554300 rs17010081 chr3 21951883 T A 4.44E-04 Multiple complex diseases LOC100505836 intron 17554300 rs10510519 chr3 21952110 G A 8.79E-04 Multiple complex diseases LOC100505836 intron 17554300 rs11719664 chr3 21955198 C T 2.00E-06 Attention deficit hyperactivity disorder LOC100505836 intron 18821565 rs1352135 chr3 21960467 G A 8.78E-06 Parkinson's disease LOC100505836 intron 21812969 rs1684524 chr3 21961267 T G 7.74E-06 Parkinson's disease LOC100505836 intron 21812969 rs1694037 chr3 21966110 T C 1.02E-05 Parkinson's disease LOC100505836 intron 21812969 rs259521 chr3 21967150 C T 1.12E-04 Bipolar disorder LOC100505836 intron 18317468 rs259521 chr3 21967150 C T 2.42E-06 Reading disability and language impairment LOC100505836 intron 24024963 rs9814232 chr3 21973175 G A 1.30E-06 Reading disability and language impairment LOC100505836 intron 24024963 rs519051 chr3 21985417 C T 8.00E-06 Urinary metabolites LOC100505836 intron 21572414 rs12489570 chr3 22003365 T C 4.97E-04 Obesity (extreme) LOC100505836 intron 21935397 rs7619247 chr3 22004458 G C 9.36E-04 Obesity (extreme) LOC100505836 intron 21935397 rs7642008 chr3 22004547 C A 9.35E-04 Obesity (extreme) LOC100505836 intron 21935397 rs17583756 chr3 22004875 G T 4.63E-05 Parkinson's disease LOC100505836 intron 21812969 rs12487974 chr3 22005305 C T 9.06E-04 Obesity (extreme) LOC100505836 intron 21935397 rs6765798 chr3 22009022 C T 3.53E-04 Obesity (extreme) LOC100505836 intron 21935397 rs9871168 chr3 22012285 A G 5.92E-05 Parkinson's disease LOC100505836 intron 21812969 rs1585863 chr3 22012418 A G 8.11E-04 Obesity (extreme) LOC100505836 intron 21935397 rs9815743 chr3 22019395 T C 2.60E-06 Urinary metabolites LOC100505836 intron 21572414 rs2291818 chr3 22019794 A G 7.95E-04 Obesity (extreme) LOC100505836 intron 21935397 rs12638192 chr3 22021630 T A 7.98E-04 Obesity (extreme) LOC100505836 intron 21935397 rs6789283 chr3 22021947 T C 1.34E-07 Femoral neck bone geometry LOC100505836 intron 22087292 rs1679255 chr3 22047934 C T 6.87E-07 Reading disability and language impairment LOC100505836 intron 24024963 rs259432 chr3 22057218 T C 8.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100505836 intron 20031582 rs779098 chr3 22061945 T A 5.60E-06 Urinary metabolites LOC100505836 intron 21572414 rs12636438 chr3 22063277 A G 5.45E-07 Reading disability and language impairment LOC100505836 intron 24024963 rs711688 chr3 22080819 G T 3.96E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs166315 chr3 22083587 A G 7.83E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259456 chr3 22084139 T C 7.76E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259458 chr3 22085607 A C 8.44E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259463 chr3 22088181 G A 6.67E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs941350 chr3 22103918 T A 3.00E-07 Urinary metabolites LOC100505836 intron 21572414 rs779167 chr3 22105044 A C 5.87E-05 Tunica Media LOC100505836 intron pha003037 rs11717259 chr3 22106222 G A 6.57E-05 Tunica Media LOC100505836 intron pha003037 rs17010728 chr3 22116971 C T 4.88E-04 Response to cytadine analogues (cytosine arabinoside) LOC100505836 intron 24483146 rs2593321 chr3 22122396 C T 8.00E-06 HIV-1 viral setpoint LOC100505836 intron 20205591 rs13069223 chr3 22129501 G C 6.04E-04 Multiple complex diseases LOC100505836 intron 17554300 rs2695642 chr3 22130392 G A 4.10E-07 Urinary metabolites LOC100505836 intron 21572414 rs779170 chr3 22137440 A G 4.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505836 intron 20877124 rs17010793 chr3 22144069 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505836 intron 22628534 rs6797769 chr3 22171297 A T 3.00E-06 IgG glycosylation LOC100505836 intron 23382691 rs4858389 chr3 22191086 A G 8.53E-04 Diabetic retinopathy LOC100505836 intron 20871662 rs1965306 chr3 22205505 C T 5.68E-04 Acute lung injury LOC100505836 intron 22295056 rs6769268 chr3 22206832 T C 7.25E-04 Acute lung injury LOC100505836 intron 22295056 rs9310685 chr3 22207033 G A 3.99E-05 Smoking quantity LOC100505836 intron 24665060 rs9868641 chr3 22207459 G A 6.57E-04 Type 2 diabetes LOC100505836 intron 17463246 rs9868641 chr3 22207459 G A 1.92E-04 Smoking quantity LOC100505836 intron 24665060 rs6782722 chr3 22212943 G A 5.58E-04 Acute lung injury LOC100505836 intron 22295056 rs6775362 chr3 22214274 A C 3.41E-04 Smoking quantity LOC100505836 intron 24665060 rs17010983 chr3 22229748 C A 3.67E-04 Alcohol dependence LOC100505836 intron 20201924 rs17029476 chr3 22231873 G C 9.58E-04 Type 2 diabetes LOC100505836 intron 17463246 rs1994727 chr3 22231931 T A 6.79E-04 Suicide attempts in bipolar disorder LOC100505836 intron 21041247 rs1405829 chr3 22235890 A G 7.56E-04 Type 2 diabetes LOC100505836 intron 17463246 rs6779779 chr3 22259851 C T 7.17E-04 Acute lung injury LOC100505836 intron 22295056 rs2638136 chr3 22261353 A G 5.81E-04 Acute lung injury LOC100505836 intron 22295056 rs2638143 chr3 22266934 C T 6.34E-04 Acute lung injury LOC100505836 intron 22295056 rs2035848 chr3 22278497 A G 1.76E-04 Multiple complex diseases LOC100505836 intron 17554300 rs2728954 chr3 22283291 C T 5.37E-04 Acute lung injury LOC100505836 intron 22295056 rs2728955 chr3 22284122 A G 3.67E-04 Acute lung injury LOC100505836 intron 22295056 rs729286 chr3 22285562 T G 7.59E-05 Acute lung injury LOC100505836 intron 22295056 rs2638150 chr3 22286262 C T 1.24E-04 Acute lung injury LOC100505836 intron 22295056 rs2638151 chr3 22287995 G C 1.32E-04 Acute lung injury LOC100505836 intron 22295056 rs1388550 chr3 22292516 C T 4.08E-04 Acute lung injury LOC100505836 intron 22295056 rs1388551 chr3 22292571 G A 2.00E-06 Waist-to-hip circumference ratio (interaction) LOC100505836 intron 23192594 rs2728958 chr3 22293609 T C 1.54E-04 Acute lung injury LOC100505836 intron 22295056 rs2728988 chr3 22300883 T C 5.66E-05 Acute lung injury LOC100505836 intron 22295056 rs2638159 chr3 22305788 C T 5.25E-04 Acute lung injury LOC100505836 intron 22295056 rs2638162 chr3 22314030 G A 8.48E-04 Acute lung injury LOC100505836 intron 22295056 rs2256818 chr3 22314463 T A 7.64E-04 Acute lung injury LOC100505836 intron 22295056 rs2638145 chr3 22318273 C A 5.64E-04 Acute lung injury LOC100505836 intron 22295056 rs1352869 chr3 22337031 T C 2.57E-04 Acute lung injury LOC100505836 intron 22295056 rs7621773 chr3 22339463 A T 1.07E-04 Acute lung injury LOC100505836 intron 22295056 rs9859862 chr3 22341338 G A 9.76E-05 Height LOC100505836 intron 17255346 rs9809134 chr3 22351154 C T 0.000679 Salmonella-induced pyroptosis LOC100505836 intron 22837397 rs9813743 chr3 22362562 C T 0.000257 Salmonella-induced pyroptosis LOC100505836 intron 22837397 rs1389661 chr3 22393482 C T 9.09E-04 Multiple complex diseases LOC100505836 intron 17554300 rs1494219 chr3 22395279 C T 2.91E-04 Response to cytidine analogues (gemcitabine) LOC100505836 intron 24483146 rs4858402 chr3 22428845 T G 2.39E-05 Schizophrenia / / 20832056 rs9852024 chr3 22471746 T A 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs9861611 chr3 22473092 T C 5.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs17011371 chr3 22473729 A G 6.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs11716879 chr3 22473843 T A 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs10510530 chr3 22484605 T A 1.79E-04 Alzheimer's disease / / 17998437 rs1450348 chr3 22504135 G A 7.23E-04 Multiple complex diseases / / 17554300 rs1450349 chr3 22504332 A G 9.11E-05 Multiple complex diseases / / 17554300 rs1901103 chr3 22513807 G T 9.12E-04 Myocardial Infarction / / pha002883 rs17011474 chr3 22535867 A G 8.46E-04 Multiple complex diseases / / 17554300 rs17011480 chr3 22535891 C G 6.92E-04 Multiple complex diseases / / 17554300 rs17011503 chr3 22545276 T C 3.42E-04 Type 2 diabetes / / 17463246 rs1597395 chr3 22552457 T C 2.21E-04 Type 2 diabetes / / 17463246 rs6550696 chr3 22562175 T A 6.30E-04 Type 2 diabetes / / 17463246 rs4392438 chr3 22562237 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs4392438 chr3 22562237 C T 3.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs4580581 chr3 22566324 C T 4.51E-04 Type 2 diabetes / / 17463246 rs1466123 chr3 22571896 G A 9.15E-04 Rheumatoid arthritis / / 21452313 rs1868577 chr3 22577278 T C 1.13E-05 Multiple complex diseases / / 17554300 rs6791874 chr3 22592585 C T 9.55E-06 Personality dimensions / / 23903073 rs13071252 chr3 22594055 C T 7.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6775609 chr3 22597882 T A 5.98E-04 Schizophrenia / / 21674006 rs6778123 chr3 22597952 T G 4.70E-05 Body Mass Index / / pha003007 rs6778123 chr3 22597952 T G 5.10E-05 Body Fat Distribution / / pha003016 rs6778123 chr3 22597952 T G 9.00E-05 Body Fat Distribution / / pha003017 rs1026527 chr3 22609529 C T 6.95E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1375823 chr3 22618061 T A,C 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1531160 chr3 22623604 C T 1.60E-04 IgE levels in asthmatics / / 23967269 rs7612139 chr3 22624379 T C 8.28E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13070085 chr3 22627609 T C 2.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1349281 chr3 22647701 C T 4.32E-04 Multiple complex diseases / / 17554300 rs6781670 chr3 22654835 C A 6.55E-04 Alzheimer's disease / / 22005930 rs6763517 chr3 22656900 G A 8.49E-04 Alzheimer's disease / / 24755620 rs17011741 chr3 22659186 A G 1.67E-04 Multiple complex diseases / / 17554300 rs3911109 chr3 22660100 T C 2.15E-04 Alzheimer's disease / / 22005930 rs1524309 chr3 22671737 C T 9.22E-05 Multiple complex diseases / / 17554300 rs9819972 chr3 22686023 T G 6.78E-04 Alzheimer's disease / / 22005930 rs1466352 chr3 22708802 T C 1.68E-04 Iron levels / / pha002876 rs9310704 chr3 22711446 G A 2.08E-04 Iron levels / / pha002876 rs3915080 chr3 22711509 A G 1.63E-04 Iron levels / / pha002876 rs11129085 chr3 22741464 A G 3.87E-04 Iron levels / / pha002876 rs11717343 chr3 22759348 T C 1.15E-05 Alzheimer's disease / / 21627779 rs6805037 chr3 22763202 A C 1.15E-05 Alzheimer's disease / / 21627779 rs17395135 chr3 22767397 A G 8.83E-06 Alzheimer's disease / / 21627779 rs7615445 chr3 22770593 C G 1.94E-04 Multiple complex diseases / / 17554300 rs11715788 chr3 22807079 C T 1.33E-05 Alzheimer's disease / / 21627779 rs11707636 chr3 22815982 T C 1.14E-05 Alzheimer's disease / / 21627779 rs17396388 chr3 22838756 C A 1.04E-05 Alzheimer's disease / / 21627779 rs33115 chr3 22840407 G A 3.57E-05 Multiple complex diseases / / 17554300 rs11718398 chr3 22860611 G A 9.20E-06 Alzheimer's disease / / 21627779 rs11718398 chr3 22860611 G A 8.25E-04 Alzheimer's disease / / 24755620 rs17337351 chr3 22865395 T C 9.13E-06 Alzheimer's disease / / 21627779 rs620918 chr3 22889452 T C 7.28E-07 Bipolar disorder / / 19488044 rs620918 chr3 22889452 T C 7.25E-06 Bipolar Disorder / / pha002858 rs299070 chr3 22905895 G A 0.0000108 Major depressive disorder / / 23149448 rs580227 chr3 22931734 T C 4.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs822759 chr3 22973112 G T 3.36E-05 Multiple complex diseases / / 17554300 rs711702 chr3 22981276 G A 4.00E-05 Obesity-related traits / / 17903300 rs711704 chr3 22983152 T C 5.69E-06 Hemoglobin / / pha003096 rs711704 chr3 22983152 T C 4.46E-05 Hematocrit / / pha003097 rs822780 chr3 22989819 A G 1.67E-04 Multiple complex diseases / / 17554300 rs822786 chr3 22994301 C T 8.37E-06 Hemoglobin / / pha003096 rs822786 chr3 22994301 C T 6.64E-05 Hematocrit / / pha003097 rs822789 chr3 22994602 G A 4.00E-05 Hemoglobin / / pha003096 rs711711 chr3 22998753 C T 5.42E-04 Multiple complex diseases / / 17554300 rs711714 chr3 23005150 T C 2.38E-04 Multiple complex diseases / / 17554300 rs711715 chr3 23010390 A G 5.25E-05 Multiple complex diseases / / 17554300 rs711716 chr3 23010422 C G 7.24E-05 Multiple complex diseases / / 17554300 rs680110 chr3 23032225 A G 6.88E-04 Iron levels / / pha002876 rs497387 chr3 23032340 A G 7.40E-04 Iron levels / / pha002876 rs9310709 chr3 23093574 T C 2.00E-06 Chronic kidney disease and serum creatinine levels / / 20686651 rs3860593 chr3 23102368 A G 5.95E-04 Body mass index / / 21701565 rs1485385 chr3 23123846 C G 8.89E-04 Body mass index / / 21701565 rs4591517 chr3 23143047 C T 3.00E-06 Colorectal cancer / / 23300701 rs9826624 chr3 23150308 C A 4.82E-05 Progressive supranuclear palsy / / 21685912 rs9827163 chr3 23150473 G C 8.01E-05 Progressive supranuclear palsy / / 21685912 rs4858477 chr3 23155165 G C 2.70E-06 Urinary metabolites / / 21572414 rs13317243 chr3 23185162 G C 5.25E-04 Substance dependence / / 21818250 rs9863600 chr3 23190832 A G 6.71E-10 Type 2 diabetes / / 22158537 rs9830468 chr3 23191098 G T 4.82E-11 Type 2 diabetes / / 22158537 rs4858060 chr3 23192695 T C 5.85E-04 Substance dependence / / 21818250 rs6762856 chr3 23193007 G A 2.85E-11 Type 2 diabetes / / 22158537 rs4619807 chr3 23193928 G A 2.00E-06 Psychosis (atypical) / / 24132900 rs6780569 chr3 23198484 G A 6.76E-09 Type 2 diabetes / / 20818381 rs6780569 chr3 23198484 G A 1.58E-11 Type 2 diabetes / / 22158537 rs6780569 chr3 23198484 G A 6.76E-09 Type 2 diabetes / / 23300278 rs6780569 chr3 23198484 G A 4.00E-07 Type 2 diabetes / / 23945395 rs9855620 chr3 23201290 C G 3.55E-08 Type 2 diabetes / / 22158537 rs7374732 chr3 23203454 C T 2.33E-08 Type 2 diabetes / / 22158537 rs9812056 chr3 23204024 T C 6.18E-08 Type 2 diabetes / / 20818381 rs9812056 chr3 23204024 T C 1.20E-10 Type 2 diabetes / / 22158537 rs9812056 chr3 23204024 T C 1.83E-08 Type 2 diabetes / / 23300278 rs7619223 chr3 23208008 C A 3.11E-05 Bipolar disorder / / 21771265 rs4311238 chr3 23209677 G T 4.42E-05 Multiple complex diseases / / 17554300 rs13314285 chr3 23212575 C A 1.76E-09 Type 2 diabetes / / 22158537 rs11927173 chr3 23225194 T C 9.99E-10 Type 2 diabetes / / 22158537 rs2014132 chr3 23234339 C T 2.64E-09 Type 2 diabetes / / 22158537 rs2291720 chr3 23237189 A G 2.36E-09 Type 2 diabetes LOC100505877 intron 22158537 rs1495130 chr3 23241009 C G 4.01E-09 Type 2 diabetes LOC100505877 intron 22158537 rs1552931 chr3 23248486 A G 1.88E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012823 chr3 23259724 C G 2.06E-09 Type 2 diabetes UBE2E2 intron 22158537 rs2055156 chr3 23262197 G A 2.70E-05 Urinary metabolites UBE2E2 intron 21572414 rs17012834 chr3 23262290 C T 1.54E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1908475 chr3 23268156 G A 1.33E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17012844 chr3 23269591 A G 1.27E-08 Type 2 diabetes UBE2E2 intron 22158537 rs10510536 chr3 23269770 T C 1.41E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1495134 chr3 23270047 C A 3.66E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012852 chr3 23270561 G A 1.19E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17012861 chr3 23275053 A G 1.31E-08 Type 2 diabetes UBE2E2 intron 22158537 rs11715035 chr3 23278691 A T 1.80E-05 Urinary metabolites UBE2E2 intron 21572414 rs13087234 chr3 23283132 T C 5.20E-09 Type 2 diabetes UBE2E2 intron 22158537 rs13083654 chr3 23286684 A C 9.71E-09 Type 2 diabetes UBE2E2 intron 22158537 rs6792370 chr3 23289892 C T 6.52E-07 Type 2 diabetes UBE2E2 intron 20818381 rs6792370 chr3 23289892 C T 1.22E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1390083 chr3 23299166 T A 1.57E-07 Type 2 diabetes UBE2E2 intron 22158537 rs2132145 chr3 23302649 G A 8.81E-08 Type 2 diabetes UBE2E2 intron 22158537 rs9846398 chr3 23312158 A G 4.10E-05 Lung cancer UBE2E2 intron 18385738 rs7630344 chr3 23317542 C T 1.84E-07 Red blood cell traits UBE2E2 intron 23222517 rs17012943 chr3 23317924 T A 6.38E-09 Type 2 diabetes UBE2E2 intron 22158537 rs10510537 chr3 23321920 C A 6.47E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1495133 chr3 23322679 A G 7.19E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012959 chr3 23332784 T G 1.50E-05 Type 2 diabetes UBE2E2 intron 22158537 rs7612463 chr3 23336450 C A 3.19E-08 Type 2 diabetes UBE2E2 intron 20818381 rs7612463 chr3 23336450 C A 4.50E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7612463 chr3 23336450 C A 2.27E-09 Type 2 diabetes UBE2E2 intron 23300278 rs7612463 chr3 23336450 C A 7.00E-09 Type 2 diabetes UBE2E2 intron 24509480 rs2055155 chr3 23343192 A G 2.29E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17012969 chr3 23344383 C T 2.58E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7648425 chr3 23346407 G C 6.40E-07 Type 2 diabetes UBE2E2 intron 22158537 rs7627380 chr3 23346795 C T 4.26E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17012988 chr3 23349775 A G 6.28E-09 Type 2 diabetes UBE2E2 intron 22158537 rs6790185 chr3 23352223 G A 1.23E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17012998 chr3 23360627 T G 1.65E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17013003 chr3 23361463 T C 3.33E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9844558 chr3 23364883 G A 1.27E-04 Type 2 diabetes UBE2E2 intron 22158537 rs6806387 chr3 23369029 C G 2.59E-05 Type 2 diabetes UBE2E2 intron 22158537 rs952134 chr3 23374559 A G 1.57E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013026 chr3 23375083 A G 3.50E-05 Type 2 diabetes UBE2E2 intron 22158537 rs4858505 chr3 23377366 C T 7.05E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013029 chr3 23378027 A G 1.61E-05 Type 2 diabetes UBE2E2 intron 22158537 rs716456 chr3 23380290 C G 3.58E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013035 chr3 23383068 C G 2.00E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013049 chr3 23385942 G T 2.78E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013104 chr3 23398680 A G 2.26E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013116 chr3 23400417 T G 2.16E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013125 chr3 23401528 C G 1.90E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013128 chr3 23401596 G T 2.08E-06 Type 2 diabetes UBE2E2 intron 22158537 rs2047340 chr3 23402038 G A 9.48E-05 Type 2 diabetes UBE2E2 intron 22158537 rs13063986 chr3 23404705 T C 3.71E-05 Type 2 diabetes UBE2E2 intron 22158537 rs13084327 chr3 23405023 A G 4.58E-06 Type 2 diabetes UBE2E2 intron 22158537 rs13098494 chr3 23415697 T G 7.56E-07 Type 2 diabetes UBE2E2 intron 22158537 rs6795968 chr3 23417027 A C 3.45E-07 Red blood cell traits UBE2E2 intron 23222517 rs17345745 chr3 23418527 C T 9.00E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013152 chr3 23419945 C G 1.47E-04 Type 2 diabetes UBE2E2 intron 22158537 rs12715048 chr3 23425959 A T 1.12E-07 Red blood cell traits UBE2E2 intron 23222517 rs1496653 chr3 23454790 A G 2.30E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1496653 chr3 23454790 A G 0.00000044 Type 2 diabetes (males) UBE2E2 intron 22885922 rs1496653 chr3 23454790 A G 0.000017 Fasting insulin-related traits UBE2E2 intron 22885922 rs1496653 chr3 23454790 A G 3.60E-09 Type 2 diabetes UBE2E2 intron 22885922 rs7613185 chr3 23455464 T C 3.89E-07 Type 2 diabetes UBE2E2 intron 22158537 rs13094957 chr3 23457080 T C 6.24E-07 Type 2 diabetes UBE2E2 intron 22158537 rs1692619 chr3 23460232 G A 2.80E-05 Urinary metabolites UBE2E2 intron 21572414 rs13090303 chr3 23463647 A G 2.25E-06 Type 2 diabetes UBE2E2 intron 22158537 rs1692617 chr3 23463814 A G 8.25E-05 Alopecia areata UBE2E2 intron 22027810 rs1692617 chr3 23463814 A G 1.92E-05 Vitiligo UBE2E2 intron 22561518 rs13095736 chr3 23464320 A C 2.52E-06 Type 2 diabetes UBE2E2 intron 22158537 rs778493 chr3 23466101 G T 1.68E-05 Type 2 diabetes UBE2E2 intron 22158537 rs7628372 chr3 23466255 A C 4.67E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9873329 chr3 23467026 T C 5.55E-09 Type 2 diabetes UBE2E2 intron 22158537 rs2359765 chr3 23467773 G A 3.69E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013216 chr3 23476008 C T 1.24E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013223 chr3 23476407 A G 7.52E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013241 chr3 23482110 T C 9.22E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013245 chr3 23482375 A G 7.50E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9836574 chr3 23493521 G C 2.54E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013286 chr3 23496134 C T 2.90E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013320 chr3 23513056 T G 3.04E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013322 chr3 23517847 T C 2.25E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1695192 chr3 23522003 G C 7.38E-06 Type 2 diabetes UBE2E2 intron 22158537 rs2173461 chr3 23522217 A C 8.79E-06 Vitiligo UBE2E2 intron 22561518 rs1692647 chr3 23522809 A C 6.34E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013333 chr3 23523106 G T 1.15E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013344 chr3 23525461 G A 1.16E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013348 chr3 23525997 G A 1.35E-09 Type 2 diabetes UBE2E2 intron 22158537 rs801277 chr3 23529021 T C 8.68E-08 Type 2 diabetes UBE2E2 intron 22158537 rs9631541 chr3 23539779 A G 7.15E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1011754 chr3 23541057 A G 2.15E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013383 chr3 23547371 A T 9.57E-10 Type 2 diabetes UBE2E2 intron 22158537 rs2133331 chr3 23549075 C T 6.50E-07 Red blood cell traits UBE2E2 intron 23222517 rs6770091 chr3 23554807 G A 4.69E-08 Red blood cell traits UBE2E2 intron 23222517 rs17013390 chr3 23556924 T C 1.24E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7632814 chr3 23567289 T G 9.11E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013429 chr3 23577554 T C 1.21E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17013433 chr3 23578594 G A 6.22E-10 Type 2 diabetes UBE2E2 intron 22158537 rs12637722 chr3 23605325 G A 6.39E-04 Oral cancers (chewing tobacco related) UBE2E2 intron 22503698 rs6550767 chr3 23639400 T G 4.58E-07 Red blood cell traits / / 23222517 rs4389424 chr3 23677525 C T 2.73E-05 Blood Pressure / / pha003048 rs4596094 chr3 23680901 C T 4.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6793612 chr3 23684312 C T 9.10E-05 White matter hyperintensity burden / / 21681796 rs6793612 chr3 23684312 C T 7.36E-05 Alcohol consumption / / 23953852 rs4516558 chr3 23692695 G A 0.000847 Salmonella-induced pyroptosis / / 22837397 rs4858524 chr3 23695943 G T 0.00013 Salmonella-induced pyroptosis / / 22837397 rs4858524 chr3 23695943 G T 8.10E-05 Heart Rate / / pha003051 rs11129122 chr3 23712616 A G 4.97E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs9812786 chr3 23735174 T C 9.04E-04 Acute lung injury / / 22295056 rs6807249 chr3 23739829 A G 1.28E-04 Acute lung injury / / 22295056 rs73048609 chr3 23746535 C T 4.25E-04 Tuberculosis / / 22306650 rs7620545 chr3 23748920 T C 3.82E-04 Smoking cessation / / 24665060 rs6550784 chr3 23753135 T C 7.36E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs751481 chr3 23768866 A G 2.39E-04 Longevity / / 22279548 rs4510335 chr3 23770133 C T 1.16E-04 Hearing function / / 17255346 rs17013700 chr3 23785623 G A 7.35E-05 Suicide attempts in bipolar disorder / / 21423239 rs6774017 chr3 23789836 A G 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs6791919 chr3 23804744 T C 7.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9825869 chr3 23822247 G A 1.15E-04 Blood pressure / / 17255346 rs9825869 chr3 23822247 G A 1.34E-04 Rheumatoid arthritis / / 21452313 rs6774787 chr3 23859061 T C 8.68E-04 Lymphocyte counts UBE2E1 intron 22286170 rs1037635 chr3 23882465 G C 7.34E-04 Aortic root size UBE2E1 intron 21223598 rs28405582 chr3 23904762 T C 1.00E-06 Acne (severe) UBE2E1 intron 24927181 rs9809225 chr3 23941023 T C 3.37E-05 Aortic root size NKIRAS1 intron 21223598 rs13317815 chr3 23988685 C T 6.69E-04 Aortic root size NR1D2 intron 21223598 rs3935253 chr3 23999756 C T 7.04E-05 Aortic root size NR1D2 intron 21223598 rs4321479 chr3 24001078 C T 3.86E-04 Insulin resistance NR1D2 intron 21901158 rs6550825 chr3 24034969 G A 0.00000229 Cytarabine sensitivity / / 23538338 rs6550826 chr3 24034988 G C 0.0000054 Cytarabine sensitivity / / 23538338 rs1567582 chr3 24036167 A C 0.00000368 Cytarabine sensitivity / / 23538338 rs1533140 chr3 24039380 G A 0.00000481 Cytarabine sensitivity / / 23538338 rs9883101 chr3 24044400 C A 0.00000426 Cytarabine sensitivity / / 23538338 rs4568061 chr3 24049520 C A 4.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4356765 chr3 24052025 C T 4.47E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7612158 chr3 24109112 G A 1.65E-05 Type 2 diabetes / / 21799836 rs6800768 chr3 24113252 T C 6.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs6781758 chr3 24119857 G A 9.10E-05 Type 2 diabetes / / 21799836 rs7630879 chr3 24128336 T C 9.56E-04 Type 2 diabetes / / 17463246 rs2360959 chr3 24143200 C A 2.97E-05 Type 2 diabetes LOC152024 intron 21799836 rs2360958 chr3 24143273 T C 1.79E-05 Type 2 diabetes LOC152024 intron 21799836 rs2063481 chr3 24143301 T G 5.02E-08 Narcolepsy LOC152024 intron 19629137 rs1511540 chr3 24152386 C T 3.44E-05 Type 2 diabetes / / 21799836 rs6782978 chr3 24165541 G A 2.78E-05 Type 2 diabetes THRB intron 21799836 rs1868573 chr3 24169493 C T 4.90E-05 Temporomandibular joint disorders THRB intron 23746317 rs826379 chr3 24172777 A C 9.94E-05 Body Fat Distribution THRB intron pha003016 rs1705734 chr3 24173744 A G 8.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) THRB intron 23648065 rs826385 chr3 24187084 A G 1.90E-04 Acute lung injury THRB intron 22295056 rs9844739 chr3 24190184 G A 7.73E-05 Body Fat Distribution THRB intron pha003016 rs2683545 chr3 24192584 C T 9.51E-05 Cognitive test performance THRB intron 20125193 rs2596623 chr3 24204984 C T 4.92E-05 Intelligence THRB intron 21826061 rs2683530 chr3 24211739 T C 6.32E-05 stroke (ischemic) THRB intron 17434096 rs2683540 chr3 24221947 G T 1.00E-04 Information processing speed THRB intron 21130836 rs2683540 chr3 24221947 G T 7.41E-05 Cognitive decline THRB intron 23732972 rs1667739 chr3 24230196 G A 3.53E-04 Multiple complex diseases THRB intron 17554300 rs6800891 chr3 24251816 G A 4.81E-04 Lung function (forced expiratory volume in 1 second) THRB intron 24023788 rs7632417 chr3 24254517 C T 8.20E-04 Bipolar disorder THRB intron 19259986 rs17014338 chr3 24255079 C T 1.00E-04 Lung function (forced expiratory volume in 1 second) THRB intron 24023788 rs826223 chr3 24267140 A G 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) THRB intron 23648065 rs826221 chr3 24268436 A G 7.00E-06 Systolic blood pressure in sickle cell anemia THRB intron 24058526 rs826218 chr3 24269690 A G 3.48E-04 Multiple complex diseases THRB intron 17554300 rs1466122 chr3 24270796 A G 5.40E-04 Multiple complex diseases THRB intron 17554300 rs4858593 chr3 24270970 C A 2.40E-06 Urinary metabolites THRB intron 21572414 rs7619754 chr3 24271599 A G 2.40E-04 Multiple complex diseases THRB intron 17554300 rs9874037 chr3 24271657 C T 1.76E-05 Parent of origin effect on language impairment (child trend) THRB intron 24571439 rs9874037 chr3 24271657 C T 7.65E-05 Parent of origin effect on language impairment (maternal) THRB intron 24571439 rs1449874 chr3 24271828 C T 5.90E-04 Multiple complex diseases THRB intron 17554300 rs4858594 chr3 24273854 G A 4.02E-05 Multiple complex diseases THRB intron 17554300 rs9829876 chr3 24277179 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes THRB intron 22628534 rs12386345 chr3 24281488 G A 0.000326 Salmonella-induced pyroptosis THRB intron 22837397 rs1505298 chr3 24284794 G T 8.92E-08 Metabolite levels THRB intron 23281178 rs826230 chr3 24306302 G A 1.89E-09 Metabolite levels THRB intron 23281178 rs826231 chr3 24306831 T G 1.89E-09 Metabolite levels THRB intron 23281178 rs862247 chr3 24307693 T C 1.89E-09 Metabolite levels THRB intron 23281178 rs826236 chr3 24314612 A C 1.62E-09 Metabolite levels THRB intron 23281178 rs826238 chr3 24316463 T C 6.38E-09 Metabolite levels THRB intron 23281178 rs826240 chr3 24317591 A G 6.38E-09 Metabolite levels THRB intron 23281178 rs1827736 chr3 24328678 G C 3.57E-04 Multiple complex diseases THRB intron 17554300 rs1868575 chr3 24330283 G A 3.09E-10 Red blood cell traits THRB intron 23222517 rs1158265 chr3 24336162 T C 1.49E-08 Red blood cell traits THRB intron 23222517 rs9830674 chr3 24337914 C T 1.88E-11 Red blood cell traits THRB intron 23222517 rs2167115 chr3 24339734 A G 5.15E-09 Red blood cell traits THRB intron 23222517 rs4858603 chr3 24340817 A G 8.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs1505307 chr3 24343330 T C 1.81E-12 Red blood cell traits THRB intron 23222517 rs1505283 chr3 24345776 A G 2.67E-11 Red blood cell traits THRB intron 23222517 rs12485694 chr3 24346109 A G 1.98E-11 Red blood cell traits THRB intron 23222517 rs9850879 chr3 24346981 G A 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs9310736 chr3 24350811 A G 3.33E-08 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 3.52E-10 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 4.00E-10 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 0.000000006 Mean corpuscular volume THRB intron 22560525 rs9310736 chr3 24350811 A G 6.00E-16 Red blood cell traits THRB intron 23222517 rs10510543 chr3 24351642 T C 5.32E-05 Type 2 diabetes THRB intron 17846125 rs7622481 chr3 24351871 C T 2.32E-07 Red blood cell traits THRB intron 23222517 rs1505297 chr3 24355634 T C 8.42E-13 Red blood cell traits THRB intron 23222517 rs7610039 chr3 24357082 T C 5.23E-09 Red blood cell traits THRB intron 23222517 rs7640580 chr3 24357243 C A 3.46E-09 Red blood cell traits THRB intron 23222517 rs7610222 chr3 24357286 T C 1.00E-05 Cognitive performance THRB intron 19734545 rs7610222 chr3 24357286 T C 3.12E-11 Red blood cell traits THRB intron 23222517 rs12639035 chr3 24357332 G C 3.96E-04 Type 2 diabetes THRB intron 17463246 rs17014539 chr3 24369366 A G 3.93E-04 Alzheimer's disease THRB intron 22005930 rs9812034 chr3 24370875 T G 1.57E-05 Acne (severe teenage) THRB intron 24114350 rs7609823 chr3 24379744 G A 1.00E-04 Cognitive impairment induced by topiramate THRB intron 22091778 rs9833191 chr3 24384005 C T 4.39E-05 Malignant pleural mesothelioma THRB intron 23626673 rs9833191 chr3 24384005 C T 7.67E-06 Malignant pleural mesothelioma THRB intron 23626673 rs7619474 chr3 24390258 T C 5.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs7619474 chr3 24390258 T C 6.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs6781111 chr3 24403210 T C 4.47E-04 Parkinson's disease THRB intron 16252231 rs6550859 chr3 24410415 G A 5.72E-05 Male-pattern baldness THRB intron 18849994 rs11919155 chr3 24413479 C A 3.66E-04 Myopia (pathological) THRB intron 21095009 rs12638970 chr3 24419005 T C 2.90E-05 Urinary metabolites THRB intron 21572414 rs3903470 chr3 24508021 T C 1.20E-04 Parkinson's disease THRB intron 17052657 rs3903470 chr3 24508021 T C 1.00E-04 Cognitive impairment induced by topiramate THRB intron 22091778 rs982952 chr3 24511270 G A 2.10E-05 Urinary metabolites THRB intron 21572414 rs4353759 chr3 24512956 A C 1.90E-04 Parkinson's disease THRB intron 17052657 rs892941 chr3 24573805 T C 2.69E-04 Coronary heart disease / / 21971053 rs9838720 chr3 24590744 G A 9.19E-04 Type 2 diabetes / / 17463246 rs9838616 chr3 24590841 C T 8.27E-04 Type 2 diabetes / / 17463246 rs17014812 chr3 24597454 G A 9.91E-05 Multiple complex diseases / / 17554300 rs12496683 chr3 24627561 G A 6.65E-04 Coronary heart disease / / 21971053 rs6795607 chr3 24631165 T C 2.40E-05 Alcohol dependence / / 20201924 rs6795607 chr3 24631165 T C 3.00E-05 Coronary restenosis / / 21878436 rs6795607 chr3 24631165 T C 2.36E-05 Alcoholism / / pha002893 rs10490837 chr3 24632124 A C 7.60E-04 Multiple complex diseases / / 17554300 rs10490837 chr3 24632124 A C 3.12E-04 Alzheimer's disease / / 17998437 rs9819865 chr3 24636524 G A 3.10E-06 Coronary restenosis / / 21878436 rs9819865 chr3 24636524 G A 6.81E-05 Alcoholism / / pha002893 rs12631757 chr3 24643573 C T 2.09E-05 Celiac disease / / 23936387 rs10490835 chr3 24646108 G A 9.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17014951 chr3 24652813 A G 7.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs11129156 chr3 24660864 A G 2.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs12495477 chr3 24666286 G A 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2362758 chr3 24669959 A C 9.90E-04 Multiple complex diseases / / 17554300 rs9861176 chr3 24670141 C G 5.75E-04 Multiple complex diseases / / 17554300 rs9817530 chr3 24681883 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9843745 chr3 24686548 G A,T 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9843745 chr3 24686548 G A,T 1.90E-04 Myasthenia gravis / / 23055271 rs7610415 chr3 24691022 C T 4.60E-04 Myasthenia gravis / / 23055271 rs4452272 chr3 24691209 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs4131483 chr3 24691492 A T 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs6793060 chr3 24696284 A G 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs2362754 chr3 24700277 G C 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs11928551 chr3 24703899 G T 1.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs9812637 chr3 24705221 G A 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs9812637 chr3 24705221 G A 1.90E-04 Myasthenia gravis / / 23055271 rs7643926 chr3 24707093 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs7643926 chr3 24707093 C T 6.99E-04 Obesity (extreme) / / 21935397 rs7644196 chr3 24707364 C G 2.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs17787397 chr3 24708074 C T 2.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6767967 chr3 24708874 A G 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs6770162 chr3 24711013 G A 2.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1984874 chr3 24715105 C T 3.91E-05 Suicide attempts in bipolar disorder / / 21041247 rs1984870 chr3 24715135 G T 3.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs2362755 chr3 24716668 G T 5.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs2362756 chr3 24716764 G T 4.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs6550889 chr3 24718439 G T 2.50E-04 Myasthenia gravis / / 23055271 rs4241531 chr3 24767611 T C 2.24E-04 Hearing function / / 17255346 rs4241531 chr3 24767611 T C 6.64E-04 Multiple complex diseases / / 17554300 rs4375990 chr3 24774912 T C 1.12E-06 Multiple complex diseases / / 17554300 rs12486584 chr3 24776203 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12486584 chr3 24776203 G T 1.58E-04 Taste perception / / 22132133 rs6766822 chr3 24778690 A G 1.51E-04 Self-reported allergy / / 23817569 rs6772760 chr3 24779648 T C 9.01E-04 Multiple complex diseases / / 17554300 rs4075988 chr3 24780266 A G 2.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs7616736 chr3 24781645 G C 9.15E-04 Aortic root size / / 21223598 rs13433781 chr3 24782701 C T 1.16E-04 Celiac disease / / 23936387 rs13072480 chr3 24782825 G C 2.98E-04 Taste perception / / 22132133 rs9853202 chr3 24788904 G T 6.86E-05 Serum metabolites / / 19043545 rs10154915 chr3 24791059 C G 4.62E-05 Odorant perception / / 23910658 rs4858647 chr3 24791375 C A 7.58E-04 Taste perception / / 22132133 rs9856194 chr3 24794547 C T 2.10E-05 Urinary metabolites / / 21572414 rs11129165 chr3 24813614 C T 3.59E-04 Cognitive decline / / 23732972 rs2362772 chr3 24918232 C A 0.0005692 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2362772 chr3 24918232 C A 5.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12493197 chr3 24919200 C G 3.33E-04 Aortic root size / / 21223598 rs10865799 chr3 24921468 C T 0.0004473 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10865799 chr3 24921468 C T 4.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10865800 chr3 24921483 C A 0.0004487 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10865800 chr3 24921483 C A 4.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6550923 chr3 24924495 G A 0.000000917 Joint damage severity in rheumatoid arthritis / / 23696630 rs10510551 chr3 24927203 T C 9.60E-06 Endometriosis / / 23104006 rs10865801 chr3 24929802 C A 5.34E-04 Aortic root size / / 21223598 rs2363518 chr3 24942213 G A 4.81E-04 Acute lung injury / / 22295056 rs9808989 chr3 24956222 T C 1.45E-04 Acute lung injury / / 22295056 rs9827612 chr3 24956953 A G 8.09E-05 Acute lung injury / / 22295056 rs9827612 chr3 24956953 A G 1.26E-04 Tourette syndrome / / 22889924 rs9827642 chr3 24957017 A G 1.96E-04 Acute lung injury / / 22295056 rs6772273 chr3 24961039 A G 2.18E-04 Acute lung injury / / 22295056 rs6772493 chr3 24961293 A G 1.46E-04 Acute lung injury / / 22295056 rs13326208 chr3 24961849 A G 3.34E-04 Smoking cessation / / 24665060 rs6779838 chr3 24963711 A G 2.19E-04 Acute lung injury / / 22295056 rs2363525 chr3 24971843 G A 4.87E-04 Tourette syndrome / / 22889924 rs12637240 chr3 24972398 C T 1.06E-04 Aortic root size / / 21223598 rs2363526 chr3 24972416 C A 5.84E-04 Acute lung injury / / 22295056 rs2363527 chr3 24972792 T C 1.40E-05 Urinary metabolites / / 21572414 rs2363527 chr3 24972792 T C 1.60E-10 Non-obstructive azoospermia / / 22197933 rs2363528 chr3 24972894 T A 4.36E-04 Acute lung injury / / 22295056 rs9878781 chr3 24974882 G A 5.19E-04 Tourette syndrome / / 22889924 rs9883836 chr3 24975890 C T 4.45E-04 Acute lung injury / / 22295056 rs2363529 chr3 24977639 T C 4.76E-04 Multiple complex diseases / / 17554300 rs2363529 chr3 24977639 T C 6.30E-06 Urinary metabolites / / 21572414 rs13070123 chr3 24977884 A G 9.20E-07 Urinary metabolites / / 21572414 rs2363530 chr3 24979142 C T 8.32E-04 Acute lung injury / / 22295056 rs11710017 chr3 24979746 C A 3.07E-04 Multiple complex diseases / / 17554300 rs11710017 chr3 24979746 C A 2.00E-06 Urinary metabolites / / 21572414 rs11710017 chr3 24979746 C A 8.44E-04 Acute lung injury / / 22295056 rs11710017 chr3 24979746 C A 7.98E-04 Smoking cessation / / 24665060 rs9882350 chr3 24980763 G A 4.64E-04 Multiple complex diseases / / 17554300 rs9882350 chr3 24980763 G A 5.05E-04 Coronary Artery Disease / / 17634449 rs9882350 chr3 24980763 G A 3.60E-04 Tourette syndrome / / 22889924 rs12629369 chr3 24981362 C T 6.91E-05 Multiple complex diseases / / 17554300 rs7648839 chr3 24981622 A T 1.50E-05 Urinary metabolites / / 21572414 rs7614855 chr3 24981701 G A 4.60E-05 Multiple complex diseases / / 17554300 rs7614855 chr3 24981701 G A 2.85E-04 Tourette syndrome / / 22889924 rs7614855 chr3 24981701 G A 3.06E-04 Lung function (forced vital capacity) / / 24023788 rs6798808 chr3 24990630 G C 3.25E-04 Multiple complex diseases / / 17554300 rs6798808 chr3 24990630 G C 1.80E-06 Urinary metabolites / / 21572414 rs13325698 chr3 24994235 T C 7.19E-04 Smoking cessation / / 24665060 rs6780762 chr3 24997512 C A 2.10E-05 Urinary metabolites / / 21572414 rs17195108 chr3 25001225 C T 2.40E-05 Urinary metabolites / / 21572414 rs4858671 chr3 25008333 G C 2.40E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs9849459 chr3 25009827 T C 5.55E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs6779328 chr3 25017218 T C 2.92E-06 Schizophrenia / / 19571811 rs11928745 chr3 25029366 G A 1.50E-05 Urinary metabolites / / 21572414 rs9826014 chr3 25040502 T A 5.25E-05 Serum metabolites / / 19043545 rs6550933 chr3 25043105 G A 3.00E-06 Urinary metabolites / / 21572414 rs9842801 chr3 25047228 C G 5.70E-06 Urinary metabolites / / 21572414 rs9842936 chr3 25047254 C A 3.80E-06 Urinary metabolites / / 21572414 rs9868031 chr3 25050175 A T 1.82E-04 Type 2 diabetes / / 17463246 rs4858681 chr3 25052109 C T 8.00E-07 Urinary metabolites / / 21572414 rs6550934 chr3 25052333 G A 1.00E-05 Urinary metabolites / / 21572414 rs4241541 chr3 25052548 G C 1.40E-06 Urinary metabolites / / 21572414 rs4241542 chr3 25052754 C T 6.04E-06 Eosinophil counts / / pha003088 rs4280597 chr3 25053482 G A 1.50E-07 Urinary metabolites / / 21572414 rs4298013 chr3 25053643 A C 5.79E-05 Type 2 diabetes / / 17463246 rs4298013 chr3 25053643 A C 5.70E-06 Urinary metabolites / / 21572414 rs1875062 chr3 25055926 G C 1.00E-05 Urinary metabolites / / 21572414 rs1021702 chr3 25059227 A G 1.20E-05 Eosinophil counts / / pha003088 rs1909520 chr3 25063701 G C 1.45E-04 Type 2 diabetes / / 17463246 rs1909520 chr3 25063701 G C 5.80E-06 Urinary metabolites / / 21572414 rs1604006 chr3 25064354 C T 5.02E-04 Multiple complex diseases / / 17554300 rs1604006 chr3 25064354 C T 6.64E-05 Serum metabolites / / 19043545 rs10865802 chr3 25064898 C G 1.31E-04 Multiple complex diseases / / 17554300 rs10865802 chr3 25064898 C G 6.73E-06 Schizophrenia / / 19571809 rs10865802 chr3 25064898 C G 1.32E-05 Schizophrenia / / pha002859 rs873429 chr3 25065129 G A 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6806291 chr3 25068162 G A 2.10E-05 Urinary metabolites / / 21572414 rs4858692 chr3 25075167 C T 2.70E-05 Endometriosis / / 21151130 rs4858692 chr3 25075167 C T 1.30E-06 Endometriosis / / 23104006 rs1603995 chr3 25075530 C T 1.60E-06 Endometriosis / / 23104006 rs9310769 chr3 25092767 T A 7.78E-06 Bipolar disorder and schizophrenia / / 20889312 rs4858695 chr3 25097838 T C 9.50E-06 Urinary metabolites / / 21572414 rs993803 chr3 25112118 C T 2.30E-05 Urinary metabolites / / 21572414 rs993804 chr3 25112171 C T 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs993804 chr3 25112171 C T 1.40E-05 Urinary metabolites / / 21572414 rs993804 chr3 25112171 C T 4.39E-05 Schizophrenia / / pha002857 rs9827724 chr3 25127498 C T 2.10E-05 Urinary metabolites / / 21572414 rs4858700 chr3 25127689 T A 2.00E-05 Urinary metabolites / / 21572414 rs13072262 chr3 25131570 A G 8.00E-06 Urinary metabolites / / 21572414 rs13072262 chr3 25131570 A G 2.01E-05 Asthma / / 23181788 rs17516267 chr3 25141279 G A 3.95E-04 Depression (quantitative trait) / / 20800221 rs17575546 chr3 25141612 T C 1.90E-04 Depression (quantitative trait) / / 20800221 rs4858142 chr3 25143427 T C 7.93E-04 Parkinson's disease / / 17052657 rs41530749 chr3 25155871 A C 8.40E-04 Multiple complex diseases / / 17554300 rs41441147 chr3 25158418 A G 6.77E-04 Multiple complex diseases / / 17554300 rs11129182 chr3 25171297 T C 3.52E-07 Cataracts in type 2 diabetes / / 20664687 rs11129184 chr3 25172600 A G 3.88E-05 Serum metabolites / / 19043545 rs11129187 chr3 25172786 G C 4.07E-05 Serum metabolites / / 19043545 rs6804502 chr3 25173349 G A 1.37E-05 Serum metabolites / / 19043545 rs4542987 chr3 25174769 T C 3.37E-05 Serum metabolites / / 19043545 rs9840225 chr3 25181030 G A 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7611139 chr3 25183414 T C 1.91E-04 Fibrinogen / / 17255346 rs17576864 chr3 25192389 A G 6.86E-04 Multiple complex diseases / / 17554300 rs2885836 chr3 25195123 A G 5.40E-05 Calcium levels / / 24068962 rs17517875 chr3 25208270 C G 9.91E-04 Multiple complex diseases / / 17554300 rs12152294 chr3 25215670 A G 5.54E-04 Multiple complex diseases / / 17554300 rs11924843 chr3 25272108 A G 6.49E-05 Serum metabolites / / 19043545 rs322668 chr3 25343615 G A 4.00E-06 IgG glycosylation / / 23382691 rs322695 chr3 25349538 G A 7.28E-04 Acute lung injury / / 22295056 rs9867006 chr3 25361852 C G 5.00E-07 Urinary metabolites / / 21572414 rs17016187 chr3 25364289 A G 4.40E-07 Urinary metabolites / / 21572414 rs11720675 chr3 25376779 A G 5.10E-07 Urinary metabolites / / 21572414 rs322684 chr3 25377223 G A 8.71E-06 Primary biliary cirrhosis / / 21399635 rs6799363 chr3 25379134 C G 2.80E-05 Urinary metabolites / / 21572414 rs4681047 chr3 25383258 A G 5.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs1483831 chr3 25383666 G A 8.34E-06 Primary biliary cirrhosis / / 21399635 rs6550966 chr3 25388856 G C 1.80E-07 Urinary metabolites / / 21572414 rs729236 chr3 25390429 C G 1.00E-05 Urinary metabolites / / 21572414 rs11709732 chr3 25391348 A C 2.10E-07 Urinary metabolites / / 21572414 rs17016260 chr3 25392580 A G 1.40E-08 Urinary metabolites / / 21572414 rs11718836 chr3 25392772 G A 5.20E-08 Osteoarthritis (knee) / / 18622395 rs6550967 chr3 25396760 G T 7.72E-05 Erythrocyte counts / / pha003101 rs17588596 chr3 25396865 C T 2.20E-06 Urinary metabolites / / 21572414 rs12631631 chr3 25398175 G A 5.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs1016787 chr3 25406510 T C 9.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs922943 chr3 25408748 G A 4.79E-04 Longevity / / 22279548 rs7622538 chr3 25414937 G C 5.03E-05 Bipolar disorder / / 18317468 rs1864911 chr3 25418008 G A 1.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4681053 chr3 25418646 T C 4.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7628541 chr3 25422696 G A 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7618590 chr3 25422776 A G 1.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9839276 chr3 25423766 A G 4.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1159899 chr3 25424428 G A 7.28E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2306624 chr3 25424561 T C 1.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6786765 chr3 25431234 T C 8.41E-04 Multiple complex diseases / / 17554300 rs6550974 chr3 25450943 G A 2.83E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6805482 chr3 25460596 A G 1.78E-05 Alzheimer's disease / / 17998437 rs6550976 chr3 25480678 C T 4.66E-05 Body Composition RARB intron pha003012 rs6550976 chr3 25480678 C T 8.75E-05 Body Mass Index RARB intron pha003021 rs6550976 chr3 25480678 C T 2.52E-05 Basophils RARB intron pha003087 rs1529672 chr3 25520582 C A 1.42E-06 Pulmonary function RARB intron 20010835 rs1529672 chr3 25520582 C A 4.00E-14 Pulmonary function RARB intron 21946350 rs1529672 chr3 25520582 C A 7.00E-11 Pulmonary function (interaction) RARB intron 23284291 rs1286664 chr3 25529280 C T 3.26E-06 Pulmonary function RARB intron 20010835 rs1286654 chr3 25531265 C A 6.01E-05 Pulmonary function RARB intron 20010835 rs1997352 chr3 25538317 C A,T 9.00E-07 Airflow obstruction RARB intron 22837378 rs2056777 chr3 25540391 T C 1.97E-05 Pulmonary function RARB intron 20010835 rs1406575 chr3 25541371 A G 8.45E-05 Pulmonary function RARB intron 20010835 rs1153582 chr3 25543275 C T 1.16E-06 Pulmonary function RARB intron 20010835 rs1286641 chr3 25543870 A T 7.34E-05 Pulmonary function RARB intron 20010835 rs17016566 chr3 25546219 C G 3.05E-04 Multiple complex diseases RARB intron 17554300 rs1560633 chr3 25548555 T C 0.00006142 Sarcoidosis RARB intron 22952805 rs17016570 chr3 25550039 A G 0.00003451 Sarcoidosis RARB intron 22952805 rs17016584 chr3 25551807 C G 0.000006682 Sarcoidosis RARB intron 22952805 rs1286750 chr3 25553292 A C 7.60E-05 Pulmonary function RARB intron 20010835 rs1435703 chr3 25560231 G T 4.00E-06 Obesity (extreme) RARB intron 19553259 rs1347459 chr3 25561156 T G 1.56E-04 Multiple complex diseases RARB intron 17554300 rs1286756 chr3 25567080 G A 7.44E-05 Cognitive test performance RARB intron 20125193 rs13099641 chr3 25568512 T A 0.0000187 Sarcoidosis RARB intron 22952805 rs1286665 chr3 25575675 C T 4.34E-05 Alcohol withdrawal symptoms RARB intron 22072270 rs7631979 chr3 25578938 T C 0.0000629 Sarcoidosis RARB intron 22952805 rs1286772 chr3 25580776 C G 0.00008274 Sarcoidosis RARB intron 22952805 rs1290443 chr3 25601835 T C 5.29E-04 Smoking initiation RARB intron 24665060 rs55684655 chr3 25614943 G A 0.00008834 Sarcoidosis RARB intron 22952805 rs868368 chr3 25623740 T C 2.11E-04 Smoking initiation RARB intron 24665060 rs1058378 chr3 25639394 T G 1.50E-05 Urinary metabolites RARB UTR-3 21572414 rs41453046 chr3 25746240 A G 1.59E-08 Multiple complex diseases / / 17554300 rs6762659 chr3 25777072 C T 4.42E-04 Multiple complex diseases NGLY1 intron 17554300 rs4681079 chr3 25872276 T G 1.00E-04 Personality dimensions / / 23903073 rs11928013 chr3 25919933 C G 1.80E-04 Obesity,menopause / / 21424828 rs7644516 chr3 25922285 G A 4.00E-06 DNA methylation (variation) / / 23725790 rs2052760 chr3 25924698 C A 3.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2052760 chr3 25924698 C A 1.45E-05 Waist Circumference / / pha003025 rs9310784 chr3 25930204 T C 4.77E-05 Waist Circumference / / pha003025 rs41406647 chr3 25938577 G A 7.97E-04 Type 2 diabetes / / 17463246 rs13101095 chr3 26011005 T C 4.90E-04 Aortic root size / / 21223598 rs11928334 chr3 26256357 A G 1.25E-04 Multiple complex diseases / / 17554300 rs2188635 chr3 26257541 G A 3.36E-04 Taste perception / / 22132133 rs10510573 chr3 26410029 A G 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1532719 chr3 26418818 T G 7.50E-08 Urinary metabolites / / 21572414 rs1502380 chr3 26419124 G A 1.30E-07 Urinary metabolites / / 21572414 rs17017980 chr3 26446285 T C 6.70E-07 Urinary metabolites / / 21572414 rs17017986 chr3 26446840 T C 2.60E-05 Urinary metabolites / / 21572414 rs9869163 chr3 26455761 A C 5.10E-07 Urinary metabolites / / 21572414 rs9851714 chr3 26455832 T G 8.00E-07 Urinary metabolites / / 21572414 rs7619880 chr3 26471474 T C 1.10E-06 Urinary metabolites / / 21572414 rs7621238 chr3 26481898 C T 7.67E-04 Multiple complex diseases / / 17554300 rs12631272 chr3 26485461 T C 1.70E-05 Urinary metabolites / / 21572414 rs1393398 chr3 26523122 T C 8.80E-07 Urinary metabolites / / 21572414 rs17018180 chr3 26539793 C T 1.90E-06 Urinary metabolites / / 21572414 rs12633182 chr3 26539885 A G 4.80E-06 Urinary metabolites / / 21572414 rs2202157 chr3 26543420 C T 8.00E-07 Tuberculosis / / 24057671 rs4973735 chr3 26556776 G A 4.92E-04 Lung function (forced vital capacity) / / 24023788 rs7638812 chr3 26557594 C T 4.97E-04 Lung function (forced vital capacity) / / 24023788 rs12715100 chr3 26567893 T C 5.52E-04 Multiple complex diseases / / 17554300 rs1907183 chr3 26577066 C T 6.54E-04 Multiple complex diseases / / 17554300 rs7611530 chr3 26588657 T C 1.02E-04 Multiple complex diseases / / 17554300 rs9817533 chr3 26623453 G A 3.86E-04 Multiple complex diseases / / 17554300 rs1826223 chr3 26647422 G T 2.00E-05 Personality dimensions / / 18957941 rs1586716 chr3 26668383 G T 9.67E-05 Cholesterol LRRC3B intron pha003078 rs1599923 chr3 26676314 G A 4.14E-04 Alzheimer's disease (late onset) LRRC3B intron 21379329 rs17018450 chr3 26685101 G A 8.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRRC3B intron 20031582 rs12496948 chr3 26685539 G A 4.00E-05 Asthma (bronchodilator response) LRRC3B intron 22792082 rs4496439 chr3 26688971 T C 9.37E-04 Response to taxane treatment (placlitaxel) LRRC3B intron 23006423 rs6551125 chr3 26698628 A G 3.58E-05 Cholesterol LRRC3B intron pha003073 rs6551125 chr3 26698628 A G 4.48E-05 Cholesterol LRRC3B intron pha003078 rs4973738 chr3 26702391 G A 9.08E-04 Suicide attempts in bipolar disorder LRRC3B intron 21423239 rs4973800 chr3 26702980 A G 7.97E-06 Cholesterol LRRC3B intron pha003073 rs4973800 chr3 26702980 A G 4.93E-05 ldl cholesterol LRRC3B intron pha003076 rs4973800 chr3 26702980 A G 1.12E-05 Cholesterol LRRC3B intron pha003078 rs7616728 chr3 26705637 C T 5.17E-04 Alzheimer's disease LRRC3B intron 17998437 rs4973801 chr3 26706382 A G 5.10E-05 Cholesterol LRRC3B intron pha003073 rs4973801 chr3 26706382 A G 7.31E-05 Cholesterol LRRC3B intron pha003078 rs923593 chr3 26710645 G A 4.31E-04 Alzheimer's disease LRRC3B intron 17998437 rs11916104 chr3 26718724 C G 4.65E-04 Alzheimer's disease LRRC3B intron 17998437 rs715642 chr3 26720690 A G 5.41E-04 Alzheimer's disease LRRC3B intron 17998437 rs6551130 chr3 26722139 T C 2.02E-04 Alzheimer's disease LRRC3B intron 17998437 rs6776559 chr3 26725121 G A 2.07E-04 Alzheimer's disease LRRC3B intron 17998437 rs7616110 chr3 26735083 C T 7.23E-04 Alzheimer's disease LRRC3B intron 17998437 rs17018559 chr3 26739650 G A 1.70E-05 Iron levels LRRC3B intron 21208937 rs4395366 chr3 26742691 T C 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC3B intron 20877124 rs1386886 chr3 26775763 C T 2.14E-06 Diabetes (gestational) / / 22233651 rs1488233 chr3 26777472 A G 4.09E-04 Alzheimer's disease / / 17998437 rs9866020 chr3 26778370 G A 5.27E-06 Diabetes (gestational) / / 22233651 rs9872064 chr3 26802920 A G 7.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1160339 chr3 26809950 G A 1.60E-05 Psoriasis / / 19169255 rs1160339 chr3 26809950 G A 2.46E-05 Dengue shock syndrome / / 22001756 rs1488219 chr3 26838752 G A 2.02E-06 Dengue shock syndrome / / 22001756 rs1155107 chr3 26843377 A G 5.71E-04 Coronary Artery Disease / / 17634449 rs1155107 chr3 26843377 A G 6.37E-05 Diabetes (gestational) / / 22233651 rs4267616 chr3 26846174 C T 3.36E-07 Dengue shock syndrome / / 22001756 rs9848111 chr3 26847785 A G 2.47E-05 Diabetes (gestational) / / 22233651 rs9877107 chr3 26891510 C G 2.00E-05 Urinary metabolites / / 21572414 rs9839380 chr3 26891616 A G 1.40E-05 Urinary metabolites / / 21572414 rs4973823 chr3 26897595 G A 1.10E-05 Urinary metabolites / / 21572414 rs4973824 chr3 26897667 G C 1.50E-05 Urinary metabolites / / 21572414 rs955027 chr3 26947415 A C 5.10E-04 Pulmonary function / / 20010834 rs955027 chr3 26947415 A C 2.01E-05 Calcium levels / / pha003085 rs12486501 chr3 26950415 T A 5.71E-04 Insulin resistance / / 21901158 rs4493387 chr3 26958669 C T 8.10E-05 Serum metabolites / / 19043545 rs17019022 chr3 26979984 T C 3.87E-04 Multiple complex diseases / / 17554300 rs9851229 chr3 27002945 T G 8.01E-05 Serum metabolites / / 19043545 rs2044573 chr3 27024947 T C 4.91E-04 Type 2 diabetes / / 17463246 rs2044573 chr3 27024947 T C 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs17019085 chr3 27024977 G C 4.91E-04 Type 2 diabetes / / 17463246 rs17019085 chr3 27024977 G C 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs7340535 chr3 27025575 T C 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs9841676 chr3 27025777 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs9822018 chr3 27026032 C T 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1348979 chr3 27027497 G C 5.90E-04 Type 2 diabetes / / 17463246 rs10510586 chr3 27028661 C T 1.90E-04 Type 2 diabetes / / 17463246 rs13093597 chr3 27037728 T C 0.0000584 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1402991 chr3 27053802 A G 1.00E-04 Prostate cancer / / 21743057 rs939838 chr3 27054896 A C 1.00E-04 Prostate cancer / / 21743057 rs6766181 chr3 27100290 C T 6.64E-04 Type 2 diabetes / / 17463246 rs6766181 chr3 27100290 C T 2.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6766181 chr3 27100290 C T 3.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9881362 chr3 27105502 G C 1.16E-04 Insulin resistance / / 21901158 rs17019325 chr3 27118517 A G 1.46E-07 Multiple complex diseases / / 17554300 rs6551174 chr3 27150110 C T 2.12E-04 Insulin resistance / / 21901158 rs1522153 chr3 27170777 G A 6.43E-04 Insulin resistance / / 21901158 rs1522153 chr3 27170777 G A 3.00E-06 Alcohol dependence / / 21956439 rs10510590 chr3 27180143 T C 4.69E-04 Hemoglobin concentration / / 20534544 rs10510590 chr3 27180143 T C 7.37E-05 Insulin resistance / / 21901158 rs1357245 chr3 27186602 C T 1.90E-07 Breast cancer / / 19330027 rs12487340 chr3 27208975 C T 3.88E-11 Breast cancer (early onset) / / 24493630 rs7653795 chr3 27217080 G A 8.96E-11 Breast cancer (early onset) / / 24493630 rs7653480 chr3 27229286 C T 1.86E-04 Type 2 diabetes / / 17463246 rs7634878 chr3 27241219 G A 1.13E-09 Breast cancer (early onset) / / 24493630 rs10049490 chr3 27241776 G T 2.93E-10 Breast cancer (early onset) / / 24493630 rs1445111 chr3 27253971 C T 1.32E-10 Breast cancer (early onset) / / 24493630 rs11129270 chr3 27257943 A G 1.42E-10 Breast cancer (early onset) NEK10 intron 24493630 rs2370946 chr3 27260283 G A 1.14E-10 Breast cancer (early onset) NEK10 intron 24493630 rs2100006 chr3 27273415 G A 1.13E-11 Breast cancer (early onset) NEK10 intron 24493630 rs2034190 chr3 27292557 T C 1.23E-11 Breast cancer (early onset) NEK10 intron 24493630 rs487930 chr3 27330335 C A 5.04E-12 Breast cancer (early onset) NEK10 intron 24493630 rs653465 chr3 27343644 C T 5.00E-12 Breast cancer (early onset) NEK10 intron 24493630 rs552647 chr3 27353716 C A 5.28E-12 Breast cancer (early onset) NEK10 intron 24493630 rs1603051 chr3 27378511 A C 3.95E-04 Suicide attempts in bipolar disorder NEK10 intron 21423239 rs9847010 chr3 27382214 A G 9.51E-04 Type 2 diabetes NEK10 intron 17463246 rs7611368 chr3 27395970 T C 2.77E-04 Suicide attempts in bipolar disorder NEK10 intron 21423239 rs12715121 chr3 27413246 T C 0.0000734 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4973768 chr3 27416013 C T 4.10E-23 Breast cancer SLC4A7 UTR-3 19330027 rs4973768 chr3 27416013 C T 6.00E-07 Breast cancer SLC4A7 UTR-3 20453838 rs4973768 chr3 27416013 C T 2.00E-08 Breast cancer SLC4A7 UTR-3 21263130 rs4973768 chr3 27416013 C T 2.00E-30 Breast cancer SLC4A7 UTR-3 23535729 rs9856538 chr3 27417601 T C 0.0000679 Nonsyndromic striae distensae (stretch marks) SLC4A7 UTR-3 23633020 rs1472256 chr3 27424718 A G 2.51E-04 Iron levels SLC4A7 cds-synon pha002876 rs1472254 chr3 27427225 A G 5.76E-10 Breast cancer (early onset) SLC4A7 intron 24493630 rs2172297 chr3 27428423 G A 1.60E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2131205 chr3 27428501 A G 1.97E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2307033 chr3 27433163 T C 0.0000585 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs2307034 chr3 27433360 G A 0.0000562 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9810587 chr3 27433911 T C 0.0000541 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9826281 chr3 27436776 T A 0.0000573 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs13318924 chr3 27440096 A G 0.0000464 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9823798 chr3 27441221 T C 0.0000593 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs35700247 chr3 27443161 A G 0.0000513 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs10510595 chr3 27443488 T C 1.20E-04 Multiple complex diseases SLC4A7 intron 17554300 rs13078798 chr3 27445971 G A 1.42E-04 Multiple complex diseases SLC4A7 intron 17554300 rs7610114 chr3 27458622 C T 4.14E-04 Iron levels SLC4A7 intron pha002876 rs3755652 chr3 27472936 C T 2.54E-04 Multiple complex diseases SLC4A7 missense 17554300 rs13077400 chr3 27473066 A G 1.65E-04 Multiple complex diseases SLC4A7 cds-synon 17554300 rs2029618 chr3 27478899 A G 4.57E-04 Hemoglobin concentration SLC4A7 cds-synon 20534544 rs17682751 chr3 27497027 T C 2.56E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2643813 chr3 27537746 A G 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs13082711 chr3 27537909 T C 5.00E-09 Blood pressure / / 21909110 rs13082711 chr3 27537909 T C 2.00E-06 Systolic blood pressure / / 21909115 rs13082711 chr3 27537909 T C 4.00E-09 Diastolic blood pressure / / 21909115 rs629462 chr3 27553839 G A 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs13091026 chr3 27563686 C T 0.0000916 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1495566 chr3 27566810 T A 0.0000776 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66893799 chr3 27617913 G A 0.0000838 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13092204 chr3 27618343 G A 0.0000855 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7625865 chr3 27619708 T C 0.0000791 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13073304 chr3 27620947 G A 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2642905 chr3 27638500 A G 1.23E-04 Multiple complex diseases / / 17554300 rs6551218 chr3 27665791 A C 1.20E-05 Urinary metabolites / / 21572414 rs6769210 chr3 27666131 C T 2.50E-05 Urinary metabolites / / 21572414 rs6551219 chr3 27666362 T C 2.70E-05 Urinary metabolites / / 21572414 rs2370990 chr3 27690531 C T 4.74E-05 Magnesium levels / / pha003092 rs4461380 chr3 27697129 G T 1.45E-04 Multiple complex diseases / / 17554300 rs3856677 chr3 27697503 A G 7.61E-04 Multiple complex diseases / / 17554300 rs17020218 chr3 27723197 A G 5.68E-05 Multiple complex diseases / / 17554300 rs2724509 chr3 27724852 G A 4.76E-04 Hemoglobin concentration / / 20534544 rs9846205 chr3 27725605 G A 6.37E-04 Premature ovarian failure / / 19508998 rs2642935 chr3 27726951 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs1494835 chr3 27729109 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs9848796 chr3 27738395 A G 4.23E-04 Hemoglobin concentration / / 20534544 rs3806624 chr3 27764623 A G 1.00E-12 Hodgkin's lymphoma / / 24149102 rs3806624 chr3 27764623 A G 1.04E-06 Hodgkin's lymphoma / / 24149102 rs3806624 chr3 27764623 A G 3.00E-08 Rheumatoid arthritis / / 24390342 rs3806624 chr3 27764623 A G 9.00E-09 Rheumatoid arthritis / / 24390342 rs3806624 chr3 27764623 A G 2.26E-04 Hodgkin's lymphoma / / 24920014 rs9878516 chr3 27782360 G A 5.54E-06 Inflammation / / pha002897 rs11129295 chr3 27788780 C T 1.00E-09 Multiple sclerosis / / 21833088 rs11129295 chr3 27788780 C T 2.19E-04 Hodgkin's lymphoma / / 24149102 rs12493245 chr3 27797810 G A 1.26E-05 Hodgkin's lymphoma / / 24149102 rs9817112 chr3 27827733 A G 3.35E-04 Gallstones / / 17632509 rs9817112 chr3 27827733 A G 3.88E-05 Hodgkin's lymphoma / / 24149102 rs730510 chr3 27833251 T C 5.11E-04 Hodgkin's lymphoma / / 24149102 rs6770352 chr3 27847279 T G 1.97E-04 Multiple complex diseases / / 17554300 rs2371121 chr3 27850725 G T 1.32E-05 Multiple complex diseases / / 17554300 rs10510597 chr3 27850945 C T 2.66E-04 Bipolar disorder / / 19259986 rs2887957 chr3 27901738 C A 1.46E-04 Multiple complex diseases / / 17554300 rs7623233 chr3 27922474 G A 2.21E-04 Multiple complex diseases / / 17554300 rs2581194 chr3 27927730 T C 9.51E-05 Post-operative nausea and vomiting / / 21694509 rs2581186 chr3 27930639 A G 2.22E-05 Post-operative nausea and vomiting / / 21694509 rs993668 chr3 27931338 C G 8.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2618115 chr3 27943158 G A 7.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs9816729 chr3 27945306 C T 8.09E-04 Multiple complex diseases / / 17554300 rs17020592 chr3 27950570 C T 1.22E-04 Multiple complex diseases / / 17554300 rs9830403 chr3 27963608 C G 1.50E-05 Urinary metabolites / / 21572414 rs1842033 chr3 27968947 A G 9.84E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10510599 chr3 27975263 T C 1.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2169820 chr3 27976288 A G 3.86E-04 Multiple complex diseases / / 17554300 rs4680886 chr3 28007973 G A 2.31E-05 Brain structure / / 22504417 rs17020708 chr3 28017802 C T 8.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs17020710 chr3 28017987 G A 5.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs12632457 chr3 28020552 T C 1.40E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs12632457 chr3 28020552 T C 6.53E-05 Coronary heart disease / / pha003032 rs12639500 chr3 28026396 A G 4.44E-05 Brain structure / / 22504417 rs6790513 chr3 28034296 T C 5.82E-04 Insulin resistance / / 21901158 rs9825129 chr3 28043715 T C 1.26E-04 Multiple complex diseases / / 17554300 rs669607 chr3 28071444 A C 2.00E-15 Multiple sclerosis / / 21833088 rs669607 chr3 28071444 A C 2.50E-05 Multiple sclerosis / / 24234648 rs170934 chr3 28079085 C T 2.00E-08 Multiple sclerosis / / 22190364 rs17020950 chr3 28119946 T C 4.11E-04 Multiple complex diseases / / 17554300 rs10510605 chr3 28123769 T G 8.40E-06 Urinary metabolites / / 21572414 rs17688561 chr3 28124209 G A 1.50E-05 Urinary metabolites / / 21572414 rs879871 chr3 28124899 A G 8.30E-06 Urinary metabolites / / 21572414 rs368524 chr3 28130759 A T 6.38E-04 Coronary Artery Disease / / 17634449 rs647616 chr3 28143749 A G 7.62E-04 Coronary Artery Disease / / 17634449 rs380560 chr3 28146941 T C 2.18E-04 Coronary Artery Disease / / 17634449 rs384620 chr3 28147286 T C 2.14E-04 Coronary Artery Disease / / 17634449 rs1395409 chr3 28148832 A G 3.83E-04 Coronary Artery Disease / / 17634449 rs440254 chr3 28149666 T C 3.82E-04 Coronary Artery Disease / / 17634449 rs401387 chr3 28149683 G C 3.13E-04 Coronary Artery Disease / / 17634449 rs6764680 chr3 28154465 G C 1.73E-04 Coronary Artery Disease / / 17634449 rs6806119 chr3 28164921 C T 1.85E-04 Coronary Artery Disease / / 17634449 rs1389155 chr3 28165662 G A 6.55E-04 Myopia (pathological) / / 21095009 rs17021139 chr3 28171237 G C 8.48E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs13094235 chr3 28178694 G C 4.17E-04 Coronary Artery Disease / / 17634449 rs7646845 chr3 28181591 G A 4.38E-04 Coronary Artery Disease / / 17634449 rs7636966 chr3 28181761 A G 5.86E-04 Coronary Artery Disease / / 17634449 rs6803625 chr3 28188749 C G 5.62E-04 Alcohol dependence / / 21314694 rs6788643 chr3 28204584 T C 2.50E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs6788643 chr3 28204584 T C 4.10E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs9310862 chr3 28206877 G A 2.30E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs9310862 chr3 28206877 G A 4.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs17710733 chr3 28211713 G A 5.07E-04 Multiple complex diseases / / 17554300 rs6800659 chr3 28270669 G A 1.68E-04 Heart Failure / / pha002885 rs4680748 chr3 28293360 G C 2.39E-05 Serum metabolites CMC1 intron 19043545 rs17021306 chr3 28304126 T G 1.17E-04 Coronary Artery Disease CMC1 intron 17634449 rs10510608 chr3 28305152 T C 2.20E-04 Multiple complex diseases CMC1 intron 17554300 rs11706542 chr3 28328583 C T 8.17E-04 Coronary Artery Disease CMC1 intron 17634449 rs11706542 chr3 28328583 C T 9.43E-05 Alcohol dependence CMC1 intron 19581569 rs17638991 chr3 28350969 G C 6.70E-04 Coronary Artery Disease CMC1 intron 17634449 rs4552313 chr3 28355386 G A 2.00E-06 Height CMC1 intron 17767157 rs11706332 chr3 28358057 C T 5.89E-04 Coronary Artery Disease CMC1 intron 17634449 rs7612033 chr3 28426978 C T 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13095628 chr3 28467123 G A 6.24E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs11720107 chr3 28472728 C T 6.51E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs1598846 chr3 28510453 A G 7.98E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs17696783 chr3 28537611 G A 6.49E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs4361241 chr3 28607548 C G 4.80E-04 Coronary Artery Disease / / 17634449 rs4133027 chr3 28624327 T C 6.97E-05 Coronary Artery Disease LOC645206 intron 17634449 rs4521182 chr3 28631124 T C 3.32E-05 Glucose levels LOC645206 intron pha003058 rs4521182 chr3 28631124 T C 4.33E-05 Glucose levels LOC645206 intron pha003061 rs4680765 chr3 28648364 C G 2.89E-04 Multiple complex diseases LOC645206 intron 17554300 rs13327669 chr3 28651451 A G 7.20E-06 Urinary metabolites LOC645206 intron 21572414 rs6776912 chr3 28652496 A G 3.78E-05 Gaucher disease severity LOC645206 intron 22388998 rs4306817 chr3 28660626 A G 3.80E-06 Urinary metabolites LOC645206 intron 21572414 rs1599489 chr3 28681632 T C 8.20E-06 Urinary metabolites LOC645206 intron 21572414 rs970624 chr3 28682296 A C 3.02E-04 Age-related macular degeneration LOC645206 intron 22125219 rs9310867 chr3 28690589 A G 7.57E-04 Parkinson's disease LOC645206 intron 21044948 rs9310867 chr3 28690589 A G 2.78E-05 Parkinson's disease LOC645206 intron 22438815 rs9310867 chr3 28690589 A G 6.15E-04 Stroke LOC645206 intron pha002886 rs6549869 chr3 28701496 C T 2.49E-05 HIV-1 viral setpoint LOC645206 intron 22174851 rs4399848 chr3 28704463 A G 9.94E-05 Multiple complex diseases LOC645206 intron 17554300 rs7617877 chr3 28705764 A G 3.00E-06 Parkinson's disease LOC645206 intron 21044948 rs13075697 chr3 28712239 G A 1.51E-05 HIV-1 viral setpoint LOC645206 intron 22174851 rs6780486 chr3 28713787 A G 1.80E-05 Urinary metabolites LOC645206 intron 21572414 rs4680773 chr3 28714733 A G 8.07E-04 Multiple complex diseases LOC645206 intron 17554300 rs6762880 chr3 28715369 G C 3.77E-04 Type 2 diabetes LOC645206 intron 17463246 rs9861037 chr3 28719312 C G 4.74E-20 Metabolite levels LOC645206 intron 22286219 rs17651822 chr3 28720126 C T 1.14E-04 Type 2 diabetes LOC645206 intron 17463246 rs1156965 chr3 28723446 C G 1.80E-06 Urinary metabolites LOC645206 intron 21572414 rs4398388 chr3 28736622 G A 1.48E-04 Alcohol dependence LOC645206 intron 20201924 rs1381392 chr3 28749314 G A 9.33E-04 Myocardial Infarction LOC645206 intron pha002883 rs1011417 chr3 28796482 T C 2.00E-06 Urinary metabolites LOC645206 intron 21572414 rs1903586 chr3 28803094 C T 3.22E-05 Serum metabolites / / 19043545 rs1461802 chr3 28819123 C T 7.36E-04 Type 2 diabetes / / 17463246 rs17021958 chr3 28827335 C T 1.97E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7633531 chr3 28828525 G T 1.30E-07 Response to statin therapy / / 20339536 rs4680784 chr3 28832119 G A 1.60E-07 Response to statin therapy / / 20339536 rs3902030 chr3 28840724 G A 2.10E-05 Response to statin therapy / / 20339536 rs11922379 chr3 28843983 T A 4.20E-04 Type 2 diabetes / / 17463246 rs7631590 chr3 28845890 A G 2.20E-05 Response to statin therapy / / 20339536 rs1392311 chr3 28846545 C T 2.20E-05 Response to statin therapy / / 20339536 rs6768567 chr3 28847358 G A 2.30E-05 Response to statin therapy / / 20339536 rs9883412 chr3 28862422 A G 2.30E-05 Response to statin therapy / / 20339536 rs9857300 chr3 28864888 C T 4.32E-04 Alzheimer's disease / / 22005930 rs11926073 chr3 28871595 G A 1.74E-05 Nephrolithiasis / / 22396660 rs12490883 chr3 28877081 T C 8.60E-05 Response to statin therapy / / 20339536 rs6770726 chr3 28879089 T A 1.84E-04 Blood pressure / / 17255346 rs6770726 chr3 28879089 T A 5.31E-04 Type 2 diabetes / / 17463246 rs11129333 chr3 28879197 C A 6.35E-04 Alzheimer's disease / / 22005930 rs7623722 chr3 28882980 A G 8.78E-04 Alzheimer's disease / / 22005930 rs13077892 chr3 28883279 C T 9.07E-04 Alzheimer's disease / / 22005930 rs1125186 chr3 28885804 C G 9.02E-04 Alzheimer's disease / / 22005930 rs2221154 chr3 28928860 T G 3.00E-06 Alzheimer's disease / / 22159054 rs4680793 chr3 28929230 G A 0.000438 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs9816337 chr3 28936109 G T 6.76E-04 Schizophrenia / / 19197363 rs9817531 chr3 28936836 G A 7.89E-04 Schizophrenia / / 19197363 rs4016429 chr3 28964801 C G 2.00E-06 Smooth-surface caries / / 24556642 rs7641837 chr3 29019592 A G 8.37E-05 Parkinson's disease / / 21248740 rs2167089 chr3 29034403 T G 6.00E-06 White matter hyperintensity burden / / 21681796 rs2167089 chr3 29034403 T G 0.000638 white matter hyperintensity burden / / 23674528 rs9828929 chr3 29044226 C T 3.29E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1449692 chr3 29051853 T C 2.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1979113 chr3 29057186 A G 1.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6772740 chr3 29059651 G C 7.24E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs619656 chr3 29105651 A G 2.60E-06 Urinary metabolites / / 21572414 rs512613 chr3 29142926 G C 8.62E-05 Serum metabolites / / 19043545 rs613516 chr3 29154358 A G 8.26E-05 Disc degeneration (lumbar) / / 24216480 rs9859945 chr3 29169954 T C 6.19E-05 Waist Circumference / / pha003023 rs13097297 chr3 29175398 C T 0.00000008 Brain microstructure and intellectual performance / / 22723713 rs6549915 chr3 29209151 T C 9.00E-06 Breast size / / 22747683 rs12496180 chr3 29212935 T A 8.77E-04 Multiple complex diseases / / 17554300 rs6780332 chr3 29218259 T C 4.02E-04 Parkinson's disease / / 17052657 rs41356346 chr3 29247332 T C 5.68E-04 Multiple complex diseases / / 17554300 rs7616684 chr3 29251992 A G 8.85E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2196554 chr3 29258751 T C 5.67E-04 Smoking initiation / / 24665060 rs13098112 chr3 29263650 C A 1.59E-05 Blood Pressure / / pha003050 rs768303 chr3 29265952 T C 2.39E-04 Smoking initiation / / 24665060 rs4680719 chr3 29275646 G A 3.00E-06 Metabolite levels (HVA) / / 23319000 rs2196556 chr3 29277986 G A 9.81E-04 Alzheimer's disease / / 17998437 rs7646464 chr3 29279486 C G 5.81E-04 Multiple complex diseases / / 17554300 rs6778464 chr3 29279779 A G 1.22E-06 Age-related macular degeneration / / pha000001 rs984462 chr3 29284286 T C 7.83E-04 Myocardial Infarction / / pha002873 rs9877517 chr3 29287651 G A 6.53E-05 Alcohol dependence / / 20201924 rs9877517 chr3 29287651 G A 6.53E-05 Alcoholism / / pha002891 rs1004644 chr3 29291048 G A 8.47E-04 Myocardial Infarction / / pha002873 rs11129357 chr3 29319887 G A 7.30E-06 Urinary metabolites / / 21572414 rs2888099 chr3 29322297 A C 6.15E-05 Pulmonary function / / 20010835 rs9832625 chr3 29329020 C A 3.00E-06 Response to radiotherapy in cancer (late toxicity) RBMS3 intron 24785509 rs9832625 chr3 29329020 C A 7.78E-05 Response to radiotherapy in cancer (late toxicity) RBMS3 intron 24785509 rs9878305 chr3 29335426 A G 1.84E-05 Nonalcoholic fatty liver disease RBMS3 intron 21423719 rs6549924 chr3 29357063 C T 2.54E-06 Stroke RBMS3 intron pha002887 rs6549924 chr3 29357063 C T 3.58E-06 Left ventricular hypertrophy RBMS3 intron pha003052 rs7349464 chr3 29357140 G A 9.64E-04 Type 2 diabetes RBMS3 intron 17463246 rs7349464 chr3 29357140 G A 4.76E-04 Alzheimer's disease (late onset) RBMS3 intron 21379329 rs6804900 chr3 29373424 A G 3.39E-05 Bipolar disorder and schizophrenia RBMS3 intron 20889312 rs7431530 chr3 29382541 C T 2.00E-06 Upper aerodigestive tract cancers RBMS3 intron 21437268 rs7644260 chr3 29384227 C T 7.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RBMS3 intron 20031582 rs7610043 chr3 29387631 G A 8.00E-04 Bipolar disorder RBMS3 intron 17486107 rs4574243 chr3 29420132 T C 4.38E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs11713209 chr3 29427676 T G 1.15E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs4377455 chr3 29428187 C T 5.39E-07 Bipolar disorder RBMS3 intron 20451256 rs4377455 chr3 29428187 C T 1.53E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs7636503 chr3 29436928 G A 6.93E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs7642033 chr3 29438500 C T 5.77E-04 Type 2 diabetes RBMS3 intron 17463246 rs4130687 chr3 29444111 A G 8.82E-04 Nicotine smoking RBMS3 intron 19268276 rs13079920 chr3 29445931 G A 8.58E-05 Left ventricular hypertrophy RBMS3 intron pha003052 rs1561374 chr3 29458092 A G 7.71E-05 Coronary restenosis RBMS3 intron 21878436 rs7634956 chr3 29463968 C T 1.54E-05 Blood Pressure RBMS3 intron pha002903 rs1438339 chr3 29482046 C T 5.56E-04 Alcohol dependence RBMS3 intron 24277619 rs17023487 chr3 29482712 G A 7.77E-07 Cholesterol RBMS3 intron pha003073 rs17023487 chr3 29482712 G A 3.35E-06 ldl cholesterol RBMS3 intron pha003076 rs17023487 chr3 29482712 G A 2.15E-05 ldl cholesterol RBMS3 intron pha003077 rs17023487 chr3 29482712 G A 4.55E-06 Cholesterol RBMS3 intron pha003078 rs17023487 chr3 29482712 G A 2.47E-05 Cholesterol RBMS3 intron pha003083 rs4146794 chr3 29484045 A G 1.01E-04 Alzheimer's disease (late onset) RBMS3 intron 21379329 rs4146794 chr3 29484045 A G 5.84E-05 Prion diseases RBMS3 intron 22210626 rs4146794 chr3 29484045 A G 5.61E-05 Diabetes Mellitus RBMS3 intron pha003059 rs7632290 chr3 29484510 T G 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBMS3 intron 20877124 rs17023578 chr3 29496026 C T 1.41E-04 Multiple complex diseases RBMS3 intron 17554300 rs4452286 chr3 29500962 C G 3.91E-04 Multiple complex diseases RBMS3 intron 17554300 rs1370788 chr3 29512221 A T 2.37E-05 Multiple complex diseases RBMS3 intron 17554300 rs10510621 chr3 29516639 G A 1.32E-04 Myopia (pathological) RBMS3 intron 21095009 rs17023679 chr3 29518548 C T 6.04E-05 Multiple complex diseases RBMS3 intron 17554300 rs17023697 chr3 29522455 C G 8.39E-05 Multiple complex diseases RBMS3 intron 17554300 rs3773047 chr3 29545182 A G 2.95E-04 Multiple complex diseases RBMS3 intron 17554300 rs9867172 chr3 29551939 C T 9.01E-04 Multiple complex diseases RBMS3 intron 17554300 rs1530057 chr3 29575463 G T 3.00E-06 Lung cancer RBMS3 intron 19654303 rs1530057 chr3 29575463 G T 3.00E-06 Nasopharyngeal carcinoma RBMS3 intron 20512145 rs35883 chr3 29597791 A G 6.67E-06 Parkinson's disease RBMS3 intron 21738487 rs35883 chr3 29597791 A G 8.60E-05 Systemic sclerosis RBMS3 intron 21750679 rs35881 chr3 29599663 C T 5.73E-05 Parkinson's disease RBMS3 intron 21738487 rs13323338 chr3 29620604 C T 1.64E-05 Parkinson's disease RBMS3 intron 21738487 rs13323338 chr3 29620604 C T 2.06E-05 Systemic sclerosis RBMS3 intron 21750679 rs2168765 chr3 29663099 C T 6.05E-04 Multiple complex diseases RBMS3 intron 17554300 rs9829357 chr3 29665461 T G 1.47E-04 Prion diseases RBMS3 intron 22210626 rs9877765 chr3 29690385 T C 4.08E-04 Multiple complex diseases RBMS3 intron 17554300 rs9862854 chr3 29691197 C G 7.23E-04 Multiple complex diseases RBMS3 intron 17554300 rs10510622 chr3 29695588 T C 9.40E-04 Type 2 diabetes and 6 quantitative traits RBMS3 intron 17848626 rs4630899 chr3 29699586 T C 3.92E-04 Multiple complex diseases RBMS3 intron 17554300 rs9831584 chr3 29700014 G T 3.29E-04 Multiple complex diseases RBMS3 intron 17554300 rs9882829 chr3 29700225 G A 2.01E-04 Prion diseases RBMS3 intron 22210626 rs9883185 chr3 29738025 A G 1.74E-25 Narcolepsy RBMS3 intron 19629137 rs17550007 chr3 29759336 G T 8.58E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1440524 chr3 29760507 T C 5.48E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371844 chr3 29761506 C T 6.23E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371846 chr3 29761649 A C 6.26E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6779932 chr3 29761943 G T 8.86E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6780134 chr3 29762129 G A 6.31E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6783723 chr3 29763238 G A 6.42E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs12374076 chr3 29764315 A G 4.20E-04 Smoking initiation RBMS3 intron 24665060 rs6549953 chr3 29764850 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) RBMS3 intron 20189245 rs1866773 chr3 29778243 T C 5.92E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs17024316 chr3 29782718 C G 5.99E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371837 chr3 29789588 A C 8.82E-04 Multiple complex diseases RBMS3 intron 17554300 rs7623158 chr3 29791640 C G 3.14E-04 Multiple complex diseases RBMS3 intron 17554300 rs7623178 chr3 29791698 C A 5.47E-04 Multiple complex diseases RBMS3 intron 17554300 rs2577120 chr3 29798434 C G 5.87E-04 Coronary heart disease RBMS3 intron 21606135 rs17551079 chr3 29800270 G A 1.20E-05 Urinary metabolites RBMS3 intron 21572414 rs9821929 chr3 29803505 C T 7.62E-05 Multiple complex diseases RBMS3 intron 17554300 rs9852393 chr3 29805345 T G 1.70E-04 Multiple complex diseases RBMS3 intron 17554300 rs10510628 chr3 29853403 G A 3.00E-06 Bone mineral density RBMS3 intron 17903296 rs2218724 chr3 29925518 A G 3.77E-05 Prostate cancer RBMS3 intron pha002878 rs17838728 chr3 29942006 A G 4.75E-04 Multiple complex diseases RBMS3 intron 17554300 rs7610139 chr3 29949712 A G 5.27E-04 Depression (quantitative trait) RBMS3 intron 20800221 rs17024608 chr3 29954690 A G 7.47E-08 Bisphosphonate-induced osteonecrosis of the jaw RBMS3 intron 22267851 rs1816996 chr3 30007105 G C 5.53E-04 Type 2 diabetes RBMS3 intron 17463246 rs3773127 chr3 30033043 A C 9.88E-04 Type 2 diabetes RBMS3 intron 17463246 rs6768053 chr3 30054818 C T 8.87E-04 Type 2 diabetes / / 17463246 rs13077725 chr3 30059761 C A 8.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7427882 chr3 30085222 C A 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs9867656 chr3 30100084 A G 3.74E-04 Type 2 diabetes / / 17463246 rs7649490 chr3 30111359 G A 1.86E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6549973 chr3 30118857 C T 7.10E-04 Multiple complex diseases / / 17554300 rs7639172 chr3 30118918 T G 2.95E-04 Multiple complex diseases / / 17554300 rs1434012 chr3 30124229 G A 6.30E-04 Multiple complex diseases / / 17554300 rs17555240 chr3 30124257 A G 7.58E-04 Multiple complex diseases / / 17554300 rs13079874 chr3 30124940 A C 2.80E-06 Urinary metabolites / / 21572414 rs11919248 chr3 30125732 G A 1.54E-04 Parkinson's disease / / 16252231 rs9840784 chr3 30132198 C T 2.10E-06 Urinary metabolites / / 21572414 rs4680872 chr3 30151116 G A 3.77E-04 Blood pressure / / 17255346 rs4680872 chr3 30151116 G A 1.80E-06 Urinary metabolites / / 21572414 rs1434019 chr3 30188747 T C 7.51E-04 Multiple complex diseases / / 17554300 rs4680878 chr3 30193543 T G 8.71E-05 Parkinson's disease / / 16252231 rs2371997 chr3 30211106 T C 2.80E-05 Myocardial Infarction / / pha002873 rs12488511 chr3 30220012 G T 1.69E-04 Height / / 17255346 rs1036308 chr3 30235221 G A 4.45E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1433991 chr3 30236309 G T 3.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs72853527 chr3 30237298 C T 0.0000999 Sarcoidosis / / 22952805 rs968896 chr3 30240425 T C 4.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1560848 chr3 30245137 T C 1.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9824898 chr3 30254185 G T 4.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6779483 chr3 30258522 G A 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6549977 chr3 30259240 G A 6.08E-06 Calcium levels / / pha003085 rs7644703 chr3 30271646 T C 9.24E-05 Schizophrenia / / 19571811 rs11926889 chr3 30278290 G A 6.10E-05 Type 2 diabetes / / 17463248 rs17564364 chr3 30285495 C A 8.27E-05 Body Mass Index / / pha003020 rs1434006 chr3 30293504 C T 4.40E-05 Type 2 diabetes / / 17463248 rs13075234 chr3 30294430 C T 5.80E-05 Type 2 diabetes / / 17463248 rs10440137 chr3 30295974 G T 4.40E-05 Type 2 diabetes / / 17463248 rs999853 chr3 30298849 C A 5.45E-04 Insulin resistance / / 21901158 rs9870410 chr3 30308759 C T 3.80E-05 Type 2 diabetes / / 17463248 rs13092602 chr3 30309945 G A 8.20E-06 Type 2 diabetes / / 17463248 rs1495586 chr3 30327788 G A 8.20E-06 Type 2 diabetes / / 17463248 rs2077164 chr3 30332349 A G 3.86E-04 Alcohol dependence / / 20201924 rs17081352 chr3 30332847 C A 5.50E-06 Type 2 diabetes / / 17463248 rs9843153 chr3 30333248 G T 8.40E-06 Type 2 diabetes / / 17463248 rs1390298 chr3 30344776 C T 4.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs10510634 chr3 30346968 A G 4.72E-06 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510634 chr3 30346968 A G 5.00E-06 Fasting plasma glucose / / 17903298 rs1495579 chr3 30347354 G T 3.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs1495578 chr3 30347455 G A 3.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs6549981 chr3 30348760 C T 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs6809482 chr3 30353412 G A 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs11129397 chr3 30354360 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs6780847 chr3 30355530 T C 2.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs6781057 chr3 30355787 T G 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs9876671 chr3 30360636 G A 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs9876727 chr3 30360854 C A 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs7653488 chr3 30368930 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs7634533 chr3 30372053 C A 5.00E-06 Dental caries / / 23259602 rs9841664 chr3 30373341 C T 8.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs17623569 chr3 30377485 G A 2.30E-05 Urinary metabolites / / 21572414 rs6778682 chr3 30381927 A G 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6778682 chr3 30381927 A G 1.90E-05 Urinary metabolites / / 21572414 rs11925190 chr3 30382639 C T 1.30E-05 Urinary metabolites / / 21572414 rs7629687 chr3 30386542 T A 4.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs9875447 chr3 30390204 C T 2.60E-05 Urinary metabolites / / 21572414 rs9826631 chr3 30395073 C G 2.20E-05 Urinary metabolites / / 21572414 rs2132298 chr3 30402863 G A 7.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2101835 chr3 30437075 T A 6.41E-04 Insulin resistance / / 21901158 rs7653262 chr3 30443869 G A 4.31E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7640543 chr3 30462403 G A 1.00E-09 Migraine / / 22683712 rs7640543 chr3 30462403 G A 1.05E-05 Migraine without aura / / 23793025 rs7640543 chr3 30462403 G A 1.32E-05 Migraine / / 23793025 rs7640543 chr3 30462403 G A 1.54E-06 Migraine - clinic-based / / 23793025 rs1117751 chr3 30467155 G A 4.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4955308 chr3 30470027 C T 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4075749 chr3 30478897 A G 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790925 chr3 30480085 C T 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790925 chr3 30480085 C T 2.00E-08 Migraine - clinic-based / / 23793025 rs6790925 chr3 30480085 C T 8.35E-05 Migraine without aura / / 23793025 rs6790925 chr3 30480085 C T 8.74E-05 Migraine / / 23793025 rs6783265 chr3 30483304 G A 2.06E-04 Multiple complex diseases / / 17554300 rs9825365 chr3 30486148 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs13062325 chr3 30488000 C G 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4325953 chr3 30488348 T C 2.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11129406 chr3 30493494 G C 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9310936 chr3 30499437 T G 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4613502 chr3 30503020 A G 1.65E-04 Pancreatic cancer / / pha002874 rs4955307 chr3 30506137 A G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4312687 chr3 30509720 T A 7.22E-05 Suicide attempts in bipolar disorder / / 21423239 rs12635464 chr3 30511330 G A 6.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9874162 chr3 30511372 T C 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4461455 chr3 30519860 C T 7.21E-04 Prostate cancer mortality / / 20978177 rs4461455 chr3 30519860 C T 2.90E-05 Urinary metabolites / / 21572414 rs11917602 chr3 30530899 G T 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9818535 chr3 30564369 C T 6.46E-04 Type 2 diabetes / / 17463246 rs9815023 chr3 30618711 C G 7.45E-04 Multiple complex diseases / / 17554300 rs2116137 chr3 30626098 G A 8.89E-04 Multiple complex diseases / / 17554300 rs2129842 chr3 30626595 C T 3.61E-04 Multiple complex diseases / / 17554300 rs6798752 chr3 30651546 A C 6.54E-04 Multiple complex diseases TGFBR2 intron 17554300 rs1991657 chr3 30658031 C T 4.84E-04 Multiple complex diseases TGFBR2 intron 17554300 rs11129420 chr3 30658541 T A 1.53E-04 Multiple complex diseases TGFBR2 intron 17554300 rs4522809 chr3 30668684 A G 7.15E-04 Alzheimer's disease TGFBR2 intron 22005930 rs10212320 chr3 30673865 C T 0.000000989 LDL cholesterol TGFBR2 intron 23063622 rs11466491 chr3 30675151 C T 0.000066 Cholesterol,total TGFBR2 intron 23063622 rs3863057 chr3 30680370 T C 8.16E-04 Acute lung injury TGFBR2 intron 22295056 rs12493607 chr3 30682939 G C 2.00E-08 Breast cancer TGFBR2 intron 23535729 rs9838771 chr3 30698782 G A 0.000000226 Triglycerides TGFBR2 intron 23063622 rs9838771 chr3 30698782 G A 1.27E-09 LDL cholesterol TGFBR2 intron 23063622 rs3773640 chr3 30709511 A T 7.58E-04 Multiple complex diseases TGFBR2 intron 17554300 rs3773643 chr3 30710243 A G 2.00E-07 Tonometry TGFBR2 intron 17903302 rs3773646 chr3 30714757 C T 0.00019 Coronary artery calcification TGFBR2 intron 23727086 rs3773651 chr3 30718532 A G 0.0000417 HDL cholesterol TGFBR2 intron 23063622 rs3773652 chr3 30718942 G A 8.01E-04 Smoking initiation TGFBR2 intron 24665060 rs2043136 chr3 30720304 G A 9.09E-05 Pancreatic cancer TGFBR2 intron pha002889 rs6804368 chr3 30753573 A G 8.00E-21 Blood metabolite levels / / 24816252 rs6550010 chr3 30772165 A G 7.22E-04 Response to cholinesterase inhibitors in Alzheimer's disease GADL1 intron 23374588 rs795448 chr3 30800620 G T 1.20E-05 Urinary metabolites GADL1 intron 21572414 rs795446 chr3 30801088 A G 4.15E-05 Varicose Veins GADL1 intron pha001411 rs797054 chr3 30801175 T C 2.23E-05 Varicose Veins GADL1 intron pha001411 rs6805561 chr3 30801713 C A 5.16E-04 Multiple complex diseases GADL1 intron 17554300 rs7649779 chr3 30817218 T C 8.60E-05 Response to statin therapy GADL1 intron 20339536 rs9882060 chr3 30817996 C A 8.70E-05 Response to statin therapy GADL1 intron 20339536 rs11129424 chr3 30848253 G A 6.45E-04 Response to cytadine analogues (cytosine arabinoside) GADL1 intron 24483146 rs11129425 chr3 30870256 C T 9.01E-05 Response to cytadine analogues (cytosine arabinoside) GADL1 intron 24483146 rs10510640 chr3 30882031 C A 3.60E-06 Urinary metabolites GADL1 intron 21572414 rs12636066 chr3 30913645 C A 5.45E-05 Cognitive test performance GADL1 intron 20125193 rs12636066 chr3 30913645 C A 8.60E-05 Endometriosis GADL1 intron 21151130 rs1494736 chr3 30981986 A G 5.82E-04 Multiple complex diseases / / 17554300 rs9821361 chr3 30992726 T C 1.12E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955351 chr3 30995589 A T 1.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs1494741 chr3 30995986 A C 1.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955352 chr3 30996395 G C 1.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026829 chr3 30996531 C G 9.98E-06 Suicide attempts in bipolar disorder / / 21423239 rs9860804 chr3 30996999 A G 1.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026833 chr3 31000622 A T 1.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs1494742 chr3 31001640 T G 8.87E-06 Suicide attempts in bipolar disorder / / 21423239 rs4955355 chr3 31002590 C A 3.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026835 chr3 31005429 G C 1.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs6788647 chr3 31007847 T C 1.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550032 chr3 31008073 G A 1.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550033 chr3 31008204 C A 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955356 chr3 31009886 C A 2.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955173 chr3 31010785 A G 8.62E-06 Suicide attempts in bipolar disorder / / 21423239 rs17433029 chr3 31012087 G A 7.80E-06 Suicide attempts in bipolar disorder / / 21423239 rs17026839 chr3 31012135 T C 1.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs1565881 chr3 31014526 A G 7.95E-06 Suicide attempts in bipolar disorder / / 21423239 rs1112792 chr3 31015186 C T 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026845 chr3 31016294 G A 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550034 chr3 31016445 C A 1.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs6791315 chr3 31016950 G A 1.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955357 chr3 31018158 C A 1.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs6807602 chr3 31018512 T C 1.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs2201438 chr3 31019238 G C 1.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs2201439 chr3 31019269 G A 1.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs6787451 chr3 31021894 C T 1.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955358 chr3 31022013 G A 1.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs6779686 chr3 31026401 A G 1.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs6804483 chr3 31026667 G C 1.98E-05 Suicide attempts in bipolar disorder / / 21423239 rs11129431 chr3 31026886 A G 1.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs6772140 chr3 31027764 T G 1.10E-05 Suicide attempts in bipolar disorder / / 21423239 rs6808005 chr3 31027867 G A 1.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955174 chr3 31028079 T C 1.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955175 chr3 31028378 C T 2.72E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955176 chr3 31028401 G A 2.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955177 chr3 31028426 T G 2.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955361 chr3 31028533 A G 2.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs6765969 chr3 31029542 C T 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs6790372 chr3 31029600 A G 2.85E-05 Suicide attempts in bipolar disorder / / 21423239 rs6793134 chr3 31029935 A T 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs9820757 chr3 31031572 C T 4.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026882 chr3 31031841 C T 3.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs12054010 chr3 31033280 G T 3.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs9831434 chr3 31033407 G T 7.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs4368536 chr3 31034632 C G 3.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026902 chr3 31040041 A G 8.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506206 chr3 31040377 T C 4.36E-04 Type 2 diabetes / / 17463246 rs1506205 chr3 31040399 C T 6.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506204 chr3 31040494 T G 5.98E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506203 chr3 31040503 G T 6.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506203 chr3 31040503 G T 8.00E-06 Eating disorders (purging via substances) / / 23568457 rs1567026 chr3 31042356 C T 5.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs9790023 chr3 31047830 T G 6.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs9883843 chr3 31048958 C A 7.03E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026930 chr3 31056398 T C 5.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs10512719 chr3 31058249 T A 6.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs9858387 chr3 31059661 T C 6.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs9844634 chr3 31060089 T C 7.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955366 chr3 31060338 G A 7.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs294314 chr3 31067452 C T 8.77E-05 Coronary heart disease / / 24778558 rs1683753 chr3 31073011 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1119709 chr3 31073762 A G 6.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683768 chr3 31074131 C T 7.21E-04 Multiple complex diseases / / 17554300 rs1385828 chr3 31074175 T A 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs839589 chr3 31076044 T C 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs839590 chr3 31076965 T G 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs865735 chr3 31078350 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4308316 chr3 31079105 A C 9.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs294309 chr3 31079270 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs294308 chr3 31079320 A G 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs294307 chr3 31079443 G A 4.97E-04 Multiple complex diseases / / 17554300 rs294305 chr3 31079959 T C 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701423 chr3 31086976 A G 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701428 chr3 31088615 T C 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs981985 chr3 31089142 T A 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683760 chr3 31089530 A G 9.75E-04 Multiple complex diseases / / 17554300 rs1485915 chr3 31089689 T C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683759 chr3 31089788 T C 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6810010 chr3 31091438 A G 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1395162 chr3 31092371 C A 7.74E-04 Multiple complex diseases / / 17554300 rs839585 chr3 31092929 G C 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs711685 chr3 31093900 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs839588 chr3 31096879 A G 9.60E-06 Left ventricular mass / / 21212386 rs839588 chr3 31096879 A G 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1098080 chr3 31100532 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs9828280 chr3 31103466 A G 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4955369 chr3 31112187 T G 0.0000665 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1683772 chr3 31118448 T C 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs294284 chr3 31126912 A C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7620843 chr3 31137630 G A 1.40E-05 Urinary metabolites / / 21572414 rs1857876 chr3 31149368 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701443 chr3 31158864 G T 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683766 chr3 31159149 G T 6.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs9848246 chr3 31161057 T G 2.50E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs839581 chr3 31163822 T G 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4955372 chr3 31171437 T C 2.96E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs7625163 chr3 31175501 T C 3.30E-04 Asperger disorder / / 21182207 rs1485916 chr3 31179339 C A 1.79E-04 Type 2 diabetes / / 22158537 rs9838192 chr3 31263782 C T 5.79E-04 Myopia (pathological) / / 21095009 rs7628394 chr3 31314100 C T 3.11E-04 Depression (quantitative trait) / / 20800221 rs6798661 chr3 31316585 A C 3.20E-04 Depression (quantitative trait) / / 20800221 rs6804612 chr3 31321856 T C 3.16E-04 Depression (quantitative trait) / / 20800221 rs9844475 chr3 31322654 C T 3.17E-04 Depression (quantitative trait) / / 20800221 rs9865155 chr3 31323210 T C 3.17E-04 Depression (quantitative trait) / / 20800221 rs9822344 chr3 31324186 C G 3.18E-04 Depression (quantitative trait) / / 20800221 rs9826665 chr3 31324352 G A 3.18E-04 Depression (quantitative trait) / / 20800221 rs9310965 chr3 31327951 C T 3.20E-04 Depression (quantitative trait) / / 20800221 rs9811300 chr3 31329185 A G 3.21E-04 Depression (quantitative trait) / / 20800221 rs9873949 chr3 31330024 T C 3.23E-04 Depression (quantitative trait) / / 20800221 rs9859166 chr3 31330858 C T 3.30E-04 Depression (quantitative trait) / / 20800221 rs9879457 chr3 31331119 T G 3.34E-04 Depression (quantitative trait) / / 20800221 rs9825803 chr3 31331273 A T 3.36E-04 Depression (quantitative trait) / / 20800221 rs9870170 chr3 31332995 G T 3.41E-04 Depression (quantitative trait) / / 20800221 rs9865912 chr3 31333290 T C 3.42E-04 Depression (quantitative trait) / / 20800221 rs6764036 chr3 31334622 T G 3.46E-04 Depression (quantitative trait) / / 20800221 rs9859409 chr3 31351988 T A 5.61E-04 Multiple complex diseases / / 17554300 rs17841960 chr3 31360453 A G 1.19E-04 Multiple complex diseases / / 17554300 rs9310966 chr3 31364686 G A 7.49E-04 Type 2 diabetes / / 17463246 rs1006965 chr3 31383105 C T 9.24E-04 Multiple complex diseases / / 17554300 rs9862255 chr3 31392328 T C 1.06E-05 Type 2 diabetes / / 17463246 rs6805533 chr3 31406542 C A 1.87E-05 Eosinophil counts / / pha003088 rs7642575 chr3 31425161 T C 1.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510650 chr3 31433240 C T 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs931567 chr3 31435577 G A 6.72E-04 Multiple complex diseases / / 17554300 rs931567 chr3 31435577 G A 1.80E-05 Type 2 diabetes / / 17903298 rs931567 chr3 31435577 G A 9.76E-06 Eosinophil counts / / pha003088 rs9310968 chr3 31439256 C T 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17027625 chr3 31445580 T C 4.00E-06 HIV-1 control / / 20041166 rs9843322 chr3 31452963 G T 5.74E-05 Orofacial clefts / / 22419666 rs4955190 chr3 31454973 A C 1.93E-04 Follicle stimulating hormone / / 24049095 rs9831111 chr3 31456161 C T 6.85E-05 Orofacial clefts / / 22419666 rs6771464 chr3 31494000 C A 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6794150 chr3 31528413 A G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7639313 chr3 31529089 A G 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs9810171 chr3 31532258 T G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800262 chr3 31533626 T C 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4611854 chr3 31537830 T C 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1902334 chr3 31726314 G A 8.93E-05 IgE levels OSBPL10 intron 17255346 rs9819360 chr3 31754338 C A 9.15E-04 Aortic root size OSBPL10 intron 21223598 rs9819360 chr3 31754338 C A 1.59E-04 Obesity (early onset extreme) OSBPL10 intron 23563609 rs2085311 chr3 31778395 A G 6.29E-04 Smoking quantity OSBPL10 intron 24665060 rs11129461 chr3 31779692 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL10 intron 20877124 rs11129461 chr3 31779692 T C 4.43E-04 Smoking cessation OSBPL10 intron 24665060 rs17028180 chr3 31787449 A G 2.62E-05 Multiple complex diseases OSBPL10 intron 17554300 rs11714423 chr3 31793857 A G 2.56E-05 Coronary heart disease OSBPL10 intron 21606135 rs11710822 chr3 31793871 T C 6.26E-05 Coronary heart disease OSBPL10 intron 21606135 rs1902341 chr3 31795570 C T 5.00E-07 Peripheral artery disease OSBPL10 intron 20610895 rs2045298 chr3 31799254 T C 2.87E-04 Alzheimer's disease OSBPL10 intron 17998437 rs2168422 chr3 31804842 G T 7.80E-04 Alcohol dependence OSBPL10 intron 20201924 rs7631385 chr3 31806071 T C 3.91E-04 Alzheimer's disease OSBPL10 intron 17998437 rs7621973 chr3 31806188 C T 5.21E-05 Alzheimer's disease OSBPL10 intron 17998437 rs7612780 chr3 31810558 A G 8.10E-04 Alcohol dependence OSBPL10 intron 20201924 rs936160 chr3 31812585 C T 1.93E-04 Alzheimer's disease OSBPL10 intron 17998437 rs936160 chr3 31812585 C T 2.16E-04 Coronary heart disease OSBPL10 intron 21606135 rs936160 chr3 31812585 C T 1.94E-04 Alzheimer's disease OSBPL10 intron pha002879 rs2219250 chr3 31817544 T C 5.03E-04 Alzheimer's disease OSBPL10 intron 17998437 rs2219250 chr3 31817544 T C 3.80E-04 Alcohol dependence OSBPL10 intron 20201924 rs2219250 chr3 31817544 T C 5.70E-04 Alcohol dependence OSBPL10 intron 20201924 rs2219250 chr3 31817544 T C 4.65E-04 Coronary heart disease OSBPL10 intron 21606135 rs2068100 chr3 31837204 A T 4.65E-04 Coronary heart disease OSBPL10 intron 21606135 rs7628972 chr3 31839097 C T 3.70E-04 Coronary heart disease OSBPL10 intron 21606135 rs7643025 chr3 31839242 T C 5.32E-04 Coronary heart disease OSBPL10 intron 21606135 rs6550070 chr3 31842635 C A 8.84E-04 Coronary heart disease OSBPL10 intron 21606135 rs4611855 chr3 31847360 T C 1.97E-04 Barrett's esophagus OSBPL10 intron 24121790 rs4611855 chr3 31847360 T C 2.57E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) OSBPL10 intron 24121790 rs6808708 chr3 31847977 T A 7.71E-05 Coronary heart disease OSBPL10 intron 21606135 rs7649767 chr3 31850663 G A 1.47E-04 Alzheimer's disease (late onset) OSBPL10 intron 21379329 rs6773772 chr3 31851726 T C 3.41E-04 Epilepsy OSBPL10 intron 22116939 rs13087711 chr3 31857836 C T 3.90E-04 Major depressive disorder OSBPL10 intron 21042317 rs4349533 chr3 31893789 G A 8.80E-06 Response to cholinesterase inhibitors in Alzheimer's disease OSBPL10 intron 23374588 rs6776254 chr3 31901848 C T 1.42E-05 Recombination rate OSBPL10 intron 21698098 rs7629505 chr3 31921624 A G 6.91E-04 Type 2 diabetes OSBPL10 intron 17463246 rs7644177 chr3 31964898 G A 8.64E-04 Parkinson's disease OSBPL10 intron 17052657 rs7644177 chr3 31964898 G A 5.23E-04 Tourette syndrome OSBPL10 intron 22889924 rs6810295 chr3 31967967 G A 6.56E-04 Multiple complex diseases OSBPL10 intron 17554300 rs6810295 chr3 31967967 G A 7.00E-06 Body mass index (education interaction) OSBPL10 intron 24281739 rs11713199 chr3 31975321 C G 6.90E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs12630254 chr3 31981227 T C 6.70E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs12630931 chr3 31981767 T C 6.00E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs9847964 chr3 32001194 C T 2.30E-05 Urinary metabolites OSBPL10 intron 21572414 rs7643045 chr3 32125010 G A 1.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1159444 chr3 32146188 G T 8.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GPD1L nearGene-5 20031582 rs17028882 chr3 32153391 T A 3.14E-04 Multiple complex diseases GPD1L intron 17554300 rs17028885 chr3 32155048 C T 3.03E-04 Cognitive decline GPD1L intron 23732972 rs11710089 chr3 32180635 C G 2.10E-05 Urinary metabolites GPD1L intron 21572414 rs1451523 chr3 32218812 G C 7.64E-04 Smoking initiation / / 24665060 rs11922715 chr3 32219726 G A 1.31E-06 Intelligence / / 21826061 rs9842565 chr3 32223481 G A 0.000257605 Hypertension (early onset hypertension) / / 22479346 rs11922502 chr3 32225203 C T 1.90E-07 Intelligence / / 21826061 rs7644491 chr3 32225326 C T 2.60E-05 Smoking initiation / / 24665060 rs9867908 chr3 32233643 G A 4.18E-04 Smoking initiation / / 24665060 rs11720070 chr3 32235481 C T 7.00E-06 Urinary metabolites / / 21572414 rs11720070 chr3 32235481 C T 3.04E-06 Heart Rate / / pha003054 rs4440157 chr3 32236058 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9825310 chr3 32240119 G A 8.00E-06 Alcohol dependence / / 22004471 rs4955256 chr3 32257143 T C 2.16E-04 Multiple complex diseases / / 17554300 rs4376071 chr3 32264991 C T 8.00E-06 IgG glycosylation / / 23382691 rs4955265 chr3 32267947 G A 3.58E-04 IgE levels / / 17255346 rs9813563 chr3 32272498 C G 8.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs4075566 chr3 32282686 G A 1.11E-06 Hemoglobin CMTM8 intron pha003096 rs4075566 chr3 32282686 G A 4.67E-06 Hematocrit CMTM8 intron pha003097 rs7621429 chr3 32302529 C T 5.66E-05 Alzheimer's disease CMTM8 intron 21098978 rs4245886 chr3 32304103 C A 9.03E-04 Multiple complex diseases CMTM8 intron 17554300 rs4245886 chr3 32304103 C A 2.31E-04 Bipolar disorder,schizoaffective CMTM8 intron 19567891 rs4245886 chr3 32304103 C A 5.52E-05 Alzheimer's disease CMTM8 intron 21098978 rs7636660 chr3 32312914 G A 1.82E-05 Alzheimer's disease CMTM8 intron 21098978 rs4132830 chr3 32315383 T C 8.23E-04 Stroke CMTM8 intron pha002886 rs4572808 chr3 32317714 G C 1.82E-05 Alzheimer's disease CMTM8 intron 21098978 rs7644602 chr3 32320408 G T 2.28E-05 Alzheimer's disease CMTM8 intron 21098978 rs11708149 chr3 32321599 A T 2.47E-05 Alzheimer's disease CMTM8 intron 21098978 rs6783478 chr3 32322975 A T 5.11E-04 Multiple complex diseases CMTM8 intron 17554300 rs6783478 chr3 32322975 A T 2.46E-05 Alzheimer's disease CMTM8 intron 21098978 rs6783478 chr3 32322975 A T 3.61E-05 Schizophrenia(age at onset) CMTM8 intron 21688384 rs12637074 chr3 32324460 T C 6.44E-05 Femoral neck bone geometry CMTM8 intron 22087292 rs4955274 chr3 32327421 A G 1.02E-05 Alzheimer's disease CMTM8 intron 21098978 rs4380451 chr3 32329497 C T 4.00E-06 Bipolar disorder CMTM8 intron 18711365 rs4276227 chr3 32330686 C T 4.57E-06 Multiple complex diseases CMTM8 intron 17554300 rs6793780 chr3 32339493 T G 6.53E-05 Cognitive test performance CMTM8 intron 20125193 rs1398101 chr3 32345699 T G 5.49E-05 Multiple complex diseases CMTM8 intron 17554300 rs17029181 chr3 32346116 A G 2.51E-05 Fibrinogen CMTM8 intron 17255346 rs4627791 chr3 32347824 A G 2.37E-06 Multiple complex diseases CMTM8 intron 17554300 rs4627791 chr3 32347824 A G 2.00E-06 Bipolar disorder CMTM8 intron 21254220 rs9875310 chr3 32348195 A G 5.40E-06 Fibrinogen CMTM8 intron 17255346 rs9875310 chr3 32348195 A G 9.70E-05 Cognitive performance CMTM8 intron 19734545 rs9875310 chr3 32348195 A G 1.71E-04 Parkinson's disease CMTM8 intron 21248740 rs1370718 chr3 32353131 C A 9.06E-04 Type 2 diabetes CMTM8 intron 17463246 rs1438182 chr3 32365788 C T 4.92E-04 Stroke CMTM8 intron pha002887 rs6776297 chr3 32378271 G A 5.00E-06 HIV-1 viral setpoint CMTM8 intron 22174851 rs17029245 chr3 32389053 A G 2.64E-06 Personality dimensions CMTM8 intron 23658558 rs4955144 chr3 32395216 C A 2.53E-05 Body Composition CMTM8 intron pha003012 rs4955144 chr3 32395216 C A 9.34E-05 Body Mass Index CMTM8 intron pha003021 rs2289244 chr3 32399181 G A 8.08E-06 Body Composition CMTM8 intron pha003012 rs2289244 chr3 32399181 G A 3.14E-05 Body Mass Index CMTM8 intron pha003021 rs4955281 chr3 32399859 T A 6.91E-34 Metabolite levels CMTM8 intron 22286219 rs4266227 chr3 32402435 T C 6.54E-05 Smoking initiation CMTM8 intron 24665060 rs11924535 chr3 32423251 T C 7.24E-05 Blood Pressure / / pha003048 rs2343849 chr3 32446152 C A 2.97E-06 Multiple complex diseases CMTM7 intron 17554300 rs9853991 chr3 32466797 C T 9.53E-06 Hypertension CMTM7 intron 21082022 rs17804246 chr3 32473512 C T 2.58E-04 Type 2 diabetes CMTM7 intron 17463246 rs17804246 chr3 32473512 C T 6.65E-05 Erythrocyte counts CMTM7 intron pha003101 rs12638540 chr3 32488534 A G 3.00E-07 Heart failure CMTM7 intron 20400778 rs3888882 chr3 32497574 G T 2.98E-05 Hypertension / / 21082022 rs164214 chr3 32498154 T C 1.44E-04 Parkinson's disease / / 21248740 rs9854574 chr3 32527218 G A 2.47E-05 Information processing speed CMTM6 intron 21130836 rs7640978 chr3 32533010 C T 1.00E-08 LDL cholesterol CMTM6 intron 24097068 rs7640978 chr3 32533010 C T 2.00E-08 Cholesterol,total CMTM6 intron 24097068 rs12488997 chr3 32535028 A T 6.84E-04 Suicide attempts in bipolar disorder CMTM6 intron 21423239 rs342763 chr3 32537791 C T 6.74E-04 Multiple complex diseases CMTM6 intron 17554300 rs6782149 chr3 32569096 C T 6.18E-04 Smoking initiation DYNC1LI1 intron 24665060 rs6550135 chr3 32592852 A G 4.48E-04 Smoking initiation DYNC1LI1 intron 24665060 rs9868569 chr3 32599939 G A 1.30E-05 Multiple complex diseases DYNC1LI1 intron 17554300 rs17029747 chr3 32644001 T C 2.06E-04 Blood pressure / / 17255346 rs6550146 chr3 32704743 A G 2.63E-04 Schizophrenia / / 20832056 rs6790023 chr3 32706557 G C 3.40E-04 Schizophrenia / / 20832056 rs9845475 chr3 32842101 T G 4.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs12629685 chr3 32880078 G A 0.0001982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRIM71 intron 23233654 rs12629685 chr3 32880078 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRIM71 intron 23233662 rs13075951 chr3 32882007 G A 0.0001987 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRIM71 intron 23233654 rs13075951 chr3 32882007 G A 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRIM71 intron 23233662 rs7610310 chr3 32883189 G A 2.52E-06 Schizophrenia TRIM71 intron 22037555 rs997520 chr3 32883581 G A 2.74E-06 Schizophrenia TRIM71 intron 22037555 rs9310995 chr3 32929115 T C 4.00E-06 Pulmonary function TRIM71 intron 21946350 rs7648704 chr3 32941852 G T 1.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs13071058 chr3 32958723 G A 5.01E-04 Multiple complex diseases / / 17554300 rs9310996 chr3 32999260 C T 8.04E-04 Multiple complex diseases / / 17554300 rs13314993 chr3 33015469 G T 3.00E-09 Celiac disease / / 20190752 rs13314993 chr3 33015469 G T 3.00E-09 Asthma / / 21150878 rs13314993 chr3 33015469 G T 3.27E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs13314993 chr3 33015469 G T 3.00E-09 Asthma / / 21907864 rs13314993 chr3 33015469 G T 3.27E-09 Multiple sclerosis / / 22190364 rs4678649 chr3 33017224 A G 8.54E-05 Parkinson's disease / / 21812969 rs4678680 chr3 33020035 G T 2.00E-07 Hepatocellular carcinoma / / 21105107 rs4678680 chr3 33020035 G T 2.00E-07 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs6778706 chr3 33024069 G A 0.000156644 Primary sclerosing cholangitis / / 23603763 rs4678523 chr3 33037721 T C 2.40E-07 Celiac disease GLB1 nearGene-3 22057235 rs9828592 chr3 33044339 T C 3.09E-04 Self-reported allergy GLB1 intron 23817569 rs4402881 chr3 33054331 T C 0.000000495 Triglycerides GLB1 intron 23063622 rs4402881 chr3 33054331 T C 0.00000155 LDL cholesterol GLB1 intron 23063622 rs4402881 chr3 33054331 T C 2.11E-10 Cholesterol,total GLB1 intron 23063622 rs12635761 chr3 33059101 G A 9.46E-04 White matter integrity GLB1 intron 22425255 rs7613051 chr3 33065339 G A 6.00E-21 Atopic dermatitis GLB1 intron 23042114 rs4679074 chr3 33082656 A G 9.13E-04 White matter integrity GLB1 intron 22425255 rs6550204 chr3 33107645 C T 1.90E-04 Smoking initiation GLB1 intron 24665060 rs4320035 chr3 33113697 G C 7.51E-05 Smoking initiation GLB1 intron 24665060 rs9827863 chr3 33118951 A G 1.40E-04 Smoking initiation GLB1 intron 24665060 rs9883177 chr3 33123354 T C 7.81E-05 Smoking initiation GLB1 intron 24665060 rs9868526 chr3 33124269 G A 1.47E-04 Smoking initiation GLB1 intron 24665060 rs73043340 chr3 33126972 C T 3.76E-07 Prostate cancer GLB1 intron 24185611 rs9810375 chr3 33127867 G T 2.57E-04 Type 2 diabetes GLB1 intron 17463246 rs4578976 chr3 33146189 C T 3.01E-04 Smoking initiation / / 24665060 rs4678681 chr3 33150829 G A 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4074418 chr3 33161165 G T 2.00E-04 Cognitive impairment induced by topiramate CRTAP intron 22091778 rs4234239 chr3 33175793 C A 0.0005188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRTAP intron 23233654 rs4234239 chr3 33175793 C A 5.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRTAP intron 23233662 rs7652193 chr3 33176824 A G 0.000519 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRTAP intron 23233654 rs7652193 chr3 33176824 A G 5.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRTAP intron 23233662 rs7623768 chr3 33182052 A C 5.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CRTAP intron 24578207 rs7623768 chr3 33182052 A C 5.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CRTAP intron 24578207 rs7623768 chr3 33182052 A C 9.51E-05 Tunica Media CRTAP intron pha003034 rs9854123 chr3 33211327 G A 3.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs4678732 chr3 33212485 G A 3.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs4678497 chr3 33213119 T C 4.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs12632512 chr3 33225343 A C 6.14E-05 Tunica Media SUSD5 intron pha003034 rs4384906 chr3 33240314 T G 4.70E-04 Response to taxane treatment (placlitaxel) SUSD5 intron 23006423 rs4389431 chr3 33243386 C T 5.63E-04 Alcohol dependence SUSD5 intron 21314694 rs4535176 chr3 33248370 T C 2.04E-04 Coronary heart disease SUSD5 intron 21971053 rs6800399 chr3 33281293 G A 5.61E-05 HIV-1 viral setpoint / / 22174851 rs7653239 chr3 33289596 G A 2.04E-04 Alcohol dependence / / 21314694 rs13323402 chr3 33293350 C G 5.27E-05 Type 2 diabetes / / 17463246 rs9880596 chr3 33293758 T C 8.54E-04 Type 2 diabetes / / 17463246 rs7628482 chr3 33336370 C T 0.0005823 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXL2 intron 23233654 rs7628482 chr3 33336370 C T 5.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXL2 intron 23233662 rs6769005 chr3 33388184 T A 8.13E-04 Multiple complex diseases FBXL2 intron 17554300 rs4678929 chr3 33413263 T G 1.73E-05 Behcet's disease FBXL2 intron 23291587 rs2291897 chr3 33419422 C T 1.47E-05 Behcet's disease FBXL2 intron 23291587 rs2291897 chr3 33419422 C T 1.82E-05 Behcet's disease FBXL2 intron pha002888 rs4045539 chr3 33421178 A C 1.56E-05 Behcet's disease FBXL2 intron 23291587 rs17029983 chr3 33442890 A G 5.44E-04 Type 2 diabetes UBP1 intron 17463246 rs1807844 chr3 33472937 T C 2.13E-05 Behcet's disease UBP1 intron 23291587 rs1807844 chr3 33472937 T C 5.56E-05 Behcet's disease UBP1 intron pha002888 rs1357540 chr3 33479982 T C 2.13E-05 Behcet's disease UBP1 intron 23291587 rs1357540 chr3 33479982 T C 2.69E-05 Behcet's disease UBP1 intron pha002888 rs6550222 chr3 33534885 T C 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6781484 chr3 33545785 T C 1.05E-04 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs6781484 chr3 33545785 T C 4.66E-06 Behcet's disease CLASP2 intron 23291587 rs9862261 chr3 33562114 A G 6.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLASP2 intron 21844884 rs12487660 chr3 33592572 T G 2.90E-05 Behcet's disease CLASP2 intron 23291587 rs12487660 chr3 33592572 T G 2.70E-05 Behcet's disease CLASP2 intron pha002888 rs4504126 chr3 33600582 A C 3.54E-04 Multiple complex diseases CLASP2 intron 17554300 rs8179967 chr3 33609330 T C 6.04E-05 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs6807542 chr3 33653622 T G 9.56E-05 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs7374396 chr3 33670344 C A 4.45E-04 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs7374396 chr3 33670344 C A 6.59E-05 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs7374396 chr3 33670344 C A 8.32E-06 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs4679073 chr3 33689633 C T 9.13E-04 Multiple complex diseases CLASP2 intron 17554300 rs9876025 chr3 33698172 G A 4.69E-04 Alcohol dependence CLASP2 intron 21314694 rs9844608 chr3 33774574 A G 9.31E-06 Attention deficit hyperactivity disorder / / 22012869 rs9843488 chr3 33838124 T G 1.71E-04 Vaspin levels / / 22907691 rs9843488 chr3 33838124 T G 0.0001714 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7626555 chr3 33865612 G A 1.85E-04 Vaspin levels PDCD6IP intron 22907691 rs7626555 chr3 33865612 G A 0.0001851 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP intron 22907730 rs3792594 chr3 33877626 G A 2.35E-04 Vaspin levels PDCD6IP missense 22907691 rs3792594 chr3 33877626 G A 0.0002346 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP missense 22907730 rs10865850 chr3 33900980 G A 2.17E-04 Vaspin levels PDCD6IP intron 22907691 rs10865850 chr3 33900980 G A 0.0002171 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP intron 22907730 rs6764014 chr3 33980449 C T 1.89E-05 Post-operative nausea and vomiting / / 21694509 rs9881576 chr3 33991181 T A 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs12629322 chr3 33991854 T C 2.23E-04 Alzheimer's disease / / 22005930 rs4678623 chr3 33997849 T C 8.98E-05 Body Fat Distribution / / pha003017 rs4350875 chr3 34001134 T C 7.54E-04 Type 2 diabetes / / 17463246 rs4350875 chr3 34001134 T C 4.17E-04 Alzheimer's disease / / 22005930 rs4380367 chr3 34002063 G A 4.47E-04 Alzheimer's disease / / 22005930 rs7620363 chr3 34013205 C T 4.60E-04 Nicotine use / / 23942779 rs7620363 chr3 34013205 C T 7.10E-04 Alcohol consumption / / 23942779 rs7620363 chr3 34013205 C T 9.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs13098651 chr3 34014094 T C 2.46E-04 Alzheimer's disease / / 22005930 rs13097841 chr3 34020900 T G 4.73E-04 Alzheimer's disease / / 22005930 rs9866710 chr3 34021986 G A 8.81E-05 Type 2 diabetes / / 17463246 rs4132587 chr3 34023066 A G 4.79E-04 Alzheimer's disease / / 22005930 rs4258910 chr3 34023225 C T 4.78E-04 Alzheimer's disease / / 22005930 rs12634235 chr3 34042955 C T 5.54E-04 Alzheimer's disease / / 22005930 rs4438609 chr3 34044652 A C 5.04E-04 Alzheimer's disease / / 22005930 rs11709925 chr3 34044916 G A 5.00E-05 Body Fat Distribution / / pha003017 rs11709925 chr3 34044916 G A 9.51E-05 Body Fat Distribution / / pha003018 rs4045199 chr3 34047586 G A 3.55E-06 Type 2 diabetes / / 17463246 rs9845173 chr3 34047877 G T 2.23E-04 Type 2 diabetes / / 17463246 rs4566485 chr3 34052641 T C 5.57E-04 Alzheimer's disease / / 22005930 rs11714011 chr3 34053980 G A 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4072315 chr3 34060079 G A 4.13E-04 Alzheimer's disease / / 22005930 rs4234232 chr3 34076846 T G 6.22E-05 Alzheimer's disease (late onset) / / 20885792 rs4373023 chr3 34077223 T C 2.33E-04 Type 2 diabetes / / 17463246 rs9852942 chr3 34120142 A G 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4044970 chr3 34120978 G T 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1595878 chr3 34135180 G A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs10049124 chr3 34149458 T C 8.60E-05 HIV-1 control / / 20041166 rs7641622 chr3 34168020 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs9863160 chr3 34170395 T A 7.11E-04 Multiple complex diseases / / 17554300 rs11705728 chr3 34176277 A C 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2336117 chr3 34179261 T C 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12638888 chr3 34182565 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs6770257 chr3 34184505 T C 2.95E-06 Longevity,exceptional / / 20595579 rs7614971 chr3 34187468 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7653017 chr3 34192975 A C 8.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs4678459 chr3 34194392 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6801432 chr3 34195620 A T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1440387 chr3 34196788 C A 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6781182 chr3 34212166 T C 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs145744974 chr3 34260092 A G 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs2139172 chr3 34288960 G A 1.20E-05 Urinary metabolites / / 21572414 rs939021 chr3 34298029 G A 1.41E-04 Type 2 diabetes / / 17463246 rs1529075 chr3 34427945 T G 5.69E-04 Alcohol dependence / / 20201924 rs17031657 chr3 34446738 A C 7.55E-04 Alcohol dependence / / 20201924 rs11714343 chr3 34462869 C T 9.60E-05 Type 2 diabetes / / 17463248 rs1529079 chr3 34544260 G A 5.46E-04 Stroke / / pha002887 rs921265 chr3 34546747 T C 5.56E-04 Type 2 diabetes / / 17463246 rs2122231 chr3 34562070 A T 7.31E-05 Multiple complex diseases / / 17554300 rs6808710 chr3 34574455 C T 3.71E-04 Type 2 diabetes / / 17463246 rs6787412 chr3 34587868 G A 4.47E-04 Type 2 diabetes / / 17463246 rs1402246 chr3 34589121 G A 6.23E-04 Type 2 diabetes / / 17463246 rs9881586 chr3 34589478 G C 5.87E-04 Type 2 diabetes / / 17463246 rs11924179 chr3 34600734 T C 1.74E-04 Type 2 diabetes / / 17463246 rs1002486 chr3 34622921 A C 5.70E-04 Stroke / / pha002887 rs13075567 chr3 34665118 T C 2.56E-05 ldl cholesterol / / pha003077 rs2358503 chr3 34744752 T C 4.50E-05 Stroke / / pha002887 rs11129615 chr3 34814789 T C 8.95E-05 Blood Pressure / / pha003044 rs655228 chr3 34817239 C T 9.35E-04 Coronary Artery Disease / / 17634449 rs13095300 chr3 34833827 T C 7.26E-04 Multiple complex diseases / / 17554300 rs7646181 chr3 34846024 A G 9.50E-04 Multiple complex diseases / / 17554300 rs6798946 chr3 34852103 C T 7.10E-04 Multiple complex diseases / / 17554300 rs2200675 chr3 34860208 C T 2.97E-04 Multiple complex diseases / / 17554300 rs559356 chr3 34865597 T C 3.00E-06 Cognitive function / / 24684796 rs479394 chr3 34875841 G T 5.02E-06 Cognitive function / / 24684796 rs1403441 chr3 34876028 G A 8.92E-04 Alzheimer's disease / / 22005930 rs613192 chr3 34876582 G T 2.10E-05 Urinary metabolites / / 21572414 rs659668 chr3 34880031 A T 3.26E-06 Cognitive function / / 24684796 rs940048 chr3 34887468 G C 1.03E-04 Birth weight / / 17255346 rs2358748 chr3 34887681 C A,G,T 1.14E-04 Birth weight / / 17255346 rs7652586 chr3 34905662 C A 1.50E-05 Urinary metabolites / / 21572414 rs7632967 chr3 34906302 A G 3.87E-04 Lung function (forced vital capacity) / / 24023788 rs1522978 chr3 34926622 C A 6.84E-05 Birth weight / / 17255346 rs41321847 chr3 34927004 A G 2.42E-05 Postoperative ventricular dysfunction / / 21980348 rs6550308 chr3 34936569 A G 2.20E-05 Cognitive function / / 24684796 rs11129625 chr3 34939893 A G 2.75E-05 Postoperative ventricular dysfunction / / 21980348 rs885314 chr3 34940732 T C 2.55E-05 Postoperative ventricular dysfunction / / 21980348 rs885315 chr3 34940818 C T 5.67E-06 Cognitive function / / 24684796 rs1403442 chr3 34941006 G A 5.84E-04 Multiple complex diseases / / 17554300 rs10514688 chr3 34962669 T C 6.00E-06 Tonometry / / 17903302 rs17691914 chr3 34962803 A G 3.42E-08 Postoperative ventricular dysfunction / / 21980348 rs9835451 chr3 34971564 G A 5.55E-06 Postoperative ventricular dysfunction / / 21980348 rs11129626 chr3 34975045 G A 1.81E-05 Postoperative ventricular dysfunction / / 21980348 rs4678726 chr3 34976020 G A 1.63E-05 Postoperative ventricular dysfunction / / 21980348 rs4678496 chr3 34993312 C T 5.50E-06 Total ventricular volume / / 21116278 rs13071005 chr3 35019950 T G 8.42E-06 Total ventricular volume / / 21116278 rs1979406 chr3 35039322 T C 4.55E-07 Postoperative ventricular dysfunction / / 21980348 rs17032625 chr3 35077009 C T 2.50E-07 Postoperative ventricular dysfunction / / 21980348 rs2035260 chr3 35089305 C A 4.50E-06 Urinary metabolites / / 21572414 rs7641653 chr3 35118418 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1382544 chr3 35127769 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11129640 chr3 35142511 G T 6.00E-08 Entorhinal cortical thickness / / 21116278 rs2127120 chr3 35142682 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2127119 chr3 35142699 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1376021 chr3 35278091 A G 9.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9811203 chr3 35282759 T C 2.29E-04 Parkinson's disease / / 17052657 rs4678766 chr3 35368128 G A 8.07E-05 Atopic dermatitis / / 23042114 rs11705929 chr3 35392137 C T 7.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1455327 chr3 35448187 T G 9.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1378394 chr3 35475083 T C 8.03E-04 Pemphigus vulgaris / / 22437316 rs17033265 chr3 35505374 G A 7.20E-06 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs7650296 chr3 35536237 C T 0.00016 Prostate cancer / / 23555315 rs7650296 chr3 35536237 C T 0.00052 Breast cancer / / 23555315 rs940070 chr3 35539957 C G 4.30E-04 Crohn's disease / / 17684544 rs6801949 chr3 35565537 T C 3.20E-04 IgE levels / / 17255346 rs17033506 chr3 35639826 G T 4.00E-07 Asthma (childhood onset) / / 23829686 rs13061600 chr3 35645818 C T 8.54E-04 Obesity (extreme) / / 21935397 rs9881157 chr3 35651949 C A 1.92E-11 Gender / / 22362730 rs1470558 chr3 35670051 T C 0.00077 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs6799641 chr3 35686732 A T 9.42E-04 Multiple complex diseases ARPP21 intron 17554300 rs17201627 chr3 35695010 C T 8.06E-04 Multiple complex diseases ARPP21 intron 17554300 rs4678789 chr3 35695512 T C 7.68E-04 Multiple complex diseases ARPP21 intron 17554300 rs11129660 chr3 35695961 C T 1.47E-04 Smoking cessation ARPP21 intron 18519826 rs7349512 chr3 35743058 G A 4.60E-05 Kawasaki disease ARPP21 intron 22446962 rs1963934 chr3 35767788 G C 8.11E-04 Type 2 diabetes ARPP21 intron 17463246 rs35102908 chr3 35774989 G A 4.02E-04 Type 2 diabetes ARPP21 intron 17463246 rs9865772 chr3 35794900 C T 1.80E-06 Smoking cessation ARPP21 intron 18519826 rs9865772 chr3 35794900 C T 6.13E-05 Diabetes (gestational) ARPP21 intron 22233651 rs1455496 chr3 35948642 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs9845811 chr3 35970883 G A 1.11E-04 Fibrinogen / / 17255346 rs12491195 chr3 35980407 C T 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6799705 chr3 35982130 C T 2.00E-07 Cognitive performance / / 19734545 rs12486302 chr3 35987444 A G 1.29E-04 Parkinson's disease / / 21248740 rs12486302 chr3 35987444 A G 8.80E-06 Urinary metabolites / / 21572414 rs4234249 chr3 35988262 G T 3.32E-04 Multiple complex diseases / / 17554300 rs4234249 chr3 35988262 G T 2.50E-05 Urinary metabolites / / 21572414 rs3996 chr3 35995866 A G 1.60E-04 Alzheimer's disease / / 17998437 rs3996 chr3 35995866 A G 6.12E-05 Alzheimer's disease / / pha002879 rs1488092 chr3 35996873 A G 1.25E-05 Cognitive test performance / / 20125193 rs6550379 chr3 36007114 G A 1.50E-05 Urinary metabolites / / 21572414 rs17827807 chr3 36008561 T C 7.34E-12 Adiponectin levels / / 20887962 rs6550380 chr3 36021077 C T 1.50E-05 Urinary metabolites / / 21572414 rs6550381 chr3 36021293 C A 6.30E-06 Urinary metabolites / / 21572414 rs986277 chr3 36027917 G A 4.40E-06 Urinary metabolites / / 21572414 rs1451799 chr3 36062609 C A 5.92E-04 Multiple complex diseases / / 17554300 rs2359957 chr3 36095941 T G 6.86E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9877548 chr3 36137084 T C 1.44E-04 Multiple complex diseases / / 17554300 rs11916736 chr3 36186144 T A 7.80E-06 Urinary metabolites / / 21572414 rs4678850 chr3 36189216 T C 2.60E-06 Urinary metabolites / / 21572414 rs10510677 chr3 36193066 A G 3.80E-06 Urinary metabolites / / 21572414 rs2044769 chr3 36194506 A T 2.50E-06 Urinary metabolites / / 21572414 rs7647206 chr3 36215009 T C 6.56E-05 Bipolar disorder / / 17486107 rs6550407 chr3 36222649 T C 1.25E-05 Bipolar disorder / / 17486107 rs6793640 chr3 36238545 A G 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs285322 chr3 36249481 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs285321 chr3 36250041 C A 2.26E-04 Type 2 diabetes / / 17463246 rs1479151 chr3 36344479 G A 7.81E-04 Multiple complex diseases / / 17554300 rs1479151 chr3 36344479 G A 4.75E-08 Narcolepsy / / 19629137 rs11706900 chr3 36348968 G A 7.10E-06 Type 2 diabetes / / 17463246 rs2046000 chr3 36352364 A C 9.42E-06 Celiac disease / / 23936387 rs1871352 chr3 36354537 A C 1.66E-05 Celiac disease / / 23936387 rs1479146 chr3 36360999 A G 2.58E-04 Celiac disease / / 23936387 rs10510683 chr3 36361555 G A 1.20E-05 Type 2 diabetes / / 17463246 rs1871350 chr3 36373765 C T 8.49E-06 Celiac disease / / 23936387 rs1842149 chr3 36391710 T G 1.91E-05 Celiac disease / / 23936387 rs1155010 chr3 36395598 T C 1.20E-05 Type 2 diabetes / / 17463246 rs1378784 chr3 36396158 C T 1.20E-05 Type 2 diabetes / / 17463246 rs1993923 chr3 36403951 C T 2.83E-05 Celiac disease / / 23936387 rs2605393 chr3 36409601 T G 6.00E-06 Celiac disease / / 23936387 rs6550422 chr3 36420628 A G 1.05E-04 Type 2 diabetes / / 17463246 rs9870425 chr3 36428232 A T 8.46E-05 Type 2 diabetes STAC intron 17463246 rs4505641 chr3 36432081 C T 2.17E-05 Blood Pressure STAC intron pha003050 rs4678878 chr3 36470307 T C 9.30E-04 Type 2 diabetes STAC intron 17463246 rs4678878 chr3 36470307 T C 7.65E-05 Blood Pressure STAC intron pha003050 rs11129714 chr3 36473840 T C 5.71E-05 Blood Pressure STAC intron pha003050 rs936154 chr3 36487492 G A 0.0006497 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAC intron 23233654 rs936154 chr3 36487492 G A 6.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAC intron 23233662 rs936156 chr3 36487696 C T 0.000791 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAC intron 23233654 rs936156 chr3 36487696 C T 7.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAC intron 23233662 rs6767011 chr3 36504281 A G 5.44E-05 Multiple complex diseases STAC intron 17554300 rs1350146 chr3 36516326 G A 4.30E-05 Malaria STAC intron 19465909 rs9881075 chr3 36517935 C A 6.39E-05 Graves' disease STAC intron 21841780 rs1456074 chr3 36524206 C T 2.10E-04 Amyotrophic Lateral Sclerosis STAC intron 17362836 rs1456074 chr3 36524206 C T 6.41E-05 Blood Pressure STAC intron pha003039 rs867840 chr3 36622550 C T 3.30E-06 Urinary metabolites / / 21572414 rs6780039 chr3 36655637 C G 1.10E-05 Urinary metabolites / / 21572414 rs9854871 chr3 36662503 C T 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6550429 chr3 36674940 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs13323950 chr3 36679558 C T 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs950146 chr3 36680099 G T 4.00E-06 Erectile dysfunction / / 22704111 rs5009838 chr3 36681026 C T 2.22E-04 Type 2 diabetes / / 17463246 rs4678541 chr3 36689524 G A 1.48E-04 Alzheimer's disease (late onset) / / 21379329 rs11707751 chr3 36690903 G A 1.30E-04 Alzheimer's disease (late onset) / / 21379329 rs1396029 chr3 36703758 C T 3.60E-04 Alzheimer's disease (late onset) / / 21379329 rs2174855 chr3 36731104 A G 2.13E-05 Smoking initiation / / 24665060 rs7625360 chr3 36748860 A C 9.78E-05 Dietary macronutrient intake / / 23636237 rs17197692 chr3 36775946 A C 1.54E-04 Multiple complex diseases DCLK3 intron 17554300 rs17197692 chr3 36775946 A C 1.76E-07 Glaucoma-related traits DCLK3 intron 22058429 rs4678550 chr3 36803994 T C 6.40E-06 Parkinson's disease / / 20711177 rs9838964 chr3 36812510 A C 5.59E-04 Smoking initiation / / 24665060 rs9838964 chr3 36812510 A C 9.34E-05 ldl cholesterol / / pha003076 rs17035576 chr3 36817025 T C 2.60E-05 Urinary metabolites / / 21572414 rs11927951 chr3 36817611 C G 3.30E-06 Urinary metabolites / / 21572414 rs13072940 chr3 36842623 T A 9.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs13072940 chr3 36842623 T A 0.0000127 Schizophrenia / / 23637625 rs13072940 chr3 36842623 T A 4.95E-05 Bipolar disorder / / 24618891 rs931913 chr3 36843149 G A 2.74E-07 Bipolar disorder / / 24618891 rs9882879 chr3 36844071 C T 2.38E-07 Bipolar disorder / / 24618891 rs9876421 chr3 36848316 C T 1.89E-07 Bipolar disorder / / 24618891 rs11707149 chr3 36850490 C T 3.52E-05 Bipolar disorder / / 24618891 rs925135 chr3 36854253 G A 3.69E-05 Bipolar disorder / / 24618891 rs9834970 chr3 36856030 T C 1.21E-06 Multiple complex diseases / / 17554300 rs9834970 chr3 36856030 T C 1.00E-12 Bipolar disorder / / 22182935 rs9834970 chr3 36856030 T C 5.41E-06 Major depressive disorder / / 22472876 rs9834970 chr3 36856030 T C 0.00000304 Bipolar disorder / / 23070075 rs9834970 chr3 36856030 T C 1.00E-07 Bipolar disorder (mood-incongruent) / / 23092984 rs9834970 chr3 36856030 T C 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs9834970 chr3 36856030 T C 0.00052 Bipolar disorder / / 23637625 rs9834970 chr3 36856030 T C 1.00E-10 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 4.00E-07 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 7.18E-05 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 4.81E-08 Bipolar disorder / / 24618891 rs906482 chr3 36856328 G A 1.10E-04 Multiple complex diseases / / 17554300 rs906482 chr3 36856328 G A 8.41E-04 Schizophrenia / / 19197363 rs1553656 chr3 36859705 T C 2.10E-05 Type 2 diabetes / / 23209189 rs1553656 chr3 36859705 T C 2.40E-07 Bipolar disorder / / 24618891 rs1532965 chr3 36861196 T G 2.73E-08 Bipolar disorder / / 24618891 rs4072458 chr3 36862680 T C 2.10E-07 Bipolar disorder / / 24618891 rs4624519 chr3 36862980 C T 4.04E-04 Multiple complex diseases / / 17554300 rs4624519 chr3 36862980 C T 2.00E-07 Schizophrenia / / 21926974 rs4624519 chr3 36862980 C T 2.61E-08 Bipolar disorder / / 24618891 rs9917659 chr3 36864160 A G 5.00E-04 Multiple complex diseases / / 17554300 rs6550435 chr3 36864489 T G 9.00E-06 Bipolar disorder / / 21926972 rs6550435 chr3 36864489 T G 0.0000454 Bipolar disorder / / 23070075 rs6550435 chr3 36864489 T G 6.00E-08 Schizophrenia / / 23974872 rs6550435 chr3 36864489 T G 2.00E-08 Bipolar disorder / / 24618891 rs4789 chr3 36869439 T C 4.32E-07 Bipolar disorder TRANK1 UTR-3 22182935 rs4789 chr3 36869439 T C 4.53E-05 Major depressive disorder TRANK1 UTR-3 22472876 rs4789 chr3 36869439 T C 3.33E-07 Bipolar disorder TRANK1 UTR-3 24618891 rs11129735 chr3 36870230 A G 2.56E-07 Bipolar disorder TRANK1 intron 24618891 rs7652637 chr3 36871507 T C 3.41E-08 Bipolar disorder TRANK1 intron 24618891 rs12637912 chr3 36871894 C A 4.81E-08 Bipolar disorder TRANK1 intron 24618891 rs3732386 chr3 36871993 C T 3.12E-08 Bipolar disorder TRANK1 intron 24618891 rs9811916 chr3 36878086 A G 2.88E-08 Bipolar disorder TRANK1 intron 24618891 rs4678909 chr3 36878563 A G 3.12E-08 Bipolar disorder TRANK1 intron 24618891 rs4234258 chr3 36878970 A G 2.45E-08 Bipolar disorder TRANK1 intron 24618891 rs9821223 chr3 36883369 T C 2.43E-08 Bipolar disorder TRANK1 intron 24618891 rs9882911 chr3 36885392 T C 4.37E-04 Multiple complex diseases TRANK1 intron 17554300 rs9882911 chr3 36885392 T C 2.09E-08 Bipolar disorder TRANK1 intron 24618891 rs4678910 chr3 36887973 C G 2.35E-08 Bipolar disorder TRANK1 intron 24618891 rs9985296 chr3 36889621 T C 1.08E-05 Bipolar disorder TRANK1 intron 24618891 rs4441609 chr3 36892717 T C 2.40E-07 Bipolar disorder TRANK1 intron 22182935 rs4441609 chr3 36892717 T C 1.30E-05 Bipolar disorder TRANK1 intron 24618891 rs17807744 chr3 36894048 C T 4.07E-08 Bipolar disorder TRANK1 intron 24618891 rs11706780 chr3 36896235 C T 5.04E-08 Bipolar disorder TRANK1 intron 24618891 rs4327336 chr3 36896270 C T 1.19E-07 Bipolar disorder TRANK1 intron 22182935 rs17201603 chr3 36898973 G A 8.75E-04 Aortic root size TRANK1 missense 21223598 rs4642070 chr3 36900944 C T 2.39E-05 Bipolar disorder TRANK1 intron 24618891 rs111687462 chr3 36903246 G C 0.0000449 Nonsyndromic striae distensae (stretch marks) TRANK1 intron 23633020 rs6808230 chr3 36911597 T C 2.31E-05 Multiple complex diseases TRANK1 intron 17554300 rs7649846 chr3 36914958 C T 2.32E-05 Multiple complex diseases TRANK1 intron 17554300 rs4296548 chr3 36915814 T G 9.04E-06 Bipolar disorder TRANK1 intron 24618891 rs9810132 chr3 36920050 G A 3.51E-05 Multiple complex diseases TRANK1 intron 17554300 rs11129740 chr3 36925194 C A 2.34E-05 Multiple complex diseases TRANK1 intron 17554300 rs6765624 chr3 36927546 G A 2.40E-05 Multiple complex diseases TRANK1 intron 17554300 rs4328757 chr3 36938180 C T 2.79E-04 Multiple complex diseases TRANK1 intron 17554300 rs4328757 chr3 36938180 C T 7.84E-06 Bipolar disorder TRANK1 intron 24618891 rs6550440 chr3 36939286 G A 2.07E-05 Multiple complex diseases TRANK1 intron 17554300 rs9864910 chr3 36940741 G T 5.42E-05 Multiple complex diseases TRANK1 cds-synon 17554300 rs4425211 chr3 36951898 A G 4.62E-05 Bipolar disorder TRANK1 intron 24618891 rs6769189 chr3 36958773 G A 3.39E-04 Multiple complex diseases TRANK1 intron 17554300 rs6769400 chr3 36958995 G A 9.47E-04 Multiple complex diseases TRANK1 intron 17554300 rs6769400 chr3 36958995 G A 1.99E-05 Longevity TRANK1 intron 21612516 rs13314421 chr3 36962388 A G 1.75E-05 Bipolar disorder TRANK1 intron 24618891 rs4678915 chr3 36964583 G A 2.38E-05 Bipolar disorder TRANK1 intron 24618891 rs4678917 chr3 36965158 T C 1.51E-04 Alzheimer's disease TRANK1 intron 22005930 rs1800734 chr3 37034946 G A 1 Drug response to Dacarbazine MLH1 UTR-5 17959715 rs1800734 chr3 37034946 G A 1 Drug response to Procarbazine MLH1 UTR-5 17959715 rs1053006 chr3 37224099 G A 3.06E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1053006 chr3 37224099 G A 2.90E-05 Alzheimer's disease / / 22005930 rs7631605 chr3 37234589 C T 1.00E-06 P-tau181p levels / / 20932310 rs6809976 chr3 37270341 A C 2.69E-04 Birth weight / / 17255346 rs169188 chr3 37507449 G A 3.16E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197721 chr3 37510036 C A 1.45E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs149816 chr3 37510766 G C 1.45E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs169111 chr3 37515533 C T 8.98E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197770 chr3 37515827 A G 1.10E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197770 chr3 37515827 A G 2.00E-08 Phospholipid levels (plasma) ITGA9 intron 22359512 rs2212020 chr3 37517462 C T 8.27E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs2212020 chr3 37517462 C T 3.29E-05 White matter integrity ITGA9 intron 22425255 rs189897 chr3 37518545 T A 7.00E-08 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs189897 chr3 37518545 T A 7.00E-08 Nasopharyngeal carcinoma ITGA9 intron 20512145 rs197757 chr3 37522828 G A 1.04E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs7611844 chr3 37542325 C T 1.84E-04 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs9809662 chr3 37545107 G A 1.76E-04 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs928799 chr3 37550382 G A 8.84E-05 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs267567 chr3 37574024 G A 3.03E-06 Crohn's disease ITGA9 intron 18587394 rs267567 chr3 37574024 G A 4.00E-11 PR interval ITGA9 intron 23139255 rs267564 chr3 37574437 A C 8.51E-04 Aortic root size ITGA9 intron 21223598 rs267554 chr3 37576985 T C 4.98E-04 Aortic root size ITGA9 intron 21223598 rs2559894 chr3 37582867 C T 3.63E-04 Coronary heart disease ITGA9 intron 21971053 rs3016003 chr3 37587444 C T 5.38E-04 Fibrinogen ITGA9 intron 17255346 rs17828003 chr3 37593585 A G 9.25E-05 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs17828003 chr3 37593585 A G 3.03E-04 Type 2 diabetes ITGA9 intron 17463246 rs919113 chr3 37600470 A G 4.95E-04 Nicotine smoking ITGA9 intron 19268276 rs9825420 chr3 37604012 T G 3.00E-08 Amyotrophic lateral sclerosis (sporadic) ITGA9 intron 24529757 rs7649363 chr3 37604726 G T 0.0000499 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs17828523 chr3 37606770 T C 0.000191 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs7642079 chr3 37607725 G A 0.000214 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs2844363 chr3 37611860 C T 5.90E-06 Lung cancer ITGA9 intron 19654303 rs6550481 chr3 37614710 T G 2.68E-04 Nicotine smoking ITGA9 intron 19268276 rs6419832 chr3 37618097 T C 1.34E-04 Smoking cessation ITGA9 intron 18519826 rs6419832 chr3 37618097 T C 7.23E-06 Smoking cessation ITGA9 intron 18519826 rs2212035 chr3 37624245 T C 2.15E-05 Smoking cessation ITGA9 intron 18519826 rs2212035 chr3 37624245 T C 5.33E-05 Smoking cessation ITGA9 intron 18519826 rs9857453 chr3 37625750 T G 2.44E-04 Smoking cessation ITGA9 intron 18519826 rs9857453 chr3 37625750 T G 3.69E-05 Smoking cessation ITGA9 intron 18519826 rs1155741 chr3 37627112 T C 1.60E-04 Smoking cessation ITGA9 intron 18519826 rs6550486 chr3 37628954 G A 1.63E-05 Smoking cessation ITGA9 intron 18519826 rs6550486 chr3 37628954 G A 4.05E-05 Smoking cessation ITGA9 intron 18519826 rs7641625 chr3 37667634 C G 1.35E-04 Acute lung injury ITGA9 intron 22295056 rs2070482 chr3 37693145 G A 6.08E-05 Heart rate ITGA9 intron 23583979 rs17036765 chr3 37705356 A G 2.00E-05 Urinary metabolites ITGA9 intron 21572414 rs6770747 chr3 37726832 A G 8.30E-06 Urinary metabolites ITGA9 intron 21572414 rs743393 chr3 37743968 T C 7.40E-04 Psychosis ITGA9 intron 23871474 rs11717973 chr3 37762014 C T 4.76E-04 Nicotine smoking ITGA9 intron 19268276 rs11129773 chr3 37855114 C T 8.00E-06 Illicit drug use ITGA9 intron 23942779 rs6780036 chr3 37858410 G A 7.04E-04 Alzheimer's disease ITGA9 intron 24755620 rs6782856 chr3 37858771 G A 5.85E-04 Alzheimer's disease ITGA9 intron 24755620 rs6794868 chr3 37887360 G A 4.35E-05 Bone mineral density / / 19181680 rs9877943 chr3 37914922 G A 5.68E-05 Bone mineral density CTDSPL intron 19181680 rs9877943 chr3 37914922 G A 3.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CTDSPL intron 24023788 rs9822761 chr3 37969439 T C 7.53E-05 Bone mineral density CTDSPL intron 19181680 rs9311168 chr3 37977417 G T 4.90E-05 Volumetric brain MRI CTDSPL intron 17903297 rs9311171 chr3 37996477 T G 4.03E-05 Blood Pressure and Arterial Stiffness CTDSPL intron 17903302 rs9311171 chr3 37996477 T G 2.00E-06 Prostate cancer CTDSPL intron 17903305 rs9311171 chr3 37996477 T G 2.00E-06 Nasopharyngeal carcinoma CTDSPL intron 20512145 rs10095 chr3 38023553 A G 3.49E-04 Tourette syndrome CTDSPL UTR-3 22889924 rs11711286 chr3 38026652 C T 5.56E-04 Tourette syndrome / / 22889924 rs6809649 chr3 38038982 T C 2.44E-04 Bulimia nervosa VILL cds-synon 23568457 rs928807 chr3 38042182 T G 5.53E-04 Tourette syndrome VILL intron 22889924 rs1123569 chr3 38140721 G T 5.45E-04 Multiple complex diseases DLEC1 intron 17554300 rs9847922 chr3 38142082 G C 4.76E-04 Multiple complex diseases DLEC1 intron 17554300 rs9847922 chr3 38142082 G C 1.80E-05 Urinary metabolites DLEC1 intron 21572414 rs6599263 chr3 38144875 G T 3.50E-06 Urinary metabolites DLEC1 intron 21572414 rs6767684 chr3 38185174 G A 7.07E-04 Multiple complex diseases / / 17554300 rs9881120 chr3 38186417 A T 8.08E-04 Multiple complex diseases / / 17554300 rs72542450 chr3 38307398 G A 0.00055 Prostate cancer (non-advanced prostate cancer) SLC22A13 missense 23555315 rs1979845 chr3 38311953 C T 8.50E-04 Myopia (pathological) SLC22A13 intron 21095009 rs116741759 chr3 38355325 G A 0.00031 Breast cancer (ER positive) SLC22A14 missense 23555315 rs696256 chr3 38375557 G A 2.97E-04 Multiple complex diseases / / 17554300 rs820296 chr3 38396543 T C 2.05E-04 Multiple complex diseases XYLB intron 17554300 rs818838 chr3 38405785 C T 1.33E-04 Multiple complex diseases XYLB intron 17554300 rs1093685 chr3 38406277 T C 1.99E-04 Multiple complex diseases XYLB intron 17554300 rs2234608 chr3 38406793 T G 3.20E-04 Multiple complex diseases XYLB intron 17554300 rs704946 chr3 38408248 G A 9.47E-05 Multiple complex diseases XYLB intron 17554300 rs2234617 chr3 38408459 A G 2.58E-04 Multiple complex diseases XYLB intron 17554300 rs818836 chr3 38410509 T C 2.28E-04 Multiple complex diseases XYLB intron 17554300 rs818833 chr3 38410632 A G 1.27E-04 Multiple complex diseases XYLB intron 17554300 rs704952 chr3 38413880 T C 7.74E-04 Multiple complex diseases XYLB intron 17554300 rs2070988 chr3 38437835 A G 2.00E-05 Electrocardiographic conduction measures XYLB intron 19389651 rs2169552 chr3 38437968 G A 4.70E-04 Multiple complex diseases XYLB intron 17554300 rs2067082 chr3 38438182 G C 6.70E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs2070488 chr3 38442490 G A 4.00E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs2234628 chr3 38442504 G A 4.00E-10 P wave duration XYLB intron 24850809 rs1002676 chr3 38444932 G T 5.10E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs12636358 chr3 38455901 G A 4.66E-10 P wave duration XYLB UTR-3 24850809 rs2268757 chr3 38505853 C T 4.60E-06 Electrocardiographic conduction measures ACVR2B intron 19389651 rs2284816 chr3 38510346 T C 3.36E-10 P wave duration ACVR2B intron 24850809 rs12637034 chr3 38512619 T C 2.27E-10 P wave duration ACVR2B intron 24850809 rs7373828 chr3 38524311 A G 6.70E-06 Electrocardiographic conduction measures ACVR2B intron 19389651 rs12636077 chr3 38525588 G A 2.51E-10 P wave duration ACVR2B UTR-3 24850809 rs1058945 chr3 38532511 G A 4.70E-06 Electrocardiographic conduction measures ACVR2B UTR-3 19389651 rs11706270 chr3 38548658 A G 7.73E-05 Body Fat Distribution EXOG intron pha003016 rs11706270 chr3 38548658 A G 3.34E-05 Body Fat Distribution EXOG intron pha003017 rs2051215 chr3 38560345 A G 5.50E-06 Electrocardiographic conduction measures EXOG intron 19389651 rs17037809 chr3 38561079 G A 2.32E-12 P wave duration EXOG intron 24850809 rs2284820 chr3 38562579 C T 4.40E-06 Electrocardiographic conduction measures EXOG intron 19389651 rs1065800 chr3 38566480 G A 4.60E-06 Electrocardiographic conduction measures EXOG UTR-3 19389651 rs12631864 chr3 38569764 G A 2.62E-12 P wave duration / / 24850809 rs11711260 chr3 38571289 C T 1.11E-04 Smoking quantity / / 24665060 rs11129795 chr3 38589163 G A 5.00E-14 QT interval SCN5A nearGene-3 19305409 rs11129795 chr3 38589163 G A 5.00E-10 Electrocardiographic traits SCN5A nearGene-3 20062063 rs7429945 chr3 38591689 T C 4.27E-14 P wave duration SCN5A UTR-3 24850809 rs1805126 chr3 38592406 A G 2.80E-06 Urinary metabolites SCN5A cds-synon 21572414 rs1805126 chr3 38592406 A G 3.00E-20 Electrocardiographic conduction measures SCN5A cds-synon 23463857 rs12053903 chr3 38593393 T C 1.00E-14 QT interval SCN5A intron 19305408 rs12053903 chr3 38593393 T C 6.88E-08 QT interval SCN5A intron 19305409 rs12053903 chr3 38593393 T C 1.00E-07 Electrocardiographic traits SCN5A intron 20062063 rs12053903 chr3 38593393 T C 2.38E-12 P wave duration SCN5A intron 24850809 rs7638909 chr3 38594973 T G 2.00E-06 Electrocardiographic conduction measures SCN5A intron 19389651 rs7638909 chr3 38594973 T G 2.91E-14 P wave duration SCN5A intron 24850809 rs6793245 chr3 38599037 G A 9.90E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs6793245 chr3 38599037 G A 1.40E-11 P wave duration SCN5A intron 24850809 rs6799868 chr3 38601556 T C 4.69E-12 P wave duration SCN5A intron 24850809 rs3935472 chr3 38602855 G A 4.80E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs3935472 chr3 38602855 G A 2.37E-14 P wave duration SCN5A intron 24850809 rs7374138 chr3 38605732 G C 1.38E-18 P wave duration SCN5A intron 24850809 rs9812912 chr3 38607229 C T 3.11E-18 P wave duration SCN5A intron 24850809 rs9861242 chr3 38609334 A G 9.60E-12 P wave duration SCN5A intron 24850809 rs4130467 chr3 38611704 C T 1.48E-12 P wave duration SCN5A intron 24850809 rs3922844 chr3 38624253 T C 3.00E-23 PR interval SCN5A intron 21347284 rs3922844 chr3 38624253 T C 5.00E-43 PR interval SCN5A intron 23139255 rs3922844 chr3 38624253 T C 2.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SCN5A intron 24023788 rs3922844 chr3 38624253 T C 1.78E-08 P wave duration SCN5A intron 24850809 rs3922843 chr3 38624343 A G 1.88E-08 P wave duration SCN5A intron 24850809 rs6599214 chr3 38629814 G A 3.02E-08 P wave duration SCN5A intron 24850809 rs7374040 chr3 38632047 C G 1.70E-16 P wave duration SCN5A intron 24850809 rs10154914 chr3 38632630 T A 8.88E-13 P wave duration SCN5A intron 24850809 rs9311191 chr3 38633110 T C 1.19E-12 P wave duration SCN5A intron 24850809 rs11708996 chr3 38633923 G C 6.00E-26 PR interval SCN5A intron 20062060 rs11708996 chr3 38633923 G C 1.00E-16 QRS duration SCN5A intron 21076409 rs11708996 chr3 38633923 G C 7.00E-06 Ventricular conduction SCN5A intron 21076409 rs11708996 chr3 38633923 G C 1.00E-14 Brugada syndrome SCN5A intron 23872634 rs11708996 chr3 38633923 G C 3.63E-11 P wave duration SCN5A intron 24850809 rs7374540 chr3 38634142 C A 3.40E-14 P wave duration SCN5A intron 24850809 rs7373862 chr3 38634343 G A 4.04E-13 P wave duration SCN5A intron 24850809 rs9311194 chr3 38635072 G A 6.43E-13 P wave duration SCN5A intron 24850809 rs3935184 chr3 38638202 C G 2.28E-13 P wave duration SCN5A intron 24850809 rs10212202 chr3 38638390 G C 9.05E-13 P wave duration SCN5A intron 24850809 rs9833775 chr3 38641084 C T 4.18E-11 P wave duration SCN5A intron 24850809 rs11714074 chr3 38643785 C T 1.15E-10 P wave duration SCN5A intron 24850809 rs1805124 chr3 38645420 T C 9.89E-13 P wave duration SCN5A missense 24850809 rs7428779 chr3 38646423 C T 5.17E-11 P wave duration SCN5A intron 24850809 rs11711602 chr3 38647047 C T 5.43E-11 P wave duration SCN5A intron 24850809 rs6599222 chr3 38648062 C T 2.26E-08 PR interval SCN5A intron 21347284 rs6599222 chr3 38648062 C T 3.19E-04 Brugada syndrome SCN5A intron 23872634 rs11710077 chr3 38657899 A T 1.00E-06 Ventricular conduction SCN5A intron 21076409 rs11710077 chr3 38657899 A T 6.00E-22 QRS duration SCN5A intron 21076409 rs186437034 chr3 38658508 T C 0.0000245 Menopause (age at onset) SCN5A intron 23424626 rs7637849 chr3 38659275 G A 3.95E-04 Response to taxane treatment (placlitaxel) SCN5A intron 23006423 rs9832895 chr3 38661533 T C 2.29E-06 QT interval SCN5A intron 19305409 rs9832895 chr3 38661533 T C 1.73E-06 Personality dimensions SCN5A intron 23658558 rs6781731 chr3 38663707 C T 2.80E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs13073578 chr3 38679364 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) SCN5A intron 20708005 rs6763048 chr3 38681394 A G 4.00E-12 PR interval SCN5A intron 23139255 rs6768664 chr3 38684466 C A 1.90E-08 PR segment SCN5A intron 24850809 rs7373934 chr3 38695708 A G 0.000306661 Hypertension (early onset hypertension) / / 22479346 rs13061927 chr3 38707352 G T 4.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9851710 chr3 38719901 C A 6.52E-20 P wave duration / / 24850809 rs9851710 chr3 38719901 C A 7.81E-10 PR segment / / 24850809 rs9851724 chr3 38719935 C T 2.00E-20 QRS duration / / 21076409 rs9851724 chr3 38719935 C T 6.00E-16 Ventricular conduction / / 21076409 rs9851724 chr3 38719935 C T 1.56E-04 Brugada syndrome / / 23872634 rs7373154 chr3 38721308 T C 4.49E-08 P wave duration / / 24850809 rs11717818 chr3 38722696 C T 8.28E-04 Multiple complex diseases / / 17554300 rs7633988 chr3 38723217 T A 2.79E-12 PR segment / / 24850809 rs7633988 chr3 38723217 T A 7.93E-23 P wave duration / / 24850809 rs7374165 chr3 38726685 A C 1.10E-08 PR segment / / 24850809 rs7374165 chr3 38726685 A C 1.41E-09 P wave duration / / 24850809 rs12639182 chr3 38736230 C T 6.65E-05 Major depressive disorder (broad) / / 20038947 rs6599239 chr3 38737984 G A 4.41E-08 PR segment / / 24850809 rs6599240 chr3 38738717 G A 1.20E-13 Brugada syndrome SCN10A nearGene-3 23872634 rs6599240 chr3 38738717 G A 4.53E-27 PR segment SCN10A nearGene-3 24850809 rs6599240 chr3 38738717 G A 7.17E-19 P wave duration SCN10A nearGene-3 24850809 rs6599242 chr3 38739845 A G 2.96E-08 PR segment SCN10A cds-synon 24850809 rs11129799 chr3 38742229 T C 1.78E-11 PR segment SCN10A intron 24850809 rs11129800 chr3 38744370 C T 2.95E-15 PR segment SCN10A intron 24850809 rs6599243 chr3 38747277 C T 1.14E-09 PR segment SCN10A intron 24850809 rs6599247 chr3 38747872 T C 1.02E-09 PR segment SCN10A intron 24850809 rs6599248 chr3 38749026 T A 1.14E-11 PR segment SCN10A intron 24850809 rs11129801 chr3 38750375 A G 8.17E-10 Multiple complex diseases SCN10A intron 17554300 rs11129801 chr3 38750375 A G 2.77E-08 Brugada syndrome SCN10A intron 23872634 rs11129801 chr3 38750375 A G 6.03E-12 PR segment SCN10A intron 24850809 rs11129802 chr3 38750436 T C 7.13E-05 Cognitive performance SCN10A intron 19734545 rs11129802 chr3 38750436 T C 8.92E-10 PR segment SCN10A intron 24850809 rs11710006 chr3 38752790 A T 1.89E-08 PR segment SCN10A intron 24850809 rs11710006 chr3 38752790 A T 3.51E-10 P wave duration SCN10A intron 24850809 rs6783110 chr3 38752935 A G 1.28E-24 P wave duration SCN10A intron 24850809 rs6783110 chr3 38752935 A G 8.75E-38 PR segment SCN10A intron 24850809 rs11129803 chr3 38752968 T C 4.56E-11 PR segment SCN10A intron 24850809 rs11928905 chr3 38756498 T C 1.87E-11 PR segment SCN10A intron 24850809 rs11924846 chr3 38756566 C T 3.72E-25 P wave duration SCN10A intron 24850809 rs11924846 chr3 38756566 C T 9.69E-39 PR segment SCN10A intron 24850809 rs6794914 chr3 38757235 C T 1.39E-12 PR segment SCN10A intron 24850809 rs6794914 chr3 38757235 C T 4.43E-08 P wave duration SCN10A intron 24850809 rs9990137 chr3 38759465 A G 1.03E-14 PR segment SCN10A intron 24850809 rs9990137 chr3 38759465 A G 3.61E-13 P wave duration SCN10A intron 24850809 rs6805187 chr3 38760506 C A 7.67E-11 P wave duration SCN10A intron 24850809 rs6805187 chr3 38760506 C A 9.24E-15 PR segment SCN10A intron 24850809 rs7617547 chr3 38763500 G C 4.05E-18 PR segment SCN10A intron 24850809 rs6771157 chr3 38763863 G C 2.76E-09 P wave duration SCN10A cds-synon 24850809 rs6771157 chr3 38763863 G C 6.20E-11 PR segment SCN10A cds-synon 24850809 rs4076737 chr3 38764782 G T 1.50E-09 PR interval SCN10A intron 21347284 rs4076737 chr3 38764782 G T 1.22E-39 PR segment SCN10A intron 24850809 rs4076737 chr3 38764782 G T 1.32E-25 P wave duration SCN10A intron 24850809 rs12632942 chr3 38764998 A G 2.27E-11 P wave duration SCN10A missense 24850809 rs12632942 chr3 38764998 A G 4.78E-10 PR segment SCN10A missense 24850809 rs7430477 chr3 38765490 C T 4.38E-30 PR segment SCN10A intron 24850809 rs7430477 chr3 38765490 C T 9.56E-24 P wave duration SCN10A intron 24850809 rs9825762 chr3 38766338 T C 2.66E-11 PR segment SCN10A intron 24850809 rs6795970 chr3 38766675 A G 3.00E-15 Electrocardiographic traits SCN10A missense 20062061 rs6795970 chr3 38766675 A G 1.00E-58 Electrocardiographic traits SCN10A missense 20062063 rs6795970 chr3 38766675 A G 4.00E-09 Electrocardiographic traits SCN10A missense 20062063 rs6795970 chr3 38766675 A G 1.45E-09 PR interval SCN10A missense 21347284 rs6795970 chr3 38766675 A G 2.20E-05 Atrial fibrillation SCN10A missense 22544366 rs6795970 chr3 38766675 A G 9.80E-04 Orofacial clefts SCN10A missense 22863734 rs6795970 chr3 38766675 A G 5.00E-27 Electrocardiographic conduction measures SCN10A missense 23463857 rs6795970 chr3 38766675 A G 1.11E-27 Brugada syndrome SCN10A missense 23872634 rs6795970 chr3 38766675 A G 4.79E-40 PR segment SCN10A missense 24850809 rs6795970 chr3 38766675 A G 8.79E-26 P wave duration SCN10A missense 24850809 rs6791171 chr3 38766701 C T 2.66E-11 PR segment SCN10A cds-synon 24850809 rs6801957 chr3 38767315 T C 1.00E-28 QRS duration SCN10A intron 21076409 rs6801957 chr3 38767315 T C 3.00E-14 Ventricular conduction SCN10A intron 21076409 rs6801957 chr3 38767315 T C 5.37E-12 PR interval SCN10A intron 21347284 rs6801957 chr3 38767315 T C 9.00E-09 PR interval SCN10A intron 23139255 rs6801957 chr3 38767315 T C 7.00E-41 PR segment SCN10A intron 24850809 rs6801957 chr3 38767315 T C 8.00E-27 P wave duration SCN10A intron 24850809 rs7433306 chr3 38770639 C G 3.00E-09 PR interval SCN10A intron 21347284 rs7433306 chr3 38770639 C G 2.47E-04 Heart rate SCN10A intron 23583979 rs7433306 chr3 38770639 C G 1.21E-39 PR segment SCN10A intron 24850809 rs7433306 chr3 38770639 C G 5.17E-26 P wave duration SCN10A intron 24850809 rs6780103 chr3 38771464 G A 1.20E-06 Urinary metabolites SCN10A intron 21572414 rs6780103 chr3 38771464 G A 1.29E-15 PR segment SCN10A intron 24850809 rs6780103 chr3 38771464 G A 2.26E-08 P wave duration SCN10A intron 24850809 rs6790396 chr3 38771925 C G 2.18E-08 PR interval SCN10A intron 21347284 rs6790396 chr3 38771925 C G 4.31E-26 P wave duration SCN10A intron 24850809 rs6790396 chr3 38771925 C G 4.84E-39 PR segment SCN10A intron 24850809 rs9874633 chr3 38771994 A G 1.66E-13 Brugada syndrome SCN10A intron 23872634 rs13096893 chr3 38772864 G A 5.96E-12 PR segment SCN10A intron 24850809 rs6800541 chr3 38774832 C T 2.00E-74 PR interval SCN10A intron 20062060 rs6800541 chr3 38774832 C T 9.70E-17 Electrocardiographic traits SCN10A intron 20062061 rs6800541 chr3 38774832 C T 5.00E-07 Atrioventricular conduction SCN10A intron 21041692 rs6800541 chr3 38774832 C T 3.37E-09 PR interval SCN10A intron 21347284 rs6800541 chr3 38774832 C T 2.80E-06 Atrial fibrillation SCN10A intron 22544366 rs6800541 chr3 38774832 C T 2.74E-39 PR segment SCN10A intron 24850809 rs6800541 chr3 38774832 C T 8.35E-26 P wave duration SCN10A intron 24850809 rs10428132 chr3 38777554 T G 1.00E-68 Brugada syndrome SCN10A intron 23872634 rs7428167 chr3 38778191 T C 1.22E-22 Brugada syndrome SCN10A intron 23872634 rs6776034 chr3 38779189 T A 3.02E-25 PR segment SCN10A intron 24850809 rs6776034 chr3 38779189 T A 4.22E-20 P wave duration SCN10A intron 24850809 rs10428168 chr3 38780059 T C 2.36E-15 Brugada syndrome SCN10A intron 23872634 rs7615140 chr3 38782026 T C 2.96E-13 PR segment SCN10A intron 24850809 rs7615140 chr3 38782026 T C 6.54E-09 P wave duration SCN10A intron 24850809 rs6599250 chr3 38784029 T C 3.56E-09 PR interval SCN10A intron 21347284 rs6599250 chr3 38784029 T C 1.47E-40 PR segment SCN10A intron 24850809 rs6599250 chr3 38784029 T C 1.90E-26 P wave duration SCN10A intron 24850809 rs7433723 chr3 38784957 G A 8.89E-12 PR interval SCN10A intron 21347284 rs7433723 chr3 38784957 G A 1.79E-26 P wave duration SCN10A intron 24850809 rs7433723 chr3 38784957 G A 2.60E-40 PR segment SCN10A intron 24850809 rs6599251 chr3 38785809 G T 6.45E-26 P wave duration SCN10A intron 24850809 rs6599251 chr3 38785809 G T 8.46E-37 PR segment SCN10A intron 24850809 rs12638572 chr3 38787797 A G 2.48E-10 Brugada syndrome SCN10A intron 23872634 rs9844265 chr3 38788506 C T 2.07E-12 PR segment SCN10A intron 24850809 rs9844265 chr3 38788506 C T 3.19E-08 P wave duration SCN10A intron 24850809 rs9844577 chr3 38788728 C A 1.89E-26 P wave duration SCN10A intron 24850809 rs6599252 chr3 38789691 T A 3.67E-09 P wave duration SCN10A intron 24850809 rs7430451 chr3 38795495 C G 9.90E-13 P wave duration SCN10A intron 24850809 rs6599254 chr3 38795555 A G 3.81E-09 PR interval SCN10A intron 21347284 rs6599254 chr3 38795555 A G 3.30E-25 P wave duration SCN10A intron 24850809 rs6599255 chr3 38796415 A C 3.31E-12 PR interval SCN10A intron 21347284 rs6599255 chr3 38796415 A C 1.06E-25 P wave duration SCN10A intron 24850809 rs12630795 chr3 38796985 A G 1.85E-09 P wave duration SCN10A intron 24850809 rs6798015 chr3 38798836 C T 2.10E-12 PR interval SCN10A intron 21347284 rs6798015 chr3 38798836 C T 4.21E-05 Orofacial clefts SCN10A intron 22863734 rs6798015 chr3 38798836 C T 3.53E-26 Brugada syndrome SCN10A intron 23872634 rs6798015 chr3 38798836 C T 3.83E-25 P wave duration SCN10A intron 24850809 rs6763876 chr3 38800747 T C 4.88E-08 P wave duration SCN10A intron 24850809 rs6599256 chr3 38801225 G T 5.09E-10 P wave duration SCN10A intron 24850809 rs7641844 chr3 38802251 A G 3.80E-08 Brugada syndrome SCN10A intron 23872634 rs7641844 chr3 38802251 A G 6.76E-10 P wave duration SCN10A intron 24850809 rs7432804 chr3 38803509 A G 8.10E-10 P wave duration SCN10A intron 24850809 rs7430438 chr3 38803618 G A 2.30E-05 Urinary metabolites SCN10A intron 21572414 rs7430438 chr3 38803618 G A 2.69E-17 P wave duration SCN10A intron 24850809 rs7430439 chr3 38803639 G A 1.10E-08 Brugada syndrome SCN10A intron 23872634 rs7430439 chr3 38803639 G A 7.67E-17 P wave duration SCN10A intron 24850809 rs7651106 chr3 38804341 T C 9.92E-16 P wave duration SCN10A intron 24850809 rs6599257 chr3 38804588 C T 8.20E-14 Electrocardiographic traits SCN10A intron 20062061 rs6599257 chr3 38804588 C T 1.01E-14 Brugada syndrome SCN10A intron 23872634 rs6599257 chr3 38804588 C T 8.93E-15 P wave duration SCN10A intron 24850809 rs7610489 chr3 38806478 A G 8.37E-15 P wave duration SCN10A intron 24850809 rs7650384 chr3 38806511 C T 8.49E-15 P wave duration SCN10A intron 24850809 rs10212338 chr3 38812650 G A 2.20E-14 P wave duration SCN10A intron 24850809 rs11717455 chr3 38843647 T C 7.00E-06 Systemic lupus erythematosus / / 23273568 rs11717588 chr3 38853160 C T 7.74E-04 Type 2 diabetes / / 17463246 rs4453791 chr3 38882519 T C 9.00E-09 Social communication problems / / 24564958 rs3923518 chr3 38886413 C A 8.00E-06 Migraine / / 23793025 rs6776510 chr3 38887253 C T 6.41E-04 Smoking initiation / / 24665060 rs4481097 chr3 38909570 T C 4.58E-04 Type 2 diabetes SCN11A intron 17463246 rs4676588 chr3 38940741 C T 4.31E-04 Multiple complex diseases SCN11A intron 17554300 rs4676588 chr3 38940741 C T 9.55E-06 Left ventricular hypertrophy SCN11A intron pha003052 rs11716902 chr3 38958010 G T 6.09E-06 Left ventricular hypertrophy SCN11A intron pha003052 rs7636049 chr3 38972592 C T 8.01E-05 Cognitive performance SCN11A intron 19734545 rs4491835 chr3 39005889 T C 4.78E-04 Ankylosing spondylitis / / 22138694 rs883565 chr3 39055317 C T 3.00E-07 Handedness / / 24065183 rs144954527 chr3 39118649 C T 0.00087 Prostate cancer WDR48 missense 23555315 rs2370860 chr3 39127685 T C 8.96E-30 Narcolepsy WDR48 intron 19629137 rs784490 chr3 39173530 A G 2.80E-05 Kidney function and endocine traits TTC21A intron 17903292 rs784498 chr3 39180099 T C 1.04E-11 Lymphocyte counts TTC21A cds-synon 22286170 rs17735402 chr3 39205176 C T 2.26E-05 Diabetes Mellitus / / pha003059 rs4676609 chr3 39214256 C T 8.90E-05 Cognitive test performance / / 20125193 rs11129816 chr3 39229044 C T 5.25E-04 Amyotrophic lateral sclerosis (sporadic) XIRP1 cds-synon 24529757 rs17729892 chr3 39234170 G A 6.43E-05 Diabetes Mellitus / / pha003059 rs7622284 chr3 39240559 T C 2.67E-05 Multiple complex diseases / / 17554300 rs2137581 chr3 39246142 T G 6.09E-04 Obesity (extreme) LOC729454 intron 21935397 rs12637451 chr3 39247658 G C 1.90E-04 Alzheimer's disease LOC729454 intron 22005930 rs12632771 chr3 39248852 A G 2.43E-05 Celiac disease LOC729454 intron 23936387 rs9809830 chr3 39251141 C G 1.45E-04 Alzheimer's disease LOC729454 intron 22005930 rs12636775 chr3 39254384 A G 2.17E-04 Alzheimer's disease LOC729454 intron 22005930 rs11720021 chr3 39254755 G A 7.82E-04 Obesity (extreme) LOC729454 intron 21935397 rs11707681 chr3 39257892 C T 8.38E-04 Obesity (extreme) / / 21935397 rs4314106 chr3 39265616 C T 3.56E-04 Alzheimer's disease / / 22005930 rs1913242 chr3 39265933 G T 2.84E-04 Alzheimer's disease / / 22005930 rs1344220 chr3 39266121 C T 1.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9833185 chr3 39266199 C T 5.64E-04 Alzheimer's disease / / 22005930 rs4676487 chr3 39303147 T C 4.16E-05 Tunica Media / / pha003038 rs17038645 chr3 39304570 G A 5.16E-04 Multiple complex diseases CX3CR1 nearGene-3 17554300 rs13088991 chr3 39310269 T C 2.12E-05 Tunica Media CX3CR1 intron pha003038 rs2853711 chr3 39318797 G T 0.00048 Coronary artery calcification CX3CR1 intron 23727086 rs9825782 chr3 39334720 C T 2.50E-05 Orofacial clefts / / 22419666 rs12107527 chr3 39369682 C T 2.37E-05 Osteoarthritis (knee and hip) / / 21177295 rs12107527 chr3 39369682 C T 5.83E-06 Osteoarthritis (knee and hip) / / 21177295 rs2201965 chr3 39388280 G A 4.48E-04 Iron levels / / pha002876 rs4464383 chr3 39444870 C G 7.86E-05 Multiple complex diseases / / 17554300 rs6806372 chr3 39445780 C T 6.05E-05 Multiple complex diseases / / 17554300 rs12638378 chr3 39455315 G A 1.01E-04 Multiple complex diseases / / 17554300 rs12638341 chr3 39455354 C T 1.04E-04 Multiple complex diseases / / 17554300 rs4676495 chr3 39457861 G T 8.41E-04 Alzheimer's disease / / 24755620 rs2039845 chr3 39463986 A G 3.69E-05 Multiple complex diseases / / 17554300 rs953275 chr3 39465777 A T 2.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510701 chr3 39466445 C T 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1009966 chr3 39473591 A G 2.13E-04 Multiple complex diseases / / 17554300 rs17038828 chr3 39475342 C T 8.00E-06 IgG glycosylation / / 23382691 rs9820623 chr3 39493858 G T 8.98E-04 Multiple complex diseases / / 17554300 rs13092508 chr3 39507945 A G 7.18E-04 Alzheimer's disease / / 17998437 rs538867 chr3 39513278 C T 1.00E-07 Alzheimer's disease (cognitive decline) MOBP intron 23535033 rs1768208 chr3 39523003 T C 5.00E-17 Progressive supranuclear palsy MOBP intron 21685912 rs1707957 chr3 39523491 C A 1.16E-09 Non-obstructive azoospermia MOBP intron 22197933 rs1609647 chr3 39533071 C T 9.79E-04 Multiple complex diseases MOBP intron 17554300 rs526446 chr3 39545772 G A 5.64E-06 Cognitive performance MOBP intron 19734545 rs666534 chr3 39545934 G T 3.85E-04 Multiple complex diseases MOBP intron 17554300 rs816488 chr3 39553788 C T 4.00E-06 Cognitive performance MOBP intron 19734545 rs864643 chr3 39555580 A G 1.00E-08 Attention deficit hyperactivity disorder MOBP UTR-3 18839057 rs1768172 chr3 39640587 G T 8.73E-04 Aortic root size / / 21223598 rs4296532 chr3 39707198 A G 2.05E-04 Multiple complex diseases / / 17554300 rs9832461 chr3 39749593 A G 3.72E-06 Temporal lobe volumes / / 20197096 rs9832461 chr3 39749593 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1527566 chr3 39772451 A G 2.32E-06 Temporal lobe volumes / / 20197096 rs1527566 chr3 39772451 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs376566053 chr3 39796726 GCTTCA G 2.90E-06 Temporal lobe volumes / / 20197096 rs376566053 chr3 39796726 GCTTCA G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9878556 chr3 39796726 G T 2.90E-06 Temporal lobe volumes / / 20197096 rs9878556 chr3 39796726 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4676517 chr3 39812292 C T 2.40E-05 Urinary metabolites / / 21572414 rs13086503 chr3 39837709 G T 5.68E-04 Acute lung injury / / 22295056 rs17079534 chr3 39847072 G A 2.00E-07 Acute lymphoblastic leukemia (childhood) / / 23007406 rs1599903 chr3 39955066 A C 5.42E-05 Nicotine smoking MYRIP intron 19268276 rs9831761 chr3 39967902 G A 3.81E-05 Coronary Artery Disease MYRIP intron 17634449 rs1598994 chr3 39975762 T G 1.03E-04 Nicotine smoking MYRIP intron 19268276 rs1304138 chr3 40004366 G A 2.40E-05 Urinary metabolites MYRIP intron 21572414 rs9985399 chr3 40008634 T C 9.00E-06 Information processing speed MYRIP intron 21130836 rs13085835 chr3 40020555 A G 3.90E-05 Kawasaki disease MYRIP intron 22446962 rs4676548 chr3 40025296 C T 3.80E-05 Kawasaki disease MYRIP intron 22446962 rs6791790 chr3 40050275 G A 4.66E-05 Hemoglobin concentration MYRIP intron 20534544 rs6791790 chr3 40050275 G A 9.82E-06 Information processing speed MYRIP intron 21130836 rs2067773 chr3 40058331 C T 3.60E-05 Kawasaki disease MYRIP intron 22446962 rs7632391 chr3 40080544 A G 4.42E-04 Hemoglobin concentration MYRIP intron 20534544 rs6599077 chr3 40096618 G A 1.00E-07 Sleep duration MYRIP intron 17903308 rs2679824 chr3 40168322 G C 1.21E-06 Schizophrenia MYRIP intron 22037555 rs9878321 chr3 40174858 A G 7.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) MYRIP intron 23648065 rs4132209 chr3 40185635 C T 4.14E-04 Multiple complex diseases MYRIP intron 17554300 rs1799428 chr3 40188011 C T 5.38E-06 Schizophrenia MYRIP intron 22037555 rs2679807 chr3 40195206 G T 7.59E-04 Multiple complex diseases MYRIP intron 17554300 rs1714414 chr3 40204178 T C 7.04E-04 Multiple complex diseases MYRIP intron 17554300 rs11714144 chr3 40219170 A G 5.76E-04 Type 2 diabetes MYRIP intron 17463246 rs2371176 chr3 40226685 C A 8.95E-05 Body Composition MYRIP intron pha003012 rs2371176 chr3 40226685 C A 8.72E-05 Body Mass Index MYRIP intron pha003021 rs1574138 chr3 40232469 G T 1.75E-05 Body Composition MYRIP intron pha003012 rs1574138 chr3 40232469 G T 2.73E-05 Body Mass Index MYRIP intron pha003021 rs2261542 chr3 40234083 A G 1.26E-05 Body Composition MYRIP intron pha003012 rs2261542 chr3 40234083 A G 1.94E-05 Body Mass Index MYRIP intron pha003021 rs2679813 chr3 40234623 G A 1.70E-05 Body Composition MYRIP intron pha003012 rs2679813 chr3 40234623 G A 2.64E-05 Body Mass Index MYRIP intron pha003021 rs2679814 chr3 40235264 T C 1.26E-05 Body Composition MYRIP intron pha003012 rs2679814 chr3 40235264 T C 1.94E-05 Body Mass Index MYRIP intron pha003021 rs2887962 chr3 40235522 C T 7.93E-05 Body Composition MYRIP intron pha003012 rs17076767 chr3 40248826 G A 6.91E-04 Multiple complex diseases MYRIP intron 17554300 rs2679798 chr3 40251282 G A 9.29E-04 Insulin resistance MYRIP intron 21901158 rs2679822 chr3 40267321 T C 6.76E-05 Epilepsy MYRIP intron 22116939 rs6599081 chr3 40273500 A G 1.28E-04 Hemoglobin concentration MYRIP intron 20534544 rs6599081 chr3 40273500 A G 1.29E-05 Epilepsy MYRIP intron 22116939 rs2371136 chr3 40275655 C T 1.28E-04 Hemoglobin concentration MYRIP intron 20534544 rs2371136 chr3 40275655 C T 1.29E-05 Epilepsy MYRIP intron 22116939 rs7639223 chr3 40285160 G A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) MYRIP intron 24529757 rs11129874 chr3 40326165 C T 8.30E-05 Age-related macular degeneration FLJ33065 intron 20861866 rs7644643 chr3 40350209 A G 7.98E-04 Type 2 diabetes FLJ33065 intron 17463246 rs6805026 chr3 40366460 T C 3.35E-05 Multiple complex diseases / / 17554300 rs4974067 chr3 40374551 C T 2.80E-05 Urinary metabolites / / 21572414 rs10865895 chr3 40378677 C T 2.70E-05 Urinary metabolites / / 21572414 rs6599094 chr3 40399593 T C 2.40E-05 Urinary metabolites / / 21572414 rs11129876 chr3 40401636 A G 1.90E-05 Urinary metabolites / / 21572414 rs9842564 chr3 40405810 C T 9.24E-05 Serum metabolites / / 19043545 rs7615540 chr3 40411129 A G 9.93E-06 Multiple complex diseases / / 17554300 rs7631893 chr3 40440869 T C 4.34E-05 Serum metabolites ENTPD3 intron 19043545 rs1037516 chr3 40441280 T G 3.99E-04 Amyotrophic lateral sclerosis (sporadic) ENTPD3 intron 24529757 rs7625736 chr3 40441345 G C 6.13E-05 Serum metabolites ENTPD3 intron 19043545 rs17078914 chr3 40445118 A G 9.42E-05 Hemoglobin concentration ENTPD3 intron 20534544 rs6599101 chr3 40447548 G A 3.09E-04 Multiple complex diseases ENTPD3 intron 17554300 rs17078941 chr3 40450888 C T 1.50E-05 Urinary metabolites ENTPD3 intron 21572414 rs17078941 chr3 40450888 C T 2.58E-24 Lymphocyte counts ENTPD3 intron 22286170 rs7648952 chr3 40457038 T C 2.90E-05 Urinary metabolites ENTPD3 intron 21572414 rs9822909 chr3 40457084 C A 1.80E-05 Urinary metabolites ENTPD3 intron 21572414 rs9332450 chr3 40458041 T C 2.90E-05 Urinary metabolites ENTPD3 intron 21572414 rs4973898 chr3 40459532 A G 3.49E-05 Serum metabolites ENTPD3 intron 19043545 rs1047855 chr3 40468896 C T 2.30E-05 Urinary metabolites ENTPD3 missense 21572414 rs11707278 chr3 40487075 T A 9.87E-05 Serum metabolites ENTPD3-AS1 intron 19043545 rs11707278 chr3 40487075 T A 2.40E-05 Urinary metabolites ENTPD3-AS1 intron 21572414 rs6801859 chr3 40493218 G T 2.84E-05 Serum metabolites / / 19043545 rs9968170 chr3 40494274 T C 1.78E-05 Serum metabolites ENTPD3-AS1 intron 19043545 rs2276871 chr3 40499273 A G 3.44E-05 Serum metabolites RPL14 intron 19043545 rs4974031 chr3 40562981 C T 7.07E-04 Smoking cessation / / 24665060 rs3924444 chr3 40576061 T C 6.55E-04 Smoking cessation ZNF621 UTR-3 24665060 rs9844316 chr3 40597520 T C 3.91E-04 Hemoglobin concentration / / 20534544 rs12491211 chr3 40613519 A G 9.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6774841 chr3 40617539 C T 4.91E-04 Smoking initiation / / 24665060 rs6599111 chr3 40631348 A G 7.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4974049 chr3 40807501 A G 7.08E-05 Type 2 diabetes / / 17463246 rs586287 chr3 40892119 C A 7.90E-04 Alzheimer's disease / / 17998437 rs17051601 chr3 40911348 G A 9.12E-04 Depression (quantitative trait) / / 20800221 rs9311253 chr3 40920689 C T 1.18E-05 Cognitive performance / / 19734545 rs7629386 chr3 40966907 C T 2.28E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs11721013 chr3 41025765 C T 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs6802072 chr3 41027680 T C 1.01E-04 Type 2 diabetes / / 17463246 rs11708803 chr3 41029087 G A 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4130762 chr3 41037669 C T 3.30E-04 Schizophrenia / / 19197363 rs4459874 chr3 41066221 G A 2.63E-04 Multiple complex diseases / / 17554300 rs1544887 chr3 41066528 G A 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1544887 chr3 41066528 G A 8.16E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs408499 chr3 41093575 A G 0.000617387 Hypertension (early onset hypertension) / / 22479346 rs6788984 chr3 41107173 A G 5.84E-05 Cognitive test performance / / 20125193 rs416183 chr3 41113201 T C 7.61E-04 Type 2 diabetes / / 17463246 rs416183 chr3 41113201 T C 7.55E-05 Lymphocyte counts / / 22286170 rs10490823 chr3 41123735 C T 9.00E-06 Bone mineral density (hip) / / 19079262 rs12634519 chr3 41127360 G A 9.90E-04 Multiple complex diseases / / 17554300 rs430727 chr3 41128564 T C 4.00E-25 Bone mineral density / / 22504420 rs430727 chr3 41128564 T C 3.15E-04 Bone mineral density / / 24249740 rs430727 chr3 41128564 T C 6.53E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs450615 chr3 41133610 G A 2.10E-05 Bone mineral density (spine) / / 19079262 rs87938 chr3 41137672 A G 8.00E-10 Bone mineral density (hip) / / 19801982 rs13314643 chr3 41139829 C T 7.18E-05 Multiple complex diseases / / 17554300 rs4437116 chr3 41161343 C T 2.39E-04 Bone mineral density / / 24249740 rs433879 chr3 41163296 C G 5.82E-04 Multiple complex diseases / / 17554300 rs7648547 chr3 41188000 A C 4.45E-05 Serum metabolites / / 19043545 rs2691678 chr3 41230323 A G 2.77E-04 Alcohol dependence / / 20201924 rs13072632 chr3 41262444 T C 8.85E-04 Multiple complex diseases CTNNB1 intron 17554300 rs10510717 chr3 41332490 T C 5.00E-05 Volumetric brain MRI ULK4 intron 17903297 rs1487569 chr3 41368428 C T 9.44E-05 Coronary Artery Disease ULK4 intron 17634449 rs9311269 chr3 41374621 T C 2.19E-04 Coronary Artery Disease ULK4 intron 17634449 rs9311269 chr3 41374621 T C 2.62E-05 Statin-induced myopathy ULK4 intron 21826682 rs11915888 chr3 41453936 A G 9.50E-04 Coronary heart disease ULK4 intron 21606135 rs9872216 chr3 41458638 T C 4.39E-04 Coronary heart disease ULK4 intron 21606135 rs17057270 chr3 41477890 T C 1.10E-05 Eosinophil counts ULK4 intron pha003088 rs10446425 chr3 41484831 C A 3.40E-06 Alcohol dependence ULK4 intron 22096494 rs10446425 chr3 41484831 C A 8.30E-06 Alcohol and nictotine co-dependence ULK4 intron 22488850 rs1495692 chr3 41485477 T C 4.32E-05 Substance dependence ULK4 intron 21818250 rs2643976 chr3 41541841 A G 8.39E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs2643977 chr3 41541987 C T 7.98E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1691983 chr3 41542342 G A 7.95E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs4258937 chr3 41544423 G A 7.88E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs9831248 chr3 41549933 C G 7.72E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1256396 chr3 41551051 A T 7.70E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs2017454 chr3 41555563 A G 7.67E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1631168 chr3 41559614 A C 7.55E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1495693 chr3 41560092 C T 7.54E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1795312 chr3 41560382 A T 7.53E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1565960 chr3 41567692 A G 7.48E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs7624356 chr3 41570772 A G 2.61E-05 Intelligence ULK4 intron 21826061 rs4580521 chr3 41576183 A C 6.51E-05 Intelligence ULK4 intron 21826061 rs1629284 chr3 41586308 C G 4.89E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs3897976 chr3 41606692 G A 8.24E-05 Body mass index ULK4 intron 22446040 rs3897976 chr3 41606692 G A 1.62E-05 Tunica Media ULK4 intron pha003038 rs7627367 chr3 41611228 T G 8.38E-07 Intelligence ULK4 intron 21826061 rs1256388 chr3 41613317 T C 3.19E-04 Gallstones ULK4 intron 17632509 rs17058895 chr3 41615845 T G 2.30E-05 Urinary metabolites ULK4 intron 21572414 rs17059208 chr3 41636664 C G 1.24E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs9941986 chr3 41638274 T C 4.00E-05 Temporomandibular joint disorders ULK4 intron 23746317 rs6599167 chr3 41750260 A G 5.27E-08 Multiple myeloma ULK4 intron 22120009 rs6599168 chr3 41750323 T C 5.26E-08 Multiple myeloma ULK4 intron 22120009 rs6771928 chr3 41750973 G A 5.31E-08 Multiple myeloma ULK4 intron 22120009 rs6763508 chr3 41750989 T C 5.32E-08 Multiple myeloma ULK4 intron 22120009 rs6809328 chr3 41751005 A C 5.29E-08 Multiple myeloma ULK4 intron 22120009 rs6794074 chr3 41751147 A G 5.27E-08 Multiple myeloma ULK4 intron 22120009 rs6794211 chr3 41751324 A T 5.32E-08 Multiple myeloma ULK4 intron 22120009 rs6781529 chr3 41751333 C T 5.33E-08 Multiple myeloma ULK4 intron 22120009 rs73069356 chr3 41752845 G A 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs73069357 chr3 41753319 T G 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs9848754 chr3 41753647 C T 5.47E-08 Multiple myeloma ULK4 intron 22120009 rs4616614 chr3 41753648 T G 5.46E-08 Multiple myeloma ULK4 intron 22120009 rs4408846 chr3 41753679 A G 5.46E-08 Multiple myeloma ULK4 intron 22120009 rs1025646 chr3 41754422 A T 5.54E-08 Multiple myeloma ULK4 intron 22120009 rs6807015 chr3 41754514 T C 5.54E-08 Multiple myeloma ULK4 intron 22120009 rs9847006 chr3 41755359 T C 3.15E-08 Multiple myeloma ULK4 intron 22120009 rs9869282 chr3 41756064 A G 5.66E-08 Multiple myeloma ULK4 intron 22120009 rs61744388 chr3 41756965 C T 5.72E-08 Multiple myeloma ULK4 missense 22120009 rs61744385 chr3 41756986 A T 5.73E-08 Multiple myeloma ULK4 missense 22120009 rs9866759 chr3 41758418 T C 5.78E-08 Multiple myeloma ULK4 intron 22120009 rs17060938 chr3 41759191 T C 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs9852303 chr3 41759525 C T 4.79E-08 Multiple myeloma ULK4 intron 22120009 rs11923562 chr3 41760331 G T 5.88E-08 Multiple myeloma ULK4 intron 22120009 rs3890604 chr3 41760625 C T 4.91E-08 Multiple myeloma ULK4 intron 22120009 rs1125203 chr3 41760895 T C 1.27E-07 Multiple myeloma ULK4 intron 22120009 rs1125203 chr3 41760895 T C 6.00E-10 Multiple myeloma ULK4 intron 23955597 rs2371623 chr3 41761083 T C 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9825741 chr3 41761828 A T 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs9863915 chr3 41762002 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9826058 chr3 41762062 A G 5.89E-08 Multiple myeloma ULK4 intron 22120009 rs9864217 chr3 41762206 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9864331 chr3 41762217 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9830469 chr3 41762535 A G 5.93E-08 Multiple myeloma ULK4 intron 22120009 rs55835726 chr3 41763049 C A,G,T 5.95E-08 Multiple myeloma ULK4 intron 22120009 rs9869440 chr3 41763155 G C 5.96E-08 Multiple myeloma ULK4 intron 22120009 rs9874975 chr3 41764300 G A 5.41E-08 Multiple myeloma ULK4 intron 22120009 rs7651190 chr3 41765955 A G 6.23E-08 Multiple myeloma ULK4 intron 22120009 rs9882329 chr3 41767154 T C 6.24E-08 Multiple myeloma ULK4 intron 22120009 rs6801343 chr3 41767234 C T 6.24E-08 Multiple myeloma ULK4 intron 22120009 rs6778699 chr3 41770835 T C 2.86E-04 Multiple complex diseases ULK4 intron 17554300 rs73069380 chr3 41771177 C T 3.35E-04 Multiple myeloma ULK4 intron 22120009 rs6599170 chr3 41772718 C G 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs28755797 chr3 41774446 C T 6.44E-08 Multiple myeloma ULK4 intron 22120009 rs9854833 chr3 41775577 C T 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9875083 chr3 41775786 T A 6.84E-08 Multiple myeloma ULK4 intron 22120009 rs6789260 chr3 41776350 G C 7.77E-08 Multiple myeloma ULK4 intron 22120009 rs6781326 chr3 41777028 T C 7.76E-08 Multiple myeloma ULK4 intron 22120009 rs73069390 chr3 41785513 C T 1.09E-07 Multiple myeloma ULK4 intron 22120009 rs6599175 chr3 41786009 T C 8.85E-08 Multiple myeloma ULK4 intron 22120009 rs6599175 chr3 41786009 T C 1.00E-09 Multiple myeloma (hyperdiploidy) ULK4 intron 23502783 rs6599175 chr3 41786009 T C 3.00E-10 Multiple myeloma ULK4 intron 23955597 rs9847975 chr3 41786904 A G 8.08E-08 Multiple myeloma ULK4 intron 22120009 rs73069392 chr3 41787009 C T 8.07E-08 Multiple myeloma ULK4 intron 22120009 rs73069394 chr3 41787233 G A 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs73069396 chr3 41787236 A T 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs6599176 chr3 41788492 T G 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs17061431 chr3 41792655 T C 6.89E-08 Multiple myeloma ULK4 intron 22120009 rs9868066 chr3 41794161 T A 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs7650227 chr3 41794937 T G 6.49E-08 Multiple myeloma ULK4 intron 22120009 rs9867627 chr3 41795841 A C,G,T 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs73071304 chr3 41797504 G C 8.22E-08 Multiple myeloma ULK4 intron 22120009 rs57479675 chr3 41798038 C T 5.98E-08 Multiple myeloma ULK4 intron 22120009 rs73071307 chr3 41798699 T C 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs7616123 chr3 41798941 A G 7.96E-08 Multiple myeloma ULK4 intron 22120009 rs76471037 chr3 41799414 T C 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs9311288 chr3 41804581 C G 5.10E-08 Multiple myeloma ULK4 intron 22120009 rs55748698 chr3 41805233 G A 6.92E-08 Multiple myeloma ULK4 intron 22120009 rs9854838 chr3 41805670 C A 4.97E-08 Multiple myeloma ULK4 intron 22120009 rs73071315 chr3 41805887 T C 6.83E-08 Multiple myeloma ULK4 intron 22120009 rs17280777 chr3 41806167 C T 6.79E-08 Multiple myeloma ULK4 intron 22120009 rs111304140 chr3 41806492 G A 6.75E-08 Multiple myeloma ULK4 intron 22120009 rs113874002 chr3 41806714 A G 6.71E-08 Multiple myeloma ULK4 intron 22120009 rs201957963 chr3 41807448 C CAT 4.77E-08 Multiple myeloma ULK4 intron 22120009 rs9865127 chr3 41807448 C T 4.77E-08 Multiple myeloma ULK4 intron 22120009 rs17214945 chr3 41808660 T G 2.83E-08 Multiple myeloma ULK4 intron 22120009 rs59583650 chr3 41809063 A G 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs57638657 chr3 41809238 G C 7.04E-08 Multiple myeloma ULK4 intron 22120009 rs111708447 chr3 41809583 G A 6.32E-08 Multiple myeloma ULK4 intron 22120009 rs73071325 chr3 41809989 T G 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs73071328 chr3 41810055 A C 6.27E-08 Multiple myeloma ULK4 intron 22120009 rs73828254 chr3 41810180 T A 6.26E-08 Multiple myeloma ULK4 intron 22120009 rs17062109 chr3 41810364 C A,T 2.97E-08 Multiple myeloma ULK4 intron 22120009 rs17214987 chr3 41810481 A G 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs73071329 chr3 41810539 G A 4.45E-08 Multiple myeloma ULK4 intron 22120009 rs73071330 chr3 41810553 T G 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs17280952 chr3 41810834 T C 6.19E-08 Multiple myeloma ULK4 intron 22120009 rs17280980 chr3 41810949 A T 6.18E-08 Multiple myeloma ULK4 intron 22120009 rs9832037 chr3 41812032 T C 4.35E-08 Multiple myeloma ULK4 intron 22120009 rs55744136 chr3 41812293 A C 7.00E-07 Multiple myeloma ULK4 intron 22120009 rs59432762 chr3 41812294 G C 7.00E-07 Multiple myeloma ULK4 intron 22120009 rs17215183 chr3 41812334 T C 2.87E-08 Multiple myeloma ULK4 intron 22120009 rs60764195 chr3 41812522 G C 6.06E-08 Multiple myeloma ULK4 intron 22120009 rs9837273 chr3 41813104 T C 4.30E-08 Multiple myeloma ULK4 intron 22120009 rs9817510 chr3 41813108 C T 4.30E-08 Multiple myeloma ULK4 intron 22120009 rs7631914 chr3 41813557 T C 4.27E-08 Multiple myeloma ULK4 intron 22120009 rs10452020 chr3 41815951 A C 4.15E-08 Multiple myeloma ULK4 intron 22120009 rs10452022 chr3 41816042 G A 4.61E-07 Multiple myeloma ULK4 intron 22120009 rs113722150 chr3 41816541 A T 6.33E-08 Multiple myeloma ULK4 intron 22120009 rs111877184 chr3 41816673 G C 4.12E-08 Multiple myeloma ULK4 intron 22120009 rs17281182 chr3 41817263 C T 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs73071337 chr3 41822518 G C 5.91E-08 Multiple myeloma ULK4 intron 22120009 rs114034165 chr3 41823297 G A 5.30E-08 Multiple myeloma ULK4 intron 22120009 rs112071272 chr3 41823363 G A 5.86E-08 Multiple myeloma ULK4 intron 22120009 rs73071338 chr3 41824328 G A 5.25E-08 Multiple myeloma ULK4 intron 22120009 rs6803652 chr3 41824556 A G 3.18E-08 Multiple myeloma ULK4 intron 22120009 rs73071341 chr3 41826211 C T 4.71E-08 Multiple myeloma ULK4 intron 22120009 rs10212536 chr3 41827026 A G 3.57E-08 Multiple myeloma ULK4 intron 22120009 rs73071344 chr3 41827062 C T 4.55E-08 Multiple myeloma ULK4 intron 22120009 rs58442057 chr3 41827209 G A 4.58E-08 Multiple myeloma ULK4 intron 22120009 rs9840037 chr3 41827522 C T 3.39E-08 Multiple myeloma ULK4 intron 22120009 rs73071352 chr3 41828300 A G 4.82E-08 Multiple myeloma ULK4 intron 22120009 rs73071354 chr3 41829186 C A 5.42E-08 Multiple myeloma ULK4 intron 22120009 rs73071356 chr3 41829486 C T 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs17215498 chr3 41829679 G C 6.72E-08 Multiple myeloma ULK4 intron 22120009 rs9852020 chr3 41830206 G A,T 4.78E-08 Multiple myeloma ULK4 intron 22120009 rs73071358 chr3 41830487 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs17215589 chr3 41831203 C T 1.39E-07 Multiple myeloma ULK4 missense 22120009 rs17215589 chr3 41831203 C T 2.00E-09 Multiple myeloma ULK4 missense 23955597 rs10510729 chr3 41831998 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs17281609 chr3 41833432 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs9834098 chr3 41833493 A G 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs73828280 chr3 41833907 A T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073323 chr3 41834051 C T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073326 chr3 41834195 G T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12185908 chr3 41834492 A C 8.29E-08 Multiple myeloma ULK4 intron 22120009 rs12186076 chr3 41834639 T C 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs73828283 chr3 41835099 T C 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs112265441 chr3 41836068 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs12185934 chr3 41836558 A C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186050 chr3 41836879 G C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186051 chr3 41836919 G A 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186109 chr3 41836920 T C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073337 chr3 41837497 T C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs766286 chr3 41838329 G A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs11129932 chr3 41838767 C A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs2371627 chr3 41839219 A G 5.05E-08 Multiple myeloma ULK4 intron 22120009 rs4621303 chr3 41839370 T A 5.05E-08 Multiple myeloma ULK4 intron 22120009 rs73073342 chr3 41839455 A C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs58360908 chr3 41839837 A G 8.29E-08 Multiple myeloma ULK4 intron 22120009 rs57809229 chr3 41840162 G A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs6776724 chr3 41841270 A G 5.06E-08 Multiple myeloma ULK4 intron 22120009 rs17215883 chr3 41841873 C T 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs6599178 chr3 41842129 C T 5.06E-08 Multiple myeloma ULK4 intron 22120009 rs73073352 chr3 41842184 T C 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs73073355 chr3 41842332 G A 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs7626217 chr3 41842415 A G 5.07E-08 Multiple myeloma ULK4 intron 22120009 rs73073358 chr3 41842527 G A 8.28E-08 Multiple myeloma ULK4 intron 22120009 rs73073361 chr3 41842926 C G 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs73073364 chr3 41843058 T C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs73073368 chr3 41843391 A G 5.08E-08 Multiple myeloma ULK4 intron 22120009 rs73073371 chr3 41843443 A G 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs57525756 chr3 41843591 A C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs56194645 chr3 41843593 T C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs55788971 chr3 41843965 T A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs60927633 chr3 41844010 C T 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs111520733 chr3 41844612 A G 3.78E-06 Multiple myeloma ULK4 intron 22120009 rs6793567 chr3 41845547 T A,C 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs78863838 chr3 41845597 C G 1.74E-04 Multiple myeloma ULK4 intron 22120009 rs56183581 chr3 41848492 C T 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs55682201 chr3 41848497 A G 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs7647561 chr3 41848627 T A 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs10510730 chr3 41849013 C G 2.99E-06 Multiple myeloma ULK4 intron 22120009 rs55916959 chr3 41849130 G A 7.31E-08 Multiple myeloma ULK4 intron 22120009 rs7648357 chr3 41849670 A G 5.14E-08 Multiple myeloma ULK4 intron 22120009 rs73077358 chr3 41850005 C T 7.29E-08 Multiple myeloma ULK4 intron 22120009 rs73077359 chr3 41850016 G A 7.29E-08 Multiple myeloma ULK4 intron 22120009 rs73077360 chr3 41850054 C T 7.28E-08 Multiple myeloma ULK4 intron 22120009 rs73077361 chr3 41850146 G A 7.28E-08 Multiple myeloma ULK4 intron 22120009 rs113683976 chr3 41850685 A C 7.16E-07 Multiple myeloma ULK4 intron 22120009 rs17215988 chr3 41851320 A C 7.21E-08 Multiple myeloma ULK4 intron 22120009 rs17063297 chr3 41851509 C G 8.49E-04 Multiple complex diseases ULK4 intron 17554300 rs73077365 chr3 41851559 T C 7.11E-08 Multiple myeloma ULK4 intron 22120009 rs6796210 chr3 41851718 T C 7.70E-08 Multiple myeloma ULK4 intron 22120009 rs73077367 chr3 41851959 G A 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs60943892 chr3 41852307 T C 7.04E-08 Multiple myeloma ULK4 intron 22120009 rs73077373 chr3 41852887 C T 7.03E-08 Multiple myeloma ULK4 intron 22120009 rs73077375 chr3 41853058 C T 7.80E-08 Multiple myeloma ULK4 intron 22120009 rs7646144 chr3 41853125 T A 6.79E-08 Multiple myeloma ULK4 intron 22120009 rs7632387 chr3 41853161 C T 6.80E-08 Multiple myeloma ULK4 intron 22120009 rs10510731 chr3 41853310 C T 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs61283393 chr3 41854135 T G 7.03E-08 Multiple myeloma ULK4 intron 22120009 rs57209010 chr3 41854743 A T 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs6599179 chr3 41855284 C T 6.90E-08 Multiple myeloma ULK4 intron 22120009 rs73077386 chr3 41857652 A G 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs7648578 chr3 41858731 C T 7.82E-08 Multiple myeloma ULK4 intron 22120009 rs73077390 chr3 41860255 T C 7.00E-08 Multiple myeloma ULK4 intron 22120009 rs9856088 chr3 41860482 G T 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs9855965 chr3 41860508 C T 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs9818169 chr3 41860599 A G 7.09E-08 Multiple myeloma ULK4 intron 22120009 rs12639255 chr3 41861738 T C 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs6783001 chr3 41862232 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs6795797 chr3 41862250 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079307 chr3 41862273 A C 6.84E-08 Multiple myeloma ULK4 intron 22120009 rs1564716 chr3 41862613 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs2128834 chr3 41862645 A G 6.23E-08 Multiple myeloma ULK4 intron 22120009 rs2128834 chr3 41862645 A G 0.0000277 Adenoma (female) ULK4 intron 22532847 rs2128835 chr3 41862873 A G 5.79E-08 Multiple myeloma ULK4 intron 22120009 rs2128835 chr3 41862873 A G 2.00E-10 Multiple myeloma ULK4 intron 23955597 rs17063649 chr3 41863406 C T 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs28733681 chr3 41863444 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs17063653 chr3 41863817 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079316 chr3 41863859 G A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079321 chr3 41863910 C T 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs74482513 chr3 41864097 G C 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs112059754 chr3 41864125 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs111465678 chr3 41864405 C A 6.81E-08 Multiple myeloma ULK4 intron 22120009 rs73079324 chr3 41864564 T C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73079325 chr3 41864565 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73830511 chr3 41864643 G T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73079327 chr3 41864697 A T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6790732 chr3 41864872 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768128 chr3 41865080 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6793520 chr3 41865289 C G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768438 chr3 41865355 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs6805880 chr3 41865397 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768542 chr3 41865474 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768563 chr3 41865541 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7649989 chr3 41865843 A C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7652541 chr3 41866093 A G 7.58E-08 Multiple myeloma ULK4 intron 22120009 rs59553563 chr3 41866599 T A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs59248949 chr3 41866657 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs59849553 chr3 41866786 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs56776628 chr3 41866856 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7432737 chr3 41867859 C T 5.29E-06 Multiple myeloma ULK4 intron 22120009 rs111821658 chr3 41870466 C G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs111634789 chr3 41871356 T C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs28642910 chr3 41871391 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs28581706 chr3 41871397 A C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs113416896 chr3 41871443 G C 1.82E-04 Multiple myeloma ULK4 intron 22120009 rs28652776 chr3 41871520 A C 5.27E-06 Multiple myeloma ULK4 intron 22120009 rs9831404 chr3 41871825 T G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs77717550 chr3 41872504 T A 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9816560 chr3 41872527 G T 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9816772 chr3 41872877 C T 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs113213296 chr3 41873097 G A 9.71E-08 Multiple myeloma ULK4 intron 22120009 rs111967505 chr3 41873157 C T 6.71E-08 Multiple myeloma ULK4 intron 22120009 rs6803198 chr3 41873778 C G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs7616844 chr3 41874343 A G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9849393 chr3 41875369 G C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9852991 chr3 41875455 C A 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs73830516 chr3 41876056 A C,G 6.67E-08 Multiple myeloma ULK4 intron 22120009 rs73079350 chr3 41876310 C T 7.53E-08 Multiple myeloma ULK4 intron 22120009 rs967619 chr3 41876710 C G 7.53E-08 Multiple myeloma ULK4 intron 22120009 rs3774372 chr3 41877414 T C 8.00E-07 Blood pressure ULK4 missense 21909110 rs3774372 chr3 41877414 T C 9.02E-14 Systolic blood pressure ULK4 missense 21909115 rs3774372 chr3 41877414 T C 2.57E-07 Multiple myeloma ULK4 missense 22120009 rs3774372 chr3 41877414 T C 9.00E-10 Multiple myeloma ULK4 missense 23955597 rs56104136 chr3 41877853 C T 6.66E-08 Multiple myeloma ULK4 intron 22120009 rs9869207 chr3 41878661 C G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs79817383 chr3 41880766 A T 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs7624372 chr3 41881107 T A 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs7622259 chr3 41881351 A T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9830064 chr3 41881801 T C 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9810731 chr3 41882101 C T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9810865 chr3 41882147 C T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs114960066 chr3 41882323 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs113341165 chr3 41882716 C A 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs114714860 chr3 41882905 G C 2.86E-06 Multiple myeloma ULK4 intron 22120009 rs113449797 chr3 41883019 A G 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs113471865 chr3 41883101 C A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs55941479 chr3 41883501 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs58940436 chr3 41883682 T A,G 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs60248638 chr3 41883692 G A 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs56121764 chr3 41883975 T C 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9873207 chr3 41884750 C T 7.78E-08 Multiple myeloma ULK4 intron 22120009 rs112736802 chr3 41884867 C T 6.64E-08 Multiple myeloma ULK4 intron 22120009 rs7642083 chr3 41884899 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56081180 chr3 41885239 C T 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56036624 chr3 41885339 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56158380 chr3 41885588 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9823027 chr3 41885655 T C 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9840532 chr3 41885697 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs11928580 chr3 41885722 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs11917248 chr3 41885723 T C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs17282671 chr3 41887455 T C 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs6797165 chr3 41887777 A G 6.91E-08 Multiple myeloma ULK4 intron 22120009 rs73079360 chr3 41888372 T A 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs17216919 chr3 41888938 G C 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs9820192 chr3 41889281 G A 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9824731 chr3 41889698 G T 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs28702390 chr3 41889920 C A 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs6791806 chr3 41889995 C T 6.59E-08 Multiple myeloma ULK4 intron 22120009 rs73081321 chr3 41890231 G A 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs17064124 chr3 41890803 A G 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9850310 chr3 41891098 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9854954 chr3 41891660 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs12107693 chr3 41892456 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs12107296 chr3 41892503 C G 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs58212289 chr3 41892643 T A 6.16E-07 Multiple myeloma ULK4 intron 22120009 rs56134026 chr3 41892644 G T 6.16E-07 Multiple myeloma ULK4 intron 22120009 rs57653201 chr3 41892693 T C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs9883369 chr3 41893771 A T 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs6802340 chr3 41894034 T C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs9846634 chr3 41894049 G A 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs1016669 chr3 41894440 T C 6.57E-08 Multiple myeloma ULK4 intron 22120009 rs9823254 chr3 41894768 G C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs73081335 chr3 41895177 A G 6.11E-08 Multiple myeloma ULK4 intron 22120009 rs9865780 chr3 41895802 A G 6.38E-08 Multiple myeloma ULK4 intron 22120009 rs1994157 chr3 41897482 G A 1.14E-07 Multiple myeloma ULK4 intron 22120009 rs1994157 chr3 41897482 G A 7.00E-10 Multiple myeloma ULK4 intron 23955597 rs376773321 chr3 41898004 AATATAT A 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs577040336 chr3 41898004 A AAT 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs7426868 chr3 41898004 A T 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs2888133 chr3 41898054 C T 6.37E-08 Multiple myeloma ULK4 intron 22120009 rs35167597 chr3 41898108 C T 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs73830532 chr3 41898814 T C 6.09E-08 Multiple myeloma ULK4 intron 22120009 rs73081341 chr3 41900335 A T 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs2625667 chr3 41900951 C A 6.36E-08 Multiple myeloma ULK4 intron 22120009 rs1717028 chr3 41902964 C T 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs1716674 chr3 41902972 G C 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs1716676 chr3 41903208 T C 6.07E-08 Multiple myeloma ULK4 intron 22120009 rs9832548 chr3 41903491 A T 6.04E-08 Multiple myeloma ULK4 intron 22120009 rs73081347 chr3 41903582 T C 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs1607908 chr3 41905196 T G 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs1716679 chr3 41905339 T C 5.91E-08 Multiple myeloma ULK4 intron 22120009 rs1717031 chr3 41905791 G T 5.88E-08 Multiple myeloma ULK4 intron 22120009 rs2625668 chr3 41905930 T C 5.87E-08 Multiple myeloma ULK4 intron 22120009 rs1613759 chr3 41906183 G A 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs1615543 chr3 41906404 C T 5.84E-08 Multiple myeloma ULK4 intron 22120009 rs73081353 chr3 41906448 T A 5.84E-08 Multiple myeloma ULK4 intron 22120009 rs1716668 chr3 41907850 T C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs116202370 chr3 41908273 T G 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs59138513 chr3 41908611 T G 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs60796012 chr3 41908668 T C 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs1716669 chr3 41908681 A G 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs9874513 chr3 41909508 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717033 chr3 41910216 C T 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1716670 chr3 41910571 T C 6.70E-05 Prion diseases ULK4 intron 22210626 rs73081361 chr3 41912535 G A 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs9815354 chr3 41912651 G A 3.00E-09 Diastolic blood pressure ULK4 intron 19430479 rs9815354 chr3 41912651 G A 3.00E-09 Coronary heart disease ULK4 intron 21347282 rs9815354 chr3 41912651 G A 6.63E-06 Blood pressure ULK4 intron 21909110 rs9815354 chr3 41912651 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs73081363 chr3 41913478 C T 1.73E-04 Multiple myeloma ULK4 intron 22120009 rs73081364 chr3 41913616 G C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717018 chr3 41913617 G A 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1617271 chr3 41914000 G T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1619558 chr3 41914213 C G 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs6599185 chr3 41914730 T A 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs17283243 chr3 41914792 C T 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs2683696 chr3 41914898 T C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs2683695 chr3 41914928 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs13325965 chr3 41914942 G T 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs2683694 chr3 41915374 T G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1717017 chr3 41915616 A C 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs73081370 chr3 41916258 G C 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1717015 chr3 41917204 G T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717014 chr3 41917395 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs73081372 chr3 41917993 C T 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1716657 chr3 41918456 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716655 chr3 41918706 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs9839213 chr3 41918992 T C 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs10865914 chr3 41919499 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73081378 chr3 41920189 G A 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs6794477 chr3 41920401 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73081383 chr3 41920614 A G 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs1716641 chr3 41921681 C T 4.35E-08 Multiple myeloma ULK4 intron 22120009 rs1716683 chr3 41923074 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs17217536 chr3 41923300 A C 5.61E-08 Multiple myeloma ULK4 intron 22120009 rs17283481 chr3 41924015 T C 5.61E-08 Multiple myeloma ULK4 intron 22120009 rs1716996 chr3 41924294 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716997 chr3 41924333 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716685 chr3 41925301 T C 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs1052501 chr3 41925398 C T 2.00E-08 Multiple myeloma ULK4 missense 22120009 rs1052501 chr3 41925398 C T 2.00E-10 Multiple myeloma ULK4 missense 23955597 rs17217746 chr3 41926021 A G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs17283677 chr3 41926148 A G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1716688 chr3 41926546 G A 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73083326 chr3 41927150 G T 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs73083329 chr3 41927151 C T 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs4973991 chr3 41927273 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1629460 chr3 41927449 T G 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1629462 chr3 41927452 G C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs73083333 chr3 41927505 G A 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs9838965 chr3 41927938 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs9839399 chr3 41928044 G A 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs9839491 chr3 41928301 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs56167033 chr3 41928317 C T 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs59873855 chr3 41929538 T C 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs1716660 chr3 41929960 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1716999 chr3 41930041 C G 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717000 chr3 41930219 A C 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs73087368 chr3 41930379 A G 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs4973995 chr3 41931473 T C 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs76313799 chr3 41931751 A C 8.41E-08 Multiple myeloma ULK4 intron 22120009 rs76276404 chr3 41931770 A G 8.41E-08 Multiple myeloma ULK4 intron 22120009 rs113941228 chr3 41932076 G A 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs62258655 chr3 41932330 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs113059632 chr3 41932858 G A 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs11717540 chr3 41932938 G A 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs113772069 chr3 41933389 T C 5.66E-08 Multiple myeloma ULK4 intron 22120009 rs1717001 chr3 41934949 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs1716696 chr3 41935811 C T 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs1717002 chr3 41936668 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs73087378 chr3 41936827 G A 5.67E-08 Multiple myeloma ULK4 intron 22120009 rs1717003 chr3 41937000 C T 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs74371586 chr3 41937890 G A 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs77572508 chr3 41938044 C A 6.53E-08 Multiple myeloma ULK4 intron 22120009 rs73069203 chr3 41938767 T C 6.53E-08 Multiple myeloma ULK4 intron 22120009 rs73069208 chr3 41939198 C T 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs73069209 chr3 41939781 G A 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs4615050 chr3 41942498 T A 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs201425733 chr3 41942664 CTTTTTTTTTTT C 5.69E-08 Multiple myeloma ULK4 intron 22120009 rs60664243 chr3 41942664 C T 5.69E-08 Multiple myeloma ULK4 intron 22120009 rs17218103 chr3 41943724 A G 4.09E-08 Multiple myeloma ULK4 intron 22120009 rs111671485 chr3 41944080 G A 2.82E-05 Multiple myeloma ULK4 intron 22120009 rs537842940 chr3 41944080 GA G 2.82E-05 Multiple myeloma ULK4 intron 22120009 rs1613233 chr3 41945144 A G 5.79E-08 Multiple myeloma ULK4 intron 22120009 rs77778906 chr3 41945612 A C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs77732985 chr3 41945872 G A 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717009 chr3 41946308 T C 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs59476821 chr3 41946481 A G 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717010 chr3 41946903 G A 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs11705749 chr3 41947294 C A,T 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs79741604 chr3 41947321 C T 6.60E-08 Multiple myeloma ULK4 intron 22120009 rs13063523 chr3 41947437 C T 1.92E-04 Multiple myeloma ULK4 intron 22120009 rs1717012 chr3 41948255 G A 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs1716664 chr3 41948378 G A 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs78342280 chr3 41948810 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs59146151 chr3 41949301 T C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs60659106 chr3 41949569 G C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs13076952 chr3 41950033 G A 5.82E-08 Multiple myeloma ULK4 intron 22120009 rs112245154 chr3 41950520 G T 6.63E-08 Multiple myeloma ULK4 intron 22120009 rs73069240 chr3 41950973 A T 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs12330363 chr3 41951186 G A 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs73069245 chr3 41951452 G A 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs113528686 chr3 41951547 T C 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs13087719 chr3 41951576 C T 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs13088394 chr3 41951715 G A 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs11711210 chr3 41951952 G C 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs4547673 chr3 41952303 A C 7.24E-08 Multiple myeloma ULK4 intron 22120009 rs4299460 chr3 41952445 A C 7.68E-08 Multiple myeloma ULK4 intron 22120009 rs4264702 chr3 41952539 T A 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs4577439 chr3 41952540 T A 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs35263917 chr3 41952852 T C 7.86E-08 Multiple myeloma ULK4 missense 22120009 rs75651509 chr3 41953564 A G 7.88E-08 Multiple myeloma ULK4 intron 22120009 rs9822598 chr3 41954587 G A 7.41E-08 Multiple myeloma ULK4 intron 22120009 rs9822288 chr3 41954588 C T 7.41E-08 Multiple myeloma ULK4 intron 22120009 rs1628874 chr3 41955714 G A 7.43E-08 Multiple myeloma ULK4 intron 22120009 rs1717034 chr3 41955913 A G 7.44E-08 Multiple myeloma ULK4 intron 22120009 rs1716698 chr3 41957466 T G 7.70E-08 Multiple myeloma ULK4 intron 22120009 rs77047799 chr3 41958895 T C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs7617397 chr3 41959037 T C 9.07E-08 Multiple myeloma ULK4 intron 22120009 rs55899232 chr3 41959357 T C 1.07E-07 Multiple myeloma ULK4 intron 22120009 rs13321282 chr3 41959452 C T 9.51E-08 Multiple myeloma ULK4 intron 22120009 rs1716975 chr3 41960006 T C 1.49E-06 Multiple myeloma ULK4 missense 22120009 rs1716975 chr3 41960006 T C 6.00E-09 Multiple myeloma ULK4 missense 23955597 rs1716981 chr3 41962662 G T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716661 chr3 41962818 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs55820810 chr3 41962832 G A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716982 chr3 41962963 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716983 chr3 41964128 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs76319026 chr3 41964542 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs9809833 chr3 41964648 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1615243 chr3 41965234 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716984 chr3 41965532 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716642 chr3 41965865 A C 7.83E-08 Multiple myeloma ULK4 intron 22120009 rs1716643 chr3 41967192 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs73069277 chr3 41967521 C T 6.33E-06 Multiple myeloma ULK4 intron 22120009 rs1612124 chr3 41967893 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716644 chr3 41968028 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716985 chr3 41968894 T G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716645 chr3 41970480 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716987 chr3 41970516 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs7622665 chr3 41970743 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs7616780 chr3 41971559 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716989 chr3 41972186 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716990 chr3 41972209 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716648 chr3 41972849 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs73069292 chr3 41973963 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716993 chr3 41974556 G C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716651 chr3 41975099 A T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716652 chr3 41975535 A T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716653 chr3 41975598 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs17218264 chr3 41975847 T C 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs939558 chr3 41976040 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs56207540 chr3 41976627 G C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs34121549 chr3 41976773 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs111419796 chr3 41976968 G A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs3934103 chr3 41977214 C T 7.83E-08 Multiple myeloma ULK4 intron 22120009 rs73071203 chr3 41977464 A C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs73071208 chr3 41978738 A T 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1717011 chr3 41980199 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1717020 chr3 41981490 C A 9.79E-08 Multiple myeloma ULK4 intron 22120009 rs73071212 chr3 41981856 C A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs113611706 chr3 41983242 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716691 chr3 41983615 G C 2.98E-04 Multiple complex diseases ULK4 intron 17554300 rs1716692 chr3 41983786 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1717021 chr3 41983860 A T 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1717023 chr3 41984213 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs113300894 chr3 41984243 G C 4.80E-06 Multiple myeloma ULK4 intron 22120009 rs199568018 chr3 41984775 G T 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1624519 chr3 41984800 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1717024 chr3 41984888 C A 9.68E-08 Multiple myeloma ULK4 intron 22120009 rs11129935 chr3 41985203 A C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716693 chr3 41985600 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs9876960 chr3 41985812 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs1716694 chr3 41986399 G T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs17284313 chr3 41986787 A C 8.82E-08 Multiple myeloma ULK4 intron 22120009 rs73071222 chr3 41986896 C T 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs17218441 chr3 41987044 A G 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs17218504 chr3 41987278 A G 1.46E-07 Multiple myeloma ULK4 intron 22120009 rs1717027 chr3 41987920 T C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs1717027 chr3 41987920 T C 5.00E-13 Blood pressure ULK4 intron 23972371 rs1716695 chr3 41988695 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs113803925 chr3 41989859 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs7372217 chr3 41990122 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs12330747 chr3 41990829 A C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs73071236 chr3 41992042 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071238 chr3 41992243 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs6599192 chr3 41992408 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs112787664 chr3 41992441 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071239 chr3 41992610 C A 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071242 chr3 41993011 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs56983571 chr3 41994473 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs11712394 chr3 41994779 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs113923306 chr3 41994948 C T 1.91E-07 Multiple myeloma ULK4 intron 22120009 rs6807562 chr3 41995655 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs6805140 chr3 41995791 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs2272007 chr3 41996136 T C 7.93E-08 Multiple myeloma ULK4 missense 22120009 rs2272007 chr3 41996136 T C 2.00E-09 Multiple myeloma (hyperdiploidy) ULK4 missense 23502783 rs2272007 chr3 41996136 T C 4.00E-10 Multiple myeloma ULK4 missense 23955597 rs17284472 chr3 41996304 G A 8.87E-08 Multiple myeloma ULK4 intron 22120009 rs73830583 chr3 41996948 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs2272006 chr3 41997059 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs60690674 chr3 41997811 G C 1.47E-07 Multiple myeloma ULK4 intron 22120009 rs9842305 chr3 41998412 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs112490357 chr3 41998940 C CAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs11455719 chr3 41998940 C CAAA,CAAAAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs549551862 chr3 41998940 CAAAAA C 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs71939903 chr3 41998940 C CAAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs56728371 chr3 41999381 T A 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs80066790 chr3 42000843 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs1474219 chr3 42000913 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs79323474 chr3 42000973 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071259 chr3 42001847 G A 1.26E-06 Multiple myeloma ULK4 intron 22120009 rs7639859 chr3 42001987 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs55916855 chr3 42002761 A G 1.22E-07 Multiple myeloma ULK4 intron 22120009 rs11717170 chr3 42002811 G C 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs73071261 chr3 42003369 C A 1.22E-07 Multiple myeloma ULK4 intron 22120009 rs73830585 chr3 42003698 T A 1.47E-07 Multiple myeloma LOC100287063 missense 22120009 rs56201224 chr3 42004427 A C 1.47E-07 Multiple myeloma LOC100287063 intron 22120009 rs55953604 chr3 42004428 A G 1.47E-07 Multiple myeloma LOC100287063 intron 22120009 rs4434125 chr3 42004681 A G 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs56290987 chr3 42004882 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs60966614 chr3 42005166 A G 1.25E-06 Multiple myeloma LOC100287063 intron 22120009 rs12492599 chr3 42005734 C A 1.01E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073226 chr3 42005838 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs74947509 chr3 42006323 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs10510732 chr3 42007339 G A 8.90E-08 Multiple myeloma LOC100287063 intron 22120009 rs1915482 chr3 42007734 G C 9.59E-04 Multiple complex diseases LOC100287063 intron 17554300 rs73073229 chr3 42007850 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs113379006 chr3 42008186 C T 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073230 chr3 42008263 G A 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs113144620 chr3 42008312 A G 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs78629637 chr3 42008781 C T 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs10510733 chr3 42009192 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs9835059 chr3 42009726 A G 1.01E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073233 chr3 42010550 A G 1.23E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073234 chr3 42012071 C T 1.24E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073235 chr3 42012693 C A 1.02E-07 Multiple myeloma LOC100287063 intron 22120009 rs56332587 chr3 42012714 T C 1.25E-07 Multiple myeloma LOC100287063 intron 22120009 rs7373694 chr3 42012719 G A 1.02E-07 Multiple myeloma LOC100287063 intron 22120009 rs58916656 chr3 42012781 C G 1.25E-07 Multiple myeloma LOC100287063 intron 22120009 rs9856633 chr3 42013850 A G 9.87E-08 Multiple myeloma LOC100287063 intron 22120009 rs73073238 chr3 42014325 G C 1.33E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073239 chr3 42014597 G C 7.27E-06 Multiple myeloma LOC100287063 intron 22120009 rs13087502 chr3 42015110 C T 6.79E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073242 chr3 42015335 G A 8.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs12108064 chr3 42016217 C T 6.24E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073250 chr3 42016559 G T 8.48E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073252 chr3 42016891 C T 6.28E-06 Multiple myeloma LOC100287063 intron 22120009 rs115754309 chr3 42017246 A G 8.55E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073253 chr3 42017494 T A 8.56E-06 Multiple myeloma LOC100287063 intron 22120009 rs13084436 chr3 42017537 T A 6.31E-06 Multiple myeloma LOC100287063 intron 22120009 rs17218866 chr3 42017634 T C 8.58E-06 Multiple myeloma LOC100287063 intron 22120009 rs6796078 chr3 42017820 A T 6.33E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073258 chr3 42017894 G A 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs6801339 chr3 42018233 T A 6.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073262 chr3 42018443 G T 8.63E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073263 chr3 42018666 C A 8.65E-06 Multiple myeloma LOC100287063 intron 22120009 rs17218936 chr3 42019392 C T 5.68E-06 Multiple myeloma LOC100287063 intron 22120009 rs7634985 chr3 42019565 C T 6.39E-06 Multiple myeloma LOC100287063 intron 22120009 rs7634985 chr3 42019565 C T 2.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs7652369 chr3 42020973 T G 6.50E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073266 chr3 42021116 A G 8.84E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073267 chr3 42021163 A T 8.84E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073268 chr3 42021403 C A 8.86E-06 Multiple myeloma LOC100287063 intron 22120009 rs1851149 chr3 42021708 T C 6.54E-06 Multiple myeloma LOC100287063 intron 22120009 rs80120812 chr3 42021760 C T 8.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs111788014 chr3 42021796 C T 8.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073272 chr3 42022446 G A 8.93E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073274 chr3 42022810 T C 8.96E-06 Multiple myeloma LOC100287063 intron 22120009 rs6798152 chr3 42023558 A T 6.65E-06 Multiple myeloma LOC100287063 intron 22120009 rs79626430 chr3 42023786 A G 9.04E-06 Multiple myeloma LOC100287063 intron 22120009 rs2683692 chr3 42024527 A G 6.70E-06 Multiple myeloma LOC100287063 intron 22120009 rs112310714 chr3 42024797 A C 9.13E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073276 chr3 42025354 G A 4.00E-05 Multiple myeloma LOC100287063 intron 22120009 rs78662667 chr3 42025579 G A 9.20E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073280 chr3 42025772 T C 9.20E-06 Multiple myeloma LOC100287063 intron 22120009 rs794902 chr3 42025939 T C 6.79E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073281 chr3 42026366 C T 1.17E-05 Multiple myeloma LOC100287063 intron 22120009 rs56008529 chr3 42026755 A T 1.17E-05 Multiple myeloma LOC100287063 intron 22120009 rs552804358 chr3 42027247 TA T 9.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs56865718 chr3 42027247 T C 9.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs1087599 chr3 42027363 G A 6.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs116717051 chr3 42027411 G C 7.14E-05 Multiple myeloma LOC100287063 intron 22120009 rs73073285 chr3 42027566 T G 9.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073288 chr3 42027637 G C 9.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073290 chr3 42027684 T G 9.38E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073291 chr3 42028004 G C 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073292 chr3 42028023 C A 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073294 chr3 42028053 A G 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073296 chr3 42028074 G A 9.42E-06 Multiple myeloma LOC100287063 intron 22120009 rs73830596 chr3 42028223 G A 9.43E-06 Multiple myeloma LOC100287063 intron 22120009 rs78402272 chr3 42028425 G C 9.45E-06 Multiple myeloma LOC100287063 intron 22120009 rs113496706 chr3 42028574 G T 9.46E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073298 chr3 42028657 G A 6.98E-06 Multiple myeloma LOC100287063 intron 22120009 rs794899 chr3 42028722 T C 6.98E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073301 chr3 42028777 T C 9.48E-06 Multiple myeloma LOC100287063 intron 22120009 rs61646756 chr3 42029352 A C 9.58E-06 Multiple myeloma LOC100287063 intron 22120009 rs17284933 chr3 42029835 T C 7.44E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073302 chr3 42029879 T C 9.67E-06 Multiple myeloma LOC100287063 intron 22120009 rs113027442 chr3 42030029 G A 5.81E-06 Multiple myeloma LOC100287063 intron 22120009 rs79239400 chr3 42030249 C A 1.23E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075204 chr3 42030392 G A 9.82E-06 Multiple myeloma LOC100287063 intron 22120009 rs115135603 chr3 42031622 T C 1.02E-05 Multiple myeloma LOC100287063 intron 22120009 rs794897 chr3 42031865 T C 7.59E-06 Multiple myeloma LOC100287063 intron 22120009 rs75308766 chr3 42031894 G A 1.03E-05 Multiple myeloma LOC100287063 intron 22120009 rs794896 chr3 42031902 C T 7.60E-06 Multiple myeloma LOC100287063 intron 22120009 rs794895 chr3 42031974 A C 7.62E-06 Multiple myeloma LOC100287063 intron 22120009 rs794894 chr3 42032483 C T 5.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs794894 chr3 42032483 C T 2.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs61182696 chr3 42032511 C T 1.05E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075211 chr3 42033424 G T 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs75047809 chr3 42033437 T C 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs76127736 chr3 42033645 A G 1.38E-05 Multiple myeloma LOC100287063 intron 22120009 rs11926737 chr3 42034007 C T 8.24E-06 Multiple myeloma LOC100287063 intron 22120009 rs794905 chr3 42034730 C T 8.50E-06 Multiple myeloma LOC100287063 intron 22120009 rs794904 chr3 42035157 G A 8.63E-06 Multiple myeloma LOC100287063 intron 22120009 rs77014899 chr3 42037880 T C 1.63E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075219 chr3 42038429 A C 1.33E-05 Multiple myeloma LOC100287063 intron 22120009 rs57945879 chr3 42038842 C G 1.35E-05 Multiple myeloma LOC100287063 intron 22120009 rs73828505 chr3 42042714 C T 1.11E-05 Multiple myeloma LOC100287063 intron 22120009 rs7629767 chr3 42043509 T G 1.65E-05 Multiple myeloma LOC100287063 intron 22120009 rs7629767 chr3 42043509 T G 6.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs60525434 chr3 42044286 T G 1.26E-05 Multiple myeloma LOC100287063 intron 22120009 rs75687617 chr3 42044664 C T 2.13E-05 Multiple myeloma LOC100287063 intron 22120009 rs113956045 chr3 42045303 G A 2.15E-05 Multiple myeloma LOC100287063 intron 22120009 rs56212772 chr3 42046780 T G 1.89E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075224 chr3 42048248 G A 1.88E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075228 chr3 42049629 T G 2.31E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075231 chr3 42051694 T C 2.06E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075234 chr3 42051801 G A 2.42E-05 Multiple myeloma LOC100287063 intron 22120009 rs12635286 chr3 42051836 T C 2.86E-05 Multiple myeloma LOC100287063 intron 22120009 rs17219090 chr3 42051952 G C 2.45E-05 Multiple myeloma LOC100287063 intron 22120009 rs794892 chr3 42052932 G T 2.67E-05 Multiple myeloma LOC100287063 intron 22120009 rs704964 chr3 42053899 G A 2.92E-05 Multiple myeloma LOC100287063 intron 22120009 rs112912733 chr3 42054910 C A 2.28E-05 Multiple myeloma LOC100287063 cds-synon 22120009 rs939561 chr3 42057101 G A 4.00E-06 Multiple myeloma LOC100287063 intron 23955597 rs73075241 chr3 42058045 C T 2.46E-05 Multiple myeloma LOC100287063 intron 22120009 rs115702638 chr3 42058594 C T 3.98E-05 Multiple myeloma LOC100287063 intron 22120009 rs7652506 chr3 42060235 C T 4.38E-05 Multiple myeloma LOC100287063 intron 22120009 rs12152489 chr3 42060402 T C 2.43E-05 Multiple myeloma LOC100287063 intron 22120009 rs56994465 chr3 42061606 A G 3.96E-05 Multiple myeloma LOC100287063 intron 22120009 rs794890 chr3 42062339 G T 3.94E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075250 chr3 42063734 A G 3.80E-05 Multiple myeloma LOC100287063 intron 22120009 rs809930 chr3 42065005 G A 5.26E-05 Multiple myeloma LOC100287063 intron 22120009 rs12106811 chr3 42076970 G T 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100287063 intron 20877124 rs1498095 chr3 42093422 T C 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio LOC100287063 intron 22589738 rs73066375 chr3 42173947 G A 0.000008435 Sarcoidosis TRAK1 intron 22952805 rs73066377 chr3 42174148 C T 0.000004058 Sarcoidosis TRAK1 intron 22952805 rs2371797 chr3 42175099 C T 0.000006553 Sarcoidosis TRAK1 intron 22952805 rs113518061 chr3 42175887 A G 0.00002181 Sarcoidosis TRAK1 intron 22952805 rs17220629 chr3 42177180 T C 0.00002029 Sarcoidosis TRAK1 intron 22952805 rs1979789 chr3 42177407 C T 0.00002741 Sarcoidosis TRAK1 intron 22952805 rs11709083 chr3 42178461 G A 0.0000226 Sarcoidosis TRAK1 intron 22952805 rs2133072 chr3 42178759 G A 0.00002516 Sarcoidosis TRAK1 intron 22952805 rs2133073 chr3 42178898 C T 0.00002219 Sarcoidosis TRAK1 intron 22952805 rs9311297 chr3 42179870 G A 0.00001571 Sarcoidosis TRAK1 intron 22952805 rs2055285 chr3 42180651 T C 0.00007907 Sarcoidosis TRAK1 intron 22952805 rs1874756 chr3 42181039 A G 0.0000969 Sarcoidosis TRAK1 intron 22952805 rs9851827 chr3 42183692 C G 0.000009875 Sarcoidosis TRAK1 intron 22952805 rs9852262 chr3 42183776 G C 0.00002037 Sarcoidosis TRAK1 intron 22952805 rs9284877 chr3 42185135 C T 1.50E-06 Iron levels TRAK1 intron 21208937 rs4234445 chr3 42226151 T C 9.39E-04 Alcohol dependence TRAK1 intron 24277619 rs2290135 chr3 42230743 G A 6.04E-04 Smoking initiation TRAK1 intron 24665060 rs2290137 chr3 42234740 G A 4.96E-04 Smoking initiation TRAK1 intron 24665060 rs2290134 chr3 42251263 C T 3.37E-05 Cognitive impairment induced by topiramate TRAK1 cds-synon 22091778 rs3196165 chr3 42252141 A G 4.70E-04 Tourette syndrome TRAK1 UTR-3 22889924 rs11928109 chr3 42259299 G A 5.86E-04 Alcohol consumption (maxi-drinks) TRAK1 intron 24277619 rs3774391 chr3 42265369 C T 8.70E-04 Alcohol dependence TRAK1 UTR-3 20201924 rs9879040 chr3 42272118 A G 2.24E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9311317 chr3 42295806 A G 6.77E-05 Insulin-related traits / / pha002901 rs8192472 chr3 42299870 C T 1.00E-06 Body mass index CCK intron 24348519 rs4377469 chr3 42303074 G T 2.00E-07 Body mass index CCK intron 22344221 rs2029127 chr3 42311742 G A 7.70E-04 Multiple complex diseases / / 17554300 rs11129950 chr3 42314587 A G 8.83E-06 Bipolar disorder / / 21771265 rs9839267 chr3 42332624 T G 0.0000305 Alcohol consumption (Heavy) / / 23422394 rs9683362 chr3 42343321 A G 2.34E-05 Intelligence / / 21826061 rs9311322 chr3 42347749 T C 6.42E-05 Cognitive test performance / / 20125193 rs1442265 chr3 42355010 G A 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1442265 chr3 42355010 G A 7.02E-05 Intelligence / / 21826061 rs17073237 chr3 42368424 T A 1.31E-04 Multiple complex diseases / / 17554300 rs1019188 chr3 42378179 G A 9.99E-05 Lipoproteins / / pha003079 rs17073898 chr3 42388026 A G 5.32E-04 Multiple complex diseases / / 17554300 rs33457 chr3 42403380 A G 3.27E-06 Multiple complex diseases / / 17554300 rs33460 chr3 42404564 A G 2.44E-04 Type 2 diabetes / / 17463246 rs33460 chr3 42404564 A G 9.56E-05 Multiple complex diseases / / 17554300 rs33470 chr3 42408243 G A 1.24E-05 Multiple complex diseases / / 17554300 rs33527 chr3 42408422 T C 7.71E-04 Multiple complex diseases / / 17554300 rs33528 chr3 42409748 T C 4.37E-04 Multiple complex diseases / / 17554300 rs33528 chr3 42409748 T C 9.92E-04 Lymphocyte counts / / 22286170 rs12636553 chr3 42427036 G A 8.06E-05 Alzheimer's disease (late onset) / / 21460841 rs11718659 chr3 42428487 C T 1.60E-05 Alzheimer's disease (late onset) / / 21460841 rs17074351 chr3 42433305 T C 2.90E-05 Urinary metabolites / / 21572414 rs17074351 chr3 42433305 T C 8.27E-05 Left ventricular hypertrophy / / pha003052 rs2286720 chr3 42448471 G A 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) LYZL4 cds-synon 21107309 rs704966 chr3 42472986 G A 4.41E-04 Multiple complex diseases / / 17554300 rs4682961 chr3 42483911 T A 3.50E-06 Urinary metabolites / / 21572414 rs621966 chr3 42495350 T G 1.48E-04 Autism spectrum disorders (language delay) / / 21519539 rs7613206 chr3 42550294 G A 6.16E-04 Multiple complex diseases VIPR1 intron 17554300 rs12493291 chr3 42550651 G A 7.40E-04 Multiple complex diseases VIPR1 intron 17554300 rs4467424 chr3 42553262 G T 2.26E-04 Multiple complex diseases VIPR1 intron 17554300 rs14380 chr3 42578579 A T 2.29E-05 Bipolar disorder VIPR1 UTR-3 19488044 rs14380 chr3 42578579 A T 1.78E-05 Bipolar disorder and schizophrenia VIPR1 UTR-3 20889312 rs14380 chr3 42578579 A T 1.21E-05 Bipolar Disorder VIPR1 UTR-3 pha002858 rs342525 chr3 42585461 G A 1.70E-05 Urinary metabolites / / 21572414 rs339707 chr3 42723827 G T 1.40E-05 Urinary metabolites / / 21572414 rs4371488 chr3 42724452 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs6805421 chr3 42728144 A G 2.94E-04 Schizophrenia(treatment response to risperidone) KBTBD5 missense 19850283 rs6773675 chr3 42774783 C T 8.83E-04 Multiple complex diseases CCDC13 intron 17554300 rs339678 chr3 42799858 T A 8.59E-06 Periodontitis (DPAL) CCDC13 intron 24024966 rs11915803 chr3 42800291 T C 8.68E-04 Alcohol dependence CCDC13 intron 20201924 rs339676 chr3 42800778 G A 6.67E-05 Schizophrenia CCDC13 intron 19571809 rs339676 chr3 42800778 G A 5.84E-05 Schizophrenia CCDC13 intron pha002859 rs339665 chr3 42808071 C T 6.00E-06 Periodontitis (DPAL) CCDC13 intron 24024966 rs339664 chr3 42808493 A G 8.73E-06 Obesity-related traits CCDC13 intron 23251661 rs11717346 chr3 42828546 G A 9.38E-06 Obesity-related traits HIGD1A intron 23251661 rs11129979 chr3 42890731 T C 4.07E-06 Obesity-related traits CCBP2 intron 23251661 rs9815043 chr3 42896639 A G 7.54E-07 Obesity-related traits CCBP2 intron 23251661 rs2228467 chr3 42906116 T C 1.89E-06 Obesity-related traits CCBP2 missense 23251661 rs2228467 chr3 42906116 T C 2.00E-07 Monocyte counts CCBP2 missense 23314186 rs2228468 chr3 42907112 A C,T 2.44E-07 Obesity-related traits CCBP2 missense 23251661 rs2228468 chr3 42907112 A C,T 5.00E-07 Monocyte counts CCBP2 missense 23314186 rs1366046 chr3 42908775 A C 2.44E-07 Obesity-related traits CCBP2 UTR-3 23251661 rs3919627 chr3 42909160 G A 2.00E-07 Obesity-related traits / / 23251661 rs11715464 chr3 42909687 A G 9.14E-07 Obesity-related traits / / 23251661 rs7612912 chr3 42910621 T C 3.73E-07 Obesity-related traits / / 23251661 rs760193 chr3 42918297 C T 7.21E-05 Serum metabolites CYP8B1 nearGene-5 19043545 rs11919400 chr3 43005979 A G 8.83E-06 Obesity-related traits / / 23251661 rs4146792 chr3 43038237 T G 1.99E-04 Amyotrophic lateral sclerosis (sporadic) FAM198A intron 24529757 rs536119 chr3 43095101 A G 6.33E-05 Weight loss (gastric bypass surgery) FAM198A missense 23643386 rs2867 chr3 43120835 T G 3.75E-04 Type 2 diabetes C3orf39 UTR-3 17463246 rs2936818 chr3 43122966 G A,C,T 1.85E-04 Smoking initiation C3orf39 UTR-5 24665060 rs488069 chr3 43132444 C T 7.60E-07 Malaria C3orf39 intron 19465909 rs12639294 chr3 43150736 C G 2.15E-04 Glycosylated haemoglobin levels / / 17255346 rs7648947 chr3 43174229 G A 4.13E-04 Smoking initiation / / 24665060 rs12629249 chr3 43191899 C A 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs938922 chr3 43214678 A C 6.15E-04 Acute lung injury / / 22295056 rs17075286 chr3 43230723 C G 8.00E-07 Bipolar disorder and schizophrenia / / 21057379 rs6800874 chr3 43234782 C G 9.18E-04 Insulin resistance / / 21901158 rs6808396 chr3 43294971 T C 1.62E-05 Orofacial clefts / / 22419666 rs6767019 chr3 43297689 A C 9.00E-06 Obesity-related traits / / 23251661 rs7646966 chr3 43300871 C A 2.08E-04 Parkinson's disease / / 21044948 rs1320163 chr3 43303296 A G 2.46E-04 Parkinson's disease / / 21044948 rs1320163 chr3 43303296 A G 8.94E-05 Orofacial clefts / / 22419666 rs7621298 chr3 43383641 A G 6.03E-04 Type 2 diabetes SNRK intron 17463246 rs17075600 chr3 43401268 G A 5.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1848069 chr3 43417349 T C 1.48E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs17075630 chr3 43417495 T C 0.000147553 Hypertension (early onset hypertension) ANO10 intron 22479346 rs17075630 chr3 43417495 T C 2.57E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs17473118 chr3 43443534 G A 2.33E-07 Obesity-related traits ANO10 intron 23251661 rs1105263 chr3 43445129 G A 6.77E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs7650267 chr3 43467895 T C 2.00E-07 Obesity-related traits ANO10 intron 23251661 rs11710107 chr3 43473914 A C 7.50E-05 Alcoholism (heaviness of drinking) ANO10 intron 21529783 rs2888312 chr3 43484967 G A 7.70E-05 Alcoholism (heaviness of drinking) ANO10 intron 21529783 rs6802567 chr3 43537085 T C 1.34E-05 Stroke ANO10 intron pha002886 rs17075780 chr3 43575362 T C 5.28E-04 Multiple complex diseases ANO10 intron 17554300 rs17409162 chr3 43591327 G A 2.17E-05 Self-reported allergy ANO10 missense 23817569 rs1013758 chr3 43626375 G A 0.000807718 Hypertension (early onset hypertension) ANO10 intron 22479346 rs6800306 chr3 43658845 G A 7.35E-04 Type 2 diabetes ANO10 intron 17463246 rs4432612 chr3 43700292 T C 5.04E-05 Post-operative nausea and vomiting / / 21694509 rs9831161 chr3 43768018 G A 9.61E-04 Alzheimer's disease / / 24755620 rs740836 chr3 43794560 A G 6.12E-04 Tourette syndrome / / 22889924 rs1076413 chr3 43795310 T C 9.97E-04 Multiple complex diseases / / 17554300 rs4073774 chr3 43836717 A G 3.44E-04 Type 2 diabetes / / 17463246 rs4535201 chr3 43880640 A G 1.96E-04 Heart Failure / / pha002885 rs6790122 chr3 43909699 T A 2.93E-05 Chronic obstructive pulmonary disease / / 19300482 rs6790122 chr3 43909699 T A 7.00E-06 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6785433 chr3 43964265 A G 6.81E-04 Type 2 diabetes / / 22158537 rs9836268 chr3 43965755 T G 6.92E-06 Type 2 diabetes / / 22158537 rs11708363 chr3 43966585 G A 9.78E-04 Type 2 diabetes / / 22158537 rs6801252 chr3 43967803 T C 6.46E-06 Type 2 diabetes / / 22158537 rs6809522 chr3 43967899 G T 6.65E-06 Type 2 diabetes / / 22158537 rs7634369 chr3 43968636 C T 1.01E-06 Type 2 diabetes / / 22158537 rs6441805 chr3 43968796 G A 6.49E-06 Type 2 diabetes / / 22158537 rs6441806 chr3 43968819 T C 9.39E-07 Type 2 diabetes / / 22158537 rs6804956 chr3 43969244 T C 6.75E-06 Type 2 diabetes / / 22158537 rs7641395 chr3 43972203 T C 1.67E-05 Type 2 diabetes / / 22158537 rs9861276 chr3 43989595 C T 9.47E-04 Type 2 diabetes / / 22158537 rs6782500 chr3 43990260 G A 2.41E-04 Type 2 diabetes / / 22158537 rs4682924 chr3 43992760 G A 6.97E-04 Type 2 diabetes / / 22158537 rs11917885 chr3 44008013 C T 7.15E-04 Multiple complex diseases / / 17554300 rs11917885 chr3 44008013 C T 8.46E-04 Type 2 diabetes / / 22158537 rs1524887 chr3 44016371 C T 1.79E-05 Type 2 diabetes / / 22158537 rs9858826 chr3 44031412 A G 9.76E-04 Multiple complex diseases / / 17554300 rs2372580 chr3 44049945 A G 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11718455 chr3 44056898 C T 0.000122 Coronary artery disease / / 23202125 rs7635417 chr3 44074449 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7635417 chr3 44074449 C T 7.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs7635417 chr3 44074449 C T 9.21E-05 Cognitive impairment induced by topiramate / / 22091778 rs9881814 chr3 44111902 C A 9.58E-05 Eosinophil counts / / pha003088 rs7626631 chr3 44197258 C T 8.70E-07 Urinary metabolites / / 21572414 rs1110330 chr3 44222317 G A 6.42E-05 Glucose levels / / pha003057 rs1105023 chr3 44222351 T G 3.46E-05 Glucose levels / / pha003058 rs4682718 chr3 44226332 A G 1.16E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6808448 chr3 44243607 G T 6.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4682949 chr3 44245155 T C 3.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10510740 chr3 44254630 T C 8.81E-04 Lymphocyte counts / / 22286170 rs10510741 chr3 44264194 G A 3.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4392391 chr3 44272966 G A 4.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4392391 chr3 44272966 G A 5.78E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs967285 chr3 44275276 C T 1.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs967285 chr3 44275276 C T 8.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9852733 chr3 44277339 C T 4.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9846155 chr3 44282840 A G 6.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809107 chr3 44282934 G A 1.46E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809107 chr3 44282934 G A 5.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9284879 chr3 44284584 G A 1.10E-04 Statin-induced myopathy C3orf77 missense 21826682 rs9284879 chr3 44284584 G A 8.41E-04 Obesity (extreme) C3orf77 missense 21935397 rs9284879 chr3 44284584 G A 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 missense 24483146 rs1488623 chr3 44291850 C T 8.30E-04 Obesity (extreme) C3orf77 intron 21935397 rs2171569 chr3 44292399 A G 8.25E-04 Obesity (extreme) C3orf77 intron 21935397 rs13067367 chr3 44293275 T C 9.30E-04 Obesity (extreme) C3orf77 intron 21935397 rs9311352 chr3 44293839 C G 8.22E-04 Obesity (extreme) C3orf77 intron 21935397 rs4682735 chr3 44295184 T C 8.18E-04 Obesity (extreme) C3orf77 intron 21935397 rs4682960 chr3 44296403 T C 8.15E-04 Obesity (extreme) C3orf77 intron 21935397 rs7631790 chr3 44299205 C T 8.10E-04 Obesity (extreme) C3orf77 intron 21935397 rs7631790 chr3 44299205 C T 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1124124 chr3 44302545 A T 8.07E-04 Obesity (extreme) C3orf77 intron 21935397 rs9821268 chr3 44303124 A G 8.06E-04 Obesity (extreme) C3orf77 intron 21935397 rs9821268 chr3 44303124 A G 2.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs11130023 chr3 44307888 A G 8.02E-04 Obesity (extreme) C3orf77 intron 21935397 rs12631341 chr3 44309268 A G 8.01E-04 Obesity (extreme) C3orf77 intron 21935397 rs12631341 chr3 44309268 A G 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs6768749 chr3 44309620 G T 7.98E-04 Obesity (extreme) C3orf77 intron 21935397 rs7349467 chr3 44314778 C T 7.95E-04 Obesity (extreme) C3orf77 intron 21935397 rs1387046 chr3 44324114 C G 7.94E-04 Obesity (extreme) C3orf77 intron 21935397 rs12486452 chr3 44324565 G A 7.91E-04 Obesity (extreme) C3orf77 intron 21935397 rs12486452 chr3 44324565 G A 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs7649004 chr3 44325471 G C 7.89E-04 Obesity (extreme) C3orf77 intron 21935397 rs6803491 chr3 44333153 T A 7.79E-04 Obesity (extreme) C3orf77 intron 21935397 rs13323323 chr3 44333324 G T 4.00E-06 IgG glycosylation C3orf77 intron 23382691 rs1565215 chr3 44334099 T C 7.70E-04 Obesity (extreme) C3orf77 intron 21935397 rs1565215 chr3 44334099 T C 2.64E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1565215 chr3 44334099 T C 7.67E-04 Response to cytadine analogues (cytosine arabinoside) C3orf77 intron 24483146 rs1565214 chr3 44334299 C A 7.69E-04 Obesity (extreme) C3orf77 intron 21935397 rs1565214 chr3 44334299 C A 1.35E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1565214 chr3 44334299 C A 6.62E-04 Response to cytadine analogues (cytosine arabinoside) C3orf77 intron 24483146 rs6780605 chr3 44338242 G A 7.65E-04 Obesity (extreme) C3orf77 intron 21935397 rs1488638 chr3 44342654 A C 7.62E-04 Obesity (extreme) C3orf77 intron 21935397 rs2372598 chr3 44343362 T C 7.60E-04 Obesity (extreme) C3orf77 intron 21935397 rs7630980 chr3 44348123 A G 7.45E-04 Obesity (extreme) C3orf77 intron 21935397 rs9853705 chr3 44353145 T G 7.03E-04 Obesity (extreme) C3orf77 intron 21935397 rs12386385 chr3 44457540 A G 7.98E-04 Obesity (extreme) / / 21935397 rs12108134 chr3 44543030 C T 6.80E-06 Urinary metabolites ZNF852 intron 21572414 rs1402751 chr3 44594030 C A 8.53E-04 Obesity (extreme) / / 21935397 rs149108320 chr3 44635975 G A 0.000014 Breast cancer(er negative) ZNF660 missense 23555315 rs1402752 chr3 44687300 G A 6.63E-04 Alzheimer's disease ZNF197 intron 21059989 rs1402752 chr3 44687300 G A 8.69E-06 Alzheimer's disease ZNF197 intron 21059989 rs4429669 chr3 44775325 A G 1.96E-05 Lymphocyte counts ZNF501 intron 22286170 rs9849390 chr3 44868381 G T 5.00E-06 Urinary metabolites KIF15 intron 21572414 rs7621143 chr3 44915992 T G 5.40E-06 Urinary metabolites / / 21572414 rs1532898 chr3 44922141 A C 7.37E-05 Interstitial lung disease TGM4 intron 23583980 rs9816639 chr3 44934381 A G 2.70E-05 Urinary metabolites TGM4 intron 21572414 rs6765789 chr3 44938586 A C 2.58E-11 Metabolite levels TGM4 intron 22286219 rs6768893 chr3 44939120 T C 2.66E-05 Height TGM4 intron pha003011 rs1995641 chr3 44943389 G A 8.70E-04 Coronary heart disease TGM4 missense 21971053 rs142655195 chr3 44943399 C A 0.00077 Breast cancer TGM4 missense 23555315 rs3749189 chr3 44986836 T C 6.60E-05 Memory performance ZDHHC3 intron 22105620 rs9835136 chr3 45036175 G A 1.41E-06 Lymphocyte counts EXOSC7 intron 22286170 rs6805138 chr3 45071538 A G 6.20E-05 HIV-1 control CLEC3B intron 20041166 rs2372851 chr3 45076308 A T 6.30E-11 Metabolite levels CLEC3B intron 22286219 rs4683029 chr3 45076823 A G 3.50E-05 Lipid levels CLEC3B intron 18193043 rs11924100 chr3 45083741 T C 4.36E-04 Smoking initiation / / 24665060 rs10514712 chr3 45083928 T C 8.07E-05 Alcohol and nictotine co-dependence / / 20158304 rs2372856 chr3 45111448 C A 6.80E-04 Urinary metabolites / / 21572414 rs6773576 chr3 45117173 A G 5.25E-04 White matter integrity / / 22425255 rs4682765 chr3 45125566 C T 0.00013 fMRI brain tests in schizophrenia CDCP1 UTR-3 22440650 rs7618923 chr3 45130725 C T 2.38E-04 Hemoglobin concentration CDCP1 intron 20534544 rs3749191 chr3 45134822 T C 7.45E-04 Coronary heart disease CDCP1 missense 21971053 rs3749191 chr3 45134822 T C 0.000021 Erectile dysfunction after radiotherapy for prostate cancer CDCP1 missense 23021708 rs2037358 chr3 45137087 T G 6.98E-05 Attention deficit hyperactivity disorder CDCP1 intron 22420046 rs4579052 chr3 45145019 G T 0.0000557 Panic disorder CDCP1 intron 23149450 rs4579052 chr3 45145019 G T 5.57E-05 Serum tamsulosin hydrochloride concentration CDCP1 intron 23151678 rs5007171 chr3 45149708 A G 2.17E-07 Multiple complex diseases CDCP1 intron 17554300 rs5007171 chr3 45149708 A G 3.10E-04 Urinary metabolites CDCP1 intron 21572414 rs12494480 chr3 45154357 G A 5.84E-04 Smoking quantity CDCP1 intron 24665060 rs4683049 chr3 45160335 G C 7.79E-05 Femoral neck bone geometry CDCP1 intron 22087292 rs6794913 chr3 45163449 A G 2.50E-04 Urinary metabolites CDCP1 intron 21572414 rs4683077 chr3 45210212 G A 8.49E-04 Multiple complex diseases / / 17554300 rs12330287 chr3 45212132 C T 1.30E-04 Urinary metabolites / / 21572414 rs4524316 chr3 45212443 T G 1.90E-04 Urinary metabolites / / 21572414 rs9850250 chr3 45213371 T A 6.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs9850250 chr3 45213371 T A 7.30E-05 Urinary metabolites / / 21572414 rs9817295 chr3 45215803 G A 4.30E-04 Urinary metabolites / / 21572414 rs4683079 chr3 45215992 C G 1.90E-05 Urinary metabolites / / 21572414 rs4683081 chr3 45216880 A G 2.60E-04 Urinary metabolites / / 21572414 rs6767173 chr3 45220085 T C 8.47E-05 Response to citalopram treatment / / 19846067 rs17077435 chr3 45227101 G A 7.00E-04 Multiple complex diseases / / 17554300 rs17077435 chr3 45227101 G A 7.11E-04 Aortic root size / / 21223598 rs17077435 chr3 45227101 G A 2.20E-04 Smoking initiation / / 24665060 rs33731 chr3 45249923 T C 1.98E-06 Serum metabolites / / 19043545 rs28294 chr3 45256191 C G 8.46E-06 Serum metabolites / / 19043545 rs33741 chr3 45257947 T C 4.27E-04 Smoking initiation / / 24665060 rs6773435 chr3 45268654 G A,T 2.15E-04 Smoking initiation / / 24665060 rs33762 chr3 45278332 A C 1.76E-04 Type 2 diabetes / / 17463246 rs33767 chr3 45281604 G A 1.28E-05 Serum metabolites / / 19043545 rs33769 chr3 45282000 C T 9.00E-04 Urinary metabolites / / 21572414 rs33773 chr3 45284315 G A 1.12E-05 Serum metabolites / / 19043545 rs33773 chr3 45284315 G A 2.71E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs28288 chr3 45290007 G A 8.66E-06 Serum metabolites / / 19043545 rs28288 chr3 45290007 G A 2.77E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs33786 chr3 45293379 G A 8.55E-04 Alcohol dependence / / 20201924 rs33794 chr3 45300605 A G 5.82E-06 Serum metabolites / / 19043545 rs33794 chr3 45300605 A G 6.00E-06 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs33798 chr3 45303313 G A 2.02E-04 Multiple complex diseases / / 17554300 rs12633044 chr3 45307445 A C 3.05E-05 Body Mass Index / / pha003019 rs2215708 chr3 45311618 G A 5.55E-04 Alzheimer's disease / / 17998437 rs33801 chr3 45314894 T G 4.20E-04 Multiple complex diseases / / 17554300 rs7650391 chr3 45325521 A G 3.02E-05 Body Mass Index / / pha003019 rs7650391 chr3 45325521 A G 5.32E-05 Body Mass Index / / pha003022 rs33805 chr3 45327512 C T 3.80E-05 Body Mass Index / / pha003019 rs33805 chr3 45327512 C T 6.05E-05 Body Mass Index / / pha003022 rs4464495 chr3 45328423 C G 4.53E-04 Multiple complex diseases / / 17554300 rs33807 chr3 45334692 G A 2.80E-07 Urinary metabolites / / 21572414 rs9861198 chr3 45335390 C T 9.07E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9809772 chr3 45335495 T C 2.01E-06 C-reactive protein / / 22492993 rs854195 chr3 45342242 C T 5.90E-04 Urinary metabolites / / 21572414 rs9816196 chr3 45346378 C T 6.70E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6441911 chr3 45347519 C A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9878275 chr3 45356039 A C 8.31E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9846284 chr3 45356966 G A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9850725 chr3 45357427 G A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9867344 chr3 45360872 G C 1.70E-06 C-reactive protein / / 22492993 rs854213 chr3 45374553 C T 3.97E-04 Multiple complex diseases / / 17554300 rs17077682 chr3 45375070 C G 6.10E-04 Multiple complex diseases / / 17554300 rs854215 chr3 45379597 G A 2.17E-06 C-reactive protein / / 22492993 rs146692665 chr3 45384683 G T 3.00E-06 Acne (severe) / / 24927181 rs11711985 chr3 45396036 C G 2.40E-04 Urinary metabolites / / 21572414 rs17077726 chr3 45397582 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs17637580 chr3 45436473 G A 2.82E-04 Cholesterol LARS2 intron 17255346 rs11707177 chr3 45441280 C G 5.70E-04 Urinary metabolites LARS2 intron 21572414 rs13084381 chr3 45444155 A C 5.99E-04 Smoking initiation LARS2 intron 24665060 rs17576051 chr3 45449980 A G 8.20E-09 Urinary metabolites LARS2 intron 21572414 rs17576051 chr3 45449980 A G 0.0000284 Migraine LARS2 intron 22678113 rs17576051 chr3 45449980 A G 2.84E-05 Migraine LARS2 intron 22683712 rs41480152 chr3 45451623 C T 4.56E-04 Smoking initiation LARS2 intron 24665060 rs62244094 chr3 45470723 G T 5.40E-09 Urinary metabolites LARS2 intron 21572414 rs2014378 chr3 45476486 A G 1.71E-04 Smoking initiation LARS2 intron 24665060 rs4682785 chr3 45479698 T C 7.39E-04 Smoking initiation LARS2 intron 24665060 rs2063810 chr3 45483897 G A 6.08E-05 Multiple complex diseases LARS2 intron 17554300 rs1877960 chr3 45496144 G A 5.35E-05 Cognitive impairment induced by topiramate LARS2 intron 22091778 rs965238 chr3 45497671 G A 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) LARS2 intron 22010049 rs3774692 chr3 45507305 T A 5.88E-05 Serum metabolites LARS2 intron 19043545 rs3774692 chr3 45507305 T A 1.52E-04 Smoking initiation LARS2 intron 24665060 rs4683118 chr3 45528134 T A 7.17E-05 Bipolar disorder and schizophrenia LARS2 intron 20889312 rs17639812 chr3 45536988 T C 2.80E-05 Urinary metabolites LARS2 intron 21572414 rs62243387 chr3 45543950 C A 5.70E-04 Urinary metabolites LARS2 intron 21572414 rs2128358 chr3 45549028 T C 9.24E-04 Amyotrophic lateral sclerosis (sporadic) LARS2 intron 24529757 rs17260680 chr3 45596445 C T 1.70E-07 Urinary metabolites / / 21572414 rs267241 chr3 45618309 G A 1.10E-05 Urinary metabolites / / 21572414 rs13084796 chr3 45619988 C T 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1021124 chr3 45623774 G A 6.47E-04 White matter integrity / / 22425255 rs1021124 chr3 45623774 G A 7.26E-05 Lymphocyte counts / / pha003094 rs1021124 chr3 45623774 G A 3.41E-05 Neutrophil count / / pha003095 rs267216 chr3 45632221 A G 1.65E-04 Multiple complex diseases / / 17554300 rs267235 chr3 45640227 A C 1.20E-04 Urinary metabolites LIMD1 intron 21572414 rs267234 chr3 45640732 G A 8.00E-04 Urinary metabolites LIMD1 intron 21572414 rs267233 chr3 45642223 C G 6.50E-04 Urinary metabolites LIMD1 intron 21572414 rs267232 chr3 45644183 G A 7.50E-05 Urinary metabolites LIMD1 intron 21572414 rs13097531 chr3 45645082 C T 5.70E-04 Urinary metabolites LIMD1 intron 21572414 rs13094545 chr3 45647523 T A 3.60E-04 Urinary metabolites LIMD1 intron 21572414 rs12630731 chr3 45648015 C T 5.50E-04 Urinary metabolites LIMD1 intron 21572414 rs12330308 chr3 45648926 G C 4.00E-04 Urinary metabolites LIMD1 intron 21572414 rs13085281 chr3 45650380 C G 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267208 chr3 45652046 G A 2.80E-06 Urinary metabolites LIMD1 intron 21572414 rs187884 chr3 45652055 G T 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267209 chr3 45652161 G A 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267210 chr3 45652275 C T 5.10E-04 Urinary metabolites LIMD1 intron 21572414 rs267211 chr3 45652393 A G 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267212 chr3 45652734 A G 5.30E-04 Urinary metabolites LIMD1 intron 21572414 rs267213 chr3 45653283 G A 5.30E-04 Urinary metabolites LIMD1 intron 21572414 rs267228 chr3 45656723 G A 1.00E-04 Urinary metabolites LIMD1 intron 21572414 rs267230 chr3 45659356 T C 5.20E-04 Urinary metabolites LIMD1 intron 21572414 rs34996077 chr3 45662650 C T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs3774675 chr3 45667387 T C 2.70E-04 Urinary metabolites LIMD1 intron 21572414 rs4683131 chr3 45667989 G A 4.45E-05 Cognitive impairment induced by topiramate LIMD1 intron 22091778 rs58879887 chr3 45668729 A T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs62242172 chr3 45671204 C T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs893563 chr3 45672210 G A 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs9311374 chr3 45672925 C T 3.18E-04 Multiple complex diseases LIMD1 intron 17554300 rs3774670 chr3 45673090 C T 1.30E-04 Urinary metabolites LIMD1 intron 21572414 rs7648681 chr3 45677398 G A 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs36136468 chr3 45677782 G A 7.50E-05 Urinary metabolites LIMD1 intron 21572414 rs13082607 chr3 45680581 T C 8.50E-04 Urinary metabolites LIMD1 intron 21572414 rs36002900 chr3 45682685 G A 7.10E-04 Urinary metabolites LIMD1 intron 21572414 rs34355059 chr3 45682897 C T 7.10E-04 Urinary metabolites LIMD1 intron 21572414 rs7648441 chr3 45683107 G A 4.56E-04 Suicide attempts in bipolar disorder LIMD1 intron 21423239 rs62242182 chr3 45683363 G A 2.70E-04 Urinary metabolites LIMD1 intron 21572414 rs1866402 chr3 45684955 C T 2.80E-04 Urinary metabolites LIMD1 intron 21572414 rs13094441 chr3 45688319 T A 3.10E-04 Urinary metabolites LIMD1 intron 21572414 rs34448158 chr3 45689473 T G 7.90E-04 Urinary metabolites LIMD1 intron 21572414 rs11710266 chr3 45690222 C T 1.40E-04 Urinary metabolites LIMD1 intron 21572414 rs35321098 chr3 45692006 G A 3.10E-04 Urinary metabolites LIMD1 intron 21572414 rs11709753 chr3 45694685 C T 1.70E-04 Urinary metabolites LIMD1 intron 21572414 rs2742408 chr3 45697817 A G 9.68E-04 Suicide attempts in bipolar disorder LIMD1 intron 21423239 rs2118752 chr3 45700125 A G 6.90E-04 Urinary metabolites LIMD1 intron 21572414 rs2578694 chr3 45701455 T C 1.70E-04 Urinary metabolites LIMD1 intron 21572414 rs12493946 chr3 45706167 C T 9.30E-04 Alzheimer's disease LIMD1 intron 17998437 rs2673023 chr3 45711367 T C 3.30E-04 Urinary metabolites LIMD1 intron 21572414 rs1318992 chr3 45711735 T C 3.30E-04 Urinary metabolites LIMD1 intron 21572414 rs2016681 chr3 45712280 G C 3.20E-04 Urinary metabolites LIMD1 intron 21572414 rs1962892 chr3 45712301 C T 3.20E-04 Urinary metabolites LIMD1 intron 21572414 rs2578679 chr3 45715688 G A 5.10E-04 Urinary metabolites LIMD1 intron 21572414 rs2742417 chr3 45731451 C T 5.00E-07 Response to antidepressant treatment SACM1L intron 22041458 rs3774666 chr3 45731732 A C 7.00E-08 Urinary metabolites SACM1L intron 21572414 rs2673051 chr3 45732409 G T 9.77E-04 White matter integrity SACM1L intron 22425255 rs11707239 chr3 45735152 A G 1.81E-04 Multiple complex diseases SACM1L intron 17554300 rs2742424 chr3 45735218 G A 5.26E-04 Alzheimer's disease SACM1L intron 17998437 rs2742424 chr3 45735218 G A 9.56E-05 Serum metabolites SACM1L intron 19043545 rs56331328 chr3 45737844 C T 3.70E-09 Urinary metabolites SACM1L intron 21572414 rs2742369 chr3 45754487 C A 9.77E-04 White matter integrity SACM1L intron 22425255 rs13086080 chr3 45762725 C T 9.70E-08 Urinary metabolites SACM1L intron 21572414 rs62242217 chr3 45767174 C T 1.50E-05 Urinary metabolites SACM1L intron 21572414 rs17078258 chr3 45773963 A G 7.16E-05 Multiple complex diseases SACM1L intron 17554300 rs2742461 chr3 45774501 C G 6.59E-04 Multiple complex diseases SACM1L intron 17554300 rs12490575 chr3 45792209 C T 4.35E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12495593 chr3 45795498 A G 2.50E-05 Urinary metabolites / / 21572414 rs4683139 chr3 45796429 A G 7.73E-04 Alzheimer's disease / / 17998437 rs9864354 chr3 45801912 C T 6.00E-12 Urinary metabolites SLC6A20 intron 21572414 rs2286489 chr3 45804069 C T 6.50E-04 Urinary metabolites SLC6A20 intron 21572414 rs6770261 chr3 45804734 C T 8.30E-06 Urinary metabolites SLC6A20 intron 21572414 rs9857669 chr3 45806066 C T 5.30E-09 Urinary metabolites SLC6A20 intron 21572414 rs9867918 chr3 45807699 G C 2.50E-11 Urinary metabolites SLC6A20 intron 21572414 rs4327428 chr3 45809329 C A 6.40E-12 Urinary metabolites SLC6A20 intron 21572414 rs4327428 chr3 45809329 C A 3.00E-12 Blood metabolite levels SLC6A20 intron 24816252 rs2108918 chr3 45809829 A G 2.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs2108917 chr3 45809843 A G 2.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs6768156 chr3 45810604 A T 4.20E-05 Urinary metabolites SLC6A20 intron 21572414 rs9818982 chr3 45812514 G A 1.40E-10 Urinary metabolites SLC6A20 intron 21572414 rs17279437 chr3 45814094 G A 3.00E-19 Urinary metabolites SLC6A20 missense 21572414 rs17279437 chr3 45814094 G A 1.00E-20 Blood metabolite levels SLC6A20 missense 24816252 rs17279437 chr3 45814094 G A 2.00E-35 Blood metabolite ratios SLC6A20 missense 24816252 rs17279465 chr3 45814748 A G 2.20E-04 Blood pressure SLC6A20 intron 21228793 rs758386 chr3 45817418 A G 2.00E-07 Immune reponse to smallpox (secreted TNF-alpha) SLC6A20 cds-synon 22610502 rs17078335 chr3 45818419 A G 0.00067 Salmonella-induced pyroptosis SLC6A20 intron 22837397 rs2742396 chr3 45819701 C T 2.70E-04 Urinary metabolites SLC6A20 intron 21572414 rs2531748 chr3 45819837 A G 7.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs2252547 chr3 45821624 T C 3.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs1860263 chr3 45832052 A T 1.31E-04 Type 2 diabetes SLC6A20 intron 17463246 rs13064991 chr3 45834811 G T 4.60E-05 Type 2 diabetes SLC6A20 intron 17293876 rs17763742 chr3 45846769 A G 3.38E-04 Multiple complex diseases / / 17554300 rs2531757 chr3 45850520 C A 8.00E-04 Urinary metabolites / / 21572414 rs11130076 chr3 45853072 C T 9.36E-06 Uric acid levels / / 21294900 rs17713054 chr3 45859651 G A 2.57E-04 Multiple complex diseases / / 17554300 rs7614952 chr3 45900621 A G 2.34E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1024626 chr3 45902844 G A 7.60E-04 Coronary Artery Disease / / 17634449 rs12639224 chr3 45916222 C T 7.43E-05 Behcet's disease / / pha002888 rs9842595 chr3 45922691 G A,T 1.90E-05 Hepatitis B vaccine response / / 21764829 rs12633699 chr3 45922735 G A 2.89E-04 Insulin resistance / / 21901158 rs12638201 chr3 45934279 G A 1.14E-05 Depression (quantitative trait) CCR9 intron 20800221 rs3774642 chr3 45937782 C G 3.37E-05 Depression (quantitative trait) CCR9 intron 20800221 rs17765088 chr3 45943595 C G 1.80E-05 Urinary metabolites CCR9 UTR-3 21572414 rs1471962 chr3 45949187 G C 4.40E-05 Urinary metabolites / / 21572414 rs12493471 chr3 45951678 T C 1.80E-04 Depression (quantitative trait) / / 20800221 rs9810934 chr3 45954352 A G 4.73E-04 Depression (quantitative trait) / / 20800221 rs7652331 chr3 45962752 T C 4.47E-05 Prostate cancer FYCO1 UTR-3 18073375 rs7652331 chr3 45962752 T C 4.97E-04 Depression (quantitative trait) FYCO1 UTR-3 20800221 rs11130079 chr3 45978473 A G 1.05E-04 HIV-1 viral setpoint FYCO1 intron 21490045 rs2234358 chr3 45989044 T G 9.70E-10 HIV-1 non-progression CXCR6 UTR-3 20704485 rs2234358 chr3 45989044 T G 9.71E-05 Monocyte chemoattractant protein-1 CXCR6 UTR-3 pha003071 rs4388012 chr3 45996501 A G 3.56E-04 Multiple complex diseases FYCO1 intron 17554300 rs1545985 chr3 46005478 G A 6.61E-06 Prostate cancer FYCO1 intron 18073375 rs1545985 chr3 46005478 G A 5.83E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13078739 chr3 46007488 G A 2.87E-05 Multiple complex diseases FYCO1 intron 17554300 rs4683159 chr3 46025013 A G 9.39E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13075758 chr3 46025048 G A 0.0000168 Primary sclerosing cholangitis FYCO1 intron 23603763 rs11130082 chr3 46025518 T C 9.44E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13086858 chr3 46026699 C A 9.51E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13086858 chr3 46026699 C A 5.57E-04 Smoking cessation FYCO1 intron 24665060 rs7653682 chr3 46029271 A G 6.96E-04 Suicide attempts in bipolar disorder FYCO1 intron 21423239 rs1873000 chr3 46029458 G C 9.57E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs7628447 chr3 46030003 C T 9.58E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs2133660 chr3 46031957 C T 8.02E-05 Behcet's disease FYCO1 intron pha002888 rs4683166 chr3 46089341 G C 3.12E-05 Telomere length / / 20139977 rs1500005 chr3 46102620 G A 8.28E-07 Inflammatory biomarkers / / 22291609 rs1388608 chr3 46118749 T G 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9990063 chr3 46123839 T G 4.48E-04 Parkinson's disease / / 17052657 rs17078589 chr3 46124511 G C 3.35E-04 Multiple complex diseases / / 17554300 rs4683177 chr3 46126467 T C 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs6767559 chr3 46127642 G C 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs902760 chr3 46127987 T C 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs751625 chr3 46128080 A G 5.90E-04 Multiple complex diseases / / 17554300 rs6808712 chr3 46131231 G C 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1491952 chr3 46141902 T C 7.16E-04 Multiple complex diseases / / 17554300 rs1873616 chr3 46143602 T C 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1392296 chr3 46143930 A G 5.35E-04 Depression (quantitative trait) / / 20800221 rs2888512 chr3 46145295 T G 0.000862752 Hypertension (early onset hypertension) / / 22479346 rs1546076 chr3 46150517 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1500004 chr3 46150937 G A 8.60E-06 Urinary metabolites / / 21572414 rs1500004 chr3 46150937 G A 9.33E-09 Macrophage inflammatory protein-1b / / 23696881 rs2087727 chr3 46153768 G C 2.10E-04 Urinary metabolites / / 21572414 rs1809733 chr3 46154473 G A 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9820016 chr3 46154841 A C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1388606 chr3 46158434 T C 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs9879257 chr3 46158717 G A 6.37E-04 Multiple complex diseases / / 17554300 rs6807578 chr3 46163873 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs4682811 chr3 46164795 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1388605 chr3 46166734 T C 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2373152 chr3 46170086 G A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2373155 chr3 46172072 T C 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774742 chr3 46173446 A C 0.00000195 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs4683182 chr3 46173936 A G 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7634822 chr3 46174936 G C 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1873618 chr3 46175976 C T 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1873617 chr3 46175980 T C 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10510749 chr3 46180416 C T 2.63E-05 Behcet's disease / / 23291587 rs10510749 chr3 46180416 C T 4.22E-05 Behcet's disease / / pha002888 rs7631551 chr3 46186310 C A 9.40E-05 Response to statin therapy / / 20339536 rs7631551 chr3 46186310 C A 7.95E-05 Behcet's disease / / pha002888 rs7616215 chr3 46205686 C T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7616215 chr3 46205686 C T 8.60E-09 Celiac disease / / 22057235 rs7616215 chr3 46205686 C T 4.00E-13 Behcet's disease / / 23291587 rs13098911 chr3 46235201 C T 3.00E-17 Celiac disease / / 20190752 rs13098911 chr3 46235201 C T 3.00E-17 Asthma / / 21150878 rs13098911 chr3 46235201 C T 3.26E-17 Celiac disease and Rheumatoid arthritis / / 21383967 rs13098911 chr3 46235201 C T 3.26E-17 Multiple sclerosis / / 22190364 rs3176953 chr3 46243718 T A 8.80E-04 Urinary metabolites CCR1 UTR-3 21572414 rs79893749 chr3 46253650 C T 0.000000188 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs79893749 chr3 46253650 C T 0.000000939 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs2373156 chr3 46266379 A T 1.70E-05 Urinary metabolites / / 21572414 rs11919943 chr3 46266726 T C 5.15E-04 Multiple complex diseases / / 17554300 rs11919943 chr3 46266726 T C 2.70E-05 Urinary metabolites / / 21572414 rs7651539 chr3 46268079 C T 1.70E-05 Urinary metabolites / / 21572414 rs13067058 chr3 46273766 G A 6.65E-05 Lymphocyte counts / / 22286170 rs58697594 chr3 46275570 G A 1.00E-04 Urinary metabolites / / 21572414 rs13096142 chr3 46281744 C T 2.35E-05 Multiple complex diseases / / 17554300 rs13096142 chr3 46281744 C T 4.52E-04 Celiac disease / / 23936387 rs13096142 chr3 46281744 C T 4.00E-08 Celiac disease / / 24999842 rs12636651 chr3 46282391 T C 7.00E-09 Monocyte chemoattractant protein-1 / / 23017229 rs12636651 chr3 46282391 T C 7.00E-09 Obesity-related traits / / 23251661 rs201395642 chr3 46284093 G GTAA 8.29E-05 Monocyte chemoattractant protein-1 CCR3 intron pha003071 rs9853223 chr3 46284093 G A 8.29E-05 Monocyte chemoattractant protein-1 CCR3 intron pha003071 rs7652290 chr3 46299765 A G 3.25E-07 Obesity-related traits CCR3 intron 23251661 rs4413345 chr3 46310921 T C 1.86E-06 Obesity-related traits / / 23251661 rs13100243 chr3 46317898 A T 9.38E-04 Multiple complex diseases / / 17554300 rs7371987 chr3 46318508 A G 1.80E-04 Multiple complex diseases / / 17554300 rs4383561 chr3 46320462 T C 9.82E-05 Cognitive performance / / 19734545 rs4383561 chr3 46320462 T C 8.65E-06 Lung adenocarcinoma / / 19836008 rs9839623 chr3 46323859 A G 3.47E-05 Multiple complex diseases / / 17554300 rs9839623 chr3 46323859 A G 7.50E-05 Response to antidepressants / / 19736353 rs7645716 chr3 46336781 G A 9.56E-08 Obesity-related traits / / 23251661 rs9990343 chr3 46339812 A G 4.00E-07 Brain structure / / 20171287 rs9990343 chr3 46339812 A G 1.87E-05 Behcet's disease / / 23291587 rs9990343 chr3 46339812 A G 2.76E-05 Behcet's disease / / pha002888 rs6441958 chr3 46341335 C A 1.32E-05 Multiple complex diseases / / 17554300 rs6441959 chr3 46342429 A G 1.30E-05 Multiple complex diseases / / 17554300 rs11711054 chr3 46345611 G A 6.41E-04 Celiac disease / / 23936387 rs11711054 chr3 46345611 G A 8.80E-08 Celiac disease / / 24999842 rs10510751 chr3 46346025 T G 3.74E-06 Obesity-related traits / / 23251661 rs12494200 chr3 46350538 C T 0.0003602 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12494200 chr3 46350538 C T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs57093591 chr3 46350716 T C 7.30E-05 Urinary metabolites / / 21572414 rs6441960 chr3 46351874 C T 1.72E-04 Multiple complex diseases / / 17554300 rs6441961 chr3 46352384 T C 4.50E-07 Multiple complex diseases / / 17554300 rs6441961 chr3 46352384 T C 3.00E-07 Celiac disease / / 18311140 rs6441961 chr3 46352384 T C 1.66E-05 Type 1 diabetes / / 18978792 rs6441961 chr3 46352384 T C 8.99E-04 Celiac disease / / 23936387 rs6441961 chr3 46352384 T C 6.63E-08 Celiac disease / / 24999842 rs2157057 chr3 46366269 A G 1.33E-06 Multiple complex diseases / / 17554300 rs2157057 chr3 46366269 A G 7.05E-05 Type 1 diabetes / / 18978792 rs2157058 chr3 46366324 C T 3.20E-05 Multiple complex diseases / / 17554300 rs2097282 chr3 46378025 C T 1.10E-20 Celiac disease / / 22057235 rs6441970 chr3 46384169 A G 3.92E-06 Multiple complex diseases / / 17554300 rs113341849 chr3 46384204 G A 1.37E-11 Macrophage inflammatory protein-1b / / 23696881 rs6441971 chr3 46391071 C T 4.33E-06 Multiple complex diseases / / 17554300 rs3918357 chr3 46393970 C A 8.49E-08 Inflammatory biomarkers CCR2 nearGene-5 22291609 rs3092962 chr3 46397039 G A 4.54E-06 Multiple complex diseases CCR2 intron 17554300 rs1799864 chr3 46399208 G A 2.82E-06 Obesity-related traits CCR2 missense 23251661 rs1799865 chr3 46399798 T C 5.99E-07 Multiple complex diseases CCR2 cds-synon 17554300 rs743660 chr3 46402018 G A 5.61E-06 Multiple complex diseases CCR2 UTR-3 17554300 rs3092957 chr3 46403961 G A 2.36E-04 Multiple complex diseases / / 17554300 rs3136536 chr3 46409636 C T 1.52E-04 Birth weight CCR5 nearGene-5 17255346 rs11575821 chr3 46422355 G A 7.29E-04 Multiple complex diseases / / 17554300 rs11575821 chr3 46422355 G A 1.40E-04 Urinary metabolites / / 21572414 rs7652037 chr3 46423063 A C 7.32E-04 Multiple complex diseases / / 17554300 rs7652037 chr3 46423063 A C 2.34E-05 HIV-1 control / / 20041166 rs7652037 chr3 46423063 A C 1.50E-04 Urinary metabolites / / 21572414 rs6441975 chr3 46428190 A C 5.00E-06 AIDS progression / / 21502085 rs17782636 chr3 46440072 T G 6.17E-04 Multiple complex diseases / / 17554300 rs916093 chr3 46444794 T C 2.60E-04 Urinary metabolites / / 21572414 rs11574428 chr3 46446721 T A 1.60E-04 Urinary metabolites / / 21572414 rs11574428 chr3 46446721 T A 0.000387 Salmonella-induced pyroptosis / / 22837397 rs6808835 chr3 46449864 G T 6.73E-05 HIV-1 control CCRL2 cds-synon 20041166 rs6808835 chr3 46449864 G T 2.80E-04 Urinary metabolites CCRL2 cds-synon 21572414 rs6441977 chr3 46450072 G A 2.07E-05 HIV-1 control CCRL2 missense 20041166 rs6441977 chr3 46450072 G A 9.80E-05 Urinary metabolites CCRL2 missense 21572414 rs6441977 chr3 46450072 G A 0.000258 Salmonella-induced pyroptosis CCRL2 missense 22837397 rs2157062 chr3 46451647 C T 3.40E-04 Urinary metabolites / / 21572414 rs1015164 chr3 46451680 A G 9.00E-06 AIDS progression / / 21502085 rs6762266 chr3 46452863 T C 9.50E-04 Multiple complex diseases / / 17554300 rs6762266 chr3 46452863 T C 1.80E-04 Urinary metabolites / / 21572414 rs6762266 chr3 46452863 T C 0.000703 Salmonella-induced pyroptosis / / 22837397 rs6791599 chr3 46458942 G A 1.70E-04 Urinary metabolites / / 21572414 rs7613132 chr3 46460163 A G 8.26E-05 Hearing function / / 17255346 rs7623238 chr3 46460351 G A 9.21E-05 Hearing function / / 17255346 rs4630979 chr3 46460718 G C 1.19E-04 Hearing function / / 17255346 rs2097276 chr3 46460794 G T 9.11E-05 Hearing function / / 17255346 rs7624805 chr3 46463424 A G 6.56E-05 Cervical cancer / / 24700089 rs6441991 chr3 46484283 T A 1.36E-04 Multiple complex diseases LTF intron 17554300 rs6441991 chr3 46484283 T A 4.80E-05 Celiac disease LTF intron 22057235 rs17141154 chr3 46491267 G A 6.21E-04 Femoral neck bone geometry LTF intron 20175129 rs11707471 chr3 46498865 T G 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTF intron 20877124 rs11707471 chr3 46498865 T G 1.73E-04 Arthritis (juvenile idiopathic) LTF intron 22354554 rs141854619 chr3 46501168 A T 0.0004 Breast cancer LTF missense 23555315 rs1126478 chr3 46501213 T C 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTF missense 20877124 rs1520483 chr3 46510209 C T 1.81E-04 Femoral neck bone geometry / / 20175129 rs1520483 chr3 46510209 C T 7.14E-04 Femoral neck bone geometry / / 20175129 rs7641783 chr3 46514272 T C 4.06E-04 Femoral neck bone geometry / / 20175129 rs7641783 chr3 46514272 T C 6.56E-05 Femoral neck bone geometry / / 20175129 rs7644995 chr3 46530169 C T 9.81E-06 Lung adenocarcinoma / / 19836008 rs883739 chr3 46538018 G T 4.99E-05 Femoral neck bone geometry / / 20175129 rs883739 chr3 46538018 G T 8.87E-05 Femoral neck bone geometry / / 20175129 rs7430431 chr3 46541147 T C 1.61E-07 Femoral neck bone geometry RTP3 intron 20175129 rs7430431 chr3 46541147 T C 1.92E-06 Femoral neck bone geometry RTP3 intron 20175129 rs11130094 chr3 46541503 G A 2.49E-04 Femoral neck bone geometry RTP3 intron 20175129 rs10514713 chr3 46543617 C A 2.68E-04 Femoral neck bone geometry / / 20175129 rs10514713 chr3 46543617 C A 3.09E-04 Femoral neck bone geometry / / 20175129 rs17030627 chr3 46556948 T G 1.89E-04 HIV-1 viral setpoint LRRC2 UTR-3 17641165 rs6791703 chr3 46569721 G T 2.93E-04 Multiple complex diseases LRRC2 intron 17554300 rs6791703 chr3 46569721 G T 1.80E-04 Femoral neck bone geometry LRRC2 intron 20175129 rs6791703 chr3 46569721 G T 8.69E-07 Femoral neck bone geometry LRRC2 intron 20175129 rs9810340 chr3 46584172 A T 1.12E-04 Multiple complex diseases LRRC2 intron 17554300 rs9810340 chr3 46584172 A T 5.33E-07 Femoral neck bone geometry LRRC2 intron 20175129 rs9810340 chr3 46584172 A T 7.70E-05 Femoral neck bone geometry LRRC2 intron 20175129 rs7648827 chr3 46586179 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) LRRC2 intron 20708005 rs11710224 chr3 46586278 C G 0.0000782 Coronary artery disease LRRC2 intron 23202125 rs1879325 chr3 46593147 A G 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC2 intron 20877124 rs13321616 chr3 46595169 G A 3.10E-04 Urinary metabolites LRRC2 intron 21572414 rs2280410 chr3 46599937 T C 5.74E-07 Non-albumin protein levels LRRC2 intron 22558069 rs2280411 chr3 46599984 A G 1.20E-04 Urinary metabolites LRRC2 intron 21572414 rs2280412 chr3 46600068 A G 7.00E-04 Urinary metabolites LRRC2 intron 21572414 rs17078953 chr3 46601753 C T 6.50E-04 Urinary metabolites LRRC2 intron 21572414 rs3827494 chr3 46602231 A G 8.60E-05 Urinary metabolites LRRC2 intron 21572414 rs2139633 chr3 46602736 A G 7.50E-05 Urinary metabolites LRRC2 intron 21572414 rs9822457 chr3 46603951 C T 7.80E-05 Urinary metabolites LRRC2 intron 21572414 rs9822459 chr3 46603955 C T 4.60E-04 Urinary metabolites LRRC2 intron 21572414 rs2385855 chr3 46604586 A G 1.10E-04 Urinary metabolites LRRC2 intron 21572414 rs871636 chr3 46605091 C T 7.10E-05 Urinary metabolites LRRC2 intron 21572414 rs3806700 chr3 46617311 A C 8.30E-04 Multiple complex diseases TDGF1 intron 17554300 rs17078977 chr3 46636530 C T 4.03E-04 Type 1 diabetes / / 21980299 rs17287638 chr3 46637687 A G 3.40E-04 Urinary metabolites / / 21572414 rs1520485 chr3 46644094 G A 1.40E-04 Urinary metabolites / / 21572414 rs6799581 chr3 46644909 T G 5.35E-05 Systemic sclerosis / / 21750679 rs9817966 chr3 46650540 A G 3.40E-05 Urinary metabolites / / 21572414 rs2176862 chr3 46650993 C T 4.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs1520489 chr3 46677519 G A 9.99E-05 Body Fat Distribution / / pha003016 rs1520489 chr3 46677519 G A 4.23E-05 Body Fat Distribution / / pha003017 rs1520489 chr3 46677519 G A 1.83E-05 Body Fat Distribution / / pha003018 rs12491236 chr3 46688481 C T 3.77E-05 Body Fat Distribution / / pha003017 rs12491236 chr3 46688481 C T 1.62E-05 Body Fat Distribution / / pha003018 rs7633770 chr3 46688562 G A 6.42E-05 Lung adenocarcinoma / / 19836008 rs9861101 chr3 46692379 C T 5.66E-04 Depression (quantitative trait) / / 20800221 rs17079097 chr3 46696797 T C 4.60E-04 Depression (quantitative trait) / / 20800221 rs6442013 chr3 46700713 C T 4.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7373994 chr3 46701114 G C 1.80E-05 Urinary metabolites / / 21572414 rs7633016 chr3 46728659 G A 3.19E-06 Leprosy ALS2CL intron pha002872 rs7642448 chr3 46729757 C G 8.74E-04 Birth weight ALS2CL missense 17255346 rs4076927 chr3 46730749 A G 2.53E-06 Leprosy ALS2CL intron pha002872 rs7639979 chr3 46774776 A G 3.17E-04 Alcohol dependence PRSS46 intron 20201924 rs6808303 chr3 46777885 T C 2.23E-04 Alcohol dependence PRSS46 UTR-5 20201924 rs6793661 chr3 46778008 C T 2.23E-04 Alcohol dependence / / 20201924 rs1077216 chr3 46892161 C T 2.00E-04 Iris characteristics / / 21835309 rs6778660 chr3 46895300 A G 5.99E-04 Smoking quantity / / 24665060 rs6781266 chr3 46895333 T C 2.48E-04 Smoking quantity / / 24665060 rs6442037 chr3 46929546 G A 4.70E-06 Type 2 diabetes PTH1R intron 21647700 rs4683301 chr3 46931478 A T 6.60E-06 Urinary metabolites PTH1R intron 21572414 rs17079313 chr3 46975317 G A 4.05E-10 Multiple complex diseases CCDC12 intron 17554300 rs4683295 chr3 46978923 A G 6.71E-04 Tourette syndrome CCDC12 intron 22889924 rs2061197 chr3 47001350 C T 8.10E-04 Multiple complex diseases CCDC12 intron 17554300 rs2305634 chr3 47043538 C T 6.29E-05 Serum metabolites NBEAL2 cds-synon 19043545 rs181413143 chr3 47047500 G A 0.0001 Breast cancer NBEAL2 missense 23555315 rs2290547 chr3 47061183 G A,C,T 6.86E-04 Type 2 diabetes SETD2 intron 17846125 rs2290547 chr3 47061183 G A,C,T 4.00E-09 HDL cholesterol SETD2 intron 24097068 rs11917361 chr3 47070497 C A 8.40E-04 Multiple complex diseases SETD2 intron 17554300 rs9828473 chr3 47159688 G A 6.84E-04 Alcohol dependence SETD2 intron 20201924 rs7639121 chr3 47303170 G T 2.04E-04 Multiple complex diseases KIF9 intron 17554300 rs295442 chr3 47335881 A C 2.59E-05 Serum metabolites KLHL18 intron 19043545 rs8180040 chr3 47388947 T A 2.59E-05 Serum metabolites / / 19043545 rs8180040 chr3 47388947 T A 2.00E-06 Colorectal cancer / / 23350875 rs4858888 chr3 47405305 C T 2.19E-05 Serum metabolites / / 19043545 rs2062278 chr3 47416761 A G 7.84E-06 Serum metabolites / / 19043545 rs138320436 chr3 47447473 C A 0.00021 Breast cancer PTPN23 missense 23555315 rs12636851 chr3 47463567 T C 8.79E-06 Serum metabolites SCAP intron 19043545 rs6800271 chr3 47470787 T A 2.19E-05 Serum metabolites SCAP intron 19043545 rs11130137 chr3 47578838 G A 2.68E-05 Serum metabolites / / 19043545 rs17303478 chr3 47897367 G C 7.90E-04 Multiple complex diseases MAP4 intron 17554300 rs34675858 chr3 47902247 C T 6.60E-04 Alcohol dependence MAP4 intron 20201924 rs17729010 chr3 47912703 G A 1.47E-04 Multiple complex diseases MAP4 intron 17554300 rs319690 chr3 47927484 T C 3.00E-08 Blood pressure MAP4 intron 21909110 rs2053767 chr3 47999674 A G 3.07E-04 Parkinson's disease MAP4 intron 17052657 rs7642590 chr3 48099750 G A 0.000073 Coronary artery disease MAP4 intron 23202125 rs10446426 chr3 48170521 C G 2.10E-04 Iris characteristics / / 21835309 rs9832957 chr3 48185266 A G 4.60E-05 Personality dimensions / / 18957941 rs3731544 chr3 48207997 C A,G,T 1.01E-04 Multiple complex diseases CDC25A intron 17554300 rs3731539 chr3 48209486 C T 6.12E-04 Alcohol dependence CDC25A intron 20201924 rs11130161 chr3 48259631 G A 4.61E-04 Coronary heart disease / / 21971053 rs6442112 chr3 48316034 A G 6.90E-05 Personality dimensions / / 18957941 rs11706277 chr3 48360433 A G 1.20E-04 Lymphocyte counts SPINK8 intron 22286170 rs11716371 chr3 48362750 C T 2.84E-05 Post-operative nausea and vomiting SPINK8 intron 21694509 rs6779517 chr3 48384388 C T 5.70E-05 Post-operative nausea and vomiting / / 21694509 rs6779517 chr3 48384388 C T 4.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7610524 chr3 48395372 A G 9.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs986739 chr3 48395539 G C 5.84E-04 Multiple complex diseases / / 17554300 rs4558783 chr3 48407462 C T 3.75E-07 Post-operative nausea and vomiting / / 21694509 rs9826195 chr3 48433635 A C 4.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FBXW12 intron 24023788 rs4858818 chr3 48450082 T C 8.68E-04 Alcohol dependence PLXNB1 intron 20201924 rs730566 chr3 48487048 C A 7.00E-06 Prion diseases / / 22210626 rs9876781 chr3 48487338 G A 1.00E-06 Longevity / / 20834067 rs3135940 chr3 48507575 G A 6.00E-06 Obesity-related traits TREX1 UTR-5 23251661 rs11710798 chr3 48570686 A C 7.63E-04 Depression (quantitative trait) PFKFB4 intron 20800221 rs9839959 chr3 48599898 G A 0.000000793 LDL cholesterol UCN2 UTR-3 23063622 rs2255532 chr3 48624611 C T 5.02E-04 Amyotrophic Lateral Sclerosis COL7A1 intron 17362836 rs139999010 chr3 48637143 C T 0.00054 Breast cancer UQCRC1 missense 23555315 rs13063312 chr3 48661985 G A 4.95E-05 Psoriasis / / 20953190 rs13063312 chr3 48661985 G A 4.30E-05 Blood Pressure / / pha003045 rs13063312 chr3 48661985 G A 2.32E-05 Blood Pressure / / pha003046 rs13063312 chr3 48661985 G A 1.62E-05 Blood Pressure / / pha003047 rs13063312 chr3 48661985 G A 2.71E-05 Blood Pressure / / pha003048 rs2276852 chr3 48666923 A G 6.65E-05 Blood Pressure SLC26A6 intron pha003047 rs13324142 chr3 48669447 C T 5.45E-05 Psoriasis SLC26A6 missense 20953190 rs13324142 chr3 48669447 C T 2.52E-05 Blood Pressure SLC26A6 missense pha003045 rs13324142 chr3 48669447 C T 2.30E-05 Blood Pressure SLC26A6 missense pha003046 rs13324142 chr3 48669447 C T 9.41E-06 Blood Pressure SLC26A6 missense pha003047 rs13324142 chr3 48669447 C T 2.57E-05 Blood Pressure SLC26A6 missense pha003048 rs7633840 chr3 48719638 T C 2.95E-04 Heart rate NCKIPSD intron 23583979 rs3172494 chr3 48731487 G T 6.10E-05 Lung adenocarcinoma IP6K2 UTR-3 19836008 rs9882443 chr3 48749064 G A 4.37E-04 Heart rate IP6K2 intron 23583979 rs11708786 chr3 48752654 C T 3.53E-04 Multiple complex diseases IP6K2 intron 17554300 rs3923913 chr3 48842864 G A 3.86E-09 HDL cholesterol PRKAR2A intron 23063622 rs7621226 chr3 48928759 T C 8.43E-04 Heart rate SLC25A20 intron 23583979 rs4974078 chr3 49009386 C T 2.20E-05 Urinary metabolites ARIH2 intron 21572414 rs4974078 chr3 49009386 C T 9.84E-04 Response to cytadine analogues (cytosine arabinoside) ARIH2 intron 24483146 rs13324117 chr3 49012672 C T 8.43E-04 Amyotrophic lateral sclerosis (sporadic) ARIH2 intron 24529757 rs11706052 chr3 49064110 A G 1 Drug response to Mycophenolic Acid IMPDH2 intron 19770842 rs4955420 chr3 49208865 T C 8.08E-04 Lymphocyte counts KLHDC8B nearGene-5 22286170 rs7617480 chr3 49210732 A C 3.00E-08 Menarche (age at onset) KLHDC8B intron 21102462 rs2117938 chr3 49263850 G A 5.71E-04 Type 2 diabetes CCDC36 intron 17463246 rs2304442 chr3 49322027 T A 5.07E-05 Multiple complex diseases USP4 intron 17554300 rs9874474 chr3 49326178 A G 1.31E-06 Crohn's disease USP4 intron 17804789 rs4410472 chr3 49329090 A T 1.75E-05 Multiple complex diseases USP4 intron 17554300 rs4410472 chr3 49329090 A T 1.53E-06 Crohn's disease USP4 intron 17804789 rs2230929 chr3 49343175 G A,C,T 1.38E-06 Crohn's disease USP4 missense 17804789 rs9864406 chr3 49352619 T C 4.57E-05 Multiple complex diseases USP4 intron 17554300 rs9873994 chr3 49359943 T C 1.63E-06 Crohn's disease USP4 intron 17804789 rs9863142 chr3 49366741 G C 6.89E-05 Multiple complex diseases USP4 intron 17554300 rs9863142 chr3 49366741 G C 1.32E-06 Crohn's disease USP4 intron 17804789 rs17080528 chr3 49389842 C T 8.75E-05 Crohn's disease LOC100289130 intron 17804789 rs8179169 chr3 49395698 C G 1.22E-14 Cholesterol,total GPX1 missense 23063622 rs8179169 chr3 49395698 C G 2.63E-23 LDL cholesterol GPX1 missense 23063622 rs2878298 chr3 49406080 T C 4.62E-06 Crohn's disease RHOA intron 17804789 rs11716445 chr3 49406095 G A 7.95E-04 Tourette syndrome RHOA intron 22889924 rs7621003 chr3 49411404 T C 4.76E-06 Crohn's disease RHOA intron 17804789 rs7648841 chr3 49416825 G A 3.63E-07 Crohn's disease RHOA intron 17804789 rs6784820 chr3 49450864 A G 1.44E-05 Multiple complex diseases TCTA intron 17554300 rs6784820 chr3 49450864 A G 1.20E-07 Crohn's disease TCTA intron 18587394 rs6997 chr3 49453834 C T 4.28E-07 Multiple complex diseases TCTA UTR-3 17554300 rs6997 chr3 49453834 C T 3.16E-07 Crohn's disease TCTA UTR-3 17804789 rs9814873 chr3 49454112 A G 2.39E-09 Multiple complex diseases AMT nearGene-3 17554300 rs11715915 chr3 49455330 C T 2.14E-09 Multiple complex diseases AMT cds-synon 17554300 rs11715915 chr3 49455330 C T 0.000000049 Fasting blood glucose AMT cds-synon 22885924 rs4855873 chr3 49459114 A C 3.25E-15 Crohn's disease AMT intron 17804789 rs1464567 chr3 49459252 C G 9.53E-06 Multiple complex diseases AMT intron 17554300 rs6446272 chr3 49463287 G A 4.17E-07 Crohn's disease NICN1 intron 17804789 rs7646366 chr3 49470668 G A 5.82E-07 Crohn's disease / / 17804789 rs885592 chr3 49497883 T G 1.61E-06 Crohn's disease / / 17804789 rs10865955 chr3 49499829 G A 2.81E-06 Crohn's disease / / 17804789 rs1568661 chr3 49520958 A G 1.92E-06 Crohn's disease DAG1 intron 17804789 rs4855864 chr3 49521974 C T 2.03E-06 Crohn's disease DAG1 intron 17804789 rs3924462 chr3 49524236 T G 3.56E-08 Crohn's disease DAG1 intron 18587394 rs3924462 chr3 49524236 T G 5.38E-04 Premature ovarian failure DAG1 intron 19508998 rs4855861 chr3 49525962 G T 1.53E-06 Crohn's disease DAG1 intron 17804789 rs7637999 chr3 49535115 C T 1.41E-06 Crohn's disease DAG1 intron 17804789 rs11130199 chr3 49538799 T C 1.85E-06 Crohn's disease DAG1 intron 17804789 rs11130199 chr3 49538799 T C 5.38E-04 Premature ovarian failure DAG1 intron 19508998 rs3870338 chr3 49557051 A G 8.11E-06 Multiple complex diseases DAG1 intron 17554300 rs3870338 chr3 49557051 A G 1.45E-06 Crohn's disease DAG1 intron 17804789 rs1801143 chr3 49570200 C T 2.21E-07 Multiple complex diseases DAG1 cds-synon 17554300 rs1801143 chr3 49570200 C T 6.45E-04 Bipolar disorder,schizoaffective DAG1 cds-synon 19567891 rs1050088 chr3 49570882 T C 1.24E-05 Multiple complex diseases DAG1 UTR-3 17554300 rs1050088 chr3 49570882 T C 1.40E-06 Crohn's disease DAG1 UTR-3 17804789 rs1050088 chr3 49570882 T C 2.62E-05 Lymphocyte counts DAG1 UTR-3 22286170 rs11720264 chr3 49580347 C T 1.79E-06 Crohn's disease / / 17804789 rs3870341 chr3 49584745 A G 4.64E-04 Heart rate / / 23583979 rs3811697 chr3 49590770 C T 3.19E-06 Crohn's disease BSN-AS2 intron 17804789 rs9858280 chr3 49597737 T C 9.76E-04 Tourette syndrome BSN intron 22889924 rs2312462 chr3 49601255 T C 2.51E-04 Sarcoidosis BSN intron 19165924 rs6446285 chr3 49626306 G A 1.97E-04 Crohn's disease BSN intron 17804789 rs9875617 chr3 49634696 G A 1.95E-07 Crohn's disease BSN intron 17804789 rs9827708 chr3 49649989 C G 1.28E-07 Multiple complex diseases BSN intron 17554300 rs9827708 chr3 49649989 C G 6.61E-08 Crohn's disease BSN intron 17804789 rs9827708 chr3 49649989 C G 9.43E-05 Personality dimensions BSN intron 18957941 rs9827708 chr3 49649989 C G 4.66E-04 Bipolar disorder,schizoaffective BSN intron 19567891 rs1352889 chr3 49652148 T C 7.74E-05 Lung adenocarcinoma BSN intron 19836008 rs11919311 chr3 49656789 G T 6.66E-06 Multiple complex diseases BSN intron 17554300 rs6803222 chr3 49665976 T G 0.000811 Height (Pygmy height) BSN intron 22570615 rs1873625 chr3 49666964 C A 6.61E-08 Crohn's disease BSN intron 17804789 rs1873626 chr3 49675142 T A 1.92E-05 Crohn's disease BSN intron 17804789 rs2329021 chr3 49679072 G A 2.69E-09 Crohn's disease BSN intron 17804789 rs9812791 chr3 49682311 G A 1.61E-08 Crohn's disease BSN intron 17804789 rs2329020 chr3 49685073 G A 5.33E-06 Multiple complex diseases BSN intron 17554300 rs2329020 chr3 49685073 G A 5.01E-04 Tourette syndrome BSN intron 22889924 rs34762726 chr3 49689210 G A 9.52E-25 Primary sclerosing cholangitis BSN missense 23603763 rs2131104 chr3 49696633 C G 1.63E-04 Multiple complex diseases BSN intron 17554300 rs11718165 chr3 49696797 A G 1.83E-08 Multiple complex diseases BSN intron 17554300 rs11718165 chr3 49696797 A G 1.48E-08 Crohn's disease BSN intron 17804789 rs9858542 chr3 49701983 G A 5.00E-08 Crohn's disease BSN cds-synon 17554261 rs9858542 chr3 49701983 G A 4.00E-08 Crohn's disease BSN cds-synon 17554300 rs9858542 chr3 49701983 G A 3.55E-12 Crohn's disease BSN cds-synon 18587394 rs9858542 chr3 49701983 G A 5.63E-05 Personality dimensions BSN cds-synon 18957941 rs9858542 chr3 49701983 G A 1.34E-04 Bipolar disorder,schizoaffective BSN cds-synon 19567891 rs9858542 chr3 49701983 G A 7.00E-09 Ulcerative colitis BSN cds-synon 19915572 rs2131109 chr3 49704987 T C 3.35E-04 Tourette syndrome BSN intron 22889924 rs1131095 chr3 49714225 T C 1.99E-06 Crohn's disease APEH cds-synon 17804789 rs4855882 chr3 49715354 G T 6.00E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma APEH intron 20558613 rs4855881 chr3 49715446 G A 2.85E-06 Multiple complex diseases APEH intron 17554300 rs4855881 chr3 49715446 G A 1.09E-05 Crohn's disease APEH intron 17804789 rs4855881 chr3 49715446 G A 0.000184 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) APEH intron 23527081 rs9822268 chr3 49719729 G A 1.26E-08 Crohn's disease APEH intron 17804789 rs9822268 chr3 49719729 G A 2.00E-17 Ulcerative colitis APEH intron 21297633 rs3197999 chr3 49721532 G A 1.00E-12 Crohn's disease MST1 missense 18587394 rs3197999 chr3 49721532 G A 4.00E-09 Ulcerative colitis MST1 missense 20228799 rs3197999 chr3 49721532 G A 6.00E-17 Crohn's disease MST1 missense 21102463 rs3197999 chr3 49721532 G A 1.00E-12 Asthma MST1 missense 21150878 rs3197999 chr3 49721532 G A 1.00E-16 Primary sclerosing cholangitis MST1 missense 21151127 rs3197999 chr3 49721532 G A 1.15E-12 Multiple sclerosis MST1 missense 22190364 rs3197999 chr3 49721532 G A 1.00E-47 Inflammatory bowel disease MST1 missense 23128233 rs3197999 chr3 49721532 G A 2.45E-26 Primary sclerosing cholangitis MST1 missense 23603763 rs11130214 chr3 49735746 C G 6.74E-05 Multiple complex diseases RNF123 intron 17554300 rs11130214 chr3 49735746 C G 8.10E-04 Bipolar disorder,schizoaffective RNF123 intron 19567891 rs6804655 chr3 49738945 C T 3.80E-04 Coronary heart disease RNF123 cds-synon 21966275 rs2291542 chr3 49751585 C T 5.32E-05 Multiple complex diseases RNF123 cds-synon 17554300 rs3749237 chr3 49770032 G A 4.45E-05 Multiple complex diseases IP6K1 intron 17554300 rs7649348 chr3 49772375 G A 2.09E-05 Crohn's disease IP6K1 intron 17804789 rs7372966 chr3 49788969 T C 2.36E-05 Crohn's disease IP6K1 intron 17804789 rs7372725 chr3 49790544 C A 1.52E-05 Crohn's disease IP6K1 intron 17804789 rs9859153 chr3 49807085 G T 2.62E-05 Crohn's disease IP6K1 intron 17804789 rs11130221 chr3 49819102 C G 2.33E-05 Crohn's disease IP6K1 intron 17804789 rs6802890 chr3 49832261 A G 0.000103 Height (Pygmy height) CDHR4 intron 22570615 rs7629936 chr3 49836707 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CDHR4 cds-synon 24023788 rs2234391 chr3 49842625 A G 1.35E-05 Crohn's disease / / 17804789 rs6775384 chr3 49853073 G A 0.000103 Height (Pygmy height) / / 22570615 rs695238 chr3 49869158 A C 1.09E-05 Crohn's disease TRAIP intron 17804789 rs2271960 chr3 49878078 T C 1.96E-05 Multiple complex diseases TRAIP intron 17554300 rs2271961 chr3 49878113 T C 5.62E-05 Multiple complex diseases TRAIP intron 17554300 rs2271961 chr3 49878113 T C 2.49E-06 Bipolar disorder,schizoaffective TRAIP intron 19567891 rs2247036 chr3 49882349 C T 1.16E-05 Crohn's disease TRAIP intron 17804789 rs2352974 chr3 49890613 C T 3.48E-05 Multiple complex diseases TRAIP intron 17554300 rs2352974 chr3 49890613 C T 2.02E-05 Crohn's disease TRAIP intron 17804789 rs2352974 chr3 49890613 C T 8.27E-07 Bipolar disorder,schizoaffective TRAIP intron 19567891 rs2352974 chr3 49890613 C T 0.000103 Height (Pygmy height) TRAIP intron 22570615 rs2777888 chr3 49898000 A G 1.32E-05 Crohn's disease CAMKV intron 17804789 rs9821675 chr3 49902544 A G 2.57E-04 Crohn's disease CAMKV intron 17804789 rs11713193 chr3 49924424 G A 2.57E-05 Crohn's disease MST1R nearGene-3 17804789 rs2230590 chr3 49936102 T C 3.91E-05 Crohn's disease MST1R missense 17804789 rs7616171 chr3 49938758 A T 1.54E-04 Multiple complex diseases MST1R intron 17554300 rs7634084 chr3 49949834 A T 3.20E-05 Crohn's disease MON1A intron 17804789 rs148635727 chr3 50006026 G A 0.00012 Breast cancer RBM6 missense 23555315 rs2681779 chr3 50011021 T C 6.15E-05 Alcohol dependence RBM6 intron 20201924 rs2681779 chr3 50011021 T C 6.15E-05 Alcoholism RBM6 intron pha002891 rs2624821 chr3 50014114 G A 6.07E-05 Alcohol dependence RBM6 intron 20201924 rs2624821 chr3 50014114 G A 6.07E-05 Alcoholism RBM6 intron pha002891 rs11130237 chr3 50039303 A G 8.73E-04 Lymphocyte counts RBM6 intron 22286170 rs6762477 chr3 50093209 G A 2.00E-08 Menarche (age at onset) RBM6 intron 21102462 rs2240328 chr3 50113004 T C 6.81E-04 Alcohol dependence RBM6 intron 20201924 rs2240327 chr3 50113034 A G 1.25E-05 Lymphocyte counts RBM6 intron 22286170 rs2013208 chr3 50129399 C T 9.00E-12 HDL cholesterol RBM5 intron 24097068 rs2624834 chr3 50132131 G T 4.44E-05 Alcohol dependence RBM5 intron 20201924 rs2624834 chr3 50132131 G T 4.44E-05 Alcoholism RBM5 intron pha002891 rs2526391 chr3 50169266 A T 5.07E-04 Multiple complex diseases LOC100129060 intron 17554300 rs13100903 chr3 50174572 C T 8.50E-04 Acute lung injury LOC100129060 intron 22295056 rs2188151 chr3 50201924 G T 7.75E-04 Multiple complex diseases SEMA3F intron 17554300 rs2518796 chr3 50207075 T C 7.21E-04 Multiple complex diseases SEMA3F intron 17554300 rs2518796 chr3 50207075 T C 9.49E-04 Acute lung injury SEMA3F intron 22295056 rs1005678 chr3 50210289 C G 9.95E-05 Crohn's disease SEMA3F intron 17804789 rs2624833 chr3 50212512 G T 5.45E-05 Crohn's disease SEMA3F intron 17804789 rs12632110 chr3 50224225 A G 1.10E-09 Progranulin levels SEMA3F intron 21087763 rs12632110 chr3 50224225 A G 4.90E-04 Lymphocyte counts SEMA3F intron 22286170 rs2236941 chr3 50247824 C T 9.38E-05 Potassium levels SLC38A3 intron pha003086 rs4688682 chr3 50267128 C A,G,T 2.15E-05 Smoking quantity / / 24665060 rs9826676 chr3 50281080 G C 3.96E-10 HDL cholesterol G/I2 intron 23063622 rs2282751 chr3 50291785 G A 7.20E-06 Esophageal cancer (squamous cell) G/I2 intron 22960999 rs1283 chr3 50337422 G A 4.50E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma HYAL1 UTR-3 20558613 rs11130248 chr3 50352200 A G 5.00E-07 Keloid / / 20711176 rs7644782 chr3 50424814 A G 2.54E-04 Alcohol dependence CAC/2D2 intron 20201924 rs7612641 chr3 50430478 G A 3.56E-04 Alcohol dependence CAC/2D2 intron 20201924 rs2282755 chr3 50442800 G T 5.64E-05 Tourette syndrome CAC/2D2 intron 22889924 rs7647409 chr3 50457599 G A 0.0000205 Primary sclerosing cholangitis CAC/2D2 intron 23603763 rs2236989 chr3 50505395 C T 3.70E-04 Tourette syndrome CAC/2D2 intron 22889924 rs1467913 chr3 50525017 C A 5.19E-06 F-cell distribution CAC/2D2 intron 21326311 rs12487817 chr3 50562566 T C 4.33E-04 Alcohol dependence / / 20201924 rs399484 chr3 50589455 T C 6.21E-04 Multiple complex diseases / / 17554300 rs2232248 chr3 50609624 T A,C,G 9.99E-04 Alzheimer's disease HEMK1 cds-synon 17998437 rs2232248 chr3 50609624 T A,C,G 2.04E-05 Multiple sclerosis (brain glutamate levels) HEMK1 cds-synon 20802204 rs417592 chr3 50610696 A G 0.000339 Height (Pygmy height) HEMK1 intron 22570615 rs2232251 chr3 50614990 T G 7.61E-04 Alcohol dependence HEMK1 missense 20201924 rs17787569 chr3 50616646 G A 7.14E-04 Alzheimer's disease HEMK1 intron 17998437 rs201198 chr3 50636111 G A 3.63E-04 Alzheimer's disease / / 17998437 rs453570 chr3 50637469 G C 3.10E-04 Alzheimer's disease / / 17998437 rs175634 chr3 50644134 C T 0.000422 Height (Pygmy height) CISH UTR-3 22570615 rs873985 chr3 50651751 A G 1.80E-05 Blood pressure MAPKAPK3 intron 21060006 rs873985 chr3 50651751 A G 6.70E-05 Blood pressure MAPKAPK3 intron 21060006 rs873985 chr3 50651751 A G 5.80E-04 Coronary heart disease MAPKAPK3 intron 21966275 rs6779819 chr3 50719345 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs6796769 chr3 50723927 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs7615703 chr3 50732402 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs7611428 chr3 50748598 C T 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs6446213 chr3 50749265 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs17051404 chr3 50751850 A C 7.44E-04 Alcohol dependence DOCK3 intron 20201924 rs7652715 chr3 50763034 A C 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs11712367 chr3 50775446 C T 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs4485709 chr3 50776497 G T 0.000487 Height (Pygmy height) DOCK3 intron 22570615 rs6446222 chr3 50837083 A C 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs9869945 chr3 50849368 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs10510754 chr3 50861611 A G 7.05E-04 Bipolar disorder DOCK3 intron 19259986 rs7638082 chr3 50880677 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs6795573 chr3 50921261 T C 0.000487 Height (Pygmy height) DOCK3 intron 22570615 rs7627266 chr3 50962368 C T 0.000714 Height (Pygmy height) DOCK3 intron 22570615 rs9868870 chr3 50977139 G A 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs7433217 chr3 50987194 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs11130267 chr3 51024903 A G 0.000324 Height (Pygmy height) DOCK3 intron 22570615 rs6446245 chr3 51037258 T G 0.000268 Height (Pygmy height) DOCK3 intron 22570615 rs7614881 chr3 51038375 C T 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs4443210 chr3 51067562 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs13088462 chr3 51071713 T C 4.00E-10 Height DOCK3 intron 20881960 rs7638732 chr3 51075876 A G 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs6795272 chr3 51107870 T C 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs12494165 chr3 51136572 A G 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs4356848 chr3 51137089 C T 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs4286453 chr3 51142359 C T 5.55E-04 Multiple complex diseases DOCK3 intron 17554300 rs9865532 chr3 51144316 G A 0.000211 Height (Pygmy height) DOCK3 intron 22570615 rs6772197 chr3 51151799 G A 0.000211 Height (Pygmy height) DOCK3 intron 22570615 rs4560329 chr3 51193805 C A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs6787805 chr3 51204788 A G 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs1480360 chr3 51311849 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs1318649 chr3 51341471 C T 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs7630259 chr3 51378548 G A 8.13E-04 Alcohol dependence DOCK3 intron 20201924 rs1031925 chr3 51379274 T C 8.00E-06 Melanoma DOCK3 intron 24980573 rs7642077 chr3 51382601 T C 8.94E-04 Alcohol dependence DOCK3 intron 20201924 rs7635095 chr3 51382652 C T 8.94E-04 Alcohol dependence DOCK3 intron 20201924 rs17051755 chr3 51387047 T C 8.13E-04 Alcohol dependence DOCK3 intron 20201924 rs12487468 chr3 51389570 A G 3.90E-06 Schizophrenia DOCK3 intron 19571808 rs4974096 chr3 51393046 G A 2.30E-06 Schizophrenia DOCK3 intron 19571808 rs4974096 chr3 51393046 G A 8.18E-04 Alcohol dependence DOCK3 intron 20201924 rs2306431 chr3 51393457 C T 8.18E-04 Alcohol dependence DOCK3 intron 20201924 rs3828395 chr3 51411797 T C 7.40E-06 Schizophrenia DOCK3 intron 19571808 rs2241785 chr3 51418135 C T 3.40E-06 Schizophrenia DOCK3 intron 19571808 rs1370124 chr3 51422188 A G 1.30E-04 Alcohol dependence MANF nearGene-5 20201924 rs2304512 chr3 51425481 T C 1.26E-04 Alcohol dependence MANF intron 20201924 rs2217938 chr3 51425674 A G 1.30E-04 Alcohol dependence MANF intron 20201924 rs3804766 chr3 51430657 A C 2.40E-06 Schizophrenia RBM15B cds-synon 19571808 rs3804766 chr3 51430657 A C 1.27E-04 Alcohol dependence RBM15B cds-synon 20201924 rs3792408 chr3 51437597 A G 1.42E-04 Alcohol dependence VPRBP intron 20201924 rs10510758 chr3 51441667 C A 2.28E-04 Alcohol dependence VPRBP intron 20201924 rs2356261 chr3 51445146 C A 1.27E-04 Alcohol dependence VPRBP intron 20201924 rs3749317 chr3 51457035 T C 2.01E-04 Alcohol dependence VPRBP intron 20201924 rs17712228 chr3 51474182 G A 1.37E-04 Alcohol dependence VPRBP intron 20201924 rs4687610 chr3 51483210 T C 1.27E-04 Alcohol dependence VPRBP intron 20201924 rs3762714 chr3 51517653 G A 1.40E-04 Alcohol dependence VPRBP intron 20201924 rs4687605 chr3 51554042 T C 8.45E-04 Alcohol dependence / / 20201924 rs11720298 chr3 51581509 A G 9.92E-05 Serum metabolites RAD54L2 intron 19043545 rs4687721 chr3 51598254 G A 9.97E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6809155 chr3 51623216 A G 8.07E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6787312 chr3 51650510 G A 6.88E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4687592 chr3 51655856 C T 6.30E-06 Schizophrenia RAD54L2 intron 19571808 rs9864693 chr3 51656370 G C 6.85E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs11917683 chr3 51668409 G A 6.83E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4494918 chr3 51683248 G C 6.66E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4234644 chr3 51695865 G C 6.52E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6445959 chr3 51772347 A G 4.49E-05 Glucose levels / / pha002899 rs6445959 chr3 51772347 A G 6.59E-05 Coronary heart disease / / pha003032 rs6445959 chr3 51772347 A G 1.40E-05 Coronary heart disease / / pha003033 rs6796373 chr3 51824167 G C 2.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9836804 chr3 51837850 T C 1.28E-05 Multiple complex diseases / / 17554300 rs12639503 chr3 51860817 G A 5.73E-05 Multiple complex diseases / / 17554300 rs12639503 chr3 51860817 G A 3.20E-05 Anger / / 24489884 rs9866552 chr3 51864849 A G 7.93E-05 Multiple complex diseases IQCF3 UTR-3 17554300 rs6762371 chr3 51871405 C T 6.20E-05 Multiple complex diseases / / 17554300 rs16943 chr3 51874679 C T 1.19E-05 Acute lung injury / / 22295056 rs710 chr3 51874679 CGGG CC,CG,CT 1.19E-05 Acute lung injury / / 22295056 rs7635409 chr3 51907736 A G 2.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1605070 chr3 51917015 C A 2.00E-09 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs379462 chr3 52004317 G A 1.98E-04 Multiple complex diseases ABHD14B intron 17554300 rs9851576 chr3 52091254 A G 2.78E-04 Alzheimer's disease (late onset) / / 21379329 rs164637 chr3 52265215 G A 3.46E-06 Waist-hip ratio TWF2 cds-synon 20935629 rs7618915 chr3 52279594 G A 3.00E-10 Bipolar disorder / / 22182935 rs7614727 chr3 52295895 C T 2.08E-05 Glaucoma (primary open-angle) WDR82 intron 22605921 rs9844183 chr3 52315192 A G 0.0002616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9844183 chr3 52315192 A G 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052058 chr3 52344680 A G 0.0001989 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17052058 chr3 52344680 A G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052061 chr3 52346240 T G 0.0001837 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17052061 chr3 52346240 T G 1.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6445386 chr3 52350212 A G 0.0001384 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6445386 chr3 52350212 A G 1.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052068 chr3 52352864 C T 0.0002359 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs17052068 chr3 52352864 C T 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11711934 chr3 52358117 T C 0.0002253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs11711934 chr3 52358117 T C 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11707931 chr3 52358417 C G 0.0002595 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs11707931 chr3 52358417 C G 2.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs6796333 chr3 52359678 T C 0.0001926 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs6796333 chr3 52359678 T C 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs13059674 chr3 52371789 T G 0.0004045 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs13059674 chr3 52371789 T G 4.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11714402 chr3 52391735 A C 9.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 cds-synon 23233662 rs1077142 chr3 52403526 A G 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs149319231 chr3 52409393 A C 0.00001 Breast cancer(er negative) D/H1 missense 23555315 rs390802 chr3 52431671 G A 0.0008707 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs390802 chr3 52431671 G A 8.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs13094687 chr3 52450043 A G 4.48E-07 Bipolar disorder PHF7 intron 22182935 rs13094687 chr3 52450043 A G 1.47E-04 Major depressive disorder PHF7 intron 22472876 rs2272088 chr3 52456973 A G 1.47E-04 Major depressive disorder PHF7 intron 22472876 rs82825 chr3 52471942 G A 0.0006614 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3G intron 23233654 rs82825 chr3 52471942 G A 6.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3G intron 23233662 rs2016575 chr3 52477080 T C 0.0006579 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3G intron 23233654 rs2016575 chr3 52477080 T C 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3G intron 23233662 rs634382 chr3 52482851 A G 0.0006625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs634382 chr3 52482851 A G 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2159607 chr3 52501451 G T 0.0005515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH intron 23233654 rs2159607 chr3 52501451 G T 5.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH intron 23233662 rs6784615 chr3 52506426 C T 4.00E-10 Waist-hip ratio NISCH intron 20935629 rs7620015 chr3 52510697 G A 5.66E-04 Alzheimer's disease NISCH intron 24755620 rs2109559 chr3 52512318 A G 5.62E-04 Alzheimer's disease NISCH intron 24755620 rs6800707 chr3 52516293 C G 0.0006352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH intron 23233654 rs6800707 chr3 52516293 C G 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH intron 23233662 rs728408 chr3 52517206 G A 5.44E-04 Alzheimer's disease NISCH intron 24755620 rs887515 chr3 52523405 C T 0.0006672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH missense 23233654 rs887515 chr3 52523405 C T 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH missense 23233662 rs13326165 chr3 52532118 A G 7.92E-05 Response to acetaminophen (hepatotoxicity) STAB1 intron 21177773 rs13326165 chr3 52532118 A G 9.00E-11 HDL cholesterol STAB1 intron 24097068 rs758801 chr3 52536308 A C 2.68E-06 Waist-hip ratio STAB1 intron 20935629 rs758801 chr3 52536308 A C 0.0001205 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAB1 intron 23233654 rs758801 chr3 52536308 A C 1.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAB1 intron 23233662 rs731831 chr3 52536514 G A 1.89E-05 Major depressive disorder STAB1 intron 22472876 rs1010553 chr3 52540773 T C 4.45E-06 Waist-hip ratio STAB1 cds-synon 20935629 rs1010554 chr3 52542919 T C 8.00E-04 Bipolar disorder STAB1 intron 17486107 rs6445528 chr3 52572447 A G 1.63E-08 Lymphocyte counts C3orf78 intron 22286170 rs2878628 chr3 52584715 A G 4.46E-04 Multiple complex diseases PBRM1 intron 17554300 rs2878628 chr3 52584715 A G 3.56E-07 Bipolar disorder PBRM1 intron 22182935 rs2878628 chr3 52584715 A G 6.90E-08 Major depressive disorder PBRM1 intron 22472876 rs2251219 chr3 52584787 T C 3.44E-04 Multiple complex diseases PBRM1 cds-synon 17554300 rs2251219 chr3 52584787 T C 2.00E-09 Major mood disorders PBRM1 cds-synon 20081856 rs2251219 chr3 52584787 T C 6.35E-07 Bipolar disorder PBRM1 cds-synon 22182935 rs2251219 chr3 52584787 T C 1.91E-08 Major depressive disorder PBRM1 cds-synon 22472876 rs1961958 chr3 52585990 A G 5.11E-04 Multiple complex diseases PBRM1 intron 17554300 rs1961958 chr3 52585990 A G 3.94E-07 Bipolar disorder PBRM1 intron 22182935 rs1961958 chr3 52585990 A G 6.98E-08 Major depressive disorder PBRM1 intron 22472876 rs17052256 chr3 52593119 A G 5.80E-08 Major depressive disorder PBRM1 intron 22472876 rs3796353 chr3 52593230 C T 2.56E-07 Bipolar disorder PBRM1 intron 22182935 rs3796353 chr3 52593230 C T 6.56E-08 Major depressive disorder PBRM1 intron 22472876 rs6778844 chr3 52596398 T C 3.63E-04 Multiple complex diseases PBRM1 intron 17554300 rs6778844 chr3 52596398 T C 4.01E-07 Bipolar disorder PBRM1 intron 22182935 rs6778844 chr3 52596398 T C 6.98E-08 Major depressive disorder PBRM1 intron 22472876 rs2289249 chr3 52597664 G A 9.02E-08 Major depressive disorder PBRM1 intron 22472876 rs6786919 chr3 52599789 A G 7.32E-08 Major depressive disorder PBRM1 intron 22472876 rs13063160 chr3 52602274 T C 7.65E-08 Major depressive disorder PBRM1 intron 22472876 rs6786043 chr3 52604861 A G 6.61E-08 Major depressive disorder PBRM1 intron 22472876 rs11714565 chr3 52606292 C T 2.38E-07 Bipolar disorder PBRM1 intron 22182935 rs11714565 chr3 52606292 C T 6.51E-08 Major depressive disorder PBRM1 intron 22472876 rs7652191 chr3 52610415 T C 1.93E-07 Bipolar disorder PBRM1 intron 22182935 rs7652191 chr3 52610415 T C 5.65E-08 Major depressive disorder PBRM1 intron 22472876 rs11720243 chr3 52618018 T C 2.05E-07 Bipolar disorder PBRM1 intron 22182935 rs11720243 chr3 52618018 T C 5.65E-08 Major depressive disorder PBRM1 intron 22472876 rs12487445 chr3 52618319 A C 2.65E-07 Bipolar disorder PBRM1 intron 22182935 rs12487445 chr3 52618319 A C 7.93E-08 Major depressive disorder PBRM1 intron 22472876 rs3852066 chr3 52621839 C T 7.88E-08 Major depressive disorder PBRM1 intron 22472876 rs2590838 chr3 52622086 G A 9.06E-05 Major depressive disorder PBRM1 intron 22472876 rs2590838 chr3 52622086 G A 2.00E-13 Adiponectin levels PBRM1 intron 22479202 rs2336146 chr3 52626646 A G 3.13E-07 Bipolar disorder PBRM1 intron 22182935 rs2336146 chr3 52626646 A G 7.38E-08 Major depressive disorder PBRM1 intron 22472876 rs2577831 chr3 52628056 C A 5.11E-05 Major depressive disorder PBRM1 intron 22472876 rs11714419 chr3 52628816 A G 8.79E-08 Major depressive disorder PBRM1 intron 22472876 rs3774366 chr3 52641255 T C 3.13E-07 Bipolar disorder PBRM1 intron 22182935 rs3774366 chr3 52641255 T C 6.48E-08 Major depressive disorder PBRM1 intron 22472876 rs12487591 chr3 52642936 A T 4.23E-04 Multiple complex diseases PBRM1 intron 17554300 rs12487591 chr3 52642936 A T 3.46E-07 Bipolar disorder PBRM1 intron 22182935 rs12487591 chr3 52642936 A T 3.09E-08 Major depressive disorder PBRM1 intron 22472876 rs3733045 chr3 52643307 A G 7.04E-04 Multiple complex diseases PBRM1 intron 17554300 rs3733045 chr3 52643307 A G 3.99E-07 Bipolar disorder PBRM1 intron 22182935 rs3733045 chr3 52643307 A G 6.20E-08 Major depressive disorder PBRM1 intron 22472876 rs3755806 chr3 52643685 T C 3.60E-04 Multiple complex diseases PBRM1 cds-synon 17554300 rs3755806 chr3 52643685 T C 9.90E-07 Bipolar disorder PBRM1 cds-synon 22182935 rs3755806 chr3 52643685 T C 3.09E-08 Major depressive disorder PBRM1 cds-synon 22472876 rs3755806 chr3 52643685 T C 0.000000421 Bipolar disorder PBRM1 cds-synon 23070075 rs13083798 chr3 52649748 A G 5.83E-05 Major depressive disorder PBRM1 intron 22472876 rs10510760 chr3 52650348 G A 1.14E-05 Major depressive disorder PBRM1 intron 22472876 rs4687638 chr3 52651966 A C 7.75E-08 Major depressive disorder PBRM1 intron 22472876 rs13064064 chr3 52657002 T C 3.57E-07 Bipolar disorder PBRM1 intron 22182935 rs13064064 chr3 52657002 T C 3.09E-08 Major depressive disorder PBRM1 intron 22472876 rs1561337 chr3 52659963 G A 3.60E-04 Multiple complex diseases PBRM1 intron 17554300 rs1561337 chr3 52659963 G A 3.26E-07 Bipolar disorder PBRM1 intron 22182935 rs1561337 chr3 52659963 G A 2.83E-08 Major depressive disorder PBRM1 intron 22472876 rs7622694 chr3 52663882 G A 6.05E-08 Major depressive disorder PBRM1 intron 22472876 rs2083180 chr3 52668119 G T 5.04E-08 Major depressive disorder PBRM1 intron 22472876 rs13068293 chr3 52672167 C A 3.34E-07 Bipolar disorder PBRM1 intron 22182935 rs13068293 chr3 52672167 C A 2.90E-08 Major depressive disorder PBRM1 intron 22472876 rs11130310 chr3 52674667 C T 5.43E-08 Major depressive disorder PBRM1 intron 22472876 rs2028216 chr3 52680823 C T 8.14E-08 Major depressive disorder PBRM1 intron 22472876 rs2289250 chr3 52682946 C A 4.05E-04 Multiple complex diseases PBRM1 intron 17554300 rs2289250 chr3 52682946 C A 3.48E-07 Bipolar disorder PBRM1 intron 22182935 rs2289250 chr3 52682946 C A 2.89E-08 Major depressive disorder PBRM1 intron 22472876 rs33967311 chr3 52683864 C A 3.40E-04 Multiple complex diseases PBRM1 intron 17554300 rs33967311 chr3 52683864 C A 2.79E-08 Major depressive disorder PBRM1 intron 22472876 rs2336149 chr3 52692124 G A 3.43E-07 Bipolar disorder PBRM1 intron 22182935 rs2336149 chr3 52692124 G A 4.85E-08 Major depressive disorder PBRM1 intron 22472876 rs7611731 chr3 52692721 T C 4.61E-07 Bipolar disorder PBRM1 intron 22182935 rs7611731 chr3 52692721 T C 5.00E-08 Major depressive disorder PBRM1 intron 22472876 rs6804145 chr3 52694198 C T 3.43E-07 Bipolar disorder PBRM1 intron 22182935 rs6804145 chr3 52694198 C T 5.04E-08 Major depressive disorder PBRM1 intron 22472876 rs11715796 chr3 52695650 A C 7.61E-04 Nicotine smoking PBRM1 intron 19268276 rs11130315 chr3 52697163 A G 3.02E-08 Major depressive disorder PBRM1 intron 22472876 rs12488461 chr3 52698417 T C 9.12E-08 Major depressive disorder PBRM1 intron 22472876 rs12496634 chr3 52709259 A C 3.44E-08 Major depressive disorder PBRM1 intron 22472876 rs10865974 chr3 52718280 G T 7.57E-04 Multiple complex diseases PBRM1 intron 17554300 rs10865974 chr3 52718280 G T 4.46E-07 Bipolar disorder PBRM1 intron 22182935 rs10865974 chr3 52718280 G T 8.48E-08 Major depressive disorder PBRM1 intron 22472876 rs10865974 chr3 52718280 G T 2.00E-06 Bipolar disorder (mood-incongruent) PBRM1 intron 23092984 rs3733039 chr3 52719088 C T 6.05E-08 Major depressive disorder PBRM1 intron 22472876 rs1866268 chr3 52719398 C A 4.04E-07 Bipolar disorder PBRM1 intron 22182935 rs1866268 chr3 52719398 C A 6.51E-08 Major depressive disorder PBRM1 intron 22472876 rs1108842 chr3 52720080 A C 1.13E-04 Major depressive disorder GNL3 UTR-5 22472876 rs1108842 chr3 52720080 A C 1.00E-13 Adiponectin levels GNL3 UTR-5 22479202 rs11554256 chr3 52720080 A AA,AC 1.13E-04 Major depressive disorder GNL3 UTR-5 22472876 rs11554256 chr3 52720080 A AA,AC 1.00E-13 Adiponectin levels GNL3 UTR-5 22479202 rs11177 chr3 52721305 G A 1.11E-07 Major depressive disorder GNL3 missense 22472876 rs11177 chr3 52721305 G A 5.00E-09 Osteoarthritis GNL3 missense 22763110 rs11177 chr3 52721305 G A 5.00E-09 Cortical thickness GNL3 missense 22792071 rs6762813 chr3 52726695 C T 3.48E-07 Bipolar disorder GNL3 intron 22182935 rs6762813 chr3 52726695 C T 1.01E-07 Major depressive disorder GNL3 intron 22472876 rs2289247 chr3 52727257 G A 6.02E-04 Multiple complex diseases GNL3 missense 17554300 rs2289247 chr3 52727257 G A 3.23E-07 Bipolar disorder GNL3 missense 22182935 rs2289247 chr3 52727257 G A 6.46E-08 Major depressive disorder GNL3 missense 22472876 rs6976 chr3 52728804 C T 1.45E-07 Major depressive disorder GLT8D1 UTR-3 22472876 rs6976 chr3 52728804 C T 2.27E-10 Osteoarthritis GLT8D1 UTR-3 22763110 rs2164885 chr3 52731269 T C 7.18E-08 Major depressive disorder GLT8D1 intron 22472876 rs11130317 chr3 52731483 C T 4.83E-08 Major depressive disorder GLT8D1 intron 22472876 rs3733041 chr3 52731598 T C 3.16E-07 Bipolar disorder GLT8D1 intron 22182935 rs3733041 chr3 52731598 T C 7.72E-08 Major depressive disorder GLT8D1 intron 22472876 rs115960994 chr3 52731828 C T 0.00000101 Alcohol consumption GLT8D1 missense 23555315 rs6765687 chr3 52733106 C T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) GLT8D1 intron 23453885 rs12635140 chr3 52738165 T C 4.34E-04 Multiple complex diseases GLT8D1 intron 17554300 rs12635140 chr3 52738165 T C 3.22E-07 Bipolar disorder GLT8D1 intron 22182935 rs12635140 chr3 52738165 T C 1.19E-07 Major depressive disorder GLT8D1 intron 22472876 rs8906 chr3 52739520 T C 1.24E-07 Major depressive disorder GLT8D1 UTR-5 22472876 rs3755798 chr3 52741160 G A 3.15E-07 Bipolar disorder SPCS1 intron 22182935 rs3755798 chr3 52741160 G A 9.87E-08 Major depressive disorder SPCS1 intron 22472876 rs34017441 chr3 52742413 T C 6.28E-08 Major depressive disorder / / 22472876 rs11716747 chr3 52748857 C T 8.61E-08 Major depressive disorder NEK4 intron 22472876 rs35526119 chr3 52749334 C T 8.63E-08 Major depressive disorder NEK4 intron 22472876 rs7624716 chr3 52751534 T C 7.51E-08 Major depressive disorder NEK4 intron 22472876 rs10780035 chr3 52764624 C T 1.39E-07 Major depressive disorder NEK4 intron 22472876 rs2079929 chr3 52765646 C T 8.17E-08 Major depressive disorder NEK4 intron 22472876 rs767418 chr3 52767427 C T 8.03E-08 Major depressive disorder NEK4 intron 22472876 rs6445535 chr3 52771468 T C 7.51E-08 Major depressive disorder NEK4 intron 22472876 rs2159644 chr3 52774530 C T 7.05E-08 Major depressive disorder NEK4 intron 22472876 rs2268026 chr3 52778347 T C 4.77E-07 Bipolar disorder NEK4 intron 22182935 rs2268026 chr3 52778347 T C 3.41E-08 Major depressive disorder NEK4 intron 22472876 rs2072390 chr3 52780509 A T 5.01E-04 Multiple complex diseases NEK4 intron 17554300 rs2072390 chr3 52780509 A T 4.36E-07 Bipolar disorder NEK4 intron 22182935 rs2072390 chr3 52780509 A T 8.00E-08 Major depressive disorder NEK4 intron 22472876 rs2336545 chr3 52787603 T C 4.38E-04 Multiple complex diseases NEK4 intron 17554300 rs2336545 chr3 52787603 T C 5.26E-07 Bipolar disorder NEK4 intron 22182935 rs2336545 chr3 52787603 T C 5.95E-08 Major depressive disorder NEK4 intron 22472876 rs12497998 chr3 52793602 C T 5.53E-07 Bipolar disorder NEK4 intron 22182935 rs12497998 chr3 52793602 C T 9.23E-08 Major depressive disorder NEK4 intron 22472876 rs2230535 chr3 52800284 T C 9.43E-07 Bipolar disorder NEK4 cds-synon 22182935 rs2230535 chr3 52800284 T C 6.89E-08 Major depressive disorder NEK4 cds-synon 22472876 rs2230534 chr3 52802402 A C 6.89E-08 Major depressive disorder NEK4 cds-synon 22472876 rs13071584 chr3 52804487 T C 1.05E-07 Major depressive disorder NEK4 intron 22472876 rs1014969 chr3 52808341 G A 5.55E-08 Major depressive disorder / / 22472876 rs3755799 chr3 52809193 G A 1.08E-07 Major depressive disorder / / 22472876 rs2019065 chr3 52809525 T C 5.46E-08 Major depressive disorder / / 22472876 rs2710323 chr3 52815905 T C 1.02E-04 Major depressive disorder ITIH1 intron 22472876 rs2710323 chr3 52815905 T C 3.00E-08 Schizophrenia,schizoaffective disorder or bipolar disorder ITIH1 intron 24166486 rs3774354 chr3 52817675 G A 5.19E-07 Major depressive disorder ITIH1 intron 22472876 rs3774356 chr3 52817891 A C 1.20E-05 Myocardial infarction ITIH1 intron 17211523 rs2239551 chr3 52818579 G A 3.49E-07 Major depressive disorder ITIH1 intron 22472876 rs1042779 chr3 52821011 A G 2.00E-07 Bipolar disorder ITIH1 missense 19416921 rs1042779 chr3 52821011 A G 1.02E-07 Major depressive disorder ITIH1 missense 22472876 rs2286798 chr3 52821177 A C 7.01E-07 Major depressive disorder ITIH1 intron 22472876 rs2300149 chr3 52822921 C T 6.27E-07 Major depressive disorder ITIH1 intron 22472876 rs2239549 chr3 52823126 G A 4.33E-07 Major depressive disorder ITIH1 intron 22472876 rs4687551 chr3 52823448 T C 4.04E-06 Major depressive disorder ITIH1 intron 22472876 rs1076425 chr3 52825462 A G 3.24E-06 Major depressive disorder ITIH1 intron 22472876 rs1075653 chr3 52825528 T C 3.38E-06 Major depressive disorder ITIH1 intron 22472876 rs9324 chr3 52825585 T C 4.17E-06 Major depressive disorder ITIH1 cds-synon 22472876 rs7549 chr3 52825912 C A 8.76E-06 Leukocyte Counts ITIH1 cds-synon pha003091 rs2071506 chr3 52826276 T C 3.24E-06 Major depressive disorder ITIH1 nearGene-3 22472876 rs2071508 chr3 52826846 G A 3.18E-05 Multiple complex diseases / / 17554300 rs2071508 chr3 52826846 G A 4.56E-06 Major depressive disorder / / 22472876 rs9881468 chr3 52828628 C T 3.68E-06 Major depressive disorder / / 22472876 rs2286797 chr3 52829633 G A 6.10E-07 Myocardial infarction ITIH3 cds-synon 17211523 rs115714636 chr3 52830527 A G 0.000000291 Alcohol consumption ITIH3 missense 23555315 rs9816589 chr3 52830547 C T 9.37E-05 HIV-1 viral setpoint ITIH3 cds-synon 22174851 rs2240920 chr3 52831009 C T 1 Drug response to Etoposide ITIH3 intron 17537913 rs2240920 chr3 52831009 C T 2.38E-04 Multiple complex diseases ITIH3 intron 17554300 rs2535629 chr3 52833219 G A 5.88E-09 Major depressive disorder ITIH3 intron 22472876 rs2535629 chr3 52833219 G A 3.00E-12 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ITIH3 intron 23453885 rs2535629 chr3 52833219 G A 0.0000129 Bipolar disorder ITIH3 intron 23637625 rs3617 chr3 52833805 C A 1.12E-05 Major depressive disorder ITIH3 missense 22472876 rs736408 chr3 52835354 C T 2.00E-06 Bipolar disorder ITIH3 intron 21926972 rs736408 chr3 52835354 C T 0.000000503 Bipolar disorder ITIH3 intron 23070075 rs4687552 chr3 52838402 T C 1.00E-08 Schizophrenia ITIH3 intron 23974872 rs9858074 chr3 52843613 G C 1.18E-04 Multiple complex diseases / / 17554300 rs17331151 chr3 52844534 C T 2.00E-09 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs2071044 chr3 52847601 C T 1.32E-05 Major depressive disorder ITIH4 intron 22472876 rs4687657 chr3 52852538 G T 1.79E-05 Major depressive disorder ITIH4 missense 22472876 rs4687657 chr3 52852538 G T 0.00027 Prostate cancer ITIH4 missense 23555315 rs4687657 chr3 52852538 G T 0.000156 Schizophrenia ITIH4 missense 23637625 rs9831977 chr3 52854140 T G 5.48E-04 Suicide attempts in bipolar disorder ITIH4 intron 21423239 rs2239547 chr3 52855229 T C 6.00E-08 Schizophrenia ITIH4 intron 21926974 rs2239547 chr3 52855229 T C 1.96E-05 Major depressive disorder ITIH4 intron 22472876 rs2535633 chr3 52859630 C G 2.00E-10 Body mass index ITIH4 intron 24861553 rs2276817 chr3 52860936 C T 3.12E-04 Major depressive disorder ITIH4 cds-synon 22472876 rs13072536 chr3 52861211 A T 0.00021 Prostate cancer ITIH4 missense 23555315 rs4687554 chr3 52864135 T C 2.74E-04 Major depressive disorder ITIH4 intron 22472876 rs13083728 chr3 52868445 G A 3.40E-04 Major depressive disorder MUSTN1 intron 22472876 rs1573815 chr3 52870132 G A 3.25E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs1139106 chr3 52871101 G A 0.0000198 Body mass index TMEM110-MUSTN1 intron 22885924 rs3733047 chr3 52871929 G A 3.30E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs6445538 chr3 52874288 T C 3.08E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs6445538 chr3 52874288 T C 0.00025 Prostate cancer TMEM110-MUSTN1 intron 23555315 rs6445539 chr3 52874296 G A 3.17E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs11720228 chr3 52877270 G A 3.88E-04 Suicide attempts in bipolar disorder TMEM110-MUSTN1 intron 21423239 rs6803519 chr3 52889771 C T 6.04E-04 Lymphocyte counts TMEM110-MUSTN1 intron 22286170 rs6803519 chr3 52889771 C T 3.25E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs13076033 chr3 52898427 T C 7.02E-04 Suicide attempts in bipolar disorder TMEM110-MUSTN1 intron 21423239 rs3796352 chr3 52913279 C T 5.00E-07 Immune reponse to smallpox (secreted IL-2) TMEM110-MUSTN1 intron 22610502 rs2581824 chr3 53022408 C A 0.000485485 Hypertension (early onset hypertension) SFMBT1 intron 22479346 rs2581824 chr3 53022408 C A 8.35E-16 Urate levels SFMBT1 intron 23263486 rs2564934 chr3 53024580 G A 2.67E-15 Urate levels SFMBT1 intron 23263486 rs6771610 chr3 53026104 T C 6.72E-04 Acute lung injury SFMBT1 intron 22295056 rs2564938 chr3 53026384 C T 8.73E-11 Urate levels SFMBT1 intron 23263486 rs2246556 chr3 53027983 T C 6.96E-04 Acute lung injury SFMBT1 intron 22295056 rs11708675 chr3 53031912 G C 9.24E-11 Urate levels SFMBT1 intron 23263486 rs2564919 chr3 53033295 A G 5.92E-11 Urate levels SFMBT1 intron 23263486 rs12635298 chr3 53033796 T C 7.54E-11 Urate levels SFMBT1 intron 23263486 rs2581792 chr3 53035044 T C 3.65E-08 Urate levels SFMBT1 intron 23263486 rs2564917 chr3 53037695 C T 2.92E-11 Urate levels SFMBT1 intron 23263486 rs2581795 chr3 53038786 A G 1.52E-11 Urate levels SFMBT1 intron 23263486 rs1529544 chr3 53039455 G A 2.01E-11 Urate levels SFMBT1 intron 23263486 rs2564947 chr3 53046216 C T 4.27E-04 Acute lung injury SFMBT1 intron 22295056 rs17304694 chr3 53051577 G A 1.49E-08 Urate levels SFMBT1 intron 23263486 rs2581777 chr3 53054727 T C 7.35E-10 Urate levels SFMBT1 intron 23263486 rs2244552 chr3 53055522 A G 2.08E-15 Urate levels SFMBT1 intron 23263486 rs2244461 chr3 53055842 G A 1.09E-09 Urate levels SFMBT1 intron 23263486 rs2581780 chr3 53058960 C T 4.27E-04 Acute lung injury SFMBT1 intron 22295056 rs2255107 chr3 53060637 C T 8.56E-05 Coronary restenosis SFMBT1 intron 21878436 rs2255107 chr3 53060637 C T 4.29E-04 Major depressive disorder SFMBT1 intron 22472876 rs9847710 chr3 53062661 T C 0.000587353 Hypertension (early onset hypertension) SFMBT1 intron 22479346 rs9847710 chr3 53062661 T C 1.00E-08 Ulcerative colitis SFMBT1 intron 23128233 rs9847710 chr3 53062661 T C 6.42E-16 Urate levels SFMBT1 intron 23263486 rs2581806 chr3 53063360 A G 8.52E-10 Urate levels SFMBT1 intron 23263486 rs2564956 chr3 53070462 C T 1.00E-15 Urate levels SFMBT1 intron 23263486 rs17304995 chr3 53070755 A G 8.09E-04 Multiple complex diseases SFMBT1 intron 17554300 rs2581818 chr3 53071652 C A 4.24E-10 Urate levels SFMBT1 intron 23263486 rs9756317 chr3 53088815 T C 2.27E-06 Waist-hip ratio / / 20935629 rs9870898 chr3 53092375 A G 9.73E-05 Acute lung injury / / 22295056 rs6770152 chr3 53100214 G T 3.00E-16 Urate levels / / 23263486 rs2581790 chr3 53101780 T C 3.29E-09 Urate levels / / 23263486 rs2336725 chr3 53118739 C T 1.00E-12 Height / / 20881960 rs2564921 chr3 53125585 T C 2.00E-12 Height RFT1 UTR-3 23563607 rs13088281 chr3 53147576 C A 3.00E-11 Immune reponse to smallpox (secreted IL-2) RFT1 intron 22610502 rs1560332 chr3 53164803 C T 8.77E-04 Multiple complex diseases RFT1 nearGene-5 17554300 rs7615501 chr3 53175557 G A 8.23E-04 Alcohol dependence / / 20201924 rs3736151 chr3 53259608 C T 8.86E-05 Waist Circumference TKT UTR-3 pha003023 rs3163 chr3 53259850 C T 1.40E-04 Smoking initiation TKT cds-synon 24665060 rs7650103 chr3 53260325 A G 2.48E-05 Orofacial clefts TKT intron 22419666 rs735940 chr3 53266531 C T 4.31E-05 Waist Circumference TKT intron pha003023 rs2242302 chr3 53267296 G A 4.12E-04 Smoking initiation TKT intron 24665060 rs7628245 chr3 53272944 C T 3.73E-95 Multiple complex diseases TKT intron 17554300 rs12493802 chr3 53278241 C T 1.81E-05 Relative hand skill TKT intron 24068947 rs4687717 chr3 53282188 T C 1.00E-13 Blood metabolite levels TKT intron 24816252 rs4687717 chr3 53282188 T C 9.00E-23 Blood metabolite ratios TKT intron 24816252 rs4687718 chr3 53282303 A G 6.00E-09 Ventricular conduction TKT intron 21076409 rs7648309 chr3 53291982 G A 1.57E-04 Multiple complex diseases TKT nearGene-5 17554300 rs7649323 chr3 53332706 G C 1.19E-04 Multiple complex diseases DCP1A intron 17554300 rs7649323 chr3 53332706 G C 0.00000742 Fear (ARBQ) in children DCP1A intron 23565138 rs2029213 chr3 53378245 C T 7.00E-06 Heart rate DCP1A intron 23583979 rs9873674 chr3 53435726 G T 6.66E-04 Multiple complex diseases / / 17554300 rs13080668 chr3 53443354 T C 4.56E-04 Multiple complex diseases / / 17554300 rs13080668 chr3 53443354 T C 1.87E-07 Heart rate / / 23583979 rs674628 chr3 53445957 G A 6.90E-05 Endometriosis / / 21151130 rs555480 chr3 53495847 G T 1.79E-04 Hemoglobin concentration / / 20534544 rs562331 chr3 53509316 T C 8.52E-04 Multiple complex diseases / / 17554300 rs17053107 chr3 53519922 C A 8.95E-04 Multiple complex diseases / / 17554300 rs312483 chr3 53524051 G A 6.89E-04 Multiple complex diseases / / 17554300 rs6763768 chr3 53537879 T C 1.97E-04 Cognition,early reading ability CAC/1D intron 17684495 rs979220 chr3 53556223 T C 3.72E-04 Multiple complex diseases CAC/1D intron 17554300 rs10049492 chr3 53596532 A G 8.46E-06 Cardiovascular disease CAC/1D intron pha003064 rs10490772 chr3 53605845 C T 1.46E-04 Alzheimer's disease CAC/1D intron 24755620 rs6445588 chr3 53630679 C T 3.26E-04 Nicotine smoking CAC/1D intron 19268276 rs6445588 chr3 53630679 C T 8.81E-04 Nicotine smoking CAC/1D intron 19268276 rs6445588 chr3 53630679 C T 1.97E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1D intron 24265751 rs6445588 chr3 53630679 C T 6.29E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1D intron 24265751 rs936450 chr3 53634426 A G 1.70E-05 Urinary metabolites CAC/1D intron 21572414 rs898414 chr3 53651291 A G 3.62E-04 Multiple complex diseases CAC/1D intron 17554300 rs3774490 chr3 53663648 C T 2.64E-04 Amyotrophic lateral sclerosis (sporadic) CAC/1D intron 24529757 rs1401492 chr3 53680124 C T 3.00E-06 Insulin resistance CAC/1D intron 21901158 rs1401492 chr3 53680124 C T 5.00E-06 Insulin resistance CAC/1D intron 21901158 rs3774519 chr3 53695242 T G 9.85E-04 Insulin resistance CAC/1D intron 21901158 rs2612017 chr3 53730773 G A 4.77E-04 Multiple complex diseases CAC/1D intron 17554300 rs3774541 chr3 53741132 G A 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1D intron 20877124 rs2169143 chr3 53750681 C G 9.90E-04 Type 2 diabetes and 6 quantitative traits CAC/1D intron 17848626 rs2253795 chr3 53778875 G T 5.18E-04 Major depressive disorder CAC/1D intron 22472876 rs3774560 chr3 53785403 T C 4.21E-04 Smoking initiation CAC/1D intron 24665060 rs17053472 chr3 53788732 A C 3.01E-05 Major depressive disorder CAC/1D intron 22472876 rs719260 chr3 53789172 T C 3.27E-04 Major depressive disorder CAC/1D intron 22472876 rs1573818 chr3 53800238 T C 1.62E-04 Smoking initiation CAC/1D intron 24665060 rs3774581 chr3 53802748 A G 9.49E-04 Type 2 diabetes CAC/1D intron 17463246 rs3774581 chr3 53802748 A G 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1D intron 20877124 rs3774581 chr3 53802748 A G 1.31E-05 Orofacial clefts CAC/1D intron 22419666 rs3774601 chr3 53822893 G A 2.98E-04 Major depressive disorder CAC/1D intron 22472876 rs3774604 chr3 53824136 C T 3.61E-04 Major depressive disorder CAC/1D intron 22472876 rs3774608 chr3 53832712 G A 2.21E-04 Major depressive disorder CAC/1D intron 22472876 rs3774609 chr3 53832903 T G 1.14E-05 Bipolar disorder CAC/1D intron 21926972 rs3774609 chr3 53832903 T G 2.16E-04 Major depressive disorder CAC/1D intron 22472876 rs2359133 chr3 53836742 G C 3.77E-04 Type 2 diabetes CAC/1D intron 17463246 rs877483 chr3 53846741 T C 7.46E-06 Major depressive disorder / / 22472876 rs893363 chr3 53847062 G A 1.33E-05 Major depressive disorder / / 22472876 rs893363 chr3 53847062 G A 8.00E-06 Axial length / / 24144296 rs14165 chr3 53847408 A G 2.00E-08 Refractive error / / 23396134 rs4687587 chr3 53849510 A G 8.90E-06 Axial length / / 24144296 rs4687747 chr3 53865433 G T 8.77E-04 Response to taxane treatment (placlitaxel) CHDH intron 23006423 rs13317328 chr3 53870840 A C 1.87E-05 Coronary heart disease CHDH intron pha003031 rs920253 chr3 53872753 G A,C,T 7.90E-04 Type 2 diabetes CHDH intron 17463246 rs3821869 chr3 53893840 C A 1.03E-04 Lung function (forced expiratory volume in 1 second) IL17RB intron 24023788 rs3821869 chr3 53893840 C A 4.42E-05 Lung function (forced vital capacity) IL17RB intron 24023788 rs6766099 chr3 53894412 C T 4.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL17RB intron 20877124 rs2232350 chr3 53899178 T C 0.000000259 HDL cholesterol IL17RB missense 23063622 rs1043261 chr3 53899276 C T 1.54E-04 Intracranial aneurysm IL17RB STOP-GAIN 22286173 rs2241806 chr3 53901611 A G 2.83E-04 Lung function (forced vital capacity) ACTR8 UTR-3 24023788 rs2241806 chr3 53901611 A G 3.69E-04 Lung function (forced expiratory volume in 1 second) ACTR8 UTR-3 24023788 rs893367 chr3 53909731 C A 2.65E-04 Lung function (forced vital capacity) ACTR8 intron 24023788 rs7636856 chr3 53934171 A G 1.29E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7636856 chr3 53934171 A G 4.75E-05 Lung function (forced vital capacity) / / 24023788 rs6803364 chr3 54036698 T G 0.00000027 Mean arterial pressure / / 22510845 rs17053682 chr3 54077334 A G 2.16E-04 Multiple complex diseases / / 17554300 rs1992965 chr3 54077726 G A 0.000000522 Femoral neck bone mineral density (premenopausal) / / 23074152 rs7637998 chr3 54086583 T C 3.63E-05 AIDS progression / / 19115949 rs750379 chr3 54111877 T C 3.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1349205 chr3 54118117 G C 1.42E-05 Bone mass and geometry / / 17903296 rs9841694 chr3 54120245 C T 4.35E-04 Type 2 diabetes / / 17463246 rs9841694 chr3 54120245 C T 6.82E-04 Insulin resistance / / 21901158 rs13322861 chr3 54122673 G A 2.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4472075 chr3 54123011 G T 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17801638 chr3 54128575 T C 7.95E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4320084 chr3 54149801 G A 1.34E-05 Heart Failure / / pha002885 rs2034444 chr3 54165888 A G 1.20E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6765381 chr3 54173258 T C 1.53E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs9880023 chr3 54178199 G T 4.43E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs9880023 chr3 54178199 G T 3.54E-05 ldl cholesterol CAC/2D3 intron pha003076 rs6796475 chr3 54188188 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs2359784 chr3 54200456 T C 4.18E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4345101 chr3 54221986 T C 1.53E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4077974 chr3 54226000 G A 9.54E-04 Obesity (extreme) CAC/2D3 intron 21935397 rs12630117 chr3 54228291 A T 0.0004874 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CAC/2D3 intron 23233654 rs12630117 chr3 54228291 A T 4.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CAC/2D3 intron 23233662 rs11717167 chr3 54229726 C T 1.36E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs6445633 chr3 54230638 A C 0.0002 Common carotid artery thickness (average of near and far wall measures) CAC/2D3 intron 23487405 rs11714003 chr3 54234467 A G 0.0003 Migraine CAC/2D3 intron 22678113 rs9839121 chr3 54240680 T C 3.62E-05 Waist Circumference CAC/2D3 intron pha003023 rs9840694 chr3 54244778 C T 3.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs9828664 chr3 54247916 C T 1.00E-04 Prostate cancer CAC/2D3 intron 21743057 rs11130399 chr3 54249650 G T 5.55E-04 Intracranial aneurysm CAC/2D3 intron 20613766 rs11130399 chr3 54249650 G T 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs11130399 chr3 54249650 G T 1.42E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs11130401 chr3 54250278 A C 6.00E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs9840489 chr3 54250489 G A 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs6806229 chr3 54253658 G A 6.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6806229 chr3 54253658 G A 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs3923436 chr3 54254041 T G 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs6763602 chr3 54258383 A G 5.70E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs6763602 chr3 54258383 A G 0.000856958 Hypertension (early onset hypertension) CAC/2D3 intron 22479346 rs6763602 chr3 54258383 A G 9.19E-05 Lipoproteins CAC/2D3 intron pha003079 rs9878916 chr3 54267797 G A 3.11E-04 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs4928020 chr3 54273364 A G 5.11E-04 Smoking initiation CAC/2D3 intron 24665060 rs4927995 chr3 54275323 T C 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs11130407 chr3 54285030 C T 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs9846140 chr3 54286459 G A 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs7615792 chr3 54305670 A G 6.72E-04 Iron levels CAC/2D3 intron pha002876 rs6792199 chr3 54326491 C T 6.55E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs3934631 chr3 54330455 A G 4.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4078006 chr3 54338062 C G 5.03E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs7431577 chr3 54339912 G T 1.16E-04 Amyotrophic lateral sclerosis (sporadic) CAC/2D3 intron 24529757 rs7431992 chr3 54353240 T A 2.62E-04 Nicotine smoking CAC/2D3 intron 19268276 rs11708620 chr3 54371791 C T 5.37E-04 Alcohol dependence CAC/2D3 intron 21314694 rs11711956 chr3 54378600 A G 2.00E-06 Musician's dystonia CAC/2D3 intron 24375517 rs2359790 chr3 54387169 T C 4.49E-05 Body mass index CAC/2D3 intron 17255346 rs2359793 chr3 54406659 A G 1.60E-04 Body mass index CAC/2D3 intron 17255346 rs2359793 chr3 54406659 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) CAC/2D3 intron 20189245 rs1449330 chr3 54409526 A G 9.40E-05 Body mass index CAC/2D3 intron 17255346 rs9862718 chr3 54424701 G A 2.39E-04 Body mass index CAC/2D3 intron 17255346 rs9851130 chr3 54435589 A G 3.75E-04 Insulin resistance CAC/2D3 intron 21901158 rs12632768 chr3 54450047 C A 1.92E-04 Body mass index CAC/2D3 intron 17255346 rs6803199 chr3 54450193 T C 2.04E-04 Bipolar disorder CAC/2D3 intron 19259986 rs9816445 chr3 54470968 G A 6.31E-04 Insulin resistance CAC/2D3 intron 21901158 rs6768189 chr3 54471010 A G 8.19E-04 Intracranial aneurysm CAC/2D3 intron 20613766 rs6768189 chr3 54471010 A G 0.0000357 Antithrombin CAC/2D3 intron 23705025 rs6796049 chr3 54503574 C G 5.27E-04 Acute lung injury CAC/2D3 intron 22295056 rs17747001 chr3 54511119 A G 5.65E-04 Acute lung injury CAC/2D3 intron 22295056 rs6773944 chr3 54516884 C A 1.99E-04 Smoking initiation CAC/2D3 intron 24665060 rs17747054 chr3 54517051 G A 5.94E-04 Acute lung injury CAC/2D3 intron 22295056 rs11708855 chr3 54525443 A T 4.62E-04 Acute lung injury CAC/2D3 intron 22295056 rs7614229 chr3 54529944 T C 4.91E-04 Acute lung injury CAC/2D3 intron 22295056 rs11706275 chr3 54535284 C T 4.92E-04 Acute lung injury CAC/2D3 intron 22295056 rs7432776 chr3 54555192 T G 8.10E-04 Acute lung injury CAC/2D3 intron 22295056 rs7372026 chr3 54592177 G A 5.65E-04 Smoking initiation CAC/2D3 intron 24665060 rs17054142 chr3 54599814 T C 3.46E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs1543208 chr3 54609024 A G 1.48E-05 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs4955861 chr3 54611163 C T 1.56E-04 Smoking cessation CAC/2D3 intron 18519826 rs4955861 chr3 54611163 C T 4.37E-04 Smoking cessation CAC/2D3 intron 18519826 rs4955866 chr3 54611753 A G 1.46E-05 Smoking cessation CAC/2D3 intron 18519826 rs6445700 chr3 54613359 G A 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs6445700 chr3 54613359 G A 3.53E-04 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs6782115 chr3 54615971 A G 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs1356895 chr3 54625797 C T 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs13064588 chr3 54632547 T A 4.00E-06 Bipolar disorder and schizophrenia CAC/2D3 intron 20889312 rs616788 chr3 54639209 A G 3.52E-04 Amyotrophic Lateral Sclerosis CAC/2D3 intron 17362836 rs12497334 chr3 54655054 T C 5.31E-05 Smoking cessation CAC/2D3 intron 24665060 rs496625 chr3 54663005 A G 2.52E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs1965072 chr3 54679831 C T 9.70E-04 Myocardial Infarction CAC/2D3 intron pha002873 rs578032 chr3 54687361 T C 1.23E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs838022 chr3 54689649 A G 2.06E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs517729 chr3 54708376 G A 5.77E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs666071 chr3 54709721 T C 1.05E-06 Smoking cessation CAC/2D3 intron 18519826 rs515920 chr3 54718721 T C 7.18E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs515920 chr3 54718721 T C 5.42E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs583190 chr3 54727077 C A 7.49E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs652424 chr3 54745555 C T 7.74E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs589281 chr3 54747244 C T 7.75E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs589281 chr3 54747244 C T 6.05E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs604132 chr3 54748234 T A 4.58E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs934083 chr3 54790379 C T 7.37E-05 Alzheimer's disease CAC/2D3 intron 24755620 rs7636321 chr3 54793450 T C 5.24E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs3732748 chr3 54798258 G A 9.47E-04 Alzheimer's disease CAC/2D3 cds-synon 24755620 rs1820616 chr3 54800316 T C 1.27E-05 Fractional exhaled nitric oxide (childhood) CAC/2D3 intron 24315451 rs1820616 chr3 54800316 T C 3.00E-06 Fractional exhaled nitric oxide (childhood) CAC/2D3 intron 24315451 rs1997463 chr3 54807240 A G 3.80E-05 Subclinical atherosclerosis CAC/2D3 intron 17903303 rs9849795 chr3 54885173 T G 5.00E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6810058 chr3 54891599 G T 6.40E-04 Alcohol dependence CAC/2D3 intron 20201924 rs17253119 chr3 54930773 A G 3.36E-04 Response to TNF antagonist treatment CAC/2D3 intron 21061259 rs9808962 chr3 54941441 G T 9.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs1918070 chr3 54941578 C T 9.92E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4245919 chr3 54948936 G A 2.53E-05 Tunica Media CAC/2D3 intron pha003034 rs1515955 chr3 54984197 A G 9.64E-05 Personality dimensions CAC/2D3 intron 18957941 rs2048809 chr3 54990157 T G 6.82E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer CAC/2D3 intron 21483023 rs4955912 chr3 54996448 C T 9.16E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs3773586 chr3 55008746 C A 5.38E-04 Nicotine smoking CAC/2D3 intron 19268276 rs3773582 chr3 55017749 A G 1.78E-04 Endometrial cancer CAC/2D3 intron 24096698 rs3773582 chr3 55017749 A G 8.00E-06 Endometrial cancer CAC/2D3 intron 24096698 rs2360667 chr3 55031354 A G 5.84E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4423737 chr3 55032038 C T 4.48E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4955826 chr3 55035874 C T 5.00E-06 Immune response to smallpox vaccine (IL-6) CAC/2D3 intron 22542470 rs17054685 chr3 55039611 G C 8.98E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21423239 rs1982862 chr3 55064740 C A 1.82E-08 Facial morphology CAC/2D3 intron 22341974 rs3773555 chr3 55065684 C T 5.36E-04 Iron levels CAC/2D3 intron pha002876 rs358493 chr3 55072187 C T 4.00E-05 Serum metabolites CAC/2D3 intron 19043545 rs358070 chr3 55105390 C A 6.88E-05 Leukocyte Counts CAC/2D3 intron pha003091 rs17323097 chr3 55107944 A G 4.31E-04 Alzheimer's disease CAC/2D3 intron 17998437 rs358077 chr3 55108358 A G 4.19E-04 Alzheimer's disease CAC/2D3 UTR-3 17998437 rs1458977 chr3 55136997 A G 2.41E-04 Iron levels / / pha002876 rs7651413 chr3 55139336 G T 3.60E-04 Primary sclerosing cholangitis / / 19944697 rs709330 chr3 55142430 G A 9.22E-04 Type 2 diabetes / / 17463246 rs6782380 chr3 55184213 C G 8.00E-06 Coronary artery calcification / / 23870195 rs11706236 chr3 55188273 A G 4.00E-06 Insomnia (caffeine-induced) / / 22754043 rs4955832 chr3 55188479 T G 5.77E-05 IgE levels / / 17255346 rs4955937 chr3 55194254 A G 0.000842 Salmonella-induced pyroptosis / / 22837397 rs753294 chr3 55194956 A G 8.40E-05 Ankylosing spondylitis / / 20062062 rs9311552 chr3 55216779 C T 5.60E-06 Cognitive impairment induced by topiramate / / 22091778 rs9311552 chr3 55216779 C T 7.40E-06 Endometriosis / / 23104006 rs6770519 chr3 55221542 A C 8.19E-04 Myocardial Infarction / / pha002873 rs1461796 chr3 55224080 T C 3.85E-04 Type 2 diabetes / / 17463246 rs1461796 chr3 55224080 T C 3.45E-05 Relative hand skill / / 24068947 rs6782687 chr3 55229775 T C 5.39E-04 Insulin resistance / / 21901158 rs1381389 chr3 55231799 G A 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs12491607 chr3 55236699 C A,G,T 5.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs10510777 chr3 55237738 C T 3.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs9860541 chr3 55237880 A T 4.70E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs6802697 chr3 55241137 T C 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs374563 chr3 55256432 C A 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs373532 chr3 55263106 C T 2.70E-05 Information processing speed / / 21130836 rs535157 chr3 55263442 A C 2.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6801136 chr3 55265321 C T 9.97E-06 Information processing speed / / 21130836 rs6801136 chr3 55265321 C T 2.50E-05 Urinary metabolites / / 21572414 rs393836 chr3 55265674 A C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs747030 chr3 55271653 T A 7.76E-04 Multiple complex diseases / / 17554300 rs4955965 chr3 55291294 T C 7.28E-04 Multiple complex diseases / / 17554300 rs1122341 chr3 55294422 T C 4.36E-04 Multiple complex diseases / / 17554300 rs459737 chr3 55305884 A G 3.99E-04 Alcohol dependence / / 20201924 rs358806 chr3 55313400 A C 3.00E-06 Type 2 diabetes / / 17554300 rs358806 chr3 55313400 A C 3.00E-06 Coronary heart disease / / 21347282 rs358806 chr3 55313400 A C 3.00E-06 Type 2 diabetes / / 21647700 rs17055095 chr3 55315152 C T 5.53E-04 Parkinson's disease / / 16252231 rs749152 chr3 55332449 C T 2.39E-05 Blood pressure / / 17255346 rs358810 chr3 55349432 T C 3.56E-05 Coronary heart disease / / pha003030 rs1000408 chr3 55356725 C T 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs358792 chr3 55360261 T G 3.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs358793 chr3 55361433 T C 1.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9839808 chr3 55377935 T C 4.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4955848 chr3 55392281 G A 7.75E-04 Multiple complex diseases / / 17554300 rs9683127 chr3 55406338 A G 2.07E-05 Serum metabolites / / 19043545 rs6763470 chr3 55424943 T G 6.05E-07 Blood pressure / / 21909110 rs17327860 chr3 55462573 G A 4.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2362199 chr3 55464381 A G 0.0007895 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2362199 chr3 55464381 A G 7.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17327979 chr3 55465656 C T 3.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1520703 chr3 55469813 A C 1.08E-05 Multiple complex diseases / / 17554300 rs1392224 chr3 55474073 A G 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs544704 chr3 55480723 T C 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3913369 chr3 55481075 G T 4.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs751193 chr3 55487317 T A 2.96E-04 Multiple complex diseases / / 17554300 rs751193 chr3 55487317 T A 2.59E-04 Insulin resistance / / 21901158 rs751194 chr3 55487428 G A 2.27E-04 Multiple complex diseases / / 17554300 rs751194 chr3 55487428 G A 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11706227 chr3 55496260 C T 1.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11710229 chr3 55497953 A T 6.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12497254 chr3 55499664 G A 1.19E-04 Multiple complex diseases WNT5A nearGene-3 17554300 rs10865994 chr3 55500408 T A 5.72E-04 Multiple complex diseases WNT5A UTR-3 17554300 rs570374 chr3 55551064 C T 4.98E-04 Smoking cessation ERC2 intron 24665060 rs528574 chr3 55556129 A G 4.70E-05 Cognitive impairment induced by topiramate ERC2 intron 22091778 rs1875110 chr3 55563344 T C 4.00E-06 Periodontitis (Mean PAL) ERC2 intron 24024966 rs1795648 chr3 55571760 G A 6.00E-06 Bipolar disorder and schizophrenia ERC2 intron 21057379 rs17263248 chr3 55574820 A G 6.10E-06 Parkinson's disease (familial) ERC2 intron 18985386 rs17263248 chr3 55574820 A G 4.60E-05 Iron levels ERC2 intron 21208937 rs1167242 chr3 55575785 G A 7.42E-04 Myocardial Infarction ERC2 intron pha002873 rs11720559 chr3 55586557 T C 4.38E-04 White matter integrity ERC2 intron 22425255 rs4538346 chr3 55607629 G A 8.52E-04 Multiple complex diseases ERC2 intron 17554300 rs904622 chr3 55625184 A G 1.00E-04 Prostate cancer ERC2 intron 21743057 rs17055623 chr3 55679808 C G 5.00E-04 Acute lymphoblastic leukemia (childhood) ERC2 intron 20189245 rs17055647 chr3 55681358 C A 0.000305 Height (Pygmy height) ERC2 intron 22570615 rs17055741 chr3 55717324 C T 5.05E-06 Kawasaki disease ERC2 intron 21221998 rs2270583 chr3 55733717 A G 2.80E-06 Urinary metabolites ERC2 intron 21572414 rs815440 chr3 55738747 T C 1.03E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815437 chr3 55739360 C T 1.10E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815425 chr3 55741141 G A 1.17E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs709339 chr3 55741894 T A 5.42E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815422 chr3 55742066 T G 1.33E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1179376 chr3 55743058 C T 8.14E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1179375 chr3 55743198 T C 7.13E-06 Uric acid levels ERC2 intron 21294900 rs1179375 chr3 55743198 T C 9.27E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1495360 chr3 55760165 G A 5.99E-04 Type 2 diabetes ERC2 intron 17463246 rs815453 chr3 55767988 C T 7.57E-04 Type 2 diabetes ERC2 intron 17463246 rs815452 chr3 55768130 T C 8.37E-04 Type 2 diabetes ERC2 intron 17463246 rs815451 chr3 55768688 G C 8.14E-04 Type 2 diabetes ERC2 intron 17463246 rs1495365 chr3 55802668 G T 5.30E-04 Rheumatoid arthritis ERC2 intron 21452313 rs9852746 chr3 55803332 A G 9.15E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs9852888 chr3 55803435 A T 2.48E-05 Esophageal cancer (squamous cell) ERC2 intron 22960999 rs4955878 chr3 55805447 C T 4.42E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4974144 chr3 55805996 G A 6.60E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs6445754 chr3 55807255 C T 7.72E-05 Sarcoidosis ERC2 intron 19165924 rs6445754 chr3 55807255 C T 1.31E-04 Acute lymphoblastic leukemia (childhood) ERC2 intron 22076464 rs6445754 chr3 55807255 C T 8.49E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs7641474 chr3 55821111 C T 1.00E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4572738 chr3 55824412 T C 7.31E-04 Rheumatoid arthritis ERC2 intron 21452313 rs4572738 chr3 55824412 T C 4.45E-05 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4459870 chr3 55829060 C T 2.88E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs12488085 chr3 55834871 G A 7.38E-04 Rheumatoid arthritis ERC2 intron 21452313 rs12488085 chr3 55834871 G A 4.64E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4129822 chr3 55839410 A G 7.49E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4260395 chr3 55846469 C A 4.96E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs9860951 chr3 55846998 C T 2.10E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs7615473 chr3 55849978 G T 3.72E-04 Rheumatoid arthritis ERC2 intron 21452313 rs7615473 chr3 55849978 G T 2.08E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs6782906 chr3 55881520 C T 2.26E-04 Alcohol dependence ERC2 intron 20201924 rs7631846 chr3 55883396 T C 3.10E-04 Alcohol dependence ERC2 intron 20201924 rs13098621 chr3 55914171 G A 0.000171952 Primary sclerosing cholangitis ERC2 intron 23603763 rs1156513 chr3 55929848 A G 6.98E-05 Eosinophil counts ERC2 intron pha003088 rs13080171 chr3 55941438 A C 6.40E-04 Insulin resistance ERC2 intron 21901158 rs4541375 chr3 55942547 G C 8.76E-04 Alzheimer's disease ERC2 intron 24755620 rs13072547 chr3 55943591 T C 8.57E-05 Alzheimer's disease ERC2 intron 24755620 rs1110225 chr3 55945666 C T 9.87E-04 Alzheimer's disease ERC2 intron 24755620 rs6794124 chr3 55946297 A C 8.24E-05 Alzheimer's disease ERC2 intron 24755620 rs11712729 chr3 55949485 G C 4.65E-04 Multiple complex diseases ERC2 intron 17554300 rs11917617 chr3 55952782 A G 4.13E-04 Alzheimer's disease ERC2 intron 24755620 rs17288603 chr3 55955214 G A 7.82E-04 Alcohol dependence ERC2 intron 20201924 rs724333 chr3 55958059 T G 1.55E-04 Diabetic retinopathy ERC2 intron 20871662 rs724334 chr3 55958082 T C 8.57E-05 Alzheimer's disease ERC2 intron 24755620 rs11712398 chr3 55969663 T C 7.28E-04 Alzheimer's disease ERC2 intron 24755620 rs4974153 chr3 55969858 G T 9.55E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs4974153 chr3 55969858 G T 1.28E-05 Post-operative nausea and vomiting ERC2 intron 21694509 rs9311590 chr3 55989518 C G 6.29E-04 Multiple complex diseases ERC2 intron 17554300 rs12495172 chr3 55993656 G A 2.79E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs17056288 chr3 55993951 C T 7.76E-04 Smoking cessation ERC2 intron 24665060 rs732255 chr3 56016672 C T 8.10E-04 Alzheimer's disease ERC2 intron 24755620 rs1379720 chr3 56023942 A C,G,T 0.000454 Salmonella-induced pyroptosis ERC2 intron 22837397 rs7641427 chr3 56026877 C T 0.00043 Salmonella-induced pyroptosis ERC2 intron 22837397 rs1379717 chr3 56037999 G A 2.27E-04 Alzheimer's disease ERC2 intron 24755620 rs13061634 chr3 56054077 T C 2.76E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs11130493 chr3 56055557 G C 0.00088 Salmonella-induced pyroptosis ERC2 intron 22837397 rs9862661 chr3 56070758 A C 1.57E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs7623143 chr3 56088978 T C 4.73E-05 Cognitive test performance ERC2 intron 20125193 rs1485674 chr3 56105313 G A 1.23E-04 Multiple complex diseases ERC2 intron 17554300 rs1352008 chr3 56142860 T C 1.56E-04 Multiple complex diseases ERC2 intron 17554300 rs9873343 chr3 56189053 C T 2.25E-04 Coronary Artery Disease ERC2 intron 17634449 rs1452206 chr3 56233022 G A 5.82E-05 Varicose Veins ERC2 intron pha001413 rs9851360 chr3 56434975 C T 8.68E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs1491158 chr3 56436161 G A 8.21E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs6763636 chr3 56440429 T G 8.71E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs9817231 chr3 56440977 A T 8.67E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs11130520 chr3 56441119 T G 8.65E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs885211 chr3 56447869 C T 3.10E-04 Aortic root size ERC2 intron 21223598 rs885211 chr3 56447869 C T 3.93E-04 Insulin resistance ERC2 intron 21901158 rs885211 chr3 56447869 C T 7.80E-04 Heart Failure ERC2 intron pha002884 rs9814545 chr3 56458160 G A 2.25E-04 Multiple complex diseases ERC2 intron 17554300 rs9855289 chr3 56471160 C T 9.33E-05 Multiple complex diseases ERC2 intron 17554300 rs1878270 chr3 56487580 C G 7.11E-05 Schizophrenia(age at onset) ERC2 intron 21688384 rs9873381 chr3 56489776 G A 2.51E-05 Schizophrenia(age at onset) ERC2 intron 21688384 rs9881216 chr3 56516645 C T 4.62E-04 Multiple complex diseases / / 17554300 rs9881216 chr3 56516645 C T 6.38E-05 Schizophrenia(age at onset) / / 21688384 rs7633140 chr3 56521164 G A 4.94E-04 Multiple complex diseases / / 17554300 rs2054989 chr3 56530709 A G 6.00E-07 Hip geometry / / 17903296 rs978979 chr3 56533016 A G 9.05E-04 Multiple complex diseases / / 17554300 rs12054450 chr3 56576503 C T 5.78E-04 Myopia (pathological) / / 21095009 rs6791987 chr3 56579538 C T 2.82E-05 Creatinine levels / / pha003069 rs13093662 chr3 56581983 T C 5.78E-04 Myopia (pathological) / / 21095009 rs17288810 chr3 56582589 G A 8.41E-04 Multiple complex diseases / / 17554300 rs7637449 chr3 56628031 G A 1.80E-06 Height CCDC66 missense 21998595 rs2317134 chr3 56648363 T C 1.04E-04 Multiple complex diseases CCDC66 intron 17554300 rs9833926 chr3 56650178 A G 7.00E-06 Height CCDC66 intron 21998595 rs9835332 chr3 56667682 G C 5.00E-13 Height FAM208A missense 20881960 rs3732513 chr3 56674303 T C 1.70E-04 Nonalcoholic fatty liver disease FAM208A intron 21423719 rs11719707 chr3 56691393 G A 5.60E-05 Lymphocyte counts FAM208A intron 22286170 rs958755 chr3 56716922 T G 9.60E-06 Height FAM208A missense 21998595 rs6773931 chr3 56735180 C A 8.00E-08 Height / / 21998595 rs6445815 chr3 56740101 A G 3.50E-07 Height / / 21998595 rs6805864 chr3 56754839 C G 2.10E-05 Urinary metabolites / / 21572414 rs13319627 chr3 56769446 C T 1.20E-05 Urinary metabolites ARHGEF3 intron 21572414 rs3732509 chr3 56784848 C G 2.00E-05 Urinary metabolites ARHGEF3 intron 21572414 rs13100723 chr3 56798495 C T 1.00E-06 Obesity-related traits ARHGEF3 intron 23251661 rs2171858 chr3 56798704 C G 2.84E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs2171857 chr3 56798749 A G 2.94E-05 Multiple complex diseases ARHGEF3 intron 17554300 rs1039384 chr3 56849189 A G 1.76E-05 Personality dimensions ARHGEF3 intron 22628180 rs1354034 chr3 56849749 T C 3.00E-54 Platelet counts ARHGEF3 intron 22139419 rs1354034 chr3 56849749 T C 3.00E-69 Mean platelet volume ARHGEF3 intron 22139419 rs1354034 chr3 56849749 T C 1.00E-19 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 4.00E-09 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 9.00E-13 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 6.00E-24 Platelet counts ARHGEF3 intron 24026423 rs1354034 chr3 56849749 T C 9.00E-34 Mean platelet volume ARHGEF3 intron 24026423 rs4681908 chr3 56865752 C T 7.44E-06 Body Mass Index ARHGEF3 intron pha003020 rs12485738 chr3 56865776 A G 4.00E-27 Mean platelet volume ARHGEF3 intron 19110211 rs12485738 chr3 56865776 A G 6.00E-31 Mean platelet volume ARHGEF3 intron 19820697 rs12485738 chr3 56865776 A G 6.60E-14 Mean platelet volume ARHGEF3 intron 22423221 rs9881237 chr3 56870534 A G 6.73E-05 Body Mass Index ARHGEF3 intron pha003020 rs10510789 chr3 56877788 C T 1.45E-05 F-cell distribution ARHGEF3 intron 21326311 rs9845092 chr3 56893125 A G 8.23E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs1500710 chr3 56914065 C A 5.20E-05 Multiple sclerosis ARHGEF3 intron 21833088 rs6445834 chr3 56915719 T C 9.72E-05 Calcium intake levels and metabolic syndrome ARHGEF3 intron 22170361 rs9823870 chr3 56917254 T C 2.31E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs4681927 chr3 56919435 C T 5.01E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs950155 chr3 56920880 G C 6.31E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs950154 chr3 56920909 G A 2.78E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs11916112 chr3 56924711 G A 7.29E-04 Alcohol dependence ARHGEF3 intron 20201924 rs4681929 chr3 56927023 G A 3.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ARHGEF3 intron 24023788 rs13070800 chr3 56942973 C T 2.26E-04 Blood pressure ARHGEF3 intron 17255346 rs9882574 chr3 56944019 T C 5.73E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs9828029 chr3 56949707 A C 6.75E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs17825630 chr3 56950055 G A 6.78E-04 Amyotrophic Lateral Sclerosis ARHGEF3 intron 17362836 rs1354035 chr3 56953624 C T 1.00E-04 Blood pressure ARHGEF3 intron 17255346 rs6792170 chr3 56958358 G A 2.64E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs41433248 chr3 56962393 T C 3.76E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs41425945 chr3 56962422 G A 6.49E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs1021734 chr3 56963344 C T 4.74E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs11130557 chr3 56964674 T C 6.97E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs2062583 chr3 56966246 G T 2.00E-06 Rheumatoid arthritis ARHGEF3 intron 21452313 rs7650541 chr3 56990550 C T 3.89E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs11925114 chr3 57014082 G A 6.19E-04 Obesity (extreme) ARHGEF3 intron 21935397 rs3924042 chr3 57020736 C T 2.36E-05 Heart Rate ARHGEF3 intron pha003054 rs11130559 chr3 57046092 G A 5.16E-04 Alzheimer's disease ARHGEF3 intron 24755620 rs11130567 chr3 57074119 C T 2.11E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs11130567 chr3 57074119 C T 2.00E-04 Cognitive impairment induced by topiramate ARHGEF3 intron 22091778 rs755871 chr3 57080938 C T 6.95E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ARHGEF3 intron 21844884 rs2291462 chr3 57132200 A G 0.000491045 Hypertension (early onset hypertension) IL17RD cds-synon 22479346 rs6445853 chr3 57134115 A G 0.000227043 Hypertension (early onset hypertension) IL17RD intron 22479346 rs2247656 chr3 57137090 A G 8.57E-04 Insulin resistance IL17RD intron 21901158 rs1545981 chr3 57139972 A G 0.000510901 Hypertension (early onset hypertension) IL17RD cds-synon 22479346 rs747089 chr3 57153869 C T 1.82E-04 Lymphocyte counts IL17RD intron 22286170 rs12495640 chr3 57160312 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes IL17RD intron 22628534 rs4535195 chr3 57186035 A C 1.00E-05 F-cell distribution IL17RD intron 17767159 rs1352343 chr3 57195276 C G 8.98E-04 Multiple complex diseases IL17RD intron 17554300 rs4283545 chr3 57200758 C A 2.16E-04 Celiac disease / / 23936387 rs11130575 chr3 57204419 A G 9.14E-04 Heart Failure / / pha002885 rs11544593 chr3 57303684 A G 8.28E-05 Orofacial clefts APPL1 missense 20023658 rs571879 chr3 57347878 C T 1.38E-04 Celiac disease D/H12 intron 23936387 rs7648819 chr3 57351327 G A 1.13E-04 Multiple complex diseases D/H12 intron 17554300 rs1916284 chr3 57394766 T C 7.87E-04 Multiple complex diseases D/H12 intron 17554300 rs1916284 chr3 57394766 T C 1.00E-06 Prostate cancer (gene x gene interaction) D/H12 intron 22219177 rs11915740 chr3 57414330 C A 9.99E-04 Stroke D/H12 intron pha002887 rs2121743 chr3 57431985 G A 1.56E-05 Pulmonary function in asthmatics D/H12 cds-synon 23541324 rs9855748 chr3 57432609 C A 7.26E-04 Multiple complex diseases D/H12 intron 17554300 rs10510793 chr3 57473750 G A 4.49E-04 Renal cell carcinoma D/H12 intron 22010048 rs4681992 chr3 57489591 C A 4.01E-05 Pulmonary function in asthmatics D/H12 intron 23541324 rs4681993 chr3 57497715 C T 2.07E-04 Alzheimer's disease D/H12 intron 22005930 rs6445905 chr3 57499769 A G 2.55E-04 Alzheimer's disease D/H12 intron 22005930 rs6768058 chr3 57501031 G A 2.02E-04 Alzheimer's disease D/H12 intron 22005930 rs7612786 chr3 57508012 T C 1.95E-04 Alzheimer's disease D/H12 intron 22005930 rs3816365 chr3 57508538 C A 4.13E-04 Multiple complex diseases D/H12 intron 17554300 rs1470552 chr3 57510660 G A 1.88E-04 Alzheimer's disease D/H12 intron 22005930 rs6786181 chr3 57516548 G A 1.62E-04 Alzheimer's disease D/H12 intron 22005930 rs6769578 chr3 57518766 C T 1.60E-04 Alzheimer's disease D/H12 intron 22005930 rs9870678 chr3 57522950 A G 3.67E-05 Multiple complex diseases D/H12 intron 17554300 rs9311651 chr3 57528503 A G 2.86E-04 Birth weight D/H12 missense 17255346 rs12488539 chr3 57586825 G T 2.49E-04 Alzheimer's disease / / 22005930 rs6762914 chr3 57612623 T C 1.86E-04 Alzheimer's disease FAM116A UTR-3 22005930 rs11130595 chr3 57640001 T A 1.88E-04 Alzheimer's disease FAM116A intron 22005930 rs2361345 chr3 57666571 T C 7.81E-05 HIV-1 control FAM116A intron 20041166 rs12638616 chr3 57672353 G C 9.93E-04 Multiple complex diseases FAM116A intron 17554300 rs9873544 chr3 57708022 T C 3.41E-04 Alzheimer's disease / / 22005930 rs4530498 chr3 57724602 A G 1.21E-04 Alzheimer's disease (late onset) / / 21379329 rs6445927 chr3 57741346 A G 3.70E-04 Alzheimer's disease (late onset) / / 21379329 rs2061573 chr3 57763642 G A 4.93E-04 Alzheimer's disease (late onset) SLMAP intron 21379329 rs6768930 chr3 57779836 T C 5.00E-06 Obesity-related traits SLMAP intron 23251661 rs17745496 chr3 57902639 G A 6.32E-05 HIV-1 control SLMAP cds-synon 20041166 rs1098018 chr3 57979767 G T 1.10E-04 Height / / 19039035 rs9828717 chr3 57998986 C T 1.63E-04 Myocardial Infarction FLNB intron pha002883 rs1718460 chr3 58006413 A G 1.04E-05 Height FLNB intron 19039035 rs1658342 chr3 58009259 G A,C 1.09E-05 Height FLNB intron 19039035 rs865726 chr3 58018879 C T 3.76E-05 Height FLNB intron 19039035 rs839232 chr3 58020826 T A 1.49E-05 Height FLNB intron 19039035 rs1718481 chr3 58025903 C T 1.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs1718481 chr3 58025903 C T 7.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs1623879 chr3 58027197 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs839230 chr3 58036792 C T 2.42E-04 Multiple complex diseases FLNB intron 17554300 rs839230 chr3 58036792 C T 2.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs839230 chr3 58036792 C T 5.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs732527 chr3 58036935 T C 3.20E-04 Multiple complex diseases FLNB intron 17554300 rs732526 chr3 58036962 C T 3.84E-04 Multiple complex diseases FLNB intron 17554300 rs1249968 chr3 58045538 C T 2.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs1249968 chr3 58045538 C T 6.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs9809315 chr3 58050265 C T 2.84E-05 Eye color FLNB intron 23118974 rs4681659 chr3 58059661 G C 6.62E-05 Lymphocyte counts FLNB intron 22286170 rs2033739 chr3 58063819 G A 8.43E-04 Myocardial Infarction FLNB intron pha002883 rs4681784 chr3 58071644 C A 3.94E-04 Height FLNB intron 19039035 rs13315037 chr3 58072471 T G 8.96E-04 Suicide attempts in bipolar disorder FLNB intron 21041247 rs9834312 chr3 58082709 G A 7.30E-06 Height FLNB intron 19039035 rs7615893 chr3 58098444 T C 6.97E-04 Alcohol dependence FLNB intron 21314694 rs13077017 chr3 58105776 C T 1.00E-06 Eating disorders (purging via substances) FLNB intron 23568457 rs4681800 chr3 58109748 T A 8.12E-04 Alcohol dependence FLNB intron 21314694 rs2362904 chr3 58112488 C T 2.44E-04 Alcohol dependence FLNB cds-synon 20201924 rs3772993 chr3 58114884 C T 5.94E-04 Height FLNB intron 19039035 rs200297468 chr3 58116540 G C 0.000061 Breast cancer FLNB missense 23555315 rs4681795 chr3 58136429 T C 1.70E-05 Alcohol dependence FLNB intron 20201924 rs4681795 chr3 58136429 T C 1.70E-05 Alcoholism FLNB intron pha002891 rs35677470 chr3 58183636 G A 0.00000017 Rheumatoid arthritis D/SE1L3 missense 23143596 rs35677470 chr3 58183636 G A 0.00000109 Rheumatoid arthritis (CCP positive) D/SE1L3 missense 23143596 rs4681824 chr3 58199669 T G 6.88E-04 Alcohol dependence D/SE1L3 intron 21314694 rs9986 chr3 58280406 A G 5.81E-06 Esophageal cancer (squamous cell) ABHD6 UTR-3 22960999 rs2363688 chr3 58282128 A G 7.69E-04 Multiple complex diseases / / 17554300 rs17059150 chr3 58292131 C A 7.36E-04 Multiple complex diseases RPP14 UTR-5 17554300 rs73081554 chr3 58302935 C T 4.60E-08 Rheumatoid arthritis RPP14 intron 24390342 rs73081554 chr3 58302935 C T 5.00E-08 Rheumatoid arthritis RPP14 intron 24390342 rs2176082 chr3 58331186 G A 5.00E-11 Systemic lupus erythematosus and Systemic sclerosis PXK intron 23740937 rs11715445 chr3 58343888 T C 1.46E-04 Multiple complex diseases PXK intron 17554300 rs6445975 chr3 58370177 G T 7.00E-09 Systemic lupus erythematosus PXK intron 18204446 rs6445975 chr3 58370177 G T 7.10E-09 Multiple sclerosis PXK intron 22190364 rs6772228 chr3 58376019 T A 3.91E-10 Telomere length PXK intron 23900074 rs11923253 chr3 58376992 G A 5.35E-04 Smoking initiation PXK intron 24665060 rs13315871 chr3 58381287 G A 4.00E-08 Cholesterol,total PXK intron 24097068 rs4681851 chr3 58395891 C G 1.87E-07 Telomere length PXK intron 23900074 rs2070662 chr3 58415590 C A 2.46E-06 Telomere length PDHB intron 23900074 rs6768547 chr3 58434969 T C 1.99E-06 Telomere length / / 23900074 rs7633553 chr3 58440236 T C 1.10E-04 Telomere length / / 23900074 rs4681861 chr3 58495739 A T 1.81E-04 Telomere length ACOX2 intron 23900074 rs4317122 chr3 58498843 C T 1.40E-04 Telomere length ACOX2 intron 23900074 rs2120577 chr3 58551800 T C 3.30E-05 HIV-1 control FAM107A UTR-3 20041166 rs11539086 chr3 58552329 C G 1.35E-04 Type 2 diabetes FAM107A missense 17463246 rs11539086 chr3 58552329 C G 5.24E-10 Adiponectin levels FAM107A missense 20887962 rs9813011 chr3 58555895 T C 2.63E-06 Telomere length FAM107A intron 23900074 rs13315591 chr3 58556841 T C 8.43E-05 Type 2 diabetes FAM107A intron 17463246 rs13315591 chr3 58556841 T C 5.00E-08 Rheumatoid arthritis FAM107A intron 20453842 rs13315591 chr3 58556841 T C 4.60E-08 Celiac disease and Rheumatoid arthritis FAM107A intron 21383967 rs13315591 chr3 58556841 T C 4.60E-08 Multiple sclerosis FAM107A intron 22190364 rs13315591 chr3 58556841 T C 6.30E-07 Rheumatoid arthritis FAM107A intron 22446963 rs13315591 chr3 58556841 T C 0.000000046 Rheumatoid arthritis FAM107A intron 23143596 rs1444189 chr3 58566057 C T 3.42E-05 Type 2 diabetes / / 17463246 rs6445991 chr3 58575110 A G 9.41E-04 Alzheimer's disease / / 17998437 rs17059467 chr3 58590414 T C 3.11E-05 Multiple complex diseases / / 17554300 rs2306667 chr3 58594655 T C 6.05E-05 Response to diuretic therapy in hypertension / / 23753411 rs900871 chr3 58595376 G A 3.44E-05 Telomere length LOC100506924 intron 23900074 rs4681875 chr3 58595823 T C 5.57E-05 Telomere length LOC100506924 intron 23900074 rs11710358 chr3 58614016 C T 7.52E-04 Type 2 diabetes / / 17463246 rs1373407 chr3 58614195 G A 5.66E-04 Tourette syndrome / / 22889924 rs753819 chr3 58614393 A G 8.39E-04 Type 2 diabetes / / 17463246 rs753821 chr3 58614420 G A 6.18E-04 Type 2 diabetes / / 17463246 rs753821 chr3 58614420 G A 7.35E-05 Multiple sclerosis / / 17660530 rs3860562 chr3 58619522 C T 6.92E-05 Coronary restenosis / / 21878436 rs11130665 chr3 58622620 G T 9.90E-04 Type 2 diabetes FAM3D intron 17463246 rs2364305 chr3 58653904 C G 1.70E-05 Urinary metabolites / / 21572414 rs2364306 chr3 58654095 T C 1.90E-06 Urinary metabolites / / 21572414 rs900878 chr3 58654265 T C 9.10E-06 Urinary metabolites / / 21572414 rs13075889 chr3 58655038 G A 1.10E-05 Urinary metabolites / / 21572414 rs6802213 chr3 58655999 T A 1.90E-05 Urinary metabolites / / 21572414 rs11130671 chr3 58754163 C T 1.10E-04 HIV-1 viral setpoint C3orf67 intron 17641165 rs17360960 chr3 58854266 T C 3.34E-04 Birth weight C3orf67 intron 17255346 rs6783793 chr3 59012177 A G 8.66E-04 Multiple complex diseases C3orf67 intron 17554300 rs2137457 chr3 59105913 G A 6.48E-04 Alcohol dependence / / 21314694 rs9824833 chr3 59126777 G T 8.59E-04 HIV-1 viral setpoint / / 17641165 rs1512823 chr3 59144273 G A 5.75E-04 Smoking initiation / / 24665060 rs4274771 chr3 59182023 T G 1.94E-04 HIV-1 viral setpoint / / 17641165 rs9838009 chr3 59265315 G T 8.40E-05 Asthma (bronchodilator response) / / 22792082 rs13321256 chr3 59295141 A G 3.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11130695 chr3 59305064 A C 7.00E-06 Asthma / / 21790008 rs9842553 chr3 59306653 G A 2.51E-04 Endometrial cancer / / 24096698 rs9842553 chr3 59306653 G A 5.80E-04 Endometrial cancer / / 24096698 rs6414594 chr3 59308131 A G 5.63E-05 Multiple complex diseases / / 17554300 rs6446030 chr3 59312883 T C 1.81E-05 Multiple complex diseases / / 17554300 rs6414595 chr3 59316581 T C 2.60E-05 Multiple complex diseases / / 17554300 rs4679621 chr3 59324733 C T 6.13E-04 Multiple complex diseases / / 17554300 rs9811499 chr3 59325384 C T 9.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6771019 chr3 59354158 G A 2.00E-06 Capecitabine sensitivity / / 22864933 rs6446043 chr3 59356425 T A 7.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446043 chr3 59356425 T A 7.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs2366434 chr3 59357436 A G 7.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11130703 chr3 59358190 T C 4.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs11130703 chr3 59358190 T C 9.37E-06 Suicide attempts in bipolar disorder / / 21041247 rs2034127 chr3 59368074 A G 8.54E-08 Primary biliary cirrhosis / / 23000144 rs2034127 chr3 59368074 A G 8.54E-08 Facial morphology / / 23028347 rs2034128 chr3 59368259 A G 9.55E-08 Primary biliary cirrhosis / / 23000144 rs2034128 chr3 59368259 A G 9.55E-08 Facial morphology / / 23028347 rs2034129 chr3 59368293 C A 9.25E-08 Primary biliary cirrhosis / / 23000144 rs2034129 chr3 59368293 C A 9.25E-08 Facial morphology / / 23028347 rs7628370 chr3 59370600 A C 2.27E-07 Primary biliary cirrhosis / / 23000144 rs7628370 chr3 59370600 A C 0.000000227 Facial morphology / / 23028347 rs7617069 chr3 59370695 C A 2.47E-07 Primary biliary cirrhosis / / 23000144 rs7617069 chr3 59370695 C A 0.000000247 Facial morphology / / 23028347 rs717463 chr3 59372700 T C 4.74E-07 Primary biliary cirrhosis / / 23000144 rs717463 chr3 59372700 T C 0.000000474 Facial morphology / / 23028347 rs894883 chr3 59373255 A G 1.34E-07 Primary biliary cirrhosis / / 23000144 rs894883 chr3 59373255 A G 0.000000134 Facial morphology / / 23028347 rs755314 chr3 59373505 C T 7.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2886671 chr3 59373745 C T 2.06E-08 Narcolepsy / / 19629137 rs7640340 chr3 59380011 A G 3.07E-07 Primary biliary cirrhosis / / 23000144 rs7640340 chr3 59380011 A G 0.000000307 Facial morphology / / 23028347 rs875143 chr3 59380371 C T 4.21E-07 Primary biliary cirrhosis / / 23000144 rs875143 chr3 59380371 C T 0.000000421 Facial morphology / / 23028347 rs6795519 chr3 59388206 C T 4.58E-07 Primary biliary cirrhosis / / 23000144 rs6795519 chr3 59388206 C T 0.000000458 Facial morphology / / 23028347 rs4679485 chr3 59405125 T C 7.95E-05 Heart Rate / / pha003054 rs1021813 chr3 59413060 T C 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9849137 chr3 59413111 G A 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2062751 chr3 59413947 G A 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs962791 chr3 59417186 A G 4.94E-04 Rheumatoid arthritis / / 21452313 rs6783485 chr3 59427797 G A 4.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1910236 chr3 59434420 G A 9.37E-06 Response to gemcitabine in pancreatic cancer / / 22142827 rs6795120 chr3 59439285 A G 0.000312 Salmonella-induced pyroptosis / / 22837397 rs12492703 chr3 59439794 T G 0.0008439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12492703 chr3 59439794 T G 8.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17060744 chr3 59445755 A G 0.0008319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17060744 chr3 59445755 A G 8.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6803293 chr3 59452332 A G 2.67E-04 Multiple complex diseases / / 17554300 rs9883195 chr3 59460320 C A 0.0006968 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9883195 chr3 59460320 C A 6.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12498091 chr3 59460477 G A 0.0005832 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12498091 chr3 59460477 G A 5.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4679576 chr3 59470877 A T 8.15E-05 Serum metabolites / / 19043545 rs6772601 chr3 59472325 T G 2.93E-05 Serum metabolites / / 19043545 rs1502618 chr3 59474415 C G 2.20E-05 Serum metabolites / / 19043545 rs7626018 chr3 59474911 T C 3.87E-05 Serum metabolites / / 19043545 rs6780771 chr3 59475736 A G 3.88E-05 Serum metabolites / / 19043545 rs10510812 chr3 59481606 A G 1.05E-04 Multiple complex diseases / / 17554300 rs11130713 chr3 59481821 G A 1.39E-04 Multiple complex diseases / / 17554300 rs7620213 chr3 59482405 C T 4.06E-05 Serum metabolites / / 19043545 rs17333781 chr3 59487381 G T 2.34E-04 Multiple complex diseases / / 17554300 rs11925209 chr3 59491084 G A 1.60E-04 Multiple complex diseases / / 17554300 rs9862576 chr3 59491566 C T 2.51E-05 Serum metabolites / / 19043545 rs11130715 chr3 59492701 C G 3.54E-05 Serum metabolites / / 19043545 rs9848067 chr3 59504497 T A 7.39E-04 Multiple complex diseases / / 17554300 rs9832635 chr3 59504894 G A 3.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9855650 chr3 59519764 C T 7.41E-04 Schizophrenia / / 19197363 rs6768376 chr3 59523538 G A 9.90E-05 Insulin-related traits / / pha002901 rs1502616 chr3 59530321 A G 3.92E-04 Type 2 diabetes / / 17463246 rs10510813 chr3 59535975 G A 2.06E-04 Multiple complex diseases / / 17554300 rs734185 chr3 59555122 C T 1.82E-04 Multiple complex diseases / / 17554300 rs2886745 chr3 59560769 T C 3.38E-04 Multiple complex diseases / / 17554300 rs1504915 chr3 59566484 A G 6.56E-04 Coronary heart disease / / 21606135 rs6809606 chr3 59568658 C G 7.16E-04 Coronary Artery Disease / / 17634449 rs7615380 chr3 59570968 C T 5.13E-04 Coronary heart disease / / 21971053 rs4679496 chr3 59580150 T G 8.92E-04 Multiple complex diseases / / 17554300 rs1504912 chr3 59598180 T G 4.43E-05 White matter integrity / / 22425255 rs1281444 chr3 59619214 G A 1.09E-04 White matter integrity / / 22425255 rs12493940 chr3 59620667 G A 1.44E-04 Multiple complex diseases / / 17554300 rs732514 chr3 59623920 C T 8.13E-05 White matter integrity / / 22425255 rs2121794 chr3 59644233 G A 1.13E-04 Alzheimer's disease / / 17998437 rs2121794 chr3 59644233 G A 2.14E-04 Alzheimer's disease / / pha002879 rs1447807 chr3 59648681 A G 2.56E-06 Conotruncal heart defects / / 24800985 rs6763159 chr3 59649521 T C 1.00E-06 Conotruncal heart defects / / 24800985 rs10510816 chr3 59655530 C A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510816 chr3 59655530 C A 2.34E-06 Osteoarthritis / / 22763110 rs10510818 chr3 59659240 C T 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1550922 chr3 59659658 G A 4.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6774996 chr3 59674664 A G 5.01E-05 Multiple complex diseases / / 17554300 rs7634315 chr3 59675336 G A 8.96E-05 Monocyte counts / / pha003089 rs17358517 chr3 59685732 C T 2.04E-05 Postoperative ventricular dysfunction / / 21980348 rs17292696 chr3 59686286 G A 2.23E-05 Postoperative ventricular dysfunction / / 21980348 rs11924953 chr3 59686425 G C 3.21E-05 Postoperative ventricular dysfunction / / 21980348 rs10510819 chr3 59691572 C G 5.73E-05 Multiple complex diseases / / 17554300 rs6766124 chr3 59693397 G A 9.60E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4679599 chr3 59695594 A C 5.20E-04 Insomnia / / 23728906 rs2366846 chr3 59705894 C A 4.53E-04 Sudden cardiac arrest / / 21658281 rs7373248 chr3 59711017 C T 3.97E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7373248 chr3 59711017 C T 9.37E-04 Stroke / / pha002886 rs1155530 chr3 59727802 A G 0.0000497 Carotid intima media thickness / / 23152477 rs812965 chr3 59736299 T C 4.80E-04 Crohn's disease FHIT intron 17684544 rs13075135 chr3 59739630 G C 5.86E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs6803403 chr3 59739919 G A 8.19E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs1385715 chr3 59741515 A C 3.99E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs1385715 chr3 59741515 A C 9.65E-06 Tuberculosis FHIT intron 24057671 rs13313901 chr3 59748732 A G 9.64E-05 Bipolar disorder FHIT intron 22925353 rs12152416 chr3 59750069 G A 8.95E-05 Bipolar disorder FHIT intron 22925353 rs17061182 chr3 59757136 C A 4.51E-05 Multiple complex diseases FHIT intron 17554300 rs812964 chr3 59757883 G A 2.85E-04 Multiple complex diseases FHIT intron 17554300 rs780358 chr3 59759119 A G 5.77E-04 Multiple complex diseases FHIT intron 17554300 rs517711 chr3 59762008 G A 1.73E-05 Personality dimensions FHIT intron 22628180 rs780346 chr3 59766184 A T 9.06E-06 Personality dimensions FHIT intron 22628180 rs780347 chr3 59767118 G A 8.74E-06 Personality dimensions FHIT intron 22628180 rs673870 chr3 59770221 C T 1.52E-05 Personality dimensions FHIT intron 22628180 rs17361780 chr3 59772328 A G 2.50E-04 Multiple complex diseases FHIT intron 17554300 rs780354 chr3 59772460 A C 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) FHIT intron 22010049 rs780354 chr3 59772460 A C 3.49E-04 Response to taxane treatment (placlitaxel) FHIT intron 23006423 rs2629877 chr3 59793062 C T 8.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs2171077 chr3 59797400 C A,G,T 0.00006 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs2605441 chr3 59797584 G C 0.0000619 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs2629899 chr3 59800539 T G 0.0000608 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs1079196 chr3 59806778 G A 8.00E-08 Personality dimensions FHIT intron 22628180 rs1079196 chr3 59806778 G A 0.00000568 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs4679614 chr3 59810867 C T 1.32E-06 Personality dimensions FHIT intron 22628180 rs4679615 chr3 59811024 T C 2.75E-06 Personality dimensions FHIT intron 22628180 rs689497 chr3 59811462 G T 6.35E-04 Alzheimer's disease FHIT intron 24755620 rs17061239 chr3 59811605 T C 3.75E-04 Smoking initiation FHIT intron 24665060 rs1872495 chr3 59811637 A G 2.76E-06 Personality dimensions FHIT intron 22628180 rs10428174 chr3 59814048 G A 4.49E-05 Cleft lip FHIT intron 20436469 rs10428174 chr3 59814048 G A 5.33E-07 Personality dimensions FHIT intron 22628180 rs639244 chr3 59839235 G C 5.77E-04 Multiple complex diseases FHIT intron 17554300 rs598678 chr3 59844944 C T 2.53E-05 Personality dimensions FHIT intron 22628180 rs620113 chr3 59869370 G A 9.65E-04 Insulin resistance FHIT intron 21901158 rs11915344 chr3 59877910 G A 9.03E-04 Multiple complex diseases FHIT intron 17554300 rs11715245 chr3 59891227 C T 2.48E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs11715245 chr3 59891227 C T 4.51E-05 Serum albumin level FHIT intron pha003084 rs294459 chr3 59898057 T C 4.35E-05 Osteoarthritis (knee and hip) FHIT intron 21177295 rs294457 chr3 59899215 A G 2.09E-05 Hepatitis B vaccine response FHIT intron 21764829 rs294454 chr3 59900739 T C 3.92E-05 Waist Circumference FHIT intron pha003025 rs294453 chr3 59900929 G T 5.03E-05 Aortic root size FHIT intron 21223598 rs1825630 chr3 59902801 C T 8.00E-06 Aortic root size FHIT intron 21223598 rs1038516 chr3 59917928 A G 6.22E-04 Multiple complex diseases FHIT intron 17554300 rs4502542 chr3 59921020 T C 2.00E-06 Response to citalopram treatment FHIT intron 22760553 rs17302202 chr3 59922638 T C 4.04E-04 Type 2 diabetes FHIT intron 17463246 rs17061517 chr3 59924843 A G 9.42E-04 Major depressive disorder FHIT intron 22472876 rs931317 chr3 59928851 A G 1.44E-05 Nicotine smoking FHIT intron 19268276 rs931317 chr3 59928851 A G 3.00E-06 Myopia (pathological) FHIT intron 23049088 rs11707783 chr3 59946384 A G 5.11E-05 Orofacial clefts FHIT intron 22419666 rs9863289 chr3 59957814 C T 3.24E-04 Aortic root size FHIT intron 21223598 rs212034 chr3 59961536 G A 5.84E-05 Orofacial clefts FHIT intron 22419666 rs802775 chr3 59968353 C T 5.30E-04 Amyotrophic Lateral Sclerosis FHIT intron 17362836 rs2630190 chr3 59970997 T C 2.60E-05 Urinary metabolites FHIT intron 21572414 rs2630167 chr3 59974515 T C 8.39E-04 Aortic root size FHIT intron 21223598 rs3772503 chr3 59980424 T C 7.89E-05 Body Composition FHIT intron pha003012 rs212016 chr3 59981525 T C 7.00E-06 Orofacial clefts FHIT intron 22419666 rs212016 chr3 59981525 T C 0.0000166 Tuberculosis with late age of onset FHIT intron 22551897 rs13086424 chr3 59982062 C T 0.0000236 Tuberculosis with late age of onset FHIT intron 22551897 rs212017 chr3 59984501 A C 5.87E-04 Alzheimer's disease FHIT intron 22005930 rs212018 chr3 59985179 G A 2.23E-04 Alzheimer's disease FHIT intron 22005930 rs9311744 chr3 59991006 C G 5.70E-04 Aortic root size FHIT intron 21223598 rs802777 chr3 59991863 G A 3.55E-04 Alzheimer's disease FHIT intron 22005930 rs802779 chr3 59993222 T C 3.48E-04 Alzheimer's disease FHIT intron 22005930 rs17061792 chr3 60000052 C T 4.17E-05 Blood Pressure FHIT intron pha003045 rs17061792 chr3 60000052 C T 3.93E-05 Blood Pressure FHIT intron pha003047 rs3845970 chr3 60000536 C A 6.38E-05 Lipoproteins FHIT intron pha003079 rs3845971 chr3 60000672 T C 1.00E-04 Type 2 diabetes FHIT intron 17846126 rs9311745 chr3 60001825 T C 5.00E-06 Pit-and-Fissure caries FHIT intron 23470693 rs3912494 chr3 60007657 C G,T 7.44E-05 Schizophrenia FHIT intron 19571809 rs3912494 chr3 60007657 C G,T 9.80E-05 Schizophrenia FHIT intron pha002859 rs9817995 chr3 60009521 C A 8.22E-04 Multiple complex diseases FHIT intron 17554300 rs9874888 chr3 60016317 T A 2.40E-04 Multiple complex diseases FHIT intron 17554300 rs9874888 chr3 60016317 T A 1.36E-09 Narcolepsy FHIT intron 19629137 rs2630161 chr3 60019926 G A 2.32E-04 Type 2 diabetes FHIT intron 17463246 rs182418 chr3 60020000 G A 2.60E-05 Urinary metabolites FHIT intron 21572414 rs212063 chr3 60022161 C T 3.56E-05 Type 2 diabetes FHIT intron 17463246 rs212062 chr3 60022470 A G 1.71E-04 Type 2 diabetes FHIT intron 17463246 rs212062 chr3 60022470 A G 3.94E-04 Myocardial Infarction FHIT intron pha002873 rs212059 chr3 60024883 T C 1.20E-05 Urinary metabolites FHIT intron 21572414 rs17257269 chr3 60025505 T C 9.79E-26 Narcolepsy FHIT intron 19629137 rs17257269 chr3 60025505 T C 1.80E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs3845972 chr3 60027834 G A 4.60E-05 Bone mineral density (BMD),in women FHIT intron 20164292 rs3856662 chr3 60028556 A G 4.35E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs212057 chr3 60028591 T C 1.25E-04 Type 2 diabetes FHIT intron 17463246 rs212051 chr3 60034455 T C 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs212049 chr3 60035129 C T 9.05E-05 Coronary heart disease FHIT intron pha003030 rs212046 chr3 60036213 T C 5.77E-05 Body Mass Index FHIT intron pha003014 rs212041 chr3 60038278 G T 3.94E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs212039 chr3 60038581 C T 3.84E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs9860107 chr3 60040105 A G 5.70E-05 Endometriosis FHIT intron 21151130 rs9860107 chr3 60040105 A G 9.96E-05 Erythrocyte counts FHIT intron pha003101 rs7638558 chr3 60045801 T C 0.000036 Primary sclerosing cholangitis FHIT intron 22521342 rs2630165 chr3 60051898 G T 9.35E-04 Type 2 diabetes FHIT intron 17463246 rs2630194 chr3 60056524 C T 9.90E-06 Urinary metabolites FHIT intron 21572414 rs2630197 chr3 60057008 C T 1.19E-04 Type 2 diabetes FHIT intron 17463246 rs2630200 chr3 60057160 G A 1.44E-04 Type 2 diabetes FHIT intron 17463246 rs2736821 chr3 60059610 G A 1.54E-04 Type 2 diabetes FHIT intron 17463246 rs17062101 chr3 60062654 A G 5.86E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs6446109 chr3 60076989 G C 3.83E-05 Multiple complex diseases FHIT intron 17554300 rs6772047 chr3 60087728 A G 2.40E-05 Urinary metabolites FHIT intron 21572414 rs6766789 chr3 60090013 C A 7.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4679636 chr3 60103026 C G 8.02E-04 Coronary Artery Disease FHIT intron 17634449 rs4679636 chr3 60103026 C G 3.48E-05 Recombination rate FHIT intron 21698098 rs722070 chr3 60112295 G A 6.15E-05 Cytomegalovirus antibody response FHIT intron 21993531 rs41355450 chr3 60115462 T G 4.56E-05 Parkinson's disease FHIT intron 23793441 rs10510828 chr3 60120243 A G 3.12E-04 Longevity FHIT intron 22279548 rs10510829 chr3 60123522 A G 7.00E-07 Adverse response to lamotrigine and phenytoin FHIT intron 22379998 rs2064020 chr3 60138099 C A 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs9876685 chr3 60171660 T C 6.29E-05 Multiple sclerosis (OCB status) FHIT intron 23785401 rs1566057 chr3 60182144 C T 8.94E-04 Body mass index FHIT intron 21701565 rs213307 chr3 60188605 T C 7.44E-04 Amyotrophic Lateral Sclerosis FHIT intron 17362836 rs11130760 chr3 60196537 G T 2.50E-04 Oral cancers (chewing tobacco related) FHIT intron 22503698 rs11717164 chr3 60218337 G T 0.0000796 Tuberculosis with early age of onset FHIT intron 22551897 rs7628950 chr3 60220307 T A 4.70E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs10510834 chr3 60221516 A G 2.05E-04 Bipolar disorder FHIT intron 19259986 rs10510834 chr3 60221516 A G 4.27E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs9311754 chr3 60221953 C G 6.10E-04 Bipolar disorder FHIT intron 19259986 rs13082004 chr3 60222035 T C 3.84E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs17062579 chr3 60224011 A G 6.20E-04 Insulin resistance FHIT intron 21901158 rs17062609 chr3 60235256 G A 6.29E-04 Insulin resistance FHIT intron 21901158 rs143018 chr3 60246190 G A 1.91E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs10510835 chr3 60247121 G T 1.90E-05 Sleep and circadian phenotypes FHIT intron 17903308 rs10510835 chr3 60247121 G T 9.42E-05 Cognitive test performance FHIT intron 20125193 rs213333 chr3 60252827 C T 2.86E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs213344 chr3 60258799 A G 7.60E-04 Type 2 diabetes and 6 quantitative traits FHIT intron 17848626 rs9879860 chr3 60272317 T C 2.79E-05 Coronary restenosis FHIT intron 21878436 rs6768755 chr3 60286486 T C 9.40E-04 Height FHIT intron 21998595 rs9829607 chr3 60289140 A G 3.50E-05 Coronary restenosis FHIT intron 21878436 rs10510837 chr3 60289842 G A 4.00E-06 Asperger disorder FHIT intron 21182207 rs1353546 chr3 60291875 T C 5.04E-05 Coronary restenosis FHIT intron 21878436 rs6776005 chr3 60295081 A G 4.40E-05 Kawasaki disease FHIT intron 22446962 rs7631389 chr3 60297746 A G 4.51E-05 Coronary restenosis FHIT intron 21878436 rs7647196 chr3 60311682 C T 7.28E-05 Multiple complex diseases FHIT intron 17554300 rs963685 chr3 60321572 A C 9.10E-05 Suicide attempts in bipolar disorder FHIT intron 21423239 rs11708562 chr3 60330356 C A 6.27E-05 Smoking quantity FHIT intron 24665060 rs17062850 chr3 60357382 T C 2.85E-04 Response to cytidine analogues (gemcitabine) FHIT intron 24483146 rs1057504 chr3 60357956 C T 1.00E-04 Cognitive impairment induced by topiramate FHIT intron 22091778 rs11130770 chr3 60364046 C T 2.69E-05 Aortic root size FHIT intron 21223598 rs4679533 chr3 60367530 G C 2.21E-04 Aortic root size FHIT intron 21223598 rs9848065 chr3 60370637 C T 2.70E-05 Urinary metabolites FHIT intron 21572414 rs17062963 chr3 60379864 C G 1.60E-05 Urinary metabolites FHIT intron 21572414 rs13098396 chr3 60382828 T C 2.40E-05 Urinary metabolites FHIT intron 21572414 rs242201 chr3 60395260 A G 6.53E-06 Kawasaki disease FHIT intron 22081228 rs242201 chr3 60395260 A G 2.50E-05 Lipid levels FHIT intron pha003082 rs2687194 chr3 60417130 C G 3.20E-06 Glycemic traits (pregnancy) FHIT intron 23903356 rs2687194 chr3 60417130 C G 5.67E-06 Glycemic traits (pregnancy) FHIT intron 23903356 rs409484 chr3 60420417 G A 1.30E-05 Urinary metabolites FHIT intron 21572414 rs4566489 chr3 60439567 C T 4.05E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs12629710 chr3 60441487 A C 7.48E-04 Type 2 diabetes FHIT intron 22158537 rs12638086 chr3 60445573 C T 7.62E-04 Type 2 diabetes FHIT intron 22158537 rs12638610 chr3 60445806 C T 6.95E-04 Type 2 diabetes FHIT intron 22158537 rs1579912 chr3 60447340 T G 7.87E-04 Type 2 diabetes FHIT intron 22158537 rs424675 chr3 60448261 C T 4.78E-04 Type 2 diabetes FHIT intron 22158537 rs378346 chr3 60448591 G A 4.67E-04 Type 2 diabetes FHIT intron 22158537 rs2594239 chr3 60449009 C G 9.91E-04 Multiple complex diseases FHIT intron 17554300 rs1447971 chr3 60465279 G A 1.02E-04 Sleep time FHIT intron 23728906 rs2205042 chr3 60471104 T C 1.19E-04 Sleep latency FHIT intron 23728906 rs2594266 chr3 60487739 C T 3.52E-04 Multiple complex diseases FHIT intron 17554300 rs9985430 chr3 60488758 C T 9.00E-06 Urinary metabolites FHIT intron 21572414 rs6789538 chr3 60491103 G A 4.42E-04 Lung function (forced vital capacity) FHIT intron 24023788 rs10212340 chr3 60504260 G A,C 4.77E-04 Multiple complex diseases FHIT intron 17554300 rs10212340 chr3 60504260 G A,C 8.60E-06 Urinary metabolites FHIT intron 21572414 rs80171647 chr3 60508340 G T 2.00E-06 Response to amphetamines FHIT intron 22952603 rs12492175 chr3 60510909 C A 7.78E-04 White matter integrity FHIT intron 22425255 rs12492175 chr3 60510909 C A 3.52E-04 Alzheimer's disease FHIT intron 24755620 rs241704 chr3 60512889 A G 3.95E-05 Prostate cancer FHIT intron pha002878 rs7426703 chr3 60516181 T C 5.30E-06 Response to amphetamines FHIT intron 22952603 rs17063477 chr3 60518998 A G 7.29E-06 Response to amphetamines FHIT intron 22952603 rs11130772 chr3 60535731 G T 3.49E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs241684 chr3 60536669 C G 8.99E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs76200451 chr3 60538853 G C 5.54E-06 Response to amphetamines FHIT intron 22952603 rs151737 chr3 60540745 A G 8.40E-05 White matter integrity FHIT intron 22425255 rs2856045 chr3 60545429 A G 6.31E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs180998 chr3 60545602 G A 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs17063532 chr3 60562327 G A 1.16E-04 Vaspin levels FHIT intron 22907691 rs17063532 chr3 60562327 G A 0.0001157 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks FHIT intron 22907730 rs2734365 chr3 60565903 T C 0.0001779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FHIT intron 23233654 rs2734365 chr3 60565903 T C 1.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) FHIT intron 23233662 rs10510850 chr3 60567102 C T 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs9833533 chr3 60568253 G A 5.00E-04 Response to cytadine analogues (cytosine arabinoside) FHIT intron 24483146 rs7651468 chr3 60572073 G A 1.99E-05 Response to cytadine analogues (cytosine arabinoside) FHIT intron 24483146 rs2252742 chr3 60580713 G C 8.09E-04 Type 2 diabetes FHIT intron 17463246 rs7617530 chr3 60585756 G A 1.00E-05 Anxiety spectrum disorders FHIT intron 20368705 rs2856030 chr3 60591219 C G 1.50E-05 Urinary metabolites FHIT intron 21572414 rs11720214 chr3 60592348 C T 1.60E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs11720214 chr3 60592348 C T 4.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs17624325 chr3 60595986 C T 5.99E-04 Smoking cessation FHIT intron 24665060 rs2885865 chr3 60610341 G A 7.26E-04 Prostate cancer mortality FHIT intron 20978177 rs11926787 chr3 60615310 G A 5.51E-04 Smoking initiation FHIT intron 24665060 rs6762641 chr3 60616153 T C 2.30E-05 Urinary metabolites FHIT intron 21572414 rs10510852 chr3 60616790 G A 1.79E-05 Rheumatoid arthritis FHIT intron 17804836 rs10510853 chr3 60625286 C G 6.86E-07 Paclitaxel sensitivity in NCI60 cancer cell lines FHIT intron 21314952 rs1623091 chr3 60654169 C G 2.93E-04 Body mass index FHIT intron 21701565 rs1735444 chr3 60664075 G T 1.86E-04 Parkinson's disease FHIT intron 17052657 rs1735457 chr3 60683737 G A 6.50E-04 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.40E-05 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.70E-05 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.67E-05 Alcoholism FHIT intron pha002892 rs1735460 chr3 60691605 T C 3.40E-05 Alcoholism FHIT intron pha002893 rs1716744 chr3 60705150 G C 6.41E-04 Aortic root size FHIT intron 21223598 rs12493219 chr3 60725603 A G 4.43E-05 Erythrocyte counts FHIT intron pha003101 rs12631593 chr3 60726844 G A 3.49E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs4974227 chr3 60748726 A G 8.34E-04 Alzheimer's disease FHIT intron 24755620 rs1569346 chr3 60750062 A G 3.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs13073028 chr3 60761472 G A 2.47E-05 Cognitive test performance FHIT intron 20125193 rs11919041 chr3 60763256 G T 2.00E-06 Breast size FHIT intron 22747683 rs12492901 chr3 60767452 G T 9.24E-04 Alzheimer's disease FHIT intron 22005930 rs6791644 chr3 60771108 A G 8.00E-06 Attention deficit hyperactivity disorder FHIT intron 18821565 rs4974230 chr3 60780913 T C 9.90E-05 Pericardial fat FHIT intron 22589742 rs1447927 chr3 60787599 T C 5.79E-04 Alzheimer's disease FHIT intron 22005930 rs17064028 chr3 60793400 G A 2.90E-05 Urinary metabolites FHIT intron 21572414 rs2142296 chr3 60794217 G A 1.50E-05 Urinary metabolites FHIT intron 21572414 rs17064029 chr3 60799235 A G 2.09E-04 Fibrinogen FHIT intron 17255346 rs2364295 chr3 60800699 G C 2.60E-05 Urinary metabolites FHIT intron 21572414 rs2205353 chr3 60807828 C G 7.06E-04 Response to cytidine analogues (gemcitabine) FHIT intron 24483146 rs2594135 chr3 60812574 G C 1.54E-04 Multiple complex diseases FHIT intron 17554300 rs2594135 chr3 60812574 G C 4.50E-06 Urinary metabolites FHIT intron 21572414 rs17064083 chr3 60852438 C G 1.13E-04 Alcohol dependence FHIT intron 21314694 rs17064094 chr3 60856466 G A 1.54E-04 Multiple complex diseases FHIT intron 17554300 rs7613542 chr3 60872879 C T 0.0000182 Sarcoidosis FHIT intron 22952805 rs2121845 chr3 60907899 A G 1.80E-05 Urinary metabolites FHIT intron 21572414 rs1562524 chr3 60933749 G A 3.20E-05 Response to statin therapy FHIT intron 20339536 rs6792544 chr3 60974088 G C 2.70E-05 Urinary metabolites FHIT intron 21572414 rs6782531 chr3 60995600 G C 8.00E-07 Blood pressure FHIT intron 24954895 rs6786392 chr3 61004199 T C 3.71E-05 Height FHIT intron 22021425 rs2365045 chr3 61021239 G A 8.21E-06 Multiple sclerosis FHIT intron 17660530 rs1898748 chr3 61021337 G C 8.12E-04 Multiple complex diseases FHIT intron 17554300 rs17064337 chr3 61027076 G A 4.77E-05 Multiple complex diseases FHIT intron 17554300 rs11715589 chr3 61043939 G C 4.31E-04 Multiple complex diseases FHIT intron 17554300 rs11715589 chr3 61043939 G C 3.62E-04 Alzheimer's disease FHIT intron 17998437 rs17064395 chr3 61045092 A G 5.94E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs7650123 chr3 61045899 T C 2.09E-04 Alzheimer's disease FHIT intron 17998437 rs9850713 chr3 61048581 C T 3.04E-04 Alzheimer's disease FHIT intron 17998437 rs1965143 chr3 61048665 T C 2.42E-04 Alzheimer's disease FHIT intron 17998437 rs10222378 chr3 61048979 A G 2.54E-04 Alzheimer's disease FHIT intron 17998437 rs9855931 chr3 61049559 C G 2.66E-04 Alzheimer's disease FHIT intron 17998437 rs7631974 chr3 61051617 G A 2.54E-04 Alzheimer's disease FHIT intron 17998437 rs11919495 chr3 61052499 A T 5.27E-04 Alzheimer's disease FHIT intron 17998437 rs9871875 chr3 61052520 C A 2.95E-04 Alzheimer's disease FHIT intron 17998437 rs9834182 chr3 61052642 A G 8.63E-04 Alzheimer's disease FHIT intron 17998437 rs9876579 chr3 61052979 G T 6.30E-05 Alzheimer's disease FHIT intron 17998437 rs9845837 chr3 61071811 G A 5.12E-05 Major depressive disorder FHIT intron 22472876 rs17687542 chr3 61077258 T C 3.66E-04 Coronary heart disease FHIT intron 21971053 rs1347852 chr3 61080782 G A,C,T 5.59E-05 Major depressive disorder FHIT intron 22472876 rs11921290 chr3 61081768 A G 8.53E-04 Coronary heart disease FHIT intron 21971053 rs9825823 chr3 61082153 T C 2.13E-05 Alcohol dependence FHIT intron 20201924 rs9825823 chr3 61082153 T C 4.08E-06 Major depressive disorder FHIT intron 22472876 rs9825823 chr3 61082153 T C 2.13E-05 Alcoholism FHIT intron pha002891 rs7626688 chr3 61106321 T G 6.42E-04 Multiple complex diseases FHIT intron 17554300 rs7626688 chr3 61106321 T G 8.47E-06 Major depressive disorder FHIT intron 22472876 rs6445194 chr3 61111195 G T 1.28E-04 Alcohol dependence FHIT intron 20201924 rs6445194 chr3 61111195 G T 6.04E-06 Major depressive disorder FHIT intron 22472876 rs6445194 chr3 61111195 G T 4.61E-05 Depression (quantitative trait) FHIT intron 23290196 rs1821942 chr3 61116009 C T 6.84E-04 Heart Failure FHIT intron pha002885 rs9830950 chr3 61122318 C T 1.24E-06 Major depressive disorder FHIT intron 22472876 rs2886261 chr3 61126821 A G 0.000863 Salmonella-induced pyroptosis FHIT intron 22837397 rs9877396 chr3 61127205 T C 3.00E-06 Bronchopulmonary dysplasia FHIT intron 23897914 rs4309721 chr3 61132698 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4309721 chr3 61132698 C T 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4309721 chr3 61132698 C T 8.14E-05 Major depressive disorder FHIT intron 22472876 rs6807748 chr3 61149967 T C 1.27E-05 Major depressive disorder FHIT intron 22472876 rs11707984 chr3 61150158 C T 1.26E-05 Major depressive disorder FHIT intron 22472876 rs1966136 chr3 61153578 A C 1.37E-05 Major depressive disorder FHIT intron 22472876 rs4020068 chr3 61153578 A AA,AC 1.37E-05 Major depressive disorder FHIT intron 22472876 rs9851485 chr3 61155891 C G 1.46E-05 Major depressive disorder FHIT intron 22472876 rs9871451 chr3 61155929 T C 1.84E-05 Major depressive disorder FHIT intron 22472876 rs1969420 chr3 61156905 T G 1.11E-05 Major depressive disorder FHIT intron 22472876 rs1550343 chr3 61159488 A C 1.87E-05 Major depressive disorder FHIT intron 22472876 rs7631246 chr3 61162404 G T 5.42E-05 Major depressive disorder FHIT intron 22472876 rs9875365 chr3 61171057 G A 1.38E-05 Suicidal ideation FHIT intron 20877300 rs9875228 chr3 61171102 C T 8.73E-04 Multiple complex diseases FHIT intron 17554300 rs1001788 chr3 61171806 G A 7.97E-04 Tourette syndrome FHIT intron 22889924 rs9846073 chr3 61186550 T G 5.13E-05 Major depressive disorder FHIT intron 22472876 rs1916800 chr3 61187197 C T 5.46E-05 Major depressive disorder FHIT intron 22472876 rs9843007 chr3 61207077 A T 9.68E-05 Major depressive disorder FHIT intron 22472876 rs6802718 chr3 61227198 G A 9.76E-05 Left ventricular hypertrophy FHIT intron pha003052 rs9817853 chr3 61240793 T C 6.16E-04 Major depressive disorder / / 22472876 rs6445200 chr3 61241048 T C 7.36E-05 Major depressive disorder / / 22472876 rs6785875 chr3 61243611 T C 8.22E-05 Major depressive disorder / / 22472876 rs7629340 chr3 61246997 G A 4.94E-05 Major depressive disorder / / 22472876 rs815718 chr3 61253888 A G 6.71E-04 Smoking cessation / / 24665060 rs815710 chr3 61262149 A G 6.26E-05 Major depressive disorder / / 22472876 rs815710 chr3 61262149 A G 9.28E-04 Tourette syndrome / / 22889924 rs704471 chr3 61268160 G A 5.11E-04 Type 2 diabetes / / 17463246 rs7651321 chr3 61281841 A G 3.08E-05 Odorant perception / / 23910658 rs9877709 chr3 61282140 C A 3.81E-04 Multiple complex diseases / / 17554300 rs7637487 chr3 61282503 A C 8.02E-04 Multiple complex diseases / / 17554300 rs7637487 chr3 61282503 A C 3.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7615788 chr3 61282721 G T 6.69E-06 ldl cholesterol / / pha003077 rs7615788 chr3 61282721 G T 5.49E-05 Cholesterol / / pha003078 rs7615788 chr3 61282721 G T 5.61E-05 Cholesterol / / pha003083 rs7652939 chr3 61287140 A G 7.51E-04 Multiple complex diseases / / 17554300 rs7652939 chr3 61287140 A G 2.24E-05 Aging (time to event) / / 21782286 rs17064749 chr3 61292646 G C 2.64E-15 Multiple complex diseases / / 17554300 rs1901892 chr3 61318721 A G 8.58E-04 Multiple complex diseases / / 17554300 rs6445205 chr3 61335812 G A,C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6414548 chr3 61337690 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17697347 chr3 61370879 T C 4.10E-04 Smoking initiation / / 24665060 rs10514718 chr3 61413814 C G 4.00E-06 Major depressive disorder / / 20125088 rs10514718 chr3 61413814 C G 0.00024 Breast cancer / / 23555315 rs4432637 chr3 61452146 C T 7.36E-04 Heart Failure / / pha002884 rs2365953 chr3 61516927 T C 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9808938 chr3 61549568 G T 7.28E-05 Multiple complex diseases PTPRG intron 17554300 rs938959 chr3 61559771 A G 9.82E-04 Multiple complex diseases PTPRG intron 17554300 rs4447759 chr3 61580912 C T 2.42E-04 Multiple complex diseases PTPRG intron 17554300 rs4580548 chr3 61581049 C G 2.22E-04 Multiple complex diseases PTPRG intron 17554300 rs4580548 chr3 61581049 C G 9.96E-04 Alcohol dependence PTPRG intron 21314694 rs13326767 chr3 61583077 C T 3.33E-04 Multiple complex diseases PTPRG intron 17554300 rs12715571 chr3 61583134 G T 2.72E-05 Multiple complex diseases PTPRG intron 17554300 rs13074575 chr3 61583283 T G 3.49E-05 Multiple complex diseases PTPRG intron 17554300 rs12715572 chr3 61586124 G A 1.58E-04 Multiple complex diseases PTPRG intron 17554300 rs2886526 chr3 61599000 G A 2.28E-04 Multiple complex diseases PTPRG intron 17554300 rs36051446 chr3 61603665 T C 1.72E-05 Attention deficit hyperactivity disorder PTPRG intron 20732625 rs4419372 chr3 61605791 T C 1.79E-05 Multiple complex diseases PTPRG intron 17554300 rs1320234 chr3 61615565 C T 4.02E-05 Prostate cancer PTPRG intron 22923026 rs17624623 chr3 61620466 T C 0.0000202 Otitis media (children 3 years old or younger) PTPRG intron 23133572 rs2365936 chr3 61648636 T C 3.81E-05 Soluble levels of adhesion molecules PTPRG intron pha003072 rs6784338 chr3 61663778 G A 8.45E-05 Cognitive performance PTPRG intron 19734545 rs4688268 chr3 61670137 T C 9.57E-05 Glucose levels PTPRG intron pha003061 rs6763976 chr3 61682383 C G 4.77E-04 Multiple complex diseases PTPRG intron 17554300 rs4688658 chr3 61696032 C T 4.95E-04 Multiple complex diseases PTPRG intron 17554300 rs12491760 chr3 61749709 A G 8.00E-05 Fibrinogen PTPRG intron 17255346 rs12629194 chr3 61750276 G A 1.93E-04 Smoking cessation PTPRG intron 24665060 rs665974 chr3 61755838 C A 3.47E-06 Waist Circumference PTPRG intron pha003023 rs660323 chr3 61762630 T C 9.81E-05 Waist Circumference PTPRG intron pha003023 rs658432 chr3 61770307 A G 2.80E-05 Urinary metabolites PTPRG intron 21572414 rs4622897 chr3 61774076 C G 5.39E-05 Fibrinogen PTPRG intron 17255346 rs666403 chr3 61775808 A T 4.80E-08 Metabolite levels PTPRG intron 23281178 rs1713534 chr3 61778264 T G 4.81E-08 Metabolite levels PTPRG intron 23281178 rs652889 chr3 61794054 C A 8.00E-07 QT interval PTPRG intron 20031603 rs1522549 chr3 61812690 A G 6.09E-05 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130855 chr3 61814181 T G 2.82E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130857 chr3 61814338 C T 3.73E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130858 chr3 61814372 T C 6.96E-04 Multiple complex diseases PTPRG intron 17554300 rs11130858 chr3 61814372 T C 1.07E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs686518 chr3 61824692 C G 9.87E-05 IgE levels PTPRG intron 22075330 rs686553 chr3 61824707 T G 9.83E-05 IgE levels PTPRG intron 22075330 rs592179 chr3 61825441 G T 9.74E-05 IgE levels PTPRG intron 22075330 rs605580 chr3 61826068 C T 9.08E-05 IgE levels PTPRG intron 22075330 rs622358 chr3 61827555 A T 9.25E-05 IgE levels PTPRG intron 22075330 rs607882 chr3 61827694 T A 9.16E-05 IgE levels PTPRG intron 22075330 rs689236 chr3 61839880 C T 7.03E-05 IgE levels PTPRG intron 22075330 rs625177 chr3 61840295 G A 7.08E-05 IgE levels PTPRG intron 22075330 rs868925 chr3 61848017 G A 8.02E-05 IgE levels PTPRG intron 22075330 rs677654 chr3 61849133 G T 8.07E-05 IgE levels PTPRG intron 22075330 rs17065527 chr3 61850090 G A 0.000000036 Mean arterial pressure PTPRG intron 22510845 rs6445243 chr3 61884868 C G 8.58E-05 IgE levels PTPRG intron 22075330 rs4234692 chr3 61904945 A G 6.99E-04 Multiple complex diseases PTPRG intron 17554300 rs2366461 chr3 61907965 G A 3.10E-05 Coronary heart disease PTPRG intron pha003031 rs1871393 chr3 61953317 A G 5.85E-05 Iron status biomarkers PTPRG intron 19084217 rs4447756 chr3 61964956 A C 1.42E-05 Follicular lymphoma PTPRG intron 21533074 rs7647959 chr3 61967036 T C 5.81E-06 Hearing function PTPRG intron 21493956 rs2189693 chr3 61968443 G C 4.50E-06 Hearing function PTPRG intron 21493956 rs6785475 chr3 61989945 C T 2.30E-06 Urinary metabolites PTPRG intron 21572414 rs739984 chr3 62000317 G A 7.20E-05 Type 2 diabetes PTPRG intron 17463248 rs9860802 chr3 62011210 G T 3.22E-04 Nonalcoholic fatty liver disease PTPRG intron 21423719 rs10490779 chr3 62011294 C T 5.50E-06 Urinary metabolites PTPRG intron 21572414 rs2366421 chr3 62019400 A T 9.94E-05 Type 2 diabetes PTPRG intron 17463246 rs7647422 chr3 62026588 T G 1.00E-06 Urinary metabolites PTPRG intron 21572414 rs7637898 chr3 62032584 C T 3.26E-05 Type 2 diabetes PTPRG intron 17463246 rs7638067 chr3 62032616 G A 3.26E-05 Type 2 diabetes PTPRG intron 17463246 rs10490775 chr3 62036724 C T 1.00E-06 Fuchs's corneal dystrophy PTPRG intron 20825314 rs6774478 chr3 62037499 T C 8.82E-04 Type 2 diabetes PTPRG intron 17463246 rs17065828 chr3 62042825 T C 3.90E-05 Melanoma PTPRG intron 21983785 rs349171 chr3 62051711 T C 9.58E-05 Schizophrenia PTPRG intron 19571811 rs11130874 chr3 62064769 A G 2.00E-06 Schizophrenia PTPRG intron 21926974 rs11130874 chr3 62064769 A G 0.00000945 Schizophrenia PTPRG intron 23637625 rs349158 chr3 62079245 T C 5.49E-04 Smoking cessation PTPRG intron 24665060 rs349153 chr3 62081495 T C 7.77E-05 Smoking initiation PTPRG intron 24665060 rs1911746 chr3 62100840 T C 8.54E-04 Oral cancers (chewing tobacco related) PTPRG intron 22503698 rs35593266 chr3 62112141 G A 5.00E-06 Metabolite levels (HVA/5-HIAA ratio) PTPRG intron 23319000 rs17066182 chr3 62116228 C T 3.98E-04 Suicide attempts in bipolar disorder PTPRG intron 21041247 rs17066200 chr3 62133088 G T 9.29E-04 Multiple complex diseases PTPRG intron 17554300 rs7632091 chr3 62134802 T C 2.52E-05 Inflammation PTPRG intron pha002897 rs11711888 chr3 62157211 A G 3.50E-06 Bipolar disorder PTPRG intron 19416921 rs11130879 chr3 62157497 A G 5.93E-04 Coronary heart disease PTPRG intron 21606135 rs1508401 chr3 62158372 T C 6.12E-04 Coronary heart disease PTPRG intron 21606135 rs17066234 chr3 62159745 C T 2.89E-04 Coronary heart disease PTPRG intron 21606135 rs7641268 chr3 62174532 A G 9.64E-05 Body Mass Index PTPRG intron pha002896 rs7631948 chr3 62178521 G A 9.22E-05 Multiple complex diseases PTPRG intron 17554300 rs6792421 chr3 62185364 C T 1.12E-04 Multiple complex diseases PTPRG intron 17554300 rs6805070 chr3 62185405 T C 5.84E-04 Response to cytadine analogues (cytosine arabinoside) PTPRG intron 24483146 rs17066275 chr3 62188720 A G 6.72E-04 Taste perception PTPRG intron 22132133 rs10510873 chr3 62206239 T C 7.20E-06 Urinary metabolites PTPRG intron 21572414 rs4560291 chr3 62212162 T A,C,G 8.17E-04 Taste perception PTPRG intron 22132133 rs6785764 chr3 62221041 A G 1.70E-05 Urinary metabolites PTPRG intron 21572414 rs1388612 chr3 62244444 G A 6.76E-04 Taste perception PTPRG intron 22132133 rs1388613 chr3 62244570 T C 7.36E-04 Taste perception PTPRG intron 22132133 rs2291540 chr3 62263047 T C 5.01E-06 Substance dependence phenotypes PTPRG intron 24832863 rs9813294 chr3 62270556 G A 8.63E-04 Type 2 diabetes PTPRG intron 17463246 rs9813294 chr3 62270556 G A 1.10E-05 Urinary metabolites PTPRG intron 21572414 rs785164 chr3 62314820 A T 1.80E-05 Urinary metabolites C3orf14 intron 21572414 rs3774700 chr3 62316394 T G 3.23E-06 Taste perception C3orf14 intron 22132133 rs6777784 chr3 62376645 G T 3.17E-05 Prion diseases / / 22210626 rs9844504 chr3 62421793 C T 5.33E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs1997366 chr3 62439586 T C 8.79E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs7635279 chr3 62473481 A T 0.000285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CADPS intron 23233654 rs7635279 chr3 62473481 A T 2.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) CADPS intron 23233662 rs7631150 chr3 62475455 T G 0.0000416 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CADPS intron 23233654 rs7631150 chr3 62475455 T G 4.16E-05 Methotrexate clearance (acute lymphoblastic leukemia) CADPS intron 23233662 rs2367089 chr3 62476790 G A 7.66E-04 Amyotrophic lateral sclerosis (sporadic) CADPS intron 24529757 rs9871763 chr3 62477699 C A 3.34E-06 Glaucoma (primary open-angle) CADPS intron 22605921 rs13325751 chr3 62478194 C T 6.00E-06 Economic and political preferences (environmentalism) CADPS intron 22566634 rs1376917 chr3 62498378 G A 7.61E-04 Multiple complex diseases CADPS intron 17554300 rs6445276 chr3 62505260 T C 2.44E-04 Nicotine smoking CADPS intron 19268276 rs6445276 chr3 62505260 T C 2.60E-05 Urinary metabolites CADPS intron 21572414 rs855586 chr3 62525450 C A 9.93E-04 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs2600859 chr3 62534165 T A 9.03E-04 Insulin resistance CADPS intron 21901158 rs755358 chr3 62534469 T C 5.81E-09 Metabolite levels CADPS intron 23281178 rs2251423 chr3 62539736 A G 9.60E-05 Blood Pressure CADPS intron pha003046 rs4447757 chr3 62544840 T A 8.48E-04 Lymphocyte counts CADPS intron 22286170 rs833661 chr3 62553061 C G 2.66E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs11130888 chr3 62562709 C A,G,T 6.96E-07 Glaucoma (primary open-angle) CADPS intron 22605921 rs833651 chr3 62563888 G A 9.05E-04 Iron levels CADPS intron pha002876 rs833637 chr3 62583180 G C 4.14E-05 Sudden cardiac arrest CADPS intron 21658281 rs1231831 chr3 62601366 T C 2.00E-06 Metabolite levels (X-11787) CADPS intron 23934736 rs833668 chr3 62615298 A G 1.50E-05 Urinary metabolites CADPS intron 21572414 rs17066711 chr3 62620842 C A 9.16E-05 Multiple complex diseases CADPS intron 17554300 rs9861841 chr3 62622267 T C 3.92E-04 Type 2 diabetes CADPS intron 17463246 rs10510883 chr3 62656259 C A 1.53E-05 Caffeine consumption CADPS intron 21490707 rs4688306 chr3 62657282 T A 2.20E-05 Serum metabolites CADPS intron 19043545 rs6445283 chr3 62658282 T C 3.09E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs1858385 chr3 62659658 T C 3.05E-05 Vaspin levels CADPS intron 22907691 rs17066793 chr3 62660566 A G 1.24E-06 Kawasaki disease CADPS intron 21221998 rs17066793 chr3 62660566 A G 1.07E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 2.32E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 6.78E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 8.42E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066811 chr3 62673292 T C 7.61E-06 Kawasaki disease CADPS intron 21221998 rs4688308 chr3 62674434 C A 3.60E-07 Urinary metabolites CADPS intron 21572414 rs4429621 chr3 62676804 T C 9.69E-06 Kawasaki disease CADPS intron 21221998 rs1948926 chr3 62678071 A C 7.47E-04 Response to cytadine analogues (cytosine arabinoside) CADPS intron 24483146 rs13090570 chr3 62686403 G T 3.47E-05 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs1344072 chr3 62688923 A G 2.70E-05 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs6445290 chr3 62691870 T C 1.04E-04 Smoking initiation CADPS intron 24665060 rs6774997 chr3 62694321 A C 7.61E-06 Kawasaki disease CADPS intron 21221998 rs6774997 chr3 62694321 A C 1.89E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 3.63E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 7.87E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 9.53E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 1.86E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 4.22E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 6.41E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 7.55E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs10510886 chr3 62697211 T G 2.34E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs952040 chr3 62698892 G A 3.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs504987 chr3 62705064 A G 9.28E-06 Kawasaki disease CADPS intron 21221998 rs493639 chr3 62705919 C T 9.28E-06 Kawasaki disease CADPS intron 21221998 rs581316 chr3 62715890 G C 3.16E-04 Multiple complex diseases CADPS intron 17554300 rs2886894 chr3 62716076 T A 6.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CADPS intron 20031582 rs569079 chr3 62720047 C G 1.76E-04 Hearing function CADPS intron 17255346 rs569079 chr3 62720047 C G 4.45E-04 Multiple complex diseases CADPS intron 17554300 rs17067111 chr3 62721971 A G 3.23E-05 Sudden cardiac arrest CADPS intron 21658281 rs564720 chr3 62729934 A G 7.50E-04 Type 2 diabetes and 6 quantitative traits CADPS intron 17848626 rs531700 chr3 62731267 G A 6.62E-05 Multiple complex diseases CADPS intron 17554300 rs526005 chr3 62731323 A G 1.83E-04 Multiple complex diseases CADPS intron 17554300 rs3843397 chr3 62733212 T C 7.25E-04 Schizophrenia CADPS intron 19197363 rs580384 chr3 62733366 C T 4.00E-06 Breast size CADPS intron 22747683 rs304170 chr3 62780639 A G 8.69E-05 Monocyte counts CADPS intron pha003089 rs304172 chr3 62782468 G A 8.00E-06 IgG glycosylation CADPS intron 23382691 rs2063621 chr3 62786855 G T 2.27E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs304230 chr3 62801073 G A 1.30E-04 Alzheimer's disease CADPS intron 17998437 rs304230 chr3 62801073 G A 1.40E-04 Alzheimer's disease CADPS intron pha002879 rs17280557 chr3 62802839 C A 2.16E-04 Alzheimer's disease CADPS intron 17998437 rs11707381 chr3 62808969 T C 4.73E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs581190 chr3 62846109 G A 4.30E-05 Major depressive disorder CADPS intron 21042317 rs581190 chr3 62846109 G A 0.0000514 Major depressive disorder CADPS intron 23149448 rs1812677 chr3 62853439 G A 8.02E-04 Alzheimer's disease CADPS intron 22005930 rs304233 chr3 62863316 G A 6.73E-04 Alzheimer's disease / / 22005930 rs304234 chr3 62863469 G A 3.56E-05 Post-operative nausea and vomiting / / 21694509 rs6775597 chr3 62868539 T G 5.65E-06 Blood Pressure / / pha003040 rs6775597 chr3 62868539 T G 1.09E-05 Blood Pressure / / pha003048 rs526163 chr3 62871502 A G 6.23E-04 Alzheimer's disease / / 22005930 rs11130901 chr3 62873406 G A 3.54E-04 Alzheimer's disease / / 22005930 rs9854059 chr3 62876133 T A 4.38E-04 Alzheimer's disease / / 22005930 rs9825965 chr3 62880928 T C 3.08E-05 Blood Pressure / / pha003040 rs6445299 chr3 62881664 A C 6.57E-04 Alzheimer's disease / / 22005930 rs1992192 chr3 62883380 C T 3.04E-05 Blood Pressure / / pha002898 rs2886966 chr3 62933534 C T 1.24E-04 Multiple complex diseases / / 17554300 rs1031246 chr3 63028072 G A 2.25E-05 Orofacial clefts / / 22419666 rs6445310 chr3 63039589 T C 4.57E-04 Insulin resistance / / 21901158 rs11711402 chr3 63040149 A C 5.52E-04 Type 2 diabetes / / 17463246 rs7644552 chr3 63050227 G A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1374682 chr3 63050385 C G 8.09E-04 Insulin resistance / / 21901158 rs1868065 chr3 63063240 C T 3.59E-05 Orofacial clefts / / 22419666 rs2053759 chr3 63073352 C T 4.39E-05 Orofacial clefts / / 22419666 rs2034318 chr3 63078242 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs982678 chr3 63088315 A C 6.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2367607 chr3 63101614 T C 6.78E-04 Suicide attempts in bipolar disorder LOC285401 intron 21423239 rs6445318 chr3 63133304 A C 6.88E-05 Intelligence / / 21826061 rs1838990 chr3 63167851 A G 5.64E-04 Rheumatoid arthritis / / 21452313 rs17365274 chr3 63177345 A G 8.91E-04 Multiple complex diseases / / 17554300 rs41470345 chr3 63204420 G C 5.16E-04 Multiple complex diseases / / 17554300 rs9311860 chr3 63214900 T C 8.11E-04 Smoking quantity / / 24665060 rs17300316 chr3 63218397 G A 2.36E-04 Multiple complex diseases / / 17554300 rs2887078 chr3 63248575 C T 6.88E-04 Type 2 diabetes / / 17463246 rs7433582 chr3 63261972 T G 1.64E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7433582 chr3 63261972 T G 2.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6792395 chr3 63271485 G A 2.36E-04 Obesity (extreme) SYNPR intron 21935397 rs6792508 chr3 63271746 C T 4.82E-04 Obesity (extreme) SYNPR intron 21935397 rs6792896 chr3 63271968 G A 2.10E-05 Urinary metabolites SYNPR intron 21572414 rs6792896 chr3 63271968 G A 4.77E-04 Obesity (extreme) SYNPR intron 21935397 rs6792744 chr3 63272034 C T 4.75E-04 Obesity (extreme) SYNPR intron 21935397 rs6768281 chr3 63272058 A C 4.73E-04 Obesity (extreme) SYNPR intron 21935397 rs6801595 chr3 63272468 A G 4.70E-04 Obesity (extreme) SYNPR intron 21935397 rs6790463 chr3 63272557 T C 4.68E-04 Obesity (extreme) SYNPR intron 21935397 rs9867170 chr3 63272826 T A 4.67E-04 Obesity (extreme) SYNPR intron 21935397 rs6777885 chr3 63273068 C T 4.66E-04 Obesity (extreme) SYNPR intron 21935397 rs6793545 chr3 63273274 T A 4.65E-04 Obesity (extreme) SYNPR intron 21935397 rs9873263 chr3 63274302 T C 4.60E-04 Obesity (extreme) SYNPR intron 21935397 rs9815672 chr3 63274436 A T 4.59E-04 Obesity (extreme) SYNPR intron 21935397 rs9853765 chr3 63274579 C G 4.55E-04 Obesity (extreme) SYNPR intron 21935397 rs2367783 chr3 63275271 C T 4.54E-04 Obesity (extreme) SYNPR intron 21935397 rs4688390 chr3 63275851 C T 4.54E-04 Obesity (extreme) SYNPR intron 21935397 rs4688391 chr3 63275929 C T 4.53E-04 Obesity (extreme) SYNPR intron 21935397 rs6767034 chr3 63276836 A G 5.38E-05 Bipolar disorder SYNPR intron 21771265 rs6767034 chr3 63276836 A G 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYNPR intron 24023788 rs6767034 chr3 63276836 A G 8.71E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SYNPR intron 24023788 rs9857192 chr3 63277968 A G 4.42E-04 Obesity (extreme) SYNPR intron 21935397 rs9311870 chr3 63278311 C T 4.38E-04 Obesity (extreme) SYNPR intron 21935397 rs2887081 chr3 63278809 T C 4.37E-04 Obesity (extreme) SYNPR intron 21935397 rs2367788 chr3 63281427 C T 4.16E-04 Obesity (extreme) SYNPR intron 21935397 rs1403703 chr3 63282650 C T 4.24E-04 Obesity (extreme) SYNPR intron 21935397 rs2056546 chr3 63283665 C T 4.27E-04 Obesity (extreme) SYNPR intron 21935397 rs2056545 chr3 63283701 C T 4.28E-04 Obesity (extreme) SYNPR intron 21935397 rs10510893 chr3 63285628 C T 4.47E-04 Obesity (extreme) SYNPR intron 21935397 rs11130920 chr3 63285738 A T 3.98E-04 Obesity (extreme) SYNPR intron 21935397 rs870364 chr3 63286254 C G 4.44E-04 Obesity (extreme) SYNPR intron 21935397 rs1608452 chr3 63294690 T A 4.32E-04 Obesity (extreme) SYNPR intron 21935397 rs7626955 chr3 63294802 T A 4.32E-04 Obesity (extreme) SYNPR intron 21935397 rs1523436 chr3 63297904 T C 4.03E-04 Obesity (extreme) SYNPR intron 21935397 rs12489378 chr3 63298608 A G 3.57E-05 Bipolar disorder SYNPR intron 21771265 rs4688393 chr3 63299052 C A 4.02E-04 Obesity (extreme) SYNPR intron 21935397 rs1851666 chr3 63299949 G A 4.02E-04 Obesity (extreme) SYNPR intron 21935397 rs7636388 chr3 63306819 G A 4.07E-04 Obesity (extreme) SYNPR intron 21935397 rs1451312 chr3 63307868 A T 4.09E-04 Obesity (extreme) SYNPR intron 21935397 rs11130924 chr3 63308160 T C 4.09E-04 Obesity (extreme) SYNPR intron 21935397 rs1376481 chr3 63309050 A G 3.57E-05 Bipolar disorder SYNPR intron 21771265 rs1376481 chr3 63309050 A G 2.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SYNPR intron 24023788 rs1349478 chr3 63311967 A C 4.15E-04 Obesity (extreme) SYNPR intron 21935397 rs2037571 chr3 63312698 T C 7.14E-04 Obesity (extreme) SYNPR intron 21935397 rs2037570 chr3 63313144 A G 2.80E-05 Urinary metabolites SYNPR intron 21572414 rs2037570 chr3 63313144 A G 4.21E-04 Obesity (extreme) SYNPR intron 21935397 rs11714718 chr3 63314568 G T 4.27E-04 Obesity (extreme) SYNPR intron 21935397 rs935786 chr3 63342866 G A 9.15E-05 Magnesium levels SYNPR intron pha003092 rs13068980 chr3 63350469 A G 0.000000772 Cytarabine sensitivity SYNPR intron 23538338 rs17068377 chr3 63352539 G T 0.000000652 Cytarabine sensitivity SYNPR intron 23538338 rs12638620 chr3 63354550 C G 0.000000717 Cytarabine sensitivity SYNPR intron 23538338 rs10510896 chr3 63355092 G A 0.00000076 Cytarabine sensitivity SYNPR intron 23538338 rs17068392 chr3 63355984 T C 0.000000717 Cytarabine sensitivity SYNPR intron 23538338 rs2167353 chr3 63361571 T C 2.13E-04 Multiple complex diseases SYNPR intron 17554300 rs17068421 chr3 63369620 A C 2.17E-04 Multiple complex diseases SYNPR intron 17554300 rs17068439 chr3 63375979 C T 4.78E-04 Multiple complex diseases SYNPR intron 17554300 rs17313993 chr3 63378419 T C 2.76E-09 Breast cancer SYNPR intron 20852631 rs1996918 chr3 63380775 T C 9.86E-05 Magnesium levels SYNPR intron pha003092 rs9856132 chr3 63385383 G C 1.09E-04 Lipid traits SYNPR intron 22028671 rs727777 chr3 63405972 T C 1.20E-05 Asthma SYNPR intron pha003127 rs17031729 chr3 63412569 A C 8.66E-04 Multiple complex diseases SYNPR intron 17554300 rs1403700 chr3 63415195 A G 6.40E-05 Serum metabolites SYNPR intron 19043545 rs1545458 chr3 63417340 A G 8.00E-07 Urinary metabolites SYNPR intron 21572414 rs1545458 chr3 63417340 A G 8.55E-05 Tourette syndrome SYNPR intron 22889924 rs12374033 chr3 63430538 T C 7.89E-05 Smoking cessation SYNPR intron 18519826 rs6766009 chr3 63437107 A G 2.37E-04 Tourette syndrome SYNPR intron 22889924 rs57891639 chr3 63449855 T C 2.22E-04 Acne (severe) SYNPR intron 24927181 rs59460117 chr3 63449954 T C 4.66E-05 Acne (severe) SYNPR intron 24927181 rs7629131 chr3 63456132 T C 9.29E-12 Metabolite levels SYNPR intron 22286219 rs13088837 chr3 63459125 A G 8.85E-04 Taste perception SYNPR intron 22132133 rs9841251 chr3 63460373 A C 8.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6765895 chr3 63464370 G A 9.01E-04 Coronary heart disease SYNPR intron 21606135 rs6772726 chr3 63466382 G T 4.85E-04 Coronary heart disease SYNPR intron 21606135 rs6783555 chr3 63469983 C T 5.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6799191 chr3 63470203 T C 5.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6799373 chr3 63470356 T C 5.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs1901303 chr3 63471314 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs9838946 chr3 63472023 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688402 chr3 63472192 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688403 chr3 63472310 A C 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688404 chr3 63472534 G T 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs7621849 chr3 63472842 C G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs935792 chr3 63473375 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6803417 chr3 63474104 A C 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6781972 chr3 63474250 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs17068808 chr3 63475294 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688412 chr3 63491925 A C 5.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs1158186 chr3 63495185 T C 3.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6769577 chr3 63495805 G A 4.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs13086578 chr3 63496778 T C 4.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs17397636 chr3 63501455 C G 2.79E-05 Smoking cessation SYNPR intron 18519826 rs17338206 chr3 63501532 T C 1.97E-04 Smoking cessation SYNPR intron 18519826 rs11918416 chr3 63505191 C T 6.94E-04 Multiple complex diseases SYNPR intron 17554300 rs7614676 chr3 63507244 A G 1.36E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7614676 chr3 63507244 A G 4.25E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2221476 chr3 63507544 A G 1.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2221476 chr3 63507544 A G 4.11E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2202492 chr3 63507662 T C 1.12E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2202492 chr3 63507662 T C 4.09E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs13067087 chr3 63508251 A T 4.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs13067087 chr3 63508251 A T 9.86E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6775133 chr3 63509964 A G 3.95E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6775133 chr3 63509964 A G 9.44E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17068905 chr3 63510844 C T 3.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17068905 chr3 63510844 C T 8.89E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7617487 chr3 63512021 T G 3.49E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7617487 chr3 63512021 T G 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11928896 chr3 63512762 A G 3.34E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11928896 chr3 63512762 A G 7.46E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6770081 chr3 63513405 A G 3.26E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6770081 chr3 63513405 A G 8.90E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11921529 chr3 63513585 G A 3.17E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11921529 chr3 63513585 G A 8.61E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs9848074 chr3 63513985 C G 3.13E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs9848074 chr3 63513985 C G 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7641936 chr3 63514176 C T 3.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7641936 chr3 63514176 C T 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6766087 chr3 63515740 T C 3.47E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6766087 chr3 63515740 T C 7.74E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6777474 chr3 63515886 A G 3.51E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6777474 chr3 63515886 A G 7.28E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130939 chr3 63518063 G T 1.43E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130939 chr3 63518063 G T 4.77E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505600 chr3 63518842 G C 1.05E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505600 chr3 63518842 G C 7.70E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394902 chr3 63519693 C T 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394902 chr3 63519693 C T 7.71E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394901 chr3 63519727 T C 2.58E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394901 chr3 63519727 T C 7.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4392412 chr3 63520037 T G 2.58E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4392412 chr3 63520037 T G 7.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985370 chr3 63520117 A G 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985370 chr3 63520117 A G 7.75E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985368 chr3 63520390 C T 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985368 chr3 63520390 C T 7.78E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985367 chr3 63520475 G T 2.40E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985367 chr3 63520475 G T 7.81E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11926493 chr3 63523311 C T 2.86E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11926493 chr3 63523311 C T 6.99E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs12054371 chr3 63524098 C T 5.03E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs12054371 chr3 63524098 C T 6.16E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505599 chr3 63524793 A C 2.11E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505599 chr3 63524793 A C 7.87E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505598 chr3 63524880 C G 1.21E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505598 chr3 63524880 C G 7.90E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4616634 chr3 63525003 A G 7.91E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4616634 chr3 63525003 A G 8.62E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505597 chr3 63526806 A G 1.03E-04 Alzheimer's disease SYNPR intron 17998437 rs1039631 chr3 63528049 G A 9.64E-04 Suicide attempts in bipolar disorder SYNPR intron 21423239 rs1039631 chr3 63528049 G A 2.00E-04 Cognitive impairment induced by topiramate SYNPR intron 22091778 rs11130944 chr3 63528914 T C 1.53E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130944 chr3 63528914 T C 6.53E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1027764 chr3 63529614 T G 1.64E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1027764 chr3 63529614 T G 6.42E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505595 chr3 63530277 C T 2.69E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505595 chr3 63530277 C T 6.30E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17399296 chr3 63535676 T C 0.000737 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SYNPR intron 23233654 rs17399296 chr3 63535676 T C 7.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) SYNPR intron 23233662 rs17399554 chr3 63567354 G A 3.49E-05 Smoking cessation SYNPR intron 18519826 rs9877629 chr3 63588304 A T 4.59E-05 Height SYNPR intron 22021425 rs10510900 chr3 63609030 C A 3.29E-04 Multiple complex diseases / / 17554300 rs7646765 chr3 63612431 T C 6.12E-04 Stroke / / pha002887 rs7609960 chr3 63618827 C T 7.47E-05 Blood Pressure / / pha003044 rs11130951 chr3 63623361 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs73111385 chr3 63645410 A G 0.000016 Breast cancer (ER positive) SNTN missense 23555315 rs6784922 chr3 63660258 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11707243 chr3 63663240 G A 6.27E-04 Multiple complex diseases / / 17554300 rs9680958 chr3 63697487 C T 2.90E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs10510911 chr3 63703641 C G 1.65E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs7623146 chr3 63703985 G A 6.58E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs17069314 chr3 63713245 A C 0.000746 Salmonella-induced pyroptosis / / 22837397 rs35059906 chr3 63738355 G A 4.60E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs10510910 chr3 63739175 A C 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs35330798 chr3 63744332 C T 6.30E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6799578 chr3 63745668 C A 6.30E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs9842724 chr3 63804761 T C 6.35E-06 Type 2 diabetes / / 22158537 rs7614311 chr3 63813654 A C 1.00E-06 Lung function (forced vital capacity) C3orf49 intron 24023788 rs7614311 chr3 63813654 A C 6.00E-06 Lung function (forced expiratory volume in 1 second) C3orf49 intron 24023788 rs6801346 chr3 63947128 G A 2.18E-05 Bipolar disorder and schizophrenia ATXN7 intron 20889312 rs13434089 chr3 63948566 T C 2.57E-05 Type 2 diabetes ATXN7 intron 22158537 rs13433909 chr3 63948609 C G 3.80E-05 Type 2 diabetes ATXN7 intron 22158537 rs62252368 chr3 63959465 C T 0.0000226 Colorectal adenoma (excluding hyperplasic) ATXN7 intron 23677573 rs62252368 chr3 63959465 C T 0.0000226 Colorectal adenoma (including hyperplasic) ATXN7 intron 23677573 rs10510903 chr3 63970192 C G 5.61E-05 Bipolar disorder and schizophrenia ATXN7 intron 20889312 rs17069612 chr3 63977676 G A 2.51E-05 Multiple complex diseases ATXN7 intron 17554300 rs3733127 chr3 63988174 C T 0.0000333 Colorectal adenoma (excluding hyperplasic) ATXN7 UTR-3 23677573 rs3733127 chr3 63988174 C T 0.0000333 Colorectal adenoma (including hyperplasic) ATXN7 UTR-3 23677573 rs35836 chr3 64009102 G T 9.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs40610 chr3 64009508 T C 4.91E-04 Stroke / / pha002887 rs35837 chr3 64013249 T C 4.38E-05 Type 2 diabetes / / 22158537 rs35840 chr3 64014904 C A 7.45E-06 Type 2 diabetes / / 22158537 rs13093232 chr3 64019642 G A 6.33E-04 Obesity (extreme) / / 21935397 rs6764606 chr3 64020447 C T 4.93E-06 Brain structure / / 22504417 rs6808752 chr3 64024529 G A 4.80E-05 Brain structure / / 22504417 rs831574 chr3 64029383 A G 1.26E-05 Cognitive test performance / / 20125193 rs831574 chr3 64029383 A G 8.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs1376338 chr3 64031906 T C 2.25E-05 Brain structure / / 22504417 rs831571 chr3 64048297 T C 8.00E-11 Type 2 diabetes / / 22158537 rs831571 chr3 64048297 T C 8.41E-11 Type 2 diabetes / / 23300278 rs831571 chr3 64048297 T C 3.70E-04 Type 2 diabetes / / 24509480 rs166230 chr3 64053207 T C 2.89E-05 Type 2 diabetes / / 22158537 rs11707025 chr3 64055501 T G 3.37E-05 Brain structure LOC100652759 intron 22504417 rs1450985 chr3 64060128 G A 3.92E-05 Brain structure LOC100652759 intron 22504417 rs153734 chr3 64078009 C T 7.00E-06 Folate pathway vitamin levels LOC100652759 intron 19303062 rs153712 chr3 64096122 C T 4.87E-05 Magnesium levels PRICKLE2 intron pha003092 rs11130957 chr3 64097856 T G 2.64E-05 Magnesium levels PRICKLE2 intron pha003092 rs1096170 chr3 64104388 C T 0.0000518 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs1096170 chr3 64104388 C T 2.53E-05 Schizophrenia PRICKLE2 intron 24253340 rs11130958 chr3 64105279 T C 5.70E-05 Response to statin therapy PRICKLE2 intron 20339536 rs830010 chr3 64108737 C A 0.0000979 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs985280 chr3 64108853 C G 2.61E-05 Neuroticism PRICKLE2 intron 23229837 rs1024895 chr3 64111658 T C 0.0000025 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs201013261 chr3 64111658 T TAC 0.0000025 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs696009 chr3 64111719 T C 7.21E-05 Schizophrenia PRICKLE2 intron 24253340 rs696010 chr3 64111897 G A 6.16E-05 Schizophrenia PRICKLE2 intron 24253340 rs696011 chr3 64125385 T C 1.92E-05 Adipocyte fatty acid-binding protein concentration,in serum PRICKLE2 intron 21863005 rs697266 chr3 64125639 G C 2.46E-05 Adipocyte fatty acid-binding protein concentration,in serum PRICKLE2 intron 21863005 rs1432583 chr3 64127012 C T 1.10E-04 Multiple complex diseases PRICKLE2 intron 17554300 rs6445392 chr3 64135500 T C 6.79E-05 Cognitive impairment induced by topiramate PRICKLE2 intron 22091778 rs17664296 chr3 64148288 C T 9.55E-04 Multiple complex diseases PRICKLE2 intron 17554300 rs7637364 chr3 64157235 G T 6.43E-04 Tourette syndrome PRICKLE2 intron 22889924 rs697277 chr3 64166741 C T 5.46E-05 Blood pressure (response to angiotensin II receptor blocker) PRICKLE2 intron 24192120 rs1035275 chr3 64173901 T C 9.00E-06 IgG glycosylation PRICKLE2 intron 23382691 rs696018 chr3 64184956 G A 1.15E-04 Glycosylated haemoglobin levels PRICKLE2 intron 17255346 rs7610343 chr3 64199364 T C 1.80E-04 Glycosylated haemoglobin levels PRICKLE2 intron 17255346 rs17666009 chr3 64205332 C T 4.12E-05 Cognitive impairment induced by topiramate PRICKLE2 intron 22091778 rs1963348 chr3 64215255 G A 8.94E-05 Response to metformin / / 21186350 rs3911778 chr3 64230433 C A 8.03E-05 Response to metformin / / 21186350 rs41325347 chr3 64240985 T C 4.09E-04 Multiple complex diseases / / 17554300 rs704409 chr3 64246829 C A 9.48E-05 Colorectal cancer / / 19723657 rs1471377 chr3 64252968 A G 7.92E-05 Stroke (ischemic) / / 22941190 rs704422 chr3 64256270 G A 6.41E-05 Alzheimer's disease / / 17998437 rs862500 chr3 64272649 A T 5.07E-04 Multiple complex diseases / / 17554300 rs17404667 chr3 64274552 C G 9.55E-07 Coronary artery calcification / / 23870195 rs1102918 chr3 64283477 G A 4.02E-04 Multiple complex diseases / / 17554300 rs1102918 chr3 64283477 G A 8.58E-04 Alzheimer's disease / / 17998437 rs4688441 chr3 64285015 C A 3.11E-04 Alzheimer's disease / / 17998437 rs17070340 chr3 64289354 A C 3.85E-04 Alzheimer's disease / / 17998437 rs9874230 chr3 64289732 C T 1.84E-04 Multiple complex diseases / / 17554300 rs853284 chr3 64290587 T C 2.22E-04 Alzheimer's disease / / 17998437 rs741013 chr3 64292637 A T 5.00E-07 Coronary artery calcification / / 23870195 rs853275 chr3 64294523 C A 7.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs853260 chr3 64314552 G A 4.40E-04 Volumetric brain MRI / / 17903297 rs853256 chr3 64315464 A G 7.50E-04 Volumetric brain MRI / / 17903297 rs6762476 chr3 64326232 A G 4.61E-04 Insulin resistance / / 21901158 rs6791551 chr3 64328025 G T 8.64E-05 Hemoglobin / / pha003096 rs6791551 chr3 64328025 G T 6.24E-05 Hematocrit / / pha003097 rs17070461 chr3 64329989 T C 2.87E-05 Cognitive test performance / / 20125193 rs7653442 chr3 64370063 T G 6.91E-05 Lipoproteins / / pha003079 rs4688187 chr3 64372607 G A 4.02E-04 Alzheimer's disease / / 17998437 rs4688187 chr3 64372607 G A 1.93E-04 Alzheimer's disease / / pha002879 rs13065232 chr3 64373715 T A 1.20E-06 Urinary metabolites / / 21572414 rs17070662 chr3 64377302 T C 0.0000027 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs719775 chr3 64391453 T A 1.80E-05 Volumetric brain MRI / / 17903297 rs9830368 chr3 64396264 G A 9.66E-06 Sleep quality / / 23728906 rs6445401 chr3 64396762 A G 4.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7611296 chr3 64415110 G A 7.94E-04 Multiple complex diseases / / 17554300 rs6787902 chr3 64439166 A C 7.38E-04 Insulin resistance / / 21901158 rs11917164 chr3 64451058 T C 0.000219494 Hypertension (early onset hypertension) / / 22479346 rs7612038 chr3 64467869 A C 0.000436372 Hypertension (early onset hypertension) / / 22479346 rs11714687 chr3 64470812 C T 1.20E-05 Urinary metabolites / / 21572414 rs6787443 chr3 64472243 C A 9.57E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4688470 chr3 64497351 A C 5.04E-04 Alcohol dependence / / 20201924 rs4688470 chr3 64497351 A C 2.81E-04 Hodgkin's lymphoma / / 24149102 rs2888015 chr3 64499343 G A 1.52E-04 Hodgkin's lymphoma / / 24149102 rs11718026 chr3 64505376 T C 0.0006589 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ADAMTS9 intron 23233654 rs11718026 chr3 64505376 T C 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) ADAMTS9 intron 23233662 rs11713906 chr3 64505542 C T 1.83E-04 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs11717554 chr3 64519156 C T 5.62E-05 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1373163 chr3 64527321 T C 4.43E-05 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1036918 chr3 64527378 G A 8.87E-04 Myopia (pathological) ADAMTS9 intron 21095009 rs9311895 chr3 64532254 A G 4.35E-04 Myopia (pathological) ADAMTS9 intron 21095009 rs80311637 chr3 64536648 C T 2.00E-06 Liver enzyme levels (aspartate transaminase) ADAMTS9 missense 24124411 rs80311637 chr3 64536648 C T 7.00E-06 Liver enzyme levels (alanine transaminase) ADAMTS9 missense 24124411 rs9311896 chr3 64539775 C T 1.24E-04 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1014640 chr3 64543615 T C 8.89E-05 Alcohol withdrawal symptoms ADAMTS9 intron 22072270 rs4405909 chr3 64575629 G A 2.90E-06 Urinary metabolites ADAMTS9 intron 21572414 rs7652817 chr3 64614313 G A 5.02E-05 Type 1 diabetes nephropathy ADAMTS9 intron 23028342 rs6445420 chr3 64617070 C T 0.0000967 post-traumatic stress disorder ADAMTS9 intron 22869035 rs6445420 chr3 64617070 C T 9.67E-05 Schizophrenia ADAMTS9 intron 22883433 rs11719363 chr3 64620801 G T 4.66E-05 Type 1 diabetes nephropathy ADAMTS9 intron 23028342 rs7632980 chr3 64627817 G A 1.03E-04 Telomere length ADAMTS9 intron 21573004 rs9861153 chr3 64634411 T C 8.47E-05 Blood Pressure ADAMTS9 intron pha003039 rs9855230 chr3 64642056 G A 1.30E-05 Alzheimer's disease (late onset) ADAMTS9 intron 21379329 rs4688495 chr3 64643533 A T 9.68E-04 Prostate cancer mortality ADAMTS9 intron 20978177 rs13085005 chr3 64650290 C T 0.00074 Endometrial cancer ADAMTS9 intron 22426144 rs9820318 chr3 64654679 G A 1.17E-04 Amyotrophic lateral sclerosis (sporadic) ADAMTS9 intron 24529757 rs6793277 chr3 64655357 T G 1.94E-04 Alzheimer's disease (late onset) ADAMTS9 intron 21379329 rs12488554 chr3 64692746 T C 1.59E-04 Alzheimer's disease ADAMTS9-AS2 intron 24755620 rs9828674 chr3 64693100 T G 6.55E-05 Alzheimer's disease ADAMTS9-AS2 intron 24755620 rs9850029 chr3 64697088 T C 7.07E-04 Alzheimer's disease ADAMTS9-AS2 intron 17998437 rs4611812 chr3 64699445 C T 0.00000033 Type 2 diabetes (females) ADAMTS9-AS2 intron 22885922 rs4611812 chr3 64699445 C T 0.0000011 Type 2 diabetes (males) ADAMTS9-AS2 intron 22885922 rs9860730 chr3 64701146 A G 4.46E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs6795735 chr3 64705365 C T 2.00E-16 Waist-hip ratio ADAMTS9-AS2 intron 20935629 rs6795735 chr3 64705365 C T 7.40E-11 Type 2 diabetes ADAMTS9-AS2 intron 22885922 rs6795735 chr3 64705365 C T 8.40E-05 Type 2 diabetes ADAMTS9-AS2 intron 23300278 rs6795735 chr3 64705365 C T 5.00E-09 Age-related macular degeneration ADAMTS9-AS2 intron 23455636 rs6795735 chr3 64705365 C T 2.10E-04 Type 2 diabetes ADAMTS9-AS2 intron 24509480 rs11720604 chr3 64710089 A G 2.05E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs918466 chr3 64710253 G A 4.68E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs13060013 chr3 64710709 C A 3.80E-05 Waist-hip ratio ADAMTS9-AS2 intron 23966867 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 18372903 rs4607103 chr3 64711904 C T 1.00E-08 Coronary heart disease ADAMTS9-AS2 intron 21347282 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 21647700 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 23300278 rs17676096 chr3 64715467 G A 6.70E-06 Aortic stiffness ADAMTS9-AS2 intron 22068335 rs2371767 chr3 64718258 G C 2.00E-06 Sexual dimorphism in anthropometric traits ADAMTS9-AS2 intron 23754948 rs7433808 chr3 64727086 A T 2.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio ADAMTS9-AS2 intron 22589738 rs7638389 chr3 64729892 G A 8.00E-06 Visceral adipose tissue adjusted for BMI ADAMTS9-AS2 intron 22589738 rs2371765 chr3 64736577 G A 8.88E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs9856731 chr3 64782724 C T 1.70E-05 HIV-1 control ADAMTS9-AS2 intron 20041166 rs10510925 chr3 64789061 G A 6.56E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs399322 chr3 64793523 T C 2.02E-04 Insulin resistance ADAMTS9-AS2 intron 21901158 rs384441 chr3 64793541 A G 9.39E-05 Insulin resistance ADAMTS9-AS2 intron 21901158 rs4142325 chr3 64794743 T C 1.70E-05 HIV-1 control ADAMTS9-AS2 intron 20041166 rs11923135 chr3 64842029 G T 5.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADAMTS9-AS2 intron 20031582 rs11923135 chr3 64842029 G T 4.99E-04 Alzheimer's disease (late onset) ADAMTS9-AS2 intron 21379329 rs2583718 chr3 64845735 G A 1.11E-05 Bleomycin sensitivity ADAMTS9-AS2 intron 21106707 rs1036797 chr3 64886110 A G 2.00E-06 White matter integrity (interaction) ADAMTS9-AS2 intron 23218918 rs704447 chr3 64891099 G T 1.32E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs17071750 chr3 64895544 T G 4.84E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs793290 chr3 64906434 A T 4.47E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs2280585 chr3 64907284 A G 1.10E-04 Longevity and age-related phenotypes ADAMTS9-AS2 intron 17903295 rs793291 chr3 64907649 A G 4.89E-05 Height ADAMTS9-AS2 intron pha003011 rs704454 chr3 64927025 C T 3.00E-06 Alzheimer's disease (age of onset) ADAMTS9-AS2 intron 22005931 rs704454 chr3 64927025 C T 6.94E-05 Height ADAMTS9-AS2 intron pha003011 rs704457 chr3 64930075 G A 3.05E-06 Alzheimer's disease (age of onset) ADAMTS9-AS2 intron 22005931 rs1357523 chr3 64938050 A G 3.50E-04 Myocardial Infarction ADAMTS9-AS2 intron pha002873 rs116309954 chr3 64956369 T C 0.00000958 Nonsyndromic striae distensae (stretch marks) ADAMTS9-AS2 intron 23633020 rs7625481 chr3 64987245 T C 0.0000988 Nonsyndromic striae distensae (stretch marks) ADAMTS9-AS2 intron 23633020 rs6785581 chr3 65010837 A C 5.63E-04 Insulin resistance / / 21901158 rs17072107 chr3 65013180 T A,C,G 8.36E-04 Depression (quantitative trait) / / 20800221 rs1517931 chr3 65018403 A G 7.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs13071619 chr3 65019442 C T 9.02E-04 Alzheimer's disease / / 22005930 rs9873203 chr3 65021946 C T 1.33E-04 Alzheimer's disease (late onset) / / 21379329 rs6445445 chr3 65037485 G T 2.73E-05 Receptive language ability / / 24687471 rs9875970 chr3 65047603 G A 7.44E-05 Hemoglobin / / pha003098 rs6767418 chr3 65048037 G C 3.01E-04 Multiple complex diseases / / 17554300 rs12636227 chr3 65065491 T C 9.90E-04 Alzheimer's disease / / 17998437 rs17342237 chr3 65072366 G A 1.33E-04 Depression (quantitative trait) / / 20800221 rs6773617 chr3 65077900 G A 2.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17072306 chr3 65082367 C T 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9818174 chr3 65083725 G C 6.05E-04 Depression (quantitative trait) / / 20800221 rs6809503 chr3 65086196 A G 7.58E-04 Smoking quantity / / 24665060 rs9842777 chr3 65090427 T C 1.37E-04 Smoking quantity / / 24665060 rs2128405 chr3 65100060 A C 7.27E-05 Depression (quantitative trait) / / 20800221 rs2128404 chr3 65100158 T C 4.42E-07 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9790242 chr3 65103850 C A 5.84E-04 Smoking quantity / / 24665060 rs17403629 chr3 65104040 A G 6.87E-05 Depression (quantitative trait) / / 20800221 rs17403692 chr3 65104083 C T 4.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs559397185 chr3 65104083 CG C 4.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9831020 chr3 65104234 A G 2.89E-05 Hemoglobin / / pha003098 rs9833943 chr3 65116677 G A 1.63E-04 Coronary Artery Disease / / 17634449 rs1482610 chr3 65121636 G C 1.68E-04 Coronary Artery Disease / / 17634449 rs9311934 chr3 65122103 G C 1.08E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs7613923 chr3 65127044 T C,G 7.98E-05 Hemoglobin / / pha003098 rs6445466 chr3 65132291 C T 6.40E-05 Creatinine levels / / pha003069 rs7626309 chr3 65133021 A G 4.94E-04 Multiple complex diseases / / 17554300 rs6807775 chr3 65133697 C T 4.74E-05 Erythrocyte counts / / pha003099 rs10510933 chr3 65148621 G A 3.46E-05 Behcet's disease / / pha002888 rs17072468 chr3 65152166 G A 3.53E-05 Receptive language ability / / 24687471 rs9311935 chr3 65153699 C T 5.39E-04 Multiple complex diseases / / 17554300 rs6786533 chr3 65175093 A G 9.51E-04 Aortic root size / / 21223598 rs7634969 chr3 65176116 A G 4.97E-04 Multiple complex diseases / / 17554300 rs7634969 chr3 65176116 A G 1.03E-04 Age-related macular degeneration / / 22125219 rs11131006 chr3 65179919 G A 2.16E-04 Age-related macular degeneration / / 22125219 rs2620525 chr3 65218668 A G 4.51E-04 Type 2 diabetes / / 17463246 rs2620525 chr3 65218668 A G 1.51E-04 Age-related macular degeneration / / 22125219 rs900371 chr3 65219673 G T 1.95E-04 Age-related macular degeneration / / 22125219 rs1384409 chr3 65222061 G T 2.29E-05 Tunica Media / / pha003036 rs17349171 chr3 65226990 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17349380 chr3 65231027 C A 8.58E-05 Cholesterol / / pha003073 rs4557104 chr3 65232772 G A 1.35E-05 Brain structure / / 22504417 rs781304 chr3 65237921 C T 6.83E-05 Height / / pha003011 rs6780864 chr3 65245294 C G 9.64E-04 Multiple complex diseases / / 17554300 rs7431862 chr3 65250132 G A 2.73E-06 Stroke (ischemic) / / 21957438 rs1531643 chr3 65262951 T C 3.50E-04 Multiple complex diseases / / 17554300 rs17072701 chr3 65271855 T C 7.51E-04 Insulin resistance / / 21901158 rs13100540 chr3 65295327 A G 3.53E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs17072783 chr3 65326224 G A 4.73E-07 Diabetes Mellitus / / pha003059 rs6764388 chr3 65326882 T C 6.00E-06 Corneal astigmatism / / 23322567 rs11720037 chr3 65368011 T G 0.0000686 Tuberculosis with early age of onset MAGI1 intron 22551897 rs1319134 chr3 65370493 A G 4.43E-04 Type 2 diabetes MAGI1 intron 17463246 rs9847394 chr3 65373365 A C 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs1016553 chr3 65379294 A G 1.46E-04 Multiple complex diseases MAGI1 intron 17554300 rs1016553 chr3 65379294 A G 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs1016553 chr3 65379294 A G 6.00E-06 Homeostasis model assessment of beta-cell function (interaction) MAGI1 intron 24204828 rs2127522 chr3 65381652 C T 9.61E-04 Insulin resistance MAGI1 intron 21901158 rs2127521 chr3 65382140 T C 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs2127521 chr3 65382140 T C 6.28E-06 Homeostasis model assessment of beta-cell function (interaction) MAGI1 intron 24204828 rs7649739 chr3 65398898 G A 6.00E-06 IgG glycosylation MAGI1 intron 23382691 rs13078969 chr3 65404650 C A 0.00087 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs13078969 chr3 65404650 C A 8.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs4396824 chr3 65405078 A G 1.70E-04 Body mass index MAGI1 intron 21701565 rs4396824 chr3 65405078 A G 0.0007357 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs4396824 chr3 65405078 A G 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs6766260 chr3 65406444 C T 6.39E-04 Multiple complex diseases MAGI1 intron 17554300 rs7428806 chr3 65409511 C T 0.000272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs7428806 chr3 65409511 C T 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs12485896 chr3 65410395 T A 3.66E-28 Narcolepsy MAGI1 intron 19629137 rs11131020 chr3 65411716 A G 8.23E-05 Heart Rate MAGI1 intron pha003053 rs11710619 chr3 65473862 T C 9.47E-05 Multiple complex diseases MAGI1 intron 17554300 rs1524968 chr3 65480973 T C 1.95E-04 Multiple complex diseases MAGI1 intron 17554300 rs1524976 chr3 65486388 A G 1.00E-04 Prostate cancer MAGI1 intron 21743057 rs1524976 chr3 65486388 A G 8.00E-06 PR interval MAGI1 intron 23534349 rs9864728 chr3 65486793 A C 2.00E-05 Prostate cancer MAGI1 intron 21743057 rs1404550 chr3 65487427 G C 2.00E-05 Prostate cancer MAGI1 intron 21743057 rs1554664 chr3 65501649 A G 5.00E-05 Prostate cancer MAGI1 intron 21743057 rs2177686 chr3 65510177 T A 6.72E-05 Multiple complex diseases MAGI1 intron 17554300 rs17073046 chr3 65510244 A G 7.30E-05 Multiple complex diseases MAGI1 intron 17554300 rs17073049 chr3 65511404 A C 5.76E-04 Multiple complex diseases MAGI1 intron 17554300 rs2091244 chr3 65517919 A G 8.21E-05 Multiple complex diseases MAGI1 intron 17554300 rs2037671 chr3 65540670 A C,T 1.38E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAGI1 intron 20463552 rs2888232 chr3 65543934 T C 4.30E-04 Multiple complex diseases MAGI1 intron 17554300 rs6787045 chr3 65544252 T G 4.35E-05 Intelligence MAGI1 intron 21826061 rs4688585 chr3 65567691 G A 7.21E-04 Insulin resistance MAGI1 intron 21901158 rs1880521 chr3 65568609 T C 2.65E-04 Alzheimer's disease (late onset) MAGI1 intron 21379329 rs12635482 chr3 65575360 A C 2.56E-04 Multiple complex diseases MAGI1 intron 17554300 rs1917527 chr3 65580498 G T 9.87E-04 Multiple complex diseases MAGI1 intron 17554300 rs4407359 chr3 65597953 C A 1.01E-04 Endometrial cancer MAGI1 intron 24096698 rs11926742 chr3 65611042 G A 1.46E-04 Alzheimer's disease (late onset) MAGI1 intron 21379329 rs9311947 chr3 65620088 G A 1.57E-05 Heart Rate MAGI1 intron pha003053 rs77162136 chr3 65620208 G C 0.00006349 Sarcoidosis MAGI1 intron 22952805 rs7618480 chr3 65691280 A T 7.37E-04 Multiple complex diseases MAGI1 intron 17554300 rs1499508 chr3 65692063 G A 3.16E-04 Alzheimer's disease MAGI1 intron 22005930 rs2372184 chr3 65698154 C A 2.50E-06 Biomarkers MAGI1 intron 17903293 rs13082646 chr3 65732113 T C 2.01E-05 Coronary heart disease MAGI1 intron 21606135 rs264096 chr3 65745435 G A 5.62E-04 Schizophrenia MAGI1 intron 19197363 rs814756 chr3 65753414 T C 9.37E-04 Coronary heart disease MAGI1 intron 21606135 rs11924265 chr3 65760342 T C 3.73E-04 Smoking quantity MAGI1 intron 24665060 rs984038 chr3 65762252 C T 4.95E-04 Coronary heart disease MAGI1 intron 21606135 rs1495453 chr3 65762547 G A 1.15E-05 Coronary heart disease MAGI1 intron 21606135 rs880167 chr3 65794968 A G 6.63E-05 Tuberculosis MAGI1 intron 24057671 rs1909492 chr3 65797540 T C 6.38E-05 Relative hand skill MAGI1 intron 24068947 rs1909492 chr3 65797540 T C 9.52E-06 Height MAGI1 intron pha003010 rs1909492 chr3 65797540 T C 1.66E-07 Height MAGI1 intron pha003011 rs17295791 chr3 65801606 T C 0.000006 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) MAGI1 intron 23080225 rs17361892 chr3 65806838 T C 6.09E-04 Type 2 diabetes MAGI1 intron 17463246 rs17073902 chr3 65813197 A G 9.33E-05 Multiple complex diseases MAGI1 intron 17554300 rs1495451 chr3 65833959 T C 3.90E-06 Triglycerides MAGI1 intron pha003081 rs1495451 chr3 65833959 T C 6.07E-06 Lipid levels MAGI1 intron pha003082 rs1021534 chr3 65837994 C T 3.62E-04 Multiple complex diseases MAGI1 intron 17554300 rs9876471 chr3 65873106 G A 6.20E-06 Insulin-related traits MAGI1 intron 19902172 rs9876471 chr3 65873106 G A 4.48E-05 Cataracts in type 2 diabetes MAGI1 intron 20664687 rs264668 chr3 65879245 C T 2.79E-05 Cataracts in type 2 diabetes MAGI1 intron 20664687 rs9864600 chr3 65881273 C T 6.17E-04 Smoking quantity MAGI1 intron 24665060 rs1390245 chr3 65893577 T C 6.49E-04 Multiple complex diseases MAGI1 intron 17554300 rs264692 chr3 65904425 G A 3.89E-05 Amyotrophic lateral sclerosis (sporadic) MAGI1 intron 24529757 rs174653 chr3 65908488 T A 3.78E-04 Multiple complex diseases MAGI1 intron 17554300 rs9880270 chr3 65944066 G A 5.55E-05 Erythrocyte counts MAGI1 intron pha003099 rs1430415 chr3 65951661 T C 1.70E-05 Urinary metabolites MAGI1 intron 21572414 rs1430416 chr3 65951752 G A 5.50E-06 Urinary metabolites MAGI1 intron 21572414 rs9823801 chr3 65952671 C T 4.77E-05 Erythrocyte counts MAGI1 intron pha003099 rs7637355 chr3 65952898 T C 2.80E-05 Urinary metabolites MAGI1 intron 21572414 rs6795228 chr3 65963727 T C 6.37E-06 Bipolar disorder MAGI1 intron 21771265 rs17074219 chr3 65965425 G T 4.77E-04 Multiple complex diseases MAGI1 intron 17554300 rs6445523 chr3 65966296 T G 1.47E-05 Brain structure MAGI1 intron 22504417 rs6445523 chr3 65966296 T G 9.84E-05 Mammographic density MAGI1 intron 22532574 rs17074228 chr3 65967673 C T 3.53E-05 Mammographic density MAGI1 intron 22532574 rs17031811 chr3 65970610 G A 6.94E-04 Multiple complex diseases MAGI1 intron 17554300 rs7620106 chr3 65971499 T C 9.10E-06 Coronary heart disease (incident CHD) MAGI1 intron 21880673 rs6763833 chr3 65978092 C T 8.18E-05 Blood Pressure and Arterial Stiffness MAGI1 intron 17903302 rs6445524 chr3 65979643 T G 3.70E-04 Tourette syndrome MAGI1 intron 22889924 rs1541855 chr3 65991856 C T 2.83E-04 Multiple complex diseases MAGI1 intron 17554300 rs6445525 chr3 65993104 C G 4.45E-04 Multiple complex diseases MAGI1 intron 17554300 rs6762527 chr3 66003745 T C 7.15E-04 Depression (quantitative trait) MAGI1 intron 20800221 rs13081023 chr3 66317480 G T 7.11E-04 Alzheimer's disease SLC25A26 intron 17998437 rs11128157 chr3 66330608 G T 7.43E-04 Multiple complex diseases SLC25A26 intron 17554300 rs6793050 chr3 66385769 C A 3.58E-05 Vaspin levels SLC25A26 intron 22907691 rs6793050 chr3 66385769 C A 0.0000358 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SLC25A26 intron 22907730 rs332354 chr3 66396845 G A 2.43E-04 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs9829376 chr3 66410397 A G 1.63E-04 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs332389 chr3 66411214 G A 1.30E-05 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs2242285 chr3 66431602 A G 1.00E-08 QRS duration LRIG1 intron 21076409 rs9827908 chr3 66445601 A G 6.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) LRIG1 intron 24554482 rs12633819 chr3 66448307 A G 2.86E-04 Amyotrophic Lateral Sclerosis LRIG1 intron 17362836 rs12633819 chr3 66448307 A G 0.000122 Salmonella-induced pyroptosis LRIG1 intron 22837397 rs12494912 chr3 66451907 T C 8.74E-05 Triglycerides LRIG1 intron pha003080 rs7651129 chr3 66474954 A G 2.00E-05 Urinary metabolites LRIG1 intron 21572414 rs12487264 chr3 66475637 C T 9.03E-04 Alzheimer's disease LRIG1 intron 22005930 rs12487264 chr3 66475637 C T 1.39E-05 Mammographic density LRIG1 intron 22532574 rs13078828 chr3 66479487 G A 5.13E-04 White matter integrity LRIG1 intron 22425255 rs13078828 chr3 66479487 G A 1.49E-05 Mammographic density LRIG1 intron 22532574 rs13078828 chr3 66479487 G A 4.00E-07 Antibody status in Tripanosoma cruzi seropositivity LRIG1 intron 24324551 rs17832271 chr3 66486380 C G 3.80E-06 Urinary metabolites LRIG1 intron 21572414 rs13096446 chr3 66488134 G T 9.42E-06 Mammographic density LRIG1 intron 22532574 rs13323717 chr3 66488656 C T 1.13E-04 Multiple complex diseases LRIG1 intron 17554300 rs6419763 chr3 66495755 T C 3.47E-04 Multiple complex diseases LRIG1 intron 17554300 rs13325263 chr3 66503207 T C 8.27E-04 Multiple complex diseases LRIG1 intron 17554300 rs3845903 chr3 66517670 C T 1.14E-14 Multiple complex diseases LRIG1 intron 17554300 rs3845905 chr3 66525963 T C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) LRIG1 intron 23648065 rs3845905 chr3 66525963 T C 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRIG1 intron 23648065 rs17044781 chr3 66570660 G T 4.43E-07 Multiple complex diseases / / 17554300 rs4241442 chr3 66580551 A G 2.66E-04 Lung function (forced vital capacity) / / 24023788 rs11918414 chr3 66618030 C T 7.48E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11918414 chr3 66618030 C T 2.81E-06 Coronary heart disease / / pha003030 rs17044826 chr3 66620523 C A 2.55E-04 Type 2 diabetes / / 17463246 rs4547637 chr3 66627521 C T 3.40E-05 Coronary heart disease / / pha003030 rs4856952 chr3 66635873 G A 7.33E-05 Coronary heart disease / / pha003030 rs17044857 chr3 66637182 A G 1.89E-04 Multiple complex diseases / / 17554300 rs7612441 chr3 66648162 C T 2.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11128158 chr3 66668365 A G 2.32E-04 Insulin resistance / / 21901158 rs9870520 chr3 66706240 C T 0.000694 Salmonella-induced pyroptosis / / 22837397 rs1563541 chr3 66709318 A G 0.000378 Salmonella-induced pyroptosis / / 22837397 rs11717412 chr3 66713592 G A 2.60E-05 Urinary metabolites / / 21572414 rs12488407 chr3 66745365 T C 8.63E-05 Socioeconomic Factors / / pha003066 rs11710109 chr3 66753674 C T 2.18E-05 Socioeconomic Factors / / pha003066 rs1379186 chr3 66760417 A T 3.25E-04 Depression (quantitative trait) / / 20800221 rs11128202 chr3 66768059 T C 5.78E-04 Type 2 diabetes / / 17463246 rs17045031 chr3 66768364 G A 4.00E-07 Carotid intima media thickness / / 21909108 rs6549373 chr3 66769884 C T 2.01E-06 Uric acid levels / / 21294900 rs2120503 chr3 66779891 C T 2.23E-05 Multiple complex diseases / / 17554300 rs2034151 chr3 66782263 C T 4.52E-04 Type 2 diabetes / / 17463246 rs9845175 chr3 66797032 C T 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13069000 chr3 66798950 C G 1.00E-19 Renal function-related traits (BUN) / / 22797727 rs17045066 chr3 66799169 C T 3.61E-05 Height / / 17255346 rs13080378 chr3 66804200 A G 8.61E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6796957 chr3 66807194 A G 2.07E-04 Prostate cancer / / 23023329 rs13069049 chr3 66809942 A T 3.00E-18 Metabolite levels / / 21909109 rs11709625 chr3 66823157 C A 1.00E-10 Blood cell counts and other traits / / 20139978 rs11709625 chr3 66823157 C A 1.46E-10 Blood cell counts and other traits / / 20139978 rs1001689 chr3 66843365 G T 2.15E-04 IgE levels / / 17255346 rs10049466 chr3 66868609 C T 9.66E-05 Diabetes (gestational) / / 22233651 rs10049470 chr3 66868827 C T 1.36E-04 IgE levels / / 17255346 rs3884663 chr3 66869791 G A 1.47E-04 IgE levels / / 17255346 rs3884663 chr3 66869791 G A 7.47E-04 Heart Failure / / pha002884 rs11719970 chr3 66890737 T A,C 1.30E-06 Urinary metabolites / / 21572414 rs4411828 chr3 66912679 T C 4.46E-04 Alzheimer's disease / / 24755620 rs6794835 chr3 66916783 G A 9.68E-05 Alzheimer's disease (late onset) / / 21379329 rs6794835 chr3 66916783 G A 3.09E-05 Alzheimer's disease / / 24755620 rs1563441 chr3 66921142 G A 2.02E-04 Alzheimer's disease (late onset) / / 21379329 rs1563441 chr3 66921142 G A 2.36E-05 Alzheimer's disease / / 24755620 rs12496807 chr3 66931388 A G 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs9681451 chr3 66940463 T A 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2219265 chr3 66942668 C T 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2219265 chr3 66942668 C T 2.60E-05 Urinary metabolites / / 21572414 rs1350164 chr3 66942979 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6778915 chr3 66956170 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6778915 chr3 66956170 T C 1.90E-05 Urinary metabolites / / 21572414 rs10446399 chr3 66957796 G C 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs9836258 chr3 66995981 C G 8.51E-08 Metabolite levels / / 23281178 rs9816008 chr3 67016686 C T 3.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1869900 chr3 67023150 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714803 chr3 67032138 T C 8.02E-08 Metabolite levels / / 23281178 rs12486952 chr3 67040146 A C 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9875436 chr3 67046187 G T 1.82E-08 Metabolite levels / / 23281178 rs2364281 chr3 67050203 T G 4.23E-04 Suicide attempts in bipolar disorder KBTBD8 intron 21423239 rs4074707 chr3 67072952 A G 1.83E-04 Alzheimer's disease (late onset) / / 21379329 rs7653502 chr3 67079104 C T 2.37E-05 Alzheimer's disease (late onset) / / 21379329 rs7641944 chr3 67132470 T C 0.0006558 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7641944 chr3 67132470 T C 6.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4392363 chr3 67143838 T A 1.00E-06 Migraine - clinic-based / / 23793025 rs4392363 chr3 67143838 T A 1.70E-04 Migraine / / 23793025 rs4417811 chr3 67145427 T C 1.52E-05 Schizophrenia / / pha002857 rs13089748 chr3 67148307 T C 1.68E-04 Alzheimer's disease (late onset) / / 21379329 rs7618179 chr3 67150373 A T 0.0005789 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7618179 chr3 67150373 A T 5.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9867793 chr3 67160633 A G 1.45E-05 Alzheimer's disease (late onset) / / 21379329 rs6762402 chr3 67172100 T C 1.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6766797 chr3 67183628 T A 1.36E-05 Postoperative ventricular dysfunction / / 21980348 rs17804294 chr3 67294182 G C 1.80E-05 Urinary metabolites / / 21572414 rs872101 chr3 67298578 G C 3.71E-06 Asthma (childhood onset) / / 23829686 rs1490244 chr3 67317284 A G 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1387862 chr3 67317393 G C 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4396908 chr3 67336441 G C 4.23E-04 Type 2 diabetes / / 17463246 rs1490270 chr3 67340025 A C 9.54E-04 Type 2 diabetes / / 17463246 rs9856163 chr3 67346041 G A 1.23E-04 Type 2 diabetes / / 17463246 rs9860348 chr3 67346325 G T 1.89E-05 Type 2 diabetes / / 17463246 rs10510963 chr3 67352876 A C 1.40E-05 Urinary metabolites / / 21572414 rs6548450 chr3 67354022 A G 5.44E-05 Type 2 diabetes / / 17463246 rs9863572 chr3 67355643 A G 2.77E-05 Type 2 diabetes / / 17463246 rs931437 chr3 67364804 G A 7.81E-04 Myocardial Infarction / / pha002883 rs79075676 chr3 67366908 C T 1.96E-06 Response to amphetamines / / 22952603 rs17805868 chr3 67366936 T C 2.50E-05 Urinary metabolites / / 21572414 rs6548463 chr3 67367341 C T 3.64E-04 Myocardial Infarction / / pha002883 rs977102 chr3 67373977 A G 2.00E-06 Response to amphetamines / / 22952603 rs7639918 chr3 67386369 G C 6.52E-04 Type 2 diabetes / / 17463246 rs1586671 chr3 67388815 A C 5.75E-04 Type 2 diabetes / / 17463246 rs17806805 chr3 67415904 G T 2.20E-05 Type 2 diabetes SUCLG2 intron 17463246 rs17806888 chr3 67416322 T C 2.00E-09 Height SUCLG2 intron 20881960 rs17806888 chr3 67416322 T C 4.14E-06 Response to amphetamines SUCLG2 intron 22952603 rs17806888 chr3 67416322 T C 7.00E-11 Blood metabolite levels SUCLG2 intron 24816252 rs2363709 chr3 67417105 G A 5.00E-06 IgE levels SUCLG2 intron 23146381 rs3952322 chr3 67421818 C A 1.40E-06 Urinary metabolites SUCLG2 intron 21572414 rs115560420 chr3 67425963 G T 5.38E-06 Response to amphetamines SUCLG2 UTR-3 22952603 rs35494829 chr3 67426281 T C 5.38E-06 Response to amphetamines SUCLG2 missense 22952603 rs11923377 chr3 67427443 C T 1.08E-04 Lung function (forced expiratory volume in 1 second) SUCLG2 intron 24023788 rs6791324 chr3 67437836 C A 4.84E-04 Tourette syndrome SUCLG2 intron 22889924 rs41356347 chr3 67440712 T A 4.65E-26 Multiple complex diseases SUCLG2 intron 17554300 rs4856782 chr3 67463065 C T 6.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SUCLG2 intron 22566498 rs4856863 chr3 67470690 G A 6.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SUCLG2 intron 22566498 rs6792584 chr3 67531388 G A 5.00E-06 Corneal astigmatism SUCLG2 intron 22144915 rs1888089 chr3 67605629 C T 1.57E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2634737 chr3 67608349 C G 8.29E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2634743 chr3 67612285 C T 4.40E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2250952 chr3 67628283 A C 7.62E-04 Response to cytidine analogues (gemcitabine) SUCLG2 intron 24483146 rs6794298 chr3 67635506 A C 5.13E-04 Response to cytidine analogues (gemcitabine) SUCLG2 intron 24483146 rs2076913 chr3 67649769 A C 6.22E-04 Type 2 diabetes SUCLG2 intron 17463246 rs1868674 chr3 67667800 T C 1.79E-05 Smoking quantity SUCLG2 intron 24665060 rs7646094 chr3 67672171 T C 2.48E-04 Obesity (extreme) SUCLG2 intron 21935397 rs10510965 chr3 67679557 C T 2.48E-04 Type 2 diabetes SUCLG2 intron 17463246 rs144647865 chr3 67795556 T TC 2.32E-05 Glucose levels / / pha003061 rs17046946 chr3 67795556 T C 2.32E-05 Glucose levels / / pha003061 rs4856894 chr3 67833293 G T 2.32E-05 Cognitive test performance / / 20125193 rs41375847 chr3 67950420 G C 8.67E-05 Smoking initiation / / 24665060 rs6795684 chr3 67964947 G C 4.35E-04 Alzheimer's disease / / 17998437 rs9857691 chr3 68065895 C G 6.32E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FAM19A1 intron 24236485 rs11920675 chr3 68069643 G T 4.64E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1447756 chr3 68069731 G A 5.16E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1447756 chr3 68069731 G A 8.27E-04 Suicide attempts in bipolar disorder FAM19A1 intron 21423239 rs9865881 chr3 68087505 T C 3.59E-04 Tourette syndrome FAM19A1 intron 22889924 rs6792324 chr3 68096404 T A 1.61E-05 Aging (time to event) FAM19A1 intron 21782286 rs7433199 chr3 68115348 T C 0.000571 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7433199 chr3 68115348 T C 5.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs6548964 chr3 68122404 G A 9.91E-04 Multiple complex diseases FAM19A1 intron 17554300 rs7610023 chr3 68123731 A C 8.26E-05 Caffeine consumption FAM19A1 intron 21490707 rs9990002 chr3 68165772 G T 3.52E-04 Alcohol dependence FAM19A1 intron 20201924 rs7617812 chr3 68177942 G A 0.0000291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7617812 chr3 68177942 G A 2.91E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs7624036 chr3 68179836 G A 0.0000289 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7624036 chr3 68179836 G A 2.89E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs1595493 chr3 68194293 G A 6.00E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1595491 chr3 68196810 T A 0.0000195 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs1595491 chr3 68196810 T A 1.95E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs1595490 chr3 68196836 G A 5.64E-05 Multiple complex diseases FAM19A1 intron 17554300 rs17047216 chr3 68200366 A G 9.49E-04 Multiple complex diseases FAM19A1 intron 17554300 rs7650009 chr3 68252679 A G 3.17E-04 Alcohol dependence FAM19A1 intron 20201924 rs12053924 chr3 68261646 G A 4.70E-04 Alzheimer's disease FAM19A1 intron 17998437 rs12494944 chr3 68268104 C T 7.80E-06 Urinary metabolites FAM19A1 intron 21572414 rs1032376 chr3 68317975 T C 1.01E-06 Cognitive test performance FAM19A1 intron 20125193 rs902719 chr3 68331611 G T 2.07E-05 Multiple complex diseases FAM19A1 intron 17554300 rs1491758 chr3 68365879 C A 6.51E-04 Suicide attempts in bipolar disorder FAM19A1 intron 21423239 rs4568137 chr3 68372690 C T 9.13E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1388505 chr3 68373086 G A 5.90E-04 Type 2 diabetes FAM19A1 intron 17463246 rs9809500 chr3 68377212 G C 0.00000999 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs9848233 chr3 68377214 C T 0.00000998 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs1491745 chr3 68379169 G A 9.04E-04 Coronary heart disease FAM19A1 intron 21971053 rs6792971 chr3 68385527 T C 2.59E-05 Reading disability and language impairment FAM19A1 intron 24024963 rs17047573 chr3 68411119 T G 8.35E-08 Cataracts in type 2 diabetes FAM19A1 intron 20664687 rs17047586 chr3 68412874 A G 7.65E-08 Cataracts in type 2 diabetes FAM19A1 intron 20664687 rs4855469 chr3 68458440 C T 3.00E-04 Response to interferon beta in multiple sclerosis FAM19A1 intron 18195134 rs9822547 chr3 68459113 A G 6.61E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs4277695 chr3 68462634 T C 4.07E-04 Bipolar disorder FAM19A1 intron 19259986 rs17047650 chr3 68464413 C T 0.0000319 Aging FAM19A1 intron 22445811 rs9850187 chr3 68468152 T C 3.73E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs876610 chr3 68470376 C A 5.83E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs4855475 chr3 68484388 A G 3.79E-05 Type 2 diabetes FAM19A1 intron 17463246 rs7634101 chr3 68485443 A G 0.0000872 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs73111013 chr3 68486196 G A 0.0000863 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs10433502 chr3 68487102 C T 0.0000349 Aging FAM19A1 intron 22445811 rs1858243 chr3 68545254 T C 8.00E-06 Urinary metabolites FAM19A1 intron 21572414 rs17245086 chr3 68583049 C A 9.73E-04 Multiple complex diseases FAM19A1 intron 17554300 rs17047811 chr3 68583643 T C 7.05E-04 HIV-1 viral setpoint FAM19A1 intron 17641165 rs1398072 chr3 68643676 A G 9.76E-04 Tourette syndrome / / 22889924 rs11721243 chr3 68650788 T C 9.17E-04 Tourette syndrome / / 22889924 rs4305427 chr3 68667357 A C 6.38E-04 Tourette syndrome / / 22889924 rs1504294 chr3 68749138 T G 5.50E-04 Obesity-related traits / / 17903300 rs6771218 chr3 68767391 G A 1.80E-04 Aortic root size / / 21223598 rs9856483 chr3 68776817 A G 8.64E-04 Tourette syndrome / / 22889924 rs6786379 chr3 68785967 A G 7.97E-04 Tourette syndrome FAM19A4 intron 22889924 rs12629919 chr3 68828723 A G 9.52E-04 Type 2 diabetes FAM19A4 intron 17463246 rs9851941 chr3 68837555 G A 1.16E-04 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs1873264 chr3 68844213 A G 2.35E-05 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs2171870 chr3 68905151 C G 9.90E-04 Multiple complex diseases FAM19A4 intron 17554300 rs6765918 chr3 68906466 G A 5.71E-04 Multiple complex diseases FAM19A4 intron 17554300 rs923512 chr3 68912531 A G 4.04E-05 Glucose levels FAM19A4 intron pha002899 rs11128100 chr3 68915052 T C 3.40E-04 Acute lung injury FAM19A4 intron 22295056 rs11128102 chr3 68918580 T C 3.47E-04 Acute lung injury FAM19A4 intron 22295056 rs13096541 chr3 68921682 A G 1.19E-04 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs17048089 chr3 68923779 A G 3.84E-04 Acute lung injury FAM19A4 intron 22295056 rs17048091 chr3 68925778 A G 4.31E-04 Multiple complex diseases FAM19A4 intron 17554300 rs4855535 chr3 68934434 T G 5.71E-05 Glucose levels FAM19A4 UTR-5 pha002899 rs17048119 chr3 68940944 C G,T 5.86E-04 Suicide attempts in bipolar disorder FAM19A4 intron 21423239 rs6770678 chr3 68961010 C T 5.29E-04 Alcohol dependence FAM19A4 intron 21314694 rs9835177 chr3 68963038 A T 4.44E-05 Multiple complex diseases FAM19A4 intron 17554300 rs6787753 chr3 68995937 C A 2.25E-05 Lymphocyte counts / / pha003094 rs6787753 chr3 68995937 C A 2.55E-05 Neutrophil count / / pha003095 rs6785239 chr3 69001402 A G 2.63E-05 Lymphocyte counts / / pha003094 rs6785239 chr3 69001402 A G 2.96E-05 Neutrophil count / / pha003095 rs2033773 chr3 69034385 G T 7.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) C3orf64 intron 23648065 rs4411889 chr3 69045948 C T 3.12E-04 Type 2 diabetes C3orf64 intron 17463246 rs12488463 chr3 69063936 G A 1.81E-04 Type 2 diabetes / / 17463246 rs1745 chr3 69070457 G A 7.73E-05 Type 2 diabetes TMF1 UTR-3 17463246 rs9862298 chr3 69072761 T C 2.13E-04 Type 2 diabetes TMF1 intron 17463246 rs7375020 chr3 69073917 A G 3.90E-04 Type 2 diabetes TMF1 intron 17463246 rs937858 chr3 69082873 G T 2.25E-04 Type 2 diabetes TMF1 intron 17463246 rs2271121 chr3 69084161 C A 7.55E-05 Type 2 diabetes TMF1 intron 17463246 rs9809889 chr3 69087412 T G 4.18E-04 Type 2 diabetes TMF1 intron 17463246 rs2271118 chr3 69093598 T C 4.93E-06 Lymphocyte counts TMF1 intron 22286170 rs3853157 chr3 69126628 C T 6.01E-04 Coronary heart disease UBA3 intron 21606135 rs3772979 chr3 69127133 T C 9.38E-04 Coronary heart disease UBA3 intron 21606135 rs3853158 chr3 69137219 C T 5.47E-04 Age-related macular degeneration ARL6IP5 intron 22125219 rs6549184 chr3 69150277 G A 1.10E-04 Alcohol dependence ARL6IP5 intron 20201924 rs9824846 chr3 69166895 A G 4.53E-04 HIV-1 viral setpoint LMOD3 intron 17641165 rs7638995 chr3 69173375 C A 2.00E-06 Alzheimer's disease (late onset) / / 22881374 rs4525874 chr3 69197709 G C 5.67E-04 Multiple complex diseases / / 17554300 rs9310139 chr3 69217344 G C 2.23E-04 Multiple complex diseases / / 17554300 rs9831516 chr3 69230061 G A 5.67E-07 Multiple complex diseases FRMD4B missense 17554300 rs6772387 chr3 69252261 T C 7.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs4376041 chr3 69252443 A T 7.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6781505 chr3 69252824 G A 7.90E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6806528 chr3 69252899 C T 2.00E-07 Celiac disease FRMD4B intron 20190752 rs6806528 chr3 69252899 C T 8.00E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6776027 chr3 69253455 T C 5.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6784841 chr3 69253632 G A 5.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs4075188 chr3 69254120 G A 6.70E-05 Diabetic retinopathy FRMD4B intron 21441570 rs11128120 chr3 69266821 G A 7.75E-05 Potassium levels FRMD4B intron pha003086 rs13073189 chr3 69273132 T A 3.20E-05 Diabetic retinopathy FRMD4B intron 21441570 rs9849591 chr3 69274066 G A 2.27E-04 Amyotrophic lateral sclerosis (sporadic) FRMD4B intron 24529757 rs9840469 chr3 69274314 T C 7.83E-05 Potassium levels FRMD4B intron pha003086 rs4447768 chr3 69280903 C T 2.33E-04 Multiple complex diseases FRMD4B intron 17554300 rs1483892 chr3 69302563 A G 0.0007011 Sarcoidosis FRMD4B intron 22952805 rs6549198 chr3 69362959 A G 5.82E-05 Orofacial clefts FRMD4B intron 22419666 rs13066342 chr3 69369296 C A 5.28E-04 Nicotine smoking FRMD4B intron 19268276 rs12629229 chr3 69411222 T C 1.07E-05 Mathematical ability FRMD4B intron 24801482 rs17005675 chr3 69413674 G A 5.81E-04 Multiple complex diseases FRMD4B intron 17554300 rs6792404 chr3 69432044 C T 5.14E-05 Multiple complex diseases FRMD4B intron 17554300 rs12330712 chr3 69432555 A C 9.18E-04 Suicide attempts in bipolar disorder FRMD4B intron 21423239 rs13099017 chr3 69434145 A C 9.47E-04 Suicide attempts in bipolar disorder FRMD4B intron 21423239 rs17005789 chr3 69434867 T G 3.70E-04 Major depressive disorder FRMD4B intron 21042317 rs981053 chr3 69437217 C G 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs922948 chr3 69442637 G A 2.00E-06 Hip geometry / / 17903296 rs11128129 chr3 69454010 C T 7.20E-05 Body Mass Index / / pha003009 rs4855311 chr3 69456914 A G 2.02E-05 Body Mass Index / / pha003009 rs9846189 chr3 69459393 A G 1.81E-05 Body Mass Index / / pha003009 rs4855312 chr3 69463211 C T 1.81E-05 Body Mass Index / / pha003009 rs4855403 chr3 69463560 T C 1.70E-05 Body Mass Index / / pha003009 rs7625432 chr3 69477220 C T 7.35E-05 Body Mass Index / / pha003009 rs6795389 chr3 69483946 A G 9.58E-05 Body Mass Index / / pha003009 rs7631421 chr3 69507299 G C 0.0000226 Adenoma (female) / / 22532847 rs9843168 chr3 69513198 C T 1.26E-05 Prostate cancer / / 22923026 rs1498839 chr3 69516937 C T 5.02E-05 Cognitive performance / / 19734545 rs374977094 chr3 69516937 C CG 5.02E-05 Cognitive performance / / 19734545 rs10510980 chr3 69520888 T C 6.50E-04 Type 2 diabetes / / 17460697 rs9834457 chr3 69521568 T C 6.10E-05 Neuroticism / / 23229837 rs9869412 chr3 69523979 C T 9.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7647186 chr3 69540495 C T 2.77E-04 Smoking initiation / / 24665060 rs9822785 chr3 69554953 T C 4.19E-04 Depression (quantitative trait) / / 20800221 rs2133343 chr3 69555087 T G 4.21E-04 Depression (quantitative trait) / / 20800221 rs3947355 chr3 69555159 C A 5.28E-04 Depression (quantitative trait) / / 20800221 rs1498854 chr3 69560235 C G 6.06E-04 Depression (quantitative trait) / / 20800221 rs9843182 chr3 69564625 A G 6.10E-04 Depression (quantitative trait) / / 20800221 rs1391774 chr3 69566966 C T 6.91E-04 Depression (quantitative trait) / / 20800221 rs1391769 chr3 69573402 T C 6.42E-04 Depression (quantitative trait) / / 20800221 rs17006074 chr3 69582315 G A 9.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs995829 chr3 69601480 A G 4.35E-04 Insulin resistance / / 21901158 rs904418 chr3 69616814 T C 7.29E-04 Smoking quantity / / 24665060 rs7647307 chr3 69623188 G A,T 0.000341142 Hypertension (early onset hypertension) / / 22479346 rs7623679 chr3 69640802 G T 3.30E-04 Response to antidepressants / / 19736353 rs10510985 chr3 69663871 C T 2.00E-04 Chronic fatigue syndrome / / 21912186 rs13086517 chr3 69694728 C A 2.00E-05 Urinary metabolites / / 21572414 rs17006293 chr3 69694906 C T 9.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1559941 chr3 69700787 G T 2.72E-05 Alzheimer's disease / / 17998437 rs6549245 chr3 69705616 T C 9.90E-05 Myopia (pathological) / / 21640322 rs890595 chr3 69708931 C T 1.51E-04 Multiple complex diseases / / 17554300 rs9821048 chr3 69750087 T C 4.20E-05 Aortic root size / / 21223598 rs7613991 chr3 69762586 G T 4.72E-05 Response to metformin / / 21186350 rs6794315 chr3 69783567 T C 4.71E-05 Serum albumin level / / pha003084 rs12489786 chr3 69788068 T C 5.17E-04 Multiple complex diseases MITF nearGene-5 17554300 rs13073599 chr3 69808638 A G 5.51E-05 Glucose levels MITF intron pha003057 rs78356356 chr3 69824093 A G 5.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity MITF intron 24324551 rs6805563 chr3 69879323 G A 4.68E-05 Glucose levels MITF intron pha003057 rs17006615 chr3 70000216 T C 2.44E-04 Multiple complex diseases MITF intron 17554300 rs17006637 chr3 70036761 T C 8.66E-04 Type 2 diabetes / / 17463246 rs9863457 chr3 70037117 G C 0.000441 Breast cancer early age of onset / / 18463975 rs765015 chr3 70135943 G T 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs4855460 chr3 70146574 G T 4.57E-04 Schizophrenia / / 19197363 rs7639059 chr3 70161591 A C 2.18E-04 Celiac disease / / 23936387 rs7633462 chr3 70186696 G T 1.00E-04 Information processing speed / / 21130836 rs6549282 chr3 70204843 C A 2.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs6549289 chr3 70224360 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4334612 chr3 70224889 C T 7.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs7431876 chr3 70246225 C T 5.25E-05 Coronary heart disease / / pha003032 rs7623693 chr3 70248282 G T 1.05E-05 Body Mass Index / / pha003007 rs7623693 chr3 70248282 G T 7.24E-05 Weight / / pha003027 rs17006842 chr3 70259702 C T 2.82E-04 Multiple complex diseases / / 17554300 rs1546734 chr3 70286279 A G 4.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs6549321 chr3 70320787 A T 1.50E-05 Urinary metabolites / / 21572414 rs6549322 chr3 70320864 T G 2.70E-05 Urinary metabolites / / 21572414 rs12634491 chr3 70329538 C T 1.44E-04 Sudden cardiac arrest / / 21658281 rs1111622 chr3 70330389 C T 3.99E-04 Type 2 diabetes / / 17463246 rs1105032 chr3 70330440 A C 1.61E-04 Type 2 diabetes / / 17463246 rs1105033 chr3 70330465 G A 1.99E-04 Type 2 diabetes / / 17463246 rs7646775 chr3 70348796 G A 1.70E-04 Type 2 diabetes / / 17463246 rs1403076 chr3 70348881 G A 1.70E-04 Type 2 diabetes / / 17463246 rs2030526 chr3 70352489 C T 4.37E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1403072 chr3 70373502 C T 8.27E-05 Body Fat Distribution / / pha003016 rs1403072 chr3 70373502 C T 4.20E-05 Body Fat Distribution / / pha003017 rs1403072 chr3 70373502 C T 2.35E-05 Body Fat Distribution / / pha003018 rs805469 chr3 70391905 T C 4.94E-04 Multiple complex diseases / / 17554300 rs1090502 chr3 70394223 A G 3.29E-05 Major depressive disorder / / 21621269 rs1090502 chr3 70394223 A G 8.12E-05 Major depressive disorder / / pha002850 rs805492 chr3 70406133 C A 2.38E-05 Creatinine levels / / pha003069 rs810912 chr3 70410209 G A 4.50E-06 Urinary metabolites / / 21572414 rs7643940 chr3 70413176 G T 5.00E-05 Sudden cardiac arrest / / 21658281 rs13314351 chr3 70417993 C T 1.60E-05 Hypothyroidism / / 22493691 rs805476 chr3 70426862 A G 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs805478 chr3 70427067 G T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1008411 chr3 70445977 T C 1.74E-04 Coronary heart disease / / 21971053 rs1024889 chr3 70463330 A G 6.00E-06 Body mass index / / 19851299 rs9820110 chr3 70469958 T G 2.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2874359 chr3 70482549 G C 4.25E-04 Multiple complex diseases / / 17554300 rs4974292 chr3 70516683 T C 2.77E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17789963 chr3 70517534 G C 7.11E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs7610220 chr3 70522017 G C 6.16E-04 Spine bone size / / 23207799 rs4638930 chr3 70528833 A G 1.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9830720 chr3 70543096 A G 6.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1491609 chr3 70550462 C A 5.95E-05 Cardiovascular disease / / 22029572 rs17790790 chr3 70565820 G A 9.91E-04 Common variable immunodeficiency / / 21497890 rs11128181 chr3 70608205 A C 4.85E-04 Amyotrophic lateral sclerosis / / 23624525 rs7628219 chr3 70626360 C T 2.00E-06 Insomnia (caffeine-induced) / / 22754043 rs4974301 chr3 70639463 G A 1.30E-04 Multiple complex diseases / / 17554300 rs725611 chr3 70671050 C A 8.29E-05 Multiple complex diseases / / 17554300 rs12631500 chr3 70671498 T C 8.15E-05 Multiple complex diseases / / 17554300 rs17792804 chr3 70673153 G C 1.64E-04 Multiple complex diseases / / 17554300 rs9828127 chr3 70674911 G C 8.11E-05 Multiple complex diseases / / 17554300 rs9864594 chr3 70681401 G A 2.10E-04 Multiple complex diseases / / 17554300 rs11915836 chr3 70684565 C T 1.00E-04 Prostate cancer / / 21743057 rs1907559 chr3 70693650 A T 1.87E-04 Multiple complex diseases / / 17554300 rs7626132 chr3 70698286 G C 1.96E-04 Multiple complex diseases / / 17554300 rs11128186 chr3 70704970 C T 6.96E-04 Multiple complex diseases / / 17554300 rs6549348 chr3 70730524 G A 6.00E-05 Prostate cancer / / 21743057 rs11918019 chr3 70784994 A G 3.51E-05 Multiple complex diseases / / 17554300 rs7633132 chr3 70791669 A C 1.51E-04 Multiple complex diseases / / 17554300 rs17007780 chr3 70807623 C T 9.12E-24 Narcolepsy / / 19629137 rs6763648 chr3 70807661 C T 6.83E-05 Multiple complex diseases / / 17554300 rs2117760 chr3 70850461 C A 5.50E-04 Intraocular pressure / / 22570627 rs10865656 chr3 70857460 T C 6.92E-05 Multiple complex diseases / / 17554300 rs7618715 chr3 70873278 G A 7.59E-04 Multiple complex diseases / / 17554300 rs1522552 chr3 70907252 A G 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2597301 chr3 70909494 C G 4.02E-04 Multiple complex diseases / / 17554300 rs1018340 chr3 70918127 G A 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2687201 chr3 70928930 A C 3.11E-04 Multiple complex diseases / / 17554300 rs2687201 chr3 70928930 A C 2.00E-06 Barrett's esophagus / / 24121790 rs2687201 chr3 70928930 A C 5.00E-09 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2687201 chr3 70928930 A C 6.00E-07 Esophageal adenocarcinoma / / 24121790 rs2597312 chr3 70938609 C T 7.52E-04 Multiple complex diseases / / 17554300 rs17007999 chr3 70958673 A G 8.13E-04 Depression (quantitative trait) / / 20800221 rs9837992 chr3 70959438 G A 1.00E-04 Barrett's esophagus / / 24121790 rs9837992 chr3 70959438 G A 2.26E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs9837992 chr3 70959438 G A 3.63E-05 Esophageal adenocarcinoma / / 24121790 rs6789153 chr3 71001255 C G 9.20E-06 Hepatitis B / / 21750111 rs17651978 chr3 71020490 G A 6.00E-06 Attention deficit hyperactivity disorder FOXP1 intron 18821565 rs17652341 chr3 71051352 T C 9.99E-04 Coronary Artery Disease FOXP1 intron 17634449 rs13093086 chr3 71055162 G A 5.00E-06 Intraocular pressure FOXP1 intron 24002674 rs9858444 chr3 71077031 T C 7.00E-05 Response to statin therapy FOXP1 intron 20339536 rs7653129 chr3 71079420 A G 6.20E-05 Response to statin therapy FOXP1 intron 20339536 rs6549371 chr3 71080759 G C 6.50E-05 Response to statin therapy FOXP1 intron 20339536 rs9861326 chr3 71081836 C A,T 6.70E-05 Response to statin therapy FOXP1 intron 20339536 rs9880715 chr3 71081865 A G 6.42E-04 Multiple complex diseases FOXP1 intron 17554300 rs9880715 chr3 71081865 A G 6.40E-05 Response to statin therapy FOXP1 intron 20339536 rs1288979 chr3 71103136 T C 5.90E-05 Response to statin therapy FOXP1 intron 20339536 rs1288980 chr3 71105863 A G 5.90E-05 Response to statin therapy FOXP1 intron 20339536 rs7616330 chr3 71115751 C A 6.00E-06 QT interval FOXP1 intron 23166209 rs10212561 chr3 71125604 T C 5.35E-05 Response to mTOR inhibitor (rapamycin) FOXP1 intron 24009623 rs2686268 chr3 71145830 A C 9.64E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs831439 chr3 71154818 G A 7.98E-04 Aortic root size FOXP1 intron 21223598 rs3846029 chr3 71155119 T C 7.58E-04 Body mass index FOXP1 intron 21701565 rs3846028 chr3 71155250 T C 2.56E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs831444 chr3 71158354 T C 3.97E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs2121783 chr3 71174475 C T 8.86E-05 Schizophrenia (cytomegalovirus infection interaction) FOXP1 intron 23358160 rs11719587 chr3 71185630 T C 1.90E-04 HDL particle features FOXP1 intron 21283740 rs6800929 chr3 71199187 G A 1.01E-04 Acute lymphoblastic leukemia (childhood) FOXP1 intron 22076464 rs13097125 chr3 71199338 T G 2.35E-04 Smoking initiation FOXP1 intron 24665060 rs9829152 chr3 71200872 C T 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FOXP1 intron 20877124 rs7653672 chr3 71201454 G A 3.45E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs11923661 chr3 71202106 A C 2.34E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs1402994 chr3 71203369 G T 1.67E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FOXP1 intron 20877124 rs1402994 chr3 71203369 G T 1.70E-05 Hodgkin's lymphoma FOXP1 intron 24149102 rs1522178 chr3 71204263 C G 2.63E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs7623157 chr3 71225021 A G 8.64E-04 Obesity (extreme) FOXP1 intron 21935397 rs6549381 chr3 71256462 A C 5.98E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs6549382 chr3 71257082 T C 7.21E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs939840 chr3 71258187 C T 8.27E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs939841 chr3 71258386 T C 8.43E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs12714772 chr3 71260194 A G 6.95E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs17008389 chr3 71283516 A T 4.26E-04 Major depressive disorder FOXP1 intron 22472876 rs4055824 chr3 71292039 A G 3.08E-04 Coronary Artery Disease FOXP1 intron 17634449 rs17008402 chr3 71300567 A G 2.00E-06 Subcutaneous adipose tissue FOXP1 intron 22589738 rs17008404 chr3 71302616 T C 3.68E-05 Coronary Artery Disease FOXP1 intron 17634449 rs1541903 chr3 71324328 C T 5.20E-04 Rheumatoid arthritis FOXP1 intron 21452313 rs1288694 chr3 71324580 T C 1.10E-05 Urinary metabolites FOXP1 intron 21572414 rs1288825 chr3 71330949 C T 6.40E-05 Brain derived neurotrophic factor levels,in serum FOXP1 intron 22047184 rs6780738 chr3 71365496 G A 1.22E-04 Rheumatoid arthritis FOXP1 intron 21452313 rs4677035 chr3 71371734 A C 0.0000596 Follicular lymphoma FOXP1 intron 23025665 rs4677602 chr3 71379806 T C 0.0000181 Follicular lymphoma FOXP1 intron 23025665 rs7638193 chr3 71387060 C A,G,T 0.0000392 Follicular lymphoma FOXP1 intron 23025665 rs9859586 chr3 71396478 A G 0.0000377 Follicular lymphoma FOXP1 intron 23025665 rs4327353 chr3 71403694 T C 7.76E-04 Body mass index FOXP1 intron 21701565 rs4327353 chr3 71403694 T C 5.59E-05 Femoral neck bone geometry FOXP1 intron 22087292 rs17008544 chr3 71408319 C T 5.68E-05 Eosinophil counts FOXP1 UTR-5 pha003088 rs10511017 chr3 71410012 T C 0.0000189 Follicular lymphoma FOXP1 intron 23025665 rs13072512 chr3 71414045 A G 6.00E-06 IgG glycosylation FOXP1 intron 23382691 rs17717911 chr3 71417200 C T 7.15E-04 Multiple complex diseases FOXP1 intron 17554300 rs864386 chr3 71425370 G C 6.46E-05 Serum metabolites FOXP1 intron 19043545 rs831072 chr3 71427707 T C 3.29E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FOXP1 intron 24023788 rs9815974 chr3 71439472 G A 9.66E-06 Anxiety and major depressive disorder FOXP1 intron 24047446 rs13063872 chr3 71464335 G A 3.62E-05 Migraine with aura FOXP1 intron 23793025 rs13063872 chr3 71464335 G A 9.00E-06 Migraine - clinic-based FOXP1 intron 23793025 rs4369992 chr3 71479212 G A 1.70E-05 Immunoglobulin A FOXP1 intron 20694011 rs6803690 chr3 71501077 C T 1.17E-04 Multiple complex diseases FOXP1 intron 17554300 rs2135548 chr3 71501895 G A 1.46E-04 Hearing function FOXP1 intron 17255346 rs11706279 chr3 71517643 T C 9.30E-06 Behcet's disease FOXP1 intron 23291587 rs9819066 chr3 71523110 C T 6.82E-05 Vaspin levels FOXP1 intron 22907691 rs9819066 chr3 71523110 C T 0.0000682 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs9819066 chr3 71523110 C T 7.07E-06 Behcet's disease FOXP1 intron 23291587 rs9819066 chr3 71523110 C T 0.00000415 Primary sclerosing cholangitis FOXP1 intron 23603763 rs9819066 chr3 71523110 C T 4.55E-06 Behcet's disease FOXP1 intron pha002888 rs6549391 chr3 71529915 A C 1.02E-04 Vaspin levels FOXP1 intron 22907691 rs6549391 chr3 71529915 A C 0.0001017 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs6549391 chr3 71529915 A C 1.32E-05 Behcet's disease FOXP1 intron 23291587 rs9828629 chr3 71530346 C T 6.36E-05 Vaspin levels FOXP1 intron 22907691 rs9828629 chr3 71530346 C T 0.0000636 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs9828629 chr3 71530346 C T 1.42E-05 Behcet's disease FOXP1 intron 23291587 rs9828629 chr3 71530346 C T 8.89E-06 Behcet's disease FOXP1 intron pha002888 rs6549392 chr3 71538696 G T 7.35E-05 Vaspin levels FOXP1 intron 22907691 rs6549392 chr3 71538696 G T 0.0000735 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs6549392 chr3 71538696 G T 2.33E-05 Behcet's disease FOXP1 intron pha002888 rs11720523 chr3 71545170 C A 2.09E-05 Behcet's disease FOXP1 intron pha002888 rs6789751 chr3 71546744 T C 1.15E-05 Behcet's disease FOXP1 intron 23291587 rs6779258 chr3 71549639 T C 1.11E-05 Behcet's disease FOXP1 intron pha002888 rs17718783 chr3 71555553 C T 1.47E-04 Bipolar disorder FOXP1 intron 18317468 rs13071862 chr3 71562157 A G 9.48E-05 Hearing function FOXP1 intron 17255346 rs17008713 chr3 71566417 C T 3.70E-06 Vitiligo FOXP1 intron 21326295 rs17008723 chr3 71573135 T G 4.81E-08 Vitiligo FOXP1 intron 22561518 rs830604 chr3 71590347 C T 1.00E-05 Type 2 diabetes and 6 quantitative traits FOXP1 intron 17848626 rs11720121 chr3 71595258 T C 2.76E-05 Behcet's disease FOXP1 intron 23291587 rs11720121 chr3 71595258 T C 1.28E-05 Behcet's disease FOXP1 intron pha002888 rs6549400 chr3 71606466 T G 1.85E-05 Behcet's disease FOXP1 intron 23291587 rs6549400 chr3 71606466 T G 8.46E-06 Behcet's disease FOXP1 intron pha002888 rs878172 chr3 71622449 A G 3.35E-04 Multiple complex diseases FOXP1 intron 17554300 rs7643734 chr3 71652888 G A 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9846001 chr3 71660196 A G 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs830637 chr3 71670465 T C 1.17E-06 Post-operative nausea and vomiting / / 21694509 rs10460943 chr3 71672306 C T 7.33E-05 Behcet's disease / / pha002888 rs830622 chr3 71677817 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs830611 chr3 71683947 G A 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs830609 chr3 71684904 A G 7.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs830609 chr3 71684904 A G 6.75E-04 Response to alcohol consumption (flushing response) / / 24277619 rs830608 chr3 71685189 A G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs12492625 chr3 71687846 G C 4.62E-04 Lymphocyte counts / / 22286170 rs704279 chr3 71711979 A G 5.75E-06 Scoliosis / / 21216876 rs704292 chr3 71726259 T C 1.75E-05 Tunica Media / / pha003034 rs3796226 chr3 71737107 A G 4.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) EIF4E3 intron 23648065 rs3796226 chr3 71737107 A G 1.55E-05 Tunica Media EIF4E3 intron pha003034 rs17008934 chr3 71745012 A G 8.66E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs4387935 chr3 71747831 A C 6.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EIF4E3 intron 20031582 rs1447905 chr3 71748643 T C 3.36E-06 Waist circumference EIF4E3 intron 19557197 rs9790104 chr3 71750728 G C 7.64E-06 Waist circumference EIF4E3 intron 19557197 rs17664691 chr3 71753742 G T 0.0007449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs17664691 chr3 71753742 G T 7.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13098806 chr3 71753949 T C 1.67E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs13070781 chr3 71753986 G A 2.82E-05 Personality dimensions EIF4E3 intron 18957941 rs13070781 chr3 71753986 G A 2.80E-05 Personality dimensions EIF4E3 intron 21173776 rs17008958 chr3 71755488 G A 4.45E-06 Waist circumference EIF4E3 intron 19557197 rs9823269 chr3 71756375 A C 0.0001549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs9823269 chr3 71756375 A C 1.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs4677039 chr3 71756765 C T 0.0002439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs4677039 chr3 71756765 C T 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13085841 chr3 71757540 T C 0.0002246 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs13085841 chr3 71757540 T C 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13091306 chr3 71758197 T C 9.44E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs6775276 chr3 71768473 T A 4.59E-04 Gallstones EIF4E3 intron 17632509 rs4677042 chr3 71781701 C G 9.23E-04 Multiple complex diseases EIF4E3 intron 17554300 rs12629971 chr3 71783318 C T 2.19E-06 Longevity,exceptional EIF4E3 intron 20595579 rs12629971 chr3 71783318 C T 3.70E-04 Coronary heart disease EIF4E3 intron 21966275 rs12629971 chr3 71783318 C T 1.90E-06 Longevity EIF4E3 intron 22279548 rs11927001 chr3 71795224 A G 3.62E-05 Depression (quantitative trait) EIF4E3 intron 23290196 rs6801173 chr3 71795743 C T 7.94E-06 Rheumatoid arthritis EIF4E3 intron 19503088 rs6801173 chr3 71795743 C T 9.33E-06 Longevity,exceptional EIF4E3 intron 20595579 rs6801173 chr3 71795743 C T 8.16E-06 Longevity EIF4E3 intron 22279548 rs7635127 chr3 71832941 C A 1.25E-11 Cholesterol,total PROK2 intron 23063622 rs7635127 chr3 71832941 C A 1.58E-10 Triglycerides PROK2 intron 23063622 rs17665418 chr3 71849165 T A 2.57E-04 Type 2 diabetes / / 17463246 rs17665418 chr3 71849165 T A 1.24E-48 Multiple complex diseases / / 17554300 rs17721983 chr3 71855936 C T 2.98E-05 Type 2 diabetes / / 17463246 rs17665544 chr3 71858990 A G 9.69E-05 Type 2 diabetes / / 17463246 rs35535279 chr3 71871180 T C 7.82E-04 Multiple complex diseases / / 17554300 rs9812198 chr3 71879327 A G 1.33E-04 Height / / 17255346 rs9841733 chr3 71889603 T G 8.57E-08 Metabolite levels / / 23281178 rs7631578 chr3 71913071 A C 4.60E-04 Tourette syndrome / / 22889924 rs2322168 chr3 71930159 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17009073 chr3 71939885 G A 9.90E-04 Tourette syndrome / / 22889924 rs17009077 chr3 71941154 A G 3.50E-04 Tourette syndrome / / 22889924 rs1995453 chr3 71948799 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7616034 chr3 71951781 C T 2.69E-05 Brain structure / / 22504417 rs2874710 chr3 71956442 C T 4.70E-06 Urinary metabolites / / 21572414 rs6801579 chr3 71956808 T A 2.90E-05 Urinary metabolites / / 21572414 rs9841665 chr3 71956987 G A 2.90E-05 Urinary metabolites / / 21572414 rs6790891 chr3 71959310 T C 3.21E-05 Telomere length / / 23001564 rs9832640 chr3 71962547 C T 9.77E-04 Depression (quantitative trait) / / 20800221 rs7648163 chr3 71969532 A C 1.11E-06 Common variable immunodeficiency / / 21497890 rs7648163 chr3 71969532 A C 7.02E-04 Heart Failure / / pha002884 rs11718781 chr3 71971643 A G 9.35E-04 Tourette syndrome / / 22889924 rs7631897 chr3 71980643 G A 3.39E-05 Celiac disease / / 23936387 rs6808405 chr3 71995328 A C 3.66E-05 Aging (time to event) / / 21782286 rs12491110 chr3 72022752 G A 9.50E-06 Cognitive test performance / / 20125193 rs2135320 chr3 72023674 G A 6.42E-06 Bilirubin levels / / 22085899 rs2135319 chr3 72023700 G A 4.00E-06 Bilirubin levels / / 22085899 rs13080489 chr3 72035087 A C 4.37E-04 Multiple complex diseases / / 17554300 rs9860628 chr3 72043000 C T 7.90E-04 Alcohol dependence / / 20201924 rs9860628 chr3 72043000 C T 4.06E-04 Insulin resistance / / 21901158 rs4677073 chr3 72044909 T C 6.24E-04 Insulin resistance / / 21901158 rs9871415 chr3 72045130 C T 2.25E-05 Insulin resistance / / 21901158 rs1532870 chr3 72046220 T G 3.92E-05 Glucose levels / / pha003058 rs1532870 chr3 72046220 T G 4.94E-05 Diabetes Mellitus / / pha003059 rs9879563 chr3 72048692 A G 3.50E-05 Glucose levels / / pha003058 rs2174546 chr3 72050088 G A 8.43E-05 Attention deficit hyperactivity disorder / / 22420046 rs1547458 chr3 72128884 A C 4.62E-05 HIV-1 viral setpoint LOC285286 intron 22174851 rs6771316 chr3 72140532 G A 5.00E-09 Venous thromboembolism (gene x gene interaction) LOC285286 intron 23509962 rs11707080 chr3 72141723 G A 9.76E-04 Alzheimer's disease LOC285286 intron 24755620 rs1580953 chr3 72154835 T A 8.42E-05 Alcohol consumption / / 23743675 rs4677086 chr3 72158332 C G 8.72E-05 Alcohol consumption / / 23743675 rs9832693 chr3 72158910 A G 1.04E-05 Alcohol consumption / / 23743675 rs9836943 chr3 72159035 T G 1.11E-05 Alcohol consumption / / 23743675 rs6549438 chr3 72161233 T A 4.00E-06 Migraine - clinic-based / / 23793025 rs4677093 chr3 72167049 A T 6.53E-04 Type 2 diabetes / / 17846124 rs17009412 chr3 72171883 T C 4.45E-05 Diabetes Mellitus / / pha003059 rs17009412 chr3 72171883 T C 5.47E-06 Diabetes Mellitus / / pha003060 rs1505975 chr3 72177083 A G 1.25E-04 Smoking initiation / / 24665060 rs7618650 chr3 72177754 C T 7.90E-04 Alzheimer's disease / / 22005930 rs4676859 chr3 72181956 T C 9.80E-04 Multiple complex diseases / / 17554300 rs9863047 chr3 72199906 A C 7.59E-04 Multiple complex diseases / / 17554300 rs7629597 chr3 72207426 A C 5.97E-04 Multiple complex diseases LOC201617 intron 17554300 rs9816781 chr3 72217198 G A 6.08E-06 Glaucoma (primary open-angle) LOC201617 intron 22605921 rs6808099 chr3 72219675 C T 6.83E-05 Orofacial clefts LOC201617 intron 22419666 rs9829428 chr3 72227587 T C 1.82E-05 Hemoglobin / / pha003098 rs7644006 chr3 72227868 A G 8.14E-04 Multiple complex diseases / / 17554300 rs7632787 chr3 72228716 T C 1.54E-04 Insulin resistance / / 21901158 rs9917700 chr3 72238235 C G 7.20E-04 Insulin resistance / / 21901158 rs13327342 chr3 72275215 G T 6.21E-05 Schizophrenia / / 19571809 rs13327342 chr3 72275215 G T 3.68E-05 Schizophrenia / / pha002859 rs13074688 chr3 72278900 G A 6.37E-05 Schizophrenia / / 19571809 rs13074688 chr3 72278900 G A 3.73E-05 Schizophrenia / / pha002859 rs11128255 chr3 72286089 T C 3.99E-04 Alzheimer's disease / / 17998437 rs4525828 chr3 72294743 C T 4.48E-04 Rheumatoid arthritis / / 21452313 rs4532099 chr3 72315956 T C 2.20E-05 Personality dimensions / / 18957941 rs11715226 chr3 72326800 A T 1.80E-05 Urinary metabolites / / 21572414 rs4677135 chr3 72334859 T C 4.91E-04 Type 2 diabetes / / 17463246 rs4677135 chr3 72334859 T C 1.85E-05 ldl cholesterol / / pha003077 rs4677135 chr3 72334859 T C 7.37E-05 Cholesterol / / pha003083 rs9847707 chr3 72344971 A G 3.01E-06 Monocyte chemoattractant protein-1 / / pha003071 rs4128691 chr3 72349863 C T 8.44E-04 Type 2 diabetes / / 17463246 rs4128691 chr3 72349863 C T 8.40E-05 Male fertility / / 22633400 rs4128691 chr3 72349863 C T 9.57E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9809213 chr3 72353932 G A 9.45E-05 Tunica Media / / pha003038 rs9682388 chr3 72354566 C A 1.18E-06 Amyotrophic lateral sclerosis / / 19193627 rs4073919 chr3 72361466 G A 7.83E-04 Type 2 diabetes / / 17463246 rs9820604 chr3 72363674 T C 3.79E-04 Smoking cessation / / 24665060 rs4676870 chr3 72365204 T C 7.85E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9820851 chr3 72366285 G A 9.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11708375 chr3 72366790 G C 5.15E-05 Smoking cessation / / 24665060 rs9811454 chr3 72371525 C T 4.53E-05 Cholesterol / / pha003073 rs9811454 chr3 72371525 C T 8.49E-05 Cholesterol / / pha003078 rs13094012 chr3 72372395 T C 5.07E-04 Smoking cessation / / 24665060 rs2322431 chr3 72375939 A T 2.56E-04 Smoking cessation / / 24665060 rs9832740 chr3 72393141 G C 5.00E-13 Height / / 23563607 rs4677150 chr3 72393982 C G 9.01E-04 Type 2 diabetes / / 17463246 rs4677156 chr3 72417857 A T 4.77E-05 Serum metabolites / / 19043545 rs9863706 chr3 72437413 C T 4.00E-13 Height RYBP intron 20881960 rs10511023 chr3 72455447 G A 2.40E-04 Type 2 diabetes and 6 quantitative traits RYBP intron 17848626 rs6776427 chr3 72455707 G A 1.97E-04 Age-related macular degeneration RYBP intron 22125219 rs12493016 chr3 72481461 A C 8.28E-05 Soluble levels of adhesion molecules RYBP intron pha003072 rs11128271 chr3 72509271 T C 6.00E-06 IgG glycosylation / / 23382691 rs11128271 chr3 72509271 T C 6.00E-07 IgG glycosylation / / 23382691 rs10049211 chr3 72514676 T C 5.11E-06 Behcet's disease / / 23291587 rs10049211 chr3 72514676 T C 5.35E-06 Behcet's disease / / pha002888 rs11128275 chr3 72515960 G A 3.80E-05 Behcet's disease / / pha002888 rs934841 chr3 72516206 C T 5.91E-04 Multiple complex diseases / / 17554300 rs934841 chr3 72516206 C T 7.01E-04 Alzheimer's disease / / 17998437 rs9832314 chr3 72518040 A G 9.00E-06 IgG glycosylation / / 23382691 rs10222493 chr3 72523385 C T 1.70E-05 Urinary metabolites / / 21572414 rs7613906 chr3 72525387 T C 8.42E-05 Height / / pha003011 rs6775777 chr3 72533244 T C 5.86E-05 Bipolar disorder / / 19488044 rs6775777 chr3 72533244 T C 6.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs6775777 chr3 72533244 T C 2.36E-05 Bipolar Disorder / / pha002858 rs10511022 chr3 72544196 C T 2.24E-05 Alcohol and nictotine co-dependence / / 20158304 rs10511022 chr3 72544196 C T 9.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9836156 chr3 72572216 T A 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4677181 chr3 72576888 A G 2.00E-04 Vaspin levels / / 22907691 rs4677181 chr3 72576888 A G 0.0001999 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs11924047 chr3 72622532 A G 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs17010000 chr3 72648022 G A 7.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10049135 chr3 72648980 A G 4.65E-05 Nicotine dependence / / 17158188 rs1490504 chr3 72650355 G C 5.99E-04 Nicotine dependence / / 17158188 rs1873350 chr3 72650886 C T 3.09E-05 Body Mass Index / / pha003007 rs1873350 chr3 72650886 C T 3.34E-05 Waist Circumference / / pha003025 rs13076653 chr3 72655715 C T 0.00000416 Major depressive disorder / / 23149448 rs12714788 chr3 72657113 A C 2.60E-05 Major depressive disorder / / 21042317 rs12714788 chr3 72657113 A C 1.97E-05 Major depressive disorder / / 22472876 rs17678033 chr3 72657311 T C 2.31E-05 Major depressive disorder / / 22472876 rs4677197 chr3 72667611 G A 5.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4676887 chr3 72673025 G A 5.27E-04 Multiple complex diseases / / 17554300 rs7637028 chr3 72674925 A G 5.32E-05 Major depressive disorder / / 22472876 rs7639455 chr3 72675032 T C 6.34E-05 Major depressive disorder / / 22472876 rs4676888 chr3 72686090 G A 1.20E-05 Urinary metabolites / / 21572414 rs923572 chr3 72697011 G A 8.50E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs1123121 chr3 72697160 G A 9.14E-05 Tunica Media / / pha003037 rs17010083 chr3 72707853 T A 2.14E-04 Cholesterol / / 17255346 rs6781545 chr3 72736603 A C 0.00009895 Sarcoidosis / / 22952805 rs17043990 chr3 72880470 T C 1.58E-06 Hypothyroidism SHQ1 intron 21981779 rs6808341 chr3 72914847 T C 4.77E-04 Multiple complex diseases / / 17554300 rs6808341 chr3 72914847 T C 3.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13090900 chr3 72946560 C A 3.64E-04 Amyotrophic Lateral Sclerosis GXYLT2 intron 17362836 rs13089190 chr3 72958877 C T 6.10E-05 Coronary heart disease GXYLT2 intron 21606135 rs17010249 chr3 72959232 G A 7.78E-05 Coronary heart disease GXYLT2 intron 21606135 rs17010250 chr3 72959472 C G 8.90E-05 Coronary heart disease GXYLT2 intron 21606135 rs7649077 chr3 72964057 C T 2.00E-05 Coronary heart disease GXYLT2 intron 21606135 rs9876619 chr3 72971749 C T 1.20E-05 Urinary metabolites GXYLT2 intron 21572414 rs9876619 chr3 72971749 C T 2.75E-05 Coronary heart disease GXYLT2 intron 21606135 rs7640661 chr3 72973732 G A 3.83E-04 Coronary heart disease GXYLT2 intron 21606135 rs2134426 chr3 72973781 G C 2.49E-07 Multiple complex diseases GXYLT2 intron 17554300 rs2322692 chr3 72980177 G A 9.81E-05 Height GXYLT2 intron pha003011 rs2322693 chr3 72982575 A G 9.06E-05 Height GXYLT2 intron pha003011 rs17742733 chr3 73004580 T A 3.10E-04 Coronary heart disease GXYLT2 intron 21606135 rs17691949 chr3 73010363 A G 1.77E-04 Coronary heart disease GXYLT2 intron 21606135 rs6793043 chr3 73020764 T C 8.13E-05 Serum metabolites GXYLT2 intron 19043545 rs9862032 chr3 73022032 G A 2.40E-06 Coronary heart disease GXYLT2 intron 22319020 rs1052278 chr3 73024350 C A 2.40E-05 Height GXYLT2 UTR-3 pha003011 rs12638019 chr3 73091447 T G 7.65E-05 Cognitive performance PPP4R2 intron 19734545 rs9824246 chr3 73102725 A G 9.95E-05 Nicotine smoking PPP4R2 intron 19268276 rs902652 chr3 73131351 G A 1.50E-06 Coronary spasm / / 18075462 rs6766673 chr3 73157288 T C 2.61E-04 Alzheimer's disease (late onset) / / 21379329 rs9835056 chr3 73179320 T C 9.00E-04 Alcohol dependence / / 20201924 rs10460946 chr3 73180606 T G 7.36E-04 Coronary Artery Disease / / 17634449 rs7636585 chr3 73251964 A G 8.40E-05 Primary sclerosing cholangitis / / 19944697 rs11128317 chr3 73252141 T A,C 4.50E-05 Primary sclerosing cholangitis / / 19944697 rs9826629 chr3 73252662 C T 3.28E-04 Multiple complex diseases / / 17554300 rs17751397 chr3 73261224 C T 6.65E-05 Cholesterol / / pha003073 rs4676908 chr3 73274994 G A 3.45E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11128319 chr3 73275553 G C 1.53E-04 Multiple complex diseases / / 17554300 rs12486903 chr3 73276952 T C 8.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs574715 chr3 73305809 G A 2.30E-05 Urinary metabolites / / 21572414 rs574715 chr3 73305809 G A 6.93E-06 Parent of origin effect on language impairment (child trend) / / 24571439 rs671986 chr3 73308948 G A 1.02E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs656016 chr3 73310251 T G 1.30E-05 Urinary metabolites / / 21572414 rs13099495 chr3 73370625 A G 0.00000478 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs4677261 chr3 73374442 T C 5.03E-05 Response to citalopram treatment / / 19846067 rs7612030 chr3 73375196 T C 2.00E-05 Urinary metabolites / / 21572414 rs966163 chr3 73375302 G A 6.54E-05 Response to citalopram treatment / / 19846067 rs6764873 chr3 73375371 T C 2.00E-05 Urinary metabolites / / 21572414 rs4677262 chr3 73376013 C T 4.69E-05 Response to citalopram treatment / / 19846067 rs7647234 chr3 73378844 A G 7.88E-04 Type 2 diabetes / / 17463246 rs7647311 chr3 73378879 A G 6.49E-04 Type 2 diabetes / / 17463246 rs11710982 chr3 73398839 A G 1.80E-04 Primary sclerosing cholangitis / / 19944697 rs11710982 chr3 73398839 A G 2.20E-05 Urinary metabolites / / 21572414 rs13070556 chr3 73399384 C T 3.76E-04 Taste perception / / 22132133 rs9866906 chr3 73405263 A C 1.20E-04 Primary sclerosing cholangitis / / 19944697 rs11128329 chr3 73411670 C T 8.48E-05 Hypertension (essential hypertension) / / 22184326 rs3912601 chr3 73411687 C T 5.94E-06 Taste perception / / 22132133 rs12638564 chr3 73413820 G A 1.00E-04 Information processing speed / / 21130836 rs3816831 chr3 73450198 G A 3.79E-04 Alcohol dependence PDZRN3 intron 21314694 rs13063715 chr3 73476665 T C 1.00E-04 Prostate cancer PDZRN3 intron 21743057 rs9883532 chr3 73489259 A G 3.31E-04 Multiple complex diseases PDZRN3 intron 17554300 rs6549543 chr3 73520059 A G 7.80E-06 Urinary metabolites PDZRN3 intron 21572414 rs4557101 chr3 73540618 T C 4.00E-06 QT interval PDZRN3 intron 23166209 rs12632755 chr3 73548335 C T 4.20E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632755 chr3 73548335 C T 5.60E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632755 chr3 73548335 C T 7.97E-04 Myocardial Infarction PDZRN3 intron pha002873 rs12632758 chr3 73548400 C T 4.90E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632758 chr3 73548400 C T 6.50E-04 Alcohol dependence PDZRN3 intron 20201924 rs9842067 chr3 73601210 A G 9.43E-04 Multiple complex diseases PDZRN3 intron 17554300 rs11128347 chr3 73619561 G C 6.00E-07 Dialysis-related mortality PDZRN3 intron 21546767 rs9830956 chr3 73636020 G A 5.11E-04 Prostate cancer mortality PDZRN3 intron 20978177 rs1022170 chr3 73705297 A C 3.46E-06 Pulmonary function / / 19300500 rs1022170 chr3 73705297 A C 3.10E-06 Pulmonary function / / 20010835 rs2036893 chr3 73706022 G A 3.47E-06 Pulmonary function / / 19300500 rs2036893 chr3 73706022 G A 3.10E-06 Pulmonary function / / 20010835 rs11128357 chr3 73708530 A C 1.01E-05 Pulmonary function / / 19300500 rs11128357 chr3 73708530 A C 2.23E-05 Pulmonary function / / 20010835 rs1858325 chr3 73710372 G A 1.48E-05 Pulmonary function / / 19300500 rs1858325 chr3 73710372 G A 2.85E-05 Pulmonary function / / 20010835 rs4677325 chr3 73710707 A G 1.49E-05 Pulmonary function / / 19300500 rs4677325 chr3 73710707 A G 2.84E-05 Pulmonary function / / 20010835 rs4677326 chr3 73710752 C G 1.49E-05 Pulmonary function / / 19300500 rs4677326 chr3 73710752 C G 2.83E-05 Pulmonary function / / 20010835 rs9310279 chr3 73710945 T C 1.50E-05 Pulmonary function / / 19300500 rs9310279 chr3 73710945 T C 2.90E-05 Pulmonary function / / 20010835 rs9847694 chr3 73711625 T A 1.77E-05 Pulmonary function / / 19300500 rs9847694 chr3 73711625 T A 2.83E-05 Pulmonary function / / 20010835 rs9824294 chr3 73711635 C T 1.51E-05 Pulmonary function / / 19300500 rs9824294 chr3 73711635 C T 2.75E-05 Pulmonary function / / 20010835 rs1511521 chr3 73711863 C T 1.52E-05 Pulmonary function / / 19300500 rs1511521 chr3 73711863 C T 2.74E-05 Pulmonary function / / 20010835 rs1355467 chr3 73714140 T C 2.02E-05 Pulmonary function / / 19300500 rs1355467 chr3 73714140 T C 5.58E-05 Pulmonary function / / 20010835 rs1039956 chr3 73714843 T A 1.72E-05 Pulmonary function / / 19300500 rs1039956 chr3 73714843 T A 4.74E-05 Pulmonary function / / 20010835 rs1912769 chr3 73715891 G T 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs1039955 chr3 73716064 T C 2.35E-05 Pulmonary function / / 19300500 rs1039955 chr3 73716064 T C 5.55E-05 Pulmonary function / / 20010835 rs2875192 chr3 73716503 C T 2.96E-04 Alzheimer's disease (late onset) / / 21379329 rs12493615 chr3 73719148 T C 3.50E-04 Alzheimer's disease (late onset) / / 21379329 rs4677328 chr3 73719944 A T 7.67E-06 Pulmonary function / / 19300500 rs4677328 chr3 73719944 A T 2.32E-05 Pulmonary function / / 20010835 rs1877252 chr3 73727540 T C 6.98E-06 Pulmonary function / / 19300500 rs1877252 chr3 73727540 T C 1.54E-05 Pulmonary function / / 20010835 rs9790264 chr3 73731306 C T 5.04E-06 Pulmonary function / / 19300500 rs9790264 chr3 73731306 C T 1.63E-05 Pulmonary function / / 20010835 rs9790092 chr3 73731538 G A 4.63E-06 Pulmonary function / / 19300500 rs9790092 chr3 73731538 G A 1.40E-05 Pulmonary function / / 20010835 rs994960 chr3 73731916 G A 4.53E-06 Pulmonary function / / 19300500 rs994960 chr3 73731916 G A 1.45E-05 Pulmonary function / / 20010835 rs6777769 chr3 73735358 C G 5.21E-06 Pulmonary function / / 19300500 rs6777769 chr3 73735358 C G 1.57E-05 Pulmonary function / / 20010835 rs11918578 chr3 73736121 G A 6.04E-06 Pulmonary function / / 19300500 rs11918578 chr3 73736121 G A 1.66E-05 Pulmonary function / / 20010835 rs1567573 chr3 73737353 G T 7.13E-05 Pulmonary function / / 19300500 rs1567574 chr3 73737467 T C 6.63E-06 Pulmonary function / / 19300500 rs1567574 chr3 73737467 T C 1.96E-05 Pulmonary function / / 20010835 rs1543070 chr3 73749237 T C 1.82E-05 Pulmonary function / / 19300500 rs1543070 chr3 73749237 T C 4.56E-05 Pulmonary function / / 20010835 rs2137064 chr3 73750993 A G 1.01E-05 Pulmonary function / / 19300500 rs2137064 chr3 73750993 A G 1.82E-05 Pulmonary function / / 20010835 rs9868151 chr3 73751432 A C 1.02E-05 Pulmonary function / / 19300500 rs9868151 chr3 73751432 A C 1.74E-05 Pulmonary function / / 20010835 rs4494867 chr3 73755403 C T 1.64E-05 Pulmonary function / / 19300500 rs4494867 chr3 73755403 C T 1.73E-05 Pulmonary function / / 20010835 rs13096120 chr3 73756085 G A 5.12E-05 Pulmonary function / / 19300500 rs13096120 chr3 73756085 G A 6.23E-05 Pulmonary function / / 20010835 rs6787034 chr3 73764542 A G 3.94E-05 Pulmonary function / / 20010835 rs952708 chr3 73767193 C T 3.28E-05 Pulmonary function / / 20010835 rs1511531 chr3 73767504 C T 3.29E-05 Pulmonary function / / 20010835 rs1877256 chr3 73769502 G A 8.55E-05 Pulmonary function / / 20010835 rs4676946 chr3 73778404 T C 2.04E-04 Type 2 diabetes / / 17463246 rs10865679 chr3 73781217 T C 1.97E-05 Type 2 diabetes / / 17463246 rs10865679 chr3 73781217 T C 1.60E-05 Urinary metabolites / / 21572414 rs2874965 chr3 73786144 T C 6.22E-05 Type 2 diabetes / / 17463246 rs2874965 chr3 73786144 T C 2.30E-05 Urinary metabolites / / 21572414 rs291475 chr3 73800888 C G 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs291479 chr3 73809294 G A 8.25E-04 Type 2 diabetes / / 17463246 rs6780964 chr3 73854671 G A 3.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs291533 chr3 73861878 C T 2.29E-04 Taste perception / / 22132133 rs9848344 chr3 73869793 G A 8.00E-05 Malaria / / 19465909 rs4627704 chr3 73871925 C T 0.0007549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4627704 chr3 73871925 C T 7.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs907336 chr3 73877100 G A 3.90E-05 Taste perception / / 22132133 rs291484 chr3 73877349 G A 3.43E-04 Type 2 diabetes / / 17463246 rs291484 chr3 73877349 G A 7.46E-04 Taste perception / / 22132133 rs4676955 chr3 73899756 G C 4.91E-04 Multiple complex diseases / / 17554300 rs1372248 chr3 73918067 C T 4.85E-04 Smoking initiation / / 24665060 rs10460948 chr3 73946281 A G 1.23E-04 Prion diseases / / 22210626 rs5012667 chr3 73958469 T C 1.62E-04 Celiac disease / / 23936387 rs1405402 chr3 73971120 G A,C,T 1.90E-04 Myopia (pathological) / / 21095009 rs13098784 chr3 73971723 T G 3.04E-05 Serum metabolites / / 19043545 rs941068 chr3 73974792 C T 1.00E-04 Prostate cancer / / 21743057 rs1918101 chr3 73976238 G T 2.32E-04 Myopia (pathological) / / 21095009 rs6770247 chr3 73976514 G A 1.00E-04 Prostate cancer / / 21743057 rs10048995 chr3 73976539 C G,T 1.00E-04 Prostate cancer / / 21743057 rs1526717 chr3 73980833 C T 9.59E-05 Type 2 diabetes / / 17463246 rs9865110 chr3 73981773 A C 1.80E-05 Endometriosis / / 21151130 rs9865110 chr3 73981773 A C 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs11718192 chr3 73987905 A G 5.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13325429 chr3 73991897 C T 5.21E-04 Multiple complex diseases / / 17554300 rs12494782 chr3 74060951 C T 2.32E-05 Coronary heart disease / / pha003032 rs6783757 chr3 74094657 A G 6.50E-07 Urinary metabolites / / 21572414 rs1526727 chr3 74095314 C T 5.20E-07 Urinary metabolites / / 21572414 rs1526728 chr3 74095484 T C 6.10E-07 Urinary metabolites / / 21572414 rs4677373 chr3 74097623 G A 2.95E-04 Smoking initiation / / 24665060 rs2197713 chr3 74169348 A G 3.48E-04 Diabetic retinopathy / / 20871662 rs17762788 chr3 74175656 G T 4.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs278392 chr3 74177720 T A 5.70E-05 Parkinson's disease (age of onset) / / 19772629 rs278405 chr3 74191690 G A 9.05E-06 Job-related exhaustion / / 23620144 rs278466 chr3 74218884 A G 5.23E-04 Smoking initiation / / 24665060 rs7627251 chr3 74219054 C T 4.13E-04 Smoking initiation / / 24665060 rs1005940 chr3 74221493 A G 4.48E-04 Smoking initiation / / 24665060 rs278468 chr3 74222026 T G 2.79E-04 Smoking initiation / / 24665060 rs278472 chr3 74226790 G T 5.01E-04 Smoking initiation / / 24665060 rs664864 chr3 74305127 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs541653 chr3 74321141 C T 2.93E-05 Tunica Media CNTN3 intron pha003036 rs668645 chr3 74324790 C A 6.60E-04 Multiple complex diseases CNTN3 intron 17554300 rs6779469 chr3 74343804 G A 1.91E-05 Weight CNTN3 intron pha003026 rs10490832 chr3 74344356 T G 5.20E-04 Suicidal ideation CNTN3 cds-synon 22030708 rs10490832 chr3 74344356 T G 6.85E-05 Bipolar disorder CNTN3 cds-synon 22925353 rs502114 chr3 74345242 A T 2.60E-05 Urinary metabolites CNTN3 intron 21572414 rs1545384 chr3 74352261 C A 5.20E-04 Suicidal ideation CNTN3 intron 22030708 rs487087 chr3 74379786 G C 1.70E-05 Urinary metabolites CNTN3 intron 21572414 rs503058 chr3 74383222 C T 1.60E-05 Urinary metabolites CNTN3 intron 21572414 rs12634243 chr3 74383419 G C 9.90E-06 Urinary metabolites CNTN3 intron 21572414 rs554676 chr3 74385011 C G 2.30E-06 Urinary metabolites CNTN3 intron 21572414 rs7613439 chr3 74442523 T C 4.54E-06 Insulin resistance CNTN3 intron 21901158 rs7613439 chr3 74442523 T C 2.67E-04 Response to cytadine analogues (cytosine arabinoside) CNTN3 intron 24483146 rs6780510 chr3 74447090 T C 3.50E-05 Coronary heart disease CNTN3 intron pha003030 rs4677395 chr3 74471410 T C 1.23E-05 Height CNTN3 intron 22021425 rs6549604 chr3 74545777 T C 3.20E-04 Cholesterol CNTN3 intron 17255346 rs9876789 chr3 74545880 G A 5.41E-04 Multiple complex diseases CNTN3 intron 17554300 rs7430259 chr3 74563488 C T 2.20E-05 Obesity-related traits CNTN3 intron 17658951 rs7430822 chr3 74564816 C A 4.25E-04 Multiple complex diseases CNTN3 intron 17554300 rs4676973 chr3 74565355 C A 6.33E-04 Myopia (pathological) CNTN3 intron 21095009 rs9814206 chr3 74573227 G T 4.47E-04 Smoking quantity / / 24665060 rs6767471 chr3 74577921 C T 3.21E-05 Orofacial clefts / / 19270707 rs9831609 chr3 74584605 A C 4.50E-06 Orofacial clefts / / 19270707 rs9836097 chr3 74591012 A G 7.74E-06 Asthma (childhood onset) / / 23829686 rs4677414 chr3 74607020 A G 1.43E-05 Orofacial clefts / / 19270707 rs2323570 chr3 74608373 C T 5.17E-04 Smoking quantity / / 24665060 rs11928037 chr3 74616253 G T 0.00000827 Asthma / / 22694930 rs7630534 chr3 74625123 A G 0.00000122 Asthma / / 22694930 rs13073838 chr3 74627703 T C 7.96E-05 Alzheimer's disease (late onset) / / 21379329 rs13073838 chr3 74627703 T C 3.00E-06 Economic and political preferences / / 22566634 rs1579905 chr3 74628590 T C 7.83E-04 Multiple complex diseases / / 17554300 rs1374879 chr3 74635097 T C 8.00E-06 Smoking quantity / / 24665060 rs6792938 chr3 74661433 T A 2.65E-04 Smoking initiation / / 24665060 rs17012697 chr3 74672571 C T 0.0000597 Asthma / / 22694930 rs6775796 chr3 74703689 G A 7.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs935523 chr3 74710819 C A 4.80E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs1447826 chr3 74718758 T C 1.10E-16 Pancreatic cancer / / 21849791 rs6762970 chr3 74742625 T A 1.90E-05 Urinary metabolites / / 21572414 rs6762970 chr3 74742625 T A 0.0000174 Adenoma / / 22532847 rs9879684 chr3 74753994 C T 1.00E-06 Urinary metabolites / / 21572414 rs7642555 chr3 74769420 A G 8.60E-07 Urinary metabolites / / 21572414 rs9861122 chr3 74770447 T C 7.50E-07 Urinary metabolites / / 21572414 rs9837543 chr3 74770492 C T 2.20E-06 Urinary metabolites / / 21572414 rs11924855 chr3 74775136 C T 2.20E-06 Urinary metabolites / / 21572414 rs4131575 chr3 74775497 C T 2.20E-06 Urinary metabolites / / 21572414 rs7635818 chr3 74783476 G C 4.10E-04 Abdominal aortic aneurysm / / 19497516 rs13061773 chr3 74787022 A G 2.90E-06 Urinary metabolites / / 21572414 rs6549652 chr3 74790990 C A 1.70E-06 Urinary metabolites / / 21572414 rs6549654 chr3 74791125 A G 7.80E-06 Urinary metabolites / / 21572414 rs1918399 chr3 74812194 A T 8.80E-04 Multiple complex diseases / / 17554300 rs12714812 chr3 74813002 A G 1.20E-05 Urinary metabolites / / 21572414 rs9859437 chr3 74816460 A G 9.70E-06 Urinary metabolites / / 21572414 rs9827925 chr3 74834053 C T 3.00E-06 Urinary metabolites / / 21572414 rs7651319 chr3 74836374 T C 4.40E-06 Urinary metabolites / / 21572414 rs1527527 chr3 74836946 G T 3.00E-06 Urinary metabolites / / 21572414 rs1918392 chr3 74880857 A G 5.22E-04 Alcohol dependence / / 20201924 rs941304 chr3 74887781 C T 6.24E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs1918394 chr3 74903904 T C 2.30E-05 Urinary metabolites / / 21572414 rs4417905 chr3 74916063 A G 6.60E-06 Urinary metabolites / / 21572414 rs12630469 chr3 74955581 G A 6.41E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4420916 chr3 74989983 A G 7.11E-05 Postoperative ventricular dysfunction / / 21980348 rs7618969 chr3 75003489 G A 8.60E-05 Endometriosis / / 21151130 rs7618969 chr3 75003489 G A 7.33E-04 Taste perception / / 22132133 rs4428227 chr3 75063638 C T 7.42E-04 Multiple complex diseases / / 17554300 rs4676989 chr3 75064460 C T 3.91E-04 Multiple complex diseases / / 17554300 rs9863767 chr3 75081957 C A 4.19E-05 Postoperative ventricular dysfunction / / 21980348 rs4635750 chr3 75097869 G A 4.63E-05 Postoperative ventricular dysfunction / / 21980348 rs12486094 chr3 75127552 T C 8.11E-05 Postoperative ventricular dysfunction / / 21980348 rs9310315 chr3 75166496 C T 5.26E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs12636203 chr3 75186326 C T 4.54E-04 Endometrial cancer / / 24096698 rs7430216 chr3 75201030 C T 7.41E-04 Acute lung injury / / 22295056 rs12186094 chr3 75217530 G A 8.83E-04 Taste perception / / 22132133 rs6803834 chr3 75221611 C T 3.20E-05 Type 2 diabetes / / 17463246 rs9810161 chr3 75222937 A G 3.94E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs9828201 chr3 75245774 C T 9.86E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4677485 chr3 75257002 C T 6.86E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs4072316 chr3 75269488 C G 1.06E-04 Acute lung injury / / 22295056 rs12495867 chr3 75275099 A G 1.06E-04 Acute lung injury / / 22295056 rs12491189 chr3 75278358 C T 1.06E-04 Acute lung injury / / 22295056 rs7430900 chr3 75292707 T G 7.23E-04 Acute lung injury / / 22295056 rs6768580 chr3 75374095 C T 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4677496 chr3 75377715 C T 2.77E-04 Multiple complex diseases / / 17554300 rs4677496 chr3 75377715 C T 0.000134 Salmonella-induced pyroptosis / / 22837397 rs2091870 chr3 75382434 C T 5.27E-04 Heart Failure / / pha002885 rs145339139 chr3 75641711 T G 8.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs352398 chr3 75727056 A C,G,T 2.81E-06 Coronary arterial lesions in patients with Kawasaki disease LOC401074 intron 23677057 rs76875512 chr3 75754704 G A 3.08E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs9865038 chr3 75754704 G A 3.08E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs200986341 chr3 75787540 T C 2.81E-06 Coronary arterial lesions in patients with Kawasaki disease ZNF717 missense 23677057 rs138304140 chr3 75789971 G A 3.99E-05 Bilirubin levels,in serum ZNF717 intron 19389676 rs3887345 chr3 75803471 T C 5.12E-05 Myopia (pathological) ZNF717 intron 21640322 rs7429112 chr3 75913502 C A 4.77E-04 Multiple complex diseases / / 17554300 rs7429112 chr3 75913502 C A 4.21E-05 Aortic root size / / 21223598 rs2220458 chr3 76110145 C A 5.52E-04 Parkinson's disease ROBO2 intron 17052657 rs1489092 chr3 76121506 T C 1.00E-04 Type 2 diabetes ROBO2 intron 17903298 rs1489091 chr3 76121631 C T 1.10E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs1489100 chr3 76132564 C T 7.00E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs6806589 chr3 76148360 C T 7.02E-05 Lung adenocarcinoma ROBO2 intron 19836008 rs17577450 chr3 76153036 G A 6.88E-04 Type 2 diabetes ROBO2 intron 17463246 rs1400237 chr3 76172232 T G 5.37E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs17013887 chr3 76206413 A C 6.61E-04 Multiple complex diseases ROBO2 intron 17554300 rs4856011 chr3 76225482 T C 2.70E-05 Soluble levels of adhesion molecules ROBO2 intron pha003072 rs1516459 chr3 76261820 T C 3.00E-06 Eating disorders (purging via substances) ROBO2 intron 23568457 rs4855973 chr3 76262385 T C 4.95E-04 Multiple complex diseases ROBO2 intron 17554300 rs17140566 chr3 76296672 A T 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs7613428 chr3 76301369 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs4855978 chr3 76358868 G T 5.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs3860545 chr3 76406576 A C 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs7611506 chr3 76413820 T C 1.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs10511047 chr3 76455579 C G 4.10E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs3849487 chr3 76464458 C G 8.34E-04 Multiple complex diseases ROBO2 intron 17554300 rs3849487 chr3 76464458 C G 6.34E-05 Serum metabolites ROBO2 intron 19043545 rs3849488 chr3 76464685 G A 7.74E-06 Asthma (childhood onset) ROBO2 intron 23829686 rs7616894 chr3 76464816 G C 5.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs9875646 chr3 76469652 C T 7.01E-04 Multiple complex diseases ROBO2 intron 17554300 rs13072871 chr3 76473371 G A 5.80E-04 Smoking cessation ROBO2 intron 24665060 rs10514733 chr3 76483391 G A 2.58E-04 Insulin resistance ROBO2 intron 21901158 rs3849491 chr3 76484183 T C 6.00E-06 Sex hormone-binding globulin levels ROBO2 intron 22675492 rs7612860 chr3 76489848 T C 5.28E-04 Coronary heart disease ROBO2 intron 21971053 rs3913578 chr3 76515427 A G 2.40E-05 Urinary metabolites ROBO2 intron 21572414 rs9883120 chr3 76516505 C G 8.03E-05 Acute lymphoblastic leukemia (childhood) ROBO2 intron 19684603 rs3849498 chr3 76526866 C T 2.90E-05 Personality dimensions ROBO2 intron 22628180 rs3849499 chr3 76533656 T C 2.69E-05 Personality dimensions ROBO2 intron 22628180 rs9878750 chr3 76546187 C A 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs7431017 chr3 76551403 C A 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs12497354 chr3 76570616 G A 3.45E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs3913574 chr3 76575853 A G 7.25E-04 Obesity (extreme) ROBO2 intron 21935397 rs11127548 chr3 76598690 T C 5.35E-04 Obesity (extreme) ROBO2 intron 21935397 rs1447793 chr3 76620047 G A 5.10E-05 Eosinophil counts ROBO2 intron pha003088 rs6793784 chr3 76653139 C T 1.20E-04 Amyotrophic lateral sclerosis (sporadic) ROBO2 intron 24529757 rs9867514 chr3 76689925 T C 1.49E-04 Endometrial cancer ROBO2 intron 24096698 rs9867514 chr3 76689925 T C 5.37E-04 Endometrial cancer ROBO2 intron 24096698 rs1349008 chr3 76721413 T G 4.90E-05 Subclinical atherosclerosis ROBO2 intron 17903303 rs197097 chr3 76722454 G A 2.66E-06 Periodontitis (PAL4Q3) ROBO2 intron 24024966 rs264537 chr3 76722766 C G 3.00E-06 Periodontitis (PAL4Q3) ROBO2 intron 24024966 rs10511052 chr3 76725903 G A 7.72E-04 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs10511052 chr3 76725903 G A 6.00E-06 IgG glycosylation ROBO2 intron 23382691 rs3849508 chr3 76739295 A C 1.26E-04 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs7630682 chr3 76741635 T A 2.27E-05 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs264553 chr3 76759892 G A 3.85E-04 Coronary heart disease ROBO2 intron 21971053 rs267122 chr3 76775169 T A 8.52E-05 Multiple sclerosis ROBO2 intron 17660530 rs267120 chr3 76775597 G T 6.10E-05 Multiple sclerosis ROBO2 intron 17660530 rs6808931 chr3 76780491 A G 8.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs774610 chr3 76780594 C T 2.90E-04 Coronary heart disease ROBO2 intron 21971053 rs810184 chr3 76783510 C T 1.36E-05 Blood Pressure ROBO2 intron pha003050 rs174812 chr3 76786877 A G 6.02E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs7630234 chr3 76787711 A G 6.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs1375963 chr3 76792468 A G 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs6797550 chr3 76796645 A G 5.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs3884314 chr3 76802905 C T 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs7609557 chr3 76806018 A G 8.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs11127559 chr3 76809834 G T 1.96E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs2608157 chr3 76810615 G T 6.53E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs774588 chr3 76821848 A G 3.74E-05 Blood Pressure ROBO2 intron pha003050 rs267103 chr3 76825682 T C 3.32E-05 Blood Pressure ROBO2 intron pha003050 rs2608131 chr3 76849447 A G 2.95E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs1167035 chr3 76850916 C T 4.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs2608132 chr3 76852241 G T 2.12E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs1166940 chr3 76882785 G T 8.35E-04 Coronary Artery Disease ROBO2 intron 17634449 rs1166974 chr3 76919042 T G 1.26E-04 Coronary Artery Disease ROBO2 intron 17634449 rs6792260 chr3 76919232 T C 2.66E-04 Multiple complex diseases ROBO2 intron 17554300 rs1166980 chr3 76928990 A G 5.53E-04 Smoking cessation ROBO2 intron 24665060 rs4855965 chr3 76929347 G T 2.15E-04 Height ROBO2 intron 17255346 rs11127566 chr3 76930358 C T 1.10E-05 Urinary metabolites ROBO2 intron 21572414 rs11127568 chr3 76933219 A G 4.20E-05 Height ROBO2 intron 17255346 rs12630815 chr3 76947105 T C 1.91E-04 Height ROBO2 intron 17255346 rs1166994 chr3 76954766 A C 5.02E-05 Left ventricular hypertrophy ROBO2 intron pha003052 rs17819911 chr3 76982025 G A 7.00E-05 Parkinson's disease (age of onset) ROBO2 intron 19772629 rs7643047 chr3 77018252 A G 1.20E-05 Urinary metabolites ROBO2 intron 21572414 rs6786589 chr3 77046740 G A 2.52E-04 Alzheimer's disease (late onset) ROBO2 intron 21379329 rs6773575 chr3 77060574 A C 5.98E-05 Fibrinogen ROBO2 intron pha003068 rs4557199 chr3 77069266 T C 1.55E-04 Major depressive disorder ROBO2 intron 22472876 rs4521284 chr3 77081899 T C 7.08E-04 Multiple complex diseases ROBO2 intron 17554300 rs11127575 chr3 77086844 T G 1.03E-05 Fibrinogen ROBO2 intron pha003068 rs7612655 chr3 77195530 C T 8.13E-04 Amyotrophic lateral sclerosis ROBO2 intron 23624525 rs9852548 chr3 77238070 G A 3.84E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs9857299 chr3 77238881 C T 3.81E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs9877746 chr3 77239172 T C 3.82E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs17015072 chr3 77244218 T C 0.00000421 HDL cholesterol particle diameter ROBO2 intron 23263444 rs17820446 chr3 77244589 T C 2.99E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs4684030 chr3 77273602 A G 5.19E-04 Rheumatoid arthritis ROBO2 intron 21452313 rs6768395 chr3 77288105 T C 3.03E-04 Fibrinogen ROBO2 intron 17255346 rs12633766 chr3 77291050 G A 2.71E-04 Amyotrophic Lateral Sclerosis ROBO2 intron 17362836 rs12491865 chr3 77291314 G C 7.95E-04 Suicide attempts in bipolar disorder ROBO2 intron 21423239 rs6764366 chr3 77295470 G C 0.00023 Endometrial cancer ROBO2 intron 22426144 rs6764328 chr3 77295661 C T 8.13E-04 Suicide attempts in bipolar disorder ROBO2 intron 21423239 rs9882239 chr3 77322334 T C 9.20E-06 Urinary metabolites ROBO2 intron 21572414 rs1992449 chr3 77329004 G A 2.63E-04 Lung function (forced expiratory volume in 1 second) ROBO2 intron 24023788 rs998037 chr3 77346963 G A 5.54E-05 Blood Pressure ROBO2 intron pha003039 rs998037 chr3 77346963 G A 9.95E-05 Blood Pressure ROBO2 intron pha003045 rs1899373 chr3 77353410 G A 9.91E-05 Blood Pressure ROBO2 intron pha003039 rs9309766 chr3 77358965 G T 4.28E-04 Alzheimer's disease ROBO2 intron 17998437 rs10084692 chr3 77378207 C T 3.47E-04 Alzheimer's disease ROBO2 intron 17998437 rs9818075 chr3 77386855 A G 1.14E-04 Alzheimer's disease ROBO2 intron 17998437 rs6548506 chr3 77439564 A G 0.000878 Salmonella-induced pyroptosis ROBO2 intron 22837397 rs6548507 chr3 77444366 A G 8.20E-05 Height ROBO2 intron pha003010 rs6548507 chr3 77444366 A G 8.93E-05 Height ROBO2 intron pha003011 rs11127593 chr3 77474818 C T 3.10E-05 Parkinson's disease (age of onset) ROBO2 intron 19772629 rs34557441 chr3 77525616 A C 8.49E-05 Bipolar disorder and schizophrenia ROBO2 intron 20889312 rs34557441 chr3 77525616 A C 6.68E-05 Femoral neck bone geometry ROBO2 intron 22087292 rs7610881 chr3 77536346 A G 1.17E-04 Hearing function ROBO2 intron 17255346 rs13081032 chr3 77541547 A G 3.64E-04 Smoking initiation ROBO2 intron 24665060 rs6797725 chr3 77544822 C T 8.36E-05 Hearing function ROBO2 intron 17255346 rs6797725 chr3 77544822 C T 2.30E-05 Femoral neck bone geometry ROBO2 intron 22087292 rs13077150 chr3 77558385 G A 4.24E-04 Smoking initiation ROBO2 intron 24665060 rs935526 chr3 77560017 C T 5.63E-05 Aging (time to event) ROBO2 intron 21782286 rs9309770 chr3 77564310 C G 5.50E-04 Obesity-related traits ROBO2 intron 17903300 rs775775 chr3 77570375 T C 1.50E-05 Sarcoidosis ROBO2 intron 19165924 rs2218647 chr3 77570419 G A 3.12E-07 Multiple complex diseases ROBO2 intron 17554300 rs775748 chr3 77596460 T A 4.80E-04 Obesity-related traits ROBO2 intron 17903300 rs1666130 chr3 77598943 C T 1.72E-04 Sarcoidosis ROBO2 intron 19165924 rs17015351 chr3 77614088 T G 8.79E-04 Multiple complex diseases ROBO2 intron 17554300 rs775713 chr3 77617219 C G 1.49E-04 Lipid traits ROBO2 intron 22028671 rs1523769 chr3 77639342 A G 6.53E-05 Sarcoidosis ROBO2 intron 19165924 rs775723 chr3 77643174 G T 6.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs73114594 chr3 77652742 G A 7.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) ROBO2 intron 23319000 rs9848106 chr3 77668346 A G 2.10E-04 Myocardial Infarction ROBO2 intron pha002883 rs876675 chr3 77675638 C T 3.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs876675 chr3 77675638 C T 4.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) ROBO2 intron 23648065 rs3821735 chr3 77684222 C T 2.27E-04 Myocardial Infarction ROBO2 intron pha002883 rs13061961 chr3 77717622 T C 1.15E-04 Multiple complex diseases / / 17554300 rs1721179 chr3 77724063 G A 1.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs990249 chr3 77725925 A C 5.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1880140 chr3 77735235 T C 6.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6548519 chr3 77735324 T C 5.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776125 chr3 77735945 G C 4.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776106 chr3 77742551 C A 5.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776107 chr3 77742903 A G 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776108 chr3 77743786 A G 3.46E-04 Multiple complex diseases / / 17554300 rs10511058 chr3 77769689 A G 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7630397 chr3 77771603 G A 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs6794930 chr3 77804193 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6798119 chr3 77836956 T C 8.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs7618756 chr3 77989402 T C 4.58E-05 Brain imaging in schizophrenia (interaction) / / 19023125 rs17775669 chr3 78012759 C T 4.30E-05 HIV-1 control / / 20041166 rs6548539 chr3 78019050 A G 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9836484 chr3 78044689 G A 4.00E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs9836484 chr3 78044689 G A 8.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7610746 chr3 78055947 C T 7.56E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs17832529 chr3 78056120 A G 0.000515 Salmonella-induced pyroptosis / / 22837397 rs1390308 chr3 78087465 T C 0.000393 Salmonella-induced pyroptosis / / 22837397 rs7614879 chr3 78132623 C T 5.20E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs2177573 chr3 78183513 T C 0.000775 Salmonella-induced pyroptosis / / 22837397 rs1917084 chr3 78184798 G T 0.000142 Salmonella-induced pyroptosis / / 22837397 rs10511131 chr3 78192927 A G 0.000162 Salmonella-induced pyroptosis / / 22837397 rs17015805 chr3 78231381 G A 8.03E-05 Fibrinogen / / 17255346 rs9882906 chr3 78234456 C T 6.08E-04 Coronary heart disease / / 21971053 rs7433616 chr3 78276135 T G 5.72E-04 Type 2 diabetes / / 17463246 rs7433616 chr3 78276135 T G 2.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs7623262 chr3 78288690 A G 2.20E-04 Multiple complex diseases / / 17554300 rs1398330 chr3 78322882 C A 6.20E-05 Bone mineral density (spine) / / 19079262 rs1512486 chr3 78325071 A G 7.42E-05 Partial epilepsies / / 20522523 rs9831754 chr3 78353591 T G 8.00E-06 Calcium levels / / 20705733 rs9831754 chr3 78353591 T G 1.12E-05 Postoperative ventricular dysfunction / / 21980348 rs6765243 chr3 78387430 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6791610 chr3 78398761 C T 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9840973 chr3 78399857 C T 6.07E-05 Cognitive test performance / / 20125193 rs11921066 chr3 78400215 C A 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9837024 chr3 78451637 A G 2.52E-05 Postoperative ventricular dysfunction / / 21980348 rs13322524 chr3 78495720 A G 2.98E-05 Postoperative ventricular dysfunction / / 21980348 rs9834373 chr3 78498997 G T 4.00E-06 Protein quantitative trait loci / / 18464913 rs4680933 chr3 78552995 G A 2.40E-05 Urinary metabolites / / 21572414 rs11721300 chr3 78553501 G T 1.42E-04 Parkinson's disease / / 17052657 rs41377648 chr3 78564700 G T 7.77E-04 Type 2 diabetes / / 17463246 rs41377648 chr3 78564700 G T 7.08E-04 Multiple complex diseases / / 17554300 rs10511127 chr3 78594711 C A 1.10E-06 Urinary metabolites / / 21572414 rs9876636 chr3 78594819 A G 6.30E-07 Urinary metabolites / / 21572414 rs1470377 chr3 78595575 T C 6.30E-07 Urinary metabolites / / 21572414 rs1444478 chr3 78596039 A C 6.30E-07 Urinary metabolites / / 21572414 rs1373524 chr3 78598282 G T 1.40E-06 Urinary metabolites / / 21572414 rs9682630 chr3 78604287 G A 5.20E-07 Urinary metabolites / / 21572414 rs6801989 chr3 78615037 A G 8.03E-04 Stroke / / pha002887 rs6807667 chr3 78640492 T C 2.85E-05 Male fertility / / 22633400 rs1507417 chr3 78650645 A G 2.41E-05 Male fertility ROBO1 intron 22633400 rs12496962 chr3 78652831 C T 1.85E-04 Alzheimer's disease ROBO1 intron 24755620 rs2660739 chr3 78693840 T C 9.64E-04 Response to alcohol consumption (flushing response) ROBO1 intron 24277619 rs1032966 chr3 78698388 T C 1.20E-06 Paclitaxel sensitivity in NCI60 cancer cell lines ROBO1 intron 21314952 rs9851228 chr3 78702439 C T 8.88E-05 Bipolar disorder ROBO1 intron 19488044 rs1865863 chr3 78803784 G A 1.61E-04 Schizophrenia ROBO1 intron 21674006 rs1865862 chr3 78803850 G T 8.58E-04 Myocardial Infarction ROBO1 intron pha002883 rs333473 chr3 78825048 C A,G,T 5.78E-04 Multiple complex diseases ROBO1 intron 17554300 rs1383407 chr3 78908171 T C 7.63E-05 Stroke (ischemic) ROBO1 intron 21940970 rs983513 chr3 79195157 G A 0.000025 Primary sclerosing cholangitis ROBO1 intron 22521342 rs1455825 chr3 79253857 G A 2.98E-05 Multiple complex diseases ROBO1 intron 17554300 rs11920171 chr3 79272194 G T 4.81E-04 Multiple complex diseases ROBO1 intron 17554300 rs9880736 chr3 79318988 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) ROBO1 intron 20708005 rs6548616 chr3 79399575 T C 8.83E-06 Kawasaki disease ROBO1 intron 21221998 rs7617893 chr3 79419101 G C 3.14E-04 Multiple complex diseases ROBO1 intron 17554300 rs6773975 chr3 79440654 T C 2.41E-04 Multiple complex diseases ROBO1 intron 17554300 rs17396958 chr3 79443051 A G 2.65E-04 Multiple complex diseases ROBO1 intron 17554300 rs4550794 chr3 79443746 T C 2.87E-04 Multiple complex diseases ROBO1 intron 17554300 rs12497294 chr3 79449194 C A 3.39E-04 Multiple complex diseases ROBO1 intron 17554300 rs9876243 chr3 79599467 T C 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7611200 chr3 79601895 G T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7617400 chr3 79604064 C T 6.00E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs9882958 chr3 79604494 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs9828140 chr3 79604842 T C 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs9834080 chr3 79605705 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs11924965 chr3 79610625 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs11924965 chr3 79610625 C T 6.16E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs12714481 chr3 79621993 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7644918 chr3 79646157 A C 6.97E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs7433360 chr3 79685538 T C 5.50E-04 Amyotrophic lateral sclerosis (sporadic) ROBO1 intron 24529757 rs9870957 chr3 79695551 A C 5.96E-04 Smoking initiation ROBO1 intron 24665060 rs4856447 chr3 79707357 G T 9.97E-04 Multiple complex diseases ROBO1 intron 17554300 rs9849596 chr3 79756484 A G 1.50E-05 Age-related macular degeneration ROBO1 intron pha002890 rs9309828 chr3 79760774 G A 3.79E-05 Age-related macular degeneration ROBO1 intron pha002890 rs6548651 chr3 79784416 G A 4.43E-04 Lymphocyte counts ROBO1 intron 22286170 rs2055451 chr3 79842129 G T 2.70E-05 Age-related macular degeneration / / 20861866 rs2055451 chr3 79842129 G T 9.34E-06 Age-related macular degeneration / / 21197116 rs2055451 chr3 79842129 G T 2.72E-06 Age-related macular degeneration / / pha000001 rs2055451 chr3 79842129 G T 2.98E-07 Age-related macular degeneration / / pha002856 rs7429136 chr3 79848404 T C 7.32E-04 Stroke / / pha002886 rs1502305 chr3 79858493 A T 2.20E-05 Age-related macular degeneration / / 20861866 rs1502305 chr3 79858493 A T 1.98E-06 Age-related macular degeneration / / pha000002 rs1502304 chr3 79858750 C T 2.50E-05 Age-related macular degeneration / / 20861866 rs1502304 chr3 79858750 C T 2.36E-06 Age-related macular degeneration / / pha000002 rs9848056 chr3 79884675 T C 4.67E-05 Pulmonary function in asthmatics / / 23541324 rs4856360 chr3 79888401 A G 4.07E-05 Pulmonary function in asthmatics / / 23541324 rs2055459 chr3 79909421 C G 5.43E-04 Type 2 diabetes / / 17463246 rs17815382 chr3 80081183 T G 3.06E-04 Alzheimer's disease (late onset) / / 21379329 rs12629494 chr3 80122427 C T 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2197383 chr3 80131214 G A 2.99E-04 Type 2 diabetes / / 17463246 rs4856497 chr3 80132645 A G 9.35E-04 Sarcoidosis / / 21540310 rs1373509 chr3 80136989 T A 3.90E-04 Type 2 diabetes / / 17463246 rs12489982 chr3 80137908 C A 4.66E-04 Type 2 diabetes / / 17463246 rs10511116 chr3 80171159 A G 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774541 chr3 80200082 A G 1.90E-05 Telomere length / / 21573004 rs7645008 chr3 80270541 G A 9.26E-04 Type 2 diabetes / / 17463246 rs950570 chr3 80302512 C T 9.50E-05 Response to alcohol consumption (flushing response) / / 24277619 rs17451453 chr3 80353541 G C 8.48E-05 Pulmonary function / / 19300500 rs1876089 chr3 80355773 T C 3.97E-05 Pulmonary function / / 19300500 rs2340392 chr3 80358300 G A 1.70E-04 Longevity and age-related phenotypes / / 17903295 rs2340392 chr3 80358300 G A 6.71E-05 Pulmonary function / / 19300500 rs10511112 chr3 80368463 T C 5.00E-06 Migraine / / 23793025 rs7641536 chr3 80403233 T C 4.04E-05 Neuroblastoma / / pha002895 rs2340388 chr3 80410159 T G 2.82E-05 Neuroblastoma / / pha002895 rs949455 chr3 80426568 A C 7.12E-05 Neuroblastoma / / pha002895 rs9862709 chr3 80467009 G C 8.51E-04 Alzheimer's disease / / 17998437 rs6795503 chr3 80478208 T A 5.68E-04 Alzheimer's disease / / 17998437 rs12634573 chr3 80489310 G A 2.30E-05 Urinary metabolites / / 21572414 rs11918372 chr3 80545136 C T 1.31E-04 Alzheimer's disease / / 17998437 rs11914812 chr3 80547244 G A 7.16E-04 Alzheimer's disease / / 17998437 rs1515002 chr3 80549257 G A 3.64E-04 Alzheimer's disease / / 17998437 rs1971568 chr3 80551182 T C 1.99E-04 Alzheimer's disease / / 17998437 rs8180054 chr3 80553618 G C 6.81E-04 Alzheimer's disease / / 17998437 rs6548709 chr3 80560408 A G 1.64E-04 Alzheimer's disease / / 17998437 rs6780379 chr3 80560525 A G 1.39E-04 Alzheimer's disease / / 17998437 rs1406784 chr3 80563194 A G 2.99E-04 Alzheimer's disease / / 17998437 rs1399556 chr3 80564338 C A 2.26E-04 Alzheimer's disease / / 17998437 rs1406780 chr3 80570997 G A 4.35E-04 Alzheimer's disease / / 17998437 rs13084778 chr3 80571946 T C 2.43E-04 Alzheimer's disease / / 17998437 rs1516584 chr3 80584747 G C 3.27E-04 Alzheimer's disease / / 17998437 rs6548713 chr3 80596593 G A 5.10E-04 Alzheimer's disease / / 17998437 rs1370205 chr3 80628901 G C 9.27E-04 Alzheimer's disease / / 17998437 rs664100 chr3 80700658 T C 7.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs485487 chr3 80711889 G A 8.60E-04 Alzheimer's disease / / 17998437 rs1402203 chr3 80720427 G A 5.33E-05 Multiple complex diseases / / 17554300 rs527157 chr3 80723865 T C 5.65E-04 Aortic root size / / 21223598 rs1437042 chr3 80748093 G A,C,T 1.30E-05 Urinary metabolites / / 21572414 rs2139685 chr3 80787263 G A 9.67E-04 Alzheimer's disease / / 17998437 rs17018312 chr3 80836506 A G 4.60E-06 Urinary metabolites / / 21572414 rs9850225 chr3 80865764 G C 5.00E-08 Erectile dysfunction / / 22704111 rs17018320 chr3 80875679 G C 8.10E-06 Urinary metabolites / / 21572414 rs12487279 chr3 80914409 C G 5.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs13060424 chr3 80933596 T C 2.00E-05 Urinary metabolites / / 21572414 rs6790313 chr3 80948443 T C 2.20E-05 Urinary metabolites / / 21572414 rs4856305 chr3 80951289 T A 2.00E-05 Urinary metabolites / / 21572414 rs2372749 chr3 80966773 C G 2.20E-05 Urinary metabolites / / 21572414 rs4298011 chr3 80984958 A G 2.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4603923 chr3 80997120 G A 1.42E-05 Alzheimer's disease / / 17998437 rs12637623 chr3 81027695 A G 6.20E-06 Urinary metabolites / / 21572414 rs2578305 chr3 81043111 C T 9.40E-04 Multiple complex diseases / / 17554300 rs2639277 chr3 81092688 A G 2.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9882538 chr3 81135791 A G 1.52E-04 Multiple complex diseases / / 17554300 rs1583673 chr3 81161078 C T 5.22E-04 Circulating vasoactive peptide levels / / 23381795 rs7612339 chr3 81270797 C T 1.07E-05 Brain structure / / 22504417 rs7614137 chr3 81283747 A T 4.14E-05 Brain structure / / 22504417 rs7628478 chr3 81293381 A C 4.82E-05 Brain structure / / 22504417 rs1487111 chr3 81296550 A G 2.38E-05 Brain structure / / 22504417 rs1487111 chr3 81296550 A G 5.48E-04 Myocardial Infarction / / pha002873 rs7630516 chr3 81297288 T A 4.51E-05 Brain structure / / 22504417 rs1982627 chr3 81318989 A G 4.23E-04 Myocardial Infarction / / pha002873 rs763855 chr3 81331298 C T 3.37E-05 Brain structure / / 22504417 rs1382261 chr3 81373838 C A 4.69E-04 Aortic root size / / 21223598 rs1871126 chr3 81385347 C T 1.71E-04 Myocardial Infarction / / pha002873 rs6796620 chr3 81385955 A G 1.40E-04 Multiple complex diseases / / 17554300 rs6780018 chr3 81405815 A T 3.18E-04 Multiple complex diseases / / 17554300 rs9877021 chr3 81406155 C T 5.90E-06 Urinary metabolites / / 21572414 rs275365 chr3 81413725 C T 5.30E-05 Endometriosis / / 21151130 rs4856343 chr3 81429555 G A 7.32E-04 Aortic root size / / 21223598 rs276105 chr3 81433234 T G 8.18E-06 Post-operative nausea and vomiting / / 21694509 rs17018881 chr3 81439098 C A 5.83E-04 Aortic root size / / 21223598 rs2372905 chr3 81504592 G C 1.93E-04 Multiple complex diseases / / 17554300 rs9874464 chr3 81505488 G C 2.31E-04 Multiple complex diseases / / 17554300 rs6783132 chr3 81534944 G A 1.35E-04 Glycosylated haemoglobin levels / / 17255346 rs843940 chr3 81547122 T A 9.22E-04 Multiple complex diseases GBE1 intron 17554300 rs17019039 chr3 81552859 G A 2.38E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs17019042 chr3 81559500 C T 1.57E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs2372908 chr3 81590296 G C 3.54E-04 Multiple complex diseases GBE1 intron 17554300 rs11922101 chr3 81604779 C T 1.41E-04 Multiple complex diseases GBE1 intron 17554300 rs9309872 chr3 81611837 T C 3.34E-04 Multiple complex diseases GBE1 intron 17554300 rs13082939 chr3 81612216 A G 1.51E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs7618973 chr3 81619588 A G 4.57E-04 Multiple complex diseases GBE1 intron 17554300 rs2172397 chr3 81643167 T C 5.03E-04 Glycosylated haemoglobin levels / / 17255346 rs6800135 chr3 81650488 C T 4.12E-04 Multiple complex diseases GBE1 intron 17554300 rs9814053 chr3 81660022 T C 4.78E-04 Multiple complex diseases GBE1 intron 17554300 rs2229519 chr3 81698130 T A,C,G 0.0000549 Body mass index GBE1 missense 23001569 rs13320194 chr3 81720076 G A 8.63E-05 Coronary heart disease GBE1 cds-synon 21606135 rs3821548 chr3 81758728 G C 1.90E-04 Multiple complex diseases GBE1 intron 17554300 rs3821548 chr3 81758728 G C 6.95E-05 Serum metabolites GBE1 intron 19043545 rs13072957 chr3 81776242 C T 5.34E-04 Multiple complex diseases GBE1 intron 17554300 rs3772891 chr3 81776760 C T 5.37E-05 Multiple complex diseases GBE1 intron 17554300 rs3772884 chr3 81802720 C A 3.67E-04 Multiple complex diseases GBE1 intron 17554300 rs3755713 chr3 81811224 A G 4.38E-04 Multiple complex diseases GBE1 nearGene-5 17554300 rs3860595 chr3 81811784 T C 8.88E-04 Multiple complex diseases GBE1 nearGene-5 17554300 rs11711331 chr3 81819040 G A 1.62E-04 Multiple complex diseases / / 17554300 rs11711331 chr3 81819040 G A 7.95E-05 Serum metabolites / / 19043545 rs6548773 chr3 81840222 T C 1.14E-04 Multiple complex diseases / / 17554300 rs6548773 chr3 81840222 T C 9.04E-05 Serum metabolites / / 19043545 rs7646435 chr3 81846607 G C 8.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1464790 chr3 81852923 T A 3.31E-04 Multiple complex diseases / / 17554300 rs1524557 chr3 81892031 T C 2.77E-04 Multiple complex diseases / / 17554300 rs1464791 chr3 81893929 G T 9.55E-05 Multiple complex diseases / / 17554300 rs1464791 chr3 81893929 G T 8.48E-05 Serum metabolites / / 19043545 rs1973804 chr3 81962522 C T 0.000764 Salmonella-induced pyroptosis / / 22837397 rs9814843 chr3 81994505 G A 2.20E-05 Urinary metabolites / / 21572414 rs7644264 chr3 82011680 C T 6.00E-05 Asthma (bronchodilator response) / / 22792082 rs7431326 chr3 82019603 G A 6.49E-04 Alcohol dependence / / 20201924 rs9875387 chr3 82050284 A G 4.24E-05 Body Mass Index / / pha002896 rs17784061 chr3 82074024 G A 3.45E-05 Multiple complex diseases / / 17554300 rs1113444 chr3 82100377 C T 3.39E-04 Multiple complex diseases / / 17554300 rs9309886 chr3 82143651 G T 9.03E-05 Body Mass Index / / pha002896 rs17728526 chr3 82147289 T A 3.16E-05 Multiple complex diseases / / 17554300 rs4618241 chr3 82184158 A T 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534671 chr3 82198467 G A 9.66E-04 Coronary heart disease / / 21971053 rs4856210 chr3 82213185 C T 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs17114 chr3 82213636 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6779875 chr3 82223946 A G 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6783449 chr3 82446513 T A 7.83E-04 Multiple complex diseases / / 17554300 rs1992984 chr3 82448822 A C 8.70E-06 Intelligence / / 21826061 rs17019771 chr3 82458130 A G 7.08E-06 Alcohol and nictotine co-dependence / / 20158304 rs1375799 chr3 82469264 A G 9.20E-04 Multiple complex diseases / / 17554300 rs9875783 chr3 82477805 T G 5.78E-05 Cognitive decline / / 22054870 rs4856389 chr3 82507996 A T 4.24E-04 Multiple complex diseases / / 17554300 rs7645265 chr3 82541672 G A 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6548822 chr3 82551142 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9814570 chr3 82589732 C T 6.95E-04 Multiple complex diseases / / 17554300 rs13079811 chr3 82614903 C A 2.69E-06 Major depressive disorder / / 20516156 rs13079811 chr3 82614903 C A 0.0000034 Major depressive disorder age at onset<30 / / 22915352 rs13079811 chr3 82614903 C A 3.49E-05 Anxiety and major depressive disorder / / 24047446 rs716764 chr3 82646519 T C 6.18E-05 Multiple complex diseases / / 17554300 rs834858 chr3 82660035 T C 6.52E-05 Multiple complex diseases / / 17554300 rs834864 chr3 82663150 T C 8.28E-05 Multiple complex diseases / / 17554300 rs834873 chr3 82667244 A T 2.58E-05 Multiple complex diseases / / 17554300 rs834849 chr3 82687133 C T 9.91E-04 Type 2 diabetes / / 17463246 rs17019986 chr3 82689239 T A 2.50E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11127782 chr3 82691819 T C 7.88E-06 Cognitive test performance / / 20125193 rs1097157 chr3 82697313 C T 1.94E-04 Multiple complex diseases / / 17554300 rs2873392 chr3 82697984 C T 3.05E-04 Multiple complex diseases / / 17554300 rs834843 chr3 82706368 A G 7.32E-05 Multiple complex diseases / / 17554300 rs1580295 chr3 82715343 A G 5.28E-05 Multiple complex diseases / / 17554300 rs1600058 chr3 82732832 A G 6.18E-05 Multiple complex diseases / / 17554300 rs6548843 chr3 82758743 T C 6.97E-04 Multiple complex diseases / / 17554300 rs11712238 chr3 82775843 G T 1.03E-04 Tourette syndrome / / 22889924 rs9880341 chr3 82850096 T G 2.13E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12493332 chr3 82896772 A C 0.00000274 VLDL cholesterol particle diameter / / 23263444 rs17020227 chr3 82906400 T C 0.0000027 VLDL cholesterol particle diameter / / 23263444 rs17020233 chr3 82922579 G A 0.00000177 VLDL cholesterol particle diameter / / 23263444 rs13075335 chr3 82923361 T C 0.00000174 VLDL cholesterol particle diameter / / 23263444 rs9309915 chr3 82925724 C A 0.00000169 VLDL cholesterol particle diameter / / 23263444 rs9867035 chr3 82926370 G C 9.00E-04 Multiple complex diseases / / 17554300 rs12486708 chr3 82936617 G C 0.00000179 VLDL cholesterol particle diameter / / 23263444 rs13091263 chr3 82937049 T A 0.00000178 VLDL cholesterol particle diameter / / 23263444 rs13094197 chr3 82958776 A C 0.00000145 VLDL cholesterol particle diameter / / 23263444 rs2047333 chr3 82959022 T G 9.12E-04 Parkinson's disease / / 17052657 rs13063170 chr3 82960559 A G 0.00000143 VLDL cholesterol particle diameter / / 23263444 rs9309919 chr3 82960892 G A 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13092936 chr3 82962078 T C 0.0000118 VLDL cholesterol particle diameter / / 23263444 rs975488 chr3 82992714 A C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs4856423 chr3 83004185 G A 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2317601 chr3 83019201 A T 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17020418 chr3 83034644 A G 8.11E-04 Type 2 diabetes / / 17463246 rs35216186 chr3 83038704 C T 1.24E-06 Asthma (childhood onset) / / 23829686 rs41514251 chr3 83054736 G A 9.52E-04 Multiple complex diseases / / 17554300 rs7618878 chr3 83089596 C T 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1080728 chr3 83107505 G A 8.23E-04 Multiple complex diseases / / 17554300 rs1473624 chr3 83169976 A G 7.18E-04 Parkinson's disease / / 17052657 rs1376967 chr3 83501948 T G 9.69E-04 Parkinson's disease / / 17052657 rs17780040 chr3 83502697 C T 2.40E-06 Urinary metabolites / / 21572414 rs6800558 chr3 83523168 T A 4.73E-04 Multiple complex diseases / / 17554300 rs8180101 chr3 83547435 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8180101 chr3 83547435 A G 1.57E-05 Magnesium levels / / pha003092 rs4856462 chr3 83609341 T G 5.68E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11710892 chr3 83617489 A G 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1357797 chr3 83775078 A G 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1357797 chr3 83775078 A G 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11715563 chr3 83791220 T C 3.91E-04 Parkinson's disease / / 17052657 rs1917372 chr3 83793414 A G 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1524783 chr3 83800798 A C 1.88E-04 Parkinson's disease / / 17052657 rs4856472 chr3 83838977 C T 2.46E-04 Parkinson's disease / / 17052657 rs17021121 chr3 83843079 T C 3.34E-05 Heart Failure / / pha002884 rs4274767 chr3 83877497 A G 6.20E-05 Serum metabolites / / 19043545 rs4413325 chr3 83877684 T G 9.27E-04 Parkinson's disease / / 17052657 rs4574309 chr3 83905418 C T 4.62E-05 Parkinson's disease / / 17052657 rs4264742 chr3 83906468 C G 1.39E-05 Serum metabolites / / 19043545 rs4396907 chr3 83906804 G A 3.40E-05 Parkinson's disease / / 17052657 rs7649903 chr3 83907751 A G 3.14E-04 Parkinson's disease / / 17052657 rs9879027 chr3 83914442 G T 5.23E-04 Parkinson's disease / / 17052657 rs11127827 chr3 83914758 A G 1.29E-04 Parkinson's disease / / 17052657 rs4260455 chr3 83921894 T A 2.36E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6777459 chr3 83937348 T C 1.00E-04 Spine bone size / / 21947420 rs6777545 chr3 83937394 T C 1.00E-04 Spine bone size / / 21947420 rs6548921 chr3 83938414 T C 6.20E-06 Urinary metabolites / / 21572414 rs6548923 chr3 83939565 A G 5.90E-06 Urinary metabolites / / 21572414 rs4128523 chr3 83940448 G A 2.11E-04 Parkinson's disease / / 17052657 rs5010174 chr3 83943663 C T 7.69E-04 Parkinson's disease / / 17052657 rs4276197 chr3 83945963 A G 6.14E-04 Premature ovarian failure / / 19508998 rs9865049 chr3 84008488 T C 1.63E-04 Parkinson's disease / / 17052657 rs4856477 chr3 84017630 C T 3.58E-05 Tunica Media / / pha003038 rs17178354 chr3 84076514 C T 2.30E-06 Urinary metabolites / / 21572414 rs4856242 chr3 84127821 G A 1.40E-06 Urinary metabolites / / 21572414 rs4856490 chr3 84147884 T C 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4856244 chr3 84184134 T C 1.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4522784 chr3 84202203 T G 7.00E-06 Obesity-related traits / / 23251661 rs6772122 chr3 84205939 C T 8.12E-04 Smoking cessation / / 24665060 rs9818995 chr3 84224057 C A 1.24E-04 Parkinson's disease / / 17052657 rs4279116 chr3 84253609 T C 1.50E-04 Multiple complex diseases / / 17554300 rs7617594 chr3 84296569 T C 8.36E-04 Heart Failure / / pha002884 rs4320067 chr3 84303380 A G 1.83E-04 Multiple complex diseases / / 17554300 rs7636111 chr3 84304241 A T 1.57E-04 Multiple complex diseases / / 17554300 rs11915176 chr3 84332255 T A 1.92E-05 Multiple complex diseases / / 17554300 rs1384300 chr3 84356646 T C 5.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1384301 chr3 84357128 A G 5.54E-04 Multiple complex diseases / / 17554300 rs4856502 chr3 84357635 G A 7.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11929542 chr3 84394801 C T 6.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12633731 chr3 84403117 T A 7.36E-04 Multiple complex diseases / / 17554300 rs7653393 chr3 84403239 A T 5.87E-04 Multiple complex diseases / / 17554300 rs1384307 chr3 84425895 C T 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12714597 chr3 84443114 G A 2.86E-04 Parkinson's disease / / 17052657 rs10511089 chr3 84481068 G T 7.00E-07 Brain structure / / 20171287 rs1471804 chr3 84616264 T C 4.88E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4373074 chr3 84688248 T C 5.98E-04 Multiple complex diseases / / 17554300 rs7642488 chr3 84688723 C T 6.72E-04 Multiple complex diseases LOC440970 intron 17554300 rs4374542 chr3 84716208 A G 4.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6783281 chr3 84791851 A G 1.70E-04 Type 2 diabetes LOC440970 intron 17463246 rs9869020 chr3 84798458 C T 2.42E-04 Multiple complex diseases LOC440970 intron 17554300 rs9818956 chr3 84819147 G T 1.13E-05 Platelet counts LOC440970 intron 21507922 rs1248845 chr3 84871763 T A 9.26E-05 Schizophrenia LOC440970 intron 19571809 rs10440084 chr3 84872804 A G 3.00E-06 Urinary metabolites LOC440970 intron 21572414 rs1248821 chr3 84930747 T C 5.59E-05 Schizophrenia / / 19571809 rs1248820 chr3 84931323 T C 5.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9882516 chr3 84941806 C G 1.35E-04 Multiple complex diseases / / 17554300 rs2132183 chr3 84966867 C T 1.26E-04 Multiple complex diseases / / 17554300 rs9683309 chr3 84977191 C T 1.42E-04 Multiple complex diseases / / 17554300 rs11127866 chr3 84978010 C A 1.20E-04 Multiple complex diseases / / 17554300 rs7614596 chr3 84986027 T G 1.22E-04 Multiple complex diseases / / 17554300 rs4856554 chr3 85022821 G A 7.46E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs6768455 chr3 85040649 C T 4.38E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs17022259 chr3 85051839 G A 3.33E-04 Insulin resistance CADM2 intron 21901158 rs17022281 chr3 85059619 G A 4.36E-04 Insulin resistance CADM2 intron 21901158 rs1994316 chr3 85069287 T G 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs1016305 chr3 85082924 G A 2.10E-05 Serum metabolites CADM2 intron 19043545 rs2171143 chr3 85084508 C T 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs2062430 chr3 85095081 A G 8.59E-04 Multiple complex diseases CADM2 intron 17554300 rs9814835 chr3 85099943 T C 5.06E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs11127876 chr3 85124697 C T 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9820587 chr3 85138172 A G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 1.66E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 3.15E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs4516626 chr3 85152987 C T 5.76E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 1.66E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 3.15E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs2034619 chr3 85281802 G A 2.92E-04 Premature ovarian failure CADM2 intron 19508998 rs818215 chr3 85371400 A C 1.46E-05 Serum metabolites CADM2 intron 19043545 rs818215 chr3 85371400 A C 0.0000044 Femoral neck bone mineral density (premenopausal) CADM2 intron 23074152 rs9822731 chr3 85405501 T C 2.14E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs7627971 chr3 85414291 T C 3.80E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs1821349 chr3 85438564 A G 3.94E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs1549979 chr3 85460131 C T 2.39E-07 Bipolar disorder CADM2 intron 22182935 rs2053108 chr3 85467972 C A 2.90E-05 Urinary metabolites CADM2 intron 21572414 rs2053108 chr3 85467972 C A 2.41E-07 Bipolar disorder CADM2 intron 22182935 rs6780968 chr3 85469041 C G 1.60E-05 Urinary metabolites CADM2 intron 21572414 rs2196096 chr3 85470642 T C 1.89E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs2326309 chr3 85477017 T G 6.08E-07 Bipolar disorder CADM2 intron 22182935 rs7609594 chr3 85482595 G A 1.90E-05 Urinary metabolites CADM2 intron 21572414 rs7609594 chr3 85482595 G A 1.68E-07 Bipolar disorder CADM2 intron 22182935 rs35827242 chr3 85482661 G A 2.10E-05 Urinary metabolites CADM2 intron 21572414 rs1865252 chr3 85488740 A G 2.20E-05 Urinary metabolites CADM2 intron 21572414 rs2082556 chr3 85490947 G A 2.15E-07 Bipolar disorder CADM2 intron 22182935 rs993137 chr3 85499035 C T 1.40E-05 Urinary metabolites CADM2 intron 21572414 rs993137 chr3 85499035 C T 2.79E-07 Bipolar disorder CADM2 intron 22182935 rs993136 chr3 85499333 T C 2.20E-05 Urinary metabolites CADM2 intron 21572414 rs993136 chr3 85499333 T C 2.72E-07 Bipolar disorder CADM2 intron 22182935 rs11920711 chr3 85502556 G A 1.39E-04 Multiple complex diseases CADM2 intron 17554300 rs13323436 chr3 85502845 T A 3.00E-06 Visceral fat CADM2 intron 22589738 rs2117153 chr3 85504452 G A 4.91E-05 Intelligence CADM2 intron 21826061 rs2117153 chr3 85504452 G A 1.95E-07 Bipolar disorder CADM2 intron 22182935 rs2875907 chr3 85518580 A G 7.44E-08 Bipolar disorder CADM2 intron 22182935 rs12637791 chr3 85525323 T G 1.00E-04 Prostate cancer CADM2 intron 21743057 rs1542248 chr3 85527334 G A 9.65E-07 Bipolar disorder CADM2 intron 22182935 rs726610 chr3 85551403 C T 1.49E-07 Bipolar disorder CADM2 intron 22182935 rs12638798 chr3 85551820 T C 1.42E-07 Bipolar disorder CADM2 intron 22182935 rs1449391 chr3 85554582 G T 7.10E-07 Bipolar disorder CADM2 intron 22182935 rs6804845 chr3 85563846 A C 1.51E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs6804845 chr3 85563846 A C 7.07E-07 Bipolar disorder CADM2 intron 22182935 rs10511083 chr3 85570959 A G 1.75E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs10511083 chr3 85570959 A G 9.08E-07 Bipolar disorder CADM2 intron 22182935 rs4856582 chr3 85577197 G A 6.77E-04 Type 2 diabetes CADM2 intron 17463246 rs4856584 chr3 85580328 A T 8.00E-05 Prostate cancer CADM2 intron 21743057 rs11127898 chr3 85587729 C G 8.00E-05 Prostate cancer CADM2 intron 21743057 rs17517121 chr3 85591108 G A 8.89E-07 Bipolar disorder CADM2 intron 22182935 rs2326319 chr3 85597135 G A 1.33E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs2326319 chr3 85597135 G A 1.09E-07 Bipolar disorder CADM2 intron 22182935 rs7652808 chr3 85603643 T G 1.20E-07 Bipolar disorder CADM2 intron 22182935 rs17518584 chr3 85604923 C T 9.85E-07 Bipolar disorder CADM2 intron 22182935 rs1375547 chr3 85608137 G A 2.20E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs17023019 chr3 85614272 A G 8.37E-08 Bipolar disorder CADM2 intron 22182935 rs1900916 chr3 85646426 T G 4.40E-07 Bipolar disorder CADM2 intron 22182935 rs12637027 chr3 85658601 C G 5.94E-07 Bipolar disorder CADM2 intron 22182935 rs7632056 chr3 85659025 A G 7.21E-07 Bipolar disorder CADM2 intron 22182935 rs6779752 chr3 85663849 G A 1.82E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs6779752 chr3 85663849 G A 8.30E-07 Bipolar disorder CADM2 intron 22182935 rs1449395 chr3 85667683 C A 3.78E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs9829032 chr3 85683600 A G 9.68E-07 Bipolar disorder CADM2 intron 22182935 rs4302392 chr3 85689076 A G 1.14E-05 Serum metabolites CADM2 intron 19043545 rs9844720 chr3 85719890 C T 5.48E-04 Response to alcohol consumption (flushing response) CADM2 intron 24277619 rs7612090 chr3 85729502 G A 3.71E-04 Response to alcohol consumption (flushing response) CADM2 intron 24277619 rs10514735 chr3 85798950 A G 3.76E-04 Multiple complex diseases CADM2 intron 17554300 rs9864042 chr3 85823561 G A 3.19E-06 Esophageal cancer (squamous cell) CADM2 intron 22960999 rs9852859 chr3 85842341 T C 5.30E-04 Type 2 diabetes CADM2 intron 17463246 rs12494658 chr3 85874476 T C 5.00E-06 Temperament CADM2 intron 22832960 rs13078807 chr3 85884150 A G 4.00E-11 Body mass index CADM2 intron 20935630 rs13078807 chr3 85884150 A G 3.94E-11 Body mass index CADM2 intron 23001569 rs13078807 chr3 85884150 A G 3.00E-11 Obesity CADM2 intron 23563607 rs9861174 chr3 85989000 G T 8.51E-05 Multiple sclerosis (age of onset) CADM2 intron 19010793 rs9829960 chr3 86065598 A G 4.37E-05 Multiple sclerosis (age of onset) CADM2 intron 19010793 rs2324999 chr3 86158885 C T 2.00E-06 Subcutaneous adipose tissue / / 22589738 rs2324999 chr3 86158885 C T 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs6796873 chr3 86168194 A G 8.55E-04 Multiple complex diseases / / 17554300 rs6549077 chr3 86196341 C T 2.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs11127920 chr3 86196664 T C 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127920 chr3 86196664 T C 7.61E-05 Coronary heart disease / / pha003030 rs6549078 chr3 86197342 A G 3.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs7432587 chr3 86199354 A G 2.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7428811 chr3 86199798 G C 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127922 chr3 86203314 A G 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127924 chr3 86203406 C G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790538 chr3 86203821 G C 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12493043 chr3 86204275 T C 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs13093222 chr3 86204867 G A 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636212 chr3 86205223 T C 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636212 chr3 86205223 T C 4.00E-05 Body Mass Index / / pha002896 rs12485540 chr3 86206285 T C 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12633890 chr3 86209277 A G 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10865615 chr3 86214243 G T 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs4688888 chr3 86221347 T C 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12486352 chr3 86223273 A T 1.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12638689 chr3 86225928 A G 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12634090 chr3 86226739 G C 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127925 chr3 86226925 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707021 chr3 86246160 C A 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs13072339 chr3 86247275 G A 2.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7636401 chr3 86249401 G A 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512914 chr3 86251199 G T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs6773947 chr3 86251656 A T 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487215 chr3 86254241 A G 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487215 chr3 86254241 A G 4.32E-05 Fibrinogen / / pha003068 rs7428796 chr3 86255672 T C 2.00E-18 Myopia (pathological) / / 23049088 rs7428796 chr3 86255672 T C 4.21E-05 Fibrinogen / / pha003068 rs4073109 chr3 86256530 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4688890 chr3 86260728 C G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs4396896 chr3 86261800 A T 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175671 chr3 86264283 T C 1.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs1512929 chr3 86265219 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2137492 chr3 86266408 A G 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2137492 chr3 86266408 A G 4.88E-05 Prion diseases / / 22210626 rs2048589 chr3 86268100 T C 2.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1949197 chr3 86273850 A G 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs13077697 chr3 86278209 A G 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs17026843 chr3 86282294 T C 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487935 chr3 86284649 A G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263293 chr3 86286959 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512934 chr3 86288495 T C 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636329 chr3 86289542 C G,T 2.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs932058 chr3 86292844 T A 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512922 chr3 86296208 C A,T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127927 chr3 86300035 A G 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175673 chr3 86301073 A T 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6788794 chr3 86303453 C T 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127928 chr3 86303487 A G 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127929 chr3 86305485 G A 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774344 chr3 86306259 A C 6.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6763450 chr3 86306651 T G 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1355686 chr3 86345140 G A 9.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs6801738 chr3 86357790 T C 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127934 chr3 86362700 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127935 chr3 86364123 C T 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707281 chr3 86372407 A C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs12495441 chr3 86376976 T C 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1170215 chr3 86381727 G C 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1170214 chr3 86381883 T C 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2669408 chr3 86385475 G C 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs979471 chr3 86385687 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs13316811 chr3 86391789 G T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9829587 chr3 86392751 C T 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs7616481 chr3 86394337 A G 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1495888 chr3 86411414 G A 2.08E-05 Personality dimensions / / 18957941 rs7643206 chr3 86441163 G A 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs9820995 chr3 86457535 T C 5.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs6786876 chr3 86462805 G A 5.52E-05 Suicide attempts in bipolar disorder / / 21423239 rs884026 chr3 86467434 T G 8.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs291956 chr3 86500544 G A 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1603320 chr3 86526422 T G 5.22E-05 Orofacial clefts / / 22419666 rs188655146 chr3 86544386 T G 9.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2035985 chr3 86555969 C T 3.22E-04 Alcohol dependence / / 24277619 rs7640494 chr3 86565981 C G 4.34E-04 Multiple complex diseases / / 17554300 rs6763219 chr3 86693588 A T 3.73E-04 Parkinson's disease / / 16252231 rs7649866 chr3 86717004 A T 8.32E-04 Parkinson's disease / / 16252231 rs1370209 chr3 86749427 A G 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6796925 chr3 86757306 T C 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9850360 chr3 86761070 A T 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11919691 chr3 86782582 A G 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9827403 chr3 86790149 T C 1.33E-04 Body mass index / / 21701565 rs9827403 chr3 86790149 T C 1.97E-05 Body mass index / / 21701565 rs9827403 chr3 86790149 T C 5.37E-04 Body mass index / / 21701565 rs4530527 chr3 86800085 A C 1.28E-04 Body mass index / / 21701565 rs9866309 chr3 86821558 G A 2.96E-04 Body mass index / / 21701565 rs9866309 chr3 86821558 G A 7.26E-05 Body mass index / / 21701565 rs11127958 chr3 86825600 A T 1.53E-06 Body mass index / / 21701565 rs11127958 chr3 86825600 A T 2.64E-05 Body mass index / / 21701565 rs7628864 chr3 86850618 A G 3.00E-09 Pubertal anthropometrics / / 23449627 rs2118188 chr3 86868436 C T 3.14E-04 Body mass index / / 21701565 rs2118188 chr3 86868436 C T 8.60E-05 Body mass index / / 21701565 rs9683166 chr3 86874663 T G 1.64E-04 Body mass index / / 21701565 rs9683166 chr3 86874663 T G 5.95E-04 Body mass index / / 21701565 rs9310023 chr3 86875458 A G 1.66E-04 Body mass index / / 21701565 rs9310023 chr3 86875458 A G 5.95E-04 Body mass index / / 21701565 rs9683172 chr3 86883956 C A 3.10E-04 Body mass index / / 21701565 rs9757252 chr3 86894478 T C 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs9310043 chr3 86911330 T A 2.89E-04 Body mass index / / 21701565 rs9310043 chr3 86911330 T A 5.28E-05 Body mass index / / 21701565 rs9682134 chr3 86913288 C T 1.65E-04 Body mass index / / 21701565 rs9682134 chr3 86913288 C T 5.95E-04 Body mass index / / 21701565 rs7642134 chr3 86916882 A G 4.00E-10 Menarche (age at onset) / / 21102462 rs7642134 chr3 86916882 A G 0.00062 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs9842925 chr3 86917446 C T 2.81E-04 Body mass index / / 21701565 rs4859048 chr3 86952516 C T 7.87E-05 Blood Pressure / / pha003040 rs6419888 chr3 86961118 A G 1.64E-04 Body mass index / / 21701565 rs6419888 chr3 86961118 A G 5.95E-04 Body mass index / / 21701565 rs4859060 chr3 86962760 G A 1.80E-04 Body mass index / / 21701565 rs4859060 chr3 86962760 G A 5.79E-04 Body mass index / / 21701565 rs6551477 chr3 86963417 C T 2.57E-04 Body mass index / / 21701565 rs6551477 chr3 86963417 C T 8.89E-04 Body mass index / / 21701565 rs7649306 chr3 86964922 A G 4.02E-04 Body mass index / / 21701565 rs7649306 chr3 86964922 A G 4.19E-05 Body mass index / / 21701565 rs7649317 chr3 86964949 A G 1.29E-04 Body mass index / / 21701565 rs13074417 chr3 86968492 A G 7.63E-05 Blood Pressure / / pha003040 rs17023661 chr3 86968509 C T 7.49E-04 Body mass index / / 21701565 rs17023661 chr3 86968509 C T 2.00E-06 Obesity-related traits / / 23251661 rs1370036 chr3 86969519 T C 5.05E-04 Body mass index / / 21701565 rs1370036 chr3 86969519 T C 5.50E-05 Body mass index / / 21701565 rs7614681 chr3 86975072 T C 7.92E-04 Body mass index / / 21701565 rs7614681 chr3 86975072 T C 7.98E-05 Body mass index / / 21701565 rs1370032 chr3 86975853 T C 7.22E-05 Blood Pressure / / pha003040 rs1898274 chr3 87050997 G A 0.00033 Endometrial cancer / / 22426144 rs2118079 chr3 87063871 C T 8.19E-04 Aortic root size / / 21223598 rs1370042 chr3 87084332 G A 0.00025 Endometrial cancer / / 22426144 rs9836203 chr3 87097872 T C 4.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17023854 chr3 87104899 T C 1.50E-05 Urinary metabolites / / 21572414 rs2660753 chr3 87110674 T C 3.00E-08 Prostate cancer / / 18264097 rs2660753 chr3 87110674 T C 3.00E-08 Nasopharyngeal carcinoma / / 20512145 rs17023900 chr3 87134800 A G 3.10E-07 Prostate cancer / / 18264097 rs17023900 chr3 87134800 A G 6.00E-08 Prostate cancer / / 22923026 rs9284813 chr3 87152169 A G 5.00E-09 Prostate cancer / / 20676098 rs9284813 chr3 87152169 A G 0.00001 Prostate cancer / / 23555315 rs17181079 chr3 87162301 G A 2.00E-04 Multiple complex diseases / / 17554300 rs9836404 chr3 87172005 G A 1.05E-04 Prostate cancer / / 23023329 rs17181170 chr3 87173324 G A 3.00E-08 Prostate cancer / / 19767753 rs17181170 chr3 87173324 G A 3.00E-08 Nasopharyngeal carcinoma / / 20512145 rs17181170 chr3 87173324 G A 0.00011 Prostate cancer / / 23555315 rs17181170 chr3 87173324 G A 8.62E-05 Cardiovascular disease / / pha003065 rs7639047 chr3 87173731 C T 6.58E-05 Cardiovascular disease / / pha003065 rs17023969 chr3 87189024 C T 2.04E-05 Cardiovascular disease / / pha003065 rs12633313 chr3 87212726 C T 2.70E-06 Urinary metabolites / / 21572414 rs1825896 chr3 87219009 G A 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1825896 chr3 87219009 G A 2.50E-05 Urinary metabolites / / 21572414 rs963622 chr3 87223646 A G 0.000684 Height (Pygmy height) / / 22570615 rs7629490 chr3 87241497 C T 1.20E-05 Urinary metabolites / / 21572414 rs7629490 chr3 87241497 C T 1.00E-07 Prostate cancer / / 21743057 rs7629490 chr3 87241497 C T 0.00004 Prostate cancer / / 23555315 rs7629490 chr3 87241497 C T 0.000061 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs17024019 chr3 87257423 A G 0.00000957 Preeclampsia / / 22432041 rs17024024 chr3 87258681 T A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1994487 chr3 87262998 A G 4.80E-06 Stroke (ischemic) / / 22384361 rs17024046 chr3 87263497 C T 2.40E-05 Urinary metabolites / / 21572414 rs6773746 chr3 87265821 T G 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12488607 chr3 87267240 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs904115 chr3 87274437 T G 5.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) CHMP2B nearGene-5 23648065 rs2279720 chr3 87276699 C T 0.00000866 Preeclampsia CHMP2B cds-synon 22432041 rs13061754 chr3 87280088 C T 1.52E-05 Cardiovascular disease CHMP2B intron pha003065 rs10511133 chr3 87284401 C T 0.000338 Height (Pygmy height) CHMP2B intron 22570615 rs9858626 chr3 87287120 G A 0.000567 Height (Pygmy height) CHMP2B intron 22570615 rs6768771 chr3 87290389 A G 1.50E-05 Cardiovascular disease CHMP2B intron pha003065 rs2879985 chr3 87293542 G A 2.84E-04 Suicide attempts in bipolar disorder CHMP2B intron 21423239 rs1044499 chr3 87299075 A C 0.00000866 Preeclampsia CHMP2B cds-synon 22432041 rs3804602 chr3 87301263 T C 3.75E-04 Suicide attempts in bipolar disorder CHMP2B intron 21423239 rs1060241 chr3 87304561 G A 2.87E-04 Suicide attempts in bipolar disorder CHMP2B UTR-3 21423239 rs7428816 chr3 87307547 G A 4.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3804605 chr3 87308553 C G 2.63E-04 Suicide attempts in bipolar disorder POU1F1 nearGene-3 21423239 rs12486159 chr3 87311893 T A 3.30E-04 Suicide attempts in bipolar disorder POU1F1 intron 21423239 rs9837195 chr3 87313147 A G 7.12E-06 Cardiovascular disease POU1F1 intron pha003065 rs9837195 chr3 87313147 A G 9.22E-05 HDL cholesterol POU1F1 intron pha003075 rs9822911 chr3 87318758 T C 3.00E-05 Cardiovascular disease POU1F1 intron pha003065 rs9822911 chr3 87318758 T C 3.48E-05 HDL cholesterol POU1F1 intron pha003075 rs17189466 chr3 87321022 T C 1.40E-05 Urinary metabolites POU1F1 intron 21572414 rs17024118 chr3 87321757 A G 3.24E-05 Cardiovascular disease POU1F1 intron pha003065 rs300978 chr3 87323334 G T 1.41E-05 Cardiovascular disease POU1F1 intron pha003065 rs300978 chr3 87323334 G T 3.40E-05 HDL cholesterol POU1F1 intron pha003075 rs2633674 chr3 87328365 G A 1.10E-05 Urinary metabolites / / 21572414 rs2172685 chr3 87342944 C T 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs300989 chr3 87344797 A G 8.34E-06 Cardiovascular disease / / pha003065 rs2642318 chr3 87347466 T C 8.68E-06 Cardiovascular disease / / pha003065 rs1497411 chr3 87349897 C T 0.0000771 Placental abruption / / 23205182 rs12492392 chr3 87350420 A G 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs903292 chr3 87351380 C T 8.68E-06 Cardiovascular disease / / pha003065 rs4345069 chr3 87352633 G A 1.50E-05 Urinary metabolites / / 21572414 rs1845427 chr3 87357589 C T 7.49E-06 Cardiovascular disease / / pha003065 rs2646229 chr3 87363580 T C 6.20E-05 Cardiovascular disease / / pha003065 rs2646229 chr3 87363580 T C 8.96E-05 HDL cholesterol / / pha003075 rs7629275 chr3 87369511 T G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs2642349 chr3 87370697 G A 1.10E-05 Urinary metabolites / / 21572414 rs6551471 chr3 87371282 G T 1.06E-05 Cardiovascular disease / / pha003065 rs6551471 chr3 87371282 G T 4.74E-05 Fibrinogen / / pha003068 rs4859055 chr3 87373894 C T 4.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs4859055 chr3 87373894 C T 7.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs11709932 chr3 87383582 G A 3.83E-04 Multiple complex diseases / / 17554300 rs11709932 chr3 87383582 G A 8.80E-06 Urinary metabolites / / 21572414 rs11127978 chr3 87386029 A T 4.61E-04 Multiple complex diseases / / 17554300 rs2342158 chr3 87386369 A G 5.25E-04 Multiple complex diseases / / 17554300 rs2342158 chr3 87386369 A G 8.20E-06 Urinary metabolites / / 21572414 rs17024255 chr3 87397099 A G 6.27E-04 Multiple complex diseases / / 17554300 rs17024255 chr3 87397099 A G 8.20E-06 Urinary metabolites / / 21572414 rs12634320 chr3 87397470 G A 1.40E-05 Urinary metabolites / / 21572414 rs12637307 chr3 87397841 T C 5.70E-05 Multiple complex diseases / / 17554300 rs12637307 chr3 87397841 T C 8.70E-06 Urinary metabolites / / 21572414 rs7626102 chr3 87398577 T C 9.50E-06 Urinary metabolites / / 21572414 rs9882711 chr3 87400383 T C 3.20E-06 Urinary metabolites / / 21572414 rs1011609 chr3 87401121 A G 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6789301 chr3 87406236 T C 1.50E-04 Smoking initiation / / 24665060 rs1494259 chr3 87417983 T A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs983717 chr3 87419255 A T 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1389679 chr3 87421298 G A 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs9848337 chr3 87424037 T G 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs9863213 chr3 87428317 A G 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13076266 chr3 87431686 T C 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs6769149 chr3 87436327 A T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4858959 chr3 87436489 T C 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494250 chr3 87438076 A T 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6776212 chr3 87438524 A C 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494252 chr3 87439974 T C 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7430556 chr3 87445713 T C 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs17024472 chr3 87447949 A G 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494255 chr3 87448376 A G 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12486356 chr3 87456495 C T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12630755 chr3 87457926 G A 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11917983 chr3 87458840 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7619499 chr3 87461795 A T 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7622319 chr3 87461843 T C 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs9846842 chr3 87462333 C G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs9873569 chr3 87466305 A G 9.60E-06 Urinary metabolites / / 21572414 rs9815149 chr3 87486475 G C 5.10E-05 Serum metabolites / / 19043545 rs9834692 chr3 87495550 C T 3.00E-09 Brain connectivity / / 23471985 rs9883474 chr3 87525449 C A 3.00E-09 Brain connectivity / / 23471985 rs17465479 chr3 87528969 C A 8.19E-05 Glycosylated haemoglobin levels / / 17255346 rs17465479 chr3 87528969 C A 9.10E-05 Lung adenocarcinoma / / 22797724 rs17525168 chr3 87532267 A T 8.19E-05 Glycosylated haemoglobin levels / / 17255346 rs1106145 chr3 87548405 G T 3.42E-04 Parkinson's disease / / 17052657 rs17525351 chr3 87548544 T C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175180 chr3 87566304 C T 2.55E-04 Multiple complex diseases / / 17554300 rs2048291 chr3 87618918 A C 3.48E-04 Dental caries / / 21940522 rs4561856 chr3 87660121 G T 0.0000179 Alcohol craving with or without dependence / / 22481050 rs9860340 chr3 87783976 A G 4.00E-06 Electroencephalographic traits in alcoholism / / 22554406 rs2880695 chr3 87833897 C T 4.66E-05 Post-operative nausea and vomiting / / 21694509 rs959132 chr3 87854277 T C 1.10E-04 Osteoarthritis / / 19508968 rs959132 chr3 87854277 T C 6.72E-05 Coronary heart disease / / pha003032 rs17025015 chr3 87875813 C T 5.16E-05 Serum metabolites / / 19043545 rs1847313 chr3 87909084 T A 1.00E-05 Urinary metabolites / / 21572414 rs12491283 chr3 87909248 C G 6.60E-06 Urinary metabolites / / 21572414 rs17025082 chr3 87909882 G A 2.60E-05 Urinary metabolites / / 21572414 rs1503434 chr3 87910388 T C 3.83E-04 Longevity / / 22279548 rs2932286 chr3 87910931 G A 2.83E-04 Smoking initiation / / 24665060 rs12497315 chr3 87920980 G A 2.60E-05 Urinary metabolites / / 21572414 rs1864617 chr3 87948318 T C 2.83E-04 Coronary heart disease / / 21971053 rs2915287 chr3 87957076 G A 4.68E-05 HIV-1 control / / 20041166 rs17025178 chr3 87978091 A G 1.90E-05 Urinary metabolites / / 21572414 rs10511135 chr3 87983962 C A 1.90E-05 Urinary metabolites / / 21572414 rs4858927 chr3 88030689 A G 4.68E-05 HIV-1 control / / 20041166 rs9863076 chr3 88033939 T G 3.43E-05 Lymphocyte counts HTR1F intron 22286170 rs1503433 chr3 88037200 C A 0.00036 Coronary artery calcification HTR1F intron 23727086 rs4858970 chr3 88048652 C T 4.68E-05 HIV-1 control / / 20041166 rs1431154 chr3 88074793 G A 4.68E-05 HIV-1 control / / 20041166 rs73144035 chr3 88077379 C T 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4616669 chr3 88086823 G A 4.73E-05 HIV-1 control / / 20041166 rs12629581 chr3 88171228 A C 9.80E-04 Alcohol consumption (maxi-drinks) CGGBP1 intron 24277619 rs4414876 chr3 88183068 A C 5.91E-07 Lymphocyte counts CGGBP1 intron 22286170 rs7432826 chr3 88190768 C A 7.44E-05 Information processing speed CGGBP1 intron 21130836 rs11916151 chr3 88280676 T A 0.00000554 Coronary artery disease / / 23202125 rs6551304 chr3 88306596 A G 7.35E-04 Schizophrenia / / 19197363 rs2061372 chr3 88336413 G A 6.95E-04 Schizophrenia / / 19197363 rs2168809 chr3 88377746 T C 3.60E-07 Primary biliary cirrhosis / / 23000144 rs2168809 chr3 88377746 T C 0.00000036 Facial morphology / / 23028347 rs9858909 chr3 88378348 A G 2.89E-07 Primary biliary cirrhosis / / 23000144 rs9858909 chr3 88378348 A G 0.000000289 Facial morphology / / 23028347 rs9874952 chr3 88381469 A C 8.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12494959 chr3 88414986 A G 1.00E-04 Major depressive disorder LOC100506944 intron 21042317 rs9816432 chr3 88442421 G A 6.55E-04 Response to taxane treatment (placlitaxel) LOC100506944 intron 23006423 rs1463473 chr3 88455499 G A 5.91E-05 Schizophrenia (cytomegalovirus infection interaction) LOC100506944 intron 23358160 rs1463473 chr3 88455499 G A 5.46E-06 Socioeconomic Factors LOC100506944 intron pha003067 rs1458005 chr3 88462605 A C 7.32E-06 Socioeconomic Factors LOC100506944 intron pha003067 rs7645228 chr3 88467206 C A 1.48E-05 Socioeconomic Factors LOC100506944 intron pha003067 rs4859028 chr3 88478666 A G 2.71E-05 Monocyte chemoattractant protein-1 LOC100506944 intron pha003071 rs4563418 chr3 88479786 G A 3.87E-05 Response to acetaminophen (hepatotoxicity) LOC100506944 intron 21177773 rs998268 chr3 88511685 A G 3.42E-04 Multiple complex diseases LOC100506944 intron 17554300 rs11713321 chr3 88514766 T A 7.15E-04 Multiple complex diseases / / 17554300 rs7640178 chr3 88514808 C T 8.72E-04 Type 2 diabetes / / 17463246 rs7638511 chr3 88520988 A T 6.57E-04 Type 2 diabetes / / 17463246 rs2880961 chr3 88524175 C T 2.00E-07 Response to acetaminophen (hepatotoxicity) / / 21177773 rs7617735 chr3 88533115 T A 1.67E-04 Multiple complex diseases / / 17554300 rs6803234 chr3 88589247 A G 2.54E-08 Metabolite levels / / 23281178 rs7614273 chr3 88591827 T C 2.54E-08 Metabolite levels / / 23281178 rs9878827 chr3 88597239 T G 2.54E-08 Metabolite levels / / 23281178 rs6419877 chr3 88609467 A G 2.54E-08 Metabolite levels / / 23281178 rs7432027 chr3 88611423 T G 5.09E-08 Metabolite levels / / 23281178 rs7432026 chr3 88611597 A C 2.54E-08 Metabolite levels / / 23281178 rs6551346 chr3 88613505 T C 2.54E-08 Metabolite levels / / 23281178 rs7372825 chr3 88620182 C A 2.54E-08 Metabolite levels / / 23281178 rs6551361 chr3 88750857 T C 6.87E-05 Depression (quantitative trait) / / 23290196 rs11927424 chr3 88757831 A G 3.02E-05 Depression (quantitative trait) / / 23290196 rs7641985 chr3 88758307 A C,T 3.14E-05 Depression (quantitative trait) / / 23290196 rs1587150 chr3 88763195 T A 3.27E-05 Depression (quantitative trait) / / 23290196 rs1353416 chr3 88775481 G A 2.97E-05 Depression (quantitative trait) / / 23290196 rs6551366 chr3 88786963 G C 3.66E-05 Depression (quantitative trait) / / 23290196 rs17026230 chr3 88790882 G A 5.86E-06 Depression (quantitative trait) / / 23290196 rs11914750 chr3 88793424 T C 5.58E-06 Depression (quantitative trait) / / 23290196 rs2046327 chr3 88793982 C T 1.29E-05 Major depressive disorder / / 19107115 rs2046327 chr3 88793982 C T 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10511142 chr3 88863054 A G 4.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1384771 chr3 88872504 G A 3.28E-05 Cognitive decline / / 23732972 rs6551374 chr3 88873356 C T 1.35E-06 Basophils / / pha003087